<SEC-DOCUMENT>0001776985-24-000027.txt : 20240320
<SEC-HEADER>0001776985-24-000027.hdr.sgml : 20240320
<ACCEPTANCE-DATETIME>20240320075734
ACCESSION NUMBER:		0001776985-24-000027
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		152
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240320
DATE AS OF CHANGE:		20240320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		24766314

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190840

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>bntx-20231231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c,d:c5e06a05a31d4c4491031d3208cef8c2-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:bntx="http://www.biontech.de/20231231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bntx-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-40">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-41">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-42">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-43">0001776985</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="dei:NoTradingSymbolFlag" id="f-44">true</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bntx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:OperatingAndBusinessEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:OperatingAndBusinessEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechBioNTainerHoldingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechBioNTainerHoldingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellGeneTherapiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellGeneTherapiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIdarObersteinServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIdarObersteinServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIndividualizedMRNAManufacturingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIndividualizedMRNAManufacturingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationAndServicesMarburgGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationAndServicesMarburgGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepDEGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NTSecurityAndServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NTSecurityAndServicesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustraliaPtyLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustraliaPtyLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRDAustriaGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRDAustriaGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechShanghaiPharmaceuticalsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechShanghaiPharmaceuticalsCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepFranceSASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BiopharmaBioNTechIsraelLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NewTechnologiesReMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepNigeriaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRwandaLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRwandaLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechSenegalSuarlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsSpainS.LMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechSwitzerlandGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTaiwanCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepTunisiaSARLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUKLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUKLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesUSLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:InstaDeepLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:MultiperiodExcessEarningsMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:InstaDeepLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerCOVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerZosterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesToJPTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesToJPTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalBusinessOfInstaDeepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalBusinessOfInstaDeepMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:DualityBiologicsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedilinkTherapeuticsSuzhouCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:BiotheusIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:DeepChainTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:DeepChainTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">bntx:CashFlowProjectionsMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">bntx:CashFlowProjectionsMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:CashAndCashEquivalents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:CashAndCashEquivalents1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MonetaryAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MonetaryAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:MonetaryLiabilityAndProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:MonetaryLiabilityAndProvisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:EuropeanCommissionToCollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:EuropeanCommissionToCollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:RyvuTherapeuticsSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:RyvuTherapeuticsSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedigeneImmunotherapiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedigeneImmunotherapiesGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-02</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-07</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-07</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-07</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgram2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-07</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:VestingPeriodAxis">bntx:ShareBasedPaymentArrangementYearOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-17</xbrli:startDate><xbrli:endDate>2021-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DoctorSierkPoettingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-12</xbrli:startDate><xbrli:endDate>2021-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-17</xbrli:startDate><xbrli:endDate>2021-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-09</xbrli:startDate><xbrli:endDate>2019-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-18</xbrli:startDate><xbrli:endDate>2017-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-18</xbrli:startDate><xbrli:endDate>2017-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-19</xbrli:startDate><xbrli:endDate>2019-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-15</xbrli:startDate><xbrli:endDate>2018-11-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-21</xbrli:startDate><xbrli:endDate>2019-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-29</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bntx:EmployeeStockOwnershipPlanESOPNameAxis">bntx:EmployeeStockOwnershipPlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bntx:EmployeeStockOwnershipPlanESOPNameAxis">bntx:EmployeeStockOwnershipPlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001776985</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-08</xbrli:startDate><xbrli:endDate>2024-02-08</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-69 f-68 f-67 f-72 f-71 f-70" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/></ix:resources></ix:header></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1"></div><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:6pt;padding-left:35.85pt;padding-right:35.85pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="margin-top:6pt;padding-right:182.75pt;text-align:justify"><span><br/></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:182.75pt;padding-right:182.75pt;text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-5">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;padding-left:24.5pt;text-indent:-24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-39081</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">BioNTech SE</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Federal Republic of <ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-10">Germany</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">An der Goldgrube 12</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">D-55131</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">Mainz</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-14">Germany</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Prof. Ugur Sahin, M.D.</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">c/o BioNTech SE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">An der Goldgrube 12</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-17">D-55131</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-18">Mainz</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-19">Germany</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-20">+49</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-21">6131-9084-0</ix:nonNumeric> (Tel), <ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelFaxNumber" id="f-22">+49 6131 9084-390</ix:nonNumeric> (Fax), <ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelEmailAddress" id="f-23">info@biontech.de</ix:nonNumeric> (E-mail)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:182.75pt;padding-right:182.75pt;text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered or to be registered, pursuant to Section&#160;12(b) of the Act</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-24">American Depositary Shares, each Representing one ordinary share</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-25">BNTX</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-27">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1*</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">The Nasdaq Stock Market LLC</ix:nonNumeric>*</span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of business covered by the annual report.</span></div><div style="margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ordinary shares, no par value, with a notional amount attributable to each share of &#8364;1 outstanding up until March 13, 2024, the most recent practicable date, no par value: <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">237,725,735</ix:nonFraction></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-30">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-31">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-32">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-33">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-34">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-35">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-36">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-37">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.&#160;GAAP&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-38">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board&#160;&#160;&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.&#160;&#160;&#160;&#160;Item&#160;17&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Item&#160;18&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-39">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">* Listed not for trading or quotation purposes, but only in connection with the registration of American Depositary Shares representing such ordinary shares pursuant to the requirements of the Securities and Exchange Commission. The American Depositary Shares are registered under the Securities Act of 1933, as amended, pursuant to a separate registration statement on Form F-6 (File No. 333-233898).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_4"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.923%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Page</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_7">GENERAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_7">4</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_10">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_10">5</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2856">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2856">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2850">OFFER STATISTICS AND EXPECTED TIMETABLE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2850">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2840">KEY INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2840">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2834">A. </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2834">[</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2834">Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2834">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2828">B. Capitalization and Indebtedness</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2828">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2822">C. Reasons for the Offer and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2822">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2806">D. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2806">7</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2736">INFORMATION ON THE COMPANY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2736">82</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2730">A. History and Development of the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2730">82</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2708">B. Business Overview</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2708">83</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2059">C. Organizational Structure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2059">160</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2053">D. Property, Plant and Equipment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2053">160</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 4A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2047">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2047">163</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2034">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2034">163</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2018">A. Operating Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_2018">164</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1750">B</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1750">. Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1750">169</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1762">C</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1762">. Research and Development, Patents and Licenses, etc</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1762">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1762">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1756">D</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1756">. Trend Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1756">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1744">E. </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1744">C</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1744">ritical Accounting Estimates</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1744">173</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1721">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1721">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1713">A. Directors and Senior Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1713">173</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1692">B. Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1692">177</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1663">C. Board Practices</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1663">186</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1606">D. Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1606">192</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1600">E. Share Ownership</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1600">193</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289692">F. </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289692">Disclosure of a Registrant</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289692">&#8217;</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289692">s Action to Recover Erroneously Awarded Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289692">193</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1591">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1591">193</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1585">A. Major Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1585">193</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1572">B. Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1572">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1513">C. Interests of Experts and Counsel</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1513">195</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1505">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1505">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1499">A. Consolidated Statements and Other Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1499">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1493">B. Significant Changes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1493">195</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1481">THE OFFER AND LISTING</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1481">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1475">A. Offer and Listing Details</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1475">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1469">B. Plan Of Distribution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1469">195</a></span></div></td></tr></table></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.923%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1463">C. Markets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1463">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1457">D. Selling Shareholders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1457">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1451">E. Dilution</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1451">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1445">F. Expenses of the Issue</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1445">195</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1426">ADDITIONAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1426">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1420">A. Share </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1420">C</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1420">apital</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1420">195</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1401">B. Memorandum and Articles of Association</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1401">196</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1308">C. Material Contracts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1308">201</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1302">D. Exchange Controls</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1302">201</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1293">E. Taxation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1293">201</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1269">F. Dividends and Paying Agents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1269">211</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1262">G. Statement by Experts</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1262">211</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1256">H. Documents on Display</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1256">211</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1214">I. Subsidiary Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1214">212</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1207">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1207">212</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1173">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1173">212</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1167">A. Debt Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1167">212</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1161">B. Warrants and Rights</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1161">213</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1155">C. Other Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1155">213</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1149">D. American Depositary Shares</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1149">213</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1063">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1063">214</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1057">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1057">214</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1047">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1047">214</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_549755817265">[R</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_549755817265">ESERVED</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_549755817265">]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_549755817265">215</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1006">Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1006">215</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1000">Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_1000">215</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_994">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_994">216</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_988">Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_988">216</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_982">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_982">217</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16F.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_976">Changes in Registrant&#8217;s Certifying Accountant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_976">218</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16G.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_967">Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_967">218</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16H.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_931">Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_931">229</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289220">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289220">229</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16J.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.75pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289698">Insider Trading Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289698">229</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM 16K.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.83pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289703">Cybersecurit</a><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289703">y</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_137988709289703">229</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.923%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM&#160;17.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_896">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_896">231</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM&#160;18.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_890">FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_890">231</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ITEM&#160;19.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_884">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_884">232</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_7"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">GENERAL INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 20-F (&#8220;Annual Report&#8221;), &#8220;BioNTech,&#8221; the &#8220;Group,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to BioNTech SE and its consolidated subsidiaries, except where the context otherwise requires.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the fact that our consolidated financial statements are published in Euro, the selected consolidated financial data is presented in Euro as well. Amounts in U.S. dollar are translated into Euro using the exchange rates as per period end or average exchange rates for the periods indicated as published by the German Central Bank (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deutsche Bundesbank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this Annual Report to &#8220;$&#8221; mean U.S. dollars and all references to &#8220;&#8364;&#8221; mean Euros.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains references to our trademarks and to trademarks belong to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark portfolio includes, but is not limited to, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Recon </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Neo-Stim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including logo versions of some of these trademarks. Brand names appearing in italics throughout this report are trademarks owned by BioNTech. All other trademarks are the property of their respective owners.</span></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_10"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains forward-looking statements concerning our business, operations and financial performance and condition as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements that are not of historical facts may be deemed to be forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;anticipates&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;intends&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;might&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;aims&#8221; or other similar expressions that convey uncertainty of future events or outcomes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our actual results of operations, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results, as well as those of the markets we serve or intend to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment in which we expect to operate in the future. Important factors that could cause those differences include, but are not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the extent to which COVID-19 vaccines continue to be necessary in the future</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">and any effects of reduced demand for our COVID-19 vaccine, including the write-down of inventory and costs relating to contract manufacturing production capacities that become redundant or unutilized;</span></div><div style="padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our expected revenues and net profit related to sales of our COVID-19 vaccine (also referred to as </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Comirnaty</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the United States and in the European Union to the extent authorized for use), respectively, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our pricing and coverage negotiations for our COVID-19 vaccine with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, safety, side-effect profile and durability of immune response; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the timing and ability of us and our collaborators to obtain regulatory approval for our COVID-19 vaccine and our product candidates, and to commercialize our approved and investigational product candidates, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the pricing and reimbursement of our COVID-19 vaccine and our product candidates, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the rate and degree of market acceptance of our COVID-19 vaccine and our product candidates, if approved;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding: the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our ability to identify research opportunities and discover and develop product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the impact of COVID-19 on our development programs, supply chain, collaborators and financial performance;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our estimates of our expenses, future revenue and capital requirements and our needs for or ability to obtain additional financing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our ability to identify, recruit and retain key personnel;</span></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our and our collaborators&#8217; ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidates, our ability to protect and defend against potential claims of others' intellectual property, and the scope of such protection;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the development of and projections relating to our competitors or our industry;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">the amount of and our ability to use net operating losses and research and development credits to offset future taxable income;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our ability, and that of our collaboration partners, as applicable,  to manage development and expansion;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our ability to effectively scale our production capabilities and manufacture our products, including our COVID-19 vaccine, and our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our expectations with respect to the timing and amount of any dividends and any potential repurchases of our outstanding ADSs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our expectations regarding the timing of customer payments for delivered COVID-19 vaccine;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">our ability to implement, maintain and improve effective internal controls; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">other factors not known to us at this time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The forward-looking statements contained in this Annual Report speak only as of the date of this report, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</span></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2862"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">PART I</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2856"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 1. Identity of Directors, Senior Management and Advisers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2850"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 2. Offer Statistics and Expected Timetable</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2840"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 3. Key Information</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2834"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. [Reserved]</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2828"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Capitalization and Indebtedness</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2822"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Reasons for the Offer and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2806"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to various risks, including those described below. You should consider carefully the risks and uncertainties described below and in our future filings. If any such risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additionally, risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2800"></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to production of our COVID-19 vaccine. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Our reported commercial revenue is partially based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer Inc., or Pfizer, that are likely to change in future periods, which may impact our reported financial results.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus and, even if we are successful, a market for vaccines against these variants may not develop.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Significant adverse events may occur during our clinical trials or even after receiving regulatory approval, which could delay or terminate clinical trials, delay or prevent regulatory approval or market acceptance of any of our product candidates. Since commercialization, we have received, and expect to continue to receive, product liability claims related to our COVID-19 vaccine.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies, or that negatively affect our results of operations.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our shares could decline.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">mRNA drug development has substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Our approved product and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2788"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our COVID-19 Vaccine and the Commercialization of our Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Demand for our COVID-19 vaccine, though difficult to predict, is expected to continue to decrease in the near future. Changing market dynamics will impact our revenue, which currently depends heavily on sales of our COVID-19 vaccine, and result in challenges relating to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">production of our COVID-19 vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our COVID-19 vaccine, we had not sold or marketed any products in our pipeline. As a result, a majority of our total revenues to date are attributable to sales of our COVID-19 vaccine. However, we have experienced and we expect to continue to experience increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine, as the virus becomes endemic and as a growing proportion of the population becomes vaccinated. We expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. Such revenues will depend on numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the extent to which a COVID-19 vaccine, including any booster shot, continues to be necessary as COVID-19 becomes an endemic virus;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">competition from other COVID-19 vaccines, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our ability to successfully and timely develop effective vaccines targeting new variants and mutations of COVID-19;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our ability to receive full regulatory approvals where we currently have emergency use authorizations or equivalents;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our ability to expand our geographic customer base;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our pricing and reimbursement negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments, including the transition towards ordinary-course insurance coverage in the public and private sectors;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the ability of countries and jurisdictions to store and distribute doses of our COVID-19 vaccine to end users at cold temperatures;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the safety profile of our COVID-19 vaccine, including if previously unknown undesirable effects or increased incidence or severity of known undesirable effects are identified with our COVID-19 vaccine; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">intellectual property litigation involving our COVID-19 vaccine and COVID-19 vaccines in general; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our manufacturing and distribution capabilities for our COVID-19 vaccine.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot accurately predict the revenues our COVID-19 vaccine will generate in future periods or for how long our COVID-19 vaccine will continue to generate material revenues, and we cannot ensure it will maintain its competitive position. Uncertainty in the demand for our COVID-19 vaccine and difficulties in targeting appropriate supply of our COVID-19 vaccines have in the past resulted, and may in the future result, in significant inventory write-downs and cancellations of contract manufacturing orders. Our business and financial condition could be materially affected by lowered COVID-19 vaccine revenues resulting from any of the above factors, or by production and supply chain difficulties. In addition, if our revenues or market share of, or other financial metrics relating to, our COVID-19 vaccine do not meet the expectations of investors or securities analysts, the market price of the ADSs representing our ordinary shares may decline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reported commercial revenue is based on preliminary estimates of COVID-19 vaccine sales and costs from Pfizer that are likely to change in future periods, which may impact our reported financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reported commercial revenue is based on preliminary estimates from Pfizer, and other assumptions and judgments that we have made, which may be subject to significant uncertainties. Our commercial revenue includes preliminary estimates in part due to a difference in Pfizer&#8217;s financial quarter for subsidiaries outside the United States, which consequently creates an additional time lag between the recognition of revenues and the receipt of payment. Although our revenue recognition policy is based on facts and circumstances known to us and various other assumptions that we believe to be reasonable under the circumstances, our actual results may deviate from such reported revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on Pfizer to determine and provide estimates of the costs and profits to be shared with us in the countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for our COVID-19 vaccine, which we refer to as the Pfizer Agreement. Because the information supplied by Pfizer is preliminary and subject to change, the commercial revenue we report based on such information is also subject to finalization. This is particularly true for vaccine sales outside of the United States, where Pfizer has a different reporting cycle than ours. As a result, we may not have the complete sales and costs results outside of the United States for months not covered by the reporting period, but we are nonetheless required to report estimated figures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has historically provided us with profit figures for our COVID-19 vaccine sales in the United States using standard U.S. transfer prices and manufacturing and shipping cost variances (as far as those have been identified) that could be subject to adjustment (e.g., due to changes in manufacturing costs or the price of our COVID-19 vaccine). Pfizer has also provided estimated profits for COVID-19 vaccine sales outside of the United States that were preliminary in nature for the last month of a quarter, as Pfizer&#8217;s subsidiaries outside of the United States have a different reporting cycle than ours. These estimated figures have changed, and in the future such estimated figures are likely to change, as we receive final data from Pfizer for the applicable period in accordance with the reporting cycle of Pfizer&#8217;s ex-U.S. subsidiaries and as actual costs become known. Further, to the extent that Pfizer does not provide such preliminary information in the future, our provisional sales figures for territories outside of the United States will be subject to an even greater level of estimate and judgment. Any changes to the preliminary data we report herein may have an impact on our reported revenues and expenses, profitability or financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in adapting our COVID-19 vaccine or developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, and even if we are successful, a market for vaccines against these variants may not develop and our ability to continue to generate income from sales of our COVID-19 vaccine is uncertain.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 disease itself is unpredictable and each variant comes with varying levels of transmissibility and severity. Consequently, the burden of the disease may wane or dissipate such that our and other COVID-19 vaccines may be less essential from individual and public health perspectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur COVID-19 vaccine was initially developed based upon the genetic sequence of the original SARS-CoV-2 virus that was first detected. The SARS-CoV-2 virus continues to evolve, and new strains of the virus or those that are already in circulation may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains observed to date. Our vaccine may not be as effective in protecting against existing and future variant strains of the SARS-CoV-2 virus as it is against the original virus. While we continue to monitor emerging SARS-CoV-2 strains, undertake investigations into the immunogenicity of our COVID-19 vaccine against new variants as they emerge and develop modified versions of our COVID-19 vaccine against new variants, these efforts may be unsuccessful, and failure to timely and successfully adapt our vaccine to variants of the SARS-CoV-2 virus could lead to significant reputational harm and adversely affect our financial results. It is also possible that we may expend significant resources adapting our COVID-19 vaccine to protect against certain variants of the SARS-CoV-2 virus, but that a market for adapted vaccines does not develop for one or more variants or that demand does not align with our projections or cost expenditures. Moreover, even if we are successful in developing an adapted vaccine and there is a market for the new vaccine, new variants continue to emerge and any adapted vaccine may not be as effective in protecting against such future variant strains.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we discover safety issues with our products, including our COVID-19 vaccine, that were not known at the time of approval, commercialization efforts for our products could be negatively affected, approved products could lose their approval or sales could be suspended, we could be subject to product liability claims and our business and reputation could be materially harmed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information. Billions of doses of our COVID-19 vaccination have now been delivered worldwide, and our COVID-19 vaccine is being more widely used by patients as an authorized product than it was used in clinical trials. As a result, undesirable effects and other problems may be observed that were not seen or anticipated, or were not as prevalent or severe, during clinical trials. We cannot provide assurance that newly discovered or developed safety issues will not arise, and we have received, and expect to continue to receive, product liability claims relating to our COVID-19 vaccine. With the use of any vaccine by a wide patient population, serious adverse events may occur from time to time that did not arise in clinical trials or that initially appeared to be unrelated to the vaccine itself and only with the collection of subsequent information were found to be causally related to the product. Safety events that arise outside of a clinical trial setting are difficult to monitor, and given the widespread use of our COVID-19 vaccine, we have experienced difficulty tracking potential treatment-related adverse events on a global basis.  Any safety issues could cause us to suspend or cease marketing of our approved products, possibly subject us to substantial liabilities, and adversely affect our ability to generate revenue and our financial condition. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause the price of the ADSs representing our ordinary shares to decline or experience periods of volatility. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unexpected safety issues, including any that we have not yet observed in our clinical trials for our COVID-19 vaccine or in real world data, could lead to significant reputational damage for us and our product development platforms going forward and other issues, including delays in our other programs, the need for re-design of our clinical trials and the need for significant additional financial resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with continuing regulatory requirements by us or our collaboration partners could adversely impact regulatory approvals for our products, result in product recalls or suspensions, subject us to fines and/or other types of liabilities.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators fail to comply with applicable continuing regulatory requirements, including good industry practices, such as good manufacturing practices (GMP), we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific drugs, product recalls and seizures, operating restrictions and/or criminal prosecutions. We and the manufacturers we engage to make our products and the manufacturing facilities in which our products are made are subject to periodic review and inspection by the U.S. Food and Drug Administration, or the FDA, and other regulatory authorities. If problems are identified during a review or inspection, we or our collaborators may be the subject of adverse regulatory action, including the issuance of untitled or warning letters, which could result in our inability </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to use the facility to make our product or a determination that inventories are not safe for commercial sale. Any of these factors could adversely affect our business prospects and our financial position could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable to our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, and/or delayed payments from government authorities could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford certain treatments, including our COVID-19 vaccine and other product candidates we may develop and sell. In addition, because our mRNA product candidates represent an entirely new therapeutic modality, we cannot accurately estimate how future products we may develop and sell would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our products. Additionally, even if pricing terms with governmental authorities are agreed upon, there may be delayed or denied payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement for newly approved products in particular in the United States, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, certain countries, including a number of member states of the European Union, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our collaborators. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for us or our collaborators, our revenues from sales by us or our collaborators, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of our product or be subject to price regulations that would delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act, or IRA, enacted in August 2022 allows the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D. The IRA&#8217;s negotiation program will apply to high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics), among other negotiation selection criteria. The negotiated prices, which will become effective in 2026 for the first round of selected drugs, will be capped at a statutorily-determined ceiling price. The IRA also penalizes drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, once the out-of-pocket maximum has been reached. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These IRA provisions will take effect progressively starting in 2023, although the drug negotiation provisions of the IRA are currently the subject of legal challenges. The effects of the IRA on our business and the healthcare industry in general are not yet known. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importing from other countries and bulk purchasing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government policies, including relating to manufacturing or export controls, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact the manufacturing and sales of our COVID-19 vaccine and other product candidates we may develop, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a heightened risk that vaccines could be subject to export controls, adverse emergency actions or supply requirements by governmental and other authorities. In the past, the European Union and other regions have imposed, or threatened to impose, export controls that would limit or block the delivery of COVID-19 vaccines manufactured in or outside their territories in instances where manufacturers have been delayed or have not fully satisfied their delivery obligations to such governments, which could have prohibited us from delivering our COVID-19 vaccine to other jurisdictions. Vaccines are also at risk of being subject to adverse emergency actions taken by governmental entities in certain countries, including intellectual property expropriation, compulsory licenses, strict price controls or other actions, such as the requirement that specific quantities of vaccine doses be set aside for designated purposes or geographic areas. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, public sentiment regarding commercialization of vaccines, the safety and efficacy of our COVID-19 vaccine, other COVID-19 vaccines and treatments, and other public perceptions and misinformation relating to COVID-19, mRNA technology, and our and other COVID-19 vaccines may limit our ability to generate income from sales of our COVID-19 vaccine and other product candidates we may develop and sell, and cause reputational damage. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition with other makers of COVID-19 vaccines and may be unable to maintain a competitive market share for our COVID-19 vaccine.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large number of vaccine manufacturers, academic institutions and other organizations currently have programs to develop COVID-19 vaccine candidates and more than thirty other vaccines have been authorized for emergency use or approved in various countries, including vaccines developed by Moderna, Inc., Johnson &amp; Johnson and University of Oxford/AstraZeneca plc. Our competitors pursuing vaccine candidates may have greater financial, product candidate development, manufacturing and marketing resources than we do. Larger pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for their products, and may have the resources to invest heavily to accelerate discovery and development of their vaccine candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to continue successful commercialization of our COVID-19 vaccine may fail if competitors develop and commercialize COVID-19 vaccines that are safer, more effective, produce longer immunity against COVID-19, require fewer administrations, have fewer or less severe undesirable effects, have broader market acceptance, are more convenient to administer or distribute or are less expensive than any vaccine candidate that we have developed or we may develop.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine to obtain permanent regulatory approval in jurisdictions where it has been authorized for emergency use or granted conditional marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine has been granted full U.S. FDA approval for individuals 12 years and older, emergency or limited use authorization in a number of countries and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for individuals 6 months to 12 years of age and approval for use in certain other countries. Our COVID-19 vaccine has not yet received full approval by regulatory authorities in certain countries where it has been authorized for emergency or temporary use. We and Pfizer intend to continue to observe our COVID-19 vaccine, including vaccine candidates that we may develop for other variants of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19, in global clinical trials. It is possible that subsequent data from these clinical trials may not be as favorable as data we submitted to regulatory authorities to support our applications for emergency use authorization or marketing or conditional marketing approval or that concerns about the safety of our COVID-19 vaccine will arise from the widespread use of our COVID-19 vaccine outside of clinical trials. Our COVID-19 vaccine may not receive approval outside of the emergency use setting in the countries where it is not currently approved, which could adversely affect our business prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our COVID-19 vaccine is sensitive to temperature, shipping and storage conditions and could be subject to risk of loss or damage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is, and other product candidates we develop could be, sensitive to temperature, storage and handling conditions. In particular, while we have improved the required shipping and storage conditions of our COVID-19 vaccine, it must be shipped and stored at cold temperatures. Loss in supply of our COVID-19 vaccine and our product candidates could occur if the product or product intermediates are not stored or handled properly. Shelf life for our product candidates may vary by product, and it is possible that supply of our COVID-19 vaccine or our product candidates could be lost due to expiration prior to use. This has in the past led, and could in the future lead, to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or for commercial purposes. Such distribution challenges may make our COVID-19 vaccine a less attractive product than other COVID-19 vaccines that do not require as cold storage, and our COVID-19 vaccine may become increasingly less competitive as additional other vaccines become authorized for emergency use. If we, our partners and customers are unable to adequately manage these issues, we may be exposed to product liability claims and the market opportunity for our COVID-19 vaccine may be reduced, each of which could adversely affect our business prospects and materially harm our financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing other product candidates and services in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to compete successfully.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals and manufacturing, marketing and selling drug products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">product candidates that are based on previously tested or accepted technologies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">products that have been approved or are in late stages of development&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborative arrangements in our target markets with leading companies and research institutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face intense competition from products that have already been approved and accepted by the medical community for the treatment of the conditions for which we may develop products in the future. We also expect to face competition from new products that enter the market. There are a number of products currently under development, which may become commercially available in the future, for the treatment of conditions for which we are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively than any products we develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate competing with the largest pharmaceutical companies in the world, many of which are currently conducting research in the fields of infectious diseases, immuno-oncology, rare genetic diseases and cancer immunotherapies. Some of these companies have greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully-integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies or shared tumor antigen and neoantigen therapeutics, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we successfully develop other product candidates, and obtain approval for them, we will face competition based on many different factors, including:</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the safety and effectiveness of our products relative to alternative therapies, if any&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the timing and scope of regulatory approvals for these products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the availability and cost of manufacturing, marketing and sales capabilities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the price of any approved immunotherapy&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reimbursement coverage&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our acquisition of InstaDeep Ltd., we also face competition in the rapidly growing and developing artificial intelligence industry. Our competitors may develop or commercialize products and services with significant advantages over any products we develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical, biotechnology or technology companies, providing them with an advantage over us. Our competitors therefore may be more successful in commercializing their products and services than we are, which could adversely affect our competitive position and business. Competitive products and services may make any products and services we develop obsolete or non-competitive before we can recover the expenses of developing and commercializing such products, if approved, and services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for some of our product candidates may be small due to the rarity of the disease, or limited to those patients who are ineligible for or have failed prior treatments. As the target patient populations for some of our programs are small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA often approves new cancer therapies initially only for use by patients with relapsed or refractory advanced cancer. We expect to seek approval initially for some of our product candidates in this context. Subsequently, for those products that prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first-line therapy but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. We are also developing product candidates for the treatment of rare diseases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our products, if approved, because the potential target populations may be small, we may be unable to achieve or maintain profitability in future periods without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to continue to increase our marketing and sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate sufficient product sales revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only relatively recently developed our sales, distribution or marketing capabilities in Germany and T&#252;rkiye, and, other than for our COVID-19 vaccine, we have not historically designed our preclinical studies and clinical trials with specific commercialization or marketing considerations in mind. In addition, with respect to our COVID-19 vaccine, we rely heavily on the sales, distribution, and marketing capabilities of our partners, except in Germany and T&#252;rkiye. To successfully commercialize any other products that may result from our development programs, several of which are undergoing pivotal clinical trials, we will need to continue developing sales and marketing capabilities in the United States, Europe and other regions, either on our own or with others. We may enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into marketing agreements on favorable terms, if at all. If our current and future collaborators do not commit sufficient resources to further commercialize our COVID-19 vaccine and our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product sales revenue to sustain our business. We compete with many companies that currently have extensive and well-funded marketing and sales operations. Without continuing to grow our internal team or obtaining the support of third parties to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to achieve or maintain profitability in future periods depends in part on our and our collaborators&#8217; ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve or maintain profitability in future periods will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our collaborators pursue&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reduced protection for intellectual property rights&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">differing medical practices and customs affecting acceptance in the marketplace&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">import or export licensing requirements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">governmental controls, trade restrictions or changes in tariffs&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">economic weakness, including inflation, or political instability, particularly in non-U.S. economies and markets&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">longer accounts receivable collection times&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">longer lead times for shipping&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">language barriers&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">foreign currency exchange rate fluctuations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the impact of epidemics, pandemics and other public health developments, such as COVID-19, on employees and the global economy&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reimbursement, pricing and insurance regimes&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the interpretation of contractual provisions governed by local laws in the event of a contract dispute.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have prior experience in all of these areas, and the experience we do have in some of these areas is limited. Our collaborators may have limited experience in these areas as well. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that we or our collaborators may develop, which would limit their commercial potential and our revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the requisite approvals, the commercial success of our products will depend in part on the medical community, patients, and third-party or governmental payors accepting immunotherapies in general, and our products in particular, as medically useful, cost-effective and safe.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product that we bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical, social and legal concerns about research involving mRNA could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, we may not generate significant product sales revenue and may not be able to achieve or maintain profitability in future periods. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the potential efficacy and potential advantages over alternative treatments&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the ability to offer our products, if approved, at competitive prices&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the prevalence and severity of any undesirable effects, including any limitations or warnings contained in a product&#8217;s approved labeling&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the prevalence and severity of any undesirable effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the relative convenience and ease of transportation, storage and administration&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">any restrictions on the use of our products, if approved, together with other medications&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the willingness of the target patient population to try new therapies, such as mRNA vaccines and therapies, and of physicians to prescribe these therapies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the strength of marketing and distribution support and timing of market introduction of competitive products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">publicity concerning our products or competing products and treatments&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for our products that are approved for marketing, we and/or our collaborator are subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with current good manufacturing practices, or GMP, and current good clinical practices, or GCP, for any clinical trials that we or a collaborator conduct post-approval. In addition, there is always the risk that we or a collaborator or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with our product candidates identified post-approval could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid in the United States, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because certain of our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">a covered benefit under its health plan&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">safe, effective and medically necessary&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">appropriate for the specific patient&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">cost-effective&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time- consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and divert our resources. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our product candidates in any particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The advancement of healthcare reform legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize any product candidates we or our collaborators develop and may adversely affect the prices for such product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the U.S. Inflation Reduction Act, or the IRA, was enacted, which sets forth meaningful changes to drug product reimbursement by Medicare. The IRA is anticipated to have significant effects on the pharmaceutical industry and may reduce the prices we can charge and reimbursement we can receive for our products in the United States, among other effects. Any reduction in reimbursement from Medicare resulting from the IRA or other legislative or policy changes, or from other government programs may result in a similar reduction in payments from private payers. We cannot be sure whether additional legislative changes will be enacted, or the effect of forthcoming guidance implementing the IRA, or what the impact of such changes on our products and product candidates may be.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to commercialize any products for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products and product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as our products may no longer be commercially viable based on their expected net present value&#894; we may have invested significant resources in product candidates that cannot be commercially developed&#894; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations may no longer be deemed commercially viable to pursue based on our collaborators&#8217; assessments of the impact of any proposed, announced, or legislated pricing reforms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare reform initiatives may be adopted in the future. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from our approved products and from product candidates that we may successfully develop and for which we may obtain regulatory approval, and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug marketing and reimbursement regulations in the European Union and elsewhere may materially affect our ability to market and receive coverage for our products in the member states of the European Union and elsewhere.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is currently approved in the United States, the European Union, and other jurisdictions, and we intend to seek approval to market other product candidates in the United States, the European Union and other selected jurisdictions. If we obtain approval for our products or product candidates in a particular jurisdiction, we will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of our products or product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our collaborators and the potential profitability of any of our product candidates in those countries would be negatively affected.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2782"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term sustainable profitability is difficult to achieve and maintain over time and is highly dependent on various factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to generate revenue and achieve and maintain long-term sustainable profitability depends on our ability, alone or with collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. Although we generate revenue from sales of our COVID-19 vaccine and additional limited revenue from other transactions, we expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. The amount of long-term revenue from such sales, including the sales of our COVID-19 vaccine, is uncertain at this time. Our ability to generate future revenues from pharmaceutical product sales and sales of our other products and services depends heavily on our success in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">completing research and preclinical and clinical development of our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seeking and obtaining U.S. and non-U.S. marketing approvals for product candidates for which we complete clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seeking and obtaining market access and favorable pricing terms in the United States, the European Union, and other key geographies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">furthering the development of our own manufacturing capabilities and manufacturing relationships with third parties in order to provide adequate (in amount and quality) products and services to support clinical development and the market demand for our approved products and product candidates, if approved&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining market acceptance of our approved products and product candidates as a treatment option&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">launching and commercializing product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which we obtain marketing approval and reimbursement, either through collaborations or, if launched independently, by establishing a sales force, marketing and distribution infrastructure&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">addressing any competing technological and market developments, in particular, declining demand for any of our approved products&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">implementing additional internal systems and infrastructure&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how&#894; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attracting, hiring and retaining qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have incurred significant costs associated with the commercialization of our COVID-19 vaccine. Our expenses could increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to perform clinical and other trials or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Accordingly, such costs could adversely affect our future ability to achieve and maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the price of the ADSs representing our ordinary shares could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this report:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and timing of orders for our COVID-19 vaccine;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failures in advancement of existing or future product candidates into the clinic or in clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of adverse events during our clinical trials or post marketing authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and manufacture our product candidates and commercialize and manufacture our COVID-19 vaccine at commercial scale&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage our growth and spending&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute our corporate objectives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of research programs, clinical trials, or other product development or approval processes conducted by us and our collaborators&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our collaborators to develop and successfully commercialize products developed from our suite of therapeutic classes&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our relationships, and any associated exclusivity terms, with collaborators&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contractual or other obligations to provide resources to fund our product candidates, and to provide resources to our collaborators or to the collaborations themselves, including take-or-pay or similar obligations&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we repurchase outstanding ADSs under any share repurchase plans we may enter in the future;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the international aspects of our business outside Germany, including the conduct of clinical trials in multiple locations and potential commercialization in such locations&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to minimize and manage product recalls or inventory losses caused by unforeseen events, cold chain interruption</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing difficulties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or decreased demand</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our ability to write down certain inventory;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to report our financial results accurately and in a timely manner&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on, and the need to attract and retain, key management and other personnel&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, protect, maintain, defend and enforce our intellectual property rights&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know-how or technologies&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our collaborators&#8217; ability to defend against claims of infringement of the intellectual property rights of third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional capital that may be necessary to expand our business&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaborators&#8217; ability to obtain and devote additional capital that may be necessary to develop and commercialize products under our collaboration agreements, including our COVID-19 vaccine&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to minimize and manage product liability claims arising from the use of our COVID-19 vaccine and our product candidates and other future products, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions such as power outages, strikes, acts of terrorism or natural disasters&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to use our net operating loss carryforwards to offset future taxable income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks of counterparty defaults within our asset management portfolio; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased or unpredictable pricing for the commodities we rely on, including as a result of inflation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the factors listed above may be affected by the changing impact of COVID-19 on the global community and the global economy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the various factors mentioned above, and others, the results of any of our periods should not be relied upon as indications of our future operating performance. Our operating results may fluctuate significantly from one reporting period to the next, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause the price of the ADSs to decline. While as a general matter we intend to periodically report on the status of our product candidate pipeline, including articulating anticipated next steps in the form of development plans or potential data readouts, we may not always be able to provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosures of any milestones related to any of our programs that are managed by our collaborators. Any disclosure by a collaborator of data that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on the price of the ADSs or our overall valuation. The price of the ADSs may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in the past and we may incur significant losses in the future.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the first full year of commercialization of our COVID-19 vaccine, we incurred significant losses and negative cash flows from operations due to our significant research and development expenses and our investment in our manufacturing capabilities, and funded our operations primarily from private placements or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuances of ordinary shares (including in the form of ADSs) in connection with our public offerings, generation of proceeds under our collaboration agreements, secured bank loans and issuance of a convertible note.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced, and we expect to continue to experience, increasing reductions in demand for COVID-19 vaccination generally, including for our vaccine. We expect that future revenues from sales of our COVID-19 vaccine will decrease as demand for vaccination wanes. We plan to continue to invest heavily in research and development as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Even for those products for which we have obtained or may obtain regulatory approval or emergency use authorization, our future revenues will depend upon the size of any markets in which such products have received approval or authorization to market, our ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If achieved, profitability is difficult to maintain over time and is highly dependent on various factors. Our future financial results will depend, in part, on the rate of our future expenditures, the extent to which we experience long-term success of our commercial products and our ability to obtain funding through revenue from commercial sales, equity or debt financings, sales of assets, collaborations or grants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue or expand our research or development of our programs in preclinical development&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue or expand the scope of our clinical trials for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">change or increase our manufacturing capacity or capability&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">change or add additional suppliers&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including new and expanded sites globally&#894; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">attract and retain skilled personnel&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">seek marketing approvals and reimbursement for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">seek to identify and validate additional product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">acquire or in-license other product candidates and technologies&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">acquire other companies;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">make milestone or other payments under any in-license agreements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">experience any delays or encounter issues with any of the above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of, and our ability to use, net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty. In addition, pending and future tax audits within our group, disputes with tax authorities and changes in tax law or fiscal regulations could lead to additional tax liabilities. We are subject to routine tax audits by the respective local tax authorities. Any additional tax liability could have an adverse effect on our business, financial conditions, results of operations or prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Germany, we have unused German tax loss carryforwards for corporate taxes for German group entities with pre tax group losses, though we have not recognized deferred tax assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such loss </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carryforwards</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for International Financial Reporting Standards, or IFRS, reporting purposes as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Deferred tax assets are recognized for unused tax losses only to the extent that it is probable that taxable profit will be available against which the losses can be utilized. In general, net operating loss, or NOL, carryforwards in Germany do not expire. Furthermore, under current German tax laws, certain substantial changes in the Company&#8217;s ownership and business may further limit the amount of NOL carryforwards that can be used annually to offset future taxable income.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the German tax group we incurred tax losses up to and including December 31, 2020. Even though we recognized deferred tax assets on a majority of German tax loss carry forwards in 2020 which were fully utilized in 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hey</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">however, subject to review and possible adjustment by the German tax authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have U.S. federal and state NOL carryforwards due to our subsidiaries in the United States, which may be subject to limitations on use after an ownership change. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to utilize a material portion of our historic or current NOLs or credits in either Germany (resulting from our German tax group or non-tax group entities in Germany) or the United States until these have been finally assessed by the tax authorities or when the limitation period has passed. In addition, the rules regarding the timing of revenue and expense recognition for tax purposes in connection with various transactions are complex and uncertain in many respects, and, if challenged, our recognition may be subject to a revised assessment. In the event any such challenge is sustained, our NOLs could be materially reduced or we could be determined to be a material cash taxpayer for one or more years, which could have an adverse effect on our business, financial conditions, results of operations or prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our ability to use our NOLs or credits is conditioned upon our attaining profitability and generating taxable income. Taxable income exceeding NOLs will be subject to taxation resulting tax liabilities. As described above, we incurred significant net losses in every year since our inception other than 2018, 2021, 2022 and 2023 and anticipate that in the future, we may incur significant losses for some of the group entities. Our ability </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to utilize our NOL or credit carryforwards in the United States and for some other group entities is uncertain.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Under German tax laws, we are obligated to withhold a percentage of wage tax and social security contributions on personnel expenses if contract services providers are considered to be our internal employees and remit those withholdings to German tax authorities and social security institutions. Late payments may subject us to penalties and fees.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German tax and social security laws, we are obligated to withhold a percentage of payments we make to third parties in consideration of the services provided, in case these are considered employment payments, and remit those withholdings to German tax authorities and social security institutions. After a significant volume of service providers were engaged to assist with research, development, manufacturing and supply of our COVID-19 vaccine, we discovered after internal review that we and certain of our subsidiaries did not withhold, report and remit certain German wage taxes and social security contributions in connection with certain contract service providers engaged in a manner comparable to internal employees, which we notified tax authorities about. If we do not properly and timely make required payments in the future, we could be subjected to fees, administrative offenses or other proceedings or penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not possible to seek the refund of these wage taxes or social security contributions from either the German tax authorities or social security institutions after filing returns. In Germany, employers are considered secondarily liable for wage taxes. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, value added taxes on invoices received by contract services providers who are considered internal employees are considered non-deductible and must be repaid to the German tax authorities.  It is possible to reclaim the VAT repaid to the German tax authorities from the service provider. There is a possibility that the relevant input VAT claims against the contract service providers may, in some instances, not be enforceable as a result of a contract service provider no longer existing, the lapse of time or any other facts preventing the enforcement of such claims.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, marketing and distribution arrangements, other collaborations and licensing arrangements, or a combination of these approaches. We may require additional capital to obtain regulatory approval for, and to commercialize, future product candidates. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to the high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the results of research and our other platform activities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the clinical development plans we establish for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the terms of any other strategic transactions, including relating to any acquisitions, into which we enter;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the number and characteristics of product candidates that we develop or may in-license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our products or product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs, including the development of modular production and clinical facilities in various markets via our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> network&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity securities, revenue from collaborations, and revenue from sales of our COVID-19 vaccine. While we are currently generating product sales and royalty revenue to finance our operations, we cannot be certain that we will continue to generate sufficient revenue from product sales and royalties to finance our operations. If we were to seek financing from outside sources, that additional funding may not be available on favorable terms, or at all. Should our revenues from product sales sufficiently decrease in the future, we expect to finance our future cash needs through a combination of product sales, public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing or distribution arrangements. Any fundraising efforts may </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all, including as a result of the impact that the shift of COVID-19 towards an endemic phase and other global events, such as political upheavals and economic downturns, may have on the capital markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of the ADSs representing our ordinary shares to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our shareholders&#8217; rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, to the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ordinary shares or ADSs, share ownership interests will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to security interests in our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements, sales of assets, collaborations, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs. We also could be required to seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or intellectual property that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates, or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations, cause the price of the ADSs to decline, and negatively impact our ability to fund operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in developing and expanding our company and managing such development and expansion, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. In addition, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a growing biotechnology company, we are actively pursuing drug classes, platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing products for, and fully understanding the regulatory and manufacturing pathways to, all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure and/or give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to effectively implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our COVID-19 vaccine and our product candidates, if approved, will depend in part on our ability to effectively manage the current and future development and expansion of our company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm the business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. The U.S. federal securities laws, including the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on public companies, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations result in substantial legal and financial compliance costs and have made some activities time-consuming and costly. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with Section 404, we document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we have needed to continue to dedicate internal resources, have engaged outside consultants, and have adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting. We will continue to implement steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that in the future neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we identify material weaknesses in our internal control over financial reporting and fail to remediate such material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining internal control over financial reporting, disclosure controls, and compliance with the other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC thereunder. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with international financial reporting standards. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected by the company&#8217;s internal controls on a timely basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our initial public offering, we identified a material weakness in our internal control which has been fully remediated, but there can be no guarantee that we will not identify additional material weaknesses in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully remediate any future material weaknesses or successfully supervise and rely on outside advisors with expertise in these matters to assist us in the preparation of our financial statements, our financial statements could contain material misstatements discovered in the future that could cause us to fail to meet our future reporting obligations and cause the price of the ADSs to decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have various international trade obligations, including customs value calculation, customs tariff number classification and other related securities requirements. Late payments to customs authorities may subject us to penalties and fees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our supply chain, production and distribution network across the globe creates an increasing level of complexity in customs and foreign trade processes. The requirements for internal control systems are increasing and must be developed simultaneously. The risk management system for customs and foreign trade, which we are continuously improving, determines which stakeholders, goods, and means of transport should be examined and to what extent. These risks include the potential for non-compliance with customs value calculation, customs tariff number classification, trade restrictions, security regulations as well as the potential failure to facilitate international trade. We have in the past discovered that </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain of our and our subsidiaries&#8217; customs value calculations were not applied correctly, following which we notified the customs authorities of potential late payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and will likely continue to be, subject to various audits that arise from time to time, including customs and potential future foreign trade audits. If we do not properly address our international trade and customs requirements, we could be subjected to penalties and fees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a &#8220;foreign private issuer,&#8221; we are exempt from a number of rules under the U.S. securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than U.S. companies. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;foreign private issuer,&#8221; as defined in the rules and regulations of the SEC, and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. For example, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we file an Annual Report on Form 20-F within four months of the close of each financial year ending December 31 and reports on Form 6-K relating to certain material events promptly after we publicly announce these events. Additionally, we rely on a provision in Nasdaq&#8217;s Listed Company Manual that allows us to follow German company law and European law applicable to European stock corporations in general, the German Stock Corporation Act (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE), or the SE Regulation, and the German Act on the Implementation of Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE) (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157/2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SE-Ausf&#252;hrungsgesetz-SEAG</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in particular with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we are exempt from regulations of Nasdaq that require a listed U.S. company to:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">have a majority of the board of directors consist of independent directors;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">require non-management directors to meet on a regular basis without management present;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">adopt a code of conduct and promptly disclose any waivers of the code for directors or executive officers that should address certain specified items;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">have an independent compensation committee;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">have an independent nominating committee;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">solicit proxies and provide proxy statements for all shareholder meetings;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">review related party transactions; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">seek shareholder approval for the implementation of certain equity compensation plans and issuances of ordinary shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are permitted to follow home country practice in lieu of the above requirements. We therefore continue to follow German corporate governance practices in lieu of the corporate governance requirements of Nasdaq in certain respects. In particular, we follow German corporate governance practices in connection with the distribution of annual and interim reports to shareholders, the application of our code of conduct to our employees and the Supervisory Board, executive remuneration disclosure, proxy solicitation in connection with shareholders&#8217; meetings, and obtaining shareholder approval in connection with the establishment of, or material amendment to, certain equity-based compensation plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to U.S. companies listed on Nasdaq. As we are a foreign </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private issuer, however, our audit committee is not subject to additional requirements of Nasdaq applicable to listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as a foreign private issuer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to catastrophic global events including natural disasters, political crises, or public</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">health epidemics and pandemics and other public health developments, that could adversely affect our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of catastrophic global events including natural disasters such as an earthquake, fire, hurricane, tornado, flood or significant power outage; public health crises such as the COVID-19 pandemic; political crises, such as terrorist attacks, war and other political instability, including the ongoing geopolitical conflicts in the Middle East and in Ukraine, and resulting sanctions imposed by the United States and other countries and retaliatory actions taken by Russia in response to such sanctions; or other catastrophic events.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:28.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ongoing conflict between Russia and Ukraine and the conflicts in the Middle East, and resulting sanctions and other economic actions, have contributed to, and are expected to continue to contribute to, rising prices and shortages of crude oil and natural gas. Prolonged or expanded conflict between Russia and Ukraine and in the Middle East, and political responses to global actions, could further reduce oil and gas supplies, increase energy volatility and have severe adverse effects on regional and global supply chains and economies and our business. Our commercial production of our COVID-19 vaccine is currently run on natural gas, although we believe our production could be powered by alternative fuel sources if needed. Additionally, we continue to evaluate the impacts that a growing or subsequent energy shortage may have on our partners, suppliers and service providers. Were any of these parties to experience significant impacts from this or any other energy shortage, our business could be materially harmed. We cannot predict with certainty the impact a continuing or more severe natural gas shortage would have on our or their operations, including on the manufacturing of our COVID-19 vaccine and the manufacturing and testing of our product candidates.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have generated revenues from sales of our COVID-19 vaccine, there remains uncertainty regarding other potential effects of COVID-19 on our business. For example, if a new variant of COVID-19 emerges for which existing vaccines, including our COVID-19 vaccine, are ineffective, infections may become even more widespread, negatively impact our ability to enroll patients in clinical studies and complete clinical trials on the timelines we currently anticipate, or result in an economic downturn that could affect demand for our products and services or our ability to raise capital, which could have a material adverse effect on our business, operating results and financial condition. Our suppliers, licensors or collaborators could also be disrupted by conditions related to COVID-19 or other pandemics and epidemics, possibly resulting in disruption to our supply chain, clinical trials, partnerships or operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. We currently maintain insurance coverage for losses relating to property damage, business interruption, transportation, product liability, cyber matters, clinical trials, and several other areas of coverage.&#160;We are dedicating resources to exploring additional avenues for more adequate coverage as our business evolves. However, the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, operating as a public company has made it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Supervisory Board, our Management Board, or our board committees.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank, or SVB, a bank which we previously used to support operations in the United States, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or the FDIC, as receiver.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a statement by the U.S. Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day following the date of closure and we received such access on March 13, 2023, and neither the amount in question nor any delays in access were material to our operations, uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. The U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments. However, widespread demands for customer withdrawals or other needs of financial institutions for immediate liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in a timely fashion or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we maintain our cash and cash equivalents in multiple financial institutions worldwide, our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired by the financial institutions with which we have arrangements directly facing liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2776"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our technology platforms. If we and our collaborators are unable to obtain approval for and effectively commercialize our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and we may not be able to obtain approvals for the commercialization of product candidates we may develop. Any product candidates we may develop and the activities associated with their development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our product candidates, we and our collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective, including in the target populations. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a new drug application, or NDA, to the FDA, a Marketing Authorization Application, or MAA, to the EMA, and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. Although our COVID-19 vaccine has received emergency use authorization and/or regulatory approvals in certain countries, it is possible that none of our other product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and may need to rely on third-party CROs, regulatory consultants or collaborators to assist us in this process. We expect to submit initial BLAs/MAAs for our mRNA-based </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates in the United States, the European Union and in other countries globally. In some of these jurisdictions, mRNA-based medicinal products may be classified in different ways and may be subject to specific requirements. Securing regulatory approval requires the submission of extensive quality, preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Benefit and risk are regularly assessed, and any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals in the United States, the European Union and elsewhere, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies and standards of care during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA, EMA and comparable regulatory authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional preclinical, clinical or other trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays or non-approval may result if an FDA panel of experts, referred to as an Advisory Committee, or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory agencies also may approve a product candidate for fewer or more limited indications or patient populations than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA and other regulatory agencies review the Quality or Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, MAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential mRNA product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining, or if we fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues will be materially impaired. Additionally, even if we are successful in obtaining marketing approval for product candidates, because our preclinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA drug development carries substantial clinical development and regulatory risks due to limited regulatory experience with mRNA immunotherapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To our knowledge, other than our and Moderna, Inc.&#8217;s COVID-19 vaccines, no mRNA immunotherapies have been approved or received emergency use authorization or conditional marketing authorization to date by the FDA or the EMA. Successful discovery and development of mRNA-based (and other) immunotherapies by either us or our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. Our product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic or clinical holds, or fail to reach the market for many reasons, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">discovery efforts aimed at identifying potential immunotherapies may not be successful&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">nonclinical or preclinical study results may show product candidates to be less effective than desired or have harmful or problematic side effects&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">clinical trial results may show the product candidates to be less effective than expected, including a failure to meet one or more endpoints or have unacceptable side effects or toxicities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">manufacturing or distribution failures or insufficient supply of GMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make our product candidates commercially unattractive&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our improvements in the manufacturing processes may not be sufficient to satisfy the clinical or commercial demand of our product candidates or regulatory requirements for clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">changes that we make to optimize our manufacturing, testing or formulating of GMP materials could impact the safety, tolerability and efficacy of our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">pricing or reimbursement issues or other factors could delay clinical trials or make any immunotherapy uneconomical or noncompetitive with other therapies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the failure to timely advance our programs or receive the necessary regulatory approvals, or a delay in receiving such approvals, due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, BLA, MAA or the equivalent application, discussions with the FDA or the EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the proprietary rights, products and technologies of our competitors may prevent our immunotherapies from being commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For administrative purposes, mRNA products are classified together with gene therapy products by the FDA. Unlike certain gene therapies that irreversibly alter cell DNA and may cause certain side effects, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA is highly unlikely to localize to the nucleus, be reverse transcribed or integrated into the genome</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Side effects observed in other gene therapies, however, could negatively impact the perception of immunotherapies despite the differences in mechanism. In addition, the regulatory pathway in the United States and many other jurisdictions for approval is uncertain. Our COVID-19 vaccine is not currently classified as a gene therapy. The regulatory pathway for an individualized therapy, such as our iNeST mRNA-based immunotherapy where each patient receives a different combination of mRNAs, remains undetermined. The number and design of the clinical and preclinical studies required for the approval of these types of medicines have not been established, may be different from those required for advanced medicinal therapy products or therapies that are not individualized or may require safety testing like gene therapy products. Moreover, the length of time necessary to complete clinical trials and submit an application for marketing approval by a regulatory authority varies significantly from one pharmaceutical product to the next and may be difficult to predict.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may not work as intended, may cause undesirable effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most biological products, use of our product candidates could be associated with undesirable effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have impaired organ function, compromised immune and other systems and may be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or comparable regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable side effects arise in the development of our product candidates, we, the FDA, competent authorities of EU member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which our studies are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA or comparable regulatory authorities could also order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring the safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our ongoing and planned clinical trials, we have contracted, and are expected to continue to contract, with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA, the EMA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. The centers using our products, if and when approved, could also have difficulty managing any adverse effects of our products, or use medicines that do not adequately control such undesirable effects or that have a detrimental impact on the efficacy of the treatment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we successfully advance our product candidates into and through clinical trials, such trials will likely only include a limited number of patients and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effects and safety consequences of taking our product candidates over a multi-year period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval and we or others later identify undesirable effects caused by such products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">regulatory authorities may withdraw their approval of the product&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we may be required to recall a product or change the way such product is administered to patients&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we could be sued and held liable for harm caused to patients&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the product may become less competitive&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates or our immunotherapy approach generally prove to be unsafe, our technology platforms and pipeline could be affected, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our pipeline is in preclinical development and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for product candidates, we must complete extensive preclinical studies, including IND-enabling Good Laboratory Practice toxicology testing, that support our planned Investigational New Drug applications, or INDs, in the United States or similar applications in other jurisdictions. We must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing. CMC activities for a new category of medicines such as mRNA therapies require extensive manufacturing processes and analytical development, which are uncertain and lengthy. For instance, batch failures have occurred as we scale up our manufacturing and may occur in the future. In addition, we have had in the past, and may in the future have, difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our preclinical or clinical </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. If we are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of preclinical or clinical trials of such product candidates. For example, we cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or other regulatory authorities will accept the results of our preclinical testing or our proposed clinical programs or if the outcome of our preclinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our control. Clinical trials of our product candidates may be delayed, certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, and we may have difficulty recruiting patients to participate in clinical trials, any of which can affect our ability to fund our company and would have a material adverse impact on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and complex and can take many years to complete. Its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates. We and our collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our collaborators conduct that could delay or prevent us or our collaborators from successfully developing our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the FDA, other regulators, IRBs or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we have optimized in the past and may in the future optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to additional studies (including bridging and bioequivalence studies) or potentially significant changes in our clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in an effort to optimize product features, we have made in the past and may continue to make changes to our product candidates after we commence clinical trials of a medicine which may require us to repeat earlier stages of clinical testing or delay later-stage testing of the medicine&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">clinical trials of any product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">differences in trial design between early-stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">preclinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our product candidates may have undesirable effects or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us or our investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate or any other of our product candidates for which a clinical trial may be ongoing&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the number of trial participants required for clinical trials of any product candidates may be larger than we anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be slower than we anticipate due to perceived adverse effects, limited patient populations, competitive trials, risks related to COVID-19  or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">despite robust sponsor oversight, our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">regulators may elect to impose a clinical hold, or we, our investigators, IRBs or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">with respect to infectious disease vaccine trials in particular, we have to wait for particular level of infection in the placebo arm in order to assess protection provided by vaccine, and we cannot control the rate of exposure or infection which can make timing uncertain;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">safety or efficacy concerns regarding our product candidates may result from any concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the DSMB. We may in the future be delayed in gaining clearance from the FDA or other regulators to initiate clinical trials through, among other things, the imposition of a clinical hold in order to address comments from such regulators on our clinical trial design or other elements of our clinical trials. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols&#894; inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold&#894; unforeseen safety issues or adverse side effects&#894; failure to demonstrate a benefit, or adequate benefit-risk ratio, from using a product candidate&#894; failure to establish or achieve clinically meaningful trial endpoints&#894; changes in governmental regulations or administrative actions&#894; or lack of adequate funding to continue the clinical trial. Many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. We must also complete extensive work on CMC activities that require extensive manufacturing processes and analytical development, which are uncertain and lengthy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA and regulatory authorities in other jurisdictions have limited experience with commercial development of several of our technologies. The FDA may require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be certain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA and other regulatory authorities have indicated that, prior to commencing later stage clinical trials for our mRNA-based product candidates, we will need to scale up and further refine assays to measure and predict the potency of a given dose of these product candidates. Any delay in the scaling and refining of assays that are acceptable to the FDA or other regulatory authorities could delay the start of future clinical trials. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data for our clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant additional preclinical or nonclinical testing and studies or clinical trial delays for our product candidates also could allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in the development of our product candidates may harm our business, financial condition and prospects significantly. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on enrollment of participants in our clinical trials for our product candidates. In the past, our collaborators have found, and we or our collaborators may in the future find, it difficult to enroll trial participants in our clinical studies, which could delay or prevent clinical studies of our product candidates. Identifying and qualifying trial participants to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends on the speed at which we can recruit trial participants to participate in testing our product candidates. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. If trial participants are unwilling to participate in our studies because of negative publicity from adverse events in our trials or other trials of similar products, or those related to specific a therapeutic area, or for other reasons, including competitive clinical studies for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product, or termination of the clinical studies altogether.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to identify, recruit and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient and subject enrollment is affected by factors including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">severity of the disease under investigation&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">complexity and design of the study protocol&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">size of the patient population&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">eligibility criteria for the study in question&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">proximity and availability of clinical study sites for prospective trial participants&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">availability of competing therapies and clinical trials, including between our own clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">efforts to facilitate timely enrollment in clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">patient referral practices of physicians&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">ability to monitor trial participants adequately during and after treatment&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">ability to recruit clinical trial investigators with the appropriate competencies and experience&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">clinicians&#8217; and trial participants&#8217; perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">our ability to obtain and maintain participant informed consent&#894; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">major changes in the approval status of competitor investigational products during the clinical trial period;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">impacts related to the spread of COVID-19; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the risk that trial participants enrolled in clinical trials will not complete a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of trial participants available to us because some trial participants who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our product candidates represent a therapeutic novelty in contrast to more traditional methods for disease treatment and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other investigational therapies rather than enroll trial participants in any future clinical trial involving more novel product candidates. Additionally, if new product candidates, such as gene editing therapies, show encouraging results, potential trial participants and their doctors may be inclined to enroll trial participants in clinical trials using those product candidates. If such new product candidates show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, certain conditions for which we plan to evaluate our current product candidates are rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing patients may prove costly. Each of the foregoing risks may continue to be affected by the spread of seasonal viral infections, including COVID-19, as well as the potential for any new pandemic caused by an as-yet-unknown agent.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are currently being conducted in several countries, and we plan to commercialize our product candidates, if approved, globally. Accordingly, we are subject to additional risks related to operating in multiple countries, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">differing regulatory requirements in such countries&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in Germany and shipping the product candidate to the patient abroad&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">import and export requirements and restrictions&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">restrictions on transfers of information, including certain technologies and personal data;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">economic weakness, including inflation, or political instability in particular economies and markets&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">taxes, including withholding of payroll taxes&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">difficulties staffing and managing operations outside of Germany&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">workforce uncertainty in countries where labor unrest is more common&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in other jurisdictions&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as Germany and the United States&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">business interruptions resulting from geopolitical actions, including war and terrorism, or public health epidemics or pandemics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 virus continues to impact our operations, including our clinical trial operations, as it becomes endemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including new outbreaks, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In the future, similar events could affect our ability to manufacture and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our partners have conducted and are expecting in the future to conduct clinical trials for our product candidates at clinical sites located outside of the United States. Although the FDA may accept data from clinical trials outside the United States that are not conducted under an IND, acceptance of this data in support of a marketing </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application or IND requires the clinical trial to have been conducted in accordance with GCPs, and that FDA is able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are considered applicable to the U.S. patient population and U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered valid without the need for an onsite inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an onsite inspection or other appropriate means. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States in support of a marketing application. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of a product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations and our collaborations with our collaborators may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim top-line or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically extensive information, and our securityholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by our securityholders or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of earlier studies and trials of our product candidates may not be predictive of future trial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we cannot be certain that we will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our tumor-specific cancer immunotherapy candidates and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies and initial </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our planned clinical trials or those of our collaborators may be less efficacious or may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our product candidates are being developed or are intended to be co-administered with other developmental therapies or approved medicines. For example, autogene cevumeran (BNT122) is being developed to be co-administered with checkpoint inhibitors. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other regulatory authorities, ethics committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts focus on the clinical trials and potential approval of our existing product candidates, a key element of our strategy is to discover, develop and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug and target discovery efforts, exploring potential collaborations for the development of new products, and in-licensing technologies. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we may fail to develop and commercialize such products successfully for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the research methodology used may not be successful in identifying potential product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">competitors may develop alternatives that render our product candidates obsolete&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified senior management and scientific personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry, as well as a current global shortage of these highly qualified individuals. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing and commercialization objectives. We are also aware of physical threats made against certain of these people. In response to these threats, we have deployed personal protection for such employees and increased our security generally. We currently do not have &#8220;key person&#8221; insurance on any of our employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will be critical to our success as well. Competition for skilled personnel, including in mRNA research, clinical development, clinical operations, regulatory affairs, therapeutic area management and manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, and the failure to succeed in preclinical studies or clinical trials or in applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could have an adverse effect on the results of our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators and consultants, despite our robust efforts to prevent such misconduct through sponsor oversight. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, to provide accurate information to the FDA, the EMA and other regulatory authorities, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment-related disputes, including employee litigation and unfavorable publicity, could negatively affect our future business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to ti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">me we may be subject to claims by our employees or regulatory authorities with respect to employment and workplace matters, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lawsuits or proceedings against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment or other employment issues. In recent years, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment- related lawsuits have </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit versions of our COVID-19 vaccine, or, if approved, our other product candidates, could have a negative impact on our financial performance or reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties have in the past and may continue to illegally distribute and sell counterfeit versions of COVID-19 vaccines. Counterfeit products are frequently unsafe or ineffective, and may even be life-threatening. Counterfeit medicines may contain harmful substances or the wrong dosage. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reports of adverse reactions to counterfeit products, increased levels of counterfeiting, or unsafe vaccines could materially affect public confidence in our COVID-19 vaccine or other product candidates. It is possible that adverse events caused by unsafe counterfeit vaccines will mistakenly be attributed to our COVID-19 vaccine, or, if approved, our other product candidates. In addition, thefts of inventory at warehouses, plants or while in-transit, which are subsequently improperly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation, and our business. Public loss of confidence in the integrity of our COVID-19 vaccine or, if approved, our other product candidates, as a result of counterfeiting or theft could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future collaborators, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from one or more ongoing or completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach of running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the EU General Data Protection Regulation, or the GDPR, relevant law of an EU member state, HIPAA, and other relevant state and federal privacy laws in the United States or in other jurisdictions. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failures, accidents or security breaches to date, in December 2020, we were informed by the EMA that the agency was subject to a cyberattack and that some documents relating to our regulatory submission for our COVID-19 vaccine candidate, which was stored on an EMA server, had been unlawfully accessed. None of our systems were breached in connection with this incident and we are unaware that any study participants were identified through the data being accessed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have put systems and procedures in place to minimize the likelihood of such incidents reoccurring&#894; however, we cannot guarantee that third parties will not be able to gain unauthorized access to or otherwise breach our systems in the future. Any such unauthorized access or breach could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and an even greater risk related to any commercialized products, such as our COVID-19 vaccine. We have received product liability claims against our COVID-19 vaccine, and expect to receive additional product liability claims in the future. If we cannot successfully defend ourselves against claims that our products and/or our product </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates have caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">decreased demand for any product or product candidate that we may develop&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">loss of revenue&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">substantial monetary awards to patients, healthy volunteers or their children&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">significant time and costs to defend the related litigation&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">withdrawal of clinical trial participants&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the inability to commercialize any products or product candidates that we may develop&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">injury to our reputation and significant negative media attention.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry clinical trial insurance and product liability insurance, which we believe to be sufficient in light of our current clinical programs and commercial operations&#894; however, the amount of coverage we have obtained may not be adequate and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the ADSs to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our products become subject to a product recall it could harm our reputation, business and financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, some governmental bodies outside the United States have the authority to require the recall of any product or product candidate in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recalls of any of our products or, if approved, our product candidates, would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are investing in AI technology systems, including through our acquisition of InstaDeep, and such systems are complex and rapidly changing. We face significant competition from other companies with respect to our AI and machine learning services, along with an evolving regulatory landscape. The introduction of AI into the development and manufacturing of our product candidates, or the provision of services relating to AI technologies and applications, may result in new or enhanced governmental or regulatory scrutiny, litigation, intellectual property risks, confidentiality or security risks, ethical concerns or other complications that could harm our business, reputation or financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty around AI may require additional investment in the development and maintenance of proprietary datasets and development of appropriate protections and safeguards for handling the use of customer data with AI technologies, which may be costly and could impact our expenses. In addition, AI may create content that appears correct but is inaccurate or flawed, and if created by third parties, may be mistakenly attributed to us. Our customers or others may rely on or use this flawed content to their detriment, which may expose us to brand or reputational harm, competitive harm or legal liability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to environmental, social and governance, or ESG, matters, including related social expectations and concerns, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the price of ADSs representing our ordinary shares to decline.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are rapid and ongoing developments and changing expectations relating to ESG matters and factors such as the impact of our operations on the environment, access to our COVID-19 vaccine, corporate governance, our practices relating to product stewardship, management of business ethics, human rights diligence in our own operations and our supply chain, and human resource development, which may result in increased regulatory, social or other scrutiny on us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we must address climate risks due to our own contribution to climate change (inside-out perspective), risks due to physical effects of climate change as well as transition risks (outside-in perspective), and interactions between both perspectives. To this end, we have set ourselves near-term scienced-based emissions reduction targets for our own operations (scope 1, 2) and for our supply chain (supplier engagement target for scope 3), validated by the  Science Based Targets initiative (SBTi) in early February 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are addressing increasingly complex regulatory requirements with respect to human rights risks, including German legislation (for example, the Act on Corporate Due Diligence Obligations for the Prevention of Human Rights Violations in Supply Chains (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lieferkettensorgfaltspflichtengesetz - LkSG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)), potential legislative planning by the European Union and local or regional regulations. We are expected by regulation to identify, prevent, mitigate and ideally end the extent of any potential adverse impacts or violations throughout our own operations and value chain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we are faced with increasing ESG related transparency and reporting obligations. These requirements arise, for example, from the EU CSRD regulation and the ESRS sustainability standards, from specific human right reporting regulations (e.g. section 10 of the German LkSG), the recently-announced SEC rules that will require registrants to provide additional climate-related disclosures in future periods, and other possible obligations.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we fail to meet our climate protection targets or if we are unable to adequately recognize and respond to such developments and governmental, societal, investor and NGO expectations relating to such ESG matters, we may have to pay substantial fines, forego corporate opportunities, become subject to additional scrutiny, incur unexpected costs or experience damage to our reputation or our various brands. If any of these events were to occur, there may be a material adverse effect on our business, financial condition, cash flows and results of operations, and the price of ADSs representing our ordinary shares may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have observed that in addition to the importance of their financial performance, companies are increasingly being judged by their performance on ESG matters. A variety of organizations measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. We may fail to comply with standards or best practices put forth by such organizations or by governmental or regulatory bodies. In addition, investment in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures to their investment decisions. In light of investors&#8217; increased focus on ESG matters, there can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to our proper role. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, the price of ADSs representing our ordinary shares, financial condition, or results of operations, including the sustainability of our business over time.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2770"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Manufacturing of our COVID-19 Vaccine, our Product Candidates and Future Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our COVID-19 vaccine and product candidates are based on novel technologies and they may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of the third-party manufacturers we work with encounter such difficulties, our ability to supply materials for clinical trials or any approved product could be delayed or stopped.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes for our COVID-19 vaccine and our product candidates are novel and complex. Due to the novel nature of this technology and the recency of our experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons, including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This has resulted in the past, and may in the future result, in our having to resupply batches for preclinical, clinical, or commercial activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our products or product candidates could materially delay our or our collaborators&#8217; ability to continue the clinical trial for that product candidate or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical, clinical or commercial supply.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2021 we received product quality complaints related </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our COVID-19 vaccine in Hong Kong.  A thorough investigation into these complaints concluded that the reported product quality complaints were due to the combination of a deficient container closure process, or crimping, at one specific contract manufacturing organization when such containers were later shipped at ultra-cold conditions created by shipping on dry ice. The investigation did not identify any safety issues related to the product quality complaints. We and our COVID-19 vaccine collaboration partner in Hong Kong, Fosun Pharma, subsequently supplied replacement COVID-19 vaccine vials, but we cannot assure you that we will not experience similar product quality complaints in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rate of innovation is high, which has resulted in, and will continue to cause a high degree of, technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of, new manufacturing infrastructure or may adversely affect third-party relationships.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process to generate mRNA medicines is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply. Additionally, for individualized therapies, we may encounter issues with our ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to the manufacturing process may impact, in turn, specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of lots and this could lead to a substantial delay in our clinical trials or an inability to supply sufficient commercial quantities of drug product. Our mRNA product candidates may prove to have a stability profile that leads to an unfavorable shelf life. This poses risk in supply requirements, wasted stock and higher cost of goods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we encounter unexpected performance issues, we could encounter delays or interruptions to clinical and commercial supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the number of different programs, we may in the future have cross contamination of products inside of our factories, CROs, external contract manufacturing organizations, or CMOs, suppliers or in the clinic that affect the integrity of our products. Additionally, for some programs the manufacturing scale is extremely small compared to the standard volumes of supply, such that we run the risk of contaminating the process each time we reopen a container to use remaining supplies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity and the pharmaceutical properties of our product candidates from IND-enabling studies through commercial launch, including shelf life stability and solubility properties of drug product and drug substance. Due to continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as six- or 12- month stability testing. That may require resupplying clinical or commercial material, or making additional GMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our COVID-19 vaccine and our product candidates. Further, now and in the future, one or more of our programs may have a single source of supply for raw materials and excipients. Some of our suppliers are located in countries different from our manufacturing sites. Export restrictions could lead to unplanned interruptions in manufacturing and thus impacting supply of both clinical and commercial material. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA products and product candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy or stability. This may lead to an inability to release mRNA products or product candidates until the manufacturing or testing process is rectified.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and product intermediates are extremely temperature sensitive, and we may learn that any or all of our products are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our products or product candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions. As we are transporting intermediate products with holding times in refrigeration (TIR) and allowed times out of refrigeration (TOR) across long distances and crossing borders, traffic issues and customs delays could lead to the loss of batches which would need to be replaced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our product candidates are uniquely manufactured for each patient and we may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we or any of the third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide such product candidates for clinical trials or, if approved, products for patients could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We custom design and manufacture certain product candidates that are unique and tailored specifically for each patient. Manufacturing unique lots of these product candidates is susceptible to product loss or failure due to issues with:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">logistics associated with the collection of a patient&#8217;s tumor, blood or other tissue sample&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">shipping such samples to a facility for genetic sequencing&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">next-generation sequencing of the tumor mRNA&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">biopsy of a sufficient quantity of cancerous tissue to allow for proper sequencing and identification of tumor-specific mutations&#894; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">identification of appropriate tumor-specific mutations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our product candidate, to assist with the design of the patient-specific mRNA, which software must be maintained and secured&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">effective design of the patient-specific mRNA that encodes for the required neoantigens&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">batch-specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">quality control testing failures&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">unexpected failures of batches placed on stability&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">successful and timely manufacture and release of the patient-specific batch&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">shipment issues encountered during transport of the batch to the site of patient care&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the ability to define a consistent safety profile at a given dose when each participant receives a unique treatment&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our reliance on single source suppliers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continue to evolve our own custom manufacturing equipment. This equipment may not function as designed, which may lead to deviations in the drug product being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, we may not be able to supply this expanded need reliably without significant investments due to the custom nature of the equipment and single-use assemblies. In addition, there will be considerable time to scale up our facilities or build new facilities before we can begin to meet any commercial demand if one or more of our individualized product candidates are approved. This expansion or addition of new facilities could also lead to product comparability issues, which can further delay introduction of new capacity.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For those of our product candidates that are manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, the sequenced data derived from such tissue sample, the results of such patient&#8217;s genomic analysis and the custom manufactured product for such patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in product mix-up, adverse patient outcomes, loss of product, or regulatory action, including withdrawal of any approved products from the market. Further, as our product candidates are developed through early-stage clinical studies to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery processes will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our inability to manufacture sufficient or appropriate quantities of our COVID-19 vaccine or any of our product candidates, or our failure to comply with applicable regulatory requirements, could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing is a vital component of our individualized immunotherapy approach, and we have invested significantly in our manufacturing facilities, including the acquisition of a manufacturing site in Marburg, Germany, the construction of a novel modular manufacturing facility that we refer to as a &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and the construction of a facility to support manufacturing of our Individualized Vaccines Against Cancer (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IVAC</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) candidates. All internal manufacturing is performed under GMP guidelines. We also rely on a network of CMOs for the manufacture of our COVID-19 vaccine. We do not rely on any external CMOs for the manufacture of our individualized product candidates and at this time, and we have limited redundancy among our facilities. Due to the individualized nature of our product candidates, we do not maintain product reserves. If any of our or our external CMOs&#8217; manufacturing facilities, including our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units, experience difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our clinical development programs may be delayed or suspended until we or our external CMOs can resume operations. We may also be required to incur significant expenditures to resolve such difficulties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:28.34pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner also have experienced, and continue to face the risk of, inventory write-downs or redundant production capacities with respect to our COVID-19 vaccine. Planned new formulations of our COVID-19 vaccine, including versions that could protect against new variants of COVID-19, have resulted or may result in significant research and development expense that was not or may not be recouped. In addition, we have experienced in the past, and may experience in the future, redundant production capacities under our agreements with CMOs due to planned new formulations, adaptations of our COVID-19 vaccine and increased internal manufacturing capacities. Significant inventory write-downs or redundant manufacturing expenses would negatively impact our results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities are subject to various regulatory requirements and may be subject to announced or unannounced inspections by the FDA or other regulatory authorities at any time during the development or commercialization phase. If we or our external CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or comparable regulatory authorities in other jurisdictions, we may not be able to rely on our or our external CMOs&#8217; manufacturing facilities for the manufacture of our product candidates. If the FDA, the EMA or another comparable regulatory authority finds our or our external CMOs&#8217; facilities inadequate for the manufacture of our COVID-19 vaccine or our product candidates or otherwise deficient, including as a result of a site inspection, such facilities may be the subject of adverse regulatory action, including the issuance of untitled or warning letters. If such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly delay or otherwise impact our ability to develop, obtain regulatory approval for or market our COVID-19 vaccine or our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may experience manufacturing difficulties due to resource constraints, labor disputes or unstable political environments. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients in clinical trials, or to provide approved products for the treatment of patients, would be jeopardized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to regulatory and operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designs of our facilities are based on current standards for biotechnology facilities. They have been reviewed and approved by local authorities and have also received GMP manufacturing licenses. We have designed our facilities to incorporate a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. We have attempted to achieve a high level of digitization for clinical and commercial manufacturing facilities relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to a delay in supply or shutdown of our facilities. Any disruption in our manufacturing capabilities could cause delays in our production capacity for our drug substances or drug products, impose additional costs, or require us to identify, qualify and establish an alternative manufacturing site, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our development and commercial capacity, we may continue to establish additional manufacturing capabilities in different jurisdictions, which may lead to regulatory delays or prove costly. If we fail to select the correct location, complete the construction in an efficient manner, recruit required personnel, and/or generally manage our growth effectively, the development and production of our products or product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our COVID-19 vaccine and certain of our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and suppliers may not be able to deliver raw materials to our specifications. In addition, some such suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under GMP by biopharmaceutical firms. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we have experienced and we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms or at all, which could have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to significant regulatory oversight with respect to manufacturing our products and product candidates. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet GMP requirements set forth in regulations promulgated by the FDA, the EMA and other comparable regulatory authorities could result in significant delays in and costs of our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of immunotherapies for clinical trials or commercial sale is subject to extensive regulation. GMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in our products and product candidates. Poor control of the GMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in loss of potential product sales revenue, cost overruns and delays to clinical timelines for our clinical programs, which could be extensive. Such production process issues include but are not limited to:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">critical deviations in the manufacturing process&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">facility and equipment failures&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">contamination of the product due to an ineffective quality control strategy&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">facility contamination as assessed by the facility and utility environmental monitoring program&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">ineffective process, equipment or analytical change management, resulting in failed lot release criteria&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">ineffective product stability&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">failed lot release or facility and utility quality control testing&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">failed or defective components or consumables.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must supply all necessary documentation in support of a BLA or other marketing authorization application on a timely basis and must adhere to the FDA&#8217;s, the EMA&#8217;s and other countries&#8217; GMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with GMPs and manufacturing controls as described in the filing. If either we or one of our third-party manufacturing sites fail to provide sufficient quality assurance or control, approval to continue delivery of our commercial product or to commercialize our product candidates may not be granted. Inspections by regulatory authorities may be announced or unannounced and may occur at any time during the development or commercialization phase. The inspections may be product-specific or facility-specific for broader GMP inspections, or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may result in adverse regulatory action, including the issuance of untitled or warning letters, which could influence our ability, or the ability of our third-party manufacturers or suppliers, to fulfill supply obligations, impacting or delaying supply or delaying programs. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including, but not limited to, clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our collaborators) and our overall business operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for any product is subject to the FDA&#8217;s, the EMA&#8217;s and other regulatory authorities&#8217; approval processes, and we may need to contract with manufacturers whom we believe can meet applicable regulatory authority requirements on an ongoing basis. If we or our third-party manufacturers are unable to reliably manufacture to specifications acceptable to the FDA, the EMA or other regulatory authorities, we or our collaborators may not obtain or maintain the approvals we or they need to release and deliver such products. Even if we or our collaborators obtain regulatory approval for any of our immunotherapies, there is no assurance that either we or our CMOs will be able to manufacture our product candidates to specifications acceptable to the FDA, the EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the foregoing could have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not have direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our CMOs are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our CMOs&#8217; facilities, and could result in the sanctions and other adverse outcomes described above. Our potential future dependence upon others for the manufacture of our products, product candidates and raw materials may adversely affect our future operating results and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the EMA and other regulatory authorities may require us to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other regulatory authorities may require that we do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our CMOs have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our own facilities or those of our third-party manufacturers could cause us and our collaborators to delay clinical trials, product launches or product supply, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">difficulties in maintaining compliance with applicable regulatory requirements. While we train and qualify all personnel around the appropriate handling of our products and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2764"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Reliance on Third Parties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties in the conduct of significant aspects of our preclinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties, such as CROs, clinical data management organizations, collaborators, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. Furthermore, we currently rely, and expect to continue to rely, on third parties to conduct certain research and preclinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA requires us to comply with GCP for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs are required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of preclinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We are also responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the regulatory authorities of the EU member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot be sure that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of GMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have designed, and in the future intend to design the clinical trials for certain of our product candidates, our collaborators will design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials results in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">have staffing difficulties&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">fail to comply with contractual obligations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">experience regulatory compliance issues&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">undergo changes in priorities or become financially distressed&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">form relationships with other entities, some of which may be our competitors&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">make human errors&#894; or</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">be subject to cyberattacks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform preclinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past, certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace. Each of the risks set forth above continues to be affected by the spread of COVID-19 globally, even as the virus begins to enter an endemic phase.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing collaborations, or any future collaboration arrangements that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop and commercialize our products and product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into collaborations under which our collaborators have provided, and may in the future provide, funding and other resources for developing and commercializing our products and product candidates. We expect to enter into additional collaborations to access additional funding, capabilities and/or expertise in the future. Our existing collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators may not perform or prioritize their obligations as expected&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the clinical trials conducted as part of such collaborations may not be successful&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators may not pursue development and commercialization of any product candidates and products that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the collaborators&#8217; focus or available funding (for example, we are aware that there have been allegations that Fosun International Ltd., an affiliate of our collaboration partner Fosun Pharma, is facing liquidity risks), or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">product candidates developed in collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in Germany or the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful development and commercialization of programs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty or other contingent payments, or otherwise yield the expected benefits under the collaborations. As a result, our development of product candidates and commercialization efforts could be delayed and we may need additional resources to develop and commercialize our product candidates. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this report apply to the activities of our collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research, development and commercialization plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and product development programs and the potential commercialization of any product candidates we develop alone or with collaborators will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Whether or not we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA or comparable regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current or future collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential collaborators. For example, we have granted exclusive rights or options to Pfizer for certain targets, and under the terms of our respective collaboration agreements with them, we will be restricted from granting rights to other parties to use our mRNA technology to pursue potential products that address those targets. Similarly, our collaboration agreements have in the past and may in the future contain non-competition provisions that could limit our ability to enter into collaborations with future collaborators.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to licenses that give us rights to third-party intellectual property, including patents and patent applications, that are necessary or useful for our business. In particular, we have obtained licenses from Acuitas Therapeutics, CellScript LLC and its affiliate, mRNA RiboTherapeutics, Inc., to patent rights claiming certain uses of modified RNA, as well as licenses from certain other parties for intellectual property useful in pharmaceutical formulations. We may enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute the patent applications we license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the scope of rights granted under the license agreement and other interpretation-related issues&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the priority of invention of patented technology; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">including amounts to be paid pursuant to certain program milestones being achieved or to royalty obligations, including the triggering of royalty obligations and amounts to be paid pursuant thereto.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, our co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to manufacture certain of our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect to continue using our own clinical manufacturing facilities where available, we also rely on outside vendors to manufacture supplies and process our product candidates. We only manufacture our COVID-19 vaccine on a commercial scale and may not be able to achieve commercial-scale manufacturing and processing for our other product candidates, if approved, and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for our product candidates, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may not be able to develop commercially viable products other than our COVID-19 vaccine.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on a limited number of CMOs exposes us to the following risks:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of regulatory authority questions, if any&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our CMOs might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">CMOs may not be able to execute our manufacturing procedures appropriately&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our future CMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the U.S. Drug Enforcement Administration and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over CMOs&#8217; compliance with these regulations and standards&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may not own, or may have to share, the intellectual property rights to any improvements made in the manufacturing process for our products&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our CMOs could breach or terminate their agreement with us&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our CMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, the approval, if any, of our COVID-19 vaccine or product candidates by the FDA or regulatory authorities in other jurisdictions or the commercialization of our COVID-19 vaccine or product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our COVID-19 or our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our collaborators currently rely on CMOs located outside of the United States to manufacture their clinical materials, and we expect to rely on CMOs located outside of the United States in the future. Such ex-U.S. CMOs may be subject to or affected by U.S. legislation, executive orders, regulations, or investigations, including but not limited to the proposed BIOSECURE Act, the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, sanctions, trade restrictions and other U.S. and other regulatory requirements, which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material, delay or impact clinical trials, have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies and adversely affect our financial condition and business prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on single source suppliers for some of the components and materials used in, and the processes required to develop, our COVID-19 vaccine and our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our COVID-19 vaccine and our product candidates. We cannot ensure that these suppliers or </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our COVID-19 vaccine and our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our COVID-19 vaccine and our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our COVID-19 vaccine and product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the FDA&#8217;s approval of our product candidates, we will also require FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single source suppliers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these suppliers, service providers and manufacturers subjects us to a number of risks that could harm our reputation, business and financial condition, including, among other things:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">delays to the development timelines for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a lack of long-term supply arrangements for key components with our suppliers&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">damage to our reputation caused by defective components produced by our suppliers&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2758"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to our Intellectual Property </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our COVID-19 vaccine or our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our COVID-19 vaccine and for our product candidates, proprietary technologies and their uses, as well as our ability to operate, develop, manufacture and commercialize our COVID-19 vaccine or one or more of our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and/or licensing patent applications in the European Union, the United States and elsewhere related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties&#8217; activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in other jurisdictions, including Europe, nor can we be certain that any claim in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our COVID-19 vaccine or our product candidates, or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that issued patents will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to apply for patents on certain aspects of our current or future products or product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even claims of issued patents may later be found invalid or unenforceable, or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our intellectual property and proprietary technology, competitors may be able to use our products, product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or collaborators will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our products or product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patenting process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">patent applications may not result in any patents being issued&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">claims of issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">other parties may have designed around our patent claims or developed technologies that may be related or competitive to our COVID-19 vaccine or to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent filings, either by claiming the same or overlapping methods, products, reagents, tools or devices or by claiming subject matter that could dominate one or more of our patent claims&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">any successful opposition to claims of any patents owned by or in-licensed to us could deprive us of rights necessary for the development and exploitation of our COVID-19 vaccine or our product candidates and other technologies, or the successful commercialization of any product candidates and other technologies that we may develop&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">because patent applications in the United States and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s)&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a court or other patent proceeding, such as an inter partes review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and/or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; existing legislation (for example, in the United States, the Public Readiness and Emergency Preparedness Act, etc.) may be interpreted, and new legislation may be passed, to permit third-party use of patented technologies relating to a public health concern, with little or no compensation to the patent holder(s)&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the U.S. Congress and in other jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as U.S. or EU laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, if any of these parties were to breach such agreements and improperly disclose such output before a patent application is filed, this could jeopardize our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring; for example, various third parties have filed opposition papers challenging our issued EP patent number 2714071, which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the claims of our issued EP patent 2714071 were upheld after opposition, there is currently a pending appeal against the opposition decision. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and/or term of patent protection of our products and product candidates and/ or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and/or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or our product(s) or product candidates, or which effectively prevent others from commercializing competitive technologies and products. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor&#8217;s or potential competitor&#8217;s product or service, and in some cases we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, patents or other intellectual property rights that we may be able to secure for our COVID-19 vaccine or our other COVID-19 vaccine candidates could be restricted or preempted if governments determine that they will not enforce, or will require compulsory licensing of, technologies useful to address the spread of COVID-19.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management, technical personnel, and other employees even if the eventual outcome is favorable to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product(s), our product candidates and other technologies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">any of our pending patent applications or those of our licensors may issue as patents&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own but that are not covered by the claims of the patents that we own or license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we will be able to successfully commercialize our products on a substantial scale, if approved, before the relevant patents that we own or license expire&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we, our co-owners or our licensors were the first to file patent applications for these inventions&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">others will not develop similar or alternative products or technologies that do not infringe the patents we own or license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">any of the claims of patents we own or license will be found to ultimately be valid and enforceable&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">a third party may not challenge the claims of patents we own or license and, if challenged, a court would hold that such patent claims are valid, enforceable and infringed&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may develop or in-license additional proprietary technologies that are patentable&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the patents of others will not have an adverse effect on our ability to issue patents, or otherwise on our business&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our competitors do not conduct research, development, testing or commercialization activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we will develop additional proprietary technologies, product(s) or product candidates that are separately patentable&#894; and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our, or our collaborators&#8217;, development and commercialization activities, including our manufacturing processes, or products will not infringe patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other companies or organizations may challenge our intellectual property rights or the intellectual property rights of our partners or may assert intellectual property rights that prevent us or our partners from developing and commercializing our COVID-19 vaccine or our product candidates and other technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We practice in new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and/or claim certain technologies, including products, reagents, formulations, tools and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, testing, manufacture and commercialization of therapeutic modalities and our delivery technologies, including lipid nanoparticles, or LNPs. If we, our co-owners or our licensors are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our products, product candidates and other technology and any other products, product candidates and technology that we may develop, our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the scientific fields mature, our known competitors and other third parties, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents, and they have filed and will continue to file patent applications claiming inventions in the fields in the United States and elsewhere. This may limit, interfere with or eliminate our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our partners&#8217; ability </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to make, use, sell, import or otherwise exploit our COVID-19 vaccine or our product candidates or other technologies. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our co-owners, our partners or our licensors may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. In the United States, the Leahy-Smith America Invents Act, or the America Invents Act, includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. We expect that our competitors and other third parties will institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. For example, various third parties have filed oppositions challenging our issued EP patent 2714071 which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the patent was upheld through the opposition proceedings, some of the opposing parties have appealed that decision.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we face ongoing COVID-19 vaccine-related patent litigation. Alnylam Pharmaceuticals Inc. has brought litigation against us and Pfizer regarding U.S. Patent Nos. 11,245,933; 11,382,979; 11,633,479; 11,633,480; 11,612,657; and 11,590,229, the latter five of which are continuations of the &#8216;933 Patent. In addition, CureVac SE initiated litigation against us regarding European patents 1857122B1 and 3708668B1 (EP&#8217;122 and EP&#8217;668 Patents), and three German utility models, or the CureVac IP, in Germany, and then a subsequent litigation was brought by us and Pfizer in the United States regarding U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493 that are &#8220;U.S. counterparts&#8221; to the CureVac IP. CureVac responded with counterclaims asserting infringement of seven additional U.S. patents, U.S. Patent Nos. 10,760,070; 11,286,492; 11,345,920; 11,471,525; 11,576,966; 11,596,686, and 11,667,910. BioNTech and Pfizer also initiated proceedings seeking the revocation of the EP&#8217;122 and EP&#8217;668 Patents in the Business and Property Courts of England and Wales.  In addition, BioNTech filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#8217;122 Patent is invalid, initiated cancellation actions against the CureVac IP in the German Patent and Trademark Office, and filed an opposition proceeding in the European Patent Office seeking the revocation of EP&#8217;668. CureVac initiated a second litigation against us in Germany regarding European patent EP4023755B1 (EP&#8217;755 Patent), and two Utility Models DE202021004123U1 and DE202021004130U1. BioNTech filed an opposition proceeding seeing the revocation of EP&#8217;755 and cancellation actions against DE&#8217;123 and DE&#8217;130. ModernaTX, Inc., or Moderna, has brought litigation against us and Pfizer regarding European patents 3590949B1 and 3718565B1 (EP&#8217;949 and EP&#8217;565 Patents) in Germany, England and Wales, the Netherlands, Ireland, and Belgium, and regarding U.S. Patent Nos. 10,898,574, </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,702,600, and 10,933,127 in the United States. BioNTech and Pfizer also initiated proceedings seeking the revocation of the EP&#8217;949 and EP&#8217;565 Patents in the Business and Property Courts of England and Wales and have filed opposition proceedings in the European Patent Office seeking the revocation of the EP&#8217;949 and EP&#8217;565 Patents. BioNTech and Pfizer have filed petitions for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review before the Patent Trial and Appeal Board in the U.S. with respect to U.S. Patent Nos. 10,702,600 and 10,933,127. Arbutus Biopharma Corp. and Genevant Sciences GmbH have brought litigation against us and Pfizer in the United States regarding U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098. Promosome initiated litigation against us and Pfizer in the United States regarding U.S. Patent No. 8,853,179; it has since been dismissed with prejudice. We cannot guarantee that we will not become subject to additional COVID-19 vaccine patent infringement lawsuits in the future.  In addition, should Pfizer not prevail in any of the ongoing COVID-19 vaccine patent infringement lawsuits to which it is a party, Pfizer may seek to require us to indemnify Pfizer for losses suffered therefrom as well as any losses from future COVID-19 vaccine patent infringement lawsuits in which it does not prevail. We believe we have strong defenses against each of these claims and intend to vigorously defend ourselves in each proceeding, but we can make no assurances regarding the ultimate outcome of any of these matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will continue to be subject to similar proceedings or priority disputes, including oppositions, in Europe or other jurisdictions relating to patents and patent applications in our portfolio.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our co-owners, our partners or our licensors are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technical personnel and other employees </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many issued and pending patent filings that claim aspects of technologies that we may need for our mRNA products or product candidates, or other product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for immunotherapies we wish to develop. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as evidenced by the lawsuits brought against Moderna, Pfizer and us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there may be additional issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for the development, manufacturing, testing and commercialization of our COVID-19 vaccine or of our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms, if we fail to invalidate relevant patents, or if a court or other governing body determines that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may be unable to perform research and development or other activities or market products covered by such patents, and we may need to cease the development, manufacture, testing and commercialization of one or more of the product candidates we may develop. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, and test product components and manufacturing processes for our development pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to certain intellectual property through our owned and in-licensed patents and other intellectual property rights relating to identification, development and testing of our product candidates or other technologies. As our activities may involve additional product candidates or services that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with academic institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or utilize services of CROs and CMOs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain aspects of our research or development under written agreements with these parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may not ensure protection of intellectual property rights in developed technology, or may fail to provide us with sufficient control of or access to such intellectual property rights. For example, agreements with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> these academic institutions typically provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies. CROs and/or CMOs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may control certain technologies that were utilized in and/or developed through work on our behalf, and may not pursue protection of such technologies, or may provide us with only non-exclusive rights in such technologies, so that relevant technologies may be shared with other parties including our competitors. In any relationship with a third party, there is a risk of disagreement over intellectual property rights (including inventorship or ownership of, rights to protect and/or enforce, and/or rights to use) in utilized or developed technologies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development and commercialization of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lifespans of our patents may not be sufficient to effectively protect our products or product candidates, technologies and business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most other jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO can also require, in certain circumstances, that the expiration date of a subject patent be shortened by the filing of a terminal disclaimer over one or more patents that may expire sooner than the subject patent. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a drug product subject to the provisions of the Hatch-Waxman Act</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we did not extend any patent for our COVID-19 vaccine. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are heavily reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product(s) or product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop, test, or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitive products in territories included in any or all of our licenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from, or that arises through collaboration with, such third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution (including preparation and filing) of our in-licensed intellectual property or of intellectual property developed through collaboration, is controlled solely by the licensor or collaborator. We may also require the agreement and/or cooperation of our licensors and collaborators to protect, enforce, utilize, or defend any in-licensed patent rights, and such agreement and/or cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our collaborators. If we and our licensors or collaborators disagree over IP protection strategies for relevant technologies, disputes may arise, and we could lose access to or control over protection of technologies important to our business. If so, we may not be able to adequately protect our product(s) or product candidates, including not being able to prevent a competitor or other third party from developing the same product(s) or product candidates for the same or a different use. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may disagree from time to time with licensors or collaborators regarding, among other things, the interpretation of each party&#8217;s obligations or the amounts payable under our agreements. For example, we are in ongoing discussions with the University of Pennsylvania and the National Institute of Health, or NIH, concerning royalties and other related amounts allegedly owed on sales of our COVID-19 vaccine since commercialization. We and the NIH have exchanged detailed characterizations of our positions and NIH has delivered a communication threatening to send a notice </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of default for breach of our agreement. While we disagree with the positions being taken by the University of Pennsylvania and NIH, the ultimate outcome of these matters is uncertain and we cannot guarantee that our interpretation of these license agreements will prevail, or that we will not ultimately need to pay some or all of the royalty and other related amounts in dispute.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to have failed to satisfy obligations or  materially breached  any of our agreements, such as licenses to third-party intellectual or any disagreements between us and our licensors, a licensor could potentially have the right or reason to terminate the license, to exercise the option of a non-exclusive license, which would allow our competitors to have access to the same intellectual property and technology licensed to us. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, including royalty payments, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which ev</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent we would not be able to develop, market and commercialize product(s) or product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop, test and commercialize the product(s) or product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are rightfully terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours, and our licensors may be able to seek additional judicial remedies. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to prevail with respect to any contractual disagreements could result in a material adverse effect on our competitive position, business, financial conditions, results of operations or prospects, particularly if discussions result in legal or other dispute resolution proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors fail to adequately protect this intellectual property, our ability to develop, test, market and commercialize our product(s) or product candidates could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop, test, market and commercialize the affected product(s) or product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our in-licensed intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights and certain reporting requirements, and compliance with such regulations may limit our exclusive rights and our ability to contract with manufacturers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain intellectual property rights that have been in-licensed, including patent applications and patents that we in-license from the University of Pennsylvania, the Louisiana State University, the Broad Institute, the NIH, Genevant, and Cellscript, have been generated through the use of U.S. government funding and are therefore subject to certain federal regulations. The U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or the Bayh-Dole Act. These U.S. government rights may include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions covered by that Act for any governmental purpose. In addition, the U.S. government may have the right, under certain limited circumstances, to require the licensor to grant exclusive, partially exclusive or non-exclusive licenses to any of these inventions to a third party if it determines that (i) adequate steps have not been taken to commercialize the invention, (ii) government action is necessary to meet public health or safety needs or (iii) government action is necessary to meet requirements for public use under federal regulations (also collectively referred to as &#8220;march-in rights&#8221;). The U.S. government may also have the right to take title to these inventions if the licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any products embodying any such inventions or produced through the use of any such inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture the products substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. We may not be able to obtain a waiver of this preference for U.S. industry, and this preference may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our owned or in-licensed future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. If we or our licensors are unable to secure an exemption to these manufacturing requirements, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if we comply with them, or if we are unable to comply with them, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may experience a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current proprietary position for certain products and product candidates depends upon our owned or in-licensed patent filings covering components, manufacturing-related methods, formulations and/or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have pursued or obtained patent protection covering components of certain product candidates and tests, manufacturing-related methods, formulations and/or methods of use, we have not yet obtained patent protection for all components of certain product candidates and tests, manufacturing-related methods, formulations and/or methods of use. For instance, we do not currently have any claims in our owned or in-licensed issued U.S. patents that cover the overall construct used in our iNeST product candidates. &#160;We also cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter, tests, manufacturing-related methods, formulations and/or methods of use of our current or future product candidates. Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, testing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or abroad. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights of third parties could adversely affect our ability to commercialize our product(s) and product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop, test or market our product(s) and product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our products and product candidates are still in early stages of development, testing or commercialization, and one or more features of the products or product candidates, or related technologies such as their manufacture, formulation, testing or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize.  Furthermore, even if all aspects of our product(s) or product candidates, or of other technology, were known, it is possible that third-party intellectual property, which may or may not currently be public, could develop in a manner (for example, through issuance of additional patents) that could impede our ability to make or use relevant products or product candidates, or other technology. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will impede or preclude our ability to commercialize products. Furthermore, while U.S. patent laws provide a &#8220;safe harbor&#8221; to our clinical product candidates under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when an NDA or BLA is submitted. Accordingly, after such submission (including for certain formulations of our COVID-19 vaccine), the 271(e)(1) safe harbor may no longer provide the same level of protection from third party patent infringement claims for that product. We may become exposed to lawsuits from third parties who consider our COVID-19 vaccine to infringe their patents. More generally, given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we might want to submit an NDA or BLA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more third parties may have issued patent claims that cover such products or critical features of their production, testing or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture, testing or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop, test or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly, licenses could not be available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, with respect to our products, product candidates and related technologies that may play a role in addressing a pandemic or other public health emergency, it is unclear whether governments around the world will protect vaccine manufacturers for liability from infringement of third party intellectual property, at least during the period of such public health emergency. Thus, it is possible that third parties may assert intellectual property rights against us relating to our COVID-19 vaccine, and that we will not be successful in arguing that commercialization of our COVID-19 vaccine is exempted from infringement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and/or liability for infringement </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(for example, under 35 U.S.C. &#167; 271(e)(1), discussed above, or under the Public Readiness and Emergency Preparedness Act, or the PREP Act, etc.).  Furthermore, even if such commercialization was deemed protected from infringement during the period of the pandemic crisis, now that various global and U.S. agencies have declared an end to the global COVID-19 public health emergency, any such exemption may be terminated so that continuing commercialization could expose us to liability, and might even be precluded if third party(ies) who hold relevant intellectual property rights are able to secure injunction(s) or are unwilling to license to us on commercially feasible terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platform or product(s) and product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18 months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platform or product candidates over time, and we might not be aware that such amendment had been made.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits or other legal proceedings to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party&#8217;s intellectual property, each of which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-U.S. patent offices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties. We have a number of opposition proceedings ongoing at the European Patent Office against third-party patents related to mRNA technologies; also, multiple oppositions have been filed against our EP patent number 2714071, which relates to our iNeST product candidates, and whose claims recite steps relating to neoantigen selection. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the claims of our issued EP patent 2714071 were upheld after opposition, there is currently an appeal pending. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products, product candidates and services may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a patent infringement proceeding, our owned or in-licensed patents may be challenged and a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product(s) and/or product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement or written description. Grounds for an </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-U.S. patent offices and may result in the revocation, cancellation or amendment of any ex-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we could lose at least part, and perhaps all, of the patent protection on a product and/or product candidate. Such a loss of patent protection would have a material adverse impact on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, testing, methods of manufacture or methods for treatment related to the use, development, testing, manufacture or commercialization of our COVID-19 vaccine or product candidates. For example, BioNTech SE and certain of our wholly owned subsidiaries are defendants in litigations initiated by CureVac SE, Alnylam Pharmaceuticals, Inc., ModernaTX, Inc., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corp. and Genevant Sciences GmbH</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regarding </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See &#8220;Legal Proceedings.&#8221; As patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product(s) and/or product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the testing or manufacturing processes of any of our product(s) and/or product candidates, any molecules formed during the testing and manufacturing processes or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop, test and commercialize such product and/or product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for testing or manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop, test and commercialize the applicable product and/or product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non-exclusive.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds we need to continue our clinical trials and research programs, to license necessary technology from third parties or to enter into development or manufacturing collaborations that would help us bring our product(s) and/or product candidates to market.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our management, technical personnel and other employees from their normal responsibilities. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of our competitors may be able to sustain the costs of such proceedings more effectively than we can because of their greater resources </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in one or more aspects, or for other reasons</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product(s) and/or product candidates, which could limit our ability to generate revenues or achieve or maintain profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our collaborators to third parties for licenses to such third parties&#8217; intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with certain license and collaboration agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, the price of the ADSs representing our ordinary shares could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies&#894; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biotechnology companies, our success is heavily dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that have affected the way patent applications are prosecuted and also affect patent litigation. Such legislation and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decisions by courts and governmental bodies in the United States and other jurisdictions may affect the value of patent applications, issued patents or other intellectual property that we own or in-license.  For example, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USPTO and other administrative agencies,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for some of our technology, product(s) and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development, testing, manufacturing and commercialization </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite our best efforts, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Any of these parties who may have access to our trade secrets, know-how and other proprietary technology may breach such agreements or orders. For example, a former employee of our COVID-19 vaccine collaborator, Pfizer, has reportedly misappropriated trade secrets on our COVID-19 vaccine. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. In addition, we cannot be certain that our proprietary technical information and related confidential documents that we have shared with our collaborators and/or have submitted to governmental agencies including regulatory agencies for evaluation and supervision of pharmaceutical products will be kept confidential. For example, certain documents relating to our COVID-19 vaccine were unlawfully accessed after a cyberattack on the EMA in December 2020. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, including alleged trade secrets of their former employers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual&#8217;s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, technical personnel and other employees</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Claims that we or our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may be subject to claims that current or former employees, consultants, independent contractors, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, collaborators and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. In addition, certain such agreements, even if successfully executed may distribute ownership or control of intellectual property rights between or among parties, for example based on subject matter, relationship to other intellectual property, and/or one or more aspects of development of the intellectual property; after the agreements are in place disputes may arise over such distribution principles or over proper treatment of particular developed intellectual property in accordance with them. Disagreements may be difficult or impossible to resolve, may be expensive to address, and may result in our failing to secure or maintain ownership in or control of intellectual property necessary or important to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants, independent contractors, collaborators or other third parties who are involved in developing and commercializing our product(s) and/or product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, operating results and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management, technical personnel and other employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the laws of some other countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the U.S. laws. A majority of our employees work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees are subject to the provisions of the German Act on Employees&#8217; Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act that may be costly to defend and take up our management&#8217;s, technical personnel&#8217;s and other employees&#8217; time and efforts whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who assign patents to us may be deemed to be insufficient and we may be required under German law to increase the compensation due to such employees for the use of the patents. In those cases, where employees&#8217; rights have not been assigned to us, we may need to pay compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the German Act on Employees&#8217; Inventions, our business, results of operations and financial condition could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product(s) and/or product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States, particularly those in Asia, including China, can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Germany and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States to the same extent as within the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product(s) and/or product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions, particularly outside of Europe and the United States. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement, misappropriation or other violation of our patents and other intellectual property or development, testing, marketing and commercialization of competing products in violation of our owned or in-licensed intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. In particular, the validity, enforceability and scope of protection of intellectual property in China, where we derive net sales and maintain collaboration partnership including licensing, are still evolving and historically, have not protected and may not protect in the future, intellectual property rights to the same extent as laws developed in Europe, including Germany, and the United States. Consequently, the time required to enforce our intellectual property rights in the legal regime of China may be lengthy and delay our recovery.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or collaborators may fail to use our trade names or trademarks appropriately or at all</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and collaborators</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or failure to use</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks, and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">others may be able to make COVID-19 vaccines or therapies, and/or personalized cancer immunotherapies that are similar to our COVID-19 vaccine and/or any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we, our co-owners or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we, our co-owners or our licensors or future collaborators might not have been the first to file patent applications covering certain of our or their inventions&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">claims of issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may not develop additional proprietary technologies that are patentable&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the patents of others may have an adverse effect on our business&#894; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2752"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administration of some of our product candidates may require the use of immuno-assays and bioinformatic tools in which patients are screened for optimal target antigens of our product candidates. If safe and effective use of a biologic product depends on an in vitro diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several years, simultaneously with approval of the biologic product. Similarly, in the European Union, an in vitro companion diagnostic may be placed on the market only if it conforms to certain &#8220;essential requirements&#8221; and bears the Conformit&#233; Europ&#233;ene Mark, or CE Mark. The conformity assessment process to obtain the CE Mark can be lengthy and we may fail to demonstrate such conformity. Further, the applicable regulatory framework for in vitro diagnostics in the EU changed in May 2022 when a new EU regulation with stricter regulatory requirements for in vitro diagnostics became applicable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our individualized immunotherapy candidates, the FDA and comparable regulatory authorities outside of the United States may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require PMA supplemental approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing companion diagnostics and plan to rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our individualized therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our individualized therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are developing some of our product candidates for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we may address in the future. For instance, we and our collaborators are applying our technology to develop therapeutics in indications such as certain rare diseases, including some for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain rare diseases may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other jurisdictions may make similar findings with respect to these endpoints.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, the EMA or other comparable regulatory authorities may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the results of our clinical trials are sufficiently compelling, we or our collaborators intend to discuss with the FDA and regulatory authorities in other countries the submission of a BLA or respective applications in other countries for our product candidates. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA for any of our product candidates. The FDA, the EMA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, the EMA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, the EMA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, the EMA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the FDA, the EMA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the FDA, the EMA or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA or comparable regulatory authorities to support the submission of a BLA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the FDA, the EMA or comparable regulatory authorities will inspect our manufacturing facilities and may not approve our facilities or our manufacturing processes and controls&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the approval policies or regulations of the FDA, the EMA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of the member states of the European Union or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we expect, and even if we are able to, one or more of these regulatory authorities may not permit us to proceed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of filing on our product candidates is dependent on further preclinical, clinical and manufacturing success. We cannot be sure that submission of an IND or IND amendment with the FDA, a clinical trial application with the regulatory authorities of the EU member states or similar application with other comparable regulatory authorities will result in the FDA, the regulatory authorities of the EU member states or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes filing for orphan drug designation where available for our product candidates. Under the U.S. Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union with respect to drugs or biologics designated as orphan medicinal products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not protect the product effectively from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union with respect to drugs or biologics designated as orphan medicinal products. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek orphan drug designation for our product candidates, we may never receive such designations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek breakthrough therapy or fast-track designation for one or more of our product candidates, but we may not receive such designations. Even if we do, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek a breakthrough therapy designation in the United States for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek Fast Track Designation in the United States for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broad discretion whether or not to grant this designation, and even if we believe a particular product candidate is eligible for this designation, we cannot be sure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect some of the product candidates we develop will be regulated as biologics in the United States and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our product candidates are classified as gene therapies by the FDA and the EMA, and the FDA has indicated that our product candidates will be reviewed within its Center for Biologics Evaluation and Research, or CBER. Even though our mRNA product candidates are designed to have a different mechanism of action from gene therapies, the association of our product candidates with gene therapies could result in increased regulatory burdens, impair the reputation of our product candidates, or negatively impact our platform or our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been few approvals of gene therapy products in the United States and other jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Gene therapy products have the effect of introducing new DNA and potentially irreversibly changing the DNA in a cell. In contrast, mRNA is highly unlikely to localize to the nucleus, be reverse transcribed or integrated into the genome. Consequently, we expect that our products or product candidates will have a different potential side effect profile from gene therapies because they lack risks associated with altering cell DNA irreversibly. Further, we may avail ourselves of ways of mitigating side effects in developing our products and product candidates to address safety concerns that are not available to other products or product candidates classified as gene therapies, such as lowering the dose of our products or product candidates during repeat dosing or stopping treatment to potentially ameliorate undesirable side effects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies is unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the European Union, mRNA has been characterized as a gene therapy medicinal product. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us. Notwithstanding the differences between our mRNA product candidates and gene therapies, the classification of some of our mRNA product candidates as gene therapies in the United States, the European Union and potentially other counties could adversely impact our ability to develop our product candidates, and could negatively impact our platform and our business. For instance, a potential future clinical hold on gene therapy products across the field due to risks associated with altering cell DNA irreversibly could apply to our mRNA product candidates irrespective of the mechanistic differences between gene therapies and mRNA.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events reported with respect to gene therapies or genome editing therapies could adversely impact one or more of our programs. Although our mRNA product candidates are designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapy products caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our approved mRNA products or investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may have a negative effect on our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory landscape that will govern our product candidates is uncertain. Regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory requirements to which our product candidates will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies, or CAT, was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As the regulatory landscape for our CAR-T-cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product sales revenue to maintain our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to market our products or product candidates in any other jurisdiction, we must establish </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union and other jurisdictions&#8217; regulatory approval processes involve all of the risks associated with the FDA approval. If we fail to comply with regulatory requirements in certain markets or to obtain and maintain required approvals, or if regulatory approvals in certain markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions may have submission requirements for drug clinical trial and marketing applications that require us or our partners to submit substantial detailed materials related to non-clinical and clinical development and manufacturing and quality control to drug regulators or testing laboratories. This can include executed batch records for the production of biological products or other records or documents that set forth detailed information about the manufacturing process. If these records are disclosed, lost, or diverted to third parties or competitors during the application preparation process, this could negatively affect our ability to protect our intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners in different countries are subject to local regulatory requirements on the manufacturing and distribution of drugs and the implementation of clinical and non-clinical research. These include but are not limited to good manufacturing, distribution, laboratory, and clinical practice rules. If these companies do not comply with applicable standards, they could become the subjects of investigations and enforcement, including orders to cease the activities pending remediation that is acceptable to the government. Such an order or other similar enforcement could interfere with our clinical development activities both in that jurisdiction and others, if it impacts supply or the quality and transfer of data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A third-party investigational product candidate used in combination with our product candidates may be unable to obtain regulatory approval, which may delay commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing several of our product candidates to be used in combination with our and third-party product candidates. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing products, we would continue to be subject to the risks that the FDA, the EMA or comparable regulatory authorities in other jurisdictions could revoke approval of the product used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing products. If the products or product candidates we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, the EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. We also plan to evaluate current and future product candidates in combination with one or more product candidates that have not yet been approved for marketing by the FDA, the EMA or comparable regulatory authorities in other jurisdictions. We will not be able to market any product candidate we develop in combination with an unapproved product candidate if that unapproved product candidate does not ultimately obtain marketing approval. In addition, unapproved product candidates face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA, EMA or comparable regulatory authority approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA, the EMA or comparable regulatory authorities in other jurisdictions do not approve these other product candidates or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the products or product candidates we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval of or market any product candidate we develop.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our COVID-19 vaccine and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">we fail to comply with regulatory requirements or experience unanticipated problems with our products or product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any other product candidates for which we receive approval or emergency use authorization are subject to continuing regulatory oversight, including the review of additional safety information, and the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar requirements apply to holders of (conditional) approvals in other countries. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In other countries, advertising and promotional material may be subject to similar rules.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">issue a warning letter asserting that we are in violation of the law&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">seek an injunction or impose civil or criminal penalties or monetary fines&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">suspend or withdraw regulatory approval or revoke a license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">suspend any ongoing clinical studies&#894; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">refuse to approve a pending BLA (or comparable approval) or supplements to a BLA (or comparable approval) submitted by us&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">seize product&#894; or</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our products or product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences following any potential marketing approval. Products or product candidates we may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our products or product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates, if approved, may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following regulatory approval of a product candidate, the FDA or other regulatory authority could require us to adopt a REMS or a risk management plan, or RMP, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including:</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">regulatory authorities may suspend or withdraw approvals or revoke licenses of such product&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">regulatory authorities may require additional warnings on the label&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we may be required to change the way a product is administered or conduct additional clinical trials&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">we could be sued and held liable for harm caused to patients and their children&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the successful approval of a product candidate, we will continue to face significant regulatory oversight of its manufacturing and distribution. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and adherence to commitments made in the BLA or comparable approval. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to additional healthcare regulation and enforcement by the U.S. federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business. Our operations may be directly, or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">e.g.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, public or private);</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">U.S. state law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents, as well as non-U.S. companies that are registered with the SEC, from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Similar statutes, healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union member states and other jurisdictions, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as &#8220;trade laws,&#8221; prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other collaborators from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or collaborators, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as &#8220;data processing&#8221;, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal data in the European Union had previously been governed by the provisions of the EU Data Protection Directive, which EU member states were required to implement. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that targets goods or services to residents in the European Union or that &#8220;monitors&#8221; their behavior in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#8220;sensitive information&#8221; which includes health and genetic information of patients residing in the European Union. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we are located in the European Union, we are subject to the GDPR. Additionally, as the GDPR applies extraterritorially, we are also subject to the GDPR even where our data processing activities occur outside of the European Union if such activities involve the personal data of individuals located in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the above-mentioned applicable law triggers apply. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. In particular, in China, where some of our clinical data are originated, the cybersecurity, data privacy, data protection, or other data-related laws and regulations, including the Human Genetic Resources Regulation (which now only regulates transfer human genetic data generated in clinical research to foreign or foreign controlled parties), are relatively new and evolving, and their interpretation and application may be uncertain. In the United States, we may be subject to restrictions and requirements under the Executive Order on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern, signed on February 28, 2024. Practices regarding the collection, use, storage, transmission and security of personal information by companies have also been subject to increasing regulatory focus. As such, we cannot assure you that we will be compliant with such new regulations in all respects, and we may be ordered to rectify and terminate any actions that are deemed illegal by the government authorities and become subject to fines and other government sanctions, which may materially and adversely affect our business, financial condition, and results of operations. In addition, the uncertainties regarding further interpretation and implementation of these laws and regulations may adversely affect the secure storage of documented work as well as the cross-border transfer of important data and personal information originated from our clinical trial activities, which are critical to the development of our pipelines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR and other international data protection regulations, especially with regard to clinical trial activities. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated, as enforcement practices vary from country to country. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the EU member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which can result in monetary penalties of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, as well as regulatory penalties. In many jurisdictions, there are legal requirements to provide notice of breaches to affected individuals and/or regulators in certain circumstances. Such a notice could harm our reputation and our ability to compete. Regulators may also have the discretion to impose penalties without attempting to resolve violations through informal means. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2746"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Ownership of the ADSs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced and may continue to experience significant volatility in the market price of the ADSs representing our ordinary shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical companies such as BioNTech SE that are developing potential therapeutics and vaccines to combat COVID-19, as well as conducting mRNA-based research in oncology and infectious disease more generally, have experienced significant volatility in the price of their securities upon publication of preclinical and clinical data as well as news about their development programs and commercialization activities. For example, during 2023, the closing sales price of the ADSs representing our ordinary shares on the Nasdaq Global Select Market ranged from $88.00 to $156.28, with significant volatility occurring, for example, shortly after announcements by us or others related to regulatory matters, to our COVID-19 vaccine, to other COVID-19 vaccines, to development and commercialization pipelines in oncology and infectious disease, and to our transactions with third parties. Additionally, we have observed the trading price of the ADSs respond significantly to news and statements by us, government agencies, other vaccine developers, financial analysts or others relating to our business as well as to other COVID-19 vaccines and COVID-19 therapeutics and the spread of COVID-19 generally, even in cases in which we believe the news does not affect our business or vaccine specifically. Given the attention being paid to COVID-19 worldwide and the public scrutiny of COVID-19 development and commercialization announcements, and given that our COVID-19 vaccine is currently among the primary vaccines being used worldwide, any news regarding manufacturing, supply and distribution of our COVID-19 vaccine or unanticipated side effects of our COVID-19 vaccine, whether or not accurate, will attract significant attention and scrutiny and, as a result, the price of the ADSs representing our ordinary shares likely will continue to be volatile. In addition, volatility in the overall market and in the market price of a particular company&#8217;s securities can result in securities litigation, including shareholder class action lawsuits. Any securities litigation can result in substantial costs and a diversion of our management&#8217;s attention and resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, joint ventures and collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">increased operating expenses and cash requirements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the assumption of additional indebtedness or contingent liabilities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals&#894; and</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in July 2023, we acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> InstaDeep, a leading global technology company in the field of AI and machine learning, for upfront consideration of cash and BioNTech shares, and potential future milestone payments. Although we believe that AI and machine learning technology has the potential to accelerate the development of therapeutic programs and further optimize manufacturing and supply chain processes, it is possible that our use of the acquired technology will not achieve the desired results, and that we will not be able to retain and grow InstaDeep&#8217;s business around the world. If demand for the services developed by InstaDeep does not continue, or if we are unable to improve our AI and machine learning technology in a timely, effective and competitive manner, we may not be able realize the expected outcomes from the InstaDeep acquisition. There is no guarantee that we will realize any anticipated benefits of this or future acquisitions, or that the diversification of our business through acquired technology or products will be successful. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Articles of Association designate specific courts in the United States as the exclusive forum for certain U.S. litigation that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association provide that the United States District Court for the Southern District of New York shall be the competent court of jurisdiction for the resolution of any litigation on the grounds of or in connection with U.S. federal or state capital market laws. In the absence of these provisions, under the Securities Act of 1933, as amended, or the Securities Act, U.S. federal and state courts have been found to have concurrent jurisdiction over suits brought to enforce duties or liabilities created by the Securities Act. This choice of forum provision will not apply to suits brought to enforce duties or liabilities created by the Securities Exchange Act of 1934, as amended, which already provides that such federal district courts have exclusive jurisdictions over such suits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The choice of forum provision contained in our Articles of Association may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our executive officers, directors, or other employees, or impose additional litigation costs on shareholders in pursuing any such claims, particularly if the shareholders do not reside in or near the state of New York, which may discourage such lawsuits. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other U.S. or German courts will enforce our choice of forum provision. The enforceability of similar choice of forum provisions in other companies&#8217; governing documents has been challenged in recent legal proceedings, and it is possible that a court in the relevant jurisdictions with respect to us could find the choice of forum provision contained our Articles of Association to be inapplicable or unenforceable. If the relevant court were to find the choice of forum provision contained in our articles of association to be inapplicable or unenforceable, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition and operating results. The choice of forum provision may also impose additional litigation costs on shareholders who assert that the provision is not enforceable or invalid. The United States District Court for the Southern District of New York may also reach different judgments or results than would other courts, including courts where a shareholder considering a U.S.-based action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our shareholders.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of the ADSs may not be able to participate in any future preemptive subscription rights issues or elect to receive dividends in shares, which may cause additional dilution to their holdings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, the existing shareholders of a company generally have a preemptive right in proportion to the amount of shares they hold in connection with any issuance of ordinary shares, convertible bonds, bonds with warrants, profit participation rights and participating bonds. However, our shareholders in a shareholders&#8217; meeting may vote, by a majority representing at least three-quarters of the share capital represented at the meeting, to waive this preemptive right provided that, from the company&#8217;s perspective, there exists good and objective cause for such waiver.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement provides that the depositary need not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our future rights offerings and may experience dilution in their holdings. For example, ADS holders were unable to participate in our summer 2020 rights offering. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount and frequency of our dividends and ADS repurchases may fluctuate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, timing and execution of any ADS repurchase program we conduct in the future and the amount and timing of any dividends we pay may fluctuate based on our priorities for the use of cash for other purposes, and any ADS repurchases would be subject to the parameters contained in the applicable repurchase plan. These purposes may include operational spending, capital spending, acquisitions and repayment of debt. Additionally, we may choose to repurchase ADSs so that such ADSs may be used to settle outstanding and future equity awards granted to our employees. Changes in cash flows, tax laws and the price of the ADSs could also impact any ADS repurchase program. Additionally, we may enter into a Rule 10b5-1 trading plan governing the repurchases, and if we do, we would have no discretion over the particular purchases made and would only be able to set minimum price floors and maximum ADS count ceilings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal shareholders and management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, five percent shareholders, and their affiliates beneficially own a majority of our ordinary shares (including ordinary shares represented by ADSs) as of December 31, 2023, and will have the ability to influence us through their ownership positions. For example, these shareholders, acting together, may be able to exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that shareholders may believe are in their best interest. Such insiders may also act in concert to waive rights to participate in rights offerings, as was done in our summer 2020 rights offering, which would have the effect of permitting the ADSs or shares underlying such waived rights to be offered to the public in an underwritten offering without contravening German law pricing requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed registration statements on Form S-8 under the Securities Act to register all ordinary shares issued or issuable under our equity plans. Such Form S-8 registration statements have become, and any other registration statements on Form S-8 we file in the future will become, effective upon filing, upon which shares registered under such registration statements become available for sale in the open market.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain sales of ADSs or our ordinary shares that we have made have included, and we may in the future make sales including, holding period restrictions or registration rights. Sales of ADSs or our ordinary shares as restrictions end or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult to sell the ADSs on favorable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are a &#8220;passive foreign investment company&#8221; for U.S. federal income tax purposes, there may be adverse U.S. federal income tax consequences to U.S. investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our income and assets, we believe that we should be treated as a PFIC for the preceding taxable year. However, the determination of our PFIC status is made annually based on the factual tests described below. Consequently, while we may be a PFIC in future years, we cannot estimate with certainty at this stage whether or not we are likely to be treated as a PFIC in the current taxable year or any future taxable years. Generally, if, for any taxable year, at least 75 percent of our gross income is &#8220;passive income&#8221; or at least 50 percent of our gross assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period) are assets that produce or are held for the production of passive income, we will be characterized as a PFIC for U.S. federal income tax purposes. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. However, rents and royalties received from unrelated parties in connection with the active conduct of a trade or business should not be considered </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">passive income for purposes of the PFIC test. For example, if we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. Holder (as defined in &#8220;Taxation &#8212;Material United States federal income tax considerations&#8221;) holds ordinary shares or ADSs, such U.S. Holder could be subject to additional taxes and interest charges upon certain distributions by us and any gain recognized on a sale, exchange or other disposition of our shares, whether or not we continue to be characterized as a PFIC. Certain adverse consequences of PFIC status can be mitigated if a U.S. Holder makes a &#8220;mark to market&#8221; election or a &#8220;Qualified Electing Fund&#8221; (QEF) election. We intend to provide U.S. holders with the information necessary to make and maintain a QEF election for any taxable year in which we are treated as a PFIC. See &#8220;Taxation &#8212;Material United States federal income tax considerations &#8212;Passive foreign investment company considerations.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition and value of our assets from time to time. Each U.S. Holder is strongly urged to consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2736"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 4. Information on the Company</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2730"></div><div style="margin-top:6pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. History and Development of the Company</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. Scientific rigor, innovation and passion are our driving forces. BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded and incorporated on June 2, 2008 as Petersberg 91, V AG, a German stock corporation (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesellschaft</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We changed our name to BioNTech AG on December 11, 2008. On March 8, 2019, we converted to a European stock corporation (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Societas Europaea</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SE</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) under the laws of Germany and the European Union called BioNTech SE. We completed our initial public offering in October 2019. ADSs representing our ordinary shares are currently listed on the Nasdaq Global Select Market under the symbol &#8220;BNTX&#8221;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service of solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c/o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2708"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:0.12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Business Overview</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2702"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I. Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical needs and major global health burdens. Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence (AI) and machine learning (ML) capabilities to discover, develop and commercialize our marketed products and product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a broad toolkit across</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigational</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> messenger ribonucleic acid, or mRNA vaccines, protein-based therapeutics (including targeted antibodies such as monoclonal, bispecific and antibody-drug conjugates, or ADCs), cell therapies and small molecules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect each platform to yield a pipeline of product candidates for further development. Our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases. We aim to expand this status into other disease areas in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we endeavor to address the continuum of cancer patients. The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient&#8217;s cancer is different and within one patient&#8217;s tumor, every cell is different. Addressing these two challenges is the core of our strategy. To augment anti-tumor activity and to counteract resistance mechanisms we seek to combine compounds with non-overlapping, synergistic mechanisms of action.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In infectious disease, our product strategy is rooted in global social responsibility and our goal of contributing to equitable access to medicine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach has generated a robust and diversified product pipeline across a range of technologies in oncology and infectious disease,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and has led to the approval of our first marketed product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3086"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">II. The BioNTech Approach</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our  key objectives are to build a sustainable respiratory infectious disease vaccine business based on the BioNTech-Pfizer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> franchise and to develop an innovative precision medicine pipeline targeting multiple product approvals in the coming years. We are uniquely positioned to pursue our objectives by leveraging our technology agnostic approach rooted in decades of research in immunology coupled with expertise in emerging mRNA technologies. Our vision is to establish a multi-product company based on our pioneering technologies and science to contribute to improving the health of people worldwide.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology Pipeline Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is one of the biggest medical challenges of humankind. Genetic and phenotypic heterogeneity, the tumor microenvironment and immune diversity make cancer a complex and heterogeneous disease. Our long-term oncology vision is to expand the number of available treatment options for cancer patients. We aim to address the full continuum of cancer treatment by developing novel therapies to best serve the needs of cancer patients from adjuvant to late-stage settings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding, we have been a multi-technology company. We believe that by combining complementary treatment modalities, we can leverage the potential of each technology to provide precise and personalized treatments to patients. Such treatments, if approved, could both increase the likelihood of therapeutic success and reduce the risk of therapeutic resistance. By building a diverse toolkit and clinical portfolio with synergistic mechanisms of action we aim to exploit the potential of our technologies:</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Immunomodulators.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are building a modality agnostic toolkit to focus on crucial immuno-oncology pathways. We target different but complementary players in the complex cancer immunity cycle to promote a thorough and durable antitumor effect. We use our in-house capabilities and collaborate with Genmab A/S, or Genmab, OncoC4, Inc., or OncoC4, and Biotheus Inc., or Biotheus, to develop next-generation immunomodulators that are designed to modulate the patient&#8217;s immune response to cancer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Targeted Therapies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We aim to develop potent and precise therapies that could reduce tumor burden across the entire disease continuum, including late lines. In 2023, we expanded our targeted therapy portfolio by adding several next-generation ADCs to our clinical pipeline through collaborations with Duality Biologics (Suzhou) Co. Ltd., or DualityBio, and MediLink Therapeutics (Suzhou) Co.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ltd., or MediLink Therapeutics. ADCs will transform cancer care. We believe they have the potential to supplement or replace chemotherapy in the future. We believe that a differentiated ADC linker technology could improve efficacy and safety compared to currently approved ADCs, and novel mechanisms of action may be able to improve tumor specific activation. We are also developing a range of cell therapies against solid tumors, including chimeric antigen receptor, or CAR-T cell therapies, neoantigen-based T-cell therapies and T-cell receptor, or TCR therapies in which the patient&#8217;s T cells are modified or primed to target cancer-specific antigens. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.53pt">mRNA Vaccines and mRNA Therapeutics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are developing a portfolio of mRNA-based therapeutic candidates to treat cancer: cancer vaccine candidates, including FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fully-owned) and iNeST (in collaboration with Genentech, Inc., a member of the Roche group, or Genentech), and mRNA-encoded cytokines and antibodies. We believe that mRNA cancer vaccine candidates, if successful, could have the potential to eliminate polyclonal residual disease by targeting multiple antigens at once for potential long-term impact.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue building our oncology pipeline in 2024 in anticipation of potential commercial oncology launches as soon as 2026, if approved. We aim to have ten indication approvals by 2030.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infectious Disease Pipeline Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious diseases remain among the leading causes of death and disability worldwide: in 2019, an estimated 13.7 million lives were lost to infectious diseases globally. Low- and middle-income countries continue to bear much of the burden of communicable diseases, which include tuberculosis, human immunodeficiency virus, or HIV, malaria, neglected tropical diseases and hepatitis B. Climate change, rising population numbers and global travel may all contribute to an increased risk of global infectious disease outbreaks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to advance and expand our infectious disease programs by developing vaccines and therapeutics for infectious diseases caused by respiratory viruses, latent viruses, bacteria and parasites. We believe our scientific approach and our mRNA technology have the potential to significantly contribute to the fight against global health threats caused by infectious diseases. We have pursued both strategic partnerships and corporate collaborations to partially fund our infectious disease global health programs. Our infectious disease programs aim to contribute to equitable access to effective and well tolerated vaccines for high medical need indications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to build a sustainable respiratory vaccine business, leveraging our COVID-19 vaccine franchise for potential combination vaccines. We expect seasonal COVID-19 vaccination to continue, driven by the continuous evolution of the virus. We are also evaluating combination vaccine candidates addressing additional respiratory diseases in collaboration with Pfizer Inc., or Pfizer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are committed to developing product candidates against latent viruses, including herpes-simplex virus (HSV) and varicella-zoster virus (shingles). Latent viruses remain in the body after an infection and can lead to lifelong medical complications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have ongoing trials evaluating mRNA vaccine candidates against diseases caused by bacteria (tuberculosis) and parasites (malaria).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Longer term, we see potential applications for our technologies beyond oncology and infectious disease, including autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, and regenerative medicines.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_141836999987072"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">III. Execution in 2023</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we executed across our four key strategic pillars to strengthen our technology platforms, digital capabilities and infrastructure, through strategic investments, acquisitions, licensing agreements and public-private partnerships impacting patients, shareholders and other stakeholders.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Leadership in COVID-19 Vaccine Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to build our COVID-19 vaccine franchise and maintained market leadership in multiple key geographies. In 2023, we and Pfizer distributed over 460 million total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">doses, of which over 190 million doses were our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. We and Pfizer introduced single-dose vials and never-frozen syringes in the United States.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Healthcare and Social Responsibility</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We advanced our goal of contributing to equitable access to medicine around the globe, with over 30% of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> doses delivered to low- and middle-income countries in 2023 in line with demand. We continue to work with non-governmental organizations (NGOs), institutes and governments to plan for equitable access to novel medicines, especially in low and middle-income countries and regions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global health goal is to advance and expand our infectious diseases programs and pipeline while contributing to equitable access to mRNA medicines. To further advance this vision, we established our Global Health Office (GHO) in 2023. The GHO provides a public health perspective supporting end-to-end development of innovative medicines that address major unmet public health needs, particularly those affecting populations in low- and middle-income countries and those with an inequity or pandemic preparedness dimension. The GHO leads on building clinical development and manufacturing capacity to support our goals; this includes the &#8220;AFRIKA KOMMT&#8221; program, where we hosted our first batch of fellows for internships in Germany in 2023. The GHO works closely with a large ecosystem of partners including the WHO, African Union, Africa CDC, local authorities, study centers, and organizations like CEPI and Gavi, the Vaccine Alliance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are progressing the development of mRNA vaccine candidates for infectious diseases with high medical need, including vaccine candidates against tuberculosis, malaria, and HIV, as well as against infectious diseases with pandemic potential, such as mpox. In December 2023, we reached an important milestone towards the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of our facility in Kigali, Rwanda. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Innovative and Diversified Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to develop our innovative oncology and infectious disease pipeline. Today, our pipeline consists of over 20 programs in oncology and seven programs in infectious disease being evaluated in over 40 clinical trials, including eight Phase 2 and two Phase 3 clinical trials in oncology. In 2023, we and our partners reported data across our portfolio at multiple medical meetings and published manuscripts in peer reviewed journals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In oncology, we started seven clinical trials and in-licensed six clinical assets throughout the year. Most importantly, we brought several assets into mid- and late-stage development, namely Phase 2 and Phase 3 clinical trials, across a range of technologies, in particular ADCs and mRNA vaccines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expanded our technology base to include ADCs by initiating new collaborations with DualityBio and MediLink Therapeutics. We believe ADCs have the potential to supplement or replace highly toxic chemotherapy regimens as a new combination backbone of cancer treatment. Our growing ADC pipeline includes ADCs directed against four distinct targets and is of interest for a broad range of cancer types. Our collaborations with OncoC4 and Biotheus complement our toolkit of technologies with next-generation immuno-oncology antibodies that offer unique mechanisms of action and have augmented our oncology pipeline with mid- to -late-stage clinical programs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In infectious diseases, we started three first-in-human Phase 1 clinical trials leveraging our proprietary mRNA prophylactic vaccine technology, including candidates being evaluated against shingles, tuberculosis, and mpox.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the next year, we aim to advance additional product candidates to late-stage development, and we expect to have ten or more potentially registrational trials running by the end of 2024. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company expects to continue building its pipeline towards its planned first oncology launch in 2026. BioNTech aims to have ten indication approvals by 2030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Innovation at Scale</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building and scaling biotech innovation with the aim of becoming a patient-centric, AI-driven, multi-product company. In 2023, we attracted top talent, including clinical and regulatory experts, to advance the development of our pipeline. We expanded our team </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to roughly 6,300 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> globally by welcoming more than 1,600 new hires. Our diverse workforce represents more than 80 nations, and we have subsidiaries in countries across five continents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we expanded our organization in Asia, Africa, North America, Australia and Europe. We increased our overall research and development and production capabilities, including completing construction of our first proprietary plasmid DNA manufacturing facility in Marburg, Germany. Furthermore, we established a corporate office in Shanghai, China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into multiple complementary agreements and collaborations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The completion of the acquisition of our long-time strategic collaboration partner, InstaDeep Ltd, or InstaDeep, which enables us to leverage AI and ML technologies across our therapeutic platforms and operations. With our acquisition of InstaDeep, we have added industry-leading AI and ML capabilities and approximately 290 highly skilled professionals to our organization. InstaDeep operates as a London-based subsidiary.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A strategic collaboration with the Government of the United Kingdom, or the UK, to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030, either in clinical trials or as authorized treatments. We plan to invest in a research and development hub in Cambridge, UK, with an expected capacity of more than 70 highly skilled scientists.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A multi-year agreement with Australia&#8217;s State of Victoria to set up and operate clinical-scale mRNA vaccine manufacturing through our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> units and establish an mRNA Innovation Center in Melbourne.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post year-end, in February 2024, in line with our goal of scaling up innovation, we and Autolus Therapeutics plc, or Autolus, announced a strategic collaboration aimed at advancing both companies&#8217; autologous CAR-T programs towards commercialization, pending regulatory authorizations. As part of the strategic collaboration, we have the option to access Autolus&#8217; commercial and clinical site network, and manufacturing capacities in the UK and commercial supply infrastructure in a cost-efficient set-up allowing for the accelerated development of our product candidate, BNT211.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we strengthened our balance sheet through strong financial performance, ending the year with approximately &#8364;17.7&#160;billion in total cash, cash equivalents and security investments. With a strong financial position, leading COVID-19 vaccine franchise, and innovative oncology and infectious disease pipeline, we believe are well positioned to continue executing our vision of pioneering novel medicines against cancer, infectious diseases and other serious diseases.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3619"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IV. Marketed Products: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comirnaty</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, our COVID-19 Vaccine Program (BNT162)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial product, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the first-ever approved mRNA-based product, and, to our knowledge, represents the fastest ever developed prophylactic vaccine from viral sampling to approval. As of December 2023, our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 vaccine products have been authorized or approved for emergency or temporary use or granted marketing authorization in more than 180 countries and regions worldwide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our efforts have resulted in more than 4.8 billion doses shipped globally.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Pfizer, we are the Marketing Authorization Holder in the United States, the European Union, or EU, the UK, Canada and other countries. Additionally, we are the holder of emergency use authorizations, or EUAs, or equivalents in the United States (jointly with Pfizer) and other countries for the COVID-19 vaccine program. Pfizer has marketing and distribution rights worldwide apart from Greater China, Germany, and T&#252;rkiye. We have the marketing and distribution rights to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Germany and T&#252;rkiye.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, Fosun Pharma has marketing and distribution rights in Mainland China, Hong Kong Special Administrative Region, or SAR, Macau SAR and Taiwan.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3626"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Commercial Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we and Pfizer continued our global COVID-19 vaccine leadership with our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine directed against the Omicron XBB.1.5 SARS-CoV-2 variant. Since declaration of the pandemic, we have developed and commercialized four COVID-19 vaccine products: the original COVID-19 vaccine, two Original/Omicron-adapted bivalent vaccines (Original/BA.1- and Original/Omicron BA.4-5-adapted bivalent vaccines) and the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. Each is referred to as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Between their introduction in December 2020 and March 2023, COVID-19 vaccines are estimated to have reduced deaths due to the pandemic by at least 57%, saving more than 1.4 million lives in the World Health Organization, or WHO, European Region. Most of those saved were aged 60 or older, the group at highest risk of severe illness and death from the SARS-CoV-2 virus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our and Pfizer&#8217;s two-billion-doses pledge to support equitable access to medicines, we and Pfizer have delivered over 1.8 billion doses of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to low- and middle-income countries since the beginning of the pandemic in line with demand.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, following regulatory approvals, we and Pfizer began shipping Omicron XBB.1.5-adapted monovalent COVID-19 vaccines in time for autumn and winter booster campaigns.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we and Pfizer are well positioned for the future as leading COVID-19 vaccine providers. We</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expect that as the market dynamics evolve across different geographies in 2024, there will be continued demand for vaccine boosting and primary vaccinations of immunologically na&#239;ve individuals, especially amongst older and immunocompromised populations. Studies have demonstrated that natural immunity acquired by SARS-CoV-2 infection is variable across individuals and the protection it offers wanes over time. A booster vaccination can restore and enhance infection-acquired immune protection and further reduce the risk of reinfection. The risk of severe COVID-19 disease remains high in vulnerable populations. Vaccination not only reduces the risk of severe COVID-19 but can also mitigate the risk of health impairments related to long-COVID. Given this, and our current understanding of COVID-19&#8217;s seasonality and its burden on healthcare systems during the autumn/winter season, we anticipate the need for annual adapted vaccines to be a long-term component of COVID-19 vaccination practices.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3633"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Manufacturing and Distribution </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e and Pfizer continue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborate with governments and health ministries around the world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to efficiently distribute </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have developed a global COVID-19 vaccine supply chain and manufacturing network </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spanning </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four continents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to meet the ongoing global demand of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we began transitioning from an advanced purchase agreement framework to commercial market ordering in some geographies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we and Pfizer announced an agreement with the European Commission, or the EC, to amend the previous COVID-19 Vaccine Purchase Agreement to deliver COVID-19 vaccines to the EU. The amended agreement reflects our and Pfizer&#8217;s commitment to working collaboratively to help address ongoing public health needs, while respecting the principles of the original agreement. The agreement rephased delivery of doses annually through 2026. In addition, the agreement includes an aggregate volume reduction, providing additional flexibility for EU Member States. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we and Pfizer announced an agreement between the Japanese government and Pfizer Japan Co., Ltd. to supply an additional nine million doses of the Omicron XBB.1.5-adapted COVID-19 vaccine for the special vaccination program in Japan which started in autumn 2023. The agreement followed an agreement between the Japanese government and Pfizer in July 2023 to supply 20 million doses and additional supplies as needed, and an agreement announced in September 2023 to provide an additional 10 million doses of the companies&#8217; Omicron XBB.1.5-adapted COVID-19 vaccine for the special vaccination program in Japan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More details on our manufacturing operations and facilities can be found in &#8220;VII. Manufacturing.&#8221;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3640"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Clinical Development</span></div><div style="margin-top:6pt;padding-left:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we and Pfizer initiated a Phase 2/3 study (NCT05997290) to investigate the safety, tolerability and immunogenicity of our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine in healthy people 12 years and older. A manuscript reporting the safety and immunogenicity one month after vaccination with our monovalent Omicron XBB.1.5-adapted COVID-19 vaccine in COVID-19 experienced individuals 12 years of age and older was published in January 2024 (Gayed et al., 2024). These data support a favorable benefit-risk profile of our XBB.1.5-adapted COVID-19 vaccine. In this analysis, the XBB.1.5-adapted vaccine demonstrated a safety and tolerability profile similar to that seen with original and the BA.4/5-adapted and BA.1-adapted COVID-19 vaccines and induced substantial increases in neutralizing antibody responses against Omicron XBB.1.5 (overall geometric mean fold rises [GMFR]: 7.0), EG.5.1 (GMFR: 8.7), and BA.2.86 (GMFR: 4.5). We believe the safety and immunogenicity data support administration of the XBB.1.5-adapted BNT162b2 in vaccine-experienced individuals 12 years of age and older.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real world data showed high vaccine effectiveness of the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine against current variants of concern, with 63% (95%CI: 33-80%) vaccine effectiveness against hospitalization observed in adults aged 18 years and older approximately 30 days post vaccination in the United States against XBB.1.5, XBB.1.16, EG.5.1, and BA.2.86. Similar real world evidence trends have been reported in EU countries. In Denmark, vaccination was associated with a 75.3% reduced risk of COVID-19 hospitalization nine days post-immunization with a monovalent XBB.1.5 in people over 65 years of age. In the Netherlands, early estimate demonstrated a high vaccine effectiveness against hospitalization (68.3 &#8211; 71.4%) and ICU admission (73.3%) in people over 60 years of age in the two months post vaccination with XBB.1.5 vaccine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we and Pfizer announced positive pre-clinical data examining our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine against multiple Omicron XBB-related sublineages, including XBB.1.5, XBB.1.16, BA.2.86, EG.5.1 and XBB.2.3, compared to the Omicron BA.4-5-adapted bivalent vaccine. These data demonstrate that the XBB.1.5-adapted COVID-19 vaccine generates improved neutralizing antibody responses against all Omicron-related sublineages mentioned above.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3647"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Regulatory Updates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, our and Pfizer&#8217;s Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine received label expansions for pediatric vaccinations and conversions from conditional or emergency use approvals or authorizations to full/standard regulatory approvals in many jurisdictions worldwide.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and Pfizer&#8217;s Omicron XBB.1.5-adapted monovalent COVID-19 vaccine received multiple regulatory approvals, including approvals, authorizations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for emergency or temporary use or marketing authorizations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than 40 countries and regions in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">riginal/Omicron BA.4-5-Adapted Bivalent COVID-19 Vaccine</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we and Pfizer received the following approvals for our Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">March 2023: U.S. Food and Drug Administration, or U.S. FDA approved an EUA for a single booster dose of our Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine for children six months through four years of age at least two months after completion of primary vaccination with three doses of the original COVID-19 vaccine.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">April 2023: U.S. FDA updated this EUA to simplify the vaccination schedule for most individuals. This action included authorizing our original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine to be used for all doses administered to individuals six months of age and older.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we and Pfizer received the following approvals for our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">August 2023: the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA recommended marketing authorization for our and Pfizer&#8217;s Omicron XBB.1.5-adapted </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monovalent COVID-19 vaccine administered as a single dose for individuals five years of age and older, regardless of prior COVID-19 vaccination history. The CHMP also recommended the updated vaccine for children six months through four years of age as part or all of the primary three-dose vaccination series, depending on how many prior doses received, or as a single dose for those with a history of completion of a COVID-19 primary vaccination course or prior SARS-CoV-2 infection. Positive EC Decisions followed CHMP recommendations the day after.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">September 2023: U.S. FDA approved a supplemental Biologics License Application (BLA) for the monovalent XBB.1.5-adapted vaccine recommended for use in the 2023-2024 autumn and winter season for individuals 12 years of age and older, and granted an EUA for children six months through 11 years of age. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other national healthcare regulatory bodies, including in the UK, Japan, Canada, Australia and South Korea, have also approved our and Pfizer&#8217;s monovalent XBB.1.5-adapted vaccine.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2605"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">V. Pipeline of Product Candidates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing a broad portfolio of product candidates derived from our four drug classes and multiple platforms, and are focused on immunotherapies for the potential treatment of cancer and mRNA vaccines to potentially prevent or treat infectious diseases.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology Pipeline</span></div><div style="margin-top:6pt;text-align:center"><img src="bntx-20231231_g1.jpg" alt="Slide1.jpg" style="height:381px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Pipeline</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="bntx-20231231_g2.jpg" alt="240319_BioNTech Clinical Pipeline_EN.jpg" style="height:249px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2648"></div><div style="margin-top:12pt;padding-left:6.25pt;text-indent:0.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. Oncology Programs</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2642"></div><div style="margin-top:6pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. mRNA Product Class in Oncology</span></div><div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a) FixVac</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our wholly owned, systemic, off-the-shelf mRNA-based cancer immunotherapy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approach</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from which we are developing several first-in-human and potential first-in-class product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates contain our non-nucleoside optimized uridine-RNA delivered in our proprietary RNA-LPX formulation for intravenous administration. Proprietary RNA-LPX is designed to deliver RNA to dendritic cells, or DCs, and protects RNA from degradation by RNAse and is designed for RNA delivery into antigen-presenting cells in lymphoid organs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates are designed to target shared antigens that have been identified to be frequently expressed across patients with a specific cancer type. These product candidates are designed to trigger both innate and adaptive immune responses.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT111 for the Treatment of Advanced Melanoma</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT111 is designed to elicit an immune response to four antigens (NY-ESO-1, MAGE-A3, tyrosinase, TPTE) that have each been found to be associated with cutaneous melanoma. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A global, randomized three-arm Phase 2 clinical trial (NCT04526899) is being conducted in collaboration with Regeneron Pharmaceuticals Inc., or Regeneron, and is evaluating BNT111 in combination with cemiplimab (Regeneron&#8217;s Libtayo) versus both agents as monotherapy in 184 patients with anti-PD-1-/anti-PD-L1 refractory/relapsed, unresectable Stage III or IV melanoma. The primary endpoint is objective response rate (ORR). Secondary endpoints include duration of response (DOR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety. The trial achieved full enrollment in September 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1 Trial (LIPO-MERIT)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-center, open-label, first-in-human, Phase 1 dose escalation clinical trial (NCT02410733) evaluating the safety and tolerability of BNT111 in patients with advanced melanoma has been completed. This was the first clinical trial worldwide in which an mRNA-based cancer immunotherapy was administered intravenously for systemic treatment. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trial started in 2015, enrollment was completed in 2020 with 115 patients and the last patient visit under the follow-up period took place in June 2023. Final biomarker and clinical data of the trial are being gathered and evaluated and will be compiled in a clinical study report.</span></div><div style="margin-top:12.1pt;padding-left:0.4pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ii. BNT112 for the Treatment of Prostate Cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT112 is designed to elicit an immune response to five antigens expressed in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and metastatic prostate cancer, including prostate-specific antigen, or PSA, a transmembrane protein that is expressed by virtually all prostate cancers, prostatic acid phosphatase, or PAP, and three additional tumor-associated antigens. </span></div><div style="margin-top:6pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> Phase 1/2a Clinical Trial (PRO-MERIT) </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRO-MERIT is a first-in-human Phase 1/2a, open-label dose titration and expansion clinical trial (NCT04382898) to evaluate the safety, immunogenicity and preliminary efficacy of BNT112 monotherapy and in combination with cemiplimab in patients with metastatic castration resistant prostate cancer, or mCRPC and high-risk localized prostate cancer (LPC) who are eligible for treatment with androgen deprivation therapy (ADT) followed by radical prostatectomy. The trial has been discontinued and the follow-up period ended in January 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final data of the trial are being gathered and evaluated and will be compiled in a clinical study report.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iii. BNT113 for the Treatment of Human Papilloma Virus 16-positive, or HPV16+, Head and Neck Cancer, or HNSCC</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#181010;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT113 encodes two HPV-16-related oncoproteins exclusively expressed in pre-malignant and malignant tissue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-associated cancers are increasing, with HPV16+ HNSCC typically occurring in younger populations. Most patients with HPV16+ HNSCC are diagnosed at more advanced clinical stages. We see a significant opportunity to improve the treatment landscape with BNT113 given that it has the potential to augment clinical responses in patients being treated with checkpoint inhibitors.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT113 Phase 2 Trial (AHEAD-MERIT)</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A global randomized Phase 2 clinical trial (NCT04534205) evaluating BNT113 in combination with pembrolizumab (Merck &amp; Co., Inc.&#8217;s Keytruda) versus pembrolizumab monotherapy as a first-line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 is ongoing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part A is a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-randomized </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">run-in portion designed to demonstrate the safety of the combination of BNT113 and pembrolizumab. Part B is the randomized portion of the trial designed to generate efficacy and safety data. The trial plans to enroll a total of 267 patients. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1/2 Trial (Investigator-Initiated and Sponsored) </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT113 was investigated by the University Hospital Southampton National Health Service (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NHS) Foundation Trust</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in an investigator-sponsored open-label, Phase 1/2 dose escalation basket clinical trial with two different arms in 29 patients with HPV16+ head and neck and other cancers in the post-adjuvant and metastatic setting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial has been terminated and the patient follow-up period ended in July 2023.</span></div><div style="margin-top:12pt;padding-left:24.38pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iv. BNT114 for the Triple Negative Breast Cancer, or TNBC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-center, open-label, three-arm Phase 1 clinical trial (NCT02316457) to evaluate BNT114 as monotherapy and in combination with our individualized neoantigen specific immunotherapy in TNBC patients who had previously received the standard of care therapy (i.e., surgery, chemotherapy and/or radiotherapy) had its last patient last visit in May 2023. The trial results of the main study phase were summarized in a clinical trial report, or CTR, in 2021. The data generated within the three-year long-term follow-up period has been described in an addendum to the CTR. </span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">v. BNT115 for the Treatment of Ovarian Cancer </span></div><div style="margin-top:6pt;padding-left:10.2pt;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1 Trial (Investigator-Initiated and Sponsored) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT115 was studied in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an investigator-initiated and -sponsored</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> first-in-human, open-label Phase 1 dose escalation clinical trial in ovarian cancer patients eligible for standard-of-care treatment with (neo-) adjuvant chemotherapy. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the original recruitment period was extended, the target number of evaluable patients, defined in the study protocol was not reached and recruitment for the trial was stopped. Recruitment of 10 patients was concluded in June 2022, and eight were ultimately dosed. The follow-up phase for the enrolled patients was completed in June 2023. The clinical data of the trial will be evaluated by the University Medical Center Groningen, Netherlands and recorded accordingly. No follow-up studies are planned with BNT115.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">vi. BNT116 for the Treatment of Non-small Cell Lung Cancer, or NSCLC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT116 is being evaluated in two clinical trials as a monotherapy and in combination with other immunotherapies and chemotherapies in patients with advanced or metastasized NSCLC. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in NSCLC 1L</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A randomized, controlled Phase 2 clinical trial (NCT05557591) is ongoing to evaluate BNT116 in combination with cemiplimab versus cemiplimab alone as first-line treatment of patients with advanced NSCLC whose tumors express PD-L1 in &#8805; 50% of their tumor cells. The primary objective of the Phase 2 trial is to assess the safety and tolerability as well as the ORR and tumor burden reduction. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2023, a Trial-in-Progress poster was presented at the European Society for Medical Oncology (ESMO) Congress.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1 Trial in NSCLC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 clinical trial (NCT05142189) is ongoing to evaluate the safety, tolerability and preliminary efficacy of BNT116 alone and in combination with cemiplimab in patients who have progressed on prior PD-1 inhibitor treatment or are not eligible for chemotherapy, in combination with docetaxel in patients who have received prior PD-1 inhibitor therapy and platinum-based chemotherapy, in combination with cemiplimab in patients with unresectable Stage III NSCLC who have undergone chemoradiotherapy, and in combination with cemiplimab with our without chemotherapy in the neoadjuvant and adjuvant settings in patients with resectable Stage II and III NSCLC.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2023, two new cohorts were added to the study: a cohort enrolling NSCLC patients to evaluate BNT116 combination with cemiplimab and chemotherapy in the neo- and adjuvant settings; and a cohort to assess the potential of BNT116 plus cemiplimab as consolidation treatment after concurrent chemoradiotherapy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First data from the trial were presented at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The tolerability profile of BNT116 was similar to other RNA-LPX-based therapeutic vaccines. In heavily pretreated NSCLC patients, early clinical activity was observed with treatment with BNT116 with the addition of cemiplimab from cycle 3 onward.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b) Autogene Cevumeran (BNT122), an Individualized Neoantigen Specific Immunotherapy, or iNeST</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autogene cevumeran is an individualized cancer immunotherapy product candidate based on specific neoantigens that are present on a patient&#8217;s tumor. Similar to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our iNeST approach is also based on a pharmacologically optimized-backbone equipped uridine mRNA, or uRNA, delivered in our proprietary RNA-LPX formulation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Proprietary RNA-LPX is designed to deliver RNA to DCs and protects RNA from degradation by RNAse and is designed for RNA delivery into antigen-presenting cells in lymphoid organs. Each patient is treated with a vaccine informed by the mutation profile of their personal cancer and manufactured on-demand. The RNA encodes a unique composition of the patient&#8217;s own tumor mutations and results in generation of neoantigen specific CD4+ and CD8+ T-cell responses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each autogene cevumeran dose includes up to 20 different neoantigens selected on a patient-by-patient basis (up to 10 neoantigens on 1 RNA). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe this modality may be well-suited for use in the adjuvant setting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> iNeST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is partnered with Genentech as part of a 50:50 collaboration in which development costs and future profits are shared.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in Adjuvant Colorectal Cancer </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">randomized, multi-site, open-label Phase 2 clinical trial (NCT04486378) evaluating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autogene cevumeran </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an adjuvant treatment of circulating tumor DNA (ctDNA) positive, surgically resected Stage II (high risk)/Stage III colorectal cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is expected </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to enroll about 200 patients to evaluate the efficacy of autogene cevumeran compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. The primary endpoint for the study is disease-free survival, or DFS. Secondary objectives include OS and safety. The trial is currently enrolling in the United States, Germany, Spain, Belgium, Sweden and the UK.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in Pancreatic Ductal Adenocarcinoma, or PDAC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the first patient was dosed in the randomized Phase 2 clinical trial (NCT05968326) evaluating the safety and efficacy of autogene cevumeran in combination with atezolizumab (Genentech&#8217;s Tecentriq) followed by standard-of-care chemotherapy (mFOLFIRINOX) in patients with resected PDAC compared to chemotherapy alone. The Phase 2 study is expected to enroll 260 patients with resected PDAC who have not received prior systemic anti-cancer treatment and showed no evidence of disease after surgery. The primary endpoint is DFS. Secondary endpoints include OS and safety. The trial has been initiated in the United States and enrollment is planned in approximately 10 countries in total.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2023, results from the investigator-initiated Phase 1 trial were published in the peer-reviewed journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Rojas, L.A et al. 2023). The paper reported preliminary evidence that adjuvant autogene cevumeran in combination with atezolizumab and mFOLFIRINOX induces substantial T-cell response in patients with surgically resected PDAC that correlates with delayed recurrence.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in First-line Melanoma with Pembrolizumab </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A randomized Phase 2 clinical trial (NCT03815058) evaluating the efficacy and safety of autogene cevumeran in combination with pembrolizumab versus pembrolizumab alone as first line in patients with previously untreated advanced melanoma is fully enrolled and follow-up is ongoing. The primary endpoint is PFS and is events-based. Secondary endpoints include ORR, OS, DOR and safety.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1a/1b Clinical Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An open-label </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1a monotherapy/1b in combination with atezolizumab clinical trial (NCT03289962) of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utogene </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evumeran in patients with locally advanced or metastatic solid tumors, including patients with melanoma, NSCLC, bladder cancer, colorectal cancer, TNBC, renal cancer, head and neck cancer and sarcomas as well as other solid tumors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is fully enrolled and follow-up is ongoing. </span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c) mRNA Intratumoral Immunotherapy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT131/SAR441000 for the Treatment of Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT131/SAR441000 comprised four mRNAs encoding the cytokines IL-12sc, IL-15sushi, IFN-&#945; and GM-CSF, which we had identified as mediators of tumor regression across different murine tumor models. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Collaboration and License Agreement with Sanofi to develop BNT131/SAR441000 was terminated effective December 30, 2023.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Phase 1 Clinical Trial </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Sanofi are running a first-in-human, multi-center, open-label, Phase 1, dose escalation and expansion clinical trial (NCT03871348) to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of BNT131/</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAR441000 administered intratumorally as monotherapy and in combination with cemiplimab. In this trial, 77 patients with certain advanced solid tumors were enrolled. The trial has stopped recruitment; treatment of patients and follow-up are ongoing. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2023, preliminary data from the dose escalation and expansion study trial were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. Anti-tumor activity across multiple dose levels was observed with treatment with BNT131/SAR441000 and was primarily limited to loco-regional disease setting. No significant overall distant non-injected lesion response was seen.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on interim analysis results, we and Sanofi have jointly decided to discontinue the development of the mRNA coding for cytokines, BNT131/SAR441000. </span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">d) RiboMabs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates, BNT141 and BNT142, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are mRNAs that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">encode cancer cell targeting antibodies. These product candidates leverage our proprietary optimized mRNA technology combining nucleoside modifications to minimize immunogenicity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our improved mRNA backbone designs with the aim of maximizing protein expression</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates are formulated using liver-targeting lipid nanoparticles, or LNPs for intravenous delivery. </span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT141 for the Treatment of Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we dosed the first patient </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an open-label, multi-site, Phase 1/2 dose escalation, safety, and pharmacokinetic clinical trial of&#160;BNT141&#160;followed by expansion cohorts in patients with CLDN18.2-positive tumors. The last patient visit was in July 2023. We have decided to discontinue the study based on observations regarding product characteristics, and are working on an optimized formulation of the product candidate for further clinical development.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ii. BNT142 for the Treatment of Solid Tumors </span></div><div style="margin-top:6pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT142 codes for a T cell engaging bispecific antibody targeting CLDN6, and is being studied in an ongoing, open-label, multi-center Phase 1/2 clinical trial (NCT05262530) in patients with CLDN6-positive advanced solid tumors that have exhausted available standard therapy or are not eligible for such available therapy. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A trial-in-progress poster was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is actively recruiting patients in the EU, the UK, the United States and Singapore.</span></div><div style="margin-top:12pt;padding-left:42.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">e) RiboCytokines </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates are designed to address the limitations of recombinantly expressed cytokines, including limited serum half-life and production costs. BNT151 and BNT152+153 are nucleoside-modified mRNAs encoding human cytokines fused to human serum albumin. The modified mRNA is formulated with liver-targeting LNPs for intravenous delivery. BNT151 encodes an IL-2 variant, BNT152 encodes IL-7, and BNT153 encodes IL-2.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT151 for the Treatment of Solid Tumors </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human, open-label, dose escalation, multi-center Phase 1/2 clinical trial (NCT04455620) evaluating BNT151 (encoding an IL-2 variant) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, pharmacokinetics and pharmacodynamics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with multiple solid tumors has been discontinued after the completion of enrollment for the Part 1 monotherapy dose escalation. The follow-up phase for enrolled patients is expected to be completed in 2024, after which the clinical data of the trial will be finally evaluated and reported accordingly.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ii. BNT152+BNT153 for the Treatment of Solid Tumors </span></div><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1 Trial of BNT152+153</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">open-label, multi-site</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-in-human </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 clinical trial (NCT04710043) is evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of a combination of BNT152 and BNT153. The clinical trial is ongoing and enrolling patients with various metastatic or unresectable solid tumors for whom there is no available standard therapy likely to confer clinical benefit or patients who are not candidates for such available therapy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial consists of two parts with adaptive design elements. Part 1 consisted of Groups A and B and was completed in May 2023. Group A was a BNT153 monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) or maximum administered dose (MAD) was defined. Group B was a BNT152 </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monotherapy dose escalation in patients with advanced solid malignancies until the MTD or optimal biological dose (OBD) was defined, whichever occured earlier. In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 2, we are currently evaluating the combination treatment of BNT152 and BNT153.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2636"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Oncology Cell Therapy Product Candidates </span></div><div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a) CAR-T-cell therapy</span><span style="color:#1e1e23;font-family:'Source Sans Pro',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> CAR-T </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT211 for the Treatment of CLDN6+ Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT211 consists of two investigational medicinal products: our first CAR-T-cell product candidate, which targets CLDN6-positive solid tumors, in combination with an mRNA named CARVac encoding CLDN6. The CAR-T cells are equipped with a second-generation CAR of high sensitivity and specificity for the tumor-specific carcino-embryonic antigen CLDN6. CARVac is intended to support </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expansion of transferred CAR-T cells to increase their persistence and efficacy. As with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST, CARVac is also based on a pharmacologically optimized-backbone equipped uRNA delivered in our proprietary RNA-LPX formulation. BNT211 has been granted Priority Medicines, or PRIME, designation by the EMA for the third- or later-line treatment of testicular germ cell tumors.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> open-label, multi-center Phase 1/2 dose escalation and dose expansion basket clinical trial (NCT04503278) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluating </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CLDN6 CAR-T cells with or without a CLDN6 CARVac in patients with CLDN6-positive relapsed or refractory advanced solid tumors, including ovarian and testicular cancers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is ongoing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary outcome measure of the trial is safety, with secondary efficacy outcome measures to include ORR, DCR and DOR. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A data update from the ongoing clinical trial was provided at the 2023 ASCO Annual Meeting describing the new dose escalation of CLDN6 CAR-T cells with and without CLDN6 CARVac using an automated manufacturing process for treatment of relapsed/refractory solid tumors. CLDN6 CAR-T cells &#177; CLDN6 CARVac showed a manageable safety profile in-line with that of manually produced CLDN6 CAR-T cells. Encouraging signs of activity were observed, with dose-dependent expansion of CAR-T cells translating into ORR of 41% with 7 responses in 17 evaluable patients (ORR 75% at dose level 2).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2023, data from the manual manufacturing process were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Mackensen, A. et al., 2023).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A second data update from the ongoing clinical trial was presented at the 2023 ESMO Congress, describing the interim results from a repeat dose escalation of CLDN6 CAR-T cells manufactured with an automated process with and without CLDN6 CARVac vaccine for treatment of relapsed/refractory solid tumors. CLDN6 CAR-T cells &#177; CLDN6 CARVac demonstrated encouraging signs of clinical activity. In several patients co-administration of CARVac improved persistence of cancer-specific CAR-T cells. The rate of treatment-emergent adverse events (TEAEs) was dose-dependent. A Phase 2 trial evaluating BNT211 in patients with germ cell tumors is planned to start in 2024. </span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b) Neoantigen-Targeting T Cells</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our neoantigen-targeting T-cell stimulation platform can be utilized to develop product candidates across several neoantigen-targeting non-engineered and engineered T-cell therapies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autologous, neoantigen-specific T cells are primed, activated and expanded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing a proprietary antigen-specific T-cell induction protocol, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neo-Stim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to target either a personal set of neoantigens for each patient or a set of selected shared neoantigens. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate under this platform is our individualized neoantigen-targeting T-cell therapy, BNT221.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT221 for the Treatment of Cancer </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT221 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our autologous, fully personalized, polyspecific T-cell therapy directed against selected sets of individual neoantigens. BNT221 is based on expanded neoantigen-specific memory T cells and induced na&#239;ve T cells. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proprietary stimulation process allows for the induction of T cells from the na&#239;ve compartment, as well as expansion of T cells from the memory compartment. Other product characteristics are (i) cells with high specificity profile towards the mutant epitope; (ii) cells exhibiting multiple effector functions; (iii) a product that contains both central and effector memory T cells; and (iv) cells that have cytotoxic response towards endogenously processed and presented antigens as well as recognition of autologous tumor. The neoantigens are selected using our proprietary </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RECON</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> bioinformatics engine. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1 Clinical Trial </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> first-in-human Phase 1 dose escalation clinical trial (NCT04625205) evaluating BNT221 in patients with checkpoint inhibitor unresponsive or refractory metastatic melanoma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is ongoing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The first portion of the trial consists of a monotherapy dose escalation of BNT221, for which recruitment and treatment of patients is complete. Currently, BNT221 is being dosed in combination with anti-PD-1 therapy after first-line treatment. Major objectives of this study include evaluation of the safety and feasibility of administering BNT221, as well as evaluations of immunogenicity and preliminary efficacy. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first monotherapy data from the dose escalation phase of this clinical trial were presented at the 2023 ESMO Congress and 2023 SITC Annual Meeting. These initial results demonstrated a manageable safety profile and signs of tumor regression in several patients with anti-PD-1 and anti-CTLA-4 pretreated advanced or metastatic melanoma.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2630"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Protein-based Therapeutic Product Candidates in Oncology </span></div><div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">a) Next-Generation Immune Checkpoint Modulators </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Genmab are developing antibodies that are designed to function as tumor-targeted and dual immunomodulators, applying Genmab&#8217;s proprietary technologies in combination with our joint target identification and product concept expertise. BNT311/GEN1046 (acasunlimab), BNT312/GEN1042, BNT313/GEN1053, BNT314/GEN1059, BNT315/GEN1055, and BNT322/GEN1056 are partnered with Genmab as part of a 50:50 collaboration in which development costs and future profits are shared. We and Genmab have five product candidates currently in clinical development: BNT311/GEN1046 (acasunlimab, DuoBody PD-L1x4-1BB), BNT312/GEN1042 (DuoBody CD40x4-1BB), BNT313/GEN1053 (HexaBody-CD27), BNT314/GEN1059 (DuoBody-EpCAMx4-1BB), and BNT322/GEN1056 (target undisclosed). In October 2023, an Investigational New Drug Application (IND) was submitted for an additional product candidate, BNT315/GEN1055 (HexaBody-OX40) and the IND has been cleared by the U.S. FDA. </span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we and OncoC4 announced entry into a strategic collaboration, which includes joint development of BNT316/ONC-392 in a range of solid tumor indications, with the parties equally sharing development costs for such joint development studies. BioNTech holds the exclusive worldwide commercialization rights for this product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced an exclusive global license and collaboration with Biotheus under which we will be developing, manufacturing and commercializing Biotheus&#8217; bispecific antibody candidate BNT327/PM8002 globally ex-Greater China.</span></div><div style="margin-top:12pt;padding-left:40.5pt;text-align:justify;text-indent:-16.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BNT311/GEN1046 (acasunlimab) a PD-L1x4-1BB Bispecific Antibody for the Treatment of Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT311/GEN1046 (acasunlimab), our jointly owned PD-L1x4-1BB product candidate, is a potential first-in-class bispecific antibody combining PD-L1 checkpoint inhibition with 4-1BB stimulation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT311/GEN1046 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acasunlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is being developed for the treatment of solid tumors using Genmab&#8217;s proprietary DuoBody technology platform. We and Genmab are currently evaluating BNT311/GEN1046 (acasunlimab) in multiple clinical trials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in Metastatic NSCLC </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, multi-center, randomized, open-label clinical trial (NCT05117242) of BNT311/GEN1046 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acasunlimab) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as monotherapy and in combination with pembrolizumab in patients with relapsed/refractory metastatic NSCLC and a tumor PD-L1 expression of tumor proportion score, or TPS, of &#8805;1% after treatment with standard of care therapy with an immune checkpoint inhibitor is ongoing. The primary endpoint is ORR according to Response Evaluation Criteria in Solid Tumors, or RECIST v1.1. Secondary endpoints include DOR, TTR, PFS, OS and safety.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are planning to share data from this clinical trial at a medical conference in 2024. Based on the data, we are engaging with health authorities on the design of a pivotal trial evaluating BNT311/GEN1046 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acasunlimab) in second line NSCLC.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Trial in Advanced Endometrial Cancer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, an open-label Phase 2 clinical trial (NCT06046274) in treatment-experienced patients with advanced (unresectable and/or metastatic) endometrial cancer was initiated to evaluate the safety and clinical activity of BNT311/GEN1046 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(acasunlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with pembrolizumab in these patients.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial in Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we and Genmab initiated a Phase 1/2, multi-center, open-label clinical trial (NCT03917381) with multiple expansion cohorts evaluating BNT311/GEN1046 (acasunlimab) as monotherapy and in combination therapies in patients with multiple solid tumors. The trial is currently ongoing.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1 Clinical Trial in Japanese Patients</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we and Genmab initiated a Phase 1 open-label, dose escalation clinical trial (NCT04937153) evaluating the safety and pharmacokinetics of BNT311/GEN1046 (acasunlimab) as monotherapy and in combination with pembrolizumab in Japanese patients with multiple solid tumors. The trial is currently ongoing.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BNT312/GEN1042, a CD40x4-1BB Bispecific Antibody for the Treatment of Solid Tumors </span></div><div style="margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT312/GEN1042 is a jointly owned, novel, agonistic, bispecific antibody that combines targeting and conditional activation of the costimulatory molecules CD40 and 4-1BB on immune cells. BNT312/GEN1042 is being developed for the treatment of solid cancers using Genmab&#8217;s proprietary DuoBody technology platform and our CD40 and 4-1BB antibodies. We and Genmab are currently evaluating BNT312/GEN1042 in multiple clinical trials.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase Clinical Trials</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2 dose-escalation clinical trial (NCT04083599) with expansion cohorts evaluating safety and anti-tumor activity of BNT312/GEN1042 as monotherapy and in combination therapies in patients with solid tumors is ongoing.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Genmab are anticipating data needed to determine next steps for this program in 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we and Genmab initiated an open-label Phase 1/2 clinical trial (NCT05491317) evaluating the safety and clinical activity of BNT312/GEN1042 in combination with radiotherapy with or without pembrolizumab in patients with metastatic solid tumors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we and Genmab initiated a Phase 1 clinical trial (NCT06057038) in Japan evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of BNT312/GEN1042 monotherapy and in combination with pembrolizumab with or without chemotherapy in patients with multiple solid tumors.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iii. &#160;&#160;&#160;&#160;BNT313/GEN1053, an Agonistic Hexabody-CD27 Antibody for the Treatment of Malignant Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT313/GEN1053 is a novel CD27 antibody with an IgG Fc domain engineered to induce clustering of CD27 on the plasma membrane of T cells with the aim of enhancing T-cell activation, proliferation and differentiation without depleting T cells. In preclinical studies, BNT313/GEN1053 increases T-cell activation, proliferation, cytokine secretion and cytotoxic activity.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2 clinical trial (NCT05435339) evaluating the safety, tolerability and preliminary efficacy of BNT313/GEN1053 as monotherapy in patients with advanced solid tumors is currently recruiting.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iv. &#160;&#160;&#160;&#160;BNT314/GEN1059, an EpCAMx4-1BB Bispecific Antibody for the Treatment of Advanced or Metastatic Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT314/GEN1059 is a potential first-in-class bispecific antibody product candidate, using Genmab&#8217;s proprietary DuoBody technology platform designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the 2023 ESMO Congress, we and Genmab presented preclinical data describing the mechanism of action of BNT314/GEN1059. In preclinical studies, BNT314/GEN1059 was shown to enhance T-cell activation, proliferation, and effector functions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and to promote antitumor activity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These results suggest that BNT314/GEN1059 may boost antitumor immunity in cancer patients with EpCAM-positive tumors.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human Phase 1/2 clinical trial (NCT06150183), which we are sponsoring, is currently recruiting to investigate the safety and preliminary antitumor activity of BNT314/GEN1059 in patients with advanced or metastatic solid tumors.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#160;&#160;&#160;&#160;BNT315/GEN1055, a HexaBody-OX40 Antibody for the Treatment of Advanced Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the 2023 ESMO Immuno-Oncology Congress, we and Genmab presented preclinical data describing BNT315/GEN1055. In preclinical studies, BNT315/GEN1055 exhibited Fc&#947;R-crosslinking-independent OX40 agonist activity, a unique mechanism of action that is distinct from conventional IgG1 OX40 agonists. BNT315/GEN1055 enhanced T-cell activation and proliferation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and showed antitumor activity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human clinical trial is planned to start in the first half of 2024 to evaluate the clinical safety and preliminary efficacy of BNT315/GEN1055 in patients with advanced solid tumors.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">vi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. &#160;&#160;&#160;&#160;BNT322/GEN1056, an Antibody for the Treatment of Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT322/GEN1056 is an antibody product candidate we are co-developing with Genmab for the treatment of solid tumors and for potential use in combination with other products. A first-in-human Phase 1 clinical trial (NCT05586321) of BNT322/GEN1056 in patients with advanced solid tumors is currently ongoing.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">vii. &#160;&#160;&#160;&#160;BNT327/PM8002, a Bispecific Antibody Candidate Targeting PD-L1 and VEGF, in Collaboration with Biotheus</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT327/PM8002 is an anti-VEGF-A antibody candidate fused to a humanized anti-PD-L1 VHH being developed in collaboration with Biotheus. BNT327/PM8002 is currently being evaluated in Phase 1 and  Phase 2/3 clinical trials in China to assess the efficacy and safety of the candidate as monotherapy or in combination with chemotherapy in various indications. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data from a Phase 1/2 trial in advanced solid tumors presented in 2023 demonstrated that BNT327/PM8002 as monotherapy was observed to have antitumor activity and a manageable safety profile. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data from Phase 2 trials in patients with small cell lung cancer, or SCLC, and TNBC presented in 2023 demonstrated that BNT327/PM8002 in combination with chemotherapy was observed to have encouraging antitumor activity and an acceptable toxicity profile as second- and first-line therapy, respectively. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional data readouts, both in monotherapy and combination, are expected across a range of solid tumors in 2024.</span></div><div style="margin-top:12pt;padding-left:42.24pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">viii.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> BNT316/ONC-392 (gotistobart), an Anti-CTLA-4 Monoclonal Antibody Candidate in Development in Collaboration with OncoC4</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT316/ONC-392 (gotistobart) is a next-generation anti-CTLA-4 antibody candidate. CTLA-4 is a molecule which inhibits T-cell immune response and reduces the activity of T cells in recognizing and eliminating cancer cells. Blocking CTLA-4 preserves T-cell activity and enhances anti-tumor activity. Our next-generation anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) was designed to preserve CTLA-4 recycling and thus function of regulatory T cells in the peripheral tissues.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 3 Clinical Trial in Metastatic, Immunotherapy-resistant NSCLC</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, a Phase 3 clinical trial (NCT05671510) was initiated to evaluate BNT316/ONC-392 (gotistobart) as monotherapy in patients with metastatic NSCLC whose disease progressed on anti-PD-1/PD-L1 antibody based therapy.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The trial initiation followed the U.S. FDA Fast Track Designation granted in 2022 and is based on Phase 1/2 safety and efficacy data for the monotherapy in metastatic, immunotherapy-resistant NSCLC. The two-stage Phase 3 clinical trial will assess the efficacy and safety of BNT316/ONC-392 (gotistobart) as monotherapy compared to the standard-of-care chemotherapy (docetaxel) in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. The primary endpoint is OS. Secondary endpoints include ORR, PFS and safety. Approximately 600 patients are planned to be enrolled at clinical site</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s in the United States, China, Australia, South Korea, T&#252;rkiye, Canada, the UK and the EU countries Germany, Spain, Italy, Belgium and the Netherlands.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 2 Clinical Trial in Platinum-resistant Ovarian Cancer</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An open-label, randomized Phase 2 clinical trial (NCT05446298) evaluating BNT316/ONC-392 (gotistobart) therapy in combination with pembrolizumab in platinum-resistant ovarian cancer is ongoing. The clinical trial is evaluating two doses of BNT316/ONC-392 (gotistobart) in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy and have disease progression after one line of therapy containing bevacizumab. The primary endpoints are ORR and safety. Secondary endpoints include DOR, DCR, PFS and OS.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial in Advanced or Metastatic Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human Phase 1/2 open-label dose escalation clinical trial (NCT04140526) evaluating BNT316/ONC-392 (gotistobart) as monotherapy and in combination with pembrolizumab in patients with advanced or metastatic solid tumors is ongoing.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At the 2023 ASCO Annual Meeting and the 2023 SITC Annual Meeting, we and OncoC4 presented data from expansion cohorts in the ongoing Phase 1/2 clinical trial that demonstrated BNT316/ONC-392 (gotistobart) was generally safe and well tolerated and TEAEs were manageable. The data also demonstrated encouraging clinical activity in patients with immunotherapy-resistant NSCLC.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An open-label, randomized Phase 1/2 clinical trial (NCT05682443) assessing the efficacy and safety of BNT316/ONC-392 (gotistobart) in combination with the radioligand therapy, lutetium Lu 177 vipivotide tetraxetan (Novartis&#8217;s Pluvicto), in patients with mCRPC who have progressed on an androgen receptor, or AR pathway inhibitor was initiated in 2023 and is recruiting patients. In December 2023, the first patient was treated as part of the trial. The primary endpoint is PFS. The trial is expected to enroll approximately 144 patients at clinical trial sites in the United States.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">b) Targeted Cancer Antibodies</span></div><div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT321 for the Treatment of Pancreatic Cancer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT321 is a high affinity, fully human IgG1 monoclonal antibody targeting sialyl Lewis A (sLea), an epitope on CA19-9 which is expressed in pancreatic and other gastrointestinal cancers. sLea plays a role in tumor adhesion and metastasis formation and is a marker of an aggressive cancer phenotype.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/1b Clinical Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/1b trial (NCT02672917) is evaluating BNT321 monotherapy and in combination with mFOLFIRINOX in patients with advanced PDAC and other CA19-9+ tumors.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Data from the trial were presented at the ASCO Gastrointestinal Cancer Symposium 2024. Preclinically, BNT321 binding was observed to be highly specific and restricted to cancer tissues with sLea expression. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most frequent dose-limiting toxicities, or DLTs, for both monotherapy and for mFOLFIRINOX combination therapy are hepatic transaminase elevations.  DLTs generally occur in cycle 1 and do not preclude subsequent BNT321 administration at reduced doses. BNT321 in combination with mFOLFIRINOX was tolerable for multiple cycles. Clinical activity (27% PR, RECIST) was observed in patients receiving the combination as first or subsequent line therapy for advanced disease.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Clinical Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2 trial (NCT06069778) evaluating the safety, tolerability, and efficacy of BNT321 in combination with mFOLFIRINOX as an adjuvant therapy following curative resection in patients with PDAC has been initiated.</span></div><div style="margin-top:12pt;padding-left:24.38pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">c) Antibody Drug Conjugates (ADCs)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we broadened our access to a new technology - ADCs - because we believe this technology has the potential to replace highly toxic chemotherapy regimens and become a potential new combination backbone for cancer treatment. Our growing ADC pipeline now includes ADCs directed against four distinct targets and is of interest for a broad range of cancer types.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced a collaboration with DualityBio for exclusive licenses to two investigational ADC assets (BNT323/DB-1303 and BNT324/DB-1311) directed against targets expressed in a broad range of human cancers. In </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 2023, we signed another exclusive agreement with DualityBio to develop, manufacture and commercialize an additional ADC, BNT325/DB-1305.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we signed a strategic research collaboration and worldwide license agreement with MediLink Therapeutics for the development of a next-generation ADC, BNT326/YL202.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT323/DB-1303, an ADC in Development in Collaboration with DualityBio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT323/DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2, or HER2, a target that is over-expressed in a variety of cancers and contributes to the aggressive growth and spread of cancer cells. The program received Fast Track Designation from the U.S. FDA for endometrial cancer in January 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the U.S. FDA granted Breakthrough Therapy designation for BNT323/DB-1303 for the potential treatment of advanced endometrial cancer in patients who progressed on or after treatment with immune checkpoint inhibitors. With the Breakthrough Therapy designation, we seek to expedite the further development of BNT323/DB-1303 in this indication.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT323/DB-1303 Phase 3 Clinical Trial in Advanced or Metastatic Hormone Receptor-positive, or HR+, HER2-low Breast Cancer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ongoing randomized, multi-center, open-label Phase 3 clinical trial (NCT06018337) is recruiting to evaluate BNT323/DB1303 versus the investigator's choice of chemotherapy in advanced or metastatic HR+, HER2-low breast cancer subjects whose disease has progressed on at least two lines of prior endocrine therapy or within six months of first line endocrine therapy + cyclin-dependent 4/6 (CDK4/6) inhibitor and no prior chemotherapy. The first patient was dosed in January 2024. The trial aims to enroll approximately 532 patients. The primary endpoint is PFS. Secondary endpoints include OS, ORR, DCR, DOR and safety as well as patient-reported outcomes. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT323/DB-1303 Phase 1/2 Clinical Trial in Advanced or Metastatic HER2-expressing Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT323/DB-1303 is being evaluated in an ongoing multi-center, non-randomized, open-label, multiple dose, first-in-human Phase 1/2 clinical trial </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(NCT05150691)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with advanced/unresectable, recurrent, or metastatic HER2-expressing solid tumors, including HER2-expressing breast cancer and endometrial cancer. Most patients in this trial were recruited in the United States.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A potential registrational single-arm trial enrolling HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with endometrial carcinoma is ongoing and plans to recruit 140 patients. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and DualityBio presented data from the ongoing trial at the 2023 ASCO Annual Meeting from patients with multiple solid tumors, including breast cancer HER2-expressing tumors. BNT323/DB-1303 was well tolerated with no DLT, and no TEAEs associated with death were observed. Preliminary antitumor activity was observed in heavily pretreated HER2-expressing patients with a median of seven prior systemic treatment regimens, including other HER2 ADCs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2023, data from the ongoing trial were presented at the European Society of Gynecological Oncology (ESGO) Congress focusing on patients with advanced/metastatic endometrial cancer. BNT323/DB-1303 was observed to have a manageable safety profile, and no new safety signals were observed. Antitumor activity was observed in patients (n=17) with advanced, recurrent or metastatic HER2-expression endometrial cancer following treatment with BNT323/1303, with an ORR of 58.8% and DCR of 94.1%.</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ii. BNT324/DB-1311, an ADC in Development in Collaboration with DualityBio</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT324/DB-1311 is a topoisomerase-1 inhibitor-based ADC directed against B7H3.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT324/DB-1311 Phase 1/2 Clinical Trial in Advanced Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human, multi-center, open-label, dose escalation and dose-expansion Phase 1/2a clinical trial evaluating the safety and tolerability of BNT324/DB-1311 in patients with advanced solid tumors has been initiated and the first patient was dosed in September 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iii. BNT325/DB-1305, an ADC in Development in Collaboration with DualityBio</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT325/DB-1305 is a topoisomerase-1 inhibitor-based ADC directed against TROP2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, we and DualityBio received Fast Track Designation for BNT325/DB-1305 from the U.S. FDA for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer in patients who have received one to three prior systemic treatment regimens. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT325/DB-1305 Phase 1/2 Clinical Trial in Advanced Solid Tumors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-center, non-randomized, open-label, multiple-dose, first-in-human Phase 1/2a clinical trial (NCT05438329) evaluating BNT325/DB-1305 in patients with advanced solid tumors is ongoing. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2023, first-in-human data from the ongoing trial were presented at the ESMO Congress, in which a manageable safety profile was observed at lower dose levels. Encouraging preliminary activity of BNT325/DB-1305 was observed with an ORR of 30.4% (7/23) and DCR of 87.0% (20/23), both unconfirmed at the time of the presentation. 13 NSCLC patients had an unconfirmed ORR of 46.2% (6/13), and an unconfirmed DCR of 92.3% (12/13).</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2023, two new cohorts were added to the study: a cohort to evaluate BNT325/DB-1305 monotherapy in cervical cancer and a cohort to assess the combination of BNT325/DB-1305 with pembrolizumab in NSCLC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">iv. BNT326/YL202, an ADC in Development in Collaboration with MediLink Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT326/YL202 is a topoisomerase-1 inhibitor-based ADC directed against HER3. HER3 is a target that is overexpressed in various cancer types, such as NSCLC and breast cancer and is closely associated with tumor metastasis and disease progression. Furthermore, HER3 expression is upregulated after frontline drug therapy, making it an adequate target for cancer treatment resistance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing BNT326/YL202 Phase 1 Clinical Trial in NSCLC and Breast Cancer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-center, open-label, first-in-human Phase 1 clinical trial (NCT05653752) evaluating BNT326/YL202 as a later-line treatment in patients with locally advanced or metastatic epidermal growth factor receptor, or EGFR-mutated NSCLC or HR-positive and HER2-negative breast cancer is ongoing.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2624"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Oncology Small Molecule Immunomodulator Product Candidates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i. BNT411, a Small Molecule TLR7 Agonist for the Treatment of Solid Tumors, including SCLC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BNT411 is a TLR7 agonist that is designed to activate both the adaptive and innate immune system through the TLR7 pathway. This activity and the release of cytokines and chemokines are designed to result in the potent stimulation of antigen-specific CD8+ T cells, B cells and innate immune cells such as natural killer cells, or NK cells, and macrophages.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ongoing Phase 1/2 Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1/2, first-in-human, open-label, dose escalation trial (NCT04101357) with expansion cohorts evaluating safety, pharmacokinetics, progression of disease and preliminary efficacy of BNT411 as monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-na&#239;ve ES-SCLC is ongoing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2684"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B. Infectious Disease Programs </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2678"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Next-Generation COVID-19 Vaccine</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i. BNT162b5/6/7</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Pfizer, we are developing vaccine candidates with a stabilized antigen design aimed to increase the magnitude and breadth of antibody responses to better protect against COVID-19.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, active controlled, observer-blind Phase 2 clinical trial to evaluate the safety, tolerability and immunogenicity of stabilized spike antigen vaccine candidates is ongoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii. BNT162b2 + BNT162b4</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Pfizer, we are aiming to develop a vaccine candidate that enhances and broadens SARS-CoV-2 T-cell responses. BNT162b4 is a next-generation COVID-19 vaccine component designed to elicit T-cell immunity across epitopes. BNT162b4 encodes variant-conserved, immunogenic segments of the SARS-CoV-2 nucleocapsid, membrane, and ORF1ab proteins, targeting diverse human leukocyte antigen, or HLA, alleles. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1 clinical trial to evaluate the safety, tolerability and immunogenicity of BNT162b4, in combination with BNT162b2 is ongoing.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2660"></div><div style="margin-top:12pt;padding-left:6.24pt;text-indent:0.28pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 &#8211; Influenza Combination mRNA Vaccine Program </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> BNT162b2 + BNT161 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we and Pfizer initiated a Phase 1/2 open-label, dose-finding trial (NCT05596734)  to evaluate the safety, tolerability and immunogenicity of a combination of the COVID-19 and influenza mRNA vaccines in 180 healthy adults 18 to 64 years of age. The combination vaccine consists of our Original/Omicron BA.4-5-adapted bivalent COVID-19 vaccine and Pfizer&#8217;s quadrivalent modified RNA (modRNA) influenza vaccine. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we and Pfizer announced that the companies received Fast Track Designation from the U.S. FDA for the mRNA-based combination vaccine candidate for influenza and COVID-19. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2023, we and Pfizer announced top-line results from a Phase 1/2 clinical trial (NCT06178991) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. In the clinical trial, the vaccine candidates were compared to licensed influenza vaccines and the Pfizer-BioNTech COVID-19 Omicron BA.4-5 adapted bivalent vaccine given separately at the same visit.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data from the trial demonstrated robust immune responses to influenza A, influenza B and SARS-CoV-2 strains, as well as a safety profile consistent with the safety profile of the companies&#8217; COVID-19 vaccine.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pivotal Phase 3 clinical trial (NCT06178991) was initiated in December 2023 and aims to enroll 7,500 healthy subjects 18 to 64 years old of age. Further development is subject to entering into a definitive agreement.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3117"></div><div style="margin-top:12pt;padding-left:6.25pt;text-indent:0.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. Influenza Vaccine Program &#8211; BNT161 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we and Pfizer entered into an agreement to collaborate on an mRNA program to develop an influenza vaccine for an initial period of three years, which ended in 2021. Pfizer has since the sole responsibility, authority and control of the development, manufacturing and commercialization of all candidates and products related to the program. Upon potential approval and commercialization, we are eligible to receive a royalty on Pfizer&#8217;s sales.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">A Pfizer-initiated, randomized Phase 3 clinical trial to evaluate the efficacy, safety, tolerability and immunogenicity of a quadrivalent modRNA influenza vaccine candidate is ongoing. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3123"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Herpes Simplex Virus (HSV) Vaccine Program &#8211; BNT163</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research collaboration with the University of Pennsylvania under which we have the exclusive option to develop and commercialize mRNA vaccine candidates against up to 10 infectious disease indications. As part of this collaboration, we are developing a HSV vaccine candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human, controlled Phase 1 clinical trial (NCT05432583) evaluating the safety, tolerability and immunogenicity of BNT163, an HSV vaccine candidate for the prevention of genital lesions caused by HSV-2, and potentially HSV-1, is ongoing. Dose escalation Part A has been completed, with the last subject visit in December 2023, and Part B (safety and dose evaluation) is opening for enrollment across sites in the United States.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3129"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Tuberculosis Vaccine Program - BNT164</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two randomized, controlled, dose-finding Phase 1 clinical trials evaluating BNT164 are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa). The clinical trials&#8217; first subjects were dosed in April and August 2023, respectively. Both clinical trials will assess the safety, reactogenicity and immunogenicity of two mRNA vaccine candidates against tuberculosis. This program is run in partnership with the Bill &amp; Melinda Gates Foundation.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3135"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. Malaria Vaccine Program &#8211; BNT165</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our malaria program aims to develop a well-tolerated and highly effective mRNA vaccine with durable immunity to prevent blood-stage </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">P. falciparum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> malaria infection, thereby aiming to reducing morbidity, mortality and onward transmission, and to develop sustainable vaccine production and supply solutions on the African continent. We plan to assess several vaccine candidates, featuring components of known targets such as circumsporozoite protein (CSP), conserved, immunogenic segments of liver stage-expressed proteins as well as other antigens.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A first-in-human Phase 1 clinical trial (NCT05581641) to evaluate the safety, tolerability and exploratory immunogenicity of a vaccine candidate had its last subject last dosed in September 2023. Follow-up is ongoing until September 2024. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized, dose escalation Phase 1/2 (NCT06069544) trial to evaluate the safety, tolerability, immunogenicity and efficacy of a second investigational RNA-based vaccine candidate in a controlled human malaria infection model has been initiated. The first subject was dosed in November 2023.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3198"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. Mpox Vaccine Program &#8211; BNT166</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fully owned BNT166 program aims to develop an effective, well-tolerated and accessible vaccine for the prevention of mpox. The multivalent BNT166 mRNA vaccine candidates encode surface antigens that are expressed in the two infectious forms of the mpox virus to efficiently fight virus replication and infectivity. The program is supported through a partnership with the Coalition for Epidemic Preparedness Innovations, or CEPI, to provide equitable access to the vaccine, if successfully developed and approved, in low- and middle-income countries.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 1/2 clinical trial (NCT05988203) evaluating the safety, tolerability, reactogenicity and immunogenicity of an mRNA-based multivalent vaccine candidate has been initiated and the first subject was dosed in October 2023. The trial aims to enroll 64 healthy subjects with and without prior history of known or suspected smallpox vaccination.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3851"></div><div style="margin-top:6pt;padding-left:6.24pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. Shingles Vaccine Program &#8211; BNT167</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer are developing the first mRNA-based vaccine candidate against shingles. While there are currently approved vaccines for shingles, the goal is to develop an mRNA vaccine candidate that potentially shows high efficacy,  better tolerability and is more efficient to produce globally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A randomized, controlled, dose-selection Phase 1/2 clinical trial (NCT05703607) to evaluate the safety, tolerability, and immunogenicity of BNT167 in up to 900 healthy volunteers, 50 through 69 years of age, was initiated in February 2023. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3141"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Anti-bacterial Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech R&amp;D (Austria) GmbH is a wholly owned subsidiary of BioNTech SE focused on the development of novel anti-bacterial drugs to treat persistent bacterial infections. These development programs are based on the proprietary LysinBuilder platform, which allows the targeted development of precision anti-bacterials. The development pipeline focuses on chronic bacterial infections where antibiotics fail to cure or destroy the natural microbiomes.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2372"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VI. The mRNA Technology</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the last decade, mRNA has progressed into a promising new class of medicine, with the potential to treat a wide variety of diseases with high unmet medical needs. mRNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In mRNA, hundreds or thousands of these nucleotides are linked in a unique order to convey genetic information to cells, where it is used to express proteins with biological effects. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the COVID-19 pandemic, mRNA-based immunization for the prevention of infectious diseases is considered an innovative alternative to conventional vaccine approaches. mRNA has shown the potential to elicit potent protective immune responses against various pathogens and may offer advantages over the use of live and inactivated virus vaccines, subunit vaccines, and other nucleic-acid-based vaccine formats. According to Beissert et al (2020),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;RNA is non-infectious, non-integrating and, by virtue of rapid degradation by normal cellular processes, is only transiently active. RNA can be administered repeatedly both to prime and to boost immune responses and is not limited by anti-vector immunity. Moreover, the RNA backbone engages pattern recognition receptors in the host cell, thereby naturally adjuvanting the response to the encoded immunogen.&#8221; According to the same study, mRNA can also enable &#8220;rapid, cost-efficient, cell- and animal-material-free, scalable production without the use of egg- or cell-based culture. Thus, RNA may facilitate how vaccines are made and has the potential to enable a rapid response to emerging infections.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synthetic mRNA can be engineered to resemble mature and processed mRNA molecules that naturally occur in the cytoplasm of eukaryotic cells and can be used to transiently deliver proteins. Established mRNA manufacturing technologies can be quickly adapted to produce mRNAs of different sequences, permitting the rapid development of mRNAs with the potential to address a variety of different conditions, including cancer, infectious disease, and rare diseases. Our mRNA pipeline addresses each of these therapeutic areas.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2463"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. General Principles of mRNA Pharmacology </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a drug, manufactured mRNA provides instructions to a target cell to produce particular encoded protein(s) with a desired prophylactic or therapeutic effect. Based on these instructions, the proteins will be either secreted or remain intracellular. The mRNA drug will eventually be degraded and eliminated from the body. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA drugs are synthesized in a cell-free system by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transcription from a DNA template. This template encodes all of a functional mRNA&#8217;s structural elements with the exception of the 5&#8217; cap structure, which is co-transcriptionally incorporated. After </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transcription is performed, the template is then digested by DNases and the mRNA is purified by conventionally-used methods for isolating nucleic acids. The mRNA molecule comprises: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">an open reading frame, or ORF, which encodes for the protein of interest; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">untranslated regions, or UTRs, which flank the ORF; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">the cap and the poly(A) tail, which are the two terminal structures of the linear mRNA, and are responsible for increased stability and translational efficiency of mRNA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mRNA drug needs to be appropriately formulated in order to protect mRNA molecules against enzymatic degradation by ribonucleases and to facilitate their delivery to the target cells. The formulation is selected based on the intended application and route of delivery. After uptake into the target cell, the mRNA molecules are loaded into ribosomes, where translation into protein takes place. Subsequently, the mRNA is degraded by cellular mechanisms. Proteins encoded by the mRNA can be secreted or maintained in or on the cell.  Encoded proteins can perform functions in the body, for example, replacing activities that are deficient, or they can trigger immune responses, for example by acting as antigens (as in the case of vaccines), or by directing the immune system to a target of interest (as in the case of many therapeutic antibodies). Also, proteins encoded by the mRNA are processed by the cellular machinery and can be displayed by specialized complexes, namely MHC I or MHC II complexes, to trigger T cell responses to epitopes present within them. These complexes present the epitopes to immune cells to provoke the desired immune response. In the case of other mRNA applications, the mRNA encodes proteins that are secreted from the cells, such as antibodies, and function extracellularly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The structural elements of the mRNA have an impact on its performance. This includes potential immunogenicity, efficiency of translation and molecular stability. We leverage our extensive experience to design, synthesize, manufacture and formulate our therapeutic mRNA, and to adapt its composition to suit the desired application.  </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">The cap is added to the 5&#8217; end of the mRNA during its synthesis. Our studies have demonstrated that incorporation of a unique cap analogue into the mRNA helps to achieve superior translational performance by stabilizing the mRNA molecule and directing the immune response. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">The composition and structure of the 5&#8217; and 3&#8217; untranslated regions of the mRNA molecule are important determinants of the intracellular stability of mRNA. As a result of rigorous screening of different mRNA sequences, we identified specific UTRs that promote increased protein translation for long duration. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-17.86pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.36pt">We have performed extensive research on the structure of the poly(A) tail and the translational performance of mRNA and customized our template design accordingly. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The translational performance of mRNA can be increased by reducing contaminating double-stranded RNA, or dsRNA, from the mRNA. We have extensive expertise in different mRNA purification procedures. We have also invented a novel mRNA purification method that greatly impacts translatability of our mRNA. Depending on the protein characteristics needed for treatment of a disease, we optimize the DNA template through a proprietary codon optimization process, changing the nucleotide sequence of the template without altering the amino acid composition of the encoded protein. We make further adjustments during mRNA production to minimize the occurrence of dsRNA by-products. We believe fine-tuning the respective molecules provides a great benefit to the purpose-adapted performance of our mRNA. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2453"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B. mRNA Formats  </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2447"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. Optimized Uridine mRNA (uRNA) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nucleotide sequence of mRNA determines the amino acid sequence of the protein. In addition, the nature of nucleosides used for production of mRNA drugs can also influence recognition of the molecule by the immune system. Presence of naturally occurring uridine (U) in our optimized uridine mRNA makes it immunogenic by activating immune sensors. We have further optimized our uridine mRNA for immunogenicity of the encoded antigen (augmented presentation on MHC I and MHC II) and pharmacological activity (enhanced stability and translational efficiency). Immunogenicity of the mRNA is an added benefit when mRNA is used for immunotherapy applications, by acting as an immunotherapy adjuvant. We believe this makes our therapeutics for iNeST and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> even more potent. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2441"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. Nucleoside-modified mRNA (modRNA) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenic reaction against mRNA drugs needs to be avoided in applications where therapeutic proteins are produced, such as in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platforms. We have profound expertise in incorporating naturally-occurring modified nucleosides into our therapeutic mRNAs. We have demonstrated that the presence of a variety of modified nucleosides in the manufactured mRNA suppresses its intrinsic immune activation, while leading to superior protein production for long duration. Deimmunizing mRNA by incorporating modified nucleosides helps to avoid the production of anti-drug antibodies and to broaden the therapeutic application of these types of mRNA drugs. We believe this customization has resulted in therapeutic mRNA that is both potent and well tolerated. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2435"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. Self-amplifying mRNA (saRNA) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our self-amplifying mRNA, or saRNA, drugs use the concept of viral mRNA replication, while not being infectious, disease-causing agents themselves. saRNA resembles conventional mRNA, encoding the protein of interest, but it also encodes an RNA-dependent RNA-polymerase, called replicase, that multiplies part of the mRNA within the target cell. Thus, lower amounts of saRNA are needed compared to a regular mRNA to obtain the same amount of active protein. As we have demonstrated, our saRNA ensures high levels of sustained antigen production with a small amount of initial mRNA input. Our scientific team has designed this mRNA technology to act as a potent tool for prophylactic vaccination, with the potential for application in infectious diseases.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2429"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. Trans-amplifying mRNA (taRNA) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded on our self-amplifying mRNA capabilities and developed a novel mRNA amplification technology which separates amplification of the target mRNA and the replicase encoding mRNA. This advancement broadens the spectrum of applications by making the development of therapeutic and prophylactic mRNAs even more flexible, as the replicase can amplify mRNA encoding of not only one protein, but several different ones. In the case of vaccines, this allows us to produce the replicase in advance for use with different vaccines. Our trans-amplifying mRNA is a proprietary mRNA format that we believe is particularly well-suited for prophylactic vaccines to prevent infectious diseases. We believe that taRNA-based split-vector systems may be advantageous over saRNA with regard to safety, versatility, and manufacturing.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><img src="bntx-20231231_g3.jpg" alt="Images for 20F_Scientific section.jpg" style="height:256px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">mRNA offers a broad technology toolbox:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> We have developed and optimized mRNA formats and delivery formulations for their potency and performance, each optimized for different therapeutic applications. </span></div><div><span><br/></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2423"></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C. mRNA Delivery Formulation Technologies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deep and broad expertise in the targeted delivery of mRNA therapeutics. We are convinced that development of suitable delivery formulations in conjunction with our own therapeutic mRNAs is a key competitive advantage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main mRNA delivery formulations, each designed for different functions and optimized for therapeutic product needs, are described below: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Lipoplex nanoparticles or RNA-LPX formulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lipoplex formulation, or LPX, embeds the mRNA between a lipid bilayer, and is used for our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST platforms. We use a proprietary size- and charge-based non-viral mRNA lipoplex that we developed to deliver mRNA to dendritic cells in lymphoid compartments (such as the spleen) for optimal antigen presentation and immune response activation. A synchronized adjuvant effect is mediated by TLR7-triggering and type-I interferon-driven innate and adaptive immune stimulation. Our RNA-LPX formulation allows for intravenous administration of our investigational mRNA cancer immunotherapies. RNA-LPX protects mRNA from degradation outside of the cell and mediates its efficient uptake and expression of encoded antigens in various dendritic cell, or DC, populations. Our RNA-LPX technology is designed to deliver multiple antigens in parallel, enabling the induction of poly-specific T-cell responses. We have demonstrated in the clinic that systemic DC targeting by mRNA cancer immunotherapies can result in potent activity against shared tumor-associated antigens at very low doses. Consequently, less material would be required for treating high patient numbers, making manufacturing potentially more cost-effective.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. Lipid nanoparticle, or LNP, formulation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other applications, we encapsulate our mRNA in lipid nanoparticles, or LNPs. These formulations are suitable for our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and prophylactic vaccines against infectious disease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccines are based on an RNA-LNP platform of nucleoside modified RNA, which has blunted innate immune sensor activating capacity and thus augmented antigen expression. Our COVID-19 vaccines are formulated in LNPs. Encapsulation into LNPs enables transfection of the RNA into host cells after intramuscular injection. These LNPs are composed of four different lipids in a defined ratio. During the mixing of the RNA and the dissolved lipids, the lipids form nanoparticles encapsulating the RNA. After injection, the LNPs are taken up by the cells, and the RNA is released into the cytosol. In the cytosol, the RNA is translated to the encoded viral protein. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Polymer nanoparticles</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio also comprises polyplexes, in which the mRNA is bound to a polymer and then forms nanoparticles,  which are being utilized in certain of our discovery programs. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2411"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D. mRNA Platforms </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing multiple mRNA-based therapeutics in the oncology space, including mRNA cancer vaccines (e.g., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST), RiboMabs, and RiboCytokines, using different RNA formats and delivery formulations. We have also implemented mRNA platforms for the development of infectious disease vaccines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, each of these platforms enables the development of multiple pharmaceutical product candidates or programs. </span></div><div style="text-align:center"><img src="bntx-20231231_g4.jpg" alt="Slide2.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Our mRNA Platforms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have multiple mRNA-based platforms utilizing different mRNA formats and delivery formulations that are directed at a range of biological targets in oncology and infectious and rare diseases. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2326"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VII. Sales, Marketing and Distribution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial organization focuses on supporting sales of our COVID-19 vaccine in Germany and T&#252;rkiye. Our commercial organization is responsible for promoting our products to health care providers and providing information to stakeholders, including governmental organizations, in Germany and T&#252;rkiye. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our partnership with Pfizer, under which our commercialization responsibilities are limited to Germany and T&#252;rkiye, we are able to maintain a lean fixed cost base for our COVID-19 vaccine business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial organization is also responsible for preparing and obtaining reimbursement from third-party payors, including governmental organizations, for our COVID-19 vaccine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to build a specialized oncology sales force in major markets, including North America and Europe, while leveraging our commercial partners for co-commercialization. We are working towards being commercial-ready in oncology by the end of 2025, in anticipation of potential commercial oncology launches as soon as 2026, if approved.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1099511631255"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VIII. Manufacturing </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a fully integrated biotechnology company, with operations spanning from research through clinical development, manufacturing, and sales and marketing. To successfully bring individualized immunotherapies and vaccines to people around the world, we believe that it is crucial to have in-house manufacturing capabilities that can be efficiently scaled for global clinical and commercial distribution. We have several manufacturing sites capable of developing automated production processes for on-demand production of our investigational therapies and vaccines. These can be classified into distinct GMP manufacturing capabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate four GMP-certified manufacturing facilities in Germany, where we manufacture mRNA therapeutics and engineered cell therapies both for our own pipeline and for external customers, including a state-of-the art, multi-platform, GMP-certified manufacturing facility located in a life science industrial park in Marburg, Germany, which we acquired in October 2020 from Novartis to increase manufacturing capacity of our COVID-19 vaccine for commercial supply. We also operate a fifth facility in Germany where we manufacture custom peptides both to support our extensive immunomonitoring activities within our development programs and for third parties. Our subsidiary BioNTech Innovative Manufacturing Services GmbH, or BioNTech IMFS, has been manufacturing GMP-certified cellular products since 1999. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach has been to proactively build capacity in anticipation of demand from both internal research and development from our collaborators. We have done so by continuing to make significant investments in our manufacturing infrastructure, including our capacity to manufacture mRNA, viral vectors, cellular products and peptides. We have also collaborated with Siemens AG to develop a process for automated, on-demand production of mRNA therapies. We believe that the development and optimization of our manufacturing processes in parallel to drug development is crucial to our success. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2320"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:2.46pt">Manufacturing Operations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our manufacturing site in Marburg was approved by the EMA for manufacturing of our COVID-19 drug product in March 2021. This approval makes it one of the largest mRNA manufacturing sites worldwide. In addition, we have two GMP facilities that currently produce our COVID-19 vaccine candidates for clinical trials. We have a broad network of sub-contractors established to provide drug substance, drug conjugate, drug product, and fill and finish services to enable production.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mRNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe scaling up manufacturing for mRNA can best be executed as part of a proprietary manufacturing approach, rather than as part of an outsourcing strategy. We believe this approach allows us to maintain control of our proprietary processes and gives us the flexibility we need for scheduling batch production for our drug substances to match our development plans as they evolve. Our mRNA manufacturing is currently conducted at our in-house BioNTech IMFS facility, our BioNTech East Wing facility, and our Marburg facility. The East Wing facility is dedicated to iNeST (finished product) and bulk mRNA manufacturing. Our mRNA manufacturing process involves standardized production of all mRNA constructs and minimal restrictions in construct length. We have the capacity to undertake sterile filtration and final filling in up to 1,200 vials of various sizes in the East Wing and about 7,000 vials at IMFS. Batch sizes range from a few milligrams for individualized applications (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, iNeST) to 10g for standard mRNA applications (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, intratumoral immunotherapies and infectious diseases), and up to 720g batches for COVID-19. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facility in Marburg is one of the largest mRNA vaccine manufacturing sites worldwide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with an annual capacity of up to three billion doses of mRNA drug substance and we believe we are well positioned to supply the quantities required by global market demand.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have produced more than 2,000 batches of mRNA drug substance to support our clinical studies. We currently have infrastructure capable of producing about 100 batches of mRNA drug substance and formulated drug product per month with a turnaround time of about 30 to 40 days from sequence identification to released product. We believe we have the capacity to meet the supply needs of our current product candidates in clinical trials up to registration. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have successfully decreased the time required to deliver iNeST to patients. In 2014, it took us over three months to manually manufacture and deliver individualized immunotherapies to patients. Since December 2017, with the implementation of semiautomatic GMP manufacturing in collaboration with Siemens and other partners, we have been consistently manufacturing and delivering individualized immunotherapies in under six weeks. This advancement represents significant progress toward our target commercial manufacturing turnaround time of less than 28 days, and we were able to demonstrate less than 30 days in 2021. We plan to continue to develop additional process improvements, which we expect will further reduce our turnaround times as we progress through clinical development. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  We have end-to-end capabilities and teams in Germany and the United States with over 20 years of experience in cell therapy manufacturing, quality control and release. Our cell therapy programs target novel and known tumor-specific antigens, including patient-specific mutant neoantigens. We also leverage our mRNA vaccine technology to further boost T cell activation, expansion, and persistence. Our state-of-the-art manufacturing processes of cellular products involve the isolation of primary human blood cells and subpopulations, such as, e.g., CD3+ T-cells. Cell products are cultured, expanded and genetically modified (e.g., CAR-T cells) in aseptic production processes in specialized cleanroom facilities. We also have the capability for in-house vector and mRNA production for the genetic modification of such innovative cell therapy products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Peptides.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our custom peptide synthesis business has developed unique technologies to produce several million peptides over the past ten years to support our growing clinical pipeline. These include fast small-scale manufacturing of peptides for target and epitope discovery as well as for neoepitope characterization and production of high content arrays. It is important to synthesize highly purified peptides in order to avoid false positives in immunomonitoring in our mRNA immunotherapy trials. We also use these peptides as starting material in our engineered cell therapies. We have developed know-how to produce highly complex and purified peptide pools that consist of overlapping peptides spanning entire antigens or neoepitopes. We are currently building a new manufacturing plant of 7,500 square meters in Berlin to double </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our manufacturing capacity, thus producing more than 100,000 purified peptides per year and more than one million unpurified peptides per year.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2314"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B. Manufacturing Facilities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing sites in Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marburg</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marburg is one of our fully owned, state-of-the-art manufacturing facilities for just-in-time delivery and scalable production. Our Marburg manufacturing facility was acquired from Novartis in 2020 for less than a hundred million euros and comprises eight large and small molecule production suites across more than 100,000 square feet. Within 6 months from acquisition, the facility was retrofitted to produce mRNA vaccines. It is now one of the largest mRNA vaccine manufacturing sites globally. As of 2022, the facility has the capacity to produce up to three billion doses of mRNA drug substance vaccine annually.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marburg is our central hub for innovation and development of novel manufacturing solutions. It is a center of excellence, not only in terms of facilities and devices, but as a know-how hub with appropriate and forward-looking staff training. We have about 700 employees on site. To ensure production, we work in flexible/different shift models, e.g. 24/5.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we completed our first proprietary plasmid DNA manufacturing facility in Marburg. This aims to increase our flexibility and autonomy in manufacturing starting materials for our oncology and COVID-19 vaccine pipelines, as well as our independence for pandemic preparedness due to local production. We also expect that this manufacturing facility will facilitate faster production cycles and shorter delivery times for plasmid DNA for a number of clinical product candidates and commercial products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Idar-Oberstein</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech Innovative Manufacturing Services (IMFS): Our manufacturing operations for retroviral vectors, cell therapy products and mRNA are housed in our wholly owned subsidiary. Founded in 1997, BioNTech IMFS specializes in services for innovative therapeutic approaches. In 2009, BioNTech IMFS became our wholly owned subsidiary, giving us access to synergistic platforms and complementary expertise for development, testing and manufacturing services. BioNTech IMFS and its predecessors have had GMP-certified cell and gene therapy manufacturing capabilities since 1999, and obtained GMP manufacturing authorization for mRNA production in 2011. In 2017, BioNTech IMFS began automated manufacturing of the iNeST product candidate and entered into its first commercial supply contract for retroviral vectors. Located near Mainz, the BioNTech IMFS facility occupies over 30,000 square feet. Almost 500 staff members are employed at this facility, with collective expertise in molecular biology, cell biology and virology and a close working relationship with our R&amp;D teams in Mainz. We consider BioNTech IMFS our powerhouse for early stage mRNA material.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mainz</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech iNeST Clinical Manufacturing (East Wing): We dedicate our GMP-certified manufacturing facility at our headquarters in Mainz, Germany to the production of iNeST immunotherapies and bulk mRNA manufacturing. In 2015, our wholly owned subsidiary, BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, and Siemens announced a collaboration for developing an automated, paperless and digitalized production site for individualized mRNA. We obtained our GMP manufacturing authorization for iNeST production at our East Wing facility in June 2018 and manufactured our first drug product there the following month. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This facility contains approximately 17,000 square feet of laboratory and office space, including 4,300 square feet of GMP facilities. Almost 200 staff members are employed at this facility and operate it seven days per week. In its first year of operation, the facility manufactured and released more than 250 batches of mRNA and has manufactured and released more than 1,200 batches of mRNA since inception. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To perform our upstream process to feed into the iNeST downstream GMP manufacturing process, our headquarters also hold our core facility, which operates under GCP for labs and is currently under review to become CLIA-certified via CAP accreditation. Incoming patients&#8217; materials (blood and tumor samples) are received and analyzed, and characteristic mutations are identified before the mRNAs are constructed for each patient individually.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech Clinical Manufacturing: Our GMP-certified manufacturing facility in Kupferbergterrasse, Mainz is authorized to conduct secondary packing, labeling, storage and batch release of primary packed investigational medicinal products. This facility contains approximately 11,500 square feet of laboratory and office space, including 1,250 square feet of GMP facilities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Berlin</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JPT: JPT, our peptide manufacturing facility, was established in 2004 and became a wholly-owned subsidiary of BioNTech in 2008. JPT is located in Berlin and occupies over 16,000 square feet of clean rooms, laboratory and office space.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global manufacturing sites</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of Europe, we have acquired a site in the United States for the clinical-scale manufacture of cell therapies and a site in Singapore for the manufacturing of clinical- and commercial-scale mRNA therapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gaithersburg Clinical Manufacturing Facility. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired our site in Gaithersburg, Maryland from Kite Pharma, Inc. in August 2021. The focus of this site is to supply cell therapy products for clinical trials in the United States and to support a potential commercial product launch upon approval. The facility also hosts our U.S.-based R&amp;D team for cell therapy development.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Singapore Manufacturing Facility</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, our Singapore affiliate, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd., entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of our expansion strategy to strengthen our global footprint in Asia. Supported by the Singapore Economic Development Board (EDB), the facility will serve as our Regional Headquarters and become our first mRNA manufacturing facility in Singapore. The facility will create regional manufacturing capacities in support of our growing pipeline of mRNA-based vaccines and therapeutics across the Asia Pacific region at both commercial and clinical scales, with the potential to expand the production to other drug classes, such as cell therapies. The site will be a fully integrated mRNA manufacturing facility bringing mRNA production capabilities across drug substance and drug product, with an expected annual production capacity of up to several hundred million doses of mRNA-based vaccines after a full build-out.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">: a platform for localized and sustainable mRNA production</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an example of our innovative approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution. It was developed to ensure sustainable, equitable access to our programs, particularly in low-income countries and regions with limited infrastructure. Introduced in February 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution that works as a &#8220;Plug &amp; Play&#8221; approach with modular design, standardized equipment, and software components. Each </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a clean room, which we equip with state-of-the-art manufacturing solutions, consisting of one drug substance and one formulation module. Each module is built of six to eight ISO-sized containers. A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> can be equipped to manufacture a range of mRNA-based vaccines targeted to regional needs: for example, our COVID-19 vaccine and our investigational malaria and tuberculosis vaccines, if they are successfully developed, approved, and authorized by regulatory authorities and in line with regional demand. Each </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is intended to become a node in a decentralized and robust end-to-end manufacturing network, aiming to offer greater independence and faster regional vaccine supply. We will initially staff and operate the facilities to enable the safe and rapid initiation of the production of mRNA-based vaccine doses under stringent good manufacturing processes, in order to prepare for the transfer of know-how to local partners to facilitate operation. We believe this solution is an important step towards improving global vaccine supply. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facility in Kigali, Rwanda, we announced in December 2023 that we intend to set up and operate a clinical-scale mRNA manufacturing facility with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units in Melbourne in the State of Victoria, Australia. The site is intended to support R&amp;D and clinical-scale manufacturing of investigational mRNA-based medicines from the local ecosystem as well as from other third parties globally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Kigali Manufacturing Facility</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, six ISO-sized shipping containers for the first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finished construction in Europe and underwent quality checks by our experts. The first shipment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> units to Kigali, Rwanda arrived in March 2023. The Kigali facility is planned to initially house two sets of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">units for bulk production of mRNA vaccines and is intended to be part of a robust end-to-end manufacturing network in Africa for mRNA-based medicines. In December 2023, we reached the next milestone in the establishment of mRNA vaccine manufacturing capacities in Africa with the inauguration of our site in Kigali, Rwanda. The inauguration took place on the occasion of the set-up of the first </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Rwandan facility is intended to be a commercial manufacturing and production facility. Once fully operational, the facility&#8217;s capacity would depend on the product and its dosage. For example, if used to produce the Pfizer-BioNTech COVID-19 vaccine, the first set of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> units could produce an estimated initial annual capacity of up to 50 million doses. The facility is expected to employ approximately 100 people once operational, with roles across a range of disciplines. BioNTech plans to complete all buildings at the Kigali site and start local training of specialized personnel in the facility in 2024, with test mRNA production for process validation to be initiated in 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with the continent&#8217;s and partner countries&#8217; needs, BioNTech is committed to establishing additional manufacturing facilities in Africa upon the successful validation of the facility in Kigali.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2308"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C. Other Certifications </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech Diagnostics has a quality management system that is certified according to ISO 13485:2016 and JPT maintains a ISO 9001:2015 certified Quality Management System to allow production of European CE marked companion diagnostics. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2302"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">D. Quality Assurance </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain several Quality Assurance systems. BioNTech IMFS, BioNTech Clinical Manufacturing and BioNTech iNeST Clinical Manufacturing have implemented GMP-certified quality assurance systems. BioNTech Diagnostics has a quality management system that is certified according to ISO 13485:2016 and JPT maintains a ISO 9001:2015 certified Quality Management System. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2289"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IX. Third-Party Collaborations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have forged productive collaborations with pharmaceutical companies and academic research institutions with area expertise and resources in an effort to advance and accelerate our discovery and development programs in oncology, and also to leverage our drug classes into additional disease indications while minimizing our incremental costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborations include, without limitation: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Autolus for certain binders and the right to utilize its manufacturing capacity;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Biotheus for certain antibodies;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">DualityBio for the research and development of certain antibody drug conjugates;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Fosun Pharma for our COVID-19 vaccine program;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Genentech for our iNeST platform in our mRNA drug class;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Genmab for our next-generation checkpoint immunomodulator platform in our protein-based therapeutics drug class;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">InstaDeep, now our wholly-owned subsidiary, for AI and ML;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">OncoC4 for the research and development of certain monoclonal anti-CTLA4 antibodies; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Pfizer for our COVID-19, influenza and joint COVID-19/influenza vaccine programs, which leverage technology from our infectious disease mRNA-based platform.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We either wholly own or retain significant rights to all of our clinical stage programs, either in the form of a global share of profit and co-commercialization rights with our collaborators in certain markets or significant royalties and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones. We plan to continue to identify potential collaborators who can contribute meaningful resources and insights to our programs and allow us to more rapidly expand our impact to broader patient populations.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_137988709289986"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A. Autolus Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2024 (with effect as of February 13, 2024), we entered into a License and Option Agreement, or the Autolus License Agreement, with Autolus Therapeutics plc&#8217;s wholly-owned subsidiaries Autolus Limited and Autolus Holdings (UK) Limited, which collectively we refer to as Autolus, pursuant to which Autolus granted to us an exclusive, worldwide, sublicensable license, which we refer to as the Autolus License, to certain binders and to exploit products that express in vivo such binders, which we refer to as the Binder Licensed Products. Autolus also granted to us several time-limited options, or the Autolus Options, to acquire additional rights to specified clinical-stage product candidates, binders and technologies of Autolus, described in more detail below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that all Autolus Options are fully exercised, Autolus would be eligible to receive maximum aggregate payments of up to $582 million pursuant to the Autolus License Agreement. This maximum amount includes upfront payments, the potential milestone payments for the Binder Licensed Products described below, all option exercise fees and potential milestone payments for licenses to optioned products and technologies, and additional payments that we may pay to Autolus for an increased revenue interest with respect to Autolus&#8217;s product candidate, obe-cel, as described below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the Autolus License and the Autolus Options, we made an initial payment to Autolus of $10 million. Autolus is eligible to receive milestone payments of up to $32 million in the aggregate upon the achievement of specified clinical development and regulatory milestones for each Binder Licensed Product that achieves such milestones. Autolus is also eligible to receive a low single-digit royalty on net sales of Binder Licensed Products, subject to customary reductions, which reductions are subject to specified limits. The royalty will be increased if we, our affiliates or our sublicensees commercialize a Binder Licensed Product in an indication and country in which Autolus or its affiliates or licensees also commercializes a product containing the same binders. Under the License Agreement, we are solely responsible for, and have sole decision-making authority with respect to, at our own expense, the exploitation of Binder Licensed Products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License Agreement, Autolus has agreed to grant us the following time-limited Autolus Options:</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.68pt">an option to obtain exclusive rights to co-fund development costs of Autolus&#8217;s development-stage programs AUTO1/22 and AUTO6NG, in return for agreed upon economic terms, including an option exercise fee, milestone payments and a profit-sharing arrangement for each such product candidate, with additional options to co-promote or co-commercialize such product candidate;</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.68pt">an option to obtain an exclusive worldwide license to exploit products that express certain additional binders in vivo or, with respect to certain binders, in an antibody drug conjugate, or the Binder Option;</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.68pt">an option to obtain a co-exclusive worldwide license to exploit products that express in vivo Autolus&#8217;s modules for activity enhancement, with a non-exclusive right, in certain agreed instances, to exploit products that include Autolus&#8217;s modules for activity enhancement but do not express in vivo such modules, or the Activity Enhancement Option; and</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-14.18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.68pt">an option to obtain a non-exclusive worldwide license to exploit products that contain Autolus&#8217;s safety switches or the Safety Switch Option, and, together with the Binder Option and the Activity Enhancement Option, the Technology Options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option exercise fee for each Technology Option is a low seven-digit amount. Each of the Activity Enhancement Option and the Safety Switch Option must be exercised with respect to a given biological target or combination of targets. There is a cap on the total option exercise fee if multiple Technology Options are exercised with respect to a given target.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a cap on milestone payments across all agreements entered into as the result of our exercising one or more of the Technology Options and a cap on royalties payable on any given product for which multiple Technology Options are exercised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Autolus License Agreement, we have also agreed to financially support the expansion of the clinical development program for, and planned commercialization of, Autolus&#8217;s lead product candidate obecabtagene autoleucel, known as obe-cel. In exchange for Autolus&#8217;s grant of rights to future revenues from the sales of obe-cel products, we made </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an upfront payment to Autolus of $40 million. Autolus will pay us a low single-digit percentage of annual net sales of obe-cel products, which may be increased up to a mid-single digit percentage in exchange for milestone payments of up to $100 million in the aggregate on achievement of certain regulatory events for specific new indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Autolus License Agreement, Autolus has agreed to grant to us the option to negotiate a joint manufacturing and commercial services agreement pursuant to which the parties may access and leverage each other&#8217;s manufacturing and commercial capabilities, in addition to Autolus&#8217;s commercial site network and infrastructure, with respect to certain of each parties&#8217; CAR-T products, including our product candidate, BNT211, or the Autolus Manufacturing and Commercial Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Autolus License Agreement will continue for so long as royalties are payable in respect of Binder Licensed Products and the revenue interest is payable in respect of obe-cel products. Subject to a cure period, either party may terminate the Autolus License Agreement in the event of the other party&#8217;s uncured material breach or the insolvency of the other party. We may terminate the Autolus License Agreement, in whole or in part, for any or no reason upon a specified period of prior written notice to Autolus.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement, Registration Rights Agreement and Letter Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Autolus License Agreement, we entered into a Securities Purchase Agreement, or the Autolus Purchase Agreement, pursuant to which we purchased from Autolus American Depositary Shares, or the Autolus ADSs, each representing one ordinary share of Autolus, or the Autolus Ordinary Shares, in a private placement transaction, or the Autolus Private Placement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the initial closing on February 13, 2024, or the Initial Closing, Autolus issued 33,333,333 Autolus ADSs, or the Initial ADSs, to us for a total aggregate purchase price of $200 million. In the event that we and Autolus enter into a an Autolus Manufacturing and Commercial Agreement within 18 months of the Initial Closing, we have agreed to purchase additional Autolus ADSs, or the Subsequent ADSs and, together with the Initial ADSs, the Private Placement ADSs, not to exceed 15,000,000 Autolus ADSs, for an aggregate purchase price of up to $20 million. The total number of Subsequent ADSs that may be issued is subject to additional limitations and restrictions. The Autolus Purchase Agreement contains customary representations, warranties, and covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with entry into the Purchase Agreement, we entered into a letter agreement, or the Autolus Letter Agreement, providing us with certain additional rights and subjecting our investment in Autolus to certain restrictions. Pursuant to the Autolus Letter Agreement, we received the right to nominate a director to Autolus&#8217;s board of directors. If we acquire beneficial ownership of at least 30% of the issued and outstanding Autolus Ordinary Shares within five years of the date of the Autolus Letter Agreement, we will have the right to designate an additional director, who shall be independent. Our director nomination rights under the Autolus Letter Agreement shall automatically terminate upon our ownership of Autolus Ordinary Shares dropping below certain specified percentages. Additionally, pursuant to the Autolus Letter Agreement, we have the right to purchase equity securities sold by Autolus in bona fide financing transactions in amounts that are based on our maintaining specified ownership thresholds following such financing transactions. Pursuant to the Autolus Letter Agreement, subject to specified exceptions, we may not sell the Private Placement ADSs without Autolus&#8217;s approval for a period of six months following the applicable closing date for such Autolus ADSs. The Autolus Letter Agreement terminates upon the earlier of (a) the later of (i) three years from its signing date and (ii) such time as no securities of Autolus are held by us or our affiliates and (b) the consummation of a change of control transaction involving Autolus.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Autolus also entered into a registration rights agreement, pursuant to which Autolus has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the Private Placement ADSs.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3932"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B. Biotheus Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2023 (with effect as of December 2, 2023), we entered into a Collaboration, Option and License Agreement, or the Biotheus Collaboration Agreement, with Biotheus for the global development, manufacturing and commercialization of PM8002, a clinical stage bispecific antibody, and certain derivatives, directed to PDL-1 and VEGF, or the PM8002 Licensed Products. Biotheus retained the right to develop and commercialize PM8002 Licensed Products in mainland China, Hong Kong, Macau and the region of Taiwan, or the Biotheus Retained Territory, and we were granted the right to develop and commercialize such products outside the Biotheus Retained Territory, which we refer to as the territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotheus granted us an exclusive, royalty-bearing, sublicensable license to research, develop, manufacture and commercialize PM8002 Licensed Products, in the territory. Biotheus also granted us exclusive options to obtain exclusive, </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty-bearing, sublicensable licenses to exploit (i) PM8003, a trispecific antibody, and certain derivatives, directed to PDL1, VEGF and TGF&#946;, or the PM8003 Licensed Products, in the territory and (ii) any preclinical stage multispecific antibodies proprietary to Biotheus and directed to PDL1, VEGF and at least one other target, or the Preclinical Multispecific Licensed Products in the territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted to Biotheus an exclusive option to obtain an exclusive, royalty-bearing, sublicensable license to exploit multispecific antibodies that are variants of PM8002 Licensed Products directed to PDL1, VEGF and at least one other target, or the BioNTech Multispecific Antibodies in the Biotheus Retained Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted to us, Biotheus received an upfront payment of $55 million in cash, and is eligible to receive payments for development, regulatory and sales milestones potentially totaling over $1 billion, as well as tiered low double-digit royalties on potential future product sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biotheus Collaboration Agreement continues on a licensed product-by-licensed product basis until the last to expire payment obligation with respect to such licensed product on a country-by-country basis in the territory. Upon the expiration of the royalty term for a licensed product in a given country in the territory, the exclusive license granted to us will become a perpetual, irrevocable, exclusive, fully paid-up, and royalty-free license with respect to such licensed product in such country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach or insolvency, we may terminate the Biotheus Collaboration Agreement in its entirety or on a licensed product-by-licensed product basis for convenience with prior written notice.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3922"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C. DualityBio Global Strategic Partnership</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into three License and Collaboration Agreements with DualityBio, which we refer to as the DualityBio Agreements. Each of the DualityBio Agreements relates to specific ADC assets. The first agreement, the HER2 Agreement, relates to the ADC asset targeting HER2 and was entered into on March 16, 2023. The second agreement, the B7H3 Agreement, relates to the ADC asset targeting B7H3 and was entered into on March 31, 2023. The third agreement, the TROP2 Agreement, relates to the ADC asset targeting TROP2 and was entered into on August 4, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the three DualityBio Agreements relates to a license granted to us with respect to certain patents and know-how owned or otherwise controlled by DualityBio and our collaboration with DualityBio in the research and development of ADC therapeutics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the DualityBio Agreements, DualityBio granted us the exclusive, royalty-bearing and sublicensable right to exploit certain patents and know-how, which we refer to as the DualityBio IP, for the research, development, manufacture and commercialization of the respective ADC compound and pharmaceutical products comprising such compound, which we refer to as the DualityBio Products, in any field in the territory, which is all countries of the world except for mainland China, Hong Kong and Macau, which we refer to as the DualityBio Retained Territory. We were also granted the sole right to exploit the DualityBio IP to develop and manufacture the DualityBio Products in the DualityBio Retained Territory solely for the purpose of developing, manufacturing and commercializing the DualityBio Products in the territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party has final decision-making authority and is generally responsible for clinical trial supply costs and regulatory activities and costs with respect to their respective territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the commercialization of any DualityBio Products in the territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B7H3 Agreement also grants DualityBio the option to share the development and commercialization costs and the profits and losses from the exploitation of the first original DualityBio Product in the United States. Under the B7H3 Agreement, we have further granted to DualityBio the option to assume a percentage of the total sales force of the first original DualityBio Product in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration of DualityBio&#8217;s granting of the licenses and rights to us under the DualityBio Agreements, we have made upfront payments to DualityBio in an aggregate amount of $220 million. In addition, we agreed to make potential payments upon the achievement of specified development, regulatory and commercial milestones. Such milestone payments could amount up to $2.6 billion in the aggregate (the TROP2 Agreement also provides for additional sales milestone payments in the event DualityBio works on, and we exercise, the option regarding the next-generation product). We further agreed to between single-digit to double-digit tiered royalties on net sales of all DualityBio Products, which also differ between the DualityBio Agreements. Royalties are subject to stacking provisions and will be reduced in case of respective biosimilar products entering the market. Furthermore, we agreed to reimburse DualityBio for certain development costs.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DualityBio Agreements end on a country-by-country and DualityBio Product-by-DualityBio Product basis upon expiration of the respective last DualityBio royalty term for a DualityBio Product in that country. Thereafter, the licenses granted to us with respect to such product in such country will convert into a perpetual, exclusive, fully paid-up and royalty-free license. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach or insolvency, we may terminate each DualityBio Agreement, in whole or in part, for convenience upon prior written notice.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2275"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">D. Fosun COVID-19 Vaccine Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2020, we entered into a Development and License Agreement with Shanghai Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, for the development and commercialization in mainland China, Hong Kong special administrative region, or SAR, Macau SAR and in the region of Taiwan, or collectively the Fosun Collaboration Territory, of immunogenic compositions generated by BioNTech and comprising uridine RNA, modified RNA and/or replicon technology for prophylaxis against SARS-CoV-2 in humans. We refer to this agreement as the Fosun Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The details of the development activities to be undertaken by Fosun Pharma are to be set forth in a development plan that is being overseen by a Joint Steering Committee. Fosun Pharma&#8217;s development activities are to be undertaken at its own cost and expense. Fosun Pharma has the sole responsibility to prepare, obtain and maintain regulatory approvals for the vaccine candidates in the Fosun Territory. We agreed to give Fosun Pharma reasonable assistance with the regulatory aspects of these activities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosun Pharma has the sole responsibility, authority and control of the commercialization of a vaccine candidate in the Fosun Collaboration Territory, but must use commercially reasonable efforts to do so in accordance with an agreed commercialization plan, including by launching a vaccine product in the Fosun Collaboration Territory within three months after receiving marketing approval for it, provided sufficient quantities of the vaccine have been delivered. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain the sole right to manufacture (or have manufactured) and supply any vaccine candidates and products for development purposes and commercial sale in the Fosun Territory. We agreed to manufacture and supply all quantities of vaccine from a GMP-certified RNA manufacturing facility. As compensation for supply of the vaccine Fosun Pharma will reimburse us our manufacturing costs plus an administrative fee that is between 10 and 19 percent. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Fosun Agreement, we granted Fosun Pharma an exclusive license under certain of our owned or in-licensed intellectual property, including our patents relating to replicons, uridine RNA and modified RNA and other mRNA technology or a vaccine to use, develop, commercialize and otherwise exploit the vaccine candidates in the Fosun Territory. In the event of any failure of the development of a vaccine, we agreed to grant Fosun Pharma a right of first negotiation on a separate competent vaccine for the prophylaxis of COVID-19 in the Fosun Collaboration Territory. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the rights granted to Fosun Pharma under the Fosun Agreement, Fosun Pharma subscribed for $50 million of our ordinary shares under a separate investment agreement. In addition, under the Fosun Agreement, Fosun Pharma made an upfront payment of $1 million and agreed to potential payments of up to $14 million upon the achievement of specified development and regulatory milestones and up to $70 million upon the achievement of specified sales milestones. Fosun Pharma further agreed to pay us a royalty rate that is between 30 and 50 percent of its profits on net sales of a vaccine product, if approved, for a period of 15 years from launch of that vaccine in the Fosun Territory. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fosun Agreement ends upon expiration of the royalty term. Fosun Pharma may elect to continue to pay royalties and extend the agreement and its rights thereunder. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach or insolvency, Fosun Pharma may terminate the agreement, in whole, for convenience and with or without reason at any time upon 180 days&#8217; prior written notice. If the agreement is terminated by Fosun Pharma for cause, the licenses to Fosun Pharma survive, we will manufacture and deliver the vaccine candidate or product for one year and we will grant a non-exclusive license to a reasonably acceptable contract manufacturing organization for manufacturing of the vaccine candidate or product thereafter for development and commercialization by Fosun Pharma in the Fosun Collaboration Territory. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Fosun Agreement, we have committed not to license to any other third party in the Fosun Collaboration Territory the intellectual property licensed to Fosun for the same purpose and not to develop or commercialize the same vaccine candidate or any coronavirus vaccine in the Fosun Collaboration Territory. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">115</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2269"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">E. Genentech iNeST Collaboration </span></div><div style="margin-top:6pt;padding-left:10.3pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, we and BioNTech RNA entered into a Collaboration Agreement with Genentech and F. Hoffman-La Roche Ltd, which, as amended on June 1, 2018 and December 6, 2019, we refer to as the Genentech Collaboration Agreement, to jointly research, develop, manufacture and commercialize certain pharmaceutical products that comprise neoepitope RNAs, or the Genentech Collaboration Products, which include our iNeST development candidates, for any use worldwide. Under the Genentech Collaboration Agreement, we and Genentech agreed to perform joint research under a research plan to further improve our technology platform for the manufacturing of Genentech Collaboration Products. Under the terms of the Genentech Collaboration Agreement, Genentech paid us $310 million in upfront and near-term milestone payments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Genentech must use commercially reasonable efforts to jointly develop one or more Genentech Collaboration Products in accordance with an agreed global development plan, with the costs of such development to be shared equally. We will continue certain clinical studies that were initiated prior to the execution of the Genentech Collaboration Agreement at our sole expense, and any future material changes in the operation of such clinical studies require Genentech&#8217;s approval. Genentech may access and use any data generated in these ongoing clinical studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the clinical studies included in the global development plan, we may propose certain additional clinical studies for indications not included in the global development plan, and if the joint development committee formed by the parties does not elect to include the proposed studies in the global development plan, then we may conduct the study at our sole expense under certain conditions, and subject to certain restrictions. Genentech has the option to select any candidate in such studies for potential further joint development and/or commercialization by Genentech as a Genentech Collaboration Product. In the case that Genentech wishes to pursue the clinical development of a Genentech Collaboration Product in an indication that we are not interested in pursuing, then under certain conditions, we may opt out of the co-funding of such development and Genentech may continue do so at its own costs, except that we are obligated to repay Genentech&#8217;s development costs in the event that such product subsequently receives regulatory approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech has the sole right to commercialize the Genentech Collaboration Products on a worldwide basis, with all profits and losses from such commercialization to be split equally with us. If we exercise our right to opt out of sharing equally in future development costs for any Genentech Collaboration Products, then we will no longer split all such profits and losses for such Genentech Collaboration Products equally with Genentech and will instead receive a royalty on annual worldwide net sales of such Genentech Collaboration Products that are covered by a valid claim included in certain of our patents and certain joint patents that arise out of the collaboration. Furthermore, for certain Genentech Collaboration Products for which we share co-promotion rights with Genentech, we have the option to assume a percentage to be determined of the total sales force in the United States. and certain other countries, including Germany and other major European markets. In addition, under certain regulatory and other circumstances, we have the right to independently commercialize Genentech Collaboration Products in indications that the joint development committee declines to pursue and that Genentech does not subsequently elect to commercialize, provided that we market such Genentech Collaboration Products under a separate brand and trademark that is approved by the joint commercialization committee established by the parties as not confusingly similar to the Genentech Collaboration Products being commercialized by Genentech. Our ability to research, develop, co-promote and/or independently commercialize Genentech Collaboration Products may be terminated or limited in the event we undergo a change of control. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted to Genentech an exclusive license under certain of our intellectual property, and our interest in any jointly-owned intellectual property developed under this agreement, to research, develop, make, sell and import any pharmaceutical products that comprise neoepitope RNA. Genentech granted to us an exclusive, non-transferable, sublicensable licenses under certain Genentech intellectual property, our intellectual property exclusively licensed to Genentech, and their interest in any jointly-owned intellectual property developed under this agreement for the performance of our ongoing clinical studies and the exercise of our rights and obligations under the Genentech Collaboration Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the first marketing approval for a Genentech Collaboration Product, we have granted Genentech the first right to negotiate an exclusive license to develop, manufacture and commercialize combination therapies involving pharmaceutical products based on neoepitope RNA and pharmaceutical products based on non-neoepitope RNA for the treatment of cancer in humans. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Genentech Collaboration Agreement will remain in effect so as long as Genentech Collaboration Products are in development or commercialization, or until the date of the expiration of the last royalty term if BioNTech has exercised its option to opt-out of joint development of Genentech Collaboration Products. If the agreement expires, the licenses granted </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Genentech become fully-paid up, royalty-free and irrevocable. Genentech may terminate the Collaboration Agreement if we fail to achieve certain milestone targets or at any time for convenience with or without reason upon 60 days&#8217; prior written notice. In the event of any such termination, all rights to the development and commercialization of Genentech Collaboration Products developed under the collaboration would revert to us and Genentech would grant us licenses under its intellectual property to further develop and commercialize Genentech Collaboration Products. We would be required to pay certain royalties to Genentech for such license(s). In addition, either party may terminate the agreement upon the other party&#8217;s uncured material breach or insolvency. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Development and Supply Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the Genentech Collaboration Agreement, we entered into a Manufacturing Development and Supply Agreement with Genentech and F. Hoffman-La Roche Ltd, or the Genentech Manufacturing Agreement, which governs the manufacturing, related manufacturing development activities and supply of Genentech Collaboration Products. Pursuant to the Genentech Manufacturing Agreement, we are responsible for clinical manufacturing and supply, for developing and implementing manufacturing processes (including pursuant to specified target turnaround times), and for constructing, commissioning, qualifying and obtaining permits for the clinical facilities. We are permitted to subcontract certain steps in the clinical manufacturing process to our affiliate, BioNTech IMFS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are responsible for developing the commercial manufacturing process, which requires more stringent turnaround times than the clinical manufacturing process. Genentech will generally be responsible for conducting commercial manufacturing. We are obligated to use commercially reasonable efforts to achieve certain predetermined clinical manufacturing capacity commitments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genentech Manufacturing Agreement, we and Genentech will jointly develop a manufacturing network plan detailing the location, capacity, scale-out, associated timing and other appropriate details of the commercial manufacturing facilities. We may participate in commercial manufacturing through our right to include as part of the commercial manufacturing network one of our own facilities in the European Union or the United States and one of our own facilities in another region to be agreed upon with Genentech (provided that in each region our facility is not the first facility to be included in the commercial manufacturing network). </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2257"></div><div style="margin-top:12pt;padding-left:10.3pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. Genmab Next-generation Immunomodulator Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2015, we entered into a License and Collaboration Agreement with Genmab (together with all amendments and side letters thereto, collectively referred to as the Genmab Agreement) to jointly research, develop and commercialize polypeptide-based bispecific antibodies against certain target combinations for the treatment of cancer worldwide, or the Genmab Agreement Field, using certain Genmab technology. In connection with our entry into the Genmab Agreement, Genmab paid us an upfront fee of $10 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genmab Agreement, we and Genmab must use commercially reasonable efforts to research and develop clinical candidates, including our next-generation checkpoint immunomodulators, with costs split equally during the research and evaluation phase. Our joint activities in this phase are governed by a research plan, which is subject to annual review and updates, and which specifies the clinical candidates to be developed. This research and evaluation phase expired on September 18, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Genmab must use commercially reasonable efforts to develop candidates selected by the joint research committee, or the Genmab Collaboration Products, through preclinical and clinical development. In addition, the joint research committee may select an additional candidate, or the Genmab Back-up Candidate, as a back-up for each Genmab Collaboration Product and may decide at any time to replace the Genmab Collaboration Product with its Genmab Back-up Candidate. The preclinical and clinical development of the Genmab Collaboration Products would be performed pursuant to a development plan to be agreed upon by us and Genmab, with costs to be split equally. The joint steering committee may designate a third party as a manufacturer of a Genmab Collaboration Product or of any of its components. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Genmab must use commercially reasonable efforts to jointly commercialize all Genmab Collaboration Products and share equally all expenses and profits arising from such commercialization. We and Genmab, on a product-by-product basis and at least 12 months prior to the anticipated start of a pivotal clinical trial for a Genmab Collaboration Product, will jointly designate between the two of us a lead party responsible for establishing the distribution and marketing operations in each geographical region. Each party would be entitled to equally co-promote the products pursuant to a separately negotiated global commercialization agreement that the parties agree to negotiate. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise agreed by the joint steering committee established under the agreement, Genmab is responsible for all regulatory actions and shall own all regulatory approvals obtained for the Genmab Collaboration Products. Genmab is obligated to provides regular updates to us on regulatory activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party grants to the other party a worldwide, co-exclusive, sublicensable, royalty-free license under certain of such first party&#8217;s intellectual property, including certain patents and know-how, to perform the research under this agreement and to research, develop, make, import, use and sell Genmab Collaboration Products in the Genmab Agreement Field pursuant to the terms of the Genmab Agreement. These licenses shall continue on a country-by-country and product-by-product basis for as long as development or commercialization activities are contemplated under the Genmab Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research and evaluation phase prior to the selection of a Genmab Collaboration Product, neither we nor Genmab may engage in any research and development activity in the Genmab Agreement Field relating to the development of any bispecific antibody which targets any combination that is the subject of our joint research plan. During the preclinical and clinical development phase for any Genmab Collaboration Product, engagement in research and development activities in the Genmab Agreement Field unilaterally by a party relating to a Genmab Collaboration Product or its Genmab Back-up Candidate or any bispecific antibody which targets the same target combination for which such Genmab Collaboration Product or Genmab Back-up Candidate has been developed would require the other party&#8217;s prior written consent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party has the right to discontinue its participation in the further development and commercialization of a Genmab Collaboration Product at two points: (i) when an IND submission package has been agreed upon by the parties and (ii) when the draft clinical trial report from the first Phase 1/2 clinical trial becomes available. The party that wishes to opt out of such further development and commercialization may choose to permit the other party to continue the development and commercialization of the Genmab Collaboration Product or divest its interest in such Genmab Collaboration Product. If the opt-out party permits continued development and commercialization, the other party may elect to pursue development and commercialization of such Genmab Collaboration Product alone as a Unilateral Product, at its sole cost and subject to pre-defined milestone and royalty payments and certain additional pre-defined terms. If the other party wishes to not pursue such continued development and commercialization on such pre-defined payment and additional terms, then the parties will jointly divest their interest in such Genmab Collaboration Product to a third party, and if such divestiture fails, the parties will cease all development and commercialization of such Genmab Collaboration Product. Alternatively, if the opt-out party seeks to unilaterally divest its interest in the applicable Genmab Collaboration Product, the other party has the right of first exclusive negotiation to obtain exclusive, worldwide rights to develop and commercialize such Genmab Collaboration Product. If such unilateral divestiture fails after the other party&#8217;s exercise of its right of first exclusive negotiation, the opt-out party may either continue development and commercialization of such Genmab Collaboration Product or offer the other party to continue such development and commercialization on such pre-defined payment and additional terms as set forth above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Genmab Agreement will remain in effect until the later of (i) the expiration of the last-to-expire royalty term for any Unilateral Product or (ii) the time when no Genmab Collaboration Products are being developed or commercialized under this agreement. Either party may terminate the agreement in its entirety or on a product-by-product basis with immediate effect upon the other party&#8217;s uncured material breach or insolvency. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2022, we and Genmab expanded our global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under this expansion, we and Genmab will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the expanded collaboration, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies leveraging Genmab&#8217;s proprietary HexaBody technology platform. The first monospecific antibody candidate, GEN1053/BNT313, entered clinical trials in late 2022. GEN1053/BNT313 is a CD27 antibody based on the HexaBody technology, specifically engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell membrane of the T cells. Under the terms of the agreement, the companies will equally share the development costs and potential future profit deriving from GEN1053/BNT313. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3927"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G. InstaDeep Acquisition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.67pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2023, we entered into a share purchase agreement, or SPA, with the shareholders of InstaDeep Ltd., or InstaDeep, a leading global technology company in the field of artificial intelligence, or AI, and machine learning, or ML, under which we agreed to acquire 100% of the remaining shares in InstaDeep, excluding the shares already owned by us. The SPA was amended on July 31, 2023 to deal with certain matters arising after its execution. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.67pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the satisfaction of several customary closing conditions and regulatory approvals as defined in the SPA, the acquisition closed on July 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.67pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration to acquire the remaining InstaDeep shares, excluding the shares already owned by BioNTech, amounts to approximately &#8364;500 million in cash, BioNTech shares, and performance-based future milestone payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.67pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">InstaDeep now operates as a UK-based global subsidiary and will continue to provide its services to clients around the world in diverse industries, including in the Technology, Transport &amp; Logistics, Industrial and Financial Services sectors. Additionally, the acquisition is enabling the creation of a fully integrated, enterprise-wide capability that leverages AI and ML technologies across our therapeutic platforms and operations.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3916"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">H. OncoC4 Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2023, we and OncoC4 entered into a License and Collaboration Agreement, or the OncoC4 Agreement, for the license, development and commercialization of ONC-392 and all other monoclonal anti-CTLA4 antibodies owned or controlled by OncoC4 (referred to as OncoC4 Licensed Compounds) as of the execution date, including development of combinations of such antibody with other products, for use in humans or animals, or the OncoC4 Field.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OncoC4 granted us an exclusive license under ONC-392 and OncoC4&#8217;s interest in joint intellectual property to exploit OncoC4 Licensed Compounds and any pharmaceutical or biologic product containing OncoC4 Licensed Compound (referred to as OncoC4 Licensed Products) in the OncoC4 Field in the entire world, which we refer to as the OncoC4 Territory. Furthermore, OncoC4 granted us an exclusive option to license AI-061, which is a biopharmaceutical composition containing as its sole active ingredients both ONC-392 and an  anti-PD-1 antibody. OncoC4 retains all rights to the anti-PD-1 antibody outside of the combination with ONC-392.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to collaborate on research, development, and commercialization of ONC-392 in the OncoC4 Territory and to use commercially reasonable efforts to conduct development activities of OncoC4 Licensed Compounds and OncoC4 Licensed Products either as a monotherapy or in combination with an anti-PD-(L)1 antibody and/or standard of care product (which we refer to collectively as the Mono/PD-1/SOC Combinations) in accordance with a joint clinical development plan which is governed by a joint steering committee. All costs associated with the joint development responsibilities are shared equally between us and OncoC4. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are solely responsible for all development activities for the OncoC4 Licensed Compounds and OncoC4 Licensed Products in any other form or combination other than the Mono/PD-1/SOC Combinations (we refer to such other combinations as OncoC4 Other Combinations) at our own expense and in accordance with a research and development plan prepared by us and shared with OncoC4 through the joint steering committee. We agreed to use commercially reasonable efforts to develop an OncoC4 Licensed Product in at least one indication for an OncoC4 Other Combination. We agreed to first offer OncoC4 the opportunity to co-fund any development of a PD-1 Combination prior to pursing such development independently or with a third party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We agreed to be solely responsible, at our expense, for commercialization of OncoC4 Licensed Products worldwide and to use commercially reasonable efforts to commercialize OncoC4 Licensed Products for each approved indication in certain major markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted to us by OncoC4, we made an upfront payment of $200 million, with a portion of the upfront payment to be used to fund OncoC4&#8217;s share of the joint research and development costs related to ONC-392, and agreed to make potential payments upon the achievement of specified development and regulatory milestones and upon the achievement of specified sales milestones. We have further agreed to pay OncoC4 double digit, tiered royalties on annual net sales of OncoC4 Licensed Products during a certain royalty term starting from launch of product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:25.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OncoC4 Agreement shall continue until the last-to-expire royalty term in all countries in the OncoC4 Territory for all OncoC4 Licensed Products. Upon the expiration of the royalty term for an OncoC4 Licensed Product in a given country in the OncoC4 Territory, the exclusive license granted to us will become a perpetual, irrevocable, non-exclusive, fully paid-up, and royalty-free license with respect to such OncoC4 Licensed Product in such country. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach or insolvency, we have the right to terminate the OncoC4 Agreement in its entirety for convenience with prior written notice to OncoC4. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2281"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I. Pfizer COVID-19 Vaccine Collaboration </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2020, effective as of March 17, 2020, we entered into a Collaboration Agreement with Pfizer for the research and development of immunogenic compositions comprising RNA encoding a SARS-CoV-2 polypeptide or fragment thereof for prophylaxis against SARS-CoV-2 in humans, which we refer to as the Pfizer Corona Field. On January 29, 2021, effective as of March 17, 2020, we entered into an amended and restated Collaboration Agreement with Pfizer for the research, development and commercialization of immunogenic compositions comprising RNA in the Pfizer Corona Field, which we refer to as the Pfizer Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer agreed to collaborate on research, development and commercialization in the Pfizer Corona Field worldwide (excluding the Fosun Collaboration Territory), which we refer to as the Pfizer Collaboration Territory. The details of such activities are set forth in a research and development plan that is governed by a joint steering committee. Each party bears its own personnel and capital expenditures costs, but the parties will share the costs of all other agreed development activities (including the costs of manufacturing material for use in clinical trials) evenly. Each party will, in good faith, seek funding from government funds, non-governmental organizations and other third-party organizations to support their research and development activities. Under the Pfizer Agreement, Pfizer is leading clinical development of and is seeking regulatory approval for any candidates or products in the United States and we are leading clinical development of and are seeking regulatory approval for any candidates or products in the European Union, and we will agree on a strategy for all other countries in the Pfizer Collaboration Territory on an ongoing basis through the joint steering committees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech can solely commercialize the vaccine in Germany and T&#252;rkiye (collectively referred to as the BioNTech Commercialization Territory, which is a subset of the Pfizer-Collaboration Territory). We have the option to opt-out of commercializing the vaccine in Germany and/or T&#252;rkiye, whereupon such countries will become part of the Pfizer Commercialization Territory of the Pfizer Collaboration Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has the right to commercialize any approved COVID-19 vaccine in the rest of the Pfizer Collaboration Territory. On a country-by-country basis in relation to the United Arab Emirates, Southeast Asia, and certain developing countries, if we obtain funding from a third-party organization that obligates us to commercialize an approved vaccine in such country, we are obligated to request from Pfizer in writing a decision as to whether Pfizer wishes to commercialize or distribute such vaccine in such country in accordance with the requirements agreed with the third-party funder. If Pfizer elects not to commercialize the vaccine in such country, then such country shall become a part of the BioNTech Commercialization Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our Collaboration Agreement with Fosun expires or is otherwise terminated for any reason, as between us and any international pharmaceutical group headquartered outside of China, we have granted Pfizer a right of first negotiation to expand the Pfizer Commercialization Territory to include the Fosun Territory. See &#8220;Fosun-COVID-19 Collaboration&#8221; below for more information on the Fosun Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share responsibilities for manufacturing and supplying our approved COVID-19 vaccines. If there is insufficient supply to satisfy the entire demand for vaccines in the Pfizer Collaboration Territory, we and Pfizer have agreed to determine by mutual consent the allocation of supplies on a fair and equitable basis, subject also to any applicable law, export controls, and taking into account any government supply obligations, or supply obligations included in any agreement reached with a third-party funding organization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Agreement, we have granted Pfizer an exclusive, sublicensable license in the Pfizer Collaboration Territory under certain of our intellectual property, including our patents and know-how, relating to uridine RNA, modified RNA and replicons in the Pfizer Corona Field as well as certain intellectual property in-licensed by us from third parties, to use, research, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Agreement. We undertake to maintain in full effect all intellectual property licenses held by us at the time we entered into the Pfizer Agreement and not to modify or amend any such license in a manner that would adversely affect any of the rights granted to Pfizer under the Pfizer Agreement. We are obligated to notify Pfizer of any breach of our current licenses and may be obligated to take steps to maintain Pfizer&#8217;s access to any intellectual property licensed under such licenses. Under the Pfizer Agreement, we are obligated to indemnify Pfizer with respect to certain patent infringement claims that Pfizer elects to control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Pfizer Agreement and a certain period thereafter, we and Pfizer have committed not to research, develop, manufacture, commercialize or otherwise exploit immunogenic compositions comprising RNA in the Pfizer Corona Field, or exploit vaccine candidates or products developed under the agreement for any use, other than pursuant to the Pfizer Agreement, provided, however, that Pfizer shall have the right to work as a contract manufacturer for a third party and Pfizer shall not be precluded from acquiring a third party, or being acquired by a third party, that at the </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time of acquisition is active in the development or commercialization of an immunogenic composition comprising mRNA in the Pfizer Corona Field. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 9, 2020, Pfizer also subscribed for $113 million of our ordinary shares under a separate investment agreement. In addition, under the Pfizer Agreement, Pfizer made an upfront payment of $72 million and agreed to make potential payments of up to $563 million upon the achievement of specified regulatory and commercial milestones. We and Pfizer agreed to share development costs equally. We and Pfizer will share the gross profits from commercializing a vaccine evenly, as well as the costs for shipping. The Pfizer Agreement continues for so long as either at least a vaccine is being developed for use in the Pfizer Collaboration Territory or a vaccine is being commercialized anywhere in the Pfizer Collaboration Territory. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach, Pfizer may terminate the agreement (i) upon our insolvency or (ii) on a country-by-country basis or in its entirety for convenience upon one (1) year&#8217;s prior written notice provided that any such termination shall not become effective less than two (2) years from the first commercial sale of an approved vaccine. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2251"></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">J. Pfizer-Influenza Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2018, we and BioNTech RNA entered into a Research Collaboration and License Agreement with Pfizer, or the Pfizer Influenza Agreement, for the research, development and Pfizer&#8217;s commercialization of immunogenic compositions comprising modified RNA and/or replicon technology for prophylaxis against influenza in humans, which we refer to as the Pfizer Influenza Agreement Field. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer agreed to collaborate on the research in the Pfizer Influenza Agreement Field for an initial period of three years, ending in August 2021. The details of such research were set forth in a research plan that is governed by a Joint Steering Committee, with Pfizer holding the final decision-making right. Each party will bear its own costs under the research plan. The research term will be extended automatically by a reasonable amount of time if the activities or deliverables under the research plan are delayed due to our material breach of our research obligations under the research plan. In addition, Pfizer may unilaterally extend the research term by up to a year by making an additional payment to us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the research term expires, Pfizer has the sole responsibility, authority and control of the development, manufacturing and commercialization of all candidates and products. Pfizer undertakes to use commercially reasonable efforts to seek regulatory approval for one product in the United States and in two countries out of France, Germany, Italy, Spain, the United Kingdom and Japan, and to commercialize such product in such countries where such product has received regulatory approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Influenza Agreement, we grant to Pfizer an exclusive, worldwide, sublicensable license under certain of our intellectual property, including our patents and know-how, relating to replicons and modified RNA in the Pfizer Influenza Agreement Field as well as certain intellectual property in-licensed by us from third parties, to use, research, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Influenza Agreement. We also grant to Pfizer a non-exclusive, royalty-free, sublicensable license under all intellectual property controlled by us or our affiliates to use, develop, manufacture, commercialize and otherwise exploit candidates and products selected under the Pfizer Influenza Agreement in the Pfizer Influenza Agreement Field. We undertake to maintain in full effect all intellectual property licenses held by us at the time we entered into the agreement and to not modify or amend any such license in a manner that would adversely affect any of the rights granted to Pfizer under the Pfizer Influenza Agreement. We are obligated to notify Pfizer of any breach of our current licenses and may be obligated to take steps to maintain Pfizer&#8217;s access to any intellectual property licensed under such licenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also granted Pfizer a right of first negotiation to acquire an exclusive worldwide license under certain intellectual property controlled by us for Pfizer to develop, manufacture and commercialize immunogenic products comprising RNA for prophylaxis against respiratory syncytial virus or human cytomegalovirus. The right of first negotiation may be exercised until the end of the research term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration of the rights granted to Pfizer under the agreement, Pfizer subscribed to shares in BioNTech AG under a separate investment agreement. In addition, under the Pfizer Influenza Agreement, Pfizer made an upfront payment of $50 million and agreed to potential payments of up to $325 million upon the achievement of specified development, regulatory and commercial milestones. Pfizer further agreed to a mid-single digit to very low double-digit tiered royalty on net sales if a product is commercialized. Royalties are subject to stacking provisions. The obligation of Pfizer to pay royalties ends, on a country-by-country and a product-by-product, basis upon the later of (i) the expiration of the last valid licensed patent right covering such product category in such country, (ii) 10 years after the first commercial sale of a product of such product category in such country and (iii) the lapse of regulatory data exclusivity for the first product in </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such product category in such country. There are only two product categories: one for modified RNA and a second for replicon products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Pfizer Influenza Agreement, we have committed not to research, develop, manufacture, commercialize or otherwise exploit immunogenic compositions compromising RNA in the Pfizer Influenza Agreement Field other than pursuant to the Pfizer Influenza Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pfizer Influenza Agreement ends on a country-by-country basis upon expiration of the last royalty term for any product in that country. Thereafter, the licenses granted to Pfizer with respect to such product in such country will convert into a perpetual, exclusive, fully paid-up and royalty-free license. In addition to termination rights granted to each party in the case of the other party&#8217;s uncured material breach, Pfizer may terminate the agreement, in whole or in part, for convenience and with or without reason at any time upon 60 days&#8217; prior written notice. In addition, Pfizer is entitled to terminate the agreement and initiate a technology transfer of certain intellectual property if one of its key competitors acquires control over us. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2227"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:17.85pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">X. Government Regulation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local levels, and in the European Union and other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, record-keeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. In addition, some jurisdictions regulate the pricing of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in other jurisdictions, along with subsequent compliance with applicable statutes and regulations and other requirements of regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2221"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A. Regulation and Procedures Governing Approval of Drug and Biological Products in the United States </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations and biologics under the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. Both drugs and biologics are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject a sponsor or marketing authorization (BLA/NDA) holder to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new drug or biological product in the United States generally must satisfactorily complete each of the following steps: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable regulations, including the FDA&#8217;s good laboratory practices, or GLP, regulations; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">approval by the IRB representing each clinical site before each clinical trial may be initiated; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance applicable regulations, including GCP; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">preparation and submission to the FDA of a NDA for a drug product, or a BLA for a biological product requesting marketing approval for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development, evidence of safety, purity and potency from preclinical testing and clinical trials, and proposed labeling; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">review of the product by an FDA advisory committee, if applicable; </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current GMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">satisfactory completion of any FDA audits of the clinical study sites to assure compliance with applicable regulations and GCP, and the integrity of clinical data in support of the NDA or BLA; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">payment of user fees and securing FDA approval of the NDA or BLA; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">compliance with applicable regulations post approval, including any post-approval requirements, such as the potential requirement to implement a REMS and to conduct any post-approval studies required by the FDA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates and any future product candidates will be granted on a timely basis, or at all. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies and Investigational New Drug Application </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any drug or biological product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of an IND application. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that patients will be exposed to unreasonable health risks, and places the trial on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, submission of the IND may result in the FDA not allowing the trial to commence or not be conducted on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold issued by the FDA may therefore delay either a proposed clinical study or cause suspension of an ongoing study, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed. This could cause significant difficulties in completing planned clinical trials in a timely manner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials in Support of an NDA or a BLA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified principal investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all patients provide their informed consent for their participation. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, dosing procedures and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of the NDA or BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the study data through an onsite inspection, if necessary. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of patients. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and receive periodic reports regarding the investigation from the investigators. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated check points based on access to certain data from the study. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Phase 1 clinical trials (or Phase 1) are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as in the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Phase 2 clinical trials (or Phase 2) are generally conducted in a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase 3 clinical trials. When a drug is intended to treat life-threatening or severely debilitating illnesses, and particularly for rare diseases, the FDA may accept well-controlled Phase 2 clinical trials as adequate to provide sufficient data on the drug&#8217;s safety and effectiveness to support a decision on its approvability for marketing, in which case Phase 3 clinical trials would not be required. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">Phase 3 clinical trials (or Phase 3) proceed if the Phase 2 clinical trials demonstrate that a certain dose or dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population, often at geographically dispersed clinical trial sites, to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the product and to provide the basis for product labeling. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve an NDA or a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and/or effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials (or Phase 4). These studies may be used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials or to comply with post approval commitments could result in withdrawal of approval for products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk for patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its DSMB may suspend a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the new drug candidate or biological product candidate has been associated with unexpected serious harm to patients. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with GMP Requirements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA or a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological product does not undergo unacceptable deterioration over its shelf life. In particular, the PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and others involved in the manufacture and distribution of drugs and biological products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing facilities may be subject to periodic announced and unannounced inspections by government authorities to ensure compliance with GMPs and other laws. Manufacturers may have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Review and Approval of an NDA or a BLA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of an NDA or a BLA requesting a license to market the product. These applications must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling. The FDA adjusts the Prescription Drug User Fee Act, or PDUFA, user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days after submission of the application to conduct an initial review to determine whether the NDA or BLA is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is substantially complete so as to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to complete its initial review of a standard application and respond to the sponsor within ten months of the 60-day filing date, and for a priority review application within six months. The FDA does not always meet its PDUFA goal dates for standard and priority NDA or BLA applications, and its review goals are subject to change from time to time. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may also be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews NDA and BLA applications to determine, among other things, whether the proposed product is safe and potent, and/or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter, denial letter or complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. Under the FDCA, the FDA may approve an NDA if it determines that the product is safe and effective for its intended use, the benefits of the drug outweigh any risks, and the methods used in manufacturing the drug and the controls used to maintain the drug&#8217;s quality are adequate to preserve the drug&#8217;s identity, strength, quality and purity. Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. If the application is not approved, the FDA may </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. If a complete response letter is issued, the sponsor may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors that receive a complete response letter who elect to address the deficiencies may submit to the FDA information that represents a complete response to the issues identified by the FDA in the response letter. Such resubmissions are classified under PDUFA as either Class&#160;1 or Class&#160;2, based on the information submitted by a sponsor in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review and act on a Class&#160;1 resubmission with two months of receipt and, with respect to a Class&#160;2 resubmission, within six months of receipt. The FDA will not approve an application until issues identified in the complete response letter have been addressed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer the application to an Advisory Committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. In particular, the FDA may refer applications for novel drug or biological products or drug or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an Advisory Committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a new product, it may limit the approved indications for use of the product, or limit the approval to specific dosages. It may also require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including risk evaluation and mitigation strategies, or REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Track, Breakthrough Therapy and Priority Review Designations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request that the FDA designate the drug or biologic as a fast track product at any time during the clinical development of the product. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or the FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to facilitate the design of clinical trials in an efficient manner. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application to six months (compared to 10 months under standard review). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation, priority review and breakthrough therapy designation may expedite the development or approval process, but do not change the standards for approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated Approval Pathway </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has stated that although it has limited experience with accelerated approvals based on intermediate clinical endpoints, such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, may lead the FDA to withdraw the product from the market. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated approval pathways are available for regenerative medicine therapies that meet certain conditions. Regenerative medicine therapies include cell therapies (both allogeneic and autologous), therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except those regulated under section 361 of the PHSA. Human gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues, may also meet the definition of a regenerative medicine therapy, as may xenogeneic cell products. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regenerative medicine therapies designed to treat, modify, reverse or cure serious conditions are eligible for FDA&#8217;s expedited programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, if they meet the criteria for such programs. They may also be eligible for Regenerative Medicine Advanced Therapy Designation, or RMAT designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investigational drug is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, it is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs for such condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMAT designation confers all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. The FDA reviews each application on a case-by-case basis to determine whether the clinical evidence is sufficient to support RMAT designation, considering factors such as the rigor of data collection, the consistency and persuasiveness of the outcomes, the number of patients, and the severity, rarity or prevalence of the condition, among other factors. The FDA may decline to grant RMAT designation if it finds the clinical evidence insufficient. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMAT designation may expedite the development or approval process, but it does not change the standards for approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergency Use Authorizations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secretary of Health and Human Services has the authority to authorize unapproved medical products, including vaccines, to be marketed in the context of an actual or potential emergency that has been designated by government officials. The COVID-19 pandemic has been designated such a national emergency. After an emergency has been announced, the Secretary of Health and Human Services may authorize the issuance of, and the FDA Commissioner may issue, Emergency Use Authorizations, or EUAs, for the use of specific products based on criteria established by statute, including that the product at issue may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. An EUA is subject to additional conditions and restrictions and is product-specific. An EUA terminates when the emergency determination underlying the EUA terminates or full approval is obtained. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, so it is not possible to predict how long an EUA may remain in place.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or for a new indication for an existing product is obtained, the sponsor will be required to comply with rigorous and extensive post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed on the particular product as part of the approval process. The sponsor will be required, among other things, to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including GMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the BLA holder and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with GMP regulations and other regulatory requirements. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market study requirements or clinical trial requirements to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">fines, untitled letters or warning letters or holds on post-approval clinical trials; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">adverse publicity; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">injunctions, fines, debarment, disgorgement of profits or the imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the United States. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies a company for certain financial incentives, including tax advantages and, if the product receives the first FDA approval for the indication for which it has orphan designation, market exclusivity for seven years following the date of the product&#8217;s marketing approval. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Once a product receives orphan drug designation from the Office of Orphan Products Development at the FDA, the product must then go through the review and approval process like any other product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, the manufacturer makes a showing of clinical superiority over the product with orphan exclusivity, or the sponsor is unable to provide sufficient quantities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Studies and Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, an NDA or a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors who are planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must also submit pediatric study plans prior to the assessment data, and no later than 60 calendar days following an end-of-Phase 2 meeting with the FDA or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. Pediatric study plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA or a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Reference Product Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2209"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">B. Regulation and Procedures Governing Approval of Medicinal Products in the European Union </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process governing approval of medicinal products, including biological medicinal products and advanced therapy medicinal products, or ATMPs, which comprise gene therapy products, somatic cell therapy products and tissue-engineered products, in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical and clinical studies to establish the safety and efficacy of the medicinal product for each proposed indication. Moreover, an applicant must also demonstrate the ability to manufacture the product to a suitable quality. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Approval </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until recently, pursuant to the Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, a sponsor must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the sponsor may only start a clinical trial at a specific study site after the independent ethics committee has issued a favorable opinion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which took effect on January 31, 2022 and replaced the Clinical Trials Directive 2001/20/EC. Commission Implementing Regulation (EU) 2017/556 replaced the GCP Directive 2005/28/EC. The Regulation has overhauled the former system of approvals for clinical trials in the European Union. Specifically, the Regulation, which is directly applicable in all member states, aims to simplify and streamline the approval of clinical trials in the European Union. For instance, Regulation (EU) No 536/2014 enables sponsors to submit one online application via a single online platform known as the Clinical Trials Information System (CTIS) for approval to run a clinical trial in several European countries, making it more efficient to carry out such multinational trials. It provides for strictly defined deadlines for the assessment of clinical trial applications. This means that one national authority takes the lead in reviewing the application and the other national authorities have only a limited involvement, although the clinical trial approval is still granted by each national competent authority. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to transitional provisions under Regulation (EU) No 536/2014, trials for which a request for approval was submitted prior to January 31, 2022 may continue under the national implementations of the Directives until January 31, 2025. In addition, until January 30, 2023, clinical trial sponsors could use CTIS to apply to run a clinical trial under the Regulation or could choose to apply to run a trial under the Clinical Trials Directive. However, since January 31, 2023, clinical trial sponsors have needed to use CTIS to apply to start a new clinical trial in the EU/EEA and such trials must be run under the Regulation. By January 31, 2025, any ongoing trials approved under the Clinical Trial Directive will fall under the Regulation and information about them must be transferred to CTIS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under either regime, clinical trials must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP. Additional GCP guidelines from the European Commission, with a focus on traceability, apply to clinical trials of ATMPs. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial application must be accompanied by a copy of the trial protocol and an investigational medicinal product dossier with supporting information prescribed by applicable legislation as further detailed in applicable guidance documents. Moreover, the sponsor must take out a clinical trial insurance policy, and in most European Union countries the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsor of a clinical trial must register the clinical trial in advance, and information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial will be made public as part of the registration. The results of the clinical trial must be submitted to the competent authorities and, with the exception of non-pediatric Phase 1 trials, will be made public at the latest within 12 months after the end of the trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the European Medicines Agency, or EMA, and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use, or CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit a marketing authorization application, or MAA, either under the centralized procedure administered by the EMA or </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one of the procedures administered by competent authorities in European Union member states (decentralized procedure, mutual recognition procedure, or if the product is to be approved in only one member state, the national procedure). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. There is an increasing trend in the European Union toward greater transparency and, while certain of the manufacturing or quality information is currently generally protected as commercially confidential information, the EMA and national regulatory authorities are now liable to disclose much of the nonclinical and clinical information in marketing authorization dossiers, including the full clinical study reports, in response to freedom of information requests after the marketing authorization has been granted. In October 2014, the EMA adopted a policy under which clinical study reports would be posted on the agency&#8217;s website following the grant, denial or withdrawal of a MAA, subject to procedures for limited redactions and protection against unfair commercial use. The operation of this policy has been suspended in recent years due to priorities. However, it continues to apply the policy to COVID-19 vaccines and therapeutics. A similar transparency requirement is contained in the Clinical Trials Regulation (EU) No 536/2014.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No.&#160;1901/2006 on medicinal products for pediatric use provides that prior to obtaining a marketing authorization in the European Union in the centralized procedure, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or deferral for one or more of the measures included in the Pediatric Investigation Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union and European Economic Area member states. Pursuant to Regulation (EC) No.&#160;726/2004, the centralized procedure is compulsory for specific products, including for medicines (including vaccines) produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure is optional. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions from the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health determined by three cumulative criteria: (i)&#160;the seriousness of the disease (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., heavy disabling or life-threatening diseases) to be treated, (ii)&#160;the absence or insufficiency of an appropriate alternative therapeutic approach, and (iii)&#160;anticipation of high therapeutic benefit. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment. The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines, which are not legally binding, provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, inter alia, the preclinical studies required to characterize ATMPs, the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances.&#8221; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital, and in the case of a radio-pharmaceutical, by an authorized person; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual re-assessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of the marketing authorization of a medicinal product under exceptional circumstances follows the same rules as a &#8220;normal&#8221; marketing authorization. After five years, the marketing authorization will then be renewed under exceptional circumstances for an unlimited period, unless the EMA decides, on justified grounds, to proceed with one additional five-year renewal. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products and vaccines) if the CHMP finds that all the following requirements are met: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the benefit-risk balance of the product is positive; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">it is likely that the applicant will be able to provide comprehensive data; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">unmet medical needs will be fulfilled; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the benefit to public health of the medicinal product&#8217;s immediate availability on the market outweighs the risks due to need for further data. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A conditional marketing authorization will contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, manufacturing information and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. Once comprehensive data on the medicinal product have been obtained, the marketing authorization may be converted into a standard marketing authorization which is no longer subject to specific obligations. Initially, this is valid for five years, but can be renewed for unlimited validity. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For COVID-19 vaccines to date, the EMA has followed a so-called &#8216;rolling review&#8217; process, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> procedure by which data is assessed as it becomes available with the aim of granting a conditional marketing authorization.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union medicines rules expressly permit the member states to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal products containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods of Authorization and Renewals </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit balance by the EMA or by the competent authority of the authorizing member states. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (referred to as the &#8220;sunset&#8221; clause). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Emergency Use Authorizations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union medicines rules, as implemented into the national laws of the EU member states, permit national authorities to authorize temporarily the distribution of an unapproved medicinal product in certain emergency situations, including suspected or confirmed spread of pathogenic agents.  Such an Emergency Use Authorization (EUA) (sometimes referred to as a &#8220;temporary exemption,&#8221; i.e., a temporary exemption from the requirement to obtain a marketing authorization) would apply for the duration of the emergency only and would be limited to the member state in which it has been issued.  When considering whether to grant an EUA, the relevant member state decides, which data it requires for the grant of the EUA.  For COVID-19 vaccines to date, the EU member states have not relied on EUAs.  Rather products have followed the centralized procedure combined with a rolling review of data with a view to granting conditional marketing authorizations.  Member states have relied on EUAs to permit the distribution and use of certain unapproved medicines in unapproved indications to assist in the treatment of COVID-19 patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Requirements after Marketing Authorization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety or efficacy studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in the manufacturing, processing and packing of products to assure their safety and identity. Specifically, medicinal products may only be manufactured in the European Union, or imported into the European Union from another country, by the holder of a manufacturing/import authorization from the competent national authority. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with European Union standards of good manufacturing practice, or GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the European Union. In principle, all advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines (including vaccines) is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under Directive 2001/83/EC, as amended, the details and the enforcement of these rules are governed by regulations in each member state and can differ from one country to another. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enforcement actions and consequences for non-compliance with the EU legislation are similar to those listed above for the United States. For centrally approved products in the EU, there is the possibility of fines for regulatory non-compliance with certain of the legal requirements, including in relation to obligations regarding placing the product on the market, safety monitoring and pediatric compliance.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Cells and Tissues </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human cells and tissues that are intended for human applications but that do not fall within the scope of rules governing medicinal products or medical devices are not subject to premarket review and approval, nor do they require extensive preclinical and clinical testing. However, there are European Union rules governing the donation, procurement, testing and storage of human cells and tissues intended for human application, whether or not they are ATMPs. These rules also cover the processing, preservation and distribution of human cell and tissues that are not ATMPs. Establishments that conduct such activities must be licensed and are subject to inspection by regulatory authorities. Such establishments must implement appropriate quality systems and maintain appropriate records to ensure that cells and tissues can be traced from the donor to the recipient and vice versa. There are also requirements to report serious adverse events and reactions linked to the quality and safety of cells and tissues. More detailed rules may exist at the national level. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Named Patient Supplies and Compassionate Use Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may in certain countries also apply to products manufactured in a country outside the European Union and imported to treat specific patients or small groups of patients. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some member state laws also provide for compassionate use on a &#8220;cohort&#8221; basis, subject to review and approval of the cohort program based on the local laws in the member state.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation and Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (EC) No.&#160;141/2000 and Regulation (EC) No.&#160;847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (i)&#160;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or (ii)&#160;a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the product in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the product has to be of significant benefit compared to products available for the condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a 10-year period of orphan market exclusivity. During this orphan market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Data Collection and Data Protection Laws </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with strict data protection and privacy legislation in the jurisdictions in which we operate, including the General Data Protection Regulation (EU) 2016/679, or GDPR. The GDPR governs our collection and use of personal data in the European Union relating to individuals (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., patients). The GDPR imposes several requirements on organizations that process such data, including: to observe core data processing principles; to comply with various accountability measures; to provide more detailed information to individuals about data processing activities; to establish a legal basis to process personal data (including enhanced consent requirements); to maintain the integrity, security and confidentiality of personal data; and to report personal data breaches. The GDPR also restricts the transfer of personal data outside of the European Economic Area (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., to the United States and other countries that are not deemed to provide adequate protection under their domestic laws). The GDPR may impose additional responsibility and liability in relation to personal data that we process, and require us to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the requirements of the GDPR and related national data protection laws of European </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Union member states may result in a variety of enforcement measures, including significant fines and other administrative measures. The GDPR has introduced substantial fines for breaches of the data protection rules, increased powers for regulators, enhanced rights for individuals, and new rules on judicial remedies and collective redress. We may be subject to claims by third parties, such as patients or regulatory bodies, that we or our employees or independent contractors inadvertently or otherwise breached GDPR and related data protection rules. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could be required to pay substantial fines and/or damages and could suffer significant reputational harm. Even if we are successful, litigation could result in substantial cost and be a distraction to management and other employees. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2203"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">C. Coverage, Pricing and Reimbursement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. Even if our product candidates are approved for marketing, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States (such as Medicare and Medicaid), commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for such product candidates. In the United States, the member states of the European Union and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Reimbursement rules and levels are not harmonized in the European Union and therefore differ from member state to member state. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services and imposing controls to manage costs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, and the cost of these studies would be in addition to the costs required to obtain FDA or other comparable marketing approvals. Even after pharmacoeconomic studies are conducted, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. For example, the payor may require co-payments that patients find unacceptably high. Further, one payor&#8217;s determination to provide coverage for a product does not assure that such coverage will continue or that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be adequate to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. The insurance coverage and reimbursement status of newly approved products for orphan diseases is particularly uncertain, and failure to obtain or maintain adequate coverage and reimbursement for any such product candidates could limit a company&#8217;s ability to generate revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs also has become a priority of U.S. federal and state and other non-U.S. governments as well as other third-party payors such as statutory health insurance funds, and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented or coverage may be ended in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, we will face challenges in ensuring and obtaining adequate coverage and payment for any product candidates we may develop. Pricing of prescription pharmaceuticals is subject to governmental control in many countries, including in particular the member states of the European Union. Pricing negotiations with governmental authorities or other third-party payors such as statutory health insurance funds can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial or non-interventional study that </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial or study could be expensive and result in delays in our commercialization efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. The European Union recently adopted Regulation (EU) 2021/2282 on health technology assessment, which provides a framework for member states to cooperate on health technology assessments at the EU level. The Regulation is directly applicable in all EU member states and will apply from January 12, 2025, although pricing will still be determined nationally. Moreover, at the national level, European Union member states may restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel trade (arbitrage between low-priced and high-priced member states) can further reduce prices. Special pricing and reimbursement rules may apply to orphan drugs. Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any product. Acceptance of any medicinal product for reimbursement may come with cost, use and often volume restrictions, which again can vary by country. In addition, results-based rules of reimbursement may apply. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For COVID-19 vaccine candidates in the European Union, no pricing and reimbursement or health technology assessments discussions have taken place with the respective health insurances and competent bodies at a national member state level.  Currently, COVID-19 vaccine candidates are supplied in the European Union based on vaccine supply agreements with the European Commission that is acting on behalf and in the name of the member states of the European Union. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2197"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">D. United Kingdom</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2016, in a national referendum, a majority of the electorate voted in favor of the United Kingdom leaving the European Union (commonly referred to as &#8220;Brexit&#8221;). On March 29, 2017, the United Kingdom Government formally notified the European Union of its intention to withdraw from the Union pursuant to Article 50 of the Treaty on the European Union.  The United Kingdom formally left the European Union on January 31, 2020. Pursuant to the terms of the Withdrawal Agreement between the European Union and the United Kingdom, a transitional period ran between February 1, 2020 and December 31, 2020, during which all applicable EU law, including the regulation of medicinal products, applied to and in the United Kingdom. This transitional period has now expired. On December 24, 2020, the United Kingdom and the European Union announced that they have reached agreement on the terms of their future relationship as set out in the Trade and Cooperation Agreement (&#8220;TCA&#8221;). The European Union and the United Kingdom had agreed to provisionally apply the terms of the TCA, while the formal execution was still ongoing. The TCA formally entered into force on May 1, 2021. While the TCA governs tariff and quota free trade between the United Kingdom and the European Union markets, it does not provide for regulatory alignment. The regulatory framework for medicinal products in the United Kingdom is predominantly derived from European Union law. The UK currently offers different routes to obtain a marketing authorisation: (a) a national application route with a 150-day assessment timeline, excluding clock stops or (b) a reliance route by which a company relies on a positive CHMP opinion with a 67-day assessment timeline. The original reliance route was available to companies until December 31, 2023, and has been replaced by the International Recognition Procedure since January 1, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic United Kingdom law provided that all existing European Union law in force on December 31, 2020 was retained in UK national law, subject to certain revisions that became necessary as a result of Brexit.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the Retained EU Law (Revocation and Reform) Act 2023 came into force on January 1, 2024. This revoked some retained EU laws (although not any relating to medicines regulation). All other retained EU laws have been renamed as &#8220;assimilated laws&#8221; and are no longer subject to the EU principles of interpretation. Thus, while at least initially the United Kingdom and the European Union laws relating to medicines are largely aligned, there is the potential for further divergence in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Northern Ireland Protocol to the Withdrawal Agreement, European Union law continues to apply to and in Northern Ireland. The terms of the Protocol are subject to renegotiation between the United Kingdom and the European Union. In March 2023, the Northern Ireland Protocol was adjusted by the Windsor Framework, which is another post-Brexit agreement between the EU and the UK. The Windsor Framework will be implemented gradually through into 2025 and aims to make it easier to move certain goods, including medicines, from Great Britain to Northern Ireland.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2185"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">E. Greater China</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mainland China</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States and the European Union, Mainland China has rules governing the approval for development and commercialization of drugs, including specialized rules for vaccines. China&#8217;s drug law and regulations require that the National Medical Products Administration&#8217;s, or NMPA&#8217;s, Center for Drug Evaluation, or CDE, approve a clinical trial application prior to initiating a study to support the safety and effectiveness of a drug, including a therapeutic or preventive biologic (i.e., a vaccine). This clinical trial application and the testing procedure that may precede it can be expedited if there is a pressing declared health emergency, as was the case with COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, vaccine clinical trials must be conducted at sites that are qualified disease prevention and control, or CDC, institutions and grade III hospitals, and the implementation of the trial must be in accordance with China&#8217;s general drug and specialized vaccine good clinical practice regulations and related guidelines. Other drug trials must be conducted at designated hospital sites in accordance with China&#8217;s general drug good clinical practice rules. Furthermore, prior to the commencement of the clinical trial in China each site&#8217;s ethics committee must approve the trial, and the Ministry of Science and Technology must approve the use of human samples containing genetic material and related genetic data. The human genetic resources, or HGR, approval requires a joint approval or record-filing application by the Chinese and foreign parties, setting forth the parties that will handle data and samples, the type and amount of samples that will be utilized during the study, the tests/analysis run, and the plans for storage or destruction, and the intellectual property sharing arrangement among the parties, among other items. If the research is exploratory (i.e., not tied to a program designed to obtain registration in China), patentable IP arising from the use of the HGR samples and data must be jointly owned by the Chinese and foreign parties. Once approved, the HGR approval/filing may require updates and amendments and additional procedures to transfer data to foreign parties that are not on the approval. A final report is due at the end of the study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a clinical trial in China is complete and/or foreign data is assembled, a company may submit an application for a marketing authorization, or MA, of the drug. This procedure will include submission of clinical data, manufacturing information and test results, among other items, and may include an onsite pre-market verification by the NMPA. This application may be considered more quickly if the applicant qualifies for admission to various expedited programs, including breakthrough designation for drugs that are new to the world in some respect, treat life threatening or quality of life altering diseases and either have no comparator on the market or represent a significant clinical advantage over existing approved therapies. Conditional approval procedures permit approval of a drug based on earlier stage data, but subject continued marketing to the fulfillment of post-market conditions with a designation period of time, such as the completion of additional studies. Therapeutic biologics and small molecule drugs follow similar steps to approval for development and marketing. These steps are similar for drugs that are imported and those that are produced domestically in China. However, domestically produced drugs must be produced at a facility that also obtains a drug manufacturing license based, in part, on a pre-marketing good manufacturing practice inspection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both the clinical trial and MA stages, applicants for imported drugs must list a regulatory agent on the application. The agent must be an entity in China, and it assists the sponsor and marketing authorization holder, or MAH, with fulfilling its drug regulatory obligations in China. The agent of the MAH is jointly liable with the MAH for these drug regulatory obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, vaccines may be procured by the CDC through platforms organized by the provincial governments.  Vaccines in China must be sold and directly distributed by domestic manufacturers or general distributors appointed to represent overseas makers to municipal level CDCs, which handle allocation and distribution to points of vaccination in China. Distribution of other drugs occurs through procurement processes for sales at public hospitals and sales to private </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals or pharmacies. Distributors of all drugs must possess a MA for the drug they are distributing or a drug distribution license.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with all drugs, once on the market, MAHs will also have post-market obligations, including fulfillment of post-marketing commitments. In the case of vaccines, MAHs must pay compensation for injuries caused adverse events following inoculation, or AEFIs, if the vaccine is not one required as part of the National Inoculation Program. The government bears the cost of NIP vaccines and related AEFIs. All drug MAHs are subject to other post-market obligations for drug marketing authorization holders, including recalls, annual reporting, and inspections. Drug MAs must be renewed every five years, and supplemental applications, notifications, or reports may need to be submitted for major, moderate and minor changes, respectively, to the original registration (e.g., significant manufacturing changes).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertisements of prescription drugs, including vaccines, must be pre-approved and may only be placed in approved medical journals. Other forms of &#8220;academic promotion&#8221; may be performed by medical representatives who are authorized in writing by MAHs (or their agents) and their information filed on government designated websites. Medical representatives are permitted to provide information about the drug to health care professionals (in accordance with certain procedural rules) and collect feedback as to drug safety.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hong Kong and Macao</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mainland China&#8217;s drug regulatory system does not apply in Hong Kong or Macao. These administrative regions are governed by separate laws on the development, approval, manufacturing, distribution and advertising and promotion of drugs, including vaccines. Similar rules restricting advertising and promotional content and, in the case of Macao, government approved advertisements, also apply.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2179"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">F. T&#252;rkiye</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries such as T&#252;rkiye and those in the Middle East have regulatory review processes and data requirements for medicinal products, including vaccines, similar to those described for the European Union. The regulatory licensing process in these countries may include local marketing authorization requirements, manufacturing/testing facility inspections, testing of drug product upon importation and other domestic requirements.  Some countries, such as T&#252;rkiye, have introduced specific emergency authorization regimes for COVID-19 vaccines.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2191"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G. Rest of the World Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements governing the conduct of clinical trials, product (including vaccine) licensing, pricing, and reimbursement vary from country to country in markets outside the European Union and the United States. In many markets, clinical trials must be conducted in accordance with Good Clinical Practice and applicable regulatory requirements. Ethical standards typically follow the Declaration of Helsinki principles. In response to the COVID-19 pandemic, some markets have granted or are considering the grant of emergency use authorizations for vaccine candidates instead of the otherwise available regulatory approval pathways. Supply of the COVID-19 vaccine to a number of countries outside of the United States and the European Union is similarly governed by vaccine supply agreements with local governments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Africa, there is limited harmonization of the regulation of drug and biological products across the continent, and the functionality and regulatory capacity of national medicines regulatory authorities varies between jurisdictions. For example, many regulators lack the technical expertise to independently assess marketing authorization applications and instead have adopted &#8220;reliance&#8221; procedures, whereby authorization by a foreign stringent regulatory authority or registration as a WHO pre-qualified product may be a condition for approval. The African Union (&#8220;AU&#8221;) has issued several harmonization initiatives for medicines, including establishing the AU Model Law on Medical Products Regulation in 2016 and the African Medicines Agency (&#8220;AMA&#8221;) in 2019. The AMA&#8217;s responsibilities will include evaluating medicines for the treatment of priority diseases, among other harmonization-related responsibilities, but has yet to issue any regulatory guidelines or procedures to date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to adhere to regulatory requirements may lead to, among others, fines, suspension or withdrawal of regulatory authorizations or approvals, product recalls, seizure of products, restrictions or suspensions of operations, or criminal prosecution. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">139</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2173"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">H. Healthcare Law and Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers, researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and abuse, anti-kickback, false claims, transparency and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations in the United States and elsewhere include, without limitation, the following: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in-cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">HIPAA, which created additional U.S. federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as healthcare providers, health plans and healthcare clearinghouses and their respective business associates; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the U.S. federal transparency requirements, known as the federal Physician Payments Sunshine Act, under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">U.S. federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs and which may be used in the calculation of reimbursement and/or discounts on marketed products; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the national anti-bribery laws and laws governing interactions with healthcare professionals of European Union member states; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the U.K. Bribery Act 2010; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">analogous laws and regulations in U.S. states and other jurisdictions, such as U.S. state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some U.S. state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and pricing information. Laws in U.S. states and other jurisdictions also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. U.S. federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2167"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I. Current and Future Healthcare Reform Legislation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. The Biden administration has discussed proposals to control drug pricing and new legislation may be proposed regarding government negotiation of drug pricing that may affect future profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">The Middle Class&#160;Tax Relief and Job Creation Act of 2012 required that CMS reduce the Medicare clinical laboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent years. In addition, effective January&#160;1, 2014, CMS also began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States and elsewhere over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the U.S. federal government, state legislatures, and other governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs to limit the growth of government-paid health care costs. For example, the U.S. federal government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation, from other countries and bulk purchasing. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2161"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">J. Packaging and Distribution in the United States and Other Jurisdictions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply in the United States (and similar laws may apply in other jurisdictions). Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example, (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2155"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">K. Other Environmental, Health and Safety Laws and Regulations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other jurisdictions, we may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain workers&#8217; compensation employers&#8217; liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_4149"></div><div style="text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">L. Regulation of Artificial Intelligence Systems and Models</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local levels have been actively engaged in advancing policy frameworks, discussion papers, standards, and proposed legislation regarding the development and use of AI by life sciences companies and, where applicable, applying existing regulatory frameworks to particular uses of AI (e.g., by the FDA). Likewise, the EU and other countries and jurisdictions extensively regulate (or intend to extensively regulate) the development and use of AI systems and models. The processes for monitoring emerging regulatory frameworks, evaluating how current and emerging requirements for AI apply to our business, along with subsequent compliance with applicable requirements, require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biotech company could use AI in a number of different contexts. It may use AI in the medicines lifecycle for drug discovery, for non-clinical research and development, for data analysis in clinical trials and with regard to real world data, for precision medicine (e.g., clinical decision support), for assessing eligibility for clinical trials, for drafting medicinal </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product information documents, in the manufacturing of medicinal products, or to assist with post-authorization safety monitoring, among other potential uses. If the AI is intended to perform a regulated activity (such as related to drug manufacturing, release testing, or producing clinical/diagnostic outputs) or otherwise be used in operations that are the subject of scrutiny by health authorities, the use of AI could trigger health authority oversight and, in some cases, application of existing laws and regulations relevant to healthcare, pharmaceuticals, and/or medical devices or sector-agnostic AI laws and regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the drug development and commercialization context, a biotech company may use AI for other operational reasons. For example, a company may have plans to use automated recruitment tools, deploy facial recognition technology to ensure security of its services, use customer service chatbots, or allow its employees to use generative AI or general-purpose AI tools to increase the efficiencies of administrative tasks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company will need to identify how it uses AI in its business operations, and identify the relevant applicable regulatory regime that applies to ensure compliance. Failure to adhere to (or remain up to date with evolving) regulatory requirements may lead to compliance actions, penalties and other risks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Congress, the White House, and various federal agencies have advanced proposed AI legislation, policy frameworks, whitepapers, and governing principles to address the use of AI, including when used in healthcare and life sciences. Of particular relevance to biotech companies, the FDA has been adapting and applying existing regulatory frameworks to account for AI and has issued guidance, discussion papers, and frameworks outlining FDA&#8217;s approach to regulation and oversight of health-related uses of AI. For example, FDA issued two discussion papers on the use of AI in drug manufacturing (March 2023) and the development of drug and biological products (May 2023). The discussion papers described the various ways in which AI can be used throughout various stages of biopharmaceutical development and commercialization processes and solicited stakeholder feedback on several issues, including human-led governance and transparency, quality and reliability of data, AI model performance, validation, and monitoring, and where guidance from FDA would be beneficial for the industry.  The discussion papers also recognized the potential utility of several existing &#8220;sector-agnostic&#8221; frameworks and standards, such as the AI Risk Management Framework issued by the National Institute of Standards and Technology and frameworks focused on AI-enabled medical devices. To date, FDA has been applying its existing regulations for drug and biologic discovery, development, clinical testing and manufacturing to companies utilizing AI in these processes, such that companies seeking to incorporate AI into processes that are subject to FDA oversight need to demonstrate compliance with the existing regulations for drug and biologic sponsors.  FDA also actively regulates some health-related AI as &#8220;software as a medical device,&#8221; or  SaMD, and has issued a number of guidance documents and papers over the years describing FDA&#8217;s regulatory approach to SaMD, including AI-based SaMD.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2023, the Biden Administration issued an Executive Order on the Safe, Secure, and Trustworthy Development of Artificial Intelligence, the AI Executive Order.  The AI Executive Order contained a number of directives that may impact the life sciences sector, including directives to HHS to establish an AI &#8220;Task Force&#8221; responsible for issuing guidance on a number of AI topics (such as long-term safety and real-world performance monitoring, predictive and generative AI, equity principles, and privacy and security standards), develop a strategy for regulating the use of AI in drug development processes, develop an &#8220;AI assurance policy&#8221; to evaluate the performance of AI-enabled healthcare tools, and establish a common framework for capturing clinical errors resulting from AI deployed in healthcare settings.  The AI Executive Order also sets forth certain reporting requirements for the development of certain AI models using primarily biological sequence data that meet outlined technical thresholds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of Congress also have introduced a number of bills on AI regulation.  In addition to proposed legislation, certain senators have released a proposed bipartisan framework for regulating AI that would, among other things, establish a licensing regime for certain types of higher-risk AI models, require transparency of essential information about training data, accuracy, limitations, and safety of the model, and mandate transparency with end users prior to their interaction with a model.  Another senator likewise released a whitepaper about the oversight and legislative role of Congress related to the deployment of AI in the life sciences sector, which disfavored a &#8220;one-size-fits-all&#8221; approach to AI regulation and instead called for approaches that take context of use into account and leverage existing frameworks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor developments in the regulation of AI in drug and biologic development and commercialization, or for more general business practices, and to assess the applicability of these evolving frameworks and policies as well as existing legal frameworks apply to  our uses of AI.  If we fail to meet regulator expectations or comply with applicable requirements, that could impact our ability to utilize AI-related processes or information in our development of product candidates or could subject us to delays, penalties or other risks.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU Artificial Intelligence Act, or the EU AI Act, which is scheduled for a final vote in the European Parliament in April 2024, will establish rules governing certain AI systems and general-purpose AI models that apply across the EU.  It will apply to various actors along the AI value chain, including &#8220;providers&#8221; and &#8220;deployers&#8221; of AI systems classified as &#8220;high-risk,&#8221; &#8220;providers&#8221; of general-purpose AI models, and &#8220;providers&#8221; of general-purpose AI models with &#8220;systemic risk.&#8221;  It also will prohibit certain AI practices and impose transparency requirements in relation to AI systems and general-purpose AI models generally. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU AI Act will apply to providers, located in or outside the EU, that place on the market or put into service AI systems in the EU, or that place on the market general-purpose AI models in the EU.  It will also apply to deployers of AI systems located or established in the EU, and to providers or deployers located or established outside the EU where the output of the system is used in the EU.  Whether a biotech company incurs obligations under the EU AI Act will depend on whether it develops, offers, or uses any AI systems or general-purpose AI models; whether it qualifies as a &#8220;provider,&#8221; &#8220;deployer,&#8221; or other regulated actor; and the jurisdiction where the system is put into service, where the system or model is placed on the market, or where the output of a system is used. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers and deployers of &#8220;high-risk AI systems&#8221; will need to comply with numerous obligations that apply to such systems.  The obligations for providers and deployers differ, with the majority of obligations falling to providers.  The EU AI Act also contemplates circumstances where a deployer or other third-party must assume the obligations of the provider, e.g., where the third-party makes a substantial modification to a high-risk AI system that has already been placed on the market or put into service, but where the modified system remains high risk.  The EU AI Act sets out an exhaustive list of &#8220;high-risk AI systems&#8221; in Annexes II and III.  The categories of such systems that might be relevant to offerings of biotech companies include products that require a notified body conformity assessment under the EU Medical Devices Regulation 2017/745 or EU </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Diagnostic Medical Devices Regulation 2017/746. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU AI Act will impose a separate set of obligations on providers of &#8220;general-purpose AI models&#8221; and an additional set of obligations on providers of &#8220;general-purpose AI models with systemic risk.&#8221; Models that have &#8220;high-impact capabilities&#8221; will by default be designated as models with &#8220;systemic risk.&#8221; General-purpose AI models&#8212;with or without &#8220;systemic risk&#8221;&#8212; do not constitute &#8220;AI systems&#8221; in and of themselves, but they may be integrated into general-purpose AI systems, or systems with an intended purpose, including a high-risk purpose.  Whether these obligations apply to a biotech company will depend on whether it develops any general-purpose AI models (or have them developed on its behalf) and place them on the market in the EU.  If so, it will need to assess whether any of these models qualify as general-purpose AI models with systemic risk, which would require it to comply with additional obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of particular relevance to the biotech industry, the EMA has published a draft reflection paper on the use of AI (July 2023), which is aimed at biopharmaceutical companies intending to use AI in the lifecycle of their medicines, including for drug discovery, design, and development. It also covers the use of medical devices with AI/machine-learning (ML) technology that are used to generate data or other evidence to support an EU marketing authorization for a medicine (i.e., used within the context of clinical trials or combined with the use of a medicine). The EMA&#8217;s view of &#8220;high risk&#8221; AI differs from the classifications used in the EU AI Act and requires biotech companies to assess whether the use of AI is &#8220;high-risk&#8221; for the purpose of the EU medicines rules.  This means determining whether there is a high-risk that it could impact or affect the integrity of data used to support an application for a medicine approval (and thus the EMA&#8217;s assessment of the safety and efficacy of that medicine for patients).  As a result, potentially, non-high-risk AI under the EU AI Act could still be relevant to the EMA if it impacts evidence generation for a medicine.  The EMA guidance puts the onus on marketing authorization applicants/marketing authorization holders to ensure AI used during the medicines lifecycle is compliant with the medicines rules. If a biotech company intends to use AI in the context of its medicines it will need to carry out a regulatory impact and risk analysis and potentially discuss higher risk uses with the EMA.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to adhere to (or remain up to date with evolving) EU regulatory requirements may lead to delays, compliance risks, and penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States and EU, the requirements governing the use and deployment of AI may vary from country to country.  A company will need to identify how it uses AI in its business operations, and identify the relevant applicable regulatory regime that applies to ensure compliance.  Failure to adhere to (or remain up to date with evolving) regulatory requirements may lead to delays, compliance risks, and penalties.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2144"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">XI. Intellectual Property </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">144</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2138"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A. Introduction </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a layered intellectual property strategy to protect our various technology platforms and their application to the treatment of serious diseases, such as cancer and infectious diseases including COVID-19. One focus of our intellectual property strategy is to provide protection for our platforms and products as they are developed. We also pursue intellectual property protection for assets that may be used in future development programs, may be of interest to our collaborators, and/or otherwise may prove valuable in the field. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various aspects of our technology platforms and our product candidates are claimed in patent filings. We also pursue other modalities of intellectual property protection, including trademark and trade secret protection, as appropriate. Many of our intellectual property assets were developed and are owned solely by us, some have been developed via collaboration and are jointly owned, and some have been acquired by acquisition and/or licensed from third parties. We expect that we will continue to make additional patent application filings, and will continue to pursue opportunities to acquire and license additional intellectual property assets, technologies, platforms and/or product candidates, as developments arise or are identified. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless, we cannot be certain that any of the patent filings or other intellectual property rights that we have pursued or obtained will provide protection for any products as commercialized. The original version of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> COVID-19 vaccine product and our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine have been approved, and our bivalent version (Original and Omicron BA.4/BA.5) has been authorized under Emergency Use Authorization (EUA) by the FDA in the United States for individuals 12 and older. In addition, both the original version  of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> COVID-19 vaccine product, our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine,  and our bivalent vaccine were also authorized by the FDA in the United States under EUA for individuals 6 months to &lt;12 years old. As further variants of SARS-CoV-2 arise, and its impact and characteristics evolve, the composition, manufacture, and use (including, e.g., dosage regimen) of our COVID-19 vaccine products may be adjusted or modified and our filings may not protect them. Our other product candidates are currently in clinical testing, with no certainty that they will be successful, or that significant modification or adjustment may not be required for successful commercialization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future commercial success depends, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents and other intellectual property; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating or violating the valid and enforceable patents and other intellectual property rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents, trade secrets or other intellectual property rights that cover these activities. With respect to both our owned and licensed intellectual property, we cannot be sure that patents will issue with respect to any of the owned or licensed pending patent applications or with respect to any patent applications that we, our co-owners or our licensors may file in the future, nor can we be sure that any of our owned or licensed patents or any patents that may be issued in the future to us or our licensors will be commercially useful in protecting any products that we ultimately attempt to commercialize or any method of making or using such products. Moreover, we may be unable to obtain patent protection for certain of our product candidates generally as well as with respect to certain indications. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; in this Annual Report on Form 20-F. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2024, our overall owned and in-licensed patent portfolio included more than 350 patent families, each of which includes at least one filing in the United States or Europe, and several of which are pending or granted in multiple jurisdictions. The patent families include at least 200 patent families that are solely or jointly owned by BioNTech, including certain families acquired through our acquisitions and others that we have licensed from a third party. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An issued patent provides its owner (or possibly its licensee) with a right to exclude others from making, using or selling that which is claimed in the patent, for a specified period of time (the &#8220;term&#8221; of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20 years from their effective filing date (which is the earliest non-provisional filing date to which the patent claims priority). However, many jurisdictions, including the United States, require the payment of periodic maintenance fees in order for patents to remain in force for the full 20-year term. The United States also has provisions that require a patent term to be shortened if its claims are too similar to another patent owned by the same party that has a shorter term. The United States and certain other jurisdictions also have provisions that permit extension of patent term for patents that claim a drug or drug product, or its approved use, if the patent was issued before clinical trials were completed and certain other requirements </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were satisfied. In the United States, such extension is called a Patent Term Extension, or PTE, and it is limited to a period of not more than five years, or the total patent term including the PTE cannot exceed 14 years after the date of regulatory approval; only one patent can be extended per product approval. We did not extend any patent for our COVID-19 vaccine (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) when it was approved by the FDA in the United States in 2021. The United States also offers a different form of patent term extension, known as Patent Term Adjustment, or PTA, whereby a particular patent&#8217;s term is automatically extended beyond the 20-year date if the U.S. Patent and Trademark Office, or the USPTO, caused delay during its examination; however, potentially available PTA is reduced by any amount of any delay caused by the patent applicant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below, we provide a summary of the contours of our current patent portfolio as it relates to different aspects of relevant technology, including noting ownership and patent terms for filings included in the portfolio that are directed to such aspects. Particularly given our pre-commercial state of development for many product candidates, we cannot be certain that any of the patent filings in our portfolio will provide meaningful protection for products that we do or attempt to commercialize. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2128"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">B. Patent Portfolio </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolios for our most advanced programs are summarized below. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted to the USPTO and similar authorities for examination can be significantly narrowed by the time they issue, if they issue at all. We expect this could be the case with respect to some of our pending patent applications referred to below. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2122"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. mRNA </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for our mRNA therapeutic platforms and product candidates includes patent filings directed to features of therapeutic mRNA structures, some of which are included in our COVID-19 vaccine and in current development candidates. Our patent portfolio also includes patent filings directed to mRNA formulations (including their production and use), including the lipoplex formulations currently utilized with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST platforms, and the lipid nanoparticles currently utilized with our mRNA, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platforms, as well as patent filings directed to mRNA manufacturing, and to uses of mRNA therapeutics. We provide more detail below regarding the patent filings directed to these features. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA Structure </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes patent filings directed to various features of mRNA structure, which may, for example, contribute to increased immunogenicity (e.g., antigen presentation), translation efficiency, and/or stability of mRNA constructs that include them. Such features include, for example, antigen-MHC fusions, 5&#8217; cap structures and related features, 3&#8217; UTR structures, polyA tails, reduced-uracil content mRNAs, and modified nucleoside RNAs. Filings directed to each of these features, and/or to RNA constructs that include them (singly or in combination), or collectively, the mRNA Structure Filings, have been made in the United States and various other jurisdictions. Some such mRNA Structure Filings are owned solely by BioNTech SE, which are referred to collectively in this section as BioNTech, some jointly by BioNTech and one or more third parties, and some by BioNTech licensors, such as Louisiana State University, or LSU, and the terms of the applicable agreement with LSU, are further summarized below in &#8220;C. In-Licensing.&#8221; We have non-exclusive rights to use certain U.S. and European patent filings owned by University of Pennsylvania and relating to RNA containing modified nucleosides through our sublicense agreements with mRNA RiboTherapeutics, Inc. (MRT) and CellScript, LLC, collectively, the MRT-CellScript Sublicenses, and summarized below in &#8220;C. In-Licensing&#8221;. Issued existing mRNA Structure Filings have, and pending existing mRNA Structure Filings, if issued, would have, 20-year terms that extend into the mid-2020s to the early-2040s.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA Formulations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes patent filings directed to various formulations for mRNA delivery, some of which are utilized with current development candidates. For example, our portfolio includes patent filings directed to lipoplex formulations and preparations thereof or collectively, the mRNA Lipoplex Filings. Issued mRNA Lipoplex Filing(s) has/have, and pending existing mRNA Lipoplex Filings, if issued, would have, 20-year terms that extend into the mid to late-2030s. Such mRNA Lipoplex Filings are solely owned by BioNTech or jointly owned by BioNTech and TRON. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our portfolio includes U.S. and other patent filings directed to lipid nanoparticles and polyplex technologies, which are solely owned by BioNTech or jointly owned by BioNTech and TRON, or collectively, the mRNA Lipid Nanoparticle/Polyplex Filings. Issued mRNA Lipid Nanoparticle/Polyplex Filings have, and pending mRNA Lipid Nanoparticle/Polyplex Filings, if issued, would have, 20 year terms that extend into the mid- to late 2030s or early 2040s. Some of such mRNA Lipid Nanoparticle/Polyplex Filings were granted in certain foreign jurisdictions, and currently include U.S. issued patents. The terms of the co-ownership of such patent filings with TRON are summarized below in &#8220;C. In-Licensing.&#8221;</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA Manufacturing </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed below, we utilize trade secret protection for many aspects of our mRNA manufacturing technologies, including as currently utilized for production of certain of our development candidates. In addition, our patent portfolio includes certain patent filings relevant to mRNA manufacturing, or collectively, the mRNA Manufacturing Filings, which we believe may provide commercial value to protect product candidates and/or support collaborations or other licensing arrangements. For example, our mRNA Manufacturing Filings include U.S. and other patent filings relating to certain aspects of mRNA purification and production. These mRNA Manufacturing Filings are either solely owned by BioNTech, or jointly owned by BioNTech and TRON and, if issued, would have 20-year terms that would extend into mid 2030 to early 2040s; there are patents granted in certain foreign jurisdictions including EP, but no U.S. patent was yet issued. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA Commercial Products and Product Candidates </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our COVID-19 vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our COVID-19 vaccine (BNT162b2), marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is our most advanced mRNA product, and is sold in monovalent (based on the Original strain as well as on the Omicron XBB.1.5 variant) and bivalent (one RNA based on the Original strain and one RNA based on an Omicron variant) formats. The monovalent format (Original and Omicron XBB.1.5) has received full U.S. FDA approval for individuals 12 and older and Emergency Use Authorization (EUA) for individuals 6 months to &lt;12 years old, as well as full and/or conditional marketing approval in various other jurisdictions. The bivalent format (Original and Omicron BA.4/BA.5) has been authorized under EUA by the FDA in the United States for individuals 6 months and older. In Europe, two bivalent versions (Original and Omicron BA.1; and Original and Omicron BA.4/BA.5) have received marketing authorization for individuals 12 years and older. Additional COVID-19 vaccine candidates, as well as various dosing regimens and use in patient populations with certain medical conditions are being tested in clinical trials. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty and Other COVID-19 Vaccine mRNA Product Candidates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both our current and previously-marketed monovalent and bivalent COVID-19 vaccines utilize modified-nucleoside mRNA formulated in lipid nanoparticles and which encode an optimized SARS-CoV-2 full-length spike protein antigen. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform patent filings relevant to our COVID-19 vaccines, collectively, the &#8220;BNT162b2 Platform Filings&#8221;, include certain mRNA Structure Filings relating to features for increasing translation efficiency and/or stability of mRNA constructs (e.g., certain 3&#8217; UTR structures containing a specific sequence element, interrupted polyA tails, and certain 5&#8217; cap/cap proximal sequence combinations), including filings that are jointly owned by BioNTech and TRON; also relevant are certain mRNA Manufacturing Filings. Issued BNT162b2 Platform Filings have, and pending BNT162b2 Platform Filings, if issued, would have 20-year terms extending into the late-2020s to the early-2040s.  We also have undertaken various patent filings specifically related to the BNT162b2 structure (including as may be tailored based on particular SARS-CoV-2 variants), composition, formulation, packaging, use and/or manufacture, collectively the BNT162b2 Filings, including filings that have arisen through collaboration with third parties such as Pfizer. Such filings relevant to our COVID-19 vaccines, if issued, would have 20-year terms that would extend into early 2040s; there is one issued U.S. patent  and one allowed U.S. patent application within the BNT162b2 Filings that covers our COVID-19 vaccines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, our MRT-CellScript Sublicenses grant us rights to use certain U.S. and European patents and applications relating to mRNA containing modified nucleosides, including as used in BNT162b2. We also have a non-exclusive license from the National Institutes of Health granting us a right to use certain technology described in U.S. and European patent filings that may relate to SARS-CoV-2 spike (S) protein mutations that lock the S protein in an antigenically preferred prefusion conformation; such a variant is utilized in BNT162b2. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have obtained third-party licenses to technologies relating to certain lipids and/or lipid nanoparticles and formulations used in BNT162b2, including a non-exclusive license from Acuitas Therapeutics Inc., or Acuitas, granting use rights relevant to proprietary lipid nanoparticles and formulations used in BNT162b2.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional COVID-19 vaccine mRNA product candidates are being developed and tested in clinical trials, which share with BNT162b2 certain structural elements, and/or features of the composition, formulation, packaging, use and/or method of manufacture.  Thus, some or all of the BNT162b2 Platform Filings and/or BNT162b2 Filings, as well as the in-licensed rights discussed above with respect to BNT162b2, may be relevant to certain of these candidates. We have also undertaken patent filings specifically related to structures and uses of certain such additional candidates, including BNT162b4, which includes a T-cell antigen mRNA encoding SARS-CoV-2 non-spike protein antigens that are highly conserved across a broad range of SARS-CoV-2 variants and were chosen based on our proprietary target prioritization platform and which is being assessed in combination with our monovalent and bivalent COVID-19 vaccine products, and BNT162b5, a bivalent product that includes RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 Original strain and an Omicron variant. Such filings specifically relevant to BNT162b4 or BNT162b5, if issued, would have 20-year terms that would extend into the early 2040s.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are currently studying safety and efficacy of our COVID-19 vaccines and vaccine candidates in various dosing regimens (including booster doses) and/or in different age groups and/or individuals with various medical conditions, and also in combination with other vaccines or therapies. Certain of our patent filings, including certain BNT162b2 Filings, cover such uses being tested in clinical trials.</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology mRNA Product Candidates </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain mRNA oncology product candidates are also in clinical development and involve various platforms. Our pipeline also includes mRNA product candidates for treatment of certain infectious diseases beyond COVID-19, and mRNA product candidates for protein replacement therapy in certain rare diseases. We currently have more than 10 clinical oncology programs in Phase 1 or Phase 2. Our most advanced clinical oncology programs involve our iNeST immunotherapy product candidates being developed with our collaborator, Genentech. We also have </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates in Phase 1 and Phase 2 clinical trials and have initiated Phase 1 clinical trials of our mRNA-based intratumoral immunotherapy developed through our collaboration with Sanofi. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">FixVac</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates share many of the structural elements involved in our iNeST product candidates. Thus, some or all of the mRNA Structure Filings relevant to our iNeST product candidates and discussed below are also relevant to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates. These patent filings, or the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform Filings, include mRNA Structure Filings relating to antigen-MHC fusions, certain 5&#8217; cap structures, 3&#8217; UTR structures containing a specific sequence element, and interrupted polyA tails, which are solely or jointly owned by BioNTech or BioNTech&#8217;s licensors. Issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform Filings have, and pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform Filings, if issued, would have, 20-year terms extending into the mid-2020s to the mid-2030s. While we have pursued or obtained patent protection covering components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates, manufacturing-related methods and/or formulations, we do not currently have any claims in our owned or in-licensed issued patents that cover the overall construct used in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio further includes U.S. and other patent filings relating to combined uses of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and iNeST product candidates. Such issued patent filings have, and such pending patent filings, if issued, would have, 20-year terms that extend into 2033, and are jointly owned by BioNTech and TRON. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates are studying such product candidates in treatment of various cancers. While we do not currently have any claims in our owned or in-licensed issued patents that are directed to use of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates in the indications of these clinical trials, certain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Platform Filings include specific reference to treatment of these indications, and if issued, would have 20-year terms extending into the mid-2030s. </span></div><div style="margin-top:12pt;padding-left:10.1pt;text-align:justify;text-indent:14.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">iNeST</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent filings relevant to our iNeST product candidates include mRNA Structure Filings relating to features for increasing antigen presentation (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., antigen-MHC fusions) and features for increasing translation efficiency and/or stability of mRNA constructs (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, certain 5&#8217; cap structures, 3&#8217; UTR structures containing a specific sequence element, and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">polyA tails of a particular length or interrupted polyA tails); mRNA Lipoplex Filings relating to negatively charged lipoplexes (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., for spleen targeting); and mRNA Manufacturing Filings, or collectively, the iNeST mRNA Platform Filings. While we have pursued or obtained patent protection covering components of iNeST product candidates, manufacturing-related methods and/or formulations, we do not currently have any claims in our owned or in-licensed issued patents that cover the overall construct used in our iNeST product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio further includes U.S. and other filings directed to the process of identifying neoantigens in patient samples and/or predicting those that will be immunoreactive in an iNeST immunotherapy product, or collectively, the Neoantigen Filings. Certain issued Neoantigen Filings have, and certain pending Neoantigen Filings, if issued, would have 20-year terms that extend into the 2030s. Many of the Neoantigen Filings are solely owned by BioNTech, or jointly owned by BioNTech and TRON; our acquisition of Neon added various Neoantigen Filings, including both BioNTech U.S.-owned and in-licensed filings. BioNTech and TRON jointly own issued EP patent number 2714071, whose claims recite steps relating to neoantigen selection, that were unsuccessfully opposed by multiple third parties; said third parties have appealed the decision to reject such opposition. In addition, related EP patent numbers 3473267 and 3892295 from the same patent family with claims reciting steps relating to neoantigen selection for an RNA vaccine encoding a recombinant polyepitopic polypeptide are being opposed by a third party; claims in the related U.S. case are granted. If we are unsuccessful in these opposition/appeal proceedings, the patent claims for our iNeST product candidates may be narrowed, or a patent may not issue at all. See &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property&#8221; in this Annual Report on Form 20-F. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently studying our iNeST product candidates for the treatment of metastatic melanoma and pancreatic cancer in Phase 2 clinical trials and those for the treatment of various solid tumors in Phase 1 clinical trials. Certain iNeST mRNA Platform Filings and Neoantigen Filings cover treatment of each of these indications. However, we do not currently have any claims in our owned or in-licensed issued patents that are directed to use of iNeST product candidates in the indications of these clinical trials. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intratumoral Immunotherapies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the mRNA Structure Filings (including some that are relevant to iNeST and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates, as discussed above) are also directed to one or more features of our intratumoral immunotherapies, including our most advanced intratumoral immunotherapy, which we are developing through our collaboration with Sanofi, and which has entered Phase 1 clinical trials. For example, mRNA Structure Filings relating to 3&#8217; UTR structures containing a specific sequence element, and interrupted polyA tail structures, which, as noted above are solely or jointly owned by BioNTech, provide protection to our current intratumoral immunotherapy development candidate.  Such issued patent filing(s) has/have, and such pending patent filings, if issued, would have, 20-year terms that extend into the mid-2030s. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain patent filings that are relevant to intratumoral immunotherapies include certain patent filings under the MRT-CellScript Sublicenses, which include patent filings directed to nucleotide-modified mRNAs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain patent filings have arisen from our collaboration relating to compositions including mRNAs encoding particular cytokines for treatment of solid tumors, or the mRNA Cytokine Filings. Such mRNA Cytokine Filings, if issued, would have 20-year terms that would extend into 2038. We have assigned certain of such mRNA Cytokine Filings (including one issued foreign patent) to Sanofi in accordance with our agreement. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">RiboMabs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">RiboCytokines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license a number of patent filings directed to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs. Many are owned solely by us, some are jointly owned, and some have been acquired or licensed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent filings relevant to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> programs include certain mRNA Structure Filings that are also relevant to our iNeST and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates, including certain patent filings relating to 3&#8217; UTR structures containing a specific sequence element, and interrupted polyA tail structures;  and patent filings under the MRT-CellScript Sublicenses relating to nucleoside-modified mRNAs as well as certain patent filings we have licensed from Acuitas and Genevant relating to lipid or non-liposomal formulations.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:10.1pt;text-align:justify;text-indent:14.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infectious Diseases beyond COVID-19 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is discussed elsewhere, we have collaborated with third parties, including Pfizer and the University of Pennsylvania, to develop infectious disease mRNA vaccine candidates, some of which are currently in clinical trials at different phases, including mRNA vaccines against influenza (Phase 3) and HSV (Phase 1). We are also developing our own mRNA vaccines against malaria, which has recently entered Phase 1 clinical trial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain patent filings that might be useful to our infectious disease mRNA vaccines include certain of the mRNA Structure Filings and the mRNA Lipid Nanoparticle/Polyplex Filings as well as certain patent filings under the MRT-CellScript Sublicenses, which include patent filings directed to nucleotide-modified mRNAs. Self-Amplifying RNA Filings as discussed above may also be relevant. We have also undertaken and continue to undertake filings specific to particular product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also licensed technologies relating to certain lipids and/or lipid nanoparticles and formulations that may be useful for certain infectious disease mRNA vaccines. </span></div><div style="margin-top:12pt;padding-left:10.3pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rare Diseases </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing mRNA-based protein replacement therapy for several rare disease indications through our collaboration with Genevant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the mRNA Structure Filings (including some that are relevant to iNeST and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates, as discussed above) and patent filings under the MRT-CellScript Sublicenses (including patent filings directed to nucleoside-modified mRNAs) also provide protection for one or more features of mRNA-based protein replacement product candidates. For example, mRNA Structure Filings include patent filings directed to 3&#8217; UTR structures containing a specific sequence element and interrupted poly A tail structures. As noted above, such mRNA Structure Filings are solely or jointly owned by BioNTech; such issued patent filing(s) has/have, and such pending patent filings, if issued, would have 20-year terms that would extend into the mid-2030s. However, there are currently no issued patents specific to our rare disease product candidates under development. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio relating to our rare disease programs also include certain patent filings that we have licensed from Genevant, or the Genevant Filings. Specifically, some of the Genevant Filings are owned by Arbutus Biopharma Corporation and relate primarily to lipid or non-liposomal formulations that might be useful in these programs, with 20-year terms that extend into mid-2020s to mid-2030s for the issued Genevant Filings and the pending Genevant Filings, if issued. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2116"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2. Cell Therapy</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Engineered Cell Therapy </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our engineered cell therapy product class features use of chimeric antigen receptor, or CAR-, T cell or individualized T-cell receptors for oncology therapy. Our patent filings relevant to these platforms and product candidates, or the CAR-T/TCR Filings, are generally co-owned by BioNTech US, BioNTech Cell &amp; Gene Therapies and TRON. For example, the CAR-T/TCR Filings include patent filings directed to various CAR-T formats and methods of enhancing CAR-T cells by nucleic acid vaccination, as well as patent filings directed to compositions of matter comprising individualized T-cell receptors, for example. The CAR-T/TCR Patent Filings, if issued, would have patent terms that would extend into the mid-2030s to early 2040s.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain CAR-T programs involve CAR-T-cell product candidates that target different members of the claudin family. Our patent portfolio includes certain patent filings specifically relevant to our claudin-specific CAR-T-cell product candidates and are jointly owned by BioNTech Cell &amp; Gene Therapies, and TRON, or the Claudin-Specific CAR-T Cell Filings. The issued Claudin-Specific CAR-T-cell filings have, and the pending Claudin-Specific CAR-T-cell filings, if issued, would have, 20-year terms extending into the mid-2030s. The terms of our co-ownership of such patent filings with TRON are summarized below in &#8220;&#8212;C. In-Licensing.&#8221;</span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Activated T Cells </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of Neon included technologies for using peripheral blood mononuclear cells, or PBMCs, (e.g., collected from apheresis material of patients) as a starting material to induce and/or expand ex vivo functional T cells specific for therapeutically-relevant neoantigens. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our BNT221 program, formerly Neon&#8217;s NEO-PTC-01 program, is a personalized adoptive T-cell therapy, which uses multiple T-cell populations expanded from an individual patient&#8217;s PBMCs that together target a set of neoantigens expressed by that patient&#8217;s tumor. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent filings relevant to BNT221, referred to herein as the T-cell Induction/Expansion Filings, are generally solely owned by BioNTech US, or co-owned by BioNTech US and the Netherlands Cancer Institute (NKI). For example, the T Cell Induction/Expansion Filings include patent filings directed to therapeutic T cell compositions and methods of ex vivo induction and/or expansion of antigen-specific T cells. An issued subsisting T-cell Induction/Expansion Filing in the United States has, and pending subsisting T-cell Induction/Expansion Filings, if issued, would have, patent terms that extend into the late-2030s to early-2040s.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2110"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3. Antibodies </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our antibodies product class features bispecific checkpoint immunomodulators for oncology therapy, which are developed through collaboration with Genmab. Our development candidates include bispecific antibodies that are designed to activate 4-1BB upon simultaneous binding to PD-L1, CD-40 or EpCAM. Our patent portfolio includes certain patent filings relevant to such bispecific antibodies, or the Bispecific Checkpoint Modulator Filings, co-owned by us and Genmab. Such Bispecific Checkpoint Modulator Filings, if issued, would have 20-year terms that would extend into the late 2030s. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also recently expanded our collaboration with Genmab to include development of monospecific antibody candidates to address malignant solid tumors. For example, BNT313 is a CD27 antibody based on Genmab&#8217;s proprietary HexaBody technology platform, specifically engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell membrane of the T cells. We have also undertaken and continue to undertake filings specific to particular product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own patent assets acquired from MabVax Therapeutics Holding, Inc., or the MabVax Filings, that relate to various antibodies, including certain antibodies targeting sialyl Lewis A and ganglioside GD2, as well as nucleic acid encoding them. Issued MabVax Filings have, and the pending MabVax Filings, if issued, would have, 20-year terms that extend into the mid-2030s.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2104"></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4. Small Molecule Immunomodulators </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule therapeutics product class features oncology treatment using small molecule product candidates that activate the immune system via TLR7 agonism. Our patent portfolio includes patent filings relevant to these TLR7 agonists, or the TLR7 Agonist Filings. Certain TLR7 Agonist Filings are directed to substituted imidazoquinolines, and, if issued, would have 20-year terms that would extend into the late 2030s. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2098"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">C. In-Licensing </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our intellectual property assets have been acquired by acquisition and/or in-licensing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have pursued a strategy of identifying and in-licensing third-party patents that we believe are complementary to or otherwise interact synergistically with our own intellectual property portfolio. In addition to the agreements described in the section &#8220;&#8212;B.IX. Third-Party Collaborations&#8221; above, we have entered into material intellectual property licensing or option arrangements with TRON, Louisiana State University, MRT-CellScript, and Acuitas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key terms of these arrangements are summarized below. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRON Agreements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we and our subsidiaries BioNTech RNA (now merged into BioNTech SE), BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, Eufets GmbH and JPT Peptide Technologies GmbH entered into a Master Agreement for Research Services with TRON. Concurrently with this Master Agreement for Research Services, or the TRON Research Agreement, we entered into a License Agreement with Ganymed </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals AG, or Ganymed, TRON, Johannes Gutenberg-Universit&#228;t Mainz and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz, or the TRON License Agreement. The TRON Research Agreement and TRON License Agreement together replaced and superseded our 2008 Cooperation, Purchase and Licensing Agreement with the University Mainz, or the 2008 Cooperation Agreement. In 2019, we and our subsidiaries BioNTech RNA (now merged into BioNTech SE), BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH and JPT Peptide Technologies GmbH, entered into a Framework Collaboration Agreement with TRON, or the TRON Collaboration Agreement. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRON Research Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TRON Research Agreement, TRON from time to time performs certain services for us under work orders, which may comprise innovative applied research projects, pre-defined research and development or clinical research services. We and TRON meet at regular intervals, but no less than annually, to prepare an overall non-binding project plan, which sets the scope, period and costs for the relevant projects contemplated for that period. Individual work orders set the specific binding terms of each project or service. TRON is obligated to render services in accordance with the scientific standards, all applicable laboratory and legal provisions and with the care customary in the industry. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are entitled to the exclusive rights to all inventions, methods, specifications, materials, documents, data, know-how and other results (together, the Results) developed or discovered by TRON or by us and TRON jointly under the TRON Research Agreement, except to the extent they constitute improvements of the technologies applied by TRON in the relevant projects. Under the TRON Research Agreement, TRON granted us a non-exclusive, royalty-free license to use TRON Improvements if such TRON Improvements are necessary for the continued development and exploitation of the Results or the manufacture or marketing of products which contain any of the Results and are covered by a patent claiming any of the Results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TRON Research Agreement, TRON&#8217;s services rendered in the field of applied research are invoiced at cost. For other services, fixed prices are to be set forth in the individual work orders. TRON invoices us monthly and our payments are due no later than 10 days thereafter. Additionally, we are obligated to pay to TRON low single-digit tiered royalties on net sales of any product developed under the TRON Research Agreement that is covered by a patent claiming any of the Results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON Research Agreement limits each party&#8217;s liability to the other to intentional and grossly negligent actions and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify TRON for all product liability claims in connection with the products and for third-party claims asserting that the Results violate third-party intellectual property rights. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON Research Agreement has an indefinite term, but may be terminated by either party on six months&#8217; notice. If one of our subsidiaries terminates its role in the TRON Research Agreement, the agreement will survive and continue without that subsidiary. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we and TRON entered into a supplementary agreement to include certain research and development activities regarding neoepitope RNA immunotherapies as work included in the TRON Research Agreement. In February 2022, we agreed to extend the term of the supplementary agreement. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRON License Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON License Agreement governs the ownership of and licenses under certain patents, inventions, know-how, technologies and other knowledge (together, the Development Results) filed and created before January 1, 2015 in the course of our collaboration with TRON, Johannes Gutenberg-Universit&#228;t Mainz and Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t Mainz (collectively, the University Parties) and Ganymed pursuant to the 2008 Cooperation Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON License Agreement sets forth the parties&#8217; rights with respect to the Development Results, mainly depending on which parties have contributed to such Development Results. Ownership of the Development Results and any patents and other intellectual property in certain shares to TRON, on the one hand, and BioNTech and/or Ganymed, on the other hand included therein is allocated. Each party may assign its share in the co-owned Development Results to its affiliates provided that such party provide notice of the transfer and the identity of the new co-owner to the other co-</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owners. However, in case of an assignment of such share to a third party (except in case of a material asset sale), the assigning party must obligate the assignee to comply with the terms of the TRON License Agreement and the assigning party will remain bound by the obligations of the TRON License Agreement unless the other co-owners have consented to discharge the assigning party from such obligations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties to the TRON License Agreement grant licenses to each other under their shares in the Development Results substantially as follows. Ganymed is exclusively entitled to use the Development Results for certain antibodies and antibody fragments that bind to certain defined targets, or the Ganymed Field of Use. We are exclusively entitled to use the Development Results in any other field of use (including immunological therapeutics, small molecule compounds, small interfering RNA (siRNA)-based therapeutics, micro-proteins, antibody based </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (except for those in the Ganymed Field of Use), diagnostics and therapeutics based on long-chain RNA as well as other cell therapy applications, immune cells transgenized with recombinant directed against certain defined targets or chimeric antigen receptors and RNA-based pharmaceuticals). The University Parties may use the Development Results for internal research purposes only. We have an obligation to use reasonable efforts to develop and commercialize products in our field of use worldwide. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TRON License Agreement, we and Ganymed must agree on which party will have the primary role in filing, prosecuting, maintaining and defending jointly owned patents. We and Ganymed each have the exclusive right to enforce the Development Results in our respective fields of use, subject to certain step-in rights of the other parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay to the University Parties low single-digit tiered royalties on net sales on any product that is covered by certain of the patents including in the Development Results. If licenses are granted to third parties, we are obligated to pay to the University Parties a mid-single-digit share of all upfront payments, milestone payments and other remuneration we receive from such third parties in consideration for the license. Regarding upfront payments only, the University Parties&#8217; share will be offset against subsequent license fees on net sales. In addition, we are obligated to pay certain development and regulatory milestones up to a low seven-figure amount to Johannes Gutenberg-Universit&#228;t Mainz. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON License Agreement contains a limitation on liability as between the parties, wherein the parties will only be liable to each other for intentional and grossly negligent actions, and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify the University Parties and Ganymed for third-party claims of product liability or violation of applicable law based on our distribution of our products or if we breach the TRON License Agreement or if we or one of our agents acts culpably. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON License Agreement will remain in effect as long as there are any obligations on us or Ganymed to pay license fees. After expiry of the TRON License Agreement, each party will have a perpetual, non-exclusive, royalty-free license to use the Developments Results. The TRON License Agreement may be terminated by any party on six months&#8217; notice. The licenses granted between the parties will survive such termination. The TRON License Agreement also grants all parties termination rights for uncured material breaches. If only one party terminates its role in the Agreement, the Agreement will survive and continue between the other parties. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRON Collaboration Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TRON Collaboration Agreement, TRON from time to time undertakes certain projects in collaboration with us under separate project specific agreements, comprising innovative non-clinical research and development projects. We and TRON meet regularly to review and update project plans, and no less than annually to agree the budget for the on-going projects for the coming calendar year. Individual project agreements set the specific binding terms of each project. TRON is obligated to perform its obligations in accordance with the scientific standards, all applicable technical laboratory and legal provisions and with the care customary in the non-clinical biotechnology research industry. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the results of a particular research project which has been funded exclusively by TRON, or the RNT Project, all of the inventions, methods, specifications, materials, documents, data, know-how and other results (together, the Results) developed or discovered by TRON or by us and TRON jointly under the TRON Collaboration Agreement are jointly owned. The Results of the RNT Project are owned exclusively by TRON. Under the TRON Collaboration Agreement, TRON grants us an exclusive, worldwide, sublicensable license under its interest in the Results to research and have researched, develop and have developed, make and have made, use, and otherwise commercialize or have commercialized, and otherwise commercially exploit, products in a field that is specified in the corresponding project agreement. The field of use is either (a) the prophylaxis, diagnosis and treatment of all indications in humans and animals; (b) the prophylaxis, diagnosis and treatment of oncological diseases, infectious diseases and rare genetic diseases; or (c) in </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the case of the Results from the RNT Project only, the prophylaxis, diagnosis and treatment of rectal neuroendocrine tumors in humans. We are required to use our reasonable efforts to develop and commercialize products that exploit the Results. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TRON Collaboration Agreement, TRON&#8217;s activities are invoiced at cost. TRON invoices us monthly and our payments are due no later than 10 days thereafter. Additionally, we are obligated to pay to TRON low single-digit tiered royalties on net sales of any product developed under the TRON Collaboration Agreement that is covered by a patent claiming any of the Results or, in certain circumstances, by a patentable invention forming part of the Results which we elect to maintain as a trade secret. If licenses under Results are granted to third parties, we are obligated to pay to TRON a mid-single-digit share of all upfront payments, milestone payments and other remuneration we receive from such third parties in consideration for the license. In addition, we are obligated to pay a one-time only milestone of a low seven-figure amount to TRON the first time annual sales of a product developed under the TRON Collaboration Agreement reach a low nine-figure number. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON Collaboration Agreement limits each party&#8217;s liability to the other to cases of willful misconduct and gross negligence and, in the case of gross negligence, liability for indirect and consequential damages and lost profits is excluded. We are obligated to indemnify TRON for all product liability claims in connection with the products and for third-party claims asserting that the Results violate third-party intellectual property rights. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRON Collaboration Agreement came into force with retroactive effect from January 2015 and has an indefinite term, but may be terminated by either party on nine months&#8217; notice. If one of our subsidiaries terminates its role in the TRON Collaboration Agreement, the agreement will survive and continue without that subsidiary. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LSU License Agreement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2015, we entered into a Patent License Agreement with the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, or LSU, and the University of Warsaw, or UW. The agreement (which we refer to as the LSU Agreement) replaces and supersedes the earlier license agreement between the parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LSU Agreement, UW and LSU granted to us an exclusive royalty-bearing license under certain patent rights relating to mRNA cap analogs and the synthesis and use of anti-reverse phosphorothioate analogs of the mRNA cap in the United States, certain jurisdictions in the European Union and other countries. As consideration for the license granted, we are obligated to pay running royalties in the low single digits on all net sales of products utilizing the licensed patents and to pay annual maintenance fees to LSU. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to use commercially reasonable efforts to develop one or more marketable products utilizing the licensed patents, upon which we would owe additional milestone payments to LSU. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LSU Agreement remains in effect until expiration of the licensed patents. We have the right to terminate the LSU Agreement for convenience with 60 days&#8217; prior notice, and LSU and UW may terminate for our uncured material breach. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CellScript and mRNA Ribotherapeutics License Agreement </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech RNA (now merged into BioNTech SE) entered into the two MRT-CellScript Sublicenses discussed above. Together, the MRT-CellScript Sublicenses grant BioNTech RNA worldwide, non-exclusive sublicenses under the Penn Modified mRNA Patent Rights (as defined in the MRT-CellScript Sublicenses) to research, develop, make, import, use and commercialize products for in vivo uses in humans and non-human animals, including therapeutic and prophylactic applications, and for certain uses in the diagnostic and prognostic field of use and certain laboratory research or screening uses. Under these sublicenses, BioNTech RNA has the right to grant sublicenses to affiliates and third parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech RNA must use reasonable efforts to develop and commercialize products under the sublicenses. Furthermore, BioNTech RNA is obliged to pay MRT and CellScript development milestone payments of up to approximately $26 million as well as royalties in the low to mid-single digits on net sales of licensed products, depending on the field of use. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements continue until the expiration or abandonment of the last licensed patent to expire or be abandoned. BioNTech RNA may terminate the agreement for convenience with respect to all or certain patent rights with 60 days&#8217; prior </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">written notice. MRT or CellScript may terminate the respective sublicense agreement for payment default, uncured material breach or the bankruptcy of BioNTech RNA. </span></div><div style="margin-top:12pt;padding-left:10.2pt;text-align:justify;text-indent:14.17pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acuitas License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020 we entered into a Non-Exclusive License Agreement with Acuitas, or the Acuitas License Agreement. Under the Acuitas License Agreement Acuitas grants us a non-exclusive worldwide license, with the right to sublicense (subject to certain conditions) under Acuitas&#8217;s LNP technology to develop, manufacture and commercialize licensed products directed to the SARS-CoV-2 surface glycoprotein. We have the option to convert the non-exclusive licenses to exclusive licenses subject to certain additional financial obligations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Acuitas License Agreement, we must pay Acuitas up to between approximately $1.6 million and $2.45 million in development milestone payments, $2.5 million and $3.75 million in regulatory milestone payments and $2.5 million and $3.75 million in commercial milestone payments upon the occurrence of certain milestone events. We are further required to pay Acuitas a low single-digit tiered percentage royalty on net sales of licensed products, subject to certain potential customary reductions. Our royalty obligations continue under the Acuitas License Agreement on a country-by-country and product-by-product basis until the later of (i) the expiration of the last-to-expire licensed valid patent claim covering such licensed product in such country, (ii) expiration of any data exclusivity, market exclusivity or supplemental protection certificates period for such product in such country, and (iii) certain years following the first commercial sale of such product in such country. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Acuitas License Agreement will continue on a product-by-product and a country-by-country basis until there are no more payments owed to Acuitas for such product in such country. Upon expiration of the Acuitas License Agreement, the license will become fully paid up and will remain in effect. We have the right to terminate the Acuitas License Agreement for convenience following a certain notice period. Either party may terminate the Acuitas License Agreement in the event of a material breach by the other party following a cure period. Alternatively, instead of exercising our right to terminate in the event of Acuitas&#8217;s material breach, we may elect to instead continue the license but reduce our milestone and royalty payment obligations to Acuitas by a certain percentage. In the event of termination of an Acuitas License Agreement by us for convenience or by Acuitas for our material breach, the licenses granted under such agreement will terminate, except that we will have the right to sell off any remaining inventories of licensed products for a certain period of time.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2092"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">D. Trademark Portfolio </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain features of our business and our product candidates are protected by trademarks. Our trademark portfolio includes, but is not limited to, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FixVac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboCytokine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RiboMab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neo-Stim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including logo versions of some of these trademarks. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brand names appearing in italics throughout this report are trademarks owned by BioNTech. All other trademarks are the property of their respective owners.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2086"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">E. Trade Secret Protection </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our technologies, including in particular certain proprietary manufacturing processes or technologies and/or neoantigen prediction technologies, are protected as trade secrets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. We protect certain of our technologies, including, in particular, certain proprietary manufacturing processes and technologies and/or neoantigen prediction technologies, as trade secrets. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, by using confidentiality agreements with any future collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2071"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">XII. Competition </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in an industry characterized by rapidly advancing technologies, intense competition and a complex intellectual property landscape. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors and potential competitors, either alone or with their collaborators, have greater scientific, research and product development capabilities as well as greater financial, marketing, sales and human resources and experience than we do. In addition, smaller or early-stage companies, including immunotherapy-focused therapeutics companies, may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our collaborators, such as Genmab, Pfizer and Sanofi, may also be competitors within the same market or other markets. Accordingly, our competitors may be more successful than us in developing and potentially commercializing technologies and achieving widespread market acceptance. In addition, our competitors may design technologies that are more efficacious, safer or more effectively marketed than ours or have fewer side effects, or may obtain regulatory approvals more quickly than we are able, which could eliminate or reduce our commercial potential. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that the key competitive factors affecting our technologies will be efficacy, safety, cost and convenience, ease of distribution, storage and administration, as well as our ability to build a fully-integrated biotechnology company. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. The timing of market introduction of our products and competitive products will also affect competition among products. We expect the relative speed with which we can develop our products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market to be important competitive factors. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, our marketed monovalent and bivalent COVID-19 vaccines and any other COVID-19 vaccines we and Pfizer develop compete with other COVID-19 vaccines that have been approved or authorized for temporary or emergency use and a large number of vaccine manufacturers, academic institutions and other organizations currently have programs to develop COVID-19 vaccine candidates.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2065"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XIII. Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, as well as other legal proceedings that arise from time to time in the ordinary course of business, including, but not limited to, personal injury, consumer, off-label promotion, securities, antitrust, employment law, tax, environmental, and/or other claims or investigations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingencies include, but are not limited to, intellectual property disputes and product liability and other product-related litigation. From time to time, in the normal course and conduct of our business, we may be involved in discussions with third parties about considering, for example, the use and/or remuneration for use of such third party&#8217;s intellectual property. As of December&#160;31, 2023, none of such intellectual property-related considerations that we have been notified of, and for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. We are subject to an increasing number of product liability claims. Such claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics/package leaflet) as well as label warnings and reliance thereon, scientific evidence and findings, actual and provable injury, and other matters. These complexities vary from matter to matter. As of December 31, 2023, none of these claims fulfill the criteria for recording a provision. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pending matters to which we are a party are discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks relating to these and other legal proceedings we face and may in the future face and our assessments thereof, see &#8220;Risk Factors&#8221; elsewhere in this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &amp; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#8216;933 Patent, is infringed by the cationic lipid used in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#8216;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#8216;979 Patent, which is a continuation of the &#8216;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479; 11,633,480; 11,612,657; and 11,590,229, all of which are continuations of the &#8216;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the proceedings have been consolidated and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are currently pending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Alnylam&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CureVac Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;122, DE&#8217;961, DE&#8216;974, DE&#8217;575, and EP&#8217;668</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP1857122B1, or the EP&#8217;122 Patent, and three Utility Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or the EP&#8217;668 Patent, to its German lawsuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the D&#252;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#8217;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668) pending validity decisions in the DE&#8217;961, DE&#8217;974, and DE&#8217;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#8217;668 opposition proceedings before the Opposition Division of the European Patent Office. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668. On December 28, 2023, the D&#252;sseldorf Regional Court stayed the infringement proceedings as to EP&#8217;122 until a final appellate decision is rendered as to the validity of EP 122 by the Federal Court of Justice.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;755, DE&#8217;123, and DE&#8217;130</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP4023755B1, or the EP&#8217;755 Patent, and two Utility Models DE202021004123U1, and DE202021004130U1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nullity Proceedings &#8211; EP&#8217;122</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#8217;122 Patent is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#8217;122 nullity action in support of the validity of the EP&#8217;122 Patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary opinion did not address any infringement of the EP&#8217;122 Patent.  The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#8217;122. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cancellation Proceedings&#8211; DE&#8217;961, DE&#8216;974, and DE&#8217;575</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent Office issued a preliminary opinion that DE&#8217;974 is likely to be cancelled based on invalidity pursuant to para. 1 (2) no. 5 Utility Model Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070; 11,286,492; 11,345,920; 11,471,525; 11,576,966; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against the EP&#8217;122 Patent and the EP&#8217;668 Patent in the Business and Property Courts of England and Wales. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#8217;122 and EP&#8217;668 patents in the Business And Property Courts of England and Wales. On December 18, 2023, we amended our pleadings to further allege non-infringement and invalidity against EP&#8217;755.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and utility models and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVac&#8217;s claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging Comirnaty&#8217;s infringement of two European Patents, 3590949B1, or the EP&#8217;949 Patent, and 3718565B1, or the EP&#8217;565 Patent.  On November 7, 2023, the European Patent Office (&#8220;EPO&#8221;) Opposition Division revoked EP&#8217;565 after a one-day oral hearing.  The Opposition Division issued a preliminary opinion on December 8, 2023 noting that it believes EP&#8217;949 is likely invalid.  As a result of these EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit asserting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of the EP&#8217;949 Patent and EP&#8217;565 Patent. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. District Court Litigation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit in the United States District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of U.S. Patent Nos. 10,898,574, 10,702,600 and 10,933,127 and seeking monetary relief. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Review</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Netherlands</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#8217;s infringement of the EP &#8216;949 Patent and the EP &#8217;565 Patent. The District Court of the Hague held a hearing on October 6, 2023 on infringement and validity with respect to the EP &#8217;949 Patent. On December 6, 2023, the Court found EP&#8217;949 to be invalid. The EP&#8217;565 case has been stayed pending Moderna&#8217;s appeal of the Opposition Division&#8217;s revocation of EP&#8217;565.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ireland</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent in the High Court of Ireland.  </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Belgium</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and the EP&#8217;565 Patent in the Brussels Dutch-speaking Enterprise Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arbutus and Genevant Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus: U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief. This proceeding is currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promosome Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Promosome LLC filed a lawsuit against Pfizer, us, and BioNTech Manufacturing GmbH in the U.S. District Court for the Southern District of California alleging that Pfizer and our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine has infringed U.S. Patent No. 8,853,179, and seeking monetary relief. On October 4, 2023, the parties filed a joint stipulation of dismissal, dismissing the lawsuit with prejudice. As part of this stipulation of dismissal, Promosome agreed to a covenant not to assert U.S. Patent No. 8,853,179 against Pfizer and us or any of their products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This matter is considered closed.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2059"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Organizational Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Item 18. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2053"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Property, Plant and Equipment </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our principal owned and leased real estate. We also lease other properties in the ordinary course of business as part of our global operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Germany:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters are located in Mainz, where we principally occupy: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 9,416 square meters of laboratory, GMP manufacturing, storage and office space at An der Goldgrube 12, 55131. We acquired ownership of the building in December 2022. </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 8,446 square meters of office and laboratory container space at Freiligrathstra&#223;e 6, 55131. The lease of the office container space expires on June 30, 2027. We own the laboratory container space.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 1,049 square meters of office and GMP manufacturing space under a lease for part of the building located at Kupferbergterstra&#223;e 15, 55161 under a lease that expires on March 31, 2027.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 4,882 square meters of laboratory and office space located at Adam-Opel-Stra&#223;e 10, 55129, which is owned by us, as well as 9,278 square meters of undeveloped land intended for construction of a laboratory and office building of up to 12,000 square meters in size. Currently the land is occupied by approximately 2,125 square meters of office container space.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">We also own a plot of land of approximately 8,753 square meters at Hechtsheimer Stra&#223;e 2b, 55131, where construction for a GMP manufacturing facility of approximately 18,000 square meters commenced in 2021.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 42,164 square meters of office space under a lease for two of three building parts at Gro&#223;e Bleiche 54-56, 55131, under a lease that expires on December 31, 2029.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Idar-Oberstein:</span></div><div style="margin-top:6pt;padding-left:45.07pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">The IMFS facility (consisting of buildings A to E and J) has a total area of approximately 13,470 square meters. This includes approximately 2,660 square meters of storage space, approximately 1,270 square meters of development and QC laboratory space, approximately 1,650 square meters of clean rooms, and approximately 2,540 square meters are office space. This facility, including the GMP-certified manufacturing suites, is owned by BioNTech.</span></div><div style="margin-top:6pt;padding-left:63.78pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.48pt">We occupy approximately 575 square meters of this space, which is used primarily for storage, under a lease that has an initial expiry date of October 1, 2021, but which we have extended until September 30, 2026. The warehouse is located in Tiefenstein.</span></div><div style="margin-top:6pt;padding-left:63.78pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.48pt">We have been renting the warehouse for GMP products since April 2022. The warehouse has an area of 1,120 square meters. The term is 5 years with the option to extend.</span></div><div style="margin-top:6pt;padding-left:63.78pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.48pt">Rental of a plot of land with 2,000 square meters. A container facility was built on it. The office container facility has a size of approximately 2,125 square meters. Both contracts currently run until June 2025. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Marburg:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.76pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Behringwerke</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">Our main manufacturing facility consists 10,240 square meters, including 4,589 square meters of GMP space, 2,422 square meters of technical and storage facilities, 540 square meters of laboratory space and 2,690 square meters of offices. The lease will expire December 31, 2034.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Our main office building consists of 4,913 square meters of office space. The lease will expire until October 31, 2027.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">We also occupy 920 square meters of office space under a lease which will expire on May 31, 2026.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">We have leased additional 779 square meters of technical and storage facilities under a lease which will expire on December 31, 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:29.76pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&#246;rzhausen</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">As part of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BioNTainer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program (BioNTech Innovation Center/BIC), we occupy approximately 2,040 square meters. Approximately 804 square meters are used as office space and 1,236 square meters are used as GMP and technical storage facilities under a lease which will expire December 31, 2031.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Our own Plasmid Production/Miami (Microbial Manufacturing) is located in M537 and M536. In M537 we occupy 3,088 square meters, including 1,021 square meters of usable GMP and laboratory space, 1,065 square meters of usable technical and storage facilities and 448 square meters of usable office space. In M536 we occupy 164 square meters. The lease will expire December 31, 2031.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Berlin:</span></div><div style="margin-top:6pt;padding-left:45.07pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">At our JPT facility, we occupy approximately 2,390 square meters of office, laboratory and general technical production space:</span></div><div style="margin-top:6pt;padding-left:63.78pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.48pt">About </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,050 square meters are occupied under a lease contract, which will expire simultaneously to our moving into our new building.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:63.78pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.48pt">For the remaining approximately 350 square meters of office space, we have a lease contract with a firm term until 2026. </span></div><div style="margin-top:6pt;padding-left:45.07pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">A new laboratory and office building, wholly owned by JPT, is under construction, with an expected completion date in mid-2025. </span></div><div style="margin-top:6pt;padding-left:45.07pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">We have been renting an office of approximately 1,700 square meters since April 2023. The contract runs until December 31, 2028. Extension options are possible.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Munich, we have leased approximately 3,700 square meters in the Werksviertel. The lease is for 60 months with options to extend.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Martinsried, we occupy approximately 1,862 square meters under a lease which will expire on December 31, 2026. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Neuried:</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We occupy approximately 1,732 square meters of laboratory and office space under a lease which will expire on November 30, 2031.</span></div><div style="margin-top:6pt;padding-left:42.51pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We leased additional space in July 2022 of approximately 1,470 square meters of laboratory, office and storage space under a lease which will expire on August 30, 2029.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Fussgoenheim, we lease approximately 3,448 square meters of freezer farm space.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Mutterstadt, we occupy approximately 5,744 square meters of freezer farm space under a rental agreement. We also lease a further 2,160 square meters of handling space. The term ends on December 31, 2027, with a one-year extension option.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Halle, we have rented an area of approximately 1,100 square meters, including approximately 100 square meters of laboratory space. The lease runs until spring 2025, with an option to extend.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to expand our capacity as follows:</span></div><div style="margin-top:6pt;padding-left:45.07pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.52pt">In January 2022, we commenced construction of a four-story building at An der Goldgrube 10 in Mainz, which we will own. We have planned laboratory space for research and development, offices, storage facilities, a conference center and cafeteria. As a result, we will take up an additional 2,400 square meters of main laboratory space and 4,000 square meters of main office space.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global locations:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Cambridge, Massachusetts, United States, we principally occupy:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pproximately 2,490 square meters of laboratory and office space under a lease for part of a building located at 40 Erie Street that has an initial term that expires on September 30, 2024.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 4,410 square meters of laboratory and office space under a lease for part of a building located at 75 Sidney Street that has an initial term that expires on January 31, 2032.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Gaithersbu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rg, Maryland, United States, we principally occupy:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 5,476 square meters under a lease which will expire on July 31, 2033.</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 823 square meters of laboratory and office space under a lease which will expire on July 31, 2033.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Cambridge, England, we principally occupy:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 120 square meters of laboratory and office space under a lease at the MRC-Laboratory of Molecular Biology with an initial term until December 31, 2024.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">Approximately 7,400 square meters of shell and core laboratory and office space under a lease with an initial term until October 13, 2033, including a tenant only break option at year 7 of the term. The building is expected to be in operation during 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Vienna, Austria, we signed a lease in September 2022 for approximately 1,300 square meters of office and laboratory space for part of the building located at Helmut-Qualtinger-Gasse 2, 1030. The lease commenced on April 1, 2023, with a lease term of eight years and an option to extend.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Kigali, Rwanda, we have leased a plot of land of approximately 35,100 square meters to develop an mRNA vaccine factory for the manufacturing of bulk drug substance and bulk drug product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Singapore, we will own a production site. The purchase will close in April 2024. The entire area covers approximately 63,300 square meters. The building is currently being upgraded. After completion, there will be office space of approximately 6,195 square meters, a production and technical building of approximately 20,000 square meters, and a warehouse of approximately 3,400 square meters.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2047"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 4A. Unresolved Staff Comments </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2034"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 5. Operating and Financial Review and Prospects</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following &#8220;Operating and Financial Review and Prospects&#8221; discussion should be read together with the information in our financial statements and related notes included elsewhere in this Annual Report. The following discussion is based on our financial information prepared in accordance with the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. Please also see &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">163</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2018"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Operating Results</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2012"></div><div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Operations Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows our consolidated statements of profit or loss for each period presented:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:66.271%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,815.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,194.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,874.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research &amp; development revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102.7</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,976.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(599.8)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,995.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,911.5)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,783.1)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,537.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(949.2)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales and marketing expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(62.7)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(59.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(50.4)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(495.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(481.7)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(276.8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating expenses </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(293.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(410.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(103.4)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">815.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">598.4</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operating income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">690.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,642.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15,283.8</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">519.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">330.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(23.9)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(18.9)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(305.1)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit before tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,186.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,954.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15,046.4</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(255.8)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,519.7)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,753.9)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit for the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9,434.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10,292.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic earnings for the period per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.87</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.78</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.18</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted earnings for the period per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.83</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37.77</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.63</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">164</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1865"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Comparison of the year ended December&#160;31, 2023 and the year ended December&#160;31, 2022</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1859"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a summary of revenues recognized for the periods indicated:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Revenues</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commercial revenues</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,815.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,194.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(13,379.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(78)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 vaccine revenues</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,776.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,145.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(13,369.0)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(78)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sales to collaboration partners</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">275.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1,224.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(949.0)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(78)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Direct product sales to customers</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">473.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,184.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(2,711.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(85)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of collaboration partners&#8217; gross profit</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,027.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">12,736.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(9,708.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(76)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other sales</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(20)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research &amp; development revenues from collaborations</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(112.5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(97)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total revenues</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(13,491.6)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(78)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2023 commercial revenues decreased by &#8364;13,379.1 million&#160;from &#8364;17,194.6 million to &#8364;3,815.5 million, in line with a lower COVID-19 vaccine market demand. We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of EUAs or equivalents in the United States (jointly with Pfizer) and other countries. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T&#252;rkiye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fosun Pharma, has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to collaboration partners represent sales of products manufactured by us to collaboration partners. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. Under the collaboration with Pfizer, from time to time, those sales are significantly influenced by amounts due to write-downs of inventories as well as costs related to production capacities derived from contracts with CMOs that became redundant. Those costs represent accrued manufacturing variances and are charged to our partner once finally materialized. These manufacturing variances are reflected as transfer price adjustments once identified. The regular reassessment of these manufacturing variances may result in adjustments to the respective prior-period revenues. Sales to collaboration partners during the years ended December 31, 2023, and 2022, amounted to &#8364;275.3 million and &#8364;1,224.3&#160;million, respectively. During the years ended December 31, 2023, and 2022 those sales included &#8364;74.5 million and &#8364;850.0&#160;million, respectively, related to the aforementioned manufacturing variances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct product sales are recognized from supplying COVID-19 vaccine in our territories Germany and T&#252;rkiye. During the years ended December 31, 2023, and 2022, we recognized &#8364;473.6 million&#160;and &#8364;3,184.7&#160;million of revenues, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on COVID-19 vaccine sales in the collaboration partners&#8217; territories, we are eligible to receive a share of their gross profit, which represents a seasonally affected net figure and is recognized as collaboration revenue during the commercial phase, together with sales milestones. M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anufacturing cost variances either reflected as transfer price adjustments as described above or resulting from costs highly probable to be incurred by the partner, were taken into account when determining the gross profit. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, &#8364;3,027.3&#160;million&#160;gross profit share has been recognized as revenue. During the year ended December&#160;31, 2022, &#8364;12,736.2 million&#160;gross profit share has been recognized as revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research &amp; Development Revenues from Collaborations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2023, research and development revenues from collaborations decreased by &#8364;112.5 million or 97% from &#8364;116.0 million to &#8364;3.5 million. This was mainly effected by one-time effects from our collaborations with Pfizer and Sanofi S.A, or Sanofi.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1853"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, cost of sales decreased by &#8364;2,395.2 million or 80% from &#8364;2,995.0 million to &#8364;599.8 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mainly due to recognizing lower cost of sales from our decreased COVID-19 vaccine sales, which included the share of gross profit that we owe our collaboration partner Pfizer based on our sales. In addition, cost of sales was impacted by expenses arising from inventory write-offs and expenses for production capacities derived from contracts with CMOs that became redundant. The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1847"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the periods indicated:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="6" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;</span></td><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(237.0)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(43.1)</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-COVID-19</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,470.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">987.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">483.1</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.9&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total research and development expenses</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,783.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,537.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">246.1</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Break-down as per internal cost allocation logic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our research and development expenses increased by &#8364;246.1 million or 16% from &#8364;1,537.0 million to &#8364;1,783.1&#160;million, mainly influenced by progressing clinical studies for pipeline candidates as well as by our newly acquired product candidates and the development of variant adapted COVID-19 vaccines. The increase was further driven by an increase in wages, benefits and social security expenses resulting from a significant increase in headcount.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1841"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ales and marketing expenses increased by &#8364;3.2 million or 5% from &#8364;59.5 million to &#8364;62.7 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mainly due to increased expenses for setup and enhancement of commercial IT platforms and an increase in wages, benefits and social security expenses resulting from an increase in headcount. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1835"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our general and administrative expenses increased by &#8364;13.3 million&#160;or 3% from &#8364;481.7 million&#160;to &#8364;495.0 million, mainly influenced by increased expenses for IT services as well as by wages, benefits and social security expenses resulting from an increase in headcount.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1829"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income / Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our other result decreased by &#8364;593.3 million&#160;or 146% from positive &#8364;405.3 million&#160;to a negative result of &#8364;188.0 million. The other operating result reflected the change in foreign exchange rates and included net negative foreign exchange differences during year ended December&#160;31, 2023 compared to net positive foreign exchange differences during the previous year period that related to our U.S. dollar denominated trade receivables which were mainly incurred under our COVID-19 vaccine collaboration with Pfizer, U.S. dollar denominated trade payables as well as U.S. dollar denominated other financial liabilities which mainly relate to obligations incurred from our license agreements. The amounts were offset by recording the change in fair value of foreign </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange forward contracts that were entered to manage some of our transaction exposures but were not designated as hedging instruments under IFRS.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1823"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Income / Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our total financial result increased by &#8364;184.3 million&#160;from a positive financial result of &#8364;311.4 million to a positive financial result of &#8364;495.7 million, which was driven by interest income earned on bank deposits and financial securities as well as fair value adjustments in relation to our money market funds. During the year ended December&#160;31, 2022, the fair value adjustments derived from remeasuring the derivative embedded in our convertible note significantly affected our finance result.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1806"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our income taxes for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current income taxes</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,629.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,386.5)</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(93)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred taxes</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(109.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(112)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">255.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,519.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3,263.9)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(93)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current income taxes represent mainly corporate and trade taxes derived by our German tax group. The decrease in profit during the year ended December&#160;31, 2023 led to lower taxable income for the year ended December&#160;31, 2023 for the German tax group. Corporate and trade tax prepayments have been made exceeding the tax charge. Refunds will become due once tax declarations have been filed and assessed.</span></div><div style="text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our accumulated tax losses comprised tax losses of German entities that were incurred prior to the establishment of a tax group with BioNTech SE or by entities that are not within the tax group (as of December&#160;31, 2023: BioNTech Real Estate Verwaltungs GmbH; as of December&#160;31, 2022: BioNTech BioNTainer Holding GmbH, BioNTech Idar-Oberstein Services GmbH, NT Security and Services GmbH, BioNTech Real Estate Verwaltungs GmbH and the Real Estate partnerships) or U.S. tax group. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deductible temporary differences, unused tax losses, and unused tax credits for which no deferred tax asset is recognized in the statement of financial position as of December 31, 2023 is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;531.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Thus a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of December&#160;31, 2023, we have not recognized deferred tax assets for unused tax losses and temporary differences in an amount of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;138.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;million (December&#160;31, 2022: &#8364;136.7&#160;million) as the criteria of the recognition guidance for IAS 12, which requires that no reliance should be placed on future events that cannot be controlled and are uncertain, are not met. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reorganization of the intellectual property rights within the group has become effective June 30, 2023 and July 1, 2023 which led to deferred tax effects in Germany, the US and Austria. As a result BioNTech SE recognized deferred tax assets and deferred tax income at the time of the transaction. In addition this transaction led to a revaluation of previously unrecognized U.S. federal and state deferred tax assets, including unused tax losses and unused tax credits. As of December 31, 2022, there were unrecognized U.S. federal and state deferred tax assets of &#8364;128.9&#160;million. As of December 31, 2023, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future, fulfilling the requirements set out by IAS 12. Therefore we no longer continue to maintain the full non-recognition of deferred tax assets of our U.S. tax group as there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized. As of December 31, 2023, we maintain the non-recognition of deferred tax assets for unused U.S. federal and state tax losses and tax credits at an amount of &#8364;31.9&#160;million and &#8364;2.8&#160;million, respectively, as there is not sufficient probability in terms of IAS 12 that future taxable income will be available against which these unused tax losses can be utilized. The material unrecognized U.S. federal and state tax losses and tax credits will begin to expire in 2036.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are subject to uncertainties. We may become subject to income tax audits and adjustments by local tax </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities. The assessments of the recoverability of deferred tax assets and the nature of uncertain tax positions are subject to significant judgment by management and subject to change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The groups does not recognize deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries, in cases where the group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries, for which deferred tax liabilities have not been recognized is &#8364;2.8&#160;million.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1800"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Information about Our Operating Segments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1794"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Related</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> Party </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Related party transactions that occurred during the years ended December 31, 2023, and 2022 are explained in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Item 7.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of this Annual Report as well as in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 21</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of our consolidated financial statements included elsewhere in this Annual Report. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_549755817449"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Key Performance Indicators</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial k</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ey performance indicators</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial performance indicators are the focus of managing our operational business development. We use the key figures on the basis of current exchange rates (not currency-adjusted) and take into account the effects of potential M&amp;A activities or collaborations to the extent that they are published. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues mainly comprises expected commercial revenue, particularly in connection with our COVID-19 business as well as other revenue sources. Revenues are heavily influenced by the volumes available under the collaboration and the agreed upon purchase quantities. As our revenues represent our share of the collaboration partners' gross profit, they are also influenced by the incurring costs. For further information on the composition of commercial COVID-19 vaccine sales and the components contained therein, see the comments on sales under Item 5. Operating Results. Our sales serve as a performance indicator of our commercial earning power.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are an indicator of our future earnings potential, as this is highly dependent on the development of the clinical pipeline and the responsible use of the financial resources generated. This figure mainly includes expenses for the development of our clinical product candidates, early exploratory research and research and development overhead costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales, general and administrative expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs include sales and marketing costs as well as general and administrative costs. We use this measure to manage the costs associated with the expansion of the sales and marketing organization to ensure the necessary infrastructure and digital capacity for future market-ready products, as well as to manage the internal administrative and coordination functions associated with the expansion of research and development, such as finance, human resources, or business development, with regard to the associated cost development. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we also use the following financial performance indicators:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in property, plant and equipment and intangible assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures for property, plant and equipment and intangible assets include expenditures for the acquisition of property, plant and equipment as well as expenditures for the acquisition of intangible assets and rights of use, unless they are made as part of business combinations. These mainly include expenditures for the expansion and improvement of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our research and development and manufacturing facilities and investments in a state-of-the-art IT infrastructure to support the company in all digitization projects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-financial k</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ey performance indicators</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D Pipeline progress</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress in research achievements, such as the development and commercialization of the COVID-19 vaccine, is a key performance indicator. We are working to clinically demonstrate the benefit of additional treatment approaches, further develop additional product candidates in the form of pivotal studies, and continuously expand collaborations and manufacturing capabilities to offer innovative treatments to patients around the world.  </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1750"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B. Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our strong financial, scientific and operational accomplishments, we believe we have the resources to diligently allocate our current capital to drive a multi-platform strategy and deliver a fully integrated global biotechnology company. We focus our research and development (R&amp;D) on rapidly advancing our diversified clinical oncology pipeline with synergistic potential, developing next generation COVID-19 vaccines to maintain leadership and pandemic preparedness as well as broaden the label of and access to the existing vaccine. We also plan to invest heavily to build out our global development organization, bringing in talent with clinical and regulatory expertise needed to accelerate our pipeline development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also diversifying our therapeutic area footprint which will enable us to fully leverage the potential of all technology platforms across autoimmune diseases, inflammatory diseases, cardiovascular disease, neurodegenerative diseases, and regenerative medicines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing. To support our future trajectory, growing the organization and expanding our team is of utmost importance. We are on the way to develop our global footprint in key regions including Europe, the United States, Asia and Africa. Additionally, investing in manufacturing capabilities for key technologies and deploying our pandemic response capabilities remain priorities for us. As a science and innovation driven company, we will continue to focus investments on R&amp;D and scaling the business for commercial readiness in oncology in multiple countries by the end of 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had cash and cash equivalents of &#8364;11,663.7&#160;million and security investments of &#8364;5,989.7&#160;million accumulating to &#8364;17,653.4&#160;million cash and security investments. Our trade receivables of &#8364;2,155.7&#160;million outstanding as of December&#160;31, 2023 were mainly due to the contractual settlement of the gross profit share under our COVID-19 collaboration with Pfizer as described in Note 6 to our consolidated financial statements included elsewhere in this Annual Report. As of December&#160;31, 2023, our trade receivables included, in addition to the profit share for the fourth quarter of 2023, trade receivables which related to the gross profit share for the third quarter of 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and financial securities are invested in accordance with our asset management and investment policy, primarily with a focus on liquidity and capital preservation, and consist primarily of cash in bank accounts and on hand as well as long- and short-term financial investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced a new research, development and commercialization collaboration with Pfizer to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV). Under the terms of the agreement, Pfizer will pay $225.0 million in upfront payments, including a cash payment and an equity investment as we will pay Pfizer $25.0 million for the company&#8217;s proprietary antigen technology. In addition, we are eligible to receive future regulatory and sales milestone payments of up to $200.0 million as well as a share of gross profits arising from future product sales. The issuance of 245,284 ordinary shares with the nominal amount of &#8364;0.5 million was registered with the commercial register (Handelsregister) on March 24, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our Management Board and Supervisory Board authorized the 2022 share repurchase program of ADSs, pursuant to which we were permitted to repurchase ADSs, each representing one ordinary share, with a value of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;billion a two-year period, commencing on May 2, 2022. The first tranche of our 2022 share repurchase program of ADSs, with a value of up to $1.0&#160;billion, concluded on October 10, 2022. The second tranche with a value of up to $0.5&#160;billion commenced on December 7, 2022 and concluded on March 17, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Management Board and Supervisory Board authorized the 2023 share repurchase program, under which we were permitted to purchase ADSs, each representing one ordinary share, with a value of up to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.5&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which started June&#160;2, 2023 and concluded on September 18, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total 9,166,684 ADSs were repurchased under the 2022 program at an average price of $142.05 (&#8364;138.37), for total consideration of $1,302.0&#160;million (&#8364;1,268.4&#160;million). For the 2023 program, in total 4,646,965 ADSs were repurchased at an average price of $107.58 (&#8364;98.24), for total consideration of $500.0&#160;million (&#8364;456.5&#160;million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we entered into a sales agreement, or the Sales Agreement, with Jefferies LLC and SVB Leerink LLC (now </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">known</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as SVB Securities LLC), as sales agents, to establish an at-the-market offering program, pursuant to which we may sell, from time to time, ADSs representing ordinary shares for aggregate gross proceeds of up to $500.0&#160;million. During the year ended December&#160;31, 2022, we sold 995,890 ADSs, each representing one of our ordinary shares and previously held in treasury, under the Sales Agreement. During the year ended December&#160;31, 2021, the aggregate gross proceeds were $200.0&#160;million (&#8364;163.6&#160;million). We did not sell any ADS during year ended December&#160;31, 2023. The plan expired in November 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for each period presented:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net cash flows from / (used in):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;5,371.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;13,577.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;889.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6,954.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(566.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing activities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(778.6)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,419.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total cash inflow (outflow)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;(2,361.7)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;12,122.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8364;417.8</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from the sale of products and services rendered.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cash flows from operating activities are significantly influenced by cash we generated as settlement payments of our gross profit as well as our use of cash for operating expenses and working capital to support the business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, our cash flows from operating activities include the settlement payments of our gross profit share from our collaboration partner Pfizer as scheduled by the contractual arrangement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements included elsewhere in this Annual Report, the contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in operating activities for the year ended December&#160;31, 2023 was &#8364;5,371.4 million, comprising a profit before tax of &#8364;1,186.1 million, negative non-cash adjustments of &#8364;393.2 million, and a net positive change in assets and liabilities of &#8364;5,574.8 million. Non-cash items primarily included net foreign exchange differences as well as share-based payment expenses without cash-effect. The net positive change in assets and liabilities was primarily due to a decrease in trade receivables related to our COVID-19 collaboration with Pfizer, as described in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements included elsewhere in this Annual Report. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in operating activities for the year ended December&#160;31, 2022 was &#8364;13,577.4 million, comprising a profit before tax of&#160;&#8364;12,954.1 million, positive non-cash&#160;adjustments of &#8364;370.9 million, and a net positive change in assets and liabilities of &#8364;4,518.5 million. Non-cash items primarily included net foreign exchange differences as well as share-based payment expenses without cash-effect. The net positive change in assets and liabilities was primarily due to a decrease in trade receivables related to our COVID-19 collaboration with Pfizer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in operating activities for the year ended December&#160;31, 2021 was &#8364;889.7 million, comprising a profit before tax of &#8364;15,046.4 million, positive non-cash&#160;adjustments of &#8364;56.0 million, and a net negative change in assets and liabilities of &#8364;10,730.4 million. Non-cash items primarily included movements in government grant, depreciation and amortization as well as share-based compensation expenses and non-cash effective finance expenses. The net negative change in assets and liabilities was primarily due to an increase in trade receivables and a decrease in payables and liabilities as well as inventories.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December&#160;31, 2023 was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;6,954.5&#160;million. The amount includes &#8364;5,912.1&#160;million spend into security investments, &#8364;330.6&#160;million caused by or driven from in-licensing arrangements as well as &#8364;336.9&#160;million for collaborations or M&amp;A transactions. Excluding those effects, the amount for capital expenditures supporting our operating activities amounts to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;275.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> whereof the majority was related to investments in building our laboratory and office facilities in Mainz, Germany. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2022 was &#8364;35.3&#160;million, comprising the release of &#8364;375.2&#160;million cash deposits and compensated by &#8364;329.2&#160;million, which was attributable to the purchase of property, plant and equipment including the amounts spent with respect to the acquisition of the land and laboratory as well as the office facility of our headquarter in Mainz, Germany. Intangible assets investments amounted to &#8364;34.1&#160;million, which was mainly attributable to certain patents and licenses. Therefore, the total capital expenditure spent on tangible and intangible assets during the year ended December 31, 2022 amounted to &#8364;363.3&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2021 was &#8364;566.1&#160;million, comprising the investments of &#8364;375.2&#160;million cash deposits, presented as financial assets as of December 31, 2021 due to their original term of six months, were shown as cash flow used in investing activities during the year ended December 31, 2021 but were returned to cash and cash equivalents during January and February 2022. In addition &#8364;127.5&#160;million was attributable to the purchase of property, plant and equipment including the amounts spent with respect to our acquired facility in Gaithersburg, Maryland, United States as well as &#8364;20.8&#160;million spent upon the acquisition of our new subsidiary in Vienna, Austria.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December&#160;31, 2023 was &#8364;778.6 million, comprising the &#8364;738.5&#160;million used for the share repurchase programs of ADS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December 31, 2022 was &#8364;1,419.3&#160;million, comprising the &#8364;986.4&#160;million used for the first tranche of our $1.5&#160;billion share repurchase program of ADS as well as the &#8364;484.3&#160;million special cash dividend paid in June 2022. Whereas &#8364;110.5&#160;million cash generated was attributable to the Pfizer equity investment as part of our HZV collaboration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash generated in financing activities for the year ended December 31, 2021 was &#8364;94.2&#160;million, primarily generated from the sale of treasury shares under the at-the-market offering program net of transaction cost and offset by the amount spent when repaying our financing arrangement which was entered with the European Investment Bank, or the EIB.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operation and Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our capital allocation strategy, we expect to continue to incur significant and increasing operating expenses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we and our collaborators:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue or expand our research or development of our programs in preclinical development&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue or expand the scope of our clinical trials for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">initiate additional preclinical, clinical, or other trials for our product candidates, including under our collaboration agreements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">change or increase our manufacturing capacity or capability&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">change or add additional suppliers&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as a public company and our product development and commercialization efforts, including new and expanded sites globally&#894; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">attract and retain skilled personnel&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">seek marketing approvals and reimbursement for our product candidates&#894;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">develop our sales, marketing, and distribution infrastructure for our COVID-19 vaccine and any other products for which we may obtain marketing approval or emergency use authorization&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">seek to identify and validate additional product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">acquire or in-license other product candidates and technologies&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">acquire other companies;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">make milestone or other payments under any in-license agreements&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">maintain, protect, defend, enforce and expand our intellectual property portfolio&#894; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">experience any delays or encounter issues with any of the above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license and research and development agreements with universities and other third parties, as well as patent assignment agreements, under which we have obtained rights to patents, patent applications and know-how. We enter into contracts in the normal course of business with CROs for clinical trials, clinical and commercial supply manufacturing, with vendors for preclinical research studies and for other services and products for operating purposes. We work together with CMOs, who manufacture our product candidates and products and enter into lease agreements to lease laboratory, GMP manufacturing, storage and office spaces. Purchase obligations under our agreements to the extent that they are quantifiable and not cancellable have been considered when defining our guidance for future cash commitments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the committed</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash outflow in 2024 is related to lease payments amounting to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;34.1&#160;million and commitments under purchase agreements and contractual obligations amounting to &#8364;401.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, we have lease payment obligation with an amount of &#8364;210.3&#160;million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments under purchase agreements and contractual obligations</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of &#8364;1,473.6&#160;million for the years 2025 and beyond.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to all of the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements, both near and long term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the initiation, progress, timing, costs, and results of preclinical or nonclinical studies and clinical trials for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the amount and timing of revenues and associated costs from sales of our COVID-19 vaccine;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the results of research and our other platform activities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the clinical development plans we establish for our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the terms of any agreements with our current or future collaborators, and the achievement of any milestone payments under such agreements to be paid to us or our collaborators&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the number and characteristics of product candidates that we develop or may in-license&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable regulatory authorities&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement, misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities sufficient to support all of our current and future programs&#894;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive marketing approval and reimbursement in regions where we choose to commercialize our products on our own; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the terms of any ADS repurchases we make.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">172</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1762"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Research and Development, Patents and Licenses, etc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full details of our research and development activities and expenditures are given in Item 4 and under the description of the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating Results</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; in this Item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> within this Annual Report.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1756"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Trend Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See the description of &#8220;Operating Results&#8221; in this Item 5, &#8220;Business Overview&#8221; in Item 4 and &#8220;Risk Factors&#8221; in Item&#160;3 within this Annual Report.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1744"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">E. Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our Significant Accounting Judgments, Estimates and Assumption please refer to Note 3 to our consolidated financial statements included elsewhere in this Annual Report. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1978"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">F. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Comparison</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%"> of the year ended December&#160;31, 2022 and the year ended December&#160;31, 2021</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our operating results for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a comparison of the years ended December 31, 2022, and 2021 please refer to Item </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Annual Report on Form 20-F for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1721"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 6. Directors, Senior Management and Employees</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1713"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Directors and Senior Management</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1707"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Board (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Vorstand</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2023, our Supervisory Board expanded our Management Board by appointing James Ryan as Chief Legal Officer (CLO), effective as of September 1, 2023. As CLO, James Ryan heads up our legal department and is responsible for developing and leading the Company&#8217;s corporate legal strategy to promote and protect BioNTech&#8217;s global operations. His current appointment to our Management Board will end on August 30, 2027. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and functions of the current members of our Management Board, their ages as of December&#160;31, 2023 and their terms:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:38.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Age</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Term Expires</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Ugur Sahin, M.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jens Holstein</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sean Marett</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Business Officer and Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sierk Poetting, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Operating Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ryan Richardson</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Strategy Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">James Ryan, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Legal Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. &#214;zlem T&#252;reci, M.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></div></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Medical Officer</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Appointed effective as of September 1, 2023. </span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sean Marett will retire as planned from the Management Board of BioNTech as of June 30, 2024. He will continue as a specialist advisor to the Company at least until the end of the year 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> address of the members of our Management Board is the same as our business address: An der Goldgrube 12, D-55131 Mainz, Germany.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a brief summary of the business experience of the members of our Management Board:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prof. Ugur Sahin, M.D. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">co-founded BioNTech in 2008 and has served as our Chief Executive Officer since that time. He is a physician, immunologist and leader in the development of novel approaches to fight cancer and infectious diseases. Ugur Sahin is one of the world&#8217;s foremost experts on messenger ribonucleic acid (mRNA) medicines. He has </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">173</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pioneered several fundamental breakthroughs enabling the development of mRNA vaccines and other types of immunotherapies. He initiated and oversaw &#8220;Project Lightspeed,&#8221; the historic development of the first mRNA vaccine for COVID-19, moving from lab and clinical testing to conditional approval within an unprecedented 11-month period. He also leads BioNTech&#8217;s research and development of neoantigen specific as well as non-neoantigen specific mRNA cancer vaccines, which can be individually tailored and produced on demand according to the profile of non-synonymous mutations identified by next-generation sequencing in patients&#8217; tumors. Ugur Sahin is co-inventor of more than 500 filed patents applications and patents. His academic credentials include serving as a Full Professor in Translational Oncology &amp; Immunology at Johannes Gutenberg University in Mainz, Germany, where he was the supervisor of more than 50 Ph.D. students. He also holds the role of Chairman of the Scientific Management Board of the Helmholtz Institute for Translational Oncology (HI-TRON). Based on his contributions to scientific discovery, Ugur Sahin has received numerous awards and recognitions, including the German Sustainability Award, the Mustafa Prize, and the German Cancer Award. He is married to &#214;zlem T&#252;reci.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jens Holstein </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our Chief Financial Officer. Prior to joining BioNTech in 2021, Jens was CFO of dual-listed MorphoSys AG (Nasdaq/FWB: MOR) where he was instrumental in building a fully integrated biopharmaceutical company. Before joining MorphoSys in 2011, Jens Holstein served in multiple CFO positions as well as general management roles within the Fresenius SE Group. He served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional CFO of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Jens Holstein was Managing Director of Fresenius ProServe GmbH, and CFO and Labor Director of the company&#8217;s subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects &amp; Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Jens Holstein also spent several years in the consulting industry, including in M&amp;A with positions in Frankfurt and London. Jens Holstein holds a Diploma in Business Administration from the University of M&#252;nster, Germany. He is also a non-executive member of the board of directors at global genomic diagnostics company Veracyte Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Marett </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our Chief Business Officer and Chief Commercial Officer. He joined BioNTech in 2012. Prior to that, he worked in global strategic and regional marketing and sales roles at GlaxoSmithKline (NYSE: GSK) in the United States and Pfizer (NYSE: PFE) in Europe, before taking business </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> executive roles at Evotec (Nasdaq: EVO; FWB: EVT) and Lorantis. He has successfully executed complex licensing transactions with large pharmaceutical companies, negotiated M&amp;A transactions and raised finance from investors. Sean Marett built and ran a contract clinical manufacturing organization with operations across Europe and the United States for over half a decade for the contract manufacturer NextPharma. Sean Marett has been Chairman of PHMR Ltd, a company specializing in market access and pharmaceutical reimbursement, since 2017. He previously held non-executive directorship of KWS BioTest Ltd (successfully sold to Charles River) from 2011 until 2018 and was a member of the investment committee of Mann BioInvest Ltd, a fund dedicated to biotechnology and pharmaceutical company investments from 2013 until 2016. He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sierk Poetting, Ph.D. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our Chief Operating Officer. He joined BioNTech in September 2014 from Novartis (NYSE: NV), where he served in various positions from May 2012 to August 2014 as Vice President and Chief Financial </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Officer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the Sandoz Division in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> America. Sierk Poetting started his career as a consultant with McKinsey &amp; Company. A German citizen, Sierk Poetting holds a Master of Science in Optical Sciences from the University of Arizona and a Ph.D. in Physics from the Ludwig-Maximilians University in Munich.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ryan Richardson </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our Chief Strategy Officer. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">He brings more than 20 years of experience in the healthcare and finance industries to BioNTech. Ryan joined BioNTech in 2018 as Senior Vice President, Corporate Development &amp; Strategy and was appointed to Chief Strategy Officer and a Member of the Management Board in 2020. Prior to joining BioNTech, Ryan Richardson was an Executive Director in the Global Healthcare Investment Banking team at J.P. Morgan in London, where he advised companies in the biotech and life sciences industry on cross-border M&amp;A, equity and debt capital financings. Earlier in his career, Ryan Richardson worked as a Management Consultant to biopharmaceutical companies in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Europe, focusing on a wide range of strategic and operational projects in the areas of commercial strategy, pricing and market access, new product planning, and R&amp;D transformation. Ryan has also worked as a Health Economist at IMS Health in London. Ryan was the recipient of the 2018 Eisenhower Zhi Xing Fellowship to China, and the 2005-6 Robert R. Bosch Fellowship to Germany. Ryan Richardson holds an International MBA from the University of Chicago Booth School of Business, an MSc from the London School of Economics, and a BS in Biology from the University of Kansas.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">James Ryan, Ph.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., is our Chief Legal Officer. He brings nearly 20 years of global legal and IP expertise in the pharmaceutical industry to BioNTech. James Ryan joined the Company in 2018 as General Counsel and Senior Vice </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President Legal &amp; IP and was appointed to Chief Legal Officer and a Member of the Management Board in 2023. He has guided BioNTech through a wide range of key business, IP and transactional activities, mergers and acquisitions, strategic collaborations and equity capital markets transactions, including the Company&#8217;s IPO in 2019. James Ryan and his teams played a pivotal role in the successful development of the Pfizer-BioNTech COVID-19 vaccine, supporting every legal aspect of the program, its launch and commercialization. Prior to joining BioNTech, he established the legal group of GW Pharmaceuticals (NASDAQ: GWPH), where he also served as Head of Legal Affairs. Earlier in his career, James Ryan worked for a number of UK and U.S. law firms, including Special Counsel at Covington &amp; Burling LLP, where he specialized in commercial and strategic transactions with a focus on companies in the life sciences sector. James has a Ph.D. in epigenetics from the University of St Andrews, is a member of the Law Society of England &amp; Wales, and is a member of the Law Society of Ireland.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prof. &#214;zlem T&#252;reci, M.D.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-founder and Chief Medical Officer of BioNTech, is a physician, immunologist, and cancer researcher with translational and clinical experience. She has helped lead the discovery of cancer antigens, the development of mRNA-based individualized and off-the-shelf vaccine candidates and other types of immunotherapies which are currently in clinical development. &#214;zlem T&#252;reci leads the clinical development of BioNTech&#8217;s &#8220;Project Lightspeed&#8221;, the company&#8217;s successful effort to develop and distribute an mRNA-based vaccine against COVID-19, a historic achievement completed in less than one year. &#214;zlem T&#252;reci previously served as CEO and Chief Medical Officer of Ganymed Pharmaceuticals AG, which she co-founded with Ugur Sahin and Christoph Huber. She is also a professor for Personalized Immunotherapy at the University Medical Center Mainz and the Helmholtz Institute for Translational Oncology Mainz (HI-TRON) and currently serves as President of the Association for Cancer Immunotherapy (CIMT) in Germany. She is a recipient of the German Sustainability Award, among other notable recognitions. &#214;zlem T&#252;reci is married to Ugur Sahin.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1701"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Aufsichtsrat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the term of office of the Supervisory Board members Ulrich Wandschneider, Christoph Huber, and Michael Motschmann, who were elected by the shareholders at the Annual General Meeting (AGM) on September 17, 2018, ended at the close of the Annual General Meeting on May 25, 2023. As part of the 2023 AGM, Ulrich Wandschneider and Michael Motschmann were re-elected as Supervisory Board members. In addition, Nicola Blackwood was appointed to our Supervisory Board. She succeeded Christoph Huber, who left the Supervisory Board after reaching the applicable retirement age limit. Ulrich Wandschneider&#8217;s, Nicola Blackwood&#8217;s and Michael Motschmann&#8217;s current appointment to our Supervisory Board will end at the AGM in 2027.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and functions of the members of our Supervisory Board during 2023, their ages as of December&#160;31, 2023, their terms (which expire on the date of the relevant year&#8217;s general shareholders&#8217; meeting) and their principal occupations outside of our Company:</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">175</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:38.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:37.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Age</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Term Expires</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Occupation</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Helmut Jeggle (Chair Supervisory Board)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Managing partner and entrepreneurial venture capital investor of Salvia GmbH (Supervisory Board member 4SC AG, AiCuris AG, APK AG and Tonies SE)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ulrich Wandschneider, Ph.D. (Deputy Chair Supervisory Board)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Managing director of beebusy capital GmbH and independent consultant to companies in the lifescience and healthcare sector</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baroness Nicola Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Managing Director and Chairman of Oxford University Innovations Limited (Equity Partner, ReCode Health Ventures LLC, Board Trustee and Director of the Alan Turing Institute, Chair of the Board of Genomics England Limited)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Christoph Huber, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Professor emeritus at the Johannes-Gutenberg University Mainz (Deputy Chair of the Supervisory Board Tirol Kliniken GmbH)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Anja Morawietz, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certified Public Accountant and Management Consultant, Professor of External Accounting and General Business Administration at the Nuremberg University of Applied Sciences Georg Simon Ohm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Michael Motschmann</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Member of the Management Board and head of equity investments of MIG Capital AG (Supervisory Board member AFFiRiS AG, APK AG, HMW-Emissionshaus AG and HMW-Innovations AG)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Rudolf Staudigl, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Independent consultant (member of the Supervisory Board of T&#220;V S&#252;d Aktiengesellschaft, member of the Supervisory Board of Groz-Beckert KG (Deputy Chair))</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Appointed effective as of May 25, 2023. </span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Supervisory Board member until May 25, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e business address of the members of our Supervisory Board is the same as our business address: An der Goldgrube 12, D-55131 Mainz, Germany.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief summary of the prior business experience of the members of our Supervisory Board (including </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christoph Huber, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who left the Supervisory Board after reaching the applicable retirement age limit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Helmut Jeggle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been Chair of our Supervisory Board since its foundation in 2008. He has a degree in business administration from the University of Applied Sciences in Neu-Ulm and an MBA (Master of Business Administration) from the Stuttgart Institute of Management and Technology. From 2000 to 2007, Helmut Jeggle held various positions at Hexal AG. From 2007 onwards, he was, among other things, in charge of Direct Investments at ATHOS KG, the family office of the Str&#252;ngmann family, from which he resigned as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">general partner (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Komplement&#228;r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in April 2021. Since 2014, Helmut Jeggle has been Managing Director of Salvia GmbH, where he acts as an entrepreneurial venture capital investor. He is currently a member of two other supervisory boards of listed companies, including 4SC AG (ETR: VSC) and Tonies SE (ETR: TNIE).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ulrich Wandschneider, Ph.D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. has served as a member of our Supervisory Board since 2018. He has more than 20 years of experience in the healthcare sector as a manager in the operative business and as a member of boards and committees. He was a Partner at Arthur Andersen until 2002 and at Deloitte from 2002 to 2004 in the healthcare and life science sector for many years. From 2004 to 2016 Ulrich Wandschneider served as Chief Executive Officer first of Mediclin AG later of Asklepios Kliniken GmbH &amp; Co. KGaA. In addition to BioNTech SE, he is part of the Supervisory </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">176</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Marienhaus GmbH, Chairman of the Board of Trustees of Oberberg GmbH, Chairman of the Advisory Board of Argentum Pflege Holding GmbH, Panorama Fachklinik GmbH and SmileEyes GmbH and a member of the Advisory Board of Creative Balloons GmbH.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Baroness Nicola Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Supervisory Board since May 25, 2023. She has been Chair of Genomics England since 2020 and Chair of Oxford University Innovation since 2021. She is a member of the House of Lords, the upper chamber of the Parliament of the United Kingdom (UK). Blackwood was elected Member of Parliament for Oxford West and Abingdon 2010 to 2017 and served as Minister for Innovation at the UK Department of Health and Social Care from 2016 to 2017 and 2019 to 2020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as a Chair of the UK House of Commons Science and Technology Select Committee and a member of the House of Lords Science and Technology Select Committee. Nicola Blackwood was educated at Trinity College of Music, London, St Anne&#8217;s College, Oxford, and Emmanuel College, Cambridge.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Christoph Huber, M.D. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a co-founder of BioNTech and has served as a member of our Supervisory Board since 2008. Christoph Huber has more than 50 years of professional experience in hematology, oncology and translational immunology. He served as Chair of the Department of Hematology and Oncology at the Johannes-Gutenberg University Mainz from 1990 to 2009 and, since 2009, has served as Chair Emeritus of the Department of Hematology and Oncology. He was a co-founder of Ganymed Pharmaceuticals AG, now a subsidiary of Astellas. Christoph Huber is an </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> board member of CIMT and a board member of Ci3. From 2018 to April 2019, He served as a member of the supervisory board of TRON. Christoph Huber earned his M.D. at the University of Innsbruck.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prof. Anja Morawietz, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Supervisory Board since 2022. She has been a professor of external accounting and general business administration at the Nuremberg University of Applied Sciences Georg Simon Ohm since 2015. Her research areas are international and national accounting, current developments in corporate governance and sustainability reporting. She also works as a freelance auditor, particularly in audit-related consulting. Previously, she worked for ten years for auditing company KPMG AG, where she conducted audits of annual and consolidated financial statements and advised clients on accounting and regulatory issues. After training as a bank clerk at Norddeutsche Landesbank in Hanover, Anja Morawietz studied business administration at Goethe University in Frankfurt am Main, where she also completed her doctorate as an external doctoral candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Motschmann </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Supervisory Board since 2008. He co-founded MIG </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verwaltungs</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MIG</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in 2004, where he serves on the Management Board and as Head of Equity Investments. In his role with MIG, Michael Motschmann currently serves on the supervisory boards of several private portfolio companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prof. Rudolf Staudigl, Ph.D.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as served as a member of our Supervisory Board since 2022. He studied chemistry at Ludwig Maximilian University of Munich, obtaining his Ph.D. (Dr. rer. nat) in 1981. After postdoctoral research at Harvard University (Cambridge, USA) and Ludwig Maximilian University, he joined Wacker Chemitronic in 1983. Mr. Staudigl became Vice President of Operations at Wacker Siltronic Corporation (Portland, Oregon, USA) in 1989 and President a year later. He joined the Executive Board of Wacker Chemitronic in 1993. In 1995, Rudolf Staudigl was appointed to the Executive Board of Wacker Chemie. In May 2008, Rudolf Staudigl was appointed President &amp; CEO of Wacker Chemie AG. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">He currently serves on various supervisory boards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span><br/></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1692"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Compensation</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1686"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compensation of Our Supervisory Board Members</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation system of our Supervisory Board as included in our Articles of Association is structured as 100% fixed compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation system for Supervisory Board members for 2023 was retained from 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sec. 113 para. 3 AktG, as amended by the Act Implementing the Second Shareholder Rights Directive, the Annual General Meeting of a listed company must pass a resolution on the compensation of the members of the Supervisory Board at least every four years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Supervisory Board receive an annual compensation of &#8364;70,000, the Chair &#8364;210,000 and the Vice Chair &#8364;105,000. The Chair of the Audit Committee receives an additional annual compensation of &#8364;30,000. The respective </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">177</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chair of another committee receives an additional annual compensation of &#8364;15,000. An ordinary committee member receives an additional annual remuneration of &#8364;5,000 per committee. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All members of the Supervisory Board are reimbursed for their expenses. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:12.797%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.416%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.536%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in thousands &#8364;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Helmut Jeggle </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ulrich Wandschneider, Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Baroness Nicola Blackwood</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Christoph Huber, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Anja Morawietz, Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Michael Motschmann</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Rudolf Staudigl, Ph.D.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chair </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Vice Chair</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Base Compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Committee Compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">226</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">114</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">46</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">30</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">105</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">80</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">90</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">225</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">140</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">80</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">35</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">95</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">35</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Nicola Blackwood was appointed to the Supervisory Board by the Annual General Meeting on May 25, 2023.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Christoph Huber served as a member of our Supervisory Board from 2008 and left the Supervisory Board on May 25, 2023 after reaching the retirement age limit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Supervisory Board who are only members of the Supervisory Board or committees, or who chair or vice-chair the Supervisory Board or the Audit Committee or another committee, for part of the financial year receive the respective compensation on a pro-rata basis.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hence, the compensation of the Supervisory Board members who either left or joined in 2023, namely Christoph Huber and Nicola Blackwood, was paid on a pro-rata basis with respect to their departure or appointment at our AGM on May 25, 2023. In addition, compensation was paid to the members of the Product Committee with effect from the date of its establishment as of October 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the reimbursement of expenses or the compensation is subject to value-added tax, the value-added tax shall be paid in addition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory Board members are included in our D&amp;O liability insurance and are co-insured at our expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current appointments of our Supervisory Board will end with the Annual General Meeting during the respective year set forth below: </span></div><div style="margin-top:12pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Helmut Jeggle: 2026</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ulrich Wandschneider: 2027</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nicola Blackwood: 2027</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anja Morawietz: 2026</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Michael Motschmann: 2027</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rudolf Staudigl: 2026</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1680"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Compensation of the Members of Our Management Board</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with all current members of our Management Board.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">178</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the agreements between us and the members of our Management Board provide for payments and benefits (including upon termination of employment) that are in line with customary market practice.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">termination date</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of the current service agreements of our Management Board: </span></div><div style="margin-top:12pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prof. Ugur Sahin, M.D.: December 31, 2026</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jens Holstein: June 30, 2025</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sean Marett: December 31, 2024</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sierk Poetting, Ph.D.: November 30, 2026</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ryan Richardson: December 31, 2026</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">James Ryan, Ph.D.: August 31, 2027</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prof. &#214;zlem T&#252;reci, M.D.: May 31, 2025</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, Ugur Sahin</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s annual fixed compensation was increased to &#8364;700,000 from &#8364;360,000 as part of an annual compensation review to ensure competitive compensation comparable to that of companies in a comparable sector and relevant peer group. Jens Holstein&#8217;s effective annual fixed compensation was &#8364;550,000 during each of the years ended December 31, 2023 and 2022. Effective April 1, 2022, Sean Marett&#8217;s annual fixed compensation was increased from &#8364;400,000 to &#8364;550,000. Hence, during the years ended December 31, 2023 and 2022, his effective annual fixed compensation amounted to &#8364;550,000 and &#8364;512,500, respectively. Sierk Poetting&#8217;s effective annual fixed compensation amounted to &#8364;550,000, respectively, during the years ended December 31, 2023 and 2022. Effective as of his appointment to the Management Board as of September 1, 2023, James Ryan&#8217;s annual fixed compensation was &#8364;550,000. His compensation is partly paid in the U.K. (in GBP) by the Company's subsidiary, BioNTech UK Limited, and partly in Germany (in Euro). During the year ended December 31, 2023, his effective annual fixed compensation as a Management Board member amounted to &#8364;183,333. Ryan Richardson&#8217;s annual fixed compensation was increased from &#8364;340,000 to &#8364;550,000 leading to the respective effective annual fixed compensation during the years ended December 31, 2023 and 2022. Effective March 1, 2022, &#214;zlem T&#252;reci&#8217;s annual fixed compensation was increased from &#8364;360,000 to &#8364;550,000. Hence, during the years ended December 31, 2023 and 2022, her effective annual fixed compensation amounted to &#8364;550,000 and &#8364;518,333, respectively. The increase in the fixed compensation payable to Sean Marett, Ryan Richardson and &#214;zlem T&#252;reci increased to &#8364;550,000 to align with the fixed compensation payable to Jens Holstein under his 2021 service agreement, which was considered necessary and in the Company's interest to retain our existing Management Board members. All of the Management Board members&#8217; activities for BioNTech Group companies are compensated by their base compensation of &#8364;550,000 and in the case of Ugur Sahin, &#8364;700,000. Management Board&#8217;s service agreements also include a short-term incentive compensation component, which is an annual performance-related bonus for the years of their respective service periods. During the year ended December&#160;31, 2022, the maximum short-term incentive compensation for each of Ugur Sahin, Jens Holstein, Sean Marett, Sierk Poetting, Ryan Richardson and &#214;zlem T&#252;reci was &#8364;180,000; &#8364;300,000; &#8364;300,000; &#8364;300,000; &#8364;170,000; and &#8364;300,000, respectively, which, considering the 2022 target achievement of 85%, led to respective annual bonus amounts of &#8364;153,000; &#8364;255,000; &#8364;255,000; &#8364;255,000; &#8364;144,500; and &#8364;255,000. Following the extension of their respective service agreements and in line with the changes in their annual fixed compensation, the maximum short-term incentive compensation for Ugur Sahin and Ryan Richardson was increased to &#8364;350,000 and &#8364;300,000 respectively. Following his appointment to the Management Board as of September 1, 2023, the maximum short-term compensation for James Ryan was defined on a pro-rata basis and amounted to &#8364;100,000 for the year ended December 31, 2023. Based on the 2023 target achievement of 90%, the annual bonus amounts for Ugur Sahin, Jens Holstein, Sean Marett, Sierk Poetting, Ryan Richardson, James Ryan and &#214;zlem T&#252;reci for the year ended December 31, 2023 amounted to &#8364;315,000; &#8364;270,000; &#8364;270,000; &#8364;270,000; &#8364;270,000; &#8364;90,000; and &#8364;270,000, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payout amount of the short-term incentive compensation depends on the achievement of certain financial </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and non-financial performance criteria of the Group in a particular financial year, which goals are set uniformly for all members of the Management Board. The Supervisory Board exercises reasonable discretion in determining whether such criteria have been achieved. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50% percent of the compensation is paid following determination of the actual achievement of the performance targets (first installment), with the remaining amount payable one year after such determination, subject to adjustment relative to the performance of the price of the American Depositary Shares representing our ordinary shares during that year (second installment).</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">179</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board&#8217;s service agreements provide for long-term incentive compensation (Management Board Grant - LTI) through an annual grant of options to acquire BioNTech shares during their respective service periods. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> granted each year are subject to the terms and conditions of the respective authorizations of the Annual General Meeting creating our Employee Stock Ownership Plan (ESOP) and the applicable option agreements thereunder. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the number of options granted to Ugur Sahin, Jens Holstein, Sean Marett, Sierk Poetting, Ryan Richardson and &#214;zlem T&#252;reci was calculated based on a target value of &#8364;750,000; &#8364;550,000; &#8364;550,000; &#8364;550,000; &#8364;280,000; and &#8364;550,000, respectively. Beginning on January 1, 2023, the target for the number of options to be granted each year for Ugur Sahin and Ryan Richardson was increased to a value of &#8364;1,050,000 and &#8364;550,000, respectively, as part of an annual compensation review to ensure competitive compensation. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the number of options granted to Ugur Sahin, Jens Holstein, Sean Marett, Sierk Poetting, Ryan Richardson and &#214;zlem T&#252;reci was calculated based on a target value of &#8364;1,050,000; &#8364;550,000; &#8364;550,000; &#8364;550,000; &#8364;550,000; and &#8364;550,000, respectively.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service agreement with James Ryan provides that granted options will generally be calculated based on a target value of &#8364;550,000. However, as the annual grant is generally made in the first half of the year, no LTI was granted for the period from his appointment on September 1, 2023 to December 31, 2023.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taking the requirements of Sec. 87a para. 1 AktG into account, the Supervisory Board adopted a compensation system for the members of the Management Board on May 7, 2021. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation system was approved by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Meeting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on June 22, 2021 </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has become effective in connection with the entry into or extension of service agreements or the initiation of specific compensation components. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comprehensive compensation system as approved </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Annual General Meeting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on June 22, 2021 includes specific provisions with respect to </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits upon termination and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available online on our website at www.biontech.com. The information and other content appearing on our website are not incorporated by reference into this Annual Report and our website address is included in this report as an inactive textual reference only.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">180</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, and 2022, the aggregated remuneration for members of our Management Board amounted to 8.3&#160;million and 15.0&#160;million, respectively.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:22.464%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in thousands &#8364;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Ugur Sahin, M.D.</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jens Holstein</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sean Marett</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sierk Poetting, Ph.D.</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ryan Richardson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">James Ryan, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. &#214;zlem T&#252;reci, M.D.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fixed compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">700</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">513</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">550</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">340</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">518</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fringe benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Short-term incentive &#8211; first installment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">158</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">135</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">128</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Short-term incentive &#8211; second installment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">291</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">247</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">141</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other variable compensation</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share-based payments (incl. long-term incentive)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,901</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(620)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">452</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">284</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,866</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">863</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,507</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,550</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">809</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,056</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,319</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">133</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">821</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,410</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">848</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">814</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,312</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,736</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,357</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,467</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">512</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,638</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For James Ryan, a part of the fixed compensation was paid by BioNTech UK Limited, a subsidiary of BioNTech SE. Approximately 30% of his total compensation is attributable to his position as a member of the Management Board and approximately 70% is attributable to his position as a director of BioNTech UK Limited.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Jens Holstein was appointed to the Management Board as Chief Financial Officer (CFO) effective as of July 1, 2021. As of his appointment, the Supervisory Board granted Jens Holstein a one-time signing bonus &#8364;800,000 in the form of 4,246 phantom shares which are included in the share-based payments amounts. The phantom shares vest in four equal installments on July 1 of 2022, 2023, 2024, and June 30, 2025 but will only be settled in cash on July 1, 2025. The cash payment is subject to an effective settlement closing price cap. This means that the settlement closing price shall effectively be adjusted to ensure that the current price of an ADS as of the settlement date does not exceed 800% of the closing price applied when the award was initially granted. In addition, the total cash payment under the award shall not exceed &#8364;6.4&#160;million. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;James Ryan was appointed to the Management Board as Chief Legal Officer (CLO) effective as of September 1, 2023. His compensation for the year ended December 31, 2023 was granted on a pro-rata basis. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes social security, health and additional insurance, company bike and travel expenses. Other fringe benefits, e.g., costs for security services, which are integral to the performance of business duties, are not included in the amount.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">181</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2023, as part of his appointment to the Management Board, James Ryan received a one-time signing cash payment in the amount of &#8364;180,000. The one-time signing cash payment provided compensation in lieu of participation in the LTI 2023 program, which was allocated before his appointment, and a pro-rata allocation for 2023 would not have been permitted under our current AGM authorizations, as ESOPs may only be issued within the first six months of each calendar year. Of this payment, James Ryan shall use 50% net of costs and expenses to purchase BioNTech shares on or before August 31, 2024 to further strengthen his long-term commitment. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During the year ended December 31, 2023, upon the recommendation of the Compensation, Nomination and Corporate Governance Committee, the Supervisory Board approved a special payment in the gross amount of &#8364;600,000 to Jens Holstein. The special payment was made to honor Jens Holstein&#8217;s contribution to the extraordinary financial performance of BioNTech and recognize his efforts to strengthen the Company&#8217;s long-term financial performance. Of this payment, Jens Holstein used &#8364;150,000 net of costs and expenses to purchase 1,620 BioNTech shares during the year ended December 31, 2023 to further strengthen his long-term commitment.</span></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#8220;Stock-based Payments.&#8221; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. It includes the share-based payment arrangements explained in footnote (1) and (2) and those explained in &#8220;Share-Based Payment Arrangements&#8221; in Note 16 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">182</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides an overview of the (phantom) share options and o</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ther share-based payment instruments </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted to our Management Board which are outstanding as of December&#160;31, 2023 - excluding future grants: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:27.449%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant Date / Allocation Date</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of Ordinary Shares Underlying Share Options / Number of Phantom Share Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Option Exercise Price (&#8364;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Earliest Option Exercise Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Option Expiration Date</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name of the Program</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Ugur Sahin, M.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10/9/2019</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,374,963</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.57</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10/9/2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10/9/2029</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEO Grant 2019</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97,420</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.86</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2024</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2030</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,780</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2031</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19,997</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,506</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jens Holstein </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/17/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,463</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">169.08</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/17/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/17/2031</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7/1/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,246</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7/1/2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Signing Bonus</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,664</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,416</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sean Marett</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11/15/2018</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11/15/2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11/15/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ESOP 2018</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,112</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.86</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2031</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,664</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,664</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31/05/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,416</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20/05/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sierk Poetting, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,968</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.86</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2024</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2030</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,112</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2031</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,664</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,416</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ryan Richardson </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33,772</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.86</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2024</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2030</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,163</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2031</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,465</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,416</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">James Ryan, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/15/2020</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,163</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/15/2024</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020 (EEP)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/10/2021</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/10/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021 (EEP)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/9/2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">740</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/9/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022 (EEP)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/8/2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">750</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;n/a </span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12/8/2027</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023 (EEP)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. &#214;zlem T&#252;reci, M.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,968</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.86</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2024</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2/13/2030</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2020</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,112</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2025</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/12/2031</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2021</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,664</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2026</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/31/2032</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2022</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,416</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.12</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2027</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5/20/2033</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">LTI 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The 18-for-1 stock split of our ordinary shares, which became effective on September 18, 2019 upon registration with the commercial register (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) is reflected in share amounts granted in advance.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Options vested in four equal installments on October 9 of 2020, 2021, 2022 and 2023. With the final installment vesting in 2023, the entire award became exercisable. As Ugur Sahin did not exercise in 2023, the options remain exercisable and can only be exercised during the exercise windows as defined by our ESOP.</span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Options vested in four equal installments on February 13 of 2021, 2022, 2023 and 2024, and are now exercisable following the expiry of the waiting period on February 13, 2024 and can only be exercised during the exercise windows as defined by our ESOP.</span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Options were issued as phantom share options and vest in four equal installments on May 12 of 2022, 2023, 2024 and 2025 for all Management Board members except Jens Holstein, and in the case of Jens Holstein, vest in four equal installments on May 17 of 2022, 2023, 2024 and 2025. The options will not become exercisable before the expiry of the waiting period on May 12, 2025 and May 17, 2025, respectively, and can only be exercised during the exercise windows as defined by our ESOP. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options were issued as phantom share options and vest in four equal installments on May 31 of 2023, 2024, 2025 and 2026 for all Management Board members. The options will not become exercisable before the expiry of the waiting period on May 31, 2026 and can only be exercised during the exercise windows as defined by our ESOP. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options vest in four equal installments on May 20 of 2024, 2025, 2026 and 2027. The options will not become exercisable before the expiry of the waiting period on May 20, 2027 and can only be exercised during the exercise windows as defined by our ESOP. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As James Ryan was not part of the Management Board at the time the 2023 LTI award was allocated, he did not receive any options under the ESOP. Prior to his appointment to the Management Board, RSUs were granted to him under the BioNTech 2020 Employee Equity Plan (EEP). RSUs issued under the LTI 2020 (EEP), LTI 2021 (EEP), LTI 2022 (EEP) and LTI 2023 (EEP) programs vest annually in equal installments over four years commencing in December 2020, December 2021, December 2022 and December 2023 respectively and will be settled after a waiting period of four years. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with Jens Holstein&#8217;s appointment to the Management Board as Chief Financial Officer (CFO) on July 1, 2021, the Supervisory Board granted him a one-time signing bonus of &#8364;800,000 in the form of 4,246 phantom shares. The phantom shares vest in four equal installments on July 1 of 2022, 2023, 2024 and June 30, 2025 but will only be settled in cash on July 1, 2025. The cash payment is subject to an effective settlement closing price cap. This means that the settlement closing price shall effectively be adjusted to ensure that the current price of an ADS as of the settlement date does not exceed 800% of the cash payment, which in respect of all phantom shares shall not exceed &#8364;6.4&#160;million. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Indicates end of the respective waiting periods, additional restrictions with respect to exercise windows may apply.</span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(10)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management Board Grant (Long-Term Incentive) in the respective years. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(11)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All options are subject to an effective exercise price cap. This means that the exercise price shall effectively be adjusted to ensure that the current price of an ADS as of the exercise does not exceed 800% of the exercise price. With respect to the ESOP 2018 Program and the CEO Grant 2019, the maximum economic benefit receivable in respect of any exercised option is capped at $240.00,  with the effective exercise price being capped at a Euro amount equivalent to $30.00. With respect to the LTI 2020, the maximum economic benefit receivable in respect of any exercised option is capped at $246.24, with the effective exercise price being capped at a Euro amount equivalent to $30.78. With respect to the phantom share options issued under the LTI 2021 and 2022 as well as the options issued under the LTI 2023 programs, the maximum compensation that the Management Board members are entitled to receive under such programs, together with other compensation components received by each such board member in the respective grant year, shall not exceed &#8364;20.0&#160;million for Ugur Sahin as Chief Executive Officer (CEO) and &#8364;10.0&#160;million for all other Management Board members. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1674"></div><div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payment Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Board Grant (Long-Term Incentive)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board&#8217;s service agreements provide for long-term incentive compensation (Management Board Grant - LTI) through an annual grant of options to acquire BioNTech shares during their respective service periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the number of issued options in 2020 occurred in February 2020. In May 2021 and May 2022, the Management Board received phantom options equivalent to the number of options the Management Board members would have been entitled to receive for 2021 and 2022. During 2023, options were granted in May 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the awards allocated as of February 13, 2020; May 12, 2021; May 17, 2021; May 31, 2022 and May 20, 2023, the exercise prices </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.78 (&#8364;27.86); $185.23 (&#8364;167.63); $186.83 (&#8364;169.08); $152.10 (138)and $113.94 (&#8364;103.12</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively (all amounts calculated as of December&#160;31, 2023 using the foreign exchange rate as published by the German Central Bank (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deutsche Bundesbank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All options are subject to an effective exercise price cap, which means that the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. With respect to the LTI 2020, the maximum economic benefit receivable in respect of any exercised option is capped at $246.24, with the effective exercise price being capped at a Euro amount equivalent to $30.78. With respect to the phantom share options </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">184</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued under the LTI 2021 and 2022 as well as the options issued under the LTI 2023 programs, the maximum compensation that the Management Board members are entitled to receive under such programs, together with other compensation components received by each such board member in the respective grant year, shall not exceed &#8364;20.0&#160;million for Ugur Sahin as Chief Executive Officer (CEO) and &#8364;10.0&#160;million for all other Management Board members. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vest annually in equal installments over four years commencing on the first anniversary of the allocation date and become exercisable four years after the allocation date. The vested options can only be exercised if each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as set out in the ESOP agreement. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer Grant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we granted Ugur Sahin an option to purchase 4,374,963 of our ordinary shares, subject to his continuous employment with us. The exercise price per share of each option is $15.00 (&#8364;13.57), being the public offering price from our initial public offering converted into Euros as of December 31, 2023, and which is subject to the effective exercise price cap and the maximum cap mechanism. Under the effective </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price cap, the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. Under </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum cap mechanism, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum economic benefit receivable in respect of any exercised option is capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240, with the effective exercise price being capped at a Euro amount equivalent to </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.00</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this CEO Grant, the options vested annually in equal installments over four years commencing on the first anniversary of our initial public offering. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5&#160;billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by us), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as defined by our ESOP. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, with the final installment vesting, all 4,374,963 options became exercisable under the rules of the ESOP and the ESOP agreement. During the year ended December 31, 2023, no options were exercised. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Ownership Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an authorization of the general meeting on August 18, 2017, we established a share option program under which we granted selected employees options to receive our shares. The program is designed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an Employee Stock Ownership Plan, or ESOP. We offered participants a certain number of option rights by their explicit acceptance of an option rights agreement. The exercise of option rights in accordance with the agreement gives the participants the right to obtain shares against payment of the exercise price. With respect to the Management Board members serving at the time of allocation, the options are subject to the effective exercise price cap and maximum cap mechanisms. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">185</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price cap, the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. Under </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum cap mechanism, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum economic benefit receivable in respect of any exercised option, is capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the effective exercise price being capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Euro amount equivalent to $30.00. Under the ESOP, the option rights (other than &#214;zlem T&#252;reci&#8217;s, and Ryan Richardson&#8217;s options) fully vest after four years and can be exercised if: (i) the waiting period of four years has elapsed; and (ii) at the time of exercise, the average closing price of the shares of the Company or the average closing price of the right or certificate to be converted into an amount per share on the previous ten trading days preceding the exercise of the option right exceeds the strike price by a minimum of 32%, with this percentage increasing by eight percentage points as of the fifth anniversary of the respective issue date and as of each subsequent anniversary date. Following the expiry of the waiting period, option rights may be exercised within a period of four weeks from the date of the Annual General Meeting or the publication of the annual financial statements, the semi-annual report or our most recent quarterly report or interim report (exercise windows). The option rights can be exercised up to eight years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of a shareholders&#8217; resolution of the general meeting on August 19, 2019, the authorization to issue such option rights was amended such that, in order for the options to be exercisable, the average closing price of the Company&#8217;s shares or the average closing price of the right or certificate to be converted into an amount per share on the ten trading days immediately preceding the exercise must exceed the strike price by a minimum of 28%, with this percentage increasing by seven percentage points as of the fifth anniversary of the issue date and as of each subsequent anniversary date. Furthermore, in addition to the aforementioned requirements, the exercise is only possible if the share price (calculated by reference to the price of the ordinary share underlying the ADS) has performed similar to or better than the Nasdaq Biotechnology Index. The changes made do not affect option rights already issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Supervisory Board determined the ESOP settlement by the delivery of treasury shares (in the form of ADSs) equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The settlement was applied during the exercise windows in 2022 and 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Out of the 5,152,410 option rights granted to our Management Board under the ESOP 2018 program 4,921,630  options were exercised during the year ended December 31, 2022. The remaining 230,780 option rights were exercised by Sean Marett in May 2023. As of December 31, 2023, no further options issued to our Management Board members are outstanding. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1663"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Board Practices</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1657"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Two-Tiered Board Structure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a European public company with limited liability (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Societas Europaea </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or SE) (also referred to as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporation</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and in the official terminology of the European legislation referred to as European public limited-liability company), having its seat in Germany. We have chosen to have a two-tiered SE structure. Hence, our corporate bodies are the Management Board (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vorstand</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Supervisory Board (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aufsichtsrat</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders&#8217;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meeting (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hauptversammlung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Our Management and Supervisory Boards are entirely separate, and, as a rule, no individual may simultaneously be a member of both boards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is responsible for the day-to-day management of our business in accordance with applicable laws, our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the Management Board&#8217;s internal rules of procedure (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gesch&#228;ftsordnung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Our Management Board represents us in our dealings with third parties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principal</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> function of our Supervisory Board is to supervise our Management Board. The Supervisory Board is also responsible for appointing and removing the members of our Management Board, representing us in connection with transactions between a current or former member of the Management </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and us, and granting approvals for certain significant matters.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board and our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supervisory</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Board are solely responsible for and manage their own areas of competency (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kompetenztrennung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); therefore, neither board may make decisions that, pursuant to applicable law, our Articles of Association or the internal rules of procedure are the responsibility of the other board. Members of both boards </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">186</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owe a duty of loyalty and care to us. In carrying out their duties, they are required to exercise the standard of care of a prudent and diligent </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">businessperson</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If they fail to observe the appropriate standard of care, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">they</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may become liable to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In carrying out their duties, the members of both boards must take into account a broad range of considerations when making decisions, including our interests and the interests of our shareholders, employees, creditors and, to a limited extent, the general public, while respecting the rights of our shareholders to be treated on equal terms. Additionally, the Management Board is responsible for implementing an appropriate and effective internal control system and risk management system with regard to the scope of business activities and the risk situation of the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Supervisory Board has comprehensive monitoring responsibilities. To ensure that our Supervisory Board can carry </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">out</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> these functions properly, our Management Board must, among other duties, regularly report to our Supervisory Board regarding our current business operations and future business planning (including financial, investment and personnel planning). In addition, our Supervisory Board or any of its members is entitled to request special reports from the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Board on all matters regarding the Company, our legal and business relations with affiliated companies and any business transactions and matters at such affiliated companies that may have a significant impact on our position at any time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, our shareholders have, as a general rule, no direct recourse against the members of our Management Board or the members of our Supervisory Board in the event that they are believed to have breached their duty of loyalty and care to us. Apart from when we are unable to fulfill our third party obligations, tortious conduct to board members or other special circumstances, only we have the right to claim damages against the members of our two boards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may waive these claims to damages or settle these claims only if at least three years have passed since a claim associated with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> violation of a duty has arisen and only if our shareholders approve the waiver or settlement at a shareholders&#8217; meeting with a simple majority of the votes cast, provided that no shareholders who in the aggregate hold one-tenth or more of our share capital oppose the waiver or settlement and have their opposition formally recorded in the meeting&#8217;s minutes.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1651"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German law requires that the Supervisory Board consists of at least three members, while a company&#8217;s articles of association may stipulate a certain higher number. Our Supervisory Board currently consists of six members.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we are not subject to co-determination, the members of our Supervisory Board are all elected by the shareholders&#8217; meeting in accordance with the provisions of the SE Regulation and the German Stock Corporation Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). German law does not require the majority of our Supervisory Board members to be independent and neither our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) nor the rules of procedure for our Supervisory Board provide otherwise. As per our Supervisory Board&#8217;s assessment, an appropriate number of shareholder representatives on the Supervisory Board (i.e. the entire Supervisory Board) are independent if the Supervisory Board has two independent members. The Supervisory Board considers Helmut Jeggle and Michael Motschmann to be independent irrespective of the fact that they will soon have been members of the Supervisory Board for a period of more than 14 years. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As stated in the declaration to the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German Corporate Governance Code, or the Corporate Governance Code, (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Entsprechenserkl&#228;rung</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">published by the Company on February&#160;27, 2024 pursuant to Section 161 para. 1 of the German Stock Corporation Act (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which in accordance with the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Gov</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ernance Code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is issued in connection with the Declaration pursuant to Section 315d in conjunction with Section 289f of the German Commercial Code (HGB), the length of membership does not give rise to any fears of material conflicts of interest on the part of the members of the Supervisory Board and therefore does not stand in the way of their independence. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the rules of procedure for our Supervisory Board provide that the Supervisory Board should have an independent member with expertise in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> field of accounting, internal control processes and auditing. Ulrich Wandschneider, Anja Morawietz, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Motschmann</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Rudolf Staudigl fulfill this role. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European law, a member of a supervisory board of an SE may be elected for a maximum term to be specified in the articles of association, which must not </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceed</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six years. Re-election, including repeated re-election, is permissible. The shareholders&#8217; meeting may specify a term of office for individual members or all of the members of our Supervisory Board which is shorter than the standard term of office and, subject to statutory limits, may set different start and end dates for the terms of members of our Supervisory Board. Our Articles of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Association</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide for a term of approximately five years, depending on the date of the annual general shareholders&#8217; meeting in the year in which the term of the relevant member is to expire.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shareholders&#8217; meeting may, at the same time as it elects the members of the Supervisory Board, elect one or more </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substitute</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members. The substitute members replace members who cease to be members of our Supervisory Board and take their place for the remainder of their </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> terms of office. Currently, no substitute members have been elected or have been proposed to be elected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of our Supervisory Board may be dismissed at any time during their term of office by a resolution of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders&#8217;</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meeting</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adopted by at least a simple majority of the votes cast. In addition, any member of our Supervisory Board may resign at any time by giving one month&#8217;s written notice &#8211; or, in the event of cause, giving written notice with immediate effect &#8211; of his or her resignation to the Management Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Supervisory Board elects a chairperson and a deputy chairperson from its members. The deputy chairperson exercises the chairperson&#8217;s rights and obligations whenever the chairperson is unable to do so. The members of our Supervisory Board have elected Helmut Jeggle as chairperson and Ulrich </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wandschneider</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> deputy </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chairperson</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, each for the term of their respective membership on our Supervisory Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> meets at least twice each calendar half-year. Our Articles of Association provide </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a quorum of the Supervisory Board members is present if at least three of its members participate in the vote. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our Supervisory Board are deemed present if they attend the meeting via telephone or other (electronic) means of communication (including via video conference) or submit their written vote through another member. Additionally, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Articles of Association allow for resolutions to be taken via telephone or other (electronic) means of communications (including via video conference). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Resolutions of our Supervisory Board are passed by the vote of a simple majority of the votes cast unless otherwise required by law, our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Articles</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Association or the rules of procedure of our Supervisory Board. In the event of a tie, the chairperson of the Supervisory Board has the casting vote. Our Supervisory Board is not permitted to make management decisions, but in accordance with European and German law and in addition to its statutory responsibilities, it has determined that certain matters require its prior consent, including:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">entering into certain large transactions;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">creating or holding any interest in businesses (except wholly owned subsidiaries) or disposing of shares in businesses (except for a sale of JPT);</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">issuing shares from authorized capital, unless the shares are issued pursuant to a redemption of stock appreciation rights; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">acquiring treasury shares in return for valuable consideration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of the Supervisory Board shall disclose any conflicts of interest to the Supervisory Board, especially those that may arise from providing advice or holding any offices or board positions at customers, suppliers, creditors or other third parties. Material conflicts of interest that are not merely temporary and that are specific to a particular Supervisory Board member shall result in this particular member leaving office. Our Supervisory Board also puts in place adequate measures to limit, prevent or resolve conflicts of interest in accordance with applicable legal requirements and the Company&#8217;s Conflicts of Interest Policy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Supervisory Board conducted a self-assessment for the year ended December&#160;31, 2023. It covered all key aspects of the Supervisory Board</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s work, including its committees, its composition, its competence profile, its main topics and its relationship with the Management Board. The results of the self-assessment have been evaluated and will subsequently be presented to the Supervisory Board. Based on the self-assessment, the Supervisory Board believes that it, its committees and the Management Board continue to operate at a professional and cooperative level. No fundamental need for change was identified.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1642"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board Practices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decisions are generally made by our Supervisory Board as a whole, however decisions on certain matters may be delegated to committees of our Supervisory Board to the extent permitted by law. The chairperson, or if he or she is prevented from doing so, the deputy chairperson, chairs the meetings of the Supervisory Board and determines the order in which the agenda items are discussed, the method and order of voting, as well as any adjournment of the discussion and </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">passing of resolutions on individual agenda items after a due assessment of the circumstances. Our Supervisory Board may designate further types of actions as requiring its approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each member of the Supervisory Board is obliged to carry out his or her duties and responsibilities personally, and such duties and responsibilities cannot be generally and permanently delegated to third parties. However, the Supervisory Board and its committees have the right to appoint independent experts for the review and analysis of specific circumstances in accordance with its control and supervision duties under applicable European and German law. We would bear the costs of any such independent experts that are retained by the Supervisory Board or any of its committees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 107 para. 3 of the German Stock Corporation Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Supervisory Board may form committees from among its members and charge them with the performance of specific tasks. The committees&#8217; tasks, authorizations and processes are determined by the Supervisory Board. Where permissible by law, important powers of the Supervisory Board may also be transferred to committees.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory Board has established an Audit Committee, a Compensation, Nominating, Governance Committee and a Capital Markets and Product Committee by resolution. The Product Committee was established as of October 1, 2023. Set forth in the table below are the members of the respective committees during the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name of Committee</span></td><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Members</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Audit Committee</span></td><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Anja Morawietz, Ph.D. (Chair), Prof. Rudolf Staudigl, Ph.D and Ulrich Wandschneider, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compensation, Nominating and Corporate Governance Committee</span></td><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231F20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Rudolf Staudigl, Ph.D. (Chair), Baroness Nicola Blackwood (since May 25, 2023), Prof. Christoph Huber, M.D (until May 25, 2023) and Michael Motschmann.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capital Markets Committee</span></td><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231F20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Helmut Jeggle (Chair), Prof. Anja Morawietz, Ph.D. and Michael Motschmann</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product Committee (est. October 1, 2023)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#231F20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ulrich Wandschneider, Ph.D. (Chair), Baroness Nicola Blackwood and Helmut Jeggle</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1636"></div><div style="margin-top:2pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Audit Committee</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee for the year ended December 31, 2023 consisted of Anja Morawietz. (Chair), Rudolf Staudigl and Ulrich Wandschneider. The Audit Committee assists the Supervisory Board in overseeing the accuracy and integrity of our financial statements, our accounting and financial reporting processes and audits of our financial statements, the effective functioning of our internal control system, our risk management system, our compliance with legal and regulatory requirements, our independent auditor&#8217;s qualifications and independence, the performance of the independent auditor and the effective functioning of our internal audit functions, and, subject to certain limitations, adopts and implements pertinent decisions on behalf of the Supervisory Board. The Audit Committee&#8217;s duties and responsibilities to carry out its purpose, include, among others:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">making a recommendation to the Supervisory Board with respect to the proposal for the appointment of the auditors;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">considering the commissioning of the audit engagement, as well as the compensation, retention and oversight of the independent auditor;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">evaluating the qualifications, independence and quality of performance of the independent auditor;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reviewing and pre-approving the audit and non-audit services to be performed by the independent auditor;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reviewing and discussing with the independent auditor and management the annual audit plan, as well as critical accounting policies and practices to be used;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">discussing and determining additional areas of audit focus, as appropriate;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eviewing and discussing with the independent auditor and management the adequacy and effectiveness of our internal accounting controls and critical accounting policies;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">reviewing and discussing with the independent auditor and management the results of our annual audit;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">189</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">reviewing non-financial reporting;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">reviewing the effectiveness of the compliance management system;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">reviewing and discussing with the independent auditor and management any quarterly or annual earnings announcements;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reviewing any related party transactions and reviewing and monitoring potential conflict of interest situations on an ongoing basis for compliance with our policies and procedures; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">overseeing procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting controls or auditing matters. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the limits of applicable European and German law, the Audit Committee shall have the resources and authority appropriate to discharge its duties and responsibilities, including the authority to select, retain, terminate, and approve the fees and other engagement terms of special or independent counsel, accountants or other experts and advisors, as it deems necessary or appropriate for so discharging its duties and responsibilities, without seeking approval of the Management Board or Supervisory Board. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All members of the Audit Committee qualify as &#8220;independent directors&#8221; as such term is defined in Rule 10A-3 under the Exchange Act and Nasdaq Rule 5605. Additionally, our Supervisory Board has determined that each of Anja Morawietz, Rudolf Staudigl and Ulrich Wandschneider qualifies as &#8220;audit committee financial expert&#8221; as that term is defined under the Exchange Act. In addition, Anja Morawietz as Chair of the Audit Committee, Rudolf Staudigl and Ulrich Wandschneider have the special knowledge and experience required by the German Corporate Governance Code in the field of accounting and expertise in the field of auditing.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1630"></div><div style="margin-top:12pt;padding-left:42.5pt;text-indent:-18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Compensation, Nominating and Corporate Governance Committee</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, Nominating and </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate Governance Committee for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of Rudolf Staudigl (Chair), Nicola Blackwood (since May 25, 2023), Christoph Huber (until May 25, 2023) and Michael Motschmann. The Compensation, Nominating and Corporate Governance Committee&#8217;s duties and responsibilities to carry out its purpose include, among others:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">preparing and discussing with management policies relating to the remuneration of the members of our Management Board;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reviewing and supervising corporate goals and objectives for the remuneration of the members of the Management Board, including evaluation of the performance of the members of the Management Board in light of these goals and proposals to the Supervisory Board for remuneration based on such evaluations;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reviewing all equity-based compensation plans and arrangements and making recommendations to the Supervisory Board regarding such plans;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">assisting with identifying and recruiting candidates to fill positions on the Management Board and the Supervisory Board;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">considering any corporate governance issue that arises and developing appropriate recommendations for the Supervisory Board; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">overseeing the evaluation of the Supervisory Board and reporting on its performance and effectiveness. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1624"></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Capital Markets Committee</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Capital Markets Committee for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of Helmut Jeggle (Chair), Anja Morawietz and Michael Motschmann. The Capital Markets Committee advises and makes recommendations to the Supervisory Board on issues in connection with capital measures and takeover, merger and acquisition activities. Its responsibilities include the following tasks:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">overseeing the activities of the Company relating to its capital structure and capital raising, including preparation for and implementation of public offerings and share issuances; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">overseeing the activities of the Company relating to takeovers, mergers and acquisitions activities.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">190</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_549755817750"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Committee</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the discussions in the Supervisory Board and related workshops with members of the Management Board during 2023, our Product Committee was establish</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed as of October 1, 2023 and consists of Ulrich Wandschneider (Chair), Nicola Blackwood and Helmut Jeggle. The Product Committee advises and makes recommendations to the Supervisory Board with respect to our strategy and investment in research and development programs and product launch preparations including commercialization. Its responsibilities include the following tasks:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">advising on strategy, execution and communication regarding relevant go-to-market efforts; </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">overseeing the activities relating to a) product development, b) launch plans and c) it&#180;s execution; and </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">advising on market potential for products in clinical development. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1618"></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Supervisory Board determines the exact number of members of our Management Board, which must consist of at least two members. Pursuant to the Articles, the Supervisory Board may also appoint a chairperson or a spokesman of the Management Board. Ugur Sahin has been appointed the chair of the Management Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our Management Board are appointed by our Supervisory Board for a term of up to five years. They are eligible for reappointment or extension, including repeated re-appointment and extension, after the completion of their term in office, in each case again for up to an additional five years. Under certain circumstances, such as a serious breach of duty or a vote of no confidence by the shareholders in a shareholders&#8217; meeting, a member of the Management Board may be removed from office by our Supervisory Board prior to the expiration of his or her term.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our Management Board conduct the daily business of the Company in accordance with applicable laws, our Articles of Association and the rules of procedure for the Management Board adopted by our Supervisory Board. They are generally responsible for the management of our company and for handling our daily business relations with third parties, the internal organization of our business and communications with our shareholders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A member of the management board of an SE governed by German law may not deal with or vote on matters relating to proposals, arrangements or contractual agreements between himself or herself and the Company, and a member of our Management Board may be liable to us if he or she has a material interest in any contractual agreement between the Company and a third party which is not disclosed to and approved by our Supervisory Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of procedure for our Management Board provide that certain matters require a resolution of the entire Management Board, in addition to transactions for which a resolution adopted by the entire Management Board is required by law or required by our Articles of Association. In particular, the entire Management Board shall decide on, among others: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">the budget plan for the following year, which is to be presented by the Management Board to the Supervisory Board by December 10 of each year;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">presentation of the Company&#8217;s financial statements and consolidated financial statements and reviews of operations of the Company and the Group;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">reporting to the Supervisory Board;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">all measures and transactions that require the Supervisory Board&#8217;s approval;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">all measures and transactions that are of fundamental importance or involve an extraordinary economic risk to us, including without limitation, establishing new lines of business or discontinuing existing ones, acquisitions or sales of material business assets, material interests, holdings and investments and material contracts or transactions;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">convening the Company&#8217;s shareholders&#8217; meetings and proposals for resolutions by the Company&#8217;s shareholders&#8217; general meetings; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">appointment and termination of key managers in the Group.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1612"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Code of Conduct and Conflicts of Interest Policy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct &amp; Ethics, or Code of Conduct, which outlines the principles of legal and ethical business conduct under which we do business. The Code of Conduct applies to all of our Supervisory Board members, Management Board members, directors of our subsidiaries and employees. The full text of the Code of Conduct is available on our website at https://www.biontech.de. The information and other content appearing on our website are not incorporated by reference into this Annual Report and our website address is included in this report as an inactive textual reference only. Any amendments or waivers from the provisions of the Code of Conduct for members of our Supervisory or Management Boards will be made only after approval by our Supervisory Board and will be disclosed on our website promptly following the date of such amendment or waiver.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also adopted a Conflicts of Interest Policy which sets forth the procedures by which we manage potential and actual conflicts of interest. Under the Conflicts of Interest Policy, which applies to all of our Supervisory Board members, Management Board members, directors of our subsidiaries and employees, an actual, potential or perceived conflict of interest must be disclosed when it first arises. If the conflict is transactional in nature and involves a member of the Management Board or the Supervisory Board, the Management or Supervisory Board, as the case may be, with the abstention of the conflicted member, shall decide whether to approve the transaction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have implemented compliance policies that describe the compliance management systems that have been implemented for us and our subsidiaries. Our compliance policies are designed to ensure compliance with applicable legal requirements, while at the same time implementing high ethical standards that are mandatory for both management and each employee. The overall responsibility for the compliance management system lies with the Management Board. The Audit Committee will receive regular reports on the operation of the compliance management system.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1606"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Employees</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of December&#160;31, 2023, we had 6,133&#160;full-time equivalent employees working for us, of whom 1,168 hold a doctoral degree or higher. The following tables provides an overview of employee full-time equivalent broken down by function and by the regions European, North America, Asia and Africa.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:18.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Full-time equivalents</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Clinical Research&#160;&amp; Development </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Scientific Research&#160;&amp; Development </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operations </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Quality </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supporting Functions </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commercial&#160;&amp; Business Development </span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8721; </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">486</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,555</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,440</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">450</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,184</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">185</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5,299</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">440</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">109</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">660</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Asia</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">28</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Africa</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">146</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total as of December 31, 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">576</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,014</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,530</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">457</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,365</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">192</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,133</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,102</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,300</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">384</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">924</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,093</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">356</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">432</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Asia</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total as of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">245</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,458</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,300</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">384</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,003</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">140</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,530</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Europe</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">143</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">812</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,015</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">290</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">503</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,846</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">North America</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">234</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Asia</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total as of December 31, 2021</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">143</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,000</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,015</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">290</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">551</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">83</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,082</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees has engaged in any labor strikes. We apply the collective labor agreements of the chemical industry and related industries at our Marburg site. We have works councils at our Idar-Oberstein, Mainz, Marburg, Munich and Berlin (JPT Peptide Technologies GmbH) sites as well as a group works council (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Konzernbetriebsrat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Further, we maintain a couple of works agreements (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Betriebsvereinbarungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and group works agreements </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">192</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Konzernbetriebsvereinbarungen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with respect to certain topics at our Idar-Oberstein, Mainz, Marburg and Berlin (JPT Peptide Technologies GmbH) sites or the group. We consider our relationship with our employees to be positive and have not experienced any major labor disputes.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1600"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">E. Share Ownership</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share ownership information with respect to Management Board and Supervisory Board members is presented in Item 7 below. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_137988709289692"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">F. Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1591"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 7. Major Shareholders and Related Party Transactions</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1585"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Major Shareholders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> table presents information, as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> regarding the beneficial ownership of our ordinary shares for:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding shares;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">each member of our Supervisory Board;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">each member of our Management Board; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.55pt">all members of our Supervisory Board and Management Board as a group.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of ordinary shares beneficially owned by each entity, person, and member of our Supervisory Board and our Management Board is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60 days </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> t</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hrough the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person. All of our ordinary shares and ADSs representing our ordinary shares vote on an equal basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentage of outstanding ordinary shares is computed on the basis of 237,725,735&#160;ordinary shares outstanding as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This amount excludes 10,826,465&#160;shares held in treasury. Amounts presented in this section include ordinary shares held in the form of ADSs. Unless otherwise indicated, the address for each beneficial owner is An der Goldgrube 12, 55131 Mainz, Germany.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">193</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;Name of Beneficial Owner</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of Shares Beneficially Owned</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Percentage Beneficially Owned</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5% shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AT Impf GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,049,145</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.8&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Medine GmbH </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40,439,542</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17.0&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">All 5% shareholders, as a group</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">144,488,687</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Members of the Supervisory Board and the Management Board</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Ugur Sahin, M.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41,295,728</span></td><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17.4&#160;</span></td><td style="background-color:#ffffff;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jens Holstein&#160;</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,620</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sean Marett </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">815,263</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                      </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sierk Poetting, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">754,784</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ryan Richardson</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,695</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                          </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">James Ryan, Ph.D.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. &#214;zlem T&#252;reci, M.D.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">913,247</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                          </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Helmut Jeggle </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,525,967</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ulrich Wandschneider, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,480</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                           </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baroness Nicola Blackwood</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Anja Morawietz, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">240</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Michael Motschmann</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prof. Rudolf Staudigl, Ph.D.</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">400</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                          </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">All members of our Supervisory Board and Management Board, as a group</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">45,323,424</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">19.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Information herein is based upon a Schedule 13G/A jointly filed with the SEC on February 7, 2024 by ATHOS KG, AT Impf GmbH and Thomas Maier. Consists of 104,049,145 ordinary shares held by AT Impf GmbH. The sole member of AT Impf GmbH is ATHOS KG, and, as a result, ATHOS KG is deemed to be the beneficial owner of the securities held by AT Impf GmbH. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. As of December&#160;31, 2023 Thomas Maier is a general partner (Komplement&#228;r) of ATHOS KG and may be deemed to be beneficial owners of the securities held by AT Impf KG. Mr. Maier disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information herein is based upon a Schedule 13G/A jointly filed with the SEC on February 14, 2024 by Medine GmbH and Ugur Sahin. The sole shareholder of Medine GmbH is Ugur Sahin, and, as a result, Ugur Sahin is deemed to be the beneficial owner of the securities held by Medine GmbH. Consists of 40,439,542 ordinary shares held by Medine GmbH, 1,328,152 of which are held for the benefit of a former colleague pursuant to a trust arrangement. Pursuant to this arrangement, Medine GmbH retains voting power, but not dispositive power, over such shares for so long as such shares are held in trust and accordingly Medine GmbH and Ugur Sahin each may be deemed beneficially to own such shares.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consists of the shares described in note 2 above, plus 856,186 ordinary shares held directly by Ugur Sahin. He is the sole shareholder of Medine GmbH.&#160;</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consists of (a) 705,936 ordinary shares held by RLG GmbH (Sean Marett is the sole shareholder of RLG GmbH), (b) 109,327 ordinary shares held directly by Sean Marett.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consists of (a) 606,025 ordinary shares held by Tofino GmbH (Sierk Poetting is sole shareholder of Tofino GmbH), (b) 148,759 ordinary shares held directly by Sierk Poetting and (c) 1,638 ordinary shares held by immediate family members of Mr. Poetting. Mr. Poetting disclaims beneficial ownership of the 1,638 ordinary shares held by immediate family members except to the extent of his pecuniary interest therein.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Consists of (a) 332,316 ordinary shares held directly by Helmut Jeggle and (b) 1,193,651 ordinary shares held by Salvia GmbH.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consists of 1,480 ordinary shares held by beebusy Capital GmbH. Ulrich Wandschneider is sole shareholder of beebusy Capital GmbH. </span></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consists of (a) 200 ordinary shares held directly by Anja Morawietz and (b) 40 ordinary shares held by immediate family members of Anja Morawietz. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less than one percent. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">194</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holdings by U.S. Shareholders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share capital consists of ordinary shares, some of which are traded in the United States by means of American Depositary Shares (ADSs), each representing one ordinary share. Our depositary, The Bank of New York Mellon, is the holder of the ordinary shares underlying the ADSs. Based on the limited information available to us and the depositary, we generally cannot determine with certainty the number of U.S. shareholders or how many shares such shareholders own.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1572"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Related Party Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Item 18. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1513"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C. Interests of Experts and Counsel</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1505"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 8. Financial Information</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1499"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Consolidated Statements and Other Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Item 18. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1493"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Significant Changes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1481"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 9. The Offer and Listing</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1475"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Offer and Listing Details</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs representing our ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#8220;BNTX&#8221; since October 10, 2019. Prior to that date, there was no public trading market for our ADSs.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1469"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Plan of Distribution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1463"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Markets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs representing our ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#8220;BNTX&#8221; since October 10, 2019.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1457"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Selling Shareholders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1451"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">E. Dilution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1445"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">F. Expenses of the Issue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1426"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 10. Additional Information</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1420"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Share Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">195</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1401"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Memorandum and Articles of Association</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1395"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporated</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a German stock corporation (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesellschaft</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with the legal name Petersberg 91. V AG under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">laws</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Federal Republic of Germany on June 2, 2008. We changed our name to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG on December 11, 2008. Effective as of March 8, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the date on which the change of legal form and company was registered with the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the local court (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amtsgericht</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of Mainz, Germany, we converted to a </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Societas Europaea </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the legal name BioNTech SE. We completed our initial public offering in October 2019. The principal legislation under which we operate and our shares are issued are the Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE), the German Law on the Implementation of Council Regulation (EC) No 2157/2001 of October 8, 2001 on the Statute for a European company (SE) (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157/2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE) (SE-Ausf&#252;hrungsgesetz&#8212;SEAG)</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the German Stock Corporation Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in each case as amended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> registered with the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the local court (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amtsgericht</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in Mainz, Germany, under number HRB 48720. Our statutory seat is in Mainz, Germany, and our registered office is An der Goldgrube 12, 55131 Mainz, Germany. Copies of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are publicly available from the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) at the local court of Mainz, Germany, electronically at www.unternehmensregister.de and as an exhibit to this Annual Report.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1389"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have share capital registered in the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in the amount of &#8364;248,552,200, which is divided into 248,552,200 registered shares (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Namensaktien</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). All shares are shares with no par value (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">St&#252;ckaktien ohne Nennbetrag</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with a notional amount attributable to each ordinary share of &#8364;1.00. Each issued ordinary share is fully paid.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1383"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form, Certification and Transferability of Shares</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The form and contents of our share certificates, collective share certificates and global share certificates are determined by our Management Board. A shareholder&#8217;s right to certification of its shares is excluded, to the extent permitted by law and to the extent that certification is not required by the stock exchange on which the shares or rights or certificates representing them are admitted to trading. We are permitted to issue collective share certificates and global share certificates that represent multiple or all of our shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shares are freely transferable under German law.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1377"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Our Share Capital During the Last Three Financial Years</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share capital as registered with the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) amounts to &#8364;248,552,200, including an amount of &#8364;10,826,465 relating to 10,826,465 ordinary shares held in treasury as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since January 1, 2021, our share capital has changed as follows:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">On March 24, 2022, our share capital as registered with the commercial register (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was increased by issuing 497,727 shares; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">On May 20, 2022, our share capital as registered with the commercial register (</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was increased by issuing 1,744,392 shares. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1371"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-takeover Provisions of Our Charter Documents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) do not include any provisions that would have a direct effect of delaying, deferring or preventing a change of control. However, in the event of a hostile takeover, we could use our authorized capital to increase our share capital to issue new shares to an investor at a premium. An increase in the number of shares outstanding could have a negative effect on a party&#8217;s ability to carry out a hostile takeover. The provisions of German law relating to public bids and takeovers that require any such bids to be carried out in a manner designed to safeguard equal and fair treatment to all shareholders and give them a right to be bought out at an adequate compensation where a party acquires &#8220;control&#8221; (as such term is defined in such provisions) over the relevant company do not apply.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">196</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1365"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Future Changes to the Share Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the relevant law, the general meeting of a European stock corporation (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Societas Europaea</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) governed by German law can authorize the Management Board, with the consent of the Supervisory Board, to issue shares in a specified aggregate nominal amount of up to 50% of the issued share capital of such company at the time the resolution becomes effective. The shareholders&#8217; authorization becomes effective upon registration in the commercial register (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and may extend for a period of no more than five years thereafter. Under &#167; 4(5) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Management Board is authorized to increase our share capital, on one or more occasions, by a total of up to &#8364;122,657,313 by issuing, on one or more occasions, up to 122,657,313 new, registered shares with no par value (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genehmigtes Kapital</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in each case with consent of the Supervisory Board. This authorization expires on June 21, 2026.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new shares issued from the authorized capital will participate in the profits starting with the financial year for which the annual financial statements have not yet been submitted to the general meeting at the time of registration of the implementation of the capital increase. Further details of a capital increase from the authorized capital may be specified by the Management Board.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conditional Capital</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to &#167; 4(6) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), our share capital is conditionally increased by &#8364;16,212,917</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through issuance of new, registered shares with no par value (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bedingtes Kapital ESOP 2017/2019</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The conditional capital may only be used to issue shares to the holders of option rights granted under our ESOP to members of our Management Board and to certain of our employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conditional capital increase will only be implemented to the extent that stock options under our ESOP are exercised and such stock options are not serviced by our providing treasury shares or through cash payments. Any new shares issued under the conditional capital pursuant to &#167; 4(6) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) shall be entitled to dividends from the beginning of the previous financial year in case they are created by the exercise of subscription rights until the start of the Annual General Meeting of the Company and otherwise from the beginning of the financial year in which they are created as a result of the exercise of the stock options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to &#167; 4(7) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), our share capital is conditionally increased by &#8364;85,754,868 through issuance of new, registered shares with no par value (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bedingtes Kapital WSV 2019</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The conditional capital may only be used to issue shares to the holders or creditors of option rights or conversion rights or those under an obligation to convert under warrant-linked or convertible bonds avail of their option rights or conversion rights or where they are under an obligation to convert, to the extent they satisfy their obligation to convert, or to the extent that we exercise a right to choose to grant our shares, in whole or in part instead of paying a monetary amount due, and to the extent cash compensation is not granted in each relevant case or treasury shares or shares of another stock-listed company are not utilized for servicing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new shares issued under the said conditional capital pursuant to the said &#167; 4(7) of our Articles of Association shall carry an entitlement to dividends from the beginning of the financial year in which they are created; however, as far as the law permits, the Management Board can confer dividend rights for new shares in derogation of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to &#167; 4(8) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), our share capital is conditionally increased by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;8,418,091 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">th</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rough issuance of new, registered shares with no par value (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bedingtes Kapital ESOP 2021</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The conditional capital serves exclusively to grant rights to the holders of stock options issued by the Company in accordance with the authorization granted by the Annual General Meeting on June 22, 2021 under agenda item 6 letter d) (the &#8220;Authorization 2021&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conditional capital increase will only be implemented to the extent that stock options under our ESOP are exercised by the holders of the stock options issued by the Company on the basis of Authorization 2021 and such stock options are not settled by the Company with treasury shares or through cash payments. Any new shares issued under the conditional capital pursuant to &#167; 4(8) of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) shall participate in profits from the beginning of the preceding financial year in case they are created by the exercise of subscription rights until the start of the annual general meeting of the Company and otherwise from the beginning of the financial year in which they are created as a result of the exercise of the stock options.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">197</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preemptive Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German law generally provides shareholders with preemptive rights when new shares convertible bonds, bonds with warrants, profit participation rights or participating bonds are issued. This requirement, however, may also be satisfied by way of a credit institution subscribing for the securities and then offering them to the shareholders for purchase (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">mittelbares Bezugsrecht</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible for a shareholder resolution approved by three-quarters of the share capital voting on the resolution to exclude preemptive rights both where the general meeting itself resolves that the new securities are to be issued and in relation to the authorized capital, </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e., </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an authorization for the Management Board, with the consent of the Supervisory Board, to resolve on the issuance of new securities; provided, however, that in each case, the exclusion or the authorization to exclude preemptive rights, respectively, must be justified by specific facts, in accordance with established case law of the German Federal Court of Justice (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BGH</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The German Federal Court of Justice (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BGH</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) considers the exclusion of subscription rights justified if it (i) serves a purpose in the company&#8217;s interests, (ii) is suitable for attaining such purpose, and (iii) is necessary and appropriate. Additionally, the Management Board must submit a written report to the shareholders&#8217; meeting in which it presents the reasons for the exclusion of the subscription rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, under our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Management Board may, with the consent of the Supervisory Board, exclude such preemptive rights in a capital increase from the authorized capital in the following circumstances:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">to exclude fractional amounts from the subscription right;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in the case of a capital increase against cash contributions, if the issue price of the new shares is not significantly lower than the market price of the company&#8217;s shares already listed on the stock exchange at the time the issue price is finally determined. However, this authorization shall only apply subject to the provision that the shares issued excluding subscription rights in accordance with Section 186(3) Sentence 4 AktG may not exceed a total of 10% of the share capital either at the time this authorization takes effect or, if this amount is lower, at the time this authorization is exercised. This limit of 10% of the share capital includes shares which are issued or disposed of during the term of this authorization until the date of its exercise in direct or equivalent application of Section 186(3) Sentence 4 AktG. Shares which are used to service bonds with convertible or option rights or convertible obligations are to be offset against the 10% limit if these bonds were issued under exclusion of shareholder subscription rights in accordance with Section 186(3) Sentence 4 AktG during the entitlement period. Treasury shares are to be offset against the 10% limit, where they were disposed of by the company during the term of this authorization with the exclusion of subscription rights pursuant to or in analogous application of Section 186(3) Sentence 4 AktG;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in the case of capital increases in exchange for contributions in kind, in particular in order to be able to offer the shares to third parties when purchasing companies, parts of companies or interests in companies as well as licenses or industrial property rights;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in order to grant subscription rights to new shares to holders of conversion or option rights in respect of bonds issued by the company or its subordinated domestic or foreign Group companies, to the extent to which they would be entitled after exercising their conversion or option rights or after fulfilling an agreed conversion obligation;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">to implement an election dividend by which shareholders are given the option to contribute their dividend entitlements (either in whole or part) as a contribution in kind against issuance of our new shares;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in capital increases, in each case if excluding subscription rights, according to the assessment by the Management Board, is expedient to the shares&#8217; successful placement in view of the requirements of eligible investors and if the discount by which the issue price of the shares may be below the current stock exchange price at the time the Management Board adopts the resolution on using authorized capital, according to the assessment by the Management Board, does not exceed the extent necessary for a successful placement and in any case does not exceed 10% of either the latest available closing price at the time when the issue price is fixed or the volume-weighted average price over a period of up to five trading days ending on the day on which the issue price is so fixed;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in case shares are to be issued to a member of our Management Board or to another person who is employed by us or one of our affiliates and a minimum holding period of at least one year and the obligation to transfer back </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the shares in the event that the beneficiary is not employed by us or one of our affiliated companies for the entire duration of the holding period or any other agreed period is agreed upon. Additional restrictions with regard to the shares issued may be agreed upon; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">in order to be able to satisfy an option to acquire additional ordinary shares or American Depositary Shares that has been agreed with the issuing banks in connection with a public offering of our shares in the form of American Depositary Shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of new shares issued from the authorized capital and under exclusion of subscription rights pursuant to bullets one through three and six above may not exceed 20% of the share capital, either at the time that the amendment to the Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), resolved upon by the general meeting of June 26, 2020, came into effect or, if lower, at the time of utilization of the authorization. To be counted against the aforementioned 20% limit are: (i) those shares issued or to be issued to service conversion or option rights or conversion or option obligations or tender rights of the issuer under bonds, if the bonds have been issued during the term of this authorization up to the time of its exercise, excluding the subscription rights of shareholders, as well as, to a certain extent (ii) treasury shares that have been disposed under exclusion of subscription rights during the term of this authorization (except in the case of certain exceptions of the resolution to item no. 8 of the general meeting of August 19, 2019).</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1359"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Purpose of our Company</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business objective, as described in &#167; 2 of our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), is to research and develop, as well as the manufacture and marketing of immunological and RNA-based drugs and test methods for the diagnosis, prevention and treatment of cancer, infectious diseases and other serious diseases.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1353"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Shareholders&#8217; Meetings and Voting Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), shareholders&#8217; meetings may be held in person or virtually at our seat or in any municipality in Germany with more than 500,000 inhabitants. Generally, shareholders&#8217; meetings are convened by our Management Board, or our Supervisory Board. Shareholders representing in the aggregate at least five percent of our ordinary shares may, subject to certain formal prerequisites, request that a shareholders&#8217; meeting be convened. Shareholders representing in the aggregate at least five percent of our ordinary shares or owning shares with an aggregate nominal value of at least &#8364;500,000 may request the addition of one or several items to the agenda of any shareholders&#8217; meeting. Shareholders&#8217; meetings may be summoned either via publication in the German Federal Gazette (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bundesanzeiger</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or via mail or email, in each case generally at least 30 days before the meeting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders may participate and vote in the shareholders&#8217; meeting if they are registered as a shareholder with the Company&#8217;s share register. A shareholder who wishes to attend the shareholders&#8217; meeting&#8212;either in person or by proxy, which may also be appointed by us (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stimmrechtsvertreter</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#8212;must register for the meeting, which registration must occur no later than six days before the meeting (or at a later date, if so determined by our Management Board).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share carries one vote at a shareholders&#8217; meeting. Resolutions are, in accordance with our Articles of Association (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), generally taken by simple majority of the votes cast. However, under applicable German and European law, a number of resolutions must be passed by either a three-quarter majority of the votes cast or a three-quarter majority of the share capital represented at the meeting. The fact that in these cases the quorum is determined in relation to the share capital or shares present (as opposed to, for example, all shares eligible to vote) means that holders of a minority of our shares could potentially control the outcome of resolutions.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1347"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Claims against Directors and Shareholders&#8217; Derivative Actions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its management board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board. This concerns, in particular, claims against members of the Management Board or the Supervisory Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so. Further, the Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can also request that a representative pursue the claim on behalf of the company. The court may appoint such a representative upon the request of shareholders holding at least 10% of the company&#8217;s share capital or a participation of at least &#8364;1,000,000 in the share capital.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the company is unable to fulfill its third-party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least 1% of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) must comply with special claim approval procedures conducted before a competent court which will allow the pertinent request only if there are circumstances justifying the assumption that damage has been afflicted on the company by improper conduct or a gross breach of the law or the articles of association.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1341"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dividend Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, distributions of dividends on shares for a given financial year are generally determined by a process in which the management board and supervisory board submit a proposal to the company&#8217;s annual general shareholders&#8217; meeting held in the subsequent financial year and such annual general shareholders&#8217; meeting adopts a resolution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German law provides that a resolution concerning dividends and distribution thereof may be adopted only if the company&#8217;s unconsolidated financial statements prepared in accordance with German law show net retained profits. In determining the profit available for distribution, the result for the relevant year must be adjusted for profits and losses brought forward from the previous year and for withdrawals from or transfers to reserves. Certain reserves are required by law and must be deducted when calculating the profit available for distribution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders generally participate in profit distributions in proportion to the number of shares they hold. Dividends on shares resolved by the general shareholders&#8217; meeting are paid annually, shortly after the general shareholders&#8217; meeting, in compliance with the rules of the respective clearing system. Dividend payment claims are subject to a three-year statute of limitation in the company&#8217;s favor.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1335"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Authorization to Purchase and Sell Our Own Shares</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not purchase our own shares unless authorized by the shareholders&#8217; meeting or in other very limited circumstances as set out in the German Stock Corporation Act. The Company&#8217;s shareholders&#8217; meeting held on August 19, 2019 authorized the Management Board until August 18, 2024, provided it complies with the legal requirement of equal treatment, to acquire treasury shares up to a total of 10% of the Company&#8217;s share capital at the time of the relevant resolution or at the time the authorization is exercised. These shares held by the Company (including shares attributable to it pursuant to the AktG) must never exceed 10% of the share capital. The shares may be purchased (i) through the stock exchange, (ii) by means of a public offer directed to all shareholders of the Company, (iii) by means of a public invitation to the shareholders to make a sales offer or (iv) from the Bill &amp; Melinda Gates Foundation under very limited circumstances as specified in the authorization. Such shares may not be purchased for trading purposes. The Management Board is authorized to use the shares only as specified in the authorization.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1320"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Squeeze-Out of Minority Shareholders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, the shareholders&#8217; meeting of a stock corporation may resolve, upon request of a shareholder that holds at least 95% of the share capital, that the shares held by any remaining minority shareholders be transferred to the majority shareholder against payment of &#8220;adequate cash compensation&#8221; (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ausschluss von Minderheitsaktion&#228;ren</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This amount must take into account the full value of the company at the time of the resolution, which is generally determined using the future earnings value method (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ertragswertmethode</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A squeeze-out in the context of a merger (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">umwandlungsrechtlicher Squeeze-Out</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) only requires a majority shareholder to hold at least 90% of the share capital.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1314"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liquidation Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from liquidation, e.g., as a result of insolvency proceedings, we may be liquidated with a vote of the holders of at least three-quarters of the share capital represented at the shareholders&#8217; meeting at which such a vote is taken. If we are liquidated, any assets remaining after all of our liabilities have been paid off would be distributed among our shareholders in proportion to their holdings in accordance with German statutory law. The German Stock Corporation Act provides certain protections for creditors, which must be observed in the event of liquidation.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1308"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Material Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise disclosed in this Annual Report (including the exhibits thereto), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of our business.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1302"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. Exchange Controls</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently no legal restrictions in the Federal Republic of Germany on international capital movements and foreign exchange transactions, except in limited embargo circumstances (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Teilembargo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) relating to certain areas, entities or persons as a result of applicable resolutions adopted by the United Nations and the European Union. Restrictions currently exist with respect to, among others, Armenia, Azerbaijan, Belarus, Bosnia, Burundi, D.R. Congo, Central African Republic, China, Guatemala, Guinea, Guinea-Bissau, Haiti, Iran, Iraq, Lebanon, Libya, Mali, Moldova and the Transnistria region, Myanmar, Nicaragua, Niger, North Korea, Russia, Somalia, South Sudan, Sudan, Syria, Tunisia, T&#252;rkiye, Ukraine, Venezuela, Yemen and Zimbabwe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For statistical purposes, there are, however, limited notification requirements regarding transactions involving cross-border monetary transfers. With some exceptions, every corporation or individual residing in the Federal Republic of Germany must report to the German Central Bank (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deutsche Bundesbank</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (i) any payment received from, or made to, a non-resident corporation or individual that exceeds &#8364;12,500 (or the equivalent in a foreign currency) and (ii) (with the exception of individuals residing in the Federal Republic of Germany) in case the sum of claims against, or liabilities payable to, non-resident corporations or individuals exceeds &#8364;5,000,000 (or the equivalent in a foreign currency) at the end of any calendar month. Payments include cash payments made by means of direct debit, checks and bills, remittances denominated in euros and other currencies made through financial institutions, as well as netting and clearing arrangements.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1293"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">E. Taxation</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1287"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">German Taxation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion addresses certain German tax consequences of acquiring, owning or disposing of the ADSs. With the exception of &#8220;&#8212;Taxation of Holders Tax Resident in Germany&#8221; below, which provides an overview of dividend taxation and of capital gains taxation with respect to holders that are residents of Germany, this discussion applies only to U.S. treaty beneficiaries (defined below) that acquire the ADSs representing our ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion is based on domestic German tax laws, including, but not limited to, circulars issued by German tax authorities, which, e.g., are not binding on the German courts, and the Treaty (defined below). It is based upon tax laws in effect at the time of filing of this report. These laws are subject to change, possibly with retroactive effect. For example, certain member states of the European Union are considering introducing a financial transaction tax (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finanztransaktionssteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) which, if introduced, may also be applicable on sales and/or transfer of ADSs. In addition, in Germany, for example, there are currently ongoing discussions on an increase of the top tax rate, which may also have an effect on the German tax consequences of acquiring, owning and disposing of the ADSs. There is no assurance that German tax authorities will not challenge one or more of the tax consequences described in this section.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, this discussion is based upon the assumption that each obligation in the deposit agreement and any related agreement will be performed in accordance with its terms. It does not purport to be a comprehensive or exhaustive description of all German tax considerations that may be of relevance in the context of acquiring, owning and disposing of ADSs.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">201</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax information presented in this report is not a substitute for tax advice. Prospective holders of ADSs should consult their own tax advisors regarding the German tax consequences of the purchase, ownership, disposition, donation or inheritance of ADSs in light of their particular circumstances, including the effect of any state, local, or other foreign or domestic laws or changes in tax law or interpretation. The same applies with respect to the rules governing the refund of any German dividend withholding tax (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kapitalertragsteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) withheld. Only an individual tax consultation can appropriately account for the particular tax situation of each investor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the circular issued by the German Federal Ministry of Finance (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BMF-Schreiben</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), dated May 24, 2013, reference number IV C 1-S2204/12/10003, as amended by the circular dated December 18, 2018 (reference number IV C 1 &#8211; S 2204/12/10003), in respect of the taxation of American Depositary Receipts, or ADRs, on domestic shares, or the ADR Tax Circular, for German tax purposes, the ADSs should, in light of the ADR Tax Circular, represent a beneficial ownership interest in the underlying shares of BioNTech and qualify as ADRs for the purpose of the ADR Tax Circular. If the ADSs qualify as ADRs under the ADR Tax Circular, dividends would accordingly be attributable to holders of the ADSs for German tax purposes, and not to the legal owner of the ordinary shares (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., the financial institution on behalf of which the ordinary shares are stored at a domestic depository for the ADS holders). Furthermore, holders of the ADSs should be treated as beneficial owners of the capital of BioNTech with respect to capital gains (see below in section &#8220;&#8212;German Taxation of Capital Gains of the U.S. Treaty Beneficiaries of the ADSs&#8221;). However, investors should note that circulars published by the German tax authorities (including the ADR Tax Circular) are not, e.g., binding on German courts, including German tax courts, and it is unclear whether a German court would follow the ADR Tax Circular in determining the German tax treatment of the ADSs. For the purpose of this German tax section, it is assumed that the ADSs qualify as ADRs within the meaning of the ADR Tax Circular.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Holders Not Tax Resident in Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion describes selected German tax consequences of acquiring the ADSs, owning the ADSs and disposing of the ADSs to a holder that is a U.S. treaty beneficiary. For purposes of this discussion, a &#8220;U.S. treaty beneficiary&#8221; is a resident of the United States for purposes of the Convention between the Federal Republic of Germany and United States of America for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to Taxes on Income and Capital and Certain Other Taxes of 1989, as amended by the Protocol as of June 4, 2008 (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abkommen zwischen der Bundesrepublik Deutschland und den Vereinigten Staaten von Amerika zur Vermeidung der Doppelbesteuerung und zur Verhinderung der Steuerverk&#252;rzung auf dem Gebiet der Steuern vom Einkommen und vom Verm&#246;gen und einiger anderer Steuern in der Fassung vom 4. Juni 2008</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), hereinafter referred to as the &#8220;Treaty,&#8221; who is eligible for relevant benefits under the Treaty.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder will be a U.S. treaty beneficiary entitled to full Treaty benefits in respect of the ADSs if it is, inter alia: </span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">the beneficial owner of the ADSs (and the dividends paid with respect thereto);</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">a U.S. tax resident corporation or individual;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">not also a resident of Germany for German tax purposes; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">not subject to the limitation on benefits (i.e., anti-treaty shopping) article of the Treaty that applies in limited circumstances. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules apply to pension funds and certain other tax-exempt investors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion does not address the treatment of ADSs that are (i) held in connection with a permanent establishment or fixed base through which a U.S. treaty beneficiary carries on business or performs personal services in Germany or (ii) part of business assets for which a permanent representative in Germany has been appointed.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1281"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Rules for the Taxation of Holders Not Tax Resident in Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-German resident holders of ADSs are subject to German taxation with respect to German source income (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">beschr&#228;nkte Steuerpflicht</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). According to the ADR Tax Circular, income from the shares should be attributed to the holder of the ADSs for German tax purposes. As a consequence, income from the ADSs should be treated as German source income.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">202</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">German Withholding Taxation of Dividends of the U.S. Treaty Beneficiaries of the ADSs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the full amount of a dividend distributed by BioNTech to a non-German resident holder, which does not maintain a permanent establishment or other taxable presence in Germany, is subject to (final) German withholding tax at an aggregate rate of 26.375%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that amount consists of 25% on dividends distributed plus solidarity surcharge of 5.5% on the amount of the withholding tax). The basis for the withholding tax is generally the dividend approved for distribution by our general shareholder&#8217;s meeting. German withholding tax is withheld and remitted to the German tax authorities by (i) the disbursing agent (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the German credit institution, financial services institution, securities trading enterprise or securities trading bank (each as defined in the German Banking Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kreditwesengesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and in each case including a German branch of a foreign enterprise, but excluding a foreign branch of a German enterprise)) that holds or administers the underlying shares in custody and (a) disburses or credits the dividend income from the underlying shares, (b) disburses or credits the dividend income from the underlying shares on delivery of the dividend coupons or (c) disburses such dividend income to a foreign agent; or (ii) the central securities depository (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wertpapiersammelbank</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in terms of the German Depositary Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depotgesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) holding the underlying shares in a collective deposit, if such central securities depository disburses the dividend income from the underlying shares to a foreign agent, regardless of whether a holder must report the dividend for tax purposes and regardless of whether or not a holder is a resident of Germany. Dividend payments, to the extent funded from BioNTech&#8217;s tax-recognized contribution account (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">steuerliches Einlagekonto</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), subject to certain prerequisites, do not form part of the taxable dividend income but should lower the holder&#8217;s acquisition costs for the ADSs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Treaty, the German withholding tax may generally not exceed (i) 15% of the gross amount of the dividends received by a U.S. treaty beneficiary other than a company holding ADSs which represent 10% or more of the voting shares in BioNTech, and (ii) 5% of the gross amount of the dividends received by a U.S. treaty beneficiary that is a company holding ADSs which represent 10% or more of the voting shares in BioNTech. The excess of the total withholding tax, including the solidarity surcharge, over the maximum rate of withholding tax permitted by the Treaty is refunded to U.S. treaty beneficiaries upon application. For example, for a declared dividend of 100, a U.S. treaty beneficiary initially receives 73.625 (100 minus the 26.375% withholding tax including solidarity surcharge). A U.S. treaty beneficiary other than a company holding ADSs which represent 10% or more of the voting shares in BioNTech is entitled to a partial refund from the German tax authorities in the amount of 11.375% of the gross dividend (of 100). As a result, the U.S. treaty beneficiary ultimately receives a total of 85 (85% of the declared dividend) following the refund of the excess withholding. However, it should be noted that there is uncertainty as to how the German tax authorities will apply the refund process to dividends on the ADSs with respect to non-German resident holders. Further, such refund is subject to the German anti-avoidance treaty shopping rule (as described below in &#8220;&#8212;Withholding Tax Refund for U.S. Treaty Beneficiaries&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">German Withholding Taxation of Capital Gains of the U.S. Treaty Beneficiaries of the ADSs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The capital gains from the disposition of the ADSs realized by a non-German resident holder, which does not maintain a permanent establishment or other taxable presence in Germany, would be treated as German source income and be subject to German tax if the ADSs qualify as a Qualifying Participation. A Qualifying Participation exists if a holder at any time during the five years preceding the disposition, directly or indirectly, owned at least 1% of BioNTech&#8217;s share capital, irrespective of whether through the ADSs or shares of BioNTech. If such holder had acquired the ADSs without consideration, the previous owner&#8217;s holding period and quota would be taken into account.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Treaty, capital gains from the disposal of a Qualifying Participation realized by a U.S. treaty beneficiary are, however, generally exempt from German taxation. Pursuant to the Treaty, U.S. treaty beneficiaries are not subject to German tax in relation to capital gains from the disposal of a Qualifying Participation even under the circumstances described in the preceding paragraph and therefore should not be subject to German taxation on capital gains from the disposition of the ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German statutory law requires the disbursing agent to levy withholding tax on capital gains from the sale of ADSs or other securities held in a custodial account in Germany. With regard to the German taxation of capital gains, disbursing agent means a German credit institution, financial services institution, securities trading enterprise or securities trading bank (each as defined in the German Banking Act and, in each case including a German branch if a foreign enterprise, but excluding a foreign branch of a German enterprise) that holds the ADSs in custody or administers the ADSs for the investor or conducts sales or other dispositions and disburses or credits the income from the ADSs to the holder of the ADSs. The German statutory law does not explicitly condition the obligation to withhold taxes on capital gains being subject to </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxation in Germany under German statutory law or on an applicable income tax treaty permitting Germany to tax such capital gains.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, a circular issued by the German Federal Ministry of Finance, dated January 18, 2016, reference number IV C 1-S2252/08/10004 :017, as most recently amended by circular dated September 16, 2019, reference number IV C 1-S2252/08/10004 :027, provides that taxes need not be withheld when the holder of the custody account is not a resident of Germany for tax purposes and the income is not subject to German taxation. The circular further states that there is no obligation to withhold such tax even if the non-resident holder owns at least 1% of the share capital of a German corporation. While circulars issued by the German Federal Ministry of Finance are generally only to be adhered to by the German tax authorities but are, for example, not binding on the German courts, in practice, the disbursing agents nevertheless typically rely on guidance contained in such circulars. Therefore, a disbursing agent would only withhold tax at 26.375% on capital gains derived by a U.S. treaty beneficiary from the sale of ADSs held in a custodial account in Germany in the event that the disbursing agent did not follow the abovementioned guidance. In this case, the U.S. treaty beneficiary may be entitled to claim a refund of the withholding tax from the German tax authorities under the Treaty, as described below in &#8220;&#8212;Withholding Tax Refund for U.S. Treaty Beneficiaries.&#8221; A refund of taxes withheld on capital gains from the disposition of the ADSs which do not qualify as Qualifying Participations may also be claimed based on German statutory domestic law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withholding Tax Refund for U.S. Treaty Beneficiaries</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treaty beneficiaries are generally eligible for treaty benefits under the Treaty, as described above in &#8220;&#8212;Taxation of Holders Not Tax Resident in Germany.&#8221; Accordingly, U.S. treaty beneficiaries are in general entitled to claim a refund of (i) the portion of the otherwise applicable 26.375% German withholding tax (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kapitalertragsteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on dividends that exceeds the applicable Treaty rate and (ii) the full amount of German withholding tax (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kapitalertragsteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on capital gains from the disposition of ADSs. The application for such claim is generally to be filed with the Federal Central Office of Taxation (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bundeszentralamt f&#252;r Steuern</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) within four years after the end of the calendar year in which the capital gains or dividends have been received (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bezogen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, in respect of dividends, the refund described in the preceding paragraph is only possible if, due to special rules on the restriction of withholding tax credit, the following three cumulative requirements are met: (i) the holder must qualify as beneficial owner of the ADSs for an uninterrupted minimum holding period of 45 days within a period starting 45 days prior to and ending 45 days after the due date of the dividends, (ii) the holder has to bear at least 70% of the change in value risk related to the ADSs during the minimum holding period as described under (i) of this paragraph and has not entered into (acting by itself or through a related party) hedging transactions which lower the change in value risk by more than 30%, and (iii) the holder must not be obliged to fully or largely compensate directly or indirectly the dividends to third parties. If these requirements are not met, then for a holder not being tax-resident in Germany who applied for a full or partial refund of the withholding tax pursuant to a double taxation treaty, no refund is available. This restriction generally does only apply if (a) the German tax underlying the refund application is below a tax rate of 15% based on the gross amount of the dividends and (b) the holder does not directly own 10% or more of the shares of BioNTech and is subject to income taxes in its state of residence, without being tax-exempt. The restriction of the withholding tax credit does not apply if the holder has beneficially owned the ADSs for at least one uninterrupted year until receipt (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zufluss</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the dividends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, as previously discussed, investors should note that it is unclear how the German tax administration will apply the refund process to dividends on the ADSs. Further, such refund is subject to the German anti treaty shopping rule. Generally, this rule requires that the U.S. treaty beneficiary (in case it is a non-German resident company) maintains its own administrative substance and conducts its own business activities. In particular, a foreign company has no right to a full or partial refund to the extent persons holding ownership interests in BioNTech would not be entitled to the refund if they derived the income directly and the gross income realized by the foreign company is not caused by the business activities of the foreign company, and there are either no economic or other considerable reasons for the interposition of the foreign company, or the foreign company does not participate in general commerce by means of a business organization with resources appropriate to its business purpose. However, this shall not apply if the foreign company&#8217;s principal class of stock is regularly traded in substantial volume on a recognized stock exchange, or if the foreign company is subject to the provisions of the German Investment Tax Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investmentsteuergesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Whether or not and to which extent the anti-treaty shopping rule applies to the ADSs has to be analyzed on a case by case basis taking into account all relevant tests. In addition, the interpretation of these tests is disputed and to date no published decisions of the German Federal Finance Court exist in this regard. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the legal structure of the ADSs, only limited guidance from the German tax authorities exists on the practical application of the refund process with respect to the ADSs and the respective limitations. Recently, the German tax authorities have indicated that for ADR programs (which are considered comparable to ADS programs) a collective tax certificate in connection with a withholding of tax amounts may no longer be issued by the domestic depositary of the shares upon request of the foreign depositary agents. Rather, individual tax certificates need to be issued which might delay a potential refund procedure. Moreover, the simplified refund procedure based on electronic data exchange (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Datentr&#228;gerverfahren</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for claims for reimbursement based on ADRs has been suspended temporarily by the tax authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation of Holders Tax Resident in Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This subsection provides an overview of dividend taxation and of capital gains taxation with regard to the general principles applicable to ADS holders that are tax resident in Germany. A holder is a German tax resident if, in case of an individual, he or she maintains a domicile (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wohnsitz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or a usual residence (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">gew&#246;hnlicher Aufenthalt</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in Germany or if, in case of a corporation, it has its place of management (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gesch&#228;ftsleitung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or registered seat (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sitz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in Germany.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The German dividend and capital gains taxation rules applicable to German tax residents require a distinction between ADSs held as private assets (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privatverm&#246;gen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and ADSs held as business assets (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Betriebsverm&#246;gen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADSs as Private Assets (Privatverm&#246;gen)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ADSs are held as private assets by a German tax resident, dividends and capital gains (other than capital gains from the disposition of a Qualifying Participation) are taxed as investment income and are principally subject to 25% German flat income tax on capital income (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abgeltungsteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (plus a 5.5% solidarity surcharge (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solidarit&#228;tszuschlag</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) thereon, resulting in an aggregate rate of 26.375%), which is levied in the form of withholding tax (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kapitalertragsteuer</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In other words, once deducted, the holder&#8217;s income tax liability on the dividends will be settled. Dividend payments to the extent funded from BioNTech&#8217;s tax-recognized contribution account (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">steuerliches Einlagekonto</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), subject to certain prerequisites, do not form part of the taxable dividend income but should lower the holder&#8217;s acquisition costs for the ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of ADSs may apply to have their capital investment income assessed in accordance with the general rules and with an individual&#8217;s personal income tax rate if this would result in a lower tax burden in which case actually incurred expenses are not deductible. The holder would be taxed on gross personal investment income (including dividends or gains with respect to ADSs), less the saver&#8217;s allowance of &#8364;801 for an individual or &#8364;1,602 for a married couple and a registered civil union (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eingetragene Lebenspartnerschaft</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) filing taxes jointly. These amounts increase from 2023 onwards to a saver's allowance of &#8364;1,000 for an individual or &#8364;2,000 for a married couple and a registered civil union (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">eingetragene Lebendspartnerschaft</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) filing taxes jointly. The deduction of expenses related to the investment income (including dividends or gains with respect to ADSs) is generally not possible for private investors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses resulting from the disposal of ADSs can only be offset against capital gains from the sale of any shares (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktien</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and other ADSs. If, however, a holder holds a Qualifying Participation, 60% of any capital gains resulting from the sale and transfer are taxable at the holder&#8217;s personal income tax rate (plus 5.5% solidarity surcharge thereon). Conversely, 60% of any capital losses are recognized for tax purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2021, the basis for the calculation of the solidarity surcharge (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solidarit&#228;tszuschlag</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) has been reduced for certain individual persons being subject to tax assessments (other than withholding taxes), and in certain cases, the solidarity surcharge has been abolished. However, the abolition or reduction of the solidarity surcharge is not applicable to corporations. In addition, the abolition or reduction of the solidarity surcharge will not affect withholding taxes. Solidarity surcharge will still be levied at 5.5% on the full withholding tax amount and withheld accordingly. There will not be any separate refund of such withheld solidarity surcharge (regardless of the aforementioned exemption limits) in case the withholding tax cannot be refunded either.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Church tax generally has to be withheld, if applicable, based on an automatic data access procedure, unless the holder of ADSs has filed a blocking notice (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sperrvermerk</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) with the Federal Central Tax Office. Where church tax is not levied by way of withholding, it is determined by means of income tax assessment.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">205</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADSs as Business Assets (Betriebsverm&#246;gen)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case the ADSs are held as business assets, the taxation depends on the legal form of the holder (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether the holder is a corporation or an individual).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irrespective of the legal form of the holder, dividends are subject to the aggregate withholding tax rate of 26.375%. The withholding tax is generally creditable against the respective holder&#8217;s corporate income tax or income tax liability. Due to special rules on the restriction of withholding tax credits in respect of dividends, a full withholding tax credit requires that the following three cumulative requirements are met: (i) the holder must qualify as beneficial owner of the ADSs for an uninterrupted minimum holding period of 45 days occurring within a period starting 45 days prior to and ending 45 days after the due date of the dividends, (ii) the holder has to bear at least 70% of the change in value risk related to the ADSs during the minimum holding period as described under (i) of this paragraph and has not entered into (acting by itself or through a related party) hedging transactions which lower the change in value risk for more than 30%, and (iii) the holder must not be obliged to fully or largely compensate directly or indirectly the dividends to third parties. If these requirements are not met, three-fifths of the withholding tax imposed on the dividends must not be credited against the holder&#8217;s corporate income tax or income tax liability, but may, upon application, be deducted from the holder&#8217;s tax base for the relevant tax assessment period. A holder that is generally subject to German income tax or corporate income tax and that has received gross dividends without any deduction of withholding tax due to a tax exemption without qualifying for a full tax credit under the aforementioned requirements has to notify the competent local tax office accordingly, has to file withholding tax returns for a withholding tax of 15% in accordance with statutory formal requirements and has to make a payment in the amount of the omitted withholding tax deduction. The special rules on the restriction of withholding tax credit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(and the corresponding notification and payment obligations) do not apply to a holder whose overall dividend earnings within an assessment period do not exceed &#8364;20,000 or that has been the beneficial owner of the ADSs for at least one uninterrupted year until receipt (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zufluss</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of the dividends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the amount withheld exceeds the income tax liability, the withholding tax will be refunded, provided that certain requirements are met (including the aforementioned requirements).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules apply to credit institutions (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kreditinstitute</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financial services institutions (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finanzdienstleistungsinstitute</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financial enterprises (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finanzunternehmen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), life insurance and health insurance companies, and pension funds.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In principle, dividends that a corporation receives from German or foreign corporations are subject to corporate income tax (and solidarity surcharge thereon) at a rate of 15.825% and also subject to trade tax of between 7.0% and 19.0% depending on the multiplier applied by the relevant municipality. However, with regard to holders in the legal form of a corporation, capital gains are in general effectively 95% tax exempt from corporate income tax (including solidarity surcharge). Dividends are also generally 95% tax exempt from corporate income tax (including solidarity surcharge), inter alia, if the holder held at least 10% of the registered share capital (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grundkapital oder Stammkapital</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of BioNTech at the beginning of the calendar year, or Qualifying Dividends. Five percent of the capital gains and five percent of the Qualifying Dividends are treated as non-deductible business expenses, respectively, and, as such, are subject to corporate income tax (including solidarity surcharge); actual business expenses incurred to generate dividends may be deducted. The acquisition of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the beginning of such calendar year for the determination of whether a dividend is a Qualifying Dividend. Participations in the share capital of BioNTech held through a partnership, including co-entrepreneurships (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mitunternehmerschaften</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), are attributable to the respective partner only on a pro rata basis at the ratio of its entitlement to the profits of the partnership.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital gains and dividend income of a German tax resident corporation are generally subject to German trade tax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of between 7.0% and 19.0% depending on the multiplier applied by the relevant municipality. The aforementioned 95% exemption for capital gains generally applies also for trade tax purposes. However, the amount of any dividends after deducting business expenses related to the dividends is not subject to trade tax if the corporation held at least 15% of BioNTech&#8217;s registered share capital at the beginning of the relevant tax assessment period. In this case, the aforementioned exemption of 95% of the dividend income also applies for trade tax purposes. Losses from the sale of ADSs are generally not tax deductible for corporate income tax and trade tax purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to individuals holding ADSs as business assets, 60% of dividends and capital gains are taxed at the individual&#8217;s personal income tax rate (plus 5.5% solidarity surcharge thereon). Correspondingly, only 60% of business expenses related to the dividends and capital gains as well as losses from the sale of ADSs are principally deductible for </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">206</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax purposes. Since 2021, the basis for the calculation of the solidarity surcharge (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solidarit&#228;tszuschlag</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) has been reduced for certain individual persons being subject to tax assessments (other than withholding taxes), and in certain cases, the solidarity surcharge has been abolished, subject to the limitations described above in &#8220;&#8212;ADSs as Private Assets (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Privatverm&#246;gen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#8221;. The dividend income and 60% of the capital gains are generally subject to trade tax, which is fully or partly creditable against the individual&#8217;s personal income tax by a lump-sum method. Dividends (after deduction of business expenses economically related thereto) are exempt from trade tax if the holder held at least 15% of BioNTech&#8217;s registered share capital at the beginning of the relevant tax assessment period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">German Inheritance and Gift Tax (Erbschaft- und Schenkungsteuer)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer of ADSs to another person by inheritance or gift generally should be subject to German inheritance and gift tax only if:</span></div><div style="margin-top:6pt;padding-left:46.8pt;text-align:justify;text-indent:-16.55pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the decedent or donor or heir, beneficiary or other transferee (a) maintained his or her domicile or a usual residence in Germany, (b) had its place of management or registered office in Germany at the time of the transfer, (c) is a German citizen who has spent no more than five consecutive years outside of Germany without maintaining a domicile in Germany or (d) is a German citizen who serves for a German entity established under public law and is remunerated for his or her service from German public funds (including family members who form part of such person&#8217;s household, if they are German citizens) and is only subject to estate or inheritance tax in his or her country of domicile or usual residence with respect to assets located in such country (special rules apply to certain former German citizens who neither maintain a domicile nor have their usual residence in Germany);</span></div><div style="margin-top:6pt;padding-left:46.8pt;text-align:justify;text-indent:-16.55pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;at the time of the transfer, the ADSs are held by the decedent or donor as business assets forming part of a permanent establishment in Germany or for which a permanent representative in Germany has been appointed; or</span></div><div style="margin-top:6pt;padding-left:46.8pt;text-align:justify;text-indent:-16.55pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the ADSs subject to such transfer form part of a portfolio that represents at the time of the transfer 10% or more of the registered share capital of BioNTech and that has been held directly or indirectly by the decedent or donor, either alone or together with related persons.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement between the Federal Republic of Germany and the United States of America for the avoidance of double taxation with respect to taxes on inheritances and gifts as of December 21, 2000 (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abkommen zwischen der Bundesrepublik Deutschland und den Vereinigten Staaten von Amerika zur Vermeidung der Doppelbesteuerung auf dem Gebiet der Nachlass-, Erbschaft- und Schenkungssteuern in der Fassung vom 21. Dezember 2000</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), hereinafter referred to as the &#8220;United States-Germany Inheritance and Gifts Tax Treaty,&#8221; provides that the German inheritance tax or gift tax can, with certain restrictions, only be levied in the cases of (i) and (ii) above. Special provisions apply to certain German citizens living outside of Germany and former German citizens. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No German transfer tax, value-added tax, stamp duty or similar taxes are assessed on dividend payments. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1275"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Material United States Federal Income Tax Considerations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion describes material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a U.S. Holder (as defined below) that acquires our ADSs and holds them as a capital asset. This discussion is based on the tax laws of the United States, including the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated or proposed thereunder, and administrative and judicial interpretations thereof, all as in effect on the date hereof. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could affect the tax consequences described herein. This section does not address the treatment of a non-U.S. holder, nor does it address the tax treatment under the laws of any state, local or foreign taxing jurisdiction.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our ADSs that, for U.S. federal income tax purposes, is:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">an individual who is a citizen or resident of the United States;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">a domestic corporation (or other entity taxable as a corporation);</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">207</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.55pt">a trust if (i) a court within the United States is able to exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all substantial decisions of the trust or (ii) a valid election under the Treasury regulations is in effect for the trust to be treated as a U.S. person.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion does not address all aspects of U.S. federal income taxation that may be applicable to U.S. Holders in light of their particular circumstances or status (including, for example, banks and other financial institutions, insurance companies, broker and dealers in securities or currencies, traders that have elected to mark securities to market, regulated investment companies, real estate investment trusts, partnerships or other pass- through entities, corporations that accumulate earnings to avoid U.S. federal income tax, tax-exempt organizations, pension plans, persons that hold our shares as part of a straddle, hedge or other integrated investment, persons subject to alternative minimum tax or whose &#8220;functional currency&#8221; is not the U.S. dollar).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our ADSs, the tax treatment of a person treated as a partner in the partnership for U.S. federal income tax purposes generally will depend on the status of the partner and the activities of the partnership. Partnerships (and other entities or arrangements so treated for U.S. federal income tax purposes) and their partners should consult their own tax advisors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, and taking into account the earlier assumptions, for U.S. federal income and German tax purposes, a holder of ADSs will be treated as the owner of the shares represented by those ADSs. Exchanges of shares for ADSs, and ADSs for shares, generally will not be subject to U.S. federal income or to German tax.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">This discussion addresses only U.S. Holders and does not discuss any tax considerations other than U.S. federal income tax considerations. Prospective investors are urged to consult their own tax advisors regarding the U.S. federal, state and local, and foreign tax consequences of the purchase, ownership, and disposition of ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. federal income tax laws, and subject to the passive foreign investment company, or PFIC, rules discussed below, the gross amount of any dividend we pay out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) is includible in income for a U.S. Holder and subject to U.S. federal income taxation. Dividends paid to a noncorporate U.S. Holder that constitute qualified dividend income will be taxable at a preferential tax rate applicable to long-term capital gains, provided that the U.S. Holder holds the ADSs for more than 60 days during the 121-day period beginning 60 days before the ex-dividend date and meets other holding period requirements. Dividends we pay with respect to the ADSs generally will be qualified dividend income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder must include any German tax withheld as part of the gross dividend payment, as described above under &#8220;&#8212;German Taxation&#8212;General Rules for the Taxation of Holders Not Tax Resident in Germany,&#8221; even though the holder does not in fact receive it. The dividend is taxable to the holder when the depositary receives the dividend, actually or constructively. Because we are not a U.S. corporation, the dividend will not be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations. The amount of the dividend distribution includible in U.S. Holder&#8217;s income will be the U.S. dollar value of the Euro payments made, determined at the spot Euro/U.S. dollar rate on the date the dividend distribution is includible in income, regardless of whether the payment is in fact converted into U.S. dollars. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend payment is included in income to the date the payment is converted into U.S. dollars will be treated as ordinary income or loss and will not be eligible for the special tax rate applicable to qualified dividend income. The gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent a distribution with respect to ADSs exceeds our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, the distribution will be treated, first, as a tax-free return of the U.S. Holder&#8217;s investment, up to the holder&#8217;s adjusted tax basis in its ADSs, and, thereafter, as capital gain, which is subject to the tax treatment described below in &#8220;&#8212;Gain on Sale, Exchange or Other Taxable Disposition.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain limitations, the German tax withheld in accordance with the Treaty and paid over to the German taxing authority will be creditable or deductible against a U.S. Holder&#8217;s U.S. federal income tax liability. To the extent a </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">208</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refund of the tax withheld is available to a U.S. Holder under German law or under the Treaty, the amount of tax withheld that is refundable will not be eligible for credit against a U.S. Holder&#8217;s U.S. federal income tax liability. See &#8220;&#8212;German Taxation&#8212;Withholding Tax Refund for U.S. Treaty Beneficiaries&#8221; above for the procedures for obtaining a tax refund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain On Sale, Exchange or Other Taxable Disposition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the PFIC rules described below under &#8220;&#8212;Passive Foreign Investment Company Considerations&#8221;, a U.S. Holder that sells, exchanges or otherwise disposes of ADSs in a taxable disposition generally will recognize capital gain or loss for U.S. federal income tax purposes equal to the difference between the U.S. dollar value of the amount realized and the holder&#8217;s tax basis, determined in U.S. dollars, in the ADSs. Gain or loss recognized on such a sale, exchange or other disposition of ADSs generally will be long-term capital gain if the U.S. Holder&#8217;s holding period in the ADSs exceeds one year. Long-term capital gains of non-corporate U.S. Holders are taxed generally at preferential rates. The gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes. A U.S. Holder&#8217;s ability to deduct capital losses is subject to limitations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Passive Foreign Investment Company Considerations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we were a PFIC for our 2023 taxable year. Because the determination of our PFIC status is made annually based on the factual tests described below, however, we cannot estimate with certainty at this stage whether or not we are likely to be treated as a PFIC in the current taxable year or any future taxable years. In particular, the total value of our asset test generally will be calculated taking into account the market price of our ADSs or ordinary shares. This value has fluctuated considerably in the past, and may fluctuate considerably in the future. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion regarding our PFIC status. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are treated as a PFIC for any taxable year in which at least 75% of our gross income is &#8220;passive income&#8221; or at least 50% of our gross assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period) are assets that produce or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions, and gains from assets that produce passive income. In addition, cash and short-term investment are treated as passive assets regardless of the fact that they may not produce any income.  Rents and royalties received from unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC test. In determining whether we are a PFIC, a pro rata portion of the income and assets of each corporation in which we own, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are classified as a PFIC in any taxable year, a U.S. Holder will be subject to special rules with respect to distributions on and sales, exchanges and other dispositions of the ADSs. In addition, a U.S. Holder that holds the ADSs at any time during a taxable year in which we are classified as a PFIC generally will continue to have to treat such ADSs as ADSs in a PFIC, even if we no longer satisfy the income and asset tests described above, unless the U.S. Holder elects to recognize gain, which will be taxed under the excess distribution rules described below as if such ADSs had been sold on the last day of the last taxable year for which we were a PFIC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain elections by a U.S. Holder, described below, generally alleviate some of the adverse consequences of the excess distribution rules and would result in an alternative treatment of the ADSs, as described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder of PFIC shares must generally file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) and will make any of the elections described below such Form attached to a timely filed U.S. federal income tax return (including available extensions). The failure to file IRS Form 8621 could result in an extension of the statute of limitations with respect to U.S. federal income tax.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Excess Distribution Rules</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are a PFIC with respect to a U.S. Holder, then unless such U.S. Holder makes one of the elections described below, a special tax regime will apply to the U.S. Holder with respect to (i) any &#8220;excess distribution&#8221; (generally, aggregate distributions in any year that are greater than 125% of the average annual distribution received by the holder in the shorter of the three preceding years or the holder&#8217;s holding period for the ADSs) and (ii) any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain  is treated as ordinary income and is subject to tax as if (a) the excess distribution or gain had been realized ratably over the U.S. Holder&#8217;s holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which is subject to tax at the U.S. Holder&#8217;s regular ordinary income rate for the current year and is not subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. If we are a PFIC, this tax treatment for U.S. Holders applies also to indirect distributions and gains deemed realized by U.S. Holders in respect of stock of any of our subsidiaries determined to be PFICs. In addition, dividend distributions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under &#8220;&#8212;Taxation of Dividends.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elective Alternative Treatment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we are a PFIC, the rules above do not apply to a U.S. Holder that makes an election to treat ADSs as stock of a &#8220;qualified electing fund&#8221; or QEF. We intend to provide to U.S. Holders the required information to make a valid QEF election and expect to provide that information after April 15, 2024 and before October 15, 2024 on our corporate website. As a result, a U.S. Holder is expected to be able to make the QEF election with respect to its ADSs with an extension to file its U.S. federal income tax return. A U.S. Holder that makes a QEF election is required to include in income its pro rata share of our ordinary earnings and net capital gain as ordinary income and long-term capital gain, respectively, subject to a separate election to defer payment of taxes, which deferral is subject to an interest charge. A U.S. Holder makes a QEF election generally by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return for the year beginning with which the QEF election is to be effective (taking into account any extensions). A QEF election can be revoked only with the consent of the IRS. We intend to annually provide or make available the information required for a U.S. Holder to make a valid QEF election.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules above also do not apply to a U.S. Holder that makes a &#8220;mark-to-market&#8221; election with respect to the ADSs. This election is available with respect to the ADSs only if they meet certain minimum trading requirements to be considered &#8220;marketable stock&#8221; for purposes of the PFIC rules. Generally, shares or ADSs are treated as marketable stock if they are &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable U.S. Treasury Regulations. ADSs generally will be considered regularly traded during any calendar year during which they are traded, other than in </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Our ADSs will be marketable stock as long as they remain listed on the Nasdaq Global Select Market and are traded regularly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a valid mark-to-market election for the first tax year in which the holder holds (or is deemed to hold) ADSs and for which we are a PFIC will be required to include each year an amount equal to the excess, if any, of the fair market value of such ADSs the holder owns as of the close of the taxable year over the holder&#8217;s adjusted tax basis in such ADSs. The U.S. Holder will be entitled to a deduction for the excess, if any, of the holder&#8217;s adjusted tax basis in the ADSs over the fair market value of such ADSs as of the close of the taxable year, but only to the extent of any net mark-to-market gains with respect to such ADSs included by the U.S. Holder under the election for prior taxable years. The U.S. Holder&#8217;s basis in such ADSs will be adjusted to reflect the amounts included or deducted pursuant to the election. Amounts included in income pursuant to a mark-to-market election, as well as gain on the sale, exchange or other taxable disposition of such ADSs, will be treated as ordinary income. The deductible portion of any mark-to-market loss, as well as loss on a sale, exchange or other disposition of ADSs to the extent that the amount of such loss does not exceed net mark-to-market gains previously included in income, will be treated as ordinary loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mark-to-market election applies to the taxable year for which the election is made and all subsequent taxable years, unless the shares cease to be treated as marketable stock for purposes of the PFIC rules or the IRS consents to its revocation. The excess distribution rules described above generally will not apply to a U.S. Holder for tax years for which a mark-to-market election is in effect. However, if we are a PFIC for any year in which the U.S. Holder owns the ADSs but before a mark-to-market election is made, the interest charge rules described above  applies to any mark-to-market gain recognized in the year the election is made.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Holders are urged to consult their tax advisors as to our status as a PFIC, and the tax consequences to them if we were a PFIC, including the reporting requirements and the desirability of making, and the availability of, a QEF election or a mark-to-market election with respect to the ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-corporate U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ADSs. A U.S. person that is an individual, estate or trust is </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">encouraged to consult its tax advisors regarding the applicability of this Medicare tax to its income and gains in respect of any investment in ADSs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Information Reporting with Respect to Foreign Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual U.S. Holders may be subject to certain reporting obligations on IRS Form 8938 (Statement of Specified Foreign Financial Assets) with respect to the ADSs for any taxable year during which the U.S. Holder&#8217;s aggregate value of these and certain other &#8220;specified foreign financial assets&#8221; exceed a threshold amount that varies with the filing status of the individual. This reporting obligation also applies to domestic entities formed or availed of to hold, directly or indirectly, specified foreign financial assets, including the ADSs. Significant penalties can apply if U.S. Holders are required to make this disclosure and fail to do so. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Holders who acquire ADSs for cash may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) with the IRS and to supply certain additional information to the IRS if (i) immediately after the transfer, the U.S. Holder owns directly or indirectly (or by attribution) at least 10% of our total voting power or value or (ii) the amount of cash transferred to us in exchange for ADSs, when aggregated with all related transfers under applicable regulations, exceeds $100,000. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Information Reporting and Backup Withholding</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, information reporting, on IRS Form 1099, will apply to dividends in respect of ADSs and the proceeds from the sale, exchange or redemption of ADSs that are paid to a holder of ADSs within the United States (and in certain cases, outside the United States), unless such holder is an exempt recipient such as a corporation. Backup withholding (currently at a 24% rate) may apply to such payments if a holder of ADSs fails to provide a taxpayer identification number (generally on an IRS Form W-9) or certification of other exempt status or fails to report in full dividend and interest income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Backup withholding is not an additional tax. A U.S. Holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the U.S. Holder&#8217;s income tax liability by filing a refund claim with the IRS.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1269"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">F. Dividends and Paying Agents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1262"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">G. Statement by Experts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1256"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">H. Documents on Display</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make available on our website, free of charge, our Annual Report and the text of our reports on Form 6-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Our website address is www.biontech.de. The information contained on our website is not incorporated by reference in this Annual Report and our website address is included in this Annual Report as an inactive textual reference only.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements contained in this Annual Report regarding the contents of any contract or other document are not necessarily complete, and, where the contract or other document is an exhibit to the Annual Report, each of these statements is qualified in all respects by the provisions of the actual contract or other documents.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1214"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">I. Subsidiary Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1207"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 11. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to various risks in relation to financial instruments, including counterparty risk and currency risk. Our risk management is coordinated by our Management Board. We do not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which we are exposed include the risks discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate default risks within our asset m</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anagement portfolio, we diversify our cash investments among various counterparties and instruments that have an investment grade rating. Transactions are carried out within the limits approved by the treasury committee. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We publish our consolidated financial statements in Euro. Revenue and expenses incurred in U.S. dollars will be translated into Euro when they are reported in our consolidated financial statements. We are subject to currency risks, as our income and expenditures are denominated in Euro and the U.S. dollar. As such, we are exposed to exchange rate fluctuations between these currencies. Cash inflows denominated in U.S. dollar mainly result </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from generating proceeds under our collaboration agreements.</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial revenues are primarily collaboration revenues from earnings based on our partners&#8217; gross profit, which is shared under the respective collaboration agreements and represents payments we receive in U.S. dollar. Cash outflows dominated in U.S. dollar mainly result from amounts spent on research and development activities and license obligations as well as expanding our global footprint further. With the aim of preserving capital, surplus liquidity is mainly invested in domestic currency investments as exchange rate fluctuations can reduce the value of our financial positions. We limit the effects of the identified risks by means of a coordinated and </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consistently</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> implemented risk strategy. Besides applying natural hedging relationships where possible, foreign exchange forward contracts are concluded, as a matter of principle, as instruments to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mitigate foreign currency exchange risk associated with foreign currency-denominated payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures relating to foreign exchange forward contracts, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. We believe the counterparties to our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments on the financial markets are continuously monitored to enable us to respond to exceptional events at short notice. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, any substantial future appreciation or decline of the U.S. dollar against the Euro could have a material effect on our revenue and profitability. As an example, if the U.S. dollar weakens by 5% against the Euro, financial assets and liabilities denominated in U.S. dollar as of December&#160;31, 2023 would have an effect of &#8364;39.2&#160;million on our profit before tax.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our quantitative and qualitative market risks, see </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1173"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 12. Description of Securities Other than Equity Securities</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1167"></div><div style="margin-top:12pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">A. Debt Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">212</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1161"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">B. Warrants and Rights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1155"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">C. Other Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1149"></div><div style="margin-top:18pt;padding-left:6.25pt;text-align:justify;text-indent:0.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">D. American Depositary Shares</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fees and Expenses</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:48.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Persons depositing or withdrawing shares or ADS holders must pay:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">For:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$.05 (or less) per ADS</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any cash distribution to ADS holders</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A fee equivalent to the fee that would be payable if securities distributed to an ADS holder had been shares and the shares had been deposited for issuance of ADSs</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$.05 (or less) per ADS per calendar year</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depositary services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Registration or transfer fees</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when an ADS holder deposits or withdraws shares</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expenses of the depositary</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cable and facsimile transmissions (when expressly provided in the deposit agreement)</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Converting foreign currency to U.S. dollars</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As necessary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any charges incurred by the depositary or its agents for servicing the deposited securities</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As necessary</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">213</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by, or affiliated with, the depositary and that may earn or share fees, spreads or commissions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment of Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS holders will be responsible for any taxes or other governmental charges payable on their ADSs or on the deposited securities represented by any of their ADSs. The depositary may refuse to register any transfer of ADS holders ADSs or allow him or her to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withdraw</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the deposited securities represented by his or her ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by his or her ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, if appropriate, it will reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1069"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">PART II </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1063"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 13. Defaults, Dividend Arrearages and Delinquencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1057"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1047"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 15. Controls and Procedures</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1041"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15 under the Exchange Act, management, including our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), has performed an evaluation of the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitations, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding our required disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the foregoing, our CEO and CFO have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in by the SEC&#8217;s rules and forms, and that the information required to be disclosed by us in the reports </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">214</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we file or submit under the Exchange Act is accumulated and communicated to our management to allow timely decisions regarding required disclosure. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1035"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Our internal control over financial reporting is a process designed by or under the supervision of the Chief Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with International Financial Reporting Standards as issued by the IASB.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No system of internal control over financial reporting, including one determined to be effective, may prevent or detect all misstatements. It can provide only reasonable assurance regarding financial statement preparation and presentation. Also, projections of the results of any evaluation of the effectiveness of internal control over financial reporting into future periods are subject to inherent risk. The relevant controls may become inadequate due to changes in circumstances or the degree of compliance with the underlying policies or procedures may deteriorate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#8220;Internal Control - Integrated Framework (2013)&#8221;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, our management has determined that the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023 is effective</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">As permitted by the SEC, the Company has elected to exclude an assessment of the internal controls of acquisitions made during the year ended December 31, 2023, namely the acquisition of InstaDeep. InstaDeep&#8217;s impact on our revenue and profit for the period has been immaterial (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">see </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">5</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">to the consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">).</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1029"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2023 has been audited by EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft, an independent registered public accounting firm. Their report is included on page F-2. EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft is a member of the Chamber of Public Accountants (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wirtschaftspr&#252;ferkammer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Berlin, Germany.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1012"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Changes in Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period covered by this report a new ERP System was implemented. The internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934) were reviewed and updated to cover all risk inherent with the change. The new control set was assessed as part of the overall management assessment and determined as effective as of December 31, 2023.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_549755817265"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16. [Reserved]</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1006"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16A. Audit Committee Financial Expert</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee for the year ended December 31, 2023 consisted of Anja Morawietz. (Chair), Rudolf Staudigl and Ulrich Wandschneider. All members of the Audit Committee qualify as &#8220;independent directors&#8221; as such term is defined in Rule 10A-3 under the Exchange Act and Nasdaq Rule 5605. Additionally, our Supervisory Board has determined that each of Anja Morawietz, Rudolf Staudigl and Ulrich Wandschneider qualifies as &#8220;audit committee financial expert&#8221; as that term is defined under the Exchange Act.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_1000"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16B. Code of Ethics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct &amp; Ethics, or Code of Conduct, which outlines the principles of legal and ethical business conduct under which we do business. The Code of Conduct applies to all of our Supervisory Board members, Management Board members, directors of our subsidiaries and employees. The full text of the Code of Conduct is available on our website at https://www.biontech.de. The information and other content appearing on our website are not </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part of this Annual Report and our website address is included in this Annual Report as an inactive textual reference only. Any amendments or waivers from the provisions of the Code of Conduct for members of our Supervisory or Management Boards will be made only after approval by our Supervisory Board and will be disclosed on our website promptly following the date of such amendment or waiver.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_994"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16C. Principal Accountant Fees and Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft, or EY, has served as our independent registered public accounting firm for the years ended December&#160;31, 2023, December&#160;31, 2022, December&#160;31, 2021 for which audited financial statements appear in this Annual Report. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the aggregate fees for professional audit services and other services rendered by EY in the periods indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Audit fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Audit-related fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All other fees</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total fees for professional audit services and other services </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.6</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.7</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December&#160;31, 2023, audit fees related to professional services associated with the integrated audit of our consolidated financial statements and our internal control over financial reporting as set out in this Annual Report, professional services associated with interim reviews, audit fees related to the remuneration report and professional services related to our statutory and regulatory filings for our subsidiaries. In the year ended December&#160;31, 2022, audit fees related to professional services associated with the integrated audit of our consolidated financial statements and our internal control over financial reporting as set out in this Annual Report, professional services associated with interim reviews, audit fees related to the remuneration report and professional services related to our statutory and regulatory filings for our subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December&#160;31, 2023, audit-related fees were attributable to assurance and related services including attest related services and accounting consultations. In the year ended December&#160;31, 2022, audit-related fees were attributable to assurance and related services including attest related services and accounting consultations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December&#160;31, 2023, tax service fees were billed for services in conjunction with transactions, especially with our financing and deal transactions. In the year ended December&#160;31, 2022, tax service fees billed for services in conjunction with transactions, especially with our financing and deal transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December&#160;31, 2023, other fees were comprised of fees for services for consultancy services around management compensation. In the year ended December&#160;31, 2022 other fees were comprised of fees for services for grant applications and consultancy services around management compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee evaluates the qualifications, independence and performance of the independent auditor as well as pre-approves and reviews the audit and non-audit services to be performed by the independent auditor. The external audit plan and fees for professional audit services and other services rendered by EY for the years ended December&#160;31, 2023 and 2022 were approved by the Audit Committee. The Audit Committee monitors compliance with the German and U.S. rules on non-audit services provided by an independent registered public accounting firm.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_988"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16D. Exemptions from the Listing Standards for Audit Committees</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see &#8220;Board Practices&#8212;Supervisory Board Practices&#8212;Audit Committee&#8221; in Item 6C of this Annual Report for the information required by this Item 16D. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_982"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our Management Board and Supervisory Board authorized the 2022 share repurchase program of ADSs, pursuant to which we were permitted to repurchase ADSs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each representing one ordinary share,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a value of up to $1.5&#160;billion a two-year period, commencing on May 2, 2022. The first tranche of our 2022 share repurchase program of ADSs, with a value of up to $1.0&#160;billion, concluded on October 10, 2022. The second tranche with a value of up to $0.5&#160;billion commenced on December 7, 2022 and concluded on March 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Management Board and Supervisory Board authorized the 2023 share repurchase program, under which we were permitted to purchase ADSs, each representing one ordinary share, with a value of up to $0.5&#160;billion, which started June&#160;2, 2023 and concluded on September 18, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:24.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.416%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program first tranche ($1.0 billion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Approximate value of ADSs that may yet be purchased (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">917,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$151.76 (&#8364;143.99)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">917,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$860.7 (&#8364;867.8)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,160,219</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$140.82 (&#8364;133.35)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,078,207</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$697.3 (&#8364;713.1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">519,320</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$162.03 (&#8364;159.40)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,597,527</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$613.2 (&#8364;630.3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,666,515</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$149.08 (&#8364;148.24)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,264,042</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$364.8 (&#8364;383.3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,280,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$135.95 (&#8364;137.66)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,545,030</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$54.6 (&#8364;69.3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">400,483</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$136.37 (&#8364;139.09)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,945,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; (&#8212;)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,945,513</span></td><td colspan="9" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:24.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.481%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program second tranche ($0.5 billion)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Approximate value of ADSs that may yet be purchased (in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618,355</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$142.26 (&#8364;131.12)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618,355</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$412.0 (&#8364;418.9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">857,620</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$138.05 (&#8364;129.06)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,475,975</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$293.6 (&#8364;308.2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">745,196</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$128.49 (&#8364;121.08)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,221,171</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$197.9 (&#8364;218.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,221,171</span></td><td colspan="9" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.486%"><tr><td style="width:1.0%"/><td style="width:24.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.416%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Program 2023 ($0.5&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Approximate value of ADSs that may yet be purchased (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,532,685</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$108.92 (&#8364;100.45)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,532,685</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$333.1 (&#8364;346.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,738,061</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$107.92 (&#8364;97.57)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,270,746</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$145.5 (&#8364;176.4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,261,706</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$105.07 (&#8364;95.85)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,532,452</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$12.9 (&#8364;55.5)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$112.22 (&#8364;105.07)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,646,965</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; (&#8212;)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,646,965</span></td><td colspan="9" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:15.02pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All purchases disclosed in the tables above were purchased under Rule 10b5-1 trading plans pursuant to such share repurchase programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total 9,166,684 ADSs were repurchased under the 2022 program at an average price of $142.05 (&#8364;138.37), for total consideration of $1,302.0&#160;million (&#8364;1,268.4&#160;million). For the 2023 program, in total 4,646,965 ADSs were repurchased at an average price of $107.58 (&#8364;98.24), for total consideration of $500.0&#160;million (&#8364;456.5&#160;million).</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_976"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16F. Change in Registrant&#8217;s Certifying Accountant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_967"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16G. Corporate Governance</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_961"></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">German Corporate Governance Code</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The German Corporate Governance Code, or the Corporate Governance Code, was originally published by the German Federal Ministry of Justice (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bundesministerium der Justiz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in 2002. The version currently in effect, dated April&#160;28, 2022, was published in the German Federal Gazette (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bundesanzeiger</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on June&#160;27, 2022. The Corporate Governance Code contains principles (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grunds&#228;tze</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), recommendations (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Empfehlungen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and suggestions (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anregungen</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) relating to the management and supervision of German companies that are listed on a stock exchange. It follows internationally and nationally recognized standards for good and responsible corporate governance. The purpose of the Corporate Governance Code is to make the German system of corporate governance transparent for investors. The Corporate Governance Code includes corporate governance principles, recommendations and suggestions with respect to shareholders and shareholders&#8217; meetings, the management and supervisory boards, transparency, accounting policies and auditing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation to comply with the recommendations or suggestions of the Corporate Governance Code. The German Stock Corporation Act (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aktiengesetz</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) requires only that the management board and supervisory board of a German company listed on a trading facility (such as a stock exchange) which is regulated and supervised by government authorities issue an annual declaration that either (i) states that the company has complied with the recommendations of the Corporate Governance Code or (ii) lists the recommendations that the company has not complied with and explains its reasons for deviating from the recommendations of the Corporate Governance Code (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Entsprechenserkl&#228;rung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In addition, a listed company is also required to state in this annual declaration whether it intends to comply with the recommendations or list the recommendations it does not plan to comply with in the future. These declarations must be made accessible to shareholders at all times. If the company changes its policy on certain recommendations between such annual declarations, it must disclose this fact and explain its reasons for deviating from the recommendations. Non-compliance with suggestions contained in the Corporate Governance Code need not be disclosed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board and Supervisory Board comply with the Corporate Governance Code except for such provisions which are listed explicitly in the annual declaration and for which they provide an explanation of non-compliance. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_955"></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Differences in Corporate Law</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable provisions of the SE Regulation in conjunction with the German Stock Corporation Act as applied to a European stock corporation that has its legal seat in Germany differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the SE Regulation in conjunction with the German Stock Corporation Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and European and German law. </span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">European Union/Federal Republic of&#160;Germany</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Board System</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A European stock corporation may choose to have a two-tier board structure composed of the Management Board (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vorstand</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the Supervisory Board (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aufsichtsrat</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We have chosen this structure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Management Board is responsible for running the company&#8217;s affairs and representing the company in dealings with third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory Board of a European stock corporation under German law has a control and supervisory function. The Supervisory Board does not actively manage the company but certain Management Board actions require the approval of the Supervisory Board.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware law, a corporation has a unitary board structure, and it is the responsibility of the board of directors to appoint and oversee the management of the corporation on behalf of and in the best interests of the stockholders of the corporation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for running the corporation and overseeing its day-to-day operations.</span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">219</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Appointment and Number of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable European and German law, a European stock corporation governed by German law with a share capital of at least &#8364;3 million generally must have at least two members on its Management Board and the number of members shall be determined by or in the manner provided in the company&#8217;s articles of association.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Supervisory Board must consist of at least three but&#8212;depending on the share capital&#8212;no more than 21 Supervisory Board members, whereby the number of Supervisory Board members must be divisible by three if this is necessary for the fulfilment of co-determination requirements. The articles of association of the company must specify if the Supervisory Board has more than three members.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supervisory Board members are either appointed by the shareholders&#8217; meeting or delegated by one or more individual shareholders if so provided for in the company&#8217;s articles of association. If the Supervisory Board consists of fewer members than is required to meet the quorum for resolutions (either statutory or pursuant to the company&#8217;s articles of association), a competent court may appoint additional members as needed to meet the quorum. The provisions of German law in relation to employees&#8217; co-determination do not apply to the Company.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">220</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Removal of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Management Board of a European stock corporation are appointed by the Supervisory Board for a maximum period of six years with an opportunity to be reelected. The articles of association may provide for a shorter term which in our case is up to five years. The members of the Management Board may be reelected, even repeatedly. The Supervisory Board may remove a member of the Management Board prior to the expiration of his or her term only for cause, such as gross breach of duties (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">grobe Pflichtverletzung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the inability to manage the business properly (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unf&#228;higkeit zur ordnungsgem&#228;&#223;en Pflichtaus&#252;bung</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or a vote of no-confidence during the shareholders&#8217; meeting (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vertrauensentzug</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The shareholders themselves are not entitled to appoint or dismiss the members of the Management Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under European law, a member of the Supervisory Board of a company may be elected for a term of up to six years. The articles of association may provide for a shorter term. Our Supervisory Board members are, if the general meeting does not resolve on a shorter term, elected for a period up to the end of the general meeting deciding on the discharge for the fourth financial year after the election. Reelection, including repeated reelection, is permissible. Members of the Supervisory Board may be removed with or without cause by way of a general meeting resolution, with the applicable majority requirement depending on the relevant company&#8217;s articles of association. </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause; or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">221</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vacancies on the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the law, vacant positions on the Management Board are filled by the Supervisory Board in accordance with the general rules of appointment, which provide that vacancies are filled by the simple majority of votes of Supervisory Board members present or represented by proxy at the vote (with, under certain circumstances, the chairman having a casting vote), unless otherwise provided by the company&#8217;s articles of association. In case of emergencies, a vacant position on the Management Board may be filled by an individual appointed by the court. Vacant positions on the Supervisory Board are filled in accordance with the general rules of appointment.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or by-laws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Annual General Meeting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A European stock corporation, which is governed by German law, must hold an annual shareholders&#8217; meeting within six months of the end of its fiscal year. The annual shareholders&#8217; meeting must be held at a location determined by the articles of association. If the articles of association do not provide for a specific location, the shareholders&#8217; meeting shall be held at the company&#8217;s seat or, if applicable, at the venue (in Germany) where its shares are listed. Under the articles of association, the Management Board is authorized to provide for the Annual General Meeting to be held without the physical presence of the shareholders or their proxies at the location of the Annual General Meeting (virtual Annual General Meeting).</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General Meeting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the law, extraordinary shareholders&#8217; meetings, in addition to the annual shareholders&#8217; meetings, may be called either by the Management Board, or the Supervisory Board. Shareholders holding at least 5% of the company&#8217;s share capital are entitled to request that an extraordinary shareholders&#8217; meeting be convened. In the event that the meeting is not then so convened, a competent court may order that the meeting be convened or authorize the shareholders or their representative to convene the meeting themselves.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">222</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notice of General Meetings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable European and German law, unless a longer period is otherwise provided for in the articles of association or applies because of registration requirements stipulated in the articles of association, the shareholders must be given at least 30 days&#8217; advance notice of the shareholders&#8217; meeting. Such notices must at least specify the name of the company, the statutory seat of the company, and the location, date and time of the shareholders&#8217; meeting. In addition, the invitation must contain the agenda items as well as the Management Board&#8217;s and the Supervisory Board&#8217;s voting proposal for each agenda item and, depending on the circumstances, certain further information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If all shareholders entitled to attend the shareholders&#8217; meeting are present or represented and do not object to the meeting being held, the formalities of calling and holding of a shareholders&#8217; meeting do not apply.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proxy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A shareholder may designate another person to attend, speak and vote at a shareholders&#8217; meeting of the company on such shareholder&#8217;s behalf by proxy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to Management Board meetings, a Management Board member may transmit its (written or verbal) vote via another Management Board member.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to Supervisory Board meetings, a Supervisory Board member may participate in voting by issuing a written vote to another Supervisory Board member or any third party entitled to attend the Supervisory Board meeting.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">223</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preemptive Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the law applicable to European stock corporations governed by German law, existing shareholders have a statutory subscription right for any additional issue of shares or any security convertible into shares pro rata to the nominal value of their respective holdings in the company, unless (i) shareholders representing three-quarters of the registered share capital present at the shareholders&#8217; meeting have resolved upon the whole or partial exclusion of the subscription right and (ii) there exists good and objective cause for such exclusion. No separate resolution on the exclusion of subscription rights is required if all shareholders waive their statutory subscription rights.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, stockholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Authority to Allot</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under applicable European and German law, the Management Board may not allot shares, grant rights to subscribe for or to convert any security into shares unless a shareholder resolution to that effect has been passed at the company&#8217;s shareholders&#8217; meeting granting the Management Board with such authority&#8212;subject to the approval of the Supervisory Board&#8212;in each case in accordance with the provisions of the German Stock Corporation Act.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under Delaware law, if the corporation&#8217;s certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">224</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liability of Directors and Officers</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, any provision, whether contained in the company&#8217;s articles of association or any contract or otherwise, that purports to exempt a Management or Supervisory Board member from any liability that would otherwise attach to such board member in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, members of both the Management Board and members of the Supervisory Board are liable to the company, and in certain cases to third parties or shareholders, for any damage caused to them due to a breach of such member&#8217;s duty of care. Apart from insolvency or special circumstances, only the company has the right to claim damages from members of either board. The company may waive claims for damages against a negligent Management or Supervisory Board member only after the expiry of three years.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160; intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;&#160;any transaction from which the director derives an improper personal benefit.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Voting Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the relevant European and German law, each share, except for statutory non-voting preferred shares (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">nicht stimmberechtigte Vorzugsaktien</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), entitles its holder to vote at the shareholders&#8217; meeting with, in the case of no-par value shares, each share conferring one vote. While German law does not provide for a minimum attendance quorum for shareholders&#8217; meetings, the company&#8217;s articles of association may so provide. In general, resolutions adopted at a shareholders&#8217; meeting may be passed by a simple majority of votes cast, unless a higher majority is required by law or under the company&#8217;s articles of association.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">225</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shareholder Vote on Certain Transactions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable European and German law, certain shareholders&#8217; resolutions of fundamental importance require the vote of at least three-quarters of the share capital present or represented in the voting at the time of adoption of the resolution. Resolutions of fundamental importance include, in particular, capital increases with exclusion of subscription rights, capital decreases, the creation of authorized or conditional share capital, the dissolution of a company, a merger into or with another company, split-offs and split-ups, the conclusion of inter-company agreements (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unternehmensvertr&#228;ge</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in particular domination agreements (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Beherrschungsvertr&#228;ge</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and profit and loss transfer agreements (</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ergebnisabf&#252;hrungsvertr&#228;ge</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;the approval of the board of directors; and</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">226</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Standard of Conduct for Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable European and German law, both Management and Supervisory Board members must conduct their affairs with &#8220;the care and diligence of a prudent business man&#8221; and act in the best interest of the company. The scope of the fiduciary duties of Management and Supervisory Board members is generally determined by European and German legislation and by the courts. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory and fiduciary duties of members of the Management Board to the company include, among others:</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;to act in accordance with the law, the company&#8217;s articles of association and the rules of procedure for the Management Board, if any;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;to report to the Supervisory Board on a regular basis as well as on certain important occasions;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;to exercise reasonable care, skill and diligence;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to maintain a proper accounting system;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;to not compete, directly or indirectly, with the company without permission by the supervisory board; and</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;to secure that no further transactions are made in case of insolvency. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory and fiduciary duties of members of the Supervisory Board to the company include, among others:</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160; to effectively supervise the Management Board&#8217;s handling of the company&#8217;s affairs; </span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;to evaluate and issue a resolution on certain transactions which can only be conducted by the Management Board after approval of the Supervisory Board;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160; to approve the company&#8217;s financial statements;</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;to appoint the Management Board members and to represent the company in transactions between the company and members of the Management Board; and</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15.1pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;to approve service contracts between individual members of the Management Board and the company.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well- informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">227</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:24.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:21.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stockholder Actions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its Management Board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can request that a representative pursues the claim on behalf of the company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the company is unable to fulfill its third- party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least one percent of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) need(s) to pass through special claim approval procedures.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and </span></div><div style="padding-left:24.5pt;text-align:justify;text-indent:-15pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;either (i) allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action, or (ii) or state the reasons for not making the effort. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">228</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_949"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Foreign Private Issuer Exemptions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;foreign private issuer,&#8221; as defined by the SEC, although we are permitted to follow certain corporate governance </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practices</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Federal Republic of Germany, instead of those otherwise required under the rules of the Nasdaq </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market LLC, or Nasdaq, for domestic issuers, we follow the Nasdaq corporate governance rules applicable to foreign private issuers. While we voluntarily follow most Nasdaq corporate governance rules, we intend to take advantage of the following limited exemptions:</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">exemption from filing quarterly reports on Form 10-Q and providing current reports on Form 8-K disclosing significant events within four days of their occurrence (however, we intend to furnish quarterly financial information under cover of Form 6-K);</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">exemption from compliance with Regulation FD, which generally requires that when a company intentionally discloses material non-public information, it do so through a public disclosure that is broadly available to all members of the public at the same time. However, we do furnish quarterly financial information and other information on a more frequent basis under cover of Form 6-K, and intend to continue doing so. Moreover, we comply with other securities laws, such as rule 10b-5 (rule targeting securities fraud), among others;</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">exemption from Section 16 rules regarding sales of ordinary shares by insiders, which will provide less data in this regard than the data provided to shareholders of U.S. companies that are subject to the Exchange Act; and</span></div><div style="margin-top:6pt;padding-left:45.1pt;text-align:justify;text-indent:-15.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:11.55pt">exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of the code of business conduct and ethics to directors and officers. Although we will require board approval of any such waiver, we may choose not to disclose the waiver in the manner set forth in the Nasdaq rules, as permitted by the foreign private issuer exemption.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nasdaq Rule 5615(a)(3) provides that, as a foreign private issuer, we may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that we nevertheless comply with Nasdaq&#8217;s Notification of Noncompliance requirement (Rule 5625) and the Voting Rights requirement (Rule 5640) and that we have an audit committee that satisfies Rule 5605(c)(3), </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisting</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although we are permitted to follow certain corporate governance rules that conform to German requirements in lieu of many of the Nasdaq corporate governance rules, we comply with the Nasdaq corporate governance rules applicable to foreign private issuers. We may utilize these exemptions for as long as we continue to qualify as a foreign </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issuer.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_931"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16H. Mine Safety Disclosure</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_137988709289220"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_137988709289698"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16J. Insider Trading Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_137988709289703"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 16K. Cybersecurity</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity approach strives to adequately protect our information, systems, assets, physical locations, and people. From a business perspective, this means protecting key information assets and complying with applicable international and national privacy laws, information security policies and contractual obligations. Our Information Security Policy, adopted in 2023, defines our information security management objectives and principles, and our Data Privacy Policy, effective since 2021, provides for a consistent level of company-wide data privacy and data protection. In addition, our Information Classification Policy, introduced internally during the year ended December 31, 2023, provides a system for classifying and protecting our physical and digital assets. These policies are applicable to BioNTech SE and its affiliates, including all Supervisory Board and Management Board members, as well as all other officers and employees, </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">229</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are part of our overall Information Security Management System (ISMS) that is currently being operationalized as part of the preparation for the ISO 27001 certification. Our processes for assessing, identifying, and managing material risks from cybersecurity threats are integrated into our overall enterprise risk management system, which was developed with input from internal and external experts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We collaborated with external experts through early 2023 to develop a Security Transformation Program. Our main cyber and information security objectives are to maintain information confidentiality, integrity, and availability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the year ended December 31, 2022, we have been using a data privacy system to assess the data privacy risks for each system in place. It also provides for proper data mapping, up-to-date recordkeeping on processing, data transfer impact assessments, and vendor data management. During the year ended December 31, 2023, we established a dedicated, standardized process to report data breaches. This process is intended to ensure that we are promptly notified of data breaches so that we can inform the people affected. The dialogue between our Data Privacy department and other functions also supports the early detection of data privacy risks. In addition, as part of the ISMS, employees are required to communicate any potential improvements or discrepancies as the system evolves.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also regularly streamline information security processes and measures in our business operations and work to ensure that newly introduced applications adhere to the &#8220;secure by design&#8221; principle. We also work to improve our cyber and information security management system on an ongoing basis to address evolving risks and regulatory requirements according to the relevant certification processes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve and preserve information security, we strive for the orderly planning, implementation, control, and optimization of all activities required for the protection of data privacy and the detection, response and recovery of data privacy risks. We rely on applicable international standards as guidance, including ISO/IEC 27001, which is internally recognized and serves as the framework for the Company&#8217;s ISMS. We aim to prepare our organization for relevant certifications in 2024 to aim for certification in 2025. We will initially seek certifications for our main manufacturing facility and an R&amp;D site in addition to the cybersecurity organization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take responsibility for the transparent communication and proper processing of personal data. This includes the storage, access, retention, and security of all personal data when engaging with patients, employees, customers, business partners, and vendors. We communicate our practices in a data privacy statement on our corporate website. We require the third parties with which we contract to adhere to contractual privacy and security provisions, and we request specific information from major vendors about their practices in protecting data privacy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When processing personal data, we are responsible for ensuring that we comply with applicable data protection laws. These include the European Union&#8217;s General Data Protection Regulation (GDPR), the German Commercial Code (HGB), the German Federal Data Protection Act (BDSG), the German IT Security Act 2.0 (IT-SiG 2.0), the German Federal Office for Information Security Act (BSIG), and other privacy and data security laws in the jurisdictions where we operate. In April 2023, we were designated as a part of Germany&#8217;s critical infrastructure (KRITIS) under the BSIG, which has resulted in heightened reporting and verification obligations. We are in the process of implementing a global data privacy framework that sets out the requirements and standards applicable to processing personal data. The framework is being designed to foster compliance with the applicable regulations and sets minimum standards for the Company. As part of our global strategy, privacy-related documents, such as informed consent forms for clinical trials, are being standardized company-wide. The forms facilitate the user-friendly implementation of the standards we have established and provide transparency on how and why we process personal data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Creating and maintaining mature levels of cyber and information security within BioNTech, in the supply chain, and in close collaboration with partners requires the commitment of all employees. In 2023, we began deploying Data Privacy Regional Leads, supported at a team level by Data Privacy Liaisons. At the end of 2023, we were continuing to recruit for these positions for further support. Members of relevant teams, such as IT and Clinical Operations, are selected to work closely with the Data Privacy team to ensure compliance with the relevant data privacy regulations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After implementing the key milestones of the Security Transformation Roadmap over the past two years, our focus in 2023 was on: </span></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">improving the operational excellence of cybersecurity services;</span></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">identifying further automatization options (e.g., introducing self-services);</span></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">optimizing the ISMS framework based on an internal audit, independent feedback and recommendations, and cooperation with external experts;</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">230</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">establishing mandatory cyber and information security training for all employees at least annually, including phishing simulations at least twice a year;</span></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">reducing the internal and external attack surface through regular vulnerability scanning, penetration testing, and maintaining IT supplier and software confidentiality; and</span></div><div style="margin-top:6pt;padding-left:56.69pt;text-indent:-21.26pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17.76pt">establishing a security reporting dashboard to provide executive stakeholders with transparency into relevant activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, there were no substantiated complaints concerning material data breaches, including leaks, thefts, or losses of personal data such as patient or customer data. Contracts and confidentiality agreements with clinical trial sites were compliant with relevant regulations. We do not believe that any cybersecurity threats in 2023, including as a result of any previous cybersecurity incidents, have materially a&#64256;ected or are reasonably likely to materially a&#64256;ect us, including our business strategy, results of operations, or financial condition. For a discussion of cybersecurity and data privacy-related risks and uncertainties, see Item 3.D, &#8220;Risk Factors,&#8221; of this Annual Report on Form 20-F.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take a centralized approach to managing cyber and information security to facilitate a consistency and compliance across entities and locations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Operating Officer (COO) and Management Board member, Sierk Poetting, is responsible for assessing and managing our material risks from cybersecurity threats. His ambit includes reviewing our information security capabilities, reporting data privacy issues to the Management Board, and supporting our Information Security Organization (ISO) in obtaining the resources it needs. The COO&#8217;s extensive experience in risk management, operations and corporate governance, with over 11 years of experience in the pharmaceutical industry in particular, are critical to the management of cyber and information security at the Company. The ISO oversees all roles and responsibilities associated with the ISMS. Representatives from the ISO provide monthly updates to the Management Board and annual updates to the Supervisory Board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COO is supported by the Chief Information Security Officer (CISO), who leads the ISO and is accountable for security strategy, operations, and policy development and implementation.  Our CISO, Raimond J&#228;hn, was the department lead of our IT security team starting in 2016, has led the cyber and information security transformation program towards a new operating model since 2021, and was formally designated as CISO by the COO in 2023. Our Head of Cyber and Information Security, Data Protection Officer, and Head of Global Security and Protection each bring in additional expertise. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overarching strategy was developed in 2021 by the COO and CISO in alignment with the Data Protection Officer and Head of Global Security and Protection, and is regularly updated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data privacy matters fall under the purview of our Chief Legal Officer (CLO) and Management Board member, James Ryan, who is supported by our Senior Director, Data Privacy. Dr.&#160;Ryan&#8217;s qualifications include close to twenty years of expertise in legal and intellectual property matters, both within the pharmaceutical industry as well as as an outside counsel with a focus on strategic life sciences transactions. Together with his deep familiarity with the Company&#8217;s history, operations, and processes, James Ryan is uniquely positioned to advise on data privacy matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:21.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on Sierk Poetting&#8217;s and James Ryan&#8217;s experience, see Item 6.A, &#8220;Directors and Senior Management.&#8221;</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_914"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_896"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 17. Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 18. </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_890"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 18. Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements are filed as part of this Annual Report beginning on page F-1. </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">231</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_884"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Item 19. Exhibits</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr style="height:7pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000177698524000012/exhibit41biontechsearticle.htm">Articles of Association of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-277105), filed with the SEC on February 15, 2024)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1201935/000101915519000234/biontechdep.htm">Form of Specimen American Depositary Receipt (included in Exhibit 2.3)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex42.htm">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1201935/000101915519000234/biontechdep.htm">Form of Deposit Agreement among the Registrant, the depositary and holders and beneficial owners of the American Depositary Shares (incorporated herein by reference to Exhibit&#160;1 to the Registration Statement on Form&#160;F-6 (File No.&#160;333-233898), filed with the SEC on September&#160;23, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit24descriptionofsecu.htm">Description of Securities of the Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex101.htm">Master Agreement for Research Services by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, Eufets GmbH, JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated January 1, 2015 (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex102.htm">Confirmation Letter by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH dated September 15, 2016 (incorporated herein by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex103.htm">Supplementary Agreement for [***] Developments to the Master Agreement for Research Services by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH (f/k/a Eufets GmbH), JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated November 28, 2017 (incorporated herein by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex104.htm">License Agreement by and among the Registrant, TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, Johannes Gutenberg-Universit&#228;t Mainz, Universit&#228;tsmedizin der Johannes Gutenberg-Universit&#228;t and Ganymed Pharmaceuticals AG, dated January 1, 2015 (incorporated herein by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex105.htm">Framework Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Diagnostics GmbH, BioNTech Protein Therapeutics GmbH, BioNTech Cell &amp; Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, JPT Peptide Technologies GmbH and TRON-Translationale Onkologie an der Universit&#228;tsmedizin der Johannes Gutenberg Universit&#228;t Mainz gemeinn&#252;tzige GmbH, dated August 29, 2019 (incorporated herein by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">232</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex106.htm">Amended Patent License Agreement by and among the Registrant, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College and Uniwersytet Warszawski, dated May 12, 2015 (incorporated herein by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312519241112/d635330dex1014.htm">Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, dated September 20, 2016 (incorporated herein by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000156459020014536/bntx-ex415_128.htm">First Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, dated June 1, 2018 (incorporated herein by reference to Exhibit 4.15 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 31, 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000156459020014536/bntx-ex416_126.htm">Second Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, dated December 6, 2019 (incorporated herein by reference to Exhibit 4.16 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 31, 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex417_789.htm">Joinder and Third Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Manufacturing GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, effective as of October 1, 2020 (incorporated herein by reference to Exhibit 4.16 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081) filed with the SEC on March 30, 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.11&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex418_411.htm">Fourth Amendment to the Collaboration Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH, BioNTech Manufacturing GmbH, Genentech, Inc. and F. Hoffman-La Roche Ltd, effective as of October 26, 2020 (incorporated herein by reference to Exhibit 4.17 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081) filed with the SEC on March 30, 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.12&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1015.htm">Patent Sublicense Agreement by and between CellScript, LLC and BioNTech RNA Pharmaceuticals GmbH, dated July 14, 2017 (incorporated herein by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.13&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex420_412.htm">Second Amendment to Patent Sublicense Agreement by and between CellScript, LLC and BioNTech RNA Pharmaceuticals GmbH, effective as of August 1, 2020 (incorporated herein by reference to Exhibit 4.19 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081) filed with the SEC on March 30, 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.14&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1016.htm">Patent Sublicense Agreement by and between mRNA RiboTherapeutics, Inc. and BioNTech RNA Pharmaceuticals GmbH, dated July 14, 2017 (incorporated herein by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.15&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000156459021016723/bntx-ex422_413.htm">Second Amendment to Patent Sublicense Agreement by and between mRNA RiboTherapeutics, Inc. and BioNTech RNA Pharmaceuticals GmbH, effective as of August 1, 2020 (incorporated herein by reference to Exhibit 4.21 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 30, 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1018.htm">Research Collaboration and License Agreement by and among the Registrant, BioNTech RNA Pharmaceuticals GmbH and Pfizer, Inc., dated July 20, 2018 (incorporated herein by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1019.htm">Collaboration and License Agreement by and between the Trustees of the University of Pennsylvania and BioNTech RNA Pharmaceuticals GmbH, dated October 9, 2018 (incorporated herein by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">233</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.18&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1025.htm">Lease Agreement by and among the Registrant and Wolfram Richter, dated August 17, 2011 (incorporated herein by reference to Exhibit 10.25 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.19&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1026.htm">Amendment No. 1 to Lease Agreement by and among the Registrant and Wolfram Richter, dated February 17, 2012 (incorporated herein by reference to Exhibit 10.26 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.20&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1027.htm">Amendment No. 2 to Lease Agreement by and among the Registrant and Wolfram Richter, dated February 1, 2013 (incorporated herein by reference to Exhibit 10.27 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.21&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1028.htm">Amendment No. 3 to Lease Agreement by and among the Registrant and Wolfram Richter, dated March 6, 2013 (incorporated herein by reference to Exhibit 10.28 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.22&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1029.htm">Amendment No. 4 to Lease Agreement by and among the Registrant and Wolfram Richter, dated December 10, 2013 (incorporated herein by reference to Exhibit 10.29 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1030.htm">Amendment No. 5 to Lease Agreement by and among the Registrant and Wolfram Richter, dated March 29, 2016 (incorporated herein by reference to Exhibit 10.30 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.24&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1031.htm">Amendment No. 6 to Lease Agreement by and among the Registrant and Wolfram Richter, dated October 6, 2017 (incorporated herein by reference to Exhibit 10.31 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.25&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1032.htm">Lease Agreement by and among the Registrant and Wista-Management GmbH, dated April 12, 2005 (incorporated herein by reference to Exhibit 10.32 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1033.htm">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated December 27, 2018 (incorporated herein by reference to Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233688), filed with the SEC on September 9, 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.27&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459020014536/bntx-ex435_184.htm">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated October 24, 2019 (incorporated herein by reference to Exhibit 4.35 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081) filed with the SEC on March 31, 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.28&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000119312520195911/d939702dex1038.htm">Amendment to Lease Agreement by and among the Registrant and Wista-Management GmbH, dated June 1, 2020 (incorporated herein by reference to Exhibit 10.38 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-233970), filed with the SEC on July 21, 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.29&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1776985/000156459021016723/bntx-ex444_416.htm">Amended and Restated Collaboration Agreement by and between the Registrant and Pfizer Inc., dated March 17, 2020 (incorporated herein by reference to Exhibit 4.44 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 30, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex451_414.htm">Advance Purchase Agreement by and among BioNTech Manufacturing GmbH, Pfizer Inc., and the European Commission, dated November 20, 2020 (incorporated herein by reference to Exhibit 4.51 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 30, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.31&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex452_415.htm">Purchase Agreement by and among BioNTech Manufacturing GmbH, Pfizer Inc., and the European Commission, dated February 17, 2021 (incorporated herein by reference to Exhibit 4.52 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 30, 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.32&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001776985/000156459021016723/bntx-ex453_417.htm">Lease for Buildings H028 and H30 by and between the Pharmaserv GmbH and Novartis Manufacturing GmbH (incorporated herein by reference to Exhibit 4.53 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 30, 2021)</a></span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">234</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.33&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex434.htm">Lease Agreement by and between the Registrant, as successor-in-interest to Kite Pharma, Inc., and Tech Park 270 III, LLC, dated as of December 1, 2017 (incorporated herein by reference to Exhibit 4.34 to the Registrant's Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.34&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex435.htm">Amendment No. 3 to Lease Agreement by and between the Registrant, as successor-in-interest to Kite Pharma, Inc., and Tech Park 270 III, LLC, dated as of July 24, 2018 (incorporated herein by reference to Exhibit 4.35 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.35&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex436.htm">Amendment No. 4 to Lease Agreement by and between the Registrant, as successor-in-interest to Kite Pharma, Inc., and Tech Park 270 III, LLC, dated as of May 23, 2019 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex436.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex436.htm">incorporated herein by reference to Exhibit 4.36 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.36&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex437.htm">License Agreement by and between the Registrant and Acuitas Therapeutics, Inc., dated as of April 7, 2020 (incorporated herein by reference to Exhibit 4.37 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.37&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex438.htm">Advanced Purchase Agreement by and among the Registrant, Pfizer Inc. and European Commission, dated as of May 20, 2021 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex438.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex438.htm">incorporated herein by reference to Exhibit 4.38 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify;text-indent:14.2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.38&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex439.htm">Transfer of Source Code for MyMUT Software Versions by and between the Registrant and TRON gGmbH, dated as of May 5, 2021 (incorporated herein by reference to Exhibit 4.39 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify;text-indent:14.2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.39&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex440.htm">Amendment No. 6 to Lease Agreement by and between the Registrant and Tech Park 270, LLC, dated as of August 2, 2021 (incorporated herein by reference to Exhibit 4.40 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify;text-indent:14.2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.40&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex441.htm">Side Letter No. 5 to License and Collaboration Agreement by and between Registrant and Genmab A/S, dated August 12, 2021 (incorporated herein by reference to Exhibit 4.41 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.41&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex442.htm">Amendment No. 1 to Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania, dated as of September 8, 2021 (incorporated herein by reference to Exhibit 4.42 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.42&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex443.htm">Transfer of Source Code MyMUT Software Versions by and between the Registrant and TRON gGmbH, dated as of September 10, 2021 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex443.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex443.htm">incorporated herein by reference to Exhibit 4.43 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.43&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex444.htm">Amendment No. 2 to Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania, dated as of December 22, 2021 (incorporated herein by reference to Exhibit 4.44 to the Registrant&#8217;s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.44&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex445.htm">Lease for Areas and Rooms in Building 536 and 537 by and between the Pharmaserv GmbH and Novartis Manufacturing GmbH, dated as of January 19, 2022 (incorporated herein by reference to Exhibit 4.45 to the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex445.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex445.htm">s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.45&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex446.htm">Amended and Restated License and Collaboration Agreement, by and between BioNTech SE and Genmab A/S, entered into July 18, 2022, effective as of May 19, 2015 (incorporated herein by reference to Exhibit 4.46 to the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex446.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex446.htm">s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.46&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex447.htm">Real Estate Purchase Contract with Conveyance Together with Inventory Purchase Contract by and between Santo Service GmbH, BioNTech Real Estate An der Goldgrube 12 GmbH &amp; Co. KG and BioNTech Manufacturing GmbH, dated as of December 12, 2022 (incorporated herein by reference to Exhibit 4.47 to the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex447.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1776985/000119312523079791/d377167dex447.htm">s Annual Report on Form 20-F (File No. 001-39081), filed with the SEC on March 27, 2023)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.47*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit447instadeepamendme.htm">Deed of Amendment of Agreement related to the Sale and Purchase of Certain Shares of the Issued Share Capital of InstaDeep Ltd by and among the Registrant, InstaDeep Ltd and the Sellers set forth therein, dated as of July 31, 2023</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:justify;text-indent:14.2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.48*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit448oncoc4agreementr.htm">License and Collaboration Agreement, by and between the Registrant and OncoC4, Inc., dated as of March 17, 2023</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.49*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit449oncoc4amendmentr.htm">Amendment No. 1 to the License and Collaboration Agreement, by and between the Registrant and OncoC4, Inc., dated as of February 14, 2024</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.50*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit450dualityher2agree.htm">License and Collaboration Agreement (HER2), by and between the Registrant and Duality Biologics (Suzhou) Co. Ltd., dated as of March 16, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.51*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit451dualityb7h3agree.htm">License and Collaboration Agreement (B7H3), by and between the Registrant and Duality Biologics (Suzhou) Co. Ltd., dated as of March 31, 2023</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.52*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit452dualitytrop2agre.htm">License and Collaboration Agreement (TROP2), by and between the Registrant and Duality Biologics (Suzhou) Co. Ltd., dated as of August 4, 2023</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.53*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">Collaboration</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">, Lice</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">nse and Option</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm"> Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">by and between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm"> the Registrant and Bio</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">heus Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">, dated as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm"> October 26, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit453biotheusagreemen.htm">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.54*&#8224;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit454autoluslicensean.htm">License and Option Agreement, by and among Autolus Limited, Autolus Holdings (UK) Limited and the Registrant, dated as of February 6, 2024</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit8subsidiariesfy2023.htm">List of Subsidiaries of the Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit121certification-us.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit122certification-jh.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit131certification-us.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit132certification-jh.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.1*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit151eyconsent20-f.htm">Consent of EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit97biontechcompensat.htm">Compensation </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit97biontechcompensat.htm">Clawback Policy</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">236</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">237</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_19"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on Form 20-F on its behalf. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.238%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.754%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BioNTech SE</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: March 20, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160; Prof. Ugur Sahin, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Prof. Ugur Sahin, M.D.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:59.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">238</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_877"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:91.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871">Reports of Independent Registered Public Accounting </a><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871">Firm (PCAOB</a><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871"> I</a><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871">D: </a>0<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-45">1251</ix:nonNumeric><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871">)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_871">2</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_772">Consolidated Statements of </a><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_772">Profit or Loss </a><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_772">for the Years ended </a>December&#160;31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_772">7</a></span></div></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_751">Consolidated Statements of Financial Position as of </a>December&#160;31, 2023 and 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_778">9</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_758">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years ended </a>December&#160;31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_758">10</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_31">Consolidated Statements of Cash Flows for the Years ended </a>December&#160;31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_31">11</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_751">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_751">12</a></span></div></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_871"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Supervisory Boards of BioNTech SE</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of BioNTech SE (the Company) as of December 31, 2023 and 2022, the related consolidated statements of profit or loss, comprehensive income, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission &#8220;(2013 framework),&#8221; and our report dated March 20, 2024, expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:14.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Valuation of Intangible assets acquired within Business Combination of InstaDeep Ltd.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in more detail in Note 5 to the consolidated financial statements, in July 2023 the Company completed its acquisition of InstaDeep Ltd. for a total purchase price of &#8364;517.5 million. As a result of the acquisition, the Company acquired Intangible assets including the DeepChain technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the valuation of the acquired intangible assets was complex due to the significant estimation uncertainty in determining the fair value of the intangible assets. The fair value determination is based on a discounted cash flow model using certain assumptions containing high subjectivity, such as future cost savings that are based on number of candidate discoveries and probability of technical success to which royalty rates are applied. These significant assumptions are forward-looking and could be affected by future economic and market conditions. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company's process for evaluating the intangible assets acquired within the Business Combination. This included testing controls over management&#8217;s review of assumptions and inputs used to calculate the valuation of the acquired intangible assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, evaluating management&#8217;s approach to determine expected number of candidate discoveries by comparing it to historical data. We tested the probability of technical success by comparing the rates used to past results of similar products in development within the industry. For royalty rates applied we benchmarked those against comparable license agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our procedures included sensitivity analysis of the significant assumptions to evaluate the change in the fair value of the acquired intangible assets resulting from changing the assumptions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with the assistance of our valuation specialists, we assessed the appropriateness of the valuation method used and the discount rate utilized by comparing to underlying source information. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the adequacy of the Company&#8217;s disclosures in relation to these matters.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition from collaboration partner&#8217;s COVID-19 vaccine sales </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in more detail in Note 6 to the consolidated financial statements, the Company recognizes revenues associated with COVID-19 vaccine sales in a total amount of &#8364;3.8 billion. This includes &#8364;3.0 billion from the Company&#8217;s share of its collaboration partner&#180;s gross profit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is contractually eligible to receive a share of the collaboration partner&#8217;s gross profit from vaccine sales in the collaboration partner&#8217;s territories. Such gross profit share is recognized as collaboration revenue. In order to determine the gross profit share, the Company uses certain information from the collaboration partner, including vaccine sales outside of the United States and associated production costs, some of which is based on preliminary data shared by the partner and might differ once final data is available.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing revenue recognition specific to the gross profit share was complex due to the significant estimation uncertainty in inputs to the calculation. Specifically, the collaboration partner&#8217;s vaccine sales outside of the United States and associated manufacturing and shipping costs are partially estimated for the last month in the period based on historical information and could change based on the actual vaccine sales and costs incurred. </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:14.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company&#8217;s controls related to revenue recognition from the collaboration partner&#8217;s vaccine sales outside of the United States. For example, we tested controls over management&#8217;s review of the significant assumptions used to determine the gross profit share the Company is eligible to receive. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, reading the contract with the collaboration partner to understand key terms and obtaining an understanding of management&#8217;s methodology and assumptions used to calculate the gross profit share. We performed a hindsight analysis to assess management&#8217;s accuracy in estimating the collaboration partner&#8217;s vaccine sales outside of the United States and manufacturing and shipping costs. We obtained a confirmation directly from the collaboration partner regarding vaccine sales and cost inputs used to estimate the profit share. We performed a sensitivity analysis of the significant assumptions to evaluate the change in the gross profit share resulting from changing the assumptions, as well as an analysis of previous estimation compared to the actual payments obtained to date. We tested the completeness and accuracy of the Company&#8217;s gross profit share calculation. We evaluated the Company&#8217;s related disclosures in the consolidated financial statements.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Claims and legal contingencies</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in more detail in Note 18 to the consolidated financial statements, the Company is involved in various claims and litigation specifically related to patent infringements and product liability matters. The Company, assisted by their internal and external legal counsel, assesses the need to record a provision or disclose a contingency on a case-by-case basis considering the underlying facts of each matter. The Company discloses contingent liabilities in circumstances where a cash outflow is probable, but management is unable to make a reasonable estimate of the expected financial effect that will result from ultimate resolution of the proceeding, or a cash outflow is reasonably possible. A provision is recorded when a cash outflow is deemed probable and reasonably estimable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management's determination of whether a loss of such patent or product liability matters is probable and reasonably estimable, reasonably possible or remote, and the related disclosures, is highly subjective and requires significant judgement.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company&#8217;s controls in assessing the completeness, valuation, presentation and disclosures with respect to such claims and legal proceedings. For example, this included testing controls related to the Company&#8217;s process for identification, recognition, measurement and disclosure of claims and legal contingencies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the completeness of the claims and legal proceedings subject to evaluation by the Company and assessed their determination of the probability of their outcomes through review of presentations for board meetings and inspection of responses to inquiry letters received from both internal and external legal counsels. Further, we held discussions with internal and external legal counsels to confirm our understanding of the allegations, reviewed legal expenses incurred, evaluated resolutions of claims already concluded against management&#8217;s assessment and obtained written representations from executives of the Company confirming the completeness and accuracy of the information provided. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated the adequacy of the Company&#8217;s disclosures in relation to these matters.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-46">EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-47">Cologne, Germany</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 20, 2024</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_786"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Supervisory Board of BioNTech SE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited BioNTech SE&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission &#8220;(2013 framework),&#8221; (the COSO criteria).  In our opinion, BioNTech SE (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As indicated in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting, management&#8217;s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of InstaDeep Ltd., which is included in the 2023 consolidated financial statements of the Company and constituted 2.2% of total assets, respectively, as of December 31, 2023 and 0.1% of revenues and constituted &#8364;31.7 million of net loss included within the &#8364;930.3 million total profit for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of InstaDeep Ltd.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of the Company as of December 31, 2023 and 2022, the related consolidated statements of profit or loss, comprehensive income, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated March 20, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-48">EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cologne, Germany</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;20, 2024</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_772"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">_Consolidated Statements of Profit or Loss</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commercial revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-49">3,815.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-50">17,194.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-51">18,874.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research &amp; development revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-52">3.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-53">116.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-54">102.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total revenues</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-55">3,819.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-56">17,310.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-57">18,976.7</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CostOfSales" scale="6" id="f-58">599.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-59">2,995.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-60">2,911.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-61">1,783.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-62">1,537.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="f-63">949.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales and marketing expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:SalesAndMarketingExpense" scale="6" id="f-64">62.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:SalesAndMarketingExpense" scale="6" id="f-65">59.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:SalesAndMarketingExpense" scale="6" id="f-66">50.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="f-67">495.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="f-68">481.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" id="f-69">276.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-70">293.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-71">410.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-72">103.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-73">105.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-74">815.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-75">598.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operating income</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="f-76">690.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-77">12,642.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-78">15,283.8</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-79">519.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-80">330.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-81">67.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finance expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-82">23.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-83">18.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-84">305.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit before tax</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-85">1,186.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-86">12,954.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-87">15,046.4</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-88">255.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-89">3,519.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-90">4,753.9</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit for the period</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLoss" scale="6" id="f-91">930.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-92">9,434.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-93">10,292.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Earnings per share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic earnings for the period per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-94">3.87</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-12" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-95">38.78</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-13" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-96">42.18</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted earnings for the period per share</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-97">3.83</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-12" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-98">37.77</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-13" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-99">39.63</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)<ix:footnote id="fn-1" continuedAt="fn-1-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">&#160;&#160;&#160;&#160;</ix:footnote></span><ix:continuation id="fn-1-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).</span></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_766"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Consolidated Statements of Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit for the period</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLoss" scale="6" id="f-100">930.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-101">9,434.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-102">10,292.5</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exchange differences on translation of foreign operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-103">19.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-104">11.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="f-105">8.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-106">19.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-107">11.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-108">8.4</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net gain on equity instruments designated at fair value through other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-109">3.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-110">10.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" format="ixt:fixed-zero" scale="6" id="f-111">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Remeasurement gain on defined benefit plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="6" id="f-112">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="6" id="f-113">0.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="6" id="f-114">0.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-115">4.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-116">11.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="6" id="f-117">0.3</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other comprehensive income / (loss) for the period, net of tax </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-118">15.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-119">22.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-120">8.7</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Comprehensive income for the period, net of tax</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-121">914.5</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-122">9,456.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-123">10,301.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_778"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Financial Position</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">December 31, </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#70AD47;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Non-current assets </span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">10</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-124">362.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-125">61.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other intangible assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">10</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-126">804.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-127">158.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Property, plant and equipment </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">11</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-128">757.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-129">609.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">20</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-130">214.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-131">211.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-132">1,176.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="6" id="f-133">80.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">14</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-134">83.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-135">6.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Deferred tax assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:DeferredTaxAssets" scale="6" id="f-136">81.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:DeferredTaxAssets" scale="6" id="f-137">229.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total non-current assets </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-138">3,479.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-139">1,357.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#70AD47;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Current assets</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">13</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-140">357.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-141">439.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="6" id="f-142">2,155.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="6" id="f-143">7,145.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Contract assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractAssets" scale="6" id="f-144">4.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractAssets" format="ixt:fixed-zero" scale="6" id="f-145">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other financial assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentFinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-146">4,885.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentFinancialAssets" scale="6" id="f-147">189.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other non-financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">14</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialAssets" scale="6" id="f-148">280.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialAssets" scale="6" id="f-149">271.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Income tax assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-150">179.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentTaxAssetsCurrent" scale="6" id="f-151">0.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-152">11,663.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-153">13,875.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total current assets </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-154">19,527.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-155">21,922.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total assets</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-156">23,006.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="6" id="f-157">23,279.1</ix:nonFraction></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Equity and liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#70AD47;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Equity </span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Share capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-158">248.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:IssuedCapital" scale="6" id="f-159">248.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Capital reserve</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CapitalReserve" format="ixt:num-dot-decimal" scale="6" id="f-160">1,229.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CapitalReserve" format="ixt:num-dot-decimal" scale="6" id="f-161">1,828.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Treasury shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:TreasuryShares" scale="6" id="f-162">10.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:TreasuryShares" scale="6" id="f-163">5.3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="6" id="f-164">19,763.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="6" id="f-165">18,833.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other reserves </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">16</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" sign="-" name="ifrs-full:OtherReserves" scale="6" id="f-166">984.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" sign="-" name="ifrs-full:OtherReserves" scale="6" id="f-167">848.9</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total equity </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-168">20,245.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-169">20,055.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#70AD47;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Non-current liabilities </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Lease liabilities, loans and borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings" scale="6" id="f-170">191.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings" scale="6" id="f-171">176.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other financial liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentFinancialLiabilities" scale="6" id="f-172">38.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentFinancialLiabilities" scale="6" id="f-173">6.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-174">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentTaxLiabilitiesNoncurrent" scale="6" id="f-175">10.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">17</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-176">8.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-177">8.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" scale="6" id="f-178">398.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" scale="6" id="f-179">48.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other non-financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">19</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" scale="6" id="f-180">13.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" scale="6" id="f-181">17.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:DeferredTaxLiabilities" scale="6" id="f-182">39.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:DeferredTaxLiabilities" scale="6" id="f-183">6.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total non-current liabilities </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentLiabilities" scale="6" id="f-184">689.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentLiabilities" scale="6" id="f-185">272.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#70AD47;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Current liabilities </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Lease liabilities, loans and borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:CurrentLeaseLiabilitiesLoansAndBorrowings" scale="6" id="f-186">28.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:CurrentLeaseLiabilitiesLoansAndBorrowings" scale="6" id="f-187">36.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:TradeAndOtherCurrentPayables" scale="6" id="f-188">354.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:TradeAndOtherCurrentPayables" scale="6" id="f-189">204.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other financial liabilities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="6" id="f-190">415.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentFinancialLiabilities" scale="6" id="f-191">785.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Refund liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentRefundsProvision" format="ixt:fixed-zero" scale="6" id="f-192">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentRefundsProvision" scale="6" id="f-193">24.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Income tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-194">525.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="f-195">595.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">17</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentProvisions" scale="6" id="f-196">269.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentProvisions" scale="6" id="f-197">367.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-198">353.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentContractLiabilities" scale="6" id="f-199">77.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other non-financial liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">19</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="6" id="f-200">125.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="6" id="f-201">860.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total current liabilities</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-202">2,070.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-203">2,950.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total liabilities </span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-204">2,760.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-205">3,223.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Total equity and liabilities </span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-206">23,006.3</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-207">23,279.1</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_758"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.955%"><tr><td style="width:1.0%"/><td style="width:32.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.686%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.766%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.435%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Equity attributable to equity holders of the parent</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Share capital</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital reserve</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Treasury shares</span></div></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Retained earnings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other reserves </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total equity </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">As of January 1, 2021</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-16" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-208">246.3</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-17" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-209">1,514.5</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-18" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-210">4.8</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-19" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-211">409.6</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-20" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-212">25.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-213">1,371.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Profit for the period</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-214">10,292.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-215">10,292.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-216">8.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-217">8.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total comprehensive income</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-22" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-218">10,292.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-219">8.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-220">10,301.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuance of treasury shares</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-5" name="bntx:IssuanceOfShareCapital" scale="6" id="f-221">162.6</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-25" decimals="-5" name="bntx:IssuanceOfShareCapital" scale="6" id="f-222">1.0</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:IssuanceOfShareCapital" scale="6" id="f-223">163.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Transaction costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-24" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="f-224">2.7</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="f-225">2.7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">16</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-23" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-226">59.8</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-227">59.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-26" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-228">246.3</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-27" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-229">1,674.4</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-28" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-230">3.8</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-29" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-231">9,882.9</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-30" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-232">93.9</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-233">11,893.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Profit for the period</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-234">9,434.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-235">9,434.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-236">22.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-237">22.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total comprehensive income</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-238">9,434.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-239">22.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="6" id="f-240">9,456.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Issuance of share capital</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-5" name="ifrs-full:IssueOfEquity" scale="6" id="f-241">0.5</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-5" name="ifrs-full:IssueOfEquity" scale="6" id="f-242">67.1</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IssueOfEquity" scale="6" id="f-243">67.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Redemption of convertible note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-34" decimals="-5" name="bntx:RedemptionOfConvertibleNote" scale="6" id="f-244">1.8</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-5" name="bntx:RedemptionOfConvertibleNote" scale="6" id="f-245">233.2</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:RedemptionOfConvertibleNote" scale="6" id="f-246">235.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Share repurchase program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-247">979.5</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-248">6.9</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-249">986.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Transaction costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="f-250">0.1</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ShareIssueRelatedCost" scale="6" id="f-251">0.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dividends</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-32" decimals="-5" name="ifrs-full:DividendsPaid" scale="6" id="f-252">484.3</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:DividendsPaid" scale="6" id="f-253">484.3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Share-based payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">16</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-35" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-254">833.1</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-36" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-255">5.4</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="6" id="f-256">1,519.8</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-257">681.3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-33" decimals="-5" sign="-" name="bntx:CurrentAndDeferredTaxExpenseIncome" scale="6" id="f-258">554.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="bntx:CurrentAndDeferredTaxExpenseIncome" scale="6" id="f-259">554.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-37" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-260">248.6</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-38" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-261">1,828.2</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-39" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-262">5.3</ix:nonFraction>)</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-40" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-263">18,833.0</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-41" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-264">848.9</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-265">20,055.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Profit for the period</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-5" name="ifrs-full:ProfitLoss" scale="6" id="f-266">930.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLoss" scale="6" id="f-267">930.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-5" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-268">15.8</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="f-269">15.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Total comprehensive profit / (loss)</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-270">930.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-5" sign="-" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-271">15.8</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ComprehensiveIncome" scale="6" id="f-272">914.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Share repurchase program</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">15</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-273">731.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-274">6.9</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue" scale="6" id="f-275">738.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Share-based payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">16</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-276">30.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-277">0.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-278">15.1</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="f-279">15.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Current and deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-43" decimals="-5" name="bntx:CurrentAndDeferredTaxExpenseIncome" scale="6" id="f-280">104.8</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentAndDeferredTaxExpenseIncome" scale="6" id="f-281">104.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Treasury shares used for acquisition of business combination</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-44" decimals="-5" name="bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination" scale="6" id="f-282">102.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-45" decimals="-5" name="bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination" scale="6" id="f-283">1.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination" scale="6" id="f-284">103.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-46" decimals="-5" name="ifrs-full:Equity" scale="6" id="f-285">248.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-47" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-286">1,229.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-48" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-287">10.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-49" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-288">19,763.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-50" decimals="-5" sign="-" name="ifrs-full:Equity" scale="6" id="f-289">984.6</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="6" id="f-290">20,245.9</ix:nonFraction></span></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_31"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Operating activities</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Profit for the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLoss" scale="6" id="f-291">930.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-292">9,434.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-293">10,292.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-294">255.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-295">3,519.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-296">4,753.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Profit before tax</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-297">1,186.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-298">12,954.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-299">15,046.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Adjustments to reconcile profit before tax to net cash flows:</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="6" id="f-300">183.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="6" id="f-301">123.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="6" id="f-302">75.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Share-based payment expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-303">51.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-304">108.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="6" id="f-305">93.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Net foreign exchange differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="6" id="f-306">298.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="6" id="f-307">625.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="6" id="f-308">387.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Loss on disposal of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" scale="6" id="f-309">3.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" scale="6" id="f-310">0.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" scale="6" id="f-311">4.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Finance income excluding foreign exchange differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForFinanceIncome" scale="6" id="f-312">519.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForFinanceIncome" scale="6" id="f-313">265.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:AdjustmentsForFinanceIncome" scale="6" id="f-314">1.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Finance expense excluding foreign exchange differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForFinanceCosts" scale="6" id="f-315">7.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForFinanceCosts" scale="6" id="f-316">18.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:AdjustmentsForFinanceCosts" scale="6" id="f-317">305.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Movements in government grants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AdjustmentsForMovementsInGovernmentGrants" scale="6" id="f-318">2.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AdjustmentsForMovementsInGovernmentGrants" scale="6" id="f-319">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:AdjustmentsForMovementsInGovernmentGrants" scale="6" id="f-320">89.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Other non-cash income / (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherAdjustmentsForNoncashItems" format="ixt:fixed-zero" scale="6" id="f-321">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherAdjustmentsForNoncashItems" format="ixt:fixed-zero" scale="6" id="f-322">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="6" id="f-323">2.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Net (gain) / loss on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="6" id="f-324">175.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="6" id="f-325">241.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="6" id="f-326">57.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Working capital adjustments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Decrease / (increase) in trade and other receivables, contract assets and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="f-327">5,374.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="f-328">4,369.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="f-329">11,808.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Decrease / (increase) in inventories</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-330">81.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-331">62.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="6" id="f-332">438.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" scale="6" id="f-333">118.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" scale="6" id="f-334">85.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" format="ixt:num-dot-decimal" scale="6" id="f-335">1,516.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Interest received and realized gains from cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-336">258.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-337">29.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="f-338">1.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Interest paid and realized losses from cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-339">5.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-340">21.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="f-341">12.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Income tax paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="6" id="f-342">482.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-343">4,222.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-344">3,457.9</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Share-based payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" scale="6" id="f-345">766.2</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" scale="6" id="f-346">51.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" scale="6" id="f-347">13.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Net cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-348">5,371.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-349">13,577.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="f-350">889.7</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Purchase of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-351">249.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-352">329.2</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-353">127.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Proceeds from sale of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-354">0.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-355">0.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="f-356">3.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Purchase of intangible assets and right-of-use assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" scale="6" id="f-357">455.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" scale="6" id="f-358">34.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" scale="6" id="f-359">26.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-360">336.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="6" id="f-361">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" scale="6" id="f-362">20.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Investment in other financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-363">7,128.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" scale="6" id="f-364">47.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" scale="6" id="f-365">19.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Proceeds from maturity of other financial assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-366">1,216.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" scale="6" id="f-367">375.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" scale="6" id="f-368">375.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Net cash flows used in investing activities</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-369">6,954.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="f-370">35.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="f-371">566.1</ix:nonFraction>)</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Proceeds from issuance of share capital and treasury shares, net of costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="6" id="f-372">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-373">110.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="f-374">160.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Proceeds from loans and borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-375">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-376">0.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-377">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Repayment of loans and borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-378">0.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-379">18.8</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="f-380">52.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Payments related to lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-381">40.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-382">41.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="f-383">14.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Share repurchase program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities" scale="6" id="f-384">738.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities" scale="6" id="f-385">986.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-386">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Dividends</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-387">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" scale="6" id="f-388">484.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-389">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Net cash flows from / (used in) financing activities</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-390">778.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-391">1,419.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="6" id="f-392">94.2</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Net increase / (decrease) in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="6" id="f-393">2,361.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="6" id="f-394">12,122.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="6" id="f-395">417.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Change in cash and cash equivalents resulting from exchange rate differences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-396">14.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-397">60.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="f-398">64.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Change in cash and cash equivalents resulting from other valuation effects</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents" scale="6" id="f-399">164.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents" scale="6" id="f-400">0.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="f-401">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%">Cash and cash equivalents at the beginning of the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-402">13,875.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-403">1,692.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-21" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-404">1,210.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%">Cash and cash equivalents as of December 31</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-405">11,663.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-406">13,875.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.6pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-407">1,692.7</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements.</span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_751"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">Notes to the Consolidated Financial Statements</span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_745"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">1&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfCorporateInformationExplanatoryTextBlock" id="f-408" continuedAt="f-408-1" escape="true">Corporate Information</ix:nonNumeric></span></div><ix:continuation id="f-408-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&#8217;s ordinary shares have been publicly traded on the Nasdaq Global Select Market since October&#160;10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE is registered in the commercial register B of the Mainz Local Court under the number HRB&#160;48720. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements, which were prepared in accordance with International Financial Reporting Standards (IFRS), present the financial position and the results of operations of BioNTech SE and its subsidiaries, hereinafter also referred to as &#8220;BioNTech,&#8221; the &#8220;Group,&#8221; &#8220;we&#8221; or &#8220;us.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Supervisory Board on March 19, 2024.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_734"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">2&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-409" continuedAt="f-409-1" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_728"></div><ix:continuation id="f-409-1" continuedAt="f-409-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-410" continuedAt="f-410-1" escape="true">Basis of Preparation</ix:nonNumeric></span></div><ix:continuation id="f-410-1" continuedAt="f-410-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-410-2">We prepare and publish our consolidated financial statements in Euros and round numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="f-411" continuedAt="f-411-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-411-1">Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment.</ix:continuation> </span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_722"></div><ix:continuation id="f-409-2" continuedAt="f-409-3"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.2&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" id="f-412" continuedAt="f-412-1" escape="true">Basis of Consolidation</ix:nonNumeric></span></div><ix:continuation id="f-412-1" continuedAt="f-412-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group controls an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if, and only if, the Group has</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">power over the investee (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, existing rights that give it the current ability to direct the relevant activities of the investee); </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expos</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ure, or rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to use its power over the investee to affect its returns. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, there is a presumption that a majority of voting rights results in control. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether an investee is controlled is re-assessed if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when control is obtained over the subsidiary and ceases when control over the subsidiary is lost. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-412-2"><ix:continuation id="f-409-3" continuedAt="f-409-4"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If control over a subsidiary is lost, the related assets (including goodwill), liabilities, non-controlling interests and other components of equity are derecognized, while any resultant gain or loss is recognized in the consolidated statements of profit or loss. Any investment retained is recognized at fair value.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_699"></div><ix:continuation id="f-409-4" continuedAt="f-409-5"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3&#160;&#160;&#160;&#160;Summary of Material Accounting Policies</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_656"></div><ix:continuation id="f-409-5" continuedAt="f-409-6"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-413" continuedAt="f-413-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currencies</span></ix:nonNumeric></div><ix:continuation id="f-413-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are presented in Euros, which is also our functional currency. For each entity, the Group determines the functional currency, and items included in the consolidated financial statements of such entities are measured using that functional currency. We use the direct method of consolidation and, on disposal of a foreign operation, the gain or loss that is reclassified to the consolidated statements of profit or loss reflects the amount that arises from using this method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions and Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation effects from the translation of operating activities include foreign exchange differences arising on operating items such as trade receivables and trade payables and are either shown as other operating income or expenses on a cumulative basis. Foreign currency translation effects presented within finance income and expenses include foreign exchange differences arising on financing items such as loans and borrowings as well as foreign exchange differences arising on cash and cash equivalents and are either shown as finance income or expenses on a cumulative basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation on Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and the transactions recorded in their consolidated statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_687"></div><ix:continuation id="f-409-6" continuedAt="f-409-7"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="bntx:DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" id="f-414" continuedAt="f-414-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current versus Non-Current Classifications</span></ix:nonNumeric></div><ix:continuation id="f-414-1" continuedAt="f-414-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities in the consolidated statements of financial position are presented based on current or non-current classification. </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-414-2"><ix:continuation id="f-409-7" continuedAt="f-409-8"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An asset is current when it is either: (i)&#160;expected to be realized or intended to be sold or consumed in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;expected to be realized within twelve months after the reporting period, or (iv)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least twelve&#160;months after the reporting period. All other assets are classified as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liability is current when it is either: (i)&#160;expected to be settled in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;due to be settled within twelve months after the reporting period, or (iv)&#160;there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_674"></div><ix:continuation id="f-409-8" continuedAt="f-409-9"><div style="margin-top:12pt;padding-left:42.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.3&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-415" continuedAt="f-415-1" escape="true">Revenue from Contracts with Customers</ix:nonNumeric></span></div><ix:continuation id="f-415-1" continuedAt="f-415-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of the Contract</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract is an agreement between two or more parties that establishes enforceable rights and obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer contracts often include bundles of licenses, goods and services. If the granting of a license is bundled together with delivering of goods and or the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment when determining the consideration that is expected to be received. If the consideration in an agreement includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenues reversal in the amount of cumulative revenues recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenues are updated at each reporting date to reflect the current facts and circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allocation of Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling prices. We have established the following hierarchy to determine the standalone selling prices.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where standalone selling prices for offered licenses, goods or services are observable and reasonably consistent across customers, our standalone selling price estimates are derived from our respective pricing history. However, due to the limited number of customers and the limited company history, this approach can rarely be used.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where sales prices for an offering are not directly observable or highly variable across customers, we follow a cost-plus-margin approach.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For offerings that have highly variable pricing and lack substantial direct costs to estimate based on a cost-plus-margin approach, we allocate the transaction price by applying a residual approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required when estimating standalone selling prices.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-415-2" continuedAt="f-415-3"><ix:continuation id="f-409-9" continuedAt="f-409-10"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenues are recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of our licensing arrangements, we provide the licensee with a research and development license, which represents a right to access our intellectual property as it exists throughout the license period (as our intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time as our customers simultaneously receive and consume the benefits from our performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements, are recognized based on the sales-based or usage-based royalty exemption; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the underlying sales occur, which is when the performance obligation has been satisfied. As described further in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> judgment is applied to certain aspects when accounting for the collaboration agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between us and the collaborator and the transactions between us and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenues. Any consideration related to activities in which we are considered the agent is accounted for as net revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from the sale of pharmaceutical and medical products (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) are recognized when we transfer control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and we have not retained any significant risks of ownership or future obligations with respect to the product. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers" id="f-416">payments from customers are due within 30 days after invoice</ix:nonNumeric>. However, with respect to our collaboration with Pfizer Inc., or Pfizer, there is a significant time lag between when revenues are recognized and the payments are received. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#8217;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenues from bill-and-hold arrangements are recognized at the point in time when the customer obtains control of the product and all of the following criteria have been met: (i)&#160;the arrangement is substantive; (ii)&#160;the product is identified separately as belonging to the customer; (iii)&#160;the product is ready for physical transfer to the customer; and (iv)&#160;we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether title and significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If we transfer goods or services to a customer before the customer pays the respective consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable represents our right to an amount of consideration that is unconditional (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., only the passage of time is required before payment of the consideration is due). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability is the obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before we transfer goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-415-3"><ix:continuation id="f-409-10" continuedAt="f-409-11"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(whichever is earlier). Contract liabilities are recognized as revenue when we fulfill our performance obligations under the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refund Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A refund liability is a consideration which has been received but which will need to be refunded to the customer in the future as it represents an amount to which we are ultimately not entitled under the contract. A refund liability is measured at the amount of consideration received (or receivable) to which we do not expect to be entitled (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounts not included in the transaction price). We update our estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_4002"></div><ix:continuation id="f-409-11" continuedAt="f-409-12"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.4&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="f-417" continuedAt="f-417-1" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><ix:continuation id="f-417-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period in which they are incurred. Regarding internal projects, we consider that regulatory approval and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained. Payments made to third parties, such as contract research and development organizations as compensation for subcontracted research and development, that are deemed not to transfer intellectual property are expensed as internal research and development expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority. We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset unless the respective intellectual property is mainly used as part of our general ongoing research and development activities without any intent to market the respective product as such. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. Sales-based milestone or royalty payments incurred under license agreements after the approval date of the respective pharmaceutical product are recognized as expenses in cost of sales as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent internal research and development costs in relation to intellectual property rights are expensed because the technical feasibility of the internal research and development activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the second quarter of 2023, we had assessed that inventory produced prior to successful regulatory approval did not meet the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because it is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. If regulatory approval for a product candidate is obtained, the relevant write-down would be reversed to a maximum of the original cost. Subsequently, inventory is recognized as cost of sales. This reassessment has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses are described in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_668"></div><ix:continuation id="f-409-12" continuedAt="f-409-13"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="f-418" continuedAt="f-418-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><ix:continuation id="f-418-1" continuedAt="f-418-2"><ix:continuation id="f-409-13" continuedAt="f-409-14"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government grants and similar grants which are accounted for in accordance with IAS 20 are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs for which the grant is intended to compensate are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated statements of profit or loss </span></ix:continuation></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-418-2"><ix:continuation id="f-409-14" continuedAt="f-409-15">over the useful life of the underlying asset subject to funding.</ix:continuation></ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_662"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-409-15" continuedAt="f-409-16"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="f-419" continuedAt="f-419-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span></ix:nonNumeric></div><ix:continuation id="f-419-1" continuedAt="f-419-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Income Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed by tax authorities, excluding interest expenses and penalties on the underpayment of taxes. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities are recognized for all taxable temporary differences, except: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recognition of Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and deferred tax items are recognized similarly to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax assets and current tax liabilities are offset if, and only if, we have a legally enforceable right to set off the recognized amounts and intend either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when we have a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-419-2" continuedAt="f-419-3"><ix:continuation id="f-409-16" continuedAt="f-409-17"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Tax Legislation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting (BEPS) project to tackle tax avoidance, the OECD/G20 Inclusive Framework (an association of about 140 countries) decided to introduce a global minimum taxation for large multinational groups (known as Pillar 2). The Global Anti-Base Erosion Rules are intended to ensure that large multinational groups pay a minimum level of tax on the income arising in each jurisdiction where they operate. In December 2021, the OECD published its Model Rules, which serve as a draft bill for implementation into national domestic law, followed by guidelines and commentaries published in March 2022. In December 2022, the EU adopted a corresponding directive (EU 2022/2523) that obliges EU member states to transpose the rules into national domestic law. If the effective tax rate in any jurisdiction is below the minimum rate (<ix:nonFraction unitRef="number" contextRef="c-12" decimals="2" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" scale="-2" id="f-420">15</ix:nonFraction>%), the Group may be subject to the so-called top-up tax or a so-called qualified domestic minimum top-up tax. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several jurisdictions in which the Group operates have transposed the OECD Model Rules into national domestic law and brought them into force. In addition, the Group is closely following the progress of the legislative process in each country in which the Group operates. As of the balance sheet date, the BEPS Pillar 2 regulations (MinBestRL UmsG) had already been transposed into German law (MinStG). The date of application of the law in Germany is for financial years beginning after December 30, 2023. Subsequently, as the OECD Model Rules have entered into force in Germany, the Group is obliged to file top-up tax information returns for all entities which are part of the Group, beginning in financial year 2024. The Group falls within the scope of these regulations. The Group carried out an analysis as of the reporting date to determine the fundamental impact and the jurisdictions in which the Group is exposed to possible effects in connection with a Pillar 2 top-up tax.</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-419-3"><ix:continuation id="f-409-17" continuedAt="f-409-18">Based on this analysis, no countries were identified in which the Group would be materially affected by a Pillar 2 top-up tax. Consequently, the average effective Group tax rate would not have changed if the Pillar 2 legislation had already been in force on the balance sheet date. BioNTech applies the exception in IAS 12, according to which no deferred tax assets and liabilities in connection with the second income taxes of the second pillar of the OECD are recognized and no disclosures are made.</ix:continuation></ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_693"></div><ix:continuation id="f-409-18" continuedAt="f-409-19"><div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.7&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" id="f-421" continuedAt="f-421-1" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-421-1" continuedAt="f-421-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to executing business combinations are recognized when they are incurred and are classified as general and administrative expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.10. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-421-2"><ix:continuation id="f-409-19" continuedAt="f-409-20"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in these circumstances is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_638"></div><ix:continuation id="f-409-20" continuedAt="f-409-21"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="f-422" continuedAt="f-422-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></ix:nonNumeric></div><ix:continuation id="f-422-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the consideration in in-licensing agreements paid by us to acquire intellectual property is recognized as an intangible asset. If in-licensing includes research and development services, the share of consideration attributable to these services is deferred and recognized in research and development expenses according to the utilization thereof. Payments depending on the achievement of specific milestones as part of the purchase of intangible assets, except for intangible assets acquired in a business combination, are recognized as subsequent acquisition cost of the intangible asset and as a financial liability once the milestone is reached.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of intangible assets are assessed as either finite or indefinite. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each reporting period at the least. The amortization expense on intangible assets with finite lives is recognized in the consolidated statements of profit or loss in the expense category that is consistent with the function of the intangible assets.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="f-423" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:84.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intellectual property rights</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-51" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-424">8</ix:nonNumeric>-<ix:nonNumeric contextRef="c-52" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-425">20</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licenses</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-53" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-426">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-54" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-427">20</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Software</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-55" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-428">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-56" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-429">8</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2.3.10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details). In the case of intangible assets not yet available for use, the point in time from which a capitalized asset can be expected to generate economic benefit for the Group cannot be determined. Such assets are not amortized, and therefore classified as having an indefinite useful life. The intangible assets not yet available for use are tested for impairment annually, or when there is an indication for impairment on an individual basis. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified advanced payments on intangible assets as intangible assets that are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An intangible asset is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2.3.4 for further details in connection with our accounting of internally generated intangible assets.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_650"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-409-21" continuedAt="f-409-22"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-430" continuedAt="f-430-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></ix:nonNumeric></div><ix:continuation id="f-430-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is stated at cost. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-431" continuedAt="f-431-1" escape="true"><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:84.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Property, plant and equipment</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-57" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-432">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c-58" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-433">33</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-59" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-434">7</ix:nonNumeric>-<ix:nonNumeric contextRef="c-60" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-435">18</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and business equipment has a useful life of <ix:nonNumeric contextRef="c-61" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-436">1</ix:nonNumeric>-<ix:nonNumeric contextRef="c-62" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-437">10</ix:nonNumeric> years and is reported under equipment, tools and installations due to immateriality. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An item of property, plant and equipment initially recognized is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss when the asset is derecognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_620"></div><ix:continuation id="f-409-22" continuedAt="f-409-23"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" id="f-438" continuedAt="f-438-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Non-Financial Assets</span></ix:nonNumeric></div><ix:continuation id="f-438-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, we assess whether there is an indication that a non-financial asset may be impaired. Goodwill is tested for impairment at least annually. Impairment is determined for goodwill by assessing the recoverable amount of each cash-generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, we estimate the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the asset does not generate independent cash inflows, the impairment test is performed for the smallest group of assets that generate largely independent cash inflows from other assets (CGU). When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or the non-current assets of the CGU are considered impaired and written down to their recoverable amount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses are recognized in the consolidated statements of profit or loss in expense categories consistent with the function of the impaired asset.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with an indefinite useful life are tested for impairment annually at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets not yet available for use are not amortized, but rather tested for impairment when a triggering event arises or at least once a year. The identification of triggering events takes place on a quarterly or on an ad hoc basis with the involvement of the responsible departments, taking internal and external information sources into consideration. The impairment test is performed annually or if there are indications of impairment by determining the asset&#8217;s value in use. In assessing value in use, the estimated discounted future cash flows are based on long-term forecast calculations reflecting the asset&#8217;s estimated product life cycles. The assumptions are based on internal estimates along with external market studies. The result of the valuation depends to a large extent on the estimates by the management of the future cash flows of the assets and the discount rate applied, and is therefore subject to uncertainty.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_632"></div><ix:continuation id="f-409-23" continuedAt="f-409-24"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-439" continuedAt="f-439-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></ix:nonNumeric></div><ix:continuation id="f-439-1" continuedAt="f-439-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-439-2" continuedAt="f-439-3"><ix:continuation id="f-409-24" continuedAt="f-409-25"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i) Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Recognition and Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets mainly include money market funds, bank deposits and reverse repos, security investments, trade receivables, cash at banks as well as equity investments. Financial assets are initially measured at fair value as of the trade date and &#8211; depending on their classification &#8211; subsequently measured at amortized cost, fair value through other comprehensive income (OCI) or fair value through profit or loss. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of financial assets depends on their classification, as described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Measured at Amortized Cost</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost include trade receivables and other financial assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are generally measured using the effective interest rate (EIR) method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to trade receivables, we applied the practical expedient, which means that they are measured at the transaction price determined in accordance with IFRS 15. Refer to the accounting policies in Note&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other financial assets measured at amortized cost are held to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in our consolidated statements of profit or loss when the financial asset is derecognized, modified or impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Designated at Fair Value through OCI (Equity Instruments)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon initial recognition, we can irrevocably elect to classify equity investments as equity instruments designated at fair value through OCI if they meet the definition of equity under IAS 32 and are not held for trading. The classification is determined on an instrument-by-instrument basis. Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the consolidated statements of profit or loss when the right of payment has been established. Equity instruments designated at fair value through OCI are not subject to impairment assessment. We elected to irrevocably classify our non-listed and listed equity investments under this category. They are recognized using trade date accounting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets at Fair Value through Profit or Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments are measured at fair value through profit or loss. A financial asset exists if the derivative has a positive fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, removed from the consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for expected credit losses (ECLs) is considered for all non-derivative financial debt investments, including cash, time deposits and debt securities of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our financial debt investments are considered to be investments with low risk, the expected credit loss in the upcoming twelve months is used to determine the impairment loss. Wherever a considerable increase in the default risk is assumed, the lifetime expected credit loss of the financial asset is considered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. This means that the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. We have established an ECL model that is based on the probability of default (PD), considers the respective country default probabilities and takes the maturities into account. In order to determine the PD of companies, we use the maturities of the trade receivables and the score of the companies. </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-439-3"><ix:continuation id="f-409-25" continuedAt="f-409-26"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is objective evidence that certain trade receivables or contract assets are fully or partially impaired, additional loss allowances are recognized to account for expected credit losses. A debtor&#8217;s creditworthiness is assumed to be impaired if there are objective indications that the debtor is in financial difficulties, such as the disappearance of an active market for its products or impending insolvency. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii) Financial Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are generally measured at amortized cost using the effective interest rate (EIR) method. Derivatives with negative fair values not designated as hedging instruments and liabilities for contingent consideration in business combinations are measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities measured at amortized cost include loans and borrowings, trade payables and other financial liabilities. They are measured at amortized cost using the EIR method. Gains and losses are recognized in the consolidated statements of profit or loss when the liabilities are derecognized as well as through the EIR amortization process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iii) Expenses and Income from Exchange Forward Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effects from foreign exchange forward contracts, which are measured at fair value through profit or loss, are shown as either other operating income or other operating expenses on a cumulative basis and might switch between those two items during the year-to-date reporting periods.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_681"></div><ix:continuation id="f-409-26" continuedAt="f-409-27"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="f-440" continuedAt="f-440-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span></ix:nonNumeric></div><ix:continuation id="f-440-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, we determine whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of fair value disclosures, classes of assets and liabilities have been determined on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_626"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-409-27" continuedAt="f-409-28"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="f-441" continuedAt="f-441-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></ix:nonNumeric></div><ix:continuation id="f-441-1" continuedAt="f-441-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost and net realizable value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw materials and supplies: purchase cost on a first-in / first-out basis; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale. Write-offs are recorded if inventories are expected to be unsaleable, do not fulfill the specification defined by our quality standards or if their shelf-life has expired. For our inventories subject to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the collaboration partners&#8217; gross profit share mechanism</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we consider the contractual compensation payments in the estimate of the net realizable value.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><ix:continuation id="f-441-2" continuedAt="f-441-3"><ix:continuation id="f-409-28" continuedAt="f-409-29"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-441-3"><ix:continuation id="f-409-29" continuedAt="f-409-30"> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained (see also Note 2.3.4 for further information on our assessment regarding the potential of our pre-launch products to produce economic benefits).</ix:continuation></ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_614"></div><ix:continuation id="f-409-30" continuedAt="f-409-31"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="f-442" continuedAt="f-442-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-442-1"><ix:continuation id="f-409-31" continuedAt="f-409-32">Cash and cash equivalents comprise cash at banks and on hand and short-term investments that we consider to be highly liquid (including deposits, money market funds and reverse repos) with an original maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Deposits with an original maturity of more than three months are recognized as other financial assets.</ix:continuation></ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3385"></div><ix:continuation id="f-409-32" continuedAt="f-409-33"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory" id="f-443" continuedAt="f-443-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></ix:nonNumeric></div><ix:continuation id="f-443-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the par value method to our repurchases of outstanding American Depositary Shares, or ADSs. Accordingly, the nominal value of acquired treasury shares is deducted from equity and shown in the separate item &#8220;Treasury shares&#8221;. Any premium paid in excess of the nominal value of a repurchased ADS is deducted from the capital reserve. On the trade date, we recognize a liability, and on the settlement date, we settle in cash. We recognize the foreign exchange differences that may occur between the trade and settlement date as profit or loss.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_644"></div><ix:continuation id="f-409-33" continuedAt="f-409-34"><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="f-444" continuedAt="f-444-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></ix:nonNumeric></div><ix:continuation id="f-444-1" continuedAt="f-444-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset &#8211; this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the asset. We possess this right when we hold the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have the right to operate the asset; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we designed the asset in a way that predetermines how and for what purpose it will be used. </span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-444-2" continuedAt="f-444-3"><ix:continuation id="f-409-34" continuedAt="f-409-35"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception or on reassessment of a contract that contains a lease component, the consideration in the contract is allocated to each lease component on the basis of their relative standalone prices. However, for leases of land and buildings in which we are a lessee, we have elected not to separate non-lease components, and instead account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the incremental borrowing rate is used as the discount rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability comprise the following: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fixed payments, including in-substance fixed payments;</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts expected to be payable under a residual value guarantee; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exercise price under a purchase option that is reasonably certain to be exercised, lease payments in an optional renewal period if it is reasonably certain that the extension option is exercised, and penalties for early termination of a lease unless it is reasonably certain that the contract will not be terminated early.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is subsequently measured at amortized cost using the EIR method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if we change our assessment of whether we will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the consolidated statements of profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets are presented separately and lease liabilities are presented under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of financial position.</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" id="f-445" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:77.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life or shorter lease term (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-63" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-446">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-64" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-447">25</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-65" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-448">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-66" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-449">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-67" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-450">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-68" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-451">3</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Automobiles</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-69" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-452">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-70" name="bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" format="ixt-sec:duryear" id="f-453">4</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-444-3"><ix:continuation id="f-409-35" continuedAt="f-409-36"><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Leases and Leases of Low-Value Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. We recognize the lease payments associated with these leases as an expense in the consolidated statements of profit or loss on a straight-line basis over the lease term.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_602"></div><ix:continuation id="f-409-36" continuedAt="f-409-37"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="f-454" continuedAt="f-454-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions</span></ix:nonNumeric></div><ix:continuation id="f-454-1" continuedAt="f-454-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When we expect some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A provision is also recognized for certain contracts with suppliers for which the unavoidable costs of meeting the obligations exceed the economic benefits expected to be received. The economic benefits considered in the assessment comprise the future benefits we are directly entitled to under the contract as well as the anticipated future benefits that are the economic consequence of the contract if these benefits can be reliably determined.</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-454-2"><ix:continuation id="f-409-37" continuedAt="f-409-38">The expense relating to a provision is presented in the consolidated statements of profit or loss net of any reimbursement.</ix:continuation></ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_596"></div><ix:continuation id="f-409-38" continuedAt="f-409-39"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-455" continuedAt="f-455-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></ix:nonNumeric></div><ix:continuation id="f-455-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions) or in cash (cash-settled transactions). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IFRS 2, share-based payments are generally divided into cash-settled and equity-settled. Both types of payment transactions are measured initially at their fair value as of the grant date. The fair value is determined using an appropriate valuation model, further details of which are given in Note 16. Rights granted under cash-settled transactions are remeasured at fair value at the end of each reporting period until the settlement date. The cost of share-based payment awards is recognized over the relevant service period, applying either the straight-line method or the graded vesting method, where applicable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves) or other liabilities, over the period in which the service is provided (the vesting period). The cumulative expense recognized for cash- and equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired, and also reflects the best estimate of the number of equity instruments expected to ultimately vest. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of our best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have a choice of settling either in cash or by providing equity instruments, the rights granted are accounted for as an equity-settled transaction, unless there is a present obligation to settle in cash. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, due to local tax regulations, an amount is withheld for the employee&#8217;s tax obligations and paid directly to the tax authorities in cash on the employee&#8217;s behalf, the entire share-based payment program remains an equity-settled plan based on the IFRS 2 classification. Accordingly, the amount withheld for the employee&#8217;s tax obligations expected to be paid directly to the tax authorities is reclassified from &#8220;Other reserves&#8221; to &#8220;Other non-financial liabilities&#8221;.</span></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_549755817243"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-409-39" continuedAt="f-409-40"><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory" id="f-456" continuedAt="f-456-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividend</span></ix:nonNumeric></div><ix:continuation id="f-456-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a liability to pay a dividend when the distribution is authorized. As per the corporate laws of Germany, a distribution is authorized when it is approved by the general shareholder meeting. A corresponding amount is recognized directly in equity.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_590"></div><ix:continuation id="f-409-40" continuedAt="f-409-41"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.4&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" id="f-457" continuedAt="f-457-1" escape="true">Standards Applied for the First Time</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="f-458" escape="true"><ix:continuation id="f-457-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:80.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.178%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IFRS 17 Insurance Contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#8211; Comparative Information</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income taxes: International Tax Reform &#8211; Pillar Two Model Rules</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr></table></div></ix:continuation></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_573"></div><ix:continuation id="f-409-41" continuedAt="f-409-42"><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.5&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="bntx:DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" id="f-459" continuedAt="f-459-1" escape="true">Standards Issued but Not Yet Effective</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-460" escape="true"><ix:continuation id="f-459-1" continuedAt="f-459-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:75.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.733%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:17.179%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:3pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-459-2"><ix:continuation id="f-409-42">We do not expect a significant impact from the application of any of these standards and amendments.</ix:continuation></ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_567"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">3&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-461" continuedAt="f-461-1" escape="true">Significant Accounting Judgements, Estimates and Assumptions</ix:nonNumeric></span></div><ix:continuation id="f-461-1" continuedAt="f-461-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant accounting judgments, as well as key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. We based our assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-461-2" continuedAt="f-461-3"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts with Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We applied the following judgments, estimates and assumptions that significantly affect the determination of the amount and timing of revenues from contracts with customers:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification and Determination of Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract is an agreement between two or more parties that establishes enforceable rights and obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of each agreement, we apply judgment when determining which promises represent distinct performance obligations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, we assess which of these promises is the predominant promise to determine the nature of the performance obligation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When licenses are granted, we determined that the grant of the license is the predominant promise within the combined performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In our view, we grant our customers a right to access or a right to use our intellectual property due to the collaboration and license agreements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of the Transaction Price</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements often include variable consideration, which is contingent on the occurrence or non-occurrence of a future event (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reaching a certain milestone). When determining deferred revenues from a collaboration and license agreement, we need to estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to our customers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As there are usually only two possible outcomes (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, milestone is reached or not), we have assessed that the method of the most likely amount is the best method to predict the amount of consideration to which we will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="INF" name="bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception" format="ixt:fixed-zero" scale="0" id="f-462">zero</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, we use judgment to determine when to include variable consideration in the transaction price in such a way that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. We have concluded that future milestone payments are fully constrained at the end of the current financial year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future milestone payments would become unconstrained upon the satisfaction of the milestone event, specifically a development event, regulatory approval or achievement of a sales milestone.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are Satisfied</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on our best estimates and interpretations of facts and circumstances of each contractual agreement and may require significant judgment to determine appropriate allocation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and reimbursement for expenses are initially deferred on our consolidated statements of financial position. We assessed that no significant financing component exists within our collaboration agreements since the overall business purpose of advanced payments is to support the payment structure rather than to provide a significant benefit of financing. For performance obligations in which the costs vary based on progress, an input-based measure that takes into account cost incurred is the most reliable indicator of the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may be the most reliable indicator of our performance toward complete satisfaction. If the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. We evaluate the measure of progress in each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net profit or loss in the period of adjustment.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-461-3" continuedAt="f-461-4"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal-Agent Considerations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under our current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner acts as a principal in each case. We recognize revenue net based on the collaboration partners&#8217; gross profit in territories where the partner is responsible for supply, and on a gross basis when directly supplying our customers in our territories when control has been transferred. Amounts paid to collaboration partners for their share of our profits earned where we are the principal in the transaction are recorded as cost of sales. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Agreement Characteristics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our collaboration with Pfizer, commercial revenues are recognized based on our collaboration partner&#8217;s gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenues pursuant to this collaboration agreement, we are reliant on our collaboration partner for details regarding its gross profit for the period at hand. Some of the information which our collaboration partner provides us with to identify the gross profit is, by necessity, preliminary and subject to change. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s gross profit share is calculated based on sales and takes into account transfer prices. The latter include manufacturing and shipping costs, which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters may be adjusted once actual costs are determined. The sales as reported by Pfizer have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are borne by the partners on the basis of revenues in the territories for which the partners are responsible and subsequently deducted as cost under the gross profit shared. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third-party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing cost variances include expenses from unused contract manufacturing capacities and overstock inventories finally scrapped. As only materialized costs &#8211; which means manufacturing capacities finally lapsed or inventories finally scrapped &#8211; are shared with the partner in a cash-effective manner, the gross profit share impact is anticipated once assessed as being highly probable to occur. Therefore, information on Pfizer&#8217;s write-downs of inventories is considered. Any changes to this assessment will be recognized prospectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to us and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. Likewise, our own cost of sales and the respective gross profit share owed to our partner may be adjusted prospectively, when changes are determined. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contract balances related to the Pfizer agreement, see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Judgment is required in determining whether a right to consideration is unconditional and thus qualifies as a receivable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions and Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently confronted with a number of claims and legal proceedings. They include claims from third parties demanding indemnification for alleged infringement of a third-party patent or other intellectual proprietary rights, as well as product liability claims. In respect of these matters, we assess whether provisions must be recorded and whether contingencies must be reported. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties relating to these matters, provisions and contingencies are based on the best information available.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-461-4" continuedAt="f-461-5"><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in the determination of whether and when a provision is to be recorded and what the appropriate amount for such provision should be. Notably, judgment is required in the following areas:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining whether an obligation exists</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining the probability of an outflow of economic benefits</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining whether the amount of an obligation is reliably estimable</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimating the amount of the expenditure required to settle the present obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each reporting period, we reassess the potential obligations related to our pending claims and litigation and adjust our respective provisions and contingencies to reflect the current best estimate. In addition, we monitor and evaluate new information that we receive after the end of the respective reporting period, but before the consolidated financial statements are authorized for issue, in order to determine whether this provides additional information regarding conditions that existed at the end of the reporting period. Changes to estimates, assumptions and outcomes compared to previous estimates and assumptions could require material adjustments to the carrying amounts of the respective provisions recorded and additional provisions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected timing or amounts of any outflows of economic benefits resulting from these lawsuits and claims are uncertain and difficult to estimate or even not estimable, as they generally depend on the duration of the legal proceedings and settlement negotiations required to resolve the litigation and claims and the unpredictability of the outcomes of legal disputes in several jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosures in respect of third-party claims and litigation for which no provisions have been recognized are made in the form of contingent liabilities, unless a potential outflow of resources is considered remote. It is not practicable to estimate the financial impact of contingent liabilities due to the uncertainties around lawsuits and claims as outlined above. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures and carrying amounts relating to provisions as well as contingencies, see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 and Note 18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities, including development of our platforms and manufacturing technologies, generate a significant amount of research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, the capitalization criteria are met. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, we have concluded that, d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ue to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, these criteria are usually not met before regulatory approval is achieved. The related expenditure is reflected in the consolidated statements of profit or loss in the period in which the expenditure is incurred. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. The allocation of consideration attributable to the acquisition of intellectual property and consideration attributable to the research and development services provided by the licensor requires management to make judgements and assumptions. These judgments and assumptions can materially affect our research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our accounting for business combinations, judgment is required in determining whether an intangible asset is identifiable and whether it should be recorded separately from goodwill. Additionally, estimating the acquisition-date fair values in conjunction with purchase price allocation involves estimation uncertainty and discretionary decisions. The necessary measurements are based on information available on the acquisition date and on expectations and assumptions that have been deemed reasonable by management. These judgments, estimates and assumptions can materially affect our financial position and profit. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant assumptions and estimates are required to determine the appropriate amount of amortization of intangible assets. They relate in particular to the determination of the underlying useful life. The useful life of an intangible asset is </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-461-5"><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our estimates regarding the period over which the intangible asset is expected to generate economic benefits for us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant assumptions and estimates are also required for the identification of a potential need to recognize an impairment loss. These estimates include management&#8217;s assumptions regarding future cash flow projections and economic risks that require significant judgment and assumptions about future developments. They can be affected by a variety of factors, including, but not limited to, changes in business strategy, internal forecasts and the estimation of weighted average cost of capital. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the assumptions underlying our assessment of the impairment of goodwill and intangible assets could require material adjustments to the carrying amount of our recognized goodwill and intangible assets, as well as to the amounts of impairment charges recognized in profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. We used valuation models such as a binomial or Monte Carlo simulation model for the measurement of the cash- and equity-settled transactions&#8217; fair value, taking into account certain assumptions relating to a number of factors, including the volatility of the stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#8217;s underlying share price. For awards which were granted after the initial public offering, the grant date&#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fluctuation assumption is applied when estimating the number of equity instruments for which service conditions are expected to be satisfied and will be revised if material differences arise. Ultimately, a true-up to the number satisfied by the settlement date will be recorded. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures relating to share-based payments, see Note 16.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in more than one tax jurisdiction. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in the form of provisions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize or we would impair deferred tax assets if it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. The assessment whether a deferred tax asset can be recognized or is impaired requires significant judgment, as we need to estimate future taxable profits to determine whether the utilization of the deferred tax asset is probable. In evaluating our ability to utilize our deferred tax assets, we consider all available positive and negative evidence, including the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are recoverable. Based on the requirements in IAS 12, to not place reliance on future events that are uncertain as they for example cannot be controlled, managements assessment takes particular into account the fact that there is an inherent risk of failure in pharmaceutical development and an uncertainty of approval which is dependent on external regulatory agencies&#8217; opinions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This also includes management&#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continued to take the view that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss-making history cannot be recognized. This includes the assessment that those subsidiaries have neither any taxable temporary differences nor any tax planning opportunities available that could support the recognition of deferred tax assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures relating to deferred taxes, see Note 8.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_561"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">4&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCompositionOfGroupExplanatory" id="f-463" continuedAt="f-463-1" escape="true">Group Information</ix:nonNumeric></span></div><ix:continuation id="f-463-1" continuedAt="f-463-2"><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Subsidiaries</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" id="f-464" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the following subsidiaries: </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:43.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.120%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">% equity interest</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech BioNTainer Holding GmbH</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-465">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-466">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Cell &amp; Gene Therapies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-467">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-468">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Halle</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-469">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-470">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Diagnostics GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-471">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-472">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Europe GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-473">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-474">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Idar-Oberstein Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-475">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-476">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Individualized mRNA Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-477">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-478">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation and Services Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-479">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-480">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-481">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-482">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovative Manufacturing Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-483">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-484">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-485">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-486">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-487">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-488">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Holding GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-489">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-490">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Verwaltungs GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-491">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-492">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep DE GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-493">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-494">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-495">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NT Security and Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-496">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-497">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">reSano GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-498">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-499">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Australia Pty Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Australia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Melbourne</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-500">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-501">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech R&amp;D (Austria) GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Austria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vienna</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-502">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-109" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-503">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">China</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shanghai</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-504">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-505">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Paris</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-506">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biopharma BioNTech Israel Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tel Aviv</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-507">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">New Technologies Re</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-508">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Nigeria Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nigeria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lagos</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-509">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Rwanda Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Rwanda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kigali</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-510">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-511">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech S&#233;n&#233;gal Suarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Senegal</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dakar</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-512">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-513">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-514">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Spain S.L</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Spain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Barcelona</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-515">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Switzerland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Switzerland</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Basel</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-516">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Taiwan Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taiwan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taipei</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-517">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Tunisia SARL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunisia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunis</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-518">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">T&#252;rkiye</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Istanbul</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-519">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-520">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech UK Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-521">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-522">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-523">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="0" id="f-524">5.3</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Research and Development, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-525">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-526">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech USA Holding, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-133" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-527">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-528">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech US Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-529">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-530">100</ix:nonFraction>&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies (US), LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-531">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dover</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-532">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies Inc.</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-139" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-533">100</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-534">100</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Included during the year ended December 31, 2023.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fully acquired during the year ended December 31, 2023.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities listed above are included in our consolidated financial statements.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-463-2"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parent Company</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" id="f-535" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AT Impf GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Munich</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-141" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-536">43.77</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-537">43.42</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity with Significant Influence over the Group</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" id="f-538" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Medine GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-539">17.01</ix:nonFraction>&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="4" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="f-540">17.38</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_555"></div><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="f-541" continuedAt="f-541-1" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="f-541-1" continuedAt="f-541-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of InstaDeep Ltd.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we acquired InstaDeep Ltd., London, United Kingdom (InstaDeep), a leading global technology company in the field of artificial intelligence (AI) and machine learning, by purchasing <ix:nonFraction unitRef="number" contextRef="c-145" decimals="INF" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-542">100</ix:nonFraction>% of the remaining shares in InstaDeep not already owned by us. The acquisition is intended to create a fully integrated, enterprise-wide capability that leverages AI and machine learning technologies across our therapeutic platforms and operations. InstaDeep also continues to provide its services to clients around the world in diverse industries, including in the technology, transport and logistics, and industrial and financial services sectors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the acquisition took place in July 2023.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed an allocation of the total consideration and the underlying assets acquired (including certain identified intangible assets such as InstaDeep</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s DeepChain technology and customer relationships) and liabilities assumed based on their fair values using the information available as of the </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-541-2" continuedAt="f-541-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition date. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="f-543" continuedAt="f-543-1" escape="true">The total consideration and the fair values in accordance with IFRS&#160;3 of the identified net assets acquired of InstaDeep as of July 31, 2023, are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-543-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:84.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fair value recognized on acquisition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Assets </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-544">187.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" scale="6" id="f-545">2.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-546">0.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade receivables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:TradeReceivablesRecognisedAsOfAcquisitionDate" scale="6" id="f-547">2.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets - current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:FinancialAssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-548">52.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" scale="6" id="f-549">21.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets non-current and current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" scale="6" id="f-550">8.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total assets</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:AssetsRecognisedAsOfAcquisitionDate" scale="6" id="f-551">275.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-552">45.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other liabilities long-term and short-term</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" scale="6" id="f-553">18.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total liabilities</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:LiabilitiesRecognisedAsOfAcquisitionDate" scale="6" id="f-554">64.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total identifiable net assets at fair value</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" scale="6" id="f-555">211.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill from the acquisition</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" scale="6" id="f-556">306.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" scale="6" id="f-557">517.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:CashTransferred" scale="6" id="f-558">358.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash to be paid in 2024</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:LiabilitiesIncurred" scale="6" id="f-559">4.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designated FX hedge</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" sign="-" name="bntx:DesignatedFXHedge" scale="6" id="f-560">8.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares transferred (approx. <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="-5" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" scale="6" id="f-561">1.1</ix:nonFraction> million shares)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:EquityInterestsOfAcquirer" scale="6" id="f-562">103.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" scale="6" id="f-563">31.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Previously held non-listed equity investment (stake of <ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="bntx:EquityMethodInvestmentsOwnershipPercentage" scale="-2" id="f-564">5.3</ix:nonFraction>%)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:PreviouslyHeldNonListedEquityInvestment" scale="6" id="f-565">27.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" scale="6" id="f-566">517.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets acquired comprise DeepChain technology and customer relationships. Their fair values were determined based on the multi-period excess earnings method (MEEM) and amount to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-5" name="ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-567">176.0</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-147" decimals="-5" name="ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-568">7.8</ix:nonFraction>&#160;million respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the shares transferred is determined based on the number of shares transferred and the closing price of the ADSs as of July 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of InstaDeep is a step acquisition in accordance with IFRS 3.41-3.42A since we already held a <ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="bntx:EquityMethodInvestmentsOwnershipPercentage" scale="-2" id="f-569">5.3</ix:nonFraction>% interest prior to the acquisition. In prior reporting periods, we recognized changes in the value of this equity interest in other comprehensive income. The amount of the remeasurement to fair value that was recognized in other comprehensive income is recognized on the same basis as would be required if we disposed directly of the previously held equity interest. Based on the total consideration for the acquired shares (<ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="bntx:PercentageOfConsiderationTransferredAcquiredShares" scale="-2" id="f-570">94.7</ix:nonFraction>%), the value of the already held shares is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="bntx:PreviouslyHeldNonListedEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="f-571">27.9</ix:nonFraction>&#160;million, which results in a loss of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-5" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-572">2.2</ix:nonFraction>&#160;million shown in other comprehensive income in the year ended December&#160;31, 2023.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-541-3" continuedAt="f-541-4"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the acquisition date, the contingent consideration was recognized at its fair value of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-573">31.8</ix:nonFraction> million based on cash flow projections in connection with performance-based future milestone cash payments to eligible shareholders after a three-year earn-out period. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero; the upper limit is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-148" decimals="-5" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-574">124.6</ix:nonFraction>&#160;million. In addition, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-145" decimals="-5" name="bntx:ConsideredRemunerationOfPotentialEarnOutPayments" format="ixt:num-dot-decimal" scale="6" id="f-575">12.5</ix:nonFraction>&#160;million of potential earn-out payments are considered remuneration and will be recognized as personnel expense over a three-year period in which services are to be provided.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-149" decimals="-5" name="ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="f-576">6.0</ix:nonFraction>&#160;million were expensed and are included in general and administrative expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill mainly comprises the value of expected synergies from including AI and machine learning technologies across our therapeutic platforms and operations and intangible assets that are not recognized separately, such as the acquired skilled workforce and its know-how. Therefore, the goodwill is allocated almost in full to the CGU immunotherapies and to a minor extent to a CGU comprising the external InstaDeep business. The goodwill is not tax deductible.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized in an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-146" decimals="-5" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="6" id="f-577">45.8</ix:nonFraction>&#160;million. In line with the deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carry forwards which existed as of the acquisition date were recognized. The deferred tax assets and liabilities were offset to the extent that the conditions for offsetting were fulfilled.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><ix:continuation id="f-541-4" continuedAt="f-541-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the acquisition, InstaDeep</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-541-5">s impact on our revenue and profit for the period has been immaterial. Accordingly, hypothetical amounts for our revenue and profit for the financial year, which were calculated on the assumption that the acquisition had taken place at the beginning of the year, would not materially differ from the actual figures reported.</ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-34</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_546"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:7pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">6&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="f-578" continuedAt="f-578-1" escape="true">Revenues from Contracts with Customers</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_540"></div><ix:continuation id="f-578-1" continuedAt="f-578-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1&#160;&#160;&#160;&#160;Disaggregated Revenue Information</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-579" continuedAt="f-579-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:55.454%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commercial revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-6" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-580">3,815.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-7" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-581">17,194.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-8" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-582">18,874.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 vaccine revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-150" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-583">3,776.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-151" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-584">17,145.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-152" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-585">18,806.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sales to collaboration partners</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-153" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-586">275.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-154" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-587">1,224.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-155" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-588">970.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Direct product sales to customers</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-589">473.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-590">3,184.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-591">3,007.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of collaboration partners&#8217; gross profit and sales milestones</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-159" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-592">3,027.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-160" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-593">12,736.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-161" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-594">14,828.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-595">39.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-163" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-596">49.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-164" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-597">67.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research &amp; development revenues from collaborations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-9" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-598">3.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-10" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-599">116.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-11" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-600">102.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-601">3,819.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-602">17,310.6</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-603">18,976.7</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, revenues recognized from Pfizer Inc., or Pfizer (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-165" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-604">3,293.0</ix:nonFraction> million) and the German Federal Ministry of Health (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-166" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-605">473.6</ix:nonFraction> million), each account for more than 10% of total revenues. During the year ended December&#160;31, 2022, revenues recognized from Pfizer (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-167" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-606">13,795.8</ix:nonFraction> million) and the German Federal Ministry of Health (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-168" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-607">3,020.5</ix:nonFraction> million) represented more than 10% of total revenues. During the year ended December&#160;31, 2021, revenues recognized from Pfizer (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-608">15,500.0</ix:nonFraction> million) and the German Federal Ministry of Health (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-170" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-609">1,945.6</ix:nonFraction> million), accounted for more than 10% of total revenues. During the year ended December&#160;31, 2023, based on the geographic region in which our customers and collaboration partners are located, we mainly recognized revenues in the United States (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-171" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-610">3,010.9</ix:nonFraction>&#160;million) and Germany (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-172" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-611">482.7</ix:nonFraction>&#160;million). During the year ended December&#160;31, 2022, the main geographic regions were United States (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-173" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-612">12,709.7</ix:nonFraction>&#160;million) and Germany (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-174" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-613">3,031.0</ix:nonFraction>&#160;million). During the year ended December&#160;31, 2021, the main geographic regions were United States (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-175" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-614">14,636.5</ix:nonFraction>&#160;million), Germany (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-176" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-615">2,241.9</ix:nonFraction>&#160;million) and Belgium (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-177" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-616">675.0</ix:nonFraction>&#160;million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide. During the year ended December&#160;31, 2023, our commercial revenues decreased in line with a lower COVID-19 vaccine market demand. In addition, write-downs by our collaboration partner Pfizer Inc. (Pfizer), significantly reduced our gross profit share and hence negatively influenced our revenues for the year ended December&#160;31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and T&#252;rkiye. Shanghai Fosun Pharmaceutical (Group) Co., Ltd, or Fosun Pharma, has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales to Collaboration Partners</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to collaboration partners represent sales of products manufactured by us to collaboration partners. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. Under the collaboration with Pfizer, from time to time, those sales are significantly influenced by amounts due to write-downs of inventories as well as costs related to production capacities derived from contracts with CMOs that became redundant. Those costs represent accrued manufacturing variances and are charged to our partner once finally materialized. These manufacturing variances are reflected as transfer price adjustments once identified. The regular reassessment of these manufacturing variances may result in adjustments to the respective prior-period revenues. Sales to collaboration partners during the years ended December&#160;31, 2023, 2022 and 2021 of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-617">74.5</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-618">850.0</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-180" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-619">31.0</ix:nonFraction>&#160;million, respectively, related to the aforementioned manufacturing variances.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-578-2" continuedAt="f-578-3"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Product Sales to Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct product sales are recognized from supplying COVID-19 vaccine in our territories Germany and T&#252;rkiye. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December&#160;31, 2023, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized &#8364;<ix:nonFraction unitRef="eur" contextRef="c-156" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-620">473.6</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-157" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-621">3,184.7</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-158" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-622">3,007.2</ix:nonFraction>&#160;million of revenues, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share of Collaboration Partners&#8217; Gross Profit and Sales Milestones</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on COVID-19 vaccine sales in the collaboration partners&#8217; territories, we are eligible to receive a share of their gross profit, which represents a seasonally affected net figure and is recognized as collaboration revenue during the commercial phase, together with sales milestones. M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anufacturing cost variances either reflected as transfer price adjustments as described above or resulting from costs highly probable to be incurred by the partner, were taken into account when determining the gross profit. During the year ended December&#160;31, 2021, those revenues included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-181" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-623">476.6</ix:nonFraction> million&#160;of sales milestones</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><ix:continuation id="f-579-1"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenues from contracts with customers disclosed above were recognized as follows: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1A1A1A;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Timing of revenue recognition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred at a point in time</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-182" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-624">776.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-183" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-625">4,447.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-184" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-626">4,034.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred over time</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-185" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-627">15.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-186" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-628">127.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-187" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="f-629">113.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-188" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-630">3,027.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-189" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-631">12,736.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-190" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-632">14,828.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-633">3,819.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-634">17,310.6</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-635">18,976.7</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents sales based on the share of the collaboration partners&#8217; gross profit and sales milestones.</span></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_534"></div><ix:continuation id="f-578-3" continuedAt="f-578-4"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.2&#160;&#160;&#160;&#160;Contract Balances</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" id="f-636" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-637">2,155.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="6" id="f-638">7,145.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-639">751.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-640">125.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refund liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:RefundsProvision" format="ixt:fixed-zero" scale="6" id="f-641">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:RefundsProvision" scale="6" id="f-642">24.4</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables significantly decreased compared to the previous year and predominantly comprise trade receivables from our COVID-19 collaboration with Pfizer as well as our direct product sales to customers in our territory. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#8217;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. Consequently, as of December&#160;31, 2023, our trade receivables included, in addition to the profit share for the fourth quarter of 2023, trade receivables which related to the gross profit share for the third quarter of 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities significantly increased compared to the previous year as advance payments in connection with the amendment of the COVID-19 vaccine purchase agreement with the European Commission, or EC, were received. As of December&#160;31, 2023, the contract liabilities included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-191" decimals="-5" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-643">386.4</ix:nonFraction> million of such payments under our collaboration with Pfizer (COVID-19 vaccine), &#8364;<ix:nonFraction unitRef="eur" contextRef="c-192" decimals="-5" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-644">302.3</ix:nonFraction> million&#160;from the German Federal Ministry of Health and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-193" decimals="-5" name="bntx:RemainingUpfrontFeesContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-645">62.3</ix:nonFraction> million&#160;of remaining upfront fees from our collaboration agreement with Pfizer (Zoster) (as of December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:RemainingUpfrontFeesContractLiabilities" scale="6" id="f-646">65.7</ix:nonFraction>&#160;million of remaining upfront fees from collaboration and commercial supply agreements and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AdvancePaymentReceivedForFutureCOVID19VaccineSale" format="ixt:num-dot-decimal" scale="6" id="f-647">56.3</ix:nonFraction>&#160;million&#160;of advance payments for future COVID-19 vaccine sales). </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-578-4" continuedAt="f-578-5"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The refund liabilities recognized as of December 31, 2022, represented consideration which was refunded to the collaboration partner during the year ended December 31, 2023. </span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" id="f-648" escape="true"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the amount of revenue recognized for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts included in contract liabilities at the beginning of the year</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="6" id="f-649">3.5</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="6" id="f-650">63.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="6" id="f-651">73.7</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_528"></div><ix:continuation id="f-578-5"><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.3&#160;&#160;&#160;&#160;Performance Obligations</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPerformanceObligationsExplanatory" id="f-652" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as of year-end are as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Within one year</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-194" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-653">353.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-195" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-654">77.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More than one year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-196" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-655">398.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-197" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-656">48.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-198" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-657">751.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-199" decimals="-5" name="ifrs-full:ContractLiabilities" scale="6" id="f-658">125.5</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-37</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_515"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">7&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfIncomeAndExpenseExplanatoryTextBlock" id="f-659" continuedAt="f-659-1" escape="true">Income and Expenses</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_3898"></div><ix:continuation id="f-659-1" continuedAt="f-659-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.1 General Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, cost of sales decreased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:IncreaseDecreaseCostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-660">2,395.2</ix:nonFraction> million or <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" sign="-" name="bntx:PercentageOfCostOfSales" scale="-2" id="f-661">80</ix:nonFraction>% from &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-662">2,995.0</ix:nonFraction> million&#160;to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-663">599.8</ix:nonFraction> million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mainly due to recognizing lower cost of sales from our decreased COVID-19 vaccine sales, which included the share of gross profit that we owe our collaboration partner  Pfizer based on our sales. In addition, cost of sales was impacted by expenses arising from inventory write-offs and expenses for production capacities derived from contracts with CMOs that became redundant. The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. Based on the regulatory approval obtained with respect to our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine during the third quarter of 2023, we reversed the initial write-down of pre-launch inventory recorded in research and development expensed to a maximum of the original cost of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-200" decimals="-5" sign="-" name="ifrs-full:WritedownsReversalsOfInventories" format="ixt:num-dot-decimal" scale="6" id="f-664">46.9</ix:nonFraction>&#160;million. Thereof &#8364;<ix:nonFraction unitRef="eur" contextRef="c-201" decimals="-5" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="6" id="f-665">27.3</ix:nonFraction>&#160;million resulted in cost of sales during the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023 as the respective inventory has been either sold or written down. The remainder is presented in inventories as of December&#160;31, 2023 and amounted to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-202" decimals="-5" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="6" id="f-666">19.6</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the year ended December&#160;31, 2022 the amount was <ix:nonFraction unitRef="eur" contextRef="c-203" decimals="-5" name="ifrs-full:Inventories" format="ixt:fixed-zero" scale="0" id="f-667">nil</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our research and development expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:IncreaseDecreaseOfResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-668">246.1</ix:nonFraction> million&#160;or <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" name="bntx:PercentageOfResearchAndDevelopmentExpense" scale="-2" id="f-669">16</ix:nonFraction>% from &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-670">1,537.0</ix:nonFraction> million&#160;to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-671">1,783.1</ix:nonFraction>&#160;million, mainly influenced by progressing clinical studies for pipeline candidates as well as by our newly acquired product candidates and the development of variant adapted COVID-19 vaccines. The increase was further driven by an increase in wages, benefits and social security expenses resulting from a significant increase in headcount.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ales and marketing expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:IncreaseDecreaseOfSalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="6" id="f-672">3.2</ix:nonFraction> million&#160;or <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" name="bntx:PercentageOfSalesAndMarketingExpense" scale="-2" id="f-673">5</ix:nonFraction>% from &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="6" id="f-674">59.5</ix:nonFraction> million&#160;to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="6" id="f-675">62.7</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, mainly due to increased expenses for setup and enhancement of commercial IT platforms and an increase in wages, benefits and social security expenses resulting from an increase in headcount. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-659-2" continuedAt="f-659-3">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our general and administrative expenses increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:IncreaseDecreaseOfGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-676">13.3</ix:nonFraction> million&#160;or <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" name="bntx:PercentageOfGeneralAndAdministrativeExpense" scale="-2" id="f-677">3</ix:nonFraction>% from &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-678">481.7</ix:nonFraction> million&#160;to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-679">495.0</ix:nonFraction> million, mainly influenced by increased expenses for IT services as well as by wages, benefits and social security expenses resulting from an increase in headcount.</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_485"></div><ix:continuation id="f-659-3" continuedAt="f-659-4"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Other Operating Expenses</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" id="f-680" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-681">252.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:fixed-zero" scale="6" id="f-682">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:fixed-zero" scale="6" id="f-683">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-207" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" format="ixt:fixed-zero" scale="6" id="f-684">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-208" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-685">385.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-209" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-686">86.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-210" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-687">29.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-211" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-688">3.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-212" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-689">9.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-690">11.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-691">21.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-692">8.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-693">293.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-694">410.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="6" id="f-695">103.4</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures relate to costs for external legal advice in connection with certain legal litigations from general and administrative expenses to other operating expense to reflect changes in internal reporting also in the external reporting.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the other expenses increased compared to the year ended December&#160;31, 2022, which was mainly derived from recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating expenses primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-659-4" continuedAt="f-659-5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-659-5" continuedAt="f-659-6">During the year ended December&#160;31, 2022, the other operating expenses increased compared to the year ended December&#160;31, 2021, mainly from recording the change in fair value of foreign exchange forward contracts that were entered into during the year ended December&#160;31, 2022, to manage some of our transaction exposures but were not designated as hedging instruments under IFRS.</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2898"></div><ix:continuation id="f-659-6" continuedAt="f-659-7"><div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.3&#160;&#160;&#160;&#160;Other Operating Income</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" id="f-696" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gain on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-216" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-697">67.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-217" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="f-698">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-218" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-699">5.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-219" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-700">2.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-220" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-701">1.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-221" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-702">137.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-204" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="f-703">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-205" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-704">727.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-206" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-705">446.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-213" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-706">35.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-214" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-707">86.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-215" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-708">9.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-709">105.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-710">815.3</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="6" id="f-711">598.4</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the other income decreased compared to the year ended December&#160;31, 2022, as foreign exchange differences arising on operating items changed from a positive effect to a negative effect, which is recorded in other operating expenses (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the other income increased compared to the year ended December&#160;31, 2021, which was mainly due to recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating income primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_479"></div><ix:continuation id="f-659-7" continuedAt="f-659-8"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Finance Income</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfFinanceIncomeExplanatoryTableTextBlock" id="f-712" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:RevenueFromInterest" scale="6" id="f-713">357.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:RevenueFromInterest" scale="6" id="f-714">48.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:RevenueFromInterest" scale="6" id="f-715">1.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" scale="6" id="f-716">162.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" scale="6" id="f-717">216.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-718">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:NetForeignExchangeGain" format="ixt:fixed-zero" scale="6" id="f-719">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:NetForeignExchangeGain" scale="6" id="f-720">65.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:NetForeignExchangeGain" scale="6" id="f-721">66.2</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-722">519.6</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-723">330.3</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-724">67.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the finance income increased compared to the year ended December&#160;31, 2022, mainly due to interest income earned on bank deposits and financial securities as well as fair value adjustments in relation to our money market funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the finance income included the final fair value measurement adjustments of the derivative embedded within the convertible note upon the early redemption of the convertible note as of March 1, 2022, the redemption date, as well as interest income from our bank deposits and increased compared to the year ended December&#160;31, 2021.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-39</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_472"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-659-8" continuedAt="f-659-9"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.5&#160;&#160;&#160;&#160;Finance Expenses</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfFinanceCostExplanatoryTableTextBlock" id="f-725" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" scale="6" id="f-726">16.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" format="ixt:fixed-zero" scale="6" id="f-727">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:NetForeignExchangeLoss" format="ixt:fixed-zero" scale="6" id="f-728">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-729">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" format="ixt:fixed-zero" scale="6" id="f-730">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" scale="6" id="f-731">277.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="us-gaap:OtherExpenses" scale="6" id="f-732">7.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="us-gaap:OtherExpenses" scale="6" id="f-733">18.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="us-gaap:OtherExpenses" scale="6" id="f-734">27.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-735">23.9</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-736">18.9</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:FinanceCosts" scale="6" id="f-737">305.1</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the finance expenses increased compared to the year ended December&#160;31, 2022, mainly due to exchange differences derived from our foreign exchange bank deposits and cash accounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the finance expenses decreased compared to the year ended December&#160;31, 2021, mainly due to final settlement of the derivative embedded within the convertible note which led to financial income whereas during the year ended December&#160;31, 2021, expenses in the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-738">277.8</ix:nonFraction> million&#160;were derived from the respective fair value measurement adjustment.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_3231"></div><ix:continuation id="f-659-9"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.6&#160;&#160;&#160;&#160;Employee Benefits Expense</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" id="f-739" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Wages and salaries</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:WagesAndSalaries" scale="6" id="f-740">617.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:WagesAndSalaries" scale="6" id="f-741">544.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:WagesAndSalaries" scale="6" id="f-742">345.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social security costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:SocialSecurityContributions" scale="6" id="f-743">76.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:SocialSecurityContributions" scale="6" id="f-744">58.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:SocialSecurityContributions" scale="6" id="f-745">31.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pension costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="6" id="f-746">4.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="6" id="f-747">2.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="6" id="f-748">1.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:EmployeeBenefitsExpense" scale="6" id="f-749">698.6</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:EmployeeBenefitsExpense" scale="6" id="f-750">605.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:EmployeeBenefitsExpense" scale="6" id="f-751">378.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wages and salaries include, among other things, expenses for share-based payments.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_466"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-752" continuedAt="f-752-1" escape="true">Income Tax</ix:nonNumeric></span></div><ix:continuation id="f-752-1" continuedAt="f-752-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax for the years ended December&#160;31, 2023, December&#160;31, 2022, and December&#160;31, 2021, comprised current income taxes, other taxes and deferred taxes. We are subject to corporate taxes, the solidarity surcharge and trade taxes. Our corporate tax rate in the reporting year remained unchanged (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="bntx:CorporateTaxRate" scale="-2" id="f-753">15.0</ix:nonFraction>%) as did the solidarity surcharge (<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="bntx:SolidaritySurchargeRate" scale="-2" id="f-754">5.5</ix:nonFraction>%) whereas the average trade tax rate changed resulting in a combined income tax rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-755">27.1</ix:nonFraction>% in the year ended December&#160;31, 2023 (during the years ended December&#160;31, 2022 and 2021: <ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-756">27.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-757">30.7</ix:nonFraction>%, respectively). Deferred taxes are calculated at a rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="bntx:TaxRateOnDeferredTaxes" scale="-2" id="f-758">27.1</ix:nonFraction>%. Current taxes for Austria are calculated at a corporate tax rate of <ix:nonFraction unitRef="number" contextRef="c-222" decimals="3" name="bntx:CorporateTaxRate" scale="-2" id="f-759">24.0</ix:nonFraction>%. Austria&#8217;s decrease of its corporate tax rate down to <ix:nonFraction unitRef="number" contextRef="c-222" decimals="3" name="bntx:DecreaseInCorporateTaxRate" scale="-2" id="f-760">23.0</ix:nonFraction>% in 2024 is be recognized from 2023 onwards for deferred taxes. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (<ix:nonFraction unitRef="number" contextRef="c-171" decimals="3" name="bntx:FederalCorporateIncomeTax" scale="-2" id="f-761">21.0</ix:nonFraction>%) as well as State Income Tax in various state jurisdictions (effective rate of <ix:nonFraction unitRef="number" contextRef="c-171" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-762">4.5</ix:nonFraction>%). The deferred tax rates calculations basis remained unchanged compared to the previous period.</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" id="f-763" escape="true"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the current and deferred taxes for the periods indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CurrentTaxExpenseIncome" scale="6" id="f-764">243.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-765">3,629.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CurrentTaxExpenseIncome" format="ixt:num-dot-decimal" scale="6" id="f-766">4,535.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-767">12.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-768">109.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncome" scale="6" id="f-769">218.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-770">255.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-771">3,519.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-772">4,753.9</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-752-2" continuedAt="f-752-3"><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" id="f-773" escape="true"><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"/><td style="width:55.454%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Profit before tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-774">1,186.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-775">12,954.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-776">15,046.4</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected tax credit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" scale="6" id="f-777">321.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-778">3,529.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-779">4,622.5</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effects </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to local tax basis</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:TaxEffectOfDeviationDueToLocalTaxBasis" scale="6" id="f-780">6.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:TaxEffectOfDeviationDueToLocalTaxBasis" scale="6" id="f-781">8.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:TaxEffectOfDeviationDueToLocalTaxBasis" scale="6" id="f-782">9.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to deviating income tax rate (Germany and foreign countries)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="6" id="f-783">0.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="6" id="f-784">7.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="6" id="f-785">9.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:TaxEffectOfChangeInValuationAllowance" scale="6" id="f-786">14.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:TaxEffectOfChangeInValuationAllowance" scale="6" id="f-787">30.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:TaxEffectOfChangeInValuationAllowance" scale="6" id="f-788">3.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects from tax losses and tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:TaxEffectOfTaxLosses" scale="6" id="f-789">66.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:TaxEffectOfTaxLosses" scale="6" id="f-790">23.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:TaxEffectOfTaxLosses" scale="6" id="f-791">19.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in deferred taxes due to tax rate change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="6" id="f-792">2.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="6" id="f-793">2.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:TaxEffectFromChangeInTaxRate" scale="6" id="f-794">7.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-deductible expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="6" id="f-795">3.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="6" id="f-796">2.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="6" id="f-797">90.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:TaxEffectNonTaxEffectiveIncome" scale="6" id="f-798">0.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="bntx:TaxEffectNonTaxEffectiveIncome" scale="6" id="f-799">87.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:TaxEffectNonTaxEffectiveIncome" scale="6" id="f-800">0.3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective share-based payment expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" scale="6" id="f-801">7.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" scale="6" id="f-802">8.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" scale="6" id="f-803">15.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax-effective equity transaction costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:TaxEffectiveEquityTransactionCosts" format="ixt:fixed-zero" scale="6" id="f-804">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:TaxEffectiveEquityTransactionCosts" format="ixt:fixed-zero" scale="6" id="f-805">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:TaxEffectiveEquityTransactionCosts" scale="6" id="f-806">1.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjustment prior year taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="6" id="f-807">5.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="6" id="f-808">31.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" scale="6" id="f-809">2.9</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-tax effective bargain purchase</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:NonTaxEffectiveBargainPurchase" format="ixt:fixed-zero" scale="6" id="f-810">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:NonTaxEffectiveBargainPurchase" format="ixt:fixed-zero" scale="6" id="f-811">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:NonTaxEffectiveBargainPurchase" scale="6" id="f-812">0.7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other effects</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="6" id="f-813">5.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="6" id="f-814">30.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="6" id="f-815">3.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="f-816">255.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-817">3,519.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="f-818">4,753.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-819">21.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-820">27.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" id="f-821">31.6</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2018, we established a share option program pursuant to which we were permitted to grant selected employees and our Management Board options to receive shares in the Company. The program is designed as an Employee Stock Ownership Plan, or ESOP. We offered the participants a certain number of rights, or option rights, subject to their explicit acceptance. Grants under the ESOP took place from November 2018 until December 2019. An exercise of option rights in accordance with the terms of the ESOP gives a participant the right to obtain shares against payment of the exercise price. By way of an updated decision of the Supervisory Board at the end of September 2022 compared to the initial settlement mechanism, an ESOP settlement may be made by delivery to the participant of such number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The respective number of ADS shall be settled with ADS acquired in the course of the share repurchase program. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise are paid in cash directly to the respective authorities. Expenses for taxation purposes resulting from the settlement are only recognized once the option rights have been exercised. After considering the settlements in the twelve months ended December 31, 2023 and taking into account the recognition criteria of IAS 12, a deferred tax is not recognized in our consolidated statement of financial position of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:DeferredTaxAssetsSettlement" format="ixt:num-dot-decimal" scale="6" id="f-822">17.8</ix:nonFraction>&#160;million&#160;which relates to future settlements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current tax savings associated with the excess were directly recognized in equity in a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" format="ixt:num-dot-decimal" scale="6" id="f-823">19.8</ix:nonFraction>&#160;million. Considering these tax amounts directly recognized in equity when calculating an effective tax rate, the tax rate would be decreased by about 1.6 percentage points. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intended settlement mechanism of Option Rights of the Chief Executive Officer Grant (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for plan details) led to a deferred tax asset in the total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-223" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-824">108.8</ix:nonFraction>&#160;million as of December&#160;31, 2023. Taking into account the </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-752-3" continuedAt="f-752-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognition criteria of IAS 12 this deferred tax asset is not recognized in our consolidated statements of profit or loss neither recognized directly in equity as other reserves in our consolidated statements of changes in stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-825" continuedAt="f-825-1" escape="true"><div style="margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes for the periods indicated relate to the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:42.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-826">15.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-827">20.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-828">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-225" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-829">44.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-226" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-830">8.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-831">55.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-832">0.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-833">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-228" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-834">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-229" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-835">56.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-836">148.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-837">35.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-838">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-231" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-839">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-232" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-840">113.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-841">162.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-842">72.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-843">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-234" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-844">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-235" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-845">90.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-846">55.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-847">2.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-848">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-237" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-849">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-238" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-850">57.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-851">10.0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-852">33.0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-853">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-855">43.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-856">7.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-857">2.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-243" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-244" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-860">4.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-861">0.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-862">0.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-863">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-246" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-864">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-247" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-865">0.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-866">188.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-867">12.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-249" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-869">58.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-250" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-870">142.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-871">11.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-872">1.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-873">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-252" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-874">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-253" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-875">9.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-876">61.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-877">106.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-878">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-255" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-879">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-256" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-880">44.9</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-881">99.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-882">5.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-883">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-258" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-259" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-885">94.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-886">360.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-887">77.8</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-888">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-889">102.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-890">179.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-891">136.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-892">65.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-893">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-264" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-894">66.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-895">138.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-896">223.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-897">12.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-898">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-899">169.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-900">41.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-266" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-901">229.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-902">20.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-903">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-267" decimals="-5" sign="-" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-904">169.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-268" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-905">81.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax liability</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-269" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-906">6.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-907">33.5</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-908">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-270" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" format="ixt:fixed-zero" scale="6" id="f-909">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-271" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-910">39.7</ix:nonFraction>)</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-752-4" continuedAt="f-752-5"><ix:continuation id="f-825-1"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:42.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.231%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-272" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-911">6.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-912">22.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-913">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-273" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-914">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-224" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-915">15.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-274" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-916">47.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-917">8.3</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-918">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-275" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-919">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-227" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-920">55.8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-276" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-921">1.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-922">147.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-923">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-277" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-230" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-925">148.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-278" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-926">95.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-927">67.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-928">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-279" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-929">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-233" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-930">162.7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-280" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-931">48.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-932">6.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-933">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-281" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-934">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-236" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-935">55.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-282" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-936">23.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-937">15.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-938">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-283" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-939">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-242" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-940">7.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-284" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-941">10.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-942">20.6</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-943">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-285" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-944">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-239" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-945">10.0</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-286" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-946">0.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-947">0.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" scale="6" id="f-948">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-287" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-949">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-245" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-950">0.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-288" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-951">6.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-952">4.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-953">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-289" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-954">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-251" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-955">11.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-290" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-956">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-957">8.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-958">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-291" decimals="-5" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" scale="6" id="f-959">179.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-248" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-960">188.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-292" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-961">1.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-962">59.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-963">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-293" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-964">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-254" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-965">61.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-294" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-966">70.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-967">28.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-968">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-295" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-969">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-257" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-970">99.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-971">14.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-972">165.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" scale="6" id="f-973">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" scale="6" id="f-974">179.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-975">360.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-976">81.0</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-5" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-977">55.7</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="f-978">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-299" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="6" id="f-979">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-980">136.7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-981">66.7</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="6" id="f-982">109.9</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" scale="6" id="f-983">0.3</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" scale="6" id="f-984">179.9</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-985">223.4</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our accumulated tax losses comprised tax losses of German entities that were incurred prior to the establishment of a tax group with BioNTech SE or by entities that are not within the tax group (as of December&#160;31, 2023: BioNTech Real Estate Verwaltungs GmbH; as of December&#160;31, 2022: BioNTech BioNTainer Holding GmbH, BioNTech Idar-Oberstein Services GmbH, NT Security and Services GmbH, BioNTech Real Estate Verwaltungs GmbH and the Real Estate partnerships) or U.S. tax group. </span><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" id="f-986" continuedAt="f-986-1" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:</span></ix:nonNumeric></div><ix:continuation id="f-986-1"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AccumulatedTaxLossesInCorporateTax" scale="6" id="f-987">260.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AccumulatedTaxLossesInCorporateTax" scale="6" id="f-988">352.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:AccumulatedTaxLossesInCorporateTax" scale="6" id="f-989">272.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade tax </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AccumulatedTaxLossesInTradeTax" scale="6" id="f-990">140.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AccumulatedTaxLossesInTradeTax" scale="6" id="f-991">204.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:AccumulatedTaxLossesInTradeTax" scale="6" id="f-992">170.6</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AccumulatedTaxLossesInFederalTaxCredits" scale="6" id="f-993">21.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AccumulatedTaxLossesInFederalTaxCredits" scale="6" id="f-994">4.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:AccumulatedTaxLossesInFederalTaxCredits" scale="6" id="f-995">0.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax credits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:AccumulatedTaxLossesInStateTaxCredits" scale="6" id="f-996">8.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:AccumulatedTaxLossesInStateTaxCredits" scale="6" id="f-997">1.6</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:AccumulatedTaxLossesInStateTaxCredits" scale="6" id="f-998">0.3</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023, deferred tax assets on tax losses were only partially recognized, as there was not sufficient probability in terms of IAS 12 that future taxable profits would have been available against which all the unused tax losses could have been utilized. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deductible temporary differences, unused tax losses, and unused tax credits for which no deferred tax asset is recognized in the statement of financial position as of December 31, 2023 is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-300" decimals="-5" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="6" id="f-999">531.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Thus a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, we have not recognized deferred tax assets for unused tax losses and temporary differences in an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-265" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1000">138.0</ix:nonFraction>&#160;million (December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-263" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" scale="6" id="f-1001">136.7</ix:nonFraction>&#160;million 31&#160;December 2021 &#8364;<ix:nonFraction unitRef="eur" contextRef="c-298" decimals="-5" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1002">81.0</ix:nonFraction>&#160;million).</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span><br/></span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-752-5"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reorganization of the intellectual property rights within the group became effective as of June 30, 2023 and July 1, 2023 which led to deferred tax effects in Germany, the U.S. and Austria. As a result, BioNTech SE recognized deferred tax assets and deferred tax income at the time of the transaction. In addition, this transaction led to a revaluation of previously unrecognized U.S. federal and state deferred tax assets, including unused tax losses and unused tax credits. As of December 31, 2022, there were unrecognized U.S. federal and state deferred tax assets of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:StateDeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1003"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:FederalDeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1004">128.9</ix:nonFraction></ix:nonFraction>&#160;million. As of December 31, 2023, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future, fulfilling the requirements set out by IAS 12. Therefore we no longer continue to maintain the full non-recognition of deferred tax assets of our U.S. tax group as there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized. As of December 31, 2023, we maintain the non-recognition of deferred tax assets for unused U.S. federal and state tax losses and tax credits at an amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-301" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1005">31.9</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-302" decimals="-5" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1006">2.8</ix:nonFraction>&#160;million, respectively, as there is not sufficient probability in terms of IAS 12 that future taxable income will be available against which these unused tax losses can be utilized. The material unrecognized U.S. federal and state tax losses and tax credits will begin to expire in 2036. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group does not recognize deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries, in cases where the Group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries, for which deferred tax liabilities have not been recognized, is &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="6" id="f-1007">2.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_460"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-1008" continuedAt="f-1008-1" escape="true">Earnings per Share</ix:nonNumeric></span></div><ix:continuation id="f-1008-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year, plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-1009" escape="true"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the income and share data used in the basic and diluted EPS calculations:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;, except per share data)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit attributable to ordinary equity holders of the parent for basic earnings </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" scale="6" id="f-1010">930.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-1011">9,434.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="6" id="f-1012">10,292.5</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average number of ordinary shares outstanding for basic EPS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:WeightedAverageShares" scale="6" id="f-1013">240.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="ifrs-full:WeightedAverageShares" scale="6" id="f-1014">243.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="ifrs-full:WeightedAverageShares" scale="6" id="f-1015">244.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of dilution from share options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-1016">2.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-1017">6.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" scale="6" id="f-1018">15.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average number of ordinary shares outstanding adjusted for the effect of dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" scale="6" id="f-1019">242.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" scale="6" id="f-1020">249.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-5" name="ifrs-full:AdjustedWeightedAverageShares" scale="6" id="f-1021">259.7</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings for the period per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1022">3.87</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-12" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1023">38.78</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-13" decimals="2" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-1024">42.18</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted earnings for the period per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-1" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1025">3.83</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-12" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1026">37.77</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-13" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-1027">39.63</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-44</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_439"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">10&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="f-1028" continuedAt="f-1028-1" escape="true">Other Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-1028-1" continuedAt="f-1028-2"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" id="f-1029" continuedAt="f-1029-1" escape="true"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:84.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Goodwill</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-303" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1030">57.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-304" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1031">3.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1032">61.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-305" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1033">61.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" scale="6" id="f-1034">306.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-306" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1035">5.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-307" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1036">362.5</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets with Indefinite Useful Lives</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" id="f-1037" escape="true"><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:19.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.876%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CGU Immunotherapies</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Product Sales of JPT</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Business of InstaDeep</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1038">352.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1039">60.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1040">0.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1041">0.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1042">9.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-5" name="ifrs-full:Goodwill" format="ixt:fixed-zero" scale="6" id="f-1043">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1044">362.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Goodwill" scale="6" id="f-1045">61.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful life</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" scale="6" id="f-1046">444.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1047">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1048">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1049">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1050">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1051">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" scale="6" id="f-1052">444.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife" format="ixt:fixed-zero" scale="6" id="f-1053">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-308" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1054">796.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-309" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1055">60.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-310" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1056">0.5</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-311" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1057">0.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-312" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1058">9.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-313" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1059">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1060">807.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" scale="6" id="f-1061">61.2</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we have total goodwill of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1062">362.5</ix:nonFraction> million, which relates almost completely to the CGU immunotherapies. The CGU immunotherapies focuses on the development of therapies to address a range of rare and infectious diseases and comprises our broad pipeline that includes mRNA-based immune activators, antigen-targeting T&#160;cells and antibodies and defined immunomodulators of various immune cell mechanisms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed our annual impairment test in October 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of the CGU immunotherapies has been determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as an observable input parameter. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of the CGU JPT and the CGU external business of InstaDeep has been determined based on the value in use. In assessing value in use, the estimated future cash flows, which are derived based on the strategic business plan approved by the management, are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the assets. A long-term growth rate of <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" scale="-2" id="f-1063">1.0</ix:nonFraction>% is applied to project future cash flows after the last year of the detailed planning period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the analysis in October 2023, we did not identify an impairment for these CGUs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives mainly comprised intangible assets not yet available for use of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1064">443.5</ix:nonFraction>&#160;million. Such assets are not amortized and therefore reviewed for impairment annually. An impairment test was performed on an individual basis of the assets in the fourth quarter of 2023. The recoverable amounts were determined based on value in use. The results did not give rise to any impairment losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering updated financial information regarding our COVID 19 vaccine business an additional impairment test for our CGU immunotherapies was performed as of December 31, 2023. The recoverable amount of the CGU immunotherapies was once again determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as of December 31, 2023. </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1028-2" continuedAt="f-1028-3"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the additional analysis for the CGU immunotherapies, we did not identify an impairment for the CGU immunotherapies. Even if our market capitalization had been approximately 10% lower, FVLCD would have still been above the respective carrying amount of the CGU. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets resulting from licensing and collaboration agreements are combined into one class of assets due to their similar nature and use in our operations and are attributed to the CGU immunotherapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of the key assumptions, future cash flows and weighted average cost of capital, was performed as part of the scheduled impairment testing of the intangible assets not yet available for use. The sensitivity analysis did not give rise to any impairment loss, either for a reduction of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="bntx:PercentageOfImpairmentLossForAReductionOfFutureCashFlows" scale="-2" id="f-1065">10</ix:nonFraction>% in future cash flows or for a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" scale="-2" id="f-1066">10</ix:nonFraction>% increase in the weighted average cost of capital.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:continuation id="f-1029-1" continuedAt="f-1029-2"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-314" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1067">191.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-315" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1068">7.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1069">199.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1070">22.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1071">11.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1072">34.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1073">0.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1074">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1075">0.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1076">6.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1077">6.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1078">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-316" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1079">1.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-317" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1080">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1081">1.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1082">222.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1083">13.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1084">235.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-318" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1085">222.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-319" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1086">13.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1087">235.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1088">489.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1089">15.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="6" id="f-1090">505.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" scale="6" id="f-1091">187.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1092">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" scale="6" id="f-1093">187.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1094">1.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1095">1.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1096">3.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1097">4.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" scale="6" id="f-1098">4.9</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1099">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-320" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1100">3.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-321" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1101">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1102">3.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-322" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1103">898.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-323" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1104">22.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1105">921.0</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative amortization and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-324" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1106">54.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-325" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1107">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1108">54.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-5" sign="-" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" scale="6" id="f-1109">22.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-5" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" format="ixt:fixed-zero" scale="6" id="f-1110">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" sign="-" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" scale="6" id="f-1111">22.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-5" sign="-" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1112">0.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" sign="-" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1114">0.1</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-327" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1115">0.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-328" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1116">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1117">0.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1118">76.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1119">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1120">76.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-330" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1121">76.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-331" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1122">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1123">76.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-5" sign="-" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" scale="6" id="f-1124">40.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-5" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" format="ixt:fixed-zero" scale="6" id="f-1125">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" sign="-" name="bntx:AccumulatedDepreciationAmortisationAndImpairment" scale="6" id="f-1126">40.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-5" sign="-" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1127">0.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-5" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1128">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" sign="-" name="ifrs-full:DisposalsIntangibleAssetsAndGoodwill" scale="6" id="f-1129">0.3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-333" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1130">0.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-334" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1131">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="6" id="f-1132">0.2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-336" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1133">116.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-337" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:fixed-zero" scale="6" id="f-1134">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-5" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1135">116.9</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1028-3"><ix:continuation id="f-1029-2"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-339" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1136">145.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-340" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1137">13.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1138">158.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-341" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1139">781.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-342" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1140">22.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="6" id="f-1141">804.1</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other intangible assets by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncreaseDecreaseInIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1142">645.6</ix:nonFraction>&#160;million from December 31, 2022 to December&#160;31, 2023 was mainly related to the acquisition of InstaDeep (see</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note 5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and licenses fulfilling the definition of identifiable assets acquired. We entered into license and collaboration agreements in which we work together with partners to develop pharmaceutical products and, provided regulatory approval is granted, commercialize them. The upfront payments in connection with the license and collaboration agreements described below resulted in the recognition of intangible assets not yet available for use in the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1143">443.5</ix:nonFraction>&#160;million and a prepayment for future development activities recognized in the other non-financial assets (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:PrepaymentForFutureDevelopmentActivities" format="ixt:num-dot-decimal" scale="6" id="f-1144">22.5</ix:nonFraction>&#160;million as at December&#160;31, 2023, see also Note 14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into license and collaboration agreements with Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, or Duality, for exclusive licenses to two investigational ADC assets (BNT323/DB-1303 and BNT324/DB-1311) directed against targets expressed in a broad range of human cancers. In August 2023, we signed another exclusive agreement with Duality to develop, manufacture and commercialize an additional ADC, BNT325/DB-1305. Duality received upfront payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1145">220.0</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-343" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1146">203.7</ix:nonFraction>&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into a licensing and collaboration agreement with OncoC4 Inc., Rockville (Maryland), United States, or OncoC4, which includes joint development of BNT316/ONC-392 in a range of solid tumor indications, with the parties equally sharing development costs for such joint development studies. BioNTech holds the exclusive worldwide commercialization rights for this product candidate. OncoC4 received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1147">200.0</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-344" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1148">181.5</ix:nonFraction>&#160;million, thereof &#8364;<ix:nonFraction unitRef="eur" contextRef="c-345" decimals="-5" name="bntx:UpfrontPaymentAcquisitionOfIntangibleAsset" format="ixt:num-dot-decimal" scale="6" id="f-1149">125.2</ix:nonFraction>&#160;million paid for the acquisition of an intangible asset) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we entered into a strategic research collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd., or MediLink Therapeutics, for the development of a next-generation ADC, BNT326/YL202, against Human Epidermal Growth Factor Receptor 3 (HER3). MediLink Therapeutics received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1150">70.0</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-346" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1151">64.1</ix:nonFraction>&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we entered into an exclusive global license and collaboration with Biotheus Inc., or Biotheus, under which we will be developing, manufacturing and commercializing Biotheus&#8217; bispecific antibody candidate BNT327/PM8002 globally ex-Greater China. We agreed to an upfront payment of  $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1152">55.0</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-347" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-1153">50.6</ix:nonFraction>&#160;million) plus future milestone and royalty payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">In July 2023, in connection with the acquisition of InstaDeep we acquired DeepChain technology. As of December&#160;31, 2023 the book value of DeepChain technology amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-348" decimals="-5" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1154">163.3</ix:nonFraction>&#160;million with a remaining useful life of <ix:nonNumeric contextRef="c-349" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-1155">6.6</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-47</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_445"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">11&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-1156" continuedAt="f-1156-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-1156-1"><ix:continuation id="f-431-1"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition and production costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-350" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1157">104.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-351" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1158">198.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-352" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1159">94.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-296" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1160">396.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1161">100.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1162">46.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1163">182.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1164">329.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1165">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1166">1.1</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1167">0.5</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1168">1.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1169">12.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1170">28.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-5" sign="-" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1171">40.2</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1172">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-353" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1173">0.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-354" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1174">0.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-355" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1175">0.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-297" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1176">1.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1177">217.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1178">273.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1179">235.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1180">725.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-356" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1181">217.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-357" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1182">273.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-358" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1183">235.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-260" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1184">725.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1185">9.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1186">50.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1187">189.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1188">249.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1189">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1190">2.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1191">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="6" id="f-1192">2.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1193">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1194">2.4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1195">0.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1196">2.6</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1197">9.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1198">22.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-5" sign="-" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" scale="6" id="f-1199">31.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" name="bntx:ReclassificationsOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1200">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-359" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1201">0.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-360" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1202">1.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-361" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1203">3.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-261" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1204">5.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-362" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1205">235.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-363" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1206">344.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-364" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1207">389.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-262" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1208">969.0</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative depreciation and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-365" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1209">14.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-366" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1210">60.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-367" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1211">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-326" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1212">74.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1213">7.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1214">34.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1215">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1216">42.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1217">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-5" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1218">0.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1219">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1220">0.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-368" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1221">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-369" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1222">0.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-370" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1223">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-329" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1224">0.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1225">22.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1226">94.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1227">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1228">116.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-371" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1229">22.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1230">94.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-373" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1231">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-332" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1232">116.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1233">14.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1234">83.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1235">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="6" id="f-1236">97.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1237">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-5" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1238">1.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-5" name="ifrs-full:DisposalsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1239">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="6" id="f-1240">1.7</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-374" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1241">0.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1242">0.3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-376" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1243">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-335" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="6" id="f-1244">0.5</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-377" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1245">36.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1246">175.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-379" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-1247">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-338" decimals="-5" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1248">211.8</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-380" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1249">195.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1250">178.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-382" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1251">235.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1252">609.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-383" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1253">199.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-384" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1254">168.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-385" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1255">389.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="f-1256">757.2</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current Assets by Region</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, non-current assets comprised &#8364;<ix:nonFraction unitRef="eur" contextRef="c-386" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1257">158.2</ix:nonFraction> million in other intangible assets, goodwill, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States (as of December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-387" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1258">188.0</ix:nonFraction> million) as well as &#8364;<ix:nonFraction unitRef="eur" contextRef="c-388" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1259">511.7</ix:nonFraction> million in the United Kingdom (as of December&#160;31, 2022: <ix:nonFraction unitRef="eur" contextRef="c-389" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:fixed-zero" scale="6" id="f-1260">nil</ix:nonFraction>), respectively. The remaining non-current assets of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-390" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1261">1,469.0</ix:nonFraction> million (as of December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-391" decimals="-5" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="f-1262">871.9</ix:nonFraction> million) mainly relate to entities incorporated in Germany.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-48</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_425"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">12&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" id="f-1263" continuedAt="f-1263-1" escape="true">Financial Assets and Financial Liabilities</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_419"></div><ix:continuation id="f-1263-1" continuedAt="f-1263-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.1&#160;&#160;&#160;&#160;Capital Risk Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital management objectives are designed primarily to finance our growth strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our treasury committee reviews the total amount of cash and cash equivalents on a regular basis. As part of this review, the committee considers total cash and cash equivalents, cash outflow, currency translation differences and refinancing activities. We monitor cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" id="f-1264" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Cash" scale="6" id="f-1265">453.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="6" id="f-1266">1,325.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash equivalents</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1267">11,210.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1268">12,549.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-392" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1269">2,589.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-393" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1270">9,401.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-394" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1271">7,446.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-395" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1272">3,148.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-396" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1273">1,175.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-397" decimals="-5" name="ifrs-full:CashEquivalents" format="ixt:fixed-zero" scale="6" id="f-1274">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1275">11,663.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1276">13,875.1</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the aim is to protect and maximize the financial resources available for further research and development projects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since December 1, 2021, we have an investment and asset management policy in place that contains policies and processes for managing cash and cash equivalents. Under this policy, our investment portfolio is to be maintained in a manner that minimizes risks to the invested capital. These risks include mainly credit risk and concentration risk. The portfolio must provide liquidity in a timely manner to accommodate operational and capital needs. The portfolio is managed by the Treasury department.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements. Our capital management objectives were achieved in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-49</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_413"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1263-2" continuedAt="f-1263-3"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.2&#160;&#160;&#160;&#160;Categories of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-1278" continuedAt="f-1278-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-1277" continuedAt="f-1277-1" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:26.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-398" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1279">7,446.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-399" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1280">7,446.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-400" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1281">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-401" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1282">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-402" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1283">7,446.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-403" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1284">27.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-404" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1285">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-405" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1286">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-406" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1287">27.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-407" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1288">27.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-408" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1289">26.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-409" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1290">26.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-410" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1291">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-411" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1292">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-412" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1293">26.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-413" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1294">2,155.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-414" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1295">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-415" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1296">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-416" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1297">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-417" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1298">2,155.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-418" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1299">5,989.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-419" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1300">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-420" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1301">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-421" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1302">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-422" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1303">5,989.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-423" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1304">18.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-424" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1305">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-425" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1306">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-426" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1307">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-427" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1308">18.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-428" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1309">2,589.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-429" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1310">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-430" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1311">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-431" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1312">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-432" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1313">2,589.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-433" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1314">1,175.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-434" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1315">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-435" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1316">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-436" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1317">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-437" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1318">1,175.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-438" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1319">453.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-439" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1320">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-440" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1321">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-441" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1322">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-442" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1323">453.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-443" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1324">0.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-444" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1325">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-445" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1326">0.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-446" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1327">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-447" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1328">0.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-448" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1329">38.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-449" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1330">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-450" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1331">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-451" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1332">38.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-452" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1333">38.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-453" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1334">216.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-454" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1335">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-455" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1336">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-456" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1337">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-457" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1338">216.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-458" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1339">2.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-459" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1340">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-460" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1341">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-461" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1342">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-462" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1343">2.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-463" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1344">354.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-464" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1345">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-465" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1346">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-466" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1347">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-467" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1348">354.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-468" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1349">414.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-469" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1350">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-470" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1351">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-471" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1352">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-472" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1353">414.9</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. </span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1263-3" continuedAt="f-1263-4"><ix:continuation id="f-1278-1" continuedAt="f-1278-2"><ix:continuation id="f-1277-1" continuedAt="f-1277-2"><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"><tr><td style="width:1.0%"/><td style="width:24.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-473" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1354">183.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-474" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1355">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-475" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1356">183.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-476" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1357">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-477" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1358">183.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-478" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1359">3,148.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-479" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1360">3,148.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-480" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1361">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-481" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1362">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-482" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1363">3,148.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-483" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1364">57.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-484" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1365">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-485" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1366">57.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-486" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1367">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-487" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1368">57.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-488" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1369">20.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-489" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1370">20.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-490" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1371">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-491" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1372">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-492" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1373">20.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-493" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1374">7,145.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-494" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1375">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-495" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1376">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-496" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1377">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-497" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1378">7,145.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-498" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1379">8.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-499" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1380">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-500" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1381">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-501" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1382">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-502" decimals="-5" name="ifrs-full:FinancialAssets" scale="6" id="f-1383">8.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-503" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1384">9,401.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-504" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1385">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-505" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1386">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-506" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1387">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-507" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1388">9,401.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-508" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1389">1,325.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-509" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1390">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-510" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1391">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-511" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="6" id="f-1392">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-512" decimals="-5" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="6" id="f-1393">1,325.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-513" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1394">6.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-514" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1395">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-515" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1396">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-516" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1397">6.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-517" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1398">6.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-518" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1399">210.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-519" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1400">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-520" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1401">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-521" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1402">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-522" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1403">210.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-523" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1404">2.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-524" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1405">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-525" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1406">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-526" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1407">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-527" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1408">2.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-528" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1409">204.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-529" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1410">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-530" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1411">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-531" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1412">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-532" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1413">204.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-533" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1414">785.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-534" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1415">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-535" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1416">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-536" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1417">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-537" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1418">785.1</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity investments designated at Fair Value through OCI</span></div><ix:continuation id="f-1278-2"><div style="margin-top:6pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:32.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.365%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.367%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net gain on equity instruments designated at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-538" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-1419">3.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-539" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-1420">10.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-1421">3.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" scale="6" id="f-1422">10.5</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of fair values</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="f-1423" continuedAt="f-1423-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:23.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Type</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Valuation technique</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Significant unobservable inputs</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1423-1" continuedAt="f-1423-2"><ix:continuation id="f-1263-4" continuedAt="f-1263-5"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:23.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward exchange contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Actual and forecasted results</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Cash position</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Nature and pricing indication of latest financing round</span></div><div style="text-indent:10.91pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quoted prices on an active market</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. </span></div></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Expected future payments</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Applied cost of capital</span></div></td></tr></table></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_407"></div><ix:continuation id="f-1263-5" continuedAt="f-1263-6"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.3&#160;&#160;&#160;&#160;Recurring Fair Values (Level 3)</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="f-1424" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the recurring fair value measurement of the contingent considerations and the effect of the measurements on our consolidated statements of profit or loss for the current period.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:38.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.367%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contingent consideration</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-540" decimals="-5" name="ifrs-full:Liabilities" scale="6" id="f-1425">6.1</ix:nonFraction></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-541" decimals="-5" name="ifrs-full:Liabilities" scale="6" id="f-1426">6.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-5" name="ifrs-full:PurchasesFairValueMeasurementLiabilities" scale="6" id="f-1427">31.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net effect on profit or loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net change in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-542" decimals="-5" name="bntx:NetChangeInFairValue" scale="6" id="f-1428">0.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-543" decimals="-5" name="ifrs-full:Liabilities" scale="6" id="f-1429">38.8</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:continuation id="f-1423-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sensitivity of the fair values of contingent considerations in fair value level 3 to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:33.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input factor</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in assumptions</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with increasing input factor (in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with decreasing input factor (in millions &#8364;)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flow projections</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-544" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1430">10</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-5" name="ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" scale="6" id="f-1431">3.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-545" decimals="-5" name="ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" scale="6" id="f-1432">3.4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-546" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="f-1433">1</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-5" name="ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" scale="6" id="f-1434">0.8</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-547" decimals="-5" name="ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" scale="6" id="f-1435">0.8</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of non-listed equity investments would, for example, increase (decrease) if price of latest financing round were to increase (decrease) and the overall company value were higher (lower).</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_401"></div><ix:continuation id="f-1263-6" continuedAt="f-1263-7"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.4&#160;&#160;&#160;&#160;Financial Instruments Risk Management Objectives and Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial liabilities mainly comprise obligations derived from license agreements, trade and other payables, lease liabilities, contingent consideration, loans and borrowings, hedging liabilities as well as other financial liabilities. The main purpose of these financial liabilities is to enable our operations. Our principal financial assets include mainly cash, security investments and trade receivables that derive directly from our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk, credit risk and liquidity risk. Our Management Board oversees the management of these risks. </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1263-7" continuedAt="f-1263-8"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treasury committee provides assurance to our Management Board that our financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with our policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_395"></div><ix:continuation id="f-1263-8" continuedAt="f-1263-9"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.5&#160;&#160;&#160;&#160;Market Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risks address the risks that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risks comprise three types of risk: interest risks, foreign currency risks and other price risks. Financial instruments affected by market risks include financial assets such as security investments, trade and other receivables, cash and cash equivalents as well as financial liabilities such as trade payables and other financial liabilities. We do not consider interest risks as well as other price risks as material risks to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in the way the risks were managed and valued during the years ended December 31, 2023, and 2022. Because of the significantly higher cash balance and security investments &#8211; the market risk exposure on counterparty risk increased compared to the previous period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign currency risks address the risks that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to currency risks, as our income and expenditures are denominated in Euro and the U.S. dollar. As such, we are exposed to exchange rate fluctuations between these currencies. Cash inflows denominated in U.S. dollar mainly result </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from generating proceeds under our collaboration agreements. Our commercial revenues are primarily collaboration revenues from earnings based on our partners&#8217; gross profit, which is shared under the respective collaboration agreements and represents payments we receive in U.S. dollar. Cash outflows dominated in U.S. dollar mainly result from amounts spent on research and development activities and license obligations as well as expanding our global footprint further. With the aim of preserving capital, surplus liquidity is mainly invested in domestic currency investments as exchange rate fluctuations can reduce the value of our financial positions. We limit the effects of the identified risks by means of a coordinated and </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consistently</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> implemented risk strategy. Besides applying natural hedging relationships where possible, foreign exchange forward contracts are concluded, as a matter of principle, as instruments to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> mitigate foreign currency exchange risk associated with foreign currency-denominated payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. However, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he foreign exchange forward contracts which we entered into were not designated as hedging instruments under IFRS.</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" id="f-1436" continuedAt="f-1436-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the monetary assets and liabilities denominated in U.S. dollar at the dates indicated are as follows:</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><ix:continuation id="f-1436-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents in U.S. dollar</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-548" decimals="-5" name="bntx:CashAndCashEquivalent" scale="6" id="f-1437">122.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-549" decimals="-5" name="bntx:CashAndCashEquivalent" format="ixt:num-dot-decimal" scale="6" id="f-1438">1,487.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary assets in U.S. dollar</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-550" decimals="-5" name="bntx:CashAndCashEquivalent" format="ixt:num-dot-decimal" scale="6" id="f-1439">1,191.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-551" decimals="-5" name="bntx:CashAndCashEquivalent" format="ixt:num-dot-decimal" scale="6" id="f-1440">7,098.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary liabilities and provisions in U.S. dollar</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-552" decimals="-5" name="bntx:CashAndCashEquivalent" scale="6" id="f-1441">567.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-553" decimals="-5" name="bntx:CashAndCashEquivalent" format="ixt:num-dot-decimal" scale="6" id="f-1442">1,527.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:CashAndCashEquivalent" scale="6" id="f-1443">747.2</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:CashAndCashEquivalent" format="ixt:num-dot-decimal" scale="6" id="f-1444">7,058.1</ix:nonFraction></span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" id="f-1445" continuedAt="f-1445-1" escape="true"><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables demonstrate the sensitivity to a reasonable, possible change in U.S. dollar exchange rates or U.S. dollar forward rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets and liabilities. The exposure to foreign currency changes for all other currencies is not material.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:26.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.845%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1 &#8364; =</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="6" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing rate</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Country</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. dollar</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-554" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-1446">1.1050</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-555" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="f-1447">1.0666</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-556" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-1448">1.0813</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-557" decimals="4" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="f-1449">1.0530</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1445-1"><ix:continuation id="f-1263-9" continuedAt="f-1263-10"><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in U.S. dollar rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on profit / (loss) before tax</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on pre-tax equity</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-5" sign="-" name="bntx:ForeignCurrencyChangesEffectOnLossBeforeTax" scale="6" id="f-1450">35.5</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-558" decimals="-5" sign="-" name="bntx:ForeignCurrencyChangesEffectOnPretaxEquity" scale="6" id="f-1451">35.5</ix:nonFraction>)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-5" name="bntx:ForeignCurrencyChangesEffectOnLossBeforeTax" scale="6" id="f-1452">39.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-559" decimals="-5" name="bntx:ForeignCurrencyChangesEffectOnPretaxEquity" scale="6" id="f-1453">39.3</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-5" sign="-" name="bntx:ForeignCurrencyChangesEffectOnLossBeforeTax" scale="6" id="f-1454">195.2</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-560" decimals="-5" sign="-" name="bntx:ForeignCurrencyChangesEffectOnPretaxEquity" scale="6" id="f-1455">191.5</ix:nonFraction>)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-5" name="bntx:ForeignCurrencyChangesEffectOnLossBeforeTax" scale="6" id="f-1456">215.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-561" decimals="-5" name="bntx:ForeignCurrencyChangesEffectOnPretaxEquity" scale="6" id="f-1457">211.7</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_389"></div><ix:continuation id="f-1263-10" continuedAt="f-1263-11"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.6&#160;&#160;&#160;&#160;Credit Risk Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risks address the risks that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risks from our operating activities, including security investments, bank deposits, reverse repos, foreign exchange transactions, trade and other receivables and cash at banks. The maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&#160;31, 2023, and December&#160;31, 2022, are the carrying amounts as illustrated in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12.2.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Investments, Bank Deposits, Reverse Repos and Cash at banks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial management is dedicated predominantly to the goal of capital preservation. Thus, all our financial activities are focused towards avoiding risks and, where they cannot be avoided, actively managing and minimizing them. Credit risks from balances with security investments, bank deposits, reverse repos and cash at banks are managed by our Treasury department in accordance with our investment and asset management policy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our security investments are solely invested in the highest-quality liquid assets (e.g. core European sovereign, supranational and agency bonds) and bank deposits with a maturity of more than 3 months (held at selected banks, exclusively rated as investment grade). They do not bear any currency risks or material credit risks. The bank deposits are held at selected banks, exclusively rated as investment grade. We limit our investment engagements individually and track each credit risk continuously. For reverse repos, only investment-grade counterparties qualify as our business partners and even secured investments are solely collateralized by high-quality liquid assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, credit risks from these financial assets are limited. Before entering into new business relationships and during ongoing business relationships, we evaluate our business partners with regard to their individual default risk. Therefore, we do not presume an increased credit risk as of the balance sheet date and determine the impairment loss based on the upcoming twelve months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculated expected credit losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not material as of December&#160;31, 2023, and December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and Other Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit risks of trade and other receivables is primarily related to transactions with corporate customers in the biopharma / biotech industry that operate in the United States or Germany, as well as </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are customers, in connection with fulfilling our commercial obligations in our territories as defined in our contracts with customers. An analysis of the aging of receivables and the creditworthiness of customers is used to evaluate this risk at each reporting date. We follow risk control procedures to assess the credit quality of our customers taking into account their financial position, past experience and other factors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, outstanding trade and other receivables were mainly due from our collaboration partner Pfizer.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Besides well-established pharmaceutical companies and governmental institutions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our other customers &#8211; to a smaller extent &#8211; are medical universities, other public institutions and peers in the biopharma industry, which have good credit ratings. Due to this customer portfolio, the credit risk on trade and other receivables is generally very low. We have not incurred material bad debt expense and do not expect that this will change with respect to the trade and other receivables outstanding as of December&#160;31, 2023. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><ix:continuation id="f-1263-11" continuedAt="f-1263-12"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected credit risk on trade and other receivables derived from applying the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simplified approach in calculating expected credit losses </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1263-12" continuedAt="f-1263-13">was not material as of December&#160;31, 2023, and December&#160;31, 2022.</ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-54</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_383"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1263-13" continuedAt="f-1263-14"><div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.7&#160;&#160;&#160;&#160;Liquidity Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to invest heavily in R&amp;D as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity management ensures the availability of cash and cash equivalents, short term financial instruments for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which are managed centrally, is always maintained to finance the operational activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor liquidity risks using a liquidity planning tool.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, the responsibility for liquidity risk management lies with our Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. We manage liquidity risks by holding appropriate reserves based on our COVID-19 sales, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities. Significant reserves currently exist and were generated during the Covid-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Concentration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations arise when the number of counterparties is small or when a larger number of counterparties is engaged in similar business activities, or activities in the same geographical region, or has economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of our performance to developments affecting a particular industry. We only have a limited number of customers mainly comprising </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical companies and governmental institutions.</span></div><ix:continuation id="f-1277-2"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" format="ixt:fixed-zero" scale="6" id="f-1458">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" scale="6" id="f-1459">2.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" format="ixt:fixed-zero" scale="6" id="f-1460">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" scale="6" id="f-1461">2.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:TradeAndOtherPayables" scale="6" id="f-1462">354.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:TradeAndOtherPayables" format="ixt:fixed-zero" scale="6" id="f-1463">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:TradeAndOtherPayables" format="ixt:fixed-zero" scale="6" id="f-1464">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:TradeAndOtherPayables" scale="6" id="f-1465">354.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1466">34.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1467">136.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1468">73.7</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1469">244.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1470">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1471">57.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1472">0.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1473">57.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1474">0.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1475">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1476">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:DerivativeFinancialLiabilities" scale="6" id="f-1477">0.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" scale="6" id="f-1478">414.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1479">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1480">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" scale="6" id="f-1481">414.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-562" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1482">803.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-563" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1483">196.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-564" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1484">74.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-565" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1485">1,073.8</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" format="ixt:fixed-zero" scale="6" id="f-1486">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" scale="6" id="f-1487">2.1</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" format="ixt:fixed-zero" scale="6" id="f-1488">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="bntx:InterestBearingLoansAndBorrowings" scale="6" id="f-1489">2.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="ifrs-full:TradeAndOtherPayables" scale="6" id="f-1490">204.1</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="ifrs-full:TradeAndOtherPayables" format="ixt:fixed-zero" scale="6" id="f-1491">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="ifrs-full:TradeAndOtherPayables" format="ixt:fixed-zero" scale="6" id="f-1492">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="ifrs-full:TradeAndOtherPayables" scale="6" id="f-1493">204.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1494">40.5</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1495">112.9</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1496">79.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-1497">232.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1498">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" format="ixt:fixed-zero" scale="6" id="f-1499">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1500">6.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination" scale="6" id="f-1501">6.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" scale="6" id="f-1502">785.1</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1503">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" format="ixt:fixed-zero" scale="6" id="f-1504">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="ifrs-full:OtherFinancialLiabilities" scale="6" id="f-1505">785.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-566" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1506">1,029.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-567" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1507">115.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-568" decimals="-5" name="ifrs-full:FinancialLiabilities" scale="6" id="f-1508">85.2</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-569" decimals="-5" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-1509">1,229.9</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-55</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_377"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1263-14"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.8&#160;&#160;&#160;&#160;Changes in Liabilities Arising from Financing Activities</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" id="f-1510" escape="true"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"/><td style="width:19.928%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2023</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1511">36.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1512">40.3</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-5" sign="-" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1513">0.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1514">34.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-571" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1515">1.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-572" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1516">28.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1517">174.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1518">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1519">51.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-5" sign="-" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1520">34.1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-574" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1521">2.5</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-575" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1522">188.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1523">2.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1524">0.2</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1525">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1526">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-577" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1527">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-578" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1528">2.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1529">212.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1530">40.1</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1531">50.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1532">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1533">3.6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1534">219.0</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"/><td style="width:19.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-579" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1535">27.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1536">41.1</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1537">14.8</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1538">33.3</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-580" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1539">1.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-570" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1540">36.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-581" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1541">153.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1542">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1543">52.6</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-5" sign="-" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1544">33.3</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-582" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1545">1.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-573" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1546">174.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-583" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1547">119.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1548">18.0</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1549">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1550">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-584" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1551">99.8</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-576" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1552">2.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note &#8211; embedded derivative</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-585" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1553">308.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1554">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1555">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1556">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-586" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1557">308.7</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-587" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1558">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-31" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1559">610.2</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1560">59.1</ix:nonFraction>)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1561">67.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-1562">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" scale="6" id="f-1563">406.3</ix:nonFraction>)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" scale="6" id="f-1564">212.2</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Related to the early redemption of our convertible note during the year ended December&#160;31, 2023, as further described in Note 15.</span></div></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_371"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">13&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="f-1565" continuedAt="f-1565-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" id="f-1566" escape="true"><ix:continuation id="f-1565-1" continuedAt="f-1565-2"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Raw materials and supplies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" scale="6" id="f-1567">347.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" scale="6" id="f-1568">409.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unfinished goods</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:WorkInProgress" scale="6" id="f-1569">4.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:WorkInProgress" scale="6" id="f-1570">21.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finished goods</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:FinishedGoods" scale="6" id="f-1571">6.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:FinishedGoods" scale="6" id="f-1572">8.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-1573">357.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Inventories" scale="6" id="f-1574">439.6</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><ix:continuation id="f-1565-2" continuedAt="f-1565-3"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or disposals resulted in &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InventoryWritedown2011" scale="6" id="f-1575">94.5</ix:nonFraction>&#160;million, compared to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:InventoryWritedown2011" format="ixt:num-dot-decimal" scale="6" id="f-1576">484.6</ix:nonFraction> million in the previous period. The inventories valued at net realizable value in our consolidated statements of financial position as of December&#160;31, 2023, take contractual compensation payments into consideration.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1565-3">pledged any inventories as securities for liabilities. During the years ended December 31, 2023, and 2022, costs of inventories in the amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1577">354.4</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1578">1,550.6</ix:nonFraction> million, respectively, were recognized as cost of sales.</ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-56</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_365"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">14&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="f-1579" continuedAt="f-1579-1" escape="true">Other Non-Financial Assets</ix:nonNumeric></span></div><ix:continuation id="f-1579-1"><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" id="f-1580" escape="true"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:DeferredExpense" scale="6" id="f-1581">313.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:DeferredExpense" scale="6" id="f-1582">120.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales tax receivable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="6" id="f-1583">5.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="6" id="f-1584">93.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepayments related to CRO and CMO contracts</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentAdvancesToSuppliers" format="ixt:fixed-zero" scale="6" id="f-1585">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentAdvancesToSuppliers" scale="6" id="f-1586">35.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:OtherCurrentAssetsOther" scale="6" id="f-1587">45.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:OtherCurrentAssetsOther" scale="6" id="f-1588">29.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNonfinancialAssets" scale="6" id="f-1589">364.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNonfinancialAssets" scale="6" id="f-1590">278.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialAssets" scale="6" id="f-1591">280.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialAssets" scale="6" id="f-1592">271.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-1593">83.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialAssets" scale="6" id="f-1594">6.5</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred expenses mainly comprise prepayments for future expenses of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-588" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1595">151.1</ix:nonFraction>&#160;million (<ix:nonFraction unitRef="eur" contextRef="c-589" decimals="-5" name="bntx:DeferredExpense" format="ixt-sec:numwordsen" scale="0" id="f-1596">nil</ix:nonFraction> as of December&#160;31, 2022) for the settlement fee of the European Commission to our collaboration partner and prepayments for our collaborations with OncoC4 Inc., Rockville, USA, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-590" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1597">22.5</ix:nonFraction>&#160;million (<ix:nonFraction unitRef="eur" contextRef="c-591" decimals="-5" name="bntx:DeferredExpense" format="ixt-sec:numwordsen" scale="0" id="f-1598">nil</ix:nonFraction> as of December&#160;31, 2022), Ryvu Therapeutics S.A., Krakau, Poland, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-592" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1599">15.7</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-593" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1600">19.7</ix:nonFraction>&#160;million as of December&#160;31, 2022) and Medigene Immunotherapies GmbH, Planegg/Martinsried, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-594" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1601">5.1</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-595" decimals="-5" name="bntx:DeferredExpense" format="ixt:num-dot-decimal" scale="6" id="f-1602">9.4</ix:nonFraction>&#160;million as of December&#160;31, 2022). Prior year deferred expenses mainly comprise service contracts and insurance obligations.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_353"></div><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-1603" continuedAt="f-1603-1" escape="true">Issued Capital and Reserves</ix:nonNumeric></span></div><ix:continuation id="f-1603-1" continuedAt="f-1603-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the number of shares outstanding was <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1604">237,725,735</ix:nonFraction>. This amount excludes <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="bntx:NumberOfSharesHeldInTreasury" format="ixt:num-dot-decimal" scale="0" id="f-1605">10,826,465</ix:nonFraction>&#160;shares held in treasury. For the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the number of shares outstanding was <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1606">243,215,169</ix:nonFraction>, excluding <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="bntx:NumberOfSharesHeldInTreasury" format="ixt:num-dot-decimal" scale="0" id="f-1607">5,337,031</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares held in treasury.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Transactions During the Year Ended December&#160;31, 2023</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our Management Board and Supervisory Board authorized the 2022 share repurchase program of ADSs, pursuant to which we were permitted to repurchase ADSs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each representing one ordinary share,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a value of up to $<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1608">1.5</ix:nonFraction>&#160;billion a two-year period, commencing on May 2, 2022. The first tranche of our 2022 share repurchase program of ADSs, with a value of up to $<ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1609">1.0</ix:nonFraction>&#160;billion, concluded on October 10, 2022. The second tranche with a value of up to $<ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1610">0.5</ix:nonFraction>&#160;billion commenced on December 7, 2022 and concluded on March 17, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfSharesRepurchaseProgramTableTextBlock" id="f-1611" continuedAt="f-1611-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program first tranche ($<ix:nonFraction unitRef="eur" contextRef="c-599" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1612">1.0</ix:nonFraction>&#160;billion)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-600" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1613">917,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-600" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1614">151.76</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-600" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1615">143.99</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1616">139.3</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-600" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1617">132.2</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-601" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1618">1,160,219</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-601" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1619">140.82</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-601" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1620">133.35</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1621">163.4</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1622">154.7</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-602" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1623">519,320</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-602" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1624">162.03</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-602" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1625">159.40</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1626">84.1</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-602" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1627">82.8</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-603" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1628">1,666,515</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-603" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1629">149.08</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-603" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1630">148.24</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1631">248.4</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-603" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1632">247.0</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-604" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1633">2,280,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-604" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1634">135.95</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-604" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1635">137.66</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1636">310.1</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-604" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1637">314.0</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-605" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1638">400,483</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-605" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1639">136.37</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-605" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1640">139.09</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1641">54.6</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-605" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1642">55.7</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-606" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1643">6,945,513</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1644">999.9</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-606" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1645">986.4</ix:nonFraction>)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program second tranche ($<ix:nonFraction unitRef="eur" contextRef="c-607" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1646">0.5</ix:nonFraction>&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-608" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1647">618,355</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-608" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1648">142.26</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-608" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1649">131.12</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1650">88.0</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-608" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1651">81.1</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-609" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1652">857,620</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-609" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1653">138.05</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-609" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1654">129.06</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1655">118.4</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-609" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1656">110.7</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-610" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1657">745,196</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-610" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1658">128.49</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-610" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1659">121.08</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1660">95.7</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1661">90.2</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-611" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1662">2,221,171</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1663">302.1</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-611" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1664">282.0</ix:nonFraction>)</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1603-2"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Management Board and Supervisory Board authorized the 2023 share repurchase program, under which we were permitted to purchase ADSs, each representing one ordinary share, with a value of up to $<ix:nonFraction unitRef="eur" contextRef="c-610" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1665">0.5</ix:nonFraction>&#160;billion, which started June&#160;2, 2023 and concluded on September 18, 2023. </span></div><ix:continuation id="f-1611-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Program 2023 ($<ix:nonFraction unitRef="eur" contextRef="c-612" decimals="-8" name="bntx:ShareRepurchaseProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="9" id="f-1666">0.5</ix:nonFraction>&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-613" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1667">1,532,685</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-613" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1668">108.92</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-613" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1669">100.45</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1670">166.9</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-613" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1671">154.0</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-614" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1672">1,738,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-614" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1673">107.92</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-614" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1674">97.57</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1675">187.6</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-614" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1676">169.6</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-615" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1677">1,261,706</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-615" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1678">105.07</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-615" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1679">95.85</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1680">132.6</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-615" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1681">120.9</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1682">114,513</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-616" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1683">112.22</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-616" decimals="2" name="bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" scale="0" id="f-1684">105.07</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1685">12.9</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-616" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1686">12.0</ix:nonFraction>)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" format="ixt:num-dot-decimal" scale="0" id="f-1687">4,646,965</ix:nonFraction></span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1688">500.0</ix:nonFraction> (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-617" decimals="-5" name="bntx:ShareRepurchaseProgramNetAmountSpent" scale="6" id="f-1689">456.5</ix:nonFraction>) </span></div></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Transactions During the Year Ended December 31, 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced a new research, development and commercialization collaboration with Pfizer to develop potentially the first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV). In connection </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with this collaboration, Pfizer agreed to make an equity investment in us, acquiring <ix:nonFraction unitRef="shares" contextRef="c-618" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1690">497,727</ix:nonFraction> ordinary shares paying a total amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-619" decimals="-5" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1691">110.6</ix:nonFraction>&#160;million. The issuance of <ix:nonFraction unitRef="shares" contextRef="c-620" decimals="0" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1692">497,727</ix:nonFraction>&#160;ordinary shares with the nominal amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-620" decimals="-5" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-1693">0.5</ix:nonFraction>&#160;million was registered with the commercial register (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on March 24, 2022. The equity investment, which was issued in a foreign currency, represents a derivative from the date of signing until the date of closing of the transaction. From the fair value measurement of this derivative, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-621" decimals="-5" name="ifrs-full:AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" format="ixt:num-dot-decimal" scale="6" id="f-1694">43.0</ix:nonFraction>&#160;million were recognized in finance income in our consolidated statements of profit or loss during the year ended December 31, 2022. At the closing date, in February 2022, this derivative and the agreed investment amount were recognized in our capital reserve and, taking an increase in share capital of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-622" decimals="-5" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="6" id="f-1695">0.5</ix:nonFraction>&#160;million into account, led to a net increase of the capital reserve of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-623" decimals="-5" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1696">67.1</ix:nonFraction>&#160;million in our consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we redeemed our convertible note by exercising our early redemption option (see Note 12), which was fulfilled in April 2022, by issuing <ix:nonFraction unitRef="shares" contextRef="c-624" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1697">1,744,392</ix:nonFraction> ordinary shares. The nominal amount of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-625" decimals="-5" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1698">1.8</ix:nonFraction>&#160;million was recorded in share capital and, finally, as a result of the transaction, the capital reserve increased by &#8364;<ix:nonFraction unitRef="eur" contextRef="c-626" decimals="-5" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="6" id="f-1699">233.2</ix:nonFraction>&#160;million in our consolidated statements of financial position. The declaratory registration with the commercial register (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was made on May 20, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, at the Annual General Meeting, our shareholders approved the proposed special cash dividend of &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-601" decimals="2" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" scale="0" id="f-1700">2.00</ix:nonFraction> per ordinary share (including those held in the form of ADSs), which led to an aggregate payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-601" decimals="-5" name="ifrs-full:DividendsPaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1701">484.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2022, the ESOP 2018 and LTI-plus awards were settled by transferring ordinary shares previously held in treasury to the entitled employees and Management Board members (see Note&#160;16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-58</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_333"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">16&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-1702" continuedAt="f-1702-1" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="f-1702-1" continuedAt="f-1702-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" id="f-1703" continuedAt="f-1703-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:50.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.187%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense arising from equity-settled share-based payment arrangements</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1704">44.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1705">46.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1706">61.0</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="6" id="f-1707">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-628" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1708">13.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-629" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1709">20.2</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Executive Officer Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-630" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1710">1.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-631" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1711">3.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-632" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1712">5.9</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1713">3.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-634" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1714">4.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-635" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1715">2.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-636" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1716">36.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-637" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1717">25.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-638" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1718">32.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">InstaDeep Employee Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-639" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1719">3.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-640" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="6" id="f-1720">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-641" decimals="-5" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="6" id="f-1721">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense / (Income) arising from cash-settled share-based payment arrangements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1722">7.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1723">61.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1724">32.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-627" decimals="-5" sign="-" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1725">0.9</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-628" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1726">53.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-629" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1727">6.3</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.2, 16.3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-5" sign="-" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1728">2.4</ix:nonFraction>)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-634" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="6" id="f-1729">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-635" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1730">3.6</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech Restricted Stock Unit Plan for North America Employees</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1731">10.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1732">8.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-5" name="ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="f-1733">22.8</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1734">51.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1735">108.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1736">93.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of sales</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-645" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1737">6.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-646" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1738">3.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-647" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1739">7.0</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-648" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1740">33.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-649" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1741">84.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-650" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1742">60.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales and marketing expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-651" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1743">1.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-652" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1744">0.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-653" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1745">0.5</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-654" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1746">10.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-655" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1747">19.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-656" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1748">25.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1749">51.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1750">108.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="6" id="f-1751">93.7</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-5" name="bntx:ReclassificationOfShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1752">1.1</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-658" decimals="-5" name="bntx:ReclassificationOfShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1753">3.3</ix:nonFraction>&#160;million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2). </span></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><ix:continuation id="f-1703-1" continuedAt="f-1703-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-1703-2">&#160;&#160;&#160;&#160;As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-659" decimals="-5" name="ifrs-full:LongtermDeposits" format="ixt:num-dot-decimal" scale="6" id="f-1754">15.0</ix:nonFraction>&#160;million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments.</ix:continuation> </span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, our share-based payment arrangements led to a cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1755">766.2</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1756">51.8</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" sign="-" name="bntx:ShareBasedPaymentsClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1757">13.4</ix:nonFraction> million, respectively. We expect to settle the equity-settled share-based payment arrangements of our 2020 Management Board Grant (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Chief Executive Officer Grant (see Note 16.4) and the Employee Stock Ownership Plan (see Note 16.5) on a net basis by delivering to the participant a number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. This reduces the dilutive impact of the respective rights compared to an all-equity settlement. If all of the equity-settled rights outstanding as of December&#160;31, 2023, were to be exercised accordingly, the cash outflow to the tax authority in 2024 would amount to approximately &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CashOutflowToTaxAuthority" format="ixt:num-dot-decimal" scale="6" id="f-1758">213.0</ix:nonFraction>&#160;million (based on the share price as of December&#160;31, 2023).</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-59</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_327"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-2" continuedAt="f-1702-3"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.1&#160;&#160;&#160;&#160;BioNTech Employee Equity Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America (Equity-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we approved the BioNTech 2020 Employee Equity Plan for employees based outside North America, or the European Plan. Under the European Plan, Restricted Stock Units, or RSUs, are offered to our employees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Award agreements were entered as of the respective grant dates in February 2021 (LTI 2020 and LTI-plus program), January 2022 (LTI 2021 program) and December 2022 (LTI 2022 program). RSUs issued under the LTI 2020, LTI 2021 and LTI 2022 programs vest annually in equal installments over respective waiting periods of <ix:nonNumeric contextRef="c-660" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1759"><ix:nonNumeric contextRef="c-661" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1760"><ix:nonNumeric contextRef="c-662" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1761">four years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>, commencing in December 2020, December 2021 and December 2022, respectively. RSUs issued under the LTI-plus program vested annually in equal installments over the waiting period of <ix:nonNumeric contextRef="c-663" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1762">two years</ix:nonNumeric>, which elapsed in December 2022. Hence, during the year ended December 31, 2022, the LTI-plus awards were settled by transferring shares previously held in treasury, see Note 15. All programs were classified as equity-settled as we have the ability to determine the method of settlement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the awards issued under the European Plan were based upon the price of our ADSs representing ordinary shares at the grant date. </span></div><ix:nonNumeric contextRef="c-664" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-1763" escape="true"><div style="margin-top:12pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-665" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1764">372,011</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-666" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1765">242,416</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-667" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1766">110,036</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-668" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="f-1767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-663" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1768">7,932</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-669" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1769">7,111</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-670" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1770">5,428</ix:nonFraction>)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-671" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Granted / Allocated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-663" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1772">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-669" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1773">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-670" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-671" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1775">396,110</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-663" decimals="INF" name="bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1776">364,079</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-669" decimals="INF" name="bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1777">&#8212;</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-670" decimals="INF" name="bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-671" decimals="INF" name="bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-672" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="f-1780">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-673" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1781">235,305</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-674" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1782">104,608</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-675" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1783">396,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-672" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="f-1784">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-673" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1785">235,305</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-674" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1786">104,608</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-675" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1787">396,110</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-676" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1788">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-677" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1789">4,400</ix:nonFraction>)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-678" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1790">3,497</ix:nonFraction>)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-679" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1791">16,141</ix:nonFraction>)</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-680" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:fixed-zero" scale="0" id="f-1792">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-681" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1793">230,905</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-682" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1794">101,111</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-683" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1795">379,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-680" decimals="INF" name="bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1796">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-681" decimals="INF" name="bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1797">175,523</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-682" decimals="INF" name="bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1798">51,905</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-683" decimals="INF" name="bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1799">96,466</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-680" decimals="INF" name="bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1800">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-681" decimals="INF" name="bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1801">55,382</ix:nonFraction></span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-682" decimals="INF" name="bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1802">49,206</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-683" decimals="INF" name="bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1803">283,503</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-684" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-1804">171.40</ix:nonFraction>.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inputs Used in Measurement of the Fair Values at Grant Dates</span></div><ix:nonNumeric contextRef="c-664" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-1805" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-680" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1806">87.60</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-681" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1807">92.21</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-682" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1808">203.22</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-683" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1809">165.03</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waiting period (in years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-676" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1810">2.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-677" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1811">4.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-678" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1812">4.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-679" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1813">4.0</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioNTech 2020 Restricted Stock Unit Plan for North America Employees (Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we approved the BioNTech 2020 Restricted Stock Unit Plan for North America Employees, or the North American Plan. Under the North American Plan, RSUs are offered to our employees. These RSUs vest over <ix:nonNumeric contextRef="c-685" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1814">four years</ix:nonNumeric>, with <ix:nonFraction unitRef="number" contextRef="c-686" decimals="INF" name="bntx:VestingPercentageOfShareBasedPaymentArrangement" scale="-2" id="f-1815">25</ix:nonFraction>% vesting one year after the service commencement date and the remainder vesting in equal quarterly installments thereafter. The first awards under the North American Plan were granted in February 2021. The service date for these awards is the date as of which the employee became employed by BioNTech US. During the years ended December 31, 2023, and 2022, further awards were granted under the North American Plan, which included awards granted </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-3" continuedAt="f-1702-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to new-hire employees and ongoing, recurring awards to existing employees on the approximate anniversary of each employee&#8217;s start date of employment with BioNTech US. As these RSUs are intended to be cash-settled upon vesting, the awards were defined as a cash-settled share-based payment arrangement. During the years ended December&#160;31, 2023, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the exercise of RSUs resulted in a cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-642" decimals="-5" name="bntx:CashOutflowForShareBasedPaymentArrangementExercise" format="ixt:num-dot-decimal" scale="6" id="f-1816">10.0</ix:nonFraction>&#160;million, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-643" decimals="-5" name="bntx:CashOutflowForShareBasedPaymentArrangementExercise" format="ixt:num-dot-decimal" scale="6" id="f-1817">9.4</ix:nonFraction>&#160;million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-644" decimals="-5" name="bntx:CashOutflowForShareBasedPaymentArrangementExercise" format="ixt:num-dot-decimal" scale="6" id="f-1818">10.1</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><ix:continuation id="f-1702-4" continuedAt="f-1702-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the liability related to these awards amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-687" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" format="ixt:num-dot-decimal" scale="6" id="f-1819">14.4</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-688" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" format="ixt:num-dot-decimal" scale="6" id="f-1820">13.4</ix:nonFraction>&#160;million&#160;as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1702-5" continuedAt="f-1702-6">).</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_319"></div><ix:continuation id="f-1702-6" continuedAt="f-1702-7"><div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16.2&#160;&#160;&#160;&#160;Management Board Grant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Short-Term Incentive (Cash-Settled)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management Board&#8217;s service agreements also include a short-term incentive compensation component, which is an annual performance-related bonus for the years of their respective service periods. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><ix:continuation id="f-1702-7" continuedAt="f-1702-8"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-633" decimals="2" name="bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares" scale="-2" id="f-1821">50</ix:nonFraction>% of those yearly awards are paid out one year after the achievement of the performance targets for the respective bonus year has been determined, subject to an adjustment relative to the performance of the price of the American Depositary Shares representing our ordinary shares during that year (second installment). The second installments represent cash-settled share-based payment arrangements. The fair values of the liabilities are recognized over the awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vesting periods beginning when entering or renewing service agreements, i.e., the service commencement date, until each separate determination date and are remeasured until the settlement date. As of December&#160;31, 2023, the liability related to these awards amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-689" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" scale="6" id="f-1822">2.1</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-690" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" scale="6" id="f-1823">2.3</ix:nonFraction>&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1702-8" continuedAt="f-1702-9">).</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_313"></div><ix:continuation id="f-1702-9" continuedAt="f-1702-10"><div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16.3&#160;&#160;&#160;&#160;Management Board Grant Long-Term Incentive (Partly Equity-Settled, Partly Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board&#8217;s service agreements provide for long-term incentive compensation (Management Board Grant - LTI) through an annual grant of options to acquire BioNTech shares during their respective service periods. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> granted each year are subject to the terms and conditions of the respective authorizations of the Annual General Meeting creating our Employee Stock Ownership Plan (ESOP) and the applicable option agreements thereunder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vest annually in equal installments over <ix:nonNumeric contextRef="c-633" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1824">four years</ix:nonNumeric> commencing on the first anniversary of the allocation date and are exercisable <ix:nonNumeric contextRef="c-633" name="bntx:OptionExercisablePeriod" format="ixt-sec:durwordsen" id="f-1825">four years</ix:nonNumeric> after the allocation date. The vested options can only be exercised if each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by <ix:nonFraction unitRef="number" contextRef="c-633" decimals="2" name="bntx:PercentageOfIncreaseInExercisePrice" format="ixt-sec:numwordsen" scale="-2" id="f-1826">seven</ix:nonFraction> percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $<ix:nonFraction unitRef="eur" contextRef="c-633" decimals="-8" name="bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" scale="9" id="f-1827">8.5</ix:nonFraction> billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, <ix:nonFraction unitRef="number" contextRef="c-633" decimals="2" name="bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" scale="-2" id="f-1828">107</ix:nonFraction>% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as set out in the ESOP agreement. The option rights can be exercised up to <ix:nonNumeric contextRef="c-691" name="bntx:OptionExercisablePeriod" format="ixt-sec:durwordsen" id="f-1829">ten years</ix:nonNumeric> after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right to receive options generally represents an equity-settled share-based payment arrangement. The allocation of the number of issued options in 2020 occurred in February 2020. In May 2021 and May 2022, the Management Board received phantom options equivalent to the number of options the Management Board members would have been entitled to receive for 2021 and 2022, which led to a modification from equity-settled to cash-settled share-based payment arrangement and a reclassification of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-657" decimals="-5" name="bntx:ReclassificationOfShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1830">1.1</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-658" decimals="-5" name="bntx:ReclassificationOfShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1831">3.3</ix:nonFraction> million between equity and non-current other liabilities as of the respective allocation dates. During 2023, options were granted in May 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-10" continuedAt="f-1702-11"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development described above. <ix:nonNumeric contextRef="c-633" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-1832" continuedAt="f-1832-1" escape="true">The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1832-1"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-692" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1833">10.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-693" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1834">29.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-694" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1835">27.64</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-695" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1836">38.88</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-696" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1837">28.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-697" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1838">168.44</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-698" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1839">179.46</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-600" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1840">147.84</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-696" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1841">28.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-697" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1842">167.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-698" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1843">169.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-600" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1844">137.65</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-696" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1845">36.6</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-697" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1846">49.7</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-698" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1847">49.7</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-600" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1848">49.7</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-696" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1849">4.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-697" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1850">4.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-698" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1851">4.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-600" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1852">5.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-696" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1853">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-697" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1854">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-698" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1855">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-600" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1856">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap.&#160;</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-699" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1857">46.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-700" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1858">43.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-701" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1859">39.97</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-702" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1860">32.86</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-703" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1861">98.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-704" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1862">95.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-705" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1863">95.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-706" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1864">95.51</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-703" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1865">105.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-704" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1866">96.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-705" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1867">99.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-706" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1868">105.13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-703" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1869">47.2</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-704" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1870">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-705" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1871">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-706" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1872">36.8</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-703" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1873">5.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-704" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1874">5.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-705" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1875">5.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-706" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1876">5.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-703" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1877">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-704" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1878">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-705" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1879">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-706" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1880">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.</span></div></ix:continuation><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the awards with estimated allocation dates, the exercise prices of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All options are subject to an effective exercise price cap, which means that the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed <ix:nonFraction unitRef="number" contextRef="c-707" decimals="INF" name="bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" scale="-2" id="f-1881">800</ix:nonFraction>% of the exercise price. With respect to the LTI 2020 agreement, the maximum economic benefit receivable in respect of any exercised option is capped at $<ix:nonFraction unitRef="usd" contextRef="c-633" decimals="2" name="bntx:MaximumEconomicBenefitsOfOptionsExercised" scale="0" id="f-1882">246.24</ix:nonFraction>, with the effective exercise price being capped at a Euro amount equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-633" decimals="2" name="bntx:EffectiveExercisePriceMaximum" scale="0" id="f-1883">30.78</ix:nonFraction>. With respect to the phantom share options issued under the LTI 2021 and 2022 as well as the options issued under the LTI 2023 programs, the maximum compensation that the Management Board members are entitled to receive under such programs, together with other compensation components received by each such board member in the respective grant year, shall not exceed &#8364;<ix:nonFraction unitRef="eur" contextRef="c-708" decimals="-5" name="bntx:MaximumCashPaymentInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1884">20.0</ix:nonFraction>&#160;million for Ugur Sahin as Chief Executive Officer (CEO) and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-709" decimals="-5" name="bntx:MaximumCashPaymentInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="6" id="f-1885">10.0</ix:nonFraction>&#160;million for all other Management Board members. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general option holder behavior for employee options. </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-11" continuedAt="f-1702-12"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><ix:nonNumeric contextRef="c-633" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="f-1886" continuedAt="f-1886-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (phantom) share options allocated and expected to be allocated to our Management Board as of December&#160;31, 2023, are presented in the table below. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Phantom) share options outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-707" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1887">248,096</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-710" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1888">45,279</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-711" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1889">6,463</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-712" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1890">86,118</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and vested but subject to performance and waiting requirements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-713" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1891">186,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-714" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1892">22,640</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-715" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1893">3,232</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-658" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1894">21,531</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-713" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1895">62,024</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-714" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1896">22,639</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-715" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1897">3,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-658" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1898">64,587</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-707" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1899">28.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-710" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1900">167.63</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-711" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1901">169.08</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-712" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1902">137.65</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:41.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share options outstanding / expected to be allocated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-716" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1903">130,586</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-717" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1904">164,148</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-718" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1905">118,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-719" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1906">93,561</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-720" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1907">130,586</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-721" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1908">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-722" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1909">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-723" decimals="INF" name="bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-1910">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-716" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1911">105.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-717" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1912">96.82</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-718" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1913">99.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-719" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1914">105.13</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><ix:continuation id="f-1886-1" continuedAt="f-1886-2"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-1886-2">Valuation parameter derived from the Monte-Carlo simulation model.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the awards with estimated allocation dates, the numbers of options expected to be allocated have been derived from a Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the share options allocated and expected to be allocated under our equity-settled share-based payment arrangements had a remaining weighted average expected life of <ix:nonNumeric contextRef="c-633" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-1915">4.1</ix:nonNumeric>&#160;years (as of December&#160;31, 2022: <ix:nonNumeric contextRef="c-634" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-1916">4.0</ix:nonNumeric>&#160;years). </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><ix:continuation id="f-1702-12" continuedAt="f-1702-13"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the liability related to the phantom option awards amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-689" decimals="-5" name="bntx:PhantomOptionAwardsLiability" format="ixt:num-dot-decimal" scale="6" id="f-1917">3.6</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-690" decimals="-5" name="bntx:PhantomOptionAwardsLiability" format="ixt:num-dot-decimal" scale="6" id="f-1918">5.6</ix:nonFraction>&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1702-13" continuedAt="f-1702-14">).</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_306"></div><ix:continuation id="f-1702-14" continuedAt="f-1702-15"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16.4&#160;&#160;&#160;&#160;Chief Executive Officer Grant (Equity-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we granted Ugur Sahin an option to purchase </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-724" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1919">4,374,963</ix:nonFraction></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our ordinary shares, subject to Sahin&#8217;s continuous employment with us. The options&#8217; exercise price per share is the Euro translation of the public offering price from our initial public offering, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-724" decimals="2" name="bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" scale="0" id="f-1920">13.60</ix:nonFraction> ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-724" decimals="2" name="bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" scale="0" id="f-1921">15.00</ix:nonFraction>), </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is subject to the effective exercise price cap and the maximum cap mechanism. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price cap the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed <ix:nonFraction unitRef="number" contextRef="c-725" decimals="INF" name="bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" scale="-2" id="f-1922">800</ix:nonFraction>% of the exercise price. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the maximum cap mechanism the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> maximum economic benefit receivable in respect of any exercised option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is capped at $<ix:nonFraction unitRef="usd" contextRef="c-726" decimals="2" name="bntx:MaximumEconomicBenefitsOfOptionsExercised" scale="0" id="f-1923">240.00</ix:nonFraction> with the effective exercise price being capped at a Euro amount equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-726" decimals="2" name="bntx:EffectiveExercisePriceMaximum" scale="0" id="f-1924">30.00</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vest annually in equal installments after <ix:nonNumeric contextRef="c-724" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1925">four years</ix:nonNumeric> commencing on the first anniversary of the initial public offering and have a waiting period of <ix:nonNumeric contextRef="c-724" name="bntx:OptionExercisablePeriod" format="ixt-sec:durwordsen" id="f-1926">four years</ix:nonNumeric> after the initial public offering. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by <ix:nonFraction unitRef="number" contextRef="c-726" decimals="2" name="bntx:PercentageOfIncreaseInExercisePrice" format="ixt-sec:numwordsen" scale="-2" id="f-1927">seven</ix:nonFraction> percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $<ix:nonFraction unitRef="eur" contextRef="c-724" decimals="-8" name="bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" format="ixt:num-dot-decimal" scale="9" id="f-1928">8.5</ix:nonFraction>&#160;billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by us), and (b) for each twelve-month period starting on the fifth or subsequent </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-15" continuedAt="f-1702-16"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the allocation date, <ix:nonFraction unitRef="number" contextRef="c-724" decimals="2" name="bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" scale="-2" id="f-1929">107</ix:nonFraction>% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as defined by our ESOP. The option rights can be exercised up to <ix:nonNumeric contextRef="c-727" name="bntx:OptionExercisablePeriod" format="ixt-sec:durwordsen" id="f-1930">ten years</ix:nonNumeric> after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte-Carlo simulation model has been used to measure the fair value at the grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&#8217;s fair value at the grant date. <ix:nonNumeric contextRef="c-630" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-1931" continuedAt="f-1931-1" escape="true">The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1931-1"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:75.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date October 9, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-728" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1932">5.63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-729" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1933">13.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-729" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1934">13.60</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-729" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1935">41.4</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-729" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1936">5.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:0 1pt"/><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-729" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1937">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general option holder behavior for employee options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, with the final installment vesting, all <ix:nonFraction unitRef="shares" contextRef="c-730" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1938">4,374,963</ix:nonFraction> options became exercisable under the rules of the ESOP and the ESOP agreement. During the year ended December 31, 2023, no options were exercised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the share options outstanding had a remaining weighted average expected life of <ix:nonNumeric contextRef="c-630" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-1939">1.1</ix:nonNumeric>&#160;years (as of December&#160;31, 2022: <ix:nonNumeric contextRef="c-631" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-1940">2.1</ix:nonNumeric> years).</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_300"></div><ix:continuation id="f-1702-16" continuedAt="f-1702-17"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16.5&#160;&#160;&#160;&#160;Employee Stock Ownership Plan (Partly Equity-Settled, Partly Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an authorization of the general meeting on August 18, 2017, we established a share option program under which we granted selected employees options to receive our shares. The program is designed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an Employee Stock Ownership Plan, or ESOP. We offered participants a certain number of option rights by their explicit acceptance of an option rights agreement. The exercise of option rights in accordance with the agreement gives the participants the right to obtain shares against payment of the exercise price. With respect to the Management Board members serving at the time of allocation, the options are subject to the effective exercise price cap and maximum cap mechanisms. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price cap, the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed <ix:nonFraction unitRef="number" contextRef="c-731" decimals="INF" name="bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" scale="-2" id="f-1941">800</ix:nonFraction>% of the exercise price. Under </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum cap mechanism, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum economic benefit receivable in respect of any exercised option, is capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-732" decimals="2" name="bntx:MaximumEconomicBenefitsOfOptionsExercised" scale="0" id="f-1942">240</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the effective exercise price being capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Euro amount equivalent to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-732" decimals="2" name="bntx:EffectiveExercisePriceMaximum" scale="0" id="f-1943">30.00</ix:nonFraction>. Under the ESOP, the option rights (other than &#214;zlem T&#252;reci&#8217;s, and Ryan Richardson&#8217;s options) fully vest after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-733" name="bntx:OptionVestingPeriod" format="ixt-sec:durwordsen" id="f-1944">four years</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and can be exercised if: (i) the waiting period of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-733" name="bntx:OptionExercisablePeriod" format="ixt-sec:durwordsen" id="f-1945">four years</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has elapsed; and (ii) at the time of exercise, the average closing price of the shares of the Company or the average closing price of the right or certificate to be converted into an amount per share on the previous ten trading days preceding the exercise of the option right exceeds the strike price by a minimum of <ix:nonFraction unitRef="number" contextRef="c-732" decimals="2" name="bntx:ExerciseOfOptionRightsMinimumStrikePricePercent" scale="-2" id="f-1946">32</ix:nonFraction>%, with this percentage increasing by <ix:nonFraction unitRef="number" contextRef="c-732" decimals="2" name="bntx:PercentageOfIncreaseInExercisePrice" format="ixt-sec:numwordsen" scale="-2" id="f-1947">eight</ix:nonFraction> percentage points as of the fifth anniversary of the respective issue date and as of each subsequent anniversary date. Following the expiry of the waiting period, option rights may be exercised within a period of four weeks from the date of the Annual General Meeting or the publication of the annual financial statements, the semi-annual report or our most recent quarterly report or interim report (exercise windows). </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-17" continuedAt="f-1702-18"><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option rights can be exercised up to eight years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of a shareholders&#8217; resolution of the general meeting on August 19, 2019, the authorization to issue such option rights was amended such that, in order for the options to be exercisable, the average closing price of the Company&#8217;s shares or the average closing price of the right or certificate to be converted into an amount per share on the ten trading days immediately preceding the exercise must exceed the strike price by a minimum of <ix:nonFraction unitRef="number" contextRef="c-734" decimals="2" name="bntx:ExerciseOfOptionRightsMinimumStrikePricePercent" scale="-2" id="f-1948">28</ix:nonFraction>%, with this percentage increasing by <ix:nonFraction unitRef="number" contextRef="c-734" decimals="2" name="bntx:PercentageOfIncreaseInExercisePrice" format="ixt-sec:numwordsen" scale="-2" id="f-1949">seven</ix:nonFraction> percentage points as of the fifth anniversary of the issue date and as of each subsequent anniversary date. Furthermore, in addition to the aforementioned requirements, the exercise is only possible if the share price (calculated by reference to the price of the ordinary share underlying the ADS) has performed similar to or better than the Nasdaq Biotechnology Index. The changes made do not affect option rights already issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share options can only be exercised by the grantee if the price of the share is equal or greater to the threshold amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at the grant date.</span></div><ix:nonNumeric contextRef="c-627" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-1950" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:54.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date <br/>November 15, 2018</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between <br/>February 21 and <br/>April 3, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between<br/>April 29 and <br/>May 31, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date December 1, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-735" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1951">7.41</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-736" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1952">6.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-737" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1953">7.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eur" contextRef="c-738" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-1954">9.49</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-739" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1955">14.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-740" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1956">15.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-741" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1957">16.03</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-742" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-1958">19.84</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-739" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1959">10.14</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-740" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1960">15.03</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-741" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1961">15.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-742" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-1962">15.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-739" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1963">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-740" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1964">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-741" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1965">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-742" decimals="3" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-1966">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-739" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1967">5.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-740" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1968">6.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-741" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1969">6.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="y" contextRef="c-742" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-1970">5.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"/><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-739" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1971">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-740" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1972">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-741" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1973">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="c-742" decimals="3" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-1974">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-1702-18" continuedAt="f-1702-19"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Settled)</span></div><ix:nonNumeric contextRef="c-627" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="f-1975" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share options <br/>outstanding</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ordinary shares underlying options</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average exercise price (&#8364;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-743" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1976">642,007</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-743" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1977">11,556,124</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-743" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1978">10.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Modified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-628" decimals="0" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1979">1,040</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-628" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1980">18,720</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-1981">10.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-628" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1982">583,383</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-628" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1983">10,500,890</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" scale="0" id="f-1984">10.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-744" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1985">57,584</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-744" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1986">1,036,514</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-744" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1987">11.10</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-744" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1988">57,584</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-744" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1989">1,036,514</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-744" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1990">11.10</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-627" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1991">39,785</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="c-627" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1992">716,121</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-627" decimals="2" name="bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" scale="0" id="f-1993">11.04</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-1994">17,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1995">320,393</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-745" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-1996">11.24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="0" name="bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1997">17,799</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-1998">320,393</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-745" decimals="2" name="bntx:WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" scale="0" id="f-1999">11.24</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="0" name="bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-2000">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-745" decimals="INF" name="bntx:NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-2001">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eurPerShare" contextRef="c-745" decimals="2" name="bntx:WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-2002">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rights have been modified to cash-settled rights, all other terms remained unchanged.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-627" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-2003">96.49</ix:nonFraction> and &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-628" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-2004">160.44</ix:nonFraction> for all settlements during the years ended December 31, 2023 and 2022, respectively.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Supervisory Board determined the ESOP settlement by the delivery of treasury shares (in the form of ADSs) equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The settlement was applied during the exercise windows in 2022 and 2023. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from and withheld upon the exercise amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-746" decimals="-5" name="ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" scale="6" id="f-2005">724.0</ix:nonFraction> million and were paid in January 2023 in cash directly to the respective authorities. The settlement mechanism decision did not change the rights as such, neither did it change the classification as equity-settled option rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the share options outstanding under our equity-settled share-based payment arrangements had a remaining weighted average expected life of <ix:nonNumeric contextRef="c-627" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-2006">0.8</ix:nonNumeric>&#160;years (as of December&#160;31, 2022: <ix:nonNumeric contextRef="c-628" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-2007">1.7</ix:nonNumeric> years).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development of Share-Options (Cash</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Settled)</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><ix:continuation id="f-1702-19" continuedAt="f-1702-20"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phantom options which were granted under the ESOP mainly during the year ended December 31, 2022 each give the participants the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an American Depositary Share of BioNTech on Nasdaq over the last ten trading days preceding the exercise date) and the exercise price. The majority of options have an </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-747" decimals="2" name="bntx:ExercisePricePhantomOptionsGranted" scale="0" id="f-2008">10.14</ix:nonFraction>. During the years ended December 31, 2023, and 2022, <ix:nonFraction unitRef="shares" contextRef="c-748" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2009">52,100</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-747" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2010">289,168</ix:nonFraction> cash-settled phantom option rights were exercised and resulted in a cash outflow of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-748" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="6" id="f-2011">4.5</ix:nonFraction>&#160;million&#160;and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-747" decimals="-5" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="6" id="f-2012">42.2</ix:nonFraction> million, respectively. The average closing prices (10-day averages) of an American Depositary Share of BioNTech on Nasdaq weighted over the various settlement dates converted from USD to Euro using the exchange rate published by the German Central Bank (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deutsche Bundesbank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on the same days was &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-748" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-2013">96.25</ix:nonFraction> and &#8364;<ix:nonFraction unitRef="eurPerShare" contextRef="c-747" decimals="2" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="f-2014">155.39</ix:nonFraction>. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-749" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-2015">109,651</ix:nonFraction> cash-settled option rights remained outstanding. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liability related to cash-settled share-based payment option rights amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-749" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" format="ixt:num-dot-decimal" scale="6" id="f-2016">8.5</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-750" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" format="ixt:num-dot-decimal" scale="6" id="f-2017">14.5</ix:nonFraction>&#160;million&#160;as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), of which &#8364;<ix:nonFraction unitRef="eur" contextRef="c-749" decimals="-5" name="bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" format="ixt:num-dot-decimal" scale="6" id="f-2018">8.3</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-750" decimals="-5" name="bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" format="ixt:num-dot-decimal" scale="6" id="f-2019">11.2</ix:nonFraction>&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1702-20">) related to rights already vested (partly subject to performance and waiting requirements). The liability is based on the fair value of the respective rights. The fair value is measured using a binomial model consistent with the grant date fair value measurement of the equity-based option rights described above, which is updated on every reporting date.</ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-66</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_2906"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfProvisionsExplanatory" id="f-2020" continuedAt="f-2020-1" escape="true">Provisions</ix:nonNumeric></span></div><ix:continuation id="f-2020-1"><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfProvisionsTableTextBlock" id="f-2021" escape="true"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.093%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual disputes</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:LegalProceedingsProvision" scale="6" id="f-2022">118.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LegalProceedingsProvision" scale="6" id="f-2023">88.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obligations from onerous CMO contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ShorttermOnerousContractsProvision" scale="6" id="f-2024">80.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ShorttermOnerousContractsProvision" scale="6" id="f-2025">235.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherProvisions" scale="6" id="f-2026">79.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherProvisions" scale="6" id="f-2027">51.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:Provisions" scale="6" id="f-2028">278.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:Provisions" scale="6" id="f-2029">375.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentProvisions" scale="6" id="f-2030">269.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentProvisions" scale="6" id="f-2031">367.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-2032">8.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentProvisions" scale="6" id="f-2033">8.6</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:LegalProceedingsProvision" format="ixt:num-dot-decimal" scale="6" id="f-2034">118.2</ix:nonFraction>&#160;million in contractual disputes mainly related to purported obligations arising out of certain contractual disputes unrelated to the below-mentioned patent proceedings (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LegalProceedingsProvision" format="ixt:num-dot-decimal" scale="6" id="f-2035">88.9</ix:nonFraction>&#160;million as of December&#160;31, 2022). Acknowledging an increase in obligations identified as contractual disputes, the change of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentOnerousContractsProvisionAdditions" format="ixt:num-dot-decimal" scale="6" id="f-2036">29.3</ix:nonFraction>&#160;million compared to the previous period related mainly to additions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ShorttermOnerousContractsProvision" format="ixt:num-dot-decimal" scale="6" id="f-2037">80.2</ix:nonFraction>&#160;million&#160;(&#8364;<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ShorttermOnerousContractsProvision" format="ixt:num-dot-decimal" scale="6" id="f-2038">235.5</ix:nonFraction>&#160;million as of December&#160;31, 2022) of obligations for production capacities derived from contracts with Contract Manufacturing Organizations, or CMOs, that became redundant The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. The related expenses were recognized in cost of sales in our consolidated statements of profit or loss. The change of &#8364;(<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" scale="6" id="f-2039">155.3</ix:nonFraction>)&#160;million compared to the previous period related to addition (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentOnerousContractsProvisionOtherAdditionalProvisions" format="ixt:num-dot-decimal" scale="6" id="f-2040">45.1</ix:nonFraction>&#160;million), to release (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentOnerousContractsProvisionRelatedToRelease" format="ixt:num-dot-decimal" scale="6" id="f-2041">126.0</ix:nonFraction>&#160;million) and usage (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:CurrentOnerousContractsProvisionRelatedToUsage" format="ixt:num-dot-decimal" scale="6" id="f-2042">74.5</ix:nonFraction>&#160;million). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-2043">79.7</ix:nonFraction> million in other obligations mainly comprising inventor remunerations as well as customs and duties (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-2044">51.4</ix:nonFraction> million as of December&#160;31, 2022, mainly comprising inventor remunerations as well as customs and duties). The change of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdditionalProvisionsOtherProvisions" format="ixt:num-dot-decimal" scale="6" id="f-2045">28.3</ix:nonFraction>&#160;million compared to the previous period related mainly to additions.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_549755817839"></div><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="f-2046" continuedAt="f-2046-1" escape="true">Contingencies and other financial commitments</ix:nonNumeric></span></div><ix:continuation id="f-2046-1" continuedAt="f-2046-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingencies include, but are not limited to, intellectual property disputes and product liability and other product-related litigation. From time to time, in the normal course and conduct of our business, we may be involved in discussions with third parties about considering, for example, the use and/or remuneration for use of such third party&#8217;s intellectual property. As of December&#160;31, 2023, none of such intellectual property-related considerations that we have been notified of, and for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. We are subject to an increasing number of product liability claims. Such claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics/package leaflet) as well as label warnings and reliance thereon, scientific evidence and findings, actual and provable injury, and other matters. These complexities vary from matter to matter. As of December 31, 2023, none of these claims fulfill the criteria for recording a provision. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pending matters to which we are a party are discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Proceedings</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2046-2" continuedAt="f-2046-3"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &amp; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#8216;933 Patent, is infringed by the cationic lipid used in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#8216;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#8216;979 Patent, which is a continuation of the &#8216;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479; 11,633,480; 11,612,657; and 11,590,229, all of which are continuations of the &#8216;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the proceedings have been consolidated and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are currently pending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Alnylam&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CureVac Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;122, DE&#8217;961, DE&#8216;974, DE&#8217;575, and EP&#8217;668</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP1857122B1, or the EP&#8217;122 Patent, and three Utility Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or the EP&#8217;668 Patent, to its German lawsuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the D&#252;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#8217;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668) pending validity decisions in the DE&#8217;961, DE&#8217;974, and DE&#8217;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#8217;668 opposition proceedings before the Opposition Division of the European Patent Office. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668. On December 28, 2023, the D&#252;sseldorf Regional Court stayed the infringement proceedings as to EP&#8217;122 until a final appellate decision is rendered as to the validity of EP 122 by the Federal Court of Justice.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;755, DE&#8217;123, and DE&#8217;130</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP4023755B1, or the EP&#8217;755 Patent, and two Utility Models DE202021004123U1, and DE202021004130U1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nullity Proceedings &#8211; EP&#8217;122</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#8217;122 Patent is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#8217;122 nullity action in support of the validity of the EP&#8217;122 Patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary opinion did not address any infringement of the EP&#8217;122 Patent.  The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#8217;122. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cancellation Proceedings&#8211; DE&#8217;961, DE&#8216;974, and DE&#8217;575</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2046-3" continuedAt="f-2046-4"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent Office issued a preliminary opinion that DE&#8217;974 is likely to be cancelled based on invalidity pursuant to para. 1 (2) no. 5 Utility Model Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070; 11,286,492; 11,345,920; 11,471,525; 11,576,966; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against the EP&#8217;122 Patent and the EP&#8217;668 Patent in the Business and Property Courts of England and Wales. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#8217;122 and EP&#8217;668 patents in the Business And Property Courts of England and Wales. On December 18, 2023, we amended our pleadings to further allege non-infringement and invalidity against EP&#8217;755.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and utility models and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVac&#8217;s claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging Comirnaty&#8217;s infringement of two European Patents, 3590949B1, or the EP&#8217;949 Patent, and 3718565B1, or the EP&#8217;565 Patent.  On November 7, 2023, the European Patent Office (&#8220;EPO&#8221;) Opposition Division revoked EP&#8217;565 after a one-day oral hearing.  The Opposition Division issued a preliminary opinion on December 8, 2023 noting that it believes EP&#8217;949 is likely invalid.  As a result of these EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit asserting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of the EP&#8217;949 Patent and EP&#8217;565 Patent. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. District Court Litigation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit in the United States District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of U.S. Patent Nos. 10,898,574, 10,702,600 and 10,933,127 and seeking monetary relief. </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2046-4" continuedAt="f-2046-5"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Review</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Netherlands</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#8217;s infringement of the EP &#8216;949 Patent and the EP &#8217;565 Patent. The District Court of the Hague held a hearing on October 6, 2023 on infringement and validity with respect to the EP &#8217;949 Patent. On December 6, 2023, the Court found EP&#8217;949 to be invalid. The EP&#8217;565 case has been stayed pending Moderna&#8217;s appeal of the Opposition Division&#8217;s revocation of EP&#8217;565.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ireland</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent in the High Court of Ireland.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Belgium</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and the EP&#8217;565 Patent in the Brussels Dutch-speaking Enterprise Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arbutus and Genevant Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus: U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief. This proceeding is currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promosome Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Promosome LLC filed a lawsuit against Pfizer, us, and BioNTech Manufacturing GmbH in the U.S. District Court for the Southern District of California alleging that Pfizer and our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine has infringed U.S. Patent No. 8,853,179, and seeking monetary relief. On October 4, 2023, the parties filed a joint stipulation of dismissal, dismissing the lawsuit with prejudice. As part of this stipulation of dismissal, Promosome agreed to a covenant not to assert U.S. Patent No. 8,853,179 against Pfizer and us or any of their products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This matter is considered closed.</span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2046-5"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other financial commitments</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="f-2047" continuedAt="f-2047-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other financial commitments were as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" scale="6" id="f-2048">154.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" scale="6" id="f-2049">105.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2050">1,721.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-2051">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="6" id="f-2052">1,875.5</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="f-2053">105.2</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations to acquire intangible assets exist in connection with in-licensing and research and development collaborations. We have entered into obligations to make milestone payments once specific targets have been reached. Provided that all of the milestone events are achieved, we would be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2054">1,721.1</ix:nonFraction>&#160;million as of December&#160;31, 2023 (<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" format="ixt:fixed-zero" scale="0" id="f-2055">nil</ix:nonFraction> as of December&#160;31, 2022) in connection with the acquisition of intangible assets. The amounts shown represent the maximum payments to be made, and it is unlikely that they will all fall due. The amounts and the dates of the actual payments may both vary considerably from those stated in the table, since the achievement of the conditions for payment is possible but uncertain. Other financial obligations from possible future sales-based milestone and license payments were not included in the table above.</span></div><ix:continuation id="f-2047-1"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected maturities of payment obligations under purchase agreements for property, plant and equipment and contractual obligations to acquire intangible assets are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" scale="6" id="f-2056">152.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-752" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" scale="6" id="f-2057">1.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-2058">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" scale="6" id="f-2059">154.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" scale="6" id="f-2060">249.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-752" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" scale="6" id="f-2061">954.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" scale="6" id="f-2062">516.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-2063">1,721.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-751" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="f-2064">401.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-752" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="f-2065">956.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-753" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="f-2066">516.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="6" id="f-2067">1,875.5</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial obligations were recognized at nominal value.</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_294"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">19&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="f-2068" continuedAt="f-2068-1" escape="true">Other Non-Financial Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" id="f-2069" escape="true"><ix:continuation id="f-2068-1"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities to employees </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:LiabilitiesForEmployeeBenefits" scale="6" id="f-2070">73.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:LiabilitiesForEmployeeBenefits" scale="6" id="f-2071">50.6</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from share-based payment arrangements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" scale="6" id="f-2072">29.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" scale="6" id="f-2073">36.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from wage taxes and social securities expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" scale="6" id="f-2074">15.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" scale="6" id="f-2075">761.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:OtherLiabilitiesOther" scale="6" id="f-2076">20.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:OtherLiabilitiesOther" scale="6" id="f-2077">29.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNonfinancialLiabilities" scale="6" id="f-2078">138.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNonfinancialLiabilities" scale="6" id="f-2079">877.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="6" id="f-2080">125.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="6" id="f-2081">860.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" scale="6" id="f-2082">13.1</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" scale="6" id="f-2083">17.0</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-71</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_284"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-2084" continuedAt="f-2084-1" escape="true">Leases</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_278"></div><ix:continuation id="f-2084-1" continuedAt="f-2084-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.1&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Financial Position</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Right-of-Use Assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-2085" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-754" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2086">209.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-755" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2087">206.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-756" decimals="-5" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="6" id="f-2088">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-757" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2089">3.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-758" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2090">4.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-759" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2091">2.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2092">214.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:RightofuseAssets" scale="6" id="f-2093">211.9</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions to the right-of-use assets during the year ended December&#160;31, 2023, were &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-2094">66.4</ix:nonFraction> million&#160;(during the year ended December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="6" id="f-2095">118.3</ix:nonFraction> million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Liability</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" id="f-2096" escape="true"><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are included in lease liabilities, loans and borrowings as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-2097">28.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="f-2098">36.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="f-2099">188.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="f-2100">174.1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-2101">216.7</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="ifrs-full:LeaseLiabilities" scale="6" id="f-2102">210.1</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_272"></div><ix:continuation id="f-2084-2" continuedAt="f-2084-3"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.2&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Profit or Loss</span></div><ix:nonNumeric contextRef="c-1" name="bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" id="f-2103" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation Charge of Right-of-Use Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-760" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2104">40.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-761" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2105">35.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-762" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2106">14.7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-763" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2107">3.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-764" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2108">23.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-765" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2109">14.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-766" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2110">1.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-767" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2111">0.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-768" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2112">0.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total depreciation charge</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2113">45.2</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2114">58.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="f-2115">29.0</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-2116">5.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-2117">5.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="f-2118">2.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense related to short-term leases and leases of low-value assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="6" id="f-2119">58.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="6" id="f-2120">27.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" scale="6" id="f-2121">9.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amounts recognized in profit or loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="bntx:LeaseExpensesRecognizedInProfitOrLoss" scale="6" id="f-2122">109.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="bntx:LeaseExpensesRecognizedInProfitOrLoss" scale="6" id="f-2123">91.0</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="bntx:LeaseExpensesRecognizedInProfitOrLoss" scale="6" id="f-2124">41.4</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_266"></div><ix:continuation id="f-2084-3" continuedAt="f-2084-4"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.3&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the total cash outflow for leases amounted to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-2125">46.0</ix:nonFraction> million (during the year ended December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-2126">46.2</ix:nonFraction> million; during the year ended December&#160;31, 2021: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="6" id="f-2127">17.0</ix:nonFraction> million).</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_259"></div><ix:continuation id="f-2084-4" continuedAt="f-2084-5"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.4&#160;&#160;&#160;&#160;Extension Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased asset portfolio and align with the Group&#8217;s business needs. Management exercises judgment in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2084-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-14" decimals="-5" name="bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2128">157.2</ix:nonFraction>&#160;million as of December&#160;31, 2023, considering terms up until 2049 (as of December&#160;31, 2022: &#8364;<ix:nonFraction unitRef="eur" contextRef="c-15" decimals="-5" name="bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-2129">163.1</ix:nonFraction>&#160;million considering terms up until 2049).</span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_220"></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">21&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-2130" continuedAt="f-2130-1" escape="true">Related Party Disclosures</ix:nonNumeric></span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_214"></div><ix:continuation id="f-2130-1" continuedAt="f-2130-2"><div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.1&#160;&#160;&#160;&#160;Parent and Ultimate Controlling Party</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of our ordinary shares. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. </span></div></ix:continuation><div id="ic5e06a05a31d4c4491031d3208cef8c2_2914"></div><ix:continuation id="f-2130-2" continuedAt="f-2130-3"><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">21.2&#160;&#160;&#160;&#160;Transactions with Key Management Personnel</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, at the Annual General Meeting, our shareholders reappointed Ulrich Wandschneider and Michael Motschmann as members of the Supervisory Board. In addition, Nicola Blackwood was appointed to our Supervisory Board. She succeeded Christoph Huber, who left the Supervisory Board after reaching the applicable retirement age limit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Management Personnel Compensation</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="f-2131" continuedAt="f-2131-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key management personnel has been defined as the members of the Management Board and the Supervisory Board. Key management personnel compensation is comprised of the following:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Board</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2132">8.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2133">15.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2134">20.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="bntx:KeyManagementPersonnelCompensationFixedCompensation" scale="6" id="f-2135">3.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="bntx:KeyManagementPersonnelCompensationFixedCompensation" scale="6" id="f-2136">2.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="bntx:KeyManagementPersonnelCompensationFixedCompensation" scale="6" id="f-2137">2.2</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; first installment</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-2138">0.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-2139">0.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="6" id="f-2140">0.6</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; second installment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" scale="6" id="f-2141">1.0</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" scale="6" id="f-2142">0.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" scale="6" id="f-2143">1.2</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other variable compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="bntx:KeyManagementPersonnelCompensationOtherVariableCompensation" scale="6" id="f-2144">0.8</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="bntx:KeyManagementPersonnelCompensationOtherVariableCompensation" scale="6" id="f-2145">0.1</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="bntx:KeyManagementPersonnelCompensationOtherVariableCompensation" format="ixt:fixed-zero" scale="6" id="f-2146">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments (incl. long-term incentive)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-769" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-2147">1.9</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-770" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-2148">10.7</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-771" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="6" id="f-2149">16.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-772" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2150">0.6</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-773" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2151">0.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-774" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2152">0.4</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total compensation paid to key management personnel</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-1" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2153">8.9</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-12" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2154">15.5</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-13" decimals="-5" name="ifrs-full:KeyManagementPersonnelCompensation" scale="6" id="f-2155">20.8</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes a one-time signing and retention cash payment agreed when renewing the service agreement agreed with Sean Marett.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><ix:continuation id="f-2131-1" continuedAt="f-2131-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="f-2131-2">&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#8220;Stock-based Payments.&#8221; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. During the years ended December&#160;31, 2023, 2022, and 2021, the amounts included expenses derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the form of <ix:nonFraction unitRef="shares" contextRef="c-775" decimals="INF" name="bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded" format="ixt:num-dot-decimal" scale="0" id="f-2156"><ix:nonFraction unitRef="shares" contextRef="c-776" decimals="INF" name="bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded" format="ixt:num-dot-decimal" scale="0" id="f-2157"><ix:nonFraction unitRef="shares" contextRef="c-777" decimals="INF" name="bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded" format="ixt:num-dot-decimal" scale="0" id="f-2158">4,246</ix:nonFraction></ix:nonFraction></ix:nonFraction> phantom shares.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management Board members participated in our ESOP program (see Note 16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Out of the <ix:nonFraction unitRef="shares" contextRef="c-778" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2159">5,152,410</ix:nonFraction> option rights granted to our Management Board under the ESOP 2018 program <ix:nonFraction unitRef="shares" contextRef="c-778" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-2160">4,921,630</ix:nonFraction> options were exercised during the year ended December 31, 2022. The remaining <ix:nonFraction unitRef="shares" contextRef="c-779" decimals="INF" name="bntx:NumberOfShareOptionsHeld" format="ixt:num-dot-decimal" scale="0" id="f-2161">230,780</ix:nonFraction> option rights were exercised by Sean Marett in May 2023. As of December 31, 2023, no further options issued to our Management Board members are outstanding. </span></div></ix:continuation><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-73</span></div></div></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_200"></div><hr style="page-break-after:always"/><div style="min-height:57.6pt;width:100%"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic5e06a05a31d4c4491031d3208cef8c2_4">s</a></span></div></div><ix:continuation id="f-2130-3" continuedAt="f-2130-4"><div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.3&#160;&#160;&#160;&#160;Related Party Transactions</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-2162" continuedAt="f-2162-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:55.848%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of various goods and services from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-780" decimals="-5" name="bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions" scale="6" id="f-2163">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-781" decimals="-5" name="bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions" scale="6" id="f-2164">0.3</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-782" decimals="-5" name="bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions" scale="6" id="f-2165">0.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of property and other assets from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-780" decimals="-5" name="ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" format="ixt:fixed-zero" scale="6" id="f-2166">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-781" decimals="-5" name="ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" scale="6" id="f-2167">62.5</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-782" decimals="-5" name="ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" format="ixt:fixed-zero" scale="6" id="f-2168">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-780" decimals="-5" name="bntx:PurchasesFromRelatedPartyTransactions" scale="6" id="f-2169">0.3</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-781" decimals="-5" name="bntx:PurchasesFromRelatedPartyTransactions" scale="6" id="f-2170">62.8</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-782" decimals="-5" name="bntx:PurchasesFromRelatedPartyTransactions" scale="6" id="f-2171">0.9</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, we entered into a purchase agreement with Santo Service GmbH, pursuant to which we acquired the real estate property An der Goldgrube 12 and the existing laboratory and office building including any movable assets for a total consideration of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-783" decimals="-5" name="ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="6" id="f-2172">62.5</ix:nonFraction> million. The purchase price was paid during the year ended December 31, 2022. Santo Service GmbH is wholly owned by AT Impf GmbH, that is controlled by ATHOS KG.</span></div><ix:continuation id="f-2162-1"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:0.28pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ATHOS KG</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-784" decimals="-5" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-2173">0.4</ix:nonFraction></span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-785" decimals="-5" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="6" id="f-2174">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-786" decimals="-5" name="ifrs-full:AmountsPayableRelatedPartyTransactions" scale="6" id="f-2175">0.4</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="eur" contextRef="c-787" decimals="-5" name="ifrs-full:AmountsPayableRelatedPartyTransactions" format="ixt:fixed-zero" scale="6" id="f-2176">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-2130-4"><ix:nonFraction unitRef="eur" contextRef="c-14" decimals="INF" name="ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" format="ixt:fixed-zero" scale="0" id="f-2177">None</ix:nonFraction> of the balances are secured and <ix:nonFraction unitRef="eur" contextRef="c-1" decimals="INF" name="ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" format="ixt:fixed-zero" scale="0" id="f-2178">no</ix:nonFraction> bad debt expense has been recognized in respect of amounts owed by related parties.</ix:continuation> </span></div><div id="ic5e06a05a31d4c4491031d3208cef8c2_194"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:111%">22&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-2179" continuedAt="f-2179-1" escape="true">Events After the Reporting Period</ix:nonNumeric></span></div><ix:continuation id="f-2179-1" continuedAt="f-2179-2"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2024, we and Autolus Therapeutics plc, or Autolus, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies' autologous CAR-T programs towards commercialization. We have entered into a license and option agreement and a securities purchase agreement under which we purchased $<ix:nonFraction unitRef="shares" contextRef="c-788" decimals="-5" name="bntx:PurchaseOfSharesUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-2180">200.0</ix:nonFraction>&#160;million of Autolus' American Deposit Shares in a private placement closed on February 13, 2024 resulting in a stake in Autolus ordinary shares of <ix:nonFraction unitRef="number" contextRef="c-789" decimals="3" name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" scale="-2" id="f-2181">12.5</ix:nonFraction>%. Under the terms of the license and option agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-5" name="bntx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-2182">50.0</ix:nonFraction>&#160;million upfront payment in exchange for the right to receive royalties on net sales of Autolus' lead asset obe-cel, co-commercialization options for Autolus' AUTO1/22 and AUTO6NG programs as well as an exclusive license and exclusive options to certain technologies owned by Autolus.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-2179-2">The Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer (CCO), effective as of July 1, 2024. She will take over the role from Sean Marett, who will retire as planned from the Management Board as of June 30, 2024.</ix:continuation> </span></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-74</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.4
<SEQUENCE>2
<FILENAME>exhibit24descriptionofsecu.htm
<DESCRIPTION>EX-2.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4894081d8d52461d8610e04699024495_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 2.4</font></div></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION OF SECURITIES</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of BioNTech SE (&#8220;BioNTech,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisions of our articles of association and German law as of the date of the filing of the Annual Report on Form 20-F of which this exhibit forms a part. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of association filed with the Securities and Exchange Commission as an exhibit to the Annual Report on Form 20-F of which this exhibit forms a part, as well as to the applicable provisions of German legislation on stock corporations. We encourage you to read our articles of association and the applicable provisions of German law for additional information.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ordinary Shares</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We were </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporated</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> as a German stock corporation (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Aktiengesellschaft</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) with the legal name Petersberg 91. V AG under the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">laws</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of the Federal Republic of Germany on June 2, 2008. We changed our name to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> AG on December 11, 2008. Effective as of March 8, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the date on which the change of legal form and company was registered with the commercial register (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Handelsregister</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of the local court (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amtsgericht</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Mainz, Germany, we converted to a </font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Societas Europaea </font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with the legal name BioNTech SE. We completed our initial public offering in October 2019. The principal legislation under which we operate and our shares are issued are the Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE), the German Law on the Implementation of Council Regulation (EC) No 2157&#47;2001 of October 8, 2001 on the Statute for a European company (SE) (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gesetz zur Ausf&#252;hrung der Verordnung (EG) NR. 2157&#47;2001 des Rates vom 8. Oktober 2001 &#252;ber das Statut der Europ&#228;ischen Gesellschaft (SE) (SE-Ausf&#252;hrungsgesetz&#8212;SEAG)</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and the German Stock Corporation Act (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Aktiengesetz</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), in each case as amended.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">are</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> registered with the commercial register (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Handelsregister</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of the local court (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Amtsgericht</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) in Mainz, Germany, under number HRB 48720. Our statutory seat is in Mainz, Germany, and our registered office is An der Goldgrube 12, 55131 Mainz, Germany. Copies of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) will be publicly available from the commercial register (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Handelsregister</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) at the local court of Mainz, Germany, electronically</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> at https&#58;&#47;&#47;www.handelsregister.de&#47;rp_web&#47;welcome.xhtml and</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> as an exhibit to this Annual Report.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have share capital registered in the commercial register (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Handelsregister</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) in the amount of &#8364;248,552,200, which is divided into 248,552,200 registered shares (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Namensaktien</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). All shares are shares with no par value (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">St&#252;ckaktien ohne Nennbetrag</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) with a notional amount attributable to each ordinary share of &#8364;1. Each issued ordinary share is fully paid.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form, Certification and Transferability of Shares</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The form and contents of our share certificates, collective share certificates and global share certificates are determined by our Management Board. A shareholder&#8217;s right to certification of its shares is excluded, to the extent permitted by law and to the extent that certification is not required by the stock exchange on which the shares or rights or certificates representing them are admitted to trading. We are permitted to issue collective share certificates and global share certificates that represent multiple or all of our shares.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our shares are freely transferable under German law.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-takeover Provisions of Our Charter Documents</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) do not include any provisions that would have a direct effect of delaying, deferring or preventing a change of control. However, in the event of a hostile takeover, we could use our authorized capital to increase our share capital to issue new shares to an investor at a premium. An increase in the number of shares outstanding could have a negative effect on a party&#8217;s ability to carry out a hostile takeover. The provisions of German law relating to public bids and takeovers that require any such bids to be carried out in a manner designed to safeguard equal and fair treatment to all shareholders and give them a right to be bought out at an adequate compensation where a party acquires &#8220;control&#8221; (as such term is defined in such provisions) over the relevant company do not apply.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Changes to the Share Capital</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Authorized Capital</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the relevant law, the general meeting of a European stock corporation (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Societas Europaea</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) governed by German law can authorize the Management Board to, with the consent of the Supervisory Board, issue shares in a specified aggregate nominal amount of up to 50% of the issued share capital of such company at the time the resolution becomes effective. The shareholders&#8217; authorization becomes effective upon registration in the commercial register (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Handelsregister</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and may extend for a period of no more than five years thereafter. Under &#167; 4(5) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Management Board is authorized to increase our share capital, on one or more occasions, by a total of up to &#8364;122,657,313 by issuing, on one or more occasions, up to 122,657,313 new, registered shares with no par value (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Genehmigtes Kapital</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), in each case with consent of the Supervisory Board. This authorization expires on June 21, 2026.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any new shares issued from the authorized capital will participate in the profits starting with the fiscal year for which the annual financial statements have not yet been submitted to the general meeting at the time of registration of the implementation of the capital increase. Further details of a capital increase from the authorized capital may be specified by the Management Board.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Conditional Capital</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to &#167; 4(6) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), our share capital is conditionally increased by &#8364;16,212,917 through issuance of new, registered shares with no par value (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bedingtes Kapital ESOP 2017&#47;2019</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The conditional capital may only be used to issue shares to the holders of option rights granted under our ESOP to members of our Management Board and to certain of our employees.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The conditional capital increase will only be implemented to the extent that stock options under our ESOP are exercised and said stock options are not serviced by our providing treasury shares or through cash payments. Any new shares issued under the conditional capital pursuant to the said &#167; 4(6) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall be entitled to dividends from the beginning of the previous financial year in case they are created by the exercise of subscription rights until the start of the annual general meeting of the Company and otherwise from the beginning of the financial year in which they are created as a result of the exercise of the stock options.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to &#167; 4(7) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), our share capital is conditionally increased by &#8364;85,754,868 through issuance of new, registered shares with no par value (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bedingtes Kapital WSV 2019</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The conditional capital may only be used to issue shares to the holders or creditors of option rights or conversion rights or those under an obligation to convert under warrant-linked or convertible bonds avail of their option rights or conversion rights or where they are under an obligation to convert, to the extent they satisfy their obligation to convert, or to the extent that we exercise a right to choose to grant our shares, in whole or in part instead of paying a monetary amount due, and to the extent cash compensation is not granted in each relevant case or treasury shares or shares of another stock-listed company are not utilized for servicing.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any new shares issued under the said conditional capital pursuant to the said &#167; 4(7) of our Articles of Association shall carry an entitlement to dividends from the beginning of the financial year in which they are created&#59; however, as far as the law permits, the Management Board can confer dividend rights for new shares in derogation of the foregoing.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to &#167; 4(8) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), our share capital is conditionally increased by &#8364;8,418,091 through issuance of new, registered shares with no par value (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bedingtes Kapital ESOP 2021</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The conditional capital serves exclusively to grant rights to the holders of stock options issued by the Company in accordance with the authorization granted by the Annual General Meeting on June 22, 2021 under agenda item 6 letter d) (the &#8220;Authorization 2021&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The conditional capital increase will only be implemented to the extent that stock options under our ESOP are exercised by the holders of the stock options issued by the Company on the basis of Authorization 2021 and such stock options are not settled by the Company with treasury shares or through cash payments. Any new shares issued under the conditional capital pursuant to &#167; 4(8) of our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall participate in profits from the beginning of the preceding financial year in case they are created by the exercise of subscription rights until the start of the annual general meeting of the Company and otherwise from the beginning of the financial year in which they are created as a result of the exercise of the stock options.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Preemptive Rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">German law generally provides shareholders with preemptive rights when new shares convertible bonds, bonds with warrants, profit participation rights or participating bonds are issued. This requirement, however, may also be satisfied by way of a credit institution subscribing for the securities and then offering them to the shareholders for purchase (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">mittelbares Bezugsrecht</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, it is possible for a shareholder resolution approved by three-quarters of the share capital voting on the resolution to exclude preemptive rights both where the general meeting itself resolves that the new securities to be issued and in relation to the authorized capital, </font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">i.e., </font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an authorization to the Management Board to, with the consent of the Supervisory Board, resolve on the issuance of new securities&#59; provided, however, that in each case the exclusion or the authorization to so exclude preemptive rights, respectively, must be justified by specific facts, in accordance with established case law of the German Federal Court of Justice (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BGH</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The German Federal Court of Justice (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BGH</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) considers the exclusion of subscription rights justified if it (i) serves a purpose in the company&#8217;s interests, (ii) is suitable for attaining such purpose, and (iii) is necessary and appropriate. Additionally, the management board must submit a written report to the shareholders&#8217; meeting in which it presents the reasons for the exclusion of the subscription rights.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, under our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Management Board may, with the consent of the Supervisory Board, exclude such preemptive rights in a capital increase from the authorized capital in the following circumstances&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to exclude fractional amounts from the subscription right&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in the case of a capital increase against cash contributions, if the issue price of the new shares is not significantly lower than the market price of the company&#8217;s shares already listed on the stock exchange at the time the issue price is finally determined. However, this authorization shall only apply subject to the provision that the shares issued excluding subscription rights in accordance with Section 186(3) Sentence 4 AktG may not exceed a total of 10% of the share capital either at the time this authorization takes effect or, if this amount is lower, at the time this authorization is exercised. This limit of 10% of the share capital includes shares which are issued or disposed of during the term of this authorization until the date of its exercise in direct or equivalent application of Section 186(3) Sentence 4 AktG. Shares which are used to service bonds with convertible or option rights or convertible obligations are to be offset against the 10% limit if these bonds were issued under exclusion of shareholder subscription rights in accordance with Section 186(3) Sentence 4 AktG during the entitlement period. Treasury shares are to be offset against the 10% limit, where they were disposed of by the company during the term of this authorization with the exclusion of subscription rights pursuant to or in analogous application of Section 186(3) Sentence 4 AktG&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in the case of capital increases in exchange for contributions in kind, in particular in order to be able to offer the shares to third parties when purchasing companies, parts of companies or interests in companies as well as licenses or intellectual property rights&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in order to grant subscription rights to new shares to holders of conversion or option rights in respect of bonds issued by the company or its subordinated domestic or foreign Group companies, to the extent to which they would be entitled after exercising their conversion or option rights or after fulfilling an agreed conversion obligation&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">to implement an election dividend by which shareholders are given the option to contribute their dividend entitlements (either in whole or part) as a contribution in kind against issuance of our new shares&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in case shares are to be issued to a member of our Management Board or to another person who is employed by us or one of our affiliates, additional restrictions with regard to the shares issued may be agreed upon&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">in order to be able to satisfy an option to acquire additional ordinary shares or American Depositary Shares that has been agreed with the issuing banks in connection with a public offering of our shares in the form of American Depositary Shares.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total number of new shares issued from the authorized capital and under exclusion of subscription rights pursuant to bullets one through three and six above may not exceed 20% of the share capital, either at the time that the amendment to the Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), resolved upon by the general meeting of June 26, 2020, has come into effect or, if lower, at the time of utilization of the authorization. To be counted against the aforementioned 20% limit are&#58; (i) those shares issued or to be issued to service conversion or option rights or conversion or option obligations or tender rights of the issuer under bonds, if the bonds have been issued during the term of this authorization up to the time of its exercise, excluding the subscription rights of shareholders, as well as, to a certain extent (ii) treasury shares that have been disposed under exclusion of subscription rights during the term of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">authorization (except in the case of certain exceptions of the resolution to item no. 8 of the general meeting of August 19, 2019).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; Meetings and Voting Rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), shareholders&#8217; meetings may be held at our seat or in any municipality in Germany with more than 500,000 inhabitants. Generally, shareholders&#8217; meetings are convened by our Management Board, or our Supervisory Board. Shareholders representing in the aggregate at least five percent of our ordinary shares may, subject to certain formal prerequisites, request that a shareholders&#8217; meeting be convened. Shareholders representing in the aggregate at least five percent of our ordinary shares or owning shares with an aggregate nominal value of at least &#8364;500,000 may request the addition of one or several items to the agenda of any shareholders&#8217; meeting. Shareholders&#8217; meetings may be summoned either via publication in the German Federal Gazette (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bundesanzeiger</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or via mail or via email, in each case generally at least 30 days before the meeting.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders may participate in and vote in the shareholders&#8217; meeting if they are registered as a shareholder with the Company&#8217;s share register. A shareholder who wishes to attend the shareholders&#8217; meeting&#8212;either in person or by proxy, which may also be appointed by us (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Stimmrechtsvertreter</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#8212;must register for the meeting, which registration must occur no later than six days before the meeting (or at a later date, if so determined by our Management Board).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each share carries one vote at a shareholders&#8217; meeting. Resolutions are, in accordance with our Articles of Association (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Satzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), generally taken by simple majority of the votes cast. However, under applicable German and European law, a number of resolutions must be passed by either a three-quarter majority of the votes cast or a three-quarter majority of the share capital represented at the meeting. The fact that in these cases the quorum is determined in relation to the share capital or shares present (as opposed to, for example, all shares eligible to vote) means that holders of a minority of our shares could potentially control the outcome of resolutions.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Claims against Directors and Shareholders&#8217; Derivative Actions</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its management board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board. This concerns, in particular, claims against members of the Management Board or the Supervisory Board.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">However, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so. Further, the Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can also request that a representative pursue the claim on behalf of the company. The court may appoint such a representative upon the request of shareholders holding at least 10% of the company&#8217;s share capital or a participation of at least &#8364;1,000,000 in the share capital.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the company is unable to fulfill its third-party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least 1% of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) must comply with special claim approval procedures conducted before a competent court which will allow the pertinent request only if there are circumstances justifying the assumption that damage has been afflicted on the company by improper conduct or a gross breach of the law or the articles of association.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividend Rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, distributions of dividends on shares for a given fiscal year are generally determined by a process in which the Management Board and Supervisory Board submit a proposal to the company&#8217;s annual general </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shareholders&#8217; meeting held in the subsequent fiscal year and such annual general shareholders&#8217; meeting adopts a resolution.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">German law provides that a resolution concerning dividends and distribution thereof may be adopted only if the company&#8217;s unconsolidated financial statements prepared in accordance with German law show net retained profits. In determining the profit available for distribution, the result for the relevant year must be adjusted for profits and losses brought forward from the previous year and for withdrawals from or transfers to reserves. Certain reserves are required by law and must be deducted when calculating the profit available for distribution.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders generally participate in profit distributions in proportion to the number of shares they hold. Dividends on shares resolved by the general shareholders&#8217; meeting are paid annually, shortly after the general shareholders&#8217; meeting, in compliance with the rules of the respective clearing system. Dividend payment claims are subject to a three-year statute of limitation in the company&#8217;s favor.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorization to Purchase and Sell Our Own Shares</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may not purchase our own shares unless authorized by the shareholders&#8217; meeting or in other very limited circumstances as set out in the German Stock Corporation Act. The Company&#8217;s shareholders&#8217; meeting held on August 19, 2019 authorized the Management Board until August 18, 2024, provided it complies with the legal requirement of equal treatment, to acquire treasury shares up to a total of 10% of the Company&#8217;s share capital at the time of the relevant resolution or at the time the authorization is exercised. These shares held by the Company (including shares attributable to it pursuant to the AktG) must never exceed 10% of the share capital. The shares may be purchased (i) through the stock exchange, (ii) by means of a public offer directed to all shareholders of the Company, (iii) by means of a public invitation to the shareholders to make a sales offer or (iv) from the Bill &#38; Melinda Gates Foundation under very limited circumstances as specified in the authorization. Such shares may not be purchased for trading purposes. The Management Board is authorized to use the shares only as specified in the authorization.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Squeeze-Out of Minority Shareholders</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, the shareholders&#8217; meeting of a stock corporation may resolve, upon request of a shareholder that holds at least 95% of the share capital, that the shares held by any remaining minority shareholders be transferred to the majority shareholder against payment of &#8220;adequate cash compensation&#8221; (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Ausschluss von Minderheitsaktion&#228;ren</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). This amount must take into account the full value of the company at the time of the resolution, which is generally determined using the future earnings value method (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Ertragswertmethode</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A squeeze-out in the context of a merger (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">umwandlungsrechtlicher Squeeze-Out</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) only requires a majority shareholder to hold at least 90% of the share capital.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidation Rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apart from liquidation, e.g., as a result of insolvency proceedings, we may be liquidated with a vote of the holders of at least three-quarters of the share capital represented at the shareholders&#8217; meeting at which such a vote is taken. If we are liquidated, any assets remaining after all of our liabilities have been paid off would be distributed among our shareholders in proportion to their holdings in accordance with German statutory law. The German Stock Corporation Act provides certain protections for creditors which must be observed in the event of liquidation.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Differences in Corporate Law</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The applicable provisions of the SE Regulation in conjunction with the German Stock Corporation Act as applied to a European stock corporation that has its legal seat in Germany differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the SE Regulation in conjunction with the German Stock Corporation Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and European and German law.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Board System</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A European stock corporation may choose to have a two-tier board structure composed of the Management Board (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Vorstand</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and the Supervisory Board (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Aufsichtsrat</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). We have chosen this structure.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Management Board is responsible for running the company&#8217;s affairs and representing the company in dealings with third parties.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Supervisory Board of a European stock corporation under German law has a control and supervisory function. The Supervisory Board does not actively manage the company but certain Management Board actions require the approval of the Supervisory Board.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a corporation has a unitary board structure, and it is the responsibility of the board of directors to appoint and oversee the management of the corporation on behalf of and in the best interests of the stockholders of the corporation.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management is responsible for running the corporation and overseeing its day-to-day operations.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Appointment and Number of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under applicable European and German law, a European stock corporation governed by German law with a share capital of at least &#8364;3 million generally must have at least two members on its Management Board and the number of members shall be determined by or in the manner provided in the company&#8217;s articles of association.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Supervisory Board must consist of at least three but&#8212;depending on the share capital&#8212;no more than 21 Supervisory Board members, whereby the number of Supervisory Board members must be divisible by three if this is necessary for the fulfilment of co-determination requirements. The articles of association of the company must specify if the Supervisory Board has more than three members.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Supervisory Board members are either appointed by the shareholders&#8217; meeting or delegated by one or more individual shareholders if so provided for in the company&#8217;s articles of association. If the Supervisory Board consists of fewer members than is required to meet the quorum for resolutions (either statutory or pursuant to the company&#8217;s articles of association), a competent court may appoint additional members as needed to meet the quorum. The provisions of German law in relation to employees&#8217; co-determination do not apply to the Company.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Removal of Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members of the Management Board of a European stock corporation are appointed by the Supervisory Board for a maximum period of six years with an opportunity to be reelected. The articles of association may provide for a shorter term, which in our case is up to five years. The members of the Management Board may be reelected, even repeatedly. The Supervisory Board may remove a member of the Management Board prior to the expiration of his or her term only for cause, such as gross breach of duties (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">grobe Pflichtverletzung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the inability to manage the business properly (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Unf&#228;higkeit zur ordnungsgem&#228;&#223;en Pflichtaus&#252;bung</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or a vote of no-confidence during the shareholders&#8217; meeting (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Vertrauensentzug</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The shareholders themselves are not entitled to appoint or dismiss the members of the Management Board.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause&#59; or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under European law, a member of the Supervisory Board of a company may be elected for a term of up to six years. The articles of association may provide for a shorter term. Our Supervisory Board members are, if the general meeting does not resolve on a shorter term, elected for a period up to the end of the general meeting deciding on the discharge for the fourth financial year after the election. Reelection, including repeated reelection, is permissible. Members of the Supervisory Board may be removed with or without cause by way of a general meeting resolution, with the applicable majority requirement depending on the relevant company&#8217;s articles of association.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vacancies on the Board of Directors</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the law, vacant positions on the Management Board are filled by the Supervisory Board in accordance with the general rules of appointment, which provide that vacancies are filled by the simple majority of votes of Supervisory Board members present or represented by proxy at the vote (with, under certain circumstances, the chairman having a casting vote), unless otherwise provided by the company&#8217;s articles of association. In case of emergencies, a vacant position on the Management Board may be filled by an individual appointed by the court. Vacant positions on the Supervisory Board are filled in accordance with the general rules of appointment.</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or by-laws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Annual General Meeting</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A European stock corporation which is governed by German law must hold an annual shareholders&#8217; meeting within six months of the end of its fiscal year. The annual shareholders&#8217; meeting must be held at a location determined by the articles of association. If the articles of association do not provide for a specific location, the shareholders&#8217; meeting shall be held at the company&#8217;s seat or, if applicable, at the venue (in Germany) where its shares are listed.</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General Meeting</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the law, extraordinary shareholders&#8217; meetings, in addition to the annual shareholders&#8217; meetings, may be called by either the Management Board, or by the Supervisory Board. Shareholders holding at least 5% of the company&#8217;s share capital are entitled to request that an extraordinary shareholders&#8217; meeting be convened. In the event that the meeting is not then so convened, a competent court may order that the meeting be convened or authorize the shareholders or their representative to convene the meeting themselves.</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Notice of General Meetings</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under applicable European and German law, unless a longer period is otherwise provided for in the articles of association or applies because of registration requirements stipulated in the articles of association, the shareholders must be given at least 30 days&#8217; advance notice of the shareholders&#8217; meeting. Such notices must at least specify the name of the company, the statutory seat of the company, and the location, date and time of the shareholders&#8217; meeting. In addition, the invitation must contain the agenda items as well as the Management Board&#8217;s and the Supervisory Board&#8217;s voting proposal for each agenda item and, depending on the circumstances, certain further information.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If all shareholders entitled to attend the shareholders&#8217; meeting are present or represented and do not object to the meeting being held, the formalities of calling and holding of a shareholders&#8217; meeting do not apply.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Proxy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A shareholder may designate another person to attend, speak and vote at a shareholders&#8217; meeting of the company on such shareholder&#8217;s behalf by proxy.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to Management Board meetings, a Management Board member may transmit its (written or verbal) vote via another Management Board member.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With respect to Supervisory Board meetings, a Supervisory Board member may participate in voting by issuing a written vote to another Supervisory Board member or any third party entitled to attend the Supervisory Board meeting.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preemptive Rights</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under the law applicable to European stock corporations governed by German law, existing shareholders have a statutory subscription right for any additional issue of shares or any security convertible into shares pro rata to the nominal value of their respective holdings in the company, unless (i) shareholders representing three-quarters of the registered share capital present at the shareholders&#8217; meeting have resolved upon the whole or partial exclusion of the subscription right and (ii) there exists good and objective cause for such exclusion. No separate resolution on the exclusion of subscription rights is required if all shareholders waive their statutory subscription rights.</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, stockholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Authority to Allot</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under applicable European and German law, the Management Board may not allot shares, grant rights to subscribe for or to convert any security into shares unless a shareholder resolution to that effect has been passed at the company&#8217;s shareholders&#8217; meeting granting the Management Board with such authority&#8212;subject to the approval of the Supervisory Board&#8212;in each case in accordance with the provisions of the German Stock Corporation Act.</font></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Under Delaware law, if the corporation&#8217;s certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Liability of Directors and Officers</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, any provision, whether contained in the company&#8217;s articles of association or any contract or otherwise, that purports to exempt a Management or Supervisory Board member from any liability that would otherwise attach to such board member in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, members of both the Management Board and members of the Supervisory Board are liable to the company, and in certain cases to third parties or shareholders, for any damage caused to them due to a breach of such member&#8217;s duty of care. Apart from insolvency or special circumstances, only the company has the right to claim damages from members of either board. The company may waive claims for damages against a negligent Management or Supervisory Board member only after the expiry of three years.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for&#58;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     intentional or negligent payment of unlawful dividends or stock purchases or redemptions&#59; or</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     any transaction from which the director derives an improper personal benefit.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Voting Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under the relevant European and German law, each share, except for statutory non-voting preferred shares (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">nicht stimmberechtigte Vorzugsaktien</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), entitles its holder to vote at the shareholders&#8217; meeting with, in the case of no-par value shares, each share conferring one vote. While German law does not provide for a minimum attendance quorum for shareholders&#8217; meetings, the company&#8217;s articles of association may so provide. In general, resolutions adopted at a shareholders&#8217; meeting may be passed by a simple majority of votes cast, unless a higher majority is required by law or under the company&#8217;s articles of association.</font></div></td><td colspan="3" style="padding:2px 1pt 2px 25.4pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shareholder Vote on Certain Transactions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under applicable European and German law, certain shareholders&#8217; resolutions of fundamental importance require the vote of at least three-quarters of the share capital present or represented in the voting at the time of adoption of the resolution. Resolutions of fundamental importance include, in particular, capital increases with exclusion of subscription rights, capital decreases, the creation of authorized or conditional share capital, the dissolution of a company, a merger into or with another company, split-offs and split-ups, the conclusion of inter-company agreements (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Unternehmensvertr&#228;ge</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), in particular domination agreements (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Beherrschungsvertr&#228;ge</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and profit and loss transfer agreements (</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Ergebnisabf&#252;hrungsvertr&#228;ge</font><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires&#58;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     the approval of the board of directors&#59; and</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard of Conduct for Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under applicable European and German law, both Management and Supervisory Board members must conduct their affairs with &#8220;the care and diligence of a prudent business man&#8221; and act in the best interest of the company. The scope of the fiduciary duties of Management and Supervisory Board members is generally determined by European and German legislation and by the courts.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory and fiduciary duties of members of the Management Board to the company include, among others&#58;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to act in accordance with the law, the company&#8217;s articles of association and the rules of procedure for the Management Board, if any&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to report to the Supervisory Board on a regular basis as well as on certain important occasions&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to exercise reasonable care, skill and diligence&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to maintain a proper accounting system&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to not compete, directly or indirectly, with the company without permission by the supervisory board&#59; and</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to secure that no further transactions are made in case of insolvency.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory and fiduciary duties of members of the Supervisory Board to the company include, among others&#58;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to effectively supervise the Management Board&#8217;s handling of the company&#8217;s affairs&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to evaluate and issue a resolution on certain transactions which can only be conducted by the Management Board after approval of the Supervisory Board&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to approve the company&#8217;s financial statements&#59;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to appoint the Management Board members and to represent the company in transactions between the company and members of the Management Board&#59; and</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     to approve service contracts between individual members of the Supervisory Board and the company.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well- informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;text-align:center;text-indent:24.5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">European Union&#47;Federal Republic of Germany</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stockholder Actions</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under German law, generally, the company, rather than its shareholders, is the proper claimant in an action with respect to a wrong committed against the company, or in cases where there is an irregularity in the company&#8217;s internal management or supervision. Therefore, such claims may only be raised by the company represented by its Management Board, or, in the case of a wrong committed by a member of the Management Board, by the Supervisory Board.</font></div><div style="margin-bottom:12pt;padding-left:24.5pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, pursuant to German case law, the Supervisory Board is obliged to pursue the company&#8217;s claims against the Management Board, unless the interest of the company keeps them from doing so.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Management Board, or, if a claim is against a member of the Management Board, the Supervisory Board, is obliged to pursue the company&#8217;s claims against the designated individuals if so resolved by a simple majority of votes cast during a shareholders&#8217; meeting. With a simple majority of votes, shareholders can request that a representative pursues the claim on behalf of the company.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the company is unable to fulfill its third- party obligations, the company&#8217;s creditors may pursue the company&#8217;s damage claims against members of the Management Board for certain wrongdoings.</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under certain circumstances, shareholders can bring forward damage claims of the company against its management on their own behalf. In order to bring forward such a claim one shareholder alone or together with other shareholders needs to hold at least one percent of the company&#8217;s share capital or a participation of &#8364;100,000 in the share capital. Additionally, the claimant(s) need(s) to pass through special claim approval procedures.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     either (i) allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action, or (ii) or state the reasons for not making the effort.</font></div><div style="margin-bottom:12pt;padding-left:39.5pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;padding-left:24.4pt"><font style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</font></div></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">American Depositary Shares</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Bank of New York Mellon, as depositary, will register and deliver the American Depositary Shares, or the ADSs. Each ADS will represent one share (or a right to receive one share) deposited with The Bank of New York Mellon SA&#47;NV as custodian for the depositary in Germany. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary&#8217;s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may hold ADSs either (i) directly (a) by having an American Depositary Receipt, or an ADR, which is a certificate evidencing a specific number of ADSs registered in your name, or (b) by having uncertificated ADSs registered in your name, or (ii) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, or DTC. If you hold ADSs directly, you are a registered ADS holder, or an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. European and German law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. Those documents are filed as exhibits to the registration statement of which this prospectus forms a part.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dividends and Other Distributions</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How will ADS holders receive dividends and other distributions on the shares&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Rights to purchase additional shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In that case, you will receive no value for them.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Distributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This means that you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deposit, Withdrawal and Cancellation</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How are ADSs issued&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How can ADS holders withdraw the deposited securities&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How do ADS holders interchange between certificated ADSs and uncertificated ADSs&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Voting Rights</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How do ADS holders vote&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&#8217; meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of the State of New York and the provisions of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Except by instructing the depositary as described above, you won&#8217;t be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed or as described in the following sentence. If (i) we asked the depositary to solicit your instructions at least 30 days before the meeting date, (ii) the depositary does not receive voting instructions from you by the specified date and (iii) we confirm to the depositary that&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we wish the depositary to vote uninstructed shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">we reasonably do not know of any substantial shareholder opposition to a particular question&#59; and</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">the particular question is not materially adverse to the interests of shareholders,</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the depositary will consider you to have authorized and directed it to vote the number of deposited securities represented by your ADSs in favor of any resolution that we proposed in the invitation to the shareholders&#8217; meeting.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as you requested.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities, if we request the depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days in advance of the meeting date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees and Expenses</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Persons depositing or withdrawing<br>shares or ADS holders must pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.25pt;padding-right:12.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:12.25pt;padding-right:12.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">For</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#58;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;padding-left:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$.05 (or less) per ADS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Any cash distribution to ADS holders</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$.05 (or less) per ADS per calendar year</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depositary services</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Registration or transfer fees</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Expenses of the depositary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cable and facsimile transmissions (when expressly provided in the deposit agreement)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Converting foreign currency to U.S. dollars</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As necessary</font></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Any charges incurred by the depositary or its agents for servicing the deposited securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">As necessary</font></td></tr></table></div><div style="margin-bottom:6pt;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary&#8217;s obligations under the deposit agreement. The methodology used to determine exchange rates used in currency conversions is available upon request.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment of Taxes</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tender and Exchange Offers&#59; Redemption, Replacement or Cancellation of Deposited Securities</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender or of those ADSs or cancel those ADSs upon notice to the ADS holders.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment and Termination</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How may the deposit agreement be amended&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">notifies ADS holders of the amendment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">How may the deposit agreement be terminated&#63;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the U.S. over-the-counter market&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">we delist our ordinary shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the United States&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">we appear to be insolvent or enter insolvency proceedings</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless&#59; or</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:31.02pt">there has been a replacement of deposited securities.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Limitations on Obligations and Liability</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Limits on our Obligations and the Obligations of the Depositary&#59; Limits on Liability to Holders of ADSs</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">are not liable if we or it exercises discretion permitted under the deposit agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">are not liable for the acts or omissions of any securities depository, clearing agency or settlement system&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:13.02pt">the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Requirements for Depositary Actions</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">satisfactory proof of the identity and genuineness of any signature or other information it deems necessary&#59; and</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Your Right to Receive the Shares Underlying your ADSs</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:69.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when temporary delays arise because (i) the depositary has closed its transfer books or we have closed our transfer books, (ii) the transfer of shares is blocked to permit voting at a shareholders&#8217; meeting or (iii) we are paying a dividend on our shares&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:69.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when you owe money to pay fees, taxes and similar charges&#59; or</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:69.1pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This right of withdrawal may not be limited by any other provision of the deposit agreement.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Registration System</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, or DRS, and Profile Modification System, or Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with and in accordance with the arrangements and procedures relating to DRS&#47;Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary&#8217;s reliance on and compliance with instructions received by the depositary through the DRS&#47;Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholder Communications&#59; Inspection of Register of Holders of ADSs</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jury Trial Waiver</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:33.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.47
<SEQUENCE>3
<FILENAME>exhibit447instadeepamendme.htm
<DESCRIPTION>EX-4.47
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i67e3fd7aaada43e29d847090ffd90bcb_1"></div><div style="min-height:141.84pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.47</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:right;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.940%"></td><td style="width:0.1%"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:113px"></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:48pt;margin-top:36pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">DATE&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">31 July </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">2023</font></div></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DEED OF AMENDMENT OF A SHARE PURCHASE AGREEMENT DATED 10 JANUARY 2023 </font></td></tr><tr style="height:27pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">Between</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">THE FME SHAREHOLDERS' REPRESENTATIVE</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">THE INVESTOR SELLERS' REPRESENTATIVE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">THE INSTITUTIONAL SELLERS</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">and</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">BIONTECH SE</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">CMS Cameron McKenna Nabarro Olswang LLP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Cannon Place</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">78 Cannon Street</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">London EC4N 6AF</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">T +44 20 7367 3000</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">F  +44 20 7367 2000</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">cms.law</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_292"></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%"> TABLE OF CONTENTS</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">1.&#160;&#160;&#160;&#160;Interpretation&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">2.&#160;&#160;&#160;&#160;Amendment of the Agreement&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">3.&#160;&#160;&#160;&#160;Supplement&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">4.&#160;&#160;&#160;&#160;General&#160;&#160;&#160;&#160;2</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Schedule 1&#160;&#160;&#160;&#160;5</font></div><div style="margin-top:3pt;text-indent:42.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Amended Agreement&#160;&#160;&#160;&#160;5</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Schedule 2&#160;&#160;&#160;&#160;6</font></div><div style="margin-top:3pt;text-indent:42.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:136%">Redline of Amended Agreement&#160;&#160;&#160;&#160;6</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_308"></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">THIS DEED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">is made the 31st day of July 2023</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">BETWEEN&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">FME Shareholders&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Investor Sellers&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(parties (3) &#8211; (9) together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Institutional Sellers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:17.68pt">BIONTECH SE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(with its statutory seat in Mainz, registered in the commercial register of the local court of Mainz, Germany, under HBR 48720) whose registered office is at An der Goldgrube 12, 55131 Mainz, Germany</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;),</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:42.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;).</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">RECITALS&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(A)&#160;&#160;&#160;&#160;On 10 January 2023, the Buyer, the Sellers (as defined in the Agreement) and InstaDeep Ltd (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;) entered into a share purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;) relating to the sale and purchase of certain of the shares in the issued share capital of the Company. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">(B)&#160;&#160;&#160;&#160;The Parties have agreed to amend the terms of the Agreement as provided in this deed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">IT IS AGREED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%"> as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:27.75pt">INTERPRETATION</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">1.1&#160;&#160;&#160;&#160;Expressions defined in the Agreement shall (unless the context otherwise requires) have those meanings when used in this deed. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">1.2&#160;&#160;&#160;&#160;Headings are used in this deed for convenience only and shall not affect its interpretation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">1.3&#160;&#160;&#160;&#160;The provisions of clause 1.2 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:158%">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">) of the Agreement shall (unless the context otherwise requires) apply to this deed as if set out in full and as if all references to the Agreement were references to this deed.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:27.75pt">AMENDMENT OF THE AGREEMENT</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">On and with effect from the date of this deed, the Agreement shall be amended so as to take the form set out in Schedule 1 to this deed (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Amended Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#8221;) and shall for all purposes be deemed as between the Parties to have been in such amended form when the Agreement was first constituted. For convenience only, Schedule 2 of this deed shows the changes (additions and deletions) implemented by virtue of this deed, in redline against the original form of the Agreement as signed on 10 January 2023.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:27.75pt">SUPPLEMENT</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">3.1&#160;&#160;&#160;&#160;Except as amended by this deed, the Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">3.2&#160;&#160;&#160;&#160;Notwithstanding any other provision of this deed, the provisions of this deed shall be without prejudice to any rights or claims of any Party arising under the terms of the Agreement prior to the date of this deed.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%;padding-left:27.75pt">GENERAL</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">4.1&#160;&#160;&#160;&#160;This deed, and any agreements and arrangements between the parties as set out in the Agreement which this deed expressly preserves, constitutes the whole and only agreement and understanding between the Parties in relation to the subject matter of the Agreement. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">4.2&#160;&#160;&#160;&#160;This deed may be executed in any number of counterparts and by the Parties on different counterparts. Each counterpart shall constitute an original of this deed but all the counterparts shall together constitute one and the same deed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">4.3&#160;&#160;&#160;&#160;No term of this deed (whether express or implied) is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 or otherwise by any person who is not a party to it (and, for avoidance of doubt, the terms of this deed may be enforced by each New FME Shareholder on becoming the registered holder of Ordinary Shares and&#47;or Employee Shares and duly executing and delivering a Deed of Adherence).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">4.4&#160;&#160;&#160;&#160;The following terms of the Agreement shall apply to this deed as if those terms referred instead to this deed and were set out in full herein&#58; clause 19.4 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:158%">Variation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">) and clause 27 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:158%">Governing law and jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">IN WITNESS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%"> of which the Parties have executed this instrument as a deed and delivered it on the date first above written.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:158%">FME Shareholders&#8217; Representative</font></div></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executed as a deed by</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; &#91;***&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as the FME Shareholders&#8217; Representative for</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and on behalf of the FME Shareholders</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in the presence of&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name of witness&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Occupation&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:158%">Investor Sellers&#8217; Representative</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executed as a deed by</font></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; &#91;***&#93;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as the Investor Sellers&#8217; Representative for</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and on behalf of the Investor Sellers</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in the presence of&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name of witness&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Occupation&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:158%">Institutional Sellers</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#91;***&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#91;***&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:158%">Buyer</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed as a deed by </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">BIONTECH SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:158%">,</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a company incorporated in Germany, acting by</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dr Sierk Poetting</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorised signatory</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Jens Holstein</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Jens Holstein</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorised signatory</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">who, in accordance with the laws of that </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">territory, is acting under the authority of the</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_321"></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">SCHEDULE 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Amended Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_216"></div><hr style="page-break-after:always"><div style="min-height:84.96pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:right;text-indent:-36pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:72px;margin-bottom:5pt;vertical-align:text-bottom;width:245px"></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:62.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.905%"></td><td style="width:0.1%"></td></tr><tr style="height:166pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:11.75pt;padding-right:11.75pt;text-align:center;text-indent:-18pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">relating to the sale and purchase of certain shares of the issued share capital of InstaDeep Ltd</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#160;&#160;&#160;&#160;10 January 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:87pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:141pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_4"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Documents in agreed form&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Signing Allocation Schedule</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contents</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.         Definitions and interpretation&#160;&#160;&#160;&#160;1</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.         Conditions precedent&#160;&#160;&#160;&#160;25</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.         Sale and purchase&#160;&#160;&#160;&#160;30</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.         Consideration&#160;&#160;&#160;&#160;33</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.         Consideration adjustment&#160;&#160;&#160;&#160;37</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.         Pre-Completion obligations&#160;&#160;&#160;&#160;39</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.         Completion&#160;&#160;&#160;&#160;40</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.         Post Completion matters&#160;&#160;&#160;&#160;43</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.         Purchaser's Employee Incentive Plan&#160;&#160;&#160;&#160;43</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.       Warranties&#160;&#160;&#160;&#160;44</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.       Tax Covenant&#160;&#160;&#160;&#160;44</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.       &#91;***&#93;&#160;&#160;&#160;&#160;44</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13.       Purchaser's remedies&#160;&#160;&#160;&#160;45</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.       Limitations on liability&#160;&#160;&#160;&#160;45</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15.       Purchaser's conduct of Third Party Claims&#160;&#160;&#160;&#160;46</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16.       The W&#38;I Policy&#160;&#160;&#160;&#160;47</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.       Protection of goodwill&#160;&#160;&#160;&#160;47</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.       Consideration Shares&#160;&#160;&#160;&#160;48</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19.       General&#160;&#160;&#160;&#160;50</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.       Announcements&#160;&#160;&#160;&#160;56</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.       Costs and expenses&#160;&#160;&#160;&#160;56</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22.       Paying Agent Agreement Indemnified Losses&#160;&#160;&#160;&#160;56</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23.       Payments&#160;&#160;&#160;&#160;57</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24.       Notices&#160;&#160;&#160;&#160;57</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25.       Service of Proceedings&#160;&#160;&#160;&#160;58</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26.       Sellers' Representatives&#160;&#160;&#160;&#160;58</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27.       Institutional Sellers' Representative&#160;&#160;&#160;&#160;60</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28.       Governing law and jurisdiction&#160;&#160;&#160;&#160;61</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 1&#160;&#160;&#160;&#160;63</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The Sellers)&#160;&#160;&#160;&#160;63</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;63</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The FME Shareholders)&#160;&#160;&#160;&#160;63</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;94</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The Investor Sellers)&#160;&#160;&#160;&#160;94</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 2&#160;&#160;&#160;&#160;103</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;103</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The Company)&#160;&#160;&#160;&#160;103</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;104</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The Group Companies (and branches))&#160;&#160;&#160;&#160;104</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 3&#160;&#160;&#160;&#160;112</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(The Properties)&#160;&#160;&#160;&#160;112</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;110</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Freehold Properties)&#160;&#160;&#160;&#160;110</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;113</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Leased Properties)&#160;&#160;&#160;&#160;113</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 4&#160;&#160;&#160;&#160;116</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Non-Tax Warranties)&#160;&#160;&#160;&#160;116</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 5&#160;&#160;&#160;&#160;141</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Limitations on liability)&#160;&#160;&#160;&#160;141</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 6&#160;&#160;&#160;&#160;145</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Tax Schedule)&#160;&#160;&#160;&#160;145</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;145</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Definitions and Interpretation)&#160;&#160;&#160;&#160;145</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;149</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Tax Warranties)&#160;&#160;&#160;&#160;149</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 3&#160;&#160;&#160;&#160;152</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Covenants to and from the Purchaser)&#160;&#160;&#160;&#160;152</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 4&#160;&#160;&#160;&#160;156</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Limitations and general)&#160;&#160;&#160;&#160;156</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 7&#160;&#160;&#160;&#160;159</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Completion obligations)&#160;&#160;&#160;&#160;159</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;159</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Sellers' obligations)&#160;&#160;&#160;&#160;159</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;162</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Purchaser's obligations)&#160;&#160;&#160;&#160;162</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 8&#160;&#160;&#160;&#160;163</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Pre Completion obligations)&#160;&#160;&#160;&#160;163</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 9&#160;&#160;&#160;&#160;165</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Completion Accounts)&#160;&#160;&#160;&#160;165</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;165</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Preparation)&#160;&#160;&#160;&#160;165</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;167</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Basis of Preparation)&#160;&#160;&#160;&#160;167</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 3&#160;&#160;&#160;&#160;170</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Illustration of Cash and Debt, as at 31 October 2022)&#160;&#160;&#160;&#160;170</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Schedule 10&#160;&#160;&#160;&#160;179</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 1&#160;&#160;&#160;&#160;179</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Calculation of Earn-out Consideration)&#160;&#160;&#160;&#160;179</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Part 2&#160;&#160;&#160;&#160;184</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Key Employees&#160;&#160;&#160;&#160;184</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_7"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is made on 10 January 2023</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Between&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.78pt">The persons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">whose names and addresses are set out in Part 1 of Schedule 1, together with the New FME Shareholders as defined in clause&#160;1.1 below, (the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;FME Shareholders&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and each, an</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;FME Shareholder&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The persons whose names and addresses are set out in Part 2 of Schedule 1 and such other persons (who as of the date of this Agreement are FME Shareholders) as the Purchaser and the FME Shareholders' Representative may agree to classify as Investor Sellers before Completion (the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;Investor Sellers&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and each, an</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;Investor Seller&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(together, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sellers&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and each, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Seller&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.78pt">BioNTech SE </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(with its statutory seat in Mainz, registered in the commercial register of the local court of Mainz, Germany, under HBR 48720) whose registered office is at An der Goldgrube 12, 55131 Mainz, Germany (the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;Purchaser&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.78pt">InstaDeep Ltd </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(with registration number 09816291) whose registered office is at 5 Merchant Square, London, England, W2 1AY (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;InstaDeep&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Background&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">The Sellers are the legal and beneficial owners of the Completion Shares (save as set out in this Agreement).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">The Sellers have agreed to sell, and the Purchaser has agreed to purchase the Completion Shares on the terms</font><font style="color:#800000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and subject to the Conditions</font><font style="color:#ff4500;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">set out in this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">This Deed witnesses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Definitions and interpretation</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;In this Agreement, including the Background, unless a contrary intention is expressly stated, the following definitions shall apply&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 &#91;***&#93; SPA&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Share Purchase Agreement between (1) the Purchasers (as defined therein)&#59; (2) &#91;***&#93;&#59; and (3) the Company, dated 6 December 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Accounts&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Stand-alone Accounts and the Group Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Accounts Date&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means 31 December 2021.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Act of God&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an unforeseeable grave natural phenomenon outside of human control&#47;activity of an exceptional, inevitable, and irresistible nature, such as a flood, a drought, an earthquake, a windstorm or another natural catastrophe.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Actual Adjustment Amount&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the aggregate of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount by which the Actual Cash is in excess or shortfall of the Target Cash Balance,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">less</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount by which the Actual Debt is in excess of the Target Debt Balance (for the avoidance of doubt, no shortfall will occur),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus &#47; minus</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the amount of the difference between the Actual Working Capital and the Target Working Capital (which shall be a positive number if the Actual Working Capital is in excess of the Target Working Capital, or a negative number if the Actual Working Capital is less than the Target Working Capital).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Actual Cash&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregate Cash as at the Effective Time, as set out in the Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Actual Debt&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregate Debt as at the Effective Time, as set out in the Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Actual Working Capital&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregate Working Capital as at the Effective Time, as set out in the Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Agreement&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means this agreement executed as a deed (including any schedule to it).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Applicable Law&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means (with respect to any person, property, transaction, event or other matter) any law, rule, statute, regulation, instrument, order, judgment, decree, treaty or other requirement having the force of law in any jurisdiction (collectively, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Law&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) relating or applicable to such person, property, transaction, event or other matter. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Applicable Law&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> also </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">includes, where appropriate, any interpretation of the Law (or any part thereof) by any person having jurisdiction over it or charged with its administration or interpretation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Applicable Jurisdiction&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any of the countries in which the Company has subsidiaries and branches from time to time being, at the date of this Agreement, Nigeria, Germany, the United States of America, Tunisia, France, the United Arab Emirates and South Africa.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;BioNTech Company Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the &#91;***&#93; Ordinary Shares, (of which &#91;***&#93; held only beneficially as of the date of this Agreement pending stamping of a stock transfer form in respect of the &#91;***&#93; Shares and updating of the Company's register of members accordingly), &#91;***&#93; Class A Shares and &#91;***&#93; Class B Shares each of &#163;0.00001 each in the capital of the Company held by the Purchaser immediately prior to Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Business&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the business carried on by the Group, or any part of it.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Business Day&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a day (other than a Saturday, a Sunday or a public holiday) on which clearing banks are open for all normal banking business in the city of London, UK and Mainz, Germany, and &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Hours</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the hours of 9am to 5pm on a Business Day.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CA2006&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Companies Act 2006.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Cash&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the aggregate amount of all unrestricted and freely available&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">cash on hand&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">cash standing to the credit of any account with a bank or other financial institution including all term deposits (for the avoidance of doubt, excluding any interest on such term deposits)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">cash equivalents&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Transaction Expenses up to &#163;&#91;***&#93; which are paid out and settled by and&#47;or invoiced to the relevant Group Company on or prior to the Completion Date&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any cash owed to the Company by &#91;***&#93; in relation to the exercise of the options&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">less</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">any cash which is not freely available or convertible within &#91;***&#93; days after the Effective Time including deposits and loans which relate to the guarantee of contractual lease agreements,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case to which the Company or any of the Subsidiaries is beneficially entitled as at the Effective Time, calculated on a consolidated basis in accordance with the accounting principles, policies, standards, practices, evaluation rules and estimation techniques specified in Part 2 of Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). An illustrative detailed mapping on account basis designated as &#34;Cash&#34; is set out in Part 3 of Schedule 9.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CBT Condition&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in sub-clause&#160;2.2(g).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CJRS&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the coronavirus job retention scheme (as it has effect from time to time) that is the subject of the direction given by the Treasury on 15 April 2020 under section 76 of the Coronavirus Act 2020.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Claim&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means a Warranty Claim and&#47;or a claim by the Purchaser against the Warrantors under the Tax Covenant (as the case may be).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Class A Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means convertible preference A shares of &#163;0.000001 each in the capital of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Class B Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means convertible preference B shares of &#163;0.000001 each in the capital of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Client&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any person to whom or which the Group shall at any time during the &#91;***&#93; month period prior to Completion have provided Restricted Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Company&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means InstaDeep Ltd, details of which are set out in Part 1 of Schedule 2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the Intellectual Property owned, enjoyed, used or licensed by the Group or arising from the existence or activities of any Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the completion of the sale and purchase of the Completion Shares in accordance with this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Accounts&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the completion accounts prepared and agreed or determined in accordance with Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Allocation Schedule&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the schedule, substantially in the form of the Signing Allocation Schedule, setting out, amongst other matters, the details of the Sellers' </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">residential addresses and country of residence, the Sellers' holdings of the Completion Shares, the FME Retained French Shares and the FME 2024 French Shares and the allocation of the Consideration payable to each of them (including, in particular, the mix of cash and Consideration ADSs used to settle the Upfront Consideration), as prepared in accordance with sub-clause&#160;4.5.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Date&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the date on which Completion occurs in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Disclosure Letter&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the letter from the Warrantors to the Purchaser delivered on Completion, disclosing matters arisen after the date of this Agreement that are exceptions to the Warranties to be given at the Completion Date, together with all documents annexed to it.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Fully-Diluted Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means, as at Completion, the total number of Shares that are in issue or are to be issued by the Company being&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Completion Shares (including any Shares issued or to be issued pursuant to the New Awards)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the BioNTech Company Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the FME Retained French Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the FME 2024 French Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Completion Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Investors Sellers' Shares and the FME Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Conditions&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means those matters set out in sub-clause&#160;2.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Confirmatory IP Assignments&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the agreements in such form as may be agreed between the FME Shareholders' Representative and the Purchaser, to be entered into on or before Completion relating to the assignment of Intellectual Property identified by the Purchaser during its due diligence exercise in respect of the Transaction as not being sufficiently vested in the Company, between&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">such persons identified by the Purchaser (acting reasonably) as being employed by, or otherwise having a contractual relationship or arrangement with, a Group Company as at the date of this Agreement pursuant to which they have created Intellectual Property in the execution of their duties and&#47;or following the instructions of the relevant Group Company, and the relevant Group Company&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the relevant Group Company identified in part (a) above and the Company,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confirmatory IP Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the aggregate consideration payable by the Purchaser to the Sellers pursuant to sub-clauses 4.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Consideration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and 3.9 for the Consideration Shares, the FME Retained French Shares and the FME 2024 French Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration ADSs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means American Depositary Shares issued pursuant to the Deposit Agreement representing the Consideration Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration ADS Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration Increase&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in sub-clause&#160;5.2(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> (Purchase price adjustment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration Reduction&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in sub-clause&#160;5.2(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Purchase price adjustment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means ordinary shares of the Purchaser that form a part of the Consideration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Contingent Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Investor Sellers' Upfront Contingent Cash Consideration plus the Earn-out Consideration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Counsel&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a barrister of not less than 10 years' standing, having experience in claims similar to a relevant Outstanding Claim, as agreed by the Sellers' Representatives and the Purchaser, or failing such agreement, as appointed by the Chair for the time being of the Bar of England and Wales on the application of either party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Cybersecurity Requirements&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all laws, regulations, codes, mandatory guidance (from regulatory and advisory bodies), international and national standards, industry schemes and sanctions relating to security of network and information systems and security breach and incident reporting requirements which are from time to time applicable to the Company or any of the Subsidiaries (or any part of their business), including the Data Protection Laws.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Dangerous Substance&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any natural or artificial substance, preparation (a mixture or solution of two or more substances) or biological agent (including, without limitation, radiation or sources of radiation) (whether in the form of a solid, liquid, gas or vapour), the presence, generation, transportation, storage, treatment, use or disposal of which (whether alone or in combination with any other substance) gives rise to a risk of causing harm to human health, comfort or safety or harm to any other living organism or causing damage to the environment, or any waste.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Data Protection Laws&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in sub-clause&#160;34 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Compliance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-Tax Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Data Room&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;Project Interstellar&#34; virtual data room hosted by HighQ and made available by the Sellers to the Purchaser from 5 December 2022 to and including 9 January 2023.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Debt&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in relation to the Company and the Subsidiaries, the aggregate amount of their respective borrowings and other financial indebtedness in the nature of borrowing, including&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">borrowings from any bank, financial institution or other entity&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">indebtedness arising under any bond, note, loan stock, debenture, commercial paper or similar instrument&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">obligations under any conditional sale, title retention, forward sale or purchase or any similar agreement or arrangement creating obligations with respect to the deferred purchase price of property (other than customary trade credit given in the ordinary course of trading)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">indebtedness under any hire purchase agreement or finance lease (whether for land, machinery, equipment or otherwise) which is a liability under applicable accounting standards&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any indebtedness for monies borrowed or raised under any other transaction that has the commercial effect of borrowing&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">any preference shares or element of preference shares shown as liabilities as required by applicable accounting standards&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any liabilities to shareholders of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any provision, accruals or liabilities relating to financial instruments, excluding accrued interests on the financial deposits&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any provision, accruals, liabilities or receivables relating to income taxes (including corporation tax, corporate income tax or any similar tax on a company's income, profits or gains)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any provisions, accruals or liabilities relating to annual bonus to employees and the long-term bonus which refers to the period ending at the Effective Time including any social security contributions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any provisions, accruals or liabilities relating to retirement obligations including, without limitation, in respect of France and Tunisia and including any social security contributions in respect thereof&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any provisions, accruals and liabilities relating to long term incentive plans and share-based payment in accordance with IFRS 2 if they are not settled as of the Effective Time&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">any provisions, accruals and liabilities for taxes and levy resulting from the vesting or exercise of the options (share-based payments) and including the effects from the Options, and awards pursuant to the French Plan which are not vested or exercised as of the Effective Time&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any lease liability obligation according to IFRS 16&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Transaction Expenses less the Transaction Expenses treated as Cash for the purposes of paragraph&#160;(d) of that definition&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Paying Agent Fee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the W&#38;I Cost&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">any minority interest which exists prior to and on the Completion Date (for the avoidance of doubt, the minority interest is the book value calculated by multiplying the minority share interest with the next assets as of the Completion Date)&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">all unpaid accrued interest on any borrowings or indebtedness referred to in the paragraphs above, together with any prepayment premiums or other penalties, fees, expenses or breakage costs arising (or which would arise) in connection with the repayment of any such borrowings or indebtedness,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as at the Effective Time, calculated on a consolidated basis in accordance with the accounting principles, policies, standards, practices, evaluation rules and estimation techniques specified in Part 2 of Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). An illustrative detailed mapping on account basis designated as &#34;Debt&#34; is set out in Part 3 of Schedule 9.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Deed of Adherence&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the deed of adherence substantially in the agreed form under which a New FME Shareholder agrees to adhere to the terms of this Agreement as a Seller in respect of the Shares acquired, or to be acquired, by them from the New Awards.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Deposit Agreement&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Deposit Agreement dated 9 October 2019, as amended from time to time, between the Purchaser, The Bank of New York Mellon, as depositary (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depositary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) and all Owners and Holders (each as defined in the Deposit Agreement), from time to time, of American Depositary Shares issued thereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Determination Date&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the date of agreement or determination of the Completion Accounts in accordance with Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Disclosed&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means fairly disclosed to the Purchaser for the purposes of this Agreement in the Disclosure Documents and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;fairly&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means disclosed with sufficient particularity to enable the Purchaser to assess the impact on the Group of the matter disclosed and to properly identify the nature and scope of the matter disclosed and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Disclose&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be construed accordingly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Disclosure Documents&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Signing Disclosure Letter and the Completion Disclosure Letter (in each case, including the general disclosures contained therein)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the documents in the Data Room, including all documents and answers provided as part of the Q&#38;A function.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Disposal&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the transfer, sale, disposal of, or the creation of any Encumbrance over, or the entry into any agreement to do any of the same in relation to (in each case whether directly, indirectly, contingently or otherwise) any Consideration Shares or any Interest in Consideration Shares, and &#34;Dispose&#34; shall be construed accordingly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Dispute Notice&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Due Amount&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the amount (if any) due for payment to the Purchaser by those Sellers due to receive the Earn-out Consideration in respect of and only to the extent of their pro-rata liability for a Resolved Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Earn-Out&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the proportion of the Consideration calculated on a contingent basis during the Earn-out Period in respect of the satisfaction of the Milestones set out in Schedule 10  (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation of Earn-out Consideration).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Earn-Out Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Schedule 10  (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation of Earn-out Consideration).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Earn-Out Consideration Completion Date&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the date being the 20th Business Day following the end of the Earn-Out Period.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Earn-Out Period&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the period commencing on the Completion Date and ending on the third anniversary of the Completion Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Effective Time&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means 11&#58;59pm (GMT) on the date of Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;EIP Conditions&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means (i) the CBT EIP Condition (as defined in the Purchaser's Employee Incentive Plan) and (ii) the registration with the South African Reserve Bank&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;EMI Option&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means a share option granted pursuant to the Stock Option Plan that is intended to qualify as an Enterprise Management Incentive option in accordance with section 527(4) and Schedule 5 of ITEPA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Employee Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means non-voting ordinary shares of &#163;0.000001 each in the capital of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Encumbrance&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any interest or equity of any person (including any right to acquire, option or right of pre-emption or conversion) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest, title retention, or any other security agreement or arrangement, or any agreement to create any of the above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimated Adjustment Amount&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the aggregate of&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount by which the Estimated Cash is in excess or shortfall of the Target Cash Balance,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">less</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount by which the Estimated Debt is in excess of the Target Debt Balance (for the avoidance of doubt, no shortfall will incur),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">plus &#47; minus</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the amount of the difference between the Estimated Working Capital and the Target Working Capital (which shall be a positive number if the Estimated Working Capital is in excess of the Target Working Capital, or a negative number if the Estimated Working Capital is less than the Target Working Capital),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as provided pursuant to clause&#160;6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Pre-Completion obligations)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and set out in the Estimates Notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimated Cash&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Sellers' reasonable good faith estimate of Cash of the Group as at the Effective Time, as provided pursuant to clause&#160;6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Pre-Completion obligations)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and set out in the Estimates Notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimated Debt&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Sellers' reasonable good faith estimate of Debt of the Group as at the Effective Time, as provided pursuant to clause&#160;6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Pre-Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and set out in the Estimates Notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimated FME Shareholders' Upfront Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the &#163;price per share calculated in accordance with the Completion Allocation Schedule after including therein&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Cash, Estimated Debt and the Estimated Working Capital amounts set out in the Estimates Notice and reflecting (if applicable) any increase or reduction of the FME Shareholders' Upfront Consideration as a result of the Estimated Adjustment Amount&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the &#91;***&#93; as a deduction in respect of the Completion Fully Diluted Consideration Shares held or to be held by FME Shareholders&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimated Liability&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in relation to an Outstanding Claim, a genuine and bona fide estimate of the amount of the liability to the Purchaser of any relevant Seller who is due to receive Earn-Out Consideration if the Outstanding Claim was to be resolved in the Purchaser's favour, as agreed or determined in accordance with sub-clause&#160;19.12(b).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Sellers' Upfront Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the &#163;price per share calculated in accordance with the Completion Allocation Schedule after inserting the Estimated Cash, Estimated Debt and the Estimated Working Capital amounts set out in the Estimates Notice and reflecting (if applicable) any increase or reduction of the Investor Sellers' Upfront Consideration as a result of the Estimated Adjustment Amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Tax Withholding</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means, in relation to an FME Shareholder who is exercising an Option on or immediately before Completion and in respect of whom an Option Tax Liability will arise, the estimated amount of that Option Tax Liability as set out in the Completion Allocation Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Working Capital</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the Sellers' reasonable good faith estimate of Working Capital of the Group as at the Effective Time, as provided pursuant to clause&#160;6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Pre-Completion obligations)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and set out in the Estimates Notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimates Notice&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in sub-clause&#160;6.3 (Pre-Completion obligations).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Exchange Rate&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means with respect to a particular currency for a particular day the spot rate of exchange (the closing mid-point) for that currency into sterling on such date as published by the European Central Bank or where no such rate is published in respect of that currency for such date at the rate quoted by Bloomberg FX Fixings (https&#58;&#47;&#47;www.bloomberg.com&#47;markets&#47;currencies&#47;fx-fixings) as at 4&#58;00pm London time on such date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Exchange Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Shares held by a Seller as at the date of this Agreement, being&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of any FME Shareholder, the Shares set out against that FME Shareholder's name in any of column C1, C2 or E2 of the table set out in Part 1 of Schedule 1&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of any Investor Seller, the Shares set out against that Investor Seller's name in any of columns C1 to C4 (inclusive) of the table set out in Part 2 of Schedule 1.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Existing Options&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the options to subscribe for Ordinary Shares or Employee Shares granted pursuant to the Stock Option Plan on or before the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME 2024 French Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Ordinary Shares set against that FME Shareholder's name in column E5 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares that remain subject to a French Award and which, following a proposed amendment to the French Plan to be made with effect from Completion, will vest on &#91;***&#93;) but excluding any such Ordinary Shares to the extent that the applicable French Award held by the FME Shareholder lapses before Completion in accordance with the terms of the French Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Cash in Hand&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#91;***&#93;% of (i) the Estimated Sellers' Upfront Payment </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ii) the number of FME Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Completion Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means all the Shares held by the FME Shareholders at Completion which, in respect of each FME Shareholder, will consist of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Ordinary Shares set against that FME Shareholder's name in column C1 of the table set out in Part 1 of Schedule 1, being Ordinary Shares held by that FME Shareholder as at the date of this Agreement (other than Ordinary Shares that remain subject to a French Holding Period)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Employee Shares set against that FME Shareholder's name in column C2 of the table set out in Part 1 of Schedule 1, being Employee Shares held by that FME Shareholder as at the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Ordinary Shares set against that FME Shareholder's name in column D1 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares that the FME Shareholder will acquire from the exercise of Existing Options immediately before Completion) but excluding any such Ordinary Shares to the extent that the applicable Existing Option held by the FME Shareholder lapses before Completion in accordance with the terms of the Stock Option Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Employee Shares set against that FME Shareholder's name in column D2 of the table set out in Part 1 of Schedule 1 (being Employee Shares that the FME Shareholder will acquire from the exercise of Existing Options immediately before Completion) but excluding any such Employee Shares to the extent that the applicable Existing Option held by the FME Shareholder lapses before Completion in accordance with the terms of the Stock Option Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Ordinary Shares set against that FME Shareholder's name in column E1 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares that will be issued to that the FME Shareholder immediately before Completion in connection with the vesting of French Awards) but excluding any such Ordinary Shares to the extent that the applicable French Awards held by the FME Shareholder lapse before Completion in accordance with the terms of the French Plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">if Completion arises after the date set against that FME Shareholder's name in column E4 of the table set out in Part 1 of Schedule 1, the Ordinary Shares set against that FME Shareholder's name in column E2 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares held by that FME Shareholder as at the date of this Agreement that remain subject to a French Holding Period but which cease to be subject to that French Holding Period on or before Completion)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if Completion arises after the date set against that FME Shareholder's name in column E4 of the table set out in Part 1 of Schedule 1, the Ordinary Shares set against that FME Shareholder's name in column E3 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares that will be issued to that the FME Shareholder immediately before Completion in connection with vesting of French Awards) but excluding any such Ordinary Shares to the extent that the applicable French Award held by the FME Shareholder lapses before Completion in accordance with the terms of the French Plan&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Employee Shares and&#47;or Ordinary Shares issued to an FME Shareholder on or before Completion pursuant to the terms of, and&#47;or following the exercise of, a New Award.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Holdback Amount&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93;% of the FME Cash in Hand in respect of the FME Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Retained French Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if Completion arises on or before the date set against that FME Shareholder's name in column E4 of the table set out in Part 1 of Schedule 1, the Ordinary Shares set against that FME Shareholder's name in column E2 of the table set out in Part 1 of Schedule 1 </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(being Ordinary Shares held by that FME Shareholder that, as at Completion, remain subject to a French Holding Period)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if Completion arises on or before the date set against that FME Shareholder's name in column E4 of the table set out in Part 1 of Schedule 1, the Ordinary Shares set against that FME Shareholder's name in column E3 of the table set out in Part 1 of Schedule 1 (being Ordinary Shares that remain subject to a French Award that has not vested as at Completion but which is due to vest in May or June 2023) but excluding any such Ordinary Shares to the extent that the applicable French Award held by the FME Shareholder lapses before Completion in accordance with the terms of the French Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Shareholders' Representative&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93; or such other person as the majority by value of Consideration receivable by the FME Shareholders may notify to the Purchaser in writing from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Shareholders' Transaction Tax Liability&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means, in respect of an FME Shareholder, the sum of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount of any Option Tax Liability, or any personal tax liability of such FME Shareholder, that arises as a result of any exercise of an Option immediately before Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount of any personal tax liability of such FME Shareholder that arises as a result of, or in connection with, the sale of any Completion Shares in accordance with this Agreement (provided that such personal tax liability is payable in respect of the tax year in which Completion occurs)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the amount of any personal tax liability of such FME Shareholder that arises as a result of, or in connection with, the sale of any FME Retained French Shares and&#47;or FME 2024 French Shares in accordance with this Agreement (provided that such personal tax liability is payable in respect of the tax year in which the sale of those Shares to the Purchaser takes place),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and, for the purposes of estimating an FME Shareholders' Transaction Tax Liability under this Agreement, the parties agree that, except for anything which can be factored in as a result of running dummy payroll runs in advance of Completion to the extent feasible&#58; (1) no account will be taken of any reliefs that are personal to an FME Shareholder and which would require knowledge of the FME Shareholder's personal circumstances&#59; and (2) all taxes will be estimated using the highest marginal rate of tax, unless the relevant payments are processed through a Group Company payroll and such reliefs and &#47; or tax rates are taken into account in respect of such payment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;FME Shareholders' Upfront Cash Completion Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the FME Cash in Hand </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">plus</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the FME Shareholders' Transaction Tax Liability of all FME Shareholders in respect of the FME Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Founder Sellers&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93; and &#91;***&#93; details for whom are set out in Part 1 of Schedule 1 (and each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Founder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;French Award&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means a right to acquire Ordinary Shares granted by the Company under the French Plan before the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;French Holding Period&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means a Holding Period (as such term is defined in the French Plan) applying to Ordinary Shares acquired pursuant to a French Award.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;French Plan&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the allocation plan of performance shares adopted by the Company on 21&#160;August 2019 in respect of the employees of InstaDeep SAS.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Good Faith&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means acting honestly, reasonably and with fair dealing, having regard to (i) the collective interests of the parties represented and (ii) the provisions, aims and purposes of this Agreement, the Paying Agent Agreements and, if applicable, the Institutional Sellers&#8217; Representative Agreement, but without an obligation to subordinate one&#8217;s own interests to the interests of the others.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Governmental Authority&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any governmental authority in the United Kingdom, France, United Arab Emirates, South Africa, Tunisia, Germany, United States of America, Nigeria or any other country in which a Group Company conducts, or has conducted in the previous 2 years preceding the date of this Agreement, its business and includes any district, county, federal, state, provincial, municipal or similar authorities.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Group Accounts&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means, in respect of the Company, the audited consolidated balance sheet as at that date and the audited consolidated income statement for that period (including all documents required by Applicable Law to be annexed to them for that period).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Group Companies&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Group&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Company, any holding company and any subsidiary and any subsidiary undertaking of the Company or such companies (as set out in Part 2 of Schedule 2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Group Companies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)) and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Group Company&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#91;***&#93;Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Shares transferred pursuant to the terms of the 2022 &#91;***&#93;SPA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Holdback Amount&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the FME Holdback Amount and the Investors Holdback Amount.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;holding company&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Section 1159, CA2006.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;HMRC&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in the Tax Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;ICAEW President&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall have the meaning given to it in sub-clause&#160;19.11 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Independent Expert</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;IFRS&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means International Financial Reporting Standards (including international accounting standards, international financial reporting standards and interpretations of such standards) adopted for use in the UK under the International Accounting Standards and European Public Limited-Liability Company (Amendment etc.) (EU Exit) Regulations 2019 (SI 2019&#47;685) and in force for the accounting period ending on the Accounts Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Indemnified Losses&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in the Paying Agent Agreements and each an &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnified Loss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Independent Expert&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means an independent expert whose appointment and terms of reference are governed by sub-clause&#160;19.11 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Independent Expert</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Instadeep Tunisia&#8221; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means InstaDeep SARL, details of which are set out in Part 2 of Schedule 2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Group Companies (and branches)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Institutional Sellers&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Institutional Sellers' Representative&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#91;***&#93; or such other person as the Institutional Sellers (acting jointly on a unanimous basis) may notify to the Purchaser in writing from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Intellectual Property&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any intellectual property or similar proprietary right, including all patents and patent applications, inventions (whether or not patentable), trade marks, trade names whether or not registered or capable of registration, registered designs, design rights, domain names, copyrights, database rights, the right to apply for and applications for any of the preceding items, together with the rights in inventions, processes, software, know how, trade or business secrets, confidential information or any process or other similar right or asset capable of protection enjoyed, owned, used or licensed and all other intellectual and industrial property rights throughout the world arising directly or indirectly and all licences of the intellectual property referred to above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Interest&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any legal or beneficial interest or any other interest as defined in section 820 (when read with sections 821 to 825 inclusive) of the CA 2006 and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Interested&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be construed accordingly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;International Armed Conflict&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means all cases of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the state of war declared in accordance with the laws of England and Wales&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any other armed conflict with significant participation of the British Armed Forces which may arise between two or more states, even if the state of war is not recognized by one of them&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">partial or total occupation of the territory of the UK, even if the said occupation meets with no armed resistance&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any other armed conflicts in which people are fighting against colonial domination and alien occupation and against racist regimes in the exercise of their right of self-determination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Investors Holdback Amount&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93;% of (i) the Estimated Sellers' Upfront Payment </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ii) the number of Completion Shares held by the Investor Sellers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Investor Sellers' Representative&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93; or such other person as the majority by value of Consideration receivable by the Investor Sellers (excluding the Institutional Sellers) may notify to the Purchaser in writing from time to time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Investor Sellers' Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the following fully paid and issued shares&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; Ordinary Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; Class A Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#91;***&#93; Class B Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; Employee Shares,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">held by the Investor Sellers in the proportions set out in Part 2 of Schedule 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and any other shares in the capital of the Company that the Purchaser and the FME Shareholders' Representative may agree to classify as Investor Sellers' Shares before Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investor Sellers' Upfront Contingent Cash Consideration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the sum of &#163;&#91;***&#93; per share held.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;ITEPA&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> has the meaning given to it in the Tax Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;IT Systems&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> has the meaning set out in sub-clause&#160;30.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Information technology</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Key Employees&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means those persons listed in Part 2 of Schedule 10.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Leases&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means all leases (including underleases) under which the Properties are held, particulars of which are set out in Part 2 of Schedule 3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Properties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Lease&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Lock-up Period&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in clause&#160;18.1.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#91;***&#93;&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#91;***&#93; acting in its capacity as paying agent and escrow agent under the relevant Paying Agent Agreement, or such other paying agent and&#47;or escrow agent as may be agreed between the Purchaser, the FME Shareholders Representative, the Investor Sellers' Representative and the Institutional Sellers.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Management Accounts&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means each of the unaudited consolidated monthly management accounts (including a balance sheet and an income statement) for the Group for the period from the Accounts Date to 31 October 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Material Adverse Change&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the occurrence or commencement, between the date of this Agreement and Completion, of a Material Adverse Change Event which is reasonably likely to sustain beyond Completion and which results in the Group as a whole having suffered any one or more impairments (as construed under IFRS as in force on the date of this Agreement, but ignoring for these purposes any impairments occurring as a result of any future changes in accounting standards or principles or interpretations of general application in relation thereto) of the assets of the Group and&#47;or having incurred one or more one-off costs or liabilities outside the ordinary course of business which, taken together, have resulted in the total assets of the Group on a consolidated basis being reduced by more than &#91;***&#93;, where&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Material Adverse Change Event&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an Act of God in the UK&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an International Armed Conflict on the territory of the UK&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a Non-International Armed Conflict on the territory of the UK&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Milestones&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Part 1 of Schedule 10.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Minority Share Transfers&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of InstaDeep Tunisia, the transfer of 1 share in the capital of InstaDeep Tunisia from &#91;***&#93; to the Company&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of InstaDeep Nigeria, the transfer of 10,000 shares in the capital of InstaDeep Nigeria from &#91;***&#93; to InstaDeep SAS,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Minority Share Transfer&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;New Articles of Association&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the new articles of association to be adopted by the Company with effect from Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;New Award&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an option or other right to acquire Employee Shares and&#47;or Ordinary Shares granted after the date of this Agreement and before the Completion Date pursuant to either the French Plan or the Stock Option (or pursuant to any other arrangement with the prior written agreement of the Purchaser).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;New FME Shareholder&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any person not set out in Part 1 of Schedule 1&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to whom a New Award is granted after the date of this Agreement and before Completion&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">who will be issued Ordinary Shares and&#47;or Employee Shares on or before Completion in respect of that New Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">who, on or before Completion, has signed a Deed of Adherence.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Non-International Armed Conflict&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means all armed conflicts, other than International Armed Conflicts, which take place on the territory of the UK between the British Armed Forces and dissident armed forces or other organised armed groups which, under responsible command, exercise control over a part of its territory, such control enabling them to carry out sustained and concerted military operations, but in each case excluding situations of internal disturbances and tensions, such as riots, isolated and sporadic acts of violence and other acts of a similar nature.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Non-Tax Claim&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any Claim which is not a Tax Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Non-Tax Warranties&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the warranties set out in Schedule 4 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-Tax Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Non-US FME Shareholders&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the FME Shareholders, other than the US FME Shareholders.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-US</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FME Shareholders' ADS Letter of Representation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the letter of representation, in a form to be agreed between each Non-US FME Shareholder and the Purchaser acting reasonably, to be provided by each Non-US FME Shareholder at Completion to the Purchaser in respect of the Consideration Shares and Consideration ADSs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Notice&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">includes any notice, demand, consent or other communication.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Open Source Materials&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any publicly available software or material that contains or is derived from, or is distributed or licensed&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">as free, libre or open-source software&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">under a licensing or distribution arrangement that requires, as a condition of use, modification and&#47;or distribution of such software or material, that other software incorporated into, derived from or distributed with such software or material be&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">disclosed or distributed in source code form&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">licensed for the purpose of making derivative works&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">licensed to permit decompilation, disassembly or reverse engineering of licensee's products&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">redistributable at no charge&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">under a licensing or distribution arrangement similar to (a) or (b) including but not limited to the GNU General Public License, GNU Lesser General Public License and Mozilla Public License.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Optionholders&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the FME Shareholders who, under the Stock Option Plan, hold an Option that is to be exercised on or immediately before Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Options&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Existing Options and the New Awards.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Option Exercise Documents&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in relation to the Options (excluding any New Award in the form of an RSU Award)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a sale notice provided by the Company to each Optionholder inviting such Optionholder to exercise their Options&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">a notice of exercise provided by each Optionholder (or a duly appointed attorney) under which each such Optionholder has elected and authorised their employing company to deduct sufficient amounts to settle the Option Exercise Price and Option Tax Liability arising on exercise of their Options&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">where applicable, a duly executed joint election pursuant to section 431 of ITEPA for full disapplication of Chapter 2 ITEPA in relation to the exercise of the Options made by each Optionholder's employing entity that is a member of the Group and each Optionholder (or a duly appointed attorney)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">a power of attorney to, inter alia, facilitate the exercise of the Options and the sale of the resulting shares provided by each Optionholder&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the board minutes of the Company approving the exercise of the Options and the issue and allotment of the Shares in respect of the exercise of the Options to the Optionholders&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in relation to the RSU Awards&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">where applicable, a duly executed joint election pursuant to section 431 of ITEPA for full disapplication of Chapter 2 ITEPA in relation to the Completion Shares to be issued to the RSU Holder, made by each RSU Holder's entity that is a member of the Group and the RSU Holder (or a duly appointed attorney)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">a power of attorney given by each RSU Holder to, inter alia, facilitate the sale of the Completion Shares held by the RSU Holder&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the board minutes of the Company approving the issue and allotment of the Shares in respect of the RSU Awards to the RSU Holders,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">each in a form to be agreed between each RSU Holder and the Purchaser acting reasonably.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Option Exercise Monies&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the aggregate exercise price payable by an Optionholder on the exercise of his&#47;her Option.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Option Tax Liability&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the amount of any income tax under PAYE and Class 1 employee National Insurance contributions (including secondary Class 1 (employer's) National Insurance contributions), or any other income tax, social security liability or other similar imposts or levies which become payable by a Group Company in any jurisdiction other than the UK, on exercise of an Option or, on the vesting in case of an RSU Award, by an FME Shareholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Ordinary Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means ordinary shares of &#163;0.000001 each in the capital of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Outstanding Claim&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means such portion of a claim under this Agreement which is against any of the Sellers who are due to receive Earn-out Consideration and that has been duly notified by the Purchaser to the relevant Sellers' Representatives or the Warrantors (as the case may be) in accordance with this Agreement, but which is not a Resolved Claim as at the Earn-out Consideration Completion Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Paying Agent Agreements&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the paying agent agreement for paying agency services to be entered into prior to Completion between (1) &#91;***&#93;, (2) the FME Shareholders' Representative, (3) the Investor Sellers' Representative, (4) the Institutional Sellers' Representative, (5) the Purchaser and (6) the Company, together with the paying agent fee letter relating to such agreement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the escrow agreement for escrow services in respect of the Investors Holdback Amount and FME Holdback Amount to be entered into prior to Completion between (1) &#91;***&#93;, (2) the Company, (3) the Purchaser, (4) the FME Shareholders' Representative, (5) the Investor Sellers' Representative and (6) the Institutional Sellers' Representative, together with the escrow fee letter relating to such agreement,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case, in a form reasonably acceptable to the Institutional Sellers, the FME Shareholders Representative, the Investor Sellers' Representative and the Purchaser (each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paying Agent Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Paying Agent Fee&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#91;***&#93;% of the aggregate amount payable to &#91;***&#93; in respect of the matters the subject of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Payment Amount&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any amount of the Earn-Out Consideration due from the Purchaser to the relevant Sellers under or in connection with this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Pension Scheme(s)&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the group personal pension scheme of the Company operated by &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Post-Completion Management Agreement&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the management agreement to be entered into between the Purchaser, the Founder Sellers and the Company regulating the governance rights of the Founder Sellers (as managers and employees (as applicable) of the Group) in respect of the Group, which shall be on terms to be agreed between the parties to it (each acting reasonably) prior to Completion, and which shall include (among other things) provisions whereby&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the prior written consent of the Founder Sellers will be required in order for the Company (or any other Group Company) to adopt or action any of the matters set out in paragraph&#160;8(c) of Part 1 of Schedule 10 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation of Earn-out Consideration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no prior written consent of the Purchaser will be required in relation to the Company (or any other Group Company) effecting any of the matters set out in paragraph&#160;8(d) of Part 1 of Schedule 10 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Calculation of Earn-out Consideration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Purchaser will consult with the Founder Sellers in respect of any change to be made to the allocation of any Purchaser's EIP Recipient pursuant to the Purchaser's Employee Incentive Plan, notwithstanding that each party acknowledges as at the date of this Agreement that the draft allocations are intended by each party to be in substantially agreed form.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Properties&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the properties leased or licensed to the Group, particulars of which are set out in Schedule 3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Properties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Property&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Prospective Client&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any person who or which was at any time during the &#91;***&#93; month period prior to Completion negotiating with or has been subject to any presentation or pitch by any Group Company for the provision of any Restricted Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's EIP Amount&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">up to &#163;&#91;***&#93; in aggregate payable to the Purchaser's EIP Recipients by the Purchaser following Completion in respect of, and in accordance with the terms of, the Purchaser's Employee Incentive Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's EIP Recipients&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means those individuals agreed between the Purchaser and the Founder Sellers as at the date of this Agreement and as set out in the Purchaser's Employee Incentive Plan (or an agreed form document referred to therein).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's Employee Incentive Plan&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the employee incentive plan, in the agreed form &#91;***&#93; in respect of the Purchaser's EIP Amount, to be established for the benefit of the Purchaser's EIP Recipients pursuant to which such persons shall, subject to the terms therein, be eligible to participate.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's Group&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Purchaser and any holding company and any subsidiary and any subsidiary undertaking of the Purchaser or such companies from time to time and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser Group Company&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's Bank Account&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Purchaser's bank account at &#91;***&#93; (and&#47;or such other bank account(s) as the Sellers' Representatives and the Purchaser may agree in writing).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Regulation S&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in the context of the Consideration Shares and Consideration ADSs, has the common meaning given in respect of US securities law with reference to the Securities and Exchange Commission.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Relevant Authority&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any of the UK Secretary of State for Business, Energy and Industrial Strategy (or a representative), the UK Investment Security Unit, the German Bundeskartellamt, the German Federal Ministry for Economic Affairs and Climate Action, the French Minister for Economy, the General Authority for Competition in Saudi Arabia or the Taiwan Fair Trade Commission.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Relevant Person&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in sub-clause&#160;13.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchaser's remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Reserved Sum&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in sub-clause&#160;19.12(a)(ii)(A) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Resolved Claim&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any claim under this Agreement that has been&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">agreed in writing between the Purchaser and the Sellers' Representatives or the Warrantors (as the case may be) as to both liability and quantum&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">finally determined by the English courts pursuant to clause&#160;28 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governing Law and jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Restricted Business&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the business of producing high quality artificial intelligence, mobile applications, websites, e-commerce, e-learning, AR&#47;VR and software solutions, as well as 3D or graphic design and social media content including, without limitation, those activities relating to life sciences and those ancillary or incidental to or in connection with such business as carried on by the Group during the &#91;***&#93;-month period prior to Completion in any jurisdiction where the Group was materially active during such time or had concrete and active plans to enter as at Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Restricted Period&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the period commencing on Completion and ending &#91;***&#93; years from Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Restricted Person&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means each of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;RSU Award&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any French Award that will vest on or immediately before Completion and will result in the issue and allotment of FME Completion Shares referred to in paragraphs (e) or (g) of the definition of FME Completion Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any New Award in the form of a conditional right to acquire Shares that will vest automatically (without needing to be exercised) on or immediately before Completion and will result in the issue and allotment of FME Completion Shares referred to in paragraph&#160;(h) of the definition of FME Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;RSU Holder&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the FME Shareholders who hold an RSU Award that is to vest on or immediately before Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Schemes&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in sub-clause&#160;35.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Particulars of employees and workers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Securities Act&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means, in the context of the Consideration Shares and Consideration ADSs, the U.S. Securities Act of 1933, as amended.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Security Incident&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any event having an actual adverse effect on the security of the IT Systems.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Seller Associate&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any person with whom a Seller and&#47;or (prior to Completion) any Group Company is either associated or connected for any Tax purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sellers' Bank Account&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the bank account maintained by &#91;***&#93; as shall be notified to the Purchaser by &#91;***&#93; (and&#47;or such other bank account(s) as the Sellers and the Purchaser may agree in writing).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sellers' Solicitors&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means CMS Cameron McKenna Nabarro Olswang LLP of Cannon Place, 78 Cannon Street, London, EC4N 6AF, United Kingdom.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sellers' Representatives&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">collectively,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the FME Shareholders' Representative, the Investor Sellers' Representative and the Institutional Sellers' Representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sellers' Upfront Consideration&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Upfront Base Consideration, as adjusted in accordance with the Completion Allocation Schedule after inserting the Actual Cash, Actual Debt and the Actual Working Capital amounts set out in the Completion Accounts and reflecting (if applicable) any increase or reduction to the Upfront Base Consideration as a result of the Actual Adjustment Amount, in respect of all Completion Fully-Diluted Shares held or to be held by the Sellers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Senior Employee&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each of the Key Employees&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any other employee of or consultant to any Group Company whose fees and&#47;or emoluments exceed &#163;&#91;***&#93; (or the equivalent amount in local currency in respect of each of the Group Companies) per annum at the relevant time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Shareholder Documents&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Share Purchase Agreement dated &#91;***&#93; between (1) the Purchaser (2) the Sellers and (3) the Company (all such terms as defined therein)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Subscription Agreement dated &#91;***&#93; between (1) the Investors&#59; (2) the Founders and (3) InstaDeep Limited (all such terms as defined therein)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Amended and Restated Shareholders' Agreement dated &#91;***&#93; between (1) the New Investors&#59; (2) the Founders&#59; (3) the Existing Shareholders and (4) the Company (all such terms as defined therein)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the 2022 &#91;***&#93; SPA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Share Purchase Options&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the following options granted by &#91;***&#93; to purchase Ordinary Shares (registered in &#91;***&#93; name as at the date of this Agreement)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an option granted on &#91;***&#93; to &#91;***&#93; to purchase from &#91;***&#93; &#91;***&#93; Ordinary Shares at a purchase price of &#163;&#91;***&#93; per Share&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an option granted on &#91;***&#93; to &#91;***&#93; to purchase from &#91;***&#93; &#91;***&#93; Ordinary Shares at a purchase price of &#163;&#91;***&#93; per Share&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">an option granted on &#91;***&#93; to &#91;***&#93; to purchase from &#91;***&#93; &#91;***&#93; Ordinary Shares (out of which &#91;***&#93; Ordinary Shares were vested as of the date when &#91;***&#93; ceased to be an employee of the relevant Group Company) at a purchase price of &#163;&#91;***&#93; per Share.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Shares&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the shares in the capital of the Company, consisting of the Ordinary Shares, Class A Shares, Class B Shares and Employee Shares.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Signing Allocation Schedule&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the schedule, in the agreed form, setting out, amongst other matters, the details of the Sellers' residential addresses and country of residence, the Sellers' holdings of the Shares and the draft allocation of the Consideration payable to each of them as prepared, and based on information known, at the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Signing Disclosure Letter&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the letter of the same date as this Agreement, in the agreed form, from the Warrantors to the Purchaser delivered immediately prior to the execution of this Agreement, disclosing matters that are exceptions to the Warranties given at the date of this Agreement, together with all documents annexed to it.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Stand-alone Accounts&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the audited balance sheet as at the Accounts Date and the audited income statement for the financial period ended on the Accounts Date in each case of each Group Company (including all documents required by Applicable Law to be annexed to them for that period).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Stock Option Plan&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the InstaDeep Ltd Share Option Plan, an employees' share scheme established by the directors of the Company on &#91;***&#93; (as amended), and each of the share options granted under it to employees of the Group.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;subordinate legislation&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Section 21(1), Interpretation Act 1978.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;subsidiary&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Section 1159, CA2006.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;subsidiary undertaking&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in Section 1162, CA2006.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Surviving Provisions&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the provisions of clause&#160;1.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions and interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), clause&#160;19 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (save for sub-clauses 19.5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effect of Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and 19.8 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further assurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)), clause&#160;20 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), clause&#160;21 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Costs and expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), clause&#160;23 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), clause&#160;24 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and clause&#160;28 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governing law and jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Systems Data&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the digital data (including personal and non-personal data) stored, processed, retrieved or transmitted by any element of the IT Systems.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Target Cash Balance&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#163;&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Target Debt Balance&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#163;&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Target Working Capital&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#163;&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Claim&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in the Tax Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Covenant&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the covenant given by the Warrantors under Part 3 of the Tax Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Schedule&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the provisions of Schedule 6 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax Schedule</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Warranties&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the warranties set out in paragraph&#160;2 of part 2 of the Tax Schedule and the warranties set out at paragraph&#160;36 of Schedule 4 insofar as any breach of such warranties would give rise to a claim for Tax and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Warranty&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Taxation&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in the Tax Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Third Party Claim&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning set out in clause&#160;15 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchaser's conduct of Third Party Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Total Earn-out Value&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#163;200,000,000, being the maximum aggregate amount that the Sellers would be entitled to receive pursuant to the Earn-out in the event that all Milestones were satisfied in accordance with the terms of this Agreement but for any Investor Seller's election to waive entitlement to &#91;***&#93;% of their pro rata proportion of such amount pursuant to sub-clause&#160;4.3.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Transaction&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Transaction Document&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means this Agreement, the Signing Disclosure Letter, the Completion Disclosure Letter, any document in the agreed form, and any other agreement entered into pursuant to the foregoing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Transaction Expenses&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means costs, expenses, fees and other payments made to advisors by any Group Company in connection with the Transaction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tunisia Completion&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given set out in sub-clause&#160;2.11.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tunisian Sellers&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means those Sellers that will, as at Completion, be resident or domiciled in Tunisia.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;TUPE Regulations&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Transfer of Undertakings (Protection of Employment) Regulations 1981 (SI 1981&#47;1794) and&#47;or, as the case may be, the Transfer of Undertakings (Protection of Employment) Regulations 2006 (SI 2006&#47;246).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Upfront Base Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the sum of &#163;&#91;***&#93; per share.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;US FME Shareholders&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means those FME Shareholders who are a &#34;U.S. person&#34; (as such term is defined in Regulation S) under the Securities Act, the final list of which will be delivered by the FME Shareholders' Representative to the Purchaser no later than &#91;***&#93; Business Days prior to Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US FME Shareholders Upfront Cash Completion Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means the Estimated Sellers' Upfront Consideration in respect of the Consideration Shares held by the relevant US FME Shareholders.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;VWAP Value&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means $&#91;***&#93;, being the Bloomberg &#91;***&#93; calendar day volume-weighted average price of the Purchaser's shares listed on NASDAQ (over that &#91;***&#93; calendar period not on a daily basis), such period ending on &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Warranties&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Non-Tax Warranties and the Tax Warranties, and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Warranty&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any one of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Warrantors&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Founder Sellers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Warranty Claim&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means a claim by the Purchaser against the Warrantors for breach of any of the Warranties.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Working Capital&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregated amount of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">trade receivables, less any loss allowance (bad debt allowance)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all other current receivables, deferred revenue, other current assets, prepaid expenses (including receivables relating to taxes other than income taxes), financial deposit and accrued interests on the financial deposits to the extent not included in Cash or Debt&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">trade payables&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">prepayments received&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">all other current provisions and accruals other than income taxes to the extent not included in Debt and separately treated in this definition&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any provisions, accruals or liabilities relating to contractual bonuses (including the commission bonuses payable to &#91;***&#93; and to &#91;***&#93;) which refers to the period ending on the Effective Time including any social security contribution&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any provisions, accruals or liabilities relating to the 13th salary including any social security contribution&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any provisions, accruals or liabilities relating to employee benefits such as unused holidays or overtime including any social security contribution which are not above the amounts legally authorized to carry-over or which are related to the legal holiday entitlement for the current year&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.9pt">all other current payables (including liabilities relating to taxes other than income taxes), to the extent not included in Debt,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case to which the Company or any of the Subsidiaries is beneficially entitled as at the Effective Time, calculated on a consolidated basis in accordance with the accounting principles, policies, standards, practices, evaluation rules and estimation techniques specified in Part 2 of Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). An illustrative detailed mapping on account basis designated as &#34;Working Capital&#34; is outlined in Part 3 of Schedule 9.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Working Time Regulations&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Working Time Regulations 1998 (SI 1998&#47;1833).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;W&#38;I Cost&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means &#163;&#91;***&#93;, being &#91;***&#93;% of the aggregate amount payable in respect of the W&#38;I Policy, including the insurance premium, brokerage costs, underwriting costs and insurance premium tax.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;W&#38;I Insurer&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the insurer for the W&#38;I Policy being principally &#91;***&#93;, together with &#91;***&#93;, &#91;***&#93; and joint insurers, &#91;***&#93;, as set out under the W&#38;I Policy.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;W&#38;I Policy&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the warranty and indemnity insurance policies in the agreed form with policy number &#91;***&#93; and &#91;***&#93;, issued by the W&#38;I Insurer in favour of the Purchaser on the date of this Agreement and relating to claims under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;W&#38;I Policy Excerpt&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means an excerpt of the W&#38;I Policy showing no subrogation rights against the Warrantors except in the case of fraud, dishonesty or wilful misconduct.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;In this Agreement&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">words in the singular include the plural and vice versa and words in one gender include any other gender&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a reference to a statute or statutory provision includes&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any subordinate legislation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any repealed statute or statutory provision which it re-enacts (with or without modification)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">any statute, statutory provision or subordinate legislation which modifies, consolidates, re-enacts or supersedes it,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided such subordinate legislation, re-enactment, statute or statutory provision came into force before the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a reference to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;party&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means each person as set out at the head of page <a href="#i67e3fd7aaada43e29d847090ffd90bcb_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">1</a> (save for InstaDeep), a reference to &#34;parties&#34; means all of the parties to this Agreement (save for InstaDeep) and, upon any succession or permitted assignment, a reference to any party shall be deemed to include a reference to that party's successors in title or permitted assigns&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;person&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">includes any individual, firm, corporation, body corporate, association or partnership, trust, unincorporated organisation, employee representative body, government or state or agency or department thereof, executors, administrators or successors in title (whether or not having a separate legal personality)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">clauses and schedules are to clauses and schedules of this Agreement and references to sub-clauses and paragraphs are references to sub-clauses and paragraphs of the clause&#160;or schedule in which they appear&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any provision of this Agreement is to that provision as amended in accordance with the terms of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any document being </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;in the agreed form&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means in a form which has been agreed in writing by the parties (or by their respective solicitors on their behalf) on or before the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any English legal term for any action, remedy, method of judicial proceeding, legal document, legal status, legal concept, state of affairs or thing or references to any English body, organisation, court or official shall in each case in respect of any jurisdiction other than England or any body corporate incorporated in any such jurisdiction, be deemed to refer to and include that which most approximates in that jurisdiction to the English legal term, body, organisation, court or official&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.9pt">any reference to any English statute, statutory provision or EU derived law applicable in England shall in each case in respect of any jurisdiction other than England or a body corporate incorporated in any such jurisdiction, be deemed to include a reference to all Applicable Law relating to the same subject matter as that English statute, statutory provision or EU derived law&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.68pt">references to times of the day are to local time in the relevant jurisdiction unless otherwise stated&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">save as expressly defined or otherwise set out in sub-clause&#160;1.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions and interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or this sub-clause&#160;1.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions and interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or in any other provision of this Agreement, words and expressions which are defined in the CA2006 shall have the meaning attributed to them in the CA2006 when used in this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.78pt">&#34;sterling&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and the sign </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#163;&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means pounds sterling in the currency of the United Kingdom&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.57pt">&#34;Euros&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and the sign </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#8364;&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means euros in the currency of the European Union&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.78pt">&#34;UK&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the United Kingdom of Great Britain and Northern Ireland&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the table of contents and headings are for convenience only and shall not affect the interpretation of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">general words shall not be given a restrictive meaning&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">if they are introduced by the word &#34;other&#34; or &#34;including&#34; or similar words by reason of the fact that they are preceded by words indicating a particular class of act, matter or thing&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">by reason of the fact that they are followed by particular examples intended to be embraced by those general words&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">where any statement is qualified by the expression </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;so far as the Warrantors are aware&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> &#34;to the best of the Warrantors' knowledge and belief&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or any similar expression, it shall be deemed to refer to the actual awareness, knowledge or belief of the Warrantors having made due and careful enquiry of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">&#91;***&#93; in respect of InstaDeep Dubai (branch) and InstaDeep Abu Dhabi (branch)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">&#91;***&#93; in respect of InstaDeep South Africa (branch)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93; (only in respect of the Non-Tax Warranties at paragraphs 35 to 40 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and paragraphs 41 to 43 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#91;***&#93; (only in respect of the Non-Tax Warranties at paragraphs 9 to 13 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraphs 16 to 17 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraphs 35 to 40 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraphs 41 to 43  (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraph&#160;18 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Contracts and commitments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraph&#160;19 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trading partners</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and paragraphs 24 to 25 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Assets</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93; (only in respect of the Non-Tax Warranties at paragraphs&#160;26 to 29 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and paragraph&#160;30 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Information technology</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.9pt">&#91;***&#93; (only in respect of the Non-Tax Warranties at paragraph&#160;18 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Contracts and commitments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraph&#160;19 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trading partners</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraph&#160;21 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Competition and trade regulation law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraph&#160;23 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Litigation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraphs&#160;26 to 29 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and paragraph&#160;34 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Data Protection</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.68pt">&#91;***&#93; (only in respect of the Non-Tax Warranties at paragraphs&#160;26 to 29 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the following individuals only in respect of (i) the Non-Tax Warranties at paragraphs 9 to 13 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), paragraphs 35 to 40 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and paragraphs 41 to 43 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pensions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of Schedule 4&#59; and (ii) the Tax Warranties&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">&#91;***&#93; only in respect of the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">&#91;***&#93; only in respect of InstaDeep SAS&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93; only in respect of InstaDeep Dubai (branch) and InstaDeep Abu Dhabi (branch)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93; only in respect of InstaDeep Nigeria Limited&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">&#91;***&#93; only in respect of InstaDeep LLC&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">&#91;***&#93; only in respect of InstaDeep Tunisia&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.57pt">&#91;***&#93; only in respect of InstaDeep South Africa (branch)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93; only in respect of InstaDeep Deutschland GmbH&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#91;***&#93; (only in respect of the Tax Warranties in respect of InstaDeep SAS).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">where any liability or obligation is undertaken by two or more parties the liability or obligation of each of them shall be several (and not joint and several), unless expressly stated to the contrary&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">for the purposes only of the membership requirement contained in subsections 1159(1)(b) and (c), CA 2006, shares registered in the name of a person (or its nominee) by way of security or in connection with the taking of security shall be treated as held by the person providing the security and shares held by a person as nominee for another shall be treated as held by the other&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">references in any Warranty to any monetary sum expressed in a sterling amount shall, where such sum is referable in whole or part to a particular jurisdiction, be deemed to be a reference to an equivalent amount in the local currency of that jurisdiction translated at the Exchange Rate as at the date on which the relevant Warranty was given&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">where it is necessary to determine whether a monetary limit or threshold set out in clause&#160;14 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) has been reached or exceeded (as the case may be) and the value of the relevant claim or any of the relevant claims is expressed in a currency other than sterling, the value of each such claim shall be translated into sterling at the Exchange Rate on the date of receipt by the Warrantors of written notification from the Purchaser in accordance with clause&#160;14 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of the existence of such claim&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">where any provision is qualified or phrased by reference to the ordinary course of business, such reference shall be construed as meaning the customary course of trading for the business of the Group in the country concerned.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Conditions precedent</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Except for the provisions of this clause&#160;2 (Conditions precedent) and the following provisions&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">clause&#160;1.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definitions and interpretation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">sub-clause&#160;3.6 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sale and purchase)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">clause&#160;6 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pre Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">sub-clause&#160;7.5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">clause&#160;10 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">clause&#160;19 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">General</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) save for sub-clauses 19.5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effect of Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and 19.8 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Further assurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">clause&#160;20 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">clause&#160;21 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Costs and expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">clause 23 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">clause&#160;24 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">clause&#160;28 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Governing law and jurisdiction</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">which shall all be effective from the date of this Agreement notwithstanding this sub-clause&#160;2.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), all other provisions of this Agreement and Completion are in all respects conditional upon satisfaction or waiver of the Conditions in accordance with this clause&#160;2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;The Conditions are that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to the extent that the Transaction amounts to a trigger event under section 5(1) of the UK National Security and Investment Act 2021 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;NSIA&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), notification having been accepted by or on behalf of the Secretary of State for Business, Energy and Industrial Strategy (or a representative) (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Secretary of State&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), and the Secretary of State for the purposes of the NSIA either&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">notifies the Purchaser that no further action will be taken by the Secretary of State in relation to the Transaction&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.8pt">makes a final order permitting the Transaction to proceed subject only to such remedies or requirements that are in all respects acceptable to the Purchaser and the Sellers (and to the extent relevant, all conditions, provisions or obligations contained in such final order which are necessary for completion of the Transaction having been satisfied or complied with), and such order is not revoked or varied before Completion&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to the extent that the Transaction requires a mandatory notification to the German Federal Cartel Office (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bundeskartellamt</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), that the German Federal Cartel Office&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">has not announced within the one month period a decision to open in-depth review proceedings in relation to the Transaction (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Hauptpr&#252;fverfahren</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">has explicitly stated to not oppose the Transaction&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">to the extent that the Transaction requires a mandatory notification to the German Federal Ministry for Economic Affairs and Climate Action (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bundesministerium f&#252;r Wirtschaft und Klimaschutz</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;BMWK&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Transaction having been approved, or </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">being deemed to have been approved, by the BMWK, or any stand-still obligation or prohibition to complete the Transaction having otherwise fallen away&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to the extent that the Transaction requires a mandatory notification to the French Minister for Economy (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Ministre de l'Economie, des Finances et de la Souverainet&#233; industrielle et num&#233;rique</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Minister for Economy&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) under Articles L.151-3 et seq. and R. 151-3 et seq. of the French Monetary and Financial Code&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Minister for Economy having concluded that prior approval of the Transaction is not required under foreign direct investment screening regulation as not all of the conditions for screening have been met, or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Minister for Economy having concluded that the Transaction is authorised (with or without condition(s))&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">any stand-still obligation or prohibition to complete the Transaction having otherwise fallen away&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to the extent that the Transaction requires a mandatory merger notification to the General Authority for Competition in Saudi Arabia (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;GAC&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Transaction having been approved, or being deemed to have been approved, by the GAC, or any stand-still obligation or prohibition to complete the Transaction having otherwise fallen away&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">to the extent that the Transaction requires a mandatory merger notification to the Taiwan Fair Trade Commission (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;TFTC&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Transaction having been approved, or being deemed to have been approved, by the TFTC, or any stand-still obligation or prohibition to complete the Transaction having otherwise fallen away&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Central Bank of Tunisia having provided its authorisation(s), approval(s) or equivalent confirmation evidencing that the Central Bank of Tunisia has no objections to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the exercise by the Tunisian Sellers of their options granted under the Stock Option Plan, in each case on or prior to Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the sale by the Tunisian Sellers of their respective Shares on terms and conditions set out in this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the receipt by the Tunisian Sellers of their respective Consideration ADSs on terms and conditions set out in this Agreement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any other matters as may be submitted to it by the relevant Tunisian Sellers and that are necessary in order to proceed to Completion under this Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">together, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CBT Condition&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;The Purchaser shall (so far as it lies within its powers) use all reasonable endeavours to procure that the Conditions are satisfied as soon as practicable and, in any event, not later than 31&#160;July&#160;2023 (or such later date as the Purchaser and the Sellers may agree), including agreeing, accepting and implementing any commercially reasonable undertakings, commitments, measures and other steps (each a &#34;Commitment&#34;) necessary to avoid or negate any action (including any order, decision, judgment or injunction) that would otherwise have the effect of preventing the Conditions from being satisfied. The Purchaser shall not accept or agree to any undertaking, commitment, divestment, condition, obligation, measure, modification or other step in connection with satisfying any of the Conditions that requires any amendment, variation or modification to the terms of this Agreement, without the prior written approval of the Sellers' Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;The Purchaser shall for the purposes of clause&#160;2.3 above&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">prepare, or procure preparation of, in a form reasonably acceptable to the Sellers, the relevant notifications or filings required in order to fulfil the Conditions as soon as possible after the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">promptly deal with all requests and enquiries from any Relevant Authority and provide all information which is required by any of them in connection with satisfying the Conditions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">promptly notify the Sellers and provide copies or, in the case of non-written communications, details, of any communications with a Relevant Authority relating to any such consent, approval or action to fulfil the Conditions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">provide the Sellers with final drafts of all submissions, notifications, filings and other communications to any Relevant Authority at such time as will allow the Sellers a reasonable opportunity to provide comments and for the Purchaser, in its reasonable </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">discretion, to take account of any comments of the Sellers on such drafts prior to their submission&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">communicate with any Relevant Authority in respect of the Transaction to the extent reasonably possible only after prior consultation with the Sellers, taking into account any reasonable comments and requests of the Sellers and provide the Sellers with copies of submissions, notifications or filings in the form submitted or sent or, in the case of non-written communications, provide details of such communications&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">where permitted by the Relevant Authority and to the extent circumstances allow, give reasonable notice of, and allow persons nominated by the Sellers to attend, all meetings, and to participate in all material telephone or other conversations&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">regularly review with the Sellers the progress of the notifications or filings, including, where necessary, seeking to identify appropriate responses to address any concerns identified by any Relevant Authority and discuss with the Sellers the scope, timing and tactics of any proposed responses with a view to obtaining satisfaction of the Conditions at the earliest reasonable opportunity.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;The Purchaser shall be responsible for paying any filing, administrative or other fees levied by any Relevant Authority and&#47;or the Central Bank of Tunisia for the purpose of satisfying the Conditions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;Each of the Purchaser and the Sellers' Representatives shall notify the other in writing of any circumstance, event, fact or matter which will or may prevent fulfilment of the Conditions as soon as such circumstance, event, fact or matter comes to their attention.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;The Sellers agree in connection with the Conditions that they will notify the Purchaser as soon as reasonably practicable of any material written communications they receive from any Relevant Authority in relation to such application, submission or information, promptly provide the Purchaser with a copy of any such communication and deal with any requests or enquiries from the relevant authority in consultation with the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;The Sellers shall co-operate fully in all actions necessary to procure the satisfaction of the Conditions (excluding the CBT Condition) including (but not limited to) the provision by the Sellers of all information reasonably necessary to make any notification or filing in order to satisfy the Conditions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;&#160;&#160;&#160;Nothing in this Agreement shall require either party to disclose to or receive from the other any information&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">which the disclosing party is prohibited from disclosing or the receiving party is prohibited from receiving by Applicable Law&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">where such disclosure would result in the loss of any privilege that subsists in relation to such information, including legal professional privilege&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">which the disclosing party or its affiliated persons reasonably considers to be commercially or competitively sensitive or where disclosure to the other party would reasonably be expected to have a material adverse effect on the disclosing party's legitimate business interests, in which case the disclosing party shall, to the extent permitted by Applicable Law, disclose the relevant information to the other party on an outside counsel basis (acting reasonably in identifying such information) and provide a non-confidential version of such information to the other party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10&#160;&#160;&#160;&#160;Subject to sub-clause&#160;2.11 the Conditions are not satisfied in full by the date specified in clause&#160;2.3 then the Purchaser, the Institutional Sellers and the Sellers Representatives (excluding the Institutional Sellers' Representative) may agree to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">waive any unsatisfied Condition (save that such waiver shall not act as a waiver of the Purchaser's or the Sellers' (as applicable) right to claim for breach of this Agreement)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">extend the period for satisfying any unsatisfied Condition to a date &#91;***&#93; days after that date (in which case the provisions of this sub-clause&#160;shall also apply as if the revised date were the date specified in sub-clause&#160;2.3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)), provided that such period for satisfaction shall not extend beyond &#91;***&#93; of the date of this Agreement&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">terminate this Agreement (other than the Surviving Provisions and the provisions of this sub-clause&#160;2.10(c) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)) by notice in writing, in which event&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Surviving Provisions and the provisions of this sub-clause&#160;2.10(c) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall continue to apply&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">no party shall have any claim under this Agreement of any nature whatsoever against any other party except in respect of any rights, liabilities and </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">obligations which have accrued before termination or which accrue under any of the Surviving Provisions or under this sub-clause&#160;2.10(c) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">except as referred to in this sub-clause&#160;2.10(c) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), all rights, liabilities and obligations of the parties under this Agreement shall cease with immediate effect.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;&#160;&#160;&#160;If the Conditions (other than the CBT Condition) have been satisfied in full (or otherwise waived pursuant to sub-clause&#160;2.10), the Purchaser, the Institutional Sellers and the Sellers' Representatives (excluding the Institutional Sellers' Representative) may agree to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">proceed to Completion in accordance with the terms of this Agreement only in respect of those Sellers who are not Tunisian Sellers, notwithstanding that the CBT Condition has not been satisfied&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">extend the period for satisfying the CBT Condition to a date agreed between the Purchaser and the FME Shareholders' Representative,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in which case the completion of the sale and purchase of the Completion Shares held by the Tunisian Sellers (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tunisia Completion&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) will occur in respect of the Completion Shares held by Tunisian Sellers only once and on such date, falling no later than 10 Business Days after the CBT Condition has been satisfied in full, as the Purchaser will notify to the FME Shareholders&#8217; Representative and the Investor Sellers&#8217; Representative (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tunisia Completion Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;) (and the provisions of this Agreement shall be deemed to have been amended, including that payment of the relevant Consideration shall only become due and payable by the Purchaser on the Tunisia Completion Date. In order to give effect to this sub-clause&#160;2.11, the Purchaser shall transfer the relevant Upfront Consideration amount due to the Tunisian Sellers (which shall include, as applicable, their relevant proportion of&#58; (i) &#91;***&#93; and (ii) the Holdback Amount plus or minus, if known at the relevant time, any applicable pro-rata Consideration Increase or Consideration Reduction finally determined in accordance with this Agreement) to the Sellers&#8217; Bank Account at least 2 Business Days prior to the Tunisia Completion Date and, if applicable, &#91;***&#93; shall, in accordance with the Paying Agent Agreements, hold in escrow an amount equal to the relevant proportion of &#91;***&#93; and the Holdback Amount in respect of the Completion Shares held by the Tunisian Sellers until such time as this is due to be released in accordance with clause 5.2.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.12&#160;&#160;&#160;&#160;In the event that the relevant parties agree to proceed to Completion and, if applicable, agree to extend the period for satisfying the CBT Condition, in each case pursuant to sub-clause&#160;2.11, each Tunisian Seller irrevocably undertakes to the Purchaser that, for as long as such Tunisian Seller remains the registered holder of the Shares after Completion but before the Tunisia Completion, such Tunisian Seller shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">hold the Shares and any dividends and other moneys or assets paid or distributed in respect of them and all rights arising out of or in connection with them from Completion in trust for the Purchaser&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">deal with the Shares and all such dividends, distributions and rights as the Purchaser may direct from Completion until the date on which the Purchaser or its nominee is entered in the register of members of the Company as the holder of the Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">unless otherwise agreed with the Purchaser, not exercise or otherwise deal with any Options held by them until the CBT Condition has been satisfied in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sale and purchase</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;Subject to the provisions of this Agreement, the Sellers shall sell, and the Purchaser shall purchase, the Completion Shares with effect from Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;The Completion Shares shall be sold with the benefit of all rights attaching to or accruing to them as at the date of Completion, including all dividends or other distributions declared, paid or made by the Company on or after the date of Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;Subject to sub-clause&#160;2.11, the Purchaser shall not be obliged to complete the purchase of the Completion Shares unless the sale and purchase of all the Completion Shares is completed simultaneously.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;Each of the Sellers hereby irrevocably and unconditionally waives all rights of pre-emption or similar rights over any of the Completion Shares conferred on him by either the articles of association of the Company or in any other way, in each case in connection with the Transaction only.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;Each of the Sellers hereby irrevocably and unconditionally waives any and all claims they have (in their capacity as shareholders of the Company only) against any Group Company as at Completion. Each Seller, in respect of such Seller's commercial agreements with any Group Company only (if any, as applicable), confirms as at the date of this Agreement that it is not </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">aware of any claims existing, threatened or pending against any Group Company. For the purposes of this clause&#160;3.5, &#34;awareness&#34; shall be deemed to refer to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of &#91;***&#93;, the actual knowledge of &#91;***&#93;&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of all other Sellers, the actual knowledge of that Seller (if the Seller is an individual) or, where the Seller is a body corporate, the actual knowledge of (i) the general counsel of that Seller&#59; or (ii) if no general counsel is in place, the person heading or leading the legal function within the relevant Seller&#59; or (iii) if no general counsel or legal role is in place, the directors of that Seller.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;Each of the Sellers severally warrants to the Purchaser in respect of itself only both at the date of this Agreement and again at Completion (save that, in respect of any Completion Shares that are not also Exchange Shares, the FME Shareholders shall only warrant at Completion and save that &#91;***&#93; Ordinary Shares held by &#91;***&#93; are subject to the provisions of clauses&#160;3.11 and 3.12) that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Completion Shares set out opposite that Seller's name in Schedule 1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Sellers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) are fully paid up (or credited as fully paid)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of the ownership of the Completion Shares&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">save for the &#91;***&#93; Shares that are not registrable by the Company as at the date of this Agreement pending confirmation of stamping, it is the sole legal owner of the Completion Shares set out opposite its name in Schedule 1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Sellers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">it is the sole beneficial owner of such Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;Each of the Sellers severally warrants to the Purchaser in respect of itself only both at the date of this Agreement and again at Completion that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">subject to confirmation of stamping and completion of the registration of transfer by the Company in the Company's statutory books of the &#91;***&#93; Shares, it has and shall have pursuant to this Agreement the right to transfer the legal and beneficial title to the Completion Shares set out opposite its name in Schedule 1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Sellers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) on the terms of this Agreement and without the consent of any third party and that they will be transferred free from any Encumbrance&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">it has the full power and authority to enter into and perform this Agreement and each of the documents to be executed by it and delivered pursuant to this Agreement, each of which shall constitute valid and binding obligations on it&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">he is not bankrupt, has not proposed a voluntary arrangement nor has made or proposed any arrangement or composition with his creditors or any class of his creditors.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;The Purchaser warrants to the Sellers both at the date of this Agreement and again at Completion that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">It has the full power and authority to enter into and perform this Agreement and each of the documents to be executed by it and delivered pursuant to this Agreement, each of which shall constitute valid and binding obligations on it&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">otherwise than as contemplated in clause&#160;2 above, it is not required to obtain any consent or approval of, or give any notice to or make any registration with, any governmental or other authority in respect of the Transaction which has not been obtained or made at the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">it is not bankrupt, has not proposed a voluntary arrangement nor has made or proposed any arrangement or composition with its creditors or any class of its creditors&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the execution and delivery by it of this Agreement and the performance of and compliance with their respective terms and provisions will not&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">result in a breach of any provision of the constitutional documentation of the Purchaser&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">conflict with or result in a breach of, or constitute a default under, any agreement or instrument to which it is a party or by which it is bound or any order, judgment or decree of any court, governmental agency or regulatory body by which it is bound&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">at Completion, it will have immediately available on an unconditional basis the necessary cash resources to meet its obligations under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Put and Call Arrangements</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;In relation to the FME Retained French Shares held, or acquired, by an FME Shareholder&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">At any time within the period of &#91;***&#93; commencing on the date set against that FME Shareholder's name in column E4 of the table set out in Part 1 of Schedule 1, the Purchaser shall have the right to purchase all (but not some only) of those FME Retained French Shares in accordance with the terms of paragraph&#160;(c). The Purchaser may exercise this right by serving a written notice on the FME Shareholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">In the event that the Purchaser does not exercise the right to purchase the FME Retained French Shares within the &#91;***&#93; day period referred to in paragraph&#160;(a) then, at any time within the period of &#91;***&#93; days commencing one day after the end of the &#91;***&#93; day period referred to in paragraph&#160;(a), the FME Shareholder shall have the right to sell all (but not some only) of their FME Retained French Shares in accordance with the terms of paragraph&#160;(c). The FME Shareholder may exercise this right by serving a written notice on the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Upon any service of a notice by the Purchaser on the FME Shareholder in accordance with paragraph&#160;(a), or by the FME Shareholder on the Purchaser in accordance with paragraph&#160;(b), a legally binding irrevocable and unconditional agreement shall immediately arise for the sale and purchase of the relevant FME Retained French Shares. Under the terms of that agreement, the FME Shareholder shall be bound to sell and the Purchaser shall be bound to purchase the FME Retained French Shares for the following Consideration per each FME Retained French Share (its pro rata share only of)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Upfront Consideration&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Contingent Consideration (calculated and payable in accordance with Schedule 10  and always subject to the rights of the Purchaser pursuant to sub-clause&#160;19.12 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The sale and purchase of the FME Retained French Shares shall complete on such date (and time) as is determined by the Purchaser, such date not to be more than &#91;***&#93; days after the service of the notice (as the case may be) by the Purchaser on the FME Shareholder in accordance with paragraph&#160;(a) or by the FME Shareholder on the Purchaser in accordance with paragraph&#160;(b). On the completion of the sale and purchase of the FME Retained French Shares&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the FME Shareholder shall deliver to the Purchaser a duly executed transfer of the FME Retained French Shares held by them in favour of the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Purchaser shall pay to the FME Shareholder the Consideration (as set out in paragraph&#160;(c)) for those FME Retained French Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If the FME Shareholder fails to comply with paragraph&#160;(d), the Purchaser is hereby irrevocably authorised to execute, or to authorise and instruct such person as it thinks fit to execute, any necessary transfer, indemnity or certificate on behalf of the FME Shareholder and, against receipt by the Company of the Consideration payable for the FME Retained French Shares, to deliver any such transfer, indemnity or certificate to the Purchaser. The Company shall hold the Consideration on trust for the FME Shareholder without any obligation to pay interest.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;In relation to any FME 2024 French Shares acquired by an FME Shareholder&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">At any time within the period of &#91;***&#93; days commencing on &#91;***&#93;, the Purchaser shall have the right to purchase all (but not some only) of those FME 2024 French Shares in accordance with the terms of paragraph&#160;(c). The Purchaser may exercise this right by serving a written notice on the FME Shareholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">In the event that the Purchaser does not exercise the right to purchase the FME 2024 French Shares within the &#91;***&#93; day period referred to in paragraph&#160; then, at any time within the period of &#91;***&#93; days commencing one day after the end of the &#91;***&#93; day period referred to in paragraph&#160;(a), the FME Shareholder shall have the right to sell all (but not some only) of their FME 2024 French Shares in accordance with the terms of paragraph&#160;(c). The FME Shareholder may exercise this right by serving a written notice on the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Upon any service of a notice by the Purchaser on the FME Shareholder in accordance with paragraph&#160;(a), or by the FME Shareholder on the Purchaser in accordance with paragraph&#160;(b), a legally binding, irrevocable and unconditional agreement shall immediately arise for the sale and purchase of the relevant FME 2024 French Shares. Under the terms of that agreement, the FME Shareholder shall be bound to sell and the Purchaser shall be bound to purchase the FME 2024 French Shares for the following Consideration per each FME 2024 French Shares (its pro rata share only of)&#58;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Sellers' Upfront Consideration&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Contingent Consideration (calculated and payable in accordance with Schedule 10  and always subject to the rights of the Purchaser pursuant to sub-clause&#160;19.12 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The sale and purchase of the FME 2024 French Shares shall complete on such date (and time) as is determined by the Purchaser, such date not to be more than &#91;***&#93; days after the service of the notice (as the case may be) by the Purchaser on the FME Shareholder in accordance with paragraph&#160;(a) or by the FME Shareholder on the Purchaser in accordance with paragraph (b). On the completion of the sale and purchase of the FME 2024 French Shares&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the FME Shareholder shall deliver to the Purchaser a duly executed transfer of the FME 2024 French Shares held by them in favour of the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Purchaser shall pay to the FME Shareholder the Consideration (as set out in paragraph (c)) for those FME 2024 French Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If the FME Shareholder fails to comply with paragraph&#160;(d), the Purchaser is hereby irrevocably authorised to execute, or to authorise and instruct such person as it thinks fit to execute, any necessary transfer, indemnity or certificate on behalf of the FME Shareholder and, against receipt by the Company of the Consideration payable for the FME 2024 French Shares, to deliver any such transfer, indemnity or certificate to the Purchaser. The Company shall hold the Consideration on trust for the FME Shareholder without any obligation to pay interest.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Notwithstanding any other provisions of this Agreement, any notice or other document which the Purchaser wishes to deliver to the FME Shareholders or any of them pursuant to this clause 3.10 may be delivered to them by being delivered to the FME Shareholders' Representative in accordance with the provisions set out in clause&#160;24&#160;(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Share Purchase Options</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;&#160;&#160;&#160;It is acknowledged that &#91;***&#93; has granted the Share Purchase Options over, in total, &#91;***&#93; of the Ordinary Shares registered in &#91;***&#93; name (out of which &#91;***&#93; Ordinary Shares have vested) (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Applicable Ordinary Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). &#91;***&#93; hereby agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; will procure that the vested Share Purchase Options are exercised in full on or before Completion (or, to the extent that they are not exercised, will procure that they lapse)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; will procure that, following the transfer of the Applicable Ordinary Shares to the holders of the Share Purchase Options, each such holder is entered as the legal owner of the Applicable Ordinary Shares in the Company's register of members no later than immediately before Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12&#160;&#160;&#160;&#160;The Purchaser and the Founders will procure that the exercise price owed to &#91;***&#93; in consideration for the transfer of the Applicable Ordinary Shares pursuant to the Share Purchase Options will be paid to &#91;***&#93; as part of the Completion funds flow, out of the consideration to be received by the holders of the Share Purchase Options from the Purchaser in respect of the sale of their respective Applicable Ordinary Shares as part of Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;&#160;&#160;&#160;Part 1, Law of Property (Miscellaneous Provisions) Act 1994 shall not apply to any disposition of the Shares made under or pursuant to this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;The Consideration payable for each Completion Share is&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Sellers' Upfront Consideration&#59; plus</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Contingent Consideration.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;The Consideration for the Completion Shares shall be satisfied as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">as to the Upfront Consideration&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">by the payment to each Investor Seller of the Sellers' Upfront Consideration multiplied by the number of Completion Shares held by each Investor Seller&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in respect of each Non-US FME Shareholder (other than the holders of FME 2024 French Shares in respect of such FME 2024 French Shares only)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">by the payment of a cash sum comprising (i) &#91;***&#93;% of the Sellers' Upfront Consideration </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the number of Completion Fully Diluted Shares held by the Non-US FME Shareholders&#59; and (ii) such </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">amount as is agreed pursuant to sub-clauses 4.4 and 4.5 between the Purchaser and the FME Shareholders' Representative as being the FME Shareholders' Transaction Tax Liability,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">subject to any further adjustments as required to account for any &#91;***&#93; in accordance with this Agreement, by the allotment by the Purchaser to the Depositary of the aggregate number of Consideration Shares and delivery by the Depositary to each Non-US FME Shareholder of such number of Consideration ADSs as is set out in the Completion Allocation Schedule and in accordance with the calculations in clause&#160;7.3(d)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">in respect of the US FME Shareholders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and the holders of FME 2024 French Shares (in respect of such FME 2024 French Shares only), subject to any further adjustments as required to account for any &#91;***&#93; in accordance with this Agreement, by the payment to each such person of the Sellers' Upfront Consideration </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the number of Completion Fully Diluted Shares held by such person as set out in the Completion Allocation Schedule&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">as to the Contingent Consideration&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">subject to sub-clause&#160;4.3, by the payment to the Investor Sellers of the Investor Sellers' Upfront Contingent Cash Consideration&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">by the payment to each FME Shareholder of their respective pro rata proportion (as set opposite his or her name in the Completion Allocation Schedule) of the Earn-out Consideration on the Earn-out Consideration Completion Date, in each case, in accordance with clause 23 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and subject to Schedule 10  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Calculation of Earn-out Consideration)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and subject always to the rights of the Purchaser pursuant to sub-clause&#160;19.12 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Each Seller who shall receive Investor Sellers' Upfront Contingent Cash Consideration pursuant to the terms of this Agreement hereby waives any and all entitlement to receive any Earn-out Consideration that may otherwise be payable to such Seller pursuant to the terms of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">FME Shareholders' Transaction Tax Liability</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;As soon as practicable after the date of this Agreement, the FME Shareholders' Representative, having taken professional advice, shall deliver to the Purchaser its methodology for estimating the FME Shareholders' Transaction Tax Liability (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Proposed Methodology&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), providing supporting evidence and information so as to allow the Purchaser to undertake a review of the Proposed Methodology. The Purchaser shall review the Proposed Methodology and discuss with the FME Shareholders' Representative any proposed amendments. The FME Shareholders' Representative and the Purchaser shall use all reasonable endeavours to reach agreement on the Proposed Methodology. If agreement on the Proposed Methodology cannot be reached within &#91;***&#93; Business Days of the date of delivery to the FME Shareholders' Representative of the first draft, any matter still in dispute may upon the direction of the Purchaser or the FME Shareholders' Representative be referred to an Independent Expert for determination. Upon agreement or determination (as the case may be), the resulting methodology shall be the agreed methodology (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Agreed Methodology&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) for the purposes of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;On the day that is no later than &#91;***&#93; Business Days prior to the Completion Date, the FME Shareholders' Representative shall deliver to the Purchaser the final Completion Allocation Schedule signed by the FME Shareholders' Representative on behalf of the FME Shareholders (prepared using the Agreed Methodology and including calculation of the FME Shareholders' Transaction Tax Liability, by reference to the FME Shareholders' Representative's reasonable estimate of the price of the Purchaser's shares listed on NASDAQ on or around the proposed Completion Date as well as the estimates and adjustment amounts contemplated by the Estimates Notice, updated with the most up-to-date information available at the relevant time, if required) and which shall be prepared in good faith and with due care and attention having undertaken such draft payroll runs as may be required (as applicable). The Purchaser shall have the right to review the Completion Allocation Schedule and the FME Shareholders' Representative shall provide reasonable access to supporting evidence and information as may reasonably be required by the Purchaser to enable the Purchaser to verify the accuracy of the Completion Allocation Schedule. The FME Shareholders' Representative and the Purchaser shall use all reasonable endeavours to reach agreement on the Proposed Completion Allocation Schedule, but to the extent that no agreement can be reached on any particular aspect, then, in respect of that matter only, the position as set out in the Completion Allocation Schedule delivered by the FME Shareholders Representative shall be deemed to be agreed for the purpose of proceedings to Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Subscription monies and Option Tax Liability</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;&#160;&#160;&#160;Each FME Shareholder&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">irrevocably agrees and confirms that they will have delivered to the Company (or, for the purpose of the Share Purchase Options, to &#91;***&#93;) a duly completed notice of exercise immediately prior to but conditional upon Completion agreeing to sell the Shares that they will acquire on the exercise of their Options (other than a New Award in the form of an RSU Award) pursuant to this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">acknowledges and affirms that any Options (or part thereof) that they hold (other than a New Award in the form of an RSU Award) and which are not exercised prior to Completion, shall not be exercised and shall lapse immediately on Completion&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">severally and irrevocably authorises, directs and instructs &#91;***&#93; to deduct from their FME Shareholders' Upfront Cash Consideration an amount equal to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Option Exercise Monies or, in the case of an RSU Award, any subscription price payable upon the vesting of the RSU Award&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">if applicable, the Estimated Tax Withholding,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and to pay those sums (i) to the Company (such sums to be applied in accordance with the provisions of clause&#160;4.16) in respect of all Options other than the Share Purchase Options and (ii) to &#91;***&#93; in respect of the Share Purchase Options.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16&#160;&#160;&#160;&#160;Each FME Shareholder directs, and the Purchaser will procure, that the Company&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">accepts, in settlement of any obligation of the FME Shareholder to pay such sums to the Company, any amount paid to it in accordance with clause&#160;4.154c)(i)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">as soon as reasonably practicable after Completion (and, in any event, within &#91;***&#93; days), withholds from the Estimated Tax Withholding paid to it in accordance with clause&#160;4.15 4c)(ii)in respect of that FME Shareholder an amount equal to the Option Tax Liability payable by that FME Shareholder and then pays the balance of the Estimated Tax Withholding (if any) to the FME Shareholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration adjustment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;After Completion the parties shall use their respective best endeavours to procure the preparation of the Completion Accounts in accordance with Schedule 9  (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;If, following agreement or determination of the Completion Accounts in accordance with Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Adjustment Amount exceeds the Actual Adjustment Amount then, subject to sub-clause&#160;5.3, the amount by which the Estimated Adjustment Amount exceeds the Actual Adjustment Amount shall be treated as a reduction from the Consideration (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration Reduction&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">if the Holdback Amount is less than the Consideration Reduction,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Purchaser and the Sellers irrevocably agree that the Holdback Amount is payable, and shall be paid to, the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Sellers shall pay to the Purchaser the amount then outstanding following the release to the Purchaser of the Holdback Amount at sub-clause&#160;5.2(a)(i)(A) in cash within &#91;***&#93; Business Days of the Determination Date and if no such payment is made by the FME </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders, then the Purchaser and the Sellers agree that the outstanding amount due by the FME Shareholders shall be released to the Purchaser from the &#91;***&#93; in settlement of the FME Shareholders obligation to pay pursuant to this clause&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">if the Holdback Amount is more than the Consideration Reduction&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">an amount equal to the Consideration Reduction is to be deducted from the Holdback Amount and the parties irrevocably agree that such amount is payable, and shall be paid to, the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the balance of the amount then outstanding following the payment at sub-clause&#160;5.2(a)(ii)(A) is payable to the Sellers from the Holdback Amount in cash within &#91;***&#93; Business Days of the Determination Date,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in each case in accordance with clause 23 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), and such set-off payment shall be apportioned between the Sellers as set out in the Completion Allocation Schedule&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Adjustment Amount is equal to the Actual Adjustment Amount, then there will be no adjustment to the Consideration and the Holdback Amount shall be payable to the Sellers within &#91;***&#93; Business Days of the Determination Date in accordance with clause 23 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Payments)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and such payment(s) shall be apportioned between the Sellers as set out in the Completion Allocation Schedule&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Estimated Adjustment Amount is less than the Actual Adjustment Amount then, subject to sub-clause&#160;5.3, the Consideration shall be treated as increased by the amount by which the Estimated Adjustment Amount is less than the Actual Adjustment Amount (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Consideration Increase&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). The Holdback Amount plus any additional Consideration required to satisfy the Consideration Increase shall be paid by the Purchaser to the Sellers in cash within &#91;***&#93; Business Days of the Determination Date. Such additional Consideration shall be apportioned between the Sellers as set out in the Completion Allocation Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;If the&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Consideration Reduction is &#163;&#91;***&#93; or less, then, for the purposes of sub-clause&#160;5.2(a), the Consideration Reduction shall be deemed to be &#91;***&#93;. If the Consideration Reduction is more than &#163;&#91;***&#93; then for the purposes of sub-clause&#160;5.2(a) the Consideration Reduction shall be the whole of the Consideration Reduction and not just the amount that exceeds &#163;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If the Consideration Increase is &#163;&#91;***&#93; or less, then, for the purposes of sub-clause&#160;5.2(c), the Consideration Increase shall be deemed to be &#91;***&#93;. If the Consideration Increase is more than &#163;&#91;***&#93; then, for the purposes of sub-clause&#160;5.2(c) the Consideration Increase shall be the whole of the Consideration Increase and not just the amount that exceeds &#163;&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;Save where the contrary is expressly stated, the agreement or determination of the Completion Accounts does not constitute or operate as a waiver of any other rights, powers or remedies of the Purchaser or of any other provision of this Agreement and does not preclude the exercise of any other right, power or remedy of the Purchaser arising under this Agreement or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pre-Completion obligations</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;In so far as it is in its power to do so as a shareholder of the Company, each Seller shall, between the date of this Agreement and Completion, comply with its obligations in Schedule 8 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pre Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;In so far as it is in their power to do so as shareholders and&#47;or directors (as applicable) of the Company, each Seller further undertakes, between the date of this Agreement and Completion&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">upon the written request of the Purchaser, to provide (or procure that a Group Company provides) to the Purchaser such information concerning the Business as the Purchaser may reasonably require from time to time (including for the purposes of the W&#38;I Policy)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to inform the Purchaser promptly in writing if it becomes aware of any new matter or circumstance arising after the date of this Agreement which constitutes or is reasonably likely to constitute a breach of any of the Warranties or the covenants set out in sub-clause&#160;3.6 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sale and purchase</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;No later than &#91;***&#93; Business Days prior to Completion, FME Shareholders Representative will deliver to the Purchaser and the Institutional Sellers a written notice (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Estimates Notice&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) setting out the amount of each of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Cash&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Debt&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Estimated Working Capital&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Estimated Adjustment Amount,</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">prepared on the basis set out in paragraph&#160;1 of Part 2 of Schedule 9 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Completion Accounts) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as well as a first draft of the Completion Allocation Schedule based on those estimates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;The FME Shareholders' Representative and the Purchaser shall engage in good faith to address any questions or comments (including the provision of documents to the Purchaser) that the Purchaser may have in connection therewith. If the Purchaser disagrees with any estimate contained within that draft Estimates Notice or anything in the draft Completion Allocation Schedule it may notify the FME Shareholders' Representatives in writing of such disagreement, in which case the Purchaser and the FME Shareholders' Representative shall attempt in good faith to resolve those matters in dispute. To the extent that no agreement can be reached on any particular aspect, then, in respect of that matter only, the position as set out in the Estimates Notice delivered by the FME Shareholders Representative (as may be updated in accordance with clause 4.5 as part of the Completion Allocation Schedule, based on the latest information available) shall be deemed to be agreed for the purpose of proceedings to Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;The Institutional Sellers Representative and the Institutional Sellers shall also engage in good faith to address any questions or comments (including the provision of documents to the Institutional Sellers) that the Institutional Sellers may have in connection therewith.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;Each Founder Seller undertakes to procure (so far as is it is in their power to do so in accordance with Applicable Law) that (save with the prior written consent of the Purchaser) each employee of the Group shall, save in respect of employees of InstaDeep SAS, by no later than &#91;***&#93;, use all accrued holiday entitlement in respect of the period prior to the date of this Agreement. In the event that any accrued holiday entitlement is not used by a relevant employee in accordance with this clause&#160;6.3, the Founder Sellers shall procure that such employee's outstanding holiday entitlement in respect of the period prior to the date of this Agreement shall, so far as is permitted by Applicable Law, lapse.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;Each Founder Seller shall, between the date of this Agreement and Completion, procure that each Minority Share Transfer is completed in accordance with all Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;&#160;&#160;&#160;Each party to the Paying Agent Agreements undertakes to enter into the Paying Agent Agreements as soon as reasonably practicable following the date of this Agreement (and in any event, at least than &#91;***&#93; Business Days prior to Completion) and otherwise to take any actions necessary thereunder to duly appoint &#91;***&#93; for the purposes of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;&#160;&#160;&#160;The Founder Sellers shall, subject to and to the extent permissible by Applicable Laws, and subject to reasonable advance notice being provided by the Purchaser to the Founder Sellers and&#47;or the Company, permit the Purchaser and&#47;or its professional advisors a right of access to the Company's premises and to inspect any Company documentation (other than any competition sensitive information in respect of the Group and the Group's business activities).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Completion</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;Completion shall take place&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">on the &#91;***&#93; calendar day (or, if not a Business Day, on the nearest Business Day prior to such &#91;***&#93; calendar day) of the &#91;***&#93; during which notification of the satisfaction or waiver of the Conditions in accordance with sub-clause&#160;2.3 or sub-clause&#160;2.10 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (as applicable) is received&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if notification of the satisfaction or waiver of the Conditions in accordance with sub-clause&#160;2.3 or sub-clause&#160;2.10 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Conditions precedent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (as applicable) occurs within the period of &#91;***&#93; Business Days before the &#91;***&#93;, on the &#91;***&#93; of the &#91;***&#93; (or, if not a Business Day, on the nearest Business Day prior to such last calendar day),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(or on such other date, time and place as the Purchaser, the Institutional Sellers and the Sellers' Representatives (excluding the Institutional Sellers' Representative) may agree, but, in any event, no later than the &#91;***&#93; of the date of this Agreement).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;At Completion, the Sellers shall comply with their relevant obligations under Schedule 7 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), provided that the Sellers shall not be required to release to the Purchaser the signed stock transfer forms contemplated by paragraph&#160;1.1(a) of Schedule 7 </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) nor the Companies House webfiling authentication code until the Purchaser has complied with its obligations under sub-clause&#160;7.3. The signed stock transfer forms and authentication code will be held in escrow by the Sellers' Solicitors until such time as the Purchaser has satisfied its obligations under sub-clause&#160;7.3, and the same shall be released immediately without any further authority, on satisfaction of that sub-clause. The Purchaser shall not be required to deliver Consideration Shares or Consideration ADSs to any Non-US FME Shareholder unless such Non-US FME Shareholder has satisfied the relevant completion obligations under Schedule 7.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;When the Sellers have complied with the provisions of sub-clause&#160;7.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the Purchaser shall, in addition to complying with its relevant obligations under Schedule 7&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">provide the Warrantors with a copy of the W&#38;I Policy Excerpt and evidence satisfactory to the Warrantors that the W&#38;I Policy has been put on risk&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">deliver to &#91;***&#93; a duly signed counterpart of the Payment Notice in respect of the Initial Disbursement Amount (as each term is defined in the Paying Agent Agreement for paying agency services)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">pay in accordance with clause 23 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Estimated Sellers' Upfront Payment to the Investor Sellers for each Investor Completion Share held by them&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Investor Sellers' Upfront Contingent Cash Consideration to the Investor Sellers for each Completion Share held by them&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the FME Shareholders' Upfront Cash Completion Payment to the Non-US FME Shareholders in respect of the Completion Shares being sold by them&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the US FME Shareholders Upfront Cash Completion Payment to the US FME Shareholders in respect of the Completion Shares being sold by them&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Holdback Amount,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided that &#91;***&#93; shall, in accordance with the Paying Agent Agreements, hold in escrow an amount equal to the Investors Holdback Amount in respect of the Investors Sellers' Shares and the FME Holdback Amount in respect of the FME Completion Shares until such time as they are due to be released in accordance with clause&#160;5.2&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">allot such total number of Consideration Shares as is set out in the Completion Allocation Schedule and which shall be calculated by&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.12pt">deducting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> from the Estimated FME Shareholders' Upfront Consideration multiplied by the number of FME Completion Shares held by the FME Shareholders the FME Shareholders' Upfront Cash Completion Payment multiplied by the same number of FME Completion Shares&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:24.9pt">dividing</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the sum resulting from (i) above </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">by</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the Consideration ADS Price to the Depositary&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">give unconditional and irrevocable instructions to the Depositary to, and procure that the Depositary shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">open depositary accounts for each individual Non-US FME Shareholder&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">deliver such number of Consideration ADSs as is set out in the Completion Allocation Schedule against each FME Shareholder's name to the Non-US FME Shareholders on these depositary accounts with the intention that it shall be no later than 5 Business Days after the Completion Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;If&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any of the requirements (or, for the purposes of the right to terminate as set out in sub-clause&#160;7.4(d)(iii), any of the material requirements) of sub-clauses 7.2 or 7.3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (excluding the delivery of the Consideration ADSs by the Depositary pursuant to sub-clause 7.3(e)(ii), which, the FME Shareholders acknowledge, shall not be within the control of the Purchaser, provided that the Purchaser has given the Depositary all relevant instructions and otherwise has done all that is within its control to do in order to procure delivery of the Consideration ADSs by the Depositary within the agreed timescale) are not complied with on the date set for Completion under sub-clause&#160;7.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any event occurs which would constitute (i) a breach of any of the Warranties when repeated at Completion&#59; or (ii) a right to claim under the Tax Covenant following Completion, and such event would, if the Purchaser was to acquire the Completion </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares in accordance with this Agreement, give rise to a liability of the Sellers towards the Purchaser under this Agreement in excess of &#163;&#91;***&#93;&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">there has been a material breach by the Sellers of this Agreement in the period between the date of this Agreement and Completion and, if the Purchaser was to acquire the Completion Shares in accordance with this Agreement, such material breach would give rise to a liability of the Sellers towards the Purchaser under this Agreement in excess of &#163;&#91;***&#93;&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">there has been a Material Adverse Change during the period between the date of this Agreement and Completion,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then the party not in breach may&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">defer Completion (including, at that party's option, with respect to some Completion Shares only, provided that such Shares are held by the party (parties) in breach) to a date &#91;***&#93; days after that date (in which case the provisions of this sub-clause&#160;shall also apply to Completion as so deferred)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">proceed to Completion so far as practicable (including, at that party's option, completion of the purchase of some Completion Shares only, provided that such Completion Shares must include all Completion Shares held by the party (parties) not in breach) but without prejudice to any other rights which it may have under this Agreement and without waiving any right to sue for breach of this Agreement or the Warranties or claim under the Tax Covenant&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">terminate this Agreement (other than the Surviving Provisions and the provisions of this sub-clause&#160;7.4(iii) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)) by notice in writing, in which event&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Surviving Provisions and the provisions of this sub-clause&#160;7.4(iii) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall continue to apply&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">no party shall have any claim under this Agreement of any nature whatsoever against any other party except in respect of any rights, liabilities and obligations which have accrued before termination or which accrue under any of the Surviving Provisions or under this sub-clause&#160;7.4(iii) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">except as referred to in this sub-clause&#160;7.4(iii) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), all rights, liabilities and obligations of the parties under this Agreement shall cease with immediate effect.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;Each Seller undertakes to promptly notify the Purchaser in writing of any breach, matter, event, condition, circumstance, fact or omission of which they become aware that may give rise to a right of termination under sub-clause&#160;7.4 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) save that a separate notification is not required under this sub-clause&#160;7.5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) where a disclosure has been made by a Seller or any Warrantor to the Purchaser pursuant to sub-clause&#160;6.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pre Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;Subject to and with effect from Completion, each party and InstaDeep acknowledges and agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each of the Shareholder Documents shall terminate and cease to have effect&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each of them shall with effect from such termination stand released and discharged from all obligations (past, present and future) arising under or resulting from the Shareholder Documents&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">none of them shall be entitled to exercise any rights or make any claims against any of the others under or in relation to the Shareholder Documents or their respective termination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Post Completion matters</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Each Seller irrevocably undertakes to the Purchaser that, for as long as they remain the registered holders of the Shares after Completion, they shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">hold the Shares and any dividends and other moneys or assets paid or distributed in respect of them and all rights arising out of or in connection with them from Completion in trust for the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">deal with the Shares and all such dividends, distributions and rights as the Purchaser may direct from Completion until the date on which the Purchaser or its nominee is entered in the register of members of the Company as the holder of the Shares.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;Each Seller irrevocably (by way of security to secure the proprietary interest of the Purchaser as purchaser of the Completion Shares) and unconditionally appoints the Purchaser as its attorney to do and perform any acts and things which the Purchaser in its absolute discretion considers necessary or desirable in connection with the Completion Shares from Completion until the date on which the Purchaser or its nominee is entered in the register of members of the Company as the holder of the Completion Shares, including (without prejudice to the generality of the foregoing)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">exercising any rights, privileges or duties attaching to the Completion Shares including, without limitation, receiving notices of, and attending and voting at, all meetings of the shareholders of the Company and meetings of the members of any particular class of the Completion Shares and all or any adjournment of such meetings&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">completing and delivering any consents, proxies or resolution and any other documents required to be signed by a Seller as a member of the Company from Completion until the date on which the Purchaser or its nominee is entered in the register of members of the Company as the holder of the Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;For the purpose of sub-clause&#160;8.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Post Completion matters</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), each Seller irrevocably and unconditionally authorises the Company from Completion to send any notices in respect of its shareholding to the Purchaser and the Company shall not be required also to send such notices to the relevant Seller.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;The Purchaser undertakes to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">without unreasonable delay, and in any event no later than &#91;***&#93; Business Days following the date of Completion, apply to HM Revenue &#38; Customs for stamping on the transfer of the Completion Shares it has acquired&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">notify the Company without delay after confirmation of stamping of the transfer of the Completion Shares it has acquired is received (and in any event no later than &#91;***&#93; Business Days thereafter), by providing a copy of the relevant confirmation received from HM Revenue &#38; Customs&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">procure that the Company updates its register of members without delay and in any event no later than &#91;***&#93; Business days after being presented by the Purchaser with a copy of the relevant confirmation received from HM Revenue &#38; Customs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Purchaser's Employee Incentive Plan</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;The Purchaser shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">within &#91;***&#93; following Completion, approve and adopt the Purchaser&#8217;s Employee Incentive Plan by resolution of its management board and supervisory board&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">as soon as practicable following Completion, procure the submission of the application to the Central Bank of Tunisia and South African Reserve Bank (as applicable) in respect of the EIP Conditions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;The implementation, payment and awards issued (as appropriate) by the Purchaser pursuant to the Purchaser's Employee Incentive Plan shall, at all times, be subject to, and made in accordance with, the Purchaser's Employee Incentive Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Warranties</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;The Warrantors severally warrant to the Purchaser in the terms of the Warranties, save as Disclosed, as at the date of this Agreement and again as at the Completion Date, by reference to the facts and circumstances existing at that time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;Each of the Warranties is a separate and independent Warranty and shall not be limited by reference to any other Warranty or anything in this Agreement (save to the extent expressly provided to the contrary in Schedule 5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or paragraph&#160;3 of the Tax Schedule).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;Unless the context otherwise requires, each of the Warranties given by or relating to the Company shall be deemed to be given by or relate to all Group Companies (or each or any of them as the context requires) and any reference to the Company in a Warranty shall be deemed to be a reference to all Group Companies (or each or any of them as the context requires).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Tax Covenant</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Warrantors covenant to the Purchaser in the terms of the Tax Covenant.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchaser's remedies</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;The rights and remedies of the Purchaser in respect of any breach of the Warranties, the &#91;***&#93; or the Tax Covenant or any other provision of this Agreement shall not be affected by Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;If any Claim &#91;***&#93; under any other provision of this Agreement is made, save in the event of fraud, no Seller shall make any claim against any Group Company or any director or employee of any Group Company (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Relevant Person&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) on whom it may have relied before agreeing to any provisions of this Agreement or authorising any statement in the Signing Disclosure Letter and&#47;or the Completion Disclosure Letter.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;Any amount paid by the Sellers to the Purchaser in respect of any of the provisions of this Agreement shall be treated as paid to the Purchaser by way of pro rata reduction in the Consideration (as such may be adjusted pursuant to clause&#160;5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchase price adjustment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;Subject to clause&#160;13.5, if in respect of or in connection with any Warranty Claim, any amount payable to the Purchaser by the Warrantors is subject to Taxation, the amount to be paid to the Purchaser by the Warrantors shall be such as to ensure that the net amount retained by the Purchaser after such Taxation has been taken into account is equal to the full amount which would be payable to the Purchaser had the amount not been subject to Taxation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;&#160;&#160;&#160;The provisions of clause&#160;13.4 shall not apply if and to the extent that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount payable in respect of or in connection with the Warranty Claim has included an amount for, or otherwise taken into account, such Taxation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Purchaser (including any other recipient of the payment) is at any time resident for Tax purposes in a jurisdiction other than Germany and the amount payable (if any) pursuant to or in consequence of clause&#160;13.4 would have been less had the Purchaser (or other recipient) been at all times so resident only in Germany.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Limitations on liability</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;The liability of the Warrantors in respect of any Claim shall be limited as provided in Schedule 5 (Limitations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) but provided always that notwithstanding any other provision in this Agreement, the provisions of this clause&#160;14 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and Schedule 5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and Part 4 of the Tax Schedule shall not apply to any Claim made against the Warrantors to the extent that the Claim (or the delay in the discovery of it) is the consequence of or is increased as a consequence of any fraud or dishonesty or any wilful misstatement, concealment or omission on the part of any of the Warrantors or their advisers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;The total aggregate liability of a Seller to the Purchaser in respect of any and all claims under this Agreement (including any liability for interest, Tax and legal, professional and other costs and expenses incurred by the Purchaser or a Group Company in relation to such claim) shall not exceed the amount of Consideration actually received by that Seller (calculated on the same basis as such Consideration is paid to the relevant Seller). The liability of a Seller to the Purchaser in connection with any claim for breach of sub-clauses 3.6 and 3.7 of this Agreement shall be limited to &#91;***&#93;, save in the event of fraud or dishonesty or wilful misconduct on the part of the relevant Seller.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;Except as otherwise provided in respect of Claims under Schedule 5 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Limitations on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), no Seller shall be liable for any claim under this Agreement unless the Purchaser has served written notice to the Sellers' Representatives, containing a reasonable details of the nature of the claim as far as it is known to the Purchaser, on or prior to the expiration of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; from the expiry of the Restricted Period in respect of a claim under clause&#160;17 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Protection of goodwill</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93; from Completion in respect of all other claims.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;Except as otherwise expressly provided in this Agreement, no Seller shall be liable in respect of all or any portion of a claim under this Agreement to the extent that the matter giving rise to it results from&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any act done or omitted to be done at the written request of or with the written approval of the Purchaser or another member of the Purchaser's Group&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any act done or omitted to be done on or after Completion by or on behalf of the Purchaser or any member of the Purchaser's Group or the Purchaser's successors in title to the Completion Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any breach by the Purchaser of its obligations under this Agreement or any other document entered into in connection with it&#59; or</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any change after Completion in the accounting policies or practices used in preparing any Group Company's accounts or in the accounting reference date of any Group Company, save for any changes required to comply with generally accepted accounting practice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;Paragraphs 3(b)(i), 7(c), 7(d), 9, 11 to 13 (inclusive) of Schedule 5 (Limitations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> on liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall apply to also limit the liability of each Seller, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;Purchaser's conduct of Third Party Claims</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;The Purchaser shall notify the Warrantors in writing of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any claim made against it by a third party which may give rise to a Non-Tax Claim&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any claim any Group Company is entitled to bring against a third party which claim is based on circumstances which may give rise to a Non-Tax Claim,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">each such claim being a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Third Party Claim&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;The Purchaser shall procure that the conduct, negotiation, settlement or litigation of such Third Party Claim is, so far as is reasonably practicable, carried out in accordance with the wishes of the Warrantors and&#47;or the W&#38;I Insurer and at their cost subject to their giving timely instructions to the Purchaser and providing reasonable security for any costs and expenses which might be incurred by the Purchaser or any Group Company and provided that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">nothing in this clause&#160;15 shall oblige the Purchaser to take any action which it considers to be detrimental to the business, trading relationships or reputation of any Group&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the provisions of this clause&#160;15 shall not apply in relation to the relevant Third Party Claim if they could render any policy of insurance (including the W&#38;I Policy) maintained by or available to the Purchaser or any other member of the Purchaser's Group void or voidable, or entitle the relevant insurer (including any W&#38;I Insurer) to repudiate or rescind any such policy in whole or in part, or in the event that a relevant insurer (including any W&#38;I Insurer) exercises its right to take over conduct of such Third Party Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;The rights of the Warrantors under this clause&#160;15 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchaser's conduct of Third Party Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall only apply to such Third Party Claim if the Warrantors jointly give notice to the Purchaser in writing of their intention to exercise their rights within &#91;***&#93; Business Days of the Purchaser giving notice of such Third Party Claim. If the Warrantors do not give notice during that period the Purchaser shall be entitled in its absolute discretion to settle, compromise, or take or resist any action, proceedings or claim in respect of such Third Party Claim. Until such time as the time period expires or the Warrantors do give notice of their intention to take conduct of the Third Party Claim, the Purchaser shall, or as the case may be shall procure that the Company shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">consult with the Warrantors as soon as reasonably practicable with regard to the Third Party Claim in question&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">provide the Warrantors on request with copies of all documents in relation to the relevant Third Party Claim, save where to do so would result in a breach of any obligation of confidentiality or the loss of legal professional privilege&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">take reasonable account of the views of the Warrantors with regard to the Third Party Claim in question&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">not admit liability in respect of or settle or compromise the relevant Third Party Claim without the prior written consent of the Warrantors, such consent not to be unreasonably withheld or delayed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;The Purchaser shall provide and shall procure that the Company provides to the W&#38;I Insurer, the Warrantors and the W&#38;I Insurer's professional advisers reasonable access to premises and personnel and to any relevant assets, documents and records within their power, possession or control for the purpose of investigating any Non-Tax Claim and&#47;or enabling the Warrantors and&#47;or the W&#38;I Insurer to take the action referred to in sub-clause&#160;15.2 and shall allow the Warrantors and&#47;or the W&#38;I Insurer and their professional advisers to take copies of any relevant documents or records at their expense.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;Subject to the prior entering into of reasonable confidentiality obligations by the Warrantors and their professional advisers, the Purchaser shall provide and shall procure that the Group provides to the Warrantors and their professional advisers reasonable access to premises and personnel and to any relevant assets, documents and records within their power, possession or control for the purpose of investigating any Third Party Claim and enabling the Warrantors to take the action referred to in sub-clause&#160;15.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchaser's conduct of Third Party Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and shall allow the Warrantors and their professional advisers to take copies of any relevant documents or records at its sole expense.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The W&#38;I Policy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;The Purchaser shall not, without the prior written consent of the Warrantors, agree to any material amendment, variation or waiver of the W&#38;I Policy with the W&#38;I Insurer, the effect of which would, or could reasonably be expected to, increase the liability of the Warrantors in respect of a Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;The Warrantors acknowledge and agree with the Purchaser that the Warrantors shall not have any interest in the W&#38;I Policy and shall not have any right or entitlement to receive any payment made by the W&#38;I Insurer under the W&#38;I Policy or to receive any payment, benefit or relief which is derived from or which is otherwise attributable to any payment under the W&#38;I Policy.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Protection of goodwill</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;&#160;&#160;&#160;In order to assure to the Purchaser the full benefit of the business and goodwill of the Group, each Restricted Person severally undertakes on his&#47;her own behalf that (save as may be bona fide in fulfilling his&#47;her duties as an employee of any Group Company thereafter) they shall not directly or indirectly (whether as principal, shareholder, partner, employee, agent or otherwise), whether on its own account or in conjunction with or on behalf of any other person, do any of the following things&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">during the Restricted Period carry on or be engaged, concerned or interested in (except as the holder of shares in a company whose shares are listed on a recognised investment exchange or overseas investment exchange (as such terms are defined in Sections 285 and 313, Financial Services and Markets Act 2000) which confer not more than &#91;***&#93;% of the votes which could normally be cast at a general meeting of that company) any business which competes with any part of the Restricted Business&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">during the Restricted Period canvass or solicit or seek to entice away the custom of any Client or Prospective Client for the purposes of providing Restricted Business&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">during the Restricted Period employ or otherwise engage any Key Employee&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">during the Restricted Period endeavour to entice away from any Group Company or encourage to terminate his employment with any Group Company (whether or not such termination would be a breach of his contract of employment) any person who is or was a Senior Employee during the &#91;***&#93; period prior to Completion&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">save as required by law, during the Restricted Period do or say anything likely or calculated to lead any person to withdraw from or cease to continue offering to any Group Company any rights (whether of purchase, sale, import, distribution, agency or otherwise) then enjoyed by it or in any other way to cease to do business or reduce the amount of business it transacts with any Group Company&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">save in the circumstances referred to in sub-clause&#160;19.10(b) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Confidentiality</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), disclose to any other person any information which is secret or confidential to the business or affairs of the Group or any Purchaser Group Company or use any such information to the detriment of the business of the Group or any Purchaser Group Company for so long as that information remains secret or confidential&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in relation to a business which is competitive or likely to be competitive with the Restricted Business, use any trade or business name or distinctive mark, style or logo used by or in the business of any Group Company at Completion or anything intended or likely to be confused with it.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;&#160;&#160;&#160;Each undertaking contained in this clause&#160;17 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Protection of goodwill</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall be construed as a separate and independent undertaking and, while the restrictions set out in this clause&#160;are considered by the parties to be reasonable in all the circumstances, it is agreed that if any one or more of such restrictions shall, either taken by itself or themselves together, be adjudged to go beyond what is reasonable in all the circumstances for the protection of the Purchaser's legitimate interests but would be adjudged reasonable if any particular restriction or restrictions were deleted or any part or parts of the wording thereof were deleted, restricted or limited in any particular manner (including without limitation any reduction in their duration or geographical scope) then the said restrictions shall apply with such deletions, restrictions or limitation as the case may be.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;&#160;&#160;&#160;Each of the Founder Sellers severally agrees that, having regard to the facts and matters set out above and having taken professional advice, the restrictions contained in this clause&#160;17 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Protection of goodwill</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) are reasonable and necessary for the protection of the legitimate business interests of the Purchaser.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration Shares</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;&#160;&#160;&#160;Subject to the remainder of this clause&#160;18, each of the Non-US FME Shareholders severally covenants with and undertakes to the Purchaser that they will not make any Disposal during the period commencing on the date of Completion and ending on the &#91;***&#93; of the Completion Date (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Lock-up Period&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;&#160;&#160;&#160;The number of Consideration Shares or Consideration ADSs that are the subject of the restriction in sub-clause&#160;18.1 shall be reduced and shall cease to be subject to the restriction in sub-clause&#160;18.1 as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">on the date that is &#91;***&#93; after the Completion Date, &#91;***&#93;% of the Consideration ADSs issued to each Non-US FME Shareholder and the Consideration Shares represented thereby&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in addition to the number of Consideration ADSs and the Consideration Shares represented thereby released pursuant to sub-clause&#160;18.2(a), on the &#91;***&#93; of the Completion Date, &#91;***&#93;% of the Consideration ADSs issued to each Non-US FME Shareholder&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in addition to the number of Consideration ADSs and the Consideration Shares represented thereby released pursuant to sub-clause&#160;18.2(a) and 18.2(b), on the &#91;***&#93; of the Completion Date, the balance of the Consideration ADSs issued to each Non-US FME Shareholder and the Consideration Shares represented thereby,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such release schedule in respect of each Non-US FME Shareholder being set out opposite his or her name in the Completion Allocation Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;&#160;&#160;&#160;Each Non-US FME Shareholder and the Purchaser hereby acknowledges and agrees that the Consideration Shares and Consideration ADSs&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">are being issued and sold outside the United States in reliance on Regulation S&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">have not been and will not be registered under the Securities Act or any other securities laws&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">may not be offered or sold within the United States (as defined in Regulation S) except pursuant to an available exemption from the registration requirements of the Securities Act&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">may bear the following or a similar restrictive legend&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#34;These shares have not been registered under the Securities Act of 1933 (&#34;the Act&#34;). These shares may not be offered for sale, sold, transferred, assigned, pledged or hypothecated except (i) pursuant to an effective registration statement under the Act, or (ii) pursuant to an available exemption from registration under the Act.&#34;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;&#160;&#160;&#160;The Purchaser warrants to the Non-US FME Shareholders both at the date of this Agreement and again at Completion that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">none of the Purchaser, any Purchaser Group Company or any person acting on its or their behalf has, directly or indirectly, made offers or sales of, or has solicited offers to buy, or otherwise has negotiated in respect of, any security under circumstances that would require the Consideration Shares or the Consideration ADSs to be registered under the Securities Act&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">none of the Purchaser, any Purchaser Group Company or any person acting on its or their behalf has engaged in any directed selling efforts (as defined in Regulation S) with respect to the Consideration Shares and the Consideration ADSs, and it and they have complied and will comply with the offering restrictions of Regulation S&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Purchaser is a &#34;foreign issuer&#34; (as such term is defined in Regulation S) and there is no &#34;substantial US market interest&#34; (as such term is defined in Regulation S) in the Consideration Shares or the Consideration ADSs or any securities of the same class as the Consideration Shares or the Consideration ADSs&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">none of the Purchaser, any Purchaser Group Company or any person acting on its or their behalf, directly or indirectly, has entered into any contractual arrangement with a distributor (as defined in Regulation S) with respect to the Consideration Shares or the Consideration ADSs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;&#160;&#160;&#160;The Purchaser irrevocably undertakes to and covenants with each of the Non-US FME Shareholders that it will, following the expiration of any applicable 40 day compliance period (as such term is used in Regulation S) in respect of any issuance of Consideration Shares or Consideration ADSs, take all necessary steps for the removal of the restrictive legend provided under sub-clause&#160;18.3(d) from the face of the applicable Consideration Shares or </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration ADSs, including if required by the Depositary, obtaining an opinion of counsel in respect of the applicable Consideration Shares or Consideration ADSs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Entire agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This Agreement and all of the documents in the agreed form sets out the entire agreement and understanding between the parties and supersedes all prior agreements, understandings or arrangements (whether oral or written) in respect of the subject matter of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Each party acknowledges that it has entered into this Agreement in reliance only upon the warranties, promises and terms specifically contained or expressly referred to in this Agreement and, save as expressly set out in this Agreement, no party shall have any liability in respect of any other warranty or promise made prior to the date of this Agreement, unless it was made fraudulently.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Contracts (Rights of Third Parties) Act 1999</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Save as expressly provided in sub-clause&#160;19.2(b), no term of this Agreement (whether express or implied) is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 or otherwise by any person who is not a party to it. For the avoidance of doubt, the terms of this Agreement may be enforced by each New FME Shareholder duly executing and delivering a Deed of Adherence.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Subject to sub-clause&#160;19.4(b) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Variation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Company may enforce sub-clause&#160;8.3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Post completion matters)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">each Group Company may enforce clause&#160;3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sale and Purchase</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">each Relevant Person (as such is defined) may enforce sub-clause&#160;13.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Purchaser's remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assignment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This Agreement shall be binding on and enure for the benefit of the successors in title of the parties but, except as set out in sub-clause&#160;19.3(b), shall not be assignable by any party without the prior written consent of the other.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Purchaser may assign the benefit of this Agreement (including, without limitation, the Warranties) to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any Purchaser Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any successor in title or any subsequent purchaser of the Completion Shares&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">by way of security to any bank or financial institution,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and, in the event of any such assignment, all references in this Agreement to the Purchaser shall be deemed to include its assigns.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Variation</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Subject to sub-clause&#160;19.4(b), no purported variation of this Agreement shall be effective unless it is in writing and signed by or on behalf of each of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the Purchaser&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">only to the extent the purported variation affects any rights of the Institutional Sellers, each Institutional Seller&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Sellers' Representatives (excluding the Institutional Sellers' Representative).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Pursuant to Section 2(3)(a), Contracts (Rights of Third Parties) Act 1999, the Purchaser, the Institutional Sellers and the Sellers' Representatives, in accordance with sub-clause&#160;19.4(a), may without limit or restriction vary this Agreement or any provision of it which may be enforced by a third party or otherwise amend this Agreement in such a way as to extinguish or alter such third party's entitlement under any such provision without the consent of that third party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Effect of Completion</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except to the extent already performed, all the provisions of this Agreement shall, so far as they are capable of being performed or observed, continue in full force and effect notwithstanding Completion.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Invalidity</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the extent that any provision of this Agreement is found by any court or competent authority to be invalid, unlawful or unenforceable in any jurisdiction, that provision shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">be deemed not to be a part of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">not affect the enforceability of the remainder of this Agreement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">not affect the validity, lawfulness or enforceability of that provision in any other jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Releases and waivers</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The rights, powers and remedies conferred on any party by this Agreement and the remedies available to any party are cumulative and are additional to any right, power or remedy which it may have under general law or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any party may, in whole or in part, release, compound, compromise, waive or postpone, in its absolute discretion, any liability owed to it or right granted to it in this Agreement by any other party or parties without in any way prejudicing or affecting its rights in respect of that or any other liability or right not so released, compounded, compromised, waived or postponed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">No single or partial exercise, or failure or delay in exercising any right, power or remedy by any party shall constitute a waiver by that party of, or impair or preclude any further exercise of, that or any right, power or remedy arising under this Agreement or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Further assurance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Completion, the Sellers shall execute such documents and take such steps as the Purchaser may reasonably require to vest the full title to the Completion Shares in the Purchaser, to fulfil the provisions of this Agreement and to give the Purchaser the full benefit of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Counterparts</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">This Agreement may be executed in any number of counterparts and by the parties on separate counterparts, but shall not be effective until each party has executed at least one counterpart.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Each counterpart, when executed, shall be an original of this Agreement and all counterparts shall together constitute one instrument.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Confidentiality</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Except as referred to in sub-clause&#160;19.10(b), each party shall treat as strictly confidential all information received or obtained as a result of entering into or performing this Agreement which relates to the provisions or subject matter of this Agreement, to any other party or to the negotiations relating to this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Any party may disclose information which would otherwise be confidential if and to the extent&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">it is required to do so by law or any securities exchange or regulatory or governmental body to which it is subject wherever situated&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">it considers it necessary to disclose the information to its professional advisers, auditors and bankers provided that it does so on a confidential basis&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the information has come into the public domain through no fault of that party&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the information is required to be disclosed to the W&#38;I Insurer or any broker advising on the W&#38;I Policy in connection with the arrangement or administration of, or any claim to be made under, the W&#38;I Policy&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the information was previously disclosed to it without any obligation of confidence&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">each party to whom it relates has given its consent in writing.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Independent Expert</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Where any matter in this Agreement is to be referred to the decision of an Independent Expert including pursuant to Schedule 9 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Completion Accounts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and clause&#160;4.4 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">FME Shareholders' Transaction Tax Liability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), the provisions of this sub-</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">clause&#160;19.11 will apply to the Independent Expert's appointment and terms of reference.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">The Independent Expert shall be Deloitte, Klynveld Peat Marwick Goerdeler (KPMG), Grant Thornton or BDO as either&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">jointly agreed between the Sellers' Representatives (or, if the decision is in relation to the Earn-Out Consideration, the FME Shareholders' Representative) and the Purchaser within &#91;***&#93; days of the referral referred to in sub-clause&#160;19.11(a)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">failing such agreement within such &#91;***&#93;-day period, to be nominated by either&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the President for the time being of the Institute of Chartered Accountants in England and Wales (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;ICAEW President&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) (or the next most senior officer available) upon the joint written application of the Sellers' Representatives (or, if the decision is in relation to the Earn-Out Consideration, the FME Shareholders' Representative) and the Purchaser (together with the applicable application fee (which shall be paid as to one half by the Purchaser and as to one half by the Sellers (or, if the decision is in relation to the Earn-Out Consideration, the FME Shareholders)) and required forms), or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">where the relevant Sellers' Representatives and the Purchaser fail to make a joint application to the ICAEW President within &#91;***&#93; days after the failure of the Sellers' Representatives and the Purchaser to agree upon the Independent Expert, the London Court of International Arbitration upon the written application of either the Sellers' Representatives (or, if the decision is in relation to the Earn-Out Consideration, the FME Shareholders' Representative) or the Purchaser (together with the applicable application fee (which shall be paid by the party making the application)).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Purchaser and the relevant Sellers' Representatives shall use all reasonable endeavours to reach agreement regarding the identity of the person to be appointed as the Independent Expert (who shall be required to have experience in M&#38;A transactions) and to agree terms of appointment with the Independent Expert and neither party shall unreasonably withhold its agreement to the terms of appointment proposed by the Independent Expert or the other party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a nominating body is called upon to nominate an Independent Expert pursuant to sub-clause&#160;19.11(b), such nominating body shall also agree the Independent Expert's terms of appointment on behalf of the Purchaser and the relevant Sellers' Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Each of the Purchaser and the relevant Sellers' Representatives shall co-operate with the Independent Expert and promptly on request supply to the Independent Expert such documents and information as the Independent Expert may require for the purpose of the reference and in order to enable the determination to be reached as soon as reasonably practicable and in any event within any time period set by this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Purchaser and the relevant Sellers' Representatives shall be entitled to make submissions to the Independent Expert and each such party shall, with reasonable promptness, supply the other party with all such information and access to its documents, books and records as the other party may reasonably require in order to make a submission to the Independent Expert in accordance with this clause.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">To the extent not provided for in this sub-clause&#160;19.11, the Independent Expert may in its reasonable discretion determine such other procedures to assist with the conduct of its determination as it considers just or appropriate.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Unless otherwise agreed by the parties or as otherwise expressly provided in this Agreement, the Independent Expert shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">be required to make its determination in writing (including reasons for its determination) within the range proposed by each party and to provide a copy to each party as soon as reasonably practicable and in any event within &#91;***&#93; Business Days of its appointment (unless the Independent Expert otherwise determines)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">be entitled to make any determination as to the interpretation of this Agreement as is necessary in the reasonable opinion of the Independent Expert to enable a determination of the matters so referred to be made&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">be entitled to take legal advice on any matter relevant to the determination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">The Independent Expert shall act as an expert and not as an arbitrator and neither the Arbitration Act 1996 nor any earlier or later enactments on arbitration shall apply.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">The Independent Expert's decision shall (in the absence of manifest error or fraud) be final and binding on the Parties for all the purposes of this Agreement. Where a manifest error results from a computational, clerical or typographical error, the relevant part of the determination shall be void and shall be referred back to the Independent Expert for correction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The costs of the Independent Expert shall be apportioned between the parties as the Independent Expert shall decide but each party shall be responsible for its own costs of presenting its case to the Independent Expert. If the Independent Expert shall not determine how its costs shall be determined, his costs shall be borne &#91;***&#93; by the Seller (or, if the decision is in relation to the Earn-Out Consideration, the FME Shareholders) &#91;***&#93; and the Purchaser &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">if the Independent Expert dies or becomes unwilling or incapable of acting, or does not deliver its determination within the period required by this&#160;sub-clause&#160;19.11, the Purchaser and the Sellers' Representatives shall use all reasonable endeavours to agree the identity and terms of appointment of a replacement Independent Expert and the provisions of sub-clause&#160;19.11(b) shall apply mutatis mutandis. This sub-clause&#160;19.11 shall apply in relation to each and any replacement Independent Expert as if it was the first Independent Expert appointed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">The Purchaser and the Sellers' Representatives shall act reasonably and co-operate to give effect to the provisions of this sub-clause&#160;19.11 and shall not do anything to hinder the Independent Expert or prevent it from making its determination.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Set-off</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If, on the Earn-out Consideration Completion Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a Due Amount (or any part of it) is outstanding, the Purchaser shall be entitled (at its sole discretion) to satisfy all (to the extent possible) or part of the relevant FME Shareholders' liability to pay such Due Amount by way of set-off against any Payment Amount, and to reduce the Purchaser's obligation to make any Payment Amount by the amount so set off&#59; and&#47;or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">there is an Outstanding Claim, the Purchaser shall be entitled (at its sole discretion) to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">withhold from the Payment Amount an amount equal to the Estimated Liability in respect of that Outstanding Claim or, if lower, the full amount of the Payment Amount (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reserved Sum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">defer payment of the Reserved Sum until such time as the Outstanding Claim has become a Resolved Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Where the provisions of sub-clause&#160;19.12(a)(ii) apply, the Purchaser and the relevant Sellers shall use all reasonable endeavours to agree the Estimated Liability in respect of the Outstanding Claim as soon as possible, and in any event, within the period of &#91;***&#93; Business Days following the Earn-out Consideration Completion Date. In the absence of such agreement, the following procedure shall apply&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">the determination of the Estimated Liability shall be referred to Counsel at the request of either party and Counsel shall be jointly appointed by the affected parties&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">Counsel shall be requested to provide their determination of the Estimated Liability within &#91;***&#93; Business Days of accepting their appointment (or such other period as the Purchaser and the relevant Sellers may otherwise agree with Counsel)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Counsel shall act as an expert and not as arbitrator and their determination regarding the amount of the Estimated Liability shall, in the absence of manifest error, be final and binding on all the parties&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Counsel's fees shall be borne by the Purchaser (on the one part) and the relevant Sellers (on the other part) equally or as Counsel may otherwise direct having regard to the respective conduct of the parties&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">if Counsel has not been able to determine the amount of the Estimated Liability, then the Estimated Liability shall be deemed to be the median value </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of the Purchaser's and the relevant Sellers' reasonable good faith estimates of such Estimated Liability&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">if Counsel has provided a determination of the Estimated Liability in the form of a range of figures, then the Estimated Liability shall be deemed to be the median value of such estimates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Where a Reserved Sum has been withheld by the Purchaser pursuant to sub-clause&#160;19.12(a)(ii) in respect of an Outstanding Claim, on that claim becoming a Resolved Claim the Purchaser shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">be entitled (at its sole discretion) to satisfy all (to the extent the Reserved Sum is sufficient) or part of the relevant Sellers' liability to pay the Due Amount in respect of the relevant Resolved Claim by way of set-off against the corresponding Reserved Sum, and to reduce the Purchaser's obligation to make any Payment Amount by the amount so set off&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">pay to the relevant Sellers the remaining balance of the corresponding Reserved Sum (if any) after the Purchaser has exercised its rights pursuant to sub-clause&#160;19.12(c)(i). Such payment shall be made by the Purchaser within &#91;***&#93; Business Days of the Outstanding Claim becoming a Resolved Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Notwithstanding the provisions of sub-clause&#160;19.12(c), where the amount of the Estimated Liability determined by Counsel in accordance with sub-clause&#160;19.12(b) is less than the Reserved Sum, the Purchaser shall pay to the relevant Sellers the balance of the corresponding Reserved Sum within &#91;***&#93; Business Days after Counsel determines the amount of the Estimated Liability in accordance with sub-clause&#160;19.12(b).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Nothing in this sub-clause&#160;19.12 shall prejudice, limit or otherwise affect&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any right or remedy the Purchaser may have against the Sellers (or any of them) from time to time under this Agreement or any of the other Transaction Documents or at law&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">the Purchaser's right to recover against the Sellers (or any of them), whether before or after the Earn-out Consideration is paid in accordance with this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The amount of a Reserved Sum withheld by the Purchaser in accordance with this sub-clause&#160;19.12 shall not be regarded as imposing any limit on the amount of any claims under this Agreement or any of the other Transaction Documents or at law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a Due Amount is not satisfied in full by way of set-off under sub-clause&#160;19.12(a)(i) or sub-clause&#160;19.12(c), nothing in this Agreement shall prevent or otherwise restrict the Purchaser's right to recover the balance from the Sellers (or any of them) and the Due Amount (to the extent not so satisfied) shall remain fully enforceable against the relevant Sellers.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Announcements</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;&#160;&#160;&#160;Except as provided in sub-clause&#160;20.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), no announcement, circular or other communication (whether oral or written) concerning the terms of this Agreement (or the transaction contemplated or referred to in it) shall be made or issued by or on behalf of any of the parties without the prior written consent of the Purchaser, such consent not to be unreasonably withheld or delayed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;&#160;&#160;&#160;Any announcement, circular or other communication made or issued by or on behalf of any party which is required by law or the rules of any regulatory or governmental body to which such party is subject, including, without limitation, any stock exchange on which any securities of such party are listed, may be made or issued by or on behalf of that party without consent if it has first sought consent and given the other parties a reasonable opportunity to comment on the subject matter and form of the announcement or circular (given the time scale within which it is required to be released or despatched).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;&#160;&#160;&#160;The obligations in this clause&#160;20 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall cease to apply to the Purchaser after Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;&#160;&#160;&#160;Nothing in this clause&#160;20 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Announcements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) shall restrict the Purchaser or any other Purchaser Group Company from&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">providing information regarding the acquisition of the Company to its shareholders&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">informing customers or suppliers of the acquisition of the Company by the Purchaser after Completion.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and expenses</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1&#160;&#160;&#160;&#160;Except as set out in sub-clause&#160;21.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Costs and expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or otherwise expressly provided in this Agreement, each party shall bear its own costs and expenses incurred in the preparation, execution and implementation of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;&#160;&#160;&#160;The Purchaser shall pay all stamp and other transfer duties and registration fees applicable to any document to which it is a party and which arise as a result of or in consequence of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;&#160;&#160;&#160;Save as expressly provided to the contrary in this Agreement&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any payment to be made pursuant to this Agreement by the Purchaser from time to time (including the Consideration) shall be made to the Sellers' Bank Account, unless otherwise agreed between the Purchaser and the relevant Seller&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any payment to be made pursuant to this Agreement by the Sellers or the Warrantors shall be made to the Purchaser's Bank Account&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">payment under sub-clauses 23.1(a) and&#47;or (b) shall be in immediately available funds by electronic transfer on the due date for payment. Receipt of the amount due shall be an effective discharge of the relevant payment obligation, including where such amount is paid by the Purchaser to &#91;***&#93; in accordance with the provisions of this Agreement and the Paying Agent Agreements.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.&#160;&#160;&#160;&#160;Notices</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;&#160;&#160;&#160;Subject to clauses&#160;25 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Service of Proceedings</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), 26.1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Sellers&#8217; Representatives</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and 27.1  (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Institutional Sellers' Representative</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), any notice to a party under this Agreement shall be in writing in English signed by or on behalf of the party giving it and shall, unless delivered to a party personally, be left at, or sent by prepaid recorded delivery (to addresses in the UK only) or by courier, or by email to the address of the party as set out in column B of Part 1 of Schedule 1 and column B of Part 2 of Schedule 1 (as applicable) and to &#91;***&#93; for the Purchaser or as otherwise notified in writing from time to time, save that delivery by email does not apply to the service of any proceedings or other documents in any legal action or proceedings or, where applicable, any arbitration or other method of dispute resolution.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;&#160;&#160;&#160;Except as referred to in sub-clauses 24.3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), a notice shall be deemed to have been served at the time of delivery if delivered personally or left at an address by a courier.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;&#160;&#160;&#160;In the case of delivery in person or by courier, if the deemed time of service is not during business hours in the country of receipt, the notice shall be deemed served at the opening of business on the next business day of that country.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;&#160;&#160;&#160;In proving service it shall be sufficient to prove&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of personal service, that it was handed to the party or delivered to or left in an appropriate place for receipt of letters at its address&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of a letter sent by recorded delivery or courier, a receipt by the courier or postal service confirming that the letter was accepted for delivery and was correctly addressed to the intended recipient in accordance with this clause&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the case of email, that it was properly addressed and despatched to the email address of the party, provided that the sender of the email does not receive an automated response from the recipient or a mail server indicating that the recipient is out of office or that the email could not be delivered.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;&#160;&#160;&#160;Any notice to be given to the Institutional Sellers (or any one of them) under clause&#160;24.1 shall be sent to each Institutional Seller directly and, if the notice is not sent by email, shall also be sent by email to the email address of the relevant Institutional Seller as set out in column B of Part 2 of Schedule 1 (which shall not constitute notice for the purposes of this clause&#160;24).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;&#160;&#160;&#160;A party shall not attempt to prevent or delay the service on it of a notice connected with this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service of Proceedings</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;&#160;&#160;&#160;If, for any reason, the Purchaser requests any Seller who is located outside of England and Wales to do so, the relevant Seller shall promptly&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">appoint an agent for service of process and any other documents in proceedings in England or any other proceedings in connection with this Agreement with an address in England&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">advise the Purchaser of the agent's name and address,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and if, following such a request the relevant Seller fails to appoint an agent, the Purchaser shall be entitled to appoint one on the relevant Seller's behalf at the relevant Seller's expense and shall promptly notify the relevant Seller of such appointment. Any claim form, judgment or other notice of legal process shall be sufficiently served on the Sellers, if delivered to the relevant agent at its address for the time being. Each Seller undertakes not to revoke the authority of the above agent unless it has&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">obtained the consent of the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">appointed another agent with an address in England and provided details of such agent to the Sellers' Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;&#160;&#160;&#160;The Purchaser irrevocably appoints &#91;***&#93; of &#91;***&#93; as its agent to receive on its behalf in England or Wales service of any proceedings arising out of or in connection with this Agreement. Such service shall be deemed completed on delivery to that agent (whether or not it is forwarded to and received by the Purchaser). If for any reason that agent ceases to be able to act as agent or no longer has an address in England or Wales, the Purchaser shall promptly appoint another person as a replacement agent and shall give notice to the Sellers' Representatives of the new agent's name and address within England and Wales.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;&#160;&#160;&#160;&#91;***&#93; shall as soon as reasonably practicable following the date of this Agreement (but, in any event, prior to Completion) appoint an agent with an address in England or Wales to receive on &#91;***&#93; behalf in England or Wales service of any proceedings arising out of or in connection with this Agreement. Such service shall be deemed completed on delivery to that agent (whether or not it is forwarded to and received by &#91;***&#93;). If for any reason that agent ceases to be able to act as agent or no longer has an address in England or Wales, &#91;***&#93; shall promptly appoint another person as a replacement agent and shall give notice to the Purchaser of the new agent's name and address within England and Wales.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sellers' Representatives</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;&#160;&#160;&#160;Each of the Sellers (excluding the Institutional Sellers)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">subject to sub-clause&#160;25.1, agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any notice or other document which the Purchaser wishes to deliver to the Sellers (excluding the Institutional Sellers) or any of them arising out of or in connection with this Agreement may be delivered to them by being delivered to the Sellers' Representatives (excluding the Institutional Sellers' Representative)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any notice, consent, agreement, direction or waiver required or permitted to be given or made by all or some of the Sellers (excluding the Institutional Sellers) (as the case may be) under this Agreement will be validly given or made on their behalf if given or made by the Sellers' Representatives (excluding the Institutional Sellers' Representative) for the purposes of this Agreement and will be binding on the relevant Sellers, as appropriate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Purchaser shall be entitled to rely on all and any communications provided by the Sellers' Representatives (excluding the Institutional Sellers' Representative) which are expressed to be made for the purposes of this Agreement in good faith as binding on all or some of the Sellers (excluding the Institutional Sellers) (as the case may be)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any communication in respect of any matter within the authority of the Sellers' Representatives (excluding the Institutional Sellers' Representative) described in this sub-clause&#160;26.1 shall be deemed (unless the context otherwise requires) to be provided to the Sellers' Representatives (excluding the Institutional Sellers' Representative) as nominee for all or some of the Sellers (excluding the Institutional Sellers) (as the case may be) and any notice served on the Sellers' Representatives (excluding the Institutional Sellers' Representative) shall be deemed to have been validly served at the same time on each Seller (excluding the Institutional Sellers) on whom it is required to be served&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">authorises the Sellers' Representatives (excluding the Institutional Sellers' Representative) as their agent to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">act in the way contemplated by this Agreement and to take any decision as they may deem fit in their absolute discretion&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">enter into the Paying Agent Agreements on behalf of the Sellers, in such form as the Sellers&#8217; Representatives (excluding the Institutional Sellers' Representative) shall agree&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">assume liability towards &#91;***&#93; under the Paying Agent Agreements on behalf of each of the Sellers (excluding the Institutional Sellers), </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided that the Sellers&#8217; Representatives (excluding the Institutional Sellers' Representative) act in Good Faith&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">irrevocably agrees that, in the absence of fraud, gross negligence or wilful misconduct, the Sellers' Representatives (excluding the Institutional Sellers' Representative) will have and accept no liability to the Sellers or to any other person in connection with or as a result of anything which the Sellers' Representatives (excluding the Institutional Sellers' Representative) do, refrain from doing or neglect or omits to do in connection with any matter contemplated by this Agreement and&#47;or the Paying Agent Agreements&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">severally undertake, in the absence of fraud, gross negligence or wilful misconduct on the part of the relevant Sellers&#8217; Representative, to indemnify the Sellers&#8217; Representatives (excluding the Institutional Sellers' Representative) from and against all actions, claims and proceedings and all losses, payments, liabilities and reasonably incurred costs and expenses suffered, made or incurred by them (in their capacity as the Sellers&#8217; Representatives) as a consequence of the performance in Good Faith of their duties, functions and&#47;or role as Sellers&#8217; Representatives under this Agreement and the Paying Agent Agreements, provided that, in no event, shall the amount payable by a relevant Seller under this clause 26.1(d) exceed (i) the liability attributable to each relevant Seller pursuant to clause 5.3 of the Paying Agent Agreements and (ii) that Seller&#8217;s pro-rata proportion of such liability calculated by reference to the number of Completion Shares held by that Seller immediately prior to Completion as against the total number of Completion Shares in issue at Completion held by all Sellers (excluding the Institutional Sellers).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;&#160;&#160;&#160;The FME Shareholders may, on any one or more occasions, notify (acting by the majority by value of Consideration receivable by the FME Shareholders) the Purchaser that they have chosen a different person to be the FME Shareholders' Representative to replace the person or entities then acting as such. Any such notice shall, notwithstanding clause&#160;26.1, be valid only if signed by (or on behalf of) the FME Shareholders (constituting the majority by value of Consideration receivable by the FME Shareholders) and otherwise shall be given in accordance with clause&#160;24. The change in identity of the FME Shareholders' Representative shall take effect &#91;***&#93; Business Days after notice of the change is received by the Purchaser or (if later) on the date (if any) specified in the notice. Until any such notice is received by the Purchaser, the Purchaser shall continue to be entitled to give notices to, and to rely on notices given (and other actions taken) by, the last FME Shareholders' Representative of whom it had actual knowledge.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;&#160;&#160;&#160;The Investor Sellers (excluding the Institutional Sellers) may, on any one or more occasions, notify (acting by the majority by value of Consideration receivable by the Investor Sellers (excluding the Institutional Sellers)) the Purchaser that they have chosen a different person to be the Investor Sellers' Representative to replace the person or entities then acting as such. Any such notice shall, notwithstanding clause&#160;26.1, be valid only if signed by (or on behalf of) the Investor Sellers (constituting the majority by value of Consideration receivable by the Investor Sellers (excluding the Institutional Sellers)) and otherwise shall be given in accordance with clause&#160;24. The change in identity of the Investor Sellers' Representative shall take effect &#91;***&#93; Business Days after notice of the change is received by the Purchaser or (if later) on the date (if any) specified in the notice. Until any such notice is received by the Purchaser, the Purchaser shall continue to be entitled to give notices to, and to rely on notices given (and other actions taken) by, the last Investor Sellers' Representative of whom it had actual knowledge.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Institutional Sellers' Representative</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;&#160;&#160;&#160;Each of the Institutional Sellers&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">agrees that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any notice or other document which the Purchaser wishes to deliver to all Institutional Sellers arising out of or in connection with this Agreement may, where specifically permitted under this Agreement, be delivered to them by being delivered to the Institutional Sellers' Representative&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any notice, consent, agreement, direction or waiver required or permitted to be given or made by all Institutional Sellers under this Agreement will be, where specifically permitted under this Agreement, validly given or made on </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">their behalf if given or made by the Institutional Sellers' Representative for the purposes of this Agreement and will be binding on the Institutional Sellers, as appropriate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the Purchaser shall, where specifically permitted under this Agreement, be entitled to rely on all and any communications provided by the Institutional Sellers' Representative which are expressed to be made for the purposes of this Agreement in good faith as binding on all Institutional Sellers&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any communication in respect of any matter which is specifically indicated in this Agreement to be within the authority of the Institutional Sellers' Representative shall be deemed (unless the context otherwise requires) to be provided to the Institutional Sellers' Representative as nominee for all Institutional Sellers and any notice served on the Institutional Sellers' Representative in such instances shall be deemed to have been validly served at the same time on each Institutional Seller on whom it is required to be served&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">authorises the Institutional Sellers' Representative to act in the way contemplated by this Agreement and agreement referred to in sub-clause&#160;27.3 and, provided &#91;***&#93; acts in Good Faith, the Institutional Sellers' Representative will have and accepts no liability to the Institutional Sellers or to any other person in connection with or as a result of anything which the Institutional Sellers' Representative does, refrains from doing or neglects or omits to do in connection with any matter relating to this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;&#160;&#160;&#160;The Institutional Sellers may, on any one or more occasions, notify (acting jointly on a unanimous basis) the Purchaser that they have chosen a different person to be the Institutional Sellers' Representative to replace the person or entities then acting as such. Any such notice shall, notwithstanding clause&#160;26.1, be valid only if signed by (or on behalf of) all Institutional Sellers and otherwise shall be given in accordance with clause&#160;24. The change in identity of the Institutional Sellers' Representative shall take effect &#91;***&#93; Business Days after notice of the change is received by the Purchaser or (if later) on the date (if any) specified in the notice. Until any such notice is received by the Purchaser, the Purchaser shall continue to be entitled to give notices to, and to rely on notices given (and other actions taken) by (in each case, where specifically so permitted under this Agreement), the last Institutional Sellers' Representative of whom it had actual knowledge.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;&#160;&#160;&#160;The Institutional Sellers and the Institutional Sellers' Representative further agree that, as soon as practically possible following the date of this Agreement (but, in any event, prior to Completion), they shall enter into an agreement regulating the rights and obligations of the parties to it in relation to the Institutional Sellers' Representative's role in connection with this Agreement, which shall be on terms to be agreed between the parties thereto (each acting reasonably), and which shall include (among other things) provisions whereby&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Institutional Sellers' Representative shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">keep the Institutional Sellers fully updated and promptly share all relevant documents with them within the specified timeframes&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">endeavour to give the Institutional Sellers the opportunity to provide comments on any relevant matters (subject to reasonable limited exceptions, for example requiring any urgent action on the side of the Institutional Sellers' Representative)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">relate to the Purchaser any reasonable comments provided by the Institutional Sellers&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">subject to the Institutional Sellers' Representative acting in Good Faith in carrying out &#91;***&#93; role as the Institutional Sellers' Representative, have and accept no liability to the Institutional Sellers or to any other person in connection with or as a result of anything which the Institutional Sellers' Representative does, refrains from doing or neglects or omits to do in connection with any matter relating to this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Institutional Sellers shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">consider any requests of the Institutional Sellers' Representative as soon as reasonably practicable and, in any event, within the period of time, which will be sufficient for the Institutional Sellers to comply with any timing requirements under this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">act reasonably and provide reasons for any proposed action or inaction, along with suggestions as to steps which may be taken in order for consent to be provided or matters agreed&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">otherwise provide clear and consistent instructions to the Institutional Sellers' Representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governing law and jurisdiction</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1&#160;&#160;&#160;&#160;This Agreement and any dispute, claim or obligation (whether contractual or non-contractual) arising out of or in connection with it, its subject matter or formation shall be governed by English law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;&#160;&#160;&#160;The parties irrevocably agree that the English courts shall have exclusive jurisdiction to settle any dispute or claim (whether contractual or non-contractual) arising out of or in connection with this Agreement, its subject matter or formation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">In witness whereof</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the parties or their duly authorised representatives have executed this Agreement as a deed and delivered it at the date first appearing at the head of this Agreement.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_10"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The Sellers)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The FME Shareholders)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The Investor Sellers)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:24pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_13"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The Company)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">InstaDeep Ltd</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09816291</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 October 2015</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Place and jurisdiction of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England &#38; Wales</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 Merchant Square, London, England, W2 1AY</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued share capital at Exchange</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Warranted as at the date of this Agreement)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;2.571256 divided into&#58;<br><br>1,529,184 Ordinary Shares of &#163;0.000001 each</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,048 Class A Shares of &#163;0.000001</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599,171 Class B of &#163;0.000001 each</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and 153,853 non-Voting Ordinary Shares (Employee Shares) of &#163;0.000001 each</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afif Baccouche</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arnaud Sylvain Barthelemy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Khaled Ben Jilani</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zohra Slim</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Victorien Vaney</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shipleys LLP, 10 Orange Street, Haymarket, London, WC2H 7DQ</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The Group Companies (and branches))</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep SARL</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B0187762014, unique identifier&#58; </font><font style="background-color:#ffffff;color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1347719P</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 April 2014</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immeuble ICC3 bloc D 4&#232;me &#233;tage, Centre Urbain, Nord Tunis 1082</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TND 5,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zohra Slim (G&#233;rante)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cabinet Hatem Ben Naji - 3 avenue Louis Braille Tunis 1002. From 2022 accounts, auditors are </font><font style="background-color:#ffffff;color:#222222;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Thornton Tunisia, Promed Building, 5th floor, Centre Urbain Nord, 1082, Tunis</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tunisia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s) at Exchange</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Warranted as at the date of this Agreement)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 Shares &#8211; the Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 share &#8211; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s) at Completion</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Warranted as at Completion)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 Shares &#8211; the Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep SAS</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842469918 RCS Paris</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 September 2018</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 bis, rue du Faubourg Poissonni&#232;re, 75010 Paris, France</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;100,000 divided into 100,000 shares of &#8364;1.00 each</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir (Pr&#233;sident) and Isabelle Levard (Directrice G&#233;n&#233;ral)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cabinet Caderas Martin - 43, rue de Li&#232;ge 75008 Paris</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep Nigeria Limited</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1563821</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 February 2019</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lagos, Nigeria</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7, Ibiyinka Olorube, Victoria Island, Lagos State, Nigeria</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGN 10,000,000 divided into 10,000,000 shares of NGN 1 each</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zohra Slim</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Isabelle Levard</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GFS Corporate Services Limited, 5th Floor, NCR Building, 6 Broad Street, Lagos</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pedabo Audit Services - 67, Norman Williams Street - Ikoyi Lagos</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s) at Exchange</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Warranted as at the date of this Agreement)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,990,000 &#8211; the Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 &#8211; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s) at Completion</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Warranted as at Completion)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,990,000 shares &#8211; the Company</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 shares &#8211; InstaDeep SAS.</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep South Africa (branch)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 &#47; 052350 &#47; 10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 January 2020</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cape Town, South Africa</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 Stand Street, Cape Town 8001, South Africa</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zohra Slim</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Khaled Ben Jilani</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afif Baccouche</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir (InstaDeep Ltd)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SJ Kruger - PO Box 264 Ferndale 2160</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A (branch of the Company)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep Dubai (branch)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97028</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 February 2020</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates, Dubai</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dubai Internet City, Premises EO 03, Ground Floor Building 07, Dubai,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir (InstaDeep Ltd)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General manager</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maher Mansour</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates, Dubai</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep DE GmbH</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amtsgericht Berlin (Charlottenburg), HRB 243790</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 May 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Berlin, Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stresemannstrasse 123 - 10963 Berlin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;25,000</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Isabelle Levard (Gesch&#228;ftsf&#252;hrer)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000 shares of EUR 1.00 each - InstaDeep SAS</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep LLC</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37-2045700</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 March 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dover (Delaware)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874 Walker Road - Suite C - Dover 19904 (Delaware)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.00</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 Shares &#8211; the Company</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">InstaDeep Abu Dhabi (branch)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registered number</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000007973</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 July 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Place of incorporation</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abu Dhabi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Address of registered office</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DD-14-122-049-WeWork Hub71, 14, Al Khatem Tower, Adgm Sqaure, Al Maryah Island, Abu Dhabi, United Arab Emirates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued share capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan capital</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Khaled Ben Jilani</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zohra Slim</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Afif Baccouche</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arnaud Sylvain Barthelemy</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Victorien Vaney</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Secretary</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karim Beguir (InstaDeep Ltd)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General manager</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maher Mansour</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting reference date</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 December</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditors</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax residence</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Arab Emirates (Abu Dhabi)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholder(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A (branch)</font></td></tr></table></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_16"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 3</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(The Properties)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_19"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 4</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Non-Tax Warranties)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Sellers</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Arrangements with Seller Associates</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Save in relation to employment contracts in relation to any Seller which have been Disclosed, there are no contracts, arrangements or liabilities, actual or contingent, outstanding or remaining in whole or in part to be performed between the Company and any Seller Associate.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Other interests of any Seller Associate</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">So far as the Warrantors are aware, no FME Shareholder has any interest, direct or indirect, in any business which has a close trading relationship with or which competes with any business now carried on by the Company and, so far as the Warrantors are aware, no Seller Associate of any FME Shareholder has or intends to do so.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Nomination agreements</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">So far as the Warrantors are aware, there is no nomination or other agreement, arrangement or commitment outstanding pursuant to which any person (other than the Sellers in relation to the Shares held by them respectively) is entitled to enjoy or exercise all or any rights of any kind in relation to the Shares pursuant to Section 145, CA2006 or the articles of association of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Brokerage, commission and other fees</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No person is entitled to receive from the Company any introduction fee, brokerage or other commission in connection with the sale of the Completion Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Interests in undertakings</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Schedule 2 contains accurate details of all Group Companies and overseas branches.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Company does not have, nor has it ever had, a participating interest (as defined in paragraph&#160;11 of Schedule 10 of The Large and Medium sized Companies and Groups (Accounts and Directors' Report) Regulations 2008) in any undertaking or in the share capital of any body corporate which is not a Group Company nor has it agreed to acquire such an interest.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Exchange Shares set out opposite each Seller's name in Schedule 1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Sellers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), together with the BioNTech Company Shares, constitute the whole of the issued share capital of the Company at the date of this Agreement. the Completion Shares set out opposite each Seller's name in Schedule 1 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Sellers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), together with the BioNTech Company Shares, will comprise the whole of the issued share capital of the Company at Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Except as set out in Schedule 2, the Company is the sole legal and beneficial owner of the whole of the allotted and issued share capital of each of the Group Companies (save for the Company) and the allotted and issued shares of the Group Companies are fully paid up (or credited as fully paid) and are free from any Encumbrance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Company is the true and lawful beneficial and record owner of &#91;***&#93; shares of Series Seed-1 Preferred Stock (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#91;***&#93; Shares&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) of &#91;***&#93; (collectively with any predecessor or successor entity thereof, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;&#91;***&#93;&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), free and clear of all Encumbrances. The &#91;***&#93; Shares constitute the Company's entire equity or ownership interest in &#91;***&#93;, and other than the &#91;***&#93; Shares, the Company does not own any interest in &#91;***&#93;, including without limitation, any debt or security exercisable for or convertible into an equity or ownership interest in &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No action, arbitration, suit, proceeding or investigation against the Company is pending, or so far as the Warrantors are aware, threatened against the Company, in relation to the Company's ownership of the &#91;***&#93; Shares.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No dividend, interim dividend, or other distribution, whether paid or still outstanding, has been declared or paid in relation to the &#91;***&#93; Shares, nor is there any other right outstanding to a distribution from or payment based upon reserves or profits of &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">There are no current liabilities of any Group Company arising from any Group Company purchasing, selling, exercising, converting, making any agreement in connection with, or being a holder of, any equity interest or other security of &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Apart from this Agreement, the Options and the subsisting awards made under the French Plan, there is no agreement, arrangement or commitment outstanding which calls for the allotment, issue or transfer of, or accords to any person the right to call for the allotment, issue or transfer of, any share or loan capital of the Company.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company resides, operates or has any branch, agency, place of business or establishment outside the country or state in which it was incorporated.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company and each Group Company is incorporated and validly subsisting under the laws of its country of incorporation and is licensed or qualified to do business under the laws of that country.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company is, in relation to any company, limited liability partnership or Societas Europaea registered in the UK, (other than another Group Company), a registrable relevant legal entity within the meaning of section 790C, CA2006.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has full corporate power to carry on its business and to own and operate its assets, properties and business as now carried on and owned and operated.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate matters</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Insolvency</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No order has been made, no resolution has been passed, no petition presented, no meeting convened for the winding up of the Company or for a provisional liquidator to be appointed in respect of the Company and the Company has not been a party to any transaction which could be avoided in a winding up.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No administration order has been made and no petition for one has been presented in respect of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No administrator, receiver or administrative receiver has been appointed in respect of the Company or any of its assets.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Company is not insolvent, has not failed nor is unable to pay any of its debts as they fall due, within the meaning of Section 123, Insolvency Act 1986.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No voluntary arrangement has been proposed under Sections 1, 256A or 263A, Insolvency Act 1986 in respect of the Company and the Company has not made or proposed any arrangement or composition with its creditors or any class of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No distress, execution or other process has been levied on the Company's assets or action taken to repossess goods in the possession of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No unsatisfied judgment is outstanding against the Company and no demand has been served on the Company under Section 123(1)(a), Insolvency Act 1986.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No event analogous to any referred to in sub-paragraphs 6.1 to 6.7 (inclusive) has occurred in any Applicable Jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">InstaDeep SAS is not insolvent </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(en &#233;tat de cessation des paiements)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, nor subject to any bankruptcy, insolvency, moratorium with creditors, conciliation procedure </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(proc&#233;dure de conciliation)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or similar proceedings under Applicable laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Statutory books and documents filed</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The statutory books, including all registers and minute books, of each Group Company have been properly kept and are up to date and contain an accurate and complete record of the matters with which those books should deal with in accordance with Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">All documents which should have been delivered by the Company to the Registrar of Companies in England and Wales or any relevant authority charged with maintaining a company's (or branch's) registry in any Applicable Jurisdiction are complete and accurate and have been properly so delivered.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The most recent copy of the articles of association of the Company that is available on Companies House is the current articles of association of the Company and has been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Since the Accounts Date the members of the Company in general meeting, or of any class of them, have not passed any resolution other than resolutions relating to the ordinary business of annual general meetings.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Information</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Accuracy and adequacy of information</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in columns C1 to E5 (inclusive) of Part 1 of Schedule 1, columns C1 to C4 (inclusive) of Part 2 of Schedule 1, Schedule 2 and Schedule 3 is accurate and complete.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Preparation and contents of the Accounts</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Accounts&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">have been prepared in accordance with the requirements of Applicable Law and all applicable accounting principles, methods and practices generally accepted and current at the Accounts Date in the jurisdiction in which, in the case of each Group Company, that Group Company was incorporated and, where the accounting practice used to prepare the Accounts differs from those applicable in the previous financial period, the effect of such differences has been Disclosed&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">have been audited by a statutory or certified auditor (as applicable) who has rendered an auditor's certificate without qualification&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">have been duly filed in accordance with the Applicable Law&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Group Accounts as at the Accounts Date have been prepared in accordance with the requirements of Applicable Law and IFRS.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Without prejudice to the generality of sub-paragraph&#160;9.1, the Accounts&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">give a true and fair view of the state of affairs of each Group Company at the Accounts Date and the profits or losses of the Company for the financial period ending on that date in accordance with the relevant financial reporting framework&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">contain proper provision or reserve for all liabilities and for all capital and revenue commitments of each Group Company as at the Accounts Date&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">make proper provision for bad and doubtful debts&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">make proper provision for depreciation of the fixed assets of each Group Company having regard to their original cost and life.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The profits and losses of the Group shown in the Accounts were not, save as disclosed in the Accounts or in any note accompanying them, affected to a material extent by any transactions entered into otherwise than on normal commercial terms nor, to any material extent affected by any extraordinary, exceptional, unusual or non-recurring income, capital gain or expenditure or by any other factor known to the Warrantors rendering any such profit or loss for such period exceptionally high or low.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Except for obligations and liabilities reflected in the Accounts, the Group has no off balance sheet obligation or liability of any nature (matured or unmatured, fixed or contingent) to, or any financial interest in, any third party or entities, the purpose or effect of which is to defer, postpone, reduce or otherwise avoid or adjust the recording of debt expenses incurred by the Group.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Group has established and maintains a system of adequate internal accounting controls sufficient to provide reasonable assurances that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">transactions are executed in accordance with the management's general or specific authorisation and to maintain accountability for assets&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount recorded for assets on the books and records of the Group is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">there are no significant deficiencies or material weaknesses in the design or operation of the Group's internal controls which could adversely affect the Group's ability to record, process, summarise and report financial data&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">there has been no change in the Group's accounting policies or estimation techniques since its incorporation, except as described in the Accounts or otherwise required by Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Accounting records</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The accounting records of the Group comply with the requirements of Sections 386 and 388, CA2006 (whichever provision is applicable to the Company at the relevant time) or Applicable Law, do not contain any material inaccuracy or discrepancy and present in accordance with generally accepted accounting principles and standards the financial position of the Group.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All relevant financial books and records of the Group are in its possession or otherwise under its direct control.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Management Accounts</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Management Accounts have been Disclosed, and have been prepared in accordance with IFRS on a basis consistent with the Accounts, give a fair view of, and do not materially misstate, the financial and trading position of the Group as at their date and for the period to which they relate, and are not affected to a material extent by any extraordinary, exceptional, unusual or non-recurring income, capital gain or expenditure or by any other factor known by the Warrantors rendering profits or losses for the period covered exceptionally high or low.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Events since the Accounts Date</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since the Accounts Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">there has not been any material deterioration in the financial or trading position or prospects of any Group Company&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">neither the turnover, direct or indirect expenses or the margin of profitability of any Group Company shows any material deterioration as compared with the position disclosed in the Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since the Accounts Date, the Group has carried on its business in the ordinary course so as to maintain it as a going concern, and paid its creditors in the ordinary course and within the credit periods agreed with such creditors.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since the Accounts Date, no supplier of any Group Company has ceased or restricted supplies or threatened in writing so to do, there has been no material loss or material curtailment of the business transacted by any Group Company with any customer which at any time in the preceding financial year represented &#91;***&#93;% or more of the turnover of any Group Company and the Warrantors are not aware of any circumstances likely to give rise to any of the above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since the Accounts Date, no Group Company has&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">incurred or committed to incur&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">material capital expenditure in excess of &#163;&#91;***&#93;&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any liability whether actual or contingent except for full value or in the ordinary course of business&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">acquired or agreed to acquire&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any asset for a consideration higher than its market value at the time of acquisition or otherwise than in the ordinary course of business&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any business or substantial part of it or any share or shares in a body corporate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">disposed of, or agreed to dispose of, any of its assets except in the ordinary course of business and for full value&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">repaid wholly or in part any loan except upon the due date or dates for repayment&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">save for the Options that are to be exercised prior to Completion and awards granted under the French Plan, issued or allotted share or loan capital, increased its authorised share capital, purchased or redeemed any shares, reduced or reorganised its share capital or agreed to do so&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">declared, made or paid any distribution of profit.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">None of the debts included in the Accounts or any of the debts subsequently arising has been the subject of factoring by any Group Company and the Warrantors are not aware of any circumstances which could result in any presently outstanding debt in excess of &#163;&#91;***&#93; not being paid in full.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Liabilities</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No Group Company has any liabilities (contingent or otherwise), except&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">those which are properly shown, provided for or reserved against in the Accounts or the Management Accounts&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">those which have been incurred in the ordinary course of business consistent with past practice since the Accounts Date.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance and working capital</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Financial commitments and borrowings</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of all overdraft, loan and other financial facilities available to the Company have been Disclosed and the Company is not in material breach of any of their terms.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not a party to, nor has agreed to enter into, any lending, or purported lending, agreement or arrangement (other than agreements to give credit in the ordinary course of its business).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not exceeding any borrowing limit imposed upon it by its bankers, other lenders, its articles of association or otherwise nor has the Company entered into any commitment or arrangement which might lead it so to do.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No overdraft or other financial facilities available to the Company are dependent upon the guarantee of or security provided by any other person.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, no event has occurred that with the passing of any time or the giving of any notice, certificate, declaration or demand, would constitute an event of default under, or breach of, any of the terms of any loan capital, borrowing, debenture or financial facility of the Company or which would entitle any person to call for repayment prior to normal maturity.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The company is not, nor has it agreed to become, bound by any guarantee, indemnity, surety or similar commitment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company does not have any credit cards in issue in its own name or that of any officer or employee of the Company or any person connected with any officer or employee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not received any grants, allowances, loans or financial aid of any kind from any government department or other board, body, agency or authority which may become liable to be refunded or repaid in whole or in part as a result of the entry into this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not engaged in financing of a type which is not required to be or has not been shown or reflected in the Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Working capital</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Having regard to existing bank and other facilities available to it, the Company has sufficient working capital for the purposes of carrying on its business, in its present form and at its present level of turnover.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insurances</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Insurance cover</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company maintains, and at all times has maintained, adequate insurance cover against all risks normally insured against by companies carrying on a similar business on the same scale as the Company, having regard to the type of business carried on by the Company, its contractual commitments, location and assets owned or used by it, and in particular has maintained all insurances required by statute.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All of the insurance policies maintained by the Company are valid and enforceable and all premiums due have been paid. There are no outstanding claims or, so far as the Warrantors are aware, circumstances likely to give rise to a claim under such insurance policies or which would be required to be notified to the insurers and nothing has been done or omitted to be done which has made or could make any of the policies void or voidable or as a result of which the renewal of any such policy might be refused or the premiums due in respect of them may be liable to be increased (other than by a factor affecting the market as a whole).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Insurance claims</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no claims outstanding or threatened in writing or, so far as the Warrantors are aware, pending, against the Company which are not fully covered by insurance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading and contracts</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Contracts and commitments</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">For the purposes of this paragraph&#160;18&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Client</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means each of</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Supplier</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#34; means each of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All contracts, agreements, transactions, obligations, commitments, understandings or arrangements (including, in each case, confirmation of whether such is with a client or supplier, as applicable) with Key Clients and Key Suppliers requiring in relation to its discharge any payment in excess of &#163;&#91;***&#93; to which the Company is a party (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Key Agreements&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) are Disclosed and remain in full force and effect.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not a party to any material agreement, arrangement or commitment which&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">has or is expected to have, so far as the Warrantors are aware, material consequences in terms of expenditure or revenue, other than in the ordinary course of business&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">can be terminated in the event of entry into or completion of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">relates to matters outside its ordinary business or was not entered into on arms' length terms&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">so far as the Warrantors are aware, cannot readily be fulfilled or performed on time&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">cannot be terminated, without giving rise to any material liabilities on it, by it giving &#91;***&#93; months' notice or less.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has no outstanding bid, tender, sale or service proposal which is material in relation to its business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not granted any power of attorney or other such authority which is still outstanding, other than ordinary course authorities at the Group Company level.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, no act or omission by the Company has caused it to be in material default of any Key Agreement and the Warrantors are not aware of any actual breach, invalidity, grounds for termination, grounds for rescission, grounds for avoidance or grounds for repudiation of, any Key Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Warrantors are not aware that any Key Client of the Company has withdrawn or is considering withdrawing from or not placing with the Company all or any part of the work placed with the Company during the &#91;***&#93; months immediately preceding the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No matter has arisen in respect of any Key Agreement which, so far as the Warrantors are aware, is or could result in a breach by any party thereto.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There have been no material written complaints within the last &#91;***&#93; made by any party thereto in respect of any Key Agreement and the Company has received no written notice of any default under any Key Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Within the &#91;***&#93; months preceding the date of this Agreement no surcharges have been levied or arisen with regard to any expenditure whether due to delay in payment by any Key Client of any sums due in respect thereof or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">No Key Client has sought to negotiate a reduction or material change in the terms of remuneration as contained in its Key Agreement with the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">There is not outstanding any contract or arrangement to which the Company is a party and to which any director of the Company is interested whether directly or indirectly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">In respect of the services agreement between the Company and InstaDeep SAS, dated &#91;***&#93;&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no party other than a Group Company has any rights or obligations pursuant to or under the terms of this agreement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">such agreement has been agreed and conducted in accordance with a transfer pricing policy implemented by the Group, which is adequate for a business of the same size and type.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company is not, and has not at any time, engaged in any activity, practice or conduct which would constitute an offence under&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Bribery Act 2010&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an Applicable Law relating to anti-bribery or anti-corruption in any jurisdiction, including, so far as the Warrantors are aware, in respect of the Company's relationship with &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">So far as the Warrantors are aware, no Company Associate has bribed another person (within the meaning of Section 7(3), Bribery Act 2010) intending to obtain or retain business or an advantage in the conduct of business for the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company has had in place, at all times in the &#91;***&#93; preceding the date of this Agreement, such procedures as it is reasonable in all circumstances to expect it to have designed to prevent Company Associates from bribing another person (within the meaning of Section 7(3), Bribery Act 2010) intending to obtain or retain business or an advantage in the conduct of business for the Company and&#47;or any Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">For the purposes of this paragraph&#160;18, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Company Associate&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any person who performs services (within the meaning of Section 8, Bribery Act 2010) for or on behalf of the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company and the meaning of &#34;adequate procedures&#34; shall be determined in accordance with Section 7(2), and any guidance issued under Section 9, Bribery Act 2010.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Trading partners</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company does not act or carry on business in partnership with any other person and is not a member of any corporate or unincorporated body, undertaking or association.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not a party to any joint venture agreement or arrangement under which it is to participate with any other person in any business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not a party to any agency, distributorship, licence or management agreement which restricts its freedom to carry on its business in such manner as it may think fit.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not, nor has it agreed to become, a party to an agreement or arrangement for sharing commissions or other income.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Licences and consents</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All licences, consents, permissions, authorisations and approvals required by the Company for the carrying on of its business in the places and in the manner in which its business is now carried on have been obtained by it and are in full force and effect.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All reports, returns and information required by Applicable Law or as a condition of any licence, consent, permission, authorisation or approval to be made or given to any person or authority in connection with the business of the Company have been made or given to the appropriate person or authority and so far as the Warrantors are aware, there are no circumstances which indicate that any licence, consent, permission, authorisation or approval might not be renewed in whole or in part or is likely to be revoked, suspended or cancelled or which may confer a right of revocation, suspension or cancellation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Competition and trade regulation law</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not nor has it been a party to any agreement, arrangement, understanding or concerted practice during the &#91;***&#93; preceding this Agreement&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">which infringes, or has infringed, any applicable competition law&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of which any filing, registration or notification is, was or will be required by, or is, was or will be advisable pursuant to, any applicable competition law (whether or not the same has in fact been made)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">which is, or was, the subject of an investigation under any applicable competition law&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in connection with which it is or has been subject to any orders or directions, or has given any undertakings or commitments or assurances under any applicable competition law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Warrantors have no reason to believe that any action or investigation under any applicable competition law is being or will be taken against the Company in relation to any of its current activities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not during the &#91;***&#93; preceding this Agreement made any complaint against any other person in relation to alleged infringements of any applicable competition law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">For the purposes of this paragraph&#160;21, the term </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;applicable competition law&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means all competition law applicable to the business carried on by the Company, whether of the United Kingdom, the European Union or any other jurisdiction, and includes (but is not limited to) any applicable rules dealing with anti-competitive agreements, arrangements or practices, abuse of dominant position, state aid, public procurement, merger control or anti-dumping, and the requirements of any special regulatory regime to which the business carried on by the Company may be subject in any area of its activities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Compliance with law</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The business of the Company has at all times been conducted in all material respects in accordance with all Applicable Laws, including applicable Sanctions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not committed and no claim has been made in writing that it has committed any criminal, illegal, unlawful or unauthorised act or breach of any obligation or duty imposed by Applicable Law, including applicable Sanctions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, no investigation or inquiry is being, or has in the last &#91;***&#93; been, conducted by, and the Warrantors have not received any request for information from any Governmental Authority in respect of the Company's affairs and, so far as the Warrantors are aware, there are no circumstances which would give rise to such investigation, inquiry or request.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">For the purposes of this paragraph&#160;22, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sanctions&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any trade, economic or financial sanctions laws, regulations, embargoes or restrictive measures administered, enacted or enforced by any of (a) the Security Council of the United Nations&#59; (b) the United States of America&#59; (c) the European Union&#59; (d) the United Kingdom&#59; (e) the governments and official institutions or agencies of any of paragraphs (a) to (d), including without limitation, the Office of Foreign Assets Control of the US Department of the Treasury&#59; the US Department of State and Her Majesty's Treasury.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Litigation and disputes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Except for actions to recover any debt incurred in the ordinary course of the business owed to the Company where each individual debt and its costs outstanding amount to less than &#163;&#91;***&#93;&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">neither the Company nor, so far as the Warrantors are aware, any person for whose acts the Company may be liable is engaged in any litigation, arbitration, administrative or criminal proceedings, whether as claimant, defendant or otherwise&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no litigation, arbitration, administrative or criminal proceedings by or against the Company or any person for whose acts it may be liable are threatened or expected and, as far as the Warrantors are aware, none are pending&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">so far as the Warrantors are aware, there are no facts or circumstances likely to give rise to any litigation, arbitration, administrative or criminal proceedings against the Company or any person for whose acts it may be liable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Full details of &#91;***&#93; have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not subject to any outstanding order or judgment given by any court or Governmental Authority and has not been a party to any undertaking or assurance given to any court or governmental or other authority, department, board, body or agency which is still in force, nor so far as the Warrantors are aware are there any facts or circumstances likely to give rise to it becoming subject to such an order or judgment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Ownership and condition of assets</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each of the assets included in the Accounts or acquired by the Company since the Accounts Date (other than the Properties and current assets subsequently disposed of or realised in the ordinary course of business) is either owned by the Company free from Encumbrance (save in respect of liens arising in the normal course of trading) or is legally in its possession or under its control.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, each item of plant and machinery, vehicle and office equipment used by the Company is&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in good repair and condition, regularly maintained and, where required by law, certified safe and without risk to health when used&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">capable of doing the work for which it was designed or purchased&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">not surplus to requirements.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not acquired, or agreed to acquire, any assets on terms that title to the asset does not pass until full payment is made or all indebtedness incurred in connection with the acquisition is discharged.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">A summary of the assets owned by the Company, together with details of all assets held under hire purchase, lease or rental agreements, have been Disclosed and such assets comprise all assets necessary for the continuation of the business of the Company as it is currently carried on.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Charges and Encumbrances over assets</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Encumbrance (other than a lien arising by operation of law in the ordinary course of trading) or other form of security or encumbrance or equity on, over or affecting the Completion Shares or the whole or any part of the undertaking or assets of the Company, including any investment in any other company, is outstanding and, apart from this Agreement, there is no agreement or commitment to give or create any of them and no claim has been made by any person to be entitled to any of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No floating charge created by the Company has crystallised and, so far as the Warrantors are aware, there are no circumstances likely to cause such a floating charge to crystallise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not received notice from any person intimating that it will enforce any security which it may hold over the assets of the Company, and so far as the Warrantors are aware, there are no circumstances likely to give rise to such a notice.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intellectual Property</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Details of Intellectual Property</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of all material Company Intellectual Property and copies of all licences and other agreements relating to it have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All Company Intellectual Property is either&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the sole legal and beneficial ownership of the Company free from all licences, charges or other encumbrances&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the subject of binding and enforceable licences to the Company granted by third parties&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">of which no notice to terminate has been received&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all parties to which have fully complied with all obligations in those licences&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in relation to which no disputes have arisen or are foreseeable,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and in either case, so far as the Warrantors are aware, nothing has been or will be done or omitted to be done prior to the Completion Date whether by the Company or by any person which would jeopardise the validity, enforceability or subsistence of any Company Intellectual Property or any such licences.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Founders, Senior Employees and any other employees, consultants, inventors or contributors involved in the development of Company Intellectual Property or any Group Company technology or any Group Company product or who otherwise provides material value in support of the Business as currently conducted have signed confidentiality and Intellectual Property rights assignment agreements or similar agreements for the transfer, assignment, or licensing of such Company Intellectual Property to the Company pursuant to which the Company has either (i) obtained ownership of and is the exclusive owner of&#59; or (ii) obtained a valid and unrestricted right to exploit such Company Intellectual Property which is, so far as the Warrantors are aware, sufficient for the operation of the Business as currently conducted.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Commercially reasonable steps have been taken by each Group Company sufficient to maintain the confidentiality of any trade secret rights held by any Group Company, or purported to be held by any Group Company, as a trade secret.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Group Companies own or otherwise have all Intellectual Property rights they need to conduct their business as currently conducted, and after the Completion Date, the Purchaser will have all rights to all Intellectual Property needed to materially conduct any Group Company's business as currently conducted.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Registration</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Any Company Intellectual Property owned by the Company which is capable of registration has been registered or is the subject of an application for registration, and is or will when duly registered be valid, binding and enforceable and&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of such registrations, all renewal fees have been paid, all renewals have been made by their due date and all such action necessary to preserve and maintain the registration has been taken&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of such registrations, each is presently used by a Group Company and is in full force and effect and has not been abandoned&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the case of pending applications, the Warrantors are aware of no reason why any such applications should not proceed to grant&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">none of the Company owned Company Intellectual Property or Company Intellectual Property that is exclusively licensed to the Company is subject to any use, claim, exploitation or attack by any other person, and none of the Company Intellectual Property that is non-exclusively licensed to the Company is subject to any claim, exploitation or attack by any other person.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Rights of third parties</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No licences, registered user or other rights have been granted or agreed to be granted by the Company to any person in respect of any Intellectual Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Group Companies do not use any Intellectual Property in respect of which any third party has any right, title or interest.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each of the Group Companies own or have the unrestricted rights to use all Intellectual Property required in connection with the conduct of its business as currently conducted.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company is indebted to any employee (past or present) for any amount whatsoever related to inventor's compensation in respect of Company Intellectual Property and the Company has not received any notice of any such claim in respect of the same.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Infringement and royalties etc.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since incorporation of the Company, so far as the Warrantors are aware, there has been no unauthorised use, misappropriation or infringement by any person of any Intellectual Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since incorporation of the Company, no person has made any claim that there has been any unauthorised use, misappropriation or infringement by any person of any Company Intellectual Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, none of the processes employed, or products or services dealt in, by the Group Company infringes or misappropriates any rights of any third party relating to any Intellectual Property nor is any Group Company liable to pay a fee or royalty on that basis, and no claims have been made, threatened or, so far as the Warrantors are aware, are pending, in relation to any Intellectual Property against the Company. There is no legal proceeding threatened, or so far as the Warrantors are aware, pending against any of Group Company relating to any infringement or misappropriation of any Intellectual Property of another person by a Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Information technology</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All contracts, agreements, transactions, obligations, commitments, understandings or arrangements between the Company and&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(together, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Material IT Agreements&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Material IT Agreement&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">have been Disclosed, remain in full force and effect and such contracts, agreements, transactions, obligations, commitments, understandings or arrangements do not deviate from those typically accepted in the Company's usual course or business, and so far as the Warrantors are aware, no act or omission by the Company or counterparty has caused such party to be in material default of any Material IT Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No act or omission by the Company has caused it to be in material default of any Material IT Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of the computer hardware, networks and software (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;IT Systems&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) used by the Company as at the date of this Agreement have been Disclosed. So far as the Warrantors are aware, the IT Systems are the only information technology required by the Company to carry on its business as currently conducted.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There has been no failure or breakdown in the &#91;***&#93; months prior to the date of this Agreement of any IT Systems used by the Company that has caused any material disruption to the business of the Company or customer of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, the Company has implemented appropriate procedures in accordance with best industry practice (including in relation to off-site working where applicable) for ensuring the security of the IT Systems and the confidentiality and integrity of the Systems Data.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has in place a data security breach plan and a disaster recovery plan which is fully documented which would enable the Business to continue if there were damage to or destruction of some or all of the IT Systems.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, during the three years period up to and including the date of this Agreement, the Company has not&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">breached any applicable data security breach or breach notification requirement under the Cybersecurity Requirements&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">suffered any Security Incident.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Disclosure of confidential information etc.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Except in the ordinary course of business or on a confidential basis in connection with fundraising rounds and as required pursuant to this Agreement and the transactions contemplated by it, no disclosure has been made of any of the confidential information, know how, technical processes, financial or trade secrets or customer or supplier lists of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Names</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any names used by the Company have been Disclosed and, so far as the Warrantors are aware, do not infringe the rights of any person.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Open Source Software</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has Disclosed all Open Source Materials used in the Business and the Company has Disclosed all scans of Company software that includes any Open Source Material used in the Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Group Company has complied in all material respects with the terms of the Open Source Material licenses it uses or has used in the Business.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company's use of Open Source Material requires any redistribution of any software or of any Company Intellectual Property under terms that (i) require disclosure or distribution of any software or other Intellectual Property of Company to third parties&#59; (ii) require the Company to license, sublicense or distribute any Company products for no consideration&#59; or (iii) allow any third party to decompile, disassemble or reverse engineer any Company products.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">incorporated or combined Open Source Materials with the Intellectual Property&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">distributed or licensed Open Source Materials in conjunction with any Intellectual Property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Data Protection</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Compliance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The definitions in this paragraph&#160;apply in this Agreement&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Data Protection Laws&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any applicable laws and regulations in any relevant jurisdiction relating to the use or processing of personal data including (i) EU Regulation 2016&#47;679 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;GDPR&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; (ii) GDPR as it forms part of the law of England and Wales, Scotland and Northern Ireland by virtue of section 3 of the European Union (Withdrawal) Act 2018 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;UK GDPR&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; (iii) any laws or regulations ratifying, implementing, adopting, supplementing or replacing the GDPR&#59; (iv) in the UK, the Data Protection Act 2018 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;DPA&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; (v) any laws and regulations implementing or made pursuant to EU Directive 2002&#47;58&#47;EC (as amended by 2009&#47;136&#47;EC)&#59; and (vi) in South Africa, the Protection of Personal Information Act No 4 of 2013&#59; (vii) in the UK, the Privacy and Electronic Communications (EC Directive) Regulations 2003&#59; (viii) in France, the Law n&#176;78-17 of 6 January 1978 on data processing, data files and individual liberties, and in each case, as updated, amended or replaced from time to time&#59; and the terms </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Data Subject&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Personal Data&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;processing&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;processor&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;controller&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall have the meanings set out in the DPA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Supervisory Authority&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any local, national, supranational, state, governmental or quasi-governmental agency, body, department, board, official or entity exercising regulatory or supervisory authority pursuant to any Data Protection Laws, including the Information Commissioner's Office in the UK.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has, as regards to all personal data (as defined in the relevant Data Protection Laws) controlled and&#47;or processed by it, complied in all material respects with all relevant requirements of the relevant Data Protection Laws, and has not been charged with or convicted of any offence under the Data Protection Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">appointed a data protection officer if required to do so under the Data Protection Laws, and details of such appointment are set out in the Disclosure Documents&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">carried out and maintained complete, accurate and up to date records of, all data protection impact assessments required by the Data Protection Laws&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">put in place an adequate data breach response plan that enables the Company and the processors to comply with the related requirements of the Data Protection Laws, details of which are set out in the Disclosure Documents.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The transfer of all personal data by the Company outside of the United Kingdom or European Economic Area has, and so far the Warrantors are aware third party processors carrying out such transfers on the Company's behalf have, complied in all material respects with all Data Protection Laws, including all appropriate safeguards having been put in place.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In the previous &#91;***&#93; years, the Company has complied with all data subject requests, including any requests for access to Personal Data, the cessation of specified processing activities or the rectification or erasure of any Personal Data, in each case in accordance with the requirements of the Data Protection Laws, and no such requests are outstanding.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Neither the Company nor any of the Processors have, in the previous &#91;***&#93; years, suffered any breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to any Personal Data.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not in the previous &#91;***&#93; years received any&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">written notice, request, correspondence or other communication from any Supervisory Authority, or been subject to any enforcement action (including any fines or other sanctions), in each case in writing relating to a breach or alleged breach of their obligations under the Data Protection Laws&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">written claim, complaint, correspondence or other communication from a data subject or any other person claiming a right to compensation under the Data Protection Laws, or alleging any breach of the Data Protection Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has duly complied with all applicable notification or registration obligations and paid the appropriate level of fees or charges in respect of its processing activities, in each case as required by the Data Protection Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Particulars of employees and workers</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The key terms and conditions of employment of all employees of the Group by category, including, in anonymised form, the date of commencement of their continuous period of employment, their remuneration (including, without limitation, bonus, commission, overtime, profit sharing, share incentive, restricted shares, phantom, share option scheme, long term incentive, car, redundancy, permanent health insurance, medical expenses insurance, life assurance and pension benefits, benefit schemes, or any other payment, benefits or arrangements and understandings whatsoever payable to employees (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Schemes&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)), job title, notice periods, holiday entitlement, sick pay entitlement, particulars of employment given to each employee pursuant to Section 1, Employment Rights Act 1996 (or as applicable in each relevant jurisdiction) and details of any current absence from work (including but not limited to secondments, maternity leave, paternity leave, adoption leave, shared parental leave, parental leave or absent for any other reason) have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There are no proposals to introduce any Schemes save as Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In respect of all persons who are consultants to or who otherwise provide their personal service to the Company (including, but not limited to, out workers, agency staff, self-employed persons, contractors, interims, locums, freelancers, secondees, zero-hours workers, contracted labour or agents) details of the terms of their engagement (whether with the Company or a third party supplier such as a staffing agency, a personal service company or some other supplier intermediary), including the date of commencement of the engagement of their services, the role they undertake, the average number of hours per week they provide services to the Company, the fees paid in respect of the services they supply, any other benefits (including but not limited to any benefits or arrangements under any Schemes) provided to them (whether or not legally binding), the notice period required to terminate the engagement or supply and any holiday arrangements have been Disclosed. The terms of engagement have been complied with by each Group Company and are in compliance with Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">True and complete copies of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all contracts of employment and engagement of those employees and officers employed or engaged as a Senior Employee&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any standard form employment contracts with the Company and which employees and&#47;or officers they apply to&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a copy of any non-standard form employment contracts not otherwise disclosed above and which employees and&#47;or officers they apply to&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all staff handbooks, employment policies and procedures relating to the employment of the employees&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all consultancy agreements and letters of engagement relating to the engagement of consultants and workers&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">all agreements with third party suppliers (including any staffing agencies) who supply the services of any of the supplied workers as disclosed under paragraph&#160;35.3,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not a party to any agreement for management services or any contract for services with any director.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Remuneration and incentives</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details have been Disclosed of any arrangements or assurances as to future remuneration or benefits to be provided to any officer or employee, worker or consultant howsoever arising (including, but not limited to, any remuneration, agreements, Schemes, obligations or benefits to be provided as a consequence of this Agreement) or as to any compensation or payment to be made to any such person in the event of retirement, redundancy or other termination of employment however arising, however funded and whether or not legally binding.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Since the Accounts Date or (where the relevant employment commenced after the beginning of such period) since the commencing date of the particular employee's employment there has been&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no material alteration in the terms of employment and&#47;or engagement or any material change in the number of officers, employees, workers or consultants employed and&#47;or engaged by a Group Company&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no fees, earnings, remuneration or benefits paid or payable to any officer, employee, consultant or worker of a Group Company have increased by more than &#91;***&#93;%, nor are any negotiations for any increase in excess of &#91;***&#93;% current or likely to take place in the next &#91;***&#93; months in respect of the same.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No agreement has been reached or negotiations are current or anticipated to take place at any time within the period from the date of this Agreement to the date that is &#91;***&#93; months following Completion in relation to any decrease and&#47;or variation in the remuneration, hours, incentive arrangements and&#47;or benefits of officers, employees and&#47;or workers of the Group Companies. In respect of any Disclosure against this warranty, any such agreement that has been reached and&#47;or negotiations that have been started, have been carried out in accordance with the officers' employees' and workers' (as applicable) terms and conditions of employment or engagement and Applicable Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In relation to all officers, employees and workers who are or have been placed on furlough leave (or equivalent in any relevant jurisdiction)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no Group Company has re-employed and&#47;or re-engaged any person, or otherwise extended any notice period and&#47;or fixed term contract of any person to enable them to participate in such furlough or other governmental job retention scheme (including, but not limited to, the CJRS)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the reason for placing such person on furlough leave was wholly connected to the detrimental effects of Coronavirus on the reasonable need and&#47;or ability of such a person to undertake their role for the relevant Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">no person has been given and&#47;or has given notice to terminate their employment with any Group Company and&#47;or otherwise been employed during their notice period at any time during which they were placed on furlough leave for the purposes of the CJRS&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Company has at all times complied with the Treasury Direction made under Sections 71 and 76 of the Coronavirus Act 2020 (in each case, as amended from time to time)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each Group Company has complied with all government guidance (as amended from time to time) in respect of any furlough or other governmental job retention scheme&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">there are no circumstances in which it could be reasonably claimed that any Group Company's use of a furlough or other governmental job retention scheme in respect of any such person is abusive or is otherwise contrary to its exceptional purpose&#59; and&#47;or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each Group Company has not submitted any dishonest, inaccurate and&#47;or fraudulent information to HMRC (or equivalent body in each relevant jurisdiction) in respect of any such person&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no worker has been placed on furlough and been paid using furlough or other governmental job retention scheme grant unless they were on the Company's payroll at the date required under the Treasury Direction made under Sections 71 and 76 of the Coronavirus Act 2020 (in each case, as amended from time to time)&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">provision has been made in the Company's accounts for payment of annual leave accrued during the furlough period in respect of any and each zero hours worker furloughed by the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In the &#91;***&#93; months preceding Completion, the Company has at all times, insofar as required by Applicable Law, required employees, workers and officers of the Company to take any accrued but unused holiday entitlement in the relevant leave year. The Company has not permitted, nor is it aware of any such circumstances in which any employees, workers or officers of the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company may claim that they are eligible to carry over any holiday entitlement in accordance with Working Time (Coronavirus) (Amendment) Regulations 2020.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company is not bound or accustomed to pay any monies other than in respect of contractual remuneration or earnings of employment to or for the benefit of any employee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No agreement has been reached with any employee, trade union or other employee representative that will on a future date result in an increase in the rate of remuneration or enhanced benefits for any employee (including but not limited to, bonus or commission payments).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No negotiations for any increase in the remuneration or benefits of any employees is current or (based on past practice) anticipated to take place within &#91;***&#93; months after the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Other than salary for the current month and accrued holiday pay for the current holiday year, no amount is owing to any present or former officer, employee, worker or consultant of the Company in respect of the period up to the date of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">There is not outstanding any agreement or arrangement to which the Company is party in relation to profit sharing or for payment of bonuses or for incentive payments or other similar matters.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Save for the Stock Option Plan and the French Plan and as disclosed in the Disclosure Documents, the Company does not operate (nor is the Company proposing to introduce) any share incentive, share option, restricted stock or phantom scheme, or any long term incentive plan, stock appreciation right, profit sharing, bonus, commission or other employees' share scheme or employee benefit trust for the benefit of all or any of its current or former directors or employees.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">In relation to the Stock Option Plan&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">details&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">of it (including copies of board minutes, the rules of the Stock Option Plan and any amendments thereto), together with details of the unique scheme reference number provided by HMRC on registration of the Stock Option Plan, copies of any advance assurance sought or obtained from HMRC, all annual returns filed with HMRC and any correspondence with HMRC Shares and Assets Valuation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">of all Options which have been granted to current or former employees and directors (including Options which have been surrendered, renounced or lapsed) and copies of all letters or agreements granting Options, forms of exercise and details of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the date of grant&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the exercise price&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the number of shares under option&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the vesting terms&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">any performance conditions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">are contained in the Disclosure Documents&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">there have been no amendments to the terms of the Options&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">each EMI Option granted was notified to the applicable authorising body in the relevant jurisdiction within &#91;***&#93; days of the date of grant&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">none of the Options granted have been exercised (prior to the date of this Agreement)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all registrations, notifications and declarations have been made to the applicable authorising body in the relevant jurisdiction within the relevant time period and no penalties have arisen or are expected to arise in respect of any such registrations, notifications and declarations&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">all EMI Options have been administered in accordance with the requirements of the Board of HMRC and ITEPA and in accordance with the powers and provisions contained in its rules and all applicable laws, regulations and requirements of any competent governmental body or regulatory authority&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no claim has been threatened or made or litigation commenced against the Company in respect of any matter arising out of or in connection with the Stock Option Plan and </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">so far as the Company is aware, there are no circumstances which may give rise to any such claim or litigation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Save under the Stock Option Plan, no employment related securities (as defined in sections 420 and 421B(8), ITEPA) have been issued or transferred and no securities options (as defined in section 420(8), ITEPA) have been granted by the Company to any current or former employee or director, and there are no agreements or promises to make any such issues, transfers or grants.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">There are no employee benefit trusts, family trusts or similar arrangements established by the Company and the Company is not aware of any relevant step taken by a relevant third party in respect of current or former employees or directors of the Company which would give rise to a liability under Part 7A of ITEPA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">All joint elections in respect of restricted securities made by the Company with current or former employees or directors under Chapter 2 of Part 7 of ITEPA have been properly made using forms approved by HMRC and within the applicable time limits.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Any shares issued or transferred or options granted over shares by the Company to employees or directors under the Stock Option Plan or as disclosed in the Disclosure Letter meet the requirements for the Company to obtain a deduction for corporation tax under Part 12 of the Corporation Tax Act 2009 (or would do so, but for the effects of Completion).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The agreements entered into between InstaDeep SAS and any of its employees and any other agreement between any InstaDeep SAS and one of its officers or directors currently in effect do not provide for indemnification, including indemnification in case of dismissal, exceeding the obligations provided for under the applicable collective bargaining agreements or applicable laws, nor do they provide for any contractual benefits beyond statutory requirements (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">avantages particuliers exceptionnels</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), including social benefits.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Compliance</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Group Company has complied in all material respects with its obligations under Applicable Laws concerning the health and safety at work of its employees and workers and so far as the Warrantors are aware, there are no claims pending or threatened by any employee or third party in respect of any accident or injury which are not fully covered by insurance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">InstaDeep SAS has complied in all material respects with its obligations under Applicable Laws concerning employment and social security matters, the provisions of any collective bargaining agreements applying to it and&#47;or to which it is a party, those relating to working hours and extra-hours, monitoring of working-time, overtime, disconnection </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(droit &#224; la d&#233;connection),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> the health and safety at work of its employees and workers, calculation and payment of social contributions, immigration, non-discrimination, work of disabled employees, regulations relating to the internal regulation </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(r&#232;glement int&#233;rieur)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, employee termination, as well as employee representation and so far as the Warrantors are aware, there are no claims pending or threatened by any employee or third party of any of such non-compliance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In relation to each of the employees (and so far as relevant to each of its former employees) so far as the Warrantors are aware each Group Company has&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">complied with all obligations imposed on it by all Applicable Laws relevant to the relations between it and any employee and any recognised trade union or other employee representative&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">complied with all relevant orders and awards affecting the conditions of service of any employee.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">InstaDeep Nigeria Limited has at all times complied in all material respects with its obligations in respect of the Nigeria Social Insurance Trust Fund (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;NSITF&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and provisions of the Nigerian Employees Compensation Act 2010, and all returns which are required to have been submitted in respect of the NSITF for the years 2020, 2021 and 2022 have been submitted to the NSITF Management Board on or before the relevant submission dates.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">InstaDeep Tunisia has at all times complied in all material respects with its obligations pursuant to Article 34 (new) of Law n&#176;60-30 of 14 December 1960 on the organization of social security schemes, including but not limited to the declaration and payment of quarterly social contributions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has paid to HMRC and any other appropriate authority all Taxation, National Insurance contributions and other levies due in respect of any employee in respect of their employment by the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has obtained and maintained up to date, adequate and suitable records regarding each employee's eligibility to work in the United Kingdom (or the relevant Applicable Jurisdiction in which they are employed) in accordance with Section 8, Asylum and </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immigration Act 1996, the Immigration, Asylum and Nationality Act 2006 and&#47;or the Immigration (Restrictions on Employment) Order 2007 (or equivalent legislation in any relevant jurisdiction).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All employees of the Company have a valid and subsisting permission or authority to remain in the country in which they are employed and work for the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There is currently no employee who is a sponsored migrant under Tier 2 of the Points Based System.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company has complied with its reporting obligations in relation to any current and former employees that are sponsored migrants.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company has maintained up to date adequate and suitable records for the purposes of the Working Time Regulations and has complied with all other obligations to its workers (as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;workers&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is defined in Regulation 2, Working Time Regulations).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company has complied in all material respects with its obligations under the Agency Workers Regulations 2010 (or equivalent legislation in the relevant Applicable Jurisdiction). The Company has no reasonable grounds to believe that it is in breach of the Agency Workers Regulations 2010 and&#47;or that any agency worker or former agency worker may bring a claim against the Company for breach of those Regulations.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">No agreements entered into by InstaDeep SAS with third parties (including consultants or fixed-term employees) could entitle such third parties to claim for requalification of their relationship with InstaDeep SAS or any Group Company as an employment agreement as defined by French Applicable Law.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Neither the Company nor InstaDeep SAS is subject to any claim outstanding or threatened in writing or, so far as the Warrantors are aware, pending, in respect of working time monitoring or overtime of any employee pursuant to the French Labour Code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">Each Group Company has complied in all material respects with their respective obligations in respect of employee whistle-blowing policies, practices and procedures pursuant to Applicable Law, including but not limited to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of InstaDeep SAS, n&#176; 2016-1691 of 9&#47;12&#47;2016 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Sapin 2 Act&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) and its implementing Decree n&#176; 2022-1284 of 3 October 2022 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Implementing Decree&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in respect of South Africa, the Protected Disclosures Act 26 of 2000.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">The Company has complied in all material respects with its obligations under Applicable Laws concerning the health and safety of its officers, employees and workers (including but not limited to compliance with The Health Protection (Coronavirus, Restrictions) (England) Regulations 2020, the carrying out of any necessary risk assessments and introduction of any &#34;COVID-19 secure&#34; measures) and so far as the Warrantors are aware, there are no claims, investigations or audits pending or threatened by any officer, employee, worker or third party in respect of any accident or injury which are not fully covered by insurance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">InstaDeep SAS complies with, and have complied in all aspects with laws and regulations relating to the implementation of put in furlough </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(activit&#233; partielle) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">relating to the French Covid-19 crisis measures since March 1, 2020, until the date hereof in such a way, notably but not only, that no reimbursement could be required from any of the Group Companies in this respect.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Termination of employment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No officer or employee of the Company has given notice or is under notice of dismissal or will be entitled to give notice solely as a result of the provisions of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All service contracts between the Company and its officers or employees can be terminated by the Company by &#91;***&#93; weeks' notice or less without giving rise to a claim for damages or compensation (other than a statutory redundancy payment or statutory compensation for unfair dismissal).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of all employees who have been dismissed or who have resigned in the last &#91;***&#93; months, together with the reason for or an explanation of the dismissal or resignation have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There is no agreement, arrangement, scheme or obligation (whether legal or moral) for the payment of any pensions allowances lump sums or other like benefits on retirement or on death or during periods of sickness or disablement for the benefit of any employee or former employees or for the benefit of dependants of such persons.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">General</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of any employee who is currently absent from work (including but not limited to those on secondments, maternity leave, paternity leave, adoption leave, shared parental leave, parental leave or absent for any other reason) or who is anticipated to be absent from work for any reason for a period of &#91;***&#93; month or more have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of any disciplinary action (including warnings, suspension with or without pay, demotion and performance management or monitoring) taken by the Company against any employee within the previous &#91;***&#93; months have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of any grievance made by any employee within the previous &#91;***&#93; months have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not made any loan or advance to any employee which is outstanding.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Industrial relations</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of any court or tribunal case, claim or action brought by any present or former officer, employee, worker or consultant within the previous &#91;***&#93; years and details of any court or tribunal case, any claim or action which the Warrantors have reasonable grounds to believe to the best of their knowledge, information and belief, that any such person may bring against the Company have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, none of the provisions of this Agreement is likely to lead to any industrial trade dispute.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not received a request for recognition pursuant to the Trade Union and Labour Relations (Consolidation) Act 1992 nor is the Company party to any contract, agreement or arrangement with any trade union or other body or organisation representing any of its employees nor has it done any act which might be construed as recognition of a trade union.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has in relation to its officers and employees and former officers and employees complied with all relevant legislation (including, without limitation, the TUPE Regulations and the Working Time Regulations), conditions of service, customs and practices and, where relevant, all collective agreements, recognition agreements, workforce agreements and relevant agreements for the time being.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There has been no recommendation made by an Employment Tribunal in relation to the Company and&#47;or any of its employees. Any recommendations made by an Employment Tribunal have been complied with.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In the &#91;***&#93; months preceding the date of this Agreement, the Company has not given notice of any redundancies to the Secretary of State or started consultations with any appropriate representatives in respect of any employees.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not been a party to any relevant transfer as defined in the TUPE Regulations and no employee has been dismissed or is under notice of termination by reason of or in connection with the TUPE Regulations and the Company has not purported to vary any contract of employment where the sole or principal reason for the change is the transfer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No dispute has arisen between the Company and a material number or category of its employees or workers nor are there any present circumstances known to the Warrantors which are likely to give rise to any such dispute.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Details of any collective agreement (whether with a trade union, staff association or any other body representing workers and whether legally binding or not) have been Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">No training schemes, arrangements or proposals exist nor have there been any such schemes, arrangements or proposals in the past &#91;***&#93; years in respect of which a levy may become payable by the Company under the Industrial Training Act 1982.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">No investigation is in progress or, so far as the Warrantors are aware, planned to be made in respect of the Company by the Health and Safety Executive, the Equality and Human Rights Commission and&#47;or any similar body. The Company is not and has not been subject to any enforcement order made by the Health and Safety Executive, the Equality and Human Rights Commission and&#47;or any similar body and there is no outstanding liability to any such body for any penalty, fine or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.99pt">No outstanding liability has been incurred by the Company for breach of any contract of employment or redundancy payments, protective awards, compensation for wrongful dismissal or unfair dismissal or for failure to comply with any order for reinstatement or re engagement of any person or in respect of any other liability arising out of termination of any contract of employment or contract for services.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pensions</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Company pension schemes or other retirement benefit schemes</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Save for the Pension Scheme(s), there is not in operation by the Company and there has not, at any time, been in operation by the Company (and no proposal has been announced by the Company to enter into or establish) and the Company has no liability in respect of any plan, scheme, agreement, arrangement, custom or practice (whether legally enforceable or not or whether or not approved or registered by HMRC) for the payment of (or for the payment of any contribution towards), any pensions, allowances, lump sum or other like benefits payable on retirement, death, termination of employment (whether voluntary or not or whether arising from a transfer of an undertaking within the meaning of the TUPE Regulations or otherwise) or during periods of sickness or disablement, for the benefit of any of the employees (or ex-employees) or directors (or ex-directors) of the Company or for the benefit of the dependants of any of such employees or directors of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">In relation to the Pension Scheme(s) and each plan, scheme or arrangement Disclosed&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">full details of all of its current and former participating employers and all employees and ex-employees who are members of it at Completion have been Disclosed&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all contributions which are payable by the Company in respect of it and all contributions due from the employees as members of it which have fallen due to be paid, and all fees, charges and expenses due have been duly paid in accordance with Applicable Law&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">every person who has had a right to join, or apply to join, it has been properly advised of that right and no employee of the Company has been excluded from membership of it or from any of the benefits under it in contravention of any of its provisions, any employment contract&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">it has been administered in all material respects in accordance with Applicable Law&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all benefits (other than a refund of contributions with interest where appropriate, spouses' death in service and ill health early retirement pensions) payable on the death of a member while in service, or during a period of sickness or disability of a member, are fully insured under a policy effected with an insurance company to which section 275 of the Finance Act 2004 applies and all insurance premiums due have been paid and the Warrantors are not aware of any circumstances in which such insurance would be invalidated. Each member has been covered for that insurance at the insurance company's usual rates and on its usual terms for persons in good health&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">prior to 6 April 2006 it has at all times been a personal pension plan (within the meaning of Chapter IV Part XIV of ICTA), and with effect from 6 April 2006 it has been a registered pension scheme within the meaning of Chapter 2 of the Finance Act 2004, and nothing has been done or omitted to be done which will or may result in the cessation of such approval or registration&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no undertakings or assurances have been given to any of the employees of the Company as to the continuance, introduction, increase or improvement of any rights or entitlements in relation to pension, death, disability or retirement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">it provides only money purchase benefits as defined in section 181 Pension Schemes Act 1993&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">no claim or complaint has been threatened or made or litigation commenced against the Company (or its trustees, administrators or principal employer or any other person whom the Company is liable to indemnify or compensate) in respect of any matter arising out of or in connection with it and so far as the Warrantors are aware there are no circumstances which may give rise to any such claim or litigation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Compliance relating to stakeholder pension schemes and auto-enrolment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company has complied with all its obligations relating to automatic enrolment including without limitation under the Pensions Act 2008 and regulations made thereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">General</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None of the employees of the Company has been transferred to it in connection with a business transfer to which the TUPE Regulations may have applied.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">The Properties</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Title</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Properties comprise all the properties presently leased, occupied, held or otherwise used by the Company.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company owns any freehold property.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each of the Properties is occupied or otherwise used by the Company under the Leases, the terms of which permit its occupation or use as tenant and there are no outstanding circumstances which would restrict the continued possession and enjoyment of any of the Properties or any part of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not had occasion to make any claim or complaint in relation to any neighbouring property or its use or occupation and there are no disputes, claims, actions, demands or complaints in respect of any Property which are ongoing nor so far as the Warrantors are aware anticipated and no notices materially affecting any Property have been given or received by the Company and not complied with.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Encumbrances</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Property is subject to any outgoings other than rent, insurance rent and service charges.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, no matter exists which is registered or is properly capable of registration against any Property as a Land Charge, Local Land Charge, notice or restriction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Where any matter has been Disclosed against sub-paragraphs 45.1 to 45.2 45.2 (inclusive), the obligations and liabilities imposed and arising under the Disclosed matter have been observed and performed in all material respects and any payments in respect of it which are due and payable have been duly paid.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Leasehold properties</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Lease is valid and in full force and there are no circumstances which would entitle any landlord or other person to exercise any power of entry or take possession of any of the Properties.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company, and each Group Company as applicable, has paid the rent and observed and performed the covenants on the part of the tenant and the conditions contained in any Lease to which it is a party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All licences, consents and approvals required from the landlords and any superior landlords for the grant of the Leases and during the continuance of the Leases have been obtained and any covenants on the part of the tenant contained in those licences, consents and approvals have been duly performed and observed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, there are no rent reviews outstanding or in progress under any Lease.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There is no obligation to reinstate any Property by removing or dismantling any alteration made to it by the Company and the Company has not incurred any liability for dilapidation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The Company has not in the past &#91;***&#93; years been the tenant of or guarantor of any leasehold premises not listed in Schedule 3 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">The Properties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) in respect of which any obligations or liabilities could still accrue to the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">The sale of the Completion Shares will not constitute an assignment or other dealing in respect of any of the Properties under the terms of the Leases.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.11pt">Regulation S</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Non-US FME Shareholder is a &#34;U.S. person&#34; (as defined in Regulation S) under the Securities Act or an underwriter or dealer within the meaning of the Securities Act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Non-US FME Shareholder is receiving Consideration Shares and Consideration ADSs for his, her or its own account for investment and not for the benefit of any U.S. person or with a view to any resale, distribution or other disposition of the Consideration Shares or Consideration ADSs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Non-US FME Shareholder is acquiring the Consideration Shares and Consideration ADSs in an &#34;offshore transaction&#34; (as defined in Regulation S).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">None of the Non-US FME Shareholders or their affiliates (as defined in Regulation 501 under the Securities Act), nor any persons acting on their behalf has engaged in any directed selling efforts (as defined in Regulation S) with respect to the Consideration Shares and the Consideration ADSs, and it and they have complied and will comply with the offering restrictions of Regulation S.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_22"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 5</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Limitations on liability)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The liability of the Warrantors under the Warranties shall be reduced if and to the extent that the loss shall have been recovered under the Tax Covenant (and vice versa).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors shall not be liable for any Warranty Claim if, and to the extent that, the fact, matter, circumstance or event giving rise to such Warranty Claim has been Disclosed in the Signing Disclosure Letter in respect of the Warranties given at the date of this Agreement and Disclosed pursuant to sub-clause&#160;6.2 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pre Completion obligations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) or in the Completion Disclosure Letter in respect of the Warranties repeated on the Completion Date, provided that nothing in the Signing Disclosure Letter and&#47;or the Completion Disclosure Letter shall limit the Warrantors' liability under the Tax Covenant. For the avoidance of doubt, where a disclosure in the Disclosure Documents includes any estimate, forecast or statement of opinion as to the amount of any liability, cost or expense then, provided such estimate, forecast or statement of opinion is given in good faith, the fact that the amount turns out to be inaccurate shall not of itself render the disclosure not Disclosed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors shall not be liable for a Claim unless&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">written notice from or on behalf of the Purchaser giving reasonable details of the Claim has been deemed served on the Warrantors in accordance with the provisions of clause&#160;24 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">in the case of any Non-Tax Claim, on or before the expiration of &#91;***&#93; years from Completion&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in the case of any Tax Claim, not later than &#91;***&#93; years from Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount of the Claim&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">exceeds &#163;&#91;***&#93;, in which case the Warrantors shall be liable for the whole amount of the Claim and not simply the excess paid. For the purposes of this paragraph&#160;3(b)(i), Claims arising from the same events or causes shall be regarded as a single Claim&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">when aggregated with all other Claims made on the same occasion or previously, is equal to or exceeds &#163;&#91;***&#93; (in which case the Warrantors shall be liable for the whole amount of all of the Claims and not simply the excess).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors shall not be liable in respect of any Warranty Claim arising from any matter if, on or before the date falling &#91;***&#93; Business Days after the day on which notice of that claim is given under paragraph&#160;3(a) above, the Warrantors either prevented the Purchaser from suffering any losses in respect of that matter or have caused any losses so suffered by the Purchaser to be made good. The Purchaser shall comply with all reasonable requests made by the Warrantors during that period for the purposes of preventing any such losses or causing them to be made good.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors shall not be liable in respect of any Warranty Claim unless legal proceedings in relation to that Warranty Claim are validly issued and served on the relevant Warrantors on or before the &#91;***&#93; anniversary of the last date on which notice of that Warranty Claim can be given under paragraph&#160;3(a)(ii). For the purposes of this Agreement, legal proceedings shall be regarded as having been served when the relevant step referred to in the Civil Procedure Rule 7.5(1) has been completed.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Except as provided in paragraph&#160;16 below, the aggregate liability of the Warrantors in respect of all Claims, irrespective of whether&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the W&#38;I Policy continues in full force and effect or not&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the W&#38;I Insurer makes payment to the Purchaser in respect thereof,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall not exceed &#163;&#91;***&#93; and subject to the other provisions of this Schedule 5 and the provisions of this Agreement, the parties agree that the Purchaser's sole right of recovery (if any) in excess of the cap on liability specified in this paragraph&#160;6 of this Schedule 5 in respect of any and all Claims shall be under the W&#38;I Policy.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors shall not be liable for any Non-Tax Claim&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">to the extent that such Non-Tax Claim arises or is increased as a result of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any act, omission, transaction, arrangement or other event occurring at the request or with the consent of the Purchaser before Completion, or pursuant to or in compliance with any Transaction Document&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">or would have been reduced but for, the Purchaser failing to act (or to procure that the relevant Group Company acts) as it is required to under this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the passing or coming into force of, or any change in, or in the interpretation, application or enforcement of, any legislation&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any change in any accounting policies or practice or in the accounting reference date of any Group Company or the Purchaser&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if, and to the extent that, a liability arises or is increased as a result of any voluntary act or deliberate omission of the Purchaser (or any persons deriving title from it) or the Group after Completion done or suffered outside the ordinary course of business and other than&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">pursuant to a legally binding obligation entered into by any Group Company before Completion&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in order to comply with any law&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">at the request of or with the consent of the Warrantors&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">based on a liability which is contingent only unless and until such contingent liability becomes an actual liability and is due and payable and capable of being quantified&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">if, and to the extent that, the loss in respect of which the Non-Tax Claim is made is recovered under an insurance policy of the Group in force on the date of such loss save to the extent that such recovery results in an increase in insurance premiums&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Warrantors' liability in respect of any Non-Tax Claim shall be reduced by an amount equal to the amount of any specific provision or specific accrual made in the Accounts and&#47;or the Management Accounts for the matter giving rise to that Non-Tax Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">If the Warrantors and&#47;or the W&#38;I Insurer make any payment to the Purchaser or the Company or any Group Company in relation to any Non-Tax Claim and the Purchaser or the Company or any Group Company subsequently receives from a third party (other than the W&#38;I Insurer) any amount referable to, or any benefit which would not have been received but for the circumstances giving rise to, the subject matter of that Non-Tax Claim, the Purchaser shall, once it or the Company or other Group Company has received such amount or benefit, immediately pay or procure the payment to the Warrantors and&#47;or the W&#38;I Insurer (as appropriate) of either&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount of such receipt (after deducting an amount equal to the reasonable costs of the Purchaser and the Company and any member of the Group incurred in recovering such receipt and any Taxation payable on it)&#59; or if lesser&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount paid by the Warrantors and&#47;or W&#38;I Insurer,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">together with any interest or repayment supplement paid to the Purchaser or the Company or any other Group Company in respect of it. Any payment made, or procured to be made by the Purchaser under this paragraph&#160;9 shall be made to the Warrantors and&#47;or the W&#38;I Insurer in the same proportions as the amounts paid by the Warrantors and&#47;or the W&#38;I Insurer to the Purchaser or the Company or other Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">In the absence of fraud or dishonesty or wilful non-disclosure on the part of any of the Warrantors, and without prejudice to the terms of clause&#160;16 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(The W&#38;I Policy),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> if the W&#38;I Insurer&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">avoids the W&#38;I Policy&#59; and or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">rescinds the W&#38;I Policy&#59; and&#47;or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">denies coverage pursuant to the terms of the W&#38;I Policy&#59; and&#47;or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in any way refuses to meet any claim under the W&#38;I Policy thereby denying the Purchaser the benefit of the W&#38;I Policy,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">then the Purchaser shall not pursue the Warrantors for any amounts that it would otherwise have been entitled to receive from the W&#38;I Insurer pursuant to the terms of the W&#38;I Policy.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Without limiting any obligations it may have at law or in equity, the Purchaser shall mitigate, and shall cause each Group Company to mitigate, any loss or liability which may give rise to a Claim.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Neither the Purchaser nor any Purchaser Group Company shall be entitled to recover damages or otherwise claim reimbursement or restitution in respect of damages, if and to the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">extent of the amount the Purchaser or any Purchaser Group Company has already recovered in respect of the same damage or loss.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Sellers shall have no liability in respect of a Claim to the extent that it is based on or comprises indirect or consequential damages (including loss of revenue, income or profits to the extent that these are indirect or consequential damages).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Purchaser waives any and all claims (including for negligence) that it might otherwise have against any officer, employee, agent, adviser or consultant of the Sellers (or any holding company, any subsidiary and any subsidiary undertaking of any Seller or such companies) (i) in respect of any information that any such person has in any capacity supplied to the Purchaser in connection with the Warranties and&#47;or the information Disclosed&#59; or (ii) otherwise in connection with the transactions contemplated by this Agreement. The Purchaser acknowledges any claims under this Agreement may only be made directly against the Sellers, the Warrantors and&#47;or pursuant to the terms of the W&#38;I Policy (as applicable).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Except as otherwise expressly provided herein, the sole remedy against the Sellers and&#47;or the Warrantors (as applicable) for any breach of any of the Warranties or any other provision of this Agreement shall be an action for damages for breach of contract (to the exclusion of any other remedy including those in tort or arising under statute) and the Purchaser irrevocably and unconditionally waives any right it may have to rescind or terminate this Agreement before or following Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The aggregate liability of the Warrantors in respect of all Claims in respect of the Warranties at paragraph&#160;18.14 to 18.17 of Schedule 4 (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-Tax Warranties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">), only in so far as they relate to matters occurring in &#91;***&#93;, shall be capped at &#163;&#91;***&#93;, provided that for this purpose the words &#34;so far as the Warrantors are aware&#34; shall be deemed to apply to all statements contained in those Warranties.</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 6</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Tax Schedule)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Definitions and Interpretation)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions and Interpretation</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">In this Agreement, unless the context otherwise requires, the following words have the following meanings&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Accounts Relief&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any Relief which&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">has been shown as an asset in the Completion Accounts&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">has been taken into account in computing (and so reducing or obviating) any provision for deferred Taxation which appears or which but for the availability or presumed availability of the Relief would have appeared in the Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;COVID-19&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the 2019 outbreak of the novel coronavirus disease.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CFA&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Criminal Finances Act 2017.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Coronavirus Support Payment&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">has the meaning given to it in Section 106(2) of the Finance Act 2020.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CTA 2009&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Corporation Tax Act 2009.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;CTA 2010&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Corporation Tax Act 2010.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Deemed Taxation Liability&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any Liability to Taxation falling within either limb (b) or limb (c) of that definition.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Event&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any event, act, omission, circumstance or transaction whatsoever, including without limitation the execution and completion of this Agreement, the expiry of a period of time, any Group Company becoming or ceasing to be associated with any other person for any Tax purpose or ceasing to be, or becoming, resident in any country for any Tax purpose, the death, winding up or dissolution of any person or the incurring of any loss or expenditure.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;ITEPA&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Income Tax (Earnings and Pensions) Act 2003.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Liability to Taxation&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any liability to make a payment or increased payment of or in respect of Taxation or any liability to repay a payment received in respect of Tax &#91;***&#93; received by a Group Company (including by way of set-off), together with any interest and penalties in respect thereof, in each case regardless of whether the liability has been paid or discharged on or before Completion and regardless of whether such liability is chargeable or attributable directly or primarily to a Group Company or to any other person&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Loss of any Accounts Relief&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the use or setting off against any liability to Taxation, or against Profits earned, accrued or received, of any Purchaser's Relief in circumstances where, but for the use or setting off, any Group Company would have had a liability to Taxation in respect of which the Purchaser (ignoring the financial limitations on claims in Schedule 5 to this Agreement) would have been able to make a claim under the Tax Covenant.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Loss&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any reduction, loss, absence, non-existence, non-availability, counteraction, nullification, disallowance, withdrawal or clawback for whatever reason (other than by way of utilisation or effluxion of time) and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;lost&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> shall be construed accordingly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;PAYE&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means pay as you earn as it applies to income tax pursuant to ITEPA and the PAYE regulations referred to in it and as it applies for national insurance contribution purposes under the Social Security Contributions and Benefits Act 1992 and regulations referred to in it.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Profits&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means income, profits and gains, the value of any supply and any other consideration, value, measure or receipt used or charged for Tax purposes.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's Tax Group&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Purchaser and any other company or companies that are, from time to time, treated as members of the same group as, or otherwise connected or associated in any way with, the Purchaser for any Tax purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Purchaser's Relief&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">an Accounts Relief&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Relief which arises to any Group Company in respect of any period after Completion or any Relief which arises in respect of any Event occurring after Completion&#59; and&#47;or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any Relief arising to any member of the Purchaser's Tax Group (other than a Group Company) at any time.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Relief&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any relief, loss, allowance, set-off or credit for Taxation or any deduction in computing Profits for the purposes of Taxation or any right to repayment of Taxation or to a payment in respect of Taxation &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Seller Associate&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any Seller and any other person with whom the Seller and&#47;or (prior to Completion) any Group Company is or was either associated or connected for any Tax purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Taxation&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any and all forms of taxes, contributions, levies, imposts, duties or charges in the nature of Taxation and all withholdings or deductions in respect thereof of any nature whenever created or imposed and whether of the UK or any other jurisdiction, and all penalties, fines, charges, surcharges, costs and interest relating to such or which arises as a result of the failure to pay any Taxation on the due date for payment or to comply with any obligation relating to Taxation, together with the cost of removing any related charge or other encumbrance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Assessment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any notice, demand, assessment, self-assessment, letter or other document issued or action taken by or on behalf of any Tax Authority or any person (including any Group Company) indicating that any person is or may be placed or sought to be placed under a Liability to Taxation for any pre-Completion period (or any other liability under the Tax Covenant or in respect of which the Warrantors may be liable for breach of the Tax Warranties).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Authority&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any taxing or other authority, body or official competent to administer, impose, assess or collect any Taxation in the UK or elsewhere.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Tax Claim&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means a claim by the Purchaser against the Warrantors under the Tax Covenant or for breach of any of the Tax Warranties.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;VAT&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means value added tax in the UK or equivalent Tax in any other jurisdiction and references to VAT shall include all law relating to value added tax in the UK and any value added, turnover, sales, purchase or similar Tax of any other jurisdiction and references to value added tax shall be construed accordingly.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">In this Schedule&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">references to Profits earned, accrued or received shall include any Profits which are for the purpose of any Tax treated or regarded as earned, accrued or received&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">references to Profits earned, accrued, or received on or before a particular time (including, without limitation, Completion) or in respect of a particular period shall include Profits which are for the purposes of any Tax treated as earned or accrued, arising or received on or before that time or in respect of that period&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">references to social security contributions shall also include references to national insurance contributions (and vice versa), and reference to either shall include apprenticeship levy or any similar Tax&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">references to any law shall include any statute, statutory instrument, law, regulation, treaty, notice, directive or similar provision relating to Taxation, whether of the UK or elsewhere&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">references to specific parts of the law of the UK shall be taken to include a reference to the law of any other jurisdiction so far as the same may apply to any Group Company and may be similar to or have a similar purpose or which most closely approximates to the law of the UK to which reference is made&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">references to the occurrence of Events on or before a particular date (including, without limitation, Completion) or in respect of a particular period shall include Events which are for the purposes of any Tax treated as having occurred or existed at or before that date or in respect of that period&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">references to a repayment of Tax shall include any repayment supplement or interest in respect of it&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any stamp duty charged on any document (or in the case of a document that is outside the UK, any stamp duty that would be charged on the document if it were brought into the UK) that is necessary to establish the title of any Group Company to any asset, and any interest, fine or penalty relating to the stamp duty, shall be deemed to be a liability of the relevant Group Company to make an actual payment of Tax because of an Event arising on the date of execution of the relevant document (and for the avoidance of doubt the payment of any stamp duty on any document, or the bringing into the UK of any document, shall not be considered a voluntary act for the purposes of paragraph&#160;1(d) of Part 4 of this Schedule)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">references to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">due date for payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> of any Tax shall be read and construed as a reference to the last day on which such Tax may by law be paid without incurring a penalty or liability for any interest, charge, surcharge, penalty, fine or other similar imposition accruing or without a surcharge liability notice being liable to be issued (after taking into account any postponement of such date which is obtained for such Tax).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">It shall be assumed for all of the purposes of this Tax Schedule (and in particular for calculating any liability to Taxation or any Relief) that the date of Completion is the end of an accounting period for the purposes of any relevant Tax and all such adjustments and apportionments as may be required consequent on such assumption shall be made in assessing any liability or in making any calculation required under this Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Any payments made by the Warrantors pursuant to or under or in respect of the Tax Covenant or for breach of any Warranty shall, so far as possible, be treated as an adjustment to the consideration paid by the Purchaser for the Shares (and so far as is possible, a reduction pro-rata of such consideration) provided always that this paragraph&#160;shall not operate in any way to limit the liability of the Warrantors under this Schedule or the Agreement or otherwise.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Any covenant, indemnity or other requirement to pay costs and&#47;or expenses in this Agreement (including by way of deduction of such costs and&#47;or expenses from any payment due to another party) shall be treated as excluding any VAT on such costs and&#47;or expenses to the extent that the party incurring such costs is able to obtain an input tax credit in respect of such VAT.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Tax Warranties)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Tax Warranties</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Each Group Company has paid all Taxation for which it is liable and made all withholdings and deductions in respect, or on account, of any Taxation from any payments made by it which it is obliged to make and has paid to the appropriate Tax Authority all amounts so withheld or deducted by the due date for payment.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Each Group Company has in the last &#91;***&#93; years (or in respect of any earlier period in respect of which any relevant Tax return is open for reassessment by any Tax Authority) prepared and submitted within applicable time limits all notices, returns accounts, computations, statements, assessments, claims, disclaimers, elections and applications for clearances or consents required for Tax purposes and provided complete and accurate information to any Tax Authority.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Each Group Company has kept and maintained complete and accurate records, invoices and other documents and information of whatever nature required by law to be kept for Tax purposes and has sufficient such records, invoices and other documents and information relating to past Events to calculate its liability to Taxation up to Completion and any Relief which has arisen on any disposal or realisation of any assets before Completion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No Group Company is currently involved in a dispute with, or has any unsettled or outstanding assessments from, or is appealing to or against any Tax Authority in respect of Taxation and no Group Company has, within the last &#91;***&#93; years, been subject to any non-routine enquiry, audit, visit, inspection or other dispute with any Tax Authority and, so far as the Warrantors are aware, there are no circumstances which could give rise to a material risk of any such enquiry, audit, visit, inspection or dispute.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No Group Company has, within the last &#91;***&#93; years, been liable to pay any material sum in respect of interest, penalty, or fine in respect of Taxation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No amount of Tax chargeable on any Group Company or subject to withholding or deduction by any Group Company during any accounting period ending on or within the last &#91;***&#93; years has to any material extent depended on any concession, agreement or, dispensation with any Tax Authority (other than in accordance with the generally applicable published guidance of such Tax Authority).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">No circumstances exist under which any of the Shares or assets of any Group Company could be subject to any charge or other Encumbrance in respect of Taxation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Accounts make proper provision or reserve in accordance with applicable generally accepted accounting principles for Tax in respect of which each Group Company was liable on the Accounts Date and proper provision has been made in the Accounts in accordance with such accounting principles for deferred tax.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Since the Accounts Date&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no Group Company has entered into any obligation to make any payment of an income or revenue nature after Completion outside the ordinary course of its business and exceeding &#163;&#91;***&#93; in aggregate which, or to provide a benefit the cost of which, will be prevented from being deductible for Tax purposes, whether as a deduction in computing the profits of a trade or as an expense of management or as a charge on income or otherwise&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no Group Company has been a party to any Event for which any Tax clearance provided for by statute has been, or could have been, obtained.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Company is, nor has at any time within the last &#91;***&#93; years been, a close company within the meaning of section 439 CTA 2010 and has no outstanding loans which have given rise to any liability under Chapter 3 or 3A, Part 10, CTA 2010 (loans to participators).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No distribution has been made or deemed to have been made by any Group Company for Tax purposes other than dividends shown in the audited accounts of the relevant Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company has been a member of a group for any Tax purpose with any other company other than another Group Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Neither the execution nor completion of this Agreement, nor any other event since the Accounts Date, will result in the clawback or disallowance of any relief or allowance previously given.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No shares or securities have been issued by any Group Company, and no options have been granted or issued in respect of such shares or securities, such that any Group Company will or may be liable to account for income tax under the PAYE system or to collect or pay any national insurance contributions including without limitation on any payment made under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">There have been no arrangements that have given rise to any liability of a Group Company to account for income tax or social security contributions as a result of the application of Part 7A ITEPA and, so far as the Warrantors are aware, there are no arrangements in place that could give rise to any such liability.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company is or may be liable to deduct and&#47;or account for income tax or social security contributions in respect of any persons directly or indirectly engaged otherwise than as employees of any Group Company (including through any personal service company or any managed service company).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Group Company&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">is registered for the purpose of, and has complied in all respects with, the Applicable Law in respect of VAT and is not subject to any conditions (including any requirement to provide security) imposed or agreed with any Tax Authority&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">is not, and has not within the last &#91;***&#93; years been, a member of a group for VAT purposes.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">All transactions or arrangements made by each Group Company have been made on arm's length terms or with parties that were unrelated to the Group Company and the processes by which prices and terms have been arrived at have, where relevant for Tax purposes, been documented in accordance (where relevant) with all applicable transfer pricing rules. No notice, enquiry or adjustment has been made by any Tax Authority in connection with any such transactions or arrangement. The Disclosure Letter contains full details of any advance pricing agreements entered into by any Group Company with a Tax Authority.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company has, within the last &#91;***&#93; years&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">entered into, or been party to, any arrangement the main purpose or one of the main purposes of which was to avoid Taxation or to obtain a Tax advantage&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">entered into any arrangements which need to be disclosed to a Tax Authority under any legislation relating to tax avoidance.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Event has occurred in the last &#91;***&#93; years in consequence of which any Group Company has incurred a Liability to Taxation primarily chargeable against some other person (other than another Group Company) and no Group Company is otherwise liable to be assessed to Tax as agent for, or on account of, or otherwise on behalf of, any other person.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Any document that may be necessary in proving the title of any Group Company to any asset which is owned by the relevant Group Company at the date of this Agreement, is duly stamped for stamp duty purposes or has had any applicable transfer or registration Tax due in respect of it paid.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company would be treated as land rich for the purposes of any transfer tax according to Section 726 of the French tax code.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Group Company has at all times been resident for Tax purposes in its jurisdiction of incorporation and has had no permanent establishment in any other jurisdiction and has not during the past &#91;***&#93; years paid or been registered for, nor been liable to pay or be registered for, Tax in any other jurisdiction.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">So far as the Warrantors are aware, no person acting in the capacity of an associated person (as defined in section 44(4) CFA) of any Group Company has committed&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a UK tax evasion facilitation offence under section 45(5), CFA&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a foreign tax evasion facilitation offence under section 46(6), CFA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">Each Group Company has in place (and has had in place at all times since &#91;***&#93;) such prevention procedures (as defined in sections 45(3) and 46(4) CFA) as, so far as the Warrantors are aware, are proportionate to its business risk and are in line with any guidance published from time to time pursuant to section 47 CFA.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No employee or officer of any Group Company has been required to carry out their duties in a jurisdiction other than their usual jurisdiction of residence, or other than the jurisdiction in which they typically carry out their duties, for a material length of time as a result of COVID-19 related travel restrictions.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:16.55pt">No Group Company has received any Coronavirus Support Payment.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 3</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Covenants to and from the Purchaser)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Tax Covenant</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Subject to the provisions of Part&#160;4 of this Schedule the Warrantors jointly and severally covenant to pay to the Purchaser an amount equal to&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Liability to Taxation of any Group Company arising&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">from any Event occurring on or before Completion&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in respect of, or by reference to, any Profits earned, accrued or received on or before Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Deemed Taxation Liability&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any Liability to Taxation of any Group Company which would not have arisen but for the failure of any person who is or has been a Seller Associate (other than a member of the Purchaser's Tax Group) to discharge a Liability to Taxation which falls upon such Seller Associate&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">arising directly or indirectly from any Event occurring or deemed to have occurred at any time by such Seller Associate&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in respect of any profits earned, accrued or received at any time by such Seller Associate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Liability to Taxation which is a liability of any Group Company or any member of the Purchaser's Tax Group to account for income tax or national insurance contributions, whether arising before, on or after Completion, in respect of the grant, exercise, surrender, exchange or other disposal of an option or other right to acquire securities, or in respect of any acquisition, holding, variation or disposal of, or any other Event occurring in relation to, employment-related securities (as defined for the purposes of Part 7, ITEPA) where the acquisition of the security or the grant of the option, or other right to acquire the security occurred on or before Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Liability to Taxation under Part 7A, ITEPA which is a liability of any Group Company or any member of the Purchaser's Tax Group, whether arising before, on or after Completion, including any liability arising as a consequence of any payments or loans made to, any assets made available or transferred to, or any assets earmarked (however informally) for the benefit of any employee or former employee of any Group Company, or for the benefit of any relevant person, by an employee benefit trust or another third party where the arrangement giving rise to the charge was entered into at a time when the third party was acting on the instructions of, or for the benefit of, a Seller Associate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">any Liability to Taxation which is a liability of the Purchaser or any Group Company or any member of the Purchaser's Tax Group to account for income tax or social security contributions arising as a result of the sale of the Shares, or the payment of (or obligation to pay), any part of the Consideration, or any agreement (whether formal or otherwise) between any of the Sellers or between any of the Sellers and any other person or persons in respect of the Consideration payable pursuant to this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Liability to Taxation arising due to a failure after Completion by any employee to make good to any Group Company (or any member of the Purchaser's Tax Group) any income tax or social security contributions for which any Group Company (or any member of the Purchaser's Tax Group) is required to account in respect of any notional payment as defined in section 222, ITEPA and arising in respect of any shares, options, rights, interests or arrangements referred to in sub-paragraph&#160;1.1(d) or in respect of any payments, loans or assets referred to in sub-paragraph&#160;1.1(e) or 1.1(f) above&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any Liability to Taxation being a liability for inheritance tax which&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">is a liability of any Group Company which arises as a result of a transfer of value occurring or being deemed to occur on or before Completion (whether or not in conjunction with the death of any person whensoever occurring)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">has given rise before or on Completion to a charge on any of the shares in or assets of any Group Company or a power to sell, mortgage or charge any of the shares in or assets of the relevant Group Company&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">gives rise at any time after Completion to a charge on or to a power to sell, mortgage or charge any of the shares in or assets of any Group Company as </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a result of the death of any person within &#91;***&#93; years of a transfer of value which occurred before Completion,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and in determining for the purposes of this sub-paragraph&#160;1.1(h) whether a charge on or power to sell, mortgage or charge any of the shares in or assets of the relevant Group Company exists at any time, the fact that the inheritance tax is not yet payable, or may be paid by instalments, shall be disregarded and such inheritance tax shall be treated as becoming due, and a charge or power to sell, mortgage or charge as arising, on the date of the transfer of value or other date or event on or in respect of which it becomes payable or arises, and the provisions of section 213, Inheritance Tax Act 1984 shall not apply&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any liability to Taxation of any Group Company arising where any Group Company is not entitled (either wholly or partially) to, or is required to repay, any Coronavirus Support Payment claimed on or before Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any liability of any Group Company to make a payment or repayment under any indemnity, covenant, warranty, mortgage, guarantee or charge entered into or created on or before Completion of a sum equivalent to or by reference to another person's liability to Taxation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">any Liability to Taxation of any Group Company arising in relation to any claims for &#91;***&#93; submitted to any Tax Authority prior to Completion,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">together with all costs and expenses reasonably and properly incurred by any Group Company or any member of the Purchaser's Tax Group in connection with the Liability to Taxation or other liability (including any related Tax Assessment) which is the subject of a successful claim under sub-paragraph&#160;1.1 above or in taking or defending any successful action under this Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date for payment</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Where the Warrantors become liable to make any payment under this Schedule or for breach of the Tax Warranties, the due date for the making of that payment (which shall be in cleared funds) shall be the later of &#91;***&#93; Business Days following a written demand from the Purchaser to the FME Shareholders' Representative and&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in a case that involves an actual payment of or in respect of Taxation, the date falling &#91;***&#93; Business Days before the due date for payment&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in a case that involves the loss of a Relief (other than a right to repayment of or in respect of Taxation, &#91;***&#93;), the date falling &#91;***&#93; Business Days before the due date for payment of the Taxation which is payable as a result of such Loss of Relief (on the assumption that the relevant Group Company would have been able to utilise fully the Relief in the accounting period during which the Relief was lost)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in a case that involves the loss of a right to repayment of, or in respect of, Tax &#91;***&#93;, the earliest date that the repayment (or payment) would have been made by the relevant Tax Authority (whether by actual repayment (or payment), credit or set-off)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in a case that falls within sub-paragraph&#160;(c) of the definition of Liability to Taxation, the date on which the Taxation saved (in consequence of the use or setting-off) would otherwise have become payable to the relevant Tax Authority&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in any other case (including costs and expenses incurred under sub-paragraph&#160;1.1) which is not covered by the preceding paragraphs, &#91;***&#93; Business Days following a written demand from the Purchaser to the FME Shareholders' Representative.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Liability to Taxation</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The amount of any liability under sub-paragraph&#160;1.1 of this Tax Covenant shall be&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of a liability under sub-paragraph&#160;(a) of the definition of Liability to Taxation, the amount of the payment so made&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in the case of a liability under sub-paragraph&#160;(b) of the definition of Liability to Taxation&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">if the Accounts Relief is a right to repayment of or in respect of Taxation &#91;***&#93;, the amount of the repayment or payment (as the case may be) that is Lost&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in any other case, the amount of Taxation that would have been saved but for the Loss of the Accounts Relief on the assumption that the relevant Group Company would have been able to fully utilise the Accounts Relief in the accounting period during which the Accounts Relief was lost&#59; and</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">in the case of a liability under sub-paragraph&#160;(c) of the definition of Liability to Taxation, the amount of Taxation that has been saved in consequence of the use or setting off.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grossing up</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">All sums payable under this Agreement (including, but not limited to, the Tax Covenant) shall be paid in full, without any set-off, counterclaim, deduction or withholding in respect of Taxation (other than any deduction or withholding required by law).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">If any deductions or withholdings are required by law to be made from any of the sums payable by any Warrantor under this Agreement, the relevant Warrantor making the deduction or withholding shall provide any evidence of the relevant withholding as the Purchaser may reasonably require and shall pay to the Purchaser such additional amount as shall ensure that the net amount received by the Purchaser will equal the full amount that would have been received had no such deduction or withholding been required to be made.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">If any sum payable by any Warrantor to the Purchaser under this Agreement (including, but not limited to, the Tax Covenant) is subject to Taxation in the hands of the Purchaser the amount to be paid to the Purchaser by the Warrantors making that payment shall be increased by such additional amount as will ensure that the net amount received by the Purchaser after such Taxation has been taken into account is equal to the full amount which would be receivable by the Purchaser had the amount not been subject to Taxation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The provisions of sub-paragraphs 1.5 and 1.6 shall not apply if and to the extent that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the amount payable in respect of or in connection with the Claim or other obligation giving rise to the payment includes an amount in respect of or otherwise taken into account such Taxation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Purchaser (including any other recipient of the payment) is at any time resident for Tax purposes in a jurisdiction other than Germany and the amount payable (if any) pursuant to or in consequence of sub-paragraphs 1.5 and 1.6 would have been less had the Purchaser (or other recipient) been at all times so resident only in Germany.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Purchaser shall be entitled to deduct any income tax or social security contributions, other than employer social security contributions, from any payments of Consideration to the extent it or any Group Company is obliged to account for such Taxes in respect of any payment of Consideration and the making of such deduction is not prohibited as a matter of law. The Purchaser shall consult in good faith with the FME Shareholders' Representative prior to seeking any ruling or guidance from any Tax Authority as to whether there is or will be such an obligation and if the Purchaser considers that it is or may be obliged to account for any such Taxes it shall in good faith consult with the FME Shareholders' Representative Sellers prior to any making any such deduction.</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 4</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Limitations and general)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Limitations on liability</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Warrantors shall not be liable under the covenant contained in sub-paragraph&#160;1.1 of Part 3 of this Schedule or for breach of the Tax Warranties if and to the extent that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">allowance, provision or reserve in respect of the liability in question was made in the Completion Accounts&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">payment or discharge of the liability in question was taken into account in calculating the net assets of the Company in the preparation of the Completion Accounts&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the liability in question arises or is increased as a result of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any increase in rates of Taxation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">any change in law or in the judicial interpretation of the law or in the published practice of any Tax Authority (other than a change targeted specifically at counteracting any tax avoidance scheme)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">any change in accounting practice or principles or any change in the bases on which the accounts of the relevant Group Company are prepared except, in either case, in order to comply with generally accepted accounting principles to the extent applicable to the relevant Group Company immediately before Completion&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">any change in the date to which the relevant Group Company makes up its accounts,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">announced and coming in to force in any such case after Completion (provided that this paragraph&#160;(c) will not apply to a liability under sub-paragraph&#160;1(f) and any related liability under 1.1(g) or any payment made under sub-paragraphs 1.5 or 1.6)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the liability in question would not have arisen but for a voluntary act carried out or effected by the Purchaser or any member of the Purchaser's Tax Group at any time or by the relevant Group Company at any time after Completion which the Purchaser knew or ought reasonably to have known would give rise to the liability in question, other than any act carried out or effected&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">under a legally binding commitment created on or before Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in order to comply with any law as it was immediately prior to Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">in the ordinary course of the business of that Group Company as carried on immediately prior to Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">in order to mitigate any penalty or interest (including without limitation, making a voluntary disclosure to any Tax Authority)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">at the written request of the FME Shareholders' Representative&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">pursuant to the Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the liability in question would not have arisen or been increased or would have been reduced or eliminated but for a failure or omission on the part of any Group Company after Completion to make any valid claim, election, surrender, or disclaimer or to give any valid notice or consent in circumstances where the making, giving or doing of which was taken into account in computing the allowance, provision or reserve for Taxation in the Completion Accounts but only to the extent that the Purchaser was aware or ought reasonably to have been aware by the due date for making the relevant claim, election, surrender, disclaimer, notice or consent that the relevant claim, election, surrender, disclaimer, notice or consent was so taken into account&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">there is available to any Group Company (at no cost to any Group Company or any member of the Purchaser's Tax Group) to relieve or mitigate the liability in question any Relief which is not a Purchaser's Relief and for these purposes it shall be assumed that any Group Company has made all such claims and elections required for such Relief to be so available&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Purchaser or the relevant Group Company has already been compensated in respect of the liability in question under any other provision of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Claims</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On the Purchaser or any Group Company becoming aware of a Tax Assessment, the Purchaser shall, or shall procure that the relevant Group Company shall as soon as </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reasonably practicable give written notice of that Tax Assessment to the FME Shareholders' Representative and shall procure that the FME Shareholders' Representative is promptly provided with copies of any correspondence with the Tax Authority and kept fully informed of any actual or proposed material developments (including meetings with a Tax Authority) relating to the Tax Assessment. This paragraph&#160;shall not apply where the provisions of clauses 4.9 to 4.12 apply.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Tax</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Returns</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Purchaser shall (or shall procure that the relevant Group Company shall)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">keep the FME Shareholders' Representative informed of all material matters relating to the submission, negotiation and agreement of the corporation tax returns and computations of each Group Company for all accounting periods ended on or prior to Completion and the pre-Completion part of the accounting period current at Completion (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Relevant Accounting Periods&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">ensure that no such computations or returns nor any material correspondence relating to such computations or returns for the Relevant Accounting Periods shall be transmitted to any Tax Authority without giving the FME Shareholders' Representative a reasonable opportunity to make representations thereon and the Purchaser shall take into account such representations and shall not unreasonably refuse to incorporate any reasonable comments of the FME Shareholders' Representative that are provided to the Purchaser in writing and on a timely basis.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Warrantors shall provide the Purchaser and each Group Company with all reasonable assistance, co-operation and information in relation to the preparation and agreement of the tax returns for Relevant Accounting Periods and any matter arising therefrom.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Where any matter relates to a Tax Assessment which is likely to or may give rise to a liability under this Schedule or in respect of the Tax Warranties (ignoring the financial limitations on claims in Schedule 5 to this Agreement), the provisions of the W&#38;I Policy (including the conduct of claims provisions set-out therein) shall take precedence over the provisions of paragraph&#160;3.1(b) and nothing in this paragraph&#160;3 shall oblige the Purchaser to do anything which would lead to a breach of, or which would otherwise prejudice or adversely impact its rights under, the W&#38;I Policy.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:27.67pt">Warrantors' Access to information</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Purchaser shall procure that all material books and records of each Group Company relating to the period prior to Completion are preserved for &#91;***&#93; years following Completion and are retained in the jurisdiction of incorporation of the relevant Group Company. The Purchaser shall make available to any Warrantor any such books and records of the relevant Group Company (or, if practicable, the relevant parts of such books and records) which are reasonably required by that Warrantor for the purpose of dealing with its or his Tax affairs and, accordingly, the Purchaser shall, upon being given reasonable notice by any Warrantor and subject to that Warrantor giving such undertaking as to confidentiality as the Purchaser shall reasonably require, procure that such books and records are made available to that Warrantor for inspection (during normal working hours) and copying for and only to the extent necessary for such purpose.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 7</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Completion obligations)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Sellers' obligations)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">On Completion&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Each Seller shall deliver (or procure the delivery of) to the Purchaser&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">stock transfer forms, duly completed and executed by the registered holders, in favour of the Purchaser (or as it may direct) in respect of the Completion Shares together with the relevant share certificate(s) (or, where such certificate(s) have been lost or destroyed, an indemnity in a form satisfactory to the Purchaser in respect of such certificate(s))&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">in so far as that Seller (other than the Founder Sellers) has the right to nominate directors of a Group Company, letters of resignation in a form to be agreed between the applicable Seller and the Purchaser acting reasonably, from each of the directors and the company secretary (as applicable) of each Group Company that such Seller nominated&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">a copy of each power of attorney under which any document to be delivered to the Purchaser by it on Completion has been executed&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Option Exercise Documents duly executed by the parties thereto&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a Deed of Adherence in respect of each New FME Shareholders, duly executed by the New FME Shareholder (or by a duly authorised attorney).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Each Non-US FME Shareholder shall deliver (or procure the delivery of) to the Purchaser (to the extent not provided prior to Completion), a duly executed Non-US FME Shareholders' ADS Letter of Representation.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Founder Sellers shall deliver (or procure the delivery of) to the Purchaser (to the extent not provided prior to Completion)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Companies House webfiling authentication code for the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">unless they are kept at a Property or held physically or electronically by a third party that is engaged by a Group Company, all cheque books, credit and charge cards held for the account of each Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">to the extent notified to the Founder Sellers by the Purchaser no later than &#91;***&#93; Business Days in advance of Completion, letters of resignation, in a form to be agreed between the Founder Sellers and the Purchaser acting reasonably, each of the persons and in respect of those positions held in one or more Group Companies, as is&#47;are specified in such notice&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">letters of resignation, in a form to be agreed between the Founder Sellers and the Purchaser acting reasonably, from the auditors of each Group Company containing the statement specified in Section 519, CA2006 (or the equivalent legislation in each relevant jurisdiction)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the New Articles of Association&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">the Completion Disclosure Letter duly signed (if applicable)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Confirmatory IP Assignments, duly executed&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">evidence satisfactory to the Purchaser that each Minority Share Transfer has been completed in accordance with all Applicable Law and is in full force and effect&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">an amended service agreement between the Company and &#91;***&#93; including (i) a provision whereby no commissions are due to by the Company &#91;***&#93; with effect from Completion&#59; and (ii) any other changes as may be agreed between &#91;***&#93; and the Company between the date of this Agreement and Completion, such amended service agreement duly signed by &#91;***&#93; and the Company, to take effect from Completion&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">to the extent the terms of a service agreement between &#91;***&#93; and the Company (or any other Group Company) is agreed between the date of this Agreement and Completion, such service agreement (in a form to be agreed between &#91;***&#93; and the Purchaser acting reasonably) duly signed by &#91;***&#93; and the Company (or any other respective Group Company), to take effect from Completion&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Post-Completion Management Agreement, duly signed by the Founder Sellers and the Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">a copy of each power of attorney under which any document to be delivered to the Purchaser by a Seller Founder on Completion has been executed&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.01pt">copies of any shareholder and&#47;or director resolution of any Group Company for which it is required in connection to Completion, together with copies of all other consents or approvals (if any) referred to in such resolutions&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">all elections by the Optionholders taken under Section 431(1), ITEPA, duly executed&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">board resolution of the Company in the Dubai Digital Authority's prescribed format approving the resignation of the general manager of the InstaDeep Dubai branch and a board resolution of the Company in the ADGM prescribed format approving the resignation of the authorised signatory of the InstaDeep Abu Dhabi branch and the appointment of the relevant replacements as directed by the Purchaser for these branches. Such resolutions must be legalised, notarised and attested up to UAE embassy level in the UK, as applicable.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Sellers&#8217; Representatives shall&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">deliver the Paying Agent Agreements, duly signed by them and the Company&#59; and </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">deliver to &#91;***&#93; a duly signed counterpart of the Payment Notice in respect of the Initial Disbursement Amount (as each term is defined in the Paying Agent Agreement for paying agency services).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">The Sellers shall procure, in so far as it is in their respective power as shareholders of the Company to do so, that a duly convened and quorate board and&#47;or shareholder meeting (or equivalent written resolution) of any Group Company for which the Purchaser and the FME Shareholders' Representative agree is required, is held at which (to the extent relevant)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the stock transfer forms referred to in sub-paragraph&#160;1.1(a) are approved and (subject to them being appropriately stamped) registered in the Company's books&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">such director and&#47;or general manager and&#47;or authorised signatories and&#47;or secretary of a Group Company as have been notified by the Purchaser in advance of Completion cease to be an officer of the relevant Group Company with immediate effect&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the persons nominated by the Purchaser are appointed as director and&#47;or general manager and&#47;or authorised signatory and&#47;or the secretary (as applicable) of any relevant Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any service agreements referred to in sub-paragraph 1.3(i) and 1.3(j) are approved&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the mandates given by each Group Company to its bankers are revoked or revised as the Purchaser may require&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">the execution and completion of the other documents to be entered into by each Group Company under this Agreement is approved as appropriate.</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Purchaser's obligations)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">On Completion, the Purchaser shall deliver (or procure the delivery of) to the Sellers (to the extent not provided prior to Completion)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Post-Completion Management Agreement, duly signed by the Purchaser&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Paying Agent Agreements, duly signed by the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 8</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Pre Completion obligations)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Between the date of this Agreement and Completion each Seller shall, in so far as it is in its power to do so as a shareholder of the Company, procure that (save with the prior written consent of the Purchaser)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Group shall carry on business in the normal and ordinary course&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">reasonable advance notice is given to the Purchaser of any meeting of the board of directors of each Group Company (together with an agenda of the business to be transacted at such meeting and all supporting documents) and that a duly authorised representative of the Purchaser is permitted to attend as an observer at such meeting&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">each Group Company does not conduct its affairs in a manner which could reasonably be considered as damaging or otherwise prejudicial to the goodwill of the Group or its relationship with its customers, suppliers or employees and that no adverse representations about the Purchaser are made by any Group Company or any of its employees, directly or indirectly to any third parties who are suppliers to or customers of the Group or otherwise&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no Group Company shall, save in the normal and ordinary course of business&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">lend any monies, other than advances (i) to any Group Company&#59; or (ii) by way of deposit with a bank or other financial institution whose normal business includes the acceptance of deposits&#59; or (iii) to any individual employee for the purposes contemplated by and in accordance with that employee's terms of employment&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">borrow any monies or otherwise create any indebtedness except in relation to the operation of bank overdrafts within existing limits or term loan from its bankers not exceeding &#163;&#91;***&#93; as required in the ordinary course of business or otherwise amend the terms of any indebtedness&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">give or allow to exist any further Encumbrance over any of its assets or undertaking&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">enter into capital expenditure commitments, hire purchase, leasing, rental or conditional sale agreements or arrangements for an aggregate amount in excess of &#163;&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">enter into any agreement or arrangement which is outside the ordinary course of its business or not capable, in accordance with its terms, of being performed in full within twelve months of the date on which it is entered into or incurred or which cannot be terminated by the relevant Group Company by giving notice or where more than &#91;***&#93; months need to lapse before the relevant Group Company can terminate&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">declare, make or pay any dividend or other distribution or allot, issue, grant any options over, redeem, purchase, consolidate, convert, reclassify, sub-divide or reduce or otherwise reorganise or change any share or loan capital or issue any share warrants or securities convertible into shares, except for granting New Awards (provided that the New Awards will not cause the number of Completion Fully-Diluted Shares to exceed &#91;***&#93;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.9pt">sell, transfer or otherwise dispose of the whole or any part of its business, undertakings or assets or otherwise make any change to its business structure or organisation&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.68pt">give any financial or other guarantees, securities or indemnities for any purpose&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">commence any litigation or compromise or settle any claim, dispute or other matter in which it is involved which has a claim value in excess of &#163;&#91;***&#93;, except for debt collection in the ordinary course of business&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">change its auditors or its accounting reference date&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">register the transfer of any of the Shares&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:19.9pt">cancel, compromise, waive or release any debt of the Company or any Group Company in excess of &#163;&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.68pt">attempt to do any of the matters set out in sub-paragraphs (d)(i) to (x) (inclusive)&#59; or</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.12pt">increase any fees, earnings, remuneration or benefits paid or payable to any officer, employee, consultant or worker of a Group Company by more than &#91;***&#93;%.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no additional directors shall be appointed to the board of directors of any Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">no resolution is passed by the shareholders of any Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">there shall be no material change in the terms and conditions of employment of any Senior Employee of any Group Company or of the terms of engagement of any contractor engaged by any Group Company for services with annual cost to the Company of &#163;&#91;***&#93; or more and no Senior Employee's employment with any Group Company shall be terminated by such Group Company or new Senior Employees engaged by such Group Company&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Group maintains in force all insurance policies that are in force on the date of this Agreement&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">each Group Company pays its creditors in the ordinary course of its business or within the normal terms of payment of such creditors.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Any Group Company may take all or any of the following actions without breach by the Sellers of paragraph&#160;1, provided the Sellers' Representatives notify the Purchaser and, where timing is not of the essence, allow the Purchaser the opportunity to provide its views and comments on the proposed actions&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any action required to be taken in order to comply with any applicable law or regulation (including any action taken by any director of a Group Company to ensure compliance with his duties as a director)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the completion or performance of any obligations pursuant to any contract or arrangement entered into before the date of this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">anything required to be done in order to effect the terms of this Agreement or any action taken at the request of the Purchaser and to which the Seller has agreed&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">any action reasonably taken in response to events (a) beyond the control of the Group Companies or any Seller&#59; or (b) within the control of the Group Companies or of any Seller, but which require urgent response&#59; in each case to the extent taken with the intention of minimising the adverse effect of those events on the business of the Group Companies or any member of the Seller Group.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 9</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Completion Accounts)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Preparation)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">For the purposes of this Schedule 9, notification to and&#47;or by the Sellers shall be satisfied by notification (in accordance with the relevant paragraph&#160;of this Schedule 9) to or by the Sellers' Representatives.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Purchaser shall within &#91;***&#93; Business Days of Completion, prepare and deliver to the Sellers&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a draft income statement of the Group in respect of the period from &#91;***&#93; to the Effective Time&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">a draft balance sheet of the Group as at the Effective Time,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(such income statement and balance sheet being the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;draft Completion Accounts&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Purchaser's calculation of the Actual Adjustment Statement based on the draft Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Founder Sellers shall procure (so far as it lies within their powers) that the Purchaser and the Purchaser's advisers and representatives shall be given full access (during normal business hours after having given reasonable advance notice provided that no such access shall unreasonably interfere with the normal business operations of the Purchaser or the Group) to the Group's accounts and records and shall be permitted to take copies of the same and generally be provided with such other information and assistance as they may reasonably require to prepare such draft Completion Accounts and in a timely fashion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Purchaser shall procure that the draft Completion Accounts are prepared in accordance with the provisions of Part 2 of this schedule and that on their preparation the draft Completion Accounts shall be delivered to the Sellers for review in accordance with paragraph&#160;2 of this schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">In order to enable the Sellers to review the draft Completion Accounts, the Purchaser shall procure that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Purchaser's advisers and&#47;or representatives shall use all reasonable efforts to provide promptly upon request such information and explanations as they may request during the course of their review of the draft Completion Accounts&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Sellers and the Sellers' advisers and&#47;or representatives are given all reasonable access at all reasonable times and without delay to the books, records and working papers in their or their adviser's respective possession or control relating to the Group and to all its staff and shall permit the Sellers and the Sellers' advisers and&#47;or representatives to take copies of such books and records&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">generally provide the Sellers and the Sellers' advisors with such other information and assistance that they may reasonably require and in a timely fashion.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Unless the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sellers' Representatives serve a written notice (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Notice&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) on the Purchaser within &#91;***&#93; Business Days of delivery of the draft Completion Accounts pursuant to paragraph&#160;2 that they do not accept the same, the parties shall at the end of that period be deemed to have accepted such draft Completion Accounts which shall then be final and binding on the parties and which together shall be the Completion Accounts for the purposes of this Agreement. For the avoidance of doubt, any line items not identified in the Notice as being in dispute will be deemed to be agreed for the purposes of this Agreement and will therefore be final and binding upon the parties, to the extent where such line item should be changed as a direct consequence of the agreement or determination of a disputed line item.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">A Notice (if any) served in accordance with paragraph&#160;6 shall specify particulars of the dispute and any adjustments proposed to be made to the draft Completion Accounts.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">If the Sellers' Representatives serve a Notice, then the Sellers' Representatives and the Purchaser shall each use all reasonable endeavours to reach agreement upon the matter or matters in dispute. If agreement on all disputed matters cannot be reached within &#91;***&#93; Business Days of the date of the Notice, any matter still in dispute may upon the direction of </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any party be referred to an Independent Expert for determination in accordance with sub-clause&#160;19.11 and this Schedule 9.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Upon the agreement or determination (as the case may be) of the disputed matter(s), such draft Completion Accounts shall then be the Completion Accounts for the purposes of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">Subject to sub-clause&#160;19.11(k), the costs of the Sellers' advisors in relation to all matters arising from this schedule shall be borne by the Sellers and the costs of the Purchaser's advisors in relation to all matters arising from this schedule shall be borne by the Purchaser.</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Basis of Preparation)</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_25"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.467%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 3</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Illustration of Cash and Debt, as at 31 October 2022)</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.349%"><tr><td style="width:1.0%"></td><td style="width:38.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101</font></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">OC_UK&#47;125258569.5</font></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_28"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 10</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 1</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Calculation of Earn-out Consideration)</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">For the purposes of this Schedule 10, the following definitions shall apply&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Aggregate Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregate of the Earn-out Consideration payable in cash to the Sellers entitled to receive the Earn-out Consideration in accordance with this Schedule 10.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Budget&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any operating and capital budget and cash flow forecast of the Group Companies.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Business Plan&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any business plan of the Group Companies.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Earn-out Consideration&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the aggregate of&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Employee Earn-out Payment (if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the IND Earn-out Payment (if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Project Earn-out Payment (if any)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Publication Earn-out Payment (if any)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the QR Earn-out Payment (if any),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">up to a maximum payment equal to the pro-rata amount of &#163;&#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Employee Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the aggregate payment of up to the pro-rata amount of &#163;&#91;***&#93;, to be paid in up to &#91;***&#93; equal tranches, each tranche being conditional upon satisfaction of an Employment Milestone.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Employment Milestone&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means each of the following employment related milestones&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">each of the following executives of the Group remain employed by the Purchaser or the Group for the duration of the Earn-out Period&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">no less than &#91;***&#93;% of the Key Employees remain employed by the Purchaser or the Group for the duration of Earn-Out Period&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Hiring Target being achieved in accordance with the terms and conditions set out therein,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(together the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Employment Milestones&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and each an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Employment Milestone&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Gross Margin&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, in respect of revenue of the Group, the amount equal to (i) the difference between&#160;revenue of the sale of a product or a service&#160;and&#160;direct costs related to such product or service sold (which direct costs are the salaries and other direct HR costs of the individuals working on such products or services (pro-rata to the time spent on the relevant project), the costs of delivery and&#47;or distribution, costs of customer support services to the extent such customer support services are covered by revenues received, and the cost of cloud or internal cluster provision in connection with the relevant product or service)&#59; divided by (ii) revenue of the sale of such product or service.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Hiring Target&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the Group, by the end of the &#91;***&#93; year period following Completion, employing in aggregate &#91;***&#93; full-time employees (for the avoidance of doubt excluding interns), or such other number of employees as may agreed from time to time in writing between the FME Shareholders' Representative and the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;IND Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the maximum aggregate payment of up to the pro-rata amount of &#163;&#91;***&#93;, to be paid in tranches of &#163;&#91;***&#93;, each tranche being conditional upon satisfaction of one IND Milestone &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;IND Milestones&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means, &#91;***&#93;.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Lighthouse Projects&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means &#91;***&#93; (and examples of such Lighthouse Projects include &#91;***&#93;).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Milestones&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Employment Milestones&#59;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the IND Milestones&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Project Milestones&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Publication Milestones&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">milestones for the QR Earn-Out Payment,</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Milestone&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means each of them.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Project Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the maximum aggregate payment of up to the pro-rata amount of &#163;&#91;***&#93;, to be paid in equal tranches of this amount divided by &#91;***&#93;, each tranche being conditional upon satisfaction of one Project Milestone.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Project Milestones&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means completion of Lighthouse Projects during the Earn-Out Period, each of which Lighthouse Project satisfies the following requirements (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Project Milestone&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Lighthouse Project must utilise no less than the equivalent of &#91;***&#93; Working Days where each </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Working Day&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is defined as an employee of the Company working on a full-time basis during normal business hours on a business day&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Lighthouse Project must not utilise &#91;***&#93;&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">the Lighthouse Project must achieve its written, quantifiable success objectives, in each case defined prior to initiation of the relevant Lighthouse Project, and any final reports and project deliverables are actually delivered&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">such other project-specific targets as may be agreed in writing between the FME Shareholders' Representative and the Purchaser from time to time (for the avoidance of doubt, if no additional project-specific targets have been so agreed in writing, then the Project Milestone shall otherwise be achieved if the relevant Lighthouse Project satisfies the requirements in items (a) to (c) (inclusive) above),</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided that if the same Lighthouse Project spans over &#91;***&#93; years, it shall be counted up to &#91;***&#93; times, one for each &#91;***&#93; days' time-period, beginning on Completion and ending on the &#91;***&#93; anniversary of Completion, provided that the requirements at paragraphs (a) to (d) above are met in respect of each relevant &#91;***&#93; day time-period during which the Lighthouse Project occurs.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Publication Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the maximum aggregate payment of up to the pro-rata amount of &#163;&#91;***&#93;, to be paid in &#91;***&#93; tranches, each tranche being conditional upon satisfaction of a Publication Milestone and compliance with paragraph&#160;4 below.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Publication Milestones&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means each of the following&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(and each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Publication Milestone&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;QR Earn-out Payment&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means the payment of up to the pro-rata amount of &#163;&#91;***&#93;, made up of the following&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93;% of any Qualifying Revenue generated by the Group during the Earn-Out Period from any InstaDeep-BioNTech partnered programs (&#91;***&#93;, but excluding &#91;***&#93;)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">&#91;***&#93;% of any revenue generated by the Group during the Earn-out Period from &#91;***&#93; or any other contracts and&#47;or programs (excluding, for the avoidance of doubt, any InstaDeep-BioNTech partnered programs referred to in paragraph&#160;(a) above of this definition).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;Qualifying Revenue&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means revenue in respect of which the Company has achieved at least a &#91;***&#93;% Gross Margin.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">In the context of the calculation of each relevant maximum earn-out payment amount (in the definition of Earn-Out Consideration and in the definition of each category of earn-out payment), references to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#34;pro rata&#34; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">are to the percentage of total share capital in the Company held in aggregate by the FME Shareholders immediately prior to Completion, as set out in the Completion Allocation Schedule.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">Subject to any adjustment required pursuant to paragraph&#160;4 below, the Earn-out Consideration shall be the payment in cash of the Aggregate Earn-out Payment to such Sellers as are entitled to receive the Earn-out Consideration in accordance with sub-clause&#160;4.2(b)(ii) of this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Aggregate Earn-out Payment shall be payable to each of the Sellers within &#91;***&#93; Business Days of the end of the Earn-out Period, in the proportion set opposite his or her name in the Completion Allocation Schedule.</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Milestones may be amended from time to time during the Earn-out Period by agreement between the FME Shareholders' Representative and the Purchaser.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">In respect of the Publication Earn-out Payment and Publication Milestone, with the purpose of compliance with the Purchaser's policy in respect of publications relating to Intellectual Property, the Purchaser shall be notified by the Company in advance of any relevant publication being made, and shall have a right to review and make any reasonable editorial amendments to the relevant publication, such review and comment to be provided by the Purchaser within &#91;***&#93; Business Days of receipt of such notification (such &#91;***&#93; Business Day period may be extended by a further &#91;***&#93; Business Day period by the Purchaser in its sole discretion if the Purchaser considers that an Intellectual Property filing may be required).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Founder Sellers severally undertake to and covenant with the Purchaser that during the Earn-out Period they shall exercise their powers as managers and employees (as applicable) of the Group (unless otherwise agreed in writing by the Purchaser) to ensure that&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">the business of the Group is carried on in the ordinary and proper course and substantially in the same manner that such business has been carried on prior to Completion, subject to any adjustments as may be implemented upon the agreement of the Founder Sellers and the Purchaser as a result of the Group becoming part of the Purchaser's group and the Purchaser's desired direction&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">the terms of the Post-Completion Management Agreement are complied with&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.11pt">the Group's affairs are conducted so far as reasonably possible to foster the long-term success of the Group.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.67pt">The Purchaser undertakes with the Sellers that, during the Earn-Out Period, it&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">shall not take any actions, or omit to take any actions, with the purpose of depriving the Sellers of any Contingent Consideration that may otherwise be payable in accordance with this Agreement&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">shall exercise its powers as shareholder to procure that the Founder Sellers are in a reasonable position to fully comply with their undertakings under paragraph&#160;7 above and to achieve the Milestones&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">shall procure that none of the following matters is effected by the Company (or any other Group Company) without prior written consent of the Founder Sellers (such consent not to be unreasonably withheld or delayed)&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">adoption of any Budget in respect of any financial year, and any material amendment of and&#47;or deviation from it ('material' in this context being changes in excess of &#163;&#91;***&#93;)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">adoption of any Business Plan in respect of any financial year, and any material update and&#47;or amendment of the same ('material' in this context being changes in excess of &#163;&#91;***&#93;)&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">dismissal of any Key Employee by the relevant Group Company, other than for cause&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">shall procure that the Founder Sellers are, subject always to the Purchaser's group policies from time to time, empowered to procure or direct the Company (or any other Group Company) to effect any of the following matters without prior written consent of the Purchaser&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:27.12pt">any pre-approved matters being those set out in the Budget from time to time (which shall include, for the avoidance of doubt, annual allocations for bonuses to new and existing employees)&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.9pt">in connection with the IND Milestones, the Project Milestones and&#47;or the milestones for the QR Earn-Out Payment, incur any reasonable and proper capital expenditure (including obligations under hire-purchase and leasing arrangements), unless it exceeds the amount for capital expenditure in the relevant capital expenditure of the Budget by more than &#91;***&#93;% or (where no items were specified but a general provision made) exceeding &#163;&#91;***&#93; whether individually or in the aggregate&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">in connection with the Employment Milestones, appoint, remove, or alter the compensation of any employee (where such alteration is indexed to bench-marked salary reports commonly used in the relevant industry with regard to AI&#47;ML engineering (e.g. Radford https&#58;&#47;&#47;radford.aon.com&#47;surveys&#47;) and reflect local hiring conditions) and in any case such alterations do not exceed per annum the higher of (i) &#91;***&#93;%&#59; and (ii) &#91;***&#93;% above the level of inflation in the </font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">country of the employing Group Company in the relevant year, unless his&#47;her gross annual salary exceeds &#163;&#91;***&#93;.</font></div><div><font><br></font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Employees</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div><div id="i67e3fd7aaada43e29d847090ffd90bcb_229"></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.400%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:6pt;margin-top:6pt;text-align:right"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">SCHEDULE 2</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:158%">Redline of Amended Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.48
<SEQUENCE>4
<FILENAME>exhibit448oncoc4agreementr.htm
<DESCRIPTION>EX-4.48
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1f4974b360fe42c5bdaba0be7aee4c10_1"></div><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.48</font></div><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTION VERSION</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This License and Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), effective as of March 17, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), is entered into by and between BioNTech SE, a public limited company in the form of a Societas Europaea organized under the laws of the Federal Republic of Germany, with its corporate seat at An der Goldgrube 12 55131 Mainz, registered with the commercial register of the Local Court of Mainz under HRB 48720 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and OncoC4, Inc., a Delaware corporation having business offices at 9640 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  OncoC4 and BioNTech are each referred to herein, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, OncoC4 Controls certain Patents and Know-How relating to certain antibody compounds and products including the product candidates known as &#8220;ONC-392&#8221; and &#8220;AI-061&#8221; (each, as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, BioNTech wishes to obtain from OncoC4 and OncoC4 wishes to grant to BioNTech, an exclusive license under the relevant Patents and Know-How Controlled by OncoC4 to Exploit the Licensed Compounds and Licensed Products comprising or containing Licensed Compounds in the Field in the Territory (as all such initially capitalized terms are defined below), in each case, in accordance with the terms and conditions more particularly set forth herein&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, BioNTech wishes to obtain from OncoC4 and OncoC4 wishes to grant to BioNTech, an exclusive option to obtain an exclusive license under the relevant Patents and Know-How Controlled by OncoC4 to Exploit AI-061 Products (defined below) in the Field in the Territory, in each case, in accordance with the terms and conditions more particularly set forth herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in connection with the foregoing, the Parties wish to enter into a collaboration for certain joint Development of Licensed Compounds and Licensed Products, in accordance with the terms and conditions more particularly set forth herein, while other Development of Licensed Compounds and Licensed Products (including any Development of combinations of ONC-392 with other products owned or controlled by BioNTech) would, as between the Parties, be conducted by BioNTech. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.7pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise specifically set forth herein or the context otherwise requires, the following capitalized terms have the respective meanings set forth below (and derivative forms of such terms shall be interpreted accordingly)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Person, GAAP (generally accepted accounting principles as practiced in the United States) or IFRS (International Financial Reporting Standards), in each case, as generally and consistently applied by such Person and its Affiliates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any claim, action, cause of action or suit (whether in contract or tort or otherwise), litigation (whether at law or in equity, and whether civil or criminal), assessment, arbitration, investigation, hearing, charge, complaint, demand, notice or proceeding of, to, from, by or before any Governmental Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Person, any entity controlling, controlled by or under common control with such first Person at the time that the determination of affiliation is made and for as long as such control exists.  For purposes of this definition, &#8220;control&#8221; means (a)&#160;direct or indirect ownership of fifty percent (50%) or more of the stock or shares having the right to vote for the election of directors of such Person (or if the jurisdiction where such Person is domiciled prohibits foreign ownership of such entity, the maximum foreign ownership interest permitted under such Laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such ownership interest provides actual control over such Person), (b) status as a general partner in any partnership, or (c) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise.  Affiliates of a Party will exclude Persons who are financial investors of such Party or under common control of such financial investors other than such Party and its subsidiary entities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Anti-PD-1 Antibody Developed by &#91;***&#93; and known as &#8220;AI-025,&#8221; as of the Execution Date, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-025 Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Know-How relating to AI-025 licensed or assigned to OncoC4 pursuant to the AI License.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-025 Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-061</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the biopharmaceutical composition containing as its sole active ingredients both ONC-392 and AI-025, &#91;***&#93; that is known as &#8220;AI-061,&#8221; as of the Execution Date, as further described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-061 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any biopharmaceutical composition containing as its sole active ingredients both ONC-392 and AI-025, &#91;***&#93; including, any biopharmaceutical composition containing as its sole active ingredient AI-061.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, those certain (a) AI-025&#47;AI-061 License and Assignment Agreement, dated on or about the Execution Date, between &#91;***&#93; and OncoC4 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI&#160;License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (b) 392 Collaboration Termination and Assignment Agreement, dated on or about the Execution Date, between &#91;***&#93; and OncoC4 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">392 Collaboration Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (c)&#160;392 License Termination and Assignment Agreement, dated on or about the Execution Date between &#91;***&#93; and OncoC4 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">392 License Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-CTLA-4 Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-PD-1 Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any product owned or controlled by BioNTech or i1ts Affiliate (for clarity, other than pursuant to this Agreement) that is (a) an Other Active used in a Combination Product with the Licensed Compound or (b) is used as part of a combination regimen with the Licensed Compound. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patents or Know-How (a) conceived, discovered, developed, reduced to practice, or otherwise made by or on behalf of BioNTech, its Affiliates and Sublicensees under this Agreement, or (b) to the extent not otherwise covered in subsection&#160;(a), Controlled by BioNTech, its Affiliates or Sublicensees as of the Effective Date or during the Term, and is necessary or reasonably useful for OncoC4 to perform its obligations under the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Material Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; a Biologics License Application (as more fully described in 21&#160;C.F.R. Part 601, or its successor regulation) filed with the FDA&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including, all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BNT PD-1 License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any day, other than a Saturday, a Sunday, or any day on which commercial banks in New York, New York or Mainz, Germany, are authorized or required by applicable Law to remain closed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each of the three month periods ending on March 31, June 30, September 30, and December 31 of any Calendar Year&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that&#58; (a) the first Calendar Quarter of the Term will extend from the Effective Date to the end of the Calendar Quarter in which the Effective Date occurs&#59; and (b) the last Calendar Quarter of the Term will extend from the beginning of the Calendar Quarter in which this Agreement expires or terminates until the effective date of such expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, for the first Calendar Year of the Term, the period beginning on the Effective Date and ending on December 31 of the year in which the Effective Date occurs, and for each Calendar Year thereafter each twelve (12) month period commencing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on January 1 and ending on December 31, except that the last Calendar Year of the Term will commence on January 1 of the year in which this Agreement expires or terminates and end on the effective date of such expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CD80&#47;CD86 Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, (a) a merger, consolidation, reorganization, amalgamation, arrangement, share exchange, tender or exchange offer, private purchase, business combination or other transaction of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity or the parent or ultimate parent of the surviving entity immediately after such merger or consolidation, or the foregoing occurs with respect to a parent or ultimate parent company of such Party, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates (if any), becomes the direct or indirect beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party or any Affiliate directly or indirectly controlling such Party, or (c) the sale or other transfer to a Third Party of all or substantially all of such Party&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">assets.  Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of financing the operations of the applicable Party or changing the form or jurisdiction of organization of such Party will not be deemed a &#8220;Change of Control&#8221; for purposes of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the transaction would otherwise fall within clause (a) or (b) of this definition, the entity with direct or indirect beneficial ownership of fifty percent (50%) or more of the combined voting power of the surviving entity or the parent or ultimate parent of the surviving entity is a financial investor that is not an operating pharmaceutical or biopharmaceutical company and is not controlled by or under common control with such an entity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to a particular item or product and a particular Patent, that such Patent claims the composition of such item or product or any of its ingredients or formulations&#59; a method of making or using it or them&#59; or an item used or present in the manufacture of such item or product (including plasmids, vectors, cell lines, and chemical intermediates, as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the original human subject data and case report forms (CRFs) collected or generated with respect to Clinical Trials of any Licensed Product, together with all analysis, reports, and results with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a study in which human subjects or patients are dosed with a drug or biologic, whether such drug or biologic is approved or investigational.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities related to the commercialization of a product, including the pre-marketing, launching, marketing, promotion (including advertising and detailing), market research, labeling, bidding and listing, pricing and reimbursement, distribution, storage, handling, Manufacturing for commercial sale (including inventory build to support launch), offering for sale, selling, having sold, importing and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exporting for sale, having imported and exported for sale, distribution, having distributed, order processing, handling returns and recalls, customer service and support, and post-marketing safety surveillance and reporting of a product, as well all regulatory compliance and conduct of administrative functions with respect to the foregoing.  For clarity, &#8220;Commercialization&#8221; includes all pre-launch marketing and other launch preparation activities, including training of personnel who will conduct Commercialization activities, as well as Manufacturing activities in preparation for and to establish and maintain commercial sales.  When used as a verb, &#8220;Commercialize&#8221; means to engage in Commercialization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compulsory License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product and a given country or jurisdiction, a right for a Third Party to develop, make, have made, use, sell, offer for sale or import a Licensed Product where such right has been obtained as a result of a licensing requirement or obligation under applicable Law or an order of a Governmental Authority in such country or jurisdiction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) all trade secrets or confidential or proprietary information (including any tangible materials embodying any of the foregoing) of the disclosing Party or its Affiliates provided or disclosed to the other Party in connection with this Agreement&#59; and (ii) the terms and conditions of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Confidential Information will not include information that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;has been published by a Third Party or otherwise is or hereafter becomes publicly known by public use, publication, general knowledge or the like through no breach of this Agreement on the part of the receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;has been in the receiving Party&#8217;s possession prior to disclosure by the disclosing Party hereunder, and not through a prior disclosure by the disclosing Party, without any obligation of confidentiality with respect to such information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;is subsequently received by the receiving Party from a Third Party who is not known by the receiving Party to be under an obligation of confidentiality to the disclosing Party under any agreement between such Third Party and the disclosing Party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;has been independently developed by or for the receiving Party without reference to, or use or disclosure of, the disclosing Party&#8217;s Confidential Information (as evidenced by the receiving Party&#8217;s or such Affiliate&#8217;s written records or other competent evidence)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that clauses (b) through (d) above will not apply to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Know-How, unpublished Licensed Patents, &#91;***&#93; and the terms and conditions of this Agreement shall be deemed the Confidential Information of both Parties, with each Party treated as the receiving Party in respect thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or otherwise) of a Person or its Affiliate to grant access, a license, or a sublicense of or under such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right, without breaching the terms of any agreement with a Third Party.  Notwithstanding the foregoing, Patents and Know-How licensed to OncoC4 under the Upstream Agreement(s) shall be deemed to be &#8220;Controlled&#8221; by OncoC4 for purposes of this Agreement to the same extent that such Patents and Know-How are licensed to OncoC4 and otherwise fall within the definition of Licensed Patents and Licensed Know-How, respectively. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; mean, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CTLA-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means non-clinical, pre-clinical, and clinical drug research and development activities, whether before or after Regulatory Approval, including drug metabolism and pharmacokinetics, translational research, toxicology, pharmacology, test method development and stability testing, process and packaging development and improvement, process validation, process scale-up, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, conduct of Clinical Trials, regulatory affairs, the preparation and submission of Regulatory Materials, Clinical Trial regulatory activities, and any other activities directed towards obtaining or maintaining Regulatory Approval of any Licensed Product, including Manufacturing in support of any of the foregoing.  Development includes use and importation of the relevant Licensed Product to conduct such Development activities.  For clarity, &#8220;Development&#8221; will not include Commercialization activities.  When used as a verb, &#8220;Develop&#8221; means to engage in Development.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means United States dollars.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the European Union, as its membership may be constituted from time to time, and any successor thereto, and the United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a pharmaceutical or biologic product, to Develop, Manufacture, make, have made (subject to the terms of this Agreement, if applicable), Commercialize, use, sell, offer for sale, import, export, and otherwise exploit such Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Federal Food, Drug and Cosmetic Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the equivalent of a full-time individual&#8217;s work time for a twelve (12) month period devoted to Development (excluding management and indirectly related personnel&#8217;s time), where &#8220;full-time&#8221; is determined by &#91;***&#93; hours per Calendar Year.  In the event that any individual who works full-time during a given Calendar Year works partially on the activities under this Agreement and partially on other work outside this Agreement, then the full-time equivalent to be attributed to such individual&#8217;s work hereunder for such Calendar Year shall be equal to the percentage of such individual&#8217;s total work time in such Calendar Year that such individual spent working on activities under this Agreement.  For avoidance of doubt, FTE shall exclude individuals responsible for managerial, secretarial, clerical and administrative activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means, with respect to a Party for any period, the applicable FTE Rate multiplied by the applicable number of FTEs of such Party performing Development activities during such period in accordance with the CDP. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; per FTE per Calendar Year&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the FTE Rate will be prorated for the period beginning on the Effective Date and ending on December 31, 2023 &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.49.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fully Burdened Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FBMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the costs incurred by or on behalf of the Parties or their Affiliates in connection with Manufacturing or purchasing from a Third Party, as applicable, the Licensed Compound or Licensed Products (or components thereof).  For quantities Manufactured by a Party or its Affiliate, FBMC shall be comprised of the following elements calculated in accordance with the applicable Accounting Standard&#58; &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.50.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable then-current standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of Clinical Trials, including, as applicable, (a) as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guideline for Good Clinical Practice (CPMP&#47;ICH&#47;135&#47;95) and any other guidelines for good clinical practice for trials on medicinal products, (b) the Declaration of Helsinki (2013) as last amended at the 64th World Medical Association in October 2013 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards) and 312 (Investigational New Drug Application), and (d) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, safety, and confidentiality of trial subjects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.51.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21&#160;C.F.R. Part 58, or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (OECD), and such standards of good laboratory practice as are required by the equivalent applicable Laws in the relevant country and other organizations and governmental agencies in countries in which the Licensed Product is intended to be sold by the Party that is subject to such standards.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.52.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable then-current standards for Manufacturing, including, as applicable, (a) the principles detailed in the U.S. Current Good Manufacturing Practices, 21&#160;C.F.R. &#167;&#167; 210, 211 and 600-680 and all applicable FDA guidelines and requirements, (b)&#160;European Directive 2003&#47;94&#47;EC for medicines and investigational medicines for human use and the applicable guidelines stated in the EudraLex guidelines, (c) the principles detailed in the applicable ICH guidelines, (d) the conduct of an inspection by a Qualified Person (as defined therein) and the execution by such Qualified Person of an appropriate certification of inspection&#59; and (e) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.53.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any national, multinational, supranational, federal, state, local, provincial, municipal, foreign or other entity, office, commission, bureau, agency, political subdivision, instrumentality, branch, department, authority, board, court, arbitral or other tribunal, official or officer, in any case, exercising executive, judicial, legislative, police, regulatory, administrative or taxing authority, or functions of any nature pertaining to government.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.54.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.55.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an application filed with a Regulatory Authority for authorization to commence Clinical Trials, including (a) an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b) any equivalent thereof in other countries or jurisdictions, (e.g., a Clinical Trial Application (CTA) in the EU) and (c) all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.56.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Person entitled to indemnification under ARTICLE XI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.57.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Party from whom indemnification is sought under ARTICLE XI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.58.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.59.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Clinical Trial, the date upon which the first patient or subject is dosed in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.60.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.61.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the joint program of Development to be conducted under the CDP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.62.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all inventions, practices, methods, protocols, formulae, knowledge, know-how, trade secrets, instructions, processes, procedures, assays, skills, experiences, techniques, information, works of authorship, drawings, assembly procedures, computer programs, apparatuses, specifications, and Materials.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.63.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any applicable federal, state, local, national, multinational, supranational, provincial, municipal, foreign, or other law, statute, legislation, constitution, principle of common law, code, treaty ordinance, regulation, rule, or order of any kind put into place by or under the authority of any Governmental Authority, together with any rules, regulations, or compliance guidance promulgated thereunder.  For clarity, &#8220;Laws&#8221; include the applicable regulations and guidance of the FDA and European Union (and national implementations thereof) that constitute GLP, GMP, and GCP (and, if and as appropriate under the circumstances, ICH guidance or other comparable regulations and guidance of any other applicable Governmental Authority).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.64.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each of (a) ONC-392, and (b) any and all Anti-CTLA-4 Antibodies Controlled by OncoC4 as of the Execution Date or during the Term (whether such Antibodies exist as of the Execution Date or arise during the Term) (including the ONC-392 backup molecules described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), in each case (clauses (a) and (b)), either in protein form or as a nucleotide sequence encoding the Antibody.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.65.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all Know-How existing as of the Execution Date or arising during the Term and Controlled by OncoC4 or its Affiliates as of the Execution Date or during the Term that is necessary or reasonably useful for the Exploitation of the Licensed Compound and Licensed Products in the Field in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (a) the Licensed Know-How shall not include Know-How relating solely to an Other Active (other than AI-025) of a Combination Product unless otherwise mutually agreed by the Parties separately in writing, and (b) if BioNTech does not exercise the Option in accordance with Section&#160;2.2, then upon and following the expiration of the Option Period, the Licensed Know-How shall exclude any Know-How relating solely to AI-061 or AI-025 unless otherwise mutually agreed by the Parties separately in writing.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.66.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) the Listed Patents and (b) any other Patents existing as of the Execution Date or arising during the Term that are Controlled by OncoC4 or its Affiliates as of the Execution Date or during the Term and that are necessary or reasonably useful for the Exploitation of the Licensed Compound and Licensed Products in the Field in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i)&#160;Licensed Patents shall not include Patents solely claiming or solely covering an Other Active (other than AI-025) of a Combination Product unless otherwise mutually agreed by the Parties separately in writing, and (ii) if BioNTech does not exercise the Option in accordance with Section&#160;2.2, then upon and following the expiration of the Option Period, the Licensed Patents shall exclude any Patents solely claiming or solely covering AI-061 or AI-025 unless otherwise mutually agreed by the Parties separately in writing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.67.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) any pharmaceutical or biologic product or composition that contains any Licensed Compound, including Combination Products, and (ii)&#160;subject to the terms and conditions of Section&#160;2.2, the AI-061 Product&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if BioNTech does not exercise the Option in accordance with Section&#160;2.2 and Section&#160;7.2 prior to the expiration of the Option Period, then upon and following the expiration of the Option Period, the AI-061 Product shall no longer be a Licensed Product under this Agreement unless otherwise mutually agreed by the Parties separately in writing.  It is understood that Licensed Products may be in the following forms, presentations or applications&#58; (a) a form consisting of the Licensed Compound as a single therapeutically active ingredient (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Single Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; or (b) a Combination Product.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.68.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Listed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) the Patents listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; (b) all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, (c) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and the like of any of the foregoing, (d) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and certificates of invention. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.69.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means damages, losses, liabilities, costs (including costs of investigation, defense), fines, penalties, taxes, expenses, or amounts paid in settlement (in each case, including reasonable attorneys&#8217; and experts&#8217; fees and expenses), in each case resulting from an Action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.70.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product and a country or jurisdiction, an application for marketing authorization for Commercialization of such product in such country or jurisdiction, including a BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the United States. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.71.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Major Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following countries&#58; &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.72.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all activities related to the production of Licensed Compound or Licensed Product, or any component or intermediate thereof, including the making, synthesis, conjugation, production, manufacture, having manufactured, processing, filling, finishing, packaging, labeling, shipping and holding of any intermediate thereof, including process development, process qualification and validation, scale-up, commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.  When used as a verb, &#8220;Manufacture&#8221; means to engage in Manufacturing activities.  References to a Person engaging in Manufacturing activities will include having any or all of the foregoing activities performed by a Third Party to the extent such performance is permitted hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.73.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means chemical and biological materials, including plasmids, constructs, and cell lines.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.74.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.75.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Licensed Product, the gross amount invoiced on sales of such Licensed Product by BioNTech or any of its Affiliates or Sublicensees to a Third Party, less the following customary deductions, determined in accordance with the Accounting Standards, to the extent allocated to the sale of such Licensed Product and actually taken, paid, accrued, allowed, or included in the gross sales prices or specifically allocated in its financial statements with respect to such sales&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, sales of the Licensed Product for clinical study purposes, bona fide charitable purposes, &#8220;compassionate use sales,&#8221; named patient sales (unpaid or at cost </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or a no-profit price) or similar use, in each case, at or below cost, shall not constitute Net Sales.  Sales and other transfers of Licensed Product between any of BioNTech, its Affiliates and Sublicensees (for clarity, including distributors) will not give rise to Net Sales, but rather the subsequent sale of Licensed Product to Third Parties will give rise to Net Sales.  Net Sales will be determined in accordance with the Accounting Standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that a Licensed Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by multiplying actual Net Sales of such Combination Product in such country during the relevant Calendar Quarter calculated pursuant to the foregoing definition of &#8220;Net Sales&#8221; by the fraction A&#47;(A+B), where &#8220;A&#8221; is the average invoice price in such country of any Licensed Product that contains the Licensed Compound, as applicable, as its sole active ingredient(s), if sold separately in such country, and &#8220;B&#8221; is the average invoice price in such country of each product that contains Other Active(s) contained in such Combination Product as its sole active ingredient(s), if sold separately in such country.  If either a Licensed Product that contains the Licensed Compound, as applicable, as its sole active ingredient or a product that contains Other Active in the Combination Product as its sole active ingredient(s) is not sold separately in a given country during the relevant Calendar Quarter, prior to the date of the First Commercial Sale of such Combination Product, then&#58; (a) if they are each sold separately in any Major Market, BioNTech shall be entitled to apply worldwide the ratio obtained by using the prices in such Major Market in the A&#47;(A+B) formula&#59; or (b) if (a) is not the case then the Parties shall negotiate in good faith and seek to reach mutual agreement on a reasonable adjustment to Net Sales in such country that takes into account the medical contribution to the Combination Product of, and all other factors reasonably relevant to the relative value of, the Licensed Compound, as applicable, on the one hand, and Other Active(s), on the other hand.  If the Parties do not reach written agreement as to such adjustment within thirty (30) days after BioNTech requests in writing such negotiations, then BioNTech may invoke and the Parties shall follow the Expert Valuation procedure set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to determine such adjustment.  Notwithstanding the foregoing or anything contained herein, for purposes of calculating Net Sales, AI-061 Products shall be deemed to be a Licensed Single Product (except where combined with &#91;***&#93; or more Other Actives)  and shall not be deemed to be a Combination Product.  For purposes of calculating royalties due under an Upstream Agreement, the definition of Net Sales shall not be adjusted for purposes of calculating Net Sales hereunder and the amounts due by BioNTech under this Agreement.  However, recognizing that OncoC4 may owe royalties under an Upstream Agreement based on a different Net Sales definition, BioNTech shall provide or cause to be provided to OncoC4 such information as OncoC4 may reasonably request to enable OncoC4 to properly report and pay royalties under, and otherwise comply with, the Upstream Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.76.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Rare Cancer Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Indication in oncology for a cancer that is not a Rare Cancer.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.77.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONC-392</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the monoclonal Anti-CTLA-4 Antibody Developed by OncoC4 and known as &#8220;ONC-392,&#8221; as of the Execution Date, the amino acid sequence of which is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.78.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the Effective Date and ending on the date &#91;***&#93; following Completion of the first Phase 1 Trial of AI-061.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Completion of the first Phase 1 Trial of AI-061</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date upon which the final subject </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enrolled in such Clinical Trial completed the safety and the efficacy assessment (as such Clinical Trial is described in the initial CDP), whether the Clinical Trial concluded according to the pre-specified protocol or was terminated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the protocol for such Clinical Trial is amended to significantly increase the number of subjects or otherwise become a &#8220;Phase 2 Trial&#8221; (including a &#8220;Phase&#160;1&#47;2&#8221; Clinical Trial), then &#8220;Completion of the first Phase 1 Trial of AI-061&#8221; shall be deemed to be the earlier of (i)&#160;the date upon which the final subject enrolled in the &#8220;Phase 1&#8221; portion of such Clinical Trial completed the safety and the efficacy assessment, and (ii) the date upon which the first subject in the &#8220;Phase 2&#8221; portion of such Clinical Trial is dosed.  As used in this definition, &#8220;completed the safety and the efficacy assessment&#8221; means, with respect to the final subject enrolled in a Clinical Trial, (A) the first date upon which both Parties have received Clinical Data from the first tumor response assessment for such final subject in such Clinical Trial or the relevant portion thereof and (B) a first summary of all safety, efficacy, pharmacokinetic and biomarker data collected as of the first tumor response assessment for such final subject in such Clinical Trial or the relevant portion thereof is available.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.79.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.80.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Out-of-Pocket Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, costs and expenses paid by such Party or its Affiliate to Third Parties (or payable to Third Parties and accrued in accordance with Accounting Standards), other than employees of such Party or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.81.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) all patents and patent applications (including provisional applications), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, re-issues, additions, renewals, extensions, confirmations, registrations, any other pre- or post-grant forms of any of the foregoing, (b) any confirmation patent or registration patent or patent of addition, utility models, patent term extensions, and supplemental protection certificates or requests for continued examinations, foreign counterparts, and the like of any of the foregoing, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including author certificates, utility models, petty patents, innovation patents and design patents and certificates of invention.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.82.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PD-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means programmed cell death protein 1 and is also known as &#8220;CD279&#8221; or the cluster of differentiation 279. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.83.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PD-1 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any biopharmaceutical composition that contains an Anti-PD-1 Antibody.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.84.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.85.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 1 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a Licensed Product that generally provides for the first introduction into humans of such Licensed Product, with the primary purpose of determining metabolism, pharmacokinetic properties, the maximum tolerated dosage, and side effects of such product, in a manner that is generally consistent with 21 C.F.R. &#167;&#160;312.21(a), or a similar clinical study prescribed by the Regulatory Authorities in a country or jurisdiction outside the United States, excluding any investigator-initiated Clinical Trials.  For </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">clarity, Phase 1 Trial includes any Clinical Trial (or portion thereof) designated as a &#8220;Phase 1a&#8221; Clinical Trial or &#8220;Phase 1b&#8221; Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.86.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 2 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a Licensed Product conducted on a sufficient number of subjects for evaluating (and the principal purpose of which is to evaluate) the effectiveness of such Licensed Product for its particular intended use and obtaining (and to obtain) information about side effects and other risks associated with the drug, in a manner that is generally consistent with 21 C.F.R. &#167; 312.21(b), or a similar clinical study prescribed by the Regulatory Authorities in a country or jurisdiction outside the United States, to permit the design of further Clinical Trials of such Licensed Product, excluding any investigator-initiated Clinical Trials.  For clarity, Phase 2 Trial includes any Clinical Trial (or portion thereof) designated as a &#8220;Phase 2a&#8221; Clinical Trial or &#8220;Phase 2b&#8221; Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.87.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase 3 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product and conducted on a sufficient number of subjects for ascertaining (and that is designed to ascertain) the overall risk-benefit relationship of the Licensed Product for its intended use and determining (and to determine) warnings, precautions, and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, in a manner that is generally consistent with 21 C.F.R. &#167; 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a country or jurisdiction outside the United States, which trial is necessary to support Regulatory Approval of such Licensed Product, excluding any investigator-initiated Clinical Trials.  For clarity, Phase 3 Trial includes any Clinical Trial (or portion thereof) designated as a &#8220;Phase 3a&#8221; Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.88.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pivotal Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial that is prospectively designed to demonstrate that a Licensed Product is safe and effective for use in a particular Indication in a manner sufficient to evaluate the overall benefit-risk relationship of the Licensed Product and to provide an adequate basis for physician labeling, and which, at the time of the initiation of such Clinical Trial, is intended and expected to be the basis for Regulatory Approval by the FDA and&#47;or the European Commission after EMA opinion in the EU of such Licensed Product for such Indication, based on discussions with the relevant Regulatory Authority.  For clarity, Pivotal Trial shall (a) always include Phase 3 Trials, and (b) include &#8220;Phase 2b&#47;3&#8221; Clinical Trials (or the appropriate portion thereof), Phase&#160;2 Trials, &#8220;Phase 1&#47;2&#8221; Clinical Trials, or other Clinical Trials, if the conditions of this definition are met.  In some cases, it may not be known whether a given Phase 2 Trial will be treated by the governing Regulatory Authority as a Pivotal Trial until after it is completed.  In these cases, if such a Phase 2 Trial is ultimately agreed by the governing Regulatory Authority to be a Pivotal Trial, then from such point forward it will be treated as a Pivotal Trial for purposes of this Agreement, and any milestones hereunder that become due based on such status will be deemed achieved only as of the date of such agreement from such governing Regulatory Authority (and any associated payment due hereunder will not be considered late based on earlier events in relation to such Clinical Trial prior to such agreement from such governing Regulatory Authority to treat it as a Pivotal Trial).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.89.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product, the governmental approval, agreement, determination or decision establishing the price or level of reimbursement for such Licensed Product, in a given country in the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.90.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, in relation to any Patents (a) to prepare and file patent applications, including re-examinations or re-issues thereof, and represent applicants or assignees before relevant patent offices or other relevant Governmental Authorities during examination, re-examination and re-issue thereof, in appeal processes and interferences, or any equivalent proceedings, (b) to defend all such applications against Third Party oppositions or other challenges, (c) to secure the grant of any patents arising from such patent application, (d) to maintain in force any issued patent (including through payment of any relevant maintenance fees), and (e) to make all decisions with regard to any of the foregoing activities.  When used as a verb, &#8220;Prosecute&#8221; means to engage in Prosecution activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.91.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rare Cancer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any cancer that affects fewer than 40,000 people per year in the U.S. based on NCI data. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.92.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the final or conditional approval of the applicable Regulatory Authority necessary for the marketing and sale of the Licensed Product in the Field in a country or jurisdiction in the Territory, including BLA approval in the United States, but excluding any separate Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.93.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any national, multinational, supranational, federal, state, local, provincial, municipal, foreign or other regulatory agency, department, bureau or other Governmental Authority with authority over the clinical development, manufacture, marketing or sale of the Licensed Product in a country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.94.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means activities to be performed by or on behalf of a Party or its Affiliates in connection with seeking Regulatory Approval of a Licensed Product in the Territory, but excluding, for clarity, any post-marketing commitments as mandated or agreed to be conducted with a Regulatory Authority for such Licensed Product.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.95.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Licensed Product, (a) all INDs, MAAs, BLAs, establishment license applications, drug master files, applications for designation as an &#8220;Orphan Product&#8221; under the Orphan Drug Act, for &#8220;Fast Track&#8221; status under Section&#160;506 of the FFDCA (21 U.S.C. &#167; 356) or for a Special Protocol Assessment under Section&#160;505(b)(4)(B) and (C) of the FFDCA (21 U.S.C. &#167; 355(b)(4)(B) and (C)) and all other similar filings (including counterparts of any of the foregoing in any country in the Territory), (b) any applications for Regulatory Approval and other applications, filings, dossiers, or similar documents (e.g., pediatric investigation plans) submitted to a Regulatory Authority in any country for the purpose of obtaining Regulatory Approval from that Regulatory Authority, (c) all supplements and amendments to any of the foregoing, and (d) all data, including Clinical Data, and other information contained in, and Regulatory Authority correspondence relating to, any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.96.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Senior Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) with respect to OncoC4, the Chief Executive Officer or any other officer on the management team (such as Chief Operating Officer or the Chief Medical Officer) of OncoC4 or his&#47;her designee or successor with appropriate decision-making authority&#59; and (b) with respect to BioNTech, the Senior Vice-President (or any more senior position thereto) of BioNTech or his&#47;her designee or successor with appropriate decision-making authority.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.97.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to OncoC4, any Third Party service provider acting on behalf of OncoC4 or its Affiliate, on a fee for service basis, in the performance of activities conducted in accordance with the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that &#8220;Service Providers&#8221; shall not include (a) Third Parties engaged to supply Licensed Compounds or Licensed Products to either Party, (b) Third Parties performing material services expected to receive consideration from either Party in excess of &#91;***&#93; in any Calendar Year, (c) any Third Party that has failed to satisfy a quality audit required under a customary quality agreement in place between the Parties or their Affiliates and such failure has not been cured within sixty (60) days of notice to the Third Party of such failure or (d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Third Parties engaged to apply for regulatory approvals or authorized to make payments or other transfers of value to other Third Parties, in particular, but not limited to, government officials, public authorities, healthcare organizations, healthcare professionals, patient advocacy groups or patients.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.98.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stage 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that second portion of the Phase 3 Trial for the NSCLC 2L Monotherapy described in the CDP utilizing a single recommended dose of the Licensed Product, subject to approval by the independent data monitoring committee (DMC) overseeing such Phase 3 Trial, or otherwise requested or recommended by the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.99.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a grant of rights from BioNTech to a Sublicensee under any of the rights licensed to BioNTech by OncoC4 under Section&#160;2.1, for clarity excluding contract research organizations, contract manufacturing organizations, and other service providers that do not obtain commercial rights (i.e., the right to sell to anyone but BioNTech, a BioNTech Affiliate or an entity deriving rights from them).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, a Third Party sublicensee of rights granted to such Party under this Agreement, or any further sublicensee of such rights (regardless of the number of tiers, layers or levels of sublicenses of such rights), for clarity excluding grants to contract research organizations, contract manufacturing organizations, and other service providers that do not obtain commercial rights (i.e., the right to sell to anyone but BioNTech, a BioNTech Affiliate or an entity deriving rights from any of them). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.101.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the entire world.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.102.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person other than a Party or their respective Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.103.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all registered and unregistered trademarks, service marks, trade dress, trade names, logos, insignias, domain names, symbols, designs, and combinations thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.104.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; mean the United States of America and its territories and possessions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.105.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upstream Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the agreements set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> pursuant to which OncoC4 obtains a license from a Third Party under certain Licensed Patents or Licensed Know-How.  Complete copies of the Upstream Agreements and any amendments or modifications thereto have been provided to BioNTech prior to the execution of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.106.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.107.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VAT and Indirect Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any value added, sales, purchase, turnover or consumption tax as may be applicable in any relevant jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.108.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.109.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means agreements between &#91;***&#93; and OncoC4 with respect to the Licensed Compound or Licensed Products, but not including the &#91;***&#93; License.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.110.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.111.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Additional Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following terms have the respective meanings set forth in the Sections indicated below&#58;  </font></div><div style="padding-left:2.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:75.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Definition</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">392 Collaboration Termination</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">392 License Termination</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Guangzhou</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AI-025 Inventions</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AI-025 Label License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AI-061 Conditions</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AI License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.10</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allegedly Breaching Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Alliance Manager</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Audited Site</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1(f)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Auditor</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Development Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Foreground Invention</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Foreground Patents</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(c)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Indemnified Parties</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Product Invention</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(c)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech Product Patents</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(c)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Biosimilar Application</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3(f)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Breaching Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CAPA</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1(f)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CDP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 10.2(i)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commercialization Plan</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3(b)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:2.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:75.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Competing Program</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Completion of first Phase 1 Trial of AI-061</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.78</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covered Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development Milestone Payment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DOJ</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Enforcement or Defense Action</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Excess Development Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exclusive License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Execution Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Indication</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.58</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FTC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GOVERNMENT OFFICIAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.17(c)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HSR Act</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incremental Withholding</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.9(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Infringement Claim</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IP Notice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Joint Development Budget</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1(b)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JSC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Single Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.67</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mediation Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 13.4(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2(l)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mono&#47;PD-1 Combinations</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Affiliate</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Breaching Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4 Indemnified Parties</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2(p)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Effective Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Exercise Fee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Exercise Notice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; License</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.105</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:2.15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:75.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Settlement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.105</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Active</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.30</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Combinations</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party and Parties</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preamble</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party Vote</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patent Extension</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pharmacovigilance Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROHIBITED CONDUCT</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.17(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Proviso Covenant</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reduction Floor</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.7(f)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representatives</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reserved Financial Decision</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5(a)(i)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reserved Rights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reversion Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 13.4(d)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reversion Products</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rules</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sales Milestone Event</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sales Milestone Payment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Securitization Transaction</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.1(a)(ii)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shared CDP Liability Claims</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subcommittee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Supply Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Technology Transfer</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2(a)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Terminated Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4(e)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Terminated Product Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4(e)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Third Party Action</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Third Party Claim</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3(a)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Withholding Action</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.9(a)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:5.04pt"><br>LICENSE GRANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">License Grant to BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, OncoC4 hereby grants to BioNTech an exclusive (but not to the exclusion of OncoC4&#8217;s Reserved Rights), non-transferable (except in accordance with Section&#160;15.1), sublicensable (through multiple tiers, subject to Section&#160;2.3), (i) royalty-bearing license under the Licensed Know-How, Licensed Patents, and &#91;***&#93;, to Exploit Licensed Compounds and Licensed Products in the Field in the Territory and (ii) royalty-free license under any AI-025 Patents or any AI-025 Know-How, the Licensed Know-How, Licensed Patents, and &#91;***&#93;, to Exploit AI-025 not co-formulated with ONC-392, but used in combination with ONC-392 (whether co-packaged, co-indicated, co-labeled or any other combined use) (for clarity, not including in AI-061 or AI-061 Products), (such license under clause (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-025 Label License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the Field in the Territory (clause (i) and (ii), collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exclusive License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the foregoing, (A) unless and until BioNTech exercises the Option in accordance with Section&#160;2.2, despite the Exclusive License granted to BioNTech under this Section&#160;2.1(a) with respect to AI-061, AI-061 Products and AI-025, BioNTech hereby covenants that its Exploitation of AI-061, AI-025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and AI-061 Products&#58;  (I)&#160;shall be limited to conducting Development and Manufacturing activities with respect to AI-061 or AI-061 Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">solely in accordance with the CDP during the Option Period, and (II) shall not include the sale, offer for sale, distribution, promotion, marketing or other Commercialization of AI-061 or AI-061 Products (or any other Licensed Product containing AI-061) (the limitations described in clauses&#160;(I) and (II) are referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-061 Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (B) in all instances BioNTech hereby covenants that its Exploitation of AI-025 shall not include the Exploitation of AI-025 other than within the context of and as part of AI-061 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proviso Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The AI-061 Conditions shall no longer apply on or after the Option Effective Date in the event BioNTech exercises the Option.  For the avoidance of doubt, unless otherwise agreed upon in writing by the Parties in the form of an amendment or restatement of this Agreement or a new license agreement, the rights granted to BioNTech with respect to AI-025 are limited to the AI-025 Label License, subject always to the Proviso Covenant, and Exploitation of AI-025 solely within the context of and as part of AI-061 or AI-061 Products (including the right to manufacture AI-025 in order to Exploit AI-061 or AI-061 Products as a Licensed Product), and under no circumstances will BioNTech or its Affiliates obtain any right or license to use AI-025 as a monotherapy or in combination with any other therapeutically active ingredient except as expressly contemplated hereby with respect to the AI-025 Label License, subject always to the Proviso Covenant, and the use of AI-025 solely within the context of and as part of AI-061 or AI-061 Products as a combination product.  It is understood that for purposes of this Agreement, despite being a product that combines two (2) active ingredients, AI-061 and AI-061 Products are deemed to be a &#8220;Licensed Single Product&#8221; rather than a &#8220;Combination Product.&#8221;  However, BioNTech retains the right (unless it allows the Option to lapse without exercise) to include AI-061 or an AI-061 Product in a Combination Product, and if BioNTech Develops AI-061 or an AI-061 Product in a Combination Product with &#91;***&#93; or more Other Actives, in such case, AI-061 or such AI-061 Product shall be treated as the Licensed Product component of such Combination Product. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">License Grant to OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, BioNTech hereby grants to OncoC4, a non-exclusive, non-transferable (except in accordance with Section&#160;15.1), sublicensable (through multiple tiers) to subcontractors, only with BioNTech&#8217;s prior written consent, except that such written consent will not be required for sublicenses to OncoC4&#8217;s Affiliates, Service Providers or any subcontractors listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, royalty-free license under the BioNTech Technology and &#91;***&#93; to carry out OncoC4&#8217;s obligations under the CDP.  For clarity, OncoC4 shall not be permitted to sublicense the entirety of its co-development obligations under the CDP to any Affiliate or Third Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">AI-061 Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 hereby grants BioNTech the exclusive option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) exercisable during the Option Period to be released from its covenant as to the AI-061 Conditions restricting its practice of the Exclusive License with respect to AI-061 Products, including that BioNTech shall be released from its covenants not to exercise the right to sell, offer for sale, distribute, promote, market and otherwise Commercialize AI-061 (or any other Licensed Product containing AI-061).  The Option shall be exercisable as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">At any time during the Option Period, BioNTech may exercise the Option by delivery of written notification to OncoC4 of its decision to exercise the Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Following the delivery of the Option Exercise Notice, BioNTech shall pay the Option Exercise Fee to OncoC4 as set forth in Section&#160;7.2.  Subject to BioNTech&#8217;s compliance with this Section&#160;2.2 and Section&#160;7.2, the date on which OncoC4 receives the Option Exercise Fee will thereafter be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; hereunder. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective upon the Option Effective Date, the AI-061 Conditions and BioNTech&#8217;s covenants in Section&#160;2.1(a) with respect thereto shall terminate and,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to the terms and conditions of this Agreement, BioNTech shall have the right to practice its Exclusive License with respect to AI-061 and AI-061 Products under Section&#160;2.1(a), and following the Option Effective Date and for the remainder of the Term AI-061 Products shall be considered a Licensed Product and a Mono&#47;PD-1 Combination hereunder, all of the foregoing happening automatically and without the need for any further action by the Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything contained herein, effective upon the Option Effective Date and thereafter during the Term&#58; (i) for any Development of AI-061 Products as a Mono&#47;PD-1 Combination (i.e., not in combination with any other therapeutically active ingredient), the AI-061 Product shall be deemed to be a Licensed Single Product for purposes of calculating milestone payments and royalties under Sections 7.4 through 7.7&#59; and (ii) if an AI-061 Product is included in a Combination Product that is not a Mono&#47;PD-1 Combination (e.g., an AI-061 Product in combination with a therapeutically active ingredient that is not a PD-1 Product), such Licensed Product shall not trigger any Development Milestone Payments set forth in Section&#160;7.4(a), but shall be eligible to trigger Sales Milestone Payments under Section&#160;7.4(b) and OncoC4 shall be eligible to receive royalties for the sales of any such Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If BioNTech does not exercise the Option prior to the expiration of the Option Period in accordance with Section&#160;2.2 and Section&#160;7.2, then (i) the AI-061 Conditions and BioNTech&#8217;s covenant with respect thereto shall remain in effect, (ii) AI-025 shall be excluded </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from the definition of Licensed Compound, and BioNTech will no longer have any option, license or right to AI-025 (including, for clarity, AI-025 included in AI-061 Products, but without otherwise limiting BioNTech&#8217;s Exclusive License with respect to ONC-392 and Anti-CTLA-4 Antibodies) as of the date of the expiration of the Option Period, (iii) neither AI-061 nor any AI-061 Product will be a Licensed Product hereunder and BioNTech will no longer have the right to pursue AI-061 or AI-061 Products as a Licensed Product or as a Mono&#47;PD-1 Combination hereunder for lack of rights to AI-025 provided that BioNTech shall still have its Exclusive License to ONC-392, including the right to exclude others from Exploiting ONC-392 as included in AI-061 or AI-061 Products, and (iv) all rights granted to BioNTech with respect to AI-025 (including, for clarity, rights to AI-025 included in AI-061 or AI-061 Products and the AI-025 Label License) shall terminate.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensing of Rights by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">BioNTech Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the requirements of Section&#160;2.3(b), BioNTech will have the right to grant Sublicenses (through one or multiple tiers) of the rights granted to BioNTech pursuant to Section&#160;2.1(a) to its Affiliates and Third Parties without the need in any case to obtain the prior written consent of OncoC4.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Sublicense Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Sublicense granted by BioNTech to a Third Party pursuant to Section&#160;2.3(a) will be in writing and will be subject and subordinate to, and consistent with, the terms and conditions of this Agreement.  No Sublicense will diminish, reduce or eliminate any obligation of either Party under this Agreement.  BioNTech will be liable for any act or omission of any Sublicensee that is in breach of any of BioNTech&#8217;s obligations under this Agreement as though the same were a breach by BioNTech, and OncoC4 will have the right to proceed directly against BioNTech without any obligation to first proceed against such Sublicensee.  Each Sublicense will contain the following provisions&#58; (i) a requirement that the Sublicensee comply with all applicable terms of this Agreement (including confidentiality and intellectual property provisions consistent with those set forth herein) and the Upstream Agreements, (ii) without limiting the foregoing, if such Sublicense contains a right to Commercialize any of the Licensed Products, such Sublicense will also contain the following provisions&#58; (A)&#160;a requirement that the Sublicensee submit applicable reports to BioNTech to the extent necessary or relevant to allow BioNTech to prepare or keep the reports required to be made or records required to be maintained under this Agreement, and (B) a requirement that allows BioNTech to perform an audit of such Sublicensee consistent with the audit requirement set forth in Section&#160;7.8, with the results thereof to be reportable to OncoC4.  Any Sublicense granted hereunder that is inconsistent with this Section&#160;2.3(b) will be null and void.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance by Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party may contract or delegate any portion of its obligations hereunder to a Third Party contractor subject to Section&#160;15.8&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) the contractor undertakes in writing commercially reasonable obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to ARTICLE IX hereof&#59; and (ii) the contractor undertakes in writing to assign or exclusively license back (with the right to sublicense) all intellectual property with respect to the Licensed Compound or a Licensed Product developed in the course of performing any such work to the Party retaining such contractor.  In addition, notwithstanding the foregoing, any such contracting or delegation by OncoC4 shall be only with BioNTech&#8217;s advance, written consent, except with respect to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4 Affiliate, Service Provider or subcontractor listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the performance by any Service Provider of activities involving a BioNTech Product hereunder shall be subject to the satisfactory completion of any customary and reasonable vendor qualification process requested by BioNTech and approved by the JSC.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Exclusive License and the rights granted under Section&#160;2.1(a) are subject to the retained, non-exclusive right of OncoC4 and its Affiliates to use and practice the Licensed Know-How, Licensed Patents, &#91;***&#93; to perform its obligations under this Agreement and the Upstream Agreements (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reserved Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and do not include any rights not expressly granted to BioNTech hereunder.  No rights, other than those expressly set forth in this Agreement, are granted to either Party under this Agreement, and no additional rights beyond those expressly set forth herein will be deemed granted to either Party by implication, estoppel or otherwise, with respect to any intellectual property rights.  All rights not expressly granted by either Party or its Affiliates to the other Party under this Agreement are reserved.  Neither Party nor any of its Affiliates will use or practice any Know-How or Patents licensed or provided to such Party or any of its Affiliates under this Agreement outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement.  For clarity, the Exclusive License and the rights granted under Section&#160;2.1(a) shall not include any right or license under the Licensed Know-How or Licensed Patents to any Other Active which Other Active is Claimed by any Patent Controlled by OncoC4 and where such Claim applies to such Other Active independently of its inclusion in a Combination Product.  If requested by either Party, the Parties will negotiate in good faith, either as a separate written agreement or an amendment to this Agreement, with respect to any other product Controlled by OncoC4 or its Affiliates that is used in combination with the Licensed Compound, if any.  For further clarity, to the extent that a Licensed Patent is directed to the combination of a Licensed Compound or Licensed Product with an Other Active, the foregoing sentences are not intended to limit BioNTech&#8217;s rights to such Patent as it relates to such combination or BioNTech&#8217;s rights to Exploit such combination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each case, that BioNTech&#8217;s rights to Exploit such Other Active in such combination are derived independently of OncoC4, its Affiliates and the CDP.  Moreover, it is understood that for any Patents that are Controlled by OncoC4 or its Affiliate that Claim combination therapies or protocols that include a Licensed Compound or Licensed Product, such Patents are included in the Licensed Patents (subject to this Section 2.5) and nothing in this Section is intended to prevent BioNTech from Developing or Commercializing any Licensed Product for or with a label for use in such combination&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each case, that any rights BioNTech or its Affiliate have or may need to Exploit the other product(s) in such combination (i.e., other than a Licensed Compound or Licensed Product) are derived independently of OncoC4, its Affiliates and this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Other than in the performance of activities under this Agreement, during the period commencing on the Execution Date and ending on the date of the First Commercial Sale of the first Licensed Product in any country in the Territory&#58; (i) OncoC4 shall collaborate exclusively with BioNTech for the Development, Manufacturing and Commercialization of Licensed Products&#59; and (ii) OncoC4 shall not (and will not permit its Affiliates to and hereby covenants that they shall not), Exploit, either alone or directly or indirectly with any Third Party, collaborate with, enter into an arrangement with, work for the benefit of, grant any license to (or assign, sell or transfer rights to) or otherwise knowingly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enable any Third Party to Exploit, any Anti-CTLA-4 Antibody, or any product with a mechanism of action that is the same as an Anti-CTLA-4 Antibody.  It is understood that such product may have one or more additional mechanisms of action, in addition to that of an Anti-CTLA-4 Antibody, such as but not limited to the cases of a protein with multiple targeting moieties and&#47;or with a targeting moiety and a payload.  For the avoidance of doubt, the exclusivity covenants set forth in this Section&#160;2.6(a) shall not apply to CD80&#47;CD86 Compounds, and nothing contained in this Section 2.6 shall prohibit, limit or otherwise restrict OncoC4 or its Affiliates from Exploiting CD80&#47;CD86 Compounds during or following the Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section&#160;2.6(a), if a Third Party becomes an Affiliate of OncoC4 through merger, acquisition, consolidation or other similar transaction (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">New Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and such New Affiliate, as of the effective date of such transaction, is engaged in Exploitation activities that, if conducted by OncoC4, would be in breach of its exclusivity obligations set forth in Section&#160;2.6(a) (such Exploitation activities, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)  then&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If such transaction results in a Change of Control of OncoC4, then such New Affiliate shall have the right to continue such Competing Program and such continuation shall not constitute a breach by OncoC4 of its exclusivity obligations set forth in Section&#160;2.6(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (A)&#160;such New Affiliate conducts such Competing Program independently of the activities under this Agreement and does not use any Licensed Know-How, &#91;***&#93;, BioNTech Technology or any Confidential Information of BioNTech in the conduct of such Competing Program&#59; (B)&#160;OncoC4 and such New Affiliate institute commercially reasonable technical and administrative procedures and safeguards designed to ensure that the requirements set forth in the foregoing clause (A) are met, including by creating &#8220;firewalls&#8221; between (X) the personnel working under such Competing Program and (Y) the personnel working on activities under the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that senior management personnel may review and evaluate plans and information regarding the research, development and commercialization of such Competing Program in connection with product portfolio decision-making, but shall not disclose information regarding Development, Commercialization, or any Licensed Product under this Agreement to the personnel directly working on the Competing Program&#59; and (C) OncoC4 shall continue to co-fund Development under the CDP, but (1) the JSC shall disband, (2) BioNTech shall only be required to provide an annual, high level summary report as to its Development program hereunder but shall not be required to provide interim (quarterly) reporting nor information as to its future plans, (3) OncoC4 shall not have the right or any obligation (subject to a reasonable transition period to be mutually agreed upon by the Parties) to conduct any further Development of Licensed Products, (4) the license granted to OncoC4 under Section&#160;2.1(b) shall terminate&#59; and (5) BioNTech shall have sole discretion over changes to the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 shall retain its rights under Section 7.8, &#91;***&#93;.  Notwithstanding the foregoing, in the event such New Affiliate does not intend to continue such Competing Program (including if such New Affiliate is required under applicable competition Laws to divest or wind down the Competing Program), the Parties shall discuss in good faith and mutually agree on procedures and safeguards to implement during a reasonable period (not to exceed &#91;***&#93; months or a shorter period prescribed by Law, if applicable) following the closing of such Change of Control during which such New Affiliate may divest or wind down the Competing Program as promptly as practicable, such divestment or wind down shall not constitute a breach by OncoC4 of its exclusivity obligations set forth in Section&#160;2.6(a), and clauses (1) through (5) above shall not apply assuming such procedures and safeguards are implemented and such divestment or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">wind down is completed within the mutually agreed period, not to exceed &#91;***&#93; months or a shorter period if prescribed by Law, if applicable, following the closing of such Change of Control.  Notwithstanding the foregoing, if BioNTech exercises the Option in accordance with Section 2.2 and this Section 2.6(b)(i) comes into effect, the Parties and the New Affiliate shall discuss in good faith and mutually agree on commercially reasonable terms and conditions to govern their ongoing interactions with respect to ONC-392, AI-025 and AI-061, which terms and conditions shall provide for, at a minimum, the sharing of information between the Parties as required by applicable Law and such other matters as may be necessary for each Party and their Affiliates to comply with applicable Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If such transaction does </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> result in a Change of Control of OncoC4, then OncoC4 and its New Affiliate shall have &#91;***&#93; months from the closing date of such transaction to wind down (or otherwise cease or suspend all Exploitation activities) or divest such Competing Program, and its New Affiliate&#8217;s conduct of such Competing Program during such &#91;***&#93; month period shall not constitute a breach by OncoC4 of its exclusivity obligations set forth in Section&#160;2.6(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">BioNTech Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section 2.6(a), if a Third Party becomes a New Affiliate of OncoC4 and such New Affiliate is a BioNTech Competitor, then, regardless of whether the New Affiliate is engaged in any Competing Program&#58; (A) such New Affiliate shall not use any Licensed Know-How, &#91;***&#93;, BioNTech Technology or any Confidential Information of BioNTech in the conduct of its business or activities&#59; (B) OncoC4 and such New Affiliate shall institute commercially reasonable technical and administrative procedures and safeguards designed to ensure that the requirements set forth in the foregoing clause (A) are met, including by creating &#8220;firewalls&#8221; between (X) the personnel working under any activities of the New Affiliate and (Y) the personnel working on activities under the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that senior management personnel may review and evaluate plans and information regarding the business activities of the New Affiliate in connection with product portfolio decision-making, but shall not disclose information regarding Development, Commercialization, or any Licensed Product under this Agreement to the personnel directly working for the New Affiliate&#8217;s activities&#59; and (C) OncoC4 shall continue to co-fund Development under the CDP, but (1) the JSC shall disband, (2) BioNTech shall only be required to provide an annual, high level summary report as to its Development program hereunder but shall not be required to provide interim (quarterly) reporting nor information as to its future plans, (3) OncoC4 shall not have the right or obligation (subject to a reasonable transition period to be mutually agreed upon by the Parties) to conduct any further Development of Licensed Products, (4) the license granted to OncoC4 under Section 2.1(b) shall terminate&#59; and (5) BioNTech shall have sole discretion over changes to the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 shall retain its rights under Section&#160;7.8, and&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4&#8217;s co-funding commitment shall not exceed its co-funding obligations as set forth in the last CDP and Joint Development Budget approved by the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in accordance with this Agreement (but not pursuant to an exercise by BioNTech of its final decision-making authority after becoming aware of a proposed transaction involving OncoC4 and a BioNTech Competitor) in effect prior to the closing of the effective date of the transaction contemplated under this Section&#160;2.6(c), and BioNTech&#8217;s right to amend the CDP shall not include the right to impose additional co-funding or any other obligations on OncoC4.  Notwithstanding the foregoing, if BioNTech exercises the Option in accordance with Section 2.2 and this Section&#160;2.6(c) comes into effect, the Parties and the New Affiliate shall discuss in good faith and mutually agree on commercially reasonable terms and conditions to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">govern their ongoing interactions with respect to ONC-392, AI-025 and AI-061, which terms and conditions shall provide for, at a minimum, the sharing of information between the Parties as required by applicable Law and such other matters as may be necessary for each Party and their Affiliates to comply with applicable Laws. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Upstream Agreements and AI Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any rights granted to BioNTech under this Agreement are Controlled by OncoC4 pursuant to an Upstream Agreement, &#91;***&#93;.  Unless otherwise expressly agreed by the Parties in writing, OncoC4 shall be solely responsible for any payments due to the Third Party licensors under any Upstream Agreement as a result of any sublicense granted to BioNTech hereunder and BioNTech&#8217;s or its Affiliate&#8217;s or a Sublicensee&#8217;s exercise of such sublicense in accordance with the terms therein and herein.  Except as otherwise mutually agreed by the Parties in writing or contemplated by this Agreement, OncoC4 shall timely perform its obligations under each of the Upstream Agreements in all material respects and maintain them in full force and effect during the Term (subject to the expiration provisions of each Upstream Agreement), including timely payment of all amounts due to be paid by OncoC4 thereunder.  Except as otherwise mutually agreed by the Parties in writing or contemplated by this Agreement, OncoC4 shall not amend any Upstream Agreement or the AI Agreements during the Term in a manner that would or would reasonably be expected to adversely affect BioNTech in any material respect without BioNTech&#8217;s advance, written consent.  &#91;***&#93;  In accordance with the provisions of the &#91;***&#93; License, a copy of the &#91;***&#93; License is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as reasonably practicable following the Effective Date (or the date of the joint press release contemplated by Section 9.2(a), if earlier), OncoC4 shall be permitted to disclose this Agreement and BioNTech&#8217;s identity with respect to this Agreement to &#91;***&#93;, and OncoC4 shall use Commercially Reasonable Efforts to obtain a written waiver or amendment of the &#91;***&#93; License to clarify that BioNTech is not subject to the sublicensing requirements under the &#91;***&#93; License.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">BioNTech Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless otherwise mutually agreed by the Parties in writing, and notwithstanding anything contained herein, BioNTech shall be solely responsible for any payments due to Third Parties (a) in respect of BioNTech Products or Other Actives Controlled by Third Parties, or (b) as a result of any sublicense granted to OncoC4 hereunder and OncoC4&#8217;s exercise of such sublicense in accordance with the terms hereof, except to the extent otherwise mutually agreed by the Parties in writing and provided in the CDP and Joint Development Budget. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer of Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As promptly as reasonably practicable after the Effective Date, OncoC4 will use Commercially Reasonable Efforts to disclose and make available to BioNTech copies or other tangible embodiments of the Licensed Know-How that exists as of the Effective Date, including transfers of the items of Licensed Know-How in the scope and forms or formats and on the timelines to be agreed upon by the Parties within &#91;***&#93; days following the Effective Date.  During the Term, OncoC4 will use reasonable efforts to respond to any reasonable requests by BioNTech for additional Licensed Know-How that is Controlled by OncoC4 and relates to the Development and Manufacture of the Licensed Compound or and Licensed Products, in the form such Licensed Know-How is maintained by OncoC4 or as otherwise mutually agreed by the Parties.  OncoC4 shall, upon or promptly following the Effective Date, provide to BioNTech a copy of the &#8220;data room&#8221; made available to BioNTech that OncoC4 established for BioNTech&#8217;s review during the negotiation of this Agreement, including its index and all of its contents as of the Effective Date, in an electronic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">format reasonably agreed upon by the Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such format shall be a format supported by OncoC4&#8217;s &#8220;data room&#8221; vendor and shall allow for downloading (if such format is online), copying and printing (for clarity, it is agreed and acknowledged that such copy of the &#8220;data room&#8221; shall not include the &#91;***&#93; Agreement).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:0.38pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Diligence&#59; Development Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Joint Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Joint Clinical Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 and BioNTech shall use Commercially Reasonable Efforts to conduct Development activities with respect to the Licensed Compound and Licensed Products, either as a monotherapy or in combination solely with a PD-1 Product (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mono&#47;PD-1 Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case, in accordance with a joint clinical development plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) approved by the JSC in accordance with the terms of this Agreement.  The CDP shall include the following items for the remainder of the then-current Calendar Year and the following Calendar Year (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (i) the proposed overall program of Development of Licensed Products in Mono&#47;PD-1 Combinations, including Clinical Trials, and regulatory plans and other elements of obtaining Regulatory Approvals of such Licensed Products in the Field in the Territory, including Development activities for AI-061 until Completion of the first Phase 1 Trial of AI-061 (and if BioNTech exercises the Option, additional Development activities for AI-061, including regulatory plans and other elements of obtaining Regulatory Approval for AI-061)&#59; (ii) the anticipated start dates and data availability dates of such Clinical Trials, and anticipated timelines and strategies for filing of applications for Regulatory Approvals in the Territory&#59; (iii) the respective roles and responsibilities of each Party in connection with such joint Development activities (including sponsorship of Clinical Trials)&#59; (iv) a detailed budget for all such joint Development (including Manufacturing) activities in the Field in the Territory for the Covered Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (v) such other items as may be approved by the JSC.  An initial draft of the CDP and estimates for the Joint Development Budget are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Parties agree and acknowledge that a complete CDP including all elements described above will be negotiated in good faith and approved by the JSC as promptly as practicable (but not more than &#91;***&#93; days) following the Effective Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that except to the extent otherwise approved by the JSC, such complete CDP shall be consistent with the initial draft CDP set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in all material respects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Amendments to the CDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On an annual basis no later than &#91;***&#93; of each Calendar Year, or by such date or more often as the Parties mutually agree, the Parties shall, through the JSC, prepare amendments to the then-current CDP including a proposed CDP and Joint Development Budget for the immediately following Covered Period, and which amendments shall be finalized, approved, and included into such CDP by the JSC, no later than &#91;***&#93; of each Calendar Year for the next Calendar Year.  Each such amended CDP shall specify the items described in Section&#160;3.1(a).  Such amended Joint Development Budget shall reflect the Parties&#8217; good faith estimate of the costs of the activities set forth in the CDP and include an updated rolling budget for the Development activities to be performed during the relevant Covered Period (broken down by Calendar Quarter under the CDP), and a forecast of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">anticipated Joint Development Budgets for each subsequent Calendar Year thereafter through completion of all Development activities set forth in such CDP.  Such updated and amended CDP shall reflect any changes (including any transfer of sponsorship of any Clinical Trials to be effected in accordance with this Agreement), re-prioritization of studies within, reallocation of resources with respect to, or additions to, respectively, the then-current CDP and Joint Development Budget.  Once approved by the JSC, the amended CDP (including the corresponding amended Joint Development Budget) shall become effective for the applicable period on the date approved by the JSC (or such other date as the JSC shall specify).  Any such approved amended CDP (including the corresponding amended Joint Development Budget) shall supersede, respectively, the previous CDP and Joint Development Budget. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">BioNTech Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech shall have the right (directly, or through its Affiliates and Sublicensees), and shall be solely responsible for all Development activities for the Licensed Compound and Licensed Products in any other form or combination other than the Mono&#47;PD-1 Combinations (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at its own expense, and in accordance with a research and development plan at a summary level of detail (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) prepared by BioNTech and shared with OncoC4 through the JSC.  BioNTech shall use Commercially Reasonable Efforts to Develop a Licensed Product in at least one (1) Indication for an Other Combination.  Without limiting BioNTech&#8217;s obligations set forth above in this Section 3.1(b), within &#91;***&#93; days following the Effective Date, and within &#91;***&#93; days following January 1 of each Calendar Year during the Term, BioNTech shall provide the JSC with a (i) then-current BioNTech Development Plan that summarizes the major research and Development activities reasonably anticipated to be undertaken by or on behalf of BioNTech with respect to the Licensed Compound and Licensed Products outside the CDP and Joint Development Program and (ii) commencing in the Calendar Year following BioNTech&#8217;s initial delivery of the BioNTech Development Plan, an annual summary update with respect to its Development activities taken during the prior Calendar Year, which may consist of a PowerPoint presentation or other written elements which would then be shared with all JSC members.  BioNTech may update the BioNTech Development Plan at its discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that BioNTech shall promptly notify OncoC4 or the JSC of any material adverse changes to the BioNTech Development Plan or the activities thereunder (e.g., a decision to cease Development of a Licensed Product or Indication).  BioNTech shall also include in each BioNTech Development Plan any Development of Mono&#47;PD-1 Combinations that it plans to conduct or has conducted outside the Joint Development Program&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, subject to the terms of any written agreement between BioNTech and a Third Party in respect of the PD-1 component of such Mono&#47;PD-1 Combinations (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BNT PD-1 License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), BioNTech shall first offer to OncoC4 in good faith, by delivery of written notice, the opportunity for OncoC4 to co-fund any and all Development of Mono&#47;PD-1 Combinations under an amended CDP (which offer shall remain open for at least &#91;***&#93; days following BioNTech&#8217;s written notice, and during such period the Parties shall discuss in good faith the possibility of adding such Mono&#47;PD-1 Combination to the CDP and BioNTech shall provide or cause to be provided to OncoC4 such information as OncoC4 may reasonably request within the first &#91;***&#93; days following BioNTech&#8217;s written notice (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such &#91;***&#93; day period shall not limit the obligation of the Parties to discuss relevant matters in good faith during such &#91;***&#93; day period or prevent OncoC4 from asking reasonable follow-up questions) in respect of such Mono&#47;PD-1 Combination), in each case, prior to pursuing such Development independently or with a Third Party and in accordance with all applicable confidentiality obligations and restrictions hereunder. In the event that as of the date of such written notice to OncoC4, there is a BNT PD-1 License, then, subject to any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">confidentiality obligations to such Third Party, BioNTech will include in its written notice reasonable information pertaining to such BNT PD-1 License, in order for OncoC4 to evaluate whether or not to elect to co-fund any or all Development of the Mono&#47;PD-1 Combinations.  Notwithstanding any other provision of this Agreement, if the terms of a BNT PD-1 License prevent OncoC4 from co-funding the Development of a Mono&#47;PD-1 Combination under an amended CDP, and because of such BNT PD-1 License such Development is not conducted under the CDP, the Parties shall discuss in good faith appropriate amendments to Section 7.4(a) so that OncoC4 is not prevented from earning an equitable portion of any Development Milestone Payment(s) as a result of such BNT PD-1 License.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Development Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will conduct its Development activities under this Agreement and the CDP in good scientific manner and in compliance with all applicable Laws, including GLP and GCP, as applicable, current standards for pharmacovigilance practice, and all applicable requirements relating to the protection of human subjects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Joint Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Section&#160;3.2, all Joint Development Costs incurred in accordance with the CDP and Joint Development Budget shall be shared equally (50&#47;50) between BioNTech and OncoC4 in accordance with Section&#160;7.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Excess Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party shall promptly inform the JSC in writing upon such Party determining that it has incurred or is likely to incur Joint Development Costs for a Calendar Year that exceed the portion of the Joint Development Costs allocated to such Party in the Joint Development Budget for such Calendar Year (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excess Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  To the extent such Excess Development Costs fall under the definition of &#8220;Joint Development Costs,&#8221; they shall be treated as Joint Development Costs hereunder and shared equally (50&#47;50) between the Parties.  In the event either Party identifies Excess Development Costs, the Parties shall discuss in good faith through the JSC the Joint Development Costs that are necessary and reasonable in order to perform the activities set forth in the CDP and any proposed amendments to the Joint Development Budget.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">AI-061 Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained herein or in the CDP or Joint Development Budget, BioNTech&#8217;s share of Joint Development Costs for the first Phase 1 Trial of AI-061 shall not exceed &#91;***&#93; unless otherwise mutually agreed by the Parties through the JSC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 may elect to fund Joint Development Costs for AI-061 incurred in accordance with the CDP that BioNTech is not responsible for as a result of this Section&#160;3.2(c) and the Parties shall continue to conduct the activities with respect to AI-061 set forth in the CDP.  For clarity, OncoC4 shall have no obligation to fund any such additional Joint Development Costs for AI-061, and if OncoC4 does not elect to fund such additional Joint Development Costs for AI-061, the Parties shall promptly wind down and terminate Development activities in support of AI-061. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">BioNTech Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech shall be solely responsible for (i) all Development costs incurred by or on behalf of BioNTech in respect of Other Combinations and BioNTech Products&#59; (ii) BioNTech&#8217;s share of Joint Development Costs </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incurred in accordance with this Agreement and the CDP&#59; and (iii) all costs incurred by or on behalf of BioNTech in respect of Development outside the Joint Development Program and CDP.  Nothing in this Agreement shall be read to prevent BioNTech (and those deriving rights from BioNTech) from Developing any Mono&#47;PD-1 Combinations outside the Joint Development Program and CDP (provided that prior to doing so, in accordance with Section&#160;3.1(b), BioNTech will offer to OncoC4 the opportunity the co-fund the applicable Development under the Joint Development Program). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Covenant of OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At all times prior to the completion of the activities contemplated by the CDP, OncoC4 and its Affiliates, collectively, shall maintain sufficient cash reserves, liquid assets, or other sources of immediately available funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in each case, with reputable financial institutions selected by OncoC4 in accordance with industry practice and the exercise of its reasonable business judgment), as reasonably necessary for OncoC4 to fund its share of Joint Development Costs during the following &#91;***&#93; months as such Joint Development Costs are anticipated in a then-current, Joint Development Budget approved by the JSC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) OncoC4 shall have at least &#91;***&#93; months following approval of a new Joint Development Budget or material amendment thereto to acquire such reserves, assets or funds and (ii) upon BioNTech&#8217;s reasonable request (not more than once per Calendar Year absent OncoC4&#8217;s failure to comply with this Section 3.2(e) or make an undisputed payment under this Agreement or the CDP), OncoC4 shall provide BioNTech with reasonable documentary evidence reasonably satisfactory to BioNTech (acting in good faith) of its compliance with this Section 3.2(e).  Without limiting the foregoing, upon BioNTech&#8217;s reasonable request (not more than once per Calendar Year without cause), OncoC4 shall disclose to BioNTech the financial institution(s) that hold the assets of OncoC4 and its Affiliates that satisfy the conditions of this Section 3.2(e).  BioNTech may comment on such financial institutions and OncoC4 will in good faith take into account and consider BioNTech&#8217;s reasonable and timely suggestions regarding OncoC4&#8217;s choice of financial institution(s).  For the avoidance of doubt, nothing in this Section 3.2(e) shall require OncoC4 or any of its Affiliates to maintain segregated accounts or restricted cash in order to satisfy its obligations hereunder.  If OncoC4 is ever not in compliance with this covenant, OncoC4 shall promptly notify BioNTech in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Certain Development Costs Related to AI-025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If (i)&#160;BioNTech exercises the Option, (ii) the first product containing AI-025 to receive Regulatory Approval in any Major Market is AI-061, and (iii) a Combination Product Controlled by OncoC4 containing AI-025 and one (1) or more Other Actives subsequently receives Regulatory Approval in the same Major Market, then, only in the case of (i), (ii) and (iii), BioNTech may deduct from the royalties payable to OncoC4 under Section&#160;7.5 with respect to AI-061 an amount equal to &#91;***&#93; of all Joint Development Costs incurred by BioNTech to Develop AI-061 for the Indication subject of such first Regulatory Approval of AI-061 up to the date of such first Regulatory Approval of AI-061.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Records and Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall maintain complete and accurate records of all work conducted by or on behalf of such Party in furtherance of seeking Regulatory Approval for Licensed Products in the Field in the Territory.  Such records will be maintained in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance with applicable Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall periodically provide to the JSC, on a Calendar Quarter basis or more frequently as reasonably requested by the JSC, an update regarding Development activities conducted by or on behalf of such Party with respect to each Licensed Product under the then-current CDP.  In addition, each Party shall promptly share with the other Party all material developments and information that it comes to possess relating to the Development or Manufacturing of any Licensed Products and all other data and information that either Party may reasonably request to support the filing of Regulatory Materials in a mutually agreed format, including, without limitation, (i) safety concerns and adverse event reports for Licensed Products, and (ii) study reports and data generated from Clinical Trials of such Licensed Products.  Without limiting the generality of the foregoing, each Party shall promptly report to the other Party in writing material developments which are reasonably expected to be materially detrimental to Development, including manufacturing failures.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Clinical Trial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees that (i) each Clinical Trial conducted pursuant to the CDP or the BioNTech Development Plan that is required to be posted pursuant to applicable Law or applicable industry codes, including the PhRMA Code, on clinicaltrials.gov or any other similar registry shall be so posted, and (ii) all results of such Clinical Trials that are necessary for obtaining a Regulatory Approval for a Licensed Product in the Territory shall be posted on clinicalstudyresults.org and on any other registry with requirements consistent with the registration and publication guidelines of the International Committee of Medical Journal Editors, to the extent required.  All data and information posted on clinicaltrials.gov, clinicalstudyresults.org or any other registry pursuant to this Section&#160;3.3(c) shall be subject to prior review and authorization (subject to requirements of applicable Law), pursuant to Sections&#160;9.2(c) and 9.2(e).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Data Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to its adverse event and safety data reporting obligations set forth in Section&#160;4.3, each Party shall promptly provide the other Party with copies of all data and results and all supporting documentation (e.g., protocols, Investigator&#8217;s Brochures, case report forms, analysis plans) Controlled by such Party that are generated by or on behalf of such Party or its Affiliates, Service Provider, Sublicensees, or contractors, if applicable, in the Development of Licensed Products in the Joint Development Program.  For such items arising outside the Joint Development Program (i.e., in BioNTech&#8217;s independent development not governed by the CDP), the JSC shall discuss in good faith the information to be provided to OncoC4, if any, beyond the required reporting under Section&#160;4.3 to support OncoC4&#8217;s activities under the CDP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in all events, BioNTech shall provide to OncoC4 such items as may be necessary or reasonably advisable for OncoC4 or its Affiliates or sublicensees to satisfy regulatory or other legal requirements.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.04pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REGULATORY MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Submissions and Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Regulatory Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech will be responsible for all regulatory activities relating to the Licensed Products, including preparing and filing all MAAs and seeking all Regulatory Approvals for the Licensed Products in the Field in the Territory in accordance with the CDP or BioNTech Development Plan, as applicable, except for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory activities that are expressly delegated or transferred to OncoC4 in the CDP, as approved by the JSC, or as expressly set forth in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Sponsorship of Clinical Trials and Ownership of Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As between the Parties, unless otherwise agreed between the Parties through the JSC, OncoC4 shall (i) be the sponsor for Clinical Trials of Licensed Products that are Mono&#47;PD-1 Combinations that are conducted under the CDP&#59; and (ii) own all Regulatory Materials, including INDs and all submissions for the Clinical Trials under subclause (i).  Notwithstanding the foregoing, (A) upon BioNTech&#8217;s reasonable request, which request may be made any time following the first anniversary of the Effective Date, and the JSC&#8217;s good faith discussion, OncoC4 shall transfer or cause to be transferred to BioNTech as promptly as practicable in accordance with applicable Law, sponsorship of any such Clinical Trial for which OncoC4 is the sponsor under the CDP, including any Regulatory Materials related thereto, as so approved by the JSC (for clarity, subject to Section&#160;6.5(a))&#59; and (B) if such sponsorship and Regulatory Materials have not already been transferred to BioNTech pursuant to subclause (A), six (6) months prior to the planned MAA submission for Regulatory Approval of a Licensed Product in a particular Indication, OncoC4 shall transfer or cause to be transferred to BioNTech as promptly as practicable in accordance with applicable Law, sponsorship of any Clinical Trial for which OncoC4 is the sponsor under the CDP (and transfer or make available to the extent not previously delivered or made available) all Regulatory Materials (including but limited to, the INDs) for the applicable Licensed Product.  In each case (A) and (B), the Parties shall cooperate to submit such notifications and any other documents or instruments required by the applicable Regulatory Authority to effect the transfer of such sponsorship Regulatory Materials, as applicable.  Furthermore, notwithstanding the foregoing, BioNTech will be the sponsor for and will own all Regulatory Materials, including all INDs and submissions for any Clinical Trials (1) conducted under the BioNTech Development Plan, or (2)&#160;set forth in the CDP or otherwise approved by the JSC for BioNTech to be the sponsor of, and any Regulatory Approval for the Licensed Products in the Field in the Territory.  For the avoidance of doubt, any transfer of sponsorship of a Clinical Trial contemplated hereby shall be conducted under the oversight of the JSC in accordance with ARTICLE VI. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Delegation or Transfer of Responsibilities for Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that BioNTech has exercised its right under this Agreement to transfer sponsorship of any Clinical Trial(s) for which OncoC4 was originally the sponsor under the CDP to BioNTech and the JSC has approved such transfer in accordance with this Agreement (for clarity, subject to Section&#160;6.5(a)), BioNTech may, notwithstanding the transfer of sponsorship thereof, delegate or transfer all or part of its responsibilities with respect to such Clinical Trial to OncoC4, in each case, as discussed and approved by the JSC in accordance with this Agreement (for clarity, subject to Section&#160;6.5(a)), and in such instance the Parties shall promptly enter into an agreement delegating such responsibility in accordance with 21 C.F.R. &#167;312.52, or any equivalent requirement in other jurisdictions or countries outside of the U.S., and shall cooperate to submit any such other notifications or other documents or instruments required by the applicable Regulatory Authority to effect such transfer or delegation of responsibilities.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Right of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby grants to the other Party, and such other Party&#8217;s Affiliates and Sublicensees, a right to cross-reference or incorporate by reference any Regulatory Materials and any Regulatory Approval Controlled by such Party for any Licensed Product, and all data and other Know-How included or referenced therein or filed in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">support thereof, subject to the scope of the licenses granted under Section&#160;2.1, for the purpose of the other Party, its Affiliates or any Sublicensee conducting its or their designated regulatory activities, including, where applicable, applying for Clinical Trials and, in BioNTech&#8217;s case, seeking or maintaining Regulatory Approvals, in each case, for Licensed Products in the Field in the Territory as permitted under this Agreement and to otherwise enable such Party to fulfill its obligations or in the case of BioNTech exercise its rights hereunder with respect to Licensed Products in the Territory.  Notwithstanding anything express or implied in the foregoing, BioNTech grants no right to cross-reference or incorporate by reference any Regulatory Materials to the extent specifically pertaining to any BioNTech Product included in a Combination Product, and unless otherwise mutually agreed by the Parties, OncoC4 shall have no right to apply for any Regulatory Approval for any Licensed Product anywhere in the world. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Regulatory Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will share with the other Party any existing or new regulatory information Controlled by such Party (including in relation to any INDs with respect to any Licensed Product) generated or received from Regulatory Authorities with respect to the Development of the Licensed Compound and Licensed Products, and each Party shall reasonably cooperate and support the other Party in all regulatory activities related to the Licensed Compound and Licensed Products in the Field in the Territory.  Without limiting the foregoing&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">With respect to any Clinical Trial for Licensed Products in any Mono&#47;PD-1 Combination which either (A) OncoC4 Controls and is the sponsor, or (B) BioNTech is the sponsor but has delegated or transferred all or part of its responsibilities with respect to such Clinical Trial to OncoC4, (I) OncoC4 shall promptly share with BioNTech all material information and all written correspondence received by OncoC4 or its Affiliate from a Regulatory Authority (or that otherwise is in OncoC4&#8217;s possession or control and for which OncoC4 is not prohibited from sharing with BioNTech pursuant to any agreement with a Third Party) relating to such Clinical Trial, and (II) BioNTech shall have the right to review, comment, amend and approve (not to be unreasonably withheld, conditioned or delayed with respect to any Clinical Trial for which OncoC4 is the sponsor) any submissions or correspondence relating to such Clinical Trial prior to OncoC4 filing with relevant Regulatory Authorities (provided, that with respect to any Clinical Trial for which OncoC4 is the sponsor, OncoC4 will have final decision-making authority with respect to such submissions or correspondence to the extent required by applicable Law or to comply with applicable Law, and nothing contained herein will prevent OncoC4 from making any submission that is necessary in order to comply with applicable Law), and, to the extent permitted by applicable Law and Regulatory Authorities, BioNTech shall have the right but not the obligation to attend all meetings or calls with such Regulatory Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">BioNTech shall keep the JSC and OncoC4 reasonably informed of any material regulatory activities, communications and correspondences with a Regulatory Authority, and shall provide OncoC4 opportunities to review and comment on material regulatory submissions or correspondences, in each case, relating to any Licensed Compound or any Licensed Product, subject to OncoC4&#8217;s compliance with its confidentiality obligations or restrictions.  BioNTech shall consider OncoC4&#8217;s timely comments thereon in good faith.  In relation to meetings regarding Mono&#47;PD-1 Combinations BioNTech will provide OncoC4 with reasonable advance notice of any scheduled meeting with any Regulatory Authority relating to regulatory matters for the Licensed Compound or any Licensed Product, and, to the extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permitted by applicable Law and Regulatory Authorities, OncoC4 shall have the right but not the obligation to attend any meetings or call with such Regulatory Authority as an observer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Health Authority Inspections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will cooperate in good faith with respect to Regulatory Authority inspections of any site or facility where Clinical Trials or Manufacturing of the Licensed Compound or Licensed Products are conducted pursuant to this Agreement (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Audited Site</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Subject to applicable Law, OncoC4 will be given a reasonable opportunity to attend any inspection by any Regulatory Authority of the Audited Sites, and the summary or wrap-up meeting with a Regulatory Authority at the conclusion of such inspection.  In the event that any Audited Site is found to be non-compliant with one or more of GLP, GCP, GMP or current standards for pharmacovigilance practice, BioNTech will submit to the JSC a proposed recovery plan or Corrective and Preventative Actions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CAPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) plan as soon as reasonably practicable after BioNTech, its Affiliates or Sublicensees or their permitted contractor receives notification of such non-compliance from the relevant Regulatory Authority and BioNTech will use reasonable efforts to implement such recovery plan or CAPA promptly after submission.  BioNTech agrees, to the maximum extent reasonably possible, to include in any contract or other written arrangement with its permitted contractors a clause permitting OncoC4 to exercise its rights under this Section&#160;4.1(f). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Recalls, Suspensions, and Withdrawals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall promptly notify the other Party (but in no event later than &#91;***&#93;) following its determination that any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal of a Licensed Product and shall include in such notice the reasoning behind such determination and any supporting facts.  As between the Parties, BioNTech shall have the final decision-making authority to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal during the Term&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that prior to any implementation of such a recall, market suspension or market withdrawal, BioNTech shall consult with OncoC4 and shall consider OncoC4&#8217;s comments in good faith.  If a recall, market suspension or market withdrawal of a Licensed Product is mandated by a Regulatory Authority, as between the Parties, BioNTech shall initiate such a recall, market suspension or market withdrawal in compliance with applicable Law.  BioNTech shall be responsible for all costs of any such recall, market suspension, or market withdrawal, except in the event and to the extent that a recall, market suspension or market withdrawal resulted from OncoC4&#8217;s material breach of its obligations hereunder or from OncoC4&#8217;s or its Representatives fraud, gross negligence or willful misconduct, in which case OncoC4 shall bear its proportionate share of the expense of such recall, market suspension or market withdrawal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days after the Effective Date and prior to commencement of any Clinical Trial for a BioNTech Product, the Parties will negotiate in good faith and finalize the actions that the Parties will employ with respect to Licensed Products to protect patients and promote their well-being in a written pharmacovigilance agreement in customary form and substance mutually agreed by the Parties and consistent with this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Pharmacovigilance Agreement shall delineate the Parties&#8217; responsibilities with respect to pharmacovigilance matters for Licensed Products and include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports and any other information concerning the safety of any Licensed Product, including recall and withdrawal responsibilities, processes and procedures.  Such guidelines and procedures will be in accordance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with, and enable the Parties to fulfill, local and national regulatory reporting obligations under applicable Laws.  Each Party hereby agrees to comply with its respective obligations under such Pharmacovigilance Agreement and to cause its Affiliates, Sublicensees and contractors to comply with such obligations.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.7pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANUFACTURE, SUPPLY AND COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture and Supply for Initial Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, until completion of the Technology Transfer as set forth in Section&#160;5.2, and subject to the terms and conditions of this Agreement, OncoC4 will, either by itself or via its Affiliates or a Third Party (i) Manufacture the Licensed Compound and Licensed Products (not including any Other Active) and supply the same to BioNTech for use in Development (including Clinical Trials) of Mono&#47;PD-1 Combinations in accordance with the CDP, and (ii) use Commercially Reasonable Efforts to Manufacture the Licensed Compound and Licensed Products (not including any Other Active) and supply the same to BioNTech for use in Development (including Clinical Trials) of Other Combinations for use under the BioNTech Development Plan.  Such Manufacture and supply by or on behalf of OncoC4 to BioNTech shall be governed by a written supply agreement to be negotiated in good faith and mutually agreed and entered into by the Parties as promptly as practicable (but not more than &#91;***&#93; days) following the Effective Date (as may be amended by mutual written agreement of the Parties from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Supply Agreement shall be in form and substance customary for a transaction of this type (for clarity, not customary for an arm&#8217;s-length Third Party supply arrangement), and include terms and conditions that are in all respects consistent with the terms, conditions, covenants and other arrangements contemplated by this Agreement (including, without limitation, with respect to the sharing of Joint Development Costs and the sharing of liabilities related to the Manufacture of Mono&#47;PD-1 Combinations for purposes of Development in accordance with the CDP), and BioNTech&#8217;s responsibility for the cost of Manufacturing for Other Combinations and the Commercialization of Licensed Products.  Except as provided under Section&#160;5.1(b) with respect to Joint Development Costs, the cost for Licensed Compound and Licensed Products supplied to BioNTech under the Supply Agreement will be the Fully Burdened Manufacturing Costs for such supply without any mark up.  The Parties will mutually agree on a mechanism for the payment or reconciliation of such costs.  Following the completion of the Technology Transfer contemplated by Section&#160;5.2, BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">either by itself or via its Affiliates or a Third Party, shall be responsible for all Manufacturing of Licensed Compounds and Licensed Products, including for the supply of the Licensed Compound and Licensed Products to OncoC4 for use by or on behalf of OncoC4 in the Development of Mono&#47;PD-1 Combinations accordance with the CDP.  Except as expressly provided in Section&#160;5.1(b), BioNTech will be responsible for the cost of all such Manufacturing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Manufacturing Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that the Fully Burdened Manufacturing Costs for Licensed Compound and Licensed Products for use in the Development of Mono&#47;PD-1 Combinations in accordance with the CDP shall be included in the Joint Development Costs to be shared by the Parties (whether such costs are incurred by OncoC4 after the Effective Date and prior to the completion of the Technology Transfer, or thereafter by BioNTech).  &#91;***&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Technology Transfer&#59; Further Development and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;5.2(c) with respect to AI-061, upon BioNTech&#8217;s written request, and to the extent permitted under applicable Third Party manufacturing agreements, OncoC4 shall (i) assign the manufacturing agreements with its Third Party manufacturer(s) relating to the Manufacture of the Licensed Compound and Licensed Products to BioNTech or its designee, or (ii) cause its Third Party manufacturer(s) of the Licensed Compound and Licensed Products to transfer the Manufacturing process of the Licensed Compound and Licensed Products, including any quality assurance, quality control and release assays Controlled by OncoC4 or its Affiliates or the applicable Third Party manufacturer, to BioNTech or its designated Third Party manufacturer to enable BioNTech or such Third Party manufacturer to Manufacture the Licensed Compound and Licensed Products (clauses (i) and (ii) together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Parties shall conduct the Technology Transfer in accordance with a mutually agreed technology transfer plan and budget, to be negotiated in good faith and mutually agreed by the Parties within &#91;***&#93; months following BioNTech&#8217;s written request for the Technology Transfer, which plan shall include (A) detailed activities and timelines for such Technology Transfer, and (B) reasonable on-site support and consultation to be provided by or on behalf of OncoC4.  The reasonable FTE Costs and Out-of-Pocket Costs of the Parties incurred in accordance with the Technology Transfer plan and budget in the conduct of such Technology Transfer shall be included in the Joint Development Costs and shared equally&#160;(50&#47;50) between the Parties.  For clarity, unless otherwise mutually agreed by the Parties in writing, &#91;***&#93; following the completion of such Technology Transfer in accordance with the Technology Transfer plan therefor, OncoC4 and its Affiliates shall have no further obligations or responsibilities with respect to conducting a Technology Transfer of ONC-392 or any other Anti-CTLA-4 Antibody except, if applicable, pursuant to Section 5.2(c).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Further Development and Commercial Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following completion of the Technology Transfer, unless otherwise mutually agreed by the Parties, BioNTech shall be solely responsible for the Manufacture and supply of the Licensed Compound and Licensed Products for all Development and Commercialization in the Field in the Territory, at its own cost, except to the extent that any such Manufacture and supply is for Development activities for Mono&#47;PD-1 Combinations included in the CDP, in which case the Fully Burdened Manufacturing Costs for such supply shall be included in the Joint Development Costs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Manufacture of AI-025 and AI-061</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless otherwise mutually agreed by the Parties in writing, the Technology Transfer pursuant to this Section&#160;5.2 shall not include an assignment of agreements for the Manufacturing of AI-025 to BioNTech or its designee but BioNTech shall have the right at any time following Option exercise to receive a technology transfer of the Manufacturing process for AI-025 and AI-061.  In that regard, Section 5.2(a) shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to provide for Technology Transfer of such processes for AI-025 and AI-061, except that OncoC4 shall not be required to assign its manufacturing contracts with respect to AI-025 and AI-061 to BioNTech.  OncoC4 shall provide all written permissions, consents, waivers, and instructions as BioNTech may reasonably request to facilitate disclosure and Technology Transfer from OncoC4&#8217;s or its Affiliates manufacturer(s) of AI-025 and AI-061 to BioNTech and&#47;or to allow BioNTech to contract with such manufacturer(s).  In addition, if BioNTech exercises the Option in accordance with Section&#160;2.2 and Section&#160;7.2, the Parties will discuss in good faith and mutually agree on terms and conditions under which OncoC4 would, itself or through an Affiliate or Third Party, Manufacture and supply AI-025 to BioNTech or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">facilitate a technology transfer of the Manufacturing process for AI-025 to BioNTech or its designee, in either case, to provide for the supply of AI-025 to BioNTech for the further Development and Commercialization of AI-061.  For clarity, unless otherwise mutually agreed by the Parties in writing, there shall only be one (1) Technology Transfer under this Section 5.2(c) (to either BioNTech or its designated Third Party manufacturer), and following the completion of such Technology Transfer in accordance with the Technology Transfer plan therefor, OncoC4 and its Affiliates shall have no further obligations or responsibilities with respect to conducting a Technology Transfer of AI-025 or AI-061.  Notwithstanding the foregoing, to the extent OncoC4 Manufactures and supplies to BioNTech, either by itself or via its Affiliates or a Third Party, any AI-025 and&#47;or AI-061, OncoC4 shall supply such AI-025 and&#47;or AI-061 at a transfer price equal to or less than OncoC4&#8217;s FBMC and otherwise pursuant to the other terms and conditions mutually agreed between the Parties in a supply agreement providing for such Manufacture and supply.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Commercialization Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech will be solely responsible for, at its expense, and will have sole discretion with respect to, Commercializing Licensed Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that BioNTech (directly, or through its Affiliates, Sublicensees or contractors) will use Commercially Reasonable Efforts to Commercialize &#91;***&#93;.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; of each Calendar Year during the Term, BioNTech will provide OncoC4 with a high-level summary of BioNTech&#8217;s Commercialization and Manufacturing activities for each Licensed Product in the Territory performed in the preceding Calendar Year  (or updating such summary for activities performed since the last such summary was given hereunder, as applicable), and a high-level summary of the future activities it expects to initiate in the next &#91;***&#93; months after the date of the report.  BioNTech shall only be required to commence such summaries as of the date that the JSC disbands.  While the JSC continues to meet, BioNTech shall make an annual presentation to the JSC summarizing BioNTech&#8217;s Commercialization achievements and plans for the following &#91;***&#93; years.  Each such report will include a high-level &#91;***&#93; forecast of estimated worldwide Net Sales, which is not required to be broken down by country, territory, region, nor Licensed Product.  In addition, BioNTech will provide OncoC4 with written notice of the First Commercial Sale of each Licensed Product in the Territory as soon as reasonably practicable after such event&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that BioNTech will inform OncoC4 of such event prior to public disclosure of such event by BioNTech.  BioNTech will provide such other information to OncoC4 as OncoC4 may reasonably request with respect to Commercialization of Licensed Products in the Territory and will keep OncoC4 reasonably informed of the material Commercialization activities of BioNTech with respect to such Licensed Products.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">OncoC4 Role In Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Prior to the commercial launch of a Licensed Product in the United States, upon OncoC4&#8217;s request to BioNTech, the Parties shall discuss in good faith whether and how OncoC4 might participate in some or all of the Commercialization activities of such Licensed Product in the United States.  Additionally, following the first anniversary of the Effective Date, upon OncoC4&#8217;s reasonable request to BioNTech (not more than once in any Calendar Year unless otherwise mutually agreed), the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Parties shall discuss in good faith the potential Commercialization of Licensed Products in China, including whether and how OncoC4 might participate in some or all of such Commercialization activities and any adjustments to the terms and conditions of this Agreement that may be necessary or desirable to make such Commercialization advantageous to both Parties on commercially reasonable terms and conditions that are consistent with the then-applicable policies, procedures and resources of each Party.  Any such participation by OncoC4 in Commercialization activities with respect to Licensed Product(s) would be subject to the negotiation and mutual agreement of the Parties in writing on an amendment to this Agreement or an ancillary agreement setting forth the terms and conditions of such participation.  Neither Party is required to agree to such an amendment or ancillary agreement and the inability to, or decision not to, enter in such amendment or ancillary agreement shall not be deemed to indicate that BioNTech has not used Commercially Reasonable Efforts.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br>GOVERNANCE&#59; COLLABORATION STEERING COMMITTEE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Formation&#59; Purposes and Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; Business Days after the Effective Date, OncoC4 and BioNTech will form a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to provide oversight and to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement.  The JSC shall be in existence from the date of its formation until the completion of all then-scheduled activities under the CDP, at which point it shall disband.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Specific Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to its overall responsibility to provide strategic oversight and to facilitate information sharing between the Parties with respect to the activities of the Parties under this Agreement, the JSC will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">review, discuss and approve the CDP and each Joint Development Budget included therein, and any proposed amendments or revisions to the CDP or Joint Development Budget&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">oversee and coordinate between the Parties with respect to the Development and Manufacturing activities and interactions with Regulatory Authorities with respect to the Licensed Compound and Licensed Products under the CDP&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">coordinate and keep OncoC4 reasonably informed of the BioNTech&#8217;s Development, Manufacture and Commercialization activities and interactions with Regulatory Authorities with respect to the Licensed Compound and Licensed Products under the BioNTech Development Plan&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">delegate responsibilities to and oversee the activities of any Subcommittees and resolve any disputes raised by the Subcommittees, and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">perform such other functions as are assigned to it in this Agreement or as appropriate to further the purposes of this Agreement to the extent agreed to in writing by the Parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC will be composed of a total of &#91;***&#93; representatives of each Party, which will be appointed by each of OncoC4 and BioNTech, respectively.  Each individual appointed by a Party as a representative to the JSC will be an employee of such Party with sufficient seniority within the applicable Party to provide meaningful input and make decisions arising within the scope of the JSC&#8217;s responsibilities, and have knowledge and expertise in the Development or Commercialization of compounds and products similar to the Licensed Products under this Agreement.  The JSC may change its size from time to time by consent of its members&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the JSC will consist at all times of an equal number of representatives of each Party, unless otherwise agreed by the Parties in writing.  Each Party may replace any of its JSC representatives at any time upon written notice to the other Party, which notice may be given by e-mail, sent to the other Party.  The JSC will be co-chaired by one designated representative of each Party, who is a member of the JSC, or alternatively by their designee who has sufficient seniority.  Each co-chairperson, or their designee, will alternate being responsible for each meeting for (a) calling and conducting meetings, (b)&#160;preparing and circulating an agenda in advance of each meeting&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the applicable co-chairperson will include any agenda items proposed by either Party on such agenda, (c)&#160;preparing minutes of each meeting that reflect the material decisions made and action items identified at such meetings promptly thereafter, and (d)&#160;sending draft meeting minutes to each member of the JSC for review and approval within &#91;***&#93; days after each JSC meeting.  Each JSC representative will have &#91;***&#93; Business Days from receipt in which to comment on and to approve or provide comments to the minutes (such approval not to be unreasonably withheld, conditioned or delayed).  Each JSC representative will be subject to confidentiality obligations no less stringent than those in Section&#160;8.1. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC will hold meetings &#91;***&#93; every &#91;***&#93; during the Term for so long as the JSC exists (i.e., until it disbands in accordance with Section&#160;6.1), unless the Parties mutually agree in writing to a different frequency.  No later than &#91;***&#93; Business Days prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the chairperson will prepare and circulate an agenda for such meeting.  Either Party may also call a special meeting of the JSC by providing at least &#91;***&#93; Business Days prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will work with the chairperson of the JSC to provide the members of the JSC no later than &#91;***&#93; Business Day prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision on the matters to be considered.  The JSC may meet in person or by audio or video conference as its representatives may mutually agree.  Other representatives of the Parties (including relevant Alliance Managers and project managers), their Affiliates, and, only with the advance, written consent of both Parties, Third Parties involved in the Development, Manufacture, or Commercialization of Licensed Products may be invited by the members of the JSC to attend meetings as observers&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such representatives are subject to confidentiality obligations no less stringent than those set forth in Section&#160;8.1.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Decision-Making&#59; Escalation to Senior Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will endeavor in good faith and in compliance with this Agreement to reach unanimous agreement with respect to all matters within the JSC&#8217;s authority.  Each Party&#8217;s representatives on the JSC will collectively have one vote (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party Vote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on all matters before the JSC, and no action or decision will be taken by the JSC without a unanimous Party Vote (i.e., the affirmative Party Vote of each Party).  A decision made in accordance with this Section 6.5 shall be deemed to be a decision made by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the JSC.  Should the JSC not be able to reach agreement with respect to a matter at a duly called meeting of the JSC, either Party may refer such matter to the Senior Officers for resolution, and the Senior Officers will attempt to resolve the matter in good faith.  If the Senior Officers fail to resolve such matter within &#91;***&#93; days after the date on which the matter is referred to the Senior Officers (unless a longer period is agreed to by the Parties), then&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">Subject to Section 2.6(c), BioNTech shall have final decision-making authority on all matters within the JSC&#8217;s authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If due to the budgetary impact of a Reserved Financial Decision, BioNTech is unable to exercise its final decision-making authority under Section 6.5(a) to add a new Clinical Trial or new Indication to the CDP and Joint Development Program, then, in any event, BioNTech reserves the right to conduct the Clinical Trial or Develop Licensed Products for the Indication outside the CDP and Joint Development Program, and, in that case, notwithstanding anything express or implied in this Agreement, BioNTech shall have the right, subject to the Reduction Floor, to credit an amount equal to &#91;***&#93; of the Joint Development Costs that would have been OncoC4&#8217;s responsibility had such Clinical Trial or Development been performed under the CDP against royalties otherwise due hereunder to OncoC4 (in due course as they become due) in respect of the applicable Licensed Product (i.e., royalties payable in respect of the relevant Licensed Product studied in the relevant Clinical Trial or subject of the Development activities conducted by BioNTech outside the CDP) and OncoC4 shall have no right to any Development Milestone Payment in Section&#160;7.4(a) in relation to any Development Milestone Event related to or resulting from such Clinical Trial or Indication, and BioNTech is hereby excused from making such Development Milestone Payments related to such Indications&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that BioNTech shall only be excused from making a Development Milestone Payment under this Section 6.5(a)(ii) if OncoC4 has not paid Joint Development Costs in respect of the relevant Clinical Trial or the Indication giving rise to the Development Milestone Payment.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">If due to the budgetary impact of a Reserved Financial Decision, BioNTech is unable to exercise its final decision-making authority under Section 6.5(a) to modify a Clinical Trial or the Development of an Indication that is included in the CDP and Joint Development Program as of the applicable time, then, in any event, BioNTech reserves the right to modify the Clinical Trial or modify the Development of Licensed Products for the Indication outside the CDP and Joint Development Program, and, in that case, notwithstanding anything express or implied in this Agreement, BioNTech shall have the right, subject to the Reduction Floor, to credit an amount equal to &#91;***&#93; of the Joint Development Costs that would have been OncoC4&#8217;s responsibility had such Clinical Trial or Development been performed under the CDP against royalties otherwise due hereunder to OncoC4 (in due course as they become due) in respect of the applicable Licensed Product and the given Indication (i.e., royalties payable in respect of the relevant Licensed Product and Indication studied in the relevant Clinical Trial or subject of the Development activities conducted by BioNTech outside the CDP).  In such event, the royalties allocable to the relevant Licensed Product and Indication will be calculated in accordance with a methodology reasonably proposed by BioNTech in good faith, taking in account the respective market share of the Indications.  If BioNTech conducts a Clinical Trial or Develops an Indication outside the CDP under this Section 6.5(a)(iii), it shall have no impact on any Development Milestone Payment in Section&#160;7.4(a) in relation to any Development Milestone </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Event related to or resulting from such Clinical Trial or Indication, and if any Development Milestone Event occurs with respect to such Clinical Trial or Indication, BioNTech shall be obligated to pay the corresponding Development Milestone Payment in accordance with Section&#160;7.4(a), </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Notwithstanding the foregoing or anything contained herein, neither the JSC nor BioNTech through exercise of its final decision-making authority will have the right or authority to (i) amend or waive any of the terms or conditions of this Agreement or otherwise determine any matter outside the authority of the JSC or that expressly requires mutual agreement of the Parties under this Agreement, or (ii) make any determination or take any action solely or specifically related to AI-025 outside the context of AI-061. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  From time to time during the Term, the JSC may establish and delegate duties to subcommittees (e.g., project teams) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on an &#8220;as needed&#8221; basis to oversee particular projects or activities.  Each Subcommittee will consist of mutually agreed number of representatives from each Party, and will meet from time to time upon mutual agreement between representatives from each Party.  The decision-making within a Subcommittee will be by consensus, with each Party&#8217;s representatives on the applicable Subcommittee collectively having one (1) vote on all matters brought before the Subcommittee.  Each Subcommittee and its activities will be subject to the direction, review and approval of, and will report to, the JSC.  In no event will the authority of the Subcommittee exceed that specified for the JSC in Section&#160;6.2.  Any matter not resolved by a Subcommittee will be referred to the JSC for resolution.  Unless otherwise mutually agreed by the Parties, each Subcommittee will disband upon completion of all the obligations designated by the JSC to such Subcommittee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will appoint a person to oversee interactions between the Parties for all matters related to the Development and Commercialization of Licensed Products between meetings of the JSC (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Alliance Managers will have the right to attend all meetings of the committees as non-voting participants and may bring to the attention of the JSC any matters or issues either Alliance Manager reasonably believes should be discussed and will have such other responsibilities as the Parties may mutually agree in writing.  Each Party may replace its Alliance Manager at any time or may designate different Alliance Managers with respect to Development and Commercialization matters, respectively, by notice in writing to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt;text-decoration:underline">Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the limitations set forth in Section 6.5, the Alliance Managers will have the responsibility of creating and maintaining a constructive work environment within the JSC and between the Parties for all matters related to this Agreement.  Without limiting the generality of the foregoing, each Alliance Manager will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">provide a single point of communication within the Parties&#8217; respective organizations and between the Parties with respect to this Agreement, including any issues that may arise that it may be possible to resolve without (or prior to) escalation to the JSC&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">coordinate cooperative efforts, internal communications and external communications between the Parties with respect to this Agreement&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">take such other steps as may be required to ensure that meetings of the JSC occur as set forth in this Agreement, that procedures are followed with respect to such meetings (including working with the co-chairpersons with respect to the giving of proper notice and the preparation and approval of minutes) and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.38pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, BioNTech will pay OncoC4 a non-refundable, non-creditable, one-time payment in the amount of two hundred million Dollars ($200,000,000), which payment will be due and payable to OncoC4 within &#91;***&#93; days following the date of BioNTech&#8217;s receipt of an invoice provided by OncoC4 in accordance with this Agreement upon or after the Effective Date, of which &#91;***&#93; is in consideration for and shall fund the performance by OncoC4 of its activities to research and Develop ONC-392 under the CDP.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following BioNTech&#8217;s delivery of an Option Exercise Notice to OncoC4 in accordance with Section&#160;2.2(a), BioNTech will pay to OncoC4 a non-refundable, non-creditable, one-time payment in the amount of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) no later than &#91;***&#93; days following the date of BioNTech&#8217;s receipt of an invoice provided by OncoC4 in accordance with this Agreement upon or after the date of OncoC4&#8217;s receipt of the Option Exercise Notice.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as otherwise provided in Section&#160;3.2, and subject to this Section&#160;7.3, all Joint Development Costs shall be shared equally (50&#47;50) between BioNTech and OncoC4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Commencing the first Calendar Quarter of the Term and continuing thereafter so long as a Party incurs Joint Development Costs under the CDP, within &#91;***&#93; days after the end of each Calendar Quarter during which either Party incurs any such Joint Development Costs, such Party shall submit to a finance designee of the other Party a report setting forth a good faith estimate of the Joint Development Costs it incurred in such Calendar Quarter, as detailed in the CDP as approved by the JSC.  Within &#91;***&#93; days following the end of such Calendar Quarter, each Party shall update such report to reflect the final amount of Joint Development Costs incurred by such Party in such Calendar Quarter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if there are any Joint Development Costs incurred in such Calendar Quarter that a Party is unable to timely include in such financial report, then such amount shall be included and reconciled in the financial report in the following Calendar Quarter.  Each such report shall specify in reasonable detail the Joint Development Costs incurred and shall include reasonably detailed supporting information.  Within &#91;***&#93; days after receipt of such reports, the finance designees from both Parties shall confer and agree in writing on whether a reconciliation payment is due from one Party to the other Party, and if so, the amount of such reconciliation payment, so that the Parties share Joint Development Costs in accordance with this Section&#160;7.3.  The Party required to pay such reconciliation payment shall make such payment to the other Party within &#91;***&#93; days after the date of such Party&#8217;s receipt of an invoice provided by the other Party upon or after the end of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such &#91;***&#93; day conferral period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the event of any good faith disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and any remaining portion subject to a good faith dispute shall be paid within &#91;***&#93; days after the date on which the Parties, using good faith efforts, resolve the dispute and the Party entitled to payment provides an updated invoice for the correct amount.  For the avoidance of doubt, no cost or expense shall be counted more than once in calculating Joint Development Costs, even if such cost or expense falls into more than one of the cost categories that comprise Joint Development Costs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Mono&#47;PD1 Combination Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, BioNTech will notify OncoC4 (or, with respect to any Clinical Trial sponsored by OncoC4, OncoC4 will notify BioNTech) in writing of the achievement by or on behalf of BioNTech, its Affiliates or Sublicensees, or OncoC4 of any milestone event set forth in this Section&#160;7.4(a) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; &#91;***&#93; and BioNTech will pay OncoC4 the corresponding non-refundable, non-creditable, milestone payments set forth in the tables below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; days following the date of BioNTech&#8217;s receipt of an invoice provided by OncoC4 on or after the date of notice of the achievement of the corresponding Development Milestone Event by BioNTech, its Affiliates or any Sublicensees, or OncoC4.  For clarity, each of the Development Milestone Events set forth in Section&#160;7.4(a)(i) below &#91;***&#93; may only be earned one time, by the first Mono&#47;PD-1 Combination to achieve the corresponding Development Milestone Event, and the Development Milestone Events set forth in Section&#160;7.4(a)(ii) below &#91;***&#93; may be earned on a &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">One-Time Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Development Milestone Payments set forth in the table below &#91;***&#93; may be earned once, upon first achievement of the applicable Development Milestone Event by a Mono&#47;PD-1 Combination.  For clarity, the maximum amount of all Development Milestone Payments that may be earned under this Section&#160;7.4(a)(i) is &#91;***&#93; as indicated below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:11.93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:65.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:14.4pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:18pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;.  </font></div><div style="padding-left:11.93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:65.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, &#91;***&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Sales Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term, BioNTech will pay to OncoC4 each of the non-refundable, non-creditable milestone payments set forth below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; days after the date of BioNTech&#8217;s receipt of an invoice provided by OncoC4 in accordance with this Agreement on or after OncoC4&#8217;s receipt of the royalty report hereunder that shows the achievement of the corresponding milestone event below (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each of the milestone payments set forth in this Section&#160;7.4(b) is payable up to one time only, upon the first achievement of such Sales Milestone Event.  For clarity, the maximum amount of all Sales Milestone Payments that may be earned under this Section 7.4(b) is &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:11.93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:65.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-right:14.4pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:3.55pt;padding-right:3.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the calculation of annual aggregate Net Sales for the purposes of the foregoing milestones, for clarity&#58; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding anything express or implied in this Section, no more than one Sales Milestone Payment shall become due with respect to Net Sales levels in any given Calendar Year.  Accordingly, if in a given Calendar Year the Net Sales levels would otherwise achieve multiple Sales Milestone Events, then only the Sales Milestone Event associated with the higher or highest such Sales Milestone Event shall be deemed achieved and the corresponding Sales Milestone Payment shall become due once properly invoiced, and the Sales Milestone Events associated with the lower Net Sales level(s) that would otherwise have been first achieved in such Calendar Year shall be deemed not to have been achieved, and will be eligible to be achieved and incur a Sales Milestone Payment in subsequent Calendar Years (subject always to the operation of this paragraph in subsequent Calendar Years).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, with respect to &#91;***&#93;, BioNTech will pay to OncoC4 non-refundable, non-creditable royalties at the &#91;***&#93; royalty rates specified in the following table with respect &#91;***&#93;&#58;</font></div><div style="padding-left:11.93pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e6e6e6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; </font></td><td colspan="3" style="background-color:#e6e6e6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the calculation of annual aggregate Net Sales for the purposes of the foregoing tiers, for clarity&#58; &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a &#91;***&#93;, unless terminated earlier by either Party pursuant to this Agreement, royalties will be due under Section&#160;7.5(a) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Payments and Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days after the end of each Calendar Quarter, commencing with the Calendar Quarter during which the First Commercial Sale of a Licensed Product is made anywhere in the Territory, BioNTech will provide to OncoC4 a report setting forth&#58; &#91;***&#93;.  Concurrent with the provision of the royalty report, BioNTech will request an invoice from OncoC4 for the royalty payment shown in the royalty report, and shall within &#91;***&#93; days after the receipt of the corresponding invoice from OncoC4 (in the amount shown in the royalty report) pay OncoC4 the royalties due to OncoC4 with respect to Net Sales by BioNTech, its Affiliates and their respective Sublicensees for such Calendar Quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Payment Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The royalties payable under Section&#160;7.5 will be subject to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If BioNTech or its Affiliate or a Sublicensee is a party to, as of the Effective Date or thereafter, enters into a license or settlement agreement with a Third Party for the right under any Patent owned or Controlled by such Third Party &#91;***&#93; &#8211; and pursuant to such agreement makes payments (which may include license fees, milestones, and net sales royalties) to such Third Party for such right to Commercialize such Licensed Product under such Patent, then, subject to Section&#160;7.7(f), BioNTech may deduct &#91;***&#93; of such payments actually paid to such Third Party for such right under such Patent in a Calendar Quarter against the royalties due and payable to OncoC4 on the Net Sales for such Licensed Product due in respect of such Calendar Quarter under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Lack of Patent Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;7.7(f), if at any time during the Royalty Term, for any Licensed Product in a given country in the Territory, the last-to-expire Valid Claim in any Licensed Patent or &#91;***&#93; Covering such Licensed Product in such country expires or otherwise ceases to be a Valid Claim, then, from the first Calendar Quarter in which this Section&#160;7.7(b) applies, and thereafter for so long as this Section&#160;7.7(b) applies, the applicable royalties in effect with respect to such Licensed Product in such country as specified in Section&#160;7.5(a) will be &#91;***&#93; by &#91;***&#93;.  For this purpose, &#8220;last-to-expire&#8221; means the last to expire or last to continue to qualify as a Valid Claim.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compulsory License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;7.7(f), if a Compulsory License is granted to a Third Party with respect to a Licensed Product in a given country with a royalty rate lower than the applicable royalty rate in such country hereunder, then the royalties payable to OncoC4 with respect to such Licensed Product in such country in an applicable Calendar Quarter shall be reduced to &#91;***&#93;.  Notwithstanding Section&#160;7.7(f), if the compulsory licensee receives its grant of rights from BioNTech at royalty rate(s) lower than those of this Agreement, they shall be excluded from the definition of &#8220;Sublicensee,&#8221; and BioNTech shall pass through the compulsory licensee&#8217;s royalties to OncoC4 but shall not owe the higher royalty rate set forth herein on the compulsory licensee&#8217;s sales.  Moreover, it is understood that the compulsory licensee, even if receiving its governmentally-mandated rights from BioNTech, shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notwithstanding anything express or implied contained herein, remain a Third Party who will be deemed not to be a Sublicensee hereunder and whose sales of Licensed Product may give rise to (and be counted towards) the existence of Biosimilar Competition in the applicable country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Biosimilar Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;7.7(f), &#91;***&#93;, during the Royalty Term for a Licensed Product in a country, if there is Biosimilar Competition with respect to such Licensed Product in such country, then, from the first Calendar Quarter in which such Biosimilar Competition occurs, and thereafter for each Calendar Quarter for which such Biosimilar Competition exists, the applicable royalties in effect with respect to such Licensed Product in such country as specified in Section&#160;7.5(a) will be &#91;***&#93; by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Cumulative Deductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, in no event will the deductions set forth in Sections&#160;&#91;***&#93;, individually or in the aggregate, reduce the royalties otherwise payable to OncoC4 under Section&#160;7.5 with respect to a given Licensed Product in a country in a Calendar Quarter by more than &#91;***&#93; (such percentage, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reduction Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) with respect to a Licensed Product in a country, if Biosimilar Material Competition occurs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with respect to such Licensed Product in such country, then, from the first Calendar Quarter in which such Biosimilar Material Competition occurs, and thereafter for each Calendar Quarter for which such Biosimilar Material Competition exists, the Reduction Floor for such Licensed Product in such country shall be decreased from &#91;***&#93; &#91;***&#93; to &#91;***&#93; of the royalties otherwise payable to OncoC4 under Section&#160;7.5 for such Licensed Product in such country in such Calendar Quarter&#59; and (ii) with respect to a Licensed Product in a country, if there is no Valid Claim in any Licensed Patent or &#91;***&#93; Covering such Licensed Product in such country, or if there is Biosimilar Competition in such country, then, from the first Calendar Quarter in which there is no Valid Claim or there is Biosimilar Competition in such country, and thereafter for each Calendar Quarter for which there is no Valid Claim or there is Biosimilar Competition in such country, the applicable Reduction Floor with respect to royalty reductions pursuant to&#58; (X) Third Party payments pursuant to Section&#160;7.7(a)&#59; (Y) Development costs as a result of a Reserved Financial Decision pursuant to Section&#160;6.5(a)&#59; and (Z) Development costs pursuant to Section 3.2(f), in each case (for clarity, together with all other royalty reductions for such Licensed Product in such country), shall be decreased from &#91;***&#93; to &#91;***&#93; of the royalties otherwise payable to OncoC4 under Section&#160;7.5 for such Licensed Product in such country in such Calendar Quarter, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, if BioNTech is unable to deduct or credit any portion of any royalty deductions or credits set forth in this Agreement not already offset against royalties hereunder in any Calendar Quarter as a result of the applicable Reduction Floor then it shall be able to carry the remaining not-yet-offset deduction(s) forward to future Calendar Quarters and offset them against royalties hereunder. For avoidance of doubt, Development costs deducted pursuant to subclauses (Y) and (Z) may be taken globally and without reference to a specific country. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Record Keeping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech and its Affiliates will, and will cause their respective Sublicensees to, keep complete, true and accurate books and records in accordance with its Accounting Standards of the items underlying (i) Net Sales and (ii) royalty payments under this Agreement.  BioNTech and its Affiliates will, and will cause their respective Sublicensees to keep, such books and records for at least &#91;***&#93; years following the Calendar Quarter to which they pertain.  OncoC4 will have the right annually, at its own expense, to have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an internationally-recognized independent, certified public accountant, selected by OncoC4 and reasonably acceptable to BioNTech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), review any such records of BioNTech and its Affiliates in the location(s) where such records are customarily maintained by BioNTech upon reasonable prior notice, during regular business hours and under obligations of confidentiality, except to the extent necessary to enforce OncoC4&#8217;s rights under this Agreement or if disclosure is required by applicable Law, for the sole purpose of verifying the basis and accuracy of payments made under this Agreement and the content of the reports described in Section&#160;7.6, within the prior &#91;***&#93; Calendar Year period after receipt of such report.  The Auditor will have the right to disclose to OncoC4 its conclusions regarding any payment owed under this Agreement.  The records for any Calendar Year may be audited no more than once with respect to records covering any specific period of time.  BioNTech shall obtain for itself or its Affiliate a commensurate right for it to audit Sublicensees, and either exercise that right itself upon the written request of OncoC4, or allow OncoC4 to hire the Auditor to conduct the audit of the Sublicensee records.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Audit Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The report prepared by the Auditor, a copy of which will be sent or otherwise provided to each Party by such Auditor at the same time before such report is considered final, will contain the conclusions of such Auditor regarding the audit and will specify that the amounts paid pursuant thereto were correct or, if incorrect, the amount of any underpayment or overpayment, and the specific details regarding any discrepancies.  No other information will be provided to OncoC4 without the prior consent of BioNTech unless disclosure is required by Laws, regulation or judicial order, and if so determined by OncoC4, it will, if permitted, give BioNTech prior notice thereof to the extent possible for BioNTech to seek a protective order against or limiting such disclosure.  If such report shows any underpayment, then BioNTech will remit to OncoC4, within &#91;***&#93; Business Days after receipt of such report, (i)&#160;the amount of such underpayment and (ii) if such underpayment exceeds &#91;***&#93; of the total amount owed for the period then being audited, the actual costs incurred by OncoC4 in conducting such review will be reimbursed.  For the avoidance of doubt, payment of the underpayment will be considered a late payment, subject to Section&#160;7.11.  If such report shows any overpayment, then BioNTech will have the right to credit the overpaid amount against future payments owed to OncoC4 or, if further payments will not be due hereunder within &#91;***&#93; days, require that OncoC4 reimburse the amount of such overpayment.  The Parties mutually agree that the information subject to review under this Section&#160;7.8 is Confidential Information of BioNTech and that OncoC4 will retain and cause the Auditor to retain all such information in confidence in accordance with confidentiality and non-use obligations no less stringent than those contained in Section&#160;8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Each Party shall also have an audit right equivalent to the audit right set forth in Section&#160;7.8(a)-(b) (applied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) to audit the other Party&#8217;s and its Affiliates records with respect to Joint Development Costs, to confirm the accuracy of the Joint Development Costs asserted by the audited Party.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly under this Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any tax paid or required to be withheld by BioNTech under applicable Laws in effect at the time of payment for the benefit of OncoC4 on account of any royalties or other payments payable to OncoC4 under this Agreement shall be deducted from the amount of royalties or other payments otherwise due.  The Parties shall reasonably cooperate with one another to reduce or minimize any such deduction or withholding required by applicable Laws, including by providing any documents, information, forms or other certifications necessary to reduce the amount of such withholding. The Parties shall also reasonably cooperate with one another, in good faith, with respect to all documentation and actions required by the German tax authorities to secure a reduction in the rate of applicable withholding taxes, including (i) obtaining a certificate of exemption from withholding taxes from the German tax authorities, or (ii) to the extent permitted under applicable Law, obtaining a repayment or refund of an amount previously withheld and remitted to the German tax authorities.  For clarity, the Parties hereby provide their consent to disclose this Agreement to the German tax authorities for purposes of obtaining such a certificate or a tax refund.  If, in accordance with the foregoing, BioNTech withholds any amount, then it will pay to OncoC4 the balance when due, timely remit to the proper taxing authority the withheld amount, and send OncoC4 proof of such remittance within &#91;***&#93; days following OncoC4&#8217;s request for such proof of remittance.  If and to the extent BioNTech receives from a tax authority a repayment or refund of an amount previously withheld and remitted pursuant to this Section 7.9(b), BioNTech shall notify OncoC4 and pay such repaid or refunded amount to OncoC4 without undue delay.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding the foregoing, BioNTech shall assume the responsibility for, and increase the amount payable hereunder such that OncoC4 receives the amount it would have received but for, any Incremental Withholding (as defined below) in the event that such Incremental Withholding arises as a result of any Withholding Action by or on behalf of BioNTech.  For purposes hereof, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; by or on behalf of BioNTech means any action taken, or caused to be taken, by BioNTech or its Affiliate (including any assignment of this Agreement, in whole or in part) that results or would result in any additional withholding or reduction from payments made hereunder (any such amount withheld or deducted, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Incremental Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which would not have resulted absent BioNTech or such Affiliate taking, or causing to be taken, such action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">VAT and Indirect Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All amounts payable under or in connection with this Agreement are exclusive of VAT and Indirect Taxes.  Any VAT and Indirect Taxes payable on the consideration shall be paid by BioNTech at the same time as the payment or provision of the consideration to which it relates.  If any VAT and Indirect Taxes are paid by OncoC4 to the relevant fiscal authority before such payment is made by BioNTech, BioNTech shall reimburse OncoC4 such VAT and Indirect Taxes within &#91;***&#93; days following receipt of the relevant invoice from OncoC4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Provision of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 is required to provide all invoice and customs related documents to &#91;***&#93; and &#91;***&#93; on a &#91;***&#93; basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Currency of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All amounts payable and calculations under this Agreement will be in Dollars.  As applicable, Net Sales and any royalty reductions will be translated into Dollars using the average exchange rates published by the European Central Bank and in accordance with the Accounting Standards (or any other qualified source that is acceptable to both Parties) for the &#91;***&#93; in which such Net Sales occurred, where Accounting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Standards refers to the Accounting Standards of the Party who owes a payment to the other Party.  All payments under this Agreement will be paid in Dollars by wire transfer to an account designated by the receiving Party (which account the receiving Party may update from time to time in writing).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment in Full</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent permitted under Section&#160;7.9 or 15.11 or otherwise required by applicable Law in effect at the time of payment, each Party will make all payments due hereunder (including any amounts payable pursuant to ARTICLE XI) in full without set-off or counterclaim of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting any other rights or remedies available to either Party hereunder, any late payment by one Party to the other will bear interest, to the extent permitted by Laws, at an annual rate of &#91;***&#93;, computed from the date such payment was due until the date the paying Party makes the payment.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Costs of Upstream Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;In accordance with and without limiting Section&#160;2.7, except as set forth in Section 10.2(k), OncoC4 shall be wholly responsible for any and all payments due pursuant to the Upstream Agreements, including all milestones and royalties due under the Upstream Agreements in respect of Development, Manufacturing (without limiting ARTICLE V), Commercialization, achievements, and sales that occur under or pursuant to a right granted in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Invoices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained herein, in the event of any good faith disagreement with respect to the amount or calculation of an amount set forth in an invoice delivered to BioNTech by OncoC4 hereunder, any undisputed portion of the applicable amount shall be paid in accordance with the terms hereof and any remaining portion subject to a good faith dispute shall be paid within &#91;***&#93; days after the date on which the Parties, using good faith efforts, resolve the dispute and, if applicable, OncoC4 provides an updated invoice for the correct remaining amount. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.72pt"><br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Licensed Know-How and Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject only to the rights expressly granted to BioNTech under this Agreement, as between the Parties, OncoC4 will retain all rights, title and interests in and to the Licensed Know-How and Licensed Patents.  In addition, each Party shall own any Patent or Know-How created or obtained by or on behalf of such Party independently and outside the scope of the collaboration between the Parties under this Agreement (as such scope may be limited pursuant to Section 2.6). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Any inventions and Know-How (whether or not patentable) that are conceived, discovered, developed, reduced to practice, or otherwise made, either solely or jointly by or on behalf of (including that arising from contractors&#8217; activities)&#58; (A) OncoC4 and its Affiliates on the one hand, or (B) BioNTech, its Affiliates and Sublicensees on the other hand, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the course of performing any activities under the CDP, including and any other intellectual property rights therein and thereto &#91;***&#93;, and any Patents that claim such &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Subject to the license grants in Section&#160;2.1 &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Any inventions and Know-How (whether or not patentable) that are conceived, discovered, developed, reduced to practice, or otherwise made, either solely or jointly by or on behalf of (A) OncoC4 and its Affiliates on the one hand, or (B) BioNTech, its Affiliates and Sublicensees on the other hand, &#91;***&#93;.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Any inventions and Know-How (whether or not patentable) that are conceived, discovered, developed, reduced to practice, or otherwise made, either solely or jointly by or on behalf of (A) OncoC4 and its Affiliates on the one hand, or (B) BioNTech, its Affiliates and Sublicensees on the other hand, in each case, in the course of performing their respective activities under this Agreement, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any inventions and Know-How (whether or not patentable) that are conceived, discovered, developed, reduced to practice, or otherwise made, either solely or jointly by or on behalf of (A) OncoC4 and its Affiliates on the one hand, or (B)&#160;BioNTech, its Affiliates and Sublicensees on the other hand, in each case, in the course of performing their respective activities under this Agreement, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Assignment Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will cause its Affiliates, sublicensees, and its and their directors, officers, employees, consultants, contractors, and agents to assign to such Party all of such individuals&#8217; right, title, and interest in and to the &#91;***&#93; that are conceived, discovered, developed, reduced to practice, or otherwise made by such individual, together with all Patents claiming such &#91;***&#93;.  OncoC4 shall and hereby does assign to BioNTech all right, title and interest in and to all &#91;***&#93;.  BioNTech shall and hereby does assign to OncoC4 all right, title and interest in and to all &#91;***&#93;.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Licensed Patents and &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cooperation in Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will, and will cause its Affiliates to, reasonably cooperate, with the other Party with respect to &#91;***&#93;, including transferring copies of relevant files and records relating to Prosecution of such Patents, providing any necessary powers of attorney, complying with any applicable duty of candor or disclosure with a patent office and executing any other required documents or instruments for such Prosecution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Patent Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If elections with respect to obtaining patent term extension or supplemental protection certificates or their equivalents in any country (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patent Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with respect to &#91;***&#93; become available, the Parties will discuss in good </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">faith and seek to mutually agree on which &#91;***&#93; to extend&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Parties cannot agree in good faith&#91;***&#93;.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Data Exclusivity, Purple Book and Patent Register Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to data exclusivity periods (such as those periods listed in the Purple Book (including any available pediatric extensions) or periods under national implementations of Article&#160;10.1(a)(iii) of Directive 2001&#47;EC&#47;83, and all equivalents in any country), (i) with respect to the Licensed Products, the Parties will coordinate, and each Party shall, in consultation with the other Party and after consideration in good faith of such other Party&#8217;s comments, seek and maintain all such data exclusivity periods that may be available for any of the Licensed Products, and determine which Licensed Patents, &#91;***&#93;, if any, will be listed with the applicable Regulatory Authorities for any Licensed Product in its field, including all so-called &#8220;Patent Register&#8221; listings required by certain Governmental Authorities, and all similar listings in any other relevant countries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Upstream Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained herein, this Section&#160;8.2 shall not apply to any Licensed Patents that OncoC4 Controls pursuant to an Upstream Agreement to the extent that there are any conflicts between the provisions hereof and the applicable Upstream Agreement, in which case, the terms and conditions of the applicable Upstream Agreement shall control with respect to the Prosecution of such Licensed Patents.  To the extent that OncoC4 is required to make any payments to a Third Party licensor under an Upstream Agreement with respect to any Prosecution of any Licensed Patents thereunder, BioNTech shall reimburse OncoC4 for such payments within &#91;***&#93; days after receipt of an undisputed invoice from OncoC4 in accordance with this Agreement regarding the same&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if these costs are due because of OncoC4&#8217;s exercise of its step-in rights, then OncoC4 shall be solely responsible for those costs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will promptly notify the other in writing of any (i)&#160;suspected, threatened or actual infringement by a Third Party of any Licensed Patent &#91;***&#93;&#59;(ii) suspected, threatened or actual unauthorized disclosure, use or misappropriation of any Licensed Know-How or &#91;***&#93; by a Third Party, or (iii) any actual or threatened allegations of alleged patent invalidity, unenforceability or non-infringement of a Licensed Patent &#91;***&#93; in connection with a Biosimilar Application, or any other similar patent certification by a Third Party, and any foreign equivalent thereof, in each case ((i) &#8211; (iii)), of which it becomes aware, and will provide the other Party with full particulars and all evidence in such Party&#8217;s possession or control supporting such infringement, unauthorized use or misappropriation, or allegations or certifications (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IP Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Biosimilar Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If either Party receives a copy of an application submitted to the FDA under subsection&#160;(k) of Section&#160;351 of the PHSA (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) naming a Licensed Product as a reference product or otherwise becomes aware that such a Biosimilar Application has been filed (including by the receipt of information disclosed pursuant to Section&#160;351(l)(2) of the PHSA, or in an instance described in Section&#160;351(l)(9)(C) of the PHSA), either Party will, within ten (10) Business Days thereafter, notify the other Party so that the other Party may seek permission to view the application and related confidential information from the filer of the Biosimilar Application under Section&#160;351(l)(1)(B)(iii) of the PHSA.  If either Party receives any equivalent or similar certification, information or notice in any other jurisdiction in the Territory naming a Licensed Product, either Party will, within ten (10) Business Days thereafter, notify and provide the other Party with copies of such communication.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Solely with respect to a Biosimilar Application referring to a Licensed Product in the Field, regardless of the Party that is the &#8220;reference product sponsor&#8221; for purposes of such Biosimilar Application, (A) &#91;***&#93; to designate pursuant to Section&#160;351(l)(1)(B)(ii) of the PHSA the outside counsel and in-house counsel who will receive confidential access to the Biosimilar Application, (B) &#91;***&#93; to (1) list any Licensed Patents, &#91;***&#93; and any other Patents, as required pursuant to Section&#160;351(l)(3)(A), Section&#160;351(l)(5)(b)(i)(II), or Section&#160;351(l)(7) of the PHSA, (2) respond to any communications with respect to such lists from the filer of the Biosimilar Application, and (3) negotiate with the filer of the Biosimilar Application as to whether to utilize a different mechanism for information exchange than that specified in Section&#160;351(l) of the PHSA&#59; and (C) &#91;***&#93;, to identify Licensed Patents, &#91;***&#93; and any Patents, and to respond to communications under any equivalent or similar listing in any other jurisdiction in the Territory in accordance with Section&#160;8.2(f).  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In any Action under Section&#160;8.3, each Party will, and will cause its Affiliates to, reasonably cooperate with the other Party, in good faith, relative to the efforts to protect the Licensed Patents &#91;***&#93; and will join such suit as a party, if requested by the other Party.  Furthermore, the Party initiating any Action pursuant to Section&#160;8.3(b) or Section&#160;8.3(c) will consider in good faith all reasonable and timely comments from the other Party on any proposed arguments asserted or to be asserted in litigation related to the enforcement or defense of any such Patents.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Upstream Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything contained herein, &#91;***&#93; are subject to the applicable terms and conditions of such Upstream Agreement with respect to any such Licensed Patents, as applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;8.3(j) and unless otherwise expressly provided for under this Section 8.3, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Allocation of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any settlements, damages or monetary awards recovered by either Party pursuant to any Action under this Section&#160;8.3 with respect to the Licensed Patents &#91;***&#93; will, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claimed Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will promptly notify the other Party if a Third Party brings any Action alleging patent infringement by BioNTech or OncoC4 or any of their respective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliates or Sublicensees with respect to the Development, Manufacture or Commercialization of any Licensed Product (any such Action, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Infringement Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the Territory.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Legal Interest&#47;Joint Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All information exchanged between the Parties regarding the prosecution and maintenance, and enforcement and defense, of Licensed Patents &#91;***&#93; under this ARTICLE VIII will be deemed Confidential Information of the disclosing Party.  In addition, the Parties acknowledge and agree that, with regard to such prosecution and maintenance, and enforcement and defense, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature.  Notwithstanding anything contained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this ARTICLE VIII is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party will not be required to disclose such information except under circumstances designed to preserve such privilege, and the Parties will in good faith cooperate to agree upon a procedure (including entering into a specific common legal interest&#47;joint defense agreement, disclosing such information on a &#8220;for counsel eyes only&#8221; basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If required by law, BioNTech will mark, and will cause all of its Affiliates and Sublicensees to mark, Licensed Products with all Licensed Patents in accordance with applicable Law, which marking obligation will continue for as long as required under applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension of Rights to BioNTech Affiliate, Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech shall be entitled to extend its rights in this ARTICLE VIII to, or exercise its rights and perform its obligations in this Article by, an Affiliate or a Sublicensee, notwithstanding anything express or implied in this Article. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Third Party Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Other than the Patents and Know-How that are Controlled by OncoC4 pursuant to the Upstream Agreements, during the Term, if OncoC4 becomes aware of Patents or Know-How of any Third Party that it believes may be useful to license for purposes of Development and&#47;or Commercialization of Licensed Compound(s) and&#47;or Licensed Product(s), OncoC4 shall notify the JSC or a patent subcommittee thereof or a committee consisting of patent counsel for each Party, of such Patents and Know-How (as applicable) for BioNTech&#8217;s consideration.  &#91;***&#93;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy&#59; Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All rights and licenses granted under or pursuant to this Agreement by a bankrupt Party to the other Party are, and shall be deemed to be, for purposes of Section&#160;365(n) of the Bankruptcy Code and any similar law or regulation in any other country, licenses of rights to &#8220;intellectual property&#8221; as defined under Section&#160;101(35A) of the Bankruptcy Code.  The Parties agree that all intellectual property rights licensed hereunder, are part of the &#8220;intellectual property&#8221; as defined under Section&#160;101(35A) of the Bankruptcy Code subject to the protections afforded </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the non-terminating Party under Section&#160;365(n) of the Bankruptcy Code, and any similar law or regulation in any other country.  &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br>CONFIDENTIALITY AND PUBLICITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Confidentiality Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Term and for a period of &#91;***&#93; years after any termination or expiration of this Agreement, each Party agrees to, and will cause its Representatives to&#58; (i) keep in confidence and not disclose the other Party&#8217;s Confidential Information to any Third Party without the prior written consent of the disclosing Party, except as expressly permitted pursuant to this Agreement&#59; and (ii) not use for any purpose, except to exercise its rights or perform its obligations under this Agreement, any Confidential Information of the other Party, without the prior written consent of the disclosing Party.  The existence and terms of this Agreement are the Confidential Information of each Party, with each Party treated as the receiving Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees that it and its Affiliates will provide or permit access to the other Party&#8217;s Confidential Information only to the receiving Party&#8217;s employees, consultants, advisors and Sublicensees, and to the employees, consultants and advisors of the receiving Party&#8217;s Affiliates (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case, of all the foregoing in this Section 9.1(b), on a need to know basis (meaning they need to know the information for purposes of performing the Party&#8217;s obligations under this Agreement or exercising its rights under this Agreement), who are subject to obligations of confidentiality and non-use with respect to such Confidential Information no less stringent than the obligations of confidentiality and non-use of the receiving Party pursuant to this Section&#160;9.1 (but of duration customary in confidentiality agreements entered into for a similar purpose).  Each Party will remain responsible for any failure by its Affiliates or Sublicensees, and its and its Affiliates&#8217; respective employees, consultants and advisors, to treat such Confidential Information as required under this Section&#160;9.1 as if such Affiliates, employees, consultants, advisors and Sublicensees were parties directly bound to the requirements of this Section&#160;9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Confidentiality Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein, each Party may use and disclose the other Party&#8217;s Confidential Information and the terms of this Agreement as follows&#58; (i) by BioNTech or its Affiliates under appropriate written confidentiality and non-use obligations no less stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose), to bona fide potential or actual collaborators, licensors, Sublicensees, licensees, or strategic partners and, on a need to know basis, to employees, directors, agents, consultants, and advisers of any such Third Parties, (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">by OncoC4 or its Affiliates under appropriate written confidentiality and non-use obligations no less stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose), to permitted contractors, sublicenses and Service Providers and, on a need to know basis, to employees, directors, agents, consultants, and advisers of any such Third Parties, (iii) by either Party to its financial advisors, attorneys and accountants, to bona fide actual or potential acquisition partners, financing sources, investors and underwriters on a need to know basis, in each case, under appropriate confidentiality and non-use obligations (which may include professional ethical obligations) no less stringent than those in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Party will remain responsible for any failure by any of the foregoing individuals or entities to treat such Confidential Information as required under Section&#160;9.1 as if such individuals or entities were parties directly bound to the requirements of this Section&#160;9.1, or (iv) as required by any court or other governmental body or as otherwise required by applicable Laws (including any such disclosures as are required by a Regulatory Authority in connection with seeking Regulatory Approval, Pricing and Reimbursement Approval, import authorization for any Licensed Product in the Territory, or the rules or regulations of the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States or of any stock exchange or listing entity)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that except for disclosures of Confidential Information to any Regulatory Authority, notice is promptly given to the other Party and the disclosing Party cooperates with reasonable requests from the other Party to seek a protective order or other appropriate remedy to protect the Confidential Information.  Notwithstanding anything to the contrary contained in this ARTICLE IX, Confidential Information that is permitted or required to be disclosed will remain otherwise subject to the confidentiality and non-use provisions of Section&#160;9.1(b) and this Section&#160;9.1(c) if it does not as a result of any of the foregoing disclosures become public.  If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar Regulatory Authority in a country other than the United States, then such Party will, a reasonable time (and in no event less than &#91;***&#93; Business Days) prior to any such filing, provide the other Party with a copy of such agreement showing any provisions hereof as to which the Party proposes to request confidential treatment, will provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions, and will take such other Party&#8217;s reasonable comments into consideration before filing such redacted version of the Agreement and use Commercially Reasonable Efforts to have terms identified by such other Party afforded confidential treatment by the applicable Regulatory Authority provided that such confidential treatment is reasonably available for the terms requested.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Secrecy of Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of Section&#160;9.1(a), during the Term each Party will protect, and will cause its Affiliates and its Sublicensees and its and their respective officers, directors, employees, and agents to protect, the secrecy and confidentiality of the Licensed Know-How and unpublished Licensed Patents &#91;***&#93; using at least the same degree of care as it uses to prevent the disclosure of its own other confidential information of like importance and in any event a reasonable duty of care.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge that in some cases it may be desirable to publicly disclose results and significant Developments regarding a Licensed Product in the Field in the Territory, and such disclosures shall be permitted in the circumstances described in this Section&#160;9.2.  Such disclosures may include achievement of milestones, significant events in the Development process with respect to Licensed Products, or Commercialization activities with respect to Licensed Products.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except for disclosures permitted in accordance with Section&#160;9.1(b), whenever either Party elects to make any public disclosure regarding this Agreement, including any milestones, significant events in the Development or Commercialization of the Licensed Products in the Territory, it will first notify the other Party of such planned press release or public announcement and provide a draft for review no less than &#91;***&#93; Business Days in advance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Laws, with as much advance notice as possible under the circumstances if it is not possible to provide notice no less than &#91;***&#93; Business Days in advance).  Each Party will have the right to review any such planned press release or public announcement proposed by the other Party with respect to Licensed Products in the Territory, or that includes Confidential Information of the other Party.  The reviewing Party will attempt to provide to the other Party its feedback as to whether it approves or withholds its consent as soon as reasonably possible, typically no later than &#91;***&#93; Business Days after its receipt thereof.  A Party desiring to make such public disclosure may issue such press release or public announcement without such prior review by the other Party if (1) the contents of such press release or public announcement have all previously been made public other than through a breach of this Agreement by such Party, and (2) such press release or public announcement is consistent with the previously issued press release or other publicly available information.  In addition, the non-disclosing Party will have the right to review, but not approve, any press release or public announcement that the proposing Party determines is required by applicable Laws based on the advice of counsel, which public disclosures are subject to Section&#160;9.2.  Notwithstanding the foregoing, the Parties have agreed to issue a joint press release in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 9.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on a date to be mutually agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The principles to be observed in such disclosures will include accuracy, compliance with applicable Laws and regulatory guidance documents, reasonable sensitivity to potential negative reactions of Regulatory Authorities and the need to keep investors informed regarding the business of the Party making such public disclosure.  Nothing in this Section&#160;9.2 will restrict a Party from making a disclosure required by Laws as reasonably determined by such Party&#8217;s counsel, including disclosures in clinical trial registries and those required by any Laws relating to the public sale of securities (as provided in Section&#160;9.1(c))&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such disclosure will include no more Confidential Information than the amount required by such applicable Laws, and the Parties will use reasonable efforts to seek confidential treatment of Confidential Information to be included in such disclosures.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except with the prior written approval of BioNTech or otherwise in accordance this ARTICLE IX, OncoC4 shall have no right to publish or present the results of the Joint Development Program.  In the event that BioNTech proposes to publish or present the results of the Joint Development Program, including any oral presentation or abstract, such publication or presentation will be subject to the prior review by OncoC4 for patentability and the inclusion of Confidential Information.  BioNTech will provide to OncoC4 the opportunity to review any proposed abstracts, manuscripts or summaries of presentations that cover the results of the Joint Development Program.  OncoC4 will respond in writing promptly and in no event later than &#91;***&#93; Business Days after receipt of the proposed material with either approval of the proposed material or a specific statement of concern, based upon either the need to seek patent protection or removal of OncoC4&#8217;s Confidential Information.  OncoC4 may also express any concern it may have regarding competitive disadvantage arising from the proposal.  In the event of any such concern provided in accordance with this Section&#160;9.2(c), BioNTech agrees not to submit such publication or to make such presentation that contains such information for a period of &#91;***&#93; days in order to provide time to seek patent protection or otherwise resolve such concern.  In addition, BioNTech will remove from such proposed publication any Confidential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Information of OncoC4 as requested by OncoC4 that is not also the Confidential Information of BioNTech.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">BioNTech will not submit or publish any article or other publication to or with any scientific journal or other publisher that requires, as a condition of publication, that BioNTech agrees to make available to the publisher or Third Parties any written materials that are the subject of the publication without prior written consent of OncoC4 before making such materials available to the publisher, such consent not to be unreasonably withheld, delayed or conditioned.  BioNTech will reasonably consider in good faith OncoC4&#8217;s timely communicated requests and concerns with respect to any publication proposed by BioNTech.  All publications made by BioNTech relating to any Licensed Product or Licensed Compound will be prepared, presented, and published in accordance with generally accepted pharmaceutical industry customs and guidelines, including with respect to attribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Notwithstanding any other provision of this Agreement, OncoC4 and its Affiliates shall have the right to publish the results or summaries of results of Clinical Trials (including meta-analysis or observational studies) conducted by or on behalf of OncoC4 or its Affiliates with respect to a Licensed Compound or Licensed Products as contemplated by Section&#160;3.3(c) to the extent required under applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or applicable industry codes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 will provide BioNTech a reasonable opportunity to review any proposed publication under this Section 9.2(e) prior to its publication for patentability and the inclusion of Confidential Information not required to be published or disclosed under appliable Laws or industry codes.  BioNTech will respond in writing promptly and in no event later than &#91;***&#93; Business Days after receipt of material proposed to be published under this Section 9.2(e) with either approval of the proposed material or a specific statement of concern, based upon either the need to seek patent protection or removal of BioNTech Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">not required to be published or disclosed under appliable Laws or industry codes.  In the event of any such concern provided in accordance with this Section&#160;9.2(e), OncoC4 agrees not to submit the applicable information for publication for a period of &#91;***&#93; days in order to provide time for BioNTech to seek patent protection or otherwise resolve such concern.  In addition, OncoC4 will remove from such proposed publication any Confidential Information of BioNTech as requested by BioNTech or required to be published under applicable Law or industry codes.  Subject to prior review by BioNTech and the express terms of this Section 9.2(e), BioNTech may not prevent OncoC4 from</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">publishing the results or summaries of results of Clinical Trials conducted by or on behalf of OncoC4 or its Affiliates to the extent required by applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or applicable industry codes, and publications made by OncoC4 in accordance with this Section 9.2(e) shall not be a breach of OncoC4&#8217;s obligations of confidentiality or non-use under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Given the nature of the Confidential Information and the competitive damage that could result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages will not be a sufficient remedy for any breach of this ARTICLE IX.  In addition to all other remedies, a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this ARTICLE IX.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:5.7pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REPRESENTATIONS AND WARRANTIES&#59; CERTAIN COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other Party that, as of the Execution Date and the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  It is a corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  It has full right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement, it has the right to grant to the other the licenses and sublicenses granted pursuant to this Agreement, and this Agreement and the performance by such Party of this Agreement do not violate such Party&#8217;s charter documents, bylaws or other organizational documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except for any Regulatory Approvals, Regulatory Materials, manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Products, all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance of this Agreement have been obtained.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  It is not under any obligation, contractual or otherwise, to any Person that would materially affect the diligent and complete fulfillment of obligations under this Agreement and the execution and delivery of this Agreement by such Party, and the performance of such Party&#8217;s obligations under this Agreement (as contemplated as of the Execution Date) and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (i) do not conflict with or violate any requirement of Laws applicable to such Party, (ii) do not conflict with or violate any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect applicable to such Party, and (iii) do not conflict with, violate, breach or constitute a default under, or give rise to any right of termination, cancellation or acceleration of, any contractual obligations of such Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its terms, subject to the general principles of equity and subject to bankruptcy, insolvency, moratorium, judicial principles affecting the availability of specific performance and other similar Laws affecting the enforcement of creditors&#8217; rights generally.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations, Warranties and Covenants of OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4 represents, warrants or covenants to BioNTech, as applicable, that, as of the Execution Date and the Effective Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All Licensed Patents existing as of the Execution Date are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, OncoC4 is either the sole and exclusive owner of or has sufficient rights to grant the rights licensed to BioNTech hereunder with respect to such Licensed Patents, all of which are free and clear of any claims, liens, charges or encumbrances (subject to the Upstream Agreements, where applicable).  To OncoC4&#8217;s knowledge, all Licensed Patents have been filed and prosecuted in good faith in the patent offices in accordance with applicable Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Listed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Execution Date and the Effective Date, the Listed Patents are the only Licensed Patents and are the only Patents Controlled by OncoC4 or any Affiliate of OncoC4 that Claim a Licensed Compound or Licensed Product.  As of the Execution Date and the Effective Date, OncoC4 Controls the Listed Patents with respect to Licensed Compound and Licensed Product.  The issued Listed Patents are to the best of OncoC4&#8217;s knowledge valid and enforceable&#59; the pending Listed Patents have been prosecuted in good faith and in accordance with all legal duties of the applicant imposed by patent Laws.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Third Party Challenges</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To OncoC4&#8217;s knowledge, there are no claims, judgments, or settlements against, or amounts with respect thereto, made against OncoC4 or any of its Affiliates relating to the Licensed Patents or the Licensed Know-How.  No claim or litigation has been received by OncoC4 or its Affiliates or, to OncoC4&#8217;s knowledge, threatened by any Person (i) alleging that the Licensed Patents are invalid or unenforceable, (ii) challenging OncoC4&#8217;s Control of the Licensed Patents (i.e., alleging that a Third Party has a right or interest in or to the Licensed Patents or Licensed Know-How) or (iii) alleging misappropriation of the Know-How of any Third Party used in the Development, Manufacture or Commercialization of Licensed Products by or on behalf of OncoC4 prior to the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Non-Infringement of Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To OncoC4&#8217;s knowledge, the (i) Development and Manufacture of the Licensed Compound and Licensed Product, as conducted by OncoC4 and its Affiliates prior to the Effective Date did not infringe any Patent or misappropriate any Know-How of any Person (in the case of pending Patents, evaluating them as if issued) and (ii) Commercialization of Licensed Compound and Licensed Product as contemplated in the CDP as of the Effective Date will not infringe the Patent of any Third Party.  No written claim of infringement or alleged infringement of the Patents that is Controlled by or misappropriation of the Know-How that is Controlled by any Third Party has been received by OncoC4, or to OncoC4&#8217;s knowledge, threatened, against OncoC4 or any of its Affiliates with respect to the Development or Manufacture of the Licensed Compound or Licensed Product.  To OncoC4&#8217;s knowledge, no Patents owned by a Third Party currently Claim Licensed Compound or Licensed Product, nor their use in any field. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Infringement Notices to Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 has not given written notice to any Third Party asserting infringement by such Third Party of all or any portion of the Licensed Patents and OncoC4 is not aware of any such infringement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">No Non-Suit Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 has not entered into any agreement with a Third Party pursuant to which OncoC4 has agreed not to pursue any infringement by such Third Party of the Licensed Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Absence of Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise disclosed to BioNTech prior to the Execution Date, there are no judgments or settlements against or owed by OncoC4 or its Affiliates, or, to OncoC4&#8217;s knowledge, pending litigation against OncoC4 or its Affiliates, or litigation threatened against OncoC4 or its Affiliates, in each case, related to any Listed Patents, Licensed Know-how, Licensed Compound or Licensed Product, including any such litigation relating to any Regulatory Materials Controlled by OncoC4 or its Affiliates as of the Execution Date and the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Inventors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Person who has or has had any ownership rights in or to any Licensed Patents purported to be owned solely by OncoC4, has assigned and has executed an agreement assigning its entire right, title, and interest in and to such Licensed Patents to OncoC4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Upstream Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Upstream Agreements are in full force and effect in accordance with their terms&#59; OncoC4 is not in breach of any Upstream Agreement and knows of no breach of any Upstream Agreement by the other party(ies) thereto&#59; and except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, OncoC4 has neither sent, provided, nor received any notice of breach or intent to terminate any Upstream Agreement.  The copies of the Upstream Agreements made available to BioNTech by OncoC4 in due diligence in connection with this Agreement were true, accurate and complete, including all amendments thereto.  During the Term, OncoC4 will not knowingly breach any Upstream Agreement, will not terminate any Upstream Agreement, and will not modify or amend any Upstream Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in any manner that would limit, restrict or otherwise adversely affect in any material respect the rights granted to BioNTech hereunder, in each case, without obtaining BioNTech&#8217;s prior written consent.  During the Term, OncoC4 will not exercise, waive, release, or assign any rights under any Upstream Agreement in any manner that would limit, restrict or otherwise adversely affect in any material respect the rights granted to BioNTech hereunder, in each case, without obtaining BioNTech&#8217;s prior written consent.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;10.2(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, OncoC4 and its Affiliates are not parties to any agreement with a Third Party with respect to Licensed Compounds, Licensed Products, Licensed Patents or Licensed Know-How, that is not included in the Upstream Agreements, other than (i) routine agreements relating to Clinical Trials entered into by OncoC4 or its Affiliates in the ordinary course of business (including ordinary course agreements with clinical investigators), (ii) routine confidentiality and non-disclosure agreements entered into by OncoC4 or its Affiliates in the ordinary course of business, and (iii) routine assignment agreements with employees that fully and completely assign rights in Licensed Patents or Licensed Know-How to OncoC4 and impose no limitations, restrictions, terms, or conditions that would in any way limit OncoC4&#8217;s Control thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 shall be responsible for any and all payments to such employees pursuant to any such agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All matters and disputes between &#91;***&#93;, on the one hand, and OncoC4 (either directly or as successor in interest to &#91;***&#93;) or any of OncoC4&#8217;s Affiliates, on the other hand, related in any way to the Listed Patents and Licensed Know-How have been fully and finally settled and all settlement and other agreements related to such matters and disputes are included in the Upstream Agreements.  Aside from the Upstream Agreements and the agreements set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 10.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, there are no other agreements between &#91;***&#93;, on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">one hand, and OncoC4 (either directly or as successor in interest to &#91;***&#93;) or any of OncoC4&#8217;s Affiliates, on the other hand.  &#91;***&#93; has not asserted any cause of action against OncoC4, any of its Affiliates, nor, to OncoC4&#8217;s knowledge, any of the named inventors on the Listed Patents, that has not been fully and finally settled by one or more Upstream Agreements, and there are no other persons who should be named on the Listed Patents, under applicable patent Laws, who have an obligation to assign their interests in the Listed Patents to &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">All license and other agreements between &#91;***&#93;, on the one hand, and OncoC4 (either directly or as successor in interest to &#91;***&#93;) or any of OncoC4&#8217;s Affiliates, on the other hand, related to Licensed Compound(s), Licensed Product(s), any component of either of the foregoing (other than an Other Active), or the manufacturing process for any Licensed Compound(s), Licensed Product(s), or any component of either of the foregoing (including any cell lines or other biological materials used in such a process, including those that are proprietary to &#91;***&#93; or any &#91;***&#93; Affiliate) are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 10.2(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">OncoC4 shall use Commercially Reasonable Efforts to amend or receive a written waiver, or cause their Affiliate to receive such written waiver, under the &#91;***&#93; License, as soon as reasonably practicable, and in any event within &#91;***&#93; months, following the Effective Date, to allow for sublicensing through multiple tiers thereunder and the transfer of the licensed cell line to a Third Party manufacturer.  In the event that OncoC4 or its Affiliate cannot obtain such amendment or written waiver, at BioNTech&#8217;s election, BioNTech may either (A) enter into a direct license with &#91;***&#93; or (B) request that OncoC4 or its Affiliate promptly grant (and OncoC4 or its Affiliate shall so promptly grant) a direct (sub)license under the &#91;***&#93; License to any Third Party reasonably requested by BioNTech in accordance with the terms of the &#91;***&#93; License in order to allow BioNTech to complete a technology transfer or otherwise exercise its rights hereunder.  In the event that BioNTech elects to enter into a direct license with &#91;***&#93; pursuant to subclause (A) (i.e., in the event that OncoC4 cannot obtain an amendment or written waiver under the &#91;***&#93; License to allow for sublicensing through multiple tiers thereunder and the transfer of the licensed cell line to a Third Party manufacturer), such direct license shall be deemed a necessary Third Party license pursuant to Section 7.7(a) and any payments thereunder would be deductible against royalties in accordance with Section 7.7(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Notwithstanding Section 7.13, royalty payments to &#91;***&#93; under the &#91;***&#93; License and Technology Transfer costs payable to &#91;***&#93; in accordance with Section 5.2(a) will be shared &#91;***&#93; between BioNTech and OncoC4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">The &#91;***&#93; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The clinical trial &#91;***&#93; conducted pursuant to the &#91;***&#93; Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (A) would not reasonably be expected to adversely impact the Joint Development Program hereunder and (B) no results from such clinical trial are available as of the Execution Date and the Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">As soon as reasonably practicable following the Effective Date, OncoC4 shall be permitted to disclose BioNTech&#8217;s identity with respect to this Agreement and the &#91;***&#93; to &#91;***&#93; and OncoC4 shall use Commercially Reasonable Efforts to obtain a written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waiver or amendment of the &#91;***&#93; Agreement to enable OncoC4 to (A) share the Joint Clinical Data (as defined in the &#91;***&#93; Agreement) thereunder with BioNTech and (B) keep BioNTech reasonably apprised of any planned patent filings under the &#91;***&#93; Agreement.  Notwithstanding any other provision of this Agreement, OncoC4 shall be responsible for &#91;***&#93; of all Joint Development Costs associated with the &#91;***&#93; until such time that BioNTech has obtained access to such Joint Clinical Data.  Promptly following the execution of any such waiver or amendment of the &#91;***&#93; Agreement, OncoC4 will provide a copy thereof to BioNTech along with a copy of the &#91;***&#93; Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 will and will cause its Affiliates to comply in all material respects with all applicable Laws in exercising its rights and fulfilling its obligations under this Agreement.  Without limiting the foregoing, OncoC4 will conduct its Development, Manufacturing and, where applicable and subject to Section&#160;5.3(d), Commercialization activities relating to the Licensed Compound and Licensed Product(s) in accordance with applicable Laws (including data privacy Laws, current international regulatory standards, and including, as applicable, GMP, GLP and GCP), and will cause all applicable contractors hereunder to comply with such applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 has accurately and completely disclosed to BioNTech all material data known OncoC4 with respect to Licensed Compounds and Licensed Products.  The data provided by OncoC4 to BioNTech in due diligence in connection with this Agreement prior to the Execution Date and the Effective Date are accurate and complete in all material respects and OncoC4 has not omitted to include in such due diligence disclosures any data or information necessary to understand or make not misleading the data and information that were disclosed in due diligence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">&#91;***&#93; Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following the Effective Date, OncoC4 shall not, directly or indirectly, Prosecute outside the United States any Patent that was licensed to OncoC4 pursuant to the &#91;***&#93; License.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Record of Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For any Listed Patents owned by OncoC4 or an Affiliate of OncoC4 for which the public record reflects as of the Effective Date a record owner that is not either (i) OncoC4 and&#47;or (ii) an Affiliate of OncoC4, including all such Listed Patents that as of the Effective Date reflect &#91;***&#93; and&#47;or any other &#91;***&#93; entity as the record owner, OncoC4 shall cause itself and&#47;or its Affiliate to be properly recorded as the record owner in the public record in accordance with applicable requirements of Law and procedures of the relevant patent office(s), as promptly as practicable, and shall provide evidence of such recording to BioNTech promptly thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Government Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 10.2(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the inventions claimed or covered by the Licensed Patents (i) were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (ii) are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. &#167; 201(f), and (iii) are not otherwise subject to the provisions of the 35 U.S.C. &#167;&#167; 200-212.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Representations, Warranties and Covenants of BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech represents, warrants and covenants to OncoC4 that, as of the Execution Date and the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">BioNTech will and will ensure that its Affiliates and Sublicensees comply in all material respects with all applicable Laws in exercising their rights and fulfilling their obligations under this Agreement.  Without limiting the foregoing, BioNTech will conduct its Development, Manufacturing and Commercialization activities relating to the Licensed Compound and Licensed Product(s) in accordance with applicable Laws (including data privacy Laws, current international regulatory standards, and including, as applicable, GMP, GLP and GCP), and will cause all permitted contractors and Sublicensees hereunder to comply with such applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limiting the generality of Section&#160;10.3(a), BioNTech will comply with all applicable Laws concerning bribery, money laundering, or corrupt practices or which in any manner prohibit the giving of anything of value to any official, agent, or employee of any government, political party, or public international organization, candidate for public office, health care professional, or to any officer, director, employee, or representative of any other organization specifically including the U.S. Foreign Corrupt Practices Act, and the UK Bribery Act, in each case, in connection with the activities conducted pursuant to this Agreement.  BioNTech will require any contractors, Sublicensees, or other Persons that provide services to BioNTech in connection with this Agreement to comply with BioNTech&#8217;s obligations under this Section&#160;10.3(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants that neither it nor any of its or its Affiliates&#8217; employees or agents performing under this Agreement has ever been, or is currently&#58; (a) debarred under 21 U.S.C. &#167; 335a or by any Regulatory Authority&#59; (b) excluded, debarred, suspended, or otherwise ineligible to participate in federal health care programs or in federal procurement or non-procurement programs&#59; (c) listed on the FDA&#8217;s Disqualified and Restricted Lists for clinical investigators&#59; or (d) convicted of a criminal offense that falls within the scope of 42 U.S.C. &#167;&#160;1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.  Each Party further covenants that if, during the Term of this Agreement, it becomes aware that it or any of its or its Affiliates&#8217; employees or agents performing under this Agreement is the subject of any investigation or proceeding that could lead to that Party becoming a debarred entity or individual, an excluded entity or individual or a convicted entity or individual, such Party will promptly notify the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investigations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of the other Party related to business in connection with this Agreement.  Upon notice of an intended investigation, the Party receiving such notice will provide, in a reasonable time, to the other Party or to a Third Party engaged by such other Party&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g., invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE X, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OTHERWISE, INCLUDING WARRANTIES OF TITLE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY WITH RESPECT TO THE LICENSED PRODUCT, VALIDITY, ENFORCEABILITY, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.  WITHOUT LIMITING THE FOREGOING, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT EITHER PARTY WILL BE ABLE TO SUCCESSFULLY ADVANCE THE LICENSED COMPOUND OR ANY LICENSED PRODUCT, OR DEVELOP, OBTAIN REGULATORY APPROVAL FOR, MANUFACTURE OR COMMERCIALIZE THE LICENSED COMPOUND OR ANY LICENSED PRODUCT, OR, IF COMMERCIALIZED, THAT ANY PARTICULAR SALES LEVEL OR PROFIT OF ANY LICENSED PRODUCT WILL BE ACHIEVED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:1.04pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNIFICATION&#59; DAMAGES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  OncoC4 will defend, indemnify and hold harmless BioNTech, its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from, against and in respect of any and all Losses incurred or suffered by any BioNTech Indemnified Party to the extent resulting from Actions brought by a Third Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) arising out of&#58;  (a) any breach by OncoC4 or its Affiliates or sublicensees under this Agreement&#59; (b) the negligence or intentional misconduct of OncoC4 or any of its Affiliates, sublicensees, or contractors, or any of their respective directors, officers, employees and agents, in performing OncoC4&#8217;s obligations under this Agreement&#59; (c) any claims, including claims for payment owed or alleged to be owed by OncoC4, under (i) any agreement between OncoC4 and a Third Party entered into prior to the Effective Date to the extent such claims relate to pre-Effective Date activities or result from or relate to the terms of this Agreement (for clarity, not including the Exploitation by or on behalf of the Parties of the Licensed Compound or Licensed Products after the Effective Date as contemplated by this Agreement) or (ii) an Upstream Agreement, in each case ((i) and (ii)), including any such claims related to joint ownership over intellectual property rights&#59; or (d) the &#91;***&#93; License&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4&#8217;s obligations pursuant to this Section&#160;11.1 will not apply to the extent such Losses result from any events or activities described in Section&#160;11.2 for which BioNTech has an obligation to indemnify any OncoC4 Indemnified Party.  In addition, OncoC4 will indemnify BioNTech Indemnified Parties for &#91;***&#93; of their Losses arising out of Third Party Actions resulting from the Joint Development Program, but excluding those Third Party Actions arising out of the causes set forth in Section&#160;11.1(a) or (b) or Section&#160;11.2(a), (b), or (c) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shared CDP Liability Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech will defend, indemnify and hold harmless OncoC4, its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OncoC4 Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from, against and in respect of any and all Losses incurred or suffered by any OncoC4 Indemnified Party to the extent resulting from Third Party Actions arising out of&#58;  (a) any breach by BioNTech or its Affiliates or Sublicensees under this Agreement&#59; (b) the negligence or intentional misconduct of BioNTech or any of its Affiliates, Sublicensees, or contractors, or any of their respective directors, officers, employees and agents, in performing BioNTech&#8217;s obligations or exercising BioNTech&#8217;s rights under this Agreement, or (c) BioNTech&#8217;s or its Affiliates&#8217; or Sublicensees&#8217; Exploitation (other than as part of the Joint Development Program) of the Licensed Compound or Licensed Products in the Field in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that BioNTech&#8217;s obligations pursuant to this Section&#160;11.2 will not apply to the extent such Losses result from any events or activities described in Section&#160;11.1 for which OncoC4 has an obligation to indemnify any BioNTech Indemnified Party.  In addition, BioNTech will indemnify, defend and hold harmless OncoC4 Indemnified Parties for &#91;***&#93; of their Losses arising out of Third Party Actions resulting from the Joint Development Program, but excluding those Third Party Actions arising out of the causes set forth in Section&#160;11.1(a) or (b) or Section&#160;11.2(a), (b), or (c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claims for Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#160;An Indemnified Party entitled to indemnification under Section&#160;11.1 or Section&#160;11.2 will give prompt written notification to the Indemnifying Party from whom indemnification is sought of the commencement of any Action by a Third Party for which indemnification may be sought (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or, if earlier, upon the assertion of such Third Party Claim by a Third Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that failure by an Indemnified Party to give notice of a Third Party Claim as provided in this Section&#160;11.3(a) will not relieve the Indemnifying Party of its indemnification obligation under this Agreement, except and only to the extent that such Indemnifying Party is materially prejudiced as a result of such failure to give notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; Business Days after delivery of a notice of any Third Party Claim in accordance with Section&#160;11.3(a), the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Third Party Claim with counsel reasonably satisfactory to the Indemnified Party.  If the Indemnifying Party does not assume control of such defense, the Indemnified Party may control such defense (with counsel reasonably selected by the Indemnified Party and approved by the Indemnifying Party, such approval not to be unreasonably withheld).  The Party not controlling such defense may participate therein at its own expense.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Party controlling the defense of any Third Party Claim will keep the other Party advised of the status and material developments of such Third Party Claim and the defense thereof and will reasonably consider recommendations made by the other Party with respect thereto.  The other Party will reasonably cooperate with the Party controlling such defense and its Affiliates and agents in defense of the Third Party Claim, with all out-of-pocket costs of such cooperation to be borne by the Party controlling such defense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Indemnified Party will not agree to any settlement of such Third Party Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld, conditioned or delayed.  The Indemnifying Party will not, without the prior written consent of the Indemnified Party, which will not be unreasonably withheld, conditioned or delayed (unless such compromise or settlement involves (i)&#160;any admission of legal wrongdoing by the Indemnified Party, (ii)&#160;any payment by the Indemnified Party that is not indemnified under this Agreement, or (iii)&#160;the imposition of any equitable relief against the Indemnified Party (in which case, (i) through (iii), the Indemnified Party may withhold, condition or delay its consent to such settlement in its sole discretion)), agree to any settlement of such Third Party Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">respect thereto or that imposes any liability or obligation on the Indemnified Party (other than a monetary obligation on the Indemnifying Party).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Mitigation of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and actions as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Third Party Claims (or potential losses or damages) under this ARTICLE XV.  Nothing in this Agreement will or will be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party, at its own expense, will maintain liability insurance in an amount consistent with industry standards during the Term, but in no event will such insurance be in an aggregate amount less than &#91;***&#93; per occurrence&#47;annual aggregate during the Term.  In addition, during the Commercialization of any Licensed Product and for a period of at least &#91;***&#93; years thereafter, BioNTech will maintain product liability insurance in accordance with industry standards.  Each Party will maintain Clinical Trial insurance in compliance with all applicable Laws pertaining to the jurisdictions in which such Clinical Trials are conducted.  Each Party will provide certificate(s) of insurance evidencing such coverages to the other Party upon written request.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:32.38pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Consequential or Punitive Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS SET FORTH IN SECTION&#160;12.2, NEITHER PARTY NOR ANY OF ITS AFFILIATES WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, INCLUDING ANY LOST PROFITS ARISING OUT OF THIS AGREEMENT, IN EACH CASE, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusion from Liability Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  THE LIMITATIONS AND DISCLAIMER SET FORTH IN SECTION&#160;12.1 WILL NOT APPLY TO A CLAIM&#58; (A) FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT&#59; (B) FOR A BREACH OF SECTION&#160;8.1 OR ARTICLE IX&#59; OR (C) FOR INDEMNIFIABLE LOSSES PURSUANT TO SECTION&#160;11.1 OR SECTION&#160;11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TO THE EXTENT SUCH DAMAGES ARE AWARDED TO A THIRD PARTY. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE XIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.72pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless terminated earlier in accordance with this ARTICLE XIII, and except with respect to ARTICLE I, ARTICLE XIV, ARTICLE XV, and Sections 2.6, 9.1, 9.2, 9.3, 10.1, 10.2, 10.3, 10.6 and 13.1, all of which shall become effective on the Execution Date, this Agreement will become effective as of the Effective Date and will continue in full force and effect until the last to expire Royalty Term in all countries in the Territory for all Licensed Products (the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If at any time there are no longer any Licensed Patents nor &#91;***&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pending or issued, and no Royalty Term is then in effect in any country with respect to any Licensed Product, the Term shall expire.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Paid-Up License Upon Expiration of Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the expiration of the Royalty Term for a Licensed Product in a given country in the Territory, the Exclusive License granted to BioNTech pursuant to Section&#160;2.1(a) will become perpetual, irrevocable, non-exclusive, fully paid-up, and royalty free with respect to such Licensed Product in such country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Early Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon any material breach of this Agreement by OncoC4 or BioNTech (the Party so allegedly breaching, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Allegedly Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will have the right, but not the obligation, to terminate this Agreement in its entirety by providing (i) at least &#91;***&#93; days&#8217; written notice to the Allegedly Breaching Party with respect to any breach of any payment obligation under this Agreement or (ii) at least &#91;***&#93; days&#8217; written notice to the Allegedly Breaching Party with respect to any other breach, which notice will, in each case (A) expressly reference this Section&#160;13.3(a) and state that it is a notice of material breach under this Section 13.3(a), (B)&#160;reasonably describe the alleged breach which is the basis of such termination, and (C) clearly state the Non-Breaching Party&#8217;s intent to terminate this Agreement if the alleged breach is not cured within the applicable cure period.  For material breaches not capable of cure within &#91;***&#93; days that may be alleged, but excluding breaches in the form of a failure to pay an amount due or a breach of Section&#160;2.6, 3.2(e) or 15.17, the &#91;***&#93; day cure period shall be extended to such longer reasonable period as in which it is possible for the Allegedly Breaching Party to cure if it provides written notice within the &#91;***&#93; days of its intent and plan to cure and subsequently proceeds to use Commercially Reasonable Efforts to carry out such plan (as it may be updated based upon circumstances subsequently encountered)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such extended cure period shall not exceed &#91;***&#93; days following the notice of breach under this Section&#160;13.3(a) and following such &#91;***&#93; day period the Non-Breaching Party shall have the right, but not the obligation, to terminate this Agreement on at least &#91;***&#93; days&#8217; prior written notice.  The termination, if not disputed, will become effective at the end of the notice period (or if applicable such extended cure period) unless the Allegedly Breaching Party cures such breach during such notice period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (i) Non-Breaching Party may, by notice to the Breaching Party, propose a later date for such termination in order to facilitate an orderly transition of activities relating to Licensed Products in which case Section 13.4(c) shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and (ii) if the termination is disputed, then the notice and cure periods under this Section&#160;13.3(a) and the right of the Parties to terminate this Agreement shall be tolled, and otherwise this Agreement and the Parties&#8217; rights hereunder (including the Exclusive License and if still in effect the Option) shall remain in full force and effect, in each case, pending the outcome of dispute resolution in accordance with this Agreement, at which time this Agreement either will or will not terminate based upon the results of the dispute resolution (i.e., in accordance with the arbitral award).  In no event shall this Agreement be terminated by a termination under this Section&#160;13.3(a) while dispute resolution with respect to whether a Party is entitled to terminate under this Section 13.3(a) is ongoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  BioNTech will have the right to terminate this Agreement in its entirety for convenience, for any reason or for no reason, at will, on no less than &#91;***&#93; months&#8217; prior written notice to OncoC4.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be terminated, to the extent permitted by applicable Laws, by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in the case of any involuntary bankruptcy, reorganization, liquidation or receivership proceeding such right to terminate will only become effective if the Party subject to such proceeding consents to the involuntary bankruptcy or such proceeding is not dismissed within ninety (90) days after the filing thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effects of Termination for BioNTech Fault or by BioNTech At Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following shall be the effects of termination only for the following terminations&#58; (X) by OncoC4 under Section&#160;13.3(a) (BioNTech uncured material breach), Section 13.3(c) (BioNTech bankruptcy) or (Y) by BioNTech under Section&#160;13.3(b) (at will).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Effects of Termination Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the effective date of termination, the Parties&#8217; rights, licenses, and obligations under this Agreement will terminate and neither Party will have any further rights or obligations under this Agreement from and after the effective date of termination, except as set forth in this Section&#160;13.4 and Sections&#160;13.6-13.8. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Reversion of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All rights that OncoC4 granted hereunder to BioNTech pursuant to the Exclusive License for Licensed Compounds and Licensed Products will terminate and revert to OncoC4.  All Licensed Single Products and Combination Products, provided that such Combination Products were Developed under the CDP that on or prior to the effective date of termination were undergoing active Development or Commercialization are &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reversion Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Reversion Products shall exclude all BioNTech Products or Combination Products containing BioNTech Product(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Winding Down of Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If there are any on-going Development or Commercialization activities with respect to Licensed Compounds or Licensed Products at termination of this Agreement, the Parties will negotiate in good faith and adopt a plan to wind-down, discontinue and terminate such activities in an orderly fashion or, at OncoC4&#8217;s election in the case of Reversion Product(s), promptly transition such activities to OncoC4 or its designee, in each case, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Trials, and take any actions the Parties deem reasonably necessary or appropriate to avoid any human health or safety problems and comply with all applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of this Agreement, OncoC4 will have the right to purchase all of BioNTech and its Affiliates&#8217; remaining inventory of Reversion Products held as of the effective date of termination of this Agreement at a price equal to BioNTech&#8217;s Fully Burdened Manufacturing Cost (excluding any portion of such costs previously paid by OncoC4 through its payment of its share of Joint Development Costs). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Further Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At OncoC4&#8217;s sole cost and expense, BioNTech will (i) provide any other assistance or take any other actions, in each case reasonably requested by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4, as necessary to transfer to OncoC4 the Development, Manufacture or Commercialization of the Reversion Product(s) and (ii)&#160;execute all documents as may be reasonably requested by OncoC4 in order to give effect to this Section 13.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon OncoC4&#8217;s request, BioNTech agrees to discuss in good faith for a reasonable period of time (not less than &#91;***&#93; days) whether BioNTech would be willing to assign to OncoC4, in whole or in part, BioNTech&#8217;s and its Affiliates&#8217; right, title and interest in and to any agreements between BioNTech or any of its Affiliates and Third Parties that relate to the Development, Manufacture or Commercialization of any Reversion Product(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Return of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; Business Days after the effective date of termination (but not expiration) of this Agreement in its entirety, each Party will, and cause its Affiliates to (i) destroy, all tangible items solely comprising, bearing or containing any Confidential Information of the other Party that are in such first Party&#8217;s or its Affiliates&#8217; possession or Control, and provide written certification of such destruction, or (ii) return all tangible items of the other Party&#8217;s Confidential Information to such other Party, as such other Party may direct, at the first Party&#8217;s expense&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that in any event, (A) each Party may retain copies of the Confidential Information of the other Party to the extent necessary to perform its obligations or exercise its rights that survive termination of this Agreement&#59; (B) each Party may retain one copy of the Confidential Information of the other Party for its legal archives&#59; and (C) each Party may retain Confidential Information contained in electronically stored backup files or other media created by or on behalf of the receiving Party in accordance with its standard or routine archiving and back-up procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will cause its Affiliates, Sublicensees and contractors to comply with the obligations in this Section&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Sublicensee Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of termination by OncoC4 pursuant to Section 13.3(a), any Sublicensee of rights to Mono&#47;PD-1 Combinations, only, that is in good standing as of the effective date of termination shall have the right, by written notice to OncoC4 given within &#91;***&#93; days after the date that such Sublicensee learns of the termination of this Agreement, to become a direct licensee of OncoC4 on terms and conditions substantially similar to those set forth in this Agreement, but only for the scope of Sublicense rights that were granted to such Sublicensee in its Sublicense and the scope of Reversion Products rights that are returned or granted to OncoC4 hereunder, and only to the extent BioNTech assigns, licenses and transfers to OncoC4 all rights, assets and information as is necessary in order for OncoC4 to fully perform and fully comply with any and all terms and conditions of such Sublicense in all respects (large and small).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effects of Termination for OncoC4 Fault</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following shall be the effects of termination only for the following terminations&#58; by BioNTech under Section&#160;13.3(a) (OncoC4 uncured material breach) or 13.3(c) (OncoC4 bankruptcy)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Exclusive License and (if still in effect) the Option shall survive (in accordance with its terms).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All rights of reference and access granted BioNTech in or in accordance with this Agreement shall survive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All diligence obligations of BioNTech shall terminate and shall not survive, and BioNTech shall have no further diligence obligations in relation to Licensed Compounds and Licensed Products, or of any kind, express or implied, notwithstanding anything in this Agreement, at law, or equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to Section 13.6 and Section 13.8, BioNTech&#8217;s obligations to pay Development Milestone Payments shall terminate and shall not survive termination of this Agreement, but BioNTech&#8217;s obligations to pay royalties and Sales Milestone Payments hereunder in due course as they come due shall survive, except that all royalty payment and Sales Milestone Payment amounts that would have been due in the absence of the termination shall be reduced by &#91;***&#93; (and, for clarity, Section&#160;7.7(f) shall not negate such &#91;***&#93; reduction&#59; rather in this circumstance, Section&#160;7.7(f) shall apply to calculate the amount that would have been due in the absence of the termination, and the reduction under this Section&#160;13.5(d) shall apply after that). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">OncoC4 shall have no further right or obligation (except as expressly provided in this Section 13.5) to participate in the Joint Development Program nor the activities that were provided for in the CDP, and OncoC4 shall have no further responsibility for any portion of Joint Development Costs incurred following, or otherwise allocable to any activity conducted after, the effective date of termination of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that OncoC4 shall continue to be responsible for its otherwise applicable share of Joint Development Costs, subject to the CDP and Joint Development Budget last approved by the JSC in accordance with this Agreement (but not pursuant to an exercise by BioNTech of its final decision-making authority after a notice of termination) as of the effective date of termination, during a &#91;***&#93; wind-down period following the effective date of termination, and BioNTech shall be entitled to offset OncoC4&#8217;s share of such costs against payments due hereunder pursuant to BioNTech&#8217;s surviving royalty payment obligations.  OncoC4 shall reasonably cooperate with BioNTech in any transition activities reasonably requested by BioNTech to transfer activities that OncoC4 or its Affiliate were performing under the Joint Development Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the effective date of termination to BioNTech or its Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The Parties&#8217; obligations under ARTICLE IX shall survive for &#91;***&#93; years after the effective date of termination, and for clarity information disclosed by either Party in connection with its surviving rights and obligations under this Agreement may qualify as Confidential Information as defined herein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Effective upon the effective date of termination, OncoC4 hereby assigns to BioNTech all right, title, and interest otherwise held by OncoC4 and its Affiliates in the &#91;***&#93; and Know-How Controlled by OncoC4 or its Affiliate that is necessary for BioNTech to Exploit Licensed Products that were actively being Developed or Commercialized at the time of the termination of this Agreement (but not including any rights with respect to any Other Active contained in a Combination Product) (and solely with respect to the Know-How, limited to the manner in which the Licensed Products were being Developed or Commercialized at the time), all Regulatory Materials in respect of such Licensed Products otherwise held by OncoC4 and its Affiliates, all inventories of such Licensed Products and Licensed Compounds for use therein </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(but not including any Other Active contained in a Combination Product), and all contracts (to the extent assignable) for the Manufacture or Development of such Licensed Products and Licensed Compounds for use therein (but not including any Other Active contained in a Combination Product) that BioNTech elects by written notice after having &#91;***&#93; days to review such contracts to take assignment of (and OncoC4 shall provide copies of such contracts that BioNTech has the right to elect assignment of, subject to applicable confidentiality restrictions, within &#91;***&#93; days after the effective date of termination).  OncoC4 shall execute and deliver to BioNTech any documents and instruments reasonably requested by BioNTech to evidence or record such assignment or to file for, prosecute, cause to issue, or enforce any of the assigned rights and&#47;or properties, in each case, in accordance with this Section 13.5(g).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">BioNTech shall have the exclusive &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">OncoC4&#8217;s obligations hereunder to maintain in full force and effect and fully perform the Upstream Agreements, including making all payments due thereunder, as described in Section&#160;2.7, shall survive, but only to the extent relating to Licensed Products actively Developed or Commercialized at the time of the termination of this Agreement.  In addition, upon BioNTech&#8217;s request, on an Upstream Agreement-by-Upstream Agreement basis, OncoC4 agrees to discuss in good faith for a reasonable period of time (not less than &#91;***&#93; days) whether OncoC4 would be willing to assign to BioNTech OncoC4&#8217;s and its Affiliates&#8217; right, title and interest in and to any such Upstream Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">All other rights and obligations of the Parties, except as provided in Sections&#160;13.6 and 13.7, shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Expiration or termination of this Agreement for any reason will not release either Party from any obligation or liability which, on the effective date of such expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions set forth in the following Sections, as well as, to the extent applicable, any other Sections or defined terms referred to in such Sections or Articles or necessary to give them effect, will survive any expiration or termination of this Agreement&#58;  Sections 4.2, 7.9, 7.10, 7.13, 8.1, 8.2 (solely with respect to Joint Patents) and 8.3 (solely with respect to Joint Patents), 8.5, 8.9, 9.1 (for the time period set forth therein), 9.3, 10.6, 13.2 (solely in the event of expiration and on a Licensed Product-by-Licensed Product and country-by-country basis), 13.4 and 13.5 (each, to the extent applicable), 13.6-13.8 (inclusive)&#59; ARTICLE VII (for the time period set forth therein), ARTICLE XI (provided that Section 11.4 shall survive solely for the time period set forth therein), ARTICLE XII, ARTICLE XIV and ARTICLE XV (except for Sections 15.17 and 15.18)&#59; and all Schedules or Exhibits that are referenced in a surviving provision.  Furthermore, any other provisions required to interpret the Parties&#8217; rights and obligations under this Agreement, including applicable definitions in ARTICLE I, will survive to the extent required.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Exclusive Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All of the effects of termination (for clarity, not expiration) set forth in this ARTICLE XIII are in addition to any other rights and remedies that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may be available to the Parties under this Agreement or applicable Law, and such effects of termination will not be construed to limit any such rights or remedies.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE XIV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.38pt"><br>DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute Resolution&#59; Escalation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties recognize that disputes as to certain matters arising out of or in connection with this Agreement may arise from time to time.  It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising out of or in connection with this Agreement in an expedited manner by mutual cooperation.  To accomplish this objective, except as specified in Section 13.4(d) any and all disputes between the Parties arising out of or in connection with this Agreement (including any dispute or failure to disagree arising at the JSC or dispute regarding Section 15.17) will first be referred to the Senior Officers for resolution and the Senior Officers will attempt to resolve the matter in good faith.  If the Senior Officers fail to resolve such matter within fifteen (15) Business Days after the date on which the matter is referred to the Senior Officers (unless a longer period is agreed to by the Parties), then either Party may submit the dispute for final resolution by binding arbitration in accordance with Section&#160;14.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth in this Section&#160;14.2 or otherwise expressly provided in this Agreement (including matters that expressly require the mutual agreement of the Parties), each dispute, difference, controversy or claim arising in connection with or related or incidental to, or question occurring under, this Agreement or the subject matter hereof that is not resolved pursuant to Section&#160;14.1 within the time from set forth therein will at the written request of either Party be referred to and finally resolved by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Each Party will within &#91;***&#93; Business Days after the institution of the arbitration proceedings appoint one (1) arbitrator and the third arbitrator to be selected by mutual agreement of the two (2) arbitrators appointed by the Parties, and each arbitrator will have significant experience in the biopharmaceutical industry.  If the two initial arbitrators are unable to select a third arbitrator within &#91;***&#93; Business Days after the selection of the second arbitrator, then the third arbitrator will be appointed in accordance with the Rules.  The foregoing arbitration proceedings may be commenced by either Party by written notice to the other Party.  Unless otherwise agreed by the Parties, all such arbitration proceedings will be held in New York, New York&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that proceedings may be conducted by telephone conference call with the consent of the Parties and the arbitrator(s).  All arbitration proceedings will be conducted in the English language.  The arbitrators will consider grants of equitable relief and orders for specific performance as co-equal remedies along with awards of monetary damages.  The arbitrators will have no authority to award punitive damages.  The allocation of expenses of the arbitration, including reasonable attorney&#8217;s fees, will be determined by the arbitrators, or, in the absence of such determination, each Party will pay its own expenses and will share equally the expenses of the third arbitrator.  The Parties hereby agree that the arbitrators have authority to issue rulings and orders regarding all procedural and evidentiary matters that the arbitrators deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment.  Except for any appeals process provided for by AAA at the time, to which each Party hereby consents, and any court appeals available under applicable law (including New York State and U.S. federal law), all rulings by the arbitrators will be final.  Notwithstanding any contrary provision of this Agreement, any Party may seek equitable measures of protection in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">form of attachment of assets or injunctive relief (including specific performance and injunctive relief) in any matter relating to the proprietary rights and interests of either Party from any court of competent jurisdiction.  The provisions of this Section&#160;14.2 may be enforced and judgment on the award (including equitable remedies) granted in any arbitration hereunder may be entered in any court having jurisdiction over the award or any of the Parties or any of their respective assets.  Except to the extent necessary to confirm an award or as may be required by Laws, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.  The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute through arbitration or other judicial determination.  Nothing in this Section&#160;14.2 will preclude either Party from seeking interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding.  Notwithstanding the Parties&#8217; agreement to arbitrate, unless the Parties agree in writing in any particular case, claims and disputes between the Parties relating to or arising out of, or for which resolution depends in whole or in part on a determination of the interpretation, scope, validity, enforceability or infringement of, Patents or Trademarks relating to any Licensed Products will not be subject to arbitration under this Agreement, and the Parties may pursue whatever rights and remedies may be available to them under law or equity, including litigation in a court of competent jurisdiction, with respect to such claims and disputes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Jury Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EACH PARTY, TO THE EXTENT PERMITTED BY LAW, KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ITS RIGHT TO A TRIAL BY JURY IN ANY ACTION OR OTHER LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS IT CONTEMPLATES TO ARBITRATE AS SET FORTH IN SECTION&#160;14.2 (ARBITRATION).  THIS WAIVER APPLIES TO ANY ACTION OR LEGAL PROCEEDING, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">ARTICLE XV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.04pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment&#59; Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement and the rights and obligations of each Party under this Agreement will not be assignable, delegable, transferable, pledged or otherwise disposed of by either Party without the prior written consent of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that either Party may assign or transfer this Agreement together with all of its rights and obligations hereunder, without such consent (but with written notice to the other Party) (A)&#160;to an Affiliate or (B) to a successor in interest in connection with the transfer or sale of all or substantially all of its business or assets to which this Agreement relates, or in the event of its merger or consolidation, reorganization or similar transaction, subject to the assignee agreeing in writing to be bound by the terms and conditions of this Agreement.  Any assignment in violation of this Section&#160;15.1(a)(i) will be null and void. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Securitization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in Section&#160;15.1(a)(i) or elsewhere in this Agreement, following the earlier of (A) substantial completion by or on behalf of OncoC4 of all material Development activities to be conducted by OncoC4 under the CDP, and (B) the First Commercial Sale of a Licensed Product, OncoC4 may assign to a Third Party its right to receive milestone payments and&#47;or royalty payments owed under ARTICLE VII (such assignment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Securitization Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) without the prior written consent of BioNTech.  In connection with a contemplated Securitization Transaction, OncoC4 may disclose to Third Parties Confidential Information to the extent reasonably necessary to enable the evaluation of the Securitization Transaction opportunity (provided that such Third Parties are under obligations of confidentiality and non-use with respect to such Confidential Information that are no less stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose)).  As part of any consummated Securitization Transaction, OncoC4 may delegate its right to receive royalty reports and to conduct audits under Section 7.6 and Section 7.8 to the counterparty in such Securitization Transaction, and to allow such counterparty to exercise its rights under such Sections, and such delegation, exercise of rights, and disclosure of Confidential Information to any such counterparty (provided that such counterparty (1) is not a BioNTech Competitor and (2) is under obligations of confidentiality and non-use with respect to such Confidential Information that are no less stringent than those in this Agreement (but of duration customary in confidentiality agreements entered into for a similar purpose)) shall not be a breach by OncoC4 of its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any permitted assignment of the rights and obligations of a Party under this Agreement will be binding on, and inure to the benefit of and be enforceable by and against, the successors and permitted assigns of the assigning Party.  The permitted assignee or transferee will assume all obligations of its assignor or transferor under this Agreement.  Any assignment or attempted assignment by either Party in violation of the terms of this Section&#160;15.1(b) will be null, void and of no legal effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Change of Control of OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein, neither OncoC4 nor any of its Affiliates will be deemed to Control any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right that is Controlled by a Third Party described in the definition of &#8220;Change of Control,&#8221; or such Third Party&#8217;s Affiliates (other than an Affiliate of OncoC4 existing prior to the Change of Control), (i)&#160;prior to the closing of such Change of Control, except to the extent that any such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right was conceived, discovered, developed, reduced to practice, or otherwise made by such Third Party prior to such Change of Control using or incorporating any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right Controlled by OncoC4 or any of its Affiliates existing prior to such Change of Control, or (ii) after such Change of Control to the extent that such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right is conceived, discovered, developed, reduced to practice, or otherwise made by such Third Party or its Affiliates (other than OncoC4 or its Affiliates existing prior to the Change of Control) after such Change of Control without using or incorporating any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right Controlled by OncoC4 or any of its Affiliates existing prior to such Change of Control. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Change of Control of BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein, neither BioNTech nor any of its Affiliates will be deemed to Control any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right that is Controlled by a Third Party described in the definition of &#8220;Change of Control,&#8221; or such Third Party&#8217;s Affiliates (other than an Affiliate of BioNTech existing prior to the Change of Control), (i)&#160;prior to the closing of such Change of Control, except to the extent that any such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right was conceived, discovered, developed, reduced to practice, or otherwise made by such Third Party prior to such Change of Control using or incorporating any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right Controlled by BioNTech or any of its Affiliates existing prior to such Change of Control, or (ii) after such Change of Control to the extent that such Know-How, Patent, Regulatory Material, Regulatory Approval or other property right is conceived, discovered, developed, reduced to practice, or otherwise made by such Third Party or its Affiliates (other than BioNTech or its Affiliates existing prior to the Change of Control) after such Change of Control without using or incorporating any Know-How, Patent, Regulatory Material, Regulatory Approval or other property right Controlled by BioNTech or any of its Affiliates existing prior to such Change of Control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Choice of Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided herein, this Agreement will be governed by and interpreted under &#91;***&#93;, without regard to any conflicts of law principles thereof.  Any dispute, controversy, claim or difference of any kind whatsoever arising out of or in connection with this Agreement will be resolved exclusively in accordance with Section&#160;14.2&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that all questions concerning (a) ownership of Patents under this Agreement will be determined in accordance with Section&#160;8.1 and (b) the construction or effect of Patents will be determined in accordance with the Laws of the country or other jurisdiction in which the particular patent or patent application within such Patents has been filed or granted, as the case may be.  Any communication or proceedings resulting from disputes under this Agreement will be in English language.  The Parties agree to exclude the application to this Agreement of the United Nations Conventions on Contracts for the International Sale of Goods (1980).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice or report required or permitted to be given or made under this Agreement by one Party to the other will be in writing and will be deemed to have been delivered (a) upon personal delivery (upon written confirmation of receipt), (b) when received by the addressee, if sent by an internationally recognized overnight courier that maintains records of delivery, or registered or certified mail, postage prepaid, return receipt requested and (c) in the case of notices provided by email (which notice will be followed by an additional notice pursuant to clause (a) or (b) above if the notice is of a default under this Agreement), upon completion of transmission, with transmission confirmed, to the addressee&#8217;s email address below (or at such other addresses as may have been furnished in writing by a Party to the other as provided in this Section&#160;15.3).  For clarity, this Section&#160;15.3 is not intended to govern day-to-day business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">communications between the Parties in performing their obligations under the terms of this Agreement.</font></div><div style="padding-left:4.91pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to OncoC4&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9640 Medical Center Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rockville, MD 20850</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with copies (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Goodwin Procter LLP </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1900 N Street, NW</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Washington, DC 20036</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to BioNTech&#58; </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech SE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">An der Goldgrube 12</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55131 Mainz</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Germany</font></div><div style="margin-bottom:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that one or more provisions of this Agreement is held invalid, illegal or unenforceable in any respect, then such provision will not render any other provision of this Agreement invalid or unenforceable, and all other provisions will remain in full force and effect and will be enforceable, unless the provisions that have been found to be invalid or unenforceable will substantially affect the remaining rights or obligations granted or undertaken by either Party.  The Parties agree to attempt to substitute for any invalid or unenforceable provision a provision which achieves to the greatest extent possible the economic objectives of the invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with all schedules and exhibits attached hereto, constitutes the entire agreement between the Parties with respect to the subject matter of this Agreement and supersedes all previous arrangements between the Parties with respect to the subject matter hereof, whether written or oral, including, effective as of the Execution Date, the Mutual Non-Disclosure Agreement between the Parties dated &#91;***&#93; (provided that from and after the Execution Date all information disclosed or exchanged under such agreement will be treated as if disclosed hereunder&#59; for clarity such MNDA shall continue to govern the Parties rights and obligations prior to the Effective Date, with respect to the information exchanged thereunder).  In the event of a conflict between the CDP or any schedules or attachments to this Agreement, on the one hand, and this Agreement, on the other hand, the terms of this Agreement will govern.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The failure of any Party to assert a right under this Agreement or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party.  The exercise by any Party of any right or election under the terms or covenants herein will not preclude or prejudice any Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder.  Notwithstanding the authority granted to the JSC under this Agreement, (a) no waiver will be effective unless it has been given in writing and signed by the Party giving such waiver, and (b) no provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Contractors&#59; No Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Party will have any responsibility for the hiring, firing or compensation of the other Party&#8217;s or such other Party&#8217;s Affiliates&#8217; employees or for any employee benefits with respect thereto.  No employee or representative of a Party or its Affiliates will have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on such other Party, without such other Party&#8217;s written approval. For all purposes, and notwithstanding any other provision of this Agreement, each Party&#8217;s legal relationship under this Agreement to the other Party will be that of independent contractor, and the relationship between the two Parties will not constitute a partnership, joint partnership, joint venture, or agency, including for all tax purposes, except as otherwise required by applicable Law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliates, Sublicensees, and Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent that this Agreement imposes obligations on Affiliates, Sublicensees or contractors of a Party, such Party will cause its Affiliates and its Sublicensees and contractors to perform such obligations, as applicable.  Either Party may use one or more of its Affiliates, Sublicensees or contractors to perform its obligations and duties or exercise its rights under this Agreement, solely to the extent permitted and as specified in this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (a) each such Affiliate, Sublicensee or contractor will perform any such obligations delegated to it in compliance with the applicable terms and conditions of this Agreement as if such Affiliate, Sublicensee or contractor were a party hereto, (b) the performance of any obligations of a Party&#8217;s by its Affiliates, Sublicensees or contractors will not diminish, reduce or eliminate any obligation of such Party under this Agreement, (c) each Party will terminate promptly any contractor, and will give the other Party notice of such termination, in the case of any material breach of this Agreement by a contractor and (d) subject to such Party&#8217;s assignment to an Affiliate pursuant to Section&#160;15.1, such Party will remain liable under this Agreement for the prompt payment and performance of all of its obligations under this Agreement.  Subject to this Section&#160;15.8, if a Party exercises its rights and performs its obligations under this Agreement through one or more of its Affiliates, &#8220;OncoC4&#8221; will be interpreted to mean &#8220;OncoC4 or its Affiliates&#8221; and &#8220;BioNTech&#8221; will be interpreted to mean &#8220;BioNTech or its Affiliates&#8221; where necessary to give each Party&#8217;s Affiliates the benefit of the rights provided to such Party in this Agreement and the ability to perform its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">their successors and permitted assigns, and they will not be construed as conferring any rights on any other Third Party.  This Agreement is not intended to and will not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, other than, to the extent provided in ARTICLE XI, the Indemnified Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-exclusive Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided herein, the rights and remedies provided herein are cumulative and each Party retains all remedies at law or in equity, including the Parties&#8217; ability to receive legal damages or equitable relief, with respect to any breach of this Agreement.  Neither Party will be required (but, for clarity, will have the right as specified in this Agreement) to terminate this Agreement due to a breach of this Agreement by the other Party.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Right of Offset&#59; Recoupment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Every liability hereunder of a Party to the other Party is subject to and conditioned upon the recoupment of any and all liabilities owing from the other Party to the first Party, so as to establish a net liability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Article and Section headings used herein are for reference and convenience only, and will not enter into the interpretation of this Agreement.  Except as otherwise expressly specified, (a) references to an Article, Section or Exhibit means an Article or Section of, or a Schedule or Exhibit to this Agreement and all subsections thereof, unless another agreement is specified&#59; (b) references in any Section to any clause are references to such clause of such Section&#59; (c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended, replaced, or supplemented and in effect at the relevant time of reference thereto&#59; (d)&#160;references to &#8220;Laws&#8221; mean such Laws as in effect as of the relevant time, including all rules and regulations promulgated thereunder and any successor Laws in effect as of the relevant time, including all then-current amendments thereto&#59; (e) words in the singular or plural form include the plural and singular form, respectively&#59; (f) unless the context requires a different interpretation, the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and&#47;or&#8221;&#59; (g) the terms &#8220;including,&#8221; &#8220;include(s),&#8221; all other conjunctions of the verb &#8220;to include,&#8221; &#8220;such as,&#8221; &#8220;e.g.&#8221; and &#8220;for example&#8221; mean including the generality of any description preceding such term and will be deemed to be followed by &#8220;without limitation&#8221;&#59; (h) whenever this Agreement refers to a number of days, such number will refer to calendar days unless Business Days are specified, and if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day&#59; (i) &#8220;monthly&#8221; means on a calendar month basis, (j) &#8220;quarter&#8221; or &#8220;quarterly&#8221; means on a Calendar Quarter basis&#59; (k) &#8220;annual&#8221; or &#8220;annually&#8221; means on a Calendar Year basis&#59; (l) &#8220;year&#8221; means a 365 day period, or 366 day period in the event of a leap year, unless Calendar Year is specified&#59; (m) references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement&#59; (n) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa)&#59; (o) references to drugs or pharmaceutical products or therapies include biological products or therapies&#59; (p) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement (including any Exhibits or Schedules)&#59; (q)&#160;neither Party or its Affiliates will be deemed to be acting &#8220;on behalf of&#8221; the other Party under this Agreement, except to the extent expressly otherwise provided&#59; (r) provisions that require that a Party, or the JSC hereunder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like will be deemed to require that such agreement, consent or approval be specific and in writing in a written agreement, letter or approved minutes, but, except as expressly provided herein, excluding e-mail and instant messaging&#59; (s) the words &#8220;will&#8221; and &#8220;shall&#8221; will be construed to have the same meaning and effect&#59; and (t) conjugates of a defined term shall have the meaning that correlates to the such conjugate as compared to the defined term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be consistent with this Agreement and reasonably necessary to carry out its provisions, including working collaboratively to correct and clerical, typographical, or other similar errors in any document that is to be recorded under this Agreement.  Neither Party shall be required under this provision to grant any license or other right not set forth elsewhere in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ambiguities&#59; No Presumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement contained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel.  Accordingly, in interpreting this Agreement or any provision hereof, no presumption will apply against any Party as being responsible for the wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement will not be construed against any Party under any rule of construction that requires language to be construed against the Party having authorized the provision, irrespective of which Party may be deemed to have authored the ambiguous provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Export Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is made subject to any restrictions required by applicable Laws concerning the export of products or technical information from the U.S. or other countries which may be imposed upon or related to the Parties from time to time.  Each Party agrees that it will not export, directly or indirectly, any technology licensed to it or other technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, except in compliance with U.S. export Laws and regulations.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart.  Signatures delivered by electronic transmission, including in portable document format (.pdf) sent by electronic mail or by any other electronic means (e.g., DocuSign) agreed by the Parties, will have the same effect as physical delivery of the paper document bearing the original signatures, and will be deemed original signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">BioNTech ABC Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">OncoC4 agrees that it will not undertake any activities which will result in a violation of any applicable laws, regulations, and applicable industry and professional codes, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including but not limited to applicable local and extraterritorial anti-bribery, anti-corruption and anti-money laundering laws (collectively &#8220;PROHIBITED CONDUCT&#8221;) in connection with the provision of professional services by OncoC4 to BioNTech for or on BioNTech&#8217;s behalf.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In particular, OncoC4 agrees (i) Not to make any offer, payment, or promise to pay money or provide anything of value to a GOVERNMENT OFFICIAL (as defined below) or any other individual and&#47;or legal entity whether directly or indirectly, for the purpose of improperly influencing any act and&#47;or decision of, and&#47;or for securing any improper advantage&#59; (ii)&#160;Not to accept, receive, agree to accept and&#47;or receive a payment and&#47;or anything of value from any individual for undue favorable treatment in obtaining, retaining, and&#47;or directing business for, and&#47;or to obtain any undue special concession on behalf of OncoC4 and&#47;or BioNTech&#59; (iii) Not to facilitate any payments to any GOVERNMENT OFFICIAL to expedite a routine government action and&#47;or other official act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The term &#8220;GOVERNMENT OFFICIAL&#8221; shall be read broadly and includes (i) individuals acting on behalf of governments on a national, regional and local level (such as elected officials, customs officials, tax officials, etc.)&#59; (ii) individuals acting on behalf of government-owned or government-controlled enterprises (such as doctors and staff of public hospitals and universities, etc.)&#59; (iii) individuals acting for political parties or as or on behalf of candidates for public office&#59; and (iv) individuals acting on behalf of public international organizations (such as the WHO, World Bank, OECD, etc.). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">OncoC4 agrees that if it becomes aware or has reason to suspect that any person or legal entity acting on OncoC4&#8217;s and&#47;or BioNTech&#8217;s behalf has engaged in any activities which will result in a violation of any applicable laws, such as local and extraterritorial anti-bribery and anti-corruption Laws, regulations, and applicable industry and professional codes related to the Agreement, then the OncoC4 will immediately report such knowledge or suspicion via the following email address&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">OncoC4 agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of BioNTech related to business in connection with the Agreement.  Upon notice of an intended investigation, OncoC4 will provide, in a reasonable time, to BioNTech or to a third party engaged by BioNTech&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g., invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">OncoC4 acknowledges that the obligations under this ABC Clause (Section&#160;15.17) apply to all its Affiliates, employees, Service Providers and subcontractors.  OncoC4 will bind subcontractors who act for or on its behalf under the Agreement by respective contractual clauses encompassing all provisions of this ABC Clause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything else in this Agreement or any other right BioNTech may have, a breach of any of the provisions included in this ABC Clause by OncoC4 shall give BioNTech the right to immediately terminate this Agreement for cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Antitrust Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of BioNTech and OncoC4 agrees to prepare and make appropriate filings under the U.S. Hart-Scott-Rodino Antitrust Improvements Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other antitrust requirements relating to this Agreement and the transactions contemplated hereby as soon as reasonably practicable, but in any event within &#91;***&#93; Business Days after the Execution Date, at each Party&#8217;s own cost and expense.  The Parties agree to cooperate in the antitrust clearance process (including (i) keeping the other Party informed of any material communication received in connection with such filings and providing a copy to the other Party if such communication is in writing and (ii)&#160;permitting the other Party or its counsel to review in advance, and in good faith consider the views of the other Party or its counsel concerning any submission, filing or communication and the documents submitted therewith intended to be given the U.S. Federal Trade Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or the Antitrust Division of the U.S. Department of Justice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DOJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) and to furnish promptly to the FTC, the DOJ and any other agency or authority, any information reasonably requested by them in connection with such filings.  Subject to Section&#160;13.1, the rights and obligations of the Parties under this Agreement shall not become effective until the waiting period provided by the HSR Act, or any other timeline required by another relevant agency or authority, shall have terminated or expired without any action by any government agency to challenge the transaction (the date of such termination or expiration shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of this Agreement).  Notwithstanding any other provision of this Agreement, each of the representations and warranties made by the Parties in ARTICLE X as of the Execution Date and as of the Effective Date, as indicated in ARTICLE X, shall be true and correct in all respects as of the Execution Date and true and correct in all material respects as of the Effective Date.  In the event that antitrust clearance from the FTC, DOJ or any other required agency or authority is not obtained within &#91;***&#93; days after the Execution Date, or such other date as the Parties may mutually agree, this Agreement may be terminated by either Party on written notice to the other.  In the event a provision of this Agreement needs to be deleted or substantially revised in order to obtain regulatory clearance of this transaction, the Parties will negotiate in good faith in accordance with Section 15.4.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, each Party has caused this License and Collaboration Agreement to be executed by their respective duly authorized officers as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BioNTech SE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BioNTech SE</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sean Marett</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jens Holstein</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Sean Marett&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Jens Holstein</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;CBO and CCO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;CFO</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OncoC4, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Yang Liu</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Yang Liu</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;President and CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.5</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AI-025 Amino Acid Sequence</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.8</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description of AI-061</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.14</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.25</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CD80&#47;CD86 Compound</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.64</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONC-392 Backup Molecules</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.68</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Listed Patents</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.75</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Expert Valuation Procedure</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Parties cannot reach consensus regarding the calculation of Net Sales of a Combination Product in a country in accordance with Section 1.75 within the &#91;***&#93; days following BioNTech&#8217;s request for negotiation, then the matter shall be resolved as set forth below, by a reputable, independent Third Party who is an expert with at least &#91;***&#93; years of experience in pharmaceutical product valuation (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Neutral Expert</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">To initiate resolution by a Neutral Expert, either Party shall send the other Party a written notice that it wishes to resolve the dispute by a Neutral Expert. The date of receipt by the other Party of such written notice is the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Notice Date</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Within &#91;***&#93; Business Days following the Notice Date, each Party shall notify the other Party in writing of its appointed expert meeting the qualifications for the Neutral Expert stated above (each, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Representative Expert</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Representative Experts for each Party shall jointly appoint the Neutral Expert within &#91;***&#93; Business Days thereafter. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Within &#91;***&#93; Business Days after the appointment of the Neutral Expert, each Party shall submit to the other Party and the Neutral Expert a written summary regarding its position with respect to the dispute. Contemporaneously with the submission of its written summary regarding its position, each Party shall provide the other Party and the Neutral Expert with copies of all documents it relied upon in its written summary&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Party may redact any portion of such documents which are covered by an applicable privilege or do not relate to the subject matter of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Within &#91;***&#93; Business Days following receipt of the other Party&#8217;s written summary regarding its position, each Party may submit an opposition statement of no more than five (5) pages in length (excluding exhibits and declarations). Neither Party will be allowed to conduct any discovery. Neither Party may have any communications (either written or oral) with the other Party&#8217;s Representative Expert or the Neutral Expert other than for the sole purpose of engaging the expert panel or as expressly permitted in this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.75</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that oral presentations and follow-up written submissions may be made to the Neutral Expert at the Neutral Expert&#8217;s request. The Neutral Expert may consult in writing with the Representative Experts regarding the submissions made by either Party&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that both Representative Experts are aware of such consultation and provided an opportunity to respond. Evaluating each Party&#8217;s written submissions, the Neutral Expert shall, within &#91;***&#93; Business Days following receipt of the written opposition statement, select in total, either BioNTech&#8217;s submission or OncoC4&#8217;s submission. Such decision shall be final, binding and not appealable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Party whose submission is not selected shall be solely responsible for the expenses and fees of the Neutral Expert and the reasonable costs and fees of the other Party&#8217;s Representative Expert.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The existence of the dispute, any negotiations, submissions, and the rulings shall be deemed to be Confidential Information of both Parties. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.77</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ONC-392 Amino Acid Sequence</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.105</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upstream Agreements</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.1(b)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Permitted Subcontractors</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.7</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; License</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 3.1(a)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial CDP</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 9.2(a)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Press Release</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i1f4974b360fe42c5bdaba0be7aee4c10_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.2(i)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third-Party Agreements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.2(j) </font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreements</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.2(k) </font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreements</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.2(q)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Government Funding</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 13.4(d)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mediation &#38; &#8220;Baseball&#8221; Arbitration for Reversion Products</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">If the Parties are unable to mutually agree on and enter into a Reversion Agreement within &#91;***&#93; days following the effective date of termination and either Party refers the matter to be resolved in accordance with this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 13.4(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or they otherwise mutually agree, the matter will first be referred to the Senior Officers for resolution.  The Senior Officers will attempt to resolve the matter in good faith.  If the Senior Officers fail to resolve the matter within &#91;***&#93; Business Days after the date on which the matter is referred to the Senior Officers (unless a longer period is agreed to by the Parties), then either Party may, by written notice to the other Party, submit the matter for resolution by mediation as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The matter shall be submitted within &#91;***&#93; Business Days following receipt of such notice for mediation, for non-binding mediation conducted in accordance with the Rules of the American Arbitration Association, and to bear equally the costs of such mediation (including any fees or expenses of the applicable mediator)&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that each Party shall bear its own costs in connection with such mediation.  The Parties agree to participate in good faith in such mediation for a period of &#91;***&#93; Business Days or such longer period as the Parties may mutually agree following receipt of the notice for mediation (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mediation Period</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">In connection with such mediation, the Parties shall cooperate with the American Arbitration Association and with one another in selecting a mediator, being a judge or attorney, with ten (10) years&#8217; experience in the development and commercialization of biopharmaceutical products, who is independent of each Party (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., not a current or former employee, consultant, officer, or director, or current stockholder, of either Party or their respective Affiliates, and who does not otherwise have any current or previous business relationship with either Party or their respective Affiliates) and in scheduling the mediation proceedings during the applicable Mediation Period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Parties further agree that all information, whether oral or written, provided in the course of any such mediation by any of the Parties, their agents, employees, experts, and attorneys, and by the applicable mediator and any employees of the mediation service, is confidential, privileged, and inadmissible for any purpose, including impeachment, in any litigation, arbitration or other proceeding involving the Parties&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any information that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in such mediation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">If the Parties cannot reach resolution for any reason, including, but not limited to, the failure of either Party to agree to enter into mediation or agree to any compromise on the Reversion Agreement proposed by the mediator, on and following the expiration of the Mediation Period, then either Party may, by written notice to the other Party, submit the matter for final resolution by binding &#8220;baseball&#8221; arbitration as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The Parties will discuss and endeavor in good faith to select and agree upon a mutually acceptable single neutral arbitrator, being a judge or attorney, with at least ten (10) years&#8217; experience in the development and commercialization of biopharmaceutical products, who is independent of each Party (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., not a current or former employee, consultant, officer, or director, or current stockholder, of either Party or their respective Affiliates, and who does not otherwise have any current or previous business relationship with either Party or their respective Affiliates), within &#91;***&#93; days following the end of the Mediation Period&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Parties are unable or fail to agree upon the arbitrator within such &#91;***&#93; day period, the arbitrator shall be appointed by the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">American Arbitration Association</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (or any successor entity thereto) within &#91;***&#93; days thereafter.  Except as otherwise mutually agreed by the Parties, the arbitration shall be conducted in accordance with the American Arbitration Association&#8217;s Final Offer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Arbitration Supplementary Rules, or the equivalent successor rules then in effect to the extent consistent with and modified by this </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 13.4(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Within &#91;***&#93; Business Days after the selection of the arbitrator (or such other time as the Parties mutually agree), each Party will submit to the arbitrator and the other Party such Party&#8217;s proposed form of Reversion Agreement and a memorandum in support thereof, not exceeding ten (10) pages in length.  Within &#91;***&#93; days after receiving each Party&#8217;s proposal, the arbitrator will, as final and binding, either (i) select one of the two proposed Reversion Agreements (without modification) provided by the Parties or (ii) introduce a Reversion Agreement containing the terms, conditions, and elements of both of the &#91;***&#93; Reversion Agreement proposed by the Parties&#59; provided, that such proposed Reversion Agreement represents compromise positions between the two Reversion Agreements proposed by the Parties, in each case that the arbitrator believes, in order of priority, is&#58; (i) most closely in accordance with the terms and conditions of the Agreement and the intent of the Parties in entering into the Agreement, (ii) most fair and equitable to both Parties under the circumstances, and (iii) most commercially reasonable.  The arbitrator may combine elements of each Parties&#8217; proposed Reversion Agreement, so long as the arbitrator&#8217;s proposed Reversion Agreement does not introduce new positions that are not a compromise between the proposals made by either Party in each Party&#8217;s proposed Reversion Agreement, or award any other relief or take any other action.  Absent fraud or manifest error, the decision of the arbitrator will be final and binding on the Parties, and the Parties shall promptly execute and enter into a Reversion Agreement in the form selected by the arbitrator.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Each Party shall pay its own costs and expenses in connection with the arbitration and shall be responsible for &#91;***&#93; of the fees and expenses of the arbitrator.  The Parties agree that the arbitrator&#8217;s decision may be enforced in any court of competent jurisdiction.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.49
<SEQUENCE>5
<FILENAME>exhibit449oncoc4amendmentr.htm
<DESCRIPTION>EX-4.49
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2b2f96e79a604b118f70cc0216aff8ea_1"></div><div style="min-height:90pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.49</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDMENT No. 1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">to the License and Collaboration Agreement</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">between BioNTech SE and OncoC4, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Amendment No. 1 to the License and Collaboration Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of February 14, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment No. 1 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between BioNTech SE, a public limited company in the form of a Societas Europaea organized under the laws of the Federal Republic of Germany, with its corporate seat at An der Goldgrube 12 55131 Mainz, registered with the commercial register of the Local Court of Mainz under HRB 48720 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and OncoC4, Inc., a Delaware corporation having business offices at 9640 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OncoC4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). OncoC4 and BioNTech are each referred to herein, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, collectively, as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, BioNTech and OncoC4 are parties to that certain License and Collaboration Agreement, dated as of March 17, 2023 and Effective Date as of April 25, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), concerning the Exploitation of Licensed Products on the terms and subject to the conditions more particularly set forth therein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Agreement provides for the joint Development of Mono&#47;PD-1 Combinations, and for BioNTech to solely Develop Other Combinations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, it was the original intent of the Parties that the Parties would jointly Develop Licensed Single Products as Mono&#47;PD-1 Combinations, including where a Licensed Single Product is used as part of a combination regimen with (i) one or more PD-1 Product, (ii)&#160;one or more SOC Product, or (iii) one or more PD-1 Product and one or more SOC Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties mutually desire to amend, modify and restate certain terms and conditions of the Agreement to clarify the joint Development by the Parties of Mono&#47;PD-1 Combinations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:53.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.3pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise defined herein, capitalized words in this Amendment shall have the meaning attributed to them in the Agreement (including as amended hereby).</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.3pt">AMENDMENTS</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties agree that, as of the Amendment No. 1 Effective Date, the Agreement is amended as set forth in this Section 2. </font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.45pt">The following definition shall be added to Article 1 in appropriate alphabetical order&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Standard of Care Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SOC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;&#8221;</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:90pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.45pt">Section 1.111 of the Agreement is hereby amended by deleting the reference to the defined term &#8220;Mono&#47;PD-1 Combinations&#8221; and replacing it, in appropriate alphabetical order, with the reference to the defined term &#8220;Mono&#47;PD-1&#47;SOC Combinations&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.45pt">The first sentence of Section 3.1(a)(i) of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;OncoC4 and BioNTech shall use Commercially Reasonable Efforts to conduct Development activities with respect to the Licensed Compound and Licensed Products, either (A) as a monotherapy, (B) as a Licensed Single Product used as part of a combination regimen with one or more (I) SOC Product or (II) PD-1 Product, or (C) as a Licensed Single Product used as part of a combination regimen with both one or more SOC Product and one or more PD-1 Product ((A)-(C) collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mono&#47;PD-1&#47;SOC Combinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in each case, in accordance with a joint clinical development plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) approved by the JSC in accordance with the terms of this Agreement.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.45pt">All references in the Agreement to &#8220;Mono&#47;PD-1 Combinations&#8221; are hereby deleted in their entirety and replaced with references to &#8220;Mono&#47;PD-1&#47;SOC Combinations&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.3pt">INTEGRATION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the sections of the Agreement specifically amended hereunder, all terms and conditions of the Agreement remain and shall remain in full force and effect. This Amendment shall hereafter be incorporated into and deemed part of the Agreement and any future reference to the Agreement shall include the terms and conditions of this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.3pt">APPLICABLE LAW &#38; JURISDICTION</font></div><div style="margin-bottom:12pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment shall be governed by, and construed in accordance with, the laws which govern the Agreement, and the Parties submit to the jurisdiction and dispute resolution provisions as set forth in the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:-35.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.3pt">COUNTERPARTS</font></div><div style="margin-bottom:12pt;padding-left:35.3pt;text-align:justify;text-indent:0.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment may be executed in counterparts, each of which, when so executed and delivered, will be deemed to be an original, and all of which counterparts, taken together, will constitute one and the same instrument even if both Parties have not executed the same counterpart. Signatures delivered by electronic transmission, including in portable document format (.pdf) sent by electronic mail or by any other electronic means (e.g., DocuSign) agreed by the Parties, will have the same effect as physical delivery of the paper document bearing the original signatures, and will be deemed original signatures.</font></div><div style="margin-bottom:12pt;margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank &#8211; Signature Page to Follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:83.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><div id="i2b2f96e79a604b118f70cc0216aff8ea_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, the Parties intending to be bound have caused this Amendment to be executed by their duly authorized representatives as of the Amendment No. 1 Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James Ryan</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; James Ryan</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Legal Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jens Holstein</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jens Holstein</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; CFO</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OncoC4, Inc.</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; James DeYonker</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; James DeYonker</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; SVP, Head of Legal and IP</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.50
<SEQUENCE>6
<FILENAME>exhibit450dualityher2agree.htm
<DESCRIPTION>EX-4.50
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7c27d20d9ff34584a9266e65703759b3_1"></div><div style="min-height:154.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.50</font></div><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Confidential </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DUALITY BIOLOGICS (SUZHOU) CO. LTD.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIONTECH SE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">dated as of March 16, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Confidential</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 1 DEFINITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................................... &#160;&#160;&#160;&#160;1</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 2 LICENSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .............................................................................................. &#160;&#160;&#160;&#160;20</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 3 GOVERNANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .................................................................................. &#160;&#160;&#160;&#160;26</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 4 DEVELOPMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................................ &#160;&#160;&#160;&#160;31</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 5 REGULATORY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">................................................................................... &#160;&#160;&#160;&#160;35</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 6 MANUFACTURE &#38; SUPPLY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ........................................................... &#160;&#160;&#160;&#160;39</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 7 COMMERCIALIZATION MATTERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ............................................ &#160;&#160;&#160;&#160;40</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 8 FINANCIAL TERMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ......................................................................... &#160;&#160;&#160;&#160;43</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 9 PAYMENT&#59; RECORDS&#59; AUDITS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .................................................... &#160;&#160;&#160;&#160;51</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 10 CONFIDENTIALITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................... &#160;&#160;&#160;&#160;54</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 11 REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ........................................................................................ &#160;&#160;&#160;&#160;58</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 12 INTELLECTUAL PROPERTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ...................................................... &#160;&#160;&#160;&#160;65</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 13 TERM&#59; TERMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................. &#160;&#160;&#160;&#160;72</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 14 INDEMNIFICATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................... &#160;&#160;&#160;&#160;82</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 15 DISPUTE RESOLUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................ &#160;&#160;&#160;&#160;84</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 16 MISCELLANEOUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .......................................................................... &#160;&#160;&#160;&#160;86</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedules</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ABC Terms</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.49&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Description of Duality Know-How &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.55&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;List of Duality Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.89&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;List of Indications</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Know-How Transfer</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 4.6&#160;&#160;&#160;&#160;Agreed Preparation Activities for Initiation of a &#91;***&#93; Clinical Trial </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 10.4 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Joint Press Release</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">This License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of March 16, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co. Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a corporation organized and existing under the laws of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), having a place of business at Unit 1105-1106, No 868 Ying Hua Road, Pudong New District, Shanghai, China, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, an company organized and existing under the laws of Germany, having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Duality is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Licensee is engaged in the research, development and commercialization of active immunotherapies for patient-specific approaches to the treatment of diseases&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee desires to obtain from Duality, and Duality desires to grant to Licensee, an exclusive sublicensable license under the Duality Licensed IP to Develop, Manufacture and Commercialize the Licensed Products in the Field in the Territory (each as defined below), subject to the terms and conditions of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, The Parties desire to collaborate in the Development, Manufacture and Commercialization of the Licensed Products in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Duality and Licensee hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a Selling Party (as defined below) International Financial Reporting Standards endorsed by the European Union or other applicable standard accounting principles used by Sublicensees.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any construct comprising an Antibody(ies) linked to a non-Antibody chemical species with a therapeutic or biological activity or function, including non-Antibody chemical species that (i) directly kills, slows or stops the growth of a tumor cell through such compound&#8217;s primary mechanism of action (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cytotoxic Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Active(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any active pharmaceutical or biologic ingredient(s) that is not the Licensed Compound. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any company or entity controlled by, controlling, or under common control with a Party or another entity.  For the purpose of this definition, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 1 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an entity shall be deemed to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; another entity, if it owns directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, capital stock, or other comparable equity or ownership interest of such entity, or possession, direct or indirect, of the power to direct or cause the direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.9.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean for a particular Licensed Product the total Net Sales for a particular Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any antibody (including murine, chimeric, human, humanized, recombinant, transgenic, grafted, phage display derived, or single chain antibody), or antigen binding fragment thereof. &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Anti-Corruption Laws&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means all applicable anti-bribery and anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010 and the PRC Anti-Money Laundering Law and the comparable Applicable Laws of any countries in which candidates or Licensed Products, payments or services will be provided or procured under or pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean collectively the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, of any Governmental Authority and any license, franchise, permit or similar right granted under any of the foregoing (including Regulatory Approvals) and any policies and other requirements of or from any court, arbitrator, Regulatory Authority or governmental agency or Governmental Authority having jurisdiction over or related to the subject item or subject person, including all applicable GXPs, Anti-Corruption Laws, Applicable Data Protection Laws, accounting and recordkeeping laws,  export control laws and laws relating to interactions with health care professionals and government officials.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Data Protection Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Applicable Laws in any jurisdiction relating to privacy or the processing or protection of personal data or personal information, including the General Data Protection Regulation (EU) 2016&#47;679 (GDPR), the UK Data Protection Act 2018, the e-Privacy Directive (2002&#47;58&#47;EC) and the comparable in other jurisdictions and all guidance issued by any applicable data protection authority.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a particular Licensed Product in a given country, a product comprising an ADC sold by a Third Party not authorized by Licensee or its Affiliates or Sublicensees that is approved by the applicable Regulatory Authority for such country through an application or submission filed with a Regulatory Authority for marketing approval of a biologic product claimed to be biosimilar or interchangeable to such Licensed Product, including an application filed under 42 U.S.C. &#167; 262(k) (or any successor thereto) or any similar laws or regulations in a country outside the United States in reliance on data generated for a Regulatory Approval of such Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any day that is not a Saturday, a Sunday or any other day on which banks are required or authorized by law to close in Mainz, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rhineland-Palatine (in Germany) or any government mandated holiday in Mainland China. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of three (3) consecutive months commencing on January 1, April 1, July 1 or October 1 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of twelve (12) consecutive months commencing on January 1 and ending on December 31 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 6.3.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to either Party&#58; (a) a merger, acquisition, reorganization, or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, acquisition, reorganization, or consolidation&#59; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party&#59; or (c) a transfer to a Third Party of all or substantially all of its assets relating to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Registrational Trial or other human clinical trial conducted after the Regulatory Approval of a product in a country, which trial may be conducted to (a) enhance scientific knowledge of such product (e.g., for expansion of product labeling), (b) due to a request or requirement of a Regulatory Authority in such country, (c) is otherwise designed to establish that a product is reasonably safe for continued testing and to identify adverse reactions and ascertain the safety of the product, or (d) investigate the safety and efficacy of the product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means chemistry, manufacturing and controls with respect to the Licensed Compound or Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Third Party contract manufacturing organization. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, any and all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, marketing, pricing, reimbursement, sale, importing, exporting or transporting such product, and distribution of such product, including strategic marketing, sales force detailing, advertising, market product support, all customer support, product distribution, and invoicing and sales activities, but excluding Development and Manufacturing.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialized&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 3.3.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitive Change of Control&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean a Change of Control of Duality where the incoming Third Party and&#47;or its Affiliates is a Competitor.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Know-How and other proprietary scientific, technical, clinical, marketing, financial or commercial information or Data Controlled by a Party or its Affiliates, which one Party or any of its Affiliates has furnished or made available to the other Party or its Affiliates, whether in oral, written or electronic form.  The existence and terms of this Agreement shall be deemed Confidential Information of each Party.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (including any variations such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall mean, with respect to any Know-How, Patents or other intellectual property rights, possession by a Party or Third Party of the right, power and authority (whether by ownership, license or otherwise, other than by virtue of any rights granted under this Agreement) to grant access to, to grant use of, or to grant a license or a sublicense to such Know-How, Patents or intellectual property rights without violating the terms of any agreement or other arrangement with any Third Party. Notwithstanding anything in this Agreement to the contrary, a Party and its Affiliates will be deemed to not Control any Know-How, Patents, or other intellectual property rights that are in-licensed or acquired by such Party or its Affiliates from a Third Party after the Effective Date, unless the other Party agrees to (a)&#160;comply with the terms and conditions of the agreement under which such Know-How, Patents, or other intellectual property rights were in-licensed or acquired by such Party&#59; and (b)&#160;pay all amounts that such Party would be obligated to pay in connection with the grant, maintenance and exercise of a (sub)license as reasonably allocable to such other Party for use in its territory under such Know-How, Patents, or other intellectual property rights.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a contract research organization.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all data, including non-clinical data, preclinical data and clinical data, including pharmacological, biological, chemical, toxicological, clinical test, safety, clinical and analytical information, quality control, trial, stability and manufacturing processes and techniques data generated by or on behalf of a Party or its Affiliates or their respective Sublicensees (in case of Licensee) and (sub)licensees (in the case of Duality) pursuant to activities conducted under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a pharmaceutical or biological product, any research activities, all non-clinical and clinical drug development activities and processes, &#91;***&#93;, regulatory affairs and other activities, in each case, which are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably necessary to prepare submissions for, and obtain or maintain, Regulatory Approval of such product and interacting with Regulatory Authorities regarding the foregoing, including lifecycle management studies and other activities.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as set forth in Section 1.39.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period from the Effective Date to the First Commercial Sale of the first Original ADC Licensed Product during which either Party is conducting any Development activities for an Original ADC Licensed Product or Licensed Compound. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a written plan approved by the JSC, describing &#91;***&#93;.  The initial Development Plan, unless otherwise agreed on by the Parties, will be agreed by the Parties latest within &#91;***&#93; of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(a).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all costs and expenses that are reasonably incurred by or on behalf of Duality and its applicable Affiliates after the Effective Date in conducting the Ongoing Trials and&#47;or performing other Development activities as agreed hereunder in the Territory pursuant to this Agreement and&#47;or the Development Plan. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any CMO engaged by Duality or any Affiliate of Duality.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How (including Data) that (a) is Controlled by Duality or any of its Affiliates as of the Effective Date or at any time during the Term and (b) are necessary or reasonably useful for the Development, Manufacture or Commercialization of or to otherwise exploit the Licensed Compound or Licensed Products in the Field in the Territory, including but not limited with respect to (a) and (b), the Know-How (including Data) contained in Duality Solely Owned Collaboration IP, &#91;***&#93;.  Notwithstanding the foregoing, Duality Know-How shall not include (i) any Know-How (including Data) Controlled by any Third Party that becomes an Affiliate of Duality after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How (including Data) is used by either Party in the Development, Manufacturing or Commercialization of the Licensed Compound or Licensed Products, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality or any of its Affiliates. A description of Duality Know-How as of the Effective Date is attached hereto on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Know-How and Duality Patents. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean any new or useful invention, discovery, adaptation, redesign, modification, improvement, enhancement, contribution or other desirable change generated in the course of performing activities under this Agreement that is solely relating to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Duality Patents claiming the Duality Linker-Payload.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EC Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means endometrial cancer.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in the introductory paragraph of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 2.8.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means shall mean the European Medicines Agency and any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EC Expansion Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 1.133 in the definition of &#8220;Phase II Dose Expansion Trial.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the U.S. Food and Drug Administration and any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all uses.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to an Original ADC Licensed Product, &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Dosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Clinical Trial, or any portion thereof, dosing of the first human subject in such Clinical Trial or such portion thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;16.10.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean full time equivalent. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fully Burdened Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Original ADC Licensed Product supplied by or on behalf of Duality&#58; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the ethical conduct of Clinical Trials, including without limitation the U.S. Code of Federal Regulations (CFR) Title 21, ICH GCP Guidelines E6(R2) as amended from time to time, national legislation implementing European Community Directive 2001&#47;20&#47;EC (if and as still applicable), European Community Directive 2005&#47;28&#47;EC, and, following the applicable transition periods, the Clinical Trial Regulation (EU) No. 536&#47;2014 (the &#8220;CTR&#8221;) and the rules, regulations and guidelines applying in the context of the CTR, and the equivalent in other countries or regions.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the treatment of human laboratory samples from Clinical Trials, including the relevant principles from GCP and the EMA&#8217;s reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, as amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Clinical Trial designed to obtain Regulatory Approvals for a Licensed Product in multiple countries through the conduct of a Clinical Trial in multiple countries, regions and&#47;or medical institutions and conducted as part of one (1) unified Clinical Trial or separately but concurrently in accordance with a common Clinical Trial protocol.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results, including without limitation the CFR Title 21, national legislation implementing European Community Directives 2004&#47;9&#47;EC and 2004&#47;10&#47;EC as amended, and the OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, and the equivalent in other countries or regions. For the purposes of this Agreement, GLP also includes the principles of Good Clinical Laboratory Practice and applicable guidelines promulgated under the ICH guidelines.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products, including without limitation the CFR Title 21, Parts 11, 210, 211, 600 and 610, applicable ICH Guidelines including without limitation Q7 for &#8220;Active Pharmaceuticals Ingredients&#8221;, national legislation implementing European Community Directive 2001&#47;83&#47;EC and Commission Directive 2003&#47;94&#47;EC as amended, EudraLex &#8211; Volume 4 of the Rules Governing Medicinal Products in the European Union including annexes, the CTR, Commission Delegated Regulation 2017&#47;1569, the Detailed Commission Guideline (2017) 8179, and the equivalent in other countries or regions. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is to be broadly interpreted and includes any multi-national or public international organization or authority, national, federal, state, local, municipal, provincial, foreign government or other governmental authority of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nature (including any governmental division, prefecture, branch, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, and any Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GXP&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collectively, all relevant and applicable good practice quality guidelines and regulations, encompassing such internationally recognized standards as GMP, GCP, GLP and GCLP, Good Distribution Practice (GDP), Good Pharmacovigilance Practice, Good Pharmacoepidemiology Practice and Good Review Practice. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) receptor tyrosine-protein kinase erbB-2, and (b) any naturally occurring variants thereof, in each case including any isoforms, polymorphisms, variants, and truncated forms, and in each case to the extent such variant, isoform, polymorphism, variant and truncated form are produced from an allele of the same gene.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2 BC Indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means HER2-positive breast cancer (as one Indication) and HER2-low breast cancer (as the other Indication).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2-Low BC Expansion Trial&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">has the meaning set forth in Section 1.133 in the definition of &#8220;Phase II Dose Expansion Trial.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an investigational new drug application, clinical study application, Clinical Trial exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.2(b).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.2(a).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the joint steering committee to be established by the Parties pursuant to Section&#160;3.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all technical, scientific, regulatory and other information, trade secrets, results, knowledge, techniques, materials (including cell lines) and data, in whatever form and whether or not confidential, proprietary, whether or not patentable, invention disclosures, plans, inventions, assays, designs, protocols, and formulas, processes, practices, methods, knowledge, know how, skill, experience, ideas, concepts, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing, pricing, distribution, cost, sales, and manufacturing data or descriptions.  &#8220;Know-How&#8221; includes any rights including copyright, database or design rights protecting such Know-How. For clarity, Know-How does not include issued Patents or published patent application or the inventions claimed thereby.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 9.3(b).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the ADC developed by or on behalf of Duality and known as DB-1303 comprising trastuzumab. The structure of the Licensed Compound is delivered to Licensee by Duality on or before the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (i) Original ADC Licensed Product, (ii) &#91;***&#93;, or (iii) &#91;***&#93;. Unless otherwise set forth herein, the term &#8220;Licensed Product&#8221; shall also include a Combination Product.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Added Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 4.4.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How that is  Controlled by Licensee or any of its Affiliates and that is comprised by the Licensee Solely Owned Collaboration IP. Notwithstanding the foregoing, Licensee Know-How shall not include (i) any Know-How Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How is used by Licensee in the Development, Manufacture or Commercialization of the Licensed Compound or Original ADC Licensed Products, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by Licensee.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Licensee Know-How and Licensee Patents.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents that are Controlled by Licensee or any of its Affiliates and that are comprised by the Licensee Solely Owned Collaboration Patents. Notwithstanding the foregoing, Licensee Patents shall not include (i) any Patent Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, and (ii) any Patent that Covers any Additional Active or other proprietary compound or product Controlled by Licensee provided that such Patent does not Cover the Licensed Compound or Original ADC Licensed Product.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 9 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an application to a Regulatory Authority for the authorization to place a product on the market in the applicable country, region or a regulatory jurisdiction, including New Drug Application and Biologics License Application, and shall include all amendments and supplements thereto, filed with the applicable Regulatory Authority to gain approval to place such product on the market in the applicable jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the holder of the Marketing Authorization. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mainland China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the mainland of the People&#8217;s Republic of China.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Major European Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; for the purpose of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Licensed Product, activities related to the manufacture and supply of such Licensed Product, including manufacturing supplies for Development or Commercialization, packaging, labeling, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of product, ongoing stability tests, storage, and shipment and regulatory activities directly related to any of the foregoing, but not including any Development or Commercialization activities.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patents and Know-How that are (i) generated, developed or conceived during the course of performing activities under this Agreement depending on Duality Licensed IP, and (ii) specifically related to, and (iii) necessary for the Manufacture of the Duality Linker-Payload&#59; notwithstanding the foregoing, Manufacturing IP shall exclude Licensee Background IP.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the authorization by all relevant Regulatory Authorities of an MAA in a given country or regulatory region&#47;jurisdiction and the granting of the required authorization for the sale of a product (but which will not include any Pricing and Reimbursement Approvals unless required by Applicable Law of the respective country to initiate marketing and selling of a product in such particular country). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the master cell bank. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Medical Affairs Activities&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean, with respect to the Territory, the coordination of medical information requests and field based medical scientific liaisons with respect to an Original ADC Licensed Product, including activities of medical scientific liaisons, activities involving key opinion leaders, and the provision of medical information services with respect to an Original ADC Licensed Product. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 10 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Multi-Specific ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.8.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">&#8220;New Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an entirely separate and distinct disease or medical condition in humans for which the Original ADC Licensed Product is authorized.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">&#8220;Non-Arbitral Subject Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.4. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offer Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 2.8.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">&#8220;Ongoing Trials&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Clinical Trials currently being conducted by Duality in the Territory and the Retained Territory entitled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">A Phase 1&#47;2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced&#47;Metastatic Solid Tumors with NCT number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NCT05150691</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarity, the Ongoing Trials include both a Phase I Clinical Trial phase, and the Phase II Dose Expansion Trials.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Package Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 11.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee or Duality individually, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee and Duality collectively.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) patent applications filed in the applicable jurisdiction&#59; (b) all patents, including supplemental protection certificates, that have issued or in the future issue from any of the foregoing, including utility models, design patents and certificates of invention&#59; and (c) all divisionals, continuations, continuations-in-part, reissues, re-examination certificates, renewals, extensions or additions to any such patents and patent applications (as applicable).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 5.7.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product, the principal purpose of which explores the optimal dose and is a determination of initial tolerance or safety of such product in healthy volunteers or the target patient population, as described in 21 CFR 312.21(a) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population (i.e. &#8220;proof of concept&#8221;), as described in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 11 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase II Dose Expansion Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Phase II Clinical Trial portion of the Ongoing Trials consisting of two (2) dose expansion cohorts meeting the following criteria&#58; (a) one cohort in HER2-low breast cancer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2-Low BC Expansion Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (b) one cohort in endometrial cancer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EC Expansion Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, in any country where a Regulatory Authority authorizes reimbursement for, or approves or determines pricing or level of reimbursement for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization and&#47;or pricing approval or determination (as the case may be).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.9. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 10.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reduced Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the reduced royalty rates for the &#91;***&#93; and &#91;***&#93; specified in the second table in Section 8.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registrational Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, a human clinical trial (regardless of whether such clinical trial is referred to as a &#8220;Phase II Clinical Trial&#8221;, &#8220;Phase IIb Clinical Trial&#8221;, &#8220;Phase II&#47;III Clinical Trial&#8221;, &#8220;Phase IIb&#47;III Clinical Trial&#8221; or &#8220;Phase III Clinical Trial&#8221;) for such product, the results of which, together with prior information concerning such product, are determined by the sponsor to be intended to be sufficient to establish that such product is safe and effective for its intended Indication to support the filing of an MAA.  &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all approvals, licenses, permits, registrations or authorizations of or from any Regulatory Authority that are necessary to market (including Marketing Authorization) and sell a pharmaceutical product in any country, region or other jurisdiction.  For clarity, unless it is required by the Applicable Law to initiate marketing and selling of a product in a particular country, Regulatory Approval shall not include Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a country, any national, federal, supranational, state or local regulatory agency, council, department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country, region or jurisdiction, including the Regulatory Approvals.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 12 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, regulatory applications (including MAA) and all applications, filings, submissions, notifications, materials, communications, registrations, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize such product in a particular country, region or jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;5.8.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.8. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.6.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.2.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.4(a)(i).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration IP and Licensee Solely Owned Collaboration IP, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration Patents and Licensee Solely Owned Collaboration Patents, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a license, sublicense, covenant not to sue or other rights granted by Licensee to a Third Party under the rights it receives from Duality in accordance with Section 2.2, to Develop, Manufacture or Commercialize a Licensed Compound or a Licensed Product, but excluding any grant of rights to or agreement with (a) any Third Party acting as a service provider or subcontractor for such Party or its Affiliates, or (b) any Third Party wholesaler, distributor, or the like.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party that is receiving rights under a Sublicense.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Successful Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with regard to an Antibody or ADC and a biological target in question , that such Antibody or ADC demonstrates meaningful binding activity to such biological target and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Targeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;9.3(b).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Dosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Clinical Trial, or any portion thereof, dosing of the &#91;***&#93; in such Clinical Trial or such portion thereof.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;13.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 13 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean worldwide except Retained Territory. For clarity, Territory shall include Taiwan.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any entity other than Licensee and its Affiliates and Duality and its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States of America, including its territories and possessions as recognized by the United Nations from time to time, but in all cases including, for clarity, Puerto Rico</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S. Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean U.S. dollars, the lawful currency of the U.S.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Wind-Down or Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a plan for the wind-down or transfer of any ongoing Development, Manufacture and Commercialization (if any) activities of Licensee with respect to the Licensed Products for which the license grant in Section 2.1 has been terminated and the transfer of relevant Licensed Products, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the working cell bank. </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>LICENSE</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants to Licensee, during the Term, an exclusive (even as to Duality and its Affiliates), royalty-bearing license, with the right to sublicense through multiple tiers (in accordance with Section 2.2), under Duality Licensed IP to Develop, have Developed, Manufacture, have Manufactured, use, sell, offer for sale, import and otherwise Commercialize or have Commercialized or exploit the Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Retained Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants to Licensee a sole license to Develop, have Developed, Manufacture or have Manufactured the Licensed Compound and the Licensed Products in the Retained Territory solely for the purpose of Developing, Manufacturing and Commercializing the Licensed Products in the Field in the Territory. For clarity and without limiting any rights granted to the Licensee hereunder, Duality has the full rights to Develop, Manufacture and have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 14 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manufactured, Commercialize and otherwise exploit the Licensed Compound and Original ADC Licensed Products in the Retained Territory.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Licensee and its Affiliates shall have the right to grant Sublicenses (through multiple tiers) under Duality Licensed IP, to (i) any Affiliate, or (ii) to any Third Party.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Sublicense Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Licensee&#8217;s Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates, Sublicensees and subcontractors hereunder is in accordance with the applicable terms of this Agreement.  With respect to a patent challenge  by the Sublicensee against any Duality Patents, if Licensee fails to cause such Sublicensee to cease such violation within a reasonable period of time, Licensee shall, in so far as it is not prohibited under the Applicable Laws, terminate the sublicense agreement. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In so far as it is not prohibited under the Applicable&#160; Laws, Licensee hereby covenants on a country-by-country basis not to, and not to permit or cause any Affiliate to &#91;***&#93;. Notwithstanding the foregoing, this Section shall in no way restrict &#91;***&#93;, its Affiliates, its Sublicensees or their CMOs and other authorized Third Party under this Agreement from undertaking any research, Development, Manufacturing, Commercialization, or other exploitation or engaging in any activities involving &#91;***&#93; that anyone not subject to this Agreement may legally undertake before the Effective Date and during the Term in the Territory and elsewhere, &#91;***&#93;. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Implied Licenses&#59; Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No right or license under any Patents or Know-How of either Party is granted or shall be granted by implication.  All such rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement.  Duality hereby expressly reserves all rights not expressly licensed to Licensee in Section&#160;2.1, including (i)&#160;all rights under the Duality Licensed IP with respect to the Licensed Compound and Original ADC Licensed Products in the Retained Territory, subject to Licensee&#8217;s co-exclusive license as set forth in Section 2.1(b), (ii)  all rights under the Duality Licensed IP to exercise its rights or perform its obligations under this Agreement, and (iii) all rights under the Duality Licensed IP to conduct Development activities in the Territory for the sole purpose of Developing or Commercializing the Original ADC Licensed Products in the Field in the Retained Territory, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided tha</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t any such Development activities in the Territory in relation to the Original ADC Licensed Product and Licensed Compound shall be undertaken for Duality by Licensee or its Affiliates, or Sublicensees or designated subcontractors.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">License to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee hereby grants to Duality a non-exclusive, non-transferrable, non-sublicensable (unless a sublicense was consented by Licensee in writing and is in compliance with the license terms set out in Section 2.2(b) which would apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), royalty-free license under the Licensee Licensed IP, during the Term of this Agreement solely to (i) perform, either itself, through its Affiliates, or through subcontractors, its obligations under this Agreement, including its Manufacturing and supply obligations under Sections&#160;6.1, 6.4 and 6.5, and (ii) limited to the Field and the Retained Territory, to Develop, Manufacture or have Manufactured (or solely for exporting to the Territory, only where requested by Licensee to supply the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 15 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Original ADC Licensed Product), or Commercialize the Licensed Compound or Original ADC Licensed Products.  Duality shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates or subcontractors hereunder is in accordance with the applicable terms of this Agreement. With respect to a patent challenge by a (sub)licensee against any Licensee Patents, if Duality fails to cause such (sub)licensee to cease such violation within a reasonable period of time, Duality shall, in so far as it is not prohibited under the Applicable Laws, terminate such (sub)license agreement. Duality shall be responsible for any actions of its Affiliates and subcontractors who act on behalf of Duality to perform activities assigned to Duality (for or on behalf of Licensee) pursuant to this Agreement, to the same extent as if such actions had been taken by Duality itself, and Licensee shall have the right to proceed directly against Duality without any obligation to first proceed against such Affiliate, sublicensee and subcontractor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days of the Effective Date, Duality shall at its cost and expense provide to Licensee &#91;***&#93; the documents embodying all Duality Know-How (including CMC documentation to the extent available to Duality or any of its Affiliates as of the Effective Date) Controlled by Duality or any of its Affiliates as of the Effective Date, including but not limited to the structure of the Licensed Compound (to the extent not transferred to Licensee prior to the Effective Date, &#91;***&#93;. A description of such documents for the initial Know-How Transfer is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto. Duality shall promptly (and in any event no later than &#91;***&#93; from the existence of such Know-How) inform Licensee of the existence of any additional Duality Know-How that becomes Controlled by Duality after the Effective Date and during the Term. The Parties shall discuss the timing and means of the transfer of additional Duality Know-How and Duality shall provide electronic copies of such additional Duality Know-How to Licensee in accordance with Licensee&#8217;s request, in a manner in line with that for the initial Know-How transfer and at no additional cost to Licensee. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>GOVERNANCE</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days following the Effective Date, the Parties shall establish a JSC comprised of an equal number of representatives from each Party to approve, plan, coordinate, integrate monitor and oversee the Parties&#8217; activities in the Territory in relation to the Development of the Original ADC Licensed Product and facilitate information exchange between the Parties under this Agreement.  The JSC, as may be conducted through the applicable Subcommittee, shall in particular&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">review, discuss and coordinate the overall strategy for the Development of the Original ADC Licensed Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">review, discuss and approve any proposed amendments or revisions to the Development Plan(s) of the Original ADC Licensed Product, including all related budgets of the Development activities&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 16 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">review, discuss and approve any study protocols relating to the Development Plan(s) (and any amendments thereto) of the Original ADC Licensed Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">review, discuss and serve as a forum for the sharing of information between the Parties regarding the operation of any Development activities of the Original ADC Licensed Product in the Territory and in the Retained Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">oversee and coordinate the on-going disclosure, sharing and&#47;or transfer of Collaboration IPs generated in or related to the Development of the Original ADC Licensed Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">review and discuss any matters relating to the Regulatory Approvals and Regulatory Materials to be submitted to any Regulatory Authority in the Territory in respect of the Original ADC Licensed Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">coordinate supply of Original ADC Licensed Product in accordance with  Article 6&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">review and discuss the clinical protocol of and Duality&#8217;s potential participation in any Global Trial (including the HER2-Low BC Phase III Global Trial) sponsored by Licensee or any of its Affiliates and Sublicensees or Licensee Added Trials&#59; and</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  From time to time during the Term, the JSC may establish and disband one or more subcommittee(s) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to oversee particular activities of the Parties, and the JSC may assign to such subcommittee(s) duties or tasks independent of the duties of the JSC, or delegate part of such duties of the JSC to such subcommittee(s) as it deems necessary and appropriate.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limiting the generality of the foregoing subsection (a), no later than &#91;***&#93; days after the Effective Date (unless otherwise agreed by the Parties) the JSC shall establish an intellectual property committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JIPC shall provide a forum for discussion of the patenting strategies of the Original ADC Licensed Products and coordinate the Parties&#8217; efforts in accordance with the provisions set forth in Article 12 and other matters related to the prosecution and maintenance of intellectual property rights hereunder, including submissions to and addressing notices from Regulatory Authorities that relate to regulatory-patent linkage procedures and proceedings. The JSC shall determine the desired membership of the JIPC and once formed, Licensee&#8217;s committee members shall determine the time, place and procedure of meetings. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of the foregoing subsection (a), no later than &#91;***&#93; days after the Effective Date, the JSC shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JDC shall (i) oversee the implementation and progress of the Development Plan in the Territory, (ii) discuss and propose </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 17 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the JSC for approval any amendments to the Development Plan, (iii) oversee any Global Trials. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Composition&#59; Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The JSC and each Subcommittee (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be composed of &#91;***&#93; representatives from each Party (or such other equal number of representatives of each of Licensee and Duality as the JSC may determine), and each Party shall notify the other Party of its initial JSC representatives within &#91;***&#93;&#160;days after the Effective Date.  Each Party shall designate a representative to be the co-chairperson of the JSC and Licensee shall designate a representative to chair each Subcommittee led by it, in each case who shall schedule meetings, prepare meeting agendas and meeting minutes and follow up on action items. Each Party may request and convene a Committee meeting and propose agenda therefor at any time. With respect to the JSC, these responsibilities will alternate between the Parties or each co-chairperson, as applicable, with Licensee&#8217;s co-chairperson taking the responsibility for the first meeting of the JSC.  Each Party may change its representatives to the JSC (or any Subcommittee) from time to time in its sole discretion, effective upon notice to the other Party of such change. Each Party&#8217;s representatives in each Committee shall possess appropriate experience with respect to the issues falling within the functions of such Committee and requisite seniority within such Party&#8217;s organization, and shall have the authority to make decisions on behalf of the Party they represent.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Non-Member Attendance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend a meeting of any Committee (in a non-voting capacity) in the event that the planned agenda for such Committee meeting would require such participants&#8217; expertise&#59; provided that if either Party intends to have any Third Party (including any consultant or counsel) attend such a meeting, such Party shall provide prior written notice to the other Party, shall obtain approval from such other Party for such Third Party to attend (which shall not be unreasonably withheld by the notified Party), and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The representatives of each Party will have, collectively, &#91;***&#93; at each Committee on all matters brought before such Committee. The Committees may not take any action or decide any matter except at a meeting attended by &#91;***&#93; representing each Party and with unanimous consent. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">JSC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JSC (including those matters referred to the JSC by any Subcommittee), the representatives of the Parties on the JSC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, such disagreement shall be referred to &#91;***&#93; (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for resolution.  If the Executive Officers cannot resolve such matter within &#91;***&#93; days (or such other timeframe as the JSC may request in consideration of the urgency of such referred matter) after such matter has been referred to them, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#91;***&#93; shall be entitled to make final decisions with respect to&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#91;***&#93; shall be entitled to make final decisions on the &#91;***&#93;&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 18 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">with respect to &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.36pt">&#91;***&#93; shall have final decision-making authority with respect to matters relating to &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:135pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.02pt">&#91;***&#93; will have final decision-making authority with respect to matters relating to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">JIPC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JIPC, together with the assistance of each Party&#8217;s outside intellectual property counsel (as required and pursuant to Section 3.4), the representatives of the Parties on the JIPC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JIPC for resolution or after such matter has been referred to the JIPC, such matter shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">JDC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JDC, the representatives of the Parties on the JDC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JDC for resolution or after such matter has been referred to the JDC, such disagreement shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Deadlock Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case of a deadlock with respect to the decision-making process of the JSC, Article 15 shall apply. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Limitations on Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, the JSC shall not have the power to amend this Agreement, and no decision of the JSC may be in contravention of any terms and conditions of this Agreement.  For clarity, the JSC shall have no decision-making authority regarding any Development, Manufacturing, Commercialization or other activity in the Retained Territory save as contemplated by Section 3.5(a) or otherwise expressly provided in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC will hold a meeting every &#91;***&#93; months until the Development Phase ends, and afterwards every &#91;***&#93; months, or as otherwise determined by the JSC.  Such meetings may be in person, via videoconference, or via teleconference.  The location of in-person meetings will be determined by the Parties.  At least &#91;***&#93; Days prior to each JSC meeting, each Party shall provide written notice to the other Party of agenda items proposed by such Party for discussion at such meeting, together with appropriate information related thereto.  Reasonably detailed written minutes will be kept for all JSC meetings.  Meeting minutes will be prepared &#91;***&#93; and sent to each member of the JSC for review and approval within &#91;***&#93; Days after the meeting.  Minutes will be deemed approved unless a member of the JSC objects to the accuracy of such minutes within &#91;***&#93; Days of receipt. In the event of any such objection that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 19 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Discontinuation of JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall continue to exist until the Parties mutually agree to disband the JSC. Once the JSC is disbanded, the JSC shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the points of contact for the exchange of information under this Agreement, and the Parties shall reach decision directly on matters that are subject to the decision of the JSC as set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Project and Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall appoint an individual, who is an employee of such Party, to act as a project manager (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties. Each Party shall appoint an individual, who is an employee of such Party, to act as its alliance manager under this Agreement within &#91;***&#93; Days after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). &#91;***&#93; The Project Managers shall&#58; (a) serve as the primary points of contact between the Parties for the purpose of providing the other Party with information on the progress of a Party&#8217;s activities under this Agreement&#59; (b) be responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties. The Alliance Managers shall&#58; (a) serve as the primary points of contact between the Parties for any issues arising under this Agreement&#59; (b) facilitate the prompt resolution of any disputes&#59; and (c) attend JSC and Subcommittee meetings (in each case, as a non-voting participant)&#59; provided that the Alliance Managers shall not count toward the number of representatives that each Party may have on each such Committee. An Alliance Manager may also bring any matter to the attention of the JSC, if such Alliance Manager reasonably believes that such matter warrants such attention. Each Party may replace its Project Manager or Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>DEVELOPMENT</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">Except as expressly provided herein with respect to the Ongoing Trials, Licensee Added Trials (as applicable) and the preparatory activities for the HER2-Low BC Phase III Global Trial as set forth in Section 4.6(b), Licensee (itself and through its Affiliates and their respective Sublicensees) shall be responsible, at its own expense, for the Development of the Original ADC Licensed Products in the Field in the Territory under the oversight of JSC. Without limiting the generality of the foregoing, Licensee shall, subject to the Development Plan (i) use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for &#91;***&#93; in the Field in each of &#91;***&#93;, and (ii) use Commercially Reasonable Efforts to perform the Development activities assigned to it under the Development Plan(s) and in compliance with Applicable Laws (including GCP)&#59; and (iii) use Commercially Reasonable Efforts to dose the first patient in a Registrational Trial within &#91;***&#93; months for the applicable HER2-low breast cancer Indication or EC Indication after Successful Completion of each of the HER2-Low BC Expansion Trial and EC Expansion Trial conducted by or on behalf of Duality, taking into account the timelines and interactions with Regulatory Authorities. Licensee&#8217;s (including its Affiliates&#8217; and Sublicensees&#8217;, as appliable) failure to dose the first patient in a Registrational Trial within such &#91;***&#93; months period shall not be a breach of this provision if the delay is caused by any safety issues, a requirement or decision from a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 20 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Authority, Force Majeure Events, or any other events that are outside the reasonable control of Licensee, its Affiliates or Sublicensees. If such a delay happens, Licensee shall promptly notify Duality (within &#91;***&#93; Days) and shall provide detailed explanations for such delay. The Parties shall engage in good faith discussions and the Licensee shall consider in good faith and reasonably address Duality&#8217;s input and comments with respect thereto. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Without limiting the foregoing, Licensee shall use Commercially Reasonable Efforts to (i) make all regulatory submissions to the applicable Regulatory Authorities within the Territory in respect of the Original ADC Licensed Product&#59; and (ii) obtain Regulatory Approval for Original ADC Licensed Products in the Territory, in each case of (i) and (ii) in accordance with the Development Plan.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">Without limiting Sections 4.3 and 4.4, where responsibility for conducting any Development activities (falling within the scope of this Agreement) is designated by Licensee to Duality or its Affiliates and subcontractors, Duality, its Affiliates and subcontractors shall perform the Development activities assigned to it under the Development Plan(s), in compliance with Applicable Laws (including GCP).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will agree on the initial Development Plan, which sets forth the scope, timeline and responsibilities of each Party of the Development activities to be conducted by or on behalf of Licensee in order to obtain Regulatory Approvals for the Original ADC Licensed Products in the Territory.  From time to time during the Term, either Party may propose written amendments and updates to the then-current Development Plan, and shall submit such amendments and updates to the JSC for review and approval.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amendment of the Development Plan shall become effective only upon the approval of JSC.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Ongoing Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date, the Parties have agreed that Duality will continue to be the sponsor of the Ongoing Trials in the Territory so that the Ongoing Trials can be continued without interruption. Subject to Licensee&#8217;s obligations to fund and reimburse Duality Costs incurred in the Territory in accordance with Section 8.2 (save, for the avoidance of doubt, with respect to the portion of the Ongoing Trials that is conducted in the Retained Territory which shall be the sole responsibility of Duality), Duality shall comply with all Applicable Laws when conducting the activities set out in the Development Plan and use Commercially Reasonable Efforts to conduct the activities set out in the Development Plan including to (a) continue to conduct the Phase I Clinical Trial phase of the Ongoing Trial, and (b) initiate and conduct the Phase II Dose Expansion Trials in the U.S., Australia and Mainland China in accordance with the Development Plan (including the timeline specified therein) and complete the First Dosing in 2023, unless Duality&#8217;s failure to comply with such timeline is caused by any safety issues, a requirement or decision of a Regulatory Authority, Force Majeure Events that are outside the reasonable control of Duality, its Affiliates or (sub)licensees. If such a delay happens, Duality shall promptly notify Licensee (within &#91;***&#93; Days) and shall provide detailed explanations for such delay. The Parties shall engage in good faith discussions and Duality shall consider in good faith and reasonably address Licensee&#8217;s input and comments with respect thereto.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Licensee Added Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Global Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 21 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Phase &#91;***&#93; Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall maintain or cause to be maintained complete, current and accurate records of all activities conducted by or on behalf of it pursuant to the Development Plan(s), and all Know-How and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.  Each Party shall, and shall ensure that its Affiliates and their Sublicensees will, document all non-clinical studies and Clinical Trials in formal written study records in accordance with all Applicable Laws, including applicable national and international guidelines such as ICH, GCP, GCLP and GLP.  To the extent permitted by the Applicable Laws, each Party shall have the right to review and copy such records of the other Party at reasonable times and to obtain access to review the original to the extent necessary or useful for regulatory, patent or other reasonable purposes for the purpose of fulfilling its obligations under this Agreement upon reasonable notice to such other Party and at a time and location mutually acceptable to the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall keep the other Party reasonably and timely informed of the progress and results of its and its Affiliates&#8217;, subcontractors&#8217; and Sublicensees&#8217;&#47;(sub)licensees&#8217; work under the Development Plan(s) (including prompt reporting of available pre-clinical and clinical data). Without limiting the generality of the foregoing, each Party shall provide the other Party with a written report no later than &#91;***&#93; days after the end of each Calendar Year setting forth in details the Development activities performed during such Calendar Year and the results thereof, and comparing such activities with the Development Plan(s) for such time period.  Such reports prepared by each Party shall be provided at a level of detail reasonably sufficient to enable the other Party to determine compliance with its obligations under this Agreement.  At each JSC meeting, the Parties shall discuss the status, progress and results of the Development activities conducted by the Parties pursuant to this Agreement.  Each Party shall promptly respond to the other Party&#8217;s reasonable questions or requests for additional information relating to such Development activities. In the event that Duality is engaged by Licensee to conduct Development activities in the Territory, Duality shall send the Development report on &#91;***&#93; basis, setting forth the Development activities performed &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>REGULATORY</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview of Conduct of Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">Licensee (itself and through its Affiliates and Sublicensees, as applicable) shall be responsible for all of the costs for all regulatory activities with respect to the Licensed Products in the Territory after the Effective Date.  &#91;***&#93;, Licensee (or its Affiliate or Sublicensees) shall be the sponsor and holder of all Regulatory Approvals for the Licensed Products in the Territory.  For clarity, Licensee (or one of its Affiliates or their Sublicensees) shall always be the MAH of the Original ADC Licensed Products in the Territory. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 22 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">Following the Effective Date, Duality shall provide Licensee with one (1) electronic copy of the Regulatory Materials related to the Licensed Compound or Original ADC Licensed Products in the Territory existing and possessed by Duality as of the Effective Date. At any time during the Term, if Duality is the sponsor or holder of the Regulatory Materials and upon Licensees&#8217; request in writing, Duality shall provide Licensee with electronic copies of the Regulatory Materials related to the Licensed Compound or Original ADC Licensed Products in the Territory received and possessed by Duality after the Effective Date promptly and no later than &#91;***&#93; Days after such Regulatory Materials become available.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Regulatory Filing&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except with respect to regulatory filings related to the Ongoing Trials and the Licensee Added Trials (if any), for which Duality shall be responsible or the Parties agree otherwise, (i) Licensee (and its Affiliates, or Sublicensees as applicable) shall lead and have sole control over preparing and submitting all regulatory filings related to the Licensed Compound and Original ADC Licensed Products, including all applications for Regulatory Approval, in the Territory at Licensee&#8217;s sole cost and expense, and (ii) Duality shall be responsible for the preparation and submission of any regulatory filings in the Retained Territory at Duality&#8217;s sole cost and expense. With respect to regulatory filings for the Ongoing Trials or and the Licensee Added Trials (if any) that are prepared by Duality, Duality shall submit all such regulatory filings to the JSC for its review and approval. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Other than any Regulatory Approvals or applications therefor that are related to the Ongoing Trials in the Territory or Licensee Added Trials for which Duality is the sponsor, Licensee (or its Affiliates, or Sublicensees as applicable) shall own any and all Regulatory Approvals (and applications for Regulatory Approvals), and any other regulatory filings related to the Licensed Compound and Licensed Products in the Territory, including Data and data in the regulatory filings and Regulatory Materials, which shall be held in the name of Licensee or its designees. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;English Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent that the original language is not English, Duality shall provide Licensee with a certified full English translation of all Regulatory Materials.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Insofar as it relates to the Ongoing Trials in the Territory and Licensee Added Trials (if any) where Duality is the sponsor, Duality shall lead interactions with Regulatory Authorities in the Territory&#59; provided that JSC shall have final decision making authority in relation to such interactions with Regulatory Authorities and Duality shall follow all instructions provided to it by the JSC in this regard and shall provide Licensee with (i) access to or copies of all material written or electronic communication received by Duality or its Affiliates from any Regulatory Authorities in the Territory and in the Retained Territory (if applicable), and (ii) copies of all meeting minutes with any Regulatory Authorities in the Territory and in the Retained Territory (if applicable). In addition, Duality shall provide Licensee with written notice of any scheduled material meeting, conference, or discussion with a Regulatory Authority related to Regulatory Approvals related to the Ongoing Trials. Licensee (or its designee) shall have the right to (i) attend and participate in all such meetings with Regulatory Authorities related to the Ongoing Trials), and all telephone conferences and preparation meetings of Duality or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 23 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Affiliates related to any such meeting, (ii) provide input on the regulatory filings in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory), and (iii) have final decision making authority in relation to any unsettled matter between the Parties with respect to regulatory filings in the Territory. Subject to the foregoing, Licensee (and&#47;or its Affiliates, or Sublicensees as applicable) shall have the sole right to conduct all communications with Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to the Licensed Compound and Licensed Products in the Territory, including in respect of the Licensee Added Trials where Licensee (or its Affiliates or Sublicensees, as applicable) is the sponsor (if any). Without limited the forgoing, the Parties agree that they will collaborate with each other as necessary to ensure the successful progression of interactions with Regulatory Authorities with respect to all trials relating to the Licensed Compound and Original ADC Licensed Products in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;, Duality shall transfer and assign, or shall cause the transfer or assignment, to Licensee or its designee (at Duality&#8217;s cost and expense for Ongoing Trials and at Licensee&#8217;s cost and expense for Licensee Added Trials), Duality&#8217;s, or any of its Affiliates&#8217;, entire right, title, and interest in and to all IND and other Regulatory Approvals in the Territory, if any, and transfer all Regulatory Materials with respect to the Licensed Compound and Original ADC Licensed Products in the Territory that are owned, controlled or possessed by Duality or any of its Affiliates, unless the Parties agree otherwise. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Licensee may decide to replace Duality to be the sponsor of any Clinical Trials in the Territory at any time after the Effective Date of the Agreement.  Once Licensee informs Duality of its decision to replace Duality as the sponsor of the Ongoing Trial or a Licensee Added Trial in writing, Duality shall transfer a copy of all Regulatory Materials in its original language&#59; to the extent that the original language is not English, Duality shall provide a certified full English translation of all documents to Licensee. If the replacement was caused by a breach of the applicable terms of this Agreement, Applicable Laws or the GXP by Duality, the costs and expenses reasonably incurred by Licensee in relation or as a result of such replacement shall be borne by Duality. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Data Access&#59; Right of Reference&#59; Access to Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days of Effective Date, the Parties shall enter into a pharmacovigilance agreement regarding the Licensed Compound and Original ADC Licensed Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall set forth standard operating procedures governing the collection, investigation, reporting, and exchange of safety information sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes. In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement, the terms of this Agreement shall prevail and govern, except to the extent such conflicting terms relate directly to the pharmacovigilance responsibilities of the Parties (including the exchange of safety data), in which case the terms of the Pharmacovigilance Agreement shall prevail and govern. Prior to the Parties entering into the Pharmacovigilance Agreement, Duality is and shall continue to be the owner of the global safety database for the Original ADC Licensed Products.  The Pharmacovigilance Agreement can be amended at Licensee&#8217;s request during the Term </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 24 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and as a preparation to the Commercialization, at least &#91;***&#93; months&#8217; ahead of the first MAA submission. At any time during the Term, upon reasonable prior notice, during regular business hours and under obligations of confidentiality, Licensee (or its designees) shall be entitled to audit (i) any of Duality&#8217;s, its Affiliates&#8217;, or any of their respective CRO or CMOs&#8217; manufacturing sites&#59; and (ii) any of Duality&#8217;s or its Affiliates&#8217; clinical sites, as selected by Licensee in its sole discretion, to assess Duality&#8217;s compliance with all GXPs and all matters arising under the Pharmacovigilance Agreement, in each case of the foregoing (i) and (ii), only in respect of any Clinical Trials run by Duality for Licensee in the Territory&#59; provided that such audit shall not be conducted more than once in any given Calendar Year, unless it is a for-cause audit.  If (a) such audit by Licensee identifies any material non-compliance by Duality (via its subcontractors) or its Affiliates (via its subcontractors) of the GXPs or the Pharmacovigilance Agreement in the Territory, and (b) such material non-compliance is confirmed to be an uncured material breach on the part of Duality pursuant to Section 13.3, then the provisions of Section 13.8 shall apply.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Remedial Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Original ADC Licensed Product may be subject to any recall, corrective action, patent regulatory procedures or other regulatory action in the Territory or the Retained Territory by any Governmental Authority or Regulatory Authority (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Parties shall assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action.  The Parties shall collaborate in good faith and endeavor to reach an agreement on Remedial Action related decisions save that were there is any unsettled issues in relation to any Remedial Action related matters (i) with respect to the Territory, Licensee shall have the final decision making authority and Duality shall take all actions reasonably requested by Licensee in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Duality&#8217;s position in respect of the Original ADC Licensed Product or any Regulatory Authorities in the Retained Territory, no action will be taken by Licensee (unless immediate action is required to comply with Applicable Laws and mitigate further damage arising from the Remedial Action) without Duality&#8217;s prior written consent, and (ii) with respect to the Retained Territory, Duality shall have the final decision making authority and Licensee shall take all actions reasonably requested by Duality in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Licensee&#8217;s position in respect of the Original ADC Licensed Product or any Regulatory Authorities in the Territory, no action will be taken by Duality without Licensee&#8217;s prior written consent.  The cost and expenses of any Remedial Action shall be borne by the Party whose action or inaction caused the Remedial Action of the Original ADC Licensed Product.  </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>MANUFACTURE &#38; SUPPLY</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Costs of CMC Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality will conduct CMC activities for the Original ADC Licensed Products according to the scope as agreed upon by the Parties in the Development Plan.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Transfer of CMC Materials from Duality to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following the Effective Date (and thereafter from time to time during the Term upon Licensee&#8217;s reasonable advance request and to the extent not previously provided), Duality shall provide to Licensee (or its designee) the CMC-related technical documents and CMC-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 25 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">related technology (and any associated manufacturing process technology) that are necessary or reasonably useful for the Manufacture of the Licensed Compound and Original ADC Licensed Product and are Controlled by Duality or any of its Affiliates as of the Effective Date and which become Controlled by Duality or any of its Affiliates during the Term, and customs and technology export licenses required by Applicable Law for such transfer(s), if any. Within &#91;***&#93; of Licensee&#8217;s request, Duality or a Duality CMO shall provide Licensee with reasonable assistance and on-site support in respect of the CMC-related technology and associated manufacturing process technology transferred to Licensee pursuant to this Section 6.2. Any assistance required in excess of &#91;***&#93; will be at the Licensee&#8217;s cost and expense. To the extent that the original language of the CMC Materials (including Third Party agreements) is not English, Duality shall provide a certified full English translation of these materials. The conclusion of new Third Party agreements regarding the CMC activities contemplated under Section 6.1 or the amendment of existing Third Party agreements regarding the same shall be subject to Licensee&#8217;s prior written approval.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Transfer of Cell Banks. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties will enter into a separate quality agreement and thereafter a supply agreement to manage the logistics and shipping of the transfer of the MCB and WCB (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) used for the Manufacturing of the Antibody incorporated into the Licensed Products within &#91;***&#93; days after the Effective Date. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Initial Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality shall, by itself or through one or more Duality CMO(s) in the Retained Territory, supply to Licensee, its Affiliates or Sublicensees, &#91;***&#93; and in accordance with a separate clinical supply agreement as contemplated below&#59; provided that Licensee shall be &#91;***&#93;. Unless otherwise agreed by the Parties, the Parties shall negotiate in good faith a clinical supply agreement and related quality agreement with such negotiation to be commenced within &#91;***&#93; days after the Effective Date and completed no later than &#91;***&#93; days after the Effective Date, which clinical supply agreement shall contain customary language regarding supply of the Original ADC Licensed Products to Licensee (including equitable allocation in the event of disruption to or shortage of product supply). &#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Ongoing Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as may otherwise be provided under the clinical supply agreement entered into by the Parties pursuant to Section 6.4 and until the Licensee has qualified a new manufacturing site to Manufacture the Licensed Compound and the Original ADC Licensed Products in the Territory, Licensee shall be solely responsible for (i) Manufacturing the Licensed Compound and Original ADC Licensed Products intended for use in the Territory and (ii) the associated costs and expenses of such Manufacturing activities, subject to Duality&#8217;s performance of its obligations under this Agreement. Once the Original ADC Licensed Product is approved, &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>COMMERCIALIZATION MATTERS</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Licensee (itself or  through its Affiliates or  Sublicensees, as applicable) shall be solely responsible for Commercialization of the Original ADC Licensed Products in the Field in the Territory including&#58; (i) developing and executing a commercial launch and pre-launch plan, (ii) developing the global pricing strategy and negotiating with applicable Governmental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 26 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorities regarding price and reimbursement of the Original ADC Licensed Products&#59; (iii) marketing, advertising and promotion&#59; (iv) booking sales&#59; (v) distribution and handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (vi) providing customer support, and performing other related functions&#59; (vii) conforming its practices and procedures to Applicable Laws relating to the marketing, detailing and promotion of the Original ADC Licensed Products in the Field&#59; and (viii) developing and implementing the global and local Medical Affairs Activities and medical information infrastructure required in the Field in the Territory.  Licensee shall bear all of the costs and expenses incurred in connection with such Commercialization activities in the Territory. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No later than &#91;***&#93; months before the anticipated date of the submission of the first MAA for an Original ADC Licensed Product in the Territory, Licensee shall prepare a written Commercialization plan that sets forth the timeline and details of all major Commercialization activities planned for such Original ADC Licensed Product in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Commercialization Plan shall be updated at least once a year.   </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Coordination of Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties recognize that they may benefit from the coordination of certain activities in support of the Commercialization of an Original ADC Licensed Product across their territories.  As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and Licensed Product positioning. For clarity, Licensee shall not conduct any Commercialization of any Original ADC Licensed Product outside the Territory without Duality&#8217;s express prior written consent and Duality shall not conduct any Commercialization of Original ADC Licensed Products outside of the Retained Territory without Licensee&#8217;s express prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall keep Duality informed of its, its Affiliates&#8217; and Sublicensees&#8217; Commercialization activities in the Territory with respect to each Original ADC Licensed Product and Duality shall keep Licensee informed of Duality&#8217;s, its Affiliates&#8217; and sublicensees&#8217; Commercialization activities in the Retained Territory with respect to each Original ADC Licensed Product.  In addition, each Party shall make available to the other Party such additional information about its Commercialization activities as may be reasonably requested by the other Party from time to time. Without limiting the generality of the foregoing, Licensee shall, &#91;***&#93;, provide Duality with &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall be responsible for the registration, filing, maintenance and enforcement of any trademarks (including domain names) developed for the Original ADC Licensed Products in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Parties will discuss in good faith and enter into a separate branding agreement outlining terms for ownership, use, management and enforcement of trademarks (including domain names) adopted to identify the Original ADC Licensed Products in the Field in the Retained Territory.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Original ADC Licensed Products Tracking in the Territory and Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; Licensee shall, and shall ensure that its Affiliates and Sublicensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC Licensed Products through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Territory. Duality shall, and shall ensure that its Affiliates and (sub)licensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC Licensed Products through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Retained Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 27 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby covenants and agrees that during the Term, and except as expressly permitted by this Agreement, it shall not (and shall cause its Affiliates and Sublicensees (with respect to Licensee), (sub)licensees (with respect to Duality) and subcontractors not to), either itself or through a Third Party, develop, use, market, promote, import, export, sell or actively offer for sale (online or otherwise) the Licensed Products in the other Party&#8217;s territory. Without limiting the generality of the foregoing, except as mutually agreed by the Parties, each Party shall not (a) engage in any advertising activities relating to the Licensed Products directed primarily to customers in the other Party&#8217;s territory, or (b) actively or intentionally solicit orders from any prospective purchaser located in the other Party&#8217;s territory or prospective purchasers whose delivery address is located in the other Party&#8217;s territory. To the extent permitted by Applicable Laws, including applicable antitrust laws, if a Party receives any order for Licensed Products from a prospective purchaser located in or with a nominated delivery address in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) the Licensed Products under such order.  If a Party should reasonably know that a customer or distributor is actively engaged itself or through a Third Party in the sale or distribution of the Licensed Products in the other Party&#8217;s territory, then such Party shall (i) within &#91;***&#93; Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of gaining knowledge of such activities, notify the other Party regarding such activities and provide all information available to such Party that the other Party may reasonably request concerning such activities and (ii) use Commercially Reasonable Efforts (including cessation of sales or delivery to such customer) necessary to limit such sale or distribution in the other Party&#8217;s territory, unless otherwise agreed in writing by the Parties prior to such sale or delivery.  </font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>FINANCIAL TERMS</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In partial consideration of Duality&#8217;s granting of the licenses and rights to Licensee hereunder, Licensee shall make a one-time, non-refundable, non-creditable payment to Duality of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; days after the receipt of an invoice issued by Duality to the Licensee on or after the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Funding Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall, within &#91;***&#93; days after the receipt of an invoice issued by Duality to the Licensee on or after the Effective Date, pay to Duality (i) an amount of &#91;***&#93; to fund Duality Costs in connection with the HER2-Low BC Expansion Trial in the Territory&#59; and (ii) an amount of &#91;***&#93; to fund Duality Costs in connection with the EC Expansion Trial in the Territory. Duality&#8217;s invoice shall include documentation regarding the occurrence of the &#91;***&#93; Dosing in each of the HER2-Low BC Expansion Trial  and EC Expansion Trial and supporting documents specifying the expenses spent. Duality will use the amount paid by Licensee solely for administration and conduct of the corresponding Phase II Dose Expansion Trial after the Effective Date (i.e., the HER2-Low BC Expansion Trial or the EC Expansion Trial, as applicable). </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 28 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Invoicing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to each of the HER2-Low BC Expansion Trial and the EC Expansion Trial, Duality will issue the first invoice for reimbursement of Duality Costs after Duality&#8217;s full consumption of the funding as specified in Section 8.2(a) above, and be accompanied with supporting documentation itemizing the breakdown of the costs and expenses that were incurred and are reimbursable hereunder. Thereafter, no later than &#91;***&#93; setting forth the amount of actual Duality Costs incurred during such Calendar Quarter in the Territory which shall be reimbursed by Licensee pursuant to this Section 8.2, along with supporting documentation itemzing the breakdown of the costs and expenses that were incurred and are reimbursable hereunder.  With respect to &#91;***&#93;, Duality will issue the first invoice for reimbursement of Duality Costs within &#91;***&#93; Days after the first Calendar Quarter after the Effective Date and thereafter the preceding sentence shall apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each invoice issued by Duality shall list Duality Costs actually incurred in U.S. Dollars (and if any item was originally in another currency, the exchange rate used for converting the original currency to U.S. Dollar in accordance with Section 9.2).  &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Other Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At Licensee&#8217;s  request, Duality shall perform any other Clinical Trial (in addition to the Ongoing Trials) of an Original ADC Licensed Product for an Indication other than the HER2 BC Indications and EC Indication. The Parties shall discuss (through the JSC) Licensee&#8217;s &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development and Regulatory Milestone Payments of the Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to the milestone events set forth in the tables below, promptly following the first achievement, whether by Duality or any of Duality&#8217;s Affiliates (when designated by Licensee) or by Licensee or any of Licensee&#8217;s Affiliates or Sublicensees, of the corresponding milestone event by the first Original ADC Licensed Product, Licensee or Duality, as the case may be, shall notify the other Party within &#91;***&#93; Days of such achievement, and Licensee shall pay to Duality the corresponding non-refundable, non-creditable milestone payment -within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee on or after the achievement of the applicable milestone event&#58;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sales Milestone Payments of the Original ADC Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall pay to Duality the additional one-time, non-refundable, non-creditable payments set forth in the table below within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee on or after the first achievement of each milestone event described below. &#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 29 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93;&#160;days after the end of the Calendar Quarter in which any milestone event set forth above in this Section&#160;8.4 for which a milestone payment is payable is achieved, Licensee shall deliver a written notice to Duality of such achievement, and Licensee shall pay to Duality the corresponding milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee.  For clarity, each of the milestone payments set forth above in this Section&#160;8.4 shall be additive such that if multiple milestone events specified above are achieved in the same Calendar Quarter, then the milestone payments for all such milestone events shall be payable by Licensee.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall pay tiered royalties to Duality on Annual Net Sales of&#58; (i) all Original ADC Licensed Products in the Territory in each Calendar Quarter as set forth below, in the first table in this Section 8.5, calculated by &#91;***&#93;&#59; and (ii) any &#91;***&#93; or &#91;***&#93; at the Reduced Royalty Rates for each respective Annual Net Sales threshold, as set forth in the second or third table, as the case may be, in this Section 8.5, calculated by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Royalties under Section&#160;8.5 shall be payable, on a &#91;***&#93; basis, during the period beginning on &#91;***&#93; and continuing until the latest of&#58; &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalty Payment Reduction of Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PAYMENT&#59; RECORDS&#59; AUDITS</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Royalties shall be calculated and reported for each Calendar Quarter within &#91;***&#93;&#160;days after the end of each Calendar Quarter.  Each payment shall be accompanied by a report of &#91;***&#93;. Except as may otherwise be expressly provided herein, Licensee shall not have the right to set off, withhold or make any deduction from any payment of royalties or other payments due to Duality hereunder for any reason whatsoever. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Exchange Rate&#59; Manner and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments hereunder shall be payable in U.S. dollars within &#91;***&#93; days after receipt of an invoice from Duality. With respect to sales of Licensed Products invoiced in a currency other than U.S. dollars,  sales milestones and royalties shall be converted into U.S. dollar using the exchange rate mechanism generally applied by Licensee or its Affiliates or Sublicensees for consolidation purposes, in accordance with the Accounting Standards, for the Calendar Quarter for which a payment is due. All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Duality, unless otherwise specified in writing by Duality. </font></div><div style="padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 30 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided in this Section&#160;9.3, Licensee shall be solely responsible for the payment of all value added taxes, fees, duties, surcharges, and other deductions or withholding taxes imposed by or on any entity in the Territory in connection with the payments and activities contemplated hereunder. Except as otherwise set forth in this Section, each Party shall be solely responsible for the payment of all taxes imposed on such Party&#8217;s income arising directly or indirectly from the activities of the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any withholding tax, fee, duty or surcharge  applicable to or assessable in respect of any of the Upfront Payment, development, regulatory or sales milestone payments, or royalty payments to be made by Licensee to Duality under this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is required to be withheld and deducted under Applicable Laws (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Licensee (or its Affiliate paying on behalf of Licensee) shall make such deduction and withholding and will pay the remaining License Payments to Duality. For clarity, Licensee&#8217;s reimbursement of Duality Costs shall not be deemed to be License Payments or subject to any Tax Withholdings.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall make such deduction of taxes and withholding tax payments to the applicable taxing authority(ies) in a timely manner and shall promptly provide Duality with the appropriate proof of payment and relevant receipt(s) with respect to such deduction or withholding. To the extent permitted by Applicable Laws, Licensee shall provide Duality reasonable assistance in order to allow Duality to obtain the benefit of any present or future treaty against double taxation or refund or reduction in taxes which may apply to the License Payments. Each Party agrees to use commercially reasonable efforts to cooperate with the other Party in claiming refunds, reductions, or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in effect. Duality will provide Licensee with any tax forms or other documentation reasonably necessary in order for Licensee not to withhold or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  If the taxes originally paid or otherwise borne by a Party are in whole or in part subsequently determined not to have been chargeable, all reasonably necessary steps will be taken by each Party to obtain a refund of these undue taxes from the applicable Governmental Authority or other fiscal authority and any amount of undue taxes repaid by such authority to the receiving Party will be transferred to the paying Party within &#91;***&#93; days of receipt.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that, by reason of Applicable Law in any country or region, it becomes impossible or illegal, after reasonable efforts by Licensee to do so, for Licensee or its Affiliate to transfer, or have transferred on its behalf, payments owed Duality hereunder, Licensee shall promptly notify Duality of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country or region to the credit of Duality in a recognized banking institution designated by Duality provided such arrangements are legal under all Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall keep, and require its Affiliates and Sublicensees to keep, complete, fair and true books of accounts and records for the purpose of determining the amounts payable to Duality pursuant to this Agreement.  Such books and records shall be kept for at least &#91;***&#93; Years following the end of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 31 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Calendar Year to which they pertain.  Duality shall have the right to cause an independent, certified public accountant reasonably acceptable to Licensee to audit such records to confirm Net Sales, royalties and other payments for a period covering not more than the preceding &#91;***&#93; Years&#59; provided that (a) such audit shall not be more frequent than once in any &#91;***&#93; month period, and (b) once such accountant has conducted a review and audit of any records pursuant to this Section 9.5 in respect of any given period, it may not subsequently re-inspect such records with respect to such period, unless, in each case of (a) and (b), for cause. Prior to engagement by an independent, certified public accountant, such accountant must have executed and delivered to Licensee and its Affiliates a confidentiality agreement as reasonably requested by Licensee, which will include provisions limiting such accountant&#8217;s disclosure to Duality to only the results and basis for such results of such inspection</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Such audits may be exercised during normal business hours upon reasonable prior written notice to Licensee.  Prompt adjustments shall be made by the Parties to reflect the results of such audit.  Duality shall bear the full cost of such audit unless such audit discloses an underpayment by Licensee of more than &#91;***&#93; of the amount of royalties or other payments due under this Agreement for any applicable Calendar Quarter, in which case, Licensee shall bear the cost of such audit and shall promptly remit to Duality the amount of any underpayment.  Any overpayment by Licensee revealed by an audit shall be fully-creditable against future payment owed by Licensee to Duality (and if no further payments are due, shall be refunded by Duality at the request of Licensee). Any underpayment by Licensee identified by an audit shall not be subject to Section 9.6.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Licensee fails to make any payment due under this Agreement (save as set out in Section 9.5), simple interest shall thereafter accrue on the sum due from the due date until the date of payment at &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.23pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) agrees that, during the Term and for &#91;***&#93; years thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement or any other written agreement between the Parties, any Confidential Information, including any Know-How, furnished or made available to it by or on behalf of the other Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its, and its Affiliates&#8217;, employees, agents, contractors, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information.  The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party&#8217;s Confidential Information. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Confidential Information shall not include any information which the Receiving Party can prove by competent evidence&#58; (a)&#160;is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 32 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Receiving Party, generally known or available to the public or part of the public domain&#59; (b)&#160;is known by the Receiving Party and&#47;or any of its Affiliates at the time of receiving such information, as evidenced by its records&#59; (c)&#160;is hereafter furnished to the Receiving Party and&#47;or any of its Affiliates by a Third Party, as a matter of right and without restriction on disclosure&#59; or (d)&#160;is independently discovered or developed by the Receiving Party and&#47;or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Section&#160;10.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">filing or prosecuting or defending Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">disclosure required in connection with any judicial, regulatory or administrative process relating to or arising from this Agreement (including any enforcement hereof) or to comply with applicable court orders&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">disclosure to Affiliates, employees, contractors, consultants or agents of the Receiving Party who have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement&#59; provided, in each case, that any such Affiliate, actual or potential licensee or Sublicensee, employee, contractor, consultant or agent agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth in this Article&#160;10&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">such disclosure is made to such Party&#8217;s attorneys, independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the Receiving Party, on the condition that such attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with the confidentiality provisions of this Agreement as they apply to the Receiving Party (provided, however, that in the case of financial advisers, including investment bankers, the term of confidentiality may be shortened to &#91;***&#93; years from the date of disclosure and in the case of attorneys, no written agreement shall be required)&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">disclosure to existing investors, acquirors or collaborators or potential bona fide investors, acquirors, licensees, Sublicensees or collaborators in connection with due diligence or similar investigations by such Third Parties&#59; provided, in each case, that any such existing or potential investor, acquiror, licensees, Sublicensees or collaborator agrees to be bound by confidentiality and non-use obligations consistent with those contained in this Agreement as they apply to the Receiving Party (but of duration customary in confidentiality agreements entered into for similar purpose)&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">disclosure to Regulatory Authorities as required by Applicable Laws in relation to Regulatory Approvals and regulatory procedures, proceedings and other filings&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">disclosure to&#58; (i) Governmental Authorities to the extent useful or necessary to make regulatory filings and obtain or maintain Regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 33 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Approvals (including fulfilling post-approval regulatory obligations) for any Licensed Product&#59; (ii) Governmental Authorities, technical committees or similar public health or scientific bodies for purposes of securing product use recommendations, tenders, direct procurement contracts or responding to relevant requests for information&#59; (iii) comply with Applicable Laws with respect to performance under this Agreement&#59; and (iv) to Governmental Authorities in order to respond to inquiries, requests or investigations relating to Licensed Products or this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">to the extent mutually agreed to by the Parties in writing.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;10.3(a) or Section&#160;10.3(b), it will, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to secure and cooperate with the other Party, as necessary, to seek and obtain, confidential treatment of such Confidential Information required to be disclosed to the extent legally permissible and will limit the disclosure of that Confidential Information required to be disclosure to (i) to advisors (including lawyers and accountants) or Governmental Authorities on a need to know basis, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement, or (ii) to the extent agreed to by the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Press Releases and Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">As soon as practicable following the Effective Date and on a date mutually agreed by the Parties, the Parties shall issue a joint press release announcing the execution of this Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by applicable securities laws (including disclosure requirements of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any stock exchange on which securities issued by a Party or its Affiliates are traded), neither Party shall make any other public announcement or statement, whether oral or written, concerning this Agreement or the subject matter hereof without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed&#59; provided that each Party may make any public statement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, or issue press releases, so long as any such public statement or press release is not inconsistent with prior public disclosures or public statements approved by the other Party pursuant to this Section&#160;10.4 and which do not reveal non-public information about the other Party.  In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text. Licensee shall have final decision making authority in respect of the proposed text of any required public announcement relating to the Licensed Product in the Territory and Retained Territory. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the event of termination of this Agreement for any reason, if in the reasonable opinion of the either Party&#8217;s legal counsel, public disclosure of such termination is required under the Applicable Law or the rules of a stock exchange on which the securities of either Party (or any controlling Affiliate of such Party) are listed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 34 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(or to which an application for listing has been submitted), the Parties shall cooperate in good faith to coordinate public disclosure, if any, of such termination and the reasons therefor. The principles to be observed in such disclosures shall be accuracy, compliance with Applicable Law, the rules of the applicable stock exchange and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news and neither Party shall make any other public announcement or statement, whether oral or written, concerning the termination of this Agreement without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Notwithstanding anything to the contrary in this Section&#160;10.4 and subject to Section 10.5, the Parties have the right to publicly disclose (A) the achievement of milestones under this Agreement&#59; and (B) the commencement, completion, material data and key results of Clinical Trials conducted under this Agreement. After a publication has been made available to the public, each Party may post such publication or a link to it on its corporate web site without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Filing of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or any stock exchange or governmental agency on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted&#59; provided that each Party will ultimately retain control over what information to disclose to the SEC or any stock exchange or other governmental agency, as the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation, neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC or any stock exchange or other governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If either Party proposes to publicly present or publish in any publication or venue, in their respective Territories, any Clinical Trial data, non-clinical data or any associated results or conclusions generated by or on behalf of Licensee pursuant to Clinical Trials (each such proposed presentation or publication, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), it shall obtain the other Party&#8217;s prior written consent and otherwise comply with this Section&#160;10.5. The proposing Party shall provide the other Party with a copy of such Proposed Publication at least &#91;***&#93; days prior to the earlier of its presentation or intended submission for publication&#59; provided that in the case of abstracts, this period shall be at least &#91;***&#93; Days (such applicable period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The proposing Party agrees that it will not submit or present any Proposed Publication (i) until the other Party has provided written comments during such Review Period on the material in such Proposed Publication, or (ii)&#160;until the applicable Review Period (as may be extended by subsection (C) below) has elapsed without written comments from the other Party, in which case the proposing Party may proceed and the Proposed Publication will be considered approved in its entirety. If the proposing Party receives written comments from the other Party during the applicable Review Period, it shall consider the comments of the other Party in good faith, but will retain the sole authority to submit the manuscript for such Proposed Publication&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that&#160;the proposing Party  agrees to (A) delete any Confidential Information of the other Party that the other Party identifies for deletion in the other Party&#8217;s written comments, (B) delete any Clinical Trial data, non-clinical data, results, conclusions or other related information that is not specific to or resulting from any Clinical Trial conducted in the proposing Party&#8217;s territory, and (C) delay such Proposed Publication for a period of up </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 35 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to an additional &#91;***&#93; days after the end of the applicable Review Period to enable the other Party to draft and file patents with respect to any subject matter to be made public in such Proposed Publication and to which the other Party has the applicable intellectual property rights to file such patents.  The proposing Party shall provide the other Party a copy of the Proposed Publication at the time of the submission or presentation.  The proposing Party shall require its Affiliates, (sub)licensees (in case that Duality is the proposing Party), Sublicensees (in case that Licensee is the proposing Party) and contractors to comply with the obligations of this Section&#160;10.5 as if they were the proposing Party, and shall be liable for their non-compliance. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Publication and Listing of Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party&#59; provided that any listings or publications made pursuant to this Section&#160;10.6 shall be considered a publication hereunder and shall be subject to Section&#160;10.5.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Prior Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date, the terms of this Article&#160;10 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) to the extent dealing with the subject of this Agreement.  Any information disclosed pursuant to any such prior agreement relating to the subject to this Agreement shall be deemed Confidential Information for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Given the nature of the Confidential Information and the competitive damage that would result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Article&#160;10. In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article&#160;10.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not (i) conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, (ii) conflict with or result in a breach of any provision of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 36 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">organizational documents, or (iii) violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it&#59; and</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">each Party shall conduct, and shall cause its Affiliates and sublicensees to conduct all activities under this Agreement in compliance with all Applicable Laws, all applicable national and international guidelines and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Duality Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality represents and warrants to Licensee, as of the Effective Date (solely with respect to the Licensed Products) and as of the date of delivery to Licensee of the data package in accordance with Section 2.7(d) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Package Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (solely with respect to the Duality Immune Agonist ADC Product) as expressly set out below in this Section 11.2.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With respect to the &#91;***&#93;, the below representations and warranties regarding Licensed Products are given as of the Effective Date but only specifically in relation to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With respect to the &#91;***&#93;, the below representations and warranties regarding Licensed Products are given as of the Effective Date but only specifically in relation to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Licensee Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee represents and warrants to Duality, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any covenants made by the Parties elsewhere in this Agreement, each Party hereby covenants to the other that&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">(i) all patient authorizations and consents required under Applicable Laws (in connection with any applicable clinical study) permit the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6, and (ii) it will comply with Applicable Laws in transferring personal and other Data in connection with the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6.  Each Party will obtain all the necessary authorizations, consents and approvals in order for such Party to grant access to its Data with the other Party, including obtaining the necessary patient authorizations and consents, and obtaining the necessary approvals from and completing all necessary filing procedures with the applicable Governmental Authorities in the Territory and within the Retained Territory (to the extent required to preserve Licensee&#8217;s position in the Territory)&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">it will not knowingly, during the Term, employ or use the services of any person who is debarred or disqualified in connection with activities relating to the Licensed Compound or Licensed Products&#59; and in the event that it becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to it with respect to any activities relating to the Licensed Compound or Licensed Products, it will immediately notify the other Party in writing and it will cease employing, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 37 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">contracting with, or retaining any such person to perform any services relating to the Licensed Compound or Licensed Products&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">it shall conduct, and shall cause its Affiliates, subcontractors, Sublicensees (in case of Licensee) or sublicensees (in case of Duality) to conduct all activities under this Agreement (including, as set forth in the Development Plan(s) with respect to the Licensed Products in the Field in the Territory) in compliance with all Applicable Laws, and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">it shall conduct its obligations with respect to Development of Licensed Products in the Territory in adherence with the Development Plan as may be amended from time to time&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">it shall comply, and ensure that shall use commercially reasonable efforts to cause its Affiliates, subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality) to comply with and commit to uphold the ABC Terms in the performance of activities under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">it shall have (and shall ensure its Affiliates and (sub)licensees, and subcontractors as applicable, have), at all times, a reasonably sufficient number of suitably qualified personnel to allow the Party (or its Affiliates,sublicensees or subcontractors, as applicable) to conduct, in compliance with all Development timeframes set out in the applicable Development Plans and GXPs, any Clinical Trials that the Party is required to conduct with respect to the Licensed Products in its territory, or in the other Party&#8217;s territory as permitted under this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">it shall not induce or solicit, or attempt to induce or solicit, any employees of the other Party or any of its Affiliates to leave the employment of, or to terminate his&#47;her employment, services or engagement with, the other Party or its applicable Affiliate, or enter into any employment or services agreement or arrangement with such Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Duality Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to any covenants made by Duality elsewhere in this Agreement, Duality hereby covenants to Licensee as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Performance by Affiliates, Sublicensees and Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a)  Subject to Licensee&#8217;s prior written consent or if explicitly stated in the Development Plan or this Agreement, Duality may perform some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or sublicensees&#59; and (b) Licensee may perform some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or Sublicensees&#59; provided that with respect to the foregoing clauses (a) and (b), the Party involving its Affiliates, subcontractors or Sublicensees (in case of Licensee) or sublicensees (in case of Duality) shall at all times be fully responsible for the performance and payment of such Affiliate, subcontractor or Sublicensees (in case of Licensee) or sublicensees (in case of Duality). </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 38 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PROVIDED BY DUALITY TO LICENSEE HEREUNDER ARE PROVIDED &#8220;AS IS,&#8221; AND DUALITY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OBTAINING SUCCESSFUL RESULTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Duality shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled by Duality or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) Licensee shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled (other than pursuant to this Agreement) by Licensee or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder, specifically relating to ADC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Solely Owned Collaboration IP and Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Data and Regulatory Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything contrary in this Section 12.1, the ownership rights to Regulatory Materials are allocated in accordance with Sections 5.2(b) and 5.4. The ownership rights to Data are allocated in accordance with Section 5.6(a).  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.19pt">Disclosures&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall, and shall ensure that each of its Affiliates, (sub)licensees (in the case of Duality), Sublicensees (in the case of Licensee) and subcontractors under this Agreement has a contractual obligation to disclose to such Party all Collaboration IP, Data and other Know-How generated, invented, discovered, developed, made or otherwise created by or for them or their employees, agents or independent contractors, and to provide sufficient documentary proof to evidence ownership, rights and interest with respect thereto, so that such Party can comply with its obligations under this Section&#160;12.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 39 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.19pt">Inventorship Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties agree that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Section&#160;12.2, the terms &#8220;prosecute,&#8221; &#8220;prosecuting&#8221; and &#8220;prosecution,&#8221; when used in reference to any Patent, shall be deemed to include, without limitation, &#91;***&#93; with respect to such Patent.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Infringement by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that either Duality or Licensee becomes aware of any infringement or threatened infringement by a Third Party of any Solely Owned Collaboration Patent, Duality Product Patent, Duality Linker-Payload Patent, &#91;***&#93; any related declaratory judgment or equivalent action, including administrative proceedings, alleging the invalidity, unenforceability or non-infringement of any such Patent, it shall notify the other Party in writing to that effect.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:112.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Licensed Product-by-Licensed Product basis, as between the Parties, &#91;***&#93; to make all patent listings of Duality Product Patents, Solely Owned Collaboration Patents, &#91;***&#93; or other patent-related submissions with Regulatory Authorities with respect to such Licensed Product, except for Duality Linker-Payload Patents &#91;***&#93;, &#91;***&#93; to make all patent listings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; will be obliged to make all patent listings or other patent-related submissions with Regulatory Authorities in &#91;***&#93;.&#160;&#91;***&#93; reasonable requests in connection therewith, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 40 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including meeting any submission deadlines, to the extent required or permitted by Applicable Laws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Right Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM&#59; TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall commence on the Effective Date, and unless terminated earlier as provided in this Article&#160;13, shall continue in full force and effect, on &#91;***&#93; except as provided otherwise in this Article 13. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Termination for Material Breach by Either Party.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Termination Right.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A Party shall have the right to terminate this Agreement (in its entirety or on a Licensed Product-by-Licensed Product and country-by-country basis) upon written notice to the other Party if such other Party is in material breach of this Agreement and has not cured such breach within &#91;***&#93;&#160;days after written notice from the terminating Party requesting cure of the breach. In case the alleged material breach is a material breach of Licensee&#8217;s diligence obligations set forth in Sections 4.1 and&#47;or 7.1 of this Agreement, Duality shall only be entitled to terminate the Agreement with effect to the country or countries with respect to which Licensee has in fact materially breached the diligence obligations with respect to the Original ADC Licensed Product and not cured such breach, If at the end of the cure period the breaching Party has failed to perform the activities of the cure plan to cure the breach, the non-breaching Party shall be entitled to terminate the Agreement with &#91;***&#93; prior notice. If the existence of material breach or the failure to cure such material breach is not disputed by the breaching Party and the Agreement is terminated by the non-breaching Party, the consequences of termination set forth in Section 13.7 or 13.8 (as the case may be) shall apply. If the existence of material breach or the failure to cure such material breach is disputed by the breaching Party, Section 13.7 or 13.8 (as the case may be) shall apply if the existence of material breach or the failure to cure such material breach is determined pursuant to Section 15.2 and the Agreement is thereafter terminated by the breaching Party. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Dispute as to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that the breaching Party disputes the existence of material breach or the failure to cure such material breach by initiating arbitration proceedings pursuant to Section 15.2 within the cure period, the non-breaching Party shall not have the right to terminate in accordance with Section 13.3(a) unless and until the relevant dispute has been resolved pursuant to Section 15.2. During the pendency of such dispute, the applicable cure period shall be tolled, all the terms of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations hereunder. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Termination for Other Causes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.3pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 41 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.62pt">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Party shall have the right to terminate this Agreement upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, dissolution, liquidation or winding up of such other Party, or the making or seeking to make or arrange an assignment of a substantial portion of such other Party&#8217;s assets for the benefit of creditors of such other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy against such other Party, or is adjudged bankrupt, or the appointment of a receiver or trustee of such other Party&#8217;s property, in each case that is not discharged within &#91;***&#93; days, or immediately upon written notice to the Party, if such Party otherwise admits to the other Party in writing its inability generally to meet its obligations as and when they fall due in the general course of business.  In the event a Party is bankrupted or a bankruptcy proceedings is commenced by or against such Party or its Affiliates or any country or jurisdiction, all rights under this Agreement will be fully exercisable and the bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall continue to perform all of the obligations provided in this Agreement to be performed by such Party. If the bankrupt Party and its successors and assigns are restricted by Applicable Laws from performing its obligations hereunder and the other Party elects to retain its rights hereunder, then the bankrupt Party shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party&#8217;s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.3pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.62pt">Mutual Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties may terminate this Agreement in full or on a Licensed Product-by-Licensed Product or a country-by-country basis, at any time during the Term upon mutual agreement in writing. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-2.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.45pt">General Effects of Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.3pt">Accrued Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither expiration nor any termination of this Agreement for whatsoever reason shall relieve either Party of any obligation or liability (incluidng but not limited to any payment obligation under Article 8) accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement for whatsoever reason preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement.  Such obligations and rights shall survive termination and expiration of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.62pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of non-expired Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of termination of the entire Agreement, all non-expired option periods under the Agreement shall automatically terminate. Upon termination of one or more Licensed Products, the option period shall only terminate with respect to the terminated Licensed Products. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Surviving Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties&#8217; rights and obligations under Articles 1 (Definitions), 8 (Financial Terms  unless otherwise set out in this Article 13 the Financial Terms only survive in accordance with the respective applicable terms with respect to Licensee&#8217;s sell-off right in Sections 13.6(e), 13.7(b)(iv) and 13.8(b)(iii)), Article 9 (Payment), Article 10 (Confidentiality), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 42 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 12.1 and with respect to &#91;***&#93; only, Sections 12.2 and 12.4, Sections 13.5 to 13.10, Article 14 (Indemnification and Insurance), Article 15 (Dispute Resolution) and Article 16 (Miscellaneous) of this Agreement shall survive expiration or any termination of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Consequences of Termination by Duality for Material Breach or Patent Challenge by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If an arbitration tribunal in accordance with the process set out in Section 15.2 confirmed the existence of a material breach on the part of Licensee, and such material breach was not or cannot be cured, or in case of an uncured patent challenge by Licensee (Section 13.4(a)(i)), the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Duality&#8217;s Election to Continue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Duality&#8217;s Election to Terminate. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality may, in its sole discretion, elect to terminate the Agreement (in part or in its entirety, as applicable) for material breach in accordance with Section 13.3. The consequences of such a termination for material breach shall be as follows&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">Licenses Granted to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of a termination of the entire Agreement, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.36pt">Rights Granted to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In case of termination of the entire Agreement, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Wind-Down or Transfer of Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Licensee shall, as directed by Duality in its sole discretion  on a Clinical Trial-by-Clinical Trial basis, either&#58;</font></div><div style="margin-bottom:12pt;padding-left:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Sublicenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality shall grant to Licensee&#8217;s or Licensee&#8217;s Affiliate&#8217;s Sublicensees a direct license, provided that (A) such sublicense agreement is consistent with the relevant terms and conditions of this Agreement at the time of termination of this Agreement, (B) such Sublicensee then is not in material breach of its sublicense agreement and (C) such Sublicensee then has not caused Licensee to be in material breach of this Agreement due to any act or omission of such Sublicensee.  The scope of such direct license shall be no less than the scope of the license granted in this Agreement and sublicensed to such Sublicensee and such direct license shall be on terms and conditions substantially similar to those set forth in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Consequences of Termination by Licensee for Material Breach or Patent Challenge by Duality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If an arbitration tribunal in accordance with the process set out in Section 15.2 confirmed (A) the existence of a material breach on the part of Duality, and such material breach was not or cannot be cured, or (B) in case of &#91;***&#93;, with the Licensee&#8217;s Executive Officer having the final say, the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 43 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br>INDEMNIFICATION</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Indemnification of Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall indemnify and hold harmless each of Duality and its Affiliates and their respective directors, officers, employees, consultants, agents and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), incurred by any Duality Indemnitee as a result of any claims, demands, actions, suits or proceedings brought by a Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) arising directly or indirectly out of&#58; (a)&#160;the practice by Licensee or its Affiliates or Sublicensees or subcontractors of the icense in Section 2.1&#59; (b)&#160;the research, Development, Manufacture or have Manufactured, use, handling, storage, Commercialization or other disposition of the Licensed Compound or the Licensed Products by Licensee or its Affiliates or Sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Licensee Indemnitee&#59; or (d)&#160;any breach of any representations, warranties or covenants by Licensee under this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Duality set forth in Section&#160;14.2, or (y) arising from or occurring as a result of a Duality Indemnitee&#8217;s negligence, illegal conduct or wilful misconduct in performing its or their obligations or exercising their rights under this Agreement. Licensee&#8217;s indemnification obligation specifically excludes any and all Third Party Claims, including but not limited the payment of royalties, that relate to or are incurred by the use of the Duality Licensed IP by Licensee, its Affiliates and&#47;or Sublicensees under this Agreement and that result from Third Party Agreements of Duality or Duality&#8217;s Affiliates existing at the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Indemnification of Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality shall indemnify and hold harmless each of Licensee and its Affiliates and their respective directors, officers, employees, consultants, agents and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), from and against any and all Losses incurred by any Licensee Indemnitee as a result of any Third Party Claims arising directly or indirectly out of&#58; (a)&#160;the practice by Duality or its Affiliates or sublicensees or subcontractors of the license granted to Duality under Section&#160;2.5&#59; (b)&#160;the Development, Manufacture, use, handling, storage, sale or other disposition of the Licensed Compound or Licensed Products by Duality or its Affiliates or sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Duality Indemnitee&#59; or (d)&#160;any breach of any representations, warranties or covenants by Duality under this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Licensee set forth in Section&#160;14.1 or (y) arising from or occurring as a result of a Licensee Indemnitee&#8217;s negligence, illegal conduct or wilful misconduct in performing its or their obligations or exercising their rights under this Agreement. In addition to the above, and not subject to (x), regardless of any information provided by Duality to Licensee regarding agreements with Third Parties entered into prior to the Effective Date, Duality&#8217;s indemnification obligation shall cover any and all Third Party Claims, including but not limited to the payment of royalties, (a) that relate to or are incurred by the use of the Duality Licensed IP by Licensee, its Affiliates and&#47;or Sublicensees under this Agreement and (b) that result from such Third Party agreements of Duality or Duality&#8217;s Affiliates existing at the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any Duality Indemnitee or Licensee Indemnitee intends to claim indemnification under this Article&#160;14 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Duality or Licensee, as the case may be, shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 44 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification. Each indemnification claim notice must contain a description of the claim, the nature and amount of such loss (to the extent known at the time). The Indemnitor shall have sole control of the defense and&#47;or settlement thereof and the Indemnitee shall be entitled to participate in (but not control) the defence of such Third Party Claim and to employ counsel of its choice for this purpose, at its own expense. The indemnity arrangement in this Article&#160;14 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed unreasonably.  The failure to deliver written notice to the Indemnitee within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article&#160;14 if and to the extent the Indemnitee is actually prejudiced thereby.  Duality or Licensee, as the case may be, and the Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by these indemnification provisions. The Indemnitor shall not settle any Third Party Claim without the prior written consent of the Indemnitee if the settlement is reasonably expected to&#58; (a) result in or impose any obligation (including any payment obligation) on the Indemnitee or otherwise adversely affect the business of the Indemnitee in any manner, or (b) result in any admission of wrong-doing or fault by the Indemnitee.  The costs and expenses, including fees and disbursements of counsel, incurred by the Indemnitee in connection with any claim shall be reimbursed by the Indemnitor on a calendar quarter basis, without prejudice to the Indemnitor&#8217;s right to contest the Indemnitee&#8217;s right to indemnification and subject to refund in the event the Indemnitee is ultimately held not to be obligated to indemnify the Indemnitee.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term.  Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. Such insurance shall not be construed to create a limit on either Party&#8217;s liability with respect to its indemnification obligations under this Article 14.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Deadlock Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event a deadlock occurs with respect to the decision-making process of the JSC, such deadlock shall be subject to binding determination by an expert panel in the Hong Kong Special Administrative Region. The expert panel shall consist of &#91;***&#93; members, &#91;***&#93; of which &#91;***&#93; appointed by each Party and the &#91;***&#93; member shall be selected by the other &#91;***&#93; members (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The panel must be appointed within &#91;***&#93;  days of the occurrence of a deadlock event or such longer period as the Parties may agree. Each Expert shall be a person having not less than &#91;***&#93; years&#8217; experience in the area of expertise in the business of pharmaceuticals (including biologics) and having no conflict of interest with either Party. If the issues in dispute involve scientific, technical or commercial matters, the experts chosen hereunder shall have educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 45 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and industry knowledge, as necessary to resolve the dispute.  With respect to any dispute to be submitted to an Expert pursuant to this Agreement, the use of the Expert shall be the exclusive remedy of the Parties, and neither Party shall attempt to adjudicate such dispute in any other forum. The decision of the Experts shall be final and binding on the applicable Parties involved in such dispute and deadlock  resolution procedure contemplated by this Section 15.1 and shall not be capable of challenge, whether by arbitration, in court or otherwise. All proceedings and communications shall be in English.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Sections 15.4 and 15.5, upon the written request of either Party to the other Party, any differences, claim, dispute, or controversy as to the breach, enforcement, interpretation or validity of this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be referred to the Executive Officers for resolution.  In the event such executives are unable to resolve such Dispute within &#91;***&#93;&#160;days after the initial written request, then, upon the written demand of either Party and subject to Section&#160;15.4 below, the Dispute shall be referred to and finally resolved by binding arbitration administered by the Hong Kong International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any successor entity thereto) pursuant to the United Nations Commission on International Trade Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Arbitration Rules in force when the notice of arbitration is submitted, as modified by the HKIAC Procedures for the Administration of Arbitration under the UNCITRAL Arbitration Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as modified by Section&#160;15.3 below.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The arbitration shall be conducted by a panel of three arbitrators experienced in the business of pharmaceuticals (including biologicals).  If the issues in dispute involve scientific, technical or commercial matters, the arbitrators chosen hereunder shall engage experts having educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  Within &#91;***&#93; days after initiation of arbitration, each of the Parties shall select one arbitrator and these two arbitrators shall jointly select a third arbitrator.  If a Party fails to select an arbitrator or if the two arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within such &#91;***&#93; day period, any unselected arbitrator or third arbitrator, as the case may be, shall be appointed in accordance with the Rules. The place of arbitration and the seat of arbitration shall be Hong Kong Special Administrative Region, and all proceedings and communications shall be in English. Unless agreed by the Parties in writing, all documents provided under or in connection with this Agreement shall be in the English language or accompanied by a certified English translation. If such document is translated into any other language, the English language version shall prevail unless the document is a constitution, statutory or other official document. The laws governing this arbitration agreement shall be the laws of Hong Kong Special Administrative Region and the arbitral award shall be final and binding on the Parties. Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor the arbitrators may disclose the existence, content, or results of arbitration without the prior written consent of both Parties. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Arbitrators&#8217; Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   The arbitrators shall, within &#91;***&#93; days after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded.  The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 46 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">decision or award rendered by the arbitrators shall be final and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall bear its own attorney&#8217;s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators&#59; provided, however, that the arbitrators shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys&#8217; fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and&#47;or the fees and costs of the HKIACand the arbitrator.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt">Protective Orders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At the request of either Party, the Tribunal shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Interim Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall be entitled to take action in any court with competent jurisdiction to apply for and be granted emergency or other interim relief and otherwise enforce by injunction, specific performance or other equitable relief, without prejudice to any other rights and remedies that it may have under this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Continued Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Provided that this Agreement has not been terminated in its entirety, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement and any disputes, claims, or actions related thereto shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions thereof.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the Schedules hereto, sets forth all of the agreements and understandings between the Parties with respect to the subject matter hereof and thereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof and thereof. There are no other agreements or understandings with respect to the subject matter hereof, either oral or written, between the Parties. Except as expressly set forth in this Agreement, no subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as any other Party may reasonably </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 47 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Relationship Between the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship or legal entity of any type between the Parties. Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Neither Party shall treat or report the relationship arising under this Agreement as a partnership for United States tax purposes unless otherwise required pursuant to a determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and of a particular scope, and shall be signed by such Party.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned by a Party without the prior written consent of the other Party (which shall not be unreasonably withheld, conditioned or delayed), except to (a) an Affiliate&#59; provided that this Agreement shall be assigned in whole, and the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate&#59; (b) a Third Party in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether in a sale of stock, sale of assets, business combination, reorganization, or other transaction or series of related transactions. Unless expressly stated otherwise in this Agreement, Duality may assign without the prior consent of Licensee its right to receive payments under this Agreement or grant any security interest in its rights, title and interest in this Agreement, in whole or in part and in their entirety or in portions, to an institutional financier in connection with a financing transaction&#59; provided that Duality has given Licensee a prior written notice regarding such assignment. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the permitted assigns of the Parties.  Any assignment not in accordance with this Agreement shall be void.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is not intended to and shall not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby. </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. The Parties shall use their commercially reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 48 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">enforceable provision(s) in a way that, to the extent practicable and legally permissible, implements the original intent of the Parties.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other.  Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58; (a)&#160;the date of actual receipt&#59; (b)&#160;if delivered by overnight courier, &#91;***&#93; Business Days after delivery&#59; or (c)&#160;if sent by facsimile, upon electronic confirmation of receipt.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Duality&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality Biologics (Suzhou) Co., Ltd</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unit 1106, No 868 Yinghua Road, Pudong New District, Shanghai, China</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Licensee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIONTECH SE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;<br>Address&#58; An der Goldgrube 12,<br>55131 Mainz,<br>Germany </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93; </font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control including but not limited to acts of God, fire, flood, explosion, earthquake, or other natural forces, regional or worldwide epidemic, pandemic, war, civil unrest, acts of terrorism, accident, destruction or other casualty, and a material change in Applicable Law (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party&#8217;s failure or delay in performance due to a Force Majeure Event must be given to the other Party within &#91;***&#93;&#160;days after its occurrence. The Party affected by a Force Majeure Event will use reasonable efforts to resume performance of its obligations and will keep the other Party informed of actions related thereto.  If any such failure or delay in a Party&#8217;s performance hereunder continues for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 49 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">more than &#91;***&#93; days, the other Party may terminate this Agreement upon written notice to the delayed Party.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section&#160;shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. The words &#8220;include&#8221;, &#8220;including&#8221;, &#8220;containing&#8221;, &#8220;comprising&#8221; and similar words shall not be deemed to be terms of limitation and shall be deemed to be followed by &#8220;without limitation,&#8221; whether or not specifically stated, and the language following such words shall not be deemed to set forth an exhaustive list. The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive. The words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. The words &#8220;pharmaceuticals&#8221; or &#8220;drugs&#8221; include biologics unless expressly indicated otherwise. All references to days in this Agreement shall mean calendar days, unless otherwise specified. All references to any Applicable Law in this Agreement shall mean such Applicable Law as amended, restated, supplanted or otherwise modified from time to time.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties hereto acknowledge and agree that&#58; (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement&#59; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two (2) or more counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties or their representative legal counsel, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one and the same instrument. Electronic, facsimile or PDF image signatures shall be treated as original signatures, with the understanding that each Party expressly agrees that such Party shall be bound by its own electronically transmitted signature and shall accept the electronically transmitted signature of the other Party (including through the use of eSignature platforms such as DocuSign&#174;).  No Party will raise the use of electronic delivery to transmit a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery as a defense to the formation of a contract.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 50 of 102</font></div><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have duly executed this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co., Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Zhongyuan John Zhu</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ugur Sahin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Zhongyuan John Zhu</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Ugur Sahin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Executive Officer</font></div></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sean Marett</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sean Marett</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Business Officer and Chief Commercial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to HER2 Collaboration And License Agreement                 Page 51 of 102</font></div><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees that it will not undertake any activities which will result in a violation of any applicable laws, regulations, and applicable industry and professional codes, including but not limited to applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws (collectively &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Prohibited Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#34;) in connection with the performance of any activities under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">In particular, each Party agrees that during the course of the performance of activities under this Agreement, it (i) shall not make any offer, payment, or promise to pay money or provide anything of value to a Government Official (as defined below) or any other individual and&#47;or legal entity whether directly or indirectly, for the purpose of improperly influencing any act and&#47;or decision of, and&#47;or for securing any improper advantage&#59; (ii) shall not accept, receive, agree to accept and&#47;or receive a payment and&#47;or anything of value from any individual for undue favorable treatment in obtaining, retaining, and&#47;or directing business for, and&#47;or to obtain any undue special concession on behalf of either Party&#59; and (iii) shall not facilitate any payments to any Government Official to expedite a routine government action and&#47;or other official act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221; shall include (i) individuals acting on behalf of governments on a national, regional and local level (such as elected officials, customs officials, tax officials, etc.)&#59; (ii) individuals acting on behalf of government-owned or government-controlled enterprises&#59; (iii) individuals acting for political parties or as or on behalf of candidates for public office&#59; and (iv) individuals acting on behalf of public international organizations (such as the WHO, World Bank, OECD, etc.). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">All transactions and expenses incurred on behalf of either Party shall be accurately recorded and maintained in the respective Party&#8217;s books and records in a timely manner and in reasonable detail in accordance with the applicable generally accepted accounting principles. False, misleading, incomplete, duplicated, inaccurate or artificial entries for the foregoing expenses in a Party&#8217;s books and records are strictly prohibited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> agrees that if it becomes aware or has reason to suspect that any person or legal entity acting on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">the Party</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8217;s and&#47;or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">the other Party</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8217;s behalf </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">has engaged in any Prohibited Conduct related to the Agreement,</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> then such Party will promptly report such knowledge or suspicion to the other Party via the following email address&#58; (a) in case that Duality is the reporting party&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#91;***&#93;</font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> and (b) in case that Licensee is the reporting party&#58; &#91;***&#93;. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Duality shall apply Commercially Reasonable Efforts to implement, operate and enforce, without undue delay after the Effective Date, a reasonably designed compliance and business ethics management and control system that is indended for the prevention and detection of criminal conduct in accordance with applicable Anti-Corruption Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 52 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of the other Party related to the performance of potentially Prohibited Conduct as described in Article 1 above. Upon notice of an intended investigation, a Party will provide, in a reasonable time, to the investigating Party or to a third party engaged by the investigating Party&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g., invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party acknowledges that the obligations under the applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws apply to all its Affiliates and employees,  subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality). Each Party will bind subcontractors who act for or on behalf of such Party to perform activities under this Agreement by such Party for or on behalf of the other Party by respective contractual clauses encompassing all or all material provisions of this Schedule.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 53 of 102</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.46</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description of Duality Know-How</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 54 of 102</font></div><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.55</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Duality Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 55 of 102</font></div><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.89</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Indications</font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 56 of 102</font></div><div><font><br></font></div></div></div><div id="i7c27d20d9ff34584a9266e65703759b3_22"></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.6</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Know-How Transfer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 57 of 102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 4.6</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreed Preparatory Activities for Initiation of a &#91;***&#93; Clinical Trial </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 58 of 102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Press Release</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 59 of 102</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.51
<SEQUENCE>7
<FILENAME>exhibit451dualityb7h3agree.htm
<DESCRIPTION>EX-4.51
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i274e375c7fa040468caeb033834ff728_1"></div><div style="min-height:154.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.51</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Confidential </font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DUALITY BIOLOGICS (SUZHOU) CO. LTD.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIONTECH SE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">dated as of March 31, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 1 DEFINITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................................... &#160;&#160;&#160;&#160;1</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 2 LICENSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .............................................................................................. &#160;&#160;&#160;&#160;23</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 3 GOVERNANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .................................................................................. &#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 4 DEVELOPMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">................................................................................ &#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 5 REGULATORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................................... &#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 6 MANUFACTURE &#38; SUPPLY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ........................................................... &#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 7 COMMERCIALIZATION MATTERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ............................................ &#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 8 FINANCIAL TERMS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">......................................................................... &#160;&#160;&#160;&#160;50</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 9 PAYMENT&#59; RECORDS&#59; AUDITS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .................................................... &#160;&#160;&#160;&#160;63</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 10 CONFIDENTIALITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................... &#160;&#160;&#160;&#160;65</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 11 REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ........................................................................................ &#160;&#160;&#160;&#160;70</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 12 INTELLECTUAL PROPERTY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">...................................................... &#160;&#160;&#160;&#160;79</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 13 TERM&#59; TERMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................. &#160;&#160;&#160;&#160;85</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 14 INDEMNIFICATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................................... &#160;&#160;&#160;&#160;95</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 15 DISPUTE RESOLUTION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ................................................................ &#160;&#160;&#160;&#160;97</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 16 MISCELLANEOUS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .......................................................................... &#160;&#160;&#160;&#160;99</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedules</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ABC Terms</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Calculation of Adjusted Net Profits </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.38&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Co-Promotion Terms</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.75&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Duality In-Licensed Agreements</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.78&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Description of Duality Know-How</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.84&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of Duality Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Know-How Transfer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93; Data Package</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.8(b)(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Illustrative Example</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for &#91;***&#93; Costs &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.8(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Example &#91;***&#93; Calculation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payments for Other ADC Licensed Products</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payments for &#91;***&#93; Licensed Products</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Joint Press Release </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 11.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Disclosure Schedule</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">This License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of March 31, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co. Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a corporation organized and existing under the laws of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), having a place of business at Unit 1105-1106, No 868 Ying Hua Road, Pudong New District, Shanghai, China, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a company organized and existing under the laws of Germany, having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Duality is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Licensee is engaged in the research, development and commercialization of active immunotherapies for patient-specific approaches to the treatment of diseases&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee desires to obtain from Duality, and Duality desires to grant to Licensee, an exclusive sublicensable license under the Duality Licensed IP to Develop, Manufacture and Commercialize the ADC Licensed Products in the Field in the Territory (each as defined below), subject to the terms and conditions of this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee desires to obtain from Duality, and Duality desires to grant to Licensee, an exclusive sublicensable license under the &#91;***&#93; In-Licensed IP to Develop, Manufacture and Commercialize the Sequence Licensed Products in the Field in the Territory (each as defined below), subject to the terms and conditions of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties desire to collaborate in the Development, Manufacture and Commercialization of the Original ADC Licensed Products in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Duality and Licensee hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a Selling Party (as defined below), International Financial Reporting Standards endorsed by the European Union or other applicable standard accounting principles used by Sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any construct comprising an Antibody(ies) linked to a non-Antibody chemical species with a therapeutic or biological activity or function, including non-Antibody chemical species that (i) directly kills, slows or stops the growth of a tumor cell through such compound&#8217;s primary mechanism of action (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cytotoxic Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Original ADC Licensed Product, &#91;***&#93; and &#91;***&#93;, but excluding any Additional Active.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Active(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any active pharmaceutical or biologic ingredient(s) that is not the Licensed Compound. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Co-Promotional Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Applicable Laws that are applicable to the marketing, promotion, distribution and sale of Co-Promotion Products, including (if applicable) the Federal Food, Drug and Cosmetic Act, the American Medical Association Guidelines on Gifts to Physicians from Industry and the Pharmaceutical Research and Manufacturers of America (&#8220;PhRMA&#8221;) Code on Interactions with Healthcare Professionals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adjusted Net Profits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and, with correlative meaning, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adjusted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any company or entity controlled by, controlling, or under common control with a Party or another entity. For the purpose of this definition, an entity shall be deemed to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; another entity, if it owns directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, capital stock, or other comparable equity or ownership interest of such entity, or possession, direct or indirect, of the power to direct or cause the direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">&#8220;Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean for a particular Licensed Product the total Net Sales for a particular Calendar Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any antibody (including murine, chimeric, human, humanized, recombinant, transgenic, grafted, phage display derived, or single chain antibody), or antigen binding fragment thereof. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">&#8220;Anti-Corruption Laws&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean all applicable anti-bribery and anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010 and the PRC Anti-Money Laundering Law and the comparable Applicable Laws of any countries in which candidates or Licensed Products, payments or services will be provided or procured under or pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean collectively the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, of any Governmental Authority and any license, franchise, permit or similar right granted under any of the foregoing (including Regulatory Approvals) and any policies and other requirements of or from any court, arbitrator, Regulatory Authority or governmental agency or Governmental Authority having jurisdiction over or related to the subject item or subject person, including all applicable GXPs, Anti-Corruption Laws, Applicable Data Protection Laws, accounting and recordkeeping laws, export control laws and laws relating to interactions with health care professionals and government officials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Data Protection Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Applicable Laws in any jurisdiction relating to privacy or the processing or protection of personal data or personal information, including the General Data Protection Regulation (EU) 2016&#47;679 (GDPR), the UK Data Protection Act 2018, the e-Privacy Directive (2002&#47;58&#47;EC) and the comparable in other jurisdictions and all guidance issued by any applicable data protection authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">B7H3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a particular Licensed Product in a given country, a product comprising an ADC sold by a Third Party not authorized by Licensee or its Affiliates or Sublicensees that is approved by the applicable Regulatory Authority for such country through an application or submission filed with a Regulatory Authority for marketing approval of a biologic product claimed to be biosimilar or interchangeable to such Licensed Product, including an application filed under 42 U.S.C. &#167; 262(k) (or any successor thereto) or any similar laws or regulations in a country outside the United States in reliance on data generated for a Regulatory Approval of such Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biologics License Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any day that is not a Saturday, a Sunday or any other day on which banks are required or authorized by law to close in Mainz, Rhineland-Palatine (in Germany) or any government mandated holiday in Mainland China. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of three (3) consecutive months commencing on January 1, April 1, July 1 or October 1 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of twelve (12) consecutive months commencing on January 1 and ending on December 31 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Lines and Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to either Party&#58; (a) a merger, acquisition, reorganization, or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, acquisition, reorganization, or consolidation&#59; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party&#59; or (c) a transfer to a Third Party of all or substantially all of its assets relating to this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Registrational Trial or other human clinical trial conducted after the Regulatory Approval of a product in a country, which trial may be conducted to (a) enhance scientific knowledge of such product (e.g., for expansion of product labeling), (b) due to a request or requirement of a Regulatory Authority in such country, (c) is otherwise designed to establish that a product is reasonably safe for continued testing and to identify adverse reactions and ascertain the safety of the product, or (d) investigate the safety and efficacy of the product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean chemistry, manufacturing and controls with respect to the Licensed Compound or ADC Licensed Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 6.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Third Party contract manufacturing organization.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Detailing and such other activities assigned to Duality in the Co-Promotion Agreement as well as distribution of such Co-Promotion Product in the Cost &#38; Profit&#47;Loss Sharing Territory by Duality or its Affiliates, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly. &#8220;Co-Promotion&#8221; shall not include any Medical Affairs Activities (including medical information), marketing, pricing, market access and reimbursement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the expenses incurred by either Party in performing Co-Promotion activities in accordance with the Co-Promotion Agreement, including &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 7.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.38.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, any and all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, marketing, pricing, reimbursement, sale, importing, exporting or transporting such product, and distribution of such product, including strategic marketing, sales force detailing, advertising, market product support, all customer support, product distribution, and invoicing and sales activities, but excluding Development and Manufacturing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 3.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitive Change of Control&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean a Change of Control of Duality where the incoming Third Party and&#47;or its Affiliates is a Competitor.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Know-How and other proprietary scientific, technical, clinical, marketing, financial or commercial information or Data Controlled by a Party or its Affiliates, which one Party or any of its Affiliates has furnished or made available to the other Party or its Affiliates, whether in oral, written or electronic form.  The existence and terms of this Agreement shall be deemed Confidential Information of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (including any variations such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall mean, with respect to any Know-How, Patents or other intellectual property rights, possession by a Party or Third Party of the right, power and authority (whether by ownership, license, sublicense or otherwise, other than by virtue of any rights granted under this Agreement) to grant access to, to grant use of, or to grant a license or a sublicense to such Know-How, Patents or intellectual property rights without violating the terms of any agreement or other arrangement with any Third Party. Notwithstanding anything in this Agreement to the contrary, a Party and its Affiliates will be deemed to not Control any Know-How, Patents, or other intellectual property rights that are in-licensed or acquired by such Party or its Affiliates from a Third Party after the Effective Date, unless the other Party agrees to (a)&#160;comply with the terms and conditions of the agreement under which such Know-How, Patents, or other intellectual property rights were in-licensed or acquired by such Party&#59; and (b)&#160;pay all amounts that such Party would be obligated to pay in connection with the grant, maintenance and exercise of a (sub)license as reasonably allocable to such other Party for use in its territory under such Know-How, Patents, or other intellectual property rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.6(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.6(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.6(c). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.6(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.6(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a contract research organization. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all data, including non-clinical data, preclinical data and clinical data, including pharmacological, biological, chemical, toxicological, clinical test, safety, clinical and analytical information, quality control, trial, stability and manufacturing processes and techniques data generated by or on behalf of a Party or its Affiliates or their respective Sublicensees (in case of Licensee) and (sub)licensees and other (sub)contractors (in the case of Duality) pursuant to activities conducted under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Detail</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Detailing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Detail</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean to engage in a Detail. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a pharmaceutical or biological product, any research activities, all non-clinical and clinical drug development activities and processes, &#91;***&#93;, regulatory affairs and other activities, in each case, which are reasonably necessary to prepare submissions for, and obtain or maintain, Regulatory Approval of such product and interacting with Regulatory Authorities regarding the foregoing, including lifecycle management studies and other activities.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as set forth in Section 1.64.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period from the Effective Date to the First Commercial Sale of the first Original ADC Licensed Product during which either Party is conducting any Development activities for an Original ADC Licensed Product or Licensed Compound. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a written plan approved by the JSC, and amended from time to time in accordance with the terms of this Agreement, describing &#91;***&#93;. The initial Development Plan, unless otherwise agreed on by the Parties, will be agreed by the Parties latest within &#91;***&#93; of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 11.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">&#8220;Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all costs and expenses that are reasonably incurred by or on behalf of Duality and its applicable Affiliates after the Effective Date in conducting the Planned Trials and&#47;or performing other Development activities as agreed hereunder in the Territory pursuant to this Agreement and the Development Plan. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any CMO engaged by Duality or any Affiliate of Duality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.6(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93; shall have the meaning provided in Section 2.10.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">&#8220;Duality In-Licensed Agreements&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean each Agreement as set forth on Schedule 1.75.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality In-Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents or Know-How that is Controlled by Duality or any of its Affiliates pursuant to the Duality In-Licensed Agreements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How (including Data) that (a) is Controlled by Duality or any of its Affiliates as of the Effective Date or at any time during the Term, and (b) are necessary or reasonably useful for the Development, Manufacture or Commercialization of or to otherwise exploit the Licensed Compound or ADC Licensed Products in the Field in the Territory, including but not limited to, with respect to (a) and (b), the Know-How (including Data) contained in Duality Solely Owned Collaboration IP, &#91;***&#93;. Notwithstanding the foregoing, Duality Know-How shall not include (i) any Know-How (including Data) Controlled by any Third Party that becomes an Affiliate of Duality after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How (including Data) is used by either Party in the Development, Manufacturing or Commercialization of the Licensed Compound or ADC Licensed Products, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by Duality or any of its Affiliates. A description of Duality Know-How as of the Effective Date is attached hereto on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Know-How and Duality Patents. Duality Licensed IP includes Duality In-Licensed IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any new or useful invention, discovery, adaptation, redesign, modification, improvement, enhancement, contribution or other desirable change generated in the course of performing activities under this Agreement solely relating to &#91;***&#93;. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents claiming the Duality Linker-Payload.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in the introductory paragraph of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.15. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean shall mean the European Medicines Agency and any successor entity thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.5(a). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.9(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Data Package Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.9(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.9(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.9(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.9(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.1. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the U.S. Food and Drug Administration and any successor entity thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all uses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to an ADC Licensed Product, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Dosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Clinical Trial, or any portion thereof, dosing of the first human subject in such Clinical Trial or such portion thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;16.11.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean full time equivalent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fully Burdened Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Original ADC Licensed Product supplied by or on behalf of Duality&#58; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the ethical conduct of Clinical Trials, including without limitation the U.S. Code of Federal Regulations (CFR) Title 21, ICH GCP Guidelines E6(R2) as amended from time to time, national legislation implementing European Community Directive 2001&#47;20&#47;EC (if and as still applicable), European Community Directive 2005&#47;28&#47;EC, and, following the applicable transition periods, the Clinical Trial Regulation (EU) No. 536&#47;2014 (the &#8220;CTR&#8221;) and the rules, regulations and guidelines applying in the context of the CTR, and the equivalent in other countries or regions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the treatment of human laboratory samples from Clinical Trials, including the relevant principles from GCP and the EMA&#8217;s reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Clinical Trial designed to obtain Regulatory Approvals for an ADC Licensed Product in multiple countries through the conduct of a Clinical Trial in multiple countries, regions and&#47;or medical institutions and conducted as part of one (1) unified Clinical Trial or separately but concurrently in accordance with a common Clinical Trial protocol.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results, including without limitation the CFR Title 21, national legislation implementing European Community Directives 2004&#47;9&#47;EC and 2004&#47;10&#47;EC as amended, and the OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, and the equivalent in other countries or regions. For the purposes of this Agreement, GLP also includes the principles of Good Clinical Laboratory Practice and applicable guidelines promulgated under the ICH guidelines.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products, including without limitation the CFR Title 21, Parts 11, 210, 211, 600 and 610, applicable ICH Guidelines including without limitation Q7 for &#8220;Active Pharmaceuticals Ingredients&#8221;, national legislation implementing European Community Directive 2001&#47;83&#47;EC and Commission Directive 2003&#47;94&#47;EC as amended, EudraLex &#8211; Volume 4 of the Rules Governing Medicinal Products in the European Union including annexes, the CTR, Commission Delegated Regulation 2017&#47;1569, the Detailed Commission Guideline (2017) 8179, and the equivalent in other countries or regions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is to be broadly interpreted and includes any multi-national or public international organization or authority, national, federal, state, local, municipal, provincial, foreign government or other governmental authority of any nature (including any governmental division, prefecture, branch, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, and any Regulatory Authority). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GXP&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collectively, all relevant and applicable good practice quality guidelines and regulations, encompassing such internationally recognized standards as GMP, GCP, GLP and GCLP, Good Distribution Practice (GDP), Good Pharmacovigilance Practice, Good Pharmacoepidemiology Practice and Good Review Practice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an investigational new drug application, clinical study application, Clinical Trial exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.&#160; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Info Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;2.6(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Clinical Trial, the date upon which the first patient is dosed in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.2(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the joint steering committee to be established by the Parties pursuant to Section&#160;3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all technical, scientific, regulatory and other information, trade secrets, results, knowledge, techniques, materials (including cell lines) and data, in whatever form and whether or not confidential, proprietary, whether or not patentable, invention disclosures, plans, inventions, assays, designs, protocols, and formulas, processes, practices, methods, knowledge, know how, skill, experience, ideas, concepts, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing, pricing, distribution, cost, sales, and manufacturing data or descriptions.  &#8220;Know-How&#8221; includes any rights including copyright, database or design rights protecting such Know-How. For clarity, Know-How does not include issued Patents, published patent application or the inventions claimed thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 9.3(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the ADC developed by or on behalf of Duality and known as DB-1311, the structure of which, is delivered to Licensee on or before the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any ADC Licensed Product and Sequence Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Added Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93; shall have the meaning provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How that is Controlled by Licensee or any of its Affiliates and that is comprised by the Licensee&#8217;s Solely Owned Collaboration IP. Notwithstanding the foregoing, Licensee Know-How shall not include (i) any Know-How Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How is used by Licensee in the Development, Manufacture or Commercialization of the Licensed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compound or Original ADC Licensed Products, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">&#8220;Licensee Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Licensee Know-How and Licensee Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents that are Controlled by Licensee or any of its Affiliates and that are comprised by the Licensee Solely Owned Collaboration Patents. Notwithstanding the foregoing, Licensee Patents shall not include (i) any Patent Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, and (ii) any Patent that Covers any Additional Active or other proprietary compound or product Controlled by Licensee provided that such Patent does not Cover the Licensed Compound or Original ADC Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an application to a Regulatory Authority for the authorization to place a product on the market in the applicable country, region or a regulatory jurisdiction, including New Drug Application and Biologics License Application, and shall include all amendments and supplements thereto, filed with the applicable Regulatory Authority to gain authorization to place such product on the market in the applicable jurisdiction. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the holder of the Marketing Authorization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mainland China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the mainland of the People&#8217;s Republic of China.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Major &#91;***&#93; Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; for the purpose of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Licensed Product, activities related to the manufacture and supply of such Licensed Product, including manufacturing supplies for Development or Commercialization, packaging, labeling, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of product, ongoing stability tests, storage, and shipment and regulatory activities directly related to any of the foregoing, but not including any Development or Commercialization activities. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Patents and Know-How that (i) are generated, developed or conceived during the course of performing activities under this Agreement depending on Duality Licensed IP, and (ii) specifically related to, and (iii) are necessary for the Manufacture of the Duality Linker-Payload&#59; notwithstanding the foregoing, Manufacturing IP shall exclude Licensee Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the authorization by all relevant Regulatory Authorities of an MAA in a given country or regulatory region&#47;jurisdiction and the granting of the required authorization for the sale of a product which will include any Pricing and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reimbursement Approvals if required by Applicable Law of the respective country to initiate marketing and selling of a product in such particular country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the master cell bank. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the coordination of medical information requests and field based medical scientific liaisons with respect to an Original ADC Licensed Product, including activities of medical scientific liaisons, activities involving key opinion leaders, and the provision of medical information services with respect to an Original ADC Licensed Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Multi-Specific</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.15.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">&#8220;Non-Arbitral Subject Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given in Section 15.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offer Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given in Section 2.15.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other ADC Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; and &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 8.8(b)(ii).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee or Duality individually, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee and Duality collectively.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) patent applications filed in the applicable jurisdiction&#59; (b) all patents, including supplemental protection certificates, that have issued or in the future issue from any of the foregoing, including utility models, design patents and certificates of invention&#59; and (c) all divisionals, continuations, continuations-in-part, reissues, re-examination certificates, renewals, extensions or additions to any such patents and patent applications (as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 5.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the principal purpose of which explores the optimal dose and is a determination of initial tolerance or safety of such product in healthy volunteers or the target patient population, as described in 21 CFR 312.21(a) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population, (i.e. &#8220;proof of concept&#8221;), as described in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PhRMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Pharmaceutical Research and Manufacturers of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Planned Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 4.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, in any country where a Regulatory Authority authorizes reimbursement for, or approves or determines pricing or level of reimbursement for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization and&#47;or pricing approval or determination (as the case may be).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.173</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.9. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.174</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 10.5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the reduced royalty rates for the &#91;***&#93; and &#91;***&#93; specified in the second table in Section 8.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.179</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registrational Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, a human clinical trial (regardless of whether such clinical trial is referred to as a &#8220;Phase II Clinical Trial&#8221;, &#8220;Phase IIb Clinical Trial&#8221;, &#8220;Phase II&#47;III Clinical Trial&#8221;, &#8220;Phase IIb&#47;III Clinical Trial&#8221; or &#8220;Phase III Clinical Trial&#8221;) for such product, the results of which, together with prior information concerning such product, are determined by the sponsor to be intended to be sufficient to establish that such product is safe and effective for its intended Indication to support the filing of an MAA. &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.180</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all approvals, licenses, permits, registrations or authorizations of or from any Regulatory Authority that are necessary to market (including Marketing Authorization) and sell a pharmaceutical product in any country, region or other jurisdiction.  For clarity, unless it is required by the Applicable Law to initiate marketing and selling of a product in a particular country, Regulatory Approval shall not include Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a country, any national, federal, supranational, state or local regulatory agency, council, department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country, region or jurisdiction. including the Regulatory Approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.183</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, regulatory applications (including MAA) and all applications, filings, submissions, notifications, materials, communications, registrations, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize such product in a particular country, region or jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.184</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;5.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean  Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.15.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.188</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 8.7(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.190</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Sales Steering Committee for the Co-Promotion Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.192</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.4(a)(i).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.193</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as provided in Section 1.157.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.194</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.196</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Patents and Know-How relating to the Sequence Licensed Product created, conceived, discovered, developed, reduced to practice, invented or otherwise generated in the course of performance of activities under this Agreement. Sequence Licensed Product IP &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Dosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Clinical Trial, or any portion thereof, dosing of the &#91;***&#93; in such Clinical Trial or such portion thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.198</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration IP and Licensee Solely Owned Collaboration IP, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.199</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration Patents and Licensee Solely Owned Collaboration Patents, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a license, sublicense, covenant not to sue or other rights granted by Licensee to a Third Party under the rights it receives from Duality in accordance with Section 2.2, to Develop, Manufacture, Commercialize or otherwise exploit a Licensed Compound or a Licensed Product, but excluding any grant of rights to or agreement with (a) any Third Party acting as a service provider or subcontractor for such Party or its Affiliates, or (b) any Third Party wholesaler, distributor, or the like.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Third Party that is receiving rights under a Sublicense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.202</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Successful Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.203</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with regard to an Antibody or ADC and a biological target in question, that such Antibody or ADC demonstrates meaningful binding activity to such biological target and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Targeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;9.3(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.205</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;13.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.206</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean worldwide except the Retained Territory. For clarity, Territory s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">hall include Taiwan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.207</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any entity other than Licensee and its Affiliates and Duality and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.208</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.6(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.209</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.210</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States of America, including its territories and possessions as recognized by the United Nations from time to time, but in all cases including, for clarity, Puerto Rico.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S. Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean U.S. dollars, the lawful currency of the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 11.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.214</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.215</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.216</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Wind-Down or Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a plan for the wind-down or transfer of any ongoing Development, Manufacture and Commercialization (if any) activities of Licensee with respect to the Licensed Products for which the license grant in Section 2.1 has been terminated and the transfer of relevant Licensed Products, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s&#8221; shall mean both the &#91;***&#93; License Agreement and the &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.218</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; In-Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents and Know-How that is exclusively granted to Duality or any of its Affiliates pursuant to the &#91;***&#93; License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.220</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.221</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the working cell bank.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>LICENSE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.3pt">Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants and shall procure its Affiliates grant to Licensee and its Affiliates, during the Term, an exclusive (even as to Duality and its Affiliates), royalty-bearing license, with the right to sublicense through multiple tiers (in accordance with Section 2.2), under (i) Duality Licensed IP to Develop, have Developed,  Manufacture, have Manufactured use, sell, offer for sale, import and otherwise Commercialize or have Commercialized or exploit the ADC Licensed Products in the Field in the Territory, and (ii) &#91;***&#93; In-Licensed IP to Develop, have Developed, Manufacture, have Manufactured, use, sell, offer for sale, import and otherwise Commercialize, have Commercialized or exploit the Sequence Licensed Products in the Field in the Territory. </font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.62pt">Retained Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants to Licensee a sole license under (i) Duality Licensed IP to Develop, have Developed, Manufacture or have Manufactured the Licensed Compound and the ADC Licensed Products in the Retained Territory solely for the purpose of Developing, Manufacturing and Commercializing the ADC Licensed Products in the Field in the Territory and (ii) &#91;***&#93; In-Licensed IP to Develop, Manufacture or have Manufactured the &#91;***&#93; Licensed Products in the Retained Territory solely for the purpose of Developing, Manufacturing and Commercializing the Sequence Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.3pt">Covenant not to sue.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms and conditions of this Agreement, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Licensee and its Affiliates shall have the right to grant Sublicenses through multiple tiers under Duality Licensed IP (including Duality In-Licensed IP), in each respect to (i) any Affiliate, or (ii) to any Third Party. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Sublicense Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Licensee&#8217;s Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates, Sublicensees and subcontractors hereunder is in accordance with the applicable terms of this Agreement.  With respect to a patent challenge by the Sublicensee against any Duality Patents, if Licensee fails to cause such Sublicensee to cease such violation within a reasonable period of time, Licensee shall, in so far as it is not prohibited under the Applicable Laws, terminate the sublicense agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In so far as it is not prohibited under the Applicable Laws, Licensee hereby covenants on a country-by-country basis not to, and not to permit or cause any Affiliate to &#91;***&#93;. Notwithstanding the foregoing, this Section shall in no way restrict &#91;***&#93;, its Affiliates, its Sublicensees or their CMOs and other authorized Third Party under this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from undertaking any research, Development, Manufacturing, Commercialization, or other exploitation or engaging in any activities involving &#91;***&#93; that anyone not subject to this Agreement may legally undertake before the Effective Date and during the Term in the Territory and elsewhere, &#91;***&#93;. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">No Implied Licenses&#59; Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No right or license under any Patents or Know-How of either Party is granted or shall be granted by implication.  All such rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement.  Duality hereby expressly reserves all rights not expressly licensed to Licensee in Section&#160;2.1, including (i)&#160;all rights under the Duality Licensed IP with respect to the Licensed Compound and Original ADC Licensed Products in the Retained Territory, subject to Licensee&#8217;s co-exclusive license as set forth in Section 2.1(b), (ii)  all rights under the Duality Licensed IP to exercise its rights or perform its obligations under this Agreement, and (iii) all rights under the Duality Licensed IP to conduct Development activities in the Territory for the sole purpose of Developing or Commercializing the Original ADC Licensed Products in the Field in the Retained Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided tha</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t any such Development activities in the Territory in relation to the Original ADC Licensed Product and Licensed Compound shall be undertaken for Duality by Licensee or its Affiliates, or Sublicensees or Licensee&#8217;s designated subcontractors. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">License to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee hereby grants to Duality a non-exclusive, non-transferrable, non-sublicensable (unless a sublicense was consented to by Licensee in writing and is in compliance with the license terms set out in Section 2.2(b), which would apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), royalty-free license under the Licensee Licensed IP, during the Term of this Agreement, solely to (i) perform, either itself, through its Affiliates, or through subcontractors, its obligations under this Agreement, including its Manufacturing and supply obligations under Sections&#160;6.1, 6.4 and 6.5, and (ii) limited to the Field and the Retained Territory, to Develop, Manufacture or have Manufactured, or Commercialize the Licensed Compound or Original ADC Licensed Products.  Duality shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates or subcontractors hereunder is in accordance with the applicable terms of this Agreement. With respect to a patent challenge by a (sub)licensee against any Licensee Patents, if Duality fails to cause such (sub)licensee to cease such violation within a reasonable period of time, Duality shall, in so far as it is not prohibited under the Applicable Laws, terminate such (sub)license agreement. Duality shall be responsible for any actions of its Affiliates and subcontractors who act on behalf of Duality to perform activities assigned to Duality (for or on behalf of Licensee) pursuant to this Agreement, to the same extent as if such actions had been taken by Duality itself, and Licensee shall have the right to proceed directly against Duality without any obligation to first proceed against such Affiliate, sublicensee and subcontractor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Cost &#38; Profit&#47;Loss Sharing Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">In partial consideration of the licenses granted to Licensee under this Agreement and the performance of the Duality Development Activities, Licensee hereby grants to Duality an exclusive option to share the Development and Commercialization costs and the profits and losses from the exploitation of the first Original ADC Licensed Product in the Cost &#38; Profit&#47;Loss Sharing Territory &#91;***&#93; in accordance with this Section 2.6 and Section 8.8 below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which option may be exercised by Duality at any time during the period commencing from &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  &#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Within &#91;***&#93; days after &#91;***&#93;, Licensee shall provide Duality with a package containing the following information &#91;***&#93;.  For clarity, this  Section 2.6 (b) shall only apply to &#91;***&#93;. The information package referred to in this Section 2.6 (b) hereinafter referred to as the (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Info Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt"> Prior to the expiration of the Cost &#38; Profit&#47;Loss Sharing Option Period, Duality shall notify Licensee in writing of its desire to exercise the Cost &#38; Profit&#47;Loss Sharing Option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, such date of the Cost &#38; Profit&#47;Loss Sharing Option Exercise Notice, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cost &#38; Profit&#47;Loss Sharing Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Know-How Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93; days of the Effective Date, Duality shall, at its cost and expense, provide to Licensee &#91;***&#93; the documents embodying all Duality Know-How (including CMC documentation to the extent available to Duality or any of its Affiliates as of the Effective Date) Controlled by Duality or any of its Affiliates as of the Effective Date, including but not limited to  &#91;***&#93; A description of such documents for the initial Know-How Transfer as of the Effective Date is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto. Thereafter, Duality shall promptly (and in any event no later than &#91;***&#93; from the existence of such Know-How) inform Licensee of the existence of any additional Duality Know-How that becomes Controlled by Duality after the Effective Date and during the Term. The Parties shall discuss the timing and means of the transfer of additional Duality Know-How and Duality shall provide, and shall cause Third Parties to provide (as applicable), electronic copies of such additional Duality Know-How to Licensee in accordance with Licensee&#8217;s request, in a manner in line with that for the initial Know-How transfer and at no additional cost to Licensee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreements and Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The licenses and other rights granted to Licensee under this Agreement (including &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days following the Effective Date, the Parties shall establish a JSC comprised of an equal number of representatives from each Party to approve, plan, coordinate, integrate monitor and oversee the Development, Manufacture, regulatory and Commercialization (solely in the Cost &#38; Profit&#47;Loss Sharing Territory after the Cost &#38; Profit&#47;Loss Sharing Option Exercise Date) activities of the Parties&#8217; in the Territory with respect to the Original ADC Licensed Product and facilitate information exchange between the Parties under this Agreement. The JSC, as may be conducted through the applicable Subcommittee, shall in particular&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">review, discuss and coordinate the overall strategy for the Development of the Original ADC Licensed Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">review, discuss and approve any proposed amendments or revisions to the Development Plan(s) of the Original ADC Licensed Products, including all related budgets of the Development activities&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">review, discuss and approve any study protocols relating to the Development Plan(s) (and any amendments thereto) of the Original ADC Licensed Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">review, discuss and serve as a forum for the sharing of information between the Parties regarding the operation of any Development activities of the Original ADC Licensed Products in the Territory and in the Retained Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">after the exercise of Cost &#38; Profit&#47;Loss Sharing Option, review, discuss and serve as a forum for the sharing of information between the Parties regarding the Commercialization strategy and the Commercialization budget for the Cost &#38; Profit&#47;Loss Sharing Territory&#59;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">oversee and coordinate the on-going disclosure, sharing and&#47;or transfer of new Collaboration IP generated in or related to the Development of the Original ADC Licensed Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">review and discuss any matters relating to the Regulatory Approvals and Regulatory Materials to be submitted to any Regulatory Authority in respect of the Original ADC Licensed Products in the Territory and matters relating to attending regulatory meetings or consultations with Regulatory Authorities in respect of the Original ADC Licensed Products in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">coordinate supply of Original ADC Licensed Products in accordance with Article 6&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">review and discuss the clinical protocol of and Duality&#8217;s potential participation in any Global Trial sponsored by Licensee or any of its Affiliates and Sublicensees, or Licensee Added Trials&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From time to time during the Term, the JSC may establish and disband one or more subcommittee(s) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to oversee particular activities of the Parties, and the JSC may assign to such subcommittee(s) duties or tasks independent of the duties of the JSC, or delegate part of such duties of the JSC to such subcommittee(s) as it deems necessary and appropriate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of the foregoing subsection (a), no later than &#91;***&#93; days after the Effective Date (unless otherwise agreed by the Parties), the JSC shall establish an intellectual property committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JIPC shall provide a forum for discussion of the patenting strategies of the Original ADC Licensed Products and coordinate the Parties&#8217; efforts in accordance with the provisions set forth in Article 12 and other matters related to the prosecution and maintenance of intellectual property rights hereunder, including submissions to and addressing notices from Regulatory Authorities that relate to regulatory-patent linkage procedures and proceedings. The JSC shall determine the desired membership of the JIPC and once formed, Licensee&#8217;s committee members shall determine the time, place and procedure of meetings. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of the foregoing subsection (a), no later than &#91;***&#93; days after the Effective Date, the JSC shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JDC shall (i) oversee the implementation and progress of the Development Plan in the Territory, (ii) discuss and propose to the JSC for approval any amendments to the Development Plan, (iii) oversee any Global Trials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Composition&#59; Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC and each Subcommittee (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be composed of &#91;***&#93; representatives from each Party (or such other equal number of representatives of each of Licensee and Duality as the JSC may determine), and each Party shall notify the other Party of its initial JSC representatives within &#91;***&#93;&#160;days after the Effective Date.  Each Party shall designate a representative to be the co-chairperson of the JSC and Licensee shall designate a representative to chair each Subcommittee led by it, in each case, who shall schedule meetings, prepare meeting agendas and meeting minutes and follow up on action items. Each Party may request and convene a Committee meeting and propose agenda therefor at any time. With respect to the JSC, these responsibilities will alternate between the Parties or each co-chairperson, as applicable, with Licensee&#8217;s co-chairperson taking the responsibility for the first meeting of the JSC.  Each Party may change its representatives to the JSC (or any Subcommittee) from time to time in its sole discretion, effective upon notice to the other Party of such change. Each Party&#8217;s representatives in each Committee shall possess appropriate experience with respect to the issues falling within the functions of such Committee and requisite seniority within such Party&#8217;s organization, and shall have the authority to make decisions on behalf of the Party they represent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Non-Member Attendance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend a meeting of any Committee (in a non-voting capacity) in the event that the planned agenda for such Committee meeting would require such participants&#8217; expertise&#59; provided that if either Party intends to have any Third Party (including any consultant or counsel) attend such a meeting, such Party shall provide prior written notice to the other Party, shall obtain approval from such other Party for such Third Party to attend (which shall not be unreasonably withheld, conditioned or delayed by the notified Party), and shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The representatives of each Party will have, collectively, &#91;***&#93; at each Committee on all matters brought before such Committee. The Committees may not take any action or decide any matter except at a meeting attended by &#91;***&#93; representing each Party and &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:26.93pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.77pt">JSC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JSC (including those matters referred to the JSC by any Subcommittee), the representatives of the Parties on the JSC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, such disagreement shall be referred to the &#91;***&#93; (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for resolution.  If the Executive Officers cannot resolve such matter within &#91;***&#93; days (or such other timeframe as the JSC may request in consideration of the urgency of such referred matter) after such matter has been referred to them, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">&#91;***&#93; shall be entitled to make final decisions with respect to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.36pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">JIPC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JIPC, together with the assistance of each Party&#8217;s outside intellectual property counsel (as required and pursuant to Section 3.4), the representatives of the Parties on the JIPC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JIPC for resolution or after such matter has been referred to the JIPC, such matter shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">JDC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JDC, the representatives of the Parties on the JDC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JDC for resolution or after such matter has been referred to the JDC, such disagreement shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Deadlock Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case of a deadlock with respect to the decision-making process of the JSC, Section 15.1 shall apply. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Limitations on Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, the JSC shall not have the power to amend this Agreement, shall not have power in relation to &#91;***&#93;, and no decision of the JSC may be in contravention of any terms and conditions of this Agreement.  For clarity, the JSC shall have no decision-making authority regarding any Development, Manufacturing, Commercialization or other activity in the Retained Territory save as contemplated by Section 3.5(a) or otherwise expressly provided in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The JSC will hold a meeting every &#91;***&#93; until the Development Phase ends, and afterwards every &#91;***&#93;, or as otherwise determined by the JSC. Such meetings may be in person, via videoconference, or via teleconference. The location of in-person meetings will be determined by the Parties. At least &#91;***&#93; prior to each JSC meeting, each Party shall provide written notice to the other Party of agenda items proposed by such Party for discussion at such meeting, together with appropriate information related thereto. Reasonably detailed written minutes will be kept for all JSC meetings. Meeting minutes will be prepared &#91;***&#93; and sent to each member of the JSC for review and approval within &#91;***&#93; Days after the meeting. Minutes will be deemed approved unless a member of the JSC objects to the accuracy of such minutes within &#91;***&#93; Days of receipt. In the event of any such objection that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Discontinuation of JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall continue to exist until the Parties mutually agree to disband the JSC. Once the JSC is disbanded, the JSC shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the points of contact for the exchange of information under this Agreement, and the Parties shall reach decision directly on matters that are subject to the decision of the JSC as set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Project and Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall appoint an individual, who is an employee of such Party, to act as a project manager (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties. Each Party shall appoint an individual, who is an employee of such Party, to act as its alliance manager under this Agreement within &#91;***&#93; Days after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  &#91;***&#93; The Project Managers shall&#58; (a) serve as the primary points of contact between the Parties for the purpose of providing the other Party with information on the progress of a Party&#8217;s activities under this Agreement&#59;  (b) be responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties. The Alliance Managers shall&#58; (a) serve as the primary points of contact between the Parties for any issues arising under this Agreement&#59; (b) facilitate the prompt resolution of any disputes&#59; and (c) attend JSC and Subcommittee meetings (in each case, as a non-voting participant)&#59; provided that the Alliance Managers shall not count toward the number of representatives that each Party may have on each such Committee. An Alliance Manager may also bring any matter to the attention of the JSC, if such Alliance Manager reasonably believes that such matter warrants such attention. Each Party may replace its Project Manager and Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as expressly provided herein with respect to the Planned Trials, Licensee Added Trials (as applicable), Licensee (itself and through its Affiliates and their respective Sublicensees) shall be responsible, at its own expense, for the Development of the Original ADC Licensed Products in the Field in the Territory under the oversight of JSC. Without limiting the generality of the foregoing, Licensee shall, in accordance with the Development Plan (i) use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for &#91;***&#93; in the Field in &#91;***&#93;, and (ii) perform the Development activities assigned to it under the Development Plan(s) and in compliance with Applicable Laws (including GXPs), with reasonable due care and in conformity with current generally accepted industry standards and procedures. Licensee shall use Commercially Reasonable Efforts to adhere to the timelines set forth in the Development Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limiting the foregoing, Licensee shall use Commercially Reasonable Efforts to (i) make all regulatory submissions to the applicable Regulatory Authorities within the Territory in respect of the Original ADC Licensed Product&#59; and (ii) obtain Regulatory Approval for Original ADC Licensed Products in the Territory, in each case of (i) and (ii) in accordance with the Development Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties will agree on the initial Development Plan, which sets forth the scope, timelines and responsibilities of each Party of the Development activities to be conducted by or on behalf of Licensee in order to obtain Regulatory Approvals for the Original ADC Licensed Products in the Territory. &#91;***&#93; From time to time during the Term, either Party may propose written amendments and updates to the then-current Development Plan, and shall submit such amendments and updates to the JSC for review and approval.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amendment of the Development Plan and the Development Budget shall become effective only upon the approval of the JSC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Clinical Trials to Be Conducted by Duality in the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date and as set forth in the Development Plan, the Parties have agreed that Duality will conduct, at its own cost and expense,  the Clinical Trials in the Territory until &#91;***&#93; in accordance with the Development Plan and in compliance with all Applicable Laws (together, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Planned Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Global Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Phase &#91;***&#93; Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Duality Development Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Where Duality is responsible for conducting Development activities under this Agreement in the Territory, including but not limited to conducting the Planned Trials, and if applicable, &#91;***&#93;  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) , &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Any intended delegation of the Duality Development Activities or any part thereof to a subcontractor shall be communicated to Licensee via the JDC in advance and shall be reflected in the Development Plan, already listing the subcontractors that Duality intends to involve. The delegation to a subcontractor requires Licensee&#8217;s prior written consent which shall not be unreasonably withheld, conditioned or delayed&#59; provided that Licensee shall be deemed to have given its consent if  Licensee&#8217;s Project Manager and Licensee&#8217;s Alliance Manager, who were informed about the identity of the subcontractor via the JDC, do not respond within &#91;***&#93; Days after both Licensee&#8217;s Project Manager&#8217;s and Licensee&#8217;s Alliance Manager&#8217;s receipt of written notice from Duality&#59; provided further that such notice contains sufficient information for Licensee to make an informed decision.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt"> Duality shall, upon request by Licensee, (i) keep Licensee copied on the main communications regarding the contract negotiations with the subcontractor and Licensee may decide, at its own discretion, to participate in the contract negotiations with the subcontractor&#59; provided that Duality does not need to reschedule negotiations because of Licensee&#8217;s unavailability, and (ii) provide Licensee with a copy of any draft subcontractor agreement proposed to it with respect to the Duality Development Activities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including but not limited to agreements with CROs. Such Third Party Agreements shall be in the English language. Any such Third Party Agreement will only be signed after obtaining a written consent of Licensee which shall not be unreasonably withheld, conditioned or delayed&#59; provided that Licensee shall be deemed to have given its consent if Licensee&#8217;s Project Manager and Licensee&#8217;s Alliance Manager were copied on the main communications regarding the contract negotiations, given the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">opportunity to participate in the contract negotiation, and regularly updated on the progress of the negotiations (together with the draft Third Party Agreement) and do not respond within &#91;***&#93; Days after both Licensee&#8217;s Project Manager&#8217;s and Licensee&#8217;s Alliance Manager&#8217;s receipt of the fully copy of such draft Third Party Agreements and the written notice from Duality. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall maintain or cause to be maintained complete, current and accurate records of all activities conducted by or on behalf of it pursuant to the Development Plan(s), and all Know-How and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall, and shall ensure that its Affiliates and their Sublicensees will, document all non-clinical studies and Clinical Trials in formal written study records in accordance with all Applicable Laws, including applicable national and international guidelines such as ICH, GCLP, GCP and GLP.  To the extent permitted by the Applicable Laws, each Party shall have the right to review and copy such records of the other Party at reasonable times and to obtain access to review the original to the extent necessary or useful for regulatory, patent or other reasonable purposes for the purpose of fulfilling its obligations under this Agreement upon reasonable notice to such other Party and at a time and location mutually acceptable to the Parties.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall keep the other Party reasonably and timely informed of the progress and results of its and its Affiliates&#8217;, subcontractors&#8217; and Sublicensees&#8217;&#47;(sub)licensees&#8217; work under the Development Plan(s) (including prompt reporting of available pre-clinical and clinical data). Without limiting the generality of the foregoing, each Party shall provide the other Party with a written report no later than &#91;***&#93; days after the end of each Calendar Year setting forth in details the Development activities performed during such Calendar Year and the results thereof, and comparing such activities with the Development Plan(s) for such time period.  Such reports prepared by each Party shall be provided at a level of detail reasonably sufficient to enable the other Party to determine the other Party&#8217;s compliance with its obligations under this Agreement.  At each JSC meeting, the Parties shall discuss the status, progress and results of the Development activities conducted by the Parties pursuant to this Agreement.  Each Party shall promptly respond to the other Party&#8217;s reasonable questions or requests for additional information relating to such Development activities. In the event that Duality is engaged by Licensee to conduct Duality Development Activities in the Territory, Duality shall send the Development report &#91;***&#93;, setting forth in more detail the Duality Development Activities performed &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>REGULATORY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview of Conduct of Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Licensee (itself and through its Affiliates and Sublicensees, as applicable) shall be responsible for all of the costs for all regulatory activities with respect to the Licensed Products in the Territory after the Effective Date.  &#91;***&#93;, Licensee (or its Affiliate or Sublicensees) shall be the sponsor and holder of all Regulatory Approvals for the Licensed Products in the Territory.  For clarity, Licensee (or one of its Affiliates or their Sublicensees) shall always be the MAH of the Original ADC Licensed Products in the Territory. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Following the Effective Date, Duality shall provide Licensee with one (1) electronic copy of the Regulatory Materials related to the Licensed Compound and Original ADC Licensed Products in the Territory existing and possessed by Duality as of the Effective Date. At any time during the Term, if Duality is the sponsor or holder of the Regulatory Materials and upon Licensees&#8217; written request, Duality shall provide Licensee with electronic copies of the Regulatory Materials related to the Licensed Compound or Original ADC Licensed Products in the Territory received and possessed by Duality after the Effective Date promptly  and in any event no later than &#91;***&#93; Days after such Regulatory Materials become available.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Regulatory Filing&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except with respect to regulatory filings related to the Planned Trials and Licensee Added Trials (if any), for which Duality shall be responsible unless the Parties agree otherwise, (i) Licensee (and its Affiliates or Sublicensee, as applicable) shall lead and have sole control over preparing and submitting all regulatory filings related to the Licensed Compound and Original ADC Licensed Products, including all applications for Regulatory Approval, in the Territory at Licensee&#8217;s sole cost and expense, and (ii) Duality shall be responsible for the preparation and submission of any regulatory filings in the Retained Territory at Duality&#8217;s sole cost and expense. With respect to regulatory filings for the Planned Trials or and the Licensee Added Trials (if any) that are prepared by Duality, Duality shall submit all such regulatory filings to the JSC for its review and approval.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Ownership.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Other than any Regulatory Approvals or applications therefor that are related to the Planned Trials or Licensee Added Trials (if any), for which Licensee has designated Duality to be the sponsor, Licensee (or its Affiliates or Sublicensees, as applicable) shall own any and all Regulatory Approvals (and applications for Regulatory Approvals), and any other regulatory filings related to the Licensed Compound and ADC Licensed Products in the Territory, including Data and data in the regulatory filings and Regulatory Materials, which shall be held in the name of Licensee or its designees. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">English Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent that the original language is not English, Duality shall provide Licensee with a certified full English translation of all Regulatory Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Insofar as it relates to the Planned Trials and Licensee Added Trials (if any) where Licensee has confirmed and consented in writing that Duality is the sponsor, Duality shall lead interactions with Regulatory Authorities in the Territory&#59; provided that JSC shall have final decision making authority in relation to such interactions with Regulatory Authorities and Duality shall follow all instructions provided to it by the JSC in this regard and Duality shall provide Licensee with (i) access to or copies of all material written or electronic communication received by Duality or its Affiliates from any Regulatory Authorities in the Territory and in the Retained Territory (if applicable), and (ii) copies of all meeting minutes with any Regulatory Authorities in the Territory and in the Retained Territory (if applicable). In addition, Duality shall provide Licensee with written notice of any scheduled material meeting, conference, or discussion with a Regulatory Authority related to Regulatory Approvals related to the Planned Trials and Licensee Added Trials (if any). Licensee (or its designee) shall have the right to (i) attend and participate in all such meetings with Regulatory Authorities related to the Planned Trials and Licensee Added Trials (if any), and all telephone conferences and preparation meetings of Duality or its Affiliates related to any such meeting, (ii) provide input on the regulatory filings in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory), and (iii) have final decision making authority in relation to any unsettled matter between the Parties with respect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory filings in the Territory.  Subject to the foregoing, Licensee (and&#47;or its Affiliates, or Sublicensees as applicable) shall have the sole right to conduct all communications with Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to the Licensed Compound and ADC Licensed Products in the Territory, including in respect of the Licensee Added Trials where Licensee (or its Affiliates or Sublicensees, as applicable) is the sponsor (if any). Without limiting the forgoing, the Parties agree that they will collaborate with each other as necessary to ensure the successful progression of interactions with Regulatory Authorities with respect to all trials relating to the Licensed Compound and Original ADC Licensed Products in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;, Duality shall transfer and assign, or shall cause the transfer or assignment, to Licensee or its designee (at Duality&#8217;s cost and expense for Planned Trials and at Licensee&#8217;s cost and expense for Licensee Added Trials), Duality&#8217;s, or any of its Affiliates&#8217;, entire right, title, and interest in and to all IND and other Regulatory Approvals in the Territory, if any, and transfer all Regulatory Materials with respect to the Licensed Compound and Original ADC Licensed Products in the Territory that are owned, controlled or possessed by Duality or any of its Affiliates, unless the Parties agree otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At any time during the Term, Licensee may decide to replace Duality to be the sponsor of any Planned Trials and Licensee Added Trials (if any) in the Territory. Once Licensee informs Duality by written notice of its decision to replace Duality as the sponsor of any such Clinical Trials in the Territory, Duality shall within &#91;***&#93; days after receipt of such written notice from Licensee (a) transfer to Licensee all Regulatory Materials (including but not limited to the applicable IND, protocol and investigator&#8217;s brochure) in connection with each of its ongoing Clinical Trials as of the date of such notice and (b) use commercially reasonable efforts to facilitate Licensee&#8217;s introduction to applicable CROs, study site(s) and investigator(s) in connection with each such Clinical Trial in order to assist Licensee in transferring such Clinical Trial to Licensee, in each case ((a) and (b)) in accordance with Applicable Law and accepted pharmaceutical industry norms and ethical practices. To the extent that the original language of the Regulatory Materials is not English, Duality shall provide a certified full English translation of all documents to Licensee. Licensee shall be responsible for all costs and expenses reasonably incurred by Duality in relation to or as a result of such replacement&#59; provided that if the replacement was caused by a breach of the applicable terms of this Agreement, Applicable Laws or the GXP by Duality, the costs and expenses reasonably incurred by Licensee in relation or as a result of such replacement shall be borne by Duality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Data Access&#59; Right of Reference&#59; Access to Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; days of the Effective Date, the Parties shall enter into a pharmacovigilance agreement regarding the Licensed Compound and Original ADC Licensed Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall set forth standard operating procedures governing the collection, investigation, reporting, and exchange of safety information sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes.  In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement, the terms of this Agreement shall prevail and govern, except to the extent such conflicting terms relate directly to the pharmacovigilance responsibilities of the Parties (including the exchange of safety data), in which case the terms of the Pharmacovigilance Agreement shall prevail and govern. Prior to the Parties entering into the Pharmacovigilance Agreement, Duality is and shall continue to be the owner of the global safety database for the Original ADC Licensed Products. The Pharmacovigilance Agreement can be amended at Licensee&#8217;s request during the Term and as a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">preparation to the Commercialization, at least &#91;***&#93; months&#8217; ahead of the first MAA submission. At any time during the Term, upon reasonable prior notice, during regular business hours and under obligations of confidentiality, Licensee (or its designees) shall be entitled to audit (i) any of Duality&#8217;s or its Affiliates&#8217;, or any of their respective CROs&#8217; or CMOs&#8217; manufacturing sites&#59; and (ii) any of Duality&#8217;s, its Affiliates&#8217; clinical sites, as selected by Licensee in its sole discretion, to assess Duality&#8217;s compliance with all GXPs and all matters arising under the Pharmacovigilance Agreement, in each case of the foregoing (i) and (ii), only in respect of any Clinical Trials run by Duality for Licensee in the Territory&#59; provided that such audit shall not be conducted more than once in any given Calendar Year, unless it is a for-cause audit. If (a) such audit by Licensee identifies any material non-compliance by Duality (via its subcontractors) or its Affiliates (via its subcontractors) of the GXPs or the Pharmacovigilance Agreement in the Territory, and (b) such material non-compliance is confirmed to be an uncured material breach on the part of Duality pursuant to Section 13.3, then the provisions of Section 13.7 shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Remedial Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Original ADC Licensed Product may be subject to any recall, corrective action, patent regulatory procedures or other regulatory action in the Territory or the Retained Territory by any Governmental Authority or Regulatory Authority (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Parties shall assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. The Parties shall collaborate in good faith and endeavor to reach an agreement on Remedial Action related decisions save that were there is any unsettled issues in relation to any Remedial Action related matters (i) with respect to the Territory, Licensee shall have the final decision making authority and Duality shall take all actions reasonably requested by Licensee in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Duality&#8217;s position in respect of the Original ADC Licensed Product or any Regulatory Authorities in the Retained Territory, no action will be taken by Licensee (unless immediate action is required to comply with Applicable Laws and mitigate further damage arising from the Remedial Action) without Duality&#8217;s prior written consent, and (ii) with respect to the Retained Territory, Duality shall have the final decision making authority and Licensee shall take all actions reasonably requested by Duality in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Licensee&#8217;s position in respect of the Original ADC Licensed Product or any Regulatory Authorities in the Territory, no action will be taken by Duality without Licensee&#8217;s prior written consent. The cost and expenses of any Remedial Action shall be borne by the Party whose action or inaction caused the Remedial Action of the Original ADC Licensed Product.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>MANUFACTURE &#38; SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Costs of CMC Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality will conduct CMC activities for the Original ADC Licensed Products according to the scope as agreed upon by the Parties in the Development Plan.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Transfer of CMC Materials from Duality to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following the Effective Date (and thereafter from time to time during the Term upon Licensee&#8217;s reasonable advance request and to the extent not previously provided), Duality shall provide to Licensee (or its designees) the CMC-related technical documents and CMC-related technology (and any associated manufacturing process technology) that are necessary or reasonably useful for the Manufacture of the Licensed Compound and Original ADC Licensed Product and are Controlled by Duality or any of its Affiliates as of the Effective Date and which become Controlled by Duality or any of its Affiliates during the Term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and customs and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">technology export licenses required by Applicable Law for such transfer(s), if any. Within &#91;***&#93; of Licensee&#8217;s request, Duality or a Duality CMO shall provide Licensee with reasonable assistance and on-site support in respect of the CMC-related technology and associated manufacturing process technology transferred to Licensee pursuant to this Section 6.2. Any assistance required in excess of &#91;***&#93; will be at the Licensee&#8217;s cost and expense.  To the extent that the original language of the CMC Materials (including Third Party agreements)  is not English, Duality shall provide a certified full English translation of these materials. The conclusion of new Third Party agreements regarding the CMC activities contemplated under Section 6.1 or the amendment of existing Third Party agreements regarding the same shall be subject to Licensee&#8217;s prior written approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Transfer of Cell Lines and Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties will enter into a separate quality agreement to manage the logistics and shipping of the transfer of the cell lines and cell banks &#91;***&#93; licensed to Duality pursuant to the Cell Line License Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Lines and Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) used for Manufacturing the Antibody incorporated in the Original ADC Licensed Product within &#91;***&#93; days after the Effective Date. &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Initial Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality shall, by itself or through one or more Duality CMO(s) in the Retained Territory, supply to Licensee &#91;***&#93; to Licensee&#8217;s designated &#91;***&#93; and in accordance with a separate clinical supply agreement as contemplated below&#59; provided that Licensee shall be &#91;***&#93;. Unless otherwise agreed by the Parties, the Parties shall negotiate in good faith a clinical supply agreement and related quality agreement with such negotiation to be commenced within &#91;***&#93; days after the Effective Date and completed no later than &#91;***&#93; days after the Effective Date, which clinical supply agreement shall contain customary language regarding supply of the Original ADC Licensed Products to Licensee (including equitable allocation in the event of disruption to or shortage of product supply).  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Ongoing Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as may otherwise be provided under the clinical supply agreement entered into by the Parties pursuant to Section 6.4 and until the Licensee has qualified a new manufacturing site to Manufacture the Licensed Compound and the Original ADC Licensed Products in the Territory, Licensee shall be solely responsible for (i) Manufacturing the Licensed Compound and Original ADC Licensed Products intended for use in the Territory, and (ii) the associated costs and expenses of such Manufacturing activities, subject to Duality&#8217;s performance of its obligations under this Agreement. Once the Original ADC Licensed Product is approved, &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br>COMMERCIALIZATION MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Licensee (itself or through its Affiliates or Sublicensees, as applicable) shall be solely responsible for Commercialization of the Original ADC Licensed Products in the Field in the Territory, including&#58; (i) developing and executing a commercial launch and pre-launch plan, (ii) developing the global pricing strategy and negotiating with applicable Governmental Authorities regarding price and reimbursement of the Original ADC Licensed Products&#59; (iii) marketing, advertising and promotion&#59; (iv) booking sales&#59; (v) distribution and handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (vi) providing customer support, and performing other related functions&#59; (vii) conforming its practices and procedures to Applicable Laws relating to the marketing, detailing and promotion of the Original ADC Licensed Products in the Field&#59; and (viii) developing and implementing the global and local Medical Affairs Activities and medical information infrastructure required in the Field in the Territory. Licensee shall bear all of the costs and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expenses incurred in connection with such Commercialization activities in the Territory. Licensee shall use Commercially Reasonable Efforts to launch the &#91;***&#93; in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; months before the anticipated date of the submission of the first MAA for an Original ADC Licensed Product in the Territory, Licensee shall prepare a written Commercialization plan that sets forth the timeline and details of all major Commercialization activities planned for such Original ADC Licensed Product in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).   The Commercialization Plan shall be updated at least once a year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Coordination of Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) The Parties recognize that they may benefit from the coordination of certain activities in support of the Commercialization of an Original ADC Licensed Product across their territories.  As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and Original ADC Licensed Product positioning. For clarity, Licensee shall not conduct any Commercialization of any Original ADC Licensed Product outside the Territory without Duality&#8217;s express prior written consent and Duality shall not conduct any Commercialization of Original ADC Licensed Products outside of the Retained Territory without Licensee&#8217;s express prior written consent. (ii) After the exercise of the Cost &#38; Profit&#47;Loss Sharing Option, the Parties will hold &#91;***&#93; meetings which shall serve as a forum for openly discussing the commercialization strategy for the Cost &#38; Profit&#47;Loss Sharing Territory and the Commercialization budget.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Licensee shall keep Duality informed of its, its Affiliates&#8217; and Sublicensees&#8217; Commercialization activities in the Territory with respect to each Original ADC Licensed Product and Duality shall keep Licensee informed of Duality&#8217;s, its Affiliates&#8217; and sublicensees&#8217; Commercialization activities in the Retained Territory with respect to each Original ADC Licensed Product. All information and reports provided to the other Party in such report shall be treated as Confidential Information of the disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Licensee shall, &#91;***&#93;, provide Duality with &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">In addition to the other provisions of this Section, each Party shall make available to the other Party such additional information about its Commercialization activities with respect to an Original ADC Licensed Product as may be reasonably requested by the other Party from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Licensee shall be responsible for the registration, filing, maintenance and enforcement of any trademarks (including domain names) developed for the Original ADC Licensed Products in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Parties will discuss in good faith and enter into a separate branding agreement outlining terms for ownership, use, management and enforcement of trademarks (including domain names) adopted to identify the Original ADC Licensed Products in the Field in the Retained Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Original ADC Licensed Products Tracking in the Territory and Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; Licensee shall, and shall ensure that its Affiliates and Sublicensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC Licensed Products through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Territory. Duality shall, and shall ensure that its Affiliates and sublicensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Products through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Retained Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby covenants and agrees that during the Term, and except as expressly permitted by this Agreement, it shall not (and shall cause its Affiliates and Sublicensees (with respect to Licensee), sublicensees (with respect to Duality) and subcontractors not to), either itself or through a Third Party, develop, use, market, promote, import, export, sell or actively offer for sale (online or otherwise) the ADC Licensed Products in the other Party&#8217;s territory. Without limiting the generality of the foregoing, except as mutually agreed by the Parties, each Party shall not (a) engage in any advertising activities relating to the ADC Licensed Products directed primarily to customers in the other Party&#8217;s territory, or (b) actively or intentionally solicit orders from any prospective purchaser located in the other Party&#8217;s territory or prospective purchasers whose delivery address is located in the other Party&#8217;s territory. To the extent permitted by Applicable Laws, including applicable antitrust laws, if a Party receives any order for ADC Licensed Products from a prospective purchaser located in or with a nominated delivery address in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) the ADC Licensed Products under such order.  If a Party should reasonably know that a customer or distributor is actively engaged itself or through a Third Party in the sale or distribution of the ADC Licensed Products in the other Party&#8217;s territory, then such Party shall (i) within &#91;***&#93; Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of gaining knowledge of such activities, notify the other Party regarding such activities and provide all information available to such Party that the other Party may reasonably request concerning such activities and (ii) use Commercially Reasonable Efforts (including cessation of sales or delivery to such customer) necessary to limit such sale or distribution in the other Party&#8217;s territory, unless otherwise agreed in writing by the Parties prior to such sale or delivery.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Co-Promotion Option. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Subject to the terms and conditions of this Agreement, with respect only to the first Original ADC Licensed Product, Licensee hereby grants to Duality an exclusive option  during the applicable Co-Promotion Option Period, to assume between &#91;***&#93; and &#91;***&#93; of the total sales force for such Original ADC Licensed Product measured in terms of number of FTEs in the Cost &#38; Profit&#47;Loss Sharing Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that Duality&#8217;s exercise of the Co-Promotion Option shall not become effective unless Duality satisfies the criteria in Section 7.8(e) . </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Within &#91;***&#93; days from the Cost &#38; Profit&#47;Loss Sharing Option Exercise Date   (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Duality may during the Co-Promotion Option Period notify Licensee in writing of its desire to exercise the Co-Promotion Option with respect to the first Original ADC Licensed Product (thereafter, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the Cost &#38; Profit&#47;Loss Sharing Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, such date of the Co-Promotion Option Exercise Notice, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If Duality elects to exercise the Co-Promotion Option it shall deliver to Licensee the Co-Promotion Option Exercise Notice during the Co-Promotion Option Period, and promptly thereafter the Parties shall engage in good faith negotiations and enter into definitive agreement not later than &#91;***&#93; months (and in any event, to be finalized no later than &#91;***&#93; months prior to the estimated date of the first submission of the MAA in the Cost &#38; Profit&#47;Loss Sharing Territory for the Co-Promotion Product, as set forth in the applicable Development Plan at the Co-Promotion Option Exercise Date)  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from the date of Licensee&#8217;s receipt of the Co-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Promotion Option Exercise Notice to enter into a co-promotion agreement in accordance with the terms and conditions set out in this Section 7.8 and the Co-Promotion Terms (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). For clarity, the Parties will discuss and agree on the sales force allocation based on the then actual sales force forecast during the Co-Promotion Agreement negotiation period.  The Parties shall agree to discuss in good faith to conclude the Co-Promotion Agreement with terms and conditions that are customary for a co-promotion agreement in the Cost &#38; Profit&#47;Loss Sharing Territory&#59; provided that such terms and conditions are consistent with the Co-Promotion Terms. If the Parties are unable to agree on the terms of the Co-Promotion Agreement within the Co-Promotion Negotiation Period, then the Co-Promotion Option shall be deemed to have expired.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If Duality does not exercise the Co-Promotion Option for the first Original ADC Licensed Product prior to the expiration of the applicable Co-Promotion Option Period, Duality shall be deemed to have irrevocably waived its right to Co-Promote the first Original ADC Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">By the latest of &#91;***&#93; months prior to the anticipated launch of the first ADC Original Licensed  Product  in the Cost &#38; Profit&#47;Loss Sharing Territory, the Parties will coordinate through the SSC to prepare and approve the co-promotion plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which Co-Promotion Plan will inter alia set forth (i) all major Co-Promotion activities of the Co-Promotion Product under a single trademark in the Cost &#38; Profit&#47;Loss Sharing Territory to be conducted by the Parties, (ii) an estimated budget related to such Co-Promotion activities, and (iii) an anticipated timeline related to such co-promotion activities. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Under the Co-Promotion Agreement, Licensee shall have the sole right to control all decisions with respect to the Co-Promotion arrangement, including the call plans and assigned states within the Cost &#38; Profit&#47;Loss Sharing Territory covered by Duality&#8217;s sales representatives, the promotional materials to be used, the training and testing applicable to such sales representatives, and restrictions with respect to the ability of each Party&#8217;s sales representatives to Detail other products&#59; provided that Licensee shall ensure allocation of assigned states and metropolitan and rural territories between the Parties are fair and equitable. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">At least &#91;***&#93; months prior to the anticipated launch of the first ADC Original Licensed  Product  in the Cost &#38; Profit&#47;Loss Sharing Territory, Duality must demonstrate to Licensee by providing adequate documentation (such as CV with a meaningful description of past work experience) that it has a &#91;***&#93; in place (representing the percentage of the total sales force assigned to Duality pursuant to Section 7.8(b)(i)). If Duality cannot demonstrate that it has such a &#91;***&#93; in the Cost &#38; Profit&#47;Loss Sharing Territory at least &#91;***&#93; months prior to the launch of the first Original ADC Licensed Product in the Cost &#38; Profit&#47;Loss Sharing Territory, Duality shall be deemed to have irrevocably waived its right to Co-Promote the first Original ADC Licensed Product in the Cost &#38; Profit&#47;Loss Sharing Territory.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">For clarity, this Co-Promotion Option is not sublicensable or transferable to any Third Party and does not apply to the &#91;***&#93;, &#91;***&#93; and Sequence Licensed Products.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:8.36pt"><br> FINANCIAL TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In partial consideration of Duality&#8217;s granting of the licenses and rights to Licensee hereunder, Licensee shall make a one-time, non-refundable, non-creditable payment to Duality of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; days after receipt of an invoice issued by Duality to the Licensee on or after the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Invoicing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; setting forth the amount of actual Duality Costs for the Planned Trials and Licensee Added Trials (if any) incurred during such Calendar Quarter in the Territory which shall be reimbursed by Licensee pursuant to this Section 8.2, along with supporting documentation itemizing the breakdown of the costs and expenses that were incurred and are reimbursable hereunder.  Each invoice issued by Duality shall list Duality Costs &#91;***&#93; in the Territory actually incurred in U.S. Dollars (and if any item was originally in another currency, the exchange rate used for converting the original currency to U.S. Dollar in accordance with Section 9.2). &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Other Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At Licensee&#8217;s request, Duality shall perform any other Clinical Trial of an Original ADC Licensed Product (other than the Planned Trials and Licensee Added Trials). The Parties shall discuss (through the JSC) Licensee&#8217;s funding &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Development and Regulatory Milestone Payments of the Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 8.8(d), with respect to the milestone events set forth in the tables below, promptly following the first achievement, whether by Duality or any of Duality&#8217;s Affiliates (when designated by Licensee) or by Licensee or any of Licensee&#8217;s Affiliates or Sublicensees, of the corresponding milestone event by the first Original ADC Licensed Product,  Licensee or Duality, as the case may be, shall notify the other Party within &#91;***&#93; Days of such achievement, and Licensee shall pay to Duality the corresponding non-refundable, non-creditable milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee on or after the achievement of the applicable milestone event&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sales Milestone Payments of the Original ADC Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Section 8.8(d), Licensee shall pay to Duality the additional one-time, non-refundable, non-creditable payments set forth in the table below within &#91;***&#93; days after receipt of an invoice issued by Duality to Licensee on or after the first achievement of each milestone event described below. &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93;&#160;days after the end of the Calendar Quarter in which any milestone event set forth above in this Section&#160;8.4 for which a milestone payment is payable is achieved, Licensee shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deliver a written notice to Duality of such achievement, and Licensee shall pay to Duality the corresponding milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee.  For clarity, each of the milestone payments set forth above in this Section&#160;8.4 shall be additive such that if multiple milestone events specified above are achieved in the same Calendar Quarter, then the milestone payments for all such milestone events shall be payable by Licensee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Licensee shall pay tiered royalties to Duality on Annual Net Sales of&#58; (i) all Original ADC Licensed Products in the Territory in each Calendar Quarter as set forth below in the first table in this Section 8.5 and subject to Section 8.8(f), calculated by &#91;***&#93;&#59; (ii) any &#91;***&#93; and&#47;or &#91;***&#93; at the Reduced Royalty Rates for each respective Annual Net Sales threshold as set forth in the second or third table in this Section 8.5 respectively, calculated by &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Royalties under Section&#160;8.5 shall be payable, on a &#91;***&#93; basis, during the period beginning on &#91;***&#93; and continuing until the latest of&#58; &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Royalty Payment Reduction of ADC Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Effects of Cost &#38; Profit&#47;Loss Sharing Option Exercise for the Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Sales Milestone Payments for Original ADC Licensed Product.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">After exercise of the Cost &#38; Profit&#47;Loss Sharing Option by Duality, in lieu of the sales milestone payments to be made by Licensee to Duality under Section 8.4, Licensee shall pay to Duality the additional one-time, non-refundable, non-creditable payments set forth in the table below after the first achievement of each milestone event described below in the Territory other than Cost &#38; Profit&#47;Loss Sharing Territory&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.03pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">After exercise of the Cost &#38; Profit&#47;Loss Sharing Option by Duality, in lieu of the royalties to be made by Licensee to Duality under Section 8.5, Licensee shall pay tiered royalties to Duality on Annual Net Sales of all Original ADC Licensed Products in the Territory other than Cost &#38; Profit&#47;Loss Sharing Territory in each Calendar Quarter as set forth below, calculated by &#91;***&#93;. For the avoidance of doubt, Section 8.7 shall apply in determining the royalties to be paid pursuant to this Section 8.8(f)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Payments for Other ADC Licensed Products.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Payments for Sequence Licensed Products.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.36pt"><br>  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PAYMENT&#59; RECORDS&#59; AUDITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Royalties shall be calculated and reported for each Calendar Quarter within &#91;***&#93;&#160;days after the end of each Calendar Quarter. Each payment shall be accompanied by a report of &#91;***&#93;. Except as may otherwise be expressly provided herein, Licensee shall not have the right to set off, withhold or make any deduction from any payment of royalties or other payments due to Duality hereunder for any reason whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Exchange Rate&#59; Manner and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All payments hereunder shall be payable in U.S. dollars within &#91;***&#93; days after receipt of an invoice from Duality. With respect to sales of Licensed Products invoiced in a currency other than U.S. dollars, sales milestones and royalties shall be converted into U.S. dollar using the exchange rate mechanism generally applied by Licensee or its Affiliates or Sublicensees for consolidation purposes, in accordance with the Accounting Standards, for the Calendar Quarter for which a payment is due.  All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Duality, unless otherwise specified in writing by Duality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Section&#160;9.3, Licensee shall be solely responsible for the payment of all value added taxes, fees, duties, surcharges, and other deductions or withholding taxes imposed by or on any entity in the Territory in connection with the payments and activities contemplated hereunder. Except as otherwise set forth in this Section, each Party shall be solely responsible for the payment of all taxes imposed on such Party&#8217;s income arising directly or indirectly from the activities of the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any withholding tax, fee, duty or surcharge  applicable to or assessable in respect of any of the Upfront Payment, development, regulatory or sales milestone payments, or royalty payments to be made by Licensee to Duality under this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is required to be withheld and deducted under Applicable Laws (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Licensee (or its Affiliate paying on behalf of Licensee) shall make such deduction and withholding and will pay the remaining License Payments to Duality. For clarity, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee&#8217;s reimbursement of Duality Costs in the Territory shall not be deemed to be License Payments or subject to any Tax Withholdings.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall make such deduction of taxes and withholding tax payments to the applicable taxing authority(ies) in a timely manner and shall promptly provide Duality with the appropriate proof of payment and relevant receipt(s) with respect to such deduction or withholding. To the extent permitted by Applicable Laws, Licensee shall provide Duality reasonable assistance in order to allow Duality to obtain the benefit of any present or future treaty against double taxation or refund or reduction in taxes which may apply to the License Payments. Each Party agrees to use commercially reasonable efforts to cooperate with the other Party in claiming refunds, reductions, or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in effect. Duality will provide Licensee with any tax forms or other documentation reasonably necessary in order for Licensee not to withhold or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  If the taxes originally paid or otherwise borne by a Party are in whole or in part subsequently determined not to have been chargeable, all reasonably necessary steps will be taken by each Party to obtain a refund of these undue taxes from the applicable Governmental Authority or other fiscal authority and any amount of undue taxes repaid by such authority to the receiving Party will be transferred to the paying Party within &#91;***&#93; days of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that, by reason of Applicable Law in any country or region, it becomes impossible or illegal, after reasonable efforts by Licensee to do so, for Licensee or its Affiliate to transfer, or have transferred on its behalf, payments owed Duality hereunder, Licensee shall promptly notify Duality of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country or region to the credit of Duality in a recognized banking institution designated by Duality provided such arrangements are legal under all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall keep, and require its Affiliates and Sublicensees to keep, complete, fair and true books of accounts and records for the purpose of determining the amounts payable to Duality pursuant to this Agreement. Such books and records shall be kept for at least &#91;***&#93; Years following the end of the Calendar Year to which they pertain.  Duality shall have the right to cause an independent, certified public accountant reasonably acceptable to Licensee to audit such records to confirm Net Sales, royalties and other payments for a period covering not more than the preceding &#91;***&#93; Years&#59; provided that (a) such audit shall not be more frequent than once in any &#91;***&#93; month period, and (b) once such accountant has conducted a review and audit of any records pursuant to this Section 9.5 in respect of any given period, it may not subsequently re-inspect such records with respect to such period, unless, in each case of (a) and (b), for cause. Prior to engagement by an independent, certified public accountant, such accountant must have executed and delivered to Licensee and its Affiliates a confidentiality agreement as reasonably requested by Licensee, which will include provisions limiting such accountant&#8217;s disclosure to Duality to only the results and basis for such results of such inspection. Such audits may be exercised during normal business hours upon reasonable prior written notice to Licensee. Prompt adjustments shall be made by the Parties to reflect the results of such audit. Duality shall bear the full cost of such audit unless such audit discloses an underpayment by Licensee of more than &#91;***&#93; of the amount of royalties or other payments due under this Agreement for any applicable Calendar Quarter, in which case, Licensee shall bear the cost of such audit and shall promptly remit to Duality the amount of any underpayment. Any overpayment by Licensee revealed by an audit shall be fully-creditable against future payment owed by Licensee to Duality (and if no further payments are due, shall be refunded by Duality at the request of Licensee). Any underpayment by Licensee identified by an audit shall not be subject to Section  9.6. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:28.6pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that either Party fails to make any payment due under this Agreement (save as set out in Section 9.5), simple interest shall thereafter accrue on the sum due from the due date until the date of payment at &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:2.36pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) agrees that, during the Term and for &#91;***&#93; years thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement or any other written agreement between the Parties, any Confidential Information, including any Know-How, furnished or made available to it by or on behalf of the other Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its, and its Affiliates&#8217;, employees, agents, contractors, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information.  The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Confidential Information shall not include any information which the Receiving Party can prove by competent evidence&#58; (a)&#160;is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available to the public or part of the public domain&#59; (b)&#160;is known by the Receiving Party and&#47;or any of its Affiliates at the time of receiving such information, as evidenced by its records&#59; (c)&#160;is hereafter furnished to the Receiving Party and&#47;or any of its Affiliates by a Third Party, as a matter of right and without restriction on disclosure&#59; or (d)&#160;is independently discovered or developed by the Receiving Party and&#47;or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Section&#160;10.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">filing or prosecuting or defending Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">disclosure required in connection with any judicial, regulatory or administrative process relating to or arising from this Agreement (including any enforcement hereof) or to comply with applicable court orders&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">disclosure to Affiliates, employees, contractors, consultants or agents of the Receiving Party who have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement&#59; provided, in each case, that any such Affiliate, actual or potential licensee or Sublicensee, employee, contractor, consultant or agent agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth in this Article&#160;10&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">such disclosure is made to such Party&#8217;s attorneys, independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the Receiving Party, on the condition </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with the confidentiality provisions of this Agreement as they apply to the Receiving Party (provided, however, that in the case of financial advisers, including investment bankers, the term of confidentiality may be shortened to &#91;***&#93; years from the date of disclosure and in the case of attorneys, no written agreement shall be required)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">disclosure to existing investors, acquirors or collaborators or potential bona fide investors, acquirors, licensees, Sublicensees or collaborators in connection with due diligence or similar investigations by such Third Parties&#59; provided, in each case, that any such existing or potential investor, acquiror, licensees, Sublicensees or collaborator agrees to be bound by confidentiality and non-use obligations consistent with those contained in this Agreement as they apply to the Receiving Party (but of duration customary in confidentiality agreements entered into for similar purpose)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">disclosure to Regulatory Authorities as required by Applicable Laws in relation to Regulatory Approvals and regulatory procedures, proceedings and other filings&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">disclosure to&#58; (i) Governmental Authorities to the extent useful or necessary to make regulatory filings and obtain or maintain Regulatory Approvals (including fulfilling post-approval regulatory obligations) for any Licensed Product&#59; (ii) Governmental Authorities, technical committees or similar public health or scientific bodies for purposes of securing product use recommendations, tenders, direct procurement contracts or responding to relevant requests for information&#59; (iii) comply with Applicable Laws with respect to performance under this Agreement&#59; and (iv) to Governmental Authorities in order to respond to inquiries, requests or investigations relating to Licensed Products or this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">to the extent mutually agreed to by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;10.3(a) or Section&#160;10.3(b), it will, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to secure and cooperate with the other Party, as necessary, to seek and obtain confidential treatment of such Confidential Information required to be disclosed to the extent legally permissible and will limit the disclosure of that Confidential Information required to be disclosure to (i) to advisors (including lawyers and accountants) or Governmental Authorities on a need to know basis, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement, or (ii) to the extent agreed to by the Parties.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Press Releases and Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.49pt">As soon as practicable following the Effective Date and on a date mutually agreed by the Parties, the Parties shall issue a joint press release announcing the execution of this Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by applicable securities laws (including disclosure requirements of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any stock exchange on which securities issued by a Party or its Affiliates are traded), neither Party shall make any other public announcement or statement, whether oral or written, concerning this Agreement or the subject matter hereof without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed&#59; provided that each Party may make any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">public statement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, or issue press releases, so long as any such public statement or press release is not inconsistent with prior public disclosures or public statements approved by the other Party pursuant to this Section&#160;10.4 and which do not reveal non-public information about the other Party.  In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text. Licensee shall have final decision making authority in respect of the proposed text of any required public announcement relating to the Licensed Product in the Territory and Retained Territory.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.16pt">In the event of termination of this Agreement for any reason, if in the reasonable opinion of the either Party&#8217;s legal counsel, public disclosure of such termination is required under the Applicable Law or the rules of a stock exchange on which the securities of either Party (or any controlling Affiliate of such Party) are listed (or to which an application for listing has been submitted), the Parties shall cooperate in good faith to coordinate public disclosure, if any, of such termination and the reasons therefor. The principles to be observed in such disclosures shall be accuracy, compliance with Applicable Law, the rules of the applicable stock exchange and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news and neither Party shall make any other public announcement or statement, whether oral or written, concerning the termination of this Agreement without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.83pt">Notwithstanding anything to the contrary in this Section&#160;10.4, and subject to Section 10.5, the Parties have the right to publicly disclose (A) the achievement of milestones under this Agreement&#59; and (B) the commencement, completion, material data and key results of Clinical Trials conducted under this Agreement. After a publication has been made available to the public, each Party may post such publication or a link to it on its corporate web site without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Filing of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or any stock exchange or governmental agency on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted&#59; provided that each Party will ultimately retain control over what information to disclose to the SEC or any stock exchange or other governmental agency, as the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation, neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC or any stock exchange or other governmental agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">If either Party proposes to publicly present or publish, in any publication or venue, in their respective Territories, any Clinical Trial data, non-clinical data or any associated results or conclusions generated by or on behalf of Licensee pursuant to Clinical Trials (each such proposed presentation or publication, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), it shall obtain the other Party&#8217;s prior written consent and otherwise comply with this Section&#160;10.5. The proposing Party shall provide the other Party with a copy of such Proposed Publication at least &#91;***&#93; days prior to the earlier of its presentation or intended submission for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">publication&#59; provided that in the case of abstracts, this period shall be at least &#91;***&#93; Days (such applicable period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The proposing Party agrees that it will not submit or present any Proposed Publication (i) until the other Party has provided written comments during such Review Period on the material in such Proposed Publication or (ii)&#160;until the applicable Review Period (as may be extended by subsection (C) below) has elapsed without written comments from the other Party, in which case the proposing Party may proceed and the Proposed Publication will be considered approved in its entirety. If the proposing Party receives written comments from the other Party during the applicable Review Period, it shall consider the comments of the other Party in good faith, but will retain the sole authority to submit the manuscript for such Proposed Publication&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that&#160;the proposing Party agrees to (A) delete any Confidential Information of the other Party that the other Party identifies for deletion in the other Party&#8217;s written comments, (B) delete any Clinical Trial data, non-clinical data, results, conclusions or other related information that is not specific to or resulting from any Clinical Trial conducted in the proposing Party&#8217;s territory, and (C) delay such Proposed Publication for a period of up to an additional &#91;***&#93; days after the end of the applicable Review Period to enable the other Party to draft and file patents with respect to any subject matter to be made public in such Proposed Publication and to which the other Party has the applicable intellectual property rights to file such patents.  The proposing Party shall provide the other Party a copy of the Proposed Publication at the time of the submission or presentation.  The proposing Party shall require its Affiliates, (sub)licensees (in case that Duality is the proposing Party), Sublicensees (in case that Licensee is the proposing Party) and contractors to comply with the obligations of this Section&#160;10.5 as if they were the proposing Party, and shall be liable for their non-compliance. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Publication and Listing of Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party&#59; provided that any listings or publications made pursuant to this Section&#160;10.6 shall be considered a publication hereunder and shall be subject to Section&#160;10.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Prior Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date, the terms of this Article&#160;10 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) to the extent dealing with the subject of this Agreement.  Any information disclosed pursuant to any such prior agreement relating to the subject to this Agreement shall be deemed Confidential Information for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Given the nature of the Confidential Information and the competitive damage that would result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Article&#160;10. In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article&#160;10.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other that, as of the Effective Date&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not (i) conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, (ii) conflict with or result in a breach of any provision of its organizational documents, or (iii) violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it&#59; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">each Party shall conduct, and shall cause its Affiliates and Sublicensees (in the case of Licensee) and sublicensees (in the case of Duality) to conduct all activities under this Agreement in compliance with all Applicable Laws, all applicable national and international guidelines and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Duality Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality represents and warrants to Licensee, as of the Effective Date and&#47;or such any other date(s) expressly stated, subject to a Disclosure Schedule (attached here to as Schedule 11.2) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as may be  updated as further described in Section 11.8 below as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.1&#160;&#160;&#160;&#160;With respect to the &#91;***&#93;, the below representations and warranties regarding Licensed Products are given as of the Effective Date but only specifically in relation to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.2&#160;&#160;&#160;&#160;With respect to the &#91;***&#93;, the below representations and warranties regarding Licensed Products are given as of the Effective Date but only specifically in relation to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.3&#160;&#160;&#160;&#160;With respect to the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Additional Licensee Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee represents and warrants to Duality, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any covenants made by the Parties elsewhere in this Agreement, each Party hereby covenants to the other that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">(i) all patient authorizations and consents required under Applicable Laws (in connection with any applicable clinical study) permit the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6, and (ii) it will comply with Applicable Laws in transferring personal and other Data in connection with the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6.  Each Party will obtain all the necessary authorizations, consents and approvals in order for such Party to grant access to its Data with the other Party, including obtaining the necessary patient authorizations and consents, and obtaining the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">necessary approvals from and completing all necessary filing procedures with the applicable Governmental Authorities in the Territory and within the Retained Territory (to the extent required to preserve Licensee&#8217;s position in the Territory)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it will not knowingly, during the Term, employ or use the services of any person who is debarred or disqualified in connection with activities relating to the Licensed Compound or Licensed Products&#59; and in the event that it becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to it with respect to any activities relating to the Licensed Compound or Licensed Products, it will immediately notify the other Party in writing and it will cease employing, contracting with, or retaining any such person to perform any services relating to the Licensed Compound or Licensed Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it shall conduct, and shall cause its Affiliates, subcontractors, Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) to conduct all activities under this Agreement (including, as set forth in the Development Plan(s) and Commercialization Plan(s) (as may apply) with respect to the ADC Licensed Products in the Field in the Territory) in compliance with all Applicable Laws, and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it shall conduct its obligations with respect to Development of the ADC Licensed Products in the Territory in adherence with the Development Plan (including the Development Budget) as may be amended from time to time&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it shall comply, and ensure that shall use commercially reasonable efforts to cause its Affiliates, subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality) to comply with and commit to uphold the ABC Terms in the performance of activities under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">it shall have (and shall ensure its Affiliates, Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) and subcontractors as applicable, have), at all times, a reasonably sufficient number of suitably qualified personnel to allow the Party (or its Affiliates Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) or subcontractors, as applicable) to conduct, in compliance with all Development timeframes set out in the applicable Development Plans and GXPs, any Clinical Trials that the Party is required to conduct with respect to the Licensed Products in its territory, or in the other Party&#8217;s territory as permitted under this Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it shall not induce or solicit, or attempt to induce or solicit, any employees of the other Party or any of its Affiliates to leave the employment of, or to terminate his&#47;her employment, services or engagement with, the other Party or its applicable Affiliate, or enter into any employment or services agreement or arrangement with such Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Duality Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to any covenants made by Duality elsewhere in this Agreement, Duality hereby covenants to Licensee as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Performance by Affiliates, Sublicensees and Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) Subject to Licensee&#8217;s prior written consent or if explicitly stated in the Development Plan or this Agreement, Duality may perform some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or sublicensees, and (b) Licensee may perform </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or Sublicensees&#59; provided that with respect to the foregoing clauses (a) and (b), the Party involving its Affiliates, subcontractors or Sublicensees (in case of Licensee) or sublicensees (in case of Duality) shall at all times be fully responsible for the performance and payment of such Affiliate, subcontractor or Sublicensees (in case of Licensee) or sublicensees (in case of Duality). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY DUALITY TO LICENSEE HEREUNDER ARE PROVIDED &#8220;AS IS,&#8221; AND DUALITY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OBTAINING SUCCESSFUL RESULTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Updated Disclosure Schedule</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">With respect to the &#91;***&#93; (Section 2.9) and the Duality Immune Agonist ADC Product (Section 2.10) that are subject to an option right, and subject to the occurrence of any change or event having a material adverse effect on it or which it believes would or would be reasonably likely to cause or constitute a material breach of any of its representations, warranties or covenants set forth herein. Duality shall be entitled to update the Disclosure Schedule (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with this Section 11.8. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">The right to update the Disclosure Schedule shall be limited to the respective option exercise period as set forth in Section 2.10 and 2.11 respectively and ends &#91;***&#93; Days before the option exercise period ends. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Notwithstanding anything in this Agreement to the contrary, no update to the Disclosure Schedule pursuant to this Section 11.8 shall cure any breach of a representation or warranty of Duality contained in this Agreement with respect to the ADC Licensed Product and&#47;or Sequence Licensed Product and shall not affect any of the Licensee&#8217;s remedies with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Duality shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled by Duality or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) Licensee shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled (other than pursuant to this Agreement) by Licensee or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder, specifically relating to the ADC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Solely Owned Collaboration IP and Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.49pt">&#91;***&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.16pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Data and Regulatory Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything contrary in this Section 12.1, the ownership rights to Regulatory Materials are allocated in accordance with Sections 5.2(b) and 5.4. The ownership rights to Data are allocated in accordance with Section 5.6.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.69pt">Disclosures&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall, and shall ensure that each of its Affiliates, (sub)licensees (in the case of Duality), Sublicensees (in the case of Licensee) and subcontractors under this Agreement has a contractual obligation to disclose to such Party all Collaboration IP, Data and other Know-How generated, invented, discovered, developed, made or otherwise created by or for them or their employees, agents or independent contractors, and to provide sufficient documentary proof to evidence ownership, rights and interest with respect thereto, so that such Party can comply with its obligations under this Section&#160;12.1.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:4.02pt">Inventorship Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Section&#160;12.2 and Sections 12.1(e) and 12.1(f), the terms &#8220;prosecute,&#8221; &#8220;prosecuting&#8221; and &#8220;prosecution,&#8221; when used in reference to any Patent, shall be deemed to include, without limitation, control of any &#91;***&#93; with respect to such Patent.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Infringement by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that either Duality or Licensee becomes aware of any infringement or threatened infringement by a Third Party of any Solely Owned Collaboration Patent, Duality Product Patent, Duality Linker-Payload Patent, &#91;***&#93;, and any related declaratory judgment or equivalent action, including administrative proceedings, alleging the invalidity, unenforceability or non-infringement of any such Patent, it shall notify the other Party in writing to that effect within &#91;***&#93; Days after becoming aware of such matter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Licensed Product-by-Licensed Product basis, as between the Parties, &#91;***&#93; to make all patent listings of Duality Product Patents, Solely Owned Collaboration Patents, &#91;***&#93; or other patent-related submissions with Regulatory Authorities with respect to such Licensed Product, except for Duality Linker-Payload Patents &#91;***&#93;, to make all patent listings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; will be obliged to make all patent listings or other patent-related submissions with Regulatory Authorities in &#91;***&#93;.&#160;&#91;***&#93; reasonable requests in connection therewith, including meeting any submission deadlines, to the extent required or permitted by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Patent Right Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM&#59; TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall commence on the Effective Date, and unless terminated earlier as provided in this Article&#160;13, shall continue in full force and effect, on &#91;***&#93; except as provided otherwise in this Article 13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Termination for Material Breach by Either Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Termination Right. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Party shall have the right to terminate this Agreement (in its entirety or on a Licensed Product-by-Licensed Product and country-by-country basis) upon written notice to the other Party if such other Party is in material breach of this Agreement and has not cured such breach within &#91;***&#93;&#160;days after written notice from the terminating Party requesting cure of the breach. In case the alleged material breach is a material breach of Licensee&#8217;s diligence obligations set forth in Sections 4.1 and&#47;or 7.1 of this Agreement, Duality shall only be entitled to terminate the Agreement with effect to the country or countries with respect to which Licensee has in fact materially </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breached the diligence obligations with respect to the Original ADC Licensed Product and not cured such breach. If at the end of the cure period the breaching Party has failed to perform the activities of the cure plan to cure the breach, the non-breaching Party shall be entitled to terminate the Agreement with &#91;***&#93; prior notice. If the existence of material breach or the failure to cure such material breach is not disputed by the breaching Party and the Agreement is terminated by the non-breaching Party, the consequences of termination set forth in Section 13.7 or Section 13.8  (as the case may be) shall apply. If the existence of material breach or the failure to cure such material breach is disputed by the breaching Party, Section 13.7 or Section 13.8 (as the case may be) shall apply if the existence of material breach or the failure to cure such material breach is determined pursuant to Section 15.2 and the Agreement is thereafter terminated by the breaching Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Dispute as to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that the breaching Party disputes the existence of material breach or the failure to cure such material breach by initiating arbitration proceedings pursuant to Section 15.2 within the cure period, the non-breaching Party shall not have the right to terminate in accordance with Section 13.3(a) unless and until the relevant dispute has been resolved pursuant to Section 15.2. During the pendency of such dispute, the applicable cure period shall be tolled, all the terms of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Termination for Other Causes. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.8pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Party shall have the right to terminate this Agreement upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, dissolution, liquidation or winding up of such other Party, or the making or seeking to make or arrange an assignment of a substantial portion of such other Party&#8217;s assets for the benefit of creditors of such other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy against such other Party, or is adjudged bankrupt, or the appointment of a receiver or trustee of such other Party&#8217;s property, in each case that is not discharged within &#91;***&#93; days, or immediately upon written notice to the Party, if such Party otherwise admits in writing to the other Party its inability generally to meet its obligations as and when they fall due in the general course of business. In the event a Party is bankrupted or a bankruptcy proceedings is commenced by or against such Party or its Affiliates or any country or jurisdiction, all rights under this Agreement will be fully exercisable and the bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall continue to perform all of the obligations provided in this Agreement to be performed by such Party. If the bankrupt Party and its successors and assigns are restricted by Applicable Laws from performing its obligations hereunder and the other Party elects to retain its rights hereunder, then the bankrupt Party shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party&#8217;s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.8pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Mutual Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties may terminate this Agreement in full or on a Licensed Product-by-Licensed Product or a country-by-country basis, at any time during the Term upon mutual agreement in writing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">General Effects of Expiration or Termination.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Accrued Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither expiration nor any termination of this Agreement for whatsoever reason shall relieve either Party of any obligation or liability (including but not limited to any payment obligation under Article 8) accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement for whatsoever reason preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement.  Such obligations and rights shall survive termination and expiration of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Termination of Non-Expired Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of termination of the entire Agreement, all non-expired option periods under the Agreement shall automatically terminate. Upon termination of one or more Licensed Products, the option period shall only terminate with respect to the terminated Licensed Product(s). </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Surviving Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties&#8217; rights and obligations under Article 1 (Definitions), Article 8 (Financial Terms, unless otherwise set out in this Article 13, the Financial Terms only survive with respect to Licensee&#8217;s sell-off right in Sections 13.6(e), 13.7(b)(iv) and 13.8(b)(iii))&#59; Article 9 (Payment)&#59; Article 10 (Confidentiality), Section 12.1 and  with respect to &#91;***&#93; only Sections 12.2 and 12.4&#59; Sections 13.5 to 13.10&#59; Article 14(Indemnification) other than Section 14.4 (Insurance)&#59; Article 15 (Dispute Resolution)&#59; Article 16 (Miscellaneous) of this Agreement shall survive expiration or any termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Consequences of Termination by Duality for Material Breach or Patent Challenge by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If an arbitration tribunal in accordance with the process set out in Section 15.2 confirmed the existence of a material breach on the part of Licensee, and such material breach was not or cannot be cured, or in case of an uncured patent challenge by Licensee (Section 13.4(a)(i)), the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Duality&#8217;s Election to Continue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Duality&#8217;s Election to Terminate. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality may, in its sole discretion, elect to terminate the Agreement (in part or in its entirety, as applicable) for material breach in accordance with Section 13.3. The consequences of such a termination for material breach shall be as follows&#58;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.49pt">Licenses Granted to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of a termination of the entire Agreement, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.16pt">Rights Granted to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of termination of the entire Agreement, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.83pt">Wind-Down or Transfer of Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Licensee shall, as directed by Duality in its sole discretion, on a Clinical Trial-by-Clinical Trial basis, either&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.49pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:43.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.82pt">Sublicenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality shall grant to Licensee&#8217;s or Licensee&#8217;s Affiliate&#8217;s Sublicensees a direct license&#59; provided that (A) such sublicense agreement is consistent with the relevant terms and conditions of this Agreement at the time of termination of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, (B) such Sublicensee then is not in material breach of its sublicense agreement and (C) such Sublicensee then has not caused Licensee to be in material breach of this Agreement due to any act or omission of such Sublicensee.  The scope of such direct license shall be no less than the scope of the license granted in this Agreement and sublicensed to such Sublicensee and such direct license shall be on terms and conditions substantially similar to those set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:22.6pt">Consequences of Termination by Licensee for Material Breach or Patent Challenge by Duality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">If an arbitration tribunal in accordance with the process set out in Section 15.2 confirmed (A) the existence of a material breach on the part of Duality, and such material breach was not or cannot be cured, or  (B) in case of &#91;***&#93;, with the Licensee&#8217;s Executive Officer having the final say, the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Indemnification of Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall indemnify and hold harmless each of Duality and its Affiliates and their respective directors, officers, employees, consultants, agents and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), incurred by any Duality Indemnitee as a result of any claims, demands, actions, suits or proceedings brought by a Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) arising directly or indirectly out of&#58; (a)&#160;the practice by Licensee or its Affiliates or Sublicensees or subcontractors of the licenses granted to Licensee under this Agreement&#59; (b)&#160;the research, Development, Manufacture or have Manufactured, use, handling, storage, Commercialization or other disposition of the Licensed Compound or the Licensed Products by Licensee or its Affiliates or Sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Licensee Indemnitee&#59;  (d)&#160;any breach of any representations, warranties or covenants by Licensee under this Agreement or (e) any breach of the obligations under Section 8.8 or Section 8.9 of this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Duality set forth in Section&#160;14.2, or (y) arising from or occurring as a result of a Duality Indemnitee&#8217;s negligence, illegal conduct or willful misconduct in performing its or their obligations or exercising their rights under this Agreement. Except as set forth in Clause (e) above, Licensee&#8217;s indemnification obligation specifically excludes any and all Third Party Claims for the use of any Patents, Know-How or other intellectual property rights under any Third Party agreements entered into by Duality prior to the Effective Date, including but not limited to the payment of royalties thereunder, other than Third Party Claims arising from or related to Licensee&#8217;s failure to make any payment under Section 8.9 or Section 8.10 of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Indemnification of Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Duality shall indemnify and hold harmless each of Licensee and its Affiliates and their respective directors, officers, employees, consultants, agents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), from and against any and all Losses incurred by any Licensee Indemnitee as a result of any Third Party Claims arising directly or indirectly out of&#58; (a)&#160;the practice by Duality or its Affiliates or sublicensees or subcontractors of the license granted to Duality under Section&#160;2.5&#59; (b)&#160;the research, Development, Manufacture or have Manufactured, use, handling, storage, Commercialization or other disposition of the Licensed Compound or Licensed Products by Duality or its Affiliates or sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Duality Indemnitee&#59; or (d)&#160;any breach of any representations, warranties or covenants by Duality under this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Licensee set forth in Section&#160;14.1, or (y) arising from or occurring as a result of a Licensee Indemnitee&#8217;s negligence, illegal conduct or willful misconduct in performing its or their obligations or exercising their rights under this Agreement. In addition to the above, and not subject to (x), regardless of any information provided by Duality to Licensee regarding Third Party Agreements entered into prior to the Effective Date, Duality&#8217;s indemnification obligation shall cover any and all Third Party Claims for the use  of any Patents, Know-How or other intellectual property rights under any Third Party Agreements entered into by Duality prior to the Effective Date, including but not limited to the payment of royalties thereunder, other than Third Party Claims arising from or related to Licensee&#8217;s failure to make any payment under Section 8.9 or Section 8.10 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Duality Indemnitee or Licensee Indemnitee intends to claim indemnification under this Article&#160;14 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Duality or Licensee, as the case may be, shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification. Each indemnification claim notice must contain a description of the claim, the nature and amount of such loss (to the extent known at the time). The Indemnitor shall have sole control of the defense and&#47;or settlement thereof and the Indemnitee shall be entitled to participate in (but not control) the defense of such Third Party Claim and to employ counsel of its choice for this purpose, at its own expense. The indemnity arrangement in this Article&#160;14 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld, conditioned or delayed unreasonably.  The failure to deliver written notice to the Indemnitee within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article&#160;14 if and to the extent the Indemnitee is actually prejudiced thereby.  Duality or Licensee, as the case may be, and the Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by these indemnification provisions.  The Indemnitor shall not settle any Third Party Claim without the prior written consent of the Indemnitee if the settlement is reasonably expected to&#58; (a) result in or impose any obligation (including any payment obligation) on the Indemnitee or otherwise adversely affect the business of the Indemnitee in any manner, or (b) result in any admission of wrong-doing or fault by the Indemnitee.  The costs and expenses, including fees and disbursements of counsel, incurred by the Indemnitee in connection with any claim shall be reimbursed by the Indemnitor on a Calendar Quarter basis, without prejudice to the Indemnitor&#8217;s right to contest the Indemnitee&#8217;s right to indemnification and subject to refund in the event the Indemnitee is ultimately held not to be obligated to indemnify the Indemnitee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. Such insurance shall not be construed to create a limit on either Party&#8217;s liability with respect to its indemnification obligations under this Article 14.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.7pt">Deadlock Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event a deadlock occurs with respect to the decision-making process of the JSC, such deadlock shall be subject to binding determination by an expert panel in the Hong Kong Special Administrative Region. The expert panel shall consist of &#91;***&#93; members, &#91;***&#93; of which &#91;***&#93; appointed by each Party and the &#91;***&#93; member shall be selected by the other &#91;***&#93; members (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The panel must be appointed within &#91;***&#93; days of the occurrence of a deadlock event or such longer period as the Parties may agree. Each Expert shall be a person having not less than &#91;***&#93; years&#8217; experience in the area of expertise in the business of pharmaceuticals (including biologics) and having no conflict of interest with either Party. If the issues in dispute involve scientific, technical or commercial matters, the Experts chosen hereunder shall have educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  With respect to any dispute to be submitted to an Expert pursuant to this Agreement, the use of the Expert shall be the exclusive remedy of the Parties, and neither Party shall attempt to adjudicate such dispute in any other forum. The decision of the Experts shall be final and binding on the applicable Parties involved in such dispute and deadlock resolution procedure contemplated by this Section 15.1 and shall not be capable of challenge, whether by arbitration, in court or otherwise. All proceedings and communications shall be in English.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Sections&#160; 15.4 and 15.5, upon the written request of either Party to the other Party, any differences, claim, dispute, or controversy as to the breach, enforcement, interpretation or validity of this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be referred to the Executive Officers for resolution.  In the event such executives are unable to resolve such Dispute within &#91;***&#93;&#160;days after the initial written request, then, upon the written demand of either Party and subject to Section 15.4 below, the Dispute shall be referred to and finally resolved by binding arbitration administered by the Hong Kong International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any successor entity thereto) pursuant to the United Nations Commission on International Trade Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Arbitration Rules in force when the notice of arbitration is submitted, as modified by the HKIAC Procedures for the Administration of Arbitration under the UNCITRAL Arbitration Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as modified by Section&#160;15.3 below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The arbitration shall be conducted by a panel of three arbitrators experienced in the business of pharmaceuticals (including biologicals). If the issues in dispute involve scientific, technical or commercial matters, the arbitrators chosen hereunder shall engage experts having educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  Within &#91;***&#93; days after initiation of arbitration, each of the Parties shall select one arbitrator and these two arbitrators shall jointly select a third arbitrator. If a Party fails to select an arbitrator or if the two arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within such &#91;***&#93; day period, any unselected arbitrator or third arbitrator, as the case may be, shall be appointed in accordance with the Rules. The place of arbitration and the seat of arbitration shall be Hong Kong Special Administrative Region, and all proceedings and communications shall be in English. Unless agreed by the Parties in writing, all documents provided under or in connection with this Agreement shall be in the English language or accompanied by a certified English translation. If such document is translated into any other language, the English language version shall prevail unless the document is a constitution, statutory or other official document. The laws governing this arbitration agreement shall be the laws of Hong Kong Special Administrative Region and the arbitral award shall be final and binding on the Parties. Except to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the extent necessary to confirm an award or as may be required by law, neither a Party nor the arbitrators may disclose the existence, content, or results of arbitration without the prior written consent of both Parties.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Arbitrators&#8217; Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The arbitrators shall, within &#91;***&#93; days after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the arbitrators shall be final and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall bear its own attorney&#8217;s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators&#59; provided, however, that the arbitrators shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys&#8217; fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and&#47;or the fees and costs of the HKIAC and the arbitrators.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Protective Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the request of either Party, the Tribunal shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.6pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Interim Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall be entitled to take action in any court with competent jurisdiction to apply for and be granted emergency or other interim relief and otherwise enforce by injunction, specific performance or other equitable relief, without prejudice to any other rights and remedies that it may have under this Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Continued Performance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Provided that this Agreement has not been terminated in its entirety, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:2.36pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt"> Rights in Bankruptcy.    </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Parties intend to take advantage of the protections of Section 365(n) (or any successor provision) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction to the maximum extent permitted by Applicable Law.  All rights and licenses granted under or pursuant to this Agreement, but only to the extent they constitute licenses of a right to &#8220;intellectual property&#8221; as defined in Section 101 of the U.S. Bankruptcy Code or in any analogous provisions in any other country or jurisdiction (as the case may be) shall be deemed to be &#8220;intellectual property&#8221; for the purposes of Section 365(n) or any analogous provisions in any other country or jurisdiction (as the case may be).  The Parties shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, including the right to obtain the intellectual property from another entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">In the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not subject to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) all such intellectual property (including all embodiments of such intellectual property), which, if not already in the non-subject Party&#8217;s possession, shall be promptly delivered to it upon the non-subject Party&#8217;s written request (i) upon commencement of a bankruptcy proceeding, unless the Party subject to such proceeding continues to perform all of its obligations under this Agreement, or (ii) if not delivered pursuant to clause (i) above because the subject Party continues to perform, upon the rejection of this Agreement by or on behalf of the subject Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Unless and until the subject Party rejects this Agreement, the subject Party shall perform this Agreement or provide the intellectual property (including all embodiments of such intellectual property) to the non-subject Party, and shall not interfere with the rights of the non-subject Party to such intellectual property, including the right to obtain the intellectual property from another entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and any disputes, claims, or actions related thereto shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, including the Schedules hereto, sets forth all of the agreements and understandings between the Parties with respect to the subject matter hereof and thereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof and thereof. There are no other agreements or understandings with respect to the subject matter hereof, either oral or written, between the Parties. Except as expressly set forth in this Agreement, no subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as any other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Relationship Between the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship or legal entity of any type between the Parties. Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Neither Party shall treat or report the relationship arising under this Agreement as a partnership for United States tax purposes unless otherwise required pursuant to a determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and of a particular scope, and shall be signed by such Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned by a Party without the prior written consent of the other Party (which shall not be unreasonably withheld, conditioned or delayed), except to (a) an Affiliate&#59; provided that this Agreement shall be assigned in whole, and the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate&#59; (b) a Third Party in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether in a sale of stock, sale of assets, business combination, reorganization, or other transaction or series of related transactions. Unless expressly stated otherwise in this Agreement, Duality may assign without the prior consent of Licensee its right to receive payments under this Agreement or grant any security interest in its rights, title and interest in this Agreement, in whole or in part and in their entirety or in portions, to an institutional financier in connection with a financing transaction&#59; provided that Duality has given Licensee a prior written notice regarding such assignment. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the permitted assigns of the Parties.  Any assignment not in accordance with this Agreement shall be void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is not intended to and shall not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.6pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. The Parties shall use their commercially reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) in a way that, to the extent practicable and legally permissible, implements the original intent of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58; (a)&#160;the date of actual receipt&#59; (b)&#160;if delivered by overnight courier, &#91;***&#93; Business Days after delivery&#59; or (c)&#160;if sent by facsimile, upon electronic confirmation of receipt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Duality&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality Biologics (Suzhou) Co., Ltd</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unit 1106, No 868 Yinghua Road, Pudong New District, Shanghai, China</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Licensee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIONTECH SE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;<br>Address&#58; An der Goldgrube 12,<br>55131 Mainz,<br>Germany&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control including but not limited to acts of God, fire, flood, explosion, earthquake, or other natural forces, regional or worldwide epidemic, pandemic, war, civil unrest, acts of terrorism, accident, destruction or other casualty, and a material change in Applicable Law (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party&#8217;s failure or delay in performance due to a Force Majeure Event must be given to the other Party within &#91;***&#93;&#160;days after its occurrence. The Party affected by a Force Majeure Event will use reasonable efforts to resume performance of its obligations and will keep the other Party informed of actions related thereto.  If any such failure or delay in a Party&#8217;s performance hereunder continues for more than &#91;***&#93; days, the other Party may terminate this Agreement upon written notice to the delayed Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section&#160;shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. The words &#8220;include&#8221;, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;including&#8221;, &#8220;containing&#8221;, &#8220;comprising&#8221; and similar words shall not be deemed to be terms of limitation and shall be deemed to be followed by &#8220; without limitation,&#8221; whether or not specifically stated and the language following such words shall not be deemed to set forth an exhaustive list. The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive. The words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. The words &#8220;pharmaceuticals&#8221; or &#8220;drugs&#8221; include biologics unless expressly indicated otherwise. All references to days in this Agreement shall mean calendar days, unless otherwise specified. All references to any Applicable Law in this Agreement shall mean such Applicable Law as amended, restated, supplanted or otherwise modified from time to time.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties hereto acknowledge and agree that&#58; (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement&#59; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.6pt">Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two (2) or more counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties or their representative legal counsel, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one and the same instrument. Electronic, facsimile or PDF image signatures shall be treated as original signatures, with the understanding that each Party expressly agrees that such Party shall be bound by its own electronically transmitted signature and shall accept the electronically transmitted signature of the other Party (including through the use of eSignature platforms such as DocuSign&#174;).  No Party will raise the use of electronic delivery to transmit a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery as a defense to the formation of a contract.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have duly executed this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the Effective Date.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co., Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Zhongyuan John Zhu</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ugur Sahin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Zhongyuan John Zhu</font></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Ugur Sahin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sean Marett</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Sean Marett</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Business Officer and Chief Commercial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to B7H3 License And Collaboration Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees that it will not undertake any activities which will result in a violation of any applicable laws, regulations, and applicable industry and professional codes, including but not limited to applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws (collectively &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Prohibited Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#34;) in connection with the performance of any activities under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">In particular, each Party agrees that during the course of the performance of activities under this Agreement, it (i) shall not make any offer, payment, or promise to pay money or provide anything of value to a Government Official (as defined below) or any other individual and&#47;or legal entity whether directly or indirectly, for the purpose of improperly influencing any act and&#47;or decision of, and&#47;or for securing any improper advantage&#59; (ii) shall not accept, receive, agree to accept and&#47;or receive a payment and&#47;or anything of value from any individual for undue favorable treatment in obtaining, retaining, and&#47;or directing business for, and&#47;or to obtain any undue special concession on behalf of either Party&#59; and (iii) shall not facilitate any payments to any Government Official to expedite a routine government action and&#47;or other official act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221; shall include (i) individuals acting on behalf of governments on a national, regional and local level (such as elected officials, customs officials, tax officials, etc.)&#59; (ii) individuals acting on behalf of government-owned or government-controlled enterprises&#59; (iii) individuals acting for political parties or as or on behalf of candidates for public office&#59; and (iv) individuals acting on behalf of public international organizations (such as the WHO, World Bank, OECD, etc.). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">All transactions and expenses incurred on behalf of either Party shall be accurately recorded and maintained in the respective Party&#8217;s books and records in a timely manner and in reasonable detail in accordance with the applicable generally accepted accounting principles. False, misleading, incomplete, duplicated, inaccurate or artificial entries for the foregoing expenses in a Party&#8217;s books and records are strictly prohibited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees that if it becomes aware or has reason to suspect that any person or legal entity acting on the Party&#8217;s and&#47;or the other Party&#8217;s behalf has engaged in any Prohibited Conduct related to the Agreement, then such Party will promptly report such knowledge or suspicion to the other Party via the following email address&#58; (a) in case that Duality is the reporting party&#58; &#91;***&#93; and (b) in case that Licensee is the reporting party&#58; &#91;***&#93;. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Duality shall apply Commercially Reasonable Efforts to implement, operate and enforce, without undue delay after the Effective Date, a reasonably designed compliance and business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">ethics management and control system that is intended for the prevention and detection of criminal conduct in accordance with applicable Anti-Corruption Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of the other Party related to the performance of potentially Prohibited Conduct as described in Article 1 above. Upon notice of an intended investigation, a Party will provide, in a reasonable time, to the investigating Party or to a third party engaged by the investigating Party&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g., invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party acknowledges that the obligations under the applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws apply to all its Affiliates and employees,  subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality). Each Party will bind subcontractors who act for or on behalf of such Party to perform activities under this Agreement by such Party for or on behalf of the other Party by respective contractual clauses encompassing all or all material provisions of this Schedule.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.7</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calculation of Adjusted Net Profits </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.38</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Co-Promotion Terms</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.76</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.78</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description of Duality Know-How</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.84</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Duality Patent Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.7</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Know-How Transfer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.9(b)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data Package</font></div><div style="padding-left:53.45pt"><font><br></font></div><div style="padding-left:53.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.8(b)(iii)    </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Illustrative Example for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.8(c)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Example </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calculation</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.9</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payments for Other ADC Licensed Products</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><div id="i274e375c7fa040468caeb033834ff728_22"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 8.10</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payments for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Press Release</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 11.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Disclosure Schedule</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">89</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.52
<SEQUENCE>8
<FILENAME>exhibit452dualitytrop2agre.htm
<DESCRIPTION>EX-4.52
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_1"></div><div style="min-height:140.4pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.52</font></div><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Version</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Confidential</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT (TROP2)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">by and between</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DUALITY BIOLOGICS (SUZHOU) CO. LTD.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BIONTECH SE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">dated as of August 4, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 1 DEFINITIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .......................................................................................&#160;&#160;&#160;&#160;1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 2 LICENSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ..............................................................................................&#160;&#160;&#160;&#160;24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 3 GOVERNANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ..................................................................................&#160;&#160;&#160;&#160;31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 4 DEVELOPMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">................................................................................&#160;&#160;&#160;&#160;36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 5 REGULATORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ...................................................................................&#160;&#160;&#160;&#160;44</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 6 MANUFACTURE &#38; SUPPLY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ...........................................................&#160;&#160;&#160;&#160;49</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 7 COMMERCIALIZATION MATTERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ............................................&#160;&#160;&#160;&#160;51</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 8 FINANCIAL TERMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .........................................................................&#160;&#160;&#160;&#160;54</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 9 PAYMENT&#59; RECORDS&#59; AUDITS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ....................................................&#160;&#160;&#160;&#160;65</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 10 CONFIDENTIALITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .......................................................................&#160;&#160;&#160;&#160;67</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 11 REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ........................................................................................&#160;&#160;&#160;&#160;71</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 12 INTELLECTUAL PROPERTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> ......................................................&#160;&#160;&#160;&#160;80</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 13 TERM&#59; TERMINATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .................................................................&#160;&#160;&#160;&#160;86</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 14 INDEMNIFICATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> .......................................................................&#160;&#160;&#160;&#160;97</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 15 DISPUTE RESOLUTION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">................................................................&#160;&#160;&#160;&#160;99</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE 16 MISCELLANEOUS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">........................................................................&#160;&#160;&#160;&#160;101</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Schedules</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ABC Terms</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Duality In-Licensed Agreements</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.57&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Description of Duality Know-How</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.63&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">List of Duality Patents</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;List of Indications</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.102&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Compound</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.141&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preliminary Original ADC Licensed Product Development Plan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.149&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pre-clinical Proof-of-Concept Criteria</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Initial Know-How Transfer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Invoicing Procedures &#38; Invoice Information</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Duality Press Release </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Schedule</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AND COLLABORATION AGREEMENT (TROP2)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">This License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of August 4, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co. Ltd.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a corporation organized and existing under the laws of the People&#8217;s Republic of China (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), having a place of business at Unit 1105-1106, No 868 Ying Hua Road, Pudong New District, Shanghai, China, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a company organized and existing under the laws of Germany, having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Duality is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Licensee is engaged in the research, development and commercialization of active immunotherapies for patient-specific approaches to the treatment of diseases&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee desires to obtain from Duality, and Duality desires to grant to Licensee, an exclusive sublicensable license under the Duality Licensed IP to research, Develop, Manufacture and Commercialize the Licensed Products in the Field in the Territory (each as defined below), subject to the terms and conditions of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties desire to collaborate in the research, Development, Manufacture and Commercialization of the Original ADC Licensed Products and&#47;or after Next Generation Option Exercise, the Next Generation ADC Licensed Products (each as defined below) in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Duality and Licensee hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean those terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a Selling Party (as defined below), International Financial Reporting Standards endorsed by the European Union or other applicable standard accounting principles used by Sublicensees.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any construct comprising an Antibody(ies) linked to a non-Antibody chemical species with a therapeutic or biological activity or function, including non-Antibody chemical species that (i) directly kills, slows or stops the growth of a tumor cell through such compound&#8217;s primary mechanism of action (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cytotoxic Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Additional Active(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any active pharmaceutical or biologic ingredient(s) or agent(s) that is not the Licensed Compound. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any company or entity controlled by, controlling, or under common control with a Party or another entity. For the purpose of this definition, an entity shall be deemed to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; another entity, if it owns directly or indirectly, more than fifty percent (50%) of the outstanding voting securities, capital stock, or other comparable equity or ownership interest of such entity, or possession, direct or indirect, of the power to direct or cause the direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.10.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.15pt">&#8220;Annual Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean for a particular Licensed Product the total Net Sales for a particular Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any antibody (including murine, chimeric, human, humanized, recombinant, transgenic, grafted, phage display derived, or single chain antibody), or antigen binding fragment thereof. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.15pt">&#8220;Anti-Corruption Laws&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean all applicable anti-bribery and anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010 and the PRC Anti-Money Laundering Law and the comparable Applicable Laws of any countries in which candidates or Licensed Products, payments or services will be provided or procured under or pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Data Protection Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Applicable Laws in any jurisdiction relating to privacy or the processing or protection of personal data or personal information, including the General Data Protection Regulation (EU) 2016&#47;679 (GDPR), the UK Data Protection Act 2018, the e-Privacy Directive (2002&#47;58&#47;EC) and the comparable in other jurisdictions and all guidance issued by any applicable data protection authority.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean collectively the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, of any Governmental Authority and any license, franchise, permit or similar right granted under any of the foregoing (including Regulatory Approvals) and any policies and other requirements of or from any court, arbitrator, Regulatory Authority or governmental agency or Governmental Authority having jurisdiction over or related to the subject item or subject person, including all applicable GXPs, Anti-Corruption Laws, Applicable Data Protection Laws, accounting and recordkeeping laws, export control laws and laws relating to interactions with health care professionals and Government Officials (as defined in Schedule 1.1).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biologics License Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a particular Licensed Product in a given country, a product comprising an ADC sold by a Third Party not authorized by Licensee or its Affiliates or Sublicensees that is approved by the applicable Regulatory Authority for such country through an application or submission filed with a Regulatory Authority for marketing approval of a biologic product claimed to be biosimilar or interchangeable to such Licensed Product, including an application filed under 42 U.S.C. &#167; 262(k) (or any successor thereto) or any similar laws or regulations in a country </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">outside the United States in reliance on data generated for a Regulatory Approval of such Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any day that is not a Saturday, a Sunday or any other day on which banks are required or authorized by law to close in Mainz, Rhineland-Palatine (in Germany) or any government mandated holiday in Mainland China. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of three (3) consecutive months commencing on January 1, April 1, July 1 or October 1 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each period of twelve (12) consecutive months commencing on January 1 and ending on December 31 (or any portion thereof at the beginning or end of the Term or other relevant period).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 6.3.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to either Party&#58; (a) a merger, acquisition, reorganization, or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent more than fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, acquisition, reorganization, or consolidation&#59; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party&#59; or (c) a transfer to a Third Party of all or substantially all of its assets relating to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Registrational Trial or other human clinical trial conducted after the Regulatory Approval of a product in a country, which trial may be conducted to (a) enhance scientific knowledge of such product (e.g., for expansion of product labeling), (b) due to a request or requirement of a Regulatory Authority in such country, (c) is otherwise designed to establish that a product is reasonably safe for continued testing and to identify adverse reactions and ascertain the safety of the product, or (d) investigate the safety and efficacy of the product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean chemistry, manufacturing and controls with respect to the Licensed Compound or Licensed Products. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 6.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Third Party contract manufacturing organization.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, any and all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, marketing, pricing, reimbursement, sale, importing, exporting or transporting such product, and distribution of such product, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including strategic marketing, sales force detailing, advertising, market product support, all customer support, product distribution, and invoicing and sales activities, but excluding Development and Manufacturing. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; would mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 3.4. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitive Change of Control&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean a Change of Control of Duality where the incoming Third Party and&#47;or its Affiliates is a Competitor.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all Know-How and other proprietary scientific, technical, clinical, marketing, financial or commercial information or Data Controlled by a Party or its Affiliates, which one Party or any of its Affiliates has furnished or made available to the other Party or its Affiliates, whether in oral, written or electronic form.  The existence and terms of this Agreement shall be deemed Confidential Information of each Party.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (including any variations such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall mean, with respect to any Know-How, Patents or other intellectual property rights, possession by a Party or Third Party of the right, power and authority (whether by ownership, license, sublicense or otherwise, other than by virtue of any rights granted under this Agreement) to grant access to, to grant use of, or to grant a license or a sublicense to such Know-How, Patents or intellectual property rights without violating the terms of any agreement or other arrangement with any Third Party. Notwithstanding anything in this Agreement to the contrary, a Party and its Affiliates will be deemed to not Control any Know-How, Patents, or other intellectual property rights that are in-licensed or acquired by such Party or its Affiliates from a Third Party after the Effective Date, unless the other Party agrees to (a)&#160;comply with the terms and conditions of the agreement under which such Know-How, Patents, or other intellectual property rights were in-licensed or acquired by such Party&#59; and (b)&#160;pay all amounts that such Party would be obligated to pay in connection with the grant, maintenance and exercise of a (sub)license as reasonably allocable to such other Party for use in its territory under such Know-How, Patents, or other intellectual property rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CRO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a contract research organization. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all data, including non-clinical data, preclinical data and clinical data, including pharmacological, biological, chemical, toxicological, clinical test, safety, clinical and analytical information, quality control, trial, stability and manufacturing processes and techniques data generated by or on behalf of a Party or its Affiliates or their respective Sublicensees (in case of Licensee) and (sub)licensees and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other (sub)contractors (in the case of Duality) pursuant to activities conducted under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a pharmaceutical or biological product, any research activities, all non-clinical and clinical drug development activities and processes, &#91;***&#93; regulatory affairs and other activities, in each case, which are reasonably necessary to prepare submissions for, and obtain or maintain, Regulatory Approval of such product and interacting with Regulatory Authorities regarding the foregoing, including lifecycle management studies and other activities.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Original ADC Licensed Product Development Budget and&#47;or the Next Generation Development Budget, as the context admits. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the phase starting with the Effective Date to the First Commercial Sale of a Licensed Product during which either Party is conducting Development activities for such Licensed Product or Licensed Compound, or after Next Generation Option Exercise, the Next Generation ADC Licensed Product or Next Generation Licensed Compound. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Original ADC Licensed Product Development Plan and&#47;or the Next Generation Development Plan, as the context admits. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 11.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.15pt">&#8220;Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(a).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any CMO engaged by Duality or any Affiliate of Duality.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all costs and expenses that are reasonably incurred by or on behalf of Duality and its applicable Affiliates after the Effective Date in conducting the Planned Trials, the Next Generation Added Trials and&#47;or performing other Development activities as agreed hereunder in the Territory pursuant to this Agreement and the respective Development Plan. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.4(a).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Immune Agonist ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.8. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.15pt">&#8220;Duality In-Licensed Agreements&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean each Agreement as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.54.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality In-Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents or Know-How that is Controlled by Duality or any of its Affiliates pursuant to the Duality In-Licensed Agreements. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How (including Data) that (a) is Controlled by Duality or any of its Affiliates as of the Effective Date or at any time during the Term, and (b) are necessary or reasonably useful for the Development, Manufacture or Commercialization of or to otherwise exploit the Licensed Compound or Licensed Products, and&#47;or after Next Generation Option Exercise, the Next Generation Licensed Compound or Next Generation ADC Licensed Products, in the Field in the Territory, including but not limited to, with respect to (a) and (b), the Know-How (including Data) contained in Duality Solely Owned Collaboration IP, &#91;***&#93;. Notwithstanding the foregoing, Duality Know-How shall not include (i) any Know-How (including Data) Controlled by any Third Party that becomes an Affiliate of Duality after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How (including Data) is used by either Party in the Development, Manufacturing or Commercialization of the Licensed Compound or Licensed Products, and&#47;or after Next Generation Option Exercise, the Next Generation Licensed Compound or Next Generation ADC Licensed Products, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by Duality or any of its Affiliates. A description of Duality Know-How as of the Effective Date is attached hereto on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.57.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Know-How and Duality Patents. Duality Licensed IP includes Duality In-Licensed IP.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any new or useful invention, discovery, adaptation, redesign, modification, improvement, enhancement, contribution or other desirable change generated in the course of performing activities under this Agreement solely relating to &#91;***&#93;. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Linker-Payload Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents claiming the Duality Linker-Payload.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Product Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in the introductory paragraph of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.13. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean shall mean the European Medicines Agency and any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;3.6(a). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.1. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the U.S. Food and Drug Administration and any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all uses.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Licensed Product, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;16.11.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the equivalent of a full-time individual&#8217;s work time for a twelve (12) month period devoted to performing activities under the Agreement, where &#8220;full-time&#8221; is determined by &#91;***&#93; hours per Calendar Year. In the event that any individual who works full-time during a given Calendar Year works partially on the activities under this Agreement and partially on other work outside this Agreement, then the full-time equivalent to be attributed to such individual&#8217;s work hereunder for such Calendar Year shall be equal to the percentage of such individual&#8217;s total work time in such Calendar Year that such individual spent working on activities under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93; for the first &#91;***&#93; years from the Effective Date. After the &#91;***&#93; anniversary of the Effective Date, the FTE rate will be adjusted on an annual basis based on the higher of (i) the average inflation rate in the countries of the Territory where the Development activities are performed by Duality or (ii) the average salary increase in the relevant categories of Duality&#8217;s employees who participate in the project on the FTE basis&#59; provided in either case that any such increase of FTE Rate each year shall not be more than &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fully Burdened Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Original ADC Licensed Product, or after Next Generation Option Exercise, a Next Generation ADC Licensed Product,  supplied by or on behalf of Duality&#58; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the treatment of human laboratory samples from Clinical Trials, including the relevant principles from GCP and the EMA&#8217;s reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, as amended from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the ethical conduct of Clinical Trials, including without limitation the U.S. Code of Federal Regulations (CFR) Title 21, ICH GCP Guidelines E6(R2) as amended from time to time, national legislation implementing European Community Directive 2001&#47;20&#47;EC (if and as still applicable), European Community Directive 2005&#47;28&#47;EC, and, following the applicable transition periods, the Clinical Trial Regulation (EU) No. 536&#47;2014 (the &#8220;CTR&#8221;) and the rules, regulations and guidelines applying in the context of the CTR, and the equivalent in other countries or regions.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Global Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Clinical Trial designed to obtain Regulatory Approvals for a Licensed Product in multiple countries through the conduct of a Clinical Trial in multiple countries, regions and&#47;or medical institutions and conducted as part of one (1) unified Clinical Trial or separately but concurrently in accordance with a common Clinical Trial protocol.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results, including without limitation the CFR Title 21, national legislation implementing European Community Directives 2004&#47;9&#47;EC and 2004&#47;10&#47;EC as amended, and the OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, and the equivalent in other countries or regions. For the purposes of this Agreement, GLP also includes the principles of Good Clinical Laboratory Practice and applicable guidelines promulgated under the ICH guidelines.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all applicable laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products, including without limitation the CFR Title 21, Parts 11, 210, 211, 600 and 610, applicable ICH Guidelines including without limitation Q7 for &#8220;Active Pharmaceuticals Ingredients&#8221;, national legislation implementing European Community Directive 2001&#47;83&#47;EC and Commission Directive 2003&#47;94&#47;EC as amended, EudraLex &#8211; Volume 4 of the Rules Governing Medicinal Products in the European Union including annexes, the CTR, Commission Delegated Regulation 2017&#47;1569, the Detailed Commission Guideline (2017) 8179, and the equivalent in other countries or regions.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is to be broadly interpreted and includes any multi-national or public international organization or authority, national, federal, state, local, municipal, provincial, foreign government or other governmental authority of any nature (including any governmental division, prefecture, branch, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, and any Regulatory Authority). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GXP&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">collectively, all relevant and applicable good practice quality guidelines and regulations, encompassing such internationally recognized standards as GMP, GCP, GLP and GCLP, Good Distribution Practice (GDP), Good Pharmacovigilance Practice, Good Pharmacoepidemiology Practice and Good Review Practice.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Immune Agonist ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an investigational new drug application, clinical study application, Clinical Trial exemption, or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.8.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;14.3. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.3(b).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.3(a). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;12.1(d).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the joint steering committee to be established by the Parties pursuant to Section&#160;3.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all technical, scientific, regulatory and other information, trade secrets, results, knowledge, techniques, materials (including cell lines) and data, in whatever form and whether or not confidential, proprietary, whether or not patentable, invention disclosures, plans, inventions, assays, designs, protocols, and formulas, processes, practices, methods, knowledge, know how, skill, experience, ideas, concepts, test data (including pharmacological, toxicological and clinical test data), analytical and quality control data, formulae, specifications, marketing, pricing, distribution, cost, sales, and manufacturing data or descriptions.  &#8220;Know-How&#8221; includes any rights including copyright, database or design rights protecting such Know-How. For clarity, Know-How does not include issued Patents, published patent application or the inventions claimed thereby.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 9.4(b).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the ADC developed by or on behalf of Duality and known as DB-1305 comprising &#91;***&#93; (as described in Schedule 1.102) and the Duality linker-payload known as L10P1021, the structures of which has been provided to Licensee in writing.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any pharmaceutical product, in any dosage form, formulation, presentation, route of administration or package configuration containing the Licensed Compound and&#47;or, upon Licensee&#8217;s option exercise, the Next Generation Licensed Compound as an active pharmaceutical ingredient, including but not be limited to (i) the Original ADC Licensed Product, (ii) after Next Generation Option </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exercise, the Next Generation ADC Licensed Product, (iii) &#91;***&#93;, and (iv) &#91;***&#93;.  The Licensed Product shall further include Combination Products.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(a). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Know-How that is Controlled by Licensee or any of its Affiliates and that is comprised by the Licensee&#8217;s Solely Owned Collaboration IP. Notwithstanding the foregoing, Licensee Know-How shall not include (i) any Know-How Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, unless such Know-How is used by Licensee in the Development, Manufacture or Commercialization of the Licensed Compound or Original ADC Licensed Products or after Next Generation Option Exercise, the Next Generation ADC Licensed Product, and (ii) any Know-How that is related to any Additional Active or other proprietary compound or product Controlled by Licensee.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.15pt">&#8220;Licensee Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Licensee Know-How and Licensee Patents.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all Patents that are Controlled by Licensee or any of its Affiliates and that are comprised by the Licensee Solely Owned Collaboration Patents. Notwithstanding the foregoing, Licensee Patents shall not include (i) any Patent Controlled by any Third Party that becomes an Affiliate of Licensee after the Effective Date as a result of a merger, acquisition or other similar transaction, and (ii) any Patent that Covers any Additional Active or other proprietary compound or product Controlled by Licensee provided that such Patent does not Cover the Licensed Compound or Original ADC Licensed Product, or after Next Generation Option Exercise, the Next Generation ADC Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Sole Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.3(c)(v).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Sole Development Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.3(c)(v).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 12.1(b). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an application to a Regulatory Authority for the authorization to place a product on the market in the applicable country, region or a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">regulatory jurisdiction, including New Drug Application and Biologics License Application, and shall include all amendments and supplements thereto, filed with the applicable Regulatory Authority to gain authorization to place such product on the market in the applicable jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the holder of the Marketing Authorization.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Mainland China</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the mainland of the People&#8217;s Republic of China.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Major &#91;***&#93; Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a Licensed Product, activities related to the manufacture and supply of such Licensed Product, including manufacturing supplies for Development or Commercialization, packaging, labeling, in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of product, ongoing stability tests, storage, and shipment and regulatory activities directly related to any of the foregoing, but not including any Development or Commercialization activities. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meanings.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Manufacturing IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Patents and Know-How that (i) are generated, developed or conceived during the course of performing activities under this Agreement depending on Duality Licensed IP, and (ii) specifically related to, and (iii) are necessary for the Manufacture of the Duality Linker-Payload&#59; notwithstanding the foregoing, Manufacturing IP shall exclude Licensee Background IP.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Marketing Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the authorization by all relevant Regulatory Authorities of an MAA in a given country or regulatory region&#47;jurisdiction and the granting of the required authorization for the sale of a product which will include any Pricing and Reimbursement Approvals if required by Applicable Law of the respective country to initiate marketing and selling of a product in such particular country.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the master cell bank. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the coordination of medical information requests and field based medical scientific liaisons with respect to an Original ADC Licensed Product or after Next Generation Option Exercise, Next Generation ADC Licensed Product, including activities of medical scientific liaisons, activities involving key opinion leaders, and the provision of medical information services with respect to an Original ADC Licensed Product or after Next Generation Option Exercise, Next Generation ADC Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Multi-Specific</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 2.13.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;&#59;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.84pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean any pharmaceutical product, in any dosage form, formulation, presentation, route of administration or package configuration containing the Next Generation Licensed Compound as an active pharmaceutical ingredient, but excluding any Additional Actives.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the package of data and information that shall be provided by Duality to the Licensee in order to assess the Pre-Clinical Proof-of-Concept of the Next Generation Licensed Compound and the Next Generation ADC Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as set out in Section 1.132.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a written plan approved by the JSC, and amended from time to time in accordance with the terms of this Agreement, describing (i) the Development strategy for the Next Generation Licensed Compound and Next Generation ADC Licensed Product in the Territory and (ii) the material pre-clinical studies, Clinical Trials and regulatory activities proposed to be performed with respect to the Next Generation ADC Licensed Product as well as (iii) the associated budget regarding the Development activities, including but not limited to the Development Costs, such as the costs for the Development activities performed by Licensee, its Affiliates or its subcontractors as well as the Duality Costs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The initial Next Generation Development Plan, unless otherwise agreed on by the Parties, will be agreed by the Parties no later than &#91;***&#93; months after Next Generation Option Exercise. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 2.9.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.15pt">&#34;Next Generation Option Exercise&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given in Section 2.9.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.15pt">&#8220;Non-Arbitral Subject Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given in Section 15.3.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offer Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have the meaning given in Section 2.13.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Added Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.2(b).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as set out in Section 1.141. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the written plan, as amended from time to time in accordance with the terms of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, describing (i) the Development strategy for the Licensed Compound and Original ADC Licensed Products in the Territory and (ii) the material pre-clinical studies, Clinical Trials and regulatory activities proposed to be performed with respect to the Original ADC Licensed Products (iii) the planned Third Party contract research organisations for the Development activities&#59; as well as (iv) the associated budget regarding the Development activities, including but not limited to the Development Costs, such as the costs for the Development activities performed by Licensee, its Affiliates or its subcontractors as well as the Duality Costs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The preliminary Original ADC Licensed Product Development Plan together with the preliminary Original ADC Licensed Product Development Budget is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee or Duality individually, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Licensee and Duality collectively.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) patent applications filed in the applicable jurisdiction&#59; (b) all patents, including supplemental protection certificates, that have issued or in the future issue from any of the foregoing, including utility models, design patents and certificates of invention&#59; and (c) all divisionals, continuations, continuations-in-part, reissues, re-examination certificates, renewals, extensions or additions to any such patents and patent applications (as applicable).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 5.6(c).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase I Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the principal purpose of which explores the optimal dose and is a determination of initial tolerance or safety of such product in healthy volunteers or the target patient population, as described in 21 CFR 312.21(a) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population, (i.e. &#8220;proof of concept&#8221;), as described in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Phase III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Planned Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 4.2(b). </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pre-clinical Proof-of-Concept&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall mean that the Next Generation Licensed Compound has successfully met the criteria as set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or as amended by mutual agreement of the Parties.  </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, in any country where a Regulatory Authority authorizes reimbursement for, or approves or determines </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">pricing or level of reimbursement for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization and&#47;or pricing approval or determination (as the case may be).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;7.5.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 3.10. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 10.5(a).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.5.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reduced Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the reduced royalty rates for the &#91;***&#93; and &#91;***&#93; specified in tables 3 and 4 in Section 8.6.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registrational Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, a human clinical trial (regardless of whether such clinical trial is referred to as a &#8220;Phase II Clinical Trial&#8221;, &#8220;Phase IIb Clinical Trial&#8221;, &#8220;Phase II&#47;III Clinical Trial&#8221;, &#8220;Phase IIb&#47;III Clinical Trial&#8221; or &#8220;Phase III Clinical Trial&#8221;) for such product, the results of which, together with prior information concerning such product, are determined by the sponsor to be intended to be sufficient to establish that such product is safe and effective for its intended Indication to support the filing of an MAA. &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all approvals, licenses, permits, registrations or authorizations of or from any Regulatory Authority that are necessary to market (including Marketing Authorization) and sell a pharmaceutical product in any country, region or other jurisdiction.  For clarity, unless it is required by the Applicable Law to initiate marketing and selling of a product in a particular country, Regulatory Approval shall not include Pricing and Reimbursement Approval.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a country, any national, federal, supranational, state or local regulatory agency, council, department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country, region or jurisdiction. including the Regulatory Approvals.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product, regulatory applications (including MAA) and all applications, filings, submissions, notifications, materials, communications, registrations, Regulatory Approvals and&#47;or other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize such product in a particular country, region or jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;5.7.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.5(a).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 2.13.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 8.8(d).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.7.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 15.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;10.4(a)(i).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Selling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning as provided in Section 1.128.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration IP and Licensee Solely Owned Collaboration IP, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.173</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Duality Solely Owned Collaboration Patents and Licensee Solely Owned Collaboration Patents, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.174</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a license, sublicense, covenant not to sue or other rights granted by Licensee to a Third Party under the rights it receives from Duality in accordance with Section 2.2, to Develop, Manufacture, Commercialize or otherwise exploit a Licensed Compound or a Licensed Product, and&#47;or after Next Generation Option Exercise, the Next Generation Licensed Compound or Next Generation ADC Licensed Products, but excluding any grant of rights to or agreement with (a) any Third Party acting as a service provider or subcontractor for such Party or its Affiliates, or (b) any Third Party wholesaler, distributor, or the like.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a Third Party that is receiving rights under a Sublicense.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Successful Completion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with regard to an Antibody or ADC and a biological target in question, that such Antibody or ADC demonstrates meaningful binding activity to such biological target and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Targeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;9.4(b).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.179</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;13.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.180</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean worldwide except the Retained Territory. For clarity, Territory shall include Taiwan.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any entity other than Licensee and its Affiliates and Duality and its Affiliates.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 4.4(c).</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.183</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 14.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.184</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Trop2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) Trophoblast cell-surface antigen 2, and (b) any naturally occurring variants thereof, in each case including any isoforms, polymorphisms, variants, and truncated forms, and in each case to the extent such variant, isoform, polymorphism, variant and truncated form are produced from an allele of the same TACSTD2 gene. </font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning given in Section 15.2.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States of America, including its territories and possessions as recognized by the United Nations from time to time, but in all cases including, for clarity, Puerto Rico.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section 11.8.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.188</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">US$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S. Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean U.S. dollars, the lawful currency of the U.S.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provided in Section&#160;8.1.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.190</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the working cell bank.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.192</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Wind-Down or Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a plan for the wind-down or transfer of any ongoing Development, Manufacture and Commercialization (if any) activities of Licensee with respect to the Licensed Products for which the license grant in Section 2.1 has been terminated and the transfer of relevant Licensed Products, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.193</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the &#91;***&#93; Cell Line Agreement as well as the following agreements&#58; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.194</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;***&#93; Cell Line Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>LICENSE</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants and shall procure its Affiliates grant to Licensee and its Affiliates, during the Term, an exclusive (even as to Duality and its Affiliates), royalty-bearing license, with the right to sublicense through multiple tiers (in accordance with Section 2.2), under Duality Licensed IP to Develop, have Developed, Manufacture, have Manufactured, use, sell, offer for sale, import and otherwise Commercialize or have Commercialized or exploit the Licensed Compound or after Next Generation Option Exercise, the Next Generation Licensed Compound, and the Licensed Products in the Field in the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Retained Territory License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement (including Duality&#8217;s retained rights in Section&#160;2.4), Duality hereby grants to Licensee a sole license under Duality Licensed IP to Develop, have Developed, Manufacture or have Manufactured the Licensed Compound or after Next Generation Option Exercise, the Next Generation Licensed Compound, and the Licensed Products in the Retained Territory solely for the purpose of Developing, Manufacturing and Commercializing the Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2.&#160;&#160;&#160;&#160;Sublicense Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Right to Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Licensee and its Affiliates shall have the right to grant Sublicenses through multiple tiers under Duality Licensed IP (including Duality In-Licensed IP), in each respect to (i) any Affiliate, or (ii) to any Third Party. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Sublicense Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Licensee&#8217;s Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates, Sublicensees and subcontractors hereunder is in accordance with the applicable terms of this Agreement.  With respect to a patent challenge by the Sublicensee against any Duality Patents, if Licensee fails to cause such Sublicensee to cease such violation within a reasonable period of time, Licensee shall, in so far as it is not prohibited under the Applicable Laws, terminate the sublicense agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3&#160;&#160;&#160;&#160;Negative Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In so far as it is not prohibited under the Applicable Laws, Licensee hereby covenants on a country-by-country basis not to, and not to permit or cause any Affiliate &#91;***&#93;. Notwithstanding the foregoing, this Section 2.3 shall in no way restrict &#91;***&#93;, its Affiliates, its Sublicensees or their CMOs and other authorized Third Party under this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from undertaking any research, Development, Manufacturing, Commercialization, or other exploitation or engaging in any activities involving &#91;***&#93; that anyone not subject to this Agreement may legally undertake before the Effective Date and during the Term in the Territory and elsewhere, &#91;***&#93;. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4&#160;&#160;&#160;&#160;No Implied Licenses&#59; Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No right or license under any Patents or Know-How of either Party is granted or shall be granted by implication.  All such rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement.  Duality hereby expressly reserves all rights not expressly licensed to Licensee in Section&#160;2.1, including (i)&#160;all rights under the Duality Licensed IP with respect to the Licensed Compound and Original ADC Licensed Products, or after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product in the Retained Territory, subject to Licensee&#8217;s co-exclusive license as set forth in Section 2.1(b), (ii) all rights under the Duality Licensed IP to exercise its rights or perform its obligations under this Agreement, and (iii) all rights under the Duality Licensed IP to conduct Development activities in the Territory for the sole purpose of Developing or Commercializing the Original ADC Licensed Products or Next Generation ADC Licensed Product in the Field in the Retained Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any such Development activities in the Territory in relation to the Original ADC Licensed Product, or Next Generation ADC Licensed Product and Licensed Compound or Next Generation Licensed Compound shall be undertaken for Duality by Licensee or its Affiliates, or Sublicensees or Licensee&#8217;s designated subcontractors. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5&#160;&#160;&#160;&#160;License to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee hereby grants to Duality a non-exclusive, non-transferrable, non-sublicensable (unless a sublicense was consented to by Licensee in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">writing and is in compliance with the license terms set out in Section 2.2(b), which would apply </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), royalty-free license under the Licensee Licensed IP, during the Term of this Agreement, solely to (i) perform, either itself, through its Affiliates, or through subcontractors, its obligations under this Agreement, including its Manufacturing and supply obligations under Sections&#160;6.1, 6.4 and 6.5, and (ii) limited to the Field and the Retained Territory, to Develop, Manufacture or have Manufactured, or Commercialize the Licensed Compound or Original ADC Licensed Products or after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product.  Duality shall use Commercially Reasonable Efforts to ensure that the performance by any of its Affiliates, sublicensees or subcontractors hereunder is in accordance with the applicable terms of this Agreement. With respect to a patent challenge by a (sub)licensee against any Licensee Patents, if Duality fails to cause such (sub)licensee to cease such violation within a reasonable period of time, Duality shall, in so far as it is not prohibited under the Applicable Laws, terminate such (sub)license agreement. Duality shall be responsible for any actions of its Affiliates, sublicensees and subcontractors who act on behalf of Duality to perform activities assigned to Duality (for or on behalf of Licensee) pursuant to this Agreement, to the same extent as if such actions had been taken by Duality itself, and Licensee shall have the right to proceed directly against Duality without any obligation to first proceed against such Affiliate, sublicensee and subcontractor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6&#160;&#160;&#160;&#160;Know-How and Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93; days of the Effective Date, Duality shall, at its cost and expense, provide to Licensee &#91;***&#93; the documents embodying all Duality Know-How, in original form and English language certified translations, (including but not limited to CMC documentation to the extent available to Duality or any of its Affiliates as of the Effective Date) Controlled by Duality or any of its Affiliates as of the Effective Date, including but not limited all Know-How that has been obtained by Duality under the &#91;***&#93; Agreement and the &#91;***&#93; Agreements as of the Effective Date, &#91;***&#93;. A description of such documents for the initial Know-How Transfer as of the Effective Date is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thereafter, Duality shall promptly (and in any event no later than &#91;***&#93; from the existence of such Know-How) inform Licensee of the existence of any additional Duality Know-How that becomes Controlled by Duality after the Effective Date and during the Term, including Know-How agreed to be provided under or  obtained under the &#91;***&#93; Agreement and the &#91;***&#93; Agreements. The Parties shall discuss the timing and means of the transfer of additional Duality Know-How. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon Licensee&#8217;s request, Duality shall provide, and shall cause Third Parties (including but not limited to the &#91;***&#93; and &#91;***&#93; entities that are party to the &#91;***&#93; Agreement or the &#91;***&#93; Agreements, as applicable) to provide (as applicable), electronic copies of such additional Duality Know-How (including CMC-Materials) and disclose, make available and support the onsite implementation of the Manufacturing process technology transfer to Licensee or Licensee&#8217;s Third Party manufacturer in accordance with Section 6.2 below, and at no additional cost to Licensee beyond the costs set out in Section 6.2. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7&#160;&#160;&#160;&#160;Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8&#160;&#160;&#160;&#160;Duality Immune Agonist ADC Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9&#160;&#160;&#160;&#160;Next Generation Licensed Compound or Next Generation ADC Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Subject to the terms and conditions of this Agreement, Duality hereby grants to Licensee an exclusive option (for clarity, this option grant is fully paid-up by the payments made under this Agreement, no additional consideration is needed for this exclusive option) to obtain an exclusive license to Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise exploit in the Territory, any Next Generation Licensed Compound and&#47;or Next Generation ADC Licensed Product, which may be exercised by Licensee in accordance with Section 2.9(b) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Next Generation Option may be exercised by Licensee upon written notice to Duality at any time until &#91;***&#93; months after successful Pre-clinical Proof-of-Concept and full disclosure by Duality of the complete Next Generation Data Package (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Next Generation Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Licensee shall be entitled to request additional data and information required for due diligence to make an informed decision in relation to the exercise of this Next Generation Option. Licensee shall complete its due diligence on the Next Generation Licensed Compound and Next Generation ADC Licensed Product within &#91;***&#93; months after delivery of the complete Next Generation Data Package by Duality to Licensee. For clarity, the Next Generation Option shall expire if the Next Generation Option Exercise does not occur within such &#91;***&#93; month period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">After the Next Generation Option Exercise with respect to a Next Generation Licensed Compound, any other Next Generation Licensed Compound (other than the one with respect to which Licensee exercised the Next Generation Option) would automatically qualify as Duality Competing Product and fall under the non-compete obligation of Duality in Section 2.7. If Licensee chooses not to exercise the Next Generation Option, any Next Generation Licensed Compound or Next Generation ADC Licensed Product (including the one with respect to which Licensee declined to exercise the Next Generation Option) would automatically become a Duality Competing Product and fall under the non-compete obligation of Duality in Section 2.7.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For the avoidance of doubt, the Next Generation Option Exercise will not trigger any additional payments, such as upfront or milestone payments, other than those set forth in Section 8.3, 8.5 and 8.6 (ii). </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.12&#160;&#160;&#160;&#160;Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1&#160;&#160;&#160;&#160;General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties have already created a governance structure and committees for the implementation of the HER2 License and Collaboration Agreement dated March 31, 2023 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2 Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, such governance structure the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HER2 Governance Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Unless otherwise agreed by the Parties in writing, the Parties agree that the HER2 Governance Structure </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall apply to this Agreement, unless the HER2 Agreement is terminated by the Parties, or unless otherwise agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2&#160;&#160;&#160;&#160;Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties have established a JSC comprised of an equal number of representatives from each Party to approve, plan, coordinate, integrate monitor and oversee the Development, Manufacture and regulatory activities of the Parties&#8217; in the Territory with respect to the Original ADC Licensed Product and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product and facilitate information exchange between the Parties under this Agreement. The JSC, as may be conducted through the applicable Subcommittee, shall in particular&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">review, discuss and coordinate the overall strategy for the Development of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">discuss the status of the Development of the Next Generation Licensed Compound (before and after Next Generation Option Exercise)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">review, discuss and approve any proposed amendments or revisions to the Development Plan(s) of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product including all related budgets of the Development activities&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">review, discuss and approve any study protocols relating to the Development Plan(s) (and any amendments thereto) of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">review, discuss and serve as a forum for the sharing of information between the Parties regarding the operation of any Development activities of the Original ADC Licensed Products in the Territory and in the Retained Territory and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">oversee and coordinate the on-going disclosure, sharing and&#47;or transfer of new Collaboration IP generated in or related to the Development of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and the Next Generation ADC Licensed Product in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">review and discuss any matters relating to the Regulatory Approvals and Regulatory Materials to be submitted to any Regulatory Authority in respect of the Original ADC Licensed Products in the Territory and matters relating to attending regulatory meetings or consultations with Regulatory Authorities in respect of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and the Next Generation ADC Licensed Product in the Territory&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">coordinate supply of Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product in accordance with Article 6&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">review and discuss the clinical protocol of and Duality&#8217;s potential participation in any Global Trial sponsored by Licensee or any of its Affiliates and Sublicensees, or Original ADC Added Trials&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.69pt">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3&#160;&#160;&#160;&#160;Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From time to time during the Term, the JSC may establish and disband one or more subcommittee(s) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to oversee particular activities of the Parties, and the JSC may assign to such subcommittee(s) duties or tasks independent of the duties of the JSC, or delegate part of such duties of the JSC to such subcommittee(s) as it deems necessary and appropriate.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless already existing under the HER2 Governance Structure, no later than &#91;***&#93; days after the Effective Date (unless otherwise agreed by the Parties), the JSC shall establish an intellectual property committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint IP Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JIPC shall provide a forum for discussion of the patenting strategies of the Licensed Compound, the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product, and coordinate the Parties&#8217; efforts in accordance with the provisions set forth in Article 12 and other matters related to the prosecution and maintenance of intellectual property rights hereunder, including submissions to and addressing notices from Regulatory Authorities that relate to regulatory-patent linkage procedures and proceedings. The JSC shall determine the desired membership of the JIPC and once formed, Licensee&#8217;s committee members shall determine the time, place and procedure of meetings. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless already existing under the HER2 Governance Structure, no later than &#91;***&#93; days after the Effective Date, the JSC shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Joint Development Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) led by Licensee and comprised of an equal number of representatives from each Party. The JDC shall (i) oversee the implementation and progress of the Development Plan in the Territory, (ii) discuss and propose to the JSC for approval any amendments to the Development Plan, (iii) oversee any Global Trials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4&#160;&#160;&#160;&#160;Composition&#59; Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If not otherwise agreed for the HER2 Governance Structure, the JSC and each Subcommittee (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be composed of &#91;***&#93; representatives from each Party (or such other equal number of representatives of each of Licensee and Duality as the JSC may determine), and each Party shall notify the other Party of its initial JSC representatives within &#91;***&#93;&#160;days after the Effective Date.  Each Party shall designate a representative to be the co-chairperson of the JSC and Licensee shall designate a representative to chair each Subcommittee led by it, in each case, who shall schedule meetings, prepare meeting agendas and meeting minutes and follow up on action items. Each Party may request and convene a Committee meeting and propose agenda therefor at any time. With respect to the JSC, these responsibilities will alternate between the Parties or each co-chairperson, as applicable, with Licensee&#8217;s co-chairperson taking the responsibility for the first meeting of the JSC.  Each Party may change its representatives to the JSC (or any Subcommittee) from time to time in its sole discretion, effective upon notice to the other Party of such change. Each Party&#8217;s representatives in each Committee shall possess appropriate experience with respect to the issues falling within the functions of such Committee and requisite seniority within such Party&#8217;s organization, and shall have the authority to make decisions on behalf of the Party they represent. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5&#160;&#160;&#160;&#160;Non-Member Attendance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend a meeting of any Committee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(in a non-voting capacity) in the event that the planned agenda for such Committee meeting would require such participants&#8217; expertise&#59; provided that if either Party intends to have any Third Party (including any consultant or counsel) attend such a meeting, such Party shall provide prior written notice to the other Party, shall obtain approval from such other Party for such Third Party to attend (which shall not be unreasonably withheld, conditioned or delayed by the notified Party), and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.6&#160;&#160;&#160;&#160;Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The representatives of each Party will have &#91;***&#93; vote at each Committee on all matters brought before such Committee. The Committees may not take any action or decide any matter except at a meeting attended by &#91;***&#93; representing each Party and with unanimous consent. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">JSC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JSC (including those matters referred to the JSC by any Subcommittee), the representatives of the Parties on the JSC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JSC for resolution or after such matter has been referred to the JSC, such disagreement shall be referred to the Chief Executive Officer of Duality and Chief Executive Officer of Licensee (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for resolution.  If the Executive Officers cannot resolve such matter within &#91;***&#93; days (or such other timeframe as the JSC may request in consideration of the urgency of such referred matter) after such matter has been referred to them, then&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#91;***&#93; shall be entitled to make final decisions with respect to&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#91;***&#93; shall be entitled to make final decisions on the &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">with respect &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">&#91;***&#93; will have final decision-making authority with respect to matters relating to &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">&#91;***&#93; will have final decision-making authority with respect to matters relating to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">JIPC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JIPC, together with the assistance of each Party&#8217;s outside intellectual property counsel, the representatives of the Parties on the JIPC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JIPC for resolution or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">after such matter has been referred to the JIPC, such matter shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">JDC Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except where consent or approval on any matter by a Party is expressly required herein, if after reasonable discussion and good faith consideration of each Party&#8217;s view on any matter within the decision-making authority of the JDC, the representatives of the Parties on the JDC cannot reach an agreement as to such matter within &#91;***&#93; Days after such matter was brought to the JDC for resolution or after such matter has been referred to the JDC, such disagreement shall be escalated to the JSC by either Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Deadlock Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In case of a deadlock with respect to the decision-making process of the JSC, Section 15.1 shall apply. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.7&#160;&#160;&#160;&#160;Limitations on Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.  Without limiting the generality of the foregoing, the JSC shall not have the power to amend this Agreement, shall not have power in relation to &#91;***&#93; or the &#91;***&#93;, and no decision of the JSC may be in contravention of any terms and conditions of this Agreement.  For clarity, the JSC shall have no decision-making authority regarding any Development, Manufacturing, Commercialization or other activity in the Retained Territory save as contemplated by Section 3.6(a) or otherwise expressly provided in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8&#160;&#160;&#160;&#160;Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The JSC will hold a meeting every &#91;***&#93; months until the Development Phase ends, and afterwards every &#91;***&#93; months, or as otherwise determined by the JSC. Such meetings may be in person, via videoconference, or via teleconference. The location of in-person meetings will be determined by the Parties. At least &#91;***&#93; Days prior to each JSC meeting, each Party shall provide written notice to the other Party of agenda items proposed by such Party for discussion at such meeting, together with appropriate information related thereto. Reasonably detailed written minutes will be kept for all JSC meetings. Meeting minutes will be prepared &#91;***&#93; and sent to each member of the JSC for review and approval within &#91;***&#93; Days after the meeting. Minutes will be deemed approved unless a member of the JSC objects to the accuracy of such minutes within &#91;***&#93; Days of receipt. In the event of any such objection that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.9&#160;&#160;&#160;&#160;Discontinuation of JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The JSC shall continue to exist until the Parties mutually agree to disband the JSC. Once the JSC is disbanded, the JSC shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the points of contact for the exchange of information under this Agreement, and the Parties shall reach decision directly on matters that are subject to the decision of the JSC as set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.10&#160;&#160;&#160;&#160;Project and Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall appoint an individual, who is an employee of such Party, to act as a project manager (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Project Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties. Each Party shall appoint an individual, who is an employee of such Party, to act as its alliance manager under this Agreement within &#91;***&#93; Days after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  &#91;***&#93; The Project Managers shall&#58; (a) serve as the primary points of contact between the Parties for the purpose of providing the other Party with information on the progress of a Party&#8217;s activities under this Agreement&#59;  (b) be responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties. The Alliance Managers shall&#58; (a) serve as the primary points of contact between the Parties for any issues arising under this Agreement&#59; (b) facilitate the prompt resolution of any disputes&#59; and (c) attend JSC and Subcommittee meetings (in each case, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as a non-voting participant)&#59; provided that the Alliance Managers shall not count toward the number of representatives that each Party may have on each such Committee. An Alliance Manager may also bring any matter to the attention of the JSC, if such Alliance Manager reasonably believes that such matter warrants such attention. Each Party may replace its Project Manager and Alliance Manager at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>DEVELOPMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1&#160;&#160;&#160;&#160;Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as expressly provided herein with respect to the Planned Trials, Original ADC Added Trials (as applicable) or after Next Generation Option Exercise, the  Next Generation Added Trials, Licensee (itself and through its Affiliates and their respective Sublicensees) shall be responsible, at its own expense, for the Development of the Original ADC Licensed Products or after the Next Generation Option Exercise, Next Generation ADC Licensed Product  in the Field in the Territory under the oversight of JSC. Without limiting the generality of the foregoing, Licensee shall, in accordance with the Development Plan (i) use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for &#91;***&#93; in the Field in &#91;***&#93;, and (ii) perform the Development activities assigned to it under the Development Plan(s) in compliance with Applicable Laws (including GXPs), with reasonable due care and in conformity with current generally accepted industry standards and procedures. Licensee shall use Commercially Reasonable Efforts to adhere to the timelines set forth in the Development Plan.  For the avoidance of doubt, Licensee shall have fulfilled its diligence obligation under Section 4.1(a) (i) if it has used Commercially Reasonable Efforts to develop and seek Regulatory Approval for either the Original ADC Licensed Products or a Next Generation ADC Licensed Product in &#91;***&#93;. Licensee is not obliged to develop and&#47;or seek Regulatory Approval for both the Original ADC Licensed Products and the Next Generation ADC Licensed Product. For the avoidance of doubt, as regards the Clinical Trials in the Retained Territory, unless otherwise agreed under this Agreement, Duality shall be solely responsible at is own expenses, for the Development of the Original ADC Licensed Products and the Next Generation ADC Licensed Product in the Retained Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limiting the foregoing, Licensee shall use Commercially Reasonable Efforts to (i) make all regulatory submissions to the applicable Regulatory Authorities within the Territory in respect of the Original ADC Licensed Product, or after Next Generation Option Exercise, the Next Generation ADC Licensed Product&#59; and (ii) obtain Regulatory Approval for Original ADC Licensed Products, or after Next Generation Option Exercise, the Next Generation ADC Licensed Product&#59; in the Territory, in each case of (i) and (ii) in accordance with the Development Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2&#160;&#160;&#160;&#160;Development of Original ADC Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The initial Original ADC Licensed Product Development Plan, which sets forth the scope, timelines and responsibilities of each Party of the Development activities to be conducted by or on behalf of Licensee in order to obtain Regulatory Approvals for the Original ADC Licensed Products in the Territory is attached hereto as Schedule 1.141. The Original ADC Licensed Product Development Plan shall in particular set out the Original ADC Licensed Product Development Budget allocated to these Development activities. From time to time during the Term, either Party may propose written amendments and updates to the then-current Original ADC Licensed Product Development Plan, and shall submit such amendments and updates to the JSC for review </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and approval.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any amendment of the Original ADC Licensed Product Development Plan and the Original ADC Licensed Product Development Budget shall become effective only upon the approval of the JSC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Clinical Trials to Be Conducted by Duality in the Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date and as set forth in the Original ADC Licensed Product Development Plan, the Parties have agreed that Duality will conduct, at its own cost and expense,  the Clinical Trials in the Territory until the &#91;***&#93; in accordance with the Development Plan and in compliance with all Applicable Laws (together, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Planned Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Global Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Phase &#91;***&#93; Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3&#160;&#160;&#160;&#160;Development of Next Generation ADC Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">No Next Generation Option Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">After Next Generation Option Exercise.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4&#160;&#160;&#160;&#160;Duality Development Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Where Duality is responsible for conducting Development activities under this Agreement in the Territory, including but not limited to conducting the Planned Trials, and if applicable, the Original ADC Added Trials and, after the Next Generation Option Exercise the Development of the Next Generation Licensed Compound and Next Generation ADC Licensed Product in accordance with Section 4.3, and, if applicable the Next Generation Added Trials (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Development Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Any intended delegation of the Duality Development Activities or any part thereof to a subcontractor shall be communicated to Licensee via the JDC in advance and shall be reflected in the initial (and updated) Development Plan, already listing the subcontractors that Duality intends to involve. The delegation to any such subcontractor requires Licensee&#8217;s prior written consent which shall not be unreasonably withheld, conditioned or delayed&#59; provided that Licensee shall be deemed to have given its consent if  Licensee&#8217;s Project Manager and Licensee&#8217;s Alliance Manager, who were informed about the identity of the subcontractor via the JDC, do not respond within &#91;***&#93; Days after both Licensee&#8217;s Project Manager&#8217;s and Licensee&#8217;s Alliance Manager&#8217;s receipt of written notice from Duality&#59; provided further that such notice contains sufficient information for Licensee to make an informed decision. . A response by Licensee can also be a request for further information or comments.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt"> Duality shall, upon request by Licensee, (i) keep Licensee copied on the main communications regarding the contract negotiations with the subcontractor and Licensee may decide, in its own discretion, to participate in the contract negotiations with the subcontractor&#59; provided that Duality does not need to reschedule negotiations because </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Licensee&#8217;s unavailability, and (ii) provide Licensee with a copy of any draft subcontractor agreement proposed to it with respect to the Duality Development Activities or Manufacture activities (such subcontractor agreements the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), including but not limited to agreements with CROs. Such Third Party Agreements shall be in the English language. Any such Third Party Agreement will only be signed after obtaining a written consent of Licensee which shall not be unreasonably withheld, conditioned or delayed&#59; provided that Licensee shall be deemed to have given its consent if Licensee&#8217;s Project Manager and Licensee&#8217;s Alliance Manager were copied on the main communications regarding the contract negotiations, given the opportunity to participate in the contract negotiation, and regularly updated on the progress of the negotiations (together with the draft Third Party Agreement) and do not respond within &#91;***&#93; Days after both Licensee&#8217;s Project Manager&#8217;s and Licensee&#8217;s Alliance Manager&#8217;s receipt of a full copy of such draft Third Party Agreements and the written notice from Duality. A response by Licensee can also be a request for further information (i.e. not information that has been provided) or comments. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.5&#160;&#160;&#160;&#160;Development Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall maintain or cause to be maintained complete, current and accurate records of all activities conducted by or on behalf of it pursuant to the Development Plan(s), and all Know-How and other information resulting from such activities. For Duality this shall also apply to any Development activities with respect to the Next Generation Licensed Compound or Next Generation ADC Licensed Product. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall, and shall ensure that its Affiliates, their Sublicensees and subcontractors will, document all non-clinical studies and Clinical Trials in formal written study records in accordance with all Applicable Laws, including applicable national and international guidelines such as ICH, GCLP, GCP and GLP.  To the extent permitted by the Applicable Laws, each Party shall have the right to review and copy such records of the other Party at reasonable times and to obtain access to review the original to the extent necessary or useful for regulatory, patent or other reasonable purposes for the purpose of fulfilling its obligations under this Agreement upon reasonable notice to such other Party and at a time and location mutually acceptable to the Parties.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.6&#160;&#160;&#160;&#160;Development Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall keep the other Party reasonably and timely informed of the progress and results of its and its Affiliates&#8217;, subcontractors&#8217; and Sublicensees&#8217;&#47;(sub)licensees&#8217; work under the Development Plan(s) (including prompt reporting of available pre-clinical and clinical data). For Duality this shall also apply to any Development activities of Duality with respect to the Next Generation Licensed Compound or Next Generation ADC Licensed Product. Without limiting the generality of the foregoing, each Party shall provide the other Party with a written report no later than &#91;***&#93; days after the end of each Calendar Year setting forth in details the Development activities performed during such Calendar Year and the results thereof, and comparing such activities with the Development Plan(s) for such time period.  Such reports prepared by each Party shall be provided at a level of detail reasonably sufficient to enable the other Party to determine the other Party&#8217;s compliance with its obligations under this Agreement.  At each JSC meeting, the Parties shall discuss the status, progress and results of the Development activities conducted by the Parties pursuant to this Agreement.  Each Party shall promptly respond to the other Party&#8217;s reasonable questions or requests for additional information relating to such Development activities. In the event that Duality is engaged by Licensee to conduct Duality Development Activities in the Territory, Duality shall send the Development report &#91;***&#93;, setting forth in more detail the Duality Development Activities performed &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>REGULATORY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1&#160;&#160;&#160;&#160;Overview of Conduct of Regulatory Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Licensee (itself and through its Affiliates and Sublicensees, as applicable) shall be responsible for all of the costs for all regulatory activities with respect to the Licensed Products in the Territory after the Effective Date.  &#91;***&#93;, Licensee (or its Affiliate or Sublicensees) shall be the sponsor and holder of all Regulatory Approvals for the Licensed Products in the Territory.  For clarity, Licensee (or one of its Affiliates or their Sublicensees) shall always be the MAH of the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product in the Territory. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Following &#91;***&#93; days after the Effective Date, Duality shall provide Licensee with one (1) electronic copy of the Regulatory Materials related to the Licensed Compound and Original ADC Licensed Products in the Territory existing and possessed by Duality as of the Effective Date. At any time during the Term, if Duality is the sponsor or holder of the Regulatory Materials and upon Licensees&#8217; written request, Duality shall provide Licensee with electronic copies of the Regulatory Materials related to the Licensed Compound or Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Products in the Territory received and possessed by Duality after the Effective Date promptly and in any event no later than &#91;***&#93; Days after such Regulatory Materials become available.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2&#160;&#160;&#160;&#160;Regulatory Filing&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except with respect to regulatory filings related to the Planned Trials and Original ADC Added Trials (if any), for which Duality shall be responsible unless the Parties agree otherwise, (i) Licensee (and its Affiliates or Sublicensee, as applicable) shall lead and have sole control over preparing and submitting all regulatory filings related to the Licensed Compound and Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product, including all applications for Regulatory Approval, in the Territory at Licensee&#8217;s sole cost and expense, and (ii) Duality shall be responsible for the preparation and submission of any regulatory filings in the Retained Territory at Duality&#8217;s sole cost and expense. With respect to regulatory filings for the Planned Trials or and the Original ADC Added Trials (if any) that are prepared by Duality, Duality shall submit all such regulatory filings to the JSC for its review and approval.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Ownership.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Other than any Regulatory Approvals or applications therefor that are related to the Planned Trials or Original ADC Added Trials (if any), for which Licensee has designated Duality to be the sponsor and with respect to which Section 5.4 applies, Licensee (or its Affiliates or Sublicensees, as applicable) shall own any and all Regulatory Approvals (and applications for Regulatory Approvals), and any other regulatory filings related to the Licensed Compound and Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation Licensed Compound and Next Generation ADC Licensed Product in the Territory, including Data and data in the regulatory filings and Regulatory Materials, which shall be held in the name of Licensee or its designees. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">English Translation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To the extent that the original language is not English, Duality shall provide Licensee with a certified full English translation of all Regulatory Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3&#160;&#160;&#160;&#160;Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Insofar as it relates to the Planned Trials and Original ADC Added Trials (if any) where Licensee has confirmed and consented in writing that Duality is the sponsor, Duality shall lead interactions with Regulatory Authorities in the Territory&#59; provided that JSC shall have final decision making authority in relation to such interactions with Regulatory Authorities and Duality shall follow all instructions provided to it by the JSC in this regard and Duality shall provide Licensee with (i) access to or copies of all material written or electronic communication received by Duality or its Affiliates from any Regulatory Authorities in the Territory and in the Retained Territory (if applicable), and (ii) copies of all meeting minutes with any Regulatory Authorities in the Territory and in the Retained Territory (if applicable). In addition, Duality shall provide Licensee with written notice of any scheduled material meeting, conference, or discussion with a Regulatory Authority related to Regulatory Approvals related to the Planned Trials and Original ADC Added Trials (if any). Licensee (or its designee) shall have the right to (i) attend and participate in all such meetings with Regulatory Authorities related to the Planned Trials, Original ADC Added Trials (if any) and Next Generation Added Trials (if any), and all telephone conferences and preparation meetings of Duality or its Affiliates related to any such meeting, (ii) provide input on the regulatory filings in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory), and (iii) have final decision making authority in relation to any unsettled matter between the Parties with respect to regulatory filings in the Territory.  Subject to the foregoing, Licensee (and&#47;or its Affiliates, or Sublicensees as applicable) shall have the sole right to conduct all communications with Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to the Licensed Compound and Original ADC Licensed Products and, after Next Generation Option Exercise, all Next Generation Licensed Compound and Next Generation ADC Licensed Products, in the Territory, including in respect of the Original ADC Added Trials where Licensee (or its Affiliates or Sublicensees, as applicable) is the sponsor (if any). Without limiting the forgoing, the Parties agree that they will collaborate with each other as necessary to ensure the successful progression of interactions with Regulatory Authorities with respect to all trials relating to the Licensed Compound and Original ADC Licensed Products, and&#47;or after Next Generation Option Exercise, all Next Generation Licensed Compound and Next Generation ADC Licensed Product, in the Territory and in the Retained Territory (to the extent this impacts the position of Licensee in the Territory).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;, Duality shall transfer and assign, or shall cause the transfer or assignment, to Licensee or its designee (at Duality&#8217;s cost and expense for Planned Trials and at Licensee&#8217;s cost and expense for Original ADC Added Trials), Duality&#8217;s, or any of its Affiliates&#8217;, entire right, title, and interest in and to all IND and other Regulatory Approvals in the Territory, if any, and transfer all Regulatory Materials with respect to the Licensed Compound and Original ADC Licensed Products, and&#47;or, after Next Generation Option Exercise, all Next Generation Licensed Compound and Next Generation ADC Licensed Product, in the Territory that are owned, controlled or possessed by Duality or any of its Affiliates, unless the Parties agree otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5&#160;&#160;&#160;&#160;Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At any time during the Term, Licensee may decide to replace Duality to be the sponsor of any Planned Trials and Original ADC Added Trials or Next Generation Added Trials (if any) in the Territory. Once Licensee informs Duality by written notice of its decision to replace Duality as the sponsor of any such Clinical Trials in the Territory, Duality shall within &#91;***&#93; days after receipt of such written notice from Licensee (a) transfer to Licensee all Regulatory Materials (including but not limited to the applicable IND, protocol and investigator&#8217;s brochure) in connection with each of its ongoing Clinical Trials as of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the date of such notice and (b) use commercially reasonable efforts to facilitate Licensee&#8217;s introduction to applicable CROs, study site(s) and investigator(s) in connection with each such Clinical Trial in order to assist Licensee in transferring such Clinical Trial to Licensee, in each case ((a) and (b)) in accordance with Applicable Law and accepted pharmaceutical industry norms and ethical practices. To the extent that the original language of the Regulatory Materials is not English, Duality shall provide a certified full English translation of all documents to Licensee. Licensee shall be responsible for all costs and expenses reasonably incurred by Duality in relation to or as a result of such replacement&#59; provided that if the replacement was caused by a breach of the applicable terms of this Agreement, Applicable Laws or the GXP by Duality, the costs and expenses reasonably incurred by Licensee in relation or as a result of such replacement shall be borne by Duality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6&#160;&#160;&#160;&#160;Data Access&#59; Right of Reference&#59; Access to Regulatory Materials&#59; pharmacovigilance&#59; audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Within &#91;***&#93; days of the Effective Date, the Parties shall enter into a pharmacovigilance agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) regarding the Licensed Compound and Original ADC Licensed Products  which shall set forth standard operating procedures governing the collection, investigation, reporting, and exchange of safety information sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes. After Next Generation Option Exercise, the Parties  shall enter into  a Pharmacovigilance Agreement regarding the Next Generation Licensed Compound and Next Generation ADC Licensed Product. In the event of any inconsistency between the terms of this Agreement and the Pharmacovigilance Agreement(s), the terms of this Agreement shall prevail and govern, except to the extent such conflicting terms relate directly to the pharmacovigilance&#47;safety responsibilities of the Parties (including the exchange of safety data), in which case the terms of the Pharmacovigilance Agreement(s) shall prevail and govern. Prior to the Parties entering into the Pharmacovigilance Agreement, Duality is and shall continue to be the owner of the global safety database for the Original ADC Licensed Products. Unless otherwise agreed by the Parties in the Pharmacovigilance Agreement, the Pharmacovigilance Agreement can be amended at Licensee&#8217;s request during the Term and as a preparation to the Commercialization, at least &#91;***&#93; months&#8217; ahead of the first MAA submission. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">At any time during the Term, upon reasonable prior notice, during regular business hours and under obligations of confidentiality, Licensee (or its designees) shall be entitled to audit (i) any of Duality&#8217;s or its Affiliates&#8217;, or any of their respective CROs&#8217; or CMOs&#8217; manufacturing sites&#59; and (ii) any of Duality&#8217;s, its Affiliates&#8217; clinical sites, as selected by Licensee in its sole discretion, to assess Duality&#8217;s compliance with all GXPs and all matters arising under the Pharmacovigilance Agreement, in each case of the foregoing (i) and (ii), only in respect of any Clinical Trials run by Duality for Licensee in the Territory&#59; provided that such audit shall not be conducted more than once in any given Calendar Year, unless it is a for-cause audit. If (a) such audit by Licensee identifies any material non-compliance by Duality (via its subcontractors) or its Affiliates (via its subcontractors) of the GXPs or the Pharmacovigilance Agreement in the Territory, and (b) such material non-compliance is confirmed to be an uncured material breach on the part of Duality pursuant to Section 13.3, then the provisions of Section 13.8 shall apply.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.7&#160;&#160;&#160;&#160;Remedial Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Original ADC Licensed Product or Next Generation ADC Licensed Product may be subject to any recall, corrective action, patent regulatory procedures or other regulatory action in the Territory or the Retained Territory by any Governmental Authority or Regulatory Authority (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Remedial Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Parties shall assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. The Parties shall collaborate in good faith and endeavor to reach an agreement on Remedial Action related decisions save that were there is any unsettled issues in relation to any Remedial Action related matters (i) with respect to the Territory, Licensee shall have the final decision making authority and Duality shall take all actions reasonably requested by Licensee in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Duality&#8217;s position in respect of the Original ADC Licensed Product, the Next Generation ADC Licensed Product or any Regulatory Authorities in the Retained Territory, no action will be taken by Licensee (unless immediate action is required to comply with Applicable Laws and mitigate further damage arising from the Remedial Action) without Duality&#8217;s prior written consent, and (ii) with respect to the Retained Territory, Duality shall have the final decision making authority and Licensee shall take all actions reasonably requested by Duality in relation to such Remedial Action, save that where such Remedial Action is reasonably likely to impact Licensee&#8217;s position in respect of the Original ADC Licensed Product, the Next Generation ADC Licensed Product or any Regulatory Authorities in the Territory, no action will be taken by Duality without Licensee&#8217;s prior written consent. The cost and expenses of any Remedial Action shall be borne by the Party whose action or inaction caused the Remedial Action of the Original ADC Licensed Product or the Next Generation ADC Licensed Product.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANUFACTURE &#38; SUPPLY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1&#160;&#160;&#160;&#160;Costs of CMC Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Duality will conduct CMC activities for the Original ADC Licensed Products and&#47;or, after Next Generation Option Exercise, the Next Generation ADC Licensed Product according to the scope as agreed upon by the Parties in the Development Plan.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2&#160;&#160;&#160;&#160;Transfer of CMC Materials from Duality to Licensee, and transfer of Manufacturing process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to the CMC documentation in the Know-How transfer under Section 2.6 above, within &#91;***&#93; following Licensee&#8217;s request (such request is at any time during the Term at Licensee&#8217;s discretion), and thereafter from time to time during the Term upon Licensee&#8217;s reasonable advance request and to the extent not previously provided, Duality shall provide to Licensee (or its designees) the updated CMC-related technical documents and CMC-related technology (and any associated manufacturing process technology with regards to manufacturing of antibody, the linker-payload and the DS, DP (drug substance, drug product) of the Licensed Compound), in original form and English language certified translations, that are necessary or reasonably useful for the Manufacture of the Licensed Compound and Original ADC Licensed Product, and&#47;or, after Next Generation Option Exercise, for the Manufacture of the Next Generation Licensed Compound and the Next Generation ADC Licensed Product and are Controlled by Duality or any of its Affiliates as of the Effective Date and which become Controlled by Duality or any of its Affiliates during the Term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CMC Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and all customs and technology export licenses required by Applicable Law for such transfer(s), if any. Within &#91;***&#93; of Licensee&#8217;s request, Duality or a Duality CMO shall provide Licensee (or its designee) with reasonable consultation and on-site support in respect of the CMC-related technology and associated manufacturing process technology transferred to Licensee pursuant to this Section 6.2. Any assistance required from Duality or Duality&#8217;s CMO, the &#91;***&#93; will be free </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of charge to Licensee. Any additional assistance in excess of &#91;***&#93; will be at the Licensee&#8217;s cost and expense, provided that Licensee will in this case pay the reasonable and market standard FTE rate incurred by Duality&#8217;s or Duality CMO&#8217;s employees involved in such consultation and&#47;or on-site support. For clarity, Licensee will not pay any manufacturing technology transfer fee owed by Duality to a Duality CMO or another Third Party. The conclusion of new Third Party agreements regarding the CMC activities contemplated under Section 6.1 or the amendment of existing Third Party agreements regarding the same shall be subject to Licensee&#8217;s prior written approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3&#160;&#160;&#160;&#160;Transfer of Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties will enter into a separate quality agreement and thereafter a supply agreement to manage the logistics and shipping of the transfer of the MCB and WCB (collectively, including cell banks that are developed in future, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cell Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) used for the Manufacturing of the Antibody incorporated into the Licensed Products, with the respective negotiations to be commenced within &#91;***&#93; days after the Effective Date. &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4&#160;&#160;&#160;&#160;Initial Clinical Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except for &#91;***&#93; and Licensee&#8217;s agents, which supply shall be provided by Licensee in accordance with Section 4.2(c) and 4.2(d), Duality shall, by itself or through one or more Duality CMO(s) in the Retained Territory, supply to Licensee &#91;***&#93; to Licensee&#8217;s designated location &#91;***&#93; and in accordance with a separate clinical supply agreement as contemplated below&#59; provided that Licensee shall be &#91;***&#93;. Unless otherwise agreed by the Parties, the Parties shall negotiate in good faith a clinical supply agreement and related quality agreement with such negotiation to be commenced within &#91;***&#93; days after the Effective Date and, unless otherwise agreed between the Parties, completed no later than &#91;***&#93; days after the Effective Date, which clinical supply agreement shall contain customary language regarding supply of the Licensed Compound or Original ADC Licensed Products, or, after Next Generation Option Exercise, the Next Generation ADC Licensed Products to Licensee (including equitable allocation in the event of disruption to or shortage of product supply, and Licensee&#8217;s right to audit any of Duality&#8217;s or its Affiliates&#8217;, or any of their respective CROs&#8217; or CMOs&#8217; manufacturing sites).  &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5&#160;&#160;&#160;&#160;Ongoing Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as may otherwise be provided under the clinical supply agreement entered into by the Parties pursuant to Section 6.4 and until the Licensee has qualified a new manufacturing site to Manufacture the Licensed Compound and the Original ADC Licensed Products, or after Next Generation Option Exercise the Next Generation Licensed Compound and the Next Generation ADC Licensed Product in the Territory, Duality shall be solely responsible for  Manufacturing the Licensed Compound and Original ADC Licensed Products and&#47;or after Next Generation Option Exercise, the Next Generation Licensed Compound and the Next Generation ADC Licensed Product intended for use (either Clinical Trial use or commercial use) in the Territory, and Licensee shall be solely responsible for  the associated costs and expenses of such Manufacturing activities. Once the Original ADC Licensed Product or Next Generation ADC Licensed Product is approved, &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br>COMMERCIALIZATION MATTERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1&#160;&#160;&#160;&#160;Overview&#59; Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Licensee (itself or through its Affiliates or Sublicensees, as applicable) shall be solely responsible for Commercialization of the Original ADC Licensed Products or after Next Generation Option Exercise, the Next Generation ADC Licensed Product in the Field in the Territory, including&#58; (i) developing and executing a commercial launch and pre-launch plan, (ii) developing the global pricing strategy and negotiating with applicable Governmental Authorities regarding price and reimbursement of such Original </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADC Licensed Products or Next Generation ADC Licensed Products&#59; (iii) marketing, advertising and promotion&#59; (iv) booking sales&#59; (v) distribution and handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (vi) providing customer support, and performing other related functions&#59; (vii) conforming its practices and procedures to Applicable Laws relating to the marketing, detailing and promotion of the Original ADC Licensed Products or Next Generation ADC Licensed Products in the Field&#59; and (viii) developing and implementing the global and local Medical Affairs Activities and medical information infrastructure required in the Field in the Territory. Licensee shall bear all of the costs and expenses incurred in connection with such Commercialization activities in the Territory. Licensee shall use Commercially Reasonable Efforts to launch &#91;***&#93; in &#91;***&#93;. For the avoidance of doubt, Licensee shall have fulfilled its diligence obligation under this Section 7.1 if it has used Commercially Reasonable Efforts to launch either the Original ADC Licensed Products or the Next Generation ADC Licensed Product in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2&#160;&#160;&#160;&#160;Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; months before the anticipated date of the submission of the first MAA for an Original ADC Licensed Product or, after Next Generation Option Exercise, the Next Generation ADC Licensed Product in the Territory, Licensee shall prepare a written Commercialization plan that sets forth the timeline and details of all major Commercialization activities planned for such Original ADC Licensed Product or such Next Generation ADC Licensed Product in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).   The Commercialization Plan shall be updated &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3&#160;&#160;&#160;&#160;Coordination of Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties recognize that they may benefit from the coordination of certain activities in support of the Commercialization of an Original ADC Licensed Product or Next Generation ADC Licensed Product across their territories.  As such, the Parties may coordinate such activities where appropriate, including scientific and medical communication and Original ADC Licensed Product or Next Generation ADC Licensed Product positioning. For clarity, Licensee shall not conduct any Commercialization of any Original ADC Licensed Product or Next Generation ADC Licensed Product outside the Territory without Duality&#8217;s express prior written consent and Duality shall not conduct any Commercialization of Original ADC Licensed Products or Next Generation ADC Licensed Product outside of the Retained Territory without Licensee&#8217;s express prior written consent. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4&#160;&#160;&#160;&#160;Commercialization Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Licensee shall keep Duality informed of its, its Affiliates&#8217; and Sublicensees&#8217; Commercialization activities in the Territory with respect to each Original ADC Licensed Product or Next Generation ADC Licensed Product and Duality shall keep Licensee informed of Duality&#8217;s, its Affiliates&#8217; and sublicensees&#8217; Commercialization activities in the Retained Territory with respect to each Original ADC Licensed Product or Next Generation ADC Licensed Product. All information and reports provided to the other Party in such report shall be treated as Confidential Information of the disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">Licensee shall, &#91;***&#93;, provide Duality with &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">In addition to the other provisions of this Section, each Party shall make available to the other Party such additional information about its Commercialization activities with respect to an Original ADC Licensed Product or after Next Generation Option Exercise, Next Generation ADC Licensed Product as may be reasonably requested by the other Party from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5&#160;&#160;&#160;&#160;Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Licensee shall be responsible for the registration, filing, maintenance and enforcement of any trademarks (including domain names) developed for the Original ADC Licensed Products or, after Next Generation Option Exercise, the Next Generation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADC Licensed Product, in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Product Marks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Parties will discuss in good faith and enter into a separate branding agreement outlining terms for ownership, use, management and enforcement of trademarks (including domain names) adopted to identify the Original ADC Licensed Products or Next Generation ADC Licensed Products in the Field in the Retained Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.6&#160;&#160;&#160;&#160;Original ADC Licensed Products Tracking in the Territory and Retained Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; Licensee shall, and shall ensure that its Affiliates and Sublicensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC Licensed Products or, after Next Generation Option Exercise, the Next Generation ADC Licensed Product, through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Territory. Duality shall, and shall ensure that its Affiliates and sublicensees, maintain adequate records to permit the Parties to trace the distribution, sale, and use of all Original ADC Licensed Products or, after Next Generation Option Exercise, all Next Generation ADC Licensed Product, through all relevant channels (e.g. wholesalers, hospitals and pharmacies) in the Retained Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.7&#160;&#160;&#160;&#160;No Diversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby covenants and agrees that during the Term, and except as expressly permitted by this Agreement, it shall not (and shall cause its Affiliates and Sublicensees (with respect to Licensee), sublicensees (with respect to Duality) and subcontractors not to), either itself or through a Third Party, develop, use, market, promote, import, export, sell or actively offer for sale (online or otherwise) the Original ADC Licensed Products or, after Next Generation Option Exercise, the Next Generation ADC Licensed Products, in the other Party&#8217;s territory. Without limiting the generality of the foregoing, except as mutually agreed by the Parties, each Party shall not (a) engage in any advertising activities relating to the Original ADC Licensed Products or Next Generation ADC Licensed Products, directed primarily to customers in the other Party&#8217;s territory, or (b) actively or intentionally solicit orders from any prospective purchaser located in the other Party&#8217;s territory or prospective purchasers whose delivery address is located in the other Party&#8217;s territory. To the extent permitted by Applicable Laws, including applicable antitrust laws, if a Party receives any order for Original ADC Licensed Products or Next Generation ADC Licensed Products from a prospective purchaser located in or with a nominated delivery address in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and shall not accept any such order or deliver or tender (or cause to be delivered or tendered) the for Original ADC Licensed Products or Next Generation ADC Licensed Products under such order.  If a Party should reasonably know that a customer or distributor is actively engaged itself or through a Third Party in the sale or distribution of the for Original ADC Licensed Products or Next Generation ADC Licensed Products in the other Party&#8217;s territory, then such Party shall (i) within &#91;***&#93; Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of gaining knowledge of such activities, notify the other Party regarding such activities and provide all information available to such Party that the other Party may reasonably request concerning such activities and (ii) use Commercially Reasonable Efforts (including cessation of sales or delivery to such customer) necessary to limit such sale or distribution in the other Party&#8217;s territory, unless otherwise agreed in writing by the Parties prior to such sale or delivery.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"> FINANCIAL TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1&#160;&#160;&#160;&#160;Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In partial consideration of Duality&#8217;s granting of the licenses and rights to Licensee hereunder, Licensee shall make a one-time, non-refundable, non-creditable payment to Duality of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;***&#93; days after receipt of an invoice issued by Duality to the Licensee on or after the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.2&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Invoicing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than &#91;***&#93; setting forth the amount of actual Duality Costs for the Planned Trials and Original ADC Added Trials (if any) incurred during such Calendar Quarter in the Territory which shall be reimbursed by Licensee pursuant to this Section 8.2, along with supporting documentation itemizing the breakdown of the costs and expenses that were incurred and are reimbursable hereunder.  Each invoice issued by Duality shall list Duality Costs &#91;***&#93; in the Territory actually incurred in U.S. Dollars (and if any item was originally in another currency, the exchange rate used for converting the original currency to U.S. Dollar in accordance with Section 9.3). &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Other Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At Licensee&#8217;s request, Duality shall perform any other Clinical Trial of an Original ADC Licensed Product (other than the Planned Trials or Original ADC Added Trials) or of an Next Generation ADC Licensed Product (other than the Next Generation Added Trials). The Parties shall discuss (through the JSC) Licensee&#8217;s funding &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3&#160;&#160;&#160;&#160;Development and Regulatory Milestone Payments of the Original ADC Licensed Product or Next Generation ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to the milestone events set forth in the tables below, promptly following the first achievement, whether by Duality or any of Duality&#8217;s Affiliates (when designated by Licensee) or by Licensee or any of Licensee&#8217;s Affiliates or Sublicensees, of the corresponding milestone event by the first Original ADC Licensed Product, or after the Next Generation Option Exercise, the Next Generation ADC Licensed Product, whichever first reaches the respective milestone event for the first time, up to &#91;***&#93; Indications only. Licensee or Duality, as the case may be, shall notify the other Party within &#91;***&#93; Days of such achievement, and Licensee shall pay to Duality the corresponding non-refundable, non-creditable milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee on or after the achievement of the applicable milestone event&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4&#160;&#160;&#160;&#160;Sales Milestone Payments of the Original ADC Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Licensee shall pay to Duality the additional one-time, non-refundable, non-creditable payments set forth in the table below within &#91;***&#93; days after receipt of an invoice issued by Duality to Licensee on or after the first achievement of each milestone event described below. &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93;&#160;days after the end of the Calendar Quarter in which any milestone event set forth above in this Section&#160;8.4 for which a milestone payment is payable is achieved, Licensee shall deliver a written notice to Duality of such achievement, and Licensee shall pay to Duality the corresponding milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee.  For clarity, each of the milestone payments set forth above in this Section&#160;8.4 shall be additive such that if multiple milestone events specified above are achieved </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the same Calendar Quarter, then the milestone payments for all such milestone events shall be payable by Licensee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.5&#160;&#160;&#160;&#160;Sales Milestone Payments of the Next Generation ADC Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. After Next Generation Option Exercise and the First Commercial Sale of the Next Generation ADC Licensed Product, Licensee shall pay to Duality the additional one-time, non-refundable, non-creditable payments set forth in the table below within &#91;***&#93; days after receipt of an invoice issued by Duality to Licensee on or after the first achievement of each sales milestone event described below. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;***&#93;&#160;days after the end of the Calendar Quarter in which any milestone event set forth above in this Section&#160;8.5 for which a milestone payment is payable is achieved, Licensee shall deliver a written notice to Duality of such achievement, and Licensee shall pay to Duality the corresponding milestone payment within &#91;***&#93; days after the receipt of an invoice issued by Duality to Licensee.  For clarity, each of the milestone payments set forth above in this Section&#160;8.5 shall be additive such that if multiple milestone events specified above are achieved in the same Calendar Quarter, then the milestone payments for all such milestone events shall be payable by Licensee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6&#160;&#160;&#160;&#160;Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Licensee shall pay tiered royalties to Duality on Annual Net Sales of&#58; </font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) all Original ADC Licensed Products in the Territory &#91;***&#93; in each Calendar Quarter as set forth below in table 1 in this Section 8.6, calculated by &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) all Next Generation ADC Licensed Products in the Territory &#91;***&#93; in each Calendar Quarter as set forth below in table 2 in this Section 8.6, calculated by &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:28.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) any &#91;***&#93; and&#47;or &#91;***&#93; at the Reduced Royalty Rates for each respective Annual Net Sales threshold as set forth in tables 3 and 4 in this Section 8.6 respectively, calculated by &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table 1</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table 2</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table 3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Table 4</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.7&#160;&#160;&#160;&#160;Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   Royalties under Section&#160;8.6 shall be payable, on &#91;***&#93; basis, during the period beginning on the date of &#91;***&#93; and continuing until the latest of&#58; &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.8&#160;&#160;&#160;&#160;Royalty Payment Reduction of Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.73pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PAYMENT&#59; RECORDS&#59; AUDITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1&#160;&#160;&#160;&#160;Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Royalties shall be calculated and reported for each Calendar Quarter within &#91;***&#93;&#160;days after the end of each Calendar Quarter. Each payment shall be accompanied by a report of &#91;***&#93;. Except as may otherwise be expressly provided herein, Licensee shall not have the right to set off, withhold or make any deduction from any payment of royalties or other payments due to Duality hereunder for any reason whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.2&#160;&#160;&#160;&#160;Invoices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality will ensure that all invoices&#58; </font></div><div style="margin-bottom:12pt;padding-left:28.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;are delivered in accordance with the procedures set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:28.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;are in such form as Licensee reasonably requires&#59; and</font></div><div style="margin-bottom:12pt;padding-left:28.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;incorporate all information required by Licensee, as set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.3&#160;&#160;&#160;&#160;Exchange Rate&#59; Manner and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All payments hereunder shall be payable in U.S. dollars within &#91;***&#93; days after receipt of an invoice from Duality. With respect to sales of Licensed Products invoiced in a currency other than U.S. dollars, sales milestones and royalties shall be converted into U.S. dollar using the exchange rate mechanism generally applied by Licensee or its Affiliates or Sublicensees for consolidation purposes, in accordance with the Accounting Standards, for the Calendar Quarter for which a payment is due.  All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Duality, unless otherwise specified in writing by Duality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.4&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Taxes on Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Section&#160;9.4, Licensee shall be solely responsible for the payment of all value added taxes, fees, duties, surcharges, and other deductions or withholding taxes imposed by or on any entity in the Territory in connection with the payments and activities contemplated hereunder. Except as otherwise set forth in this Section, each Party shall be solely responsible for the payment of all taxes imposed on such Party&#8217;s income arising directly or indirectly from the activities of the Parties under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any withholding tax, fee, duty or surcharge  applicable to or assessable in respect of any of the Upfront Payment, development, regulatory or sales milestone payments, or royalty payments to be made by Licensee to Duality under this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is required to be withheld and deducted under Applicable Laws (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Licensee (or its Affiliate paying on behalf of Licensee) shall make such deduction and withholding and will pay the remaining License Payments to Duality. For clarity, Licensee&#8217;s reimbursement of Duality Costs in the Territory shall not be deemed to be License Payments or subject to any Tax Withholdings. If Licensee did not conduct the Tax Withholding when making its payment(s) to Duality, but is later determined by Applicable Law to pay an amount of tax on account of Duality to the tax authorities, Duality will promptly refund that amount of Tax Withholdings to Licensee, provided that Duality shall not be liable for any interest or other penalty on such payments.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Tax Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall make such deduction of taxes and withholding tax payments to the applicable taxing authority(ies) in a timely manner and shall promptly provide Duality with the appropriate proof of payment and relevant receipt(s) with respect to such deduction or withholding. To the extent permitted by Applicable Laws, Licensee shall provide Duality reasonable assistance in order to allow Duality to obtain the benefit of any present or future treaty against double taxation or refund or reduction in taxes which may apply to the License Payments. Each Party agrees to use commercially reasonable efforts to cooperate with the other Party in claiming refunds, reductions, or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in effect. Duality will provide Licensee with any tax forms or other documentation reasonably necessary in order for Licensee not to withhold or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  If the taxes originally paid or otherwise borne by a Party are in whole or in part subsequently determined not to have been chargeable, all reasonably necessary steps will be taken by each Party to obtain a refund of these undue taxes from the applicable Governmental Authority or other fiscal authority and any amount of undue taxes repaid by such authority to the receiving Party will be transferred to the paying Party within &#91;***&#93; days of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.5&#160;&#160;&#160;&#160;Blocked Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that, by reason of Applicable Law in any country or region, it becomes impossible or illegal, after reasonable efforts by Licensee to do so, for Licensee or its Affiliate to transfer, or have transferred on its behalf, payments owed Duality hereunder, Licensee shall promptly notify Duality of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country or region to the credit of Duality in a recognized banking institution designated by Duality provided such arrangements are legal under all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.6&#160;&#160;&#160;&#160;Records&#59; Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall keep, and require its Affiliates and Sublicensees to keep, complete, fair and true books of accounts and records for the purpose of determining the amounts payable to Duality pursuant to this Agreement. Such books and records shall be kept for at least &#91;***&#93; Years following the end of the Calendar Year to which they pertain.  Duality shall have the right to cause an independent, certified public accountant reasonably acceptable to Licensee to audit such records to confirm Net Sales, royalties and other payments for a period covering not more than the preceding &#91;***&#93; Years&#59; provided that (a) such audit shall not be more frequent than once in any &#91;***&#93; month period, and (b) once such accountant has conducted a review and audit of any records pursuant to this Section 9.6 in respect of any given period, it may not subsequently re-inspect such records with respect to such period, unless, in each case of (a) and (b), for cause. Prior to engagement by an independent, certified public accountant, such accountant must have executed and delivered to Licensee and its Affiliates a confidentiality agreement as reasonably requested by Licensee, which will include provisions limiting such accountant&#8217;s disclosure to Duality to only the results and basis for such results of such inspection. Such audits may be exercised during normal business hours upon reasonable prior written notice to Licensee. Prompt adjustments shall be made by the Parties to reflect the results of such audit. Duality shall bear the full cost of such audit unless such audit discloses an underpayment by Licensee of more than &#91;***&#93; of the amount of royalties or other payments due under this Agreement for any applicable Calendar Quarter, in which case, Licensee shall bear the cost of such audit and shall promptly remit to Duality the amount of any underpayment. Any overpayment by Licensee revealed by an audit shall be fully-creditable against future payment owed by Licensee to Duality (and if no further payments are due, shall be refunded by Duality at the request of Licensee). Any underpayment by Licensee identified by an audit shall not be subject to Section  9.7. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.7&#160;&#160;&#160;&#160;Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that either Party fails to make any payment due under this Agreement (save as set out in Section 9.6), simple interest shall thereafter accrue on the sum due from the due date until the date of payment at &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.23pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1&#160;&#160;&#160;&#160;Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) agrees that, during the Term and for &#91;***&#93; years thereafter, it shall keep confidential and shall not publish or otherwise disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement or any other written agreement between the Parties, any Confidential Information, including any Know-How, furnished or made available to it by or on behalf of the other Party (in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to ensure that its, and its Affiliates&#8217;, employees, agents, contractors, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information.  The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party&#8217;s Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2&#160;&#160;&#160;&#160;Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Confidential Information shall not include any information which the Receiving Party can prove by competent evidence&#58; (a)&#160;is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available to the public or part of the public domain&#59; (b)&#160;is known by the Receiving Party and&#47;or any of its Affiliates at the time of receiving such information, as evidenced by its records&#59; (c)&#160;is hereafter furnished to the Receiving Party and&#47;or any of its Affiliates by a Third Party, as a matter of right and without restriction on disclosure&#59; or (d)&#160;is independently discovered or developed by the Receiving Party and&#47;or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3&#160;&#160;&#160;&#160;Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the provisions of Section&#160;10.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">filing or prosecuting or defending Patents as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">disclosure required in connection with any judicial, regulatory or administrative process relating to or arising from this Agreement (including any enforcement hereof) or to comply with applicable court orders&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">disclosure to Affiliates, employees, contractors, consultants or agents of the Receiving Party who have a need to know such information in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement&#59; provided, in each case, that any such Affiliate, actual or potential licensee or Sublicensee, employee, contractor, consultant or agent agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth in this Article&#160;10&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">such disclosure is made to such Party&#8217;s attorneys, independent accountants or financial advisors for the sole purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the Receiving Party, on the condition that such attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations consistent with the confidentiality provisions of this Agreement as they apply to the Receiving Party (provided, however, that in the case of financial advisers, including investment bankers, the term of confidentiality may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shortened to &#91;***&#93; years from the date of disclosure and in the case of attorneys, no written agreement shall be required)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">disclosure to existing investors, acquirors or collaborators or potential bona fide investors, acquirors, licensees, Sublicensees or collaborators in connection with due diligence or similar investigations by such Third Parties&#59; provided, in each case, that any such existing or potential investor, acquiror, licensees, Sublicensees or collaborator agrees to be bound by confidentiality and non-use obligations consistent with those contained in this Agreement as they apply to the Receiving Party (but of duration customary in confidentiality agreements entered into for similar purpose)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">disclosure to Regulatory Authorities as required by Applicable Laws in relation to Regulatory Approvals and regulatory procedures, proceedings and other filings&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">disclosure to&#58; (i) Governmental Authorities to the extent useful or necessary to make regulatory filings and obtain or maintain Regulatory Approvals (including fulfilling post-approval regulatory obligations) for any Licensed Product&#59; (ii) Governmental Authorities, technical committees or similar public health or scientific bodies for purposes of securing product use recommendations, tenders, direct procurement contracts or responding to relevant requests for information&#59; (iii) comply with Applicable Laws with respect to performance under this Agreement&#59; and (iv) to Governmental Authorities in order to respond to inquiries, requests or investigations relating to Licensed Products or this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">to the extent mutually agreed to by the Parties in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160;10.3(a) or Section&#160;10.3(b), it will, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to secure and cooperate with the other Party, as necessary, to seek and obtain confidential treatment of such Confidential Information required to be disclosed to the extent legally permissible and will limit the disclosure of that Confidential Information required to be disclosure to (i) to advisors (including lawyers and accountants) or Governmental Authorities on a need to know basis, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement, or (ii) to the extent agreed to by the Parties.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.4&#160;&#160;&#160;&#160;Pubic Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Press Releases and Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">As soon as practicable following the Effective Date and on a date mutually agreed by the Parties, Duality shall issue a press release announcing the execution of this Agreement in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as required by applicable securities laws (including disclosure requirements of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any stock exchange on which securities issued by a Party or its Affiliates are traded), neither Party shall make any other public announcement or statement, whether oral or written, concerning this Agreement or the subject matter hereof without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed&#59; provided that each Party may make any public statement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, or issue press releases, so long as any such public statement or press release is not inconsistent with prior public disclosures or public statements approved by the other Party pursuant to this Section&#160;10.4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and which do not reveal non-public information about the other Party.  In the event of a required public announcement, to the extent practicable under the circumstances, the Party making such announcement shall provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such other Party a reasonable opportunity to review and comment upon the proposed text. Licensee shall have final decision making authority in respect of the proposed text of any required public announcement relating to the Licensed Product in the Territory and Retained Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">In the event of termination of this Agreement for any reason, if in the reasonable opinion of the either Party&#8217;s legal counsel, public disclosure of such termination is required under the Applicable Law or the rules of a stock exchange on which the securities of either Party (or any controlling Affiliate of such Party) are listed (or to which an application for listing has been submitted), the Parties shall cooperate in good faith to coordinate public disclosure, if any, of such termination and the reasons therefor. The principles to be observed in such disclosures shall be accuracy, compliance with Applicable Law, the rules of the applicable stock exchange and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news and neither Party shall make any other public announcement or statement, whether oral or written, concerning the termination of this Agreement without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Notwithstanding anything to the contrary in this Section&#160;10.4, and subject to Section 10.5, the Parties have the right to publicly disclose (A) the achievement of milestones under this Agreement&#59; and (B) the commencement, completion, material data and key results of Clinical Trials conducted under this Agreement. After a publication has been made available to the public, each Party may post such publication or a link to it on its corporate web site without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Filing of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or any stock exchange or governmental agency on which securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted&#59; provided that each Party will ultimately retain control over what information to disclose to the SEC or any stock exchange or other governmental agency, as the case may be, and provided further that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with any other governing bodies. Other than such obligation, neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC or any stock exchange or other governmental agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.5&#160;&#160;&#160;&#160;Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">If either Party proposes to publicly present or publish, in any publication or venue, in their respective Territories, any Clinical Trial data, non-clinical data or any associated results or conclusions generated by or on behalf of Licensee pursuant to Clinical Trials (each such proposed presentation or publication, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Proposed Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), it shall obtain the other Party&#8217;s prior written consent and otherwise comply with this Section&#160;10.5. The proposing Party shall provide the other Party with a copy of such Proposed Publication at least &#91;***&#93; days prior to the earlier of its presentation or intended submission for publication&#59; provided that in the case of abstracts, this period shall be at least &#91;***&#93; Days (such applicable period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The proposing Party agrees that it will not submit or present any Proposed Publication (i) until the other Party has provided written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">comments during such Review Period on the material in such Proposed Publication or (ii)&#160;until the applicable Review Period (as may be extended by subsection (C) below) has elapsed without written comments from the other Party, in which case the proposing Party may proceed and the Proposed Publication will be considered approved in its entirety. If the proposing Party receives written comments from the other Party during the applicable Review Period, it shall consider the comments of the other Party in good faith, but will retain the sole authority to submit the manuscript for such Proposed Publication&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided that&#160;the proposing Party agrees to (A) delete any Confidential Information of the other Party that the other Party identifies for deletion in the other Party&#8217;s written comments, (B) delete any Clinical Trial data, non-clinical data, results, conclusions or other related information that is not specific to or resulting from any Clinical Trial conducted in the proposing Party&#8217;s territory, and (C) delay such Proposed Publication for a period of up to an additional &#91;***&#93; days after the end of the applicable Review Period to enable the other Party to draft and file patents with respect to any subject matter to be made public in such Proposed Publication and to which the other Party has the applicable intellectual property rights to file such patents.  The proposing Party shall provide the other Party a copy of the Proposed Publication at the time of the submission or presentation.  The proposing Party shall require its Affiliates, (sub)licensees (in case that Duality is the proposing Party), Sublicensees (in case that Licensee is the proposing Party) and contractors to comply with the obligations of this Section&#160;10.5 as if they were the proposing Party, and shall be liable for their non-compliance. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.6&#160;&#160;&#160;&#160;Publication and Listing of Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party&#59; provided that any listings or publications made pursuant to this Section&#160;10.6 shall be considered a publication hereunder and shall be subject to Section&#160;10.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.7&#160;&#160;&#160;&#160;Prior Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date, the terms of this Article&#160;10 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) to the extent dealing with the subject of this Agreement.  Any information disclosed pursuant to any such prior agreement relating to the subject to this Agreement shall be deemed Confidential Information for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.8&#160;&#160;&#160;&#160;Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Given the nature of the Confidential Information and the competitive damage that would result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages would not be a sufficient remedy for any breach of this Article&#160;10. In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article&#160;10.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">REPRESENTATIONS AND WARRANTIES&#59; LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not (i) conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, (ii) conflict with or result in a breach of any provision of its organizational documents, or (iii) violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it&#59; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">each Party shall conduct, and shall cause its Affiliates and Sublicensees (in the case of Licensee) and sublicensees (in the case of Duality) to conduct all activities under this Agreement in compliance with all Applicable Laws, all applicable national and international guidelines and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2&#160;&#160;&#160;&#160;Additional Duality Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.1&#160;&#160;&#160;&#160;Duality represents and warrants to Licensee, as of the Effective Date and&#47;or such any other date(s) expressly stated, subject to a Disclosure Schedule (attached here to as Schedule 11.2) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as may be  updated as further described in Section 11.8 below as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.2&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.3&#160;&#160;&#160;&#160;&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3&#160;&#160;&#160;&#160;Additional Licensee Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee represents and warrants to Duality, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4&#160;&#160;&#160;&#160;Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In addition to any covenants made by the Parties elsewhere in this Agreement, each Party hereby covenants to the other that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">(i) all patient authorizations and consents required under Applicable Laws (in connection with any applicable clinical study) permit the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6, and (ii) it will comply with Applicable Laws in transferring personal and other Data in connection with the granting of access of Data that such Party is required to provide to the other Party pursuant to Section 5.6.  Each Party will obtain all the necessary authorizations, consents and approvals in order for such Party to grant access to its Data with the other Party, including obtaining the necessary patient authorizations and consents, and obtaining the necessary approvals from and completing all necessary filing procedures with the applicable Governmental Authorities in the Territory and within the Retained Territory (to the extent required to preserve Licensee&#8217;s position in the Territory)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it will not knowingly, during the Term, employ or use the services of any person who is debarred or disqualified in connection with activities relating to the Licensed Compound or Licensed Products&#59; and in the event that it becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services to it with respect to any activities relating to the Licensed Compound or Licensed Products, it will immediately notify the other Party in writing and it will cease employing, contracting with, or retaining any such person to perform any services relating to the Licensed Compound or Licensed Products&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it shall conduct, and shall cause its Affiliates, subcontractors, Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) to conduct all activities under this Agreement (including, as set forth in the Development Plan(s) and Commercialization Plan(s) (as may apply) with respect to the Licensed Products in the Field in the Territory) in compliance with all Applicable Laws, and any Regulatory Authority and Governmental Authority health care programs having jurisdiction, each as may be amended from time to time&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it shall conduct its obligations with respect to Development of the Licensed Products in the Territory in adherence with the Development Plan (including the Development Budget) as may be amended from time to time&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">it shall comply, and ensure that shall use commercially reasonable efforts to cause its Affiliates, subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality) to comply with and commit to uphold the ABC Terms in the performance of activities under this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">it shall have (and shall ensure its Affiliates, Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) and subcontractors as applicable, have), at all times, a reasonably sufficient number of suitably qualified personnel to allow the Party (or its Affiliates or Sublicensees (in the case of Licensee) or sublicensees (in the case of Duality) or subcontractors, as applicable) to conduct, in compliance with all Development timeframes set out in the applicable Development Plans and GXPs, any Clinical Trials that the Party is required to conduct with respect to the Licensed Products in its territory, or in the other Party&#8217;s territory as permitted under this Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">it shall not induce or solicit, or attempt to induce or solicit, any employees of the other Party or any of its Affiliates to leave the employment of, or to terminate his&#47;her employment, services or engagement with, the other Party or its applicable Affiliate, or enter into any employment or services agreement or arrangement with such Party or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.5&#160;&#160;&#160;&#160;Duality Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to any covenants made by Duality elsewhere in this Agreement, Duality hereby covenants to Licensee as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.6&#160;&#160;&#160;&#160;Performance by Affiliates, Sublicensees and Subcontractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (a) Subject to Licensee&#8217;s prior written consent or if explicitly stated in the respective Development Plan or this Agreement, Duality may perform some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or sublicensees, and (b) Licensee may perform some or all of its respective obligations under this Agreement through one or more Affiliates, subcontractors or Sublicensees&#59; provided that with respect to the foregoing clauses (a) and (b), the Party involving its Affiliates, subcontractors or Sublicensees (in case of Licensee) or sublicensees (in case of Duality) shall at all times be fully responsible for the performance and payment of such Affiliate, subcontractor or Sublicensees (in case of Licensee) or sublicensees (in case of Duality). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.7&#160;&#160;&#160;&#160;Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY DUALITY TO LICENSEE HEREUNDER ARE PROVIDED &#8220;AS IS,&#8221; AND DUALITY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OBTAINING SUCCESSFUL RESULTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.8&#160;&#160;&#160;&#160;Updated Disclosure Schedule</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">With respect to the Next Generation Licensed Compound, Next Generation ADC Licensed Product and the Duality Immune Agonist ADC Product that are subject to an option right, and subject to the occurrence of any change or event having a material adverse effect on it or which it believes would or would be reasonably likely to cause or constitute a material breach of any of its representations, warranties or covenants set forth herein, Duality shall be entitled to update the Disclosure Schedule (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Updated Disclosure Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with this Section 11.8. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">The right to update the Disclosure Schedule shall be limited to the respective option exercise period as set forth in Section 2.8 and 2.9 respectively and ends &#91;***&#93; Days before the option exercise period ends. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Notwithstanding anything in this Agreement to the contrary, no update to the Disclosure Schedule pursuant to this Section 11.8 shall cure any breach of a representation or warranty of Duality contained in this Agreement with respect to the Original ADC Licensed Product and shall not affect any of the Licensee&#8217;s remedies with respect thereto.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.1&#160;&#160;&#160;&#160;Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (i) Duality shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled by Duality or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) Licensee shall retain all right, title and interest in and to any Patents, Know-How, and other intellectual property rights Controlled (other than pursuant to this Agreement) by Licensee or any of its Affiliates on or prior to the Effective Date or during the Term independent of the activities hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Solely Owned Collaboration IP and Solely Owned Collaboration Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Data and Regulatory Materials.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding anything contrary in this Section 12.1, the ownership rights to Regulatory Materials are allocated in accordance with Sections 5.2(b) and 5.4. The ownership rights to Data are allocated in accordance with Section 5.6.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.69pt">Disclosures&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall, and shall ensure that each of its Affiliates, (sub)licensees (in the case of Duality), Sublicensees (in the case of Licensee) and subcontractors under this Agreement has a contractual obligation to disclose to such Party all Collaboration IP, Data and other Know-How generated, invented, discovered, developed, made or otherwise created by or for them or their employees, agents or independent contractors, and to provide sufficient documentary proof to evidence ownership, rights and interest with respect thereto, so that such Party can comply with its obligations under this Section&#160;12.1.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:33.69pt">Inventorship Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.2&#160;&#160;&#160;&#160;Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Section&#160;12.2 and Sections 12.1(e), the terms &#8220;prosecute,&#8221; &#8220;prosecuting&#8221; and &#8220;prosecution,&#8221; when used in reference to any Patent, shall be deemed to include, without limitation, control of &#91;***&#93; with respect to such Patent.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.3&#160;&#160;&#160;&#160;Infringement by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that either Duality or Licensee becomes aware of any infringement or threatened infringement by a Third Party of any Solely Owned Collaboration Patent, Duality Product Patent, Duality Linker-Payload Patent, &#91;***&#93; and any related declaratory judgment or equivalent action, including administrative proceedings, alleging the invalidity, unenforceability or non-infringement of any such Patent, it shall notify the other Party in writing to that effect within &#91;***&#93; Days after becoming aware of such matter.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.4&#160;&#160;&#160;&#160;Infringement of Third Party Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.5&#160;&#160;&#160;&#160;Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.6&#160;&#160;&#160;&#160;Patent Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Licensed Product-by-Licensed Product basis, as between the Parties, &#91;***&#93; to make all patent listings of Duality Product Patents, Solely Owned Collaboration Patents, &#91;***&#93; or other patent-related submissions with Regulatory Authorities with respect to such Licensed Product, except for Duality Linker-Payload Patents &#91;***&#93;, &#91;***&#93; to make all patent listings </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; will be obliged to make all patent listings or other patent-related submissions with Regulatory Authorities in &#91;***&#93;.&#160;&#91;***&#93; reasonable requests in connection therewith, including meeting any submission deadlines, to the extent required or permitted by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.7&#160;&#160;&#160;&#160;Patent Right Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#160; &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TERM&#59; TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.1&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall commence on the Effective Date, and unless terminated earlier as provided in this Article&#160;13, shall continue in full force and effect, on a &#91;***&#93; except as provided otherwise in this Article 13.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.3&#160;&#160;&#160;&#160;Termination for Material Breach by Either Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Termination Right. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A Party shall have the right to terminate this Agreement (in its entirety or on a Licensed Product-by-Licensed Product and country-by-country basis) upon written notice to the other Party if such other Party is in material breach of this Agreement and has not cured such breach within &#91;***&#93;&#160;days after written notice from the terminating Party requesting cure of the breach. In case the alleged material breach is a material breach of Licensee&#8217;s diligence obligations set forth in Sections 4.1 and&#47;or 7.1 of this Agreement, Duality shall only be entitled to terminate the Agreement with effect to the country or countries with respect to which Licensee has in fact materially breached the diligence obligations with respect to the Original ADC Licensed Product and not cured such breach. If at the end of the cure period the breaching Party has failed to perform the activities of the cure plan to cure the breach, the non-breaching Party shall be entitled to terminate the Agreement with &#91;***&#93; prior notice. If the existence of material breach or the failure to cure such material breach is not disputed by the breaching Party and the Agreement is terminated by the non-breaching Party, the consequences of termination set forth in Section 13.7 or Section 13.8  (as the case may be) shall apply. If the existence of material breach or the failure to cure such material breach is disputed by the breaching Party, Section 13.7 or Section 13.8 (as the case may be) shall apply if the existence of material breach or the failure to cure such material breach is determined pursuant to Section 15.2 and the Agreement is thereafter terminated by the breaching Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Dispute as to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that the breaching Party disputes the existence of material breach or the failure to cure such material breach by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">initiating arbitration proceedings pursuant to Section 15.2 within the cure period, the non-breaching Party shall not have the right to terminate in accordance with Section 13.3(a) unless and until the relevant dispute has been resolved pursuant to Section 15.2. During the pendency of such dispute, the applicable cure period shall be tolled, all the terms of this Agreement shall remain in effect, and the Parties shall continue to perform all of their respective obligations hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.4&#160;&#160;&#160;&#160;Termination for Other Causes. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Party shall have the right to terminate this Agreement upon written notice to the other Party upon the filing or institution of bankruptcy, reorganization, dissolution, liquidation or winding up of such other Party, or the making or seeking to make or arrange an assignment of a substantial portion of such other Party&#8217;s assets for the benefit of creditors of such other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy against such other Party, or is adjudged bankrupt, or the appointment of a receiver or trustee of such other Party&#8217;s property, in each case that is not discharged within &#91;***&#93; days, or immediately upon written notice to the Party, if such Party otherwise admits in writing to the other Party its inability generally to meet its obligations as and when they fall due in the general course of business. In the event a Party is bankrupted or a bankruptcy proceedings is commenced by or against such Party or its Affiliates or any country or jurisdiction, all rights under this Agreement will be fully exercisable and the bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a trustee) shall continue to perform all of the obligations provided in this Agreement to be performed by such Party. If the bankrupt Party and its successors and assigns are restricted by Applicable Laws from performing its obligations hereunder and the other Party elects to retain its rights hereunder, then the bankrupt Party shall provide to the other Party copies of all information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly upon such other Party&#8217;s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:30.8pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Mutual Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties may terminate this Agreement in full or on a Licensed Product-by-Licensed Product or a country-by-country basis, at any time during the Term upon mutual agreement in writing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.5&#160;&#160;&#160;&#160;General Effects of Expiration or Termination.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Accrued Rights and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Neither expiration nor any termination of this Agreement for whatsoever reason shall relieve either Party of any obligation or liability (including but not limited to any payment obligation under Article 8) accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement for whatsoever reason preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement.  Such obligations and rights shall survive termination and expiration of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.12pt">Termination of Non-Expired Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of termination of the entire Agreement, all non-expired option periods under the Agreement shall automatically </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terminate. Upon termination of one or more Licensed Products, the option period shall only terminate with respect to the terminated Licensed Product(s). </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:30.8pt">Surviving Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties&#8217; rights and obligations under Article 1 (Definitions), Article 8 (Financial Terms, unless otherwise set out in this Article 13, the Financial Terms only survive with respect to Licensee&#8217;s sell-off right in Sections 13.6(e), 13.7(b)(iv) and 13.8(b)(iii))&#59; Article 9 (Payment)&#59; Article 10 (Confidentiality), Section 12.1 and  with respect to &#91;***&#93; only Sections 12.2 and 12.4&#59; Sections 13.5 to 13.10&#59; Article 14 (Indemnification) other than Section 14.4 (Insurance)&#59; Article 15 (Dispute Resolution)&#59; Article 16 (Miscellaneous) of this Agreement shall survive expiration or any termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Licenses Granted to Licensee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon termination of the entire Agreement, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Licenses Granted to Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In case of termination of the entire Agreement, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.03pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.03pt">Wind-Down or Transfer of Activities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Licensee shall, as directed by Duality in its sole discretion, on a Clinical Trial-by-Clinical Trial basis, either&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Sublicenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality shall grant to Licensee&#8217;s or Licensee&#8217;s Affiliate&#8217;s Sublicensees a direct license&#59; provided that (A) such sublicense agreement is consistent with the relevant terms and conditions of this Agreement at the time of termination of this Agreement, (B) such Sublicensee then is not in material breach of its sublicense agreement and (C) such Sublicensee then has not caused Licensee to be in material </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of this Agreement due to any act or omission of such Sublicensee.  The scope of such direct license shall be no less than the scope of the license granted in this Agreement and sublicensed to such Sublicensee and such direct license shall be on terms and conditions substantially similar to those set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.8&#160;&#160;&#160;&#160;Consequences of Termination by Licensee for Material Breach or Patent Challenge by Duality. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If an arbitration tribunal in accordance with the process set out in Section 15.2 confirmed (A) the existence of a material breach on the part of Duality, and such material breach was not or cannot be cured, or  (B) in case of &#91;***&#93;, with the Licensee&#8217;s Executive Officer having the final say, the following shall apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Licensee&#8217;s Election to Terminate. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensee may terminate the Agreement in its entirety, on a country-by-country basis or on a Licensed Product-by-Licensed Product basis. In this case, the following would apply&#58;</font></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.1&#160;&#160;&#160;&#160;Indemnification of Duality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Licensee shall indemnify and hold harmless each of Duality and its Affiliates and their respective directors, officers, employees, consultants, agents and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), incurred by any Duality Indemnitee as a result of any claims, demands, actions, suits or proceedings brought by a Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) arising directly or indirectly out of&#58; (a)&#160;the practice by Licensee or its Affiliates or Sublicensees or subcontractors of the licenses granted to Licensee under this Agreement&#59; (b)&#160;the research, Development, Manufacture or have Manufactured, use, handling, storage, Commercialization or other disposition of the Licensed Compound or the Licensed Products by Licensee or its Affiliates or Sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Licensee Indemnitee&#59; or  (d)&#160;any breach of any representations, warranties or covenants by Licensee under this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Duality set forth in Section&#160;14.2, or (y) arising from or occurring as a result of a Duality Indemnitee&#8217;s negligence, illegal conduct or willful misconduct in performing its or their obligations or exercising their rights under this Agreement. Licensee&#8217;s indemnification obligation specifically excludes any and all Third Party Claims for the use of any Patents, Know-How or other intellectual property rights under any Third Party agreements entered into by Duality prior to the Effective Date, including but not limited to the payment of royalties thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.2&#160;&#160;&#160;&#160;Indemnification of Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Duality shall indemnify and hold harmless each of Licensee and its Affiliates and their respective directors, officers, employees, consultants, agents and successors and assigns of any of the foregoing (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensee Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), from and against any and all Losses incurred by any Licensee Indemnitee as a result of any Third Party Claims arising directly or indirectly out of&#58; (a)&#160;the practice by Duality or its Affiliates or sublicensees or subcontractors of the license granted to Duality under Section&#160;2.5&#59; (b)&#160;the research, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development, Manufacture or have Manufactured, use, handling, storage, Commercialization or other disposition of the Licensed Compound or Licensed Products by Duality or its Affiliates or sublicensees or subcontractors&#59; (c)&#160;the negligence or willful misconduct of any Duality Indemnitee&#59; or (d)&#160;any breach of any representations, warranties or covenants by Duality under this Agreement&#59; except, in each case, (x) to the extent such Third Party Claims fall within the scope of the indemnification obligations of Licensee set forth in Section&#160;14.1, or (y) arising from or occurring as a result of a Licensee Indemnitee&#8217;s negligence, illegal conduct or willful misconduct in performing its or their obligations or exercising their rights under this Agreement. In addition to the above, and not subject to (x), regardless of any information provided by Duality to Licensee regarding Third Party Agreements entered into prior to the Effective Date, Duality&#8217;s indemnification obligation shall cover any and all Third Party Claims for the use  of any Patents, Know-How or other intellectual property rights under any Third Party Agreements entered into by Duality prior to the Effective Date, including but not limited to the payment of royalties thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.3&#160;&#160;&#160;&#160;Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any Duality Indemnitee or Licensee Indemnitee intends to claim indemnification under this Article&#160;14 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Duality or Licensee, as the case may be, shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification. Each indemnification claim notice must contain a description of the claim, the nature and amount of such loss (to the extent known at the time). The Indemnitor shall have sole control of the defense and&#47;or settlement thereof and the Indemnitee shall be entitled to participate in (but not control) the defense of such Third Party Claim and to employ counsel of its choice for this purpose, at its own expense. The indemnity arrangement in this Article&#160;14 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld, conditioned or delayed unreasonably.  The failure to deliver written notice to the Indemnitee within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this Article&#160;14 if and to the extent the Indemnitee is actually prejudiced thereby.  Duality or Licensee, as the case may be, and the Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by these indemnification provisions.  The Indemnitor shall not settle any Third Party Claim without the prior written consent of the Indemnitee if the settlement is reasonably expected to&#58; (a) result in or impose any obligation (including any payment obligation) on the Indemnitee or otherwise adversely affect the business of the Indemnitee in any manner, or (b) result in any admission of wrong-doing or fault by the Indemnitee.  The costs and expenses, including fees and disbursements of counsel, incurred by the Indemnitee in connection with any claim shall be reimbursed by the Indemnitor on a Calendar Quarter basis, without prejudice to the Indemnitor&#8217;s right to contest the Indemnitee&#8217;s right to indemnification and subject to refund in the event the Indemnitee is ultimately held not to be obligated to indemnify the Indemnitee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.4&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. Such insurance shall not be construed to create a limit on either Party&#8217;s liability with respect to its indemnification obligations under this Article 14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.1&#160;&#160;&#160;&#160;Deadlock Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event a deadlock occurs with respect to the decision-making process of the JSC, such deadlock shall be subject to binding determination by an expert panel in the Hong Kong Special Administrative Region. The expert panel shall consist of &#91;***&#93; members, &#91;***&#93; of which &#91;***&#93; appointed by each Party and the &#91;***&#93; member shall be selected by the other &#91;***&#93; members (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Experts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The panel must be appointed within &#91;***&#93; days of the occurrence of a deadlock event or such longer period as the Parties may agree. Each Expert shall be a person having not less than &#91;***&#93; years&#8217; experience in the area of expertise in the business of pharmaceuticals (including biologics) and having no conflict of interest with either Party. If the issues in dispute involve scientific, technical or commercial matters, the Experts chosen hereunder shall have educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  With respect to any dispute to be submitted to an Expert pursuant to this Agreement, the use of the Expert shall be the exclusive remedy of the Parties, and neither Party shall attempt to adjudicate such dispute in any other forum. The decision of the Experts shall be final and binding on the applicable Parties involved in such dispute and deadlock resolution procedure contemplated by this Section 15.1 and shall not be capable of challenge, whether by arbitration, in court or otherwise. All proceedings and communications shall be in English.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.2&#160;&#160;&#160;&#160;Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Sections&#160; 15.4 and 15.5, upon the written request of either Party to the other Party, any differences, claim, dispute, or controversy as to the breach, enforcement, interpretation or validity of this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be referred to the Executive Officers for resolution.  In the event such executives are unable to resolve such Dispute within &#91;***&#93;&#160;days after the initial written request, then, upon the written demand of either Party and subject to Section 15.4 below, the Dispute shall be referred to and finally resolved by binding arbitration administered by the Hong Kong International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HKIAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (or any successor entity thereto) pursuant to the United Nations Commission on International Trade Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UNCITRAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Arbitration Rules in force when the notice of arbitration is submitted, as modified by the HKIAC Procedures for the Administration of Arbitration under the UNCITRAL Arbitration Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as modified by Section&#160;15.3 below.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.3 Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The arbitration shall be conducted by a panel of three arbitrators experienced in the business of pharmaceuticals (including biologicals). If the issues in dispute involve scientific, technical or commercial matters, the arbitrators chosen hereunder shall engage experts having educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  Within &#91;***&#93; days after initiation of arbitration, each of the Parties shall select one arbitrator and these two arbitrators shall jointly select a third arbitrator. If a Party fails to select an arbitrator or if the two arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within such &#91;***&#93; day period, any unselected arbitrator or third arbitrator, as the case may be, shall be appointed in accordance with the Rules. The place of arbitration and the seat of arbitration shall be Hong Kong Special Administrative Region, and all proceedings and communications shall be in English. Unless agreed by the Parties in writing, all documents provided under or in connection with this Agreement shall be in the English language or accompanied by a certified English translation. If such document is translated into any other language, the English language version shall prevail unless the document is a constitution, statutory or other official document. The laws governing this arbitration agreement shall be the laws of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hong Kong Special Administrative Region and the arbitral award shall be final and binding on the Parties. Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor the arbitrators may disclose the existence, content, or results of arbitration without the prior written consent of both Parties.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Arbitrators&#8217; Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The arbitrators shall, within &#91;***&#93; days after the conclusion of the arbitration hearing, issue a written award and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The decision or award rendered by the arbitrators shall be final and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall bear its own attorney&#8217;s fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fees and costs of the arbitrators&#59; provided, however, that the arbitrators shall be authorized to determine whether a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys&#8217; fees, costs and disbursements (including, for example, expert witness fees and expenses, photocopy charges, travel expenses, etc.), and&#47;or the fees and costs of the HKIAC and the arbitrators.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.02pt">Protective Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. At the request of either Party, the tribunal shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.5&#160;&#160;&#160;&#160;Interim Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Party shall be entitled to take action in any court with competent jurisdiction to apply for and be granted emergency or other interim relief and otherwise enforce by injunction, specific performance or other equitable relief, without prejudice to any other rights and remedies that it may have under this Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.6&#160;&#160;&#160;&#160;Continued Performance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Provided that this Agreement has not been terminated in its entirety, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.73pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.1&#160;&#160;&#160;&#160;Rights in Bankruptcy.    </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">The Parties intend to take advantage of the protections of Section 365(n) (or any successor provision) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction to the maximum extent permitted by Applicable Law.  All rights and licenses granted under or pursuant to this Agreement, but only to the extent they constitute licenses of a right to &#8220;intellectual property&#8221; as defined in Section 101 of the U.S. Bankruptcy Code or in any analogous provisions in any other country or jurisdiction (as the case may be) shall be deemed to be &#8220;intellectual property&#8221; for the purposes of Section 365(n) or any analogous provisions in any other country or jurisdiction (as the case may be).  The Parties shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, including the right to obtain the intellectual property from another entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.02pt">In the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not subject to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) all such intellectual property (including all embodiments of such intellectual property), which, if not already in the non-subject Party&#8217;s possession, shall be promptly delivered to it upon the non-subject Party&#8217;s written request (i) upon commencement of a bankruptcy proceeding, unless the Party subject to such proceeding continues to perform all of its obligations under this Agreement, or (ii) if not delivered pursuant to clause (i) above because the subject Party continues to perform, upon the rejection of this Agreement by or on behalf of the subject Party.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.7pt">Unless and until the subject Party rejects this Agreement, the subject Party shall perform this Agreement or provide the intellectual property (including all embodiments of such intellectual property) to the non-subject Party, and shall not interfere with the rights of the non-subject Party to such intellectual property, including the right to obtain the intellectual property from another entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.2&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and any disputes, claims, or actions related thereto shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law provisions thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.3&#160;&#160;&#160;&#160;Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, including the Schedules hereto, sets forth all of the agreements and understandings between the Parties with respect to the subject matter hereof and thereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof and thereof. There are no other agreements or understandings with respect to the subject matter hereof, either oral or written, between the Parties. Except as expressly set forth in this Agreement, no subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.4&#160;&#160;&#160;&#160;Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as any other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.5&#160;&#160;&#160;&#160;Relationship Between the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship or legal entity of any type between the Parties. Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. Neither Party shall treat or report the relationship arising under this Agreement as a partnership for United States tax purposes unless otherwise required pursuant to a determination within the meaning of Section 1313 of the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.6&#160;&#160;&#160;&#160;Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and of a particular scope, and shall be signed by such Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.7&#160;&#160;&#160;&#160;Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned by a Party without the prior written consent of the other Party (which shall not be unreasonably withheld, conditioned or delayed), except to (a) an Affiliate&#59; provided that this Agreement shall be assigned in whole, and the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate&#59; (b) a Third Party in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether in a sale of stock, sale of assets, business combination, reorganization, or other transaction or series of related transactions. Unless expressly stated otherwise in this Agreement, Duality may assign without the prior consent of Licensee its right to receive payments under this Agreement or grant any security interest in its rights, title and interest in this Agreement, in whole or in part and in their entirety or in portions, to an institutional financier in connection with a financing transaction&#59; provided that Duality has given Licensee a prior written notice regarding such assignment. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the permitted assigns of the Parties.  Any assignment not in accordance with this Agreement shall be void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.8&#160;&#160;&#160;&#160;Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is not intended to and shall not be construed to give any Third Party any interest or rights (including any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.9&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part. The Parties shall use their commercially reasonable efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) in a way that, to the extent practicable and legally permissible, implements the original intent of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.10&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58; (a)&#160;the date of actual receipt&#59; (b)&#160;if delivered by overnight courier, &#91;***&#93; Business Days after delivery&#59; or (c)&#160;if sent by facsimile, upon electronic confirmation of receipt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Duality&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Duality Biologics (Suzhou) Co., Ltd</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unit 1106, No 868 Yinghua Road, Pudong New District, Shanghai, China</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">if to Licensee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BIONTECH SE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;<br>Address&#58; An der Goldgrube 12,<br>55131 Mainz,<br>Germany&#160;&#160;&#160;&#160;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.11&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control including but not limited to acts of God, fire, flood, explosion, earthquake, or other natural forces, regional or worldwide epidemic, pandemic, war, civil unrest, acts of terrorism, accident, destruction or other casualty, and a material change in Applicable Law (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. Notice of a Party&#8217;s failure or delay in performance due to a Force Majeure Event must be given to the other Party within &#91;***&#93;&#160;days after its occurrence. The Party affected by a Force Majeure Event will use reasonable efforts to resume performance of its obligations and will keep the other Party informed of actions related thereto.  If any such failure or delay in a Party&#8217;s performance hereunder continues for more than &#91;***&#93; days, the other Party may terminate this Agreement upon written notice to the delayed Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.12&#160;&#160;&#160;&#160;Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section&#160;shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. The words </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;include&#8221;, &#8220;including&#8221;, &#8220;containing&#8221;, &#8220;comprising&#8221; and similar words shall not be deemed to be terms of limitation and shall be deemed to be followed by &#8220; without limitation,&#8221; whether or not specifically stated and the language following such words shall not be deemed to set forth an exhaustive list. The word &#8220;or&#8221; means &#8220;and&#47;or&#8221; unless the context dictates otherwise because the subject of the conjunction are mutually exclusive. The words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. The words &#8220;pharmaceuticals&#8221; or &#8220;drugs&#8221; include biologics unless expressly indicated otherwise. All references to days in this Agreement shall mean calendar days, unless otherwise specified. All references to any Applicable Law in this Agreement shall mean such Applicable Law as amended, restated, supplanted or otherwise modified from time to time.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.13&#160;&#160;&#160;&#160;Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties hereto acknowledge and agree that&#58; (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement&#59; and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.14&#160;&#160;&#160;&#160;Counterparts&#59; Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in two (2) or more counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties or their representative legal counsel, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one and the same instrument. Electronic, facsimile or PDF image signatures shall be treated as original signatures, with the understanding that each Party expressly agrees that such Party shall be bound by its own electronically transmitted signature and shall accept the electronically transmitted signature of the other Party (including through the use of eSignature platforms such as DocuSign&#174;).  No Party will raise the use of electronic delivery to transmit a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery as a defense to the formation of a contract.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><font><br></font></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto have duly executed this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> License and Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Biologics (Suzhou) Co., Ltd.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.05pt;padding-right:3.05pt;text-indent:-5.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Zhongyuan John Zhu</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; U&#287;ur Sahin</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Zhongyuan John Zhu</font></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Ugur Sahin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.05pt;padding-right:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sean Marett</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Sean Marett</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.07pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Business Officer and Chief Commercial Officer</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature Page to Trop2 License And Collaboration Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ABC Terms</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees that it will not undertake any activities which will result in a violation of any applicable laws, regulations, and applicable industry and professional codes, including but not limited to applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws (collectively &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Prohibited Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#34;) in connection with the performance of any activities under this Agreement.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">In particular, each Party agrees that during the course of the performance of activities under this Agreement, it (i) shall not make any offer, payment, or promise to pay money or provide anything of value to a Government Official (as defined below) or any other individual and&#47;or legal entity whether directly or indirectly, for the purpose of improperly influencing any act and&#47;or decision of, and&#47;or for securing any improper advantage&#59; (ii) shall not accept, receive, agree to accept and&#47;or receive a payment and&#47;or anything of value from any individual for undue favorable treatment in obtaining, retaining, and&#47;or directing business for, and&#47;or to obtain any undue special concession on behalf of either Party&#59; and (iii) shall not facilitate any payments to any Government Official to expedite a routine government action and&#47;or other official act.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221; shall include (i) individuals acting on behalf of governments on a national, regional and local level (such as elected officials, customs officials, tax officials, etc.)&#59; (ii) individuals acting on behalf of government-owned or government-controlled enterprises&#59; (iii) individuals acting for political parties or as or on behalf of candidates for public office&#59; and (iv) individuals acting on behalf of public international organizations (such as the WHO, World Bank, OECD, etc.). </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">All transactions and expenses incurred on behalf of either Party shall be accurately recorded and maintained in the respective Party&#8217;s books and records in a timely manner and in reasonable detail in accordance with the applicable generally accepted accounting principles. False, misleading, incomplete, duplicated, inaccurate or artificial entries for the foregoing expenses in a Party&#8217;s books and records are strictly prohibited.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees that if it becomes aware or has reason to suspect that any person or legal entity acting on the Party&#8217;s and&#47;or the other Party&#8217;s behalf has engaged in any Prohibited Conduct related to the Agreement, then such Party will promptly report such knowledge or suspicion to the other Party via the following email address&#58; (a) in case that Duality is the reporting party&#58; &#91;***&#93; and (b) in case that Licensee is the reporting party&#58; &#91;***&#93;. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Duality shall apply Commercially Reasonable Efforts to implement, operate and enforce, without undue delay after the Effective Date, a reasonably designed compliance and business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">ethics management and control system that is intended for the prevention and detection of criminal conduct in accordance with applicable Anti-Corruption Laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of the other Party related to the performance of potentially Prohibited Conduct as described in Article 1 above. Upon notice of an intended investigation, a Party will provide, in a reasonable time, to the investigating Party or to a third party engaged by the investigating Party&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g., invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments).</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%;padding-left:9pt">Each Party acknowledges that the obligations under the applicable local and extraterritorial anti-bribery, Anti-Corruption Laws and anti-money laundering laws apply to all its Affiliates and employees,  subcontractors and Sublicensees (in case of Licensee) or sublicensees (in case of Duality). Each Party will bind subcontractors who act for or on behalf of such Party to perform activities under this Agreement by such Party for or on behalf of the other Party by respective contractual clauses encompassing all or all material provisions of this Schedule.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.54</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality In-Licensed Agreements </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.57</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description of Duality Know-How</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_16"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.63</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Duality Patent Rights</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.94</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">List of Indications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_19"></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.102</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Licensed Compound</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.127%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:62.64pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.141</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original ADC Licensed Product </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Preliminary Development Plan as of the Effective Date</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:92.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.127%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i4e3ab8a01e7a467a994fd4c95121f6ca_22"></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 1.149</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pre-clinical Proof-of-Concept Criteria </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 2.6</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Initial Know-How Transfer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 9.2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Invoicing Procedures &#38; Invoice Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 10.4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Duality Press Release</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule 11.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Disclosure Schedule</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:147.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">92</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.573%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">ACTIVE&#47;123841245.19 </font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.53
<SEQUENCE>9
<FILENAME>exhibit453biotheusagreemen.htm
<DESCRIPTION>EX-4.53
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie77d95f8839f452aa1ff9e02534412b5_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.53</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:11pt;text-align:right"><font><br></font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">Dated 26 October 2023</font></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font><br></font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#160;&#160;&#160;&#160;BIOTHEUS INC. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#26222;&#31859;&#26031;&#29983;&#29289;&#25216;&#26415;(&#29664;&#28023;)&#26377;&#38480;&#20844;&#21496;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">)&#160;&#160;&#160;&#160;(1)</font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#160;&#160;&#160;&#160;AND</font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:162%">&#160;&#160;&#160;&#160;BIONTECH SE&#160;&#160;&#160;&#160;(2)</font></div><div style="margin-bottom:12pt;padding-right:85.05pt"><font><br></font></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;padding-left:103.65pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.676%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:140%">COLLABORATION, LICENSE AND OPTION AGREEMENT</font></td></tr></table></div><div style="margin-bottom:11pt;text-align:center"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div></div><div id="ie77d95f8839f452aa1ff9e02534412b5_4"></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">CONTENTS</font></div><div style="margin-bottom:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Clause&#160;&#160;&#160;&#160;Heading&#160;&#160;&#160;&#160;Page</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;&#160;&#160;&#160;DEFINITIONS ................................................................................................................ 3</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 &#160;&#160;&#160;&#160;OPTIONS ..................................................................................................................... 48</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 &#160;&#160;&#160;&#160;LICENSES&#59; EXCLUSIVITY .......................................................................................... 53</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 &#160;&#160;&#160;&#160;GOVERNANCE. .......................................................................................................... 62</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#160;&#160;&#160; DEVELOPMENT AND COMMERCIALIZATION ......................................................... 69</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 &#160;&#160;&#160;&#160;REGULATORY AFFAIRS ............................................................................................ 77</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 &#160;&#160;&#160;&#160;MANUFACTURING AND TECHNOLOGY TRANSFER .............................................. 79</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 &#160;&#160;&#160;&#160;FINANCIAL TERMS ..................................................................................................... 86</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY .................................................................................... 107</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 &#160;&#160;&#160;&#160;CONFIDENTIALITY ................................................................................................... 117</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 &#160;&#160;&#160;&#160;REPRESENTATIONS, WARRANTIES, AND COVENANTS .................................... 122</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 &#160;&#160;&#160;&#160;INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE .............................. 132</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;&#160;&#160;&#160;TERM AND TERMINATION ...................................................................................... 135</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;&#160;&#160;&#160;MISCELLANEOUS .................................................................................................... 143</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 1 Global CDP &#38; Joint CDP ................................................................................................. 154</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 2 Exceptions to Representations and Warranties .............................................................. 157</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 3 Licensed Patent Rights ................................................................................................... 158</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 4 Manufacturing and CMC Information .............................................................................. 160</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 5 BioNTech Background Know-How .................................................................................. 165</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 6 Biotheus Background IP .................................................................................................. 166</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 7 BioNTech Competitors .................................................................................................... 167</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 8 Biotheus In-Licenses ....................................................................................................... 168</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 9 Biotheus Press Release .................................................................................................. 169</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 10 PM8002 Licensed Compound ....................................................................................... 171</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule 11 PM8003 Licensed Compound ....................................................................................... 172</font></div><div style="height:70.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><div id="ie77d95f8839f452aa1ff9e02534412b5_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">COLLABORATION, LICENSE AND OPTION AGREEMENT</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%"> COLLABORATION, LICENSE AND OPTION AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> (this &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) is entered into this 26</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:209%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> day of October, 2023 (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Execution Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), by and between </font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.23pt">BIOTHEUS INC. (in Chinese&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#26222;&#31859;&#26031;&#29983;&#29289;&#25216;&#26415;(&#29664;&#28023;)&#26377;&#38480;&#20844;&#21496;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">), a limited company incorporated in the People's Republic of China (Unified Social Credit Code&#58; 91440400MA51YKAW2M), having its registered office at Unit 10-B, Building 4, No. 1, Keji 7th Road, Tangjiawan Town, High-Tech Zone, Zhuhai City, Guangdong Province, the People's Republic of China (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Biotheus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;)&#59; and</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.23pt">BIONTECH SE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, a company incorporated in Germany having its registered office at An der Goldgrube 12, D-55131 Mainz, Germany (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus and BioNTech are sometimes referred to herein individually as a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34; and collectively as the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">.&#34;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">WHEREAS, Biotheus is a biopharmaceutical company focused on the discovery and development of novel drugs to treat cancer and inflammatory diseases&#59;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">WHEREAS, BioNTech is a German biotechnology company based in Mainz focused on the developent and manufacture of active immunotherapies for patient-specific approaches to the treatment of diseases&#59;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">WHEREAS, BioNTech desires to obtain from Biotheus an exclusive license with respect to PM8002 Licensed Products under the applicable Licensed Patent Rights and the applicable Licensed Know-How to Develop, Manufacture and Commercialize PM8002 Licensed Products in the Field in the Territory, under the terms and conditions set forth herein, and Biotheus desires to grant to BioNTech such license with respect to PM8002 Licensed Products, while Biotheus retains the right to Develop, Manufacture and Commercialize PM8002 Licensed Products in the Retained Territory in close coordination with BioNTech&#59;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(D)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">WHEREAS, BioNTech desires to obtain options to an exclusive license with respect to PM8003 Licensed Products and Preclinical Multispecific Licensed Products under the terms and conditions set forth herein, and Biotheus desires to grant such options.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">NOW, THEREFORE, the Parties agree as follows&#58;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">DEFINITIONS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The following terms, whether used in the singular or plural, will have the following meanings&#58;</font></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">1st line HCC&#47;CRC&#47;PROC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means First Line Hepatocellular carcinoma &#47; Colorectal Cancer&#47;Platinum Resistant Ovarian Cancer&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">1st line nccRCC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means First Line non clear cell renal cell carcinomas&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">1st line SCLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means First Line Small Cell Lung Cancer&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">1st line TNBC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means First Line Triple Negative Breast Cancer&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">2nd line NSCLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means Second Line Non Small Cell Lung Cancer&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">2nd line RCC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means Second Line renal cell carcinoma&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">2nd line SCLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means Second Line Small Cell Lung Cancer&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Accelerated Approval</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means drugs for serious conditions that fill an unmet medical need approved based on a surrogate endpoint as defined by FDASIA Section 901 and 21 CFR 314 Subpart H&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Accounting Standards</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means (a) with respect to BioNTech, its Affiliates or their respective Sublicensees, International Financial Reporting Standards as issued by the International Accounting Standards Board and endorsed by the EU, consistently applied or any other applicable standard accounting principles used by Sublicensees&#59; and (b) with respect to Biotheus, Accounting Standards for Business Enterprises as promulgated by Chinese Accounting Standards Committee of Ministry of Finance of the People&#8217;s Republic of China or its successor organization or any other applicable standard accounting principles used by the applicable Affiliates of Biotheus&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">ADC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Additional Third Party Licences</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.5(b) (Adjustments to Royalties)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Affiliate</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, with respect to any Person, any Person controlling, controlled by or under common control with such Person.  For the purposes of this Section 1.12 (Affiliate), the term &#34;control&#34; (including, with correlative meaning, the terms &#34;controlled by&#34; and &#34;under common control with&#34;), means the possession, directly or indirectly, of more than 50% of the voting stock or other ownership interest of such Person, or the possession, directly or indirectly, of the power to direct or cause the direction of the affairs or management and policies of such Person or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of such Person.  The Parties acknowledge that in the case of certain entities organised under the laws of certain countries outside the United States, the maximum percentage ownership permitted by Applicable Law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage will be substituted in the preceding sentence&#59; provided that such foreign investor has the power to direct the management and policies of such entity&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Agreement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in the Preamble&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Alliance Manager</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 4.3 (Alliance and Project Managers)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.15 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Antibody</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Anti-Corruption Laws</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all applicable anti-bribery and anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010, and the comparable Applicable Laws of any countries in which Licensed Products, payments or services will be provided or procured under or pursuant to this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Applicable Data Protection Law</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all Applicable Laws in any jurisdiction relating to privacy or the processing or protection of personal data or personal information, including the General Data Protection Regulation (EU) 2016&#47;679 (GDPR), the UK Data Protection Act 2018, the e-Privacy Directive (2002&#47;58&#47;EC) and the comparable in other jurisdictions and all guidance issued by any applicable data protection authority&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Applicable Law</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any law, statute, rule, regulation, order, judgment, ordinance or guidance of any Governmental Authority, including all applicable GxPs, Anti-Corruption Laws, Applicable Data Protection Laws, accounting and recordkeeping laws, and laws relating to interactions with healthcare professionals and Government Officials.  For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof shall be deemed to include all then-current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, promulgation, order, writ, judgment, injunction, decree, stipulation, ruling, guidance or determination thereto&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Audited Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.12(a) (Books and Records)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Auditing Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.12(a) (Books and Records)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Auditor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.12(a) (Books and Records)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Bankrupt Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 13.2(d) (Termination for Bankruptcy)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.23</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Bankruptcy Code</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 14.15 (Rights in Bankruptcy)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.24</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in the Preamble&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Background IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means BioNTech Background Know-How and BioNTech Background Patent Rights&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Background Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Know-How that is Controlled by BioNTech or its Affiliates (a) as of the Effective Date or (b) during the Term other than pursuant to Section 3.1 (License Grants to BioNTech) of this Agreement that, in each case (a) and (b) is necessary or useful for the Development of the applicable Licensed Products in the Field in the Territory in accordance with the Global CDP and Joint CDP. A description of BioNTech Background Know-How as of the Execution Date is set out in Schedule 5 and such Schedule may be updated by agreement of the JSC from time to time&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.27</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Background Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Patent Rights Controlled by BioNTech or its Affiliates as of the Effective Date or during the Term that claim or Cover any BioNTech Background Know-How&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.28</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Competing Products</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.29</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Competitor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Persons listed in Schedule 7 as such list may be updated by BioNTech from time to time&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.30</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Retained Territory Competitor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.31</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Foreground IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the BioNTech Foreground Know-How and BioNTech Foreground Patent Rights&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.32</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Foreground Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.33</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Foreground Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all Patent Rights that claim or Cover BioNTech Foreground Know-How&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.34</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Indemnitees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 12.2 (Indemnification of BioNTech by Biotheus)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.35</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech Multispecific Antibody</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a Licensed Product that is a Multispecific Antibody &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.36</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BioNTech-Prosecuted Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.2(d) (BioNTech-Prosecuted Patent Rights)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.37</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biosimilar Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.38</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in the Preamble&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.39</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Background IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Patent Rights and Know-How relating to Biotheus' proprietary platform technology and set out or described in Schedule 6. Such Schedule may be updated by agreement of the Joint IP Committee from time to time&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.40</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Foreground IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Biotheus Foreground Know-How and Biotheus Foreground Patent Rights&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.41</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Foreground Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.42</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Foreground Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all Patent Rights that claim or Cover Biotheus Foreground Know-How&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.43</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Indemnitees</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 12.1 (Indemnification of Biotheus by BioNTech)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.44</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus In-Licenses</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any agreement between Biotheus and a Third Party pursuant to which Biotheus or its Affiliates Controls the Licensed IP, as set forth in Schedule 8A&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.45</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Platform Foreground IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.46</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Platform Foreground Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.47</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus Foreground Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all Patent Rights that claim or Cover Biotheus Foreground Know-How&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.48</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Biotheus-Prosecuted Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.2(e) (Biotheus-Prosecuted Patent Rights)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.49</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.50</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Bispecific Antibody</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.51</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Bispecific Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.52</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Bispecific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.53</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">BLA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an application filed with the FDA or applicable Regulatory Authorities outside the United States for approval to commercially market, import and sell a biological product&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.54</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Breakthrough Designation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a drug as defined by FDASIA Section 902 that&#58; (a) intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and (b) preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.55</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Business Day</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a day that is not a Saturday, Sunday, or a day on which banking institutions in Mainz, Germany, Hong Kong, and Zhuhai, China are authorized or required by Applicable Law to remain closed&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.56</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Calendar Quarter</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means each period of three consecutive calendar months ending on March 31, June 30, September 30, or December 31, except that the first Calendar Quarter of the Term will commence on the Effective Date, and the last Calendar Quarter of the Term will end on the effective date of the termination or expiration of this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.57</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Calendar Year</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means each period of twelve (12) consecutive calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term will commence on the Effective Date, and the last Calendar Year of the Term will end on the effective date of the termination or expiration of this Agreement&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.58</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">C.F.R. </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the U.S. Code of Federal Regulations&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.59</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">cGCP </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the ethical conduct of clinical trials, including without limitation the U.S. Code of Federal Regulations (CFR) Title 21, ICH GCP Guidelines E6(R2) as amended from time to time, national legislation implementing European Community Directive 2001&#47;20&#47;EC (if and as still applicable), European Community Directive 2005&#47;28&#47;EC, and, following the applicable transition periods, the Clinical Trial Regulation (EU) No. 536&#47;2014 (the &#34;CTR&#34;) and the rules, regulations and guidelines applying in the context of the CTR, China Good Clinical Practice Rules and the equivalent in other countries or regions&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.60</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">cGLP </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all laws, rules, regulations, guidelines and generally accepted standards and requirements regarding quality control for laboratories to ensure the consistency and reliability of results, including without limitation the CFR Title 21, national legislation implementing European Community Directives 2004&#47;9&#47;EC and 2004&#47;10&#47;EC as amended, and the OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring, China Drug Good Laboratory Practice Rules (China Non-Clinical Research Quality Management Standard) and the equivalent in other countries or regions.  For the purposes of this Agreement, GLP also includes the principles of &#34;Good Clinical Laboratory Practice&#34; which means any and all laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the treatment of human laboratory samples from Clinical Trials, including the relevant principles from GCP and the EMA's reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, as amended from time to time&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.61</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">cGMP </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all laws, rules, regulations, guidelines and generally accepted standards and requirements regarding the quality control and manufacturing of pharmaceutical products, including without limitation the CFR Title 21, Parts 11, 210, 211, 600 and 610, applicable ICH Guidelines including without limitation Q7 for &#34;Active Pharmaceuticals Ingredients&#34;, national legislation implementing European Community Directive 2001&#47;83&#47;EC and Commission Directive 2003&#47;94&#47;EC as amended, EudraLex &#8211; Volume 4 of the Rules Governing Medicinal Products in the European Union including annexes, the CTR, Commission Delegated Regulation 2017&#47;1569, the Detailed Commission Guideline (2017) 8179, and the equivalent in other countries or regions including in China&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.62</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">cGood Pharmacovigilance Practice or cGVP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the current Good Pharmacovigilance Practices applicable to the conduct of specific pharmacovigilance activities, including US Code of Federal Regulations (&#34;CFR&#34;) Title 21 covering US Food and Drug Administration (&#34;FDA&#34;) regulations (&#34;FDA 21 CFR&#34;), as amplified by relevant FDA guidance, Compliance guides, and other relevant regulatory materials, International Council on Harmonisation (&#34;ICH&#34;) of Technical Requirements for Registration of Pharmaceuticals for Human Use (Codes, E2A, E2B, E2C, E2D), European Union (&#34;EU&#34;) regulations and directives and&#47;or local regulations, China Good Pharmacovigilance Practice Rule (China Pharmacovigilance Quality Management Standard).in each case as applicable&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.63</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">China</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the People's Republic of China (including mainland China, Hong Kong, Macau and Taiwan)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.64</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Claim</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 14.1(a) (Escalation)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.65</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Clinical Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.66</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">CMC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means chemistry, manufacturing and controls&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.67</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.68</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Combination Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;. Each such additional &#91;***&#93; shall be &#34;an Other Component&#34;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.69</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Commercialization or Commercialize</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means activities related to the commercialization of a product, including the pre-marketing, launching, marketing, promotion (including advertising and detailing), market research, labeling, bidding and listing, market access activities, pricing and reimbursement, distribution, storage, handling, Manufacturing for commercial sale (including inventory build to support launch), offering for sale, selling, having sold, importing and exporting for sale, having imported and exported for sale, distribution, having distributed, order processing, handling returns and recalls, customer service and support, and post-marketing safety surveillance and reporting of a product, medical affairs and medical science liaison activities, as well all regulatory compliance and conduct of administrative functions with respect to the foregoing.  For clarity, &#34;Commercialization&#34; includes all pre-launch marketing and other launch preparation activities, including training of personnel who will conduct Commercialization activities, as well as manufacturing activities in preparation for and to establish and maintain commercial sales.  When used as a verb, &#34;Commercialize&#34; means to engage in Commercialization&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.70</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Commercially Reasonable Efforts</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.71</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Competitive Infringement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.3(a) (Notification)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.72</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Confidential Information</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:5.78pt">the existence and terms of this Agreement&#59; and</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:5.78pt">with respect to each Party, Know-How, inventions, Materials, and other proprietary information including data and all other scientific, pre-clinical, clinical, regulatory, Manufacturing, marketing, financial and commercial information or data that is disclosed, made available to, or provided by or on behalf of such Party to the other Party or to any of the Receiving Party's employees, consultants, Affiliates, or Sublicensees, whether or not specifically marked or designated by the Disclosing Party as confidential&#59;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">Notwithstanding the foregoing, Confidential Information constituting&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:5.78pt">&#91;***&#93; Background Know-How and &#91;***&#93; Foreground Know-How shall be considered Confidential Information &#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:5.78pt">subject to Section 10.3 (Publications and Presentations), Licensed Know-How shall be considered Confidential Information &#91;***&#93; PROVIDED THAT Product-Specific Know-How shall, during the Term be deemed to be the Confidential Information &#91;***&#93;&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:6.34pt">Joint Know-How shall be the Confidential Information of both Parties (and both Parties shall be the Receiving Party and the Disclosing Party with respect thereto)&#59; and</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:5.78pt">the existence, scope and terms and conditions of this Agreement shall be the Confidential Information of both Parties (and both Parties shall be the Receiving Party and the Disclosing Party with respect thereto).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">For clarity, (i) specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party&#59; and (ii) any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.73</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Confidentiality Agreement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 10.1(b) (Confidential Information of Each Party)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.74</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Control or Controlled</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the possession by a Party (whether by ownership, license or otherwise, other than pursuant to this Agreement) of&#58;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">with respect to any materials or other tangible Know-How, the legal authority or right to physical possession of such materials or tangible Know-How, with the right to provide such materials or tangible Know-How to the other Party on the terms set forth herein&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">with respect to Patent Rights, Regulatory Authorizations, Regulatory Filings, intangible Know-How or other intellectual property, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such Patent Rights, Regulatory Authorizations, Regulatory Filings, intangible Know-How or other intellectual property on the terms set forth herein&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">in each case (a) and (b), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use, license, or sublicense&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.75</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Cost of Goods</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.76</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Cover, Covers, or Covered</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.77</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Development or Develop</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, with respect to any product, any and all internal and external research, development, pharmacovigilance activities, and regulatory activities regarding such product, including&#58;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">research, process development, non-clinical testing, toxicology, non-clinical activities, IND-enabling studies, and Clinical Trials, and</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Authorization of such product, but excluding any activities directed to Manufacturing or Commercialization.  Development will include research, development, and regulatory activities for additional presentations or Indications for a product after receipt of Regulatory Authorization of such product, including Clinical Trials initiated following receipt of Regulatory Authorization or any Clinical Trial to be conducted after receipt of Regulatory Authorization that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Authorization with respect to an approved Indication (such as post-marketing approval studies and observational studies, if required by any Regulatory Authority in any country in the Territory to support or maintain Regulatory Authorization for a product in such country).  &#34;Develop&#34;, &#34;Developing&#34; and &#34;Developed&#34; will be construed accordingly&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.78</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Development Milestone Event</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.3 (Development and Approval Milestone Payments for Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.79</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Development Milestone Payment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.3 (Development and Approval Milestone Payments for Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.80</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Directed</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.81</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Disclosing Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 10.1(a) (General)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.82</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Effective Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means with respect to this Agreement the date of the expiration or termination of any applicable waiting period under the HSR Act&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.83</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Eligible Development Costs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.84</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">EMA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the European Medicines Agency or any successor agency or authority thereto&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.85</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">European Union or EU </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all countries or territories that are officially part of the European Union, as constituted from time to time&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.86</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Executive Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 14.1(a) (Escalation)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.87</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Exploit</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means Develop, have Developed, make, have made, use, have used, perform medical affairs, have performed medical affairs, offer for sale, have offered for sale, sell, have sold, export, have exported, import, have imported, Manufacture, have Manufactured, Commercialize or have Commercialized.  &#34;Exploitation&#34; and &#34;Exploiting&#34; will be construed accordingly&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.88</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Extensions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.2(h) (Patent term extension and supplementary protection certificates)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.89</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">External Expenses</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means documented expenses paid to Third Parties (or payable to Third Parties and accrued in accordance with Accounting Standards) by a Party (or its Affiliate) in the performance of activities under this Agreement, including capital expenditures that are specifically allocated to such activities and travel expenses incurred for carrying out such activities, but excluding financing costs&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.90</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">FDA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the United States Food and Drug Administration and any successor agency or authority thereto&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.91</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">FD&#38;C Act</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the United States Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder, as may be in effect from time to time&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.92</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Field </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all therapeutic, prophylactic, palliative, analgesic and diagnostic uses in humans and animals&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.93</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">First Commercial Sale</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, on a Licensed Product-by-Licensed Product basis, the first sale of such Licensed Product by BioNTech, its Affiliate, or their Sublicensee to a Third Party or Governmental Authority in a country following Marketing Authorization in such country.  Sales or transfers of reasonable quantities of a Licensed Product for Development, including proof of concept studies or other Clinical Trial purposes, or for compassionate use or named patient supply shall not be considered a First Commercial Sale&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.94</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Force Majeure</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any act of God, pandemic, flood, fire, explosion, earthquake, strike, lockout, labor dispute (except for any strike, lockout, or labor dispute involving a Party's own employees), casualty or accident, or war, revolution, civil commotion, or act of terrorism&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.95</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">FTE </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the equivalent of the time of a full-time employee of Biotheus or its applicable Affiliate for a twelve (12) month period devoted to Development and Manufacturing (excluding management and indirectly related personnel's time), where &#34;full-time&#34; is determined by &#91;***&#93; hours per Calendar Year.  In the event that any individual who works full-time during a given Calendar Year works partially on the activities under this Agreement and partially on other work outside this Agreement, then the full-time equivalent to be attributed to such individual's work hereunder for such Calendar Year shall be equal to the percentage of such individual's total work time in such Calendar Year that such individual spent working on activities under this Agreement.  For avoidance of doubt, FTE shall exclude individuals responsible for managerial, secretarial, clerical and administrative activities&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.96</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">FTE Costs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an amount equal to the product of the FTE Rate and the actual number of FTEs who performed the applicable activities. For clarity, FTE shall be pro-rated on a daily basis if necessary&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.97</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">FTE Rate </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an annual rate of&#58; (a) in respect of activities conducted in the &#91;***&#93;, &#91;***&#93; for activities conducted &#91;***&#93;&#59; and (b) in respect of activities conducted in the &#91;***&#93;, (i) &#91;***&#93; for activities conducted &#91;***&#93;&#59; and (ii) &#91;***&#93; for activities conducted &#91;***&#93;, subject to &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.98</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Global CDP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.3(a) (Global CDP)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.99</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Global CDP Activities</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the activities to be conducted by the Parties pursuant to the Global CDP&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.100</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Global Commercialization Strategy</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.1(a) (Global Commercialization Strategy)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.101</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Global Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.3(a) (Global CDP)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.102</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Governmental Approval</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 11.3(f) (Biotheus Covenants)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.103</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Government or Governmental Authority</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means (a) any national, federal, state, local, provincial, regional or foreign government, or level, ranch, or subdivision thereof&#59; (b) any multinational or public international organization or authority&#59; (c) any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power&#59; (d) any court, tribunal, or governmental arbitrator or arbitral body&#59; (e) any government-owned or controlled institution or entity&#59; (f) any enterprise or instrumentality performing a governmental function&#59; (g) any political party, and (h) any Regulatory Authority&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.104</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Government Official</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means (a) any elected or appointed government official (e.g., a member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office, (d) any member of a military or a royal or ruling family, and (e) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity, healthcare providers employed by Government-owned or -controlled hospitals, or a person serving on a healthcare committee that advises a Government, will be considered Government Officials.  In addition, all healthcare providers in a given country will be considered Government Officials where this is required by Applicable Law&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.105</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">GxP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, collectively, all relevant good practice quality guidelines and regulations and related implementation guidelines, encompassing such internationally recognized standards as cGCP, cGMP, cGLP, cGVP&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.106</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">HSR Act</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, codified at 15 U.S.C. &#167; 18a, as may be amended from time to time, and the rules and regulations promulgated thereunder, or foreign equivalent thereof under Applicable Law (including all additions, supplements, extensions and modifications thereto)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.107</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">IFRS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, at any time, the International Financial Reporting Standards promulgated by the International Accounting Standards Board, as amended, supplemented, or replaced from time to time and as endorsed by the European Union&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.108</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Investigational New Drug Application or IND </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, an Investigational New Drug application in the US filed with the FDA or an analogous application or submission with any analogous Regulatory Authority in other countries &#47; regions &#47; regulatory jurisdictions for the purposes of obtaining permission to conduct Clinical Trials, including Clinical Trial applications submitted to Regulatory Authorities in the EU via the CTIS&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.109</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Improved Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a Licensed Product that is &#91;***&#93;. For clarity, a Preclinical Multispecific Licensed Product shall not be deemed to be an Improved Licensed Product&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.110</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Improved Licensed Product Conditions</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 3.7 (BioNTech Exclusivity and Improved Licensed Product Conditions)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.111</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Indemnitee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 12.3 (Conditions to Indemnification)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.112</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Indication</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.113</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Indirect Taxes</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means value added, sales, consumption, goods, and services taxes or other similar taxes required by Applicable Law to be disclosed as a separate item on the relevant invoice&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.114</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Infringement</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.3(a) (Notification)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.115</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Infringement Action</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.3(b) (Infringement Actions)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.116</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">In-Licensed BioNTech Products</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any compound or product the rights to which are owned by a Third Party and either as at the Effective Date or during the Term are licensed to or otherwise acquired by BioNTech or its Affiliates&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.117</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Intellectual Property Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Know-How, Patent Rights, Trademarks, copyrights, trade secrets, and any other intellectual property rights however denominated throughout the world&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.118</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Interest Rate</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.14 (Late Fees)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.119</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Internal Costs</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, for any period, the product obtained by multiplying&#58;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">the actual total FTEs (or portion thereof) devoted to the performance of an activity under this Agreement during such period, by</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">the applicable FTE Rate&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.120</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Invention</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any invention, discovery, or Know-How that is discovered, generated or conceived by or on behalf of a Party or its Affiliate or Sublicensee in the performance of activities under this Agreement&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.121</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">JCWG</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.1(b) (Formation of Joint Commercialization Working Group)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.122</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint CDP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.3(b) (Joint CDP)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.123</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint CDP Activities</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the activities to be conducted by the Parties pursuant to the Joint CDP&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.124</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint Development and Operations Working Group</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 4.2(b) (Joint Development and Operations Working Group)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.125</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all Joint Know-How and Joint Patent Rights&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.126</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint IP Committee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 4.2(c) (Joint IP Committee)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.127</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.128</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Patent Rights that Cover or otherwise claim Joint Know-How&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.129</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint Steering Committee or JSC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 4.1(a) (Formation and Purpose of the JSC)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.130</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Joint Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.3(b) (Joint CDP)&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.131</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any proprietary records, know-how, processes, techniques, show-how, design information, information, biomarkers, formulations, technology, practices, trade secrets, inventions, methods, data (including animal data, clinical data, and quality control data), standard operating procedures, algorithms, research tools, reports, batch records, chemical structures, composition of matter, formulae and results in any form whatsoever, whether or not patented or patentable&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.132</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Licensed Compound</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all of the following&#58;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">a PM8002 Licensed Compound&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">a PM8003 Licensed Compound, provided that this item (b) shall only become a Licensed Compound after the PM8003 Option Exercise Date&#59; or</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:24.34pt">a Preclinical Multispecific Licensed Compound, provided that this item (c) shall only become a Licensed Compound after the Preclinical Multispecific Option Exercise Date&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.133</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Licensed IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all Licensed Know-How and Licensed Patent Rights&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.134</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Licensed Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Know-How that is Controlled by Biotheus or any of its Affiliates as of the Effective Date or during the Term (including Inventions solely owned by Biotheus pursuant to Section 9.1(a) (Ownership), and including Biotheus' interest in Joint Know-How) that is necessary or useful for the Exploitation of Licensed Products in the Field in the Territory. Notwithstanding the foregoing, Licensed Know-How shall not include (i) any Know-How that is Controlled by any Third Party that acquires more than fifty percent (50%) of the issued share capital of Biotheus and thereby becomes an Affiliate of Biotheus after the Effective Date as a result of a merger, acquisition or other similar transaction, or (ii) any Know-How that is related to any other proprietary compound, component or product Controlled by Biotheus or any of its Affiliates and is not necessary or useful for the Exploitation of the applicable Licensed Products in the Field in the Territory&#59; </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.135</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Licensed Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the Patent Rights Controlled by Biotheus or any of its Affiliates as of the Effective Date or during the Term (including Patent Rights which Cover or otherwise claim Inventions solely owned by Biotheus pursuant to Section 9.1(a) (Ownership), and including Biotheus&#8217; interest in Joint Patent Rights) that are necessary or useful for the Exploitation of any Licensed Products in the Field in the Territory including, but not limited to, the Patent Rights listed in Schedule 3.  Notwithstanding the foregoing, Licensed Patent Rights shall not include (i) any Patent Right that is Controlled by any Third Party that acquires more than fifty percent (50%) of the issued share capital of Biotheus and thereby becomes an Affiliate of Biotheus after the Effective Date as a result of a merger, acquisition or other similar transaction, or (ii) any Patent Right that Covers any other proprietary compound, component or product Controlled by Biotheus or any of its Affiliates and is not necessary or useful for the Exploitation of any Licensed Products in the Field in the Territory&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.136</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any and all of the following&#58;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">a PM8002 Licensed Product&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">a PM8003 Licensed Product, provided that this item (b) shall only become a Licensed Product after the PM8003 Option Exercise Date&#59; or</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:24.34pt">a Preclinical Multispecific Licensed Product, provided that this item (c) shall only become a Licensed Product after the Preclinical Multispecific Option Exercise Date.</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.137</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93; License</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.138</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.139</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Losses</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 12.1 (Indemnification of Biotheus by BioNTech)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.140</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Major Markets</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.141</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Manufacture or Manufacturing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, with respect to a Licensed Product, activities directed to the sourcing and purchasing of materials, producing, manufacturing, processing, compounding, filling, finishing, packing, packaging, labelling, leafleting, quality assurance, quality control testing and release, shipping, storage, and sample retention of such Licensed Product.  &#34;Manufacturing&#34; and &#34;Manufactured&#34; will be construed accordingly&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.142</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Manufacturing Technology Transfer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.143</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Marketing Authorization or MA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the authorization by all relevant Regulatory Authorities of a Marketing Authorization Application in a given country or regulatory region &#47; jurisdiction and the granting of the required authorization&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.144</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Marketing Authorization Application or MAA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an application to a Regulatory Authority for authorization to place a Licensed Product on the market (including Pricing and Reimbursement Approval) in a country, region or a regulatory jurisdiction (including for example an NDA &#47; BLA in the US and the comparable applications in other jurisdictions)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.145</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Materials</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any tangible compositions of matter, articles of manufacture, assays, chemical, biological or physical materials, and other similar materials&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.146</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Multispecific Antibody</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an Antibody that is &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.147</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Multispecific Antibody Option</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.2 (Option to Biotheus)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.148</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Multispecific Antibody Option Exercise Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.2 (Option to Biotheus)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.149</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Multispecific Antibody Option Exercise Notice</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.2 (Option to Biotheus)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.150</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Multispecific Antibody Option Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the period from the &#91;***&#93; with respect to a Licensed Product in the form of a Multispecific Antibody&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.151</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Net Sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.152</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Non-Bankrupt Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 13.2(d) (Termination for Bankruptcy)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.153</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Non-Withholding Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.17 (Withholding Taxes)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.154</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Opted-Out Indication</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.6 (Data Sharing)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.155</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Opted-Out Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 5.6 (Data Sharing)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.156</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Orphan Drug Designation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a drug intended for use in a rare disease or condition as defined in section 526 of the Federal Food, Drug, and Cosmetic Act as amended by section 2 of the Orphan Drug Act (sections 525&#8211;528 (21 U.S.C. 360aa&#8211;360dd))&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.157</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Other Component</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 1.68 (Combination Product)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.158</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Outside Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 14.16 (HSR)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.159</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in the Preamble&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.160</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.161</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Patent Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all rights, title and interests in and to</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">all national, regional, and international patents and patent applications filed in any country, region or territory of the world including provisional patent applications and all supplementary protection certificates&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority to any of the foregoing, including any continuation, continuation-in part, divisional, provisional, converted provisionals and continued prosecution applications, or any substitute applications&#59;</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:24.34pt">any patent issued with respect to or in the future issued from any such patent applications, including utility models, petty patents, design patents and certificates of invention&#59; and </font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%;padding-left:23.78pt">any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.162</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Payments</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.17 (Withholding Taxes)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.163</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PDL1 Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.164</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Person</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including any Governmental Authority (or any department, agency, or political subdivision thereof)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.165</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Phase I Clinical Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a Clinical Trial that generally provides for the first introduction into humans of a Licensed Product with the primary purpose of determining initial safety or tolerance, metabolism and PK&#47;PD properties of such product, in a manner that is generally consistent with 21 CFR &#167; 312.21(a), as amended (or its successor regulation)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.166</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Phase II Clinical Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a Clinical Trial, the principal purpose of which is to make a preliminary determination as to whether a pharmaceutical product is safe for its intended use and to obtain sufficient information about such product's efficacy for its intended use (proof of concept) in a manner that is generally consistent with 21 CFR &#167; 312.21(b), as amended (or its successor regulation), to permit the design of further Clinical Trials&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.167</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Phase III Clinical Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a pivotal&#47;registrational Clinical Trial with a defined dose or a set of defined doses of a Licensed Product designed to ascertain efficacy and safety of such Licensed Product, in a manner that is generally consistent with 21 CFR &#167; 312.21(c), as amended (or its successor regulation), for the purpose of enabling the preparation and submission of an application for Regulatory Authorization.  This can include Phase IIb Clinical Trials&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.168</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8002 Licensed Compound</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.169</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8002 Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.170</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8002 Product-Specific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Licensed Patent Right (including any Joint Patent Rights) that solely identifies or discloses or solely Covers a&#160; PM8002 Licensed Product(s) or its or their use or process of manufacture and does not claim or Cover any proprietary products Controlled by Biotheus other than&#160; such PM8002 Licensed Product(s).&#160; &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.171</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Licensed Compound</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means Biotheus&#8217; &#91;***&#93;</font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%"></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.172</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.173</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Option</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(a) (PM8003 Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.174</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Option Exercise Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(a) (PM8003 Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.175</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Option Exercise Notice</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(a) (PM8003 Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.176</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Option Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the period from the &#91;***&#93; until &#91;***&#93; days after the Improved Licensed Product Conditions are met&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.177</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">PM8003 Product-Specific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Licensed Patent Right (including any Joint Patent Rights) that solely identifies or discloses or solely Covers a&#160; PM8003 Licensed Product(s) or its or their use or process of manufacture and does not claim or Cover any proprietary products Controlled by Biotheus other than&#160; such PM8003 Licensed Product(s).&#160; &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.178</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Licensed Compound</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.179</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Licensed Product</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, from and after the Preclinical Multispecific Option Exercise Date only, &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.180</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Option</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(b) (Preclinical Multispecific Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.181</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Option Exercise Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(b) (Preclinical Multispecific Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.182</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Option Exercise Notice</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 2.1(b) (Preclinical Multispecific Option)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.183</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Option Period</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, on a Preclinical Multispecific Licensed Compound-by Preclinical Multispecific Licensed Compound basis, the period from &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.184</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Preclinical Multispecific Product-Specific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, on a Preclinical Multispecific Licensed Product-by-Preclinical Multispecific Licensed Product basis, any Licensed Patent Right (including any Joint Patent Rights) that solely identifies or discloses or solely Covers a Preclinical Multispecific Licensed Product(s) or its or their use or process of manufacture and does not claim or Cover any proprietary products Controlled by Biotheus other than&#160; such Preclinical Multispecific Licensed Product(s). &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.185</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Pricing and Reimbursement Approval</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means in any country where a Regulatory Authority authorizes, approves or determines reimbursement for or use of, and &#47; or pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination as effective, publication) of such reimbursement and &#47; or pricing approval or determination (as the case may be)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.186</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Product-Specific IP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, all Product-Specific Know-How and Product-Specific Patent Rights&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.187</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Product-Specific Know-How</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, for the purpose of Section 1.72 (Confidential Information) and Article 10 (Confidentiality), with respect to a Licensed Product any Licensed Know-How that solely relates to such Licensed Product&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.188</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Product-Specific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, on a Licensed Product-by-Licensed Product basis, any Licensed Patent Right (including any Joint Patent Rights) that solely identifies or discloses or solely Covers a  Licensed Product(s) or its or their use or process of manufacture and does not claim or Cover any proprietary products Controlled by Biotheus other than such Licensed Product(s), including PM8002 Product-Specific Patent Right, PM8003 Product-Specific Patent Right and Preclinical Multispecific Product-Specific Patent Right&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.189</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Prohibited Conduct</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 11.3(c) (No Bribery)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.190</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Project Manager</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 4.3 (Alliance and Project Managers)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.191</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Proposed In-Licensed Rights</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 3.8 (New Biotheus In-Licenses)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.192</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Prosecution and Maintenance</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 9.2(d) (BioNTech-Prosecuted Patent Rights)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.193</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Qualification Date</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Article 8 (Financial Terms)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.194</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Receiving Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 10.1(a) (General)&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.195</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Registrational Clinical Trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a Clinical Trial of a product that is designed to, and for which the competent Regulatory Authority has provided guidance that the design of such Clinical Trial is sufficient to, ascertain efficacy and safety of such product in support of the preparation and submission of an MAA for such product to the competent Regulatory Authority, regardless of whether such trial is referred to as a Phase II Trial, Phase IIb Trial or Phase III Trial or otherwise.  If a Clinical Trial of a product is not initially designed as a Registrational Clinical Trial but is later re-designed, converted or expanded into such a trial, then it shall be deemed to be a Registrational Clinical Trial as of the date of such re-design, conversion or expansion&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.196</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Regulatory Authority</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory authority, department, bureau, commission, council or other competent authority involved in the granting of any IND, Marketing Authorization, or other Regulatory Authorization including China&#8217;s Human Genetic Resources Office, and China General Customs Administration&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.197</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Regulatory Authorization</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of INDs, MAAs, BLAs, variations, extensions, supplements and amendments, and labelling approvals and licences and permissions for the export of data and materials) of any Regulatory Authority, necessary or useful for the use, Development, Manufacture, and Commercialization of a pharmaceutical or biopharmaceutical product in a regulatory jurisdiction, including Pricing and Reimbursement Approvals&#59;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.198</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Regulatory Documentation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all applications, filings, registrations, licenses, authorizations and approvals, including all Regulatory Authorizations, all correspondence submitted to or received from Regulatory Authorities and all supporting documents relating to the Licensed Products and all data contained in any of the foregoing, including all IND, NDA, BLA, MAA, Pricing and Reimbursement Approvals, regulatory drug list, advertising and promotion documents, clinical data, adverse events files and complaint files&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.199</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.200</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Regulatory Filing</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, with respect to the Licensed Product, any submission to a Regulatory Authority of any appropriate regulatory application with respect to such Licensed Product, including any submission to a regulatory advisory board, MAA, and any variation, extension, supplement or amendment thereto.  For the avoidance of doubt, Regulatory Filing shall include any IND, NDA, BLA, MAA or the corresponding applications in any other country or group of countries with respect to the Licensed Product&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.201</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Retained Territory</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means China&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.202</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Royalties</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.5(a) (Royalty Rates for  Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.203</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Royalty Rates</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.5(a) (Royalty Rates for Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.204</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Royalty Report</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.10 (Royalty Reports&#59; Payments)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.205</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Royalty Term</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means, &#91;***&#93;&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.206</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Sales Milestone Event</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.4 (Sales Milestone Payments for Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.207</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Sales Milestone Payment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.4 (Sales Milestone Payments for  Licensed Products)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.208</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Single Agent Activity</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.209</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Sublicensee</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Person, other than a Party or an Affiliate or Third Party Distributor of a Party, to whom a Party grants a sublicense of the licenses granted to such Party under this Agreement&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.210</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Target</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.211</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Tax or Taxation</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any form of tax or taxation, levy, duty, charge, social security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge, or interest) imposed by, or payable to, a tax authority&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.212</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Technology Transfer Payment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.2 (Technology Transfer Payment)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.213</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Term</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 13.1 (Term)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.214</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Terminated Products</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 13.3 (Effects of Termination)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.215</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Territory</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all countries of the world and all territories and possessions thereof excluding the Retained Territory&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.216</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Third Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Person other than a Party or an Affiliate of a Party&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.217</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Third Party Distributor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means any Third Party, other than a Sublicensee, that distributes (but does not Develop or Manufacture) a Licensed Product directly to customers&#59;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.218</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Third Party License</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means a written agreement between a Party or its Affiliates and a Third Party to license or acquire Third Party Intellectual Property Rights for use in connection with the Development, Manufacture or Commercialization of a Licensed Product, but excluding any agreements with Third Party Distributors&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.219</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Third Party Upstream Licensor</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.10 (Royalty Reports&#59; Payments)&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Trademarks</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means all registered and unregistered trademarks, service marks, trade dress, trade names, logos, insignias, symbols, designs, and all other indicia of ownership, and combinations thereof&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.221</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Trispecific Patent Right</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.222</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">United States or U.S.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the United States of America and all of its districts, territories and possessions&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.223</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Upfront Payment</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.1 (Upfront Payment)&#59;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.224</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Valid Claim</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:160%">1.225</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">VDR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means the virtual data room containing information, documents and data relating to the Licensed Compounds and Licensed Products made available by Biotheus to BioNTech prior to the Execution Date&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">1.226</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">Withholding Party</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">has the meaning set forth in Section 8.17 (Withholding Taxes)&#59; </font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:36.85pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.706%"><tr><td style="width:1.0%"></td><td style="width:6.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">1.227</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">1.228</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:9pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:160%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:150%">means &#91;***&#93;.</font></td></tr></table></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">OPTIONS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">2.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Options to BioNTech</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">PM8003 Option</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">As of the Effective Date Biotheus shall and shall procure that its Affiliates pause all clinical Development activities in relation to PM8003 Licensed Products until the expiry of the PM8003 Option Period. As of the Effective Date, Biotheus hereby grants to BioNTech the exclusive option, free of charge, exercisable at BioNTech's sole discretion during the PM8003 Option Period, to obtain the exclusive license set forth in Section 3.1(b) (PM8003 Licensed Products) with respect to PM8003 Licensed Products (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:190%">&#34;PM8003 Option&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">).  BioNTech may exercise the PM8003 Option by delivering written notice of such exercise to Biotheus within the PM8003 Option Period (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:190%">&#34;PM8003 Option Exercise Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">&#34;).  &#91;***&#93;  Upon BioNTech's delivery to Biotheus within the PM8003 Option Period of a PM8003 Option Exercise Notice the Parties shall determine whether filings are required under the HSR Act in connection therewith and, subject to the termination or expiration of any applicable waiting period or other applicable clearance under the HSR Act if any such filings are required (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:190%">PM8003 Option Exercise Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">&#8221;), BioNTech will be granted the license set forth in Section 3.1(b) (PM8003 Licensed Products) with respect to the PM8003 Licensed Products.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:190%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">The exercise of the PM8003 Option shall not involve any upfront or option exercise payments being due to Biotheus and any milestones that have already been triggered by a Licensed Product(s) prior to the PM8003 Option Exercise Date shall not be due in respect of the PM8003 Licensed Product PROVIDED THAT any applicable milestones and royalties set forth in Article 8 (Financial Terms) will be reduced in accordance with the terms and conditions set forth in Section 8.7 (PM8003 Licensed Products). If the Parties determine that a filing is required under the HSR Act they will cooperate in good faith with the respect to the preparation and submission of such a filing as soon as reasonably possible and with respect to responding promptly to any questions raised in relation to such filing. BioNTech will be responsible for paying any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:190%">filing fees required to be paid in connection with such a filing. &#91;***&#93;  After the PM8003 Option Exercise Date, BioNTech will be responsible for all Development, Manufacturing, regulatory activities for and Exploitation of PM8003 Licensed Products in the Territory and the costs and expenses in connection therewith and Biotheus will transfer to BioNTech the ownership of the IND for PM8003 Licensed Product for the Territory and any other Regulatory Filings for PM8003 Licensed Product for the Territory that are possessed or controlled by Biotheus or its Affiliates no more than &#91;***&#93; days following the PM8003 Option Exercise Date.  At BioNTech's discretion, following the PM8003 Option Exercise Date and subject to Biotheus&#8217; then-current capacity, BioNTech may request that Biotheus continues certain activities in relation to PM8003 Licensed Product, &#91;***&#93; and in accordance with a PM8003 Licensed Product development plan as approved by the Parties in the JSC, following the PM8003 Option Exercise Date.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Preclinical Multispecific Option</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">As of the Effective Date, Biotheus hereby grants to BioNTech the exclusive option, free of charge, exercisable at BioNTech's sole discretion during the Preclinical Multispecific Option Period, to obtain the exclusive license set forth in Section 3.1(c) (Preclinical Multispecific Licensed Products) with respect to Preclinical Multispecific Licensed Products (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Preclinical Multispecific Option&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">).  BioNTech may exercise the Preclinical Multispecific Option by delivering written notice of such exercise to Biotheus within the Preclinical Multispecific Option Period (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Preclinical Multispecific Option Exercise Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;). &#91;***&#93;  Biotheus shall keep BioNTech regularly updated via the JSC of all Preclinical Multispecific Licensed Compounds and Preclinical Multispecific Licensed Products it is currently working on and provide updates on Development activities in respect of the same at each meeting of the JSC.  The exercise of the Preclinical Multispecific Option shall not involve the payment to Biotheus of any upfront or option exercise payments and any milestones that have already been triggered by a Licensed Product(s) prior to the Preclinical Multispecific Option Exercise Date shall not be due in respect of Preclinical Multispecific Licensed Products, provided that any applicable milestones and royalties payable under Article 8 (Financial Terms) shall be reduced in accordance with the terms and conditions set forth in Section 8.8 (Preclinical Multispecific Licensed Products).  Upon BioNTech's delivery to Biotheus within the Preclinical Multispecific Option Period of a Preclinical </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Multispecific Option Exercise Notice the Parties shall determine whether filings are required under the HSR Act in connection therewith and, subject to the termination or expiration of any applicable waiting period or other applicable clearance under the HSR Act if any such filings are required (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Preclinical Multispecific Option Exercise Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;), BioNTech will be granted the license set forth in Section 3.1(c) (Preclinical Multispecific Licensed Products) with respect to the Preclinical Multispecific Licensed Products.  If the Parties determine that a filing is required under the HSR Act they will cooperate in good faith with the respect to the preparation and submission of such a filing as soon as reasonably possible and with respect to responding promptly to any questions raised in relation to such filing. BioNTech will be responsible for paying any filing fees required to be paid in connection with such a filing. Promptly and in any event within &#91;***&#93; days of the Preclinical Multispecific Option Exercise Date, Biotheus will at its cost and expense, provide BioNTech with the equivalent of the information set out in Section 3.4(a) (Knowledge and Technology Transfer) in respect of each such Preclinical Multispecific Licensed Product.  After the Preclinical Multispecific Option Exercise Date, BioNTech will be responsible for all Development, Manufacturing, regulatory activities for and Exploitation of Preclinical Multispecific Licensed Products in the Territory and the costs and expenses in connection therewith.  At BioNTech's discretion, following the Preclinical Multispecific Option Exercise and subject to Biotheus&#8217; then-current capacity, BioNTech may request that Biotheus continues certain activities in relation to Preclinical Multispecific Licensed Compound, &#91;***&#93; and in accordance with a Preclinical Multispecific Licensed Product development plan as approved by the Parties in the JSC, following the Preclinical Multispecific Option Exercise Date.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Biotheus Obligations</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">During the PM8003 Option Period and Preclinical Multispecific Option Period (as the case may be) Biotheus shall not and shall procure that its Affiliates shall not enter into or discuss entering into any agreement or other arrangement with any Third Party pursuant to which such Third Party is granted rights or an option to obtain rights in relation to the PM8003 Licensed Compound or PM8003 Licensed Product or Preclinical Multispecific Licensed Compound or Preclinical Multispecific Licensed Product, as the case may be.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Option Exercise</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">If BioNTech does not exercise the PM8003 Option during the PM8003 Option Period then BioNTech will not receive the license set forth in Section 3.1(b) (PM8003 Licensed Products), BioNTech will have no further rights or obligations with respect to PM8003 Licensed Compounds or PM8003 Licensed Products, PROVIDED THAT Biotheus may not resume Development and other Exploitation of PM8003 Licensed Compounds and PM8003 Licensed Products until the expiry of the PM8003 Option Period&#59;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">If BioNTech does not exercise the Preclinical Multispecific Option during the Preclinical Multispecific Option Period, then BioNTech will not receive the license set forth in Section 3.1(c) (Preclinical Multispecific Licensed Products), BioNTech will have no further rights or obligations with respect to such Preclinical Multispecific Licensed Compounds or Preclinical Multispecific Licensed Products, PROVIDED THAT Biotheus may not resume Development and other Exploitation of such Preclinical Multispecific Licensed Compounds and Preclinical Multispecific Licensed Products until the First Commercial Sale of a Licensed Product pursuant to this Agreement by or on behalf of BioNTech, its Affiliate or Sublicensee.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">2.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Option to Biotheus</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">LICENSES&#59; EXCLUSIVITY</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">License Grants to BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">.  Subject to terms and conditions of this Agreement,</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">PM8002 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Effective as of the Effective Date, Biotheus hereby grants BioNTech an exclusive, royalty-bearing, sublicensable through multiple tiers (in accordance with Section 3.2 (Sublicensing Rights)) license under the Licensed IP to Exploit PM8002 Licensed Products in the Field in the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">PM8003 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Effective as of the PM8003 Option Exercise Date, Biotheus hereby grants BioNTech an exclusive, royalty-bearing, sublicensable through multiple tiers (in accordance with Section 3.2 (Sublicensing Rights)) license under the Licensed IP to Exploit PM8003 Licensed Products in the Field in the Territory.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Preclinical Multispecific Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Effective as of the Preclinical Multispecific Option Exercise Date with respect to a Preclinical Multispecific Licensed Product and on a Preclinical Multispecific Licensed Product -by -Preclinical Multispecific Licensed Product basis, Biotheus hereby grants BioNTech an exclusive, royalty-bearing, sublicensable through multiple tiers (in accordance with Section 3.2 (Sublicensing Rights)) license under the Licensed IP to Exploit any applicable Preclinical Multispecific Licensed Product in the Field in the Territory.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Product License Exclusivity</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The licenses granted in Sections 3.1(a) (PM8002 Licensed Products), 3.1(b) (PM8003 Licensed Products) and 3.1(c) (Preclinical Multispecific Licensed Products) shall be exclusive in the Territory, even as to Biotheus, except as required for Biotheus to perform its obligations under the Global CDP and Joint CDP in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Retained Rights in the Retained Territory</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">Following the Effective Date and during the Term&#58;</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">Biotheus may not license, assign, transfer or grant any rights relating to the Licensed Compounds or Licensed Products in the Retained Territory to a BioNTech Retained Territory Competitor&#59; and</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">Biotheus shall ensure that any transfer, licence or other grant of rights relating to the Licensed Compounds or Licensed Products in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Retained Territory to a Third Party that is not a BioNTech Retained Territory Competitor shall be subject to the rights granted to BioNTech pursuant to this Agreement.  Biotheus will ensure that any such transfer, licence or other grant of rights&#58; (1) is consistent with the terms of this Agreement, and (2) requires the relevant transferee, licensee or other assignee or partner to comply with Biotheus' relevant obligations under this Agreement, including in relation to intellectual property, confidentiality and publications.  Biotheus will remain responsible and liable for the performance of all its transferees, licensees and other assignees or partners under their respective licensed, assigned or transferred or partnered rights to the same extent as if such activities were conducted by Biotheus.  Biotheus will deliver to BioNTech prompt written notice of any license or other partnering, assignment or transfer agreement relating to the Licensed Products in the Retained Territory with a Third Party no later than &#91;***&#93; days following the execution thereof and shall provide BioNTech with a copy of each such license or other agreement (and any amendment thereto) within &#91;***&#93; days after execution thereof (which copy may be redacted of any confidential or proprietary information that is not necessary for BioNTech to confirm or verify Biotheus' compliance with this Agreement). Subject to Section 3.1(e)(i) (Retained Rights in the Retained Territory), Biotheus retains the right to Exploit Licensed Products in the Field in the Retained Territory, except as required for BioNTech to (i) perform its obligations under the Global CDP and Joint CDP in accordance with the terms of this Agreement and (ii) exercise its rights pursuant to Section 3.1(f) (Manufacture in the Retained Territory).</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">For clarity, subject to Section 3.3 (Subcontractors) and Section 4.5(b) (Escalation) the provisions of Sections 3.1(e)(i)(A) and 3.1(e)(i)(B) above shall not prevent Biotheus &#91;***&#93; to conduct any activities with respect to the Exploitation of the Licensed Products in the Retained Territory and the restrictions in Section 3.1(e)(i)(A) and the reporting requirements in Section 3.1(e)(i)(B) shall not apply to &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">Manufacture in the Retained Territory</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Effective as of the Effective Date in respect of PM8002 Licensed Compounds, as of the PM8003 Option Exercise Date in respect of PM8003 Licensed Compounds, and as of the Preclinical Multispecific Option Exercise Date in respect of Preclinical Multispecific Licensed Products, Biotheus hereby grants BioNTech a co-exclusive royalty-free, sublicensable through multiple tiers (in accordance with Section 3.2 (Sublicensing Rights)) license under the Licensed IP (and any equivalent Patent Rights and Know-How Controlled by Biotheus and its Affiliates in the Retained Territory)  to Manufacture the Licensed Compounds and Licensed Products in the Retained Territory&#59; PROVIDED THAT&#58; (i) such Manufacture is solely for the purpose of Developing and Commercialising the Licensed Compounds and Licensed Products in the Field in the Territory&#59; and &#91;***&#93; and acting reasonably and in good faith, subject to Biotheus demonstrating it has sufficient then-current capacity and capability, and the Parties shall  for a period of &#91;***&#93; days thereafter discuss &#91;***&#93; terms for a manufacture and supply agreement under which Biotheus will manufacture and supply BioNTech's requirements for such Licensed Compounds and&#47;or Licensed Products in the Retained Territory.  For clarity, if the Parties do not agree the terms of such manufacture and supply agreement within &#91;***&#93; days then BioNTech will be free to use a Third Party to Manufacture such Licensed Compounds and Licensed Products in the Retained Territory, &#91;***&#93;. &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Sublicensing Rights</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Sublicenses</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the terms of this Agreement, including Section 3.2(b) (Sublicense Requirements), BioNTech may grant sublicenses of any rights granted by Biotheus under Section 3.1 (License Grants to BioNTech) through multiple tiers to any of its Affiliates or to one or more Sublicensees.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Sublicense Requirements</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech will ensure that all permitted sublicenses granted under this Agreement&#58; (a) are consistent with the terms of this Agreement, and (b) require the Sublicensee to comply with BioNTech's obligations under this Agreement, including the confidentiality and non-use obligations set forth in Section 10.1 (Confidentiality).  BioNTech will remain responsible and liable for the performance of all Affiliates and Sublicensees under their respective sublicensed rights to the same extent as if such activities were conducted by BioNTech.  &#91;***&#93;. If BioNTech or any of its Affiliates grants a sublicense to any Sublicensee under the rights granted hereunder in relation to  the Licensed Compounds, &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Subcontractors</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party may perform any of its obligations or exercise its rights under this Agreement through one or more subcontractors&#59; provided that (a) the subcontracting Party will not engage any subcontractor that has been debarred by any Regulatory Authority&#59; (b) the subcontracting Party remains fully responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself&#59; (c) the subcontractor undertakes in writing obligations of confidentiality and non-use applicable to the Confidential Information that are at least as stringent as those set forth in Section 10.1 (Confidentiality)&#59; (d) in the case of Biotheus any such subcontractor appointed by Biotheus in connection with performing services for Biotheus under the Global CDP or the Joint CDP under this Agreement in the Retained Territory or the Manufacturing activities contemplated to be conducted by Biotheus under Article 7 (Manufacturing and Technology Transfer) has been both successfully qualified and prior approved by BioNTech in writing (unless otherwise agreed by the Parties in writing)&#59; (e) the subcontractor agrees in writing to assign or grant a sublicensable license to the subcontracting Party to all Know-How and Patent Rights developed or invented by the subcontractor in performing services for the Party under this Agreement that are necessary or useful for the Development, Manufacture or Commercialization of any Licensed Product&#59; and (f) the subcontracting Party will be liable for any act or omission of any subcontractor that is a breach of any of the subcontracting Party's obligations under this Agreement as though the same were a breach by the subcontracting </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Party, and the non-subcontracting Party will have the right to proceed directly against the subcontracting Party without any obligation to first proceed against such subcontractor.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Knowledge and Technology Transfer</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Within &#91;***&#93; days of the Effective Date, (1) Biotheus will deliver to BioNTech and cause its Affiliates to deliver&#58; (i) &#91;***&#93; copies of the VDR with the content as it existed at the Execution Date&#59; and (ii) any information, documents or data in the possession or control of Biotheus or its Affiliates relating to the Licensed Compounds and Licensed Products that are not included in the VDR and (2) Biotheus will share such information &#91;***&#93; as agreed between the Parties.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Throughout the Term, Biotheus will to BioNTech, and cause its Affiliates to deliver, copies of (a) the written Licensed Know-How related to each Licensed Product, (b) documents and files related to the Licensed Patent Rights related to each Licensed Product, and (c) any other Licensed Know-How that is necessary or useful for the Exploitation of any Licensed Product in accordance with this Agreement&#59; PROVIDED THAT any Licensed Know-How relating to Manufacturing will be disclosed to BioNTech in accordance with Article 7 (Manufacturing and Technology Transfer).</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.74pt">As part of any Know-How transfer in accordance with Section 3.4(a) (Knowledge and Technology Transfer), and as otherwise required by the Global CDP and Joint CDP, (a) Biotheus will transfer to BioNTech Biotheus Materials, and (b) BioNTech will transfer to Biotheus BioNTech Materials, in each case related to any Licensed Product to the extent necessary or useful for the Parties to perform their respective obligations, and in the case of BioNTech to exercise the rights granted to it, under this Agreement.  Any Materials provided by a Party in accordance with this Section 3.4(c) (Knowledge and Technology Transfer) will remain the sole property of the supplying Party.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Biotheus will be responsible for all costs and expenses associated with the transfer to BioNTech of documentation and Materials and any Licensed Know-How in accordance with Sections 3.4(a) to 3.4(c) (Knowledge and Technology Transfer).  Unless otherwise agreed by the Parties in writing, Biotheus will make appropriate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">personnel who are fluent in English available to BioNTech at reasonable times and upon reasonable prior notice at no cost for the purpose of assisting BioNTech in understanding and using the Licensed Know-How in accordance with this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">No Implied Licenses&#59; Retained Rights</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party acknowledges that the rights and licenses granted under this Agreement are limited to the scope expressly granted herein, and Biotheus expressly reserves the rights under the Licensed IP to exercise its rights in the Retained Territory and perform its obligations under the Global CDP and Joint CDP.  Except for the rights expressly granted under this Agreement, no rights, title, licenses, or other interests of any nature whatsoever are granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  Accordingly, BioNTech will not practice or Exploit the Licensed Know-How and Licensed Patent Rights other than as expressly licensed in this Agreement, and Biotheus will not practice or Exploit the BioNTech Background IP or the BioNTech Foreground IP other than as expressly licensed in this Agreement. For clarity, (a) the licenses granted by Biotheus to BioNTech under this Agreement shall not include any license to Exploit any Biotheus propietary component or product in combination with a Licensed Product&#59; and (b) Biotheus shall not be entitled to Exploit the Licensed Products in the Retained Territory in combination with any BioNTech proprietary product or In-Licensed BioNTech Product without BioNTech&#8217;s prior consent, which shall not be unreasonably withheld or conditioned.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Biotheus Exclusivity</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Biotheus Exclusivity</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">During the period from the Effective Date until the First Commercial Sale of a Licensed Product, except for the Exploitation of Licensed Products in the Retained Territory, Biotheus shall not (and shall procure that its Affiliates do not) either on its own or with a Third Party (i) research, Develop, Manufacture or Commercialize &#91;***&#93;&#59; or (ii) clinically Develop, Manufacture or Commercialize any &#91;***&#93;.  For clarity, the foregoing shall not restrict Biotheus from Developing or otherwise Exploiting any products containing &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">BioNTech Competitor</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If a BioNTech Competitor becomes an Affiliate of Biotheus after the Execution Date (i) such Affiliate shall not have any access to any BioNTech Background IP or BioNTech Foreground IP or any Confidential Information of BioNTech&#59; and (ii) Biotheus and such Affiliate shall institute commercially reasonable technical and administrative procedures and safeguards designed to ensure that the requirements set forth in the foregoing Section 3.6(c)(i) are met, including by creating &#34;firewalls&#34; between (X) the personnel working on any activities of such Affiliate and (Y) the personnel working on activities under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">BioNTech Exclusivity and Improved Licensed Product Conditions</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">New Biotheus In-Licenses</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If Biotheus or any of its Affiliates intends to become a party to a license, sublicense or other agreement for additional rights that are necessary or reasonably useful for the Exploitation of any Licensed Product in the Field in the Territory, then Biotheus shall provide BioNTech with the proposed details of the applicable rights and Biotheus' proposal for the terms of the applicable agreement in advance (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Proposed In-Licensed Rights</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;).  Where such Proposed In-Licensed Rights are necessary for the Exploitation of any Licensed Product in the Field in the Territory, (a) BioNTech shall have the first right to negotiate and execute such license PROVIDED THAT in relation to (i) PM8003 Licensed Products prior to the PM8003 Option Exercise Date or (ii) Preclinical Multispecific Licensed Products prior to the Preclinical Multispecific Option Exercise Date, the Parties shall mutually agree on  whether to negotiate such a license and which Party should take the lead in such negotiations&#59; and (b) if BioNTech does not negotiate and execute such license, Biotheus shall obtain BioNTech's prior written consent to such Proposed In-Licensed Rights in advance in writing and shall consult and take </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">account of BioNTech's comments in the negotiation of any agreement relating to such Proposed In-Licensed Rights.  In the case of the foregoing (b), Biotheus shall ensure that Proposed In-Licensed Rights are sublicensable to BioNTech pursuant to this Agreement.  Promptly following execution of any agreement relating to any Proposed In-Licensed Rights, Biotheus shall provide BioNTech with such agreement, subject to customary and reasonable redaction.  If BioNTech notifies Biotheus in writing that it wishes to take a sublicense under Proposed In-Licensed Rights pursuant to this Agreement, then (1) the Proposed In-Licensed Rights shall automatically be included in the Licensed IP hereunder&#59; and (2) such license, sublicense or other agreement shall be a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Biotheus In-License</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221; hereunder. Otherwise, notwithstanding anything to the contrary in this Agreement, the Proposed In-Licensed Rights will not be included within the Licensed IP and such license, sublicense or other agreement shall not be a &#8220;Biotheus In-License&#8221; hereunder.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">3.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">GOVERNANCE.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Joint Steering Committee </font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Formation and Purpose of the JSC</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Promptly, but no later than &#91;***&#93; days after the Effective Date, the Parties will establish a Joint Steering Committee (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">JSC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), which JSC will coordinate and oversee the Parties' activities hereunder in accordance with this Section 4.1 (Joint Steering Committee).  The JSC will have the responsibilities set forth herein and will continue in operation for the Term unless dissolved earlier by the mutual agreement of the Parties..  Notwithstanding the foregoing, &#91;***&#93; may at its option and by prior written notice to &#91;***&#93; determine that the JSC under this Agreement (and any applicable Subcommittees) &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Membership</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will designate &#91;***&#93; representatives with appropriate expertise and seniority to serve as members of the JSC, and who have the authority to bind such Party with respect to matters within the purview of the JSC.  Each Party may replace its JSC representatives at any time upon written notice to the other Party.  &#91;***&#93; will designate &#91;***&#93; of its JSC members as the chairperson of the JSC.  The Parties, through the Alliance Managers, will alternate in calling meetings and preparing and circulating an agenda in advance of each meeting.  The Party that was not responsible for preparing the meeting agenda will prepare and circulate for review and approval by the other Party written minutes of such meeting within &#91;***&#93; days after such meeting.  The Parties will agree on the minutes of each meeting promptly, but in no event later than &#91;***&#93; Business Days after receipt of such minutes.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Meetings</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It is the intention of the Parties that the JSC will hold meetings &#91;***&#93;, save that each Party may request and convene a JSC meeting and propose agenda therefor at any time.  The JSC will meet virtually save that the JSC will have the option of meeting in person once per year alternately at a location agreed by the Parties.  The Alliance Manager of each Party or his or her designee will attend each meeting of the JSC as a non-voting participant.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> Each Party will be responsible for all of its own expenses of participating in any JSC meeting.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Meeting Agendas</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will disclose to the other Party the proposed agenda items along with appropriate information at least &#91;***&#93; Business Days in advance of each meeting of the JSC.  Notwithstanding the foregoing, under exigent circumstances requiring JSC input, a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such JSC meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Specific Responsibilities of the JSC</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The responsibilities of the JSC will be to&#58;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">oversee the overall strategic relationship between the Parties and the Development, Manufacturing and Commercialization of Licensed Products in the Territory and the Retained Territory&#59;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">review and discuss the Development of Licensed Products pursuant to the Global CDP and Joint CDP&#59;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">review, discuss and approve the Global CDP and Joint CDP and any updates thereto&#59;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">provide a forum to discuss and coordinate the Parties' respective activities in the Territory and the Retained Territory in respect of Licensed Products (including but not limited to the adoption of and amendments to clinical development plans and clinical protocols specific to the Territory or the Retained Territory)&#59; and</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.79pt">perform such other functions as appropriate to further the purposes of this Agreement as determined by the Parties.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Subcommittees</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">General</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The JSC will be entitled to form subcommittees or working groups to which it may delegate responsibilities to carry out certain activities allocated by the JSC&#59; any such subcommittees will be governed by the rules established by the JSC and may make such decisions in lieu of the JSC as delegated by the JSC.  Any disputes arising from such a subcommittee shall be escalated to the JSC for resolution.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Joint Development and Operations Working Group</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Without limiting Section 4.2(a) (Subcommittees)&#58;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">Promptly after the Effective Date, the JSC shall establish a joint development and operations working group (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Joint Development and Operations Working Group</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;) chaired by BioNTech comprised of an equal number of representatives from each Party. The Joint Development and Operations Working Group shall act as a forum for the Parties to (A) discuss and align on Development activities in their respective territories&#59; (B) oversee the implementation and progress of the Global CDP and the Joint CDP&#59; (C) to discuss and propose to the JSC for approval any amendments to the Global CDP or Joint CDP&#59; and (D) oversee any Global Trials.  The Joint Development and Operations Working Group will continue in operation for the Term unless dissolved earlier by the mutual agreement of the Parties.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">The JSC shall determine the desired membership of the Joint Development and Operations Working Group and once formed, the Parties shall mutually determine the time, place and procedure of meetings. The Parties, through their designated lead individuals, will alternate in calling meetings and preparing and circulating an agenda in advance of each meeting of the Joint Development and Operation Working Group. &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Joint IP Committee</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Without limiting Section 4.2(a) (Subcommittees)&#58;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">No later than &#91;***&#93; days after the Effective Date, the JSC shall establish a joint intellectual property committee (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Joint IP Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;) chaired by BioNTech and comprised of an equal number of representatives from each Party. The Joint IP Committee shall act as a forum for the Parties to discuss and align on patenting strategies with regard to Licensed Products and coordinate the Parties' efforts in accordance with the provisions of Article 9 (Intellectual Property) and other matters related to the prosecution and maintenance of Intellectual Property Rights hereunder, including submissions to and addressing notices from Regulatory Authorities that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">relate to regulatory-patent linkage procedures and proceedings.  The Joint IP Committee will continue in operation for the Term unless dissolved earlier by the mutual agreement of the Parties.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">The JSC shall determine the desired membership of the Joint IP Committee and once formed, the Parties, through their designated IP leads, shall determine the time, frequency, place and procedure of meetings. The Parties, through their designated IP leads, will alternate in calling meetings and preparing and circulating an agenda in advance of each meeting of the Joint IP Committee and will also alternate in preparing and circulating meeting minutes of each meeting of the Joint IP Committee. &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Alliance and Project Managers</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each of the Parties will appoint a project manager (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Project Manager</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) who shall be responsible for implementing and coordinating activities and facilitating the exchange of information between the Parties.  Each of the Parties will also appoint a single individual to ensure clear and responsive communication between the Parties and the effective exchange of information (each, an &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Alliance Manager</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).  The role of the Alliance Manager is to act as a single point of contact between the Parties to ensure a successful relationship under this Agreement.  The Alliance Managers will attend any JSC meetings.  Alliance Managers will be non-voting participants in all JSC meetings that they attend&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that an Alliance Manager may bring any matter to the attention of the JSC if such Alliance Manager reasonably believes that such matter warrants such attention.  Each Party will designate its initial Alliance Manager promptly after the Effective Date and each Party may change its designated Alliance Manager at any time upon written notice to the other Party.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other Party.  Each Alliance Manager will also&#58; (a) be the point of first referral in all matters of conflict resolution&#59; and (b) identify and bring disputes to the attention of the JSC in a timely manner.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Additional Participants</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">With the consent of the other Party, not to be unreasonably withheld, conditioned, or delayed, other employees of either Party or any of its Affiliates involved in the Development, Manufacturing or Commercialization of any Licensed Products may attend meetings of the JSC as non-voting participants.  In addition, with the consent of each Party, consultants, representatives, or advisors involved in the Development, Manufacturing or Commercialization of any Licensed Products may attend meetings of the JSC as non-voting observers&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that such Third Party participants and observers are under written obligations of confidentiality and non-use applicable to the Confidential Information of each Party that are at least as stringent as those set forth in Section 10.1 (Confidentiality).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Decision-Making</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Committee Decisions</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party's representatives on the JSC will&#91;***&#93; on all matters brought before such committee for a decision by consensus.  The JSC will make decisions as to matters within its jurisdiction by unanimous vote, which vote may either be reflected in the minutes of the committee meeting or by written consent signed by the chairperson or his or her designee identified in writing.  No vote will be binding on either Party unless each Party has &#91;***&#93; members of JSC as representatives in attendance.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Escalation</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In the event the JSC is unable to reach a decision by unanimous consensus, at the election of either Party, such Party may refer any other matters requiring the approval of the JSC to the Party's Executive Officer.  The Executive Officers will use good faith efforts to resolve any such disagreement so referred to them as soon as practicable, and any final decision that the Executive Officers agree to in writing will be conclusive and binding on the Parties.  If the Executive Officers are unable to resolve any disagreement so referred within a period of &#91;***&#93; days after such matter is referred to them (or such longer period as the Executive Officers may agree upon), then (i) BioNTech will have final decision-making authority with respect to the final resolution </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">of any disagreement requiring the approval of the JSC regarding activities in the Territory, all Global Trials, the Global CDP, the Joint CDP&#59; &#91;***&#93; (ii) subject to Section 4.5(b)(i) above, Biotheus will have final decision-making authority with respect to the final resolution of any disagreement requiring the approval of the JSC regarding activities in the Retained Territory&#59; and (iii) each Party will have final say in relation to the matters which such Party has final control over in Article 9 (Intellectual Property)&#59; PROVIDED THAT (A) both Biotheus and BioNTech shall conduct all Development and other Exploitation of the Licensed Products in the Retained Territory in accordance with the Global CDP and the Global Commercialization Strategy&#59; &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">4.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">General Authority</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The JSC and Alliance Manager will have solely the powers expressly assigned to them in this Article 4 (Governance) and elsewhere in this Agreement.  In conducting themselves on the JSC and as Alliance Managers, and in exercising their rights under this Article 4 (Governance), all representatives of each Party will consider diligently, reasonably and in good faith all input received from the other Party, and will use good faith efforts to reach unanimity, where required, on all matters before them.  Notwithstanding anything to the contrary set forth in this Agreement, the JSC will not have the right to make any decisions&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">to amend or modify this Agreement, or waive compliance with this Agreement&#59;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">in a manner that excuses such Party from any obligation specifically enumerated under this Agreement&#59;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.74pt">in a manner that negates any consent right or other right specifically allocated to the other Party under this Agreement&#59;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">to resolve any dispute involving the breach or alleged breach of this Agreement&#59;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">to resolve a matter if the provisions of this Agreement specify that agreement of the Parties, including consent of each Party, is required for such matter&#59;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:25.97pt">in a manner that the other Party reasonably believes would require such other Party to perform any act that would cause such Party to violate any Applicable Law or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">requirements of any Regulatory Authority, or otherwise breach any of its obligations hereunder&#59; or</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">otherwise expand the rights or reduce the obligations of either Party under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">DEVELOPMENT AND COMMERCIALIZATION</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Responsibilities</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Global Commercialization Strategy</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech shall prepare and have final say with regard to (including all updates thereto) a global commercialization strategy relating to the Commercialization of Licensed Products on a worldwide basis on the overall global branding (which is only applicable if the Parties agree to global branding), marketing, communication, positioning and medical strategies for Licensed Products, a description of any global level programs to be conducted and pricing guidelines and policy with respect to the Licensed Products (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Global Commercialization Strategy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).  &#91;***&#93; BioNTech shall provide Biotheus with its draft Global Commercialization Strategy and any draft amendments thereto sufficiently in advance of the proposed adoption to afford Biotheus a reasonable opportunity to review and comment on the drafts and shall consider Biotheus&#8217; comments and suggestions in good faith and shall incorporate any local requirements required by Applicable Law for the Retained Territory. Each Party will comply with the Global Commercialization Strategy in Commercializing Licensed Products in the Territory or the Retained Territory, as applicable. Notwithstanding the foregoing, Biotheus shall not be bound by any provisions in the Global Commercialization Strategy (as may be amended and supplemented) that are related to &#91;***&#93; of the Licensed Products in the Retained Territory.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Formation of Joint Commercialization Working Group</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The Parties will form a joint commercialization working group (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">JCWG</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;). The working group will provide a forum for the Parties to coordinate Commercialization activities in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">relation to Licensed Products as between the Territory and the Retained Territory, for BioNTech to provide any updates to Biotheus with regards to the Global Commercialization Strategy, and for Biotheus to provide any updates to BioNTech on its Commercialization activities in the Retained Territory to as to demonstrate consistency with the Global Commercialization Strategy. The JCWG will consist of an equal number of representatives from each Party having experience in the Commercialization of pharmaceutical products. The JCWG will meet &#91;***&#93; or at such other frequency as the JCWG shall agree.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Responsibilities in the Territory</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the terms of this Agreement, BioNTech, either on its own or through Affiliates or Third Parties, shall have sole discretion over, and the sole right and responsibility for, at its sole cost and expense, the Development, Manufacture and Commercialization of Licensed Products in the Territory.  Subject to Section 4.5 (Decision-Making), as between BioNTech and Biotheus, BioNTech shall have the sole decision-making authority for the operations, Development, Manufacture and Commercialization strategies and decisions, including funding and resourcing, related to the Development, Manufacture and Commercialization of Licensed Products in the Territory.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Responsibilities in the Retained Territory</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the terms of this Agreement, Biotheus, either on its own or through Affiliates or Third Parties, shall have sole discretion over, and the sole right and responsibility for, at its sole cost and expense, the Development, Manufacture and Commercialization of Licensed Products in the Retained Territory. Subject to Section 4.5 (Decision-Making), as between BioNTech and Biotheus, Biotheus shall have the sole decision-making authority for the operations, Development, Manufacture and Commercialization strategies and decisions, including funding and resourcing, related to the Development, Manufacture and Commercialization of Licensed Products in the Retained Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Diligence Obligation</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech shall use Commercially Reasonable Efforts to &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Clinical Development Plans</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Global CDP</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The Parties will agree in the JSC on a detailed clinical development plan (including any preclinical studies required to support clinical development activities) for any globally conducted trials for Licensed Products that recruit patients from both the Territory and the Retained Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Global Trials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;), including a budget for development and manufacturing costs (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Global CDP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;). BioNTech shall propose the draft of Global CDP to the JSC within &#91;***&#93; Business Days after the Effective Date and the Global CDP will be amended with new data&#47;information as appropriate&#59; &#91;***&#93;.  An outline of the Global CDP is set out in Schedule 1. Pursuant to the Global CDP, &#91;***&#93; will be responsible for recruiting from the Retained Territory &#91;***&#93; of the total number of patients proposed for the applicable Global Trial, PROVIDED THAT such percentage may be adjusted by agreement of the Parties if required by a relevant Regulatory Authority.  Any Global Trial will be run by or on behalf of BioNTech and BioNTech will be the regulatory sponsor of any Global Trial.  Each Party will bear the costs associated with the conduct of any Global Trial in its respective territory, meaning that &#91;***&#93; shall bear the costs of recruiting from the Retained Territory &#91;***&#93; of the total number of patients for a Global Trial as set out in this Section 5.3(a) (Global CDP) (or, if applicable, any adjusted percentage agreed between the Parties if required by a relevant Regulatory Authority). &#91;***&#93; For clarity, Biotheus shall not be obligated to bear any costs or expenses of any Global Trials save as expressly contemplated by this Section 5.3(a) (Global CDP) (unless otherwise agreed between the Parties).</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Joint CDP</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to Biotheus&#8217; then-current capacity, the Parties will agree in the JSC on a detailed clinical development plan for any trials for Licensed Products to be conducted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">by Biotheus on BioNTech&#8217;s behalf at BioNTech&#8217;s cost that recruit patients from the Territory (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Joint Trials</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;), including a budget for development and manufacturing costs (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Joint CDP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;). Such Joint CDP will be agreed between the Parties within two &#91;***&#93; after the Effective Date and will be amended from time to time.  An outline of the &#91;***&#93;.  The Joint CDP will include&#58; (a) the principal Development objectives to be undertaken, (b) the specific activities to be performed by Biotheus and any activities to be performed by BioNTech, and (c) the estimated timelines and a budget for expected Internal Costs and estimated External Expenses for the performance of such activities by Biotheus. Biotheus will provide BioNTech with updates on material developments (including preclinical and clinical Development activities), findings and issues as soon as they arise in respect of activities undertaken by Biotheus pursuant to the Joint CDP in addition to regular updates in writing at least &#91;***&#93; on activities completed and progress made under such plan.  Biotheus shall also provide with each update to BioNTech all data and results generated in carrying out the activities under the Joint CDP since the last update and shall make available Biotheus personnel to discuss such data and results.  Any Joint Trial will be run by Biotheus on behalf of BioNTech and BioNTech will be the regulatory sponsor of any Joint Trial.  The costs of such Joint Trials will be borne by BioNTech in accordance with Section 5.3(d) (Eligible Development Costs for the Joint CDP).</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.79pt">Changes to Global CDP and Joint CDP</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The JSC shall review the Global CDP and the Joint CDP as appropriate and shall update the plan accordingly. Either Party may suggest to the JSC modifications to the Global CDP and the Joint CDP which modifications will be reviewed and agreed by the JSC.  If the JSC cannot reach consensus with respect to changes to the Global CDP and the Joint CDP within &#91;***&#93; days of updates thereto being proposed to the JSC, subject to the restriction set forth in Sections 4.5(b) (Escalation) and 5.3(a) (Global CDP), BioNTech shall have final say with regard to setting the content of such Global CDP and the Joint CDP.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Eligible Development Costs for the Joint CDP</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the provisions of Section 7.1(b) (Supplies of PM8002 Licensed Products for Global CDP and Joint CDP), BioNTech will be responsible for the Eligible Development Costs incurred by Biotheus in the performance of Joint CDP Activities allocated to Biotheus under the Joint CDP, unless agreed otherwise by the Parties.  BioNTech shall reimburse Biotheus for such Eligible Development Costs incurred in accordance with the budget set out in the Joint CDP by quarterly payments in arrears.  BioNTech shall have no obligation to reimburse Biotheus for Eligible Development Costs incurred by Biotheus that are not included in the budget set out in the Joint CDP. Biotheus shall submit invoices for Eligible Development Costs to BioNTech at &#91;***&#93; and BioNTech shall make payment for Eligible Development Costs within &#91;***&#93; days following the receipt of an undisputed invoice from Biotheus. Each such invoice shall be accompanied by reasonable supporting documentation with respect to the Eligible Development Costs included in such invoice.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Eligible Development Costs for the Global CDP</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the provisions of Section 7.1(b) (Supplies of PM8002 Licensed Products for Global CDP and Joint CDP), each Party will bear the Eligible Development Costs incurred in carrying out the Global CDP Activities in its respective territory, which in the case of Biotheus shall include the costs of recruiting patients from the Retained Territory for a Global Trial as set out in Section 5.3(a) (Global CDP).</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">BioNTech Right to Carry out Activities</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech shall have the right but not the obligation to carry out any Joint CDP Activities or Global CDP Activities that are allocated to Biotheus if Biotheus fails to carry out such Joint CDP Activities or Global CDP Activities in accordance with the Joint CDP or Global CDP and the terms of this Agreement.  In such circumstances BioNTech shall have no obligation to reimburse Biotheus for the Eligible Development Costs incurred by Biotheus for the activities which Biotheus failed to carried out in accordance with the Joint CDP or Global CDP and the terms of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Conduct of Global CDP and</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Joint CDP Activities</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Following the Effective Date, BioNTech will take over as regulatory sponsor with respect to any Clinical Trials with respect to Licensed Products ongoing as at the Effective Date in the Territory.  The Parties will discuss and agree the timing and process for such transfer via the JSC.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Each Party will ensure that it allocates the appropriate number of suitably qualified staff to carry out the Global CDP Activities and Joint CDP Activities. All communications in respect of the Global CDP Activities and Joint CDP Activities will be carried out in English.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.74pt">Each Party will execute (itself or through its Affiliates or any subcontractor) the Global CDP Activities and Joint CDP Activities allocated to it set forth therein in accordance with the Global CDP and Joint CDP to achieve the objectives in the Global CDP and Joint CDP as applicable.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Each Party&#58; (a) will comply with all Applicable Laws in the performance of work under this Agreement and the Global CDP and Joint CDP and shall ensure that its Affiliates and subcontractors (as applicable) execute any Global CDP Activities and Joint CDP Activities on such Party's behalf under this Agreement and the Global CDP and Joint CDP in compliance with all Applicable Laws, and (b) shall, and shall procure that its Affiliates and subcontractors (as applicable), undertake the Global CDP Activities and Joint CDP Activities in good scientific manner and using appropriately skilled personnel.  Without limiting the foregoing or any other provision of this Agreement, if a relevant Regulatory Authority finds (via an inspection or otherwise) that Biotheus, its Affiliates or subcontractors are not complying with the requirements of this Section 5.4(d) (Conduct of Global CDP and Joint CDP Activities) then the Parties shall via the JSC discuss and agree a remediation plan and Biotheus shall follow such plan so as to cure any non-compliance.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Each Party will maintain laboratories, offices, and all other facilities at its own expense and risk necessary to carry out its responsibilities under the Global CDP and Joint CDP.  Each Party agrees to make its employees reasonably available at their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">respective places of employment to consult with the other Party on issues arising during the performance of any Global CDP Activities and Joint CDP Activities.  BioNTech and Biotheus will cooperate with each other in carrying out the Global CDP and Joint CDP.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Clinical Trials in the Territory and Combination Trials</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus may not conduct any Clinical Trials or other studies in relation to the Licensed Products in the Territory except pursuant to the Joint CDP or as set out in this Section 5.5 (Clinical Trials in the Territory and Combination Trials).  &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Data Sharing</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">To the extent permitted under Applicable Law, each Party hereby grants to the other Party (and its Affiliates and their respective licensees (in case of Biotheus) or Sublicensees (in case of BioNTech)), &#91;***&#93; the right to access the clinical and non-clinical data Controlled by that Party or its Affiliates and to cross-reference such data in the Regulatory Fillings of the other Party or any of its Affiliates and their respective licensees (in case of Biotheus) or Sublicensees (in case of BioNTech) in the other Party&#8217;s territory.  &#91;***&#93; where Biotheus uses the clinical data generated by or on behalf of BioNTech in an Opted-Out Trial in Biotheus&#8217; Regulatory Filings with the Regulatory Authorities in the Retained Territory for the purpose of obtaining Regulatory Authorizations of a Licensed Product for the Opted-Out Indication with respect to such Opted-Out Trial, then such use by Biotheus shall be subject to reimbursement of &#91;***&#93; of BioNTech's costs incurred for generating such clinical data in an Opted-Out Trial for the relevant Opt-Out Indication, calculated in accordance with Section 5.3(e) (Eligible Development Costs for the Global CDP) multiplied by &#91;***&#93;. For the purpose of this Section 5.6 (Data Sharing), if BioNTech proposes to conduct a Global Trial for a given Indication and Biotheus does not share in the costs of such trial in accordance with Section 5.3 (Clinical Development Plans), then such Clinical Trial is an &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Opted-Out Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221; and such Indication is an</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Opted-Out Indication</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;. If any BioNTech Background IP or BioNTech Foreground IP is incorporated in the Licensed Products Developed under the Global CDP in which Biotheus shares in the costs under such Global CDP in accordance with Section 5.3 (Clinical Development Plans) above, (a) BioNTech hereby grants to Biotheus a non-exclusive, sublicensable (through multiple tiers), &#91;***&#93; under such BioNTech Background IP or BioNTech </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Foreground IP that is so incorporated by or on behalf of BioNTech&#59; and (b) at Biotheus&#8217; request, BioNTech shall promptly transfer or cause its contractor(s) to transfer to Biotheus or its designated Third Party contractor all Know-How within such BioNTech Background IP or BioNTech Foreground IP, in each case (a) and (b) for the sole purpose of Biotheus Exploiting such Licensed Products in the Retained Territory.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Reporting</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Activities in the Territory</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech agrees to keep Biotheus reasonably updated regarding BioNTech's material Development activities in the Territory with respect to each Licensed Product by providing &#91;***&#93; written updates in the JSC in accordance with Article 4 (Governance) and following dissolution of the JSC, to Biotheus &#91;***&#93; on a Licensed Product-by-Licensed Product basis a written summary of Development activities in the Territory carried out by BioNTech in &#91;***&#93; since the date of the last update.  Such reports shall be the Confidential Information of BioNTech.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Activities in the Retained Territory</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus agrees to keep BioNTech reasonably updated regarding Biotheus' material Development activities in the Retained Territory with respect to each Licensed Product by (i) providing &#91;***&#93; written updates in the JSC in accordance with Article 4 (Governance) and following dissolution of the JSC, to BioNTech &#91;***&#93; in each &#91;***&#93; on a Licensed Product-by-Licensed Product basis a written summary of Development activities in the Retained Territory carried out by Biotheus in &#91;***&#93; since the date of the last update&#59; (ii) submitting draft clinical development plans (including designs and protocols for proposed Clinical Trials) for comment by BioNTech in advance of commencing any clinical Development activities in respect of Licensed Products in the Retained Territory and considering in good faith any comments received from BioNTech&#59; and (iii) promptly providing to BioNTech the results (including interim results) of any Clinical Trials relating to Licensed Products conducted by or on behalf of Biotheus in the Retained Territory. Such reports shall be the Confidential Information of Biotheus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">5.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Cooperation</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The Parties will collaborate in good faith to achieve smooth coordination and alignment between the Parties' Development and Commercialization activities with respect to Licensed Products in their respective territories subject and pursuant to the Global Commercialization Strategy.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">REGULATORY AFFAIRS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">6.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Regulatory Filings</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Regulatory Filings in the Territory</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Promptly upon request from BioNTech, Biotheus shall transfer all existing INDs relating to the Licensed Products in the Territory to BioNTech, along with all information and data required to support and maintain such INDs.  Prior to such transfer of such INDs, Biotheus will maintain and manage such INDs in accordance with any written instructions received from BioNTech.  In addition, until all existing INDs relating to the Licensed Products in the Territory have been transferred to BioNTech, Biotheus shall on written request from BioNTech file new INDs relating to the Licensed Products in the Territory in Indications specified by BioNTech. Promptly upon written request from BioNTech, Biotheus shall transfer all such new INDs to BioNTech, along with all information and data required to support and maintain such new INDs.  Prior to such transfer of such new INDs, Biotheus will maintain and manage such new INDs in accordance with any written instructions received from BioNTech. BioNTech shall bear and reimburse Biotheus for all External Expenses incurred by or on behalf of Biotheus in connection with maintenance or management of such INDs relating to the Licensed Products in the Territory (including External Expenses approved in advance in writing by BioNTech and incurred for filing of new INDs at BioNTech&#8217;s request) on or following the Execution Date until completion of the transfers of INDs.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Save for the transitional measures set out immediately above, BioNTech shall own and shall be responsible for the preparation and submission of all Regulatory Filings for all Licensed Products in the Territory at its own cost and expense and in its own name, including all communications, meetings and inspections with the Regulatory Authorities, save that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus shall, at its own cost and expense, provide (and use its reasonable efforts to procure that its Third Party CMOs provide) to BioNTech such support and input as BioNTech may from time to time request in writing, as may be reasonably necessary in respect of the preparation, filing and maintenance of Regulatory Filings for or inspections by a Regulatory Authority in relation to a Licensed Product in the Territory, including providing all documents, reports or other materials as may be necessary or useful for BioNTech or its Affiliates or their Sublicensees in dealing with such an inspection or preparing, filing and maintaining Regulatory Filings for the Licensed Products.  Biotheus shall review and comment on any proposed material Regulatory Filings provided to it by BioNTech promptly and in good time before any deadlines and use Commercially Reasonable Efforts to assist BioNTech in its efforts to prepare and submit any Regulatory Filings to obtain, support, or maintain Regulatory Authorizations for any Licensed Product in the Territory&#59; &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Regulatory Filings in the Retained Territory</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus shall own and shall be responsible for the preparation and submission of all Regulatory Filings for all Licensed Products in the Retained Territory at its own cost and expense and in its own name, including all communications, meetings and inspections with the Regulatory Authorities.  The Parties shall discuss and co-operate with each other to ensure that such Regulatory Filings including but not limited to Regulatory Filings made to any cross-border data privacy regulators are made in sufficient time so that to the extent reasonably possible there are no delays to the ability of BioNTech to exercise its rights under the licenses granted to BioNTech by Section 3.1 (License Grants to BioNTech) of this Agreement, and that if there are delays they are minimised to the extent reasonably possible.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Right of Reference</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">6.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">PV Agreement</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Within &#91;***&#93; days of the Effective Date, the Parties shall agree in good faith and execute a pharmacovigilance agreement to govern the exchange of safety data with respect to the PM8002 Licensed Compound and PM8002 Licensed Product.  Following the PM8003 Option </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Exercise Date or the Preclinical Multispecific Option Exercise Date, if BioNTech determines that a pharmacovigilance agreement should be executed between the Parties to govern the exchange of safety data with respect to the PM8003 Licensed Compound and PM8003 Licensed Product or a Preclinical Multispecific Licensed Compound and Preclinical Multispecific Licensed Product as applicable, BioNTech will notify Biotheus and the Parties shall agree in good faith and execute such agreement within &#91;***&#93; days following such notification.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">6.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Data Privacy</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If the Parties are going to share any patient data, patient records, safety data or other personal data, the Parties will transfer such data in accordance with Applicable Data Protection Law. To comply with the Applicable Data Protection Law, the Parties agree to enter into a separate data transfer agreement which sets out the data protection obligations of each Party including appropriate safeguards for cross-border transfers.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">MANUFACTURING AND TECHNOLOGY TRANSFER</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">7.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Manufacturing of PM8002 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Prior to Technology Transfer of PM8002 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">As promptly as reasonably practicable following the Execution Date, Biotheus shall conduct or procure that its existing CMO &#91;***&#93; conduct the CMC development work and Manufacturing preparatory work for the PM8002 Licensed Product the scope of which is &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">As promptly as reasonably practicable following the Execution Date and following discussion between the Parties and approval by BioNTech of the &#91;***&#93;, Biotheus shall Manufacture and&#47;or procure that &#91;***&#93; Manufacture a cGMP batch of PM8002 Licensed Product and carry out related activities the scope of which is &#91;***&#93;, and &#91;***&#93; shall bear the costs of such work as listed on &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">As promptly as reasonably practicable following the Execution Date, Biotheus shall conduct and&#47;or procure that &#91;***&#93; conduct the &#91;***&#93; for the PM8002 Licensed Product the scope of which is &#91;***&#93;, and &#91;***&#93; shall bear the costs of such work as listed on &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">As promptly as reasonably practicable following the Qualification Date, Biotheus shall conduct and&#47;or procure that &#91;***&#93; conduct the &#91;***&#93; activities for the PM8002 Licensed Product the scope of which is exclusively listed on &#91;***&#93;, and the costs of such work shall be shared between the Parties &#91;***&#93; by &#91;***&#93; and &#91;***&#93; by &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.79pt">As promptly as reasonably practicable following the Qualification Date, at the request of BioNTech in writing, Biotheus will procure that &#91;***&#93; conduct the &#91;***&#93; activities for the PM8002 Licensed Product the scope of which is exclusively listed on &#91;***&#93;, and &#91;***&#93; shall bear the costs in relation to such work carried out on behalf of BioNTech as listed on &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">For clarity, if BioNTech requests Biotheus to conduct any work that is not expressly listed on Schedule 4 and Biotheus agrees to conduct such work, such work shall be conducted at &#91;***&#93; cost.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:19.35pt">To the extent that any of the activities set out in &#91;***&#93; relate to drug product for PM8002 Licensed Products then such activities shall continue to be carried out at &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(viii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:17.13pt">Following completion of Manufacturing Technology Transfer each Party shall &#91;***&#93; work in its respective territory.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ix)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">&#91;***&#93; following the Effective Date, the Parties will negotiate and execute a manufacturing development and clinical supply agreement and quality agreement pertaining to PM8002 Licensed Product upon mutually agreed upon terms and conditions, pursuant to which Biotheus will Manufacture and supply BioNTech&#8217;s reasonable requirements for supply of PM8002 Licensed Product in the Territory for use in Clinical Trials. The Parties shall negotiate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">in good faith and enter into such agreement within &#91;***&#93; days of the Effective Date.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Supplies of PM8002 Licensed Products for Clinical Trials</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">From the Effective Date until successful completion of a Manufacturing Technology Transfer in respect of PM8002 Licensed Products pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), (A) Biotheus shall be responsible for having &#91;***&#93; complete the Manufacturing and release (it being understood that the release testing will be conducted first by Biotheus' qualified person, before BioNTech's qualified person conducts the final IMP release and BioNTech performs the sponsor release) of the PM8002 Licensed Products needed for the Global CDP and&#47;or Joint CDP and&#47;or any other Clinical Trials conducted by BioNTech in the Territory, as applicable&#59; (B) BioNTech shall be responsible for reimbursing Biotheus' Cost of Goods without mark-up in connection with any PM8002 Licensed Product supplied to BioNTech under this Section 7.1(b) (Supplies of PM8002 Licensed Products for Global CDP and Joint CDP)&#59; and (C) for clarity, save for such Cost of Goods, Biotheus shall be responsible for bearing any other costs, fees or other sums associated with its existing CMO agreements.  &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">In respect of Global Trials, on a Global Trial-by-Global Trial basis the Manufacture of PM8002 Licensed Products for each Global Trial will take place at a single Manufacturing site.  For Global Trials commenced prior to successful completion of a Manufacturing Technology Transfer in respect of PM8002 Licensed Products pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), Biotheus shall be responsible for having &#91;***&#93; complete the Manufacturing and release of PM8002 Licensed Products for such Global Trials at a single Manufacturing site in accordance with Section 7.1(b)(i) (Supplies of PM8002 Licensed Products for Clinical Trials) above.  For clarity, drug substance of PM8002 Licensed Compounds is Manufactured by Biotheus or its applicable Affiliates at Biotheus&#8217; location at Room 802-803, 8&#47;F, Building A, Venture Outsourcing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Center, No.188 Tongsheng Road, Nantong City, Jiangsu Province, China and drug product of PM8002 Licensed Product is Manufactured by &#91;***&#93;, in both cases, if approved and qualified by BioNTech for related manufacturing operations. For Global Trials commenced after successful completion of a Manufacturing Technology Transfer in respect of PM8002 Licensed Products pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), BioNTech shall be responsible for Manufacture of PM8002 Licensed Products for such Global Trials at a single Manufacturing site.  In circumstances where BioNTech will be supplying Biotheus PM8002 Licensed Products for the purpose of a Global Trial pursuant to this Section 7.1(b)(ii) (Supplies of PM8002 Licensed Products for Clinical Trials), the Parties will negotiate and execute a manufacturing development and clinical supply agreement and quality agreement to cover such supply pursuant to which Biotheus will be responsible for reimbursing BioNTech's Cost of Goods &#91;***&#93; in connection with any PM8002 Licensed Products supplied to Biotheus under this Section 7.1(b)(ii) (Supplies of PM8002 Licensed Products for Clinical Trials).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">7.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Manufacturing Technology Transfer for PM8002 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Promptly following the Effective Date (unless otherwise requested by BioNTech), Biotheus will, at its cost and expense, transfer and at BioNTech's request cause its designated Third Party Manufacturer of the PM8002 Licensed Products to transfer the Manufacturing process and analytical methods for PM8002 Licensed Products to BioNTech, including transferring&#58; all Licensed Know-How (including the information set out in Schedule 4 (Manufacturing and CMC Information)) necessary or useful to enable BioNTech or its Affiliates (or a Third Party designated on BioNTech's behalf) to Manufacture such PM8002 Licensed Products and to replicate the processes employed by or on behalf of Biotheus (including Biotheus' Third Party manufacturers) (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Manufacturing Technology Transfer&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">). For clarity, (i) Biotheus will only bear the  costs and expenses in connection with the Manufacturing Technology Transfer to &#91;***&#93; designated by BioNTech, and all and any costs and expenses in connection with the Manufacturing Technology Transfer to &#91;***&#93; shall be borne by &#91;***&#93;&#59; and (ii) the foregoing costs and expenses to be borne by Biotheus shall mean &#91;***&#93;.  Within &#91;***&#93; days after the Effective Date, the Parties shall initiate good-faith discussion on a technology transfer plan that will set </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">out (a) the detailed activities and timelines required to achieve the Manufacturing Technology Transfer consistent with the Manufacturing Technology Transfer activities as set forth in &#91;***&#93;, and (b) the on-site support and consultation to be provided by Biotheus, with a goal to adopt such technology transfer plan as soon as reasonably practicable following the Effective Date. The costs associated with the Manufacturing Technology Transfer borne by Biotheus shall include licensing and royalty payments, if any, due to Biotheus' existing cell line licensor and&#47;or manufacturer under Biotheus' existing agreements regarding the Manufacture of PM8002 Licensed Products. If BioNTech desires to continue using in relation to the Manufacture of PM8002 Licensed Products the cell line licensed from &#91;***&#93; to Biotheus, BioNTech acknowledges that it will need to obtain a separate license from &#91;***&#93; for such purpose (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#91;***&#93; License</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;). Biotheus will provide reasonable assistance to BioNTech to enable BioNTech to obtain such a &#91;***&#93; License and Biotheus shall reimburse BioNTech for any sums charged by &#91;***&#93; for the grant of such a license. For clarity, BioNTech shall be solely responsible for any and all payments (including but not limited to licensing and royalty payments) due to any cell line licensor and&#47;or manufacturer that is not Biotheus&#8217;s existing cell line licensor (or its successor) and&#47;or existing manufacturer (or its successor) and is designated or engaged by BioNTech. Biotheus will maintain in force its existing agreements with &#91;***&#93; as listed on Schedule 8B attached hereto with respect to the Manufacture of PM8002 Licensed Products until such time as the Manufacturing Technology Transfer has been completed in accordance with this Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products).  In addition to the CMC documents, Biotheus shall provide BioNTech or its external service provider with the following samples (including but not limited)&#58; Reasonable amounts of MCB (Master Cell Bank) and WCB (Working Cell Bank), analytical reference standards, process intermediates and any other samples that are required for a successful technology transfer of the Licensed Products.  If BioNTech obtains a &#91;***&#93; License pursuant to this Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), Biotheus agrees to provide reasonable assistance to BioNTech at Biotheus' cost to enable BioNTech to use the cell line to which such license relates including providing any letters of authorisation or assurances as to origin that BioNTech reasonably requests relating to any feed media for the cell line, and providing reasonable assistance to BioNTech for the purposes of responding to questions from any Regulatory Authority regarding any feed media for the cell line.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">7.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Following Completion of Manufacturing Technology Transfer for PM8002 Licensed Products</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Following the successful completion of the Manufacturing Technology Transfer pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), and subject to any agreement between the Parties for supply of PM8002 Licensed Products, as between the Parties, BioNTech either on its own or through Affiliates or a Third Party manufacturer on its behalf, will have sole discretion over, and the sole right and responsibility for, at its sole cost and expense, Manufacture in respect of PM8002 Licensed Products for the Territory, including all activities related to developing the process, analytics and formulation for the Manufacture of clinical and commercial quantities of PM8002 Licensed Products, the production, Manufacture, processing, filling, finishing, packaging, labelling, inspection, testing, receiving, holding and shipping of PM8002 Licensed Products, or any raw materials or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process qualification and validation, commercial Manufacture, stability, in-process and release testing, quality assurance and quality control.  Notwithstanding the foregoing, the Parties will reasonably co-operate in order to align their manufacturing process (and&#47;or those of their CMOs) for PM8002 Licensed Products in their respective territories.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">7.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Manufacturing of PM8003 Licensed Products and&#47;or Preclinical Multispecific Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">From the PM8003 Option Exercise Date or the Preclinical Multispecific Option Exercise Date as applicable, the terms set out in Section 7.1 (Manufacturing of PM8002 Licensed Products), Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products) and Section 7.3 (Following Completion of Manufacturing Technology Transfer for PM8002 Licensed Products) will apply mutatis mutandis to the manufacture of the PM8003 Licensed Compound and the PM8003 Licensed Product or the Preclinical Multispecific Licensed Compound and the Preclinical Multispecific Licensed Product, as applicable.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">7.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">BioNTech Audit Rights</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.57pt">For so long as Biotheus or its applicable Affiliate continues to Manufacture and supply any Licensed Product to BioNTech or to Manufacture any Licensed Product to be used in the Global Trials or Joint Trials, upon reasonable notice at least &#91;***&#93; days in advance of a proposed audit, during </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">regular business hours and under obligations of confidentiality, BioNTech (or its designees) shall be entitled to audit (either in person, online or on paper) and qualify Biotheus and all subcontractors or Third Parties used by Biotheus to Manufacture any Licensed Product that is supplied to BioNTech or used in the Global Trials or Joint Trials under this Agreement including Biotheus, its Affiliates, or any of their respective C(D)MOs or any other Third Party involved in such activities, and any activities relating to the creation or storage of any cell bank in connection with the Licensed Product that is supplied to BioNTech, to assess compliance with the applicable cGMP requirements and contractual agreements including but not limited to EudraLex Vol. 4 Part IV, and applicable EudraLex Annex 1 parts, US FDA 21 CFR Parts 11, 210, 211, WHO&#47;ICH&#47;PIC&#47;s Regulations and applicable quality agreements agreed between the Parties.  If such audit by BioNTech identifies any material non-compliance by Biotheus (including via its subcontractors) or its Affiliates (including via its subcontractors) with any of the foregoing then Biotheus shall take, and shall require its Affiliates or subcontractors to take, remedial actions to cure such non-compliance, and if such material non-compliance is confirmed to be an uncured material breach on the part of Biotheus pursuant to Section 13.2(b) (Termination for Breach), then the provisions of Section 13.2(b) (Termination for Breach) shall apply.  For clarity, any uncured failure to qualify on the part of Biotheus or &#91;***&#93; shall be deemed an alleged uncured material breach on the part of Biotheus pursuant to Section 13.2(b) (Termination for Breach) and the provisions of Section 13.2(b) (Termination for Breach) shall apply.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:24.35pt">For so long as Biotheus or its applicable Affiliate continues to conduct activities assigned to it under the Global CDP or Joint CDP and&#47;or any other activities relevant for Clinical Trials conducted by BioNTech in the Territory, as applicable, upon reasonable notice at least &#91;***&#93; days in advance of a proposed audit, during regular business hours and under obligations of confidentiality, BioNTech (or its designees) shall be entitled to audit (either in person, online or on paper) and qualify Biotheus and all subcontractors or Third Parties used by Biotheus to carry out activities under the Global CDP or Joint CDP and&#47;or activities relevant for Clinical Trials conducted by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech in the Territory, as applicable, including (a) Biotheus, its Affiliates, or any of their respective CROs or any other Third Party involved in clinical Development activities, testing activities (including clinical and preclinical testing) and any other activities under the Global CDP or Joint CDP&#59; and (b) any of Biotheus&#8217; or its Affiliates&#8217; clinical sites, as selected by BioNTech in its sole discretion, in each case of the foregoing (a) and (b), to assess compliance with all GxPs including but not limited to applicable cGCP requirements and all matters arising from any pharmacovigilance agreement agreed between the Parties pursuant to Section 6.2 (PV Agreement).  If such audit by BioNTech identifies any material non-compliance by Biotheus (including via its subcontractors and clinical sites) or its Affiliates (including via its subcontractors and clinical sites) with any of the foregoing then Biotheus&#180; shall take, and shall require its Affiliates, subcontractors or clinical sites to take, remedial actions to cure such non-compliance, and if such material non-compliance is confirmed to be an uncured material breach on the part of Biotheus pursuant to Section 13.2(b) (Termination for Breach), then the provisions of Section 13.2(b) (Termination for Breach) shall apply.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">In addition if BioNTech identifies any material non-compliance or failure to qualify on the part of any relevant Third Party pursuant to this Section 7.5 (BionTech Audit Rights) Biotheus shall at BioNTech's request terminate any agreement with such Third Party.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">FINANCIAL TERMS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech's payment obligations set out in the Article 8 (Financial Terms) are conditional on and subject to the completion of a successful audit by BioNTech to BioNTech&#8217;s reasonable satisfaction of, and at BioNTech&#8217;s discretion also qualification of, both Biotheus and &#91;***&#93; pursuant to Section 7.5(i) (BioNTech Audit Rights) (the date on which BioNTech is so satisfied being the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Qualification Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).  BioNTech shall commence such audit (which may be conducted by a Third Party acting for BioNTech) as soon as reasonably possible following the Execution Date but in no event later than &#91;***&#93;, and shall notify Biotheus promptly in writing with the results of such audit and, as applicable, qualification following BioNTech's completion of the audit and, as applicable, qualification, both of which shall take place no later than &#91;***&#93;.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If such audit or, as applicable, qualification, identify any non-compliance by Biotheus or &#91;***&#93;, Biotheus shall take such steps or procure that &#91;***&#93; takes such steps to cure such non-compliance.  If either Biotheus or &#91;***&#93; does not successfully complete such audit and, as applicable, qualification to BioNTech's reasonable satisfaction, BioNTech shall be entitled to terminate this Agreement without further liability pursuant to Section 13.2(a) (Termination for Convenience by BioNTech or Biotheus). If BioNTech does not complete such audit and, as applicable, qualification and notify Biotheus of the results thereof in writing on or before &#91;***&#93;, Biotheus shall be entitled to terminate this Agreement without further liability pursuant to Section 13.2(a) (Termination for Convenience by BioNTech or Biotheus). For clarity, no payments shall be due from BioNTech to Biotheus under this Agreement unless and until the Qualification Date is achieved, except that if this Agreement is terminated as a whole by Biotheus pursuant to Section 13.2(a) (Termination for Convenience by BioNTech or Biotheus), then BioNTech shall reimburse Biotheus for &#91;***&#93; of any costs and expenses incurred by Biotheus in conducting the activities requested by BioNTech in writing pursuant to  Section 7.1(a)(iii) (Prior to Technology Transfer of PM8002 Licensed Products). &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Upfront Payment</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech will pay to Biotheus a non-refundable (except as provided in this Agreement), non-creditable upfront payment of fifty five million United States Dollars ($55,000,000) (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Upfront Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).  The Upfront Payment shall become due and be paid by BioNTech to Biotheus no later than &#91;***&#93; days after BioNTech's receipt of an invoice from Biotheus, which invoice shall include the relevant PO number provided by BioNTech and be sent to BioNTech at &#91;***&#93;. Such invoice may be issued on or following the Qualification Date.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Technology Transfer Payment</font></div><div style="padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech will pay to Biotheus a payment of ten million United States Dollars ($10,000,000) (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Technology Transfer Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) upon successful completion of the Manufacturing Technology Transfer for PM8002 Licensed Products pursuant to Article 7 (Manufacturing and Technology Transfer) provided that such sum may be reduced in accordance with the provisions of Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products).  The Technology Transfer Payment shall become due and be paid by BioNTech to Biotheus no later than &#91;***&#93; days after BioNTech's receipt of an invoice from Biotheus, which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">invoice shall include the relevant PO number provided by BioNTech and be sent to BioNTech at &#91;***&#93;. Such invoice may be issued on or following the date the Manufacturing Technology Transfer for PM8002 Licensed Product is successfully completed pursuant to Article 7 (Manufacturing and Technology Transfer) as evidenced by a technology transfer report signed by the Parties (it being agreed and understood that the Parties shall sign such report if the successful completion of the Manufacturing Technology Transfer for PM8002 Licensed Products, as defined below, has occurred). For the purpose of this Section 8.2 (Technology Transfer Payment), the &#8220;successful completion of the Manufacturing Technology Transfer for PM8002 Licensed Products&#8221; shall mean &#91;***&#93;. Each Party shall use reasonable efforts to comply with any timelines agreed in the transfer plan.</font></div><div style="padding-left:35.45pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Development and Approval Milestone Payments for Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Following the Effective Date, BioNTech will pay Biotheus the amounts set forth in Table 8.3 below (each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Development Milestone Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) no later than &#91;***&#93; days after receipt of an invoice from Biotheus (except that for the Development Milestone Payment for Development Milestone Event Number 1 in the table below, such payment shall be payable by BioNTech within &#91;***&#93; Business Days after receipt of an invoice from Biotheus, which invoice shall be issuable after &#91;***&#93;.  An invoice shall be issuable by Biotheus after the first occurrence of each milestone event described below (each, a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Development Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) triggered by the first Licensed Product &#91;***&#93;, to achieve such  Development Milestone Event. BioNTech shall notify Biotheus in writing within &#91;***&#93; days of the achievement of each of the  Development Milestone Events set forth in Table &#91;***&#93;, whether the relevant milestone is achieved by BioNTech, its Affiliates or their respective Sublicensees. Irrespective of the number of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Licensed Products that has achieved a Development Milestone Event, the Development Milestone Payments shall be payable once only.  &#91;***&#93; </font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">For the purposes of Development Milestone Event 1 in the table below, &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Sales Milestone Payments for Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech will pay to Biotheus the amounts set forth in Table &#91;***&#93; below (each a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Sales Milestone Payment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) no later than &#91;***&#93; days after receipt of an undisputed invoice from Biotheus, which invoice shall be issuable after the first achievement of each event described below (each a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Sales Milestone Event</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) triggered by &#91;***&#93;.  BioNTech shall notify Biotheus in writing within &#91;***&#93; days of the end of the &#91;***&#93; in which the Sales Milestone Events set forth in Table &#91;***&#93; are achieved, whether the relevant milestone is achieved by BioNTech, its Affiliates or their respective Sublicensees. Irrespective of the number of Licensed Products that have achieved a Sales Milestone Event and how many times the same Sales Milestone Event is achieved, the Sales Milestone Payments shall be payable once only. </font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.23pt">Achievement of Multiple Sales Milestones</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If two or more Sales Milestone Events are achieved in the same &#91;***&#93;, then BioNTech will pay the Sales Milestone Payment in respect of the first such Sales Milestone Event to occur in that &#91;***&#93; when such milestone payment falls due, and the second Sales Milestone Event will be treated as having been achieved on the first day of the subsequent &#91;***&#93;.  In the event that a further Sales Milestone Event occurs in that subsequent &#91;***&#93;, such further Sales Milestone Event will be treated as having been achieved on the first day of the next &#91;***&#93;, and so forth. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Royalty Payments</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Royalty Rates for Licensed Products </font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the provisions of Section 8.5(b) (Adjustments to Royalties) and Sections 8.6 (Improved Licensed Products), 8.7 (PM8003 Licensed Products) or 8.8 (Preclinical Multispecific Licensed Products) in relation to Improved Licensed Products, PM8003 Licensed Products and&#47;or Preclinical Multispecific Licensed Products, &#91;***&#93;, BioNTech will pay to Biotheus tiered royalties based on annual Net Sales of a Licensed Product (on a Licensed Product-by-Licensed Product basis) by BioNTech and its Affiliates and its Sublicensees in a Calendar Year in the Territory during the Royalty Term for each such Licensed Product in such country at the rates set forth in Table &#91;***&#93; below.  The royalty payments made pursuant to this Section 8.5(a) (Royalty Rates for Licensed Products), the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Royalties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34; and the rates set forth in Table &#91;***&#93;, the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Royalty Rates&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">.</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;margin-top:18pt;padding-left:70.9pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.23pt">Adjustments to Royalties</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.57pt">Biosimilar Products</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.35pt">Compulsory Licenses </font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:22.13pt">Third Party Licenses</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(A)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">If in the absence of a license from a Third Party to any Patent Rights, the Development, Manufacture or Commercialization of a Licensed Product by BioNTech, its Affiliates or its or their Sublicensees would infringe such Patent Rights controlled by a Third Party and BioNTech obtains or prior to the Effective Date has obtained a license to such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Third Party Patent Rights (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#34;Additional Third Party Licenses&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">), BioNTech would be solely responsible for, as applicable, negotiating, obtaining and maintaining any such Additional Third Party Licenses but would not be obliged to do so.</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(B)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:22.13pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:141.75pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(C)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.57pt">Notwithstanding any provision to the contrary in this Agreement, Biotheus will remain solely responsible for the payment of any royalty, milestone, and other payment obligations, if any, due to Third Parties in connection with any agreement between Biotheus or its Affiliate relating to the Licensed IP including the Biotheus In-Licenses.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.57pt">No Valid Claim</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">On a Licensed Product-by-Licensed Product and country-by-country basis, if there is no Valid Claim of a Licensed Patent Right Covering such Licensed Product in such country but such Licensed Product is still the subject of Regulatory Exclusivity in such country, then the Royalty Rates for Royalties due to Biotheus pursuant to Section 8.5(a) (Royalty Rates for Licensed Products) with respect to such Licensed Product in such country for such Calendar Quarter shall be reduced by &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Cumulative Effect of Royalty Reductions</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">On a  &#91;***&#93; basis, in no event will the royalty reductions for a Licensed Product permitted under Section &#91;***&#93; in relation to Improved Licensed Products, PM8003 Licensed Products and&#47;or Preclinical Multispecific Licensed Products reduce the  Royalties due to Biotheus for such  Licensed Product pursuant to Section 8.5(a) (Royalty Rates for Licensed Products) in a country in a given &#91;***&#93; in the aggregate by &#91;***&#93; of the amount otherwise payable.  In the event that BioNTech would, but for the restriction set forth in this Section 8.5(c) (Cumulative Effect of Royalty Reductions), have the right to reduce the  Royalties due to Biotheus for a  Licensed Product pursuant to Section 8.5(a) (Royalty Rates for  Licensed Products) in a country in a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93; under Section&#160;8.5(a) (Royalty Rates for Licensed Products) to &#91;***&#93; then any such unused reduction may be carried forward and used as a credit in one or more future &#91;***&#93; for such  Licensed Product in the same country, and such unused reduction shall be carried forward until such time as such unused credit has been exhausted &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Improved Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Following the date that the Improved Licensed Product Conditions are met, (a) the applicable remaining milestone(s) that have not previously been triggered by another Licensed Product but are triggered by an Improved Licensed Product and royalty payments payable for such Improved Licensed Product under Sections 8.3 (Development and Approval Milestone Payments for Licensed Products) and 8.5 (Royalty Payments for Licensed Products) above shall all be reduced by &#91;***&#93; of the sums otherwise payable in respect of such Improved Licensed Product&#59; and (b) the applicable Sales Milestone Payments payable for such Improved Licensed Product under Section 8.4 (Sales Milestone Payments for Licensed Products) shall be reduced in proportion to the annual Net Sales of such Improved Licensed Product as a proportion of overall annual Net Sales of Licensed Products.  For example, where there are two Licensed Products&#58; Licensed Product A (a Bispecific Antibody in protein form) and Licensed Product B (a Bispecific Antibody in nucleotide form) and the annual Net Sales of both Licensed Products combined is $&#91;***&#93; with each Licensed Product contributing &#91;***&#93; of Net Sales then the $&#91;***&#93;  Sales Milestone Payment that would otherwise be due pursuant to Section 8.4 (Sales Milestone Payments for Licensed Products) shall be reduced as follows&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;For clarity, no milestones that have previously been triggered by another Licensed Product pursuant to Section 8.3 (Development and Approval Milestone Payments for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Licensed Products) will be due a second time if such Improved Licensed Product achieves the relevant Milestone Event.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">PM8003 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Following the PM8003 Option Exercise Date, (a) the applicable remaining milestone(s) that have not previously been triggered by another Licensed Product but are triggered by a PM8003 Licensed Product and royalty payments payable for such PM8003 Licensed Product under Sections 8.3 (Development and Approval Milestone Payments for Licensed Products), 8.4 (Sales Milestone Payments for Licensed Products) and 8.5 (Royalty Payments for Licensed Products) above shall all be reduced by &#91;***&#93; of the sums otherwise payable in respect of such PM8003 Licensed Product.  For clarity, no milestones that have previously been triggered by another Licensed Product pursuant to Section 8.3 (Development and Approval Milestone Payments for Licensed Products) will be due a second time if such PM8003 Licensed Product achieves the relevant Milestone Event.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Preclinical Multispecific Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Following the Preclinical Multispecific Option Exercise Date, (a) the applicable remaining milestone(s) that have not previously been triggered by another Licensed Product but are triggered by a Preclinical Multispecific Licensed Product and royalty payments payable for such Preclinical Multispecific Licensed Product under Sections 8.3 (Development and Approval Milestone Payments for Licensed Products), 8.4 (Sales Milestone Payments for Licensed Products) and 8.5 (Royalty Payments for Licensed Products) above shall all be reduced by &#91;***&#93; of the sums otherwise payable in respect of such Preclinical Multispecific Licensed Product.  For clarity, no milestones that have previously been triggered by another Licensed Product pursuant to Section 8.3 (Development and Approval Milestone Payments for Licensed Products) will be due a second time if such Preclinical Multispecific Licensed Product achieves the relevant Milestone Event.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Combinations with In-Licensed BioNTech Products</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In the event that a milestone under Section 8.3 (Development and Approval Milestone Payments for Licensed Products) is triggered by (a) &#91;***&#93;&#59; or (b) &#91;***&#93;, then the respective </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">milestone payment will be payable for such Licensed Product under Section 8.3 (Development and Approval Milestone Payments for Licensed Products) above shall be reduced &#91;***&#93; of the sums otherwise payable in respect of such Licensed Product&#59; &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Royalty Reports&#59; Payments</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Commencing on the First Commercial Sale of a Licensed Product and for so long as Royalties are due under this Agreement, no later than &#91;***&#93; days after the end of each &#91;***&#93;, BioNTech will provide to Biotheus a written report (each, a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Royalty Report</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), which Royalty Report will set forth&#58; &#91;***&#93;.  All Royalty Reports will be the Confidential Information of BioNTech. BioNTech will make all Royalty payments for each &#91;***&#93; no later than &#91;***&#93; days after receipt of an invoice from Biotheus, which invoice shall be provided promptly following the receipt by Biotheus of each Royalty Report from BioNTech pursuant to this Section 8.10 (Royalty Reports&#59; Payments).  &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Other Payments</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the terms and conditions of this Agreement, each Party will pay to the other Party any other undisputed amounts due under this Agreement no later than &#91;***&#93; days after receipt of the relevant invoice. &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Records and Audits</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Books and Records</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will (a) keep complete, true, and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including in relation to, Eligible Development Costs, Cost of Goods, and Net Sales of Licensed Products in sufficient detail to enable amounts owed or payable to the other Party hereunder to be determined&#59; and (b) maintain such books and records for at least &#91;***&#93; following the &#91;***&#93; to which they pertain.  Each Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Auditing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) may, upon written request, cause an internationally-recognized independent &#34;Top Four&#34; accounting firm (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Auditor</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), that is reasonably acceptable to the other Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Audited Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) to inspect the relevant records of such Audited Party and its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Affiliates to verify the payments made and amounts reported by the Audited Party and the related reports, statements, and books of accounts, as applicable.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Audit Procedure</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Before beginning its audit, the Auditor will execute a written agreement acceptable to the Audited Party by which the Auditor agrees to keep confidential all information reviewed during the audit, which agreement will contain terms of non-disclosure and non-use no less stringent than those set forth in this Agreement.  The Auditor will have the right to disclose to the Auditing Party only its conclusions regarding any payments owed under this Agreement.  Each Party and its Affiliates will make their records available for inspection by the Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the Auditing Party.  The records will be reviewed solely to verify the accuracy of the Audited Party's Royalties and other payment obligations and compliance with the financial terms of this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Frequency&#59; Overpayments and Underpayments</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Such inspection right will not be exercised more than once in any &#91;***&#93; and not more than once with respect to records covering any specific period of time.  In addition, the Auditing Party will only be entitled to audit the books and records of the Audited Party for the &#91;***&#93;  prior to the &#91;***&#93; in which the audit request is made.  The Auditing Party agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any Applicable Law or judicial order.  The Auditor will provide its audit report and the conclusions of its determination to the Audited Party at the time such report is provided to the Auditing Party before it is considered final.  In the event that the final result of the inspection reveals an underpayment or overpayment by either Party, the underpaid or overpaid amount will be settled promptly.  The Auditing Party will pay for such inspections, as well as its expenses associated with enforcing its rights with respect to any payments hereunder&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that if an underpayment of more than &#91;***&#93; of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">total payments due hereunder for the applicable year is discovered, then the fees and expenses charged by the Auditor will be paid by Audited Party.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Currency of Payment</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">All amounts to be paid pursuant to this Agreement will be paid in United States Dollars.  When conversion of payments from any foreign currency is required to be undertaken by BioNTech, the United States Dollar equivalent will be calculated using BioNTech's then-current standard exchange rate methodology as applied in its external reporting for the conversion of foreign currency sales into United States Dollars.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Late Fees</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If any payment due to either Party under this Agreement is not paid when due, then such paying Party shall pay interest thereon (before and after any judgment) at an &#91;***&#93; rate &#91;***&#93; of &#91;***&#93;, such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Currency Restrictions</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In the event that, by reason of Applicable Law in any country, it becomes impossible or illegal for a Party to transfer, or have transferred on its behalf, payments owed to the other Party hereunder, such Party will promptly notify the other Party of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of &#91;***&#93; days, in a recognized banking institution selected by the transferring Party, as the case may be, and identified in a written notice given to the other Party.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">No Refunds&#59; Offsets</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Except as expressly set forth under this Agreement, all payments under this Agreement will be irrevocable, non-refundable, and non-creditable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Withholding Taxes</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The Royalties, milestone payments, and other amounts payable by a Party to the other Party pursuant to this Agreement (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) shall not be reduced on account of Taxes unless required by Applicable Law.  The receiving Party alone shall be responsible for paying any and all Taxes (other than withholding Taxes required by Applicable Law to be paid by the paying Party) levied on account of, or measured in whole or in part by reference to, any Payments it receives.  Either Party (a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Withholding Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) shall deduct or withhold from the Payments due to the other Party (a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Non-Withholding Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) any Taxes that it is required by Applicable Law to deduct or withhold.  If, however, the Non-Withholding Party is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, then it may deliver to the Withholding Party or the appropriate Governmental Authority (with the assistance of the Withholding Party to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the Withholding Party of its obligation to withhold tax, and the Withholding Party shall apply the reduced rate of withholding, or dispense with withholding, as the case may be, PROVIDED THAT the Withholding Party has received evidence, in a form reasonably satisfactory to the Withholding Party, of the Non-Withholding Party's delivery of all applicable forms prior to the time that the Payments are due and the respective approval from the authorities.  If the Withholding Party withholds any Taxes from the Payments while the Non-Withholding Party is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, then the Withholding Party shall cooperate with the Non-Withholding Party with respect to any documentation required by the appropriate Governmental Authority or reasonably requested by the Non-Withholding Party to secure a reduction of the rate of, or the elimination of, the applicable Taxes withheld. Notwithstanding anything to the contrary contained herein, BioNTech&#8217;s reimbursement of the Eligible Development Costs shall not be deemed to be the Payments or subject to any deduction or withholding of Taxes.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">8.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Indirect Taxes</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Notwithstanding anything to the contrary contained in this Article 8 (Financial Terms) or elsewhere in this Agreement, the following shall apply with respect to Indirect Taxes.  All Payments are stated exclusive of Indirect Taxes.  If any Indirect Taxes are chargeable in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">respect of any Payments, then the paying Party shall pay such Indirect Taxes at the applicable rate in respect of any such Payments following the receipt, where applicable, of an Indirect Taxes invoice issued in the appropriate form by the receiving Party in respect of those Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which such Indirect Taxes relate.  The Parties shall issue invoices for all goods and services supplied under this Agreement consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate form, the Parties shall cooperate to provide such information or assistance as may be necessary to enable the issuance of such invoice consistent with Indirect Tax requirements. Biotheus shall provide any documents necessary for tax and customs clearance in a format as reasonably required and specified by BioNTech.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:29.89pt">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Ownership of Inventions</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Ownership </font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.57pt">Background IP</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">As between the Parties, and subject to the licenses granted under this Agreement, (i) BioNTech and its Affiliates shall solely own (or retain ownership of) all rights, title and interests in and to any of the BioNTech Background IP, (ii) Biotheus and its Affiliates shall solely own (or retain ownership of) all rights, title and interests in and to any of the Licensed IP and (iii) each Party or its Affiliates, as applicable, shall solely own (or retain ownership of) any other Know-How and Inventions that are developed by or on behalf of that Party outside and independently of the activities under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.35pt">Foreground IP</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to Section 5.6 (Data Sharing), as between the Parties, &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Disclosure</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">During the Term, each Party will promptly disclose to the other Party all Inventions that it develops or invents in the course of carrying out activities pursuant to the Joint CDP or Global CDP, whether solely or jointly with others (in any event, prior to the filing of any patent application with respect to such Inventions), including all invention disclosures or other similar documents submitted to such Party by its or its Affiliates' employees, agents, or independent contractors relating thereto.  Each Party will also respond promptly to reasonable requests from the other Party for additional information relating to such Inventions.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Personnel Obligations</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each employee, agent, or independent contractor of a Party or its respective Affiliates or Sublicensees performing work under this Agreement will, prior to commencing such work, be bound by invention assignment obligations, including&#58; (a)&#160;promptly reporting any invention, discovery, process or other Intellectual Property Rights&#59; (b)&#160;presently assigning to the applicable Party all of his or her rights, title and interests in and to any invention, discovery, process, or other Intellectual Property Rights&#59; (c)&#160;cooperating in the Prosecution and Maintenance and enforcement of any patent and patent application&#59; and (d)&#160;performing all acts and signing, executing, acknowledging, and delivering any and all documents required for effecting the obligations and purposes of this Agreement.  It is understood and agreed that such invention assignment agreement need not reference or be specific to this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Patent Prosecution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:209%">. </font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">PM8002 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">PM8003 Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Preclinical Multispecific Licensed Products</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:25.97pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:26.52pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Patent Enforcement</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Notification</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will promptly notify the other in the event of any actual, likely or suspected infringement of &#91;***&#93;, including any Infringement that arises as a result of the making, using, offering to sell, selling, or importing of a product that would be competitive with a Licensed Product and that is Directed to the same Target as such Licensed Product (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Competitive Infringement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;).  In addition, each Party will promptly notify the other in the event such Party becomes aware of any action by a Third Party for a declaration that any of the Product-Specific Patent Rights are not infringed or are invalid, or unenforceable.  In all cases, each Party will provide any available evidence of such Infringement or other conduct with such notification. </font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Infringement Actions</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Collaboration</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will provide the other Party with reasonable assistance in the enforcement action brought under this Section 9.3 (Patent Enforcement), at the enforcing Party's request and expense, including to be named in such action if required by, or desirable under, Applicable Laws to pursue such action.  The enforcing Party will keep the non-enforcing Party regularly informed of the status and progress of such enforcement efforts, will reasonably consider the non-enforcing Party's comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.  The non-enforcing Party will be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but will at all times cooperate with the enforcing Party in good faith.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Expenses and Recoveries</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The enforcing Party will be solely responsible for any expenses (including attorneys' fees and costs) incurred by the enforcing Party as a result of such claim, suit, or action.  If the enforcing Party recovers monetary damages in such claim, suit, or action, then such recovery will be allocated first to the reimbursement of any expenses incurred by the enforcing Party in bringing suit and the reimbursement of any expenses incurred by the non-enforcing Party in such litigation, allocated in proportion to the amounts the Parties have incurred, and any remaining amounts shall be treated as Net Sales for the purposes of this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:21.56pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Use of Trademarks</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">9.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:21.56pt">Marking</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party shall, and shall cause its Affiliates and their Sublicensees to, mark the Licensed Products sold under this Agreement with the number of each issued and granted Licensed Patent Right that applies to the relevant Licensed Products if required by Applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.33pt">CONFIDENTIALITY</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Confidential Information</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">General</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Receiving Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) will maintain all Confidential Information disclosed to it or its representatives by or on behalf the other Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Disclosing Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) in confidence during the Term of this Agreement and for a period of &#91;***&#93; years after the expiration or termination of this Agreement&#59; provided that any Confidential Information of either Party that constitutes a trade secret will continue to be subject to the terms of this 10.1 (Confidentiality) in perpetuity, so long as such information remains a trade secret.  Each Party will use all such disclosed Confidential Information of the Disclosing Party only to the extent necessary for purposes of this Agreement, including exercising the licenses and rights hereunder and will not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except as permitted under this Agreement.  The Parties will agree a policy for managing trade secrets provided by a Party under this Agreement.  Each Party will notify the other Party promptly on discovery of any unauthorized use or disclosure by a Party of the other Party's Confidential Information, including the other Party's trade secrets.  Product-Specific Know-How is the Confidential Information of both Parties provided that (i) other than for the purposes permitted in Section 10.1(d) (Permitted Disclosures) below and Section 10.3 (Publications and Presentations) below, Biotheus shall not disclose the Product-Specific Know-How to a Third Party or otherwise publish the Product-Specific Know-How without the prior written consent of BioNTech and (ii) other than for the purposes permitted in Section 10.1(d) (Permitted Disclosures) below and Section 10.3 (Publications and Presentations) below, BioNTech shall not disclose  the Product-Specific Know-How to a Third Party or otherwise publish the Product-Specific Know-How without the prior written consent of Biotheus.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Confidential Information of Each Party</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Except as otherwise specified in this Agreement, all information disclosed prior to the Execution Date pursuant to the Confidential Disclosure Agreement between the Parties dated &#91;***&#93; (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Confidentiality Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) by Biotheus to BioNTech will be Confidential Information of Biotheus and by BioNTech to Biotheus will be Confidential Information of BioNTech.  During the Term, Biotheus shall not disclose to a Third Party any Licensed Know-How that is specific to a Licensed Compound or Licensed Product without the prior written consent of BioNTech.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Exceptions to Confidentiality</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The following information will not be Confidential Information of the Disclosing Party and accordingly, the obligations of each Receiving Party imposed by Section 10.1(a) (General) will not apply to any such information that&#58; (a) was known to the Receiving Party without an obligation to keep such information confidential prior to the Execution Date other than as a result of disclosure under any other agreement between the Parties, including the Confidentiality Agreement (as demonstrated by documentary evidence)&#59; (b) is or becomes generally available to the public through means other than an unauthorized disclosure by the Receiving Party, its Affiliates, or any of its agents to whom it or they disclosed such information&#59; (c) was or subsequently is disclosed to the Receiving Party without restriction by a Third Party having a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> right to disclose such Confidential Information without breaching any obligation to the Disclosing Party&#59; or (d) is developed independently by the Receiving Party without use of or reference to any of the Disclosing Party's Confidential Information.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Permitted Disclosures</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.57pt">General</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Notwithstanding any provision to the contrary set forth in this Section 10.1 (Confidential Information), each Receiving Party may use and make disclosures of Confidential Information of the Disclosing Party&#58; (i) to its Affiliates, and the Receiving Party's or its Affiliates' employees, directors, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">agents, consultants, or advisors, or actual or potential Sublicensees to the extent necessary for the potential or actual performance of its obligations or exercise of its licenses and other rights under this Agreement, in each case, who are under an obligation of confidentiality and non-use with respect to such information that is no less stringent than the terms of this Agreement&#59; (ii) subject to Section 10.1(a) (General), to patent offices in any country in which Patent Rights are sought for purposes of filing and prosecuting any applications for any Patent Rights which may be filed in accordance with this Agreement or defending any such Patent Rights in challenges to the validity of such Patent Rights as contemplated by this Agreement&#59; (iii) to Regulatory Authorities or Governmental Authorities as necessary to pursue Development, Commercialization, Manufacturing, Regulatory Filing, or Marketing Authorization of Licensed Products&#59; provided, that such Confidential Information will be disclosed only to the extent reasonably necessary to do so, and where permitted, subject to confidential treatment&#59; (iv) to the extent required to comply with Applicable Law or a court or administrative order, including of any national regulatory agency or listing authority&#59; or (v) to any tax authority, in each case, to the extent applicable to such Party at such time&#59; provided, however, that in respect of part (iv) the Party who is required to make such disclosure (A) provides the other Party with reasonable prior written notice, (B) coordinates with the other Party with respect to the wording and timing of any such disclosure and affords the other Party an opportunity to oppose or limit, or secure confidential treatment for such required disclosure, (C) if unsuccessful in its efforts pursuant to clause (B), takes all reasonable and lawful actions to obtain confidential treatment for such disclosure, and (D) discloses the minimum amount and scope of the Confidential Information necessary to comply with Applicable Law.  Notwithstanding the foregoing, any Confidential Information so disclosed will remain subject to the terms of this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:113.4pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.35pt">Agreement</font></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Solely with respect to the terms of this Agreement, either Party may disclose the terms of this Agreement to any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> actual or prospective acquirers, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:106.3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">underwriters, investors, lenders or other financing sources (including in connection with any royalty monetization transaction) and any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">bona fide</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%"> actual or prospective licensors, Sublicensees, licensees, or strategic partners and to employees, directors, agents, consultants, and advisers of such Third Party, who are under an obligation of confidentiality with respect to such information that is no less stringent than the terms of this Agreement, and PROVIDED THAT such Confidential Information will be disclosed only to the extent reasonably necessary to evaluate the proposed transaction or perform its obligations or exercise its rights granted under the applicable agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Publicity</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">At a date to be agreed between the Parties following the Execution Date &#91;***&#93;, Biotheus may issue a press release in the form agreed and set out in Schedule 9 (Biotheus Press Release). Except for the foregoing and as required by Applicable Law, legal process or stock exchange rules, Biotheus shall not issue a press or news release or make any similar public announcement related to the execution or terms of this Agreement, the conduct of Development activities or the Commercialization of Licensed Products without the prior written consent of BioNTech.  For clarity, any such press or news release or similar public announcement by Biotheus shall take into account any comments or edits required by BioNTech as a condition of approval. BioNTech will in its discretion be entitled to make press or news releases or similar public announcements related to the conduct of Development activities or the Commercialization of Licensed Products in the Territory, provided that BioNTech shall provide Biotheus with a draft of such announcement in advance and shall consider any comments received from Biotheus in good faith.  For clarity if &#91;***&#93; wishes to make such an announcement regarding the execution or terms of this Agreement &#91;***&#93; prior written consent shall be required.  In the event of termination of this Agreement for any reason, if either Party intends to make a public announcement related to such termination or the public disclosure of such termination is required under the Applicable Law or the rules of a stock exchange on which the securities of either Party (or any controlling Affiliate of such Party) are listed (or to which an application for listing has been submitted), the Parties shall cooperate in good faith to coordinate public announcement or disclosure, if any, of such termination and the reasons </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">therefor. The principles to be observed in such disclosures shall be accuracy, compliance with Applicable Law, the rules of the applicable stock exchange and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">No Use of Name</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the terms of this Agreement, neither Party will use the name or Trademarks of the other Party in any promotional materials or advertising without the prior written consent of the other Party, except as provided under this Agreement or required by Applicable Law, in which case the Party disclosing such name or Trademarks will give advance notice of such use and otherwise comply with Section 11.3(a) (Compliance with Law). &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">10.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Publications and Presentations</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech shall have the sole right, either itself or through its Affiliates or Sublicensees, to present or publish the results of, or scientific information relating to, any activities under this Agreement PROVIDED THAT prior to the &#91;***&#93; the Parties will agree through the JSC on the content of any publications relating to the &#91;***&#93; and&#47;or &#91;***&#93;.  Biotheus shall not make any publication or presentation relating to a Licensed Compound or Licensed Product without the prior written consent of BioNTech.  If, in accordance with the requirements and limitations of this Section 10.3 (Publications and Presentations), a Party desires to publicly present or publish results or scientific information relating to a Licensed Compound or Licensed Product which publication contains the Confidential Information of the non-publishing Party, prior to doing so, the publishing Party will provide non-publishing Party with drafts of proposed abstracts, manuscripts or summaries of presentations that include such results or information.  The non-publishing Party will respond no later than &#91;***&#93; days after receipt of such proposed publication or presentation or such shorter period as may be agreed to by the Parties.  The publishing Party will delay any such proposed publication or presentation for a period up &#91;***&#93; days after the non-publishing Party receives such proposed publication or presentation to permit the non-publishing Party to make filings for patent protection and will otherwise remove its Confidential Information identified by the non-publishing Party in such publication or presentation.  The Parties agree to acknowledge the contributions of one another in accordance with standard academic practice regarding authorship of scientific publication.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party agrees to comply, with respect to the listing of Clinical Trials or the publication of Clinical Trial information and results with respect to Licensed Products and to the extent applicable to its activities conducted under this Agreement, with any Applicable Law or applicable court order, stipulations, consent agreements and settlements entered into by such Party&#59; provided that any listings or publications made pursuant to this Section 10.3 (Publications and Presentations). &#91;***&#93; will provide such assistance as &#91;***&#93; may reasonably require to obtain any consent or permission that may be required in order to publish data that originates from &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.33pt">REPRESENTATIONS, WARRANTIES, AND COVENANTS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">11.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Mutual Representations and Warranties</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">As of the Execution Date, Biotheus and BioNTech each hereby represents and warrants to the other as follows&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Organization</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Authorization</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action and will not violate (a) such Party's certificate of incorporation or bylaws (or equivalent charter or organizational documents), (b) any agreement, instrument or contractual obligation to which such Party is bound, (c) any requirement of any Applicable Law or regulations or court or administrative under, or (d) any order, writ, judgment, injunction, decree, determination, or award of any court or Governmental Authority presently in effect applicable to such Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">No Inconsistent Obligation</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It is not under any obligation, contractual, or otherwise, to any Person that conflicts with or is inconsistent in any respect with the terms of this Agreement or that will impede the diligent and complete fulfilment of its obligations hereunder.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">No Litigation</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">There is no action or proceeding pending or, to the knowledge of such Party, threatened that could reasonably be expected to impair or delay the ability of such Party to perform its obligations under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Government Authorizations</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">All consents, approvals, and authorizations from all Governmental Authorities or other Third Parties required to be obtained by such Party in connection with this Agreement, including the grant of any licenses, have been obtained.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">Debarment</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither such Party, nor any Affiliate of such Party, has been debarred by any Regulatory Authority, including under the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;301 et seq.), and the Drug Administration Law and the Human Genetic Resource Regulations in China, is under investigation for debarment action by any Regulatory Authority, has been disqualified as an investigator pursuant to 21 C.F.R. &#167;312.70, and the Drug Administration Law and the Human Genetic Resource Regulations in China, has a disqualification hearing pending or is currently employing or using any Person that has been so debarred or disqualified by any Regulatory Authority to perform any of such Party's obligations under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">11.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Additional Representations of Biotheus as of the Execution Date</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">As of the Execution Date, and as of the PM8003 Option Exercise Date and the Preclinical Multispecific Option Exercise Date (as applicable), Biotheus further represents and warrants to BioNTech, that, except as set forth in Schedule 2 (Exceptions to Representations and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Warranties) (which may be updated by Biotheus with respect to the PM8003 Licensed Compound and&#47;or PM8003 Licensed Products or Preclinical Multispecific Licensed Compound and&#47;or Preclinical Multispecific Licensed Products (as applicable) only upon written notice by Biotheus to BioNTech at any time after the Execution Date and prior to the PM8003 Option Exercise Date or Preclinical Multispecific Option Exercise Date (as applicable), provided that any such updates may relate solely to matters that have arisen in the period following the Execution Date)&#58; </font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Licensed Patent Rights</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Schedule 3 sets forth a complete and accurate list of all Licensed Patent Rights in existence as at the Execution Date, all of which are owned or Controlled by Biotheus.  Biotheus and its Affiliates have not committed, and to the knowledge of Biotheus no Third Party has committed, any act, or omitted to commit any act, that may cause the Licensed Patent Rights to expire prematurely or be declared invalid or unenforceable, and all application, registration, maintenance and renewal fees in respect of the Licensed Patent Rights have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining the Licensed Patent Rights set forth in Schedule 3.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Licensed Know-How and Trade Secrets</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus and its Affiliates have maintained in confidence and have not disclosed to any Third Party the Licensed Know-How, except under terms which require any such Third Party to keep the Licensed Know-How confidential.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Biotheus Inventions and Assignments</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">With respect to any Licensed IP owned by Biotheus, (a) Biotheus and its Affiliates have obtained from all individuals who contributed to the conception or reduction to practice thereof, effective assignments of all ownership rights of such individuals in such Licensed IP, either pursuant to written agreement or by operation of law, (b) all of its employees, officers, and consultants have executed agreements or have existing obligations under Applicable Law requiring assignment to Biotheus or its Affiliates, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">applicable, of all inventions made prior to the Execution Date, and no officer or employee of Biotheus or its Affiliates is subject to any agreement with any other Third Party that requires such officer or employee to assign any interest in any Licensed IP to any Third Party, and (c) the conception, development, and reduction to practice of any such Licensed IP has not constituted or involved the misappropriation of any trade secrets or other rights or property of any Person.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">License to BioNTech</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus has the right and authority to&#58; (a) grant to BioNTech and its Affiliates the licenses under the Licensed IP that Biotheus grants to BioNTech in accordance with the terms and conditions of this Agreement&#59; and (b) use, disclose and Exploit, and to enable BioNTech and its Affiliates to use, disclose and Exploit the Licensed IP in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">No Biotheus Infringement</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">There is no pending action or proceeding alleging that the use of the Licensed IP infringes, misappropriates or otherwise violates any Intellectual Property Rights of any Third Party, and there is no pending action or proceeding alleging that the use of the Licensed IP as contemplated under this Agreement infringes, misappropriates, or otherwise violates any Intellectual Property Rights of any Third Party.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">No Third Party Infringement</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">To the knowledge of Biotheus, no Patent Right or trade secret right owned or controlled by a Third Party will be infringed or misappropriated by the performance of the Global CDP Activities or Joint CDP Activities or the Exploitation of the Licensed Products, in each case, in accordance with this Agreement, nor has Biotheus or its Affiliates received in writing any notice alleging such infringement or misappropriation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">No Claims</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">There are no claims, judgments, or settlements against or amounts with respect thereto owed by Biotheus or any of its Affiliates relating to the Licensed Product or Licensed IP.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Biotheus In</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Licenses</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">As of the Execution Date, there are no agreements or other arrangements to which Biotheus or its Affiliates are a party that could be a Biotheus In-License except the &#91;***&#93; License.  Biotheus is not a party to any agreement or arrangement containing terms that conflict with or would prevent Biotheus from performing its obligations and granting the rights set out in this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.52pt">&#91;***&#93; IP</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">No background intellectual property of &#91;***&#93; has been used in the development of the Licensed IP or Licensed Products.  Biotheus has paid all outstanding fees to its CMOs including &#91;***&#93; pursuant to the &#91;***&#93; between Biotheus and &#91;***&#93;.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.52pt">No Government Funding</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The preclinical  and clinical development of the Licensed Products was not carried out and all inventions claimed or Covered by the Licensed IP were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by a government or any agency thereof or public institution such as the Chinese Academy of Sciences that would entitle any government or governmental agency or public institution to claim any ownership right or interest in the Licensed Products or the Licensed IP.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">Compliance with Applicable Law</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The pre-clinical  and clinical development by or on behalf of Biotheus of Licensed Products has been carried out in accordance with Applicable Law and there are no pending or concluded inquiries, investigations, or proceedings by any Regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Authority or Governmental Authority or public institution in relation to Licensed Products.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(l)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:26.52pt">Clinical Trials</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus and its Affiliates are not aware of any adverse event or other safety issue in relation to a Licensed Product arising from the conduct of the Clinical Trials that have been conducted or are in the process of being conducted in relation to Licensed Products as at the Execution Date. Biotheus has disclosed to BioNTech all data and information arising from such trials. Biotheus and its Affiliates have not received any notice of any actual or potential claim, proceedings or other dispute arising out of or relating to such Clinical Trials.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(m)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:20.41pt">Accuracy of information</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">All information provided by Biotheus to BioNTech in writing for due diligence purposes in relation to and in contemplation of this Agreement is accurate in all material respects.  Without limiting the foregoing, Biotheus has disclosed to BioNTech and made available to BioNTech for review all material data, and all other material information relating to the Licensed IP and to Licensed Products that is in the possession and Control of Biotheus or its Affiliates.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(n)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Financial Position</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus and its Affiliates (a) are solvent, (b) have sufficient financial resources to conduct its business in the ordinary course, meet all of its debts and financial obligations, and have no reasonable basis on which to expect that its operations may be impaired by financial instability or insolvency, and (c) shall take no actions during the Term of this Agreement that would materially impair its financial ability to meet its obligations hereunder, or otherwise materially impairing its ability to meet its debts and financial obligations in the ordinary course.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(o)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Export Restrictions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The are no Applicable Laws (including pursuant to the Export Control Law of the People's Republic of China, Administrative Measures for the Import and Export Permits of Dual-use Items and Technology, Administrative Regulations of the People's Republic of China on Technology Import and Export (Revised in 2020) and the Human Genetic Resources regulation in China) that will materially restrict Biotheus' ability to comply with the terms of this Agreement including with respect to the transfer to BioNTech of the Licensed IP and any materials that are to be supplied by Biotheus to BioNTech. And, to the extent required by Applicable Laws, Biotheus has obtained or will obtain at the time of transfer all clearances, authorizations and&#47;or consents required for transferring all Licensed IP and materials to BioNTech under the applicable technology and data reporting control laws in the Territory, including a filing in the Retained Territory under the Administrative Measures for the Registration of Technology Import and Export Contracts, if applicable.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">11.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Compliance Covenants</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each of BioNTech and Biotheus covenant to the other as follows&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Compliance with Law</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It will, and will ensure that its Affiliates will, comply with all Applicable Law in connection with the performance of its and its Affiliates' activities under this Agreement, including Applicable Data Protection Law. In addition Biotheus will implement and maintain an internal control and compliance management program designed to effectively prevent and detect wrongdoing by employees and the management of Biotheus that is suitable for a Chinese biotech company of comparable size.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">No Inconsistent Obligations</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It will not, and will ensure that its Affiliates will not, take any action or enter into any agreement with any Third Party that conflicts with or in any way diminishes the rights granted to the other Party under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.74pt">No Bribery</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It will not undertake any activities which will result in a violation of any Applicable Laws, regulations, and applicable industry and professional codes, including but not limited to applicable local and extraterritorial anti-bribery, anti-corruption and anti-money laundering laws (collectively &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Prohibited Conduct</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) in connection with the performance of any activities under this Agreement.  In particular, each Party agrees that during the course of the performance of activities under this Agreement, it (i) shall not make any offer, payment, or promise to pay money or provide anything of value to a Government Official (as defined below) or any other individual and&#47;or legal entity whether directly or indirectly, for the purpose of improperly influencing any act and&#47;or decision of, and&#47;or for securing any improper advantage&#59; (ii) shall not accept, receive, agree to accept and&#47;or receive a payment and&#47;or anything of value from any individual for undue favorable treatment in obtaining, retaining, and&#47;or directing business for, and&#47;or to obtain any undue special concession on behalf of the other Party&#59; (iii) shall not facilitate any payments to any Government Official to expedite a routine government action and&#47;or other official act. All transactions and expenses incurred by a Party on behalf of the other Party shall be accurately recorded and maintained in the incurring Party's books and records in a timely manner and in reasonable detail in accordance with generally accepted accounting principles.  False, misleading, incomplete, duplicated, inaccurate or artificial entries in a Party's books and records are strictly prohibited.  Each Party agrees that if it becomes aware or has reason to suspect that any person or legal entity acting on a Party's behalf has engaged in any Prohibited Conduct related to the Agreement, then the Party will immediately report such knowledge or suspicion to the other Party and if &#91;***&#93; is the notifying Party it shall notify &#91;***&#93; via the following email address&#58; &#91;***&#93;.  Each Party agrees to provide reasonable cooperation in any investigation that may be conducted by or on behalf of the other Party related to business in connection with the Agreement.  Upon notice of an intended investigation, the notified Party will provide, in a reasonable time, to the other Party or to a Third Party engaged by the other Party&#58; (a) access to the relevant persons&#59; and&#47;or (b) access to relevant documents and data (e.g. invoices and requests for expense reimbursement, supporting receipts and substantiation, and original entry records for charges and payments).  Each Party acknowledges that the obligations under this Section apply to all its employees and sub-contractors who act </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">for or on behalf of such Party to perform activities under this Agreement.  Each Party will bind sub-contractors who act for or on its behalf under the Agreement by respective contractual clauses encompassing all material provisions of this Section.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Export Control</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither it nor its Affiliates will export, transfer, or sell any Licensed Product to any country or territory except in compliance with Applicable Law.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Debarment</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">It will not engage, in any capacity in connection with this Agreement or any ancillary agreements, any officer, employee, contractor, consultant, agent, representative, or other person who has been debarred by any Regulatory Authority, including under the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;301 et seq.), is under investigation for debarment action by any Regulatory Authority, has been disqualified as an investigator pursuant to 21 C.F.R. &#167;312.70, has a disqualification hearing pending or is currently employing or using any Person that has been so debarred or disqualified by any Regulatory Authority to perform any of such Party's obligations under this Agreement.  Each Party will inform the other Party in writing promptly if it or any person engaged by it or any of its Affiliates who is performing any obligations under this Agreement or any ancillary agreements is debarred or excluded, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to each Party's knowledge, is threatened, pursuant to which a Party, any of its Affiliates or any such person performing obligations hereunder or thereunder may become debarred or excluded.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">Biotheus Covenants</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus will not enter into any agreement with respect to or assign, transfer, license, convey or otherwise encumber its right, title or interest in or to (i) the Licensed IP (including by granting any covenant not to sue with respect thereto) or (ii) any intellectual property or proprietary right that would be Licensed IP, but for such assignment, transfer, license, conveyance or encumbrance, in each case of (i) and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(ii), that is inconsistent with the rights and licenses granted to BioNTech under this Agreement.  Biotheus shall, and shall ensure that its Affiliates shall, maintain the Biotheus In-Licenses in full force and effect in accordance with their terms and conditions and without any amendment that conflicts with the rights granted to BioNTech under this Agreement or may otherwise adversely affect the rights granted to BioNTech under this Agreement, except with BioNTech's prior written consent.  In the event that Biotheus or any of its Affiliates or sublicensees receives notice of an alleged breach or default of a Biotheus In-License where the Third Party licensor or counterparty to such Biotheus In-License may terminate such agreement or otherwise take action that would diminish the scope or exclusivity of the licenses granted to BioNTech herein, then Biotheus shall promptly, but in no event less than &#91;***&#93; Business Days thereafter, notify BioNTech of such alleged breach or default in writing and hereby grants to BioNTech the right (but not the obligation) to&#58; (i) cure such undisputed breach or default that has been confirmed by Biotheus and (ii) offset any reasonable costs or expenses incurred in connection therewith, including payments made to the Third Party licensor by BioNTech on behalf of Biotheus to cure said confirmed breach or default by Biotheus against any payments due or that may become due from BioNTech to Biotheus under this Agreement.  Biotheus shall keep BioNTech promptly informed of any Know-How or Patent Rights related to Licensed Products created or filed by the respective licensors under the Biotheus In-Licenses including any such Patent Rights and Know-How in relation to which Biotheus has an option to negotiate the terms of a license from the applicable licensor pursuant to a Biotheus In-License.  This provision will not restrict or eliminate any of BioNTech's remedies under this Agreement or otherwise available for BioNTech under any law or equity.</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If Biotheus has an obligation under this Agreement to provide data, materials and information to BioNTech or to grant licenses to intellectual property rights, Biotheus will at its cost obtain any approvals, permissions, consents, or other documentation that are necessary to have for exporting such data, information and materials from China to BioNTech or to grant licenses to such intellectual property rights, (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Governmental Approval</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;).  If, prior to the date on which Manufacturing Technology Transfer is successfully completed for PM8002 Licensed Product pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), Biotheus </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">does not obtain such Governmental Approvals required under Applicable Law in China within a reasonable period of time with the result that BioNTech is not able to receive the material benefit of this Agreement in respect of PM8002 Licensed Product, BioNTech will be entitled to terminate this Agreement in respect of PM8002 Licensed Product and obtain a refund of the Upfront Payment that has been made by BioNTech to Biotheus under this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In addition, where Biotheus has an obligation under this Agreement to provide reports, information, documentation and the like they shall be accompanied with an English translation if the original documents are not in English.</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus will not obtain any funding from a Governmental Authority that could restrict Biotheus' ability to comply with the terms of this Agreement including but not limited to the provisions of Section 3.1 (License Grants to BioNTech).</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Within &#91;***&#93; prior to successful completion of the Manufacturing Technology Transfer for PM8002 Licensed Product pursuant to Section 7.2 (Manufacturing Technology Transfer for PM8002 Licensed Products), Biotheus will provide to BioNTech a copy of Biotheus' unaudited financial statements for the previous &#91;***&#93; period. Any such statements and accounts shall be the Confidential Information of Biotheus and shall only be used by BioNTech for the purposes of monitoring Biotheus' financial position. The foregoing information furnishing obligations shall (i) suspend once Biotheus (or its applicable Affiliate) files for an initial public offering to be listed on an international or national  stock exchange that requires public disclosure of financial statements, as long as the financial statements of Biotheus (or its applicable Affiliate) contained in such filing remains no more than &#91;***&#93; old and (ii) terminate upon closing of Biotheus&#8217; (or its applicable Affiliate&#8217;s) initial public offering on an international or national stock exchange that requires public disclosure of financial statements.</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Notwithstanding the foregoing Biotheus will give written notice to BioNTech immediately if at any time Biotheus becomes aware of its inability to carry on as a going concern.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Biotheus agrees, on behalf of itself and its Affiliates, not to take any action or fail to take any action in the period between the Execution Date and the Effective Date that would cause or be reasonably likely to cause any of the representations and warranties by Biotheus set forth in Sections 11.1 (Mutual Representations, Warranties and Covenants) or 11.2 (Additional Representations of Biotheus as of the Execution Date) to be untrue in any material respect if made as of the Effective Date.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Tax Evasion</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither Party, nor any of its Affiliates shall commit a tax evasion facilitation offence under Part 3 of the UK Criminal Finances Act 2017 in connection with or otherwise attributable to this Agreement or the transactions contemplated hereby.  Each Party shall promptly report to the other Party any apparent breach of this Section 11.3(g) (Tax Evasion) and shall (a) answer, in reasonable detail, any written or oral inquiry from the other Party related to its and its Affiliates' compliance with this Section 11.3(g) (Tax Evasion), (b) facilitate the interview of employees of such Party by the other Party (or any agent of such Party) at any reasonable time specified by the inquiring Party related to such Party's compliance with this Section 11.3(g) (Tax Evasion), and (c) co-operate with the inquiring Party or any Governmental Authority in relation to any investigation relating to the matters referred to in this Section 11.3(g) (Tax Evasion), in all cases, as reasonably required to enable that other Party to comply with its undertaking in this Section 11.3(g) (Tax Evasion).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.33pt">INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">12.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Indemnification of Biotheus by BioNTech</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to Section 12.3 (Conditions to Indemnification), BioNTech will defend, indemnify, and hold harmless Biotheus and its Affiliates, and their respective employees, officers, and directors (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Biotheus Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) from and against any and all liability, damage, loss, cost or expense of any nature (including reasonable attorney's fees and litigation expenses) (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Losses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) incurred or imposed upon the Biotheus Indemnitees or any one of them in connection with any claims, suits, actions, demands, proceedings, causes of action or judgments resulting from a Third Party claim arising out of or relating to&#58; (a) the conduct of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">activities under the Global CDP by a BioNTech Indemnitee&#59; (b) the Development, Manufacture or Commercialization of any Licensed Product by or on behalf of any BioNTech Indemnitee&#59; (c) the breach by any BioNTech Indemnitee of any term of this Agreement&#59; or (d) the negligence or wilful misconduct of any BioNTech Indemnitee except, in each case ((a) through (d)), to the extent that any such claim results or arises from a matter for which Biotheus is obligated to indemnify BioNTech under Section 12.2 (Indemnification of BioNTech by Biotheus).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">12.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Indemnification of BioNTech by Biotheus</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to Section 12.3 (Conditions to Indemnification), Biotheus will defend, indemnify, and hold harmless BioNTech and its Affiliates, Sublicensees, and licensees, and their respective employees, officers and directors (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">BioNTech Indemnitees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) from and against any and all Losses incurred or imposed upon the BioNTech Indemnitees or any one of them in connection with any claims, suits, actions, demands, proceedings, causes of action, or judgments resulting from a Third Party claim arising out of or relating to (a) the conduct of activities under the Global CDP or the Joint CDP by a Biotheus Indemnitee&#59; (b) the Development, Manufacture or Commercialization of any Licensed Product by or on behalf of any Biotheus Indemnitee , (c) the breach by any Biotheus Indemnitee of any term of this Agreement&#59; or (d) the negligence or wilful misconduct of any Biotheus Indemnitee except, in each case ((a) through (d)), to the extent that any such claim results or arises from a matter for which BioNTech is obligated to indemnify Biotheus under Section 12.1 (Indemnification of Biotheus by BioNTech).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">12.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Conditions to Indemnification</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Any Person seeking indemnification (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Indemnitee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;) under this Section 12 (Indemnification&#59; Limitation Of Liability&#59; Insurance) will give prompt written notice of the indemnity claim to the indemnifying Party and promptly provide a copy to the indemnifying Party of any complaint, summons, or other written or verbal notice that the Indemnitee receives in connection with any such claim.  An Indemnitee's failure to deliver written notice will relieve the indemnifying Party of liability to the Indemnitee under this Section 12 (Indemnification&#59; Limitation of Liability&#59; Insurance) only to the extent such delay is prejudicial to the indemnifying Party's ability to defend or settle such claim.  The indemnifying Party will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">have the right to assume and control the defense of the indemnification claim at its own expense with counsel selected by the indemnifying Party and reasonably acceptable to the Indemnitee&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that an Indemnitee will have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying Party, if representation of such Indemnitee by the counsel retained by the indemnifying Party would be inappropriate due to actual or potential differing interests between the Indemnitee and any other party represented by such counsel in such proceedings.  The indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim.  If the indemnifying Party does not assume the defense of the indemnification claim as described in this Section 12.3 (Conditions to Indemnification), then the Indemnitee may defend the indemnification claim but will have no obligation to do so.  The Indemnitee will not settle or compromise the indemnification claim without the prior written consent of the indemnifying Party, and the indemnifying Party will not settle or compromise the indemnification claim in any manner which would have an adverse effect on the Indemnitee's interests (including any rights under this Agreement or the scope, validity, or enforceability of any Patent Rights, Confidential Information, or other rights licensed to BioNTech by Biotheus hereunder), without the prior written consent of the Indemnitee, which consent, in each case (by the indemnifying Party or the Indemnitee, as the case may be), will not be unreasonably withheld, conditioned, or delayed.  The Indemnitee will reasonably cooperate with the indemnifying Party at the indemnifying Party's expense and will make available to the indemnifying Party all pertinent information under the control of the Indemnitee, which information will be subject to 10.1 (Confidentiality).  The indemnifying Party will not be liable for any settlement or other disposition of the claims by the Indemnitee if such settlement is reached without the written consent of the indemnifying Party pursuant to this Section 12.3 (Conditions to Indemnification).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">12.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Limited Liability</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">NEITHER OF THE PARTIES WILL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL, OR PUNITIVE DAMAGES OR DAMAGES FOR LOSS OF PROFIT OR LOST OPPORTUNITY IN CONNECTION WITH THIS AGREEMENT, ITS PERFORMANCE OR LACK OF PERFORMANCE HEREUNDER, OR ANY LICENSE GRANTED HEREUNDER, EXCEPT TO THE EXTENT RESULTING FROM (A) A PARTY'S WILLFUL MISCONDUCT OR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">NEGLIGENCE UNDER THIS AGREEMENT, (B) A BREACH OF THE OBLIGATIONS OF A PARTY UNDER 10.1 (CONFIDENTIAL INFORMATION), OR (C) AMOUNTS REQUIRED TO BE PAID AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER ARTICLE 12 (INDEMNIFICATION&#59; LIMITATION OF LIABILITY&#59; INSURANCE).  No provision of this Agreement shall limit a Party's liability for death or personal injury caused by its negligence or for fraud or any other liability that cannot be excluded under Applicable Law.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">12.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Insurance Obligations</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party will maintain during the Term and for a period of at least &#91;***&#93; years after the last commercial sale of any Licensed Product pursuant to this Agreement, at its cost, reasonable insurance (including but not limited to product liability insurance) with a reputable solvent insurer against liability and other risks associated with its activities contemplated by this Agreement in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement.  Without limiting the preceding sentence, where a Party is carrying out Clinical Trials pursuant to this Agreement, such Party will maintain, at its cost, specific Clinical Trials insurance that is appropriate for such activities in the applicable territory, in accordance with applicable law.  For clarity, if Biotheus conducts the Joint Trials on BioNTech&#8217;s behalf pursuant to the terms of this Agreement, the costs of Clinical Trials insurance for any such Joint Trials shall &#91;***&#93; and be solely borne by &#91;***&#93;.  Each Party will furnish to the other Party evidence of all such insurance upon request.  Notwithstanding the foregoing, such obligation may be satisfied by a program of self-insurance.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.33pt">TERM AND TERMINATION</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">13.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Term</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement will commence on the Effective Date (except for Section 10.1 (Confidential Information), Article 11 (Representations, Warranties and Covenants) and Section 14.16 (HSR) which shall commence on the Execution Date) and, unless otherwise terminated pursuant to Section 13.2 (Termination), will continue on a Licensed Product-by-Licensed Product basis until the earlier of (a) the expiration of all applicable payment obligations with respect to each such Licensed Product on a country-by-country-basis in the Territory&#59; (b) in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">respect of PM8003 Licensed Products, in the event that BioNTech does not exercise the PM8003 Option, until the end of the PM8003 Option Period (including any extensions thereto)&#59; or (c) in respect of Preclinical Multispecific Licensed Products, in the event that BioNTech does not exercise the Preclinical Multispecific Option, until the end of the Preclinical Multispecific Option Period (including any extensions thereto) for each such Preclinical Multispecific Licensed Product (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;).  On a Licensed Product-by-Licensed Product and country-by-country basis (and, in the case of PM8003 Licensed Products and&#47;or Preclinical Multispecific Licensed Products (as applicable), subject to BioNTech's exercise of the PM8003 Option or Preclinical Multispecific Option (as applicable)), effective upon the expiration of the Royalty Term for such Licensed Product in such country (but not upon any earlier termination of this Agreement for any reason), the licenses granted to BioNTech will each become exclusive, fully paid-up, royalty-free, irrevocable, and perpetual in such country with respect to such Licensed Product.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">13.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Termination</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement may be terminated as follows&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Termination for Convenience by BioNTech or Biotheus</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech may, at any time, terminate this Agreement as a whole or on a Licensed Product-by-Licensed Product basis at will, in its sole discretion&#58; (i) on &#91;***&#93; (or &#91;***&#93; days where BioNTech terminates the Agreement pursuant to Article 8 (Financial Terms) due to the Qualification Date not being achieved) prior written notice to Biotheus where the notice for termination of a  Licensed Product is provided before the completion of a Registrational Clinical Trial in respect of such Licensed Product&#59; and (ii) on &#91;***&#93; prior written notice to Biotheus where the notice for termination of a Licensed Product is provided after the completion of a Registrational Clinical Trial in respect of such Licensed Product&#59; provided that if the termination of this Agreement by BioNTech pursuant to this Section 13.2(a) (Termination for Convenience by BioNTech or Biotheus) requires a notice period of &#91;***&#93; under the foregoing clause (ii) and a milestone is achieved by or on behalf of BioNTech pursuant to Section 8.3 (Development and Approval Milestone Payments for Licensed Products) during said notice period of &#91;***&#93; days, BioNTech shall have no obligation to pay to Biotheus the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">applicable milestone payment corresponding to such achieved milestone.  If BioNTech does not complete the audit and, as applicable, qualification contemplated in Article 8 (Financial Terms) and notify Biotheus of the results thereof in writing on or before &#91;***&#93;, Biotheus shall be entitled to terminate this Agreement as a whole on &#91;***&#93; days prior written notice to BioNTech.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Termination for Breach</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">If a Party commits a material breach of this Agreement, then the other Party may terminate this Agreement with respect to the applicable Licensed Product that is the subject of such material breach, unless such material breach is cured within (a) the &#91;***&#93; day period after receipt of written notice from the non-breaching Party with respect to any breach of any payment obligation under this Agreement, or (b) the &#91;***&#93; period after receipt of written notice from the non-breaching Party with respect to any other material breach under this Agreement, provided that if the alleged breaching Party disputes in good faith the existence or materiality of any such material breach specified in the notice provided by the other Party, and the alleged breaching Party provides notice of such dispute within such &#91;***&#93; period, then the Party alleging such material breach will not have the right to terminate this Agreement unless and until such material breach has been confirmed through the dispute resolution process in accordance with Section 14.1 (Dispute Resolution).</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.74pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Termination for Bankruptcy</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:199%">This Agreement may be terminated in its entirety by a Party (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:199%">Non-Bankrupt Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:199%">&#34;) by providing written notice of termination to the other Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:199%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:199%">including in each case occurrence of the applicable or similar corresponding event under the Enterprise Bankruptcy Law of the People&#8217;s Republic of China, as may be modified (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:199%">Bankrupt Party</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:199%">&#34;)&#59; provided, however, that in the event of any involuntary bankruptcy or receivership proceeding such right to terminate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:199%">will only become effective if the Bankrupt Party consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within &#91;***&#93; days after the filing of such bankruptcy or receivership.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Effects of Termination</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In the event of any termination of this Agreement, effective as of the effective date of termination, the following provisions will apply with respect to the terminated Licensed Products (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Terminated Products</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), as applicable&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.74pt">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Ongoing Clinical Trials</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Notwithstanding any other provision in this Section 13.3 (Effects of Termination), if there are any Clinical Trials or patient treatments using a Licensed Product being conducted as of the effective date of termination, BioNTech shall be entitled to continue Developing or Exploiting Licensed Products to the extent and for the period necessary to effect an orderly transfer or wind down of such Clinical Trials or patient treatments in a timely manner and in accordance with all Applicable Laws. In addition, as promptly as practicable after such termination, BioNTech shall&#58; (i) transfer or assign, or cause to be transferred or assigned, to Biotheus or its designee (or to the extent not so assignable, take all reasonable actions to make available to Biotheus or its designee the benefits of) all Regulatory Filings, Regulatory Documentation and Regulatory Authorization to the extent they solely relate to such Licensed Products in the Territory, whether held in the name of BioNTech or its Affiliate, or (ii) provide Biotheus with a right of reference with respect to any such Regulatory Filings and Regulatory Documentation at no cost to Biotheus&#59; and (iii) take such other actions and execute such other instruments, assignments and documents as may be reasonably necessary to effect, evidence, register and record the transfer, assignment or other conveyance of rights under this Section 13.3(d) (Ongoing Clinical Trials) to Biotheus, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">in each case at the cost of BioNTech if this Agreement is terminated by BioNTech pursuant to Section 13.2(a) (Termination for Convenience by BioNTech or Biotheus) or by Biotheus pursuant to Section 13.2(b) (Termination for Breach) or 13.2(d) (Termination for Bankruptcy), or at the cost of Biotheus if this Agreement is terminated for any other reason whatsoever.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Accrued Rights and Obligations</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither expiration nor any termination of this Agreement for whatsoever reason shall relieve either Party of any obligation or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement for whatsoever reason preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement.  Such obligations and rights shall survive termination and expiration of this Agreement. For clarity, (i) except in the circumstances set out in Section 13.2(a)(ii), if any milestone event is achieved during the applicable termination notice period, then the corresponding milestone payment is accrued and BioNTech shall remain responsible for the payment of such milestone payment even if the due date of such milestone payment may come after the effective date of the termination&#59; and (ii) BioNTech shall make payment to Biotheus for all applicable Eligible Development Costs incurred up to the effective date of termination of this Agreement and not yet paid for (if any) (including all non-cancellable documented commitments incurred consistent with the Joint CDP prior to the date of notice of termination of this Agreement).</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:25.97pt">Other Effects</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">13.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Confidential Information and Materials</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Upon termination of this Agreement for any reason, the Receiving Party will&#58; (i) return to the other Party any Materials provided to it in connection with this Agreement, within &#91;***&#93; days of termination except to the extent necessary for the Receiving Party to exercise any other license or right that survives such termination of this Agreement, provided that the Receiving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Party's use of such Materials will continue to be subject to Section 3.4(c) (Knowledge and Technology Transfer)&#59; and (ii) destroy all written, electronic, or other materials containing Confidential Information of the Disclosing Party provided to it by the Disclosing Party in connection with this Agreement, including all copies thereof, within &#91;***&#93; days of such termination and provide certification of such destruction to the Disclosing Party&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a) the Receiving Party may retain one copy in its archives solely for the purpose of monitoring its ongoing confidentiality obligations hereunder, and (b) the Receiving Party will not be obligated to destroy such materials containing Confidential Information of the Disclosing Party that are necessary for the Receiving Party to exercise any other license or right of the Receiving Party that survives such termination of this Agreement&#59; PROVIDED THAT the Receiving Party's use of such Confidential Information of the Disclosing Party will continue to be subject to the requirements and restrictions set forth in Section 10.1 (Confidential Information).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">13.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Surviving Provisions</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Subject to the other terms and conditions regarding the termination and survival of obligations under this Agreement in the event of expiration or termination of this Agreement, upon expiration or termination of this Agreement, all provisions of this Agreement will cease to have any effect, except that the following provisions will survive any such expiration or termination for any reason for the period of time specified therein, or if not specified, then they will survive indefinitely&#58; Article 1 (Definitions)&#59; Section 8.12 (Records and Audits)&#59; Section 9.1(a) (Ownership), Section 10.1 (Confidential Information)&#59; Article 12 (Indemnification, Limitation of Liability, Insurance), Article 13 (Term and Termination) and Article 14 (Miscellaneous). Termination of this Agreement will not relieve either Party of any liability that accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.  The remedies provided in this Article 13 (Term and Termination) are not exclusive of any other remedies a Party may have in law or equity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:24.33pt">MISCELLANEOUS</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Dispute Resolution</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Escalation</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In the event of any dispute, claim, controversy, or cause of action asserted by a Party against the other Party or by the Biotheus Indemnitees against BioNTech or by the BioNTech Indemnitees against Biotheus arising out of or related to this Agreement or performance of this Agreement (other than matters within the purview of the JSC, which will be resolved as set forth in Section 4.5 (Decision-Making)) (a &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Claim</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), including any alleged breach of this Agreement or claim for indemnification pursuant to Article 12 (Indemnification&#59; Limitation of Liability&#59; Insurance), such Party may, by written notice to the other Party, refer such matter to the Parties' respective officers designated below for attempted resolution (each, an &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;)&#58;</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">For BioNTech&#58;&#160;&#160;&#160;&#160; CEO (or other senior executive designated by BioNTech for such purpose)</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">For Biotheus&#58;&#160;&#160;&#160;&#160;CEO (or other senior executive designated by Biotheus for such purpose)</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">Arbitration</font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Except as otherwise expressly set forth in</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">this Agreement, if such Executive Officers do not resolve the dispute within &#91;***&#93; days after receipt of such request, then any dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by binding arbitration administered by the Hong Kong International Arbitration Centre (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">HKIAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;) (or any successor entity thereto) pursuant to the United Nations Commission on International Trade Law (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">UNCITRAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;) Arbitration Rules in force when the notice of arbitration is submitted, as modified by the HKIAC Procedures for the Administration of Arbitration under the UNCITRAL Arbitration Rules.  The number of arbitrators shall be &#91;***&#93;.  If the issues in dispute involve scientific, technical or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">commercial matters, the arbitrators chosen hereunder shall engage experts having educational training or industry experience sufficient to demonstrate a reasonable level of relevant scientific, medical and industry knowledge, as necessary to resolve the dispute.  The seat, or legal place, of arbitration shall be Hong Kong.  The language to be used in the arbitral proceedings shall be English.  The governing law of the Agreement shall be the substantive law of England and Wales as set out in Section 14.4 (Governing Law).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Designation of Affiliates</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party may discharge any obligations and exercise any rights under this Agreement through delegation of its obligations or rights to any of its Affiliates.  Each Party hereby guarantees the performance by its Affiliates of such Party's obligations under this Agreement, and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.  Any breach by a Party's Affiliate of any of such Party's obligations under this Agreement will be a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party's Affiliate.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Injunctive Relief</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Notwithstanding anything to the contrary set forth in this Agreement, the Parties each stipulate and agree that (a) the other Party's Confidential Information includes highly sensitive trade secret information, (b) a violation of the licenses granted to BioNTech under Section 3.1 (License Grants to BioNTech) or a breach of 10.1 (Confidential Information) by a Party with respect to such information may cause irrevocable harm for which monetary damages would not provide a sufficient remedy, and (c) in such case of a breach of Section 3.1 (License Grants to BioNTech) or 10.1 (Confidential Information), the non-breaching Party will be entitled to equitable relief (including temporary or permanent restraining orders, specific performance or other injunctive relief) from any court of competent jurisdiction.  In addition, and notwithstanding anything to the contrary set forth in this Agreement, in the event of any other actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including temporary or permanent restraining orders, specific performance or other injunctive relief) from any court of competent jurisdiction without first submitting to the dispute resolution procedures set forth in Section 14.1 (Dispute Resolution).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Governing Law</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement and any issues, disputes or claims arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) will be governed by and construed in accordance with the laws of England and Wales without taking into consideration any choice of law principles that would lead to the application of the laws of another jurisdiction.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Cumulative Remedies</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The rights and remedies of the Parties under this Agreement are cumulative and not exclusive and, accordingly, are in addition to and not in lieu of any other rights and remedies of the Parties at law or in equity.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Notices</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Any notice or report required or permitted to be given or made under this Agreement by either Party to the other will be in writing and delivered to the other Party at its address indicated below or to such other address as the addressee will have theretofore furnished in writing to the addressor by hand, courier or by registered or certified airmail (postage prepaid), in writing, by registered or certified airmail (postage prepaid)&#58;</font></div><div style="padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">If to BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#58;&#160;&#160;&#160;&#160;BioNTech SE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;An der Goldgrube 12, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;55131 Mainz, Germany</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Attention&#58; &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Email&#58; &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:23.18pt">If to Biotheus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#58;&#160;&#160;&#160;&#160;Biotheus Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;12A, Building 4, No. 1 Keji 7th Road, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Tangjiawan Town, Zhuhai, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Guangdong, China 519080 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Attention&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Email&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Copy to (which copy will not constitute notice)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Goodwin Procter LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;The New York Times Building</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;620 Eighth Avenue</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;New York, NY 10018 USA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Attention&#58; &#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#160;&#160;&#160;&#160;Email&#58; &#91;***&#93;</font></div><div style="margin-bottom:18pt;padding-left:34.9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:70.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">All notices will be deemed effective&#58; (a) if by courier, on the Business Day of delivery as evidenced by the courier's receipt (or if delivered or sent on a non-Business Day, then on the next Business Day)&#59; or (b) if sent by registered or certified airmail, on the Business Day of receipt as evidenced on the return receipt.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Amendment&#59; Waiver</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement may be amended, modified, superseded or cancelled only by a written agreement between the Parties, and any of the terms of this Agreement may be waived only by a written instrument executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. Except as otherwise provided in this Agreement, the Schedules to this Agreement may be amended, modified, superseded or cancelled only by a written agreement between the Parties. The delay or failure of either Party at any time or times to require performance of any provisions will in no manner affect the rights at a later time to enforce the same.  No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, will be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Cyber Security Requirements</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">In performing its obligations and exercising its rights under this Agreement, each Party warrants and represents to the other Party that it will maintain adequate administrative, technical, and physical measures, controls, tools, systems, policies and procedures in accordance with good cyber security industry practice and all Applicable Laws.</font></div><div style="margin-bottom:18pt;padding-left:70.85pt;text-align:justify;text-indent:-35.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:23.18pt">Each Party will notify the other Party, in writing, of any security incident affecting, or which may affect, any IT Infrastructure or&#160;data&#160;or facilities owned, leased or used by and&#47;or provided for use by such Party, which may affect the delivery of services under this Agreement, without undue delay and in any event within &#91;***&#93; hours after such Party becomes aware of or suspects that a security incident has occurred.  Such notification will be, in the first instance, sent by e-mail to the following e-mail address&#58; &#91;***&#93; (for notification to &#91;***&#93;) &#47; e-mail address&#58; &#91;***&#93; (for notification to &#91;***&#93;) and immediately followed up by telephone to &#91;***&#93; (for notification to &#91;***&#93;).</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:16pt">Assignment and Successors</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither Party may assign or transfer this Agreement in whole or in part, or the licenses granted under this Agreement, without the other Party's prior written consent </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">unless </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">such assignment is to&#58; (a) a Third Party successor or purchaser of all or substantially all of the assets or businesses to which this Agreement relates whether pursuant to a sale of assets, merger, or other similar transaction, in which case the assigning Party will provide prior written notice to the other Party and need not obtain the other Party's consent, or (b) an Affiliate of such Party, in which case the assigning Party will provide prior written notice to the other Party and need not obtain the other Party's consent&#59; provided that, in either case, the assigning Party remains fully liable for the performance of its obligations hereunder by such assignee.  Any other assignment of this Agreement by a Party requires the prior written consent of the other Party.  An assignment to an Affiliate will terminate, and all rights so assigned will revert to the assigning Party, if and when such Affiliate ceases to be an Affiliate of the assigning Party.  For clarity, any assignment in violation of this Section 14.9 (Assignment and Successors) will be null, void, and of no legal effect.  This Agreement will be binding upon and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Force Majeure</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Neither BioNTech nor Biotheus will be liable for failure of or delay in performing obligations set forth in this Agreement, and neither will be in breach of its obligations, to the extent such failure or delay is due to a Force Majeure&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, that a Force Majeure will not excuse any Party from any payment obligations to the other Party under this Agreement.  In event of such Force Majeure, the Party affected will use reasonable efforts to avoid or remove such causes of non-performance, and will continue to perform hereunder with reasonable dispatch whenever such causes are removed.  The Party invoking such Force Majeure rights of this Section 14.10 (Force Majeure) must promptly notify the other Party by courier or overnight dispatch (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">e.g.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, Federal Express) within a period of &#91;***&#93; days of both the first and last day of the Force Majeure. If the affected Party&#8217;s failure to perform due to such Force Majeure continues for a period of &#91;***&#93; days or more, then the Parties will discuss in good faith a plan to resolve the matter. Notwithstanding the foregoing, the payment of invoices due and owing hereunder shall in no event be delayed by the payer because of a Force Majeure affecting the payer.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Interpretation</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">The Parties acknowledge and agree that&#58; (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the interpretation of this Agreement&#59; and (c) the terms and provisions of this Agreement will be construed fairly as to each Party and not in a favor of or against either Party, regardless of which Party was generally responsible for the preparation of this Agreement.  In addition, except as otherwise explicitly specified to the contrary, (i) references to a section, schedule or exhibit means a section of, or schedule or exhibit to this Agreement, unless another agreement is specified, (ii) the word &#34;including&#34; (in its various forms) means &#34;including without limitation,&#34; (iii) the words &#34;shall&#34; and &#34;will&#34; have the same meaning, (iv) references to a particular statute or regulation include all rules and regulations thereunder and any predecessor or successor statute, rules or regulations, in each case as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">amended or otherwise modified from time-to-time, (v) words in the singular will be held to include the plural and vice versa, and words of one gender will be held to include the other gender as the context requires, (vi) references to a particular Person include such Person's successors and assigns to the extent not prohibited by this Agreement, (vii) references to &#34;days&#34; will mean calendar days, unless otherwise specified, (viii) the word &#34;or&#34; will not be exclusive, unless the context otherwise requires, (ix) references to &#34;written&#34; or &#34;in writing&#34; include in electronic form, (x) the titles and headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement, (xi) the terms &#34;hereof,&#34; &#34;hereby,&#34; &#34;hereto,&#34; and derivative or similar words refer to this entire Agreement, including any schedules or exhibits hereto, and (xii) unless otherwise specified, &#34;$&#34; is in reference to United States Dollars.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Integration</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement, together with all agreements referred to herein and all exhibits and schedules attached hereto, sets forth the entire agreement with respect to the subject matter hereof and thereof and supersedes all other agreements and understandings between the Parties with respect to such subject matter, including the Confidentiality Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Severability</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each Party hereby agrees that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty, or decision of any government agency or executive body thereof of any country or community or association of countries.  Should one or more provisions of this Agreement be or become invalid, the Parties will substitute, by mutual consent, valid provisions for such invalid provisions, which valid provisions in their economic effect are sufficiently similar to the invalid provisions such that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be agreed upon, the invalidity of one or several provisions of this Agreement will not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement such that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid provisions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Further Assurances</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Each of BioNTech and Biotheus agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, the filing of such additional assignments, agreements, documents and instruments, as the other Party may at any time and from time-to-time reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Rights in Bankruptcy</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">All licenses and rights to licenses granted under or pursuant to this Agreement by the Bankrupt Party to the Non-Bankrupt Party are, and will otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Bankruptcy Code</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#34;), licenses of rights to &#34;intellectual property&#34; as defined under Section 101(35A) of the Bankruptcy Code and that all Development Milestone Payments, Sales Milestone Payments, and Royalties will be &#34;royalties&#34; under the Bankruptcy Code.  The Parties agree that the Non-Bankrupt Party, as a licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code.  The Parties further agree that upon commencement of a bankruptcy proceeding by or against the Bankrupt Party under the Bankruptcy Code, the Non-Bankrupt Party will be entitled to a complete duplicate of, or complete access to (as the Non-Bankrupt Party deems appropriate), all such intellectual property and all embodiments of such intellectual property.  Such intellectual property and all embodiments of such intellectual property will be promptly delivered to the Non-Bankrupt Party (a) upon any such commencement of a bankruptcy proceeding and upon written request by the Non-Bankrupt Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Bankrupt Party and upon written request by the Non-Bankrupt Party.  The Bankrupt Party (in any capacity, including debtor-in-possession) and its successors and assigns (including any trustee) agrees not to interfere with the exercise by the Non-Bankrupt Party or its Affiliates of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agrees to assist the Non-Bankrupt Party and its Affiliates in obtaining such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as reasonably necessary or desirable for the Non-Bankrupt Party to exercise such rights and licenses in accordance with this Agreement.  The foregoing provisions are without prejudice to any rights the Non-Bankrupt Party may have arising under the Bankruptcy Code or other Applicable Law.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%;padding-left:10.44pt">HSR</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">BioNTech and Biotheus shall as soon as reasonably practicable, but in any event within &#91;***&#93; Business Days after the Execution Date, file a Notification and Report Form (an &#8220;HSR Filing&#8221;) pursuant to the HSR Act and each Party shall use commercially reasonable efforts to obtain early termination or expiration of the waiting period under the HSR Act, including by requesting early termination of the HSR waiting period.  In connection with obtaining any necessary approvals under the HSR Act, each Party shall promptly and in good faith respond to any request for additional information by the U.S. Federal Trade Commission and U.S. Department of Justice in connection with such notification and otherwise cooperate in good faith with each other and such Governmental Authority, provided that no Party shall have any obligation to (i) litigate any action or claim filed by a Governmental Authority in state or federal court alleging violation of any antitrust or other laws, (ii) sell, divest, hold separate or license any of their assets or lines of business, or (iii) change or modify any course of conduct or otherwise make any commitments to any Governmental Authority regarding future operations of BioNTech's or Biotheus' business.  For the avoidance of doubt, BioNTech shall be responsible for paying any filing fees required in connection with such HSR Act filing.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">For any HSR Filings required, neither BioNTech nor Biotheus shall, and each shall use reasonable best efforts to cause their respective Affiliates not to, directly or indirectly take any action, including, directly or indirectly, acquiring or investing in any person or acquiring, leasing or licensing any assets, or agreement to do any of the foregoing, if doing so would reasonably be expected to impose any material delay in the obtaining of, or significantly increase the risk of not obtaining, any required approval under the HSR Act. BioNTech and Biotheus will promptly provide the other with copies of all substantive written communications (and memoranda setting forth the substance of all substantive oral communications) between each of them, any of their subsidiaries and their respective agents, representatives and advisors, on the one hand, and any Governmental Authority, on the other hand, with respect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">to this Agreement. Without limiting the foregoing, BioNTech and Biotheus shall&#58; (i) promptly inform the other of any communication to or from the U.S. Federal Trade Commission or the U.S. Department of Justice regarding the Agreement&#59; (ii) permit each other to review in advance any proposed substantive written communication to any such Governmental Authority and incorporate reasonable comments thereto&#59; (iii) give the other prompt written notice of the commencement of any legal proceeding with respect to the Agreement&#59; (iv) not agree to participate in any substantive meeting or discussion with any such Governmental Authority in respect of any filing, investigation or inquiry concerning this Agreement unless, to the extent reasonably practicable, it consults with the other Party in advance and, to the extent permitted by such Governmental Authority, gives the other Party the opportunity to attend&#59; (v) keep the other reasonably informed as to the status of any such legal proceeding&#59; and (vi) promptly furnish each other with copies of all correspondence, filings (except for filings made under the HSR Act) and written communications between such Party and their Affiliates and their respective agents, representatives and advisors, on one hand, and any such Governmental Authority, on the other hand, in each case, with respect to this Agreement&#59; provided that materials required to be supplied pursuant to this clause may be redacted (1) to remove references concerning valuation, (2) as necessary to comply with contractual arrangements, (3) as necessary to comply with applicable Law, and (4) as necessary to address reasonable privilege or confidentiality concerns&#59; provided further, that a Party may reasonably designate any competitively sensitive material provided to another party under this clause as &#8220;Outside Counsel Only&#8221;.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Either Party may terminate this Agreement by notice in writing to the other Party if the expiration or termination of any applicable waiting period under the HSR Act with respect to this Agreement has not been satisfied (or if permitted by applicable Law, waived) on or before &#91;***&#93; days following the Execution Date (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Outside Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#8221;). If a Party terminates this Agreement pursuant to this Section 14.16 (HSR) then this Agreement shall be of no further force or effect, except that the rights and obligations of the Parties set forth in Section 10.1 (Confidential Information) and this Section 14.16 (HSR) and any relevant definitions in Article 1 (Definitions), shall survive such termination of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.17</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Counterparts</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">This Agreement may be executed simultaneously in any number of counterparts by digital or telephonic facsimile transmission (including PDF), each of which will be an original and both of which, together, will constitute a single agreement.</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">14.18</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%;padding-left:10.44pt">Relationship of the Parties</font></div><div style="margin-bottom:18pt;padding-left:35.45pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">In entering into this Agreement and performing their respective duties and obligations with respect to the Agreement, the Parties are acting, and intend to be treated, as independent entities, and the activities and resources of each Party shall be managed by such Party, acting independently and in its individual capacity.  The relationship between the Parties is that of independent contractors, and neither Party shall have the power to bind or obligate the other Party in any manner.  Nothing contained in this Agreement shall be construed or implied to create an agency, partnership, joint venture, fiduciary, or employer-employee relationship between the Parties.  Except as otherwise expressly provided in this Agreement, neither Party may make any representation, warranty or commitment, whether express or implied, on behalf of or incur any charges or expenses for or in the name of the other Party.  Neither Party shall hold itself out, or take any action, contrary to the terms of this Section 14.18 (Relationship of the Parties), and neither Party shall become liable due to any such representation, warranty, commitment, act or omission made by the other Party contrary to the provisions of this Section 14.18 (Relationship of the Parties).  Subject to the terms of this Agreement, the activities and resources of each Party shall be managed by such Party, acting independently and in its individual capacity.</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">&#91;Remainder of page intentionally left blank.&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">, the Parties have caused this Agreement to be executed by their duly authorized representatives.</font></div><div style="margin-bottom:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">BIOTHEUS INC. </font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#26222;&#31859;&#26031;&#29983;&#29289;&#25216;&#26415;(&#29664;&#28023;)&#26377;&#38480;&#20844;&#21496;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">)</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">By&#58; &#47;s&#47; Xiaolin Liu</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Name&#58; Xiaolin Liu</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Title&#58; CEO</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">BIONTECH SE</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">By&#58; &#47;s&#47; Jens Holstein</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Name&#58; Jens Holstein</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Title&#58; CFO</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">By&#58; &#47;s&#47; Sierk Poetting</font></div><div style="margin-bottom:18pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Name&#58; Sierk Poetting</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">Title&#58; Managing Director</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:209%">&#91;Signature Page to the Collaboration, License and Option Agreement&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>GLOBAL CDP &#38; JOINT CDP</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>EXCEPTIONS TO REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>LICENSED PATENT RIGHTS</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>MANUFACTURING AND CMC INFORMATION</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>BIONTECH BACKGROUND KNOW-HOW</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>BIOTHEUS BACKGROUND IP  </font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>BIONTECH COMPETITORS  </font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>(A) BIOTHEUS IN-LICENSES</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:19.26pt"><br><br>BIOTHEUS PRESS RELEASE</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.7pt"><br><br>PM8002 LICENSED COMPOUND</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:18pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Schedule 11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:13.7pt"><br><br>PM8003 LICENSED COMPOUND</font></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:209%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.54
<SEQUENCE>10
<FILENAME>exhibit454autoluslicensean.htm
<DESCRIPTION>EX-4.54
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i857b9c9ce9bd48cea54dffb091d10ab1_1"></div><div style="min-height:77.04pt;width:100%"><div style="margin-bottom:3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.54</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type of information that the Registrant treats as private or confidential.</font></div></td></tr></table></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE AND OPTION AGREEMENT</font></div><div style="margin-top:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY AND AMONG</font></div><div style="margin-bottom:72pt;margin-top:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTOLUS LIMITED<br><br>AUTOLUS HOLDINGS (UK) LIMITED<br><br>AND<br><br>BIONTECH SE</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">299246678 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_4"></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1......... Definitions.&#160;&#160;&#160;&#160;1</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2......... Scope and Governance. &#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Collaboration Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160; 24</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.3         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;26</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;26</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3......... Collaboration Agreements. &#160;&#160;&#160;&#160;26</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Manufacturing and Commercial Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;26</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Research and Development Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;27</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4......... Product Options. &#160;&#160;&#160;&#160;27</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Product Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;27</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Provision of Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;28</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.3         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Negotiation of Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.5         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Option Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.6         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Failure to Exercise Option or Rejection of Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.7         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Rights of BioNTech if Autolus does not wish to Develop.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.8         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Next Generation Products Option.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.9         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Negotiation of Next Gen Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.10       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Referral to Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.11       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Failure to Exercise Option or Rejection of Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.12       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Next Gen Option Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.13       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">If Autolus does not wish to Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5......... License To &#91;***&#93; and &#91;***&#93; Binders. &#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Right of Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.3         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sublicense Rights&#59; Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;35</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Retention of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.5         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.6         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Scope</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.7         &#91;***&#93; &#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.8         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Transfer of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.9         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Development and Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;37</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">299246678 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.10       &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> Licensed Product Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.11       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.12       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6......... Technologies Options. &#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Non-Exclusive License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Transfer of Technologies Option Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.3         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;39</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Gatekeeping for Other AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.5         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.6         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.7         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Failure to Exercise Technologies Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7......... Obe-Cel Product. &#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.2         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Potential Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.3         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Obe-cel Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.5         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Obe-cel Revenue Interest Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.6         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Obe-cel Product Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8......... &#91;***&#93; &#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9......... Financial Provisions. &#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.1         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">License Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.2         &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.3         &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;49</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.4         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cap on Option Exercise and Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;50</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.5         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Existing Third Party Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;50</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10....... Reports and Payment Terms. &#160;&#160;&#160;&#160;50</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Reports&#59; Timing of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">and Royalty Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;50</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Mode of Payment and Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;51</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;51</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;52</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;52</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;52</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11....... Intellectual Property Rights. &#160;&#160;&#160;&#160;54</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-ii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">299246678 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;54</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;54</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Patent Prosecution and Maintenance of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;55</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Enforcement of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;56</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Infringement Claims by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Defense of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.7       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">UPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">   &#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">11.8       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Patent Linkage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12....... Confidentiality.&#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Duty of Confidence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;57</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;58</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Authorized Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;58</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.4       &#91;***&#93; &#160;&#160;&#160;&#160;59</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Disclosure of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;59</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Ongoing Obligation for Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;60</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.7       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Use of Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;60</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.8       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;60</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.9       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;60</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">12.10    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;60</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13....... Term and Termination.&#160;&#160;&#160;&#160;61</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Term&#59; Effect of Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;61</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Termination for Material Breach&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;61</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">13.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Termination by BioNTech Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;62</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14....... Effects of Termination. &#160;&#160;&#160;&#160;62</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;62</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BioNTech&#8217;s Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;63</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">14.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;63</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15....... Warranties and Covenants. &#160;&#160;&#160;&#160;63</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warranties by Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;63</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warranties by Autolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;64</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Warranties by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;66</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;66</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;68</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-iii-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">299246678 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:115.2pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(continued)</font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Upstream Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;68</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.7       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;68</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.8       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Compliance with Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;70</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">15.9       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Regulatory Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;70</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16....... Indemnification&#59; Liability.&#160;&#160;&#160;&#160;71</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Indemnification by Autolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;71</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Indemnification by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;72</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Indemnification Procedure&#59; Settlement&#59; Quantification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;72</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;72</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Special, Indirect and other Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;72</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">16.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">After-Tax Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17....... Governing Law and Dispute Resolution.&#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Patent Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">17.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. &#160;&#160;&#160;&#160;73</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18....... General Provisions.&#160;&#160;&#160;&#160;74</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Assignment&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">74</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;75</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Extension to Affiliates&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">75</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;75</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.5       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;75</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.6       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;76</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.7       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;76</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.8       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Further Assurances&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">77</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.9       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;77</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.10    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;77</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.11    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;77</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.12    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;77</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.13    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;78</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.14    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Entire Agreement&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">78</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.15    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;78</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">18.16    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.&#160;&#160;&#160;&#160;78</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-iv-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">299246678 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE AND OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License and Option Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered into this 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> day of February, 2024 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), subject to Section 13.1(a), by and among (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a company organized under the laws of England and Wales, with company number 09115837, and its registered office address at The Mediaworks, 191 Wood Lane, London, England, W12 7FP, (b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Holdings (UK) Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a company organized under the laws of England and Wales, with company number 11365111, and its registered office address at The Mediaworks, 191 Wood Lane, London, England, W12 7FP ((a) and (b) collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and (c)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioNTech SE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> a corporation organized and existing under the laws of Germany, registered with the commercial register of the lower court (Amtsgericht) of Mainz under HRB 48720 and having its place of business at An der Goldgrube 12, D-55131 Mainz, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Autolus and BioNTech are each referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Autolus is a clinical stage biotechnology company that owns or otherwise controls certain products and technologies applicable to CAR-T cell therapy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, BioNTech is a biotechnology company with expertise in the research, development, and commercialization of drug products&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, pursuant to the terms and conditions of this Agreement, Autolus desires to grant, and BioNTech desires to accept, certain rights, options and licenses to develop, manufacture and commercialize products on the terms, and subject to the conditions, set out below&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, simultaneously with entering into this Agreement, Autolus and BioNTech are entering into (a) that certain securities purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Share Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Autolus will sell to BioNTech, and BioNTech will purchase from Autolus, Autolus&#8217;s ordinary shares in the form of American depository shares, all in accordance with the terms and conditions set forth in the Share Purchase Agreement, and (b)&#160;that certain side letter agreement and that certain registration rights agreement pursuant to which Autolus will grant BioNTech certain rights (including registration rights) in connection with BioNTech&#8217;s purchase of Autolus&#8217;s ordinary shares in the form of American depository shares&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Share Purchase Agreement contemplates a staggered signing and Initial Closing (as defined in the Share Purchase Agreement), and save as specifically provided herein, the terms of this Agreement shall become effective as of the Initial Closing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Now, Therefore, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in consideration of the mutual covenants and agreements herein contained, the Parties agree as follows.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The terms in this Agreement with initial letters capitalized have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means IFRS (International Financial Reporting Standards) or U.S. GAAP (Generally Accepted Accounting Principles), as generally and consistently applied by a Party, its Affiliates, Sublicensees or Autolus Licensees (as applicable).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person that becomes an Affiliate of a Party following the Effective Date as a result of an Acquisition. &#8220;Acquirer&#8221; does not include any Person that was an Affiliate of a Party prior to such Acquisition. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party or an Affiliate, from and after the Effective Date&#58; (a) a merger, consolidation or similar transaction involving such Person, in which the shareholders of such Person immediately prior to such transaction cease to control (as defined in Section&#160;1.11) such Person after such transaction&#59; (b) a sale, transfer or other disposition of all or substantially all of the business or assets of such Person to a Third Party&#59; or (c) a sale of a controlling (as defined in Section&#160;1.11) interest of such Person to a Third Party. Notwithstanding the foregoing, a sale of stock of such Person to underwriters in an underwritten public offering of such Person&#8217;s stock solely for the purpose of financing does not constitute an Acquisition.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Activity Enhancement Licensed Know-How and the Activity Enhancement Licensed Patents.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, including &#91;***&#93;, that is (a)&#160;Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b)&#160;necessary or reasonably useful for (i) the Exploitation of the Activity Enhancement Licensed Technology, or (ii) the Exploitation of such Activity Enhancement Licensed Technology in an Activity Enhancement Licensed Product. Notwithstanding the foregoing, the Activity Enhancement Licensed Know-How excludes &#91;***&#93;, except &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents, including Patents that Cover &#91;***&#93;, that (a) are Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b)&#160;claim or Cover (i) Activity Enhancement Licensed Technology, (ii) Activity Enhancement Licensed Know-How, or (iii)&#160;the Exploitation of such Activity Enhancement Licensed Technology or Activity Enhancement Licensed Know-How in an Activity Enhancement Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product that includes any Activity Enhancement Licensed Technology. For the purposes of this Agreement, &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each module listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:15.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the options granted by Autolus to BioNTech in Section&#160;6.3(d) and Section 6.3(e).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an antibody-drug conjugate, being a pharmaceutical or biologic product that contains an antibody, or an antibody derivative, that can be linked directly or indirectly to a payload such as a chemical moiety. Such antibody or antibody derivative and payload &#91;***&#93;. For these purposes, &#8220;antibody derivative&#8221; includes antibodies that have (a) been modified via isotype switching&#59; (b) undergone a modification of effector function&#59; (c) been adapted to enable the antibody to carry payloads&#59; (d) been altered to change the expression characteristics, stability or biological half-life of the antibody&#59; (e) been mutated using an affinity maturation strategy designed to modify the affinity of either the variable regions and&#47;or the constant regions of the antibody for any ligands, antigens or receptors&#59; or (f) been modified or combined to bind additional moieties. Antibody derivatives may be full length antibodies, monoclonal and polyclonal antibodies, and multispecific antibodies (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, bi-specific antibodies), as well as antibody fragments and antibody-like fragments (including Fab, Fab&#8217;, F(ab&#8217;)2, Fv fragments, scFv, diabodies, linear antibodies and single-chain antibodies). Antibodies and antibody derivatives can be of any origin, whether human, humanized, chimeric or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, any Person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, &#8220;control&#8221; shall mean, direct or indirect, ownership of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest, in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. In the case of entities organized under the laws of certain countries, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%) and, in such case, such lower percentage shall be substituted in the preceding sentence&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that such foreign investor has the power to direct the management and policies of such entity.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Sherman Act, as amended, the Clayton Act, as amended, the HSR Act, the Federal Trade Commission Act, as amended, and all other applicable laws and regulations (including non-U.S. laws and regulations) issued by a governmental authority that are designed or intended to preserve and protect competition, prohibit and restrict monopolization, attempted monopolization, restraint of trade and abuse of dominant position, or to prevent acquisitions, mergers or other business combinations and similar transactions, the effect of which may be to lessen or impede competition or to tend to create or strengthen a dominant position or to create a monopoly. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Data Protection Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Applicable Laws in any jurisdiction relating to privacy or the processing or protection of Personal Data, including the General Data Protection Regulation (EU) 2016&#47;679 (EU GDPR), the UK Data Protection Act 2018, the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the UK Data Protection Act 2018), the e-Privacy Directive (2002&#47;58&#47;EC), the UK Privacy and Electronic Communications Regulations 2003 (SI 2003 No. 2426) as amended and the comparable Applicable Laws in other jurisdictions and all guidance issued by any applicable data protection authority, including the Information Commissioner&#8217;s Office statutory data sharing code of practice which came into force on 5 October 2021, as updated or amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all applicable laws, statutes, rules, regulations and other pronouncements having the effect of law of any federal, national, multinational, state, cantonal, provincial, county, city or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or other requirements of the Regulatory Authorities that may be in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 10.5(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 10.5(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 10.5(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 16.2.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; Licensed IP, (b) &#91;***&#93; Licensed IP, (c)&#160;Safety Switch Licensed IP, (d) Activity Enhancement Licensed IP, and (e) &#91;***&#93; Licensed IP.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How included within the Autolus IP. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Licensees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a licensee or sublicensee (regardless of how many tiers of (sub)licensee there are) of Autolus or any of its Affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, notwithstanding any provision to the contrary set forth in this Agreement, distributors and wholesalers will not be considered Autolus Licensees.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) &#91;***&#93; Licensed Patents, (b) &#91;***&#93; Licensed Patents, (c) Safety Switch Licensed Patents, (d) Activity Enhancement Licensed Patents, and (e) &#91;***&#93; Licensed Patents. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an AUTO1&#47;22 Product, AUTO6NG Product, and Obe-cel Product, in each case in the form in which such product exists as of the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus&#8217;s Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; knowledge &#91;***&#93;, of any of&#58; &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTO1&#47;22 Next Gen Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any AUTO1&#47;22 Product Developed by Autolus or its Affiliates to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTO1&#47;22 Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Autolus&#8217;s proprietary autologous CAR-T Cell Therapy targeting CD19 and CD22 in the form under Development as of the Effective Date, as more particularly set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, together with any new dosage forms, strengths, methods of manufacture, or methods of administration thereof and any improvements or modifications of such products, but excluding any AUTO1&#47;22 Next Gen Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTO6NG Next Gen Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any AUTO6NG Product Developed by Autolus or its Affiliates to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTO6NG Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Autolus&#8217;s proprietary autologous CAR-T Cell Therapy targeting GD2 in the form under Development as of the Effective Date, as more particularly set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, together with any new dosage forms, strengths, methods of manufacture, or methods of administration thereof and any improvements or modifications of such products, but excluding any AUTO6NG Next Gen Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; has the meaning &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; has the meaning &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 11.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the baseball arbitration procedure set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) that certain Binder of &#91;***&#93;, and (b) &#91;***&#93;, provided that clause (b) shall not include any Binder that (i) &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Know-How and the &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Patents.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, including &#91;***&#93;, that is (a) Controlled by Autolus or its Affiliates, as of the Effective Date or during the Term, and (b) necessary or reasonably useful for (i) the Development of the &#91;***&#93; Licensed Binder, or (ii) the Exploitation of such Binder in a &#91;***&#93; Licensed Product. Notwithstanding the foregoing, the &#91;***&#93; Licensed Know-How &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents, including Patents that Cover &#91;***&#93;, that (a) are Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b) claim or Cover (i) the &#91;***&#93; Licensed Binder, (ii) the &#91;***&#93; Licensed Know-How, or (iii) the Exploitation of the &#91;***&#93; Licensed Binder in a &#91;***&#93; Licensed Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product that expresses In Vivo one or more &#91;***&#93; Licensed Binder(s), including any dosage strengths, presentations, formulations or methods of administration. For the purposes of this Agreement, &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that ***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.3(b). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a protein domain that is capable of binding an antigen. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; has the meaning set out in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioNTech Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 16.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Biosimilar Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in a particular country with respect to a particular &#91;***&#93; Licensed Product, a product that&#58; (a) has received all necessary approvals by the applicable Regulatory Authorities in such country to place on the market such product as a biopharmaceutical product&#59; (b) is marketed or sold by a Third Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship with, BioNTech or any of its Affiliates or Sublicensees&#59; and (c) is approved as a &#8220;biosimilar&#8221; (in the United States) or a &#8220;similar biological medicinal product&#8221; (in the EU) or using a comparable procedure in other countries whereby the &#91;***&#93; Licensed Product is the &#8220;reference medicinal product&#8221; and an expedited Regulatory Approval process for the approval of generic versions of biological products is used based on Applicable Laws and once all regulatory exclusivities and intellectual property rights for the &#91;***&#93; Licensed Product have expired. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BNT211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 3.1(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a day other than a Saturday, Sunday, or a bank or other public holiday in London, England or Mainz, Germany.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that&#58; (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first such three (3)-month period thereafter&#59; and (b) the final Calendar Quarter of the Term shall extend from the first day of such three (3)-month period until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a period of twelve (12) consecutive calendar months ending on December&#160;31&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that&#58; (a) the first Calendar Year of the Term shall extend from the Effective Date to December 31&#59; and (b) the final Calendar Year of the Term shall extend from January 1 until the last day of the Term.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a chimeric antigen receptor.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CAR-T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a T-cell incorporating a CAR.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CAR-T Cell Therapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a therapy comprising a T-cell that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; means a protein product of the &#91;***&#93; molecule gene.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;&#8221; means a protein product of the &#91;***&#93; molecule gene.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 1.70.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) that certain Binder of &#91;***&#93;, and (b) &#91;***&#93;, provided that clause (b) shall not include any Binder that (i) &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) that certain Binder of &#91;***&#93;, and (b) &#91;***&#93;, provided that clause (b) shall not include any Binder that (i) &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Binder </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Patents (a) Controlled by BioNTech or its Affiliates and (b) that claim or Cover &#91;***&#93; Licensed Binder and&#47;or a &#91;***&#93; Licensed Binder that were made by or on behalf of BioNTech, its Affiliates, Sublicensees, or their Subcontractors unless &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 9.2(c).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 5.1(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; Licensed Know-How and the &#91;***&#93; Licensed Patents. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How that is (a) Controlled by Autolus or its Affiliates, as of the Effective Date or during the Term, and (b) necessary or reasonably useful for (i) the Development of a &#91;***&#93; Licensed Binder and&#47;or a &#91;***&#93; Licensed Binder, or (ii) the Exploitation of a &#91;***&#93; Licensed Product. Notwithstanding the foregoing, the &#91;***&#93; Licensed Know-How excludes &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents that are (a) are Controlled by Autolus or its Affiliates, as of the Effective Date or during the Term, and (b) that claim or Cover (i) a &#91;***&#93; Licensed Binder and&#47;or a &#91;***&#93; Licensed Binder, (ii) &#91;***&#93; Licensed Know-How, or (iii) the Exploitation of such Binders in a &#91;***&#93; Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product that expresses In Vivo one or more &#91;***&#93; Licensed Binder(s) and&#47;or &#91;***&#93; Licensed Binder(s), including any dosage strengths, presentations, formulations or methods of administration. For the purposes of this Agreement, &#91;***&#93; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;. For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product and country-by-country basis, the period commencing on the date of First Commercial Sale of such &#91;***&#93; Licensed Product in such country and expiring on &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; to a Third Party (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means complementarity determining sequences.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Third Party demands, claims, actions, proceedings and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Study Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the final clinical study report containing the results of a &#91;***&#93;, in the form in which it is provided to Autolus by the Sponsor (or prepared by Autolus, if Autolus is the Sponsor).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any human clinical study or trial of a product, including Phase 1 Trials, Phase 2 Trials, Pivotal Trials, Phase 3 clinical trials and Phase 4 clinical trials or any other equivalent, combined or other trial a product is administered to a human subject.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Co-Exclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of BioNTech and Autolus and their respective Affiliates may practice the Activity Enhancement Licensed IP with respect to products owned or controlled by such Party or one of its Affiliates, and that neither Party nor any of its Affiliates may grant Third Parties, &#91;***&#93;, any right or license to practice the Activity Enhancement Licensed IP with any products other than products owned or controlled by such Party or one of its Affiliates. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) a Revenue-Bearing Product in combination with &#91;***&#93; other therapeutically active ingredients&#59; (b) a co-packaged Revenue-Bearing Product containing &#91;***&#93; separate pharmaceutical products (one of which is a Revenue-Bearing Product) in the same presentation&#59; or (c) a Revenue-Bearing Product used as part of a treatment regimen where such Revenue-Bearing Product is approved for use with other pharmaceutical or biologic products (whether </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or not each such pharmaceutical or biologic product is sold separately) and sold for a single price. For the avoidance of doubt, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to market, promote, distribute, import, export, offer to sell or sell a product or conduct other commercialization activities with respect to a product, including activities relating to marketing, promoting, distributing, importing, exporting, offering for sale or selling a product, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning. Commercialize and Commercialization do not include Manufacture, Manufactured or Manufacturing or Develop, Development or Developed.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party&#8217;s activities, such &#91;***&#93; efforts to undertake an activity as &#91;***&#93; would normally use to accomplish a similar objective under similar circumstances, with respect to a product that is of similar market and economic potential as the applicable product, and at a similar stage in its development or product life as such product, taking into account &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 11.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How and other proprietary information and data of any kind, including of a financial, scientific, commercial or technical nature that the Disclosing Party has supplied or otherwise made available to the Recipient Party, whether made available orally, in writing or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data (including Personal Data), designs or formulae in relation to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any Know-How, material, Patent, or other property right, the possession of the right, whether directly or indirectly, and whether by ownership, license, covenant not to sue, or otherwise (other than by operation of the license and other grants in this Agreement), for a Party or its Affiliates to grant a license, sublicense, or other right to or under such Know-How, material, Patent, or other property right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, neither such Party nor its Affiliates shall be deemed to &#8220;Control&#8221; any Know-How, material, Patent, or other property right that&#58; (a) &#91;***&#93; of such Party, to the extent that &#91;***&#93; (i) &#91;***&#93;, or (ii) &#91;***&#93;, in each case ((i) or (ii)), except if ***&#93;, or (b) &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">unless</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;***&#93; such Know-How, material, Patent, or other property right ***&#93; Know-How, material, Patent, or other property right &#91;***&#93;, and such license &#91;***&#93; the license or sublicense is under any Know-How, material, Patent &#91;***&#93;, or other property right, and &#91;***&#93;, as applicable. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a country-by-country basis, with respect to a particular subject matter at issue &#91;***&#93; and one or more claim(s) in a relevant Patent, that, in the absence of ownership of, or a license under, such Patent, the Exploitation of such subject matter in such country would infringe one or more issued Valid Claims of such Patent, or, as to a pending claim included in such Patent, the Exploitation of such subject matter would infringe such Patent if such pending claim were to issue in an issued patent, in such country.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the AUTO1&#47;22 Product, AUTO6NG Product, AUTO1&#47;22 Next Gen Product and AUTO6NG Next Gen Product, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means drug research and development activities, including test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance&#47;quality control development, technical development, process development, statistical analysis, pre-clinical and Clinical Trials, packaging development, regulatory affairs, and the preparation, filing and prosecution of Regulatory Filings. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has a correlative meaning. Develop, Development and Developed do not include Manufacture, Manufactured or Manufacturing or Commercialize or Commercialization.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Plan Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.3.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 12.1. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in Section 17.2.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the lawful currency of the United States.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Drug Approval Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a New Drug Application, submitted to the FDA pursuant to 21 CFR &#167;&#160;314.50 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (b) a Biologics License Application submitted to the FDA pursuant to Section 351(a) of the Public Health Service Act and the regulations promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (c) an application for authorization to market or sell a biological or pharmaceutical product submitted to a Regulatory Authority in any country or jurisdiction other than the U.S., including, with respect to the European Union, a marketing authorization application filed with the EMA pursuant to the Centralized Approval Procedure or with the applicable Regulatory Authority of a country in the European Economic Area with respect to the decentralized procedure, mutual recognition or any national approval procedure (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; or (d) with respect to any biological or pharmaceutical product for which an NDA, BLA or MAA has been approved by the applicable Regulatory Authority, an application to supplement or amend such NDA, BLA or MAA to expand the approved label for such biological product to include use of such biological product for an additional Indication.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the date of the Initial Closing.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the preamble. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency or any successor entity thereto.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Evaluation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to make, have made, import, have imported, export, have exported, use, have used, sell, have sold, offer for sale, or have offered for sale, including to research, Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured, hold, or keep (whether for disposal or otherwise), or otherwise dispose of.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.6(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.6(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.6(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the U. S. Food and Drug Administration or any successor entity thereto. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the treatment and prophylaxis of diseases and conditions in humans.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to an Obe-cel Product, or &#91;***&#93; Licensed Product, as the case may be, in a country, the first arm&#8217;s length sale for monetary value&#58; (a) in respect to Obe-cel Products, of such Obe-cel Product by Autolus, its Affiliates, or Autolus Licensees, or (b) in respect of &#91;***&#93; Licensed Products by BioNTech, its Affiliates, or their Sublicensees, as applicable to a Third Party for end use or consumption in such country following Regulatory Approval for sale of such Obe-cel Product or &#91;***&#93; Licensed Product in such country. Sales prior to receipt of Regulatory Approval for such product, such as so-called &#8220;treatment IND sales,&#8221; &#8220;named patient sales,&#8221; and &#8220;compassionate use sales,&#8221; shall not be construed as a First Commercial Sale. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Investment Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Applicable Laws that are designed or intended to screen, prohibit, restrict or regulate actions by Persons seeking to acquire rights in or control over domestic equities, securities, entities, assets, land or other interests in order to address national security or public order goals. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a full time equivalent person-year based upon a total of &#91;***&#93; working hours per Calendar Year of scientific or technical work carried out by a duly qualified employee of Autolus on or directly related to the work to be conducted under the Agreement. The portion of a FTE </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">billable by Autolus for one (1) individual during a given accounting period shall be determined by dividing the number of hours worked directly by said individual on the work to be conducted under the Agreement during such accounting period and the number of FTE hours applicable for such accounting period based on &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that hours worked will not be counted by any multiplier (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, overtime or time-and-a-half).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the rate of FTE costs incurred by Autolus, which for the purpose of this Agreement shall be &#91;***&#93; per FTE per Calendar Year. Beginning on &#91;***&#93;, and on &#91;***&#93; of each subsequent Calendar Year during the Term, the FTE Rate is subject to annual adjustment by the percentage increase in the &#91;***&#93; in the preceding Calendar Year.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeper</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a mutually agreed independent Third Party patent attorney.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the good laboratory practice standards set out in Schedules 1 and 2 of Directive 2004&#47;10&#47;EC and Directive 2004&#47;9&#47;EC, or the equivalent Applicable Law in the relevant jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) any officer, employee (including physicians, hospital administrators or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital&#59; (b) any candidate for political office, any political party or any official of a political party&#59; or (c)&#160;any person acting in an official capacity on behalf of any of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any multi-national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as codified at 15 U.S.C. &#167;18a, as may be amended from time to time, and the rules and regulations promulgated thereunder. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HSR Clearance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the expiration or termination of all applicable waiting periods and requests for information (and any extensions thereof) under the HSR Act with respect thereto with respect to any Technologies Option or other option exercise.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HSR Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means filings by Autolus or BioNTech with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice of a Notification and Report Form, together with all required documentary attachments thereto with respect to any Technologies Option or other option exercise.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Investigational New Drug application in the U.S. filed with the FDA or the corresponding application for the investigation of pharmaceutical or biologic products in any other country or group of countries, as defined in Applicable Law and filed with the Regulatory Authority of a given country or group of countries.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 16.3.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in Section 16.3.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a separate and distinct disease or medical condition in humans, and &#91;***&#93;, for which &#91;***&#93; with &#91;***&#93;, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inflation Reduction Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means 42 U.S.C. &#167;&#167; 1320f et seq., (or any amended or successor act).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning given to it in the Share Purchase Agreement. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Tech Transfer Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, &#91;***&#93;, that are in the possession of Autolus or its Affiliates at the Effective Date, that form part of the (a) &#91;***&#93; Licensed Know-How, (b) &#91;***&#93; Licensed Know-How, (c) Activity Enhancement Licensed Know-How, (d) Safety Switch Licensed Know-How, or (e)&#160;&#91;***&#93; Licensed Know-How and &#91;***&#93;, or &#91;***&#93;, in the format held by Autolus or its Affiliates on the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (a) with respect to a Phase 1 Trial, the first dosing of the &#91;***&#93; human subject in such Phase 1 Trial, and (b) with respect to any other Clinical Trial, the first dosing of the &#91;***&#93; human subject in such Clinical Trial.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, in relation to either Party, any of the following&#58; (a)&#160;that a Party admits in writing to that the other Party that is has or will cease to function as a going concern by suspending or discontinuing its business&#59; (b) that Party shall commence any case, proceeding or other action (i) under any existing or future law of any jurisdiction relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (ii) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or any such Party shall make a general assignment for the benefit of its creditors&#59; (c) there shall be commenced against such Party any case, proceeding or other action of a nature referred to in clause (b)&#160;above that (1)&#160;results in the entry of an order for relief or any such adjudication or appointment or (2)&#160;remains undismissed, undischarged or unbonded for a period of &#91;***&#93;&#59; (d) any case, proceeding or other action has been commenced against such Party seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of its assets that results in the entry of an order for any such relief that shall not have been vacated, discharged, or stayed or bonded pending appeal within &#91;***&#93; from the entry thereof&#59; or (e) such Party shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clauses (b), (c) or (d) above.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Internal Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an internal Autolus research program for which Autolus or any of its Affiliates has &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Intra-Group License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain License Agreement, dated &#91;***&#93;, by and between Autolus Limited and Autolus Holdings (UK) Limited.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">In Vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; in which &#91;***&#93; in any &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">In Vivo AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.3(d).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 2.2(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to compounds, formulations, compositions, products or to their Manufacture, Development, registration, use, Commercialization or other Exploitation, or methods of assaying or testing them or processes for their Manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data (including Personal Data), instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the Development, Manufacture, registration, use, Commercialization or other Exploitation of or which may be useful in studying, testing, Developing, producing or formulating products, or intermediates for the synthesis thereof.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; has the meaning set out in &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 16.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Major Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a compound or product, activities directed to the sourcing and purchasing of materials, producing, manufacturing, supplying, processing, compounding, filling, finishing, packing, packaging, labeling, leafleting, quality assurance, quality control testing and release, shipping, storage, and sample retention of such compound or product. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufactured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; have correlative meanings. Manufacture and Manufacturing do not include Develop or Developed or Commercialize or Commercialization.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MCSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 3.1(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MCSA Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 3.1(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Module Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the Safety Switch Option, or (b) the Activity Enhancement Option. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Module Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.4(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (i) with respect to any Obe-cel Product, the gross amounts &#91;***&#93; by Autolus, its Affiliates or Autolus Licensees to Third Party customers for sales of such Obe-cel Product, or (ii) with respect to any &#91;***&#93; Licensed Product, the gross amount &#91;***&#93; by BioNTech, its Affiliates or Sublicensees to Third Party customers for sales of such &#91;***&#93; Licensed Product, in each case ((i) and (ii)) less the following to the extent reasonable and customary and paid, incurred, or otherwise taken and not reimbursed by any Third Party in accordance with applicable Accounting Standards with respect to such sales&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;, </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding any provision to the contrary set forth in this Agreement, &#91;***&#93;. Net Sales will only be determined on the first sale by a Selling Party to (1) &#91;***&#93; or (2) &#91;***&#93;. Notwithstanding the foregoing, amounts received or invoiced by a Selling Party for the sale of such Revenue-Bearing Product to &#91;***&#93; for resale will not be included in the computation of Net Sales hereunder, and the amounts invoiced by &#91;***&#93; on such resale to &#91;***&#93; will be included in the computation of Net Sales hereunder. For purposes of determining Net Sales, a Revenue-Bearing Product will be deemed to be sold when &#91;***&#93;. Net Sales will be accounted for in accordance with the applicable Accounting Standards. A particular deduction may only be accounted for once in the calculation of Net Sales. Net Sales will exclude any Revenue-Bearing Product made available to the patient &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Revenue-Bearing Product is sold as part of a Combination Product, the Net Sales of such Revenue-Bearing Product, for the purposes of determining royalty payments, shall be determined by &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of the Revenue-Bearing Product when sold separately in finished form can be determined but the weighted average sale price of the other active compound(s)&#47;active ingredient(s) when sold separately in finished form cannot be determined, Net Sales shall be calculated by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of the other active compound(s)&#47;active ingredient(s) when sold separately in finished form can be determined but the weighted average sale price of the Revenue-Bearing Product when sold separately in finished form cannot be determined, Net Sales, shall be calculated by ***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of both the Revenue-Bearing Product and the other active compound(s)&#47;active ingredient(s) in the Combination Product, in each case, when sold separately in finished form, cannot be determined, the Net Sales of the Revenue-Bearing Product shall be determined by &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The weighted average sale price for a Revenue-Bearing Product, other active compound(s)&#47;active ingredient(s), or Combination Product ***&#93;. When determining the weighted average sale price of a Revenue-Bearing Product, other active compound(s)&#47;active ingredient(s), or Combination Product, the weighted average sale price shall be calculated by &#91;***&#93;. Any overpayment or underpayment due to &#91;***&#93; will be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Development Plan Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.8(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.8(c).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Notification Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.8(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in Section 4.12(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) AUTO1&#47;22 Next Gen Product or (b) AUTO6NG Next Gen Product, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.8(c).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.8(b). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.9.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.8(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Next Gen Product-by-Next Gen Product basis, the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nominated Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in Section 6.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nomination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 1.153. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 7.4(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 7.4(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 7.4(a).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the autologous CD19 CAR-T Cell Therapy known as obecabtagene autoleucel or obe-cel, as further set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, regardless of the brand name under which it is sold, Indication, or dose.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Product Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; to a Third Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Revenue Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 7.5.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Revenue Interest Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a &#91;***&#93;, with respect to &#91;***&#93; Obe-cel Product by Autolus, its Affiliates or Autolus Licensees, the period commencing on &#91;***&#93; and &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OP&#47;NGOP Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 1.159.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.3.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of (a) AUTO1&#47;22 Product and (b)&#160;AUTO6NG Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product or Next Gen Option Product Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; to a Third Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OP&#47;NGOP Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.7(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.3(e).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all national, regional and international patents and patent applications, including provisional patent applications and any and all rights to claim priority thereto, (b)&#160;all patent applications filed either from such patents, patent applications, or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, continued prosecution applications and reissue applications, (c)&#160;any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations, and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications or other patents resulting from post-grant proceedings ((a), (b), and (c)), and (e) any similar patent rights, including so-called pipeline protection or any importation, revalidation, confirmation, or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Paying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;10.6(b)(i).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any information collected or received by Autolus and provided to BioNTech as a Data Package pursuant to this Agreement and that relates to an identified or identifiable natural person in accordance with Applicable Data Protection Law. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 1 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product that satisfies the requirements for a Phase 1 study as defined in 21&#160;CFR &#167;&#160;312.21(a) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 2 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product that satisfies the requirements for a Phase 2 study as defined in 21&#160;CFR &#167;&#160;312.21(b) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 3 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product that satisfies the requirements for a Phase 3 study as defined in 21&#160;CFR &#167;&#160;312.21(c) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pivotal Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population in order to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling and the filing for Regulatory Approval, or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the trials referred to in 21 C.F.R. &#167;312.21(c), as amended.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.4(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.173</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.4(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.174</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section&#160;4.5(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period commencing on &#91;***&#93; and ending on (a) with respect to AUTO1&#47;22 Product, &#91;***&#93; and (b)&#160;with respect to the AUTO6NG Product, &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if BioNTech provides a Development Plan Trigger Notice pursuant to Section 4.3, then the Product Option Period for the applicable Option Product shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Qualified Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.179</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means has the meaning set out in Section 10.6(b)(ii).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.180</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 12.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product in any country or other jurisdiction, any approval (including, where required, pricing and reimbursement approvals), registration, license or authorization from a Regulatory Authority in such country or other jurisdiction that is necessary to market and sell such product in such country or jurisdiction, including in the US, an EUA.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any governmental agency or authority responsible for granting Regulatory Approvals for biopharmaceutical products, including the FDA, EMA, European Commission and any corresponding national or regional regulatory authorities.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.183</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.184</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product, any submission to a Regulatory Authority of any appropriate regulatory application with respect to such product, including any submission to a regulatory advisory board, Drug Approval Application, and any supplement or amendment thereto, including any IND, or the corresponding application in any other country or group of countries with respect to such product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 3.2.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reserved Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.4(c).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; the meaning set forth in Section 6.4(d). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.188</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; have the meaning set forth in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Revenue-Bearing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) Obe-cel Product when Autolus or its Affiliate, or an Autolus Licensee is the Selling Party or (b) &#91;***&#93; Licensed Product when BioNTech, its Affiliate, or a Sublicensee is the Selling Party. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.190</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 4.7(a). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all uses, subject to the limitations set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Part B.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.192</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Safety Switch Licensed Know-How and the Safety Switch Licensed Patents.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.193</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, including &#91;***&#93;, that is (a)&#160;Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b)&#160;necessary or reasonably useful for (i) the Exploitation of the Safety Switch Licensed Technology, or (ii)&#160;the Exploitation of such Safety Switch Licensed Technology in a Safety Switch Licensed Product. Notwithstanding the foregoing, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.194</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents, including Patents that Cover &#91;***&#93;, that (a) are Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b) claim or Cover (i) the Safety Switch Licensed Technology, (ii) the Safety Switch Licensed Know-How, or (iii) the Exploitation of such Safety Switch Licensed Technology in a Safety Switch Licensed Product. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product, in any form, that contains or incorporates any Safety Switch Licensed Technology. For the purposes of this Agreement, &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.196</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each regulatable control module listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Part A.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.3(c). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.198</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sales Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any sales, goods, services, value-added, turnover, consumption, use or similar tax and any tax charged on the import or export of any goods or services. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.199</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Selling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) with respect to Obe-cel Product, Autolus, its Affiliates or Autolus Licensees, as applicable and (b) with respect to any &#91;***&#93; Licensed Product, BioNTech, its Affiliates or Sublicensees, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Share Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in the recitals to this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sponsor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the sponsor of the &#91;***&#93; of the applicable Option Product or Next Gen Product.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.202</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 2.4.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.203</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 5.3 </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Third Party to whom BioNTech or any of its Affiliates has granted a sublicense of any of its rights under this Agreement to Exploit &#91;***&#93; Licensed Products&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, notwithstanding any provision to the contrary set forth in this Agreement, Subcontractors, distributors and wholesalers will not be considered Sublicensees.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.205</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means one or more biological targets identified by BioNTech in respect of which BioNTech wishes to exercise any Module Option, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, other than in respect of &#91;***&#93;, if &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.206</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; has the meaning set out in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.207</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any taxes, duties, levies or imposts and other charges in the nature of tax and all related withholding or deductions.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.208</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.5.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.209</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the &#91;***&#93; Option, (b) the Safety Switch Option, (c)&#160;the Activity Enhancement Option, or (d) &#91;***&#93; Option, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.210</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 1.217.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.6.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Fee Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.6.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.5.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.214</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the &#91;***&#93; Licensed IP, (b) the Safety Switch Licensed IP, (c) Activity Enhancement Licensed IP, and (d) &#91;***&#93; Licensed IP. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.215</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period of time commencing on the Effective Date and ending on the later of the expiration of (a) the &#91;***&#93; Option Period, (b) the Module Option Period, and (c) &#91;***&#93; Option Period.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.216</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; Licensed Binder, &#91;***&#93; Licensed Binder, Safety Switch Licensed Technology, Activity Enhancement Licensed Technology, and &#91;***&#93; Licensed Binder.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93; to a Third Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.218</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">has the meaning set out in Section 13.1(b).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.220</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.221</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Evaluator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Subcontractors performing activities in connection with the research or development of products being researched or developed, in whole or in part, by or on behalf of BioNTech or its Affiliates alone or in conjunction with a Third Party collaborator.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transferred Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.2(a).</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.225</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.226</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the Field and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.227</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any of the Binders of &#91;***&#93;, and (b) &#91;***&#93;, provided that clause (b) shall not include any Binder that (i) &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.228</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Binder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any of the Binders of &#91;***&#93;, and (b) &#91;***&#93;, provided that clause (b) shall not include any Binder that (i) &#91;***&#93;, or (ii) &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.229</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Know-How and the &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensed Patents. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.230</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How, including &#91;***&#93;, that is (a) Controlled by Autolus or its Affiliates, as of the Effective Date or during the Term, and (b) necessary or reasonably useful for (a) the Development of the &#91;***&#93; Licensed Binder and&#47;or the &#91;***&#93; Licensed Binder, or (b) the Exploitation of such Binders in a &#91;***&#93; Licensed Product, or &#91;***&#93;. Notwithstanding the foregoing, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.231</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patents, including Patents that Cover &#91;***&#93;, that (a) are Controlled by Autolus or any of its Affiliates, as of the Effective Date or during the Term, and (b) claim or Cover (i) the &#91;***&#93; Licensed Binder or the &#91;***&#93; Licensed Binder, (ii) the &#91;***&#93; Licensed Know-How, or (iii) the Exploitation of the &#91;***&#93; Licensed Binder and&#47;or the &#91;***&#93; Licensed Binder in a &#91;***&#93; Licensed Product or &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.232</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical or biologic product (a)&#160;that expresses In Vivo, or (b) is an ADC that contains, in each case of (a) and (b), the &#91;***&#93; Licensed Binder and&#47;or the &#91;***&#93; Licensed Binder, including any dosage strengths, presentations, formulations or methods of administration, but excluding a &#91;***&#93;. For the purposes of this Agreement, &#91;***&#93; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;. For clarity, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.233</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.3(a). </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.234</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 6.1.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.236</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.237</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.238</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.239</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America, its territories and possessions.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.240</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set out in Section 7.3.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.241</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:6.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.242</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; of&#58; (a) a &#91;***&#93; Patent &#91;***&#93;, which &#91;***&#93; and &#91;***&#93; and &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such &#91;***&#93; to which such &#91;***&#93; patent &#91;***&#93; is &#91;***&#93;, excluding, however, any &#91;***&#93; that &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that from and after such &#91;***&#93;, unless and until &#91;***&#93;, and &#91;***&#93;&#59; or (b) any &#91;***&#93; Patent for which &#91;***&#93; any of the following&#58; &#91;***&#93;&#59; or &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that in no event will any &#91;***&#93; with respect to &#91;***&#93;. For the purposes of this Agreement, &#91;***&#93; shall be subject to subparagraphs (a)&#160;or (b) hereof, or &#91;***&#93;. For the purpose of this definition, &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Scope and Governance</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Overview.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Under and pursuant to the terms of this Agreement&#58; (a)&#160;the Parties shall discuss &#91;***&#93; (i) one or more agreements with respect to manufacturing and commercial services pursuant to Section 3.1 and (ii) a potential research and development collaboration agreement pursuant to Section 3.2&#59; (b) Autolus shall grant BioNTech certain exclusive options to obtain certain exclusive rights to certain agreed programs Controlled by Autolus, pursuant to Article&#160;4&#59; (c)&#160;Autolus shall grant BioNTech an exclusive license to &#91;***&#93; Licensed Binders and &#91;***&#93; Licensed Binders pursuant to Article 5&#59; (d) Autolus shall grant BioNTech options to obtain licenses related to (i)&#160;&#91;***&#93; Licensed Binders and &#91;***&#93; Licensed Binders, (ii) Safety Switch Licensed Technology, (iii) Activity Enhancement Licensed Technology, and (iv) &#91;***&#93; Licensed Binders, each in accordance with Article 6&#59; (e) Autolus shall pay to BioNTech the Obe-cel Revenue Interest pursuant to Section 7.5&#59; and (f) BioNTech shall pay the license payment to Autolus set out in Section 9.1, purchase shares in Autolus set out in the Share Purchase Agreement, as further set out in the Recitals, and make the other payments set out under this Agreement in accordance with the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Within &#91;***&#93;, the Parties shall establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to provide a forum for communication between the Parties and to oversee the relationship between the Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the JSC shall have no authority to amend this Agreement. The JSC is formed to aid in the exchange of information and discussions by the Parties &#91;***&#93;. The JSC shall disband upon the later of (i)&#160;&#91;***&#93;, and (ii) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that upon BioNTech&#8217;s written request, the term of the JSC shall continue for &#91;***&#93; beyond such period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The JSC shall be comprised of an equal number of representatives from each of Autolus and BioNTech. The exact number of such representatives shall be &#91;***&#93; for each Party, or such other number as the Parties may agree. Autolus and BioNTech shall each designate one of its JSC members as co-chairperson of the JSC. Each Party may replace any or all of its representatives or appoint a proxy at any time by giving prior written notification to the other Party. Each Party may, in its reasonable discretion, invite other employees and agents of such Party who are under written obligations of confidentiality to attend meetings of the JSC. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">From &#91;***&#93; until &#91;***&#93;, the JSC will hold meetings on a &#91;***&#93; basis, and thereafter shall hold meetings &#91;***&#93;, in each case unless otherwise agreed by the Parties. All meetings will be held by videoconference, telephone, web conference, or face to face, unless otherwise agreed by the JSC. The co-chairpersons of the JSC will set the agenda for meetings of the JSC. The co-chairpersons will issue minutes of each meeting of the JSC &#91;***&#93; following each meeting. The minutes will be considered as accepted if, within &#91;***&#93; following receipt, no one has objected in writing (including by electronic mail) to the co-chairpersons disputing the accuracy of such minutes. The minutes of each JSC meeting are the Confidential Information of both Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The JSC will&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">review and discuss Autolus&#8217;s &#91;***&#93; updates provided under Section 4.2(a), any Data Package provided under Section 4.2(b), and any commencement by Autolus of Development activities on any Next Gen Product notified under Section 4.2(c)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">following delivery of any Development Plan Trigger Notice or Next Gen Development Plan Trigger Notice, review and discuss the Option Product Development Plan or Next Gen Development Plan (as applicable), in accordance with Section 4.3 and Section 4.8(c) respectively&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">review the &#91;***&#93; updates provided by BioNTech pursuant to Section&#160;6.2(d)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">review and discuss the report regarding the Obe-cel Product set forth in Section 7.1, and any updates to such report&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">review and discuss &#91;***&#93; updates on Development of Obe-cel Product with respect to Indications other than &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">during the &#91;***&#93;, including Autolus&#8217;s &#91;***&#93; updates provided under Section 8.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">review and discuss any &#91;***&#93; under Section&#160;3.1(b), and oversee &#91;***&#93; pursuant to Section&#160;3.1(b)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">review and discuss each report provided by BioNTech under Section&#160;5.11&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">review and discuss &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">perform other responsibilities specifically assigned to the JSC pursuant to this Agreement or as may be mutually agreed upon by the Parties in writing from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Without prejudice to any obligation on Autolus to provide any of the information referenced for review and discussion at the JSC on particular timelines elsewhere in this Agreement, Autolus shall ensure that such information for discussion and review will be made available to BioNTech in writing reasonably in advance of each JSC meeting. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">The Parties will &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93;, each Party shall appoint an individual (who is not a member of the JSC) who possesses a general understanding of this Agreement to act as the alliance manager for such Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Alliance Manager may attend meetings of the JSC as a nonvoting observer and the Alliance Managers may bring to the attention of the JSC any matters or issues such Alliance Manager reasonably believes should be discussed. The Alliance Managers will be a key point of contact for the Parties regarding the contractual and business aspects of the collaboration during the Term. Each Party may replace its Alliance Manager at any time by giving prior written notification to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The JSC may establish one or more subcommittees of the JSC (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Subcommittee shall be established on mutually agreed terms, and have agreed specific responsibilities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that no Subcommittee shall have the authority to amend this Agreement or any other agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Collaboration Agreements</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing and Commercial Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">During the period commencing on the Effective Date and ending on the eighteen (18) month anniversary of the Effective Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MCSA Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Parties shall &#91;***&#93; negotiate the terms of and execute a joint manufacturing and commercial services agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MCSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to which (i) Autolus may obtain access to BioNTech&#8217;s manufacturing and commercial site services capabilities for Autolus&#8217;s CAR-T products, and (ii) BioNTech may obtain access to Autolus&#8217;s manufacturing and commercial site services capabilities for BioNTech&#8217;s CAR-T products, including the product known as BNT211 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BNT211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including, in each case, &#91;***&#93;. The MCSA will reflect the terms set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">During the MCSA Negotiation Period, Autolus (1) shall provide updates to the JSC on the progress of its Manufacturing facilities to allow BioNTech to monitor the progress of such facilities and (2) &#91;***&#93;. For the avoidance of doubt, subject to Autolus reserving the requisite capacity for BioNTech, (i) this Section 3.1(b) does not prevent, inhibit or otherwise affect Autolus&#8217;s ability to Manufacture any product that has been Developed by Autolus or its Affiliates (including Obe-cel Product), whether for sale by itself or any Third Party, (ii) &#91;***&#93;, and (iii)&#160;&#91;***&#93; after &#91;***&#93;, the Parties shall &#91;***&#93;, which shall &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus will &#91;***&#93; ensure that its manufacturing facility is ready and available to manufacture BNT211 by &#91;***&#93; such that the batches produced at Autolus&#8217;s manufacturing facility can be &#91;***&#93;, subject to (i)&#160;Section&#160;3.1(d), (ii) BioNTech fulfilling its obligations in &#91;***&#93;, and (iii) BioNTech &#91;***&#93;. If a Party&#8217;s performance of its obligations under &#91;***&#93; is adversely affected in a material manner by the other Party&#8217;s failure to perform its obligations under this Agreement, then the impact of such performance failure will be taken into account in determining whether such first Party has used the required efforts to perform any such affected obligations, but only to the extent such other Party&#8217;s performance failure is the cause of such first Party&#8217;s failure to meet such obligations and such first Party continues to use the required efforts to reduce the impact of the other Party&#8217;s performance failure. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If the MCSA is not entered into within &#91;***&#93; following &#91;***&#93;, then the timeline of &#91;***&#93; in Section 3.1(c) shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If upon expiry of the MCSA Negotiation Period, the Parties are unable to agree the terms of the MCSA, BioNTech may, in its sole discretion, refer the terms of the MCSA for resolution using Baseball Arbitration, which referral must occur within &#91;***&#93; of expiry of the MCSA Negotiation Period. If (i) BioNTech does not refer the terms of the MCSA for resolution using Baseball Arbitration within &#91;***&#93; of expiry of the MCSA Negotiation Period, or (ii), BioNTech chooses not to enter into the MCSA within &#91;***&#93; after the arbitrator has given a final decision in Baseball Arbitration then, without any further action required on the part of either Party, the obligations set out in Section 3.1(a), Section&#160;3.1(b) and Section&#160;3.1(c) shall expire and, if an MCSA has not been entered into by such date, then there shall be no further obligation to continue negotiations on either Party and Autolus, at its sole discretion, may enter into an agreement with a Third Party pursuant to which Autolus would Manufacture a Third Party&#8217;s CAR-T Cell Therapy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. During &#91;***&#93;, the Parties shall discuss &#91;***&#93; the terms, including financial terms, of a research and development collaboration agreement regarding products that utilize the expertise of both Parties (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that neither Party is required to enter into such Research and Development Collaboration Agreement, and the obligation to discuss shall expire at the end of such &#91;***&#93; period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Product Options</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. With effect from the Effective Date, Autolus hereby grants to BioNTech, on an Option Product-by-Option Product basis, the exclusive option to obtain the exclusive right to co-fund certain development costs in respect of the relevant Option Product in return for a &#91;***&#93; profit sharing arrangement, and to obtain the exclusive option to co-promote and co-commercialize the Option Product, in each case, for all oncology Indications and subject to and as further set out in this Article 4 and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;4.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Provision of Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus shall, within &#91;***&#93;, deliver to BioNTech, all information and data received or otherwise Controlled by Autolus in relation to the Development of the Option Products, &#91;***&#93;, in the formats such information and data are held by Autolus &#91;***&#93;. During the applicable Product Option Period, Autolus shall provide additional data received by or otherwise Controlled by Autolus in relation to the Development of the Option Products to BioNTech &#91;***&#93; following such data becoming available to Autolus. Autolus will provide the JSC with updates on the progress of the Sponsor&#8217;s activities in relation to such Option Product or Next Gen Product, as applicable, every &#91;***&#93; during the applicable (i) Product Option Period for each Option Product, and, (ii) Next Gen Product Option Period for each Next Gen Product. Autolus will also provide the JSC with updates on the progress of the Development of each Option Product and Next Gen Product &#91;***&#93; from &#91;***&#93; until the end of the Product Option Period for the applicable Option Product and from &#91;***&#93; until the end of the Next Gen Product Option Period for the applicable Next Gen Product. Autolus shall, during the applicable Product Negotiation Period on an Option Product-by-Option Product basis and, during the applicable Next Gen Product Negotiation Period on a Next Gen Product-by-Next Gen Product basis, on BioNTech&#8217;s request, request from the Sponsor any additional relevant data that the Sponsor has in relation to the Option Products or Next Gen Products, as applicable, which has not been provided to Autolus. On BioNTech&#8217;s request during the applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product Negotiation Period or Next Gen Product Negotiation Period, Autolus will &#91;***&#93; facilitate access for BioNTech to the Sponsor&#8217;s principal investigators working on the Development of the applicable Option Products and Next Gen Products. Autolus will &#91;***&#93; provide BioNTech with &#91;***&#93; (1) of AUTO6NG Product during the applicable Product Option Period and any applicable ROFN Period, and (2)&#160;of any Next Gen Product during the applicable Next Gen Product Option Period. To the extent that any data to be provided under this Section 4.2(a), Section&#160;4.2(b) or Section&#160;4.7(b) constitutes Personal Data, Autolus shall only be obliged to deliver such Personal Data to BioNTech to the extent to which it can be delivered in compliance with Applicable Data Protection Law. If the current formats are not compatible with the transfer of such information and data to BioNTech in compliance with Applicable Data Protection Law, then Autolus shall &#91;***&#93; (A) to obtain such information and data in an anonymized or other format that (x) can be transferred to BioNTech and (y)&#160;results in the applicable information and data no longer constituting Personal Data under Applicable Data Protection Law, or (B) to facilitate an appropriate data transfer agreement under which such data can be provided to BioNTech in compliance with Applicable Data Protection Law, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus shall deliver to BioNTech the applicable Data Package&#58; (i) within &#91;***&#93; after &#91;***&#93;, with respect to the AUTO1&#47;22 Product, (ii) &#91;***&#93;, with respect to the AUTO6NG Product, or (iii) during the applicable Next Gen Product Option Period, &#91;***&#93;. Autolus shall provide reasonable assistance to BioNTech in analyzing each Data Package, at BioNTech&#8217;s written request and &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If Autolus commences Development activities on any Next Gen Product during the Next Gen Product Option Period, it shall inform BioNTech &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On an Option Product-by-Option Product basis, at any time during the applicable Product Option Period after BioNTech has received the relevant Data Package pursuant to Section&#160;4.2(b), BioNTech may notify Autolus in writing that it wishes to receive a Development plan for such Option Product (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Plan Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Within &#91;***&#93; after Autolus receives a Development Plan Trigger Notice, Autolus shall provide to BioNTech a reasonably detailed written Development plan and associated budget for the applicable Option Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Option Product Development Plan would include &#91;***&#93;. Upon BioNTech&#8217;s request, the Parties, through the JSC, would discuss the Option Product Development Plan and associated budget and Autolus shall &#91;***&#93;. For clarity, &#91;***&#93;. If BioNTech provides a Development Plan Trigger Notice, and Autolus does not, at such time, intend to Develop further such Option Product, then Section 4.7 applies. For the period from provision of the Data Package until the earlier of&#58; (i) the relevant Product Option Period expires without a Development Plan Trigger Notice being received by Autolus, (ii) &#91;***&#93; after BioNTech&#8217;s receipt of the applicable Option Product Development Plan, if no Negotiation Trigger Notice is received by Autolus, or (iii)&#160;expiry of the Product Negotiation Period and any period during which a Baseball Arbitration procedure is ongoing with respect to such Option Product, Autolus shall not grant a Third Party rights to Exploit the relevant Option Product without BioNTech&#8217;s prior written consent, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation of Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Negotiation Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within &#91;***&#93; after BioNTech&#8217;s receipt of the Option Product Development Plan, BioNTech may notify Autolus in writing that it wishes to enter into exclusive negotiations with Autolus to finalize the terms of and execute an agreement in respect of the Exploitation of a particular Option Product for the treatment of one or more oncology Indications, providing for co-funding and &#91;***&#93; profit share arrangements and an exclusive option for BioNTech to co-promote and co-commercialize (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which agreement shall include the terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;4.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Option Product Development Plan would be included as an initial Development plan to the Product Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Negotiation of Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall, on an Option Product-by-Option Product basis, negotiate exclusively &#91;***&#93; for a period of &#91;***&#93; from the date of Autolus&#8217;s receipt of the Negotiation Trigger Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to agree the definitive terms of the applicable Product Agreement. If the anticipated start date for the Development activities included in the Option Product Development Plan is more than &#91;***&#93; after BioNTech&#8217;s receipt of the Option Product Development Plan, the Parties would &#91;***&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Referral to Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, upon expiry of the applicable Product Negotiation Period, the Parties are unable to agree the terms of such Product Agreement, BioNTech may, in its sole discretion, refer the terms of the Product Agreement (&#91;***&#93;) for resolution using Baseball Arbitration, which referral must occur within &#91;***&#93; of expiry of the applicable Product Negotiation Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within &#91;***&#93; after (i) the Parties have agreed on a Product Agreement for the applicable Option Product or (ii) the arbitrator has given a final decision in Baseball Arbitration, as applicable, BioNTech may notify Autolus in writing that it wishes to execute the applicable Product Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). If BioNTech provides such a Product Option Exercise Notice, then the Parties shall execute such Product Agreement within &#91;***&#93; after Autolus&#8217;s receipt of the Product Option Exercise Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioNTech shall pay Autolus the applicable option exercise fee set forth below for the corresponding Product Agreement within &#91;***&#93; after the receipt of an invoice from Autolus following the execution of such Product Agreement&#58;</font></div><div style="padding-left:117.18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise Fee</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AUTO1&#47;22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AUTO6NG</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Exercise Option or Rejection of Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Autolus does not receive a Development Plan Trigger Notice during the applicable Product Option Period, or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Autolus does not receive a Negotiation Trigger Notice within &#91;***&#93; after BioNTech&#8217;s receipt of an Option Product Development Plan, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">the Parties fail to enter into a Product Agreement during the applicable Product Negotiation Period and BioNTech does not refer such matter for resolution using Baseball Arbitration in the period described in Section 4.4(c), or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Autolus does not receive a Product Option Exercise Notice within &#91;***&#93; after the Parties have agreed on a Product Agreement for the applicable Option Product or the arbitrator has given a final decision in Baseball Arbitration, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">BioNTech chooses not to enter into the applicable Product Agreement within &#91;***&#93; after the Parties have agreed on a Product Agreement for the applicable Option Product or the arbitrator has given a final decision in Baseball Arbitration, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">then in each case of (i)&#8211;(v), with effect from the date of expiry of such period, and without any further action required on the part of either Party, the applicable Product Option shall expire and then the terms of this Article&#160;4 shall no longer apply to such Option Product and, without limiting the generality of the foregoing, Autolus may commence Development of such Option Product or enter into an agreement with a Third Party for such Option Product, on terms determined at Autolus&#8217;s sole discretion without further reference to BioNTech, save as provided in Section 4.6(b).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Autolus elects to commence Development of an Option Product in accordance with Section 4.6(a)(ii)&#8211;(v) where Autolus received a Development Plan Trigger Notice, but for which the Parties have not entered into a Product Agreement, (i) Autolus shall, on BioNTech&#8217;s written request during the &#91;***&#93; from the date of expiry of the applicable period in Section&#160;4.6(a), provide BioNTech with a report on Autolus&#8217;s Development spend under the applicable Development Plan reconciled against the budget for the applicable Development Plan, and &#91;***&#93; (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Autolus will notify BioNTech in writing (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the provisions of Section&#160;4.2(b) and Section 4.8 shall apply to any Next Gen Product of such Option Product, for which Autolus obtains, within &#91;***&#93; after the BioNTech&#8217;s receipt of the Failure to Develop Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Develop Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), sufficient data and information to provide BioNTech with a Data Package.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rights of BioNTech if Autolus does not wish to Develop.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If Autolus notifies BioNTech pursuant to Section 4.3 that it does not, at the time of receipt by Autolus of a Development Plan Trigger Notice, intend to Develop further such Option Product, then Autolus shall and hereby does grant BioNTech (i) a right of first negotiation, as set out in this Section 4.7, in relation to such Option Product if Autolus intends (1) &#91;***&#93;, or (2)&#160;&#91;***&#93; ((1) and (2) collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Product Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) the right to negotiate a Product Agreement in accordance with Sections 4.3&#8211;4.6 if Autolus intends to Develop such Option Product itself or with or through any Affiliate, in the case of both (i) and (ii) for a period of &#91;***&#93; commencing on the date of receipt by Autolus of the applicable Development Plan Trigger Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ROFN Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), subject to and as further set out in Section 4.7(b). Notwithstanding the foregoing, the rights in this Section&#160;4.7 do not apply to an Acquisition of Autolus or its Affiliate. For clarity, Section&#160;4.7 remains in full force and effect following an Acquisition of Autolus or its Affiliate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If Autolus notifies BioNTech pursuant to Section 4.3 that it does not, at the time of receipt by Autolus of a Development Plan Trigger Notice, intend to Develop further such Option Product, and thereafter during the ROFN Period Autolus intends to Develop such Option Product itself or with or through any Affiliate or to grant any Third Party an Option Product Right, then, prior to commencing such Development or engaging in discussions or entering into any agreement with any Third Party for the grant of such rights (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Autolus shall provide BioNTech with prior written notice and all material information and data relating to such Option Product then in its possession (to the extent not previously provided pursuant to Section&#160;4.2) and, (i) in the event that Autolus intends to grant any Third Party an Option Product Right, for a period of &#91;***&#93; after receipt of such notice and information, BioNTech has an exclusive right of first negotiation to enter into a definitive agreement with Autolus granting BioNTech rights in relation to such Option Product, and during such &#91;***&#93;, Autolus would negotiate &#91;***&#93; with BioNTech and would not perform any Restricted Act, and (ii) in the event that Autolus intends to Develop such Option Product itself or with or through any Affiliate, to an option on the terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;4.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in which case the provisions of Sections 4.3&#8211;4.6 shall apply, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that BioNTech provides a Development Plan Trigger Notice to Autolus within &#91;***&#93; of receiving written notice and all material information and data from Autolus regarding Autolus&#8217;s proposed further Development of such Option Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding the ROFN Period, if the Parties fail to enter into a definitive agreement prior to (i) in the case of Autolus intending to Develop such Option Product through the grant of any Option Product Rights to any Third Party, the expiration of the &#91;***&#93; period set forth in Section&#160;4.7(b), and (ii)&#160;in the case of Autolus intending to Develop such Option Product itself or with or through any Affiliate, the date of expiry of the applicable period set forth in Sections 4.6(a)(i)&#8211;4.6(a)(v), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, then (1) for a period of &#91;***&#93; after the ROFN Period, Autolus will notify BioNTech if Autolus intends to grant a Third Party a Product Option Right, and (2) all of the terms of this Section&#160;4.7 shall no longer apply to such Option Product and, for clarity, and without limiting the generality of the foregoing, Autolus may commence Development of such Option Product, engage in discussions with a Third Party or enter into an agreement with a Third Party for such Option Product, on terms determined at Autolus&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Generation Products Option.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Next Gen Product Option and Next Gen Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus hereby grants to BioNTech, on a Next Gen Product-by-Next Gen Product basis, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the exclusive option </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">in relation to any Next Gen Product for which Autolus provides BioNTech with a Data Package pursuant to Section 4.2(b), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to obtain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the exclusive right to co-fund certain development costs in respect of the relevant Next Gen Product in return for a &#91;***&#93; profit sharing arrangement, in each case, for all oncology Indications, and obtain the exclusive option to co-promote and co-commercialize such Next Gen Product for all oncology Indications, in each case, subject to and as set out in this Section 4.8 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Next Gen Product Development Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> At any time during the &#91;***&#93; period after BioNTech&#8217;s receipt of a Data Package for a Next Gen Product pursuant to Section 4.2(b) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Notification Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), BioNTech may notify Autolus in writing that it wishes to receive a Development plan for such Next Gen Product (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Development Plan Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Within &#91;***&#93; after Autolus receives a Next Gen Development Plan Trigger Notice, Autolus shall provide to BioNTech a reasonably detailed written Development plan and associated budget for the applicable Next Gen Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Next Gen Product Development Plan would include &#91;***&#93;. Upon BioNTech&#8217;s request, the Parties, through the JSC, would discuss the Next Gen Product Development Plan and associated budget and Autolus shall &#91;***&#93;. For clarity, &#91;***&#93;. For the period from receipt by Autolus of a Next Gen Development Plan Trigger Notice until the earlier of (i) &#91;***&#93; after BioNTech&#8217;s receipt of the applicable Next Gen Product Development Plan, if no Next Gen Negotiation Trigger Notice is received by Autolus, or (ii) the expiry of the Next Gen Product Negotiation Period and any period during which a Baseball Arbitration procedure is ongoing with respect to such Next Gen Product, Autolus shall not grant a Third Party rights to Exploit the relevant Next Gen Product without BioNTech&#8217;s prior written consent, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Negotiation Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within &#91;***&#93; after BioNTech&#8217;s receipt of the Next Gen Product Development Plan, BioNTech may notify Autolus in writing that it wishes to enter into exclusive negotiations with Autolus to agree the terms of and execute an agreement in respect of the Exploitation of the applicable Next Gen Product for the treatment of one or more oncology Indications, providing for co-funding and &#91;***&#93; profit share arrangements and an exclusive option for BioNTech to co-promote and co-commercialize (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Trigger Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which agreement shall include the terms set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 4.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Next Gen Product Development Plan would be included as an initial Development plan to the Next Gen Product Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Negotiation of Next Gen Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties shall, on a Next Gen Product-by-Next Gen Product basis, negotiate exclusively &#91;***&#93; for a period of &#91;***&#93; from the date of Autolus&#8217;s receipt of the Next Gen Negotiation Trigger Notice to agree the definitive terms of the applicable Next Gen Product Agreement (such period and any mutually agreed extension, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to agree the definitive terms of the applicable Next Gen Product Agreement. If the anticipated start date for the Development activities included in the Next Gen Product Development Plan is more than &#91;***&#93; after BioNTech&#8217;s receipt of the Next Gen Product Development Plan, the Parties would &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Referral to Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If, upon expiry of the applicable Next Gen Product Negotiation Period, the Parties are unable to agree the terms of such Next Gen Product Agreement, BioNTech may, in its sole discretion, refer the terms of the Next Gen Product Agreement (&#91;***&#93;) for resolution using Baseball Arbitration, which referral must occur within &#91;***&#93; of expiry of the applicable Next Gen Product Negotiation Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Exercise Option or Rejection of Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus does not receive a Next Gen Development Plan Trigger Notice during the applicable Next Gen Notification Period, or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus does not receive a Next Gen Negotiation Trigger Notice within &#91;***&#93; after BioNTech&#8217;s receipt of a Next Gen Product Development Plan, or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the Parties fail to enter into a Next Gen Product Agreement during the applicable Next Gen Product Negotiation Period and BioNTech does not refer such matter for resolution using Baseball Arbitration in the period described in Section 4.10, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus does not receive a Next Gen Option Exercise Notice within &#91;***&#93; after the Parties have agreed on a Next Gen Product Agreement for the applicable Next Gen Product or the arbitrator has given a final decision in Baseball Arbitration, or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">BioNTech chooses not to enter into the applicable Next Gen Product Agreement within &#91;***&#93; after the Parties have agreed on a Next Gen Product Agreement for the applicable Next Gen Product or the arbitrator has given a final decision in Baseball Arbitration, </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">then in each case of (a)&#8211;(e), with effect from the date of expiry of such period, and without any further action required on the part of either Party, the applicable Next Gen Product Option shall expire and then the terms of this Article&#160;4 shall no longer apply to such Next Gen Product and, without limiting the generality of the foregoing, Autolus may commence Development of such Next Gen Product or enter into an agreement with a Third Party for such Next Gen Product, on terms determined at Autolus&#8217;s sole discretion without further reference to BioNTech.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Option Exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within &#91;***&#93; after (i) the Parties have agreed on a Next Gen Product Agreement for the applicable Next Gen Product or (ii) the arbitrator has given a final decision in Baseball Arbitration, as applicable, BioNTech may notify Autolus in writing that it wishes to execute the applicable Next Gen Product Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). If BioNTech provides such a Next Gen Option Exercise Notice, then the Parties shall execute such Next Gen Product Agreement within &#91;***&#93; after Autolus&#8217;s receipt of the Next Gen Option Exercise Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Next Gen Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioNTech shall pay Autolus the applicable option exercise fee set forth below for the corresponding Next Gen Product Agreement within &#91;***&#93; after the receipt of an invoice from Autolus following the execution of such Next Gen Agreement&#58;</font></div><div style="padding-left:117.18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Next Gen Product</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise Fee</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AUTO1&#47;22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AUTO6NG</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">If Autolus does not wish to Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If BioNTech provides a Next Gen Development Plan Trigger Notice, and Autolus does not, at such time, intend to Develop further such Next Gen Product, then Autolus shall provide BioNTech with written notice and all material information and data relating to such Next Gen Product then in Autolus&#8217;s possession and, for a period of &#91;***&#93; after receipt of such notice and information, BioNTech has a right of first negotiation to such Next Gen Product to obtain rights in such Next Gen Product. During such &#91;***&#93;, Autolus may not perform any Development, engage in discussions or enter into any agreement with any Third Party for the grant of any rights in relation to such Next Gen Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">License To &#91;***&#93; and &#91;***&#93; Binders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, with effect from the Effective Date, Autolus hereby grants to BioNTech&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">an exclusive (including as to Autolus and its Affiliates), sub-licensable (subject to Section 5.3), payment-bearing, worldwide license under the &#91;***&#93; Licensed IP (i) to Develop the &#91;***&#93; Licensed Binder and the &#91;***&#93; Licensed Binder in connection with a &#91;***&#93; Licensed Product, and (ii) to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exploit &#91;***&#93; Licensed Products directed to &#91;***&#93;, in each case of (i) and (ii), in the Field in the Territory (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a non-exclusive, non-transferable, limited, non-sublicensable (other than to Third Party Evaluators) license under the &#91;***&#93; Licensed IP to research and Develop (only up to and including &#91;***&#93;) a CAR-T Cell Therapy&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right of Negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If BioNTech, its Affiliates or Sublicensees wishes to Exploit any &#91;***&#93; Licensed Product in combination with a CAR-T Cell Therapy that &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus &#91;***&#93; CAR-T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then prior to &#91;***&#93;, BioNTech shall provide Autolus with prior written notice and grants, and shall procure the grant of, to Autolus, for a period of &#91;***&#93; after receipt of such notice, a right of first negotiation to, &#91;***&#93;, negotiate and enter into an agreement with BioNTech, its Affiliate or Sublicensee (as applicable) for Autolus or its Affiliate to be BioNTech&#8217;s partner for such combination therapy, whereby &#91;***&#93; Licensed Product would be used in combination with such Autolus &#91;***&#93; CAR-T. Prior to or during such &#91;***&#93; period, BioNTech, its Affiliates and Sublicensees shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicense Rights&#59; Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, BioNTech may sublicense the rights granted to it by Autolus under Section 5.1, including in connection with subcontracting to Third Parties whose business is to provide services to other entities, including contract research organizations, contract laboratory testing providers, contract manufacturing organizations, contract sales force providers, contract employees, and scientific, regulatory or other expert consultants and professional advisors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subcontractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) the rights or performance of tasks and obligations with respect to the Exploitation of &#91;***&#93; Licensed Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">BioNTech is not permitted to grant a sublicense under the rights granted to it by Autolus under Section 5.1 that permits the Sublicensee to Develop or otherwise use a &#91;***&#93; Licensed Binder and&#47;or a &#91;***&#93; Licensed Binder&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">for any purpose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;***&#93;, and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">for any purpose </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; under&#58; (1) &#91;***&#93; described in clause (i), or (2) &#91;***&#93; described in clause (i), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, if &#91;***&#93;, then unless &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any such sublicenses shall be in writing and be consistent with the applicable terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">BioNTech shall remain responsible for the performance of all of its Sublicensees to the same extent as if such activities were conducted by BioNTech, and, as between the Parties, BioNTech shall remain responsible for any payments due to Autolus under this Agreement with respect to activities of any Sublicensees&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">within &#91;***&#93; after the execution of any sublicense agreement with a Sublicensee, BioNTech shall provide Autolus with a copy of such sublicense agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that BioNTech may redact any terms of such sublicense agreement (i) &#91;***&#93; or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Retention of Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus hereby expressly reserves the right to practice, and to grant licenses under, the &#91;***&#93; Licensed IP outside the scope of the licenses granted to BioNTech pursuant to Section 5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly provided in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication, estoppel, or otherwise, under or to any Patents, Know-How, information, or other intellectual property owned or controlled by the other Party. BioNTech shall not, nor shall it permit any of its Affiliates or Sublicensees to, practice any Patents or Know-How licensed to it by Autolus outside the scope of the licenses granted to it under this Agreement, except as permitted under Applicable Law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Scope</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For clarity, subject to the terms of this Agreement (including Section 5.1 and Section 5.2), the licenses granted to BioNTech by Autolus to Exploit &#91;***&#93; Licensed Products extend to BioNTech being able to Exploit &#91;***&#93; Licensed Products in conjunction with BioNTech&#8217;s own products, product components, or other technologies or Third Party products, product components, or other technologies, in each case, whether through co-formulation, co-packaging, co-administration, or any other use as part of a Combination Product or combination therapy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;&#91;***&#93;. In the event that &#91;***&#93;, BioNTech hereby grants to Autolus a non-exclusive, &#91;***&#93; irrevocable, perpetual license in the Field in the Territory under &#91;***&#93; Binder &#91;***&#93; Patent in the field of &#91;***&#93; only in the Territory solely for Autolus, its Affiliates and Autolus Licensees to Exploit &#91;***&#93; in the field of &#91;***&#93; in the Territory. Any sublicenses shall be in writing and be consistent with the applicable terms and conditions of this Agreement. As used in this Section 5.7, &#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer of Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;, Autolus shall transfer, disclose and otherwise make available to BioNTech the Initial Tech Transfer Package. If, following such initial transfer BioNTech notifies Autolus, in writing, of any specific (a) &#91;***&#93; Licensed Know-How, (b) &#91;***&#93; Licensed Know-How, (c) Activity Enhancement Licensed Know-How, (d) Safety Switch Licensed Know-How or (e) &#91;***&#93; Licensed Know-How, in Autolus&#8217;s or its Affiliates&#8217; Control, or Autolus identifies such Know How, in each case which has not previously been provided to BioNTech (&#91;***&#93;), then Autolus shall &#91;***&#93; disclose to BioNTech such Know-How. At BioNTech&#8217;s written request &#91;***&#93;, Autolus shall provide reasonable assistance to BioNTech in analyzing and understanding the (i) &#91;***&#93; Licensed Know-How, (ii) &#91;***&#93; Licensed Know-How, (iii) Activity Enhancement Licensed Know-How, (iv) Safety Switch Licensed Know-How, (v) &#91;***&#93; Licensed Know-How, and (vi) Initial Tech Transfer Package, including making relevant personnel available to BioNTech, which may include &#91;***&#93;. Autolus shall, if requested &#91;***&#93;, make no fewer than &#91;***&#93; FTEs, who shall be scientific or technical personnel of Autolus, available to BioNTech for &#91;***&#93;. For the avoidance of doubt, &#91;***&#93; the Initial Tech Transfer Package, the &#91;***&#93; Licensed Know-How, &#91;***&#93; Licensed Know-How, Activity Enhancement Licensed Know-How, Safety Switch Licensed Know-How or &#91;***&#93; Licensed Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development and Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech is responsible for conducting, at its sole expense, the Development and Commercialization of &#91;***&#93; Licensed Products in the Field in the Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Licensed Product Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech shall use Commercially Reasonable Efforts&#58; to (a) &#91;***&#93;, and (b) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech shall, within &#91;***&#93; after &#91;***&#93; until &#91;***&#93;, provide Autolus with a written report summarizing, &#91;***&#93; in respect of the &#91;***&#93; Licensed Binder, the &#91;***&#93; Licensed Binder, and &#91;***&#93; Licensed Products. All information and reports provided to Autolus pursuant to this Section 5.11 shall be deemed the Confidential Information of BioNTech hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, BioNTech has the sole responsibility for preparing and submitting all Regulatory Filings and all Drug Approval Applications for all &#91;***&#93; Licensed Products in the Field in each country within the Territory. At the request of BioNTech &#91;***&#93;, Autolus shall provide such assistance as is &#91;***&#93; for BioNTech to prepare and submit Regulatory Filings for &#91;***&#93; Licensed Products in the Field. BioNTech shall own and maintain all Regulatory Filings and Regulatory Approvals for &#91;***&#93; Licensed Products in the Field. &#91;***&#93;, BioNTech shall notify Autolus of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Adverse Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Within &#91;***&#93;, the Parties will discuss whether a pharmacovigilance agreement, governing each Party&#8217;s respective obligations with respect to adverse event reporting, monitoring, maintenance of safety databases and submissions to Regulatory Authorities and other similar obligations with respect to &#91;***&#93; Licensed Products &#91;***&#93;. If a &#91;***&#93;, then within &#91;***&#93;, the Parties shall &#91;***&#93;. Such &#91;***&#93;. Notwithstanding any other provisions of this Agreement, if &#91;***&#93;, or &#91;***&#93; Licensed Product, or &#91;***&#93;, then such Party shall provide the other Party with &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Recalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, BioNTech has the sole right to determine whether and how to implement a recall or other market withdrawal of a &#91;***&#93; Licensed Product in the Field in each country within the Territory.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Technologies Options</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Exclusive License Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement and during the applicable Technologies Option Period, Autolus hereby grants to BioNTech a non-exclusive, non-transferable, limited, non-sublicensable (other than to Third Party Evaluators) license under the Technologies Option IP for BioNTech&#8217;s internal research purposes to evaluate whether BioNTech wishes to exercise a Technologies Option in respect of all or part of the Technologies Option Technology (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Evaluation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For the avoidance of doubt, BioNTech shall conduct the Evaluation solely in relation to (a)&#160;Activity Enhancement Licensed Products in the Field (and, with respect to Other AE Licensed Products, solely with respect to a Target that has been pre-cleared pursuant to Section 6.4), (b) &#91;***&#93; Licensed Products in the Field, (c) Safety Switch Licensed Products in the Safety Switch Field, and (d) &#91;***&#93; Licensed Products in the &#91;***&#93; Field. Such license shall commence on the Effective Date and shall expire&#58; (i) in respect to the &#91;***&#93; Option, on the &#91;***&#93; (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (ii) in respect to the &#91;***&#93; Option, on the &#91;***&#93; (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (iii) in respect to each Module Option, on the &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Module Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). BioNTech shall ensure that any sublicenses of the rights under this Section 6.1 to Third Party Evaluators shall be in writing and be consistent with the applicable terms and conditions of this Agreement. BioNTech shall remain responsible for the performance of all of its Third Party Evaluators to the same extent as if such activities were conducted by BioNTech.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer of Technologies Option Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;, Autolus shall transfer to BioNTech such of the Technologies Option Technology, and in such quantities, as set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transferred Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). BioNTech shall use the Transferred Materials and all Technologies Option Technology solely for the purposes of the Evaluation and for no other purpose. The Transferred Materials and all tangible embodiments of the Technologies Option Technology shall (i) at all times remain solely under the control of BioNTech or one of its Affiliates or Third Party Evaluators, (ii) be used in compliance with Applicable Laws, (iii) not be used by or delivered by BioNTech to or for the benefit of any Third Party, other than a Third Party Evaluator, without the prior written consent of Autolus, and (iv) not be used by BioNTech for any research or testing involving human subjects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">BioNTech, its Affiliates, and its Third Party Evaluators shall not attempt to reverse engineer, design around, deconstruct or in any way determine the structure or composition of the Transferred Materials without the prior written consent of Autolus, but it is acknowledged that as part of the Evaluation, BioNTech may &#91;***&#93;. BioNTech shall &#91;***&#93; and nothing in this Agreement restricts &#91;***&#93;. Autolus shall &#91;***&#93; and nothing in this Agreement restricts &#91;***&#93;, unless and until &#91;***&#93;. BioNTech shall &#91;***&#93; in writing, providing &#91;***&#93;. BioNTech &#91;***&#93;. If any &#91;***&#93;, neither Party shall be permitted to&#58; (i) &#91;***&#93;&#59; or (ii)&#160;&#91;***&#93;, in each case (i) and (ii), unless and until a Technologies License Agreement regarding the Technologies Option Technology to which such &#91;***&#93; relates is executed, whereupon the terms of such Technologies License Agreement shall govern the Parties rights to use and Exploit &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Transferred Materials supplied to BioNTech are for experimental use only and are provided &#8220;as is&#8221; with no warranties of any kind, express or implied, including any warranty of merchantability or fitness for a particular purpose. Save as set forth in Article 15, the Technologies Option Technology supplied to BioNTech are for experimental use only and are provided &#8220;as is&#8221; with no warranties of any kind, express or implied, including any warranty of merchantability or fitness for a particular purpose.  To the extent the Transferred Materials comprise cell lines, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">BioNTech shall provide Autolus with &#91;***&#93; updates on &#91;***&#93;. Each such update will be provided &#91;***&#93;, and BioNTech shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">When BioNTech has completed the Evaluation, following the expiry of the Technologies Option Period without a Technologies License Agreement having been entered into, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BioNTech shall &#91;***&#93; return to Autolus or destroy, at Autolus&#8217;s instruction, any remaining Transferred Materials and cease all use of the Technologies Option Technology. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus grants to BioNTech, with effect from the Effective Date, the option (which is an exclusive option, solely with respect to (1) the &#91;***&#93; Option, (2) the &#91;***&#93; Option and (3) the option for a Co-Exclusive license in respect of the In Vivo AE Licensed Products), during the Technologies Option Period, to receive, in any combination, one or more of the following licenses, which (i) with respect to the &#91;***&#93; Option is solely exercisable in respect of &#91;***&#93;, (ii)&#160;with respect to the &#91;***&#93; Option is solely exercisable in respect of &#91;***&#93;, and (iii) with respect to each Module Option is exercisable on a Target-by-Target basis in respect of a specified Target, without a cap on the number of times that BioNTech may exercise a Module Option&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">(i) an exclusive, payment-bearing, license under the &#91;***&#93; Licensed IP (1) to Develop the &#91;***&#93; Licensed Binder and the &#91;***&#93; Licensed Binder in connection with a &#91;***&#93; Licensed Product, and (2) to Exploit &#91;***&#93; Licensed Products directed to &#91;***&#93;, in each case of (1) and (2), in the &#91;***&#93; Field, (ii) a non-exclusive, non-transferable, limited, non-sublicensable (other than to Third Party Evaluators) license under the &#91;***&#93; Licensed IP to research and Develop (only up to and including &#91;***&#93;) a CAR-T Cell Therapy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that (A) &#91;***&#93;, and (B) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93; and (iii) a non-exclusive license under the &#91;***&#93; Licensed IP to Exploit &#91;***&#93; in conjunction with one or more &#91;***&#93; Licensed Products in the &#91;***&#93; Field (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;),</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">(i) an exclusive, payment-bearing, license under the &#91;***&#93; Licensed IP (1) to Develop the &#91;***&#93; Licensed Binder in connection with a &#91;***&#93; Licensed Product, and (2) to Exploit &#91;***&#93; Licensed Products in the Field, and (ii) a non-exclusive, non-transferable, limited, non-sublicensable (other than to Third Party Evaluators) license under the &#91;***&#93; Licensed IP to research and Develop (only up to and including &#91;***&#93;) a CAR-T Cell Therapy </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that (A)&#160;&#91;***&#93;, and (B) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93; (the &#8220;&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;),</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a non-exclusive, payment-bearing, license under the Safety Switch Licensed IP to Exploit Safety Switch Licensed Products directed to such specified Target, in the Safety Switch Field (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a Co-Exclusive, payment-bearing license under the Activity Enhancement Licensed IP to Exploit Activity Enhancement Licensed Products that express In Vivo any Activity Enhancement Licensed Technology (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">In Vivo AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and are directed to such specified Target in the Field, and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a non-exclusive, payment-bearing license under the Activity Enhancement Licensed IP to Exploit Activity Enhancement Licensed Products that do not express In Vivo any Activity Enhancement Licensed Technology (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Other AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and are directed to such specified Target in the Field, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such non-exclusive license in relation to a given Target is not effective unless and until such Target has been deemed Available pursuant to the gatekeeping procedure in Section&#160;6.4. For clarity, if a specified Target is not Available then BioNTech may still exercise the Activity Enhancement Option on such Target to practice the Co-Exclusive license granted in relation to In Vivo AE Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The licenses for which BioNTech has an option under this Section 6.3 and that will be granted under the applicable Technologies License Agreement following BioNTech&#8217;s exercise of a Technologies Option, if any, may be sublicensed on the terms set forth in Section 2.2 of the applicable Technologies License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If BioNTech, its Affiliates or Sublicensees wishes to Exploit any &#91;***&#93; Licensed Product in combination with a CAR-T Cell Therapy that &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus &#91;***&#93; CAR-T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then prior to &#91;***&#93;, BioNTech shall provide Autolus with prior written notice and grants, and shall procure the grant of, to Autolus, for a period of &#91;***&#93; after receipt of such notice, a right of first negotiation to, &#91;***&#93;, negotiate and enter into an agreement with BioNTech, its Affiliate or Sublicensee (as applicable) for Autolus or its Affiliate to be BioNTech&#8217;s partner for such combination therapy, whereby such &#91;***&#93; Licensed Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">would be used in combination with such Autolus &#91;***&#93; CAR-T. Prior to or during such &#91;***&#93; period, BioNTech, its Affiliates and Sublicensees shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If BioNTech, its Affiliates or Sublicensees wishes to Exploit any &#91;***&#93; Licensed Product in combination with a CAR-T Cell Therapy that &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus &#91;***&#93; CAR-T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then prior to &#91;***&#93;, BioNTech shall provide Autolus with prior written notice and grants, and shall procure the grant of, to Autolus, for a period of &#91;***&#93; after receipt of such notice, a right of first negotiation to, &#91;***&#93;, negotiate and enter into an agreement with BioNTech, its Affiliate or Sublicensee (as applicable) for Autolus or its Affiliate to be BioNTech&#8217;s partner for such combination therapy, whereby such &#91;***&#93; Licensed Product would be used in combination with such Autolus &#91;***&#93; CAR-T. Prior to or during such &#91;***&#93; period, BioNTech, its Affiliates and Sublicensees shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gatekeeping for Other AE Licensed Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties shall, within &#91;***&#93;, appoint a Gatekeeper. The fees and expenses of the Gatekeeper&#8217;s responsibilities under this Agreement shall be borne by &#91;***&#93;. For the avoidance of doubt, no gatekeeping procedure is required in relation to any Activity Enhancement Licensed Product other than Other AE Licensed Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Nomination of Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If BioNTech wishes to conduct the Evaluation or exercise its Activity Enhancement Option, in each case, for Other AE Licensed Products in relation to a given Target, BioNTech must first clear such Target pursuant to the remainder of this Section 6.4(b). &#91;***&#93;, BioNTech may provide Autolus with a written request that Autolus provide the Gatekeeper with a complete, accurate and then-current list of Targets that are not Available (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nomination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Within &#91;***&#93; after BioNTech provides Autolus with such Nomination Notice, (i) Autolus shall provide the Gatekeeper with a complete, accurate and then-current list of Targets that are not Available and (ii) BioNTech shall provide the Gatekeeper with a list of &#91;***&#93; Targets that BioNTech wishes to nominate as a Target for which BioNTech may commence its Evaluation or exercise its Activity Enhancement Option, in each case, for Other AE Licensed Products directed to such specified Target (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nominated Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). To identify a Target as a Nominated Target, BioNTech shall provide the Gatekeeper with a confidential written description of each Nominated Target, including the name, aliases, and UniProt&#47;SwissProt database identifier for such Nominated Target. Within &#91;***&#93; following Gatekeeper&#8217;s receipt of both Autolus&#8217;s list of Targets that are not Available and BioNTech&#8217;s list of Nominated Targets, the Gatekeeper shall notify BioNTech in writing whether or not each Nominated Target is Available (as defined below) (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties hereby acknowledge and agree that a Nominated Target shall be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Available</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; unless &#91;***&#93;. Within &#91;***&#93; after BioNTech&#8217;s receipt of an Availability Notice, BioNTech may (A)&#160;&#91;***&#93;, (B) &#91;***&#93;, or (C) &#91;***&#93;. The Gatekeeper shall not disclose the identity of a Nominated Target to Autolus unless it is designated as a Reserved Target or the identity of any Targets that Autolus has provided to the Gatekeeper unless it is a Nominated Target. For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Reserved Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If BioNTech desires to reserve an Available Nominated Target, then BioNTech shall notify both Autolus and the Gatekeeper in writing of the identity of such Nominated Target within &#91;***&#93; after BioNTech&#8217;s receipt of an Availability Notice, including the name, aliases, and UniProt&#47;SwissProt database identifier for such Nominated Target (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reserved Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Autolus shall not enter into an agreement with a Third Party for Other AE Licensed Products directed to such Reserved Target if such agreement would prejudice BioNTech&#8217;s option rights to such Reserved Target until the end of the Module Option Period. For clarity, &#91;***&#93;. During the Module Option Period, BioNTech may designate &#91;***&#93;, and may &#91;***&#93;. For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Restricted Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus may notify the Gatekeeper in writing of the identity of &#91;***&#93; Targets within &#91;***&#93; following the appointment of the Gatekeeper, including the name, aliases, and UniProt&#47;SwissProt database identifier for such Target (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restricted Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). &#91;***&#93; during the Module Option Period, Autolus may provide the Gatekeeper with a confidential written description of any Targets that it wishes to substitute for any existing Restricted Targets, including the name, aliases, and UniProt&#47;SwissProt database identifier for such Target (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nominated Restricted Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and identify which of the existing Restricted Targets that it wishes to substitute for each Nominated Restricted Target (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Substitutability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Within &#91;***&#93; following the Gatekeeper&#8217;s receipt of Autolus&#8217;s list of Nominated Restricted Targets, the Gatekeeper shall notify Autolus in writing whether or not each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nominated Restricted Target is Substitutable (as defined below). The Parties hereby acknowledge and agree that a Nominated Restricted Target shall be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Substitutable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; unless such Target (i) &#91;***&#93;, or (ii) &#91;***&#93;. On notification to Autolus that a Nominated Restricted Target is Substitutable, the Gatekeeper shall replace the previously Restricted Target indicated in the applicable Substitutability Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech may notify Autolus in writing that it wishes to exercise any of the Technologies Options, identifying (a) precisely which Technologies Option Technology such Technologies Option will be exercised in relation to, including, where applicable, the relevant regulatable control module of the Safety Switch Licensed Technology, and module of the Activity Enhancement Licensed Technology, and (b) the identity of the applicable Target (which with respect to the &#91;***&#93; Option will be &#91;***&#93;, and with respect to the &#91;***&#93; Option, will be &#91;***&#93;) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). For clarity, with respect to any Activity Enhancement Option, with respect to an Other AE Licensed Product, such Target must either have been identified as being Available under Section&#160;6.4(b) within the &#91;***&#93; prior to the date of delivery of such Technologies Option Exercise Notice or be a Reserved Target under Section&#160;6.4(c). On receipt of such Technologies Option Exercise Notice, &#91;***&#93; shall, within &#91;***&#93;, prepare the license agreement reflecting the details set out in such Technologies Option Exercise Notice, which shall be in the form set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Parties shall &#91;***&#93; execute the Technologies License Agreement after it has been finalized, and the Technologies Option Exercise Fee for the applicable Technology Option shall be paid in accordance with Section 6.6. BioNTech may exercise any Technologies Option on one or more occasions during the applicable Technologies Option Period. For the avoidance of doubt, &#91;***&#93; only one Technologies Option Exercise Fee will have to be paid for each such &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93;, Autolus shall submit to BioNTech an invoice for the applicable Technologies Option exercise fee (if any) set out in the below table (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, if a particular Technologies Option is exercised in respect of &#91;***&#93; of the &#91;***&#93; Option, &#91;***&#93; Option, any Safety Switch Licensed Technology module, and any Activity Enhancement Licensed Technology module in respect of the same Target, then the applicable Technologies Option Exercise Fee shall be &#91;***&#93;&#58; (a) &#91;***&#93;, and (b) &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Fee Cap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Activity Enhancement Option (per module)</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Safety Switch Option (per regulatable control module)</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Option</font></div></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Option</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Technologies Option Exercise Fee</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Failure to Exercise Technologies Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On expiry of the &#91;***&#93; Option Period, the &#91;***&#93; Option shall expire without any further action required on the part of either Party, and Autolus will have no further obligations to BioNTech under this Article 6 with respect to &#91;***&#93; and, except to the extent it would conflict with the terms of any Technologies License Agreement, Autolus, at its sole discretion, may negotiate with any Third Party a transaction, including an exclusive license, in respect of the &#91;***&#93; Licensed IP, and all rights relating thereto, without reference to BioNTech. BioNTech shall &#91;***&#93; destroy </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any data, results, and information generated by it pursuant to the Evaluation with respect to the expired &#91;***&#93; Option, other than data, results, and information pertaining to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On expiry of the &#91;***&#93; Option Period, the &#91;***&#93; Option shall expire without any further action required on the part of either Party, and Autolus will have no further obligations to BioNTech under this Article 6 with respect to &#91;***&#93; and, except to the extent it would conflict with the terms of any Technologies License Agreement, Autolus, at its sole discretion, may negotiate with any Third Party a transaction, including an exclusive license, in respect of the &#91;***&#93; Licensed IP, and all rights relating thereto, without reference to BioNTech. BioNTech shall &#91;***&#93; destroy any data, results, and information generated by it pursuant to the Evaluation with respect to the expired &#91;***&#93; Option, other than data, results, and information pertaining to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Module</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On expiry of the Module Option Period, each Module Option shall expire without any further action required on the part of either Party, and Autolus will have no further obligations to BioNTech under this Article 6 with respect to the Activity Enhancement Licensed Technology and the Safety Switch Licensed Technology and, except to the extent it would conflict with the terms of any Technologies License Agreement, Autolus, at its sole discretion, may negotiate with any Third Party a transaction, including an exclusive license, in respect of the Activity Enhancement Licensed IP and Safety Switch Licensed IP, and all rights relating thereto, without reference to BioNTech. BioNTech shall &#91;***&#93; destroy any data, results, and information generated by it pursuant to the Evaluation with respect to the expired Module Option, other than data, results, and information pertaining to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Obe-Cel Product</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reporting Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus shall, within &#91;***&#93;, and on &#91;***&#93; thereafter, until &#91;***&#93;, provide BioNTech with a written report &#91;***&#93;, Development activities conducted during &#91;***&#93; in respect of the Obe-cel Product for all Indications other than &#91;***&#93;. All information and reports provided to BioNTech pursuant to this Section 7.1 shall be treated as Confidential Information of Autolus hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus shall, at the end of &#91;***&#93; following &#91;***&#93;, provide BioNTech with &#91;***&#93; of the Commercialization of Obe-cel Product in &#91;***&#93; in such &#91;***&#93;, including &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that upon &#91;***&#93;, the reports provided under this Section 7.1(b) will be provided &#91;***&#93; and will be limited to &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, further, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">At BioNTech&#8217;s request, within &#91;***&#93; following BioNTech&#8217;s receipt of the reports detailed in Section 7.1(a) or Section 7.1(b), the Parties shall meet to discuss the reports and the progress of the activities detailed in such reports, as well as the anticipated activities to be undertaken by Autolus during the forthcoming &#91;***&#93; period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Potential Support </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties may discuss potential commercial support which could be provided by BioNTech in support of the Commercialization of Obe-cel Product. For clarity, unless BioNTech and Autolus subsequently enter into an exclusivity agreement in relation to the Commercialization of Obe-cel Product (which for clarity, neither Party is under an obligation to enter into), Autolus may discuss and conclude agreements with Third Parties for the Commercialization of Obe-cel Product without any obligation to notify BioNTech.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As partial consideration for the Obe-cel Revenue Interest, within &#91;***&#93; after the receipt of an invoice issued by Autolus on or after the Effective Date BioNTech shall pay to Autolus the non-refundable, non-creditable sum of Forty Million Dollars ($40,000,000) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As partial consideration for the rights granted under this Agreement, BioNTech may, at its sole discretion, elect to pay to Autolus the non-refundable, non-creditable milestone payments upon the achievement of each of the following milestone events by the Obe-cel Product (whether by or on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">behalf of Autolus, its Affiliates or Autolus Licensees). Each milestone will be payable a maximum of once. For clarity, &#91;***&#93;&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Milestone 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$100,000,000</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Notice and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus shall notify BioNTech in writing within &#91;***&#93; after the first achievement of any milestone event set forth in this Section 7.4 by or on behalf of Autolus, its Affiliates or Autolus Licensees. If BioNTech elects to make a milestone payment in respect of the achievement of such milestone event, BioNTech shall notify Autolus within &#91;***&#93; following receipt of Autolus&#8217;s notification of the first achievement of such milestone event, and Autolus shall send to BioNTech the invoice for the appropriate milestone payment, which shall be paid by BioNTech within &#91;***&#93; of receipt of such invoice. For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Revenue Interest Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As partial consideration for the receipt by Autolus of the Upfront Payment, on a country-by-country basis in the Territory during the Obe-cel Revenue Interest Term in such country, Autolus shall pay to BioNTech an amount equal to &#91;***&#93; of annual Net Sales of Obe-cel Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Revenue Interest Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). As consideration for the receipt by Autolus of milestone payments under Section 7.4, the Initial Obe-cel Revenue Interest Percentage shall be increased as set forth in the table below upon Autolus&#8217;s receipt of the applicable milestone payment under Section 7.4 (the Initial Obe-cel Revenue Interest Percentage and any Additional Revenue Interest Percentage, collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Revenue Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="padding-left:57.18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.801%"><tr><td style="width:1.0%"></td><td style="width:61.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Revenue Interest Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:72pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By way of example, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obe-cel Product Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus shall use Commercially Reasonable Efforts&#58; to (a) &#91;***&#93;, and (b)&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;&#91;***&#93; hereby grants &#91;***&#93; a &#91;***&#93; with &#91;***&#93; granting &#91;***&#93; and &#91;***&#93; if &#91;***&#93; intends (a) to &#91;***&#93;, or to &#91;***&#93;, or (b) to &#91;***&#93; related to &#91;***&#93; ((a) and (b) constituting an &#8220;&#91;***&#93;&#8221;) for a period of &#91;***&#93; commencing on the Effective Date (the &#8220;&#91;***&#93;&#8221;), subject to and as further set out in Section 8.3. Notwithstanding the foregoing, the rights in this Section 8.1 do not apply to &#91;***&#93;. For clarity, this Section 8.1 remains in full force and effect following &#91;***&#93;. For further clarity, &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;&#91;***&#93; shall, within &#91;***&#93; after the Effective Date, deliver to &#91;***&#93;, all information and data &#91;***&#93; in relation to the &#91;***&#93;. Upon &#91;***&#93; request, &#91;***&#93; shall deliver to &#91;***&#93; (to the extent such &#91;***&#93;) in the formats such information and data are held by &#91;***&#93; at the time of such request. &#91;***&#93; will provide the JSC with updates on the progress of &#91;***&#93; in relation to &#91;***&#93;, every &#91;***&#93; during the &#91;***&#93;. During &#91;***&#93; shall on &#91;***&#93; reasonable request (a) request from &#91;***&#93; in relation to &#91;***&#93; which has not been provided to &#91;***&#93;, (b) &#91;***&#93; facilitate access for &#91;***&#93; to the &#91;***&#93;, and (c) &#91;***&#93; provide &#91;***&#93;. To the extent that any data to be provided under this Section 8.2 constitutes Personal Data, &#91;***&#93; shall only be obliged to deliver such Personal Data to &#91;***&#93; to the extent to which it can be delivered in compliance with Applicable Data Protection Law. If the current formats are not compatible with the transfer of such information and data to &#91;***&#93; in compliance with Applicable Data Protection Law, then &#91;***&#93; shall use &#91;***&#93; (i) to obtain such information and data in an anonymized or other format that (1) can be transferred to &#91;***&#93; and (2) results in the applicable information and data no longer constituting Personal Data under Applicable Data Protection Law, or (ii) to facilitate an appropriate data transfer agreement under which such data can be provided to &#91;***&#93; in compliance with Applicable Data Protection Law, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that if &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;If, during the &#91;***&#93; is contemplating &#91;***&#93;, then, prior to &#91;***&#93; (an &#8220;&#91;***&#93;&#8221;), &#91;***&#93; shall provide &#91;***&#93; with prior written notice and all material information and data relating to &#91;***&#93; then in its possession (to the extent not previously provided pursuant to Section&#160;8.2) and for a period of &#91;***&#93; after receipt of such notice and information, &#91;***&#93; has a &#91;***&#93;, and during such &#91;***&#93; would not &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;If the Parties &#91;***&#93; may engage &#91;***&#93; with a &#91;***&#93; or enter into &#91;***&#93; with a &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Financial Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As partial consideration for the rights granted under this Agreement with respect to the &#91;***&#93; Licensed IP and the Technologies Option Technology, within &#91;***&#93; after the receipt of an invoice issued by Autolus on or after the Effective Date BioNTech shall pay to Autolus the non-refundable, non-creditable sum of Ten Million Dollars ($10,000,000).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In partial consideration of the license granted to BioNTech pursuant to Section 5.1, on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product and country-by-country basis, during the applicable &#91;***&#93; Royalty Term for such &#91;***&#93; Licensed Product and such country, BioNTech shall pay to Autolus royalties on Net Sales of such &#91;***&#93; Licensed Product in such country at a rate of &#91;***&#93;, as may be increased pursuant to Section 9.2(c) and as may be decreased pursuant to Section 9.2(b) (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Royalty Rate Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">&#91;***&#93;. For any period during the &#91;***&#93; Royalty Term in which &#91;***&#93; (A) &#91;***&#93;, the royalty rate with respect to Net Sales of such &#91;***&#93; Licensed Product for the remainder of the applicable &#91;***&#93; Royalty Term shall be reduced by &#91;***&#93;, and (B) &#91;***&#93;, the royalty rate with respect to Net Sales of such &#91;***&#93; Licensed Product for the remainder of the applicable &#91;***&#93; Royalty Term shall be reduced by &#91;***&#93;. The Parties &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.58pt">Biosimilar Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On a country-by-country and &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product basis, during the &#91;***&#93; Royalty Term for such &#91;***&#93; Licensed Product in such country, if &#91;***&#93;, the &#91;***&#93; of such &#91;***&#93; Licensed Product in such country &#91;***&#93;, then, thereafter, the &#91;***&#93; Royalties payable with respect to &#91;***&#93; of such &#91;***&#93; Licensed Product in such country will be reduced by percentage set forth in the following table.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Reduction</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.53pt">Third Party Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If BioNTech or one of its Affiliates obtains a license to &#91;***&#93; owned or otherwise controlled by a Third Party that &#91;***&#93;, and &#91;***&#93;, then, thereafter, BioNTech may deduct &#91;***&#93; of the &#91;***&#93; paid by BioNTech to the applicable Third Party (&#91;***&#93;) as an offset to the royalties payable by BioNTech to Autolus for the applicable &#91;***&#93; Licensed Product with respect to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:20.13pt">IRA Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If a &#91;***&#93; Licensed Product is designated as a &#8220;selected drug&#8221; by the Secretary of the U.S. Department of Health and Human Services, and BioNTech is required to negotiate a maximum fair price that shall apply to sales of such &#91;***&#93; Licensed Product during the price applicability period as specified in the Inflation Reduction Act, then the royalties payable with respect to all sales of such &#91;***&#93; Licensed Product in the United States shall be reduced by &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Royalty Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Save as provided in &#91;***&#93;, when royalties may be reduced to &#91;***&#93;, on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product and country-by-country basis, in no event will the aggregate amount of &#91;***&#93; Royalties due to Autolus for such &#91;***&#93; Licensed Product in such country in a Calendar Quarter during the applicable &#91;***&#93; Royalty Term be reduced pursuant to this Section&#160;9.2(b) by more than &#91;***&#93; of the amount that would otherwise be due to Autolus in the absence of such reductions </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that BioNTech may carry over and apply any such royalty reductions that are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter, to any subsequent Calendar Quarters (subject to the floor in this Section 9.2(b)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Royalty Rate Increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding Section&#160;9.2(a), but subject to Section&#160;9.2(b) if BioNTech, its Affiliates or Sublicensee Commercializes a &#91;***&#93; Licensed Product and, during the applicable &#91;***&#93; Royalty Term for such &#91;***&#93; Licensed Product, Autolus, its Affiliates or Autolus Licensees has obtained or does obtain Regulatory Approval for a product containing a &#91;***&#93; Licensed Binder and&#47;or a &#91;***&#93; Licensed Binder in both the same Indication and in the same country as such &#91;***&#93; Licensed Product (&#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Competing Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then, on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product basis and country-by-country basis, the royalty rate in respect of such &#91;***&#93; Licensed Product in such Indication in such countries shall be increased to &#91;***&#93; from First Commercial Sale of the &#91;***&#93; Competing Product during any Calendar Quarter in which sales of the &#91;***&#93; Competing Product in such Indication and country are made. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93; Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In partial consideration of the rights granted by Autolus to BioNTech hereunder and subject to the terms and conditions set forth in this Agreement, BioNTech shall pay to Autolus on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product basis, the non-refundable, non-creditable milestone payments upon the first achievement of each of the following milestone events for each &#91;***&#93; Licensed Product to achieve such milestone event (whether by or on behalf of BioNTech, its Affiliates or Sublicensees). Each milestone will be payable a maximum of once for a given &#91;***&#93; Licensed Product. For clarity, &#91;***&#93;&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:42.33pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.051%"><tr><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Number</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="background-color:#dbe5f1;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total Per &#91;***&#93; Licensed Product</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:36pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$32,000,000</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Notice and Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech shall notify Autolus in writing within &#91;***&#93; after the first achievement of any milestone event set forth in this Section 9.3 by or on behalf of BioNTech, its Affiliates or Sublicensees. Based on this notice, Autolus shall then issue and send to BioNTech the invoice for the appropriate milestone payment, which shall be paid by BioNTech within &#91;***&#93; of receipt of such invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Skipped Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any of the &#91;***&#93; milestones set out in Section&#160;9.3(a) is skipped for any reason, then such skipped milestone shall become payable on the achievement of the next milestone to be achieved, as if both the following milestone and the skipped milestone had been achieved simultaneously, but the &#91;***&#93; milestones are payable only as and when achieved. By way of example, if &#91;***&#93; is achieved, and then &#91;***&#93; is achieved without &#91;***&#93; having been achieved, then the milestone payments in respect of both &#91;***&#93; and &#91;***&#93; would become payable upon the achievement of &#91;***&#93;. If &#91;***&#93; is achieved before &#91;***&#93; have been achieved, then upon the achievement of &#91;***&#93; each of &#91;***&#93; will be payable to the extent not already paid. However, if &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cap on Option Exercise and Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the terms of this Article 9 or the terms of any Technologies License Agreement, the total amount payable by BioNTech to Autolus for all milestone payments and Technologies Option Exercise Fees under this Agreement and all Technologies License Agreements shall not exceed &#91;***&#93;. For the avoidance of doubt, this cap does not apply to royalty payments. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Third Party Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus is solely responsible for any payments owed to any Third Parties under the Upstream License Agreements and for any payments owed under the Intra-Group License. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Reports and Payment Terms</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reports&#59; Timing of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">and Royalty Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Obe-cel Revenue Interest and &#91;***&#93; Royalties shall accrue at the time the payment for the sale of the applicable product is &#91;***&#93;. For each &#91;***&#93; during the Obe-cel Revenue Interest Term and &#91;***&#93; Royalty Term the Paying Party shall send to the Receiving Party within &#91;***&#93; a statement of &#91;***&#93;. Where there are Net Sales of Obe-cel Product or &#91;***&#93; Licensed Product other than &#91;***&#93;, the Paying Party shall also provide details of &#91;***&#93;. The Selling Party shall procure that the foregoing information is obtained from any Autolus Licensee with respect to Obe-cel Product or Sublicensee with respect to &#91;***&#93; Product, as applicable. Each Party shall &#91;***&#93; require any Autolus Licensee (in the case of Autolus) and Sublicensee (in the case of BioNTech) to provide such statement within &#91;***&#93; after the end of such &#91;***&#93;. Royalty and revenue interest obligations that have accrued during a particular &#91;***&#93; shall be paid by the applicable Paying Party, on a &#91;***&#93; basis, within &#91;***&#93; after the end of such &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">BioNTech has no payment obligations to &#91;***&#93;, but to enable Autolus to comply with its reporting obligations under &#91;***&#93;, with effect on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product basis from the First Commercial Sale of such &#91;***&#93; Licensed Product and throughout the remainder of the &#91;***&#93; Royalty Term for such &#91;***&#93; Licensed Product, within &#91;***&#93; following &#91;***&#93;, BioNTech shall provide Autolus with a written report showing &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Mode of Payment and Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All payments hereunder shall be made by deposit of Dollars in the requisite amount to such bank account as the recipient may from time to time designate by written notice to the Paying Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such bank account is located in the European Union, the United Kingdom, or the United States. With respect to sales not denominated in Dollars, the Paying Party shall convert applicable sales in foreign currency into Dollars by using the then-current and reasonable standard exchange rate methodology applied to its external reporting. Based on the resulting sales in Dollars, the Paying Party shall calculate the applicable Obe-cel Revenue Interest or &#91;***&#93; Royalties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If either Party fails to pay any undisputed payment under this Agreement by the date when such payment is due, then, without limiting any other right or remedy of the other Party, such late payment shall be paid together with interest thereon at an annual rate &#91;***&#93;, from the date on which such payment was originally due until the date of payment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, such rate shall not exceed the rate permissible under Applicable Law).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. (a) Autolus shall, and shall cause its Affiliates and Autolus Licensees to, keep complete and accurate financial books and records pertaining to the Exploitation of Obe-cel Products, and (b) BioNTech shall, and shall cause its Affiliates and Sublicensees to, keep complete and accurate financial books and records pertaining to the Exploitation of &#91;***&#93; Licensed Products, in each case ((a) and (b)) in sufficient detail to calculate all amounts payable hereunder with respect thereto and to verify compliance with its obligations under this Agreement. Such books and records shall be retained by the Parties and their Affiliates and, Autolus Licensees and Sublicensees (as applicable), until &#91;***&#93; after the end of the Calendar Year to which such books and records pertain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Either Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) may, upon written request to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Audited Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), cause an internationally recognized independent accounting firm (which is reasonably acceptable to the Audited Party) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to inspect the relevant records of the Audited Party or its Affiliates to verify the royalties or revenue interest payable by such Audited Party under this Agreement, and the related reports, statements and books of accounts, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, the Auditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">may only inspect the relevant books and records of the Audited Party to verify sums payable under this Agreement by the Audited Party with respect to the &#91;***&#93; prior to the &#91;***&#93; in which such inspection request is made. Before beginning its audit, the Auditor will execute an undertaking acceptable to the Audited Party by which the Auditor shall agree to keep confidential all Confidential Information reviewed during such audit. The Auditor will disclose to the Auditing Party only its conclusions regarding any payments owed under this Agreement. On written request by Autolus, following a written request to Autolus by &#91;***&#93; to audit Autolus in accordance with &#91;***&#93;, BioNTech shall, &#91;***&#93;, provide to Autolus &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the foregoing obligations shall expire &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Audited Party shall make its relevant records available for inspection by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from the Auditing Party. The records shall be reviewed solely to verify the accuracy of the Audited Party&#8217;s payments under this Agreement. The Auditing Party shall not exercise such inspection right more than once in any &#91;***&#93; and not more frequently than once with respect to records covering any specific period of time. The Auditing Party shall hold in strict confidence all Confidential Information received and all Confidential Information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any law, regulation or judicial order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If the final result of the inspection reveals an undisputed underpayment or overpayment by the Audited Party, then the underpaid or overpaid amount shall be settled &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Auditing Party shall pay for the fees and expenses of the Auditor, except that (i) BioNTech shall pay for such fees with respect to audits initiated by Autolus if BioNTech is found to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">have underpaid Autolus by more than &#91;***&#93; of the amount that should have been paid for the audited period and (ii) Autolus shall pay for such fees with respect to audits initiated by BioNTech if Autolus is found to have underpaid BioNTech by more than &#91;***&#93; of the amount that should have been paid for the audited period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Sales Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">All payments and other consideration under this Agreement are stated exclusive of Sales Tax. If any Sales Tax is chargeable in respect of any supply made by Autolus to BioNTech pursuant to this Agreement and Autolus, or any Affiliate of it, is required to account for such Sales Tax to a tax authority, BioNTech shall pay to Autolus an amount equal to such Sales Tax in addition to the payment or other consideration in respect of that supply. Such Sales Tax shall be payable at the same time as such payment or other consideration is due or otherwise required to be provided and Autolus, where applicable, shall provide BioNTech with a valid Sales Tax invoice. If any Sales Tax is chargeable in respect of any supply made by BioNTech to Autolus pursuant to this Agreement and BioNTech, or any Affiliate of it, is required to account for such Sales Tax to a tax authority, Autolus shall pay to BioNTech an amount equal to such Sales Tax in addition to the payment or other consideration in respect of that supply. Such Sales Tax shall be payable at the same time as such payment or other consideration is due or otherwise required to be provided and BioNTech, where applicable, shall provide Autolus with a valid Sales Tax invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Where a Party is required under this Agreement to indemnify, pay or otherwise reimburse an amount in respect of any liability, cost, charge or expense incurred by another Party, the payor shall not be required to indemnify, pay or reimburse any amount in respect of Sales Tax which is recoverable (whether by way or repayment, credit or set off) by the payee (or any Affiliate of it), subject to the payee (or such Affiliate) using &#91;***&#93; to recover such Sales Tax.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Withholding Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">All sums payable and other consideration provided under this Agreement shall be paid or provided by the Party making the payment or providing the consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Paying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) without any withholding or deduction for, or on account of, any Taxes, except for taxes that are required to be withheld or deducted by Applicable Law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">If any deductions or withholdings for or on account of Tax are required to made by Applicable Law in respect of any amounts payable or other consideration provided under this Agreement, the Paying Party shall withhold or deduct an amount equal to any such Tax, account for such Tax to the relevant tax authority within the time required by Applicable Law and provide to the party entitled to receive such amount or other consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) reasonable evidence of the payment of such Tax, including official receipts (where available), and such withheld or deducted Taxes shall be treated for all purposes of this Agreement as having been paid to the Receiving Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">The Parties shall, in respect of the payment or other consideration in question (other than any payment of interest), cooperate and take all steps reasonably and lawfully available to them, including completing such procedural formalities as are necessary, to establish the Receiving Party&#8217;s entitlement to any exemption from, or diminution in the amount of, any relevant deduction or withholding for or on account of Tax and to enable the Paying Party to obtain any necessary authorization to make payment or provide consideration without, or subject to a reduced amount of, deduction or withholding for or on account of Tax (including, in each case and for the avoidance of doubt, in relation to any applicable exemption certificate) and to provide the Receiving Party with such assistance as is reasonably required to obtain a refund of, or credit with respect to, any such Tax required to be deducted or withheld. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">If a Party takes any action (not required by the terms of this Agreement), including any assignment, transfer, sublicense, change of place of incorporation or tax residence, or a change of the place of business or other permanent establishment through which it receives the supplies </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">made under this Agreement or with which the performance of its obligations under this Agreement is effectively connected, which results in an obligation, or increased obligation, to withhold or deduct tax with respect to payments to be made or other consideration to be provided to the other Party pursuant to this Agreement, then &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event that (i) a withholding tax deduction was omitted, (ii) an exemption certificate of the Receiving Party as required under the German anti-treaty-shopping rules for the Paying Party to abstain from a withholding obligation has become invalid, and (iii) it is detected after a payment to the Receiving Party that a withholding tax deduction should have been made under such rules in respect of such payment, the Paying Party may withhold such amount as ought to have been so withheld from subsequent payments under this Agreement, or the Receiving Party shall reimburse the Paying Party for such amounts &#91;***&#93;. In respect of any such subsequent deduction or reimbursement, any effect resulting from currency conversion is benefit or burden of Receiving Party as taxpayer and not borne by Paying Party. Each of the Paying Party and the Receiving Party shall notify the other Party &#91;***&#93; after becoming aware that an exemption certificate (that has reduced or eliminated any obligation to deduct or withhold an amount of, or in respect of, Tax, from any payment under this Agreement) has become invalid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">The Parties&#8217; assessment of currently Applicable Law is that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Information and Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall, &#91;***&#93; following a request in writing by the other Party &#91;***&#93;, provide to that other Party (or any of its Affiliates) such information within its possession and assistance concerning the matters contemplated by this Agreement (including any matters contemplated by any MCSA and any Research and Development Collaboration Agreement referred to in Section 3.2) as the relevant Party may reasonably request in connection with its (or any Affiliate&#8217;s) tax affairs (including in connection with any claim for research and development tax credits that such Party (or any of its Affiliates) may wish to make).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Customs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus shall provide to BioNTech any documents necessary for tax and customs clearance for the Transferred Materials in a format as required and specified by BioNTech. Any shipment of Transferred Materials by Autolus to BioNTech or its Affiliates must be announced &#91;***&#93; in advance at &#91;***&#93;. An invoice for customs purposes showing exact costs per shipped good must be provided. Shipments of Transferred Materials to BioNTech will be made &#91;***&#93; designated by BioNTech. Deviation must be discussed in advance with &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly set forth herein, as between the Parties, each Party is and shall remain the owner of all intellectual property that it owned or otherwise controlled as of the Effective Date or that it develops, licenses, or otherwise acquires thereafter pursuant to activities independent of this Agreement (with respect to each Party, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Save as provided in &#91;***&#93;, as between the Parties, &#91;***&#93;. Save as provided in Section 11.2(b), &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding Section 11.2(a), or any other provision to the contrary set forth in this Agreement, the terms of the MCSA, the Research and Development Collaboration Agreement and any &#91;***&#93;, and any &#91;***&#93; shall govern ownership of inventions generated under such agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Prosecution and Maintenance of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; has the &#91;***&#93; right, but not the obligation, to prepare, file, prosecute and maintain the &#91;***&#93; Licensed Patents, at &#91;***&#93; sole cost and expense. &#91;***&#93; shall keep &#91;***&#93; reasonably informed of all steps with regard to the preparation, filing, prosecution, and maintenance of the &#91;***&#93; Licensed Patents. &#91;***&#93; shall provide &#91;***&#93; with a copy of &#91;***&#93; communications to and from the patent authorities regarding the &#91;***&#93; Licensed Patents, including drafts of &#91;***&#93; shall consider &#91;***&#93; reasonable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">comments with respect to such drafts. Without limitation to the generality of the foregoing, &#91;***&#93; shall during the Term&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">on a &#91;***&#93; basis, keep &#91;***&#93; informed of &#91;***&#93; with respect to those &#91;***&#93; Licensed Patents that &#91;***&#93; (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> Licensed Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the status of, filing, prosecution and maintenance activities therefor, including providing &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">&#91;***&#93;, give &#91;***&#93; (1) an opportunity to review and comment (for not less than &#91;***&#93;) on the proposed text of any papers related to the filing of &#91;***&#93; Licensed Product-Specific Patents, and (2) an opportunity to review and comment (for not less than &#91;***&#93;) on the proposed text of any papers related to prosecution of &#91;***&#93; Licensed Product-Specific Patents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">supply &#91;***&#93; with a copy of each such &#91;***&#93; Licensed Product-Specific Patent application as filed, together with notice of its filing date and serial number&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">provide copies of any papers, office actions and other &#91;***&#93; correspondence received related to the prosecution of such &#91;***&#93; Licensed Product-Specific Patents within &#91;***&#93; prior to the deadline for taking action with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; agrees that, in consultation with &#91;***&#93; and at &#91;***&#93; request, &#91;***&#93; shall (i) prepare, file, prosecute, and maintain the &#91;***&#93; Licensed Patents in a manner that will generate one or more &#91;***&#93; Licensed Product-Specific Patents, and (ii) include any reasonable comments of &#91;***&#93; on all such potential filings of &#91;***&#93; pursuant to clause (i) of this sentence so as to generate a mutually agreeable filing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Enforcement of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If either Party knows or believes that an infringement, unauthorized use, misappropriation, ownership claim, threatened infringement or other similar activity by a Third Party exists or has occurred with respect to any &#91;***&#93; Licensed Patent, or if a Third Party claims that any &#91;***&#93; Licensed Patent is invalid or unenforceable, then such Party shall notify the other Party and provide it with all details that are known by such Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Right to Bring an Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, &#91;***&#93; has the &#91;***&#93; right, but not the obligation, to enforce and defend under its control, at its own expense, the &#91;***&#93; Licensed Patents (including the &#91;***&#93; Licensed Product-Specific Patents) where the putative infringing activity &#91;***&#93; (collectively a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Competitive Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the foregoing, &#91;***&#93; shall not take any action in respect of any Competitive Infringement that &#91;***&#93;, without the express written consent of &#91;***&#93;. &#91;***&#93; has the &#91;***&#93; right, but not the obligation, at its own expense, to enforce any other infringements of the &#91;***&#93; Licensed Patents. &#91;***&#93; also has the right to defend the &#91;***&#93; Licensed Patents where such defense arises outside the context of a Competitive Infringement. If the validity or enforceability of a &#91;***&#93; Licensed Patent is challenged in the course of a Competitive Infringement or any action that &#91;***&#93; is controlling, then &#91;***&#93; shall have the &#91;***&#93; right to control such challenge in accordance with Section&#160;11.6. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Reasonable Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon request from the other Party, each Party shall provide reasonable assistance to the other Party to prosecute and to settle any enforcement or defense action under the control of the prosecuting Party in accordance with Section 11.4(b), including joining as a party to such action, providing access to relevant documents and other evidence and making its employees available, subject to &#91;***&#93;. If either Party is unable to initiate or prosecute an action without joinder of the other Party, then such Party will join such action voluntarily and will execute and cause its Affiliates to execute all documents necessary for such Party to initiate litigation under Section 11.4(b). Notwithstanding the foregoing, &#91;***&#93; shall not settle any Competitive Infringement in a manner that &#91;***&#93;, without the express written consent of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any recovery realized as a result of such litigation described in this Section 11.4 (whether by way of settlement or otherwise) shall &#91;***&#93;. Any remainder after such reimbursement is made shall &#91;***&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Infringement Claims by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If the Exploitation of a &#91;***&#93; Licensed Product in the Territory pursuant to this Agreement results in, or may result in, any claim, suit, or proceeding by a Third Party alleging patent infringement by &#91;***&#93;, then &#91;***&#93; has the &#91;***&#93; right, but not the obligation, to defend and control the defense of any such claim, suit, or proceeding at its own expense, using counsel of its own choice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the provisions of Section 11.4 shall govern the right of &#91;***&#93; to assert a counterclaim of infringement of any &#91;***&#93; Licensed Patent, and where the validity or enforceability of a &#91;***&#93; Licensed Patent is challenged in the course of such litigation, the provisions of Section&#160;11.6 shall govern the right of &#91;***&#93; to defend such &#91;***&#93; Licensed Patent. &#91;***&#93; shall &#91;***&#93; notify &#91;***&#93; of any such claim, suit, or proceeding where the alleged patent infringement relates to &#91;***&#93;, and keep &#91;***&#93; reasonably informed of all material developments in connection with any such claim, suit, or proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Defense of &#91;***&#93; Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall &#91;***&#93; notify the other Party in writing of any alleged or threatened assertion by a Third Party of invalidity or unenforceability of any of the &#91;***&#93; Licensed Patents, in each case in the Territory and of which such Party becomes aware. As between the Parties, &#91;***&#93; shall have the &#91;***&#93; right, but not the obligation, to defend and control the defense of the validity and enforceability of the &#91;***&#93; Licensed Patents, at its sole cost and expense. &#91;***&#93; shall assist and cooperate with &#91;***&#93; as &#91;***&#93; may reasonably request from time to time, at &#91;***&#93; sole cost and expense, in connection with its activities set forth in this Section 11.6, including by being joined as a party plaintiff in such action or proceeding, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours. Where &#91;***&#93; exercises its right to control the defense of a challenge to the validity or enforceability of a &#91;***&#93; Licensed Patent in the course of a Competitive Infringement action or proceeding pursuant to Section 11.4, or a Third Party infringement action or proceeding pursuant to Section 11.5, the Parties shall fully consult and cooperate as regards the conduct of such action or proceeding. Notwithstanding the foregoing, &#91;***&#93; shall not settle the defense of a challenge to the validity or enforceability of a &#91;***&#93; Licensed Patent in the course of any Competitive Infringement action or proceeding pursuant to Section 11.4, or any Third Party infringement action or proceeding pursuant to Section 11.5, &#91;***&#93; without the express written consent of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. &#91;***&#93; has the &#91;***&#93; right to determine whether to opt in or opt out (and to opt in again) of the Unified Patent Court system with respect to the &#91;***&#93; Licensed Patents, and if requested by &#91;***&#93; shall &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Linkage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, &#91;***&#93; shall have the &#91;***&#93; right, at its sole cost and expense, to obtain patent term extensions, supplementary protection certificates, and equivalents thereof with respect to any &#91;***&#93; Licensed Patent in any country in the Territory, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93; shall &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Confidentiality </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Duty of Confidence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to the other provisions of this Article 12, all Confidential Information disclosed by or on behalf of a Party or any of its Affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) under this Agreement will be maintained in confidence and otherwise safeguarded by the recipient Party and its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Recipient Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) during the Term and for a period of &#91;***&#93; thereafter. Notwithstanding the foregoing, (a) &#91;***&#93; and any statement in respect of the Obe-cel Revenue Interest provided under Section 10.1 is the Confidential Information of Autolus, (b) any information and reports delivered under Section 5.11, any notice delivered under Section&#160;9.3(b), any statement in respect of the &#91;***&#93; Royalties provided under Section 10.1, and any &#91;***&#93; is the Confidential Information of BioNTech, and (c) the terms of this Agreement are the Confidential Information of both Parties. The Recipient Party may only use the Confidential Information of the Disclosing Party for the purposes set forth in this Agreement. Subject to the other provisions of this Article 12, each Recipient Party shall hold as confidential such Confidential Information of the Disclosing Party or its Affiliates &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The obligations under this Article 12 shall not apply to any information to the extent that &#91;***&#93; such information&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the public domain through no breach of this Agreement by the Recipient Party&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">was known to, or was otherwise in the possession of, the Recipient Party prior to the time of disclosure by the Disclosing Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is disclosed to the Recipient Party on a non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the Disclosing Party or a Third Party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">is independently developed by or on behalf of the Recipient Party, &#91;***&#93;, without reference to the Confidential Information disclosed by the Disclosing Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any combination of Confidential Information shall not be considered in the public domain or in the possession of the Recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Recipient Party unless the combination and its principles are in the public domain or in the possession of the Recipient Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authorized Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Recipient Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement (including under Section 12.10), or if and to the extent such disclosure is necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">filing or prosecuting Know-How or Patents without breaching this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">complying with applicable court orders, Applicable Laws, Applicable Data Protection Law, or the listing rules of any exchange on which such Recipient Party&#8217;s securities (or the securities of its parent entity) are traded (subject to Section 12.5 with respect to any disclosure of the terms of this Agreement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">in the case of BioNTech as the Recipient Party only, disclosure of such of Autolus&#8217;s Confidential Information in Regulatory Filings that the Recipient Party has the right to file, or holds&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">in the case of BioNTech as the Recipient Party only, disclosure of such of Autolus&#8217;s Confidential Information to BioNTech&#8217;s Affiliates, licensees, sublicensees&#47;Sublicensees (through multiple tiers), subcontractors, and other Third Party collaboration partners, and potential licensees, sublicensees&#47;Sublicensees, subcontractors, and other Third Party collaboration partners, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">disclosure to a Tax authority in connection with the Tax affairs or a reporting obligation of the Recipient Party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">disclosure to such Recipient Party&#8217;s directors, employees, &#91;***&#93; who have a need to know such information in order for the Recipient Party to exercise its rights or fulfill its obligations under this Agreement and &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">disclosure to (i) &#91;***&#93;, and (ii) &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in each case, that &#91;***&#93;, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">in the case of Autolus as the Recipient Party only, disclosure of (i) &#91;***&#93;, and (ii) &#91;***&#93;, in each case (i) and (ii) as reasonably required to enable Autolus and its Affiliates to comply with the terms of each Upstream License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, and subject to Section 12.5 with respect to any disclosure of the terms of this Agreement, if the Recipient Party is required to disclose Confidential Information of the Disclosing Party in connection with Section 12.3(b), then the Recipient Party shall (i)&#160;&#91;***&#93;&#59; (ii)&#160;&#91;***&#93;&#59; (iii) &#91;***&#93;&#59; and (iv) &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> always that nothing in this Section 12.3 shall require the Recipient Party to breach or otherwise violate any applicable court order, Applicable Law, or the listing rules of any exchange on which such Party&#8217;s securities (or the securities of its parent entity) are traded.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Nothing in this Agreement shall prevent a Party from &#91;***&#93;. A Party shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosure of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, either Party may disclose the relevant terms of this Agreement to the extent required, in the reasonable opinion of such Party&#8217;s counsel, to comply with the listing rules of any exchange on which such Party&#8217;s securities (or the securities of its parent entity) are traded, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such Party shall&#58; (a) &#91;***&#93;&#59; (b) &#91;***&#93;&#59; (c) &#91;***&#93;&#59; and (d) &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ongoing Obligation for Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Following the expiration or early termination of this Agreement, each Party and its Affiliates shall &#91;***&#93;, upon request of the Disclosing Party, return to the other Party or destroy, at &#91;***&#93; election, any Confidential Information of the other Party or any of its Affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the other Party may retain one (1) copy of such Confidential Information for the sole purpose of performing any continuing obligations under this Agreement, as required by Applicable Law, or for legal archival purposes, and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that upon expiry of the &#91;***&#93; Royalty Term with respect to a given &#91;***&#93; Licensed Product, such &#91;***&#93; Licensed Product and all related &#91;***&#93; Licensed IP shall not be returned or destroyed. Notwithstanding the foregoing, such other Party also may retain such additional copies of or any computer records or files containing such Confidential Information that have been created solely by such Party&#8217;s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party&#8217;s standard archiving and back-up procedures, but not for any other use or purpose. All such copies of Confidential Information retained or archived as permitted under this Agreement remain subject to the obligations of confidentiality and non-use set out in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Use of Name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly permitted in this Agreement, (including in connection with any authorized disclosure under Section 12.3, Section 12.5, Section 12.8 or Section 12.9) neither Party shall use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance, &#91;***&#93;. The restrictions imposed by this Section 12.7 shall not prohibit either Party from making any disclosure identifying the other Party that, in the reasonable opinion of the disclosing Party&#8217;s counsel, is required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly permitted under Section 12.3, Section 12.5, Section&#160;12.7, this Section 12.8, or Section 12.9, neither Party shall make any public announcement regarding this Agreement without the prior written consent of the other Party (&#91;***&#93;), except for those disclosures reiterating information for which consent has already been obtained for the relevant purpose, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Promptly following the Effective Date, the Parties shall issue a mutually agreed joint press release announcing the execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If BioNTech proposes to make any scientific or other publication or presentation that &#91;***&#93;, BioNTech shall provide Autolus with an advance copy of each proposed publication or presentation at least &#91;***&#93; prior to its proposed date of publication or presentation. Autolus will have &#91;***&#93; to review and provide any comments on the proposed publication or presentation and BioNTech shall &#91;***&#93;. BioNTech shall comply with any written request of Autolus (i) to delete Autolus&#8217;s Confidential Information from such publication or presentation and (ii)&#160;withhold publication or presentation for an additional &#91;***&#93; in order to permit Autolus to obtain Patent protection in accordance with the terms of this Agreement. BioNTech shall acknowledge Autolus&#8217;s contribution and authorship according to customary standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Save as permitted under the relevant Technologies License Agreement, BioNTech shall not have the right to make any scientific or other publication or presentation regarding any information BioNTech may generate during the performance of the Evaluation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus may make any scientific or other publication or presentation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, such publications or presentations shall not contain any Confidential Information of BioNTech and if Autolus proposes to make any scientific or other publication or presentation that (i) &#91;***&#93;, or (ii) &#91;***&#93;, Autolus shall provide BioNTech with an advance copy of each proposed publication or presentation at </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">least &#91;***&#93; prior to its proposed date of publication or presentation. BioNTech will have &#91;***&#93; to review and provide any comments on the proposed publication or presentation and Autolus shall &#91;***&#93;. Autolus shall comply with any written request of BioNTech (1) to delete BioNTech&#8217;s Confidential Information from such publication or presentation and (2)&#160;withhold publication or presentation for an additional &#91;***&#93; in order to permit BioNTech to obtain Patent protection in accordance with the terms of this Agreement. Autolus shall acknowledge BioNTech&#8217;s contribution and authorship according to customary standards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Term and Termination</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term&#59; Effect of Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Notwithstanding any provision to the contrary set forth in this Agreement, (i) this Section 13.1(a), Section 14.3 (Survival), Article 17 (Governing Law and Dispute Resolution), Article 18 (General Provisions), and Article 1 (solely with respect to defined terms used in the foregoing Sections or Articles) will be effective as of the Execution Date, and (ii) all other terms of this Agreement will be automatically effective as of the Effective Date. If the Initial Closing has not occurred within &#91;***&#93; following the Execution Date, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The term of this Agreement will commence upon the Effective Date and expire&#58; (i) with respect to the &#91;***&#93; License, on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product and country-by-country basis until the expiration of the last to expire &#91;***&#93; Royalty Term with respect to such &#91;***&#93; Licensed Product in such country, and finally in its entirety with respect to all &#91;***&#93; Licensed Products in all countries upon expiration of the &#91;***&#93; Royalty Term with respect to the last &#91;***&#93; Licensed Product in the last country in the Territory&#59; (ii) with respect to the Obe-Cel Revenue Interest, upon the expiration of the Obe-cel Revenue Interest Term&#59; and (iii) in its entirety upon the later of clause (i) and (ii) above, in each case, unless earlier terminated as permitted by this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following the expiration of the &#91;***&#93; Royalty Term with respect to a given &#91;***&#93; Licensed Product and country, the license grant in Section 5.1 for such &#91;***&#93; Licensed Product and country shall automatically become fully paid-up, perpetual, irrevocable and royalty-free.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination for Material Breach&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If either Autolus or BioNTech is in material breach of any material obligation hereunder, then the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such material breach, and if such material breach is not cured within &#91;***&#93; after the breaching Party&#8217;s receipt of such notice, or, if such breach (other than with respect to undisputed payments under this Agreement) is not capable of being cured within &#91;***&#93; after the breaching Party&#8217;s receipt of such notice, the non-breaching Party may terminate this Agreement immediately by giving written notice to the breaching Party to such effect </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that if the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party, and such alleged breaching Party provides the other Party notice of such dispute within &#91;***&#93;, then the other Party shall not have the right to terminate this Agreement under this Section&#160;13.2(a) unless and until the dispute resolution process in accordance with Section 17.2, has determined that the alleged breaching Party has materially breached a material obligation under the Agreement and such Party has failed to cure such breach within &#91;***&#93; following such decision. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus may terminate this Agreement on &#91;***&#93; written notice if BioNTech fails to pay Autolus the Upfront Payment when due and such failure to pay is not cured within such &#91;***&#93; period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Either Autolus or BioNTech may terminate this Agreement on written notice if an Insolvency Event occurs in relation to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination by BioNTech Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech may terminate this Agreement on a &#91;***&#93; Licensed Product-by-&#91;***&#93; Licensed Product basis or in its entirety (a) on &#91;***&#93; prior written notice to Autolus if the First Commercial Sale of a &#91;***&#93; Product has not occurred or (b) on &#91;***&#93; prior written notice to Autolus if the First Commercial Sale of a &#91;***&#93; Product has occurred.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effects of Termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination, but not expiry, of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">All licenses granted to BioNTech in respect of the &#91;***&#93; Licensed IP under Section 5.1 terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that upon termination of this Agreement for any reason, upon the request of any Sublicensee of BioNTech who is not then in breach of its sublicense agreement or the terms and conditions of this Agreement applicable to such Sublicensee, Autolus will enter into a direct license to such Sublicensee on the same terms as the relevant terms of this Agreement, taking into account any difference in license scope, territory and duration of sublicense grant&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">To the extent not prohibited by Applicable Law, BioNTech shall wind down any ongoing Clinical Trials with respect to any &#91;***&#93; Licensed Product in a manner and on a timeline reasonably determined by BioNTech and, in each case, consistent with BioNTech&#8217;s ethical obligations&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If applicable, BioNTech and its Affiliates and Sublicensees shall be entitled, during the &#91;***&#93; period following such termination, to sell any commercial inventory of such &#91;***&#93; Licensed Product which remains on hand as of the date of the termination, including any further Commercialization activities in connection with the same, and to continue the Manufacture of in-progress &#91;***&#93; Licensed Product, so long as BioNTech pays to Autolus the royalties applicable to such subsequent sales in accordance with the terms and conditions set forth in this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each Receiving Party shall return or destroy all Confidential Information of the Disclosing Party to the extent requested pursuant to Section 12.6&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Solely if such termination was by Autolus pursuant to Section 13.2(b), the Obe-cel Revenue Interest payments set out in Section 7.5 shall terminate as of the effective date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioNTech&#8217;s Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon termination of this Agreement, to the extent that any MCSA Negotiation Period, Product Option Period, or Technologies Option Period have not expired, such periods shall expire with effect from the effective date of termination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Warranties and Covenants</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Warranties by Each Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party warrants to the other Party, as of the Effective Date that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">it is an entity duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all corporate action required by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with this Agreement have been obtained other than any such consents, approvals and authorizations that may be required under Antitrust Laws, including the HSR Act, with respect to any Technologies Option, other option exercise or any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">collaboration contemplated by this Agreement (including the MCSA and the Research and Development Collaboration Agreement)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby do not&#58; (i) conflict with or result in a breach of any provision of its organizational documents&#59; (ii) result in a breach of any other agreement to which it is a party&#59; or (iii) violate any Applicable Law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Warranties by Autolus</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Autolus warrants to BioNTech, as of the Effective Date that&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except for those rights licensed to Autolus under the Upstream License Agreements, Autolus is the sole and exclusive owner of all of the Autolus IP and the Autolus IP is free from encumbrances&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus has the right to grant to BioNTech the rights that Autolus purports to grant BioNTech hereunder, including the right to grant&#58; the Product Options&#59; exclusive licenses under the &#91;***&#93; Licensed IP, &#91;***&#93; Licensed IP and &#91;***&#93; Licensed IP&#59; co-exclusive and non-exclusive licenses under the Activity Enhancement Licensed IP&#59; non-exclusive licenses under the Safety Switch Licensed IP and non-exclusive internal research license under the Technologies Option IP to conduct the Evaluation, in each case subject to, and as further set out in, the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus has, prior to the Effective Date, obtained and provided BioNTech with true, accurate and complete copies of, all relevant consents and waivers from Third Parties, including &#91;***&#93; that enable Autolus to grant, as of the Effective Date (with regards to the &#91;***&#93; License and Obe-cel Revenue Interest and the non-exclusive internal research license under the Technologies Option IP to conduct the Evaluation) or anytime immediately after the Effective Date (with regards to each of the options within the Product Option and Technologies Option), the rights to BioNTech that are contemplated under this Agreement without any further action required to be taken&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">to Autolus&#8217;s Knowledge, the Development, Manufacture and Commercialization of the &#91;***&#93;, the Obe-cel Products, the Autolus Products, and the Option Products does not violate any license and does not infringe or misappropriate any intellectual property rights of any Third Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Autolus and its Affiliates have conducted, and to Autolus&#8217;s Knowledge, their respective consultants and subcontractors have conducted, all research, Development, Manufacture, and other Exploitation of the &#91;***&#93;, the Obe-cel Products, the Autolus Products, and the Option Products in material compliance with all Applicable Law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">other than the Upstream License Agreements, there are no agreements or other arrangements to which Autolus or any of its Affiliates is a party relating to the Autolus IP that materially restrict (i) BioNTech&#8217;s ability to research, Develop, Manufacture, use, import, offer for sale, sell, have sold and otherwise Commercialize &#91;***&#93; Licensed Products or (ii) Autolus&#8217;s ability to research, Develop, Manufacture, use, import, offer for sale, sell, have sold and otherwise Commercialize the Autolus Products, the Obe-Cel Products or the Option Products&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">neither Autolus nor any of its Affiliates are delinquent in any payment obligations to any Third Party, or engaged in any dispute with any Third Party, in each case, that, to Autolus&#8217;s Knowledge, would limit (i) BioNTech&#8217;s ability to research, Develop, Manufacture, use, import, offer for sale, sell, have sold and otherwise Commercialize &#91;***&#93; Licensed Products or (ii)&#160;Autolus&#8217;s ability to research, Develop, Manufacture, use, import, offer for sale, sell, have sold and otherwise Commercialize the Obe-cel Product, the Autolus Products, or the Option Products&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">no claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings or other proceedings are pending or, to Autolus&#8217;s Knowledge, have been threatened&#58; (i) as to the Autolus Patents, including any seeking to invalidate or otherwise challenge the Autolus Patents&#59; or (ii) asserting that Autolus is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">infringing or has misappropriated or otherwise is violating any Patent right, trade secret, or other proprietary right of any Third Party as would reasonably be expected to impair the ability of Autolus to fulfil any of its obligations or BioNTech to exercise any of its rights under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">to Autolus&#8217;s Knowledge, no Third Party is infringing, misappropriating, or otherwise violating, or threatening to infringe, misappropriate or otherwise violate, the Autolus IP&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the inventions claimed, covered or encompassed by the Autolus IP (i) were not conceived, discovered, developed, invented, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States (or any agency thereof) or the government of any other country, (ii) are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. &#167; 201(e), (iii) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, codified at 35 U.S.C. &#167;&#167; 200-212, or any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401, (iv) in the case of clauses (ii) or (iii), are not subject to similar obligations or restrictions under the Applicable Law of any other country, and (v) are not the subject of any licenses, options or other rights of any Governmental Authority, within or outside the United States&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Schedule&#160;15.2(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> contains all Autolus Patents that are Controlled by Autolus as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">all issued Autolus Patents are subsisting, and to Autolus&#8217;s Knowledge, are not invalid or unenforceable, in whole or in part&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">to Autolus&#8217;s Knowledge, (i) the Autolus Patents are being diligently prosecuted in the respective patent offices in the Territory in accordance with Applicable Law, (ii) Autolus has not taken any action that would render any invention claimed in the Autolus Patents unpatentable, and (iii) the Autolus Patents have been filed and maintained properly and correctly, and all necessary ownership and priority right assignments from named inventors to Autolus have been procured and timely filed and recorded with appropriate patent offices&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all required application, registration, maintenance, other related fees and renewal fees in respect of the Autolus Patents have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of obtaining or maintaining the Autolus Patents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">all current and former officers, employees, agents, advisors, consultants, contractors or other representatives of Autolus or any of its Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any Autolus IP have, where Applicable Law does not automatically vest such individual&#8217;s rights in Autolus, executed and delivered to Autolus or any such Affiliate a valid and enforceable written assignment or other agreement regarding the protection of proprietary information and the assignment to Autolus of any Autolus IP&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">to Autolus&#8217;s Knowledge, no Person who claims to be an inventor of an invention claimed in an Autolus Patent is not identified as an inventor of such invention in the filed patent documents for such Autolus Patent&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">to Autolus&#8217;s Knowledge, no dispute regarding inventorship, authorship, or ownership has been alleged or threatened with respect to any Autolus IP&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">Autolus and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality and value of all Autolus Know-How that constitutes trade secrets under Applicable Law, including by requiring all employees, consultants and subcontractors to execute binding and enforceable agreements requiring all such employees, consultants and subcontractors to maintain the confidentiality of all such Know-How&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.4pt">there are no claims, judgements, settlements, litigations, suits, actions, disputes, arbitration, judicial or legal, administrative or other proceedings, or governmental investigations pending or, to Autolus&#8217;s Knowledge, threatened against Autolus or any of its Affiliates that could reasonably be expected to adversely affect or restrict the ability of Autolus to consummate or perform the transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and obligations contemplated under this Agreement, or that would affect the Autolus IP, Autolus&#8217;s Control thereof, or the &#91;***&#93; Licensed Products, the Autolus Products, the Obe-Cel Products, or the Option Products&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Autolus is not in material breach of or material default under the Upstream License Agreements and has not taken or failed to take any action that with or without notice, lapse of time or both would constitute a material breach of or material default under the Upstream License Agreements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Upstream License Agreements, to Autolus&#8217;s Knowledge, are valid, binding, enforceable, and in full force and effect, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus has received no written notice regarding any material violation, breach, or default under the any Upstream License Agreements&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt">Autolus has not waived any rights under any Upstream License Agreements in a manner that would adversely affect in any material respect BioNTech&#8217;s rights hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">the Upstream License Agreements are the only agreements under which Autolus receives rights under the Autolus IP, and Autolus has provided BioNTech with true, complete, and correct copies of each such Upstream License Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; has, as required by &#91;***&#93;, consented to &#91;***&#93; under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Warranties by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech warrants to Autolus, as of the Effective Date that neither it, nor its Affiliates, develops, sells or manufactures tobacco products or makes the majority of its profits from the importation, marketing, sale or disposal of tobacco products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each Party hereby covenants that it shall not employ or use the services of any Person who is debarred under the United States Federal Food, Drug and Cosmetic Act or comparable laws in any other country or jurisdiction, in connection with the Exploitation of &#91;***&#93; Licensed Products (in the case of BioNTech) or the Exploitation of Obe-cel Products and Option Products (in the case of Autolus). If a Party becomes aware of the debarment or threatened debarment of any Person providing services to such Party (including the Party itself and its Affiliates, and any Autolus Licensees and Sublicensees (as applicable)) that directly or indirectly relate to activities under this Agreement, such Party shall &#91;***&#93; notify the other Party in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus hereby covenants it shall not (1) &#91;***&#93;, and (2) &#91;***&#93;, unless &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">breach its obligations under any Upstream License Agreement in any way that results in, or would reasonably be expected to result in, the termination of such Upstream License Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">modify or amend any Upstream License Agreement in any way that would adversely affect BioNTech&#8217;s rights hereunder in any material respect, without BioNTech&#8217;s prior written consent, &#91;***&#93;. Following any modification or amendment to an Upstream License Agreement, Autolus shall provide BioNTech with a copy of the applicable modification to or amendment of the applicable Upstream License Agreement, &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">terminate any Upstream License Agreement in whole or in part without BioNTech&#8217;s prior written consent, &#91;***&#93;&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">within &#91;***&#93; after Autolus&#8217;s knowledge thereof, provide BioNTech with notice of and information relating to any alleged or suspected breach or default by Autolus or the other party(s) to the Upstream License Agreements that would adversely affect in any material respect Autolus or BioNTech or its rights hereunder and, following BioNTech&#8217;s request, reasonably consult with BioNTech before taking any action in relation to such alleged or suspected breach or default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each Party hereby covenants that it shall not, and shall not permit its Affiliates, Autolus Licensees (in the case of Autolus) or Sublicensees (in the case of BioNTech) or anyone acting on its or their behalf under this Agreement to grant or otherwise convey to any Third Party any rights that would be inconsistent with the other Party&#8217;s rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither Autolus nor its Affiliates shall grant any option, right or license to any Third Party under the Autolus IP in a manner that conflicts with any of the rights or licenses granted to BioNTech, or any obligations of Autolus, hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If Autolus receives notice of an alleged payment default by Autolus or its Affiliates under any Upstream License Agreement that Autolus does not cure within &#91;***&#93;, Autolus hereby grants to BioNTech the right (but not the obligation) to&#58; (i) &#91;***&#93;&#59; and (ii) &#91;***&#93;. The foregoing shall not preclude any other right or action that BioNTech may have against Autolus for such breach of Section&#160;15.4(b)(iv).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">If Autolus has not obtained and provided to BioNTech prior to the Effective Date&#58; (i) &#91;***&#93;&#59; and (ii) &#91;***&#93;, in each case ((i) and (ii)), then Autolus will &#91;***&#93;. In each case, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Other Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as expressly stated in this Article&#160;15&#58; (a)&#160;no representation, condition or warranty whatsoever is made or given by or on behalf of BioNTech or Autolus&#59; and (b)&#160;all other conditions and warranties, whether arising by operation of law or otherwise, are hereby expressly excluded, including any conditions and warranties of merchantability, fitness for a particular purpose or non-infringement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary in this Agreement, the licenses and rights granted hereunder are subject to those terms of the Upstream License Agreements that are set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and BioNTech will, and will procure that its Affiliates, Subcontractors and Sublicensees will, comply with such terms set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to the extent applicable. Subject to the foregoing, and without limitation to any remedy that may be available to Autolus, if &#91;***&#93;, then &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Compliance with Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In connection with this Agreement, the Parties shall comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the UK Bribery Act 2010, as amended, any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International Business Transactions, and any other applicable equivalent laws. Without limiting the foregoing, in performing its obligations under this Agreement, neither Party shall, directly or indirectly, pay any money to, or offer or give anything of value to, any Government Official, in order to obtain or retain business or to secure any commercial or financial advantage for any Party, including the other Party or for itself or any of their respective Affiliates or Autolus Licensees or Sublicensees (as applicable).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Prohibited Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the other obligations of the Parties set forth in this Section 15.7, each Party covenants to the other that, as of the Effective Date and in the performance of its obligations under this Agreement through the expiration or termination of this Agreement, such Party and, to its knowledge, its Affiliates and its and its Affiliates&#8217; employees and contractors, in connection with the performance of their respective obligations under this Agreement, have not made, offered, given, promised to give, or authorized, and shall not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly through Third Parties, to any Government Official for the purpose of (i) improperly influencing any act or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">decision of the Government Official, (ii) inducing the Government Official to do or omit to do an act in violation of a lawful or otherwise required duty, (iii)&#160;securing any improper advantage, or (iv)&#160;inducing the Government Official to improperly influence the act or decision of any organization, including any government or government instrumentality, to assist any Party in obtaining or retaining business. If, during the Term of this Agreement, either Party becomes aware that any Person acting on that Party&#8217;s behalf has engaged in any prohibited conduct pursuant to this Section 15.7(b) related to the performance of such Party&#8217;s obligations under this Agreement, then such Party will &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Compliance with Export Control and Sanctions Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In connection with this Agreement, (i) the Parties shall comply with all applicable local, national, and international laws, and regulations regarding export controls, economic sanctions, trade embargoes, and anti-boycott matters including sanctions regulations administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Office of Financial Sanctions Implementation in the United Kingdom, and (ii) except as permitted by applicable government license or authorization, each Party shall not engage in any direct or indirect transactions or dealings with (including export, reexport, or transfer of any items to) (1) any country or territory that is subject to an embargo by the U.S. government, European Union or the United Kingdom, or (2) any Person identified on, or fifty percent (50%) or more owned (individually or in the aggregate) by Persons identified on, any list of designated or prohibited parties maintained by the United States, the European Union or the United Kingdom or other applicable jurisdictions (including the List of Specially Designated Nationals and Blocked Persons, the Foreign Sanctions Evaders List, and the Sectoral Sanctions Identifications List, which are maintained by OFAC, and the Entity List, Denied Persons List, and Unverified List, which are maintained by the Bureau of Industry and Security of the U.S. Commerce Department).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Compliance with Data Protection Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In connection with this Agreement the Parties are independent Data Controllers (as defined in the EU GDPR and UK GDPR) in respect of the Personal Data provided by Autolus to BioNTech (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shared Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and shall disclose, make available, transfer, store, use and process the Shared Personal Data in accordance with Applicable Data Protection Law. Without limiting the obligations of the Parties set forth in Applicable Data Protection Law, each Party covenants to the other that it shall&#58; (i) provide such assistance to the other Party as is reasonably required to enable the other Party to comply with requests by patients to exercise their rights under, and within the time limits imposed by, Applicable Data Protection Law&#59; (ii) have in place throughout the term of this Agreement appropriate technical and organizational security measures to prevent the unauthorized or unlawful processing of the Shared Personal Data and the accidental loss or destruction of, or damage to, the Shared Personal Data, and to ensure a level of security appropriate to the harm that might result from such unauthorized or unlawful processing or accidental loss, destruction or damage and the nature of the Shared Personal Data to be protected&#59; (iii) ensure that any transfer of the Shared Personal Data other than to the United Kingdom or within the European Economic Area is either to a country approved under the EU GDPR or UK GDPR as providing adequate protection, or that there are appropriate safeguards or binding corporate rules in place pursuant to the EU GDPR or UK GDPR, or one of the derogations for specific situations in the EU GDPR or UK GDPR applies to the transfer&#59; and (iv) inform the other Party of any Personal Data Breach (as defined in the EU GDPR and UK GDPR) irrespective of whether there is a requirement to notify any applicable data protection authority or patients.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. (a) Autolus and BioNTech shall coordinate and cooperate fully with each other in mutually determining whether any filings or submissions pursuant to Antitrust Laws or Foreign Investment Laws in connection with the transactions contemplated hereby would be necessary, (b) if BioNTech determines that any such filings or submissions, including HSR Filings, are required with respect to BioNTech&#8217;s exercise of any Technologies Option, other option exercise, or any other collaboration contemplated by this Agreement (including but not limited to the MCSA and Research and Development Collaboration Agreement), then the Parties shall cooperate to make an HSR Filing within &#91;***&#93; (unless otherwise agreed to in writing by counsel for the Parties), and any other filings or submissions under other Antitrust Laws or Foreign Investment Laws &#91;***&#93;, and (c) any information required to be provided under this Agreement by one Party to the other or to the JSC shall be subject to applicable Antitrust Laws relating to the exchange of competitively sensitive information. The Parties shall cooperate with one another to the extent necessary in the preparation of any such filings or submissions, shall consult and cooperate with each other in connection with obtaining HSR Clearance (if required) and all other required clearances under other Antitrust </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Laws or Foreign Investment Laws and shall &#91;***&#93; resolve &#91;***&#93; any objections that may be asserted by any applicable Governmental Authority with respect to the transactions notified in any such filings or submissions, including HSR Filings. Each Party shall be responsible for its own costs and expenses associated with any such filings. &#91;***&#93; shall be responsible for the filing fees associated with any such filings or submissions under Antitrust Laws or Foreign Investment Laws, including any HSR Filing. Notwithstanding any other terms of this Agreement, (i) if BioNTech, after coordinating and consulting with Autolus, determines that an HSR Filing is required with respect to BioNTech&#8217;s exercise of any Technologies Option, including the &#91;***&#93; Option or the &#91;***&#93; Option, no option exercise fee shall be payable until after the date of HSR Clearance with respect to the applicable disclosure and (ii) any such option exercise will not be effective prior to receipt of any approvals, non-disapprovals, or expirations or terminations of any applicable waiting period in jurisdictions (if any) where necessary filings or submissions pursuant to Antitrust Laws or Foreign Investment Laws are to be made. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Efforts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Cooperation for Antitrust&#47;Foreign Investment approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without limiting the foregoing, neither Autolus nor BioNTech, and none of their Affiliates, without the consent of the other Party, shall enter into any agreement with any Governmental Authority pursuant to which Autolus, BioNTech or any of their respective Affiliates, as applicable, agree not to consummate the transactions contemplated hereunder, withdraw any filing, or authorize the extension of any investigation, for any period of time. Each Party shall (i) notify the other &#91;***&#93; upon the receipt by it or any Affiliates of any communication from any Governmental Authority in connection with the transactions contemplated by this Agreement, (ii) permit the other to review in advance any proposed communication by either Party to any Governmental Authority, (iii) provide copies of all communications received from or provided to any Governmental Authority in connection with the transactions contemplated by this Agreement&#59; and (iv)&#160;provide advance notice of any meeting, whether in person or by telephone or video conference, with any Governmental Authority in connection with the transactions contemplated by this Agreement and, &#91;***&#93;, allow the other to attend unless prohibited by such Governmental Authority. Each Party shall, and shall cause their Affiliates to, &#91;***&#93; collaborate in reviewing and commenting on in advance, provide information and providing such assistance as the other may reasonably request in connection with, and to consult the other on, any (proposed) filing, notification or submission made with, or (proposed) communication with, any Governmental Authority in connection with any filing, submission, investigation or inquiry in connection with the transactions contemplated by this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that (1) a party may designate any competitively sensitive materials provided to the other as &#8220;outside counsel only,&#8221; and such materials and information shall be given only to outside counsel of the recipient and will not be disclosed by such outside counsel to employees, officers, or directors of the recipient without the advance written consent of the party providing such materials, and (2) a party may redact such materials to comply with contractual arrangements, and address reasonable attorney-client or other established legal privilege concerns, to the extent they are not governed by a common interest privilege or doctrine. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Other Conduct Prior to Antitrust&#47;Foreign Investment approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary in this Agreement, this Section 15.9 and &#91;***&#93; does not require that either Party&#58; (i) offer, negotiate, commit to, or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of it or any of its Affiliates&#59; (ii) agree to any restrictions on its or its affiliates&#8217; business(es)&#59; or (iii) pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order or other order in any suit or proceeding that would otherwise have the effect of preventing or delaying the transactions contemplated by this Agreement (collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Antitrust Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign Investment Remedy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), where such Antitrust Remedy or Foreign Investment Remedy would have a material effect on its ability to operate, exercise control or otherwise enjoy any part of its business(es), including any part of its business transferred or contemplated to be transferred by the transactions contemplated in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Outside Date for Any Antitrust&#47;Foreign Investment Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If any filings or submissions, including HSR Filings, are required under Antitrust Laws or Foreign Investment Laws with respect to BioNTech&#8217;s exercise of any Technologies Option, other option exercise, or any other collaboration contemplated by this Agreement (including but not limited to the MCSA and Research and Development Collaboration Agreement), for each such option or collaboration, the option exercise shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be deemed withdrawn or the collaboration abandoned if such option or collaboration has not become effective on the date that is &#91;***&#93; following the applicable option exercise date or execution of an agreement contemplated hereunder for failure to obtain the necessary approvals, non-disapprovals, or expirations or terminations of any applicable waiting period in jurisdictions where necessary filings or submissions pursuant to Antitrust Laws or Foreign Investment Laws are to be made (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option End Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), unless agreed otherwise by the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the rights under this Section&#160;15.9(c) shall not be available to any Party whose breach of this Agreement has been a principal cause of or resulted in the failure of the effectiveness of the option or collaboration to occur on or before the Option End Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification&#59; Liability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification by Autolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Autolus shall indemnify BioNTech, its Affiliates, and their respective officers, directors, and employees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BioNTech Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against any and all liabilities, damages, losses, costs, fees, or expenses of any nature (including reasonable attorneys&#8217; fees and litigation expenses) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) incurred by or imposed upon the BioNTech Indemnitees or any of them in connection with any Claim to the extent arising or resulting from&#58; (a) Autolus&#8217;s or any of its Affiliates&#8217;, (sub)licensees&#8217; or contractors&#8217; Exploitation of Obe-cel Product (including, for clarity, actual or alleged infringement of any Third Party&#8217;s intellectual property)&#59; (b) the gross negligence or willful misconduct of Autolus or any Autolus Indemnitee&#59; and (c) the material breach of any provision (including any representation or warranty) of this Agreement by Autolus&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Autolus shall not be obliged to so indemnify the BioNTech Indemnitees for any Claims to the extent that BioNTech has an indemnification obligation to an Autolus Indemnitee under Section 16.2.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification by BioNTech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech shall indemnify Autolus, its Affiliates, their respective officers, directors, and employees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Autolus Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses incurred by or imposed upon the Autolus Indemnitees or any of them in connection with any Claim, in each case, to the extent arising or resulting from&#58; (a) BioNTech&#8217;s, or any of its Affiliates&#8217;, Sublicensees&#8217; or Subcontractors&#8217; Development of a &#91;***&#93; Licensed Binder or a &#91;***&#93; Licensed Binder or Exploitation of &#91;***&#93; Licensed Products&#59; (b) the gross negligence or willful misconduct of BioNTech or any BioNTech Indemnitee&#59; or (c) the material breach of any provision of this Agreement by BioNTech&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that BioNTech shall not be obliged to so indemnify the Autolus Indemnitees for any Claims to the extent that Autolus has an indemnification obligation to a BioNTech Indemnitee under Section 16.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification Procedure&#59; Settlement&#59; Quantification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If any of the BioNTech Indemnitees or Autolus Indemnitees (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) receives written notice of the commencement of any Claim, and such Indemnified Party intends to seek indemnification pursuant to this Article 16, then the Indemnified Party shall &#91;***&#93; provide BioNTech (if such Indemnified Party is a BioNTech Indemnitee) or Autolus (if such Indemnified Party is a Autolus Indemnitee) written notice of such Claim, and such Party shall provide the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with written notice of such Claim within &#91;***&#93; of its receipt of notice from the Indemnified Party, stating the nature, basis and the amount thereof, to the extent known, along with copies of the relevant documents evidencing such Claim and the basis for indemnification sought. Failure of the Indemnified Party to give such notice within the time frame specified will not relieve the Indemnifying Party from its indemnification obligations hereunder, except to the extent that the Indemnifying Party is actually and materially prejudiced thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Indemnifying Party may assume the defense, appeal or settlement proceedings of the Indemnified Party against the Claim with counsel of its choice. The Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense, appeal or settlement proceedings of the Claim, and cooperate, and cause the individual indemnitees to cooperate, with the Indemnifying Party in the defense, settlement or compromise of such Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">In no event shall the Indemnifying Party compromise or settle any claim or suit in a manner which admits fault or negligence on the part of the Indemnified Parties without the prior written consent of the Indemnified Party. The Indemnified Party and the Indemnifying Party will act in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">good faith in responding to, defending against, settling or otherwise dealing with Claims. The Indemnified Party and the Indemnifying Party will also cooperate in any such defense, appeal or settlement proceedings, and give each other reasonable access to all information relevant thereto. Whether or not the Indemnifying Party has assumed the defense, appeal or settlement proceedings with respect to a Claim, such Indemnifying Party will not be obligated to indemnify the Indemnified Party for any settlement entered into or any judgment that was consented to without the Indemnifying Party&#8217;s prior written consent (&#91;***&#93;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall maintain, at its own cost, insurance with respect to its activities and obligations under this Agreement in such amounts as are commercially reasonable in the industry for companies conducting similar business and shall require any of its Affiliates undertaking activities under this Agreement to do the same. BioNTech may fulfill the foregoing insurance obligations through self-insurance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Special, Indirect and other Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except for &#91;***&#93;, neither Party nor any of its Affiliates shall be liable in contract, tort, negligence breach of statutory duty or otherwise for any special, indirect, incidental, punitive or consequential damages or for any economic loss or loss of profits suffered by the other Party, regardless of any notice of the possibility of such damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">After-Tax Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All payments made under Section&#160;16.1 and Section&#160;16.2 shall be on an after-tax basis. &#8220;After-tax basis&#8221; shall mean that the amount payable pursuant to the indemnities given by the Parties under Section&#160;16.1 and Section&#160;16.2 will be calculated in such a manner as will ensure that, after taking into account&#58; (a) the amount of any Tax payable by the Indemnified Party as a result of the payment being subject to Tax in the hands of the Indemnified Party (or would be subject to Tax but for a relief (save for any relief described in (b)))&#59; and (b) all reliefs that arise to the Indemnified Party in respect of either that Tax or a matter giving rise to the payment, the Indemnified Party is in the same position as it would have been in if the matter giving rise to the payment had not occurred.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Governing Law and Dispute Resolution</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement is governed by, and will be interpreted in accordance with, the substantive laws of &#91;***&#93; without giving effect to any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The provisions of the United Nations Convention on Contracts for the International Sale of Goods are expressly excluded.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In the event of any disputes, controversies or differences between the Parties, arising out of, in relation to, or in connection with this Agreement, including any alleged breach of this Agreement or any issue relating to the formation, scope, validity, construction, interpretation, enforceability, breach, performance, application, or termination of this Agreement a (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then upon the written request of either Party, the Parties agree to a meeting of the appropriate subject matter expert at each Party, and discuss in good faith an amicable resolution thereof. If the Dispute is not resolved within &#91;***&#93; following the written request for amicable resolution, then either Party may then escalate the matter to the &#91;***&#93;. If &#91;***&#93; cannot resolve the Dispute within &#91;***&#93; following escalation thereto for amicable resolution, and a Party wishes to pursue the matter, it may commence litigation. The Parties irrevocably and unconditionally submit to the exclusive jurisdiction of the courts in &#91;***&#93; for the resolution of all Disputes. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As between the Parties, notwithstanding anything herein to the contrary, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Patent shall &#91;***&#93;. With respect to any Patent issues related to the enforceability or validity of a Patent, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Specific Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Parties agree that irreparable damage may occur if &#91;***&#93; this Agreement was not performed in accordance with the terms thereof and that each Party may seek specific performance of the terms thereof, in addition to any other remedy to which it is entitled at law or in equity. It is therefore agreed that each Party may seek a temporary, preliminary, or permanent injunction or injunctions to prevent breaches of &#91;***&#93; this Agreement, without posting any bond or other undertaking, in addition to any other remedy to which they are entitled at law or in equity, and if any action should be brought in equity to enforce any of the provisions of &#91;***&#93; this Agreement, the other Party shall not raise the defense that there is an adequate remedy at law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">General Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Assignment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Neither Party may assign or transfer this Agreement or its rights and obligations under this Agreement without &#91;***&#93;, except that, and without prejudice to Section 18.1(b) (a)&#160;&#91;***&#93; this Agreement or its rights and obligations under this Agreement &#91;***&#93; without &#91;***&#93;&#59; and (b)&#160;&#91;***&#93; this Agreement &#91;***&#93; without &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93; this Agreement &#91;***&#93; and this Agreement &#91;***&#93;. The assigning Party shall provide the other Party with &#91;***&#93; written notice of any such assignment. Any permitted assignee shall assume all obligations of its assignor under this Agreement (&#91;***&#93;). Any attempted assignment in contravention of the foregoing is void. This Agreement is binding upon and inures to the benefit of the Parties hereto and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Autolus may&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">enter into an Obe-cel Product Transaction at any time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that &#91;***&#93; in accordance with the terms of the foregoing Section 18.1(a), Autolus shall &#91;***&#93; pursuant to which &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">subject to &#91;***&#93;, enter into an Option Product or Next Gen Option Product Transaction at any time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, &#91;***&#93; in accordance with the terms of the foregoing Section 18.1(a), Autolus shall &#91;***&#93; pursuant to which &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">enter into a &#91;***&#93; Transaction at any time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, &#91;***&#93; in accordance with the terms of the foregoing Section 18.1(a), Autolus shall &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">enter into a Technologies Option Transaction at any time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, &#91;***&#93; in accordance with the terms of the foregoing Section 18.1(a) &#91;***&#93;, Autolus shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No Party shall be liable for delay or failure in the performance of any of its obligations hereunder if such delay or failure is due to a cause beyond the reasonable control of a Party, including acts of God, fires, floods, earthquakes, acts of war, terrorism, or civil unrest, or hurricane or other inclement weather, explosions, embargoes, epidemics, pandemics, quarantines, or any other event similar to those enumerated above (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the affected Party &#91;***&#93; notifies the other Party, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the affected Party shall &#91;***&#93; avoid or remove such causes of non-performance and to mitigate the effect of such occurrence, and shall continue performance with the utmost dispatch whenever such causes are removed. Such excuse from liability will be effective only to the extent and duration of the Force Majeure event causing the failure or delay in performance and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that a Party has not caused such events to occur. When such circumstances arise, the Parties shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extension to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Without prejudice to the provisions of any Section in this Agreement that explicitly refers to a Party&#8217;s Affiliates, the Parties agree that any Affiliates of a Party may exercise any of the rights granted to such Party in this Agreement or perform any of such Party&#8217;s obligations in this Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that such Party shall be responsible for the performance of any of its obligations that are performed by its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Should one (1) or more of the provisions of this Agreement become invalid or unenforceable as a matter of law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be in full force and effect, and the Parties will &#91;***&#93; substitute for the invalid or unenforceable provision a valid and enforceable provision that conforms as nearly as possible with the original intent of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The failure of any Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">effective unless it has been given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind or to take any action that will be binding on the other Party without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. The Parties (and any successor, assignee, transferee, or Affiliate of a Party) shall not treat or report the relationship between the Parties arising under this Agreement as a partnership for tax purposes, unless required by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. All notices, consents, waivers, and other communications under this Agreement must be in writing and will be deemed to have been duly given when&#58; (a)&#160;delivered by hand (with written confirmation of receipt)&#59; (b)&#160;when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), or (c) delivered by electronic mail followed by delivery via either of the methods set forth in Section 18.7(a) or Section 18.7(b), in each case, to the appropriate addresses set forth below (or to such other addresses as a Party may designate by notice)&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Autolus&#58;<br><br>Autolus Limited and Autolus Holdings (UK) Limited<br>The Mediaworks</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191 Wood Lane</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">London</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">England</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">W12 7FP</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attn&#58; General Counsel<br>Email&#58; &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;<br><br>Cooley LLP<br>11951 Freedom Drive<br>One Freedom Square<br>Reston Town Center<br>Reston, VA 20190-5656<br>Attn&#58; &#91;***&#93;<br>Telephone&#58; &#91;***&#93;<br>Email&#58; &#91;***&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to BioNTech&#58;<br><br>BioNTech SE<br>An d. Goldgrube 12, <br>55131 Mainz, <br>Germany<br>Attn&#58; &#91;***&#93;<br>Email&#58; &#91;***&#93;<br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with a copy to&#58;<br><br>&#91;***&#93;<br>Attn&#58; &#91;***&#93;<br>Email&#58; &#91;***&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. BioNTech and Autolus each hereby covenant and agree, without the necessity of any further consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party shall perform its obligations under this Agreement in accordance with all Applicable Laws. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except for the rights of Sublicensees under Section&#160;14.1(a), the provisions of this Agreement are for the sole benefit of the Parties and no other Person or entity shall have any right or claim against either Party by reason of these provisions or be entitled to enforce any of these provisions against either Party (including under the Contracts (Rights of Third Parties) Act 1999). The rights of the Parties to amend this Agreement are not subject to the consent of any other Person. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement is written and executed in the English language. Any translation into any other language shall not be an official version of this Agreement and, in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail. All notices and other communications given under this Agreement shall be in the English language.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In this Agreement, unless otherwise specified&#58; (a) &#8220;includes&#8221; and &#8220;including&#8221; shall mean respectively includes and including without limitation&#59; (b) &#8220;hereof,&#8221; &#8220;herein,&#8221; and &#8220;herewith,&#8221; and words of similar import, shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement&#59; (c) &#8220;in writing&#8221; or &#8220;written&#8221; includes any mode of reproducing words in a legible and non-transitory form, including emails and faxes, unless another form is prescribed by Applicable Law&#59; (d) &#8220;or&#8221; is disjunctive but not necessarily exclusive&#59; (e) a Party includes its permitted assignees or the respective successors in title to substantially the whole of its undertaking&#59; (f) a statute or statutory instrument or any of their provisions is to be construed as a reference to that statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted in accordance with any requirements with respect to such amendment or re-enactment&#59; (g) words denoting the singular shall include the plural and vice versa and words denoting any gender shall include all genders&#59; (h) the Exhibits, Schedules and other attachments form part of the operative provision of this Agreement and references to this Agreement shall, unless the context otherwise requires, include references to the Exhibits, Schedules and attachments&#59; (i) the headings in this Agreement are for information only and shall not be considered in the interpretation of this Agreement&#59; (j) general words shall not be given a restrictive interpretation by reason of their being preceded or followed by words indicating a particular class of acts, matters or things&#59; (k) the word &#8220;any&#8221; shall mean &#8220;any and all&#8221; and (l) &#8220;shall&#8221; has the same meaning as &#8220;will&#8221; wherever referenced, and vice versa. The Parties agree that the terms and conditions of this Agreement are the result of negotiations between the Parties and that this Agreement shall not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement, together with its Schedules, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including, for clarity, the confidentiality agreement entered into by &#91;***&#93; dated &#91;***&#93;. Each Party acknowledges that in entering into this Agreement it does not rely on, and shall have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement. Each Party agrees that it shall not have any claim for innocent or negligent misrepresentation based on any statement in this Agreement. In the event of any inconsistency between the terms of this Agreement and the pharmacovigilance agreement entered into pursuant to Section&#160;5.12(b) the terms of this Agreement shall prevail and govern, except to the extent such conflicting terms relate directly to the pharmacovigilance responsibilities of the Parties (including the exchange of safety data), in which case the terms of the pharmacovigilance agreement shall prevail and govern.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures (including .pdf) and such signatures shall be deemed to bind each Party hereto as if they were original signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;57</font></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives as of the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BIONTECH SE</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Ryan Richardson&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Ryan Richardson</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Management Board Member and Chief Strategy Officer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sierk Poetting&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Sierk Poetting</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Management Board Member and Chief Operating Officer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTOLUS LIMITED</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Christian Itin&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Christian Itin</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUTOLUS HOLDINGS (UK) LIMITED</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Christian Itin&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Christian Itin</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SIGNATURE PAGE TO LICENSE AGREEMENT</font></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.8<br><br>ACTIVITY ENHANCEMENT LICENSED TECHNOLOGY</font></div><div style="margin-bottom:60pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.27<br><br>AUTO1&#47;22 PRODUCT</font></div><div style="text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.29<br><br>AUTO6NG PRODUCT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.30<br><br>&#91;***&#93; PRODUCT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.36<br><br>BASEBALL ARBITRATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.38<br><br>&#91;***&#93; LICENSED BINDER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.60<br><br>&#91;***&#93; LICENSED BINDERS</font></div><div style="margin-bottom:84pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.61<br><br>&#91;***&#93; LICENSED BINDERS</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.152<br><br>OBE-CEL PRODUCT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.191<br><br>SAFETY SWITCH</font></div><div style="margin-bottom:60pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:60pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.227<br><br>&#91;***&#93; LICENSED BINDER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 1.228<br><br>&#91;***&#93; LICENSED BINDER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 3.1<br><br>MANUFACTURING AND COMMERCIAL SERVICES AGREEMENT TERMS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 3.1(B)<br><br>PROCESS TIMELINES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 4.4(A)<br><br>PRODUCT AGREEMENT TERMS</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:24pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 6.2<br><br>TRANSFERRED MATERIALS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 6.5<br><br>FORM TECHNOLOGIES LICENSE AGREEMENT</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 15.2<br><br>AUTOLUS DISCLOSURES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE 15.2(K)<br><br>AUTOLUS PATENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i857b9c9ce9bd48cea54dffb091d10ab1_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCHEDULE&#160;15.6<br><br>UPSTREAM OBLIGATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8
<SEQUENCE>11
<FILENAME>exhibit8subsidiariesfy2023.htm
<DESCRIPTION>EX-8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8d931cf5d8cf4a1a84a68f73ceb44a80_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 8</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:69.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Subsidiary</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech (Shanghai) Pharmaceuticals Co., Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">China</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Australia Pty Ltd</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech BioNTainer Holding GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Cell &#38; Gene Therapies GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:6.25pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech Delivery Technologies (US), LLC</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Delivery Technologies GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Diagnostics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.57pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Europe GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Idar-Oberstein Services GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:6.25pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech Individualized mRNA Manufacturing GmbH</font></div></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Innovation and Services Marburg GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Innovation GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Innovative Manufacturing Services GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Israel Ltd.</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Manufacturing GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Manufacturing Marburg GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Pharmaceuticals Spain S.L.U.</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech R&#38;D (Austria) GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Real Estate Holding GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Real Estate Verwaltungs GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Research and Development, Inc.</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Rwanda Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rwanda</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech S&#233;n&#233;gal Suarl</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Senegal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:6.25pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech Switzerland GmbH</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:6.25pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech Taiwan Co. Ltd.</font></div></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;t&#305;rma Ticaret Anonim &#350;irketi</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech UK Limited</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">UK</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech US Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">BioNTech USA Holding LLC</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep DE GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep LLC</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep Ltd</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">UK</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep Nigeria Limited</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nigeria</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 8</font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:69.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Subsidiary</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep SARL</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tunisia </font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InstaDeep SAS</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">JPT Peptide Technologies GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">JPT Peptide Technologies, Inc.</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New Technologies Re</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NT Security and Services GmbH</font></td><td colspan="3" style="background-color:#deeaf6;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.27pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">reSano GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>12
<FILENAME>exhibit121certification-us.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7bb041d678cc4c78bf1433cbd5095232_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Ugur Sahin, certify that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I have reviewed this annual report on Form 20-F of BioNTech SE&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.485%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 20, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Prof. Dr. Ugur Sahin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prof. Dr. Ugur Sahin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>13
<FILENAME>exhibit122certification-jh.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8ebb4015286e43588017bed334d9952e_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Jens Holstein, certify that&#58; </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I have reviewed this annual report on Form 20-F of BioNTech SE&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.485%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 20, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Jens Holstein</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jens Holstein</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>14
<FILENAME>exhibit131certification-us.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7464adc8df374c69a36f8ad1e478bf68_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 13.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2023 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Ugur Sahin, Chief Executive Officer of BioNTech SE (the &#8220;Company&#8221;), certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.484%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 20, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Prof. Dr. Ugur Sahin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Prof. Dr. Ugur Sahin</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>15
<FILENAME>exhibit132certification-jh.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib9b8a9006a1e4eb39922f4ffb58a4e7f_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 13.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2023 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Jens Holstein, Chief Financial Officer of BioNTech SE (the &#8220;Company&#8221;), certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.485%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; March 20, 2024</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Jens Holstein</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jens Holstein</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>16
<FILENAME>exhibit151eyconsent20-f.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2709267155ee4e22818c037fbbe0d6d8_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 15.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:24.34pt">Registration Statement (Form S-8 No. 333-253263) pertaining to the 2020 Employee Equity Plan, the 2020 Restricted Stock Unit Plan for North America Employees, the 2017 Employee Stock Ownership Plan and the 2020 Management Board ESOP of BioNTech SE,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(2)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:24.34pt">Registration Statement (Form S-8 No. 333-269740) pertaining to the 2020 Employee Equity Plan, 2020 Restricted Stock Unit Plan for North America Employees and 2021 Employee Stock Ownership Plan of BioNTech SE, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(3)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:24.34pt">Registration Statement (Form S-8 No. 333-277105) pertaining to the 2024 Non-North America Employee Participation Plan and 2024 North America Employee Participation Plan of BioNTech SE,</font></div><div style="margin-bottom:12pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of our reports dated March 20, 2024, with respect to the consolidated financial statements of BioNTech SE and the effectiveness of internal control over financial reporting of BioNTech SE  included in this Annual Report (Form 20-F) of BioNTech SE for the year ended December 31, 2023.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; EY GmbH &#38; Co. KG Wirtschaftspr&#252;fungsgesellschaft</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cologne, Germany</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 20, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>17
<FILENAME>exhibit97biontechcompensat.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i30f908b158d845208072ffcd0ddfb706_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compensation Clawback Policy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adopted November 29, 2023<br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purpose</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Supervisory Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) of BioNTech SE (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) has adopted this compensation clawback policy (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement.  This Policy is intended to comply with Section 10D of the Securities Exchange Act of 1934 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Act</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and the rules promulgated thereunder by the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), any other applicable rules and regulations of the SEC, the listing standards of Nasdaq, and the laws of the jurisdiction in which the Corporation is organized or has its principal place of business (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicable Rules</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and will be interpreted consistent therewith.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Applicability and Effective Date </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Policy is effective October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) and is applicable to all Incentive-Based Compensation (as defined below) received by Executive Officers (as defined below) after the Effective Date.  The Policy will be administered by the Board or, if so designated by the Board, the Compensation, Nominating and Corporate Governance Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), in which case references to the Board will be deemed to be references to the Committee.  Any determination made by the Board under this Policy will be final and binding on all affected individuals.  Each Executive Officer shall be required to execute the acknowledgement in Appendix A of this Policy as soon as practicable after the later of (i) the Effective Date and (ii) the date on which the employee is designated as an Executive Officer&#59; provided, however, that failure to execute such acknowledgement shall have no impact on the enforceability of this Policy. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restatement Clawback</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event the Corporation is required to prepare an Accounting Restatement (as defined below), any Executive Officer who received Excess Compensation (as defined below) during the three (3) completed fiscal years preceding the date the Corporation is required to prepare an Accounting Restatement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Look-Back Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall be required to repay or forfeit such Excess Compensation reasonably promptly.  For purposes of this Policy, the date the Corporation is required to prepare an Accounting Restatement is deemed to be the earlier of the date (i) the Board (or a designated committee thereof) concludes, or reasonably should have concluded, that the Corporation is required to prepare an Accounting Restatement, or (ii) a court, regulator, or other legally authorized body directs the Corporation to prepare an Accounting Restatement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Method of Repayment&#59; Conditions for Non-Recovery</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board shall have discretion to determine the appropriate means of recovery of Excess Compensation, which may include, without limitation, direct payment in a lump sum from the Executive Officer, recovery over time, cancellation of outstanding awards, the reduction of future pay and&#47;or awards, and&#47;or any other method which the Board determines is advisable to achieve reasonably prompt recovery of Excess Compensation.  At the direction of the Board, the Corporation shall take all actions reasonable and appropriate to recover Excess Compensation from any applicable Executive Officer, and such Executive Officer shall be required to reimburse the Corporation for any and all expenses reasonably incurred (including legal fees) by the Corporation in recovering such Excess Compensation in accordance with this Policy.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee, or in the absence of the Committee, a majority of the independent directors on the Board, may determine that repayment of Excess Compensation (or a portion thereof) is not required only where</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">it determines that recovery would be impracticable and one of the following circumstances exists&#58; (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered, provided the Corporation has (A) made a reasonable attempt to recover such Excess Compensation, (B) documented such reasonable attempt, and (C) provided such documentation to Nasdaq&#59; (ii) recovery would violate home country law where the law was adopted </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">prior to November 28, 2022, provided the Corporation has (A) obtained an opinion of home country counsel acceptable to Nasdaq that recovery would result in such violation and (B) provided such opinion to the Nasdaq&#59; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Corporation, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No Fault Application, No Indemnification</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recovery of Excess Compensation under this Policy is on a &#8220;no fault&#8221; basis, meaning that it will occur regardless of whether the Executive Officer engaged in misconduct or was otherwise directly or indirectly responsible, in whole or in part, for the Accounting Restatement.  No Executive Officer may be indemnified by the Corporation, or any of its affiliates, from losses arising from the application of this Policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definitions</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Policy, the following definitions will apply&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Accounting Restatement&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an accounting restatement due to the material noncompliance of the Corporation with any financial reporting requirement under securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that corrects an error that is not material to previously issued financial statements but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes to financial statements that do not constitute an Accounting Restatement include retroactive&#58; (i) application of a change from one generally accepted accounting principle to another generally accepted accounting principle&#59; (ii) revisions to reportable segment information due to a change in internal organization&#59; (iii) reclassification due to a discontinued operation&#59; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control&#59; (v) adjustments to provisional amounts in connection with a prior business combination&#59; and (vi) revisions for stock splits, reverse stock splits, stock dividends, or other changes in capital structure.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Excess Compensation&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means any amount of Incentive-Based Compensation received by an Executive Officer after commencement of service as an Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the Accounting Restatement, computed without regard to any taxes and social security paid.  For Incentive Compensation based on stock or American Depositary Share (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) price or total shareholder return, where the amount to be recovered is not subject to mathematical recalculation directly from information in the Accounting Restatement, the amount to be recovered shall be based on a reasonable estimate of the effect of the Accounting Restatement on the stock or ADS price or total shareholder return, as applicable, and the Corporation shall retain documentation of the determination of such estimate and provide such documentation to Nasdaq if so required by the Applicable Rules.  Incentive-Based Compensation is deemed received during the fiscal year during which the applicable financial reporting measure, stock or ADS price and&#47;or total shareholder return measure, upon which the payment is based, is achieved, even if the grant or payment occurs after the end of such period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Executive Officer&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means an individual who is, or was during the Look-Back Period, an executive officer of the Corporation within the meaning of Rule 10D-1(d) under the Act.  A determination that an individual is an Executive Officer for the purposes of this Policy shall not imply that she or he is an &#8220;executive officer&#8221; of the Corporation with respect to any other requirement of applicable law.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Incentive-Based Compensation&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means any compensation that is granted, earned or vested based wholly or in part on stock or ADS price, total shareholder return, and&#47;or the attainment of (i) any financial reporting measure(s) that are determined and presented in accordance with the accounting principles used in </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">preparing the Corporation&#8217;s financial statements and&#47;or (ii) any other measures that are derived in whole or in part from such measures. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation that does not constitute &#8220;Incentive-Based Compensation&#8221; includes equity incentive awards for which the grant is not contingent upon achieving any financial reporting measure performance goal for an individual to receive such award and that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or based on subjective goals or goals unrelated to financial reporting measures.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Administration, Amendment, and Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Policy will be enforced and, if applicable, appropriate proxy disclosures and exhibit filings will be made in accordance with the Applicable Rules.  The terms of this policy shall be construed and&#47;or enforced in accordance with the Applicable Rules.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board shall have authority to (i) exercise all of the powers granted to it under the Policy, (ii) construe, interpret, and implement this Policy, and (iii) make all determinations necessary or advisable in administering this Policy.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition, the Board may amend this Policy from time to time in its discretion, and shall amend this Policy as it deems necessary, including to reflect changes in applicable law.  The Board may terminate this Policy at any time in accordance with the Applicable Rules.  Any such amendment (or provision thereof) or termination shall not be effective if such amendment or termination would (after taking into account any actions taken by the Corporation contemporaneously with such amendment or termination) cause the Corporation to violate the Applicable Rules.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The terms contained in this Policy are intended to be construed in addition to any terms contained in any Executive Officer employment or service agreement. In the event of any conflict or inconsistency between this Policy and any other policies, plans, or other materials of the Corporation (including any agreement between the Corporation and any Executive Officer subject to this Policy), this Policy will govern.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Policy will be deemed to be automatically updated to incorporate any requirement of law, the SEC, exchange listing standard, rule or regulation applicable to the Corporation.   </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix A&#58; </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BioNTech SE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compensation Clawback Policy</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ACKNOWLEDGMENT</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The undersigned acknowledges and agrees that the undersigned (i) is, and will be, subject to the Compensation Clawback Policy (the &#8220;Policy&#8221;) to which this acknowledgement is appended with respect to any Incentive-Based Compensation received on or after October 2, 2023, and (ii) will abide by the terms of the Policy, including by returning Excess Compensation (as defined in the Compensation Clawback Policy) pursuant to whatever method the Board determines is advisable to achieve reasonably prompt recovery of such Excess Compensation, as prescribed under the Policy. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms used but not defined have the meanings set forth in the Policy.</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:216pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.394%"><tr><td style="width:1.0%"></td><td style="width:82.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.221%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Print Name</font></td></tr><tr style="height:24pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Signature</font></td></tr><tr style="height:17pt"><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dated&#58;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Cambria',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;- 4 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>bntx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bntx="http://www.biontech.de/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biontech.de/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bntx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.biontech.de/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.biontech.de/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofProfitorLoss" roleURI="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss">
        <link:definition>0000003 - Statement - Consolidated Statements of Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofFinancialPosition" roleURI="http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition">
        <link:definition>0000005 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.biontech.de/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CorporateInformation" roleURI="http://www.biontech.de/role/CorporateInformation">
        <link:definition>0000008 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.biontech.de/role/SignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingJudgementsEstimatesandAssumptions" roleURI="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions">
        <link:definition>0000010 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GroupInformation" roleURI="http://www.biontech.de/role/GroupInformation">
        <link:definition>0000011 - Disclosure - Group Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.biontech.de/role/BusinessCombinations">
        <link:definition>0000012 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomers" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomers">
        <link:definition>0000013 - Disclosure - Revenues from Contracts with Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpenses" roleURI="http://www.biontech.de/role/IncomeandExpenses">
        <link:definition>0000014 - Disclosure - Income and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTax" roleURI="http://www.biontech.de/role/IncomeTax">
        <link:definition>0000015 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biontech.de/role/EarningsperShare">
        <link:definition>0000016 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwill" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill">
        <link:definition>0000017 - Disclosure - Other Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biontech.de/role/PropertyPlantandEquipment">
        <link:definition>0000018 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilities" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities">
        <link:definition>0000019 - Disclosure - Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.biontech.de/role/Inventories">
        <link:definition>0000020 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialAssets" roleURI="http://www.biontech.de/role/OtherNonFinancialAssets">
        <link:definition>0000021 - Disclosure - Other Non-Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IssuedCapitalandReserves" roleURI="http://www.biontech.de/role/IssuedCapitalandReserves">
        <link:definition>0000022 - Disclosure - Issued Capital and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biontech.de/role/ShareBasedPayments">
        <link:definition>0000023 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Provisions" roleURI="http://www.biontech.de/role/Provisions">
        <link:definition>0000024 - Disclosure - Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandotherfinancialcommitments" roleURI="http://www.biontech.de/role/Contingenciesandotherfinancialcommitments">
        <link:definition>0000025 - Disclosure - Contingencies and other financial commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialLiabilities" roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilities">
        <link:definition>0000026 - Disclosure - Other Non-Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biontech.de/role/Leases">
        <link:definition>0000027 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.biontech.de/role/RelatedPartyDisclosures">
        <link:definition>0000028 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsAftertheReportingPeriod" roleURI="http://www.biontech.de/role/EventsAftertheReportingPeriod">
        <link:definition>0000029 - Disclosure - Events After the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GroupInformationTables" roleURI="http://www.biontech.de/role/GroupInformationTables">
        <link:definition>9954473 - Disclosure - Group Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.biontech.de/role/BusinessCombinationsTables">
        <link:definition>9954474 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersTables" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersTables">
        <link:definition>9954475 - Disclosure - Revenues from Contracts with Customers (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesTables" roleURI="http://www.biontech.de/role/IncomeandExpensesTables">
        <link:definition>9954476 - Disclosure - Income and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxTables" roleURI="http://www.biontech.de/role/IncomeTaxTables">
        <link:definition>9954477 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biontech.de/role/EarningsperShareTables">
        <link:definition>9954478 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwillTables" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables">
        <link:definition>9954479 - Disclosure - Other Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentTables">
        <link:definition>9954480 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesTables" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables">
        <link:definition>9954481 - Disclosure - Financial Assets and Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.biontech.de/role/InventoriesTables">
        <link:definition>9954482 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialAssetsTables" roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsTables">
        <link:definition>9954483 - Disclosure - Other Non-Financial Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IssuedCapitalandReservesTables" roleURI="http://www.biontech.de/role/IssuedCapitalandReservesTables">
        <link:definition>9954484 - Disclosure - Issued Capital and Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biontech.de/role/ShareBasedPaymentsTables">
        <link:definition>9954485 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsTables" roleURI="http://www.biontech.de/role/ProvisionsTables">
        <link:definition>9954486 - Disclosure - Provisions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandotherfinancialcommitmentsTables" roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables">
        <link:definition>9954487 - Disclosure - Contingencies and other financial commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialLiabilitiesTables" roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables">
        <link:definition>9954488 - Disclosure - Other Non-Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.biontech.de/role/LeasesTables">
        <link:definition>9954489 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresTables" roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresTables">
        <link:definition>9954490 - Disclosure - Related Party Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954491 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails">
        <link:definition>9954492 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails">
        <link:definition>9954493 - Disclosure - Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails" roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails">
        <link:definition>9954494 - Disclosure - Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails">
        <link:definition>9954495 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GroupInformationSummaryofInformationaboutSubsidiariesDetails" roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails">
        <link:definition>9954496 - Disclosure - Group Information - Summary of Information about Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GroupInformationSummaryofInformationaboutParentCompanyDetails" roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails">
        <link:definition>9954497 - Disclosure - Group Information - Summary of Information about Parent Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails" roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails">
        <link:definition>9954498 - Disclosure - Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" roleURI="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails">
        <link:definition>9954500 - Disclosure - Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails">
        <link:definition>9954501 - Disclosure - Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersAdditionalInformationDetails" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails">
        <link:definition>9954502 - Disclosure - Revenues from Contracts with Customers - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersSummaryofContractBalancesDetails" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails">
        <link:definition>9954503 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails">
        <link:definition>9954504 - Disclosure - Revenues from Contracts with Customers - Summary of Revenue Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails" roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails">
        <link:definition>9954505 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesAdditionalInformationDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails">
        <link:definition>9954506 - Disclosure - Income and Expenses - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesOtherOperatingExpenseDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails">
        <link:definition>9954507 - Disclosure - Income and Expenses - Other Operating Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesOtherOperatingIncomeDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails">
        <link:definition>9954508 - Disclosure - Income and Expenses - Other Operating Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesFinanceIncomeDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails">
        <link:definition>9954509 - Disclosure - Income and Expenses - Finance Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesFinanceExpensesDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails">
        <link:definition>9954510 - Disclosure - Income and Expenses - Finance Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails" roleURI="http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails">
        <link:definition>9954511 - Disclosure - Income and Expenses - Summary of Employee Benefits Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxAdditionalInformationDetails" roleURI="http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails">
        <link:definition>9954512 - Disclosure - Income Tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails" roleURI="http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails">
        <link:definition>9954513 - Disclosure - Income Tax - Summary of Current and Deferred Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails" roleURI="http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails">
        <link:definition>9954514 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxSummaryofDeferredTaxesDetails" roleURI="http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails">
        <link:definition>9954515 - Disclosure - Income Tax - Summary of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxSummaryofAccumulatedTaxLossesDetails" roleURI="http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails">
        <link:definition>9954516 - Disclosure - Income Tax - Summary of Accumulated Tax Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails" roleURI="http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails">
        <link:definition>9954517 - Disclosure - Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>9954518 - Disclosure - Other Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails">
        <link:definition>9954519 - Disclosure - Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwillAdditionalInformationDetails" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails">
        <link:definition>9954520 - Disclosure - Other Intangible Assets and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails" roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails">
        <link:definition>9954521 - Disclosure - Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails" roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails">
        <link:definition>9954522 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentAdditionalInformationDetails" roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails">
        <link:definition>9954523 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails">
        <link:definition>9954524 - Disclosure - Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails">
        <link:definition>9954525 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails">
        <link:definition>9954526 - Disclosure - Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails">
        <link:definition>9954527 - Disclosure - Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details">
        <link:definition>9954528 - Disclosure - Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails">
        <link:definition>9954529 - Disclosure - Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails">
        <link:definition>9954530 - Disclosure - Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails">
        <link:definition>9954531 - Disclosure - Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails" roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails">
        <link:definition>9954532 - Disclosure - Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetails" roleURI="http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails">
        <link:definition>9954533 - Disclosure - Inventories - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesAdditionalInformationDetails" roleURI="http://www.biontech.de/role/InventoriesAdditionalInformationDetails">
        <link:definition>9954534 - Disclosure - Inventories - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialAssetsSummaryofOtherAssetsDetails" roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails">
        <link:definition>9954535 - Disclosure - Other Non-Financial Assets - Summary of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1" roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1">
        <link:definition>9954535 - Disclosure - Other Non-Financial Assets - Summary of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialAssetsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails">
        <link:definition>9954536 - Disclosure - Other Non-Financial Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IssuedCapitalandReservesAdditionalInformationDetails" roleURI="http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails">
        <link:definition>9954537 - Disclosure - Issued Capital and Reserves - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails" roleURI="http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails">
        <link:definition>9954538 - Disclosure - Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails">
        <link:definition>9954539 - Disclosure - Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>9954540 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails" roleURI="http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails">
        <link:definition>9954541 - Disclosure - Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails" roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails">
        <link:definition>9954542 - Disclosure - Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails" roleURI="http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails">
        <link:definition>9954543 - Disclosure - Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsProvisionsDetails" roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails">
        <link:definition>9954544 - Disclosure - Provisions - Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsProvisionsDetails_1" roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails_1">
        <link:definition>9954544 - Disclosure - Provisions - Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/ProvisionsAdditionalInformationDetails">
        <link:definition>9954545 - Disclosure - Provisions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails" roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails">
        <link:definition>9954546 - Disclosure - Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails" roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails">
        <link:definition>9954547 - Disclosure - Contingencies and other financial commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails" roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails">
        <link:definition>9954548 - Disclosure - Other Non-Financial Liabilities - Summary of Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1" roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1">
        <link:definition>9954548 - Disclosure - Other Non-Financial Liabilities - Summary of Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails" roleURI="http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails">
        <link:definition>9954549 - Disclosure - Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.biontech.de/role/LeasesAdditionalInformationDetails">
        <link:definition>9954550 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails" roleURI="http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails">
        <link:definition>9954551 - Disclosure - Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" roleURI="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails">
        <link:definition>9954552 - Disclosure - Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails">
        <link:definition>9954553 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresAdditionalInformationDetails" roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails">
        <link:definition>9954554 - Disclosure - Related Party Disclosures - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails">
        <link:definition>9954555 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails">
        <link:definition>9954556 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsAftertheReportingPeriodAdditionalInformationDetails" roleURI="http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails">
        <link:definition>9954557 - Disclosure - Events After the Reporting Period - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bntx_EmployeeStockOwnershipPlanESOPNameAxis" abstract="true" name="EmployeeStockOwnershipPlanESOPNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsSettledInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_DisclosureOfCorporateInformationExplanatoryAbstract" abstract="true" name="DisclosureOfCorporateInformationExplanatoryAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_TaxEffectOfDeviationDueToLocalTaxBasis" abstract="false" name="TaxEffectOfDeviationDueToLocalTaxBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CashAndCashEquivalents1LineItems" abstract="true" name="CashAndCashEquivalents1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_PrepaymentForFutureDevelopmentActivities" abstract="false" name="PrepaymentForFutureDevelopmentActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" abstract="false" name="IncreaseDecreaseOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_OptionVestingPeriod" abstract="false" name="OptionVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bntx_ForeignCurrencyChangesEffectOnPretaxEquity" abstract="false" name="ForeignCurrencyChangesEffectOnPretaxEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherCurrentAssetsOther" abstract="false" name="OtherCurrentAssetsOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechRwandaLtd.Member" abstract="true" name="BioNTechRwandaLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechSenegalSuarlMember" abstract="true" name="BioNTechSenegalSuarlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" abstract="true" name="COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EstimatedAllocationDateOneMember" abstract="true" name="EstimatedAllocationDateOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" abstract="false" name="FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" abstract="false" name="ForeignCurrencyChangesEffectOnLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherNonFinancialAssetsAbstract" abstract="true" name="OtherNonFinancialAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_TaxRateOnDeferredTaxes" abstract="false" name="TaxRateOnDeferredTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_OperatingAndBusinessEquipmentMember" abstract="true" name="OperatingAndBusinessEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" abstract="false" name="AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" abstract="false" name="NonCurrentLeaseLiabilitiesLoansAndBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_InstaDeepFranceSASMember" abstract="true" name="InstaDeepFranceSASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_OtherIncomeExpenseMember" abstract="true" name="OtherIncomeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" abstract="false" name="DisclosureOfIncomeAndExpenseExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_TradePayablesAndOtherPayablesMember" abstract="true" name="TradePayablesAndOtherPayablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_SupervisoryBoardMember" abstract="true" name="SupervisoryBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" abstract="true" name="EmployeeEquityPlanLongTermIncentivePlusProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" abstract="false" name="NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CashSettledShareBasedPaymentArrangementMember" abstract="true" name="CashSettledShareBasedPaymentArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinanceCostExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_LiabilitiesRollForward" abstract="true" name="LiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_EmployeeStockOptionPlanMember" abstract="true" name="EmployeeStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AccumulatedTaxLossesInFederalTaxCredits" abstract="false" name="AccumulatedTaxLossesInFederalTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanMember" abstract="true" name="EmployeeEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PercentageOfResearchAndDevelopmentExpense" abstract="false" name="PercentageOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_InstaDeepEmployeeIncentivePlanMember" abstract="true" name="InstaDeepEmployeeIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" abstract="false" name="UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bntx_FederalCorporateIncomeTax" abstract="false" name="FederalCorporateIncomeTax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_LossOnDerivativeInstrumentsAtFairValueMember" abstract="true" name="LossOnDerivativeInstrumentsAtFairValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IncomeAndExpensesByNatureDomain" abstract="true" name="IncomeAndExpensesByNatureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NonListedEquityInvestmentsMember" abstract="true" name="NonListedEquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_AccumulatedDepreciationAmortisationAndImpairment" abstract="false" name="AccumulatedDepreciationAmortisationAndImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" abstract="true" name="OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_VestingPeriodDomain" abstract="true" name="VestingPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_MonetaryAssetsMember" abstract="true" name="MonetaryAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DeferredTaxAssetsSettlement" abstract="false" name="DeferredTaxAssetsSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_InstaDeepNigeriaLimitedMember" abstract="true" name="InstaDeepNigeriaLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_SolidaritySurchargeRate" abstract="false" name="SolidaritySurchargeRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_BioNTechIdarObersteinServicesGmbHMember" abstract="true" name="BioNTechIdarObersteinServicesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_TaxEffectOfChangeInValuationAllowance" abstract="false" name="TaxEffectOfChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" abstract="false" name="KeyManagementPersonnelCompensationOtherVariableCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramTrancheTwoMember" abstract="true" name="ShareRepurchaseProgramTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" abstract="false" name="ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_BioNTechInnovationAndServicesMarburgGmbHMember" abstract="true" name="BioNTechInnovationAndServicesMarburgGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PercentageOfIncreaseInExercisePrice" abstract="false" name="PercentageOfIncreaseInExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" abstract="false" name="OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" abstract="true" name="EmployeeEquityPlanLongTermIncentive2021ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_JensHolsteinMember" abstract="true" name="JensHolsteinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ProfessorUgurSahinMDMember" abstract="true" name="ProfessorUgurSahinMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NetEmployeeDefinedBenefitLiabilitiesMember" abstract="true" name="NetEmployeeDefinedBenefitLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" abstract="false" name="PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" abstract="true" name="EmployeeEquityPlanLongTermIncentive2020ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_MedineGmbHMember" abstract="true" name="MedineGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_TaxEffectiveEquityTransactionCosts" abstract="false" name="TaxEffectiveEquityTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DualityBiologicsSuzhouCoLtdMember" abstract="true" name="DualityBiologicsSuzhouCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" abstract="true" name="EmployeeEquityPlanLongTermIncentive2022ProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" abstract="false" name="AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" abstract="false" name="AdvancePaymentReceivedForFutureCOVID19VaccineSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CashAndCashEquivalents1Member" abstract="true" name="CashAndCashEquivalents1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ExternalProductSalesToJPTMember" abstract="true" name="ExternalProductSalesToJPTMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_LicenseAndOptionAgreementMember" abstract="true" name="LicenseAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_LiabilitiesForEmployeeBenefits" abstract="false" name="LiabilitiesForEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" abstract="true" name="OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BioNTechManufacturingGmbHMember" abstract="true" name="BioNTechManufacturingGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ConstructionInProgressAndAdvancePaymentsMember" abstract="true" name="ConstructionInProgressAndAdvancePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_SeanMarettMember" abstract="true" name="SeanMarettMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramNetAmountSpent" abstract="false" name="ShareRepurchaseProgramNetAmountSpent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CGUImmunotherapiesMember" abstract="true" name="CGUImmunotherapiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CurrentObligationsUnderLeaseContractsMember" abstract="true" name="CurrentObligationsUnderLeaseContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InventoriesAbstract" abstract="true" name="InventoriesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_OtherDeferredTaxesMember" abstract="true" name="OtherDeferredTaxesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_Inventories1Member" abstract="true" name="Inventories1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" abstract="true" name="BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ATHOSKGMember" abstract="true" name="ATHOSKGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DoctorSierkPoettingMember" abstract="true" name="DoctorSierkPoettingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FairValueThroughOCIMember" abstract="true" name="FairValueThroughOCIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_TradeAndOtherReceivablesMember" abstract="true" name="TradeAndOtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InterestBearingLoansAndBorrowingsMember" abstract="true" name="InterestBearingLoansAndBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AssetsRecognisedAsOfAcquisitionDate" abstract="false" name="AssetsRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechRDAustriaGmbHMember" abstract="true" name="BioNTechRDAustriaGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CashAndCashEquivalentsTable" abstract="true" name="CashAndCashEquivalentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" abstract="false" name="CurrentLeaseLiabilitiesLoansAndBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechDiagnosticsGmbHMember" abstract="true" name="BioNTechDiagnosticsGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EquityMethodInvestmentsOwnershipPercentage" abstract="false" name="EquityMethodInvestmentsOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_IncomeAndExpensesByNatureAxis" abstract="true" name="IncomeAndExpensesByNatureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_NonTaxEffectiveBargainPurchase" abstract="false" name="NonTaxEffectiveBargainPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechUSInc.Member" abstract="true" name="BioNTechUSInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareBasedPaymentArrangementYearOneMember" abstract="true" name="ShareBasedPaymentArrangementYearOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_WorkingCapitalAdjustmentsAbstract" abstract="true" name="WorkingCapitalAdjustmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_AccumulatedTaxLossesInTradeTax" abstract="false" name="AccumulatedTaxLossesInTradeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherNonFinancialLiabilitiesAbstract" abstract="true" name="OtherNonFinancialLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" abstract="false" name="DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_RevenueFromContractsWithCustomersAbstract" abstract="true" name="RevenueFromContractsWithCustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_EmployeeStockOwnershipPlanESOPNameDomain" abstract="true" name="EmployeeStockOwnershipPlanESOPNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PhantomOptionAwardsLiability" abstract="false" name="PhantomOptionAwardsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" abstract="true" name="NumberOfOrdinarySharesUnderlyingOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_AdvancePaymentsMember" abstract="true" name="AdvancePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BiotheusIncMember" abstract="true" name="BiotheusIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechManufacturingMarburgGmbHMember" abstract="true" name="BioNTechManufacturingMarburgGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CurrentAndDeferredTaxExpenseIncome" abstract="false" name="CurrentAndDeferredTaxExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechBioNTainerHoldingGmbHMember" abstract="true" name="BioNTechBioNTainerHoldingGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" abstract="true" name="BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ChiefExecutiveOfficerGrantMember" abstract="true" name="ChiefExecutiveOfficerGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" abstract="true" name="UnsatisfiedOrPartiallyUnsatisfiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_WeightedAverageExercisePriceAbstract" abstract="true" name="WeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_JPTPeptideTechnologiesInc.Member" abstract="true" name="JPTPeptideTechnologiesInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechRealEstateHoldingGmbHMember" abstract="true" name="BioNTechRealEstateHoldingGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_VestingPercentageOfShareBasedPaymentArrangement" abstract="false" name="VestingPercentageOfShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" abstract="true" name="AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_PfizerCOVID19VaccineMember" abstract="true" name="PfizerCOVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ATImpfGmbHMember" abstract="true" name="ATImpfGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechUSAHoldingLLCMember" abstract="true" name="BioNTechUSAHoldingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InstaDeepLtdMember" abstract="true" name="InstaDeepLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_MedigeneImmunotherapiesGmbHMember" abstract="true" name="MedigeneImmunotherapiesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DerivativeLiabilitiesMember" abstract="true" name="DerivativeLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" abstract="false" name="IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_MoneyMarketFundMember" abstract="true" name="MoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ValuationAdjustmentMember" abstract="true" name="ValuationAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" abstract="false" name="PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_EffectiveExercisePriceMaximum" abstract="false" name="EffectiveExercisePriceMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsVestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_CurrentOnerousContractsProvisionRelatedToRelease" abstract="false" name="CurrentOnerousContractsProvisionRelatedToRelease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramAuthorizedAmount" abstract="false" name="ShareRepurchaseProgramAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherFinancialAssetsMember" abstract="true" name="OtherFinancialAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AccumulatedTaxLossesInCorporateTax" abstract="false" name="AccumulatedTaxLossesInCorporateTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" abstract="false" name="DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" abstract="false" name="ShareRepurchaseProgramRepurchasedDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ReclassificationsOfPropertyPlantAndEquipment" abstract="false" name="ReclassificationsOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechInnovationGmbHMember" abstract="true" name="BioNTechInnovationGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EmployeeStockOwnershipPlanMember" abstract="true" name="EmployeeStockOwnershipPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfFinanceIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_KeyManagementPersonnelCompensationFixedCompensation" abstract="false" name="KeyManagementPersonnelCompensationFixedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" abstract="true" name="AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" abstract="false" name="ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_COVID19VaccineDirectProductSalesToCustomersMember" abstract="true" name="COVID19VaccineDirectProductSalesToCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ListOfAccountingPoliciesAbstract" abstract="true" name="ListOfAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_NoncurrentObligationsUnderLeaseContractsMember" abstract="true" name="NoncurrentObligationsUnderLeaseContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" abstract="false" name="TradeReceivablesRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_COVID19VaccineRevenuesMember" abstract="true" name="COVID19VaccineRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" abstract="true" name="COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ExternalBusinessOfInstaDeepMember" abstract="true" name="ExternalBusinessOfInstaDeepMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_OtherFinancialLiabilitiesMember" abstract="true" name="OtherFinancialLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_GeneralAndAdministrativeExpensesMember" abstract="true" name="GeneralAndAdministrativeExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" abstract="false" name="PercentageOfImpairmentLossForAReductionOfFutureCashFlows" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" abstract="false" name="FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgram2023Member" abstract="true" name="ShareRepurchaseProgram2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" abstract="true" name="SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareOptionsOutstandingAbstract" abstract="true" name="ShareOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_GovernmentGrantsMember" abstract="true" name="GovernmentGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ResearchAndDevelopmentExpensesMember" abstract="true" name="ResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" abstract="false" name="ShareRepurchaseProgramClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ReclassificationOfShareBasedPaymentArrangement" abstract="false" name="ReclassificationOfShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_PfizerZosterMember" abstract="true" name="PfizerZosterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EstimatedAllocationDateTwoMember" abstract="true" name="EstimatedAllocationDateTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramPeriodDomain" abstract="true" name="ShareRepurchaseProgramPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechTaiwanCo.Ltd.Member" abstract="true" name="BioNTechTaiwanCo.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" abstract="false" name="TreasurySharesUsedForAcquisitionOfBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" abstract="false" name="KeyManagementPersonnelCompensationPhantomSharesAwarded" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_EuropeanCommissionToCollaborationPartnerMember" abstract="true" name="EuropeanCommissionToCollaborationPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" abstract="false" name="UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_FixedAssetsMember" abstract="true" name="FixedAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_RedemptionOfConvertibleNote" abstract="false" name="RedemptionOfConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DesignatedFXHedge" abstract="false" name="DesignatedFXHedge" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_InstaDeepLtd.Member" abstract="true" name="InstaDeepLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_RemainingUpfrontFeesContractLiabilities" abstract="false" name="RemainingUpfrontFeesContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ThereofDeferredTaxLiabilityMember" abstract="true" name="ThereofDeferredTaxLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" abstract="false" name="NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_MaximumCashPaymentInShareBasedPaymentArrangement" abstract="false" name="MaximumCashPaymentInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" abstract="true" name="AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_VestingPeriodAxis" abstract="true" name="VestingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BioNTechEuropeGmbHMember" abstract="true" name="BioNTechEuropeGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" abstract="false" name="DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_BioNTechCellGeneTherapiesGmbHMember" abstract="true" name="BioNTechCellGeneTherapiesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_LitigationCostsMember" abstract="true" name="LitigationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EstimatedAllocationDateThreeMember" abstract="true" name="EstimatedAllocationDateThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" abstract="false" name="ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherSalesMember" abstract="true" name="OtherSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CashOutflowForShareBasedPaymentArrangementExercise" abstract="false" name="CashOutflowForShareBasedPaymentArrangementExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BiopharmaBioNTechIsraelLtd.Member" abstract="true" name="BiopharmaBioNTechIsraelLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" abstract="true" name="PositiveFivePercentageChangeInForeignExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ExercisePricePhantomOptionsGranted" abstract="false" name="ExercisePricePhantomOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" abstract="false" name="DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" abstract="false" name="AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CashOutflowToTaxAuthority" abstract="false" name="CashOutflowToTaxAuthority" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OptionExercisablePeriod" abstract="false" name="OptionExercisablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" abstract="false" name="ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherLiabilitiesOther" abstract="false" name="OtherLiabilitiesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" abstract="false" name="KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" abstract="true" name="ContingenciesAndOtherFinancialCommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" abstract="false" name="PercentageOfAmericanDepositorySharesToOrdinaryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_BioNTechMember" abstract="true" name="BioNTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DecreaseInCorporateTaxRate" abstract="false" name="DecreaseInCorporateTaxRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_LoansAndBorrowingsMember" abstract="true" name="LoansAndBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ListedEquityInvestmentsMember" abstract="true" name="ListedEquityInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CashFlowProjectionsMeasurementInputMember" abstract="true" name="CashFlowProjectionsMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PurchasesFromRelatedPartyTransactions" abstract="false" name="PurchasesFromRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ConsideredRemunerationOfPotentialEarnOutPayments" abstract="false" name="ConsideredRemunerationOfPotentialEarnOutPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" abstract="false" name="EffectOfOtherValuationChangesOnCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" abstract="true" name="BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CurrentOnerousContractsProvisionRelatedToUsage" abstract="false" name="CurrentOnerousContractsProvisionRelatedToUsage" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" abstract="false" name="DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_PreviouslyHeldNonListedEquityInvestment" abstract="false" name="PreviouslyHeldNonListedEquityInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_MedilinkTherapeuticsSuzhouCoLtdMember" abstract="true" name="MedilinkTherapeuticsSuzhouCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" abstract="false" name="ExerciseOfOptionRightsMinimumStrikePricePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" abstract="false" name="ShareBasedPaymentsClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" abstract="false" name="NumberOfOrdinarySharesUnderlyingOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" abstract="true" name="DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_InstaDeepTunisiaSARLMember" abstract="true" name="InstaDeepTunisiaSARLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_Leases1Abstract" abstract="true" name="Leases1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" abstract="false" name="InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_IntangibleAssetsAbstract" abstract="true" name="IntangibleAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" abstract="false" name="DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_IntellectualPropertyRightsMember" abstract="true" name="IntellectualPropertyRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_MonetaryLiabilityAndProvisionsMember" abstract="true" name="MonetaryLiabilityAndProvisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" abstract="false" name="FederalDeferredTaxAssetsOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_OtherOperatingEquipmentMember" abstract="true" name="OtherOperatingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" abstract="false" name="ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_IncreaseDecreaseOfSalesAndMarketingExpense" abstract="false" name="IncreaseDecreaseOfSalesAndMarketingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechRealEstateVerwaltungsGmbHMember" abstract="true" name="BioNTechRealEstateVerwaltungsGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" abstract="true" name="FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechDeliveryTechnologiesUSLLCMember" abstract="true" name="BioNTechDeliveryTechnologiesUSLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_COVID19VaccineSalesToCollaborationPartnersMember" abstract="true" name="COVID19VaccineSalesToCollaborationPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NetChangeInFairValue" abstract="false" name="NetChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_NewTechnologiesReMember" abstract="true" name="NewTechnologiesReMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PurchaseOfSharesUnderAgreement" abstract="false" name="PurchaseOfSharesUnderAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" abstract="false" name="DisclosureOfCorporateInformationExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_NTSecurityAndServicesGmbHMember" abstract="true" name="NTSecurityAndServicesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ForeignExchangeDifferencesMember" abstract="true" name="ForeignExchangeDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_GermanFederalMinistryOfHealthMember" abstract="true" name="GermanFederalMinistryOfHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" abstract="false" name="CurrentOnerousContractsProvisionOtherAdditionalProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfIncomeAndExpensesTable" abstract="true" name="DisclosureOfIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BusinessCombinations1Abstract" abstract="true" name="BusinessCombinations1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_SalesAndMarketingExpenseMember" abstract="true" name="SalesAndMarketingExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_RelatedPartyAbstract" abstract="true" name="RelatedPartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" abstract="true" name="EmployeeEquityPlanLongTermIncentiveProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ReSanoGmbHMember" abstract="true" name="ReSanoGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" abstract="false" name="StateDeferredTaxAssetsOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechInnovativeManufacturingServicesGmbHMember" abstract="true" name="BioNTechInnovativeManufacturingServicesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsHeld" abstract="false" name="NumberOfShareOptionsHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="bntx_LeaseExpensesRecognizedInProfitOrLoss" abstract="false" name="LeaseExpensesRecognizedInProfitOrLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EstimatedAllocationDateFourMember" abstract="true" name="EstimatedAllocationDateFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" abstract="true" name="DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_ProductionFacilitiesMember" abstract="true" name="ProductionFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CorporateTaxRate" abstract="false" name="CorporateTaxRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_TaxEffectNonTaxEffectiveIncome" abstract="false" name="TaxEffectNonTaxEffectiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" abstract="false" name="LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfProvisionsTableTextBlock" abstract="false" name="DisclosureOfProvisionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BioNTechDeliveryTechnologiesGmbHMember" abstract="true" name="BioNTechDeliveryTechnologiesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_LiabilitiesRecognisedAsOfAcquisitionDate" abstract="false" name="LiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" abstract="true" name="NegativeFivePercentageChangeInForeignExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramTrancheOneMember" abstract="true" name="ShareRepurchaseProgramTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" abstract="false" name="PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" abstract="true" name="GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InterestBearingLoansAndBorrowings" abstract="false" name="InterestBearingLoansAndBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_PfizerIncMember" abstract="true" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" abstract="false" name="PurchasesOfGoodsAndServiceRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BioNTechUKLtd.Member" abstract="true" name="BioNTechUKLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" abstract="true" name="DisclosureOfEffectOfChangesInForeignExchangeRatesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_EquipmentToolsAndInstallationsMember" abstract="true" name="EquipmentToolsAndInstallationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfIncomeAndExpensesLineItems" abstract="true" name="DisclosureOfIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_ShareBasedPaymentArrangementsAbstract" abstract="true" name="ShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_RyvuTherapeuticsSAMember" abstract="true" name="RyvuTherapeuticsSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" abstract="false" name="IncreaseDecreaseOfGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" abstract="false" name="CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" abstract="false" name="UpfrontPaymentAcquisitionOfIntangibleAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" abstract="false" name="ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bntx_ShareRepurchaseProgramPeriodAxis" abstract="true" name="ShareRepurchaseProgramPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bntx_CashAndCashEquivalent" abstract="false" name="CashAndCashEquivalent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ReverseRepoMember" abstract="true" name="ReverseRepoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" abstract="false" name="RightOfUseAssetsRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_PercentageOfSalesAndMarketingExpense" abstract="false" name="PercentageOfSalesAndMarketingExpense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_DeferredExpense" abstract="false" name="DeferredExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_JPTPeptideTechnologiesGmbHMember" abstract="true" name="JPTPeptideTechnologiesGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_AmortizedCostMember" abstract="true" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ManagementBoardGrantMember" abstract="true" name="ManagementBoardGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_EventsAfterReportingPeriodAbstract" abstract="true" name="EventsAfterReportingPeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" abstract="true" name="BioNTechIndividualizedMRNAManufacturingGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InstaDeepDEGmbHMember" abstract="true" name="InstaDeepDEGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ThereofDeferredTaxAssetsMember" abstract="true" name="ThereofDeferredTaxAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ConvertibleNoteEmbeddedDerivativeMember" abstract="true" name="ConvertibleNoteEmbeddedDerivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_PercentageOfGeneralAndAdministrativeExpense" abstract="false" name="PercentageOfGeneralAndAdministrativeExpense" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_CashAtBanksAndOnHandMember" abstract="true" name="CashAtBanksAndOnHandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_FairValueThroughProfitOrLossMember" abstract="true" name="FairValueThroughProfitOrLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" abstract="false" name="DisclosureOfSharesRepurchaseProgramTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_NumberOfSharesHeldInTreasury" abstract="false" name="NumberOfSharesHeldInTreasury" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" abstract="true" name="ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_CurrentOnerousContractsProvisionAdditions" abstract="false" name="CurrentOnerousContractsProvisionAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_BankDepositsMember" abstract="true" name="BankDepositsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_AccumulatedTaxLossesInStateTaxCredits" abstract="false" name="AccumulatedTaxLossesInStateTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_MaximumEconomicBenefitsOfOptionsExercised" abstract="false" name="MaximumEconomicBenefitsOfOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ManufacturingVariancesMember" abstract="true" name="ManufacturingVariancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechPharmaceuticalsSpainS.LMember" abstract="true" name="BioNTechPharmaceuticalsSpainS.LMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_IncreaseDecreaseCostOfSales" abstract="false" name="IncreaseDecreaseCostOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" abstract="false" name="EstimatedMilestonePaymentToBeReceivedAtContractInception" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_DeepChainTechnologyMember" abstract="true" name="DeepChainTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" abstract="true" name="BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ContractLiabilitiesMember" abstract="true" name="ContractLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_InstaDeepLLCMember" abstract="true" name="InstaDeepLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" abstract="true" name="OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechSwitzerlandGmbHMember" abstract="true" name="BioNTechSwitzerlandGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IssuanceOfShareCapital" abstract="false" name="IssuanceOfShareCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" abstract="false" name="ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_PercentageOfConsiderationTransferredAcquiredShares" abstract="false" name="PercentageOfConsiderationTransferredAcquiredShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_AdjustmentsForMovementsInGovernmentGrants" abstract="false" name="AdjustmentsForMovementsInGovernmentGrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bntx_EmployeeStockOwnershipPlan2018Member" abstract="true" name="EmployeeStockOwnershipPlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechResearchAndDevelopmentInc.Member" abstract="true" name="BioNTechResearchAndDevelopmentInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_OncoC4IncMember" abstract="true" name="OncoC4IncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_ManagementBoardMember" abstract="true" name="ManagementBoardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" abstract="true" name="BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_IncomeTaxesAbstract" abstract="true" name="IncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_PercentageOfCostOfSales" abstract="false" name="PercentageOfCostOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bntx_BioNTechAustraliaPtyLtd.Member" abstract="true" name="BioNTechAustraliaPtyLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" abstract="false" name="OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>bntx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofProfitorLoss"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_7ce727e6-fca1-4ac5-8436-8e439be73059" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_7ce727e6-fca1-4ac5-8436-8e439be73059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_bcea1c8a-f8c6-4266-8684-a96fb777c1ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_bcea1c8a-f8c6-4266-8684-a96fb777c1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_49b7c2ac-f1ee-4368-8722-f3fa03958a48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_49b7c2ac-f1ee-4368-8722-f3fa03958a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_2cb651de-2640-4825-8ff0-fa37d6334945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_2cb651de-2640-4825-8ff0-fa37d6334945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_9e060e63-847c-4918-bdec-402a532beac6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_9e060e63-847c-4918-bdec-402a532beac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_91dae547-f1be-44b5-ace8-a2c26b2da15b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_CostOfSales_91dae547-f1be-44b5-ace8-a2c26b2da15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d4c4f4d6-b339-4810-b96c-9591982314ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_67090d06-ae6c-4b91-84a5-9c352fc39029" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d4c4f4d6-b339-4810-b96c-9591982314ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_2a925bc7-04e3-4d8a-a184-abe71521a95b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_5e2dffd7-730b-4d2e-92b6-9088377d058e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_2a925bc7-04e3-4d8a-a184-abe71521a95b" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_5e2dffd7-730b-4d2e-92b6-9088377d058e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_49b85640-b5a5-4b01-843b-3684cb0e13ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_2a925bc7-04e3-4d8a-a184-abe71521a95b" xlink:to="loc_ifrs-full_FinanceCosts_49b85640-b5a5-4b01-843b-3684cb0e13ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_b741fb01-6486-4c3c-8f69-7fe6f1647e13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_2a925bc7-04e3-4d8a-a184-abe71521a95b" xlink:to="loc_ifrs-full_FinanceIncome_b741fb01-6486-4c3c-8f69-7fe6f1647e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d86731ec-04b6-46e3-89c7-235224ea226b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_516105e9-a828-4dbe-b79c-5a6cb3f79c8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d86731ec-04b6-46e3-89c7-235224ea226b" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_516105e9-a828-4dbe-b79c-5a6cb3f79c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_41964f15-3de8-45ec-87bd-4df978ded351" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_d86731ec-04b6-46e3-89c7-235224ea226b" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_41964f15-3de8-45ec-87bd-4df978ded351" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_fe506df8-db7b-4b47-9fc5-1a209cb82f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a221ee66-5bc0-4fa0-84da-9efda781de87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_fe506df8-db7b-4b47-9fc5-1a209cb82f5a" xlink:to="loc_ifrs-full_ProfitLoss_a221ee66-5bc0-4fa0-84da-9efda781de87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_4f5832da-a1f8-45b9-a305-746f5ddd1169" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_fe506df8-db7b-4b47-9fc5-1a209cb82f5a" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_4f5832da-a1f8-45b9-a305-746f5ddd1169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fd66bdf1-1139-444a-92e6-d12eef6c10f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_c5b7ce48-60c8-4d61-b599-a1473b80b5de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fd66bdf1-1139-444a-92e6-d12eef6c10f0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_c5b7ce48-60c8-4d61-b599-a1473b80b5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_5a835b5b-0dd1-4ee4-bd1c-c3d46be54e2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_fd66bdf1-1139-444a-92e6-d12eef6c10f0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_5a835b5b-0dd1-4ee4-bd1c-c3d46be54e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_256d910b-0ceb-4d18-a6fd-3f2f46ba1ed0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_e27a60a2-39c3-44ca-8701-79924f789e34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_256d910b-0ceb-4d18-a6fd-3f2f46ba1ed0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_e27a60a2-39c3-44ca-8701-79924f789e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d1d12bd0-0d3d-44cd-bd3f-d5780add0547" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_256d910b-0ceb-4d18-a6fd-3f2f46ba1ed0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_d1d12bd0-0d3d-44cd-bd3f-d5780add0547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_8b5a666d-664a-4a41-a4b1-382b328c4064" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_5b580ee3-211c-41c4-b1f8-ea2e8e42d91d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_8b5a666d-664a-4a41-a4b1-382b328c4064" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_5b580ee3-211c-41c4-b1f8-ea2e8e42d91d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofFinancialPosition"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_bc4938eb-08dd-4dcf-ba1f-74db8159a043" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_Inventories_bc4938eb-08dd-4dcf-ba1f-74db8159a043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_66721a2f-1eb1-4048-9a20-23b83ed3ab7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_66721a2f-1eb1-4048-9a20-23b83ed3ab7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_75422bfd-0f14-4baf-a79e-765799f067c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_ContractAssets_75422bfd-0f14-4baf-a79e-765799f067c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_779d8856-5cda-4e65-9708-81957f26745d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_779d8856-5cda-4e65-9708-81957f26745d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialAssets_45b3088b-f36b-4277-a1a7-1d4e42286424" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialAssets_45b3088b-f36b-4277-a1a7-1d4e42286424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_9d6449eb-efbb-4e6c-af4c-5efb15bfde7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_9d6449eb-efbb-4e6c-af4c-5efb15bfde7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_535cbb8c-6b64-4a24-83e8-fcf5856e8478" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_54f808eb-bd9d-4adc-a90b-2019e1e79ae5" xlink:to="loc_ifrs-full_CashAndCashEquivalents_535cbb8c-6b64-4a24-83e8-fcf5856e8478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_aa99829c-c351-4db6-88c5-0ababb6db993" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_aa99829c-c351-4db6-88c5-0ababb6db993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_0baac7e4-2031-4bf9-b5e9-e1dfada30af5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_0baac7e4-2031-4bf9-b5e9-e1dfada30af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_d1fef938-e082-4f38-984f-bfad8963d956" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_DeferredTaxAssets_d1fef938-e082-4f38-984f-bfad8963d956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_8ad4bae3-f444-46d3-a247-b48294c86ab9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_RightofuseAssets_8ad4bae3-f444-46d3-a247-b48294c86ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_3ba14ecc-3dfb-4703-8ca9-2ec50608fa82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_3ba14ecc-3dfb-4703-8ca9-2ec50608fa82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_8aaa99ba-bc52-404b-9040-7639990f6542" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_8aaa99ba-bc52-404b-9040-7639990f6542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_c6d2b28e-68d5-43b8-aef9-d452e948937f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_e1be8559-1bd6-467c-82bc-d1672dc7c414" xlink:to="loc_ifrs-full_Goodwill_c6d2b28e-68d5-43b8-aef9-d452e948937f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_d3fd2a9a-8e8b-4368-b2e3-1d7499816767" xlink:href="bntx-20231231.xsd#bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_d3fd2a9a-8e8b-4368-b2e3-1d7499816767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_3807f9a3-a54e-4516-8f86-87c4f9f324f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_3807f9a3-a54e-4516-8f86-87c4f9f324f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_23175ef6-545d-4520-a822-86c10a9488d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_23175ef6-545d-4520-a822-86c10a9488d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_3d4b0621-71df-4287-b59c-9375aa6cc403" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_3d4b0621-71df-4287-b59c-9375aa6cc403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_848b918e-90b4-46f6-a8bb-7d844658054b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_NoncurrentProvisions_848b918e-90b4-46f6-a8bb-7d844658054b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_ab1e45d2-e9b8-4a7c-9d70-549c60a3c6a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_ab1e45d2-e9b8-4a7c-9d70-549c60a3c6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_4d33878f-e24a-4a26-b21e-f0407b22375b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_ff1ba423-5024-4e4d-8a40-a6498680ab1a" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_4d33878f-e24a-4a26-b21e-f0407b22375b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_e5414da3-3a30-4cbc-a5c6-70650dd55ba1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_CurrentRefundsProvision_e5414da3-3a30-4cbc-a5c6-70650dd55ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_42775145-548e-4937-9c80-35c0ea412fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_CurrentProvisions_42775145-548e-4937-9c80-35c0ea412fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_9b617968-82b5-4b3e-bebf-bcf502b50b28" xlink:href="bntx-20231231.xsd#bntx_CurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_9b617968-82b5-4b3e-bebf-bcf502b50b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_09568893-352b-4b6a-b167-9027f69afc1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_CurrentContractLiabilities_09568893-352b-4b6a-b167-9027f69afc1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_37705605-d808-4064-b2e8-240465fa4e0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_37705605-d808-4064-b2e8-240465fa4e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities_f96eb110-29d5-43d2-b242-1cf0d59a135f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities_f96eb110-29d5-43d2-b242-1cf0d59a135f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_f492000d-74bd-492a-b33d-b79c146d4f00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_f492000d-74bd-492a-b33d-b79c146d4f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_280b9b42-9cd5-4ace-8fe3-d4a7e302b10f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_e4d11770-2e1a-46ad-8243-499494a80abc" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_280b9b42-9cd5-4ace-8fe3-d4a7e302b10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_b0006f9f-6625-420a-bd24-80ec66ba17c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:to="loc_ifrs-full_OtherReserves_b0006f9f-6625-420a-bd24-80ec66ba17c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_b2791bd6-4c74-495c-8566-736deba72f7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:to="loc_ifrs-full_TreasuryShares_b2791bd6-4c74-495c-8566-736deba72f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_ff9fc3e9-2858-4ffa-b698-db66ace89f8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:to="loc_ifrs-full_IssuedCapital_ff9fc3e9-2858-4ffa-b698-db66ace89f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserve_c8adac1a-f32b-48e3-8308-9fc52790da94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:to="loc_ifrs-full_CapitalReserve_c8adac1a-f32b-48e3-8308-9fc52790da94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_c4a2e160-0973-4552-95da-07aeb7db7a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_091af5cf-86db-4e19-ad93-8f155b0464c7" xlink:to="loc_ifrs-full_RetainedEarnings_c4a2e160-0973-4552-95da-07aeb7db7a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_8775dfdd-f24a-4f2a-aa3f-b5bf3b6b8f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_82b11ecc-f8d6-4d1d-913d-ee20997f27c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_8775dfdd-f24a-4f2a-aa3f-b5bf3b6b8f0a" xlink:to="loc_ifrs-full_CurrentLiabilities_82b11ecc-f8d6-4d1d-913d-ee20997f27c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4a805a54-a99e-4930-9441-95e3f126948f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_8775dfdd-f24a-4f2a-aa3f-b5bf3b6b8f0a" xlink:to="loc_ifrs-full_NoncurrentLiabilities_4a805a54-a99e-4930-9441-95e3f126948f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_1afd07ee-d0f2-4e38-904b-9c4a98029eaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_20b8bfca-f8e8-4eec-9421-f3a4274f314a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_1afd07ee-d0f2-4e38-904b-9c4a98029eaa" xlink:to="loc_ifrs-full_Liabilities_20b8bfca-f8e8-4eec-9421-f3a4274f314a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_a8cd3d18-4b63-4625-89d1-50099a8bf817" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_1afd07ee-d0f2-4e38-904b-9c4a98029eaa" xlink:to="loc_ifrs-full_Equity_a8cd3d18-4b63-4625-89d1-50099a8bf817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_16facf29-4716-4d36-a4ba-cbcd98fd365c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_ad802e05-2e60-46bc-b8cf-f6960056f3c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_16facf29-4716-4d36-a4ba-cbcd98fd365c" xlink:to="loc_ifrs-full_NoncurrentAssets_ad802e05-2e60-46bc-b8cf-f6960056f3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_09237171-5f53-4755-92b9-88e60ff8f250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_16facf29-4716-4d36-a4ba-cbcd98fd365c" xlink:to="loc_ifrs-full_CurrentAssets_09237171-5f53-4755-92b9-88e60ff8f250" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_330c8b50-ff4a-4287-b724-138a784d0984" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_330c8b50-ff4a-4287-b724-138a784d0984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_012941d8-4c8d-4620-b61e-3a4f776827fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_012941d8-4c8d-4620-b61e-3a4f776827fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4dae6109-89cb-4a76-a6b6-7b38002872ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_4dae6109-89cb-4a76-a6b6-7b38002872ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_a456709f-4a66-4179-a8e3-c299ac889875" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_a456709f-4a66-4179-a8e3-c299ac889875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_992a3d36-ce89-4878-b3ef-c838c1942488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_992a3d36-ce89-4878-b3ef-c838c1942488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_034c38d7-2176-478a-a562-40e5bed73a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_034c38d7-2176-478a-a562-40e5bed73a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_e1b23385-8315-43a5-bc28-4edffa447741" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_e1b23385-8315-43a5-bc28-4edffa447741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForMovementsInGovernmentGrants_f09f29c7-5cf2-4807-b875-36d715b26ea5" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_bntx_AdjustmentsForMovementsInGovernmentGrants_f09f29c7-5cf2-4807-b875-36d715b26ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a2878bed-da00-40ba-8b43-887c8dc696bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a2878bed-da00-40ba-8b43-887c8dc696bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_911283f0-5168-4385-935c-bd48500e6622" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_911283f0-5168-4385-935c-bd48500e6622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_60009eba-af2d-4bad-b9d6-fc003661cbf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_60009eba-af2d-4bad-b9d6-fc003661cbf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_7a363277-cd10-4609-a000-c621b5433036" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_7a363277-cd10-4609-a000-c621b5433036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_72de5a37-3c29-4817-8caa-d391ee9b5a92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_72de5a37-3c29-4817-8caa-d391ee9b5a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_b4999c34-9c9b-419d-8030-cc51a75bd621" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_b4999c34-9c9b-419d-8030-cc51a75bd621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_2c7593df-37a2-43a8-92e3-91f4479de181" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_2c7593df-37a2-43a8-92e3-91f4479de181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1ae57151-71b2-4cd5-872e-7659408d370b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_1ae57151-71b2-4cd5-872e-7659408d370b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_ac6de986-03d2-4c54-a4aa-8b3772424e0f" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentsClassifiedAsOperatingActivities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_59d48aef-e915-4e81-b998-1ada633f8865" xlink:to="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_ac6de986-03d2-4c54-a4aa-8b3772424e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_4c349aa3-0ce1-4564-92a4-dd29e911e19a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5522b377-fa47-44e8-b9d6-afd84b445266" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_4c349aa3-0ce1-4564-92a4-dd29e911e19a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5522b377-fa47-44e8-b9d6-afd84b445266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b9f11d83-909b-4e4b-bdf7-c26cc889f225" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_4c349aa3-0ce1-4564-92a4-dd29e911e19a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b9f11d83-909b-4e4b-bdf7-c26cc889f225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_eee58758-7df7-48f4-9706-1f74f248aa24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_4c349aa3-0ce1-4564-92a4-dd29e911e19a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_eee58758-7df7-48f4-9706-1f74f248aa24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_9f152e27-f4c7-4ca1-8699-0d8b324bba30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_9f152e27-f4c7-4ca1-8699-0d8b324bba30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_332689a6-0fff-40a7-a535-7971cfdfcb7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_332689a6-0fff-40a7-a535-7971cfdfcb7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_693b3217-665e-4a1f-9ee6-e4754d1653b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_693b3217-665e-4a1f-9ee6-e4754d1653b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_8727abae-3c4b-4a8e-bf57-e9438aa2a9a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_8727abae-3c4b-4a8e-bf57-e9438aa2a9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_ecea7d9b-f4b7-49b1-8535-218f8f870a24" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_ecea7d9b-f4b7-49b1-8535-218f8f870a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_5b7bfd9c-ddc3-4639-9798-25885dda8585" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_795a163c-6de9-47bd-bd9c-d263b21f1723" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_5b7bfd9c-ddc3-4639-9798-25885dda8585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_f14e4558-29df-44c9-b25a-ef77baa90b80" xlink:href="bntx-20231231.xsd#bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_f14e4558-29df-44c9-b25a-ef77baa90b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_dc2074a9-6c23-441d-bed3-aaf019692af9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_dc2074a9-6c23-441d-bed3-aaf019692af9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_7a2103c2-e6b9-424e-8118-5a8158412ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_7a2103c2-e6b9-424e-8118-5a8158412ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_772b0030-210d-441b-a51f-c20b2b7be0f5" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_772b0030-210d-441b-a51f-c20b2b7be0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_66edb978-42e7-40d9-ab32-8869788ed532" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_66edb978-42e7-40d9-ab32-8869788ed532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_5708904e-b8d4-4dac-9b58-d80e5bfcb761" xlink:href="bntx-20231231.xsd#bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_c5a587dd-2d8b-4812-92a2-10453233fdd6" xlink:to="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_5708904e-b8d4-4dac-9b58-d80e5bfcb761" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_296b9be2-538c-44dc-b926-b906265becb4" xlink:href="bntx-20231231.xsd#bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_ae7f2e7a-6b6c-4c09-9dad-a3ed92385f9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_296b9be2-538c-44dc-b926-b906265becb4" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_ae7f2e7a-6b6c-4c09-9dad-a3ed92385f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_72932fc9-99fe-4c4f-b52b-68c708da03e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_296b9be2-538c-44dc-b926-b906265becb4" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_72932fc9-99fe-4c4f-b52b-68c708da03e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_44f50d6f-5a1f-4d1e-bf9f-03d8cb428255" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_e08a1ef2-1ebe-4dbf-be3c-6513ab90b591" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_44f50d6f-5a1f-4d1e-bf9f-03d8cb428255" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_e08a1ef2-1ebe-4dbf-be3c-6513ab90b591" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_ee02a0c7-9984-40da-93c2-c022ab892f8a" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_44f50d6f-5a1f-4d1e-bf9f-03d8cb428255" xlink:to="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_ee02a0c7-9984-40da-93c2-c022ab892f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DesignatedFXHedge_dff1e400-1d66-49e9-b16c-242f2f782c19" xlink:href="bntx-20231231.xsd#bntx_DesignatedFXHedge"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_bntx_DesignatedFXHedge_dff1e400-1d66-49e9-b16c-242f2f782c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_c269fd4d-edfb-453d-a560-501c2e225c96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_c269fd4d-edfb-453d-a560-501c2e225c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_9ff1231f-6f01-4895-8df3-11444435b808" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_ifrs-full_CashTransferred_9ff1231f-6f01-4895-8df3-11444435b808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncurred_8101299a-3b6f-44e1-940b-4a3431e65efd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_ifrs-full_LiabilitiesIncurred_8101299a-3b6f-44e1-940b-4a3431e65efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_87e1fd8e-ad2b-4be6-b0d1-f5cea747d655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_87e1fd8e-ad2b-4be6-b0d1-f5cea747d655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment_0db6bf79-5a87-45e6-a514-7a65824a69b9" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_99da72ac-913e-4e4e-a179-6508fc88da2f" xlink:to="loc_bntx_PreviouslyHeldNonListedEquityInvestment_0db6bf79-5a87-45e6-a514-7a65824a69b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_d2733650-cff6-48f8-8cb5-547f179998a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_da05f410-32fe-43f7-a5f6-7ed9274fe87e" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_d2733650-cff6-48f8-8cb5-547f179998a3" xlink:to="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_da05f410-32fe-43f7-a5f6-7ed9274fe87e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_4e044bd8-b48f-43c9-b4de-92f1af03c714" xlink:href="bntx-20231231.xsd#bntx_AssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_d2733650-cff6-48f8-8cb5-547f179998a3" xlink:to="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_4e044bd8-b48f-43c9-b4de-92f1af03c714" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:href="bntx-20231231.xsd#bntx_AssetsRecognisedAsOfAcquisitionDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_caaa00c2-fab9-4eb1-910f-8b0c7012f7c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_caaa00c2-fab9-4eb1-910f-8b0c7012f7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_f494419c-0e09-4e35-9e76-138478b376f2" xlink:href="bntx-20231231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_f494419c-0e09-4e35-9e76-138478b376f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_a0300ce8-7699-46fd-affc-fc6472a911b9" xlink:href="bntx-20231231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_a0300ce8-7699-46fd-affc-fc6472a911b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_3d0601b0-4335-48e6-ae35-95061b33c19d" xlink:href="bntx-20231231.xsd#bntx_TradeReceivablesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_3d0601b0-4335-48e6-ae35-95061b33c19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_67fba97d-913c-4321-9a2a-99446307d54b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_67fba97d-913c-4321-9a2a-99446307d54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_abe5bf70-7cf2-4510-a0ce-9670ee7f6a00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_abe5bf70-7cf2-4510-a0ce-9670ee7f6a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_835d56c9-02c6-4a59-94ca-a6bf40204247" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_06344e3a-4a32-42a1-9133-b2bd99fbea22" xlink:to="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_835d56c9-02c6-4a59-94ca-a6bf40204247" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesFinanceIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_ca78a6a4-a577-421c-8085-bc9ad08c747f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_9bc04506-9673-4499-a7fa-8a1ba0aa8a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_ca78a6a4-a577-421c-8085-bc9ad08c747f" xlink:to="loc_ifrs-full_NetForeignExchangeGain_9bc04506-9673-4499-a7fa-8a1ba0aa8a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_16af0c4c-baad-4435-8c52-23c4adaabd2c" xlink:href="bntx-20231231.xsd#bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_ca78a6a4-a577-421c-8085-bc9ad08c747f" xlink:to="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_16af0c4c-baad-4435-8c52-23c4adaabd2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_08fc536f-7490-40d1-abdf-5be5e19bfd2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceIncome_ca78a6a4-a577-421c-8085-bc9ad08c747f" xlink:to="loc_ifrs-full_RevenueFromInterest_08fc536f-7490-40d1-abdf-5be5e19bfd2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesFinanceExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_79efc9af-b2a1-4fa5-9b8d-eda63320ccf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_e512606d-84c9-4d4e-ae9a-e0f166fff033" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_79efc9af-b2a1-4fa5-9b8d-eda63320ccf7" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_e512606d-84c9-4d4e-ae9a-e0f166fff033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_beeabf1f-b29f-4415-8e6c-43f11ec1f387" xlink:href="bntx-20231231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_79efc9af-b2a1-4fa5-9b8d-eda63320ccf7" xlink:to="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_beeabf1f-b29f-4415-8e6c-43f11ec1f387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_614bf8f0-11fa-4a60-9ab1-3b4509fe5f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_79efc9af-b2a1-4fa5-9b8d-eda63320ccf7" xlink:to="loc_us-gaap_OtherExpenses_614bf8f0-11fa-4a60-9ab1-3b4509fe5f9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_559d5f41-afc8-4cea-a04e-1513d34cc0b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_9b53ad4b-9156-4d10-b4c4-41d891e43fdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_559d5f41-afc8-4cea-a04e-1513d34cc0b9" xlink:to="loc_ifrs-full_SocialSecurityContributions_9b53ad4b-9156-4d10-b4c4-41d891e43fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_5a84425b-6bc5-472e-a8bd-294dddba9fd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_559d5f41-afc8-4cea-a04e-1513d34cc0b9" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_5a84425b-6bc5-472e-a8bd-294dddba9fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_f2aef8b4-7542-4519-b974-d3c0b96cc58a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_559d5f41-afc8-4cea-a04e-1513d34cc0b9" xlink:to="loc_ifrs-full_WagesAndSalaries_f2aef8b4-7542-4519-b974-d3c0b96cc58a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_62cc641e-e897-42ce-9517-57530a78fd89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_f3ad6fc8-b0e1-4123-a8de-bc2ff0b51d40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_62cc641e-e897-42ce-9517-57530a78fd89" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_f3ad6fc8-b0e1-4123-a8de-bc2ff0b51d40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_dec5421a-b8ad-44ec-aa37-35f1f0c07a89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_62cc641e-e897-42ce-9517-57530a78fd89" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_dec5421a-b8ad-44ec-aa37-35f1f0c07a89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ecf55e0e-00d5-45ab-b4e2-51bfcd09fffc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_ecf55e0e-00d5-45ab-b4e2-51bfcd09fffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_7b16cb6e-48c4-4a27-85c1-e8263fe9c6b6" xlink:href="bntx-20231231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_7b16cb6e-48c4-4a27-85c1-e8263fe9c6b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6fb61eaa-809e-463d-b3f2-643b9474a8df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_6fb61eaa-809e-463d-b3f2-643b9474a8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectiveEquityTransactionCosts_945e0d94-6d28-41de-91a8-0ea785690821" xlink:href="bntx-20231231.xsd#bntx_TaxEffectiveEquityTransactionCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_TaxEffectiveEquityTransactionCosts_945e0d94-6d28-41de-91a8-0ea785690821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_296b693c-8e68-4369-8114-fe4f6b5706e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_296b693c-8e68-4369-8114-fe4f6b5706e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_14701b5b-3ab3-4d2f-8f92-4656455146e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_14701b5b-3ab3-4d2f-8f92-4656455146e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonTaxEffectiveBargainPurchase_ef0f24da-9b61-4230-9995-9ae4fde2f7d7" xlink:href="bntx-20231231.xsd#bntx_NonTaxEffectiveBargainPurchase"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_NonTaxEffectiveBargainPurchase_ef0f24da-9b61-4230-9995-9ae4fde2f7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectNonTaxEffectiveIncome_b7831cf2-bc79-45e5-bb84-076d3b0bb29f" xlink:href="bntx-20231231.xsd#bntx_TaxEffectNonTaxEffectiveIncome"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_TaxEffectNonTaxEffectiveIncome_b7831cf2-bc79-45e5-bb84-076d3b0bb29f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfChangeInValuationAllowance_d07102b9-3eef-4a92-bae2-2d37661df043" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfChangeInValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_TaxEffectOfChangeInValuationAllowance_d07102b9-3eef-4a92-bae2-2d37661df043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_dc073acd-92c5-4b31-8363-7efb054cc10f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_dc073acd-92c5-4b31-8363-7efb054cc10f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_041f6ff5-17e0-4ca6-b1a0-92e740979997" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_041f6ff5-17e0-4ca6-b1a0-92e740979997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_e60c98e5-631b-4174-ab1d-9b90b6c432b1" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfDeviationDueToLocalTaxBasis"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_e60c98e5-631b-4174-ab1d-9b90b6c432b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_a2dc0a6b-f6ef-4414-a315-480b000db67d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f309618-cfc0-4067-b202-b39d93f4dbda" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_a2dc0a6b-f6ef-4414-a315-480b000db67d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_d002eb18-d1f8-478d-95a8-97b06053e17b" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_7278c608-5294-45dc-a5d7-91ae0b4485c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_d002eb18-d1f8-478d-95a8-97b06053e17b" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_7278c608-5294-45dc-a5d7-91ae0b4485c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_1dfa2da5-2f6f-45e8-85fc-90fba4ef6063" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_d002eb18-d1f8-478d-95a8-97b06053e17b" xlink:to="loc_ifrs-full_Goodwill_1dfa2da5-2f6f-45e8-85fc-90fba4ef6063" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d1befef7-d080-4dbf-afb2-942c863ab1a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_837e0a10-2ac5-4043-8a98-f51e445182c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_d1befef7-d080-4dbf-afb2-942c863ab1a6" xlink:to="loc_ifrs-full_CashEquivalents_837e0a10-2ac5-4043-8a98-f51e445182c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_ad5c7084-5d16-43ea-b5c6-3ba20b16d7f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_d1befef7-d080-4dbf-afb2-942c863ab1a6" xlink:to="loc_ifrs-full_Cash_ad5c7084-5d16-43ea-b5c6-3ba20b16d7f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowings_1c09a898-f4a9-4a3b-b0ec-585ef09f3949" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_bntx_InterestBearingLoansAndBorrowings_1c09a898-f4a9-4a3b-b0ec-585ef09f3949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialLiabilities_8a562ebe-c009-4cdb-97ca-32669c8b6193" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_ifrs-full_OtherFinancialLiabilities_8a562ebe-c009-4cdb-97ca-32669c8b6193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_1d6ba251-5cd0-466a-af93-a617c7d6ef54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_ifrs-full_TradeAndOtherPayables_1d6ba251-5cd0-466a-af93-a617c7d6ef54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_0cfa5086-fe78-4a9a-8afc-ff61ed3246ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_0cfa5086-fe78-4a9a-8afc-ff61ed3246ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_8004df56-7599-410f-85b0-c2f94ecdb9eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_ifrs-full_LeaseLiabilities_8004df56-7599-410f-85b0-c2f94ecdb9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_18f9ac7a-e605-4bd3-9316-dca45b885775" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_17870e2a-7936-4a37-aa39-87de697f9eb3" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_18f9ac7a-e605-4bd3-9316-dca45b885775" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_0c5cc15c-6870-44d1-8730-260c72159736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_d11df343-4e44-4a96-9c6b-d8de91f8b9c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_0c5cc15c-6870-44d1-8730-260c72159736" xlink:to="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_d11df343-4e44-4a96-9c6b-d8de91f8b9c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_a5ce87b3-3318-4468-9965-7f643dc5902b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_0c5cc15c-6870-44d1-8730-260c72159736" xlink:to="loc_ifrs-full_FinishedGoods_a5ce87b3-3318-4468-9965-7f643dc5902b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_1d8aa481-7e54-42ed-b323-79561075a0cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_0c5cc15c-6870-44d1-8730-260c72159736" xlink:to="loc_ifrs-full_WorkInProgress_1d8aa481-7e54-42ed-b323-79561075a0cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsSummaryofOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialAssets_e7e19ee6-ef9f-40ae-99f8-1edceec1793d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherCurrentAssetsOther_bbfaed6c-84b6-4eb3-87bb-903861643406" xlink:href="bntx-20231231.xsd#bntx_OtherCurrentAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_e7e19ee6-ef9f-40ae-99f8-1edceec1793d" xlink:to="loc_bntx_OtherCurrentAssetsOther_bbfaed6c-84b6-4eb3-87bb-903861643406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_f871fdd4-30d7-4d32-ba29-4e151e9ae0af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_e7e19ee6-ef9f-40ae-99f8-1edceec1793d" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_f871fdd4-30d7-4d32-ba29-4e151e9ae0af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredExpense_e0110af8-9417-4332-a597-1540cb052719" xlink:href="bntx-20231231.xsd#bntx_DeferredExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_e7e19ee6-ef9f-40ae-99f8-1edceec1793d" xlink:to="loc_bntx_DeferredExpense_e0110af8-9417-4332-a597-1540cb052719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_b149da84-2c99-4c6b-999c-b1a12bb963e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_e7e19ee6-ef9f-40ae-99f8-1edceec1793d" xlink:to="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_b149da84-2c99-4c6b-999c-b1a12bb963e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialAssets_0aae98f1-ca9e-4e1c-ac7a-321c9a95636c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialAssets_9a1a1a04-49a3-4c8a-ae30-4c2dbbd403cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_0aae98f1-ca9e-4e1c-ac7a-321c9a95636c" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialAssets_9a1a1a04-49a3-4c8a-ae30-4c2dbbd403cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_bed0dc0e-f17b-4c83-b5c5-7b13406ded69" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialAssets_0aae98f1-ca9e-4e1c-ac7a-321c9a95636c" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_bed0dc0e-f17b-4c83-b5c5-7b13406ded69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a1b70833-dd83-46ad-8844-5838558a6b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e87acb86-a9d3-425e-b0e5-53ee8b525e57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a1b70833-dd83-46ad-8844-5838558a6b22" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_e87acb86-a9d3-425e-b0e5-53ee8b525e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_beee8a16-fc94-4322-bb9e-5bd602dcdb66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a1b70833-dd83-46ad-8844-5838558a6b22" xlink:to="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_beee8a16-fc94-4322-bb9e-5bd602dcdb66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ProvisionsProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_0ae47caa-c8f6-4774-9920-2c7566d111ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_78be901e-2014-4560-b556-307fd83833eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_0ae47caa-c8f6-4774-9920-2c7566d111ef" xlink:to="loc_ifrs-full_CurrentProvisions_78be901e-2014-4560-b556-307fd83833eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_16e0b08d-fb0d-478c-bba8-aa4a8ebbae43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_0ae47caa-c8f6-4774-9920-2c7566d111ef" xlink:to="loc_ifrs-full_NoncurrentProvisions_16e0b08d-fb0d-478c-bba8-aa4a8ebbae43" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsProvisionsDetails_1"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/ProvisionsProvisionsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_f9d40ba6-b4d4-4da1-9d8b-caf396fa5be5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_1fc3a8dc-512d-4530-b745-86e0d6f2c6a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_f9d40ba6-b4d4-4da1-9d8b-caf396fa5be5" xlink:to="loc_ifrs-full_OtherProvisions_1fc3a8dc-512d-4530-b745-86e0d6f2c6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermOnerousContractsProvision_74ffa93f-deca-4d83-92e6-911bf4ed7447" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_f9d40ba6-b4d4-4da1-9d8b-caf396fa5be5" xlink:to="loc_ifrs-full_ShorttermOnerousContractsProvision_74ffa93f-deca-4d83-92e6-911bf4ed7447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvision_03498522-03f2-46df-8c0a-9a48600620e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvision"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_f9d40ba6-b4d4-4da1-9d8b-caf396fa5be5" xlink:to="loc_ifrs-full_LegalProceedingsProvision_03498522-03f2-46df-8c0a-9a48600620e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialLiabilities_b5789ecb-6ba1-4983-846d-efd64137ab97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_ec6fdb6a-48d5-40e3-bf4f-975388c2f655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_b5789ecb-6ba1-4983-846d-efd64137ab97" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_ec6fdb6a-48d5-40e3-bf4f-975388c2f655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_8ae5938c-6d2d-4a04-808d-b4e71ff44111" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_b5789ecb-6ba1-4983-846d-efd64137ab97" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_8ae5938c-6d2d-4a04-808d-b4e71ff44111" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialLiabilities_caca6db0-6b16-4774-8969-66cec6393296" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_d128742a-fb76-4f57-b53b-04ad1ad4369d" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_caca6db0-6b16-4774-8969-66cec6393296" xlink:to="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_d128742a-fb76-4f57-b53b-04ad1ad4369d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesForEmployeeBenefits_61a159bd-211d-4a6e-8161-727ed04636e2" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesForEmployeeBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_caca6db0-6b16-4774-8969-66cec6393296" xlink:to="loc_bntx_LiabilitiesForEmployeeBenefits_61a159bd-211d-4a6e-8161-727ed04636e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesOther_90cf1d19-1693-4a75-b014-00f8b7137dfc" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_caca6db0-6b16-4774-8969-66cec6393296" xlink:to="loc_bntx_OtherLiabilitiesOther_90cf1d19-1693-4a75-b014-00f8b7137dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_f3f5c1ce-4a57-4d0d-b40e-7e817a9c357a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities_caca6db0-6b16-4774-8969-66cec6393296" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_f3f5c1ce-4a57-4d0d-b40e-7e817a9c357a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_5e3d05cf-6722-4cb4-891a-cfe8e95b9d23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_4900dd9e-7582-455d-8846-c12f10875e31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_5e3d05cf-6722-4cb4-891a-cfe8e95b9d23" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_4900dd9e-7582-455d-8846-c12f10875e31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_44f1f0fc-66c0-49d6-9d2b-3fadeeb22380" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_5e3d05cf-6722-4cb4-891a-cfe8e95b9d23" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_44f1f0fc-66c0-49d6-9d2b-3fadeeb22380" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_56ad145d-acb0-4869-976e-5e860d199f41" xlink:href="bntx-20231231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_d2c6d031-5e7b-43b4-b7ae-02bbfc1742df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_56ad145d-acb0-4869-976e-5e860d199f41" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_d2c6d031-5e7b-43b4-b7ae-02bbfc1742df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_df68f3a6-138c-4bbb-b6b7-cebd8a43ba3e" xlink:href="bntx-20231231.xsd#bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_56ad145d-acb0-4869-976e-5e860d199f41" xlink:to="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_df68f3a6-138c-4bbb-b6b7-cebd8a43ba3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_4ff915e1-f235-41e1-aa0c-2e2dc09c3e02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_56ad145d-acb0-4869-976e-5e860d199f41" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_4ff915e1-f235-41e1-aa0c-2e2dc09c3e02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_da1e7133-d8eb-43bd-97b4-6d0dfd1d9bbd" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:to="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_da1e7133-d8eb-43bd-97b4-6d0dfd1d9bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_b69bf969-ce6f-4123-9c4d-0fc13110d0a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_b69bf969-ce6f-4123-9c4d-0fc13110d0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5b5bb8b1-fa42-4d0b-b3ef-df85edafd9f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5b5bb8b1-fa42-4d0b-b3ef-df85edafd9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_be7ee83e-d604-475c-91ac-08f26a6e04c1" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:to="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_be7ee83e-d604-475c-91ac-08f26a6e04c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_c64a9d06-8d53-4f05-b62f-6d35ae69e1d2" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationOtherVariableCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_fe6d90a7-e356-4457-a74c-2fb268a664cb" xlink:to="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_c64a9d06-8d53-4f05-b62f-6d35ae69e1d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"/>
  <link:calculationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesFromRelatedPartyTransactions_1fca250a-2ee3-43ec-b7a2-78513bad1923" xlink:href="bntx-20231231.xsd#bntx_PurchasesFromRelatedPartyTransactions"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_084a04a7-3d8c-4cc9-b1cb-4653432be44f" xlink:href="bntx-20231231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_PurchasesFromRelatedPartyTransactions_1fca250a-2ee3-43ec-b7a2-78513bad1923" xlink:to="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_084a04a7-3d8c-4cc9-b1cb-4653432be44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_96c3d85d-61f4-4536-8d45-58f9c95b98b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bntx_PurchasesFromRelatedPartyTransactions_1fca250a-2ee3-43ec-b7a2-78513bad1923" xlink:to="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_96c3d85d-61f4-4536-8d45-58f9c95b98b0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>bntx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biontech.de/role/Cover" xlink:type="simple" xlink:href="bntx-20231231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_b97de47b-b566-460c-a42d-6e6b277deb16_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:to="loc_dei_AddressTypeDomain_b97de47b-b566-460c-a42d-6e6b277deb16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:to="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_1f60fd51-6e93-46bb-ba99-b716830cb041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:to="loc_dei_BusinessContactMember_1f60fd51-6e93-46bb-ba99-b716830cb041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_5fb7da3d-2626-47c1-a225-095a748894d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_5fb7da3d-2626-47c1-a225-095a748894d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_11a047b9-f5aa-4e0b-95e8-82c9a7bba454" xlink:href="bntx-20231231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:to="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_11a047b9-f5aa-4e0b-95e8-82c9a7bba454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_88d18602-0967-4b92-a03d-33ffae25b1e1" xlink:href="bntx-20231231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:to="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_88d18602-0967-4b92-a03d-33ffae25b1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f940e6f8-9d52-419d-9605-515770af849f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentType_f940e6f8-9d52-419d-9605-515770af849f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_64888ad9-e064-4c28-aede-110412f14308" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentRegistrationStatement_64888ad9-e064-4c28-aede-110412f14308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_52d6fe01-a5fa-4aee-8153-c5460060eaf6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentAnnualReport_52d6fe01-a5fa-4aee-8153-c5460060eaf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a6174770-98b2-40c1-927e-2cdec73ae5d0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentPeriodEndDate_a6174770-98b2-40c1-927e-2cdec73ae5d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_58949b55-4db9-44f0-b96d-56f31f568a9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_CurrentFiscalYearEndDate_58949b55-4db9-44f0-b96d-56f31f568a9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4c2b83df-a983-41c8-a959-d84ad29ee444" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentTransitionReport_4c2b83df-a983-41c8-a959-d84ad29ee444" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_5ee64a2f-0550-45fa-944e-45d0e7785829" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentShellCompanyReport_5ee64a2f-0550-45fa-944e-45d0e7785829" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ec17492a-663c-4022-b61e-f10b6da08009" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityFileNumber_ec17492a-663c-4022-b61e-f10b6da08009" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0bcab9aa-b3fa-4f46-89bb-9dc1af6222d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityRegistrantName_0bcab9aa-b3fa-4f46-89bb-9dc1af6222d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_35fbf416-c0b7-4386-915b-fe518c842d8e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_35fbf416-c0b7-4386-915b-fe518c842d8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_47601776-1c6c-4f6c-a39e-df45d10fca2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressAddressLine1_47601776-1c6c-4f6c-a39e-df45d10fca2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8453de4f-21a3-4278-bd98-9adddf3ca73f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressPostalZipCode_8453de4f-21a3-4278-bd98-9adddf3ca73f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8cf81ff2-ba95-402f-8e61-88c6372f2b37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressCityOrTown_8cf81ff2-ba95-402f-8e61-88c6372f2b37" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_367cc283-1d42-414c-a0b1-cadeaf067da4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressCountry_367cc283-1d42-414c-a0b1-cadeaf067da4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_2f38e7d5-9b2b-4a87-8a3a-ba72b4e8cd94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelName_2f38e7d5-9b2b-4a87-8a3a-ba72b4e8cd94" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7d845005-5d6d-48f1-bf9e-33c1e5b41048" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_CityAreaCode_7d845005-5d6d-48f1-bf9e-33c1e5b41048" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9f2fbda2-e4c1-4768-badd-650a5fe36477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_LocalPhoneNumber_9f2fbda2-e4c1-4768-badd-650a5fe36477" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber_df21908a-f26b-4399-a7cd-6d950f3ce7cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelFaxNumber_df21908a-f26b-4399-a7cd-6d950f3ce7cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_45ff6881-fc37-4924-bdf5-dfed1f20af2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelEmailAddress_45ff6881-fc37-4924-bdf5-dfed1f20af2d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1ab00546-af32-4244-b705-55ca8f8c7679" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_Security12bTitle_1ab00546-af32-4244-b705-55ca8f8c7679" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_42e6dba9-13e5-4a78-8b2e-9269c29ad1d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_TradingSymbol_42e6dba9-13e5-4a78-8b2e-9269c29ad1d7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2059b9bd-f720-47a5-b321-f5b838d10f1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_SecurityExchangeName_2059b9bd-f720-47a5-b321-f5b838d10f1f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_430ba38c-7613-4880-b5c3-451a026d80ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_430ba38c-7613-4880-b5c3-451a026d80ec" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e5d11895-ec22-432b-8582-af0887796531" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e5d11895-ec22-432b-8582-af0887796531" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_714b6d2f-8c4c-4c8a-8d48-f9ccbc447509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityVoluntaryFilers_714b6d2f-8c4c-4c8a-8d48-f9ccbc447509" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_42693b3d-e82c-4662-ad6e-39c8be4fc9a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCurrentReportingStatus_42693b3d-e82c-4662-ad6e-39c8be4fc9a8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_38f3db6c-703d-41e4-894a-3578d466046c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityInteractiveDataCurrent_38f3db6c-703d-41e4-894a-3578d466046c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_45dd1635-ed51-4636-8dc5-44d3f85d85ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityFilerCategory_45dd1635-ed51-4636-8dc5-44d3f85d85ac" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6b10a9e8-b0e3-41d0-98f1-c3f92e4147d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityEmergingGrowthCompany_6b10a9e8-b0e3-41d0-98f1-c3f92e4147d6" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_449d640b-1514-4200-bf17-d957a6ce9709" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_449d640b-1514-4200-bf17-d957a6ce9709" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6f4ee5a2-d044-4d34-b444-089a30a93e72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6f4ee5a2-d044-4d34-b444-089a30a93e72" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_88b866c8-aeee-4970-a666-f525fe04e7cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentAccountingStandard_88b866c8-aeee-4970-a666-f525fe04e7cb" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d3feae36-5aaf-49bb-8b66-912cb8bc525a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityShellCompany_d3feae36-5aaf-49bb-8b66-912cb8bc525a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f9406ad3-dcd0-44e2-83cc-ff5e7814aa37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_AmendmentFlag_f9406ad3-dcd0-44e2-83cc-ff5e7814aa37" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3149f7d7-18c1-4468-8d61-dabdcd8693e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3149f7d7-18c1-4468-8d61-dabdcd8693e7" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9fd02def-24f7-4415-8c2f-eea215dd0ee5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFiscalYearFocus_9fd02def-24f7-4415-8c2f-eea215dd0ee5" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e2e3bb48-1420-427f-a801-e7f7190be2c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCentralIndexKey_e2e3bb48-1420-427f-a801-e7f7190be2c4" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_a6c6251d-43ed-4a37-a25d-f839c924f476" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_NoTradingSymbolFlag_a6c6251d-43ed-4a37-a25d-f839c924f476" xlink:type="arc" order="37"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofProfitorLoss"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:to="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:to="loc_srt_ProductsAndServicesDomain_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:to="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_561a26d0-6138-477a-91c2-fba4e1633678" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:to="loc_bntx_CommercialMember_561a26d0-6138-477a-91c2-fba4e1633678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentMember_e97c3d0c-0ac0-47e2-93ae-c33e4b4233ed" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:to="loc_bntx_ResearchAndDevelopmentMember_e97c3d0c-0ac0-47e2-93ae-c33e4b4233ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_6effa19e-97ea-4cc1-9983-926eb8eb3170" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_6effa19e-97ea-4cc1-9983-926eb8eb3170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_211d6573-4865-4bac-aa5a-777b45af7a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_CostOfSales_211d6573-4865-4bac-aa5a-777b45af7a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2ec45905-cb4d-4a07-9281-e120c16134d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2ec45905-cb4d-4a07-9281-e120c16134d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_3364150a-0b33-43c1-a236-e06937e08792" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_3364150a-0b33-43c1-a236-e06937e08792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_3b937bc9-7b21-42a5-a1a5-96bcdefd6606" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_3b937bc9-7b21-42a5-a1a5-96bcdefd6606" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_eb330817-abeb-4557-8567-5b2be8740d4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_eb330817-abeb-4557-8567-5b2be8740d4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d17148c7-ca08-4961-a724-9a0f60d87a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d17148c7-ca08-4961-a724-9a0f60d87a26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0d2faa8a-fdf0-4d01-a69d-ece2dc6072b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_0d2faa8a-fdf0-4d01-a69d-ece2dc6072b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_5603c912-3f1c-4aab-aba9-4be2b5c89906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_FinanceIncome_5603c912-3f1c-4aab-aba9-4be2b5c89906" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_613a4bab-b894-4f94-9fb0-904b28ba2f8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_FinanceCosts_613a4bab-b894-4f94-9fb0-904b28ba2f8d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_397f7eab-5fde-440f-9c85-269dc67d47b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_397f7eab-5fde-440f-9c85-269dc67d47b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b20076ef-4cad-484a-b133-7a8eefb46af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b20076ef-4cad-484a-b133-7a8eefb46af4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9f35363e-73de-4481-9dd2-c7675fc2bb86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLoss_9f35363e-73de-4481-9dd2-c7675fc2bb86" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_4d4cd1ad-c72d-439e-81cd-479b47164de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_4d4cd1ad-c72d-439e-81cd-479b47164de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_4f1be671-78af-49c8-ab6d-ba6b427eeb68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_4f1be671-78af-49c8-ab6d-ba6b427eeb68" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_c59a4958-0722-4c92-b773-f3f67aafa5dc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:to="loc_ifrs-full_EquityMember_c59a4958-0722-4c92-b773-f3f67aafa5dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:to="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_5065226d-7422-4111-8ef2-30ba682049f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_IssuedCapitalMember_5065226d-7422-4111-8ef2-30ba682049f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_eed39d03-b0e3-4604-81cd-196c47cf197a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_CapitalReserveMember_eed39d03-b0e3-4604-81cd-196c47cf197a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_c8fafc6d-1b32-4551-82c4-d1aa8767ead6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_TreasurySharesMember_c8fafc6d-1b32-4551-82c4-d1aa8767ead6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_954ef36e-a846-47d7-9d30-89f6b7c3795c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_954ef36e-a846-47d7-9d30-89f6b7c3795c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_654d3673-9288-4a8e-a364-ae6f75fbf4a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_OtherReservesMember_654d3673-9288-4a8e-a364-ae6f75fbf4a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_dde3d587-85cc-4a9f-8aad-e758b7739a9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_Equity_dde3d587-85cc-4a9f-8aad-e758b7739a9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3c154eff-ddf6-4aa0-8ae6-d9751b133d5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ProfitLoss_3c154eff-ddf6-4aa0-8ae6-d9751b133d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_9d72b3c2-0ab0-47a5-9d39-02738b785e59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_9d72b3c2-0ab0-47a5-9d39-02738b785e59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_407c9b43-f2a5-40f9-a5dd-e2ebeba75c06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ComprehensiveIncome_407c9b43-f2a5-40f9-a5dd-e2ebeba75c06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IssuanceOfShareCapital_bab85a33-449f-4dbc-bc18-9db6b21b600b" xlink:href="bntx-20231231.xsd#bntx_IssuanceOfShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_IssuanceOfShareCapital_bab85a33-449f-4dbc-bc18-9db6b21b600b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_67df4890-5420-4582-b5ff-c57805eb5c01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_IssueOfEquity_67df4890-5420-4582-b5ff-c57805eb5c01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RedemptionOfConvertibleNote_126c4df3-15f7-4e9b-8ef2-c8d0df404c16" xlink:href="bntx-20231231.xsd#bntx_RedemptionOfConvertibleNote"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_RedemptionOfConvertibleNote_126c4df3-15f7-4e9b-8ef2-c8d0df404c16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_89a977ff-e6d0-49b6-a5c4-54bf7468eade" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_89a977ff-e6d0-49b6-a5c4-54bf7468eade" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0c869a0e-9e1e-4a73-a80e-00b75c390eb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0c869a0e-9e1e-4a73-a80e-00b75c390eb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid_78fae470-46a7-4e98-8a27-1baf5b7d9363" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_DividendsPaid_78fae470-46a7-4e98-8a27-1baf5b7d9363" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_99ac86fd-14f7-4f3c-84f7-f5996afbc106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_99ac86fd-14f7-4f3c-84f7-f5996afbc106" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentAndDeferredTaxExpenseIncome_f8c0e3b3-cebd-4035-addd-f8dcbccb0e07" xlink:href="bntx-20231231.xsd#bntx_CurrentAndDeferredTaxExpenseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_CurrentAndDeferredTaxExpenseIncome_f8c0e3b3-cebd-4035-addd-f8dcbccb0e07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_bc12f4bf-a9de-47b3-8ac3-b96490f77228" xlink:href="bntx-20231231.xsd#bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_bc12f4bf-a9de-47b3-8ac3-b96490f77228" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d46149bd-a478-4073-846e-bb9a87d7a92a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_fcfd316a-9e8a-4580-a383-c9c30ddf2982_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_fcfd316a-9e8a-4580-a383-c9c30ddf2982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanMember_222d98fe-1675-4d84-b94b-1bd2294a7f62" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_EmployeeEquityPlanMember_222d98fe-1675-4d84-b94b-1bd2294a7f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_ea521ed9-573a-482a-ae75-8dadffc878b5" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_ManagementBoardGrantMember_ea521ed9-573a-482a-ae75-8dadffc878b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_7ef8c680-0117-4d20-a8f5-f8337dfd3a11" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_7ef8c680-0117-4d20-a8f5-f8337dfd3a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_09b71e0d-4888-486d-b4c4-2bca8ea8f958" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_09b71e0d-4888-486d-b4c4-2bca8ea8f958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_3d47f66a-9e2e-4c24-84e9-dbad5b8a9832" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_3d47f66a-9e2e-4c24-84e9-dbad5b8a9832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c05f801e-7638-4d96-8e1e-412d0d85c002" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c05f801e-7638-4d96-8e1e-412d0d85c002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2c941d71-d657-4bca-8c22-1d9856b1c480" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2c941d71-d657-4bca-8c22-1d9856b1c480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_3d64a982-41ea-4116-a6ff-2507bf1680c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_3d64a982-41ea-4116-a6ff-2507bf1680c9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_dc1fb471-0b75-46c8-98d1-72aec1950b8a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_dc1fb471-0b75-46c8-98d1-72aec1950b8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OperatingAndBusinessEquipmentMember_16b9fb94-9e7d-400f-95e5-ddc8ecc1638e" xlink:href="bntx-20231231.xsd#bntx_OperatingAndBusinessEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:to="loc_bntx_OperatingAndBusinessEquipmentMember_16b9fb94-9e7d-400f-95e5-ddc8ecc1638e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:to="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a31a081a-83c0-4fd6-8139-8315f59fe471_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:to="loc_ifrs-full_RangesMember_a31a081a-83c0-4fd6-8139-8315f59fe471_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:to="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e2f4555b-5842-410a-9bc6-693f6c6b8ff5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:to="loc_ifrs-full_BottomOfRangeMember_e2f4555b-5842-410a-9bc6-693f6c6b8ff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2020b107-329a-4cdb-b3ff-a7b4b2677f2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:to="loc_ifrs-full_TopOfRangeMember_2020b107-329a-4cdb-b3ff-a7b4b2677f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_683ee720-67c9-437f-b2e5-e306f3691191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_683ee720-67c9-437f-b2e5-e306f3691191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_ed69cf2d-7ea8-4026-83b8-66c9cd7ec228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_ed69cf2d-7ea8-4026-83b8-66c9cd7ec228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_af57c4cc-18c7-42ae-8b42-9f72ead05e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_af57c4cc-18c7-42ae-8b42-9f72ead05e22" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a16b3aed-1065-4410-887e-4320f0e4cdde_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_a16b3aed-1065-4410-887e-4320f0e4cdde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntellectualPropertyRightsMember_03ce48c8-e94e-4d15-b0da-02a535dbae68" xlink:href="bntx-20231231.xsd#bntx_IntellectualPropertyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_bntx_IntellectualPropertyRightsMember_03ce48c8-e94e-4d15-b0da-02a535dbae68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_8782cac5-4dee-482e-b70f-fa0b096f2aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_ifrs-full_LicencesMember_8782cac5-4dee-482e-b70f-fa0b096f2aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_53df2f55-26dd-49f9-b12a-7c89541b3545" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_ifrs-full_ComputerSoftwareMember_53df2f55-26dd-49f9-b12a-7c89541b3545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:to="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a4389651-b5d5-4c3f-8927-56972cee7cd3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:to="loc_ifrs-full_RangesMember_a4389651-b5d5-4c3f-8927-56972cee7cd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:to="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c2555de1-4bd3-4752-8ba9-961b04a4092c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:to="loc_ifrs-full_BottomOfRangeMember_c2555de1-4bd3-4752-8ba9-961b04a4092c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_5d995be5-3f12-4524-ab15-6f12279fbd62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:to="loc_ifrs-full_TopOfRangeMember_5d995be5-3f12-4524-ab15-6f12279fbd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_fea23f77-432a-4890-a84f-d6a2ca1ab4b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_fea23f77-432a-4890-a84f-d6a2ca1ab4b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_5faa75d8-239a-4d5a-9168-433b2cd915ff_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_5faa75d8-239a-4d5a-9168-433b2cd915ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_fc38ac56-71fb-4d2f-847c-4b901b25f255" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:to="loc_ifrs-full_BuildingsMember_fc38ac56-71fb-4d2f-847c-4b901b25f255" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_059a7eaf-26fc-4835-aafd-07ea59ff5bc3" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_059a7eaf-26fc-4835-aafd-07ea59ff5bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:to="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:to="loc_ifrs-full_RangesMember_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:to="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_085844b1-6b31-4642-a7e4-35fa61d3714c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:to="loc_ifrs-full_BottomOfRangeMember_085844b1-6b31-4642-a7e4-35fa61d3714c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_7b3044b6-b0e7-442d-9e82-c31baeb6a89e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:to="loc_ifrs-full_TopOfRangeMember_7b3044b6-b0e7-442d-9e82-c31baeb6a89e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_7c07e51c-d7db-4749-b906-f24450652d59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_7c07e51c-d7db-4749-b906-f24450652d59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_b4cdb0d8-65ee-48c1-954c-8a304c65a559" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_ifrs-full_BuildingsMember_b4cdb0d8-65ee-48c1-954c-8a304c65a559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_38242689-c666-4d33-89d6-309a8c582229" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_38242689-c666-4d33-89d6-309a8c582229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_4e17f9d4-fbc2-46f9-9eaf-f0173d39d3e0" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_bntx_ProductionFacilitiesMember_4e17f9d4-fbc2-46f9-9eaf-f0173d39d3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_72b5ea8a-00ea-4a29-bc03-e881502bf6a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_ifrs-full_VehiclesMember_72b5ea8a-00ea-4a29-bc03-e881502bf6a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:to="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_f24d23a3-dd22-4bc0-91b1-6589385bf6b0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:to="loc_ifrs-full_RangesMember_f24d23a3-dd22-4bc0-91b1-6589385bf6b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:to="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_67416008-7ed0-4480-a7dc-bd7f4338a26e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:to="loc_ifrs-full_BottomOfRangeMember_67416008-7ed0-4480-a7dc-bd7f4338a26e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_68f86ceb-fe96-4d8f-a91e-4a91994ea868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:to="loc_ifrs-full_TopOfRangeMember_68f86ceb-fe96-4d8f-a91e-4a91994ea868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_9f748a6f-210e-4506-a069-37b88c985298" xlink:href="bntx-20231231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:to="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_9f748a6f-210e-4506-a069-37b88c985298" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutSubsidiariesDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_5bee3310-91dc-489d-b2ea-c238463dc6f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_5bee3310-91dc-489d-b2ea-c238463dc6f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechBioNTainerHoldingGmbHMember_24b41b47-bc3e-438d-87e0-04aa53e3c61a" xlink:href="bntx-20231231.xsd#bntx_BioNTechBioNTainerHoldingGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechBioNTainerHoldingGmbHMember_24b41b47-bc3e-438d-87e0-04aa53e3c61a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechCellGeneTherapiesGmbHMember_9f6eddb8-0044-4768-ad37-4eca8cd17654" xlink:href="bntx-20231231.xsd#bntx_BioNTechCellGeneTherapiesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechCellGeneTherapiesGmbHMember_9f6eddb8-0044-4768-ad37-4eca8cd17654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember_548f4443-821c-4cc4-a9d9-911c851b9d01" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember_548f4443-821c-4cc4-a9d9-911c851b9d01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDiagnosticsGmbHMember_ca91ea21-4cee-4c46-8a8d-5eca25b05969" xlink:href="bntx-20231231.xsd#bntx_BioNTechDiagnosticsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDiagnosticsGmbHMember_ca91ea21-4cee-4c46-8a8d-5eca25b05969" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEuropeGmbHMember_5b1bc2db-eabe-409b-b2b0-3619c675d7bc" xlink:href="bntx-20231231.xsd#bntx_BioNTechEuropeGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechEuropeGmbHMember_5b1bc2db-eabe-409b-b2b0-3619c675d7bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIdarObersteinServicesGmbHMember_a3f34aa6-5dab-4f60-9468-cdaef46dbf10" xlink:href="bntx-20231231.xsd#bntx_BioNTechIdarObersteinServicesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechIdarObersteinServicesGmbHMember_a3f34aa6-5dab-4f60-9468-cdaef46dbf10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_5f457845-a54d-4a0c-98f2-e232e1e595d2" xlink:href="bntx-20231231.xsd#bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_5f457845-a54d-4a0c-98f2-e232e1e595d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_32838915-28da-45f2-9192-c9f2148ea101" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationAndServicesMarburgGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_32838915-28da-45f2-9192-c9f2148ea101" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationGmbHMember_0201b697-c620-491c-87eb-00572f05b95d" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovationGmbHMember_0201b697-c620-491c-87eb-00572f05b95d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_7c9ef032-47b7-40db-800b-ad41ebe83ad2" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_7c9ef032-47b7-40db-800b-ad41ebe83ad2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingGmbHMember_a53a6ab0-8542-4ab3-821c-69fab1428b1a" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechManufacturingGmbHMember_a53a6ab0-8542-4ab3-821c-69fab1428b1a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingMarburgGmbHMember_342e1955-10ea-4a1e-84fd-9f2d1c0c9cb9" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechManufacturingMarburgGmbHMember_342e1955-10ea-4a1e-84fd-9f2d1c0c9cb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateHoldingGmbHMember_129267fb-3de3-4b54-834f-e764ce9f08d6" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRealEstateHoldingGmbHMember_129267fb-3de3-4b54-834f-e764ce9f08d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember_d72015a7-deb4-41c0-8dce-ccf3f52f9380" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember_d72015a7-deb4-41c0-8dce-ccf3f52f9380" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepDEGmbHMember_8b79f707-125c-42a9-a45d-cb2bb989bae4" xlink:href="bntx-20231231.xsd#bntx_InstaDeepDEGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepDEGmbHMember_8b79f707-125c-42a9-a45d-cb2bb989bae4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesGmbHMember_2ec47add-3a8e-4d59-b72b-92d791616914" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_JPTPeptideTechnologiesGmbHMember_2ec47add-3a8e-4d59-b72b-92d791616914" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NTSecurityAndServicesGmbHMember_718438d4-259b-4891-a3a7-ea5158178487" xlink:href="bntx-20231231.xsd#bntx_NTSecurityAndServicesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_NTSecurityAndServicesGmbHMember_718438d4-259b-4891-a3a7-ea5158178487" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReSanoGmbHMember_77dbca6f-04c2-41c2-b4e9-d706de367414" xlink:href="bntx-20231231.xsd#bntx_ReSanoGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_ReSanoGmbHMember_77dbca6f-04c2-41c2-b4e9-d706de367414" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechAustraliaPtyLtd.Member_e0dd6ff7-c3f7-418d-9ad6-4a51c865ce38" xlink:href="bntx-20231231.xsd#bntx_BioNTechAustraliaPtyLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechAustraliaPtyLtd.Member_e0dd6ff7-c3f7-418d-9ad6-4a51c865ce38" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRDAustriaGmbHMember_23eb24e5-df4e-4b1b-bbae-f45f7e648369" xlink:href="bntx-20231231.xsd#bntx_BioNTechRDAustriaGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRDAustriaGmbHMember_23eb24e5-df4e-4b1b-bbae-f45f7e648369" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_0838ae0b-1ac8-4706-945a-594065722ee9" xlink:href="bntx-20231231.xsd#bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_0838ae0b-1ac8-4706-945a-594065722ee9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepFranceSASMember_105b480f-5536-4ec7-9931-4974a7969391" xlink:href="bntx-20231231.xsd#bntx_InstaDeepFranceSASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepFranceSASMember_105b480f-5536-4ec7-9931-4974a7969391" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiopharmaBioNTechIsraelLtd.Member_f5a123fd-0ad9-4cbf-be39-883be51f2236" xlink:href="bntx-20231231.xsd#bntx_BiopharmaBioNTechIsraelLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BiopharmaBioNTechIsraelLtd.Member_f5a123fd-0ad9-4cbf-be39-883be51f2236" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NewTechnologiesReMember_60e71280-3adc-4913-8d80-955737bf4f7f" xlink:href="bntx-20231231.xsd#bntx_NewTechnologiesReMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_NewTechnologiesReMember_60e71280-3adc-4913-8d80-955737bf4f7f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepNigeriaLimitedMember_5bd5fc56-05a5-4149-acbf-dcfc4a60d5c0" xlink:href="bntx-20231231.xsd#bntx_InstaDeepNigeriaLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepNigeriaLimitedMember_5bd5fc56-05a5-4149-acbf-dcfc4a60d5c0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRwandaLtd.Member_4cd34503-fe14-4752-850b-2ec4d01cf20e" xlink:href="bntx-20231231.xsd#bntx_BioNTechRwandaLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRwandaLtd.Member_4cd34503-fe14-4752-850b-2ec4d01cf20e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSenegalSuarlMember_0f4f0e8a-49fa-4ace-8f6f-b28d740f3c30" xlink:href="bntx-20231231.xsd#bntx_BioNTechSenegalSuarlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechSenegalSuarlMember_0f4f0e8a-49fa-4ace-8f6f-b28d740f3c30" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_6d1f10c9-50f8-4125-b649-410ae3efe05b" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_6d1f10c9-50f8-4125-b649-410ae3efe05b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember_9dfc6b34-9266-4923-9ae7-e9bcbbdfc0b3" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsSpainS.LMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember_9dfc6b34-9266-4923-9ae7-e9bcbbdfc0b3" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSwitzerlandGmbHMember_b9b7401e-2519-435b-9381-2364551a549e" xlink:href="bntx-20231231.xsd#bntx_BioNTechSwitzerlandGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechSwitzerlandGmbHMember_b9b7401e-2519-435b-9381-2364551a549e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTaiwanCo.Ltd.Member_f8f6a074-d6ba-49d7-aaac-fca3c6ea9ace" xlink:href="bntx-20231231.xsd#bntx_BioNTechTaiwanCo.Ltd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechTaiwanCo.Ltd.Member_f8f6a074-d6ba-49d7-aaac-fca3c6ea9ace" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepTunisiaSARLMember_78d1bd93-087b-4d3b-b00b-0f3547f0b626" xlink:href="bntx-20231231.xsd#bntx_InstaDeepTunisiaSARLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepTunisiaSARLMember_78d1bd93-087b-4d3b-b00b-0f3547f0b626" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_b06ce18e-e477-4d9c-a83a-432a10ddc55c" xlink:href="bntx-20231231.xsd#bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_b06ce18e-e477-4d9c-a83a-432a10ddc55c" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUKLtd.Member_2998e566-7c23-4247-892b-524695860e42" xlink:href="bntx-20231231.xsd#bntx_BioNTechUKLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUKLtd.Member_2998e566-7c23-4247-892b-524695860e42" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtd.Member_b006bc7a-4e7f-4eee-b59f-e3e65b8a3e31" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepLtd.Member_b006bc7a-4e7f-4eee-b59f-e3e65b8a3e31" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechResearchAndDevelopmentInc.Member_8bb93fd8-1333-46a2-8b23-d6faa3996856" xlink:href="bntx-20231231.xsd#bntx_BioNTechResearchAndDevelopmentInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechResearchAndDevelopmentInc.Member_8bb93fd8-1333-46a2-8b23-d6faa3996856" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSAHoldingLLCMember_3a858f44-6ddd-4ebd-8f0b-9b455a44a138" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSAHoldingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUSAHoldingLLCMember_3a858f44-6ddd-4ebd-8f0b-9b455a44a138" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSInc.Member_5fe1fa50-c571-4495-b554-c1ce4a4fea19" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUSInc.Member_5fe1fa50-c571-4495-b554-c1ce4a4fea19" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember_c55a093b-9e5e-4946-b5d0-a8c81f433ca6" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesUSLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember_c55a093b-9e5e-4946-b5d0-a8c81f433ca6" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLLCMember_83431bb7-468d-4583-8ef8-8347039fd1ba" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepLLCMember_83431bb7-468d-4583-8ef8-8347039fd1ba" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesInc.Member_c91651c9-e1f9-4320-b287-22b0f5fbc6bb" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_JPTPeptideTechnologiesInc.Member_c91651c9-e1f9-4320-b287-22b0f5fbc6bb" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_a8a8fbbe-3dfd-4f28-b414-bd5f828ec8e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_a8a8fbbe-3dfd-4f28-b414-bd5f828ec8e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutParentCompanyDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:to="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:to="loc_srt_OwnershipDomain_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:to="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechMember_838c5f1e-e1c0-4ea4-8463-c05dd63a96fe" xlink:href="bntx-20231231.xsd#bntx_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:to="loc_bntx_BioNTechMember_838c5f1e-e1c0-4ea4-8463-c05dd63a96fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATImpfGmbHMember_3a34bc3f-9216-423e-964f-85f31dec399e" xlink:href="bntx-20231231.xsd#bntx_ATImpfGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:to="loc_bntx_ATImpfGmbHMember_3a34bc3f-9216-423e-964f-85f31dec399e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_59cac306-71e6-4126-8650-55d53ff9f05b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_59cac306-71e6-4126-8650-55d53ff9f05b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:to="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3802c116-e11c-4d09-950c-b3031ca1db66_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:to="loc_srt_OwnershipDomain_3802c116-e11c-4d09-950c-b3031ca1db66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:to="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechMember_f2e287bf-613b-4741-9b03-5867c70c0a02" xlink:href="bntx-20231231.xsd#bntx_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:to="loc_bntx_BioNTechMember_f2e287bf-613b-4741-9b03-5867c70c0a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_957e7417-9e93-4cd6-bd81-fbf777947000_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_957e7417-9e93-4cd6-bd81-fbf777947000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedineGmbHMember_b43439fd-80ad-463d-81f1-b0200e2c8d93" xlink:href="bntx-20231231.xsd#bntx_MedineGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:to="loc_bntx_MedineGmbHMember_b43439fd-80ad-463d-81f1-b0200e2c8d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_0ec62471-a296-499d-b7f1-6f0f001d995e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_0ec62471-a296-499d-b7f1-6f0f001d995e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8c1e7a49-5506-4f53-8df6-9c0f31bd2184_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8c1e7a49-5506-4f53-8df6-9c0f31bd2184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtdMember_f38f013c-d238-4961-bc4e-020d7dbc3d96" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:to="loc_bntx_InstaDeepLtdMember_f38f013c-d238-4961-bc4e-020d7dbc3d96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_4122f6ba-62ae-413c-a37e-4e269d5a5ba2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:to="loc_ifrs-full_RangesMember_4122f6ba-62ae-413c-a37e-4e269d5a5ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:to="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d6c8ae-fdcd-4a90-8eb2-32e30d4bc705" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:to="loc_srt_MaximumMember_d5d6c8ae-fdcd-4a90-8eb2-32e30d4bc705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiperiodExcessEarningsMethodMember_b1785a1f-03ea-4583-8c7b-60abd55703a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiperiodExcessEarningsMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:to="loc_ifrs-full_MultiperiodExcessEarningsMethodMember_b1785a1f-03ea-4583-8c7b-60abd55703a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_d3c64262-2e4c-47d6-866b-3e1f7c979db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_d3c64262-2e4c-47d6-866b-3e1f7c979db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_05ac4f11-df2c-409a-afd7-199a52ade7c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_05ac4f11-df2c-409a-afd7-199a52ade7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_dab25fea-33c5-47a9-b119-c3e8552cb9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_dab25fea-33c5-47a9-b119-c3e8552cb9b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_bd145f8b-76a9-4e5e-9331-465e62ebe4b1" xlink:href="bntx-20231231.xsd#bntx_EquityMethodInvestmentsOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_bd145f8b-76a9-4e5e-9331-465e62ebe4b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares_bdd73602-1a99-4f6d-b514-bfa428223288" xlink:href="bntx-20231231.xsd#bntx_PercentageOfConsiderationTransferredAcquiredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares_bdd73602-1a99-4f6d-b514-bfa428223288" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment_46895f61-8a54-45f6-b998-7aec16573665" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_PreviouslyHeldNonListedEquityInvestment_46895f61-8a54-45f6-b998-7aec16573665" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_64cc01e5-c2c8-47fc-a1d4-4c2a38e93883" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_64cc01e5-c2c8-47fc-a1d4-4c2a38e93883" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_c902e443-4ffb-4414-93dd-313c50828c94" xlink:href="bntx-20231231.xsd#bntx_ConsideredRemunerationOfPotentialEarnOutPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_c902e443-4ffb-4414-93dd-313c50828c94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_e99046ab-4dd3-4e9a-942f-62133c3809ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_e99046ab-4dd3-4e9a-942f-62133c3809ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_834a2fc7-0b5b-4576-863f-734a5acdcc28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_834a2fc7-0b5b-4576-863f-734a5acdcc28" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtdMember_d578d85b-7122-4c8d-b4d6-aaaf468af1f7" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:to="loc_bntx_InstaDeepLtdMember_d578d85b-7122-4c8d-b4d6-aaaf468af1f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_b42b6f23-e947-4c05-8e79-61f58184ce70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_b42b6f23-e947-4c05-8e79-61f58184ce70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_4f1cb06e-b6ae-4c52-bc2f-9d963a8c01bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_4f1cb06e-b6ae-4c52-bc2f-9d963a8c01bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_6ae8aeac-fd6f-4c0d-9ac9-f59c5cb115ef" xlink:href="bntx-20231231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_6ae8aeac-fd6f-4c0d-9ac9-f59c5cb115ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_d5082f91-e0a8-4206-88b8-966e95bdd000" xlink:href="bntx-20231231.xsd#bntx_TradeReceivablesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_d5082f91-e0a8-4206-88b8-966e95bdd000" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_179ed190-1629-4c1b-9c67-4b9dc1829245" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_179ed190-1629-4c1b-9c67-4b9dc1829245" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_a8fcc34b-3935-4019-95e2-dcb56f883df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_a8fcc34b-3935-4019-95e2-dcb56f883df5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_72acecbd-55be-4f9d-bcab-2f6fd022b980" xlink:href="bntx-20231231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_72acecbd-55be-4f9d-bcab-2f6fd022b980" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_1aa29a1a-fc4d-4610-8b52-a507934aaaab" xlink:href="bntx-20231231.xsd#bntx_AssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_1aa29a1a-fc4d-4610-8b52-a507934aaaab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_00e7b499-9aa1-48f1-b37b-95c92bcb7f6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_00e7b499-9aa1-48f1-b37b-95c92bcb7f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_817cdf75-aa58-4d16-be79-a3bc5a19985e" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_817cdf75-aa58-4d16-be79-a3bc5a19985e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_1b7a80e5-aef9-42c8-a043-96f1e3ca6d27" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_1b7a80e5-aef9-42c8-a043-96f1e3ca6d27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_8c4ef723-1f16-4805-bad2-3ea53bb62d48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_8c4ef723-1f16-4805-bad2-3ea53bb62d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_fcb89924-ad82-4445-aba4-d048d47c325d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_fcb89924-ad82-4445-aba4-d048d47c325d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_a00e232d-7682-474d-b5c9-bfc6971f972d" xlink:href="bntx-20231231.xsd#bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_a00e232d-7682-474d-b5c9-bfc6971f972d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_919dad76-8c3f-4eda-8886-184ee7d66c61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_CashTransferred_919dad76-8c3f-4eda-8886-184ee7d66c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncurred_c4bf0f36-c0ab-4e65-ad8d-040e90dec9e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_LiabilitiesIncurred_c4bf0f36-c0ab-4e65-ad8d-040e90dec9e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DesignatedFXHedge_8759cf2d-6a6c-4f1f-9d17-49e53077ee9e" xlink:href="bntx-20231231.xsd#bntx_DesignatedFXHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_bntx_DesignatedFXHedge_8759cf2d-6a6c-4f1f-9d17-49e53077ee9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_fd899f3a-cb33-4726-841f-6a4aa86853dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_fd899f3a-cb33-4726-841f-6a4aa86853dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_82b52491-6045-4ef4-a594-a32f524ae639" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_82b52491-6045-4ef4-a594-a32f524ae639" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment_31850498-524d-4f81-8b7c-9044d1fa55af" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_bntx_PreviouslyHeldNonListedEquityInvestment_31850498-524d-4f81-8b7c-9044d1fa55af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_f870e796-8046-4111-a0ce-75cbefa7a477" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_f870e796-8046-4111-a0ce-75cbefa7a477" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1c677034-072e-4661-b6fa-96025dc309bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1c677034-072e-4661-b6fa-96025dc309bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_dddfb631-aa7d-4725-8a0c-eabac5c8722c" xlink:href="bntx-20231231.xsd#bntx_EquityMethodInvestmentsOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_dddfb631-aa7d-4725-8a0c-eabac5c8722c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3707326-1b1f-44ce-9810-d256deab10ca_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:to="loc_srt_ProductsAndServicesDomain_d3707326-1b1f-44ce-9810-d256deab10ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:to="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_f6f58210-417d-41ff-a146-c457e860f809" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:to="loc_bntx_CommercialMember_f6f58210-417d-41ff-a146-c457e860f809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentMember_38d4fc1c-f26d-468f-bb5e-1c7ce373677c" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:to="loc_bntx_ResearchAndDevelopmentMember_38d4fc1c-f26d-468f-bb5e-1c7ce373677c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_2c2eeccb-938c-4211-8aff-9803f07a612f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:to="loc_ifrs-full_MajorCustomersMember_2c2eeccb-938c-4211-8aff-9803f07a612f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:to="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:to="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_63fdfbfd-0742-4f61-b536-92800002cf12" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineSalesToCollaborationPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_63fdfbfd-0742-4f61-b536-92800002cf12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_ab1fe550-f44d-4513-a374-5584e924be5b" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineDirectProductSalesToCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_ab1fe550-f44d-4513-a374-5584e924be5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_93ffcb20-635e-4762-8c2e-baadad93b62f" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_93ffcb20-635e-4762-8c2e-baadad93b62f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherSalesMember_89e4b40b-8407-4630-b9c4-3cb15cfdea92" xlink:href="bntx-20231231.xsd#bntx_OtherSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:to="loc_bntx_OtherSalesMember_89e4b40b-8407-4630-b9c4-3cb15cfdea92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_74f7f991-5a61-40d2-b40f-174548ecb5ce_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_74f7f991-5a61-40d2-b40f-174548ecb5ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_6482eb08-8454-4b30-a0a1-06e1eb0bac35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_6482eb08-8454-4b30-a0a1-06e1eb0bac35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_c2a0b951-baf6-40b3-814d-83d4e7559915" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_c2a0b951-baf6-40b3-814d-83d4e7559915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_d7b05769-b29d-49a9-9bb2-4cb334b394d9" xlink:href="bntx-20231231.xsd#bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_d7b05769-b29d-49a9-9bb2-4cb334b394d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_29617cdd-8a19-4505-93e3-e8fa14d72428" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_29617cdd-8a19-4505-93e3-e8fa14d72428" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_c933ac67-7522-45ec-8233-19895be3dc2d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:to="loc_ifrs-full_MajorCustomersMember_c933ac67-7522-45ec-8233-19895be3dc2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:to="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerIncMember_afe5a9b8-4ac4-4873-8d40-6fce67a09e7d" xlink:href="bntx-20231231.xsd#bntx_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerIncMember_afe5a9b8-4ac4-4873-8d40-6fce67a09e7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GermanFederalMinistryOfHealthMember_b042194c-b466-4143-a823-fecd2004be12" xlink:href="bntx-20231231.xsd#bntx_GermanFederalMinistryOfHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_GermanFederalMinistryOfHealthMember_b042194c-b466-4143-a823-fecd2004be12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_0409f5ad-900e-4fd7-b34e-3a66ff37f049" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineSalesToCollaborationPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_0409f5ad-900e-4fd7-b34e-3a66ff37f049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_c517b2fe-4e1a-45fb-b013-3afb7ab8f61a" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineDirectProductSalesToCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_c517b2fe-4e1a-45fb-b013-3afb7ab8f61a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_280cb5de-4b54-4ba2-92c6-a1218139995c" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_280cb5de-4b54-4ba2-92c6-a1218139995c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerCOVID19VaccineMember_37dff228-ce7e-4b14-92b9-51ec9db6a262" xlink:href="bntx-20231231.xsd#bntx_PfizerCOVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerCOVID19VaccineMember_37dff228-ce7e-4b14-92b9-51ec9db6a262" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerZosterMember_cc201fb1-3d16-42db-b42c-a638aeaff401" xlink:href="bntx-20231231.xsd#bntx_PfizerZosterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerZosterMember_cc201fb1-3d16-42db-b42c-a638aeaff401" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2659d23-ad48-483e-9855-b5e45a194a05_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:to="loc_srt_SegmentGeographicalDomain_c2659d23-ad48-483e-9855-b5e45a194a05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:to="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_93417b32-5c05-4d33-85f7-035cc6d476bd" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_US_93417b32-5c05-4d33-85f7-035cc6d476bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f4bcea8e-f3a1-47c0-b74b-d2403cad63f8" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_DE_f4bcea8e-f3a1-47c0-b74b-d2403cad63f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE_dd1aacf3-da82-4afc-9599-83d0293ef2be" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_BE_dd1aacf3-da82-4afc-9599-83d0293ef2be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38d32f12-37b2-4c76-bed0-dcb4703c1287_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:to="loc_srt_ProductsAndServicesDomain_38d32f12-37b2-4c76-bed0-dcb4703c1287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:to="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_94512a3f-8fcb-48bd-9ec5-003dd665e5a3" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:to="loc_bntx_CommercialMember_94512a3f-8fcb-48bd-9ec5-003dd665e5a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_cb26c0b4-b148-4694-94a4-6a29610c5a0f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_cb26c0b4-b148-4694-94a4-6a29610c5a0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManufacturingVariancesMember_43eb85c3-b073-417a-b626-a9f1a8728808" xlink:href="bntx-20231231.xsd#bntx_ManufacturingVariancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:to="loc_bntx_ManufacturingVariancesMember_43eb85c3-b073-417a-b626-a9f1a8728808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_a1718a1c-f65d-482d-95ea-09e851a7603a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_a1718a1c-f65d-482d-95ea-09e851a7603a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_a940b702-80a5-402c-92b6-d671607b454c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_ifrs-full_ContractLiabilities_a940b702-80a5-402c-92b6-d671607b454c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RemainingUpfrontFeesContractLiabilities_307562fe-0e5d-41fa-bcac-8086e980ffc1" xlink:href="bntx-20231231.xsd#bntx_RemainingUpfrontFeesContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_bntx_RemainingUpfrontFeesContractLiabilities_307562fe-0e5d-41fa-bcac-8086e980ffc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_37a71acc-4e17-4888-ac28-b0f7100a8abe" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_37a71acc-4e17-4888-ac28-b0f7100a8abe" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:to="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:to="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_921465de-4746-4e7c-896e-bc6c24b4aada_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:to="loc_ifrs-full_PerformanceObligationsMember_921465de-4746-4e7c-896e-bc6c24b4aada_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:to="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_a9afebb6-6448-4002-9621-f10a9023870b" xlink:href="bntx-20231231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:to="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_a9afebb6-6448-4002-9621-f10a9023870b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:to="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_ad2b566d-98de-4cc5-9363-c21d7196a74e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_ad2b566d-98de-4cc5-9363-c21d7196a74e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_f09f5e58-6fa3-4302-88c6-7f29332ff91b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_f09f5e58-6fa3-4302-88c6-7f29332ff91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_6af3d5f9-184d-4772-abae-023f4a52d3be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:to="loc_ifrs-full_LaterThanOneYearMember_6af3d5f9-184d-4772-abae-023f4a52d3be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6438f4a2-f859-4e73-a5df-13e2b48140ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:to="loc_ifrs-full_ContractLiabilities_6438f4a2-f859-4e73-a5df-13e2b48140ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:to="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d42c0900-77a0-434c-ae42-f5f605023a49_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:to="loc_srt_RangeMember_d42c0900-77a0-434c-ae42-f5f605023a49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:to="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbf08dc5-4acb-4281-bae1-bc154a8cab7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:to="loc_srt_MaximumMember_fbf08dc5-4acb-4281-bae1-bc154a8cab7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:to="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1b848cae-dee2-4d7a-91bd-4be32c529550_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:to="loc_srt_ProductsAndServicesDomain_1b848cae-dee2-4d7a-91bd-4be32c529550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:to="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_6a199833-6eef-4405-b828-5e00ce9564b9" xlink:href="bntx-20231231.xsd#bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:to="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_6a199833-6eef-4405-b828-5e00ce9564b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseCostOfSales_2a2680cb-eee6-4fb3-a2a6-ba7c8beb34aa" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseCostOfSales_2a2680cb-eee6-4fb3-a2a6-ba7c8beb34aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfCostOfSales_89b17f4d-1aed-4b2d-9351-943563dc4158" xlink:href="bntx-20231231.xsd#bntx_PercentageOfCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfCostOfSales_89b17f4d-1aed-4b2d-9351-943563dc4158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_49763f77-e017-46ec-b7ae-2431a3756e9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_CostOfSales_49763f77-e017-46ec-b7ae-2431a3756e9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfInventories_6395f1cf-c2fd-4480-bf39-5b286c341d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_WritedownsReversalsOfInventories_6395f1cf-c2fd-4480-bf39-5b286c341d1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_d2f72363-6116-4aa5-969c-323cc96d751d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_Inventories_d2f72363-6116-4aa5-969c-323cc96d751d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_4389c8b3-4d79-4b44-92ac-7f7f668da3c4" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_4389c8b3-4d79-4b44-92ac-7f7f668da3c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfResearchAndDevelopmentExpense_48d56245-c737-4138-b12b-919ad63a44ff" xlink:href="bntx-20231231.xsd#bntx_PercentageOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfResearchAndDevelopmentExpense_48d56245-c737-4138-b12b-919ad63a44ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_5b8a94de-1dfe-4f4c-8643-5b93d965421b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_5b8a94de-1dfe-4f4c-8643-5b93d965421b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_fcfa3d21-cc3f-44ae-b674-db818dad62d0" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfSalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_fcfa3d21-cc3f-44ae-b674-db818dad62d0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfSalesAndMarketingExpense_30529242-4f62-4a47-bcf1-4f1a0ba61315" xlink:href="bntx-20231231.xsd#bntx_PercentageOfSalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfSalesAndMarketingExpense_30529242-4f62-4a47-bcf1-4f1a0ba61315" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_0022712c-1b36-4808-8acb-146d796492cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_0022712c-1b36-4808-8acb-146d796492cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_3434a8d0-14a6-4a8a-8c67-30c9a7941e4e" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_3434a8d0-14a6-4a8a-8c67-30c9a7941e4e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfGeneralAndAdministrativeExpense_ad6417f9-2c29-4362-ba0f-d4fb567109bf" xlink:href="bntx-20231231.xsd#bntx_PercentageOfGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfGeneralAndAdministrativeExpense_ad6417f9-2c29-4362-ba0f-d4fb567109bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f9040609-1a08-4bec-9f2b-2af33d61fa1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f9040609-1a08-4bec-9f2b-2af33d61fa1e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_a469e895-5de7-4b88-8ec7-2ffbc00b5969" xlink:href="bntx-20231231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_a469e895-5de7-4b88-8ec7-2ffbc00b5969" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesOtherOperatingExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:to="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_a32bd76f-9b9a-424b-9f2d-2b30b62d5410_default" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_a32bd76f-9b9a-424b-9f2d-2b30b62d5410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignExchangeDifferencesMember_fe5b9c4b-a568-4bf5-9ae2-a82be6d93c91" xlink:href="bntx-20231231.xsd#bntx_ForeignExchangeDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_ForeignExchangeDifferencesMember_fe5b9c4b-a568-4bf5-9ae2-a82be6d93c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember_9dede62a-8a26-4b2f-bf13-cc473f823c4b" xlink:href="bntx-20231231.xsd#bntx_LossOnDerivativeInstrumentsAtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember_9dede62a-8a26-4b2f-bf13-cc473f823c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LitigationCostsMember_4eb8b4db-ac2c-4c02-9f5c-49629c8346bb" xlink:href="bntx-20231231.xsd#bntx_LitigationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_LitigationCostsMember_4eb8b4db-ac2c-4c02-9f5c-49629c8346bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherIncomeExpenseMember_1487b8d8-960c-4158-a14d-10a4fbf98c49" xlink:href="bntx-20231231.xsd#bntx_OtherIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_OtherIncomeExpenseMember_1487b8d8-960c-4158-a14d-10a4fbf98c49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_1a6fe1a5-a6d9-4c45-b0a4-487da551c90d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_1a6fe1a5-a6d9-4c45-b0a4-487da551c90d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesOtherOperatingIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:to="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_08883bb4-1a28-4d4d-836b-beef9c1bd2eb_default" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_08883bb4-1a28-4d4d-836b-beef9c1bd2eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_34676fff-6378-4fa0-9b3c-91ecff2ae123" xlink:href="bntx-20231231.xsd#bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_34676fff-6378-4fa0-9b3c-91ecff2ae123" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GovernmentGrantsMember_593be800-4843-4475-b5aa-92217d417b06" xlink:href="bntx-20231231.xsd#bntx_GovernmentGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_GovernmentGrantsMember_593be800-4843-4475-b5aa-92217d417b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignExchangeDifferencesMember_df3ac741-894c-4669-a696-dac73c37f490" xlink:href="bntx-20231231.xsd#bntx_ForeignExchangeDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_ForeignExchangeDifferencesMember_df3ac741-894c-4669-a696-dac73c37f490" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherIncomeExpenseMember_634e8305-b3f7-47a3-b5a1-b40bc79574cf" xlink:href="bntx-20231231.xsd#bntx_OtherIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_OtherIncomeExpenseMember_634e8305-b3f7-47a3-b5a1-b40bc79574cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_b4232360-19f6-43ec-a5e2-1c89e46d3854" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_b4232360-19f6-43ec-a5e2-1c89e46d3854" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_16479e19-583f-450e-9051-ccaa51c70f9f" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_16479e19-583f-450e-9051-ccaa51c70f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5c6cbcb9-6d42-436f-a2b1-4699cfac4653_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:to="loc_ifrs-full_CarryingAmountMember_5c6cbcb9-6d42-436f-a2b1-4699cfac4653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:to="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ValuationAdjustmentMember_57dc6ff3-de6f-4b06-ad4d-50effb023c68" xlink:href="bntx-20231231.xsd#bntx_ValuationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:to="loc_bntx_ValuationAdjustmentMember_57dc6ff3-de6f-4b06-ad4d-50effb023c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_edb2f932-5b79-4e8c-888d-9a84986b3d8b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:to="loc_srt_SegmentGeographicalDomain_edb2f932-5b79-4e8c-888d-9a84986b3d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:to="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AT_f3c7435a-a77b-4416-8315-825e4795329f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:to="loc_country_AT_f3c7435a-a77b-4416-8315-825e4795329f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4745284-4dc2-42d0-88fd-038a105c2176" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:to="loc_country_US_c4745284-4dc2-42d0-88fd-038a105c2176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_a2ac210e-4af4-4f41-9b93-77b3339b2c26_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_a2ac210e-4af4-4f41-9b93-77b3339b2c26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_323e0157-1204-4547-a61a-456cf6284a8b" xlink:href="bntx-20231231.xsd#bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_323e0157-1204-4547-a61a-456cf6284a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_66aec35c-1b23-402d-81b3-7781b9d0967b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_66aec35c-1b23-402d-81b3-7781b9d0967b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_d8b4c68c-2e6e-4cb8-b451-2bb6b75a91ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_d8b4c68c-2e6e-4cb8-b451-2bb6b75a91ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CorporateTaxRate_97bc718a-3fcb-40a5-83d9-3dfd2e82d6aa" xlink:href="bntx-20231231.xsd#bntx_CorporateTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_CorporateTaxRate_97bc718a-3fcb-40a5-83d9-3dfd2e82d6aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SolidaritySurchargeRate_72c9a7bd-9497-404e-a4ba-0332b44aaf0a" xlink:href="bntx-20231231.xsd#bntx_SolidaritySurchargeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_SolidaritySurchargeRate_72c9a7bd-9497-404e-a4ba-0332b44aaf0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_2268072e-3a59-476d-8e28-1eff538010bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_ApplicableTaxRate_2268072e-3a59-476d-8e28-1eff538010bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxRateOnDeferredTaxes_33bec5d5-3d2d-4aaa-b607-21607dce4b70" xlink:href="bntx-20231231.xsd#bntx_TaxRateOnDeferredTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_TaxRateOnDeferredTaxes_33bec5d5-3d2d-4aaa-b607-21607dce4b70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DecreaseInCorporateTaxRate_a6fa5ae0-c5e5-4412-a7ba-ada2c3277153" xlink:href="bntx-20231231.xsd#bntx_DecreaseInCorporateTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_DecreaseInCorporateTaxRate_a6fa5ae0-c5e5-4412-a7ba-ada2c3277153" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalCorporateIncomeTax_f25d2973-f2c8-4e00-85be-13a9f3bb4635" xlink:href="bntx-20231231.xsd#bntx_FederalCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_FederalCorporateIncomeTax_f25d2973-f2c8-4e00-85be-13a9f3bb4635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_6293eb7a-ad1c-4f09-8921-315f908d3275" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_6293eb7a-ad1c-4f09-8921-315f908d3275" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxAssetsSettlement_e6ece0c4-e95e-4a8e-bbf2-dcdfa66ba77f" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxAssetsSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_DeferredTaxAssetsSettlement_e6ece0c4-e95e-4a8e-bbf2-dcdfa66ba77f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_8ca8d3a5-80f3-4a4c-99be-6d409f4100fd" xlink:href="bntx-20231231.xsd#bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_8ca8d3a5-80f3-4a4c-99be-6d409f4100fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_c293ed64-2863-478b-b176-cec4ffc31c29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_DeferredTaxAssets_c293ed64-2863-478b-b176-cec4ffc31c29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_2918fbb3-0ea6-4cab-a104-64fafd17cc82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_2918fbb3-0ea6-4cab-a104-64fafd17cc82" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_9b1bdc39-5f47-4695-a89f-beea49c6dbf3" xlink:href="bntx-20231231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_9b1bdc39-5f47-4695-a89f-beea49c6dbf3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_205ff075-63bb-42d9-aaf6-66aae818f76e" xlink:href="bntx-20231231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_205ff075-63bb-42d9-aaf6-66aae818f76e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_8679eb52-0dd4-4594-b989-da6effeda83d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_8679eb52-0dd4-4594-b989-da6effeda83d" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofDeferredTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2000ae92-76b9-4334-a67f-1a8fb074bf0f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2000ae92-76b9-4334-a67f-1a8fb074bf0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FixedAssetsMember_4d1fa5fe-cffb-4ca1-b709-df682af03125" xlink:href="bntx-20231231.xsd#bntx_FixedAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_FixedAssetsMember_4d1fa5fe-cffb-4ca1-b709-df682af03125" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_5b2e942d-7c6b-42fc-a38e-97eaaca2d9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_RightofuseAssetsMember_5b2e942d-7c6b-42fc-a38e-97eaaca2d9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Inventories1Member_74323195-3527-44e3-b20f-a723428e67a0" xlink:href="bntx-20231231.xsd#bntx_Inventories1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_Inventories1Member_74323195-3527-44e3-b20f-a723428e67a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeAndOtherReceivablesMember_4f7a0367-e84d-4aef-b677-886a936ec0f0" xlink:href="bntx-20231231.xsd#bntx_TradeAndOtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_TradeAndOtherReceivablesMember_4f7a0367-e84d-4aef-b677-886a936ec0f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_54f2d788-e5ce-4b74-af41-af1195845f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_54f2d788-e5ce-4b74-af41-af1195845f0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContractLiabilitiesMember_4420119b-2338-4aac-8b5f-831f41a6e66f" xlink:href="bntx-20231231.xsd#bntx_ContractLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ContractLiabilitiesMember_4420119b-2338-4aac-8b5f-831f41a6e66f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LoansAndBorrowingsMember_41316e63-66d5-471c-9bf0-b4eb71ffa695" xlink:href="bntx-20231231.xsd#bntx_LoansAndBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_LoansAndBorrowingsMember_41316e63-66d5-471c-9bf0-b4eb71ffa695" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_186c9cd3-54ec-4402-bd74-056661c9e007" xlink:href="bntx-20231231.xsd#bntx_NetEmployeeDefinedBenefitLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_186c9cd3-54ec-4402-bd74-056661c9e007" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_98b02f18-3252-40d7-a7ab-33b3d1d758a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_98b02f18-3252-40d7-a7ab-33b3d1d758a3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_d42622fd-35b4-49b8-a884-9c5aee952b67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_OtherProvisionsMember_d42622fd-35b4-49b8-a884-9c5aee952b67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherDeferredTaxesMember_ecb6daa4-ffbe-4db4-99dd-22f3b4fd97af" xlink:href="bntx-20231231.xsd#bntx_OtherDeferredTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_OtherDeferredTaxesMember_ecb6daa4-ffbe-4db4-99dd-22f3b4fd97af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_af58243b-1b7c-431a-a950-70b107bd7783" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_af58243b-1b7c-431a-a950-70b107bd7783" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxAssetsMember_bc40e820-21b2-4664-8d9b-e7a9d8b1741b" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ThereofDeferredTaxAssetsMember_bc40e820-21b2-4664-8d9b-e7a9d8b1741b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxLiabilityMember_92120bd7-98f3-4f62-94be-f53aa4020465" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ThereofDeferredTaxLiabilityMember_92120bd7-98f3-4f62-94be-f53aa4020465" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_0a4b506f-2794-49c3-8017-1eee6fe017ad_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:to="loc_ifrs-full_CarryingAmountMember_0a4b506f-2794-49c3-8017-1eee6fe017ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:to="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_99f47c06-86ce-421e-87fd-574590e14873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_99f47c06-86ce-421e-87fd-574590e14873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ValuationAdjustmentMember_afcfc724-1fce-488b-a083-22a021a21aca" xlink:href="bntx-20231231.xsd#bntx_ValuationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:to="loc_bntx_ValuationAdjustmentMember_afcfc724-1fce-488b-a083-22a021a21aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_82e7445d-9ad2-45fe-8087-43d1637ae0d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_82e7445d-9ad2-45fe-8087-43d1637ae0d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_433cb6d0-6bff-4d28-8d0a-a930885568c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_433cb6d0-6bff-4d28-8d0a-a930885568c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_92fbd6d5-090f-4e5b-a6fb-41d60002fa22" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_92fbd6d5-090f-4e5b-a6fb-41d60002fa22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_37ca5025-2983-4291-98fd-567d1982dce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_37ca5025-2983-4291-98fd-567d1982dce1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_666a5ea3-4ff8-4a18-80c3-da70e41f56cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_666a5ea3-4ff8-4a18-80c3-da70e41f56cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_3ebd17fd-f910-4812-8d55-8a3d21ffd935" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_3d340300-51c0-4d75-a9fc-f59a505aa472_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:to="loc_ifrs-full_CarryingAmountMember_3d340300-51c0-4d75-a9fc-f59a505aa472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:to="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1cd4cb30-7ddd-469d-8074-3d47ceef5418" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1cd4cb30-7ddd-469d-8074-3d47ceef5418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_d06e0efd-1d1d-47bd-a7cb-7b794190e235_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_d06e0efd-1d1d-47bd-a7cb-7b794190e235_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_daf921ce-9c49-4323-844d-d1d4d2ef4069" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:to="loc_ifrs-full_GoodwillMember_daf921ce-9c49-4323-844d-d1d4d2ef4069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_da39ef9a-4340-4ec0-8bff-01c15316b393" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_da39ef9a-4340-4ec0-8bff-01c15316b393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_12677b16-403c-4c10-9add-ec37ca09f310" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_12677b16-403c-4c10-9add-ec37ca09f310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_0984ac2c-4a5c-4cec-946e-e127d6138c43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_0984ac2c-4a5c-4cec-946e-e127d6138c43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_f96c6861-e70a-4e8b-9aa3-f0a2597bbcb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_54eae171-f1f7-4c94-ab04-079b018c4e05_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_54eae171-f1f7-4c94-ab04-079b018c4e05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CGUImmunotherapiesMember_7c6be174-cdc7-40f9-b2e1-14789fee674f" xlink:href="bntx-20231231.xsd#bntx_CGUImmunotherapiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_CGUImmunotherapiesMember_7c6be174-cdc7-40f9-b2e1-14789fee674f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalProductSalesToJPTMember_424d98d1-f735-4309-a14b-82dc3d58c621" xlink:href="bntx-20231231.xsd#bntx_ExternalProductSalesToJPTMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_ExternalProductSalesToJPTMember_424d98d1-f735-4309-a14b-82dc3d58c621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalBusinessOfInstaDeepMember_24db7810-7b3c-4000-a6eb-9e23bc6b0aa1" xlink:href="bntx-20231231.xsd#bntx_ExternalBusinessOfInstaDeepMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_ExternalBusinessOfInstaDeepMember_24db7810-7b3c-4000-a6eb-9e23bc6b0aa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_85329ae0-f172-4578-ad66-c2fcd3c8374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_ifrs-full_Goodwill_85329ae0-f172-4578-ad66-c2fcd3c8374c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_3927c462-0f75-40af-ae4d-2d3c288382c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_3927c462-0f75-40af-ae4d-2d3c288382c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_5aa1b7a8-f687-40cc-a43c-fb894399b1c3" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_5aa1b7a8-f687-40cc-a43c-fb894399b1c3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DualityBiologicsSuzhouCoLtdMember_07aacf81-2c0f-4303-bd4a-b2ead313f636" xlink:href="bntx-20231231.xsd#bntx_DualityBiologicsSuzhouCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_DualityBiologicsSuzhouCoLtdMember_07aacf81-2c0f-4303-bd4a-b2ead313f636" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OncoC4IncMember_e704432d-10c9-47de-af26-5fb975635d41" xlink:href="bntx-20231231.xsd#bntx_OncoC4IncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_OncoC4IncMember_e704432d-10c9-47de-af26-5fb975635d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_bf1a4756-3c87-4078-a964-cf16bb686b2b" xlink:href="bntx-20231231.xsd#bntx_MedilinkTherapeuticsSuzhouCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_bf1a4756-3c87-4078-a964-cf16bb686b2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiotheusIncMember_dff3d59c-d227-4473-a2c7-011ccad049de" xlink:href="bntx-20231231.xsd#bntx_BiotheusIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_BiotheusIncMember_dff3d59c-d227-4473-a2c7-011ccad049de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4b07306b-980f-4911-b57b-2c0a03130f22_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_4b07306b-980f-4911-b57b-2c0a03130f22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeepChainTechnologyMember_9c94e068-0a3b-43d6-8695-9dfc2c9d512f" xlink:href="bntx-20231231.xsd#bntx_DeepChainTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:to="loc_bntx_DeepChainTechnologyMember_9c94e068-0a3b-43d6-8695-9dfc2c9d512f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_c55dc062-9e9d-4db4-a87b-9236d94d788a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_Goodwill_c55dc062-9e9d-4db4-a87b-9236d94d788a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_5f5f7632-1522-4308-aa45-1d5aa8ac2104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_5f5f7632-1522-4308-aa45-1d5aa8ac2104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPayment_70db2fb6-133c-4295-8a3a-54bf85954db2" xlink:href="bntx-20231231.xsd#bntx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_UpfrontPayment_70db2fb6-133c-4295-8a3a-54bf85954db2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_778a150f-4b39-4734-b96b-92c7fb42094d" xlink:href="bntx-20231231.xsd#bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_778a150f-4b39-4734-b96b-92c7fb42094d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_40f83b8e-671d-4514-9715-86b77a5bf7b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_40f83b8e-671d-4514-9715-86b77a5bf7b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_025a3b58-d709-4a99-aa8a-9a22a74ccab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_025a3b58-d709-4a99-aa8a-9a22a74ccab1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PrepaymentForFutureDevelopmentActivities_9353602b-2f80-41d3-ae51-9cf038082e84" xlink:href="bntx-20231231.xsd#bntx_PrepaymentForFutureDevelopmentActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_PrepaymentForFutureDevelopmentActivities_9353602b-2f80-41d3-ae51-9cf038082e84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_af77ac91-1f5f-49d8-bb34-bbd873cb8d9d" xlink:href="bntx-20231231.xsd#bntx_UpfrontPaymentAcquisitionOfIntangibleAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_af77ac91-1f5f-49d8-bb34-bbd873cb8d9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_dd61ce83-14ff-40b7-a088-c4c9a60ec1f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_dd61ce83-14ff-40b7-a088-c4c9a60ec1f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_4432ac2c-97d9-462d-9f16-8effde2de42a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_4432ac2c-97d9-462d-9f16-8effde2de42a" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_5fc05b64-076f-489b-abb4-0ae6711f19dc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_5fc05b64-076f-489b-abb4-0ae6711f19dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_3e3ebb28-359f-4d49-aa82-4d59de588506" xlink:href="bntx-20231231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:to="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_3e3ebb28-359f-4d49-aa82-4d59de588506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentsMember_8840712a-2710-4dfb-a0da-f658c809b843" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:to="loc_bntx_AdvancePaymentsMember_8840712a-2710-4dfb-a0da-f658c809b843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_9e4bdf3d-7385-4897-9e35-96946bd110a9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:to="loc_ifrs-full_CarryingAmountMember_9e4bdf3d-7385-4897-9e35-96946bd110a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:to="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_dfff7538-eef5-48ac-aeaf-6086ad3f1ca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_dfff7538-eef5-48ac-aeaf-6086ad3f1ca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_36401b4a-e3b9-4ea3-9de3-ce6627d1fb79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_36401b4a-e3b9-4ea3-9de3-ce6627d1fb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_1a001cb2-4cc5-484e-8046-4b4dbbfccc9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_1a001cb2-4cc5-484e-8046-4b4dbbfccc9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ce3d19c4-b403-4129-aa3c-46da4d2bc2ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ce3d19c4-b403-4129-aa3c-46da4d2bc2ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_e50f9674-9267-4fbe-9fdc-cc2d75ce42a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_e50f9674-9267-4fbe-9fdc-cc2d75ce42a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_c4fcf1bb-2b90-4cb0-8033-fe11a7e73843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_c4fcf1bb-2b90-4cb0-8033-fe11a7e73843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_c624913e-d983-40cb-9b48-0b0a9314abad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_c624913e-d983-40cb-9b48-0b0a9314abad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_898a98ae-fe6d-4f20-a965-90f0a33dd66c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_898a98ae-fe6d-4f20-a965-90f0a33dd66c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment_e294dee4-5ea3-4ca7-affe-578a6b79bdcb" xlink:href="bntx-20231231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment_e294dee4-5ea3-4ca7-affe-578a6b79bdcb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_5ed5933a-9e0c-4d24-b6cb-e2ded887f7da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_2171a49a-5ca1-4cd3-99dd-7d208b707144_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_2171a49a-5ca1-4cd3-99dd-7d208b707144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_4109fc15-44fe-4717-8a31-75b84ea6d81e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_ifrs-full_LandAndBuildingsMember_4109fc15-44fe-4717-8a31-75b84ea6d81e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_1040bf27-228c-45f0-9513-95ad9d24318d" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_1040bf27-228c-45f0-9513-95ad9d24318d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember_eb429612-b86d-44ba-bc50-1719a6c33820" xlink:href="bntx-20231231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember_eb429612-b86d-44ba-bc50-1719a6c33820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_bbfdbe85-ddf5-431c-832a-614c60569e98_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:to="loc_ifrs-full_CarryingAmountMember_bbfdbe85-ddf5-431c-832a-614c60569e98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:to="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_91568ad6-3d2f-4432-92dc-c753caa409eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_91568ad6-3d2f-4432-92dc-c753caa409eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f1c2a1a9-aca6-4c27-b61e-ac3e091fd556" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f1c2a1a9-aca6-4c27-b61e-ac3e091fd556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_5b620958-0d9f-42d2-8fc0-357c1dd83ce4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_5b620958-0d9f-42d2-8fc0-357c1dd83ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9688bc92-a539-48fa-a6b5-cac8f9d2b220" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9688bc92-a539-48fa-a6b5-cac8f9d2b220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_1e40abed-4455-49e7-b286-58e7b0fa4e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_1e40abed-4455-49e7-b286-58e7b0fa4e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment_960e329d-e5a1-4f2b-8fc5-5f8bb8aa17c9" xlink:href="bntx-20231231.xsd#bntx_ReclassificationsOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment_960e329d-e5a1-4f2b-8fc5-5f8bb8aa17c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_21e977c3-055b-41f7-8f9a-b816c159b9f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_21e977c3-055b-41f7-8f9a-b816c159b9f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_d30c493c-2b88-4b62-8079-d7ba29c02f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_d30c493c-2b88-4b62-8079-d7ba29c02f18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_94f4559b-8fac-49fb-a430-d0c57d0c6577" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_94f4559b-8fac-49fb-a430-d0c57d0c6577" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_3ab6d7ac-db97-4c9b-82e1-ca5dfb405d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_e8a61959-898b-4a9f-adff-c8b0171b26c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_NoncurrentAssets_e8a61959-898b-4a9f-adff-c8b0171b26c6" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:to="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c8b8224f-8d1a-4554-bd8e-deb37408b946_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:to="loc_srt_SegmentGeographicalDomain_c8b8224f-8d1a-4554-bd8e-deb37408b946_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:to="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ad59b7cf-cffe-4aaf-b1f6-399e2a734751" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_US_ad59b7cf-cffe-4aaf-b1f6-399e2a734751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1aaabb83-9030-4810-a5fd-0e0f28ecbcea" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_GB_1aaabb83-9030-4810-a5fd-0e0f28ecbcea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4fd74dd3-b87f-41f9-bae4-dfdbb464d18f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_DE_4fd74dd3-b87f-41f9-bae4-dfdbb464d18f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1c6d53d1-4aef-4706-b98b-3f08a327f873_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_1c6d53d1-4aef-4706-b98b-3f08a327f873_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubsidiariesMember_b9aea14a-afa6-4552-badb-13fe278329db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:to="loc_ifrs-full_SubsidiariesMember_b9aea14a-afa6-4552-badb-13fe278329db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_4c3a1d5a-d1d1-4431-acac-ce42f6b1b184" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:to="loc_ifrs-full_NoncurrentAssets_4c3a1d5a-d1d1-4431-acac-ce42f6b1b184" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_28ad9e25-0498-439b-a4ec-59d75e49d694_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_28ad9e25-0498-439b-a4ec-59d75e49d694_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BankDepositsMember_6ab8639e-ec97-457d-b6b8-789e1571cf94" xlink:href="bntx-20231231.xsd#bntx_BankDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_BankDepositsMember_6ab8639e-ec97-457d-b6b8-789e1571cf94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MoneyMarketFundMember_481a6a20-b61c-4a9b-8ee3-399aff8405b5" xlink:href="bntx-20231231.xsd#bntx_MoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_MoneyMarketFundMember_481a6a20-b61c-4a9b-8ee3-399aff8405b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReverseRepoMember_f6e2ac29-38a3-4398-bef2-cd001c5c592c" xlink:href="bntx-20231231.xsd#bntx_ReverseRepoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_ReverseRepoMember_f6e2ac29-38a3-4398-bef2-cd001c5c592c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_af4b76ed-8619-4a2e-891c-9125debe83d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_Cash_af4b76ed-8619-4a2e-891c-9125debe83d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_c68db369-bd6f-4aaf-a1f3-d0923ac3993c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_CashEquivalents_c68db369-bd6f-4aaf-a1f3-d0923ac3993c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4cb7fa39-226d-4837-997a-3f73e1a71402" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4cb7fa39-226d-4837-997a-3f73e1a71402" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:to="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_502e59c1-a114-47e4-8f67-4f4ec6f331f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_502e59c1-a114-47e4-8f67-4f4ec6f331f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_729c2603-76ea-4ecf-8d7c-449e852d909b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_729c2603-76ea-4ecf-8d7c-449e852d909b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e656d74d-23a5-4553-93f6-0e6f9f792f47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e656d74d-23a5-4553-93f6-0e6f9f792f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_77338b18-e5d2-4c6d-b559-11b3d04ebe3b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:to="loc_ifrs-full_FinancialAssetsMember_77338b18-e5d2-4c6d-b559-11b3d04ebe3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:to="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_09d5667b-1c0c-4d23-87e2-c5c029277916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_ifrs-full_DerivativesMember_09d5667b-1c0c-4d23-87e2-c5c029277916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MoneyMarketFundMember_67d3d883-d968-4929-ae8e-1e0e03bb0f23" xlink:href="bntx-20231231.xsd#bntx_MoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_MoneyMarketFundMember_67d3d883-d968-4929-ae8e-1e0e03bb0f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonListedEquityInvestmentsMember_c76f1868-5a6c-4d26-991e-bd6dc2758413" xlink:href="bntx-20231231.xsd#bntx_NonListedEquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_NonListedEquityInvestmentsMember_c76f1868-5a6c-4d26-991e-bd6dc2758413" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListedEquityInvestmentsMember_e057d895-7748-4f8c-908d-7d38393e0a14" xlink:href="bntx-20231231.xsd#bntx_ListedEquityInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_ListedEquityInvestmentsMember_e057d895-7748-4f8c-908d-7d38393e0a14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_265cdcd0-3585-43a3-bbb1-36c406250d19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_ifrs-full_TradeReceivablesMember_265cdcd0-3585-43a3-bbb1-36c406250d19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesInvestmentMember_dc960400-98aa-4f64-998d-4dff4f92f45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesInvestmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_us-gaap_SecuritiesInvestmentMember_dc960400-98aa-4f64-998d-4dff4f92f45a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialAssetsMember_6f8d7cf6-8dbb-48e1-8350-6d5b47560d03" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_OtherFinancialAssetsMember_6f8d7cf6-8dbb-48e1-8350-6d5b47560d03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BankDepositsMember_0512446a-6894-49e3-a847-1a9dd3a83246" xlink:href="bntx-20231231.xsd#bntx_BankDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_BankDepositsMember_0512446a-6894-49e3-a847-1a9dd3a83246" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReverseRepoMember_f1bdb0b3-9e14-4e44-86e9-47b41b69ddd6" xlink:href="bntx-20231231.xsd#bntx_ReverseRepoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_ReverseRepoMember_f1bdb0b3-9e14-4e44-86e9-47b41b69ddd6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAtBanksAndOnHandMember_d16b28e0-3d8a-4389-8a1c-9faf9d3cb7f4" xlink:href="bntx-20231231.xsd#bntx_CashAtBanksAndOnHandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_CashAtBanksAndOnHandMember_d16b28e0-3d8a-4389-8a1c-9faf9d3cb7f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_77f318aa-0b96-4cfc-be42-c6873a79a619_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_77f318aa-0b96-4cfc-be42-c6873a79a619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DerivativeLiabilitiesMember_1951347d-5684-4dec-92e6-fe1a7d2bd21b" xlink:href="bntx-20231231.xsd#bntx_DerivativeLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_DerivativeLiabilitiesMember_1951347d-5684-4dec-92e6-fe1a7d2bd21b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_962e4c4f-b5fc-4e7a-93ce-780a9224b16d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_ifrs-full_ContingentConsiderationMember_962e4c4f-b5fc-4e7a-93ce-780a9224b16d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_dafc6b58-688c-4e54-b712-488fc9b5a1b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_dafc6b58-688c-4e54-b712-488fc9b5a1b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LoansAndBorrowingsMember_a949ce70-431b-4428-85e7-3fdb02a05ed6" xlink:href="bntx-20231231.xsd#bntx_LoansAndBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_LoansAndBorrowingsMember_a949ce70-431b-4428-85e7-3fdb02a05ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradePayablesAndOtherPayablesMember_47a3fade-c571-4895-8763-659dd6932e81" xlink:href="bntx-20231231.xsd#bntx_TradePayablesAndOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_TradePayablesAndOtherPayablesMember_47a3fade-c571-4895-8763-659dd6932e81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialLiabilitiesMember_040e998b-7fe6-40b5-aea6-b50791bb6e0e" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_OtherFinancialLiabilitiesMember_040e998b-7fe6-40b5-aea6-b50791bb6e0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_36a646e2-e2cc-4dcc-9f20-7d0172fcc215_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_36a646e2-e2cc-4dcc-9f20-7d0172fcc215_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_5d4c4729-e752-4aec-8519-d200d8197254" xlink:href="bntx-20231231.xsd#bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:to="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_5d4c4729-e752-4aec-8519-d200d8197254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_14e7e24a-3d73-41ce-948d-04b726c99cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_14e7e24a-3d73-41ce-948d-04b726c99cc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_a63b4b24-3618-4471-9ed0-ba9f9b4610ff_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_a63b4b24-3618-4471-9ed0-ba9f9b4610ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_c8f4e409-b13a-46de-82cc-7c23b3f6a98c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_c8f4e409-b13a-46de-82cc-7c23b3f6a98c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_310a8590-c1c7-4844-8424-7832f43ae357" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_310a8590-c1c7-4844-8424-7832f43ae357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_e7e76d8b-1cac-43aa-9807-9c53fbc4d1c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_e7e76d8b-1cac-43aa-9807-9c53fbc4d1c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_513dd054-3687-4d1d-a499-d6056b57b564_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_513dd054-3687-4d1d-a499-d6056b57b564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughProfitOrLossMember_19530a53-cdbe-4311-9b23-d097cf906707" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughProfitOrLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_FairValueThroughProfitOrLossMember_19530a53-cdbe-4311-9b23-d097cf906707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughOCIMember_831f8ffd-c166-45f7-974a-b801b1aa817b" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughOCIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_FairValueThroughOCIMember_831f8ffd-c166-45f7-974a-b801b1aa817b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmortizedCostMember_c5e592f7-6bda-4501-8e01-ef4cce0dde0a" xlink:href="bntx-20231231.xsd#bntx_AmortizedCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_AmortizedCostMember_c5e592f7-6bda-4501-8e01-ef4cce0dde0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_fba441b0-23cb-4dea-915b-74713797276d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_fba441b0-23cb-4dea-915b-74713797276d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_68aa312e-adcb-4f2e-a5cd-42653412d4ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:to="loc_ifrs-full_AtFairValueMember_68aa312e-adcb-4f2e-a5cd-42653412d4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_d0d8e98b-d7cb-4c59-a976-e6955987103f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:to="loc_ifrs-full_FinancialAssets_d0d8e98b-d7cb-4c59-a976-e6955987103f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_e7daed50-9387-43fb-b0c8-d1301239cc1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:to="loc_ifrs-full_FinancialLiabilities_e7daed50-9387-43fb-b0c8-d1301239cc1c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_8d7426b5-ae76-4848-b280-1f32eba75702_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_8d7426b5-ae76-4848-b280-1f32eba75702_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_f7df8a02-4c97-43f2-b5e0-bce8f1e82a73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_f7df8a02-4c97-43f2-b5e0-bce8f1e82a73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_286745db-4542-40ce-873f-da6754ea8148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_286745db-4542-40ce-873f-da6754ea8148" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_df7f6970-0e8c-4a4b-8b73-341ddca2fda6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_df7f6970-0e8c-4a4b-8b73-341ddca2fda6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_62308ae3-2d4c-44a5-8197-e4d218fd1d6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_62308ae3-2d4c-44a5-8197-e4d218fd1d6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_e46b3643-e766-4a60-a985-190f8eb4a2ff_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:to="loc_ifrs-full_LiabilitiesMember_e46b3643-e766-4a60-a985-190f8eb4a2ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:to="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_ec39931b-3fce-4ae9-9dda-0ca65cb234ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:to="loc_ifrs-full_ContingentConsiderationMember_ec39931b-3fce-4ae9-9dda-0ca65cb234ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:to="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_2dd48380-5bb4-4e84-a6d1-7d480eaf350b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_Liabilities_2dd48380-5bb4-4e84-a6d1-7d480eaf350b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4ded54a1-7585-440c-ae7a-0f8f8a539d8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities_a1c875c5-1838-4fab-b8b9-bce1ffb4b415" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities_a1c875c5-1838-4fab-b8b9-bce1ffb4b415" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetChangeInFairValue_e85f55da-cd94-4a38-a55e-9664e941f35f" xlink:href="bntx-20231231.xsd#bntx_NetChangeInFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_bntx_NetChangeInFairValue_e85f55da-cd94-4a38-a55e-9664e941f35f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_e7dd1641-0193-459f-a662-8278f7864d0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_1d2c9964-4917-44ea-a48e-37a5899395c5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:to="loc_ifrs-full_LiabilitiesMember_1d2c9964-4917-44ea-a48e-37a5899395c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:to="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_e3dbc396-e9bb-4af5-baad-18c4359f9b43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:to="loc_ifrs-full_ContingentConsiderationMember_e3dbc396-e9bb-4af5-baad-18c4359f9b43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_74b9325f-c891-4be0-b76d-f82f5cd85453_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_74b9325f-c891-4be0-b76d-f82f5cd85453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1fa22ebb-79bd-4dac-8c37-b85fc3cd516d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1fa22ebb-79bd-4dac-8c37-b85fc3cd516d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_b7aa3681-cf59-4a5e-a276-851259c1e1af_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:to="loc_ifrs-full_UnobservableInputsMember_b7aa3681-cf59-4a5e-a276-851259c1e1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:to="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashFlowProjectionsMeasurementInputMember_22283177-1d1c-4b64-8f8e-f86631fa933d" xlink:href="bntx-20231231.xsd#bntx_CashFlowProjectionsMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:to="loc_bntx_CashFlowProjectionsMeasurementInputMember_22283177-1d1c-4b64-8f8e-f86631fa933d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_12e934f3-706c-43e3-9112-7d91059d3570" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_12e934f3-706c-43e3-9112-7d91059d3570" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_18afb2e2-a7e2-4f32-808f-a28bb4180a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_18afb2e2-a7e2-4f32-808f-a28bb4180a2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_135568ad-0af4-42be-ae4b-92c41db223b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_135568ad-0af4-42be-ae4b-92c41db223b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_e2a86daa-c411-43c0-b069-5acbca81a09c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_e2a86daa-c411-43c0-b069-5acbca81a09c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:to="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_fae62762-8f94-4bfa-a3a6-1251e528fb72_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:to="loc_ifrs-full_TypesOfRisksMember_fae62762-8f94-4bfa-a3a6-1251e528fb72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:to="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_9d80b9bb-084f-445c-85d8-892cc33696a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:to="loc_ifrs-full_CurrencyRiskMember_9d80b9bb-084f-445c-85d8-892cc33696a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_f855fcd8-2a45-47cd-b471-9b1198143334_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_f855fcd8-2a45-47cd-b471-9b1198143334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1Member_33f09619-0a4c-4a5d-ad6a-f62c90bd8743" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:to="loc_bntx_CashAndCashEquivalents1Member_33f09619-0a4c-4a5d-ad6a-f62c90bd8743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_43ffe9f7-904e-4582-a3b4-19c84cae0bed_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:to="loc_ifrs-full_FinancialAssetsMember_43ffe9f7-904e-4582-a3b4-19c84cae0bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:to="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryAssetsMember_9b3274a6-1347-4e0b-a0ca-2643289b2b2b" xlink:href="bntx-20231231.xsd#bntx_MonetaryAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:to="loc_bntx_MonetaryAssetsMember_9b3274a6-1347-4e0b-a0ca-2643289b2b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_1b0cc64b-d08e-404b-9a38-3d7d629acb24_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_1b0cc64b-d08e-404b-9a38-3d7d629acb24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryLiabilityAndProvisionsMember_78e46be9-f6e6-40e2-b290-acc466cbb36a" xlink:href="bntx-20231231.xsd#bntx_MonetaryLiabilityAndProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:to="loc_bntx_MonetaryLiabilityAndProvisionsMember_78e46be9-f6e6-40e2-b290-acc466cbb36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalent_7987a02d-a050-4557-b910-8db1d05a6bd5" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:to="loc_bntx_CashAndCashEquivalent_7987a02d-a050-4557-b910-8db1d05a6bd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:to="loc_srt_SegmentGeographicalDomain_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:to="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_16d996cf-7b19-48db-a29c-656d9a51d1c1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:to="loc_country_US_16d996cf-7b19-48db-a29c-656d9a51d1c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_ef84f433-a958-4319-ac43-f8705b8aa612_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:to="loc_currency_AllCurrenciesDomain_ef84f433-a958-4319-ac43-f8705b8aa612_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:to="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_8811214e-b037-460f-ac7c-ec92a0d61ad1" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:to="loc_currency_USD_8811214e-b037-460f-ac7c-ec92a0d61ad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_a4a98338-7b5c-4461-b97a-5d023d97fbd1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:to="loc_ifrs-full_TypesOfRisksMember_a4a98338-7b5c-4461-b97a-5d023d97fbd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:to="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_f4ec46f0-2a5f-4eba-a4f9-84809dd14e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:to="loc_ifrs-full_CurrencyRiskMember_f4ec46f0-2a5f-4eba-a4f9-84809dd14e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_341bdc29-8521-4ae5-9fde-fcb04a2689a4" xlink:href="bntx-20231231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:to="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_341bdc29-8521-4ae5-9fde-fcb04a2689a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_caa2283c-e9fb-404d-ac87-8488cfbe50b3" xlink:href="bntx-20231231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:to="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_caa2283c-e9fb-404d-ac87-8488cfbe50b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_b3827110-0b8b-4ff9-9468-cc565e152964" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_b3827110-0b8b-4ff9-9468-cc565e152964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_ae4df442-9848-46e3-92e7-79356db9f324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_ae4df442-9848-46e3-92e7-79356db9f324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_98dff2db-fee7-4210-9f32-c02f17ba2cfe" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_98dff2db-fee7-4210-9f32-c02f17ba2cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_2c2c3f7f-3224-4011-888c-8bfadb6762ae" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_2c2c3f7f-3224-4011-888c-8bfadb6762ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:to="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_f53eecaf-3a79-44e8-947b-3040b1eb7bb7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:to="loc_ifrs-full_TypesOfRisksMember_f53eecaf-3a79-44e8-947b-3040b1eb7bb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:to="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember_cf6d0b6e-8b87-4cfb-b099-299f78f1ed14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:to="loc_ifrs-full_LiquidityRiskMember_cf6d0b6e-8b87-4cfb-b099-299f78f1ed14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:to="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_70eace01-30a7-407d-920c-2a03c1600741_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_70eace01-30a7-407d-920c-2a03c1600741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_af13ca53-e059-45f2-b119-fd7beecd0816" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_af13ca53-e059-45f2-b119-fd7beecd0816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_bfac2718-c0c6-4c3b-9ac0-cf0cdcd5e08f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_bfac2718-c0c6-4c3b-9ac0-cf0cdcd5e08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4c3e003b-d969-4d42-8602-f04ce3cbf259" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4c3e003b-d969-4d42-8602-f04ce3cbf259" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowings_0ae31723-6792-4b75-b763-042c4f715a5d" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_bntx_InterestBearingLoansAndBorrowings_0ae31723-6792-4b75-b763-042c4f715a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_92beb979-51ba-4520-b0da-83a7e2f68e34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_TradeAndOtherPayables_92beb979-51ba-4520-b0da-83a7e2f68e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_db4896b7-24d8-434a-a8f1-c8e2b813102b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_LeaseLiabilities_db4896b7-24d8-434a-a8f1-c8e2b813102b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b7f5b525-2443-489f-83e6-569227a55f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b7f5b525-2443-489f-83e6-569227a55f01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_bf603c98-3888-41ff-b3e0-acd9844c24d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_bf603c98-3888-41ff-b3e0-acd9844c24d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialLiabilities_25b6e3a2-42e9-4575-842c-42bb4ad33d2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_OtherFinancialLiabilities_25b6e3a2-42e9-4575-842c-42bb4ad33d2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_bc60d1c1-0a5f-45bd-904f-9d1a29abcee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_FinancialLiabilities_bc60d1c1-0a5f-45bd-904f-9d1a29abcee4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_deb495ef-a250-4cef-a058-44c3748aea6f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_deb495ef-a250-4cef-a058-44c3748aea6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentObligationsUnderLeaseContractsMember_df5157c0-29b9-4e4b-97d7-7e09faef992c" xlink:href="bntx-20231231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_CurrentObligationsUnderLeaseContractsMember_df5157c0-29b9-4e4b-97d7-7e09faef992c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember_89bb48e4-ceb1-4ffc-ab9a-62b53595d8ae" xlink:href="bntx-20231231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember_89bb48e4-ceb1-4ffc-ab9a-62b53595d8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowingsMember_c1db5005-3123-46e6-94f6-7a5374d1572c" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_InterestBearingLoansAndBorrowingsMember_c1db5005-3123-46e6-94f6-7a5374d1572c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember_ffc6f136-14db-440e-b535-b5088500ddbe" xlink:href="bntx-20231231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember_ffc6f136-14db-440e-b535-b5088500ddbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_85aba43c-21de-4c15-8709-c1fe3ecfd0d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_85aba43c-21de-4c15-8709-c1fe3ecfd0d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d0bd7d67-ddd8-4b43-ab0b-5c2a3456aca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d0bd7d67-ddd8-4b43-ab0b-5c2a3456aca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_1bb1ad03-e73d-49b3-8166-b135b5d1e903" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_1bb1ad03-e73d-49b3-8166-b135b5d1e903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_b08676af-0fa7-4315-84c4-75626019aaab" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_b08676af-0fa7-4315-84c4-75626019aaab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_147ad4ae-024d-4a3c-9570-3ebb654446d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_147ad4ae-024d-4a3c-9570-3ebb654446d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_482e7e44-493e-4efd-acce-e658026d95ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:to="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_1b565363-6eb8-4b06-9de1-e6f3e4236450_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:to="loc_ifrs-full_MajorCustomersMember_1b565363-6eb8-4b06-9de1-e6f3e4236450_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:to="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EuropeanCommissionToCollaborationPartnerMember_f71fe437-b92a-40d6-b50b-4087d1fb502b" xlink:href="bntx-20231231.xsd#bntx_EuropeanCommissionToCollaborationPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:to="loc_bntx_EuropeanCommissionToCollaborationPartnerMember_f71fe437-b92a-40d6-b50b-4087d1fb502b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_7d01c27a-610f-4b51-a3ac-fb618b830651_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_7d01c27a-610f-4b51-a3ac-fb618b830651_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OncoC4IncMember_28dfa3ad-4a4b-42d8-8256-c934db92408c" xlink:href="bntx-20231231.xsd#bntx_OncoC4IncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_OncoC4IncMember_28dfa3ad-4a4b-42d8-8256-c934db92408c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RyvuTherapeuticsSAMember_09bfe62b-dcb0-436b-a017-8b1024661843" xlink:href="bntx-20231231.xsd#bntx_RyvuTherapeuticsSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_RyvuTherapeuticsSAMember_09bfe62b-dcb0-436b-a017-8b1024661843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedigeneImmunotherapiesGmbHMember_c3cfde4f-ace8-4d51-8d6a-85859c585f06" xlink:href="bntx-20231231.xsd#bntx_MedigeneImmunotherapiesGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_MedigeneImmunotherapiesGmbHMember_c3cfde4f-ace8-4d51-8d6a-85859c585f06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredExpense_cb951413-55ca-48d2-ba11-22d5f156f1b3" xlink:href="bntx-20231231.xsd#bntx_DeferredExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:to="loc_bntx_DeferredExpense_cb951413-55ca-48d2-ba11-22d5f156f1b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReservesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0752ca4-3265-4c42-ab37-9a3faf4e549d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0752ca4-3265-4c42-ab37-9a3faf4e549d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerIncMember_1769984d-7827-4ed0-a539-a8a5b2564706" xlink:href="bntx-20231231.xsd#bntx_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:to="loc_bntx_PfizerIncMember_1769984d-7827-4ed0-a539-a8a5b2564706" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_defa4e5e-95bc-46e4-a8b8-066147aa15fa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:to="loc_ifrs-full_EquityMember_defa4e5e-95bc-46e4-a8b8-066147aa15fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:to="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7bb8ab08-6efa-4040-93a7-c98e36aa1b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:to="loc_ifrs-full_IssuedCapitalMember_7bb8ab08-6efa-4040-93a7-c98e36aa1b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_66d59b66-01d5-4722-b8bb-82867257e719" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:to="loc_ifrs-full_CapitalReserveMember_66d59b66-01d5-4722-b8bb-82867257e719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:to="loc_ifrs-full_NonadjustingEventsMember_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:to="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_ed9ae16c-1857-4b7b-9e24-f804e816bb35" xlink:href="bntx-20231231.xsd#bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:to="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_ed9ae16c-1857-4b7b-9e24-f804e816bb35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd_default" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e65af2c8-ffba-4f5a-80d4-bf2c5c83a111" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e65af2c8-ffba-4f5a-80d4-bf2c5c83a111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_71306931-679d-4447-89bd-90f7dd72c5d1" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_71306931-679d-4447-89bd-90f7dd72c5d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_992c5a66-eff0-4767-b1b0-11e6af469343" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_992c5a66-eff0-4767-b1b0-11e6af469343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfSharesHeldInTreasury_bf8b840f-d969-4606-9b87-ae2f4c1985ce" xlink:href="bntx-20231231.xsd#bntx_NumberOfSharesHeldInTreasury"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_bntx_NumberOfSharesHeldInTreasury_bf8b840f-d969-4606-9b87-ae2f4c1985ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_cb85f760-a378-4ff6-a085-fde5d11bbae9" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_cb85f760-a378-4ff6-a085-fde5d11bbae9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_7b229b61-0bbd-4713-aeb4-10cd334689e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_NumberOfSharesIssued_7b229b61-0bbd-4713-aeb4-10cd334689e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_069d4d57-fc6b-47a5-aba6-06f87e5e7edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_IssueOfEquity_069d4d57-fc6b-47a5-aba6-06f87e5e7edf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_d92b55f7-a9c9-4967-8907-18012db969d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_IssuedCapital_d92b55f7-a9c9-4967-8907-18012db969d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_4d941948-f58c-4dd6-b3a2-753c3a7a062c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_4d941948-f58c-4dd6-b3a2-753c3a7a062c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_db9c17c9-f0cf-4823-8274-719e37f7c378" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_db9c17c9-f0cf-4823-8274-719e37f7c378" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_d9761810-998e-4745-8116-f4dbcf50af56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_d9761810-998e-4745-8116-f4dbcf50af56" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e_default" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e47d1724-195b-4d61-906b-efa6549a017f" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e47d1724-195b-4d61-906b-efa6549a017f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_2d128e8d-54cb-4274-ae59-be4c38312c0f" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_2d128e8d-54cb-4274-ae59-be4c38312c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgram2023Member_7a5abaa3-8b92-49a4-a3a8-e82aba68bf33" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgram2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgram2023Member_7a5abaa3-8b92-49a4-a3a8-e82aba68bf33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_ce17461a-b4d7-4d3b-a91b-4430d4c11397" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_ce17461a-b4d7-4d3b-a91b-4430d4c11397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_f76dd0dc-ee83-4259-8df5-ef858aab5559" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_f76dd0dc-ee83-4259-8df5-ef858aab5559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_eda1cf03-3992-4735-979b-2a82a7ead7c1" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_eda1cf03-3992-4735-979b-2a82a7ead7c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNetAmountSpent_d23c70f7-fe3e-4529-95a0-44d10c9489e3" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNetAmountSpent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramNetAmountSpent_d23c70f7-fe3e-4529-95a0-44d10c9489e3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_50fa3620-892f-4cbc-928d-13157ae1d58f" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_50fa3620-892f-4cbc-928d-13157ae1d58f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_deb2f319-6dee-4a00-a5d0-583aaf2fd9fb" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_deb2f319-6dee-4a00-a5d0-583aaf2fd9fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_c47a7130-b764-477b-a407-bf1687fd0a19" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_ManagementBoardGrantMember_c47a7130-b764-477b-a407-bf1687fd0a19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_1d36b2e0-1e7c-48da-b001-6c566ce2f143" xlink:href="bntx-20231231.xsd#bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_1d36b2e0-1e7c-48da-b001-6c566ce2f143" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepEmployeeIncentivePlanMember_37adc026-775b-4668-b4ef-afdb96c0a896" xlink:href="bntx-20231231.xsd#bntx_InstaDeepEmployeeIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_InstaDeepEmployeeIncentivePlanMember_37adc026-775b-4668-b4ef-afdb96c0a896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_82985859-c1e9-482e-a977-c2d1c67e46ac" xlink:href="bntx-20231231.xsd#bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_82985859-c1e9-482e-a977-c2d1c67e46ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_94a9e5d4-81b7-4ce7-a783-89538c68350e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_94a9e5d4-81b7-4ce7-a783-89538c68350e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_ae654044-86f6-444b-b58b-563ab587763b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_ifrs-full_CostOfSalesMember_ae654044-86f6-444b-b58b-563ab587763b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentExpensesMember_4c72b6e8-b989-4e96-b87a-61a23143f2c9" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_ResearchAndDevelopmentExpensesMember_4c72b6e8-b989-4e96-b87a-61a23143f2c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesAndMarketingExpenseMember_20e3e64c-2c0c-4bff-a9a6-2b327f3c05e0" xlink:href="bntx-20231231.xsd#bntx_SalesAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_SalesAndMarketingExpenseMember_20e3e64c-2c0c-4bff-a9a6-2b327f3c05e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GeneralAndAdministrativeExpensesMember_8a60bd5f-d780-4122-a5af-9bc0cc9b0ccb" xlink:href="bntx-20231231.xsd#bntx_GeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_GeneralAndAdministrativeExpensesMember_8a60bd5f-d780-4122-a5af-9bc0cc9b0ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_fa901e30-2562-46d9-a358-ef72e1870ca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_fa901e30-2562-46d9-a358-ef72e1870ca8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_841b4f0c-e7ec-4a9c-bc87-39ab151baa12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_841b4f0c-e7ec-4a9c-bc87-39ab151baa12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a775c432-fbbd-4da4-bb47-2ec41d79bad8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a775c432-fbbd-4da4-bb47-2ec41d79bad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_a95ace5a-cb88-40fd-b0ba-bdde176d59fd" xlink:href="bntx-20231231.xsd#bntx_ReclassificationOfShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_a95ace5a-cb88-40fd-b0ba-bdde176d59fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits_5e106327-a7cc-49e1-b150-acae5b582a53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_LongtermDeposits_5e106327-a7cc-49e1-b150-acae5b582a53" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_4a1892ba-104e-4120-86eb-5829957e9907" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_4a1892ba-104e-4120-86eb-5829957e9907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_b82f36e5-2284-4777-9a9f-e80e19c0d613" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_b82f36e5-2284-4777-9a9f-e80e19c0d613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_aacbf8e3-4fab-48ba-8c81-7ea0c5932827" xlink:href="bntx-20231231.xsd#bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_aacbf8e3-4fab-48ba-8c81-7ea0c5932827" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_4b1e7553-b7a2-4a8e-8759-f1fd9009c177" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_ManagementBoardGrantMember_4b1e7553-b7a2-4a8e-8759-f1fd9009c177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_0de0f24f-0bbd-4034-9d93-db21f4e23f5e" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_0de0f24f-0bbd-4034-9d93-db21f4e23f5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_2632f663-c4fe-4b64-b462-4dfbd336da28" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_2632f663-c4fe-4b64-b462-4dfbd336da28" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashSettledShareBasedPaymentArrangementMember_226876a1-bfde-422c-ab8e-b1bcb71bb498" xlink:href="bntx-20231231.xsd#bntx_CashSettledShareBasedPaymentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_CashSettledShareBasedPaymentArrangementMember_226876a1-bfde-422c-ab8e-b1bcb71bb498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodDomain_7a1aff2f-9467-4727-a4a2-52fe012fbf21_default" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:to="loc_bntx_VestingPeriodDomain_7a1aff2f-9467-4727-a4a2-52fe012fbf21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:to="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementYearOneMember_c39076db-a055-48d4-aed3-606dfdcd54dc" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementYearOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:to="loc_bntx_ShareBasedPaymentArrangementYearOneMember_c39076db-a055-48d4-aed3-606dfdcd54dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08e05e10-446e-42ca-aee4-6850bc06dce4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08e05e10-446e-42ca-aee4-6850bc06dce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProfessorUgurSahinMDMember_f229d5b4-c9d3-44cd-9957-9a4e5aa35992" xlink:href="bntx-20231231.xsd#bntx_ProfessorUgurSahinMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:to="loc_bntx_ProfessorUgurSahinMDMember_f229d5b4-c9d3-44cd-9957-9a4e5aa35992" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DoctorSierkPoettingMember_7ab82fa4-6af4-4f20-986d-75b3ab2c8856" xlink:href="bntx-20231231.xsd#bntx_DoctorSierkPoettingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:to="loc_bntx_DoctorSierkPoettingMember_7ab82fa4-6af4-4f20-986d-75b3ab2c8856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_406ba450-63e6-407a-9ae6-a8769c65cfbc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_406ba450-63e6-407a-9ae6-a8769c65cfbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2e8aad32-aac2-40f7-867b-1e02c5f6a230" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:to="loc_ifrs-full_OrdinarySharesMember_2e8aad32-aac2-40f7-867b-1e02c5f6a230" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dad51593-41c1-4c06-9679-10d0527818e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:to="loc_srt_RangeMember_dad51593-41c1-4c06-9679-10d0527818e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:to="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_487b85d7-2a21-4626-8ec6-89dc8c61e087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:to="loc_srt_MaximumMember_487b85d7-2a21-4626-8ec6-89dc8c61e087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockDomain_91f0bb38-5ba0-4779-b426-720bb63b11fa_default" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:to="loc_bntx_SaleOfStockDomain_91f0bb38-5ba0-4779-b426-720bb63b11fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:to="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOptionPlanMember_c92e8f3c-81a7-4738-a66d-d4d6aca3cba9" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:to="loc_bntx_EmployeeStockOptionPlanMember_c92e8f3c-81a7-4738-a66d-d4d6aca3cba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_a3fe5bbe-43ab-43fb-9454-2b6291728f84" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentsClassifiedAsOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_a3fe5bbe-43ab-43fb-9454-2b6291728f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowToTaxAuthority_74cd69e6-828b-4851-b458-0ae6ad20dd12" xlink:href="bntx-20231231.xsd#bntx_CashOutflowToTaxAuthority"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_CashOutflowToTaxAuthority_74cd69e6-828b-4851-b458-0ae6ad20dd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionVestingPeriod_219c31c4-1c79-4f6a-b0fc-21233f782587" xlink:href="bntx-20231231.xsd#bntx_OptionVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_OptionVestingPeriod_219c31c4-1c79-4f6a-b0fc-21233f782587" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement_918dc8fc-adc2-4eb1-9488-9e394014c1cf" xlink:href="bntx-20231231.xsd#bntx_VestingPercentageOfShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement_918dc8fc-adc2-4eb1-9488-9e394014c1cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise_e9cf83c3-cad0-4ceb-b64b-723d00d15754" xlink:href="bntx-20231231.xsd#bntx_CashOutflowForShareBasedPaymentArrangementExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise_e9cf83c3-cad0-4ceb-b64b-723d00d15754" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_7e4d4ffc-f197-4f1e-baaa-6d2ac9894d87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_7e4d4ffc-f197-4f1e-baaa-6d2ac9894d87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_bf6e829f-18d2-44e9-9049-66f92c407ffc" xlink:href="bntx-20231231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_bf6e829f-18d2-44e9-9049-66f92c407ffc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionExercisablePeriod_1bac2c8e-6efd-4901-8e32-ac8299cce667" xlink:href="bntx-20231231.xsd#bntx_OptionExercisablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_OptionExercisablePeriod_1bac2c8e-6efd-4901-8e32-ac8299cce667" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfIncreaseInExercisePrice_9db2d5ac-9688-4981-a190-483a6a2aa84b" xlink:href="bntx-20231231.xsd#bntx_PercentageOfIncreaseInExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfIncreaseInExercisePrice_9db2d5ac-9688-4981-a190-483a6a2aa84b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_7848cc70-0749-42df-b961-e6d8707c2e93" xlink:href="bntx-20231231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_7848cc70-0749-42df-b961-e6d8707c2e93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_8f83886b-88b8-4071-8dfb-2801eb4cbe8e" xlink:href="bntx-20231231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_8f83886b-88b8-4071-8dfb-2801eb4cbe8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionExercisablePeriod_845fcb9a-5898-44d9-9736-5dcecbe7b54e" xlink:href="bntx-20231231.xsd#bntx_OptionExercisablePeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_25bf7cda-8f11-41a4-8265-e688215fd0a9" xlink:href="bntx-20231231.xsd#bntx_ReclassificationOfShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_25bf7cda-8f11-41a4-8265-e688215fd0a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_cb2f7405-9b76-4da6-8f9c-7229efc63361" xlink:href="bntx-20231231.xsd#bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_cb2f7405-9b76-4da6-8f9c-7229efc63361" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised_e25f7846-8159-40b7-91e6-cd87afab72ff" xlink:href="bntx-20231231.xsd#bntx_MaximumEconomicBenefitsOfOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised_e25f7846-8159-40b7-91e6-cd87afab72ff" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EffectiveExercisePriceMaximum_ee8cc473-7036-4fbf-9f59-cb11af49107e" xlink:href="bntx-20231231.xsd#bntx_EffectiveExercisePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_EffectiveExercisePriceMaximum_ee8cc473-7036-4fbf-9f59-cb11af49107e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_3af6780c-5be3-48f1-a0be-551915e478d5" xlink:href="bntx-20231231.xsd#bntx_MaximumCashPaymentInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_3af6780c-5be3-48f1-a0be-551915e478d5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8c961f11-6c61-449b-976b-7e34063c6f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8c961f11-6c61-449b-976b-7e34063c6f44" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PhantomOptionAwardsLiability_5c5316b4-7ee0-4cdf-8e9b-760e42aef368" xlink:href="bntx-20231231.xsd#bntx_PhantomOptionAwardsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PhantomOptionAwardsLiability_5c5316b4-7ee0-4cdf-8e9b-760e42aef368" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_a6d0df55-9136-40ea-b651-5e847ff0709e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_a6d0df55-9136-40ea-b651-5e847ff0709e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_ed4f8fd1-35ee-4c9e-ac54-4fd907260d87" xlink:href="bntx-20231231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_ed4f8fd1-35ee-4c9e-ac54-4fd907260d87" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_5d708c24-b74b-403e-801c-e94edd3e540a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_5d708c24-b74b-403e-801c-e94edd3e540a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_850b637c-2efb-4be4-a846-a7a688df4cf8" xlink:href="bntx-20231231.xsd#bntx_ExerciseOfOptionRightsMinimumStrikePricePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_850b637c-2efb-4be4-a846-a7a688df4cf8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1ef94a6e-3867-4411-ba0b-616ed78b55d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1ef94a6e-3867-4411-ba0b-616ed78b55d3" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePricePhantomOptionsGranted_bd50e6ac-7434-4882-8e72-a989f87a1caf" xlink:href="bntx-20231231.xsd#bntx_ExercisePricePhantomOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExercisePricePhantomOptionsGranted_bd50e6ac-7434-4882-8e72-a989f87a1caf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_418a829f-13dd-40c4-a53c-fd882b451198" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_418a829f-13dd-40c4-a53c-fd882b451198" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_29fda2de-0341-4454-bd23-36582433e943" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_29fda2de-0341-4454-bd23-36582433e943" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_ca1a74f6-1e30-49f3-b2d1-85350f004146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_ca1a74f6-1e30-49f3-b2d1-85350f004146" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_2c446537-280b-4fae-b3ff-810bca58c6a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_2c446537-280b-4fae-b3ff-810bca58c6a7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_f554520d-3d4a-4fc8-9309-93b9fbb838f6" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_f554520d-3d4a-4fc8-9309-93b9fbb838f6" xlink:type="arc" order="29"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_1e61c841-1d5a-4432-bf4a-efdafba940b4" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_1e61c841-1d5a-4432-bf4a-efdafba940b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_82f5664c-7384-418c-9473-2d16ac01dfa9" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_82f5664c-7384-418c-9473-2d16ac01dfa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_a7f27a8a-0276-4bb6-89dc-95fab86a8a36" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_a7f27a8a-0276-4bb6-89dc-95fab86a8a36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_172228fd-201c-45a5-a1f5-286fdb399127" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_172228fd-201c-45a5-a1f5-286fdb399127" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_ce8c633b-e5d6-4a40-9e69-fd28ae1a2918" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_ce8c633b-e5d6-4a40-9e69-fd28ae1a2918" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_0eeae749-5ab8-4090-9e77-3b2c3d17c5f6" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_0eeae749-5ab8-4090-9e77-3b2c3d17c5f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:href="bntx-20231231.xsd#bntx_ShareOptionsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_ddb1bf2a-5d98-423f-bdc0-55b47e0f9b3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_ddb1bf2a-5d98-423f-bdc0-55b47e0f9b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9d8b2d29-9e78-4c52-b3a7-6c42fe8fc4a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9d8b2d29-9e78-4c52-b3a7-6c42fe8fc4a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_9275e41b-d29d-4a28-bb95-bb965999bf13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_9275e41b-d29d-4a28-bb95-bb965999bf13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_e1507b84-fb4b-4f97-86b6-e1ef463bc4ab" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_e1507b84-fb4b-4f97-86b6-e1ef463bc4ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1804f4e8-d76b-40e1-bf6c-be227b85213f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1804f4e8-d76b-40e1-bf6c-be227b85213f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_e1645238-2972-4115-b1cb-138ed724a2c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_6b96a837-c6d0-4251-9630-4b6157d6a141" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_6b96a837-c6d0-4251-9630-4b6157d6a141" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_204011ff-4ab7-46fd-96ef-684d44598e28" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_204011ff-4ab7-46fd-96ef-684d44598e28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_269edd1c-2b6a-4481-b987-104ac8734312" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_269edd1c-2b6a-4481-b987-104ac8734312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_304c6626-0646-4dbf-96bd-8bf8eb6e2c0d" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_304c6626-0646-4dbf-96bd-8bf8eb6e2c0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_c3c12644-55c8-4ccb-9c8a-83d4403ee809" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_c3c12644-55c8-4ccb-9c8a-83d4403ee809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_165f71f7-d548-4b63-878b-00d646fc5e8b" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_5416a990-9ae3-4014-bfe0-e79e2249281a" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_5416a990-9ae3-4014-bfe0-e79e2249281a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_63a18f92-de79-4f74-a1c5-6bbe0b79d88c" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_63a18f92-de79-4f74-a1c5-6bbe0b79d88c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4349e886-cf0b-4da9-8add-a50475877913" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4349e886-cf0b-4da9-8add-a50475877913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_42421a81-4ebb-4030-a077-73817e99548f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_42421a81-4ebb-4030-a077-73817e99548f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_03609db5-44bb-4cc2-8833-a7e1f10ebfe0" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_03609db5-44bb-4cc2-8833-a7e1f10ebfe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_b80538d8-4abc-4c7f-9433-d2cf23287ea6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_75aa3529-6393-4c62-b6a7-af1f10eec25d" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_75aa3529-6393-4c62-b6a7-af1f10eec25d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_c9a674ba-6b45-4242-9d78-924421f79d9b" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_c9a674ba-6b45-4242-9d78-924421f79d9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_c9c0bc40-71d6-4414-af95-83da309691b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_c9c0bc40-71d6-4414-af95-83da309691b1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d05528be-6f12-4ca2-907d-d84e2da55739_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d05528be-6f12-4ca2-907d-d84e2da55739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_20ea9ea5-9511-4052-a0d6-5493c60fc619" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_20ea9ea5-9511-4052-a0d6-5493c60fc619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_b6aa9555-017b-4538-92fe-d34b93c7336b" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_b6aa9555-017b-4538-92fe-d34b93c7336b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_09ab4481-5866-458a-aee4-243720e41b9c" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_09ab4481-5866-458a-aee4-243720e41b9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_89d72db4-fddc-4684-a835-1d3ab0c93b04" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_89d72db4-fddc-4684-a835-1d3ab0c93b04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_cb0e315e-cc2a-4d87-88e5-f48cb7300b50" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_ManagementBoardGrantMember_cb0e315e-cc2a-4d87-88e5-f48cb7300b50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_7348fec6-b489-4aa7-97ac-154d10d114a4" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_7348fec6-b489-4aa7-97ac-154d10d114a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_2545e7e5-d922-4f6a-baf1-12b54a9f0de0" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_2545e7e5-d922-4f6a-baf1-12b54a9f0de0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_70f3ede4-3561-408b-8ba0-abaeccc54d9f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_70f3ede4-3561-408b-8ba0-abaeccc54d9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_081a69dc-6e85-426d-a119-776d74fd4e8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:to="loc_srt_ScenarioForecastMember_081a69dc-6e85-426d-a119-776d74fd4e8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_980cef80-2be8-4975-ac33-046fda8c57d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_980cef80-2be8-4975-ac33-046fda8c57d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateOneMember_fc3cb5d1-225c-4527-8df3-7fda9f2186a8" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateOneMember_fc3cb5d1-225c-4527-8df3-7fda9f2186a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateTwoMember_78a734e1-a92f-44e9-b434-b055997a4da7" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateTwoMember_78a734e1-a92f-44e9-b434-b055997a4da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateThreeMember_7f3dfb4f-3f29-45f7-9f14-03c00c9aa66c" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateThreeMember_7f3dfb4f-3f29-45f7-9f14-03c00c9aa66c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateFourMember_1d3afef6-37ea-4c83-9264-d820e98dea2a" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateFourMember_1d3afef6-37ea-4c83-9264-d820e98dea2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9c910714-c06b-4a8d-a211-156196b9933b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9c910714-c06b-4a8d-a211-156196b9933b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_838867d2-72fa-4742-be98-92a34e4f4349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_838867d2-72fa-4742-be98-92a34e4f4349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_e66d79b9-adad-477e-98e1-37133a40241d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_e66d79b9-adad-477e-98e1-37133a40241d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_c3e0da05-cc91-4e70-bd99-566fc2e30927" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_c3e0da05-cc91-4e70-bd99-566fc2e30927" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_8205903a-a24a-479f-9ec0-a71d098a87a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_8205903a-a24a-479f-9ec0-a71d098a87a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_20c049a5-265f-4f95-8e5a-341a500f7847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_20c049a5-265f-4f95-8e5a-341a500f7847" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0d598417-6048-4702-b83f-16852a6c274e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0d598417-6048-4702-b83f-16852a6c274e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_89fbf4c4-5ec0-48cb-9a34-9b6eba4b7431" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:to="loc_bntx_ManagementBoardGrantMember_89fbf4c4-5ec0-48cb-9a34-9b6eba4b7431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_ac6d3795-b383-487e-984d-3268e10ccfdd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:to="loc_ifrs-full_NonadjustingEventsMember_ac6d3795-b383-487e-984d-3268e10ccfdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:to="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateOneMember_5362e317-1479-4e3f-94bc-ab7ecfaef6f9" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateOneMember_5362e317-1479-4e3f-94bc-ab7ecfaef6f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateTwoMember_be1c4339-ca2e-40fd-980a-c09ca553fa01" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateTwoMember_be1c4339-ca2e-40fd-980a-c09ca553fa01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateThreeMember_1d12c266-84cc-4aeb-9f2b-0a914b822b53" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateThreeMember_1d12c266-84cc-4aeb-9f2b-0a914b822b53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateFourMember_c219377c-38a5-4b31-9b47-5cf593899252" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateFourMember_c219377c-38a5-4b31-9b47-5cf593899252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_bc39a34e-f220-421e-9f2c-b2be6f7945c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_bc39a34e-f220-421e-9f2c-b2be6f7945c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_8459f37e-4846-4d35-a25c-688df9adc122" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_8459f37e-4846-4d35-a25c-688df9adc122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_3d6ae9eb-baa8-4163-9d2c-0060328a3c28" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_3d6ae9eb-baa8-4163-9d2c-0060328a3c28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_eb225bd0-e1a3-4b25-8849-258e067981be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_eb225bd0-e1a3-4b25-8849-258e067981be" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:to="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_70328aed-adf1-4457-8d69-6f01ea4d8fb5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_70328aed-adf1-4457-8d69-6f01ea4d8fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_694ec5f4-8b20-4d29-9f46-69646fc2fb7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_694ec5f4-8b20-4d29-9f46-69646fc2fb7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_df941ced-9240-4abb-81ce-9f6b38335660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_df941ced-9240-4abb-81ce-9f6b38335660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_11a6aa6d-f4b1-4ac3-82c1-c8a1f2383c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_11a6aa6d-f4b1-4ac3-82c1-c8a1f2383c5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_ed857bfd-0e3f-4f06-bad5-4f445a3e2f25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_ed857bfd-0e3f-4f06-bad5-4f445a3e2f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_e3e7cb3a-59ef-4a02-982e-a5b63a14fd17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_e3e7cb3a-59ef-4a02-982e-a5b63a14fd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_7e1ade11-3ece-4f89-89b9-e7ef5f5433c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_7e1ade11-3ece-4f89-89b9-e7ef5f5433c5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_452818ef-9f36-4b43-90d9-a9bf71da7d2d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_452818ef-9f36-4b43-90d9-a9bf71da7d2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_b577aa63-3a32-477b-b018-dba2dd5e5280" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_ifrs-full_BuildingsMember_b577aa63-3a32-477b-b018-dba2dd5e5280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_9ba60bfd-abce-415a-9c7c-240002389bda" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_bntx_ProductionFacilitiesMember_9ba60bfd-abce-415a-9c7c-240002389bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherOperatingEquipmentMember_61d16a8d-829c-4c9d-9890-1b37b08569bb" xlink:href="bntx-20231231.xsd#bntx_OtherOperatingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_bntx_OtherOperatingEquipmentMember_61d16a8d-829c-4c9d-9890-1b37b08569bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_0a8d460b-e818-4892-b2ec-16d2518f094d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:to="loc_ifrs-full_RightofuseAssets_0a8d460b-e818-4892-b2ec-16d2518f094d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_4e09111e-10df-4560-b068-2798c83a39e2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_4e09111e-10df-4560-b068-2798c83a39e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_70d0a010-0c3e-4264-9e60-f3808ef57e09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_ifrs-full_BuildingsMember_70d0a010-0c3e-4264-9e60-f3808ef57e09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_52810f2b-8ed7-49ce-9fbb-ae9587f97f43" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_bntx_ProductionFacilitiesMember_52810f2b-8ed7-49ce-9fbb-ae9587f97f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherOperatingEquipmentMember_c216a1da-d3e9-4d08-bc88-b36eb44615b6" xlink:href="bntx-20231231.xsd#bntx_OtherOperatingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_bntx_OtherOperatingEquipmentMember_c216a1da-d3e9-4d08-bc88-b36eb44615b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_27782d65-4d0f-40e5-872c-ec4364048cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_27782d65-4d0f-40e5-872c-ec4364048cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7365bc4d-e19f-4a76-b1f7-5c355722fc64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7365bc4d-e19f-4a76-b1f7-5c355722fc64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_de412823-b767-425a-a26d-14de396cac8b" xlink:href="bntx-20231231.xsd#bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_de412823-b767-425a-a26d-14de396cac8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_f614c206-2248-4952-af04-8595b9c730ab" xlink:href="bntx-20231231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_f614c206-2248-4952-af04-8595b9c730ab" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:to="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98170719-0cc6-4ff8-b068-53deec9ed1db_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98170719-0cc6-4ff8-b068-53deec9ed1db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardMember_95c94386-62f7-467a-acc5-a71633128bc4" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:to="loc_bntx_ManagementBoardMember_95c94386-62f7-467a-acc5-a71633128bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SupervisoryBoardMember_d6bc4356-c7f6-465d-813d-81b7d9ce86f5" xlink:href="bntx-20231231.xsd#bntx_SupervisoryBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:to="loc_bntx_SupervisoryBoardMember_d6bc4356-c7f6-465d-813d-81b7d9ce86f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:to="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d9026027-34a8-479a-a906-d0a1684395f2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d9026027-34a8-479a-a906-d0a1684395f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JensHolsteinMember_6059d206-2366-4e6d-8d74-d0ed5d32c816" xlink:href="bntx-20231231.xsd#bntx_JensHolsteinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:to="loc_bntx_JensHolsteinMember_6059d206-2366-4e6d-8d74-d0ed5d32c816" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_204d7e88-5e10-49c4-9c52-3d461b00abcf" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_204d7e88-5e10-49c4-9c52-3d461b00abcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_61520f30-d6db-454d-a445-49074cd0253c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_61520f30-d6db-454d-a445-49074cd0253c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_1a2d901e-d869-457f-a969-2f6b452e6cc4" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_1a2d901e-d869-457f-a969-2f6b452e6cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_fd7be7ff-6e2f-4307-8732-2f25ff6b7dc5" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationOtherVariableCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_fd7be7ff-6e2f-4307-8732-2f25ff6b7dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_8a4f11f1-016d-4a60-9eaa-4de0e8a32f7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_8a4f11f1-016d-4a60-9eaa-4de0e8a32f7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_f3986388-8c2f-4a0b-b242-78d4c3bc7996" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_f3986388-8c2f-4a0b-b242-78d4c3bc7996" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_944a6d33-3365-4bf0-8449-589e663e48a3" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_944a6d33-3365-4bf0-8449-589e663e48a3" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_28e8612c-c6c3-4000-b3e1-9e327fdd05fb_default" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:to="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_28e8612c-c6c3-4000-b3e1-9e327fdd05fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:to="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlan2018Member_0bb59f77-bf20-4ab0-8894-61cabe1f03a2" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:to="loc_bntx_EmployeeStockOwnershipPlan2018Member_0bb59f77-bf20-4ab0-8894-61cabe1f03a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_eb4a76c2-8aae-4801-836d-8eafb062a1b0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_eb4a76c2-8aae-4801-836d-8eafb062a1b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOptionPlanMember_31ad447b-99a6-4469-86f2-86714750e57c" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:to="loc_bntx_EmployeeStockOptionPlanMember_31ad447b-99a6-4469-86f2-86714750e57c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79d12565-5b98-4738-85ca-7dc04640f8ed_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_79d12565-5b98-4738-85ca-7dc04640f8ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SeanMarettMember_643aceab-ed39-49ec-b0a5-46b1ae0109f3" xlink:href="bntx-20231231.xsd#bntx_SeanMarettMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:to="loc_bntx_SeanMarettMember_643aceab-ed39-49ec-b0a5-46b1ae0109f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_f168b5ea-3fe4-4481-b705-05a6b6209d45_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_f168b5ea-3fe4-4481-b705-05a6b6209d45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_361686fb-f4f0-4d51-9632-ba5ef768bd30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_361686fb-f4f0-4d51-9632-ba5ef768bd30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_f623397e-3f54-410d-8b4b-1032915c9eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_f623397e-3f54-410d-8b4b-1032915c9eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3edb0fb8-5e71-477f-b7d1-6c7affb36048" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3edb0fb8-5e71-477f-b7d1-6c7affb36048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsHeld_48b372c1-f995-4036-95f3-15ccb170925d" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_bntx_NumberOfShareOptionsHeld_48b372c1-f995-4036-95f3-15ccb170925d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_e5188107-5cd0-4930-afff-048cda57065c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_e5188107-5cd0-4930-afff-048cda57065c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_26c52f3e-3c1d-486a-a5d4-2d86997d1552" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_26c52f3e-3c1d-486a-a5d4-2d86997d1552" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_ee5b0c96-122c-4a4d-8e6c-2cdd256090c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_ee5b0c96-122c-4a4d-8e6c-2cdd256090c4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_57138aa7-501c-4dc9-9f69-ee53d96c5ad4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_57138aa7-501c-4dc9-9f69-ee53d96c5ad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_da5991a9-f2eb-454f-837f-a49e6252ba4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_da5991a9-f2eb-454f-837f-a49e6252ba4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_bfd7cf57-4dd0-4f1f-a312-f51c8a0e1fe5" xlink:href="bntx-20231231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_bfd7cf57-4dd0-4f1f-a312-f51c8a0e1fe5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_f6a8c0b0-fde0-4019-a223-a01ffd8ae66e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_f6a8c0b0-fde0-4019-a223-a01ffd8ae66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesFromRelatedPartyTransactions_e083bbd3-6ae8-4997-8045-132e64663ab5" xlink:href="bntx-20231231.xsd#bntx_PurchasesFromRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_bntx_PurchasesFromRelatedPartyTransactions_e083bbd3-6ae8-4997-8045-132e64663ab5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1ecd9399-e7e8-4526-b5de-63c1559f651a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1ecd9399-e7e8-4526-b5de-63c1559f651a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_d478c57a-f911-4909-83f1-3d513fa70ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_d478c57a-f911-4909-83f1-3d513fa70ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:to="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATHOSKGMember_507834a0-5539-406f-ba06-62d06d9362ff" xlink:href="bntx-20231231.xsd#bntx_ATHOSKGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:to="loc_bntx_ATHOSKGMember_507834a0-5539-406f-ba06-62d06d9362ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_91044813-a824-462b-8c54-d89d5b48c018" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_91044813-a824-462b-8c54-d89d5b48c018" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#EventsAftertheReportingPeriodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_1f04dec8-4b62-41b5-89fd-ff86c320c381_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:to="loc_ifrs-full_NonadjustingEventsMember_1f04dec8-4b62-41b5-89fd-ff86c320c381_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:to="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LicenseAndOptionAgreementMember_298ebc81-1b5f-4f65-9de3-250ea1abe4d1" xlink:href="bntx-20231231.xsd#bntx_LicenseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:to="loc_bntx_LicenseAndOptionAgreementMember_298ebc81-1b5f-4f65-9de3-250ea1abe4d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfSharesUnderAgreement_e85c4964-3a8c-443f-b65d-08a83e597399" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfSharesUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_bntx_PurchaseOfSharesUnderAgreement_e85c4964-3a8c-443f-b65d-08a83e597399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_b2b8886f-ee72-45cb-85d1-5442aae931cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_b2b8886f-ee72-45cb-85d1-5442aae931cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPayment_6cbf2295-b19f-4f79-b151-1f02b33cd299" xlink:href="bntx-20231231.xsd#bntx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_bntx_UpfrontPayment_6cbf2295-b19f-4f79-b151-1f02b33cd299" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>bntx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_c95d4351-f70e-4804-9a26-c7b7b3ea34c7_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of dilution from share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on weighted average number of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lab_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OperatingAndBusinessEquipmentMember_5b943cb9-dc32-47c2-9911-27bcd9d15e94_terseLabel_en-US" xlink:label="lab_bntx_OperatingAndBusinessEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating And Business Equipment</link:label>
    <link:label id="lab_bntx_OperatingAndBusinessEquipmentMember_label_en-US" xlink:label="lab_bntx_OperatingAndBusinessEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Business Equipment [Member]</link:label>
    <link:label id="lab_bntx_OperatingAndBusinessEquipmentMember_documentation_en-US" xlink:label="lab_bntx_OperatingAndBusinessEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Business Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OperatingAndBusinessEquipmentMember" xlink:href="bntx-20231231.xsd#bntx_OperatingAndBusinessEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OperatingAndBusinessEquipmentMember" xlink:to="lab_bntx_OperatingAndBusinessEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_7e7d647b-a168-40fd-a909-1cc1539411f8_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DeferredTaxAssetsSettlement_687e9cbe-5209-4e3b-8e0d-9e37ea1a5384_terseLabel_en-US" xlink:label="lab_bntx_DeferredTaxAssetsSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets settlement</link:label>
    <link:label id="lab_bntx_DeferredTaxAssetsSettlement_label_en-US" xlink:label="lab_bntx_DeferredTaxAssetsSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Settlement</link:label>
    <link:label id="lab_bntx_DeferredTaxAssetsSettlement_documentation_en-US" xlink:label="lab_bntx_DeferredTaxAssetsSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxAssetsSettlement" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxAssetsSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DeferredTaxAssetsSettlement" xlink:to="lab_bntx_DeferredTaxAssetsSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PerformanceObligationsAxis_f27d743f-5d13-4d2f-af40-fdee2e42c449_terseLabel_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations [axis]</link:label>
    <link:label id="lab_ifrs-full_PerformanceObligationsAxis_label_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance obligations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PerformanceObligationsAxis" xlink:to="lab_ifrs-full_PerformanceObligationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SaleOfStockDomain_b55aef95-dcf6-4c41-b04a-7bd6be8600c8_terseLabel_en-US" xlink:label="lab_bntx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_bntx_SaleOfStockDomain_label_en-US" xlink:label="lab_bntx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_bntx_SaleOfStockDomain_documentation_en-US" xlink:label="lab_bntx_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockDomain" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SaleOfStockDomain" xlink:to="lab_bntx_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_f608abe2-4251-4846-acc1-13da1bc68f8a_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average price paid per ADS (in dollar per share and euro per share)</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Average Price Per American depositary Share (ADS)</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Average Price Per American depositary Share (ADS)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:to="lab_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_47ae8aa8-9c19-4988-ae7f-5c40ea05df60_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_646a39e3-bd7d-46af-84a4-8cd01f77b98e_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_9ed85886-dd05-44f6-8c91-a036b13f4f91_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7b1570f6-6c20-4f92-a5b2-64bb7193f2ff_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments (incl. long-term incentive)</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechEuropeGmbHMember_56e997dc-fcff-4c8e-a881-2febe50ee024_terseLabel_en-US" xlink:label="lab_bntx_BioNTechEuropeGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Europe GmbH</link:label>
    <link:label id="lab_bntx_BioNTechEuropeGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechEuropeGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Europe GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechEuropeGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechEuropeGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Europe GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEuropeGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechEuropeGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechEuropeGmbHMember" xlink:to="lab_bntx_BioNTechEuropeGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialLiabilities_d1842fb8-478b-4382-81ee-e9bdc92c4e6c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialLiabilities_75a2ea65-9712-42c9-8a1b-c87915635d93_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:to="lab_ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_e95730d5-9bc1-4fc8-bfab-31a5c1355413_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember_7a30d144-36aa-403a-ae0b-e4a60856b352_terseLabel_en-US" xlink:label="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current obligations under lease contracts</link:label>
    <link:label id="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember_label_en-US" xlink:label="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Obligations Under Lease Contracts [Member]</link:label>
    <link:label id="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember_documentation_en-US" xlink:label="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Obligations Under Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:href="bntx-20231231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:to="lab_bntx_NoncurrentObligationsUnderLeaseContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentProvisions_f6700dec-9c09-41f2-abd7-84634713f9c8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_a18f8ab7-c8a7-473d-a872-4ceb40e5cba3_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_16f2ed33-a53c-4bf6-b631-b5ccd1c6569a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_4bcca6ec-c1a8-450d-8ba0-b0d03a8e096b_terseLabel_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of collaboration partners&#8217; gross profit and sales milestones</link:label>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_label_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones [Member]</link:label>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_documentation_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:to="lab_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsLineItems_e688530e-43b1-4f43-931f-8c2f5ee91d0f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of performance obligations [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of performance obligations [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_9bbcbd39-d747-47b4-82bd-5b5a9d87c852_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of loans and borrowings</link:label>
    <link:label id="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_1e619664-51cd-453a-875c-2e672422df94_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments under purchase agreements for property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_7f7fa2c2-6751-47c1-8a19-1d999bcd9843_terseLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wages and salaries</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechDiagnosticsGmbHMember_de163fa9-8bdf-4a6d-a5e3-64f966bfa1c3_terseLabel_en-US" xlink:label="lab_bntx_BioNTechDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Diagnostics GmbH</link:label>
    <link:label id="lab_bntx_BioNTechDiagnosticsGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Diagnostics GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechDiagnosticsGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechDiagnosticsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Diagnostics GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDiagnosticsGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechDiagnosticsGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechDiagnosticsGmbHMember" xlink:to="lab_bntx_BioNTechDiagnosticsGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_cf6f3b15-8c45-4304-bd13-9bc5787b5883_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_222f5c59-b788-4aa8-a97a-fb7b977108bb_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="lab_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_f7228095-6a50-4651-b8e9-80d4e7889621_terseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof allocated and un-vested (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_4ea15b67-0dd9-491f-bb24-3944af141b6a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashOutflowToTaxAuthority_3966212d-bd95-4d91-9c15-40468bb1bf55_terseLabel_en-US" xlink:label="lab_bntx_CashOutflowToTaxAuthority" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash outflow to tax authority</link:label>
    <link:label id="lab_bntx_CashOutflowToTaxAuthority_label_en-US" xlink:label="lab_bntx_CashOutflowToTaxAuthority" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Outflow To Tax Authority</link:label>
    <link:label id="lab_bntx_CashOutflowToTaxAuthority_documentation_en-US" xlink:label="lab_bntx_CashOutflowToTaxAuthority" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Outflow To Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowToTaxAuthority" xlink:href="bntx-20231231.xsd#bntx_CashOutflowToTaxAuthority"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashOutflowToTaxAuthority" xlink:to="lab_bntx_CashOutflowToTaxAuthority" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CommercialMember_1e103d2c-1ca7-4f92-bece-bb1d7879ff9d_terseLabel_en-US" xlink:label="lab_bntx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial revenues</link:label>
    <link:label id="lab_bntx_CommercialMember_label_en-US" xlink:label="lab_bntx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_bntx_CommercialMember_documentation_en-US" xlink:label="lab_bntx_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CommercialMember" xlink:to="lab_bntx_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheTwoMember_5ed66ee3-a1de-41f1-bd77-7e237e05638c_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche Two</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheTwoMember_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche Two [Member]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheTwoMember_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:to="lab_bntx_ShareRepurchaseProgramTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_758acb6c-b02a-47b6-b67e-f89dbd7f370e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_496fb2ca-30b3-4b14-aeee-0b6ec2e17dbe_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_d72c66de-3b58-49a3-a8b0-40c7f52e1163_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goods and services transferred over time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred over time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_a5633dde-8664-4707-a643-5a79fa53d19b_terseLabel_en-US" xlink:label="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax losses</link:label>
    <link:label id="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label id="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:href="bntx-20231231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_7afcc672-fc26-485b-8ce7-5bdf623abadf_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets - current</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_3f291901-6549-4fa7-96be-98c44d48acff_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_DisposalsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0f497bd2-a18a-46db-8bf8-df4248c1998a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_b0db176c-151e-4e7b-a2eb-b570d88da7fb_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_289dd5b3-6273-4b16-8cb3-b0620aaf00b9_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_label_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechResearchAndDevelopmentInc.Member_6fbfe5f9-9f37-4a36-9b08-e635081e319e_terseLabel_en-US" xlink:label="lab_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Research and Development, Inc.</link:label>
    <link:label id="lab_bntx_BioNTechResearchAndDevelopmentInc.Member_label_en-US" xlink:label="lab_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Research and Development, Inc. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechResearchAndDevelopmentInc.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Research and Development, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechResearchAndDevelopmentInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:to="lab_bntx_BioNTechResearchAndDevelopmentInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ProductionFacilitiesMember_61e1aaf2-a4e7-4ae5-a486-71bdeadefc23_terseLabel_en-US" xlink:label="lab_bntx_ProductionFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Production facilities</link:label>
    <link:label id="lab_bntx_ProductionFacilitiesMember_label_en-US" xlink:label="lab_bntx_ProductionFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Production Facilities [Member]</link:label>
    <link:label id="lab_bntx_ProductionFacilitiesMember_documentation_en-US" xlink:label="lab_bntx_ProductionFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Production Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ProductionFacilitiesMember" xlink:to="lab_bntx_ProductionFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_778e4a59-176e-4a30-a7c4-d55256a77a03_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_e0894d21-91db-44c2-aebe-d75e3432b528_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_e5759e54-7b79-4430-ad5c-abf7e0874dfd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments, class</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_d1d90b8a-6658-4b44-a6d9-b39abb05c6ea_negatedTerseLabel_en-US" xlink:label="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets and right-of-use assets</link:label>
    <link:label id="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities</link:label>
    <link:label id="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:to="lab_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2166ae16-a8c8-4071-be65-5f5f6d682916_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_54de9420-e546-45bb-9a1f-d6f289ac1cb7_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:to="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowings_1248c75a-43a6-420f-93f2-cbe75c6ca0ff_terseLabel_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans and borrowings</link:label>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowings_label_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Loans And Borrowings</link:label>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowings_documentation_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Bearing Loans And Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowings" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InterestBearingLoansAndBorrowings" xlink:to="lab_bntx_InterestBearingLoansAndBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_3746c03c-f9b8-4651-81cb-486bed74f99f_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_6e755409-c19e-4a93-a879-c42562ed1a55_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain on equity instruments designated at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits_edec9130-476d-4fc1-b1c5-4189b201123f_terseLabel_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax credits</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits_label_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Federal Tax Credits</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits_documentation_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Federal Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:to="lab_bntx_AccumulatedTaxLossesInFederalTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_cae74d7f-88c9-4d4f-8051-8781f0724f7f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_19848f67-d49f-42ba-a1bd-98693395108c_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents resulting from exchange rate differences</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_aac44451-77f3-4d34-8f24-6b04df9d796a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_label_en-US" xlink:label="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current raw materials and current production supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="lab_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_de6840e0-6f11-468b-b70e-969fe2c015db_verboseLabel_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_AmountsPayableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts payable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_151a313b-7d40-4bcd-a897-88f67ab44a37_verboseLabel_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_cffe02d4-957b-4cb5-a35e-492649e1bf8f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_050bd199-d6e3-4e0f-9d72-f67239b802ca_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid and realized losses from cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_671efd27-1c49-4e58-92d0-510ce1ba60bb_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_491fb995-5bd5-462b-a4a8-994f27c49144_terseLabel_en-US" xlink:label="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum cash payment</link:label>
    <link:label id="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Cash Payment In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Cash Payment In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_MaximumCashPaymentInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:to="lab_bntx_MaximumCashPaymentInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RedemptionOfConvertibleNote_c69c6bae-67ad-484e-a53e-9436c1b71eb1_terseLabel_en-US" xlink:label="lab_bntx_RedemptionOfConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of convertible note</link:label>
    <link:label id="lab_bntx_RedemptionOfConvertibleNote_label_en-US" xlink:label="lab_bntx_RedemptionOfConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of Convertible Note</link:label>
    <link:label id="lab_bntx_RedemptionOfConvertibleNote_documentation_en-US" xlink:label="lab_bntx_RedemptionOfConvertibleNote" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Of Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RedemptionOfConvertibleNote" xlink:href="bntx-20231231.xsd#bntx_RedemptionOfConvertibleNote"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RedemptionOfConvertibleNote" xlink:to="lab_bntx_RedemptionOfConvertibleNote" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisions_96ddab2d-19c0-4a43-8a2c-3a51353c0bc8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_OtherProvisions_label_en-US" xlink:label="lab_ifrs-full_OtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisions" xlink:to="lab_ifrs-full_OtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_7d82d851-bb87-472a-b92a-feff8cf9568a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Preparation</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems_3d91f5c3-1b66-431e-a08b-279f81178fdd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reserves within equity [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reserves within equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_21ed2425-9ba0-455a-a45c-d32455c2b912_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SeanMarettMember_43ad5d96-ad28-481b-b943-e2fac424d10e_terseLabel_en-US" xlink:label="lab_bntx_SeanMarettMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sean Marett</link:label>
    <link:label id="lab_bntx_SeanMarettMember_label_en-US" xlink:label="lab_bntx_SeanMarettMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sean Marett [Member]</link:label>
    <link:label id="lab_bntx_SeanMarettMember_documentation_en-US" xlink:label="lab_bntx_SeanMarettMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sean Marett</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SeanMarettMember" xlink:href="bntx-20231231.xsd#bntx_SeanMarettMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SeanMarettMember" xlink:to="lab_bntx_SeanMarettMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesFairValueMeasurementLiabilities_f3fcc747-7e06-4ece-8264-faa769938d6b_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_ifrs-full_PurchasesFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_PurchasesFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases, fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_PurchasesFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_78fada0d-0ee3-46ad-9529-3a61c1887e9b_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherFinancialLiabilitiesMember_fbdd2430-c0d0-4dfa-9ddc-bd45c376fb23_terseLabel_en-US" xlink:label="lab_bntx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_bntx_OtherFinancialLiabilitiesMember_label_en-US" xlink:label="lab_bntx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities [Member]</link:label>
    <link:label id="lab_bntx_OtherFinancialLiabilitiesMember_documentation_en-US" xlink:label="lab_bntx_OtherFinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialLiabilitiesMember" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherFinancialLiabilitiesMember" xlink:to="lab_bntx_OtherFinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_a3e10eb0-f092-4ceb-93bc-7518da474f31_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_11870cb0-a43c-48fa-a054-5feb0a4e1432_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_f9dea7e5-5c27-41bb-a0a9-3f9b4edcbdaf_terseLabel_en-US" xlink:label="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concessions, licenses, in-process R&amp;D and similar rights</link:label>
    <link:label id="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_label_en-US" xlink:label="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concessions, Licenses, In-Process Research And Development And Similar Rights [Member]</link:label>
    <link:label id="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_documentation_en-US" xlink:label="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concessions, Licenses, In-Process Research And Development And Similar Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:href="bntx-20231231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:to="lab_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SalesAndMarketingExpenseMember_3bb78348-5022-4b5b-8ca6-c3aca1a4f665_terseLabel_en-US" xlink:label="lab_bntx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:label id="lab_bntx_SalesAndMarketingExpenseMember_label_en-US" xlink:label="lab_bntx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales And Marketing Expense [Member]</link:label>
    <link:label id="lab_bntx_SalesAndMarketingExpenseMember_documentation_en-US" xlink:label="lab_bntx_SalesAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales And Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesAndMarketingExpenseMember" xlink:href="bntx-20231231.xsd#bntx_SalesAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SalesAndMarketingExpenseMember" xlink:to="lab_bntx_SalesAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AmortizedCostMember_752e968d-6de7-46f1-b87a-046e76d47d1d_terseLabel_en-US" xlink:label="lab_bntx_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AC</link:label>
    <link:label id="lab_bntx_AmortizedCostMember_label_en-US" xlink:label="lab_bntx_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost [Member]</link:label>
    <link:label id="lab_bntx_AmortizedCostMember_documentation_en-US" xlink:label="lab_bntx_AmortizedCostMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmortizedCostMember" xlink:href="bntx-20231231.xsd#bntx_AmortizedCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AmortizedCostMember" xlink:to="lab_bntx_AmortizedCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_f214588c-f736-4398-9197-ebaea5cd1aab_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_6d57984c-00ce-4103-ac2b-f8f636ff13b8_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goods and services transferred at a point in time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred at point in time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_62f0bcd5-da9c-449d-97c5-eaa02232fd5d_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_308f3b80-683c-42d2-9614-8508ec54069c_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash at banks and on hand</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesIncurred_0611a7bd-3e98-44cc-a09d-27fd53decc35_verboseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash to be paid in 2024</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesIncurred_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncurred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesIncurred" xlink:to="lab_ifrs-full_LiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_ff7e9cc4-024a-4203-95cc-13a9c564c3bb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_4359a22c-9e9b-45c1-a555-51fceae715c0_terseLabel_en-US" xlink:label="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_label_en-US" xlink:label="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:label id="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_documentation_en-US" xlink:label="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:href="bntx-20231231.xsd#bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:to="lab_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_4755928e-28fc-4f15-aaa5-fbc380ed98a3_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets with indefinite useful life</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets with indefinite useful life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:to="lab_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_39250387-3159-44df-ab03-c3b89f383c42_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, class</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EquityMethodInvestmentsOwnershipPercentage_e0ee30d4-2964-470b-99cc-bf27fcd95eae_terseLabel_en-US" xlink:label="lab_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership (as a percent)</link:label>
    <link:label id="lab_bntx_EquityMethodInvestmentsOwnershipPercentage_label_en-US" xlink:label="lab_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Ownership Percentage</link:label>
    <link:label id="lab_bntx_EquityMethodInvestmentsOwnershipPercentage_documentation_en-US" xlink:label="lab_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:href="bntx-20231231.xsd#bntx_EquityMethodInvestmentsOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:to="lab_bntx_EquityMethodInvestmentsOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_95c5ac88-4863-4309-8d7e-dbbb3514cb1f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange differences</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_77be1fac-0456-4417-92c0-65cd63566f37_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment prior year taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="lab_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_34deeb6a-af3c-404c-8446-8592d352cff1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_8df2d0b7-4f2b-4746-8958-0d9b785b5fa2_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expenses</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_label_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense" xlink:to="lab_ifrs-full_SalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_bc0def18-7410-491d-96bf-59434cb423a5_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of option rights vested (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_2da99223-db85-4bd6-b418-657812692964_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_01afd38a-2655-4365-9fc5-49db695be0ba_terseLabel_en-US" xlink:label="lab_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proposed dividends per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_label_en-US" xlink:label="lab_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:to="lab_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_d6b2e037-1272-4546-ae59-754e9f992435_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PreviouslyHeldNonListedEquityInvestment_320f257c-60ee-41c3-be14-861870e8c64f_terseLabel_en-US" xlink:label="lab_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously held non-listed equity investment (stake of 5.3%)</link:label>
    <link:label id="lab_bntx_PreviouslyHeldNonListedEquityInvestment_label_en-US" xlink:label="lab_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously-held Non-listed Equity Investment</link:label>
    <link:label id="lab_bntx_PreviouslyHeldNonListedEquityInvestment_documentation_en-US" xlink:label="lab_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Previously-held Non-listed Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:to="lab_bntx_PreviouslyHeldNonListedEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a9301b0e-e35a-46f4-96bf-2f975afbb8cc_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill (in years)</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_05156f1d-0158-494c-af81-bee0dfa04574_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_80c6d039-698f-4930-91ef-cc166bc96af9_terseLabel_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phantom shares awarded (in shares)</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_label_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Phantom Shares Awarded</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_documentation_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Phantom Shares Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:to="lab_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities_7ec2566c-78c9-4179-9d80-1df0f7edd672_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities_a657d866-eff5-4ffd-9209-8355d9e6a4d4_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total non-current</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_NoTradingSymbolFlag_c032fe09-c577-4c20-b52c-f90589a5753b_terseLabel_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:label id="lab_dei_NoTradingSymbolFlag_label_en-US" xlink:label="lab_dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">No Trading Symbol Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_NoTradingSymbolFlag" xlink:to="lab_dei_NoTradingSymbolFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_e0afa6a3-3b3e-4601-9d97-f923e064d74b_terseLabel_en-US" xlink:label="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average cost of capital (as a percent)</link:label>
    <link:label id="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_label_en-US" xlink:label="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lab_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e593f11c-5266-42b5-be19-e702d6cfd28b_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ListOfAccountingPoliciesAbstract_815bbab2-5317-4b9e-8dde-febeefb2770f_terseLabel_en-US" xlink:label="lab_bntx_ListOfAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">List Of Accounting Policies [Abstract]</link:label>
    <link:label id="lab_bntx_ListOfAccountingPoliciesAbstract_label_en-US" xlink:label="lab_bntx_ListOfAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">List Of Accounting Policies [Abstract]</link:label>
    <link:label id="lab_bntx_ListOfAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_bntx_ListOfAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">List Of Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract" xlink:to="lab_bntx_ListOfAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_1b77ea49-239c-4bde-a1f4-e4125d9796bb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ReSanoGmbHMember_5e2df649-afea-4d87-8dff-1cd064e2ea03_terseLabel_en-US" xlink:label="lab_bntx_ReSanoGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">reSano GmbH</link:label>
    <link:label id="lab_bntx_ReSanoGmbHMember_label_en-US" xlink:label="lab_bntx_ReSanoGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">reSano GmbH [Member]</link:label>
    <link:label id="lab_bntx_ReSanoGmbHMember_documentation_en-US" xlink:label="lab_bntx_ReSanoGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">reSano GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReSanoGmbHMember" xlink:href="bntx-20231231.xsd#bntx_ReSanoGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ReSanoGmbHMember" xlink:to="lab_bntx_ReSanoGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechIdarObersteinServicesGmbHMember_8a9176f8-3200-48f9-9622-6849a11c5d81_terseLabel_en-US" xlink:label="lab_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Idar-Oberstein Services GmbH</link:label>
    <link:label id="lab_bntx_BioNTechIdarObersteinServicesGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Idar-Oberstein Services GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechIdarObersteinServicesGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Idar-Oberstein Services GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechIdarObersteinServicesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:to="lab_bntx_BioNTechIdarObersteinServicesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_9eb06211-be61-48a1-bbb5-0b42996ea27c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_fd316119-64d2-4e66-b856-25856ccff951_totalLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable net assets at fair value</link:label>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_label_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_26daeda0-3038-4fee-9ebc-6a974f9327ca_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_24d4abb5-bc51-4cfd-b180-bffe0d8aa142_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement_4278ec09-7b38-457b-8221-88922809da88_terseLabel_en-US" xlink:label="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage after one year (as a percent)</link:label>
    <link:label id="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Percentage Of Share Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Percentage Of Share Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_VestingPercentageOfShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:to="lab_bntx_VestingPercentageOfShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BiopharmaBioNTechIsraelLtd.Member_49882677-242f-4d2b-8cd6-6c970c6a494c_terseLabel_en-US" xlink:label="lab_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma BioNTech Israel Ltd.</link:label>
    <link:label id="lab_bntx_BiopharmaBioNTechIsraelLtd.Member_label_en-US" xlink:label="lab_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma BioNTech Israel Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BiopharmaBioNTechIsraelLtd.Member_documentation_en-US" xlink:label="lab_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharma BioNTech Israel Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:href="bntx-20231231.xsd#bntx_BiopharmaBioNTechIsraelLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:to="lab_bntx_BiopharmaBioNTechIsraelLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SaleOfStockAxis_1ffa8a58-3d00-420d-bbec-873f081f5bdc_terseLabel_en-US" xlink:label="lab_bntx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_bntx_SaleOfStockAxis_label_en-US" xlink:label="lab_bntx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_bntx_SaleOfStockAxis_documentation_en-US" xlink:label="lab_bntx_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockAxis" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SaleOfStockAxis" xlink:to="lab_bntx_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_f05b20db-5ade-4e3b-8763-aedbf23ad107_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AT_3bfe25ab-9a7a-4619-950b-fc2f836b9a57_terseLabel_en-US" xlink:label="lab_country_AT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Austria</link:label>
    <link:label id="lab_country_AT_label_en-US" xlink:label="lab_country_AT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AUSTRIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AT" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AT" xlink:to="lab_country_AT" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_ba7a6e69-78c5-4ed6-b351-f9ec064292f9_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_4f1d3c0f-04bf-4f69-a5b8-e0470452b881_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_0b7f0a1a-36ad-4d9e-a264-f8c0650fb243_terseLabel_en-US" xlink:label="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non tax-effective share-based payment expenses</link:label>
    <link:label id="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_label_en-US" xlink:label="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Recognition Of Tax Effect On Share-Based Payment Expenses</link:label>
    <link:label id="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_documentation_en-US" xlink:label="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Recognition Of Tax Effect On Share-Based Payment Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:href="bntx-20231231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:to="lab_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_ccc808a5-5bed-4c1a-882e-c486cf0cfe33_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6663d8b7-520b-4085-8985-3d3dfa2d4796_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_695cdc67-13e3-4b4d-a868-a55e67f3ee1d_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxAssetsCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxAssetsCurrent" xlink:to="lab_ifrs-full_CurrentTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BE_713fc692-535a-40b3-934c-97f7ef034d1c_terseLabel_en-US" xlink:label="lab_country_BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Belgium</link:label>
    <link:label id="lab_country_BE_label_en-US" xlink:label="lab_country_BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BELGIUM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BE" xlink:to="lab_country_BE" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_0dd40350-8fc6-4549-a497-9543f5262258_terseLabel_en-US" xlink:label="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">-5 %</link:label>
    <link:label id="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_label_en-US" xlink:label="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Negative Five Percentage Change In Foreign Exchange Rate [Member]</link:label>
    <link:label id="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_documentation_en-US" xlink:label="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Negative Five Percentage Change In Foreign Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:href="bntx-20231231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:to="lab_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_684759c1-edff-40d9-ad0f-be4f25c64cb0_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Standards Issued but Not Yet Effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_8baef6e3-f132-4b7e-9ffb-723b78458429_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total compensation paid to key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_e6243183-bdb4-4daa-9107-e1e105b20d76_totalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_8564b2f3-c6d7-43c3-a1fd-e48ef5ccde9e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease / (increase) in inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f79309a7-924a-44b4-88bf-11acbaa6f368_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock_aa44a66f-3e6f-479e-b984-a5425b148c35_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Employee Benefits Expense</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Employee Benefits Expense Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashAndCashEquivalentsTable_2f57ad42-0b8f-4916-8f3e-a69baed8aacf_terseLabel_en-US" xlink:label="lab_bntx_CashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Table]</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalentsTable_label_en-US" xlink:label="lab_bntx_CashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Table]</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalentsTable_documentation_en-US" xlink:label="lab_bntx_CashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalentsTable" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashAndCashEquivalentsTable" xlink:to="lab_bntx_CashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_68f02847-6734-4003-aff9-4abd260c570f_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_9f70642b-cd50-499d-989a-8014504d8c5e_verboseLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_0e5ddfd7-8949-435d-82b5-f38ed006ab9f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExternalBusinessOfInstaDeepMember_9e20b360-875b-43fc-ae20-ca43bb375ac9_terseLabel_en-US" xlink:label="lab_bntx_ExternalBusinessOfInstaDeepMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External Business of InstaDeep</link:label>
    <link:label id="lab_bntx_ExternalBusinessOfInstaDeepMember_label_en-US" xlink:label="lab_bntx_ExternalBusinessOfInstaDeepMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">External Business of InstaDeep [Member]</link:label>
    <link:label id="lab_bntx_ExternalBusinessOfInstaDeepMember_documentation_en-US" xlink:label="lab_bntx_ExternalBusinessOfInstaDeepMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External Business of InstaDeep</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalBusinessOfInstaDeepMember" xlink:href="bntx-20231231.xsd#bntx_ExternalBusinessOfInstaDeepMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExternalBusinessOfInstaDeepMember" xlink:to="lab_bntx_ExternalBusinessOfInstaDeepMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_0bc87382-2bda-4dad-871a-ab8e445564b5_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_49d28ff4-4d9c-4624-889d-4c0cc5d6a388_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_826441fe-686b-4b8f-a14a-4dd7a8a814d0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_dbcaa386-3615-4bdd-9f95-10bd99f327ee_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Expense Recognized for Employee Services Received</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of effect of share-based payments on entity's profit or loss [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:to="lab_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment_855c91b9-0b37-4b34-bef6-c98cb7b0f0a5_terseLabel_en-US" xlink:label="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications Of Property, Plant And Equipment</link:label>
    <link:label id="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassifications Of Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:href="bntx-20231231.xsd#bntx_ReclassificationsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:to="lab_bntx_ReclassificationsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_344889de-b6d0-4f6a-a42d-2f311033a1a4_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_bba7da65-c2c2-4a77-9f30-fc71710de092_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_36827adb-1523-4794-a19a-c8dd70fbacc2_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finance expenses</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_0f7504ff-397b-4abd-a67c-52ca9e6ddda2_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for consolidated structured entities [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for consolidated structured entities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:to="lab_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember_ace26715-7890-4129-91b3-6584da54b8bf_terseLabel_en-US" xlink:label="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on derivative instruments at fair value through profit or loss</link:label>
    <link:label id="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember_label_en-US" xlink:label="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Derivative Instruments At Fair Value [Member]</link:label>
    <link:label id="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember_documentation_en-US" xlink:label="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Derivative Instruments At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:href="bntx-20231231.xsd#bntx_LossOnDerivativeInstrumentsAtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:to="lab_bntx_LossOnDerivativeInstrumentsAtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_6a226f07-dc77-4a53-9858-6020407611f0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share options outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_dd2f4e5f-f7d0-483f-8855-4f0777b20455_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_d7677972-6bfa-481a-9b63-01437898cdd1_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_af8c00c7-8835-4741-ac40-fa9f18a90e67_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Phantom) share options outstanding (expected to be allocated) (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_26451e16-51c0-4f26-85a5-27c3600289c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Financial Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_f9aeb21b-3fdb-4357-b9ef-e14c2482e70a_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ADS to ordinary shares (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_label_en-US" xlink:label="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of American Depository Shares To Ordinary Shares</link:label>
    <link:label id="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_documentation_en-US" xlink:label="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of American Depository Shares To Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:href="bntx-20231231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:to="lab_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_0e6bf7bd-5e0d-4c7e-87b0-f7b02bf25280_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption_57264397-0721-49e7-aecb-1c55225fe344_terseLabel_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related to release and consumption</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption_label_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Release And Consumption</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption_documentation_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Release And Consumption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:to="lab_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeStockOptionPlanMember_ba283ed0-9e49-498b-a03b-6671273ea2d5_terseLabel_en-US" xlink:label="lab_bntx_EmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option Plan</link:label>
    <link:label id="lab_bntx_EmployeeStockOptionPlanMember_label_en-US" xlink:label="lab_bntx_EmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option Plan [Member]</link:label>
    <link:label id="lab_bntx_EmployeeStockOptionPlanMember_documentation_en-US" xlink:label="lab_bntx_EmployeeStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Option Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOptionPlanMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeStockOptionPlanMember" xlink:to="lab_bntx_EmployeeStockOptionPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_cb55bf3f-9892-4864-859e-f002d06f2963_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_00b74430-f1fe-4a30-85be-267cfd208543_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_30dd384f-f890-4602-a29d-5d17f47baf93_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NewTechnologiesReMember_430d19d8-b746-4c6e-8e9b-f72462fcc792_terseLabel_en-US" xlink:label="lab_bntx_NewTechnologiesReMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Technologies Re&#8203;</link:label>
    <link:label id="lab_bntx_NewTechnologiesReMember_label_en-US" xlink:label="lab_bntx_NewTechnologiesReMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Technologies Re&#8203; [Member]</link:label>
    <link:label id="lab_bntx_NewTechnologiesReMember_documentation_en-US" xlink:label="lab_bntx_NewTechnologiesReMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Technologies Re&#8203;</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NewTechnologiesReMember" xlink:href="bntx-20231231.xsd#bntx_NewTechnologiesReMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NewTechnologiesReMember" xlink:to="lab_bntx_NewTechnologiesReMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_04459a40-4acf-450e-b800-1672e692a28b_terseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof un-vested (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Unested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Unested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_c1f7387d-ddf3-41eb-a8c4-e8791539e0ce_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_36c92b1b-d644-4a67-b834-cc3ec8462f3a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_82cff4cc-4b52-461b-885a-cf337c7aafc8_terseLabel_en-US" xlink:label="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Innovation and Services Marburg GmbH</link:label>
    <link:label id="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Innovation and Services Marburg GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Innovation and Services Marburg GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationAndServicesMarburgGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:to="lab_bntx_BioNTechInnovationAndServicesMarburgGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_b96601cd-1cca-46d9-9be6-2c4b2ba631d1_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_db0cd676-9b0e-4777-92a6-be2e68174046_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DerivativeLiabilitiesMember_0bfaa032-3ba6-43b1-9808-da272c28ece3_terseLabel_en-US" xlink:label="lab_bntx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_bntx_DerivativeLiabilitiesMember_label_en-US" xlink:label="lab_bntx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liabilities [Member]</link:label>
    <link:label id="lab_bntx_DerivativeLiabilitiesMember_documentation_en-US" xlink:label="lab_bntx_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DerivativeLiabilitiesMember" xlink:href="bntx-20231231.xsd#bntx_DerivativeLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DerivativeLiabilitiesMember" xlink:to="lab_bntx_DerivativeLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_f64a97b6-5de9-49ef-8522-e022284c33e2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_1b2ddf90-c2b0-4d2e-942f-9df4e29a8955_terseLabel_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of collaboration partners' sales milestones</link:label>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_label_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones [Member]</link:label>
    <link:label id="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_documentation_en-US" xlink:label="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:to="lab_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechUSAHoldingLLCMember_6bf8f6c8-fee5-4afd-88fd-9b6b0e15111f_terseLabel_en-US" xlink:label="lab_bntx_BioNTechUSAHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech USA Holding, LLC</link:label>
    <link:label id="lab_bntx_BioNTechUSAHoldingLLCMember_label_en-US" xlink:label="lab_bntx_BioNTechUSAHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech USA Holding, LLC [Member]</link:label>
    <link:label id="lab_bntx_BioNTechUSAHoldingLLCMember_documentation_en-US" xlink:label="lab_bntx_BioNTechUSAHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech USA Holding, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSAHoldingLLCMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSAHoldingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechUSAHoldingLLCMember" xlink:to="lab_bntx_BioNTechUSAHoldingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_529d1b8b-73d2-4176-8c13-3f47a90406d2_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_f1bd404c-e8d2-49fe-949f-f9452377041a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Intangible Assets and Goodwill</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_3515e083-96a7-4483-b86d-f5aff9447169_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesTable_1ceb393f-5726-461b-a6bc-824d36fe2dbe_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesTable_label_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable" xlink:to="lab_bntx_DisclosureOfIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EffectiveExercisePriceMaximum_61039da7-6493-4f73-aecf-e1f109b3b3f1_terseLabel_en-US" xlink:label="lab_bntx_EffectiveExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective exercise price maximum (in dollars per share)</link:label>
    <link:label id="lab_bntx_EffectiveExercisePriceMaximum_label_en-US" xlink:label="lab_bntx_EffectiveExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Exercise Price Maximum</link:label>
    <link:label id="lab_bntx_EffectiveExercisePriceMaximum_documentation_en-US" xlink:label="lab_bntx_EffectiveExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Exercise Price Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EffectiveExercisePriceMaximum" xlink:href="bntx-20231231.xsd#bntx_EffectiveExercisePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EffectiveExercisePriceMaximum" xlink:to="lab_bntx_EffectiveExercisePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_9c9d13fa-222f-4d75-8fb5-d988865a98f1_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CorporateTaxRate_a89ffe6e-a0d2-49de-b786-8315ae6e5101_terseLabel_en-US" xlink:label="lab_bntx_CorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate tax rate (as a percent)</link:label>
    <link:label id="lab_bntx_CorporateTaxRate_label_en-US" xlink:label="lab_bntx_CorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Tax Rate</link:label>
    <link:label id="lab_bntx_CorporateTaxRate_documentation_en-US" xlink:label="lab_bntx_CorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CorporateTaxRate" xlink:href="bntx-20231231.xsd#bntx_CorporateTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CorporateTaxRate" xlink:to="lab_bntx_CorporateTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease_00421eb9-8380-4f7b-b2e1-e9faca883f91_terseLabel_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to release</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease_label_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Release</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease_documentation_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Release</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToRelease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:to="lab_bntx_CurrentOnerousContractsProvisionRelatedToRelease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_40518997-d264-41d9-a80e-2d866860594a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock_07bdfef5-97e8-4c9a-8d2e-97a7ae26b404_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Goodwill Recognized</link:label>
    <link:label id="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_8d4a3baa-8c52-46c6-9226-fabb140ae390_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_8200e83d-5853-4590-af80-fe4bc52e5f51_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_f2752bd4-ec1b-42e2-a1be-e984d2f520aa_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c9d79270-1543-4516-a64d-87d158f23615_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_8ca5fdac-6051-4937-a28b-5430b3621adf_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember_b0f1b420-1326-43e6-bae4-b9fb2bcfcc8f_terseLabel_en-US" xlink:label="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress and advance payments</link:label>
    <link:label id="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember_label_en-US" xlink:label="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction In Progress And Advance Payments [Member]</link:label>
    <link:label id="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember_documentation_en-US" xlink:label="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Construction In Progress And Advance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:href="bntx-20231231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:to="lab_bntx_ConstructionInProgressAndAdvancePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_6dd1bf6a-aeb3-4ae5-8f2b-6eb517c7eb7f_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities have not been recognized</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember_780ff2aa-305d-400e-9b54-a55bf55126b0_terseLabel_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Spain S.L</link:label>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember_label_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Spain S.L [Member]</link:label>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember_documentation_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Spain S.L</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsSpainS.LMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:to="lab_bntx_BioNTechPharmaceuticalsSpainS.LMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_dea8c432-8d1f-46d4-98e3-421418d92e2e_terseLabel_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 (Fair value)</link:label>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_872afc18-5bf5-4593-bd03-d205d90e3cd4_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_7962cffb-7390-458b-9c64-459cddcddf92_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit attributable to ordinary equity holders of the parent for basic earnings</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DesignatedFXHedge_c1d32465-8ca1-421f-aca3-3eb0af84e99d_terseLabel_en-US" xlink:label="lab_bntx_DesignatedFXHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated FX hedge</link:label>
    <link:label id="lab_bntx_DesignatedFXHedge_label_en-US" xlink:label="lab_bntx_DesignatedFXHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated FX-Hedge</link:label>
    <link:label id="lab_bntx_DesignatedFXHedge_documentation_en-US" xlink:label="lab_bntx_DesignatedFXHedge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Designated FX-Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DesignatedFXHedge" xlink:href="bntx-20231231.xsd#bntx_DesignatedFXHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DesignatedFXHedge" xlink:to="lab_bntx_DesignatedFXHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialLiabilities_a1bfcf14-c6a6-4720-9a4e-89000d6f6910_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_4cb5df85-cb40-4081-967b-2f1243876707_terseLabel_en-US" xlink:label="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price in translation for IPO (in dollar per share and euro per share)</link:label>
    <link:label id="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_label_en-US" xlink:label="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Currency Translation Of Public Offering Price Per Share</link:label>
    <link:label id="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_documentation_en-US" xlink:label="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Currency Translation Of Public Offering Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:href="bntx-20231231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:to="lab_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_6206c18e-d7fd-42f0-9c35-bf890d66957c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_389d68de-fb84-4f84-aad9-92c19aae2c82_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number and Weighted-Average Exercise Price of Share Options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_1fb6c21c-b541-4053-8d62-80da7c2b5459_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Unobservable Inputs Used in Fair Value Measurement</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlan2018Member_b513ba22-5b8e-44fd-803a-551b9f01c0f3_terseLabel_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan 2018</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlan2018Member_label_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan 2018 [Member]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlan2018Member_documentation_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlan2018Member" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeStockOwnershipPlan2018Member" xlink:to="lab_bntx_EmployeeStockOwnershipPlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_961f784e-08c2-4876-8e55-7c85a4aeb029_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_39ff90f9-125c-43de-b081-d4b8af62bd5d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_9140f90a-2207-4f81-9674-0428e157374b_terseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof vested (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_302022d0-c576-49b1-a3b2-7b80942c3788_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayables" xlink:to="lab_ifrs-full_TradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4c7f29a6-8282-4e67-a1cd-cae8dfc2431c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares_75c563ad-0860-4756-9d07-eec660b50899_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquired shares (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares_label_en-US" xlink:label="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Consideration Transferred, Acquired Shares</link:label>
    <link:label id="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares_documentation_en-US" xlink:label="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Consideration Transferred, Acquired Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:href="bntx-20231231.xsd#bntx_PercentageOfConsiderationTransferredAcquiredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:to="lab_bntx_PercentageOfConsiderationTransferredAcquiredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_c15feaa5-2b79-4672-84fa-5e4b807d5565_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsLineItems_aae18363-d8c0-4ce6-a595-2b04cfc0882f_terseLabel_en-US" xlink:label="lab_dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings [Line Items]</link:label>
    <link:label id="lab_dei_EntityListingsLineItems_label_en-US" xlink:label="lab_dei_EntityListingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsLineItems" xlink:to="lab_dei_EntityListingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_c6713fb9-49ce-49e8-b9e6-944ef71dfd88_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_44a013b8-b82e-4254-8be5-aa65915bbd9d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Useful Lives Applied to the Group's Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_638de3e4-7f8c-4559-87bb-5bf87007c3ff_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_68696486-b880-49c6-bb1b-8a991b7f71ad_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average rate</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_6fc188a8-a819-43bc-90f5-5c5c8b469537_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_8199979a-b8b8-4200-998e-68c6b8ae0452_terseLabel_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired (as a percent)</link:label>
    <link:label id="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired_label_en-US" xlink:label="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="lab_ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepFranceSASMember_0370da48-99ac-4c72-b2a6-09fb8c9acc08_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep France SAS</link:label>
    <link:label id="lab_bntx_InstaDeepFranceSASMember_label_en-US" xlink:label="lab_bntx_InstaDeepFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep France SAS [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepFranceSASMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepFranceSASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep France SAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepFranceSASMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepFranceSASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepFranceSASMember" xlink:to="lab_bntx_InstaDeepFranceSASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_96052788-9452-4c40-a8ba-0aa4d1ad4594_terseLabel_en-US" xlink:label="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments of financial instruments measured at fair value</link:label>
    <link:label id="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_label_en-US" xlink:label="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value</link:label>
    <link:label id="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_documentation_en-US" xlink:label="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:href="bntx-20231231.xsd#bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:to="lab_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_f29ec015-f0f2-440c-b60f-465fd82040b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Right-of-Use Assets within Consolidated Statements of Financial Position</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramNetAmountSpent_664bf74c-cc14-4edf-883f-4313fefebe29_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net amount spend</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramNetAmountSpent_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Net Amount Spent</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramNetAmountSpent_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Net Amount Spent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNetAmountSpent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:to="lab_bntx_ShareRepurchaseProgramNetAmountSpent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_488b63a6-5f59-4f8f-b845-e0ceb4afe70e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherFinancialLiabilities_1575fc60-aa3a-4b3b-9f8e-7c6cbfdb094c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherFinancialLiabilities" xlink:to="lab_ifrs-full_OtherFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_df9bb646-95e2-4994-8688-c085b7298a64_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_b2722653-7202-48a2-892a-6386861dcfdf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Compensation of Key Management Personnel</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about key management personnel [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_0512dc62-f5d3-4c67-83f4-117abf115e0c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_9c0798e1-0d7b-4cef-a910-598d030846fa_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_ee084546-ac49-4e1f-9927-0235ae0d1573_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_436d4d66-44a3-4aef-976a-2a73861d94b4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_32e3b8b6-8c00-4155-a86e-e34c73850fa6_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax losses / tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TaxEffectOfChangeInValuationAllowance_b60f0f88-870d-4a1a-9955-a41d9bbe9e86_terseLabel_en-US" xlink:label="lab_bntx_TaxEffectOfChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_bntx_TaxEffectOfChangeInValuationAllowance_label_en-US" xlink:label="lab_bntx_TaxEffectOfChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change In Valuation Allowance</link:label>
    <link:label id="lab_bntx_TaxEffectOfChangeInValuationAllowance_documentation_en-US" xlink:label="lab_bntx_TaxEffectOfChangeInValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change In Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfChangeInValuationAllowance" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfChangeInValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TaxEffectOfChangeInValuationAllowance" xlink:to="lab_bntx_TaxEffectOfChangeInValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_59e59b78-2396-4908-ad03-255024e27746_terseLabel_en-US" xlink:label="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsatisfied Or Partially Unsatisfied</link:label>
    <link:label id="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_label_en-US" xlink:label="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsatisfied Or Partially Unsatisfied [Member]</link:label>
    <link:label id="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_documentation_en-US" xlink:label="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unsatisfied Or Partially Unsatisfied</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:href="bntx-20231231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:to="lab_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_bd28bd1e-fd2f-4c3b-a235-1dd948785f77_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_e7fbfc37-6f9e-486b-88fe-d0bc58e16b22_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_99fd6ce3-ae61-4e4f-a8dd-6a6604032c06_terseLabel_en-US" xlink:label="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold amount of dividend by number of shares outstanding immediately following initial public offering</link:label>
    <link:label id="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_label_en-US" xlink:label="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering</link:label>
    <link:label id="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_documentation_en-US" xlink:label="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:href="bntx-20231231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:to="lab_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_86aba840-fa00-4701-b5d5-72bfaf7eabc7_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_JPTPeptideTechnologiesInc.Member_b030b922-908e-4045-b6fa-dae6cc7b2a24_terseLabel_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies Inc.</link:label>
    <link:label id="lab_bntx_JPTPeptideTechnologiesInc.Member_label_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies Inc. [Member]</link:label>
    <link:label id="lab_bntx_JPTPeptideTechnologiesInc.Member_documentation_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesInc.Member" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_JPTPeptideTechnologiesInc.Member" xlink:to="lab_bntx_JPTPeptideTechnologiesInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_338441fa-490d-4d0b-92f7-80a6dee6eb0d_terseLabel_en-US" xlink:label="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Considered remuneration of potential earn-out payments</link:label>
    <link:label id="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_label_en-US" xlink:label="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Considered Remuneration Of Potential Earn-out Payments</link:label>
    <link:label id="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_documentation_en-US" xlink:label="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Considered Remuneration Of Potential Earn-out Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:href="bntx-20231231.xsd#bntx_ConsideredRemunerationOfPotentialEarnOutPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:to="lab_bntx_ConsideredRemunerationOfPotentialEarnOutPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_8ec639df-dee2-4206-9cfd-5bf181dba52e_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NetChangeInFairValue_fd9859a5-a438-4bbd-9cd1-7da2ca63c00a_terseLabel_en-US" xlink:label="lab_bntx_NetChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in fair value</link:label>
    <link:label id="lab_bntx_NetChangeInFairValue_label_en-US" xlink:label="lab_bntx_NetChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Change In Fair Value</link:label>
    <link:label id="lab_bntx_NetChangeInFairValue_documentation_en-US" xlink:label="lab_bntx_NetChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetChangeInFairValue" xlink:href="bntx-20231231.xsd#bntx_NetChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NetChangeInFairValue" xlink:to="lab_bntx_NetChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_891b37f4-d9e2-4902-82e6-b6efc784e70c_periodStartLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_3c2e9e3c-2c63-4d3a-9c96-1950acdeec9a_periodEndLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Outstanding</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_594f95a9-5f62-4000-aa60-6cca04b97306_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_31e9cf2f-6a52-4578-b368-761191d0a0d3_terseLabel_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3 (Fair value)</link:label>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_068f6434-1a35-40bb-9e14-d5d937f0adff_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_7752686a-ca4d-45cd-b0f4-b6d13d25bd60_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_52f31a6e-dbc0-4ddf-80df-8d7281ecb4d2_terseLabel_en-US" xlink:label="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment, acquisition of intangible asset</link:label>
    <link:label id="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_label_en-US" xlink:label="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment, Acquisition of Intangible Asset</link:label>
    <link:label id="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_documentation_en-US" xlink:label="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment, Acquisition of Intangible Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:href="bntx-20231231.xsd#bntx_UpfrontPaymentAcquisitionOfIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:to="lab_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_4646cc7c-c725-4813-b654-363df9b0bd91_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_1394c6ad-e4b7-4818-b469-89cc10ec82b2_verboseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">As of January 1, 2022</link:label>
    <link:label id="lab_ifrs-full_Liabilities_2d922874-e00d-4e7b-8a0f-83a2d0dc169b_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">As of January 1, 2023</link:label>
    <link:label id="lab_ifrs-full_Liabilities_66cd46e2-5c36-4c2e-a84f-e2e664497f01_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">As of December 31, 2023</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_9af66822-91dc-4077-bbb9-48f7199571c0_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_75f79068-3b69-4a94-b655-8d357a7293b5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_03828845-f72d-488e-9f55-f5f9ef914a6f_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_70014dfe-9576-460f-a8bf-6ceb85694f5b_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 to 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_WeightedAverageExercisePriceAbstract_d31bea72-7f49-4719-9f72-5e78239e15e0_terseLabel_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (&#8364;)</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceAbstract" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract" xlink:to="lab_bntx_WeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_1b2b43ef-3911-4c45-8b7c-5129f001bbdc_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedMeasurementMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedMeasurementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedMeasurementMember" xlink:to="lab_ifrs-full_AggregatedMeasurementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MoneyMarketFundMember_73ff0988-e216-491e-8071-70864f781ae3_terseLabel_en-US" xlink:label="lab_bntx_MoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_bntx_MoneyMarketFundMember_label_en-US" xlink:label="lab_bntx_MoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Fund [Member]</link:label>
    <link:label id="lab_bntx_MoneyMarketFundMember_documentation_en-US" xlink:label="lab_bntx_MoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Money Market Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MoneyMarketFundMember" xlink:href="bntx-20231231.xsd#bntx_MoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MoneyMarketFundMember" xlink:to="lab_bntx_MoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_5416ca17-62d2-44cf-89dc-8dffe58534de_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. dollar</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccumulatedTaxLossesInStateTaxCredits_5f64139a-d388-4d02-9804-3a237aa1022f_terseLabel_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax credits</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInStateTaxCredits_label_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In State Tax Credits</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInStateTaxCredits_documentation_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In State Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:to="lab_bntx_AccumulatedTaxLossesInStateTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_b3146cd7-0f38-4ee8-9808-701f2c8d3ed3_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of target share price applicable for prior twelve month period (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_label_en-US" xlink:label="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Target Share Price Applicable For Prior Twelve Month</link:label>
    <link:label id="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_documentation_en-US" xlink:label="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Target Share Price Applicable For Prior Twelve Month</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:href="bntx-20231231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:to="lab_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_7d5744c9-ba82-4924-868f-0c62e6ef6f94_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized directly in equity</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lab_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_987d7163-f809-4856-bdfe-1df4e10a52ce_terseLabel_en-US" xlink:label="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_label_en-US" xlink:label="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:to="lab_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_0749aac3-cf0c-4149-a74b-27b201ecaa61_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life (in years)</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate_6219249c-07bb-49d8-b45c-80223b50bf0d_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rate effect</link:label>
    <link:label id="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_a7f73c39-7799-49a1-a1bd-3241a324a512_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average share price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_ce8540f5-a446-4833-b8c1-b70acb31ed2c_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_b71d6d7c-6f55-4b59-8f6c-05cd4702460d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LoansAndBorrowingsMember_8a564006-eaeb-4af1-8883-51932367d421_terseLabel_en-US" xlink:label="lab_bntx_LoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans and borrowings</link:label>
    <link:label id="lab_bntx_LoansAndBorrowingsMember_label_en-US" xlink:label="lab_bntx_LoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans And Borrowings [Member]</link:label>
    <link:label id="lab_bntx_LoansAndBorrowingsMember_documentation_en-US" xlink:label="lab_bntx_LoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loans And Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LoansAndBorrowingsMember" xlink:href="bntx-20231231.xsd#bntx_LoansAndBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LoansAndBorrowingsMember" xlink:to="lab_bntx_LoansAndBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_9d012627-6438-4f03-8e5f-5c1ca36212cc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember_ebd33f5e-9eab-48f5-8e81-9d33807588b9_terseLabel_en-US" xlink:label="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Verwaltungs GmbH</link:label>
    <link:label id="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Verwaltungs GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Verwaltungs GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:to="lab_bntx_BioNTechRealEstateVerwaltungsGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AdvancePaymentsMember_3dc52e6a-a1c3-4859-8d24-6c0b10cc5458_terseLabel_en-US" xlink:label="lab_bntx_AdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance payments</link:label>
    <link:label id="lab_bntx_AdvancePaymentsMember_label_en-US" xlink:label="lab_bntx_AdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Payments [Member]</link:label>
    <link:label id="lab_bntx_AdvancePaymentsMember_documentation_en-US" xlink:label="lab_bntx_AdvancePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentsMember" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AdvancePaymentsMember" xlink:to="lab_bntx_AdvancePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_cf425f6b-266d-4e02-807b-53876b224ae8_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from / (used in) financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsTable_4bf5efe2-c4d9-4345-947b-03da109ff4ac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of performance obligations [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of performance obligations [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:to="lab_ifrs-full_DisclosureOfPerformanceObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_3749b580-e799-45ef-843e-93d79f585c19_terseLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof vested, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanMember_f6391f98-ccbf-49a6-828d-e939a8636aba_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Equity Plan</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanMember" xlink:to="lab_bntx_EmployeeEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_8077cedc-5e40-490c-9ad2-42bfa433e7c1_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_76f802e1-4122-4dbb-80c8-02b1fe51408b_terseLabel_en-US" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer-related intangible assets recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer-related intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract_2a1fc75b-e4be-4439-a718-2ea13f1cb874_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Corporate Information Explanatory [Abstract]</link:label>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract_label_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Corporate Information Explanatory [Abstract]</link:label>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract_documentation_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Corporate Information Explanatory [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:to="lab_bntx_DisclosureOfCorporateInformationExplanatoryAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock_d46a1612-090e-42f0-8af2-e6ab8f586f6f_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit</link:label>
    <link:label id="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherOperatingEquipmentMember_9f89eb92-d031-46e5-81cf-d1c10c0051ad_terseLabel_en-US" xlink:label="lab_bntx_OtherOperatingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating equipment</link:label>
    <link:label id="lab_bntx_OtherOperatingEquipmentMember_label_en-US" xlink:label="lab_bntx_OtherOperatingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Equipment [Member]</link:label>
    <link:label id="lab_bntx_OtherOperatingEquipmentMember_documentation_en-US" xlink:label="lab_bntx_OtherOperatingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Operating Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherOperatingEquipmentMember" xlink:href="bntx-20231231.xsd#bntx_OtherOperatingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherOperatingEquipmentMember" xlink:to="lab_bntx_OtherOperatingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_daad7a96-5910-46a6-a3c7-12117bcbcb16_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total depreciation charge</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_fcfd7d5f-9840-4818-8498-777badcbb401_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued Capital and Reserves</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReservesMember_e8dad173-7a3c-4a1b-b848-9dcdb1468271_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReservesMember_label_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_d32f5bf9-752f-47c2-81d8-d765c0bce64d_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
    <link:label id="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_5adefe6d-f50e-435d-9633-6e29dd20b1b2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Financial Commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_fff3b644-0061-4a23-af5b-720b8275f5fb_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock_0e05811b-8512-40e8-a6b9-352892c65ebc_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenue Recognized</link:label>
    <link:label id="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Recognition Of Revenue Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Recognition Of Revenue Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheOneMember_235a33c9-fa7f-49ac-830c-5d4291de2d48_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche One</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheOneMember_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche One [Member]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramTrancheOneMember_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:to="lab_bntx_ShareRepurchaseProgramTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_7354cc36-9770-4440-bb3e-ba4430b2ff64_terseLabel_en-US" xlink:label="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifi-cation</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:to="lab_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_99ddaa12-d712-4dc4-9c66-b373ebf2ecce_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received and realized gains from cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10819e2d-e8bb-40c5-98dd-4b7b78a925b7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ContractLiabilitiesMember_c7a2eb56-843f-406e-b62d-0b9f79ec28b8_terseLabel_en-US" xlink:label="lab_bntx_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_bntx_ContractLiabilitiesMember_label_en-US" xlink:label="lab_bntx_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liabilities [Member]</link:label>
    <link:label id="lab_bntx_ContractLiabilitiesMember_documentation_en-US" xlink:label="lab_bntx_ContractLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContractLiabilitiesMember" xlink:href="bntx-20231231.xsd#bntx_ContractLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ContractLiabilitiesMember" xlink:to="lab_bntx_ContractLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b214be18-aaa3-4a62-8b75-b2718a3767cf_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense arising from equity-settled share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherNonFinancialLiabilitiesAbstract_label_en-US" xlink:label="lab_bntx_OtherNonFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non-Financial Liabilities [Abstract]</link:label>
    <link:label id="lab_bntx_OtherNonFinancialLiabilitiesAbstract_documentation_en-US" xlink:label="lab_bntx_OtherNonFinancialLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Non-Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialLiabilitiesAbstract" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract" xlink:to="lab_bntx_OtherNonFinancialLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_9313ebbb-de5a-428c-ad92-b449d83c09f0_negatedTerseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Classified As Financing Activities</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Classified As Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:to="lab_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_f7f7d837-bd9a-49ba-857a-373666f97246_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, class</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_COVID19VaccineRevenuesMember_036ea9b9-b9ec-4482-9793-c47814520ec1_terseLabel_en-US" xlink:label="lab_bntx_COVID19VaccineRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COVID-19 vaccine revenues</link:label>
    <link:label id="lab_bntx_COVID19VaccineRevenuesMember_label_en-US" xlink:label="lab_bntx_COVID19VaccineRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine Revenues [Member]</link:label>
    <link:label id="lab_bntx_COVID19VaccineRevenuesMember_documentation_en-US" xlink:label="lab_bntx_COVID19VaccineRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineRevenuesMember" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_COVID19VaccineRevenuesMember" xlink:to="lab_bntx_COVID19VaccineRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock_4ae2165e-f900-48a4-b599-2b3993169680_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Information about Entity with Significant Influence Over Group</link:label>
    <link:label id="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Entity With Significant Influence Over Group Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_68bc20c0-ff89-4b11-8db7-7cc8ebfbca8b_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income / (loss) for the period, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_f0102354-3a89-415f-bc12-3fdbae249d11_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepTunisiaSARLMember_13a7cf9b-733e-4fe6-bb6f-acb28cc44083_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepTunisiaSARLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep Tunisia SARL</link:label>
    <link:label id="lab_bntx_InstaDeepTunisiaSARLMember_label_en-US" xlink:label="lab_bntx_InstaDeepTunisiaSARLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep Tunisia SARL [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepTunisiaSARLMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepTunisiaSARLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep Tunisia SARL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepTunisiaSARLMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepTunisiaSARLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepTunisiaSARLMember" xlink:to="lab_bntx_InstaDeepTunisiaSARLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentObligationsUnderLeaseContractsMember_43b60b1f-0169-4d64-99cf-823764ded55f_terseLabel_en-US" xlink:label="lab_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current obligations under lease contracts</link:label>
    <link:label id="lab_bntx_CurrentObligationsUnderLeaseContractsMember_label_en-US" xlink:label="lab_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Obligations Under Lease Contracts [Member]</link:label>
    <link:label id="lab_bntx_CurrentObligationsUnderLeaseContractsMember_documentation_en-US" xlink:label="lab_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Obligations Under Lease Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:href="bntx-20231231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:to="lab_bntx_CurrentObligationsUnderLeaseContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_56fd4b5f-7bbd-472f-9cd0-21ac6a79c7dc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_d013b923-3f41-40a1-b2ac-57734444d8fb_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d16d8dc2-0b74-41e3-ade9-485aed37f8b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_4724fb6f-d2e7-4328-8008-ac029ad9da57_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_6c9903da-0b47-4fe3-a4ee-a9c910edb884_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_93b5cad0-4d2b-41b6-a115-daf64f7209de_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value with increasing input factor (in millions &#8364;)</link:label>
    <link:label id="lab_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_label_en-US" xlink:label="lab_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:to="lab_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_1e623af1-3084-47f9-9e5c-2dd968442366_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_0ef16aa3-a112-4681-b219-2f9a783904dd_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense / (Income) arising from cash-settled share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from cash-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_71522efe-ed78-4d0e-9e45-d3f4dfbbde7f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PurchaseOfSharesUnderAgreement_f0a5151a-5f4d-4a18-8cdf-6ec1f4098260_terseLabel_en-US" xlink:label="lab_bntx_PurchaseOfSharesUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of shares under agreement (in shares)</link:label>
    <link:label id="lab_bntx_PurchaseOfSharesUnderAgreement_label_en-US" xlink:label="lab_bntx_PurchaseOfSharesUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Of Shares Under Agreement</link:label>
    <link:label id="lab_bntx_PurchaseOfSharesUnderAgreement_documentation_en-US" xlink:label="lab_bntx_PurchaseOfSharesUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Of Shares Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfSharesUnderAgreement" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfSharesUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PurchaseOfSharesUnderAgreement" xlink:to="lab_bntx_PurchaseOfSharesUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_b45d12ca-3101-41e2-80ad-b7ac725ccbb7_terseLabel_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable wage taxes and social security contributions resulting from and withheld upon exercise</link:label>
    <link:label id="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables on social security and taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechInnovationGmbHMember_bbd1973a-aac3-4351-a978-6c172db064ea_terseLabel_en-US" xlink:label="lab_bntx_BioNTechInnovationGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Innovation GmbH</link:label>
    <link:label id="lab_bntx_BioNTechInnovationGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechInnovationGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Innovation GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechInnovationGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechInnovationGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Innovation GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechInnovationGmbHMember" xlink:to="lab_bntx_BioNTechInnovationGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_70817961-c019-4c11-ab6f-ca045a362034_terseLabel_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:label id="lab_ifrs-full_LineItemsByFunctionMember_label_en-US" xlink:label="lab_ifrs-full_LineItemsByFunctionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line items by function [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LineItemsByFunctionMember" xlink:to="lab_ifrs-full_LineItemsByFunctionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FixedAssetsMember_20adc08b-d34f-4070-9e6a-dfe75541ce03_terseLabel_en-US" xlink:label="lab_bntx_FixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_bntx_FixedAssetsMember_label_en-US" xlink:label="lab_bntx_FixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Assets [Member]</link:label>
    <link:label id="lab_bntx_FixedAssetsMember_documentation_en-US" xlink:label="lab_bntx_FixedAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FixedAssetsMember" xlink:href="bntx-20231231.xsd#bntx_FixedAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FixedAssetsMember" xlink:to="lab_bntx_FixedAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_2ec0dddd-c810-4128-b3a8-8953487c76fe_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_Inventories_928b7640-dab3-40f4-a034-754c44aa6082_totalLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember_df12d3ea-5e7b-4435-b8cf-eda865e6b643_terseLabel_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies GmbH</link:label>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:to="lab_bntx_BioNTechDeliveryTechnologiesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_e8c496d6-bcea-4ec8-9fe7-6351ccca29e2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_9a2f37d4-c220-45c4-97b7-8b7c8e07d90a_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0972196e-b93b-4f8a-8a4d-182e4913ab27_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_ce761727-cac7-4784-8cbe-680ea3b6a680_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 to 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_5b9bde72-7b88-416a-9b18-c66ddf1632b4_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_dec04841-c675-41f9-8a3b-d9070e89cf73_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingIncome_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_681539de-6310-4ac7-87b2-54e74dd8416d_terseLabel_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_label_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:to="lab_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_861e65a4-a5f4-40b0-a977-25979bf9d30c_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_30b59f96-ba47-4ec5-83de-509e7c17c2ef_terseLabel_en-US" xlink:label="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">+5 %</link:label>
    <link:label id="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_label_en-US" xlink:label="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive Five Percentage Change In Foreign Exchange Rate [Member]</link:label>
    <link:label id="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_documentation_en-US" xlink:label="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Positive Five Percentage Change In Foreign Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:href="bntx-20231231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:to="lab_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ATImpfGmbHMember_3cfd5dbe-0177-4bf7-bd4f-2bbb9580f790_terseLabel_en-US" xlink:label="lab_bntx_ATImpfGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AT Impf GmbH</link:label>
    <link:label id="lab_bntx_ATImpfGmbHMember_label_en-US" xlink:label="lab_bntx_ATImpfGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AT Impf GmbH [Member]</link:label>
    <link:label id="lab_bntx_ATImpfGmbHMember_documentation_en-US" xlink:label="lab_bntx_ATImpfGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AT Impf GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATImpfGmbHMember" xlink:href="bntx-20231231.xsd#bntx_ATImpfGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ATImpfGmbHMember" xlink:to="lab_bntx_ATImpfGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_35c06da1-5738-4149-afc5-ce507bac27a5_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_0891d122-1192-496f-89f9-f131d2d1329e_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_4d15946a-d734-419c-8c19-47db16bd0f59_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Liabilities at Amortized Cost</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_353819bd-5572-4ae0-b2f7-25698c443f99_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis" xlink:to="lab_ifrs-full_HedgingInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_a47cf238-9d0f-4bc0-9a73-a09f5ad99535_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets and Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExternalProductSalesToJPTMember_f051a2f0-3b47-42a6-9b5e-14943a93f566_terseLabel_en-US" xlink:label="lab_bntx_ExternalProductSalesToJPTMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External Product Sales of JPT</link:label>
    <link:label id="lab_bntx_ExternalProductSalesToJPTMember_label_en-US" xlink:label="lab_bntx_ExternalProductSalesToJPTMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">External Product Sales To JPT [Member]</link:label>
    <link:label id="lab_bntx_ExternalProductSalesToJPTMember_documentation_en-US" xlink:label="lab_bntx_ExternalProductSalesToJPTMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">External Product Sales To JPT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalProductSalesToJPTMember" xlink:href="bntx-20231231.xsd#bntx_ExternalProductSalesToJPTMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExternalProductSalesToJPTMember" xlink:to="lab_bntx_ExternalProductSalesToJPTMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativesMember_b25f47ad-2b47-4d68-b2a7-bb8dd63417be_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange forward contracts</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_label_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BuildingsMember_265a104b-9689-4cfc-8459-6e9cea1b61ed_terseLabel_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_ifrs-full_BuildingsMember_label_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember" xlink:to="lab_ifrs-full_BuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_5074e8df-1750-4ba3-8f5d-449541c6babc_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_8f6684cf-3e79-4760-900d-1718dffed9ab_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative depreciation and impairment charges</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation_51764686-e689-4310-9715-a329deab9f67_terseLabel_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed compensation</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation_label_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Fixed Compensation</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation_documentation_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Fixed Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:to="lab_bntx_KeyManagementPersonnelCompensationFixedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromInterest_29023c0d-f622-4c08-be34-f55194e75301_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_ifrs-full_RevenueFromInterest_label_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechAustraliaPtyLtd.Member_120b9cac-590d-4141-b337-56cef10fea79_terseLabel_en-US" xlink:label="lab_bntx_BioNTechAustraliaPtyLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Australia Pty Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechAustraliaPtyLtd.Member_label_en-US" xlink:label="lab_bntx_BioNTechAustraliaPtyLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Australia Pty Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechAustraliaPtyLtd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechAustraliaPtyLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Australia Pty Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechAustraliaPtyLtd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechAustraliaPtyLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechAustraliaPtyLtd.Member" xlink:to="lab_bntx_BioNTechAustraliaPtyLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_219001de-9a90-41a4-af9b-719c8d53ccaa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_6a89ce80-342e-4783-a7d2-3a902c18d163_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DecreaseInCorporateTaxRate_8a5c1c35-273d-4d0c-85ba-cc7dbe70dbfc_terseLabel_en-US" xlink:label="lab_bntx_DecreaseInCorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in corporate tax rate (as a percent)</link:label>
    <link:label id="lab_bntx_DecreaseInCorporateTaxRate_label_en-US" xlink:label="lab_bntx_DecreaseInCorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Corporate Tax Rate</link:label>
    <link:label id="lab_bntx_DecreaseInCorporateTaxRate_documentation_en-US" xlink:label="lab_bntx_DecreaseInCorporateTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease In Corporate Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DecreaseInCorporateTaxRate" xlink:href="bntx-20231231.xsd#bntx_DecreaseInCorporateTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DecreaseInCorporateTaxRate" xlink:to="lab_bntx_DecreaseInCorporateTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_36f17787-344d-4148-a154-10c796e7eb84_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from Contracts with Customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_0002bd26-0662-49e0-a17a-1f0436ed3cc2_terseLabel_en-US" xlink:label="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Liabilities at Fair Value Through Other Comprehensive Income, Category</link:label>
    <link:label id="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_label_en-US" xlink:label="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities At Fair Value Through Other Comprehensive Income, Category [Member]</link:label>
    <link:label id="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_documentation_en-US" xlink:label="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Liabilities At Fair Value Through Other Comprehensive Income, Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:href="bntx-20231231.xsd#bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lab_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ForeignExchangeDifferencesMember_8b0a48cf-d2d4-46d5-9e19-d2f12832903f_terseLabel_en-US" xlink:label="lab_bntx_ForeignExchangeDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange differences, net</link:label>
    <link:label id="lab_bntx_ForeignExchangeDifferencesMember_label_en-US" xlink:label="lab_bntx_ForeignExchangeDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Differences [Member]</link:label>
    <link:label id="lab_bntx_ForeignExchangeDifferencesMember_documentation_en-US" xlink:label="lab_bntx_ForeignExchangeDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Exchange Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignExchangeDifferencesMember" xlink:href="bntx-20231231.xsd#bntx_ForeignExchangeDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ForeignExchangeDifferencesMember" xlink:to="lab_bntx_ForeignExchangeDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_d0b6a850-ccfd-4c6f-a3e2-9a9bf816085d_terseLabel_en-US" xlink:label="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated milestone payment to be received</link:label>
    <link:label id="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_label_en-US" xlink:label="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Milestone Payment To Be Received At Contract Inception</link:label>
    <link:label id="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_documentation_en-US" xlink:label="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Milestone Payment To Be Received At Contract Inception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:href="bntx-20231231.xsd#bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:to="lab_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashSettledShareBasedPaymentArrangementMember_33aa2c31-3cec-4095-ba2c-f4f4cd9a9759_terseLabel_en-US" xlink:label="lab_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash-Settled Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_CashSettledShareBasedPaymentArrangementMember_label_en-US" xlink:label="lab_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash-Settled Share-Based Payment Arrangement [Member]</link:label>
    <link:label id="lab_bntx_CashSettledShareBasedPaymentArrangementMember_documentation_en-US" xlink:label="lab_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash-Settled Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:href="bntx-20231231.xsd#bntx_CashSettledShareBasedPaymentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:to="lab_bntx_CashSettledShareBasedPaymentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherCurrentAssetsOther_3f62ed8b-28d7-4984-81e8-be4398bc647a_terseLabel_en-US" xlink:label="lab_bntx_OtherCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bntx_OtherCurrentAssetsOther_label_en-US" xlink:label="lab_bntx_OtherCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets, Other</link:label>
    <link:label id="lab_bntx_OtherCurrentAssetsOther_documentation_en-US" xlink:label="lab_bntx_OtherCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherCurrentAssetsOther" xlink:href="bntx-20231231.xsd#bntx_OtherCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherCurrentAssetsOther" xlink:to="lab_bntx_OtherCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramAuthorizedAmount_dd931b4d-7994-43f3-bf5a-dc4c1ba05eb2_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program authorized amount</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramAuthorizedAmount_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Authorized Amount</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramAuthorizedAmount_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:to="lab_bntx_ShareRepurchaseProgramAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents_9706f464-4b55-4b02-ac92-5a163e274853_terseLabel_en-US" xlink:label="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents resulting from other valuation effects</link:label>
    <link:label id="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect Of Other Valuation Changes On Cash And Cash Equivalents</link:label>
    <link:label id="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents_documentation_en-US" xlink:label="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect Of Other Valuation Changes On Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:href="bntx-20231231.xsd#bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:to="lab_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_4cd30009-75ac-4216-8f43-6d1a45bf6314_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_28f809db-b86b-4e45-bfa5-b8129c255474_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5cb62a16-2f9e-4fbe-a702-cabcae5b4ca6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PfizerCOVID19VaccineMember_f9221f71-bce1-4208-9947-ac3ce2d0fb7c_terseLabel_en-US" xlink:label="lab_bntx_PfizerCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer (COVID-19 vaccine)</link:label>
    <link:label id="lab_bntx_PfizerCOVID19VaccineMember_label_en-US" xlink:label="lab_bntx_PfizerCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer (COVID-19 vaccine) [Member]</link:label>
    <link:label id="lab_bntx_PfizerCOVID19VaccineMember_documentation_en-US" xlink:label="lab_bntx_PfizerCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer (COVID-19 vaccine)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerCOVID19VaccineMember" xlink:href="bntx-20231231.xsd#bntx_PfizerCOVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PfizerCOVID19VaccineMember" xlink:to="lab_bntx_PfizerCOVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PrepaymentForFutureDevelopmentActivities_3e2ff2eb-4e0a-4272-b95a-591d8d37ebf7_terseLabel_en-US" xlink:label="lab_bntx_PrepaymentForFutureDevelopmentActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment for future development activities</link:label>
    <link:label id="lab_bntx_PrepaymentForFutureDevelopmentActivities_label_en-US" xlink:label="lab_bntx_PrepaymentForFutureDevelopmentActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment For Future Development Activities</link:label>
    <link:label id="lab_bntx_PrepaymentForFutureDevelopmentActivities_documentation_en-US" xlink:label="lab_bntx_PrepaymentForFutureDevelopmentActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment For Future Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PrepaymentForFutureDevelopmentActivities" xlink:href="bntx-20231231.xsd#bntx_PrepaymentForFutureDevelopmentActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PrepaymentForFutureDevelopmentActivities" xlink:to="lab_bntx_PrepaymentForFutureDevelopmentActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_188846dd-49a5-4fc1-bce7-f685b1d4518d_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialAssets_bb1876c3-e6ab-4579-a2a6-e8dae3740011_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialAssets_96804d8e-0f87-4305-9be0-f2f3c4bc4aaa_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherCurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_8afc8539-ef41-4b0f-a497-fc74a53b9340_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for related parties</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ReclassificationOfShareBasedPaymentArrangement_2457bd88-c802-4d4a-b069-2a70c41e7496_terseLabel_en-US" xlink:label="lab_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification for share-based payment arrangement</link:label>
    <link:label id="lab_bntx_ReclassificationOfShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_ReclassificationOfShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Of Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_ReclassificationOfShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:to="lab_bntx_ReclassificationOfShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_a5e4b078-85e0-47f2-9888-c5f0ffb050c6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechRealEstateHoldingGmbHMember_7422848a-7b35-4d42-93c4-0f167fa573c4_terseLabel_en-US" xlink:label="lab_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Holding GmbH</link:label>
    <link:label id="lab_bntx_BioNTechRealEstateHoldingGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Holding GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechRealEstateHoldingGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Real Estate Holding GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:to="lab_bntx_BioNTechRealEstateHoldingGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_8312cfb8-7cad-4669-b60f-eeea45f72d75_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LTI-plus program</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive Plus Program [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive Plus Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:to="lab_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_508fce3b-528c-40b2-af60-506e9264cbfb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiquidityRiskMember_91eb86b9-7e6e-4a4a-a4f3-3c98af8db0a0_terseLabel_en-US" xlink:label="lab_ifrs-full_LiquidityRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity risk</link:label>
    <link:label id="lab_ifrs-full_LiquidityRiskMember_label_en-US" xlink:label="lab_ifrs-full_LiquidityRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember" xlink:to="lab_ifrs-full_LiquidityRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_5fcd2789-9d5d-4135-9caf-21cc666d37aa_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_799c7a98-41a9-4f64-b245-942d119f3965_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherIncomeExpenseMember_e088c99d-af48-4539-aa79-2118fa1679c5_terseLabel_en-US" xlink:label="lab_bntx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bntx_OtherIncomeExpenseMember_label_en-US" xlink:label="lab_bntx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income Expense [Member]</link:label>
    <link:label id="lab_bntx_OtherIncomeExpenseMember_documentation_en-US" xlink:label="lab_bntx_OtherIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherIncomeExpenseMember" xlink:href="bntx-20231231.xsd#bntx_OtherIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherIncomeExpenseMember" xlink:to="lab_bntx_OtherIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_4ffe06a7-ae1c-4cc9-8193-58199f07d492_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings for the period per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_9563358c-af13-46fb-8805-5231763f7830_verboseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted profit for the period per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InventoryWritedown2011_3e1d3d44-c623-4b3e-8d07-c0173828c8d5_terseLabel_en-US" xlink:label="lab_ifrs-full_InventoryWritedown2011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-offs</link:label>
    <link:label id="lab_ifrs-full_InventoryWritedown2011_label_en-US" xlink:label="lab_ifrs-full_InventoryWritedown2011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoryWritedown2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoryWritedown2011" xlink:to="lab_ifrs-full_InventoryWritedown2011" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IntangibleAssetsAbstract_ee8d878b-f4bc-427f-a3e4-d7b270b60c1e_terseLabel_en-US" xlink:label="lab_bntx_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_bntx_IntangibleAssetsAbstract_label_en-US" xlink:label="lab_bntx_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_bntx_IntangibleAssetsAbstract_documentation_en-US" xlink:label="lab_bntx_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IntangibleAssetsAbstract" xlink:to="lab_bntx_IntangibleAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_VestingPeriodDomain_7464da73-51f3-4ffb-a6ee-1c93f41370a8_terseLabel_en-US" xlink:label="lab_bntx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_bntx_VestingPeriodDomain_label_en-US" xlink:label="lab_bntx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period [Domain]</link:label>
    <link:label id="lab_bntx_VestingPeriodDomain_documentation_en-US" xlink:label="lab_bntx_VestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodDomain" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_VestingPeriodDomain" xlink:to="lab_bntx_VestingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_23251f29-c060-429a-88aa-2e3a691852ac_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
    <link:label id="lab_ifrs-full_AdditionalProvisionsOtherProvisions_label_en-US" xlink:label="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="lab_ifrs-full_AdditionalProvisionsOtherProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_b1333f5b-1338-4cb1-a473-1e0ba87f6518_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PerformanceObligationsMember_b443a339-c01f-4ac5-9e0d-273666191962_terseLabel_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations [member]</link:label>
    <link:label id="lab_ifrs-full_PerformanceObligationsMember_label_en-US" xlink:label="lab_ifrs-full_PerformanceObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance obligations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PerformanceObligationsMember" xlink:to="lab_ifrs-full_PerformanceObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BusinessCombinations1Abstract_c562770e-543d-4f70-9d0a-9d8224c04123_terseLabel_en-US" xlink:label="lab_bntx_BusinessCombinations1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_bntx_BusinessCombinations1Abstract_label_en-US" xlink:label="lab_bntx_BusinessCombinations1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations 1 [Abstract]</link:label>
    <link:label id="lab_bntx_BusinessCombinations1Abstract_documentation_en-US" xlink:label="lab_bntx_BusinessCombinations1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BusinessCombinations1Abstract" xlink:href="bntx-20231231.xsd#bntx_BusinessCombinations1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BusinessCombinations1Abstract" xlink:to="lab_bntx_BusinessCombinations1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_d55772bc-e53f-4eaa-94d9-7f6df4258ae9_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of total consideration transferred [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentRefundsProvision_5ae63a05-7015-4e31-bb74-f8117e360678_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentRefundsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refund liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentRefundsProvision_label_en-US" xlink:label="lab_ifrs-full_CurrentRefundsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentRefundsProvision" xlink:to="lab_ifrs-full_CurrentRefundsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_8261f1cb-b381-4d3f-82fc-c5e68158aac4_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of subsidiaries and businesses</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_3f7e3162-a6a5-49d1-b622-96dfc9d52764_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CGUImmunotherapiesMember_f507f293-22eb-4375-8cb4-c609f3813675_terseLabel_en-US" xlink:label="lab_bntx_CGUImmunotherapiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CGU Immunotherapies</link:label>
    <link:label id="lab_bntx_CGUImmunotherapiesMember_label_en-US" xlink:label="lab_bntx_CGUImmunotherapiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CGU Immunotherapies [Member]</link:label>
    <link:label id="lab_bntx_CGUImmunotherapiesMember_documentation_en-US" xlink:label="lab_bntx_CGUImmunotherapiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CGU Immunotherapies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CGUImmunotherapiesMember" xlink:href="bntx-20231231.xsd#bntx_CGUImmunotherapiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CGUImmunotherapiesMember" xlink:to="lab_bntx_CGUImmunotherapiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_7649b75c-f773-4111-bd4d-9b067cbedcce_terseLabel_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of research and development expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of Research And Development Expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:to="lab_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_GermanFederalMinistryOfHealthMember_81b9d892-f038-4036-94db-f3669545c499_terseLabel_en-US" xlink:label="lab_bntx_GermanFederalMinistryOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">German Federal Ministry of Health</link:label>
    <link:label id="lab_bntx_GermanFederalMinistryOfHealthMember_label_en-US" xlink:label="lab_bntx_GermanFederalMinistryOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">German Federal Ministry of Health [Member]</link:label>
    <link:label id="lab_bntx_GermanFederalMinistryOfHealthMember_documentation_en-US" xlink:label="lab_bntx_GermanFederalMinistryOfHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">German Federal Ministry of Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GermanFederalMinistryOfHealthMember" xlink:href="bntx-20231231.xsd#bntx_GermanFederalMinistryOfHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_GermanFederalMinistryOfHealthMember" xlink:to="lab_bntx_GermanFederalMinistryOfHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentConsiderationMember_fd165df7-d8a0-4770-99f6-eae7b57c80e3_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ifrs-full_ContingentConsiderationMember_label_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationMember" xlink:to="lab_ifrs-full_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_63c94566-7c6c-4d1c-91a6-97ce415a635a_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_b725f20b-45d7-4fd4-9ec0-139b148ef792_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments related to CRO and CMO contracts</link:label>
    <link:label id="lab_ifrs-full_CurrentAdvancesToSuppliers_label_en-US" xlink:label="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current advances to suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAdvancesToSuppliers" xlink:to="lab_ifrs-full_CurrentAdvancesToSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_7522f777-3fbe-4089-ac16-e6ae2b177f15_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted, share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_a1802da5-6dde-4a01-a5ba-1908082002fd_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in intangible assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechUKLtd.Member_cd350bdb-3d5f-4cc2-99d5-b22d0b538bdc_terseLabel_en-US" xlink:label="lab_bntx_BioNTechUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech UK Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechUKLtd.Member_label_en-US" xlink:label="lab_bntx_BioNTechUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech UK Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechUKLtd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech UK Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUKLtd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechUKLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechUKLtd.Member" xlink:to="lab_bntx_BioNTechUKLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersMember_eae0f97e-c585-4f16-afe0-a0458a6cf3e9_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customers</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersMember_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersMember" xlink:to="lab_ifrs-full_MajorCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_c52a3e2d-6abd-47f7-bc8c-c59eb1987aec_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_95277d66-c40c-422f-b37a-5d6bbc8edbce_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill from the acquisition</link:label>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock_e4910e75-bd2f-4ee2-8d6c-1261e690b1f7_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Amounts Recognized in Consolidated Statement of Operations</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d360e0f1-bfc0-47e4-a666-b65590158744_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1748176c-8468-46d1-8b05-bd3f2cd59622_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Transactions Between Other Related Parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TaxRateOnDeferredTaxes_74f6fd80-ad37-4280-8f82-482338457d74_terseLabel_en-US" xlink:label="lab_bntx_TaxRateOnDeferredTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax rate for deferred taxes (as a percent)</link:label>
    <link:label id="lab_bntx_TaxRateOnDeferredTaxes_label_en-US" xlink:label="lab_bntx_TaxRateOnDeferredTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Rate On Deferred Taxes</link:label>
    <link:label id="lab_bntx_TaxRateOnDeferredTaxes_documentation_en-US" xlink:label="lab_bntx_TaxRateOnDeferredTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Rate On Deferred Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxRateOnDeferredTaxes" xlink:href="bntx-20231231.xsd#bntx_TaxRateOnDeferredTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TaxRateOnDeferredTaxes" xlink:to="lab_bntx_TaxRateOnDeferredTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_60f84a3b-3507-406d-b1b9-e18a8fc75263_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average expected life (in years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_a003fe32-0957-4ab3-be4a-723105f6537a_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual obligation to acquire intangible assets</link:label>
    <link:label id="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_label_en-US" xlink:label="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:to="lab_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock_31a7a144-16bb-4560-9f54-38045da3efa4_terseLabel_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standards Issued but Not Yet Effective</link:label>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:href="bntx-20231231.xsd#bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:to="lab_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_b4351b14-f181-4ea5-a416-f413dac139bc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_e1e798fb-28fe-4171-9030-1c856c8d5275_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_94edbafb-0649-4dc3-a522-b4f72c4f1417_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechTaiwanCo.Ltd.Member_f786a139-fcd9-4fa2-9884-5b943a9c0c1c_terseLabel_en-US" xlink:label="lab_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Taiwan Co. Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechTaiwanCo.Ltd.Member_label_en-US" xlink:label="lab_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Taiwan Co. Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechTaiwanCo.Ltd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Taiwan Co. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechTaiwanCo.Ltd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:to="lab_bntx_BioNTechTaiwanCo.Ltd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccumulatedTaxLossesInCorporateTax_be86615f-669e-4829-8be4-82100898436e_terseLabel_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInCorporateTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate tax</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInCorporateTax_label_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInCorporateTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Corporate Tax</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInCorporateTax_documentation_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInCorporateTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Corporate Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInCorporateTax" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInCorporateTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccumulatedTaxLossesInCorporateTax" xlink:to="lab_bntx_AccumulatedTaxLossesInCorporateTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_be6ff164-3c5b-4950-89eb-3a813cb89cfd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_5f6d9d03-42d0-41f9-b669-7f441f7d0632_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_12f65179-5006-4460-86ee-fe7eeffddb4d_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of instruments or interests issued or issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_b451bf4e-2c23-4cec-9528-9af8c5fd2b64_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_63f8d233-f0d3-4299-867c-85b63d4b028b_terseLabel_en-US" xlink:label="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Announcement Of Research, Development And Commercialization Collaboration Agreement</link:label>
    <link:label id="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_label_en-US" xlink:label="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Announcement Of Research, Development And Commercialization Collaboration Agreement [Member]</link:label>
    <link:label id="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_documentation_en-US" xlink:label="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Announcement Of Research, Development And Commercialization Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:href="bntx-20231231.xsd#bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:to="lab_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DeepChainTechnologyMember_33db6d4c-1491-4d72-9965-0361f059255d_terseLabel_en-US" xlink:label="lab_bntx_DeepChainTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DeepChain Technology</link:label>
    <link:label id="lab_bntx_DeepChainTechnologyMember_label_en-US" xlink:label="lab_bntx_DeepChainTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DeepChain Technology [Member]</link:label>
    <link:label id="lab_bntx_DeepChainTechnologyMember_documentation_en-US" xlink:label="lab_bntx_DeepChainTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DeepChain Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeepChainTechnologyMember" xlink:href="bntx-20231231.xsd#bntx_DeepChainTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DeepChainTechnologyMember" xlink:to="lab_bntx_DeepChainTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0be8b8ea-cfc5-452a-b898-eadb2c865043_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_86ac07c5-a5b5-412e-b7da-e22f2cb9470b_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_7601afe5-9538-4cb6-8504-cf5780d0a8d7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_VestingPeriodAxis_29af23f6-0c7f-48af-b9ce-40f11c46529c_terseLabel_en-US" xlink:label="lab_bntx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_bntx_VestingPeriodAxis_label_en-US" xlink:label="lab_bntx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_bntx_VestingPeriodAxis_documentation_en-US" xlink:label="lab_bntx_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodAxis" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_VestingPeriodAxis" xlink:to="lab_bntx_VestingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1d65a1d2-352a-4183-9107-a748ea33aa97_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase / (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_70877a8a-98c6-466a-93b6-42c42889d77a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash outflow for leases</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_6861ca7e-a135-4daa-acc6-063a81c9e923_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForSubsidiariesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="lab_ifrs-full_EntitysTotalForSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_65654543-bb79-4760-b29f-47ccd444af29_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term incentive &#8211; first installment</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_d730de02-0d37-4679-b28f-a893a0394132_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement derivative</link:label>
    <link:label id="lab_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_label_en-US" xlink:label="lab_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" xlink:to="lab_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowingsMember_2d614967-e844-43d2-a4ac-b9d1fd4fbd43_verboseLabel_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loans and borrowings</link:label>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowingsMember_label_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Loans And Borrowings [Member]</link:label>
    <link:label id="lab_bntx_InterestBearingLoansAndBorrowingsMember_documentation_en-US" xlink:label="lab_bntx_InterestBearingLoansAndBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Bearing Loans And Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowingsMember" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InterestBearingLoansAndBorrowingsMember" xlink:to="lab_bntx_InterestBearingLoansAndBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_a1065d84-6349-4e46-b0f5-8ddda272fcec_terseLabel_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other variable compensation</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_label_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Other Variable Compensation</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_documentation_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Other Variable Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationOtherVariableCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:to="lab_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_23f83f18-d228-4660-b219-1be75f9e770a_terseLabel_en-US" xlink:label="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions</link:label>
    <link:label id="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_label_en-US" xlink:label="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions</link:label>
    <link:label id="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_documentation_en-US" xlink:label="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:to="lab_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_237ffe16-c82b-47e3-82d9-d830ebfa4573_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_c8006d4c-8346-4f92-9bd1-bc31b902f37d_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfSharesHeldInTreasury_63ff5bee-9b65-431a-b66c-0dfdb7dda4f2_terseLabel_en-US" xlink:label="lab_bntx_NumberOfSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfSharesHeldInTreasury_label_en-US" xlink:label="lab_bntx_NumberOfSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Held In Treasury</link:label>
    <link:label id="lab_bntx_NumberOfSharesHeldInTreasury_documentation_en-US" xlink:label="lab_bntx_NumberOfSharesHeldInTreasury" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Held In Treasury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfSharesHeldInTreasury" xlink:href="bntx-20231231.xsd#bntx_NumberOfSharesHeldInTreasury"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfSharesHeldInTreasury" xlink:to="lab_bntx_NumberOfSharesHeldInTreasury" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_cd212844-cab7-4409-b623-10423a9ac9f4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_cd983c98-ab82-400f-a9a3-92871e277d5f_terseLabel_en-US" xlink:label="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum strike price (as a percent)</link:label>
    <link:label id="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_label_en-US" xlink:label="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Option Rights, Minimum Strike Price Percent</link:label>
    <link:label id="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_documentation_en-US" xlink:label="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Of Option Rights, Minimum Strike Price Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:href="bntx-20231231.xsd#bntx_ExerciseOfOptionRightsMinimumStrikePricePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:to="lab_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_22644acc-0fe4-4667-b01c-49f00f1a0e20_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_VehiclesMember_055f2eb5-6b74-4446-99b5-1e3689d98655_terseLabel_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automobiles</link:label>
    <link:label id="lab_ifrs-full_VehiclesMember_label_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_c2c3e4fd-7324-459e-ae10-14d1668f4227_terseLabel_en-US" xlink:label="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
    <link:label id="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities</link:label>
    <link:label id="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="bntx-20231231.xsd#bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashAtBanksAndOnHandMember_af02f3c5-435f-4870-9cdb-7e26ef4f9575_terseLabel_en-US" xlink:label="lab_bntx_CashAtBanksAndOnHandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash at banks and on hand</link:label>
    <link:label id="lab_bntx_CashAtBanksAndOnHandMember_label_en-US" xlink:label="lab_bntx_CashAtBanksAndOnHandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash At Banks And On Hand [Member]</link:label>
    <link:label id="lab_bntx_CashAtBanksAndOnHandMember_documentation_en-US" xlink:label="lab_bntx_CashAtBanksAndOnHandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash At Banks And On Hand</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAtBanksAndOnHandMember" xlink:href="bntx-20231231.xsd#bntx_CashAtBanksAndOnHandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashAtBanksAndOnHandMember" xlink:to="lab_bntx_CashAtBanksAndOnHandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_90ecf371-33b2-4737-9118-31dccadaaff3_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_5ffb3f30-20d8-488f-a802-1e992cbd27fd_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total non-current</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_bec513fa-9490-4467-87b6-0da472fb0965_terseLabel_en-US" xlink:label="lab_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and other assets from entities controlled by ATHOS KG</link:label>
    <link:label id="lab_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and other assets, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:to="lab_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_941a5a49-73ad-4eb4-b187-e293b3cc6456_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_7bbf0884-3af1-4ad9-a7a2-5f6ea4ba5a05_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_d531c954-8034-46e6-bf8f-d5ea9e65b5b4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_bc6b04ae-b277-4479-b1f9-f8bcb403ba6f_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income for the period, net of tax</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNonfinancialAssets_81f40189-ef93-40e4-b70a-def8c3425c90_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_feccad9e-7504-4f5a-b496-a322a12fd6d5_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_24d27aad-f279-40a8-8c5d-b220803eb6e0_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_755fc556-7bb4-4b0a-b0aa-d314defde681_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as of December 31</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_24309b4c-72ce-43ef-850e-9cdaed560d73_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ListedEquityInvestmentsMember_815c0c6f-7d88-4e08-8b81-2d9a2be6e5fb_terseLabel_en-US" xlink:label="lab_bntx_ListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Listed equity investments</link:label>
    <link:label id="lab_bntx_ListedEquityInvestmentsMember_label_en-US" xlink:label="lab_bntx_ListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listed Equity Investments [Member]</link:label>
    <link:label id="lab_bntx_ListedEquityInvestmentsMember_documentation_en-US" xlink:label="lab_bntx_ListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Listed Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListedEquityInvestmentsMember" xlink:href="bntx-20231231.xsd#bntx_ListedEquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ListedEquityInvestmentsMember" xlink:to="lab_bntx_ListedEquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_4df59cab-1f97-4105-958c-ebbc41d768a6_terseLabel_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of general and administrative expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of General And Administrative Expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:to="lab_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6c85e3b8-48ef-42e5-9b5c-23d474304453_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_6d964a1b-77e6-41c6-a5cf-718a34b7eb0e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized directly in equity</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis_f234741e-7d49-4a3b-a765-4c4c77795843_terseLabel_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis_label_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis_documentation_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:to="lab_bntx_EmployeeStockOwnershipPlanESOPNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_2ec64e52-ce00-4915-8f0b-6de7d5b1b476_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_1c3a5bf1-ca9c-4fb5-8dd2-699cb17f9f64_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_06b59d8b-b61d-4da6-beb4-57b2f4e875a7_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash-settled option rights, exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_11e745ce-1728-4599-9d29-51e3260ba327_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised, share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_37a003a6-9696-436b-9c46-303f94eb1f30_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share options, exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_fc8d98f4-47a5-47cc-ad61-8219fa7ded9a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_2bbeed48-cca4-4c27-9dfc-1739611ba98f_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_969806b4-90bc-43b9-8200-315b9e4e721e_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_c375b562-ce52-4e4a-a946-6a0586d1c884_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ValuationAdjustmentMember_373661e7-22e2-4513-b594-22accc0881ba_terseLabel_en-US" xlink:label="lab_bntx_ValuationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation adjustment</link:label>
    <link:label id="lab_bntx_ValuationAdjustmentMember_label_en-US" xlink:label="lab_bntx_ValuationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Adjustment [Member]</link:label>
    <link:label id="lab_bntx_ValuationAdjustmentMember_documentation_en-US" xlink:label="lab_bntx_ValuationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ValuationAdjustmentMember" xlink:href="bntx-20231231.xsd#bntx_ValuationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ValuationAdjustmentMember" xlink:to="lab_bntx_ValuationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_352a040d-b064-4c90-b4e2-0f2ee588f7d9_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:to="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_d2a2e1cf-d019-4373-92f0-4731a03749ca_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value with decreasing input factor (in millions &#8364;)</link:label>
    <link:label id="lab_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:to="lab_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_65d9180e-d944-4bd2-91a2-ec96e895b33e_totalLabel_en-US" xlink:label="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_label_en-US" xlink:label="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Acquired (Liabilities Assumed), Including Goodwill</link:label>
    <link:label id="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_documentation_en-US" xlink:label="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Acquired (Liabilities Assumed), Including Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:href="bntx-20231231.xsd#bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:to="lab_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_5c43e778-119b-4142-93bb-88216f21f69e_terseLabel_en-US" xlink:label="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of ADS as a percentage of exercise price, maximum (as a percent)</link:label>
    <link:label id="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_label_en-US" xlink:label="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Price Of American Depository Share As A Percentage Of Exercise Price, Maximum</link:label>
    <link:label id="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_documentation_en-US" xlink:label="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price Of American Depository Share As A Percentage Of Exercise Price, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:href="bntx-20231231.xsd#bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:to="lab_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_c13cbf80-da4b-4662-9319-b2c13eed3bd6_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange differences, net</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeGain_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeGain" xlink:to="lab_ifrs-full_NetForeignExchangeGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_3139e531-e401-4a7f-ad63-4b9ee38d4a5e_totalLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_d7bef8ef-a037-42de-9ec8-a5ceb6d382c4_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_dd5d26ed-7cb4-46ad-bed0-72188627f583_negatedTerseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settled (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Settled In Share-based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Settled In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_WorkingCapitalAdjustmentsAbstract_70692a30-82ca-4cac-bffb-5bd5d1c2295e_terseLabel_en-US" xlink:label="lab_bntx_WorkingCapitalAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital adjustments:</link:label>
    <link:label id="lab_bntx_WorkingCapitalAdjustmentsAbstract_label_en-US" xlink:label="lab_bntx_WorkingCapitalAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital Adjustments [Abstract]</link:label>
    <link:label id="lab_bntx_WorkingCapitalAdjustmentsAbstract_documentation_en-US" xlink:label="lab_bntx_WorkingCapitalAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WorkingCapitalAdjustmentsAbstract" xlink:href="bntx-20231231.xsd#bntx_WorkingCapitalAdjustmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_WorkingCapitalAdjustmentsAbstract" xlink:to="lab_bntx_WorkingCapitalAdjustmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_961bc764-775c-4217-96e8-1307e91f401c_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_1b7cdfb8-77d6-477e-b43b-ba9408142e18_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Non-Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_b7ff199a-fea2-4917-831c-9942bb7b19b2_terseLabel_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of sales and marketing expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_label_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of Sales And Marketing Expense</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_documentation_en-US" xlink:label="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Of Sales And Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfSalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:to="lab_bntx_IncreaseDecreaseOfSalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_a96428cd-1850-42b9-955c-9962a1423d86_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_daf1b7fe-0595-47fa-be63-3b652304404c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_2e7f8b3a-275e-4083-a6ef-a002cb9faae2_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to purchase ordinary shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RefundsProvision_070b3b31-8c0b-4d92-8319-8173862d57e7_terseLabel_en-US" xlink:label="lab_ifrs-full_RefundsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refund liabilities</link:label>
    <link:label id="lab_ifrs-full_RefundsProvision_label_en-US" xlink:label="lab_ifrs-full_RefundsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RefundsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RefundsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RefundsProvision" xlink:to="lab_ifrs-full_RefundsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherSalesMember_c1149381-9fbd-4e86-afac-deb1d5e7bd4d_terseLabel_en-US" xlink:label="lab_bntx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other sales</link:label>
    <link:label id="lab_bntx_OtherSalesMember_label_en-US" xlink:label="lab_bntx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sales [Member]</link:label>
    <link:label id="lab_bntx_OtherSalesMember_documentation_en-US" xlink:label="lab_bntx_OtherSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherSalesMember" xlink:href="bntx-20231231.xsd#bntx_OtherSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherSalesMember" xlink:to="lab_bntx_OtherSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_cd131b9f-8eb5-4331-abf6-a76355738b61_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_30befa3b-69e7-4599-95cf-c41b9c5e9049_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of consolidation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis_a35042ee-741c-4e99-96b2-febab32c7c83_terseLabel_en-US" xlink:label="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated structured entities [axis]</link:label>
    <link:label id="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated structured entities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:to="lab_ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_4e66f9da-d96a-4001-aa11-35d04d7d080f_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfProvisionsTableTextBlock_c0a05e79-e624-44b9-b989-d8e5b1bcb33b_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Provisions</link:label>
    <link:label id="lab_bntx_DisclosureOfProvisionsTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfProvisionsTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfProvisionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfProvisionsTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfProvisionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfProvisionsTableTextBlock" xlink:to="lab_bntx_DisclosureOfProvisionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_1756fb30-e8d0-4e9a-9382-8c0211bbc8fe_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding for basic EPS (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_83ea5e15-6a89-4fcc-ae99-d8711f1c6c5e_totalLabel_en-US" xlink:label="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_label_en-US" xlink:label="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets With Indefinite Useful Life And Goodwill</link:label>
    <link:label id="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_documentation_en-US" xlink:label="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets With Indefinite Useful Life And Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:to="lab_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_d8c03681-8757-4764-a902-6d3efc57f26e_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssetsMember_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssetsMember" xlink:to="lab_ifrs-full_RightofuseAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LicenseAndOptionAgreementMember_392dd72a-fb6a-43ae-87e3-f259b07b665f_terseLabel_en-US" xlink:label="lab_bntx_LicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Option Agreement [Member]</link:label>
    <link:label id="lab_bntx_LicenseAndOptionAgreementMember_label_en-US" xlink:label="lab_bntx_LicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Option Agreement [Member]</link:label>
    <link:label id="lab_bntx_LicenseAndOptionAgreementMember_documentation_en-US" xlink:label="lab_bntx_LicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LicenseAndOptionAgreementMember" xlink:href="bntx-20231231.xsd#bntx_LicenseAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LicenseAndOptionAgreementMember" xlink:to="lab_bntx_LicenseAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_0d9ea3b8-4553-4c88-a670-80cd7a08dd04_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OptionExercisablePeriod_f07f2d7e-25eb-4a3d-be27-fbe803814ead_terseLabel_en-US" xlink:label="lab_bntx_OptionExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option rights exercisable period (in years)</link:label>
    <link:label id="lab_bntx_OptionExercisablePeriod_label_en-US" xlink:label="lab_bntx_OptionExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercisable Period</link:label>
    <link:label id="lab_bntx_OptionExercisablePeriod_documentation_en-US" xlink:label="lab_bntx_OptionExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Exercisable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionExercisablePeriod" xlink:href="bntx-20231231.xsd#bntx_OptionExercisablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OptionExercisablePeriod" xlink:to="lab_bntx_OptionExercisablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6864d7c2-da3c-485e-b6bd-523f048d2c36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ed4592fc-dc4d-43ae-bc93-86d07b826920_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechManufacturingGmbHMember_892cbe0b-8821-4b82-8d2d-f71fcf7d7885_terseLabel_en-US" xlink:label="lab_bntx_BioNTechManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing GmbH</link:label>
    <link:label id="lab_bntx_BioNTechManufacturingGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechManufacturingGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechManufacturingGmbHMember" xlink:to="lab_bntx_BioNTechManufacturingGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_4bca3754-01db-4901-bff5-36a1adb8040a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_15634d68-169d-4775-ac89-c8a3ee042512_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_cdeaa0ab-0f3f-42c4-8a03-736115c3091c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance income excluding foreign exchange differences</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechCellGeneTherapiesGmbHMember_a3b68d8c-97b2-4eff-8e5f-90de5822de1f_terseLabel_en-US" xlink:label="lab_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Cell &amp; Gene Therapies GmbH</link:label>
    <link:label id="lab_bntx_BioNTechCellGeneTherapiesGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Cell &amp; Gene Therapies GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechCellGeneTherapiesGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Cell &amp; Gene Therapies GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechCellGeneTherapiesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:to="lab_bntx_BioNTechCellGeneTherapiesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_c525b4cb-38e4-47c0-a5cf-823ee5c9ce07_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_cf5f7ccb-9c78-400d-a58e-6a373f5047cf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_488ecfd2-df5d-4bef-9e9f-50564918bb12_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_db5ff6b2-5f8a-4148-bf02-462ed52f04f0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PhantomOptionAwardsLiability_ffde185c-4f32-480e-81f0-ec599bc64202_terseLabel_en-US" xlink:label="lab_bntx_PhantomOptionAwardsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the phantom option awards</link:label>
    <link:label id="lab_bntx_PhantomOptionAwardsLiability_label_en-US" xlink:label="lab_bntx_PhantomOptionAwardsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phantom Option Awards, Liability</link:label>
    <link:label id="lab_bntx_PhantomOptionAwardsLiability_documentation_en-US" xlink:label="lab_bntx_PhantomOptionAwardsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phantom Option Awards, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PhantomOptionAwardsLiability" xlink:href="bntx-20231231.xsd#bntx_PhantomOptionAwardsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PhantomOptionAwardsLiability" xlink:to="lab_bntx_PhantomOptionAwardsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_c42413d4-1e57-4d2c-a735-72a4f37b8868_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Values of Identifiable Net Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashAndCashEquivalents1LineItems_cc06d8d0-257e-42a6-be99-fc8349c6e2c2_terseLabel_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalents1LineItems_label_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents 1 [Line Items]</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalents1LineItems_documentation_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1LineItems" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems" xlink:to="lab_bntx_CashAndCashEquivalents1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_1fed0e18-5db4-4c4c-a595-a4dc04cd6b0e_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in deferred taxes due to tax rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractAssets_799340ca-4dd5-41ab-b309-02bbbd088256_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_ifrs-full_ContractAssets_label_en-US" xlink:label="lab_ifrs-full_ContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractAssets" xlink:to="lab_ifrs-full_ContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_a4239d4d-8c9e-434c-afb6-fa70a3b5cd22_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_979dfc22-8250-4ad3-9980-42e583a708e5_terseLabel_en-US" xlink:label="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Payments, Classified As Operating Activities</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based Payments, Classified As Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentsClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:to="lab_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_ec0e11db-dc81-4602-a056-fee930ba7404_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_55ed7739-e053-408c-8dd5-7f31db2f0b7c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_49c2897e-44ef-43f2-8628-e37de81bc27e_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="lab_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ResearchAndDevelopmentExpensesMember_011bca68-01d5-4594-aab2-4eda3b2b982c_terseLabel_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_bntx_ResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expenses [Member]</link:label>
    <link:label id="lab_bntx_ResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentExpensesMember" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ResearchAndDevelopmentExpensesMember" xlink:to="lab_bntx_ResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_57c81469-c1c4-4581-9950-b32fbecbe906_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_069f7ee6-2bc7-47bf-a204-b221c0a27fdf_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_080bc7ae-d992-4328-b66c-e32ab6302098_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_dfa17c05-a868-4f99-bd92-ee3f483c46b1_totalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_191d6595-17f9-4fd6-8181-da8993623317_terseLabel_en-US" xlink:label="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1</link:label>
    <link:label id="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_label_en-US" xlink:label="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member]</link:label>
    <link:label id="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_documentation_en-US" xlink:label="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:href="bntx-20231231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:to="lab_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_e057da2c-fbe3-4a8d-afd8-817b7410ebc1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_c012d9ac-1b84-4321-9789-5bc8c4bbe7ec_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage_5ebd559f-5bfd-4ec7-86be-a0a4700cc1c6_terseLabel_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to usage</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage_label_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Usage</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage_documentation_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Related To Usage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToUsage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:to="lab_bntx_CurrentOnerousContractsProvisionRelatedToUsage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_eb7a8d17-be1b-4f2d-acb6-e6cab52b1dcf_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RyvuTherapeuticsSAMember_42847d20-c524-4eb0-8c3f-0b60f2907fc4_terseLabel_en-US" xlink:label="lab_bntx_RyvuTherapeuticsSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ryvu Therapeutics S.A.</link:label>
    <link:label id="lab_bntx_RyvuTherapeuticsSAMember_label_en-US" xlink:label="lab_bntx_RyvuTherapeuticsSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ryvu Therapeutics S.A. [Member]</link:label>
    <link:label id="lab_bntx_RyvuTherapeuticsSAMember_documentation_en-US" xlink:label="lab_bntx_RyvuTherapeuticsSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ryvu Therapeutics S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RyvuTherapeuticsSAMember" xlink:href="bntx-20231231.xsd#bntx_RyvuTherapeuticsSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RyvuTherapeuticsSAMember" xlink:to="lab_bntx_RyvuTherapeuticsSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_538aa8a0-6169-40c9-ba95-ec9798905753_terseLabel_en-US" xlink:label="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies And Other Financial Commitments [Abstract]</link:label>
    <link:label id="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_label_en-US" xlink:label="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies And Other Financial Commitments [Abstract]</link:label>
    <link:label id="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_documentation_en-US" xlink:label="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingencies And Other Financial Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:href="bntx-20231231.xsd#bntx_ContingenciesAndOtherFinancialCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:to="lab_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ManagementBoardMember_0416783c-8ae6-49fa-8f0a-842b131e8888_terseLabel_en-US" xlink:label="lab_bntx_ManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management Board</link:label>
    <link:label id="lab_bntx_ManagementBoardMember_label_en-US" xlink:label="lab_bntx_ManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Board [Member]</link:label>
    <link:label id="lab_bntx_ManagementBoardMember_documentation_en-US" xlink:label="lab_bntx_ManagementBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Management Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardMember" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ManagementBoardMember" xlink:to="lab_bntx_ManagementBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccumulatedTaxLossesInTradeTax_919f9ba0-0990-4859-8ffd-f662568bf558_terseLabel_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInTradeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade tax</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInTradeTax_label_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInTradeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Trade Tax</link:label>
    <link:label id="lab_bntx_AccumulatedTaxLossesInTradeTax_documentation_en-US" xlink:label="lab_bntx_AccumulatedTaxLossesInTradeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Tax Losses In Trade Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInTradeTax" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInTradeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccumulatedTaxLossesInTradeTax" xlink:to="lab_bntx_AccumulatedTaxLossesInTradeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_2beb3241-6e53-45ab-b843-74e9a6731111_terseLabel_en-US" xlink:label="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Individualized mRNA Manufacturing GmbH</link:label>
    <link:label id="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Individualized mRNA Manufacturing GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Individualized mRNA Manufacturing GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:to="lab_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepEmployeeIncentivePlanMember_ce7ffdcb-60ba-4b85-96eb-482194998a75_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep Employee Incentive Plan</link:label>
    <link:label id="lab_bntx_InstaDeepEmployeeIncentivePlanMember_label_en-US" xlink:label="lab_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep Employee Incentive Plan [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepEmployeeIncentivePlanMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep Employee Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepEmployeeIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:to="lab_bntx_InstaDeepEmployeeIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_dbd9990e-0c53-4f1c-8b07-5526f80d1b24_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_50b3b2fa-2cda-48aa-9feb-44977185a193_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_label_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCapitalCommitments" xlink:to="lab_ifrs-full_ContractualCapitalCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementYearOneMember_5995f3e7-dadf-4ac0-8c25-1e782bd79016_terseLabel_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One year</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementYearOneMember_label_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Year One [Member]</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementYearOneMember_documentation_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementYearOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:to="lab_bntx_ShareBasedPaymentArrangementYearOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MedineGmbHMember_3c573363-6385-40e2-9ed7-2eeeabfc056a_terseLabel_en-US" xlink:label="lab_bntx_MedineGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medine GmbH</link:label>
    <link:label id="lab_bntx_MedineGmbHMember_label_en-US" xlink:label="lab_bntx_MedineGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medine GmbH [Member]</link:label>
    <link:label id="lab_bntx_MedineGmbHMember_documentation_en-US" xlink:label="lab_bntx_MedineGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medine GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedineGmbHMember" xlink:href="bntx-20231231.xsd#bntx_MedineGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MedineGmbHMember" xlink:to="lab_bntx_MedineGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_6a25f367-eb99-4fce-8069-2fd70a227503_terseLabel_en-US" xlink:label="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derivative instruments at fair value through profit or loss</link:label>
    <link:label id="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_label_en-US" xlink:label="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain On Derivative Instruments At Fair Value Through Profit Or Loss [Member]</link:label>
    <link:label id="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_documentation_en-US" xlink:label="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain On Derivative Instruments At Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:href="bntx-20231231.xsd#bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:to="lab_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodDomain_2a684491-3cfe-41af-ac0d-b35126ea7dc2_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period [Domain]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodDomain_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period [Domain]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodDomain_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain" xlink:to="lab_bntx_ShareRepurchaseProgramPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesInvestmentMember_c96da2bf-2fe0-4521-975a-6ba2c147d9e1_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security investments</link:label>
    <link:label id="lab_us-gaap_SecuritiesInvestmentMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesInvestmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Investment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesInvestmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesInvestmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesInvestmentMember" xlink:to="lab_us-gaap_SecuritiesInvestmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_78e0d86a-2da8-4caf-8e0a-f8e7479c64af_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_3cf587ad-807a-45e5-93ce-01bf32121f5b_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_711e3b23-27c8-4484-969a-be8a7f432e65_terseLabel_en-US" xlink:label="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to short-term leases and leases of low-value assets</link:label>
    <link:label id="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_label_en-US" xlink:label="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:label id="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_documentation_en-US" xlink:label="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="bntx-20231231.xsd#bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lab_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_1fa8fbe4-fd75-4273-87dd-9a726c6eca07_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_ff3694b5-0753-41d0-a861-8d44f37a8553_terseLabel_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term incentive &#8211; second installment</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_label_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment</link:label>
    <link:label id="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_documentation_en-US" xlink:label="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:to="lab_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_5e4cd5c2-a760-4081-907b-70b6ef3f2d1d_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax with average rate (as a percent)</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_191118d1-49a7-4e9b-9b57-2a7d37638842_verboseLabel_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_ifrs-full_AverageEffectiveTaxRate_label_en-US" xlink:label="lab_ifrs-full_AverageEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageEffectiveTaxRate" xlink:to="lab_ifrs-full_AverageEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_f598d7da-1783-4b1e-91b9-5d6ebf05c6b7_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_ca41112f-9beb-488d-af72-a6b415ef3c9e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_058e62aa-58c6-4998-b21c-bca8c2dc6b60_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EstimatedAllocationDateTwoMember_fa38946c-e5b9-4032-81d7-a393b2db653c_terseLabel_en-US" xlink:label="lab_bntx_EstimatedAllocationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated allocation date 2024</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateTwoMember_label_en-US" xlink:label="lab_bntx_EstimatedAllocationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Two [Member]</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateTwoMember_documentation_en-US" xlink:label="lab_bntx_EstimatedAllocationDateTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateTwoMember" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EstimatedAllocationDateTwoMember" xlink:to="lab_bntx_EstimatedAllocationDateTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember_0f244835-7a43-467c-86f6-ac9bd3d81895_terseLabel_en-US" xlink:label="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to collaboration partners</link:label>
    <link:label id="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember_label_en-US" xlink:label="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Sales To Collaboration Partners [Member]</link:label>
    <link:label id="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember_documentation_en-US" xlink:label="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Sales To Collaboration Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineSalesToCollaborationPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:to="lab_bntx_COVID19VaccineSalesToCollaborationPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_5920a3e2-d8ae-4912-b1a4-78f4df6ae97e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_be431fbd-1733-4065-8bc1-b4688be3fb7a_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ProfessorUgurSahinMDMember_0ab75a20-8751-440e-9857-f982664ea244_terseLabel_en-US" xlink:label="lab_bntx_ProfessorUgurSahinMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prof. Ugur Sahin, M.D.</link:label>
    <link:label id="lab_bntx_ProfessorUgurSahinMDMember_label_en-US" xlink:label="lab_bntx_ProfessorUgurSahinMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professor Ugur Sahin MD [Member]</link:label>
    <link:label id="lab_bntx_ProfessorUgurSahinMDMember_documentation_en-US" xlink:label="lab_bntx_ProfessorUgurSahinMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professor Ugur Sahin MD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProfessorUgurSahinMDMember" xlink:href="bntx-20231231.xsd#bntx_ProfessorUgurSahinMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ProfessorUgurSahinMDMember" xlink:to="lab_bntx_ProfessorUgurSahinMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AtFairValueMember_f26c70c2-be7e-4888-a4f8-b32021c62f48_terseLabel_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_AtFairValueMember_label_en-US" xlink:label="lab_ifrs-full_AtFairValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At fair value [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AtFairValueMember" xlink:to="lab_ifrs-full_AtFairValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_82645ccb-0a46-42ba-be08-a491e17b4d6f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_1534790e-0ed3-416a-85a4-601eed5a06bc_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_6e88453d-75c3-426e-bf53-cc257b126774_terseLabel_en-US" xlink:label="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets non-current and current</link:label>
    <link:label id="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Non-current And Current Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Assets Non-current And Current Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PfizerZosterMember_5158af96-f19a-4010-a066-f7b96ee9ccbf_terseLabel_en-US" xlink:label="lab_bntx_PfizerZosterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer (Zoster)</link:label>
    <link:label id="lab_bntx_PfizerZosterMember_label_en-US" xlink:label="lab_bntx_PfizerZosterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer (Zoster) [Member]</link:label>
    <link:label id="lab_bntx_PfizerZosterMember_documentation_en-US" xlink:label="lab_bntx_PfizerZosterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer (Zoster)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerZosterMember" xlink:href="bntx-20231231.xsd#bntx_PfizerZosterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PfizerZosterMember" xlink:to="lab_bntx_PfizerZosterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_GovernmentGrantsMember_4533859a-ea4b-4fd4-9f7e-ee8c8cda4955_terseLabel_en-US" xlink:label="lab_bntx_GovernmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
    <link:label id="lab_bntx_GovernmentGrantsMember_label_en-US" xlink:label="lab_bntx_GovernmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants [Member]</link:label>
    <link:label id="lab_bntx_GovernmentGrantsMember_documentation_en-US" xlink:label="lab_bntx_GovernmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GovernmentGrantsMember" xlink:href="bntx-20231231.xsd#bntx_GovernmentGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_GovernmentGrantsMember" xlink:to="lab_bntx_GovernmentGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_07b64256-f985-4fb8-a7d0-1ba62c68569d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other effects</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_fe6fa324-e424-4df0-a5c1-034f8cc1e6c9_terseLabel_en-US" xlink:label="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deviation due to local tax basis</link:label>
    <link:label id="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_label_en-US" xlink:label="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Deviation Due To Local Tax Basis</link:label>
    <link:label id="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_documentation_en-US" xlink:label="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Deviation Due To Local Tax Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfDeviationDueToLocalTaxBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:to="lab_bntx_TaxEffectOfDeviationDueToLocalTaxBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_aca81603-0daf-46df-82e4-187ce64c2112_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings for the period per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_2d66ed67-a899-488c-8589-4239251402cf_verboseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic profit for the period per share (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_5a991346-537b-4e51-9fcf-04d21df3f070_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement gain on defined benefit plans</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock_c225a8c9-bed3-4525-87fe-be4a66f131d0_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Inventories Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Inventories Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelFaxNumber_acfa4d6c-c004-4fc5-9768-38386292111c_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelFaxNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Fax Number</link:label>
    <link:label id="lab_dei_ContactPersonnelFaxNumber_label_en-US" xlink:label="lab_dei_ContactPersonnelFaxNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Fax Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber" xlink:to="lab_dei_ContactPersonnelFaxNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfIncreaseInExercisePrice_00908c3f-c089-4e8e-9f9b-9bcf3a0731ea_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfIncreaseInExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of exercise price increase (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfIncreaseInExercisePrice_label_en-US" xlink:label="lab_bntx_PercentageOfIncreaseInExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Exercise Price</link:label>
    <link:label id="lab_bntx_PercentageOfIncreaseInExercisePrice_documentation_en-US" xlink:label="lab_bntx_PercentageOfIncreaseInExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Increase In Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfIncreaseInExercisePrice" xlink:href="bntx-20231231.xsd#bntx_PercentageOfIncreaseInExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfIncreaseInExercisePrice" xlink:to="lab_bntx_PercentageOfIncreaseInExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherFinancialAssetsMember_74f26aee-302b-4677-97e2-afc85e89d37b_terseLabel_en-US" xlink:label="lab_bntx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_bntx_OtherFinancialAssetsMember_label_en-US" xlink:label="lab_bntx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Assets [Member]</link:label>
    <link:label id="lab_bntx_OtherFinancialAssetsMember_documentation_en-US" xlink:label="lab_bntx_OtherFinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialAssetsMember" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherFinancialAssetsMember" xlink:to="lab_bntx_OtherFinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherDeferredTaxesMember_021eea2f-1c1b-4ae9-8a8b-f9356c8b3249_terseLabel_en-US" xlink:label="lab_bntx_OtherDeferredTaxesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (incl. deferred expenses)</link:label>
    <link:label id="lab_bntx_OtherDeferredTaxesMember_label_en-US" xlink:label="lab_bntx_OtherDeferredTaxesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Deferred Taxes [Member]</link:label>
    <link:label id="lab_bntx_OtherDeferredTaxesMember_documentation_en-US" xlink:label="lab_bntx_OtherDeferredTaxesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Deferred Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherDeferredTaxesMember" xlink:href="bntx-20231231.xsd#bntx_OtherDeferredTaxesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherDeferredTaxesMember" xlink:to="lab_bntx_OtherDeferredTaxesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepDEGmbHMember_4d97c0dc-6c39-4b56-9d0d-9bb573dbd674_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepDEGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep DE GmbH</link:label>
    <link:label id="lab_bntx_InstaDeepDEGmbHMember_label_en-US" xlink:label="lab_bntx_InstaDeepDEGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep DE GmbH [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepDEGmbHMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepDEGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep DE GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepDEGmbHMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepDEGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepDEGmbHMember" xlink:to="lab_bntx_InstaDeepDEGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_GeneralAndAdministrativeExpensesMember_42871574-bfeb-4458-8891-b7851749f8f0_terseLabel_en-US" xlink:label="lab_bntx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_bntx_GeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_bntx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses [Member]</link:label>
    <link:label id="lab_bntx_GeneralAndAdministrativeExpensesMember_documentation_en-US" xlink:label="lab_bntx_GeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GeneralAndAdministrativeExpensesMember" xlink:href="bntx-20231231.xsd#bntx_GeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_GeneralAndAdministrativeExpensesMember" xlink:to="lab_bntx_GeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock_d854776b-60d2-49f8-956c-1e689ec5c8a3_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Information about Parent Company</link:label>
    <link:label id="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Significant Investments By Parent Company Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_5bdbf807-bf26-450a-a96e-af09da7c1a78_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange forward contracts</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9e378158-675a-4b60-b2ba-35a4fa1b47be_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_c430adbe-07c3-4e64-9e8a-7c6ca217fc43_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_d0158a49-49ef-4201-95d5-422bcf993aa6_terseLabel_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:label id="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_label_en-US" xlink:label="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="lab_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_f1e91e81-1ee9-411d-bd9a-facca9d69a55_terseLabel_en-US" xlink:label="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049</link:label>
    <link:label id="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_label_en-US" xlink:label="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities</link:label>
    <link:label id="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_documentation_en-US" xlink:label="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:href="bntx-20231231.xsd#bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:to="lab_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_dfb6f6ab-acbe-47a8-b3cf-505f57e6e4fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock_a0bd8b9e-260c-4fe6-82fb-116b0146bdfd_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income and Expenses</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expense Explanatory [Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expense Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:to="lab_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_58bc817b-2d19-4d3b-a818-f840345bd192_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_cfbca913-e415-41e5-99c2-578bc735b358_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock_dd63c127-9f6f-4a2b-b279-a9c240d39665_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Assets</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Assets Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_6ccc4900-38f1-4e3d-9e75-1940d2bf8bcb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Dividend</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for dividends [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DoctorSierkPoettingMember_7fb57c4e-dd1b-4b0c-b39d-e7b8bf71d088_terseLabel_en-US" xlink:label="lab_bntx_DoctorSierkPoettingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sierk Poetting, Ph.D.</link:label>
    <link:label id="lab_bntx_DoctorSierkPoettingMember_label_en-US" xlink:label="lab_bntx_DoctorSierkPoettingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Doctor Sierk Poetting [Member]</link:label>
    <link:label id="lab_bntx_DoctorSierkPoettingMember_documentation_en-US" xlink:label="lab_bntx_DoctorSierkPoettingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Doctor Sierk Poetting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DoctorSierkPoettingMember" xlink:href="bntx-20231231.xsd#bntx_DoctorSierkPoettingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DoctorSierkPoettingMember" xlink:to="lab_bntx_DoctorSierkPoettingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_a1fbc4ef-c93a-4530-8bc4-fcdcc886e2ea_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Non-Financial Assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of non-financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_e9cf680c-d5c6-4cf5-9d45-058e7fcbed2e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for business combinations and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_76831c64-9042-4b04-a44d-46ce1520cb4c_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LTI 2021 program</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2021 Program [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2021 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:to="lab_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_947bde6d-0e6a-4570-a34c-bd719456c7e4_terseLabel_en-US" xlink:label="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of other financial assets</link:label>
    <link:label id="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities</link:label>
    <link:label id="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:href="bntx-20231231.xsd#bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:to="lab_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_8eb42d04-4988-4ff8-acd2-b7c9e9bdd3e8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average share price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePrice2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePrice2019" xlink:to="lab_ifrs-full_WeightedAverageSharePrice2019" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_4c61bb4c-e6a8-4c63-980b-004f9700ba3e_terseLabel_en-US" xlink:label="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America</link:label>
    <link:label id="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_label_en-US" xlink:label="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Employee Equity Plan For Employees Based In Europe [Member]</link:label>
    <link:label id="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_documentation_en-US" xlink:label="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Employee Equity Plan For Employees Based In Europe</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:to="lab_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfTaxLosses_ba69e530-861a-410f-9127-bc104a4c54b1_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects from tax losses and tax credits</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfTaxLosses_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of tax losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfTaxLosses" xlink:to="lab_ifrs-full_TaxEffectOfTaxLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_372eea00-3034-46e6-8777-22d9d4a50fb7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_2c8e3d72-571d-4223-907d-4a9e873b8884_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for gain (loss) on disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_1671a353-5c4d-4085-a4ed-ec23dfa0d122_totalLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_cc3def1b-6b75-43c7-b21c-a26e7bdfa6c6_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_52ce3ea5-2ddd-4d0d-baeb-43be2d601b06_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_f06d6899-b2d0-4977-991a-e18f0f37d0db_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and other financial commitments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_2011af45-73bd-487d-a22e-43c7ac61e042_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_433b424f-2a6e-4b27-a4ba-1b4152a0840f_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain_af054a77-e65c-4f85-9b7e-0ba31bc24392_terseLabel_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Domain]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain_label_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Domain]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain_documentation_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:to="lab_bntx_EmployeeStockOwnershipPlanESOPNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ATHOSKGMember_1b94e447-310c-4c96-8958-1193e455ea97_terseLabel_en-US" xlink:label="lab_bntx_ATHOSKGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATHOS KG</link:label>
    <link:label id="lab_bntx_ATHOSKGMember_label_en-US" xlink:label="lab_bntx_ATHOSKGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATHOSKG [Member]</link:label>
    <link:label id="lab_bntx_ATHOSKGMember_documentation_en-US" xlink:label="lab_bntx_ATHOSKGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATHOSKG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATHOSKGMember" xlink:href="bntx-20231231.xsd#bntx_ATHOSKGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ATHOSKGMember" xlink:to="lab_bntx_ATHOSKGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_1ba15732-ac41-46a5-9975-951b559fa6ca_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_label_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_documentation_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:to="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ReverseRepoMember_54289a83-0c66-4b68-b9b9-95cdfcc0caa6_terseLabel_en-US" xlink:label="lab_bntx_ReverseRepoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Repo</link:label>
    <link:label id="lab_bntx_ReverseRepoMember_label_en-US" xlink:label="lab_bntx_ReverseRepoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Repo [Member]</link:label>
    <link:label id="lab_bntx_ReverseRepoMember_documentation_en-US" xlink:label="lab_bntx_ReverseRepoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reverse Repo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReverseRepoMember" xlink:href="bntx-20231231.xsd#bntx_ReverseRepoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ReverseRepoMember" xlink:to="lab_bntx_ReverseRepoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IntellectualPropertyRightsMember_b02a38a8-b36d-4a46-b57f-feecb2f34679_terseLabel_en-US" xlink:label="lab_bntx_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property rights</link:label>
    <link:label id="lab_bntx_IntellectualPropertyRightsMember_label_en-US" xlink:label="lab_bntx_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Rights [Member]</link:label>
    <link:label id="lab_bntx_IntellectualPropertyRightsMember_documentation_en-US" xlink:label="lab_bntx_IntellectualPropertyRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntellectualPropertyRightsMember" xlink:href="bntx-20231231.xsd#bntx_IntellectualPropertyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IntellectualPropertyRightsMember" xlink:to="lab_bntx_IntellectualPropertyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_c57f1fa7-c513-4e49-b5af-fe9570bcbfcd_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SolidaritySurchargeRate_198b1d0c-1fbc-4608-b5c5-cabe81c48c26_terseLabel_en-US" xlink:label="lab_bntx_SolidaritySurchargeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solidarity surcharge rate (as a percent)</link:label>
    <link:label id="lab_bntx_SolidaritySurchargeRate_label_en-US" xlink:label="lab_bntx_SolidaritySurchargeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solidarity Surcharge Rate</link:label>
    <link:label id="lab_bntx_SolidaritySurchargeRate_documentation_en-US" xlink:label="lab_bntx_SolidaritySurchargeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solidarity Surcharge Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SolidaritySurchargeRate" xlink:href="bntx-20231231.xsd#bntx_SolidaritySurchargeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SolidaritySurchargeRate" xlink:to="lab_bntx_SolidaritySurchargeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_bb6b2a1f-3c36-42be-b113-c0ed77acfa64_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForAssociatesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember" xlink:to="lab_ifrs-full_EntitysTotalForAssociatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_2ce70488-3c9d-4d9b-9dd1-d0678459b721_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_5273d044-7afb-44e0-ad7a-70807019168e_terseLabel_en-US" xlink:label="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Innovative Manufacturing Services GmbH</link:label>
    <link:label id="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Innovative Manufacturing Services GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Innovative Manufacturing Services GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:to="lab_bntx_BioNTechInnovativeManufacturingServicesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_2d78b068-72ec-4a3e-929f-00bd142573ed_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_9b735ec1-27ca-495a-9a58-b41f36f78a90_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_07f50297-8330-4a82-a4f0-5d580327e00d_terseLabel_en-US" xlink:label="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</link:label>
    <link:label id="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_label_en-US" xlink:label="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</link:label>
    <link:label id="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_documentation_en-US" xlink:label="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:href="bntx-20231231.xsd#bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:to="lab_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_5bdff3eb-10e1-408d-8f3b-a7db1500a7a4_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deviation due to deviating income tax rate (Germany and foreign countries)</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_287fedf8-5ca4-4f4c-b8f5-6edead075563_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_712993d4-c228-492e-b639-b27b7f095b00_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechRDAustriaGmbHMember_f9eac043-0c33-4ea0-a2f1-061b834f6bc6_terseLabel_en-US" xlink:label="lab_bntx_BioNTechRDAustriaGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech R&amp;D (Austria) GmbH</link:label>
    <link:label id="lab_bntx_BioNTechRDAustriaGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechRDAustriaGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech R&amp;D (Austria) GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechRDAustriaGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechRDAustriaGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech R&amp;D (Austria) GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRDAustriaGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechRDAustriaGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechRDAustriaGmbHMember" xlink:to="lab_bntx_BioNTechRDAustriaGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_e9cb5c59-c201-4725-8ace-b225f776cf8a_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_d24ca1e4-0443-40f7-b221-7bf99bc7f4fa_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Profit for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_643a3789-16ee-4d2a-b77c-4ec5d0c1ee21_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f1fec6a7-468d-4e8e-ad10-6b26c292b3d0_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LegalProceedingsProvision_bb11b22d-4d43-4be0-9139-ee58053b1d1e_terseLabel_en-US" xlink:label="lab_ifrs-full_LegalProceedingsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual disputes</link:label>
    <link:label id="lab_ifrs-full_LegalProceedingsProvision_label_en-US" xlink:label="lab_ifrs-full_LegalProceedingsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LegalProceedingsProvision" xlink:to="lab_ifrs-full_LegalProceedingsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_743df7be-1a6b-46bf-b02b-ccd4ab987af8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_d8bf02fb-45a7-4733-b90d-baeb8e7e522c_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LTI 2020 program</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2020 Program [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2020 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:to="lab_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepNigeriaLimitedMember_ee470ed1-0ddd-43b0-af56-ba6c4c7a537b_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepNigeriaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep Nigeria Limited</link:label>
    <link:label id="lab_bntx_InstaDeepNigeriaLimitedMember_label_en-US" xlink:label="lab_bntx_InstaDeepNigeriaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep Nigeria Limited [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepNigeriaLimitedMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepNigeriaLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep Nigeria Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepNigeriaLimitedMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepNigeriaLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepNigeriaLimitedMember" xlink:to="lab_bntx_InstaDeepNigeriaLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechBioNTainerHoldingGmbHMember_66bdde3e-3ac6-4b5c-9c6a-48f20f4341cb_terseLabel_en-US" xlink:label="lab_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech BioNTainer Holding GmbH</link:label>
    <link:label id="lab_bntx_BioNTechBioNTainerHoldingGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech BioNTainer Holding GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechBioNTainerHoldingGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech BioNTainer Holding GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechBioNTainerHoldingGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:to="lab_bntx_BioNTechBioNTainerHoldingGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_b16afd0d-e44f-47b2-af23-528f90ccca2a_terseLabel_en-US" xlink:label="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares used for acquisition of business combination</link:label>
    <link:label id="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_label_en-US" xlink:label="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Shares Used For Acquisition Of Business Combination</link:label>
    <link:label id="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_documentation_en-US" xlink:label="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Shares Used For Acquisition Of Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:href="bntx-20231231.xsd#bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:to="lab_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LitigationCostsMember_5f8a47f3-0f05-4828-8346-d4e1ccc9abdd_terseLabel_en-US" xlink:label="lab_bntx_LitigationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation costs</link:label>
    <link:label id="lab_bntx_LitigationCostsMember_label_en-US" xlink:label="lab_bntx_LitigationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Costs [Member]</link:label>
    <link:label id="lab_bntx_LitigationCostsMember_documentation_en-US" xlink:label="lab_bntx_LitigationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LitigationCostsMember" xlink:href="bntx-20231231.xsd#bntx_LitigationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LitigationCostsMember" xlink:to="lab_bntx_LitigationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfResearchAndDevelopmentExpense_74f3b808-5717-4a2b-83fc-e19901af27fa_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Research And Development Expense</link:label>
    <link:label id="lab_bntx_PercentageOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:href="bntx-20231231.xsd#bntx_PercentageOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:to="lab_bntx_PercentageOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_f1e72707-8e24-4c8d-87b5-e9039b7d067b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NonListedEquityInvestmentsMember_36f1c858-69f1-45ab-b121-9839ec77e4c2_terseLabel_en-US" xlink:label="lab_bntx_NonListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-listed equity investments</link:label>
    <link:label id="lab_bntx_NonListedEquityInvestmentsMember_label_en-US" xlink:label="lab_bntx_NonListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Listed Equity Investments [Member]</link:label>
    <link:label id="lab_bntx_NonListedEquityInvestmentsMember_documentation_en-US" xlink:label="lab_bntx_NonListedEquityInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Listed Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonListedEquityInvestmentsMember" xlink:href="bntx-20231231.xsd#bntx_NonListedEquityInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NonListedEquityInvestmentsMember" xlink:to="lab_bntx_NonListedEquityInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise_9a51f07f-8fdc-4dac-8d71-1d3d2bcd6e4a_terseLabel_en-US" xlink:label="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash outflow for share based payment exercise</link:label>
    <link:label id="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise_label_en-US" xlink:label="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Outflow For Share Based Payment Arrangement Exercise</link:label>
    <link:label id="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise_documentation_en-US" xlink:label="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Outflow For Share Based Payment Arrangement Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:href="bntx-20231231.xsd#bntx_CashOutflowForShareBasedPaymentArrangementExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:to="lab_bntx_CashOutflowForShareBasedPaymentArrangementExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_Inventories1Member_9a221851-b1a0-4c3f-b82b-0c74ff97485a_terseLabel_en-US" xlink:label="lab_bntx_Inventories1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_bntx_Inventories1Member_label_en-US" xlink:label="lab_bntx_Inventories1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories 1 [Member]</link:label>
    <link:label id="lab_bntx_Inventories1Member_documentation_en-US" xlink:label="lab_bntx_Inventories1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventories 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Inventories1Member" xlink:href="bntx-20231231.xsd#bntx_Inventories1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_Inventories1Member" xlink:to="lab_bntx_Inventories1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_c784da68-349b-44bd-a4d0-9f1a272c1094_terseLabel_en-US" xlink:label="lab_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets recognised as of acquisition date</link:label>
    <link:label id="lab_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_728df1da-a037-4baf-9439-e354bc91ffff_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfinished goods</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_1ebe9208-c6f1-47f1-a49f-38f65aa1816b_terseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof allocated and vested but subject to performance and waiting requirements (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepLtdMember_edb69926-e77a-4d0f-813e-0efd521c8533_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd.</link:label>
    <link:label id="lab_bntx_InstaDeepLtdMember_label_en-US" xlink:label="lab_bntx_InstaDeepLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepLtdMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtdMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepLtdMember" xlink:to="lab_bntx_InstaDeepLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_d8ed4af2-ba82-48f9-97c9-489106389210_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in euros per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfGeneralAndAdministrativeExpense_0e9ca6ca-802f-47a2-9d69-632820b99bc6_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of General And Administrative Expense</link:label>
    <link:label id="lab_bntx_PercentageOfGeneralAndAdministrativeExpense_documentation_en-US" xlink:label="lab_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:href="bntx-20231231.xsd#bntx_PercentageOfGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:to="lab_bntx_PercentageOfGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentAndDeferredTaxExpenseIncome_929ad135-365d-4b05-82c0-28b660c24fff_negatedLabel_en-US" xlink:label="lab_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current and deferred taxes</link:label>
    <link:label id="lab_bntx_CurrentAndDeferredTaxExpenseIncome_label_en-US" xlink:label="lab_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current And Deferred Tax Expense (Income)</link:label>
    <link:label id="lab_bntx_CurrentAndDeferredTaxExpenseIncome_documentation_en-US" xlink:label="lab_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current And Deferred Tax Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:href="bntx-20231231.xsd#bntx_CurrentAndDeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:to="lab_bntx_CurrentAndDeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncreaseDecreaseCostOfSales_171f1495-e9b3-49a2-8f1d-b63fcda090c5_terseLabel_en-US" xlink:label="lab_bntx_IncreaseDecreaseCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease cost of sales</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseCostOfSales_label_en-US" xlink:label="lab_bntx_IncreaseDecreaseCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Cost Of Sales</link:label>
    <link:label id="lab_bntx_IncreaseDecreaseCostOfSales_documentation_en-US" xlink:label="lab_bntx_IncreaseDecreaseCostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Cost Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseCostOfSales" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncreaseDecreaseCostOfSales" xlink:to="lab_bntx_IncreaseDecreaseCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_edcf91c5-a11e-4036-b4e0-9742974a12aa_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_8640b71a-8c76-45bb-8a89-b2c63f96f710_terseLabel_en-US" xlink:label="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares, each Representing one ordinary share</link:label>
    <link:label id="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_label_en-US" xlink:label="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares Each Representing One Ordinary Share [Member]</link:label>
    <link:label id="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_documentation_en-US" xlink:label="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depositary Shares Each Representing One Ordinary Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:href="bntx-20231231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:to="lab_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubsidiariesMember_11b23101-d74d-4f1f-90a8-ae6713aeeb7b_terseLabel_en-US" xlink:label="lab_ifrs-full_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_ifrs-full_SubsidiariesMember_label_en-US" xlink:label="lab_ifrs-full_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubsidiariesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubsidiariesMember" xlink:to="lab_ifrs-full_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_dbd938f2-9ded-435e-9ff3-4b8a97c92c52_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory tax rate (as a percent)</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementsAbstract_72bb74fe-6ba8-4548-a07a-f6659b1cd3b6_terseLabel_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract" xlink:to="lab_bntx_ShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_1d4f2c9c-4509-4286-8691-4386d76dfc00_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c1600b8f-3c8d-4921-a2c7-c197850a1db2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FairValueThroughProfitOrLossMember_b79d3ee8-2ce0-4c50-a8da-263b4a977411_terseLabel_en-US" xlink:label="lab_bntx_FairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FVTPL</link:label>
    <link:label id="lab_bntx_FairValueThroughProfitOrLossMember_label_en-US" xlink:label="lab_bntx_FairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Through Profit Or Loss [Member]</link:label>
    <link:label id="lab_bntx_FairValueThroughProfitOrLossMember_documentation_en-US" xlink:label="lab_bntx_FairValueThroughProfitOrLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Through Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughProfitOrLossMember" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughProfitOrLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FairValueThroughProfitOrLossMember" xlink:to="lab_bntx_FairValueThroughProfitOrLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FederalCorporateIncomeTax_8c5f924e-b30c-4ffa-b126-ccd84633da94_terseLabel_en-US" xlink:label="lab_bntx_FederalCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal corporate income tax (as a percent)</link:label>
    <link:label id="lab_bntx_FederalCorporateIncomeTax_label_en-US" xlink:label="lab_bntx_FederalCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Corporate Income Tax</link:label>
    <link:label id="lab_bntx_FederalCorporateIncomeTax_documentation_en-US" xlink:label="lab_bntx_FederalCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalCorporateIncomeTax" xlink:href="bntx-20231231.xsd#bntx_FederalCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FederalCorporateIncomeTax" xlink:to="lab_bntx_FederalCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_11323cff-3ed4-4e7a-8e40-e8cfd40acc33_terseLabel_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension costs</link:label>
    <link:label id="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense in profit or loss, defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="lab_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EventsAfterReportingPeriodAbstract_f864e245-f020-4c4b-8a58-8fd7f831777c_terseLabel_en-US" xlink:label="lab_bntx_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events After Reporting Period [Abstract]</link:label>
    <link:label id="lab_bntx_EventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_bntx_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Events After Reporting Period [Abstract]</link:label>
    <link:label id="lab_bntx_EventsAfterReportingPeriodAbstract_documentation_en-US" xlink:label="lab_bntx_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Events After Reporting Period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EventsAfterReportingPeriodAbstract" xlink:href="bntx-20231231.xsd#bntx_EventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EventsAfterReportingPeriodAbstract" xlink:to="lab_bntx_EventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_d195869c-eb2f-48e4-ac3c-435f378e9848_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_30f444ff-8f51-409c-8d67-919e7e79087d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Detailed Information About Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechSenegalSuarlMember_988caca2-1cbe-4512-9275-daadcc24dba2_terseLabel_en-US" xlink:label="lab_bntx_BioNTechSenegalSuarlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech S&#233;n&#233;gal Suarl</link:label>
    <link:label id="lab_bntx_BioNTechSenegalSuarlMember_label_en-US" xlink:label="lab_bntx_BioNTechSenegalSuarlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech S&#233;n&#233;gal Suarl [Member]</link:label>
    <link:label id="lab_bntx_BioNTechSenegalSuarlMember_documentation_en-US" xlink:label="lab_bntx_BioNTechSenegalSuarlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech S&#233;n&#233;gal Suarl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSenegalSuarlMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechSenegalSuarlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechSenegalSuarlMember" xlink:to="lab_bntx_BioNTechSenegalSuarlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock_dbd9feb8-a63a-45ff-a885-e779cdbf1fab_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Finance Expense</link:label>
    <link:label id="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Cost Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Cost Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AuditInformationAbstract_label_en-US" xlink:label="lab_bntx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bntx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bntx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AuditInformationAbstract" xlink:href="bntx-20231231.xsd#bntx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AuditInformationAbstract" xlink:to="lab_bntx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_88f9c673-2aa5-445c-b414-66ae34e47490_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_3699c000-d26d-4095-8e09-566d44184592_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TradePayablesAndOtherPayablesMember_279468b1-a6df-4c95-8eb2-6e73c5b7510d_terseLabel_en-US" xlink:label="lab_bntx_TradePayablesAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_bntx_TradePayablesAndOtherPayablesMember_label_en-US" xlink:label="lab_bntx_TradePayablesAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Payables And Other Payables [Member]</link:label>
    <link:label id="lab_bntx_TradePayablesAndOtherPayablesMember_documentation_en-US" xlink:label="lab_bntx_TradePayablesAndOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade Payables And Other Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradePayablesAndOtherPayablesMember" xlink:href="bntx-20231231.xsd#bntx_TradePayablesAndOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TradePayablesAndOtherPayablesMember" xlink:to="lab_bntx_TradePayablesAndOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_9f88cbca-31fe-48bf-ac6d-65d5824b616a_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityInterestsOfAcquirer_f4828541-2470-4c2e-8ec1-e0591f6cc636_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares transferred (approx. 1.1 million shares)</link:label>
    <link:label id="lab_ifrs-full_EquityInterestsOfAcquirer_label_en-US" xlink:label="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity interests of acquirer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityInterestsOfAcquirer" xlink:to="lab_ifrs-full_EquityInterestsOfAcquirer" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RemainingUpfrontFeesContractLiabilities_7847f3d7-ff2d-487f-aa2b-8bbb6c88eb69_terseLabel_en-US" xlink:label="lab_bntx_RemainingUpfrontFeesContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining upfront fees contract liabilities</link:label>
    <link:label id="lab_bntx_RemainingUpfrontFeesContractLiabilities_label_en-US" xlink:label="lab_bntx_RemainingUpfrontFeesContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Upfront Fees Contract Liabilities</link:label>
    <link:label id="lab_bntx_RemainingUpfrontFeesContractLiabilities_documentation_en-US" xlink:label="lab_bntx_RemainingUpfrontFeesContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining Upfront Fees Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RemainingUpfrontFeesContractLiabilities" xlink:href="bntx-20231231.xsd#bntx_RemainingUpfrontFeesContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RemainingUpfrontFeesContractLiabilities" xlink:to="lab_bntx_RemainingUpfrontFeesContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialLiabilities_7fcdd870-3b61-4491-809f-0c891ecf6ee8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="lab_ifrs-full_OtherCurrentFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_f640f417-66d0-4c30-bf04-a7a4467fd395_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNonfinancialLiabilities_42cf8ed5-918f-45b5-9736-7b141b86b364_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_OtherNonfinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherNonfinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNonfinancialLiabilities" xlink:to="lab_ifrs-full_OtherNonfinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_Leases1Abstract_ab21332b-f226-408c-a0c1-747b09f6e82a_terseLabel_en-US" xlink:label="lab_bntx_Leases1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_bntx_Leases1Abstract_label_en-US" xlink:label="lab_bntx_Leases1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases 1 [Abstract]</link:label>
    <link:label id="lab_bntx_Leases1Abstract_documentation_en-US" xlink:label="lab_bntx_Leases1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_Leases1Abstract" xlink:to="lab_bntx_Leases1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_065eef81-0db8-4b40-9b70-d2a160b8f806_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_b92d2c92-2f09-46c3-a0ba-593147cf03e1_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_bd31c9ac-1c19-4cd2-a97d-b8339af3c330_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less than 1 year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_1d4752bd-3a17-4055-907c-c0e6eef13a33_terseLabel_en-US" xlink:label="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model</link:label>
    <link:label id="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_label_en-US" xlink:label="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Or Usage Based Royalty Recognition Constraint Model [Member]</link:label>
    <link:label id="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_documentation_en-US" xlink:label="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Based Or Usage Based Royalty Recognition Constraint Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:href="bntx-20231231.xsd#bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:to="lab_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0ea09339-6891-4db3-bf24-d81da6f2cff8_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_f9b4b399-79db-45d0-9c48-d1e1d23b9e71_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than one year</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearMember" xlink:to="lab_ifrs-full_LaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_36fc7659-9046-4672-b793-15d525ea54fe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Liabilities Arising from Financing Activities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_e11c71cf-b8bd-4fbf-b43b-fdc51a86c39a_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_86a5d044-c09f-4c8d-bbe3-f28f5df7d36d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_d1710db8-5cb2-48b3-9531-401f8d225ea8_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bad debt expense has been recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_label_en-US" xlink:label="lab_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense recognised during period for bad and doubtful debts for related party transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:to="lab_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_263cd18c-d082-4885-8086-3777a6d0f477_terseLabel_en-US" xlink:label="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities long-term and short-term</link:label>
    <link:label id="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_8ade136e-d50d-4ccb-9c61-9c707db83d96_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other related parties</link:label>
    <link:label id="lab_ifrs-full_OtherRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRelatedPartiesMember" xlink:to="lab_ifrs-full_OtherRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_8cdf1737-8de7-4f2f-822c-e15520cf0441_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ManufacturingVariancesMember_0d0a7b38-badc-4a48-8a74-1d1e4ffb29b9_terseLabel_en-US" xlink:label="lab_bntx_ManufacturingVariancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Variances</link:label>
    <link:label id="lab_bntx_ManufacturingVariancesMember_label_en-US" xlink:label="lab_bntx_ManufacturingVariancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Variances [Member]</link:label>
    <link:label id="lab_bntx_ManufacturingVariancesMember_documentation_en-US" xlink:label="lab_bntx_ManufacturingVariancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Variances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManufacturingVariancesMember" xlink:href="bntx-20231231.xsd#bntx_ManufacturingVariancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ManufacturingVariancesMember" xlink:to="lab_bntx_ManufacturingVariancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_df721e84-831e-4adb-ba89-acc4cd33c733_terseLabel_en-US" xlink:label="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease / (increase) in trade and other receivables, contract assets and other assets</link:label>
    <link:label id="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_label_en-US" xlink:label="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets</link:label>
    <link:label id="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_documentation_en-US" xlink:label="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:to="lab_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f04bb634-9d90-484f-a99a-e9c392ed6d85_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechMember_7b386a89-6af6-4c9d-9c45-4ea3a929c1e9_terseLabel_en-US" xlink:label="lab_bntx_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech</link:label>
    <link:label id="lab_bntx_BioNTechMember_label_en-US" xlink:label="lab_bntx_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_bntx_BioNTechMember_documentation_en-US" xlink:label="lab_bntx_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechMember" xlink:to="lab_bntx_BioNTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_712d058f-86fc-4e0e-9de1-2fe5400822b8_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_444d3aa4-7c93-4cab-80d0-63bfa05a333b_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_7f4d5152-83dc-4fec-a637-8cf3e056eb6d_terseLabel_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Social security costs</link:label>
    <link:label id="lab_ifrs-full_SocialSecurityContributions_label_en-US" xlink:label="lab_ifrs-full_SocialSecurityContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Social security contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SocialSecurityContributions" xlink:to="lab_ifrs-full_SocialSecurityContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_033687f5-bd1b-403f-9205-3fe4d3c25d9f_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of subsidiaries and businesses</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodAxis_f333b0d6-5c13-47b0-aa3c-3d24846aad5d_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period [Axis]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodAxis_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period [Axis]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramPeriodAxis_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodAxis" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis" xlink:to="lab_bntx_ShareRepurchaseProgramPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_3d2b1327-0b0f-4cd6-beba-f850a933393c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ResearchAndDevelopmentMember_ce94ba49-9b2e-4f9e-b6ed-51185264a086_terseLabel_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; development revenues</link:label>
    <link:label id="lab_bntx_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_bntx_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bntx_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentMember" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ResearchAndDevelopmentMember" xlink:to="lab_bntx_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_619ae103-5888-4d9a-83ba-efba96dbf5bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:to="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_bbd5f592-85bd-47c2-80f0-6b882ffefed3_terseLabel_en-US" xlink:label="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of various goods and services from entities controlled by ATHOS KG</link:label>
    <link:label id="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_label_en-US" xlink:label="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases Of Goods And Service Related Party Transactions</link:label>
    <link:label id="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_documentation_en-US" xlink:label="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchases Of Goods And Service Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:href="bntx-20231231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:to="lab_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherLiabilitiesOther_cbeb8141-6c40-49ba-8da8-8c8e54c3ad9f_terseLabel_en-US" xlink:label="lab_bntx_OtherLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bntx_OtherLiabilitiesOther_label_en-US" xlink:label="lab_bntx_OtherLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Other</link:label>
    <link:label id="lab_bntx_OtherLiabilitiesOther_documentation_en-US" xlink:label="lab_bntx_OtherLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesOther" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherLiabilitiesOther" xlink:to="lab_bntx_OtherLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashTransferred_fa20091d-cba1-4f94-baa2-2685a311d7a6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_ifrs-full_CashTransferred_label_en-US" xlink:label="lab_ifrs-full_CashTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashTransferred" xlink:to="lab_ifrs-full_CashTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss_bc825ef0-78a7-4da3-84d7-6fbd71ebcb07_totalLabel_en-US" xlink:label="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amounts recognized in profit or loss</link:label>
    <link:label id="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss_label_en-US" xlink:label="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Expenses Recognized In Profit Or Loss</link:label>
    <link:label id="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss_documentation_en-US" xlink:label="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Expenses Recognized In Profit Or Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:href="bntx-20231231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:to="lab_bntx_LeaseExpensesRecognizedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_a77468d6-620f-46ed-82ba-af252c43d6a1_terseLabel_en-US" xlink:label="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_4f6a33d1-276c-4798-80ef-4d0d13573ea9_terseLabel_en-US" xlink:label="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits</link:label>
    <link:label id="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits [Member]</link:label>
    <link:label id="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_documentation_en-US" xlink:label="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="bntx-20231231.xsd#bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WritedownsReversalsOfInventories_ccdb43af-02bf-40b9-9124-1d0e4bbbc295_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_WritedownsReversalsOfInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Write-downs (reversals of write-downs) of inventories</link:label>
    <link:label id="lab_ifrs-full_WritedownsReversalsOfInventories_label_en-US" xlink:label="lab_ifrs-full_WritedownsReversalsOfInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write-downs (reversals of write-downs) of inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WritedownsReversalsOfInventories" xlink:to="lab_ifrs-full_WritedownsReversalsOfInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_feadd363-7d1a-486f-b594-50d1a1fd4993_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_b802c014-9950-4e29-a1cd-c67f6ca7a790_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RevenueFromContractsWithCustomersAbstract_73c08a3c-1cc8-46de-8ebd-393dd2567bee_terseLabel_en-US" xlink:label="lab_bntx_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers [Abstract]</link:label>
    <link:label id="lab_bntx_RevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_bntx_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers [Abstract]</link:label>
    <link:label id="lab_bntx_RevenueFromContractsWithCustomersAbstract_documentation_en-US" xlink:label="lab_bntx_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contracts With Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract" xlink:to="lab_bntx_RevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_e7f22468-6a03-46c6-bc8f-cc9950e3fc11_terseLabel_en-US" xlink:label="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medilink Therapeutics (Suzhou) Co. Ltd.,</link:label>
    <link:label id="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_label_en-US" xlink:label="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medilink Therapeutics (Suzhou) Co. Ltd., [Member]</link:label>
    <link:label id="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_documentation_en-US" xlink:label="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medilink Therapeutics (Suzhou) Co. Ltd.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:href="bntx-20231231.xsd#bntx_MedilinkTherapeuticsSuzhouCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:to="lab_bntx_MedilinkTherapeuticsSuzhouCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_aec51d4f-4f9c-4f98-843e-38d68fddb1e7_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_d90c5d9d-1fe6-47e1-b233-84fea79d559e_terseLabel_en-US" xlink:label="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net employee defined benefit liabilities</link:label>
    <link:label id="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_label_en-US" xlink:label="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Employee Defined Benefit Liabilities [Member]</link:label>
    <link:label id="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_documentation_en-US" xlink:label="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Employee Defined Benefit Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:href="bntx-20231231.xsd#bntx_NetEmployeeDefinedBenefitLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:to="lab_bntx_NetEmployeeDefinedBenefitLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_3a5c3199-bc8a-4313-8681-7a99adb05ba6_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_01652e34-c4f6-42d0-b850-296c8e55c761_terseLabel_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on pre-tax equity</link:label>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_label_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Changes Effect On Pretax Equity</link:label>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_documentation_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Changes Effect On Pretax Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:to="lab_bntx_ForeignCurrencyChangesEffectOnPretaxEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechSwitzerlandGmbHMember_3385597a-ec09-4848-a142-54d540511f5c_terseLabel_en-US" xlink:label="lab_bntx_BioNTechSwitzerlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Switzerland GmbH</link:label>
    <link:label id="lab_bntx_BioNTechSwitzerlandGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechSwitzerlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Switzerland GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechSwitzerlandGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechSwitzerlandGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Switzerland GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSwitzerlandGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechSwitzerlandGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechSwitzerlandGmbHMember" xlink:to="lab_bntx_BioNTechSwitzerlandGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_2363ac4e-4574-46f9-ac3c-82b48a436afc_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_19e6e67a-a9d8-44f1-ba1f-a32d0a91bd8e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ManagementBoardGrantMember_2360b19b-7c64-4e30-8aa8-f8d110fc6d35_terseLabel_en-US" xlink:label="lab_bntx_ManagementBoardGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management Board Grant</link:label>
    <link:label id="lab_bntx_ManagementBoardGrantMember_label_en-US" xlink:label="lab_bntx_ManagementBoardGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Board Grant [Member]</link:label>
    <link:label id="lab_bntx_ManagementBoardGrantMember_documentation_en-US" xlink:label="lab_bntx_ManagementBoardGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Management Board Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ManagementBoardGrantMember" xlink:to="lab_bntx_ManagementBoardGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_b1e0db02-953d-4418-8f4f-0be558be97fb_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash outflow</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_8feed218-a74e-494a-a042-e7a8c9ff6af2_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of share capital</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_4d36f438-229f-443d-8575-e6f79f77262e_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issueance of share capital</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityTable_d0673f2f-e149-485d-ad02-53d40ed94b79_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reserves within equity [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reserves within equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:to="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EuropeanCommissionToCollaborationPartnerMember_cb061f3e-4f57-4405-86e2-c8074ab0164f_terseLabel_en-US" xlink:label="lab_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Commission To Collaboration Partner</link:label>
    <link:label id="lab_bntx_EuropeanCommissionToCollaborationPartnerMember_label_en-US" xlink:label="lab_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Commission To Collaboration Partner [Member]</link:label>
    <link:label id="lab_bntx_EuropeanCommissionToCollaborationPartnerMember_documentation_en-US" xlink:label="lab_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">European Commission To Collaboration Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:href="bntx-20231231.xsd#bntx_EuropeanCommissionToCollaborationPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:to="lab_bntx_EuropeanCommissionToCollaborationPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_2c50622e-5178-43d7-b388-71a1a14d1499_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncome" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b4e3eca0-26db-4c27-98a0-395ed46335e3_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lab_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_b6ccd6c4-3731-4ea8-bfbe-48c581d8257e_terseLabel_en-US" xlink:label="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, loans and borrowings</link:label>
    <link:label id="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_label_en-US" xlink:label="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current Lease Liabilities, Loans And Borrowings</link:label>
    <link:label id="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_documentation_en-US" xlink:label="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-current Lease Liabilities, Loans And Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:href="bntx-20231231.xsd#bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:to="lab_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MeasurementAxis_6cb58d55-8873-47b8-98df-fe27798ded93_terseLabel_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_MeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_MeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MeasurementAxis" xlink:to="lab_ifrs-full_MeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_9486afb8-2fe1-4bf0-b632-c4c9650dbac2_terseLabel_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof un-vested, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_e5b839b9-c123-41c4-bda2-3dcffbab764c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_2f9c81ea-44f3-4fcb-a69e-5d1f25fd3a95_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OptionVestingPeriod_8f077542-967b-4eb5-909d-a765b6542a78_terseLabel_en-US" xlink:label="lab_bntx_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option rights vesting period (in years)</link:label>
    <link:label id="lab_bntx_OptionVestingPeriod_label_en-US" xlink:label="lab_bntx_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Vesting Period</link:label>
    <link:label id="lab_bntx_OptionVestingPeriod_documentation_en-US" xlink:label="lab_bntx_OptionVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionVestingPeriod" xlink:href="bntx-20231231.xsd#bntx_OptionVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OptionVestingPeriod" xlink:to="lab_bntx_OptionVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_683dca4f-e6bc-46be-b192-9ee567920dc7_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss for a reduction of future cash flows (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_label_en-US" xlink:label="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Impairment Loss For A Reduction Of Future Cash Flows</link:label>
    <link:label id="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_documentation_en-US" xlink:label="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Impairment Loss For A Reduction Of Future Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:href="bntx-20231231.xsd#bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:to="lab_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OtherNonFinancialAssetsAbstract_label_en-US" xlink:label="lab_bntx_OtherNonFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Non-Financial Assets [Abstract]</link:label>
    <link:label id="lab_bntx_OtherNonFinancialAssetsAbstract_documentation_en-US" xlink:label="lab_bntx_OtherNonFinancialAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Non-Financial Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialAssetsAbstract" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract" xlink:to="lab_bntx_OtherNonFinancialAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_759c3824-6d46-48f0-a1ab-112c72a5c5c4_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from loans and borrowings</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_7ce56d02-d44c-4290-9179-a773bf4c29b5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ExercisePricePhantomOptionsGranted_f921aaab-e54c-4145-8402-ab9b2dbf4c36_terseLabel_en-US" xlink:label="lab_bntx_ExercisePricePhantomOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of phantom options granted (in euro per share)</link:label>
    <link:label id="lab_bntx_ExercisePricePhantomOptionsGranted_label_en-US" xlink:label="lab_bntx_ExercisePricePhantomOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price, Phantom Options Granted</link:label>
    <link:label id="lab_bntx_ExercisePricePhantomOptionsGranted_documentation_en-US" xlink:label="lab_bntx_ExercisePricePhantomOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price, Phantom Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePricePhantomOptionsGranted" xlink:href="bntx-20231231.xsd#bntx_ExercisePricePhantomOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ExercisePricePhantomOptionsGranted" xlink:to="lab_bntx_ExercisePricePhantomOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock_b9282cb8-23f6-4a7f-b72d-a120951be41f_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accumulated Tax Losses</link:label>
    <link:label id="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accumulated Tax Losses Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ChiefExecutiveOfficerGrantMember_51998475-4a29-42e4-9495-609e870dbba5_terseLabel_en-US" xlink:label="lab_bntx_ChiefExecutiveOfficerGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Grant</link:label>
    <link:label id="lab_bntx_ChiefExecutiveOfficerGrantMember_label_en-US" xlink:label="lab_bntx_ChiefExecutiveOfficerGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Grant [Member]</link:label>
    <link:label id="lab_bntx_ChiefExecutiveOfficerGrantMember_documentation_en-US" xlink:label="lab_bntx_ChiefExecutiveOfficerGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chief Executive Officer Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ChiefExecutiveOfficerGrantMember" xlink:to="lab_bntx_ChiefExecutiveOfficerGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_98d9d4e8-b723-4512-b06f-62e214c89878_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_336e5540-efc0-40c0-a27f-486b07914374_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DualityBiologicsSuzhouCoLtdMember_5848a929-366f-42b2-adc0-77f8d354256a_terseLabel_en-US" xlink:label="lab_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duality Biologics (Suzhou) Co. Ltd.,</link:label>
    <link:label id="lab_bntx_DualityBiologicsSuzhouCoLtdMember_label_en-US" xlink:label="lab_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Duality Biologics (Suzhou) Co. Ltd., [Member]</link:label>
    <link:label id="lab_bntx_DualityBiologicsSuzhouCoLtdMember_documentation_en-US" xlink:label="lab_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duality Biologics (Suzhou) Co. Ltd.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:href="bntx-20231231.xsd#bntx_DualityBiologicsSuzhouCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:to="lab_bntx_DualityBiologicsSuzhouCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_ed37b718-4429-4c59-82cd-f0388989f523_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_6f0d1bc4-6c8e-4fb7-bce7-a770048493bc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments related to lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfSalesAndMarketingExpense_449e2534-bd85-4cb7-ad73-2df39e0596a0_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing expense (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfSalesAndMarketingExpense_label_en-US" xlink:label="lab_bntx_PercentageOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sales And Marketing Expense</link:label>
    <link:label id="lab_bntx_PercentageOfSalesAndMarketingExpense_documentation_en-US" xlink:label="lab_bntx_PercentageOfSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Sales And Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfSalesAndMarketingExpense" xlink:href="bntx-20231231.xsd#bntx_PercentageOfSalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfSalesAndMarketingExpense" xlink:to="lab_bntx_PercentageOfSalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_7ae49e7e-c536-4b75-b3d4-1d1b494dde7f_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases and disposals</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember_3cf7b6c9-13c7-4f0f-96c8-acff09bd7813_terseLabel_en-US" xlink:label="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct product sales to customers</link:label>
    <link:label id="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember_label_en-US" xlink:label="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Direct Product Sales To Customers [Member]</link:label>
    <link:label id="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember_documentation_en-US" xlink:label="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COVID-19 Vaccine, Direct Product Sales To Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineDirectProductSalesToCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:to="lab_bntx_COVID19VaccineDirectProductSalesToCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_551d79cf-1b2a-43ac-8169-ecf475a2e9f2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net (gain) / loss on derivative instruments at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on financial liabilities at fair value through profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_864f5142-8364-47b0-848b-fcffc6421e24_terseLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof un-vested, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSalesMember_e698703e-e917-4ffb-af50-e22d2340f17e_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSalesMember_label_en-US" xlink:label="lab_ifrs-full_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSalesMember" xlink:to="lab_ifrs-full_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TaxEffectNonTaxEffectiveIncome_75bc8129-afb5-4880-b108-21301aad5ceb_terseLabel_en-US" xlink:label="lab_bntx_TaxEffectNonTaxEffectiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non tax-effective income</link:label>
    <link:label id="lab_bntx_TaxEffectNonTaxEffectiveIncome_label_en-US" xlink:label="lab_bntx_TaxEffectNonTaxEffectiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect, Non Tax Effective Income</link:label>
    <link:label id="lab_bntx_TaxEffectNonTaxEffectiveIncome_documentation_en-US" xlink:label="lab_bntx_TaxEffectNonTaxEffectiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect, Non Tax Effective Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectNonTaxEffectiveIncome" xlink:href="bntx-20231231.xsd#bntx_TaxEffectNonTaxEffectiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TaxEffectNonTaxEffectiveIncome" xlink:to="lab_bntx_TaxEffectNonTaxEffectiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cb992805-6042-456d-a5ae-8fe9eb670ec2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_59294bd9-1ae5-4c92-b6c2-56d03900442d_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_22fc598a-1bb3-4ac4-9aa0-e07adc5e949e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepLtd.Member_47419d31-3955-4944-aeeb-b62f520d3b60_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd.</link:label>
    <link:label id="lab_bntx_InstaDeepLtd.Member_label_en-US" xlink:label="lab_bntx_InstaDeepLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd. [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepLtd.Member_documentation_en-US" xlink:label="lab_bntx_InstaDeepLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtd.Member" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepLtd.Member" xlink:to="lab_bntx_InstaDeepLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock_38be970f-8a46-4d53-a5f3-f27878f19989_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contract Balances</link:label>
    <link:label id="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Contract Balances From Contracts With Customers Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Contract Balances From Contracts With Customers Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock_199aac2d-6dcb-435a-95e2-3177b13f3e13_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Operating Expenses</link:label>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Expenses Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Expenses Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_SupervisoryBoardMember_82aefaaf-828d-49d1-b98d-845cfc683523_terseLabel_en-US" xlink:label="lab_bntx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supervisory Board</link:label>
    <link:label id="lab_bntx_SupervisoryBoardMember_label_en-US" xlink:label="lab_bntx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supervisory Board [Member]</link:label>
    <link:label id="lab_bntx_SupervisoryBoardMember_documentation_en-US" xlink:label="lab_bntx_SupervisoryBoardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supervisory Board</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SupervisoryBoardMember" xlink:href="bntx-20231231.xsd#bntx_SupervisoryBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_SupervisoryBoardMember" xlink:to="lab_bntx_SupervisoryBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InventoriesAbstract_74c1ed3e-e88f-46b5-a9d2-e4f35eb7cf54_terseLabel_en-US" xlink:label="lab_bntx_InventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories [Abstract]</link:label>
    <link:label id="lab_bntx_InventoriesAbstract_label_en-US" xlink:label="lab_bntx_InventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Abstract]</link:label>
    <link:label id="lab_bntx_InventoriesAbstract_documentation_en-US" xlink:label="lab_bntx_InventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventories [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InventoriesAbstract" xlink:href="bntx-20231231.xsd#bntx_InventoriesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InventoriesAbstract" xlink:to="lab_bntx_InventoriesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LiabilitiesForEmployeeBenefits_256d001d-4d99-4ca7-9a6c-953f997ceda9_terseLabel_en-US" xlink:label="lab_bntx_LiabilitiesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to employees</link:label>
    <link:label id="lab_bntx_LiabilitiesForEmployeeBenefits_label_en-US" xlink:label="lab_bntx_LiabilitiesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities For Employee Benefits</link:label>
    <link:label id="lab_bntx_LiabilitiesForEmployeeBenefits_documentation_en-US" xlink:label="lab_bntx_LiabilitiesForEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities For Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesForEmployeeBenefits" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesForEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LiabilitiesForEmployeeBenefits" xlink:to="lab_bntx_LiabilitiesForEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_894ca117-bd86-44c8-9d2d-e6d22b6ea224_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_f61a7632-4ec0-4715-be75-bf04422f57f0_terseLabel_en-US" xlink:label="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance payment received for future COVID 19 vaccine sale</link:label>
    <link:label id="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_label_en-US" xlink:label="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Payment Received For Future COVID-19 Vaccine Sale</link:label>
    <link:label id="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_documentation_en-US" xlink:label="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advance Payment Received For Future COVID-19 Vaccine Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:to="lab_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_b1f73c90-e648-4ca2-b802-55a9572908b1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_f181a42d-d3f8-447a-8e8e-397fd6b36ad2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit before tax to net cash flows:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_e5dc0062-f7b8-4958-9e5c-43b16b9ec97d_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LTI Program</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive Program [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:to="lab_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TaxEffectiveEquityTransactionCosts_27398285-3784-4ef6-9a1c-e8a36571f2ab_terseLabel_en-US" xlink:label="lab_bntx_TaxEffectiveEquityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax-effective equity transaction costs</link:label>
    <link:label id="lab_bntx_TaxEffectiveEquityTransactionCosts_label_en-US" xlink:label="lab_bntx_TaxEffectiveEquityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effective Equity Transaction Costs</link:label>
    <link:label id="lab_bntx_TaxEffectiveEquityTransactionCosts_documentation_en-US" xlink:label="lab_bntx_TaxEffectiveEquityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effective Equity Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectiveEquityTransactionCosts" xlink:href="bntx-20231231.xsd#bntx_TaxEffectiveEquityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TaxEffectiveEquityTransactionCosts" xlink:to="lab_bntx_TaxEffectiveEquityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_7a3840c1-b581-4377-802d-e162c54afb21_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts included in contract liabilities at the beginning of the year</link:label>
    <link:label id="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_label_en-US" xlink:label="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue that was included in contract liability balance at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="lab_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_549ece17-0f9a-4972-8c84-36d941ea8eb0_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lab_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechUSInc.Member_69b49020-67d4-454d-af4b-64c104a50e48_terseLabel_en-US" xlink:label="lab_bntx_BioNTechUSInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech US Inc.</link:label>
    <link:label id="lab_bntx_BioNTechUSInc.Member_label_en-US" xlink:label="lab_bntx_BioNTechUSInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech US Inc. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechUSInc.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechUSInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech US Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSInc.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechUSInc.Member" xlink:to="lab_bntx_BioNTechUSInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsTable_cb4fca14-8d2e-4d43-9c20-85534a517dea_terseLabel_en-US" xlink:label="lab_dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings [Table]</link:label>
    <link:label id="lab_dei_EntityListingsTable_label_en-US" xlink:label="lab_dei_EntityListingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsTable" xlink:to="lab_dei_EntityListingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EstimatedAllocationDateThreeMember_753f640e-1e60-4b71-bcf3-4a35185bd9dc_terseLabel_en-US" xlink:label="lab_bntx_EstimatedAllocationDateThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated allocation date 2025</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateThreeMember_label_en-US" xlink:label="lab_bntx_EstimatedAllocationDateThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Three [Member]</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateThreeMember_documentation_en-US" xlink:label="lab_bntx_EstimatedAllocationDateThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateThreeMember" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EstimatedAllocationDateThreeMember" xlink:to="lab_bntx_EstimatedAllocationDateThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MonetaryAssetsMember_52a31b4a-3936-483b-822e-9cc5bca273c8_terseLabel_en-US" xlink:label="lab_bntx_MonetaryAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary assets in U.S. dollar</link:label>
    <link:label id="lab_bntx_MonetaryAssetsMember_label_en-US" xlink:label="lab_bntx_MonetaryAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monetary Assets [Member]</link:label>
    <link:label id="lab_bntx_MonetaryAssetsMember_documentation_en-US" xlink:label="lab_bntx_MonetaryAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monetary Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryAssetsMember" xlink:href="bntx-20231231.xsd#bntx_MonetaryAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MonetaryAssetsMember" xlink:to="lab_bntx_MonetaryAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_f67fe985-269f-4af8-96eb-2850ac91ffdf_negatedTerseLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MedigeneImmunotherapiesGmbHMember_0bed0f1e-22c3-4ed9-8c31-3c058025c3eb_terseLabel_en-US" xlink:label="lab_bntx_MedigeneImmunotherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medigene Immunotherapies GmbH</link:label>
    <link:label id="lab_bntx_MedigeneImmunotherapiesGmbHMember_label_en-US" xlink:label="lab_bntx_MedigeneImmunotherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medigene Immunotherapies GmbH [Member]</link:label>
    <link:label id="lab_bntx_MedigeneImmunotherapiesGmbHMember_documentation_en-US" xlink:label="lab_bntx_MedigeneImmunotherapiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medigene Immunotherapies GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedigeneImmunotherapiesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_MedigeneImmunotherapiesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MedigeneImmunotherapiesGmbHMember" xlink:to="lab_bntx_MedigeneImmunotherapiesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashFlowProjectionsMeasurementInputMember_2cf05c2b-a193-42a0-97aa-49fe87d32778_terseLabel_en-US" xlink:label="lab_bntx_CashFlowProjectionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow projections</link:label>
    <link:label id="lab_bntx_CashFlowProjectionsMeasurementInputMember_label_en-US" xlink:label="lab_bntx_CashFlowProjectionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Projections, Measurement Input [Member]</link:label>
    <link:label id="lab_bntx_CashFlowProjectionsMeasurementInputMember_documentation_en-US" xlink:label="lab_bntx_CashFlowProjectionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow Projections, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashFlowProjectionsMeasurementInputMember" xlink:href="bntx-20231231.xsd#bntx_CashFlowProjectionsMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashFlowProjectionsMeasurementInputMember" xlink:to="lab_bntx_CashFlowProjectionsMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechManufacturingMarburgGmbHMember_9c36f288-e28f-4d3d-9b49-5f9000fcdbe5_terseLabel_en-US" xlink:label="lab_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing Marburg GmbH</link:label>
    <link:label id="lab_bntx_BioNTechManufacturingMarburgGmbHMember_label_en-US" xlink:label="lab_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing Marburg GmbH [Member]</link:label>
    <link:label id="lab_bntx_BioNTechManufacturingMarburgGmbHMember_documentation_en-US" xlink:label="lab_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Manufacturing Marburg GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:to="lab_bntx_BioNTechManufacturingMarburgGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_fed75e87-9296-401f-b1b3-84a813c1b7c0_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesLineItems_a93cb482-9406-4700-9f57-c21ce4dd3247_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Income And Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:to="lab_bntx_DisclosureOfIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InstaDeepLLCMember_ceff08aa-7ff1-484a-81e5-8f19872abee1_terseLabel_en-US" xlink:label="lab_bntx_InstaDeepLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InstaDeep LLC</link:label>
    <link:label id="lab_bntx_InstaDeepLLCMember_label_en-US" xlink:label="lab_bntx_InstaDeepLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InstaDeep LLC [Member]</link:label>
    <link:label id="lab_bntx_InstaDeepLLCMember_documentation_en-US" xlink:label="lab_bntx_InstaDeepLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InstaDeep LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLLCMember" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InstaDeepLLCMember" xlink:to="lab_bntx_InstaDeepLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_556eb325-076f-442e-af52-a7ab0fa75ad8_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_2c9b4896-c4ec-4384-a96f-53e017bdee9e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_1a56c0d8-a63b-405a-a2c8-5ddc20d6fd2d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Group Information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of composition of group [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCompositionOfGroupExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_5ccad04f-ff62-4824-9c9f-66b4cdc8b4f3_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock_7000c3df-befd-41d9-ba29-e2ee2a55dc1e_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information</link:label>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Corporate Information Explanatory [Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Corporate Information Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:to="lab_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_d7b23883-3720-413e-a843-c82bf23b44f6_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashAndCashEquivalents1Member_29925e9a-f924-40ef-a589-7221db22c4c1_terseLabel_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in U.S. dollar</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalents1Member_label_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents 1 [Member]</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalents1Member_documentation_en-US" xlink:label="lab_bntx_CashAndCashEquivalents1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1Member" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashAndCashEquivalents1Member" xlink:to="lab_bntx_CashAndCashEquivalents1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureDomain_fd2efe37-b3b5-4ed5-a24a-a4fdea324633_terseLabel_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature [Domain]</link:label>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureDomain_label_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature [Domain]</link:label>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureDomain_documentation_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain" xlink:to="lab_bntx_IncomeAndExpensesByNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermDeposits_d4a587b6-ad3f-40fa-ba92-f4d65fa0de91_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term deposits</link:label>
    <link:label id="lab_ifrs-full_LongtermDeposits_label_en-US" xlink:label="lab_ifrs-full_LongtermDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermDeposits" xlink:to="lab_ifrs-full_LongtermDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_2e023138-da2f-4e80-96c5-702d68ac8834_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock_f75bc20c-3e5c-4312-bf89-d8ef3fd2b30c_verboseLabel_en-US" xlink:label="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Shares Repurchase Program</link:label>
    <link:label id="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Shares Repurchase Program [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Shares Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:to="lab_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_722ac7c9-a2a9-49e7-a2df-1a42e727cffb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance expense excluding foreign exchange differences</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AdjustmentsForMovementsInGovernmentGrants_975622b1-3da8-4932-8ece-488556a4674c_terseLabel_en-US" xlink:label="lab_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements in government grants</link:label>
    <link:label id="lab_bntx_AdjustmentsForMovementsInGovernmentGrants_label_en-US" xlink:label="lab_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Movements In Government Grants</link:label>
    <link:label id="lab_bntx_AdjustmentsForMovementsInGovernmentGrants_documentation_en-US" xlink:label="lab_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Movements In Government Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:to="lab_bntx_AdjustmentsForMovementsInGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_cd0f5d02-1a5a-49b4-a2e4-81681aedecba_terseLabel_en-US" xlink:label="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized in OCI</link:label>
    <link:label id="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Expense (Income) Recognised In Other Comprehensive Income</link:label>
    <link:label id="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Expense (Income) Recognised In Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:to="lab_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfShareOptionsHeld_2fac5e5e-e619-4e3b-b952-32b0e94534e1_terseLabel_en-US" xlink:label="lab_bntx_NumberOfShareOptionsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options held (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsHeld_label_en-US" xlink:label="lab_bntx_NumberOfShareOptionsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Held</link:label>
    <link:label id="lab_bntx_NumberOfShareOptionsHeld_documentation_en-US" xlink:label="lab_bntx_NumberOfShareOptionsHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsHeld" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfShareOptionsHeld" xlink:to="lab_bntx_NumberOfShareOptionsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_a367c58d-1c69-4fc4-ae89-14bb53e43776_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_c2a6efc3-cd04-4601-b51b-d5e2856b27c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized in P&amp;L</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FairValueThroughOCIMember_df391907-803e-4553-9e8a-7d5a53a3321c_terseLabel_en-US" xlink:label="lab_bntx_FairValueThroughOCIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FVTOCI</link:label>
    <link:label id="lab_bntx_FairValueThroughOCIMember_label_en-US" xlink:label="lab_bntx_FairValueThroughOCIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Through OCI [Member]</link:label>
    <link:label id="lab_bntx_FairValueThroughOCIMember_documentation_en-US" xlink:label="lab_bntx_FairValueThroughOCIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Through OCI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughOCIMember" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughOCIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FairValueThroughOCIMember" xlink:to="lab_bntx_FairValueThroughOCIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ThereofDeferredTaxAssetsMember_a225f39d-8672-4017-b45b-ea3423ee6720_terseLabel_en-US" xlink:label="lab_bntx_ThereofDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereof deferred tax assets</link:label>
    <link:label id="lab_bntx_ThereofDeferredTaxAssetsMember_label_en-US" xlink:label="lab_bntx_ThereofDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereof Deferred Tax Assets [Member]</link:label>
    <link:label id="lab_bntx_ThereofDeferredTaxAssetsMember_documentation_en-US" xlink:label="lab_bntx_ThereofDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Thereof Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxAssetsMember" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ThereofDeferredTaxAssetsMember" xlink:to="lab_bntx_ThereofDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_18275aa1-eac7-4755-b319-7ee6bc01a6c0_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_7ea7dd11-0851-4ffa-9efc-2f2724874209_verboseLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid, classified as financing activities</link:label>
    <link:label id="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_a587e82e-d7db-43f7-bce7-1730e18d7c17_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillMember_3c903b5f-cc04-434d-a622-36558528152d_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillMember_label_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillMember" xlink:to="lab_ifrs-full_GoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_b40f937a-eb5a-4bd6-9cad-3f3af89cf6c7_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of share capital and treasury shares, net of costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock_1101f710-39c9-4867-902e-f7e354bc0039_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Non-Financial Liabilities</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_783d48c8-67f7-412c-b6b6-5fe079ab5197_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_40665377-6699-4958-99fb-17c45c3f1042_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_b6fecc35-720a-432b-a445-c49f7a03d5e2_terseLabel_en-US" xlink:label="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Receivables Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade Receivables Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_TradeReceivablesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EstimatedAllocationDateFourMember_278a17dd-8ebe-4fc9-a06b-aa0a5e8f54bd_terseLabel_en-US" xlink:label="lab_bntx_EstimatedAllocationDateFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated allocation date 2026</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateFourMember_label_en-US" xlink:label="lab_bntx_EstimatedAllocationDateFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Four [Member]</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateFourMember_documentation_en-US" xlink:label="lab_bntx_EstimatedAllocationDateFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateFourMember" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EstimatedAllocationDateFourMember" xlink:to="lab_bntx_EstimatedAllocationDateFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_c3b1ff02-7cca-4813-a647-b51fa3ebe588_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_baa2f5d5-cbc1-4dfc-8a28-1066b310732d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_82d777e6-b2c6-42f8-84a1-f5c84681fcd8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_ed2dc845-8d20-4a1f-9997-df6dbfeab160_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax (assets) and liabilities, net recognized</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_17bf36bc-c7b3-4dfc-97e4-017caf433a8d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance deferred tax assets net</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_39d37485-daa1-478b-be65-5b95774a7e3a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance deferred tax assets net</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_b4b6343c-89be-45d4-a684-d61cdd53b3ea_terseLabel_en-US" xlink:label="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, loans and borrowings</link:label>
    <link:label id="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_label_en-US" xlink:label="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Lease Liabilities, Loans And Borrowings</link:label>
    <link:label id="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_documentation_en-US" xlink:label="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Lease Liabilities, Loans And Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:href="bntx-20231231.xsd#bntx_CurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:to="lab_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_e9ed55ca-2367-4f0a-b8d0-6190e41c32d9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Disaggregation of Revenues from Contracts with Customers</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_20f49f9c-a9d3-418b-8757-a7bc5c736cb9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_25d5f5be-dff4-406a-a342-3ac6856b1d51_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechRwandaLtd.Member_d3fcb188-706f-464c-8c67-3af7891c85b1_terseLabel_en-US" xlink:label="lab_bntx_BioNTechRwandaLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Rwanda Ltd.</link:label>
    <link:label id="lab_bntx_BioNTechRwandaLtd.Member_label_en-US" xlink:label="lab_bntx_BioNTechRwandaLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Rwanda Ltd. [Member]</link:label>
    <link:label id="lab_bntx_BioNTechRwandaLtd.Member_documentation_en-US" xlink:label="lab_bntx_BioNTechRwandaLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Rwanda Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRwandaLtd.Member" xlink:href="bntx-20231231.xsd#bntx_BioNTechRwandaLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechRwandaLtd.Member" xlink:to="lab_bntx_BioNTechRwandaLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EstimatedAllocationDateOneMember_1c28324d-4622-482b-95cd-a7af363dc125_terseLabel_en-US" xlink:label="lab_bntx_EstimatedAllocationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation date May 2023</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateOneMember_label_en-US" xlink:label="lab_bntx_EstimatedAllocationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date One [Member]</link:label>
    <link:label id="lab_bntx_EstimatedAllocationDateOneMember_documentation_en-US" xlink:label="lab_bntx_EstimatedAllocationDateOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Allocation Date One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateOneMember" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EstimatedAllocationDateOneMember" xlink:to="lab_bntx_EstimatedAllocationDateOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock_09ba66fe-846f-403c-a838-9b754de5ef9f_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Operating Income</link:label>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Operating Income Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionAdditions_f052381d-4487-4aab-90ef-de3dc8d2ffe9_terseLabel_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current onerous provision addition</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionAdditions_label_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Additions</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionAdditions_documentation_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionAdditions" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentOnerousContractsProvisionAdditions" xlink:to="lab_bntx_CurrentOnerousContractsProvisionAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_75a882cd-3882-4f03-ac7f-6cdce21dbbf9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasuryShares_6f42e321-7f82-480a-a14e-569b9d700207_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_label_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_42c8c4a2-56c5-4883-b5c1-b2bf86a0a611_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Standards Applied for the First Time</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EquipmentToolsAndInstallationsMember_70085f26-8b40-4673-84af-006b68fc982e_terseLabel_en-US" xlink:label="lab_bntx_EquipmentToolsAndInstallationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment, tools and installations</link:label>
    <link:label id="lab_bntx_EquipmentToolsAndInstallationsMember_label_en-US" xlink:label="lab_bntx_EquipmentToolsAndInstallationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment, Tools And Installations [Member]</link:label>
    <link:label id="lab_bntx_EquipmentToolsAndInstallationsMember_documentation_en-US" xlink:label="lab_bntx_EquipmentToolsAndInstallationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment, Tools And Installations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EquipmentToolsAndInstallationsMember" xlink:to="lab_bntx_EquipmentToolsAndInstallationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_b7f646cf-852e-4775-92ac-01f63ba20a5b_terseLabel_en-US" xlink:label="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax losses</link:label>
    <link:label id="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label id="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Federal Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:href="bntx-20231231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_JensHolsteinMember_8e365e92-9898-4c79-8448-2a1c55b7e5c9_terseLabel_en-US" xlink:label="lab_bntx_JensHolsteinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jens Holstein</link:label>
    <link:label id="lab_bntx_JensHolsteinMember_label_en-US" xlink:label="lab_bntx_JensHolsteinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jens Holstein [Member]</link:label>
    <link:label id="lab_bntx_JensHolsteinMember_documentation_en-US" xlink:label="lab_bntx_JensHolsteinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jens Holstein</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JensHolsteinMember" xlink:href="bntx-20231231.xsd#bntx_JensHolsteinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_JensHolsteinMember" xlink:to="lab_bntx_JensHolsteinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PfizerIncMember_8f3ce37f-1eab-4551-879a-7bd3876de927_terseLabel_en-US" xlink:label="lab_bntx_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_bntx_PfizerIncMember_label_en-US" xlink:label="lab_bntx_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_bntx_PfizerIncMember_documentation_en-US" xlink:label="lab_bntx_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerIncMember" xlink:href="bntx-20231231.xsd#bntx_PfizerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PfizerIncMember" xlink:to="lab_bntx_PfizerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermOnerousContractsProvision_4622bfa5-c905-4975-8062-478c2f7101e8_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermOnerousContractsProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligations from onerous CMO contracts</link:label>
    <link:label id="lab_ifrs-full_ShorttermOnerousContractsProvision_label_en-US" xlink:label="lab_ifrs-full_ShorttermOnerousContractsProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current onerous contracts provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermOnerousContractsProvision" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermOnerousContractsProvision" xlink:to="lab_ifrs-full_ShorttermOnerousContractsProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FinancialInstrumentsAbstract_d06f614b-a91f-434f-a2f9-2b78e429cb40_terseLabel_en-US" xlink:label="lab_bntx_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_bntx_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_bntx_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_bntx_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_bntx_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FinancialInstrumentsAbstract" xlink:to="lab_bntx_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DividendsPaid_0089a70f-0627-4b5a-b01e-d097f629b89c_negatedLabel_en-US" xlink:label="lab_ifrs-full_DividendsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ifrs-full_DividendsPaid_label_en-US" xlink:label="lab_ifrs-full_DividendsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaid" xlink:to="lab_ifrs-full_DividendsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_6b039cda-dc4f-4711-bd89-d69810ec945f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NTSecurityAndServicesGmbHMember_31480119-f8a2-446b-8d04-160c566279ed_terseLabel_en-US" xlink:label="lab_bntx_NTSecurityAndServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NT Security and Services GmbH</link:label>
    <link:label id="lab_bntx_NTSecurityAndServicesGmbHMember_label_en-US" xlink:label="lab_bntx_NTSecurityAndServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NT Security and Services GmbH [Member]</link:label>
    <link:label id="lab_bntx_NTSecurityAndServicesGmbHMember_documentation_en-US" xlink:label="lab_bntx_NTSecurityAndServicesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NT Security and Services GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NTSecurityAndServicesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_NTSecurityAndServicesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NTSecurityAndServicesGmbHMember" xlink:to="lab_bntx_NTSecurityAndServicesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_b5edc6a1-8a17-45af-a76e-567878188285_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_41c18490-a801-42f8-85fd-b43794ffd976_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_e5b41d8e-8a74-4b20-a68a-871333c5ceb5_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_741f2985-f893-41d8-b88b-b9bba286be83_terseLabel_en-US" xlink:label="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments of financial instruments measured at fair value</link:label>
    <link:label id="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_label_en-US" xlink:label="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustments Of Financial Instruments Measured At Fair Value</link:label>
    <link:label id="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_documentation_en-US" xlink:label="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Adjustments Of Financial Instruments Measured At Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:href="bntx-20231231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:to="lab_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2cef901f-018c-40e1-a7e2-3d61736cbe26_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inputs Used in Measurement of Fair Value at Grant Date</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_1f5958dc-5943-4f09-85ff-c5f06c439d72_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of inventories</link:label>
    <link:label id="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_label_en-US" xlink:label="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lab_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_TradeAndOtherReceivablesMember_bc41ee30-2f77-4dcf-9ffd-e7e422ba082a_terseLabel_en-US" xlink:label="lab_bntx_TradeAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_bntx_TradeAndOtherReceivablesMember_label_en-US" xlink:label="lab_bntx_TradeAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade And Other Receivables [Member]</link:label>
    <link:label id="lab_bntx_TradeAndOtherReceivablesMember_documentation_en-US" xlink:label="lab_bntx_TradeAndOtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade And Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeAndOtherReceivablesMember" xlink:href="bntx-20231231.xsd#bntx_TradeAndOtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_TradeAndOtherReceivablesMember" xlink:to="lab_bntx_TradeAndOtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_7c60aa73-0194-4647-a283-f1aa3566c36e_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_cf13b40d-5c3a-4222-bfff-e5ba3800b05e_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalReserve_df337f70-6b84-4b14-9e34-cb753a20b836_terseLabel_en-US" xlink:label="lab_ifrs-full_CapitalReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital reserve</link:label>
    <link:label id="lab_ifrs-full_CapitalReserve_label_en-US" xlink:label="lab_ifrs-full_CapitalReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalReserve" xlink:to="lab_ifrs-full_CapitalReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_9e6255db-c0e5-463a-9cc7-563e9b3ccb60_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47875c31-6b47-4808-803e-d82429bb8f02_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_JPTPeptideTechnologiesGmbHMember_4086820d-a208-4d7c-8305-7f0c32153970_terseLabel_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies GmbH</link:label>
    <link:label id="lab_bntx_JPTPeptideTechnologiesGmbHMember_label_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies GmbH [Member]</link:label>
    <link:label id="lab_bntx_JPTPeptideTechnologiesGmbHMember_documentation_en-US" xlink:label="lab_bntx_JPTPeptideTechnologiesGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JPT Peptide Technologies GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesGmbHMember" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_JPTPeptideTechnologiesGmbHMember" xlink:to="lab_bntx_JPTPeptideTechnologiesGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_da1dfa7c-fff9-42e0-bcca-3a74ae931c11_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_02d5d093-5cae-464d-9f98-603ac3be9882_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of subsidiaries and businesses, net of cash acquired</link:label>
    <link:label id="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2dd6353e-c4bb-4fb2-bf8e-bee655552eed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_f462fbdc-f754-4831-b99b-2672ab733fcf_terseLabel_en-US" xlink:label="lab_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balances of related party transactions</link:label>
    <link:label id="lab_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_label_en-US" xlink:label="lab_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for doubtful debts related to outstanding balances of related party transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:to="lab_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock_8a6735e8-3a6a-4b8b-8616-f93a2d9e9507_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Current and Deferred Tax Expense</link:label>
    <link:label id="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Current And Deferred Tax Expense Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_34e5f42e-1255-4c09-b173-2aa1562e0d6e_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock_387e2452-7746-42eb-9c69-bd70ebaf45b1_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Finance Income</link:label>
    <link:label id="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Income Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Finance Income Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_8274e688-2359-4c1d-9c50-eae51af2db13_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_3309cfda-ec1f-4c7a-9dbe-1fd26241df6a_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_a23112d9-8f8f-4a41-9595-91382d97b970_totalLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_2021879f-aef7-4a0a-837f-69ece957008f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised_4c96e2a7-d26e-488b-b574-5be029379307_terseLabel_en-US" xlink:label="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum economic benefits of options exercised</link:label>
    <link:label id="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised_label_en-US" xlink:label="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Economic Benefits Of Options Exercised</link:label>
    <link:label id="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised_documentation_en-US" xlink:label="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Economic Benefits Of Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:href="bntx-20231231.xsd#bntx_MaximumEconomicBenefitsOfOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:to="lab_bntx_MaximumEconomicBenefitsOfOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureAxis_07c38b94-a6e1-4ff2-8acc-6a722908f723_terseLabel_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature [Axis]</link:label>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureAxis_label_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature [Axis]</link:label>
    <link:label id="lab_bntx_IncomeAndExpensesByNatureAxis_documentation_en-US" xlink:label="lab_bntx_IncomeAndExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income And Expenses By Nature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureAxis" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis" xlink:to="lab_bntx_IncomeAndExpensesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DeferredExpense_39ead615-da80-4cec-9553-f54b7ad2c490_terseLabel_en-US" xlink:label="lab_bntx_DeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred expenses</link:label>
    <link:label id="lab_bntx_DeferredExpense_label_en-US" xlink:label="lab_bntx_DeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Expense</link:label>
    <link:label id="lab_bntx_DeferredExpense_documentation_en-US" xlink:label="lab_bntx_DeferredExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredExpense" xlink:href="bntx-20231231.xsd#bntx_DeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DeferredExpense" xlink:to="lab_bntx_DeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_c93b8930-a7cd-4244-80af-8bafc1f624b7_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_aacb75c2-e5cb-465a-ae89-84f5bbbf620b_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_e9a93a73-fd71-410b-bdb1-4a9c88ef7d4a_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_e07d600e-4a1c-4f19-947a-a71fb3db39d3_terseLabel_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash-settled related to rights vested and exercisable</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_label_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Payment Arrangement, Related To Rights Vested And Exercisable</link:label>
    <link:label id="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_documentation_en-US" xlink:label="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payment Arrangement, Related To Rights Vested And Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:to="lab_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AssetsRecognisedAsOfAcquisitionDate_c8bb2483-72e8-449e-9a09-e3fb915711cb_totalLabel_en-US" xlink:label="lab_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_bntx_AssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_AssetsRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_AssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_AssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_ba456573-6436-4741-9d32-cc60ef45136a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_644fc054-b8c9-4122-8600-f018d98c0dde_terseLabel_en-US" xlink:label="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, useful life (in years)</link:label>
    <link:label id="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_label_en-US" xlink:label="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful Life Measured As Period Of Time, Right-Of-Use Assets</link:label>
    <link:label id="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_documentation_en-US" xlink:label="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Useful Life Measured As Period Of Time, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:href="bntx-20231231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:to="lab_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_c7238579-a7ee-48a4-96c4-62daa1ce5f08_verboseLabel_en-US" xlink:label="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Restricted Stock Unit Plan for North America Employees</link:label>
    <link:label id="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_dc97c1cf-da9e-48aa-9189-75feb146243a_terseLabel_en-US" xlink:label="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech 2020 Restricted Stock Unit Plan For North America Employees</link:label>
    <link:label id="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_label_en-US" xlink:label="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member]</link:label>
    <link:label id="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_documentation_en-US" xlink:label="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech 2020 Restricted Stock Unit Plan For North America Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:href="bntx-20231231.xsd#bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:to="lab_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_9ca34593-05d4-41cc-aa3e-79f357959de8_terseLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ordinary shares underlying options</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options [Abstract]</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LiabilitiesRollForward_3e760c81-f0ba-4bd3-92c1-44d7f5d7ec69_terseLabel_en-US" xlink:label="lab_bntx_LiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities [Roll Forward]</link:label>
    <link:label id="lab_bntx_LiabilitiesRollForward_label_en-US" xlink:label="lab_bntx_LiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Roll Forward]</link:label>
    <link:label id="lab_bntx_LiabilitiesRollForward_documentation_en-US" xlink:label="lab_bntx_LiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRollForward" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LiabilitiesRollForward" xlink:to="lab_bntx_LiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NonTaxEffectiveBargainPurchase_a528bae0-9fb7-4171-b79a-306073cc7459_negatedTerseLabel_en-US" xlink:label="lab_bntx_NonTaxEffectiveBargainPurchase" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-tax effective bargain purchase</link:label>
    <link:label id="lab_bntx_NonTaxEffectiveBargainPurchase_label_en-US" xlink:label="lab_bntx_NonTaxEffectiveBargainPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Tax Effective Bargain Purchase</link:label>
    <link:label id="lab_bntx_NonTaxEffectiveBargainPurchase_documentation_en-US" xlink:label="lab_bntx_NonTaxEffectiveBargainPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Tax Effective Bargain Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonTaxEffectiveBargainPurchase" xlink:href="bntx-20231231.xsd#bntx_NonTaxEffectiveBargainPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NonTaxEffectiveBargainPurchase" xlink:to="lab_bntx_NonTaxEffectiveBargainPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareOptionsOutstandingAbstract_1da3423d-21e2-4f06-9259-36a44749d56c_terseLabel_en-US" xlink:label="lab_bntx_ShareOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share options outstanding</link:label>
    <link:label id="lab_bntx_ShareOptionsOutstandingAbstract_label_en-US" xlink:label="lab_bntx_ShareOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options Outstanding [Abstract]</link:label>
    <link:label id="lab_bntx_ShareOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_bntx_ShareOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareOptionsOutstandingAbstract" xlink:href="bntx-20231231.xsd#bntx_ShareOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract" xlink:to="lab_bntx_ShareOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_8f27a3ce-12c3-469b-9286-19a5cdbfd6f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections (as a percent)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lab_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock_c36e1788-885e-4be9-98c6-337e1fe9ff62_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standards Applied for the First Time</link:label>
    <link:label id="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:to="lab_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_f1ead46e-8bab-433d-8a1d-141c2f7adf25_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_393e042d-93a1-403b-ab19-0153c414355d_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 (Fair value)</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_8fd2ec88-9736-4d39-b956-e289c1fdfaa3_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_e925863b-9ec8-4ff2-8b75-4cec0ca0609e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_5c66b2d0-899c-4755-8ed7-f8767669cdc2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_66eb064f-1ee8-43a5-a13c-2452c47cc9dc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_f777166c-192f-4d92-9eed-33b12ac7a5c3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_9960dc37-2f92-451c-8137-2c07ef22f67e_totalLabel_en-US" xlink:label="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_bntx_LiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_bca43f3c-b6ec-4543-9c40-137d09da64b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Number and Share Price of Restricted Stock Units</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ThereofDeferredTaxLiabilityMember_d72a443f-8456-403b-b589-4560fe2db408_terseLabel_en-US" xlink:label="lab_bntx_ThereofDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereof deferred tax liability</link:label>
    <link:label id="lab_bntx_ThereofDeferredTaxLiabilityMember_label_en-US" xlink:label="lab_bntx_ThereofDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thereof Deferred Tax Liability [Member]</link:label>
    <link:label id="lab_bntx_ThereofDeferredTaxLiabilityMember_documentation_en-US" xlink:label="lab_bntx_ThereofDeferredTaxLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Thereof Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxLiabilityMember" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ThereofDeferredTaxLiabilityMember" xlink:to="lab_bntx_ThereofDeferredTaxLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsExplanatory_a88e54f7-55a2-485c-9e1a-c59adf516803_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPerformanceObligationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of performance obligations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPerformanceObligationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_769cd871-4187-42d3-a086-4f74dfea7d3b_terseLabel_en-US" xlink:label="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves and Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves and Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves and Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="bntx-20231231.xsd#bntx_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_d7a52b8f-3c61-409e-9912-423445f32ab6_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">% equity interest</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_5b5a707a-5deb-457e-ab9a-e2cae48405eb_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ownership of ordinary shares in BioNTech (in %)</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_deec404d-87fe-443c-86e9-4a630780c547_negatedTerseLabel_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised, number of ordinary shares underlying options (in shares)</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement</link:label>
    <link:label id="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:to="lab_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_62aa9428-cb89-4cce-a1f7-e4a186994496_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_label_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_documentation_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:to="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_ce7c2cc1-7a39-4bf3-94c6-b86a32eed2e6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_9c5491fc-665c-4214-ba94-11b5c54b8d98_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_6dcd2f88-b211-4e44-b884-38859ac23ba0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_8e6c01c2-50ba-4673-bb81-e283e1fc4122_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected tax credit</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_dd065ca0-51eb-4147-9332-66e5090c62a4_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_3ed4da2e-7859-452d-9ebc-e5afcb420d4a_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:label id="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_label_en-US" xlink:label="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lab_ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_c1d4dc76-6167-4bc0-b755-59a2b898b142_negatedTerseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Repurchased During Period, Value</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:to="lab_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock_d234d8b8-10c1-498f-b445-6296f5ac656b_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Estimated Useful Lives of the Assets or Shorter Lease Term</link:label>
    <link:label id="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_acd0f925-4c1b-497c-99af-3dacd8cad366_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_8b6bff52-1aaf-4587-bc21-b4e4417f4c56_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_0133a01f-b2de-479e-8682-04a669b7a5f7_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BiotheusIncMember_f82feb40-c4a0-42a7-a9c7-ced3fa3d8806_terseLabel_en-US" xlink:label="lab_bntx_BiotheusIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biotheus Inc.,</link:label>
    <link:label id="lab_bntx_BiotheusIncMember_label_en-US" xlink:label="lab_bntx_BiotheusIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biotheus Inc., [Member]</link:label>
    <link:label id="lab_bntx_BiotheusIncMember_documentation_en-US" xlink:label="lab_bntx_BiotheusIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biotheus Inc.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiotheusIncMember" xlink:href="bntx-20231231.xsd#bntx_BiotheusIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BiotheusIncMember" xlink:to="lab_bntx_BiotheusIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_ed5ebd16-5b7d-4128-8b5a-4e95815292a3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a130161a-1edc-419a-9666-178740df6d90_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_e4218058-72ad-4962-9e8d-7ac0f6b050db_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock_d675d6eb-ec43-4891-8dc0-f07abfcebe3b_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Carrying Amount of Monetary Assets</link:label>
    <link:label id="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Foreign Currency Risk Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Foreign Currency Risk Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_3bc0baae-5a0c-4925-9c3b-54908a18744b_terseLabel_en-US" xlink:label="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non cash current tax relating to items credited (charged) directly to equity</link:label>
    <link:label id="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_label_en-US" xlink:label="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity</link:label>
    <link:label id="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_documentation_en-US" xlink:label="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:href="bntx-20231231.xsd#bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:to="lab_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanMember_e5f9aac6-1696-4891-8509-327ec2c24f76_terseLabel_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanMember_label_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan [Member]</link:label>
    <link:label id="lab_bntx_EmployeeStockOwnershipPlanMember_documentation_en-US" xlink:label="lab_bntx_EmployeeStockOwnershipPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeStockOwnershipPlanMember" xlink:to="lab_bntx_EmployeeStockOwnershipPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_InterestsInOtherEntitiesAbstract_c5640188-c031-430c-b87e-61289d7ea842_terseLabel_en-US" xlink:label="lab_bntx_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_bntx_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_bntx_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_bntx_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_bntx_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract" xlink:to="lab_bntx_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MultiperiodExcessEarningsMethodMember_9eccdca9-de25-4e01-b1b1-5a9c574ad23f_terseLabel_en-US" xlink:label="lab_ifrs-full_MultiperiodExcessEarningsMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multi-period excess earnings method</link:label>
    <link:label id="lab_ifrs-full_MultiperiodExcessEarningsMethodMember_label_en-US" xlink:label="lab_ifrs-full_MultiperiodExcessEarningsMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Multi-period excess earnings method [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiperiodExcessEarningsMethodMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiperiodExcessEarningsMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MultiperiodExcessEarningsMethodMember" xlink:to="lab_ifrs-full_MultiperiodExcessEarningsMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_35c6ca59-a773-4d44-b5c5-40b401fb7150_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8adc8b25-ea35-4662-ba52-29f94a45976a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_3c895e4f-54fe-413d-9c69-b58700ace4a5_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_c03e7265-2af0-48dd-9116-2e0d15f6bf03_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of contingent liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfContingentLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_2ef1092c-5e60-4a57-9fb7-592222795fce_terseLabel_en-US" xlink:label="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales tax receivable</link:label>
    <link:label id="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_7fb510cd-00e9-45e0-80df-9c10b8edd3a2_verboseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_5b4229b8-f20f-4b3e-af56-19012c884fa5_netLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net gain on equity instruments designated at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_a3c65b73-ce6d-4a56-9a90-67d0c9acc5bc_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property, Plant and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_UpfrontPayment_781423dd-14da-4305-ba31-6f4ceb200e5d_terseLabel_en-US" xlink:label="lab_bntx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_bntx_UpfrontPayment_label_en-US" xlink:label="lab_bntx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_bntx_UpfrontPayment_documentation_en-US" xlink:label="lab_bntx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPayment" xlink:href="bntx-20231231.xsd#bntx_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_UpfrontPayment" xlink:to="lab_bntx_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_0f4ff8fd-2596-4858-8986-8328908bf221_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_RelatedPartyAbstract_1ef28d6b-4195-4ed1-a0d0-15b94edbe7c9_terseLabel_en-US" xlink:label="lab_bntx_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_bntx_RelatedPartyAbstract_label_en-US" xlink:label="lab_bntx_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_bntx_RelatedPartyAbstract_documentation_en-US" xlink:label="lab_bntx_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_RelatedPartyAbstract" xlink:to="lab_bntx_RelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_d9e36e9d-9582-4099-81d5-01f61901ef12_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of ADSs purchased (in shares)</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:to="lab_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_5288d4e4-ba26-4760-8a35-e8bbe6a82e85_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_41af4694-f44c-407c-84b9-cb58ad0959d1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash income / (loss)</link:label>
    <link:label id="lab_ifrs-full_OtherAdjustmentsForNoncashItems_label_en-US" xlink:label="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="lab_ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CashAndCashEquivalent_99d3d812-8f2f-45bb-a79d-a2b8a4fcf939_terseLabel_en-US" xlink:label="lab_bntx_CashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalent_label_en-US" xlink:label="lab_bntx_CashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent</link:label>
    <link:label id="lab_bntx_CashAndCashEquivalent_documentation_en-US" xlink:label="lab_bntx_CashAndCashEquivalent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalent" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CashAndCashEquivalent" xlink:to="lab_bntx_CashAndCashEquivalent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_9ae2903f-9ebd-418f-8dab-248449e2450a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_d9a9ea49-9b12-4f0d-a706-b1c99a995ff3_terseLabel_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange differences, net</link:label>
    <link:label id="lab_ifrs-full_NetForeignExchangeLoss_label_en-US" xlink:label="lab_ifrs-full_NetForeignExchangeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net foreign exchange loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetForeignExchangeLoss" xlink:to="lab_ifrs-full_NetForeignExchangeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_48a586f7-87cd-469e-abb7-84c866cc7e9a_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_910ecd17-5e0f-43af-b8d5-84d4f93d86f6_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_6bebf4c5-65f7-4aec-af9c-f977c6a50e51_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_106d04b2-950c-4470-9a83-e3b9241a6972_terseLabel_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging instruments</link:label>
    <link:label id="lab_ifrs-full_HedgingInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_HedgingInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging instruments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_HedgingInstrumentsMember" xlink:to="lab_ifrs-full_HedgingInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_3fc79353-da5c-428f-8dd0-200c64372414_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3760e1de-2f9b-4ec1-b96a-f4f3e2ca174d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_f3f3a7ff-48ae-42af-a1f2-57de9be3572f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Judgements, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_6275c924-76e6-4c1b-9eb0-3a70e539a5f5_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_label_en-US" xlink:label="lab_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:to="lab_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock_4284016e-8f69-4c96-93bb-27d34f2f982a_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Effect of Changes in Foreign Exchange Rates</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block]</link:label>
    <link:label id="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:to="lab_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember_6eeea53b-c7ec-4889-9f1b-8bad8411da2e_terseLabel_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies (US), LLC</link:label>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember_label_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies (US), LLC [Member]</link:label>
    <link:label id="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember_documentation_en-US" xlink:label="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Delivery Technologies (US), LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesUSLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:to="lab_bntx_BioNTechDeliveryTechnologiesUSLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_ea8a5019-11d9-4d16-86bc-33b88bad9d83_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_8db19be9-afab-4787-acf7-26e521e955cd_terseLabel_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LTI 2022 program</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_label_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2022 Program [Member]</link:label>
    <link:label id="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_documentation_en-US" xlink:label="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Equity Plan, Long-Term Incentive 2022 Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:to="lab_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ShareRepurchaseProgram2023Member_41cad1d5-ca8b-4bde-a0a5-24636a5aba89_terseLabel_en-US" xlink:label="lab_bntx_ShareRepurchaseProgram2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program 2023</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgram2023Member_label_en-US" xlink:label="lab_bntx_ShareRepurchaseProgram2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program 2023 [Member]</link:label>
    <link:label id="lab_bntx_ShareRepurchaseProgram2023Member_documentation_en-US" xlink:label="lab_bntx_ShareRepurchaseProgram2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgram2023Member" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgram2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ShareRepurchaseProgram2023Member" xlink:to="lab_bntx_ShareRepurchaseProgram2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_aaa77cd0-cb1d-4da6-8671-201b85c16923_terseLabel_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:to="lab_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PurchasesFromRelatedPartyTransactions_35ac0a01-f3c6-4b1f-9ae1-cc310ff90133_totalLabel_en-US" xlink:label="lab_bntx_PurchasesFromRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bntx_PurchasesFromRelatedPartyTransactions_label_en-US" xlink:label="lab_bntx_PurchasesFromRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases From Related Party Transactions</link:label>
    <link:label id="lab_bntx_PurchasesFromRelatedPartyTransactions_documentation_en-US" xlink:label="lab_bntx_PurchasesFromRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchases From Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesFromRelatedPartyTransactions" xlink:href="bntx-20231231.xsd#bntx_PurchasesFromRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PurchasesFromRelatedPartyTransactions" xlink:to="lab_bntx_PurchasesFromRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_MonetaryLiabilityAndProvisionsMember_0a998417-9d5c-4923-8575-d7b7558de7d8_terseLabel_en-US" xlink:label="lab_bntx_MonetaryLiabilityAndProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary liabilities and provisions in U.S. dollar</link:label>
    <link:label id="lab_bntx_MonetaryLiabilityAndProvisionsMember_label_en-US" xlink:label="lab_bntx_MonetaryLiabilityAndProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monetary Liability And Provisions [Member]</link:label>
    <link:label id="lab_bntx_MonetaryLiabilityAndProvisionsMember_documentation_en-US" xlink:label="lab_bntx_MonetaryLiabilityAndProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monetary Liability And Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryLiabilityAndProvisionsMember" xlink:href="bntx-20231231.xsd#bntx_MonetaryLiabilityAndProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_MonetaryLiabilityAndProvisionsMember" xlink:to="lab_bntx_MonetaryLiabilityAndProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember_1a0dc824-3556-49e2-a766-1ab98b7096a2_terseLabel_en-US" xlink:label="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note &#8211; embedded derivative</link:label>
    <link:label id="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember_label_en-US" xlink:label="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note, Embedded Derivative [Member]</link:label>
    <link:label id="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember_documentation_en-US" xlink:label="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Note, Embedded Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:href="bntx-20231231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:to="lab_bntx_ConvertibleNoteEmbeddedDerivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_fa35255a-36f5-4ac5-88dd-d7ad22e94636_terseLabel_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:to="lab_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5ead29aa-0d47-4bda-a262-b1d8f73253bc_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesMember_ba1d786f-29d4-4b86-93e2-aa20e943c4c5_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation techniques [member]</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesMember_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation techniques [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesMember" xlink:to="lab_ifrs-full_ValuationTechniquesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_9b09b36e-6143-485e-8352-b00e1cc1e3ec_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_ccef6323-064c-4d91-a5ec-635698f7bf8d_terseLabel_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">thereof vested, weighted-average exercise price (in euros per share)</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="lab_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_67498e02-a79a-4e43-a7a2-bf1d91da2b95_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Information about Subsidiaries</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_ff02a836-9c97-460f-aac6-7e957f863665_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_a6acd3a3-7e76-4508-9192-beabe912bca2_terseLabel_en-US" xlink:label="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</link:label>
    <link:label id="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_label_en-US" xlink:label="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_documentation_en-US" xlink:label="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:href="bntx-20231231.xsd#bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:to="lab_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock_e89efa7e-bb48-47d8-9f8d-b725d515623c_terseLabel_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current versus Non-Current Classifications</link:label>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Assets And Liabilities Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:href="bntx-20231231.xsd#bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:to="lab_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_bae0b25e-ca17-46bd-a537-b06766b079b8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in other financial assets</link:label>
    <link:label id="lab_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other cash payments to acquire interests in joint ventures, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9d6e2e72-e1d1-4654-98af-9574e79192b9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment_adc03003-ea25-4f81-b403-ce7610b8c932_negatedTerseLabel_en-US" xlink:label="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment_label_en-US" xlink:label="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Amortisation And Impairment</link:label>
    <link:label id="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment_documentation_en-US" xlink:label="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Amortisation And Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:href="bntx-20231231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:to="lab_bntx_AccumulatedDepreciationAmortisationAndImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_ba52d743-be06-4dd7-9f86-6eb8cd9a9421_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_e2ab6622-4a9b-4399-b765-24c117a4ca7c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currencies</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions_4eb5a7d1-0397-4159-ba69-cf6b5340ffbf_terseLabel_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other additional provisions</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions_label_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Other Additional Provisions</link:label>
    <link:label id="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions_documentation_en-US" xlink:label="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Onerous Contracts Provision, Other Additional Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:to="lab_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IssuanceOfShareCapital_272bff61-7178-4366-9373-559d16b698f6_terseLabel_en-US" xlink:label="lab_bntx_IssuanceOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of treasury shares</link:label>
    <link:label id="lab_bntx_IssuanceOfShareCapital_label_en-US" xlink:label="lab_bntx_IssuanceOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Share Capital</link:label>
    <link:label id="lab_bntx_IssuanceOfShareCapital_documentation_en-US" xlink:label="lab_bntx_IssuanceOfShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance Of Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IssuanceOfShareCapital" xlink:href="bntx-20231231.xsd#bntx_IssuanceOfShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IssuanceOfShareCapital" xlink:to="lab_bntx_IssuanceOfShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CapitalReserveMember_a0bf08f8-12d7-4971-a2c6-af6ab28aa33e_terseLabel_en-US" xlink:label="lab_ifrs-full_CapitalReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital reserve</link:label>
    <link:label id="lab_ifrs-full_CapitalReserveMember_label_en-US" xlink:label="lab_ifrs-full_CapitalReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital reserve [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CapitalReserveMember" xlink:to="lab_ifrs-full_CapitalReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_PercentageOfCostOfSales_ca04f101-0a37-49eb-845d-9417dfa0fd9a_terseLabel_en-US" xlink:label="lab_bntx_PercentageOfCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales (as a percent)</link:label>
    <link:label id="lab_bntx_PercentageOfCostOfSales_label_en-US" xlink:label="lab_bntx_PercentageOfCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Cost Of Sales</link:label>
    <link:label id="lab_bntx_PercentageOfCostOfSales_documentation_en-US" xlink:label="lab_bntx_PercentageOfCostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Cost Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfCostOfSales" xlink:href="bntx-20231231.xsd#bntx_PercentageOfCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_PercentageOfCostOfSales" xlink:to="lab_bntx_PercentageOfCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_6557d039-f250-44ad-89ee-301d71a64cdb_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_960c63f2-094c-4cc7-b5c9-8a1dcb799a4c_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Profit before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_ec815e1f-acf7-4448-ba5c-8c3e613ce4a3_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Profit before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_47830aa6-7b49-4566-874f-2d06d8ded8ab_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_IncomeTaxesAbstract_5db23bf7-a887-42c2-a2bc-ebd58720aca9_terseLabel_en-US" xlink:label="lab_bntx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_bntx_IncomeTaxesAbstract_label_en-US" xlink:label="lab_bntx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_bntx_IncomeTaxesAbstract_documentation_en-US" xlink:label="lab_bntx_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_IncomeTaxesAbstract" xlink:to="lab_bntx_IncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_25e73ead-4eea-4ea0-b4ca-60083f4006c4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_3d4eb56f-b848-4c1f-aa37-91d74fbb1058_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_2d1387f2-eb3c-43e4-abb7-363dbe4f93f6_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment terms in contracts with customers</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of significant payment terms in contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:to="lab_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_05b653fc-90cb-4173-a871-76fe519eb3e9_terseLabel_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on profit / (loss) before tax</link:label>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_label_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Changes Effect On Loss, Before Tax</link:label>
    <link:label id="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_documentation_en-US" xlink:label="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Changes Effect On Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:to="lab_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_a51c22ee-e644-45b3-b081-c1004ae51748_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_cc0e4832-bd70-4202-8734-4a85bf379a90_terseLabel_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land and buildings</link:label>
    <link:label id="lab_ifrs-full_LandAndBuildingsMember_label_en-US" xlink:label="lab_ifrs-full_LandAndBuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land and buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandAndBuildingsMember" xlink:to="lab_ifrs-full_LandAndBuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BankDepositsMember_4093a403-a493-4a5f-bb75-23a561ff60d7_terseLabel_en-US" xlink:label="lab_bntx_BankDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank deposits</link:label>
    <link:label id="lab_bntx_BankDepositsMember_label_en-US" xlink:label="lab_bntx_BankDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Deposits [Member]</link:label>
    <link:label id="lab_bntx_BankDepositsMember_documentation_en-US" xlink:label="lab_bntx_BankDepositsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bank Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BankDepositsMember" xlink:href="bntx-20231231.xsd#bntx_BankDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BankDepositsMember" xlink:to="lab_bntx_BankDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_7812f7ae-42aa-452b-b168-3cb414863bc0_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="lab_ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_c3607be8-78a7-4a3b-8509-71d3d33109aa_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_428de5df-8268-4ef2-a2e9-3420ec0cfd09_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_d9e668f9-10f1-48f1-b970-c0419201e079_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:label id="lab_ifrs-full_MajorCustomersAxis_label_en-US" xlink:label="lab_ifrs-full_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorCustomersAxis" xlink:to="lab_ifrs-full_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_dbd33d17-52b1-4c90-b27e-8aa5968567a1_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_a6a63365-6d45-4b0e-9fff-0cdc9e4beab1_terseLabel_en-US" xlink:label="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</link:label>
    <link:label id="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_label_en-US" xlink:label="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi [Member]</link:label>
    <link:label id="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_documentation_en-US" xlink:label="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:href="bntx-20231231.xsd#bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:to="lab_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Provisions_c9bee587-ad30-48eb-b1c3-0bc387368db5_totalLabel_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_Provisions_label_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Provisions" xlink:to="lab_ifrs-full_Provisions" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_d452247d-600b-4523-bb8a-58affacd8ecb_terseLabel_en-US" xlink:label="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities from wage taxes and social securities expenses</link:label>
    <link:label id="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_label_en-US" xlink:label="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities From Wage Taxes And Social Securities Expenses</link:label>
    <link:label id="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_documentation_en-US" xlink:label="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities From Wage Taxes And Social Securities Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:to="lab_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bntx_OncoC4IncMember_824cd3f2-9d0c-4c77-ac88-372a69475af0_terseLabel_en-US" xlink:label="lab_bntx_OncoC4IncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OncoC4 Inc.</link:label>
    <link:label id="lab_bntx_OncoC4IncMember_label_en-US" xlink:label="lab_bntx_OncoC4IncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OncoC4 Inc. [Member]</link:label>
    <link:label id="lab_bntx_OncoC4IncMember_documentation_en-US" xlink:label="lab_bntx_OncoC4IncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OncoC4 Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OncoC4IncMember" xlink:href="bntx-20231231.xsd#bntx_OncoC4IncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntx_OncoC4IncMember" xlink:to="lab_bntx_OncoC4IncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_cfa032c0-fa90-4065-be3c-159f623442a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events After the Reporting Period</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_606c9ab9-810f-46e4-afee-9a7b26f2fdcd_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_d205a762-681c-437e-9b95-7882a062c5cb_totalLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>bntx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:65014126-5376-4f52-9e24-a92115e4f98f,g:0059aac7-51d5-4642-94e2-b36e52753a6c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biontech.de/role/Cover" xlink:type="simple" xlink:href="bntx-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cb2d1016-396a-48d9-b807-0a48e685504b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb2d1016-396a-48d9-b807-0a48e685504b" xlink:to="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_b97de47b-b566-460c-a42d-6e6b277deb16" xlink:to="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_1f60fd51-6e93-46bb-ba99-b716830cb041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_9f32b0f9-8463-4890-b115-6a154dc323fe" xlink:to="loc_dei_BusinessContactMember_1f60fd51-6e93-46bb-ba99-b716830cb041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5fb7da3d-2626-47c1-a225-095a748894d5" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_11a047b9-f5aa-4e0b-95e8-82c9a7bba454" xlink:href="bntx-20231231.xsd#bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:to="loc_bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember_11a047b9-f5aa-4e0b-95e8-82c9a7bba454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_88d18602-0967-4b92-a03d-33ffae25b1e1" xlink:href="bntx-20231231.xsd#bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_60b9dfd6-2540-4cc7-8b35-75f222d93bf8" xlink:to="loc_bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember_88d18602-0967-4b92-a03d-33ffae25b1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsTable_c7e46956-05d4-4cc3-9a12-78befbcb905e" xlink:to="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f940e6f8-9d52-419d-9605-515770af849f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentType_f940e6f8-9d52-419d-9605-515770af849f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_64888ad9-e064-4c28-aede-110412f14308" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentRegistrationStatement_64888ad9-e064-4c28-aede-110412f14308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_52d6fe01-a5fa-4aee-8153-c5460060eaf6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentAnnualReport_52d6fe01-a5fa-4aee-8153-c5460060eaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a6174770-98b2-40c1-927e-2cdec73ae5d0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentPeriodEndDate_a6174770-98b2-40c1-927e-2cdec73ae5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_58949b55-4db9-44f0-b96d-56f31f568a9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_CurrentFiscalYearEndDate_58949b55-4db9-44f0-b96d-56f31f568a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4c2b83df-a983-41c8-a959-d84ad29ee444" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentTransitionReport_4c2b83df-a983-41c8-a959-d84ad29ee444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_5ee64a2f-0550-45fa-944e-45d0e7785829" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentShellCompanyReport_5ee64a2f-0550-45fa-944e-45d0e7785829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ec17492a-663c-4022-b61e-f10b6da08009" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityFileNumber_ec17492a-663c-4022-b61e-f10b6da08009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0bcab9aa-b3fa-4f46-89bb-9dc1af6222d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityRegistrantName_0bcab9aa-b3fa-4f46-89bb-9dc1af6222d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_35fbf416-c0b7-4386-915b-fe518c842d8e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_35fbf416-c0b7-4386-915b-fe518c842d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_47601776-1c6c-4f6c-a39e-df45d10fca2c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressAddressLine1_47601776-1c6c-4f6c-a39e-df45d10fca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8453de4f-21a3-4278-bd98-9adddf3ca73f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressPostalZipCode_8453de4f-21a3-4278-bd98-9adddf3ca73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8cf81ff2-ba95-402f-8e61-88c6372f2b37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressCityOrTown_8cf81ff2-ba95-402f-8e61-88c6372f2b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_367cc283-1d42-414c-a0b1-cadeaf067da4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityAddressCountry_367cc283-1d42-414c-a0b1-cadeaf067da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_2f38e7d5-9b2b-4a87-8a3a-ba72b4e8cd94" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelName_2f38e7d5-9b2b-4a87-8a3a-ba72b4e8cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7d845005-5d6d-48f1-bf9e-33c1e5b41048" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_CityAreaCode_7d845005-5d6d-48f1-bf9e-33c1e5b41048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9f2fbda2-e4c1-4768-badd-650a5fe36477" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_LocalPhoneNumber_9f2fbda2-e4c1-4768-badd-650a5fe36477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelFaxNumber_df21908a-f26b-4399-a7cd-6d950f3ce7cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelFaxNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelFaxNumber_df21908a-f26b-4399-a7cd-6d950f3ce7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_45ff6881-fc37-4924-bdf5-dfed1f20af2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_ContactPersonnelEmailAddress_45ff6881-fc37-4924-bdf5-dfed1f20af2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1ab00546-af32-4244-b705-55ca8f8c7679" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_Security12bTitle_1ab00546-af32-4244-b705-55ca8f8c7679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_42e6dba9-13e5-4a78-8b2e-9269c29ad1d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_TradingSymbol_42e6dba9-13e5-4a78-8b2e-9269c29ad1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2059b9bd-f720-47a5-b321-f5b838d10f1f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_SecurityExchangeName_2059b9bd-f720-47a5-b321-f5b838d10f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_430ba38c-7613-4880-b5c3-451a026d80ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_430ba38c-7613-4880-b5c3-451a026d80ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e5d11895-ec22-432b-8582-af0887796531" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e5d11895-ec22-432b-8582-af0887796531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_714b6d2f-8c4c-4c8a-8d48-f9ccbc447509" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityVoluntaryFilers_714b6d2f-8c4c-4c8a-8d48-f9ccbc447509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_42693b3d-e82c-4662-ad6e-39c8be4fc9a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCurrentReportingStatus_42693b3d-e82c-4662-ad6e-39c8be4fc9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_38f3db6c-703d-41e4-894a-3578d466046c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityInteractiveDataCurrent_38f3db6c-703d-41e4-894a-3578d466046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_45dd1635-ed51-4636-8dc5-44d3f85d85ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityFilerCategory_45dd1635-ed51-4636-8dc5-44d3f85d85ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6b10a9e8-b0e3-41d0-98f1-c3f92e4147d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityEmergingGrowthCompany_6b10a9e8-b0e3-41d0-98f1-c3f92e4147d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_449d640b-1514-4200-bf17-d957a6ce9709" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_449d640b-1514-4200-bf17-d957a6ce9709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_6f4ee5a2-d044-4d34-b444-089a30a93e72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_6f4ee5a2-d044-4d34-b444-089a30a93e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_88b866c8-aeee-4970-a666-f525fe04e7cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentAccountingStandard_88b866c8-aeee-4970-a666-f525fe04e7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d3feae36-5aaf-49bb-8b66-912cb8bc525a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityShellCompany_d3feae36-5aaf-49bb-8b66-912cb8bc525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f9406ad3-dcd0-44e2-83cc-ff5e7814aa37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_AmendmentFlag_f9406ad3-dcd0-44e2-83cc-ff5e7814aa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3149f7d7-18c1-4468-8d61-dabdcd8693e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3149f7d7-18c1-4468-8d61-dabdcd8693e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9fd02def-24f7-4415-8c2f-eea215dd0ee5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_DocumentFiscalYearFocus_9fd02def-24f7-4415-8c2f-eea215dd0ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e2e3bb48-1420-427f-a801-e7f7190be2c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_EntityCentralIndexKey_e2e3bb48-1420-427f-a801-e7f7190be2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_NoTradingSymbolFlag_a6c6251d-43ed-4a37-a25d-f839c924f476" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsLineItems_565b8d99-2237-476e-b380-d12c6dcf507c" xlink:to="loc_dei_NoTradingSymbolFlag_a6c6251d-43ed-4a37-a25d-f839c924f476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/AuditInformation" xlink:type="simple" xlink:href="bntx-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AuditInformationAbstract_d1cff45d-a64a-4199-9b0d-d78aab1fdfc6" xlink:href="bntx-20231231.xsd#bntx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1ca7e53d-1d5c-4591-877d-c05d91541d5a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_AuditInformationAbstract_d1cff45d-a64a-4199-9b0d-d78aab1fdfc6" xlink:to="loc_dei_AuditorFirmId_1ca7e53d-1d5c-4591-877d-c05d91541d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_0a55618d-2426-4e45-b729-79ea4b7c8d26" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_AuditInformationAbstract_d1cff45d-a64a-4199-9b0d-d78aab1fdfc6" xlink:to="loc_dei_AuditorName_0a55618d-2426-4e45-b729-79ea4b7c8d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_03ca5e5e-e075-46ad-99bb-efb46d37e776" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_AuditInformationAbstract_d1cff45d-a64a-4199-9b0d-d78aab1fdfc6" xlink:to="loc_dei_AuditorLocation_03ca5e5e-e075-46ad-99bb-efb46d37e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofProfitorLoss"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_9af57320-779f-40b2-b1af-a7d2ec90fa73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_9af57320-779f-40b2-b1af-a7d2ec90fa73" xlink:to="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:to="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ae342bf9-4c9e-4a3c-ada0-429a528ef1ef" xlink:to="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_561a26d0-6138-477a-91c2-fba4e1633678" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:to="loc_bntx_CommercialMember_561a26d0-6138-477a-91c2-fba4e1633678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentMember_e97c3d0c-0ac0-47e2-93ae-c33e4b4233ed" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_323ff048-1178-4d14-aaf9-ee52a9f2a879" xlink:to="loc_bntx_ResearchAndDevelopmentMember_e97c3d0c-0ac0-47e2-93ae-c33e4b4233ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_c0c6b237-efc9-428f-8dce-53319fbf221f" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_6effa19e-97ea-4cc1-9983-926eb8eb3170" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_5bdf59bc-9ab7-4380-89f3-658af940e916" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_6effa19e-97ea-4cc1-9983-926eb8eb3170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_211d6573-4865-4bac-aa5a-777b45af7a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_CostOfSales_211d6573-4865-4bac-aa5a-777b45af7a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2ec45905-cb4d-4a07-9281-e120c16134d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2ec45905-cb4d-4a07-9281-e120c16134d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_3364150a-0b33-43c1-a236-e06937e08792" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_3364150a-0b33-43c1-a236-e06937e08792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_3b937bc9-7b21-42a5-a1a5-96bcdefd6606" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_3b937bc9-7b21-42a5-a1a5-96bcdefd6606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_eb330817-abeb-4557-8567-5b2be8740d4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_eb330817-abeb-4557-8567-5b2be8740d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d17148c7-ca08-4961-a724-9a0f60d87a26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_d17148c7-ca08-4961-a724-9a0f60d87a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_0d2faa8a-fdf0-4d01-a69d-ece2dc6072b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_0d2faa8a-fdf0-4d01-a69d-ece2dc6072b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_5603c912-3f1c-4aab-aba9-4be2b5c89906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_FinanceIncome_5603c912-3f1c-4aab-aba9-4be2b5c89906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_613a4bab-b894-4f94-9fb0-904b28ba2f8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_FinanceCosts_613a4bab-b894-4f94-9fb0-904b28ba2f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_397f7eab-5fde-440f-9c85-269dc67d47b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_397f7eab-5fde-440f-9c85-269dc67d47b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b20076ef-4cad-484a-b133-7a8eefb46af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b20076ef-4cad-484a-b133-7a8eefb46af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9f35363e-73de-4481-9dd2-c7675fc2bb86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_ProfitLoss_9f35363e-73de-4481-9dd2-c7675fc2bb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_0ea10d25-d310-4ae5-949d-e282d1b820ea" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_4d4cd1ad-c72d-439e-81cd-479b47164de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_4d4cd1ad-c72d-439e-81cd-479b47164de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_4f1be671-78af-49c8-ab6d-ba6b427eeb68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_724da2dd-3a46-48db-905f-a12af8abc5bc" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_4f1be671-78af-49c8-ab6d-ba6b427eeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_80372ff6-a18a-4980-aa0e-8642e3b08052" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_dba9ec07-30c0-4979-a781-5e3700e482e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_80372ff6-a18a-4980-aa0e-8642e3b08052" xlink:to="loc_ifrs-full_ProfitLoss_dba9ec07-30c0-4979-a781-5e3700e482e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_97bafbf2-c53a-4053-aea8-9d7e21d40808" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_80372ff6-a18a-4980-aa0e-8642e3b08052" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_97bafbf2-c53a-4053-aea8-9d7e21d40808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1c851d2e-5789-4cb9-9ea9-da48dd043bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_97bafbf2-c53a-4053-aea8-9d7e21d40808" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1c851d2e-5789-4cb9-9ea9-da48dd043bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a5102028-4157-4fad-8cfa-6d126687dcf6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1c851d2e-5789-4cb9-9ea9-da48dd043bf5" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a5102028-4157-4fad-8cfa-6d126687dcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_f20f38f4-5611-4744-a698-7afa7c9fdd60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_1c851d2e-5789-4cb9-9ea9-da48dd043bf5" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_f20f38f4-5611-4744-a698-7afa7c9fdd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_8da15173-a7a8-4b20-9188-7b196e48e395" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_97bafbf2-c53a-4053-aea8-9d7e21d40808" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_8da15173-a7a8-4b20-9188-7b196e48e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_ce9dbc65-0fdf-4c95-9610-65791e87e2c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_8da15173-a7a8-4b20-9188-7b196e48e395" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_ce9dbc65-0fdf-4c95-9610-65791e87e2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_82e79dce-17eb-4a76-b4ed-20d0cf2d93b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_8da15173-a7a8-4b20-9188-7b196e48e395" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_82e79dce-17eb-4a76-b4ed-20d0cf2d93b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a53967fb-0f41-4ed9-b829-fa0cfb60bfb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_8da15173-a7a8-4b20-9188-7b196e48e395" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a53967fb-0f41-4ed9-b829-fa0cfb60bfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_2e99fc36-a986-4fe1-a59d-d22000679041" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_97bafbf2-c53a-4053-aea8-9d7e21d40808" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_2e99fc36-a986-4fe1-a59d-d22000679041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_2daa56e1-bab1-4943-83e4-14c03d082d61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_80372ff6-a18a-4980-aa0e-8642e3b08052" xlink:to="loc_ifrs-full_ComprehensiveIncome_2daa56e1-bab1-4943-83e4-14c03d082d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofFinancialPosition"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_55ef8e9c-156b-42fe-af33-cd81d4894b9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_09c7adf6-d6b7-456d-b8d8-793af9a2b5f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_55ef8e9c-156b-42fe-af33-cd81d4894b9d" xlink:to="loc_ifrs-full_AssetsAbstract_09c7adf6-d6b7-456d-b8d8-793af9a2b5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_09c7adf6-d6b7-456d-b8d8-793af9a2b5f2" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_c99da249-e0ab-432a-a226-22ed7882d281" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_Goodwill_c99da249-e0ab-432a-a226-22ed7882d281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_e724266a-9cd6-4677-8f15-ce01fd0c6165" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_e724266a-9cd6-4677-8f15-ce01fd0c6165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1135a125-9c40-4a33-969b-3418ebbff3aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1135a125-9c40-4a33-969b-3418ebbff3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_33cbbe67-bc18-4dd7-856a-e34efc804c3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_RightofuseAssets_33cbbe67-bc18-4dd7-856a-e34efc804c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_5136c062-2b8e-497e-8917-68b888f76dc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_5136c062-2b8e-497e-8917-68b888f76dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_7b249037-d171-4427-bd75-42d22bbcd38e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_7b249037-d171-4427-bd75-42d22bbcd38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_9a514df3-ef2e-4090-8cc2-97bfeb892e8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_DeferredTaxAssets_9a514df3-ef2e-4090-8cc2-97bfeb892e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_5d215d14-6c16-41c9-84a3-c5a0f8dfedb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_d176c6a1-8092-433e-91db-06f32d08732f" xlink:to="loc_ifrs-full_NoncurrentAssets_5d215d14-6c16-41c9-84a3-c5a0f8dfedb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_09c7adf6-d6b7-456d-b8d8-793af9a2b5f2" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_a8e1ab21-71a8-41d1-aad6-de5c775c6055" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_Inventories_a8e1ab21-71a8-41d1-aad6-de5c775c6055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_320be57f-82c6-44c9-8c53-afc47948c8fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_320be57f-82c6-44c9-8c53-afc47948c8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractAssets_297e7fae-f9c8-46b2-9de5-c6e2b15e6196" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_ContractAssets_297e7fae-f9c8-46b2-9de5-c6e2b15e6196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialAssets_942879b9-643d-4b14-a5b3-4b98e5e19e6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_OtherCurrentFinancialAssets_942879b9-643d-4b14-a5b3-4b98e5e19e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialAssets_b7f30d05-757c-4445-90e1-b917836d00fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialAssets_b7f30d05-757c-4445-90e1-b917836d00fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxAssetsCurrent_e196f17a-5ab1-4a5d-8f79-5dea24dc82db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_CurrentTaxAssetsCurrent_e196f17a-5ab1-4a5d-8f79-5dea24dc82db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fe43e32c-d003-449b-aa73-9ea66c3c9634" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fe43e32c-d003-449b-aa73-9ea66c3c9634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_a63e3679-cc7f-4a56-a127-91c06895117e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_aa8d2232-16fc-4536-9241-4cc20bdd8098" xlink:to="loc_ifrs-full_CurrentAssets_a63e3679-cc7f-4a56-a127-91c06895117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_bcc53cfa-8fa3-4fe7-aca8-1b14f65601f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_09c7adf6-d6b7-456d-b8d8-793af9a2b5f2" xlink:to="loc_ifrs-full_Assets_bcc53cfa-8fa3-4fe7-aca8-1b14f65601f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_55ef8e9c-156b-42fe-af33-cd81d4894b9d" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:to="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_3a63f5a1-2dfd-45e5-9505-7f69af9cd795" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_IssuedCapital_3a63f5a1-2dfd-45e5-9505-7f69af9cd795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserve_02ebb492-473d-48f0-b15d-94ed1ea0c466" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_CapitalReserve_02ebb492-473d-48f0-b15d-94ed1ea0c466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_b23ab23f-cd04-4fa2-8809-0a82ff67a7fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_TreasuryShares_b23ab23f-cd04-4fa2-8809-0a82ff67a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_6c009252-9d1e-47e8-b8c1-76d839a68e92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_RetainedEarnings_6c009252-9d1e-47e8-b8c1-76d839a68e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_b89b3e66-e58d-4b8f-8925-39f6f78cdeb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_OtherReserves_b89b3e66-e58d-4b8f-8925-39f6f78cdeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d76df46c-7af1-4b90-a0b9-b508b2d76cdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b11568f4-43cc-4ceb-9ce7-3e3449cf1e1d" xlink:to="loc_ifrs-full_Equity_d76df46c-7af1-4b90-a0b9-b508b2d76cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_8276d997-b729-4de3-a5c3-7df3a6d46d28" xlink:href="bntx-20231231.xsd#bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings_8276d997-b729-4de3-a5c3-7df3a6d46d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_bdfbdbd1-9a1b-419f-9cf9-8a8445060a9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialLiabilities_bdfbdbd1-9a1b-419f-9cf9-8a8445060a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_9a3c0395-9213-4b25-af12-fea748355646" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesNoncurrent_9a3c0395-9213-4b25-af12-fea748355646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_cf9988b3-3198-453e-8840-af5a7e6ea3df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_NoncurrentProvisions_cf9988b3-3198-453e-8840-af5a7e6ea3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_cca91317-3076-4b90-9ff3-23bdde3bdf06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_cca91317-3076-4b90-9ff3-23bdde3bdf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_d375bc1b-3095-4578-830d-1d4677ad2898" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_d375bc1b-3095-4578-830d-1d4677ad2898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_19425a22-16a8-4af0-988c-2a4cadde0200" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_19425a22-16a8-4af0-988c-2a4cadde0200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_9dea8c18-824d-40be-acd5-63acc4313a6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_832d8951-d723-45f7-95f8-06cac1bdee24" xlink:to="loc_ifrs-full_NoncurrentLiabilities_9dea8c18-824d-40be-acd5-63acc4313a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_4e635a96-5af1-4bcf-b1b3-94b99935d30f" xlink:href="bntx-20231231.xsd#bntx_CurrentLeaseLiabilitiesLoansAndBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings_4e635a96-5af1-4bcf-b1b3-94b99935d30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_0bf83663-19e1-4727-951d-2200c30eac8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_0bf83663-19e1-4727-951d-2200c30eac8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentFinancialLiabilities_6cd72765-9777-4a9f-95b8-332d59bbf7b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_OtherCurrentFinancialLiabilities_6cd72765-9777-4a9f-95b8-332d59bbf7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRefundsProvision_842f4671-d25f-4f1e-badd-9beb0e68b243" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_CurrentRefundsProvision_842f4671-d25f-4f1e-badd-9beb0e68b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_a9c8f4ca-ae8d-4984-aabc-e9688fc2d446" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_a9c8f4ca-ae8d-4984-aabc-e9688fc2d446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_21d12792-965b-4f56-8627-5e700fa8a4a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_CurrentProvisions_21d12792-965b-4f56-8627-5e700fa8a4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_d2c36dd0-4856-4814-8d08-66fa39244074" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_CurrentContractLiabilities_d2c36dd0-4856-4814-8d08-66fa39244074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_1a9519c7-65c2-4e0f-823d-706e3892152f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_1a9519c7-65c2-4e0f-823d-706e3892152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_66a1dc8a-2ea5-4b40-851a-446071ce5647" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_5770da33-f975-43de-a92b-fcd85474647b" xlink:to="loc_ifrs-full_CurrentLiabilities_66a1dc8a-2ea5-4b40-851a-446071ce5647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_ffe439e5-42e8-4035-af39-3fe019b1d900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:to="loc_ifrs-full_Liabilities_ffe439e5-42e8-4035-af39-3fe019b1d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_ab34c0e2-e1e4-41a9-b6e8-883dec76bd37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b59dfa27-f1e9-47e9-9b65-11b0e53c9827" xlink:to="loc_ifrs-full_EquityAndLiabilities_ab34c0e2-e1e4-41a9-b6e8-883dec76bd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_5b687c99-1b9b-457f-9faa-b9e1919f9e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_5b687c99-1b9b-457f-9faa-b9e1919f9e9a" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c59a4958-0722-4c92-b773-f3f67aafa5dc" xlink:to="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_5065226d-7422-4111-8ef2-30ba682049f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_IssuedCapitalMember_5065226d-7422-4111-8ef2-30ba682049f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_eed39d03-b0e3-4604-81cd-196c47cf197a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_CapitalReserveMember_eed39d03-b0e3-4604-81cd-196c47cf197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_c8fafc6d-1b32-4551-82c4-d1aa8767ead6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_TreasurySharesMember_c8fafc6d-1b32-4551-82c4-d1aa8767ead6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_954ef36e-a846-47d7-9d30-89f6b7c3795c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_954ef36e-a846-47d7-9d30-89f6b7c3795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_654d3673-9288-4a8e-a364-ae6f75fbf4a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_141450de-30cb-4aa3-98f3-4175146610ab" xlink:to="loc_ifrs-full_OtherReservesMember_654d3673-9288-4a8e-a364-ae6f75fbf4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_91933458-0f3b-4c0e-b9d6-1ca08a0a114f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_dde3d587-85cc-4a9f-8aad-e758b7739a9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_Equity_dde3d587-85cc-4a9f-8aad-e758b7739a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_3c154eff-ddf6-4aa0-8ae6-d9751b133d5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ProfitLoss_3c154eff-ddf6-4aa0-8ae6-d9751b133d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_9d72b3c2-0ab0-47a5-9d39-02738b785e59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_9d72b3c2-0ab0-47a5-9d39-02738b785e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_407c9b43-f2a5-40f9-a5dd-e2ebeba75c06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ComprehensiveIncome_407c9b43-f2a5-40f9-a5dd-e2ebeba75c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IssuanceOfShareCapital_bab85a33-449f-4dbc-bc18-9db6b21b600b" xlink:href="bntx-20231231.xsd#bntx_IssuanceOfShareCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_IssuanceOfShareCapital_bab85a33-449f-4dbc-bc18-9db6b21b600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_67df4890-5420-4582-b5ff-c57805eb5c01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_IssueOfEquity_67df4890-5420-4582-b5ff-c57805eb5c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RedemptionOfConvertibleNote_126c4df3-15f7-4e9b-8ef2-c8d0df404c16" xlink:href="bntx-20231231.xsd#bntx_RedemptionOfConvertibleNote"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_RedemptionOfConvertibleNote_126c4df3-15f7-4e9b-8ef2-c8d0df404c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_89a977ff-e6d0-49b6-a5c4-54bf7468eade" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue_89a977ff-e6d0-49b6-a5c4-54bf7468eade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_0c869a0e-9e1e-4a73-a80e-00b75c390eb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_0c869a0e-9e1e-4a73-a80e-00b75c390eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaid_78fae470-46a7-4e98-8a27-1baf5b7d9363" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_DividendsPaid_78fae470-46a7-4e98-8a27-1baf5b7d9363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_99ac86fd-14f7-4f3c-84f7-f5996afbc106" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_99ac86fd-14f7-4f3c-84f7-f5996afbc106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentAndDeferredTaxExpenseIncome_f8c0e3b3-cebd-4035-addd-f8dcbccb0e07" xlink:href="bntx-20231231.xsd#bntx_CurrentAndDeferredTaxExpenseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_CurrentAndDeferredTaxExpenseIncome_f8c0e3b3-cebd-4035-addd-f8dcbccb0e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_bc12f4bf-a9de-47b3-8ac3-b96490f77228" xlink:href="bntx-20231231.xsd#bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination_bc12f4bf-a9de-47b3-8ac3-b96490f77228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d46149bd-a478-4073-846e-bb9a87d7a92a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7d75d029-b44a-401b-9923-de7f9ffbb7ca" xlink:to="loc_ifrs-full_Equity_d46149bd-a478-4073-846e-bb9a87d7a92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="bntx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_094701e2-82ac-4303-aca1-7dcb86b6430a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_ProfitLoss_094701e2-82ac-4303-aca1-7dcb86b6430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3f9a94f9-51b0-4d48-b1b7-12d56b1d5767" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_3f9a94f9-51b0-4d48-b1b7-12d56b1d5767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_17c70aa1-544c-49bd-856e-6da0fceeb942" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_17c70aa1-544c-49bd-856e-6da0fceeb942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_019946af-8329-4aac-ab53-18cc288ca322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_019946af-8329-4aac-ab53-18cc288ca322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_021e5239-e55e-4427-b300-eae5061eadad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_021e5239-e55e-4427-b300-eae5061eadad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_627433b3-7688-4442-8324-0659f91298a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_627433b3-7688-4442-8324-0659f91298a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_e4daff05-058d-45bb-8ebe-8172a8df702e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_e4daff05-058d-45bb-8ebe-8172a8df702e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_1793116b-ad8c-4b0d-ad78-8893d6f0c906" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_1793116b-ad8c-4b0d-ad78-8893d6f0c906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_76b4e638-b774-4562-af88-ae8bad7f7e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_76b4e638-b774-4562-af88-ae8bad7f7e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForMovementsInGovernmentGrants_fcf5a18a-729a-4971-a814-9eef0ece28ee" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForMovementsInGovernmentGrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_bntx_AdjustmentsForMovementsInGovernmentGrants_fcf5a18a-729a-4971-a814-9eef0ece28ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherAdjustmentsForNoncashItems_e73dfb5a-40ed-4720-a1b5-d87f78db98a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_OtherAdjustmentsForNoncashItems_e73dfb5a-40ed-4720-a1b5-d87f78db98a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_15cfebef-c2b7-480d-88b5-b4cc81dc8f61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_9986a854-b193-4450-ae1b-875d6c103564" xlink:to="loc_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss_15cfebef-c2b7-480d-88b5-b4cc81dc8f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WorkingCapitalAdjustmentsAbstract_9624a967-1143-4b6d-ba19-fca8c53f020c" xlink:href="bntx-20231231.xsd#bntx_WorkingCapitalAdjustmentsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_bntx_WorkingCapitalAdjustmentsAbstract_9624a967-1143-4b6d-ba19-fca8c53f020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_ec36e72e-fd98-42e1-aa6f-aa7f30907a54" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WorkingCapitalAdjustmentsAbstract_9624a967-1143-4b6d-ba19-fca8c53f020c" xlink:to="loc_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets_ec36e72e-fd98-42e1-aa6f-aa7f30907a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b7d0f757-9765-415f-9788-429c29466128" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WorkingCapitalAdjustmentsAbstract_9624a967-1143-4b6d-ba19-fca8c53f020c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_b7d0f757-9765-415f-9788-429c29466128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_68c2823a-ffc9-458f-b8f6-f63d63b6c5e1" xlink:href="bntx-20231231.xsd#bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WorkingCapitalAdjustmentsAbstract_9624a967-1143-4b6d-ba19-fca8c53f020c" xlink:to="loc_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions_68c2823a-ffc9-458f-b8f6-f63d63b6c5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b05d6da7-3634-4371-9fd3-0216658d8baa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b05d6da7-3634-4371-9fd3-0216658d8baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_a2009b06-bc12-41f5-bce1-c23afb82e45e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_a2009b06-bc12-41f5-bce1-c23afb82e45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_84621414-1a40-4707-9a89-db3624fab9df" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_84621414-1a40-4707-9a89-db3624fab9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_067ab89a-3c6e-4caa-8300-0920cca6a228" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentsClassifiedAsOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_067ab89a-3c6e-4caa-8300-0920cca6a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4f9bd4fb-4e6b-404b-9f13-aff9f013ff3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_493904da-f5d3-4b35-852d-8576f9d138f1" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4f9bd4fb-4e6b-404b-9f13-aff9f013ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_7412159f-7cac-4109-8ca7-baf9274fa631" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_7412159f-7cac-4109-8ca7-baf9274fa631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8342e57a-f468-4e3a-8824-4203a81f3c23" xlink:href="bntx-20231231.xsd#bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8342e57a-f468-4e3a-8824-4203a81f3c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_7d7077bc-586a-4b1c-8ac8-b8e1b9f390a7" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities_7d7077bc-586a-4b1c-8ac8-b8e1b9f390a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_00630f8b-de06-4b7e-a913-7e858b2b5581" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_00630f8b-de06-4b7e-a913-7e858b2b5581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_90bf700b-df58-4dc5-a095-1780aae5715c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities_90bf700b-df58-4dc5-a095-1780aae5715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_8cbf88de-575d-4149-ae05-29be034ad031" xlink:href="bntx-20231231.xsd#bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities_8cbf88de-575d-4149-ae05-29be034ad031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_71fbed91-d80c-4a21-8d21-85d85eb3e0a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_29a86bc0-1d44-4c76-9393-9c8d646ba015" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_71fbed91-d80c-4a21-8d21-85d85eb3e0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_cd5f1ea0-191a-486d-a4ec-4881752dc819" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_cd5f1ea0-191a-486d-a4ec-4881752dc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_fe955b09-d243-43cb-a1e2-9f88eb5187af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_fe955b09-d243-43cb-a1e2-9f88eb5187af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_3b1dae6f-3836-46a4-ad91-3fa770099984" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_3b1dae6f-3836-46a4-ad91-3fa770099984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_143b9157-44ac-4da8-a5e8-db62623575ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_143b9157-44ac-4da8-a5e8-db62623575ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_7f242418-4980-4fe5-81c2-e5a4455b95d2" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities_7f242418-4980-4fe5-81c2-e5a4455b95d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_63aad2fd-b972-4802-8fa0-87758f1d17a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_63aad2fd-b972-4802-8fa0-87758f1d17a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a01b5d37-d493-46c1-8aaa-65fd6d33d92e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_b9fd0263-f64b-4d13-b60a-e44a37612480" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_a01b5d37-d493-46c1-8aaa-65fd6d33d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_e4c43a45-47bc-430b-affb-a0ffbff10e7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_e4c43a45-47bc-430b-affb-a0ffbff10e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_f46c355e-1b0e-43b5-9432-430e5750fff6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_f46c355e-1b0e-43b5-9432-430e5750fff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents_f9cd43d4-bb9f-4818-a9a5-c37efafdf669" xlink:href="bntx-20231231.xsd#bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents_f9cd43d4-bb9f-4818-a9a5-c37efafdf669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_bd08f2f7-eb6b-49d8-926f-fe29f79544b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_CashAndCashEquivalents_bd08f2f7-eb6b-49d8-926f-fe29f79544b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_f7c9edda-ea52-46eb-bc68-430c2821f1bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_54150f9b-5808-4cd8-9213-e842b18c0fce" xlink:to="loc_ifrs-full_CashAndCashEquivalents_f7c9edda-ea52-46eb-bc68-430c2821f1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/CorporateInformation" xlink:type="simple" xlink:href="bntx-20231231.xsd#CorporateInformation"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/CorporateInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCorporateInformationExplanatoryAbstract_9f1792df-808f-4854-8663-c3d5d9df94f7" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock_0e252f2d-e3dd-4ed1-be41-b5f2e9f861be" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCorporateInformationExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfCorporateInformationExplanatoryAbstract_9f1792df-808f-4854-8663-c3d5d9df94f7" xlink:to="loc_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock_0e252f2d-e3dd-4ed1-be41-b5f2e9f861be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_92f35392-0dbd-476a-8eaf-d9d5ba9393f9" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_160a94e0-b571-4948-9309-14fc101e1918" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_92f35392-0dbd-476a-8eaf-d9d5ba9393f9" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_160a94e0-b571-4948-9309-14fc101e1918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingJudgementsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_5b74fc6b-d62d-40a6-a5cb-dde5b145278b" xlink:href="bntx-20231231.xsd#bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_33729254-4ca7-4027-a367-e5f7e4336364" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_5b74fc6b-d62d-40a6-a5cb-dde5b145278b" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_33729254-4ca7-4027-a367-e5f7e4336364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformation" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformation"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/GroupInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract_a735581e-fdc3-4346-8614-a3fb9360f0c6" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_577443ab-db12-456b-9b74-a07dbaf4724d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCompositionOfGroupExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_a735581e-fdc3-4346-8614-a3fb9360f0c6" xlink:to="loc_ifrs-full_DisclosureOfCompositionOfGroupExplanatory_577443ab-db12-456b-9b74-a07dbaf4724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinations" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BusinessCombinations1Abstract_d2dd8878-1f3c-4733-98ab-8039330d5996" xlink:href="bntx-20231231.xsd#bntx_BusinessCombinations1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_187fa3d8-f30f-4519-9fb2-c2356a983ad1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_BusinessCombinations1Abstract_d2dd8878-1f3c-4733-98ab-8039330d5996" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_187fa3d8-f30f-4519-9fb2-c2356a983ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomers" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomers"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomers" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_0c84c43e-b534-446d-9e7e-e5b55d0b65ac" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_041cbec6-28fc-412b-a0fb-807298fe0942" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_0c84c43e-b534-446d-9e7e-e5b55d0b65ac" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_041cbec6-28fc-412b-a0fb-807298fe0942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpenses" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpenses"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9b2e7b4b-f7a9-4ea6-b2c9-beb302d16d8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock_f89de2b5-2463-4efc-97a5-7b04429f1aad" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_9b2e7b4b-f7a9-4ea6-b2c9-beb302d16d8f" xlink:to="loc_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock_f89de2b5-2463-4efc-97a5-7b04429f1aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTax" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTax"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_f3bd7b3f-c12b-4c4f-b9d4-e2a541ac3a5c" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_0f021920-8789-44a5-ad10-d88e8ec1e287" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_f3bd7b3f-c12b-4c4f-b9d4-e2a541ac3a5c" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_0f021920-8789-44a5-ad10-d88e8ec1e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EarningsperShare" xlink:type="simple" xlink:href="bntx-20231231.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_a10d6cc2-8c1c-468b-b48a-43aab05a017b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_38d94d0a-5a9a-4531-a695-3e7802f91e28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a10d6cc2-8c1c-468b-b48a-43aab05a017b" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_38d94d0a-5a9a-4531-a695-3e7802f91e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_a8a90f78-6231-4f15-8dc6-e69938b1107d" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_636a9613-fc36-405e-a67c-70d53ecfae8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_a8a90f78-6231-4f15-8dc6-e69938b1107d" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_636a9613-fc36-405e-a67c-70d53ecfae8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_db590e91-5075-4a78-8e0f-c8ee6db76af1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_a1f6d583-0b2c-4c74-a240-5139984d783b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_db590e91-5075-4a78-8e0f-c8ee6db76af1" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_a1f6d583-0b2c-4c74-a240-5139984d783b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilities"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_26cbc899-8131-45d1-9c26-8022186f9ef5" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_85effaf7-2a17-4edb-8c10-eaab3c2c26bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_26cbc899-8131-45d1-9c26-8022186f9ef5" xlink:to="loc_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_85effaf7-2a17-4edb-8c10-eaab3c2c26bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/Inventories" xlink:type="simple" xlink:href="bntx-20231231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InventoriesAbstract_246e2a48-23a8-4546-be2a-548a27ceec15" xlink:href="bntx-20231231.xsd#bntx_InventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_d80318c6-66a4-4086-a09e-98df3f88ea09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_246e2a48-23a8-4546-be2a-548a27ceec15" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_d80318c6-66a4-4086-a09e-98df3f88ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssets" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssets"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialAssetsAbstract_9752f48e-d991-4509-972f-d2b8b484e7df" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_809c1b24-b6ae-4499-8c94-461c944f4c6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_9752f48e-d991-4509-972f-d2b8b484e7df" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_809c1b24-b6ae-4499-8c94-461c944f4c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReserves" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReserves"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReserves" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_2602fb30-19f6-4693-bc6e-e8c83a3a63ee" xlink:href="bntx-20231231.xsd#bntx_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_50ce9059-6bec-4262-8bad-2c2d0b936a74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_2602fb30-19f6-4693-bc6e-e8c83a3a63ee" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_50ce9059-6bec-4262-8bad-2c2d0b936a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPayments" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_6f1b4dbc-2e26-4629-8366-e3abf3cb562f" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fbb58409-2fb8-4cee-aa72-94a709732b58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_6f1b4dbc-2e26-4629-8366-e3abf3cb562f" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fbb58409-2fb8-4cee-aa72-94a709732b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/Provisions" xlink:type="simple" xlink:href="bntx-20231231.xsd#Provisions"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/Provisions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_3345ac50-6a36-4af9-8da9-02898dba816c" xlink:href="bntx-20231231.xsd#bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_1e1b4eb5-e9dd-4cc7-b88c-ae97a6c77d28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_3345ac50-6a36-4af9-8da9-02898dba816c" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_1e1b4eb5-e9dd-4cc7-b88c-ae97a6c77d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/Contingenciesandotherfinancialcommitments" xlink:type="simple" xlink:href="bntx-20231231.xsd#Contingenciesandotherfinancialcommitments"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/Contingenciesandotherfinancialcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_6ba219c9-5b71-43da-b1c1-b3735d2161fe" xlink:href="bntx-20231231.xsd#bntx_ContingenciesAndOtherFinancialCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_c086fd2d-3fc1-4ec8-9d6e-d4bfb23e4a06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_6ba219c9-5b71-43da-b1c1-b3735d2161fe" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_c086fd2d-3fc1-4ec8-9d6e-d4bfb23e4a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilities" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilities"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialLiabilitiesAbstract_83b30cc6-afcb-4557-b59a-76cdc6b80dcd" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_d7b2c766-161a-43d6-b3e3-85a2146242e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_83b30cc6-afcb-4557-b59a-76cdc6b80dcd" xlink:to="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_d7b2c766-161a-43d6-b3e3-85a2146242e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/Leases" xlink:type="simple" xlink:href="bntx-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_2f3a0e29-3168-45b1-a902-08ef60a274b3" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_03da0fed-c317-4c92-9386-ecef77e4b8c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_2f3a0e29-3168-45b1-a902-08ef60a274b3" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_03da0fed-c317-4c92-9386-ecef77e4b8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_259b65f4-27a1-4fb3-8c70-886077acb4c7" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_4ce81ae4-068d-4932-a577-82e5d210a359" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_259b65f4-27a1-4fb3-8c70-886077acb4c7" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_4ce81ae4-068d-4932-a577-82e5d210a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EventsAftertheReportingPeriod" xlink:type="simple" xlink:href="bntx-20231231.xsd#EventsAftertheReportingPeriod"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/EventsAftertheReportingPeriod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EventsAfterReportingPeriodAbstract_8d377307-e7c0-405f-9fa1-03d800043d7d" xlink:href="bntx-20231231.xsd#bntx_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_8121bbf0-e3e2-46f5-b917-6a8302f0e810" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_EventsAfterReportingPeriodAbstract_8d377307-e7c0-405f-9fa1-03d800043d7d" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_8121bbf0-e3e2-46f5-b917-6a8302f0e810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_52b9575c-7317-4429-a49b-4376e5dcc499" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_52b9575c-7317-4429-a49b-4376e5dcc499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_56c5365e-5a80-4e9e-90d0-eb02163647c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_56c5365e-5a80-4e9e-90d0-eb02163647c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_36bb6c6c-edcb-4d81-9aa9-a5f246207139" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_36bb6c6c-edcb-4d81-9aa9-a5f246207139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_d235acf4-1462-4d76-8575-a6ea4aebc186" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_d235acf4-1462-4d76-8575-a6ea4aebc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock_ec337395-d350-4741-bddc-f9929a3a5038" xlink:href="bntx-20231231.xsd#bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock_ec337395-d350-4741-bddc-f9929a3a5038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_97c77bb4-8820-42e7-8675-920b914cb085" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_97c77bb4-8820-42e7-8675-920b914cb085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_048ac1e5-baf6-4567-84fe-4042f2d42bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_048ac1e5-baf6-4567-84fe-4042f2d42bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_e9d3be51-78a0-4014-99ce-617c0b6c095b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_e9d3be51-78a0-4014-99ce-617c0b6c095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_66305ec8-5e4a-44a1-a166-c424f848988c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_66305ec8-5e4a-44a1-a166-c424f848988c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_dc898711-1e67-4714-84ee-c319a818eab5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory_dc898711-1e67-4714-84ee-c319a818eab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_29e8f368-407e-4e62-81ac-43442d4208a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_29e8f368-407e-4e62-81ac-43442d4208a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_225e2aec-97b2-45e2-a475-51c9a55c4f09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_225e2aec-97b2-45e2-a475-51c9a55c4f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_64b3e02f-e457-449d-8cfb-3ec9760c789d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory_64b3e02f-e457-449d-8cfb-3ec9760c789d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_d30f0711-3a6c-45fd-a07c-1964c4b8d14b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_d30f0711-3a6c-45fd-a07c-1964c4b8d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_f6b46a10-51dd-48f7-92fd-32a3e3c2c412" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_f6b46a10-51dd-48f7-92fd-32a3e3c2c412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_a20557d1-01d3-4ed8-94a8-ce42c20d8fd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_a20557d1-01d3-4ed8-94a8-ce42c20d8fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_49f2309a-502f-4cb2-8fca-c4eeb006afbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_49f2309a-502f-4cb2-8fca-c4eeb006afbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_665e322b-b0a0-4873-9926-b88437fbccd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_665e322b-b0a0-4873-9926-b88437fbccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0168a02b-7f9d-49c7-9d66-93d8ab0a31b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_0168a02b-7f9d-49c7-9d66-93d8ab0a31b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_aaa7043a-e61c-49bd-bf0d-255779aefde1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_aaa7043a-e61c-49bd-bf0d-255779aefde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_d52e3d8d-722d-49f3-9498-e347f16593b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_d52e3d8d-722d-49f3-9498-e347f16593b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_1c5f99f7-554e-4c74-9b47-f19353bd2629" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory_1c5f99f7-554e-4c74-9b47-f19353bd2629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock_f03076d7-4c9f-4d39-bf71-7a5da2b4306d" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock_f03076d7-4c9f-4d39-bf71-7a5da2b4306d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock_e4745a20-cff5-468e-aa26-bf4b95d8cd86" xlink:href="bntx-20231231.xsd#bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_c5239bd2-fc1c-459d-b941-50a88a7601fc" xlink:to="loc_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock_e4745a20-cff5-468e-aa26-bf4b95d8cd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_a71f7c7f-50f9-4ceb-af0c-94e089ee2d10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_a71f7c7f-50f9-4ceb-af0c-94e089ee2d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_f7212f9e-af75-4162-ae3a-f19190a9b507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_f7212f9e-af75-4162-ae3a-f19190a9b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock_4a13034c-5d50-4872-82b7-3501dca7435d" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:to="loc_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock_4a13034c-5d50-4872-82b7-3501dca7435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_b0335bb2-f313-4dff-9185-6ab8e7a00992" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_b0335bb2-f313-4dff-9185-6ab8e7a00992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_f626a16f-fe8f-4f9f-8a9f-9227496d280d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_39df288c-acc5-4ad5-ac34-5b6bfd3b9f16" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_f626a16f-fe8f-4f9f-8a9f-9227496d280d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/GroupInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract_967832ea-6ff5-4982-9ebc-0478e8cc4189" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_249a2b71-6412-4bff-b312-c2100ef17fb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_967832ea-6ff5-4982-9ebc-0478e8cc4189" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_249a2b71-6412-4bff-b312-c2100ef17fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock_f59fd868-7c6a-467b-b225-f98ef406b5cb" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_967832ea-6ff5-4982-9ebc-0478e8cc4189" xlink:to="loc_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock_f59fd868-7c6a-467b-b225-f98ef406b5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock_a5c4bf2f-9b67-474a-88be-fbe30a1aabc7" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_967832ea-6ff5-4982-9ebc-0478e8cc4189" xlink:to="loc_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock_a5c4bf2f-9b67-474a-88be-fbe30a1aabc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BusinessCombinations1Abstract_aa2d5d8e-304f-4fa3-9481-8d5ea9d91b73" xlink:href="bntx-20231231.xsd#bntx_BusinessCombinations1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_a39967f8-6ded-4e2c-afb9-855f8d769477" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_BusinessCombinations1Abstract_aa2d5d8e-304f-4fa3-9481-8d5ea9d91b73" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_a39967f8-6ded-4e2c-afb9-855f8d769477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_288abc84-347f-48da-a525-beaa5af9630e" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_a7de2504-fbd1-4315-9965-76b1cc909da5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_288abc84-347f-48da-a525-beaa5af9630e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_a7de2504-fbd1-4315-9965-76b1cc909da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock_103db3b8-0518-4a13-baff-52bbc9c1e802" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_288abc84-347f-48da-a525-beaa5af9630e" xlink:to="loc_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock_103db3b8-0518-4a13-baff-52bbc9c1e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock_0d46126f-be69-4c34-b2ab-de61d1713f4b" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_288abc84-347f-48da-a525-beaa5af9630e" xlink:to="loc_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock_0d46126f-be69-4c34-b2ab-de61d1713f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsExplanatory_a8f6900f-9add-4f4e-af3a-a7cfe713cfbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_288abc84-347f-48da-a525-beaa5af9630e" xlink:to="loc_ifrs-full_DisclosureOfPerformanceObligationsExplanatory_a8f6900f-9add-4f4e-af3a-a7cfe713cfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock_cadf3219-29c6-412e-adbe-6fd2119b9790" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:to="loc_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock_cadf3219-29c6-412e-adbe-6fd2119b9790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock_42d5709f-9175-4f3a-9ca5-f49eaeb555df" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:to="loc_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock_42d5709f-9175-4f3a-9ca5-f49eaeb555df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock_db216145-2bf1-4d87-9dbf-9a081bb10c88" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:to="loc_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock_db216145-2bf1-4d87-9dbf-9a081bb10c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock_0f74d4e0-7226-48c9-9f8b-675b51fcd192" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:to="loc_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock_0f74d4e0-7226-48c9-9f8b-675b51fcd192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock_57f87b70-751a-4b0f-bf79-a5bd43f4ce2f" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5acadee6-b9e3-4b16-a359-e58d19f267d8" xlink:to="loc_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock_57f87b70-751a-4b0f-bf79-a5bd43f4ce2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_6cf9807e-6ae2-4751-a0b3-8f812c8ae23d" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock_90821f88-06ad-4fb7-8593-86ce0f56c809" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_6cf9807e-6ae2-4751-a0b3-8f812c8ae23d" xlink:to="loc_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock_90821f88-06ad-4fb7-8593-86ce0f56c809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock_443205d6-6bb4-4247-9eb7-0aa31669afa9" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_6cf9807e-6ae2-4751-a0b3-8f812c8ae23d" xlink:to="loc_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock_443205d6-6bb4-4247-9eb7-0aa31669afa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2cd3fd7d-40dd-410c-900f-7868a13ec8ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_6cf9807e-6ae2-4751-a0b3-8f812c8ae23d" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_2cd3fd7d-40dd-410c-900f-7868a13ec8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock_d7f9df05-673c-4c55-bac5-55f453f140ae" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_6cf9807e-6ae2-4751-a0b3-8f812c8ae23d" xlink:to="loc_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock_d7f9df05-673c-4c55-bac5-55f453f140ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EarningsperShareTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_1322ac3b-7a11-4478-a51a-95359618cf63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_e9a9b8b0-124d-4083-a8db-b0c62724d514" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_1322ac3b-7a11-4478-a51a-95359618cf63" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_e9a9b8b0-124d-4083-a8db-b0c62724d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_935e1722-58dc-4025-acba-8ca45637ea46" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_e0212ae9-e0bd-40c6-bbc7-a82662fe3c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_935e1722-58dc-4025-acba-8ca45637ea46" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_e0212ae9-e0bd-40c6-bbc7-a82662fe3c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock_496f1f8f-3c85-485b-a8b4-8e0e6fcda893" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_935e1722-58dc-4025-acba-8ca45637ea46" xlink:to="loc_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock_496f1f8f-3c85-485b-a8b4-8e0e6fcda893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_feb553ac-b226-478d-9740-7bd4d605040f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7bad6f22-4155-4b24-b71b-4a2357c67ec9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_feb553ac-b226-478d-9740-7bd4d605040f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7bad6f22-4155-4b24-b71b-4a2357c67ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_1264a96c-1ee8-4437-bc01-17f14f8dfd20" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock_1264a96c-1ee8-4437-bc01-17f14f8dfd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_5e01ab6c-99a9-4778-be40-a1ebbca88cbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_5e01ab6c-99a9-4778-be40-a1ebbca88cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_9975161f-436e-418e-87f8-23ceb6a61f5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_9975161f-436e-418e-87f8-23ceb6a61f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_149e08c2-6684-4a8b-baa2-dd7e4c422029" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_149e08c2-6684-4a8b-baa2-dd7e4c422029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_4b34155f-a248-45c8-852e-7828c7cb615a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_4b34155f-a248-45c8-852e-7828c7cb615a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_de3b3a20-469e-4102-b4dc-5a4956622021" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_de3b3a20-469e-4102-b4dc-5a4956622021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock_ad58ba11-1233-4f6a-acb2-e7b082630fb0" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock_ad58ba11-1233-4f6a-acb2-e7b082630fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock_3889c0c5-f15a-465c-ba7c-be3074d760df" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock_3889c0c5-f15a-465c-ba7c-be3074d760df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_1658de64-552c-4e81-9dbc-bfc380a6cbe0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_11c09f1a-c9ac-47ef-be5b-f66f84bb4eb2" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_1658de64-552c-4e81-9dbc-bfc380a6cbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/InventoriesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InventoriesAbstract_8b61dd13-ceea-4f13-bfb4-58d0700fe612" xlink:href="bntx-20231231.xsd#bntx_InventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock_fa79d608-0db3-4d36-9cdd-c674133edb30" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_8b61dd13-ceea-4f13-bfb4-58d0700fe612" xlink:to="loc_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock_fa79d608-0db3-4d36-9cdd-c674133edb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialAssetsAbstract_4d4defb5-6f17-4629-854d-861adc74d39e" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock_5705116b-7406-42d5-aefb-ed7056b93382" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_4d4defb5-6f17-4629-854d-861adc74d39e" xlink:to="loc_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock_5705116b-7406-42d5-aefb-ed7056b93382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReservesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReservesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReservesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_e4b87ca5-a8ba-4d42-85a8-d789cbe4854f" xlink:href="bntx-20231231.xsd#bntx_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock_5e7e9431-7325-40fb-a87e-f861aec59d5d" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_e4b87ca5-a8ba-4d42-85a8-d789cbe4854f" xlink:to="loc_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock_5e7e9431-7325-40fb-a87e-f861aec59d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_a9b68da7-55e2-4c56-9259-515ece5da613" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_a9b68da7-55e2-4c56-9259-515ece5da613" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fcfd316a-9e8a-4580-a383-c9c30ddf2982" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanMember_222d98fe-1675-4d84-b94b-1bd2294a7f62" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_EmployeeEquityPlanMember_222d98fe-1675-4d84-b94b-1bd2294a7f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_ea521ed9-573a-482a-ae75-8dadffc878b5" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_ManagementBoardGrantMember_ea521ed9-573a-482a-ae75-8dadffc878b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_7ef8c680-0117-4d20-a8f5-f8337dfd3a11" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_7ef8c680-0117-4d20-a8f5-f8337dfd3a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_09b71e0d-4888-486d-b4c4-2bca8ea8f958" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_674be0ef-1640-42ee-a77f-253e810e795a" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_09b71e0d-4888-486d-b4c4-2bca8ea8f958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c9966545-cfdf-4960-98a4-97c3c7e6a46e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_3d47f66a-9e2e-4c24-84e9-dbad5b8a9832" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss_3d47f66a-9e2e-4c24-84e9-dbad5b8a9832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c05f801e-7638-4d96-8e1e-412d0d85c002" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c05f801e-7638-4d96-8e1e-412d0d85c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2c941d71-d657-4bca-8c22-1d9856b1c480" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_2c941d71-d657-4bca-8c22-1d9856b1c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_3d64a982-41ea-4116-a6ff-2507bf1680c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_27498fab-45a0-4d45-a63e-17bfd50ab020" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_3d64a982-41ea-4116-a6ff-2507bf1680c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ProvisionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_d218cf46-d86c-4478-82cb-bce3c24dc8dc" xlink:href="bntx-20231231.xsd#bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfProvisionsTableTextBlock_f465b43a-31d0-4b19-9459-f8a157dd016f" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfProvisionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_d218cf46-d86c-4478-82cb-bce3c24dc8dc" xlink:to="loc_bntx_DisclosureOfProvisionsTableTextBlock_f465b43a-31d0-4b19-9459-f8a157dd016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#ContingenciesandotherfinancialcommitmentsTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_051e5cf9-690f-4492-804c-2e6b4e99c4b4" xlink:href="bntx-20231231.xsd#bntx_ContingenciesAndOtherFinancialCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_d8f6b60c-4d3e-4140-b17f-d251baa3741e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_051e5cf9-690f-4492-804c-2e6b4e99c4b4" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsExplanatory_d8f6b60c-4d3e-4140-b17f-d251baa3741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialLiabilitiesAbstract_b7c6e234-0745-4c27-bf6b-84ade56d7f43" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock_9f72bf13-c737-46d7-a803-06041f38f7d9" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_b7c6e234-0745-4c27-bf6b-84ade56d7f43" xlink:to="loc_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock_9f72bf13-c737-46d7-a803-06041f38f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_d30d8fc4-59f5-4a83-a78b-f525d3537160" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_305282e0-b476-4cda-86c1-66c4ea4dd5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_d30d8fc4-59f5-4a83-a78b-f525d3537160" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_305282e0-b476-4cda-86c1-66c4ea4dd5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_0d39a04c-3559-4c40-96bb-07097fc738d0" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_d30d8fc4-59f5-4a83-a78b-f525d3537160" xlink:to="loc_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock_0d39a04c-3559-4c40-96bb-07097fc738d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock_10e7017b-ce9c-4db4-b573-0bad47de656a" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_d30d8fc4-59f5-4a83-a78b-f525d3537160" xlink:to="loc_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock_10e7017b-ce9c-4db4-b573-0bad47de656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresTables" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_7f402e98-2df0-40ee-8bd6-19fe68a3877b" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_efc62061-aa3d-4c0c-838e-f607d8d26fc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_7f402e98-2df0-40ee-8bd6-19fe68a3877b" xlink:to="loc_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_efc62061-aa3d-4c0c-838e-f607d8d26fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_57d9b6c3-03c2-4ce0-9ca5-d6e720466d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_7f402e98-2df0-40ee-8bd6-19fe68a3877b" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_57d9b6c3-03c2-4ce0-9ca5-d6e720466d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_25df281f-31f8-4373-9f21-1107274e6a69" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_25df281f-31f8-4373-9f21-1107274e6a69" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_dc1fb471-0b75-46c8-98d1-72aec1950b8a" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OperatingAndBusinessEquipmentMember_16b9fb94-9e7d-400f-95e5-ddc8ecc1638e" xlink:href="bntx-20231231.xsd#bntx_OperatingAndBusinessEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_73336e5e-e87a-4e24-91fe-5f9baa4aa43a" xlink:to="loc_bntx_OperatingAndBusinessEquipmentMember_16b9fb94-9e7d-400f-95e5-ddc8ecc1638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:to="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_a31a081a-83c0-4fd6-8139-8315f59fe471" xlink:to="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e2f4555b-5842-410a-9bc6-693f6c6b8ff5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:to="loc_ifrs-full_BottomOfRangeMember_e2f4555b-5842-410a-9bc6-693f6c6b8ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_2020b107-329a-4cdb-b3ff-a7b4b2677f2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_9f832d98-4790-4073-92e5-c42e2670558a" xlink:to="loc_ifrs-full_TopOfRangeMember_2020b107-329a-4cdb-b3ff-a7b4b2677f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_2e8f7f1b-c61e-40a3-847a-274bb7d314ad" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_683ee720-67c9-437f-b2e5-e306f3691191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers_683ee720-67c9-437f-b2e5-e306f3691191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_ed69cf2d-7ea8-4026-83b8-66c9cd7ec228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_TaxRateEffectFromChangeInTaxRate_ed69cf2d-7ea8-4026-83b8-66c9cd7ec228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_af57c4cc-18c7-42ae-8b42-9f72ead05e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_665fd1a7-eea8-4a64-89a2-10839d2b0b29" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_af57c4cc-18c7-42ae-8b42-9f72ead05e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_52b2a03e-6db8-4301-a361-9be1538d2217" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_52b2a03e-6db8-4301-a361-9be1538d2217" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_a16b3aed-1065-4410-887e-4320f0e4cdde" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntellectualPropertyRightsMember_03ce48c8-e94e-4d15-b0da-02a535dbae68" xlink:href="bntx-20231231.xsd#bntx_IntellectualPropertyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_bntx_IntellectualPropertyRightsMember_03ce48c8-e94e-4d15-b0da-02a535dbae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_8782cac5-4dee-482e-b70f-fa0b096f2aea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_ifrs-full_LicencesMember_8782cac5-4dee-482e-b70f-fa0b096f2aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_53df2f55-26dd-49f9-b12a-7c89541b3545" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_2339b8fb-41df-446c-ae63-464356507096" xlink:to="loc_ifrs-full_ComputerSoftwareMember_53df2f55-26dd-49f9-b12a-7c89541b3545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:to="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_a4389651-b5d5-4c3f-8927-56972cee7cd3" xlink:to="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_c2555de1-4bd3-4752-8ba9-961b04a4092c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:to="loc_ifrs-full_BottomOfRangeMember_c2555de1-4bd3-4752-8ba9-961b04a4092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_5d995be5-3f12-4524-ab15-6f12279fbd62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_742d6acb-ef7d-4209-a331-14575dad3aa7" xlink:to="loc_ifrs-full_TopOfRangeMember_5d995be5-3f12-4524-ab15-6f12279fbd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_d62ced39-e031-434d-bcce-19dd905e2e9a" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_fea23f77-432a-4890-a84f-d6a2ca1ab4b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_7481c909-51ec-4ca5-86f0-025e70ea76b7" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_fea23f77-432a-4890-a84f-d6a2ca1ab4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_e7f1fa0f-d8b8-408a-8f94-04a6dad7640f" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_e7f1fa0f-d8b8-408a-8f94-04a6dad7640f" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5faa75d8-239a-4d5a-9168-433b2cd915ff" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_fc38ac56-71fb-4d2f-847c-4b901b25f255" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:to="loc_ifrs-full_BuildingsMember_fc38ac56-71fb-4d2f-847c-4b901b25f255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_059a7eaf-26fc-4835-aafd-07ea59ff5bc3" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_4cfc1128-396b-4537-86db-5bb1f495909c" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_059a7eaf-26fc-4835-aafd-07ea59ff5bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:to="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_5dc024e9-2ea2-4e53-b63d-eceb7b8fc74d" xlink:to="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_085844b1-6b31-4642-a7e4-35fa61d3714c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:to="loc_ifrs-full_BottomOfRangeMember_085844b1-6b31-4642-a7e4-35fa61d3714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_7b3044b6-b0e7-442d-9e82-c31baeb6a89e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_157be573-eaf5-4e3d-996d-120ac0334ca5" xlink:to="loc_ifrs-full_TopOfRangeMember_7b3044b6-b0e7-442d-9e82-c31baeb6a89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_3197aa96-aa03-4ce7-b5d4-9af2de0ff2d3" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_7c07e51c-d7db-4749-b906-f24450652d59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f9760ca0-fd4c-4e89-bc0e-b126e957905f" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_7c07e51c-d7db-4749-b906-f24450652d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListOfAccountingPoliciesAbstract_2ed7088e-d31f-475f-9506-9d8f6786a751" xlink:href="bntx-20231231.xsd#bntx_ListOfAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ListOfAccountingPoliciesAbstract_2ed7088e-d31f-475f-9506-9d8f6786a751" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_cd5955c0-f7d2-44b6-b1ed-1b5c2ac1a589" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_b4cdb0d8-65ee-48c1-954c-8a304c65a559" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_ifrs-full_BuildingsMember_b4cdb0d8-65ee-48c1-954c-8a304c65a559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_38242689-c666-4d33-89d6-309a8c582229" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_38242689-c666-4d33-89d6-309a8c582229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_4e17f9d4-fbc2-46f9-9eaf-f0173d39d3e0" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_bntx_ProductionFacilitiesMember_4e17f9d4-fbc2-46f9-9eaf-f0173d39d3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_72b5ea8a-00ea-4a29-bc03-e881502bf6a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_26eb67ef-34c7-44fd-803b-d465c8589f9e" xlink:to="loc_ifrs-full_VehiclesMember_72b5ea8a-00ea-4a29-bc03-e881502bf6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:to="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_f24d23a3-dd22-4bc0-91b1-6589385bf6b0" xlink:to="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_67416008-7ed0-4480-a7dc-bd7f4338a26e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:to="loc_ifrs-full_BottomOfRangeMember_67416008-7ed0-4480-a7dc-bd7f4338a26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_68f86ceb-fe96-4d8f-a91e-4a91994ea868" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_a6d64440-3244-484c-9a5a-9f2ccd9a234c" xlink:to="loc_ifrs-full_TopOfRangeMember_68f86ceb-fe96-4d8f-a91e-4a91994ea868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_1120760f-2078-41ea-8418-a8828b54df94" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_9f748a6f-210e-4506-a069-37b88c985298" xlink:href="bntx-20231231.xsd#bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_21eb28e1-6a05-483e-8767-468fdb176ac2" xlink:to="loc_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets_9f748a6f-210e-4506-a069-37b88c985298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_6a909c20-0a4d-47d8-b8a8-a7ad01617cdf" xlink:href="bntx-20231231.xsd#bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_daedbb88-66b6-48da-aa42-4553c663c2be" xlink:href="bntx-20231231.xsd#bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_6a909c20-0a4d-47d8-b8a8-a7ad01617cdf" xlink:to="loc_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception_daedbb88-66b6-48da-aa42-4553c663c2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutSubsidiariesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract_80c34a91-a204-413c-ba2f-99dbda781058" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_80c34a91-a204-413c-ba2f-99dbda781058" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_5bee3310-91dc-489d-b2ea-c238463dc6f5" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechBioNTainerHoldingGmbHMember_24b41b47-bc3e-438d-87e0-04aa53e3c61a" xlink:href="bntx-20231231.xsd#bntx_BioNTechBioNTainerHoldingGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechBioNTainerHoldingGmbHMember_24b41b47-bc3e-438d-87e0-04aa53e3c61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechCellGeneTherapiesGmbHMember_9f6eddb8-0044-4768-ad37-4eca8cd17654" xlink:href="bntx-20231231.xsd#bntx_BioNTechCellGeneTherapiesGmbHMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechCellGeneTherapiesGmbHMember_9f6eddb8-0044-4768-ad37-4eca8cd17654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember_548f4443-821c-4cc4-a9d9-911c851b9d01" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesGmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDeliveryTechnologiesGmbHMember_548f4443-821c-4cc4-a9d9-911c851b9d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDiagnosticsGmbHMember_ca91ea21-4cee-4c46-8a8d-5eca25b05969" xlink:href="bntx-20231231.xsd#bntx_BioNTechDiagnosticsGmbHMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDiagnosticsGmbHMember_ca91ea21-4cee-4c46-8a8d-5eca25b05969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEuropeGmbHMember_5b1bc2db-eabe-409b-b2b0-3619c675d7bc" xlink:href="bntx-20231231.xsd#bntx_BioNTechEuropeGmbHMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechEuropeGmbHMember_5b1bc2db-eabe-409b-b2b0-3619c675d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIdarObersteinServicesGmbHMember_a3f34aa6-5dab-4f60-9468-cdaef46dbf10" xlink:href="bntx-20231231.xsd#bntx_BioNTechIdarObersteinServicesGmbHMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechIdarObersteinServicesGmbHMember_a3f34aa6-5dab-4f60-9468-cdaef46dbf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_5f457845-a54d-4a0c-98f2-e232e1e595d2" xlink:href="bntx-20231231.xsd#bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember_5f457845-a54d-4a0c-98f2-e232e1e595d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_32838915-28da-45f2-9192-c9f2148ea101" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationAndServicesMarburgGmbHMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovationAndServicesMarburgGmbHMember_32838915-28da-45f2-9192-c9f2148ea101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovationGmbHMember_0201b697-c620-491c-87eb-00572f05b95d" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovationGmbHMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovationGmbHMember_0201b697-c620-491c-87eb-00572f05b95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_7c9ef032-47b7-40db-800b-ad41ebe83ad2" xlink:href="bntx-20231231.xsd#bntx_BioNTechInnovativeManufacturingServicesGmbHMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechInnovativeManufacturingServicesGmbHMember_7c9ef032-47b7-40db-800b-ad41ebe83ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingGmbHMember_a53a6ab0-8542-4ab3-821c-69fab1428b1a" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingGmbHMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechManufacturingGmbHMember_a53a6ab0-8542-4ab3-821c-69fab1428b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechManufacturingMarburgGmbHMember_342e1955-10ea-4a1e-84fd-9f2d1c0c9cb9" xlink:href="bntx-20231231.xsd#bntx_BioNTechManufacturingMarburgGmbHMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechManufacturingMarburgGmbHMember_342e1955-10ea-4a1e-84fd-9f2d1c0c9cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateHoldingGmbHMember_129267fb-3de3-4b54-834f-e764ce9f08d6" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateHoldingGmbHMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRealEstateHoldingGmbHMember_129267fb-3de3-4b54-834f-e764ce9f08d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember_d72015a7-deb4-41c0-8dce-ccf3f52f9380" xlink:href="bntx-20231231.xsd#bntx_BioNTechRealEstateVerwaltungsGmbHMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRealEstateVerwaltungsGmbHMember_d72015a7-deb4-41c0-8dce-ccf3f52f9380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepDEGmbHMember_8b79f707-125c-42a9-a45d-cb2bb989bae4" xlink:href="bntx-20231231.xsd#bntx_InstaDeepDEGmbHMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepDEGmbHMember_8b79f707-125c-42a9-a45d-cb2bb989bae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesGmbHMember_2ec47add-3a8e-4d59-b72b-92d791616914" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesGmbHMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_JPTPeptideTechnologiesGmbHMember_2ec47add-3a8e-4d59-b72b-92d791616914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NTSecurityAndServicesGmbHMember_718438d4-259b-4891-a3a7-ea5158178487" xlink:href="bntx-20231231.xsd#bntx_NTSecurityAndServicesGmbHMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_NTSecurityAndServicesGmbHMember_718438d4-259b-4891-a3a7-ea5158178487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReSanoGmbHMember_77dbca6f-04c2-41c2-b4e9-d706de367414" xlink:href="bntx-20231231.xsd#bntx_ReSanoGmbHMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_ReSanoGmbHMember_77dbca6f-04c2-41c2-b4e9-d706de367414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechAustraliaPtyLtd.Member_e0dd6ff7-c3f7-418d-9ad6-4a51c865ce38" xlink:href="bntx-20231231.xsd#bntx_BioNTechAustraliaPtyLtd.Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechAustraliaPtyLtd.Member_e0dd6ff7-c3f7-418d-9ad6-4a51c865ce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRDAustriaGmbHMember_23eb24e5-df4e-4b1b-bbae-f45f7e648369" xlink:href="bntx-20231231.xsd#bntx_BioNTechRDAustriaGmbHMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRDAustriaGmbHMember_23eb24e5-df4e-4b1b-bbae-f45f7e648369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_0838ae0b-1ac8-4706-945a-594065722ee9" xlink:href="bntx-20231231.xsd#bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member_0838ae0b-1ac8-4706-945a-594065722ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepFranceSASMember_105b480f-5536-4ec7-9931-4974a7969391" xlink:href="bntx-20231231.xsd#bntx_InstaDeepFranceSASMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepFranceSASMember_105b480f-5536-4ec7-9931-4974a7969391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiopharmaBioNTechIsraelLtd.Member_f5a123fd-0ad9-4cbf-be39-883be51f2236" xlink:href="bntx-20231231.xsd#bntx_BiopharmaBioNTechIsraelLtd.Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BiopharmaBioNTechIsraelLtd.Member_f5a123fd-0ad9-4cbf-be39-883be51f2236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NewTechnologiesReMember_60e71280-3adc-4913-8d80-955737bf4f7f" xlink:href="bntx-20231231.xsd#bntx_NewTechnologiesReMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_NewTechnologiesReMember_60e71280-3adc-4913-8d80-955737bf4f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepNigeriaLimitedMember_5bd5fc56-05a5-4149-acbf-dcfc4a60d5c0" xlink:href="bntx-20231231.xsd#bntx_InstaDeepNigeriaLimitedMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepNigeriaLimitedMember_5bd5fc56-05a5-4149-acbf-dcfc4a60d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechRwandaLtd.Member_4cd34503-fe14-4752-850b-2ec4d01cf20e" xlink:href="bntx-20231231.xsd#bntx_BioNTechRwandaLtd.Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechRwandaLtd.Member_4cd34503-fe14-4752-850b-2ec4d01cf20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSenegalSuarlMember_0f4f0e8a-49fa-4ace-8f6f-b28d740f3c30" xlink:href="bntx-20231231.xsd#bntx_BioNTechSenegalSuarlMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechSenegalSuarlMember_0f4f0e8a-49fa-4ace-8f6f-b28d740f3c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_6d1f10c9-50f8-4125-b649-410ae3efe05b" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member_6d1f10c9-50f8-4125-b649-410ae3efe05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember_9dfc6b34-9266-4923-9ae7-e9bcbbdfc0b3" xlink:href="bntx-20231231.xsd#bntx_BioNTechPharmaceuticalsSpainS.LMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechPharmaceuticalsSpainS.LMember_9dfc6b34-9266-4923-9ae7-e9bcbbdfc0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechSwitzerlandGmbHMember_b9b7401e-2519-435b-9381-2364551a549e" xlink:href="bntx-20231231.xsd#bntx_BioNTechSwitzerlandGmbHMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechSwitzerlandGmbHMember_b9b7401e-2519-435b-9381-2364551a549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTaiwanCo.Ltd.Member_f8f6a074-d6ba-49d7-aaac-fca3c6ea9ace" xlink:href="bntx-20231231.xsd#bntx_BioNTechTaiwanCo.Ltd.Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechTaiwanCo.Ltd.Member_f8f6a074-d6ba-49d7-aaac-fca3c6ea9ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepTunisiaSARLMember_78d1bd93-087b-4d3b-b00b-0f3547f0b626" xlink:href="bntx-20231231.xsd#bntx_InstaDeepTunisiaSARLMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepTunisiaSARLMember_78d1bd93-087b-4d3b-b00b-0f3547f0b626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_b06ce18e-e477-4d9c-a83a-432a10ddc55c" xlink:href="bntx-20231231.xsd#bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember_b06ce18e-e477-4d9c-a83a-432a10ddc55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUKLtd.Member_2998e566-7c23-4247-892b-524695860e42" xlink:href="bntx-20231231.xsd#bntx_BioNTechUKLtd.Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUKLtd.Member_2998e566-7c23-4247-892b-524695860e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtd.Member_b006bc7a-4e7f-4eee-b59f-e3e65b8a3e31" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtd.Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepLtd.Member_b006bc7a-4e7f-4eee-b59f-e3e65b8a3e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechResearchAndDevelopmentInc.Member_8bb93fd8-1333-46a2-8b23-d6faa3996856" xlink:href="bntx-20231231.xsd#bntx_BioNTechResearchAndDevelopmentInc.Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechResearchAndDevelopmentInc.Member_8bb93fd8-1333-46a2-8b23-d6faa3996856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSAHoldingLLCMember_3a858f44-6ddd-4ebd-8f0b-9b455a44a138" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSAHoldingLLCMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUSAHoldingLLCMember_3a858f44-6ddd-4ebd-8f0b-9b455a44a138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechUSInc.Member_5fe1fa50-c571-4495-b554-c1ce4a4fea19" xlink:href="bntx-20231231.xsd#bntx_BioNTechUSInc.Member"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechUSInc.Member_5fe1fa50-c571-4495-b554-c1ce4a4fea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember_c55a093b-9e5e-4946-b5d0-a8c81f433ca6" xlink:href="bntx-20231231.xsd#bntx_BioNTechDeliveryTechnologiesUSLLCMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_BioNTechDeliveryTechnologiesUSLLCMember_c55a093b-9e5e-4946-b5d0-a8c81f433ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLLCMember_83431bb7-468d-4583-8ef8-8347039fd1ba" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLLCMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_InstaDeepLLCMember_83431bb7-468d-4583-8ef8-8347039fd1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JPTPeptideTechnologiesInc.Member_c91651c9-e1f9-4320-b287-22b0f5fbc6bb" xlink:href="bntx-20231231.xsd#bntx_JPTPeptideTechnologiesInc.Member"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_73abfcd0-f01c-44a1-8154-3ff438baecfb" xlink:to="loc_bntx_JPTPeptideTechnologiesInc.Member_c91651c9-e1f9-4320-b287-22b0f5fbc6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_91a4befb-1f78-4ad2-8e0e-818b71ff4ba6" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_a8a8fbbe-3dfd-4f28-b414-bd5f828ec8e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_1842303b-1abc-4223-bc39-969051e09a49" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_a8a8fbbe-3dfd-4f28-b414-bd5f828ec8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutParentCompanyDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract_be093c63-fd4d-45e6-9120-8b7727c8cd22" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_be093c63-fd4d-45e6-9120-8b7727c8cd22" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:to="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_455c209e-fd35-4aaa-9d7c-abcf9c18ab7c" xlink:to="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechMember_838c5f1e-e1c0-4ea4-8463-c05dd63a96fe" xlink:href="bntx-20231231.xsd#bntx_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_53e2757d-1f63-4d56-b58d-11c22eef79ce" xlink:to="loc_bntx_BioNTechMember_838c5f1e-e1c0-4ea4-8463-c05dd63a96fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_123fa3c2-2bc0-4d0a-b3dd-0188a4717e12" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATImpfGmbHMember_3a34bc3f-9216-423e-964f-85f31dec399e" xlink:href="bntx-20231231.xsd#bntx_ATImpfGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_1d61abb1-6145-43af-95d5-d5932055283e" xlink:to="loc_bntx_ATImpfGmbHMember_3a34bc3f-9216-423e-964f-85f31dec399e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_b2c940c9-792b-4c71-bdaf-9b783810f0ae" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_59cac306-71e6-4126-8650-55d53ff9f05b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_839e012b-0c22-4cba-849a-384ea11b419f" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_59cac306-71e6-4126-8650-55d53ff9f05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestsInOtherEntitiesAbstract_18528927-326e-4da5-b13a-95671b8d5f5c" xlink:href="bntx-20231231.xsd#bntx_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InterestsInOtherEntitiesAbstract_18528927-326e-4da5-b13a-95671b8d5f5c" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:to="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3802c116-e11c-4d09-950c-b3031ca1db66" xlink:to="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechMember_f2e287bf-613b-4741-9b03-5867c70c0a02" xlink:href="bntx-20231231.xsd#bntx_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7be8b7ce-f045-44d1-9554-fd402e0cc87b" xlink:to="loc_bntx_BioNTechMember_f2e287bf-613b-4741-9b03-5867c70c0a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_957e7417-9e93-4cd6-bd81-fbf777947000" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedineGmbHMember_b43439fd-80ad-463d-81f1-b0200e2c8d93" xlink:href="bntx-20231231.xsd#bntx_MedineGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_8867de9c-512e-4aaf-af3e-08f520f03e91" xlink:to="loc_bntx_MedineGmbHMember_b43439fd-80ad-463d-81f1-b0200e2c8d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_dfe8d640-57ed-470e-91ae-4d8accc815b9" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_0ec62471-a296-499d-b7f1-6f0f001d995e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_257775c1-fe5a-48fc-b5ca-85f1c625c1cc" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_0ec62471-a296-499d-b7f1-6f0f001d995e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BusinessCombinations1Abstract_93efae16-6d24-474a-8501-a0dcedc2ad4d" xlink:href="bntx-20231231.xsd#bntx_BusinessCombinations1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_BusinessCombinations1Abstract_93efae16-6d24-474a-8501-a0dcedc2ad4d" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_8c1e7a49-5506-4f53-8df6-9c0f31bd2184" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtdMember_f38f013c-d238-4961-bc4e-020d7dbc3d96" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8468313f-ccc7-48b3-af57-a1574a88dd2e" xlink:to="loc_bntx_InstaDeepLtdMember_f38f013c-d238-4961-bc4e-020d7dbc3d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_4122f6ba-62ae-413c-a37e-4e269d5a5ba2" xlink:to="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d5d6c8ae-fdcd-4a90-8eb2-32e30d4bc705" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_245aee07-3758-42e8-bb7b-84257c38bce1" xlink:to="loc_srt_MaximumMember_d5d6c8ae-fdcd-4a90-8eb2-32e30d4bc705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_fa0ea6b4-068f-4927-a9ea-8cba5aeafb0c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MultiperiodExcessEarningsMethodMember_b1785a1f-03ea-4583-8c7b-60abd55703a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MultiperiodExcessEarningsMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesMember_981951a0-bf6a-4b40-bb78-3d75573dc8c0" xlink:to="loc_ifrs-full_MultiperiodExcessEarningsMethodMember_b1785a1f-03ea-4583-8c7b-60abd55703a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_3b8c289f-b67c-4047-80cd-cd9fe3ab27b0" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_d3c64262-2e4c-47d6-866b-3e1f7c979db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_d3c64262-2e4c-47d6-866b-3e1f7c979db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_05ac4f11-df2c-409a-afd7-199a52ade7c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate_05ac4f11-df2c-409a-afd7-199a52ade7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_dab25fea-33c5-47a9-b119-c3e8552cb9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate_dab25fea-33c5-47a9-b119-c3e8552cb9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_bd145f8b-76a9-4e5e-9331-465e62ebe4b1" xlink:href="bntx-20231231.xsd#bntx_EquityMethodInvestmentsOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_bd145f8b-76a9-4e5e-9331-465e62ebe4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares_bdd73602-1a99-4f6d-b514-bfa428223288" xlink:href="bntx-20231231.xsd#bntx_PercentageOfConsiderationTransferredAcquiredShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_PercentageOfConsiderationTransferredAcquiredShares_bdd73602-1a99-4f6d-b514-bfa428223288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment_46895f61-8a54-45f6-b998-7aec16573665" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_PreviouslyHeldNonListedEquityInvestment_46895f61-8a54-45f6-b998-7aec16573665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_64cc01e5-c2c8-47fc-a1d4-4c2a38e93883" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_64cc01e5-c2c8-47fc-a1d4-4c2a38e93883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_c902e443-4ffb-4414-93dd-313c50828c94" xlink:href="bntx-20231231.xsd#bntx_ConsideredRemunerationOfPotentialEarnOutPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_bntx_ConsideredRemunerationOfPotentialEarnOutPayments_c902e443-4ffb-4414-93dd-313c50828c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_e99046ab-4dd3-4e9a-942f-62133c3809ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination_e99046ab-4dd3-4e9a-942f-62133c3809ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_834a2fc7-0b5b-4576-863f-734a5acdcc28" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_45e073a5-872c-49cd-9820-69747ed2896b" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_834a2fc7-0b5b-4576-863f-734a5acdcc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BusinessCombinations1Abstract_0366e9df-9239-493f-aa6d-c8a97bbde81a" xlink:href="bntx-20231231.xsd#bntx_BusinessCombinations1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_BusinessCombinations1Abstract_0366e9df-9239-493f-aa6d-c8a97bbde81a" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_2b6cf9b8-5c6e-4fb6-9a17-ce27c76d6f04" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepLtdMember_d578d85b-7122-4c8d-b4d6-aaaf468af1f7" xlink:href="bntx-20231231.xsd#bntx_InstaDeepLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_8b3bc2f5-d8b6-4418-9aad-2b7f39610c48" xlink:to="loc_bntx_InstaDeepLtdMember_d578d85b-7122-4c8d-b4d6-aaaf468af1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ba6097ee-eb8d-4fed-9940-061d206fa4a6" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_b42b6f23-e947-4c05-8e79-61f58184ce70" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_b42b6f23-e947-4c05-8e79-61f58184ce70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_4f1cb06e-b6ae-4c52-bc2f-9d963a8c01bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_4f1cb06e-b6ae-4c52-bc2f-9d963a8c01bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_6ae8aeac-fd6f-4c0d-9ac9-f59c5cb115ef" xlink:href="bntx-20231231.xsd#bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate_6ae8aeac-fd6f-4c0d-9ac9-f59c5cb115ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_d5082f91-e0a8-4206-88b8-966e95bdd000" xlink:href="bntx-20231231.xsd#bntx_TradeReceivablesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate_d5082f91-e0a8-4206-88b8-966e95bdd000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_179ed190-1629-4c1b-9c67-4b9dc1829245" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate_179ed190-1629-4c1b-9c67-4b9dc1829245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_a8fcc34b-3935-4019-95e2-dcb56f883df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_a8fcc34b-3935-4019-95e2-dcb56f883df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_72acecbd-55be-4f9d-bcab-2f6fd022b980" xlink:href="bntx-20231231.xsd#bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate_72acecbd-55be-4f9d-bcab-2f6fd022b980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_1aa29a1a-fc4d-4610-8b52-a507934aaaab" xlink:href="bntx-20231231.xsd#bntx_AssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract_b23fe7b2-a0a1-4f1b-92a2-052d5d7f9a63" xlink:to="loc_bntx_AssetsRecognisedAsOfAcquisitionDate_1aa29a1a-fc4d-4610-8b52-a507934aaaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_00e7b499-9aa1-48f1-b37b-95c92bcb7f6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_00e7b499-9aa1-48f1-b37b-95c92bcb7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_817cdf75-aa58-4d16-be79-a3bc5a19985e" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate_817cdf75-aa58-4d16-be79-a3bc5a19985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_1b7a80e5-aef9-42c8-a043-96f1e3ca6d27" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_dbc3c589-3076-4e1d-b2df-4648076471bd" xlink:to="loc_bntx_LiabilitiesRecognisedAsOfAcquisitionDate_1b7a80e5-aef9-42c8-a043-96f1e3ca6d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_8c4ef723-1f16-4805-bad2-3ea53bb62d48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_8c4ef723-1f16-4805-bad2-3ea53bb62d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_fcb89924-ad82-4445-aba4-d048d47c325d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_fcb89924-ad82-4445-aba4-d048d47c325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_a00e232d-7682-474d-b5c9-bfc6971f972d" xlink:href="bntx-20231231.xsd#bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill_a00e232d-7682-474d-b5c9-bfc6971f972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashTransferred_919dad76-8c3f-4eda-8886-184ee7d66c61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_CashTransferred_919dad76-8c3f-4eda-8886-184ee7d66c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesIncurred_c4bf0f36-c0ab-4e65-ad8d-040e90dec9e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_LiabilitiesIncurred_c4bf0f36-c0ab-4e65-ad8d-040e90dec9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DesignatedFXHedge_8759cf2d-6a6c-4f1f-9d17-49e53077ee9e" xlink:href="bntx-20231231.xsd#bntx_DesignatedFXHedge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_bntx_DesignatedFXHedge_8759cf2d-6a6c-4f1f-9d17-49e53077ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityInterestsOfAcquirer_fd899f3a-cb33-4726-841f-6a4aa86853dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityInterestsOfAcquirer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_EquityInterestsOfAcquirer_fd899f3a-cb33-4726-841f-6a4aa86853dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_82b52491-6045-4ef4-a594-a32f524ae639" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate_82b52491-6045-4ef4-a594-a32f524ae639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PreviouslyHeldNonListedEquityInvestment_31850498-524d-4f81-8b7c-9044d1fa55af" xlink:href="bntx-20231231.xsd#bntx_PreviouslyHeldNonListedEquityInvestment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_0d3294dd-f16f-4798-adb0-82f9146e6a34" xlink:to="loc_bntx_PreviouslyHeldNonListedEquityInvestment_31850498-524d-4f81-8b7c-9044d1fa55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_f870e796-8046-4111-a0ce-75cbefa7a477" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_f870e796-8046-4111-a0ce-75cbefa7a477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1c677034-072e-4661-b6fa-96025dc309bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_1c677034-072e-4661-b6fa-96025dc309bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_dddfb631-aa7d-4725-8a0c-eabac5c8722c" xlink:href="bntx-20231231.xsd#bntx_EquityMethodInvestmentsOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_e3e17761-df0f-4f08-b762-737ef71c8194" xlink:to="loc_bntx_EquityMethodInvestmentsOwnershipPercentage_dddfb631-aa7d-4725-8a0c-eabac5c8722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_0f1d0cc1-865b-4e4e-8c1f-7fe4b2ebf24e" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_0f1d0cc1-865b-4e4e-8c1f-7fe4b2ebf24e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d3707326-1b1f-44ce-9810-d256deab10ca" xlink:to="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_f6f58210-417d-41ff-a146-c457e860f809" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:to="loc_bntx_CommercialMember_f6f58210-417d-41ff-a146-c457e860f809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentMember_38d4fc1c-f26d-468f-bb5e-1c7ce373677c" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91ebe50f-6a0e-4589-a768-474894edcde5" xlink:to="loc_bntx_ResearchAndDevelopmentMember_38d4fc1c-f26d-468f-bb5e-1c7ce373677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_2c2eeccb-938c-4211-8aff-9803f07a612f" xlink:to="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:to="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_63fdfbfd-0742-4f61-b536-92800002cf12" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineSalesToCollaborationPartnersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_63fdfbfd-0742-4f61-b536-92800002cf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_ab1fe550-f44d-4513-a374-5584e924be5b" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineDirectProductSalesToCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_ab1fe550-f44d-4513-a374-5584e924be5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_93ffcb20-635e-4762-8c2e-baadad93b62f" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_COVID19VaccineRevenuesMember_66e4daaf-1f90-4e0d-8680-741d508ea538" xlink:to="loc_bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember_93ffcb20-635e-4762-8c2e-baadad93b62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherSalesMember_89e4b40b-8407-4630-b9c4-3cb15cfdea92" xlink:href="bntx-20231231.xsd#bntx_OtherSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_6776d5a5-32aa-4b69-9e1c-bb1b3268fb23" xlink:to="loc_bntx_OtherSalesMember_89e4b40b-8407-4630-b9c4-3cb15cfdea92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_74f7f991-5a61-40d2-b40f-174548ecb5ce" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_6482eb08-8454-4b30-a0a1-06e1eb0bac35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_6482eb08-8454-4b30-a0a1-06e1eb0bac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_c2a0b951-baf6-40b3-814d-83d4e7559915" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_c2a0b951-baf6-40b3-814d-83d4e7559915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_d7b05769-b29d-49a9-9bb2-4cb334b394d9" xlink:href="bntx-20231231.xsd#bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesMember_da6cf8fc-575c-4f32-a0b4-0853efca3d96" xlink:to="loc_bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember_d7b05769-b29d-49a9-9bb2-4cb334b394d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_3983fd58-18a5-4a1c-9f60-2513eee3bdfc" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_29617cdd-8a19-4505-93e3-e8fa14d72428" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_6def8d2f-2d6a-466e-8c73-859d4b50d08b" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_29617cdd-8a19-4505-93e3-e8fa14d72428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_6a346416-f395-42c1-b19f-30f644fb5f19" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_6a346416-f395-42c1-b19f-30f644fb5f19" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_c933ac67-7522-45ec-8233-19895be3dc2d" xlink:to="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerIncMember_afe5a9b8-4ac4-4873-8d40-6fce67a09e7d" xlink:href="bntx-20231231.xsd#bntx_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerIncMember_afe5a9b8-4ac4-4873-8d40-6fce67a09e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GermanFederalMinistryOfHealthMember_b042194c-b466-4143-a823-fecd2004be12" xlink:href="bntx-20231231.xsd#bntx_GermanFederalMinistryOfHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_GermanFederalMinistryOfHealthMember_b042194c-b466-4143-a823-fecd2004be12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_0409f5ad-900e-4fd7-b34e-3a66ff37f049" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineSalesToCollaborationPartnersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineSalesToCollaborationPartnersMember_0409f5ad-900e-4fd7-b34e-3a66ff37f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_c517b2fe-4e1a-45fb-b013-3afb7ab8f61a" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineDirectProductSalesToCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineDirectProductSalesToCustomersMember_c517b2fe-4e1a-45fb-b013-3afb7ab8f61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_280cb5de-4b54-4ba2-92c6-a1218139995c" xlink:href="bntx-20231231.xsd#bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember_280cb5de-4b54-4ba2-92c6-a1218139995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerCOVID19VaccineMember_37dff228-ce7e-4b14-92b9-51ec9db6a262" xlink:href="bntx-20231231.xsd#bntx_PfizerCOVID19VaccineMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerCOVID19VaccineMember_37dff228-ce7e-4b14-92b9-51ec9db6a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerZosterMember_cc201fb1-3d16-42db-b42c-a638aeaff401" xlink:href="bntx-20231231.xsd#bntx_PfizerZosterMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_554b0d50-4bc6-4c15-98e4-38154d85cb62" xlink:to="loc_bntx_PfizerZosterMember_cc201fb1-3d16-42db-b42c-a638aeaff401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c2659d23-ad48-483e-9855-b5e45a194a05" xlink:to="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_93417b32-5c05-4d33-85f7-035cc6d476bd" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_US_93417b32-5c05-4d33-85f7-035cc6d476bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_f4bcea8e-f3a1-47c0-b74b-d2403cad63f8" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_DE_f4bcea8e-f3a1-47c0-b74b-d2403cad63f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BE_dd1aacf3-da82-4afc-9599-83d0293ef2be" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_24b35763-549c-4e73-aed3-22042d3b792c" xlink:to="loc_country_BE_dd1aacf3-da82-4afc-9599-83d0293ef2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_38d32f12-37b2-4c76-bed0-dcb4703c1287" xlink:to="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CommercialMember_94512a3f-8fcb-48bd-9ec5-003dd665e5a3" xlink:href="bntx-20231231.xsd#bntx_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_938eff66-1796-4ae7-ae24-c5b1e472ea5a" xlink:to="loc_bntx_CommercialMember_94512a3f-8fcb-48bd-9ec5-003dd665e5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_cb26c0b4-b148-4694-94a4-6a29610c5a0f" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManufacturingVariancesMember_43eb85c3-b073-417a-b626-a9f1a8728808" xlink:href="bntx-20231231.xsd#bntx_ManufacturingVariancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_62eb4966-b01f-4740-81e5-73b449458fd4" xlink:to="loc_bntx_ManufacturingVariancesMember_43eb85c3-b073-417a-b626-a9f1a8728808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_aab52f8e-8c6b-401e-b742-8e471edb78b3" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_a1718a1c-f65d-482d-95ea-09e851a7603a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_a1718a1c-f65d-482d-95ea-09e851a7603a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_a940b702-80a5-402c-92b6-d671607b454c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_ifrs-full_ContractLiabilities_a940b702-80a5-402c-92b6-d671607b454c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RemainingUpfrontFeesContractLiabilities_307562fe-0e5d-41fa-bcac-8086e980ffc1" xlink:href="bntx-20231231.xsd#bntx_RemainingUpfrontFeesContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_bntx_RemainingUpfrontFeesContractLiabilities_307562fe-0e5d-41fa-bcac-8086e980ffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_37a71acc-4e17-4888-ac28-b0f7100a8abe" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_db8a4027-2fb4-49f3-b4ff-d01c657333b5" xlink:to="loc_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale_37a71acc-4e17-4888-ac28-b0f7100a8abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_39684f3d-d390-4999-aed3-53f43774575b" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_f2b2b252-0d8e-469a-b428-eea6658a8632" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_39684f3d-d390-4999-aed3-53f43774575b" xlink:to="loc_ifrs-full_CurrentTradeReceivables_f2b2b252-0d8e-469a-b428-eea6658a8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_5ec0583f-e9d5-413e-8a0b-391f913980d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_39684f3d-d390-4999-aed3-53f43774575b" xlink:to="loc_ifrs-full_ContractLiabilities_5ec0583f-e9d5-413e-8a0b-391f913980d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RefundsProvision_6d0e3adb-1f05-4323-8b85-55ef228e48bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RefundsProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_39684f3d-d390-4999-aed3-53f43774575b" xlink:to="loc_ifrs-full_RefundsProvision_6d0e3adb-1f05-4323-8b85-55ef228e48bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_1f0ed02a-6623-425a-81ee-963bec00786a" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_a2d33ed6-2e1f-4c3e-bce1-9537823e64c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_1f0ed02a-6623-425a-81ee-963bec00786a" xlink:to="loc_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_a2d33ed6-2e1f-4c3e-bce1-9537823e64c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RevenueFromContractsWithCustomersAbstract_3d1c2c37-c883-4f2e-be92-78749df4de01" xlink:href="bntx-20231231.xsd#bntx_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RevenueFromContractsWithCustomersAbstract_3d1c2c37-c883-4f2e-be92-78749df4de01" xlink:to="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:to="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PerformanceObligationsAxis_921465de-4746-4e7c-896e-bc6c24b4aada" xlink:to="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_a9afebb6-6448-4002-9621-f10a9023870b" xlink:href="bntx-20231231.xsd#bntx_UnsatisfiedOrPartiallyUnsatisfiedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PerformanceObligationsMember_c96d3cb1-df7d-47b3-9a9f-16b289740664" xlink:to="loc_bntx_UnsatisfiedOrPartiallyUnsatisfiedMember_a9afebb6-6448-4002-9621-f10a9023870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:to="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_ad2b566d-98de-4cc5-9363-c21d7196a74e" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_f09f5e58-6fa3-4302-88c6-7f29332ff91b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_f09f5e58-6fa3-4302-88c6-7f29332ff91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearMember_6af3d5f9-184d-4772-abae-023f4a52d3be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_a5a0d904-fe89-47d5-927e-7f1f5f58c4f3" xlink:to="loc_ifrs-full_LaterThanOneYearMember_6af3d5f9-184d-4772-abae-023f4a52d3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsTable_24c58256-347a-4591-9115-6c9d8ba931da" xlink:to="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_6438f4a2-f859-4e73-a5df-13e2b48140ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPerformanceObligationsLineItems_281c7864-bef3-4139-8744-2b2992aee109" xlink:to="loc_ifrs-full_ContractLiabilities_6438f4a2-f859-4e73-a5df-13e2b48140ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e966880f-6890-455f-b757-abe5cdeb4881" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e966880f-6890-455f-b757-abe5cdeb4881" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:to="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d42c0900-77a0-434c-ae42-f5f605023a49" xlink:to="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fbf08dc5-4acb-4281-bae1-bc154a8cab7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a54aee74-9e13-43e5-872c-c5d81ee1a2c8" xlink:to="loc_srt_MaximumMember_fbf08dc5-4acb-4281-bae1-bc154a8cab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:to="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1b848cae-dee2-4d7a-91bd-4be32c529550" xlink:to="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_6a199833-6eef-4405-b828-5e00ce9564b9" xlink:href="bntx-20231231.xsd#bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d6bd474a-2444-40e3-98dc-b6bb7c3eb6c3" xlink:to="loc_bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember_6a199833-6eef-4405-b828-5e00ce9564b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_ca838cd2-9939-4011-bf78-81e85cf1379c" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseCostOfSales_2a2680cb-eee6-4fb3-a2a6-ba7c8beb34aa" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseCostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseCostOfSales_2a2680cb-eee6-4fb3-a2a6-ba7c8beb34aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfCostOfSales_89b17f4d-1aed-4b2d-9351-943563dc4158" xlink:href="bntx-20231231.xsd#bntx_PercentageOfCostOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfCostOfSales_89b17f4d-1aed-4b2d-9351-943563dc4158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_49763f77-e017-46ec-b7ae-2431a3756e9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_CostOfSales_49763f77-e017-46ec-b7ae-2431a3756e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WritedownsReversalsOfInventories_6395f1cf-c2fd-4480-bf39-5b286c341d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_WritedownsReversalsOfInventories_6395f1cf-c2fd-4480-bf39-5b286c341d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_d2f72363-6116-4aa5-969c-323cc96d751d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_Inventories_d2f72363-6116-4aa5-969c-323cc96d751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_4389c8b3-4d79-4b44-92ac-7f7f668da3c4" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense_4389c8b3-4d79-4b44-92ac-7f7f668da3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfResearchAndDevelopmentExpense_48d56245-c737-4138-b12b-919ad63a44ff" xlink:href="bntx-20231231.xsd#bntx_PercentageOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfResearchAndDevelopmentExpense_48d56245-c737-4138-b12b-919ad63a44ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_5b8a94de-1dfe-4f4c-8643-5b93d965421b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_5b8a94de-1dfe-4f4c-8643-5b93d965421b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_fcfa3d21-cc3f-44ae-b674-db818dad62d0" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfSalesAndMarketingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfSalesAndMarketingExpense_fcfa3d21-cc3f-44ae-b674-db818dad62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfSalesAndMarketingExpense_30529242-4f62-4a47-bcf1-4f1a0ba61315" xlink:href="bntx-20231231.xsd#bntx_PercentageOfSalesAndMarketingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfSalesAndMarketingExpense_30529242-4f62-4a47-bcf1-4f1a0ba61315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_0022712c-1b36-4808-8acb-146d796492cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_0022712c-1b36-4808-8acb-146d796492cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_3434a8d0-14a6-4a8a-8c67-30c9a7941e4e" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense_3434a8d0-14a6-4a8a-8c67-30c9a7941e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfGeneralAndAdministrativeExpense_ad6417f9-2c29-4362-ba0f-d4fb567109bf" xlink:href="bntx-20231231.xsd#bntx_PercentageOfGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_PercentageOfGeneralAndAdministrativeExpense_ad6417f9-2c29-4362-ba0f-d4fb567109bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f9040609-1a08-4bec-9f2b-2af33d61fa1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f9040609-1a08-4bec-9f2b-2af33d61fa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_a469e895-5de7-4b88-8ec7-2ffbc00b5969" xlink:href="bntx-20231231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_1b681bff-4dff-4709-8c4e-dff70549f6dc" xlink:to="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_a469e895-5de7-4b88-8ec7-2ffbc00b5969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesOtherOperatingExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_197a2216-3ee0-45df-b966-e00827fcf399" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_197a2216-3ee0-45df-b966-e00827fcf399" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:to="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_a32bd76f-9b9a-424b-9f2d-2b30b62d5410" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignExchangeDifferencesMember_fe5b9c4b-a568-4bf5-9ae2-a82be6d93c91" xlink:href="bntx-20231231.xsd#bntx_ForeignExchangeDifferencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_ForeignExchangeDifferencesMember_fe5b9c4b-a568-4bf5-9ae2-a82be6d93c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember_9dede62a-8a26-4b2f-bf13-cc473f823c4b" xlink:href="bntx-20231231.xsd#bntx_LossOnDerivativeInstrumentsAtFairValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_LossOnDerivativeInstrumentsAtFairValueMember_9dede62a-8a26-4b2f-bf13-cc473f823c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LitigationCostsMember_4eb8b4db-ac2c-4c02-9f5c-49629c8346bb" xlink:href="bntx-20231231.xsd#bntx_LitigationCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_LitigationCostsMember_4eb8b4db-ac2c-4c02-9f5c-49629c8346bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherIncomeExpenseMember_1487b8d8-960c-4158-a14d-10a4fbf98c49" xlink:href="bntx-20231231.xsd#bntx_OtherIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_d06d6fb3-8359-4021-856e-380aa0a8325c" xlink:to="loc_bntx_OtherIncomeExpenseMember_1487b8d8-960c-4158-a14d-10a4fbf98c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_72ee158e-e225-48aa-b6c8-2ca3025bf243" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_1a6fe1a5-a6d9-4c45-b0a4-487da551c90d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_852558ea-9897-419e-bedc-86bb2dd7f1c8" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_1a6fe1a5-a6d9-4c45-b0a4-487da551c90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesOtherOperatingIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6771e1e3-1796-497d-82be-e1bfb183e86a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6771e1e3-1796-497d-82be-e1bfb183e86a" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:to="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:href="bntx-20231231.xsd#bntx_IncomeAndExpensesByNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureAxis_08883bb4-1a28-4d4d-836b-beef9c1bd2eb" xlink:to="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_34676fff-6378-4fa0-9b3c-91ecff2ae123" xlink:href="bntx-20231231.xsd#bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember_34676fff-6378-4fa0-9b3c-91ecff2ae123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GovernmentGrantsMember_593be800-4843-4475-b5aa-92217d417b06" xlink:href="bntx-20231231.xsd#bntx_GovernmentGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_GovernmentGrantsMember_593be800-4843-4475-b5aa-92217d417b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignExchangeDifferencesMember_df3ac741-894c-4669-a696-dac73c37f490" xlink:href="bntx-20231231.xsd#bntx_ForeignExchangeDifferencesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_ForeignExchangeDifferencesMember_df3ac741-894c-4669-a696-dac73c37f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherIncomeExpenseMember_634e8305-b3f7-47a3-b5a1-b40bc79574cf" xlink:href="bntx-20231231.xsd#bntx_OtherIncomeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeAndExpensesByNatureDomain_3761ee74-706d-4ead-bec5-15c9327b2216" xlink:to="loc_bntx_OtherIncomeExpenseMember_634e8305-b3f7-47a3-b5a1-b40bc79574cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_63e2474e-a622-4583-92ec-9c9af083a281" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingIncome_b4232360-19f6-43ec-a5e2-1c89e46d3854" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_88c9c433-8993-4a49-bf91-d2f72c1a7f69" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingIncome_b4232360-19f6-43ec-a5e2-1c89e46d3854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesFinanceIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1d94c2b-3561-410e-8ffd-14848a6efe29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_8fff311a-a64d-4bcc-a87e-982a2ad16322" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1d94c2b-3561-410e-8ffd-14848a6efe29" xlink:to="loc_ifrs-full_RevenueFromInterest_8fff311a-a64d-4bcc-a87e-982a2ad16322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_d5bbb7e1-73e5-4e4c-9be4-c057b83b6a20" xlink:href="bntx-20231231.xsd#bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1d94c2b-3561-410e-8ffd-14848a6efe29" xlink:to="loc_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_d5bbb7e1-73e5-4e4c-9be4-c057b83b6a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeGain_7aa72067-fbeb-451f-a38e-0a4bf5de0993" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1d94c2b-3561-410e-8ffd-14848a6efe29" xlink:to="loc_ifrs-full_NetForeignExchangeGain_7aa72067-fbeb-451f-a38e-0a4bf5de0993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_8104e36a-cc8f-45fd-a075-a7c4f88aee00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f1d94c2b-3561-410e-8ffd-14848a6efe29" xlink:to="loc_ifrs-full_FinanceIncome_8104e36a-cc8f-45fd-a075-a7c4f88aee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesFinanceExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_61a2e4a9-e205-41f1-bf0d-ffc012f6054b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetForeignExchangeLoss_1dc677e4-fe04-414d-a577-4d50f831e951" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetForeignExchangeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_61a2e4a9-e205-41f1-bf0d-ffc012f6054b" xlink:to="loc_ifrs-full_NetForeignExchangeLoss_1dc677e4-fe04-414d-a577-4d50f831e951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_30d71360-3ba8-4db3-9c9a-9cfd655a3ddf" xlink:href="bntx-20231231.xsd#bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_61a2e4a9-e205-41f1-bf0d-ffc012f6054b" xlink:to="loc_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue_30d71360-3ba8-4db3-9c9a-9cfd655a3ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_4799adf8-8276-4d89-a825-28121c468b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_61a2e4a9-e205-41f1-bf0d-ffc012f6054b" xlink:to="loc_us-gaap_OtherExpenses_4799adf8-8276-4d89-a825-28121c468b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_18b5f4b9-1921-4ff8-818d-f49b3cfe1c2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_61a2e4a9-e205-41f1-bf0d-ffc012f6054b" xlink:to="loc_ifrs-full_FinanceCosts_18b5f4b9-1921-4ff8-818d-f49b3cfe1c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_035c6744-5544-44c9-b1d4-c1e83b7ed3a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_41a996ff-559c-48f7-b224-a90cc854f0dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_035c6744-5544-44c9-b1d4-c1e83b7ed3a3" xlink:to="loc_ifrs-full_WagesAndSalaries_41a996ff-559c-48f7-b224-a90cc854f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SocialSecurityContributions_d8018f9b-6f4b-4508-8d5c-af6ed54a5761" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SocialSecurityContributions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_035c6744-5544-44c9-b1d4-c1e83b7ed3a3" xlink:to="loc_ifrs-full_SocialSecurityContributions_d8018f9b-6f4b-4508-8d5c-af6ed54a5761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_24152ab1-edc9-4903-a45f-f4f1051d8618" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_035c6744-5544-44c9-b1d4-c1e83b7ed3a3" xlink:to="loc_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_24152ab1-edc9-4903-a45f-f4f1051d8618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_b0e945b1-2bb2-469e-b087-3e75e861250a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_035c6744-5544-44c9-b1d4-c1e83b7ed3a3" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_b0e945b1-2bb2-469e-b087-3e75e861250a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_9048a1ed-4651-419e-a724-6feed1c26ad5" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_9048a1ed-4651-419e-a724-6feed1c26ad5" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_03d2dc52-ce5a-4c69-9327-aa8224bd6bf8" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_16479e19-583f-450e-9051-ccaa51c70f9f" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_73ca1e17-edda-468b-b157-b18fd6729503" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_16479e19-583f-450e-9051-ccaa51c70f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5c6cbcb9-6d42-436f-a2b1-4699cfac4653" xlink:to="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ValuationAdjustmentMember_57dc6ff3-de6f-4b06-ad4d-50effb023c68" xlink:href="bntx-20231231.xsd#bntx_ValuationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_f4144aa6-3eee-4917-af9e-2817fc178113" xlink:to="loc_bntx_ValuationAdjustmentMember_57dc6ff3-de6f-4b06-ad4d-50effb023c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_edb2f932-5b79-4e8c-888d-9a84986b3d8b" xlink:to="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AT_f3c7435a-a77b-4416-8315-825e4795329f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:to="loc_country_AT_f3c7435a-a77b-4416-8315-825e4795329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4745284-4dc2-42d0-88fd-038a105c2176" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9a12eb8f-a336-45b2-a6ed-23d1b76e8102" xlink:to="loc_country_US_c4745284-4dc2-42d0-88fd-038a105c2176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_a2ac210e-4af4-4f41-9b93-77b3339b2c26" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_323e0157-1204-4547-a61a-456cf6284a8b" xlink:href="bntx-20231231.xsd#bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember_323e0157-1204-4547-a61a-456cf6284a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_66aec35c-1b23-402d-81b3-7781b9d0967b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_66aec35c-1b23-402d-81b3-7781b9d0967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_d8b4c68c-2e6e-4cb8-b451-2bb6b75a91ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_e0d3fec5-13a4-4ae9-b58a-5bf90783244d" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_d8b4c68c-2e6e-4cb8-b451-2bb6b75a91ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f4afca49-e394-4214-b475-5aa03c365414" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CorporateTaxRate_97bc718a-3fcb-40a5-83d9-3dfd2e82d6aa" xlink:href="bntx-20231231.xsd#bntx_CorporateTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_CorporateTaxRate_97bc718a-3fcb-40a5-83d9-3dfd2e82d6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SolidaritySurchargeRate_72c9a7bd-9497-404e-a4ba-0332b44aaf0a" xlink:href="bntx-20231231.xsd#bntx_SolidaritySurchargeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_SolidaritySurchargeRate_72c9a7bd-9497-404e-a4ba-0332b44aaf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_2268072e-3a59-476d-8e28-1eff538010bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_ApplicableTaxRate_2268072e-3a59-476d-8e28-1eff538010bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxRateOnDeferredTaxes_33bec5d5-3d2d-4aaa-b607-21607dce4b70" xlink:href="bntx-20231231.xsd#bntx_TaxRateOnDeferredTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_TaxRateOnDeferredTaxes_33bec5d5-3d2d-4aaa-b607-21607dce4b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DecreaseInCorporateTaxRate_a6fa5ae0-c5e5-4412-a7ba-ada2c3277153" xlink:href="bntx-20231231.xsd#bntx_DecreaseInCorporateTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_DecreaseInCorporateTaxRate_a6fa5ae0-c5e5-4412-a7ba-ada2c3277153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalCorporateIncomeTax_f25d2973-f2c8-4e00-85be-13a9f3bb4635" xlink:href="bntx-20231231.xsd#bntx_FederalCorporateIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_FederalCorporateIncomeTax_f25d2973-f2c8-4e00-85be-13a9f3bb4635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_6293eb7a-ad1c-4f09-8921-315f908d3275" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_6293eb7a-ad1c-4f09-8921-315f908d3275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxAssetsSettlement_e6ece0c4-e95e-4a8e-bbf2-dcdfa66ba77f" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxAssetsSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_DeferredTaxAssetsSettlement_e6ece0c4-e95e-4a8e-bbf2-dcdfa66ba77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_8ca8d3a5-80f3-4a4c-99be-6d409f4100fd" xlink:href="bntx-20231231.xsd#bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity_8ca8d3a5-80f3-4a4c-99be-6d409f4100fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_c293ed64-2863-478b-b176-cec4ffc31c29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_DeferredTaxAssets_c293ed64-2863-478b-b176-cec4ffc31c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_2918fbb3-0ea6-4cab-a104-64fafd17cc82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_2918fbb3-0ea6-4cab-a104-64fafd17cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_9b1bdc39-5f47-4695-a89f-beea49c6dbf3" xlink:href="bntx-20231231.xsd#bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards_9b1bdc39-5f47-4695-a89f-beea49c6dbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_205ff075-63bb-42d9-aaf6-66aae818f76e" xlink:href="bntx-20231231.xsd#bntx_StateDeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards_205ff075-63bb-42d9-aaf6-66aae818f76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_8679eb52-0dd4-4594-b989-da6effeda83d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0939340e-c6b5-4055-820a-b1010c8f7d05" xlink:to="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_8679eb52-0dd4-4594-b989-da6effeda83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_8c53d8ab-3682-46e9-b2e4-c2e8ee5c0aa9" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_2622d541-7766-47b3-99ba-3a937fafbec1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_8c53d8ab-3682-46e9-b2e4-c2e8ee5c0aa9" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_2622d541-7766-47b3-99ba-3a937fafbec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncome_0f2fe05e-3ce9-4410-b497-6910ac8e0931" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_8c53d8ab-3682-46e9-b2e4-c2e8ee5c0aa9" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncome_0f2fe05e-3ce9-4410-b497-6910ac8e0931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_e75c99a8-7f9e-40b0-b34c-96c1946b281e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_8c53d8ab-3682-46e9-b2e4-c2e8ee5c0aa9" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_e75c99a8-7f9e-40b0-b34c-96c1946b281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_f9a8a1e5-f055-42c3-8eca-bf3445ae2143" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_f9a8a1e5-f055-42c3-8eca-bf3445ae2143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_191ce6a7-c9dd-467e-961a-061c1821eb20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_191ce6a7-c9dd-467e-961a-061c1821eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:to="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_34396dc8-c014-428d-97e0-c7e5402270f3" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfDeviationDueToLocalTaxBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_TaxEffectOfDeviationDueToLocalTaxBasis_34396dc8-c014-428d-97e0-c7e5402270f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_34998749-6f0c-4035-ad2a-9989d057be56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_34998749-6f0c-4035-ad2a-9989d057be56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectOfChangeInValuationAllowance_f2277744-e628-48da-bf98-12d283f9db92" xlink:href="bntx-20231231.xsd#bntx_TaxEffectOfChangeInValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_TaxEffectOfChangeInValuationAllowance_f2277744-e628-48da-bf98-12d283f9db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfTaxLosses_b26ef1ab-9f15-4ee3-aed0-f85d66223f19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_TaxEffectOfTaxLosses_b26ef1ab-9f15-4ee3-aed0-f85d66223f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_8c4c7f01-3af6-424e-83fd-d012af988458" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_8c4c7f01-3af6-424e-83fd-d012af988458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_e90d5c11-5f73-4ab9-92d1-db7dae66bd78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_e90d5c11-5f73-4ab9-92d1-db7dae66bd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectNonTaxEffectiveIncome_38ad128e-6536-4ad5-9e13-96643468b9d9" xlink:href="bntx-20231231.xsd#bntx_TaxEffectNonTaxEffectiveIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_TaxEffectNonTaxEffectiveIncome_38ad128e-6536-4ad5-9e13-96643468b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_2ecb3190-b3a0-41d0-848c-482b58ed2867" xlink:href="bntx-20231231.xsd#bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses_2ecb3190-b3a0-41d0-848c-482b58ed2867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TaxEffectiveEquityTransactionCosts_b08e27e1-fcd8-42ec-a913-0716d07bc1e1" xlink:href="bntx-20231231.xsd#bntx_TaxEffectiveEquityTransactionCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_TaxEffectiveEquityTransactionCosts_b08e27e1-fcd8-42ec-a913-0716d07bc1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_698a3d9a-9bc4-428f-bbbe-73b4815ab33d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_698a3d9a-9bc4-428f-bbbe-73b4815ab33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonTaxEffectiveBargainPurchase_34e5e656-0c91-472d-a2f4-c0b5c0cfad4a" xlink:href="bntx-20231231.xsd#bntx_NonTaxEffectiveBargainPurchase"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_bntx_NonTaxEffectiveBargainPurchase_34e5e656-0c91-472d-a2f4-c0b5c0cfad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_e03544ef-f954-4e72-82df-444f32d25c1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_db8955cc-3727-46b9-915d-25aa43e7a214" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_e03544ef-f954-4e72-82df-444f32d25c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b09f07fe-59a2-4760-80e7-d3dcb37bc22d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_b09f07fe-59a2-4760-80e7-d3dcb37bc22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageEffectiveTaxRate_b6e4a8e0-9465-4c3c-ab6c-9058c977341a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_0eb85d01-f50d-4fea-a1c8-9d2b05b40b6a" xlink:to="loc_ifrs-full_AverageEffectiveTaxRate_b6e4a8e0-9465-4c3c-ab6c-9058c977341a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_b35cd49f-4876-4796-bc81-020715e756f3" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_b35cd49f-4876-4796-bc81-020715e756f3" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_2000ae92-76b9-4334-a67f-1a8fb074bf0f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FixedAssetsMember_4d1fa5fe-cffb-4ca1-b709-df682af03125" xlink:href="bntx-20231231.xsd#bntx_FixedAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_FixedAssetsMember_4d1fa5fe-cffb-4ca1-b709-df682af03125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssetsMember_5b2e942d-7c6b-42fc-a38e-97eaaca2d9b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_RightofuseAssetsMember_5b2e942d-7c6b-42fc-a38e-97eaaca2d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Inventories1Member_74323195-3527-44e3-b20f-a723428e67a0" xlink:href="bntx-20231231.xsd#bntx_Inventories1Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_Inventories1Member_74323195-3527-44e3-b20f-a723428e67a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradeAndOtherReceivablesMember_4f7a0367-e84d-4aef-b677-886a936ec0f0" xlink:href="bntx-20231231.xsd#bntx_TradeAndOtherReceivablesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_TradeAndOtherReceivablesMember_4f7a0367-e84d-4aef-b677-886a936ec0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_54f2d788-e5ce-4b74-af41-af1195845f0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_54f2d788-e5ce-4b74-af41-af1195845f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContractLiabilitiesMember_4420119b-2338-4aac-8b5f-831f41a6e66f" xlink:href="bntx-20231231.xsd#bntx_ContractLiabilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ContractLiabilitiesMember_4420119b-2338-4aac-8b5f-831f41a6e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LoansAndBorrowingsMember_41316e63-66d5-471c-9bf0-b4eb71ffa695" xlink:href="bntx-20231231.xsd#bntx_LoansAndBorrowingsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_LoansAndBorrowingsMember_41316e63-66d5-471c-9bf0-b4eb71ffa695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_186c9cd3-54ec-4402-bd74-056661c9e007" xlink:href="bntx-20231231.xsd#bntx_NetEmployeeDefinedBenefitLiabilitiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_NetEmployeeDefinedBenefitLiabilitiesMember_186c9cd3-54ec-4402-bd74-056661c9e007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_98b02f18-3252-40d7-a7ab-33b3d1d758a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_98b02f18-3252-40d7-a7ab-33b3d1d758a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_d42622fd-35b4-49b8-a884-9c5aee952b67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_OtherProvisionsMember_d42622fd-35b4-49b8-a884-9c5aee952b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherDeferredTaxesMember_ecb6daa4-ffbe-4db4-99dd-22f3b4fd97af" xlink:href="bntx-20231231.xsd#bntx_OtherDeferredTaxesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_OtherDeferredTaxesMember_ecb6daa4-ffbe-4db4-99dd-22f3b4fd97af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_af58243b-1b7c-431a-a950-70b107bd7783" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_af58243b-1b7c-431a-a950-70b107bd7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxAssetsMember_bc40e820-21b2-4664-8d9b-e7a9d8b1741b" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxAssetsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ThereofDeferredTaxAssetsMember_bc40e820-21b2-4664-8d9b-e7a9d8b1741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThereofDeferredTaxLiabilityMember_92120bd7-98f3-4f62-94be-f53aa4020465" xlink:href="bntx-20231231.xsd#bntx_ThereofDeferredTaxLiabilityMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2531fdb7-aaf8-4939-a774-6652469c46da" xlink:to="loc_bntx_ThereofDeferredTaxLiabilityMember_92120bd7-98f3-4f62-94be-f53aa4020465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0a4b506f-2794-49c3-8017-1eee6fe017ad" xlink:to="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_99f47c06-86ce-421e-87fd-574590e14873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_99f47c06-86ce-421e-87fd-574590e14873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ValuationAdjustmentMember_afcfc724-1fce-488b-a083-22a021a21aca" xlink:href="bntx-20231231.xsd#bntx_ValuationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_3f50339d-c7a2-408c-ab12-05777b30a482" xlink:to="loc_bntx_ValuationAdjustmentMember_afcfc724-1fce-488b-a083-22a021a21aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_a1f158a7-7d3d-470b-ab31-e3d7fb3574ba" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_82e7445d-9ad2-45fe-8087-43d1637ae0d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_82e7445d-9ad2-45fe-8087-43d1637ae0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_433cb6d0-6bff-4d28-8d0a-a930885568c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_433cb6d0-6bff-4d28-8d0a-a930885568c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_92fbd6d5-090f-4e5b-a6fb-41d60002fa22" xlink:href="bntx-20231231.xsd#bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome_92fbd6d5-090f-4e5b-a6fb-41d60002fa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_37ca5025-2983-4291-98fd-567d1982dce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_37ca5025-2983-4291-98fd-567d1982dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_666a5ea3-4ff8-4a18-80c3-da70e41f56cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_666a5ea3-4ff8-4a18-80c3-da70e41f56cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_3ebd17fd-f910-4812-8d55-8a3d21ffd935" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fe1e3e2a-4ce1-4cc6-b40d-4e0584c0eeef" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_3ebd17fd-f910-4812-8d55-8a3d21ffd935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IncomeTaxSummaryofAccumulatedTaxLossesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncomeTaxesAbstract_9782496a-c231-42b1-80d0-eb4f7c05d4c8" xlink:href="bntx-20231231.xsd#bntx_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInCorporateTax_3bf88b2b-6b4d-4556-bb79-876e65452120" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInCorporateTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_9782496a-c231-42b1-80d0-eb4f7c05d4c8" xlink:to="loc_bntx_AccumulatedTaxLossesInCorporateTax_3bf88b2b-6b4d-4556-bb79-876e65452120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInTradeTax_094e69e6-9f18-4304-bcd9-754a28b4a74d" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInTradeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_9782496a-c231-42b1-80d0-eb4f7c05d4c8" xlink:to="loc_bntx_AccumulatedTaxLossesInTradeTax_094e69e6-9f18-4304-bcd9-754a28b4a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInFederalTaxCredits_cb67b8d0-45e1-4fcb-b0c6-80ac98d6b0db" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInFederalTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_9782496a-c231-42b1-80d0-eb4f7c05d4c8" xlink:to="loc_bntx_AccumulatedTaxLossesInFederalTaxCredits_cb67b8d0-45e1-4fcb-b0c6-80ac98d6b0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedTaxLossesInStateTaxCredits_fe05ece0-a370-477f-bd3c-fd5a88e017e4" xlink:href="bntx-20231231.xsd#bntx_AccumulatedTaxLossesInStateTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IncomeTaxesAbstract_9782496a-c231-42b1-80d0-eb4f7c05d4c8" xlink:to="loc_bntx_AccumulatedTaxLossesInStateTaxCredits_fe05ece0-a370-477f-bd3c-fd5a88e017e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_faa13395-bff1-4596-9655-41abe59f6191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_faa13395-bff1-4596-9655-41abe59f6191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_8904fb53-56b6-4654-aea6-bb8fd06c1ff9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:to="loc_ifrs-full_WeightedAverageShares_8904fb53-56b6-4654-aea6-bb8fd06c1ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_5e7c2b7d-771d-4d2a-8862-dd52c2eaeb2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:to="loc_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_5e7c2b7d-771d-4d2a-8862-dd52c2eaeb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_32c7e4d1-ce5d-4001-888b-a0062668c610" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_32c7e4d1-ce5d-4001-888b-a0062668c610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_c86b9d02-ae04-42b3-a463-b6a5dd675e65" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_30e06eee-6126-47f7-8e62-d1d28b7c6680" xlink:to="loc_ifrs-full_BasicEarningsPerShareAbstract_c86b9d02-ae04-42b3-a463-b6a5dd675e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_f13a712c-8a87-438d-90f2-d6be737bb5b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_c86b9d02-ae04-42b3-a463-b6a5dd675e65" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_f13a712c-8a87-438d-90f2-d6be737bb5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_e3ea3fc0-7659-41a9-aa71-c02e58749c51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_c86b9d02-ae04-42b3-a463-b6a5dd675e65" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_e3ea3fc0-7659-41a9-aa71-c02e58749c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_d22717f5-822c-433b-853c-4aa15e9d09d0" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_d22717f5-822c-433b-853c-4aa15e9d09d0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_3d340300-51c0-4d75-a9fc-f59a505aa472" xlink:to="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_1cd4cb30-7ddd-469d-8074-3d47ceef5418" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_d2a47d5a-31d8-4192-8846-f3ef985d2251" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_1cd4cb30-7ddd-469d-8074-3d47ceef5418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_d06e0efd-1d1d-47bd-a7cb-7b794190e235" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_daf921ce-9c49-4323-844d-d1d4d2ef4069" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_b510dd87-8207-4fed-a696-9b2f8bff4b4f" xlink:to="loc_ifrs-full_GoodwillMember_daf921ce-9c49-4323-844d-d1d4d2ef4069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_e5aa3eb1-dd23-459e-9c6c-46128e275b31" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_da39ef9a-4340-4ec0-8bff-01c15316b393" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_da39ef9a-4340-4ec0-8bff-01c15316b393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_12677b16-403c-4c10-9add-ec37ca09f310" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_12677b16-403c-4c10-9add-ec37ca09f310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_0984ac2c-4a5c-4cec-946e-e127d6138c43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_0984ac2c-4a5c-4cec-946e-e127d6138c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_f96c6861-e70a-4e8b-9aa3-f0a2597bbcb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_48465d87-2695-43ee-a3b9-faf2fc1e22b4" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_f96c6861-e70a-4e8b-9aa3-f0a2597bbcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_158826b1-cf96-41fb-a47f-b174fb38be5e" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_158826b1-cf96-41fb-a47f-b174fb38be5e" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:to="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ConsolidatedStructuredEntitiesAxis_54eae171-f1f7-4c94-ab04-079b018c4e05" xlink:to="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CGUImmunotherapiesMember_7c6be174-cdc7-40f9-b2e1-14789fee674f" xlink:href="bntx-20231231.xsd#bntx_CGUImmunotherapiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_CGUImmunotherapiesMember_7c6be174-cdc7-40f9-b2e1-14789fee674f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalProductSalesToJPTMember_424d98d1-f735-4309-a14b-82dc3d58c621" xlink:href="bntx-20231231.xsd#bntx_ExternalProductSalesToJPTMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_ExternalProductSalesToJPTMember_424d98d1-f735-4309-a14b-82dc3d58c621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExternalBusinessOfInstaDeepMember_24db7810-7b3c-4000-a6eb-9e23bc6b0aa1" xlink:href="bntx-20231231.xsd#bntx_ExternalBusinessOfInstaDeepMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember_dce229b2-c8cd-485c-913d-21ebc7918a55" xlink:to="loc_bntx_ExternalBusinessOfInstaDeepMember_24db7810-7b3c-4000-a6eb-9e23bc6b0aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_5e257678-8ae4-4729-abc2-da781b348b93" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_85329ae0-f172-4578-ad66-c2fcd3c8374c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_ifrs-full_Goodwill_85329ae0-f172-4578-ad66-c2fcd3c8374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_3927c462-0f75-40af-ae4d-2d3c288382c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife_3927c462-0f75-40af-ae4d-2d3c288382c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_5aa1b7a8-f687-40cc-a43c-fb894399b1c3" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bb32d889-3478-42cb-9952-52efbd38fca2" xlink:to="loc_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill_5aa1b7a8-f687-40cc-a43c-fb894399b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_76285b89-cf6d-43e4-8457-f142f287e97b" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_76285b89-cf6d-43e4-8457-f142f287e97b" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_3431b6c9-ad79-4b28-a975-ca9cc90c1fa6" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DualityBiologicsSuzhouCoLtdMember_07aacf81-2c0f-4303-bd4a-b2ead313f636" xlink:href="bntx-20231231.xsd#bntx_DualityBiologicsSuzhouCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_DualityBiologicsSuzhouCoLtdMember_07aacf81-2c0f-4303-bd4a-b2ead313f636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OncoC4IncMember_e704432d-10c9-47de-af26-5fb975635d41" xlink:href="bntx-20231231.xsd#bntx_OncoC4IncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_OncoC4IncMember_e704432d-10c9-47de-af26-5fb975635d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_bf1a4756-3c87-4078-a964-cf16bb686b2b" xlink:href="bntx-20231231.xsd#bntx_MedilinkTherapeuticsSuzhouCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_MedilinkTherapeuticsSuzhouCoLtdMember_bf1a4756-3c87-4078-a964-cf16bb686b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BiotheusIncMember_dff3d59c-d227-4473-a2c7-011ccad049de" xlink:href="bntx-20231231.xsd#bntx_BiotheusIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_57f40a59-fc1f-49f0-bc1f-7cbae7fb4c35" xlink:to="loc_bntx_BiotheusIncMember_dff3d59c-d227-4473-a2c7-011ccad049de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_4b07306b-980f-4911-b57b-2c0a03130f22" xlink:to="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeepChainTechnologyMember_9c94e068-0a3b-43d6-8695-9dfc2c9d512f" xlink:href="bntx-20231231.xsd#bntx_DeepChainTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForBusinessCombinationsMember_26bb55c5-e006-4025-bc67-7620c1298758" xlink:to="loc_bntx_DeepChainTechnologyMember_9c94e068-0a3b-43d6-8695-9dfc2c9d512f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_c8f9f5ec-84c6-4aab-be0b-295bb68ccd6b" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_c55dc062-9e9d-4db4-a87b-9236d94d788a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_Goodwill_c55dc062-9e9d-4db4-a87b-9236d94d788a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_5f5f7632-1522-4308-aa45-1d5aa8ac2104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_5f5f7632-1522-4308-aa45-1d5aa8ac2104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPayment_70db2fb6-133c-4295-8a3a-54bf85954db2" xlink:href="bntx-20231231.xsd#bntx_UpfrontPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_UpfrontPayment_70db2fb6-133c-4295-8a3a-54bf85954db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_778a150f-4b39-4734-b96b-92c7fb42094d" xlink:href="bntx-20231231.xsd#bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows_778a150f-4b39-4734-b96b-92c7fb42094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_40f83b8e-671d-4514-9715-86b77a5bf7b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_40f83b8e-671d-4514-9715-86b77a5bf7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_025a3b58-d709-4a99-aa8a-9a22a74ccab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill_025a3b58-d709-4a99-aa8a-9a22a74ccab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PrepaymentForFutureDevelopmentActivities_9353602b-2f80-41d3-ae51-9cf038082e84" xlink:href="bntx-20231231.xsd#bntx_PrepaymentForFutureDevelopmentActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_PrepaymentForFutureDevelopmentActivities_9353602b-2f80-41d3-ae51-9cf038082e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_af77ac91-1f5f-49d8-bb34-bbd873cb8d9d" xlink:href="bntx-20231231.xsd#bntx_UpfrontPaymentAcquisitionOfIntangibleAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset_af77ac91-1f5f-49d8-bb34-bbd873cb8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_dd61ce83-14ff-40b7-a088-c4c9a60ec1f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_dd61ce83-14ff-40b7-a088-c4c9a60ec1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_4432ac2c-97d9-462d-9f16-8effde2de42a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_eb4bcdad-f837-4fd9-9452-055677f7237c" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_4432ac2c-97d9-462d-9f16-8effde2de42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IntangibleAssetsAbstract_8cbe7974-f63b-45f2-8638-1661795340e5" xlink:href="bntx-20231231.xsd#bntx_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_IntangibleAssetsAbstract_8cbe7974-f63b-45f2-8638-1661795340e5" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5fc05b64-076f-489b-abb4-0ae6711f19dc" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_3e3ebb28-359f-4d49-aa82-4d59de588506" xlink:href="bntx-20231231.xsd#bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:to="loc_bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember_3e3ebb28-359f-4d49-aa82-4d59de588506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AdvancePaymentsMember_8840712a-2710-4dfb-a0da-f658c809b843" xlink:href="bntx-20231231.xsd#bntx_AdvancePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c7c38612-8363-44ff-9a79-5c23c1490b3b" xlink:to="loc_bntx_AdvancePaymentsMember_8840712a-2710-4dfb-a0da-f658c809b843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9e4bdf3d-7385-4897-9e35-96946bd110a9" xlink:to="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_dfff7538-eef5-48ac-aeaf-6086ad3f1ca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_dfff7538-eef5-48ac-aeaf-6086ad3f1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_36401b4a-e3b9-4ea3-9de3-ce6627d1fb79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_2c0186bb-e0ed-4c4f-b9cd-ce460e6a4973" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_36401b4a-e3b9-4ea3-9de3-ce6627d1fb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable_6d0fa99d-4cd4-46cd-b3b5-f81b1ebf8b89" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_1a001cb2-4cc5-484e-8046-4b4dbbfccc9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_1a001cb2-4cc5-484e-8046-4b4dbbfccc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ce3d19c4-b403-4129-aa3c-46da4d2bc2ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ce3d19c4-b403-4129-aa3c-46da4d2bc2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_e50f9674-9267-4fbe-9fdc-cc2d75ce42a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_e50f9674-9267-4fbe-9fdc-cc2d75ce42a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_c4fcf1bb-2b90-4cb0-8033-fe11a7e73843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_DisposalsIntangibleAssetsAndGoodwill_c4fcf1bb-2b90-4cb0-8033-fe11a7e73843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_c624913e-d983-40cb-9b48-0b0a9314abad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill_c624913e-d983-40cb-9b48-0b0a9314abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_898a98ae-fe6d-4f20-a965-90f0a33dd66c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_898a98ae-fe6d-4f20-a965-90f0a33dd66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment_e294dee4-5ea3-4ca7-affe-578a6b79bdcb" xlink:href="bntx-20231231.xsd#bntx_AccumulatedDepreciationAmortisationAndImpairment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_bntx_AccumulatedDepreciationAmortisationAndImpairment_e294dee4-5ea3-4ca7-affe-578a6b79bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_5ed5933a-9e0c-4d24-b6cb-e2ded887f7da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems_efe58e1e-f588-4b02-b3c3-1a730c7f74c6" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_5ed5933a-9e0c-4d24-b6cb-e2ded887f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_35e98a1d-4fc9-4d64-89c0-9d946fbd6a34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_35e98a1d-4fc9-4d64-89c0-9d946fbd6a34" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_2171a49a-5ca1-4cd3-99dd-7d208b707144" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandAndBuildingsMember_4109fc15-44fe-4717-8a31-75b84ea6d81e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LandAndBuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_ifrs-full_LandAndBuildingsMember_4109fc15-44fe-4717-8a31-75b84ea6d81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EquipmentToolsAndInstallationsMember_1040bf27-228c-45f0-9513-95ad9d24318d" xlink:href="bntx-20231231.xsd#bntx_EquipmentToolsAndInstallationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_bntx_EquipmentToolsAndInstallationsMember_1040bf27-228c-45f0-9513-95ad9d24318d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember_eb429612-b86d-44ba-bc50-1719a6c33820" xlink:href="bntx-20231231.xsd#bntx_ConstructionInProgressAndAdvancePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_90c73856-cf10-42ab-918c-955e0b42ab8d" xlink:to="loc_bntx_ConstructionInProgressAndAdvancePaymentsMember_eb429612-b86d-44ba-bc50-1719a6c33820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bbfdbe85-ddf5-431c-832a-614c60569e98" xlink:to="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_91568ad6-3d2f-4432-92dc-c753caa409eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_91568ad6-3d2f-4432-92dc-c753caa409eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f1c2a1a9-aca6-4c27-b61e-ac3e091fd556" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_282297e4-57fc-4fc0-a498-8cd3a2657dc8" xlink:to="loc_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_f1c2a1a9-aca6-4c27-b61e-ac3e091fd556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_70cf8638-7efa-4444-90db-c93ad46a5e78" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_5b620958-0d9f-42d2-8fc0-357c1dd83ce4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_5b620958-0d9f-42d2-8fc0-357c1dd83ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9688bc92-a539-48fa-a6b5-cac8f9d2b220" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_9688bc92-a539-48fa-a6b5-cac8f9d2b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_1e40abed-4455-49e7-b286-58e7b0fa4e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_1e40abed-4455-49e7-b286-58e7b0fa4e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment_960e329d-e5a1-4f2b-8fc5-5f8bb8aa17c9" xlink:href="bntx-20231231.xsd#bntx_ReclassificationsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_bntx_ReclassificationsOfPropertyPlantAndEquipment_960e329d-e5a1-4f2b-8fc5-5f8bb8aa17c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_21e977c3-055b-41f7-8f9a-b816c159b9f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_21e977c3-055b-41f7-8f9a-b816c159b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_d30c493c-2b88-4b62-8079-d7ba29c02f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_d30c493c-2b88-4b62-8079-d7ba29c02f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_94f4559b-8fac-49fb-a430-d0c57d0c6577" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_94f4559b-8fac-49fb-a430-d0c57d0c6577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_3ab6d7ac-db97-4c9b-82e1-ca5dfb405d1b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_3ab6d7ac-db97-4c9b-82e1-ca5dfb405d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_e8a61959-898b-4a9f-adff-c8b0171b26c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_80f1b3a3-0d54-4ca1-96f1-fd3b828097f4" xlink:to="loc_ifrs-full_NoncurrentAssets_e8a61959-898b-4a9f-adff-c8b0171b26c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#PropertyPlantandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_603e7e48-e47f-46db-aeb9-04d07b7c2e82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentAbstract_603e7e48-e47f-46db-aeb9-04d07b7c2e82" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:to="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c8b8224f-8d1a-4554-bd8e-deb37408b946" xlink:to="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ad59b7cf-cffe-4aaf-b1f6-399e2a734751" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_US_ad59b7cf-cffe-4aaf-b1f6-399e2a734751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1aaabb83-9030-4810-a5fd-0e0f28ecbcea" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_GB_1aaabb83-9030-4810-a5fd-0e0f28ecbcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4fd74dd3-b87f-41f9-bae4-dfdbb464d18f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7cace557-f394-4308-b4e6-16a4519a6933" xlink:to="loc_country_DE_4fd74dd3-b87f-41f9-bae4-dfdbb464d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:to="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1c6d53d1-4aef-4706-b98b-3f08a327f873" xlink:to="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubsidiariesMember_b9aea14a-afa6-4552-badb-13fe278329db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForSubsidiariesMember_91fd830b-ec7b-41e7-ad4d-1668df29c717" xlink:to="loc_ifrs-full_SubsidiariesMember_b9aea14a-afa6-4552-badb-13fe278329db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f5735ea9-1d2b-4745-b999-4c441b429560" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_4c3a1d5a-d1d1-4431-acac-ce42f6b1b184" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_b953fce0-a88c-4b38-a346-b61fe0e43b18" xlink:to="loc_ifrs-full_NoncurrentAssets_4c3a1d5a-d1d1-4431-acac-ce42f6b1b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_4b5381cc-aac9-4ff6-bc70-b644642712ef" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_4b5381cc-aac9-4ff6-bc70-b644642712ef" xlink:to="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_28ad9e25-0498-439b-a4ec-59d75e49d694" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BankDepositsMember_6ab8639e-ec97-457d-b6b8-789e1571cf94" xlink:href="bntx-20231231.xsd#bntx_BankDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_BankDepositsMember_6ab8639e-ec97-457d-b6b8-789e1571cf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MoneyMarketFundMember_481a6a20-b61c-4a9b-8ee3-399aff8405b5" xlink:href="bntx-20231231.xsd#bntx_MoneyMarketFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_MoneyMarketFundMember_481a6a20-b61c-4a9b-8ee3-399aff8405b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReverseRepoMember_f6e2ac29-38a3-4398-bef2-cd001c5c592c" xlink:href="bntx-20231231.xsd#bntx_ReverseRepoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_4e282cdf-2d70-4dc0-870d-4cc8d0cc2804" xlink:to="loc_bntx_ReverseRepoMember_f6e2ac29-38a3-4398-bef2-cd001c5c592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_9366d62a-bf18-4dbe-b4ce-7aca29afc2e1" xlink:to="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_af4b76ed-8619-4a2e-891c-9125debe83d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_Cash_af4b76ed-8619-4a2e-891c-9125debe83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_c68db369-bd6f-4aaf-a1f3-d0923ac3993c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_CashEquivalents_c68db369-bd6f-4aaf-a1f3-d0923ac3993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4cb7fa39-226d-4837-997a-3f73e1a71402" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_1cfdc737-dd96-4f1a-b33c-c7a2bd1b21bf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4cb7fa39-226d-4837-997a-3f73e1a71402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_7c1ac5c1-e8c3-4501-9129-10085f273c42" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_7c1ac5c1-e8c3-4501-9129-10085f273c42" xlink:to="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_502e59c1-a114-47e4-8f67-4f4ec6f331f5" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_729c2603-76ea-4ecf-8d7c-449e852d909b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_729c2603-76ea-4ecf-8d7c-449e852d909b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e656d74d-23a5-4553-93f6-0e6f9f792f47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_f389c874-37b7-473f-8ce0-3dc38bacc5d7" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_e656d74d-23a5-4553-93f6-0e6f9f792f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_77338b18-e5d2-4c6d-b559-11b3d04ebe3b" xlink:to="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_09d5667b-1c0c-4d23-87e2-c5c029277916" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_ifrs-full_DerivativesMember_09d5667b-1c0c-4d23-87e2-c5c029277916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MoneyMarketFundMember_67d3d883-d968-4929-ae8e-1e0e03bb0f23" xlink:href="bntx-20231231.xsd#bntx_MoneyMarketFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_MoneyMarketFundMember_67d3d883-d968-4929-ae8e-1e0e03bb0f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NonListedEquityInvestmentsMember_c76f1868-5a6c-4d26-991e-bd6dc2758413" xlink:href="bntx-20231231.xsd#bntx_NonListedEquityInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_NonListedEquityInvestmentsMember_c76f1868-5a6c-4d26-991e-bd6dc2758413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ListedEquityInvestmentsMember_e057d895-7748-4f8c-908d-7d38393e0a14" xlink:href="bntx-20231231.xsd#bntx_ListedEquityInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_ListedEquityInvestmentsMember_e057d895-7748-4f8c-908d-7d38393e0a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_265cdcd0-3585-43a3-bbb1-36c406250d19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_ifrs-full_TradeReceivablesMember_265cdcd0-3585-43a3-bbb1-36c406250d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesInvestmentMember_dc960400-98aa-4f64-998d-4dff4f92f45a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuritiesInvestmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_us-gaap_SecuritiesInvestmentMember_dc960400-98aa-4f64-998d-4dff4f92f45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialAssetsMember_6f8d7cf6-8dbb-48e1-8350-6d5b47560d03" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_OtherFinancialAssetsMember_6f8d7cf6-8dbb-48e1-8350-6d5b47560d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BankDepositsMember_0512446a-6894-49e3-a847-1a9dd3a83246" xlink:href="bntx-20231231.xsd#bntx_BankDepositsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_BankDepositsMember_0512446a-6894-49e3-a847-1a9dd3a83246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReverseRepoMember_f1bdb0b3-9e14-4e44-86e9-47b41b69ddd6" xlink:href="bntx-20231231.xsd#bntx_ReverseRepoMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_ReverseRepoMember_f1bdb0b3-9e14-4e44-86e9-47b41b69ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAtBanksAndOnHandMember_d16b28e0-3d8a-4389-8a1c-9faf9d3cb7f4" xlink:href="bntx-20231231.xsd#bntx_CashAtBanksAndOnHandMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_6957c833-d350-4b1c-93a6-fde028287d40" xlink:to="loc_bntx_CashAtBanksAndOnHandMember_d16b28e0-3d8a-4389-8a1c-9faf9d3cb7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_77f318aa-0b96-4cfc-be42-c6873a79a619" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DerivativeLiabilitiesMember_1951347d-5684-4dec-92e6-fe1a7d2bd21b" xlink:href="bntx-20231231.xsd#bntx_DerivativeLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_DerivativeLiabilitiesMember_1951347d-5684-4dec-92e6-fe1a7d2bd21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_962e4c4f-b5fc-4e7a-93ce-780a9224b16d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_ifrs-full_ContingentConsiderationMember_962e4c4f-b5fc-4e7a-93ce-780a9224b16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_dafc6b58-688c-4e54-b712-488fc9b5a1b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_dafc6b58-688c-4e54-b712-488fc9b5a1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LoansAndBorrowingsMember_a949ce70-431b-4428-85e7-3fdb02a05ed6" xlink:href="bntx-20231231.xsd#bntx_LoansAndBorrowingsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_LoansAndBorrowingsMember_a949ce70-431b-4428-85e7-3fdb02a05ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_TradePayablesAndOtherPayablesMember_47a3fade-c571-4895-8763-659dd6932e81" xlink:href="bntx-20231231.xsd#bntx_TradePayablesAndOtherPayablesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_TradePayablesAndOtherPayablesMember_47a3fade-c571-4895-8763-659dd6932e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherFinancialLiabilitiesMember_040e998b-7fe6-40b5-aea6-b50791bb6e0e" xlink:href="bntx-20231231.xsd#bntx_OtherFinancialLiabilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_85f9cba6-978a-474f-b5ed-759686283bfd" xlink:to="loc_bntx_OtherFinancialLiabilitiesMember_040e998b-7fe6-40b5-aea6-b50791bb6e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_36a646e2-e2cc-4dcc-9f20-7d0172fcc215" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_5d4c4729-e752-4aec-8519-d200d8197254" xlink:href="bntx-20231231.xsd#bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:to="loc_bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember_5d4c4729-e752-4aec-8519-d200d8197254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_14e7e24a-3d73-41ce-948d-04b726c99cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_2f934128-c3c6-4b5f-8a5d-a19580ef3c7d" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_14e7e24a-3d73-41ce-948d-04b726c99cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_a63b4b24-3618-4471-9ed0-ba9f9b4610ff" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_c8f4e409-b13a-46de-82cc-7c23b3f6a98c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_c8f4e409-b13a-46de-82cc-7c23b3f6a98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_310a8590-c1c7-4844-8424-7832f43ae357" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_310a8590-c1c7-4844-8424-7832f43ae357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_e7e76d8b-1cac-43aa-9807-9c53fbc4d1c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_79eb2f1e-0e77-4bcd-8edd-f0015d52083b" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_e7e76d8b-1cac-43aa-9807-9c53fbc4d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_513dd054-3687-4d1d-a499-d6056b57b564" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughProfitOrLossMember_19530a53-cdbe-4311-9b23-d097cf906707" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughProfitOrLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_FairValueThroughProfitOrLossMember_19530a53-cdbe-4311-9b23-d097cf906707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FairValueThroughOCIMember_831f8ffd-c166-45f7-974a-b801b1aa817b" xlink:href="bntx-20231231.xsd#bntx_FairValueThroughOCIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_FairValueThroughOCIMember_831f8ffd-c166-45f7-974a-b801b1aa817b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AmortizedCostMember_c5e592f7-6bda-4501-8e01-ef4cce0dde0a" xlink:href="bntx-20231231.xsd#bntx_AmortizedCostMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_5f2af866-61c6-49a2-a7f8-140b7f00a941" xlink:to="loc_bntx_AmortizedCostMember_c5e592f7-6bda-4501-8e01-ef4cce0dde0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MeasurementAxis_fba441b0-23cb-4dea-915b-74713797276d" xlink:to="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AtFairValueMember_68aa312e-adcb-4f2e-a5cd-42653412d4ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedMeasurementMember_9caf6269-d49c-4c89-811a-43d4bf351f4b" xlink:to="loc_ifrs-full_AtFairValueMember_68aa312e-adcb-4f2e-a5cd-42653412d4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable_8265273d-0655-4f2a-8d17-1677e6243981" xlink:to="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_d0d8e98b-d7cb-4c59-a976-e6955987103f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:to="loc_ifrs-full_FinancialAssets_d0d8e98b-d7cb-4c59-a976-e6955987103f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_e7daed50-9387-43fb-b0c8-d1301239cc1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5ebd68d-68ad-4250-8cf2-e959b5cad660" xlink:to="loc_ifrs-full_FinancialLiabilities_e7daed50-9387-43fb-b0c8-d1301239cc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_30bdc355-2234-4c94-911a-5512d5ab341d" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_30bdc355-2234-4c94-911a-5512d5ab341d" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_8d7426b5-ae76-4848-b280-1f32eba75702" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_f7df8a02-4c97-43f2-b5e0-bce8f1e82a73" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_68a95675-aa3a-47c5-ad89-930367c0853b" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_f7df8a02-4c97-43f2-b5e0-bce8f1e82a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsTable_c3bbb7ff-dd1b-47f6-adb1-76c722fe4bd4" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_286745db-4542-40ce-873f-da6754ea8148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsLineItems_c785388a-65ab-4220-8fc5-526191399003" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_286745db-4542-40ce-873f-da6754ea8148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_a20a82eb-70b5-40f2-8103-39d696f7d3e7" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_a20a82eb-70b5-40f2-8103-39d696f7d3e7" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_df7f6970-0e8c-4a4b-8b73-341ddca2fda6" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_62308ae3-2d4c-44a5-8197-e4d218fd1d6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_bb38392f-0462-4cee-a4d2-2a78485f9bc3" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_62308ae3-2d4c-44a5-8197-e4d218fd1d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_e46b3643-e766-4a60-a985-190f8eb4a2ff" xlink:to="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_ec39931b-3fce-4ae9-9dda-0ca65cb234ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_5130f535-aa5a-45b8-abde-a38046ecb0b3" xlink:to="loc_ifrs-full_ContingentConsiderationMember_ec39931b-3fce-4ae9-9dda-0ca65cb234ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_feef23e0-6e69-45b4-bc61-908f14d67756" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_b5d6b0a3-6f78-495a-a7e5-7e7abe32ccd4" xlink:to="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_2dd48380-5bb4-4e84-a6d1-7d480eaf350b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_Liabilities_2dd48380-5bb4-4e84-a6d1-7d480eaf350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_4ded54a1-7585-440c-ae7a-0f8f8a539d8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_Liabilities_4ded54a1-7585-440c-ae7a-0f8f8a539d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities_a1c875c5-1838-4fab-b8b9-bce1ffb4b415" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_PurchasesFairValueMeasurementLiabilities_a1c875c5-1838-4fab-b8b9-bce1ffb4b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NetChangeInFairValue_e85f55da-cd94-4a38-a55e-9664e941f35f" xlink:href="bntx-20231231.xsd#bntx_NetChangeInFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_bntx_NetChangeInFairValue_e85f55da-cd94-4a38-a55e-9664e941f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_e7dd1641-0193-459f-a662-8278f7864d0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_LiabilitiesRollForward_062f23b3-15dc-4581-acaf-121c2e6508e9" xlink:to="loc_ifrs-full_Liabilities_e7dd1641-0193-459f-a662-8278f7864d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_8717f5c6-e288-47d5-a99d-80cf4e29d811" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_8717f5c6-e288-47d5-a99d-80cf4e29d811" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_1d2c9964-4917-44ea-a48e-37a5899395c5" xlink:to="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_e3dbc396-e9bb-4af5-baad-18c4359f9b43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_2ddd698c-9008-4f3e-838e-1e0819811bfc" xlink:to="loc_ifrs-full_ContingentConsiderationMember_e3dbc396-e9bb-4af5-baad-18c4359f9b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_74b9325f-c891-4be0-b76d-f82f5cd85453" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_1fa22ebb-79bd-4dac-8c37-b85fc3cd516d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_8b3e223f-8c5c-46fd-a231-e3f7343c59f8" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_1fa22ebb-79bd-4dac-8c37-b85fc3cd516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b7aa3681-cf59-4a5e-a276-851259c1e1af" xlink:to="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashFlowProjectionsMeasurementInputMember_22283177-1d1c-4b64-8f8e-f86631fa933d" xlink:href="bntx-20231231.xsd#bntx_CashFlowProjectionsMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:to="loc_bntx_CashFlowProjectionsMeasurementInputMember_22283177-1d1c-4b64-8f8e-f86631fa933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_12e934f3-706c-43e3-9112-7d91059d3570" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_28539096-c280-4ec0-9066-4c08d2f0a66f" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_12e934f3-706c-43e3-9112-7d91059d3570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_13d0985f-503b-4432-b063-9ef8fada9173" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_18afb2e2-a7e2-4f32-808f-a28bb4180a2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_18afb2e2-a7e2-4f32-808f-a28bb4180a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_135568ad-0af4-42be-ae4b-92c41db223b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_135568ad-0af4-42be-ae4b-92c41db223b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_e2a86daa-c411-43c0-b069-5acbca81a09c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_394dd7c6-ab6f-4cf8-9755-17876c62aa99" xlink:to="loc_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities_e2a86daa-c411-43c0-b069-5acbca81a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_645818c0-bbcc-4496-a9b5-25df48dc1c58" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_645818c0-bbcc-4496-a9b5-25df48dc1c58" xlink:to="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_fae62762-8f94-4bfa-a3a6-1251e528fb72" xlink:to="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_9d80b9bb-084f-445c-85d8-892cc33696a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_583ab822-0f3c-4373-953c-0f479b5d0949" xlink:to="loc_ifrs-full_CurrencyRiskMember_9d80b9bb-084f-445c-85d8-892cc33696a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_f855fcd8-2a45-47cd-b471-9b1198143334" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1Member_33f09619-0a4c-4a5d-ad6a-f62c90bd8743" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_d67d4d4d-ce03-46f3-9bdb-86c7ea73fe1c" xlink:to="loc_bntx_CashAndCashEquivalents1Member_33f09619-0a4c-4a5d-ad6a-f62c90bd8743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_43ffe9f7-904e-4582-a3b4-19c84cae0bed" xlink:to="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryAssetsMember_9b3274a6-1347-4e0b-a0ca-2643289b2b2b" xlink:href="bntx-20231231.xsd#bntx_MonetaryAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_23cb9047-c4c7-4a69-b4fd-74b35b6797bc" xlink:to="loc_bntx_MonetaryAssetsMember_9b3274a6-1347-4e0b-a0ca-2643289b2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_1b0cc64b-d08e-404b-9a38-3d7d629acb24" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MonetaryLiabilityAndProvisionsMember_78e46be9-f6e6-40e2-b290-acc466cbb36a" xlink:href="bntx-20231231.xsd#bntx_MonetaryLiabilityAndProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_5fc9a527-a6c2-4de3-b1c2-6c23073f4400" xlink:to="loc_bntx_MonetaryLiabilityAndProvisionsMember_78e46be9-f6e6-40e2-b290-acc466cbb36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalents1LineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalentsTable_b6c99df6-a5b4-4e48-a5df-03692dc6d8e3" xlink:to="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashAndCashEquivalent_7987a02d-a050-4557-b910-8db1d05a6bd5" xlink:href="bntx-20231231.xsd#bntx_CashAndCashEquivalent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_CashAndCashEquivalents1LineItems_f8b043be-bb1c-49a4-ad93-5ac036e8bcc4" xlink:to="loc_bntx_CashAndCashEquivalent_7987a02d-a050-4557-b910-8db1d05a6bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_85acc314-2886-4ded-b868-eed853d11ac3" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_85acc314-2886-4ded-b868-eed853d11ac3" xlink:to="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e8855bdd-f9e0-4e29-93d8-6cf96f62ca8a" xlink:to="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_16d996cf-7b19-48db-a29c-656d9a51d1c1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cd620ac4-6fb6-4621-9eeb-e71d2f059e11" xlink:to="loc_country_US_16d996cf-7b19-48db-a29c-656d9a51d1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_ef84f433-a958-4319-ac43-f8705b8aa612" xlink:to="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_8811214e-b037-460f-ac7c-ec92a0d61ad1" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_539b4ea1-c8de-4d6f-9d0e-0e1000b6d71b" xlink:to="loc_currency_USD_8811214e-b037-460f-ac7c-ec92a0d61ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_a4a98338-7b5c-4461-b97a-5d023d97fbd1" xlink:to="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_f4ec46f0-2a5f-4eba-a4f9-84809dd14e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_194c6723-f688-4bd0-8f56-260cea2ebc66" xlink:to="loc_ifrs-full_CurrencyRiskMember_f4ec46f0-2a5f-4eba-a4f9-84809dd14e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsAxis_6e92eeb0-4bae-4167-a6f2-59e7fe947f9e" xlink:to="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_341bdc29-8521-4ae5-9fde-fcb04a2689a4" xlink:href="bntx-20231231.xsd#bntx_PositiveFivePercentageChangeInForeignExchangeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:to="loc_bntx_PositiveFivePercentageChangeInForeignExchangeRateMember_341bdc29-8521-4ae5-9fde-fcb04a2689a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_caa2283c-e9fb-404d-ac87-8488cfbe50b3" xlink:href="bntx-20231231.xsd#bntx_NegativeFivePercentageChangeInForeignExchangeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_HedgingInstrumentsMember_94c54a7d-d577-4819-9d0b-0b7a42030997" xlink:to="loc_bntx_NegativeFivePercentageChangeInForeignExchangeRateMember_caa2283c-e9fb-404d-ac87-8488cfbe50b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable_f2ef7c3f-676a-4922-a61f-9b59b9c8ad75" xlink:to="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_b3827110-0b8b-4ff9-9468-cc565e152964" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_b3827110-0b8b-4ff9-9468-cc565e152964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_ae4df442-9848-46e3-92e7-79356db9f324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_ae4df442-9848-46e3-92e7-79356db9f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_98dff2db-fee7-4210-9f32-c02f17ba2cfe" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax_98dff2db-fee7-4210-9f32-c02f17ba2cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_2c2c3f7f-3224-4011-888c-8bfadb6762ae" xlink:href="bntx-20231231.xsd#bntx_ForeignCurrencyChangesEffectOnPretaxEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems_4d42833f-18a1-4e79-a17c-aaf5c5c0760b" xlink:to="loc_bntx_ForeignCurrencyChangesEffectOnPretaxEquity_2c2c3f7f-3224-4011-888c-8bfadb6762ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_be45bedf-0b8d-44ef-a02d-4fc32c8e8f70" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_be45bedf-0b8d-44ef-a02d-4fc32c8e8f70" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:to="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_f53eecaf-3a79-44e8-947b-3040b1eb7bb7" xlink:to="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember_cf6d0b6e-8b87-4cfb-b099-299f78f1ed14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_e833d66f-d592-4a1b-9135-9b87a2355638" xlink:to="loc_ifrs-full_LiquidityRiskMember_cf6d0b6e-8b87-4cfb-b099-299f78f1ed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:to="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_70eace01-30a7-407d-920c-2a03c1600741" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_af13ca53-e059-45f2-b119-fd7beecd0816" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_af13ca53-e059-45f2-b119-fd7beecd0816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_bfac2718-c0c6-4c3b-9ac0-cf0cdcd5e08f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember_bfac2718-c0c6-4c3b-9ac0-cf0cdcd5e08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4c3e003b-d969-4d42-8602-f04ce3cbf259" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_90f009b2-9281-4b25-a63e-f58adde97b24" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4c3e003b-d969-4d42-8602-f04ce3cbf259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesTable_747a39b8-bf59-43ea-bd31-88793c5cf9cc" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowings_0ae31723-6792-4b75-b763-042c4f715a5d" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_bntx_InterestBearingLoansAndBorrowings_0ae31723-6792-4b75-b763-042c4f715a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_92beb979-51ba-4520-b0da-83a7e2f68e34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_TradeAndOtherPayables_92beb979-51ba-4520-b0da-83a7e2f68e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_db4896b7-24d8-434a-a8f1-c8e2b813102b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_LeaseLiabilities_db4896b7-24d8-434a-a8f1-c8e2b813102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b7f5b525-2443-489f-83e6-569227a55f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination_b7f5b525-2443-489f-83e6-569227a55f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_bf603c98-3888-41ff-b3e0-acd9844c24d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_bf603c98-3888-41ff-b3e0-acd9844c24d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherFinancialLiabilities_25b6e3a2-42e9-4575-842c-42bb4ad33d2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_OtherFinancialLiabilities_25b6e3a2-42e9-4575-842c-42bb4ad33d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_bc60d1c1-0a5f-45bd-904f-9d1a29abcee4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_6f022198-76d6-4d25-9d66-db1b571233f9" xlink:to="loc_ifrs-full_FinancialLiabilities_bc60d1c1-0a5f-45bd-904f-9d1a29abcee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_FinancialInstrumentsAbstract_548ec00b-c2ba-47fd-8b8a-2aaffa02012f" xlink:href="bntx-20231231.xsd#bntx_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_FinancialInstrumentsAbstract_548ec00b-c2ba-47fd-8b8a-2aaffa02012f" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_deb495ef-a250-4cef-a058-44c3748aea6f" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentObligationsUnderLeaseContractsMember_df5157c0-29b9-4e4b-97d7-7e09faef992c" xlink:href="bntx-20231231.xsd#bntx_CurrentObligationsUnderLeaseContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_CurrentObligationsUnderLeaseContractsMember_df5157c0-29b9-4e4b-97d7-7e09faef992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember_89bb48e4-ceb1-4ffc-ab9a-62b53595d8ae" xlink:href="bntx-20231231.xsd#bntx_NoncurrentObligationsUnderLeaseContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_NoncurrentObligationsUnderLeaseContractsMember_89bb48e4-ceb1-4ffc-ab9a-62b53595d8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InterestBearingLoansAndBorrowingsMember_c1db5005-3123-46e6-94f6-7a5374d1572c" xlink:href="bntx-20231231.xsd#bntx_InterestBearingLoansAndBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_InterestBearingLoansAndBorrowingsMember_c1db5005-3123-46e6-94f6-7a5374d1572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember_ffc6f136-14db-440e-b535-b5088500ddbe" xlink:href="bntx-20231231.xsd#bntx_ConvertibleNoteEmbeddedDerivativeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ed01887d-91ac-4408-94d9-d10a172479c1" xlink:to="loc_bntx_ConvertibleNoteEmbeddedDerivativeMember_ffc6f136-14db-440e-b535-b5088500ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_fd1d9883-5991-4ac9-a8b5-a594ffbab6a8" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_85aba43c-21de-4c15-8709-c1fe3ecfd0d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_85aba43c-21de-4c15-8709-c1fe3ecfd0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d0bd7d67-ddd8-4b43-ab0b-5c2a3456aca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d0bd7d67-ddd8-4b43-ab0b-5c2a3456aca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_1bb1ad03-e73d-49b3-8166-b135b5d1e903" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_1bb1ad03-e73d-49b3-8166-b135b5d1e903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_b08676af-0fa7-4315-84c4-75626019aaab" xlink:href="bntx-20231231.xsd#bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities_b08676af-0fa7-4315-84c4-75626019aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_147ad4ae-024d-4a3c-9570-3ebb654446d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_147ad4ae-024d-4a3c-9570-3ebb654446d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_482e7e44-493e-4efd-acce-e658026d95ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_265f1231-74af-45fa-b6d9-2d69b751ecc2" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_482e7e44-493e-4efd-acce-e658026d95ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#InventoriesSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InventoriesAbstract_fb185612-9a6e-425e-890c-d1310237d567" xlink:href="bntx-20231231.xsd#bntx_InventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_3797a376-9285-46c6-9f63-f3725183dace" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_fb185612-9a6e-425e-890c-d1310237d567" xlink:to="loc_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_3797a376-9285-46c6-9f63-f3725183dace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_5536d6e3-6869-4ed8-a810-620c4f032bbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_fb185612-9a6e-425e-890c-d1310237d567" xlink:to="loc_ifrs-full_WorkInProgress_5536d6e3-6869-4ed8-a810-620c4f032bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_99ecaa34-ae56-4ef5-8ee2-cfff8440333b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_fb185612-9a6e-425e-890c-d1310237d567" xlink:to="loc_ifrs-full_FinishedGoods_99ecaa34-ae56-4ef5-8ee2-cfff8440333b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_eecb2343-47bc-44be-afd7-f12f2d7e5bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_fb185612-9a6e-425e-890c-d1310237d567" xlink:to="loc_ifrs-full_Inventories_eecb2343-47bc-44be-afd7-f12f2d7e5bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/InventoriesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#InventoriesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/InventoriesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InventoriesAbstract_6b75a52a-3dc1-45e5-b378-92a8035ad2be" xlink:href="bntx-20231231.xsd#bntx_InventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoryWritedown2011_7c366e1e-5b99-4b83-bd06-9e86fe7ade46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_6b75a52a-3dc1-45e5-b378-92a8035ad2be" xlink:to="loc_ifrs-full_InventoryWritedown2011_7c366e1e-5b99-4b83-bd06-9e86fe7ade46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_a57be769-c3bd-432e-a813-b7c0c112815f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_InventoriesAbstract_6b75a52a-3dc1-45e5-b378-92a8035ad2be" xlink:to="loc_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod_a57be769-c3bd-432e-a813-b7c0c112815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsSummaryofOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredExpense_6e3ee098-4657-4d26-a856-fa67c8dbe611" xlink:href="bntx-20231231.xsd#bntx_DeferredExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_bntx_DeferredExpense_6e3ee098-4657-4d26-a856-fa67c8dbe611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_ba247b0e-d3c1-4335-8a32-3dbd00d43552" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_ba247b0e-d3c1-4335-8a32-3dbd00d43552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAdvancesToSuppliers_7733bbf5-6a94-47c2-9a0e-83550b96d3d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_ifrs-full_CurrentAdvancesToSuppliers_7733bbf5-6a94-47c2-9a0e-83550b96d3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherCurrentAssetsOther_2e826e61-3b4b-47a0-8285-da5bad33e393" xlink:href="bntx-20231231.xsd#bntx_OtherCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_bntx_OtherCurrentAssetsOther_2e826e61-3b4b-47a0-8285-da5bad33e393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialAssets_ecf163cd-1eed-461e-8d02-c31e308edb37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_ifrs-full_OtherNonfinancialAssets_ecf163cd-1eed-461e-8d02-c31e308edb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialAssets_1c4efb0e-0f76-4d0d-9807-8a56b929e06a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialAssets_1c4efb0e-0f76-4d0d-9807-8a56b929e06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_7ea2e7a6-414c-4cde-adcf-bf02a44cb208" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_739fbd9d-de96-4582-93c3-2aab79b862ff" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_7ea2e7a6-414c-4cde-adcf-bf02a44cb208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialAssetsAbstract_6e962426-7cb0-497e-acfb-bbbf688a425b" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialAssetsAbstract_6e962426-7cb0-497e-acfb-bbbf688a425b" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:to="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersAxis_1b565363-6eb8-4b06-9de1-e6f3e4236450" xlink:to="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EuropeanCommissionToCollaborationPartnerMember_f71fe437-b92a-40d6-b50b-4087d1fb502b" xlink:href="bntx-20231231.xsd#bntx_EuropeanCommissionToCollaborationPartnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorCustomersMember_3bdfea34-38b5-479c-a3f6-1da04a92168e" xlink:to="loc_bntx_EuropeanCommissionToCollaborationPartnerMember_f71fe437-b92a-40d6-b50b-4087d1fb502b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:to="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SignificantInvestmentsInAssociatesAxis_7d01c27a-610f-4b51-a3ac-fb618b830651" xlink:to="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OncoC4IncMember_28dfa3ad-4a4b-42d8-8256-c934db92408c" xlink:href="bntx-20231231.xsd#bntx_OncoC4IncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_OncoC4IncMember_28dfa3ad-4a4b-42d8-8256-c934db92408c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RyvuTherapeuticsSAMember_09bfe62b-dcb0-436b-a017-8b1024661843" xlink:href="bntx-20231231.xsd#bntx_RyvuTherapeuticsSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_RyvuTherapeuticsSAMember_09bfe62b-dcb0-436b-a017-8b1024661843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MedigeneImmunotherapiesGmbHMember_c3cfde4f-ace8-4d51-8d6a-85859c585f06" xlink:href="bntx-20231231.xsd#bntx_MedigeneImmunotherapiesGmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForAssociatesMember_c082e17e-21f3-4ffb-9f4d-d03a167d2b61" xlink:to="loc_bntx_MedigeneImmunotherapiesGmbHMember_c3cfde4f-ace8-4d51-8d6a-85859c585f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:href="bntx-20231231.xsd#bntx_DisclosureOfIncomeAndExpensesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesTable_07425bcf-7e3b-4ff8-bfad-6540b9fc765f" xlink:to="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DeferredExpense_cb951413-55ca-48d2-ba11-22d5f156f1b3" xlink:href="bntx-20231231.xsd#bntx_DeferredExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_DisclosureOfIncomeAndExpensesLineItems_77ecd95d-ab65-4073-bf15-1f43a7303b47" xlink:to="loc_bntx_DeferredExpense_cb951413-55ca-48d2-ba11-22d5f156f1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReservesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_4132753c-4295-46e8-9e1b-592a3b3743e8" xlink:href="bntx-20231231.xsd#bntx_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_4132753c-4295-46e8-9e1b-592a3b3743e8" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e0752ca4-3265-4c42-ab37-9a3faf4e549d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PfizerIncMember_1769984d-7827-4ed0-a539-a8a5b2564706" xlink:href="bntx-20231231.xsd#bntx_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93e52aeb-fc35-4a19-8713-abe734cfe0d4" xlink:to="loc_bntx_PfizerIncMember_1769984d-7827-4ed0-a539-a8a5b2564706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_defa4e5e-95bc-46e4-a8b8-066147aa15fa" xlink:to="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7bb8ab08-6efa-4040-93a7-c98e36aa1b7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:to="loc_ifrs-full_IssuedCapitalMember_7bb8ab08-6efa-4040-93a7-c98e36aa1b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CapitalReserveMember_66d59b66-01d5-4722-b8bb-82867257e719" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a5ab7a21-32ef-47b2-8e7a-2477a50fc505" xlink:to="loc_ifrs-full_CapitalReserveMember_66d59b66-01d5-4722-b8bb-82867257e719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d0d8fcc4-1511-4597-9dbd-7b1a9ffc2d8b" xlink:to="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_ed9ae16c-1857-4b7b-9e24-f804e816bb35" xlink:href="bntx-20231231.xsd#bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_590ceb10-6a00-464a-bc63-ec65b0005750" xlink:to="loc_bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember_ed9ae16c-1857-4b7b-9e24-f804e816bb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_e7396cb9-1c41-497c-9aaf-ea34cb6d40cd" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e65af2c8-ffba-4f5a-80d4-bf2c5c83a111" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e65af2c8-ffba-4f5a-80d4-bf2c5c83a111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_71306931-679d-4447-89bd-90f7dd72c5d1" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_4fbaff14-1f0c-447d-9e98-5c2b37515038" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_71306931-679d-4447-89bd-90f7dd72c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_e42aac51-7920-436f-9ba7-bd815d4a93cb" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_992c5a66-eff0-4767-b1b0-11e6af469343" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_992c5a66-eff0-4767-b1b0-11e6af469343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfSharesHeldInTreasury_bf8b840f-d969-4606-9b87-ae2f4c1985ce" xlink:href="bntx-20231231.xsd#bntx_NumberOfSharesHeldInTreasury"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_bntx_NumberOfSharesHeldInTreasury_bf8b840f-d969-4606-9b87-ae2f4c1985ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_cb85f760-a378-4ff6-a085-fde5d11bbae9" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_cb85f760-a378-4ff6-a085-fde5d11bbae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_7b229b61-0bbd-4713-aeb4-10cd334689e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_NumberOfSharesIssued_7b229b61-0bbd-4713-aeb4-10cd334689e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_069d4d57-fc6b-47a5-aba6-06f87e5e7edf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_IssueOfEquity_069d4d57-fc6b-47a5-aba6-06f87e5e7edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_d92b55f7-a9c9-4967-8907-18012db969d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_IssuedCapital_d92b55f7-a9c9-4967-8907-18012db969d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_4d941948-f58c-4dd6-b3a2-753c3a7a062c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments_4d941948-f58c-4dd6-b3a2-753c3a7a062c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_db9c17c9-f0cf-4823-8274-719e37f7c378" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_db9c17c9-f0cf-4823-8274-719e37f7c378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_d9761810-998e-4745-8116-f4dbcf50af56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_e88e674c-1fe2-414b-8a81-38d82a2fd848" xlink:to="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_d9761810-998e-4745-8116-f4dbcf50af56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_50c9c7cd-cedd-453f-b6e2-4f93a6c5379f" xlink:href="bntx-20231231.xsd#bntx_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract_50c9c7cd-cedd-453f-b6e2-4f93a6c5379f" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodAxis_085fcb9c-b6b6-47cc-8e1a-379f20ff5b1e" xlink:to="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e47d1724-195b-4d61-906b-efa6549a017f" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheOneMember_e47d1724-195b-4d61-906b-efa6549a017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_2d128e8d-54cb-4274-ae59-be4c38312c0f" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgramTrancheTwoMember_2d128e8d-54cb-4274-ae59-be4c38312c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgram2023Member_7a5abaa3-8b92-49a4-a3a8-e82aba68bf33" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgram2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareRepurchaseProgramPeriodDomain_b805bc92-44a0-4cf6-899f-7e7036390a89" xlink:to="loc_bntx_ShareRepurchaseProgram2023Member_7a5abaa3-8b92-49a4-a3a8-e82aba68bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_2fad22de-ce7c-4048-b591-7f1ad5b213b7" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_ce17461a-b4d7-4d3b-a91b-4430d4c11397" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramAuthorizedAmount_ce17461a-b4d7-4d3b-a91b-4430d4c11397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_f76dd0dc-ee83-4259-8df5-ef858aab5559" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased_f76dd0dc-ee83-4259-8df5-ef858aab5559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_eda1cf03-3992-4735-979b-2a82a7ead7c1" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS_eda1cf03-3992-4735-979b-2a82a7ead7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareRepurchaseProgramNetAmountSpent_d23c70f7-fe3e-4529-95a0-44d10c9489e3" xlink:href="bntx-20231231.xsd#bntx_ShareRepurchaseProgramNetAmountSpent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_7cba08e2-7697-466f-a739-a2805c71bd55" xlink:to="loc_bntx_ShareRepurchaseProgramNetAmountSpent_d23c70f7-fe3e-4529-95a0-44d10c9489e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_50c4dce1-f082-4f8c-b371-b57196cc6255" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_50c4dce1-f082-4f8c-b371-b57196cc6255" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1fab7b0a-7de1-404f-8f0b-f7f6802c1a10" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_50fa3620-892f-4cbc-928d-13157ae1d58f" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_50fa3620-892f-4cbc-928d-13157ae1d58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_deb2f319-6dee-4a00-a5d0-583aaf2fd9fb" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_deb2f319-6dee-4a00-a5d0-583aaf2fd9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_c47a7130-b764-477b-a407-bf1687fd0a19" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_ManagementBoardGrantMember_c47a7130-b764-477b-a407-bf1687fd0a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_1d36b2e0-1e7c-48da-b001-6c566ce2f143" xlink:href="bntx-20231231.xsd#bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember_1d36b2e0-1e7c-48da-b001-6c566ce2f143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_InstaDeepEmployeeIncentivePlanMember_37adc026-775b-4668-b4ef-afdb96c0a896" xlink:href="bntx-20231231.xsd#bntx_InstaDeepEmployeeIncentivePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_InstaDeepEmployeeIncentivePlanMember_37adc026-775b-4668-b4ef-afdb96c0a896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_82985859-c1e9-482e-a977-c2d1c67e46ac" xlink:href="bntx-20231231.xsd#bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_64ec9633-5d53-42bc-90b2-06ecf240ee2a" xlink:to="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_82985859-c1e9-482e-a977-c2d1c67e46ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:to="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_94a9e5d4-81b7-4ce7-a783-89538c68350e" xlink:to="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSalesMember_ae654044-86f6-444b-b58b-563ab587763b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_ifrs-full_CostOfSalesMember_ae654044-86f6-444b-b58b-563ab587763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ResearchAndDevelopmentExpensesMember_4c72b6e8-b989-4e96-b87a-61a23143f2c9" xlink:href="bntx-20231231.xsd#bntx_ResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_ResearchAndDevelopmentExpensesMember_4c72b6e8-b989-4e96-b87a-61a23143f2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SalesAndMarketingExpenseMember_20e3e64c-2c0c-4bff-a9a6-2b327f3c05e0" xlink:href="bntx-20231231.xsd#bntx_SalesAndMarketingExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_SalesAndMarketingExpenseMember_20e3e64c-2c0c-4bff-a9a6-2b327f3c05e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_GeneralAndAdministrativeExpensesMember_8a60bd5f-d780-4122-a5af-9bc0cc9b0ccb" xlink:href="bntx-20231231.xsd#bntx_GeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LineItemsByFunctionMember_84cda87c-de84-4af1-8e77-003d15e9b50f" xlink:to="loc_bntx_GeneralAndAdministrativeExpensesMember_8a60bd5f-d780-4122-a5af-9bc0cc9b0ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_cfb0a868-7db8-44b9-8c73-46366dbd1815" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_fa901e30-2562-46d9-a358-ef72e1870ca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_fa901e30-2562-46d9-a358-ef72e1870ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_841b4f0c-e7ec-4a9c-bc87-39ab151baa12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_841b4f0c-e7ec-4a9c-bc87-39ab151baa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a775c432-fbbd-4da4-bb47-2ec41d79bad8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a775c432-fbbd-4da4-bb47-2ec41d79bad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_a95ace5a-cb88-40fd-b0ba-bdde176d59fd" xlink:href="bntx-20231231.xsd#bntx_ReclassificationOfShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_a95ace5a-cb88-40fd-b0ba-bdde176d59fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermDeposits_5e106327-a7cc-49e1-b150-acae5b582a53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ffe1431d-eddf-4019-befc-8e5091f441a2" xlink:to="loc_ifrs-full_LongtermDeposits_5e106327-a7cc-49e1-b150-acae5b582a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_628be208-35c6-4653-a043-0ee5896ee9c4" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_628be208-35c6-4653-a043-0ee5896ee9c4" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4d1e2f4c-a494-4aad-bf2f-7e3d5abff59c" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_4a1892ba-104e-4120-86eb-5829957e9907" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_4a1892ba-104e-4120-86eb-5829957e9907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_b82f36e5-2284-4777-9a9f-e80e19c0d613" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_b82f36e5-2284-4777-9a9f-e80e19c0d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_aacbf8e3-4fab-48ba-8c81-7ea0c5932827" xlink:href="bntx-20231231.xsd#bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember_aacbf8e3-4fab-48ba-8c81-7ea0c5932827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_4b1e7553-b7a2-4a8e-8759-f1fd9009c177" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_ManagementBoardGrantMember_4b1e7553-b7a2-4a8e-8759-f1fd9009c177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_0de0f24f-0bbd-4034-9d93-db21f4e23f5e" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_0de0f24f-0bbd-4034-9d93-db21f4e23f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_2632f663-c4fe-4b64-b462-4dfbd336da28" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_2632f663-c4fe-4b64-b462-4dfbd336da28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashSettledShareBasedPaymentArrangementMember_226876a1-bfde-422c-ab8e-b1bcb71bb498" xlink:href="bntx-20231231.xsd#bntx_CashSettledShareBasedPaymentArrangementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_74d34f52-aaa1-4545-ac9c-bd898031632c" xlink:to="loc_bntx_CashSettledShareBasedPaymentArrangementMember_226876a1-bfde-422c-ab8e-b1bcb71bb498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:href="bntx-20231231.xsd#bntx_VestingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_VestingPeriodAxis_7a1aff2f-9467-4727-a4a2-52fe012fbf21" xlink:to="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementYearOneMember_c39076db-a055-48d4-aed3-606dfdcd54dc" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementYearOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_VestingPeriodDomain_ca895bfe-146e-428d-9d60-5f9c716183e4" xlink:to="loc_bntx_ShareBasedPaymentArrangementYearOneMember_c39076db-a055-48d4-aed3-606dfdcd54dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_08e05e10-446e-42ca-aee4-6850bc06dce4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProfessorUgurSahinMDMember_f229d5b4-c9d3-44cd-9957-9a4e5aa35992" xlink:href="bntx-20231231.xsd#bntx_ProfessorUgurSahinMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:to="loc_bntx_ProfessorUgurSahinMDMember_f229d5b4-c9d3-44cd-9957-9a4e5aa35992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_DoctorSierkPoettingMember_7ab82fa4-6af4-4f20-986d-75b3ab2c8856" xlink:href="bntx-20231231.xsd#bntx_DoctorSierkPoettingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eade1247-2d86-42dc-822a-7f8e6b1d56ea" xlink:to="loc_bntx_DoctorSierkPoettingMember_7ab82fa4-6af4-4f20-986d-75b3ab2c8856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_406ba450-63e6-407a-9ae6-a8769c65cfbc" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_2e8aad32-aac2-40f7-867b-1e02c5f6a230" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0093183c-dc89-4f4e-9bf3-cbf587623152" xlink:to="loc_ifrs-full_OrdinarySharesMember_2e8aad32-aac2-40f7-867b-1e02c5f6a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dad51593-41c1-4c06-9679-10d0527818e9" xlink:to="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_487b85d7-2a21-4626-8ec6-89dc8c61e087" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f125dc9-8ef0-4326-a60d-a54a07dcd7b1" xlink:to="loc_srt_MaximumMember_487b85d7-2a21-4626-8ec6-89dc8c61e087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:href="bntx-20231231.xsd#bntx_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_SaleOfStockAxis_91f0bb38-5ba0-4779-b426-720bb63b11fa" xlink:to="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOptionPlanMember_c92e8f3c-81a7-4738-a66d-d4d6aca3cba9" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_SaleOfStockDomain_54e0f687-3d81-4f00-b833-b8b32239539c" xlink:to="loc_bntx_EmployeeStockOptionPlanMember_c92e8f3c-81a7-4738-a66d-d4d6aca3cba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_14251cd1-79de-4990-9ccf-bee53556c94d" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_a3fe5bbe-43ab-43fb-9454-2b6291728f84" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentsClassifiedAsOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities_a3fe5bbe-43ab-43fb-9454-2b6291728f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowToTaxAuthority_74cd69e6-828b-4851-b458-0ae6ad20dd12" xlink:href="bntx-20231231.xsd#bntx_CashOutflowToTaxAuthority"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_CashOutflowToTaxAuthority_74cd69e6-828b-4851-b458-0ae6ad20dd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionVestingPeriod_219c31c4-1c79-4f6a-b0fc-21233f782587" xlink:href="bntx-20231231.xsd#bntx_OptionVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_OptionVestingPeriod_219c31c4-1c79-4f6a-b0fc-21233f782587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement_918dc8fc-adc2-4eb1-9488-9e394014c1cf" xlink:href="bntx-20231231.xsd#bntx_VestingPercentageOfShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_VestingPercentageOfShareBasedPaymentArrangement_918dc8fc-adc2-4eb1-9488-9e394014c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise_e9cf83c3-cad0-4ceb-b64b-723d00d15754" xlink:href="bntx-20231231.xsd#bntx_CashOutflowForShareBasedPaymentArrangementExercise"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_CashOutflowForShareBasedPaymentArrangementExercise_e9cf83c3-cad0-4ceb-b64b-723d00d15754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_7e4d4ffc-f197-4f1e-baaa-6d2ac9894d87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_7e4d4ffc-f197-4f1e-baaa-6d2ac9894d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_bf6e829f-18d2-44e9-9049-66f92c407ffc" xlink:href="bntx-20231231.xsd#bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares_bf6e829f-18d2-44e9-9049-66f92c407ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionExercisablePeriod_1bac2c8e-6efd-4901-8e32-ac8299cce667" xlink:href="bntx-20231231.xsd#bntx_OptionExercisablePeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_OptionExercisablePeriod_1bac2c8e-6efd-4901-8e32-ac8299cce667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfIncreaseInExercisePrice_9db2d5ac-9688-4981-a190-483a6a2aa84b" xlink:href="bntx-20231231.xsd#bntx_PercentageOfIncreaseInExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfIncreaseInExercisePrice_9db2d5ac-9688-4981-a190-483a6a2aa84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_7848cc70-0749-42df-b961-e6d8707c2e93" xlink:href="bntx-20231231.xsd#bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering_7848cc70-0749-42df-b961-e6d8707c2e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_8f83886b-88b8-4071-8dfb-2801eb4cbe8e" xlink:href="bntx-20231231.xsd#bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth_8f83886b-88b8-4071-8dfb-2801eb4cbe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OptionExercisablePeriod_845fcb9a-5898-44d9-9736-5dcecbe7b54e" xlink:href="bntx-20231231.xsd#bntx_OptionExercisablePeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_25bf7cda-8f11-41a4-8265-e688215fd0a9" xlink:href="bntx-20231231.xsd#bntx_ReclassificationOfShareBasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ReclassificationOfShareBasedPaymentArrangement_25bf7cda-8f11-41a4-8265-e688215fd0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_cb2f7405-9b76-4da6-8f9c-7229efc63361" xlink:href="bntx-20231231.xsd#bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum_cb2f7405-9b76-4da6-8f9c-7229efc63361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised_e25f7846-8159-40b7-91e6-cd87afab72ff" xlink:href="bntx-20231231.xsd#bntx_MaximumEconomicBenefitsOfOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_MaximumEconomicBenefitsOfOptionsExercised_e25f7846-8159-40b7-91e6-cd87afab72ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EffectiveExercisePriceMaximum_ee8cc473-7036-4fbf-9f59-cb11af49107e" xlink:href="bntx-20231231.xsd#bntx_EffectiveExercisePriceMaximum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_EffectiveExercisePriceMaximum_ee8cc473-7036-4fbf-9f59-cb11af49107e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_3af6780c-5be3-48f1-a0be-551915e478d5" xlink:href="bntx-20231231.xsd#bntx_MaximumCashPaymentInShareBasedPaymentArrangement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_MaximumCashPaymentInShareBasedPaymentArrangement_3af6780c-5be3-48f1-a0be-551915e478d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8c961f11-6c61-449b-976b-7e34063c6f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_8c961f11-6c61-449b-976b-7e34063c6f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PhantomOptionAwardsLiability_5c5316b4-7ee0-4cdf-8e9b-760e42aef368" xlink:href="bntx-20231231.xsd#bntx_PhantomOptionAwardsLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_PhantomOptionAwardsLiability_5c5316b4-7ee0-4cdf-8e9b-760e42aef368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_a6d0df55-9136-40ea-b651-5e847ff0709e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_a6d0df55-9136-40ea-b651-5e847ff0709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_ed4f8fd1-35ee-4c9e-ac54-4fd907260d87" xlink:href="bntx-20231231.xsd#bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare_ed4f8fd1-35ee-4c9e-ac54-4fd907260d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_5d708c24-b74b-403e-801c-e94edd3e540a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_5d708c24-b74b-403e-801c-e94edd3e540a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_850b637c-2efb-4be4-a846-a7a688df4cf8" xlink:href="bntx-20231231.xsd#bntx_ExerciseOfOptionRightsMinimumStrikePricePercent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent_850b637c-2efb-4be4-a846-a7a688df4cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1ef94a6e-3867-4411-ba0b-616ed78b55d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_1ef94a6e-3867-4411-ba0b-616ed78b55d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExercisePricePhantomOptionsGranted_bd50e6ac-7434-4882-8e72-a989f87a1caf" xlink:href="bntx-20231231.xsd#bntx_ExercisePricePhantomOptionsGranted"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ExercisePricePhantomOptionsGranted_bd50e6ac-7434-4882-8e72-a989f87a1caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_418a829f-13dd-40c4-a53c-fd882b451198" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_418a829f-13dd-40c4-a53c-fd882b451198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_29fda2de-0341-4454-bd23-36582433e943" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_29fda2de-0341-4454-bd23-36582433e943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_ca1a74f6-1e30-49f3-b2d1-85350f004146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_ca1a74f6-1e30-49f3-b2d1-85350f004146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_2c446537-280b-4fae-b3ff-810bca58c6a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_2c446537-280b-4fae-b3ff-810bca58c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_f554520d-3d4a-4fc8-9309-93b9fbb838f6" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_cda75533-cb7e-4f76-af93-4d57145f6c83" xlink:to="loc_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable_f554520d-3d4a-4fc8-9309-93b9fbb838f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_26f8c636-c96a-46c6-ad3f-2a76943fe10b" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_26f8c636-c96a-46c6-ad3f-2a76943fe10b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f8f180e0-2b8e-42cb-9a48-01acbcdc2afa" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_1e61c841-1d5a-4432-bf4a-efdafba940b4" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_1e61c841-1d5a-4432-bf4a-efdafba940b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_82f5664c-7384-418c-9473-2d16ac01dfa9" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_82f5664c-7384-418c-9473-2d16ac01dfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_a7f27a8a-0276-4bb6-89dc-95fab86a8a36" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_a7f27a8a-0276-4bb6-89dc-95fab86a8a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_172228fd-201c-45a5-a1f5-286fdb399127" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_172228fd-201c-45a5-a1f5-286fdb399127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_ce8c633b-e5d6-4a40-9e69-fd28ae1a2918" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentiveProgramMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentiveProgramMember_ce8c633b-e5d6-4a40-9e69-fd28ae1a2918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_0eeae749-5ab8-4090-9e77-3b2c3d17c5f6" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_014c2042-1eed-41cf-a776-d8d86d3124b6" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_0eeae749-5ab8-4090-9e77-3b2c3d17c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_849c4f8c-385e-4145-b7b8-4cd4e2ec30e8" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:href="bntx-20231231.xsd#bntx_ShareOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_ddb1bf2a-5d98-423f-bdc0-55b47e0f9b3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_ddb1bf2a-5d98-423f-bdc0-55b47e0f9b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9d8b2d29-9e78-4c52-b3a7-6c42fe8fc4a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_9d8b2d29-9e78-4c52-b3a7-6c42fe8fc4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_9275e41b-d29d-4a28-bb95-bb965999bf13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_9275e41b-d29d-4a28-bb95-bb965999bf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_e1507b84-fb4b-4f97-86b6-e1ef463bc4ab" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement_e1507b84-fb4b-4f97-86b6-e1ef463bc4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1804f4e8-d76b-40e1-bf6c-be227b85213f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_1804f4e8-d76b-40e1-bf6c-be227b85213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_e1645238-2972-4115-b1cb-138ed724a2c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_e1645238-2972-4115-b1cb-138ed724a2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_6b96a837-c6d0-4251-9630-4b6157d6a141" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_6b96a837-c6d0-4251-9630-4b6157d6a141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_204011ff-4ab7-46fd-96ef-684d44598e28" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareOptionsOutstandingAbstract_ea0ab278-4ef1-429e-94f8-e9472ad13d5d" xlink:to="loc_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement_204011ff-4ab7-46fd-96ef-684d44598e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_269edd1c-2b6a-4481-b987-104ac8734312" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_269edd1c-2b6a-4481-b987-104ac8734312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_304c6626-0646-4dbf-96bd-8bf8eb6e2c0d" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement_304c6626-0646-4dbf-96bd-8bf8eb6e2c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_c3c12644-55c8-4ccb-9c8a-83d4403ee809" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement_c3c12644-55c8-4ccb-9c8a-83d4403ee809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_165f71f7-d548-4b63-878b-00d646fc5e8b" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding_165f71f7-d548-4b63-878b-00d646fc5e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_5416a990-9ae3-4014-bfe0-e79e2249281a" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement_5416a990-9ae3-4014-bfe0-e79e2249281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_63a18f92-de79-4f74-a1c5-6bbe0b79d88c" xlink:href="bntx-20231231.xsd#bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract_dd94fc97-567e-4043-9283-b077d535a16e" xlink:to="loc_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement_63a18f92-de79-4f74-a1c5-6bbe0b79d88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4349e886-cf0b-4da9-8add-a50475877913" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_4349e886-cf0b-4da9-8add-a50475877913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_42421a81-4ebb-4030-a077-73817e99548f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_42421a81-4ebb-4030-a077-73817e99548f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_03609db5-44bb-4cc2-8833-a7e1f10ebfe0" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement_03609db5-44bb-4cc2-8833-a7e1f10ebfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_b80538d8-4abc-4c7f-9433-d2cf23287ea6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_b80538d8-4abc-4c7f-9433-d2cf23287ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_75aa3529-6393-4c62-b6a7-af1f10eec25d" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement_75aa3529-6393-4c62-b6a7-af1f10eec25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_c9a674ba-6b45-4242-9d78-924421f79d9b" xlink:href="bntx-20231231.xsd#bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_WeightedAverageExercisePriceAbstract_3cfa692f-262c-4abf-963d-72a9c0d1b58b" xlink:to="loc_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement_c9a674ba-6b45-4242-9d78-924421f79d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePrice2019_c9c0bc40-71d6-4414-af95-83da309691b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_76a770d2-4f15-4055-a752-ec467bec7835" xlink:to="loc_ifrs-full_WeightedAverageSharePrice2019_c9c0bc40-71d6-4414-af95-83da309691b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_dc8567f5-f116-459c-bcc9-f53c2f9f1f4e" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_dc8567f5-f116-459c-bcc9-f53c2f9f1f4e" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_d05528be-6f12-4ca2-907d-d84e2da55739" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_20ea9ea5-9511-4052-a0d6-5493c60fc619" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember_20ea9ea5-9511-4052-a0d6-5493c60fc619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_b6aa9555-017b-4538-92fe-d34b93c7336b" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember_b6aa9555-017b-4538-92fe-d34b93c7336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_09ab4481-5866-458a-aee4-243720e41b9c" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember_09ab4481-5866-458a-aee4-243720e41b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_89d72db4-fddc-4684-a835-1d3ab0c93b04" xlink:href="bntx-20231231.xsd#bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember_89d72db4-fddc-4684-a835-1d3ab0c93b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_cb0e315e-cc2a-4d87-88e5-f48cb7300b50" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_ManagementBoardGrantMember_cb0e315e-cc2a-4d87-88e5-f48cb7300b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ChiefExecutiveOfficerGrantMember_7348fec6-b489-4aa7-97ac-154d10d114a4" xlink:href="bntx-20231231.xsd#bntx_ChiefExecutiveOfficerGrantMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_ChiefExecutiveOfficerGrantMember_7348fec6-b489-4aa7-97ac-154d10d114a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanMember_2545e7e5-d922-4f6a-baf1-12b54a9f0de0" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d00f12e8-a0b9-488a-8ad2-5766d8c1476e" xlink:to="loc_bntx_EmployeeStockOwnershipPlanMember_2545e7e5-d922-4f6a-baf1-12b54a9f0de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_70f3ede4-3561-408b-8ba0-abaeccc54d9f" xlink:to="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_081a69dc-6e85-426d-a119-776d74fd4e8b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_108533b4-7ea7-4dde-91b3-1d7aadc89cad" xlink:to="loc_srt_ScenarioForecastMember_081a69dc-6e85-426d-a119-776d74fd4e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_980cef80-2be8-4975-ac33-046fda8c57d5" xlink:to="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateOneMember_fc3cb5d1-225c-4527-8df3-7fda9f2186a8" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateOneMember_fc3cb5d1-225c-4527-8df3-7fda9f2186a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateTwoMember_78a734e1-a92f-44e9-b434-b055997a4da7" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateTwoMember_78a734e1-a92f-44e9-b434-b055997a4da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateThreeMember_7f3dfb4f-3f29-45f7-9f14-03c00c9aa66c" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateThreeMember_7f3dfb4f-3f29-45f7-9f14-03c00c9aa66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateFourMember_1d3afef6-37ea-4c83-9264-d820e98dea2a" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_804119de-263c-44c7-bff9-f1c9976147e8" xlink:to="loc_bntx_EstimatedAllocationDateFourMember_1d3afef6-37ea-4c83-9264-d820e98dea2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c6788240-23ef-481e-a285-3dfe4f4d06c6" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9c910714-c06b-4a8d-a211-156196b9933b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_9c910714-c06b-4a8d-a211-156196b9933b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_838867d2-72fa-4742-be98-92a34e4f4349" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_838867d2-72fa-4742-be98-92a34e4f4349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_e66d79b9-adad-477e-98e1-37133a40241d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_e66d79b9-adad-477e-98e1-37133a40241d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_c3e0da05-cc91-4e70-bd99-566fc2e30927" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_c3e0da05-cc91-4e70-bd99-566fc2e30927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_8205903a-a24a-479f-9ec0-a71d098a87a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_8205903a-a24a-479f-9ec0-a71d098a87a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_20c049a5-265f-4f95-8e5a-341a500f7847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_29511561-e60f-4ccf-8105-df700447eb82" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_20c049a5-265f-4f95-8e5a-341a500f7847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ShareBasedPaymentArrangementsAbstract_760fe7e2-dda4-41c5-984f-b11975a35241" xlink:href="bntx-20231231.xsd#bntx_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ShareBasedPaymentArrangementsAbstract_760fe7e2-dda4-41c5-984f-b11975a35241" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0d598417-6048-4702-b83f-16852a6c274e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardGrantMember_89fbf4c4-5ec0-48cb-9a34-9b6eba4b7431" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_eca330ec-e100-48a4-aaaa-c8dd56ed74ce" xlink:to="loc_bntx_ManagementBoardGrantMember_89fbf4c4-5ec0-48cb-9a34-9b6eba4b7431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ac6d3795-b383-487e-984d-3268e10ccfdd" xlink:to="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateOneMember_5362e317-1479-4e3f-94bc-ab7ecfaef6f9" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateOneMember_5362e317-1479-4e3f-94bc-ab7ecfaef6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateTwoMember_be1c4339-ca2e-40fd-980a-c09ca553fa01" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateTwoMember_be1c4339-ca2e-40fd-980a-c09ca553fa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateThreeMember_1d12c266-84cc-4aeb-9f2b-0a914b822b53" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateThreeMember_1d12c266-84cc-4aeb-9f2b-0a914b822b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EstimatedAllocationDateFourMember_c219377c-38a5-4b31-9b47-5cf593899252" xlink:href="bntx-20231231.xsd#bntx_EstimatedAllocationDateFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_52b0a301-63ef-4264-8b26-bc3b60a987b4" xlink:to="loc_bntx_EstimatedAllocationDateFourMember_c219377c-38a5-4b31-9b47-5cf593899252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3203df11-b5d8-46d3-ab43-2d9386327455" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_bc39a34e-f220-421e-9f2c-b2be6f7945c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_bc39a34e-f220-421e-9f2c-b2be6f7945c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_8459f37e-4846-4d35-a25c-688df9adc122" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement_8459f37e-4846-4d35-a25c-688df9adc122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_3d6ae9eb-baa8-4163-9d2c-0060328a3c28" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement_3d6ae9eb-baa8-4163-9d2c-0060328a3c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_eb225bd0-e1a3-4b25-8849-258e067981be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c96596bd-75b3-4957-b471-9b0c78bcf63e" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_eb225bd0-e1a3-4b25-8849-258e067981be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ProvisionsProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_28f960bc-ca87-415c-8ebc-951057a6fc78" xlink:href="bntx-20231231.xsd#bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_28f960bc-ca87-415c-8ebc-951057a6fc78" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvision_34fed0a9-571f-4f60-ba7a-d8399176f9da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_LegalProceedingsProvision_34fed0a9-571f-4f60-ba7a-d8399176f9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermOnerousContractsProvision_411d3817-b765-4612-96a6-ab3e821d9985" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_ShorttermOnerousContractsProvision_411d3817-b765-4612-96a6-ab3e821d9985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_6305ae53-d742-4ee7-828e-022a45f45490" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_OtherProvisions_6305ae53-d742-4ee7-828e-022a45f45490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_5d5a624f-37e4-4545-a2e7-370c964e1f68" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_Provisions_5d5a624f-37e4-4545-a2e7-370c964e1f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_0d0aa4c2-c6bf-4e30-9e19-47b6b4024df0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_CurrentProvisions_0d0aa4c2-c6bf-4e30-9e19-47b6b4024df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_f86d4708-c138-4f0d-82b2-56059b68c7a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_781df828-ab1e-46d5-b29f-1aa26b544940" xlink:to="loc_ifrs-full_NoncurrentProvisions_f86d4708-c138-4f0d-82b2-56059b68c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsProvisionsDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsProvisionsDetails_1"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ProvisionsProvisionsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biontech.de/role/ProvisionsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ProvisionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ProvisionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:href="bntx-20231231.xsd#bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvision_82e94919-48e3-4108-9fd5-fa3fa3a57e55" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_ifrs-full_LegalProceedingsProvision_82e94919-48e3-4108-9fd5-fa3fa3a57e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionAdditions_58fe00a4-f11a-4549-8348-679888fd85e4" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_bntx_CurrentOnerousContractsProvisionAdditions_58fe00a4-f11a-4549-8348-679888fd85e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermOnerousContractsProvision_c782691c-454a-4c1f-ba7a-09d5ae2257ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermOnerousContractsProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_ifrs-full_ShorttermOnerousContractsProvision_c782691c-454a-4c1f-ba7a-09d5ae2257ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption_6903837c-e716-438c-9a2c-480ca8553dd8" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption_6903837c-e716-438c-9a2c-480ca8553dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions_92353c9c-edda-4067-9029-69d477ed0453" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions_92353c9c-edda-4067-9029-69d477ed0453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToRelease_bf54c653-cd91-44d9-b9d8-c1e0c5117656" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToRelease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_bntx_CurrentOnerousContractsProvisionRelatedToRelease_bf54c653-cd91-44d9-b9d8-c1e0c5117656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_CurrentOnerousContractsProvisionRelatedToUsage_d2eb5057-0378-44b8-9aad-16245dbd08a8" xlink:href="bntx-20231231.xsd#bntx_CurrentOnerousContractsProvisionRelatedToUsage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_bntx_CurrentOnerousContractsProvisionRelatedToUsage_d2eb5057-0378-44b8-9aad-16245dbd08a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisions_80a3fa05-8f9e-4642-8f41-fc2c25a368e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_ifrs-full_OtherProvisions_80a3fa05-8f9e-4642-8f41-fc2c25a368e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalProvisionsOtherProvisions_0779567b-6d27-4385-b61d-8f5c89099944" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract_1afac5b4-252d-45e4-b369-6a07f5e31349" xlink:to="loc_ifrs-full_AdditionalProvisionsOtherProvisions_0779567b-6d27-4385-b61d-8f5c89099944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_4d1aa4fe-3faf-4623-a64e-dee78a86e7e5" xlink:href="bntx-20231231.xsd#bntx_ContingenciesAndOtherFinancialCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_4d1aa4fe-3faf-4623-a64e-dee78a86e7e5" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:to="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_70328aed-adf1-4457-8d69-6f01ea4d8fb5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_694ec5f4-8b20-4d29-9f46-69646fc2fb7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_694ec5f4-8b20-4d29-9f46-69646fc2fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_df941ced-9240-4abb-81ce-9f6b38335660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_df941ced-9240-4abb-81ce-9f6b38335660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_11a6aa6d-f4b1-4ac3-82c1-c8a1f2383c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_f7437b78-4aa0-46b5-99da-47667883687b" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_11a6aa6d-f4b1-4ac3-82c1-c8a1f2383c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesTable_c0c8484c-0af4-4ff5-925b-63a8d2d73d67" xlink:to="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_ed857bfd-0e3f-4f06-bad5-4f445a3e2f25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_ed857bfd-0e3f-4f06-bad5-4f445a3e2f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_e3e7cb3a-59ef-4a02-982e-a5b63a14fd17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_e3e7cb3a-59ef-4a02-982e-a5b63a14fd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_7e1ade11-3ece-4f89-89b9-e7ef5f5433c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfContingentLiabilitiesLineItems_d25ac06a-d046-4047-8458-e64f1b319843" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_7e1ade11-3ece-4f89-89b9-e7ef5f5433c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_6555caf0-9001-4d2c-88e3-77b53bc7c776" xlink:href="bntx-20231231.xsd#bntx_ContingenciesAndOtherFinancialCommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_d23496ed-1e00-4eb7-94b2-74d14ea2760d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract_6555caf0-9001-4d2c-88e3-77b53bc7c776" xlink:to="loc_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets_d23496ed-1e00-4eb7-94b2-74d14ea2760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:href="bntx-20231231.xsd#bntx_OtherNonFinancialLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesForEmployeeBenefits_e05b2216-c7f0-48cb-b1ef-e28112eaf6f2" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesForEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_bntx_LiabilitiesForEmployeeBenefits_e05b2216-c7f0-48cb-b1ef-e28112eaf6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_ccc5d0a8-81b6-41ac-b792-bb2b1670d829" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011_ccc5d0a8-81b6-41ac-b792-bb2b1670d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_7d45637d-ccd9-44aa-b0bb-766f364b0fc4" xlink:href="bntx-20231231.xsd#bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses_7d45637d-ccd9-44aa-b0bb-766f364b0fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherLiabilitiesOther_0d98064b-1ead-4d8c-8115-d4897576a199" xlink:href="bntx-20231231.xsd#bntx_OtherLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_bntx_OtherLiabilitiesOther_0d98064b-1ead-4d8c-8115-d4897576a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNonfinancialLiabilities_4ca04681-3b06-4d88-a867-342671837708" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNonfinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_ifrs-full_OtherNonfinancialLiabilities_4ca04681-3b06-4d88-a867-342671837708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_4afa3845-5ace-404c-aadc-45e25afe22f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_ifrs-full_OtherCurrentNonfinancialLiabilities_4afa3845-5ace-404c-aadc-45e25afe22f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_35ef8e24-4e12-45c5-8b98-07fd9d76edb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_OtherNonFinancialLiabilitiesAbstract_8de7f0f3-fbaf-464e-9987-e6b013cb71af" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialLiabilities_35ef8e24-4e12-45c5-8b98-07fd9d76edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1" xlink:type="simple" xlink:href="bntx-20231231.xsd#OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_e06ef10e-fd30-4f48-99b7-8a7d35f69443" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_e06ef10e-fd30-4f48-99b7-8a7d35f69443" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_452818ef-9f36-4b43-90d9-a9bf71da7d2d" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_b577aa63-3a32-477b-b018-dba2dd5e5280" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_ifrs-full_BuildingsMember_b577aa63-3a32-477b-b018-dba2dd5e5280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_9ba60bfd-abce-415a-9c7c-240002389bda" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_bntx_ProductionFacilitiesMember_9ba60bfd-abce-415a-9c7c-240002389bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherOperatingEquipmentMember_61d16a8d-829c-4c9d-9890-1b37b08569bb" xlink:href="bntx-20231231.xsd#bntx_OtherOperatingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_cc2e7733-9667-4f74-8c6a-c93a0ef493ef" xlink:to="loc_bntx_OtherOperatingEquipmentMember_61d16a8d-829c-4c9d-9890-1b37b08569bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5793d373-98fb-4b58-ab3a-e69ffacd438e" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_0a8d460b-e818-4892-b2ec-16d2518f094d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_6d00bfab-399a-4c46-9c95-883d62f49189" xlink:to="loc_ifrs-full_RightofuseAssets_0a8d460b-e818-4892-b2ec-16d2518f094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_c746b895-89d2-402c-bf88-1ffe25869198" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_9b0fbad7-e21c-4676-8344-80214a591d01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c746b895-89d2-402c-bf88-1ffe25869198" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_9b0fbad7-e21c-4676-8344-80214a591d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_2a7272b5-3e00-41a7-99da-9a554672454b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c746b895-89d2-402c-bf88-1ffe25869198" xlink:to="loc_ifrs-full_CashOutflowForLeases_2a7272b5-3e00-41a7-99da-9a554672454b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_cb006d70-3201-470b-97b3-1a007a6888fc" xlink:href="bntx-20231231.xsd#bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c746b895-89d2-402c-bf88-1ffe25869198" xlink:to="loc_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities_cb006d70-3201-470b-97b3-1a007a6888fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_c007ea05-8f60-455d-b5bc-501b89e073c6" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_d430674e-acdd-4462-bc4a-af023155dc17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c007ea05-8f60-455d-b5bc-501b89e073c6" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_d430674e-acdd-4462-bc4a-af023155dc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_630e01fe-457a-4eb1-a873-9cb4e4529e33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c007ea05-8f60-455d-b5bc-501b89e073c6" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_630e01fe-457a-4eb1-a873-9cb4e4529e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_83cddeca-7c00-4058-bdf0-d5932b313b19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_c007ea05-8f60-455d-b5bc-501b89e073c6" xlink:to="loc_ifrs-full_LeaseLiabilities_83cddeca-7c00-4058-bdf0-d5932b313b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_Leases1Abstract_886fa16b-70f1-4bcd-a6c6-14cf057a5c4e" xlink:href="bntx-20231231.xsd#bntx_Leases1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_Leases1Abstract_886fa16b-70f1-4bcd-a6c6-14cf057a5c4e" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_4e09111e-10df-4560-b068-2798c83a39e2" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_70d0a010-0c3e-4264-9e60-f3808ef57e09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_ifrs-full_BuildingsMember_70d0a010-0c3e-4264-9e60-f3808ef57e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ProductionFacilitiesMember_52810f2b-8ed7-49ce-9fbb-ae9587f97f43" xlink:href="bntx-20231231.xsd#bntx_ProductionFacilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_bntx_ProductionFacilitiesMember_52810f2b-8ed7-49ce-9fbb-ae9587f97f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_OtherOperatingEquipmentMember_c216a1da-d3e9-4d08-bc88-b36eb44615b6" xlink:href="bntx-20231231.xsd#bntx_OtherOperatingEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_43ac5bc7-2d2f-47db-9309-490cd64ef52b" xlink:to="loc_bntx_OtherOperatingEquipmentMember_c216a1da-d3e9-4d08-bc88-b36eb44615b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_5915df14-72ad-4c4c-bd08-1bb20e58ccf3" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_27782d65-4d0f-40e5-872c-ec4364048cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_27782d65-4d0f-40e5-872c-ec4364048cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7365bc4d-e19f-4a76-b1f7-5c355722fc64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_7365bc4d-e19f-4a76-b1f7-5c355722fc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_de412823-b767-425a-a26d-14de396cac8b" xlink:href="bntx-20231231.xsd#bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed_de412823-b767-425a-a26d-14de396cac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_f614c206-2248-4952-af04-8595b9c730ab" xlink:href="bntx-20231231.xsd#bntx_LeaseExpensesRecognizedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_3186542e-8a3c-4373-b589-84204ef30d0f" xlink:to="loc_bntx_LeaseExpensesRecognizedInProfitOrLoss_f614c206-2248-4952-af04-8595b9c730ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_d228a9e2-7529-411a-ab84-802f02b2bdac" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_d228a9e2-7529-411a-ab84-802f02b2bdac" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:to="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_98170719-0cc6-4ff8-b068-53deec9ed1db" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ManagementBoardMember_95c94386-62f7-467a-acc5-a71633128bc4" xlink:href="bntx-20231231.xsd#bntx_ManagementBoardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:to="loc_bntx_ManagementBoardMember_95c94386-62f7-467a-acc5-a71633128bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SupervisoryBoardMember_d6bc4356-c7f6-465d-813d-81b7d9ce86f5" xlink:href="bntx-20231231.xsd#bntx_SupervisoryBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_52d307a7-02b2-40fc-a49f-0518c78dc481" xlink:to="loc_bntx_SupervisoryBoardMember_d6bc4356-c7f6-465d-813d-81b7d9ce86f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:to="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d9026027-34a8-479a-a906-d0a1684395f2" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_JensHolsteinMember_6059d206-2366-4e6d-8d74-d0ed5d32c816" xlink:href="bntx-20231231.xsd#bntx_JensHolsteinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5edda96a-d3fa-43ba-8540-70293b89b595" xlink:to="loc_bntx_JensHolsteinMember_6059d206-2366-4e6d-8d74-d0ed5d32c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8243c9a1-e16c-4f19-af29-0b36628efac5" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_204d7e88-5e10-49c4-9c52-3d461b00abcf" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationFixedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationFixedCompensation_204d7e88-5e10-49c4-9c52-3d461b00abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_61520f30-d6db-454d-a445-49074cd0253c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_61520f30-d6db-454d-a445-49074cd0253c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_1a2d901e-d869-457f-a969-2f6b452e6cc4" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment_1a2d901e-d869-457f-a969-2f6b452e6cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_fd7be7ff-6e2f-4307-8732-2f25ff6b7dc5" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationOtherVariableCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation_fd7be7ff-6e2f-4307-8732-2f25ff6b7dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_8a4f11f1-016d-4a60-9eaa-4de0e8a32f7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_8a4f11f1-016d-4a60-9eaa-4de0e8a32f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_f3986388-8c2f-4a0b-b242-78d4c3bc7996" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_f3986388-8c2f-4a0b-b242-78d4c3bc7996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_944a6d33-3365-4bf0-8449-589e663e48a3" xlink:href="bntx-20231231.xsd#bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_9d4edc56-3824-48e7-89dc-4fc32277979a" xlink:to="loc_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded_944a6d33-3365-4bf0-8449-589e663e48a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_4f2e2a15-d3e8-4e12-8106-654153b33c52" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_4f2e2a15-d3e8-4e12-8106-654153b33c52" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlanESOPNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameAxis_28e8612c-c6c3-4000-b3e1-9e327fdd05fb" xlink:to="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOwnershipPlan2018Member_0bb59f77-bf20-4ab0-8894-61cabe1f03a2" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOwnershipPlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_EmployeeStockOwnershipPlanESOPNameDomain_a8bc4196-2e65-455a-bc24-f46637797ded" xlink:to="loc_bntx_EmployeeStockOwnershipPlan2018Member_0bb59f77-bf20-4ab0-8894-61cabe1f03a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_eb4a76c2-8aae-4801-836d-8eafb062a1b0" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EmployeeStockOptionPlanMember_31ad447b-99a6-4469-86f2-86714750e57c" xlink:href="bntx-20231231.xsd#bntx_EmployeeStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_693e2bda-0aee-41e8-9eb0-40dae24783fb" xlink:to="loc_bntx_EmployeeStockOptionPlanMember_31ad447b-99a6-4469-86f2-86714750e57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_79d12565-5b98-4738-85ca-7dc04640f8ed" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_SeanMarettMember_643aceab-ed39-49ec-b0a5-46b1ae0109f3" xlink:href="bntx-20231231.xsd#bntx_SeanMarettMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d78999d5-3713-4cd6-91b3-73d6f78cbe08" xlink:to="loc_bntx_SeanMarettMember_643aceab-ed39-49ec-b0a5-46b1ae0109f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_f168b5ea-3fe4-4481-b705-05a6b6209d45" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_361686fb-f4f0-4d51-9632-ba5ef768bd30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fab829e6-a8a3-4551-bc36-bdfbb6566725" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_361686fb-f4f0-4d51-9632-ba5ef768bd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_91547126-f4f3-4e66-8468-ef746bcb4970" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_f623397e-3f54-410d-8b4b-1032915c9eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_f623397e-3f54-410d-8b4b-1032915c9eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3edb0fb8-5e71-477f-b7d1-6c7affb36048" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3edb0fb8-5e71-477f-b7d1-6c7affb36048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_NumberOfShareOptionsHeld_48b372c1-f995-4036-95f3-15ccb170925d" xlink:href="bntx-20231231.xsd#bntx_NumberOfShareOptionsHeld"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_bntx_NumberOfShareOptionsHeld_48b372c1-f995-4036-95f3-15ccb170925d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_e5188107-5cd0-4930-afff-048cda57065c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_e5188107-5cd0-4930-afff-048cda57065c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_26c52f3e-3c1d-486a-a5d4-2d86997d1552" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction_26c52f3e-3c1d-486a-a5d4-2d86997d1552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_ee5b0c96-122c-4a4d-8e6c-2cdd256090c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_00c82e2f-6266-423f-8b5f-4107b9213893" xlink:to="loc_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction_ee5b0c96-122c-4a4d-8e6c-2cdd256090c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_522a6e97-f355-4c14-9957-edc451dadc72" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_522a6e97-f355-4c14-9957-edc451dadc72" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_57138aa7-501c-4dc9-9f69-ee53d96c5ad4" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_da5991a9-f2eb-454f-837f-a49e6252ba4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_2f9fda03-259c-4edb-b08c-4942ab63b7dd" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_da5991a9-f2eb-454f-837f-a49e6252ba4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_4f3c02c0-3f05-4960-a650-cd4d3bcd33d0" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_bfd7cf57-4dd0-4f1f-a312-f51c8a0e1fe5" xlink:href="bntx-20231231.xsd#bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions_bfd7cf57-4dd0-4f1f-a312-f51c8a0e1fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_f6a8c0b0-fde0-4019-a223-a01ffd8ae66e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions_f6a8c0b0-fde0-4019-a223-a01ffd8ae66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchasesFromRelatedPartyTransactions_e083bbd3-6ae8-4997-8045-132e64663ab5" xlink:href="bntx-20231231.xsd#bntx_PurchasesFromRelatedPartyTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_98da7b25-c532-48d2-b382-b3747fae7dbe" xlink:to="loc_bntx_PurchasesFromRelatedPartyTransactions_e083bbd3-6ae8-4997-8045-132e64663ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_RelatedPartyAbstract_ceaa3822-77ab-4bbb-8f41-f35fdbba6177" xlink:href="bntx-20231231.xsd#bntx_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_RelatedPartyAbstract_ceaa3822-77ab-4bbb-8f41-f35fdbba6177" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_1ecd9399-e7e8-4526-b5de-63c1559f651a" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRelatedPartiesMember_d478c57a-f911-4909-83f1-3d513fa70ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_fd2abd58-626c-4ee3-8e24-e529139220c6" xlink:to="loc_ifrs-full_OtherRelatedPartiesMember_d478c57a-f911-4909-83f1-3d513fa70ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:to="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5e3912c4-83a3-4e02-881f-fc5a9b1f5b4c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_ATHOSKGMember_507834a0-5539-406f-ba06-62d06d9362ff" xlink:href="bntx-20231231.xsd#bntx_ATHOSKGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d96c456e-df9d-4caa-897f-8f770bf83c3a" xlink:to="loc_bntx_ATHOSKGMember_507834a0-5539-406f-ba06-62d06d9362ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_89b8286f-e919-44df-9873-d8a9e963b8bc" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_91044813-a824-462b-8c54-d89d5b48c018" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_2f13c726-778f-4f28-a2c6-cfaa4ef17228" xlink:to="loc_ifrs-full_AmountsPayableRelatedPartyTransactions_91044813-a824-462b-8c54-d89d5b48c018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails" xlink:type="simple" xlink:href="bntx-20231231.xsd#EventsAftertheReportingPeriodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bntx_EventsAfterReportingPeriodAbstract_becfc0c6-1024-4ca2-a419-27c94a5631f7" xlink:href="bntx-20231231.xsd#bntx_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntx_EventsAfterReportingPeriodAbstract_becfc0c6-1024-4ca2-a419-27c94a5631f7" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1f04dec8-4b62-41b5-89fd-ff86c320c381" xlink:to="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_LicenseAndOptionAgreementMember_298ebc81-1b5f-4f65-9de3-250ea1abe4d1" xlink:href="bntx-20231231.xsd#bntx_LicenseAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_582d2412-4f7d-49b2-8a6e-f4119d1add87" xlink:to="loc_bntx_LicenseAndOptionAgreementMember_298ebc81-1b5f-4f65-9de3-250ea1abe4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b9cf7c09-2d1f-4aab-bd52-74c894f77525" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_PurchaseOfSharesUnderAgreement_e85c4964-3a8c-443f-b65d-08a83e597399" xlink:href="bntx-20231231.xsd#bntx_PurchaseOfSharesUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_bntx_PurchaseOfSharesUnderAgreement_e85c4964-3a8c-443f-b65d-08a83e597399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_b2b8886f-ee72-45cb-85d1-5442aae931cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_ifrs-full_PercentageOfVotingEquityInterestsAcquired_b2b8886f-ee72-45cb-85d1-5442aae931cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bntx_UpfrontPayment_6cbf2295-b19f-4f79-b151-1f02b33cd299" xlink:href="bntx-20231231.xsd#bntx_UpfrontPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_e4c1ec81-ba05-42fd-aba6-112a1164fe15" xlink:to="loc_bntx_UpfrontPayment_6cbf2295-b19f-4f79-b151-1f02b33cd299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>bntx-20231231_g1.jpg
<TEXT>
begin 644 bntx-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *'!&,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_T O_)O_P"PH_X:"?\ Z 7_ )-__85Q_P"L^6?SO[F>URL]EHKQK_AH)_\
MH!?^3?\ ]A1_PT$__0"_\F__ +"C_6;+/YW]S#E9[+17C7_#03_] +_R;_\
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M?\-!/_T O_)O_P"PH_X:"?\ Z 7_ )-__84?ZS99_._N8<K/9:*\:_X:"?\
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M%>-?\-!/_P! +_R;_P#L*/\ AH)_^@%_Y-__ &%'^LV6?SO[F'*SV6BO&O\
MAH)_^@%_Y-__ &%'_#03_P#0"_\ )O\ ^PH_UFRS^=_<PY6>RT5XU_PT$_\
MT O_ ";_ /L*/^&@G_Z 7_DW_P#84?ZS99_._N8<K/9:*\:_X:"?_H!?^3?_
M -A1_P -!/\ ] +_ ,F__L*/]9LL_G?W,.5GLM%>-?\ #03_ /0"_P#)O_["
MC_AH)_\ H!?^3?\ ]A1_K-EG\[^YARL]EHKQK_AH)_\ H!?^3?\ ]A1_PT$_
M_0"_\F__ +"C_6;+/YW]S#E9[+17C7_#03_] +_R;_\ L*/^&@G_ .@%_P"3
M?_V%'^LV6?SO[F'*SV6BO&O^&@G_ .@%_P"3?_V%'_#03_\ 0"_\F_\ ["C_
M %FRS^=_<PY6>RT5XU_PT$__ $ O_)O_ .PH_P"&@G_Z 7_DW_\ 84?ZS99_
M._N8<K/9:*\:_P"&@G_Z 7_DW_\ 84?\-!/_ - +_P F_P#["C_6;+/YW]S#
ME9[+17C7_#03_P#0"_\ )O\ ^PH_X:"?_H!?^3?_ -A1_K-EG\[^YARL]EHK
MQK_AH)_^@%_Y-_\ V%'_  T$_P#T O\ R;_^PH_UFRS^=_<PY6>RT5XU_P -
M!/\ ] +_ ,F__L*/^&@G_P"@%_Y-_P#V%'^LV6?SO[F'*SV6BO&O^&@G_P"@
M%_Y-_P#V%'_#03_] +_R;_\ L*/]9LL_G?W,.5GLM%>-?\-!/_T O_)O_P"P
MH_X:"?\ Z 7_ )-__84?ZS99_._N8<K/9:*\:_X:"?\ Z 7_ )-__84?\-!/
M_P! +_R;_P#L*/\ 6;+/YW]S#E9[+17C7_#03_\ 0"_\F_\ ["C_ (:"?_H!
M?^3?_P!A1_K-EG\[^YARL]EHKQK_ (:"?_H!?^3?_P!A1_PT$_\ T O_ ";_
M /L*/]9LL_G?W,.5GLM%>-?\-!/_ - +_P F_P#["C_AH)_^@%_Y-_\ V%'^
MLV6?SO[F'*SV6BO&O^&@G_Z 7_DW_P#84?\ #03_ /0"_P#)O_["C_6;+/YW
M]S#E9[+17C7_  T$_P#T O\ R;_^PH_X:"?_ * 7_DW_ /84?ZS99_._N8<K
M/9:*\:_X:"?_ * 7_DW_ /84?\-!/_T O_)O_P"PH_UFRS^=_<PY6>RT5XU_
MPT$__0"_\F__ +"C_AH)_P#H!?\ DW_]A1_K-EG\[^YARL]EHKQK_AH)_P#H
M!?\ DW_]A1_PT$__ $ O_)O_ .PH_P!9LL_G?W,.5GLM%>-?\-!/_P! +_R;
M_P#L*/\ AH)_^@%_Y-__ &%'^LV6?SO[F'*SV6BO&O\ AH)_^@%_Y-__ &%'
M_#03_P#0"_\ )O\ ^PH_UFRS^=_<PY6>RT5XU_PT$_\ T O_ ";_ /L*/^&@
MG_Z 7_DW_P#84?ZS99_._N8<K/9:*\:_X:"?_H!?^3?_ -A1_P -!/\ ] +_
M ,F__L*/]9LL_G?W,.5GLM%>-?\ #03_ /0"_P#)O_["C_AH)_\ H!?^3?\
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M"_\ )O\ ^PH_X:"?_H!?^3?_ -A1_K-EG\[^YARL]EHKQK_AH)_^@%_Y-_\
MV%'_  T$_P#T O\ R;_^PH_UFRS^=_<PY6>RT5XU_P -!/\ ] +_ ,F__L*/
M^&@G_P"@%_Y-_P#V%'^LV6?SO[F'*SV6BO&O^&@G_P"@%_Y-_P#V%'_#03_]
M +_R;_\ L*/]9LL_G?W,.5GLM%>-?\-!/_T O_)O_P"PH_X:"?\ Z 7_ )-_
M_84?ZS99_._N8<K/9:*\:_X:"?\ Z 7_ )-__84?\-!/_P! +_R;_P#L*/\
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M_E8Y.S^ ?BV3X>V'ANZM_"5O/I,&CV%MJ=JLQNKN"RNXY6:64QC8I2/Y80'
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MCZ?KHU*(1W4T+-;FQ^SM&ULD7EO*&Y\YG9G4[<H!@]?_ ,->?!OC_BX&C_\
M?QO\*/\ AKSX.?\ 10-'_P"_C?X5MS5K6L<#I8)OXEO?<\R\-_LG^*+:S\4:
M5<:S9:1HVH^'[G1+6&SO)KX1&1@4:(3QB6UB !+0">56+=1M&?3?@;\)=2\
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M:9(KF.5XW*HY 94*_=/6M[QU\1O#?PQT>'5/%6M6^B:?-.+9+BZ)"M*59@O
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M_B;5-(\26,/]DR--XJ?Q%IEU'JMY97*"5&1P)88\V\J;CM;$R,,@HO!'6?\
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M/;N2VP$ MR!P-P_.ATY)7:''$4I-)33?J>B45%',LRED;<,D<>H.#_*I:@Z
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M/*@2-ROSE6@=6VY"GY2=P8+N^)O"UWK6K>#+F"2%(]&U)KVY$A(+(;.Y@PF
M<MNF0\X& ><X!?8>&;JV^(^M>(&>$V=[I=E8QHI/F"2&6Z=B1C&")TQ@GHW
MXS'-IN='LO>^%6OV6UO\RQ_PKOPK_P!"UI'_ ( Q?_$TO_"N_"O_ $+6D?\
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M\$,O_P 8H_X:$_9[_O:3_P""&7_XQ6?_ ,, ^ ?^@WXE_P# BW_^,4?\, ^
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M^& ? /\ T&_$O_@1;_\ QBCF7?\ ,/\ C(/^?%/[S0_X:$_9[_O:3_X(9?\
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MY6?;-";;0I1C&#25C?U/1-.URW2#4K"VU"%6#B.ZA610P& V&!YP3S[UE_\
M"N_"O_0M:1_X Q?_ !-="OW12TN9K9E.G"6K29SW_"N_"O\ T+6D?^ ,7_Q-
M)_PKOPK_ -"UI'_@#%_\37144^:7<7LJ?\J^XY[_ (5WX5_Z%K2/_ &+_P")
MI/\ A7?A7_H6M(_\ 8O_ (FNBHHYI=P]E3_E7W'._P#"NO"O_0M:1_X Q?\
MQ-'_  KOPK_T+6D?^ ,7_P 37144<TNX>QI_RK[CG?\ A7?A7_H6M(_\ 8O_
M (FE_P"%=^%?^A:TC_P!B_\ B:Z&BCFEW#V-/^5?<<]_PKOPK_T+6D?^ ,7_
M ,31_P *[\*_]"UI'_@#%_\ $UT-%'-+N'LJ?\J^XYW_ (5WX5_Z%K2/_ &+
M_P")H_X5UX5_Z%K2/_ &+_XFNBHHYI=P]C3_ )5]QSO_  KOPK_T+6D?^ ,7
M_P 32_\ "N_"O_0M:1_X Q?_ !-=#11S2[A[*G_*ON,K2_">B:'<&XT[1["P
MG92AEM;9(V*D@D94#C(!Q[5'J'@OP_JUW)=7NAZ;>74F-\T]I&[M@ #+$9/
M _"MFBE=[E>SA:UM#G?^%<^%/^A9TC_P!B_^)I?^%=^%>O\ PC6D9_Z\8O\
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M%%9':%%%% !1110 4444 %%%% !1110 VH[>UAL[>.""*."")!'''&H544#
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M\)?^AG;_ ,%]U_\ &J/^&R/A+_T,[?\ @ONO_C5<=_PP#X!_Z#?B7_P(M_\
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M "BBB@ HHHH **** "BBB@ HHHH *H7&@Z9>3-+/IUI-*W622!68_4D5?HH
MS/\ A&='_P"@38_^ R?X4?\ ",Z/_P! FQ_\!D_PK3HH S/^$9T?_H$V/_@,
MG^%'_",Z/_T";'_P&3_"M.B@#,_X1G1_^@38_P#@,G^%'_",Z/\ ] FQ_P#
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M'_P&3_"C_A&='_Z!-C_X#)_A6G10!F?\(SH__0)L?_ 9/\*/^$9T?_H$V/\
MX#)_A6G10!FQ^'=*AE22/3+..1&#*ZVZ @CH0<=:Q/B7_8W_  C=K_;WFBR_
MMC2O+\D_-]J_M"W^RY_V?/\ *S[9KK#VKD?B5J6G:7X=M9M4L?[1MFUC2X$A
MSC;-)?V\<,G_ &SE>.3_ (!3CNC.I\+.GNK"VU"%8[JWBN8P=P29 PSZX/>J
MG_",Z/\ ] FQ_P# 9/\ "M)?NBEI%K8S/^$9T?\ Z!-C_P" R?X4?\(SH_\
MT";'_P !D_PK3HH&9G_",Z/_ - FQ_\  9/\*/\ A&='_P"@38_^ R?X5IT4
M 9G_  C.C_\ 0)L?_ 9/\*/^$9T?_H$V/_@,G^%:=% &9_PC.C_] FQ_\!D_
MPH_X1G1_^@38_P#@,G^%:=% &9_PC.C_ /0)L?\ P&3_  H_X1G1_P#H$V/_
M (#)_A6G10!F?\(SH_\ T";'_P !D_PH_P"$9T?_ *!-C_X#)_A6G10!F?\
M",Z/_P! FQ_\!D_PH_X1G1_^@38_^ R?X5IT4 4[/1[#3Y#):V-M;2$;2T,*
MH<>F0.E-N-"TV\F::XT^UGE;K)) K,>,<DCTJ]10!F?\(SH__0)L?_ 9/\*/
M^$9T?_H$V/\ X#)_A6G10!F?\(SH_P#T";'_ ,!D_P */^$9T?\ Z!-C_P"
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M@8./1+6X%U!%,H=4D4.!)&R-@C(RK8(/L1GV%#36XXU(R;42S1112- HHHH
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MA=_T,I_\ +K_ .-4?\-8?"[_ *&4_P#@!=?_ !JN3_X8;\#?]!?Q#_X$0?\
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MP2:G LD<A8HJ,"^0Q8%0#SD$5<7Q]X875-5T[_A)-)-_I<7VB_M/MT7FV<>
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M#EO:W-Q+!+-:3VUT[77ER X7$97)7&\<<]*/9JVX?6*E[*!]*!@">Q^M(&'
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MZ]2.O&:\)^-7PW\4>*OB;HNJZ;H%Q>C39-+FLM2MS8[8O+O-]TDC7#&6,B,
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M_P!OH_X8+?\ Z'8?^"K_ .WU.IX_UK,O^?"^\^BO^%P>!/\ H=/#W_@T@_\
MBZ/^%P>!/^AT\/?^#2#_ .+KYU_X8+?_ *'8?^"K_P"WT?\ #!;_ /0[#_P5
M?_;Z-0^M9E_SX7WGT5_PN#P)_P!#IX>_\&D'_P 71_PN#P)_T.GA[_P:0?\
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MB%\5?#NH> ?$EKX;\>>'K7Q!-IES'ITW]KP*([EHF$39W<8<J<UXS_PP6_\
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MJI9N .-Y7(!QGFO1=OL!2XI.;>AK'#QB^;^N@ZBBBLSJ"BBB@ HHHH ****
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M &^C_AW?-_T/B_\ @H_^WUIRQ/E_[0S_ /Z!(_\ @1],?\+N^'F/^1[\-_\
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MIK=&=3X6=8/NBEI%^Z*6D6MA*,4M% Q*,4M% "44M% "44M% !1110 4444
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MYZWW_@PG_P#BZ/\ A'K7_GK??^#"?_XNM(4M<QZYF?\ "/6O_/6^_P#!A/\
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MCMK_ ,];[_P83_\ Q=:E%9'<9?\ PCMK_P ];[_P83__ !='_".VO_/6^_\
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ME!8!>H!/O7@6B:?XFOM!4"W\6W15]#DU)-<6Z=EU-+U6NG@64$B-5 8F$>0
MJE.C56\*Z=XBOM>\"?\ "16_C*X\16^HV,[&>&\?3H[,:?@O(2/(63SF<.6_
M?[R0?W>*OV>[N8?6Y75H;GT>FEZ>]V]H+RY:ZC19'@&I3;T1BP5B/,S@E' .
M.=K8Z&K/_".VW_/6]_\ !A/_ /%UXOX^L=0T'XF>(-<LK;Q&\DEKH<S/IRWL
M\$EO%?O]K14CRC.(MI,:@NRL^%(9L\_K5OXS\5:+>7T;>,+!HK3Q#>V,<,EW
M:R&47D1L-R *Q/EY*1.""I*E2 14^SO;4J6+Y6_=;:_SL?1'_"/VO_/6]_\
M!A/_ /%TG_"/6G_/2]_\#Y__ (NOG3Q7I/B71]2UK3O,\=2Z/"]XNBRZ==7\
M\S7[6]FUN9)%8L8O,:ZQYS&W!#*^ % V_%'ASQ/<:+XWU*XU'Q19ZFVH6MO"
MUBU[<0QVHALWF,5K!/$S(9%E4O ?-&9 O=2>SVU']:>ON'MD^BV-M"\LUQ>1
MQ1J69VU"<  =23OXK$FU[PA::MINE3>)X(M4U*+SK&Q?7'$]VA!.^)/-W.N
M>5!'!KS?1;S7;K]GZU_MJTOK22/4K>.]_M&>>5Y+ 7T?GN3=1I-Y7D[QMG7S
M/+'S,^=[:DEU:^'_ !AXKTS6?"6L:[<:UJUI?6<EGI37$$T:QP+&6N,"*(PR
M0NV)70C 9<EAE<F^I3Q#TTM=+\?^&.NT;Q5X)\2:Y=:+I/BZSU/6+8MY^GV7
MB!IKB'8P5]\:REEVMP<C@]:N^'M0\,^+H[M]"\1)K26DOV>X;3]:>X$,@ZH^
MR0[6'<'FO)O#,DNL6_AWP]'H&MIJVD^([Z_N)[S1KFVMXK<SW99EGFC6*3S$
ME$85&8D39QM#,+.FMK-]=^*=1\&Z9KEI<2:99VMI#JFFIIWV*:*5O*LT66-$
M>V422%Y$$C;6<1R,?+5:=-:V)CB)-)V_JQZCXDO_  WX,TT:AX@U]-"L"XB%
MUJ6M26\6\YPNYY ,X!X]C5NWM=*OKAX;;4IIYEC28QQZI,S+&^[8Q DZ-M?!
MZ':<=*\ILKKQ+X:U;PKXC\?:9J&I7=O;:A8W3Z/I[7Z6MQ)+$R/!%;*\HMV2
M)U1W4R ;1(0S&K'AOQ1I_@WQI<22^%?$6@Z;J&AZ9%8V5OX?NKH6^R6[S$YM
M8Y8XRHDCRI8;0P]\3R::,I8A\R35O^&.UT?Q9X(\1:S=:1I?B^RU+5K7S/M%
MA9^(&EGAV,%DWHLI9=K<'(&"<&M""Y\.W-K:W$.N>;;W=N;NWF76)"DT*A2T
MJ$2?,@#*2PX&X>M>0:!)<:Q9:!X?@T/6H-8TKQ#?W\UU=Z/<VT$$!FNR62>6
M-4D\Q)0@$;,2)<XP"1QW_"N_%6G>$_#GA[3M$O$L_P#A%)IT)M3MMY9#9&YL
MW4E<,Q25U1BN[S'4;=G%^R5[7,?K=1*ZA?\ I'T3H&M>$_%-G!=Z+XFAUBUG
MG-M%<6.MO/')*%+&-624@N%!8J.< FM[_A'[7_GM??\ @PG_ /BZ\4M6OY/!
MOB*ZC.I:C+<:II[:5JFNZ4FFW]S<>9$JB2(0P$JC  ,T8)7</F49/O9SSZ=N
M*RE'EV.RE4=17:U*'_"/6O\ SUOO_!A/_P#%T?\ "/6O_/6^_P#!A/\ _%UI
M4M0=!F?\(]:_\];[_P &$_\ \71_PCUK_P ];[_P83__ !=:=% &9_PCUK_S
MUOO_  83_P#Q='_"/6O_ #UOO_!A/_\ %UIT4 94>AV\<B.DMYN4A@&O9F''
MJ"^"/8UD^,O$WACP^UF/$>OVNA>=O^S_ &G4S9>;C;NQ\Z[L97UQD>M=0.G3
M%>+?M&?L[M\>V\/E=>&B?V4+C.;3[1YGF^7_ --$QCR_?[W;%4DKZG!C:F(I
MT)3PL.>>ED].NOX'0?\ "R/AE_T4#2__  IS_P#'J/\ A9'PR_Z*!I?_ (4Y
M_P#CU?/?_#N^;_H?%_\ !1_]OH_X=WS?]#XO_@H_^WUIRQ/EO[0S_P#Z!(_^
M!'T)_P +(^&/_10-+_\ "G/_ ,>H_P"%C_#'_H?]+_\ "G/_ ,>KY[_X=WS?
M]#XO_@H_^WT?\.[YO^A\7_P4?_;Z.6(_[0S_ /Z!(_\ @1]"?\+(^&7_ $4#
M2_\ PIS_ /'J?;_%+X:V=PLL?Q T<NN<"7Q&)%Y&.5:4@]:^>/\ AW?-_P!#
MXO\ X*/_ +?1_P .[YO^A\7_ ,%'_P!OHY8B_M#/_P#H$C_X$>[>)/CA\-EU
MKPEYWB+0=3D;4G$-W'J<#+I[?8[G,[G=PI4-#D_Q3J.]:]]\6OAOJ/E^9X^T
M1 F<>1KR0YSCKLD&>G?U/K7RKX@_86N=#U;PQ9IXN-TFLZ@]C),FE$"V5;6X
MN!*?WQR";<)C(&9 <\8.[_P[OE_Z'Q?_  4?_;Z;C'34F.89_=_[''_P(^A/
M^%D?#+_HH&E_^%.?_CU'_"R/AE_T4#2__"G/_P >KY[_ .'=\W_0^+_X*/\
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M>VH?^#&Y_P#CE'_"-V?_ #VU#_P8W/\ \<K5HI&AE?\ "-V?_/;4/_!C<_\
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M$K1L,%2$ (Q]:F4>5;W-:5=U)-6LK(=_PC=G_P ]M0_\&-S_ /'*/^$;L_\
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MK6GB]%RMF;7[4GF^>T?FK%MSG>8P7"]2O/2MJC7J":>SN9?_  CL''^EW_\
MX&2?XT?\([!_S]W_ /X&2?\ Q55?%'CKPYX)CMG\0Z_IFA)<N8X6U.\CMQ*P
MYPI=ADX["MN&59D5T961AN#*<@CL1[4K.UPYTVTGJC._X1V'_G[U#_P,D_\
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MOA6SMI.L[5"V']LWPLL=#'YS9(]O,\W';&,<8KMJQEH['?"7-%-F5_PCL/\
MS^:A_P"!DO\ \51_PCL/_/YJ'_@9+_\ %5JT4BS*_P"$=A_Y_-0_\#)?_BJ/
M^$=A_P"?S4/_  ,E_P#BJU:* ,K_ (1V'_G\U#_P,E_^*H_X1V'_ )^]0_\
M R7_ .*K5HH RH]#BMY$D%U?,58':]V[*<=B">14FH6<-X4$D\\&W./)F:/.
M<=<=<>]7\>U>+?M&?L[M\>FT KKXT0:5]HSFT^T>9YOE_P#31-N/+]_O=L54
M;7U.3%5*U*E*=&'/+2RO;\3U#^QK;_H(7O\ X&R?XT?V-;?]!"]_\#9/\:^2
M_P#AW?+_ -#XO_@H_P#M]'_#N^7_ *'Q?_!1_P#;ZTY8]SY_^T,U_P"@/_R9
M'UI_8UM_T$+W_P #9/\ &C^QK;_H(7O_ (&R?XU\E_\ #N^7_H?%_P#!1_\
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M )_-0_\  R7_ .*K5HH RO\ A'8?^?S4/_ R7_XJC_A'8?\ G\U#_P #)?\
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MXPL##:>(;VQCADN[60RB\B-AN0!6)\O)2)P05)4J0"*2IWL[ERQ3BW[EVO\
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M4 9/]@?]1+4/^_\ _P#6H_L#_J):A_W_ /\ ZU:U% &3_8'_ %$M0_[_ /\
M]:C^P/\ J(ZA_P!__P#ZU:U% &3#H_ER(_V^^8JP.UIL@X[$8J74;5;IH@US
M/;8S_J7V9Z=:O?AS]*^?OVK/@#XB^.3^&#H-WIMK_9?VH3?VA+(F[S/)V[=B
M-G_5G.<=NM4DKZG#C:];#T)5:$'.2MIWU/:?[)C_ .@K??\ @1_]:C^R8_\
MH*WW_@1_]:OAK_A@3XA_]!7PW_X%3_\ QBC_ (8$^(?_ $%?#?\ X%3_ /QB
MKY8]SY7^VLU_Z )?>C[D_LF/&?[5OL?]?'_UJ<FB^8N1J6H$?]=__K5\,_\
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M /6H_L#_ *B6H?\ ?_\ ^M6M12-#)_L#_J):A_W_ /\ ZU']@?\ 42U#_O\
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M3;O?8?11161UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFFVU<ZW2H<D9\CU>UV1W_P"S9J.EPB6\^/'Q M86=8A)/JL2*69@J+DIC))
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MD>49Q%M)C4%RK/A2&;//ZU;^,_%6BWE]&WC"P,-IXAO;&.&2[M9#*+R(V&Y
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MX_Z H_\ @;_S-C_A!?#'_1U?B+_PJ+3_  H_X07PQ_T=7XB_\*BT_P *Q_\
MAW?-_P!#XO\ X*/_ +?1_P .[Y?^A\7_ ,%'_P!OHY_[WY!SYQ_T!1_\#?\
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M*:EINFR_$[P_J$M_Y6KP:1J4%M8X_P!=#)-8M-)G_8:.%?\ MK6/\5OA;?\
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MR[SO;F1FX4+7]F^O5]#5OOV9]5T^UFNKKXZ_$*WMH4,DLTVJ1*D:@$EF8H
M!G))Q4D/[+^L7$*2Q?'/XBR1N RLNIQ$$'H<B/T-<GKVG^(I?AO'9ZW<>-M8
MTN;3M4CL#ING:C!<R73,%@2XA,LTYC*F39]K8H03YH'R5]-^%XI(/#6DQ2QM
M'*EI$K(PP5(09!'UI2G.*WN:4J%"I)KD:5EU9XK_ ,,KZY_T7#XC?^#*/_XW
M1_PROKG_ $7#XC?^#*/_ .-U] T?G6/MI]_P.SZC0_E_%_YGS]_PROKG_1</
MB-_X,H__ (W1_P ,KZY_T7#XC?\ @RC_ /C=?0/YT?G1[:??\ ^HT/Y?Q?\
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M'MI]_P  ^HT/Y?Q?^9\_?\,KZ[_T7#XC?^#*/_XW5O1OV:=9TG5[&^D^,OQ
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M_P#QFC^Q;O\ Z#NH?]\6W_QFLNX^*'A"Q\3+X;G\5Z)%XA:18AI,FHPK=%V
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MA5V ,K[68JN3R=JLV!GA2>@HNK^WL8P]S/%;Q[TC#2N%!9V"HN2>K,0H'<D
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MOKBR"]?(6,[NF,[T;]*O44 9/]BWG_0=U#_OW;__ !FC^Q;S_H.ZA_W[M_\
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MUY_T'M0_[]V__P 9H_L:\_Z#VH?]^[?_ .,UK44 9/\ 8UY_T'M0_P"_=O\
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M*=B*2\\0>+=;\=>+8],NO&,GB>VUG1O[,@M7NO[-MXVM[5[Q)T_U*#8925G
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MB-$-N?E0H  H4#T?'6DVC(/>DYFD,.HN]_Z[#Z***S.L**** "BBB@ HHHH
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M>\6:MX7NV\3W?BW4F@OM(N]1M(M.U6V:&Y6]4W!A8W4C2A5WL?LB+#@(R@8
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M _X97US_ *+A\1O_  91_P#QNC_AE?7/^BX?$;_P91__ !NOH'-'YT>VGW_
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M_P" ?4:'\OXO_,^?O^&5]<_Z+A\1O_!E'_\ &Z/^&5]<_P"BX?$;_P &4?\
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M-XACC\Y])77K<W:1X'S&+;O"X8'=CN*UIOV8-8MX7FF^.?Q$CCC4LSMJ<8
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M%_\ !1_]OHY_[WY!SYQ_T!1_\#?^9L?\(+X8_P"CJ_$7_A46G^%'_""^&/\
MHZOQ%_X5%I_A6/\ \.[YO^A\7_P4?_;Z/^'=\W_0^+_X*/\ [?1S_P![\@Y\
MX_Z H_\ @;_S.HT#PSX6T/7=-U&3]IS6=3CL[J.X>RN_$UJT-P$<,T4@[HP&
M"!V->G?$/XD?#;QAX"\2:!=>/]"M[;5--N;"6:WU*"26-9(F1F5 QW, Q(4
MD\<5X1_P[PEX_P"*\4]O^01_]OK*\5?L*V_@WPSJVO:CX^QIVEV<U[<-'HVY
MA%&A=RH\_DX4\>M0[2:;>IM#%9W2BU'!Q2_Q7/HWQ]\0O OC7PK?:/;?%?3?
M#<UP8]NIZ3K=O'<P[75SL8L0,A=IR.C&O(/^$%\,?]'5^(O_  J+3_"L8?\
M!/";_H>U_P#!1_\ ;Z7_ (=WR_\ 0^+_ ."C_P"WT1:BK)A4Q&=5GS3P2_\
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MBBB@ HHHH 2BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4
M-[FJ=O?6DUY/:Q3PR7-OM,T*N"\>X97<,Y&0"1GTJV<\U\Z^+FUIO!;VD#:M
M;WUUXJU!-3O-+BO9I8%#SM;F2.R:.X9&B6V52LL04-&78J"CW&/-U.>M4]FK
MVN?1?X"C:/2OF?1;GQ'>:/X/E\6+X^CU#^P-.^PIH<=TDAU(,_VD72K^[W'%
MN#]M_<X+'/\ K#67#=>/+KQWXK,4GBZU@O--UF!XA97\HLYTFB6V>%Y98[:0
MM'YC1BV6+Y<J7D?YZT]E_>.7ZXK)\CU/JOA>V/PHVCZU\S_#WQ#XJT'2]+N=
M1L_%-QI5CXAD6:Y2WU:X>YMWLI54_9;I#>+&)3$2KF95=R0Y51LET?2_&FH:
M7I&K7[>*X-4L=.\/O':_:[M$,[W;B]66)6VS'R@N_>&VKS\O6CV?F..,32]Q
MW/H+3]>TS5KB>&QU&TO)X#^]CMYTD:/#NGS $D?/'(OU1AU4UH%5ZX&:^8M)
M\+^*M0\4KIEP/$VF^'Y=3NI)18SW5FFTS:P^?,C*E0Q-J201G,7/(K.U#3_&
M>GZ'I=E-/XQ\O5++2KB_OF;5+MK>[:"Z:<&*W=)U4O' K1Q2PHA9&;C<LC]G
MK\1G]<?*FZ9]1QWUK)?3VB3P/=0HLDL"NI=%;<%9ESD E6P3UVGTI]K>6]XK
M26TL=PBNT3/$X8!U8JZY&?F5@01V((KY2T>+Q=/<Z#J.H6?C&#Q//X;T*.VE
MMX+R.!K])Y_M*WNWY#A64L)_E 9L?,1GZ!\$M)_PF/C@1#&GK>6X7;T-Q]GC
M\W'X>5G'?=WS4SAR];FU'$>T:O&W],[;:/2EVCKCFEHK$[AH4+T&*6EHH *2
MEHH&0;ASSTQVI_'7 XZ?XU\H_$^%VO?BUI(B=K?Q%<R":1<E$%GIT%PP;D ;
MU.SWQSD"NYOOBQ<0>.F\*G5XQJ#>(%MET[;&)AIYTKS@Y7&[RS."!)_>^7=P
M0-_9Z7N>>L5JU)>1[7>V-KJ5K);7D$-W;2</#.@=&P01E3D'D"G7EK!J%K+:
MW4$=S;3HT<L,RATD0C#*RG@@CC'O7Q9X7\4ZCX-^']S=Z=XB,^KV[)<1P75O
M:W#V('AKS(I$41!U!*A<DY98MHZON[/Q!\1-:-N+_0=='Q _L?4[B32]2,,;
M"6;^R+IW@/V:-5D\M_[J[ANVG+"G[%WT9DL;%J[CJ?5'3& ,4M>1?L\>+M9\
M6Z'K$FI^)--\5007:I;ZCIMZMZN#$K-&T\=G:Q.03T1,KNVL<C%<MJ/Q5\0:
M3^T(=!;7!?6%Q,\%MH5F]LTJ 6P8-+;211W(4OE_M$4LT6%92B?>7/V;NUV.
MIXB*A&36^A]!_=X^@H]!_P#JKY:L/'FJ^+/#,7VCQ)_PE,)FT&]O&-O"HTR_
M>_3SK+]TBXVX7]U+ND7'SL=PQ0\*^-+CQ%JGPVM=4\30V>H0:GI_V;PG':P1
M*;8Z<6%TJJBR ,TC#>I\D<1A0X)J_9;ZF/UQ724=SZU5OFQGOZ4[';M7@'CS
MQ3+X'^+7B34G\4/8QBRT!Y;.Y-N(8K)M0ECN9N4WJBJS;G+83SB2?N;<36OB
MIXHU[1KW4]$\5/9VEK:>(=1MY;:UMY5NUM+R*.V&6C8&(HS E<,P((8'FI5)
MNSN7+%*-TUJCZ:^E'Z5\P>*OB1XG\,ZEK6D7GCVXTU-.>\-AJ5Q9VGFZE=I;
MV<L%B5\G8^YKB4".)5F<* K95B=WQ-XL\8KHOC;61XN_L$V.H6NGP6MW'!!:
M6:/#9RRN\YM9FC8>9*HDD5HU#_,IX93V6VHOK2U]W5'O_3G./7B@L.F[ZCBO
M#/#WCW4?&GP!LM0FN;NYFO-3M]+N[V7R&:2WDOHX9666U8PR#RW9?.BVJ2"V
MU,%%YF]^&,VN>/O&5]IOAGPU8QZ;K=NX\2^:4U2WCBLK5FMH8U@'[MUS'CSU
M $KY4@;6%36MV$L0[)PC>Y],AP>G/O0I'X5\Q?!N_P#!^E0^"KKX:Z=IFKZE
M'X>W>(;+PDUJKS'RH1&+@[TC\_S=VSSF5L>?@_>KN--^)WA_0?BMK+^*M2L_
M!5]J.C:;Y.F>(-0M8+@D37H*C;*R.?N_<9OO#G/%#AV+AB%*W-U^[:Y[)N^8
M^N?PIV=O)./6O);6UE\/?%?XB7EM>W4]W+X=L+I9;J*6]$3";4 J1V\14LBA
M5'E1X9\=2[,QY'Q%XV^)/BOX6ZP+_P &ZEI-Y/*]O>6>EF*.XLK/R-QD6>:9
M(YC(<<Q',0D92#)'DI0N]PEB%%:IWUV\CZ'].WTJ*:.*ZADBF5)(I%*-'( 5
M8$8((/!KSOX=^(M5U3PIX;TL^&==TF&?183_ &T9;!HK=O)'\(G=R^<8_=,N
M2,\9KQCQ-I.C6OPZ\*:?JVH>'[/2(?&^N1M=>-X?[0LN)=2"F<33(9')QAFD
MSN.>>E5&%W9L53$6BFE?3_(^JX(X+.WB@@2.&"-1'''&H544#   Z #C'2I1
MV':OC*\L_#TUKX(AU[5?AY8:7'!KOV*]\5:8EUI%Q']NA\IK*&2YC$2%"/+"
MR,%087<I#'VOX;37=A'\+BT$\=_?>'F@U!9G=G:.*.)DDD+C<2KN0-W(\]@1
MD\$J?*MR*>*<W9KM^G^9[/M'I1M'I2T5B>@)@=<4;1UQS2T4 )@>E&!Z4M%
M%9;.V2\ENE@C6ZD18WG5!O=%+%5+=2 7<@=MQ]32R2+&P#$#/2IOKTKYB_;/
M^$/BWXJ-X1_X1?2#JHL!>"XQ<11;/,\C;_K'7.=C=,XQVJX^\]3SL?B*F$PT
MJU*GSM6]U==3Z9^T1?WU_.C[1%_?7\Z_-#_AD7XM?]"DW_@PM?\ X[1_PR+\
M6O\ H4F_\&%K_P#':U]FCXW_ %DQ_P#T R_KY'Z7_:(O[Z_G1]HB_OK^=?FA
M_P ,B_%K_H4F_P#!A:__ !VC_AD7XM?]"DW_ (,+7_X[1[-!_K)C_P#H!E_7
MR/TO^T1?WU_.C[1'_P ]%_.OS0_X9%^+7_0I-_X,+7_X[1_PR+\6O^A2;_P8
M6O\ \=H]F@_UDQ__ $ R_KY'Z!^+M;TFQ\0>"(;VS6\N;S5Y(+&8$?Z),+"[
MD,OXQQRQ\?\ /6NJ%U#VD6OS%OOV7?BAIMUIUO<>%95FU"<V]N%N[=@T@BDE
M()$AV?)$_P S$#H,Y(!N_P##(OQ:_P"A2;_P86O_ ,=INFM-28\29A=_[#+^
MOD?I?]HB_OK^='VB+^^OYU^:'_#(OQ:_Z%)O_!A:_P#QVC_AD7XM?]"DW_@P
MM?\ X[2]FBO]9,?_ - ,OZ^1^E_VB+^^OYT?:(O[Z_G7YH?\,B_%K_H4F_\
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M6&:!4:MUP>]!)[MBCJ*ZM<EHJ+<>#VS4M Q!1G%+418B@1+129_*EH&%%%%
M!1110 4444 %%%% ""@U&S;%Y_#_ #^="MD\'(_E3Z7%=;$M%%%(844F?\:9
MN+#(H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;UJ(,HS]W-2'
MO7R#X%M])C^)5M<:9?\ @ZZUQO$>LB_L-'L5AUZ.$M>C?=W"SLTD(/EG:\2J
M28><A=VD8\USEK5?9M:7N?7.X#J0%^M&Y< 97'K7R[\+_#MCJ$_PT\&^(-,A
MUO1V\+3W]K'JEO\ :8987%DS1,'!!:.7. 1\JM%Z&K^C^!?AAX=^#>GW&K:3
MX1\._;KF=!?:QI:?V>\Z23K%]K4-&D@5=P02N.2-A#8JG!+2YA&O*6O*EI_E
M_F?2F/NXP/3B@;58\#/T]:\*TW39)H?@9J,]SJ3/;WOV.."ZN2RL!IMZ//<
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M&[/=^(5EA50P),B>>=R\9*X.1D5]D?%33=/UCX7^+M/UG4/[+TFZT>[@O;[
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MM/\ +_,^E?3&,=N*3C<"1S7A.FZ<\T/P-U">ZU,O;WGV.."ZN2RL!IMZ//<
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M_P "I_\ XQ6G+'N?+_VUFO\ T 2^]'WU]IB_OK^='VF+^^OYU\"_\,"?$/\
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MQ]370T478E&*V1QE_P##^VU6PTRQO='\-WEEI;I)86T^EAX[1T&$:)2<(5'
M*XP.E/\ ^$&B_P"$F/B/^RO#O_"0F/R3JW]F#[7Y>,;/-SNVXXQG%=A11=AR
MQ['(^'_!2>$VO&T33/#^C&]E,]T=/TWR//D/5WV$;FY/)YK<M5U59U-Q-9M!
MW$<+JW3U+D5I44AI):(S[T:BT@-I-:I%MY$T3,<_4,*A\O7/^?BP_P"_#_\
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M%6>K:E=:)+KT%F+RYU&:>ZMA]@DNY;<7#L9228D^\Y8+.P!&% [CX<R3^(?
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M/_\ %T>7K?\ S\6'_?A__BZ\S\#_ &?4M2B\3ZKXNOK/69==O=-.GRZJPM)
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M[/S*_P!8Z_\ T U/P/N[R];_ .?FP_[\/_\ %T>7K?\ S\V'_?A__BZ^$?\
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M$W<UL\>W@0Q,IS]2QKX+_P"%4_M,_P#/YXF_\*=?_DBC_A5/[3/_ #^>)O\
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M*VBU>KMH?0GX4?A7Y]_\+5_::_Y\_$W_ (3*?_(]'_"U/VF?^?/Q-_X3*?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=I<>*KBR\7_;_%EDFJ!/ /V&.7R(X2XMYBL<?VB,,J1OYDC.DGG!4 +Q@4O
M?C;QAXPM](TY/']K=V]]KK6AUO0I[?49/*&GS3M&)FL(8"PD1#\L3%02K'/1
M>S=KW*^M*ZBHO4^F,"C:/2D7(4=2?>G5D=P4444 %%%% !24M% '(^+]1TZQ
M\1>!X;VP^V7-YJ\L%C-G_CTF%A>2&7WS%'+'_P!M*ZT5R_BS69-+\0>#;:.P
M2]74=5DM9)F4DVBBQNIO-7T),0C^DI'>NHI]$1'=^HM%%%(L**** "BBB@!M
M<G\5M2TW1OAEXNOM9L/[5TFUTB[GO;#_ )^8%A=I(O\ @2@K^-=97,?$W6)?
M#OPY\4ZK!IZ:M-8Z7=72:?(I9;EDA9A$1W#$;<=\TX[HB?PLZBEI*6D6%)2T
M4 )M'I12T4 %%%% '):D=&_X6CX>\_S?^$A_L?4OL>W_ %?V7SK+[1G_ &M_
MV7'MNKK*Y+4M2TZ/XG^'[&2P\S5I](U*>WOP?]3"DUDLL7_ VD@;_ME76BF]
MD9QW?J+1112- HHHH **** &UR?Q*U+3M*\.VLVJ6/\ :5LVL:7 D.<;9I+^
MWCAD_P"V<KQR?\ KK*YCXAZU)H.@VUS'IZ:FTFJZ9:F&12P59KZ"$R_6,.9
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M_"U/VF?^?/Q-_P"$RO\ \CU^@M%7[7R/EO\ 5RO_ -!M3\#\^O\ A:G[3/\
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M%%% !1110 4444 %%%% !1110 4444 %%%% "44M% !1110 E+110 4E+10
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M9T,<L$]R[I(I&"K*3@@CL:F_X1N ?\O5_P#^!DG^-:U%(9D_\(Y#_P _=_\
M^!DG^-'_  CL'_/W?_\ @9)_\56M6?\ VYIRW@M#?VPNC-]F$'G+O,OE^;LV
MYSN\OY\==O.,4!IU(?\ A'(/^?N__P# R3_&C_A'(?\ G[O_ /P,D_QK6HH&
M9/\ PCD/_/W?_P#@9)_C2_\ ".P_\_>H?^!DG^-:M% &3_PCD/\ S]7_ /X&
M2?XT?\([#_S]ZA_X&2?_ !5:U5+O4+;3_*^U7,5N)I5AC\UPF]V/RJ,]6//
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M#_S]ZA_X&2__ !5:M% &5_PCL/\ S^:A_P"!DO\ \51_PCL/_/YJ'_@9+_\
M%5JT4 97_".P_P#/YJ'_ (&2_P#Q5'_".P_\_FH?^!DO_P 56K10!E?\([#_
M ,_FH?\ @9+_ /%4?\([#_S^:A_X&2__ !5:M% &5_PCL/\ S^:A_P"!DO\
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M0?V/J7V/;_J_LWG67VC/^UO^S8]MU=7VI]$9PWEZF7_PCL/_ #^:A_X&2_\
MQ5'_  CL/_/YJ'_@9+_\56K12-#*_P"$=A_Y_-0_\#)?_BJ/^$=A_P"?S4/_
M  ,E_P#BJU:* ,K_ (1V'_G\U#_P,E_^*H_X1V'_ )_-0_\  R7_ .*K5HH
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M#(TD\4/G?\LWVJC"'_1R& 3^*OHFSL[?3[6"UM8([:VA18XH84"HB@855 X
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M_",V7_/74/\ P8W/_P 76M10!D_\(S9?\]=0_P#!C<__ !='_",V7_/74/\
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M6\-RNS9X?%S^]87&)%+!=P*@;O,?AF4IUOC;XP>)?"+M+J<UGJESH-[+</\
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M_P">VH?^#&Y_^.5JT4BS*_X1NS_Y[:A_X,;G_P".4?\ "-V?_/;4/_!C<_\
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M"5P%^9PP!W'G(!S44?PW\)0ZQ9:M'X6T5-5LH4M[6^73XA/!&@PB(^W<JJ.
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3
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M7 HVBCVD^Y'U6C_*>2M^SGH<&EV^G6&L:OIL%M9V%M"MO]F?RWM+AIX+@+)
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M*NFSZ8HKY[T_XR>)(;C4OLW]EQZ=HU^B7EO>"XFNKM;C5;FU412--^Z*K$"
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M(I86FZM>7+%;MGJ-&:^9?^'@'@#_ * OB3_P'M__ (_1_P / / '_0%\2?\
M@/;_ /Q^JY)=CQ_]8LI_Z"(GTUFC-?,O_#P#P!_T!?$G_@/;_P#Q^C_AX!X
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MGW%R16R.>\&^$;?P;I4MI%=7.HW%Q/)=76H7OE^?=3.<EY/+1%SC"@*H 55
M  %,D^&OA"3Q0/$C^%M%?Q&&##6&T^$W8(7:#YVW?G;QUZ<5T8 6EZT7>X<D
M;6MH84G@'PQ+J5AJ+^'=)?4+!Y)+2[:RB,MLTC%I&C?;E"S,Q8@C)8D]:)/
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MCFF']G9;_P ^H?<CQK_AC?X2_P#0KM_X,;K_ ..T?\,;_"7_ *%=O_!C=?\
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MG_T%_P#R67_&C^SM3/\ S%O_ "57_&DI-%2HPG:YXI\+O@'JGA633V.E^'_
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M%3__ !BC_A@/XA_]!;PW_P"!4_\ \8K[J_L[5/\ H+_^2J_XT?V=JG_07_\
M)5?\:/:,/]4LM_O_ /@3/A7_ (8#^(?_ $%O#?\ X%3_ /QBC_A@/XA_]!;P
MW_X%3_\ QBONK^SM4_Z"_P#Y*K_C4EM9WT,RO-J7GQCK'Y*KGC'4&E[1B_U2
MRW^__P"!,_/S5_V*_&NB:AHEC=:OX>6XUB\:QM MQ<$&5;>6X(/[CC]W!)S[
M"M3_ (8$^(?_ $%O#?\ X%3_ /QBOM+Q?J6G6/B+P/#>V'VRYO=7E@L9L_\
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MMQM\E4Y]<@T 8.I:;ITGQ0\/7\M_Y>K0:1J4%O8X_P!=#)-9-+)G_8:.%?\
MMK75]JY34SHW_"TO#WG^;_PD']CZE]CV_P"K^S>=9?:,_P"UO^S8]MU=!?6U
MU<;/L]V;7&=W[L/GIZ_C3Z(SCO+U+M%9/]G:I_T%_P#R57_&C^SM4_Z"_P#Y
M*K_C2-#6HK)_L[5/^@O_ .2J_P"-']G:I_T%_P#R57_&@#6HK)_L[5/^@O\
M^2J_XT?V=JG_ $%__)5?\: -4]JY/XE_V-_PC=K_ &]YHLO[8TKR_)/S?:O[
M0M_LN?\ 9\_RL^V:V(K'48Y49]4\U P)7[.HR/3.:Q?B5J6G:7X=M9M4L?[1
MMFUC2X$ASC;-)?V\<,G_ &SE>.3_ (!36Z,ZGP,Z2\U&VTZ$27,Z01D[0SG
MSZ54_P"$JTC_ *",'_?=:J]!2TBUL9/_  E6D?\ 01@_[[H_X2K2/^@C!_WW
M6M10,R?^$JTC_H(P?]]T?\)5I'_01@_[[K6HH R?^$JTC_H(P?\ ?='_  E6
MD?\ 01@_[[K6HH R?^$JTC_H(P?]]T?\)5I'_01@_P"^ZUJ* ,G_ (2K2/\
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MOVLO"'Q8\60^'=,M-6L+^:)Y(FU"*)(Y"@R5!21CNVY;IC"FI?\ ACGX2_\
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M+?\ #<WPI_Z"&K_^"2[_ /C=>_&,,.1FF^6G916B<+:HY)0KN7NS27H>!?\
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M9&N[EH%3R6MC(O 5E8KM?>O*KEJ?+'^5@ZM2*3]JM?(I?\-S?"G_ *"&K_\
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M/A3_ ,_^K?\ @DN__C='_#<OPI_Z"&K_ /@DN_\ XW7T!Y:>@H\M/04<U/\
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M;H_X;F^%/_00UC_P27?_ ,;K5_X;#^$7_0S?^4ZZ_P#C5'_#8?PB_P"AF_\
M*==?_&JUM'^7\3R_[2H_]!4/P_S,K_AN7X4?]!#5_P#P27?_ ,;H_P"&Y?A1
M_P!!#5__  27?_QNM7_AL/X1?]#-_P"4ZZ_^-4?\-A_"+_H9O_*==?\ QJBT
M?Y?Q#^TJ/_05#\/\S+_X;F^%/_00U?\ \$EW_P#&ZW? G[5WP_\ B1XJL?#N
MAW>IS:I>F3R4GTJXA0[(VD;+N@4?*AZGTJM_PV%\(_\ H9S_ ."ZZ_\ C5(O
M[8GPD7IXG(_[AUU_\:I<JMI$<<RH*2YL3!KY?YGH_B:SUFZUSPE+I<WE65OJ
M;RZJF_'FVWV.Y15_VOW[6YQ_LY[5A?%7XZ>%/@PVF?\ "3W%Y!_:7F_9_LMC
M-<Y\O9NSY:G'^L7&>O/I7FOB;]J+X8:UKGA.]M_&K6T.D:G)>W,?]GW@^T1M
M9W, C_U7]^='Y_N5T!_;$^$;?>\3?^4ZZ_\ C50HO2Z-99I@[24*\4[]6O(R
M_P#AN;X4_P#00UC_ ,$EW_\ &Z/^&YOA3_T$-8_\$EW_ /&ZU?\ AL/X1?\
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MO_XW7OS*&7UI/*3^Z/RJ$X6U1V5(UF_W<DEZ7/ /^&Y?A3_T$-7_ /!)=_\
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M+^\(NM-VC53^1X;_ ,-R_"G_ *"&K_\ @DN__C='_#<OPI_Z"&K_ /@DN_\
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MS'?]"^I]Z#E7<]DXI:\:_P"%;^/O^AE/_@PG_P#B:/\ A6_C[_H93_X,)_\
MXFC^W,=_T+ZGX!RKN>R<45XW_P *W\??]#*?_!A/_P#$T?\ "M_'W_0RG_P8
M3_\ Q-']N8[_ *%]3[T'*NY9\4? E?$FK:Q?'67M_P"T9;N1HEM\K^^LH[9
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MW\??]#*?_!A/_P#$T?VYCO\ H7U/O0<J[GLG%%>-_P#"M_'W_0RG_P &$_\
M\31_PK?Q]_T,I_\ !A/_ /$T?VYCO^A?4^]!RKN>Q?>QQ7F'QH_9]\/_ !Q;
M2&UV]U*T.F>;Y/\ 9\L:!O,V;MV]&S]P=,=ZS/\ A6_C[_H93_X,)_\ XFC_
M (5OX^_Z&4_^#"?_ .)JO[=QRVR^I]Z.?$82CBJ;HUTI1?3H<1_PP#X!_P"@
MWXE_\"+?_P",4?\ # 7@#_H-^)?_  (M_P#XQ7<?\*V\??\ 0S?^5"?_ .)H
M_P"%;>/O^AF_\J$__P 35?V_F'_0!4^^)XO^K>4?\^(_<</_ ,,!> /^@WXE
M_P# BW_^,4?\,!> /^@WXE_\"+?_ .,5W'_"MO'W_0S?^5"?_P")H_X5MX^_
MZ&;_ ,J$_P#\31_;^8?] %3[XA_JYE'_ #XC]QP__# 7@#_H-^)?_ BW_P#C
M%'_# /@'_H-^)?\ P(M__C%=Q_PK;Q]_T,W_ )4)_P#XFC_A6WC[_H9O_*A/
M_P#$T?V_F'_0!4^^(_\ 5S*?^?$?N/-M2_89^'.FWVDV\WB77K9[ZY:VABEF
M@+7#B&278F(1A@L3MDY&U&XR01H_\, ^ ?\ H-^)?_ FW_\ C%=?<_";QG>S
M6DUQKD,\UI*9K>26\F9H9"C1ET)3Y6V.ZY'.'8=":L_\*W\??]#,?_!A/_\
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MX=%EH.O:/X?O)[2]L+UK'PY'%9M#<,&/D6T<J^6Z8&UG>3.6WA^,>P:/I_\
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MHHH ,>U%%% !1110 48HHH **** #'M1@>E%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !BBBB@ HHHH **** "BBB@ Q1@>E%% !11
M10 4444 %%%% !@4;1Z444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 8HP/2BB@ HHHH **** # ]*-H]*** "BBB@ HHHH **** "BBB@ HH
KHH **** "BBB@ HHHH **** "BBB@ HHHH *,#THHH 6BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>bntx-20231231_g2.jpg
<TEXT>
begin 644 bntx-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &G!&,# 2(  A$! Q$!_\0
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MBO&_#?[76G>&_"_@/3/$NF>(O$GC'6_#-OK8&AZ6MPUXS@AD5(RI#DJ[?=5
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M277'W0"#@YI1I3E9)&M3&T*:NY?TSZJW9/3/:EW>M?//A/\ :-TGPSX.\?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[4FX^E&X^E "Y]J,^U)N/I1N/I0 N?:C/M2;CZ4;CZ4 +GVHS[4FX^E&X^E
M"Y]J,^U)N/I1N/I0 N?:C/M2;CZ4;CZ4 +GVHS[4FX^E&X^E "Y]J,^U)N/I
M1N/I0 N?:C/M2;CZ4;CZ4 +GVHS[4FX^E&X^E "Y]J,^U)N/I1N/I0 N?:C/
MM2;CZ4;CZ4 +GVHS[4FX^E&X^E "Y]J,^U)N/I1N/I0 N?:C/M2;CZ4;CZ4
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M>,_\76_VO_)6C_BZW^U_Y*U[-NHW4?ZN_P#454^\.?R/&?\ BZW^U_Y*T?\
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M_M?^2M'_ !=;_:_\E:]FW4;J/]7?^HJI]X<_D>,_\76_VO\ R5H_XNM_M?\
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MN7UMO^!ZC]*^>OCA^T!K7PY\>:AHUEJ_A?2X;3PZNLVUKK5N\ESJEP99D%K
M5N(\,PC4#".<MT/2OH7WKFE\!V$?Q"N/& FN3J4VF1Z4T.Y?)$22O*& VYW;
MI""<XQCCO6<&D_>5SJKQJ2BE3=CB8/VC=+CN=;AU'P_K&G1^'K.&\UV]D2'[
M/IWF6HN%4@R"60X)3"1L=PY &#27'[2FAZ7%J$>KZ!X@T75[9;1X=&N[6)KJ
M]6YE\F P^7*Z$O)E-KLK*0=P4<UTEY\'?#^IR>.?MRW%Y!XP6--2MY9 $"I
ML $>T!E^50<DDYY&.E<]+^SCHFH6VI-JNNZ]K.K7:6D<.LWDT N[);:7S;<0
M&.)$&R3+Y9&+$G<6'%6O9O<YI+%KX6NOZV_0R?!?[14VK>+=8TG7M#N=+_XJ
M2+0--MO*03QLUB+EC<$3,AY#@-&2"-F <[JT;7]I?0]4TK3+O2M U_6+F^6^
MF73;&VB:ZC@M+@P3S%3* RA\!50L[;AA"<@)%^S5I$<EU=_\)-XB;6KC6H=>
M.L-+;?:$NH[?[/D+Y'E;6CW J4(^8XQQANF_LR:#H>BZ/9:3XA\1Z3=:;%>V
MRZI9W4*7<T%U.9IHG;RBH!?!#(JNNT%6!R2W[(RBL:M&UU_,TO!_QBNO$GQ"
M\;Z'=^'KO2M)\/PVTR:E<^6/,62,R$NF\NI*\JNS("G=M;"U%I_[06GZEX9N
M==3PQXDBL%MK>]LY9K.-8]0@F;$<D<OF^7&#P2)VB**0SA1S70Z7\*]-TGQ7
MKNN17FH2C6[2&TO=/N)$E@D\I-B2;F4R[]F5/[S!R21GFN/?]F/19/#,6@OX
MF\326%FUH=,CDNX6335MI/,A2*(Q>6^#A2TR2.5 !8@"I_=M_<;-8I+37?\
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MI%%S)F94;>/WBXR,IZ_2_BWPW:^,O"VL^'[UYHK/5+*:RFDMR!(J2H48J2"
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M1+V:[CM#'974VWR%D*7#%E<.F&C#@;ANVU;D_9ST;4(KY]7U_7]<U"[-BO\
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MJ+?%W_PEO_MM+_PWO\#/^AU/_@IOO_C%'_#>_P #/^AU/_@IOO\ XQ1[-_\
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MT7_#>?P*W9_X38_^"F^_^,4>RFGK!L'C*,H)0K)?<+_PU[_U1;XN_P#A+?\
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MQ4\\'KR_B:JA7BK*KIZ(^??^&OC_ -$6^+O_ (2W_P!MH_X:^/\ T1;XN_\
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M  +M?_D:OL&BCZU6_F8?V3@?^?2/C[_AU_\ "[_H8?%__@7:_P#R-1_PZ_\
MA=_T,/B__P "[7_Y&K[!HH^M5OYF']DX'_GTCX^_X=?_  N_Z&'Q?_X%VO\
M\C4?\.O_ (7?]##XO_\  NU_^1J^P:*/K5;^9A_9.!_Y](^/3_P2_P#A=@_\
M5!XN_P# NU_^1JSO#G_!,KX<W?A_39[[Q/XBN[V2VC:XGTZ[MA;2.5!9H@8"
M1&225R2<$<FOM%ONFN4^%>G:=HWPQ\):?H]__:NDVFD6D%G??\_,*PHL<O\
MP)0&_&G]:K6^)D/*L%S+]TCYK_X=?_"[_H8?%_\ X%VO_P C4?\ #K_X7?\
M0P^+O_ NU_\ D:OL&BE]:K?S,O\ LG _\^D?'W_#K_X7?]##XN_\"[7_ .1J
M/^'7_P +O^AA\7_^!=K_ /(U?8-%'UJM_,P_LG _\^D?'W_#K_X7?]##XO\
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ML/[5TFTTB[GO+'./M,*PNSQY_P!I05_&NJJNAFOC?HA]%%%2:!1110 4444
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M&2YKR_[_ "V[(^!O^&^_B)_T"?#?_@+/_P#'Z/\ AOOXB?\ 0)\-_P#@+/\
M_'Z^^?LT7]Q?R%'V:+^XOY"ES1[%_P!BYK_T'R^Y'P-_PWW\1/\ H$^&_P#P
M%G_^/T?\-]_$3_H$^&__  %G_P#C]??/V:+^XOY"C[-%_<7\A1S1[!_8N:_]
M!\ON1\#?\-]_$3_H$^&__ 6?_P"/T?\ #??Q$_Z!/AO_ ,!9_P#X_7WS]FB_
MN+^0H^S1?W%_(4<T>P?V+FO_ $'R^Y'P-_PWW\1/^@3X;_\  6?_ ./T?\-]
M_$3_ *!/AO\ \!9__C]??/V:+^XOY"C[-%_<7\A1S1["_L7-?^@^7W(^!O\
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M%G4+]T4M(OW12TBUL%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M2EHHH 2C%+10 F**6B@!-M&*6B@!,48I:* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $KA_$GA6TUK7KF>XTN2ZL[ZP;3-2M9+='COH,
ML8QDN"I0O+U!R)&&,X([FFA0.E-:;":4M&>8P?"OPS#I]Y:MHOB*Z^U-"SW5
MYK-U<72^3()(@EQ)<M+&JN-P5& SDXY-0/\ !GP9+>:A<R^%M7G:^AN[::.?
M4)Y(A%=,&N$CC:<K&KL,D(% /(Q7JU%/FEW,?8T_Y3R]/A+X172YM/?POJES
M;S2/+(UU>RS2NSP-;D&5YRY41,4"[L*/N@8%#_"?PR=835(='\2V5XN[YK'7
M+NV1MTSSL&2.Y56!DD=B&!^]CI@5ZA13YI=Q^QI_RGFR?#'PHNHZK>-X4OY6
MU**:&XMYIVDMMLV#/Y<#2F.(R$9<HJECDDDDU>\)>#=%\$V^IPZ;H6K2#4G#
MWDFH7DE])<$($&]YYG8@( N"<8 %=W12YF]V-4H1=TCQO4/@EX=FTF6QL=*U
MFT$T]FS27%]-=M'!;W"3"" R7!,"$K@"(J%RIQ\HK<M?AIX7LX=/C3PSJ;FQ
M<RPRS73RRF0SQW!=W:8M(YEAC8LY8G;@G&17H^T4M/GEW%[&FOLGE[?"7PAY
M^FR+X6U.(:>$6&&&\DCB9$E,L<<L:S!98XW)*1R!ECSA0HXJ]X[\ >'OB3Y0
MU_P_J]P$MYK0K;WLEL)89=OF1R"*91(AV+\KY (R,&O0J*7-*][C]E3MRVT.
M(A\*Z+!(LB^';\NMXNH;FEW9G6 6X<YDY_= +@\<9QGFN,\2_!NSG\-VNF^&
MM/N-&N;?R(XK[4)+N[EAAA\[RUBDCOX9HR//E4,)/N,R$%< >TXQVI-OYT^=
MH4J-.2M8\FTCX.>&=/TWP]!<Z#J5U-H]M#;++'.UO'<K$V]!-%'*$E59,LJ2
M!@I)QU.>A7PW9:?&DNDZ+=6.HP+>&SN9,3"&2YD\R9RGG#?F0!L$]L+@5W.T
M$4;0!ZBDY2>['&E".R.;\.V\7A?0K'2;+2M1^S6<*PH9/+9B%&,L=_)/4GN2
M:TO[8E_Z!5]_WS'_ /%UIT5)HDHJR,W^V9?^@5??]\Q__%T?VU+_ - J^_[Y
MC_\ BZTJ*!F;_;4O_0*OO^^8_P#XNC^VI?\ H%7W_?,?_P 76E10!F_VU+_T
M"K[_ +YC_P#BZ/[:E_Z!5]_WS'_\76E10!7M+I[J,LUM+;D'&R;;D^_!-4O[
M<F_Z!%__ -\Q_P#Q=:NVH;JY2TM9IW^Y$C.V!V S0!G_ -N3?] B_P#^^8__
M (NC^W9O^@1?_P#?,?\ \77G&G_$3Q?I_@J?QOK%MHUUH$^D/JL&G62RPW-J
M2JO##),SLLVY6PSK''M*\*X/":EXL^(WAN6?3;Q?#^LZQ=Z7<:CIOV"RG@02
M6[1>9:NK3.9"ZR@)*"@RIRG(%:<AS?6(I7:9Z1_;LW_0(O\ _OF/_P"+I%UV
M?_H$WQ_X#'_\77G/C3XQ7D.FC4/"BV-[:P^'9O$=Q+=12./):,_95&UEP9'#
MGG^&%QP2"*_A;XB>,96TG6-7FT.Y\/:IK%QI*V=EI\UO=6NV::**0RM<.LN3
M$H*B-/\ 6;@?EP3V<K7)^LPYN4]0_MR;_H$7_P#WS'_\71_;DW_0(O\ _OF/
M_P"+KG?B9XRU?PCI^DW&E:;!>)<:I8VEU<74NU((9KJ&%BJCYGD/F_*.%&&)
M/ 5^.F^-EY8?%5] N[[18H#JD>EQ:#Y3C5&1XD=;W>9-IAW-MP(L?]--WR%*
M$GJ7*O3B[,]3_MR;_H$7_P#WS'_\71_;DW_0(O\ _OF/_P"+K0\P9ZBN'^*/
MQ*'PWAT>]F@\_3Y9KC[:(XR\HBBM)Y_W8!'S9B4<\$$CK@TE%MV+E4A%7;.G
M_MZ;_H$WW_?,?_Q=']NS?] B_P#^^8__ (NO,O&'QJUBW\$ZA=Z%X5U&W\1V
M^KVNCR:=J4=K*T#SF(K*RI=K'(I290 LP.Y@&V@,5O\ A7XU176DZD=8MG.H
M:;=K;SFRB"1L)=0GLX"H:0G.8<MD]^,]!7LY6N9?6:7-R7Z7._\ [<F_Z!%_
M_P!\Q_\ Q=']N3?] B__ .^8_P#XNO,5_:H\%2:[XBTN.26>31;>[N)'MY[6
M9IOLW^N184F,R,"& \V.,-M.TD8)W'^,FWP]J^I-X2UR.XT>Y^SZAILT^GQ3
M6Z>2LWGM(]V(?*V.IR)21G! PV%R2[%+$4GM([+^W)O^@1?_ /?,?_Q=']NS
M?] B_P#^^8__ (NO/=7_ &B-&\/WOA.UU?1M6T>;Q%Y ACU!K2%X&FD6-$9&
MG#2,"REU@$IC# OMR*]67GZ5+BXZLTC4C.ZB]C+_ +<F_P"@1?\ _?,?_P 7
M1_;DW_0(O_\ OF/_ .+K5HI&A5DNV6S%P+::1BH;R$V[^<<=<<?7M5/^VIO^
M@1J'_?,?_P 76KMYS2T 9/\ ;<W_ $![_P#[YC_^+H_MN7_H#W__ 'S'_P#%
MUK44 9/]MR_] >__ .^8_P#XNC^VY?\ H#W_ /WS'_\ %UK44 9/]MR_] >_
M_P"^8_\ XNC^VY?^@/?_ /?,?_Q=:U% &3_;<O\ T![_ /[YC_\ BZM6-\]Y
MOWV=Q:;>GGA?FZ]-K'TJY2;10!R?PUTW3])\.W4&EWYU*V;6-5G>8C!6:2_N
M))H_^V<KR1_\ K;N=6EMIFC&G7DX'_+2,)M_,L*Q?AL-&'AVZ_L$S&R_MC5?
M,\[[WVG[?<?:<?[/G^;CVQ75XIOJ9T_A1E?VW-_T![__ +YC_P#BZ/[;E_Z
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MT_FPJ+^VY?\ H#W_ /WS'_\ %UK;114FAD_VW+_T![__ +YC_P#BZ/[;E_Z
M]_\ ]\Q__%UK44 9/]MR_P#0'O\ _OF/_P"+H_MN;_H#W_\ WS'_ /%UK44
M97]N3?\ 0'O_ /OF/_XND_MR;_H$:A_WS'_\76M10!E?VY-_T"+_ /[YC_\
MBZN6=XUY"SM;36I!V[)MN[Z\$U9I-HH Y3X5Z=IVC?#'PEI^CW_]K:1::1:0
M6=]WN85A18Y?^!* WXUL3:U+'(Z#2[Z4*VW?&(R#[C+]*QOA2NC?\*Q\(_\
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MT4 97]N3?] B_P#^^8__ (NC^W)O^@1?_P#?,?\ \76K10!E?VY-_P! B_\
M^^8__BZ/[<F_Z!%__P!\Q_\ Q=:M% &5_;DW_0(O_P#OF/\ ^+H_MR;_ *!%
M_P#]\Q__ !=:M% &5_;DW_0(O_\ OF/_ .+H_MR;_H$7_P#WS'_\76K10!E?
MVY-_T"+_ /[YC_\ BZ/[<F_Z!%__ -\Q_P#Q=:M% &5_;DW_ $"+_P#[YC_^
M+JY8WCWD9=K::U(;;LFV[OKP35FC:* ,K^W)O^@1?_\ ?,?_ ,71_;DW_0(O
M_P#OF/\ ^+K5HH RO[<F_P"@1?\ _?,?_P 71_;DW_0(O_\ OF/_ .+K5HH
MRO[<F_Z!%_\ ]\Q__%T?VY-_T"+_ /[YC_\ BZU:* ,K^W)O^@1?_P#?,?\
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MP[77+6*WN=)T^**&S#1[P)DC5!MD(D()S@X&1D9J)2I:V1O2IXRZ]I+35?\
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M(F2=H9U) RS''N?6JGC#X3Z%XQ\/Z?HDJ2Z9IMA')%;0::$B2-'MI+?8JE2
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M+X=_]")X;_\ !3!_\13YX=CR_P"S\_\ ^@R/_@)\Q_\ #Q";_H0U_P#!L?\
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M ,8H_P"'B$W_ $(:_P#@V/\ \8KZ<_X4E\._^A$\-_\ @I@_^(H_X4E\._\
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M .(H_P"%)?#O_H1/#?\ X*8/_B*GGAV*_L_/_P#H,C_X"?,?_#Q";_H0U_\
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MI71_\*3^'?\ T(GAO_P4P?\ Q%#E&^Q,<OSYI<N,C_X"?,G_  \0F_Z$-?\
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M'_?=O_\ ':UZ* ,G^VKO_H ZA_WW;_\ QVC^VKO_ * .H?\ ?=O_ /':UJ*
M,G^VKO\ Z .H?]]V_P#\=H_MJ[_Z .H?]]V__P =K6HH R?[:N_^@#J'_?=O
M_P#':/[:N_\ H ZA_P!]V_\ \=K6HH R?[:N_P#H ZA_WW;_ /QVC^VKO_H
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M$T(5N,\;I ?TJ/\ MJ\_Z 6H?]]V_P#\=KX5_P"&^/B'_P! GPW_ . MQ_\
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M_P -]?$/_H$^&_\ P%N/_C]'_#?7Q#_Z!/AO_P !;C_X_1[.0?ZVY=_>_P#
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M>+J=Q<68MXH)H8V>)9;599=PF#+NCCSM()'6O6:AQ:.BG4C45XF7_;5W_P!
M'4/^^[?_ ..T?VU=_P#0!U#_ +[M_P#X[6M14FID_P!M7?\ T =0_P"^[?\
M^.T?VU=_] '4/^^[?_X[6M10!D_VU=_] '4/^^[?_P".T?VU=_\ 0!U#_ONW
M_P#CM:U% &3_ &U=_P#0!U#_ +[M_P#X[6J#D#M2TE "T444 %%%% !1110
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MHH RO[<F_P"@1?\ _?,?_P 71_;DW_0(O_\ OF/_ .+K5HH RO[<F_Z!%_\
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M1_Z E]_WS'_\76U11=]P]G#^5&+_ &D?^@)??]\Q_P#Q=']I'_H"7W_?,?\
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MHH RO[<F_P"@1?\ _?,?_P 71_;DW_0(O_\ OF/_ .+K5HH RO[<F_Z!%_\
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M 01@5'HWQXCDT_PW]OT+4+BYOM/TN[O[W3XXA:637K^5%NWS"0J9 P^17*@
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M\//^A$\-X_[!,'_Q%6G'J>'CJ.9U*B>#JQC&VS5]3QO_ (> > /^@+XD_P#
M>W_^/T?\/ / '_0%\2?^ ]O_ /'Z]E_X4E\._P#H1?#?_@I@_P#B*/\ A27P
M[_Z$7PW_ ."F#_XBJO#L>=]6S[_H(A_X _\ ,\:_X> > /\ H"^)/_ >W_\
MC]'_  \ \ ?] 7Q)_P" ]O\ _'Z]E_X4E\._^A%\-_\ @I@_^(H_X4E\._\
MH1?#?_@I@_\ B*+P[!]6S[_H(A_X _\ ,R_@W\>O#_QNM=2FT.WOK4Z>Z)-%
MJ$:(WS E6&QV!'##KGY3[&O2-U8_AOP?H/A"WEAT/1M/T:*9@\D>GVJ0*Y Q
MDA0,G%:_X5#M?0^BPT:\:,5B9*4^K2LON'TAZ&EI#T-2=9R7PV_L7_A';K^P
M#,;'^V-4\SSOO?:OM]Q]I_X#Y_FX]L5UF?SKD_AMJ6FZMX=NYM+T_P#LVV76
M-5@>'.=TT>H7$<TN?^FDJO)CMOKJQ^9IRW9G3^%#Z***1H%%%% !1110 444
M4 -S7)_"G^Q?^%8^$?\ A&_.'A[^R+0:;Y_^L^S>2OE;O?9MS^-=7^M<K\*]
M2T[6?ACX2O\ 1[#^RM)N](M)[.QSG[-"T*,D>?\ 94A?PJNAF_B7H_T.MHHH
MJ30**** "BBB@ HHHH *0]#2TAZ&@#DOA3_8O_"L?"/_  C?G?\ "/?V1:#3
M?/\ ]9]F\E/*W>^S;G\:ZS/YUR?PKU/3M:^&7A*_T>P_LK2;K2+2>SL<Y^SP
MM"C)'G_94A?PKJQ^9IRW9G#X4/HHHI&@4444 %%%% !1110!R/Q5&B_\*Q\7
M?\)'YQ\/?V1=_P!I>1_K/LWDMYNWWV;L?A769KE/BIJ6G:-\,?%M_K%A_:ND
MVFD7<]Y8YQ]IA6%V>//^TH*_C75570S7QOT0^BBBI- HHHH **** "BBB@!N
M?SKD_BM_8O\ PK'Q=_PDGF_\(]_9%V-2\C_6?9O)?S=OOLW8_"NK/Y&N4^*F
MI:=HOPR\6W^L6']JZ3:Z1=S7ECG'VF%879X\_P"TH*_C3CNC.I\+.LSTKS+Q
M!+XD\5>.M4T;1_$DOAF+2-/M[N/R+2"87<\S3@";S58^2ODC*Q^6YW-B0<8]
M,_E7)>,/A3X:\>7<=SK%G<2S+"UL[6M]<6OGP,<F&80N@FC)S^[DW+\S<?,<
MN+2W)J1<DK'.77Q:U.'Q5+IK:)"=(COQHSZHEX1,+PVHGR+?RR/)Y"[_ #-V
MX_<Q\U>7:?\ M-:YX8\$R:EJ5FGB:^2*.[E3<T,D<":=9S3,([>WE<_O)W)=
MU2)=P#2IE ?<X_A+X6B\2#7(M-,5ZN"L<=Q*MLKB+R1*+<-Y0E$0$8E";PGR
M[L<5B:A^SKX"U*Q%E)I-REKY#6K16^IW<*RPM#%"T<FR4>8FR"$;6R,H#C<2
M3M&5/JCBG2Q#UC+N86G_ !DUBS\::_!>:='>>%X=;BTV+4!<A)[=I+&"9%6#
MR_WB;W.79PP,@ ! .$M?CYK4ND+<3>$H([V]ATV[TRV352RS07EP($\YS"/*
MD3<&95$@P>&;G'9VOP;\)VGB;^WX]/F_M$R+,VZ^N&A>40B%9&A+F-G$8"AR
MI8#.",FDT;X,^$= A>*STV14:6VE7SKR>8Q?9Y!)!'&7<F.*-QN6%,1C)^7D
MY7-3[%JGB/YNYQNH?'S5=/\ 'UIX5E\.V33S[K1KJWOYYH8;X6;W/E-(MKY:
MI\NWYW2;#!_)V$$Y/@_XT>*[RS\-V$VDVNJ^*=8TK3KA(9M2$%CNDBNI7E:1
M;7>C%+<$J$<;F55"@,Y]*N?@]X5O/&"^)I;*Y?55N1>KG4+GR%G$)A\T0>9Y
M08QG:3LY'7-4X_@3X-CTVVLH[&^B%K'#%;W$6K7B7,"1>:(Q'.)1(FU;B9/E
M8?(Y3[N 'S4[;$^RQ/-?FZO[M#G(?CYJ-])I]Q9^&8FTIH-,GU":YU'RY[;[
M9</ JQQ+$ZRE&0ELN@(^[N/%>Q[OSKEH_ACX8AM3;1:5'#;>19VPAB=T01VL
MADMU !P CL3QUS@Y'%=3M'6LI-=#JI1J1_B.XZBBBH.@**** "BBB@ HHHH
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MVMJ'_0$N/^_T7_Q5:U% &1_:FH?] 2X_[_1?_%4?VIJ'_0%N/^_T7_Q5:]%
M&3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?
MVMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U%
M&3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?
MVMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U%
M&3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?
MVMJ'_0$N/^_T7_Q5:U% &3_:VH?] 2X_[_1?_%4?VMJ'_0$N/^_T7_Q5:U%
M%6RNIKB)FFM7M6!P$=E8D>ORDU3_ +6U#_H"7'_?Z+_XJM7;2T 9/]K:A_T!
M+C_O]%_\52?VKJ'_ $!+C_O]%_\ %5KT4 9']JZA_P! 2X_[_1?_ !5']JZA
M_P! 6X_[_1?_ !5:]% &3_:VH?\ 0$N/^_T7_P 51_:VH?\ 0$N/^_T7_P 5
M6M10!D_VMJ'_ $!+C_O]%_\ %4?VMJ'_ $!+C_O]%_\ %5K44 9/]K:A_P!
M2X_[_1?_ !5']K:A_P! 2X_[_1?_ !5:U% &3_:VH?\ 0$N/^_T7_P 51_:V
MH?\ 0$N/^_T7_P 56M10!D_VMJ'_ $!+C_O]%_\ %4?VMJ'_ $!+C_O]%_\
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M8\>JZG:B&-"H98;Z>)9<>LBH)">Y<FMBYU"[AF9(],FN$[2+)& ?S8']*R_
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M_/IXF_\ "93_ .1ZKV?F>7_K70_Y\5/_  %GZ";J-U?GW_PM;]IG_GT\3?\
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M<1%UZ-L<$9'8XK-U#X7>#-4T_3;&]\):'=V6F(T=C;SZ;"\=JK !EB4KA 0
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M5KT4 9'G:Y_S[Z?_ -_W_P#B*/.US_GWT_\ [_O_ /$5KT4 9'G:Y_S[Z?\
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MYD^=KG_/OI__ '_?_P"(H\[7/^??3_\ O^__ ,16O14EF1YVN?\ /OI__?\
M?_XBCSM<_P"??3_^_P"__P 16O10!D>=KG_/OI__ '_?_P"(H\[7/^??3_\
MO^__ ,16O10!D>=KG_/OI_\ W_?_ .(H\[7/^??3_P#O^_\ \16O10!D>=KG
M_/OI_P#W_?\ ^(H\[7/^??3_ /O^_P#\16O24 5))KD68,:0FZP/E=R$#=^<
M$XZ]N:J>=K?_ #[Z?_W_ '_^(KC_ (^:MXGT/X3ZY?>#H[F3Q%%Y'V06=J+F
M4YGC#XC*MN^0MV/&37R"/BK^TSU%IXF_\)E/_D>M(PN?.9CG=++:JI3IRE=7
M]U7/N_SM;_Y]]/\ ^_[_ /Q%'G:W_P ^^G_]_P!__B*^$/\ A:W[3/\ SZ>)
MO_"93_Y'H_X6M^TS_P ^GB;_ ,)E/_D>J]GYGE?ZUT/^?%3_ ,!9]W^=K?\
MS[Z?_P!_W_\ B*/.UO\ Y]]/_P"_[_\ Q%?"'_"UOVF?^?3Q-_X3*?\ R/1_
MPM;]IG_GT\3?^$RG_P CT>S\Q_ZUT/\ GQ4_\!9]W^=K?_/OI_\ W_?_ .(H
M\[6_^??3_P#O^_\ \17PA_PM;]IG_GT\3?\ A,I_\CT?\+6_:9_Y]/$W_A,I
M_P#(]'L_,/\ 6NA_SXJ?^ L^[_.UO_GWT_\ [_O_ /$59L9;YMXO(K>/IM\B
M1F]<YR!CM7P/_P +6_:9_P"?3Q-_X3*?_(]'_"U?VF?^?/Q-_P"$PG_R/1[/
MS%_K70_Y\5/_  %GVQ\-=1T[5/#MW-IEA_9ULFL:K \.<[IH]0N(YI,_]-)4
M>3';?6U<R:JL["W@LW@XPTDKANG/ 4]Z^!;'XJ?M'^2WV.S\0>3YDF[R/#,>
M/,WMOZ6_WMV[/?.<\U8_X6I^TS_SY^)O_"97_P"1Z;IZ[DQXJHJ*_<5/_ 6?
M=_G:W_S[Z?\ ]_W_ /B*/.UO_GWT_P#[_O\ _$5\(?\ "UOVF?\ GT\3?^$R
MG_R/1_PM;]IG_GT\3?\ A,I_\CTO9^9?^M=#_GQ4_P# 6?=_G:W_ ,^^G_\
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M%O!9M!QAI97#=.> I[U%YVN?\^^G_P#?]_\ XBM;:#UYI:1H9'G:Y_S[Z?\
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MSM<_Y]]/_P"_[_\ Q%'G:Y_S[Z?_ -_W_P#B*UZ*DV,CSM<_Y]]/_P"_[_\
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M<_Y]]/\ ^_[_ /Q%:]% &1YVN?\ /OI__?\ ?_XBM9>G-+24 +1110 4444
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M8H ROM6N?] [3_\ P/D_^,4?:M<_Z!VG_P#@?)_\8K5Q1B@#*^U:Y_T#M/\
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MVK7/^@=I_P#X'R?_ !BC[5KG_0.T_P#\#Y/_ (Q6KBC% &5]JUS_ *!VG_\
M@?)_\8JW9S7<D+&[@A@DS@+#,9%QZY*K^6*M8I"HQ0!S?PZNM8U#X?\ ANZ\
M10?9O$$^FVTNHP!=OEW)B4RKCMA]PQ6A)=:P)7$5A8M&&(1GO74D>I'E'!]L
MFJ'PYM-9T_X?^&K7Q%-]IU^#3+:+4IMX?S+E8E$K;AURX8Y]ZZ(*/PIO=F</
MA1F?:M<_Z!VG_P#@?)_\8H^U:Y_T#M/_ / ^3_XQ6KBC%(T,K[5KG_0.T_\
M\#Y/_C%'VK7/^@=I_P#X'R?_ !BM7%&* ,K[5KG_ $#M/_\  ^3_ .,4?:M<
M_P"@=I__ ('R?_&*U<48H ROM6N?] [3_P#P/D_^,4?:M<_Z!VG_ /@?)_\
M&*U<48H Y+QQ?>([/X=^)KO2+.%O$<&GW4FFV\+F=9+@1,81RJY)? V_K76#
MM7-_$6SUC4/ /B6V\.S?9O$,VFW,6FS[POEW+1,(FW'IARIS[5T@_AI]$9KX
MW\C,ENM9$CB*PL6CW$*SWKJ2.Q(\HX/MDTGVK7/^@=I__@?)_P#&*U-HI<4C
M0ROM6N?] [3_ /P/D_\ C%'VK7/^@=I__@?)_P#&*U<48H ROM6N?] [3_\
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MJQD2=;QW5!/)Y \DIL+/M608^[N/RU7LY&7UFFM#U,7FN?\ 0/T\_P#;^_\
M\9H^V:Y_T#M/_P# ^3_XS7AG_#0?B7PW8O;7WANXUWQ%-J6I$V5G'<SI!:V\
MPC"H]K:2LY^= ID1 1DLZ'Y:Z+5/BOXAU3Q5H$&DZ4+#PZ=>BTV[O+F91=2L
M;5Y7C-NT?R(&*+N#[]R$;0OS%^RD0L929ZC]LUO_ *!^GYQDXOG_ /C-+]JU
MS_H':?\ ^!\G_P 9KS7Q7\4==\*_$C6[2/3HM4\.Z?I^FW=V9+D026BSW%Q&
MSQ+Y;><V(PQ5G0 1\'+8.]X9^*C^(]>M-&_LDV^I+-?1ZE&;@$62V[A ^=HW
M^87B91A24<M_#@IP=KFD<1"3Y3J_MFM_] _3_P#P.?\ ^,T&\US_ *!^GYQ_
MS_/^/_+&N'MI/$_BSQ?K]S8>)9-&L]#U.*QCTE;2&2"[010RRM.S*9-S"5@A
MC= NU"0_(/G>G>,O&O\ PA/C_P 37.I^*HOL-KJSV5Q=0Z0=-5H9I4B,"1(;
MEF54'^N!5L-G.11R7(EB5%VM_2/>_MNN9Q_9VG_^!TG_ ,9H^V:YVT_3R?\
MK_D_^,UXKX7\8>*Y/%6F6%MK>O7^B7M\L$6H^*="6QN9)/L5Y))%Y7V>W)C0
MQ6[!@BDEF&]@"!VO@W6O%%UJFD1ZK]O#26L)N()+ )!M-JKO*TFP8E\\LA3/
M _@'WJ;I\HX8A3Z=3N/M6N?] [3_ /P/D_\ C%:J].:,45D=8M%%% !1110
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M)X]-IQS[U']NUC_H%V__ (&?_85J[:*DT,K[=K'_ $"[?_P,_P#L*/MVL?\
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M?MVL?] NW_\  S_["M7;12-#*^W:Q_T"[?\ \#/_ +"C[=K'_0+M_P#P,_\
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M4?\ "R/'_P#T+7_E/G_^*KV/%&*\[^P\=_T,*GW1'S+L>.?\+(\?_P#0M?\
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M7#,(HT"("=W)VJ.:]YQ1BC^P\=_T,*GW(5XWO8\<_P"%D>/_ /H6O_*?/_\
M%4?\+(\?_P#0M?\ E/G_ /BJ]CQ1BC^P\=_T,*GW(?,NQXY_PLCQ_P#]"U_Y
M3Y__ (JC_A9'C_\ Z%K_ ,I\_P#\57L>*,4?V'CO^AA4^Y!S+L>.?\+(\?\
M_0M?^4^?_P"*H_X61X__ .A:_P#*?/\ _%5['BC%']AX[_H85/N0<R['CG_"
MR/'_ /T+7_E/G_\ BJ/^%D>/_P#H6O\ RGS_ /Q5>QXHQ1_8>._Z&%3[D',N
MQXY_PLCQ_P#]"U_Y3Y__ (JD_P"%D>/_ /H6O_*?/_\ %5[)BC%']AX[_H85
M/N0<R['@WA7Q%XQ\&^&=(T#3?##)IVEV<-C;+)97#,(HT"("=W)VJ.:U?^%D
M>/O^A:_\I\__ ,57LF*,4?V'CO\ H85/NB).*5DCQS_A9'C_ /Z%K_RGS_\
MQ5'_  LCQ_\ ]"U_Y3Y__BJ]CQ1BC^P\=_T,*GW(?,NQXY_PLCQ__P!"U_Y3
MY_\ XJC_ (61X_\ ^A:_\I\__P 57L>*,4?V'CO^AA4^Y!S+L>.?\+(\?_\
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M*$WA/EW8XK$O_AZ=2L192^ [A+7R&M6BMY-2A62%H8H6CDV3CS$V00C:V1E
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M4O),<]\PJ?<BX\L=$CQS_A9'C_\ Z%K_ ,I\_P#\51_PLCQ__P!"U_Y3Y_\
MXJO8\48H_L/'?]#"I]R*YEV/'/\ A9'C_P#Z%K_RGS__ !5'_"R/'_\ T+7_
M )3Y_P#XJO8\48H_L/'?]#"I]R#F78\<_P"%D>/_ /H6O_*?/_\ %4?\+(\?
M_P#0M?\ E/G_ /BJ]CQ1BE_8>._Z&%3[D',NQXY_PLCQ_P#]"U_Y3Y__ (JO
M2/!^J:CK'AVUN]4M?L=])O\ ,A\MH]N'8#Y6.1D 'GUK:QS2;1S7I8#+L1@Z
MCG6Q4JJM:SM;UT);3Z#Z***^@)"BBB@ HHHH 2LS6M7;2+/[0MM)=_O%0K&0
M-H)QN))X _$^U:E4]0LTU&TDMY"RHY!)!Y&""/7T% &-XH\6GP_>6D&=-C,\
M;R;]2U#[*ORE1A3L;)^;VZ59D\7:=:R3Q7$YBEMT9Y=L<C1@J 657VX<@'.T
M?-["M"2QCDOXKLEO,CB:(+GY=K%22>.ORC]:R[CPC;75Q.[W5UY,NYA:[E$:
M.PPSK\N[)&>"2/F/'- $EYXD6VNM*A2"5A?;FW21RIY<:KN)(V'#<CY6V]3S
MQBGR^*M.B:$&:1S-M"+%!([$LNX<*I.,#/MWQ5B>UM=0O%=I-TEL61D5N 74
M9#>^TC\ZHZ5X0@TN2*4WMW>21D%6N"G01E N%0# !H KZ;X\T_4)H4*SVXGA
MCFB,T,@X<,0'.W"?=.,GYL<9JW!XPTRX$&R6XW3RB&.-K2979B,@[2N0N 3N
MQMP"<X!ID'@NRBM4MY)KBXC58T_>%<E4#!5.%'&&(_ >^8O#_@2P\.,C6SN2
MK[Q^Y@BS\A7YO+C7=P>IR?>@"2[\865GJ1M',A\M7::3R9-J[5!PIVX<_,!A
M3G) QDXIR^,;%IX8E6[<R12R\6DNY?+*[E9-NX-\PPN,GC'49BU#P-9ZI-=&
M>ZNFMYE<"U/EF.-GQN890DDD X8D>V"14,/P]L;:P2TBNIX45)4)@BMX@PDV
MYRB1!#]Q?X><8.02" 3MXRM6\AHLF*1]C>>KP2)^\5#N1U!&,YYP>G&#FKUI
MX@M;[3Y;V$7/DQYSYEK*CG SE490S<=, YZ"LW3O %AI<,,<$TZ"%MZ%5B0
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MWDCN+A'A>-U(9>=D9CP?EZ%6.?KVK.L_!1M;U#_:-T;2&*%(XLQ_.8]VTO\
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M6.G^2T[3)%)'YI/D2,Z ]"R!2RC 8DM@#'/7BS_PD5CM9A,[@;N$A=F.U0Q
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M^BP*<VK^81LE!<Y<<9/RY]!0!7E^'<5TS2W-O:W-Q(6$DMQ^\>13"%56;;R
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MF#]TDC&#@Y&WBLJR\.^')/#L"VVI,-/N8))EE-O;F,QY5W)5HC&H!'0J,9.
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M]K$4=[::W%Q]HCBEDR&($80(C!RQ[9!Z8SFK$?B^P::&!Y2LTK$ I#(T8PS
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MN%7:,\'H>1Q0!WE-W'=@5RFE^(M4_L6[N;[[+-<6\<5R3;0NB^6RAF&UG))
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MMGQ]G0G]XX &]B,] S!<8[9YR* -FBBB@ HHHH **** "BBB@ HHHH ****
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M\G\:EHH ;MJ*ZLXKR%H9E+Q,,,N2 P]#CM_GO4]% #=HIU%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>bntx-20231231_g3.jpg
<TEXT>
begin 644 bntx-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '5!+L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *3-!QWJGJVJ66BZ=/?ZC=P6-C;J9)KF
MYD$<4:CJS,2  /4T";L7-P]:*\\7Q]KOBQC_ ,(5H2W-B?\ F-:X[VEJX]88
M]IEF['.U$8<K(:/^$#\6ZS\^N>/;RWS_ ,NOARRALH?Q:432Y]Q(OTJ^7N8^
MUO\ #%L]#S1D5X)\6M/T+X4Z'I]W/J_C36-3U*_@TVPTRU\37:37<\K !5_>
M8  RQXQP!W%=O_PJ_4].RVB>/?$=BR\K#?20W\)]F$T;2$?[LBGWHY5W#GJ?
MR?B>B;AZTM>=-K/C[PO\VKZ5I_BNP7[]UX?W6UVH]?LLKLK =]LV[^ZA/%=-
MX5\9:-XQMYI])OX[IH6$=Q"P:.>W?'W)8F >)O\ 98 TN5E1J*3MLS?HIJTZ
MI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *3--DX YQS7#:IXJU?7M4NM'\(16V^U?R;W6K]6>UM7XS''&
MI!GD&>5#*JYY;<-E-*Y$IJ.YW>X>M%>=K\))=0^?6_&7BG5)&^]Y&I-IR?15
MM!%@#MDD^K'K1_PHOP]_T%?&'_A::Q_\E4[1[F?/4_E_$]%I,BO._P#A1GA[
M_H*>,/\ PM-8_P#DJD_X4;X=V_\ (4\8?^%IK'_R51:/<?-4_E_$]%W#UHR/
M6ODG]J[5-%^ /@%=5T>7Q/K.K27<=N;6;QSK(6V1@Y\Z15N]VTE @Z#+CGL>
MP^ 3:C\5?A+X?\::'XJU[P_>WT3^;8WMV-5MA(DCQL&$X:3:2F[Y9$;!'/6M
M72:@IO9G)'&*59T$M4?0]%<9X;\7:A'JR:'XGM(-/UB16:VN+5RUIJ  RWE%
ML,K@ EHFY R5+J"1V0(-8M6.^,E+86BDI:104444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !29H-(: %I
M:;FB@!U%(*6@ I,BBD]SQ0 ZBD!I: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BD:DR.E "TM-S2[J %HI-U&:0"T4F:,T +129HS0 M%)FC- "T4F:
M,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M)N
M'K0:8WW>N.:8&7XI\2V?A71Y=0O&<HI6-(85W2SR,=J11K_$[,0H'<FN<TOP
M??>([ZVUKQ>(I;B%_-LM$B;?:V#9R'8X_?3#^^1A>B <L]7P;GQ]KDWB^X_>
M:5;R/;^'X3]SRQE);P>K2DLJ-S^Z"E<>:X/H*@BKVT,%^\U>PD:E>,<T]L]J
M6AJ@W/CCX]?$'6M-_:$N?%%AHUKXBT#X7:;#)?V-S<^24FO0V98VVD;P@CX(
M/W3@9P:[&R^.WQ2\*KX9\1>._"F@V7@KQ#=6]K'_ &7<2O?:9YYQ$UP&.UQD
MC.P9]<'BI/@WX9TOXG:I^T#::RGVBVU7Q+/H]U&K8D$,,*QI@]1C)P?:D;]E
M'Q)X@M=-T+Q9\4]4UKPAHS+)IEC;V45M=)(JD1/)/\QD,>>,CD@=*K3L1KNC
MZ.QNSUVGWKFO$_@>'6[J+4[&X;1O$%NFRWU2V7+;<Y\N5<@2Q$]4;ZJ5;##R
M ^,OB?\  'Y/&-I)\2O!4?3Q)I$(74K-!WN+<?ZP =67L"2<D"O;/!_B[2/'
MWAJQU_0;M-1TB^0R0W"*5#X)4C!P00000>00<TM@<5+1E/PCXLN-2NKK1]9M
MX]/\0V(4S01.6BGC/W9X20"48Y![JP*G. 3U.:\>\?>+K77OB/#X/\/PRR>.
MM(L'UB'48P!;662H6WN&SG9.,*RX) VN!N567T;P?XFMO&'AVRU>V22&.X0A
MX)@!)!*I*R0N.SHZLC#LRL*IKJB(R:?+(W**2EJ#8*2BCB@!:2C=1NH *6FK
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./^*VO7FA
M^$7BTN01:SJ=Q#I=A(1N\J:=Q&)<=Q&I:4CN(S6UX<\/V7A?1;/2K"(Q6EK&
M(T5CN8^K,QY9B<L6/+%B3DFN2^*3%O%7PMA/,<WB9PX]=NEZA(O_ (\BG\*]
M!]:IZ)&$=:DF^@44M)4&X5YC^T5\94^!'PPOO%ATB;6WMY8H4M8Y/+7<[!0S
MO@[5!/7!Y('>MGXQ?%'3/@W\.=8\7ZO#<7-EIZ)F&V ,DC.ZQHHSP,LZ\G@"
MOASPCX1\3_M0?%:[^-FC[-4\+6MVEK?>%=2F5KAXXXXC-9(CH89$=6W#<5!+
M8.UOFKJHTE+WI_"CR,=BW3M1HZS?X+N6O@;\)=;^+7CN?]H2QVZE9W5_<S7'
MA.Y?,\VX-'+ DKCRV158;-P ;:$)3&X?5\%K#JD<OCOX;7$,%^[%-5T2[W6\
M%\T?RO%.A&;>Z0#;YFW/ 5PRA=M71=#L(].3Q;\)$L[)5'D7WADQ_9+2Z,8V
MM"\6T?9;I,!0Q4= K@C!7YH^.GQ=N_C9XJM+/X"WFIZ=XZ56&O6=M*;"XN4C
MV! S%A'*T3!E."3M/!9 <=&M>7DOP/-]S 4KO6<OO;[K_(]M^'_[2G@G]K#^
MW/"/AU-5T77;&W&HV5S?01J8G1E"7$921QE)&3*G&X''(+ >X?#OQ0?&G@S2
M-;>$6MQ=VRO<6P.?(G'RRQ9]4<,O_ :\^_9U^ &A_"/P[9ZJ_A^RTWQQJ-A$
MNMW5JS,KS8#2! 6*QJ7Y*QA4R!@8 KHO@3QX+U%?X4\2:^BCT4:O=@#\  /P
MKEJ<EVH;(]?"^W48NO\ $ST2BBBL#T@HHHH **2BD M%)MHVTP%HI-M&V@!:
M*3;1MH 6BDVT;: %HI-M&V@!:*3;1MH 6BDVT;: %HI-M&V@!:*3;1MH 6BD
MVT;: %HI-M&VD M)2?2D=OEZ9I@.R*J:GJEGH]C->:A=PV-G"N^6XN)!'&B^
MK,2 !]:PO%?BZ31;JVTO3;+^UM?O@S6UCYGEHJ @--,^#Y<2EAEL$DD!0Q(%
M9FG?#&VNM0BU7Q5<MXIUB-M\9NTQ9VK?].]MDJA&2-YW28X+D&JMU9BZC;:@
MM2M_PNS0KPDZ'9ZQXHCZ?:-%TR6>V/NMP0(G_P" N:4?%B[C^:?X?^+H(_[_
M -EMY?TCG9OTKOUPHP!@>U+N'KG\:>G8GEGUG^!QVA_%[PKK6IQZ:=1;2M6F
M.(]-UBWDL+J0_P"Q%,J,_P!5!'O7:;AZUG:UH.G>(]-EL-5L+;4K&88DM[N%
M98V^JMD&N,'A_6/ANIGT&6\U[0%_UNA74YEGMU_O6DKDL<?\\9&(QC8R8VL6
M3V'S3CK+5'HF:Y?XA?$KPS\+?#\VM>*=9M='T^/I)<-R[8SM1!EG;C.U03Q6
MKH^M6?B+2K;4M.N$NK&X0/%(N>1WR#@@@\$'D$$'GBOBWP+XX^&UO/KGQ3^)
MMZWB'Q'/XCU"'PMIEQ*][<1V:S[88[:UR0"'#@.0 #CYEJZ=/G9S8K%>QY8Q
MMK?5[*Q[/\'_ -IZ\^*7QBN_"3^#=0\.Z4^A'7-.O=6;RKFZA%PL(<P8.U'+
M$J2V<)G!W_+[]N'K7Q!XKU+X@:C\0I?C7?:EI/P/TF/1_P"PK6+Q.%NKR]MQ
M,TXW6P&59FQ\H.\!> <G.E\*/B5^TG\4KZ.?2(M!7PHLBN/$&N:3+8B\C# D
M0Q!V=@1D!MH!'=36\Z-]8V1P8?'./[N:<FWH[=/T/LW</6EID8/?KBGUQ'OA
M1110 4444 %%%% !1110 4E%&10 9HI/TH% #J*3G-+0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !112%J %I,TUONXQ7&Z]XTNY=4ET+PS:)
MJNN1X%Q/,2MGI^0"#,XZO@@B)?F.5)V*V\"39$I**NSI=<US3_#NFS:AJ=_;
M:;8P#=+<W<JQQH.F69B /QKC#\4+_P 0+CPAX5U'7(S]W4+_ /XEMD?0AY1Y
MCCT:.)U(SST!N:/\,+./4H-8U^=O%&OPG?%?7R#R[5O^G:'E(1U&X N1PSMC
M-=FJ]NU7HC/]Y/R7XGG_ /9?Q.U8;I]<\-^'HVZV]GITU_(GTG>6)3^,-(?A
MWXMN!B?XG:U!N^]]AT[3TV_[OF6\F/QW?AV]$I:7,P]C'K=GG7_"K_$7)_X6
MQXP_\!M'_P#D"D_X5?XB_P"BL>,/_ 71_P#Y7UZ-11S,?L8=CSG_ (5?XB_Z
M*QXP_P# 71__ )7T?\*O\1?]%8\8?^ NC_\ ROKT:BGS,/8P['G/_"K_ !%_
MT5CQA_X"Z/\ _*^C_A5_B+_HK'C#_P !='_^5]>C44<S#V,.QYS_ ,*O\1?]
M%8\8?^ NC_\ ROH_X5?XB_Z*QXP_\!='_P#E?7HU%',P]C#L><_\*O\ $7_1
M6/&'_@+H_P#\KZ/^%7^(O^BL>,/_  %T?_Y7UZ-11S,/8P['G/\ PJ_Q%_T5
MCQA_X"Z/_P#*^C_A5_B+_HK'C#_P%T?_ .5]>C44<S#V,.QYS_PJ_P 1?]%8
M\8?^ NC_ /ROH_X5?XB_Z*QXP_\  71__E?7HU%',P]C#L><_P#"K_$7_16/
M&'_@+H__ ,KZ/^%7^(O^BL>,/_ 71_\ Y7UZ-11S,/8P['G/_"K_ !%_T5CQ
MA_X"Z/\ _*^C_A5_B+_HK'C#_P !='_^5]>C44<S#V,.QYS_ ,*O\1?]%8\8
M?^ NC_\ ROH_X5?XB_Z*QXP_\!='_P#E?7HU%',P]C#L><_\*O\ $7_16/&'
M_@+H_P#\KZ/^%7^(O^BL>,/_  %T?_Y7UZ-11S,/8P['G/\ PJ_Q%_T5CQA_
MX"Z/_P#*^C_A5_B+_HK'C#_P%T?_ .5]>C44<S#V,.QYS_PJ_P 0_P#16/&'
M_@+H_P#\KZY#XG>"/$=CHMEI<7Q0\67=QK]]#I"P2PZ6@:.3)N#NCLD<%;=)
MW!5E.4X(ZU[HU>>>+C]L^,'@&R;_ %<%MJ>J =M\:0P _P#?-V_YTXR;>IC5
MI14=#NM/L8=/M8;6WC6&WAC6...-=JHH& H'8 "K.*0'YJ=69UI)*R$H;ZT4
MC8I#/C?X?_!%_%/Q(^+VJZ!XEU+P;XWT[Q5<20:A9OOBE@F594CG@/RR)N+G
MMUSEL 5V\?COXP^./%&J^$_"UYX9L;WPE#;1:SK-_;RF._OI(]YCAB!RD8&<
ML><CY>#BJ$/Q.\*?"7]JWQ[_ &OXBTRPTGQ)HUEJ3W$EPI6.ZMR8#"0#PY3+
M8ZFN(^)/COP;XJ\<ZAK_ ,)?$_C63Q5J$<=KJD?@O27N8+S:-J-)YH1$<+@>
M8I.T<@9R3H1TT/H[X"?%*[^+'@634-3L(M,US3KZ?2M3M;=RT2W,) <QDDG:
M<J0"21G&3C)\D_:2\23Q^-/#^C_##Q!K"_%"#]U%H>C3*^GI SY=[Z)LQH!D
MD$C=TR"-I',?"7]GGXL*9;>UU_4OA1X,NXE6XTK^TUU+4IGZO.)-@6&60\LR
MX()^[@ 5]+?#'X/^%_A)I+V?AW31#-,=]U?W#>9=W;]WEF(W,<DGL!DX J=F
M&Z,CX'?",_"W0;R?5+QM:\8:U+]MUS6).6N9\<*O'$:9*J,#CG S@6M!7_A%
M_BWKNCK\MCKUHNN6R=A/$4@N@/0$-:-_O.Y[UZ#T^E>>_$(_8_B+\,KU3B6?
M4KO3&]XY+"XG(_[ZM$/X54==#.KHE+L>B"C-(#Z4-T-0;BGFL;7_ !5IOAT1
M)=SYN9O]3:0(99YO]R-06;W(&!W(K.U#6KW7+R?3-"<1>2QBN]59 R6Y[I&#
MQ)+VQ]U#RV<;6OZ#X5T[P\TLEM 6NY\&>\N',L\W^_(Q+''89P.@P.*9BY2E
MI'[S)_M7Q?K.?L.D6>AP'I-J\WG3_P#?F$[<?]ML^H%'_",^*;KFY\8-"WII
M^G0QK^4GF']:ZY<<=J7@8YH#V=]VV<?_ ,(+J_7_ (3[Q$#[0:=C\/\ 1*7_
M (0;6/\ H?\ Q%_WYT[_ .1*[#K33U!!XIW#V4.QR/\ P@NL?]#_ .(O^_&G
M?_(E'_"#:Q_T/_B+_OSIW_R)789YHR.QI78>S@<?_P (-K'_ $/_ (B_[\Z=
M_P#(E)_P@VL?]#_XB_[\Z=_\B5U[-T[_ $H&.WI3U#V<>QR/_"#:Q_T/_B+_
M +\Z=_\ (E'_  @NL?\ 0_\ B+_OQIW_ ,B5V'84F[WI:C]E'L<A_P (-K'_
M $/_ (B_[\Z=_P#(E'_"#:Q_T/\ XB_[\Z=_\B5UX-&?6C4/9P.0_P"$&UC_
M *'_ ,1?]^=._P#D2D_X0?6/^B@>(O\ OSIW_P B5V&[)ZBD..OI1<7LX'(?
M\(-K!Z?$#Q%_WYT[_P"1*7_A!=8_Z'_Q%_WXT[_Y$KKQ@>U+^M%P]E$X_P#X
M076/^A_\1?\ ?C3O_D2C_A!=8_Z'_P 1?]^-._\ D2NPHHNQ^SAV./\ ^$%U
MC_H?_$7_ 'XT[_Y$H_X0;6/^A_\ $7_?G3O_ )$KK\CI1G-%V+V<#D/^$%UC
M_H?_ !%_WXT[_P"1*/\ A!=8_P"A_P#$7_?C3O\ Y$KL!UQ3J+L?LX'CGC+P
MW?Z/X^^%,UUXGU;6HV\1S(+>^CM%13_9&HG</*@C;/!')QR>.A'L->>_%+_D
M<OA-_P!C/-_Z9]2KT'CO3ELB*:49R2\A?2L/QQXRTOX?^$M4\1:U<&VTO383
M/<2*I8A1V '4DX 'J:OZQJ]GH.CWVIZA<+::?8PO<W-Q(?ECC12SL?8 $_A7
MP+\;?BEXY_:<\71)\&;R\\1^![.V%MJNE+$($=V:0N9XY"K21R1J GNK !6Y
M.M&DZK[(YL9BUA866LWLBCK^M>-/VN/BDWC'P!/J>I_#W33!!J7AF^FBA<1K
M\TL)MC+Y<WFA25)/4X)78"/J7PGX.TG0=!A\1?!B&UL[5<QWOADEK>VO&4X>
M-U;FVNT(V[B!R-D@(VLF;\-_AGH7@'P['XB^",2+8RD_VAX>NKF4I?%2=R%I
MBSV]S&=RC=@9^20#AD\^^/\ \<+#P_I\WB'X5:D+3XGW.V+4_#;1J;IXE5E8
MW%F02TT.T$,/FV9.6B%=+;J-4X;?UN>/3BL+&6(K_$]7_P#:_P"1@?M#?'0:
ME=I_PI/4+ZU^*<\@@US1;:R<WCPQJX99('C*23Q.@4E"9%0-@E.1Z=^RI^S?
MIW@W3;#X@^(=!;3OB3JEM(U^K292 R2%F*1#"QNZ[690/E)*@*/EKDOV3?V=
MX-<U*P^-GB_3=1TSQY?RW-RUC(!#;>9(70W/DE0ZM(C%L%MN6+* "H'U^O3I
M4UIJ"]G#YG1@L-*M/ZU77HNWGZB],\5Y]\"_^1-U3_L9O$'_ *>+RO06]*\^
M^!7_ ")NJ?\ 8S>(/_3Q>5QI:,]N7\2/S/1*2CO2?I69L+1D52U+4HM/C7<&
MEE?B."(9>0^@']> .Y%4?[-OM5RU_.;:$C_CUM'(R/\ :D&"?HNT#D?-UK"=
M:SY8*[&6M0U_3M/D$4]W&LYY$*G=(1[(,D_@*K#Q+OY@TW4;@>OV<Q?I(5J_
M8Z7:Z;'Y=I;Q6Z=2(E"Y]SCJ?>K8^E9\N(GO)+T5_P PT,3_ (2"[SQX?U(^
M^^W'_M6C_A(+S_H7M3_[[MO_ ([6Y13]E6_Y^?@@T[&'_P )!>?]"]J?_?=M
M_P#':/\ A(+S_H7M3_[[MO\ X[6Y11[*M_S\_!#T[&'_ ,)!>?\ 0O:G_P!]
MVW_QVC_A(+S_ *%[4_\ ONV_^.UN44>RK?\ /S\$&G8P_P#A(+S_ *%[4_\
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M "4QUIYKE_B!XHG\.Z-''IL4=UKNI3+8Z9;29VO.P)#/CGRT4-(^.=D;8R<
MBW)E)15V4/$.L7OB+6G\-:!<M:RQ[7U358P#]AC8 K&F009Y!R 0=BG>W5%?
MI/#_ (?L?#.F1:?IMN+:UCR0N2Q9B<L[,>6=B22S$EB22<FJO@WPO!X0T:.P
MAD>YE+-+=7DW^MNIV.9)7/JS$G X P!@  ;U4^R(A&WO/<;^E''UI)20O%?"
MNA_MF?&GQQ;^+[;PC\/=%UN^\/WLIN=0&^.V@M5+85D:<-)*=K'Y&Z+]PYR-
M*=*52_+T.;$8NEA6O:7U[:GW7QZU1UWQ%I7A?29]4UG4K/2--M\&:\OIUAAC
MR0HW.Q &20.3U(KXDM?VY/BEX\^&L_B+P/\ #>SG_L*%I/$>I7\N^TA*AF(@
M02I(PV!7/+%<D$'ACU/QH^+47QP_8!USQ>MD+"2\C@2>TW[Q'*E]$C $]02N
M1GL15_5Y1:4CE_M2C.$G2U:5]>I]!+^T)\+9&"K\2?"+,> !KEJ2?_'Z[%M>
MTQ-&?5VU"U724A-RU\9E\A8@NXR%\[=H )W9QBOS2\#M^R0OPCTL^*%N)/&G
M]F@WJV_]I^8;K9SMP1#NW=#G;G&>*]'_ &4--\0V7[$WQ4DU2*YBT:XLM2FT
MA;G()C-FP=D!'"%QQCC<'/<D[3P\8[-[V..AFE2I+EE%:IO1WM;HS[>\,^+M
M"\::;_:'A_6=/UVPWF/[5IMTEQ%N&,KN0D9&1Q[U'H/CCPYXJO=1L]%U_3-7
MN].D\J]M["\CFDM7RPVR*I)0Y5AAL?=/I7YK_L'?%R_^#WC;3]&U]'M_"'C@
ME;&ZD(\L7D;F,.#NPN3^[8$ Y,1Z 9]O_81_Y+'^T'CMKBXQ_P!?-Y2JX7V7
M-=[%87-OK/LDHV<FT_(^LO%?Q&\*> S;#Q+XFT?P\;G=Y']JW\5MYNW&[;O8
M;L9&<=,BMRSO+?4+2&ZM9X[FVF19(IH7#)(I&0RD<$$'((K\_?C)X1NOVO?V
MG/&GAZTE(TKP3H4]M:.C$(U_M&T,>V9F(/M!7NO[!/Q'E\=? 6QTV];_ (F?
MAF9M'F1N&"( 8LCV0A?JAJ)T.2FI7UZG1A\P=;$.DX^[K9][;GTED5S4OQ.\
M'0^)E\.2>*]$C\0,XC726U&$718C(41;MV2.V*F\;:IJ^B^%=1OM!T7_ (2+
M5X(]]OI?VI+;[2V1\GFO\J\9Y/I7P/\ L!>9>:SK^O:QX T_6+6/49KJ\\;Z
MA<P--I4BPF3:L;J7.XL<NA'WN>E13I<T'-]#?$XQT:U.E%?%N^R/T7W#UHW#
MUKXH@_:Y^,OQ7U'5=2^$7PQL]7\'Z;,T37NJDB6YQS\@\V(!BN#L4.1N7/)
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M0CMH[JX>5(5\V<80,3M'RJ./05Y!HWP^N]0_9YT+QOH0,'B+PU=W%QYD7#/
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M\)O^QGF_],^I5WTKB-"S,%5>22<8 K@OBJNSQ+\,+DG$=OXF8M_P/3;Z)?\
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M5[HPHHHH **** $/Y5YWXH/E?&KP),_,4FGZK;*#T\QOLT@/UVQ2#\:]#:N
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M=S8]LG ]A7:5QRW/HZ=^17"BBBD:!1110 4444 %%%% !1110 4444 %%%%
M!1110 U_NUY[X=QXR^)FMZY(-UCH ;1-/[AIF$<EW*/Q$,([@PR_WC77^*M<
MMO"_AO5-9O#BST^UENYCZ)&A=OT!K#^$N@W'ASX=:#:7W_(4>V%S?L>K7<Q,
ML[?C+(Y_&J6B,)>]44?F=<IYI]-"XIU2;#).E?$'[!?_ !Z_'!CG']J,,_\
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MBK>I^<7[,_[+/C[XJ>";GX@6/Q7UCP%/XAO)I9HM,AE#7FUV'FR,D\>3O,F
M0<<D'YC72?L\Z3J?[+'[7VH_#W6]9DUNT\5V"2QZK-&83<S -(DA4N_(;SX^
M6))8'OBOOO;A<8_PHV#=FD\5*7,GLRJ>4TZ/).FWS1>_?O\ >-F_U,GT-?#G
M_!/_ ,/GQ9\#/BKH?FFW_M+4)[/S02-GF6P3/'INK[F8'! HV[><5A"IRQ<5
MU/0K855JL:CZ)K[S\\O@;^TM+^R!X3O_ (:?$'P/K46L6MY-+I[V$2%+K>W3
M+,N5W=)$WY##@8YO> /AGXE\-_LK_'?QEXHTZ31;SQ?#-?1:9*"KQ1#S'#%#
M]W)E; (!PH)ZBOOYDW8XHVYXQ@5O]86Z6^YY\<LE;DG.\8II*W<^9_V:?E_8
M9L3W&BZEGI_?GKQ_]G<?\:[?B7D?\L]4ZCK^X2OOC8.XH51MZ5'MM]-W<W^H
M*T%?X8N/WGP+9J?^'6,P/'RN?_*L>:S_ (G^,/%WAC]F?X#+I^J:SX?\$7-K
M OB+5M$RL\$9\L+EEY4%6EP.A( .>!7Z$A!M(QD>E*J^H'\JOZQK>W6Y@\K;
MC93M[JC]Q^9/A&R\#:'^U_\ "F^\#KK3^%[MO+77M>CG4ZI=;95=XVE5=V-\
M2'"@;NW<]Y\0OB);_ 3]OW6/%?B/2-5GTO5M,AM;)K&!7:9FB@CW)O905#1N
M#@D@CIS7WSY8Z[:-@+ D9--XCF=VNEA0RMP7NRUYE+8_/3X]Z3\)?$GQ6\4P
M_%CPSK7PHU,2"2Q\2Z3+-=VNMC& Y06Y4' 4G:,D[@S@J,^N_P#!/33?&&F^
M!?$D>N3:K-X6%ZB>'6U>-HI&@"G<\<;$E(V'ED*"5!W8[D_5S1JV,C-/5?08
M%3*OS4^2QM1R[V>(]OS=_*]^XHZYIU)2UR'LA1110 4444 (:8W*D$=ZDI&Z
M=,T"/"?%'A36_P#A$]?^%6DZM'X?&I+C0M3F1F5=/9Q]IM4Q_P M(4,BHO\
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M^2L3CWH]XC]S+5LV_"WP\T3PA--<6%K(]_.-L^H7L\EU=S#J%::5F<KGHN[
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MLUS=WMM]K2UTW3KF[F>$ ;IC#"CR)'D@;F& 2%)R11J!V6:3C=7DWPI^,?\
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MFEI:* $HQ2T4 )BC%+10 E%+10 E&*6BF 4E+10 AI.?K3J*0!1113 ****
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MRSG0/%-"P964]P:NYKX*_81^.N[6(_#4UTTNCZL"UF)&_P!5.!G:,_WAGCU
M]:^\Q7+*/*['NX>M[:'-U0ZEIJTZH.D**** "BBB@ HHHH **** "BBB@ HH
MHH \[^.G_(FZ5_V,_A__ -/%G7H7^%>>_'3_ )$W2O\ L9_#_P#Z>+.O0O\
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M9X9(HD:1 _G AL;<HP8@[<T?^&YO@CC/_";Q=,_\>%W_ /&J3_AN?X)-@?\
M";Q G_IQNN_0_P"JJ_8U?Y6<W]H83_GZOO,/X*^&M:M=<\#W=YX;U+188Y/%
M$DMO<VK1_91->1/"C$ JNY0=ISA@#MR!5[0O!NL+\)_@?8'2KZTOK#48FNU^
MRLLMD#9W2F208!C 9UR3CEAW->Y^$_%6D^--"M-9T._AU+3+I=\5S V5?G!^
MA!!!!Y!!!K7:LG=.S.Z#C**E%W3/E;P5X+O(/"?A3P/KM]\1I+_3+RUCETNR
MT6T33HY+>42K.M\;15,.4#Y%QYC!MN"Y(KUW]H31;W7OAP;2QL)K^=M5TQS;
MV\32L46^A9SM / 522>F 2>!3?B%^TM\-/A5K1TCQ/XJ@L-3"AGM8X)KAXP0
M"-XB1MO!!^;!P17+_P##<GP3Z?\ ":\_]@J^_P#C%+5E:'21:'>K\?/%&I'3
MY_L$WA>SMH[KR3Y;R">X+1J^,%@"I*@YY'M7EGPB^%5]JFJ>"(]=L/$6D06?
M@6*WDEM+N\TQH[C[5DQ.\+QDMMY\MB<<$C@5UQ_;D^"?/_%:]/\ J%7O_P 8
MJWI_[9GP>U9F2T\7B:11DI_9UVIQZX,0IZD2G&"YI.R."U#P5K?AOX4_$GP*
MVAZKK&KQWEO>6^OK;S7,NNP27$;*\DQW%YXE4HRYX" @!:ZCXS>#-;TOQWX8
MO=!TRZU+0M8\2:?>:I':QM)]AN('YN=B@X22(;7;& 8D/5JZ,?M7_"X_\S*?
M_ "Y_P#C5+_PU=\+0./$Q/\ W#[G_P"-4KG+]<PW_/Q?>87A3X2:OX^L_%GB
M/6O$/B+PR_B^:1)M%CMK,;;% T,$<@N+:216,?S$ K@R'@')/;? 9M;L_A_;
M:'XB@NDU7P_-)H[75U$R?;8X2%BN$)'SJ\>P[@2-VX9R#C&'[5_PMV_\C.>O
M_/A<_P#QJC_AJ[X6_P#0S'_P7W/_ ,:H*6,PW_/Q?>>OTF:\A'[5WPM_Z&8G
M_N'W/_QJC_AJ_P"%O_0S'_P N?\ XU2#Z[A_^?B^\]>HR*\B'[5WPM8@?\),
M>?6PN?\ XU6-+^V_\%89&C;QI\ZG:<:7>D?F(:9M3KTJM^22=NQ[M2UX,O[<
MGP3[>-<_]PJ^_P#C%'_#<OP2_P"AU_\ *5>__&*+,VNCWFDKP=OVY/@G_P!#
MKW_Z!5[_ /&:Z_X=_M%_#CXJ:E_9_ACQ5::A?E2RVKQR6\K@==J2JI; YXSQ
MS19A='I5%-8CN:\XUW]HKX<^&[^2ROO$]N+B,X=;>&6< ],;HT89_&A7>P72
MW/2:*\E_X:H^%W_0S\_]@^Z_^-4?\-4_"[I_PD_/_8/NO_C5%GV%S+N>M45Y
M+_PU1\+O^AG_ /*?=?\ QJGP_M1?#"XD1$\4*"QP"UE<*/S,8%/E8<R[GJ]%
M4])U:SURQ@OM/NH;VSG7='/ X=&&<<$?0_E5NI*%HHHH **** "BBB@!*3_&
MEI/\:3 \]T7_ )."\8?]BQHG_I5JM>B5YWHO_)P7C#_L6-$_]*M5KT2KD8T_
MM>K..\=_\C%X _[#DG_INO:Z_P#AKD/'?_(Q> /^PY)_Z;KVNO\ X:01^.7R
M#M29!XS3+F:.VMWFFD2&*,%VDD("J ,DDGH *\D\ _M$:+XW^(.M: L]C96E
MFP@L[F6\3=J$F]E)B .&' QM))R.E(52O3I2C&;LWL>N^F*7)K$UCQOX=\/W
MD5IJNO:9IMU+S'!=WD<3N,XX5B">:V5D79OW#;USGC%4:*<6VD]AWUH'I6%I
MOCOPWK=^UAI^OZ7?WR9#6MK>1R2#'7*J21BO/O%7Q<U?0OCYX<\$PV]D=(U&
MT-Q--(C^>K8E.%._:!^[7JIZFD85,32IQ4G+38]>HQ6/H?C#0?$TLT>D:UI^
MJ20_ZU;*ZCF,?./F"DX_&EF\8:%!?7EE)K>G)>64?G75NUT@D@3CYG7.5'(Y
M/J*#7VD+7NK&NOI1QV.>U9>A^*-%\46[3Z-JMCJT*-M:2RN$F53Z$J2,U'KW
MC#0/"OE_VSK>GZ1YA^3[==)#N^FXC- >TCR\U]#8/K_.BJUKJ$%_9K=6D\5U
M"Z[TEA<,C#L01P17F/[._P 5M7^+'AO5=0U>WLK:6TOVM46QC=%*A%()#.QS
M\WM01*O!3C3OJ]OD>K]Z/6L*Z\?>&;'5AI=SXBTJVU,D*+.6]C68D]!L+9_2
MMO>H4MN  Y)-!HIPELQ:5>/:N?@^(GA:ZAOI8?$NDRQV(S=R)?1%;<9QF0AO
MD&>.<5RGQ@^(VJ>%_ ]AK?A"?0;]KJZ2-9M3O8X[9XF5SN20RQJ3D#&&/&>#
M3,YUH0@YWO;L>ET=,>E9MQK5GH^CC4-5O+;3K5$5Y9YYECB3..K$XQSZT_1?
M$6E>)+,W6DZE9ZG:ABIFLYUE3(ZC*DC-2:*<6[7U- &EKGM3^('AC0]0^PZE
MXCTG3[WC_1KF]BCDYZ?*S UO+()%#*=RGD$'K3'&<9:19)131UIU(L**** "
MBBB@ HHHH **** .-^*O_(N:?_V'-(_].-M78=A7'_%7_D7-/_[#FD?^G&VK
ML.PI]C*/QR^0HH/:@4'M4FIB>'?^0CXA_P"OY?\ TFAK<K#\._\ (1\0_P#7
M\O\ Z30UN5R8/^!'Y_F-[A114=Q+';PO+*ZQQH"S.QP% '))/8"NP1)36/OB
MN1M?&]CXVT/68O">I13ZI#;L(3)&T>UV5A%)AU&Y"PX8 J<'!KAOASXJ'A[7
M-;AUR^U#0[&SL;0W,?BJ^4LUT_F>9-$[.08VP!P0I93M5<'(!Z3;^//#]SXB
M?0H]5MWU9"RFV5N=ZC+(#T+ $$J.0.<5OU\^6/B+PY:_$R.-O%6/"4$DFN0+
M-;>5"E]*T@<&ZVA63$KN!G/S=2 !6]\3-4N=?\1:-;:*^H:[;7NF74EI%X?U
M,6_DW*F/9<2NKJ#&-VT$EAEN5.: /9:*Y>'Q7I_AN+1=*\0:W8PZ[<01JR23
M*AFEP%9E!QP7.!QU./:NG4@X(.1VH =1139/NT +1D5Y/\"?&6NZPWB_PUXJ
MO1J'B3PSJ\EL]TT"0M<6L@\RVE*(JJ-R'' 'W?SR+/XR"'X@?$#7M:U^#1_A
MMX76+1U\Z-0D^H</.^[:79DW+$$4X))^4G&&(]OS17 ?#7XZ>!?B\+\^$O$,
M.K-8X-Q&8I()(U_O;954E>V[&..M4_"7[1OPW\>>+I?"^@^*[/4=<0NHMD61
M1+MR6\J1E"2\ GY&/ STI#/2\BC</6O-/&'[1WPV\!^+8_#.O^++/3M;?:&M
MW61ECW $"615*1<8/SL."#5_5_%UIH?Q"N$O/%'DV5KX?DU.;0_[/+_NTE^:
M\\\+G@#9Y0Z]<4 =YFBO+?"_[37PP\8>*+3PYHWC"RO=8NT62"!5D4294-M#
ML@7?SRF=V<@C(J3QO^TG\-/AQXDCT#Q#XLM=.U=MN;81RRF+(!'F%%98^"#\
MY'!STH ].S17%^//C%X,^&7AVSUWQ)X@MM/TN\*BVG4--Y^X!@8UC#,PP0<@
M$8(]:N_#WXD^&?BEH0UGPKJ\&KZ?O,;20AE:-Q@[71@&4X(.& ."#WH ZBBB
MB@ HHHH **** "BBB@ HHHH **** "L.X_Y'33O^O"Z_]&6];E8=Q_R.FG?]
M>%U_Z,MZX\3M#_$AHW****ZQ!1113 **** "BBB@ HHHH 1J\ _;8U1['X+R
MP+D"ZO8HW_W02Q_E7O[5\X?MTMM^$UB,X)U&/'_?#5=/XT<F+;]A.Q^1WQ*C
MBU7XE6]G/.R022102.HR4!8 X'KS7I_Q"\2:KX'\-OJ6B>*+2ZM8)_['TZ!0
M#)%;JNV48]=W?_9-<C>:3I.G_$"3Q)XG2Z708+N..)+9"7GEQN ![*I /N3B
MM>\L?#EQH7BW1Y=,N+6![U)8M:N#E(;J5P'15]074<=E)-=J6K/FI2C:-]D>
M#R2-(SNY+,Y)8GN<YYKZ%^&NFIXD\ Z+/:Z7X>+Z5=8F<LXNG+@@C''S8YZD
M5Y7XM^'/_"+^/AX;744OPRJ?M5K&92,J21M!Y/'2NZ\'_#K2=%U3PQJUGXBC
MOKAHI;JYL)D:%B "JE%(YY(SFIIIQ9TXB4)P5F?0E]X@TGPU\-5MEL(;:YM?
M#[0.^<K',%&77J3S@?A7R3<>/M!UGPS;Z=J7A.W740)6EU6R98Y&D*$1G:.
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M/NM](=&2- .B@F1@HZ [54D9Y'4>A:W\&!J_QB\/^.$U,6T6DVOV8::MKD.
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M9A@^6[$%., 8YX')Q7HGPQ^&^E_"WPK#H6E>9)"CM+)-.09)I&/+,0![#IT
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M5"1P01A$11T"J. /PJTPI:221(HV=V5$499F. !ZFH\SH2459',^(OACX/\
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MBEJ6D6.L6,UG?V5O?6DPVR6]Q$LD;CT92""*X\_ /X9,V3\.O"9..IT2U_\
MC=:>O?%CP/X4U.33M;\9>']'U"-59[2_U2""55(R"4=P0".1Q6DOC+P^VEZ?
MJ2Z[IK:=J,B0V5X+N/R;F1SA$C?.'9B" %))QQ0'*ELCFO\ A07PR_Z)UX3_
M /!':_\ QNE_X4#\,?\ HG7A/_P1VO\ \;KLKC5K&SO;2SGO;>"[O"RVUO)*
MJR3E5W,$4G+$ $G'0"HIO$&EV^M6^D2ZE9QZM<1M-#8/.@GEC7AG6/.XJ.Y
MP*-1V1R+? +X9?\ 1.?"9_[@=K_\;K:\-?#GPKX,DDD\/^&='T.248D?3=/A
MMV<>A**,UT=+2"PSGL*Y[4?ASX4UJ\DN]1\,:/?W4GWIKJPBD=OJS*2>M=)1
M0,Y+_A4?@;_H2_#W_@K@_P#B*/\ A4?@;_H2_#W_ (*X/_B*ZVBG=BLCDO\
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M.\&*.:X&>BJJS_4]#L_AOX3T[45O[/PQH]K?*Q9;F"PB20$]3N"YS^-=$H/
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M%GPF2RU76-<;Q9;W_A;4-9ELY;6"WCAN;9(9 L)C16$3><5Q(SL H.[.<V?
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M=,TRU01P6EK9VZ1QCT $WJ<Y/)))YS6G_P -Q>!6&/[(\0_^ \'_ ,>KQ!O
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M#+;Z-KBVTEC;:E-<0M:+*1N0@8<R [XUWL%#$%LCHXQ7V@E-]#W$?MN>!O\
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M,<@^7C QA>VH<MO>_IFBP.8^T4N6%K=O*QX_-\4OA9'^S/X"M;FPMKB2WO\
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M*ZMXW\066B:%83:EJEXXCAMX!EB3W]@!DDG  !)XK]A_^%!_#'H?ASX3Q_V
M[7_XW6SX:^'/A3P7-+-X?\,:-H4TR[99--T^&W:0>C%%&>U'-V#D/$_%7P(U
M+P9^SOH^A^%]LFO:-8&"Z-O$ADNXY03=(A(R,L=PQS@$#EJ^7-)^)OBCPY':
M6UM?^2EC']GBBEM8G$:^;YN,.A.5D^92<LA/RXS7Z8A?; KG-0^&OA/6+Z2\
MU#PMHM[=R\R3W&GPR.Q]V9,G\:J,[;DRI\VQ^<FI>/O$&L^'TT6^U.6ZT])?
M.\N15WLV7/S28W, 9'(4L0"QP.33Y_'VLW7AVVT.>6SN-/MHVA@\[3K9Y849
MMQ"2F,NN6)/#5^B'_"H_ W_0F>'O_!7!_P#$4O\ PJ/P-_T)?A[_ ,%<'_Q%
M5[2/8GV3[GYS6_C36+%-%6WO6A719FN+'9&H,,C.'+=/F)*CKG@ 4X^.-;^V
M:7<K?&*?2YGGLVABCC\IVD,C$!5 .7R>1T.,8 %?HO\ \*C\#?\ 0E^'O_!7
M!_\ $4L?PI\%6\B20^#]!CE1@RNFFPJRD=""%R*?M8]@]D^YY)^RKX1U^YDU
M3QYXG#I>ZI!%:V:O&D7^CJ =RHH 5#M0* !PI.,$&OH>F(NWC&/2GU@W=W-X
MKE5@HHHI%!1110 4444 )2?XTM)_C28'GNB_\G!>,/\ L6-$_P#2K5:]$KSO
M1?\ DX+QA_V+&B?^E6JUZ)5R,:?VO5G'>._^1B\ ?]AR3_TW7M=?_#7(>._^
M1B\ ?]AR3_TW7M=?_#2"/QR^0C?=KY]TGP!J7CC1IXH'-O9_:?&%M]I9\>1=
MR:T7M9 O7*M$S!@.,>XKZ!D.V,G&:^/?#O[9WBW6(_'\DW@N(?V%:-<P0QK(
M&MR)DCVW!)YP'9SMV\1-QSD;4Z,ZJ;CT./%XZA@W%5F]>ROL=+X9TF%O#H6:
M\32[/1M \,P7MS?@H()[#49Y;BW;;G]Z F HSG>AZ,"=.QM_$<7AOQ+K/B&U
MGL-1U;QOX?N(/,39(EH]WINRWSW$89XV .W<)#_$<^&2_M=:G?7WA?Q%=_"S
M0+O79)C&=7:P8S7*J54+:R$%T89QRSX)'':O4+C]J;Q!J'QD\1>#;GP-#J&F
M:6MQ/#:F-FNC+:(T\4ISE,,\<>S"C:S(06(&>AX*LEK^9YD<^P4U=-[VV9]6
MKZGKZ9KAOC1EO!]AM&3_ ,)'H)X_["]I7R;_ ,-[>-V\,2WH\):;YJWHA%]M
MF^R!2I;RB-V?,P,YW=.=O2O0KC]K;Q1_PMWPAX77P>MO8ZQ!8R31S"0W0-Q&
MCLR'@;8RS Y7_EFV2M#P-:.FGWCCG^!FM&^G1]3H[SP+J7A;XA>#?$NJ7"6>
MG_\ "0ZH;Z6:3<H226];3R6!PHQ=.O)ZR(O!.*XZ_P#"6OWWP]L=%TKS!JEQ
MX#L8[_3XE;[5;_9(KJ5(G7'!FGG@0(>75)^,*0>3U+]N3Q?=V7BRWF\"V,EO
M;GR52XCE>.U1G*&.[&<-NY7C;SQ@\U;?]JK5/ASX;\"?\(Y\-=*T:VUZ)KVZ
MM;2T,,=PYG>(K;A N'8(K98,<2)UZE_4ZWE]Y*S[ ZN[T\GWL?3/A]I?^%R>
M)H7=MB>&]%/EY^56-QJ8) [= /? ]*[WMZU\<^+?VP_$OA;XI^,=-MO MM<#
M3X9(!((W%UL@W%)9G&081O9@, #S#\WS9/-:3^WMXZN-!UF>7PII=Y/;I&4O
M+6*9;>V+.%S,I=B0V<+AE.?6G]1K-75OO)EQ%@(RY6W=7Z/H>YZEX3_X2_QM
MXCL6L6N;)O'$:WDD<8)@@_X1V%@^[JF)VC8,""'((.35'PC:ZDVH^%K_ %>X
MCN=7NO&:QWJJ#N2XM]#FM)2P(XW/;M*N."DB'O7GFN?MC>)_#>F^#-1L_ MG
M%/XFB-[?YBD!O)%D-N!$5Y+E(8B"P?Y6C'(P3S_Q0_:#O&^+'BS3Y_ ,EPNF
M1RQ 6E[=VLTHB&!-=B&14EAQ@[77A6 W4E@ZK[?>:2S[ Q5VW;T?74]2^%6@
MW7BK6O!=KXLTZUUC2;?0KFRMK:^A2ZA$MF;.*2Y4L"NYY9;A=XX9(T*G!Y]7
M_9]L;2S^"O@FXMK.UM)+[1;&]NFMH%B$T[VT9>5@H&6; R>O KYNE_;.\5:/
M\'= UNU\':=;2S7\VG"41R)8"*%(RHC0-E20[*!N('E-UY W-)_::UKPS\0_
MA_\ #_3?!"Z?X?N+#3($M9O-:YCCEACYC8G[L0)4[AD^6V2#TF6$JI7TL5'/
M,&[6;UMT?78^N%;-</\ %CP+?^.HO"BV$MO$=)\06>K3_:&8;HH2Q95PIRQR
M, X'N*[>/J?RJ2N$^B\CR+XC?!K4/'GC/7;Y+^*PTW5/"%QX=\Q"QGCFDEWA
M]N,% /\ :!)XP.M>96/P ^*]X_@NUU&Z\ Z9H_A?5K._CM- L9X&O5B.TO*Y
M7Y'V%\*@VDMSC KZJHIW%9'E&B_"O5M-\(_$_2I)[-KCQ1J&HWEFRNY2-+B(
M(@E^4$$$'.-W'<US5]\&?'GAC_A$->\#:OH5OXITOP_!X?U*SUJ.633[Z*/!
M5PT8$BLK%R"%&=P!P <^^44@L?*GQ2^&WB+PW\"?B[XH\::I8ZGXLU^Q@2==
M+A=+.S@A8"."+>=Q +N2QP3D<<9/7V_PJ^)GC37-"L_''B70;OP9H=Y#J$(T
MFSECOM4DBYB%UO)C0!L,1'D$C&.01[AK&D6.O:;/I^IV5OJ-C.-LMK=Q++%(
M,YPRL"",@=1VJS'&(U 4;0!@ =J=PL?+FL?LZ?$NWD\;:+H&I^"X?#WB6ZO+
MJ76K[3Y7UI5N"6:(L!L8#.P.23CD 8 'HWPZ^$^N^%_%OA;5]2FT]TTSP=#X
M>N$M99#NN4E1BZ90?N\*<$G/.,=Z]@HHN%CYV\2_ GQOJ%O\4M%LK_0F\.>*
M[I-5LVG,R7D%UNM_,60A2OE[(6QMRV<>];?BSX;_ !)\/^.M:\1_#35/#B)X
MAC@&IV'B:&8I#+"GEK- T/))3 *OQE<YYP/;J*+@>57'PO\ $-]XD^&NI:IK
M<.N3^'8[T:I>S1"WDNVG@\L-''&NQ0"3QD$+CECG/CT?[)OBO03)H.B:?\+[
MSPZS.(->UWPV+C6K:-B2H(V^5,Z @!G/S=P*^MJ* L>(?%#X3^--0TO1M-\*
M?\(7K.AVEE'9R^'?&>D*UD&086>+[.@*-C V ; !P!6Y^SW\(;KX/^%=2L[Z
MXL7O=4U"349K3286AL;-G55\F!&)(0;<Y/7/05ZG10%CC?BK_P BYI__ &'-
M(_\ 3C;5V'85Q_Q5_P"1<T__ +#FD?\ IQMJ[#L*.QG'XY?(44'M0*#VJ34Q
M/#O_ "$?$/\ U_+_ .DT-;E8?AW_ )"/B'_K^7_TFAK<KDP?\"/S_,;W"BBB
MNP04FX>M8?BSQGHO@NQCNM9U"&RCD;9#&V6EG?\ N11J"TC?[*@FN8C\4^-/
M$R!]#\*PZ+:,?EO/$USY<NWLPM8@S8_V7>-O44P/GCX>:'J4'[1FC7,FGW4=
MNOCSQA,9FA8((WLX CYQC:Q! /0X.*^RLCUKR_Q$?&7AO3)=3UCQWH>GV<3*
M#);>'71,LP5=V^Z<GD@'!';ISG0_XN/IJ"47'AGQ1&6_U"6T^E2;>.CF2Y5F
MZ_PH#[=0[/<SC.+?(GKV/0-P/0TM<1H?Q1L+C58='URSNO"VNS-LBLM4"JER
MWI!,I,<QQSM5MX'55KMMP]:DT%IK9QQ3J* . M?A?:R6NM:3J$?F:)/J;:I8
M&TNIK>YM9)#OEV21E6C/FM*P:-@2LK*>^[H=(\'Z=X?L[&UTZ.:VAL_,,2_:
M9F#M(27>7+DS.S$L6D+,6+'.22=ZB@#Q'X?_  1U#1_&<.LZK9:9I<5GIUU8
M11Z/JM[.)?/:,EH8YMHL(U$9VPPLP!D.&&T$^KZMX;L->\.WFAZA ]WIEU:M
M9SQ232;I(V7:RE\[B2#][.??-:]% '*>)OAIX?\ &-Q!<:K92R2Q1FW(@NY[
M=)X2<^5.L;J)X\Y_=R!E^9N/F.8]2^%?AK6/$*ZW<V$S7OF0S21I>3QVT\D6
M/*>6W5Q%(Z87:SH2-B8/RKCKZ* .4M?AIX>M/$C:_%93#43(TZJUW.;:.9UV
MM,EN7\E)&!8&14#'<V3\QSR7@'X :#X=\(P6.L6*ZCJ$EA+87?\ IEQ-;A)?
M]<((W;;#YF 7,:H6(R><5ZQ10!PVJ?!OPKK$=DE[8W=PMK;+9?-J=UFXMP<B
M&Y/F_P"DQY+?+-O'S-Q\QST>E^';'1;K4[BQMOL\VI7 NKI@S'S)!&D0."2
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MM/A'X6B\21ZZNGS#48KQK^+_ $V?R([AU99)4@\SRT9@[[B%&XG<V3S7:44
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MDY,[0=:=29I:Y3W0HHHH **** "BBB@ HHHH **** /._CI_R)NE?]C/X?\
M_3Q9UZ%_A7GOQT_Y$W2O^QG\/_\ IXLZ]"_PIRV1C'XY?(44M(*6D;"4<5S'
MQ-\9?\*]\!ZUXC^QF_\ [/@,WV?>8U?D#YGVMM49RS8. ">U8&DWWQ#M[[1+
MNYN/#GBS0M0(%P^BVCV4EHCKN2X1Y+J59XQC!"A6(8,N<%26 ]%_$T5Q.I_&
M+PEH^N3Z5=:E)'<03QVMQ<+93O9VTSXV137*H88G.]?E=P?G7^\*\X^('Q^U
MGPWXKU3P_9VT,<XU^UTJUO!HM[J*Q1/8K<R.\=N09)-QVJ@921S@A&HL(]]S
M[BES67J6LVWAS0I=2UF\AMK:UA#W-RP*(, 9(4DGD]%Y/(')KG+/XQ>%+S2]
M>O3>W5E'H5O]KU&#4-.NK2XMX=I82&"6-9"I"M@JI!*D#D4#.WS1FO-H_P!H
M+P+<7$<$6IWLD\T7GVD,>D7K/?QYY>U40YN5 ^8F'> HW'Y1FK%U\=_!%K:Z
M-<'5Y)3K*RG3[>WL+F:XN&B=4EC6%(S)YB%@&C*[QAN/E; !Z#NIH]B*\XU;
MXMVUY;^"[SPY/;ZAIVN:Z=)N'N(I$DB"PW#.NP[6CE62$*5<9'(('4<GKGQY
MN(=2\!6.DW\5W#KMG-J-UK4?AC4;B!X8]@ BAC?<A8N<EG;RP 6'SB@5SW3@
MT5Q>N?$W0++PO;ZM%K4%O#J&FSZG8WDEI+<1F&.#SFG:-,,55"I(RI.0H.2*
M@UCXQ>%?#%U;Z=J.HW$VIR6$>I?9M/TRZN9&MV+ 3B.*-V"91LD_=^7=C<,O
M4-#N^/7]:,=JXK5/C#X3TFWTN8ZE)J U.U^WVD>D65QJ$DEOQ^^\NWC=A'EE
M&]@!DXSFM?P7XXT3XB:#'K7AZ_74]*DDDBCNHU959HW*-C<!D;E.#T/4<4AF
M]1QUS^M<3XH^,'A;P=KTFC:E?7)U:.T6^:QLM-NKR46Y+#S=L,3G8"C MT7C
M.-PRS0/C1X/\5:G866E:L]U)J*,;&Z6SG%K=[5+,L5P4$4CJ VY%<L-K@@%3
MAB.ZZ49KP;P_X\^)?B'X2R^/(]3\)I&EM=7@TF31;E2RPO(#&;G[:0I(C^_Y
M9 )S@XJW=?'Z\M?B1X/L6TV&'PAK6A6^I7-Y(2L]C+/*(X-YW;3&69(S\N0T
M@.< T@/;=PZTN:X?P_XVO-3^)/C30;I+:'3]$@L9895#+(?.21I-Y)P0-@Q@
M#J<YZUROP?\ C1J?CSQ9>V.KV-KI]AJ-JVJ^'9(@PDNK);B2%B^YCEL"&3Y0
M!MG7CC- 'L76BBEH&)12T4 %%%% !1110 E+110 4444 %%%% !1110 E)_C
M2TG^-)@>>Z+_ ,G!>,/^Q8T3_P!*M5KT2O.]%_Y."\8?]BQHG_I5JM>B5<C&
MG]KU9QWCO_D8O '_ &')/_3=>UU_\-<AX[_Y&+P!_P!AR3_TW7M=?_#2"/QR
M^0V1@L9)KY%\"_M=^&8[SXIZB='OC!YRZO;X5=TT:QVMF$/]TEU1N2<!S_=Y
M^NW7<N*X^T^$O@RQ;6&@\+Z7&VKJ4ORMHG^DJ>2K\<@GG'3//6NBC.$;J:N>
M=CL/B:TH2H24;7O=7Z'R#HO[77AG2_"_PFL'T.]>;PQ,@ORNW[L=G+:[HR?O
M%C+OP<8VD'UKTJQ_:@\-V7[0GC&VETZ]$$6E_8OM"H"6DL/M<\QVYS@B1E'O
M&/[W'M,7P/\  ,<.FP+X.T?RM-<RVJFT0^6QQD\CG.!U]!Z"M2'X8^%8?$EW
MX@3P]IXUJZC,<U]]G7S)%(P03CN.#ZCKFNJ5;#O[+^\\BGE^91LY58[I_#V5
MCXQ_X:\\/?\ "NY=.&@WG]H#Q1_;7DEDV& ZF;[&_P#O8'EX(]^G%>GZA^U%
MX;N_C]X'AATR^>*ZTL6?G,@#(^H&SFA.W.2%5%!P?XSC..?:#\!_AZNEMIR^
M#M'%B;C[5Y(M$QYG3=^1(^F1T-:UQ\+_  I<Z_I^MR>'=-;5;"-8K6Z^S+OB
M5?NA3CC;V].V*)5Z#U47]Y-/+<SBM:L=U]GLSXZUO]K?PSJ/A_XNZ='H]]YW
MB1Y/[/D;;@A[.*TR_P#<QY7F8Y^]C@CGL/'G[7GAAC\+-671;XQ"=]6FCPH:
M&+R[JR*KV8[V=ATR$'0MQ]"R?!'P'.NJ(_A+22-4;?>?Z*F9FSN!)QQSSQT/
M/6I[OX0^"]072$N/"NERQZ1_QXQM:(1!SGY1C &><>O/6FZ^'TM%_>-9;F*Y
MDZL;/RZ7N?.FO_M>>&/"/QG\;/<:/?30QZ?#I22(%'F3VLMRS9!/RJQG*YY(
M\O.#GCRKP?\ M,Z'H_P9\;>%+K1;E=2U2PCM+5XF4QEAI]O9%F. 5P83)@9^
M]C.1D_<5U\(_!=]K&H:K<>&-+N-1U"(PW-S+:HS2H1@ALCN.">IK-L_@#\.M
M/TV\T^#P=I,=K>!5G0VX/F '*\GD8//!Z\]:<<1ATK.#Z=3&>5YG*;FJL>OV
M>YX'XZ_:\\,-_P *LU9=%OFB$[ZM-'A0T,?EW5D57LQWL[#ID(.A;A=>_:\\
M,>$?C-XV:XT>^GBCT^+2HWC"@R7%K)<LP()^56:?;N[;,D8/'T7=_"'P7J"Z
M2EQX5TJ6/2?^/%&M$(@YS\HQCKSCUYZTZZ^$?@R^UG4-5N/"^EW&HZA$8;JX
MEM49ID(P0V1W'!]>]1&M0ZQ?WG1++\R>U6/3[/96/E";]J#0;#]G/P-:#2+N
M6\L;ZQM)H?E5'.GO:3RL&]'78!D#!<Y^[SW&H?M0>&[SX^^!X(--OFANM+%G
MYS*JM&^H&SFA.WG(544'G^,]<<^X2?!;P/+X=MM"?PII;Z3:S>?#:M;*520]
M7'?)[GN.#5Z;X9^$YO$&GZXWA[3O[6L(UBM;O[,N^%5'RA3CC;V].V*3KT'M
M%]>O<J&7YC%QO5C]G[/;<Z:)<'^52U''FI*\T^K"BBBF 4444 %%%% !1110
M 4444 %%%% !1110!QOQ5_Y%S3_^PYI'_IQMJ[#L*X_XJ_\ (N:?_P!AS2/_
M $XVU=AV%/L91^.7R%%![4"@]JDU,3P[_P A'Q#_ -?R_P#I-#6Y6'X=_P"0
MCXA_Z_E_])H:W*Y,'_ C\_S&]Q#[URGC[QJ?"MM:6EA:C4_$>IN8=,TW?M\U
MP/F=S_#$@(9W[# &690>ID;:I)( '))Z5Y]\+X3XH:\\>729EUM0NFJW_+#3
M5), 'H9<F9L=Y%7D(#7:(O\ A'X?IHU[+KFL71U[Q5<+MFU25-HB7KY5O'TA
MB']T$D]6+'FNP&1@=\=\USWCKQYI/P[T&75]8G\JW5@JI&-SR.<X51W.!^A-
M>8>%_P!K+PMX@UB.PN[6ZT=)FV1W5T5,0)./F()VC)^]T]\9K6-&I-<T5H>1
MB,VP.$K+#XBJHR?1E#]K#2]?UG1M+BM6MTT87,:R1M(?,GG=MB*%Q@A02>O\
M73BO1_AC-=^'O#^C^&?$FI:>WB:*V)2WCN@TL\"$*)0I 8@ J"<8SWYKE(+T
M?&CXA6%U:;I/!OAR47"W1!"7MZ.%V>JIR<^N.H.:X?XG7UMJ7QU\#>/?#]P4
MN?#JW&GWR2)^[U&SF RBGJI1LLIQ@D\\5QYAFF#RZG"&+J*%SS,#A54QU;,:
M;;4K16NC2W:\NQ]%Z]X>T[Q3I-SI>K64=_87"[98)AD'T(/8@C((.00",&N*
MT75-1^'?B*T\-Z[?3:GHNHMY6BZS=',JR@9^QW#_ ,3D#,<AY?!5OG4%^UTG
M7K'6-*34[>X4V;*6+N0NS'4-GIC%5_&GA>V\:>%[_1KJ1X8[E!LGB/SP2*0\
M<J'LZ.JNI[%150J1J14X.Z9]4;2\<=J=7*_#/Q)=^*?"=M=:BB1:M;R36&H)
M'G:+F"5H92N>=K,A9<_PLM=2U: 8?B;Q]X8\%^3_ ,)#XCTG0?.SY7]IWT5O
MYF.NW>PS^%6IO%&C6^AC6I=7L8]'*JXU![E!;[6("MYF=N"2 #GO7SWXR^'J
M>&?BEXM\5>)_A:WQ5TK5_(DM+RVBM[ZXT^-(E3[.+2<KQN4L&CR2&YY%4X=<
M\$^#_@K\1M6\$Z:TD$=Y!-?>"O$UF5@TNX9XE*&T8*T:L,/C<5W+\I&"*=A'
MU'N!Z'-%>'^*?B1\2/$GCO6O#GPST?PY)!X>2)-4U'Q)+.L<L\B"000+%R"$
M*DLW'S8XQSRUO^T5X[D^$^GZ\WAC2V\4W/C#_A')-%+N(Q^]:,J)-[ ,"N#)
MRO4[<46"Y],Y'K1N'K[5XCX(^)_Q"M?&WB'PCXYT'1)]9M]'.N::_ANYD6*Y
MB#E/(9KC&)-XQN)5>1QCFO-O"_[6WB>3XC>%])UNZ\ ZC8Z]>QV?]F>&+^>[
MO[!I#A3+,,P.%;"ML/.<CBBPKGU#_P )AH//_$[T[B]&FG_2X^+L]+?K_K?]
MC[WM6MFOEW0_$/\ PCYUHG3=/U+[;\6C99U"W\[R-X0>;$,C;*O\+<XS5K5_
MC9\7[H?$#4O#OAOPM-H7@[5;JWGDU">X6XO8845V2%%R!(J]78X.X!5)!HL.
MY],49'K7A>O?&7QEXNU3P_H?PST;1Y=8O]%AU^]O/$<LHL[*WF_U4?[K#M(Q
M##@<;<X.>-?X$_$;QCXUU+QGI/C32=,T?5?#U[#9B'3"[1N&A#^9N8G*MD,O
M (! /-%@N>NT5X]\2OB-XVT[XF6/@KP9I6CWU]J&BRZC'<:N\B0VSI,B%Y2A
MW,F#C:J[BS+R #7"+\</C'K'A#7;_2O"7AB"^\(SW-MX@DOKJ5H;N2$;G2R5
M2"/DVMNE(&6V\D&BP7/IS(ZYXJIJVL6&@V$M]J=[;Z=918,ES=RK%&F2 ,LQ
M ') _&O%]>^,WC#Q1?>&-$^'&B:3+K>JZ'%XAN[KQ#-(+2QMY,"-&\KYG=FW
M 8/&W)&#D<3\3?B+XA\2?!7XF^%O&NEV.E^+M"6Q:X;2Y&>RNX)9D,4\1<;@
M"4D4JW(VCGG +,+H^J=P]:*^<?BA^T3K>F?$+4/"'A34_ >@2:/% ]]J'CS5
M&M4EDD7>(H(D*LV%VDM]WG'7KH0_M+7>L_"FPU;1=(LM1\8:AK/_  CD&GP7
MZS61ON29!.GWH?+'F9'."![T6871[]FC->1:+XN^*&@>%?&-QXZT3P_%>:3I
MSWVGZEH4\CV5TRQR,8FBD82J5*+DDX8/QC%/U?XL:Q8^ /AGKD=O9&[\3W^E
MVMXC1N4C6YCW2&,!P00?NY)]\T6"Z/3]/UG3]6:Y%C?6UZ;69K:<6\RR>5*N
M"T;X/RL,C*GD9JW7RU9_%I?@_P"%?B+J$4-I<:EJ'Q!N].LH]2N5MK42R+&=
M\TQX1%568D]< #KFNA^$7[0&L:YX[M/"?BG5? FNW6I033V-]X$U4W42-$,O
M%-&[%U8KE@XX.TC&:+!='T)D>M+7R?X&_:D\;>.?%$!M(O KZ?+J!M&\*RZG
M+:^(84$I1CB;;$[*H+E5Z@$#FOJQ: N25AW'_(Z:=_UX77_HRWK<K#N/^1TT
M[_KPNO\ T9;UQ8G:'^)%(W****ZQ!1113 **** "BBB@!*ANK6.]M9K>9!)%
M*IC=3W4C!'Y5/10!S6F?#[P]H]GHUI::1;PP:.6:Q4+_ ,>[,#DK[G)KHP/R
MIU%,226QS/Q,TX:M\/?$=GC/FZ?,O_CA-?B=\:]<^P6^G0>4[7'VV.^6?=PN
MQ""OU.5Y_P!FOW0O;=;RSF@?E)4*,/8C!K\1/VG/#OV*6[14_P"/&]D@/'10
MQ7^E=%+9GC8Z*]I"3/I3XE:;'XF_9C^($OF, FEPZG'&A^4XQD_DI'XUX/\
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MHH **** "BBB@ HHHH \[^.G_(FZ5_V,_A__ -/%G7H7^%>>_'3_ )$W2O\
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M3>&)[B^:QTZ,7ES>DN5C,4=N3EP.N,YY]*KV;T\S)8N'O/\ ET?S.]&.>>E
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MPZ)\2--MO^$-BBQ:2:M?JVIVJ@?(B"/?O3MLE964'@X4*?L)5'I^E.;UKZ/
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M\%_#-KM"RS6PNI<=VD)?^1 _"B>D$9X9<^*<NQZ9WI:2EKE/?"BBB@ HHHH
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MRE">2I7:02,G.>]4?A;X;\2^+?'ND:7X0N)+/Q%+(3:W4<C1F!E4L9"RY*@
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M?\.UWZ'XAC&>/^))_P#=%?<%%>?8C^S<+_*?#_\ P[7?_HH@W=<_V)W/4_\
M'Q1_P[7?_HH7X?V+_P#='-?<%%,/[-PW2)\0K_P37(92?B&2,\XT7!_]*.OO
M_A7O7P)_9E\,? F.>ZL3-JFN3IY4NIW6 VS(.Q%'"+P">I.!D] /9**5C:G@
M</1GSPCJ>(?'C]F^W^+4T>KZ;=II?B"-!$TDRDQ7"#. ^.01_>P>!C%>(_\
M#$?CG_H*>'O_  (G_P#C-?;M%:J<HZ(ZG3C)W/B/_AB/QU_T%?#W_@1/_P#&
M:/\ AB/QU_T%?#W_ ($3_P#QFOMRBG[20O91/B+_ (8C\==/[5\/8_Z^9_\
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M]J0Q:*3(]:,CUH 6BBDS0 M%)10 M%%% !1110 4444 %%%% !1110 4444
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M&D:E/X1UO4]#T.;6;?4?"K7+V1,8P8I!, S'=M;*'&#C(/-<O\2/%GQH\:>
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MCX7_ /0S_P#E/NO_ (U3Y6+F7<]9I*\F/[5'PO'_ #,__DA=?_&JU_#/Q]\
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M_!OB;5X=7OI=<U*ZL)8+*_BM5CV-&$=2T$F>';(/7C!&.>V7X$^#;WXB^/\
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MW)]C3T]TI:7I=KH]FEK9P+;VR%BL:C@$L6/ZDU;QWIV<T9%*YJE;81:=24M
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MT /HKCSX_*_%E/!7V'AM%.K_ &[S?2<1>7LV^^=V[MTYS77YH 6DS1Q1D>U
M!FEI.*,B@!:*2EH **** "BBB@#C?BK_ ,BYI_\ V'-(_P#3C;5V'85Q_P 5
M?^1<T_\ [#FD?^G&VKL.PI]C*/QR^0HH/:@4'M4FIB>'?^0CXA_Z_E_])H:W
M*P_#O_(1\0_]?R_^DT-;E<F#_@1^?YC>XC9[5EZCX?M=8MS!J,$-]!YHF$4\
M>Y0RMN1@">JD Y]JU*#78(J?8_\ ;YSZ56D\/6<VIQ:C);PM?PQM#%=-$#(B
M,060-UP2!Q["M)I%C5G<JJ*-Q8G  ]37.7OQ.\':;<-!=^+-#M9U.&CFU&%&
M'U!:@#:^P_[>/^ T?83_ '_TK+TOX@>%]<F\G3?$FCZA-G'EVM_%*WTPK&M_
M/O2 J?83_?\ TIT=F4<-OSCVJS2TP$I:*1NG3- !N&,YXI:^8_BYH_QC\&ZE
MI5U8_&798Z[X@@TN"R_X1:S/V..=VVG>Q)DV  <@%L5W%IXQ/P!T5A\6/B;'
MK\][))-:7DNBK9;(XT4O&%@#!CD@C/S$M@ TQ'L=&X>M>3^*OVHOA=X+M]*F
MUGQ5#9_VI:QWMK']DN))6A<91VC6,O&"#D;PM;'B#X[> ?"^CZ-JVI^)[.UT
MO6(I)K"].YXIU1=S;6 (SCH#R2=H!/% 71Z!FBN \*_'3P%XR\&ZCXKTCQ-9
MW&@:=N^V7DF^'[/M_OK( P]LK\W;-0_#;]H+X??%[4+JQ\)^);?5;VW3?);M
M#+!+MS@L$E52P!(!(!QD9ZTAGHN:*\S'[2'PV/CX>"QXML_^$D,XMOLNURGG
M$X\KS=OE[\_+MW9SQC-6]?\ CMX&\,>,(?"NI:ZMOX@FN8;2+3UMYI'>250T
M8&U"-I&,M]U>Y&: /0<TM>3:!\9/#/AOP+H%]XE\=1:JFI/>"#6KC3VLTN?)
M:1G!C"XCV*A7YL;]G&2PID?[37P^UOX=^(_%GA_Q';:G::+"9)E\B97C<C$>
MZ(H)-K,0 V,=>>#0(];R/6EKP[X8_&ZR^*^G?#?5;7Q5'976I1W$.H:-!IDA
M2]NX[97FB65US$(6;<&!PW0$UL:Y^U)\*O#OBZ3PUJ'C.Q@U>.4P21[)'BBD
M'!5YE0QH01@@L,'K0,]8HSCKQ7G_ ,0/COX$^%MY]D\4^(X-'N6M/ML<<D<C
MF2(OLRFU3O.[^%<M@$XP":Z#P3XYT'XC>&[;7?#6IPZMI5QD1W$.1R."K*0&
M5AW4@'IQ0!T!8#J<49'K7S+H/Q[/C[]IS4?#>F>/X-)\/:(OE_V+_9!8ZG)&
MDINB]Q(H\@1,HYSA@./4^B^%OVGOA=XT\61^&=%\76E]K3LR1PK%,J2L.H25
MD".?3#'..,TQ7/5<T9KS/QA^T=\-_ /BR/PSK_BRST[6FV[K=UD98BV"OFNJ
ME(LY!^=AP0>AS6)KG[1FBZ#^T)I?PXN;VWB6[L-S?Z/,TIO9)(_(B# %0K1E
MVSTXY(Z%#/9\T5Y/KG[4WPI\.^+'\-:CXTL;?5TE\B5-LC11."05>95\M"""
M""PP>M;/Q ^.G@;X6WT=IXGUY-*N984GCB,$LK2(SF-2H1&W'<#P.<#/3F@5
MST"BO*?$G[4/PN\)>+/^$:U?Q=:V6LJZQR0R12E(F..)) A1" >0S#'?%>I0
MNLBAT8.K#(8'((]10,DK#N/^1TT[_KPNO_1EO6Y6'<?\CIIW_7A=?^C+>N/$
M[0_Q(:-RBBBNL04444P"BBB@ HHHH **** "BBB@!*J:M?)INEW=Y)_J[>)Y
MF^BJ3_2K=07EI#?6LUM.@E@F4I(C=&4C!'Y4"=[:'XS?'J'5OBQJ6H:@MP'N
M+JZ:YDWG[X)R![8KHOV4]<U'X5^*?#EYJ/[@65ZJ2;3D&%CM;]&/Y5]X>(_V
M'?!.KW$DNGW=_I&Y<+&CB5$/J-W/X9KG)?V ]*-U&\7BRYCC60,4:R4G9W4$
M.,$^N#]*[.>%CYSZKB8V7G<[?]L7QV?"_P '9K6U?,^M2K:JP/\ RS^^Y_(
M?C7Y5Z/X7UIO'UQKDY6&W9BNPG)*]J_7+XU_L^VGQB\/Z+IC:M-I+:6X,4WD
MB;<NT @C<O.!USZ\5YG:_L#^'HW4W'B.^E3>252!4^7L!\QP<]ZFG.,5J=&)
MH8BK4YH[6.6_8)\:2Q:KKGA>4YMYXEO8,GHZD*X'U!4_A7V@O/Y5YE\)_P!G
MOPI\(;AKO1X9I=1>(Q/=W$FYBI() 4<#H.E>G=S6-1IRNCT,)3G1I*$]T+11
M169V!1110 4444 %%%% !1110 4444 %%%% !1110!YW\=?^1-TK_L9_#_\
MZ>+.O0O\*\^^.R_\4/92'I#X@T.<_1-5M'/Z+7H(YJGLC&/\27R#TI.BTZFM
MT-2:GY:_MYZ7=^ ?VI(?$[1B>*[2SU.W5AE3Y(1"I_&'I[UY_P#%.Y^'7C#Q
MYKWCJ+QM.\.JWJ:C'X?M]-G-^C2.&FBDD?;"@3+8=)).V%Q7ZA_&CX">%/CS
MX?ATOQ1:RG[.YDMKJU8)/ Q&#L8@@9&,@@@X%>(?\.R_A9Q_Q-?%!_[?(/\
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M-7DD\V1]\JQ2/DDL\*N(W))))93DG)S7>Q^#])C\5KXC6S":PEC_ &<MP'8
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MFLZY'&HA9HM!\/.]FEPP&5CFO2#*03P3&(N#T-9_[*VN-J_P:T&(Z9?6,=G
M+=9[M$5+D@G+Q88DKVW$#)Z9KUR3YE(I/1EPE[2"EW/B7X-?M57/@WQ)JNB>
M*M,73M'16BL]*TJT"&QG1C^Y5,\EB2"S$_-@D\L:^UXF+#+#;D9QGI7@VK?L
M@^&]1\=6_BC^VM6DO5OTOKF*\D2=)R'#%>BL 0,=3C/ K?TWQQXB\._&B'PC
MJ]]#K.EWUI%*MY]F6![:ZE%T\<*!2<QF.RF/S$L#MY.[ N?*]C##QJQO[0]?
MI&/'')I/U]JY30_BCX4\4:Z^CZ1KMKJ5ZB,^VV8O&X4@.J2 ;'92RAE!)7<,
M@9K([3GM-^)Q6QU#5WCN=9AOM;ETC1='T](A-,T!>.7#2,BDEX;B0L[JH1 !
MS][L/"WBVR\6^'4U:W$MK#F2.>"[ 26VEC9DEBD&2 R,C*2"5."02,$^9S?!
MU?%6@WWAO4+>U=]&\0W&K:=+K&F?;;"Y2X:67:\)9!*JBXECVAU*M&K?W<]S
MX3\!MX3\*V6AQ'338(L_VNVL=+CLXI3(2VV&.-@L2@L1AMY(QN8MEB",SPO\
M9M.\3^(-)TM-$UJP&L6LU[IM[?0Q+#>6T6S,JXD9E!$B$+(JMALE177>*-/U
M'5?#]_::1J;:+J<L)%M?)$DODR8RK%'!4C.,C'3."#R/#/A?HOB&\\;>&HXY
M=431_#>AWEA;KJ_AZ;3C:,Y@2&.5F?9>2!8VR\!5,)G(WJ3]!6Z3+;QB=TDF
M"C>\:%%9L<E5)) ]LGZ]Z /+/"/Q U_XC:_I^GP02Z%+H)(\5+Y *F["E5LH
MF=3N1B1-YBG/E^5@_O.+R_&^SAN+N/4_#/B+1%73+O5K:34;:&/[9!;%?,**
M)2Z/B1"%F6,_,.G-=-X>\'MH>I>*[K[8TAUR_%Z J!3;_P"C0P;0<G)_<[LX
M'WL8XR?*O#W[+[Z3-<7$^M:8U[-HUYHTM[9:$MM<WGVA4!N;J7SF>>8%<EB0
M#EL*N<TP.CNOV@+.UAO7E\'>*%:UL%U=T^SVV[[ V_\ TH?O\ #8<Q-B;G_5
MD XV=?\ B[;>'M3ACE\/:]-I+3VEN^NPV\0LDDN618Q\\JR.,R(&:.-U4M@G
M(8!NI?"DZA_:O_$S\LWWAI?#W_'OG9CS/WWWQG_6?<[;?O<UQVN?LU2:YX@7
M49M:TV;RKFQNK>XO-#6>_MOLPBQ!#<F7]W QC9BBH&S*YW\D$T#4ZO0?C5IV
MN>(+/38]$UFVM[S4;O2H-3N(H?LTEU;>;YD8VRF3D0.P8IM( &0W R]>^-$C
M:1KMK#X?U[PUJ?\ 8E_JFEWFK6L*I.+=5!<()'="#)&VR9$.#R.HK6L?A&;*
M+04&K-_Q*M<U#60ZVX5I/M7VOY!\QVE/M7WN=WE]!GCB=!_9?DTB:XN9];TN
M2^FT6\T:6^LM!6WN;OSU4&YNI3,S3S;EW%B0#N;Y5R31H&IVVA?%F#4?#]Y>
MVFD:QKL>GP1)+=:;;)(EU=G"O!"-REF5F^9L")#N!<;'QM^"?',7C0:M$=+U
M#0M0TJY^QW>GZD(O,C<QI(K PR2(RE9%((<_A7'ZG\"YFT/4]&T;6X=(TJ^A
MLS+8G3_,@>> QJY9!(N89HHUCDA&-P'WAEMVQ\(_A.GPM@UQ(YM/9=5O%O6M
M]*TQ-/MK=A$D92.)68*OR \DG).2QY*#4YG1OB5XB;QQXWDN-"\4:A8Z=J46
MCZ=H^GP:>\+DP12F4OY@=6.YGW2R)&$=%QYA*C=M?C=9:GI]@=-\-Z]J6KW4
MEW&=#ACMTN[?[++Y4[2EYEB 60JHQ(=Q8;=V#BEXN^!\WB)M6:/5K-H]0UQ-
M8ET_5M,-Y8SJMFEOY,\(E0RJ&C65?F #JIVG&:I>&/@+J'@.QTQ_#7B#3[#5
M;%KZ,2SZ(&M6M[J<3M$+>*:/84=5V%6"@9!4YR&&II6_QF>/Q=XEAU+1[W3?
M#.D:!:ZVVI7$*QR1B03-(LD9D\W.(P OE!@T<@/6/=+<?'33].T_4)=3\.Z]
MI6HVAL_^)5<QV[7,J7<WDP.A29H\-(&4@N"NT[@.,NU+X/7.LW>L_P!H>(9;
MRTUKP]'H>I;[1%N973SMMQ&Z%4C;]^^5$9&0O(P<U7^#>K:U/+J'B#Q+!?ZP
MTVE[)[+3#;0I!970N0GEF9SOD;<&;?C[N%XY-!:FU9_%5+SQ&=(C\,Z\SP/!
M#J%Q&EO)'IT\T8D6*8),SDA73+QJ\:[OOX5BM_P/XAO-0UGQ5HVH-YMSH]^$
MCFVA?-MY8UFB)  &5#M&>.?+SW-<YXJ^#<_BSQ_I_B"XU/3TALKFWN87.C(=
M3MQ$VXP0WH<%('8'>C1N2))%W ,-NWX!TN[_ .$D\9:[=P26RZGJ"Q6T<J%'
M\FWB6(,5('WG65@>ZE3T(I%';4444 %%%% !6'<?\CIIW_7A=?\ HRWK;-8D
MR[O&%F1_RSL9P?\ @4D./_037'B?L?XD-&Y12"EKK$%%%%,!*;3J3U^M(#SS
MQ1_Q5'Q0\/>'F)-AIMN^O7<?:257$=HK>J[_ #I/9H(S7H*K^!KS_1R6_: \
M6 \B/PSHQ7VW76J;OSV+^5>B5I(PI[R;[B4GXTIIO'TJ#<'^[_\ 7KXD_:"_
M;*\;? O]H:^T:2PTG4O"L5G T.G"95GFW)N:4R+EHGWY4)(NTJN1]X,?IOXX
M?%JS^#?@&[UN6)K_ %&1UM-,TR+F2]O'XBA4#DY/)QS@'&3Q7%_"']G2QM/A
M]JJ_$2QM/$_BGQ9*=0\12WD:R*96Y6%/18@0%VXP02N. .JCRP]^HKH\?&^U
MKM4,/+EDM6^WE\SY=\)>./#?C?X0ZXD/V#Q]\:_B9J)LKG3[R G^SSSL.UQE
M(8$&\,.-P'.$^7OM#_X)_:Y\._B!X/U[P5X]FLX+)H?[4DN R7&U=IE$)3AT
MD(.8Y.%!ZMTKQOQI^SCKW@G]H+5M,^ ]YJ&IZCH-G'J$WEW"12Z9)*^%MO.8
MA)"4P^Q\Y3*G)!K]'?A^NOIX+T0>*OLY\2?8XO[1-K_J_/VC?M_'/3CTXKJK
M5/9Q7LWHSQ\#A5B9R6)A[T-FO\^_<YOXPH=$TG3_ !?#^[N?#=TEU(^.#9.P
M2[0^H\DLX']^*,]J[?5(7NM)NXXEWR20.JKQR2I %<9^T-Q\ _B2>A'AK4B#
MZ$6LA!KO(?\ 5K]*\W[)]2M*C7='S'\+_$WQM^&_P^\/>&/^%%G4#I-FEI]K
M'B^QC\W:,;MN#C/IDUTNM:;\2_AQ\1=?\3>$_!EKXTTSQ1':S7>F-J\5C<6%
MU%$(VQ(XVO&5"],G=GH ,^]K3JDVL?-?_"E?'A\&MXCD73'^(9\5+XM.EK,1
M:';'Y(LQ)C@^5_'TW]R.:ZNUF^+GQ'\'^,;?5M T[X<3W6ER6ND0IJ(O;M;I
MD8><\\6$1!D !5+9R<C'/M-%,+'Q)X?^!7C.'5/ C6/P3T3P>OA_6[&[U#4X
MM:AN;V^2-@'>-MV53!+E'8L2%QDCGZ4^#?A/5O"L_CIM4M?LJZEXFO-0M#YB
M-YL#K&%?Y2<9VGAL'CH*]'HHN%@HHHI#"BBB@ HHHH **** "BBB@ HHHH *
M*** &MTKSUO^*+^+!;_5Z3XM3YC_  IJ4,8 _&6W3'UM1W:O0ZQ/&/ABV\8>
M';O2[AWA$H5XKB$XDMYD8/',A[.CJK ^JBFG;<SJ1NKKH;2]32MTKEO OB>Y
MUB&ZTW5TCM_$6ELL-]#'D(^<^7/&#SY4@!*GG!#H3N1L=1NYQ0U8J,N971PG
MC+P;J[^*M.\7^&&L3KMI;-836.I$QP7MJ\B.4:5%=HG5EW*X5QRRE?FW+SWB
M#X?>-_'NG^*I=<U&RTN6^T.ZT?3-#TZ]GFL8WFCP;BXD:-/-<M\H'E (H.-Q
M8X[WQ!\0O"OA&9H]=\3:/HLBA&9-0OXH" ^[82'8<-L?'KM;T-+:>//#.J:T
MVBV7B+2;S65B$YTV"^B>X\LJ&#^6&W;2K*<XQA@>]!1SWA_X?WVE^/)=:N);
M=[*3PY9Z,8XW;S/-BDF=F^Z!M(D&#G.0>!67\._"?CGP+I>C>%4_L&;PUI;>
M0NK27$[WDMFN=D?V8(J+)@JI?S6'RD[#G RM'^,WC77/A^_C6U\#Z--H:137
M7DCQ%+]L:*)W#;8S9!"V(R0ID Z?,*U&^/FFK\1_"GAM-.F?3?$6DIJ5KK/F
M?)&TC8BCD3'R[\8#;OO%5QR#0(YOP[\(_'&G6?@#0;N?0CH7@_4_M*WD5Q,U
MS?PB.>.(F,Q!87595RH9PV2=RXPV;H7[/WB/P^OASSM/\*^([G3]#MM-BFU>
M25ET>YCDD9KJU0P-YA;>A(S$Q\I1O Y'K^A^.#K7CSQ1X:-EY']B16<OVHRY
M\[ST=L;<?+MV>ISFN=^%?QL@^)7B36M+72I--BMD-SIUT\V\:C:B>6 S*-HV
M@20GCGY70YYP 6AC_#7X/Z_X17X;+J5QIT@\*Z7?Z9.;620^<)6A$+J"@Q\L
M1+#^$G +#D=C\8O!5]\0OASJV@:=+!!>W9A,<ETS+&NR9'.2H)Z(>W7%=KQ2
MTAV/.O'?P]U.^\8>'_%_A>2ULO$.GR"VO1=.R1:AI[',D$A522RG#QDC"L".
MC'%#2?@_</X7\:Z3J=Q#'+K6NW.LV%W:Y=[-V9'@E^91B2-T#8&1\HY.:]4H
MIA8^?_ /[.^H_8?">G?$&+0O$.E:#:7C_80C7$,]]<7#N9FCDC"[4B.U00<&
M1^!M!/12_">V^&OCJ'Q?X*TO0= TI=*N;36=.C064,ZJ/-@E'E1D;E?>I)&=
MKD\X /KU-==RXH"QG:!?RZQH6FW\]J;*>ZMHIY+5FW&%F0$IG R021G Z=*\
M\T/P?XY\#WFKZ;H/]@W>A:AJLVI17^J7,_VBR$\IDFC^S(FV<!F?:?.C^^,@
M[?F]37.[D?K3Z0SQZY^$6LW'P[U[05GLEN[_ ,3MK43F1Q&L)U)+K:QV9W[%
M(P 1N_B(YKG)_P!G=M,U+6H['P/\/?$-OJ.I2W\6M>)+,RWEJ)I/,E1X1 ?M
M 5BVW]]'D;5.-N3]"44"L>.:E\'=7N=!^+UA!/I\;^+H_+TX#<D<7^@QV_[T
M!#M&Y#]W=\N.^13/B/\ !S6_%\>G"RN+&,VWA75-"?SY77,]S#%'&PPA^0&-
MLD\X(P#R![-13 \MN/ OB?PWXLL?$GAQ-+U.XDT:#1M0T_4KR6TC/DLSQS1R
MI#*<@R2*5*<A@01@AL+7OA3XKUSQ=9^(M1T_PCXBU(Z9#:))J2S+'HMRLLCM
M<6D;1R&0D.F<O$S&%?F0'Y?;Z*+C/G:+]GWQ1_PKSPYH$UWI/VK2?#&L>'S(
MLTOER-<I&D$F/+R!B/+C^$GY=]:D?@R#6/COX=>UU*"Y&AZ/$=<L[<J^VZA#
M+9>:0,J2+JX<!L$B-3BO=&[4U5P<]/:D*PV56:-@FT-CY2R[AGL<9'>O&--^
M$NMW'Q"T;Q+?Z%X2\-W^GW$MQ?Z]X=EE6YUA6C9&CFA,*!48LLAWRS;3& "<
MEA[936Y7IFF,^>/!_P -?^$JT'XN3Z+J=KJ&G>($O=+\/W*OFUCBE6264JZ
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M"UO4=?@\,:D8S!NG"E)E#'Y0I=>022"">&Y%>J^!?"%IX%\*Z?H5B[2V]HA
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M !1110 4444 %%%% !1110 4444 %%%(:  UBZ;FZ\1:I<]5A6.T7Z@%V/\
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M68N9'U?D>M&1ZUP7A3QQ?ZY\4/'?AN>&W2QT%+ VTL2L)6,\3.^\EB#@J ,
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M#N=+1110,**** $--;[M/HH Y7QAX5GU6:UU;29UT_Q#8!A;7+J3'(C8WP3
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MC_A;_@3_ *'7P]_X-8/_ (NNJ\I/[HH\I/[HHT#]YY'*_P#"W_ G_0Z^'O\
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MX-8/_BZ/^%O^!/\ H=?#W_@U@_\ BZZKRD_NC\J/*3^Z*-#;]YY'*_\ "W_
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M7'_C6KY*_P!T4>2O]T4?[3_=_$-#*_X3+0/^@YIW_@7'_C1_PF6@?]!S3O\
MP+C_ ,:U?)7^Z*/)7^Z*/]I_N_B&AE?\)EH'_0<T[_P+C_QH_P"$RT#_ *#F
MG?\ @7'_ (UJ^2O]T4>2O]T4?[3_ '?Q#0RO^$RT#_H.:=_X%Q_XT?\ "9:!
M_P!!S3O_  +C_P :U?)7^Z*/)7^Z*/\ :?[OXAH97_"9:!_T'-._\"X_\:/^
M$S\/_P#0<TW_ ,"X_P#&M7R5_NBO./B5\2'\*SKI^GQ1O>LNZ21QD1@] !W/
M?_\ 77FYAF$LLH/$8EI17J-13.R_X3/P_P#]!S3?_ N/_&C_ (3/P_\ ]!S3
M?_ N/_&O*/!WQBO?[3BMM9$<]K,VWSEC"-&3T)QP17M2HO91^5<V59PLXINI
MAVM-T[W"4>4S/^$RT#_H.:=_X%Q_XT?\)EH'_0<T[_P+C_QK5\E?[HH\E?[H
MKV_]I_N_B+0RO^$RT#_H.:=_X%Q_XT?\)EH'_0<T[_P+C_QK5\E?[HH\E?[H
MH_VG^[^(:&5_PF6@?]!S3O\ P+C_ ,:/^$RT#_H.:=_X%Q_XUJ^2O]T4>2O]
MT4?[3_=_$-#*_P"$RT#_ *#FG?\ @7'_ (T?\)EH'_0<T[_P+C_QK5\E?[HH
M\E?[HH_VG^[^(:&5_P )EH'_ $'-._\  N/_ !H_X3+0/^@YIW_@7'_C6KY*
M_P!T4>4O]T4?[3_=_$-#(;Q?I#<PWL=Y[6>9S^2 TG]K7U]\MEIDJK_SVOF\
MI?P7EOP(%;"H.PI]+V=:7Q3MZ?YB,:/07N6$NI3_ &^0'(B*[8%/LF>?JQ)]
M,5KHN.U/HK>G2A3^$04445L 4444 %%%% "4T^N*?10!P?Q"TN[LM2T3Q=IE
MO)=7NBM+%<VL(+/<6,H7ST11RS*T<4H Y)AVC[U=7INJ6NMZ9:ZC87,=Y97,
M:S0SPL&61&&0RD=00:O2#*UPVI?#V^T_4+C4O"&L_P#"/W=PYEN;*XM_M6GW
M,AY:1H0R,CD\EHW3))+!C5JSW,&G!N4>IYQ\,OA[XA^(?Q2OOBC\0M-DTV6Q
M>6P\+^'KC!.GVX8AKEP"1YTOUX&.2-H7W\<YR.*\^_M/XJPML7PUX1OMO'GM
MXANK8M[[/L,F/IO/UH_MCXK?]"?X/_\ "KNO_E;52][=F-%1I)VB[O?0]#6E
MKSO^VOBM_P!"?X/_ /"KNO\ Y6T?VU\5?^A/\'_^%9=?_*VHY?,W]IY/[CT3
M(IK8P:\\;6/BKC_D3_!__A5W1_\ <;3O[!\?>)_DUC6=.\-6#?ZRU\/*\URP
M]!=RA0H/?;"&]&4T<OF)U'TBP\5?\5]XJT[PW;#S=+TJ\AU'69AR@>(B6VM@
M>[F012L!]U(P&_UJY[YFVIN;@#J2<8'K_GTJEX?\/V'AC3(=.TRV6TLX0=L:
MDDDDY9F8DLS,22S,26)))))-/\0WECI^@ZE=:GG^S8+:26YVQLY\I5)?Y5!8
M_*#P 2>U#?0N,;7;W9XO)^U]X7::>?3_  QXTUKP[ S+)XFTW0I)M-4(2';S
M,[BJX.2%->S:!KEAXDT>RU72[F.\TV\A6>WN(C\DB,,@C_ \BO#O!_AOXA^$
M?!>D?\*W\1>&_&7@AK=)=,LO$%I-:W*V9&Y(EN(B58[2,-)&#_>JKIWCJVF\
M/?"3Q[X;LYO#7A,W\FCZKX?MF$5K;_:': .T:$1D1W2* X'20G R<(NY]&9J
MOJ%]!IMC<7ES((K:WC:660]%102QX]!7R]K5_P#$+Q[\+_$_BSPE>:Q=Q:UX
MF_<6FF7PANDT6 F FS+Y6*61HS)D#)#9YXK!\!:T/$GA+XA>#[KQ;\2M/GFT
M.2\ATKQM#Y6JP^7S)+#=_P 4391"C*#@G'!-%A7/K;P[KUEXHT/3]9TV;[1I
MU_;QW-O-M*[XW4,IP>1D'H:T<CUKX@NM;USX?_!SX/>%-*U3QW?VOB;3FU34
M)O#JB]U>*$6T)%M: @>5"&D&"#E0OOBNP^$?C+Q5:V_CC1OLOQ)'AZ'0)K^Q
MU3X@Z>T-[!<J&#1K<*<.&#*R@D,NPX&!FG8.8^KZJ:QJ TK2KR]^SSWGV:%Y
MOL]HF^:7:I.U%_B8XP!W)KY(BT[Q[I'@GX5^.;3XF:Y-KGB:73=,GLKYA/ID
M<-S%@.+<_>E0;6,C,2[ DX!Q71MI_B/X5>,O'/AQ/'7B+Q)8W7@JZUR*36[K
MSI[6[1V3=%(H&Q<'(4#C ]*5AW/I'1-4_MC2;*_-I<V NH$G^RWL?ESP[E!V
M2+D[6&<$=B#5ZOE_3T\1?&+5/!/A"3QKKWAC3+?P78Z[>7>B7?DZA?W$I\L%
MIR&.Q=A)X.XN<]B/?/A[X;U;PGX8MM+UGQ#/XHN[=I%74KJ$1S/&7)C63!(9
ME4A2W\6,X&:0'2T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!K=/QK\]?^"HGQ^\4>"[SPY\/_#NH7.B
M6NH69U'4;FT<QR3H9#''$'7D+F-RP!YRH/&<_H4W2OFG]LW]CV#]J#1-+N=/
MU&/1?%6DATM;JX4F&:)R"T4NWD#(W*P!QR,<\=V!G3IUXRJ['%C(U)T9*GN?
MGW^PW^T1XN^'OQT\,:$=7O;_ ,.^(K^'2[O3;B9Y(PTK[(Y4!)V,KLI)7J,@
M\=/V83Z8XK\]/V,OV"9O OQ8U3Q+XRU:SU'4?!VHBTMK#30[6YN6M89UF,CJ
MK$*ERF%VCYP3T4;OT+52O6NC-*M*M63HG-EL*D*7[P?Z4M)[4M>2>L%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )C
M-&*6B@!.M)MIU% #=M&VG44 -VT;:=10 W;1MIU% #3\M?F[^T1I6I:3\9/$
MZZEO,D]TT\+MDAH6YCP?0*0OU!K](9!G'UKD_'?PO\,_$:VBC\1:1%J @R8Y
M-SQR)[!T(8#VSCBBUSQ<UP+QU%1B[-:GQE^Q[I>HWWQFM+NS5OL5G;S27C#A
M=C1E5!]R[*0/]DGM7WR.O2N!^!?AS2M#^&/AN?3--@TXZAIUO>7 A!^>62)7
M8DDDGECC).*]!HV-,KPCP>'5.3NQM&VG44'K#=M&VG44 -VT;:=10 W;1MIU
M% ";:-M+10 E+110 4444 %%%% !1110 4444 %%%% "44M% "?2CFEHH 3F
MCFEHH 3FCFEHH 3FCFEHH 3FCFEHH :V<=/RKQ#XS>#[V/6GUJ")YK695$I4
M$^6P&.?08 Y]:]PI&&:\'.<JI9QA7AJKMU3*C+E/E[P?X1O/%VJ0P01L+8,#
M-. <(N?7IG@X%?4"K@ 5C^$RSZ?<,[%V^VW:Y8Y.!<2 #Z <?A6W7G<-Y)2R
MC#MP=Y3W?H.4KL3Z4<TM%?7D"<T<TM% "<T<TM% "<T<TM% "<TG/I3J*0""
MEHHH ****8!1110 4444 %%%% !1110 AI/I3J* &CZDT'\:6@^M ')?$#QP
MG@O34=(Q/=S$K%&3@#'<^U<AX+^,EQJFL166J0QJL[;(Y(QC:QZ UI?&3PC>
M:[8VUY91M/):[@T2]2I[CWKSWP+X%U/5/$-J\EI-;6]O())))4*=.<>YK\OS
M7'YS3SJG1P\7[/3IH^]WY%JUKL^BZ44BTZOT\@3%,FC6:)D=0Z,"&4C((/6I
M**8'@]S^Q_X86>YCTKQ-XS\.Z%<R/)-X;T;7&@TUM_WQY6TD!NX# =AP *D^
M.&@QZ#\)+?X:>$O!&HZG!K5NVEV/]FP9M-,(V[9KB0L#& 3YFX\LR$DY//NE
M%,5CSC5?@;X?UOX9Z)X+N&N[:VT:* 6&H:?,;>ZM9HDVK/$X^Z_+<G(^8\&J
M7@7]GG0?!5W?W]UJOB#QAJUY:-I[:CXGU)KV=+9N6A0X 521DX&??M7JE%%P
M/&(?V6O#4?@&P\+-K/B69-+NFNM)U9M2VZAIA*!-EO*JC:@4<*01^F-;P9^S
M[H?@ZTUP/JVO^(=4UBS:PNM:U_4#=WOV<AOW:L5VJH+$X"]<9SBO4:*0'"2?
M!_1Y?"7@WP\US?\ V+PK<65S92>8GFR-;+MC$IV8((Z[0OMBIO$7PITGQ-XB
MU#6KJ>\2ZO="E\/R1PN@C%O(Y9F *9WY/4DCVKM:*!GDWBG]G+0/$VC^&[>'
M5_$'A_5- LDTVSUW0[_[)?\ V8*JF-Y%3#*=H)&WKTQDUV/P[^'ND_#+PW%H
MNCK.8 [SS7%W,TUQ<S.<R2RR-RSL>2?RP.*ZBB@04444#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TIM.
MI/X: ///A;_R.7Q7_P"QGA_],^FUZ)7GGPM_Y'+XL?\ 8S0_^F?3:]$JI;F-
M'^&A,4M%%2;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:CFSY+?2I:9-_JV^E
M-;DR^%G)?![_ ))/X*_[ EE_Z(2NPKC_ (/?\DE\%?\ 8$LO_1"5V%(FG\""
MBBB@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!*&I:0]J0&)X1_Y!MS_P!?]Y_Z4R5N
M5A^$?^0;<_\ 7_>?^E,E;E<F$_@1&]PHHHKL$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 E+110 UNE8^@$M?:[DYQ>@ >
MG[B+I_GO6R:QO#__ !_:[_U^C_T1%7%4_CTUZC-FEHHKM$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 E)VI::V*0'GGPO8+XR^+&3C_BIH
M?_3/IM>A^:G]X5QNM?!OP1XDU:YU35?"VF7VHW)4SW4UNIDE*J$4L<<D*JC)
M[ >E4O\ A0/PY_Z$W2/_  &6M6XMW.:,:D%RJQW_ )J?WA1YJ?WA7 ?\*!^'
M/_0FZ1_X#+1_PH'X<_\ 0FZ1_P" RU/NE7J]D=_YJ?WA1YJ?WA7 ?\*!^'/_
M $)ND?\ @,M'_"@?AS_T)ND?^ RT>Z%ZO9'?^:G]X4>:G]X5P'_"@?AS_P!"
M;I'_ (#+1_PH'X<_]";I'_@,M'NA>KV1W_FI_>%'FI_>%<!_PH'X<_\ 0FZ1
M_P" RT?\*!^'/_0FZ1_X#+1[H7J]D=_YJ?WA1YJ?WA7 ?\*!^'/_ $)ND?\
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MKCPG_P!"QH__ ( 1?_$T?\*X\)_]"QH__@!%_P#$T!^^\OQ-C^V+#_G]M_\
MOZO^-']L6'_/[;_]_5_QK'_X5QX3_P"A8T?_ , (O_B:/^%<>$_^A8T?_P
M(O\ XF@/WWE^)L?VQ8?\_MO_ -_5_P :/[8L/^?VW_[^K_C6/_PKCPG_ -"Q
MH_\ X 1?_$T?\*X\)_\ 0L:/_P" $7_Q- ?OO+\38_MBP_Y_;?\ [^K_ (T?
MVQ8?\_MO_P!_5_QK'_X5QX3_ .A8T?\ \ (O_B:/^%<>$_\ H6-'_P# "+_X
MF@/WWE^)L?VQ8?\ /[;_ /?U?\:/[8L/^?VW_P"_J_XUC_\ "N/"?_0L:/\
M^ $7_P 31_PKCPG_ -"QH_\ X 1?_$T!^^\OQ-C^V+#_ )_;?_OZO^-']L6'
M_/[;_P#?U?\ &L?_ (5QX3_Z%C1__ "+_P")H_X5QX3_ .A8T?\ \ (O_B:
M_?>7XFQ_;%A_S^V__?U?\:/[8L/^?VW_ ._J_P"-8_\ PKCPG_T+&C_^ $7_
M ,31_P *X\)_]"QH_P#X 1?_ !- ?OO+\38_MBP_Y_;?_OZO^-(=8L/^?VW]
M?]:O^-8__"N/"?;PQHW_ ( 1?_$T'X;^$_\ H6-'_P# "+_XFD'[WR'^$;VW
M_LVX_?Q\WUV1\P[W$A%;?VZW_P">\?\ WT*S;?PEHMNHCBT>PBC7HBVJ #\,
M5+_PC&D?] JR_P# =/\ "O/I4\32@H+ET]3HT9=^W6__ #WC_P"^A1]NM_\
MGO'_ -]"J7_",:1_T"K+_P !T_PH_P"$8TC_ *!5E_X#I_A6O^U?W?Q#0N_;
MK?\ Y[Q_]]"C[=;_ //>/_OH52_X1C2/^@59?^ Z?X4?\(QI'_0*LO\ P'3_
M  H_VK^[^(:%W[=;_P#/>/\ [Z%'VZW_ .>\?_?0JE_PC&D?] JR_P# =/\
M"C_A&-(_Z!5E_P" Z?X4?[5_=_$-"[]NM_\ GO'_ -]"C[=;_P#/>/\ [Z%4
MO^$8TC_H%67_ (#I_A1_PC&D?] JR_\  =/\*/\ :O[OXAH7?MUO_P ]X_\
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M  H_VK^[^(:%W[=;_P#/>/\ [Z%'VZW_ .>\?_?0JE_PC&D?] JR_P# =/\
M"C_A&-(_Z!5E_P" Z?X4?[5_=_$-"[]NM_\ GO'_ -]"C[=;_P#/>/\ [Z%4
MO^$8TC_H%67_ (#I_A1_PC&D?] JR_\  =/\*/\ :O[OXAH7?MUO_P ]X_\
MOH4?;K?_ )[Q_P#?0JE_PC&D?] JR_\  =/\*/\ A&-(_P"@59?^ Z?X4?[5
M_=_$-"Z;ZW_Y[Q_]]"LKPY(LEYKC*P8&]&"#G_EA%4Y\+Z1_T"K(_P#;NG^%
M7+.QM[",QVT$=O&3G;$@49]<"H5.M*K&=1K3M?J!9HI*6N\04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "'FDZT44 'W:,FBB@ R:,FBB@
MR:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,F
MBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@ R:,FBB@
MR:,FBB@ R:,FBB@ R:/QHHI, S1GVHHI@&?:C/M110 9]J,^U%% !GVHS[44
M4 &?:C/M110 9]J,^U%% !GVHS[444 &?:C/M110 9]J,^U%% !GVHS[444
M&?:C/M110 9]J,^U%% !GVHS[444 &?:C/M110 9]J,^U%% !GVHS[444 &?
M:C/M110 9]J,^U%% !]Z@BBBF =J-U%%( W4;J** #=1NHHH -U&ZBB@ W4;
MJ** #=1NHHH -U&ZBB@ W4;J** #=1NHHH -U&ZBB@ W4;J** #=1NHHH -U
M&ZBB@ W4;J** #K3J**GJ 4444T 4444P"BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>bntx-20231231_g4.jpg
<TEXT>
begin 644 bntx-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %(!*D# 2(  A$! Q$!_\0
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M^KUOY6+^TL'_ ,_5]Y]0T5\O?\/&_@Y_S^ZM_P""YO\ &C_AXW\'/^?W5O\
MP7-_C1]7K?RL/[2P?_/U?>?4-%?+W_#QOX.?\_NK?^"YO\:/^'C?P<_Y_=6_
M\%S?XT?5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O
M_!<W^-'U>M_*P_M+!_\ /U?>?4-%?+W_  \;^#G_ #^ZM_X+F_QH_P"'C?P<
M_P"?W5O_  7-_C1]7K?RL/[2P?\ S]7WGU#17R]_P\;^#G_/[JW_ (+F_P :
M/^'C?P<_Y_=6_P#!<W^-'U>M_*P_M+!_\_5]Y]0T5\O?\/&_@Y_S^ZM_X+F_
MQH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_/U?>?4-%?+W_#QOX.?\_NK?^"YO
M\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL'_P _5]Y]0T5\O?\ #QOX.?\ /[JW
M_@N;_&C_ (>-_!S_ )_=6_\ !<W^-'U>M_*P_M+!_P#/U?>?4-%?+W_#QOX.
M?\_NK?\ @N;_ !H_X>-_!S_G]U;_ ,%S?XT?5ZW\K#^TL'_S]7WGU#17R]_P
M\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M+!_\_5]Y]0T5\O?\
M/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_ #]7WGU#17R]
M_P /&_@Y_P _NK?^"YO\:/\ AXW\'/\ G]U;_P %S?XT?5ZW\K#^TL'_ ,_5
M]Y]0T5\O?\/&_@Y_S^ZM_P""YO\ &C_AXW\'/^?W5O\ P7-_C1]7K?RL/[2P
M?_/U?>?4-%?+W_#QOX.?\_NK?^"YO\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL
M'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M+
M!_\ /U?>?4&:3=7SE<?M\?">W\-V&NO>:I]@O;NXL82+!MWF0I \F1G@8N8L
M'OD^E9C?\%&?@VW_ "^ZO_X+G']:GV%7^4<LQPD=ZB/J&EKY>_X>-_!S_G]U
M;_P7-_C1_P /&_@Y_P _NK?^"YO\:KZO6_E8O[2P?_/U?>?4-%?+W_#QOX.?
M\_NK?^"YO\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL'_S]7WGU#17R]_P\;^#G
M_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M+!_\ /U?>?4-%?+W_  \;
M^#G_ #^ZM_X+F_QH_P"'C?P<_P"?W5O_  7-_C1]7K?RL/[2P?\ S]7WGU#1
M7R]_P\;^#G_/[JW_ (+F_P :/^'C?P<_Y_=6_P#!<W^-'U>M_*P_M+!_\_5]
MY]0T5\O?\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_/U?
M>?4-%?+W_#QOX.?\_NK?^"YO\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL'_P _
M5]Y]0T5\O?\ #QOX.?\ /[JW_@N;_&C_ (>-_!S_ )_=6_\ !<W^-'U>M_*P
M_M+!_P#/U?>?4-%?+W_#QOX.?\_NK?\ @N;_ !H_X>-_!S_G]U;_ ,%S?XT?
M5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'
MU>M_*P_M+!_\_5]Y]0T5\O?\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1
M]7K?RL/[2P?_ #]7WGU#17R]_P /&_@Y_P _NK?^"YO\:/\ AXW\'/\ G]U;
M_P %S?XT?5ZW\K#^TL'_ ,_5]Y]0T5\O?\/&_@Y_S^ZM_P""YO\ &C_AXW\'
M/^?W5O\ P7-_C1]7K?RL/[2P?_/U?>?4-%?+W_#QOX.?\_NK?^"YO\:/^'C?
MP<_Y_=6_\%S?XT?5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW
M\'/^?W5O_!<W^-'U>M_*P_M+!_\ /U?>?4&ZC-?+_P#P\:^#?_/[J_\ X+F_
MQK3\._M[?"GQ/>7%K8W>J&6"SN;Y]]@P'E00O-(1SR=D;<>M+ZO5_E8UF.$;
M251?>?1M+7R]_P /&O@Y_P _NK_^"Y_\:/\ AXW\'/\ G]U;_P %S?XT_J];
M^5B_M+!_\_4?4-%?+W_#QOX.?\_NK?\ @N;_ !H_X>-_!S_G]U;_ ,%S?XT?
M5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'
MU>M_*P_M+!_\_5]Y]0T5\O?\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1
M]7K?RL/[2P?_ #]7WGU#17R]_P /&_@Y_P _NK?^"YO\:/\ AXW\'/\ G]U;
M_P %S?XT?5ZW\K#^TL'_ ,_5]Y]0T5\O?\/&_@Y_S^ZM_P""YO\ &C_AXW\'
M/^?W5O\ P7-_C1]7K?RL/[2P?_/U?>?4-%?+W_#QOX.?\_NK?^"YO\:/^'C?
MP<_Y_=6_\%S?XT?5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW
M\'/^?W5O_!<W^-'U>M_*P_M+!_\ /U?>?4-%?+W_  \;^#G_ #^ZM_X+F_QH
M_P"'C?P<_P"?W5O_  7-_C1]7K?RL/[2P?\ S]7WGU#17R]_P\;^#G_/[JW_
M (+F_P :/^'C?P<_Y_=6_P#!<W^-'U>M_*P_M+!_\_5]Y]0T5\O?\/&_@Y_S
M^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_/U?>?4-%?+W_#QOX.?\
M_NK?^"YO\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL'_P _5]Y]0T5\O?\ #QOX
M.?\ /[JW_@N;_&C_ (>-_!S_ )_=6_\ !<W^-'U>M_*P_M+!_P#/U?>?4-%?
M+W_#QOX.?\_NK?\ @N;_ !H_X>-_!S_G]U;_ ,%S?XT?5ZW\K#^TL'_S]7WG
MU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M+!_\_5]Y
M]0T5\O?\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_ #]7
MWGU!NHW5\O\ _#QCX.-C-[J^/^P<_P#C6GXD_;V^%/A74EL-0N]46Y:VM[O"
M6#$;)X4FCYSUV2+GWI?5ZO\ *P_M'"6;]HOO/HVEKY>_X>-_!S_G]U;_ ,%S
M?XT?\/&_@Y_S^ZM_X+F_QI_5ZW\K#^TL'_S]7WGU#17R]_P\;^#G_/[JW_@N
M;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M+!_\ /U?>?4-%?+W_  \;^#G_ #^Z
MM_X+F_QH_P"'C?P<_P"?W5O_  7-_C1]7K?RL/[2P?\ S]7WGU#17R]_P\;^
M#G_/[JW_ (+F_P :/^'C?P<_Y_=6_P#!<W^-'U>M_*P_M+!_\_5]Y]0T5\O?
M\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[2P?_/U?>?4-%?+W
M_#QOX.?\_NK?^"YO\:/^'C?P<_Y_=6_\%S?XT?5ZW\K#^TL'_P _5]Y]0T5\
MO?\ #QOX.?\ /[JW_@N;_&C_ (>-_!S_ )_=6_\ !<W^-'U>M_*P_M+!_P#/
MU?>?4-%?+W_#QOX.?\_NK?\ @N;_ !H_X>-_!S_G]U;_ ,%S?XT?5ZW\K#^T
ML'_S]7WGU#17R]_P\;^#G_/[JW_@N;_&C_AXW\'/^?W5O_!<W^-'U>M_*P_M
M+!_\_5]Y]0T5\O?\/&_@Y_S^ZM_X+F_QH_X>-_!S_G]U;_P7-_C1]7K?RL/[
M2P?_ #]7WGU#17R]_P /&_@Y_P _NK?^"YO\:/\ AXW\'/\ G]U;_P %S?XT
M?5ZW\K#^TL'_ ,_5]Y]0T5\O?\/&_@Y_S^ZM_P""YO\ &C_AXW\'/^?W5O\
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M]J,^U)11H OW><5Z!\<<#QY  !_R ]%_]-5I7G[?TKT#XY?\C]#_ -@+1?\
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M\>N?CI\1O^QDU+_TJDK-_&OZ['3'^!+U7ZG!TM%'-:7.8**.:.: "BCFCF@
MHHYHYH %ZU[I^Q3XAM/"W[0_A_4=2UBTT+288;H7ES?7T=K"R- X5&+LH?\
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MS>)-'U35_'VLM'HEEI.JPW92$32.+F1XG980%ERI=@V5Y KXV5NF>GX4FW'
MX%<M2C[25[GJ4,<Z%/V:CW_%6/T#U;]H:WT;]LKP_#_PF^F_\*]NX8'NKBTU
M"WFMGN!9S0JTTJ$E/WCX(8@?*C'@*0WP5J4!O_@+I=MJ&A^-==TFUURUN+;3
MM<M+BXM'8%X&BS(5+A(]L>2$! &]1\P_/_(QC''3_(K;\(^--8\#:PVIZ+<)
M;7;0R6[^;!%/')$Z[7C>.161T8$@JP(K.6&TLF=D,T?-><-&[_BG^A[M^VLW
MB^'6O ^F^)],UJR@T[1([*WO-;NXI9-1E3 GN2L4TT<;L=FX;V; 4L3QCTB'
MQUIWB[7O@)(_Q1L]%T[3O#RQWK27\+207D<,@<LDP9(92 L:RR ',B[-Q''R
M+XH\>:QXS^QKJDMM]GLU9;:UL;*"RMHMQ!8K# B1@L0,L%R<#).!C 4^WO5J
MBW%)O8YY8Y1K3G!73MOY:GZ!VOQ$\.3?%H:Y%XI\. 7_ ,,/L5W*==MPL^IY
MPL4KR29DDZ &3)P,DXS3_P!EWQMXZ\9_#VU\2PZ/J'B/5]/UJ;[:VC7EE VJ
MK'8B"&&\,DT6Q5W1E7 E)\LL5!PQ_/@9/7'^/K_GVKL]!^+_ (H\,Z):Z19W
M-A+86<[W-HFH:39WK6TC[=[Q/-$[1DE5)*$<J#UYK*6&?+[KNSKHYFO:ISC9
M:['T]I_Q"\/Z+\%;*.Z-O<:V9=:M?&&B:AXECL99+F9F437$,D4L]XR@KL:,
MY5E''WL>:?M+>.(O&/PU^$0LO%<&J6]IX?@MKS3$OS)+%>*&61Y(<G8P&%W,
M 6##;D9QX!?WL^IWUS>7<\EU>7,C2S7$S;GD=CEF8GDDDDY)[U#NY)''^?\
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MPU'_ ..UT/X"C\!1[2?\S#ZGAO\ GVON.>_X9%_9O_Z%=O\ P8:C_P#':/\
MAD7]F_\ Z%=O_!AJ/_QVNA_ 4?@*/:3_ )F'U/#?\^U]QSW_  R+^S?_ -"N
MW_@PU'_X[1_PR+^S?_T*[?\ @PU'_P".UT/X"C\!1[2?\S#ZGAO^?:^XYS_A
MD7]G#=_R*_3D9U#4>/\ R+6GXF_9;^ /B#Q)JVJ:QX<,VK7UW-<WDGV[4%WS
MNY:0X60*,L3P  .P%:/\.,9]NU7_ ! /^)]J7 _X^9/_ $,T>TG_ #,/JF'M
M;V:^XX[_ (9%_9O_ .A7;_P8:C_\=H_X9%_9O_Z%=O\ P8:C_P#':Z'\!1^
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MAO\ GVON.=_X9%_9O_Z%=O\ P8:C_P#':/\ AD7]F_\ Z%<_^##4?_CM=%^
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M@*?M:G\S']3PW_/M?<<[_P ,B_LW_P#0KG_P8:C_ /':/^&1?V<-O_(KG/\
MV$-1_P#CM=%CD# R>GO1^5'M*G\S%]3PW_/M?<<]_P ,B_LW_P#0KM_X,-1_
M^.T?\,B_LW_]"NW_ (,-1_\ CM=#^ H_ 4O:5/YF/ZGAO^?<?N.=_P"&1?V<
M,_\ (KG'_80U'_X[2_\ #(O[-_\ T*Y_\&&H_P#QVNA_ 4?@*?M*G\S#ZGAO
M^?:^XY[_ (9%_9O_ .A7;_P8:C_\=H_X9%_9O_Z%=O\ P8:C_P#':Z'\!1^
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MT/X"C\!1[2?\S#ZGAO\ GVON.>_X9%_9O_Z%=O\ P8:C_P#':/\ AD7]F_\
MZ%=O_!AJ/_QVNA_ 4?@*/:3_ )F'U/#?\^U]QSO_  R+^S?_ -"NW_@PU'_X
M[1_PR+^S?_T*Y_\ !AJ/_P =KHOP%'X"G[2I_,P^IX;_ )]K[CG?^&1?V;^/
M^*7/_@PU'_X[1_PR+^SAN_Y%8X_["&H__':Z+\!1^ H]K4_F8?4\-_S[7W'.
M_P##(O[-_&/"Q_\ !AJ/_P =H_X9%_9PW?\ (K''_80U'_X[71?@*/P%'M*G
M\S#ZGA_^?:^XYW_AD7]F_P#Z%=O_  8:C_\ ':/^&1?V;_\ H5S_ .##4?\
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M+8&6*C< PP:T?#.CWT&HZAK&K06EGJ-\D43VUE<-/$$BW[3O9(R[$N<_*,
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M%>?1>#];;Q];:ZD%EHRNR/?RZ?J<[?:P(MOE2V[1".4ACQ-E7P ,8&T^@#@
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M4-M/N,X_"M"JNF?;#I]N=02".]* S):LS1*W=59@"0.F2!G&<#I5J@84444
M%%%% !1110 4444 %%%% !1110 4444 >@_"G_5ZE]8_Y-7?>M<#\*?]7J7U
MC_DU=_6;W-H[!1112*&LVVC<!R:5AFF'.": \SP>Z_X^9?\ ?;^=1U\A:M^W
M]J%IJEY!_P (+IS^5,Z;C?2C.&(SP*J_\/!M0_Z$/3?_  /FKTE@ZKU2/F99
MY@HMIR?W'V/17QQ_P\&U#_H0]-_\#YJ/^'@VH?\ 0AZ;_P"!\U/ZG6[$_P!N
MX'^9_<?8]%?''_#P;4/^A#TW_P #YJ/^'@VH?]"'IO\ X'S4?4ZW8/[=P/\
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M (>#:A_T(>F_^!\U'U.MV#^W<#_,_N/L?VS@'KCOT_PH_3T]J^./^'@VH?\
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M:4I;,"874_O">"IS2N'*S@<?YQ28_P XKMO^$=TK_GU?_OZ?\*7_ (1[2O\
MGU?_ +^G_"G<.5G$8_SBC'^<5V__  CVE?\ /J__ ']/^%'_  CVE?\ /J__
M ']/^%%PY6<1C_.*,?YQ7;_\(]I7_/J__?T_X4?\(]I7_/J__?T_X47#E9Q&
M/\XHQ_G%=O\ \(]I7_/J_P#W]/\ A1_PCVE?\^K_ /?T_P"%%PY6<1C_ #BC
M'^<5V_\ PCVE?\^K_P#?T_X4?\(]I7_/J_\ W]/^%%PY6<1C_.*,?YQ7;_\
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M_/J__?T_X4?\(]I7_/J__?T_X47#E9Q&/\XHQ_G%=O\ \(]I7_/J_P#W]/\
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MZO\ ]_3_ (4?\(]I7_/J_P#W]/\ A1<.5G$8_P XHQ_G%=O_ ,(]I7_/J_\
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MK']EWDETM\;*345CBL9Y0\,9 D*,B%68%E^127^9?EY&?+?&GQFU2S\0:?\
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MC:B\,#GY<FC\*?'U]XYM];75;6&QO+*^VI##N!-K+&DUL[!N=YCDPV.-RMT
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M\C!J?_7U+_Z&:SZT/$7_ ",&I_\ 7U+_ .AFL^OM([(_":GQL****9F%%%%
M!1110 4444 *>WTKN_CW_P EU^(Q_P"IDU+_ -*I*X7 . .O/\J[KX^?\EU^
M(W_8R:E_Z525F_C7I_D=4?X$O5?J<)11R.^/QHS_ +7ZUH<P449_VOUHS_M?
MK0 449_VOUHS_M?K0 449_VOUHS_ +7ZT %%&?\ :_6C/^U^M !11G_:_6C/
M^U^M !V(Q7??"OQ/X?\ #MCXQMM>NM5M%UG2#IL#:78QW.&,T4I9P\T7 \D
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M9_VOUHS_ +7ZT %%&?\ :_6C/^U^M !11G_:_6C/^U^M !11G_:_6C/^U^M
M!11G_:_6C/\ M?K0 449_P!K]:,_[7ZT ?H]_P $Y_\ D@^L?]C)<_\ I+:5
M]25\M_\ !.<9^ ^L?]C+<_\ I+:5]25\MB/XK/V+*O\ <J?H%%%%<IZU@HHH
MIA8**** L%%%% 6"BBB@+$=PTJP2-;HDDX4F-9'*J6QP"P!*C/< _2O+=6^%
M^M^+_!FF#49+#0?&&F2R&VO--G:YB,,A(EA9GB1BDD9*D;>"%89*BO5J* L>
M1M\%4F\>:MJ%QHGAJZM-0O!?KKLELIU:U;8JM FZ)AMRF5E$BL@<@+D!JQQ\
M#?$/B'PO8:%X@NM)BCT/1KC1].O;/?,;P.(U26>%T58P%A3=&K2!BQ^90H!]
MTHH#E/G#Q9HS_#5_ LEOH?@CPOK=]XDA$>D:?.+2RF*6ERA<S+;K(S,954#R
MW"EHU .2S=#+\'_$LRL"NC>;J5KK1U"87<H\B>^VD+$ODGS$3RXU+$H3\S!0
M<+7MN <^XQ_];^5+01RH\8O/AGXSNH]05$T$)XAT&'0]5@FO)I19F,RHL\#>
M0//!CG8F)Q%EE&'Y)KG-)T6[\9>,_B#X,TF[T:YT*'5=,^W7$FH/)?PK!;6V
MY1 J$-N,&S>SKM;?PQ7%?17X9'H:/QS]1U_P_P#KT!RH\8\/_ \Z)<:LA\-^
M#;C<;PP:LUFIN]12<N?)N_W.54!\,RR,7V+PH)![#X4^$]7\'Z5>VVIR^5 \
MX:STY=4FU)+*,(J[$N)HTD*D@D*P.W. 2, =O105RA1110.P4444!8**** L
M%%%% 6"BBB@+!4]G_K)/^N;_ /H)J"I[//F2?]<W_P#030%B"BBB@+!1110%
M@HHHH"P4444!8**** L%%%% 6"BBB@+'#^.O#&NZAXFT+6] 33IKBRMKRREC
MU*>2)5CN/*/F+LC<LRF$?(=H;)^9>M>=:+\#O%%U8Z+HGB4Z'/I%GX970WO]
M-NIX[F&9622.>*-XR-T;11@-Y@)*[\+P@]]HHN+E/./#]E\1_M7AZ/Q#9^&[
MN*R$D5[J%KJ,XEN 5"B583;;58XR5WXYZUDO\(]7\/:)XFT;09K.^T75I88K
M;3KZZDM5L+)F9KFWCDCC=L'?)LZ%1(!D"-<^NT4!RGF?A?X:ZCX'^*%YJ6CX
MF\-:CI\-O>/J>MW=Y?">)Y"CH)ED^7:Y4KYHZY &,-Z9110.P4444!8****
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M?]^$_P */^$QU'_IA_WX3_"L2BG8+FW_ ,)CJ/\ TP_[\)_A1_PF.H_],/\
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M?X5B446"YM_\)CJ/_3#_ +\)_A1_PF.H_P#3#_OPG^%8E%%@N;?_  F.H_\
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M_P#A,=1_Z8?]^$_PH_X3'4?^F'_?A/\ "L2BBP7-O_A,=1_Z8?\ ?A/\*/\
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M_P#"8ZC_ -,/^_"?X4?\)CJ/_3#_ +\)_A6)118+FW_PF.H_],/^_"?X4?\
M"8ZC_P!,/^_"?X5B446"YM_\)CJ/_3#_ +\)_A1_PF.H_P#3#_OPG^%8E%%@
MN>G?#S5[C5EOC<;/W93&Q O7=Z?2NQK@?A3_ *O4OK'_ ":N_K-[FL=@HHHI
M%"=S39/NFG=S39/NFCJ)['X*>(O^1@U/_KZE_P#0S6?6AXB_Y&#4_P#KZE_]
M#-9]?:1V1^$U/C84444S,<,]J]S^$#3:#\/XO$^BZ;=7_B6SU"^C@W>)CIL/
ME^1;,PCMXY8[BXDV[\K!(IY3<'!"UX8O?K[UZS\*=2DT?P['J-Y=>$--MK:_
M=])U#Q+'=W$L-UL0RF&&U63=A1"29XF0$+M^;=6-7X3T,&[5-2W\4- E;X<V
M.M:Y;:-_PD<TEG,G_"/Z:EDMM9W,$DL<=TD<<<9=\!HVC5CQ()'X11XT2>AY
M]Z]8^,GQ.U+7%;P[+I?AVRM8UL6%YH*76RZ@AMS':X-S(S!%BD.!M1OF^8$C
MCR=O;I12NEJ3BG%U+1$HHHK8X16[?2N\^/?_ "7;XC?]C)J7_I5)7!MV^E=Y
M\>_^2[?$;_L9-2_]*I*R?Q_+_(ZH_P "7JOU."HHHK9G*%%%%( HHHH ****
M "BBB@ HHHH <&V]A7M?P)\)Z)XI\"^/Y[WPMH.M:OH]O;75C<:YJDUA%^\G
M2)XWD%U!&%VDD9()8XR>!7B5>@^!?B-HWA7P#XQ\.WVA7^HW'B.&*!KRWU-+
M=(%CD66/$;6[[CO7D[AE3@;2-U95$Y1TW.S"RC&I>>UG^1U^J?"U-=?7RECX
M-\'6VF:M:Z'>7KZM>W$4%T3-^]B!:5UADV*IDE5AE058 2;;&A?"/1_A/\6?
M#NB_$G^Q_$%CJER]C<Z=#-?12VBF4Q1W1(6']VS ,OS-OC);'*D<;\._B'X:
M\+^%]5T3Q%X5O?$MMJ%_:7LJ0:NMG&5@WE8V'D.Q#>8X9E93C&W:1DN^)WQ4
MT_XF:#HBW&@3V_B33A) ^L_;8RMQ:EW:*$P) BKY0951@>%7;C&T)C[]^7H=
MO-A^13^U_P $Z+3/AC9G1_%VDZ[;>&O"NN1:RUI:ZGJ]Y>+]G\J0)/!!'&9#
M,=\L(!*/A?-+'@$8O_"@=5L=8U'3M>\0^'O"IM=5FT:*XUFZEC@N[B+'F>6R
MQ-MC :,^9+L7$B\YR!O6'[21F\6S^(=9\/-=:DVDVVGQ:AIEW':7EO-&5:6Z
MCE:"4))*0^XJH8!R PQDGCKX_>'?B9>:H/$/@V_DL)M7EUBQ2RUM(9[629%%
MQ$\AMF66)VCC91L5EP1O()I+VJ=D.7U6<7)O4\5N(6MIY(7*EXV*$QN'7(..
M&!((]P<'M4=27$B2W$KQQ+!&S%EB4DA 3PH)))Q[G-1UV'C/?0****!!1110
M 4444 %%%% !1110 4444 ??G["W_)![S_L9+S_TELZ^@J^??V%O^2#WG_8R
M7G_I+9U]!5\QB/XK/U_*_P#<J7H%%%%<QZ@4444 %%%% !1110 5S?Q%U#5]
M)\%ZI=Z%!-<:G'&"B6T0EF";@'>-#P[JA<JIZL!P>E=)6;XATV[U;2VM['4'
MTNZ\R.1+F- ^-CJQ4J3@A@"I]B: /*;KQUJ)\#ZIK>A^,H]:L;.[LX=TFF*;
MZ+_2"EQ%-"JKB5@R@8C'RK@)G]X>S7XF+)IUS-;^&];N;VVO&LY]-BC@\Z)A
M$)=S,9O+"E&4@E\DL!C<<5E:I\*]6UFWUBXN=<TZ/7-2:T62ZMM)=(!%;R&1
M%,1N"S.68@N9/N@  <YBU3X3ZUJEQJTC^(;!H-1U,7\ME)I<IMY$^SB PRJ+
MD>8N$0C)"Y!)4\!0#5TOXP:5KFH6-II^GZI=&YL(-3:?[.L4,%O+GYWDD95^
M7'S!2QZX!VMBAHOQ^\*^(%U+[%+)</:K&\4,$T$SW@D<1QB,)(VUF;:-LNQE
MWJ6"@YH\#?"C4?"K6L-[KEIJ.G0Z,FBFWATY[=WC1F*-O\]AG#$'Y>P((J27
MX7:I>>&X=+O/$QFFT\PG2;J.SV>08G5XVG3S"L[_ "J"0$!&[ 4L30!9^&7B
MK6?$,GBYM;@GM9+#6&MX+2:WC1X8A!"X4B-Y Y)<G.]LYR ,[15N/C=IFFV=
M[+J.A:_ILEJ+60VLMFLDSQ7#LD<@2)WV@%6R&VL, ;=Q .MX/\%ZKH-QXCN]
M1UY+ZZUF=9\65D+6&V98EBRBL\C$D(I.7(X& .<\/;_ 76K5=0:/Q/I@N;ZW
MM(KBY;1I7DF>WF,B2R,UV2[MDJQ)Z8 P!B@#HM0^+SQQVJ67AW5'OFUA=*N;
M*80)+"QB\W/,P4[D*D?/GJ#C&*=;_%BRAT\36MCKVO74UQ?%+/[-!'<Q16\I
M25L.8@$4E5 8^8<KD$[J;+\,]8;4+^]CU^Q2>;6H]8@!TQRD6V 0&-Q]H!<%
M%3D%<$$XQ@#DO&?A'4]-DM+2^OYI8I+B^O5O=-\/:A,@,[J3 ?L=P)E/+YW,
M$=2,J2N0"U.GO/V@O#&G?V(+[S;&75(8;CR+BXM5EMHY6Q$SIYVYMW7$0D('
M+ 5HZ+\8-+UO5H;./3-8M8IKVXTY+R\M!#%]HA5W9,,WF<I&S [,=B0WRU7T
M'P=KCFWU$7\&AB]M([74=-M[(H"D181FW*RYMF,;8()DVC:!RNXQ6?PQURVO
MM-N#XBL2+/6KG5]JZ4X+^<CH8QFX(&T2OAL'DCCCD&=+X/\ &T/C.W:XM].O
MK.V*+)#<7/E-%<(Q8!HWCD=3RIRI(9>-P&171UQG@GX?R>%-:U;5);JQ>XU
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MGBRVU^>--/GD>\C@M+9%U;3XY6'VA?-C/EN\0WC!"GG 7<"/0? MQ=^(//\
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M]3PS_/2C_/2N^_X7]\1_^ATU?_P(-'_"_OB/_P!#IJ__ ($&K]\QM2\S@?\
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MB/\ ]#IJ_P#X$&G[X?NN[.!_STH_STKOO^%_?$?_ *'35_\ P(-'_"_OB/\
M]#IJ_P#X$&CWQ6I=V<#_ )Z4?YZ5WW_"_OB/_P!#IJ__ ($&C_A?WQ'_ .AT
MU?\ \"#1[X6I>9P/^>E'^>E=]_PO[XC_ /0Z:O\ ^!!H_P"%_?$?_H=-7_\
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M=Q1110,**** "BBB@ HHHH **** "I[/_62?]<W_ /034%3V?^LD_P"N;_\
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MRF*0P/=Z?,C7Y$#.SQ7:R-%YF]6!MV1'V@L"PVY N>G44#@ 'KCFB@84444
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MFCW,/9S[''45V/\ PIWQ_P#]"/XD_P#!3/\ _$4?\*=\?_\ 0C^)/_!3/_\
M$4<T>X>SGV..HKL?^%.^/_\ H1_$G_@IG_\ B*/^%.^/_P#H1_$G_@IG_P#B
M*.:/</9S[''45V/_  IWQ_\ ]"/XD_\ !3/_ /$4?\*=\?\ _0C^)/\ P4S_
M /Q%'-'N'LY]CCJ*['_A3OC_ /Z$?Q)_X*9__B*/^%.^/_\ H1_$G_@IG_\
MB*.:/</9S[''45V/_"G?'_\ T(_B3_P4S_\ Q%'_  IWQ_\ ]"/XD_\ !3/_
M /$4<T>X>SGV(;?XH>(;7P./"$5Q:1Z"MR+Q8ETZV$XG!R)!<>7YH?'R[M^0
MOR_=XKH=2_:.\?ZLUQ+<ZK8F[N+BWO);V+1;&*ZDG@8-#*TRPARZD<,3G!()
M()%8G_"G?'__ $(_B3_P4S__ !%'_"G?'_\ T(_B3_P4S_\ Q%1:F;QJ8B*L
MKEJ;XW>,V\2:5KL&KII]_I3R267]G65O:0Q/)_K6\F*-8F9QPY93O  ;(  1
M?C9XL6:^?[3IVR\LQI[V[:-9&".W#%C%#%Y.R!2Q+'RE7+?,<MS5;_A3OC__
M *$?Q)_X*9__ (BC_A3OC_\ Z$?Q)_X*9_\ XBERTPY\1YE[1_CMXTT65I(=
M3MIW;2H]#W7^EVEV18H"!;CS8FPA!(('WN-V<"K<O[17CZ:P%HVK6BH);2<S
MQ:39QW#2VN/L\C3B+S&= H 8L3C(.036-_PIWQ__ -"/XD_\%,__ ,11_P *
M=\?_ /0C^)/_  4S_P#Q%'+3*57$QV;)KOXS>*[S5K34)+RRWVJ3)%;1Z39Q
MVG[T8F9K98A"S2# 9BA+!5!) &.>\2>*-2\7:H=0U26*2X\M8E2"WCMX8T5<
M*B11JJ(H ^ZJ@9)/>MO_ (4[X_\ ^A'\2?\ @IG_ /B*/^%.^/\ _H1_$G_@
MIG_^(IKD6J,Y.M)6E=G'FDKL?^%.^/\ _H1_$G_@IG_^(H_X4[X__P"A'\2?
M^"F?_P"(J^:/<R]G/L<=178_\*=\?_\ 0C^)/_!3/_\ $4?\*=\?_P#0C^)/
M_!3/_P#$4<T>X>SGV..HKL?^%.^/_P#H1_$G_@IG_P#B*/\ A3OC_P#Z$?Q)
M_P""F?\ ^(HYH]P]G/L<=178_P#"G?'_ /T(_B3_ ,%,_P#\11_PIWQ__P!"
M/XD_\%,__P 11S1[A[.?8XZBNQ_X4[X__P"A'\2?^"F?_P"(H_X4[X__ .A'
M\2?^"F?_ .(HYH]P]G/L<=178_\ "G?'_P#T(_B3_P %,_\ \11_PIWQ_P#]
M"/XD_P#!3/\ _$4<T>X>SGV/N[_@G/\ \D'UC_L9+G_TEM*^I*^</V O"NM^
M&O@EJMIK&CW^E73>(;B58+ZU>%RAMK4!@K '!*D9Z9!KZ5^QS\_N)/\ ODU\
MOB/XK/U[*TU@Z:\B&BIOL=Q_SPD_[Y-'V.X_YX2?]\FN4]4AHJ;['<?\\)/^
M^31]CN/^>$G_ 'R:8$-%3?8[C_GA)_WR:/L=Q_SPD_[Y- $-%3?8[C_GA)_W
MR:/L=Q_SPD_[Y- $-%3?8[C_ )X2?]\FC['<?\\)/^^30!5N(%NK>6&0L$D0
MQMY;E&P>N&7!!]P1V]!7%V/P7\*::NF+;0:G%_9MK/9VF-;O3Y44W^L4$S9Y
M."">053!&U<=]]CN/^>$G_?)H^QW'_/"3_ODT <?X5^&/A_P5)NTB&^@ LX]
M/59M4NYU2",DQJHDE8+MR<$ $9.#S6;;? _PC9Z59:=;VVI0V]E),]N\>MWJ
MRQB4J9$$HF\SRW*@F,MMR <9YKT+['<?\\)/^^31]CN/^>$G_?)H$94V@Z=/
MH,FBFTC32I+<VAM8EV((2NW8 N,#;QQ[>E<;>? ?P=J$<:3VVJLJQQ1DC7K\
M%Q$YDA+D3Y=D8Y5VR5  !  QZ/\ 8[C_ )X2?]\FC['<?\\)/^^30,\SU[X4
MPV7@[4-*\,VY9[W4(M0N(-2UB]42N)5DDV7 9Y+=B5#!HP<$=,G<(?#OPE%[
MI4\/BD73;KJ.ZM;:+Q'J%])82(&7S(;Z5DG5F#'(38,$K\V6+>I?8[C_ )X2
M?]\FC['<?\\)/^^31<5CD+KX9>';R[@N9+2=)H;(Z=^YO9XE> @_*ZK(%D(+
M,07#$$D]>:TO#?A73_"=O-#IXNV,S^9+-?7T]Y.[8P,RS.[D8Z#.!VZUN_8[
MC_GA)_WR:/L=Q_SPD_[Y- R&BIOL=Q_SPD_[Y-'V.X_YX2?]\F@"&BIOL=Q_
MSPD_[Y-'V.X_YX2?]\F@"&BIOL=Q_P \)/\ ODT?8[C_ )X2?]\F@"&BIOL=
MQ_SPD_[Y-'V.X_YX2?\ ?)H AHJ;['<?\\)/^^31]CN/^>$G_?)H AJ>S_UD
MG_7-_P#T$TGV.X_YX2?]\FIK6UF61\Q2#,; ?*?[IH IT5-]CG_YXR?]\FC[
M'<?\\)/^^30!#14WV.X_YX2?]\FC['<?\\)/^^30!#14WV.X_P">$G_?)H^Q
MW'_/"3_ODT 0T5-]CN/^>$G_ 'R:/L=Q_P \)/\ ODT 0T5-]CN/^>$G_?)H
M^QW'_/"3_ODT 0T5-]CN/^>$G_?)H^QW'_/"3_ODT 0UR?B#X6>'/%&H:G>Z
ME;WLT^I6/]FW7EZG=1));YSY81) JY.<E0#AF&?F.>R^QW'_ #PD_P"^31]C
MN/\ GA)_WR: .$F^#?A.Z74DNK"YO4U&QATVY2[U*ZF5X(?]4 'D(5E/(D&'
MR2<Y))EN/A'X7NM#32Y;*XDB2Z%^MVVH7)O?M &!+]J\SSM^W"[M^=OR_=^6
MNV^QW'_/"3_ODT?8[C_GA)_WR:!'G6D? ?P5H.I:??V&GWMM=V-U)>13+JUX
M6>:0YDDE_?8E9QA6,@8E0%)V@ 2_\*3\)K?274-OJ5F\E[_:+0V6M7MO!]I)
M),@B28(I))) 7!SR#7H'V.X_YX2?]\FC['<?\\)/^^30!S?B+P+H?BG[:VH6
M1:2\LS83S6\\EO*]N6#>49(V5MN<]^[#^(YAU'X>Z)JVI:!J%TEZ]WH/_'A*
MFI7*%,@ []L@\PD+@F3=GG/4YZK['<?\\)/^^31]CN/^>$G_ 'R:!D/UZT5-
M]CN/^>$G_?)H^QW'_/"3_ODT 0T5-]CN/^>$G_?)H^QW'_/"3_ODT 0T5-]C
MN/\ GA)_WR:/L=Q_SPD_[Y- $-%3?8[C_GA)_P!\FC['<?\ /"3_ +Y- $-%
M3?8[C_GA)_WR:/L=Q_SPD_[Y- $-%3?8[C_GA)_WR:/L=Q_SPD_[Y- $-3WG
M^O\ ^ )_Z"*;]CG_ .>,G_?)J>\M9FFRL4C#8O(4_P!T4 4Z*F^QW'_/"3_O
MDT?8[C_GA)_WR: (:*F^QW'_ #PD_P"^31]CN/\ GA)_WR: (:*F^QW'_/"3
M_ODT?8[C_GA)_P!\F@"&BIOL=Q_SPD_[Y-'V.X_YX2?]\F@"&BIOL=Q_SPD_
M[Y-'V.X_YX2?]\F@"&BIOL=Q_P \)/\ ODT?8[C_ )X2?]\F@"&H[FW2[MY8
M)&D5)%*,896B< \95T(92.S Y!Z5:^QW'_/"3_ODT?8[C_GA)_WR: //M%^"
M?A7P^UI]CCU<):;S;PSZ_?S10LRLI=(Y)V56P[88 $9)!!K7L?AUX?L?"K>&
M_L<EWHK/O-O?W<UV<[P^0\KLX(8 CYOE(!&*ZK['<?\ /"3_ +Y-'V.X_P">
M$G_?)H Y72OA[HNB^*]1\26JWPU?4$"7,LNIW4L;J#D#RGD* #)VX4;=QQU-
M2-X#T9_$G]N-'>->^8)?+.H7!MO,"[1)]F,GE;PO ;9GWKIOL=Q_SPD_[Y-'
MV.X_YX2?]\F@"'^=%3?8[C_GA)_WR:/L=Q_SPD_[Y- $-%3?8[C_ )X2?]\F
MC['<?\\)/^^30!#14WV.X_YX2?\ ?)H^QW'_ #PD_P"^30!#14WV.X_YX2?]
M\FC['<?\\)/^^30!#14WV.X_YX2?]\FC['<?\\)/^^30!#14WV.X_P">$G_?
M)H^QW'_/"3_ODT 0T5-]CN/^>$G_ 'R:/L=Q_P \)/\ ODT ;'AG[ES]5_D:
MW*Q?#L3PK<!T922N,C'K6U4%BT444 )W--D^Z:=W--D^Z:.HGL?@IXB_Y&#4
M_P#KZE_]#-9]:'B+_D8-3_Z^I?\ T,UGU]I'9'X34^-A1113,PHHHH ****
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M^$AU3_H*7O\ X$/_ (UG44<J#VD^[-'_ (2'5/\ H*7O_@0_^-'_  D.J?\
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M:9?^>LG_ 'T?\:CHHL!)]IE_YZR?]]'_ !H^TR_\]9/^^C_C4=%%@)/M,O\
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M)_WT?\:CHHL!)]IE_P">LG_?1_QH^TR_\]9/^^C_ (U'118"3[3+_P ]9/\
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M9EZ%TC:,N "W\0Z_G9M_#5I)H3Z9J<%MJL5QN>[6>W4Q3NQW,3&<C&X\ YP
M!SC- 'FVJ^+M>M;S6KFWUN9W\/ZK8Z8^D300?Z?%*( 9)#Y8<2/YSE#&57*
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MBBB@ K0U[_D(#_KA!_Z*2L^M#7O^0@/^N$'_ **2@?0SZ***!!1110 4444
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M*CD/^$5U3_GW7_O\G_Q5'_"*ZI_S[K_W^3_XJNOHHN'*CD/^$5U3_GW7_O\
M)_\ %4?\(KJG_/NO_?Y/_BJZ^BBX<J.0_P"$5U3_ )]U_P"_R?\ Q5'_  BN
MJ?\ /NO_ '^3_P"*KKZ*+ARHY#_A%=4_Y]U_[_)_\51_PBNJ?\^Z_P#?Y/\
MXJNOHHN'*CD/^$5U3_GW7_O\G_Q5'_"*ZI_S[K_W^3_XJNOHHN'*CD/^$5U3
M_GW7_O\ )_\ %4?\(KJG_/NO_?Y/_BJZ^BBX<J.0_P"$5U3_ )]U_P"_R?\
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MK_W^3_XJNOHHN'*CD/\ A%=4_P"?=?\ O\G_ ,51_P (KJG_ #[K_P!_D_\
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MR0QAF.!N=R%49ZEB .I(%13PM;W$D+E#)&Q0^6ZN"0<'!4D,/0@D'MFOK/\
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MYB&1(WVR1[2/ED5BN,^C6NO?"OXB>%_"/@[3=7L+6RGM6MK32C>*M_92HB[
M59BZ3QL <GYMRYR<\@:GL5CXNT[4/$E_H,(OO[1L466?S=.N(X0K?=*S-&(V
MSZ*Q/!]#A_AOQ7I'B^VO+C1[Z.^AL[R:PG>/($<\3;9$.1U!_/((R*\FA^(6
ML>%]"\51^*9[;3O$NGQVNC0:E?.MM::C<.91;W*'/RJX=2X ^0K*!]RD^$VI
M2^"?BEKG@S6CI6EWNI6-IJ.GV%GJK7K.R1FWE.YXHFW%8(VVA#GYF!.#A%'N
M%%'X8[8]/:B@ HHHH **** "I[S_ %__  !/_014%3WG^O\ ^ )_Z"* (***
M* "BBB@ HHHH **** "BBB@ HHHH *BNKE+.UEGD#F.)#(PCC:1R ,G:J@LQ
M]E!/YBI:BNKR&PM9;FYFCMK>%#)++*^U$4#EF/88!YX_2@#"\/\ C_1_%'AB
M;Q!IOV^;2X@Y+OIEU%*^WKLB>,2/Z#:IR00,D8JK!\5/#=WX-F\46UW<W6CP
M2O!,UOI]S)/#(CE'1X%C,JLK @@J",9.!S7!?!3XN>#(O ?AS2H_$NDW6J2&
M939VMY%)+$H>61I'56RB*@+%FX ]R,X$UQ#I_AV;QSX+EBU[0M9B?3]>M=+9
M907):.*\4@XWID)(.ICP3S&,@'HUS\?/!EC>W%K>7>J6#VWD_:9+W0K^"&V$
MIQ&TLKP!(E)_B<@<'G@UZ%VR.1ZXXKYTUO3T^*'Q>^)'A'3?&.CV%M?:98VF
MI6R6Z75[)$AF69(CYP$14.%8M')M,B\ \5NKJB:%\<+'2XM8^WQO(EO%IUCK
M<D=S9QK;'Y9M/=BDL.5#_:(@KACM.5#$@CVZBBB@84444 %%%% !1110 444
M4 %%%% !1110!O>&?N7/U7^1K<K#\,_<N?JO\C6Y4%BT444 )W--D^Z:=W--
MD^Z:.HGL?@IXB_Y&#4_^OJ7_ -#-9]:'B+_D8-3_ .OJ7_T,UGU]I'9'X34^
M-A6CX=T.?Q-X@TS2+9HTN=0N8[6)IB0@9V"@L0"0!G)P#Q6>>@IT;M&P='*.
MI#!@<$8Y!_ T^A,;7U/</"OCK0_"GAOPSI^MZYXIT9=-U :E:OX;BCD@O52:
MX1IT,DL+02N',6]T=@L297'RUY5X\U1M=\;:]J3:4-#-[?3W']F*I46N]RWE
M $#[N<=!TKUZV^*FOP^%=!O_ !!\;/B#:7%Y#*4MM%1[I(0DSJ4EE:^A)EXW
M8P<(\?..!YSXAUB.S^,-[JD^HZW<0QZR;F345Q9ZFZB7<902/W<Y^\#C ;MQ
M7+3OSMV/6KI>SBEHM#K/ \WPQB\(V%QK<.CSZZD+VXL[IM30S7#SG;/=O"=H
MMXH2I"P8E9NHP.?.?&UG9:;XPURUTT8TZ*]F2V^25/W0<[/EE D QCAQN]>:
M^DO!VN:MK'AOP[#X%L_BUJ6F.94DM_#_ (UB":=*UPY(G6*Q^3=GS-\VT$.<
M$A6(^?\ XNW,5Y\5/%\\%T+Z"35KIX[E;@7 E4RMAO-  ?(YW#KUI4[N;N/$
MI>Q@EKM^1R5)2FDKK/&%;M]*[SX]_P#)=OB-_P!C)J7_ *525P;=OI7>?'O_
M )+M\1O^QDU+_P!*I*R?Q_+_ ".J/\"7JOU."HHHK9G*%%%%( HHHH *6DHH
M&&%_N@#O_G^M.!'ISW..O^?\/2FT4K(?,SJOAQX^E^&OB/\ MFUTK3]6G^RS
MV@AU(3>4JS1F*0CRI(VR8V9?O8&XG&0".8FD$DCLL:Q*Q)")DA<YX&23CMR2
M?K3**7*D[FGM9N*BWH;VC>*ET/1=0LK?2;%KV[1H1JTGG&Y@B9=KQQ@2"+#+
MD$LA;#'!%87&[/OGI_3\:2BGRH3J3>[%XXQV&/\ /Z_G1PIRH /TI**+(7M)
M]Q>.WX>U*&[=NE-HHMI8GF;W%X_'.<CC\?K1P#ZC_/:DHHLA\\NXOZ_7O^/6
MCCK[YI**.5#]I/N+QR.V,'T-+QW&>,4VBBR)YGW%I***8@HHHH$%%%% !111
M0!^C_P#P3G_Y(/K'_8R7/_I+:5]25\M_\$Y_^2#ZQ_V,ES_Z2VE?4E?+8C^*
MS]CRG_<J?H%%%%<IZH4444P"BBB@ HHHH **** "ES_G_/7_ #]*2B@ &/3]
M?TXQ_GM2YY!'4?Y_"DHH !GUQVS_ %K \6>%7\3"QDMM:U+0+NRE,L5UIK1$
M\HR%626.2-AANI3</X2N3G?HHN!E>'/#L/ANQ>!;BXOYYI#/<7MX4,UQ*0 7
M?8JKG"@850H    K5YYYSGJ3W_S_ %HHH /7''^?\_YXHHHH **** "BBB@
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MK.2)'4<!FSD@>M?;O_#JASC_ (N<,9R1_8'_ -TT?\.J9#R?B>,]_P#B0?\
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MOOS_ (=4R?\ 13A_X(/_ +IH_P"'5,G_ $4\?^"#_P"Z:T^O4.YS_P!A8_\
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MD_Z*>/\ P0?_ '31_P .J9/^BGC_ ,$'_P!TT?7J'</["Q_\GXH^ Z*^_/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M(+"7EE[!:_83W=-X"%Z3;CF'-[GM*S<9RG/L2]&Y\9_TRO-U?FDY8'JJ;-B
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4(H]NW[76KYP     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
MB5!.1PT*&@H    -24A$4@  !?\   '%" 8   !,R8/W    "7!(67,  "XC
M   N(P%XI3]V   @ $E$051XVNS=88R;UWWO^9\-$QAI!<PH5E:1<VW2RO6X
MMF\S%)4V\3KV4.X-[33%S/BJBZ3)!$,GW:*-]T;T3;O9BV)'M/JFQ=Z%Z.+>
MW3>]$(7J+K 7R#4E;#<I<1MSFJ:I-]<T)XWC1DXE3M)8-NZXF@&\]@!\X7WQ
M'$HDAS/BS)#/<\YYOA]@8,]8%CGG/,_A\_S.>?[GMO???U\          , ?
MM],$          #XA? ?          #/$/X#         . 9PG\
M #Q#^ \         @&<(_P$         \ SA/P          GB'\!P
M  # ,X3_          !XAO ?          #/$/X#         . 9PG\
M     #Q#^ \         @&<(_P$         \ SA/P          GB'\!P
M      # ,X3_          !XAO ?          #/$/X#         . 9PG\
M         #Q#^ \         @&<(_P$         \ SA/P          GB'\
M!P        # ,X3_          !XAO ?          #/$/X#         . 9
MPG\          #Q#^ \         @&<(_P$         \ SA/P
MGB'\!P        # ,X3_          !XAO ?          #/$/X#
M . 9PG\          #Q#^ \         @&<(_P$         \ SA/P
M    GB'\!P        # ,X3_          !XAO ?          #/$/X#
M     . 9PG\          #Q#^ \         @&<(_P$         \ SA/P
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M%+SSWH:N_,,UO?GV=5TS$P5[L*)@(J BJ7:I=&:-(PW ;G@2]O<B_ <
M6(7P']XPF_)F)<UIERO[VR'_1^^[]\:*_<Z5^:Y[[<K*C8F!'[Q^=:^3 LL*
M)@(JETIG&AR! +:S.C_9'I^S\K/,&N$_     , JA/]PVDQAL1TDS6F'*T<[
M@_X'/Y)2\J[#VC\V%KLV;#\M\*._;^K*S]_43W[VQFXF!-9U<R*@PI$)P-3M
M[QRCQSW_E0G_ 0    !6(?R'<TS@W_X:.$PZ<N=!34T>U3_[IRD]>#1E5;D>
MVZQ>7]>/KC1UU3PA\/K/WMCI7W%1-R<#* \$Q&7LN!GXSTF:C=FO3_@/
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M9/HA??P7?T'''[R?QK/,RS_Z\4XG LXKF 2HT7J G5;G)[,*0O\%6F-+A/\
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MC>F)AX_K,X]^0H<.4ET"@7<W-O3-[[RD;WS[N[<J"<0D +!+A/XC0_@/
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M'9_2'W[URSIRY\'>_]3>!R!/*V$O5N<GLV+E,."41"8WU^_:"I&8DM0PDS$
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M>%(+,T_02, >/79\2G_TU2]OMQ$P=8?1U^K\Y,3J_&3?R5D ]B+X=PX3
M $ /PG_'=03_79M&'M@WIG_[]6?TV''VD@2&Y8&C2?TA$P#8@=7YR2TG9P'8
MB^#?6>?8!!@   "XB?#?829H;*A/\/^'7_VR[CERF$8"ANR>(X?U)Z?_E>Z[
M^Z[>_S0N)@#0H2/X9Q86<$@BDYL3P;_+:DP       '"?T>9@+$F*=GY\_ON
MODM_<OI?$?P#([1_;$Q_\$R>"0!LB> ?<),)C<NTA-/&%4P I&@*    Q-UM
M[[__/JW@F([@?[SSY_?=?9?^X)D\&_L"(?K?_Z^+^M;W7N[]\;JD_*72F0HM
M%#^K\Y-I217U3,[">TN'+ES.T@SN2F1R$Y*:O==7CEN6M-;Q?:WGOW<>LQ/R
M:\)R65*V5:^N<73'XOP-ZZ;V1*M>K='B  # %7?0!&XA^ ?L\I7/!J7<>R8
MQB6],%-8?/I2Z4R95HH/$_QO&J,!.,'E<W?)O/^FI.9>PDDS"9*6E#+_3$N:
M=K!-IA0\Q3''H0T  ("X8N6_0[8*_I]\^/B- !) -+9X D"2F "("8+_V&/E
MO\,2F5Q9TH)#;WE9P1-&M;!6(2<RN:R"(#TKMYX0>+95KY8XRKT_AUGY#P
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M / ;P3_@-E/NY[1E;VM%04F1.9="_UZM>K71JE>SDIY64/;.)N5$)C?!&0
M ("X(/RW4$?PWQ4JW7?W703_@$.VF0 HF_,<[BJ)X!]P6=FR]W->04WZFB\-
MW*I7RY)2"IYDL,6X&;\!  " 6"#\M_>&=%/P_P?/Y&D9P#%;3 !,*7@"@ D
M!ZW.3Y8E+= 2@)L2F5Q>TK0E;V==TM.FQ(]WF]&VZM4ULQ_ LQ:]K06S23$
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MV8[P?T1F"HMSZJDA_6CZ(1U_\'X:!\! [CER6 N?^97>'T]3_F?O3+D?+JH
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M+.;5\ZC.9Q[]! T#P&H?>^A^'=@WIG?>VVC_:%S!4TQ%GW[/U?G)E'HV8P>
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M $Z8_MA'-]V@>[#Q;YZ>!=!'%.$-0<?H92-XS>9>_X)6O5J1=#%F?954\"1
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M[/VQ,V&Z*?DS2T\"N(5:1*^;I^F';LZW8ZA5KS85/ %P/J9]VIX 2'%X P
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M_/F85C2KLU=,R9X]:]6K#44S$36;R.3*#O1O+:*7+W.& =N*8NR=DE2)RP2
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M4?6OQ*I_8%!135RV2P!Y=V^=R.3RB4RNJ:#<6;+/'^%)SPYQ7?G?=2/%9K\
MXN[H/SD2Y8U^E]7YR0FQV2^ <,PINB#I5A9T<Q+ VINV1":7-77]KYKW;*,5
MA5OJ*6L^QT[+CTD )N0=9%9#UB*\IBJ-Z$F;4H3-.BM+@C13XN+%"/MW/>*^
M %Q2CO"UVQ, >1\:<H#0OXWPOP/AO]CL%P#^VP\<M.E&GY !0"A,^1_;;PX6
M)+V2R.0:B4RN8,/3 &:5?\'<?+THN^KZ]Q-*N9\M[C4Z)P%*KI5T,BN+DR&>
MDS5&ICWWV81Y"N><_ R&2XIVTG;*C,G%B/HWG<CDVB4NHE0*>5P%7+_>/!_A
M6QB7=,[5TI+MFOX#AOXW?F=?)CR&(:[A?[;SFP]^@%)0 .(M==>FNO]17A00
M_@,(\X:L'/$-V:"F))U5\#1 >R(@M/'2K/ OFM#IJGDO20?:[;D( N7T%C?>
MIW3S:8ZL(Z=(,<376G&@/:R^<30;;;<W/(S2R()A\_?:L.+\="*3:X85+O64
M5IN*^'=GU3]@]^?I5F8E-5QY(M%<>Y8E75<PX9ETL,VM<$=,?^]4YS=L]@L@
M[I*;P_\H;RI2] B D!44!+93CKS?]D2 $IG<NH*PKZ9@8];F7L-N$TRG3)ND
M96<-_T%<-'L[1-$_VUE04#]\14& 5K9Q!:VYX0ZS[VL.'%,O)#*Y\Y**9B6G
M+7V551!RV'"NMH_K42HI*.45]01D4L%JVN*HSF73MWG955:MR*I_8&=:]6HS
MD<D]KV A0)3:3R06$IE<>]RRZ?,L9<:\88SQR40FE^6IPOB&_UT'T -'DP*
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M>SPN.B<!\F:,=FU\/F_&6JZ!@'A=6Q;-^)4WX]>T9[_FLOD<J_ YMG.$_P
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MV>TT 0  \-'J_&2:5@      Q!7A/P  \%66)@      Q!7A/P  \%66)@
M    Q!7A/P#@AI]>>ZOW1RNT"APVNSH_F:(9      !Q1/@/ +CA_WMOH_='
M35H%CLO3!     " .(IU^/_NQ@9'  #8HT$38 0*J_.3$S0#     "!NXA;^
MUSJ_:?[\38X  +#'&DV $1B75*09      !Q0]D? , -/!$%3YU:G9_,T@P
M    @#@A_ < W-#GB2A*\< 79<K_      #B)&[A?U=)B;?^D0H3 +"3<7/$
MF&C *"4EU9@       #$1=S"_ZY@Z:VWKW,$ ( E#EVXS(PL1FU*3
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M) "(O3Z3H5&4X*E).DUO $# A/US"L+^K*2H'EF=,E^S'>]MQ5Q;UR15F P
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M/0DP07,     PT?X+^F__B/A/X!XZS,)VHSP[=3H$0 ^(/0?R(*"<D!%F@(
M   8KKB&_\W.;W[P^E6.! "Q=O7G;_;^J&;+& T KDED<A,FS&Z(T'\0XY).
M)S*Y9B*3R](<    P'"P\E_2FVSZ"R#FKOS#M=X?-:-Z+X<N7&[2(P!<9<+K
MAJ33BE]-_[U*2GK1; I,*2    !@CV(9_E\JG:EU?G_M[>MZ=V.#HP% ;+W^
MLS=Z?]2(^"TMT2L 7&)6^U<DO:@@Q,;NG9+4X"D     8&]NC_'OOMSYS<H;
M;W$T (BEU>OK>N>][@G02Z4S48?_#7H&@"L2F=R<@B>F9FF-H6D_!5"D*0
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M A F@G^GG4MD<FF: 0    @0_O<$2]?>OJ[5Z^NT"@#OO;)YLK-FVWND[C^
M")1%\._TM3T3     $ @]N'_I=*93<'2]U_],4<& *^]_*--X]SZI=*9AJ5O
MMT:/ 0B#V3AVEI9PVKBDLGF" P   (BU.V@"24&IBQLKO'[XDZOZ]"=_F58!
MX*T?_J39;QRT>8P^1:\!&"53+W[!\5]C65)34D/2FOFG)#5;]6ISB]][0E)[
MI7S[W]O_3"L(TUTSI> )CCF.;    ,09X7^@(NET^YOO-%[5,QL;VC\V1LL
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MNUPJG5E3SR/*E/X!X(L_^\[?]/[(I9(_;25Z$L 0QI%Q2][+14EIG\-J\Q3
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MJW-0,FM6, # R!'^;R_?^8>KM25]N/P1K0(@$.XVF[IX9:'[X3 %YK/FRP<
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M!DGOGY^..O8-]-CTJ#\+4V[,S[TYUDW?D_>X[UF3E(TD4K-R!S^\'-QA]C^
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MS8;H7I3_(?P'L 'A_X@4G9S3W;&?>_,=75]JT#@ ^D*YG]&)%FIE22=I"0!
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M8" H_)B=G*39$7(L2P9\$DFD\I:^-.K)!T.,)@! ^&^!HI.;E33=^=B=>VY
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MZO39.5V\LM#]<$-2TFS\C8"(%FII,0  V*[LPW-.4OH' ##JZYLEP?L^/@H
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M ,* 8!'HTJJ4ULP^+W[?^TU(*D<2J;C'UYUU#][WNB1*#.T-]R( "/^#A $
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MZJU5*7EYWY$,81/&.8HPY'-R3>Y,=1M6?CJ11"H^PO?J9?^3YN@"@,$1_H?
M5@, =^XU]0??.J5+"V1.P%Y=7VKH&\^]J.7;J]V_:L@-_JNT$GJ)%FIK8@
M\(W9^'?>QY<P(6F6F8N]F=FIC^_PUR@#M#6O0L;)$ [ <#QA5-><M 4O94)2
M><37'J]6.60XL@!@<(3_(5%T<NUP:=.7VZ=?.J>9XO=I)&! EQ86]?7G7M2=
M>YOVTEB4%"?XQTZBA=I:M%"+RX[-X(!QE/7Y^2?E[_X#5C*S4L_T^=<I ]2;
ME_<@4R$Z]F)R]^4 AJY5*<U*>L*"ES+J 8"R1^]COP=EC  @M C_0Z3HY-:*
M3BZI'N'2N3??T;?S9]D(&-BETV?G]/1+YWK]:D[NC/\U6@G]BA9J:4DG:0G
M6Z8\P;S/+^-P))'*\VFX3/!?'N"?4@9H(R_#_W2(VHU9_QCU=<>1'9,^1CGX
M7/;P?60YJ@!@,(3_(51T<FGUF&EPN7I-3YW*LP\ T(>[S::>?.8%7;RRT.O7
M,T4G-T7PCT%$"[6,I&E: O"<#<'!408 -@3_$P/^7U &Z#XOP__)4=80]QAE
M1#!RK4HI+3O*/HYJ\+GLX7O8'TFDLAQ5 +![A/\A571RCJ2OJ*L.Z(V;M_2-
MYUYD'P!@&]>7&OJ]$W_2:V-?29HV VS P**%6E[2H[)C0SA@+%@R^U\:\P&
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M*8Q"M%!;BQ9J4^JQ5PN D<C*GI);DW(' -)A;>Q((K4ODDC-2GIVQ$\USF6
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MMC_A?PCZ[E&%_^9]E&7'Y(Y%2<E!!P LO9;.2<KO93!X2)]Q3.YJM/20^ZG
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M;^DWO\P$'(S6]:6&_OS5"[IQ\]9V7RXS12<W2VMA7*P<.;!M'XV1(OP/&08
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MZ).T!K G4^;: KM-CWI3V8#*RET)"2!@6I521M*<!2]E0E+>;%Z[V_=0ESL
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M.7+@TY(^,\ __7_10NT.+0@     L 7A/P          (?-3- $
M .%"^ \         0,@0_@,         $#*$_P          A SA/P
M    (4/X#P        ! R!#^ P         0,H3_          "$#.$_
M       A0_@/         $#($/X#         ! RA/\          (0,X3\
M         "%#^ \         0,@0_@,         $#*$_P          A SA
M/P          (4/X#P        ! R!#^ P         0,H3_          "$
M#.$_           A0_@/         $#($/X#         ! RA/\
M (0,X3\          "%#^ \         0,@0_@,         $#*$_P
M    A SA/P          (91C!!8   %0241!5$/X#P        ! R!#^ P
M       0,H3_          "$#.$_           A0_@/         $#($/X#
M         ! RA/\          (0,X3\          "%#^ \         0,@0
M_@,         $#*$_P          A SA/P          (4/X#P        !
MR!#^ P         0,H3_          "$#.$_           A0_@/
M $#($/X#         ! RA/\          (0,X3\          "%#^ \
M    0,@0_@,         $#*$_P          A SA/P          (4/X#P
M      ! R!#^ P         0,H3_          "$#.$_           A\_\!
43J)/5%H;?]4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794567792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioNTech SE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">2M<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">An der Goldgrube 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D-55131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,725,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001776985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember', window );">American Depositary Shares, each Representing one ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each Representing one ordinary share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember', window );">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#8364;1*<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">An der Goldgrube 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D-55131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Mainz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Prof. Ugur Sahin, M.D.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6131-9084-0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">+49 6131 9084-390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@biontech.de<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788789499040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EY GmbH & Co. KG Wirtschaftspr&#252;fungsgesellschaft<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Cologne, Germany<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793418832">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Profit or Loss - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,819.0<span></span>
</td>
<td class="nump">&#8364; 17,310.6<span></span>
</td>
<td class="nump">&#8364; 18,976.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(599.8)<span></span>
</td>
<td class="num">(2,995.0)<span></span>
</td>
<td class="num">(2,911.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,783.1)<span></span>
</td>
<td class="num">(1,537.0)<span></span>
</td>
<td class="num">(949.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(62.7)<span></span>
</td>
<td class="num">(59.5)<span></span>
</td>
<td class="num">(50.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(495.0)<span></span>
</td>
<td class="num">(481.7)<span></span>
</td>
<td class="num">(276.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(293.0)<span></span>
</td>
<td class="num">(410.0)<span></span>
</td>
<td class="num">(103.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">815.3<span></span>
</td>
<td class="nump">598.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">690.4<span></span>
</td>
<td class="nump">12,642.7<span></span>
</td>
<td class="nump">15,283.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">519.6<span></span>
</td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">67.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23.9)<span></span>
</td>
<td class="num">(18.9)<span></span>
</td>
<td class="num">(305.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,186.1<span></span>
</td>
<td class="nump">12,954.1<span></span>
</td>
<td class="nump">15,046.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(255.8)<span></span>
</td>
<td class="num">(3,519.7)<span></span>
</td>
<td class="num">(4,753.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 930.3<span></span>
</td>
<td class="nump">&#8364; 9,434.4<span></span>
</td>
<td class="nump">&#8364; 10,292.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings for the period per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.87<span></span>
</td>
<td class="nump">&#8364; 38.78<span></span>
</td>
<td class="nump">&#8364; 42.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings for the period per share (in euros per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.83<span></span>
</td>
<td class="nump">&#8364; 37.77<span></span>
</td>
<td class="nump">&#8364; 39.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3,815.5<span></span>
</td>
<td class="nump">&#8364; 17,194.6<span></span>
</td>
<td class="nump">&#8364; 18,874.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember', window );">Research &amp; development revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.5<span></span>
</td>
<td class="nump">&#8364; 116.0<span></span>
</td>
<td class="nump">&#8364; 102.7<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790913616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="nump">&#8364; 930.3<span></span>
</td>
<td class="nump">&#8364; 9,434.4<span></span>
</td>
<td class="nump">&#8364; 10,292.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="num">(19.8)<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods</a></td>
<td class="num">(19.8)<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Net gain on equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement gain on defined benefit plans</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss) for the period, net of tax</a></td>
<td class="num">(15.8)<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income for the period, net of tax</a></td>
<td class="nump">&#8364; 914.5<span></span>
</td>
<td class="nump">&#8364; 9,456.7<span></span>
</td>
<td class="nump">&#8364; 10,301.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794560272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 362.5<span></span>
</td>
<td class="nump">&#8364; 61.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Other intangible assets</a></td>
<td class="nump">804.1<span></span>
</td>
<td class="nump">158.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">757.2<span></span>
</td>
<td class="nump">609.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">214.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">1,176.1<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-financial assets</a></td>
<td class="nump">83.4<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">81.3<span></span>
</td>
<td class="nump">229.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">3,479.0<span></span>
</td>
<td class="nump">1,357.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">357.7<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">2,155.7<span></span>
</td>
<td class="nump">7,145.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">4,885.3<span></span>
</td>
<td class="nump">189.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other non-financial assets</a></td>
<td class="nump">280.9<span></span>
</td>
<td class="nump">271.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax assets</a></td>
<td class="nump">179.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">11,663.7<span></span>
</td>
<td class="nump">13,875.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">19,527.3<span></span>
</td>
<td class="nump">21,922.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">23,006.3<span></span>
</td>
<td class="nump">23,279.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">248.6<span></span>
</td>
<td class="nump">248.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">1,229.4<span></span>
</td>
<td class="nump">1,828.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="nump">19,763.3<span></span>
</td>
<td class="nump">18,833.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="num">(984.6)<span></span>
</td>
<td class="num">(848.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">20,245.9<span></span>
</td>
<td class="nump">20,055.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings', window );">Lease liabilities, loans and borrowings</a></td>
<td class="nump">191.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent', window );">Income tax liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">398.5<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Other non-financial liabilities</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">39.7<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">689.9<span></span>
</td>
<td class="nump">272.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings', window );">Lease liabilities, loans and borrowings</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other payables</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">415.2<span></span>
</td>
<td class="nump">785.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Refund liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Income tax liabilities</a></td>
<td class="nump">525.5<span></span>
</td>
<td class="nump">595.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">269.3<span></span>
</td>
<td class="nump">367.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">353.3<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Other non-financial liabilities</a></td>
<td class="nump">125.1<span></span>
</td>
<td class="nump">860.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">2,070.5<span></span>
</td>
<td class="nump">2,950.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,760.4<span></span>
</td>
<td class="nump">3,223.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 23,006.3<span></span>
</td>
<td class="nump">&#8364; 23,279.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentLeaseLiabilitiesLoansAndBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Lease Liabilities, Loans And Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentLeaseLiabilitiesLoansAndBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current Lease Liabilities, Loans And Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity&#8217;s future performance).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794298128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Capital reserve</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Other reserves</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">&#8364; 1,371.8<span></span>
</td>
<td class="nump">&#8364; 246.3<span></span>
</td>
<td class="nump">&#8364; 1,514.5<span></span>
</td>
<td class="num">&#8364; (4.8)<span></span>
</td>
<td class="num">&#8364; (409.6)<span></span>
</td>
<td class="nump">&#8364; 25.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="nump">10,292.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,292.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income for the period, net of tax</a></td>
<td class="nump">10,301.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,292.5<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IssuanceOfShareCapital', window );">Issuance of treasury shares</a></td>
<td class="nump">163.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="nump">59.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="nump">11,893.7<span></span>
</td>
<td class="nump">246.3<span></span>
</td>
<td class="nump">1,674.4<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
<td class="nump">9,882.9<span></span>
</td>
<td class="nump">93.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="nump">9,434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,434.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income for the period, net of tax</a></td>
<td class="nump">9,456.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,434.4<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">67.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RedemptionOfConvertibleNote', window );">Redemption of convertible note</a></td>
<td class="nump">235.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">233.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue', window );">Share repurchase program</a></td>
<td class="num">(986.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(979.5)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(484.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="num">(681.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833.1<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,519.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentAndDeferredTaxExpenseIncome', window );">Current and deferred taxes</a></td>
<td class="nump">554.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2022</a></td>
<td class="nump">20,055.6<span></span>
</td>
<td class="nump">248.6<span></span>
</td>
<td class="nump">1,828.2<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="nump">18,833.0<span></span>
</td>
<td class="num">(848.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="nump">930.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="num">(15.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive income for the period, net of tax</a></td>
<td class="nump">914.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">930.3<span></span>
</td>
<td class="num">(15.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue', window );">Share repurchase program</a></td>
<td class="num">(738.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(731.6)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payments</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentAndDeferredTaxExpenseIncome', window );">Current and deferred taxes</a></td>
<td class="num">(104.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination', window );">Treasury shares used for acquisition of business combination</a></td>
<td class="nump">103.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.6<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2023</a></td>
<td class="nump">&#8364; 20,245.9<span></span>
</td>
<td class="nump">&#8364; 248.6<span></span>
</td>
<td class="nump">&#8364; 1,229.4<span></span>
</td>
<td class="num">&#8364; (10.8)<span></span>
</td>
<td class="nump">&#8364; 19,763.3<span></span>
</td>
<td class="num">&#8364; (984.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentAndDeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current And Deferred Tax Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentAndDeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IssuanceOfShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IssuanceOfShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RedemptionOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption Of Convertible Note</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RedemptionOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Repurchased During Period, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Shares Used For Acquisition Of Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794349056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit for the period</a></td>
<td class="nump">&#8364; 930.3<span></span>
</td>
<td class="nump">&#8364; 9,434.4<span></span>
</td>
<td class="nump">&#8364; 10,292.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">255.8<span></span>
</td>
<td class="nump">3,519.7<span></span>
</td>
<td class="nump">4,753.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="nump">1,186.1<span></span>
</td>
<td class="nump">12,954.1<span></span>
</td>
<td class="nump">15,046.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile profit before tax to net cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets</a></td>
<td class="nump">183.4<span></span>
</td>
<td class="nump">123.3<span></span>
</td>
<td class="nump">75.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expenses</a></td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">93.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Net foreign exchange differences</a></td>
<td class="num">(298.0)<span></span>
</td>
<td class="nump">625.5<span></span>
</td>
<td class="num">(387.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income excluding foreign exchange differences</a></td>
<td class="num">(519.6)<span></span>
</td>
<td class="num">(265.3)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense excluding foreign exchange differences</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">305.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AdjustmentsForMovementsInGovernmentGrants', window );">Movements in government grants</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(89.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other non-cash income / (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Net (gain) / loss on derivative instruments at fair value through profit or loss</a></td>
<td class="nump">175.5<span></span>
</td>
<td class="num">(241.0)<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WorkingCapitalAdjustmentsAbstract', window );"><strong>Working capital adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets', window );">Decrease / (increase) in trade and other receivables, contract assets and other assets</a></td>
<td class="nump">5,374.0<span></span>
</td>
<td class="nump">4,369.9<span></span>
</td>
<td class="num">(11,808.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventories</a></td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="num">(438.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions', window );">Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions</a></td>
<td class="nump">118.9<span></span>
</td>
<td class="nump">85.7<span></span>
</td>
<td class="nump">1,516.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received and realized gains from cash and cash equivalents</a></td>
<td class="nump">258.2<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid and realized losses from cash and cash equivalents</a></td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax paid</a></td>
<td class="num">(482.9)<span></span>
</td>
<td class="num">(4,222.1)<span></span>
</td>
<td class="num">(3,457.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities', window );">Share-based payments</a></td>
<td class="num">(766.2)<span></span>
</td>
<td class="num">(51.8)<span></span>
</td>
<td class="num">(13.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">5,371.4<span></span>
</td>
<td class="nump">13,577.4<span></span>
</td>
<td class="nump">889.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(249.4)<span></span>
</td>
<td class="num">(329.2)<span></span>
</td>
<td class="num">(127.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets and right-of-use assets</a></td>
<td class="num">(455.4)<span></span>
</td>
<td class="num">(34.1)<span></span>
</td>
<td class="num">(26.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities', window );">Acquisition of subsidiaries and businesses, net of cash acquired</a></td>
<td class="num">(336.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities', window );">Investment in other financial assets</a></td>
<td class="num">(7,128.4)<span></span>
</td>
<td class="num">(47.8)<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities', window );">Proceeds from maturity of other financial assets</a></td>
<td class="nump">1,216.3<span></span>
</td>
<td class="nump">375.2<span></span>
</td>
<td class="num">(375.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(6,954.5)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(566.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of share capital and treasury shares, net of costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">110.5<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from loans and borrowings</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of loans and borrowings</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(18.8)<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments related to lease liabilities</a></td>
<td class="num">(40.3)<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities', window );">Share repurchase program</a></td>
<td class="num">(738.5)<span></span>
</td>
<td class="num">(986.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities', window );">Dividends</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(484.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows from / (used in) financing activities</a></td>
<td class="num">(778.6)<span></span>
</td>
<td class="num">(1,419.3)<span></span>
</td>
<td class="nump">94.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase / (decrease) in cash and cash equivalents</a></td>
<td class="num">(2,361.7)<span></span>
</td>
<td class="nump">12,122.8<span></span>
</td>
<td class="nump">417.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Change in cash and cash equivalents resulting from exchange rate differences</a></td>
<td class="num">(14.5)<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">64.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents', window );">Change in cash and cash equivalents resulting from other valuation effects</a></td>
<td class="nump">164.8<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">13,875.1<span></span>
</td>
<td class="nump">1,692.7<span></span>
</td>
<td class="nump">1,210.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents as of December 31</a></td>
<td class="nump">&#8364; 11,663.7<span></span>
</td>
<td class="nump">&#8364; 13,875.1<span></span>
</td>
<td class="nump">&#8364; 1,692.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdjustmentsForMovementsInGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Movements In Government Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdjustmentsForMovementsInGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Other Valuation Changes On Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Payments, Classified As Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareBasedPaymentsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program Classified As Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WorkingCapitalAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working Capital Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WorkingCapitalAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid by the entity, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire interests in joint ventures (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788792876352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfCorporateInformationExplanatoryAbstract', window );"><strong>Disclosure Of Corporate Information Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock', window );">Corporate Information</a></td>
<td class="text">Corporate Information<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&#8217;s ordinary shares have been publicly traded on the Nasdaq Global Select Market since October&#160;10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech SE is registered in the commercial register B of the Mainz Local Court under the number HRB&#160;48720. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements, which were prepared in accordance with International Financial Reporting Standards (IFRS), present the financial position and the results of operations of BioNTech SE and its subsidiaries, hereinafter also referred to as &#8220;BioNTech,&#8221; the &#8220;Group,&#8221; &#8220;we&#8221; or &#8220;us.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Supervisory Board on March 19, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCorporateInformationExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Corporate Information Explanatory [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCorporateInformationExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCorporateInformationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Corporate Information Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCorporateInformationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793443104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ListOfAccountingPoliciesAbstract', window );"><strong>List Of Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1&#160;&#160;&#160;&#160;Basis of Preparation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepare and publish our consolidated financial statements in Euros and round numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment. </span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.2&#160;&#160;&#160;&#160;Basis of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group controls an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if, and only if, the Group has</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">power over the investee (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, existing rights that give it the current ability to direct the relevant activities of the investee); </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expos</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ure, or rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to use its power over the investee to affect its returns. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, there is a presumption that a majority of voting rights results in control. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether an investee is controlled is re-assessed if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when control is obtained over the subsidiary and ceases when control over the subsidiary is lost. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If control over a subsidiary is lost, the related assets (including goodwill), liabilities, non-controlling interests and other components of equity are derecognized, while any resultant gain or loss is recognized in the consolidated statements of profit or loss. Any investment retained is recognized at fair value.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3&#160;&#160;&#160;&#160;Summary of Material Accounting Policies</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are presented in Euros, which is also our functional currency. For each entity, the Group determines the functional currency, and items included in the consolidated financial statements of such entities are measured using that functional currency. We use the direct method of consolidation and, on disposal of a foreign operation, the gain or loss that is reclassified to the consolidated statements of profit or loss reflects the amount that arises from using this method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions and Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation effects from the translation of operating activities include foreign exchange differences arising on operating items such as trade receivables and trade payables and are either shown as other operating income or expenses on a cumulative basis. Foreign currency translation effects presented within finance income and expenses include foreign exchange differences arising on financing items such as loans and borrowings as well as foreign exchange differences arising on cash and cash equivalents and are either shown as finance income or expenses on a cumulative basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation on Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and the transactions recorded in their consolidated statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current versus Non-Current Classifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities in the consolidated statements of financial position are presented based on current or non-current classification. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An asset is current when it is either: (i)&#160;expected to be realized or intended to be sold or consumed in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;expected to be realized within twelve months after the reporting period, or (iv)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least twelve&#160;months after the reporting period. All other assets are classified as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liability is current when it is either: (i)&#160;expected to be settled in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;due to be settled within twelve months after the reporting period, or (iv)&#160;there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</span></div><div style="margin-top:12pt;padding-left:42.5pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.3&#160;&#160;&#160;&#160;Revenue from Contracts with Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of the Contract</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract is an agreement between two or more parties that establishes enforceable rights and obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer contracts often include bundles of licenses, goods and services. If the granting of a license is bundled together with delivering of goods and or the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment when determining the consideration that is expected to be received. If the consideration in an agreement includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenues reversal in the amount of cumulative revenues recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenues are updated at each reporting date to reflect the current facts and circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allocation of Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling prices. We have established the following hierarchy to determine the standalone selling prices.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where standalone selling prices for offered licenses, goods or services are observable and reasonably consistent across customers, our standalone selling price estimates are derived from our respective pricing history. However, due to the limited number of customers and the limited company history, this approach can rarely be used.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where sales prices for an offering are not directly observable or highly variable across customers, we follow a cost-plus-margin approach.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For offerings that have highly variable pricing and lack substantial direct costs to estimate based on a cost-plus-margin approach, we allocate the transaction price by applying a residual approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required when estimating standalone selling prices.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenues are recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of our licensing arrangements, we provide the licensee with a research and development license, which represents a right to access our intellectual property as it exists throughout the license period (as our intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time as our customers simultaneously receive and consume the benefits from our performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements, are recognized based on the sales-based or usage-based royalty exemption; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the underlying sales occur, which is when the performance obligation has been satisfied. As described further in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> judgment is applied to certain aspects when accounting for the collaboration agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between us and the collaborator and the transactions between us and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenues. Any consideration related to activities in which we are considered the agent is accounted for as net revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from the sale of pharmaceutical and medical products (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) are recognized when we transfer control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and we have not retained any significant risks of ownership or future obligations with respect to the product. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, payments from customers are due within 30 days after invoice. However, with respect to our collaboration with Pfizer Inc., or Pfizer, there is a significant time lag between when revenues are recognized and the payments are received. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#8217;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenues from bill-and-hold arrangements are recognized at the point in time when the customer obtains control of the product and all of the following criteria have been met: (i)&#160;the arrangement is substantive; (ii)&#160;the product is identified separately as belonging to the customer; (iii)&#160;the product is ready for physical transfer to the customer; and (iv)&#160;we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether title and significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If we transfer goods or services to a customer before the customer pays the respective consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable represents our right to an amount of consideration that is unconditional (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., only the passage of time is required before payment of the consideration is due). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability is the obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before we transfer goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(whichever is earlier). Contract liabilities are recognized as revenue when we fulfill our performance obligations under the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refund Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A refund liability is a consideration which has been received but which will need to be refunded to the customer in the future as it represents an amount to which we are ultimately not entitled under the contract. A refund liability is measured at the amount of consideration received (or receivable) to which we do not expect to be entitled (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounts not included in the transaction price). We update our estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.4&#160;&#160;&#160;&#160;Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period in which they are incurred. Regarding internal projects, we consider that regulatory approval and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained. Payments made to third parties, such as contract research and development organizations as compensation for subcontracted research and development, that are deemed not to transfer intellectual property are expensed as internal research and development expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority. We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset unless the respective intellectual property is mainly used as part of our general ongoing research and development activities without any intent to market the respective product as such. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. Sales-based milestone or royalty payments incurred under license agreements after the approval date of the respective pharmaceutical product are recognized as expenses in cost of sales as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent internal research and development costs in relation to intellectual property rights are expensed because the technical feasibility of the internal research and development activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the second quarter of 2023, we had assessed that inventory produced prior to successful regulatory approval did not meet the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because it is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. If regulatory approval for a product candidate is obtained, the relevant write-down would be reversed to a maximum of the original cost. Subsequently, inventory is recognized as cost of sales. This reassessment has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses are described in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government grants and similar grants which are accounted for in accordance with IAS 20 are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs for which the grant is intended to compensate are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated statements of profit or loss </span>over the useful life of the underlying asset subject to funding.<div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Income Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed by tax authorities, excluding interest expenses and penalties on the underpayment of taxes. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities are recognized for all taxable temporary differences, except: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recognition of Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and deferred tax items are recognized similarly to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax assets and current tax liabilities are offset if, and only if, we have a legally enforceable right to set off the recognized amounts and intend either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when we have a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Tax Legislation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting (BEPS) project to tackle tax avoidance, the OECD/G20 Inclusive Framework (an association of about 140 countries) decided to introduce a global minimum taxation for large multinational groups (known as Pillar 2). The Global Anti-Base Erosion Rules are intended to ensure that large multinational groups pay a minimum level of tax on the income arising in each jurisdiction where they operate. In December 2021, the OECD published its Model Rules, which serve as a draft bill for implementation into national domestic law, followed by guidelines and commentaries published in March 2022. In December 2022, the EU adopted a corresponding directive (EU 2022/2523) that obliges EU member states to transpose the rules into national domestic law. If the effective tax rate in any jurisdiction is below the minimum rate (15%), the Group may be subject to the so-called top-up tax or a so-called qualified domestic minimum top-up tax. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several jurisdictions in which the Group operates have transposed the OECD Model Rules into national domestic law and brought them into force. In addition, the Group is closely following the progress of the legislative process in each country in which the Group operates. As of the balance sheet date, the BEPS Pillar 2 regulations (MinBestRL UmsG) had already been transposed into German law (MinStG). The date of application of the law in Germany is for financial years beginning after December 30, 2023. Subsequently, as the OECD Model Rules have entered into force in Germany, the Group is obliged to file top-up tax information returns for all entities which are part of the Group, beginning in financial year 2024. The Group falls within the scope of these regulations. The Group carried out an analysis as of the reporting date to determine the fundamental impact and the jurisdictions in which the Group is exposed to possible effects in connection with a Pillar 2 top-up tax.</span></div>Based on this analysis, no countries were identified in which the Group would be materially affected by a Pillar 2 top-up tax. Consequently, the average effective Group tax rate would not have changed if the Pillar 2 legislation had already been in force on the balance sheet date. BioNTech applies the exception in IAS 12, according to which no deferred tax assets and liabilities in connection with the second income taxes of the second pillar of the OECD are recognized and no disclosures are made.<div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.7&#160;&#160;&#160;&#160;Business Combinations and Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to executing business combinations are recognized when they are incurred and are classified as general and administrative expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.10. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in these circumstances is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the consideration in in-licensing agreements paid by us to acquire intellectual property is recognized as an intangible asset. If in-licensing includes research and development services, the share of consideration attributable to these services is deferred and recognized in research and development expenses according to the utilization thereof. Payments depending on the achievement of specific milestones as part of the purchase of intangible assets, except for intangible assets acquired in a business combination, are recognized as subsequent acquisition cost of the intangible asset and as a financial liability once the milestone is reached.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of intangible assets are assessed as either finite or indefinite. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each reporting period at the least. The amortization expense on intangible assets with finite lives is recognized in the consolidated statements of profit or loss in the expense category that is consistent with the function of the intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intellectual property rights</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8-20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licenses</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-20</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Software</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-8</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2.3.10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details). In the case of intangible assets not yet available for use, the point in time from which a capitalized asset can be expected to generate economic benefit for the Group cannot be determined. Such assets are not amortized, and therefore classified as having an indefinite useful life. The intangible assets not yet available for use are tested for impairment annually, or when there is an indication for impairment on an individual basis. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified advanced payments on intangible assets as intangible assets that are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An intangible asset is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2.3.4 for further details in connection with our accounting of internally generated intangible assets.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is stated at cost. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Property, plant and equipment</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10-33</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7-18</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and business equipment has a useful life of 1-10 years and is reported under equipment, tools and installations due to immateriality. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An item of property, plant and equipment initially recognized is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss when the asset is derecognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Non-Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, we assess whether there is an indication that a non-financial asset may be impaired. Goodwill is tested for impairment at least annually. Impairment is determined for goodwill by assessing the recoverable amount of each cash-generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, we estimate the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the asset does not generate independent cash inflows, the impairment test is performed for the smallest group of assets that generate largely independent cash inflows from other assets (CGU). When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or the non-current assets of the CGU are considered impaired and written down to their recoverable amount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses are recognized in the consolidated statements of profit or loss in expense categories consistent with the function of the impaired asset.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with an indefinite useful life are tested for impairment annually at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets not yet available for use are not amortized, but rather tested for impairment when a triggering event arises or at least once a year. The identification of triggering events takes place on a quarterly or on an ad hoc basis with the involvement of the responsible departments, taking internal and external information sources into consideration. The impairment test is performed annually or if there are indications of impairment by determining the asset&#8217;s value in use. In assessing value in use, the estimated discounted future cash flows are based on long-term forecast calculations reflecting the asset&#8217;s estimated product life cycles. The assumptions are based on internal estimates along with external market studies. The result of the valuation depends to a large extent on the estimates by the management of the future cash flows of the assets and the discount rate applied, and is therefore subject to uncertainty.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i) Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Recognition and Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets mainly include money market funds, bank deposits and reverse repos, security investments, trade receivables, cash at banks as well as equity investments. Financial assets are initially measured at fair value as of the trade date and &#8211; depending on their classification &#8211; subsequently measured at amortized cost, fair value through other comprehensive income (OCI) or fair value through profit or loss. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of financial assets depends on their classification, as described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Measured at Amortized Cost</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost include trade receivables and other financial assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are generally measured using the effective interest rate (EIR) method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to trade receivables, we applied the practical expedient, which means that they are measured at the transaction price determined in accordance with IFRS 15. Refer to the accounting policies in Note&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other financial assets measured at amortized cost are held to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in our consolidated statements of profit or loss when the financial asset is derecognized, modified or impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Designated at Fair Value through OCI (Equity Instruments)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon initial recognition, we can irrevocably elect to classify equity investments as equity instruments designated at fair value through OCI if they meet the definition of equity under IAS 32 and are not held for trading. The classification is determined on an instrument-by-instrument basis. Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the consolidated statements of profit or loss when the right of payment has been established. Equity instruments designated at fair value through OCI are not subject to impairment assessment. We elected to irrevocably classify our non-listed and listed equity investments under this category. They are recognized using trade date accounting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets at Fair Value through Profit or Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments are measured at fair value through profit or loss. A financial asset exists if the derivative has a positive fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, removed from the consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for expected credit losses (ECLs) is considered for all non-derivative financial debt investments, including cash, time deposits and debt securities of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our financial debt investments are considered to be investments with low risk, the expected credit loss in the upcoming twelve months is used to determine the impairment loss. Wherever a considerable increase in the default risk is assumed, the lifetime expected credit loss of the financial asset is considered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. This means that the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. We have established an ECL model that is based on the probability of default (PD), considers the respective country default probabilities and takes the maturities into account. In order to determine the PD of companies, we use the maturities of the trade receivables and the score of the companies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is objective evidence that certain trade receivables or contract assets are fully or partially impaired, additional loss allowances are recognized to account for expected credit losses. A debtor&#8217;s creditworthiness is assumed to be impaired if there are objective indications that the debtor is in financial difficulties, such as the disappearance of an active market for its products or impending insolvency. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii) Financial Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are generally measured at amortized cost using the effective interest rate (EIR) method. Derivatives with negative fair values not designated as hedging instruments and liabilities for contingent consideration in business combinations are measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities measured at amortized cost include loans and borrowings, trade payables and other financial liabilities. They are measured at amortized cost using the EIR method. Gains and losses are recognized in the consolidated statements of profit or loss when the liabilities are derecognized as well as through the EIR amortization process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iii) Expenses and Income from Exchange Forward Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effects from foreign exchange forward contracts, which are measured at fair value through profit or loss, are shown as either other operating income or other operating expenses on a cumulative basis and might switch between those two items during the year-to-date reporting periods.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, we determine whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of fair value disclosures, classes of assets and liabilities have been determined on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost and net realizable value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw materials and supplies: purchase cost on a first-in / first-out basis; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale. Write-offs are recorded if inventories are expected to be unsaleable, do not fulfill the specification defined by our quality standards or if their shelf-life has expired. For our inventories subject to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the collaboration partners&#8217; gross profit share mechanism</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we consider the contractual compensation payments in the estimate of the net realizable value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained (see also Note 2.3.4 for further information on our assessment regarding the potential of our pre-launch products to produce economic benefits).<div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div>Cash and cash equivalents comprise cash at banks and on hand and short-term investments that we consider to be highly liquid (including deposits, money market funds and reverse repos) with an original maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Deposits with an original maturity of more than three months are recognized as other financial assets.<div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the par value method to our repurchases of outstanding American Depositary Shares, or ADSs. Accordingly, the nominal value of acquired treasury shares is deducted from equity and shown in the separate item &#8220;Treasury shares&#8221;. Any premium paid in excess of the nominal value of a repurchased ADS is deducted from the capital reserve. On the trade date, we recognize a liability, and on the settlement date, we settle in cash. We recognize the foreign exchange differences that may occur between the trade and settlement date as profit or loss.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset &#8211; this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the asset. We possess this right when we hold the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have the right to operate the asset; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we designed the asset in a way that predetermines how and for what purpose it will be used. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception or on reassessment of a contract that contains a lease component, the consideration in the contract is allocated to each lease component on the basis of their relative standalone prices. However, for leases of land and buildings in which we are a lessee, we have elected not to separate non-lease components, and instead account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the incremental borrowing rate is used as the discount rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability comprise the following: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fixed payments, including in-substance fixed payments;</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts expected to be payable under a residual value guarantee; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exercise price under a purchase option that is reasonably certain to be exercised, lease payments in an optional renewal period if it is reasonably certain that the extension option is exercised, and penalties for early termination of a lease unless it is reasonably certain that the contract will not be terminated early.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is subsequently measured at amortized cost using the EIR method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if we change our assessment of whether we will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the consolidated statements of profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets are presented separately and lease liabilities are presented under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:77.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life or shorter lease term (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-25</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-5</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-3</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Automobiles</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-4</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Leases and Leases of Low-Value Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. We recognize the lease payments associated with these leases as an expense in the consolidated statements of profit or loss on a straight-line basis over the lease term.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When we expect some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A provision is also recognized for certain contracts with suppliers for which the unavoidable costs of meeting the obligations exceed the economic benefits expected to be received. The economic benefits considered in the assessment comprise the future benefits we are directly entitled to under the contract as well as the anticipated future benefits that are the economic consequence of the contract if these benefits can be reliably determined.</span></div>The expense relating to a provision is presented in the consolidated statements of profit or loss net of any reimbursement.<div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions) or in cash (cash-settled transactions). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IFRS 2, share-based payments are generally divided into cash-settled and equity-settled. Both types of payment transactions are measured initially at their fair value as of the grant date. The fair value is determined using an appropriate valuation model, further details of which are given in Note 16. Rights granted under cash-settled transactions are remeasured at fair value at the end of each reporting period until the settlement date. The cost of share-based payment awards is recognized over the relevant service period, applying either the straight-line method or the graded vesting method, where applicable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves) or other liabilities, over the period in which the service is provided (the vesting period). The cumulative expense recognized for cash- and equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired, and also reflects the best estimate of the number of equity instruments expected to ultimately vest. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of our best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have a choice of settling either in cash or by providing equity instruments, the rights granted are accounted for as an equity-settled transaction, unless there is a present obligation to settle in cash. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, due to local tax regulations, an amount is withheld for the employee&#8217;s tax obligations and paid directly to the tax authorities in cash on the employee&#8217;s behalf, the entire share-based payment program remains an equity-settled plan based on the IFRS 2 classification. Accordingly, the amount withheld for the employee&#8217;s tax obligations expected to be paid directly to the tax authorities is reclassified from &#8220;Other reserves&#8221; to &#8220;Other non-financial liabilities&#8221;.</span></div><div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.3.19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividend</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a liability to pay a dividend when the distribution is authorized. As per the corporate laws of Germany, a distribution is authorized when it is approved by the general shareholder meeting. A corresponding amount is recognized directly in equity.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.4&#160;&#160;&#160;&#160;Standards Applied for the First Time</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:80.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IFRS 17 Insurance Contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#8211; Comparative Information</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income taxes: International Tax Reform &#8211; Pillar Two Model Rules</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr></table></div><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.5&#160;&#160;&#160;&#160;Standards Issued but Not Yet Effective</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:75.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.733%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>We do not expect a significant impact from the application of any of these standards and amendments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ListOfAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>List Of Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ListOfAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793056800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract', window );"><strong>Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Accounting Judgements, Estimates and Assumptions</a></td>
<td class="text">Significant Accounting Judgements, Estimates and Assumptions<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant accounting judgments, as well as key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. We based our assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts with Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We applied the following judgments, estimates and assumptions that significantly affect the determination of the amount and timing of revenues from contracts with customers:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identification and Determination of Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract is an agreement between two or more parties that establishes enforceable rights and obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of each agreement, we apply judgment when determining which promises represent distinct performance obligations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, we assess which of these promises is the predominant promise to determine the nature of the performance obligation. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When licenses are granted, we determined that the grant of the license is the predominant promise within the combined performance obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In our view, we grant our customers a right to access or a right to use our intellectual property due to the collaboration and license agreements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of the Transaction Price</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements often include variable consideration, which is contingent on the occurrence or non-occurrence of a future event (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reaching a certain milestone). When determining deferred revenues from a collaboration and license agreement, we need to estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to our customers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As there are usually only two possible outcomes (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, milestone is reached or not), we have assessed that the method of the most likely amount is the best method to predict the amount of consideration to which we will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">zero</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, we use judgment to determine when to include variable consideration in the transaction price in such a way that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. We have concluded that future milestone payments are fully constrained at the end of the current financial year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future milestone payments would become unconstrained upon the satisfaction of the milestone event, specifically a development event, regulatory approval or achievement of a sales milestone.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are Satisfied</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on our best estimates and interpretations of facts and circumstances of each contractual agreement and may require significant judgment to determine appropriate allocation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and reimbursement for expenses are initially deferred on our consolidated statements of financial position. We assessed that no significant financing component exists within our collaboration agreements since the overall business purpose of advanced payments is to support the payment structure rather than to provide a significant benefit of financing. For performance obligations in which the costs vary based on progress, an input-based measure that takes into account cost incurred is the most reliable indicator of the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may be the most reliable indicator of our performance toward complete satisfaction. If the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. We evaluate the measure of progress in each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net profit or loss in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal-Agent Considerations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under our current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner acts as a principal in each case. We recognize revenue net based on the collaboration partners&#8217; gross profit in territories where the partner is responsible for supply, and on a gross basis when directly supplying our customers in our territories when control has been transferred. Amounts paid to collaboration partners for their share of our profits earned where we are the principal in the transaction are recorded as cost of sales. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Agreement Characteristics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our collaboration with Pfizer, commercial revenues are recognized based on our collaboration partner&#8217;s gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenues pursuant to this collaboration agreement, we are reliant on our collaboration partner for details regarding its gross profit for the period at hand. Some of the information which our collaboration partner provides us with to identify the gross profit is, by necessity, preliminary and subject to change. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s gross profit share is calculated based on sales and takes into account transfer prices. The latter include manufacturing and shipping costs, which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters may be adjusted once actual costs are determined. The sales as reported by Pfizer have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are borne by the partners on the basis of revenues in the territories for which the partners are responsible and subsequently deducted as cost under the gross profit shared. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third-party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing cost variances include expenses from unused contract manufacturing capacities and overstock inventories finally scrapped. As only materialized costs &#8211; which means manufacturing capacities finally lapsed or inventories finally scrapped &#8211; are shared with the partner in a cash-effective manner, the gross profit share impact is anticipated once assessed as being highly probable to occur. Therefore, information on Pfizer&#8217;s write-downs of inventories is considered. Any changes to this assessment will be recognized prospectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer&#8217;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to us and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. Likewise, our own cost of sales and the respective gross profit share owed to our partner may be adjusted prospectively, when changes are determined. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contract balances related to the Pfizer agreement, see </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Judgment is required in determining whether a right to consideration is unconditional and thus qualifies as a receivable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions and Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently confronted with a number of claims and legal proceedings. They include claims from third parties demanding indemnification for alleged infringement of a third-party patent or other intellectual proprietary rights, as well as product liability claims. In respect of these matters, we assess whether provisions must be recorded and whether contingencies must be reported. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties relating to these matters, provisions and contingencies are based on the best information available.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in the determination of whether and when a provision is to be recorded and what the appropriate amount for such provision should be. Notably, judgment is required in the following areas:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining whether an obligation exists</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining the probability of an outflow of economic benefits</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determining whether the amount of an obligation is reliably estimable</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Estimating the amount of the expenditure required to settle the present obligation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of each reporting period, we reassess the potential obligations related to our pending claims and litigation and adjust our respective provisions and contingencies to reflect the current best estimate. In addition, we monitor and evaluate new information that we receive after the end of the respective reporting period, but before the consolidated financial statements are authorized for issue, in order to determine whether this provides additional information regarding conditions that existed at the end of the reporting period. Changes to estimates, assumptions and outcomes compared to previous estimates and assumptions could require material adjustments to the carrying amounts of the respective provisions recorded and additional provisions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected timing or amounts of any outflows of economic benefits resulting from these lawsuits and claims are uncertain and difficult to estimate or even not estimable, as they generally depend on the duration of the legal proceedings and settlement negotiations required to resolve the litigation and claims and the unpredictability of the outcomes of legal disputes in several jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosures in respect of third-party claims and litigation for which no provisions have been recognized are made in the form of contingent liabilities, unless a potential outflow of resources is considered remote. It is not practicable to estimate the financial impact of contingent liabilities due to the uncertainties around lawsuits and claims as outlined above. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures and carrying amounts relating to provisions as well as contingencies, see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 and Note 18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities, including development of our platforms and manufacturing technologies, generate a significant amount of research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, the capitalization criteria are met. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, we have concluded that, d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ue to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, these criteria are usually not met before regulatory approval is achieved. The related expenditure is reflected in the consolidated statements of profit or loss in the period in which the expenditure is incurred. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. The allocation of consideration attributable to the acquisition of intellectual property and consideration attributable to the research and development services provided by the licensor requires management to make judgements and assumptions. These judgments and assumptions can materially affect our research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our accounting for business combinations, judgment is required in determining whether an intangible asset is identifiable and whether it should be recorded separately from goodwill. Additionally, estimating the acquisition-date fair values in conjunction with purchase price allocation involves estimation uncertainty and discretionary decisions. The necessary measurements are based on information available on the acquisition date and on expectations and assumptions that have been deemed reasonable by management. These judgments, estimates and assumptions can materially affect our financial position and profit. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant assumptions and estimates are required to determine the appropriate amount of amortization of intangible assets. They relate in particular to the determination of the underlying useful life. The useful life of an intangible asset is </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our estimates regarding the period over which the intangible asset is expected to generate economic benefits for us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant assumptions and estimates are also required for the identification of a potential need to recognize an impairment loss. These estimates include management&#8217;s assumptions regarding future cash flow projections and economic risks that require significant judgment and assumptions about future developments. They can be affected by a variety of factors, including, but not limited to, changes in business strategy, internal forecasts and the estimation of weighted average cost of capital. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the assumptions underlying our assessment of the impairment of goodwill and intangible assets could require material adjustments to the carrying amount of our recognized goodwill and intangible assets, as well as to the amounts of impairment charges recognized in profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. We used valuation models such as a binomial or Monte Carlo simulation model for the measurement of the cash- and equity-settled transactions&#8217; fair value, taking into account certain assumptions relating to a number of factors, including the volatility of the stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#8217;s underlying share price. For awards which were granted after the initial public offering, the grant date&#8217;s share prices on the Nasdaq Global Select Market were included in the valuation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A fluctuation assumption is applied when estimating the number of equity instruments for which service conditions are expected to be satisfied and will be revised if material differences arise. Ultimately, a true-up to the number satisfied by the settlement date will be recorded. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures relating to share-based payments, see Note 16.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in more than one tax jurisdiction. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in the form of provisions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize or we would impair deferred tax assets if it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. The assessment whether a deferred tax asset can be recognized or is impaired requires significant judgment, as we need to estimate future taxable profits to determine whether the utilization of the deferred tax asset is probable. In evaluating our ability to utilize our deferred tax assets, we consider all available positive and negative evidence, including the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are recoverable. Based on the requirements in IAS 12, to not place reliance on future events that are uncertain as they for example cannot be controlled, managements assessment takes particular into account the fact that there is an inherent risk of failure in pharmaceutical development and an uncertainty of approval which is dependent on external regulatory agencies&#8217; opinions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This also includes management&#8217;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management continued to take the view that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss-making history cannot be recognized. This includes the assessment that those subsidiaries have neither any taxable temporary differences nor any tax planning opportunities available that could support the recognition of deferred tax assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further disclosures relating to deferred taxes, see Note 8.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793535024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory', window );">Group Information</a></td>
<td class="text">Group Information<div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Subsidiaries</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the following subsidiaries: </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:43.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">% equity interest</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech BioNTainer Holding GmbH</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Cell &amp; Gene Therapies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Halle</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Diagnostics GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Europe GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Idar-Oberstein Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Individualized mRNA Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation and Services Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovative Manufacturing Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Holding GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Verwaltungs GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep DE GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NT Security and Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">reSano GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Australia Pty Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Australia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Melbourne</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech R&amp;D (Austria) GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Austria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vienna</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">China</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shanghai</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Paris</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biopharma BioNTech Israel Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tel Aviv</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">New Technologies Re</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Nigeria Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nigeria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lagos</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Rwanda Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Rwanda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kigali</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech S&#233;n&#233;gal Suarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Senegal</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dakar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Spain S.L</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Spain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Barcelona</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Switzerland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Switzerland</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Basel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Taiwan Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taiwan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taipei</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Tunisia SARL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunisia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">T&#252;rkiye</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Istanbul</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech UK Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.3%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Research and Development, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech USA Holding, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech US Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies (US), LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dover</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies Inc.</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Included during the year ended December 31, 2023.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fully acquired during the year ended December 31, 2023.</span></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities listed above are included in our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parent Company</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AT Impf GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Munich</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43.77&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43.42&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity with Significant Influence over the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Medine GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17.01&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17.38&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCompositionOfGroupExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Subsidiaries [member]; Parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCompositionOfGroupExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793088176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_BusinessCombinations1Abstract', window );"><strong>Business Combinations 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of InstaDeep Ltd.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we acquired InstaDeep Ltd., London, United Kingdom (InstaDeep), a leading global technology company in the field of artificial intelligence (AI) and machine learning, by purchasing 100% of the remaining shares in InstaDeep not already owned by us. The acquisition is intended to create a fully integrated, enterprise-wide capability that leverages AI and machine learning technologies across our therapeutic platforms and operations. InstaDeep also continues to provide its services to clients around the world in diverse industries, including in the technology, transport and logistics, and industrial and financial services sectors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the acquisition took place in July 2023.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed an allocation of the total consideration and the underlying assets acquired (including certain identified intangible assets such as InstaDeep</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s DeepChain technology and customer relationships) and liabilities assumed based on their fair values using the information available as of the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition date. The total consideration and the fair values in accordance with IFRS&#160;3 of the identified net assets acquired of InstaDeep as of July 31, 2023, are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fair value recognized on acquisition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Assets </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade receivables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets - current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets non-current and current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total assets</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">275.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other liabilities long-term and short-term</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total liabilities</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">64.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total identifiable net assets at fair value</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill from the acquisition</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">306.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">517.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">358.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash to be paid in 2024</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designated FX hedge</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares transferred (approx. 1.1 million shares)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Previously held non-listed equity investment (stake of 5.3%)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">517.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets acquired comprise DeepChain technology and customer relationships. Their fair values were determined based on the multi-period excess earnings method (MEEM) and amount to &#8364;176.0&#160;million and &#8364;7.8&#160;million respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the shares transferred is determined based on the number of shares transferred and the closing price of the ADSs as of July 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of InstaDeep is a step acquisition in accordance with IFRS 3.41-3.42A since we already held a 5.3% interest prior to the acquisition. In prior reporting periods, we recognized changes in the value of this equity interest in other comprehensive income. The amount of the remeasurement to fair value that was recognized in other comprehensive income is recognized on the same basis as would be required if we disposed directly of the previously held equity interest. Based on the total consideration for the acquired shares (94.7%), the value of the already held shares is &#8364;27.9&#160;million, which results in a loss of &#8364;2.2&#160;million shown in other comprehensive income in the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the acquisition date, the contingent consideration was recognized at its fair value of &#8364;31.8 million based on cash flow projections in connection with performance-based future milestone cash payments to eligible shareholders after a three-year earn-out period. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero; the upper limit is &#8364;124.6&#160;million. In addition, &#8364;12.5&#160;million of potential earn-out payments are considered remuneration and will be recognized as personnel expense over a three-year period in which services are to be provided.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of &#8364;6.0&#160;million were expensed and are included in general and administrative expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill mainly comprises the value of expected synergies from including AI and machine learning technologies across our therapeutic platforms and operations and intangible assets that are not recognized separately, such as the acquired skilled workforce and its know-how. Therefore, the goodwill is allocated almost in full to the CGU immunotherapies and to a minor extent to a CGU comprising the external InstaDeep business. The goodwill is not tax deductible.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized in an amount of &#8364;45.8&#160;million. In line with the deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carry forwards which existed as of the acquisition date were recognized. The deferred tax assets and liabilities were offset to the extent that the conditions for offsetting were fulfilled.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the acquisition, InstaDeep</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span>s impact on our revenue and profit for the period has been immaterial. Accordingly, hypothetical amounts for our revenue and profit for the financial year, which were calculated on the assumption that the acquisition had taken place at the beginning of the year, would not materially differ from the actual figures reported.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_BusinessCombinations1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_BusinessCombinations1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788926094384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Revenues from Contracts with Customers</a></td>
<td class="text">Revenues from Contracts with Customers<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1&#160;&#160;&#160;&#160;Disaggregated Revenue Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"></td><td style="width:55.454%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commercial revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,815.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,194.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,874.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 vaccine revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,776.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,145.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,806.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sales to collaboration partners</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">275.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1,224.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">970.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Direct product sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">473.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,184.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,007.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of collaboration partners&#8217; gross profit and sales milestones</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,027.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">12,736.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">14,828.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research &amp; development revenues from collaborations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">102.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,976.7</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, revenues recognized from Pfizer Inc., or Pfizer (&#8364;3,293.0 million) and the German Federal Ministry of Health (&#8364;473.6 million), each account for more than 10% of total revenues. During the year ended December&#160;31, 2022, revenues recognized from Pfizer (&#8364;13,795.8 million) and the German Federal Ministry of Health (&#8364;3,020.5 million) represented more than 10% of total revenues. During the year ended December&#160;31, 2021, revenues recognized from Pfizer (&#8364;15,500.0 million) and the German Federal Ministry of Health (&#8364;1,945.6 million), accounted for more than 10% of total revenues. During the year ended December&#160;31, 2023, based on the geographic region in which our customers and collaboration partners are located, we mainly recognized revenues in the United States (&#8364;3,010.9&#160;million) and Germany (&#8364;482.7&#160;million). During the year ended December&#160;31, 2022, the main geographic regions were United States (&#8364;12,709.7&#160;million) and Germany (&#8364;3,031.0&#160;million). During the year ended December&#160;31, 2021, the main geographic regions were United States (&#8364;14,636.5&#160;million), Germany (&#8364;2,241.9&#160;million) and Belgium (&#8364;675.0&#160;million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide. During the year ended December&#160;31, 2023, our commercial revenues decreased in line with a lower COVID-19 vaccine market demand. In addition, write-downs by our collaboration partner Pfizer Inc. (Pfizer), significantly reduced our gross profit share and hence negatively influenced our revenues for the year ended December&#160;31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and T&#252;rkiye. Shanghai Fosun Pharmaceutical (Group) Co., Ltd, or Fosun Pharma, has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales to Collaboration Partners</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to collaboration partners represent sales of products manufactured by us to collaboration partners. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. Under the collaboration with Pfizer, from time to time, those sales are significantly influenced by amounts due to write-downs of inventories as well as costs related to production capacities derived from contracts with CMOs that became redundant. Those costs represent accrued manufacturing variances and are charged to our partner once finally materialized. These manufacturing variances are reflected as transfer price adjustments once identified. The regular reassessment of these manufacturing variances may result in adjustments to the respective prior-period revenues. Sales to collaboration partners during the years ended December&#160;31, 2023, 2022 and 2021 of &#8364;74.5 million, &#8364;850.0 million and &#8364;31.0&#160;million, respectively, related to the aforementioned manufacturing variances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Product Sales to Customers</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct product sales are recognized from supplying COVID-19 vaccine in our territories Germany and T&#252;rkiye. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December&#160;31, 2023, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized &#8364;473.6 million, &#8364;3,184.7 million and &#8364;3,007.2&#160;million of revenues, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share of Collaboration Partners&#8217; Gross Profit and Sales Milestones</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on COVID-19 vaccine sales in the collaboration partners&#8217; territories, we are eligible to receive a share of their gross profit, which represents a seasonally affected net figure and is recognized as collaboration revenue during the commercial phase, together with sales milestones. M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anufacturing cost variances either reflected as transfer price adjustments as described above or resulting from costs highly probable to be incurred by the partner, were taken into account when determining the gross profit. During the year ended December&#160;31, 2021, those revenues included </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;476.6 million&#160;of sales milestones</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenues from contracts with customers disclosed above were recognized as follows: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1A1A1A;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Timing of revenue recognition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred at a point in time</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">776.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,447.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,034.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred over time</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,027.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,736.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,828.7</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,976.7</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents sales based on the share of the collaboration partners&#8217; gross profit and sales milestones.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.2&#160;&#160;&#160;&#160;Contract Balances</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">751.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refund liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24.4</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other receivables significantly decreased compared to the previous year and predominantly comprise trade receivables from our COVID-19 collaboration with Pfizer as well as our direct product sales to customers in our territory. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#8217;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. Consequently, as of December&#160;31, 2023, our trade receivables included, in addition to the profit share for the fourth quarter of 2023, trade receivables which related to the gross profit share for the third quarter of 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities significantly increased compared to the previous year as advance payments in connection with the amendment of the COVID-19 vaccine purchase agreement with the European Commission, or EC, were received. As of December&#160;31, 2023, the contract liabilities included &#8364;386.4 million of such payments under our collaboration with Pfizer (COVID-19 vaccine), &#8364;302.3 million&#160;from the German Federal Ministry of Health and &#8364;62.3 million&#160;of remaining upfront fees from our collaboration agreement with Pfizer (Zoster) (as of December&#160;31, 2022: &#8364;65.7&#160;million of remaining upfront fees from collaboration and commercial supply agreements and &#8364;56.3&#160;million&#160;of advance payments for future COVID-19 vaccine sales). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The refund liabilities recognized as of December 31, 2022, represented consideration which was refunded to the collaboration partner during the year ended December 31, 2023. </span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the amount of revenue recognized for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts included in contract liabilities at the beginning of the year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.7</span></td></tr></table></div><div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.3&#160;&#160;&#160;&#160;Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as of year-end are as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Within one year</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">353.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More than one year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">398.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.4</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">751.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">125.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783273360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock', window );">Income and Expenses</a></td>
<td class="text">Income and Expenses<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.1 General Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, cost of sales decreased by &#8364;2,395.2 million or 80% from &#8364;2,995.0 million&#160;to &#8364;599.8 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mainly due to recognizing lower cost of sales from our decreased COVID-19 vaccine sales, which included the share of gross profit that we owe our collaboration partner  Pfizer based on our sales. In addition, cost of sales was impacted by expenses arising from inventory write-offs and expenses for production capacities derived from contracts with CMOs that became redundant. The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. Based on the regulatory approval obtained with respect to our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine during the third quarter of 2023, we reversed the initial write-down of pre-launch inventory recorded in research and development expensed to a maximum of the original cost of &#8364;46.9&#160;million. Thereof &#8364;27.3&#160;million resulted in cost of sales during the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023 as the respective inventory has been either sold or written down. The remainder is presented in inventories as of December&#160;31, 2023 and amounted to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;19.6&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the year ended December&#160;31, 2022 the amount was nil.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our research and development expenses increased by &#8364;246.1 million&#160;or 16% from &#8364;1,537.0 million&#160;to &#8364;1,783.1&#160;million, mainly influenced by progressing clinical studies for pipeline candidates as well as by our newly acquired product candidates and the development of variant adapted COVID-19 vaccines. The increase was further driven by an increase in wages, benefits and social security expenses resulting from a significant increase in headcount.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ales and marketing expenses increased by &#8364;3.2 million&#160;or 5% from &#8364;59.5 million&#160;to &#8364;62.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, mainly due to increased expenses for setup and enhancement of commercial IT platforms and an increase in wages, benefits and social security expenses resulting from an increase in headcount. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div>From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our general and administrative expenses increased by &#8364;13.3 million&#160;or 3% from &#8364;481.7 million&#160;to &#8364;495.0 million, mainly influenced by increased expenses for IT services as well as by wages, benefits and social security expenses resulting from an increase in headcount.<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.2&#160;&#160;&#160;&#160;Other Operating Expenses</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">252.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">385.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">293.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">410.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">103.4</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures relate to costs for external legal advice in connection with certain legal litigations from general and administrative expenses to other operating expense to reflect changes in internal reporting also in the external reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the other expenses increased compared to the year ended December&#160;31, 2022, which was mainly derived from recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating expenses primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.</span></div>During the year ended December&#160;31, 2022, the other operating expenses increased compared to the year ended December&#160;31, 2021, mainly from recording the change in fair value of foreign exchange forward contracts that were entered into during the year ended December&#160;31, 2022, to manage some of our transaction exposures but were not designated as hedging instruments under IFRS.<div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.3&#160;&#160;&#160;&#160;Other Operating Income</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gain on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">727.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">446.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">105.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">815.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">598.4</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the other income decreased compared to the year ended December&#160;31, 2022, as foreign exchange differences arising on operating items changed from a positive effect to a negative effect, which is recorded in other operating expenses (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.2). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the other income increased compared to the year ended December&#160;31, 2021, which was mainly due to recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating income primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.4&#160;&#160;&#160;&#160;Finance Income</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">357.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">162.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66.2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">519.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">330.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">67.7</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the finance income increased compared to the year ended December&#160;31, 2022, mainly due to interest income earned on bank deposits and financial securities as well as fair value adjustments in relation to our money market funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the finance income included the final fair value measurement adjustments of the derivative embedded within the convertible note upon the early redemption of the convertible note as of March 1, 2022, the redemption date, as well as interest income from our bank deposits and increased compared to the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7.5&#160;&#160;&#160;&#160;Finance Expenses</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">277.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">23.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">305.1</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the finance expenses increased compared to the year ended December&#160;31, 2022, mainly due to exchange differences derived from our foreign exchange bank deposits and cash accounts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, the finance expenses decreased compared to the year ended December&#160;31, 2021, mainly due to final settlement of the derivative embedded within the convertible note which led to financial income whereas during the year ended December&#160;31, 2021, expenses in the amount of &#8364;277.8 million&#160;were derived from the respective fair value measurement adjustment.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.6&#160;&#160;&#160;&#160;Employee Benefits Expense</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Wages and salaries</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">617.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">544.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">345.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social security costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.7</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58.6</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pension costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">698.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">605.5</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">378.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wages and salaries include, among other things, expenses for share-based payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income And Expense Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783177568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Tax</a></td>
<td class="text">Income Tax<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax for the years ended December&#160;31, 2023, December&#160;31, 2022, and December&#160;31, 2021, comprised current income taxes, other taxes and deferred taxes. We are subject to corporate taxes, the solidarity surcharge and trade taxes. Our corporate tax rate in the reporting year remained unchanged (15.0%) as did the solidarity surcharge (5.5%) whereas the average trade tax rate changed resulting in a combined income tax rate of 27.1% in the year ended December&#160;31, 2023 (during the years ended December&#160;31, 2022 and 2021: 27.2% and 30.7%, respectively). Deferred taxes are calculated at a rate of 27.1%. Current taxes for Austria are calculated at a corporate tax rate of 24.0%. Austria&#8217;s decrease of its corporate tax rate down to 23.0% in 2024 is be recognized from 2023 onwards for deferred taxes. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (21.0%) as well as State Income Tax in various state jurisdictions (effective rate of 4.5%). The deferred tax rates calculations basis remained unchanged compared to the previous period.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the current and deferred taxes for the periods indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,629.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,535.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(109.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">255.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,519.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,753.9</span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"></td><td style="width:55.454%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Profit before tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,186.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,954.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15,046.4</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected tax credit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">321.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,529.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,622.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effects </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to local tax basis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to deviating income tax rate (Germany and foreign countries)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(14.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects from tax losses and tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(66.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in deferred taxes due to tax rate change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7.5)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-deductible expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(87.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective share-based payment expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax-effective equity transaction costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjustment prior year taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(31.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-tax effective bargain purchase</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other effects</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.0)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">255.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,519.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,753.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27.2%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">31.6%</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2018, we established a share option program pursuant to which we were permitted to grant selected employees and our Management Board options to receive shares in the Company. The program is designed as an Employee Stock Ownership Plan, or ESOP. We offered the participants a certain number of rights, or option rights, subject to their explicit acceptance. Grants under the ESOP took place from November 2018 until December 2019. An exercise of option rights in accordance with the terms of the ESOP gives a participant the right to obtain shares against payment of the exercise price. By way of an updated decision of the Supervisory Board at the end of September 2022 compared to the initial settlement mechanism, an ESOP settlement may be made by delivery to the participant of such number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The respective number of ADS shall be settled with ADS acquired in the course of the share repurchase program. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise are paid in cash directly to the respective authorities. Expenses for taxation purposes resulting from the settlement are only recognized once the option rights have been exercised. After considering the settlements in the twelve months ended December 31, 2023 and taking into account the recognition criteria of IAS 12, a deferred tax is not recognized in our consolidated statement of financial position of &#8364;17.8&#160;million&#160;which relates to future settlements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current tax savings associated with the excess were directly recognized in equity in a total amount of &#8364;19.8&#160;million. Considering these tax amounts directly recognized in equity when calculating an effective tax rate, the tax rate would be decreased by about 1.6 percentage points. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intended settlement mechanism of Option Rights of the Chief Executive Officer Grant (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for plan details) led to a deferred tax asset in the total amount of &#8364;108.8&#160;million as of December&#160;31, 2023. Taking into account the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognition criteria of IAS 12 this deferred tax asset is not recognized in our consolidated statements of profit or loss neither recognized directly in equity as other reserves in our consolidated statements of changes in stockholders&#8217; equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span></div><div style="margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes for the periods indicated relate to the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:42.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(44.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.4)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(56.6)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(162.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(90.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10.0)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33.0)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(43.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(58.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(106.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(44.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(77.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(102.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(136.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(66.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">223.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(12.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(169.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">41.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">229.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(169.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">81.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(6.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(33.5)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(39.7)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:42.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(47.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.3)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(95.6)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(67.1)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(162.7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(15.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(20.6)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10.0)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">179.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">165.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(81.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.7)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(136.7)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(66.7)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">109.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">223.4</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our accumulated tax losses comprised tax losses of German entities that were incurred prior to the establishment of a tax group with BioNTech SE or by entities that are not within the tax group (as of December&#160;31, 2023: BioNTech Real Estate Verwaltungs GmbH; as of December&#160;31, 2022: BioNTech BioNTainer Holding GmbH, BioNTech Idar-Oberstein Services GmbH, NT Security and Services GmbH, BioNTech Real Estate Verwaltungs GmbH and the Real Estate partnerships) or U.S. tax group. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">260.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">272.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade tax </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">170.6</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2023, deferred tax assets on tax losses were only partially recognized, as there was not sufficient probability in terms of IAS 12 that future taxable profits would have been available against which all the unused tax losses could have been utilized. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of deductible temporary differences, unused tax losses, and unused tax credits for which no deferred tax asset is recognized in the statement of financial position as of December 31, 2023 is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;531.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Thus a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, we have not recognized deferred tax assets for unused tax losses and temporary differences in an amount of &#8364;138.0&#160;million (December&#160;31, 2022: &#8364;136.7&#160;million 31&#160;December 2021 &#8364;81.0&#160;million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reorganization of the intellectual property rights within the group became effective as of June 30, 2023 and July 1, 2023 which led to deferred tax effects in Germany, the U.S. and Austria. As a result, BioNTech SE recognized deferred tax assets and deferred tax income at the time of the transaction. In addition, this transaction led to a revaluation of previously unrecognized U.S. federal and state deferred tax assets, including unused tax losses and unused tax credits. As of December 31, 2022, there were unrecognized U.S. federal and state deferred tax assets of &#8364;128.9&#160;million. As of December 31, 2023, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future, fulfilling the requirements set out by IAS 12. Therefore we no longer continue to maintain the full non-recognition of deferred tax assets of our U.S. tax group as there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized. As of December 31, 2023, we maintain the non-recognition of deferred tax assets for unused U.S. federal and state tax losses and tax credits at an amount of &#8364;31.9&#160;million and &#8364;2.8&#160;million, respectively, as there is not sufficient probability in terms of IAS 12 that future taxable income will be available against which these unused tax losses can be utilized. The material unrecognized U.S. federal and state tax losses and tax credits will begin to expire in 2036. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group does not recognize deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries, in cases where the Group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries, for which deferred tax liabilities have not been recognized, is &#8364;2.8&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793846608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (EPS) is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year, plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the income and share data used in the basic and diluted EPS calculations:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit attributable to ordinary equity holders of the parent for basic earnings </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9,434.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10,292.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average number of ordinary shares outstanding for basic EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">243.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">244.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of dilution from share options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average number of ordinary shares outstanding adjusted for the effect of dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">242.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">249.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">259.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per share</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings for the period per share</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.87</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.78</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.18</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted earnings for the period per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.83</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37.77</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.63</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794858992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Other Intangible Assets and Goodwill</a></td>
<td class="text">Other Intangible Assets and Goodwill<div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Goodwill</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">306.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.6)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">362.5</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets with Indefinite Useful Lives</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:19.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CGU Immunotherapies</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Product Sales of JPT</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Business of InstaDeep</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">362.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful life</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">796.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">807.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">61.2</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we have total goodwill of &#8364;362.5 million, which relates almost completely to the CGU immunotherapies. The CGU immunotherapies focuses on the development of therapies to address a range of rare and infectious diseases and comprises our broad pipeline that includes mRNA-based immune activators, antigen-targeting T&#160;cells and antibodies and defined immunomodulators of various immune cell mechanisms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed our annual impairment test in October 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of the CGU immunotherapies has been determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as an observable input parameter. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of the CGU JPT and the CGU external business of InstaDeep has been determined based on the value in use. In assessing value in use, the estimated future cash flows, which are derived based on the strategic business plan approved by the management, are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the assets. A long-term growth rate of 1.0% is applied to project future cash flows after the last year of the detailed planning period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the analysis in October 2023, we did not identify an impairment for these CGUs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives mainly comprised intangible assets not yet available for use of &#8364;443.5&#160;million. Such assets are not amortized and therefore reviewed for impairment annually. An impairment test was performed on an individual basis of the assets in the fourth quarter of 2023. The recoverable amounts were determined based on value in use. The results did not give rise to any impairment losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering updated financial information regarding our COVID 19 vaccine business an additional impairment test for our CGU immunotherapies was performed as of December 31, 2023. The recoverable amount of the CGU immunotherapies was once again determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as of December 31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the additional analysis for the CGU immunotherapies, we did not identify an impairment for the CGU immunotherapies. Even if our market capitalization had been approximately 10% lower, FVLCD would have still been above the respective carrying amount of the CGU. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets resulting from licensing and collaboration agreements are combined into one class of assets due to their similar nature and use in our operations and are attributed to the CGU immunotherapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sensitivity analysis of the key assumptions, future cash flows and weighted average cost of capital, was performed as part of the scheduled impairment testing of the intangible assets not yet available for use. The sensitivity analysis did not give rise to any impairment loss, either for a reduction of 10% in future cash flows or for a 10% increase in the weighted average cost of capital.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">222.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">222.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">489.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">505.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.2)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4.9)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">898.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">921.0</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative amortization and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">54.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">54.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">76.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">76.9</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.9</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">145.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">781.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">804.1</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other intangible assets by &#8364;645.6&#160;million from December 31, 2022 to December&#160;31, 2023 was mainly related to the acquisition of InstaDeep (see</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note 5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and licenses fulfilling the definition of identifiable assets acquired. We entered into license and collaboration agreements in which we work together with partners to develop pharmaceutical products and, provided regulatory approval is granted, commercialize them. The upfront payments in connection with the license and collaboration agreements described below resulted in the recognition of intangible assets not yet available for use in the amount of &#8364;443.5&#160;million and a prepayment for future development activities recognized in the other non-financial assets (&#8364;22.5&#160;million as at December&#160;31, 2023, see also Note 14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into license and collaboration agreements with Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, or Duality, for exclusive licenses to two investigational ADC assets (BNT323/DB-1303 and BNT324/DB-1311) directed against targets expressed in a broad range of human cancers. In August 2023, we signed another exclusive agreement with Duality to develop, manufacture and commercialize an additional ADC, BNT325/DB-1305. Duality received upfront payments totaling $220.0&#160;million (&#8364;203.7&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into a licensing and collaboration agreement with OncoC4 Inc., Rockville (Maryland), United States, or OncoC4, which includes joint development of BNT316/ONC-392 in a range of solid tumor indications, with the parties equally sharing development costs for such joint development studies. BioNTech holds the exclusive worldwide commercialization rights for this product candidate. OncoC4 received an upfront payment of $200.0&#160;million (&#8364;181.5&#160;million, thereof &#8364;125.2&#160;million paid for the acquisition of an intangible asset) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we entered into a strategic research collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd., or MediLink Therapeutics, for the development of a next-generation ADC, BNT326/YL202, against Human Epidermal Growth Factor Receptor 3 (HER3). MediLink Therapeutics received an upfront payment of $70.0&#160;million (&#8364;64.1&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we entered into an exclusive global license and collaboration with Biotheus Inc., or Biotheus, under which we will be developing, manufacturing and commercializing Biotheus&#8217; bispecific antibody candidate BNT327/PM8002 globally ex-Greater China. We agreed to an upfront payment of  $55.0&#160;million (&#8364;50.6&#160;million) plus future milestone and royalty payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">In July 2023, in connection with the acquisition of InstaDeep we acquired DeepChain technology. As of December&#160;31, 2023 the book value of DeepChain technology amounted to &#8364;163.3&#160;million with a remaining useful life of 6.6 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793158160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition and production costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">182.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">329.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(40.2)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">273.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">273.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">189.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(31.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">344.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">969.0</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative depreciation and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">175.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">195.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">178.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">609.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">199.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">168.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">757.2</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current Assets by Region</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, non-current assets comprised &#8364;158.2 million in other intangible assets, goodwill, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States (as of December&#160;31, 2022: &#8364;188.0 million) as well as &#8364;511.7 million in the United Kingdom (as of December&#160;31, 2022: nil), respectively. The remaining non-current assets of &#8364;1,469.0 million (as of December&#160;31, 2022: &#8364;871.9 million) mainly relate to entities incorporated in Germany.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781814560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Financial Assets and Financial Liabilities</a></td>
<td class="text">Financial Assets and Financial Liabilities<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.1&#160;&#160;&#160;&#160;Capital Risk Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital management objectives are designed primarily to finance our growth strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our treasury committee reviews the total amount of cash and cash equivalents on a regular basis. As part of this review, the committee considers total cash and cash equivalents, cash outflow, currency translation differences and refinancing activities. We monitor cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">453.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11,210.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,549.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11,663.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13,875.1</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the aim is to protect and maximize the financial resources available for further research and development projects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since December 1, 2021, we have an investment and asset management policy in place that contains policies and processes for managing cash and cash equivalents. Under this policy, our investment portfolio is to be maintained in a manner that minimizes risks to the invested capital. These risks include mainly credit risk and concentration risk. The portfolio must provide liquidity in a timely manner to accommodate operational and capital needs. The portfolio is managed by the Treasury department.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements. Our capital management objectives were achieved in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.2&#160;&#160;&#160;&#160;Categories of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity investments designated at Fair Value through OCI</span></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:32.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net gain on equity instruments designated at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10.5</span></td></tr></table></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of fair values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:23.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Type</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Valuation technique</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Significant unobservable inputs</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:23.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward exchange contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Actual and forecasted results</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Cash position</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Nature and pricing indication of latest financing round</span></div><div style="text-indent:10.91pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quoted prices on an active market</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. </span></div></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Expected future payments</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Applied cost of capital</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.3&#160;&#160;&#160;&#160;Recurring Fair Values (Level 3)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the recurring fair value measurement of the contingent considerations and the effect of the measurements on our consolidated statements of profit or loss for the current period.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:38.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contingent consideration</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net effect on profit or loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net change in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.8</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sensitivity of the fair values of contingent considerations in fair value level 3 to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:33.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input factor</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in assumptions</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with increasing input factor (in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with decreasing input factor (in millions &#8364;)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flow projections</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10&#160;</span></td><td style="background-color:#c6e0b4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.8)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of non-listed equity investments would, for example, increase (decrease) if price of latest financing round were to increase (decrease) and the overall company value were higher (lower).</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.4&#160;&#160;&#160;&#160;Financial Instruments Risk Management Objectives and Policies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial liabilities mainly comprise obligations derived from license agreements, trade and other payables, lease liabilities, contingent consideration, loans and borrowings, hedging liabilities as well as other financial liabilities. The main purpose of these financial liabilities is to enable our operations. Our principal financial assets include mainly cash, security investments and trade receivables that derive directly from our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk, credit risk and liquidity risk. Our Management Board oversees the management of these risks. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treasury committee provides assurance to our Management Board that our financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with our policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.5&#160;&#160;&#160;&#160;Market Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risks address the risks that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risks comprise three types of risk: interest risks, foreign currency risks and other price risks. Financial instruments affected by market risks include financial assets such as security investments, trade and other receivables, cash and cash equivalents as well as financial liabilities such as trade payables and other financial liabilities. We do not consider interest risks as well as other price risks as material risks to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in the way the risks were managed and valued during the years ended December 31, 2023, and 2022. Because of the significantly higher cash balance and security investments &#8211; the market risk exposure on counterparty risk increased compared to the previous period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign currency risks address the risks that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to currency risks, as our income and expenditures are denominated in Euro and the U.S. dollar. As such, we are exposed to exchange rate fluctuations between these currencies. Cash inflows denominated in U.S. dollar mainly result </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">from generating proceeds under our collaboration agreements. Our commercial revenues are primarily collaboration revenues from earnings based on our partners&#8217; gross profit, which is shared under the respective collaboration agreements and represents payments we receive in U.S. dollar. Cash outflows dominated in U.S. dollar mainly result from amounts spent on research and development activities and license obligations as well as expanding our global footprint further. With the aim of preserving capital, surplus liquidity is mainly invested in domestic currency investments as exchange rate fluctuations can reduce the value of our financial positions. We limit the effects of the identified risks by means of a coordinated and </span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">consistently</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> implemented risk strategy. Besides applying natural hedging relationships where possible, foreign exchange forward contracts are concluded, as a matter of principle, as instruments to</span><span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> mitigate foreign currency exchange risk associated with foreign currency-denominated payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. However, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he foreign exchange forward contracts which we entered into were not designated as hedging instruments under IFRS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the monetary assets and liabilities denominated in U.S. dollar at the dates indicated are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,487.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary assets in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,191.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,098.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary liabilities and provisions in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">567.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,527.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">747.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7,058.1</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables demonstrate the sensitivity to a reasonable, possible change in U.S. dollar exchange rates or U.S. dollar forward rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets and liabilities. The exposure to foreign currency changes for all other currencies is not material.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.845%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1 &#8364; =</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing rate</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. dollar</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1050</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0666</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0813</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0530</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in U.S. dollar rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on profit / (loss) before tax</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on pre-tax equity</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.5)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.5)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.2</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.3</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(195.2)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(191.5)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215.7</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211.7</span></td></tr></table></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.6&#160;&#160;&#160;&#160;Credit Risk Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risks address the risks that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risks from our operating activities, including security investments, bank deposits, reverse repos, foreign exchange transactions, trade and other receivables and cash at banks. The maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&#160;31, 2023, and December&#160;31, 2022, are the carrying amounts as illustrated in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 12.2.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Investments, Bank Deposits, Reverse Repos and Cash at banks</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial management is dedicated predominantly to the goal of capital preservation. Thus, all our financial activities are focused towards avoiding risks and, where they cannot be avoided, actively managing and minimizing them. Credit risks from balances with security investments, bank deposits, reverse repos and cash at banks are managed by our Treasury department in accordance with our investment and asset management policy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our security investments are solely invested in the highest-quality liquid assets (e.g. core European sovereign, supranational and agency bonds) and bank deposits with a maturity of more than 3 months (held at selected banks, exclusively rated as investment grade). They do not bear any currency risks or material credit risks. The bank deposits are held at selected banks, exclusively rated as investment grade. We limit our investment engagements individually and track each credit risk continuously. For reverse repos, only investment-grade counterparties qualify as our business partners and even secured investments are solely collateralized by high-quality liquid assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, credit risks from these financial assets are limited. Before entering into new business relationships and during ongoing business relationships, we evaluate our business partners with regard to their individual default risk. Therefore, we do not presume an increased credit risk as of the balance sheet date and determine the impairment loss based on the upcoming twelve months.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculated expected credit losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not material as of December&#160;31, 2023, and December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and Other Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to credit risks of trade and other receivables is primarily related to transactions with corporate customers in the biopharma / biotech industry that operate in the United States or Germany, as well as </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which are customers, in connection with fulfilling our commercial obligations in our territories as defined in our contracts with customers. An analysis of the aging of receivables and the creditworthiness of customers is used to evaluate this risk at each reporting date. We follow risk control procedures to assess the credit quality of our customers taking into account their financial position, past experience and other factors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, outstanding trade and other receivables were mainly due from our collaboration partner Pfizer.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Besides well-established pharmaceutical companies and governmental institutions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our other customers &#8211; to a smaller extent &#8211; are medical universities, other public institutions and peers in the biopharma industry, which have good credit ratings. Due to this customer portfolio, the credit risk on trade and other receivables is generally very low. We have not incurred material bad debt expense and do not expect that this will change with respect to the trade and other receivables outstanding as of December&#160;31, 2023. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected credit risk on trade and other receivables derived from applying the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simplified approach in calculating expected credit losses </span>was not material as of December&#160;31, 2023, and December&#160;31, 2022.<div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.7&#160;&#160;&#160;&#160;Liquidity Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to invest heavily in R&amp;D as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity management ensures the availability of cash and cash equivalents, short term financial instruments for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which are managed centrally, is always maintained to finance the operational activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor liquidity risks using a liquidity planning tool.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, the responsibility for liquidity risk management lies with our Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. We manage liquidity risks by holding appropriate reserves based on our COVID-19 sales, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities. Significant reserves currently exist and were generated during the Covid-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Concentration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations arise when the number of counterparties is small or when a larger number of counterparties is engaged in similar business activities, or activities in the same geographical region, or has economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of our performance to developments affecting a particular industry. We only have a limited number of customers mainly comprising </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmaceutical companies and governmental institutions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.1</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136.6</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">244.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.5</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">414.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">803.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">196.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,073.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">232.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">785.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,029.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">115.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">85.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,229.9</span></td></tr></table></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12.8&#160;&#160;&#160;&#160;Changes in Liabilities Arising from Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2023</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(40.3)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">28.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51.1</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(34.1)</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.5)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">188.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">212.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(40.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">50.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">219.0</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(41.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.8</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33.3</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">174.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(18.0)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(99.8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note &#8211; embedded derivative</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">308.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(308.7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">610.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(59.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">67.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(406.3)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">212.2</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Related to the early redemption of our convertible note during the year ended December&#160;31, 2023, as further described in Note 15.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Offsetting financial assets and financial liabilities<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783112528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Raw materials and supplies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">409.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unfinished goods</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finished goods</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">357.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">439.6</span></td></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or disposals resulted in &#8364;94.5&#160;million, compared to &#8364;484.6 million in the previous period. The inventories valued at net realizable value in our consolidated statements of financial position as of December&#160;31, 2023, take contractual compensation payments into consideration.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not </span>pledged any inventories as securities for liabilities. During the years ended December 31, 2023, and 2022, costs of inventories in the amount of &#8364;354.4 million and &#8364;1,550.6 million, respectively, were recognized as cost of sales.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794113136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialAssetsAbstract', window );"><strong>Other Non-Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other Non-Financial Assets</a></td>
<td class="text">Other Non-Financial Assets<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales tax receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepayments related to CRO and CMO contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">278.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">280.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">271.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83.4</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred expenses mainly comprise prepayments for future expenses of &#8364;151.1&#160;million (nil as of December&#160;31, 2022) for the settlement fee of the European Commission to our collaboration partner and prepayments for our collaborations with OncoC4 Inc., Rockville, USA, &#8364;22.5&#160;million (nil as of December&#160;31, 2022), Ryvu Therapeutics S.A., Krakau, Poland, &#8364;15.7&#160;million (&#8364;19.7&#160;million as of December&#160;31, 2022) and Medigene Immunotherapies GmbH, Planegg/Martinsried, &#8364;5.1&#160;million (&#8364;9.4&#160;million as of December&#160;31, 2022). Prior year deferred expenses mainly comprise service contracts and insurance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783141840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves and Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Issued Capital and Reserves</a></td>
<td class="text">Issued Capital and Reserves<div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the number of shares outstanding was 237,725,735. This amount excludes 10,826,465&#160;shares held in treasury. For the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the number of shares outstanding was 243,215,169, excluding 5,337,031 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares held in treasury.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Transactions During the Year Ended December&#160;31, 2023</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our Management Board and Supervisory Board authorized the 2022 share repurchase program of ADSs, pursuant to which we were permitted to repurchase ADSs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each representing one ordinary share,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a value of up to $1.5&#160;billion a two-year period, commencing on May 2, 2022. The first tranche of our 2022 share repurchase program of ADSs, with a value of up to $1.0&#160;billion, concluded on October 10, 2022. The second tranche with a value of up to $0.5&#160;billion commenced on December 7, 2022 and concluded on March 17, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program first tranche ($1.0&#160;billion)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">917,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$151.76 (&#8364;143.99)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$139.3 (&#8364;132.2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,160,219</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$140.82 (&#8364;133.35)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$163.4 (&#8364;154.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">519,320</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$162.03 (&#8364;159.40)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$84.1 (&#8364;82.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,666,515</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$149.08 (&#8364;148.24)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$248.4 (&#8364;247.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,280,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$135.95 (&#8364;137.66)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$310.1 (&#8364;314.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">400,483</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$136.37 (&#8364;139.09)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$54.6 (&#8364;55.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,945,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$999.9 (&#8364;986.4)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program second tranche ($0.5&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618,355</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$142.26 (&#8364;131.12)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$88.0 (&#8364;81.1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">857,620</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$138.05 (&#8364;129.06)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$118.4 (&#8364;110.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">745,196</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$128.49 (&#8364;121.08)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$95.7 (&#8364;90.2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,221,171</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$302.1 (&#8364;282.0)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Management Board and Supervisory Board authorized the 2023 share repurchase program, under which we were permitted to purchase ADSs, each representing one ordinary share, with a value of up to $0.5&#160;billion, which started June&#160;2, 2023 and concluded on September 18, 2023. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Program 2023 ($0.5&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,532,685</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$108.92 (&#8364;100.45)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$166.9 (&#8364;154.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,738,061</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$107.92 (&#8364;97.57)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$187.6 (&#8364;169.6)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,261,706</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$105.07 (&#8364;95.85)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$132.6 (&#8364;120.9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$112.22 (&#8364;105.07)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$12.9 (&#8364;12.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,646,965</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$500.0 (&#8364;456.5) </span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Transactions During the Year Ended December 31, 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we announced a new research, development and commercialization collaboration with Pfizer to develop potentially the first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV). In connection </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with this collaboration, Pfizer agreed to make an equity investment in us, acquiring 497,727 ordinary shares paying a total amount of &#8364;110.6&#160;million. The issuance of 497,727&#160;ordinary shares with the nominal amount of &#8364;0.5&#160;million was registered with the commercial register (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on March 24, 2022. The equity investment, which was issued in a foreign currency, represents a derivative from the date of signing until the date of closing of the transaction. From the fair value measurement of this derivative, &#8364;43.0&#160;million were recognized in finance income in our consolidated statements of profit or loss during the year ended December 31, 2022. At the closing date, in February 2022, this derivative and the agreed investment amount were recognized in our capital reserve and, taking an increase in share capital of &#8364;0.5&#160;million into account, led to a net increase of the capital reserve of &#8364;67.1&#160;million in our consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we redeemed our convertible note by exercising our early redemption option (see Note 12), which was fulfilled in April 2022, by issuing 1,744,392 ordinary shares. The nominal amount of &#8364;1.8&#160;million was recorded in share capital and, finally, as a result of the transaction, the capital reserve increased by &#8364;233.2&#160;million in our consolidated statements of financial position. The declaratory registration with the commercial register (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Handelsregister</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) was made on May 20, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, at the Annual General Meeting, our shareholders approved the proposed special cash dividend of &#8364;2.00 per ordinary share (including those held in the form of ADSs), which led to an aggregate payment of &#8364;484.3&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2022, the ESOP 2018 and LTI-plus awards were settled by transferring ordinary shares previously held in treasury to the entitled employees and Management Board members (see Note&#160;16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves and Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783955856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:50.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense arising from equity-settled share-based payment arrangements</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.0</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">13.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">20.2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Executive Officer Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">5.9</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2.4</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">36.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">25.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">32.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">InstaDeep Employee Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense / (Income) arising from cash-settled share-based payment arrangements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(0.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">53.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">6.3</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.2, 16.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.6</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech Restricted Stock Unit Plan for North America Employees</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">8.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22.8</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">51.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">108.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">93.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of sales</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.0</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales and marketing expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">51.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">108.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">93.7</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of &#8364;1.1&#160;million and &#8364;3.3&#160;million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2). </span></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of &#163;15.0&#160;million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments. </span></div><div style="text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, our share-based payment arrangements led to a cash outflow of &#8364;766.2 million, &#8364;51.8 million and &#8364;13.4 million, respectively. We expect to settle the equity-settled share-based payment arrangements of our 2020 Management Board Grant (see Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Chief Executive Officer Grant (see Note 16.4) and the Employee Stock Ownership Plan (see Note 16.5) on a net basis by delivering to the participant a number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. This reduces the dilutive impact of the respective rights compared to an all-equity settlement. If all of the equity-settled rights outstanding as of December&#160;31, 2023, were to be exercised accordingly, the cash outflow to the tax authority in 2024 would amount to approximately &#8364;213.0&#160;million (based on the share price as of December&#160;31, 2023).</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.1&#160;&#160;&#160;&#160;BioNTech Employee Equity Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America (Equity-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we approved the BioNTech 2020 Employee Equity Plan for employees based outside North America, or the European Plan. Under the European Plan, Restricted Stock Units, or RSUs, are offered to our employees. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Award agreements were entered as of the respective grant dates in February 2021 (LTI 2020 and LTI-plus program), January 2022 (LTI 2021 program) and December 2022 (LTI 2022 program). RSUs issued under the LTI 2020, LTI 2021 and LTI 2022 programs vest annually in equal installments over respective waiting periods of four years, commencing in December 2020, December 2021 and December 2022, respectively. RSUs issued under the LTI-plus program vested annually in equal installments over the waiting period of two years, which elapsed in December 2022. Hence, during the year ended December 31, 2022, the LTI-plus awards were settled by transferring shares previously held in treasury, see Note 15. All programs were classified as equity-settled as we have the ability to determine the method of settlement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the awards issued under the European Plan were based upon the price of our ADSs representing ordinary shares at the grant date. </span></div><div style="margin-top:12pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">372,011</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242,416</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110,036&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,932)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,111)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5,428)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Granted / Allocated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396,110&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(364,079)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235,305</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">104,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">396,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235,305</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,608&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396,110&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,400)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,497)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(16,141)</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">230,905</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">101,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">379,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">175,523</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">51,905&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">96,466&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">55,382</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">49,206&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">283,503&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#8364;171.40.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inputs Used in Measurement of the Fair Values at Grant Dates</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87.60&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92.21&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203.22&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165.03&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waiting period (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BioNTech 2020 Restricted Stock Unit Plan for North America Employees (Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we approved the BioNTech 2020 Restricted Stock Unit Plan for North America Employees, or the North American Plan. Under the North American Plan, RSUs are offered to our employees. These RSUs vest over four years, with 25% vesting one year after the service commencement date and the remainder vesting in equal quarterly installments thereafter. The first awards under the North American Plan were granted in February 2021. The service date for these awards is the date as of which the employee became employed by BioNTech US. During the years ended December 31, 2023, and 2022, further awards were granted under the North American Plan, which included awards granted </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to new-hire employees and ongoing, recurring awards to existing employees on the approximate anniversary of each employee&#8217;s start date of employment with BioNTech US. As these RSUs are intended to be cash-settled upon vesting, the awards were defined as a cash-settled share-based payment arrangement. During the years ended December&#160;31, 2023, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the exercise of RSUs resulted in a cash outflow of &#8364;10.0&#160;million, &#8364;9.4&#160;million and &#8364;10.1&#160;million, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the liability related to these awards amounted to &#8364;14.4&#160;million (&#8364;13.4&#160;million&#160;as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span>).<div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16.2&#160;&#160;&#160;&#160;Management Board Grant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Short-Term Incentive (Cash-Settled)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management Board&#8217;s service agreements also include a short-term incentive compensation component, which is an annual performance-related bonus for the years of their respective service periods. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50% of those yearly awards are paid out one year after the achievement of the performance targets for the respective bonus year has been determined, subject to an adjustment relative to the performance of the price of the American Depositary Shares representing our ordinary shares during that year (second installment). The second installments represent cash-settled share-based payment arrangements. The fair values of the liabilities are recognized over the awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vesting periods beginning when entering or renewing service agreements, i.e., the service commencement date, until each separate determination date and are remeasured until the settlement date. As of December&#160;31, 2023, the liability related to these awards amounted to &#8364;2.1&#160;million (&#8364;2.3&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span>).<div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">16.3&#160;&#160;&#160;&#160;Management Board Grant Long-Term Incentive (Partly Equity-Settled, Partly Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management Board&#8217;s service agreements provide for long-term incentive compensation (Management Board Grant - LTI) through an annual grant of options to acquire BioNTech shares during their respective service periods. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> granted each year are subject to the terms and conditions of the respective authorizations of the Annual General Meeting creating our Employee Stock Ownership Plan (ESOP) and the applicable option agreements thereunder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vest annually in equal installments over four years commencing on the first anniversary of the allocation date and are exercisable four years after the allocation date. The vested options can only be exercised if each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as set out in the ESOP agreement. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right to receive options generally represents an equity-settled share-based payment arrangement. The allocation of the number of issued options in 2020 occurred in February 2020. In May 2021 and May 2022, the Management Board received phantom options equivalent to the number of options the Management Board members would have been entitled to receive for 2021 and 2022, which led to a modification from equity-settled to cash-settled share-based payment arrangement and a reclassification of &#8364;1.1 million and &#8364;3.3 million between equity and non-current other liabilities as of the respective allocation dates. During 2023, options were granted in May 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development described above. The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;10.83</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;29.05</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;27.64</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;38.88</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;28.20</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;168.44</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;179.46</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;147.84</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;28.32</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;167.63</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;169.08</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;137.65</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.6&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap.&#160;</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;46.29</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;43.67</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;39.97</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;32.86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;98.93</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;105.42</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;96.82</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;99.74</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;105.13</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47.2&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.8&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.</span></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the awards with estimated allocation dates, the exercise prices of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All options are subject to an effective exercise price cap, which means that the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. With respect to the LTI 2020 agreement, the maximum economic benefit receivable in respect of any exercised option is capped at $246.24, with the effective exercise price being capped at a Euro amount equivalent to $30.78. With respect to the phantom share options issued under the LTI 2021 and 2022 as well as the options issued under the LTI 2023 programs, the maximum compensation that the Management Board members are entitled to receive under such programs, together with other compensation components received by each such board member in the respective grant year, shall not exceed &#8364;20.0&#160;million for Ugur Sahin as Chief Executive Officer (CEO) and &#8364;10.0&#160;million for all other Management Board members. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general option holder behavior for employee options. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (phantom) share options allocated and expected to be allocated to our Management Board as of December&#160;31, 2023, are presented in the table below. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Phantom) share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">248,096</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,279</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,463</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86,118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and vested but subject to performance and waiting requirements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">186,072</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22,640</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,232</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">21,531</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">62,024</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22,639</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,231</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">64,587</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.32</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">169.08</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share options outstanding / expected to be allocated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130,586</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">164,148</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118,312</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93,561</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">130,586</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.42</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96.82</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.74</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.13</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Valuation parameter derived from the Monte-Carlo simulation model. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the awards with estimated allocation dates, the numbers of options expected to be allocated have been derived from a Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the share options allocated and expected to be allocated under our equity-settled share-based payment arrangements had a remaining weighted average expected life of 4.1&#160;years (as of December&#160;31, 2022: 4.0&#160;years). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the liability related to the phantom option awards amounted to &#8364;3.6&#160;million (&#8364;5.6&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span>).<div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16.4&#160;&#160;&#160;&#160;Chief Executive Officer Grant (Equity-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we granted Ugur Sahin an option to purchase </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,374,963</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our ordinary shares, subject to Sahin&#8217;s continuous employment with us. The options&#8217; exercise price per share is the Euro translation of the public offering price from our initial public offering, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;13.60 ($15.00), </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is subject to the effective exercise price cap and the maximum cap mechanism. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price cap the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the maximum cap mechanism the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> maximum economic benefit receivable in respect of any exercised option</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is capped at $240.00 with the effective exercise price being capped at a Euro amount equivalent to $30.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vest annually in equal installments after four years commencing on the first anniversary of the initial public offering and have a waiting period of four years after the initial public offering. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5&#160;billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by us), and (b) for each twelve-month period starting on the fifth or subsequent </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as defined by our ESOP. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte-Carlo simulation model has been used to measure the fair value at the grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&#8217;s fair value at the grant date. The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:75.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date October 9, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;5.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;13.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;13.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41.4&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general option holder behavior for employee options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, with the final installment vesting, all 4,374,963 options became exercisable under the rules of the ESOP and the ESOP agreement. During the year ended December 31, 2023, no options were exercised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the share options outstanding had a remaining weighted average expected life of 1.1&#160;years (as of December&#160;31, 2022: 2.1 years).</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16.5&#160;&#160;&#160;&#160;Employee Stock Ownership Plan (Partly Equity-Settled, Partly Cash-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Share-Based Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an authorization of the general meeting on August 18, 2017, we established a share option program under which we granted selected employees options to receive our shares. The program is designed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as an Employee Stock Ownership Plan, or ESOP. We offered participants a certain number of option rights by their explicit acceptance of an option rights agreement. The exercise of option rights in accordance with the agreement gives the participants the right to obtain shares against payment of the exercise price. With respect to the Management Board members serving at the time of allocation, the options are subject to the effective exercise price cap and maximum cap mechanisms. Under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price cap, the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. Under </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum cap mechanism, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the maximum economic benefit receivable in respect of any exercised option, is capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$240</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the effective exercise price being capped at </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Euro amount equivalent to $30.00. Under the ESOP, the option rights (other than &#214;zlem T&#252;reci&#8217;s, and Ryan Richardson&#8217;s options) fully vest after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and can be exercised if: (i) the waiting period of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four years</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has elapsed; and (ii) at the time of exercise, the average closing price of the shares of the Company or the average closing price of the right or certificate to be converted into an amount per share on the previous ten trading days preceding the exercise of the option right exceeds the strike price by a minimum of 32%, with this percentage increasing by eight percentage points as of the fifth anniversary of the respective issue date and as of each subsequent anniversary date. Following the expiry of the waiting period, option rights may be exercised within a period of four weeks from the date of the Annual General Meeting or the publication of the annual financial statements, the semi-annual report or our most recent quarterly report or interim report (exercise windows). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option rights can be exercised up to eight years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of a shareholders&#8217; resolution of the general meeting on August 19, 2019, the authorization to issue such option rights was amended such that, in order for the options to be exercisable, the average closing price of the Company&#8217;s shares or the average closing price of the right or certificate to be converted into an amount per share on the ten trading days immediately preceding the exercise must exceed the strike price by a minimum of 28%, with this percentage increasing by seven percentage points as of the fifth anniversary of the issue date and as of each subsequent anniversary date. Furthermore, in addition to the aforementioned requirements, the exercise is only possible if the share price (calculated by reference to the price of the ordinary share underlying the ADS) has performed similar to or better than the Nasdaq Biotechnology Index. The changes made do not affect option rights already issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Measurement of Fair Values</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share options can only be exercised by the grantee if the price of the share is equal or greater to the threshold amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at the grant date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:54.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date <br/>November 15, 2018</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between <br/>February 21 and <br/>April 3, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between<br/>April 29 and <br/>May 31, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date December 1, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;7.41</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;6.93</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;7.04</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;9.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;14.40</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.72</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;16.03</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;19.84</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;10.14</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.03</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.39</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.82</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Settled)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share options <br/>outstanding</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ordinary shares underlying options</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average exercise price (&#8364;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">642,007</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,556,124</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.23</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Modified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,040)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(18,720)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(583,383)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10,500,890)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57,584</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,036,514</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11.10</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57,584</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,036,514</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.10</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(39,785)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(716,121)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.04</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,799</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">320,393</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11.24</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">17,799</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">320,393</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">11.24</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rights have been modified to cash-settled rights, all other terms remained unchanged.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was &#8364;96.49 and &#8364;160.44 for all settlements during the years ended December 31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Supervisory Board determined the ESOP settlement by the delivery of treasury shares (in the form of ADSs) equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The settlement was applied during the exercise windows in 2022 and 2023. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from and withheld upon the exercise amounted to &#8364;724.0 million and were paid in January 2023 in cash directly to the respective authorities. The settlement mechanism decision did not change the rights as such, neither did it change the classification as equity-settled option rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the share options outstanding under our equity-settled share-based payment arrangements had a remaining weighted average expected life of 0.8&#160;years (as of December&#160;31, 2022: 1.7 years).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Development of Share-Options (Cash</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Settled)</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phantom options which were granted under the ESOP mainly during the year ended December 31, 2022 each give the participants the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an American Depositary Share of BioNTech on Nasdaq over the last ten trading days preceding the exercise date) and the exercise price. The majority of options have an </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8364;10.14. During the years ended December 31, 2023, and 2022, 52,100 and 289,168 cash-settled phantom option rights were exercised and resulted in a cash outflow of &#8364;4.5&#160;million&#160;and &#8364;42.2 million, respectively. The average closing prices (10-day averages) of an American Depositary Share of BioNTech on Nasdaq weighted over the various settlement dates converted from USD to Euro using the exchange rate published by the German Central Bank (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deutsche Bundesbank</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on the same days was &#8364;96.25 and &#8364;155.39. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 109,651 cash-settled option rights remained outstanding. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the liability related to cash-settled share-based payment option rights amounted to &#8364;8.5&#160;million (&#8364;14.5&#160;million&#160;as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), of which &#8364;8.3&#160;million (&#8364;11.2&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span>) related to rights already vested (partly subject to performance and waiting requirements). The liability is based on the fair value of the respective rights. The fair value is measured using a binomial model consistent with the grant date fair value measurement of the equity-based option rights described above, which is updated on every reporting date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783968912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text">Provisions<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual disputes</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obligations from onerous CMO contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">278.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">375.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">269.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">367.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.6</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;118.2&#160;million in contractual disputes mainly related to purported obligations arising out of certain contractual disputes unrelated to the below-mentioned patent proceedings (&#8364;88.9&#160;million as of December&#160;31, 2022). Acknowledging an increase in obligations identified as contractual disputes, the change of &#8364;29.3&#160;million compared to the previous period related mainly to additions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;80.2&#160;million&#160;(&#8364;235.5&#160;million as of December&#160;31, 2022) of obligations for production capacities derived from contracts with Contract Manufacturing Organizations, or CMOs, that became redundant The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. The related expenses were recognized in cost of sales in our consolidated statements of profit or loss. The change of &#8364;(155.3)&#160;million compared to the previous period related to addition (&#8364;45.1&#160;million), to release (&#8364;126.0&#160;million) and usage (&#8364;74.5&#160;million). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our current provisions included &#8364;79.7 million in other obligations mainly comprising inventor remunerations as well as customs and duties (&#8364;51.4 million as of December&#160;31, 2022, mainly comprising inventor remunerations as well as customs and duties). The change of &#8364;28.3&#160;million compared to the previous period related mainly to additions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793810000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and other financial commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract', window );"><strong>Contingencies And Other Financial Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Contingencies and other financial commitments</a></td>
<td class="text">Contingencies and other financial commitments<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contingencies include, but are not limited to, intellectual property disputes and product liability and other product-related litigation. From time to time, in the normal course and conduct of our business, we may be involved in discussions with third parties about considering, for example, the use and/or remuneration for use of such third party&#8217;s intellectual property. As of December&#160;31, 2023, none of such intellectual property-related considerations that we have been notified of, and for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. We are subject to an increasing number of product liability claims. Such claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics/package leaflet) as well as label warnings and reliance thereon, scientific evidence and findings, actual and provable injury, and other matters. These complexities vary from matter to matter. As of December 31, 2023, none of these claims fulfill the criteria for recording a provision. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain pending matters to which we are a party are discussed below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &amp; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#8216;933 Patent, is infringed by the cationic lipid used in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#8216;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#8216;979 Patent, which is a continuation of the &#8216;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479; 11,633,480; 11,612,657; and 11,590,229, all of which are continuations of the &#8216;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the proceedings have been consolidated and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are currently pending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Alnylam&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CureVac Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;122, DE&#8217;961, DE&#8216;974, DE&#8217;575, and EP&#8217;668</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP1857122B1, or the EP&#8217;122 Patent, and three Utility Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or the EP&#8217;668 Patent, to its German lawsuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the D&#252;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#8217;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668) pending validity decisions in the DE&#8217;961, DE&#8217;974, and DE&#8217;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#8217;668 opposition proceedings before the Opposition Division of the European Patent Office. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#8217;961, DE&#8217;974, DE&#8217;575, and EP&#8217;668. On December 28, 2023, the D&#252;sseldorf Regional Court stayed the infringement proceedings as to EP&#8217;122 until a final appellate decision is rendered as to the validity of EP 122 by the Federal Court of Justice.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;755, DE&#8217;123, and DE&#8217;130</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#252;sseldorf Regional Court, alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of one European patent, EP4023755B1, or the EP&#8217;755 Patent, and two Utility Models DE202021004123U1, and DE202021004130U1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nullity Proceedings &#8211; EP&#8217;122</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#8217;122 Patent is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#8217;122 nullity action in support of the validity of the EP&#8217;122 Patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary opinion did not address any infringement of the EP&#8217;122 Patent.  The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#8217;122. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cancellation Proceedings&#8211; DE&#8217;961, DE&#8216;974, and DE&#8217;575</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent Office issued a preliminary opinion that DE&#8217;974 is likely to be cancelled based on invalidity pursuant to para. 1 (2) no. 5 Utility Model Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070; 11,286,492; 11,345,920; 11,471,525; 11,576,966; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against the EP&#8217;122 Patent and the EP&#8217;668 Patent in the Business and Property Courts of England and Wales. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#8217;122 and EP&#8217;668 patents in the Business And Property Courts of England and Wales. On December 18, 2023, we amended our pleadings to further allege non-infringement and invalidity against EP&#8217;755.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and utility models and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVac&#8217;s claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Germany</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Infringement Proceedings &#8211; EP&#8217;949 and EP&#8217;565</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#252;sseldorf Regional Court alleging Comirnaty&#8217;s infringement of two European Patents, 3590949B1, or the EP&#8217;949 Patent, and 3718565B1, or the EP&#8217;565 Patent.  On November 7, 2023, the European Patent Office (&#8220;EPO&#8221;) Opposition Division revoked EP&#8217;565 after a one-day oral hearing.  The Opposition Division issued a preliminary opinion on December 8, 2023 noting that it believes EP&#8217;949 is likely invalid.  As a result of these EPO proceedings, the D&#252;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit asserting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of the EP&#8217;949 Patent and EP&#8217;565 Patent. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. District Court Litigation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Moderna filed a lawsuit in the United States District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of U.S. Patent Nos. 10,898,574, 10,702,600 and 10,933,127 and seeking monetary relief. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Review</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Netherlands</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#8217;s infringement of the EP &#8216;949 Patent and the EP &#8217;565 Patent. The District Court of the Hague held a hearing on October 6, 2023 on infringement and validity with respect to the EP &#8217;949 Patent. On December 6, 2023, the Court found EP&#8217;949 to be invalid. The EP&#8217;565 case has been stayed pending Moderna&#8217;s appeal of the Opposition Division&#8217;s revocation of EP&#8217;565.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ireland</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and EP&#8217;565 Patent in the High Court of Ireland.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Belgium</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s infringement of the EP&#8217;949 Patent and the EP&#8217;565 Patent in the Brussels Dutch-speaking Enterprise Court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the above proceedings are currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Arbutus and Genevant Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus: U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098, through the use of Genevant&#8217;s lipid nanoparticle technology and methods for producing such lipids in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and seeking monetary relief. This proceeding is currently pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevant&#8217;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promosome Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Promosome LLC filed a lawsuit against Pfizer, us, and BioNTech Manufacturing GmbH in the U.S. District Court for the Southern District of California alleging that Pfizer and our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> vaccine has infringed U.S. Patent No. 8,853,179, and seeking monetary relief. On October 4, 2023, the parties filed a joint stipulation of dismissal, dismissing the lawsuit with prejudice. As part of this stipulation of dismissal, Promosome agreed to a covenant not to assert U.S. Patent No. 8,853,179 against Pfizer and us or any of their products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This matter is considered closed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other financial commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other financial commitments were as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">154.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,721.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,875.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">105.2</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations to acquire intangible assets exist in connection with in-licensing and research and development collaborations. We have entered into obligations to make milestone payments once specific targets have been reached. Provided that all of the milestone events are achieved, we would be obligated to pay up to &#8364;1,721.1&#160;million as of December&#160;31, 2023 (nil as of December&#160;31, 2022) in connection with the acquisition of intangible assets. The amounts shown represent the maximum payments to be made, and it is unlikely that they will all fall due. The amounts and the dates of the actual payments may both vary considerably from those stated in the table, since the achievement of the conditions for payment is possible but uncertain. Other financial obligations from possible future sales-based milestone and license payments were not included in the table above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected maturities of payment obligations under purchase agreements for property, plant and equipment and contractual obligations to acquire intangible assets are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">154.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249.4</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">954.9</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">516.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,721.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">956.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">516.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,875.5</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other financial obligations were recognized at nominal value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies And Other Financial Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ContingenciesAndOtherFinancialCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783315952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialLiabilitiesAbstract', window );"><strong>Other Non-Financial Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other Non-Financial Liabilities</a></td>
<td class="text">Other Non-Financial Liabilities<div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities to employees </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from share-based payment arrangements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from wage taxes and social securities expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">761.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">138.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">877.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">860.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788925007152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_Leases1Abstract', window );"><strong>Leases 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.1&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Financial Position</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Right-of-Use Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">206.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">214.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.9</span></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions to the right-of-use assets during the year ended December&#160;31, 2023, were &#8364;66.4 million&#160;(during the year ended December&#160;31, 2022: &#8364;118.3 million).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Liability</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are included in lease liabilities, loans and borrowings as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">216.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">210.1</span></td></tr></table></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.2&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Profit or Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation Charge of Right-of-Use Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total depreciation charge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">45.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">58.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">29.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense related to short-term leases and leases of low-value assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amounts recognized in profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">109.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">91.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">41.4</span></td></tr></table></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.3&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the total cash outflow for leases amounted to &#8364;46.0 million (during the year ended December&#160;31, 2022: &#8364;46.2 million; during the year ended December&#160;31, 2021: &#8364;17.0 million).</span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.4&#160;&#160;&#160;&#160;Extension Options</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased asset portfolio and align with the Group&#8217;s business needs. Management exercises judgment in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &#8364;157.2&#160;million as of December&#160;31, 2023, considering terms up until 2049 (as of December&#160;31, 2022: &#8364;163.1&#160;million considering terms up until 2049).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_Leases1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_Leases1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788782030208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Disclosures</a></td>
<td class="text">Related Party Disclosures<div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.1&#160;&#160;&#160;&#160;Parent and Ultimate Controlling Party</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of our ordinary shares. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. </span></div><div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">21.2&#160;&#160;&#160;&#160;Transactions with Key Management Personnel</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, at the Annual General Meeting, our shareholders reappointed Ulrich Wandschneider and Michael Motschmann as members of the Supervisory Board. In addition, Nicola Blackwood was appointed to our Supervisory Board. She succeeded Christoph Huber, who left the Supervisory Board after reaching the applicable retirement age limit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Management Personnel Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key management personnel has been defined as the members of the Management Board and the Supervisory Board. Key management personnel compensation is comprised of the following:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; first installment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; second installment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other variable compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments (incl. long-term incentive)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total compensation paid to key management personnel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes a one-time signing and retention cash payment agreed when renewing the service agreement agreed with Sean Marett.</span></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#8220;Stock-based Payments.&#8221; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. During the years ended December&#160;31, 2023, 2022, and 2021, the amounts included expenses derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the form of 4,246 phantom shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management Board members participated in our ESOP program (see Note 16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Out of the 5,152,410 option rights granted to our Management Board under the ESOP 2018 program 4,921,630 options were exercised during the year ended December 31, 2022. The remaining 230,780 option rights were exercised by Sean Marett in May 2023. As of December 31, 2023, no further options issued to our Management Board members are outstanding. </span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.3&#160;&#160;&#160;&#160;Related Party Transactions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of various goods and services from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of property and other assets from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">62.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.9</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, we entered into a purchase agreement with Santo Service GmbH, pursuant to which we acquired the real estate property An der Goldgrube 12 and the existing laboratory and office building including any movable assets for a total consideration of &#8364;62.5 million. The purchase price was paid during the year ended December 31, 2022. Santo Service GmbH is wholly owned by AT Impf GmbH, that is controlled by ATHOS KG.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:0.28pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td></tr></table></div>None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed by related parties.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794843728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EventsAfterReportingPeriodAbstract', window );"><strong>Events After Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events After the Reporting Period</a></td>
<td class="text">Events After the Reporting Period<div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2024, we and Autolus Therapeutics plc, or Autolus, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies' autologous CAR-T programs towards commercialization. We have entered into a license and option agreement and a securities purchase agreement under which we purchased $200.0&#160;million of Autolus' American Deposit Shares in a private placement closed on February 13, 2024 resulting in a stake in Autolus ordinary shares of 12.5%. Under the terms of the license and option agreement, we made a $50.0&#160;million upfront payment in exchange for the right to receive royalties on net sales of Autolus' lead asset obe-cel, co-commercialization options for Autolus' AUTO1/22 and AUTO6NG programs as well as an exclusive license and exclusive options to certain technologies owned by Autolus.</span></div>The Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer (CCO), effective as of July 1, 2024. She will take over the role from Sean Marett, who will retire as planned from the Management Board as of June 30, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Events After Reporting Period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788792742176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ListOfAccountingPoliciesAbstract', window );"><strong>List Of Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Basis of Preparation</a></td>
<td class="text">Basis of Preparation<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). </span></div>We prepare and publish our consolidated financial statements in Euros and round numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div>Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Basis of Consolidation</a></td>
<td class="text">Basis of Consolidation<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group controls an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if, and only if, the Group has</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">power over the investee (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, existing rights that give it the current ability to direct the relevant activities of the investee); </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expos</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ure, or rights, to variable returns from its involvement with the investee; and </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to use its power over the investee to affect its returns. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, there is a presumption that a majority of voting rights results in control. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether an investee is controlled is re-assessed if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when control is obtained over the subsidiary and ceases when control over the subsidiary is lost. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with the Group&#8217;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If control over a subsidiary is lost, the related assets (including goodwill), liabilities, non-controlling interests and other components of equity are derecognized, while any resultant gain or loss is recognized in the consolidated statements of profit or loss. Any investment retained is recognized at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currencies</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are presented in Euros, which is also our functional currency. For each entity, the Group determines the functional currency, and items included in the consolidated financial statements of such entities are measured using that functional currency. We use the direct method of consolidation and, on disposal of a foreign operation, the gain or loss that is reclassified to the consolidated statements of profit or loss reflects the amount that arises from using this method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions and Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions in foreign currencies are initially recorded by the Group&#8217;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation effects from the translation of operating activities include foreign exchange differences arising on operating items such as trade receivables and trade payables and are either shown as other operating income or expenses on a cumulative basis. Foreign currency translation effects presented within finance income and expenses include foreign exchange differences arising on financing items such as loans and borrowings as well as foreign exchange differences arising on cash and cash equivalents and are either shown as finance income or expenses on a cumulative basis. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation on Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and the transactions recorded in their consolidated statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock', window );">Current versus Non-Current Classifications</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current versus Non-Current Classifications</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities in the consolidated statements of financial position are presented based on current or non-current classification. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An asset is current when it is either: (i)&#160;expected to be realized or intended to be sold or consumed in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;expected to be realized within twelve months after the reporting period, or (iv)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least twelve&#160;months after the reporting period. All other assets are classified as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A liability is current when it is either: (i)&#160;expected to be settled in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;due to be settled within twelve months after the reporting period, or (iv)&#160;there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue from Contracts with Customers</a></td>
<td class="text">Revenue from Contracts with Customers<div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of the Contract</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract is an agreement between two or more parties that establishes enforceable rights and obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Identification of Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customer contracts often include bundles of licenses, goods and services. If the granting of a license is bundled together with delivering of goods and or the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply judgment when determining the consideration that is expected to be received. If the consideration in an agreement includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenues reversal in the amount of cumulative revenues recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenues are updated at each reporting date to reflect the current facts and circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allocation of Transaction Prices</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling prices. We have established the following hierarchy to determine the standalone selling prices.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where standalone selling prices for offered licenses, goods or services are observable and reasonably consistent across customers, our standalone selling price estimates are derived from our respective pricing history. However, due to the limited number of customers and the limited company history, this approach can rarely be used.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Where sales prices for an offering are not directly observable or highly variable across customers, we follow a cost-plus-margin approach.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For offerings that have highly variable pricing and lack substantial direct costs to estimate based on a cost-plus-margin approach, we allocate the transaction price by applying a residual approach.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment is required when estimating standalone selling prices.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recognition of Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenues are recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of our licensing arrangements, we provide the licensee with a research and development license, which represents a right to access our intellectual property as it exists throughout the license period (as our intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time as our customers simultaneously receive and consume the benefits from our performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues based on the collaboration partners&#8217; gross profit, which is shared under the respective collaboration agreements, are recognized based on the sales-based or usage-based royalty exemption; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the underlying sales occur, which is when the performance obligation has been satisfied. As described further in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> judgment is applied to certain aspects when accounting for the collaboration agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between us and the collaborator and the transactions between us and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenues. Any consideration related to activities in which we are considered the agent is accounted for as net revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from the sale of pharmaceutical and medical products (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) are recognized when we transfer control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and we have not retained any significant risks of ownership or future obligations with respect to the product. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, payments from customers are due within 30 days after invoice. However, with respect to our collaboration with Pfizer Inc., or Pfizer, there is a significant time lag between when revenues are recognized and the payments are received. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#8217;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenues from bill-and-hold arrangements are recognized at the point in time when the customer obtains control of the product and all of the following criteria have been met: (i)&#160;the arrangement is substantive; (ii)&#160;the product is identified separately as belonging to the customer; (iii)&#160;the product is ready for physical transfer to the customer; and (iv)&#160;we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether title and significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If we transfer goods or services to a customer before the customer pays the respective consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Receivables</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A receivable represents our right to an amount of consideration that is unconditional (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., only the passage of time is required before payment of the consideration is due). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract liability is the obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before we transfer goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(whichever is earlier). Contract liabilities are recognized as revenue when we fulfill our performance obligations under the contract.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Refund Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A refund liability is a consideration which has been received but which will need to be refunded to the customer in the future as it represents an amount to which we are ultimately not entitled under the contract. A refund liability is measured at the amount of consideration received (or receivable) to which we do not expect to be entitled (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounts not included in the transaction price). We update our estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development Expenses<div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period in which they are incurred. Regarding internal projects, we consider that regulatory approval and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained. Payments made to third parties, such as contract research and development organizations as compensation for subcontracted research and development, that are deemed not to transfer intellectual property are expensed as internal research and development expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority. We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset unless the respective intellectual property is mainly used as part of our general ongoing research and development activities without any intent to market the respective product as such. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. Sales-based milestone or royalty payments incurred under license agreements after the approval date of the respective pharmaceutical product are recognized as expenses in cost of sales as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent internal research and development costs in relation to intellectual property rights are expensed because the technical feasibility of the internal research and development activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the second quarter of 2023, we had assessed that inventory produced prior to successful regulatory approval did not meet the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because it is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. If regulatory approval for a product candidate is obtained, the relevant write-down would be reversed to a maximum of the original cost. Subsequently, inventory is recognized as cost of sales. This reassessment has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses are described in Note </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government Grants</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government grants and similar grants which are accounted for in accordance with IAS 20 are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs for which the grant is intended to compensate are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consolidated statements of profit or loss </span>over the useful life of the underlying asset subject to funding.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes</span><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Income Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed by tax authorities, excluding interest expenses and penalties on the underpayment of taxes. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities are recognized for all taxable temporary differences, except: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recognition of Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and deferred tax items are recognized similarly to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax assets and current tax liabilities are offset if, and only if, we have a legally enforceable right to set off the recognized amounts and intend either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when we have a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales Tax</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Tax Legislation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting (BEPS) project to tackle tax avoidance, the OECD/G20 Inclusive Framework (an association of about 140 countries) decided to introduce a global minimum taxation for large multinational groups (known as Pillar 2). The Global Anti-Base Erosion Rules are intended to ensure that large multinational groups pay a minimum level of tax on the income arising in each jurisdiction where they operate. In December 2021, the OECD published its Model Rules, which serve as a draft bill for implementation into national domestic law, followed by guidelines and commentaries published in March 2022. In December 2022, the EU adopted a corresponding directive (EU 2022/2523) that obliges EU member states to transpose the rules into national domestic law. If the effective tax rate in any jurisdiction is below the minimum rate (15%), the Group may be subject to the so-called top-up tax or a so-called qualified domestic minimum top-up tax. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several jurisdictions in which the Group operates have transposed the OECD Model Rules into national domestic law and brought them into force. In addition, the Group is closely following the progress of the legislative process in each country in which the Group operates. As of the balance sheet date, the BEPS Pillar 2 regulations (MinBestRL UmsG) had already been transposed into German law (MinStG). The date of application of the law in Germany is for financial years beginning after December 30, 2023. Subsequently, as the OECD Model Rules have entered into force in Germany, the Group is obliged to file top-up tax information returns for all entities which are part of the Group, beginning in financial year 2024. The Group falls within the scope of these regulations. The Group carried out an analysis as of the reporting date to determine the fundamental impact and the jurisdictions in which the Group is exposed to possible effects in connection with a Pillar 2 top-up tax.</span></div>Based on this analysis, no countries were identified in which the Group would be materially affected by a Pillar 2 top-up tax. Consequently, the average effective Group tax rate would not have changed if the Pillar 2 legislation had already been in force on the balance sheet date. BioNTech applies the exception in IAS 12, according to which no deferred tax assets and liabilities in connection with the second income taxes of the second pillar of the OECD are recognized and no disclosures are made.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.</span></div><div style="margin-top:12pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to executing business combinations are recognized when they are incurred and are classified as general and administrative expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.10. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in these circumstances is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The portion of the consideration in in-licensing agreements paid by us to acquire intellectual property is recognized as an intangible asset. If in-licensing includes research and development services, the share of consideration attributable to these services is deferred and recognized in research and development expenses according to the utilization thereof. Payments depending on the achievement of specific milestones as part of the purchase of intangible assets, except for intangible assets acquired in a business combination, are recognized as subsequent acquisition cost of the intangible asset and as a financial liability once the milestone is reached.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The useful lives of intangible assets are assessed as either finite or indefinite. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized generally on a straight-line basis over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each reporting period at the least. The amortization expense on intangible assets with finite lives is recognized in the consolidated statements of profit or loss in the expense category that is consistent with the function of the intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intellectual property rights</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8-20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licenses</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-20</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Software</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-8</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite useful lives are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2.3.10</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details). In the case of intangible assets not yet available for use, the point in time from which a capitalized asset can be expected to generate economic benefit for the Group cannot be determined. Such assets are not amortized, and therefore classified as having an indefinite useful life. The intangible assets not yet available for use are tested for impairment annually, or when there is an indication for impairment on an individual basis. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have classified advanced payments on intangible assets as intangible assets that are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An intangible asset is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2.3.4 for further details in connection with our accounting of internally generated intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress is stated at cost. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Property, plant and equipment</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10-33</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7-18</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and business equipment has a useful life of 1-10 years and is reported under equipment, tools and installations due to immateriality. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An item of property, plant and equipment initially recognized is derecognized upon disposal (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss when the asset is derecognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory', window );">Impairment of Non-Financial Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Non-Financial Assets</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, we assess whether there is an indication that a non-financial asset may be impaired. Goodwill is tested for impairment at least annually. Impairment is determined for goodwill by assessing the recoverable amount of each cash-generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, we estimate the asset&#8217;s or CGU&#8217;s recoverable amount. The recoverable amount is the higher of an asset&#8217;s or CGU&#8217;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the asset does not generate independent cash inflows, the impairment test is performed for the smallest group of assets that generate largely independent cash inflows from other assets (CGU). When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or the non-current assets of the CGU are considered impaired and written down to their recoverable amount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses are recognized in the consolidated statements of profit or loss in expense categories consistent with the function of the impaired asset.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with an indefinite useful life are tested for impairment annually at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets not yet available for use are not amortized, but rather tested for impairment when a triggering event arises or at least once a year. The identification of triggering events takes place on a quarterly or on an ad hoc basis with the involvement of the responsible departments, taking internal and external information sources into consideration. The impairment test is performed annually or if there are indications of impairment by determining the asset&#8217;s value in use. In assessing value in use, the estimated discounted future cash flows are based on long-term forecast calculations reflecting the asset&#8217;s estimated product life cycles. The assumptions are based on internal estimates along with external market studies. The result of the valuation depends to a large extent on the estimates by the management of the future cash flows of the assets and the discount rate applied, and is therefore subject to uncertainty.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i) Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Initial Recognition and Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets mainly include money market funds, bank deposits and reverse repos, security investments, trade receivables, cash at banks as well as equity investments. Financial assets are initially measured at fair value as of the trade date and &#8211; depending on their classification &#8211; subsequently measured at amortized cost, fair value through other comprehensive income (OCI) or fair value through profit or loss. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsequent Measurement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement of financial assets depends on their classification, as described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Measured at Amortized Cost</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at amortized cost include trade receivables and other financial assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are generally measured using the effective interest rate (EIR) method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With respect to trade receivables, we applied the practical expedient, which means that they are measured at the transaction price determined in accordance with IFRS 15. Refer to the accounting policies in Note&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other financial assets measured at amortized cost are held to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in our consolidated statements of profit or loss when the financial asset is derecognized, modified or impaired. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Designated at Fair Value through OCI (Equity Instruments)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon initial recognition, we can irrevocably elect to classify equity investments as equity instruments designated at fair value through OCI if they meet the definition of equity under IAS 32 and are not held for trading. The classification is determined on an instrument-by-instrument basis. Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the consolidated statements of profit or loss when the right of payment has been established. Equity instruments designated at fair value through OCI are not subject to impairment assessment. We elected to irrevocably classify our non-listed and listed equity investments under this category. They are recognized using trade date accounting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets at Fair Value through Profit or Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivatives not designated as hedging instruments are measured at fair value through profit or loss. A financial asset exists if the derivative has a positive fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, removed from the consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Financial Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for expected credit losses (ECLs) is considered for all non-derivative financial debt investments, including cash, time deposits and debt securities of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our financial debt investments are considered to be investments with low risk, the expected credit loss in the upcoming twelve months is used to determine the impairment loss. Wherever a considerable increase in the default risk is assumed, the lifetime expected credit loss of the financial asset is considered.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. This means that the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. We have established an ECL model that is based on the probability of default (PD), considers the respective country default probabilities and takes the maturities into account. In order to determine the PD of companies, we use the maturities of the trade receivables and the score of the companies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there is objective evidence that certain trade receivables or contract assets are fully or partially impaired, additional loss allowances are recognized to account for expected credit losses. A debtor&#8217;s creditworthiness is assumed to be impaired if there are objective indications that the debtor is in financial difficulties, such as the disappearance of an active market for its products or impending insolvency. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii) Financial Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are generally measured at amortized cost using the effective interest rate (EIR) method. Derivatives with negative fair values not designated as hedging instruments and liabilities for contingent consideration in business combinations are measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities measured at amortized cost include loans and borrowings, trade payables and other financial liabilities. They are measured at amortized cost using the EIR method. Gains and losses are recognized in the consolidated statements of profit or loss when the liabilities are derecognized as well as through the EIR amortization process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statements of profit or loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iii) Expenses and Income from Exchange Forward Contracts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effects from foreign exchange forward contracts, which are measured at fair value through profit or loss, are shown as either other operating income or other operating expenses on a cumulative basis and might switch between those two items during the year-to-date reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 inputs are unobservable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, we determine whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of fair value disclosures, classes of assets and liabilities have been determined on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost and net realizable value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in bringing each product to its present location and condition are accounted for as follows:</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw materials and supplies: purchase cost on a first-in / first-out basis; or</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale. Write-offs are recorded if inventories are expected to be unsaleable, do not fulfill the specification defined by our quality standards or if their shelf-life has expired. For our inventories subject to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the collaboration partners&#8217; gross profit share mechanism</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we consider the contractual compensation payments in the estimate of the net realizable value.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning with the second quarter of 2023, pre-launch products from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comirnaty</span> product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained (see also Note 2.3.4 for further information on our assessment regarding the potential of our pre-launch products to produce economic benefits).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span>Cash and cash equivalents comprise cash at banks and on hand and short-term investments that we consider to be highly liquid (including deposits, money market funds and reverse repos) with an original maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Deposits with an original maturity of more than three months are recognized as other financial assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the par value method to our repurchases of outstanding American Depositary Shares, or ADSs. Accordingly, the nominal value of acquired treasury shares is deducted from equity and shown in the separate item &#8220;Treasury shares&#8221;. Any premium paid in excess of the nominal value of a repurchased ADS is deducted from the capital reserve. On the trade date, we recognize a liability, and on the settlement date, we settle in cash. We recognize the foreign exchange differences that may occur between the trade and settlement date as profit or loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset &#8211; this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the asset. We possess this right when we hold the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we have the right to operate the asset; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">we designed the asset in a way that predetermines how and for what purpose it will be used. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception or on reassessment of a contract that contains a lease component, the consideration in the contract is allocated to each lease component on the basis of their relative standalone prices. However, for leases of land and buildings in which we are a lessee, we have elected not to separate non-lease components, and instead account for the lease and non-lease components as a single lease component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a right-of-use asset and a lease liability at the lease commencement date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#8217;s incremental borrowing rate. Generally, the incremental borrowing rate is used as the discount rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability comprise the following: </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fixed payments, including in-substance fixed payments;</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; </span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts expected to be payable under a residual value guarantee; and</span></div><div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exercise price under a purchase option that is reasonably certain to be exercised, lease payments in an optional renewal period if it is reasonably certain that the extension option is exercised, and penalties for early termination of a lease unless it is reasonably certain that the contract will not be terminated early.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is subsequently measured at amortized cost using the EIR method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if we change our assessment of whether we will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the consolidated statements of profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets are presented separately and lease liabilities are presented under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:77.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life or shorter lease term (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-25</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-5</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-3</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Automobiles</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-4</span></div></td></tr></table></div><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Leases and Leases of Low-Value Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. We recognize the lease payments associated with these leases as an expense in the consolidated statements of profit or loss on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provisions</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When we expect some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A provision is also recognized for certain contracts with suppliers for which the unavoidable costs of meeting the obligations exceed the economic benefits expected to be received. The economic benefits considered in the assessment comprise the future benefits we are directly entitled to under the contract as well as the anticipated future benefits that are the economic consequence of the contract if these benefits can be reliably determined.</span></div>The expense relating to a provision is presented in the consolidated statements of profit or loss net of any reimbursement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-Based Payments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions) or in cash (cash-settled transactions). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IFRS 2, share-based payments are generally divided into cash-settled and equity-settled. Both types of payment transactions are measured initially at their fair value as of the grant date. The fair value is determined using an appropriate valuation model, further details of which are given in Note 16. Rights granted under cash-settled transactions are remeasured at fair value at the end of each reporting period until the settlement date. The cost of share-based payment awards is recognized over the relevant service period, applying either the straight-line method or the graded vesting method, where applicable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves) or other liabilities, over the period in which the service is provided (the vesting period). The cumulative expense recognized for cash- and equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired, and also reflects the best estimate of the number of equity instruments expected to ultimately vest. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of our best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have a choice of settling either in cash or by providing equity instruments, the rights granted are accounted for as an equity-settled transaction, unless there is a present obligation to settle in cash. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, due to local tax regulations, an amount is withheld for the employee&#8217;s tax obligations and paid directly to the tax authorities in cash on the employee&#8217;s behalf, the entire share-based payment program remains an equity-settled plan based on the IFRS 2 classification. Accordingly, the amount withheld for the employee&#8217;s tax obligations expected to be paid directly to the tax authorities is reclassified from &#8220;Other reserves&#8221; to &#8220;Other non-financial liabilities&#8221;.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory', window );">Cash Dividend</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Dividend</span><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a liability to pay a dividend when the distribution is authorized. As per the corporate laws of Germany, a distribution is authorized when it is approved by the general shareholder meeting. A corresponding amount is recognized directly in equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock', window );">Standards Applied for the First Time</a></td>
<td class="text">Standards Applied for the First Time<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:80.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IFRS 17 Insurance Contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#8211; Comparative Information</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income taxes: International Tax Reform &#8211; Pillar Two Model Rules</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock', window );">Standards Issued but Not Yet Effective</a></td>
<td class="text">Standards Issued but Not Yet Effective<div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:75.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.733%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>We do not expect a significant impact from the application of any of these standards and amendments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Assets And Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ListOfAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>List Of Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ListOfAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790380800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ListOfAccountingPoliciesAbstract', window );"><strong>List Of Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Summary of Useful Lives Applied to the Group's Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the useful lives applied to the Group&#8217;s intangible assets is as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intellectual property rights</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8-20</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Licenses</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-20</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Software</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-8</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Property, plant and equipment</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10-33</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7-18</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition and production costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">182.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">329.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(40.2)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">273.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">273.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">189.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(31.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">344.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">969.0</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative depreciation and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">175.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">195.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">178.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">609.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">199.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">168.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">757.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock', window );">Summary of Estimated Useful Lives of the Assets or Shorter Lease Term</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:77.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life or shorter lease term (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-25</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-5</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2-3</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Automobiles</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3-4</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Summary of Standards Applied for the First Time</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:80.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IFRS 17 Insurance Contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#8211; Comparative Information</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 12 Income taxes: International Tax Reform &#8211; Pillar Two Model Rules</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2023</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Summary of Standards Issued but Not Yet Effective</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:75.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.733%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Standards / Interpretations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Date of application</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2024</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 1, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ListOfAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>List Of Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ListOfAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791197040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Summary of Information about Subsidiaries</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the following subsidiaries: </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:43.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">% equity interest</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech BioNTainer Holding GmbH</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Cell &amp; Gene Therapies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Halle</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Diagnostics GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Europe GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Idar-Oberstein Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Individualized mRNA Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation and Services Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovation GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Innovative Manufacturing Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Idar-Oberstein </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Manufacturing Marburg GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Marburg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Holding GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Real Estate Verwaltungs GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Holzkirchen</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep DE GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Berlin </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">NT Security and Services GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">reSano GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Australia Pty Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Australia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Melbourne</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech R&amp;D (Austria) GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Austria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vienna</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">China</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shanghai</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Paris</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biopharma BioNTech Israel Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Israel</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tel Aviv</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">New Technologies Re</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Luxembourg</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Nigeria Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nigeria</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lagos</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Rwanda Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Rwanda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Kigali</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech S&#233;n&#233;gal Suarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Senegal</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dakar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Singapore</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Pharmaceuticals Spain S.L</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Spain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Barcelona</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Switzerland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Switzerland</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Basel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Taiwan Co. Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taiwan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Taipei</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Tunisia SARL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunisia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Tunis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">T&#252;rkiye</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Istanbul</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech UK Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United Kingdom</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">London</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.3%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Research and Development, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech USA Holding, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech US Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BioNTech Delivery Technologies (US), LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">InstaDeep LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Dover</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">n/a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">JPT Peptide Technologies Inc.</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cambridge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">100&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Included during the year ended December 31, 2023.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Fully acquired during the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock', window );">Summary of Information about Parent Company</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">AT Impf GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Munich</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43.77&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43.42&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock', window );">Summary of Information about Entity with Significant Influence Over Group</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Ownership of ordinary shares in BioNTech (in %)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Country of incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Registered office</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Medine GmbH</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Germany</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Mainz</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17.01&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17.38&#160;</span></td><td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Entity With Significant Influence Over Group Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Significant Investments By Parent Company Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788789962048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_BusinessCombinations1Abstract', window );"><strong>Business Combinations 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Summary of Fair Values of Identifiable Net Assets</a></td>
<td class="text">The total consideration and the fair values in accordance with IFRS&#160;3 of the identified net assets acquired of InstaDeep as of July 31, 2023, are as follows:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fair value recognized on acquisition</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">InstaDeep Ltd.</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Assets </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property, plant and equipment </span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade receivables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial assets - current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other assets non-current and current</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total assets</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">275.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other liabilities long-term and short-term</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total liabilities</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">64.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total identifiable net assets at fair value</span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill from the acquisition</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">306.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">517.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">358.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash to be paid in 2024</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Designated FX hedge</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares transferred (approx. 1.1 million shares)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Previously held non-listed equity investment (stake of 5.3%)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total consideration </span></td><td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">517.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_BusinessCombinations1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_BusinessCombinations1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784350352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Disaggregation of Revenues from Contracts with Customers</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the disaggregation of the Group&#8217;s revenues from contracts with customers:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"></td><td style="width:55.454%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commercial revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,815.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,194.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,874.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COVID-19 vaccine revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,776.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,145.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,806.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sales to collaboration partners</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">275.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1,224.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">970.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Direct product sales to customers</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">473.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,184.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,007.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of collaboration partners&#8217; gross profit and sales milestones</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,027.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">12,736.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">14,828.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research &amp; development revenues from collaborations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">102.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,976.7</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenues from contracts with customers disclosed above were recognized as follows: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#1A1A1A;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Timing of revenue recognition</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred at a point in time</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">776.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,447.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,034.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goods and services transferred over time</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">127.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,027.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,736.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,828.7</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,819.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,310.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18,976.7</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents sales based on the share of the collaboration partners&#8217; gross profit and sales milestones.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock', window );">Summary of Contract Balances</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">751.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refund liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock', window );">Summary of Revenue Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is the amount of revenue recognized for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amounts included in contract liabilities at the beginning of the year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.7</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsExplanatory', window );">Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as of year-end are as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Within one year</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">353.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More than one year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">398.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.4</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">751.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">125.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Contract Balances From Contracts With Customers Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Recognition Of Revenue Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of performance obligations in contracts with customers. [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 119<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_119&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790755360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock', window );">Summary of Other Operating Expenses</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">252.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">385.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation costs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">293.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">410.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">103.4</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures relate to costs for external legal advice in connection with certain legal litigations from general and administrative expenses to other operating expense to reflect changes in internal reporting also in the external reporting.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock', window );">Summary of Other Operating Income</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gain on derivative instruments at fair value through profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">727.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">446.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">105.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">815.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">598.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock', window );">Summary of Finance Income</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">357.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">162.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66.2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">519.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">330.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">67.7</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock', window );">Summary of Finance Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange differences, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustments of financial instruments measured at fair value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">277.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">23.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">305.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock', window );">Summary of Employee Benefits Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Wages and salaries</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">617.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">544.8</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">345.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Social security costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.7</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58.6</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pension costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">698.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">605.5</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">378.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Employee Benefits Expense Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Finance Cost Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Finance Income Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Operating Expenses Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Operating Income Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794910048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock', window );">Summary of Current and Deferred Tax Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the current and deferred taxes for the periods indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">243.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,629.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,535.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(109.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">218.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">255.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,519.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,753.9</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock', window );">Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit</a></td>
<td class="text"><div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"><tr><td style="width:1.0%"></td><td style="width:55.454%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Profit before tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,186.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,954.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15,046.4</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected tax credit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">321.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,529.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,622.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Effects </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to local tax basis</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deviation due to deviating income tax rate (Germany and foreign countries)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(14.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects from tax losses and tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(66.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in deferred taxes due to tax rate change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.3)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7.5)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-deductible expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(87.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non tax-effective share-based payment expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax-effective equity transaction costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjustment prior year taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(31.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-tax effective bargain purchase</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other effects</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.0)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">255.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,519.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,753.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27.2%</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">31.6%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of Deferred Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes for the periods indicated relate to the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:42.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(44.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.4)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(56.6)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">113.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(162.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(90.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10.0)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33.0)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(43.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(58.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">142.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(106.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(44.9)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(77.8)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(102.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(136.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(66.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(138.0)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">223.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(12.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(169.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">41.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">229.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(169.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">81.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Thereof deferred tax liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(6.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(33.5)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(39.7)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:42.253%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, <br/>2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in P&amp;L</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized in OCI</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recognized directly in equity</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(47.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8.3)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.8)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inventories </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">147.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(95.6)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(67.1)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(162.7)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(15.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(20.6)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10.0)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net employee defined benefit liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">179.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other (incl. deferred expenses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax losses / tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets net (before valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">165.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.9</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">360.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(81.0)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55.7)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(136.7)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deferred tax assets / (liabilities), net (after valuation adjustment)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(66.7)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">109.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">179.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">223.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock', window );">Summary of Accumulated Tax Losses</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up until the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:</span><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Corporate tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">260.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">272.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade tax </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">140.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">170.6</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State tax credits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accumulated Tax Losses Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Current And Deferred Tax Expense Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784123072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the income and share data used in the basic and diluted EPS calculations:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;, except per share data)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Profit attributable to ordinary equity holders of the parent for basic earnings </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">930.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9,434.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10,292.5</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average number of ordinary shares outstanding for basic EPS</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">240.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">243.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">244.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effects of dilution from share options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average number of ordinary shares outstanding adjusted for the effect of dilution</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">242.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">249.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">259.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings per share</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings for the period per share</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.87</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.78</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.18</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Diluted earnings for the period per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.83</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37.77</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.63</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790307632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Summary of Detailed Information About Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Goodwill</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">306.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.6)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">362.5</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">191.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">199.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">222.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">222.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">489.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">505.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">187.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.2)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4.9)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">898.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">921.0</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative amortization and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">54.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">54.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.1)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">76.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">76.9</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.9</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Concessions, licenses, in-process R&amp;D and similar rights </span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">145.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">158.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">781.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">804.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock', window );">Summary of Goodwill Recognized</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:19.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CGU Immunotherapies</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Product Sales of JPT</span></td><td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">External Business of InstaDeep</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Goodwill</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">362.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Intangible assets with indefinite useful life</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">444.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">796.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">807.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">61.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783123360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Summary of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:84.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Property, plant and equipment</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Useful life (years)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10-33</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment, tools and installations </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7-18</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Acquisition and production costs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">182.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">329.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.1)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(40.2)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">217.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">273.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">217.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">273.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">725.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">189.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquisition of subsidiaries and businesses</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.6)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reclassifications</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(31.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5.4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">344.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">969.0</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cumulative depreciation and impairment charges</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">14.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">60.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.4)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">94.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">116.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disposals</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.7)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Currency differences</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.2)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.3)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.5)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">175.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Land and buildings</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Equipment, tools and installations</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Construction in progress and advance payments</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">195.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">178.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">609.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">199.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">168.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">389.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">757.2</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781479216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">453.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11,210.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">12,549.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11,663.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">13,875.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.1</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136.6</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">244.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.5</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">414.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">803.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">196.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,073.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">232.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">785.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,029.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">115.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">85.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,229.9</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Summary of Financial Liabilities at Amortized Cost</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.1</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">136.6</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">244.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.5</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">414.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">803.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">196.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">74.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,073.8</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other payables</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">112.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">232.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">785.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,029.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">115.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">85.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,229.9</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:</span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,446.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,155.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security investments</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,989.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,589.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Reverse Repo</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,175.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">453.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">216.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">354.0</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">414.9</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"><tr><td style="width:1.0%"></td><td style="width:24.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.385%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Category</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Carrying amount</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 1 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 2 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Level 3 (Fair value)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign exchange forward contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">183.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,148.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTOCI</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.0</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial assets not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade and other receivables </span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,145.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial assets</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bank deposits</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,401.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash at banks and on hand</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,325.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FVTPL</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial liabilities not measured at fair value</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liabilities</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade payables and other payables</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">204.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other financial liabilities</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AC</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">785.1</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.</span></div><div style="margin-top:6pt;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:32.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net gain on equity instruments designated at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7</span></td><td colspan="3" style="border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">10.5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Summary of Significant Unobservable Inputs Used in Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:23.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Type</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Valuation technique</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Significant unobservable inputs</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:23.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.816%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward exchange contracts</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-listed equity investments</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Actual and forecasted results</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Cash position</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Nature and pricing indication of latest financing round</span></div><div style="text-indent:10.91pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Listed equity investments</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Money market funds</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Quoted prices on an active market</span></div></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n/a</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contingent consideration</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. </span></div></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Expected future payments</span></div><div style="padding-left:14.17pt;text-indent:-7.09pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt">Applied cost of capital</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sensitivity of the fair values of contingent considerations in fair value level 3 to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent consideration</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:33.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input factor</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in assumptions</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with increasing input factor (in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in fair value with decreasing input factor (in millions &#8364;)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash flow projections</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10&#160;</span></td><td style="background-color:#c6e0b4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3.4)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.8)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the recurring fair value measurement of the contingent considerations and the effect of the measurements on our consolidated statements of profit or loss for the current period.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:38.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contingent consideration</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.8</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net effect on profit or loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net change in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">38.8</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock', window );">Summary of Carrying Amount of Monetary Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the monetary assets and liabilities denominated in U.S. dollar at the dates indicated are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,487.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary assets in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,191.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,098.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Monetary liabilities and provisions in U.S. dollar</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">567.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,527.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">747.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7,058.1</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock', window );">Summary of Effect of Changes in Foreign Exchange Rates</a></td>
<td class="text"><div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables demonstrate the sensitivity to a reasonable, possible change in U.S. dollar exchange rates or U.S. dollar forward rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets and liabilities. The exposure to foreign currency changes for all other currencies is not material.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:26.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.845%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1 &#8364; =</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing rate</span></td><td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Country</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. dollar</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States </span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1050</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0666</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0813</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0530</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change in U.S. dollar rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on profit / (loss) before tax</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Effect on pre-tax equity</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.5)</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(35.5)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.2</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39.3</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(195.2)</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(191.5)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">-5 %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215.7</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">211.7</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Summary of Changes in Liabilities Arising from Financing Activities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2023</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.0</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(40.3)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(0.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1.1)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">28.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51.1</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(34.1)</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2.5)</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">188.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#c6e0b4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">212.2</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(40.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">50.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(3.6)</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">219.0</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"><tr><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">January 1, 2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flows</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">New leases and disposals</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Reclassifi-cation</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(41.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.8</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33.3</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current obligations under lease contracts</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">153.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(33.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">174.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loans and borrowings</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(18.0)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(99.8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note &#8211; embedded derivative</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">308.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(308.7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">610.2</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(59.1)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">67.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(406.3)</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">212.2</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Related to the early redemption of our convertible note during the year ended December&#160;31, 2023, as further described in Note 15.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Foreign Currency Risk Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783971776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Raw materials and supplies</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">347.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">409.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unfinished goods</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finished goods</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">357.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">439.6</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Classes Of Inventories Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783177568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Financial Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialAssetsAbstract', window );"><strong>Other Non-Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock', window );">Summary of Other Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120.0</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales tax receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepayments related to CRO and CMO contracts</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">364.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">278.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">280.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">271.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83.4</span></td><td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Assets Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781217168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves and Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock', window );">Summary of Shares Repurchase Program</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program first tranche ($1.0&#160;billion)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">917,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$151.76 (&#8364;143.99)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$139.3 (&#8364;132.2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,160,219</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$140.82 (&#8364;133.35)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$163.4 (&#8364;154.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">519,320</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$162.03 (&#8364;159.40)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$84.1 (&#8364;82.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,666,515</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$149.08 (&#8364;148.24)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$248.4 (&#8364;247.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,280,988</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$135.95 (&#8364;137.66)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$310.1 (&#8364;314.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 2022</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">400,483</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$136.37 (&#8364;139.09)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$54.6 (&#8364;55.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,945,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$999.9 (&#8364;986.4)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Program second tranche ($0.5&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">618,355</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$142.26 (&#8364;131.12)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$88.0 (&#8364;81.1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">857,620</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$138.05 (&#8364;129.06)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$118.4 (&#8364;110.7)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">745,196</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$128.49 (&#8364;121.08)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$95.7 (&#8364;90.2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2,221,171</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$302.1 (&#8364;282.0)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following repurchases under the programs occurred:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Program 2023 ($0.5&#160;billion)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Period</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ADSs purchased</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Average price paid per ADS</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net amount spent (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,532,685</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$108.92 (&#8364;100.45)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$166.9 (&#8364;154.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">July 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,738,061</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$107.92 (&#8364;97.57)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$187.6 (&#8364;169.6)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 2023</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,261,706</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$105.07 (&#8364;95.85)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$132.6 (&#8364;120.9)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 2023</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114,513</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$112.22 (&#8364;105.07)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$12.9 (&#8364;12.0)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,646,965</span></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$500.0 (&#8364;456.5) </span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Shares Repurchase Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves and Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790297408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss', window );">Summary of Expense Recognized for Employee Services Received</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:50.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.187%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense arising from equity-settled share-based payment arrangements</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.0</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">13.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">20.2</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Executive Officer Grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">5.9</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2.4</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">36.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">25.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">32.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">InstaDeep Employee Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense / (Income) arising from cash-settled share-based payment arrangements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Stock Ownership Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.5</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(0.9)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">53.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">6.3</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Management Board Grant</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.2, 16.3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(2.4)</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3.6</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BioNTech Restricted Stock Unit Plan for North America Employees</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">10.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">8.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22.8</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">51.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">108.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">93.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of sales</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.0</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales and marketing expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25.7</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">51.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">108.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">93.7</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of &#8364;1.1&#160;million and &#8364;3.3&#160;million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span>&#160;&#160;&#160;&#160;As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of &#163;15.0&#160;million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember', window );">Employee Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of Number and Share Price of Restricted Stock Units</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Outstanding Share-Options</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">372,011</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">242,416</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">110,036&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,932)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,111)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5,428)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Granted / Allocated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396,110&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Settled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(364,079)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">235,305</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">104,608</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">396,110</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235,305</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104,608&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">396,110&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forfeited / Modified</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,400)</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,497)</span></td><td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(16,141)</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">230,905</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">101,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">379,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">175,523</span></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">51,905&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">96,466&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">55,382</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">49,206&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">283,503&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#8364;171.40.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI-plus program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2020 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2021 program</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LTI 2022 program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87.60&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92.21&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203.22&#160;</span></td><td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">165.03&#160;</span></td><td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Waiting period (in years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.0</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text">The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;10.83</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;29.05</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;27.64</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;38.88</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;28.20</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;168.44</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;179.46</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;147.84</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;28.32</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;167.63</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;169.08</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;137.65</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.6&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49.7&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.6&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap.&#160;</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;46.29</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;43.67</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;39.97</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;32.86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average share price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;98.93</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;95.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;105.42</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;96.82</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;99.74</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;105.13</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47.2&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47.7&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.8&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life (years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.7&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of Number and Weighted-Average Exercise Price of Share Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (phantom) share options allocated and expected to be allocated to our Management Board as of December&#160;31, 2023, are presented in the table below. </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date February 2020</span></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 12, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation date May 17, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Phantom) share options outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">248,096</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,279</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,463</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86,118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and vested but subject to performance and waiting requirements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">186,072</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22,640</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,232</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">21,531</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">62,024</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">22,639</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">3,231</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">64,587</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.32</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">167.63</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">169.08</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">137.65</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:41.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allocation date May 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated allocation date 2026</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share options outstanding / expected to be allocated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">130,586</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">164,148</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118,312</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93,561</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof allocated and unvested</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">130,586</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average exercise price (&#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.42</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96.82</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.74</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.13</span></td></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span>Valuation parameter derived from the Monte-Carlo simulation model.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text">The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:75.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date October 9, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;5.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;13.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;13.60</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41.4&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5&#160;</span></td><td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in Measurement of Fair Value at Grant Date</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:54.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date <br/>November 15, 2018</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between <br/>February 21 and <br/>April 3, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant dates<br/>between<br/>April 29 and <br/>May 31, 2019</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant date December 1, 2019</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average fair value</span></td><td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;7.41</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;6.93</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;7.04</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;9.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average share price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;14.40</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.72</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;16.03</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;19.84</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;10.14</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.03</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.39</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8364;15.82</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46.0&#160;</span></td><td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.8</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of Number and Weighted-Average Exercise Price of Share Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: </span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Share options <br/>outstanding</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Number of ordinary shares underlying options</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Weighted average exercise price (&#8364;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">642,007</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,556,124</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.23</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Modified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,040)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(18,720)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(583,383)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(10,500,890)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.14</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">57,584</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,036,514</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11.10</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January 1, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57,584</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,036,514</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.10</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(39,785)</span></div></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(716,121)</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.04</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">As of December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,799</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">320,393</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">11.24</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof vested</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">17,799</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">320,393</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">11.24</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">thereof unvested</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.</span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Rights have been modified to cash-settled rights, all other terms remained unchanged.</span></div><div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was &#8364;96.49 and &#8364;160.44 for all settlements during the years ended December 31, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788926473968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfProvisionsTableTextBlock', window );">Disclosure of Provisions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual disputes</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">118.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obligations from onerous CMO contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80.2</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">235.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51.4</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">278.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">375.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">269.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">367.2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.6</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783977488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and other financial commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract', window );"><strong>Contingencies And Other Financial Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Schedule of Other Financial Commitments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other financial commitments were as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">154.4</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,721.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,875.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">105.2</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected maturities of payment obligations under purchase agreements for property, plant and equipment and contractual obligations to acquire intangible assets are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.777%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Year ended December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1 to 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commitments under purchase agreements for property, plant and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">152.5</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">154.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual obligation to acquire intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249.4</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">954.9</span></td><td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">516.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,721.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">401.9</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">956.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">516.8</span></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,875.5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies And Other Financial Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ContingenciesAndOtherFinancialCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784187632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Non-Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialLiabilitiesAbstract', window );"><strong>Other Non-Financial Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock', window );">Summary of Other Non-Financial Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities to employees </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73.3</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from share-based payment arrangements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities from wage taxes and social securities expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">761.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29.2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">138.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">877.8</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">860.8</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.1</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788921835504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_Leases1Abstract', window );"><strong>Leases 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Right-of-Use Assets within Consolidated Statements of Financial Position</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">209.8</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">206.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.4</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">214.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">211.9</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock', window );">Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following amounts are included in lease liabilities, loans and borrowings as of the dates indicated: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-current</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">188.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">174.1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">216.7</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">210.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock', window );">Summary of Amounts Recognized in Consolidated Statement of Operations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation Charge of Right-of-Use Assets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Buildings</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.7</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Production facilities </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other operating equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total depreciation charge</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">45.2</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">58.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">29.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest on lease liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expense related to short-term leases and leases of low-value assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27.1</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.5</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amounts recognized in profit or loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">109.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">91.0</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">41.4</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Lease Liabilities Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_Leases1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_Leases1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783210816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Summary of Compensation of Key Management Personnel</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key management personnel has been defined as the members of the Management Board and the Supervisory Board. Key management personnel compensation is comprised of the following:</span></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Management Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15.0</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.9</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.9</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; first installment</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term incentive &#8211; second installment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.0</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other variable compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.8</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based payments (incl. long-term incentive)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.9</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.7</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Supervisory Board</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.6</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.5</span></td><td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total compensation paid to key management personnel</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">8.9</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">15.5</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.8</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#8220;Share-based Payments.&#8221; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#8217;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. </span></div><div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes a one-time signing and retention cash payment agreed when renewing the service agreement agreed with Sean Marett.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span>&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#8220;Stock-based Payments.&#8221; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. During the years ended December&#160;31, 2023, 2022, and 2021, the amounts included expenses derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the form of 4,246 phantom shares.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Summary of Transactions Between Other Related Parties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:55.848%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Years ended <br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of various goods and services from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.3</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Purchases of property and other assets from entities controlled by ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62.5</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.3</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">62.8</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.9</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the periods indicated:</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:0.28pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(in millions &#8364;)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2023</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ATHOS KG</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.4</span></td><td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">0.4</span></td><td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781701936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers', window );">Payment terms in contracts with customers</a></td>
<td class="text">payments from customers are due within 30 days after invoice<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Tax rate effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_OperatingAndBusinessEquipmentMember', window );">Operating And Business Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_OperatingAndBusinessEquipmentMember', window );">Operating And Business Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the significant payment terms in contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 119<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_119_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_OperatingAndBusinessEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_OperatingAndBusinessEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790771328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember', window );">Intellectual property rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember', window );">Intellectual property rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licenses | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">Licenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=bntx_IntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793414672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">33 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794194960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Automobiles | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Automobiles | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets', window );">Right-of-use assets, useful life (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful Life Measured As Period Of Time, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788789942464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract', window );"><strong>Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception', window );">Estimated milestone payment to be received</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Milestone Payment To Be Received At Contract Inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788785834960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Subsidiaries (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechBioNTainerHoldingGmbHMember', window );">BioNTech BioNTainer Holding GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellGeneTherapiesGmbHMember', window );">BioNTech Cell &amp; Gene Therapies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember', window );">BioNTech Delivery Technologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember', window );">BioNTech Diagnostics GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember', window );">BioNTech Europe GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIdarObersteinServicesGmbHMember', window );">BioNTech Idar-Oberstein Services GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember', window );">BioNTech Individualized mRNA Manufacturing GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationAndServicesMarburgGmbHMember', window );">BioNTech Innovation and Services Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationGmbHMember', window );">BioNTech Innovation GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember', window );">BioNTech Innovative Manufacturing Services GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember', window );">BioNTech Manufacturing GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember', window );">BioNTech Manufacturing Marburg GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember', window );">BioNTech Real Estate Holding GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember', window );">BioNTech Real Estate Verwaltungs GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepDEGmbHMember', window );">InstaDeep DE GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember', window );">JPT Peptide Technologies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NTSecurityAndServicesGmbHMember', window );">NT Security and Services GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember', window );">reSano GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustraliaPtyLtd.Member', window );">BioNTech Australia Pty Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRDAustriaGmbHMember', window );">BioNTech R&amp;D (Austria) GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member', window );">BioNTech (Shanghai) Pharmaceuticals Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepFranceSASMember', window );">InstaDeep France SAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BiopharmaBioNTechIsraelLtd.Member', window );">Biopharma BioNTech Israel Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NewTechnologiesReMember', window );">New Technologies Re&#8203;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepNigeriaLimitedMember', window );">InstaDeep Nigeria Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRwandaLtd.Member', window );">BioNTech Rwanda Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSenegalSuarlMember', window );">BioNTech S&#233;n&#233;gal Suarl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member', window );">BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsSpainS.LMember', window );">BioNTech Pharmaceuticals Spain S.L</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSwitzerlandGmbHMember', window );">BioNTech Switzerland GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTaiwanCo.Ltd.Member', window );">BioNTech Taiwan Co. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepTunisiaSARLMember', window );">InstaDeep Tunisia SARL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember', window );">BioNTech Turkey T&#305;bbi &#220;r&#252;nler Ve Klinik Ara&#351;tirma Ticaret Anonim &#350;irketi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLtd.Member', window );">BioNTech UK Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLtd.Member', window );">InstaDeep Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">530.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentInc.Member', window );">BioNTech Research and Development, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember', window );">BioNTech USA Holding, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSInc.Member', window );">BioNTech US Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesUSLLCMember', window );">BioNTech Delivery Technologies (US), LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLLCMember', window );">InstaDeep LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesInc.Member', window );">JPT Peptide Technologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% equity interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechBioNTainerHoldingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechBioNTainerHoldingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellGeneTherapiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechCellGeneTherapiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDiagnosticsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechEuropeGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIdarObersteinServicesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIdarObersteinServicesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationAndServicesMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationAndServicesMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovationGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechInnovativeManufacturingServicesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechManufacturingMarburgGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateHoldingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRealEstateVerwaltungsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepDEGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepDEGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NTSecurityAndServicesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NTSecurityAndServicesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ReSanoGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRDAustriaGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRDAustriaGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepFranceSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepFranceSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BiopharmaBioNTechIsraelLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BiopharmaBioNTechIsraelLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NewTechnologiesReMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_NewTechnologiesReMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepNigeriaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepNigeriaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRwandaLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechRwandaLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSenegalSuarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSenegalSuarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsSpainS.LMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechPharmaceuticalsSpainS.LMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSwitzerlandGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechSwitzerlandGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTaiwanCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTaiwanCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepTunisiaSARLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepTunisiaSARLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUKLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechResearchAndDevelopmentInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSAHoldingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechUSInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesUSLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_BioNTechDeliveryTechnologiesUSLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_InstaDeepLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_JPTPeptideTechnologiesInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788943912080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Parent Company (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bntx_BioNTechMember', window );">BioNTech | AT Impf GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership of ordinary shares in BioNTech (in %)</a></td>
<td class="nump">43.77%<span></span>
</td>
<td class="nump">43.42%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bntx_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bntx_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ATImpfGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_ATImpfGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784179136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bntx_BioNTechMember', window );">BioNTech | Medine GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership of ordinary shares in BioNTech (in %)</a></td>
<td class="nump">17.01%<span></span>
</td>
<td class="nump">17.38%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bntx_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bntx_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_MedineGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=bntx_MedineGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794081152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ConsideredRemunerationOfPotentialEarnOutPayments', window );">Considered remuneration of potential earn-out payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_MultiperiodExcessEarningsMethodMember', window );">Multi-period excess earnings method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Technology-based intangible assets recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Customer-related intangible assets recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 124.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember', window );">InstaDeep Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EquityMethodInvestmentsOwnershipPercentage', window );">Equity method investment, ownership (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfConsiderationTransferredAcquiredShares', window );">Consideration transferred, acquired shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PreviouslyHeldNonListedEquityInvestment', window );">Previously held non-listed equity investment (stake of 5.3%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination', window );">Transaction costs</a></td>
<td class="nump">&#8364; 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 45.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ConsideredRemunerationOfPotentialEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Considered Remuneration Of Potential Earn-out Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ConsideredRemunerationOfPotentialEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EquityMethodInvestmentsOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EquityMethodInvestmentsOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfConsiderationTransferredAcquiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Consideration Transferred, Acquired Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfConsiderationTransferredAcquiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PreviouslyHeldNonListedEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Previously-held Non-listed Equity Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PreviouslyHeldNonListedEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_m&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for customer-related intangible assets acquired in a business combination. [Refer: Customer-related intangible assets [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_MultiperiodExcessEarningsMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_MultiperiodExcessEarningsMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790596176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="nump">&#8364; 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember', window );">InstaDeep Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intangible assets</a></td>
<td class="nump">&#8364; 187.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate', window );">Trade receivables</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate', window );">Financial assets - current</a></td>
<td class="nump">52.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">21.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate', window );">Other assets non-current and current</a></td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AssetsRecognisedAsOfAcquisitionDate', window );">Total assets</a></td>
<td class="nump">275.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities</a></td>
<td class="nump">45.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate', window );">Other liabilities long-term and short-term</a></td>
<td class="nump">18.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LiabilitiesRecognisedAsOfAcquisitionDate', window );">Total liabilities</a></td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total identifiable net assets at fair value</a></td>
<td class="nump">211.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill from the acquisition</a></td>
<td class="nump">306.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill', window );">Total consideration</a></td>
<td class="nump">517.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract', window );"><strong>Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash paid</a></td>
<td class="nump">358.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesIncurred', window );">Cash to be paid in 2024</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DesignatedFXHedge', window );">Designated FX hedge</a></td>
<td class="num">(8.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityInterestsOfAcquirer', window );">Shares transferred (approx. 1.1 million shares)</a></td>
<td class="nump">103.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration</a></td>
<td class="nump">31.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PreviouslyHeldNonListedEquityInvestment', window );">Previously held non-listed equity investment (stake of 5.3%)</a></td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">&#8364; 517.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EquityMethodInvestmentsOwnershipPercentage', window );">Equity method investment, ownership (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Acquired (Liabilities Assumed), Including Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DesignatedFXHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Designated FX-Hedge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DesignatedFXHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EquityMethodInvestmentsOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EquityMethodInvestmentsOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets Non-current And Current Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PreviouslyHeldNonListedEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Previously-held Non-listed Equity Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PreviouslyHeldNonListedEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TradeReceivablesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade Receivables Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TradeReceivablesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityInterestsOfAcquirer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityInterestsOfAcquirer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for financial assets acquired in a business combination. [Refer: Financial assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_InstaDeepLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794167008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 3,819.0<span></span>
</td>
<td class="nump">&#8364; 17,310.6<span></span>
</td>
<td class="nump">&#8364; 18,976.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Goods and services transferred at a point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">776.3<span></span>
</td>
<td class="nump">4,447.2<span></span>
</td>
<td class="nump">4,034.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Goods and services transferred over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">127.2<span></span>
</td>
<td class="nump">113.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember', window );">Revenue recognition applying the sales-based or usage-based royalty recognition constraint model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,027.3<span></span>
</td>
<td class="nump">12,736.2<span></span>
</td>
<td class="nump">14,828.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,815.5<span></span>
</td>
<td class="nump">17,194.6<span></span>
</td>
<td class="nump">18,874.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues | COVID-19 vaccine revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,776.2<span></span>
</td>
<td class="nump">17,145.2<span></span>
</td>
<td class="nump">18,806.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues | Sales to collaboration partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">275.3<span></span>
</td>
<td class="nump">1,224.3<span></span>
</td>
<td class="nump">970.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues | Direct product sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">473.6<span></span>
</td>
<td class="nump">3,184.7<span></span>
</td>
<td class="nump">3,007.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues | Share of collaboration partners&#8217; gross profit and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,027.3<span></span>
</td>
<td class="nump">12,736.2<span></span>
</td>
<td class="nump">14,828.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues | Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">39.3<span></span>
</td>
<td class="nump">49.4<span></span>
</td>
<td class="nump">67.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember', window );">Research &amp; development revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 3.5<span></span>
</td>
<td class="nump">&#8364; 116.0<span></span>
</td>
<td class="nump">&#8364; 102.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793284896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 3,819.0<span></span>
</td>
<td class="nump">&#8364; 17,310.6<span></span>
</td>
<td class="nump">&#8364; 18,976.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RemainingUpfrontFeesContractLiabilities', window );">Remaining upfront fees contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale', window );">Advance payment received for future COVID 19 vaccine sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_CommercialMember', window );">Commercial revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,815.5<span></span>
</td>
<td class="nump">17,194.6<span></span>
</td>
<td class="nump">18,874.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,010.9<span></span>
</td>
<td class="nump">12,709.7<span></span>
</td>
<td class="nump">14,636.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">482.7<span></span>
</td>
<td class="nump">3,031.0<span></span>
</td>
<td class="nump">2,241.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BE', window );">Belgium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">3,293.0<span></span>
</td>
<td class="nump">13,795.8<span></span>
</td>
<td class="nump">15,500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_GermanFederalMinistryOfHealthMember', window );">German Federal Ministry of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">473.6<span></span>
</td>
<td class="nump">3,020.5<span></span>
</td>
<td class="nump">1,945.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">302.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember', window );">Sales to collaboration partners | Commercial revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">275.3<span></span>
</td>
<td class="nump">1,224.3<span></span>
</td>
<td class="nump">970.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember', window );">Sales to collaboration partners | Commercial revenues | Manufacturing Variances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="nump">850.0<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember', window );">Direct product sales to customers | Commercial revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">473.6<span></span>
</td>
<td class="nump">&#8364; 3,184.7<span></span>
</td>
<td class="nump">3,007.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember', window );">Share of collaboration partners' sales milestones | Commercial revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 476.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerCOVID19VaccineMember', window );">Pfizer (COVID-19 vaccine)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">386.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_PfizerZosterMember', window );">Pfizer (Zoster)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RemainingUpfrontFeesContractLiabilities', window );">Remaining upfront fees contract liabilities</a></td>
<td class="nump">&#8364; 62.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance Payment Received For Future COVID-19 Vaccine Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RemainingUpfrontFeesContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Upfront Fees Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RemainingUpfrontFeesContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_GermanFederalMinistryOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_GermanFederalMinistryOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineSalesToCollaborationPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ManufacturingVariancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=bntx_ManufacturingVariancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineDirectProductSalesToCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_PfizerCOVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_PfizerCOVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_PfizerZosterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_PfizerZosterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784350352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Summary of Contract Balances (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade and other receivables</a></td>
<td class="nump">&#8364; 2,155.7<span></span>
</td>
<td class="nump">&#8364; 7,145.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">125.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RefundsProvision', window );">Refund liabilities</a></td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">&#8364; 24.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788926094384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Summary of Revenue Recognized (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Amounts included in contract liabilities at the beginning of the year</a></td>
<td class="nump">&#8364; 3.5<span></span>
</td>
<td class="nump">&#8364; 63.1<span></span>
</td>
<td class="nump">&#8364; 73.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790425808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 751.8<span></span>
</td>
<td class="nump">&#8364; 125.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember', window );">Unsatisfied Or Partially Unsatisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">751.8<span></span>
</td>
<td class="nump">125.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember', window );">Unsatisfied Or Partially Unsatisfied | Within one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">353.3<span></span>
</td>
<td class="nump">77.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember', window );">Unsatisfied Or Partially Unsatisfied | More than one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 398.5<span></span>
</td>
<td class="nump">&#8364; 48.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=bntx_UnsatisfiedOrPartiallyUnsatisfiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788792993536">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseCostOfSales', window );">Decrease cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (2,395.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfCostOfSales', window );">Cost of sales (as a percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(80.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 599.8<span></span>
</td>
<td class="nump">&#8364; 2,995.0<span></span>
</td>
<td class="nump">&#8364; 2,911.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">357.7<span></span>
</td>
<td class="nump">439.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense', window );">Increase of research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 246.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfResearchAndDevelopmentExpense', window );">Research and development expense (as a percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,783.1<span></span>
</td>
<td class="nump">1,537.0<span></span>
</td>
<td class="nump">949.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseOfSalesAndMarketingExpense', window );">Increase of sales and marketing expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfSalesAndMarketingExpense', window );">Sales and marketing expense (as a percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 62.7<span></span>
</td>
<td class="nump">59.5<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense', window );">Increase of general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 13.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfGeneralAndAdministrativeExpense', window );">General and administrative expense (as a percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 495.0<span></span>
</td>
<td class="nump">481.7<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue', window );">Fair value adjustments of financial instruments measured at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">&#8364; 277.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember', window );">Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19.6<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfInventories', window );">Write-downs (reversals of write-downs) of inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 46.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustments Of Financial Instruments Measured At Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Cost Of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Of General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseOfSalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Of Sales And Marketing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseOfSalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Cost Of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfSalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Sales And Marketing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfSalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WritedownsReversalsOfInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised resulting from the write-down of inventories to net realisable value or reversals of those write-downs. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WritedownsReversalsOfInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794465840">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Other Operating Expense (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 293.0<span></span>
</td>
<td class="nump">&#8364; 410.0<span></span>
</td>
<td class="nump">&#8364; 103.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember', window );">Foreign exchange differences, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">252.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LossOnDerivativeInstrumentsAtFairValueMember', window );">Loss on derivative instruments at fair value through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">385.5<span></span>
</td>
<td class="nump">86.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LitigationCostsMember', window );">Litigation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 11.6<span></span>
</td>
<td class="nump">&#8364; 21.5<span></span>
</td>
<td class="nump">&#8364; 8.1<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">&#160;&#160;&#160;&#160;<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LossOnDerivativeInstrumentsAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LossOnDerivativeInstrumentsAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_LitigationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_LitigationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791163824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Other Operating Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 105.0<span></span>
</td>
<td class="nump">&#8364; 815.3<span></span>
</td>
<td class="nump">&#8364; 598.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember', window );">Gain on derivative instruments at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">67.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember', window );">Government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">137.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember', window );">Foreign exchange differences, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">727.4<span></span>
</td>
<td class="nump">446.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 35.2<span></span>
</td>
<td class="nump">&#8364; 86.5<span></span>
</td>
<td class="nump">&#8364; 9.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_GovernmentGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_ForeignExchangeDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeAndExpensesByNatureAxis=bntx_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790262608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Finance Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">&#8364; 357.6<span></span>
</td>
<td class="nump">&#8364; 48.5<span></span>
</td>
<td class="nump">&#8364; 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue', window );">Fair value adjustments of financial instruments measured at fair value</a></td>
<td class="nump">162.0<span></span>
</td>
<td class="nump">216.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange differences, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">&#8364; 519.6<span></span>
</td>
<td class="nump">&#8364; 330.3<span></span>
</td>
<td class="nump">&#8364; 67.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793126480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Finance Expenses (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Foreign exchange differences, net</a></td>
<td class="nump">&#8364; 16.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue', window );">Fair value adjustments of financial instruments measured at fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">277.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="nump">&#8364; 23.9<span></span>
</td>
<td class="nump">&#8364; 18.9<span></span>
</td>
<td class="nump">&#8364; 305.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustments Of Financial Instruments Measured At Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790332192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income and Expenses - Summary of Employee Benefits Expense (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">&#8364; 617.8<span></span>
</td>
<td class="nump">&#8364; 544.8<span></span>
</td>
<td class="nump">&#8364; 345.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">76.7<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Pension costs</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total</a></td>
<td class="nump">&#8364; 698.6<span></span>
</td>
<td class="nump">&#8364; 605.5<span></span>
</td>
<td class="nump">&#8364; 378.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781488160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CorporateTaxRate', window );">Corporate tax rate (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_SolidaritySurchargeRate', window );">Solidarity surcharge rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory tax rate (as a percent)</a></td>
<td class="nump">27.10%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
<td class="nump">30.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TaxRateOnDeferredTaxes', window );">Tax rate for deferred taxes (as a percent)</a></td>
<td class="nump">27.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">State income tax with average rate (as a percent)</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
<td class="nump">31.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxAssetsSettlement', window );">Deferred tax assets settlement</a></td>
<td class="nump">&#8364; 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity', window );">Non cash current tax relating to items credited (charged) directly to equity</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">81.3<span></span>
</td>
<td class="nump">&#8364; 229.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax (assets) and liabilities, net recognized</a></td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">223.4<span></span>
</td>
<td class="num">&#8364; (66.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards', window );">Federal tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards', window );">State tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures', window );">Deferred tax liabilities have not been recognized</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember', window );">Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">531.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax (assets) and liabilities, net recognized</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Tax losses / tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax (assets) and liabilities, net recognized</a></td>
<td class="nump">&#8364; 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AT', window );">Austria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CorporateTaxRate', window );">Corporate tax rate (as a percent)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DecreaseInCorporateTaxRate', window );">Decrease in corporate tax rate (as a percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_FederalCorporateIncomeTax', window );">Federal corporate income tax (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">State income tax with average rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember', window );">Valuation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax (assets) and liabilities, net recognized</a></td>
<td class="num">&#8364; (138.0)<span></span>
</td>
<td class="num">&#8364; (136.7)<span></span>
</td>
<td class="num">&#8364; (81.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax (assets) and liabilities, net recognized</a></td>
<td class="nump">&#8364; 108.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CorporateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CorporateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DecreaseInCorporateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease In Corporate Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DecreaseInCorporateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredTaxAssetsSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredTaxAssetsSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FederalCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FederalCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Deferred Tax Assets Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SolidaritySurchargeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Solidarity Surcharge Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SolidaritySurchargeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_StateDeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State Deferred Tax Assets Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_StateDeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxRateOnDeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Rate On Deferred Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxRateOnDeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794389328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Current and Deferred Tax Expense (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">&#8364; 243.1<span></span>
</td>
<td class="nump">&#8364; 3,629.6<span></span>
</td>
<td class="nump">&#8364; 4,535.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred taxes</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="num">(109.9)<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">&#8364; 255.8<span></span>
</td>
<td class="nump">&#8364; 3,519.7<span></span>
</td>
<td class="nump">&#8364; 4,753.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793531408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit before tax</a></td>
<td class="nump">&#8364; 1,186.1<span></span>
</td>
<td class="nump">&#8364; 12,954.1<span></span>
</td>
<td class="nump">&#8364; 15,046.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected tax credit</a></td>
<td class="nump">321.8<span></span>
</td>
<td class="nump">3,529.7<span></span>
</td>
<td class="nump">4,622.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Effects</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TaxEffectOfDeviationDueToLocalTaxBasis', window );">Deviation due to local tax basis</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Deviation due to deviating income tax rate (Germany and foreign countries)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TaxEffectOfChangeInValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(14.3)<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Effects from tax losses and tax credits</a></td>
<td class="num">(66.5)<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Change in deferred taxes due to tax rate change</a></td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible expenses</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">90.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TaxEffectNonTaxEffectiveIncome', window );">Non tax-effective income</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(87.9)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses', window );">Non tax-effective share-based payment expenses</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_TaxEffectiveEquityTransactionCosts', window );">Tax-effective equity transaction costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustment prior year taxes</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(31.5)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NonTaxEffectiveBargainPurchase', window );">Non-tax effective bargain purchase</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other effects</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">&#8364; 255.8<span></span>
</td>
<td class="nump">&#8364; 3,519.7<span></span>
</td>
<td class="nump">&#8364; 4,753.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
<td class="nump">31.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Recognition Of Tax Effect On Share-Based Payment Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NonTaxEffectiveBargainPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Tax Effective Bargain Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NonTaxEffectiveBargainPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectNonTaxEffectiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect, Non Tax Effective Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectNonTaxEffectiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectOfChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change In Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectOfChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectOfDeviationDueToLocalTaxBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Deviation Due To Local Tax Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectOfDeviationDueToLocalTaxBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_TaxEffectiveEquityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effective Equity Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_TaxEffectiveEquityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788792296784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Deferred Taxes (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">&#8364; 223.4<span></span>
</td>
<td class="num">&#8364; (66.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(12.7)<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(169.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">223.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">360.1<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(77.8)<span></span>
</td>
<td class="nump">165.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(102.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">360.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember', window );">Valuation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="num">(136.7)<span></span>
</td>
<td class="num">(81.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">65.1<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(66.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(138.0)<span></span>
</td>
<td class="num">(136.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_FixedAssetsMember', window );">Fixed assets | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(44.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(8.4)<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="num">(55.8)<span></span>
</td>
<td class="num">(47.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(56.6)<span></span>
</td>
<td class="num">(55.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_Inventories1Member', window );">Inventories | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">148.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="nump">147.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">113.6<span></span>
</td>
<td class="nump">148.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_TradeAndOtherReceivablesMember', window );">Trade and other receivables | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="num">(162.7)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">72.7<span></span>
</td>
<td class="num">(67.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(90.0)<span></span>
</td>
<td class="num">(162.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">55.2<span></span>
</td>
<td class="nump">48.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">55.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ContractLiabilitiesMember', window );">Contract liabilities | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(33.0)<span></span>
</td>
<td class="num">(20.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(43.0)<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="num">(15.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_NetEmployeeDefinedBenefitLiabilitiesMember', window );">Net employee defined benefit liabilities | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_SharebasedPaymentArrangementsMember', window );">Share-based payments | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">188.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(58.3)<span></span>
</td>
<td class="nump">179.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">142.1<span></span>
</td>
<td class="nump">188.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherProvisionsMember', window );">Other provisions | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_OtherDeferredTaxesMember', window );">Other (incl. deferred expenses) | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(106.4)<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">(44.9)<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Tax losses / tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember', window );">Tax losses / tax credits | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">99.5<span></span>
</td>
<td class="nump">70.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Recognized directly in equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">94.4<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxAssetsMember', window );">Thereof deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="nump">229.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="num">(169.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="nump">81.3<span></span>
</td>
<td class="nump">229.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxLiabilityMember', window );">Thereof deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance deferred tax assets net</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Recognized in P&amp;L</a></td>
<td class="num">(33.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome', window );">Recognized in OCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Recognized directly in equity</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance deferred tax assets net</a></td>
<td class="num">&#8364; (39.7)<span></span>
</td>
<td class="num">&#8364; (6.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Expense (Income) Recognised In Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=bntx_ValuationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_FixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_FixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_Inventories1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_Inventories1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_TradeAndOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_TradeAndOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_LoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_LoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_NetEmployeeDefinedBenefitLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_NetEmployeeDefinedBenefitLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_SharebasedPaymentArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_SharebasedPaymentArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_OtherDeferredTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_OtherDeferredTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=bntx_ThereofDeferredTaxLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794635296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax - Summary of Accumulated Tax Losses (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInCorporateTax', window );">Corporate tax</a></td>
<td class="nump">&#8364; 260.7<span></span>
</td>
<td class="nump">&#8364; 352.3<span></span>
</td>
<td class="nump">&#8364; 272.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInTradeTax', window );">Trade tax</a></td>
<td class="nump">140.1<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
<td class="nump">170.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInFederalTaxCredits', window );">Federal tax credits</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedTaxLossesInStateTaxCredits', window );">State tax credits</a></td>
<td class="nump">&#8364; 8.7<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInCorporateTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Tax Losses In Corporate Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInCorporateTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInFederalTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Tax Losses In Federal Tax Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInFederalTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInStateTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Tax Losses In State Tax Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInStateTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedTaxLossesInTradeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Tax Losses In Trade Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedTaxLossesInTradeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793414544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit attributable to ordinary equity holders of the parent for basic earnings</a></td>
<td class="nump">&#8364; 930.3<span></span>
</td>
<td class="nump">&#8364; 9,434.4<span></span>
</td>
<td class="nump">&#8364; 10,292.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares outstanding for basic EPS (in shares)</a></td>
<td class="nump">240.6<span></span>
</td>
<td class="nump">243.3<span></span>
</td>
<td class="nump">244.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Effects of dilution from share options (in shares)</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares)</a></td>
<td class="nump">242.7<span></span>
</td>
<td class="nump">249.8<span></span>
</td>
<td class="nump">259.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic profit for the period per share (in euros per share)</a></td>
<td class="nump">&#8364; 3.87<span></span>
</td>
<td class="nump">&#8364; 38.78<span></span>
</td>
<td class="nump">&#8364; 42.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted profit for the period per share (in euros per share)</a></td>
<td class="nump">&#8364; 3.83<span></span>
</td>
<td class="nump">&#8364; 37.77<span></span>
</td>
<td class="nump">&#8364; 39.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781224256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill - Goodwill (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">&#8364; 158.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">804.1<span></span>
</td>
<td class="nump">&#8364; 158.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">199.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">921.0<span></span>
</td>
<td class="nump">235.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">61.2<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">306.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">&#8364; 362.5<span></span>
</td>
<td class="nump">&#8364; 61.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790259760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">&#8364; 362.5<span></span>
</td>
<td class="nump">&#8364; 61.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife', window );">Intangible assets with indefinite useful life</a></td>
<td class="nump">444.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill', window );">Total</a></td>
<td class="nump">807.0<span></span>
</td>
<td class="nump">61.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember', window );">CGU Immunotherapies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">352.2<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife', window );">Intangible assets with indefinite useful life</a></td>
<td class="nump">444.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill', window );">Total</a></td>
<td class="nump">796.7<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesToJPTMember', window );">External Product Sales of JPT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife', window );">Intangible assets with indefinite useful life</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill', window );">Total</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalBusinessOfInstaDeepMember', window );">External Business of InstaDeep</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife', window );">Intangible assets with indefinite useful life</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill', window );">Total</a></td>
<td class="nump">&#8364; 9.8<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets With Indefinite Useful Life And Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_CGUImmunotherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesToJPTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalProductSalesToJPTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalBusinessOfInstaDeepMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsolidatedStructuredEntitiesAxis=bntx_ExternalBusinessOfInstaDeepMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788792686592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill - Additional Information (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 362.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 61.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Growth rate used to extrapolate cash flow projections (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 443.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows', window );">Impairment loss for a reduction of future cash flows (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation', window );">Weighted average cost of capital (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill', window );">Increase (decrease) in intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 645.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PrepaymentForFutureDevelopmentActivities', window );">Prepayment for future development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 158.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=bntx_DeepChainTechnologyMember', window );">DeepChain Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 163.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_DualityBiologicsSuzhouCoLtdMember', window );">Duality Biologics (Suzhou) Co. Ltd.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 203.7<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember', window );">OncoC4 Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 181.5<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset', window );">Upfront payment, acquisition of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 125.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedilinkTherapeuticsSuzhouCoLtdMember', window );">Medilink Therapeutics (Suzhou) Co. Ltd.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">&#8364; 64.1<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BiotheusIncMember', window );">Biotheus Inc.,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50.6<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Impairment Loss For A Reduction Of Future Cash Flows</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PrepaymentForFutureDevelopmentActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment For Future Development Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PrepaymentForFutureDevelopmentActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UpfrontPaymentAcquisitionOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment, Acquisition of Intangible Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UpfrontPaymentAcquisitionOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=bntx_DeepChainTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=bntx_DeepChainTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_DualityBiologicsSuzhouCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_DualityBiologicsSuzhouCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedilinkTherapeuticsSuzhouCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedilinkTherapeuticsSuzhouCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BiotheusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BiotheusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793000688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">&#8364; 158.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">804.1<span></span>
</td>
<td class="nump">&#8364; 158.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">199.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">505.0<span></span>
</td>
<td class="nump">34.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">921.0<span></span>
</td>
<td class="nump">235.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="num">(76.9)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedDepreciationAmortisationAndImpairment', window );">Amortization</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="num">(116.9)<span></span>
</td>
<td class="num">(76.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, licenses, in-process R&amp;D and similar rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">145.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">781.7<span></span>
</td>
<td class="nump">145.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, licenses, in-process R&amp;D and similar rights | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">222.3<span></span>
</td>
<td class="nump">191.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">489.2<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">187.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">898.6<span></span>
</td>
<td class="nump">222.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember', window );">Concessions, licenses, in-process R&amp;D and similar rights | Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="num">(76.9)<span></span>
</td>
<td class="num">(54.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedDepreciationAmortisationAndImpairment', window );">Amortization</a></td>
<td class="nump">40.5<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="num">(116.9)<span></span>
</td>
<td class="num">(76.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember', window );">Advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember', window );">Advance payments | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(4.9)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember', window );">Advance payments | Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems', window );"><strong>Disclosure of reconciliation of changes in intangible assets and goodwill [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill', window );">Disposals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency differences</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_AccumulatedDepreciationAmortisationAndImpairment', window );">Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Ending balance</a></td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_AccumulatedDepreciationAmortisationAndImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated Depreciation, Amortisation And Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_AccumulatedDepreciationAmortisationAndImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets and goodwill resulting from disposals. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=bntx_AdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788789789744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">&#8364; 609.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">757.2<span></span>
</td>
<td class="nump">&#8364; 609.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">3,479.0<span></span>
</td>
<td class="nump">1,357.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">725.5<span></span>
</td>
<td class="nump">396.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">249.4<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationsOfPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">969.0<span></span>
</td>
<td class="nump">725.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(116.3)<span></span>
</td>
<td class="num">(74.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="nump">42.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(211.8)<span></span>
</td>
<td class="num">(116.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">199.2<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">217.0<span></span>
</td>
<td class="nump">104.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationsOfPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">235.4<span></span>
</td>
<td class="nump">217.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember', window );">Land and buildings | Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(22.0)<span></span>
</td>
<td class="num">(14.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(36.2)<span></span>
</td>
<td class="num">(22.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">178.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">168.5<span></span>
</td>
<td class="nump">178.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">273.0<span></span>
</td>
<td class="nump">198.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationsOfPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">344.1<span></span>
</td>
<td class="nump">273.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember', window );">Equipment, tools and installations | Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="num">(94.3)<span></span>
</td>
<td class="num">(60.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">83.3<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="num">(175.6)<span></span>
</td>
<td class="num">(94.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember', window );">Construction in progress and advance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">235.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">389.5<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember', window );">Construction in progress and advance payments | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">235.5<span></span>
</td>
<td class="nump">94.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">189.4<span></span>
</td>
<td class="nump">182.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationsOfPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(31.6)<span></span>
</td>
<td class="num">(40.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition of subsidiaries and businesses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">389.5<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember', window );">Construction in progress and advance payments | Cumulative depreciation and impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, beginning balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency differences</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment, ending balance</a></td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ReclassificationsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassifications Of Property, Plant And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ReclassificationsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandAndBuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_EquipmentToolsAndInstallationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=bntx_ConstructionInProgressAndAdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788797107376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">&#8364; 3,479.0<span></span>
</td>
<td class="nump">&#8364; 1,357.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">158.2<span></span>
</td>
<td class="nump">188.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom | Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">511.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">&#8364; 1,469.0<span></span>
</td>
<td class="nump">&#8364; 871.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781333232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at banks and on hand</a></td>
<td class="nump">&#8364; 453.1<span></span>
</td>
<td class="nump">&#8364; 1,325.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">11,210.6<span></span>
</td>
<td class="nump">12,549.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total</a></td>
<td class="nump">11,663.7<span></span>
</td>
<td class="nump">13,875.1<span></span>
</td>
<td class="nump">&#8364; 1,692.7<span></span>
</td>
<td class="nump">&#8364; 1,210.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_BankDepositsMember', window );">Bank deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">2,589.5<span></span>
</td>
<td class="nump">9,401.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_MoneyMarketFundMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">7,446.1<span></span>
</td>
<td class="nump">3,148.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ReverseRepoMember', window );">Reverse Repo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">&#8364; 1,175.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashAndCashEquivalents1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashAndCashEquivalents1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_BankDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_BankDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_MoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_MoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ReverseRepoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ReverseRepoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788786003088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember', window );">Derivative Liabilities | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember', window );">Derivative Liabilities | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | FVTPL | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember', window );">Derivative Liabilities | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 1 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember', window );">Derivative Liabilities | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 2 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember', window );">Derivative Liabilities | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 3 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">&#8364; 6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | FVTPL | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 1 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 2 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Financial Liabilities at Fair Value Through Other Comprehensive Income, Category | Level 3 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">216.7<span></span>
</td>
<td class="nump">210.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">216.7<span></span>
</td>
<td class="nump">210.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Financial liabilities at amortised cost, category | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Financial liabilities at amortised cost, category | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Financial liabilities at amortised cost, category | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Financial liabilities at amortised cost, category | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember', window );">Loans and borrowings | Financial liabilities at amortised cost, category | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost, category | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost, category | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost, category | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost, category | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember', window );">Trade payables and other payables | Financial liabilities at amortised cost, category | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember', window );">Other financial liabilities | Financial liabilities at amortised cost, category | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">414.9<span></span>
</td>
<td class="nump">785.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember', window );">Other financial liabilities | Financial liabilities at amortised cost, category | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">414.9<span></span>
</td>
<td class="nump">785.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember', window );">Other financial liabilities | Financial liabilities at amortised cost, category | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember', window );">Other financial liabilities | Financial liabilities at amortised cost, category | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember', window );">Other financial liabilities | Financial liabilities at amortised cost, category | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Foreign exchange forward contracts | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Foreign exchange forward contracts | FVTPL | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Foreign exchange forward contracts | Level 1 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Foreign exchange forward contracts | Level 2 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Foreign exchange forward contracts | Level 3 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Money market funds | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">7,446.1<span></span>
</td>
<td class="nump">3,148.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Money market funds | FVTPL | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">7,446.1<span></span>
</td>
<td class="nump">3,148.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Money market funds | Level 1 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">7,446.1<span></span>
</td>
<td class="nump">3,148.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Money market funds | Level 2 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Money market funds | Level 3 (Fair value) | FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Non-listed equity investments | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">57.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Non-listed equity investments | FVTOCI | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">57.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Non-listed equity investments | Level 1 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Non-listed equity investments | Level 2 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">57.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Non-listed equity investments | Level 3 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Listed equity investments | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Listed equity investments | FVTOCI | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Listed equity investments | Level 1 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Listed equity investments | Level 2 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets at fair value through other comprehensive income, category | Listed equity investments | Level 3 (Fair value) | FVTOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Trade and other receivables | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,155.7<span></span>
</td>
<td class="nump">7,145.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Trade and other receivables | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,155.7<span></span>
</td>
<td class="nump">7,145.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Trade and other receivables | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Trade and other receivables | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Trade and other receivables | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Security investments | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">5,989.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Security investments | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">5,989.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Security investments | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Security investments | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Security investments | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Other financial assets | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Other financial assets | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Other financial assets | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Other financial assets | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Other financial assets | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Bank deposits | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,589.5<span></span>
</td>
<td class="nump">9,401.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Bank deposits | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,589.5<span></span>
</td>
<td class="nump">9,401.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Bank deposits | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Bank deposits | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Bank deposits | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Reverse Repo | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Reverse Repo | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Reverse Repo | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Reverse Repo | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Reverse Repo | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Cash at banks and on hand | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">453.1<span></span>
</td>
<td class="nump">1,325.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Cash at banks and on hand | AC | Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">453.1<span></span>
</td>
<td class="nump">1,325.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Cash at banks and on hand | Level 1 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Cash at banks and on hand | Level 2 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets at amortised cost, category | Cash at banks and on hand | Level 3 (Fair value) | AC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Assets And Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_DerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_FairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_FairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_LoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_TradePayablesAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_MoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_MoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_NonListedEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_NonListedEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_FairValueThroughOCIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=bntx_FairValueThroughOCIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_ListedEquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_ListedEquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_SecuritiesInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=us-gaap_SecuritiesInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_OtherFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_BankDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_BankDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_ReverseRepoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_ReverseRepoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_CashAtBanksAndOnHandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_CashAtBanksAndOnHandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793862960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Net gain on equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 3.7<span></span>
</td>
<td class="nump">&#8364; 10.5<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Net gain on equity instruments designated at fair value through other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Net gain on equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">&#8364; 3.7<span></span>
</td>
<td class="nump">&#8364; 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793544688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LiabilitiesRollForward', window );"><strong>Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of January 1, 2022</a></td>
<td class="nump">&#8364; 2,760.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of January 1, 2023</a></td>
<td class="nump">3,223.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of December 31, 2023</a></td>
<td class="nump">2,760.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 (Fair value) | Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LiabilitiesRollForward', window );"><strong>Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of January 1, 2022</a></td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">&#8364; 6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of January 1, 2023</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesFairValueMeasurementLiabilities', window );">Purchases</a></td>
<td class="nump">31.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NetChangeInFairValue', window );">Net change in fair value</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">As of December 31, 2023</a></td>
<td class="nump">&#8364; 38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NetChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NetChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in the fair value measurement of liabilities resulting from purchases of those liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790657552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details) - Contingent consideration - Level 3 (Fair value)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Cash flow projections</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities', window );">Change in fair value with increasing input factor (in millions &#8364;)</a></td>
<td class="nump">&#8364; 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities', window );">Change in fair value with decreasing input factor (in millions &#8364;)</a></td>
<td class="nump">&#8364; 3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities', window );">Change in fair value with increasing input factor (in millions &#8364;)</a></td>
<td class="nump">&#8364; 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities', window );">Change in fair value with decreasing input factor (in millions &#8364;)</a></td>
<td class="nump">&#8364; 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=bntx_CashFlowProjectionsMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=bntx_CashFlowProjectionsMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139789053600880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">&#8364; 747.2<span></span>
</td>
<td class="nump">&#8364; 7,058.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Monetary liabilities and provisions in U.S. dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">567.3<span></span>
</td>
<td class="nump">1,527.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Monetary assets in U.S. dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">1,191.9<span></span>
</td>
<td class="nump">7,098.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Cash and cash equivalents in U.S. dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalents1LineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashAndCashEquivalent', window );">Total</a></td>
<td class="nump">&#8364; 122.6<span></span>
</td>
<td class="nump">&#8364; 1,487.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashAndCashEquivalents1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashAndCashEquivalents1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_MonetaryLiabilityAndProvisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=bntx_MonetaryLiabilityAndProvisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=bntx_MonetaryAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=bntx_MonetaryAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_CashAndCashEquivalents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_CashAndCashEquivalents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781151536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=bntx_PositiveFivePercentageChangeInForeignExchangeRateMember', window );">+5 %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax', window );">Effect on profit / (loss) before tax</a></td>
<td class="num">&#8364; (35.5)<span></span>
</td>
<td class="num">&#8364; (195.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity', window );">Effect on pre-tax equity</a></td>
<td class="num">(35.5)<span></span>
</td>
<td class="num">(191.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=bntx_NegativeFivePercentageChangeInForeignExchangeRateMember', window );">-5 %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax', window );">Effect on profit / (loss) before tax</a></td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">215.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity', window );">Effect on pre-tax equity</a></td>
<td class="nump">&#8364; 39.3<span></span>
</td>
<td class="nump">&#8364; 211.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | U.S. dollar | Currency risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems', window );"><strong>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">1.1050<span></span>
</td>
<td class="nump">1.0666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">1.0813<span></span>
</td>
<td class="nump">1.0530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ForeignCurrencyChangesEffectOnLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Changes Effect On Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ForeignCurrencyChangesEffectOnLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ForeignCurrencyChangesEffectOnPretaxEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Changes Effect On Pretax Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ForeignCurrencyChangesEffectOnPretaxEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=bntx_PositiveFivePercentageChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=bntx_PositiveFivePercentageChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=bntx_NegativeFivePercentageChangeInForeignExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=bntx_NegativeFivePercentageChangeInForeignExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793110176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 216.7<span></span>
</td>
<td class="nump">&#8364; 210.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Loans and borrowings</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">244.4<span></span>
</td>
<td class="nump">232.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Foreign exchange forward contracts</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">414.9<span></span>
</td>
<td class="nump">785.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,073.8<span></span>
</td>
<td class="nump">1,229.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk | Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Loans and borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">354.0<span></span>
</td>
<td class="nump">204.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Foreign exchange forward contracts</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">414.9<span></span>
</td>
<td class="nump">785.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">803.4<span></span>
</td>
<td class="nump">1,029.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk | 1 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Loans and borrowings</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">136.6<span></span>
</td>
<td class="nump">112.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Foreign exchange forward contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">196.4<span></span>
</td>
<td class="nump">115.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk | More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InterestBearingLoansAndBorrowings', window );">Loans and borrowings</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">79.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent consideration</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Foreign exchange forward contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other financial liabilities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 74.0<span></span>
</td>
<td class="nump">&#8364; 85.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InterestBearingLoansAndBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Bearing Loans And Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InterestBearingLoansAndBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788788270928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 212.2<span></span>
</td>
<td class="nump">&#8364; 610.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="num">(40.1)<span></span>
</td>
<td class="num">(59.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">67.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassifi-cation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(406.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">219.0<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember', window );">Current obligations under lease contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">36.0<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="num">(40.3)<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassifi-cation</a></td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">33.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember', window );">Non-current obligations under lease contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">174.1<span></span>
</td>
<td class="nump">153.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="nump">51.1<span></span>
</td>
<td class="nump">52.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassifi-cation</a></td>
<td class="num">(34.1)<span></span>
</td>
<td class="num">(33.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">188.6<span></span>
</td>
<td class="nump">174.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember', window );">Loans and borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">119.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassifi-cation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(99.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember', window );">Convertible note &#8211; embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure of reconciliation of liabilities arising from financing activities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">308.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">New leases and disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities', window );">Reclassifi-cation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(308.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_CurrentObligationsUnderLeaseContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_NoncurrentObligationsUnderLeaseContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_InterestBearingLoansAndBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=bntx_ConvertibleNoteEmbeddedDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793397120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">&#8364; 347.5<span></span>
</td>
<td class="nump">&#8364; 409.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Unfinished goods</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total</a></td>
<td class="nump">&#8364; 357.7<span></span>
</td>
<td class="nump">&#8364; 439.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790240112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_InventoriesAbstract', window );"><strong>Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-offs</a></td>
<td class="nump">&#8364; 94.5<span></span>
</td>
<td class="nump">&#8364; 484.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Costs of inventories</a></td>
<td class="nump">&#8364; 354.4<span></span>
</td>
<td class="nump">&#8364; 1,550.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_InventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_InventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794363776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Financial Assets - Summary of Other Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialAssetsAbstract', window );"><strong>Other Non-Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">&#8364; 313.2<span></span>
</td>
<td class="nump">&#8364; 120.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Sales tax receivable</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepayments related to CRO and CMO contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherCurrentAssetsOther', window );">Other</a></td>
<td class="nump">45.9<span></span>
</td>
<td class="nump">29.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNonfinancialAssets', window );">Total</a></td>
<td class="nump">364.3<span></span>
</td>
<td class="nump">278.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Total current</a></td>
<td class="nump">280.9<span></span>
</td>
<td class="nump">271.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Total non-current</a></td>
<td class="nump">&#8364; 83.4<span></span>
</td>
<td class="nump">&#8364; 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781310528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Financial Assets - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">&#8364; 313.2<span></span>
</td>
<td class="nump">&#8364; 120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember', window );">OncoC4 Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_RyvuTherapeuticsSAMember', window );">Ryvu Therapeutics S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedigeneImmunotherapiesGmbHMember', window );">Medigene Immunotherapies GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=bntx_EuropeanCommissionToCollaborationPartnerMember', window );">European Commission To Collaboration Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DisclosureOfIncomeAndExpensesLineItems', window );"><strong>Disclosure Of Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_DeferredExpense', window );">Deferred expenses</a></td>
<td class="nump">&#8364; 151.1<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_DisclosureOfIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Income And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_DisclosureOfIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_OncoC4IncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_RyvuTherapeuticsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_RyvuTherapeuticsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedigeneImmunotherapiesGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_MedigeneImmunotherapiesGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=bntx_EuropeanCommissionToCollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=bntx_EuropeanCommissionToCollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791607008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Additional Information (Details)<br> &#8364; / shares in Units, &#8364; in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 24, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,725,735<span></span>
</td>
<td class="nump">243,215,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfSharesHeldInTreasury', window );">Treasury shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,826,465<span></span>
</td>
<td class="nump">5,337,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="nump">&#8364; 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,744,392<span></span>
</td>
<td class="nump">1,744,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issueance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 248.6<span></span>
</td>
<td class="nump">248.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare', window );">Proposed dividends per share (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities', window );">Dividends paid, classified as financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 484.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="nump">484.3<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember', window );">Share Repurchase Program, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember', window );">Share Repurchase Program, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">&#8364; 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember', window );">Announcement Of Research, Development And Commercialization Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issueance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember', window );">Capital reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issueance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 233.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_PfizerIncMember', window );">Pfizer Inc. | Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issueance of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 110.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments', window );">Fair value measurement derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfSharesHeldInTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Held In Treasury</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfSharesHeldInTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss. [Refer: Derivatives [member]; Increase (decrease) in fair value of financial assets designated as measured at fair value through profit or loss related credit derivatives or similar instruments; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid by the entity, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 137<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_137_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788784618720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="27">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased', window );">Number of ADSs purchased (in shares) | shares</a></td>
<td class="nump">114,513<span></span>
</td>
<td class="nump">114,513<span></span>
</td>
<td class="nump">1,261,706<span></span>
</td>
<td class="nump">1,261,706<span></span>
</td>
<td class="nump">1,738,061<span></span>
</td>
<td class="nump">1,738,061<span></span>
</td>
<td class="nump">1,532,685<span></span>
</td>
<td class="nump">1,532,685<span></span>
</td>
<td class="nump">745,196<span></span>
</td>
<td class="nump">745,196<span></span>
</td>
<td class="nump">857,620<span></span>
</td>
<td class="nump">857,620<span></span>
</td>
<td class="nump">618,355<span></span>
</td>
<td class="nump">618,355<span></span>
</td>
<td class="nump">400,483<span></span>
</td>
<td class="nump">400,483<span></span>
</td>
<td class="nump">2,280,988<span></span>
</td>
<td class="nump">2,280,988<span></span>
</td>
<td class="nump">1,666,515<span></span>
</td>
<td class="nump">1,666,515<span></span>
</td>
<td class="nump">519,320<span></span>
</td>
<td class="nump">519,320<span></span>
</td>
<td class="nump">1,160,219<span></span>
</td>
<td class="nump">1,160,219<span></span>
</td>
<td class="nump">917,988<span></span>
</td>
<td class="nump">917,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,221,171<span></span>
</td>
<td class="nump">2,221,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,646,965<span></span>
</td>
<td class="nump">4,646,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,945,513<span></span>
</td>
<td class="nump">6,945,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS', window );">Average price paid per ADS (in dollar per share and euro per share) | (per share)</a></td>
<td class="nump">$ 112.22<span></span>
</td>
<td class="nump">&#8364; 105.07<span></span>
</td>
<td class="nump">$ 105.07<span></span>
</td>
<td class="nump">&#8364; 95.85<span></span>
</td>
<td class="nump">$ 107.92<span></span>
</td>
<td class="nump">&#8364; 97.57<span></span>
</td>
<td class="nump">$ 108.92<span></span>
</td>
<td class="nump">&#8364; 100.45<span></span>
</td>
<td class="nump">$ 128.49<span></span>
</td>
<td class="nump">&#8364; 121.08<span></span>
</td>
<td class="nump">$ 138.05<span></span>
</td>
<td class="nump">&#8364; 129.06<span></span>
</td>
<td class="nump">$ 142.26<span></span>
</td>
<td class="nump">&#8364; 131.12<span></span>
</td>
<td class="nump">$ 136.37<span></span>
</td>
<td class="nump">&#8364; 139.09<span></span>
</td>
<td class="nump">$ 135.95<span></span>
</td>
<td class="nump">&#8364; 137.66<span></span>
</td>
<td class="nump">$ 149.08<span></span>
</td>
<td class="nump">&#8364; 148.24<span></span>
</td>
<td class="nump">$ 162.03<span></span>
</td>
<td class="nump">&#8364; 159.40<span></span>
</td>
<td class="nump">$ 140.82<span></span>
</td>
<td class="nump">&#8364; 133.35<span></span>
</td>
<td class="nump">$ 151.76<span></span>
</td>
<td class="nump">&#8364; 143.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramNetAmountSpent', window );">Net amount spend</a></td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="nump">&#8364; 12.0<span></span>
</td>
<td class="nump">$ 132.6<span></span>
</td>
<td class="nump">&#8364; 120.9<span></span>
</td>
<td class="nump">$ 187.6<span></span>
</td>
<td class="nump">&#8364; 169.6<span></span>
</td>
<td class="nump">$ 166.9<span></span>
</td>
<td class="nump">&#8364; 154.0<span></span>
</td>
<td class="nump">$ 95.7<span></span>
</td>
<td class="nump">&#8364; 90.2<span></span>
</td>
<td class="nump">$ 118.4<span></span>
</td>
<td class="nump">&#8364; 110.7<span></span>
</td>
<td class="nump">$ 88.0<span></span>
</td>
<td class="nump">&#8364; 81.1<span></span>
</td>
<td class="nump">$ 54.6<span></span>
</td>
<td class="nump">&#8364; 55.7<span></span>
</td>
<td class="nump">$ 310.1<span></span>
</td>
<td class="nump">&#8364; 314.0<span></span>
</td>
<td class="nump">$ 248.4<span></span>
</td>
<td class="nump">&#8364; 247.0<span></span>
</td>
<td class="nump">$ 84.1<span></span>
</td>
<td class="nump">&#8364; 82.8<span></span>
</td>
<td class="nump">$ 163.4<span></span>
</td>
<td class="nump">&#8364; 154.7<span></span>
</td>
<td class="nump">$ 139.3<span></span>
</td>
<td class="nump">&#8364; 132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.1<span></span>
</td>
<td class="nump">&#8364; 282.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="nump">&#8364; 456.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999.9<span></span>
</td>
<td class="nump">&#8364; 986.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember', window );">Share Repurchase Program, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember', window );">Share Repurchase Program, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgram2023Member', window );">Share Repurchase Program 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareRepurchaseProgramAuthorizedAmount', window );">Share repurchase program authorized amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Average Price Per American depositary Share (ADS)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramNetAmountSpent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Net Amount Spent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramNetAmountSpent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgramTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgram2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareRepurchaseProgramPeriodAxis=bntx_ShareRepurchaseProgram2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790170944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)<br> &#8364; in Millions, &#163; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44.1<span></span>
</td>
<td class="nump">&#8364; 46.5<span></span>
</td>
<td class="nump">&#8364; 61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense / (Income) arising from cash-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
<td class="nump">108.0<span></span>
</td>
<td class="nump">93.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_ResearchAndDevelopmentExpensesMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">84.6<span></span>
</td>
<td class="nump">60.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_SalesAndMarketingExpenseMember', window );">Sales and marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_GeneralAndAdministrativeExpensesMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense / (Income) arising from cash-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense / (Income) arising from cash-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationOfShareBasedPaymentArrangement', window );">Reclassification for share-based payment arrangement</a></td>
<td class="nump">&#8364; 3.3<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember', window );">BioNTech 2020 Employee Equity Plan for Employees Based Outside North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_InstaDeepEmployeeIncentivePlanMember', window );">InstaDeep Employee Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense arising from equity-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Long-term deposits | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember', window );">BioNTech Restricted Stock Unit Plan for North America Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense / (Income) arising from cash-settled share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.6<span></span>
</td>
<td class="nump">&#8364; 8.1<span></span>
</td>
<td class="nump">&#8364; 22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ReclassificationOfShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ReclassificationOfShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from cash-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_ResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_ResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_SalesAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_SalesAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_GeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=bntx_GeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_InstaDeepEmployeeIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_InstaDeepEmployeeIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788789175616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 19, 2019</div></th>
<th class="th">
<div>Aug. 18, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>Oct. 09, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 17, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 12, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities', window );">Share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (766.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (51.8)<span></span>
</td>
<td class="num">&#8364; (13.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashOutflowToTaxAuthority', window );">Cash outflow to tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 36.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Applicable wage taxes and social security contributions resulting from and withheld upon exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 724.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember', window );">LTI Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 171.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember', window );">LTI-plus program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember', window );">BioNTech 2020 Restricted Stock Unit Plan For North America Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CashOutflowForShareBasedPaymentArrangementExercise', window );">Cash outflow for share based payment exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.4<span></span>
</td>
<td class="nump">&#8364; 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember', window );">BioNTech 2020 Restricted Stock Unit Plan For North America Employees | One year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_VestingPercentageOfShareBasedPaymentArrangement', window );">Vesting percentage after one year (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares', window );">Percentage of ADS to ordinary shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering', window );">Threshold amount of dividend by number of shares outstanding immediately following initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth', window );">Percentage of target share price applicable for prior twelve month period (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ReclassificationOfShareBasedPaymentArrangement', window );">Reclassification for share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.3<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum', window );">Price of ADS as a percentage of exercise price, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_MaximumEconomicBenefitsOfOptionsExercised', window );">Maximum economic benefits of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EffectiveExercisePriceMaximum', window );">Effective exercise price maximum (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options outstanding, weighted-average expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PhantomOptionAwardsLiability', window );">Liability related to the phantom option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,118<span></span>
</td>
<td class="nump">6,463<span></span>
</td>
<td class="nump">45,279<span></span>
</td>
<td class="nump">248,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Prof. Ugur Sahin, M.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_MaximumCashPaymentInShareBasedPaymentArrangement', window );">Maximum cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Sierk Poetting, Ph.D.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_MaximumCashPaymentInShareBasedPaymentArrangement', window );">Maximum cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum', window );">Price of ADS as a percentage of exercise price, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_MaximumEconomicBenefitsOfOptionsExercised', window );">Maximum economic benefits of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EffectiveExercisePriceMaximum', window );">Effective exercise price maximum (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options outstanding, weighted-average expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering', window );">Threshold amount of dividend by number of shares outstanding immediately following initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth', window );">Percentage of target share price applicable for prior twelve month period (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Option to purchase ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,374,963<span></span>
</td>
<td class="nump">4,374,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare', window );">Exercise price in translation for IPO (in dollar per share and euro per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant | Ordinary shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PercentageOfIncreaseInExercisePrice', window );">Percentage of exercise price increase (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum', window );">Price of ADS as a percentage of exercise price, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_MaximumEconomicBenefitsOfOptionsExercised', window );">Maximum economic benefits of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EffectiveExercisePriceMaximum', window );">Effective exercise price maximum (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Options outstanding, weighted-average expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable in share-based payment arrangement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,374,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent', window );">Minimum strike price (as a percent)</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Cash-settled option rights, exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,785<span></span>
</td>
<td class="nump">39,785<span></span>
</td>
<td class="nump">583,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 96.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 160.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,584<span></span>
</td>
<td class="nump">642,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionVestingPeriod', window );">Option rights vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OptionExercisablePeriod', window );">Option rights exercisable period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_CashSettledShareBasedPaymentArrangementMember', window );">Cash-Settled Share-Based Payment Arrangement | Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ExercisePricePhantomOptionsGranted', window );">Exercise price of phantom options granted (in euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Cash-settled option rights, exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,100<span></span>
</td>
<td class="nump">52,100<span></span>
</td>
<td class="nump">289,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Cash outflow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 96.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 155.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share options outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable', window );">Cash-settled related to rights vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashOutflowForShareBasedPaymentArrangementExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Outflow For Share Based Payment Arrangement Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashOutflowForShareBasedPaymentArrangementExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CashOutflowToTaxAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Outflow To Tax Authority</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CashOutflowToTaxAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EffectiveExercisePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Exercise Price Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EffectiveExercisePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ExerciseOfOptionRightsMinimumStrikePricePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Of Option Rights, Minimum Strike Price Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ExerciseOfOptionRightsMinimumStrikePricePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price Currency Translation Of Public Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ExercisePricePhantomOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price, Phantom Options Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ExercisePricePhantomOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MaximumCashPaymentInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Cash Payment In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MaximumCashPaymentInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_MaximumEconomicBenefitsOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Economic Benefits Of Options Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_MaximumEconomicBenefitsOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option Exercisable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OptionVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OptionVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of American Depository Shares To Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfIncreaseInExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Increase In Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfIncreaseInExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Share Price Applicable For Prior Twelve Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PhantomOptionAwardsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Phantom Option Awards, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PhantomOptionAwardsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price Of American Depository Share As A Percentage Of Exercise Price, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ReclassificationOfShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ReclassificationOfShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Payment Arrangement, Related To Rights Vested And Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareBasedPaymentsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Payments, Classified As Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareBasedPaymentsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_VestingPercentageOfShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Percentage Of Share Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_VestingPercentageOfShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_VestingPeriodAxis=bntx_ShareBasedPaymentArrangementYearOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_VestingPeriodAxis=bntx_ShareBasedPaymentArrangementYearOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_ProfessorUgurSahinMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_DoctorSierkPoettingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_DoctorSierkPoettingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_CashSettledShareBasedPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_CashSettledShareBasedPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_SaleOfStockAxis=bntx_EmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_SaleOfStockAxis=bntx_EmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790680976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember', window );">LTI-plus program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareOptionsOutstandingAbstract', window );"><strong>Share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, share options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">372,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement', window );">Settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(364,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, share options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement', window );">thereof un-vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember', window );">LTI 2020 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareOptionsOutstandingAbstract', window );"><strong>Share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, share options (in shares)</a></td>
<td class="nump">235,305<span></span>
</td>
<td class="nump">242,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options (in shares)</a></td>
<td class="num">(4,400)<span></span>
</td>
<td class="num">(7,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement', window );">Settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, share options (in shares)</a></td>
<td class="nump">230,905<span></span>
</td>
<td class="nump">235,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested (in shares)</a></td>
<td class="nump">175,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement', window );">thereof un-vested (in shares)</a></td>
<td class="nump">55,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember', window );">LTI 2021 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareOptionsOutstandingAbstract', window );"><strong>Share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, share options (in shares)</a></td>
<td class="nump">104,608<span></span>
</td>
<td class="nump">110,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options (in shares)</a></td>
<td class="num">(3,497)<span></span>
</td>
<td class="num">(5,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement', window );">Settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, share options (in shares)</a></td>
<td class="nump">101,111<span></span>
</td>
<td class="nump">104,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested (in shares)</a></td>
<td class="nump">51,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement', window );">thereof un-vested (in shares)</a></td>
<td class="nump">49,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember', window );">LTI 2022 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareOptionsOutstandingAbstract', window );"><strong>Share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, share options (in shares)</a></td>
<td class="nump">396,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options (in shares)</a></td>
<td class="num">(16,141)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted, share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement', window );">Settled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, share options (in shares)</a></td>
<td class="nump">379,969<span></span>
</td>
<td class="nump">396,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested (in shares)</a></td>
<td class="nump">96,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement', window );">thereof un-vested (in shares)</a></td>
<td class="nump">283,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember', window );">LTI Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted average exercise price (&#8364;)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 171.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ShareOptionsOutstandingAbstract', window );"><strong>Share options outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, share options (in shares)</a></td>
<td class="nump">57,584<span></span>
</td>
<td class="nump">642,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited, share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised, share options (in shares)</a></td>
<td class="num">(39,785)<span></span>
</td>
<td class="num">(583,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, share options (in shares)</a></td>
<td class="nump">17,799<span></span>
</td>
<td class="nump">57,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested (in shares)</a></td>
<td class="nump">17,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement', window );">thereof un-vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract', window );"><strong>Number of ordinary shares underlying options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Beginning balance, number of ordinary shares underlying options (in shares)</a></td>
<td class="nump">1,036,514<span></span>
</td>
<td class="nump">11,556,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement', window );">Forfeited, number of ordinary shares underlying options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement', window );">Exercised, number of ordinary shares underlying options (in shares)</a></td>
<td class="num">(716,121)<span></span>
</td>
<td class="num">(10,500,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding', window );">Ending balance, number of ordinary shares underlying options (in shares)</a></td>
<td class="nump">320,393<span></span>
</td>
<td class="nump">1,036,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested, number of ordinary shares underlying options (in shares)</a></td>
<td class="nump">320,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement', window );">thereof un-vested, number of ordinary shares underlying options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted average exercise price (&#8364;)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning balance, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 11.10<span></span>
</td>
<td class="nump">&#8364; 10.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement', window );">Exercised, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">11.04<span></span>
</td>
<td class="nump">10.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">11.24<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement', window );">thereof vested, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">11.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement', window );">thereof un-vested, weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Weighted average share price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 96.49<span></span>
</td>
<td class="nump">&#8364; 160.44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Settled In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Unested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Vested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ShareOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ShareOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentiveProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791270240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 17, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 12, 2021 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 01, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 09, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Nov. 15, 2018 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Apr. 03, 2019 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2026 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>yr </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>yr</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="nump">&#8364; 27.64<span></span>
</td>
<td class="nump">&#8364; 29.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 38.88<span></span>
</td>
<td class="nump">&#8364; 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in euros per share)</a></td>
<td class="nump">&#8364; 179.46<span></span>
</td>
<td class="nump">&#8364; 168.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 147.84<span></span>
</td>
<td class="nump">&#8364; 28.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="nump">&#8364; 169.08<span></span>
</td>
<td class="nump">&#8364; 167.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 137.65<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">49.70%<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
<td class="nump">36.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember', window );">LTI-plus program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 87.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember', window );">LTI 2020 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 92.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember', window );">LTI 2021 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 203.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember', window );">LTI 2022 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 165.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 46.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 98.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Management Board Grant | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32.86<span></span>
</td>
<td class="nump">&#8364; 39.97<span></span>
</td>
<td class="nump">&#8364; 43.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 95.51<span></span>
</td>
<td class="nump">&#8364; 95.51<span></span>
</td>
<td class="nump">&#8364; 95.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105.13<span></span>
</td>
<td class="nump">&#8364; 99.74<span></span>
</td>
<td class="nump">&#8364; 96.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.80%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember', window );">Chief Executive Officer Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember', window );">Employee Stock Ownership Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7.04<span></span>
</td>
<td class="nump">&#8364; 6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16.03<span></span>
</td>
<td class="nump">&#8364; 15.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15.39<span></span>
</td>
<td class="nump">&#8364; 15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ChiefExecutiveOfficerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793318944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details) - Management Board Grant<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 17, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 12, 2021 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>May 30, 2022 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">(Phantom) share options outstanding (expected to be allocated) (in shares)</a></td>
<td class="nump">6,463<span></span>
</td>
<td class="nump">45,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement', window );">thereof allocated and vested but subject to performance and waiting requirements (in shares)</a></td>
<td class="nump">3,232<span></span>
</td>
<td class="nump">22,640<span></span>
</td>
<td class="nump">21,531<span></span>
</td>
<td class="nump">186,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement', window );">thereof allocated and un-vested (in shares)</a></td>
<td class="nump">3,231<span></span>
</td>
<td class="nump">22,639<span></span>
</td>
<td class="nump">64,587<span></span>
</td>
<td class="nump">62,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 169.08<span></span>
</td>
<td class="nump">&#8364; 167.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 137.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Allocation date May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">(Phantom) share options outstanding (expected to be allocated) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement', window );">thereof allocated and un-vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Estimated allocation date 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">(Phantom) share options outstanding (expected to be allocated) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement', window );">thereof allocated and un-vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 96.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Estimated allocation date 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">(Phantom) share options outstanding (expected to be allocated) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement', window );">thereof allocated and un-vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember', window );">Estimated allocation date 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">(Phantom) share options outstanding (expected to be allocated) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement', window );">thereof allocated and un-vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted-average exercise price (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 105.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_ManagementBoardGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_EstimatedAllocationDateFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794247600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions - Provisions (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvision', window );">Contractual disputes</a></td>
<td class="nump">&#8364; 118.2<span></span>
</td>
<td class="nump">&#8364; 88.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermOnerousContractsProvision', window );">Obligations from onerous CMO contracts</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">51.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total</a></td>
<td class="nump">278.1<span></span>
</td>
<td class="nump">375.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Total current</a></td>
<td class="nump">269.3<span></span>
</td>
<td class="nump">367.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Total non-current</a></td>
<td class="nump">&#8364; 8.8<span></span>
</td>
<td class="nump">&#8364; 8.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for legal proceedings. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 10 A court case<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex10_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermOnerousContractsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermOnerousContractsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793530976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract', window );"><strong>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvision', window );">Contractual disputes</a></td>
<td class="nump">&#8364; 118.2<span></span>
</td>
<td class="nump">&#8364; 88.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentOnerousContractsProvisionAdditions', window );">Current onerous provision addition</a></td>
<td class="nump">29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermOnerousContractsProvision', window );">Obligations from onerous CMO contracts</a></td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">235.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption', window );">Related to release and consumption</a></td>
<td class="nump">155.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions', window );">Other additional provisions</a></td>
<td class="nump">45.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentOnerousContractsProvisionRelatedToRelease', window );">Provision related to release</a></td>
<td class="nump">126.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_CurrentOnerousContractsProvisionRelatedToUsage', window );">Provision related to usage</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Other</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="nump">&#8364; 51.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additional provisions, other provisions</a></td>
<td class="nump">&#8364; 28.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentOnerousContractsProvisionAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Onerous Contracts Provision, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentOnerousContractsProvisionAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Onerous Contracts Provision, Other Additional Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentOnerousContractsProvisionRelatedToRelease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Onerous Contracts Provision, Related To Release</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentOnerousContractsProvisionRelatedToRelease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Onerous Contracts Provision, Related To Release And Consumption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_CurrentOnerousContractsProvisionRelatedToUsage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Onerous Contracts Provision, Related To Usage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_CurrentOnerousContractsProvisionRelatedToUsage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provision for legal proceedings. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 10 A court case<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex10_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermOnerousContractsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermOnerousContractsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791067200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments under purchase agreements for property, plant and equipment</a></td>
<td class="nump">&#8364; 154.4<span></span>
</td>
<td class="nump">&#8364; 105.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Contractual obligation to acquire intangible assets</a></td>
<td class="nump">1,721.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total</a></td>
<td class="nump">1,875.5<span></span>
</td>
<td class="nump">&#8364; 105.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments under purchase agreements for property, plant and equipment</a></td>
<td class="nump">152.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Contractual obligation to acquire intangible assets</a></td>
<td class="nump">249.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total</a></td>
<td class="nump">401.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">1 to 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments under purchase agreements for property, plant and equipment</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Contractual obligation to acquire intangible assets</a></td>
<td class="nump">954.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total</a></td>
<td class="nump">956.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems', window );"><strong>Disclosure of contingent liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments under purchase agreements for property, plant and equipment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Contractual obligation to acquire intangible assets</a></td>
<td class="nump">516.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total</a></td>
<td class="nump">&#8364; 516.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 74<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_74_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788783257216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and other financial commitments - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract', window );"><strong>Contingencies And Other Financial Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets', window );">Contractual obligation to acquire intangible assets</a></td>
<td class="nump">&#8364; 1,721.1<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ContingenciesAndOtherFinancialCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies And Other Financial Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ContingenciesAndOtherFinancialCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788791774128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Non-Financial Liabilities - Summary of Other Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherNonFinancialLiabilitiesAbstract', window );"><strong>Other Non-Financial Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LiabilitiesForEmployeeBenefits', window );">Liabilities to employees</a></td>
<td class="nump">&#8364; 73.3<span></span>
</td>
<td class="nump">&#8364; 50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment arrangements</a></td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">36.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses', window );">Liabilities from wage taxes and social securities expenses</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">761.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_OtherLiabilitiesOther', window );">Other</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNonfinancialLiabilities', window );">Total</a></td>
<td class="nump">138.2<span></span>
</td>
<td class="nump">877.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Total current</a></td>
<td class="nump">125.1<span></span>
</td>
<td class="nump">860.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Total non-current</a></td>
<td class="nump">&#8364; 13.1<span></span>
</td>
<td class="nump">&#8364; 17.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LiabilitiesForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities For Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LiabilitiesForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities From Wage Taxes And Social Securities Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_OtherNonFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Financial Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_OtherNonFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793553680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 214.4<span></span>
</td>
<td class="nump">&#8364; 211.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="nump">206.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember', window );">Other operating equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">&#8364; 4.6<span></span>
</td>
<td class="nump">&#8364; 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788790096000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_Leases1Abstract', window );"><strong>Leases 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">&#8364; 66.4<span></span>
</td>
<td class="nump">&#8364; 118.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Total cash outflow for leases</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">46.2<span></span>
</td>
<td class="nump">&#8364; 17.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities', window );">Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049</a></td>
<td class="nump">&#8364; 157.2<span></span>
</td>
<td class="nump">&#8364; 163.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_Leases1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_Leases1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788926094384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_Leases1Abstract', window );"><strong>Leases 1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">&#8364; 28.1<span></span>
</td>
<td class="nump">&#8364; 36.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">188.6<span></span>
</td>
<td class="nump">174.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 216.7<span></span>
</td>
<td class="nump">&#8364; 210.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_Leases1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_Leases1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788781015184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Total depreciation charge</a></td>
<td class="nump">&#8364; 45.2<span></span>
</td>
<td class="nump">&#8364; 58.8<span></span>
</td>
<td class="nump">&#8364; 29.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense related to short-term leases and leases of low-value assets</a></td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_LeaseExpensesRecognizedInProfitOrLoss', window );">Total amounts recognized in profit or loss</a></td>
<td class="nump">109.8<span></span>
</td>
<td class="nump">91.0<span></span>
</td>
<td class="nump">41.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Total depreciation charge</a></td>
<td class="nump">40.7<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember', window );">Production facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Total depreciation charge</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember', window );">Other operating equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Total depreciation charge</a></td>
<td class="nump">&#8364; 1.5<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_LeaseExpensesRecognizedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Expenses Recognized In Profit Or Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_LeaseExpensesRecognizedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_ProductionFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=bntx_OtherOperatingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788943858960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation paid to key management personnel</a></td>
<td class="nump">&#8364; 8.9<span></span>
</td>
<td class="nump">&#8364; 15.5<span></span>
</td>
<td class="nump">&#8364; 20.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_ManagementBoardMember', window );">Management Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationFixedCompensation', window );">Fixed compensation</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term incentive &#8211; first installment</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment', window );">Short-term incentive &#8211; second installment</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation', window );">Other variable compensation</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments (incl. long-term incentive)</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation paid to key management personnel</a></td>
<td class="nump">&#8364; 8.3<span></span>
</td>
<td class="nump">&#8364; 15.0<span></span>
</td>
<td class="nump">&#8364; 20.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_ManagementBoardMember', window );">Management Board | Jens Holstein</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded', window );">Phantom shares awarded (in shares)</a></td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
<td class="nump">4,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bntx_SupervisoryBoardMember', window );">Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total compensation paid to key management personnel</a></td>
<td class="nump">&#8364; 0.6<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="nump">&#8364; 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationFixedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Fixed Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationFixedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationOtherVariableCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Other Variable Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationOtherVariableCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Phantom Shares Awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_ManagementBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_ManagementBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_JensHolsteinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_JensHolsteinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_SupervisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_SupervisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794197776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction', window );">Outstanding balances of related party transactions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction', window );">Bad debt expense has been recognized | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">Other related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions', window );">Purchases of property and other assets from entities controlled by ATHOS KG | &#8364;</a></td>
<td class="nump">&#8364; 62,500,000<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 62,500,000<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EmployeeStockOwnershipPlanESOPNameAxis=bntx_EmployeeStockOwnershipPlan2018Member', window );">Employee Stock Ownership Plan 2018 | Employee Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of option rights vested (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,152,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Share options, exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,921,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_EmployeeStockOwnershipPlanESOPNameAxis=bntx_EmployeeStockOwnershipPlan2018Member', window );">Employee Stock Ownership Plan 2018 | Employee Stock Option Plan | Sean Marett</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_NumberOfShareOptionsHeld', window );">Number of share options held (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_NumberOfShareOptionsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_NumberOfShareOptionsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised during the period in respect of bad or doubtful debts due from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions for doubtful debts related to the amount of outstanding balances in related party transactions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property and other assets purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_EmployeeStockOwnershipPlanESOPNameAxis=bntx_EmployeeStockOwnershipPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_EmployeeStockOwnershipPlanESOPNameAxis=bntx_EmployeeStockOwnershipPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=bntx_EmployeeStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bntx_SeanMarettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bntx_SeanMarettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794808512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details) - Other related parties - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions', window );">Purchases of various goods and services from entities controlled by ATHOS KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="nump">&#8364; 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions', window );">Purchases of property and other assets from entities controlled by ATHOS KG</a></td>
<td class="nump">&#8364; 62.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PurchasesFromRelatedPartyTransactions', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="nump">&#8364; 62.8<span></span>
</td>
<td class="nump">&#8364; 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchasesFromRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases From Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchasesFromRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases Of Goods And Service Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property and other assets purchased by the entity in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788793590816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details) - Other related parties - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Total</a></td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember', window );">ATHOS KG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Total</a></td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="nump">&#8364; 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_OtherRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bntx_ATHOSKGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bntx_ATHOSKGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139788794779856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events After the Reporting Period - Additional Information (Details)<br> &#8364; in Millions, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 443.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_LicenseAndOptionAgreementMember', window );">License And Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_PurchaseOfSharesUnderAgreement', window );">Purchase of shares under agreement (in shares) | shares</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Percentage of voting equity interests acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bntx_UpfrontPayment', window );">Upfront payment | $</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_PurchaseOfSharesUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Shares Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_PurchaseOfSharesUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_LicenseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=bntx_LicenseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>146
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  H/W18KC56SAT(  !J,P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+V;:W/B.!:&_XJ*J9K:2PB^D4M/0BTA83:UG72VDYG9WJW](&P%7&U+K"SG
M,K]^CF6#0K=\[+CP?DG ^+SHU?71$3Y[%O)KMF),D9<TX=GY8*74^L-HE(4K
MEM+L4*P9AT\>A4RI@K=R.<K6DM%(!Z7)R'.<HU%*8SZ8G.EK=W)R)G*5Q)S=
M29+E:4KEZP5+Q//YP!UL+GR.ERM57!A-SM9TR>Z9^F5])^'=:*L2Q2GC62PX
MD>SQ?#!U/\S&?A&@[_@U9L_9F]>DL+(0XFOQYCHZ'SA%B5C"0E5(4/CWQ&8L
M20HE*,?_*M'!]CN+P+>O-^IS;1[,+&C&9B+Y+8[4ZGQP,B 1>Z1YHCZ+Y[^S
MRM"XT M%DNF_Y+FZUQF0,,^42*M@*$$:\_(_?:DJHDV 5P5XWP2X04V 7P7H
MFAN5)=.V+JFBDS,IGHDL[@:UXH6N&QT-;F)>-..]DO!I#'%J,A-/3)(AR594
MLNQLI$"S^&045O$79;Q7$^]ZY$9PM<K(%8]8M"LP@L)L2^1M2G3AH8J7+#PD
MOGM /,?S+06:X>$W5!X2U]?A 5(<?UM!OM;S:_2NN(K5*_D89RKFRXS\YR/<
M0*X52[/_VJJK5 OL:L6@_)"M:<C.!S#J,B:?V&#RXP_ND?.3S>J>Q':,!UOC
M :8^N11A#N-5D8?7-;,YQ<,]9SBW64*C.EH:;RV-VUGZS);0GI+JF>1>46A-
MN&PSB0L^TB2SU<T,#>OH\FCK\JB=RRGG.4W [%I(JSE<1\G<Z@V-ZNCM>.OM
MN)VW.R9C$163#H%YS]H_&Y0VTTSM/(/&=_1YLO5Y@I9NEDM9V)S'60A-^(51
MB7K%U89#UQOZKLTD&MC1Y.G6Y&G+&492X (]&.L[*ZY5.Q+1L(X&7<>LKDX[
MB_<K(!4R$^F:\E?$98->K4T\KJO/-Q3AHN6J5LEYG#!RFZ<+)JWF<!''<8?^
MJ7-B[:AX;%>#GC'HM3&X63B@16]I:AV*#4(7L;A]8.&*W%]9;:+176T:V'%1
MI-C8O.:AD-!%]0)Y4*Z01$CHOSE7\A7^1W;ON+IW8[7<!^6X!G-<'%0JR],H
M O7L8/.":,[[Q.T^<<DIAYV$)#^+)%K*?,&(ZUF-]\%"KH$A%X>7;XW?B4S!
M6O/O>%W?O@U\-1R/7?LZ@T=V]6J0R,59YENOL^(==.@'\<RM1G&Y&]@?_VZU
MV0<<N8:.7!QJOK-9CE>KPP8\LL].?3"1:Z#(Q3FFL@>K:*JY781?87+2.U?R
M*5?0?7D$FS2KW3V!3E4/I=I8JQ69DJ>)YQ\?>^-C?WPV>K*9-%#DXB13F?P-
M>&'XE4/_)/>,9H*SB%QG65ZSLN*:7ZQ;^QD>U;$Y/0-''@XSE=-?10*]E,H2
M'Z0U"=&@="NLB8(^F,@S3.2U8J(-RI?,!]U3+Z>YW2:N6-.,>%17GP:-O%9H
M=,T5DV56KMBFT(UQJT]<L<YG'VSD&3;R6K&1[J1D!D2T%/:IM4'G(Y5+1J9A
MR$ (9*)2TNJX#S3R#!IYK=#H*F5R673<GT%!K3:[&*MU7+!V^X+'=35J4,C#
MP>5Z-O],IGD4*V""J5(,EA*]'9TGU+J<-.C5I4[PL*XV#05Y+3-#\YA3'L9
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M:]HK4YCGSQ4XV"D;J)4!+0W=Q-FX&":X;8R+M0H&@S$L4L%LR^V5EB&53G)
MO>9HE/(=$0LW CA^5')QI@,"!MZDL*EP*'2=,3!2 5W+\6;SI1,?4*\^/E8C
M2Q*9Z1:58'#=B?I0X6PY$B?)H@ ZOMOOZ2&53H) O09IND9T#!!3&A 304H3
M)2=OHN3":3)L53#'=L;S1*3 00N%:$Y3P4Y[0%^[)(AP68BIC$DN@!UPJ9X"
MM KFI:N#1;U%2WD;!K#3.E"O2ZXP2V- GL(X'!I=5,$;L;(EIY+V(OU6&>KZ
M<V%_&C6"L;I3H0+##\;C9@H3Q07.%8U.TD"]$MFFV4DN\1>D':IH3_)%@1+%
M8S(!*&"B8-EJVJC3,4BO8S8TSTD9IS]8$NJ]O#1;%O46+>5M&,%..R'XTSL0
M2"N[7ARV);U%2WD;AJT3:4@OTGZ\#=$X\ <3@A#%8^VLP$$?ALYD*Z(!]C<V
M8!#X,VH =4(-Z85:NXQ_C?/CN\%"7LMOT?VI1;U%2WD;1K33B\CY^9S22LT7
MAVU);]%2WH9AZV0ITLO29^24.\VI:4*YTSR!DV2:>A+Z;6[5@Z0>'3[I]!S2
M;R9]@5_!^^3?$^/USCNGX"A*<GGV760=V*7[DX@E2$Y$OHD/N-C+I1_8G8KJ
MJ$7NVF09C7%U[D)W8/_CO9SJ'9W9Y0!O&"'@#\H)\ WTUE!UG=D[<!#U=5^=
M]# 0TU/!ZZW:]FE[FG15G:&,GF_@>005S]\C[WPKHJIZXXLWU<&4V7VZ/M;Z
MA,M]6C"0D9UHAF7XHA/+^J2HON'T6!V%W%'.:5Y='@A.2"D!XOV."MK-C?Q
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MQ/X/?G0HJON;BZ)J_@?[@VT2CH+YME)B?6RL%:SS\O#*?AX#T6J J*,!/C;
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M//P.YG# V:[Y&<8CXYQMF[<;FJ2TK W$]T^,\;>#^I<=QU\CS?\#4$L#!!0
M   ( "@_=%B&YFH-] D  (\N   8    >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULK9IKC]NV$H;_BN "10*L;?&BB]/=!1*[00.<M(L$/?VLM6A;)[+H4O1N
MTE]_AI)L73CB.JGS(>O+R[%>7H8/1[I]ENI+N1-">U_W>5'>379:'][,Y^5Z
M)_9).9,'4< W&ZGVB8:W:CLO#THD:=5HG\^I[X?S?9(5D_O;ZK,'=7\KCSK/
M"O&@O/*XWR?JVSN1R^>["9F</OB4;7?:?#"_OSTD6_%9Z#\/#PK>S<]1TFPO
MBC*3A:?$YF[REKQ9\= TJ!3_S<1SV7GM&2N/4GXQ;SZD=Q/?7)'(Q5J;$ G\
M>1)+D><F$ES'WTW0R?DW3</NZU/T]Y5Y,/.8E&(I\[^R5._N)O'$2\4F.>;Z
MDWS^332& A-O+?.R^M][;K3^Q%L?2RWW36.X@GU6U'^3KTU'=!J0<*0!;1K0
M80,^TH U#=BE#7C3@%<]4UNI^F&5Z.3^5LEG3QDU1#,OJLZL6H/]K##C_EDK
M^#:#=OI^*8M2YEF::)%ZGS7\@4'5I2<WWC(I=]Y[F!BE-_5^_?.3]^KGGV(6
M\E]>>\T++RN\CUF>PP"6MW,-EV."SM?-3[^K?YJ._#2AWD=9Z%WI_5JD(NT'
MF(./LQEZ,O...B.NQ'KF,7+C49\RY(*6ES>G2//5Y<V)PPT[#PVKXK&1>'\<
MA$IT5FSKQ9'I3*"]7$?A>!23-]Z4AV0M[B:0&$JAGL3D_N>?2.C_@O70-8.M
MKA2LUWO\W'O<%?W^0<E-ICW(C)[>"0_Z,I,IUGUUF*@*8[+DT_V"^3.8/D_=
M?D%4G/$9[\M6MHSX=$%GP5G7,Q.<S01.,Q^*M=P+3R=?\2E0MXX[/TN#8!8/
M/-@J%I#%+!IXL&4\"MAL@5L(SQ;"2\;C4<"(5$XP'Z'UTX3$X8P,C" RN@CX
M4+="=('/P\ZH]:Q$9RN1<V&^3?\'B;G.DUK"[K>6Q3K+89(-/9JO"]B\UR:5
M;DPJ?8/9CJZY@J\9;'6E8+UNCL_='#MGS$I T'66U'Q0I%ZRETIG_]0?P 8%
MW0W+6G^[\0YY4N@;3_Q]S YF7&Y@9]))L<T>8522LA0P4B:",A0PE9OIL3Q]
MCHU';,^;F W7^A)1439,'"M;%04SBD_ Q;EG%LZ>^;Q+E)@:W$F]0_+-./;$
M5T#!$D\/"^L: F+9L47$CV?AP(ZM6D!J\#O_".Z-^"V1^$YWOXLJ;0.Q%>!J
MO8-Q%%Z:;39"B6*-.VQ"!IWKFM+%, $VJN[5AS3H).?:(R*;LC@:2^*DPUK$
MZ>P_L@2R*L!,>9!EDB.3N)JFYWF,6B5V&K=2/2+RK;%$1+PCZINDK4GJ-/D^
M*Q(8)EB!U9X%(Y@?4T,QWSVFU!X&LU^%0Z^(CH:!M1(Q'1D=U);2B!-CSGZ;
M!?AO##,[5W2VW<:M+2+Q4+5"5,P?S3NDA2KBIJJ/\JDY( #Z;^&-*JKLLU4P
M=W%3W&83*_<@(@O!5HVHM\;C$2HA+5D1-UK] 72HO$(6TVJ3;F;MW'N5PV)]
MC3H*K.OPAWY>E*R(C5E3.CI +641-V:9Y/EJ"^?]U^ A/^4;@-^GQ!RPP5^I
MU;$>P@3R;)(I[RG)CX K.R6/V]T)8H";37.T Q"NBJPTNFQD_9S,AXR&! NB
MSMCW^Z%%-.)FM+^D^F+6X#HY9!HR;=(R&XI@Y*H,=M5HJVM%ZW=EBV'D)0Y;
M*P&L818%+(_J]6NS_K5*4E%M6+):1$!K N89,%=YXP$3P_=KW<6O6C;.7<V%
M=&=,P"(K6=A(Q5FXL'.@K9O"<0*@9@Q16OXB;@ ;[9*L>((I)M7(49W8^!23
M,7QJW-I-0FI[M553SN*QDPYM88RZ8>Q#XZX=;P#.9HCKX=Q4^U\&:RS/DL<L
MK^H4IR]['YVG1.]3)39'F!N=SZJY FGH*2O'*DO41C1B;X-+1!8'UH$7"Q:0
M<&R:T);WJ)OW/A0:MOM2-RL#:+TZA(@DS_Z!-R9-E]Y&R7U]0#1?5B\,_T%2
M%B-;*K6YC09Q9^]HS".RA;6K(BHRM@W1%@*I&P+/S@])-G!M=A7Q0[8Q'K10
M E-18C$^)B.C^R]M:9"Z:;"MU%3641\VFTUY;*WI):JCE%IE#DS(>!"-E6QH
MBWO4C7O(01,?&IO?IE$8VE,2T<%1-!X:0F2$C2:SEO6HF_5^[Y5BZBDH+ZRR
M4IO78&^RC]&(CK @BJQ2(2*,XVXUKF^R)4 :.LGG VQ!Y26&G"#YO<1SU6BK
M:T7K=V$+C]1)5/</1P4G-MCT?N1\WL3N)R"^L"<*HF.0H.EPGB Z0D>K$;3E
M.NKFN@<EUT*DS3HH(?'^F%\$L_SA'KM$5'9! A&-K_H6UJ@;UKJC^:_*@A2#
MK #9@A =LZO3F(R&8^/*6F1C;F1[NX;A*K-3E;0\/I99FB7J1%:/QQ):F$WX
MIBI.@Z;>ATT[-;P1U]QCPDIB++3V+&;7X88'7RP4]3M[0-]V"UOL)=@R>:^J
M1@"K#MET?%29#4#3B-#8&E9,R"-K\\)D9#$ZK"U2,3=2]9?K/M%'E>EO9O2^
MPZM-/80"Z0[O=B$ZUBM;-U81B&+CY6W6N?/IIJC!1GTT_-&<KB[9VA@"1*&Y
M030L46!"9E<.,5D0CAX06,M7C#OWZKIV>($A)Z9]]SW>:T9;72M:OPM;IF-N
MINLOBZPLCU4UUB0^ Z]M 0@RGS9'V:/Z5G_527^R'%DO+Y?Z&,)[Q+?.&Y@L
M],<(G;6TQUZ\K=JQG\ND:)*\5! +9A;NRRZZV;>\49&5[>PBGS_BJ<4OYL:O
M3^)T4PO&YF)+"";YUIUC3$5BVQ4B"^C8O1'6(A=[ ;F:,Q2<AO/JB1LMO;PJ
MKW3*'Z@[!+(X,F28C%CD@<D('TUG+6FQ"^Y+@K?#B;@ )K<JV:..$/J)6&RG
M:$2WB$/K.-7H+IB(O"4I[B:I%:3D5!0I.B3\1=19<@1U>,RM_<49JG_M+0YQ
M-PYA9]VY]ZK92E^?<.'%K8=C>!19-X:7F(YP8A><$.&"CR$#;_&(N_'(^#V5
M8HW15'3*LM]59^)8!8F%Q#K3($*@*4JM=(((.8G&D)>WF,3=F+2L;RNZ#,)J
M+(]YQ4S5%#C?BU20?UZZ(<D1[B$V12&RT$J]*TS%Q\H=O/.8E[M$]0-]4/.R
MN>M5/THBH!/6(W/!KD01N.KA[79$-K49@-LW,,>6>8L_W(T_RU'3B:X>?'L4
MVZPHC'?83%]X$@XK7<7 \\-=%!.&"VH5UC$=!3@:6^PM]7 W]3A<5X^NKL1:
M[!]AD!E!C=;1>X_ID3!D]@I'A%B/K#!AOT=JI_/.D[I[H;;5$\\E .BQT/5S
MKN=/ST]5OZV>)1Y\_HZ\6=7/1K=AZD>U/R9J:^XKY&(#(?U9!(.@ZJ>?ZS=:
M'JKG@1^EUG)?O=R))!7*".#[C93Z],;\P/D9]/O_ U!+ P04    "  H/W18
MPXO(@?T#  "4"   &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;)U6VV[;
M.!#]E8$*%!O L"ZVFYMMP,ZM 9HVL-O=A\4^4-+8(D*1*DG%<;]^A]2EWL+)
M+O8E$<F9,V?.##F>[I1^,@6BA9=22#,+"FNKBS T68$E,T-5H:23C=(EL[34
MV]!4&EGNG4H1)E'T(2P9E\%\ZO<>]7RJ:BNXQ$<-IBY+IO=+%&HW"^*@VUCQ
M;6'=1CB?5FR+:[3?JD=-J[!'R7F)TG E0>-F%BSBB^78V7N#WSGNS,$WN$Q2
MI9[<XCZ?!9$CA (SZQ 8_7O&*Q3" 1&-[RUFT(=TCH??'?JMSYUR29G!*R7^
MX+DM9L%9 #EN6"WL2NT^8IO/Q.%E2AC_%W:-[>0\@*PV5I6M,S$HN6S^LY=6
MAP.'L^@5AZ1U2#SO)I!G><TLFT^UVH%VUH3F/GRJWIO(<>F*LK::3CGYV?F5
MTI72S"+<RZ;$I-4TM 3M#,*LA5DV,,DK,'$"#TK:PL"-S#'_)T!(G'IB24=L
MF;R)>(W9$$;Q )(H&;V!-^H3'7F\T6MXW&1"F5HC?-G T;3AYJ423#*K]![^
M7*3&:FJ:OXZIT<0:'X_E+M*%J5B&LX!NBD']C,'\_;OX0W3Y1B;C/I/Q6^C_
MO63_ P:67'W^BED!ZQO@!A@(7G*+.62JK)C< Y=9YY@#DSGDJN09%[3B$NZ0
M@.1^"(L2-<^8A&NLE.&6+CRL"T9JP&^+Z_4)76@OC;1<;@^COG]WEL2GEP:4
MSKET;J9Q*]@S0HHHH:I3P3.Q!ZH/-1L0;5L@?&8F9]_A3JB4"5C[BP\/3#_1
MTV:(-A4^LRI%#7'DVBH^'\)7\M.XY<:B=DB;#2<[2ERHS&=(.3W0T_9CT*5&
M]"5=>PUW2N1;7:<(<3* R20>Q8WIR?!7%0\B\(8KJ4D"99R(=H>PI/#^T*/
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M1B$<:V;P>-#.--Z4+)[6MK]'96MO60_)+ZQ#;'=@1A! VB8!$(R&;0K!Z/V
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M4.#S# _TP(-"]N_M/1+,2O5U5F_W#J^(L\&8=%0I4Q>//H,R!7T ,N&*HS+
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M9^*V$W"</:]1#Q!ER=01&]C6\+O1==M08E''3*1HZ0VQSH/M#=?E)X!\(A+
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MG!"!AUKBW-+XQS_?O;U^_N\ 4)H&(SG143@-XES+SN4T5[Y@*X0BRK+-$A&
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M,IY\9*[CT;YNU; ZV23+/4Y:&1R/H4TQD\X=0:ZNQ87*[(GG:>MQ_W(TYW[
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M<>*U]%=<FBMQ9YIFHR%1W4>0R^6/U/4N1,:-?<$T4O8BJ$TMU[Q#[UK3!1D
MQ00? CN8"(_]XX]K&/5&^PX'LWG^,[Z3SM:?WRBC'B=;'- Y':^YY-)63(C#
M9)EU*QPTX5Y(.;D<JT65S>=<O.S)G-L7G0=B-3Q>5F>XDTQA?;7LU?'2:R$3
M]!C76T@=V/JPT.KITDV^R8/9*4DC&N-)L;RXLX::T\^]VL^^E4K()YQS"D9
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M#:Y1X?)M&MV^$0IW"KX](+Q]T-I<W! 8TP3BB8SO:)Q 84PR<JB923!F!?V
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M3Z#PI#R=G)X@+JUW:4KZ< H'ML/P>*VXN:\VD;%ZB$K4X[\/(*KY<VJ;9K6
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M!E(NUF+0M6<DMO/!T5NB0J?[1UZ,IFR0L"(VO3B3*<Z,+:ROPI.=0S0F>XX
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M<FMS:&5E=',O<VAE970Q-"YX;6SM66N/VS86_2N$BQ8MX-%8DI_)S "9O#I
MLPF2M.EBL1]HB;*YD4B%E,:9_OH]EY1DV>-Y)MU/^\$/2>3E?9Q[[B5ULM'F
MLUT+4;&O1:[LZ6!=5>63XV.;K$7!;:!+H? DTZ;@%2[-ZMB61O#432KRXV@T
MFAX77*K!V8F[]\Z<G>BZRJ42[PRS=5%P<W4N<KTY'82#]L9[N5I7=./X[*3D
M*_%!5+^7[PRNCCLIJ2R$LE(K9D1V.G@6/CD?TW@WX \I-K;WGY$E2ZT_T\5%
M>CH8D4(B%TE%$CA^+L5SD><D"&I\:60.NB5I8O]_*_V5LQVV++D5SW7^2:;5
M^G0P'[!49+S.J_=Z\ZMH[)F0O$3GUGVSC1\[C@8LJ6VEBV8R-"BD\K_\:^.'
MWH3YZ(8)43,A<GK[A9R6+WC%STZ,WC!#HR&-_CA3W6PH)Q4%Y4-E\%1B7G5V
MH1)=",95REY^1:2ML"?'%033X^.D$7+NA40W" DC]D:K:FW92Y6*=%? ,33J
MU(I:M<ZC6R6^$$G XG#(HE$4WR(O[LR,G;SX!GG/%,^OK+1,9TQN31;>9/8O
MOK25 4+^?<AX+WI\6#1ES1-;\D2<#I 65IA+,3C[Z8=P.GIZB^+C3O'Q;=+O
M&Y\'"V&S(&2OA1*&Y]N;S[6MR$4?>(ZK5T87K%H+=B6X88)"RQ 842R%:8,3
ML4K?-28>LJ01;)W@5"0@$(NARROVTP_S>#I^&@WCQ22(@/$\IW35ALU'/[*,
M=.B&+#!DU W!RLV3R6(1S-O[0T9DE%^QM!8TQHA$KY3\2ZH5 P=!KUUMW!*Z
M-CVUGK_]X^+%4;A@ESQ)X$P_<L@V:YFL"4!Y38:2W7;-C2!A*Z.M9:71F:SP
MA%=L@_OTJ6G%/.=+;;BCHI*;"IYG[S+YE_"LDC*R&2/=2@&[ &&EJ:R</;OZ
M;KAEL@#B*N] T4:/&VG)2&>05)="5=I<L8V1E3C266;[F(?=<#'436O/CPF'
M2"SHXF- E:D7E""S*36PL*S6[/F;M]:;MQ0)!ZJ,2&N5<E4%["/\(;),N,$"
M;DE)CB(E:51"RAU>D=.$/*??K#;PJX%ZMH(>F$)N7N5Z":3V9BM1$>%[K6[T
M,8RI.R&W831@YVT8:*@1JSKGSG^\Q*J76%PO*P +8]R2R/42EA+":/6WA4P,
M)O]Y?AZ$P>2(I[RD !5:T63$XCJJ>JI5:VE2]J6&UE *L?9YLR%-+F%&@S:I
MX"^HXF.:ZHVBL>"=HYS7RF&S#3O!WI"IDJJGA>EX3 !((3#794$J-6!(R0I.
M=446=4$B:3%MY$J".#O\-=DVG@:+-ME<T(W8/HQF0=QE*-9%=?0Z[%' _:)"
M@/#A<,X&FGH6KO%P*8 O(1UBK,Y3X@UR3H7;Y!X/2B.($@!K)BE%X0W5:-5*
M:T (_0[H *?Q0M=NSI9TPD4PW;KATQXF[N9-#/!2748KF0?L?3].+WIQZACZ
M.W(RH?8N8%@BN^M<#02$?:8.I[M,'0XG\>P@4X?#V3S>3NZX6JHLKX5*_#I(
MN!54<VR6H)K)!"BT59W*EK=D*:C*@4-4*E->[7((1)!U2FP@FB=?:@G^:<EC
M9X[R>=4W'1BX!)6"T5B;Q/N9:SVL6M^X +:\M>4\KK8C +4-FES4D"6*+DJ$
M7]OJA-+9B@3Y4/6XW&=.Q^:<68D:EL$14*LO=8U./"$4!4W5)K%ON/DLW.R_
M"SA8IUVLZ!:[%33Q;G&?[")FL@@F!^ RC8)9=WN_L&]7V:EI5E1UZ4N=6G-
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M??$!&*D5Z( &;5,%CSZZW7'_Q_K@SF,K-<L52[M&.P?P*M+:N5JZDF6Q-CA
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MXW ^#4 /W7R86-7Y#EHH2_W8#QMZ *%V K1?*TJRX\09&)]4FW\!4$L#!!0
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MR](J!MHGOMF;I-)D4;*FTW I$GT+E5F7S'7=:G%0]VMNV$((!7X1]KEEV2F
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M&6D!WB\UZCA_0P>TWV4]_0]02P,$%     @ *#]T6$&'L2/B!   (@T  !D
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M,4Q9 WR^D](, QM@_"S:_ -02P,$%     @ *#]T6"_QTG O&@  RU(  !D
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M10Q;[T$2@?_2Y$DI"? 6IZRM)*LB5+(MXTW$R#,Y.X-IV7*">W+&4,LHX#,
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M!!PKUDGWJ/L/..JY\'BEEC8\H1]\LSR"LK-.-V,P,6B$&O[9\YB'HX!E^HN
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M!#6+Q(I"T_CR(@(S3/!AX70;IN96.YK!X;6FCQX:[T#[E=;N9>$/F#ZCF_\
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MB1.,,$0#+@,A2 *)EG%87COV)UZ60'"P9_L^1=1SER9IYL/\-^R5(FJ=A4Z
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MFZ(!^+Z1\'5X( /3S?[YOP!02P,$%     @ *#]T6/@U*RDB'@  ('<  !D
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MBW6'?2I(CJ=FK"W$=N6PE0XQE9*R)@QF?1C8FP8"W/Y)Y(G0"0#\![X3A_[
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M,2+0D7NT&2K^6.4'Z?==Q[!KKJN<PF<IZC=VQ[7\IX9&;RQU2 @G]YCRC!>
M@1&5%AP=_(IA@SR'@ H6F""#FFT?@U!&B*>I<5)0BIYY94.OY<9Y""0H&SME
MMIC0GK8&3Y_4FGX(LU&*;XT-9+'^K,>F1J^K#N01N&5 7X.GJ8H#^S;)\(![
MA8/&#0N9V6$8\"+T@PO]X;@"%VHQ&-?.*"F"MO/XH%8(*4/.N?04.V6<J^T\
M*<5WX]DLG@S^=S7VRK"KF^D,AU(#-#@C$90.C=-*C)-Y/.I$L+<$JQQN.9W
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MF[)PX^-J5"[H-75E8H/;-5?NWJ-<QXI(XK99*7(#O>#G/$N" HX% _&_-%J
MU\ $S)PF4N96,S5PS6-DRP 7P:V%6*P-@QL-(]P&5QKO7F?Q-<8 $? 'DR5_
M96'&Q1I430Y.55ZPU*[@%8FF-9'.(8TP@%<-]!>5;&*P03R4,O(QKN<Z*5.=
M,]O\(-T#)[9<-"EO?_SA9#B8G=INH?6",TMOP6YT<@79>-L),=^T)MCY<B5
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M0 &'T"K]&ZLKC>"B\A1SEF'!I('Q:I)DKHDQ"^M,29&+0%]#WW23E6E2DBN
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M%,J3L71MG ,MB!^:#;JY*H5=29ZUKW[^1%Y<EYC]7@='@V^XQ#LZ34=@/IZ
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MKV9^+1M[#EA>:@H7OFD>UR:''4IKYTW9; :"4NGX*YX;/ZQL.!KLV) T&Y*
M.RH**#\(+\Y.K)F3Y=60QG^"J6$WP"G-0;GW%D\5]OFSK[(07F9T)ZQ_H0_*
MI85QM97NI.\AGA?UTT;41125[! U3.C&:)\[^DUG,EL7T >N%ERR '>1O"KQ
M@TQ[-!IV*1DDHU?DC5IC1T'>Z(>,_<?YQ'F+M/CG-ENCI/%V25PJ[UTE4GG:
M02TX:9]DY^S77X:'@^-7<(Y;G./7I/]W0?E)490,>T.^+;4GH3/Z5GB%+)=T
MB2!:4T#2K-EV_G!]>T^?K[IT;8J_'I4%->@N74F4A7XAY<CGDIPI\)5#8FZ*
M3%HR4^RD3V4UI:MR<MVEFUJK-%]N9+43J>54I4H49.8Z[C(U?FRF-&@B2G2]
M%@0]*;$FEW+A4(@T12@-I1$]F2?(NE#FRX-,\U"X&8$%E'<@( 1>:,\Z6[RP
MMDOS'/BHXJ10J2B*%Y):3 IX2WF"</DL;:J<#/:6XE_&*K@'B)^,9W=9Y@#'
M*ROA'$@+/JF9?1P)'\PZU[J&VBM8;?%[@[H-F@T>7=WT."H)/5BAG4CCQKGR
M.7V6+W0C-&BRY'C=2>N,UK*@3QKW7T*!=%D' ]NI _I7XL/X1%49I3E!OA66
M;?\#,0'S:ZDX@AR@&]P6T'1C/!X@;J!21Z4L)RP"MK/*^[I"#2AG$+ +(VS6
M8V0BRQ0;T:4O"D0EZ*(0Z>/<F(SFD+%4#H<QN"U2[CFQZC25$I1"E[E5H,0J
MI^L:ZCE@A@HY]=M!D)AZ6 $STYS#PXN@M$!L$53<]\I&A\*Q5*A2^=YN5U^:
M$JW0B=!-;@'W$2O+Y<JJ7<D).9%2<WM /6;LL) QZTY;T=+ A;MW>//S+EWI
M*BI4(E_#29SM4<L4I6SF,/\]_5T*:)?,SK2G-/H)JIQS[-=?CD:'X^/]D$?\
ME?#7<!/A46]$PX/> (][8_JHGB%I#<&H]XZ2\$D0.V/]&T2@)*53"$'_957)
M<'A,4V6=QWU48E$$#8/>6WP.P^?5K4ZBR+.UO7O#?1H"%LO@"KJ%Y9:>A%4A
MTFL0]Y)]K#O"9QA%)L?0A[)X$UFB$B\LT[&+TJ)'A=&S[Z#LT]Z(%;ZC8=!X
M"&=L9E\TYH#850\&6-=Q5$*%S-^91D<L_P "$H;+)CYP/(5BRXI:+B*\Q1^+
M)]O<N 8B,EZ;L&D!WE)3%7-64"I<_L9)[PO<<9M.(F'!50WR>>!AUA:2OJJM
MJT&S;".#L7)6%R*2&O!]^OCUGI(0@61PO!J NR8 O? , 7_(N<6$2,*B>2RF
MRIHW%B-/A,42EYZ3SVPA:!M3:Z/;53(,@$@\+73H-R\H!SP5; 4O2<U,J[^X
M<KAW!+*8(XXA1]X>.WJ2+K \]"C#G6NFM.8;PBU#@11(@X]A0AK]DG%7W0O?
M<S1.%"!\Q/L,<Y.67)SM3C&S,FQS^U0C8# &[(7'E; L8>'@&+X@E&DC6E!*
MP<T]:W;&P+48>B'U/R&IZTQR=(V6;]#T 5O-HB&0!%;D1(%P#OXRT(PKBP:T
MH%=-;H&W2[EQW4O!'0I"0:U<-#M2>%O]_4_YY$WZ^/_/)^01QGTV?6I-26Y%
MRUI9_<>\Z]&'VBY<^++"RYAY0Y=HY][PG71#;)B4NS$S2U.SCU2,9K:$B+X-
M=5D$N"7&$Z-K1S.4;=-Y?\<^'NR<ETHWN<P.:MIS"&GC\HU^@ VQQX!AL&W<
M3<:'5.60S=YI)K>-78L^B)3&G*6J,*%"%,\ O]W?WG$L +"D/2<E?3'(\>'A
M/O70=5MJ.^@.#Y+N>#@@4P67-[/7BF$L;D-WK;.FN(.F9# \:M6-N^_@W\/1
M0B924"(5%E-?1MEZS':$+.F%+$<YXE#,ZY/1H/OVZ'NDW\F>O*P6"[MC,=AA
M]@U!V9(:VM"TMJ'9+2 KY^I7[%_X/N1X[7D0YMDW3)XC6C\NK,VA;)(/72SF
M7@C$QJ#:3NF&O>,Q_DFWF,F+:*6*G4*X9C19LG0D5D[J#",:</S$R')7XW0B
MN!!X+,< 8#C;#8OE"FK8RL7RV(&P-6( E\3/NW7!R!B ]?$(8X+_T3BE_T&Y
MB['C,$%W7US$$8'5X?91T'FKET%G#HA,,)>QA82B09P%4V/ MD+"D7VY$)%6
MD:'C(6R51F/WASR1_EDK%AA)"SC0Z[BWM(:>\S1KZ0I'AYG%\$TX[B_F5?FL
M8F<LQ,2 0WD$"HZ93EGOI%;A?-6056PTF'G,4Z#@A>.0!*+),+C-\0$DDBG\
MW40[^*M)@5ADK>48>J&*$RO,53]<J9LNXBD:YPH^_?&)M(G<ZCDVS QJ5W0C
ML)7:PNFS /7'S/FIDH$99>2+E:I93AU;ZF9[K6PPR*9'5I-_O)&;[9UM;SGZ
M*Z^A2FEGX64;FP*VB&^DVKOM^[SS^!IKN3R^# 0)8KARX6QWVL&,?=")M+FX
MP"$PO-2:&(]6$_[F4B!E> &>3PVZ1G/!"MJWG&?_!E!+ P04    "  H/W18
MD \#<=@#  !M"   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RE5DUS
MVS80_2L[;-I<;%&B9,?C2IJ1[23M(8G''\VATP,$KD2,08 %0,GNK^\#*,J:
MU/%TVHN(C]VW;W>QNYINK7OP%7.@QUH;/\NJ$)KS//>RXEKX@6W8X&9E72T"
MMFZ=^\:Q*)-2K?-B.#S-:Z%,-I^FLVLWG]HV:&7XVI%OZUJXIPO6=CO+1EE_
M<*/658@'^7S:B#7?<KAOKAUV^1ZE5#4;KZPAQZM9MAB=7TRB?!+X3?'6'ZPI
M>K*T]B%N?BUGV3 28LTR1 2!SX8O6>L(!!I_[C"SO<FH>+CNT3\DW^'+4GB^
MM/JK*D,UR\XR*GDE6AUN[/87WOES$O&DU3[]TK:3G<"B;'VP]4X9^UJ9[BL>
M=W$X4#@;?D>AV"D4B7=G*+&\$D',I\YNR45IH,5%<C5I@YPR,2FWP>%602_,
MWV_8!$^+56!'H6*ZX<:ZH,R:KMDI6T[S #-1.)<[R(L.LO@.Y*B@3]:$RM-[
M4_(W #GX[4D6/<F+XE7$*Y8#&H^.J!@6XU?PQGNGQPEO_&^<_M9A^GVQ],'A
MN?SQDN\=\N1EY%A"Y[X1DF<9:L2SVW V_^F'T>GPYU=X3_:\)Z^A_[=D_4](
M^F+H R]=BY*ELY2"R1%MF80I:=$&JUM/=Q4[T7 ;E/34:'E$UO671R1(PJR2
M0A_[@$JGI;)-)5!3,JD(3=+6C3!/J*<-^D03S1M^#,=K-D!.]=LXNW:BKKFD
M.Y(HXT@75A5'$\;8UDC<"8K)"[Q6$JA:BZ7= 0@5=44@46Z$D='&TH9J9QLP
M;TE$RG9MX=+EXN;XKC?J*=BM<*6/PC4[J816?R78 7UEJL2&"8%D!PO*! L:
M6DGTKBY.MND8K!TS.EI(AV#*LG4JP#0UK9.5B.)[F1;5XVA;*5G%>/<2);U!
MQQT,T0VTCJAVU8?Z+2U #@$U=(4T>A7H%G$&O()Q.*,VB P2A, G$U+;"&@/
M4CP:=SE&Q_7H;#%*21F9>^"X['-N7:E,U/"="= 8%8.3'P=TGXC'QX2 U.DF
M;EX+2'I1M2AQ2V].#KUKFY5#-Z%&/"7*8,"/"(3!.\),2L@NMEZD")PEH\F3
MLT]"I[@"P6"T>:$[BOM(:4PP$M[CTB[Y& _J",D]_D=^=U1],O8<Y_N[+Z.\
M*+HJP.;T\\?GQR(\W,$#Q5<DNM")M XC\'S:&P!_R2Y@D")NLC+Q)287M@8Y
M6C[UU@<O=9+\8 3 @74:=/&YMB9TTV!_NI^EBVZ$/(MW@_B3<&L%/II74!T.
MWIUD783[3;!-&BBH'HRGM*P03791 /<K:T._B0;V_S#F?P-02P,$%     @
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M[V\#B,AY=^_Q21@VJ1@%-A"&6)R8@>9@=P^ XB3.P7^IDOC[;BA0\ZV8X0R
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MNS-XC/"#*NK;+UK0NHA+-=RWEX @HXX ^_$+[%*!>F#/C;D'"* BHI%#G"/
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MSDR9\;/[HIQA,)#:GI2.N]:-32N_1J.**[,^5I&&4KB;5ECRL%@@=:BRQZ0
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M_LQTR6F:!!9D2FT^"4!W;U^WL:KQ[\U:67J]_+*BSP743H'."Z7L;N,<[#]
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M^RQ^'7100UP'(_ ;^"%,/"B+<% 4)C26]*/ KZ,P <>87XE7)@3E5IHK@VR
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MXW'\M#N%WIMW9_D/3->H!/S,5>@:^!EV=MV=C[L;JS;MF?1&63SAMM,U_J4
M[0QPO5+*#C?N!>.?E-4?4$L#!!0    ( "@_=%A6O'5/ P@  )\6   9
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M%C=9FH49)/$-6[!P M]]I9-6_HB:&A?(KMF3,L(;J;Q*HNBLL12\2]\S@<L
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M+W-H965T,S@N>&ULS5=;;]LV%/XKA H$"=!)HFZ6&]N 8W==!A0+DG1[&/9
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MU%"[ #HOE+([PUW0/Y/I'U!+ P04    "  H/W18T#,Z3J8"  "T!0  &0
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MQCUWDI#62MTR7T,D)]86DKYNK&LDYF$CD[&T:LJ@-53 YP^W<Y&&"*3#B]T
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M+$4WVPQB2V1UF)X$G>QS7(+1Q^ 1Y-="EJC52.&G? ^FE5@3BF/'_=MRW1.
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MT,"QL*')R;G=KU1[?= VC*S]D7TIC9&5?UPAS5&Y#^S[0DKSV' #])<XL_\
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M4*'I>0#.$Q!(5(&!1(6O<VP<P%D"G+/\\_:>W8I%+2?"[$P5'._@7;31LPF
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MQ=63NEAT=RA\*.JZF'</9X)/1-D:-.\_%D7]\J1=8'.7R\O_ 5!+ P04
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MG9MP0]09BC=V#BVYTE/-+BO]WP%A'/1YR;G:&"; \"?+_@)02P,$%     @
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MO:ZO@.G9BE-1S1G0OMHJY8A[9:RM84R"L4-$0U3L9>+R@NJD2/K*'MC,[Z@
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M\_PAW7$=4(N&Z\:-Z\;?R*NU>K9&\3<>$5:08YT""<: P SG31KG34Y@6IM
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M9HC',YBK>R$;G,/<T7=3@MB!DYV>!!/_<JS\_T1V8$;4FQ$=8\^^"UP PJQ
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MPD[5YCO6>LX=7Z:$\5_8U+;M +*5L:JLP11!R67U9\]U'G8 4?<=0%P#XM>
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M_\@B0:Y"ND\YN&!D1YC<S3+IL:]:+M5[="2SNP7 V#6\=F8/6@ ,A=;D3A4
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M,7HL3K18Y;.U9Z&U2//#)5*C\3,#LQ\+DW9YDEV@&@#/_@=02P,$%     @
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M7#41SO'P+KQ8A D3:TX!FP%)ERO&U1 %43R;44[3D)Z!=;H6- )2-:,J*J@
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M#9Y?X;.D.2([NFE.[#ZKF917 A6P42Y59:LZX<TA6',CV;X^%EHS*5E97^Z
M9L U0+W?,":?;_0?=$>1J_\ 4$L#!!0    ( "@_=%CR\A>Y7 T  /YU   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;,U=76_;.!;]*X('*#K V!9)
M?;9)@&DZLUN@W2G:SNS#8A\4FTFT8TL>24F:Q?[XI6S%)$7JBI(IP'V8<9*K
MJTM*Y#DBCX\NGO+BS_*>TLKYOMUDY>7LOJIV;Y;+<G5/MTFYR'<T8W^YS8MM
M4K$?B[MEN2MHLMX?M-TLL>L&RVV29K.KB_WO/A=7%_E#M4DS^KEPRH?M-BF>
MW]%-_G0Y0[.77WQ)[^ZK^A?+JXM=<D>_TNKWW>>"_;0\9EFG6YJ5:9XY!;V]
MG/V,WEPC$M9'[$/^2.E3*7QVZK;<Y/F?]0\?UI<SMRZ);NBJJG,D['^/])IN
M-G4J5LA?3=;9\:3U@>+GE^R_[EO/6G.3E/0ZW_PS75?WE[-HYJSI;?*PJ;[D
M3W^G38O\.M\JWY3[_SI/3:P[<U8/995OFX-9!=LT._P_^=[TA'  "CH.P,T!
MN'V UW$ :0X@^X8>*MLWZWU2)5<71?[D%'4TRU9_V/?-_FC6FC2KK^/7JF!_
M3=EQU=6';)5OJ?,M^>[,G:^'B^GDM\Y[>DN+@J[KO]#2>?V>5DFZ*7]D4;_\
M_L5Y_>J'B 3>VQ^=YH.39LZG=+-AEZ:\6%:LLCK_<M54\>Y0!>ZH F'G4YY5
M]Z7S2[:F:SG!DC7IV"[\TJYW&,SXGJX6#D$_.=C%1%/0M?GA&"B''+N9[/.1
MKGQIN=KDY4-!Z\ZMZ':7%W5/K]-;UL\T6]&?G(?LH60=7K%+P4)+UNM)MA9_
MNV+7(ZU*YU]U=B=E6<I_Z_KZ4(JG+Z6>&-Z4NV1%+V=LY)>T>*2SJU<_H,!]
MJ^LG2\FD7O..O>9!V:_>T;LTR]+LCHW43<(ZJ1Z@A]NR[H^$=1+KCHQ6NEXX
MI [WJ>O9[/$*8[+P+I:/8O/4J'D0+,)CE%2W?ZS;!^O^0E?Y79;^E]7)AL7G
M5\EV]_:CKL9#FD@\.\+"V0\UJE'(C1>QOL;@6&,PH,;?KC_HZCND\(4SNZW:
M J4V=T'TE87'RD+3RM9IP:;[S7-=(OWK(:V>=56&FEX,X@5JE0J>=>2='!W;
M%-EM$YANZ!B.U!LH[+R!XF.38K!);*8>.3)CI1P/+8+6U5*#Y.$KU8Q<#G<N
M6/7?"C:U.JND*)[KZI-M_I!IBX3S#+T"MK+)K19 'IT/_#2UV.HY2]GDGL.\
MY_!T$-3D%F]B$KC*Q*0)0U[7+(HXY4 @-INC4)-'FD##<!&URU3#4. + U>N
MDX,\@E'>"(F:'! 4-2%&6(0XE"-C+#>;N9$.U%T5U>'SCKVQ.?PC8_PW;!>8
M;_"P5HD#@$F(<P<$DX?QJ(14&E%7U,8E39@\IN7".4% ,$/X(]D\)(<GV_5_
MV',?>U;6EVF5&=C*)C>:4P@4GQ$N@7QF<,]9RB8_W7(>@V$><Q(N-;GE*8H$
MRA35Q(F3[CSJN-,Q)R,8A&QS7&KRB&4RO'%C\5^[8O60N>]W/<]A3@,P3 .,
M,*K) 6$4&"+7QG$>&^.\V4R.-7C/'GH]5_C7YBAP#6-O=\X1L#%',&PCF&_H
M8,<0^Y";Q(D%AHG%>*1J$OOR\&W3-:SC(:1S;0-SYH!AYO!K^IV5V93X/\?X
MB0I.._B26,HF=P+G&3@\'^3"EI8NFIZ;8B$$<Z*#8:)S&G)IEC)\Y4E%$S4/
M%G['C<_9"H97/,R!2[-XX2YPNTK=$D?7 POAS(# S, (JHB*[&VH D/DVCCT
M$V/H-YO&B0;//4]9Q85/._*6)IP=$&-V8-@L,-_@)7IC4D&$_0J85(Q')Z)A
M%Y%ZQ32+">) ELOF/('T\(1ZUVZ>W\[9'#L"HN#L@Z^+I6QR7W""0?SS@2AB
M:36CZ;DIUD8(9S@$9C@G01115S;J1Y V1NG"O+ +I @G)L1X]P0&*:+9-G'5
M,C51T8*X^F<%N69."8CQ[@@ 65$_9$$A<FT<](DQZ!O.[7%_G5.L'7B<(7C&
M#,&L27"^H8/;,R86'B<6'DPLQL.5IULQ")1E/VU8)V!YG#IX,'7XD#W2K,J+
ME X"*CCKX"MB*9O<!YQK>&<DCO"LJB-L99-[3M!'3"F04/=+D!<MVDMJNK#.
M^YZ3$\^21,+3+&,07WA,:JK4B"08G'9 D\>I@&=!)N'UZR3 $+DV#O6>9:%$
MDP^L<XK% 8\S <^R3@+.-W@X&Q,(CQ,(;RJ=A*<N$"!$5&C2A$GC6-8P<9K@
MPS3A6Y&LZ7Z:S:M[6CCL<M#T,;G9#(,J^"Q#KY"M;'*?<)[AGY&0PK<JI+"5
M3>XY3G3\"844OJJ0F*- HY33Q,7^PM=O&<DMX73%MZ2K\-4UCE!3LVXW)NS:
MYI)KYD3!MZ"Q\/LU%F"(7)L@EK2LL/#5_0^ESBD6$'S.&GS+X@HXW^"A;DPV
M?$XV_*F$%;[*.N:Q<L&T(D[<J<3EC,*'&<5'FI34V:3)3;I)JX&/67#NP9=E
M"K&%SXF(?T9B"]^JV,)6-EDIS9E0,*'8(E#%%KZO; 9IHAB'Z[C[ \Y7 DM:
MBR:/.$B5$C5RC*[URH#S@L""LB+H5U: (7)M'.D#R\J*)A]8YQ0K!@$G H%E
M(06<;^A #HSY0\#Y0S"5D")0%PW\4!V:FBAQ ,ME"]^_@#G"=9Y51;*JQF(3
MG'[PA9E"3A%P=A&<D9PBL"JGL)5-[CG.;X()Y12!NMXQ1\J,I=%<N%VR[X#3
MD<"2FB)0-U3FI+W^%ZB+('/<667(H3^TH*8(^]448(A<&P?WT+*:(E1!7JES
MBE6"D+.!T+*2 LXW="R'QB0BY"0BG$I)$:IL8NZU;WQ=$.HJFM.$$*8)'_,D
M.\RO-WG!CF8M& 1.</K!EV4*(47("49X1D**T*J0PE8VN><XQPDG%%*$JD(B
M5!:_-4&8=&W[A,)74"VI*$+-N@565!2Z*.1W/3R%'/Q#"\*)L%\X 8;(M7%\
M#RT+)\)^X01\RK'?X>5D(+(LG(#S#?X:KS&'B#B'B*823D3J<H"GW/B:H+"+
ME$6<)40P2_@'K1PV"V_R9[HOF?V9 17-V*?1CU/P*0=?JBD4%1'G'-$9*2HB
MJXH*6]GDGN/$)YI041&I4@E7V>_1!G5L\$2<HT26]!211D^A?B59']6!5Q'G
M Y$%-474KZ:(!MA.1!ST(\MZBJA?3P&?<NSM+-A.V/:=L&L\8<PK(LXKHJGT
M%)&Z1N JA%(;U+$.'W/F$,/,X>M]4M!Y[3>U=G;)<_WEWD'H!*<?>EEL99,[
M@W..^(Q$%+%5$86M;'+/<>(33RBBB#4V$Y'ZS8S8> TDYGPDMB29B-75#-1>
MCX]5P434!4TQ!_[8@D(B[E=(@"%R;1S<8\L*B5@#WWZDB"8U89 Q$(?Y&(;Y
M$ZR!-+80'E;HB2Y,NI7EPCD#B&$&\-M>Z+8K\L>T-BH<-D5;W56PE4WN",X;
MXNB,IFBKG,-6-KGG!%<LF)Z<-D6K2R!(N?=5@A)TVMRXHC'6D)T.R"[(U=E'
M*-NFNC"OBTDA5_"R<H=H&KK\@MS^O0XXIE4?%NJSO(?QDA"N=8H5!>0*;E*N
M93%$3\+A%FJ0N*+5+,%\RH5Q_P3#(%=]DH\74<=7XUX:H=(#U.4=Y HF52[,
M$ [ ]3K-5IL%;P/]OJ,9FYA_'()C/:<:?MDF\;ER!:,K-S@?+'LIQEKO3:'+
M0*[@I^7"E.@T SQ7W?@(D$#67UJI\=[J-)9S!4\M=\C^"(AI&LL(UOG*TY$N
MT._V+7,%*RQWB!ZB$];Z-TG@F):#I, />IPSA\__J%\6T7/2T<:8HC.F91%%
M3\+A_I;F)$2TK>SQK3P!UC1VE+7G1OM[@;HX:6RW:A>81H]QY3<^"R_%R5=?
MK5V282M=J_$"'VEL*L\#K6!KSN&]-X50 XEFG3UNG:?<]NIBB+J1WW/^T2T4
MV$R/;V?7X!A$\2Q[>=I*U^H4@:2@,Y*/(MB"='CO3;'4@T3GT1[KT=,H'E()
M41RK%$\3%KJ+V,!'!(E^HK#MY@#"AS2"45^U9M:$X:B3F@K^G:C'P-.,[FD<
M.!4*!<:TZA-XD;E+IR$OP@8K+O!)1[MY"[S(W,C3M%E6A2'(W $4"1:@J,<#
M] 3<T[B!QAYL!JH])NZD?H+-)^KQ^?QVSZ9K-H5K&J OWBY_L96NU7Z!O^ S
MDIHBV*%T>.]-PHT$8U+4XTQZHEF_1DJ*-0;@DSB/(L%Z%,$.G0- #JOK*ECU
M^.HYW^@6"0RDQQ/4$ S[A:P])QK=%(&!F)N$F@*,AHGHWE_3<^:Q;1.<15&/
MM>@)*$/4S: (*1O2NC!Y#+9J%_A,C_6H%EE>M*+Z"V/+5?2E;9-P'\&E%#5&
MH.<!+G8]3JVE:_6>^#85F&*=!BXZ5]1 W3.%:QC=2H& ]1FHFK\T1MW]FA.B
M/OA-XH**!!M4!+N%&H(+Z3<5Z3G1Z*8(!*?'F'0XN)!^,6W/24<W2R T/9ZE
MI^#*(;/T C\2JR_;T<4%RI>XE\*+-+>TN-N_7[1T5O5"VN'=D\??'E]B^O/^
MS9VMW[^K7VZZ?T$G3W-X,^JGI&#S2.ELZ"U+Z2[J;V@5AW>-'GZH\MW^=9TW
M>57EV_W'>YJL:5$'L+_?YGGU\D-]@N,K7Z_^#U!+ P04    "  H/W18=.JG
M@_8"  #L"   &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6RM5EMOVC 8
M_2M6*E6MM.5.PEJ(!*35*JU25=KM8=J#23X@:A)GMKGLW\^7D 4(K _E@?CR
MG>-S/CO^,M@0^L:6 !QMB[QD0V/)>75C62Q90H&922HHQ<R<T )ST:4+BU44
M<*I 16ZYMAU8!<Y*(QJHL2<:#<B*YUD)3Q2Q55%@^F<,.=D,#<?8#3QGBR67
M U8TJ/ "IL!?JR<J>E;#DF8%E"PC):(P'QHCYR8.9;P*^)[!AK7:2#J9$?(F
M.P_IT+"E(,@AX9(!B\<:)I#GDDC(^%US&LV2$MAN[]COE7?A98893$C^(TOY
M<FCT#93"'*]R_DPV7Z'VTY-\"<F9^D>;.M8V4+)BG!0U6"@HLE(_\;;.0PO@
M!"< ;@UP#P'^"8!7 [SW OP:X*O,:"LJ#S'F.!I0LD%41@LVV5#)5&AA/ROE
MMD\Y%;.9P/'HH4Q( >@%;]%G--5[C\@<C9)D5:QRS"%5D]\(8\#050P<9SF[
M%M%WK\_HZO*B[P7^[36J&R@KT6.6YV)/V<#B0J%<QTIJ-6.MQCVAQG'1(RGY
MDJ&[,H5TG\ 2UAI_[L[?V#W+&$-B(L_YA%S;]3H$3=X/=SO@\?OASADW7K-;
MGN+S_KM;8B]^CF:,4_'B_.I*M";RNXGD97+#*IS T!"W!0.Z!B.ZO' "^[8K
M21])%G\0V5X"_2:!_CGV:$)H1:@XU8CC;5?:-#Q4<'EEKB,WL,UP8*W;^3B.
M\GJNZ>U'Q3HJ:'.%;A.SI[_7Z.^=U?]"<7I2NX;V6^LYOFTZ!]J/HUS;/XR*
M.[A"VPRZU0>-^N"L^GM(@>)<ZD<)A33CG7=$<*S0.4SN1 ?U6D'^@85C&MOL
M=QL(&P/A60-37A^=<_+#H\/1-X,O>[\#+\<(IY5J[>8XQF[E1+NQ6G6@ +I0
M]92AA*Q*KJ_,9K0IV2-5J0[&QZ*4Z\K[CT9_!SQBNLA*AG*8"TKQ9H@=H+JV
MZ@XGE:HV,\)%[5+-I?@< 2H#Q/R<$+[KR 6:#YSH+U!+ P04    "  H/W18
M0A_.*0 $  !Q#0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6RU5UV/
MFS@4_2L6E:H9:9;O$#)-(C7#K-J'D:*)IGVH]L$!$[P%3&V3M/]^KPVAA##9
M62G[DF#[W(//\?6UF1\8_RXR0B3Z6>2E6!B9E-6]98DX(P46)JM("2,IXP66
MT.0[2U2<X$0'%;GEVG9@%9B6QG*N^]9\.6>US&E)UAR)NB@P_[4B.3LL#,<X
M=CS37295A[6<5WA'-D2^5&L.+:MC26A!2D%9B3A)%\9'YSYR;!6@$5\H.8C>
M,U)2MHQ]5XW/R<*PU8Q(3F*I*##\[<D#R7/%!//XT9(:W3M58/_YR/ZG%@]B
MMEB0!Y9_I8G,%D9HH(2DN,[E,SM\(JV@B>*+62[T+SJT6-M <2TD*]I@F$%!
MR^8?_VR-Z 4XP2L!;AO@#@/\5P*\-L![:X#?!OC:F4:*]B'"$B_GG!T05VA@
M4P_:3!T-\FFIUGTC.8Q2B)/+1\Q+6NX$J@A'FPQS@OY FR8)$$O1YS)F!4&X
M3-I1]1;T(DB":(ED1M *"QIK0$+S6L+ XWJ#'G >USE6:RO0340DIKFX!>['
MEV=T\_Y=Z 7^AUO4/B +"<4N%.E+2:6XZX:@YXGFN2*ZZZ&.?7-+@@U*C!6W
MDE>-9/<5R8Z+GE@I,X$>RX0DIP06^->9Z!Y-7+D7&2,2F\AS[I!KN][(A![>
M'NZ.A$=O#W<NJ/&ZE/ TG_>6E-"&HV]X*R2'/?K7F-T-G3].IPK7O:AP3!8&
M5"9!^)X8R_?OG,#^,&;5-<FB*Y&=V.AW-OJ7V)=KSE(J$9:2TVTM\38G2#+$
M>$)+M;G(CYK*7RAC>4*X4'M-[:8*["XE@H*NRAEL+-*NQICQS02F>@*JP.^7
M,\\V(0/W?4='4+[GF_XI+#J'.;8[<\U)ASNQ8=+9,+EHPU==>:$JX#WA<)*@
MLBZVD%B@M[.BW=5P+ D)A03D]@Q0U>0&-GP#NAWSH9E!V)NZZ]MF,/!A#.4-
MW8H:U.0$Y8];$'06!!<M>$Q3..7T$NL2J<Z[E+.BW5RL:JOD99'!^?1-9R#Q
M'!/TUJ\1>(YQ)N9T7.&T4SC]/Q89)W_#"0=A:K55]A/MU(E1_^+*=&11W9Z<
MQI<QU,P,!\Z,H":SUZP).VO"_UA-QV2$URRAUR2+KD1VXMVL\VYV,:V:JT75
M%-)CCH"/E"6]PTEE"*DYZUD\FBK-NV:]Y?7,<)@I(Z#0G XSY1P%2>>$XYGB
MV+_O8O9%O5%[@;J6XO9U \G#\V$,-36G V>B,=C,#+R!:*MW%RT(W^D[O4 Q
MJTO9W*BZWNZ[X:.^+0_Z5^I[0M]Q?],T'R-/F.\H%,R<I$!IFU.HUKRYWS<-
MR2I]X]TR"?=G_9C!-Q'A"@#C*6/RV% OZ+ZREO\ 4$L#!!0    ( "@_=%CN
M?JA;Y ,  +$0   9    >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;,U848^;
M.!#^*Q:5JE:Z!0R!D&T2:;/;:_NPNM56O7LXW8,#D\0JV*EM-EWI?OS90( $
M0G>[.:DO&]O,?'S?>#R,=[KCXJO< "CT/4N9G%D;I;:7CB/C#61$VGP+3#]9
M<9$1I:=B[<BM )(43EGJ>*X;.AFAS)I/B[4[,9_R7*64P9U ,L\R(AX7D/+=
MS,+6?N&>KC?*+#CSZ9:LX3.H+]L[H6=.C9+0#)BDG"$!JYEUA2^O\=@X%!9_
M4MC)UA@9*4O.OYK)IV1FN881I! K T'TSP-<0YH:),WC6P5JU>\TCNWQ'OWW
M0KP6LR02KGGZ%TW49F9%%DI@1?)4W?/=1Z@$!08OYJDL_J)=9>M:*,ZEXEGE
MK!EDE)6_Y'L5B)8##D\X>)6#=^PP.N'@5PY^(;1D5LBZ(8K,IX+OD##6&LT,
MBM@4WEH-968;/RNAGU+MI^9_J T(](DIPM9TF0*ZDA*41(0EZ /GR8ZF*;IH
MAF]N0!&:RK=Z\?V7>_3F]:O(#T?OWJ)J@"A#M]I2[Y&<.DI3-"]RXHK.HJ3C
MG:"#/73+F=I(])XED!P".%I;+=#;"UQX@X@W$-O(Q[\AS_7\'D+73W?W!NCX
M=;S] L\_A4=EG'*9"T!\I<]!S%E,4TJ*G-8K\49O!$@31=IL"FDV9;W?B;\-
M-*(*,OE/7Z!+'J-^'J8Z7,HMB6%FZ>,O03R -7_]"H?NN[X@G0GL(&2C.F2C
M(?3Y M:4,<K6^KRFA,70I[:$&!<0IG0]S'$0V<'4>6C+&'S13\H(:AG!H R=
MT#_04/I'+0V1.[+QD8;@!TH/R(4UN7"0W ?!I40Q$>+1D"09SYGJXS@(\]RL
M.A/8@>)QK7C\BQS$\3E#=B:P@Y!%=<BBEQ_$J)/$GA_8HZ,D[EKAR:1E=<!O
M4O.;#/*[SH4 %C^BA*Y68(;0^PF:=%Y^X=OA$<.N$;8G_?RPVWQLW4&&5_&W
MG$JZSS&9+R5-*!$4RIQ:YE)[Z!SK_W2Z74[1N!/;80X_F2.XU5#@%]:Y"B!H
MZ9AXQV6N,CJ=2(?TO(:>]_Q*A_ZM.YQ>PH.0SSW"YT([#$#3@.!?I0/!9VU!
MSH5V&+:F"<%GZ$(JC';2AMCVCE.[:Q6,[>A$9C?]!1YN,)Y:_G"WS[@(.O6O
MQ\H_>?J:-@,/]QDO+(!AEY,;MLIR1?W_Z"MPTUC@P8_P4PK@N-/#^:'7Z59[
MS ZRJ>3GM"Y_&8AU<2?6%<[4M?*:5*_6]^ZKXK9YM+XP]_'B4MG E)?Y6R)T
M\DN4PDI#NO98YX8H[\?E1/%M<<5<<J4OK,5P R0!80ST\Q7G:C\Q+ZC_2S'_
M#U!+ P04    "  H/W186T2$'N$#  #($@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6S%6&UOVS80_BN$"A0ML%JB9,MV:AMHDJYU@6)&TFP?AGV@
MI;--E!(]DHJS_?J1DJ*72-8<0T'R(2:E>X[//>3I#IP=N/@I=P */40LEG-K
MI]3^PK9EL(.(R '?0ZS?;+B(B-)3L;7E7@ )4U#$;-=Q?#LB-+86L_392BQF
M/%&,QK 22"911,0_E\#X86YAZ_'!#=WNE'E@+V9[LH5;4'?[E= SN_ 2T@AB
M27F,!&SFUB=\<>4Z!I!:_$[A("MC9$)9<_[33);AW'(,(V 0*.."Z)][N +&
MC"?-X^_<J56L:8#5\:/W7]/@=3!K(N&*LS]HJ'9S:V*A$#8D8>J&'[Y"'M#(
M^ LXD^E_=,AM'0L%B50\RL&:043C[)<\Y$)4 'AX!.#F /=4@)<#O#30C%D:
MUC519#$3_("$L=;>S"#5)D7K:&ALMO%6"?V6:IQ:_*9V(- R5B3>TC4#]$E*
M4!*1.$1?. \/E#'T =UFNXSXIGQZ P'?QO1?"-&[:U"$,OE>FWZ^NT'OWKZ9
M>/[PXWN4#Q"-T7<-TCLG9[;2Q,WR=I"3O,Q(ND=(7D,P0![^!;F.Z[7 KTZ'
MNW6XK>4J-',+S=S4GW?,'Y4!XS(18/0(T]"U"#3.LBH]G6N=,OI)(2O)9/W3
M^$)4023_:M,A6WC8OK!)Z0NY)P',+9VS$L0]6(NW;[#O?&Q3I2=G-8V\0B.O
MR_OB\92T!9DAQRG2?&;N%Y[O#D8S^[[*OFGEXX%;&-58#0M6PTY6R\:&'*C:
MZ7W2B4]CO2THD;!)&&)T VW4,_>3"JGA<-B@GEF-*E9..^]1P7O4R?L'5Z15
MRE%CI8DS?L)FU.!\7$B_(.1W$KKZ<H>6493$W'P_R)Y":UIW.GGN<>[)62W>
M<1'O^+52?MRG1CTYJVDT*32:G)WRD\89]$9NY1!F[)M6OC,8MY_4:<%J^K(I
M/STIY:>GICQVRLKLG)?T.:Y*:3SU!T_SOL7LN)RXTC#@3EJ?'Q2(F#"T$CQ,
M H5N"0-ITN+;ZD<KW4Y_SSWA?7FK1U^6?OQJM1_W6OS[\E;7J2S_^/SZGT.K
M!]-I)-3_&-5IE?4?OW #@+MJ>\[\Y/*/R_J/SVP <+.ZMVC9;53G5+8 N+L'
M*#X$EXG4KV3Z#5C&4I%K@'TKV5[[@;Z\U<,O.P+\:BT![K4GZ,M;7:>R*\#G
MMP6X6?&G@XE3_<-/S_+DY.PJ6P3\PCT"[BK_.>^3.P2W[!#<,SN$'#=^AJXY
MQ._@9U>N&<P=SW<BMC26B,%&8W1KH8,3V;5)-E%\G]X\K+E2/$J'.R A"&.@
MWV\X5X\3<YE17%XM_@-02P,$%     @ *#]T6&$'?V9)"   X58  !D   !X
M;"]W;W)K<VAE971S+W-H965T-SDN>&ULQ9Q=;Z-(&H7_2LDS&J6EC WX,YG$
M4B=\:WNGU3V9N5CM1<64;;8QQ4 YZ>ROW^(CQMBD&K1'2E]T#.9]JB#GI=ZJ
M0[AYYNFW;,N8(-]W49S=#K9")->C4;;:LAW-ACQAL?QFS=,=%7(SW8RR)&4T
M*()VT<C0M-EH1\-XL+PI]GU.ES=\+Z(P9I]3DNUW.YJ^W+&(/]\.],'KCB_A
M9BOR':/E34(W["L3#\GG5&Z-#I0@W+$X"WE,4K:^'7S4KWUCD0<41_P9LN?L
MZ#/)3^61\V_YAA?<#K2\1RQB*Y$CJ/SQQ.Y9%.4DV8^_*^C@T&8>>/SYE6X7
M)R]/YI%F[)Y'?X6!V-X.%@,2L#7=1^(+?W99=4+3G+?B45;\3YZK8[4!6>TS
MP7=5L.S!+HS+G_1[=2&. @SCC0"C"C"Z!HRK@''7@$D5,.D:,*T"IET#9E7
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M!"1I'?45$I#.Z9/I1,=GD!*4$J$"E&2-GI 2^G%A?R7"CN_H'VQ>0HE LK-
MIZ)$(*>]A2MO:MID;X$<*!'H&4J$:4RW$H$DJZ,>2@0Z2(DP6W451<GER(T2
M@0Y2(@Q6G4H$EJ2.^RD1^" E A^N1&#)Q;BO$H$/5"),=@<J$5A2-+93]-7B
M3N $F^A!U%GCE;:[.+92N/*F!BPY'Y^*NH"=J@NNO*EI:SU*X.)9 H.Z@+3?
MX>TS/3<2V:_@ON("UE4#WBCM]_P&*R58%9YL +!=6MB_(8^1"^RNCUYQ+T'I
M6%(Z/A6Y #N5"UQY4],F&POL0"[ !AW <*/J5N.NS@?+_@+WT JPWB[X06O.
M!IC!RN]2]0+9500O*14$>C>Q_V.X??[G/D8E6Y.@ATP0'"(3-$8'_)H?R XD
M<" 2!/K^_TQ7"4Q6G3)!(%N&P(U,T+BQK@";B0I/4G/05R$(3%M_C= ,5MV$
M%K2>WK/SK8'0^N_Y[7,>6[)=>5,S)"D_.)4]?^"T07#E34V;;! "!WO^QH?U
MGK29J-@D"P<]MO?-6"LFFXF*21)OX&9C'^A/_&GP;";J<[22?<-^>_KP:7ZU
MFJBP)&F&???SC8/0!LQF4@,;M=Y<2 FO>^*%#M[UBUZ_?FA_=W;WTLA5]:K$
MWOEK_WQ>O_HAW=1OHGSAY91F#"1DR5UZPS%/5%&_W%%_*/--]7[$;5Z6>5H=
MKDFT((4PX-\O\[Q\_" FV+UB,_L?4$L#!!0    ( "@_=%C<M\D<%0D  )U&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;,U<78_;MA+]*X(+%"V0
MV.*'2#G=-9!LTGLOT "+Y/;VH>B#UJ9WA<J2*\F[7>#^^%(?\8@B1:]7%.!]
M2&1[.#HSHF:.CBA=/67YG\6#$*7W]RY)B^O90UGNWRT6Q?I![*)BGNU%*G_9
M9ODN*N7'_'Y1[',1;>I!NV2!?9\M=E&<SE97]7>W^>HJ.Y1)G(K;W"L.NUV4
M/W\02?9T/4.S;U]\B>\?RNJ+Q>IJ']V+KZ+\=7^;RT^+HY=-O!-I$6>IEXOM
M]>P]>G<3XFI ;?&_6#P5G6VO"N4NR_ZL/OQG<SWS*T0B$>NR<A')_Q[%C4B2
MRI/$\5?K=';<9S6PN_W-^\]U\#*8NZ@0-UGR6[PI'ZYGX<S;B&UT2,HOV=._
M11M04/E;9TE1_^L]M;;^S%L?BC+;M8,E@EV<-O]'?[>)Z Q ;&  ;@?@_@ Z
M,("T T@=:(.L#NMC5$:KJSQ[\O+*6GJK-NK<U*-E-'%:'<:O92Y_C>6X<G6;
MRQF1E\]OO-LD2DLO2C?>I[\.\5X>JM)[ZWUM#J^7;3V[Z0\?11G%2?&C'/3I
MUR_>#]]_%Q)&?_K1:S>\./4^QTDB#UYQM2@E]@K!8MWB_-#@Q ,X$?8^9VGY
M4'B?THW8J X6,NACY/A;Y!^PU>-'L9Y[!+WQL(^) =#-RX=C"QQR/!"D]D>&
M_,7%.LF*0RZJ7&_J9(J-3%ISJM93_DZ>A][^>!CVQ\,@CH?A]\JO%Y=B5_QA
MRG(#@II!5#7C7;&/UN)Z)HM"(?)',5M]_QUB_D^F##ERIN2+'O-%;=X[$]>0
MAC?>G;B/TS1.[^5)+G]?"U,RFCWP>@]5O7M<,7\YET?SL1NE%<<KHPR.409C
MHA3IYD2(C?NP$R(/N!9B<"(1"G9VQ,ZLV/^;E5'BI5GZ=GW(\VIR1D4A2N/)
MWW@*.@ (Y<L>2J;%@H@,!IEA\B-,;H7YKSPK"F\=Y?ESE<MHEQW2TH31ZN;<
M4\>1,R7B\!AQ> FE)G29+T?.E'PMC_E:3EYJEOIYB(-YT)OANA59LCDW3W#D
M0X_WK0&\WVSB<K#O^MI.,5W.:0^:P8S@P1J!.OP#6;')R;C/BB@Q8T,ZMCGK
M(].-4,=(Q84!%[;B^B+6B:Q7\39>1\.YPUK=\OOH;"8J-J *R-I95S=U/5T_
M>YMXNQ75IC##(UIF OW ZD9OT>!QA?:,[/WY_5J>(44][:HJ4QSNBG@31WDL
MBOH$NCL4<H1L"&;DU'#@41_Y%)T906M&$_?FUG]W:BQ9O^DA0P=7*H>*'IHS
MLG?GF\/ND$35-93L #(_Z[BM_#**>+>/XKPN\NN'*+\?.$;6'9Q;X%UY4],!
M) #Q2^B)R"F)<.5-S1G0"&3MND[Z8KL+M?H@-B?]T\!@Q^E@F8+6CNR]W=Y^
M]'XL2R/O0S-8^9TRJUZ=0M/&]J;]TB*/]<8L=]]G%@8K?X@Y8VC>^$3S[E0.
M(S:]-2^YED"#%<6#"80.CNT=?'1];OTKF<4(S<,^?H.=.H?5"*#/8WN?_Z6"
MW#3+.*G0FB> TVMZ5][4D($V8'H)=1@[H@YMSJ8@(AB("!Y%1%Y4A['.1=!2
M*R)6'*^-$R@+ME.6\2>T04%8ZH(/UM6(;BY4], PL%UGT$]F[__>B\4'N_.S
M)^P4Q $#<< 7(4!@IPJ$*V]JSH"HX.E%B'87W8F-D=:-=3J#?#K$%0CP&3)"
MA" Z/5G.V5+YZ^$T#$&^/\0("7 :,D*0:,?:+OBM)BHFH#+$@1A!=!JRG!._
M^]>_@B:Z.(&&$MBYD>%&G2"Z\.!KXH[!2++; 46, ,T@4ZH3K7/K+)B"$A"@
M!&1B;8+HL@,FNGA$=-K0K2@J>FCTQ-[HC:URO&!AW^O9-[^F$"P(T ER$8(%
M<<H[7'E3<P:\@TPO6+2[Z,[XM[C/((E)U1A4*PB0 #)"K2!Z=]>JDLU$O0T+
M?9VZT2FH4:?0;K;Z+T8('9V.4RFHX08"U4J=P8IWI  5&W1V.K%(00WB V%Z
M7O5.WYVV*GIH]=3>ZC\!TC++DJ9WQFE11DDR3%3L3L^M*:Z\J2GH+$.X",&"
M.A4L7'E3<P;LA$XO6%"=H" >:MJB'<EK(P4F0R>6+*A!LF"A)N^:S)1LJ/B!
M95"[:''Z!#]'Q+#O[.Q)/ 69H$ FZ$6(&-2IB.'*FYHSX"]T>A&#&D0,WK]=
M1 TBQC(<4N0#(#O!"!$CT!E.X&MWL@Q6='"-1P D)Q@A6P2F=11]@F,P0D.R
M3P $)W @700ZB<%8SYS!*APBU0&0F,"-7A'H4@325](9]8KE $9@&<&4>D7P
MDM44=@2O7>?86>@X]4I'G1 02O4P#8H%'ZH+T.<#>Y]_49\<KV#849S;#%QY
M4W,&W"*X" 4C<$HZ7'E3<P:D(YA>P0@,XL22ZM76('2P@6OQ !A ,$+!"%ZT
MWL)D-;C>@D%K9VYT#&;4,?K9,U@-KK=@T.39."6#Z2T\)#HVW8K0H163##H]
MFUC*8*9U%#S0[@F8[)0)K 8 1("=( *R3)?YH7F^*$ZKNG,O3^*FF$>;QPJW
MMX^>JWC,4\.IL.'*FYH-H!SL(H0-YE38<.5-S1F0&#:]L,',=U[Z5_QV)*^-
MM/-LQ\3"!M,5"Q(N]3!U,S4;*GX@'\PN;)QUKI^C<=CW>_9\GH)N,* ;["(T
M#N94XW#E3<T9,!PVO<;!=(ICK &ZV7 ?Y,"$^ B1@QN6783ZXR)&,SR(#1@0
M'R%S<)W8Z'>8C$8#]80#^>$.9 YNNE>#-'YC,J.#*ULX\!ON1NC@NH9!=)"F
MU1L#))P#Z>!3ZAS\]+H,^_Y?61PX$ 0^L<K!#2J'H6T:S"QMDT/;YR>>&CFS
M;8Z7/.R SG[L<@K)@W<>-;T(R8.[?51U"@["@8/PZ24/KFL96F&PF:C0@0KP
M$6('/[U<PVJB/OH+S3UT(W.$MH48#3RKB0H/^GLX3N$(3R_ M)JHL*"]AQ-K
M&ZU_9L-M,VEP+SHO^M@)63*K]Y_(RY+J8J1Y\\7QV^,[5M[7;Q;I??\!O;MI
MWI0";IH7MWR6E3A."R\16^G2GU>=)&_>A=)\*+-]_3J1NZPLLUV]^2"BC<@K
M _G[-LO*;Q^J'1S?2+/Z!U!+ P04    "  H/W18A&XHMCD#  #*#0  &0
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M=<.WWZ%L:&#X(DYE_HFV9:UCH2B3BB<E6"M(""N^\4-I1 W@]M\ >"7 >R_
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M$#T_Q=(2G*6Q X"XX,73LIYD%QMMJ:*1J5=M,V6EB%S1]-HHBI@R:9N'.!@
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M.6SAC/H 7HJ[T!!A48SZ7:8C4$P,FD,%<+$19!L;/Z@@+NKQK*W[@"N<469
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M$%!7T[R>1VSAC"H"BEGXE;UY_8S8PAGU 0P2MP4B@H @>Z-CC/0 @;-T%5H
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M&2)*EK7CA<]Y\IT \FCI5?,4E% 7WW@J]EW@A*L""QTIO8K+DM?WABV<41]
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M72/T+MV%T-JE,XL&Y%\TG*?U]F8:V3I@!T$X[UKP(V/DR+_E/J'T]EXZM.Y
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M75\%JG'.4'HNHX7.W,0Y1[$#+P)*/P64'AE0],-RS+?=:S*+%___YF(F;/S
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MU@[DII4V$K?2_->W//Y!>DRJDW^3Y=OX<Y)7"Q7)[_?)[G+#J_0F.7("L'C
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MY8*'3>J@D[JHYJ&:/VR'!,.&A>C:(E2+42VAM/;QWY1UC>^5=4=65L3>Z"1
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M >KSNS25SV^R!-5CT/-_ 5!+ P04    "  H/W18F9T:I-0"  !)"   &@
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MIP$SW9!W!NK6S\E*(TV=7];T+H)Q#G2^UAK?##=ZPTN;_P502P,$%     @
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M=WVK3%&9R9PHZR0*;+V4Z[:9KFCHVF$C>@4Y:" '!T,N!,^1S+" ,[/EYZC
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MG0$> YE_).0;+3;9G'TO-$[MV7*-'U8@30 ^7PJA]QLSNI>?:L%_4$L#!!0
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MBL C;N822$KUNC&+)N:K@OV#8G1&OI-_:N0KV* C\C;=199@K<@/F\@/NU>
M2D'LIZ9# >[$G!I@F[#0)BRR!&MI<=%H<?'6>\B%3=5LPD*;L,@2K*7:J%%M
MU+F"9FL18[JJ-HY28#6B]PS<5 @W:XM*"4J2I> Y@4(QHUN,#W2"9QE*N7@B
MU[]]N9N37SYWI[C1B_U@& P\_==.3K<O&^ZGKV-141>J%:W+)EJ7G=&*\C+C
M3P!DKGC\@]QM"A R9269X>Z+CV;^"(.PWZ@TC]"ZQ:&X=#H\=8[;A(4V89$E
M6$LUW]M6/-Y;YZ;:HR7AK-)"J[3(%JVMW4ZUZG>NN5_7^0(3$>K&JY4D](L
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M+W  HOJV4)TH7IJ7YPNN%,_-80HT :$;X/TEY^KY1#MHOO!,_P-02P,$%
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M@BB,@=Z?<Z[6$^.@:BV#OU!+ P04    "  H/W18!H9(SY,"   ,"   &@
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  H/W18+&%?CG4'   [3   #P   'AL+W=O<FMB;V]K+GAM;,6<76_;-A2&
M_XK@JPZ89TG6EXNF0)JDG8>B#>*NMX4BT3%1?7BDE#3]]:.D)CE,Y'>[.=95
M8MF6'E,B'Q[RD&_N:O7]NJZ_.S_*HM(GLUW3[%\O%CK;B3+5?]1[49EWMK4J
MT\:\5#<+O5<BS?5.B*8L%K[K1HLRE=7L[9N'<UVJ!7U1-R)K9%V9@]V!KU+<
MZ:?WNY?.K=3R6A:RN3^9]?\78N:4LI*E_"GRDYD[<_2NOONS5O)G735IL<E4
M710G,V]XXZM0C<Q>'-YTD%_2:]T?:=+KJ]2 G,PBUYQP*Y5N^D_TYT\-XZTP
M'QY>M4W]7A:-4.=I(SZHNMW+ZJ8[C?D5"_(S^G)X^#L4XFOU?XJQWFYE)L[K
MK"U%U0SEJ$31 59Z)_=ZYE1I*4YF9_6M4-WO,1=8Y\-O:PP4*2GU6IHWU#KO
M\?A03MM<-LZZ&KYLWB58/L#R>;'.S.NZD+FY>NYL.HCN"]JIMXYY^K8$<@D@
MEY-!GM7EGD & #*8#/*]K%("&0+(<+J2W*7TF8P 9#0=9*IW!#(&D#$WI-K7
MRES[0)U. %K"B[:1-Y4TGTVKQCG-LKJM&M, .Y>F3#,I-(%< <C5))!_M?E-
M=[MIH^VB5MOEQ>SU=> 6>U GS#YYUVI9":V[%O#:M"_]!R@<DHK';)4K<2NJ
M5FAGJ^K2$%:-,GT$[=S)9N><M103:<5C]LJZRNI2.&F5.Q<_S'FT53D\)!./
MV2:_T+ZD/R@1,H?'K(Z+5%6FAFIG+Y2SV:5*4#*D"X_9%Y^;G4%:F[YM==-=
MVCG5VG0L^_OZH:XI)A*&QVP,TY\R1=?<_^Y<%EVKUS]V_[1RWWV/0B)U>,SN
MZ+HJ52;3@A;BTT&*B>3A,=MC79D&IC$AC55C?60*G]D4PU/XJ:[FS\N0$B)E
M^,S*6&O=FA[56;J7)@SL[^R5T$+=VH4(HQ%F<?3MROQ=J@WG97K?]_LH&[*%
MSVP+4W^[B]J:]9$D?/Z0H^LTB:KKUO7WL^X?PNWP %),9 Z?V1QC->.C3/M!
MBV<5&&G$9];(1Y':'0 ?V<)GML55=["O!489SKG465'K5MF R!0^LRDN;ON@
M['3;F)MK[K!I2TQ -$0:0ED/'S*%/TV<,01#WWPZP('LL62V!\9<4DRDD"6S
M0EZ$0\ZK+ZE!T+]10F20);-!1N.B44HXH,7L$A@@V4\E$LSR.%$(#9!&BQ+9
M9<ELEZ=(:10-&67);)27(=,H(M+,DEDS,':R'T0DFR6S;&#LY+RBF$@V2V;9
MP.C)*LT R29@E@V)GL8>R  9)F VS.$PJD>EF$@S ;-F0"S5<5),Y)F V3-C
M\=3H+8<3)\R6>0JL1M&07 +^^9+#$99=H9%H@J.,@!V(L&Q,))N 639#A#5Z
MDY%< F:Y' RU!E**B>023!K)!'2"$<DEG#22"2DF\DS([!F,&5%,Y)F0>T ,
M8L84$WDFY/8,FLVS&J 0F29D-LW+\'7N;-JR3-5]-[M,,>$D/;-U(*9=FL@Z
M(;-U,"8=LPB1=4)FZXR/",R=TSPW=J330R&R4,ALH4.8OTJ48B(+A<P6PB,7
M]*9'R$(1LX4P)I5EA"P4,5L(8U)91LA"T93S^98L(V2A:-)1-2K+"%DHFF!4
M[;$YLC+%(F2AZ#@#:\\PAU#C\Y[._D<P68S90A#3DF6$+!0Q6V@<<PC7A+.F
MF,A"$;.%,.8%Q406BMCG_\<P'SL?-$4062AF'VA[')LF%;QXZ#-13&2AF#LQ
M@&*2_O!9JY2=FQ(C"\7<8VX',*]$5MO3W3&R4'R<K+(7F.=B*Y25-14C"\5'
MRS"S,4WXUI8M'?6(D87BHZ>=6;@4$UDHGC('S>H6QS!I>=+I'MHMCI&%8F8+
M84S:+8Z1A6)F"V%,VBU.D(429@OAR;,YQ4062I@M!#&MCER"+)0P6PC/\=&:
MGB +)<P6PIBTIB?(0@FSA3 FK>D)LE#";"&,:=5T9*&$V4(8DP; ";)0PFPA
MC)E03+B,9LI<Z&\KBHDLE$R8=/"M7SSS@+E"%EHQ6PAC>A0366C%'@L]Y498
M_>+A#8J)++1BCX4HYHO0DF(B"ZV8+02R.;K"I9C(0BMF"T',TYQB(@NMN$?D
M0-*)X:28R$(K[A$YB+FAF,A"*V8+C>;&/%5YBHDLM.)>S3F.^5#E*29<SLF=
MG3".^6MLA@XG>"Y>T,F=GX!NNQ5F>"Y<X.ER9RB,@F[,F?/6Q)H6*%SLZ3*[
MB.1OS1V:S'4NFO39K8?+/=VCK>#YK^%8SX6+/]TI%_98,:;GPC6A[J3Y<8$%
M"I>(NI-FR-DE"A>)NL?)D;,'N.7-KIG7V_G?UOID%RX4=9F]] CZLB(]7R?O
MPJ6B+K.9QDJT/S8\ !04;S7 O=? (Z@FH_%EETNE.X]:H'CK ?:LA4,)DWTA
M6Z#03/S[$!P&-8^M!0K-Q+T3 2Q1NU."MR7@WI< @UKM*-ZM@'V[ K0\\5F)
M0C,-NQ<L^H_KMV]R8=PF\D_F(MH<S](BNU1.]Z<_EQ^$W<+X;5L49^;8Y^IC
MG>8/>U\][-OU]E]02P,$%     @ *#]T6,DP(5,X P  %T0  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W;.TXC01A%X:T@+X"NO]XU J))2$=L
MP#+-0_@E=X\&=C\6!'!+$TR"^D16&U&^B3^AIL_5KW&[GI\/^^GI^3A=O.ZV
M^^EZ]33/QQ_#,&V>QMUZNCP<Q_WY)P^'TVX]GR]/C\-QO7E9/XZ#=RX/IZ]G
MK&ZNOIYY<?=V'/_GQ,/#P_-F_'G8_-Z-^_D?!P]_#J>7Z6D<Y]7%W?KT.,[7
MJ^%U^_GV-+R_V.7YY-7%[?WUZG1[;ZMAZ4%>!OGE!P49%)8?%&507'Y0DD%I
M^4%9!N7E!Q495)8?5&5077Y0DT%M^4'F5$8'F-1A#=#:E&L#>&T*M@'$-B7;
M &:;HFT M4W9-H#;IG ;0&Y3N@U@MRG>!M#;J]X>H+=7O3U ;]_]L0W0VZO>
M'J"W5[T]0&^O>GN WE[U]@"]O>KM 7I[U=L#]/:JMP?H'53O - [J-X!H'=0
MO0- []#=+ 'H'53O - [J-X!H'=0O0- [Z!Z!X#>0?4. +V#ZAT >D?5.P+T
MCJIW!.@=5>\(T#NJWA&@=^QN=@/TCJIW!.@=5>\(T#NJWA&@=U2](T#OJ'I'
M@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U4[P30.W7_K 3HG53O!- [J=X)H'=2
MO1- [Z1Z)X#>6?7. +VSZIT!>F?5.P/TSJIW!NB=5>\,T#NKWAF@=^X>-@'H
MG57O#- [J]X9H'=6O3- [Z)Z%X#>1?4N +V+ZET >A?5NP#T+JIW >A=5.\"
MT+NHW@6@=^D>%@3H753O M"[J-X%H'=5O2M [ZIZ5X#>5?6N +VKZET!>E?5
MNP+TKJIW!>A=5>\*T+NJWA6@=^T>]@;H757O"M"[J=X-H'=3O1M [Z9Z-X#>
M3?5N +V;ZMT >C?5NP'T;JIW ^C=5.\&T+NIW@V@=^MB'8#>YOI<!^"WN2[8
M<0#!S77)C@,8;JZ+=AQ <7-=MN, CIOKPAT'D-Q<E^XX@.7FNGC' 30WU^4[
M#N"YN2[@<031^P"346#V"29!]#["1%28?8:)Z##[$!-18O8I)J+%[&/,;ZTQ
MI_EM.TZ?BSZNNP'?J?=\_MWQ\_/?+S_>[+_O[UP/7V=,-W\!4$L#!!0    (
M "@_=%B\;2HCC (  &-!   3    6T-O;G1E;G1?5'EP97-=+GAM;,W<3V^;
M,!C'\;<2<:T"M@$;IJ:7=M>MA[T!!DZ#PC]AMTO?_1S25MK41:LR:=]+4&+[
M^3W8TN?F7'][GJQ;'?IN<)MHY_WT*4E<O;-]Y>)QLD,8V8YS7_GP=7Y(IJK>
M5P\V44+HI!X';P>_]L<:T<WUG=U6CYU??3Z$GUT[#IMHMIV+5K>GB<>L351-
M4]?6E0_CR=/0_):R?DF(P\IECMNUD[L*$Z+DW83CR)\#7M9]?;+SW#9V=5_-
M_DO5AUG)H4N<?^ZLB\^7>*?'<;MM:]N,]6,?EL1NFFW5N)VUON_B4]&K\\D^
M[+ ]?<J+\Y<RYP+#S/MYG%PXL=E^/.[U2(ZKUU,H9&??GG_%M\10^N+WL\?3
M;FSSE]EA>W^,\WXY#Y<LC\OW^-<S?JO_P3X4I(\4TD<&Z2.']*$A?1A('P6D
MCQ+2AQ241BBB2@JIDF*JI* J*:I*"JN2XJJDP"HILBJ*K(HBJZ+(JBBR*HJL
MBB*KHLBJ*+(JBJR*(FM*D36ER)I29$TILJ8465.*K"E%UI0B:TJ1-:7(FE%D
MS2BR9A19,XJL&476C")K1I$UH\B:463-*++F%%ESBJPY1=:<(FM.D36GR)I3
M9,TILN8467.*K)HBJZ;(JBFR:HJLFB*KILBJ*;)JBJR:(JNFR&HHLAJ*K(8B
MJZ'(:BBR&HJLAB*KH<AJ*+(:BJP%1=:"(FM!D;6@R%I09"THLA8460N*K 5%
MUH(B:TF1M:3(6E)D+2FREA192XJL)476DB)K29&UI,@J!856*2BV2D'!50J*
MKE)0>)6"XJL4%&"EH @K!858*3#&@JYC88SE7,CBW,CB7,GBW,GZKY>ROH_C
M_A_'+\^XK]KA-3]9_EOAYB=02P$"% ,4    "  H/W18!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M "@_=%AL;)!L[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( "@_=%B97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *#]T6*XU
M5LX="   :C,  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( "@_=%CFEW@?5 (  -X%   8
M  " @6$0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  H
M/W18E',X^@<&  "[&P  &               @('K$@  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ *#]T6%UXQ2=2!   VQ   !@
M         ("!*!D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( "@_=%CRE4ZB  <  - C   8              " @; =  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  H/W18"ML!((0'  "9-
M&               @('F)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ *#]T6(;F:@WT"0  CRX  !@              ("!H"P  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "@_=%C#B\B!_0,
M )0(   8              " @<HV  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  H/W18*\3.W+(G   ,A0  &               @(']
M.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ *#]T6!_8
M(TGD&@  ;E,  !D              ("!Y6(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  H/W18DA6&:.@&  #L$P  &0
M    @($ ?@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M "@_=%B/]\Q>;@D  )47   9              " @1^%  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ *#]T6,J!#'1S#   <"4  !D
M             ("!Q(X  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  H/W18[0P,]^0)  !_'P  &0              @(%NFP  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "@_=%CZ9KX>,Q
M .0O   9              " @8FE  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ *#]T6 +-<12= P  7@D  !D              ("!
M\[4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  H/W18
MMSLPY@\-  "C)0  &0              @(''N0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( "@_=%A!A[$CX@0  "(-   9
M      " @0W'  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ *#]T6"_QTG O&@  RU(  !D              ("!)LP  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  H/W18HJ^O(6$#  !2!P
M&0              @(&,Y@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( "@_=%CE!Z2DFP,  $D(   9              " @23J  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ *#]T6"G&\ZDW
M"0  Y1<  !D              ("!]NT  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  H/W18^#4K*2(>   @=P  &0
M@(%D]P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "@_
M=%@DT]S#CP0  +\+   9              " @;T5 0!X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ *#]T6&(0\G%D%0  5DP  !D
M         ("!@QH! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  H/W18BED9R9\"   -!@  &0              @($>, $ >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( "@_=%A\H^Y>8P4  '(-
M   9              " @?0R 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ *#]T6%-!#;Q4"   \10  !D              ("!CC@!
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  H/W18D \#
M<=@#  !M"   &0              @($900$ >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( "@_=%C(<QF]#T(  $SP   9
M  " @2A% 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M*#]T6$<54M0G"   K!<  !D              ("!;H<! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  H/W18L[ Y O4&  "G%   &0
M            @(',CP$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( "@_=%A*&DMJ^P,  (P(   9              " @?B6 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ *#]T6"S*SY1A!0
M.@X  !D              ("!*IL! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  H/W18)P'*,9P$  "P#   &0              @('"
MH $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "@_=%A6
MO'5/ P@  )\6   9              " @96E 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ *#]T6)F9 M5) P  :@<  !D
M     ("!SZT! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "@_=%C0,SI.I@(  +0%   9              "
M@0?+ 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ *#]T
M6"H2]SZ%!   G@H  !D              ("!Y,T! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  H/W18S9.%.@X-  #@+@  &0
M        @(&@T@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( "@_=%@EKVPAHP(  *0%   9              " @>7? 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ *#]T6 "PX-@O P  Y0<
M !D              ("!O^(! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  H/W18N8O7<*T"   !!@  &0              @($EY@$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( "@_=%@W_ 64
M_P,  .\)   9              " @0GI 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ *#]T6+C4,E="!0  ]0P  !D
M ("!/^T! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  H
M/W18HHUV+6H#  "C#0  &0              @(&X\@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "@_=%AGKIB%@P,  - 1   9
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M970U-2YX;6Q02P$"% ,4    "  H/W18[(P__9<"  #5!@  &0
M    @(%]#P( >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M "@_=%B3&L"\I0(  /(&   9              " @4L2 @!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ *#]T6'0YL4K=!   /A8  !D
M             ("!)Q4" 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    "  H/W18#)3"Y1H%  #W$@  &0              @($[&@( >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( "@_=%BD&5I 308
M ,XK   9              " @8P? @!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ *#]T6 C.2=Y$!P  X#<  !D              ("!
M$"8" 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  H/W18
M4B/E%(H"  "8!@  &0              @(&++0( >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( "@_=%ABLCC0L (   8'   9
M      " @4PP @!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ *#]T6,$QMP%* P  QPT  !D              ("!,S," 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  H/W18Z!4/)?@%  #L'@
M&0              @(&T-@( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( "@_=%A?JY3V>@0   P6   9              " @>,\ @!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ *#]T6$]F'X0,
M!   EQ0  !D              ("!E$$" 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    "  H/W18)OQ%DB #   M"0  &0
M@('710( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( "@_
M=%CD7.'<% ,  " )   9              " @2Y) @!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ *#]T6$)/2.\% P   0D  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( "@_=%ATZJ>#]@(  .P(   9
M  " @?AL @!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
M*#]T6$(?SBD !   <0T  !D              ("!)7 " 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    "  H/W18[GZH6^0#  "Q$   &0
M            @(%<= ( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( "@_=%A;1(0>X0,  ,@2   9              " @7=X @!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ *#]T6&$'?V9)"
MX58  !D              ("!CWP" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX
M;6Q02P$"% ,4    "  H/W187#7GXGP'  !N,P  &0              @($/
MA0( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( "@_=%C<
MM\D<%0D  )U&   9              " @<*, @!X;"]W;W)K<VAE971S+W-H
M965T.#$N>&UL4$L! A0#%     @ *#]T6(1N*+8Y P  R@T  !D
M     ("!#I8" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "@_=%BR;B<B.@,  ,4*   9              "
M@7.X @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ *#]T
M6#=M &Y$ P  8@T  !D              ("!Y+L" 'AL+W=O<FMS:&5E=',O
M<VAE970X."YX;6Q02P$"% ,4    "  H/W18<K!O>;,#  "G#@  &0
M        @(%?OP( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0
M   ( "@_=%A_R3(II@4  *D@   9              " @4G# @!X;"]W;W)K
M<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ *#]T6$D;@[L-!@  ^B$
M !D              ("!)LD" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q0
M2P$"% ,4    "  H/W18QG9#.88"  #@!@  &0              @(%JSP(
M>&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( "@_=%@0X2+F
M@ (  %T&   9              " @2?2 @!X;"]W;W)K<VAE971S+W-H965T
M.3,N>&UL4$L! A0#%     @ *#]T6"8CT"4# P  \0@  !D
M ("!WM0" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    "  H
M/W18=Z E?X0#  #+#P  &0              @($8V ( >&PO=V]R:W-H965T
M<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( "@_=%BJPE(3Z@H  "V2   9
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M970Q,# N>&UL4$L! A0#%     @ *#]T6#.Y-KH"$   )P ! !H
M     ("!9B(# 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%
M  @ *#]T6(IDCA/=!@  $CT  !H              ("!H#(# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ *#]T6)F=&J34 @  20@
M !H              ("!M3D# 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL
M4$L! A0#%     @ *#]T6&GA=KB. P  +0P  !H              ("!P3P#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @ *#]T6."7
MNAO[ P  XA0  !H              ("!AT # 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#4N>&UL4$L! A0#%     @ *#]T6,NF[XA? @  =04  !H
M     ("!ND0# 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%
M  @ *#]T6+T72W$# P  )PD  !H              ("!44<# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @ *#]T6%6?=V<_ P  M@T
M !H              ("!C$H# 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL
M4$L! A0#%     @ *#]T6,1! 8 9 P  [P@  !H              ("! TX#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L! A0#%     @ *#]T6!7Q
MN%J! @  ; 8  !H              ("!5%$# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,3 N>&UL4$L! A0#%     @ *#]T6 D)$[I8!   ,!0  !H
M     ("!#50# 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%
M  @ *#]T6- .@<B8!   _14  !H              ("!G5@# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @ *#]T6)K47EJ4!   [1D
M !H              ("!;5T# 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL
M4$L! A0#%     @ *#]T6)P8Z!PV P  9@H  !H              ("!.6(#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&UL4$L! A0#%     @ *#]T6 :&
M2,^3 @  # @  !H              ("!IV4# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,34N>&UL4$L! A0#%     @ *#]T6$LS)M7G P  MA$  !H
M     ("!<F@# 'AL+W=O<FMS:&5E=',O<VAE970Q,38N>&UL4$L! A0#%
M  @ *#]T6#+#"<^$ P  K1@   T              ( !D6P# 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  H/W18EXJ[',     3 @  "P
M@ % < , 7W)E;',O+G)E;'-02P$"% ,4    "  H/W18+&%?CG4'   [3
M#P              @ $I<0, >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M*#]T6,DP(5,X P  %T0  !H              ( !RW@# 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *#]T6+QM*B., @  8T$  !,
M             ( !.WP# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     'P
,?  L(@  ^'X#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>790</ContextCount>
  <ElementCount>505</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>225</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Profit or Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss</Role>
      <ShortName>Consolidated Statements of Profit or Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/CorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions</Role>
      <ShortName>Significant Accounting Judgements, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Group Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/GroupInformation</Role>
      <ShortName>Group Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenues from Contracts with Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomers</Role>
      <ShortName>Revenues from Contracts with Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpenses</Role>
      <ShortName>Income and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Other Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill</Role>
      <ShortName>Other Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities</Role>
      <ShortName>Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Other Non-Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialAssets</Role>
      <ShortName>Other Non-Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Issued Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IssuedCapitalandReserves</Role>
      <ShortName>Issued Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/Provisions</Role>
      <ShortName>Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Contingencies and other financial commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/Contingenciesandotherfinancialcommitments</Role>
      <ShortName>Contingencies and other financial commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Other Non-Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialLiabilities</Role>
      <ShortName>Other Non-Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Events After the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/EventsAftertheReportingPeriod</Role>
      <ShortName>Events After the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biontech.de/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Group Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/GroupInformationTables</Role>
      <ShortName>Group Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/GroupInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/BusinessCombinations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Revenues from Contracts with Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersTables</Role>
      <ShortName>Revenues from Contracts with Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/RevenuesfromContractswithCustomers</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Income and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesTables</Role>
      <ShortName>Income and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/IncomeandExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/IncomeTax</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/EarningsperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Other Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables</Role>
      <ShortName>Other Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/PropertyPlantandEquipment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Financial Assets and Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables</Role>
      <ShortName>Financial Assets and Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/Inventories</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Other Non-Financial Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialAssetsTables</Role>
      <ShortName>Other Non-Financial Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/OtherNonFinancialAssets</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Issued Capital and Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IssuedCapitalandReservesTables</Role>
      <ShortName>Issued Capital and Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/IssuedCapitalandReserves</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/ShareBasedPayments</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Provisions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ProvisionsTables</Role>
      <ShortName>Provisions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/Provisions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Contingencies and other financial commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables</Role>
      <ShortName>Contingencies and other financial commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/Contingenciesandotherfinancialcommitments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Other Non-Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables</Role>
      <ShortName>Other Non-Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/OtherNonFinancialLiabilities</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/Leases</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Related Party Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosuresTables</Role>
      <ShortName>Related Party Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biontech.de/role/RelatedPartyDisclosures</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Group Information - Summary of Information about Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails</Role>
      <ShortName>Group Information - Summary of Information about Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Group Information - Summary of Information about Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails</Role>
      <ShortName>Group Information - Summary of Information about Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails</Role>
      <ShortName>Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails</Role>
      <ShortName>Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Revenues from Contracts with Customers - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Revenues from Contracts with Customers - Summary of Revenue Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Summary of Revenue Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails</Role>
      <ShortName>Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Income and Expenses - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails</Role>
      <ShortName>Income and Expenses - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Income and Expenses - Other Operating Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails</Role>
      <ShortName>Income and Expenses - Other Operating Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Income and Expenses - Other Operating Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails</Role>
      <ShortName>Income and Expenses - Other Operating Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income and Expenses - Finance Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails</Role>
      <ShortName>Income and Expenses - Finance Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income and Expenses - Finance Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails</Role>
      <ShortName>Income and Expenses - Finance Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income and Expenses - Summary of Employee Benefits Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails</Role>
      <ShortName>Income and Expenses - Summary of Employee Benefits Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails</Role>
      <ShortName>Income Tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Tax - Summary of Current and Deferred Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails</Role>
      <ShortName>Income Tax - Summary of Current and Deferred Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails</Role>
      <ShortName>Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Income Tax - Summary of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails</Role>
      <ShortName>Income Tax - Summary of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Income Tax - Summary of Accumulated Tax Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails</Role>
      <ShortName>Income Tax - Summary of Accumulated Tax Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails</Role>
      <ShortName>Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Other Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Other Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails</Role>
      <ShortName>Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Other Intangible Assets and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Other Intangible Assets and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails</Role>
      <ShortName>Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - Inventories - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails</Role>
      <ShortName>Inventories - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - Inventories - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/InventoriesAdditionalInformationDetails</Role>
      <ShortName>Inventories - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - Other Non-Financial Assets - Summary of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails</Role>
      <ShortName>Other Non-Financial Assets - Summary of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - Other Non-Financial Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails</Role>
      <ShortName>Other Non-Financial Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - Issued Capital and Reserves - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails</Role>
      <ShortName>Issued Capital and Reserves - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails</Role>
      <ShortName>Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails</Role>
      <ShortName>Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails</Role>
      <ShortName>Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails</Role>
      <ShortName>Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails</Role>
      <ShortName>Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - Provisions - Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ProvisionsProvisionsDetails</Role>
      <ShortName>Provisions - Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - Provisions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ProvisionsAdditionalInformationDetails</Role>
      <ShortName>Provisions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails</Role>
      <ShortName>Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - Contingencies and other financial commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails</Role>
      <ShortName>Contingencies and other financial commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - Other Non-Financial Liabilities - Summary of Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails</Role>
      <ShortName>Other Non-Financial Liabilities - Summary of Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails</Role>
      <ShortName>Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954551 - Disclosure - Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails</Role>
      <ShortName>Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9954552 - Disclosure - Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails</Role>
      <ShortName>Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9954553 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9954554 - Disclosure - Related Party Disclosures - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails</Role>
      <ShortName>Related Party Disclosures - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9954555 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9954556 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails</Role>
      <ShortName>Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="bntx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9954557 - Disclosure - Events After the Reporting Period - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails</Role>
      <ShortName>Events After the Reporting Period - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="bntx-20231231.htm">bntx-20231231.htm</File>
    <File>bntx-20231231.xsd</File>
    <File>bntx-20231231_cal.xml</File>
    <File>bntx-20231231_def.xml</File>
    <File>bntx-20231231_lab.xml</File>
    <File>bntx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bntx-20231231_g1.jpg</File>
    <File>bntx-20231231_g2.jpg</File>
    <File>bntx-20231231_g3.jpg</File>
    <File>bntx-20231231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="1642">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>152
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bntx-20231231.htm": {
   "nsprefix": "bntx",
   "nsuri": "http://www.biontech.de/20231231",
   "dts": {
    "inline": {
     "local": [
      "bntx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "bntx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bntx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bntx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bntx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bntx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 343,
   "keyCustom": 162,
   "axisStandard": 43,
   "axisCustom": 5,
   "memberStandard": 56,
   "memberCustom": 158,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 790,
   "entityCount": 1,
   "segmentCount": 225,
   "elementCount": 917,
   "unitCount": 8,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1642,
    "http://xbrl.sec.gov/dei/2023": 48,
    "http://fasb.org/us-gaap/2023": 3
   },
   "report": {
    "R1": {
     "role": "http://www.biontech.de/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biontech.de/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
     "longName": "0000003 - Statement - Consolidated Statements of Profit or Loss",
     "shortName": "Consolidated Statements of Profit or Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossFromOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
     "longName": "0000005 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biontech.de/role/CorporateInformation",
     "longName": "0000008 - Disclosure - Corporate Information",
     "shortName": "Corporate Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCorporateInformationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCorporateInformationExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biontech.de/role/SignificantAccountingPolicies",
     "longName": "0000009 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions",
     "longName": "0000010 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions",
     "shortName": "Significant Accounting Judgements, Estimates and Assumptions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biontech.de/role/GroupInformation",
     "longName": "0000011 - Disclosure - Group Information",
     "shortName": "Group Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biontech.de/role/BusinessCombinations",
     "longName": "0000012 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomers",
     "longName": "0000013 - Disclosure - Revenues from Contracts with Customers",
     "shortName": "Revenues from Contracts with Customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.biontech.de/role/IncomeandExpenses",
     "longName": "0000014 - Disclosure - Income and Expenses",
     "shortName": "Income and Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfIncomeAndExpenseExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfIncomeAndExpenseExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biontech.de/role/IncomeTax",
     "longName": "0000015 - Disclosure - Income Tax",
     "shortName": "Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biontech.de/role/EarningsperShare",
     "longName": "0000016 - Disclosure - Earnings per Share",
     "shortName": "Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill",
     "longName": "0000017 - Disclosure - Other Intangible Assets and Goodwill",
     "shortName": "Other Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biontech.de/role/PropertyPlantandEquipment",
     "longName": "0000018 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities",
     "longName": "0000019 - Disclosure - Financial Assets and Financial Liabilities",
     "shortName": "Financial Assets and Financial Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biontech.de/role/Inventories",
     "longName": "0000020 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biontech.de/role/OtherNonFinancialAssets",
     "longName": "0000021 - Disclosure - Other Non-Financial Assets",
     "shortName": "Other Non-Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biontech.de/role/IssuedCapitalandReserves",
     "longName": "0000022 - Disclosure - Issued Capital and Reserves",
     "shortName": "Issued Capital and Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.biontech.de/role/ShareBasedPayments",
     "longName": "0000023 - Disclosure - Share-Based Payments",
     "shortName": "Share-Based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biontech.de/role/Provisions",
     "longName": "0000024 - Disclosure - Provisions",
     "shortName": "Provisions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfProvisionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biontech.de/role/Contingenciesandotherfinancialcommitments",
     "longName": "0000025 - Disclosure - Contingencies and other financial commitments",
     "shortName": "Contingencies and other financial commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.biontech.de/role/OtherNonFinancialLiabilities",
     "longName": "0000026 - Disclosure - Other Non-Financial Liabilities",
     "shortName": "Other Non-Financial Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biontech.de/role/Leases",
     "longName": "0000027 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosures",
     "longName": "0000028 - Disclosure - Related Party Disclosures",
     "shortName": "Related Party Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.biontech.de/role/EventsAftertheReportingPeriod",
     "longName": "0000029 - Disclosure - Events After the Reporting Period",
     "shortName": "Events After the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biontech.de/role/GroupInformationTables",
     "longName": "9954473 - Disclosure - Group Information (Tables)",
     "shortName": "Group Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biontech.de/role/BusinessCombinationsTables",
     "longName": "9954474 - Disclosure - Business Combinations (Tables)",
     "shortName": "Business Combinations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersTables",
     "longName": "9954475 - Disclosure - Revenues from Contracts with Customers (Tables)",
     "shortName": "Revenues from Contracts with Customers (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biontech.de/role/IncomeandExpensesTables",
     "longName": "9954476 - Disclosure - Income and Expenses (Tables)",
     "shortName": "Income and Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biontech.de/role/IncomeTaxTables",
     "longName": "9954477 - Disclosure - Income Tax (Tables)",
     "shortName": "Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biontech.de/role/EarningsperShareTables",
     "longName": "9954478 - Disclosure - Earnings per Share (Tables)",
     "shortName": "Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables",
     "longName": "9954479 - Disclosure - Other Intangible Assets and Goodwill (Tables)",
     "shortName": "Other Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.biontech.de/role/PropertyPlantandEquipmentTables",
     "longName": "9954480 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables",
     "longName": "9954481 - Disclosure - Financial Assets and Financial Liabilities (Tables)",
     "shortName": "Financial Assets and Financial Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biontech.de/role/InventoriesTables",
     "longName": "9954482 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biontech.de/role/OtherNonFinancialAssetsTables",
     "longName": "9954483 - Disclosure - Other Non-Financial Assets (Tables)",
     "shortName": "Other Non-Financial Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biontech.de/role/IssuedCapitalandReservesTables",
     "longName": "9954484 - Disclosure - Issued Capital and Reserves (Tables)",
     "shortName": "Issued Capital and Reserves (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfSharesRepurchaseProgramTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfSharesRepurchaseProgramTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsTables",
     "longName": "9954485 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biontech.de/role/ProvisionsTables",
     "longName": "9954486 - Disclosure - Provisions (Tables)",
     "shortName": "Provisions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfProvisionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfProvisionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables",
     "longName": "9954487 - Disclosure - Contingencies and other financial commitments (Tables)",
     "shortName": "Contingencies and other financial commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables",
     "longName": "9954488 - Disclosure - Other Non-Financial Liabilities (Tables)",
     "shortName": "Other Non-Financial Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biontech.de/role/LeasesTables",
     "longName": "9954489 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosuresTables",
     "longName": "9954490 - Disclosure - Related Party Disclosures (Tables)",
     "shortName": "Related Party Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954491 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails",
     "longName": "9954492 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)",
     "shortName": "Significant Accounting Policies - Summary of Useful Lives Applied to the Group's Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails",
     "longName": "9954493 - Disclosure - Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)",
     "shortName": "Significant Accounting Policies - Summary of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-57",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
     "longName": "9954494 - Disclosure - Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)",
     "shortName": "Significant Accounting Policies - Summary of Estimated Useful Lives of the Assets or Shorter Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-63",
      "name": "bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-63",
      "name": "bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails",
     "longName": "9954495 - Disclosure - Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)",
     "shortName": "Significant Accounting Judgements, Estimates and Assumptions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails",
     "longName": "9954496 - Disclosure - Group Information - Summary of Information about Subsidiaries (Details)",
     "shortName": "Group Information - Summary of Information about Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
     "longName": "9954497 - Disclosure - Group Information - Summary of Information about Parent Company (Details)",
     "shortName": "Group Information - Summary of Information about Parent Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-141",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
     "longName": "9954498 - Disclosure - Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)",
     "shortName": "Group Information - Summary of Information about Entity with Significant Influence Over Group (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-143",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - Business Combinations - Additional Information (Details)",
     "shortName": "Business Combinations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-145",
      "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "bntx:ConsideredRemunerationOfPotentialEarnOutPayments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails",
     "longName": "9954500 - Disclosure - Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)",
     "shortName": "Business Combinations - Summary of Fair Values of Identifiable Net Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-145",
      "name": "ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails",
     "longName": "9954501 - Disclosure - Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)",
     "shortName": "Revenues from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-182",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
     "longName": "9954502 - Disclosure - Revenues from Contracts with Customers - Additional Information (Details)",
     "shortName": "Revenues from Contracts with Customers - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "bntx:RemainingUpfrontFeesContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails",
     "longName": "9954503 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Balances (Details)",
     "shortName": "Revenues from Contracts with Customers - Summary of Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentTradeReceivables",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails",
     "longName": "9954504 - Disclosure - Revenues from Contracts with Customers - Summary of Revenue Recognized (Details)",
     "shortName": "Revenues from Contracts with Customers - Summary of Revenue Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails",
     "longName": "9954505 - Disclosure - Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)",
     "shortName": "Revenues from Contracts with Customers - Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-198",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfPerformanceObligationsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
     "longName": "9954506 - Disclosure - Income and Expenses - Additional Information (Details)",
     "shortName": "Income and Expenses - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:IncreaseDecreaseCostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:IncreaseDecreaseCostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
     "longName": "9954507 - Disclosure - Income and Expenses - Other Operating Expense (Details)",
     "shortName": "Income and Expenses - Other Operating Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-204",
      "name": "ifrs-full:MiscellaneousOtherOperatingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails",
     "longName": "9954508 - Disclosure - Income and Expenses - Other Operating Income (Details)",
     "shortName": "Income and Expenses - Other Operating Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-216",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails",
     "longName": "9954509 - Disclosure - Income and Expenses - Finance Income (Details)",
     "shortName": "Income and Expenses - Finance Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfFinanceIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfFinanceIncomeExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails",
     "longName": "9954510 - Disclosure - Income and Expenses - Finance Expenses (Details)",
     "shortName": "Income and Expenses - Finance Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NetForeignExchangeLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfFinanceCostExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NetForeignExchangeLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfFinanceCostExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails",
     "longName": "9954511 - Disclosure - Income and Expenses - Summary of Employee Benefits Expense (Details)",
     "shortName": "Income and Expenses - Summary of Employee Benefits Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WagesAndSalaries",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
     "longName": "9954512 - Disclosure - Income Tax - Additional Information (Details)",
     "shortName": "Income Tax - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:CorporateTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:CorporateTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails",
     "longName": "9954513 - Disclosure - Income Tax - Summary of Current and Deferred Tax Expense (Details)",
     "shortName": "Income Tax - Summary of Current and Deferred Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails",
     "longName": "9954514 - Disclosure - Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details)",
     "shortName": "Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails",
     "longName": "9954515 - Disclosure - Income Tax - Summary of Deferred Taxes (Details)",
     "shortName": "Income Tax - Summary of Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails",
     "longName": "9954516 - Disclosure - Income Tax - Summary of Accumulated Tax Losses (Details)",
     "shortName": "Income Tax - Summary of Accumulated Tax Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:AccumulatedTaxLossesInCorporateTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:AccumulatedTaxLossesInCorporateTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails",
     "longName": "9954517 - Disclosure - Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details)",
     "shortName": "Earnings per Share - Summary of Income and Share Data Used in the Basic and diluted EPS Calculations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
     "longName": "9954518 - Disclosure - Other Intangible Assets and Goodwill - Goodwill (Details)",
     "shortName": "Other Intangible Assets and Goodwill - Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-303",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails",
     "longName": "9954519 - Disclosure - Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details)",
     "shortName": "Other Intangible Assets and Goodwill - Summary of Goodwill Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
     "longName": "9954520 - Disclosure - Other Intangible Assets and Goodwill - Additional Information (Details)",
     "shortName": "Other Intangible Assets and Goodwill - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Goodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails",
     "longName": "9954521 - Disclosure - Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details)",
     "shortName": "Other Intangible Assets and Goodwill - Summary of Detailed Information About Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-261",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
     "longName": "9954522 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-296",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
     "longName": "9954523 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-386",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
     "longName": "9954524 - Disclosure - Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
     "longName": "9954525 - Disclosure - Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Financial Assets and Liabilities at Amortized Cost and at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-447",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-447",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails",
     "longName": "9954526 - Disclosure - Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Equity Securities Measured at Fair Value Through Other Comprehensive Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-538",
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails",
     "longName": "9954527 - Disclosure - Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Liabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-540",
      "name": "ifrs-full:Liabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
     "longName": "9954528 - Disclosure - Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Fair Values of Financial Instruments in Fair Value Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-544",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-544",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
     "longName": "9954529 - Disclosure - Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Carrying Amount of Monetary Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "bntx:CashAndCashEquivalent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "bntx:CashAndCashEquivalent",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
     "longName": "9954530 - Disclosure - Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Effect of Changes in foreign Exchange Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-558",
      "name": "bntx:ForeignCurrencyChangesEffectOnLossBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-558",
      "name": "bntx:ForeignCurrencyChangesEffectOnLossBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
     "longName": "9954531 - Disclosure - Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-565",
      "name": "bntx:InterestBearingLoansAndBorrowings",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails",
     "longName": "9954532 - Disclosure - Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)",
     "shortName": "Financial Assets and Financial Liabilities - Summary of Changes in Liabilities Arising From Financing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails",
     "longName": "9954533 - Disclosure - Inventories - Summary of Inventories (Details)",
     "shortName": "Inventories - Summary of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.biontech.de/role/InventoriesAdditionalInformationDetails",
     "longName": "9954534 - Disclosure - Inventories - Additional Information (Details)",
     "shortName": "Inventories - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InventoryWritedown2011",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails",
     "longName": "9954535 - Disclosure - Other Non-Financial Assets - Summary of Other Assets (Details)",
     "shortName": "Other Non-Financial Assets - Summary of Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "bntx:DeferredExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails",
     "longName": "9954536 - Disclosure - Other Non-Financial Assets - Additional Information (Details)",
     "shortName": "Other Non-Financial Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "bntx:DeferredExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-590",
      "name": "bntx:DeferredExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
     "longName": "9954537 - Disclosure - Issued Capital and Reserves - Additional Information (Details)",
     "shortName": "Issued Capital and Reserves - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails",
     "longName": "9954538 - Disclosure - Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)",
     "shortName": "Issued Capital and Reserves - Share Repurchase Program Authorized Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-610",
      "name": "bntx:ShareRepurchaseProgramAuthorizedAmount",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-616",
      "name": "bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
     "longName": "9954539 - Disclosure - Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)",
     "shortName": "Share-Based Payments - Summary of Expense Recognized for Employee Services Received (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
     "longName": "9954540 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bntx:ShareBasedPaymentsClassifiedAsOperatingActivities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:CashOutflowToTaxAuthority",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
     "longName": "9954541 - Disclosure - Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)",
     "shortName": "Share-Based Payments - Reconciliation of Outstanding Share-Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-672",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-676",
      "name": "ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
     "longName": "9954542 - Disclosure - Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)",
     "shortName": "Share-Based Payments - Summary of Inputs Used in Measurement of Fair Value at Grant Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-694",
      "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-694",
      "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
     "longName": "9954543 - Disclosure - Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)",
     "shortName": "Share-Based Payments -Schedule of Number and Weighted-Average Exercise Price of Share Options Allocated and Expected to be Allocated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-711",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-715",
      "name": "bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.biontech.de/role/ProvisionsProvisionsDetails",
     "longName": "9954544 - Disclosure - Provisions - Provisions (Details)",
     "shortName": "Provisions - Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:LegalProceedingsProvision",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Provisions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails",
     "longName": "9954545 - Disclosure - Provisions - Additional Information (Details)",
     "shortName": "Provisions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:LegalProceedingsProvision",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfProvisionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bntx:CurrentOnerousContractsProvisionAdditions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails",
     "longName": "9954546 - Disclosure - Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details)",
     "shortName": "Contingencies and other financial commitments - Schedule of Other Financial Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails",
     "longName": "9954547 - Disclosure - Contingencies and other financial commitments - Additional Information (Details)",
     "shortName": "Contingencies and other financial commitments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCommitmentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R107": {
     "role": "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails",
     "longName": "9954548 - Disclosure - Other Non-Financial Liabilities - Summary of Other Liabilities (Details)",
     "shortName": "Other Non-Financial Liabilities - Summary of Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "bntx:LiabilitiesForEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "bntx:LiabilitiesForEmployeeBenefits",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
     "longName": "9954549 - Disclosure - Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)",
     "shortName": "Leases - Summary of Right-of-Use Assets within Consolidated Statements of Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-754",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.biontech.de/role/LeasesAdditionalInformationDetails",
     "longName": "9954550 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails",
     "longName": "9954551 - Disclosure - Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)",
     "shortName": "Leases - Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
     "longName": "9954552 - Disclosure - Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details)",
     "shortName": "Leases - summary of Amounts Recognized in Consolidated Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
     "longName": "9954553 - Disclosure - Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)",
     "shortName": "Related Party Disclosures - Summary of Compensation of Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
     "longName": "9954554 - Disclosure - Related Party Disclosures - Additional Information (Details)",
     "shortName": "Related Party Disclosures - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
     "longName": "9954555 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)",
     "shortName": "Related Party Disclosures - Summary of Transactions Between Related Parties Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-780",
      "name": "bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-780",
      "name": "bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails",
     "longName": "9954556 - Disclosure - Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)",
     "shortName": "Related Party Disclosures - Summary of Transactions Between Related Parties Outstanding Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-786",
      "name": "ifrs-full:AmountsPayableRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-786",
      "name": "ifrs-full:AmountsPayableRelatedPartyTransactions",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails",
     "longName": "9954557 - Disclosure - Events After the Reporting Period - Additional Information (Details)",
     "shortName": "Events After the Reporting Period - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-145",
      "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-788",
      "name": "bntx:PurchaseOfSharesUnderAgreement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bntx-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AT",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Austria",
        "label": "AUSTRIA"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ATHOSKGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ATHOSKGMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATHOS KG",
        "label": "ATHOSKG [Member]",
        "documentation": "ATHOSKG"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ATImpfGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ATImpfGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AT Impf GmbH",
        "label": "AT Impf GmbH [Member]",
        "documentation": "AT Impf GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]",
        "label": "Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]",
        "documentation": "Accounting Policies, Changes In Accounting Estimates And Errors [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement derivative",
        "label": "Accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss. [Refer: Derivatives [member]; Increase (decrease) in fair value of financial assets designated as measured at fair value through profit or loss related credit derivatives or similar instruments; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "bntx_AccumulatedDepreciationAmortisationAndImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccumulatedDepreciationAmortisationAndImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization",
        "label": "Accumulated Depreciation, Amortisation And Impairment",
        "documentation": "Accumulated Depreciation, Amortisation And Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative depreciation and impairment charges",
        "label": "Accumulated depreciation, amortisation and impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r69",
      "r114",
      "r123",
      "r126"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "bntx_AccumulatedTaxLossesInCorporateTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccumulatedTaxLossesInCorporateTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax",
        "label": "Accumulated Tax Losses In Corporate Tax",
        "documentation": "Accumulated Tax Losses In Corporate Tax"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AccumulatedTaxLossesInFederalTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccumulatedTaxLossesInFederalTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax credits",
        "label": "Accumulated Tax Losses In Federal Tax Credits",
        "documentation": "Accumulated Tax Losses In Federal Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AccumulatedTaxLossesInStateTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccumulatedTaxLossesInStateTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax credits",
        "label": "Accumulated Tax Losses In State Tax Credits",
        "documentation": "Accumulated Tax Losses In State Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AccumulatedTaxLossesInTradeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AccumulatedTaxLossesInTradeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofAccumulatedTaxLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade tax",
        "label": "Accumulated Tax Losses In Trade Tax",
        "documentation": "Accumulated Tax Losses In Trade Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration",
        "label": "Acquisition-date fair value of total consideration transferred [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of subsidiaries and businesses",
        "label": "Acquisitions through business combinations, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of subsidiaries and businesses",
        "label": "Acquisitions through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional provisions, other provisions",
        "label": "Additional provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to right-of-use assets",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment prior year taxes",
        "label": "Adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease / (increase) in inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "bntx_AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease / (increase) in trade and other receivables, contract assets and other assets",
        "label": "Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets",
        "documentation": "Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance expense excluding foreign exchange differences",
        "label": "Adjustments for finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance income excluding foreign exchange differences",
        "label": "Adjustments for finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property, plant and equipment",
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "bntx_AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions",
        "label": "Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions",
        "documentation": "Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AdjustmentsForMovementsInGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AdjustmentsForMovementsInGovernmentGrants",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movements in government grants",
        "label": "Adjustments For Movements In Government Grants",
        "documentation": "Adjustments For Movements In Government Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile profit before tax to net cash flows:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment expenses",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange differences",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r355",
      "r434"
     ]
    },
    "bntx_AdvancePaymentReceivedForFutureCOVID19VaccineSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AdvancePaymentReceivedForFutureCOVID19VaccineSale",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payment received for future COVID 19 vaccine sale",
        "label": "Advance Payment Received For Future COVID-19 Vaccine Sale",
        "documentation": "Advance Payment Received For Future COVID-19 Vaccine Sale"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AdvancePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AdvancePaymentsMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payments",
        "label": "Advance Payments [Member]",
        "documentation": "Advance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated measurement [member]",
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r125",
      "r161"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r176",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r200",
      "r235",
      "r336",
      "r375",
      "r377"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All levels of fair value hierarchy [member]",
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r162"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares, each Representing one ordinary share",
        "label": "American Depositary Shares Each Representing One Ordinary Share [Member]",
        "documentation": "American Depositary Shares Each Representing One Ordinary Share"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AmortizedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AmortizedCostMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AC",
        "label": "Amortized Cost [Member]",
        "documentation": "Amortized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsPayableRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Amounts payable, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r89"
     ]
    },
    "ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Announcement Of Research, Development And Commercialization Collaboration Agreement",
        "label": "Announcement Of Research, Development And Commercialization Collaboration Agreement [Member]",
        "documentation": "Announcement Of Research, Development And Commercialization Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory tax rate (as a percent)",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r161",
      "r162",
      "r165",
      "r260",
      "r262"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AssetsAcquiredLiabilitiesAssumedIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Assets Acquired (Liabilities Assumed), Including Goodwill",
        "documentation": "Assets Acquired (Liabilities Assumed), Including Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_AssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets Recognised As Of Acquisition Date",
        "documentation": "Assets Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r125",
      "r161"
     ]
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attribution of expenses by nature to their function [axis]",
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r411"
     ]
    },
    "bntx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.biontech.de/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.biontech.de/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.biontech.de/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax with average rate (as a percent)",
        "verboseLabel": "Effective tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average rate",
        "label": "Average foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "country_BE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BE",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Belgium",
        "label": "BELGIUM"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BankDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BankDepositsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank deposits",
        "label": "Bank Deposits [Member]",
        "documentation": "Bank Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings for the period per share (in euros per share)",
        "verboseLabel": "Basic profit for the period per share (in euros per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsPerShareAbstract",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BioNTech Restricted Stock Unit Plan for North America Employees",
        "terseLabel": "BioNTech 2020 Restricted Stock Unit Plan For North America Employees",
        "label": "BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member]",
        "documentation": "BioNTech 2020 Restricted Stock Unit Plan For North America Employees"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechAustraliaPtyLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechAustraliaPtyLtd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Australia Pty Ltd.",
        "label": "BioNTech Australia Pty Ltd. [Member]",
        "documentation": "BioNTech Australia Pty Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechBioNTainerHoldingGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechBioNTainerHoldingGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech BioNTainer Holding GmbH",
        "label": "BioNTech BioNTainer Holding GmbH [Member]",
        "documentation": "BioNTech BioNTainer Holding GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechCellGeneTherapiesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechCellGeneTherapiesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Cell &amp; Gene Therapies GmbH",
        "label": "BioNTech Cell &amp; Gene Therapies GmbH [Member]",
        "documentation": "BioNTech Cell &amp; Gene Therapies GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechDeliveryTechnologiesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechDeliveryTechnologiesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Delivery Technologies GmbH",
        "label": "BioNTech Delivery Technologies GmbH [Member]",
        "documentation": "BioNTech Delivery Technologies GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechDeliveryTechnologiesUSLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechDeliveryTechnologiesUSLLCMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Delivery Technologies (US), LLC",
        "label": "BioNTech Delivery Technologies (US), LLC [Member]",
        "documentation": "BioNTech Delivery Technologies (US), LLC"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechDiagnosticsGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechDiagnosticsGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Diagnostics GmbH",
        "label": "BioNTech Diagnostics GmbH [Member]",
        "documentation": "BioNTech Diagnostics GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech 2020 Employee Equity Plan for Employees Based Outside North America",
        "label": "BioNTech Employee Equity Plan For Employees Based In Europe [Member]",
        "documentation": "BioNTech Employee Equity Plan For Employees Based In Europe"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechEuropeGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechEuropeGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Europe GmbH",
        "label": "BioNTech Europe GmbH [Member]",
        "documentation": "BioNTech Europe GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechIdarObersteinServicesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechIdarObersteinServicesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Idar-Oberstein Services GmbH",
        "label": "BioNTech Idar-Oberstein Services GmbH [Member]",
        "documentation": "BioNTech Idar-Oberstein Services GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechIndividualizedMRNAManufacturingGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechIndividualizedMRNAManufacturingGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Individualized mRNA Manufacturing GmbH",
        "label": "BioNTech Individualized mRNA Manufacturing GmbH [Member]",
        "documentation": "BioNTech Individualized mRNA Manufacturing GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechInnovationAndServicesMarburgGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechInnovationAndServicesMarburgGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Innovation and Services Marburg GmbH",
        "label": "BioNTech Innovation and Services Marburg GmbH [Member]",
        "documentation": "BioNTech Innovation and Services Marburg GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechInnovationGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechInnovationGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Innovation GmbH",
        "label": "BioNTech Innovation GmbH [Member]",
        "documentation": "BioNTech Innovation GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechInnovativeManufacturingServicesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechInnovativeManufacturingServicesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Innovative Manufacturing Services GmbH",
        "label": "BioNTech Innovative Manufacturing Services GmbH [Member]",
        "documentation": "BioNTech Innovative Manufacturing Services GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechManufacturingGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechManufacturingGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Manufacturing GmbH",
        "label": "BioNTech Manufacturing GmbH [Member]",
        "documentation": "BioNTech Manufacturing GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechManufacturingMarburgGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechManufacturingMarburgGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Manufacturing Marburg GmbH",
        "label": "BioNTech Manufacturing Marburg GmbH [Member]",
        "documentation": "BioNTech Manufacturing Marburg GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech",
        "label": "BioNTech [Member]",
        "documentation": "BioNTech"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.",
        "label": "BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member]",
        "documentation": "BioNTech Pharmaceuticals Asia Pacific Pte. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechPharmaceuticalsSpainS.LMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechPharmaceuticalsSpainS.LMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Pharmaceuticals Spain S.L",
        "label": "BioNTech Pharmaceuticals Spain S.L [Member]",
        "documentation": "BioNTech Pharmaceuticals Spain S.L"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechRDAustriaGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechRDAustriaGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech R&amp;D (Austria) GmbH",
        "label": "BioNTech R&amp;D (Austria) GmbH [Member]",
        "documentation": "BioNTech R&amp;D (Austria) GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechRealEstateHoldingGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechRealEstateHoldingGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Real Estate Holding GmbH",
        "label": "BioNTech Real Estate Holding GmbH [Member]",
        "documentation": "BioNTech Real Estate Holding GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechRealEstateVerwaltungsGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechRealEstateVerwaltungsGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Real Estate Verwaltungs GmbH",
        "label": "BioNTech Real Estate Verwaltungs GmbH [Member]",
        "documentation": "BioNTech Real Estate Verwaltungs GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechResearchAndDevelopmentInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechResearchAndDevelopmentInc.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Research and Development, Inc.",
        "label": "BioNTech Research and Development, Inc. [Member]",
        "documentation": "BioNTech Research and Development, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechRwandaLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechRwandaLtd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Rwanda Ltd.",
        "label": "BioNTech Rwanda Ltd. [Member]",
        "documentation": "BioNTech Rwanda Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechSenegalSuarlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechSenegalSuarlMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech S\u00e9n\u00e9gal Suarl",
        "label": "BioNTech S\u00e9n\u00e9gal Suarl [Member]",
        "documentation": "BioNTech S\u00e9n\u00e9gal Suarl"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechShanghaiPharmaceuticalsCo.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechShanghaiPharmaceuticalsCo.Ltd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech (Shanghai) Pharmaceuticals Co. Ltd.",
        "label": "BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member]",
        "documentation": "BioNTech (Shanghai) Pharmaceuticals Co. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechSwitzerlandGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechSwitzerlandGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Switzerland GmbH",
        "label": "BioNTech Switzerland GmbH [Member]",
        "documentation": "BioNTech Switzerland GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechTaiwanCo.Ltd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechTaiwanCo.Ltd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Taiwan Co. Ltd.",
        "label": "BioNTech Taiwan Co. Ltd. [Member]",
        "documentation": "BioNTech Taiwan Co. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech Turkey T\u0131bbi \u00dcr\u00fcnler Ve Klinik Ara\u015ftirma Ticaret Anonim \u015eirketi",
        "label": "BioNTech Turkey T\u0131bbi \u00dcr\u00fcnler Ve Klinik Ara\u015ftirma Ticaret Anonim \u015eirketi [Member]",
        "documentation": "BioNTech Turkey T\u0131bbi \u00dcr\u00fcnler Ve Klinik Ara\u015ftirma Ticaret Anonim \u015eirketi"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechUKLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechUKLtd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech UK Ltd.",
        "label": "BioNTech UK Ltd. [Member]",
        "documentation": "BioNTech UK Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechUSAHoldingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechUSAHoldingLLCMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech USA Holding, LLC",
        "label": "BioNTech USA Holding, LLC [Member]",
        "documentation": "BioNTech USA Holding, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BioNTechUSInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BioNTechUSInc.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioNTech US Inc.",
        "label": "BioNTech US Inc. [Member]",
        "documentation": "BioNTech US Inc."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BiopharmaBioNTechIsraelLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BiopharmaBioNTechIsraelLtd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biopharma BioNTech Israel Ltd.",
        "label": "Biopharma BioNTech Israel Ltd. [Member]",
        "documentation": "Biopharma BioNTech Israel Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_BiotheusIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BiotheusIncMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biotheus Inc.,",
        "label": "Biotheus Inc., [Member]",
        "documentation": "Biotheus Inc.,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r194",
      "r211",
      "r360",
      "r362",
      "r443"
     ]
    },
    "ifrs-full_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BuildingsMember",
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "bntx_BusinessCombinations1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "BusinessCombinations1Abstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations 1 [Abstract]",
        "documentation": "Business Combinations 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations [axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "bntx_CGUImmunotherapiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CGUImmunotherapiesMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CGU Immunotherapies",
        "label": "CGU Immunotherapies [Member]",
        "documentation": "CGU Immunotherapies"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_COVID19VaccineDirectProductSalesToCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "COVID19VaccineDirectProductSalesToCustomersMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct product sales to customers",
        "label": "COVID-19 Vaccine, Direct Product Sales To Customers [Member]",
        "documentation": "COVID-19 Vaccine, Direct Product Sales To Customers"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_COVID19VaccineRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "COVID19VaccineRevenuesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 vaccine revenues",
        "label": "COVID-19 Vaccine Revenues [Member]",
        "documentation": "COVID-19 Vaccine Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_COVID19VaccineSalesToCollaborationPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "COVID19VaccineSalesToCollaborationPartnersMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales to collaboration partners",
        "label": "COVID-19 Vaccine, Sales To Collaboration Partners [Member]",
        "documentation": "COVID-19 Vaccine, Sales To Collaboration Partners"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of collaboration partners\u2019 gross profit and sales milestones",
        "label": "COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones [Member]",
        "documentation": "COVID-19 Vaccine, Share Of Collaboration Partners' Gross Profit And Sales Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of collaboration partners' sales milestones",
        "label": "COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones [Member]",
        "documentation": "COVID-19 Vaccine, Share Of Collaboration Partners' Sales Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve",
        "label": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_CapitalReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalReserveMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital reserve",
        "label": "Capital reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalisationRateOfBorrowingCostsEligibleForCapitalisation",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average cost of capital (as a percent)",
        "label": "Capitalisation rate of borrowing costs eligible for capitalisation"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average of interest and other costs that an entity incurs in connection with the borrowing of funds applicable to the borrowings of the entity that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying asset. [Refer: Weighted average [member]; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r65",
      "r114",
      "r116",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r227",
      "r241",
      "r242"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r116",
      "r122",
      "r124",
      "r125",
      "r227",
      "r241",
      "r242"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at banks and on hand",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "bntx_CashAndCashEquivalent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashAndCashEquivalent",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Cash And Cash Equivalent",
        "documentation": "Cash And Cash Equivalent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "periodEndLabel": "Cash and cash equivalents as of December 31",
        "totalLabel": "Total",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r136",
      "r153"
     ]
    },
    "bntx_CashAndCashEquivalents1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashAndCashEquivalents1LineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents [Line Items]",
        "label": "Cash And Cash Equivalents 1 [Line Items]",
        "documentation": "Cash And Cash Equivalents 1"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CashAndCashEquivalents1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashAndCashEquivalents1Member",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents in U.S. dollar",
        "label": "Cash And Cash Equivalents 1 [Member]",
        "documentation": "Cash And Cash Equivalents 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "bntx_CashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashAndCashEquivalentsTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents [Table]",
        "label": "Cash And Cash Equivalents [Table]",
        "documentation": "Cash And Cash Equivalents [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CashAtBanksAndOnHandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashAtBanksAndOnHandMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at banks and on hand",
        "label": "Cash At Banks And On Hand [Member]",
        "documentation": "Cash At Banks And On Hand"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "bntx_CashFlowProjectionsMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashFlowProjectionsMeasurementInputMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow projections",
        "label": "Cash Flow Projections, Measurement Input [Member]",
        "documentation": "Cash Flow Projections, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from / (used in) financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r138"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r138"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r138"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of subsidiaries and businesses, net of cash acquired",
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash outflow for leases",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "bntx_CashOutflowForShareBasedPaymentArrangementExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashOutflowForShareBasedPaymentArrangementExercise",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash outflow for share based payment exercise",
        "label": "Cash Outflow For Share Based Payment Arrangement Exercise",
        "documentation": "Cash Outflow For Share Based Payment Arrangement Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CashOutflowToTaxAuthority": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashOutflowToTaxAuthority",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash outflow to tax authority",
        "label": "Cash Outflow To Tax Authority",
        "documentation": "Cash Outflow To Tax Authority"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CashSettledShareBasedPaymentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CashSettledShareBasedPaymentArrangementMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-Settled Share-Based Payment Arrangement",
        "label": "Cash-Settled Share-Based Payment Arrangement [Member]",
        "documentation": "Cash-Settled Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid",
        "label": "Cash transferred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of related parties [axis]",
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "bntx_ChiefExecutiveOfficerGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ChiefExecutiveOfficerGrantMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer Grant",
        "label": "Chief Executive Officer Grant [Member]",
        "documentation": "Chief Executive Officer Grant"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r167",
      "r187"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [member]",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r167",
      "r187"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r248",
      "r249",
      "r266",
      "r267"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r243",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments, class",
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r243",
      "r245",
      "r246"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r266",
      "r267"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets and goodwill [axis]",
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.biontech.de/role/Cover",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.biontech.de/role/Cover",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Closing rate",
        "label": "Closing foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "bntx_CommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CommercialMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial revenues",
        "label": "Commercial [Member]",
        "documentation": "Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax",
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income for the period, net of tax",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r40",
      "r142",
      "r144",
      "r151",
      "r357"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "bntx_ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concessions, licenses, in-process R&amp;D and similar rights",
        "label": "Concessions, Licenses, In-Process Research And Development And Similar Rights [Member]",
        "documentation": "Concessions, Licenses, In-Process Research And Development And Similar Rights"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ConsideredRemunerationOfPotentialEarnOutPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ConsideredRemunerationOfPotentialEarnOutPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Considered remuneration of potential earn-out payments",
        "label": "Considered Remuneration Of Potential Earn-out Payments",
        "documentation": "Considered Remuneration Of Potential Earn-out Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ConsolidatedStructuredEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConsolidatedStructuredEntitiesAxis",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated structured entities [axis]",
        "label": "Consolidated structured entities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "bntx_ConstructionInProgressAndAdvancePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ConstructionInProgressAndAdvancePaymentsMember",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress and advance payments",
        "label": "Construction In Progress And Advance Payments [Member]",
        "documentation": "Construction In Progress And Advance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Email Address",
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Fax Number",
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ContingenciesAndOtherFinancialCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ContingenciesAndOtherFinancialCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies And Other Financial Commitments [Abstract]",
        "label": "Contingencies And Other Financial Commitments [Abstract]",
        "documentation": "Contingencies And Other Financial Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent consideration [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an obligation of the acquirer to transfer additional assets or equity interests to the former owners of an acquiree as part of the exchange for control of the acquiree if specified future events occur or conditions are met."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration",
        "label": "Contingent consideration recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentLiabilitiesRecognisedInBusinessCombination",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent liabilities recognised in business combination"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_ContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity\u2019s future performance)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172"
     ]
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "verboseLabel": "Total",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172"
     ]
    },
    "bntx_ContractLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ContractLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract Liabilities [Member]",
        "documentation": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractualCapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Contractual capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractualCommitmentsForAcquisitionOfIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual obligation to acquire intangible assets",
        "label": "Contractual commitments for acquisition of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments under purchase agreements for property, plant and equipment",
        "label": "Contractual commitments for acquisition of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "bntx_ConvertibleNoteEmbeddedDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ConvertibleNoteEmbeddedDerivativeMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note \u2013 embedded derivative",
        "label": "Convertible Note, Embedded Derivative [Member]",
        "documentation": "Convertible Note, Embedded Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CorporateTaxRate",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate (as a percent)",
        "label": "Corporate Tax Rate",
        "documentation": "Corporate Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of inventories",
        "label": "Cost of inventories recognised as expense during period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of sales",
        "terseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r46"
     ]
    },
    "ifrs-full_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of sales [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of all expenses directly or indirectly attributed to goods or services sold. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r411"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r278",
      "r279",
      "r286",
      "r382",
      "r384"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r256"
     ]
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments related to CRO and CMO contracts",
        "label": "Current advances to suppliers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "bntx_CurrentAndDeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentAndDeferredTaxExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current and deferred taxes",
        "label": "Current And Deferred Tax Expense (Income)",
        "documentation": "Current And Deferred Tax Expense (Income)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r147",
      "r357"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "bntx_CurrentLeaseLiabilitiesLoansAndBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentLeaseLiabilitiesLoansAndBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, loans and borrowings",
        "label": "Current Lease Liabilities, Loans And Borrowings",
        "documentation": "Current Lease Liabilities, Loans And Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r149",
      "r357"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentObligationsUnderLeaseContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentObligationsUnderLeaseContractsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current obligations under lease contracts",
        "label": "Current Obligations Under Lease Contracts [Member]",
        "documentation": "Current Obligations Under Lease Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentOnerousContractsProvisionAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentOnerousContractsProvisionAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current onerous provision addition",
        "label": "Current Onerous Contracts Provision, Additions",
        "documentation": "Current Onerous Contracts Provision, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentOnerousContractsProvisionOtherAdditionalProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentOnerousContractsProvisionOtherAdditionalProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other additional provisions",
        "label": "Current Onerous Contracts Provision, Other Additional Provisions",
        "documentation": "Current Onerous Contracts Provision, Other Additional Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentOnerousContractsProvisionRelatedToRelease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentOnerousContractsProvisionRelatedToRelease",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision related to release",
        "label": "Current Onerous Contracts Provision, Related To Release",
        "documentation": "Current Onerous Contracts Provision, Related To Release"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related to release and consumption",
        "label": "Current Onerous Contracts Provision, Related To Release And Consumption",
        "documentation": "Current Onerous Contracts Provision, Related To Release And Consumption"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_CurrentOnerousContractsProvisionRelatedToUsage": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "CurrentOnerousContractsProvisionRelatedToUsage",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision related to usage",
        "label": "Current Onerous Contracts Provision, Related To Usage",
        "documentation": "Current Onerous Contracts Provision, Related To Usage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Total current",
        "label": "Current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRawMaterialsAndCurrentProductionSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials and supplies",
        "label": "Current raw materials and current production supplies"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]"
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "ifrs-full_CurrentRefundsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRefundsProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liabilities",
        "label": "Current refunds provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax assets",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income taxes",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax liabilities",
        "label": "Current tax liabilities, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_CurrentTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax liabilities",
        "label": "Current tax liabilities, non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328"
     ]
    },
    "ifrs-full_CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer-related intangible assets recognised as of acquisition date",
        "label": "Customer-related intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for customer-related intangible assets acquired in a business combination. [Refer: Customer-related intangible assets [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DecreaseInCorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DecreaseInCorporateTaxRate",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in corporate tax rate (as a percent)",
        "label": "Decrease In Corporate Tax Rate",
        "documentation": "Decrease In Corporate Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value with decreasing input factor (in millions \u20ac)",
        "label": "Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of decrease in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "bntx_DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits",
        "label": "Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits [Member]",
        "documentation": "Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DeepChainTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DeepChainTechnologyMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DeepChain Technology",
        "label": "DeepChain Technology [Member]",
        "documentation": "DeepChain Technology"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DeferredExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred expenses",
        "label": "Deferred Expense",
        "documentation": "Deferred Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24",
      "r54"
     ]
    },
    "bntx_DeferredTaxAssetsSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DeferredTaxAssetsSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets settlement",
        "label": "Deferred Tax Assets Settlement",
        "documentation": "Deferred Tax Assets Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Deferred tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "bntx_DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized in OCI",
        "label": "Deferred Tax Expense (Income) Recognised In Other Comprehensive Income",
        "documentation": "Deferred Tax Expense (Income) Recognised In Other Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized in P&amp;L",
        "label": "Deferred tax expense (income) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r24",
      "r54"
     ]
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred tax liabilities recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax (assets) and liabilities, net recognized",
        "periodStartLabel": "Beginning balance deferred tax assets net",
        "periodEndLabel": "Ending balance deferred tax assets net",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized directly in equity",
        "label": "Deferred tax relating to items credited (charged) directly to equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "calculation": {
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails": {
       "parentTag": "bntx_LeaseExpensesRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total depreciation charge",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange forward contracts",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "bntx_DerivativeLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DerivativeLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivative Liabilities [Member]",
        "documentation": "Derivative Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange forward contracts",
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r358",
      "r361",
      "r373",
      "r379"
     ]
    },
    "bntx_DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current versus Non-Current Classifications",
        "label": "Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Assets And Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations and Goodwill",
        "label": "Description of accounting policy for business combinations and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for business combinations and goodwill. [Refer: Business combinations [member]; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDividendsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDividendsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Dividend",
        "label": "Description of accounting policy for dividends [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for dividends. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currencies",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Description of accounting policy for government grants [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Non-Financial Assets",
        "label": "Description of accounting policy for impairment of non-financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contracts with Customers",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Description of accounting policy for segment reporting [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "bntx_DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standards Issued but Not Yet Effective",
        "label": "Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Description of accounting policy for treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Standards Issued but Not Yet Effective",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Growth rate used to extrapolate cash flow projections (as a percent)",
        "label": "Growth rate used to extrapolate cash flow projections"
       }
      },
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Standards Applied for the First Time",
        "label": "Disclosure of initial application of standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_DescriptionOfSignificantPaymentTermsInContractsWithCustomers": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfSignificantPaymentTermsInContractsWithCustomers",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment terms in contracts with customers",
        "label": "Description of significant payment terms in contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the significant payment terms in contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "bntx_DesignatedFXHedge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DesignatedFXHedge",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated FX hedge",
        "label": "Designated FX-Hedge",
        "documentation": "Designated FX-Hedge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings for the period per share (in euros per share)",
        "verboseLabel": "Diluted profit for the period per share (in euros per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of dilution from share options (in shares)",
        "label": "Dilutive effect of share options on weighted average number of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Judgements, Estimates and Assumptions",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "bntx_DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standards Applied for the First Time",
        "label": "Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accumulated Tax Losses",
        "label": "Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Accumulated Tax Losses Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Consolidation",
        "label": "Disclosure of basis of consolidation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Disclosure of business combinations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "bntx_DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Cash Equivalents",
        "label": "Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Cash And Cash Equivalents Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inventories",
        "label": "Disclosure Of Classes Of Inventories Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Classes Of Inventories Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/Contingenciesandotherfinancialcommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies and other financial commitments",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Financial Commitments",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfCompositionOfGroupExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCompositionOfGroupExplanatory",
     "presentation": [
      "http://www.biontech.de/role/GroupInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group Information",
        "label": "Disclosure of composition of group [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Subsidiaries [member]; Parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesLineItems",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities [line items]",
        "label": "Disclosure of contingent liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesTable",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of contingent liabilities [table]",
        "label": "Disclosure of contingent liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to contingent liabilities."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "bntx_DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contract Balances",
        "label": "Disclosure Of Contract Balances From Contracts With Customers Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Contract Balances From Contracts With Customers Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfCorporateInformationExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfCorporateInformationExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Corporate Information Explanatory [Abstract]",
        "label": "Disclosure Of Corporate Information Explanatory [Abstract]",
        "documentation": "Disclosure Of Corporate Information Explanatory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfCorporateInformationExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfCorporateInformationExplanatoryTextBlock",
     "presentation": [
      "http://www.biontech.de/role/CorporateInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information",
        "label": "Disclosure Of Corporate Information Explanatory [Text Block]",
        "documentation": "Disclosure Of Corporate Information Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Current and Deferred Tax Expense",
        "label": "Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Current And Deferred Tax Expense Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Values of Identifiable Net Assets",
        "label": "Disclosure of detailed information about business combination [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "bntx_DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Employee Benefits Expense",
        "label": "Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Employee Benefits Expense Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Useful Lives Applied to the Group's Intangible Assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "bntx_DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Amounts Recognized in Consolidated Statement of Operations",
        "label": "Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings",
        "label": "Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Lease Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Assets",
        "label": "Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Assets Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Non-Financial Liabilities",
        "label": "Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentTables",
      "http://www.biontech.de/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Property, Plant and Equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Disaggregation of Revenues from Contracts with Customers",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per Share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Effect of Changes in Foreign Exchange Rates",
        "label": "Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesLineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]",
        "label": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]",
        "documentation": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfEffectOfChangesInForeignExchangeRatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]",
        "label": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]",
        "documentation": "Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information about Entity with Significant Influence Over Group",
        "label": "Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Entity With Significant Influence Over Group Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events After the Reporting Period",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "bntx_DisclosureOfFinanceCostExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfFinanceCostExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Finance Expense",
        "label": "Disclosure Of Finance Cost Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Finance Cost Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfFinanceIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfFinanceIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Finance Income",
        "label": "Disclosure Of Finance Income Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Finance Income Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [Line Items]",
        "label": "Disclosure Of Financial Assets And Liabilities [Line Items]",
        "documentation": "Disclosure Of Financial Assets And Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfFinancialAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [Table]",
        "label": "Disclosure Of Financial Assets And Liabilities [Table]",
        "documentation": "Disclosure Of Financial Assets And Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [line items]",
        "label": "Disclosure of financial assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial assets [table]",
        "label": "Disclosure of financial assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss",
        "terseLabel": "Summary of Financial Liabilities at Amortized Cost",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [line items]",
        "label": "Disclosure of financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of financial liabilities [table]",
        "label": "Disclosure of financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "bntx_DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Carrying Amount of Monetary Assets",
        "label": "Disclosure Of Foreign Currency Risk Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Foreign Currency Risk Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Goodwill Recognized",
        "label": "Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfIncomeAndExpenseExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfIncomeAndExpenseExplanatoryTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income and Expenses",
        "label": "Disclosure Of Income And Expense Explanatory [Text Block]",
        "documentation": "Disclosure Of Income And Expense Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfIncomeAndExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfIncomeAndExpensesLineItems",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Income And Expenses [Line Items]",
        "label": "Disclosure Of Income And Expenses [Line Items]",
        "documentation": "Disclosure Of Income And Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfIncomeAndExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfIncomeAndExpensesTable",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Income And Expenses [Table]",
        "label": "Disclosure Of Income And Expenses [Table]",
        "documentation": "Disclosure Of Income And Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.biontech.de/role/IncomeTax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inputs Used in Measurement of Fair Value at Grant Date",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Compensation of Key Management Personnel",
        "label": "Disclosure of information about key management personnel [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Intangible Assets and Goodwill",
        "label": "Disclosure of intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number and Share Price of Restricted Stock Units",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Number and Weighted-Average Exercise Price of Share Options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Financial Liabilities",
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Financial Assets",
        "label": "Disclosure of other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Non-Financial Liabilities",
        "label": "Disclosure of other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "bntx_DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Operating Expenses",
        "label": "Disclosure Of Other Operating Expenses Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Other Operating Expenses Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Operating Income",
        "label": "Disclosure Of Other Operating Income Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Other Operating Income Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of other provisions [line items]",
        "label": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPerformanceObligationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Contract Liabilities Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)",
        "label": "Disclosure of performance obligations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of performance obligations in contracts with customers. [Refer: Performance obligations [member]]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_DisclosureOfPerformanceObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsLineItems",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of performance obligations [line items]",
        "label": "Disclosure of performance obligations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPerformanceObligationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsTable",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of performance obligations [table]",
        "label": "Disclosure of performance obligations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to performance obligations in contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/Provisions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Disclosure of provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "bntx_DisclosureOfProvisionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfProvisionsTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/ProvisionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Provisions",
        "label": "Disclosure Of Provisions [Table Text Block]",
        "documentation": "Disclosure Of Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Right-of-Use Assets within Consolidated Statements of Financial Position",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]",
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "bntx_DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue Recognized",
        "label": "Disclosure Of Recognition Of Revenue Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Recognition Of Revenue Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Detailed Information About Intangible Assets",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillLineItems",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]",
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "bntx_DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit",
        "label": "Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Liabilities Arising from Financing Activities",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Disclosures",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_DisclosureOfReservesWithinEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReservesWithinEquityLineItems",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reserves within equity [line items]",
        "label": "Disclosure of reserves within equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReservesWithinEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReservesWithinEquityTable",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reserves within equity [table]",
        "label": "Disclosure of reserves within equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to reserves within equity."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from Contracts with Customers",
        "label": "Disclosure of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178"
     ]
    },
    "bntx_DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Useful Lives of the Assets or Shorter Lease Term",
        "label": "Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Capital and Reserves",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "bntx_DisclosureOfSharesRepurchaseProgramTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfSharesRepurchaseProgramTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Shares Repurchase Program",
        "label": "Disclosure of Shares Repurchase Program [Table Text Block]",
        "documentation": "Disclosure of Shares Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information about Parent Company",
        "label": "Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block]",
        "documentation": "Disclosure Of Significant Investments By Parent Company Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Information about Subsidiaries",
        "label": "Disclosure of subsidiaries [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [line items]",
        "label": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [table]",
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Unobservable Inputs Used in Fair Value Measurement",
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Taxes",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Transactions Between Other Related Parties",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [line items]",
        "label": "Disclosure of transactions between related parties [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of transactions between related parties [table]",
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DiscountRateMeasurementInputMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Discount rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ifrs-full_DisposalsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsIntangibleAssetsAndGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals",
        "label": "Disposals, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_DividendsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends",
        "label": "Dividends recognised as distributions to owners"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DividendsPaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends",
        "verboseLabel": "Dividends paid, classified as financing activities",
        "label": "Dividends paid, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid by the entity, classified as financing activities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proposed dividends per share (in euros per share)",
        "label": "Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "bntx_DoctorSierkPoettingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DoctorSierkPoettingMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sierk Poetting, Ph.D.",
        "label": "Doctor Sierk Poetting [Member]",
        "documentation": "Doctor Sierk Poetting"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_DualityBiologicsSuzhouCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "DualityBiologicsSuzhouCoLtdMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duality Biologics (Suzhou) Co. Ltd.,",
        "label": "Duality Biologics (Suzhou) Co. Ltd., [Member]",
        "documentation": "Duality Biologics (Suzhou) Co. Ltd.,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareLineItems",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [line items]",
        "label": "Earnings per share [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareTable",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [table]",
        "label": "Earnings per share [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in cash and cash equivalents resulting from exchange rate differences",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130"
     ]
    },
    "bntx_EffectOfOtherValuationChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EffectOfOtherValuationChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in cash and cash equivalents resulting from other valuation effects",
        "label": "Effect Of Other Valuation Changes On Cash And Cash Equivalents",
        "documentation": "Effect Of Other Valuation Changes On Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EffectiveExercisePriceMaximum": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EffectiveExercisePriceMaximum",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective exercise price maximum (in dollars per share)",
        "label": "Effective Exercise Price Maximum",
        "documentation": "Effective Exercise Price Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r46",
      "r325"
     ]
    },
    "bntx_EmployeeEquityPlanLongTermIncentive2020ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanLongTermIncentive2020ProgramMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LTI 2020 program",
        "label": "Employee Equity Plan, Long-Term Incentive 2020 Program [Member]",
        "documentation": "Employee Equity Plan, Long-Term Incentive 2020 Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeEquityPlanLongTermIncentive2021ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanLongTermIncentive2021ProgramMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LTI 2021 program",
        "label": "Employee Equity Plan, Long-Term Incentive 2021 Program [Member]",
        "documentation": "Employee Equity Plan, Long-Term Incentive 2021 Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeEquityPlanLongTermIncentive2022ProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanLongTermIncentive2022ProgramMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LTI 2022 program",
        "label": "Employee Equity Plan, Long-Term Incentive 2022 Program [Member]",
        "documentation": "Employee Equity Plan, Long-Term Incentive 2022 Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeEquityPlanLongTermIncentivePlusProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanLongTermIncentivePlusProgramMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LTI-plus program",
        "label": "Employee Equity Plan, Long-Term Incentive Plus Program [Member]",
        "documentation": "Employee Equity Plan, Long-Term Incentive Plus Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeEquityPlanLongTermIncentiveProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanLongTermIncentiveProgramMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LTI Program",
        "label": "Employee Equity Plan, Long-Term Incentive Program [Member]",
        "documentation": "Employee Equity Plan, Long-Term Incentive Program"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeEquityPlanMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Equity Plan",
        "label": "Employee Equity Plan [Member]",
        "documentation": "Employee Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeStockOptionPlanMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option Plan",
        "label": "Employee Stock Option Plan [Member]",
        "documentation": "Employee Stock Option Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeStockOwnershipPlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeStockOwnershipPlan2018Member",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Ownership Plan 2018",
        "label": "Employee Stock Ownership Plan 2018 [Member]",
        "documentation": "Employee Stock Ownership Plan 2018"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeStockOwnershipPlanESOPNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeStockOwnershipPlanESOPNameAxis",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "documentation": "Employee Stock Ownership Plan (ESOP) Name"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeStockOwnershipPlanESOPNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeStockOwnershipPlanESOPNameDomain",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Domain]",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Domain]",
        "documentation": "Employee Stock Ownership Plan (ESOP) Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EmployeeStockOwnershipPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EmployeeStockOwnershipPlanMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Ownership Plan",
        "label": "Employee Stock Ownership Plan [Member]",
        "documentation": "Employee Stock Ownership Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings [Line Items]",
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings [Table]",
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForAssociatesMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for associates [member]",
        "label": "Entity's total for associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r159"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for business combinations",
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r228"
     ]
    },
    "ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForConsolidatedStructuredEntitiesMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for consolidated structured entities [member]",
        "label": "Entity's total for consolidated structured entities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Consolidated structured entities' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for related parties",
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for subsidiaries [member]",
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r158"
     ]
    },
    "bntx_EquipmentToolsAndInstallationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EquipmentToolsAndInstallationsMember",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, tools and installations",
        "label": "Equipment, Tools And Installations [Member]",
        "documentation": "Equipment, Tools And Installations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity at beginning of period",
        "periodEndLabel": "Equity at end of period",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r33",
      "r141",
      "r143",
      "r161",
      "r162",
      "r165"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityInterestsOfAcquirer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityInterestsOfAcquirer",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares transferred (approx. 1.1 million shares)",
        "label": "Equity interests of acquirer"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "bntx_EquityMethodInvestmentsOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EquityMethodInvestmentsOwnershipPercentage",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment, ownership (as a percent)",
        "label": "Equity Method Investments, Ownership Percentage",
        "documentation": "Equity Method Investments, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EstimatedAllocationDateFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EstimatedAllocationDateFourMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated allocation date 2026",
        "label": "Estimated Allocation Date Four [Member]",
        "documentation": "Estimated Allocation Date Four"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EstimatedAllocationDateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EstimatedAllocationDateOneMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation date May 2023",
        "label": "Estimated Allocation Date One [Member]",
        "documentation": "Estimated Allocation Date One"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EstimatedAllocationDateThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EstimatedAllocationDateThreeMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated allocation date 2025",
        "label": "Estimated Allocation Date Three [Member]",
        "documentation": "Estimated Allocation Date Three"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EstimatedAllocationDateTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EstimatedAllocationDateTwoMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated allocation date 2024",
        "label": "Estimated Allocation Date Two [Member]",
        "documentation": "Estimated Allocation Date Two"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EstimatedMilestonePaymentToBeReceivedAtContractInception": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EstimatedMilestonePaymentToBeReceivedAtContractInception",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingJudgementsEstimatesandAssumptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated milestone payment to be received",
        "label": "Estimated Milestone Payment To Be Received At Contract Inception",
        "documentation": "Estimated Milestone Payment To Be Received At Contract Inception"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EuropeanCommissionToCollaborationPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EuropeanCommissionToCollaborationPartnerMember",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "European Commission To Collaboration Partner",
        "label": "European Commission To Collaboration Partner [Member]",
        "documentation": "European Commission To Collaboration Partner"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_EventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "EventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events After Reporting Period [Abstract]",
        "label": "Events After Reporting Period [Abstract]",
        "documentation": "Events After Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ExerciseOfOptionRightsMinimumStrikePricePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExerciseOfOptionRightsMinimumStrikePricePercent",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum strike price (as a percent)",
        "label": "Exercise Of Option Rights, Minimum Strike Price Percent",
        "documentation": "Exercise Of Option Rights, Minimum Strike Price Percent"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price in translation for IPO (in dollar per share and euro per share)",
        "label": "Exercise Price Currency Translation Of Public Offering Price Per Share",
        "documentation": "Exercise Price Currency Translation Of Public Offering Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ExercisePricePhantomOptionsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExercisePricePhantomOptionsGranted",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of phantom options granted (in euro per share)",
        "label": "Exercise Price, Phantom Options Granted",
        "documentation": "Exercise Price, Phantom Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in euros per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense / (Income) arising from cash-settled share-based payment arrangements",
        "label": "Expense from cash-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from cash-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails": {
       "parentTag": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense arising from equity-settled share-based payment arrangements",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash outflow",
        "label": "Expense from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bad debt expense has been recognized",
        "label": "Expense recognised during period for bad and doubtful debts for related party transaction"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised during the period in respect of bad or doubtful debts due from related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "bntx_ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails": {
       "parentTag": "bntx_LeaseExpensesRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense related to short-term leases and leases of low-value assets",
        "label": "Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used",
        "documentation": "Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Expense Recognized for Employee Services Received",
        "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "bntx_ExternalBusinessOfInstaDeepMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExternalBusinessOfInstaDeepMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Business of InstaDeep",
        "label": "External Business of InstaDeep [Member]",
        "documentation": "External Business of InstaDeep"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ExternalProductSalesToJPTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ExternalProductSalesToJPTMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Product Sales of JPT",
        "label": "External Product Sales To JPT [Member]",
        "documentation": "External Product Sales To JPT"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments of financial instruments measured at fair value",
        "label": "Fair Value Adjustments Of Financial Instruments Measured At Fair Value",
        "documentation": "Fair Value Adjustments Of Financial Instruments Measured At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_FairValueThroughOCIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FairValueThroughOCIMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FVTOCI",
        "label": "Fair Value Through OCI [Member]",
        "documentation": "Fair Value Through OCI"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_FairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FairValueThroughProfitOrLossMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FVTPL",
        "label": "Fair Value Through Profit Or Loss [Member]",
        "documentation": "Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_FederalCorporateIncomeTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FederalCorporateIncomeTax",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal corporate income tax (as a percent)",
        "label": "Federal Corporate Income Tax",
        "documentation": "Federal Corporate Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_FederalDeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FederalDeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax losses",
        "label": "Federal Deferred Tax Assets Operating Loss Carryforwards",
        "documentation": "Federal Deferred Tax Assets Operating Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance expenses",
        "totalLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "totalLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "bntx_FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments of financial instruments measured at fair value",
        "label": "Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value",
        "documentation": "Finance Income, Fair Value Adjustments Of Financial Instruments Measured At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r237",
      "r241",
      "r242",
      "r245",
      "r372"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets at amortised cost, category",
        "label": "Financial assets at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial assets at fair value through other comprehensive income, category",
        "netLabel": "Net gain on equity instruments designated at fair value through other comprehensive income",
        "label": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, category",
        "label": "Financial assets, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class",
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r248",
      "r249",
      "r266",
      "r267"
     ]
    },
    "ifrs-full_FinancialAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets - current",
        "label": "Financial assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for financial assets acquired in a business combination. [Refer: Financial assets; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370"
     ]
    },
    "bntx_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial liabilities",
        "totalLabel": "Financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, category",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "bntx_FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Liabilities at Fair Value Through Other Comprehensive Income, Category",
        "label": "Financial Liabilities At Fair Value Through Other Comprehensive Income, Category [Member]",
        "documentation": "Financial Liabilities At Fair Value Through Other Comprehensive Income, Category"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, category [member]",
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, class",
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r266",
      "r267"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r424"
     ]
    },
    "bntx_FixedAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "FixedAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Fixed Assets [Member]",
        "documentation": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ForeignCurrencyChangesEffectOnLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ForeignCurrencyChangesEffectOnLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on profit / (loss) before tax",
        "label": "Foreign Currency Changes Effect On Loss, Before Tax",
        "documentation": "Foreign Currency Changes Effect On Loss, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ForeignCurrencyChangesEffectOnPretaxEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ForeignCurrencyChangesEffectOnPretaxEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on pre-tax equity",
        "label": "Foreign Currency Changes Effect On Pretax Equity",
        "documentation": "Foreign Currency Changes Effect On Pretax Equity"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ForeignExchangeDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ForeignExchangeDifferencesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange differences, net",
        "label": "Foreign Exchange Differences [Member]",
        "documentation": "Foreign Exchange Differences"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derivative instruments at fair value through profit or loss",
        "label": "Gain On Derivative Instruments At Fair Value Through Profit Or Loss [Member]",
        "documentation": "Gain On Derivative Instruments At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net (gain) / loss on derivative instruments at fair value through profit or loss",
        "label": "Gains (losses) on financial liabilities at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial liabilities at fair value through profit or loss. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "bntx_GeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "GeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expenses [Member]",
        "documentation": "General And Administrative Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_GermanFederalMinistryOfHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "GermanFederalMinistryOfHealthMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "German Federal Ministry of Health",
        "label": "German Federal Ministry of Health [Member]",
        "documentation": "German Federal Ministry of Health"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods and services transferred at a point in time",
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goods and services transferred over time",
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails": {
       "parentTag": "bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r103",
      "r107",
      "r227"
     ]
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill from the acquisition",
        "label": "Goodwill recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370"
     ]
    },
    "bntx_GovernmentGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "GovernmentGrantsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants",
        "label": "Government Grants [Member]",
        "documentation": "Government Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r114",
      "r123",
      "r126",
      "r227",
      "r242",
      "r245",
      "r372"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments [axis]",
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r236"
     ]
    },
    "ifrs-full_HedgingInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging instruments",
        "label": "Hedging instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r236"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ]
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsAcquiredLiabilitiesAssumedIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets at fair value",
        "label": "Identifiable assets acquired (liabilities assumed)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370"
     ]
    },
    "bntx_IncomeAndExpensesByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncomeAndExpensesByNatureAxis",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income And Expenses By Nature [Axis]",
        "label": "Income And Expenses By Nature [Axis]",
        "documentation": "Income And Expenses By Nature"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IncomeAndExpensesByNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncomeAndExpensesByNatureDomain",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income And Expenses By Nature [Domain]",
        "label": "Income And Expenses By Nature [Domain]",
        "documentation": "Income And Expenses By Nature [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeTaxSummaryofCurrentandDeferredTaxExpenseDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes",
        "terseLabel": "Income taxes",
        "totalLabel": "Income taxes",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r49",
      "r51",
      "r52",
      "r91",
      "r157",
      "r259"
     ]
    },
    "bntx_IncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Abstract]",
        "label": "Income Taxes [Abstract]",
        "documentation": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r345"
     ]
    },
    "bntx_IncreaseDecreaseCostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncreaseDecreaseCostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease cost of sales",
        "label": "Increase (Decrease) Cost Of Sales",
        "documentation": "Increase (Decrease) Cost Of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase / (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in intangible assets",
        "label": "Increase (decrease) in intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "bntx_IncreaseDecreaseOfGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncreaseDecreaseOfGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of general and administrative expense",
        "label": "Increase (Decrease) Of General And Administrative Expense",
        "documentation": "Increase (Decrease) Of General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IncreaseDecreaseOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncreaseDecreaseOfResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of research and development expense",
        "label": "Increase (Decrease) Of Research And Development Expense",
        "documentation": "Increase (Decrease) Of Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IncreaseDecreaseOfSalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncreaseDecreaseOfSalesAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of sales and marketing expense",
        "label": "Increase (Decrease) Of Sales And Marketing Expense",
        "documentation": "Increase (Decrease) Of Sales And Marketing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized directly in equity",
        "label": "Increase (decrease) through business combinations, deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows",
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency differences",
        "negatedTerseLabel": "Currency differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Currency differences",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Increase (decrease) through other changes, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "bntx_IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifi-cation",
        "label": "Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities",
        "documentation": "Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Increase (decrease) through transfers and other changes, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ifrs-full_IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value with increasing input factor (in millions \u20ac)",
        "label": "Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of increase in the fair value measurement of liabilities due to a change in multiple unobservable inputs to reflect reasonably possible alternative assumptions."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New leases and disposals",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r352",
      "r355"
     ]
    },
    "bntx_InstaDeepDEGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepDEGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep DE GmbH",
        "label": "InstaDeep DE GmbH [Member]",
        "documentation": "InstaDeep DE GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepEmployeeIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepEmployeeIncentivePlanMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep Employee Incentive Plan",
        "label": "InstaDeep Employee Incentive Plan [Member]",
        "documentation": "InstaDeep Employee Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepFranceSASMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepFranceSASMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep France SAS",
        "label": "InstaDeep France SAS [Member]",
        "documentation": "InstaDeep France SAS"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepLLCMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep LLC",
        "label": "InstaDeep LLC [Member]",
        "documentation": "InstaDeep LLC"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepLtd.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep Ltd.",
        "label": "InstaDeep Ltd. [Member]",
        "documentation": "InstaDeep Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepLtdMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep Ltd.",
        "label": "InstaDeep Ltd [Member]",
        "documentation": "InstaDeep Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepNigeriaLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepNigeriaLimitedMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep Nigeria Limited",
        "label": "InstaDeep Nigeria Limited [Member]",
        "documentation": "InstaDeep Nigeria Limited"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InstaDeepTunisiaSARLMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InstaDeepTunisiaSARLMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InstaDeep Tunisia SARL",
        "label": "InstaDeep Tunisia SARL [Member]",
        "documentation": "InstaDeep Tunisia SARL"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets [Abstract]",
        "label": "Intangible Assets [Abstract]",
        "documentation": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofDetailedInformationAboutIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill",
        "label": "Intangible assets and goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill [member]",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r339",
      "r364"
     ]
    },
    "ifrs-full_IntangibleAssetsWithIndefiniteUsefulLife": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsWithIndefiniteUsefulLife",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails": {
       "parentTag": "bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets with indefinite useful life",
        "label": "Intangible assets with indefinite useful life"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets assessed as having an indefinite useful life. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r118"
     ]
    },
    "bntx_IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillSummaryofGoodwillRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Intangible Assets With Indefinite Useful Life And Goodwill",
        "documentation": "Intangible Assets With Indefinite Useful Life And Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IntellectualPropertyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IntellectualPropertyRightsMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property rights",
        "label": "Intellectual Property Rights [Member]",
        "documentation": "Intellectual Property Rights"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InterestBearingLoansAndBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InterestBearingLoansAndBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans and borrowings",
        "label": "Interest Bearing Loans And Borrowings",
        "documentation": "Interest Bearing Loans And Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InterestBearingLoansAndBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InterestBearingLoansAndBorrowingsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loans and borrowings",
        "label": "Interest Bearing Loans And Borrowings [Member]",
        "documentation": "Interest Bearing Loans And Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails": {
       "parentTag": "bntx_LeaseExpensesRecognizedInProfitOrLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest paid and realized losses from cash and cash equivalents",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received and realized gains from cash and cash equivalents",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "bntx_InterestsInOtherEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InterestsInOtherEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]",
        "documentation": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r73",
      "r327"
     ]
    },
    "bntx_Inventories1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "Inventories1Member",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventories 1 [Member]",
        "documentation": "Inventories 1"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_InventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories [Abstract]",
        "label": "Inventories [Abstract]",
        "documentation": "Inventories [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoryWritedown2011",
     "presentation": [
      "http://www.biontech.de/role/InventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-offs",
        "label": "Inventory write-down"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r75"
     ]
    },
    "bntx_InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturity of other financial assets",
        "label": "(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities",
        "documentation": "(Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_IssuanceOfShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "IssuanceOfShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of treasury shares",
        "label": "Issuance Of Share Capital",
        "documentation": "Issuance Of Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of share capital",
        "verboseLabel": "Issueance of share capital",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "bntx_JPTPeptideTechnologiesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "JPTPeptideTechnologiesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JPT Peptide Technologies GmbH",
        "label": "JPT Peptide Technologies GmbH [Member]",
        "documentation": "JPT Peptide Technologies GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_JPTPeptideTechnologiesInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "JPTPeptideTechnologiesInc.Member",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JPT Peptide Technologies Inc.",
        "label": "JPT Peptide Technologies Inc. [Member]",
        "documentation": "JPT Peptide Technologies Inc."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_JensHolsteinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "JensHolsteinMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jens Holstein",
        "label": "Jens Holstein [Member]",
        "documentation": "Jens Holstein"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total compensation paid to key management personnel",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "bntx_KeyManagementPersonnelCompensationFixedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "KeyManagementPersonnelCompensationFixedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed compensation",
        "label": "Key Management Personnel Compensation, Fixed Compensation",
        "documentation": "Key Management Personnel Compensation, Fixed Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_KeyManagementPersonnelCompensationOtherVariableCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "KeyManagementPersonnelCompensationOtherVariableCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other variable compensation",
        "label": "Key Management Personnel Compensation, Other Variable Compensation",
        "documentation": "Key Management Personnel Compensation, Other Variable Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_KeyManagementPersonnelCompensationPhantomSharesAwarded": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "KeyManagementPersonnelCompensationPhantomSharesAwarded",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phantom shares awarded (in shares)",
        "label": "Key Management Personnel Compensation, Phantom Shares Awarded",
        "documentation": "Key Management Personnel Compensation, Phantom Shares Awarded"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments (incl. long-term incentive)",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "bntx_KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term incentive \u2013 second installment",
        "label": "Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment",
        "documentation": "Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term incentive \u2013 first installment",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_LandAndBuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LandAndBuildingsMember",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land and buildings",
        "label": "Land and buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 5 years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r200",
      "r375",
      "r376",
      "r378"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1 to 5 years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r378"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than one year",
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1 to 5 years",
        "label": "Later than two years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "bntx_LeaseExpensesRecognizedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LeaseExpensesRecognizedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total amounts recognized in profit or loss",
        "label": "Lease Expenses Recognized In Profit Or Loss",
        "documentation": "Lease Expenses Recognized In Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "totalLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r353",
      "r356"
     ]
    },
    "bntx_Leases1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "Leases1Abstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases 1 [Abstract]",
        "documentation": "Leases 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LegalProceedingsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LegalProceedingsProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails_1": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails",
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual disputes",
        "label": "Legal proceedings provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provision for legal proceedings. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 (Fair value)",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r162"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 (Fair value)",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 (Fair value)",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r162"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "verboseLabel": "As of January 1, 2022",
        "periodStartLabel": "As of January 1, 2023",
        "periodEndLabel": "As of December 31, 2023",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r161",
      "r162",
      "r165",
      "r260",
      "r263"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities",
        "label": "Liabilities arising from financing activities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "bntx_LiabilitiesForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LiabilitiesForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities to employees",
        "label": "Liabilities For Employee Benefits",
        "documentation": "Liabilities For Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesFromSharebasedPaymentTransactions2011",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from share-based payment arrangements",
        "label": "Liabilities from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "bntx_LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from wage taxes and social securities expenses",
        "label": "Liabilities From Wage Taxes And Social Securities Expenses",
        "documentation": "Liabilities From Wage Taxes And Social Securities Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash to be paid in 2024",
        "label": "Liabilities incurred"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of liabilities incurred (for example, a liability for contingent consideration) as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "bntx_LiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities Recognised As Of Acquisition Date",
        "documentation": "Liabilities Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_LiabilitiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LiabilitiesRollForward",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities [Roll Forward]",
        "label": "Liabilities [Roll Forward]",
        "documentation": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licenses",
        "label": "Licences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "bntx_LicenseAndOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LicenseAndOptionAgreementMember",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Option Agreement [Member]",
        "label": "License And Option Agreement [Member]",
        "documentation": "License And Option Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line items by function [member]",
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r411"
     ]
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity risk",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r371"
     ]
    },
    "bntx_ListOfAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ListOfAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "List Of Accounting Policies [Abstract]",
        "label": "List Of Accounting Policies [Abstract]",
        "documentation": "List Of Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ListedEquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ListedEquityInvestmentsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listed equity investments",
        "label": "Listed Equity Investments [Member]",
        "documentation": "Listed Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_LitigationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LitigationCostsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation costs",
        "label": "Litigation Costs [Member]",
        "documentation": "Litigation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_LoansAndBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LoansAndBorrowingsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans and borrowings",
        "label": "Loans And Borrowings [Member]",
        "documentation": "Loans And Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deposits",
        "label": "Long-term deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term deposits held by the entity."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "bntx_LossOnDerivativeInstrumentsAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "LossOnDerivativeInstrumentsAtFairValueMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on derivative instruments at fair value through profit or loss",
        "label": "Loss On Derivative Instruments At Fair Value [Member]",
        "documentation": "Loss On Derivative Instruments At Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers",
        "label": "Customers [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "bntx_ManagementBoardGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ManagementBoardGrantMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management Board Grant",
        "label": "Management Board Grant [Member]",
        "documentation": "Management Board Grant"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ManagementBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ManagementBoardMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management Board",
        "label": "Management Board [Member]",
        "documentation": "Management Board"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ManufacturingVariancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ManufacturingVariancesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Variances",
        "label": "Manufacturing Variances [Member]",
        "documentation": "Manufacturing Variances"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r176",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r200",
      "r235",
      "r247",
      "r336",
      "r375"
     ]
    },
    "bntx_MaximumCashPaymentInShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MaximumCashPaymentInShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum cash payment",
        "label": "Maximum Cash Payment In Share-Based Payment Arrangement",
        "documentation": "Maximum Cash Payment In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_MaximumEconomicBenefitsOfOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MaximumEconomicBenefitsOfOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum economic benefits of options exercised",
        "label": "Maximum Economic Benefits Of Options Exercised",
        "documentation": "Maximum Economic Benefits Of Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r281",
      "r288",
      "r296",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r307",
      "r309",
      "r321",
      "r322",
      "r385",
      "r386",
      "r389",
      "r391",
      "r449",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement [axis]",
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r125",
      "r161"
     ]
    },
    "bntx_MedigeneImmunotherapiesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MedigeneImmunotherapiesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medigene Immunotherapies GmbH",
        "label": "Medigene Immunotherapies GmbH [Member]",
        "documentation": "Medigene Immunotherapies GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_MedilinkTherapeuticsSuzhouCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MedilinkTherapeuticsSuzhouCoLtdMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medilink Therapeutics (Suzhou) Co. Ltd.,",
        "label": "Medilink Therapeutics (Suzhou) Co. Ltd., [Member]",
        "documentation": "Medilink Therapeutics (Suzhou) Co. Ltd.,"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_MedineGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MedineGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medine GmbH",
        "label": "Medine GmbH [Member]",
        "documentation": "Medine GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other operating expenses",
        "terseLabel": "Other operating expenses",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Miscellaneous other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "bntx_MonetaryAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MonetaryAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monetary assets in U.S. dollar",
        "label": "Monetary Assets [Member]",
        "documentation": "Monetary Assets"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_MonetaryLiabilityAndProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MonetaryLiabilityAndProvisionsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monetary liabilities and provisions in U.S. dollar",
        "label": "Monetary Liability And Provisions [Member]",
        "documentation": "Monetary Liability And Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_MoneyMarketFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "MoneyMarketFundMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Fund [Member]",
        "documentation": "Money Market Fund"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MultiperiodExcessEarningsMethodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MultiperiodExcessEarningsMethodMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multi-period excess earnings method",
        "label": "Multi-period excess earnings method [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing the excess earnings over periods of time, and is used to measure the fair value of some intangible assets. [Refer: Income approach [member]]"
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "bntx_NTSecurityAndServicesGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NTSecurityAndServicesGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NT Security and Services GmbH",
        "label": "NT Security and Services GmbH [Member]",
        "documentation": "NT Security and Services GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NegativeFivePercentageChangeInForeignExchangeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NegativeFivePercentageChangeInForeignExchangeRateMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "-5 %",
        "label": "Negative Five Percentage Change In Foreign Exchange Rate [Member]",
        "documentation": "Negative Five Percentage Change In Foreign Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NetChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NetChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in fair value",
        "label": "Net Change In Fair Value",
        "documentation": "Net Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NetEmployeeDefinedBenefitLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NetEmployeeDefinedBenefitLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net employee defined benefit liabilities",
        "label": "Net Employee Defined Benefit Liabilities [Member]",
        "documentation": "Net Employee Defined Benefit Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange differences, net",
        "label": "Net foreign exchange gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r413",
      "r425"
     ]
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange differences, net",
        "label": "Net foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r413",
      "r425"
     ]
    },
    "bntx_NewTechnologiesReMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NewTechnologiesReMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Technologies Re\u200b",
        "label": "New Technologies Re\u200b [Member]",
        "documentation": "New Technologies Re\u200b"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Trading Symbol Flag",
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash current tax relating to items credited (charged) directly to equity",
        "label": "Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity",
        "documentation": "Non Cash Effective Current Tax Relating To Items Credited (Charged) Directly To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NonCurrentLeaseLiabilitiesLoansAndBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NonCurrentLeaseLiabilitiesLoansAndBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, loans and borrowings",
        "label": "Non-current Lease Liabilities, Loans And Borrowings",
        "documentation": "Non-current Lease Liabilities, Loans And Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NonListedEquityInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NonListedEquityInvestmentsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-listed equity investments",
        "label": "Non-Listed Equity Investments [Member]",
        "documentation": "Non-Listed Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non tax-effective share-based payment expenses",
        "label": "Non-Recognition Of Tax Effect On Share-Based Payment Expenses",
        "documentation": "Non-Recognition Of Tax Effect On Share-Based Payment Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NonTaxEffectiveBargainPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NonTaxEffectiveBargainPurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-tax effective bargain purchase",
        "label": "Non Tax Effective Bargain Purchase",
        "documentation": "Non Tax Effective Bargain Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r148",
      "r357"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofLeaseLiabilityIncludedinInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r150",
      "r357"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NoncurrentObligationsUnderLeaseContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NoncurrentObligationsUnderLeaseContractsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofChangesinLiabilitiesArisingFromFinancingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current obligations under lease contracts",
        "label": "Noncurrent Obligations Under Lease Contracts [Member]",
        "documentation": "Noncurrent Obligations Under Lease Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Total non-current",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.biontech.de/role/ContingenciesandotherfinancialcommitmentsScheduleofOtherFinancialCommitmentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "verboseLabel": "Less than 1 year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r188",
      "r189",
      "r200",
      "r375",
      "r378"
     ]
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to purchase ordinary shares (in shares)",
        "label": "Number of instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Number of instruments or interests issued or issuable"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsAbstract",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares underlying options",
        "label": "Number Of Ordinary Shares Underlying Options [Abstract]",
        "documentation": "Number Of Ordinary Shares Underlying Options"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised, number of ordinary shares underlying options (in shares)",
        "label": "Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement",
        "documentation": "Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited, number of ordinary shares underlying options (in shares)",
        "label": "Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement",
        "documentation": "Number Of Ordinary Shares Underlying Options Forfeited In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsOutstanding",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, number of ordinary shares underlying options (in shares)",
        "periodEndLabel": "Ending balance, number of ordinary shares underlying options (in shares)",
        "label": "Number Of Ordinary Shares Underlying Options Outstanding",
        "documentation": "Number Of Ordinary Shares Underlying Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof un-vested, number of ordinary shares underlying options (in shares)",
        "label": "Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement",
        "documentation": "Number Of Ordinary Shares Underlying OptionsUnvested In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof vested, number of ordinary shares underlying options (in shares)",
        "label": "Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement",
        "documentation": "Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of option rights vested (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options outstanding (in shares)",
        "periodStartLabel": "Beginning balance, share options (in shares)",
        "periodEndLabel": "Ending balance, share options (in shares)",
        "verboseLabel": "(Phantom) share options outstanding (expected to be allocated) (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r207",
      "r211"
     ]
    },
    "bntx_NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof allocated and un-vested (in shares)",
        "label": "Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof allocated and vested but subject to performance and waiting requirements (in shares)",
        "label": "Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options exercisable in share-based payment arrangement (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-settled option rights, exercised (in shares)",
        "negatedTerseLabel": "Exercised, share options (in shares)",
        "verboseLabel": "Share options, exercised (in shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited, share options (in shares)",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted, share options (in shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "bntx_NumberOfShareOptionsHeld": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsHeld",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options held (in shares)",
        "label": "Number Of Share Options Held",
        "documentation": "Number Of Share Options Held"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfShareOptionsSettledInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsSettledInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settled (in shares)",
        "label": "Number Of Share Options Settled In Share-based Payment Arrangement",
        "documentation": "Number Of Share Options Settled In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfShareOptionsUnestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsUnestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof un-vested (in shares)",
        "label": "Number Of Share Options Unested In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Unested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof vested (in shares)",
        "label": "Number Of Share Options Vested In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Vested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_NumberOfSharesHeldInTreasury": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "NumberOfSharesHeldInTreasury",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares (in shares)",
        "label": "Number Of Shares Held In Treasury",
        "documentation": "Number Of Shares Held In Treasury"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding (in shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "bntx_OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine",
        "label": "Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine [Member]",
        "documentation": "Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OncoC4IncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OncoC4IncMember",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OncoC4 Inc.",
        "label": "OncoC4 Inc. [Member]",
        "documentation": "OncoC4 Inc."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OperatingAndBusinessEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OperatingAndBusinessEquipmentMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating And Business Equipment",
        "label": "Operating And Business Equipment [Member]",
        "documentation": "Operating And Business Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OptionExercisablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OptionExercisablePeriod",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option rights exercisable period (in years)",
        "label": "Option Exercisable Period",
        "documentation": "Option Exercisable Period"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OptionVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OptionVestingPeriod",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option rights vesting period (in years)",
        "label": "Option Vesting Period",
        "documentation": "Option Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r417"
     ]
    },
    "bntx_OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value, with a notional amount attributable to each ordinary share of \u20ac1",
        "label": "Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member]",
        "documentation": "Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-cash income / (loss)",
        "label": "Other adjustments for non-cash items"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "bntx_OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets non-current and current",
        "label": "Other Assets Non-current And Current Recognised As Of Acquisition Date",
        "documentation": "Other Assets Non-current And Current Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Investment in other financial assets",
        "label": "Other cash payments to acquire interests in joint ventures, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire interests in joint ventures (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities. [Refer: Joint ventures [member]]"
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income / (loss) for the period, net of tax",
        "verboseLabel": "Other comprehensive income (loss)",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r44",
      "r152"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r44"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEquitySecuritiesMeasuredatFairValueThroughOtherComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net gain on equity instruments designated at fair value through other comprehensive income",
        "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r44"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement gain on defined benefit plans",
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r44",
      "r421"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods",
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332"
     ]
    },
    "bntx_OtherCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Current Assets, Other",
        "documentation": "Other Current Assets, Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r154"
     ]
    },
    "ifrs-full_OtherCurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-financial assets",
        "verboseLabel": "Total current",
        "label": "Other current non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_OtherCurrentNonfinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentNonfinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-financial liabilities",
        "verboseLabel": "Total current",
        "label": "Other current non-financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "bntx_OtherDeferredTaxesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherDeferredTaxesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (incl. deferred expenses)",
        "label": "Other Deferred Taxes [Member]",
        "documentation": "Other Deferred Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesFinanceExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "bntx_OtherFinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherFinancialAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "label": "Other Financial Assets [Member]",
        "documentation": "Other Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "bntx_OtherFinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherFinancialLiabilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other Financial Liabilities [Member]",
        "documentation": "Other Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OtherIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherIncomeExpenseMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingExpenseDetails",
      "http://www.biontech.de/role/IncomeandExpensesOtherOperatingIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Income Expense [Member]",
        "documentation": "Other Income Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_LiabilitiesRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities long-term and short-term",
        "label": "Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date",
        "documentation": "Other Liabilities Long-term And Short-term Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OtherLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Other",
        "documentation": "Other Liabilities, Other"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OtherNonFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherNonFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Non-Financial Assets [Abstract]",
        "documentation": "Other Non-Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_OtherNonFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherNonFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Non-Financial Liabilities [Abstract]",
        "documentation": "Other Non-Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial liabilities",
        "label": "Other non-current financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r155"
     ]
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-financial assets",
        "verboseLabel": "Total non-current",
        "label": "Other non-current non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_OtherNoncurrentNonfinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-financial liabilities",
        "verboseLabel": "Total non-current",
        "label": "Other non-current non-financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_OtherNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "ifrs-full_OtherNonfinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNonfinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialLiabilitiesSummaryofOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other non-financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "bntx_OtherOperatingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherOperatingEquipmentMember",
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating equipment",
        "label": "Other Operating Equipment [Member]",
        "documentation": "Other Operating Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails_1": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails",
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r109"
     ]
    },
    "bntx_OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherProvisionsContingentLiabilitiesAndContingentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "label": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]",
        "documentation": "Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_OtherRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherRelatedPartiesMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other related parties",
        "label": "Other related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for related parties that the entity does not separately disclose in the same statement or note. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36"
     ]
    },
    "bntx_OtherSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "OtherSalesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other sales",
        "label": "Other Sales [Member]",
        "documentation": "Other Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other effects",
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applicable wage taxes and social security contributions resulting from and withheld upon exercise",
        "label": "Payables on social security and taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments related to lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfAmericanDepositorySharesToOrdinaryShares",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ADS to ordinary shares (as a percent)",
        "label": "Percentage Of American Depository Shares To Ordinary Shares",
        "documentation": "Percentage Of American Depository Shares To Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfConsiderationTransferredAcquiredShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfConsiderationTransferredAcquiredShares",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred, acquired shares (as a percent)",
        "label": "Percentage Of Consideration Transferred, Acquired Shares",
        "documentation": "Percentage Of Consideration Transferred, Acquired Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfCostOfSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfCostOfSales",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales (as a percent)",
        "label": "Percentage Of Cost Of Sales",
        "documentation": "Percentage Of Cost Of Sales"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfGeneralAndAdministrativeExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfGeneralAndAdministrativeExpense",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense (as a percent)",
        "label": "Percentage Of General And Administrative Expense",
        "documentation": "Percentage Of General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfImpairmentLossForAReductionOfFutureCashFlows": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfImpairmentLossForAReductionOfFutureCashFlows",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss for a reduction of future cash flows (as a percent)",
        "label": "Percentage Of Impairment Loss For A Reduction Of Future Cash Flows",
        "documentation": "Percentage Of Impairment Loss For A Reduction Of Future Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfIncreaseInExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfIncreaseInExercisePrice",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price increase (as a percent)",
        "label": "Percentage Of Increase In Exercise Price",
        "documentation": "Percentage Of Increase In Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfResearchAndDevelopmentExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfResearchAndDevelopmentExpense",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense (as a percent)",
        "label": "Percentage Of Research And Development Expense",
        "documentation": "Percentage Of Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfSalesAndMarketingExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfSalesAndMarketingExpense",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expense (as a percent)",
        "label": "Percentage Of Sales And Marketing Expense",
        "documentation": "Percentage Of Sales And Marketing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PercentageOfTargetSharePriceApplicableForPriorTwelveMonth": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PercentageOfTargetSharePriceApplicableForPriorTwelveMonth",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target share price applicable for prior twelve month period (as a percent)",
        "label": "Percentage Of Target Share Price Applicable For Prior Twelve Month",
        "documentation": "Percentage Of Target Share Price Applicable For Prior Twelve Month"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting equity interests acquired (as a percent)",
        "label": "Percentage of voting equity interests acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations [axis]",
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_PerformanceObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations [member]",
        "label": "Performance obligations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "bntx_PfizerCOVID19VaccineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PfizerCOVID19VaccineMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer (COVID-19 vaccine)",
        "label": "Pfizer (COVID-19 vaccine) [Member]",
        "documentation": "Pfizer (COVID-19 vaccine)"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PfizerIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PfizerIncMember",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "documentation": "Pfizer Inc"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PfizerZosterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PfizerZosterMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer (Zoster)",
        "label": "Pfizer (Zoster) [Member]",
        "documentation": "Pfizer (Zoster)"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PhantomOptionAwardsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PhantomOptionAwardsLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the phantom option awards",
        "label": "Phantom Option Awards, Liability",
        "documentation": "Phantom Option Awards, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PositiveFivePercentageChangeInForeignExchangeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PositiveFivePercentageChangeInForeignExchangeRateMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "+5 %",
        "label": "Positive Five Percentage Change In Foreign Exchange Rate [Member]",
        "documentation": "Positive Five Percentage Change In Foreign Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension costs",
        "label": "Post-employment benefit expense in profit or loss, defined benefit plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "bntx_PrepaymentForFutureDevelopmentActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PrepaymentForFutureDevelopmentActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment for future development activities",
        "label": "Prepayment For Future Development Activities",
        "documentation": "Prepayment For Future Development Activities"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PreviouslyHeldNonListedEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PreviouslyHeldNonListedEquityInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously held non-listed equity investment (stake of 5.3%)",
        "label": "Previously-held Non-listed Equity Investment",
        "documentation": "Previously-held Non-listed Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of ADS as a percentage of exercise price, maximum (as a percent)",
        "label": "Price Of American Depository Share As A Percentage Of Exercise Price, Maximum",
        "documentation": "Price Of American Depository Share As A Percentage Of Exercise Price, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from loans and borrowings",
        "label": "Proceeds from borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of share capital and treasury shares, net of costs",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "bntx_ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property, plant and equipment",
        "label": "Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities",
        "documentation": "Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r323",
      "r387",
      "r390",
      "r406",
      "r447",
      "r448",
      "r450",
      "r459"
     ]
    },
    "bntx_ProductionFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ProductionFacilitiesMember",
     "presentation": [
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails",
      "http://www.biontech.de/role/LeasessummaryofAmountsRecognizedinConsolidatedStatementofOperationsDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Production facilities",
        "label": "Production Facilities [Member]",
        "documentation": "Production Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r323",
      "r387",
      "r390",
      "r406",
      "r447",
      "r448",
      "r450",
      "r459"
     ]
    },
    "bntx_ProfessorUgurSahinMDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ProfessorUgurSahinMDMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prof. Ugur Sahin, M.D.",
        "label": "Professor Ugur Sahin MD [Member]",
        "documentation": "Professor Ugur Sahin MD"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.biontech.de/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Profit for the period",
        "terseLabel": "Profit for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r38",
      "r128",
      "r142",
      "r144",
      "r260",
      "r261",
      "r357",
      "r365"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit attributable to ordinary equity holders of the parent for basic earnings",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Profit before tax",
        "verboseLabel": "Profit before tax",
        "terseLabel": "Profit before tax",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r325",
      "r326",
      "r380",
      "r381"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r338",
      "r418"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment, beginning balance",
        "periodEndLabel": "Property, plant and equipment, ending balance",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [abstract]",
        "label": "Property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [member]",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r66",
      "r339",
      "r364"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r368",
      "r370"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutEntitywithSignificantInfluenceOverGroupDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutParentCompanyDetails",
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "% equity interest",
        "verboseLabel": "Ownership of ordinary shares in BioNTech (in %)",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r92",
      "r94",
      "r146"
     ]
    },
    "ifrs-full_Provisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Provisions",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biontech.de/role/ProvisionsProvisionsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding balances of related party transactions",
        "label": "Provisions for doubtful debts related to outstanding balances of related party transaction"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provisions for doubtful debts related to the amount of outstanding balances in related party transactions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "bntx_PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of intangible assets and right-of-use assets",
        "label": "Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities",
        "documentation": "Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "bntx_PurchaseOfSharesUnderAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PurchaseOfSharesUnderAgreement",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of shares under agreement (in shares)",
        "label": "Purchase Of Shares Under Agreement",
        "documentation": "Purchase Of Shares Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchasesFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchasesFairValueMeasurementLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofSignificantUnobservableInputsLevel3UsedforRecurringFairValueMeasurementsandtheEffectoftheMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Purchases, fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in the fair value measurement of liabilities resulting from purchases of those liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "bntx_PurchasesFromRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PurchasesFromRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Purchases From Related Party Transactions",
        "documentation": "Purchases From Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_PurchasesOfGoodsAndServiceRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "PurchasesOfGoodsAndServiceRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails": {
       "parentTag": "bntx_PurchasesFromRelatedPartyTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of various goods and services from entities controlled by ATHOS KG",
        "label": "Purchases Of Goods And Service Related Party Transactions",
        "documentation": "Purchases Of Goods And Service Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails": {
       "parentTag": "bntx_PurchasesFromRelatedPartyTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and other assets from entities controlled by ATHOS KG",
        "label": "Purchases of property and other assets, related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property and other assets purchased by the entity in related party transactions. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r194",
      "r211",
      "r360",
      "r362",
      "r443"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r296",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r307",
      "r309",
      "r321",
      "r322",
      "r385",
      "r386",
      "r389",
      "r391",
      "r392",
      "r446",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r296",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r307",
      "r309",
      "r321",
      "r322",
      "r385",
      "r386",
      "r389",
      "r391",
      "r392",
      "r446",
      "r449",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges [member]",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r194",
      "r211",
      "r360",
      "r362",
      "r443"
     ]
    },
    "bntx_ReSanoGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ReSanoGmbHMember",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "reSano GmbH",
        "label": "reSano GmbH [Member]",
        "documentation": "reSano GmbH"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails": {
       "parentTag": "ifrs-full_OtherNonfinancialAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsSummaryofOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales tax receivable",
        "label": "Receivables from taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "bntx_ReclassificationOfShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ReclassificationOfShareBasedPaymentArrangement",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification for share-based payment arrangement",
        "label": "Reclassification Of Share-Based Payment Arrangement",
        "documentation": "Reclassification Of Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ReclassificationsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ReclassificationsOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassifications Of Property, Plant And Equipment",
        "documentation": "Reclassifications Of Property, Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects",
        "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_RedemptionOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RedemptionOfConvertibleNote",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of convertible note",
        "label": "Redemption Of Convertible Note",
        "documentation": "Redemption Of Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RefundsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RefundsProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refund liabilities",
        "label": "Refunds provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r341",
      "r343"
     ]
    },
    "bntx_RelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Abstract]",
        "label": "Related Party [Abstract]",
        "documentation": "Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_RemainingUpfrontFeesContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RemainingUpfrontFeesContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining upfront fees contract liabilities",
        "label": "Remaining Upfront Fees Contract Liabilities",
        "documentation": "Remaining Upfront Fees Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of loans and borrowings",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofTransactionsBetweenRelatedPartiesOutstandingBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r278",
      "r279",
      "r286",
      "r383",
      "r384"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "bntx_ResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expenses [Member]",
        "documentation": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research &amp; development revenues",
        "label": "Research And Development [Member]",
        "documentation": "Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Revenue from contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171"
     ]
    },
    "bntx_RevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue From Contracts With Customers [Abstract]",
        "label": "Revenue From Contracts With Customers [Abstract]",
        "documentation": "Revenue From Contracts With Customers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesFinanceIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r258",
      "r264",
      "r411"
     ]
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofRevenueRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts included in contract liabilities at the beginning of the year",
        "label": "Revenue that was included in contract liability balance at beginning of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "bntx_ReverseRepoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ReverseRepoMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Repo",
        "label": "Reverse Repo [Member]",
        "documentation": "Reverse Repo"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_RightOfUseAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RightOfUseAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-Of-Use Assets Recognised As Of Acquisition Date",
        "documentation": "Right-Of-Use Assets Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition",
      "http://www.biontech.de/role/LeasesSummaryofRightofUseAssetswithinConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186"
     ]
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "bntx_RyvuTherapeuticsSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "RyvuTherapeuticsSAMember",
     "presentation": [
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ryvu Therapeutics S.A.",
        "label": "Ryvu Therapeutics S.A. [Member]",
        "documentation": "Ryvu Therapeutics S.A."
       }
      }
     },
     "auth_ref": []
    },
    "bntx_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "Sale Of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofProfitorLoss",
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sales and marketing expenses",
        "terseLabel": "Sales and marketing expenses",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "bntx_SalesAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SalesAndMarketingExpenseMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expenses",
        "label": "Sales And Marketing Expense [Member]",
        "documentation": "Sales And Marketing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition applying the sales-based or usage-based royalty recognition constraint model",
        "label": "Sales Based Or Usage Based Royalty Recognition Constraint Model [Member]",
        "documentation": "Sales Based Or Usage Based Royalty Recognition Constraint Model"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r282",
      "r444"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r282",
      "r404",
      "r444"
     ]
    },
    "bntx_SeanMarettMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SeanMarettMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sean Marett",
        "label": "Sean Marett [Member]",
        "documentation": "Sean Marett"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuritiesInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuritiesInvestmentMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security investments",
        "label": "Securities Investment [Member]",
        "documentation": "This member categorizes all investments in securities to segregate them from other than security investments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r297",
      "r298",
      "r299",
      "r303",
      "r305",
      "r308",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r324",
      "r388",
      "r392",
      "r450",
      "r459"
     ]
    },
    "bntx_ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash-settled related to rights vested and exercisable",
        "label": "Share Based Payment Arrangement, Related To Rights Vested And Exercisable",
        "documentation": "Share Based Payment Arrangement, Related To Rights Vested And Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareBasedPaymentArrangementYearOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareBasedPaymentArrangementYearOneMember",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One year",
        "label": "Share-Based Payment Arrangement, Year One [Member]",
        "documentation": "Share-Based Payment Arrangement, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareBasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareBasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangements [Abstract]",
        "label": "Share-based Payment Arrangements [Abstract]",
        "documentation": "Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareBasedPaymentsClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareBasedPaymentsClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Share based Payments, Classified As Operating Activities",
        "documentation": "Share based Payments, Classified As Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital, Reserves and Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves and Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves and Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transaction costs",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "bntx_ShareOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareOptionsOutstandingAbstract",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options outstanding",
        "label": "Share Options Outstanding [Abstract]",
        "documentation": "Share Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgram2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgram2023Member",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program 2023",
        "label": "Share Repurchase Program 2023 [Member]",
        "documentation": "Share Repurchase Program 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program authorized amount",
        "label": "Share Repurchase Program Authorized Amount",
        "documentation": "Share Repurchase Program Authorized Amount"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average price paid per ADS (in dollar per share and euro per share)",
        "label": "Share Repurchase Program, Average Price Per American depositary Share (ADS)",
        "documentation": "Share Repurchase Program, Average Price Per American depositary Share (ADS)"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchase program",
        "label": "Share Repurchase Program Classified As Financing Activities",
        "documentation": "Share Repurchase Program Classified As Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramNetAmountSpent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramNetAmountSpent",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net amount spend",
        "label": "Share Repurchase Program, Net Amount Spent",
        "documentation": "Share Repurchase Program, Net Amount Spent"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ADSs purchased (in shares)",
        "label": "Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased",
        "documentation": "Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramPeriodAxis",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program Period [Axis]",
        "label": "Share Repurchase Program Period [Axis]",
        "documentation": "Share Repurchase Program Period"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramPeriodDomain",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program Period [Domain]",
        "label": "Share Repurchase Program Period [Domain]",
        "documentation": "Share Repurchase Program Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchase program",
        "label": "Share Repurchase Program, Repurchased During Period, Value",
        "documentation": "Share Repurchase Program, Repurchased During Period, Value"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramTrancheOneMember",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program, Tranche One",
        "label": "Share Repurchase Program, Tranche One [Member]",
        "documentation": "Share Repurchase Program, Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ShareRepurchaseProgramTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ShareRepurchaseProgramTrancheTwoMember",
     "presentation": [
      "http://www.biontech.de/role/IssuedCapitalandReservesAdditionalInformationDetails",
      "http://www.biontech.de/role/IssuedCapitalandReservesShareRepurchaseProgramAuthorizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program, Tranche Two",
        "label": "Share Repurchase Program, Tranche Two [Member]",
        "documentation": "Share Repurchase Program, Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_ShorttermOnerousContractsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermOnerousContractsProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ProvisionsProvisionsDetails_1": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ProvisionsAdditionalInformationDetails",
      "http://www.biontech.de/role/ProvisionsProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obligations from onerous CMO contracts",
        "label": "Current onerous contracts provision"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for onerous contracts. [Refer: Onerous contracts provision]"
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherNonFinancialAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Associates [axis]",
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r159"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.biontech.de/role/GroupInformationSummaryofInformationaboutSubsidiariesDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries [axis]",
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r158"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable input, liabilities",
        "label": "Significant unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_SocialSecurityContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SocialSecurityContributions",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security costs",
        "label": "Social security contributions"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "bntx_SolidaritySurchargeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SolidaritySurchargeRate",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solidarity surcharge rate (as a percent)",
        "label": "Solidarity Surcharge Rate",
        "documentation": "Solidarity Surcharge Rate"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_StateDeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "StateDeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax losses",
        "label": "State Deferred Tax Assets Operating Loss Carryforwards",
        "documentation": "State Deferred Tax Assets Operating Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r297",
      "r298",
      "r299",
      "r303",
      "r305",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r324",
      "r388",
      "r392",
      "r450",
      "r459"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation",
        "label": "Statement of IFRS compliance [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r282",
      "r404",
      "r405",
      "r444"
     ]
    },
    "ifrs-full_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r93",
      "r95",
      "r158"
     ]
    },
    "bntx_SupervisoryBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "SupervisoryBoardMember",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supervisory Board",
        "label": "Supervisory Board [Member]",
        "documentation": "Supervisory Board"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectFromChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in deferred taxes due to tax rate change",
        "label": "Tax effect from change in tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "bntx_TaxEffectNonTaxEffectiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TaxEffectNonTaxEffectiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non tax-effective income",
        "label": "Tax Effect, Non Tax Effective Income",
        "documentation": "Tax Effect, Non Tax Effective Income"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_TaxEffectOfChangeInValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TaxEffectOfChangeInValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Tax Effect Of Change In Valuation Allowance",
        "documentation": "Tax Effect Of Change In Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_TaxEffectOfDeviationDueToLocalTaxBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TaxEffectOfDeviationDueToLocalTaxBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deviation due to local tax basis",
        "label": "Tax Effect Of Deviation Due To Local Tax Basis",
        "documentation": "Tax Effect Of Deviation Due To Local Tax Basis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deviation due to deviating income tax rate (Germany and foreign countries)",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects from tax losses and tax credits",
        "label": "Tax effect of tax losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "bntx_TaxEffectiveEquityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TaxEffectiveEquityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax-effective equity transaction costs",
        "label": "Tax Effective Equity Transaction Costs",
        "documentation": "Tax Effective Equity Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofReconciliationofExpectedIncomeTaxBenefittoActualIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected tax credit",
        "label": "Tax expense (income) at applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_TaxRateEffectFromChangeInTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectFromChangeInTaxRate",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate effect",
        "label": "Tax rate effect from change in tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "bntx_TaxRateOnDeferredTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TaxRateOnDeferredTaxes",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate for deferred taxes (as a percent)",
        "label": "Tax Rate On Deferred Taxes",
        "documentation": "Tax Rate On Deferred Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology-based intangible assets recognised as of acquisition date",
        "label": "Technology-based intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for technology-based intangible assets acquired in a business combination. [Refer: Technology-based intangible assets [member]; Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities have not been recognized",
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "bntx_ThereofDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ThereofDeferredTaxAssetsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereof deferred tax assets",
        "label": "Thereof Deferred Tax Assets [Member]",
        "documentation": "Thereof Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ThereofDeferredTaxLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ThereofDeferredTaxLiabilityMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereof deferred tax liability",
        "label": "Thereof Deferred Tax Liability [Member]",
        "documentation": "Thereof Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold amount of dividend by number of shares outstanding immediately following initial public offering",
        "label": "Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering",
        "documentation": "Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [axis]",
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofDisaggregationofRevenuesfromContractswithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services",
        "label": "Timing of transfer of goods or services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r445",
      "r452"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresSummaryofCompensationofKeyManagementPersonnelDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r194",
      "r211",
      "r360",
      "r362",
      "r443"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other payables",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables",
        "label": "Trade and other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r31"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "bntx_TradeAndOtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TradeAndOtherReceivablesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables",
        "label": "Trade And Other Receivables [Member]",
        "documentation": "Trade And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_TradePayablesAndOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TradePayablesAndOtherPayablesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and other payables",
        "label": "Trade Payables And Other Payables [Member]",
        "documentation": "Trade Payables And Other Payables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFinancialAssetsandLiabilitiesatAmortizedCostandatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other receivables",
        "label": "Trade receivables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r240",
      "r244",
      "r372",
      "r411"
     ]
    },
    "bntx_TradeReceivablesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TradeReceivablesRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails": {
       "parentTag": "bntx_AssetsRecognisedAsOfAcquisitionDate",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsSummaryofFairValuesofIdentifiableNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Trade Receivables Recognised As Of Acquisition Date",
        "documentation": "Trade Receivables Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biontech.de/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury shares",
        "label": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r330"
     ]
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares",
        "label": "Treasury shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "bntx_TreasurySharesUsedForAcquisitionOfBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "TreasurySharesUsedForAcquisitionOfBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury shares used for acquisition of business combination",
        "label": "Treasury Shares Used For Acquisition Of Business Combination",
        "documentation": "Treasury Shares Used For Acquisition Of Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r233",
      "r238",
      "r239"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofCarryingAmountofMonetaryAssetsDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofMaturityProfileofFinancialLiabilitiesBasedonContractualUndiscountedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks",
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r199",
      "r233",
      "r238",
      "r239"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/RelatedPartyDisclosuresAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofExpenseRecognizedforEmployeeServicesReceivedDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails",
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/PropertyPlantandEquipmentAdditionalInformationDetails",
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "verboseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofEffectofChangesinforeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dollar",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049",
        "label": "Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities",
        "documentation": "Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [axis]",
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r439"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.biontech.de/role/FinancialAssetsandFinancialLiabilitiesSummaryofFairValuesofFinancialInstrumentsinFairValueLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [member]",
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r439"
     ]
    },
    "bntx_UnsatisfiedOrPartiallyUnsatisfiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "UnsatisfiedOrPartiallyUnsatisfiedMember",
     "presentation": [
      "http://www.biontech.de/role/RevenuesfromContractswithCustomersSummaryofContractLiabilitiesAllocatedtoRemainingPerformanceObligationsUnsatisfiedorPartiallyUnsatisfiedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unsatisfied Or Partially Unsatisfied",
        "label": "Unsatisfied Or Partially Unsatisfied [Member]",
        "documentation": "Unsatisfied Or Partially Unsatisfied"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxCreditsMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses / tax credits",
        "label": "Unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "bntx_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/EventsAftertheReportingPeriodAdditionalInformationDetails",
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payment",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_UpfrontPaymentAcquisitionOfIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "UpfrontPaymentAcquisitionOfIntangibleAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment, acquisition of intangible asset",
        "label": "Upfront Payment, Acquisition of Intangible Asset",
        "documentation": "Upfront Payment, Acquisition of Intangible Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.biontech.de/role/OtherIntangibleAssetsandGoodwillAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofUsefulLivesAppliedtotheGroupsIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life measured as period of time, intangible assets other than goodwill (in years)",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life (in years)",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "bntx_UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, useful life (in years)",
        "label": "Useful Life Measured As Period Of Time, Right-Of-Use Assets",
        "documentation": "Useful Life Measured As Period Of Time, Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_ValuationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "ValuationAdjustmentMember",
     "presentation": [
      "http://www.biontech.de/role/IncomeTaxAdditionalInformationDetails",
      "http://www.biontech.de/role/IncomeTaxSummaryofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation adjustment",
        "label": "Valuation Adjustment [Member]",
        "documentation": "Valuation Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValuationTechniquesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValuationTechniquesMember",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques [member]",
        "label": "Valuation techniques [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis",
     "presentation": [
      "http://www.biontech.de/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques used in fair value measurement [axis]",
        "label": "Valuation techniques used in fair value measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.biontech.de/role/SignificantAccountingPoliciesSummaryofEstimatedUsefulLivesoftheAssetsorShorterLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automobiles",
        "label": "Vehicles [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "bntx_VestingPercentageOfShareBasedPaymentArrangement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "VestingPercentageOfShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage after one year (as a percent)",
        "label": "Vesting Percentage Of Share Based Payment Arrangement",
        "documentation": "Vesting Percentage Of Share Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_VestingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "VestingPeriodAxis",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Period [Axis]",
        "label": "Vesting Period [Axis]",
        "documentation": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_VestingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "VestingPeriodDomain",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting Period [Domain]",
        "documentation": "Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesSummaryofEmployeeBenefitsExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and salaries",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "bntx_WeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "WeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (\u20ac)",
        "label": "Weighted Average Exercise Price [Abstract]",
        "documentation": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, weighted-average exercise price (in euros per share)",
        "label": "Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, weighted-average exercise price (in euros per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsScheduleofNumberandWeightedAverageExercisePriceofShareOptionsAllocatedandExpectedtobeAllocatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, weighted-average exercise price (in euros per share)",
        "periodEndLabel": "Ending balance, weighted-average exercise price (in euros per share)",
        "terseLabel": "Weighted-average exercise price (in euros per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r207"
     ]
    },
    "bntx_WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof un-vested, weighted-average exercise price (in euros per share)",
        "label": "Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Share Options Unvested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "bntx_WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "thereof vested, weighted-average exercise price (in euros per share)",
        "label": "Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, weighted-average expected life (in years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://www.biontech.de/role/ShareBasedPaymentsReconciliationofOutstandingShareOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price (in euros per share)",
        "label": "Weighted average share price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://www.biontech.de/role/ShareBasedPaymentsSummaryofInputsUsedinMeasurementofFairValueatGrantDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average share price (in euros per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.biontech.de/role/EarningsperShareSummaryofIncomeandShareDataUsedintheBasicanddilutedEPSCalculationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding for basic EPS (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biontech.de/role/InventoriesSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfinished goods",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r329",
      "r424"
     ]
    },
    "bntx_WorkingCapitalAdjustmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biontech.de/20231231",
     "localname": "WorkingCapitalAdjustmentsAbstract",
     "presentation": [
      "http://www.biontech.de/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustments:",
        "label": "Working Capital Adjustments [Abstract]",
        "documentation": "Working Capital Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WritedownsReversalsOfInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WritedownsReversalsOfInventories",
     "crdr": "debit",
     "presentation": [
      "http://www.biontech.de/role/IncomeandExpensesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write-downs (reversals of write-downs) of inventories",
        "label": "Write-downs (reversals of write-downs) of inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised resulting from the write-down of inventories to net realisable value or reversals of those write-downs. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "137",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_137_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "74",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_74_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "23",
   "IssueDate": "2023-01-01",
   "Paragraph": "26",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2023-en-r&anchor=para_26_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "d",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_10_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Nature of the risks associated with an entity's interests in consolidated structured entities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS12_g14-17_TI",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_9_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F_TI",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_21_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "Example 10 A court case",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10_TI",
   "URIDate": "2023-03-23"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI",
   "URIDate": "2023-03-23"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2023-03-23"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B11_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>153
<FILENAME>0001776985-24-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001776985-24-000027-xbrl.zip
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M955@C7Y[,AWN,''AS1N[W+OL/-F4NV,VW=2),9NZ*S'E<EH 2,H"2$S8[ 2
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M=,JIP03G" >YQ]S@;]ML3Z805 H@V:;8$&_M*NMK[E^>DIJ9.07IV!0%J.,
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MA2CY#5J6R5+5S3]IXY9EME>A*TV&KB8QL2VGH(^=01RUZWJ<5JXF,<VNH)7
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M/Z4P&<E%,Z4P,E?QE,*H-%4ZA9&Y+*<41D$4("IQG2T5$$T^B=VL$GU.3/I
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M$@@/%6YVQ4UVJ*;$1%<7\M@QDEDY]6.BRP[;DY#O!%'H%WHY'M^9';8G(6F
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MWXO?1H"H8054ORC6\[47WE*:0=)W&Z5]1R-*\FP/9TI%(U(_N_K"G/L^-<:
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MLG,XCD&1>3[53$0M04P!(>L4PE>Q-""<PR)R%>U/'X)9C$*W)E%,3$EY$;-
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M:S]$J#FVM,6M+ID'0#1VD/\U]3W7@)?X@F;>'<"S)_7DKS[GCSDMTWK8L*S
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M\@M%QVD"VDCLE8#1&\3/(2B#>!BN_(AAVY@2"TYD-C:7Y<LQ.^2J$&DB)&8
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MKCDV]BN=3P3$^"?X>]Z!ZSSL(6")&4;KS<I%>5?T6GV:=U45+*Y'OM.@E^G
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M_F4!6Q?8!QNEO22GQKX._/8;/97_JGL4C>!?>YK+_%)__>M+= K2)?%&2^E
M%W(!J4#?<6"BVW69O53<D UDD$W34CO3[94N9S_FQ_\NR U6#98]/P*X('RI
M=1EX/1E.<4HA2IZ/OVQJ*>SS8J$RT;]F%B=F!VJJT68L[2L-FC_E^Q:/LV8S
MO^F9"6T@!EUS=:L4.7-&F-#3<(:2:X8E>]-%)OT.RJ%6LKFN23?:\:H9GMR3
M'<0,D8Q%M@=<P3PG>8.R3IP#3[NK^X?#U" V)'$DLF*FF[)-P+^ZG6=XB -)
M5Q4DRLYW;H]-3KT1.()ELKU"K-7.:]FZ&"44Q3U2]1P/ED&\5%?08X)0>F@5
MYZ(]L@<>*\H(DA>PC=I.4R4R<T<$&#:52%<S)3<Y)R!UXS*R2XT[(PY?" S,
M"^'=?0<V+K0P2QEWZLF*G,?*-3$>*/CA.U:]2.[OH$]67 2H>'NXIT:(CK/C
M"!*3TS1>R,KM XFTE2>K!"Q&T$9H9\%NN&/.5=W"Z &X>9U1O_-^><VB=H&]
M(*EKKIJ%D JP&WVQZ 7>8^A1+G!FYM<9W+A2N[YH^SJZJ2C,[#NZ>6Q79R>[
MC?3# J<PC4F[B_"UH5[*QX&H-!@R$# 1%/'CUH5M"U'?LBTY7+"M+E];0^>L
MXT[5-'Q:XW.H2+D96T#"?21DS#RL&N%8H04C&2X13\/)OV'OT.T(!AZ1DAJJ
M0-HB/Z=WJXVMV6&+DMN\IGO7762]XV>C8^R:O!NQC"$Q"&];EC5Q"]Z^"PQ\
MO#@[LM[1D6?>&W@^U!'!K["5!%B019R=<6[L!IG*(>Z7QU-W $<\A"6 .^A2
MB\G*=4G.WLT(9A2!5BM B>KKW<U>\'D#BK 1D$D+\AG;HH+P;0>+B9FX?\(8
M!M"D2M.NXT%\_*#WHV=B:F)P.Y,MXJG,S3@V+::]$A_J<ZV^W,JFC[W+!=P2
MZT,E&9D5'%-9Z!UC6$DH9+% I%>8]KI3[LX\(OI2(7)^MMS0*62AJ"#]FS;!
M:2V,U!CM2$[R\GTK>MZ;D_NN7BD,[B=329Q=\1*C9_[NIRL*9FO9D&G&KOIK
MLM+9\\^>/Y=PN_L5@0/ST2L7_@!D9YZ5.+E\C7D%'?2%[A?LL,?)ZP:APNQ'
MSI+_&=_#/[\6U""]3*09<23\AKH2;Z8$]R4]&B<7+ESSSHRM?!TN!#>ECX:'
M.>"$E^R?,%?,'V?[4%+$\LFS9_HO_G-\HT]SF3/_9%TPP.^"B4?;JI0WB<.V
M5-<H\F^)0P8NAJQIAV;L#[%#2/HBL8, 28R[,%Q!$"(Q+F/$\G*&-BH^XWLN
M+:WW%Y'"C/.IY.L VT)/$4=9.\(">+2XSXI=H!P9HO4JS8N;?[<Z,H=F#/PT
MV)N-+"5V1N*WH 55@QZD886\YVZF1"G"^4.Q,E,M?_;5LJG9KVC6 ;]X]M6D
M57TMQW8MSA8/ZQ>\X[G<Q%H)6@V-(;E#.LI:WC#>5)M^P\CJBV9UL6T67#%
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M"%LX%VB[ 5S.+IJ^/!Q*8"]O1%JXWZA0]'6HM=VUL1]]\ZJR8$:[$*0Y;U^
M\2,WYN4-^5*12())E>60E.-P$M<N%&=36:"GG6$3"<*,&-_VSD/9V<)!]T=@
M_0TL$\?LZ!B*P046.?-;AQ9T@Z+FXV!OAY-19^3:GYY]?D:NG9%KC^\E/D[D
MVCDL?N]A\;@?61QSU&:'C%!V4H@$B[)\2R^9^"="4E'OSWFM$YQF\*\Z7JYL
M:I7@/#5=:<RVFY!@BL);$K5'LU 5*WIY%3_(.\?.1G&"1K%C@ERM0"Q8L.28
MP'1D>CT7)TYU/D>R>PN%5APO/H&385%NHWS\>7)/<'*31$7MY*RRS,-YWDYL
MWH;\BR).<"X1G>!43;,S6=+C:>>BOX6VFO%JE8M_]Y7*.]-V\QVS@GT=PG;V
MM]WR$EDJE$U&62I3C%$,&;W1G1TQ#KK(F'7PY*^5$(MSEHO$HCLF]O"UG Q7
MS$P(F0!O1#["T?6XPW)Y2_^1<NUM: ^5'%*F+=';1\WL=85R?CEO;@72;:!C
M_<! AF"(%?.OD25=]7$A@")M-):!1?EI,NU:#)*NZ*6= N*)5(EBY#9R)PA@
MZGC(</3=>-CYU40"R1=^',$%^G[37.@]'.E(/B>6Q >'Z+T088],C&+C0O\J
MV.'+V0O_D<E;1D!Y-MVYI:2Y;SBO&81CHF[J"_\(*@8E:KP\3Q@VB8^V8&ES
M, "S^N'H>![D"9'J^% ?'<#YYRG@N;476 'C2)\&]Z5L6$?,T=BV9:L$0@KB
MXPBX\!P&^"!$O"VDO;MI%. 1:$S1W@'PN_(<,@Y:I%@:SQ<+6EB$4X(A,/+E
M;;.--,\3+R)$3J!LX6?W@'T'\@>*.@S4;;W\''-XJP*T"&)AC7.OX/T<0:YC
M@7D'M)7Q:==MV-:8 Z-9[1(.H4/N0BN8J>"FNB3<V5.K!!GW+W)'4#09D1!=
ME]M. $*T9[8X#_:RR2Z"E4:!.$A@@RZ$UYX-Q6[U )O'25MUP&/0@'-;C;7"
MLO"=1.N9/+T(F/&KJF!ZXG99F^ZUX&7O#-!_^$EGH6S75>"55,O&ES (0&Z;
M4B)OZ5SGA!#1Q1KL,!*IF/J<4+W6S>RZ+T%5H@U5AWBJ37#9]8-:!U4FRC1^
M0KFO<I''MJI(3Q]S'7$="E%68\5SOUA&S;':H0&_R!T"$U,WB=I 4=V*Z4_;
MU?Q!)O9?P6AX97]VF)G0;+F3D;9BS "C6+@H&GG+(N@@[9<)O<^_\&;.W),M
M%_HO9\KA66"I=[M^6>GI(>TN<IC3,&Y*$4%CA>!:Z?3;0*9A'.>2"(O3)4I=
M\?EA$DF>M5;].I$9[W?Z7)".$I=(UAF$'C/YRIW7'.65M%PR%3I.AO$1<U\K
M(]]3SSW%_UB/#!FAG3;)*,4CO4?:G29 B]D3+3XY&>0!KV<>A+@S>]=XCKKS
MTY_RC^RD?$J.FH >\CY$#PJ,2F\\Y_=E&4U;I;FKE0];)5ZJ5O6-'5QGT-%E
M3'**G3]D^1YJ=E"(<H(S>F"F(#Q6-EM'BF8WE%=3D=&G[3V]TE89^$.N],.1
M*UP)Q[#7MS(R1=[PFQ%A9/9 ,_074,9)\OKG__H_S[]X_E7[NMH'/;=5JH&W
MS4-=J45LYV&3(2^)^<T7I>!S5')$K"7U>-AI@*!MT,TLJ03CSIYH\LE>AVR'
MC@V+ZUF?EZ9SD!@8JLX?? O(#1@E9U-'/8_!B(Z$6;(UMLHZBIE@'F6[(V--
M)UJ3 YORE M2(Q[BI.ZE4S$2\98^ [K&F*<0PDA1$4YP12 +KAOX3=5MLQO[
M60DA58>0$X,YITM6XY$AF=H("B7P'Q/WTXA50LR;[5:)15G</X@H Q8\1M5U
MGG,YTL5S4_^NPHA*VF0#ZH3!MIGWRKO7$ 'GJ9/0/8:[5@+SL;,0&7"8/$&W
MNQU+O:(/'0D8P5HJ(A!/E@FC6T\]VT:U\]MB1BR[$J]K8$)'J2#LD,Y<AEKI
MR$?'CV5OX$4&MEE1X)Q>#7$.IYV(!^_R0HO0"=6>ZVB'+62(4A4*-WBGD/KD
MK,ZI#4W><+V^X Q@6$X>H<W6]A>ZF3HPN@Z4T9TSKW@J%6/G)K9R@Y1E='2P
MEQB7T2H_=$$4$%JFBY]\ GHX.R:G!G&JVSKRS(KS+#AP)VCZ -#H&<#XIV>_
M/P,8SP#&Q_<2'Q^ \2D%?3_D;$"_)-!>!M97A^O%9XR=PW;B9XZ%:K?[6QI=
M2#!^0&W3*Y0Q+N8L<W*R3$@SQO7SOJ7A]Z$?DYC)SWVMC+8X!LNN:Q8BOXZC
M7(]3X_B)Y[ Q]?$3. Z;H]0W3SM,? <F S]?[&9D-@[A!-B3_AP).KR;*@[)
M('S) Y>[R-"5?]57;#F4T]Y03508'2/ZKU"-/$S_X!4S[#(J*Z?FVG=&IS=A
MB0]J\#A#1GYKR$CTI@L@!I3(<G\QWU_H/QE/4*GPD[*%\G'NG.J,(S3R=:H+
M/6#.5R;2,\SKU R!ITR.%>OE6^]C+R=^#&\DN:2\2FY:R3C*-TR8!).!,6$+
M<N>3B%5G,H4HPBUNLJSE\<T,7$GA;#HG9CI*GL<GQ4ZU>T4&8 J-UO+5SNC<
M4YM#:<A$^5&9"[:@J%P$S^#8J1N(;3\JX$QH_Y[G]\3F5T3)G=*P*'/*/IXV
MY?.\G=B\96R#21.8(LEE&(C>MZ8^CO5(GOIJ=9[/4YO/0'/8,*GD72A?<Q"=
MJ^NNUJJARXB-AC/^"Y3K.XLR!QKQ--,,\X0JDEXZ*QR=#>#4#$##:7:2.@J%
M!,\M)<<(E^;P'DRT_KQMR[N8F8EDW>V0"=M7BDIHUITMX,0L0.4+-5KJ%#&/
MH)K#'?6@69?YO'I/=.Z854UF2*"N*DIPGJY3FR[RAWKN$)F7;5N%]KR@3FV&
MN"6%QE+A!(L]8WL$RXI:R6K=<_X 'NYY[DYL[CCFI[BR7 !^$;85Z-*Y88L<
M4/QSS(I^$\KU[L9CJAA+!?1ZYP1\Z0 ,F^VZV8>0=!VT<"9^[CF#?&KFD#4*
MHS]A89@;"F#Z%JDB1J1%Q^;</GQ2$XCUS/7A;1MVL?Z'I$,9L[BW58=T@R0F
MA/!TW7"4NB[O(C!1=#2XT3]^GV& VW[W+L'%)]@;\BH8J!"P.&G2R9G9N<DO
MMF"4C#4O'%--_*0(@H@45AV[J=RWN.M(^R&L\W58^<6WK6<B?PI_(25TO)Q]
MFU12,N1;7=Y6UZ)$SM\Z!#;@6^)NUG 2)N52I!OAEY2PK>E6D!)R*P&>>J6F
MV(1AV P%/'Y\O0[C+I=#S2&'FM6<8EF2H&0<I%=:<J6 <M,P^/EFWW$O7@UG
M0-H,B]E-TVWYT9&_M"X= 2,Z3R'N(6,*Y82-'8ASJ;$^;4 *)C-2ZR)KW]'"
M]FU_6G<?#,N(!NT +F5RT/T$RBY5M<L+_@K23UE^>EON><&*.2"A.6!_9754
MP)/729G)XTN\&B!M2OHP:ZB+T4Y4@ SH(G;$*)YW]<0;5J[25AEWRGFK0&FW
M#+/E.5Z:W/+KUN6XR:_()E<FLWC(PARV_06Z#@@>@#V3?5@   ,I6,?D?-NL
MH;2U^>GO5XHKTD:,JIY P<$'B?4/T3RB,;JIYM7.L.$96P+]P&LA]5R:8%W.
M"6:GM\&]P#,A(G7T"BS'Q$Y-'-2LMRLA[UTKX33T7C+THY:P7P RD][-9>#>
M"*')&L[[P1[LK$-LM*72\Q;93@%\4&H2?1OBWL?LRV,)GJ@OS^#@(VQ;T1$*
MW E2+O9Y:_N84<938D9NB"<<:#_>N77(U(:1&\<ZE 'L]3PSC.HXS^H)SJIK
MTI>V8%J5B@KF>(EQ_UTE36_B!&7E8\@<<DQ41D3 7=DRN%-H-N@T 2L ;>-J
M*8I3[](I0'%76-]?RC@W,OWIV1?G1J9S(]/C>XF/KY'I?("=\ $VQ+XL;L+B
M];:AX(=.*H1SG%+@#!7*2"+CU'B&JT.,X& S<G3@9X_G! TF,O*3@T*A<15-
M1RA8F(N(;LN(507&J=Z]B*Y]+/3LCW-^><7G$%7)'_7=,"DQC%AVS77 <G>D
M$Y)U>NI(@,<YT^@AK*#_:[H;1\DDA:A+U!:<]H;A ) #5$J-6/ZW#R$?N7*I
M3'37DITMVFIN%:KX^;.IG*"IT)80ZFM>V:L!.4=&%6/<'C  D7E("<Z*H?"&
MI-6.M2&3[GGR3VSR!03$#J$6 HRO.SIM3:1-3MR3N@4,$I)/%CSR.*?6L0WY
M*E)"_IAR@!#,9E A9*6URFC4"?XXX0V^W#/UY$6SNM@V"]D M'&^2Z26Z;[^
M;K& D]WV:>-0K/)?NG2_58 8B+,N]V"UC21:68E !;50>A+5W@=2S173]2=7
MC5/R,ZE[O:Z9BHQ[AM<SI,=FU0ZPEK*O*1!47 L]&AT#, /N-%4<R@0^8%B?
MUGJTNIW"$+SK!@_4*>D;FN"RTETB 8OE.HYGA:'#T#'''S%U1&9W 7?40!NV
M;(/]/:I(2U"DE<](CB]0&]4EGN]'+/V.05P;MVUP:)B883G'!(#0[FFOAHR[
M<,CG*C5U9 M\+30Z)B(742__>P*=)-SGB:XE-Y\(M6GHV+N.1>OKLC4U _[N
MINHZ=6*<D)VB9AGOD%RDJF9"LR1SVX8MS Y-"(Z97WGF)FD&E=ULO9]]PM T
MWI\=876V?*"[P(5_^<*G2@:@K'K73;,<M!_%GF$TL/WE^Q\+;1YVWX@[QN##
M+WXL(C!L2&#I\&%E/O[&;(V!,B3,@*PR<G1+[EW@,U7W^LAE<4:-62MF&S:J
M&;,JL^4CW<6$*!!%E\V,GH"VTXVFI6*E)7_ %.HHP8ZU>Y$-]'72U/89M':V
M:L&/OMB+;L2ZPO9JB* N#.@5.J!EUDHZ&%G"5PGCIW80DVMDB+TEU [1MLNK
M5]SN[]]((1L '):I3\U>SV#B.=-@X32SH^J[&C8G!6672ER!'QM\[X4Y,3(D
M7H=IS(=-=B/2:7)@*RXS4EF':S&+8V _KV@"S9%J!Z5FAF3M5#I R/0/TA4/
M$CD&7EGOGS9$ZV62E%&&RP>!;@J'K1F)WR&H=08P[<8:X<[(ZTEUX0RC)PT8
MBU+828W,5G>C[^%2M7(_^:%:'B";I3&C)V-AB)9WT.NR5@J@;B <DY!DP(8:
MX>Q+=U0F&#$W %7=#ICDZ,,<7 4=/4O?677A@%2!0H:/06 '!X91NML:.JQB
M00<P8]CH43B5A<N5Y+C&9\\D$D1"HU %'D&9T=%(%Z)-V&C[!SSR!AB+;,03
M9/9/VG7[<2ALHU[),OK_:8Q5F*)JTVG2&>!4N+Z5@WJT6)BWS"Q+ /JMPF)7
M:H-BDSF9GMPKWI]"@<A-^ZM6+IW<K;;^TX.Q9=FLI[#J:<_ZS^-16096L]#5
M+&7 /"W$T[$7IW>A FG*K;?A1FL1AO4)@-E/V710)%6.IT/;#[!+]]M[,9!"
M:<UK.TDT"2Y[=.4(OED&9K"NZC(Q8&F))+F/57=&5YY.LJL4"^/P6Y(*POP^
MX^R"=CA2T'^N2)[:O'%\7<SR_H'49!#;2\[S=F+S!L=JVU9H"5?UJ:AGH9GC
M\Z2=V*3EO3KGHLT)3E&MNB#2&JH18@WNQEL.2*Z5*/II.YL'O/;<6<^\,6%I
M<H%URJ&-'4A./((LY@+:.OTF::MR>LXZDSP#M]4)>@4W(.*QF%*NJL5QJ,6@
M[,9[89$RIW:#M *1]J>(L8Q;Z 00A]N)1J[WU$--2 IJ7<A#T@?Y:ZL< ?5E
M\J427<WRY_3#S7B@&050:TZYKL;E0Y^VF@<;UC-V_0AV_0]G[/H9N_[X7N+C
MQ*Z/%\JIG: "W:+#<*=\"UK9GM+9C&<LBGVS:][QTTY?K;2[W4#A^2G<BN(A
M]*T3XL11"\2N6DVQ9SE3$S^6A'8%U7O-M4\<W#DP8-'0W_:6:"HCJK'C&A97
MUC4U-V=%+!J:RUG,7(K8U[IZS?E'EDSKPJ%\,GV,3[\X1N0[Q'SGV"=AS\)2
MBSB2D?7*VX_91Y#B<CQI#Z:S+V<O PW 1*92'8:8C=IU8;W"^ R46*T$Q1GU
M;A?*I22_;'X$CF.8_,I315A)*]YYF12K90RL9NZ2ZJUX3\L>%C'N N AHN%>
M.NE<R;J2]</[H/\6LQ??O^1$>]4%+0[G188]/>M&KI,GBO-:BM3*O??#UXHE
ME1_CBWX;PNPEPUOZM7B:/_0[P\C^V#805>3LQ(]B;[.7> #S<YQ$(8H9PKT>
M;V-&BI(&6&,6+/$+/J9;J2^,[-P2XY;X%IN!$S:\;AP-R-9)WC+]L14K>J$\
MQ*SCEESDB<J3K"1YA_CDFDN+??GR28'?7)M8IQ:4XW<PJX=?L=#5@QM-H)5S
M-/'A!?JT Z'O)@M]=<.X(2CI,27Q8ER9'&\6$5MCU3R4_L;S O8".CV;-A0/
MOB9-QTSXZOU6QUL%C #AD4 &F]8M_*8.QQ/O*=(:G%$1.->$3@Z7SJ%F!*@C
M*PG5!TBH3U[*[:',F6%;MQN6<95_N+.*/";^)9&88XJH%LI2T7GU1^Q9)APT
M\[FT-HBF=ZU2BQSTR\E2IY=.5'U/V_I?"?M9O12(0WB=&)*26O,A6,SDRN%?
MB28KO2;]3<$M8C%T@D(S/5=M!B5)<I8>P-&$AFZN?D?NG.R*27 V%Q9K>Y.8
M]8PJE=:?_!7<20)%((3X&0OYCHYWG+_RLL8:)?Q_M%G,*\ 6%RAMNF>8(K?'
MW63O][?3B]$)T.PJKTB;7<. 6IQCX%UBQR"6*&B,Q<,'OT!-DY"HZT&P\<[2
M/7&PR4'*>-CB$V:N8@)>QN:$*3P;]$+CQT>9&GF"-*FCAX'+%U58W?Y@O2^7
MLQ^T<PKURD[EPM?KYLZKN3;DP;Y1AU@0;%#]  :23W^&:DE9DS;Q:J>R/CI=
M>B'%"N^,CH:N<U>R&BMY*M@J:1RT, 8'0.KI-V7'6 L>4IK$O2P_IN6YXI29
M.#F%";+3]*AK'=E\X5G/ T\<'2(+EU$*4*ZB(73%\T[TA >XW 'THQJ;^H)<
MLNYBWK2H\&T4<<E'#0WD!48KTNW3><=!4)G!7]P8F!VSZ59.;^MI[ZP_QR%W
MV*:'(':$&CT<9*T;\!5A%?+!QQ.U\KYGVG8GW%]&1$Z>_H>Q&]!(YJPYO(()
M8]_>E.V&S*O?*=95YMT!<9UG$F\(_\J@]8?= HF"^665*YGQRS2<O+FED#MA
M^^]'4'$DN5."$!PUM9!0-4[$^L%34\P0Q$[</WN_0^\T!UQTC5^'B#X3UJN/
M#@+*2P<T38M8AG!Q%#SG#7.K59UV5O((ZHXI1TL$<.YC3<!!.=7/.' "9CB^
M@?"D7[2'J#M->=+Z)T9RHN8HA#&&_;>*NGZ[X.H$ZX*_^],!OY6,"UCN>0AU
M/.^M?X##$8>"BN8'JMH*_MEML"H1[,O9+(Y^VOS BUOR0L>I^SUX )]_]NPS
M<1]_3 D1$Y7CQ[CB1ILE=I47?+4K-#MP@!F@-J^-,W\57^.%85F_05,.7^0G
MI@_GK)_\>"7DY7)?C="N7ER1UTP7W5*<QR!=V?3(<:7=$K#,]3YJ+2&9P%2[
MSKNI.@6VRP/-FY&?"D)"25:@0RY8BB(/:"7+(3>!QL_@6"&[)C,G]P%>%Y[;
M@6SY!*FON^A!!8'#<?9MTV\2OK<-<ZSBYDZ>-_5TL(\5LS'I"U^W_34-)'^+
MYX<3-,+9\&8GLR!)-/Q=$SAL#/2T%1VP/7O H6Y9ZP3;>[SN84AQP?A8FO6J
MNT$FM&8VZE4DAR_?!+1YY4_.CK<B>.=MB0?3/O$MYAX@PL+8(3<-+X$2'F-*
MVC$&].MT@%V76VZ?@]=FK\;=&"["\%CF-G!P/NSYB:=;:N1)-/IJ@$_;(227
M^ZJ_IL>EA??\>9'L^SM3P"+SLN9N+'%=FM_]I$LSU"7[^W%M!O%/:*%M*-BF
MD68H_B+E(7FNX\G2#G&?-M^RCN@F<(A<&\Y.F;A]:MT(;!2[?V!IQK//)1_U
MQ!,<.#]E.^F;Z=_-TQKUK4TG'?P&H(]( 56M#X 11=YXA$2.1C]@Y-%Q3Q '
MO]^K3MDB;HB%="HQ6AT?=DYXELMUY*XTJF1C99L_X71JEWZ+[H%7$4./M 8+
MJ-\(98@#)/@'-5NP5$@T(+6LH/KF*S$C<GO0.M&3!P+&=%NSMHAAB7"(RYVM
M:EW"\&+L?II;&W+1#CTH<7R?]JH7HMIUA5@_=V35E/-DV;"4$H^ %-)9;UBZ
M'&T%[6V4+?6)J$E,C\MPH$%P RC*&[IM)X4&-+-QNHB77ZUXJ(+#%3EARWKT
MU.OR3HE6>6%<SOZNWW)K09XN?V+7;XF]1E+<LG JRVHA)!VUF?A1/>->CN!>
M_GC&O9QQ+X_O)<ZXE]/$O;@3[$&G3>ZZH090\ULB"1V5$6XH$+OEO""0$^D6
M\WYY'78L?\$EC5W+,08NA4/KFW\,$OTX1,3-DCAKBHOM88<C^\AT3@2F"S]X
M:G$<U&_7UAS'KW"1<O=3A3 [3GT2D1Z MD%]/BXKW=&!KZG3/)TDLC*10(Z"
M74.JFO0,G=AT,I;[ ^FM0PVZ-DZ.!2 ,NMV9N> 6)[)VUZOW2%=TS-P'<V?3
MC:GCIWS:_F!*H0L#1W+<QRE.BNK8R^\4\D.SP5D$<^;+9;,=Y8H+C#C-L\<'
M1\T@[0K46ISWS'!1YAOB.<I!*\F%-R\S1Q^/<3G+L.&/CV*W V% D\4OMCBM
ML-!9<53UM786>]@'R6Y[9#^Z0P^?>KT]GBM/Y?+G=:FAHU&+#$;JL):85D8R
M16F'T[=%1OK@)LV2P1(Z<?:ERT=)\ \S55V=>W$;^MIMA;-]7@I63$N88E+T
MFQK;@W1GTUKJK05%%3M468LA#V%Y@/?'P2#<$,G.'://[)ETW(QM%A%BT!Y2
M0TN)M7?(6>#?NE.S2\_)K5E 57U[HQ2H#H%AM^7+.AXEKG/74MY<25')?XDA
M/#O>DSE]:=$4-TE;59H'$IO6H!CJ;ZS/V[2>P,6CN 0DUD9X8:H$X+P93>4R
MT#FSG)Q1KL71.=2[N1W5%HPGC)^KZS;&GI)'XKKETFX!'00:.L[.2=!OR0%D
M!67YR%[SQ$%>*7-"BX,A'I+"&&^Y/I6O=;G)?386,K-\BT.6\+'N!3]A*@*'
M5:*B>!"0=31"=)25$6)!RY=8-:6'J;N<O>2]1R<P(Z.I$\>.'M)UEMHS<;A$
ML1!IH++=6M-0T[O!G=6>G6B>]U:RXQZPV8-<%$6JEB6G OEG6N^'^'*<TV&W
M_85EM*=4/$6=(B<8'12=A]"G2;Q66'?A#B6Q#7S)= Q.>GW&@(>[2>HV P%.
MY7!SSUWWL6./\K3I=)A2S\2 C0@8M!@)[F1K]*'(.R=DEB/NXA;T /"?0#T_
M//S/W. I*.!)  &GQO]7@ +=N.E4^&=UC9/;?I>=$<,0M^_ ";IZP&">.! Q
M<]0F=#C!XGF4B2H3=\OKS@?HJ"(6ZAA2^P"IS1$ JYUW[&!@1Y4R-*#C-G$J
M>G<X,'S:3ML0HXB,3T*?-OVN0X?P]"9D+G"T7H&UPX':<!5V[K@OYT#C,_6;
M<<R5=^+0&.>H5$DSLD$Q?KZT]\HFS..6TU=W]*P&UU< I*1+! N98T,F=E%-
M.=%[;V4!\OLP]TI^C +WKJD<(!(0QJ:\5J+$]?D8B8UB:DJS78G'V!I@#"V8
MOU]91[9-WK=<M??P?6]ZL@_1H_PIH.2S2+L6NHYH-=# ,=/D$,P+YF1V#<,Z
M(T]'B%.V\VJ'=3H/NSM&\CC$*@I09&(1P>HO7&#7LEC2&G3P(I>SJ^RSXJIJ
MMUWI:#G0C6!=#Z-7GV'*%*Z&3C&)+O@2&&%$OE4;]*.U_EM'UB4PO3QF;'-3
M4/*Z7%CU<.()O(CQY.&FSOK<,?/ZUO<!KCM5R*W/_:$X;\E3'=@>&:4GE>TQ
MQ)OW @$F)RR?%P\=I'3;M#(C\QT:<##=])H4H:.W!98N83W3L=H:E61%IW.;
MIF+0DI^IT*%U9XB&]4+$ DA/:-'Q@HH/W6()IX33>.#(//]:L4:,</H4Z5[&
M*7W T5?=UU6#IY$7=.DT-:QL<^5G*Q*_7&$KW=S(>1@<JW1E1B9/W?]R]B.X
M\6,UVU!&G4#:QJ36;>9D0'J=%Y%+ 4TY0F%JMJ1C2#'I8J:] >BW[K&2%Q;7
M"!Q6FQ]VY-@-83JLCK[2"3_:WN[0 )8]*C/D 5&7,9ERHD:)U!B:OZ APZLC
M>5MDZNYRGHC3,V=]WVE,:BS4>%[T? LYOAXKJTRD\_?.N"=<AZ*Y,H<=DW-!
M_D_/OCQ<D.?'KY;_]^_N+R\^_^.7SW_W_NOX])*+"QHXYJW^WZ[?T*#NOWIB
MQ?WL'<,;"+!]]<$?\%U4_)_ FTW" )[ >ST$&_"^%M]O&-J-DI38 G^JNM<=
M.?Z1$8F/G6]CGO=%EN=]40J-PD\N^'IW@>_G7SZ&K.[?FOKZ@FMILXY>@[Q<
MK/?\$"<O(A&7TYB6BYLJ&.&C.<>@RY \#$.P.X1#:V-[A7-2Q[A+J5Z??MXU
MPR^DG@]Q<]$')XS4*#M,#>OZ ?,C0QS1L?KK@F(![3P3I0GON($%+"NP:(^M
MMCFY6F6STFRO!$32C3 JM'2)\',$UB@.,J1<K<GYZZ]1R!F-B?- U7\<9;&E
MIS!!E-6YS7F^!5O*RI>E):GO<K"$YL.F?-]#=]9TGU;2RLYC$^0SXN7?E770
M/M[$G)PF-7]7KKKAMD.P[M%G*<3-M^X,H!CH-]*_.##".,B3KSP=6>K=1TG0
M+(&? SFB2=Z$\K:2'"A_12V.WNZ7$3!__H#-X.+9>.,]LN2O.-EP:*$_?UI,
ME9]??BE<HM).CR)]%] K)IF!D#,>V@_Y=G!@-?\*RMCSM+Z+:>5"F^6)4Q4$
MG4# !S;U!7X8UT4Z3PESL'\\GA # H;SQ)_DQ+LR5J>@BY@5C!WT@0$>OZ3J
M^SKLZ3!AR-*6O);N//T?;OHU0VF^PL1FS40DN;;8HMR*5V!M,/F?)6M&KM)-
MM>U,GJ-JEU*@'F3*K783"YJ?L!<BS@Y?&F2SN_VG!UP%.**B33MYX%B*4>UY
M@ &=AA=-P2:=4M!YQ_K )CNY2R6%R[>96/2K>Q;#[:^4KS_/\+N882D0)7+N
M% XZ+>*IM_FMHO/NZ,V_I/_[13=_V&S.3G >Z2!Y4!O%&(=0S)3Y?G?3(IH?
MH)6;%KNOJQG&I! 7^N;[U(R*&VF828^S",4 <IAIFE?UJBUC75%!XN=%_\$6
M/?V.JZ0R5WNG/9[4=BVVC*=Y0C(7TJAN"#A&S,,A8!Q,.O1=.7%T1)QW_0]L
M %ECOTO,,1JTA:J!XGV0(YY8O>>Y^V!S%T&8#&F+D6*,$&5!NWV]F*W)?Z^Q
MVB-6)P.5H(4F ^JC.OX!9OJ#'ZV/QABTD@+R(,QL+TU@=7<.\C_DZK2"$'H(
MEV$5:A%(W"JC%_\[L*!YA(K2K&F#&O*U%%^OFG75\.')V_&:$?.]9/FW ;2(
M_ BYX$RYDX-YUU)P3R'[H@T:B+$^]\5-<_<KE:C.QO%._*X=*ODP@INJ36!A
MB[)%[P<ZXZ'MFKH.[[(;^@-5NH].X55T/CC$N O6H8JFE[Q#]: <;1:V1BSA
M5 E.ZFRV3VK[1.RSFX=]PXG3WOIIK2UD90W"$1"KC'O??GTU2,!^']D#KJY9
MM1Z0Y&^^%]JD1H'%J2K+GU$^8IIQ8/NSTHX514&@#(SKZ^ 9OOA9\Y0@?4@3
M>=&)JQ*.7KASFB[$#C[7713[ R]G5XM% ^XVGA6A=L+HRXB-&"WY,;12Z8J8
MDX7RK"3^+IOS'@>.@^U/"9RDK->OM>5[M68'F_.R&7XV*6"\#IT?Z/%5,O"'
M]KD"JMI,WG15HBV*D;_>W%//DG%^SZZ^?NE4O^VH@H$PCJ"[*=NXFB08_ A:
M]0YUI8X'&EL:0VH2#GM+ 96TX(ER<X*<)#,05$0=W)U8L+")?-\UC=-L*5\K
MY08"Y8T*S9N,#$*(P^,>%[GGGW03T;<R%EHJ$4J5C)D!&R%HI7D\.&5EHH.T
M2]IL:'L@.UR"O!'(/$[RDODC&-+?Z7:MPT]+@6DWY\$WTV+^*ZPF\O0>![KB
M:89.P.L(1<V203C:H8ER6>K<&WH0AV.KWQ#8?A\L]+30[O_S(>CGSK#U1P&"
M/L/6']M[_0)*N_/A]<X/+S"\(2)D'0\TZR'*RS038B]Y$X.&R<XN$R1&X"E]
MIX\8._8T)YPGJ%E(L"Z!623XN442?ZGA?]^.A)= 5]WM?(56FB@E67*>U@\W
MK0,6G9SK,=+Z'^.0&-(MCK\X1N/O,@TALI3'5-7[* Q!1"$P??2H=SL!?G=;
M*2=\3+-U0I,2WH0%9P<D>=)N&W1H-"#Q8=*VCV1&3G+]X'SL=RRKA\:7V#!A
M?(W%\%AT&?D)U4_TVQN2:LMRRYU4#,""(16 7G;@*9;&CV9YGJPQ.&:#,1W"
MX*@=-MBY S6B6B/'::),[/IJ9SGRMMRB'8NL#.2<9QLX@0,U@\<K9W6]]R5$
M$[W #L\0FF*B"?,\ER<PE\C.EP*%B!MW,Z=1-4*\U.&0N(Q!#*-[]%2S@3)7
M37YQO&V(Q+94G#/D+/UJTX7U[: CM'P=+IKV@FFUF2A:!7_<0W],EO6A#P3H
MM*$TZN0\MS3;PCC=[R)1-,J=H@#'VP7*F_ZSVW59=QE4+N<&_D@F]"2WBA;$
M$E,@$<6V*M*U9,JV7>R1CM5 (Q7\"QT&-/G#!F]C09N0MV80/BN(;==AMFX6
MNC.())*1+HV!*LSOQ/"*^(W'A(Y_FB8T#,59.=+E5B#I&S7UF'!-.+YJSL.!
M]ZN14*$T%L.>\7X4CX1:DW4L?KQ>,HZGJL4NVQ[M4.^GU^5ATU0<N?EJ]9ZK
M]*?9:$,N M*E$5A3A>/M2.][E*#M8K*FTFQQD@-7Q,#8+:2[EL,E%@Z/"J5Q
MT9R/S)/9[P29(DBS"#PR*%/))0@Z5U4.!=3;3& "HMRZ_B!- ^?9',ZFM>UQ
MH4C9  0O)EQ;"D-VV.,"/ %RN"6=2<F-&1#Y/+,G,+-NG4KC9^PL*"+$UOH.
MI+L O0:2LS[63G">W=.:75-SXW5+_ULI'_2*B[S:S+NI.F2HMZW*NL>TR&W5
MK#,<_.3,#]I%BM@K@CQ'[ 0]YS)/PS8.5!I$#\J7D&7M7[,&.U-UE-6FDV:B
M9#Q1-.K(CB"?<60B9POX<!:04@C ^.S*:R-:%YM  W=D>LX2#O$O3O^-U[S@
M13@["A1SHOH <Z"8 #,$,M?V0GN#Q[;21-$UT-5,=))'^<+'UOK]-"UITHOP
M/> +95N-N'@P?#O.2&E8S-)FYUD]@5F][V2PJ69VCG!+6\1;S;JOEQXHD4K*
M?"2#2&=1&T*DCK!TZA0TZ6Q')V!'#\Q]KDT_TWR,LJU ,J!B2(%57(XRPAY!
MM6DC309:S;G!SE;RX:PD5DM\[KJ+(KM;*'XT/;R48L9$0*]1;-6""W^G(6/9
ML&-0ES3')71\RH[^<F)GR4?-+C'8#;">Z5>L,9RZ'+G<0<NW;?>KIKTKVZ44
MSU<K5D71%;PKWZ#1@W;_9A,^9 K]HS.L#U^,Y5HIDTR&5K1\*$(MD4Q6[1U8
M&0LM^P1DY,$X*<Z*CV'2C YAR;MS7VL?>49':_IF[ <V2R$G!9P"#.+>R0/I
MHPK$2PY"$E,GN 7^[D]/6TWQFY).9\W[6(?RNH(./+GJMU'TS:M18I*9;8+G
M,BF,1V].-;:NU\U<T0U]S8>%51ST#V'1U,WF86P/CW9\O^ZM;WPHGS$#TUI3
MVT@[?F9E6[#RVD"&"]W^Y%?=@%E!9>]IE3&10+_ER*J#1J"!3?1[(X((I1;A
MWC!A0'DK!HI$1""E0;WB@(A :4)$/D__3A-ZH9\4/<"J2SEI]\[Z./P*_!SZ
MHN7LNFF6[@4'[^??ZMR5_7!K15?V\\_.7=EO?5Z>N[(?^YN=N[(?]R'[G1!<
M.K5W.5^* QQ'"].H%)XCP0$[:B^R<2F%*,%^N=YWNXCGZX1%1_#"<BF@^@XP
M)"%+*NQ'LU<WU3J(^ZM:J72T[1@J?"=E-P6>X^E%MC4B;\2I8IWA_K"2^6Q;
M;<-:9(62NZW#HC3,QN>U%*H@\O6V444"7&,LN>IZG@38C'9A*R#1K=B!+Y<,
MC(W:P'Q"RU& @QH$I E%KWF BW730._BNJ<G%C"*U+,CV8I0D:6'&RB\WP53
MJ/72TNGK+!>[;CK3JF7+()OC:6,"MC:IR^7:IN@'4T^E#1IUPM\=I=$O9U?T
MU70?_E"9?03/P8,4KT=SN@@5\QV77=1&92L*TK/0XHW@+>&+@BY/2GCX5+KD
M78B%?;P3QV9%*N:5;%>AU=(@.L+-4:\/V*E2VT#.?KTF;W4M#$<B?S7^/-]+
M#7L8T/6U+*>P',I"VPKD %_4S3:LL#Z8A<QX]?&[<L4\5MK7+HLBC$BE[0H?
M'X7<JV,DB0H^'M&,!14=7W#?VL'/BV=]>9+1^3ND*3M!1KD?Z1R(W46KJNTX
M=TJ+<Q_*5C)H#Z2X+.2 .6P:T)C278F.D^Z&XK[F3I7E7"2FQ'+-P& R)3)_
M>$1632OMR F*OVF6[["VC83$#$8(2W^4\X/0AD0S7%D@2C_>XOQ;EPLEL&[:
M]Y-$^Q4B$;^5W51=U_/9VBEW6<;(^$G:7 >G/N_KGX+GA;&="Y% Y$X9;*U0
M/^<4/M2*.I-[-[-#.W18/JS@"_>*3]>R?DTF6&I/C#TWSFU^"MK[=Q4[$G0X
MOE_VR-]J:FR?YH715HS&71:V&9NJ92XWFCY9&"NM.+/L^BD%H==8&*Q]&7QU
M-]=9[Y+1V44>W%>_M;+F*^F;&[ZR;!)1?Y+>[^ &4VK/W6MV>CIR![DSH^5=
MC*XS[ZLU[QP"B-*\8][/?UW6MG>*0@F[&V0Q^(9OX::U4])K-#O::NH=N8!#
MCF)[D5#?P(8SE:XDKF(B"[PBR\6_^THR29SS<^BH8B"P,);Y.M'S^!NR%2T%
ML!<?82"9/ U6@"!/I*+ ;H@B42;D:?D3-&8MN)-1<,RHB@J?_XO&JI;(F'=)
MBT9J1PL*0'R$U2,/!N<[/C">L0WFM+M'R6XNO"Q\I6+8VF),QUW/C4(5V]M(
M,*O(Q7@,)E%1H"1UL6VY1[@I8KFJT::7D1Y4;.(\UOI"3YP;_+N5#>RRN$?J
M^M?)6R,GKE8U[GEQYA6E;PJ+KH0")LM+PQ&B'8/#TF)VH/4X;?69=+2(0$;.
MBDC2E(FK34/X%,D9]Y],LMCS/8EP,3.9&WYSOK/7QFD?]WU49:5;,=>)FE'H
M1:?[$Z<.ONHPUW$Z%")'QX VZ_(I1/-_O2\.G^GCD$L:I^+IGI)6T8.V^JJV
MC2*_HJ$9GZ,IL9,@P/&[L-9(:=_U<VYKYU0.GZXKV5QPD$X"RG\9(?'OO[A\
M]I!:^Q>7GWTX=^S1@&^>77[QA<@_JQ4UK<?<1O\H0:\'@L^2WP+7?IB2ZOP5
M"*OS3/]&,PT79D%[0]Q]!G0#YM&_4X'O\_2^C^FEB6/!K@QO[99F8B9SE&3W
MSK*/[NZ/P\\V<6(V,1$#:Y*L8A!-(_'HGD/-'2=M.O4KE'9"CP#^,@\_1[$U
MN;[K=]6W=Y[T]S+I$.Z1ZJ(Z:--IT86ZYC&QL#_/Y<G.)?W9[^PLDKZN?AV0
M_3QE[V/*!A,U2+MIK</$L[3B7,1?4##<MY+(68=K'-N<X:N0 4P]*_S:6^S6
M; C&I.'*&:B@:HH=J+AZ/^J&R=*>@X8K.=K#BDZ%O*&JIJ%+@H(H_G [C>1"
MU_M?0RQUML?W8H\C'HY9]YK"=R__=]Y$3FS2NA!>3ZBM=V.Y]7.(]GAFU;I;
M4>V6!&F<X^(^0?N#8E&1<3:CF1Y42%Q!9&Q6]]1#SG9T8G:$W<%'96P!-(\"
MV<OB_U/9$SYXFOW133)JN:W&<1>BKAX&5/*#?N:W",O/'0L'.A:>G3L6SAT+
MYXZ%)_)>OU9'[GSF?9@S#Z><Y"U^,2?8>>Y^T[D#9"XV1CC9FW(O^-G$=>_\
MF7/QZ(0GU)@^(_FGT/X5D>\S)0*/4']&D@7-#?Y2IH7S++^/6780,5Z:2?*3
M?B5\&D!1!R'2L-X8T3YJ;A^&H7Y@8\R' 6>]95\,-R^5&QX9&H=)!O*>.Z?&
M[#7!DG<'@,<+IL#8W4MK8P0*70]%.!1LE>=\76TJ:SGDJ_>U_F6W'[2\J<*?
MMD/8769ECR=PC"FH,Q2<EMKV.[,!^2@21-K0N!3^!FWQH3^O2_"[KBK6?30(
M+AY,&AS7H926N92KP->JB' 6#%J;O2@]S(X37NY9E3Z"1G4K^GC0N%@/GU$Z
M[ [<;:\/)9UN==(\!4<%8S ]"V'AP)M<*C>T]333@)!2B@S(>^TWN&^I//_\
MV>KY>VZ:C7(F!LGN:ZA3R.]ES,<\3IRG3$*']"'%)NJW8((L@*,,,&R!6S58
M^9NL+@;! I)J-^?^QY8BB.N:WF*)LPO=2C -8$Y/4P]"NS1_R;.]]TD^S1';
M-:<Y6*JYTYVHH67+\#1'D/>![S))I6_CYOM3Y(EYR9I:_!* MGWW[4\O"\\B
MT]/>@N.WD]S-A^NC^SHLPF;.^A7/_O#95Y\_*V;//WO^^4D._>7LZXD-4[K(
MXYZZ GD7]GC;W!G37Z_WUF1J30F,(*]VW"I!Q^%<>OGY=^;<2..%X,JYV?^V
MK-;X@U&,2R6++QF5CVK^)'D$S ^[A(>C76E3[A=,X^\__*T8G#Y5/+:,!8 \
MXHHQ\-_V+0>PW%!>:/ JRNB[[$ K[[AW05TPAX3/7")Z[!>"PE#*7!JE.WI6
MUHR$_Q3)+D&1)'<6ATY\;?,X^16&/(@\CC8:/!5E7?= XM_C2KXK?X0I\$[-
M&_E6FQO<3(FSX/N6G<W27\#@L'10%UNM,UVHGUU*-UKR,^YQ+Q@<2Q/Z+W9"
M$39-.D(S;XM\FUBUY:(OU&+-R/43]#B[DSQ1;L+^)#<SWK<FE<<^^(C](L_@
MO8_737-'D6E;9,%7N*T4^T7':8<NZG+)^P'"5PW$G(5GX=<3WFJ&9#((/OYQ
M^?)RM@I+</) _7G'T<UX]_8$"'1X5,NJ;*MT:ORCKIB6Y.5.T/BR,XQ3 #[T
MIUT'$ XN3'(XFPX:.9&>>#_=JY#1^REKD.Z@GL@&_F&BN+BIF(B)&0G2.4_3
MA1#><C,T*:'"T6P^PR<2]D=&<K[2Z,P!&0\-:_Q%C&:3]_'I3$^L;,;)[Z '
MY]]W:EAS%GCD# 2?"Q ![Q*+YC S P10$$M*)F*\BC?,HLV76 [20\BH]&NP
M&UV7;=0E39Q(UO:I"6"D\O4PQ!W06T@/$WWO"1((ZX_=M33;I5(/L(,I/>UO
M\AP6E$]YQ#75(RW,(&LGLUZO UFV$G3Y!QDOE1([&?PDC![O7GA_N*NW H;=
M2^P6K\R.:T=+  WF<A?81F3^,JL"P=:R7T@;^EU(GU@&[KY%@SHS"62F"((4
M&J]MN6=">JZ=.#8C9F<9$(2]]U35T]XC,M?^ /_X:.UW:0R-&15?W9FD3=X\
MSM9KC":0Z<Y<[]G/>58WO&&R$_X@[FMQD+-;O@!,.NTXHY3I%?-C=(NVFB<6
MV$-$/1PB)5XF/N[WP@-$MA.EW)A6 'NDM(O1^4'^Y[,O"_5"Z?\_QXMR&*LX
MQ+QK.*-\*NYEB&+3[W@\M,:0;Y?20F\#?)*>DSMJU(B2#8TCS_%^;]PF,@@)
MZ^^.C"YMBN^R^O)A:N!O67WY!\+P4?A])Z4"U;R7'9;/F!L60"Z%*P]R5FQ7
M=_Q?G)3LEC5"5R#TC-J0H0!<N%(1(Y^:W_G(X8\QJI[>[+9B8B2E)6SM"*M9
MX+N-F[V51UO.804ZWYI]B!4AB?*9<L,>FBD2^)O3[O3DDW.6I-K)@U_._@;R
M*BN]\YJSK:3OA!*2'B1>:T7/\AOSO_R!#>X!1<L1,I%-^N)S?!ML3HMRK88]
M+[L@J+.GS>(V6@13YO +%D8T%R- 0@[/:?.I%P?+CCQ=Z"$?K *A,%F40F+:
MA>&:D 4@;*!ZT^+]K84KB82R\^:V6?=RS.BSNP6,Q MY?>#K9(^1HEW.0++3
M:N7;PM=NBT%S)1Z)&_3V1_GSF/"3F63XK,8CQ@U"8VUCYD2!5=U@O6 6*RXK
MX6VW$;/LMQM2^[H.HNV!!\8OWP4G?'>[W' ?=*-H UA)$HQEFY6?W6*R\7Y8
MI(8%>A^:*\NG^?F>-ST[["M'W"I8$Y6+CDK1KSDF :!LF6Q[[)!$#UUW2)GT
M%1ZG7+(X%0A8N+;,9'4X A*Z25CJ8*/L0-NV^L0=Z.^0RL?06RZ(>Q'1EX!R
M//,$Z>[ 2SF9&WR;8]:&,%JC[,,9I:GK^%6O*VI%KABX[6BV:R'^C45JM;KQ
MB=VQDL12R"#9O5Y+[TUZB2.3>\;5'\#5/S_CZL^X^C.N_HF\U[M7 O@%F?WW
M?\KYI"@3F*.Y3GP2U+F95*6!XQN)'>?[H\'AW4TS/&ZFPL+\$YP\7@H]*ZHN
M3-U)0R@Z/=NRBA(YAZHO,SFO_5G-S$!E)1*:_[SZ^4$72J*;0W</I.XMTJ2E
MWD83:BCRPR58!]:4IM?=]CO<TA0]M<(O6E\'_4F*81%5(#/"7P A<6&)?H4D
M"V8@IX\O#U^6O@UFQ,"46.3GH1$7V?)R*[JB8'DT4GC1"X7"Y!8I\)VEQO7V
MQI$FV6.\WT>'D-4"C+K>&23" 3 C%:1G-@7DM"G7QD]*8UVMC39#NI<I(.TB
M22(7V(7Z%%9-1BLX#]9(6(,[@UU[P:KW*IVQ9CM",:305#TJ+\C-@V;S $-&
M$A,XR).1PH*45C^G51Y+6B67+!.5$C9DY> 9;"JH19GTFM8+&:E1OZZ;NUH*
M"9&(&P7)(($E@B2_$.B-.]K5FMHR['QKE)F,9-6HTMM(2W^$5_6:4PJULE''
MQ'TB %8&UPD"5D<,,*0B*-N6!T$S-=:>E?&U\G>DJT<T8K(OM-B$-W.CZXZ1
M(2@(:/DKX-MO'%.ZX<TQ5F=:@S+B(#%SXN'%0./9]4TKI*="-F'.HG>T#5D1
MWQ$MRRP9!8/5AYLI&3PVG%CI&,ZVO4FU,M+E5)C#L;\J;QO)D'#C]RH]RS8L
M.'EE;+#@]7&I."V.= ;M1P7IEDG!YR*S64?J'CKO&O[(F/_'0-A<C;U5W\$I
M#C++L>\JL/0?ETAW-_&TQ-8=K\#FQ8$ZYU60.[*TUW[4 G%(A2@E,OO:DD>!
MMI6-E)GPO'U<2G?*&F]VM,HI3(=V/M[-W=L_Z22.YZ-66F<=,UVV<UKH9#5E
M*XN;J?#YG"PR+O2FSO9"QQ5%%R!/C_TS'+?8_L[4OZ?3^L4K1UE#I2N(/1S
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M3TJA;?81O@% G(2-EL8YP0SXX]@0GNW$9-*\0#?G 1490I.A1,(TZUP3F $
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M&^ N9&$\UKXDAXZ,3%]Q!$2I^";DI7HJP4E[((56[XB"L7(6(+,O*8/MB+6
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MK6/4 *"4(;^*G,JP;M^YMS]:7$'J$*/!16@9!$<K'A,]3&S"\Y9P'00]&*<
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MS*BHS,D)G16I5JZ^)KWO*"+^FB6KZ9]O(4]V=T+P_.;KUV^959;"6 JM7KM
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M?L;#)07Y5\T]?8=C(G]7FIFO)FK% OK][BL\3*;KCGJ\17PXD4 -C81)'QY
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M,!I#N$847L@8SN1=Y)JS"\8>,N[3TY=FK][/VJOOOBI4&(?2[W@J'Z'C7L#
ML$@6%'HB&N[:GW.F/^?_7/MSKOTY']]+7/MS+K,_I_3AC719D"_A+;;B4_H<
M.X(_KW#"K8DA+P'13F5_OWWY0^@1]J<$G39$"BTMOO=^4!C$1(3#X>C)W9$%
MF.DX\:Y0!3+Z( Q<[2"YX-RA9T"E^:QQA-,ON]/MZB?DB>-M=I)GFF&ST0X]
ML"PUT<V[CN0#>23\@4&(O[[BHSD>5X&"0H[VY(R,0FVAH5TPPDI?$8>??\ZW
MH/8">4H\=UFW#67"T='"N0[^.W+=#1W0Q/TMUS,J=$BLS>EE,3/X[$"^KN%:
M*S*S0.T#+-8N["GKTU+#,T1R-^U=XQ?A-O(^N2)XM7SZ]_:QL1RP;KRSP1W*
M3DAYLO.>*#P#>*W_U(O*>B@;^S/NJ@@+(\[-V95Y=@7&YB7#=D6ZRMRITK%X
M!=VUI9:!L0MJ#6%-/.J Q7UVSKT[XU"95<;R#W+[;>M_AB4Y?82LS-\2PAZZ
M)P^((^KJ9^I&B,79="XCU'U!&^-!A7"X8X;7C+=W-S2OXR%TVP1A%*3D&-F_
M]V$XGG"B@Y&1RG[FU!&L#V%PQ]F.E:#TJ!TFMD"J@4W4O6%*K" @.=/#>:PM
MQ8J6#(AE8465HXDDHUD^TZAA?6I]1J]H.BI_#K;'FQHJIZQI2FUKC;=89H<:
MY339GSAG$9,V[8AP2U)4_5Y.U^K QP+]OU'L+*5FBHMS8L6TQ6D(:UM6_*TY
MFTXYC)T>8&B-VXZ=1H93H$9(JDXXG$BCC+&2S[MEZ9OI)""%@"Y!F:9J.O^L
M_929?JNOMRBBA^0/7S$X"V8:4WZ>EF^'E2#GB^@:S?;W4]8-M-\AT7<H?X9<
M[W@X2@J/W(6#YO/\TVY"!8^S3)1CZ_G?/5(K>O9 Y+UG%AFZ:VC44L$5D9/=
MN.J>15'V)3L=+0[&L1$+Q")^H8^UK&7]K5[X>\J2%<T?G0IM5]9MUCD<M:RO
M2U5M\2TYL6/4_4(E*>@ M9W\A 6@XNNBM,D.C P(75Z4N]BC">W?E$ZT)RIF
M(3KG81!8.]F^[O9V]8-95%!REI<47[,GKD^RS;]@UZ<R6NG^ENX[LY3B.(0
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M9JJG:XP96D#*;JNZFQ.A\XJI[:A%?0LC9IEH>*TT$=(MU*%-CO3@/3E"/UK
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M,4,I* X]KJ @!.9;)$;\/J3M'@-U=*33)]3ZCX?E07KFKC6[%CPQ\PEKQT&
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MJ4O5]NI8 O,*CAC28)<JY4#\(-$8TYZ_3OJ'F73F1:XK91Y/8?@!3O_L2_A
M-%FN$*A-NR<VT@IVS/;'<O"O3;+4YL0))0)51/TPQ0]Y!Z6*XCO3)G;I=N%_
M$?@-=]M ((A_'ZF_V<AJ$5_!7+G.\P  <8W04B2-FHHC >HEZ6FWDL34 :$
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M$3NT$)%5A\/8M$PO* :T)$X8:4T150B*7@G,'T/:.K#$38$(&IY-=:+*C9_
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MH1J4G*T38)K6X([CVF]N9.@Q:("H)2BP4,'CC4M!U7W5&FW#NGSHK260=H8
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MP0CQ]]9?#=I=T-",G2OMD1$Y0\OFS,!D[%J  %8%JJAL^;WKD*B+S_)?&Q1
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MIB'>WD" FRZ> R/" BYDL+1M*@-DRB0"P+KY1^U 7F5QW?B%<26:&8=<;=U
MI.D\XF>9=,$3,N$1L#NZJ>E@<E 9#_;9/\Z<004],XK7$$Q"UZ;WLQ9N.R"
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M3=_*/J.&S"WML6ZRZ3A'2*1$ VBHFC'=,*Z6T 6YA5O4:_V*I 5>Y-H/I.F
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ME\J@DCFT^U'JZ[PZ3FUUJ!_/W$K$,V<T]1SKEXY84L^HLE.>3HKI,>,_=RD
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M@//4G]C4\TXFCAU"'%Q7&RJ.)?._;1 FB05:X,58#%B"K;4?CRA&25]EO B
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M^E$Y@,Z#BWG5E:A;1HQ9G8F]]'C>=R13+Q?EV,P9Z_W&ZVKC'V&!$"=,O+&
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M:.#$*^PG>1#@O1S!9/9::QF)BWBAW6*@:F*?65W>]MI%40K. 3 84*N?MYV
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M"N/$M%VKJN;,=47/0G]+Y)/]8;GF-+L/2:"AEK*S5906CH*]^-VS9Z4TO8Z
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MB*3H#G:&A4<A#5<3K<D.-"SP8B)#K[01/;&2*Q8LP>40;"@),6*HEY@7PN'
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MT5OX/7IX 6"<U^>)K4]3IM?<92 \R&H<1=G*(.%XGMH3FUJ;*P[,^D'OJCG
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M=C#F?)>^Z1.=:WD8/]4R?%C1]I'&;)G+%(]G]Y'-V0(J@6@U/6 -U>Z,> $
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M&=+& '#,P*"A=I4\<H-<8?HQF]%3DA:_DL\H+\3^K;;:2SO\9=ZXT.(4G?6
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M20YD;PCC4SS/ C97-,[\DSC46Y9UE[=*_8U])P<8<:.6HD3,[6F!;5(B".;
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MMCHH),56H'39+ZFYK TBD-[B^>.&Y8C/LW_[:)H>5<L\ J?PWIP;"II:O(U
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MG/BN0&*9P9R/,47/971D4'0\,*8FE07@2CN8#T$:I3A,T_8V.?9XP/#7@=5
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M</@G,%=B-BTT[V\F')*2?1K(E5NTW(KJ THG"QN,QJ90+FJX$GEWQIR#B (
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M<"3+F:H'<L1T)&8$K2V:^8ZDFR)R;^8*TS/C["Y\C"CJFFU(A +G+K?F@!^
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M45U:!X0*PMFV<7VU0W)KI*C/<9=?Q]03ZS0KT.@E/F7U]0_U#3\RQGT?@QH
M0"B1"BX[J3['0)0^IE5$4C3U\AR4%[0:UP4I:/G%<V^\9QZ/.>%0%/0C*?U8
M\TM'0D%$ED%7L54" 5%5OSC6<GFY8!SH2P"CTK&=<0*H*E6;6?D--7LE*"-
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MMD#<D)%$N"3]HK0++;H;1)+>8WVO&DFO1V$VB*5_"S%V6AF28#\!T3%6!AE
MC7Z(I\!=%X-.24?DWY#":5X9#I(U_8@D;)2?$9N,']MCCSYO! .EY4GPDM,;
MK@GS;7&XK>.IAA:?JJP=,P))/U-NFQO1;@89VF6J2R;[<%]<9.0OKR,H: 5G
MNE'V]@B)EB)=61=0.BVS66%=#K^B'BRGM>L4]!$C.!^"_UM=282!_:P?&:/
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MM\)M9G/K]*'+&8:[3UL!/8TW^#3P;<YZZ._T(E'W C39M,U3;&.)@E@W.)^
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MUU;JAUBI0'#J-)>-X]TDS$CSP$U[\N)H NE6 A$'#NY%<$AR BM__'R64^A
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M3=+GW#GKP](1:K@2.EXMK/(!LJK.FUO!*9G[&>PU%*1L1)MNG9(!#P[ 09<
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MJ(LQ'%"%,6Z!8GJ%E"N8U>LW,7<N5=TFT74Z-5\^VZD^ 9M"[16:S*,N))W
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M@P,)9>=&L([?GB$C6-IZWQ35>FURIQ&SDN6\I?;KJG8!'T\_FO!CHW9*HM1
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M#(P+NKF)4>ZR%A1L,X\<?#O=I>$CQPN"3SJJI-\;G;V?@[/SAHAC;OH[R#5
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M:6[9>;@4#2?9T&[AGC__)1Q/7A_;]C0M ,.QL":/+0E_(0BVG]ZHC/N Q*]
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M3;C\EWH#^-!@N#@^4X":,>%EQ/I:!'P3'CBW5D.7I<;:M7;C_(#8QV+&"14
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MNA>X>*",AONH1@CV%/&\2(2V7V7\'M?@@)F?Q;\FMV 7"XM.O!OJ_'B3DK_
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M W\&QN[SQT- 89:]X ;.&' 8!98:,;^^<(2Z^.IULYP3 C@(>%R[[S;S4_S
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M&?,;J-8(H/RK<./.?+B\TX:%9 -3R[-P'S=S-IC?7/SXYN1Y\X^3<\]G2O;
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MXAL^O4D<\0U\4#[0%0WSDVRTM+C<ZNIZ3&!C@/@P])'KT]^>J]W7YV'XB'V
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MP5>#O*@$DR>W=@P#W<[5O2+:(37 [._+I782+H?[,L5+Q%U>WMW(]2G(.-V
MUJ0DJ*<M3()OOGL]]4]Z=I2<WUURPN6\JKK.,>&1:<EWVJN_O_#7'AP[@:48
M(ZNZU%SO )W1JUFZ+!=$=I7_%&2N@E@)FWO<_=]_]^T6N61.K%<_?D6!!XJ?
ML%$./6];UH6;0G<S_83[5POZ2 .8\^.6?H"K(/:"QS&>4]FK>"$$(#YQR+?A
M$TEA^HY8QZJ.G8>N6)2$>@:X:,9PC_46!0!B L0TH0!>8T\R"DLW7=*3;)I=
M+O??*]\\?WV4I0]B5@#<IF&:\<MB$EPV88.!Q6D(*/PI^'3RX8 9*@2EP[%"
M*]10QL0!<4HDQ0TQC(LKO?#M'M'B ++3V DRL?8<Y$E$N:1*7CEI=DJV5AJC
M!P8 ?&^CR;7)[TV/WU2AXCQ-#2\?Q?_W%__@P5?A\9DP4,%<#<$/_F;5D5D[
MBP5_A% T=;9CTXYHMK^>G9\?T6Q'--NG-XD_)IKM>*^\-Y\[!M4LI*9,/\[4
MH2NFJ@'K04!;[J&TIC;\%ZIR$7_G_V8>>A>3:11ADU0 4LT5G'9WN4V%RFD=
MQD&9@0TW?9I.8I]Z[>S04= _3X)HL=0WW[_.4@RU_@P)BFL%#K@1K\HP4FEI
MKMS%>*^Y, 3+)]>TO2G]H"W:1+;8!A7*W28,XXI:P&AV/_HL1TOJHY)XRCS!
MF K2NC$ACR&'S79^A\!#YP1H1_(MSUD&U]%2C@!,7:GC&DUZ*DX 4&ZMT KZ
M,KDTX3@$Y^4H,A_ ]XSE3ML..5X)77?EC%4?I,9A!/(]HR\?]^WWWK<]CR9A
MGUS2-%Y70,4FP"A_D4REE1IGRF.UF_L.J)@56$ L15]__R8R+M3PX?HOT22(
M/&BN$=$@9(>10F3 0PQ!I*$'%X_H9?8-G) C$:9"M3&&2+ .7K.B%AI@1:X:
M]UG$6"RD K\72XQ-0Q9;1&L&OJ$D-PHU!DR;QKB\T]8)#>CTBN6>M!@?-:YJ
MI->2V]XW+MGW"I6I4N88/J,! %!UX9([[T_&_Z-+LKNG&:<FHC3?[<I_QV"U
MX^T:CF8CKP57ZZH9"N2=3EYG?[0F&3[]609!WQ9FS=M[KLL5Y>WOIDE>%I?=
MIC#6G4@ DB5T*6#/3RXSM8B@*U,WW8D._*6:A7\P $K5H46X\CGDJ6*USLA#
MH/:)7,:IT=MMMTF 1X*#ZIED7J$;8]5V&:V_WD (QW+%?:GPY-0'<L%=4CG%
M\FYC=MV4M<Q-42UQ!Z5&7QA]6%PJ&=<H<!%#K_;5\)=-,P,TF-%G4L;C8N!A
M4[1U5#]QRG/$'U/J+21*.Y<I?<SE!5*F"VZ?]<9=100= @.D).'8D2+<EH$"
MBZIC<']0M35@61Q>Q^)?-MK44TM\V[X0Y--'7-I?T?9PO'X=Y@,?+Q*-\0.(
M/Z5VO$S7# QLJ^YGC7(OBYF WCB!R-4U'BP%M#*7QA1$QK*1E50\C%KV-'<(
M(-T^RQMN*4<]HS8%X[?H"S9P6[XR3V%2-T2DH]_GK?_A-.)%QQ1VX71-L]R(
MKB0E;?D;B@BBI:+[NE!<3]P@9:U"SJ-5<G\1(;YWM32.9*^Z(HQ7$/5(*R#"
MK/LGKPP#T09.]XNQD.,:5!']GI@,\/&CDW" A!/0[OP!<"/-W,",U0:K,+MN
M*%3"]B/]5V&H.0F+ /N4RV<<-?^LRV5XZK$.M&140R"+J 5'[ )[)*1(=LW%
MF *XQ;KJ]S(K]2)]ZR1L]3;Y"M=*44@'T@]R/F,:'CCX['O3U OB6TN1@ZYW
M*KXW%:H1-&1UY\ZV$&B]2VH#IP$=8OF9SUNJ&I@G!YF(S4#-4Y5SNW"PBZ!?
M].8,YH2-)/Z'M]>5 C]ES.%4AL?,J(IQ7E%'L.U2RUDT#D&L$$MB(NKEXIBE
M2,Q()BLZ#+7PU@F$R'HB.U+GN--H\@=+]&ECAS)?2"& Y!QI<JR)VROZC =K
MFW\+J,5S79:W)E]O8M I?$'B%YPR/P1)>]X[43>XG@%*=[CN>"=5F;?2E[P@
M2&Q+W E8NBQ;;J,331'!O<_#-5*P3K^D.ZPL4MJU;KNF.@55:H@60^NL@QC/
MJG6Q=.-I")X= ;+KZ[N.$,HU=R(M@PPW=ZQP&\\OQ#>G7'B.KEC*S0: EM\\
M?YU%/:0YLNM$F40\KMFSC0L@).-:9U$+J%,;$ K[2B6P<)HH&ZKY=A6MO]V%
MCPS7@AK%G8 LN 1NI""O005 L'#-Q)<[ S/J]+J3ZF,">+<50-WBD!5ML:)^
MBIULY)81(+YF3N$7\Z83GA^M*-*;Q<SL&JD+>8,\41VH.=VC.K>(8LJL1 U(
MN'H0^PT([SCK(7#(>UT&LX .X<1'K/KM=9/T#Y;86[Z8VMFU#T8/U]-T<KDE
MBC-F39AJ9^6^N>3>,&#6"UM7;89F07L;AIW#WZA0FTYS+O3\TVEBNTIQ2]A:
M]B:-@S][I-OT75D&W_]AX"D5^_\G\Y*,&K&8%-$G8QW6)=YW$TQ+$NAC1 O)
M#A6[@.H@'-Y9YW$MWCPC$CMRZ(C"BYBJ-.[ B@%+L;ENF^W5-5N)@(W&3"9
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M"($"X22(=T1^%/W8P[DYE4;G:<(HUF> \CN6$&2ZO!;T)"QQ!<<&KTT<DZ2
MO>H\>I,N&4:$TKXM.'MN52IX.9K]60J'LG0=J(OT33(NL/YL^/%&0>G;T75
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M+@W$]%!V6O!5)]6N:1)3D;T2?Q/R:VR1]''@@Q=UE9]I@J,*FB3\0WO+2I*
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M/U\A$I0P)@$N0$K-^?5/Y<E+9>%"R3T](UO-_;#C%DF@4*C*RLO)<_J'O'*
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M9^&F)R<"=A)NB]ONZ".G(3%YI9N-@I;NB,)0OGWX].DWZ3W"AA\T!EQJ<-=
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MS]"WO3AG/CY\\8*[P5ETG >HVXX>9V@.CB9_V?;>#?=$J3:$7,EVZMAL. <
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MO4,)Y92(S5RI>((B8&(30T;E*L9_)&L[<TD298/4C\/![V5X.B7WSC"5=PT
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M<]ZXJ@/("ZR &26TAS\\;;H2'4*GJ"Y9GQ#XBVJ=3.$!+F^9;%J]=$Q=L.A
M6X3S3K/!:%V;,2.S(".2>S+-8$P^IP.BFOGT4K3>^-6J)AWL02LM/&$%S=F7
M2W^O>2CMMAJ6T]YOJ<Z6DJQ^ HS!>_*(U;);F9D5Q3*5SC+^=6>Q-ZI:7%*Y
M;$GQT11Y)K]_D8EDM+X#LJ=)2PQH4>I^ZB!CTG7 P:Q5HS(I9G"1;L,[(FE2
M<)TKQ33LA+)=MER:X=B_#S^BMHKNZ81<MDNN4J!6L1:B(1);8.B10L")<1Y\
MM@IC)/W'"MEHB\\RK^;!1Y@!I<)]E<_^9; ?*"*EEFA]V0=QKVU?848X/VT%
MF.X#:1^M;:0].&@7..CI'ART!P=]?0_QQP,'?5&,&EH1]?D3%K=6-8L<3J54
MV3UP5IW*A$G Y049E!I/<M7[:5A,0W_N3F)*,7KN+$YS0,@U(ES533/5^J%S
M$&,B*0\"T];7!+-/T+'A"^9T-C0=_+GS>OG8IH.6B\3@KZ+L"7P#2J18 Q%'
M7>@MGQ'EX-'DER+*)$4AM45>+J4?PS6N12(_7X[L=3IEYE=0EB*<W44X:^MM
MP?U_9&"A*%*M1;V3E85)E@8,JT@(T2_I55R75,CE>9SU3^01S^*G<$1>)/2M
M,4].] '%G/(R^05QZZXU/XYG5C (T[9>;'+0G7$B>8->/5IH? $)CNVWPF,W
MIR<7]!4EQ8/3D=&?ILK'X&/Y51A>?_%(;\4L7X9#4-\=_9KJ ;3ZW=H- <)F
MK8X)=>8>35Y<%96,@^$\&/A\$\:QB#/#5XR[QP]C6K<,DR&R>L8C,<*% QSK
M;XU;QM[Q4/ZIG/V?_[K9/IV</'K\7U]QVNK;0;-U1MS1%&Z3UNW;IIPJ_NQ=
M42[/-\'1Q4S>AUS5>[<L-Y7@)=9;+2-Q588+*SPALI?]/)!AW[1*3SH@@Q+[
M0:_9= F!BJ]$2$$_[@2R0@/7 N1+.QGHPHYS@%@&6MGWET,_1@\WVS+FLPQ&
M,C.UYU_7A:<$@!T]I*]L:<_737(6<6H,SR^,]@(^L+)H&G,^4#O\&O#,AB>2
M_Z.<'62^J4\N6 (_URC8CG8P==,T19KTB6+PR3MR*1.-7=/7!D@:OYR1^4*C
M5^]1LH&B2#<K$8NO_'HP*9V0.^:[T)C)N"#C);=JI#6-E4V'"EV?NT'RAQ),
ML57$KD.9+L!@HRPJ=+3QTKLOF+,W,DG<1=9@D1C_5VS<=W F,KW46YY,KZ"_
M*++GB=;D AG\NMI1,DU[V7SK5 *Q(;/N@2R*O^,[Q;)VC5SMR-:4#3FC(=8K
MI>*TA<0-<]#Q'MCXU/&F:VNM4-D\.>K "!%9"'!(C6]0]M8THS<'>?&:T'&5
M9S+*^6T)(T-W[7.)S1H,Q5'2+G3#F?J;M,5Z'9=.R66P]%&3,GMR_WS;ZVJL
MF> ^SJ$:+"10NFN.(>+P)\,@PAN;7A(#>G61#@E[^M=\6:;R@4#X(6MJ:<IV
M?5@PD".84GI&I_F;J$O9WE D6RMP$.Y9-[]!%_A]./!>58QB1/F/TKL[CS8N
M4\>=@Q6P!#_*>><<8L;NW/A":.5!V@$[@^'<Q)4B('HA9"DT?:ML,Z4;7PKQ
M^+P7[M:C=<?:]F,7V%1YU<LM(]U#//;)#?#NKYS=+Y^?FL?OJ15<Y5N.]%;.
M="9D&GUP-J3"]9 -V2K,:!W[A6?0=I5)66Q=P "H(?'JZ*P<35C)KQ54?-XW
M_MP.8%;L5N92_7&**,.3;5N*X*K)9ETNG);BF#<",V%KB-Z1$!<L<Y2,%Q&W
M+DG5"EX1W)Q=^=.!=&N8 $L$4].ZV%!CS+#)222N!DWJK"Z8Z;A$/I83Y]68
ME]$P.Z:(:)D=!-PI6#,TD$>3RLD!3F9/Z_!ZMJXIPMP%TK\C5C2@,'(2[+T,
M6S)<E)5^,K08=Y^/SY&85;_E0QKO1B[=&/8#T]<IJTW!6)'P'=X08MKQE00%
M>X.M&=RU\!_0A3#^8]=D[8Y?@N[0@<>3R[%KW:2G4'H=-BAR&[?A_#E?5-CI
MFS8IG?$I);Z. \&Q[BJAA@0OXUI% (^351W!<,PT+^^!=QICY#Z@.A?>1YX<
ML+LBDJJX'FQ]]FB,LF565G)V3+87@M$2#_&KF,=2A-A +%CM@=$)NL5I,F80
MV)R 3"@>)+:$\XC*,K A 'R;XGX<S1\8OT?3J3#$KI/-FXG1AR1=@AU;F@S
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MC!"='?@SP/,VX3*J?'G\]-'A+/?^&/ 8=,ID3$2$73Q=U--/Q$>]@E?^X/P
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MP=$(GH_3H1PVR><-IXJ(>,?#E=D^PF4U^C\A#I5:@0&2+'/HW2K__*Z37=-
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M\+IZ6K3,.PW .VU^1AV'CZ^A-TP_SP2X5DS+EMF7>*2Z)^V*,_T&Y67#R7[
MOV3A2JSX\$I+\3+A3W95??F!\[G7,PP?[W$QNW Q)WM:ESW Y>M[B#\>P&5G
M%/&?/L8TS^^Y/6;U="/'O9Y*244AK+AHE&/2JT8H2HC15I)IW'J8\(Q+Q!G]
MGQ34'6-[<OI0!D#?U*M)V2ER%PVPU[DY9D95NYT\T!Y]Q\"" W29PB:(+X;:
M(*CK0$46^'F0=I1C*;S+_*(*CU).T6&P6;<'%D%";-PQGKK4I[&;H>U'$L+D
M)RDZ_WQKL;AOXG9ITO#<[%6$D_'B(M+$.)%E(Q(8@J4Z->BD$#48/QM[3D+;
MEG7@ APX/%3E9)SWC,0!L]LTO-5#FZXP_L'<PKWP -^(!#SB ;AGG:  $ED-
M.;^Z^L7Y(^[4KO?H7,&YI2=L-<'!R]N^F'B>7 "Q(K/PAY=(EPLKI5Z*AG-8
M=^5:>LH X9\5E)&;A!U12CWNHA+JHZC"@%H[,-&>$J@DA(11G-.=5&E0_TQE
MNW7PL-@R</F>?F5I0!TBF@"XK3H\?/@N_V%Q**I3]%<,6"KI#>_92S#^E(@]
M2PX0.Y0BZ[S]=$_6VJF]9C LJ'2*:#]L$1F6:XZ4.9B@J;:2LM=R1LU&?Y>P
M9HU!42Y0\H$UBP3[LB9BX!@6YI 2]@.@#R@9/=FL5/F;CX>"RD+!'!V,(E^<
M7+8/4?OD'"[FI\+*[=[Z+;-)=Y1@&UX(20KI7BSMX;*K=HCQ<?C+9?AP\F,M
M&J2SR57>D(17A"Q>B!7@[A8DQ0J7WJ*#*&:XLJ%DV37=0]-DL25'&E'"U5<+
M7OGY;$8C2\]I7Z^\OBPJ<P@<M JI/9\P.YJ\F?M$E^Q$+KFD!X1Y!B^?G\8&
MP'R6LQX4:FZW3Z[E4V3&+%5$W%@YH1G;#?42"F7>8 (129UXL> 0D9L4;A8&
M%L%*A.(BDC*D$2P?G#(?&=W8H;II,='7.>7HH65PZ^NZ/RS%VD6WJ:P&/+[)
M@]=(D9P\.GE\8(7RI#(A5 C#34HM76#+/^>L7G\D,S2MG4NWMZY3<-Q9:R6Y
M=<S4L^&V\*;>7$"D1[_?KJF62L,)H^C@-6]V,V*N$44>UADM .K]5%S6BQEX
M#HH9N'SKV)V)*4Y*[Y>D97*XL 93-K^=WJAL\K^;?*%B1>%E6@V1IA.IH_#$
M2(:JW\[+ZRK\:J:X;>1+750 30$Z1(S!$05L6@K76I%F73-X+UJJCR1K(R\(
MU6;Q=?XIK\F%'6L;N<Z*;2<TG#]ZUG%R\=?C9WY3"(!:$^T:C4@D\XXJ_Z\-
MX3=YJ3_4)2[9[9_5\WNE0ITTJO=Z7=S%J65U-N8\!'&TN*B]_-5A."?/Z2UV
M?/:PB/E SCIV14T)'+8A^)KE)/U.\0G*) 49,WP<:74:;(7P*I8/\!;^";2[
M9D9;ET*7*17B'/U16Q2?Y$IA 1MY&J[ B#;9%!:8.90./7XT3>I?S8HE-QFN
MBUZ*G#/@MYX:8O9J:^JJQ[T8BZ\%G:B<@.BM8Q;)0K>V^NKY^AJG"77QI^\S
MT[481C!YG[]^GG5-N\])V[ZR>)]+0F)1M2\<7 !JUKJ&W@.@G<WG>T<S$E;@
M.1@PZ(-[XI$GW#%AC;X)5H%FEDX'/JJ9X2=M4+$744U>L+AC\%?>L*PRGV$$
ML\LF[RG6$F?G0Q.>/NSJ]>5V\CP]K$;*JYG:FLX]Q"CV/]#N[\X287'I\"U'
MO2205?!_)M4_MHO^M?N?UY,??WR/P*$E8JFRI4H%C436]8<0K-&A/RUT$3,;
M'B/N:4_1S '2K>NV3FLL"!-7)%-C^1^J=1V2]I[FG?B "K$EUS7<:90</JNF
M0)U0F+Z2"#6;4(1"3/3F%6HM=8 ]UXZ! S.))&0)DR(2AVH[I-[:]V'\@>]L
MH%VNTCF$H5! #;NX.IDT\5Q(Y-#9/SGN9D>$<U@E38!28WQK<#B 0]=S"T6<
MX(FR)3=C7S0-M;%W$&AAD)QWZ/G'PMG1CJ]26,WP-1A9PKI(:_<(TZ;!]])-
MH[]2IZ1EE5]Z@<$"D;Z9<_VX0DI6DDIHO NH;X,=7SHFZ CFP^TR/"JY5_<D
MZ?":5=YHRC0<XS> (*ND[GYF0_*[D%D[X'6X4S&\TE<IL_80\B!J^K1A-1*C
MFC*)+)A *??L( B<PO-U%J+;3F01P-=&_N(P>XA?U]9QI3D/3U*SWJ[8(;\,
M,U0TA\!OV@IRA7%/&D YU[85U]*GV/-S2'(2>P%C)\E)#E%9V+OD3SMF**4=
MA?F2)DC<4S&O%1(JR6TYNU)I9V58U[4*]I:-YTR68C]?,+RCTTI@43S]81P,
MK?!O(,;)^A2719J&3I@2FYIK5+:"7$Z>]R;9 CO/K! ^?+8HKW@[SZ_J!N,1
MVU>'U4N+^W >?-:PI19J^;Q?DJQ)02^W:THP43-#P?Q;^@,]]"AHTLPMC9$,
M-#Q*C:+YD06E:"YA],7OAS7XI4B(7>6X]+;5<$Y-"@&+)UD:+-P4Q[) .] R
MC::)%S&IN5(Y,M$ K@5B@"%H+M.B.0XA-.78C=9P6"*/&-DH8[4$O5K^%PJM
M ;;&9RVH8'7-_8?6X6<^LI!@*BES,T81G")NALEO'5DG!TMT7EK$$&,=X)D2
MVG[Z=>= '*#VQ.CHGBF1-UA)AZ&4-^1=]QB-/Q\_>;S':.PQ&E_?0_SQ,!I?
M8VDH[5*[%S['!P;TCH'((4,J,1Y][17_A9U$HF80\A#QZP!&74RNZK7)H-B<
MO<W#HLI5 N@TN,P+RN0\R;C@&L.$9D-EH%@;<L&DA_X.U+ EUK1"*K6@-[7X
M*R\^DO.PYKN9?Z'E@'R*8(BQNY+:87WPZ66XN<^YB#MLU+#F!H=!R6<2?L?/
M4N3RE$A+PWPS4ZC\AJ(>Q#R68QR[D=+Z#3U\YH?Q6;]D)TESH!AI<"%I0$?Z
M<YH^A*>8PY5TP/L79!ZCDMC1+48U[KG56_Q8#AYN]X;ED\7OVOG^!>Q";*_.
M"G5<Q]2U('2?Y!0Z=,R+C^+&LL)XK: R(A< YFJS%B8'@8ZXJ=:-^E%V^LA5
MQM^&7<!O,&3?]1EL/W0V@CX0>>ZZ_R/'-XU(XHY$NR1>;>3WZ<Q(D0M!-,!E
M&N2+.@ ).[7^KN$Q?KDLF-NGAR)"LU@81KB7RH5$:J'..YR!J83F\5JN%W:+
M1 8$VB'$.H-W-EQ*W/K)&<;I\)P_\U=$;7 NL57>W?Q=<Z*SYTL9$E]XG%_=
M/+/ZK6_K<+,9YZ^[O++^MY@"H5C@Z[2\9NGZPC0,O:F\\Y[NR99_:RN:VPG<
M!ND>"&Y1Z#M+,$H^R+5>>+] W8$(,A<BJN;K22+8?UG(<P<'QTT662S/+?-_
MU I82RX2C+.*[.BUY%YQCTA7<O WPOA9U=PS^6AWD]T_KE0O5PM2,$K*+V7E
MN&&H,))NA0DW4L1EEEPH_T1;*.FR\:P=K!DU\%9X?JD&F"]"4#G;BGS!P"H?
MLL7<K!O'Q/<D, %?G;%=+>[,YW%W(I&OIT1A6,;%KY<Y+?8K2O"UZUNN)SJ]
MJZKX-4S *T:KO'KU2NY#)O:B;@0!Z%>/).N1E3QW,#=JB:*%0@E@05BD0!O5
MFX^P#UQ),[PY]2GS')S7,_ .48(%^ <DH.!%)F;WM91IGPM4UO5(GCPZ_O;A
MMT^>TMR';_Z;V>P_,Z1X54W^7JZ;^HXX]C&&R?,(O[YY'K^Y)P9XP.<2?S68
M@"*8!$KZ$RE[Q[0Q^D>]$=M=HT>U#P_R1 CG=[BXM!D.>NNO732$(H^W Y+H
MG.8K:_!/SI9S\&[EU.I]7@CY,KL&[>WCA1]VS<GQR3-<02BRR'P-74RN);\@
M73HF_3#$3JS,]FT:X' X Y9ML;B*Q A1F8Z5_\2M#H9K8*KENO!0U/()VUWL
MF)#O^T#1'Q;RL7,M.5WN7[Z=T'VO\V9W$M[C^#HAD# 6 <V%_HA/)^"8B\M\
M,6?$'CO_^%YZ=B5^?C@)ZHP&D+@B4A_0\25T@#(2]E;)DM\4BR;K0),.C$S3
MDZ)<]Q@(X_YR<WL_"D0[L*ST8G31*$!/VK5?,^QLM='P*.?63^+^6PCE*%<;
M>QC/!W_=+ 2-Z9(^>7BF&377]Y&3_H1?%R:TF';@QKY;7AME$YMR_?X9ZLIE
M2Y1U>W"/+#6!+R;0X6X7#9;)Z:N'8=B7-,6+(N=$TX/7/QTD?1F*8F,,J=J&
MM2 5S!LMR%[+>Y".7*"//GJIMJ1'BY-EL;^W/"J.,KX-C4X5A&-%M-M,S*6M
M<\ CS!F7YXT7%@AM6 %1Z)O4.5*?T)M98$?@Y+>1S4C354I>ET;+YLU'&N!V
MP./K&X<.%*>?"#/<IR0@U4R(5T_S:[W<2!K"80T76A8YE!((E\3E?W=/LAIM
M8IOQGLMN";#Q)'=1'U8 M[8FW OWO6"=-VSJ@ \XIMZTNC<CHCMZMIJ?B(@J
M].'D4[&F0,C(E>=1O8&XDB>G+3KV"!"4>1KB#,WL20PPE+>0DN0:/D#JTJLQ
M*:DW2::IC8M?(5R]A]=P)?PT2L5OUCP#=;6!US.V4V1.P\,]'/L*PZU]RPP]
M&[V>F0!?1[K^R]8@IVL7TG;7%!$E#J2!R+RU?>/F-BT=K/%JW:-RFC?-EJ,V
M#_*4Y8?=1._)* 6XB!YII05W+6@9_C+22/8D8<;#W-^+D^^W-SZ%I7V;WB<M
MNSL,,LKM64IX=F^[GMX5G"OXA5";]V+)^.;1OC( )\Q3)(BK.>G9%--?#C]%
MZ^8J1\M/."&9 6?+?BC^25;X:^@F_#>W$_[V+75;FM@G3_Y=-+'4MW/1D.CY
MH:S7.?[OV>^_>GLT7T"R_-]71U*)#2X("4Z]I3(JI2GW^)]=^)\GOX]VT>/O
M]MI%>]C0%_\0?SS84%](]^3HY*GN'I/-_?;HN_\$1>&P[3Z%Z8[TF_="].,7
MQ-_MAM+C"U)TYH1I/*!6>D!9ZPT7_]:J7Z!0&Y=AH;(?57:,4[MLDBA:HLY(
MJ(VF4;Y,B'^*/+8JYE#QF"+I2".#E*[_GDLLG;WY^ZOGA\??'TW>((*>;EJE
M:+[AD<I$@-)I]H!1A#CYDR>*"DTM)YTIFV3)UTC-+#,[?//.72A/L';=8HX:
M1TAD.]U,(C8BWZ6X5%5*A;HP+"$C.H_D,Y%\AWY)CUP $06[J93D9;&X94'^
MBU_@?U<D6+N"*(TLB-'5ZA08/*R;M:,Y10I]3S+08:(6W'?5>>.<0%S6LYQK
M,/IZ=JV"A+"^R6<%)4:T97P&$ID&6L+Q![D0!JP:8OB&N-5V]XJ7509!B%@M
M0 V+N"BO*?$8G$1JK85R229]M4:E&G]T5>9NB6E;"%WF'W6X>;@"+B=M..E5
M\JEH=9]O^=_LH>H:Y7XB0A]RKM(QRV.JN1U 6I0*CL62%@MJ/'$5 WE;22*/
MWYRTRW<OH*\1.<!-Q>\0C2M2R08A!0;I[[-KSK.XY$!)D:RZA_70HL,+3MI$
MPEIF"GJ:9HD>R]MB9[[XK?H.#)H+D)=$(8!@W*R5#,&O%9\ZNS!F[H??0T.W
M:FW5,.437C209O6Y]/$J"G+H+*";>^OO6V_H/0!U$V[$>%EJ[8H"*E\60N&L
M7I9-E:^W=PI1T",['$%3Y+U-SDI,\9ME.6W"'/[?O_SEZ/CHZ2&(6PHP7E#B
MG5Y_[QK.SB _KT8(?+ZE_$I?SH,W^KKH*WJ[OYP>/7D8_M_3 \?MX(07D6)_
M02S"0+]^I%QQDKU^\.+CZ8&C6QYFLD9WMJE/MY/C$Q[H BWG":U[".<Y_=M;
M7OOU]?GK*_NMBRN;#"PEN39.54;(QJ5RTQ*0I?3QM+<8OJ%QK"]Q\/S/8OTL
M+ ZFE*C).3L-JV?3P-R1!TZE%+"<G+Y[?WA6__WPA \+2302*#M6(*:7.0&Z
MPYP2.*CE!*!P'U!:3Q)&F==HSXRN^X'Y*0J\F]4M=7!RBK(ZT 4Y-OFM.JWY
MC,X@-K\&C]/I5:ON]"W64K=;!@]_8XI](\X:TWVS &F71D6@CI5IRJ^E+ QO
M_EJJ9%&N+D*HO<)*@B*DPP&/ _]<!WUNJ6ANI8B7['=M_IY%B+L[Q.G%2, 2
MGU"?6[ NS(]*'EU&1<).6R8?Q-*D+5(LZL$961U[O<4Z;WJ15+SM8JM*\E3J
M-(^?[B[RL.SS?ZKJZT/*W;L6:T_^_LS$"JEF2Z!%@M%O&AF6)]$;=#V>$2\&
MP4(+K27.V7G+M<D6(8ES\UL&EG'!H# D58A_J?2)%;PLV^C\@UW61!BET@&6
M*#]FQ'BW'+.Z2W"U$@?\3?JZVK L)QWU)W+;@Q,N(EHLQ5HL6%1+(:3X;<%*
M>/R6\!!> (]V441'K<$;M&8:3H4-R6DO@V5CNO.YLW2>/\=IG"JU3ULX=> 0
MD3#]>[L22B0<U9#S0CSE@H61W$K'W45%AQLVY%TQC)$(<)1KWF[FW&&^G8^?
M5%&U'P"9AF7W6D-?%9<YD[3"(=V(>S;H#WPW:K.B]Q7,=LPCB+19!9J3BIXR
M>3P7K@Z,79Y=O6[Y3Y\@$4J@5/<1I?O^V-2H)]8A'&=DBLO*; @HMIR/K]$"
M$;$0'2PUGZT)V:X(M>C^ZTB71=BL "CR%N!&$/H',EI12^UUW12TI+S^W:92
MG6\Q@_(^NC9.(J)4,M*?@=9+Y3OSNR]<+T-NQU3EB]X7AKX$X]I+;J(3J";]
MB?##B:$<+&DYP"8DJTZKBCY^!\H9VM OB8?ZY-'ARWL2OY["6OXU^$QT*AUG
MT@>)Y0U&O(6S".&A.DM]0O,RKQ=EK3CZ&1,XA#5831X_?63Q+@T>282"Z#G"
M/07#Q[^"0 ZQCM D%^)'#3N?!)U'(Z=D:82XSZX(76-596XF%TTX2'G#+6E#
MK!9I$Y$JMJ3#M*X &];)H]ZS1%2>I)_"[9(\$CG2?RGKGXFX+]$XE"5L%[+<
MDK!#LGL1DTSNY.LD ]*T4^X.M5LV)'[Y*]1HU*)9H31'BP@!9AU  1'LWN+/
M,BW%@9+>X$QDF1]^L3*9_6.?J<VE9PA3K6!3ETN-F1S1.YF0?>)@8$55 09[
M$_KA 7U7;!.A %T#;+S*@;'O)PUN1B+J,D>E\ON9+&2'39=W*L5!VZXR4F9'
M$E/GPL?;A(,!#-I$G19&=?)(8C9%798-@?Z8W$VW)I 8#VQJX.=05S7E\@G=
MAY?4<HK1_\2\(/=$F%=A+@H.VL'1Y,?ZNL A@X?H"*]ZC=3>PWO)HE5N4!E^
M)^64O?."J4WG1>&4]02]R =VK;B3$F?7M##D)PF!TP% 4X0I8_O1@?4P<58[
ML6GHM17)LV/26>:X#>%W^!LM, ;LR;P(.5L(X\+NREEW0:B;Y")F;!BJN2S8
M +AF,+GXCA%3B*T']+HG=^NHP+J/M")DZUKELT0$WCU<,J]P2>FQ@/S>8+/A
M?V..H\&S:Q:,]6S+)'=Z'2DNSXMYC2I'BDE&5D/56&<##Y<@A?8PEETPEJ=[
M&IL]'N7K>X@_'AYEQ).[([<-)IB$AUNN]@W[*H@NX]%!3A9S\^63MVSL/] 9
M\D*_@?/A[8<7FB*F7X _47J^G/-%B8D8BLS)=X%;8R0RZWH=ZZPXJE+/(MQ&
M$QRB9GW\1#PCV#A\"4Y-N%N7&_DJ7P07KZ)(H(J.#O/ XWEG["G&XI'\"L7B
M$!!/^+YK3N%9CD/!';T\]8-]*:4WB -69RC993"7XJ;R1DD-QB?'HXX=DV60
M!V-"CY"GZC@^15RTE*RM*)GA%_6II=YE59\*'0 !#'QW'5_4NG-XJ;:J]D-^
M#\G$ZJ(Z+[:UD&6HFXI%*C[4QZ/W1SH,YIM6V,8;:NPI;'M\?/_VPYLLK%GN
M7R$$M7:Q,%&\"= _(PPY^^N^*R2_RH._2D=)>#0:< APP2!+SQ=6=+X$H2:U
MB55;N8'<3=Y0FM>CUKI[$='^I5C4UTB@F?YY,(3+)65@)"HD8$>]:0SZHT*P
MO:Q+CFX>K@$P::.M28<>BKU324%!K1U1'%#@BQ3I9;D2:GA;RESTU>*6)7HT
M#K;!6#Z$N<"U*PV0.(R%5IXNZ[!"+H)1KB096!SZTLM:S*K'CX$<U"4Z$]3)
M;\%>"#]F''^"HJ#.O? URK5V$IF]1.NL1AYU),<ZM&IO"_X^^>XV;05?.@KU
M+V9QWMI<_WZ-/7>WD5WBT!91:T?TLB8V&*=.!/2C:%'0;N=:.QD#FY_PK18L
MZ.P,Y9-%45V0%("0O&9J@F,2I9W6*VM$E91!2? O&.%V<QZ\(T?!#+/.F5/)
M)WCM\KD(\8AE5X_%59##-:N\:8+!-S.]YB:?8LM1N8;K\I^40@U#24%PZ'<4
M71>,FU3>NIE^ /"T6K"C*A1<ZJ)I^!%E.O^%'7?RK^VX\:5ZQYLP^#/+=S^?
MWH\C=&CGQ8U'CTEIGGP%,H!A)+0O/%D5HG-"^'-L7N14JU,F)[LX[M:NFPT@
M)XH^3<H1_L0<=-XE9:NGO#_UXBBYBMWW ,@EO<T#8* T#29>\R )>$H[V108
M&WRQ@VZ^=5&NZM6B^#6]4D2N"$&U< %\>1BOE^6O?\^G=PKPPMO^N7C_(2[,
MS CNPOQ2\)=7-4< 1$"Z:W;IK69?V!R_*\_KU_GYG4_RES<K9]MU_2E\<J=3
MXU==K+/?9#DZ<LK"AJE\^%V;RZ!W\Z5K8/?7Q)2/$YKR)7EC1F7'O1FZHL;W
M,R+ Y(@^?G1TBR/M^ E]ZPX:X7LG-EX4YO2]GBSWX^ >/,)N<WI%$=!X#*='
MK]("+?-M9HXL%"4IFF[*\PW7'U55F/A5EINJOB@JDDS<3AXP,I3X%B^(-)'P
M;Q4K.!QD3!TL_'.F1;RU'B7B?#7]"0P,Q&!-#!054L!@T/<4%MO#R&>=<<M(
M#E__>#:9;UHN?SZ51! 1ICF_0^48 7'1ZV:3Q_KMCQ_>)5[*JEYLPXX-.Q)5
M4V1F#DF1IN2V$B!"PV.TJM8H4-=J$XZD&G0&].G1Y.7 RU*,1[IY;:["-VZ:
MH,D#JL4SIH(\(S ,Z:NHN5&L$$4]!@%W=LM+;9:)R/HE8>@&,WY>97:@^AG>
M%OETR&0,WV:P%4FA'Y/W+S+G#?IPQ3^&@8Y:R34$HQS1(_ J%5WB+PYD2%5,
M5#HE@36Z3B;_&X.8Q8[%GVH"F^15SG-"$P2P/B']PJ5_>O\Q^BB<$Y*0TU$_
MY!=-P3*7<$_X-TUAH.]NV$M/+,B(,ZH0'/ZDHDS&V_>+X%P(4P#H1EM&Z*0P
MWFBZ!ZE-,&HHT7NWV4;KY/'AZ"G>%E75;A<A4"_SN(T$[BD+=2WB30/[H$U0
M.RUQFTF7E4Z'@-BP=,@+^.#.R2P\]_1H\N#UNP_,>7<6SN/WTZ9<K;/)3S^=
M90-+/7SW,'XMF!*]I;[O6\^S3'/X(]?3309G9)G3NS#2C%FB/SRV_PC,@(MG
M0IC'U_ 0"MG_4NT ]R%V=#D[/'ET\JC5W 4A3+;A3T\>?0;[S3WQ U[Z<&OO
M"L 5\%."[#!-U*Q8E$S0UP_$T_#IIG [4:5.,\6W&>9PI,P9""9U%1!-T124
MY1H]U'[2"[W4UEW9K4.?/FC1_O7PIIW:O>B_N%'QP&$NPNY\_*@5]V;P1@E@
MLHN2W FAY'K5NS<_[X@"]I"=/Q\_^68/V=E#=KZ^A]A#=KZX,SIIYQTY LWM
M3C"I(R=B+[<I@HQ;'!$IW4 \M_^UXV)7P/@3AO2S&]+#MSJ:L>/VIA\,>,FW
M_>F.4WAR&W=9C^$)CF&(T:#2SCXSA[&JG'#KQP&4R_516/M""#?#JNWBLX&V
M=9VL'-1CE21 ?NF\2()):]0B%((.M+.BX+O1>QTLI=X<4_[1(H?7/G'[.];=
M_Q.ES-&F):&<U;<. (AJHXYPST0 28=7IY_>[A@BQZ,_6(QQH! !P'=ZW<8B
MC+YY'8V'](J=S>!9D8?2]..6+UT69G^L1S7,:QF&;91+E/%S$!U6I'.\6D,]
M[9(:%5[JA'G'=;%&*>Z\"5;F@G,F _'7^+A3,S-Z&/G$CDZH6PRX_BI<V#KD
M7;T8PN8?6#Y@?!QDDHJ2LUTCAU9VNU.+_C%R' S%9/RI/Q,H*J-C@!.R=@H\
MXXB3^^2D+^.VQMWMA!=O6<"BJGG.76_&E@0:I$7ICV9LS^(.>6N<.^&-R'],
MSN+N^%J2.)]9YGPS '"XRW(GPR;Z>.F__/SA^)N3\Y.#3!C?65'FRZH9?Q$P
MZHR@:'U$&UM+[=L"J*$EH\?=AY&.YL$YBFW"AF#4141D"/-K%6C]1LIPHU0Q
M!R(HKU>EF@>-8/?5I3B2?#',H-[#KLVJZ>*2NL'SWT<8EV2$S+<4PIRB)'@Y
M.@1A$PEA;G(+NWB3N&IQ(S73Y[#M)+5]#$E.XVE=&?F;TS'089;5[DK8!ZB[
MW&9V;L=']?'TLQFG[+%3WBGM"E]?USW*K'9\C**'=?,C4-U)W_$N-97.2Y:.
MD3C4TTB^U[-*'2(]?7_Z1F8UW"0A+6J-WHC]PI)=QY7EFCG++0>Z:L_8^V=G
MY;Q@?[?5\S]MI;RG)_@-UI87 9:_O:*_RRN"V>L?YU_+:;Z[,T%98+0T(M6*
M*UI]B^VA'93.0B96N;N@6PO*M'!ZZ  $"2*1E]]8BHC#DF =:VJ7"('5:ETN
M84<<>QB9N4-&3$_:5?E)J!!Q#@!)<4\:2-XX=M]= >$0UK0=*BA+PD1=HLE;
MO;B$-9(YR2S,,J,R7";V<99A7-@V GLC?+$#>)I;P6D$J*.#&,&X^+*]\3-,
M)VWQOQNH!(6)XN8KD! W&]#H); 8WS?N83</"7H3EM:OY1+:B7)!!U)I$]RL
MOAOKC[DY^GO&N-XHL-%T)GTP_+14Y>B;',A-CG[W=M$GAYQ,UR*92"D$CE3N
M)\8\C*O!#UCGGXKH>'26M+XZ-#0XNC.ZL W>WKM'->=&VT=OM 9[KWJ!KL'.
MF1#E)3S(4E9!5\,E$HWII_Q"*$,*7;()\6 "[$D&&B=W>'TP,P?Q(%8&+$DY
MBT55R;.7*8KG[3R8D4;19;<W"?]"FF$@M4#A0F545SX]8 YY>)=H(?$?>JYC
MISW7G3E';-8./\_]8"4\;:DQCZ+2\_I*,F#CR!_.X1"-V.>!H_AX[?331.N]
MO 7^J9,@50IX?6]'Z7[/.U@N14N9QM_/N7C'KU18%<FY'XM\$=8]'I/NM&D]
MK8]_5,>3'D879NJ<!W0C/LQXVMC(T'6=:6"/XL'[ _,JEINU9YM;U--/>(+W
M]@VX'NI]B 5;&0"0_@58I\I*2SLM[V:U15";UU1S,J][%,0N%,2W>Q3$'@7Q
M]3W$'@7QY9W$EK%9,.\I#C(CWX<K=LB46W8<DW_JBHB#I2<$NU8F&PM]$_A@
M]W!-1;YWG*RGTTVY#J>SQQX#>HQRE'R:^>/58-;>?_0<QK]IP/?$-]N1P_-Y
M\2[#-V?;4A63T=R;%F/;2_HIO'[SA74):=@3?B3Q;&RSZ'2L?GY XTAA+;2!
MA*Z)K!#MP6*A-QB/.N6*_2#()3G7$#>.#*.R^F*E'WYPKTL\[@0)]?QR=75X
M[D7QU7?M+8!OZL+06X:?G=X;[82S-P,G+JX3G]J->U9&_R3K\:%./AQ.,3/2
MCH1EA008_<[YI;3I![-=+N% RKQA])1#(4KO,)?3IF[I+N=-G8>YIK)[AXO?
M*/J1?P.CWF5-4:F%T$+C:P8A_+\+0"Y Y*@Y<<M4Q3Q>V<I.8*5I6?TQ?>+:
M6V^9:#12#LYMR+0^S:"7++_1/>F;C5IT,<5Y+:I+Y6M0WSR9V]:((-U,#56=
M^D6F3E3>75:V9G5)3.*&>?HO1>B6@)E\9NO$EVR!$R+J5#RA76]F6W!7#ZN6
M#^8,I >L6X;Q];!N]<4EFL[KNB5*L/"5HCU0<Q=^Z^AX+@A$5V]6;?PX%HJP
MX/5&_5(-KVII]1_8*:*I(8_"*S0<\Z!Z/^OP;B?6;8B6N&^EF44>%@UF[J:B
MT1^H9O2FFG*J8:0N=#\J#F<^]5SK(X\X.;9,=55X^!M374"\)>9[M2%=*"[*
M5;$ +49";3'F5\$@>UG&R!#?5UX4=C3=_M+<NN/*>J8V11CEE+L;>7-M/5RJ
M8=HKO@M<BVB/8*DC%>'QHS@S?BJ9'BA<Z^TEL>$<@Q0._SSA>4GA%SNOP?,+
M33T037"GLXY[X%&[CJD=P%Z1,9O\4%24U)E>=I)Z7Q9JY@O@^!@DF;$W"T08
MO]H>=S%]ACEE$B>RL/JS[E<=?O60G;)PWH<WM0F+C: <R4N/[]:WJPY4%MZ'
M@&Y>_H$*_[M28>E2^JIM^)L]%\^M]BF'VTO'&S@09*N--4XG(?3I7>YH/%P>
M+YXGY;JQ*\-2='#P\?SM7F7_YF]\\PKO[GK($O#M9[ S@P-X 8&'W (6,LAM
M,@2V2%A+_E6H!WN?(W"/?K_9+IP^1>?R;Z/F-5X- V+L%\T-BV8 D+*?LYLW
MVFUZ]0>0.3U*#?X#6O9_N209M%TJPWU=+R0&D#N@W')5B*+G_@W>>-AD::?6
MH2:6.>EN.2)?2\F$:YA8CCO1)3DKQOV:BM/YE'K:?^F -%@+*OAE2#LKWNP=
MB%LZ$/<F4.B3JPJ'TRW;OI-R)]*512R1[)?3;E;0@86%TD&J@S;O':#<+9TR
M)<\_Z\CH-9:'L^&Q))]OA5N]1UM ,?#=K ME!?>K]^8X&HZTE6*<C&@G*9;D
M;C4E/*4D9^.]DM_]X.L*%5#E>V^</B>=R17[693GM2I[%\B@@=U^8F\*AS2$
MMB 6:%%$L>2R^[W"<^U>@,2WOPVT[R*!WYSY/;Y5YO>NS/JN/"].WOO C?&F
M5^*]?4+Q,](W8UT]0^2Y7YHV57%T<:<-Z8/$OMS>_.]HEOKB)O_H+F?_/Y1D
MW$/S=T'SO]M#\_?0_*_O(?YXT/SAC7)'KHTKUD UT+=P2M<W3LW!\L[!LQ$Z
M6N_55,5%+CV;TTL"L\Z,Q;?X$D_2.W9CR$EIP^10IRJ@OV$:#YY%2-4(Q=@@
M)QD[I0RBZ\1$OVMI8LSY_>KR\>.YPM\Q _=%Q#&W3T*/",BH>A[>/SU:>%):
M&551&U3>4:BTH)RS5QY"&=#?0*NF;@N!69-6Y'DA(*O@I6 U2\/G#M#=R/+_
MV8825[V"+F65]+_B4K]&#RAA??_+GP$A[X+')2WPVD%B!@:SBZCUEIQWS["R
M\^G_DA:%<BF&6X$FL8@:'8-/Y\#8U"FCUZ8E<LBWY.I_W'YSG>D^^9X;J\[_
MB[>Z(*O-\CRLMI-OCY\\^O:8@ -U:]J+8>65:\I\%JONX6*#;HL%6ZE,-42)
MG+YJ-U-:ID1C$NZ\"IX^SU.P..LR+,FTZ?]96*CEK$,$P-9GM2KR1<%B'<%G
M*-''L"90T#^H:P;)6%R_9%K#A(=2+5_W>=O)XR??/C[YYEO,TN/OOC\Y^?YI
M;-L.NR9"9V 1A'_(30LRP;>:&)PM82?1>:"H?&O2R.EJC(&'>5ALBU49K!I)
M_1%Y;;%:0U77&J[<7.9NPK;/G)&F9]!'AUF!)F4>J6_#-,VUV<"_*_DQ98]M
M2A_R*V##4\QXA3JE*[FM*A:.9F2DI4D5-[&-<KT(?4AG3RJS^;XP/I=W9?MI
M\C)8IKH!A<OQ"?[43M[%+B:Z_:OP>#!(&Z8M7 5CLE4%%E6E.:TJ^OA= 2[/
M\(9(D8*LQ\M[<N+\,MI'LO,5:3]0DIH-7D-.(L:D#QGFN@JC$U%EY'3H[USA
MB*C@820PGSB#]U!C&&PNF0$"_28@XQZ3EYTGXZX6[CE@V\4I\;=/-9Y<%OIH
M\J/*@?\'RS8[DIJWKE-\W9CGWYA1>.4AXZ^<RU+>$U*SLZ0'="RY[9JY -6U
MM>:SY[S(Q"_\LJ+!+Z"6-114Y;T&WH.(4?;;V$N8^<9EV-ZQKH8..W>?HW2\
M'\(Q7<.B<'<$._FW:(_(7#<KL5LBGSK>JM$AL[Y%@>7?AW1-<MUX KPFQS5T
M6PQL9L3@+NX6GT+1$S=WI*2LZ$>3<:Q+7]OHWX!X^:VUT*_!! [Q'?5LW([-
MUN/_ZUR0.5UODJA+.MUWZ84PQQ3Y\H?&.P5-RM^SA?D.90P26I&1*?5T<(BU
M^F:I@[73&,2SM2_3+G>7.)V*(O% 'Z5W+*T+@EG.Y4<Q5Q'UOKJ?_4NMZV$3
M?N>(&MHVO,ABYFD=VM$;^R/=T=$IL3W/\P%(OF#2D;N9!A=I1F='[( T&<>O
MVSW\?^S]>7?;1M8NBG\5K.X^N?9:$,-Y:-^WUY)E)W$Z'H[E).?<_R"R2*(-
M FP,DIE/?_=4A0((4*0&BZ1X?[_SMB.20 V[=NWAV<]^L)(XZ>Z=/)VML6ET
M>]?X^[:EU&*[K^MY#*"8/ZDYKQ/%AA/)TT$\4"$;;J#] P/*Z7MRJ/+^K8H^
M2$_M U$-OD3+J]I"FVK0-42UU:TY[UI-T?"88R,Z,'(D$;=/FW%J^R=BIX.W
M]P=O6XIRX_M45DN? CV[!GK6:80V5 1]E^#&*T="[CN[J,7LE"$Z+CFA-G==
MS9PU8B'/.-I4C#@Z)%0AP;-?R<2*('E([88 %+@2N(.,P1[4>\ G@.&_6MW1
M"6!X A@>WB2>'\#PR,I(WN648V]J*,>.PJ&&V\^W,SLJ2-0-]G[(Z9'S&*6F
M$RL@56R+@;M62+Z;NG]1VRZN9_BDPC!9!7!)^IZ+MZ.D#2KHW=C6J^JEE4CC
MXYSBP^Y0O)YY3RWBQB6F= KCM5\#7Y[!S9]@IF,:@)WRE^>\X"Q0AVLZ?KG\
M0_^E]9)YTTP"+,\Z20Z\YMEP_2.)J&MEG+ 7&8U_<^KI2%S%31F,!7X/83)9
MHA"/HVWXS?*Q[BEL3A!KZ=RZ;?;MYN%W2Y<XERJ8GITOEH$@'W$.UCC+',N(
M+"(!M>B4Z_F2"7\8(6TX=P0V'ZUQW1*#>)Y[J "O'H6P%A;*V/Z/00=O.I;D
MTH]IG'H&S.(1N$=&H_/T&8V[!MU1_9K;^2CRNW^N@1@L3LA-#*:$X%>$,R]0
MF!;@4K< (K0+>V2Y\A-<:%_@0G<,XEA;=.NE61'>><GJNP+A0JC=&KC2+>>N
MJEQC&V30%K?__6)JE2$U9RVFUG#*7<GR_'N%R;0=C$@:7CT6XF=[DGP+]F,@
MK-S1KN@QA%$9F6H;.*@F"[JT I3* FP!H(Y$>596[=BV3M7B<-S>)ONN,YBE
M6*(JJ*IO(0-4,9'5'*-B=5S(7<*J[UIY.Y#3\_@J2\&$ GD%7S!>>,Y%%"_U
M'8A"*?WBEK$/FX65#]L%<:O=%U-.H)?&Y7OV%MQ:@=K/2+*!CHO KL]4W!I]
MI,I?L Y5E8SZD__YV^UQH7:KU?_;KD9FM]UH]VZ7][/6H#'\'K;^H#+6W$9<
M/7AYW%=I]6P00G_[U]L0)J0H]&"OP%'$MU"/J7Q^U(AGC3T_\)(DO_RE#F$\
MAW'$<!/H$@J,TRR)/!].XL7YYS/7^<(/++0 H>Z.TO)'_T0*A#2_OPQ FB34
MY\Y%>^BF"M+$>]W8$LV 8_KRXY>+SU97)JQZ D404W.:<72V7K+W^Z6;_P?M
M_P]@PKPB_2&BX(O'RKQP!3.G\KW;6#FZZ(5^['#/3'Z++M3%TA1JXH/:C+^&
MBYK@Z,G8P[T9^[K9BW3 LH(U&]Y>0%=27ZP4N[[@GV,_83JEC1O*-=.R#,0W
M;2V#P"%NP4W*\+8W9IQBD][C"+%H+XTW>*WS!?V9U[["^J)5DV95>9QWH;C*
M47=+"SQT'J26L7#H<M/&%"+7&"RU39[(E^8WG!GC<?.H;R=AK#V&KCF'^:F7
MEU\67LZ/,!;3E]QPJ/X^#W:=B=*V*+;XY7T)C<EDQ\'R]Z1L1/16G,S]I8$*
MES/T:%E1Q2\Y*]D"#;B_#)T^[*C44DK]Y 46RY[]1J8G/* A59+/Z-H_Q[IU
M2NJPM&P(H9V@"/]J]9HG*,()BG!XDWBF4(1]#ZY4<6.($5+*,*&AF9%-NH37
M+><4X[\*HFA"337)%,;Z'U3A9!5\>OW^ O[U AGZ7$U1HL,K'CY )3Y2$H!^
M\KU D//(F(*Q4NPEFJ28J<+L@_X.U9.!(6-ZRJIO2VK'^,VY]J^1T"4<2W]4
M;:8;:VAJVAA2MV(TH<Z,"651MQQ1Z.SUAR]@36ASEIOT*K3<<9]-EY$/;S^>
M??IR<=:TONGC^L-&)[B69,!XDVA)E#1B:I7J7HF+W1"+:*LS6IK8%.^4V?_0
M<FWTOIL1D>B(61V!58U</&)?@U0HJB:SR7;@V3'W?;U:\<_*3Z2JLR/9V0TP
M=]YPETE^8W8R\:!A*1IW1):=>8>GB)A%WN*^$*%+C;M>Q\%#+GL4U[GSQF[_
M0/L7P'\FV,<222K>A;"D*=A?SHL/_W[WLL*9%\]APS"W\>ZMXZZ#) 67N^SG
MBQ;Q]5L+6B81':G)5HUB$4W3<,X-MT^278%N(]UUZX)K1HG?0Q^'?9F2=S;W
MDF(7FUT>6>\ K7O[93\?(\\E1_^LSM'?.EK;/-)H;0<W/?6OHHE_++E_L@KR
M.=5$)Z]\(_[CN1I_76(00<J[%_"+P*N--]J-L=:;2%8# A;>%4=,*FO\<UU@
M#<N:0\[SHJ3@%QN&B=_I=,]:KU\[V1);<_MX@WEPM60X13YX\-U/;\Y^ ZUZ
M\>:LVT25]W9Y<?[^CB$<6UU3!*%RS":N\CK_]")?Z/=ZB>V>RKD:SDPQ "T<
M%5-O_:![)CTI<[4#V<$V_F2+=,$^H*]RE*0V9^I1++#V;+"R;-JBB[%>,)K+
M&[\J1!4C)%%#NP;AFK V*#1V#7WIVH2[O]/JL.5V\:8]R!_*^ $8&0_*&$5P
MMI>QK\"R6CF_P'->XY>-T;\R(7^W&'>T$AG(W(YT3UZ8OVV.(X)+_H4G\72Y
M-Q/_FR7@+_G$Z4/F(QT36W@17X=TQ6$,-?9"DU@U5^V^8 </07H1!BQ*"'2X
MPOR&K@$E6_R]=_6']TVBNV0L)<XO48#[XH*1,6X8923?-*J"U( DJZUDBJW&
MUNNX;,6L65Y!.+Q@%3B_J1NDAJ-MG'GA#!0J0FF<G]^T"SF50N+%T%# $!>F
M4V)QK#6QY/*$'H+BY>YF4K-[I&92%^Z@!5+/O@=? LZ;$F(PRU(XEBQO0O-<
MZ'FF]J&JL:5R \FPI7"@I?2LNLR3L60(EX$+JYQDE:1J >Z,YWSY[3/<!;,H
M])/%;3;+K5E@ZV%I;J307\_YK^M\LU6?KM'NH7O#/B$<*CA,WE\1Z"BXB!!7
M3 ?WD2V3+0]I<S2\WR'=CQ-9RCL=Q?&[% 264+SE%*1+H2#5UU\%&0(RN5JA
M4/'[#7<DIN:.(L_]9XGS'(.L6%(U6Y7)K ODQGR[^O'DC'ANBPR:-[B8@:^$
MZ TC+ P"1;L2<],QTVG#U:X8$^HA:? J5+!NB81B<WXDHDBNW#ZCL H,PYJ4
MV_ J)>CGC6/_BLG-B4Q8H+;%Y.OKQKO_@WE>G-<GFM>%;<@GFK)6H*D:**@+
MI!@FIT/3U4/.EP]78<G"%8-).Y.AFH2QZ_P6H?QYH<<Q(*MNS2WADMF0D;KO
MXQ!,S+9_5:L\X\[W36&MJE+J1TJBM::U>9$06'">R_E1!)S@*+>;K1Z=+Z+>
M1RL*@YT3'S9:)7E0&5'A+\+H!MQ"ZJ5!!]!\>OGVI04A>^-[,W"PR>[Z>7'U
MB_71)P'2%QR>TG?J$6C\Q;?9%&\2_ \:]*^?OCB?A"?\BYTVHV\4-(8'7D>"
M,"^SD10F^PSB[L4X#Q5?@]:P5 .84F C&KBX+GY-MGQ0;J:A^)B/S:]HY4M#
M_$UXK?)'<U3#"U<+=6I'M1FBT3I!-$X0C<.;Q FB\;3]J#Y1,<A8T F)<_XS
M:6[1N:Y8B;]&<R_$<O.?03F&5W 3GAE#\8>_M]O#5RG<"W[X%]U+Y8\2>)+_
M%UQ^6"^T]:.*-\C:W<!8R9K;)>^!LGZGF.2^U+1-I"0+@0=*!]?;S>80+D T
MJ 5<_2F#-U W#?AV[L.6[JH2]4-Q(N6'VI-A@V1T6 :)^>*[,(RNZ;(M]<LR
M=L5V1HM;-@E^BKV%NHGBKT4OJ;SL!50P[7O-UY^?Y5YQ.(XA[O*[J9ZM-3#I
M V[MXR^X\S3^+YP^+BG1N8%$RRBCS:2ND80NBN&?AKX".0JD3 )C"D;DO>4R
MP)+;6 \"/''L490@M[R"&V9*[=W,QW@,"HFY..<[,5_2HV*R%:W.%@KA2)C_
MF%$&B2(;U]2>_"I+L:@SP-Q=.J?D&#:[H>9<6 *LED39$IJ6;%C3IU-A,F+,
MOH5ZNA2VHD#&&%262Q"\:"+9KB3-R_),Q%;/F[)A:K'D!CW\-<1'T0-0UQD0
MEK7*A+&BU^EDF4F&:_><VK7HH5+5/ZU1@]<&?)/H"J15=P4"SP4WTFQO!34V
MS\ZG !06%*<P.2^>8.P7<SZXKV.RLD271#'U*X9%GG' Y9K:4G'FVSQQS)6V
M"3@7&(W*F[? G^+5D9#9"%T#+ET:Y%WJU+=QD"5X*F+\,F>4 XQ47>-7J>.@
MH)^L#*_^0.):\,])-,XHW@#_]%+/=;["E7<VAVLO[Y0'9R4+L#NTOM(9QO69
M__S2 GJ K&!)/DH^QUU)8."O.6ZAT#$MNUV[P$3A%LNGG0HEQ8I;'3+2S%^@
MC$C@1-+)!8"K5AUZ2'D/K^*):CC;*CQI]$73HB-N=L1UXFCE!>GJ; H_,2S2
MTGZ(?OS.'J\OU2;KG^#&API;AZ%\:S6@4^!%Y<9(V640^:G)REN[9"CYC=G
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M=,MW"2^C;1&<^90*:&-:[PVNF?FJ[A;#C_)FK'((ZID%2QC$L220-QP!.W8
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M"__9>+*B:D=REQ16A8I3[E7SD\N]M90-YZ<L1L'!2[^T$1I#E)MN(/ST!NL
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MQ2=T&H/"$ZHJDXLHE]N?D4MEU3,H1$SR->9F?DS(I^4C_P6B5=(<*S=E+[6
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MC$SY$$TDDGM0XEFVCA9%EN=H&^%7<-Q$/)YL?1J+)?0X[A,H<!,HL'<"!9Y
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MQ;:;Q=[B2,*^U$H U(V_9"">\(U]5:M"K!7CH+3Y+,4"D2NLGVX])6=@Q0<
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MQP@I/*GL49\5!*R Q=9V'3/- B8)5/N[<-R@I+%\ PQZ/U <SK]),C_75A;
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M*ZLBC-F.Z>"O!]HYND!L=0%JS14'$)0.NNC0M9[^E05F(UAIBD$!#IEI++1
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MG3N>$T0W*G;6 /*P1U]5"L.!)9PTG#^5@TD]G!=_@GWEO2R=1['_%^?WYE$
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MXA3N)-?<DPN5-IS?PUMD#K\=JS-MRCCP(N5QA_LHIM*IB;:W^*OF:?IB_X:
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M%C[KYLG[_/ WK+M_PP+)56A,99!RIN94%A4P7U?\T&*RA:U66(O$@F-6C:D
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M&DXDRUTCP2<@#8P!AAIAO%/S]:)]NL3?_Z/=;%K#M(Z/ET-H;=V*>L)/*(6
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M<[+#1NLGKN&\V;YK%0<AP0B<.*-1SQV.FIN]$_:,RV,EP$5..3]7 5.<QU2
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M:5^E!V47][50;J>SBY1[V6 7&$1!]]"YZZK<YTO8YAB-^N>CXO9IK<A8S$E
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MH*G'*P#HT4>OW4VYEME2A4,OX03R]"0_GGIX6&1#65;743AHL#^&J#TZ(^Q
M][GQKO%"M^.Q(*R^.IL#8O>TY@";3W/5:FB=\@!!SSLNY10]EB7MQI45EMGE
M=RHJ B-,6F</X5U;<]9?.1@/'^$ "?>"NLKLS8'GN/E\,)GGEMD98&$KJ9?6
M:C;-)=YGH?9=YA(W.(#[LQ/Q)#$\8IW*R;/SB)44DQII(IVU!-R.,=5MZ08J
MRD!0DSEJ-RJ<2STGYB*I_Z!U^$SJT];P \'[\NPZZ;Y&9Z'XTT5>#+C3?-'C
MT3=V'0)?I JWZ]'+V7;;Q"&?48O:%9@4K*X]81AY^NXN,P4*QGWUL#U-/PZ-
M434#H$ZGQ@I3W8"UCWSB1D667XI-D-JV$?=+%KXO*0_/NIENX_1I^J^]6 &V
M5U> ]XW5U=DVK!NP,(MCWUA=(?_G0=&Q)>0@TR*V&$ B<O:?GUMVY\T/GX_9
M+?S<;;V)N.NM)XHV%V8[<\6ZJ^@2&X;9MKFLN@_U_KPDR#;'V3[S/A7_S>5M
MKRB-:Z54LF(7F&ZCN<*,@B/YW',#815EBCK7/%J9$BEXL_]=BVYXME)6XKG(
MS<3JP>6YJ2OF",[FV>\X9G,_\08P.(^HM-".R*Z%GW!L*4YN\YT Q[!1&WS,
M+IU)QP7\JRQ?20Z_I@%7*;F=!OO(Q:(X/\<+4EK68?&$4\,M;#K7IW1J-6U%
MYAPS)Z$)0PG# EE?S "C.6)YG2!]8+<'FMR.>!7%+-M7JVT/6FNM^JIE+9>:
M<E-/D &?PUDDBH27)&ACJCX^%CMCP6BU*3YJJ=?L'"?91>Q#Z/>'4=KCS&Y9
M[-U1MVNW;5C2"WY8[ ./<)S-1OOCK!VZMW6M+\PR^>M)E!YRXUZ$ZEJ<CH$2
MLH&H&;%I,U57(]V5)R+5G-)F$ED)9-7IG(\BOK6CUPV/!OAY$.&9E*:1C,U3
M"M6.@+'@K%'>5RQF3N8; UIPN1R_"3LDN4ZT,QE-8P]D.<#!&X]3T5-8]I+%
M6B)J>CTS1PTH)PCAGZ)KI^...(UD&.#>Q01/$4OV M(UPS3&<GDLR(YUV.,6
MJ.>PH,O[,/+[6;$1CE@;8U]2(F#1S1-@&_-@"*M'7B\,4M?GGLL<%XRL@_'7
M+^>'\ 08+4CX=$0$D.D@.=_0LT_:\SM(FE:0IA5D70^Q?ZT@JR]*W?2X"0"$
MTYCF&,1%Y/@TR-%!H0$_$PM)1C3Z 'MX8*]I6:M:DB[(S-6(ML*4\NE$S'(3
MP@I_YTP\R>WEZ$"4AO@"SM%T[E5O,)#[-#'T=]PMV*^\;ZD68?C]D8?CKD&8
ME#:"?QMX$8@A?4M4>:M&R5EL'-[A.<C,]IU>:=@@C]708#"B^R0Q'#_O=RT[
MD@$2TP '&7)D>G &VSX: [Q'#-6WL$\G=/R8QB_WX]GBW+GM)%%8\Q!';0]Y
M($SW 4K-?,)[$ 9'58_0D:4X5\BP9"-O^#6.8 (>[=UY_=3Q_2G#]I9A).$O
MNG!SJO3M\S'U<W'ATO0E,&@^!2ACGN!&N(=X"O^=CE%=&*>)G)3A(3Q@.V(8
M3(!7 #8I*Y"!S/Y)0;?%-0&($_@E]LJ20&%).@ZC&94#U"HON(/G<&C40(P[
M -4H8-UF$X>2\+X:5S\[IE[^010^.RXH2&, E!L1UFBJI&S3)8; 8U4VJEG4
M_Q-53U!@:!H'NXW@FHEI(.AC#?"&#J?L/\YX\H9]4JH8.5)^#4?HQXG9!] Q
M E#=A^R/P$/R]FCZ2,E2M&27=-2H'&F%9F7OY0.+H#7#,9GR7)+*1F"3BI>C
M4&#H8N1X^ %U+6YH @ 12I5?"1_YR/TQ+)3\8)\"N 4)[)^NSIS#'WS\='3[
M]>K+88.]!5V12&=$" NRGO.D:,;YI[$-$UYU.+:&953\9(_Y/HZ<XA$2E7./
M&3VRP[P;#@-/CN?-YV3@K@4<V0VP6 "L:' _9>?WJNZ:?<:_#!Q *+#&?*"9
M?.]"7!AZ7BG:P,@C3\PDKHZ'[4K[VVJCJU"D4D]#W],-J)FB@ ;B6G@Y_PYI
M(E')(FO9%J-3XI6[>'^%-P"YXA$Z20'QG\-H,@IOIC$[_\ .OCAQW_GGU?N_
MWKYFGZ^^'A9O+,[_B5(I,V'U7NKY8C812%/DL^C('T8DZ7I>6)I=[0H/+%PA
MCB94MM]\![1A6VTX0XNT).&G,4ZQGL"MQX,H*R?6)8;@P#Z."%$7']E$G/?7
MY.P]2J3 @WMW<\D^ &XG=!MR@_4K#76 5? SJLN4F/3 +C]?LH/+% <5O?I,
MA:_LTHF30SGG57 </)9JFH, S[_X&]Q:]@Y $KLC'U_Y,.Y];, #(3:U:AXC
M(@$&34O!O+"7V:7.8P^NNR/$XN])OV&Q'G$H..M''$/]&_Q'(Q+JRJCUPRC#
M^G[Y$4!:W""H:.N"R>#>J'$VCC@LO":&>!3;?<1I+_;Z'OJ$_O*2!%!&WP;6
M]!OJ)M] TI]_: !807G%V4 9GB4.\ZUDG2<_2+0+?D]?'H7QA+K>.* 21&JW
M6OJX]BSN4NIAL91T>$2X8+F[*@6F7 0$7!@Z?.62VN?Q5D2!$BH"X46HDV #
M[0:H5:FGHIV<I%CLP8FD3\I$'[@K2I5<-J"DI5V?BW%).<0(6D[P#8?L" R!
MIA<&Y>\+F>H YB8^<"Q\+4O!/^^#_>Q12Q:D_RQDHTEZ..YG(3$0DU'N&E;>
M'#R>0YH4SSQ PMF7>065=.[GO:82U=<%*"0<DTAUAD$H9C)*HF)_ K3<*8CO
M3\%SMFI_1.O7M7L(]8!:+=V"!5'UH!H.HA04"#,>1;M5X%Y.(CAC&'T33$Z2
MB&P9A.8#*5&2:6IC?.#78N"VD = 71]\YWMX,X8;@WR'@_3[?V\N7[,/-[\=
MJHL'1(["[";)^N9>#P @D7KV^OTE/2L$ O!>(=H2YQM^,^,=M50L-%.LEM3$
M<EZ1H>SR#CM *3WE-;O\\^H-(VWE\L_;0\GA(K07<S]KG+HN($%H*&)-FL..
M4\B^,S&KE31LU/W5V$+BHSYP#; %J]08#PW.@ ]#:=@K_EM8A$C1\>*L<3(7
M[!.-/+3J88_ZG49U*I$O!=1C%*P+!P=6*9.]./@LC(:PD1^"+XLY>5D#+# !
MHQ H3Q!F9@D4Z9DF7 ,3!S#Y ^P<R]%NS#2>[/OY9^'9+\ HKPDDQ=TCJ'L<
M9+=NCEU__/P5U1)+M4P%CJUB]#^DZ)(# AW"DK!EBQ O#-VR9,@ .,,)H7@2
M\3MTY -R1]SOEZ1,)DY&W@0W]-M?-\A@;@'^N"]V4*".&.0@\ADX0H04]Q5%
MW*% &FJF,FD ?A1QCGNRH8N23""7-$^<  8*#B<K%72# #_]B?ZN@()>*( [
M)C0EP@P#Q3D;HCBM H>"8_ZA.-MA.]_AL;@ 4K*_O8%; PIA3.P*MN&.^!BE
M^E2\^QL@ ^R#T/<YD+S0$H1*"PA^>RX>@B-@1 5$?,[=;W#@F;\K0> Y@K>J
M&&\+1/!,5=0\,9NG6@'A= 2ROX1W./DU5J+NRY^'F@,GM\G@*8JCY4JGI)4I
M26\D:=E/C]:&&_,GZM77H$:3!TW3"W+KMI8"LY1O6"N\9TS[!L 9_@!-_LZC
M%N!U=6M\P::#]03E.2BGP&E!O!7N/6P0+@00/7G^0.BA3AL+.8W6&4Y>("G\
MV05N&G/E,[U0?H]SY8ASX:+\X(%5_H!BUI\=XK&8 ^F*! G XM5$L'_YJWB>
M)78>>3] ]Y5]R@6K@M>O*9ZNO?5[VK_WAD>?G>\> -$#@)6=MV#QNJ/=YNRE
MBLHMX.GE"K;'R:&U7V^0,[V(=(K<J=]J2J\&#G3-DW^DJ37BCI^,R%5##4BE
MPBS]'9Y(Y%!"JR$:TU9;C*=X+667ZJ*L0?^/:C6K37]3+A\%VDRURW*322>L
M K^\9I\+*N!LSAUY8IL+G+46*Y,B;2#04F8RMYH$V =A^7[,X?8I5SW?.L$W
M,8_;&5.HIG'=0$\K6 SXOE#P-'E.V;+2+"+K1GU%JJ,B[\8;<!'B<.D!X8G"
M8 @9&T>BRD#90A;C_Z3(2T3<KX<)..024U-D@#IR+Y\7:'RU AK"X'<$>\S
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M8:X+"'LO?U1"RHTMR>#>WDB[D:S2.1_^#7T?\7J]L"\6&2S53V]T7(?%"CI
MH;23;#HI:P,0K_ZT(&BE?U0T5D=<?KJ6B8M QNJ2EKAFQMD+$E=K""_EKEY7
MH8E>%8RY $X6<U\?&D'BV"0^+DI\[)C$1Y/XN'V',(F/+S3GJ%I$Y.XT(1QD
MNM;U(ENF."'D 89,.XNM#%.O4 0@<RAG],5O?)I%PRRU+2U6@K(I&RYM,5 4
MAUR.&W)<L")BE1"5*YXNCG#HA9&6 R?M#65F"(4R+L1DRBE5Y5$DGZZOI"@[
M*T@\JFK TBFPIZA^<8JZ)9MX=R%^BE+1I##-(PI5.9LB?GB404PE:ZH\1@MS
MXG#6&>X0<P&F2G9CW"1;!C3C8>2,X3AP0-]) VFBY5JV# PMM#FQ^#'&8FDO
M'DEY+CZ&5@C%2S[\Q:X+R@'Z@\]OWIW_WZ_A;]<?=9^PR&+(LFA N::(OB"S
M\\' \:+Y!I\&:ZFY#VB:89 J@OSC-SKA'XV;!ISX'K-?QP5\WHC 4JYWH'V(
MJ8X)Z+;B0KQ-(\KL_?WW:]V9K2)2PJ.M62H4-<Y(;C9"Z @KB4S@LJE9M)9C
MLMT539&5DCOG^ 3S6WE2<- 5=>N;A)T'_8C?QY8HD"E&G7X'@-R$\#'Q]&4P
MI.PB<>J_,.YMJ4$]2U[]A.I6T-_Q7(K56X#4RA5H;7A7U<"LI]OT0A6IZ:DG
MI=X1>IVYM;#P3%P?F7.N4MKA1V(#22%MN)!EGSLZ&^QF)*3FB/L3+LK81(V!
M2A4F/XFJ4J.<]]B:5X5PI/+\5)X[L2]RQPP&1_#2$?!T?Y!5!L"Z?9KBO$K9
M@LRE1Z>B'/Q$V9WYL;0-S;M&LAZ ,@DJ7M-!GXG?N341LB3"FI-0F$E</L!I
M5BCMY*>$]Q$CW9BGC;YE'7H*.,[0P>16K73"R2LO'!=(YXZKD/[$YXD0%#X&
MP,FUC<6":'+/A866I9!+R(O+J\6D^0%..89GRR+X_(.J=H@)'%DU)E&CEFXN
M5H_P)),1^YCVT%^ 9)AGY4VRY'\4N-<@<9"(B9@^:41!"?\EL:1V?$$6L\CV
MS[Q>#TRQ%R]GB?;B$F6D1S"C1-]<T97BZQSV#M=5)"=B]8NX/\6]'UQ\^GQ+
MJ0^9GTU!8=;+MS#-WAEC5JVX/; ^F6YZSOY<"B@FV^<X>L(LUN;26:Q;T*"B
M>JS/[#S$;1F@>9X.0'X VP*M<7N':*Y(.1L<9_@ID.,S\<KB"$%J&T"\,RL$
MFB$BU6'@#S]"[OD7<)G8'04<. K8("5.*43^9W3%@S7Q.<2<?=@VA<U"=H_&
M _=!3(D",#+]@$]S=-ASD;],_$D,L,XRU+G(1STX__#Y$.T&K<W1B44^5$O.
MC98+N'X89T>:LUHH1HJVNMH43QS0F0<N6FV0&I^MRI//.:<X8L2/U"DQK#H/
MI U@\]@_A+B@Q;YX0 <.>^L#M=^'884/HG+JJ6#+),\Y@F &(PAY[.@T![_D
M#(4MH\B6%KZLE!-\&AL0B:&E0S30QAYH+U404:K%[$$RI:,:9OE,T_FS1V>W
MG0T?533SX;-TM9P\9R.BS1IBZYA*6NH8,@O9ODB5S3C%*J-)U8,TEY0="$6+
MTVP]O&BDCV,&@=P#V,O\#B/0J #F(VGE#=59@JK^'(M;>ZC-0)W -D$-P2&V
MKIM.I%,K3!-4=M3QI+/J"7U0)/9_^6\O>O6+B<,LBL.4FR^:.(R)PVS!(?8K
M#F.&0N_J4.AG_)X9'5V7=OEF='0-X?+ T=%K!E#M[M-UIIE?99KY_@V;1F]N
MFK!?^7 ( O2 :OQFS:W#%Z*?G9D^W38 6\?,HGH.[-X$P+)>'N@-#*2K#Y :
M\4G$ YY&F.6 +:=2#/7)Q!E5GTQY!XY_YSG4M8(=S//^L<[-!06ESKT+6%($
MJ,ZO?U,M,FY#2HRXN3Q\".?<&B!7>Y-%=L?!.SY)DRG;,,?<HCM^W#(P>>0
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M73L/5EW7'O"\J##?-8_.%6BOGYW &0H;C)3756EY*RVCOS@;.:!ATZ R,G_
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MJ*30(C*>=+EUQ77115_E>%7@:=NE*W+2?-*_SV:9A'RDI$"LMS+DI:QYU()
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M2!A(&$AL#R3LTU4DWR,A\7B'3?T 52:9[0IP+E-_6KNO_NS.G6T?K\2]=N?
M*[+K'3JPO1)7WJ$#[QN&VYT].S#U 6FMDB:S1SJ%??H0G:*NHM4\];2G#-KW
M\BF#]KU\ZL$.=5E)\ SI#0\M-7N!Z!\5+[S'V@6>36==2^BOVS@MQ_ZJIP3-
MB_W9BX-_'1/\JU>@RRQB@G\F^+='KNQCX](75J6!@PAMK.+4W@= &(*0G-YP
MB ?[XDS@KPI8)OBW74_MT-U=B8?MSG%/]NNXI_MUW,Y^';>U9]1L8G[/HD[4
M5:J:ITP R#QET&Z>>@:TU]-FG--KH6IH(@DV^PV;&3=GK,N:1'_,(B8B9B)B
M>^3GM;LK^1/V 1)M$P0QD#"0,)!8XI!<(R!VR8M5IIBM-&Y,0&P7KNS)GCG5
M[=:>!8G,@7?]P"<K96KMSGE-7&PYT1LO^5X^9="^ET\9M._E4\]K-HKI+)ML
M8[DP,!9S-PSZ59&Q9]WJ;(_+*H'[V!Z775/F5J\ EEG$!/5,4&^/7-2M,]LX
MZT4/G3,#"%'@90J;!"#.3%M'R20Z*WG%]P 2]CHOQRXYX$XZ)J)72Z5F[R)Z
M>];[T#[=LW"/W5E)@]V= [=6RZ_9G0/O65V?B><M;RQN//Q[^91!^UX^9="^
MET_M6CSO*AGQB-TYD>?T?,ZJYM.9,%@M0CYF$1,&,V&P/?+K/D,/LV?HJ%P&
MT:::0N5S[Y[U\^O-)3EYP&!P0]$&&@8:&X'&EO%"^W0;>>'Q\_'"G7 ?FJZ;
M=58P]RXD^5P>?G/HNA]ZWV8K[B62S:%-E-)TXS1/F9#5WC]ET+Z73QFT[^53
M!NU[^91!^UX^M6OI*#<C)^)'Z#7NLXDSQ1+RF!UX@>LWF!\&PU+E^>$6^L%/
M37UYO9)(S"(FL<8DUJPMN%H_EYAMG35-A;F Q8'=/#2@$* X;AE8J/(F<S]4
MNV0S8U>*O].5:MY,F7G7-(ZNIVZS=SD=7>OT>,^FJ9X>[UMMO=5M[EM_<*O;
MW;,<EN.5&D'MSGE-)D<%:VN>F2P.\Y1!^UX^9="^ET]MI?58'=N[#1/'-^9C
M32(\9A$3]5KEUIJH5R6]U-E\J$9DVVJNJ5'H]L'"MMKV>EHK;R$LVBMYS/8
M$J>M]42]M@\2MM6QU]-H>OM@<=I9SXAI@L1V^J?F ,I^4']E>721<_BPL]=1
M2=J;P-A<A&VE^[D:G\>@'SQ@8N,^@,2V3MH/B"7N TA:5KO[@-#;?H"D<VQ
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M ,,<V'' !UX26XPWA@U\/0:!A!2GO@D_@.AU.3RBB\2$ [7YZA* >$9ABEM
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M_6+/9HL5&UAF_Y:-ON@V%9NAL$D4PN[&DB,X00"L *X:6MT57 %H2+",*7=
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MED"<&-E$'4_:3>ODM+S5TMIP76ZX@PU0(L!XL17*^;R,VB $DX?8=KGP;AX
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M1,^?'I8,<Y58%X5@&F,$L8R,Z@*FC<,<SU)+2,L* VHZC4%@7UV3W3:JEO(
MW9.@*W24D9V@'BKRO5V7LKT=UHM"I\]H)**P$4!?!-;LR&R_$0]0?:7D;Z7
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ML>@<5:9BGV!@;H6=W(]"Q8F<X1"%'5@LU(0XA!.CT47-9K'NM6!,8:<-#-V
MT@3B9=%)@GYV_S$*-<FD$?58]DEMPZ0GGK%$><8LX6;L!6E2F<&Q<HF1O:P(
MZ[$#6C=>8S0C6':ZM"B7Z,JYJ<V<K;#-T)Z3OH<2<Y1R1KD/'%4UD%&=HP7=
M'"WH1NFBB3>A\FRM4:)L!BSZ)8JDI8H-"9O#GQ:V%GO?LQETNRWESF.EC&#9
MN-8/T0V/5,6TUCQQJ1)%=6:@R*BVH;*L>A'GG-->DMBD",I*)GISR;Z2:2ET
M9^E4D10H^FI>Y(4W[!P.LBVQ]/-O8#IC%3]/?M12NH*MK%WUK#.9O/."-C29
M5TT<BGJ$PP_OQ80'681#Q>9-1NVZ,VJ#L-2$.D]/&,BF.[/(DVJ+,##NJ>#_
MG)I85#^?LVU0=.-X3-[BDB,V;V6K\8<\G8ZR%F+5ZZ2BULAKP";(9J,2@]E'
M#HD?Z80F>WM4>R+1MM$?SL:05B<3*G]\S#YR?YPF[%<^'/K"O_P9VWYQGWT.
MD]@= <Z""JKW(JT/E.J3@GZ"W/JDMD%Q"# 0=B?F#6I,N/HLE&ZD=7,:B_;V
M 'V[(XR0QD9[\@'=4/NG3,'L<S" HJRGSSR'V0LK-1=93>$''/T2D'RZ"/O<
M4CZ%!4]4<JK-,:3+((FQ(1"ZV7GTS1>IYM$<'O5RK&B39$CQ*NJ)+K64K*]=
MP-[S7I0ZT51,*FF=4 N+3B$Q[$8F^-K'-GIKG :SU95\N$[RC&=^9M7CI;!Q
M:*EI>]7ZX";IM'#/:RG4=>:ST5;[7M;3I2H-'O#X3N/U5=>I;7?5NW^K6@!Z
M63W0.CT;E"[:!4[BBLCCB0!@!Q\_O)4ERC[0=D(SI:38Q*;[F?Z*G>LQ+$M.
M6+SZ W+1X=,.C9FBL/  ;I(P#%7P/&M,J8W,62J6I<4B<E'S/5"ZB9*$LFV>
M\,WDN@*V^*TEW7T,[SE(/NOQ^N0";T$\"E-?>JO@S+.JF2 ,_GV"/?1B:N);
M2Y\I'*^6V&,#C_ND(LJD$QIG,Y,10>A$-5Z$RM(^M1=ML#_\"!GV7_!;4'+!
M?NLC)9P'?SN@]T;.O0<BI:;)4[/Z>3T11'V$TW[H#T";0,@/_2Q81"T9 3]\
MUVN@1? P[T6"X4.]'-S)JL&0=XB0F&BO?G.9M;N5#BEA&ZF.X.C@DH89A<P&
M7FZ4S/$W*C6%LK:0?]>2OD6#SWK2-'I7I17ZE1\18D1[]2R+(P(^3_9A5/@[
MN1O&GFC3*?L-+G LDF.8L(I=30G5Z)JB6=\B24SK.9!'4-%].2O2JX58/A]Z
M%$:%KIU9$FGINY1*I_E9T1!.$UR14NMB2VR;)ZSOT2"@@#2$2/C(.&8".QA+
MRJ8S8I:<IM[,W:OP@.N.M5H2KN;MJR?U*KU%,!*%77)K 4^1\RA1K202MYC0
M6;2!D7H?;=GP6N4[+'&39YT<X>=\A*+:@J@JDF,;)7,4M;+4'7Q!AHDI'/K%
M/CTQA4.F<&C[#F$*A[9'CUU!8;'4D([_G[TW;6X;2=:%_PJB)V9>*0)FDY2H
MI7UF(N2EW9X9=_M:GNGWWB\WBD!11!L$V%@DR[_^YE:% @@NLBV)I' B3H],
M$D"A*BLKER>?I*ZYU*E#Y5Y4L/V:;Q1H\/G'"!BQ4)&M/.N1X+V(P/S94N^X
MEO^I!FL7 ,S46 75OQ&[$V"C;W$IUF?+,2*$A1\<[^&[&<N.&9E#RP81;6EI
M?I7#VLY5M!8R6^ ][Z7!?!"TM&5=JU2;\1IA2:H/,8&9YHP&K3S+/0>*O%LG
MR^)GAU&.'AKW?#+@9H>*'*2XX1%1SXG%CB!;*>L[0WNXE;,GY]QVSI@*T[D@
MEBPR;0,\9Z.&!"6^"DPMWRD9M46N[1%X\%5TS8XBU4$54PNBN(&'8[.7)$5N
M=X\^'SP'M>378>M4L5IB2R^Y5>-"BI?;)C%2!5?=;N)A2!&5'>$P<(BUI/P"
MS=)^Z[QVR*!88@H;KT09EQ5Q8!Q]?40=NU\0Z-^I'&)CHN6'IAZ<;3SG&RL$
MIG4( IFKN@"J*, <3/,Z=/ZK"H,03KJ4'[[6+*&CSAQ]#6Q+OO#:D@782HU3
M2TULI][9RGE3^79.ENR;K9PS9U]LY>3YW%7+#1Q7GH4#1'/RY%*OMAA+WF^]
MWX3[;:6X;3'W'MIYN8/OOT'3@X0OP+:KH4)O*IX\PUCV8EK"Q?N:8/M6K@ B
M%[9S 93W9YEFY6QIB,BM8Q:T;4N]6J/FF8A;D3JTT,;J1#OXZY I]Y_AYU%O
MYP*MK)\(M<:N@,ZZ<"$J&O*A6Y#E74>8@8KU?"JQ/J[^/"#;+4N3*#B$WZK$
M4 S.RL3T975JYO$NN,M2PCIQ8\-#JAHKQ[/($)D83P*7'.4C+:^PGR,_D46D
M2=:QE7(!\[Z=,K%,!V+WV1LZMJL@B25-49]P2;Y:#/*U<K#OV)(/SIRNW)52
ML2M08=H%##U9%R$ )RPF-@M3.%'1@,'-;"W\5FX6(Y/;N6/:V3=;4(C+,1%O
M&]$3V$B1=/YU_=REYRB5C>"/8:%I#]&!V!XXB!CO21B60MH^$OVHPS#D$#F-
MRZ(-"VUA4.A[.S59 B)U^^!2FR6++VG2Z?B85L+QUSJC@@E@"B@KQ@TN\L+;
MS;,(F9/A/E308Y7'3YM6N=8:*QZ/>H/UBN/98-3K/T1KQ79H ,9?AB>M<=Z'
M&4)]S@:#WH@F@^ 2C S!>DU9M)@[OCH,)L^[I7GHI<'6V-S&/*/:?28ANZW@
MX[!0AFT&AG* :+UY@?E#++]/;Q+J63[.HS!2&6Q5LL;"*)]S(W%3,)<ON0]#
MDW+%Z(9_OO]XV,G @\L 5D%01V9>*8H#F^[UR!O$= V^L0YLE30W39(:BAH1
M-2CB4,_F)DG&_0\1>*;-"<@1XN>>TS:N6_"'6G 5X#%):<Y&X_ (>R869484
M&]0?G*+R-3['QPVIW;LA^1JC/_7F%FWU'HB]!3T7Q$AA@AJSO?I&TE%MR!=A
M/HK13&<>%&'E(AH8WH8<52*E'%YC;*JAICDQ38DP!I,;?",%M0*8]'1&5!5Y
M2?W-LQI9IO6_ZNUNO'>K*XIHH(:( 6Z/.-("MGN:J>Q6:H?D%P)5#U@K<%@&
M&?>6QGED9KE].\=NHMR]4'X6:^[/:9 2[78L=5"9EP4)-F-65(B<G02A0,G7
MY)\2H!GY;L2Z%@?V6B^9@37MMHC<36S1&?49,A00+QM,(2_=V[\UMW^?PF>/
M3+-Y[_ML"<L)$X8A*,/+=3QY5A7EVWQ 2XMX+GXU_=O!60+AQSIGO ^(TR<,
M2E':8#D6[6&]VO.-YN@;@!OW#S#Q;M+LDUL+@5X7QFS0962GC2E31255'U#[
M$.)-F41(FT>A6W0)0**C@'<+?F8I$3'#8\LRVSLHL<:PR]N4'0<H1:<:25@2
M"FL!&+!(BTGL.F-MXIDZ7*J^>]X+E3,%<,O3EK6<%7(^X1U"C5.?LJ4-Y*B^
M+4I*RH\SUZAFHB^<0W@J!3*9S"\5+M)K5$37.NYYOR)K7Q(JO!_\*M%27!1,
MB:_Y!F&;J"BHIN@;J+*.AT^'*LM[GZ'3&E0!I[TDS7IEV\W@:2[%'S'VH@D)
M!K0D"(F8$W0186]/N>S6:5P#>Z89MS&(/!T3BUS(M$YV6RR-=LKV9(IO)US%
MT4I6#$YPC-@PHHDW)3LJ1XKQW!SZN"?0X@I3<H527^@^FN@7G_^1N]F--974
M-FK%%R%A7:,P!C8[[$_0!GK&,XV698E17$-F!2:B]+W*!&=[G7(-K$)>+%!B
M..E@$:KP#YBKQ'0)I9?@FQDJJJZX9E5QS5E77-,5U^S>2SR]XIKVC;)M!RCF
MXB00ZN9$T\0MZ:VK?U0HQ JK'48RH\MK-,G+W%X\3D/!Q")/?L9._NU<2L0-
M7[A)F!CCW32=W'/05 T&K3<)]R#4&'&L8IE0RP9LG.)@D+FE@/1DK:>OA-"?
MD0;X V)F7W5!H!*,K8Q=DTLZ \#;LY]2,Y8: 9P:UTF[4=+P/!9YMJ71;(W+
MA/E+<J?PYSK2-T)+K^+;/&)24A/UJ4EK6]2$1\'<'3PS/%:T562"2)NXX94E
M:<6>]SO<E&A8QA@@H-V2&@97L(QHUMO>QD:K,HU6:94Z7]=BH9J_/=\Q[]O(
MQ/JG0B9V]/5D8EM(B+G]!*?+MC6J?63&=O<U)W.H]8D+D*-(P903L%/3)XAH
MHG1&Y-JX0]V=7*C\DU0$5'<W5:'TI6]S1DXC%(>/A^!B-GV_;(?!+D;>*9<^
MPV)/(@PQ%RB&<]!OJ_BK*(J.L=^Q))@G.LN:;N7:/2M^#6W;O=C&[>2@"*S0
MH*,-Q2 ,^ *)DXBKC*8*.6PP<JV37(AE?DV9;1D=T!JAI%PA528OA>G]G<H^
M:0F#O\]2:@E1_79\Z]A&+&.+/[IICI*6_[>@2/'DMH'?2TUQXF)J<)\%G1EC
MC<@TT]&V49;L(,J=G5,5 FXGX&EM%'PKE==&!^52TYX7TX8=,!2"[Q&K>:Y_
M,G\\1_A!K&Y_BA)Z/EWTO+ZG87,^OT8JMD#%\A1Z('\M?OKY>>_\Z!Q=]2*#
M_P_-@\6+[\'[_+CX^?%9[[S?_E6_-VC]_-MN!>^-4_KW'XY^,+\Q,Y"DX(1]
MYU_]2).1+?NYK HGG.<%]AB/0N\OIWT5'I\^EV])C2Y\*<GJGX;SSUXCN8^W
M:R[8+ K#6-][H*@](/PKDAZ _K *RLIU$:Z9FHQOL[]ST\"SKYB1)R&G<)-'
MBF8VCO$G*:+M,P/VQ:2WP/_X?MI[U?,.7F* 'ZQL_E&#TY!_Y9:3-D@EZ2:[
M+/L[(][+3%):G"6$Y]]M*WQ':0>CZ^?[,KH<:6\59$?<7Z@LI::"OT8P,.6]
MB,%8O$G3T#O@YE_OP*L:CMBXM-OCY32+<I"!J?=+.4;Y?P>[XP )6N/Z!4N:
M#71;Y4&V2L,1>Z(;H<X0T%#T[:=!N]3NA-":^,6R8WS7A7HQ2'"@D>:D$10X
MW%S&U\W8/NR!%5;+)F<![H?:-MJ&K? C^?A?@UDZ.EF#61HN(,^'O>'(K+'%
MF9_VSI;BS.\UB-WN@BVS_/<1HT15^?7W7045]4Q\S/31TT3!7=?^SE9H<IHO
ML_PY<-D<"*9_<V%#;&WDB\9IKK4)-:H@*#,5W$J17*&OW$9EMF<X%<LQMIAK
M,BM6?&Y ;G_(_;WQ\Q9N_'SUC0E;1<1+&!LU_=8EG8V7+?#OY[<PGS,>$MB%
MG]R"0?<[1('&494'K/IA<TMV*0.L$-2^/,]IQ%82BMU"J?\L07 GMEJ8YZ_J
M2N&WI3?PHY9[6ASF9B]/5U7MZ/T%YFQ;\88P<],CF5B\9)Q8E\M <>H/D=3J
M*Q$L,-9(0[$TX=$J>W9F5F6::^EL*ILL,Z0,-+A>C/U3]H@*!?*N>/+!BW5F
MZA/M:NIU.YLA4L0E.FMA>L<-)3D-\RLF@@19-8I1LOLNM$2$OZO"?(0J3*FO
M,J< I:$(L2GZQJX/'&97HE!KT$^YRHF'9(BRM_U'Z9@A:,=RM=<M_,-71G,Q
M@EGW^AGFUPXP6D;Z =L#FQUEW9H^^)HR*,I88O-,/V-<G37Q:!]3']DT><;_
MRE&'!]J0I<C:5CB);F6W;V4-K!ZY2PU\9IDQZ9C!3C,-7GMP9Y.:+@_ Y,=H
M@6O4S[$DT%AQ<U-[(N)2YCK<3W&P57!+Q.&141A+Y,21#+?^@\MX#>T4HE$8
MQ"+^0PK7D!PXC8>?YJH^ZN)]%>?6O<_6=],\5/XL\07KWE*H;\&MK;2/N/>"
M&URAGAY!7A]]:79./7VW8\RIN:48E'.J+1>$KLKL'X.S\Z[*K*LRV[V7>)I5
M9MU9M0UG%3K++6F-SN+8IK&M7<5:5L68G29X*1FAA9Q1M\;;-+;[M"JQN [\
M$VQ0B_2"UJ;4*DN(: $+(TL0$LJ6[:=WO#,AL%LFZ-%<>'I;H_*4;*,K$K,T
MP25G=Y%R$P[#6(U>"^S[4ME":7CS-+DB6HZQP@I3XJYI))#1_VC$R(12MR,9
M?!Q)<8 -U5HXE<.!CN9%,TV%?(0V*4EKK**$F*#@Y]?49OM*94Q_9Z,/_NJ8
M!6H1U#;<MY((9_:=*OQWV!)2_\:]NJ7Q\YH2:L9(-"$LS,A7%8CK'#9;8&$D
M5/,)N]^)6E(7)S@ N, 4'[\"@N RB'%ZQ-P1>XX3,;POE=F^QX%4> 07TG-B
MA<<U,01:3&E8Y4FKMHK"N.BE=20)B@P\R#?2HU#B+#>BJ1*GYX64:><P;510
M_X/<2S3B:I#[,,UJTX#"GE=386@65DX&:C/$8L#6X;R_<#(8.VF!&BQM90O?
M;_F^ (%L%'$VI993J4C[1TWC8#CNDH<1:!0$.]!W@^?X,^('H%Y#$3*-3ZA.
M&7;1AQ)VS*!_\>Q(N CP<:\_"WL:EK;C2OZJ\E#]R3\>G?1'S0X3R_J7+9*:
M$R/% B)M<R":R2+KW'EYSC$$%4#.>E(LW\X\T"":\]#^YHV6@O41X[T(1+=D
MB>[P1E;YF!W\*4EO8AU><5:<7B&B)+G;L,"A)%A2#1+:]C P77'(Y"@U(!W/
M#O*Q+OQ0SI1O(,P[ZF]"F-=$GRZ"3\^V"'GZ/8IR]A6ENL)&N_?GKUR7K2P5
M7RTLUI+<0@]Y5XOSZXCHIG:VB.@-Z\,:E6%W*@HC/.LWJ))OPKYVT-<M<2'G
MF9ZK;%E(R0D;6<^?LXCH2:2F,WV9"&^],4,:366;!G475'ID7)7E ",GWNSR
MJU3%IJ/P'QP^=J,)*Y>YS6]RW4Z#PJPN;@%7KKF?1_C^"F";NT,V\.M\.6J;
MNZ8YKS$V!-/DEU1#[**>CRJ@X'FBBU'</N,%<D'7!.632$&6H9-4L?\+C+\.
MXE\A#U6@B]:?[MRM_,.W2J'Z+7OF"$_ZK=%5L)Q9R:'% /X=P;*R83%!7OFJ
M&8?PQ"\H#5-HM+#^W5(_:A$&-W2ISAYK85*W(\,8&9EBNA")]M.YC==)_*^Y
MV<UQM;C:78KBD5,4W%JQ:0:T4Z=6)95(X\M%>]9:6,!5ML5B-PT0#8^_)D"T
M_>7)Z^DH]C4$M/3-NWC&?<<SEI!_-(/6JP(22Q>/$D/:6GKDB6YHZ*$.P4.%
M^)%AP(GPZY*](;WWJF959##  U*B=Y[I[$HSB()ZNK&Y003?UQ%30;^E[&DC
M\B$!#@YHI]BUF70@TKAV88['/H:JU3/'D'0-JT4WB']:I",OLC(HL'TPX?/E
MTTR1#^TZNAQ0X2-N(N@;6WQN3[YY.08UCJW5R!ABH:,&@22I1.;=62R[(RI&
M7^1&8>1-C9&[*J-#[J] [I_WER/W-[?L1L?GIZ/1V>#T=%2E #O@?P?\W]:7
M>'K _QWUK!8XT?;:H_JYLEUK?<YR@]98YL S;!4;6.;3=)Y+0FE-A%\8X='=
M83S/&I;ZQTSW+V/(EQZ1";-2P?>M>)OEJ=X%^K=E?/W?X!$U"6QPJL'$A26[
M,KQ8US#)M#+4L#H'[Q3>P8G$<58P2Z\R-;,I&!IAK,H$X^F5)9P[!C*-,$.(
MD;2QZ!RH';"*2=8D'F<$Q??T9QV4%EF,*ULF0JWB9%= %^AK["ERE<+*/)N1
M:X\1O#3#_O3=8FZ/B^/Z-.K0[FAGR_O>^-#N<)N+"P[!6_[;7P9G_>=Y)17/
M5S?#[-;W 3:K[+:J' 2#$K*N' ^#FQ+7@+/(WQ)0'YRM":CO;!79DE8,E0WS
M,(+0/HQ:@_6]M$3;&S$V.O_JSZ#-O*0TS0;7()%\Z1 \@UDP-ALAC\&*T0K^
M+FY2<X^>Y_9H([0U4@['.E_5+8QZ9)E&?\IM<TRE#!Y8/6"Y(8!ZB4W<\_YS
MA6^NL-P$P>S48EWNJ#FW';@8\(4;['>APL?U>#/J2E7-V-*FVA2O95P^W*F<
M,\K@FCENN37;+=U+PQQ1WS2&%-68'C/NE9T3HK(R>\$8UN01,5F9_3TCX.T%
MW)K45NMJ)U4**\PE _C!) J(0)1+&0*58X=K)$#%$?'(5>)2(;GO\1^J-#"4
MJ;4.DCYC8:B]."Y(6H+ 9:9>(L1.W31)UW">X"=)2O6%$?/G244 !;*G:1SB
MFF!+RMHGIJ6==/;&SF?UYJ +RR>]RS,]2Z]-$W&>@N5K.8>Q9U7W\GE40=><
MEJ(XH=W^P"4D.X]<? 5C\,9E'KFUXR;HW=)@U"EZB]6-T @;U4A5-GF>@K]7
M52 BG+"4+VWAHLW.+NY>I/%=L6^=C5GU<K7^9%S=V8&SRDP$\EI$Z(PR 7_$
M9#G!EXV98-L8G5DIMW;ZP?I2?2TUDFEVI1)Q;\VC['T67*6\JJ]U]\F>R^5%
M8]<[BS/FK"WVE/4N7PLVB 6@JJ0DK8 M?$,-,\XSF(E>2DP5:LVAL1!1OXX=
MI%KGI$#&/VX5G6GY9JR+&SQMI]$LUT@.35J#_C2"+!M#BB6==VK=:*+)XHBV
M"XP)U&L$&DGCK7/XGREI7A@]3"J,Q=9KX[XCP%3+..TPW8W*PZF$]%8L'=!]
M-&E1'L1IS@T[G3K/%;MLO\7QXW*EU+J21#<:"D[-'*65U%&)'#%*FZZ;1L[1
M#<O:P=+VO*9SRRWUQV'P^M5NZ6C&%;?&-7>+]G#SD-U2?;1"95,!(JFYH(R5
M-+Q>]B0N9$9>]1"W8:.\HPL%/'@H !=K7(97FDE0[5%81531)O0KY2#LN!CQ
M31S16ECII:%EN,#V@1CT49C(>L3'=(C;QZCOR5W@B7-$V *NMLX4-HF!37C(
M;UGZ*T;NLW$YUR;@W[ ;S7'Y!G3\O).#1RBO,(#:91NW6Y2'C]/&3=BA>^:3
M96$LB=8ELSO8,%AT:[B-:XB.*:C#"1BWBE" ,2("83MR[1LRI5RG\35""S$4
ME*D4\V9(=J)! Z>S*.!&/^0NN#$E0V12-;WQJ]0X$?K!B\<4&X7G5RY]1N9_
MBA0,)17G?98"'&Q(YM=1:^B7*+$*K5M2^;)YKK%ST(+# I^A&VNQC54^V>2K
MY0+CT="3W+GK9/DQRG.N=6+2@DTS844,KUF"R6%1XZ;DQHC<Y(X2P;%W[E"P
MCZ/6&B%JPPHE9N0G?2L!F\P"@<BTZZ"M*Z&M@^\!;1V<#(8=I+6#M&[]2SQ1
M2.O7[)1'AS$04Q?(VTM)!3$!##.'DO'WUH2BWR,3R.U>0PU^U\R'9N*KRC/3
M\\)8OF:>_J9F\^?>ZV(:!9CZRKS&1)K0&MCIL44IS#,PXJ.YF-559TZ-MW'M
M:Y.88VXXOM.-]L+4_L3P^#16#W-R7":/#HJD(UH0"IP8]%LR%>8;R^-G[I*7
MXSP*(Y49UA\]F\?IK=8REDD)3\0UKF) ]<%%<-FUBF)6<0G=]$;#30N-P(MI
M4<SSGW[\\>;FIC>.4(4$TUXH*-@HH3+@JND>$4@&K&CPM36SV31O"RX8ICU@
MVDW).44J01. 4%/5>4*!$1C;!?,A?Z"("3_$O5,89K@RD46HAFP 49"=+\%I
M@0\5]S7%J2B)3]T\*TWB6VR&?NNA/QC:+-2-BA"9QPENZ2EY;3J4ML\E6MJ-
M[*Z[RNEBY@*SC;! 8\RXA3P601U8'LRE276<#'-UE4%JS#7<9#8OX*Z3.G1<
M,6* \07FO:O7WO/\DE4IA =R],IR%2O['3UL7&>A^':8?L>WE4I@:]S!^7']
M&4E>X#[$>.@&!L)2M7P41H$]CDKQ"<9"K^$[+X<81IT)87$KP34ANFIB>C/5
MR"7@3:(L-]02/>^MX<:7>V *I(I"4$3# [_'5'Y*J"9?#UI91D3A-W_>QB[K
MVX:CB.SAK+%?T;R#!V0HG=/Z^+699K^>BX.7)TU9I#5&7^=5]WS_U5A4;V0S
MVL)<81D2NG/+=4;ANU#G01:-]=H>"O)[NC.!]-S;$RXKM\>)*_$][[=ZO^Z*
M91VD#AX/,\V)>IU@G'&!F=U%X) M46_K#?LWII.5L%F@>KT"9K8:'6KH*4R5
M-3\0"Q;246'CES/\A%J&XXN 3SZM]Q0(.<MG]BT?UHC;0!FLU7;<VASDJKGT
M2-=8@5\$17YL(22FHTEXS*7+>2:'LN4'LBFJ3;IB? /Q;/]D':_(63-@=>(4
MORW?7OW>X"'"58M>P@!VT:N>]]JHYG7Z0@(WI#+VP2FXR-NB=(_.&X)RW$X8
M(GHN]$[\P=$1?X?&^3/:_J@BP-A#8;>G+97KH3I@;>7CO6^F8(P._,')&47T
MX> +4SR\J6( (4B$BH(!@0G']K]3K#5&%T>@,F05HTK =#'A N2Q7NN@QEGZ
M"71HF-XD:.A,RB2P5K_$DV&+DVULN/:1P13-I(L93&6@?.\BCQ1=<#'!#]8>
M<4M$=LFI!P)*;UA%*C,PJ% ,8C7/]4_FC^=@@\QC=?M3E-#RT47/ZX_$C7^-
M--B@?^4I]$#^6F)TY^>]\Z-S#-,5&?Q_:!XL$;P>B,./+9^?]49'IZU?@2YI
MOV39K0:]X=E)=ZN'O]7Q=UK!X][I^>I!_4BRQ?(%$HP;YN\_'/U019GIQ/II
M./_L-=(K>(@UA9CE]Y'B[3^WZ)7JV"K"9>^XJ-.#$]T?'S^7'<ZIDCE8"8B.
M\?YRVE?A\>GS%5.3X:@>:6Z6Q/M,V=<'J>WE\X'#6:^<$M]NOFB^+L$@1U[*
M*.AF;+,9^ZT"@W4S0C/RO[!K"#A W73PEBKG!I3VLUAWG:A4/3Z$)<'5,C;[
M\##J1K[->%R[/:%_^\O9*7;?J<W6&EM'WI]<@+N\_=890NP@W;N@W'FB'E-,
MVF?J^.RDFZ8-D"S^:#3J)FJ3B3H^[G<3M<'&&W73M)$\#<Z.NXG:8*+.[E\_
M+3.,=G$6VZVFD3\\/[^+R;1+5E$M6/SD_([V.3F_1RV\4Q-QK\?V3LW$:3</
MW3RX)VO_O)N)^Y:(?0J]G)ST]]6$P 1SMQEL)=-@^+R;C6XV%F9C>(\NZTY-
M1"<6-1N[FX>'D8I]LB:&9WMK3$RZ0$2G*9=4#G<3P0');B*Z_='B8IYU$]&9
M$G<U)0;')WL.!VE_[X\I<A!Q\QK+U==L,]HE%U>DQ4X[E,@FIKK?'W3)ZDT4
MD3\ZZN /&TS4\>C^8^Y[,$T#_^BD@V=M,E'GPPXE\NT)'JPOW'-+ZEN!M7NW
MH99%^C<R()_(; S\07\C!?-DYN.HOY&=\T3FXV@S+.<3F8WSS=*$3V0V!IL!
MT#H+A/P"OW]^)PMDEXR,.^-4GV0X<W]>^FBT471I?U[X2:[RDWSIS>*F^_.^
MWVN1]RGK<GPTW->3>E,XZ/X(^+=[MSOUND]2:7<O_51>^MMC=SOUNMWIW)+:
MOLO9;(CMDC31PBG6_4IOP**V@PF0NT-)GF;D>PD4XGBC?.P3F8V!?SS:"+'W
M9.;CJ>9%VN?CJ>9%EDE'O_\TLZK+8)M=9N0.F9$FM&S_3),.F[%A1O%I:I'V
MV3@;/$W[=!DRHS]XFA;JDKCF9D0X3V0V1D_4_EBB.;[;9.R_^3'TS^Y69+-+
M%D8'S'A:+STX^_:@Q4Z]\)-<Y2?YTL<=,./)IWZ&1\?[>E(_/6#&D]1BW4MW
M+[W'+]V!K;HSNH-G/!P\P[2#_&[QF9V";PPVWWCK)FJ/0H++4I)WB EVL^7W
M[P)WZ.;K;LF9)S]?=TK>//G9&HTZ3;_Y;-TE^?-MD[7_R:$COW_68M#^2 VR
M_[&T2_?F7>2/SN[<1OX^O1KJU_XKF*!H;J5EYC1>GX(-II,K=:5#+\(FY[=>
MK&"E8=A9]$GG/>]W[:GY/.;.YS#86 =%=*WE9PH[L6,[2#+EZ"=3/:,&OS =
M,#O9+35"SW2L"GH&?1AA5_:"QO).9>,RN_+RJ-#TM*F"NV-#^!P>5R9!%-O?
MO@U5]NPWL!7S0D>)#]=&R1??W +^*),HF-(#7^@,YL [^.?[C]Y[/2^B4'L?
M=3!-8+JO\/%O9N-?#NFI.1JB-SHF@U1YN$KS^@"\ R,M#[VD]*B?(K"6HV"#
M1?Y7FGS163+6.,7C/%/%8PU\Y3 />][/90;2DODP\=X,EK%0*'XXX?.8Y)07
MP)&O75F#%S+YH/% 2,<J*Y,KG6SG.M!6<07>F6^K()OJ4&XQ.NVA-IRGL(>B
M%/0\;G'0#,^E$WP?G^!>)\=2O[I$C>$4*8OEESB:=S"LJ]X !JFS1^-%'M:G
MQ_WO-*M2%5?ZV3C3ZM,S-8'1_J3B&W6;8R3 ?4EXP_J<;C =FQU$QPOGD#-#
MD\F]B1:/(]1!RJVX?P(9)X6L83AJ:\;B33,]^?L/?XF"D>Z?J/Y('0W"X^#X
M^'S0A[^.AOVS0$_.@N'_/?[A'Q_1.D#-]#\_JIU]B9?P')"-77Z%G ;?LOON
MLE&VS3K;E<.M86#LQ!EW$Q53,$#S.5BN7I%Z ;@B:&V =$3!AK;EW6U*,([1
M'*;#E>S:($URN"*CI_%A"9],HSD/L&Z7PS#'VN.#$LQA?#K9Q4E:>/KS'*9"
M)P'8TVBPS]0?\#"VQS'@# =JWEL\O:/P[S^LWV"#DW[_A]4[:G"&QSX[?.Q+
MGO2&H_7G4;\W&*TZC^[-YQL@*K_G74Y5IKW?;A)88YCVI?;-G4_9Q;=Z=*G_
M"**7T_NFYGW!]YJDV8S$;F%/O%,)V"IH^'DO4I6%)'&7)0C:=92GX,3QIS.*
MU.=>E'MSN!I-,/(;WQ9ZYIV"R,;I3:_%<MQ0]HY.S\_.3OOGP[/SD_/A/HKA
MSSWO590'<9J7&1D3RON@KR)PB5524.+Q]'GN702T2+ N'^"X!"7KO<XR\-_3
M,@='_.(&E@+F_64ZF^LDIP7=:V'^%90>QB"B $VPKU=MH_/!)C*UUEIX*&'A
M7=6#S8D*GM37-(U#W("X/3](3.6]RHI;[R-(4*Y(</*OGZ&ST;H9&N[@KKMH
MF\.]WC*H_[_&'!L>#2;#^QS8)(WAC #AV4ICT:,0L#G;<O?(]"5=W3;NAQJ>
M297_[2]@ICUO=L[8KIG,]!4<4[#09 :/=:(G41"IV#%()!J=XL\4V!ADL.0>
M3/E/FV[.FB8Z'O4&ZS?LL\&HUW\(7;0<730\>?Y(8@1#J,_98- ;T61H%4P]
ML/=R%'50E1P51 ME,HGBB$X:_CKWO4\)K*(WOO5*<E7H'W:%P409_15O,4LS
MFW)(RR(OX-1"@>!U?MZM\:.L,=OP9ET6;/QN6;9A69K^V'.T^+J5>>B5 65F
M?=YE&X9L\47_V:826_R5]=F-[V9IWKM!AY9F4EK9;9SEM5,!3_X03PT2>'BE
MJ+CU[9F#T[A&-]%OVK8'!B1"7>AL%B62R0X"&(M* LVQ#C1"LC+6-D]]^?HE
M/Q/_X89&X%8894O ULISE<&,8=8:?$^*Q,'5K;;,!)/A";PC9C6]>9G-TUSW
MO/]@C-O+2WA?>KK??G64!'$98B8:;]&80PH W$PQL\UC!1&*PA)N@-G[/,6L
M1,8_#KWKM, C=I[>X#QF\.MKG1<T4_R9F^MN>5@Q547;8VC^<-GQO%?!GV64
M\<S"7)_TO5#=YE_E<-R[(=J9[)L[/UOI,4[AX5<L^OJSSH(HY\ 9"N^</;,;
ME6'\#.6=]Q]):L][_3G0\X(<-_SX!B^5O:Q#WOUY.?Y#8J!5B,D+TMFL3$ ]
M@2N8@A(J$!9S [L71R%6L)>H&>L:_) =1XK1TXZ4?8B/6-B"S> KGC+-?3C5
M,:E*VH_\Q)YW@3]L=YKP01>O+G.XKWBO^/BV7\+(8 (1Z^/I/W%[CU4>M24,
M]NR4VLX]!TN+2 8XS7AE*R^IN6X1PI%FF-T)<?G(J\:5P^N&1Z?^Z7#DGQZ-
M6-$LG"'.C;LXQAV&VO,^3F&.U0S&@*DW.:<'??]L>.(?G\A\N[L6-4*F55YF
MM[!EZ<)&NJ3 6^::H_QR]K=K -$N:)W@HN$.1Z,"+(DE.@U_#:9LAC] FX1,
MK:;-@;)TD7AHFKQ)X_ J*\?:&PQ];S0:' U,ZO,-F%.@93?2#"NS[/_XGW'V
MXS^6WJ;#$_UCX'21Z?!$'9YH9U[B:>&)1.,<P>C66T4@F6P4UL'Y"*%6\US_
M9/YX;HH$HX1>D2YZ7G\B)M@:"'IZ('\M^_O\O'=^=(Y;7"H,Y<&R^WNP^W]<
M_/RTWQN<G[=^!=_\]=&J*3<:_."H-QRU?^4,?O-;M5]B;O5]B2EF41C&^I%*
M(-AJ^14\&-1 +RK[@. Q&Y2:/'PM[5=7F//)OE73_ZL-F%VRL??"C9/A&H0;
MK,%]E9]OX82]K]RD-5,EF[1A7 KX8-,^R^)D;%3RU,?IVZ:B\W6O\RVU<FM>
M]ML>_4V59W9DZVKLEPUQE]3WZ*_L)3:A+%NEK[].%AY5TAY+F&PYI&-SUD%6
MCY::N_CHO9W-)X1MOI>8T0G&"S=(T"W$!5 ?/#OJM=C&8Y5K=@X/!H<-TWZ/
MMLBFQ;8/I*J6A#;ZQW[_^-P?K.A$,OR>,]+W=F)>CH]Z9VR%-Z=EPZG8T+"C
MV>AO]US\]4Z- O9?Y[[3, I-*O=^XO3WJW.'G<Y]9-W2]X^/SOW1\7+FMJ>H
M<@>GO7ZG<K^GRMT;0C+,K#><*M_!<.V3@_5=>5P>U0L>'!_[QV=G_LG9Z?WI
MN8VG:^N48/NDG?1[9X^'LS21Y^^L@.\BT]NEG=L7:?NT\Z-.Q[L*@DO0S59<
M*'[3Q(4^.;W=Q6=WP+U[GZ63GO>?*X0XJRF1#?1>]>['TQOUSK[-U1NL]O6.
M.E_OD7V]@3\\'_FGP^4]8IZHKW?<^7I=>*UM/OZID]S[!5X=F5X:0M(IL4?9
MK?[)<"/NW'O-^MW5%'8DNSF[WWL>[S=@>]YVB'=ZXE+#,]^I3!?%+H;ACSO3
M['&UVME@Y ]/-B)NW@:]UK83]T6O/<;R>QO]7Z=YVS1OI+-/WOL4-"^,QO?>
M3\%!WDG_>-0IX<=5PJ>C8__T[+A3PH^OA+^_BB/O^W1K<HOM$OCA%I[Y(0JF
M*@MSAZJOTP0/[&0>^R?G&_6SZ13!4[7&[M<BVPEU]4^%-T.EU;"[.H7UX*GR
MC1M1/K3&VHW)ZAPI3C7^[2_#P?'S+[&>>1_A[]'P>::#B-..>^6>7+S:-;$]
M'QSYP^/E^*7.*NFLDBY.M&SZ?M'QK"R\?^JKJ[B=\'C+I>_D<:7O7AY^?K=G
M[\7!LWOVTL ?#4?^^4EW]&S!T=,I=4<R_Q-GR'7YNTK"/)@F&IOFW&<*X'X7
M^;1+ #RVHCL^VQELR3XKN>VVKY]ZV.^%P@Y#.=PO@D<J[T4,;W>3IGN%H=\I
MQ=6%_[KPWW<)_UTD?RCO79JIFT@77W;7E#K;+U-J]X*5P^/.D-H"0ZKS%AV9
M?(? "AV#?BO 6X3;)9V2V+J3>$L41>MD/:K5W9DMR\V6#V68QA/OLE!E&%W%
M331"M[L?8VG@TVW<V4_-!-CN6,IW-%1$)(0'^_NQF6P=Q\'%U[8:VWF>FG5K
M^Q \-H]*/G0\\H^&1_[Q<#E*??,2[ON>S:VK_U["#73>&^PLS<VZ-7S"-#@_
M4GN$C5HTU(S9P<9M, ??W^S=I,@(.UI\;9'1X'[L@K5 #NJ0Q)*^^-^W3D_%
MJ<YT1*T5<=2A5\ZQ 9EW&4QU6,;:&QR]^?'"^R.-DB*^]291#+^Q;1LO7[_$
MAE<_ZW%68G^D4VH7=8S=T2X^_O+;I?>O-[[GTA33,?EQ"F^68R\CG?6\EVF2
M1WE!1ZO#2+NT[9I[.VP!)5W=JOZ4M>=A.R4[$GBX',EPPS(N?/L==ZG4V#6N
M2+VQ;NV,;4B.<AV4&4C#TD'9NUY'JCX<[-<8:F^B GA,  N8I3%WD7P1I;]^
MU-@1BI8!NT_!G.3E&)N#%3@&RX!'=7?<=7*>P9U0\F!M=(+[+X?K\!UL0SX<
M\4S]D6;8,P_>0-K?D4JA%M%SE6-O.NK/%&'W/%60C7.1)-B#[@W,0@;_^TYK
MKOA+X:LW[^ M:<G:&X;5UA@G%ZP@N<]<905.YL&_TMD\)FOI;W\9#L^>9X>\
M>C)WU'14W>)BU%9FH4OG!LORKS<][QW(&@\';*,@5M$L7]K[G+J"BMQI[E0(
M#^<^A]A41QX99=X<'II$**81=F;0.;7HQ"W5:]C:G4)L,-"ZP[Z_9G+?IBD?
M47G?FY(>'%=:VJ4SQ@U7,5\YJM6AWD3!=Z^!$;ED68L*MOKV6U6L\]CZH5%1
MZBX],YQK?6\ )OV9/Q@-\6)6H_!C_BWVY:O&1?M<48L_&!JL>ZS55:FQAW!>
M8E=3[!#J%1GL3H_ZG++SU_/>.S^@CH+.MWYM C-=J"C):\V!?6]<%M3I&+TX
MVF?7VGQ%AX6KGW#(>>K%*?>/=+^RKT5]#VF4L,;<?QF>%J]:?VY/6%? M9;1
M\&JP9.[SUK8C?)(*[^AP"Y6+NW]HO[' A#H/LFC,K3 3[$8[]-081,[WYG&9
M>V>C$W]P=M*^S\(HTP'J']APKA[Y1>/6+]9KDUX;X5,G10W&F"WR(UPI.E"'
MWFE_Y)\?+1$/D(H/_W[#JN; Y>]9(1SF@D/?.Q@?@GMP#KK[=+WX.;?OE-)J
M[HN'L<+N^7VV7,/BWCCIG_C]X7*W]F,ZB9+4;(\:R0KND+;=X5QB-LCQF7\Z
M.M]@@]0?@$?_00#7^R='9TN'&,W "(A4@?XK3I@;%$?ORMRN5_O7!NX6;O^O
M?/0R[PR-KA6^6:<4'J[B:;/]XFUZR!P=#?VCP08V2+T"C40<MX@_.#_R3T:#
MI;)VJ6*,VY!%TLG)RKJ)SH7?^ R@6H>E,C?6>ESFM]Y+-8\*#+J1E]M6;K/L
M,&B_PS?(;]_V3G:D%3_<-7$]>V!QW:A%]M;+*ZK:87^)Q+IJM@YAMGKV>+FP
MK[(CZG?;6("IT;?3^'NU0*_6R+LHX^?;&&3X-]:L%%-X;@H>_IS[!*]84KEX
M=-H[P>5;F KI!M['>[O7B0STJTO4F+(9RR]9T2.>6RP_5D7<^7$#H>/\=VI;
M)\_5E7XVSK3Z]$Q-8+0_J?A&W>8(]'!?$MZP/J<;3,?)^DTR/.X=K]HBD\F]
MJ4T>1Z@#T!"TTJ"_=<:;X'_4UHS%FV9Z\O<?_A(%(]T_4?V1.AJ$Q\'Q\?F@
M#W\=#?MG@9Z<!</_>_S#/SYBV@YUW__\J';V)>#H0-=KEU\AI\&W[+[-],;&
M.V6=Y3$\&DR&]X3=(+W\"^>0<PK4]BY[W.F^V;!ZQ:MOIB-&C_GF[2?2;V7&
MQH@7B)D<."9/PU[QP<Z>Z7J2J,A4R-%Q##?\)XD*^-=E ;8,S>9,P^#(C)G!
M  -X\U>:#B6\ZR5;00<7KR[S0Y_S*YF>PV<P81@HP5.R/H:>AR,.[3U\2LJ]
M4,DG? A.RO].LT_>.QW':>*;2&KE%."_FE88[XY;?"!^C:/IP2T%=( ?Q=&,
MWBMR,I#J6D4Q*:HB]<K<MG5RQW:C39(?;#IX><I@:3B>9ACAIWQD !:,BI+B
MEBY.2H/9(#%T6_PARF":WGBPY';D5:K)_NBF+903A7__8?V.'XQ.AS^LV>)G
M33/RI#<<K1?^/IEKCX#,&F"U<,_[@!83+.![E<%,?\S@;@@3 5%_S-U][Q[5
MI=9?X^G=N];QWA9ZY@W.VDS?365U<+1.5H>[):OL</:\MQ*:);7Y^C-X"05K
MEY>P8N#?[+7$_@H:4LWG,1P5H%J_13[ZHTUTV>(D/9*2HAT!&^)G.)H22@@X
M<)>OGH7C\_,]VR4T61>,=T'(L++V!D))>*/\ADF-36=RCS;/'JO[X_-]4_?&
M-+F$@443-(T+[^44,5'[;9,T-/QV"NS7R^G98/>.G7.&-OXVF8#:1 7Z;W
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MFARXM>$9@+ -)3ND&ZW,*JXSJ1H<NBV9C@'F.22%M>B1[KGM];9NW438-,#
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ME^9EB!H%L=6-LSWAZN>T P=M @>==>"@#AST_";Q\L!!SX3CB[O_&$B#=XN
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M:$DMV6@ K1L%;ZL\6RI:!/SXV/DXF1UH:J#J2]0,Y+Y0$5XG\HH5:"+<*M:
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MY3^^^<=,<'S_X<4\RZ4L'*M\G"4A%0]6 4(KT4AVS!6^D$UZG4"T8%C ]+D
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M6'54U/XN8+&&L,C?1]',I9O;&6-Z-\.XB/>;FGLL,==:MG=: IQ@[\HZM&D
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M3)?090#*P-XVGPU$I^\+N-T.77+G?+,5>,3?( I]7+C.G "MKYW9S/(\6%>
MG=^<9^Z[;.\'G_JQN_D*^*PO?(I*'0&?F> 3VZ0'<\V."9MKI>%*QD8: )N[
MXN,"-@5L9H%-4;8C8#,3;*H F]UHTM#8<:4/"VN*5/6DW]I*CZ+@;VH[SB1G
M37=AI<_+_N:@2!I ="\&7C-CXZYH^/&Q432JS726L5&M)AK59@7R<F.4:%0K
M&M5N<K1H5"L:U8I&M:)1;8T;U0JSN+IFL:C//@NSV-LK5UQ1V]U^MR]?FFJW
M"^:QB=F/VLY"FOBH=!.'(GJ+T8AXGN.")0'_#R!'/)H5]+^6']C+S8A[D3HB
MOQON#TGIMJ7;VULZ$3SP+K(IB\O.%_M4*,+YCPEL_W?.!C3+>%=4X5RL+8J*
MTFV!HME05,_:/>W(P,I2%K5]:G7RS3T7V'KFV"I*O06V9L/6V*;GN_JM'1E;
MOQH K2HOZRF')_2$9'IS]CN04;CNZI<OA*L0KEF$J^@4((1K-LP*4B+2#"U>
M*TNX&BTL'T3@(V"<,:?CB+W58>],/K*V*GN6*JB[.N0+>!3PF 4>16L  8_9
MX+&W4J=@)A8JK)L<D21;>M6._-J(,<%3M,[8F.B=O3'1V\N8V%4&+:1E!FFY
M+2$B+H5.UEI**-8&OP[=RQT[<C3A>YI$2#R#0LH**9L)Z_A$A4> *P]P#>7@
M@P.2EH"8-%FF]M?7K[\_PJ=C_\5PB?1/XJ+L]%*8*8_W=]^DIVBGB:6DU?>K
M9%%WC5<0,"M@]A@P*[I3")C-!+-:["B&7?W%=Z%J-# 2$Q3A0[>5_0!6VS64
M00"L -@C *PF&EL(@,T&L'R PX,%2NL7XON@RBZGW7 /.X+G=;I60&N0^YG8
M,V,H75T^A W+&<C*^Z+LT?I8U!UE3^!;/QDLBH85 A:SP:(2IW=2[%D%0@2Y
M?0*1^-&C"TA("-4]\=^_V_"RKF?YK_C)=V+;WNOTV; M8U5/778&[^T)HD?K
M:B% M#X@*MI7"!#-!J+J;A]I_O[1)3+*9Q^/#';_?..1P0YD%(Y':VLBA&-]
MA*,H8A7",1LX;8SO0.A0RF%A+$<E[>NF.5JWYOJ!:/K?GPVZBN)6@:[9T%5?
M;YMWY<*?K+N]X\P\"> KZ*0GZ6J'?J.KW1SZZ*U5L<+WM ,IG>*F*)F1-*:0
M]7PU>DY6+DK.?A^$+!4&R1:1*6J6A<C,ABF[!L&DB 0WUT5GV,G[X>-&+)@V
M&(/[6C8(-]KH06:Q#+ WR'A,1MB9-9+TR*2GG'' -;!!3*7J^4J-CI">T7T0
MTG,OZ2D:+6>4QHJJBT;+68L?RRV?1:-ET6AYDZ-%HV71:%DT6A:-EFO<:+G^
MCA/1CT8X3K*9D[P?S3T!4_(C=9@L>RZ@#H1[P&Q&^-<S>:7C(Q^=)P(FI,N^
MN(7/;=]Q7V-^N>96>3#09_) W&<+;L,"#J&K)?H.5[8$ZY8^.U/SR5T,B20K
M+'[Q-V,V?P_W;TG_^YG>>N?,M?A>Q\J>T8R8UCCET ]/>'#.WA_3%?X8$<W8
M*92[?Q=2N>Y2F;\/P(%E@P0S"9D;+#F*P<,- 5;',MTP8PK_$69$43<C7,'E
MRX,Q9>&*4*#"U== - ,$U,/$<)=94;>>MX ?T@^E:V-N^8!!\-TMO@8\=2Y]
M@3.RLV?2ZJ5!^M4#F4Z)ZTD>\3$'@8$42LB81M>JS-"JIF E:GKWQKZ>P+[S
MP;Z> _KT2#,"6'-7>UUFB;_&Y(3>P<VOM;B&ETQEXF.2ZPI"YZ0Q]05JG ]J
M]#EJ!)J1N[5Z%4&A<#!9CEVGTSL43>!)U?%$;PL\.1L\T=OF C;5?P5K1:&J
M2&HM1'KSV\=[Y6T:_+AAST#OX]1YLD:>].9A\=?$6;REODDPI.)UE,X>.HHJ
M,*6$F"(+3#D?3)$YI@R[$S4KIGSH_J86B2DU=[Z<$Z8H E/.!U,4CBF^Z\RI
MHI(!4Q[O[[X7I*CP'F>: )6:@(HJ0.5\0$4=6@Z@P,(+G+ ,5%: I$*Q^J1U
M-:D_J$8+"I#_;EXS2D7=<S5:UJH KM'"XG0)T"%JM,(JY6XEK04_H;[L&JUI
M12VMT;JDNY'OT/XTS!E8HZ7E9RZ4U"JHG/*O">7_?)1_S5CXSG3A39D+P; W
M/0I,KXR)E;+4L"MV ]"J9Q9@;S/\X#>'=IOQI#>__^_;X.LP5RR:318;2^V(
M4&J.WH138$GO[RL5-0([:H4=/6\Q]"S3,ER+>.-7]/P%V.'15-6'R/=!ZNE:
M%83@ZRKRM:RT9,':-69M69%'N+=CV%V\\&+A<9]@]%/:4M.U[)$UQR*LGV2T
MH%UL[L9P!=@JWQ>NMT _@.](]XLIK$)6C0M9>V.\I5J K)O\7_0]> ;Y:.%:
M/B+&QY^CB6$_$>EJ1.%$[JM:$Y6$*].9^VS.;WC_!^R@ Z^DMI4 :AX,=VC8
MQ+NX^SDEK\%=E#:WG@3T5!1Z% $]M88>915Z_C-)A)Y/EFW G_"7@!X!/85!
MCRJTGGI#CYJWUB/WI-];#ZWK5@@2LJJW$Y&DW^X()*DWD@@EIMY(DK<2(Y!$
M#!+(CC-Z5&,Y6<>H?3<MN'%B"T?1KW&_[G\!6NDR>1TYMD=L7VE?C(/T+_H!
M@L3'?\7TT?G#<GT/S*2Q[\W=O_VBZ,K[\<)^\IZ(1Z93]HU EIHB2[];85P1
MNLTANDV_.X2O?3*:C)S9G-B>X0> P?^)BD?U$E2VKVMJO. 9E+X[4VOT*C"M
MA@996V[=?GLX@DE6_;WZ/Q_NO[#V/]CL[L89+6:TYW%DZP0O5)B^R L/U[\)
M7DC+"X_&3\=V9J_2QY\^B V4?@^C"9D9@CEJ1W!DCNNK+X(Y#F".:V,Z6DR9
MFOC%LG\,L5>=8)6ZD1]9Y>;C)\$J![#*#1E;MB4XI?Z<\N7J@^"4 SCEBS$D
M4\$D]24\,LGW^X^"20Y@DN\N09=^:M5+##[+N/&*VA&#S\XPD"8&GXG!9PS:
MD-72Q*N/._8,(*/59K"19>Y9O]?JM^._6ALQMB88^KMTJM3SHU).X5S=#Q4%
M$KO!!4KE=[+>:L=/GUL!P M^7=Z2HY_BN#8&?__;+W*G_7[S?S_1>1_81!]G
M?K2V3BF+&;]7O5W@9<?;]B(89F#98\>=,2UF8GC2$-M8D9^CZ0+'.(]=9T83
MGCCDP-<C8P%Z#OQIP<6./Y'>6&\EV_$EN F\J#&E.>%O+/@4?^B_SBE,1Y_C
M3PQ_O;V%#Q+<]S %:^Y:SSB!R''AQ-MC"_<2;KN=7$*!VJ9 =;<K4+@HR_R?
M1C)TR_U&\5I7VK2DV($.)9PR* .B#QYN/W^[>OS]_N-#$M3L'NL9??>M!M41
M3A7%E<=5OD4T';Y*/$,3'D.9&^!A1@CR\W0:Y$RZY,^%Y=*B=P\'FN#X)8#4
MU4%-K*"=W0'AR,3I)A1R6+&[L? GC@NOR^K>J2KBP6ZQT2WX%WQN[9P%!?^P
M? 2ZB3$=MZ0L4J"$0UCWU$9TK:6H^4QAE5M=7<ME"JO2ZNCYS'-5]5:OK^2V
MO&XADV$+]7OU:^2""2<,/GQ,X8.4]5HX(>M5'Y*J'*+00W0#.N6[8+A?.VB'
M4LFTRY/PX.N[/-S%E9IQ':\ 77J7S(22OKL.*!"_/RU<Z<&8X&"VKZV;5NI#
ME3LOEAQ[DJ9@HUK5;BE5GX&=<"K$>3@$+$I([^N)1<:;M:M[$SPQ4-1O=;2B
M'1WE]6GT\O!I]+K=,C@UJA4U.OF[Y!$@JM8B8F-!U5I"FK!/61QVM]]N/OX?
MZ?%.NK[[]G#WY?;FZO'CC?3I]MO5M^O;JR_2PR-\\/7CM\=$AUX]O49]N=53
MLKI/MCB@6OWN;E_/D2S3F66:4[++,M4[ZD@^<3';R=\E/<_WNG)CP!RO'AN$
M;9(YH3*..XZ)2ROLAU-K)%V-1D!#'QW!\2A7E15_LMR9].;[]=7=AVHO1+JM
M]OO?O*,GJ?VK]?.=[=C?%C-XGQ'&$O$1]WBKT87<D&QC!JLSB?7N:F%:ON,B
M!6_-!E4AQQ>:C@W2=/G7RY7[5'ACWFZIMCP>OB8KQBZN^T2.G4\7P>8<_^F9
M-?#3O$O&$Y>M&XJLE,)Q+_2.:F)<MZNP1AOH.Z0]T!]\^ ^+-V^U ZNR,/0J
M6CXFQ7QQ/*_BB\'H/X;O_T4,UY-0-S3IBF[(B,R&Q&7^]6"N)OU?A8;_X0]9
M2# AP8XAP>A)[6:38.68%'T""98UC^N(R)7Y;)[L73*<35W>*>N6_>^^<Y<_
M'PBR'64#?%4$O@I\/0Z^]AJ#OK 0!+Z6\&SJO9WX>DT[FGN29<,7SNC'Q)EB
M(BKFW,O=]]+'/Q<X\EFHN0*&RP_#>-3EML!A@</E.YSJ;C7WVO FTJ>I\^()
MK!586WZLQ>,LRP)J!=26[VQ2E\(WQ\<2+D=: =VE-V$)OR*6*&#SJ$=3WAE,
M+$-WE<W:^;)FT7ZZ6%=Y]LRBE446K<BB+?TBSB2+=CNCG"JIEHK"^X_?[^X?
MI;M/$J;7?O\(__/M4;K_^/GVX?'C_<<;Z?OO'[[<7DM7U]=WOW][O/WV6?IT
M>__U@)+Y=4!0>_DWX4A;+>^P>4$3PR7<24BMSH?%G+C/EN>XK]('QW!-:L_&
M%;JF6OZ1UQI/Z+NY9=-)3#9=<[S6F+RJ="!_0IK^0:2)\4PD ],&>2,"8X2#
M#@S[%1-91U'EV5OQ6(S#30GTBC6Z2V_P=M?L9F]YU"YP8D@;P;HF;ZTPI<_:
M\>!YF#\R=3RO*>'KPI'$9G:P%,N&?Q/X=.G7]F+\VH3YM?'A(W2]C$/7"S'@
M[7FC!Q^ C4BOU!%CL;, A]UR3.Z6V5A-D[=]6"[$IG;(&\Q[Q^%;SV3Z"M^-
MB>NR1@^&1R^G/6[:[U>6O=SAY0;0Z^3W;UO2+>SWPI4<=E39[B7^'#:/]OJ3
MQH;E3E^;N"IL;!%VO(&OY_">'KM?/(TC9)4,?R=)E[OA+::,?-BQPH%=I$*$
M00A^E"\5X#+LN..X,Z0R]DB"_8(EVO2I*V/56'XW'G9@;MND /;F]M/] SVR
MEN<MX!'#5_K8U7M$$KZ#GS($3.S'5!5P,*:>LX(0[,# NEV3SGF@.XL[XX5[
MQXG&D^*#<Q+9J[MGVNADXK/-DM[\;ENA0]1[RS//WS:CY^R_D?)T[Z<T_=EU
MII(#]XF<4#>DXQ:D:4K8U])$4!^Y%CWO$O'0VK*\"7P.*[L-GG'-GG&!'SRY
MS'7@&C/RXK@_ULX$O"$<,I]0W?)ACASHTF6Z3X9M_<6/.=^51S F3+ AV*\\
MVGZ3L_X;I2VKTCAXRMLF9W7*(<CI;($28^[5ZO^F1'XB9[/>,M+"_G,!IVIL
MX6JY*/.QO8UCISJ:95)&X@7T!\.S&%!P45T+CGN< #C'XS8H70&0XA&SAM84
MD6T5C8%+X!W :,7?M*0[>FA6KK>H2XP?%CPJSJJFPV_$I:07_RXA&^&II,#@
MM21$"WA'0YHSQC>6##_&>A)W62\3@@9E=-8,R0V[*E&I.$1!OBRVH;_@H@F_
MCDJ@+8"$8S&E,0&9CR^_G.$]-5Z\4"P9\SF\*S4,73H.'+^ -^5S"$*VC<P
MQRO".> 1+@YN2==4&P$ 6&LN1@@X2UJG%P%T*Z3'B>-%O^5T9LVQ7D"63PVV
M?2#446(SRN"CD-3.D#;W ]ST0.@BI0R 7Y<^VA@Z"[C%A""XK2DL:[PS=AE
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M;E3J/XPHIG-,"D#9-4;9&:FJY6YLN$>0@!,$LJ5((*+)LQ)"G[7E+KODX&V
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M>9V&>5C7#(,VAZ-I9[3C!>,TQ]W.6M%SLW7CFG%D8L7Y,\"3S?9O$46GB4_
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M7D,M6LVN3V")4#Q4?T\Q^8 ^7'E?AOD';(S,W<-=^/)O6]+&^)/M@V=F6&Y
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M<3U?]%9/3]-(8;-U"V[N!5@+,=7YV.F6-=YX(R])GW9 M]  A 9P5 V <R5
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M[[@6.6-S1DY5K"3LF>RY>.'ABL%]K0W"'% _WPF)PI0YB"9R8Z"IAQHQE4+
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M!&X>@)N'<):&G-7M)+;.$X!Y/, \A)YZ8Z V%45-$H#ID'+H^+XS6R6/81Y
MN[(B*9]<9*SF(F4 U<-V*AWH%ON,!%!.>K@ [7TF)5W9YB'<CI$EM=EN=PYR
MGQY&6@'O&>$]%\IW*>65;C^56_;2Q[(#^*]I/0]^A?\)MG!FN$^638G4"<A@
MV2:HZ^\4K:7V #%6]WP3)L;T_]X?3 RYG>3,4=J(UQ,B&:.1,X.7>H4C)-F.
M#W?'[0/XEBR@Q9,+B#XW7%]RQI(_(1Y!&M$#:/C$C%0<>#Y\,(/5>JUPT]:W
MB#]=[]+#,G<\"S?YG4NFAF\]D_<OENE/X.WQY:*_XUS57O[$&,([+/SM/^'4
MX+]4X7$1^LA*G'\X;Y9(I@+EB$\7_=4-B_XOK@C/J3722;MCM'5#E4UMI&E]
MN0U_J4J[-R+CWDCY=U?O-8)?3=RE4_R)7 Q=8ORX,,:PQG?&],5X]5!V13<+
M]F65-@G;NG+(V1[^9^'YUOAU_=QK&\<^LJ_C<6&GF[T'<+WC&O3$ )L1%Z^"
MUS%*\R[2Q$6L^R69OF!=/"+R("/^>FE4=A$8)X.S4>4E>/3E8W@VGE%.A#:;
M\E=F20M+]'X(,1M/U?7$L)_@298-7SBC'Q-G"MOCT7SM[GN)R=JMV+X3<..Q
M K: "M,U'0JV8FK,/?(N^.-]4+9AV71!]$?O5Q^HSS<4'?I ]C7'LWZ_U=>I
M%L+--?Y@CG8M0+O+S<]5I:7UE=BOVBTYX^>=7B>7.RFM;E_-](MMR^NW-#7;
MZK;=J=?J=K*MKOAW2G6G/*N.*OY6^LZW2IF8D#)2?\AE:!LD><YV&O3TRY+D
M#'13F4X?N6/%]UUKN&#(Z3N!OX6C-=?346>G4C;1<$UWI"K9PB?<5GK#=Y8/
M#QNET,C?@ 2$YTPQU5$"\:=VM/=O:Y>HDN[0?0.3<*]$%6[+%L.<.\]01"DI
M7.M*MXD/$^!&:63,\0BN*8[[[VG==^V:[9?D$OC],Q'[EG+?'L'<]Q;NJ^3A
ML?/2[UMM).4]\0WXT)2(X=HINZ_E669^[B>0Y7QROHV$?I).8*XTB!<\JX2(
M<;@?%),K'RNLQ.3R2/ XZ*B>8 .NJ$K\#\->& ")<E-2VHI\0(;'ROKWS/#8
MXQXY*U!'C RE(U.FN% G75PH+MC3P_+VPV)\9[;9W;2;G3'LUF\,Y*8N:P?E
M%U:?%F\R$:.W3@P/WA_^RL ",K9BBDF>3F/AGNFN]W/8=1EVO=V/R;I,L^\%
M*$;5IV$6$BKMO46&C(G0^GY)?070+:O*6F^RRL4()UE%X:1VY8**3,JK1&]M
M^S"V?-Q$YER&FSBF4*)/QSKQ9 I;:]51D(LEG^^2,\D$)4DF,#3[XGB9<P5E
M#>1"NZGTE?VLEC/7XPX]ST*=*MC65PMD'3TMZU0JM)RB]P$FV+ID0FS/>B:2
M1=L-YA]-/D@#*N>!/A0NQ*K$JNHCL*JT0YGTM42AP]I$1%&4]6R-DS*=QJ"W
MW]36(RH7Y23E,?2'+*3LIB!EY:O4LT1Q]U0D2E.KOI<3ID0U;NEH=;AY+I8L
MEES")>?KA(D5 AE-RE[YO3'UIG*BO$\IZOM5T-K.DL3)*ET.C*RT*2.K;?G
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M^P9&6]S_J283"J-5K$JLJL*64)5V*-\4BUM[A!%B<D/8?Q\GKK-XFE 90$7
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M0OR$P@]U;&)B/8*2]R2SDDLMUQD18G*7DP<[(N177;@HC3,WH'_@RD7K],'
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M;0W>QC5I)_X7RY](=."K3?D>;K"4!/=PW%UZID$FV*;AFG#@;S_=/[QM2OS
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MD2([-LM'QYEN M/(8'=7:HQ=)@+.![GZ7<4U5W99/C'_XQ=4)Y>)*8CY$];
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M"Q-%)2M3&XB54_:24<=M8D(.H8TS>NHRK&@^_[=RR._5J7XH.6Q9C&HXS'6
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MKV.K3@IY-.$CT7 -74B?9^'A4^P@>L;*L[Q*A1K>)-%?O**(3@ S*+4X \.
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MB)5'Q\\YGA51H,S4M.L8.3>3HK"-A3F[[,<1*Q!=Y(-<\3$N/%*&W?LEW5S
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MC&Z&6Z@^9?UCQY6CBAE9)#6REGU3&$-\QGJ/\,9UR=M*;_3@O:1+PV"Y1&?
MY$:7B2X\,JZVF*8('^+%H(\;-IK <!HC@CED9ZLX?7*KI+'2-7=D4F0+#U75
M$H\Q5(-#O@$;$^X\7G\]:Q%;DE@U\:(Q:3EO?>2;%%NTL<8*@7O3@=7H1HS"
MT*K\XO*MR-Y)T[4DN#R_"O;[/:+D1!!^' XU0_*0DM@R+.JI*5&L2B&*U)5P
MR[H0!2H>(7S:0&DJ]1AM;1M;\^@%F6_7R;OYU+OD>5(E&E=2,>Z-DFJ/1@>&
M21LXT/)5L]^IF"@:I2M%P5Q H"#AM9.73L&@]X3F6L6GOA"KHP<F:PYVFMB4
MH!8UISJOG%,8)B=53HA<Z%[;:4US>^FK%K0T_M!Z5VZ>]6;A=,/)3"@4D5*+
M0&P"'CTQY_T*%=3',G.A8X89A&P6!)&1ZQ;!R^@:--U[W"Y1#XH51,0Q<VJ-
M)^%GRG)3H\4!"+HHE)X'N$/<BIM^OS/A& 4+L)ESG:U20)T2Y?8L%;Z&D=N*
MF^Z]B]Z2J$A@1C-SBAHU'L@D\ZV6$^"(:7HG1T?=1I)>,\1QT]H](U_)G;U7
MQ'/:\6T]$)!PL-<.2, )8#+T_O3JT?'^BP[&T,$8UGT2VPQCF"-N//X+OA?W
M,HG<=WV>2"[50C_[^W#K#__YC_WCO3?U_XM@C21-?B\G\. AF1@PZ,^X?,.=
M_1=!$DY@F-$XRW>P<>!K6W#\<7R!K:!98G\<_PI6[/3=-U3'9 B_,+"/IC:+
M!_ALE0_#*3P=8YLO?J8'@+-F8+.D;.S8*GO4!C*A)S>\KW^_Z/NQVKHM1N?
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MPIOM=6_[@BJ81$6Y%9Y,>Z&:@A="6;P"K]!B?TR8T7R\04S,2 @JZ,"@:-T
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M%=16H! 8,B?>)<+!L+?;0"YX(%QDT]X%:CS(BH#7\DSH-,LU"28&,/6]&SU
M5(0CI5$@O&E$3.@H@!=@W,C;''T 4GL?$9&*&6PXBI)!A>#%]H&."WQR8.>,
M):X8$3=M%#<=/M0\\S5\P\U!&'NPY('P(2JE23BG2]O9$0"?& AP>BJ[!"]%
M)T2D.8MA&<BW( \;YZG)L#>?C1)R;C^][1^2_T TPM$1;CE#54M06,P<3<24
MB''/'H$\K QMA68)_!2&4"N8=-[$LMQ2,]/=Y?)1!1<O(?A+O!]EWQ:[*_O%
MRA(ZQOFOX+();/A'.&$S0.U--C<<63X365X^V#&.+,^1Y2]@$=>)+)\$AB[>
MC(HBRY^18WWKQ0;Q8&J*.0):RB'5H<,&+AQ.4MJ/?NKT$%HVFVEG/-N3Y&W0
M1B&;EJ;]@B.E_D/H9=1]@(59[)\L] @&]F L<L-^O?0]<(GQEN#:V!9A]]JH
MKS0^0#>9 ,_0K UUNU:V":L%_Q8- +@G'O ZN6$6676L&]OW O>>^>#P4H0:
MZ]"36T  20T"?@"VTZ7WAI^AA=^.ADFE.3A]?Q''?L^&"&TVM'EY;7BEO<'I
M6= :47%!!..HN'M.$@VF,,GH46^Q3I>0>K_A HG^E:Q]*UCIP_*+C5K64,U/
M0.('W_L2L$?A92JXS(1T\;XK2!DC>&*$JT*>Q(D*VO9-,:[;OBK-3M!NE<5>
M9 F* CC%16F ._[8@%L)//=\R,%!8A $ASGBVREH^,B@:(_-;,LW O'\%2\-
MV0*^T6S7*Q]JS H<.P09P#M\8%2./C'*?+:=R'OM+OA&-BJ.]3-?/SOV.G(_
MD#_6?&#IM-E@PS[<J_U+&#52F'W'O7EV I4FH ,>8^DRY!XVTXRE%4"7 +^R
MD7NJ#OXRQ)@.C3;"WW5IWMY3V$"&DQ_-UVVRW]V/\G'E&I[8NZ^P.W38(NTX
MVPV#:V) 8S %\?!D@N:#D&PXD3*B1]PM!_:W8^?V\RW?8:7PYXOM?(?G:80]
M &[YW;)?;B#&I681_$/;"=R;[?Y@UHC-T$.^,=<VRW*A\(2)M;M?_A",->@[
MFRV.KMBB,S!5L.&6#:;VAQ?DMU1Z>;#=X4PV_-JQ@/EVB<M%(!G,8$=?!U>/
M.#; MSZP.FQ01_@R#:4G.%["O8(-)^L-./?.JZ ;2[@>1[-N'93#(ZP@-1'N
M)6Y[J&:81MC/+.*\Q&UVLAD?M10P3D&%.$E!S8E[+4@#YH/B-NEI^Q_,%^SO
M7Q%L=C9QJ"S@+5$':*H#7\.*7E1'=P.33GZPNJ#=%,+#H..07$PLDM[G<#@B
M_:&]7,*7H<"&THCZ)/!KF??FTEPMNYBNB?X8"+>D"J1(!JNTY*5'F*/$"%,Y
MD;1^HP<D![3J7]:\SS@%3[&31TBNX'Q08[T!"<:0$@VH0YX)< #E<_![EQ!E
MA0<,@:>\ C%:$&*A40+1P4'" ^&6GG<!3Z.57+UNT%;1@H= Y06L?_P!NU'$
MZ)F'F7$J)' GS:<.9'@4HFZ=OIVD1<5ZI:+<?H?W9)-]@TL6!.2&NA"!*@@>
M1<]MT/:%:S)#+1-M@O=\>+FE\>0[U&[@V1:5VT-""ZDFDZ>>,?4\2D\]XP*0
M0[,3:73\ 4]8\X3UF2^BRPGK9$'!%HB],G$F%EG"<Y,E/8U57(H@]&/FP,;_
M6V4(ZE=F[3!W@6R OK+[)WC$85U4XN33R33NBDVF\<FGP<V#H'E[?^9R;Y]P
M?/IH$74[[&6<4["73'AUZ:A.K8U56G0 DZMVQP,QC8N *]2G)X<\42<F()T0
M&8X;FPI;>O#N[DDT)5:.!V<)A)S%>;"2J51.E@SX!N$:)I@7!$]0#);1T?<V
M+G00?P&&V@2>O1NZKX',:?LR%U:LXLC?XRF3P)V3X65SC8-N?:[O4):+SO55
ME,%(&67-]4UHBPA?&QB>-'!5KI<798B0CT\2/M6MCF]I/?.-JY-@EJ?'+'EZ
M;=,C?X^J[/^#^,\-*HO^L7!^GH?E1;20M8W>NH963>_8_*#CAH4WJ8LJ9N7O
ME$_##Z/T]J!2_6XG;:#"BK8J#;D7N6*I\HIK;GD\]8:(5SE,^\Y>@P]%\X"A
MMW4I>FB<0P^5I=/Y<6B1PZO,HZO,**7H0=44PE6Y/Q65+&#,"HKFRHB8V>Y5
M/Q$16672%V=)=5)-FXOK)')F<5S]1$8LEFE_.KE&.*Z[AW_??[P19\*SJFEX
M8-Y%FW>FPE(#W(0R;%]<L$BX/YF,L^:]="AFJ(-28ON4&C'K-5*:(-5E!CMU
M4%)JGY(*,U'#\9D!,&'*^&QR2-]@UVC_ ,U(+X)#1V&C.IY%3Z)RXAIQN]8.
MO8I)G5R#U,4%:\QFK,8;S3MGRAHESJA]E8C@(GT)2PNOWK8U2MK,ANY2<C?M
MS6>3845 L_85]>FOXEM2=$N2PG)1/GU<7E!J/U+H#BQ:Q<X(P=TZ.[M*&QZQ
MGPFMBFG8.I+3<0V+^/(3N8F\Y541I_VD\XR>'(C3)*0:[MG42-KV4\TS$4D[
M'$XJSDH^O<T].RM_^A<\NRWIB.-# ;VP'#(YK1/41@I/M LWZ.FA<^2IA[2%
MF>#^T?F0M)B>SNSSKU]/2U1/2Q.>&*I&NW'[YU,S&1$_^A.YD0,J[C_M:-O^
MB=8,3[1&_:DTK3@YY?2V^^R\A=._X-EMR246=#Q0+$OJ^W"'YQ*.D\=U'"?'
M-:4"'LSL&MR7&BG1R!'C;-R;CV:#T=7[(C42JH[CQCBA)KWYN&IFYI(JW;\2
MEZB.MA+^KJXW[V%'GXEI;RA6^6&?823PYF;E$LIHZXB9XQ*",Y2;J&?O+!G$
M.N+?.!UF$ :)2;B 5VI3:B!4'<'L(:'&PR&.^91XL,J#5;XE?$OXEO M.8^K
MRD\*K=2:=G8A$!T_>9$!319M>.?H/F11NR<5XZ'(VG]GE9QT3N0B1&Z]+V<\
ME&B'E2P.*]7952,S[Q_>XX(ZDK@%N4"FW5FSR3A7H!>?N&M%X/$JH2RW 5^8
M F_N.R'>>^:LM/XNO1B!**>9QB]+^+LCW%O:H"_83OCO-V7PRL=U="X4Y(01
M:GUI)B=H_1#>Z.UVGNDO!.?B")^)3F<S_,:F,M#9C/\DJNFM2JZ[=;"+\5!)
M*S;>KKHO$!6G%V@:Q:!'T.6U[= YF)8@#G^B>'=TOF3(' .A %-)V4Q5;C-;
MK_\=#\>@3N3^9)8$<]\>%[5>'3L>3EC5U3 AQ;Q;MT,V#G$1R4VOE8/$ICBH
M]?*U\7 *'*3TE>'PE'IHTGKMUWB(B?'^;*0<UT2!$D+JUJR&P+;MS;5^(O:3
MHVY6A@;W>S+8=&8&+(]H]-O>'39Q/K&^E0Z%"6:TT/'%P5";"(]N^388"?('
MD 4^_N;!;]R2Q&L_9!)IW\-03.H*W)ONP3B7<>UKR>6U'RN($!&.IDEG ?N+
M*VKV\#)DB3BO!>-!ZN"&]IUJ46)EG,-9YH[5P ZM]R^/10JC,I3%K.E>Q1A"
M;(DAVO>M15;[.9;'6=/\0,-7XX;V'6@1'&BI+XW$?+KO S&?#']=<GGMN[0B
MCK&;*-FLWNRLKU,"M-,H.8(M&:+GYUEQV<D?)Y](5,QSTN+(F[%!9MMI.*Z_
MV8 7M&OT <<-7:H8H-F+[9@X_I44=>2H@Y;P2L#F#J%.GA$=,J8&@V=C+P"$
M_$X\^!ELIWXP3_7% 54,PO,"NGGQ&CPRP0N,)D:$-^P?H.9<8 =C:6BJY5&/
M4/<U]#WA+GO=4'2,+MVJ%0XM$RR*,?],X#>&M31]_%"/CD=RMT.1L@??;T&J
M3Y%V^I.P0:FK<)N1OJKOK6S'^(OM(!L?G.@:,UOYR7?L#8%WA^^0)I'+_@=N
MI]OKOG"G6JJNLDF.M,":!A".@?>@^\H>@D,E@5^>8$-?!=\E^Z_B8D:+_-<W
MGH%A<2A5LKO^']N@Y*1<%9 ZZ<F#D"EP)%9D]7"EC@&<L?#I!M!\KKN3@]U,
M//)#(YMPV,#=RK#4G>7$VSS^_6^2(KUWOANO(#W?($1Z6JF&\-EV?4OX DRU
M5C4Z[!+$XPT=5/!6N+,'?>%73Z?IN^B5_9SO"9L2O,H_;;CL?_ _[H90&3P8
M7<J\&OJD;[=?^\)OJJ;Z^-=M:!L$7;"\1]5X42TV62^8>1E\D_U*.EGBB$7!
M(P[(JXV;OXOCV(R]Y,A-\W#JGPIR:%B:L5'-#ABX_"U%;-1%B%-QM[='7Q)!
MN:J8OQ/.]LP 'MNEK':F*H#Q0(&P_"6.=L-)CPO4&NDW&@A_@@(G.$0:[K?!
M@=3;29"!+MG=+F3HP%#" S6<$AJ,%8E9*7=E++VMW,2^QADE.""9C:3L!X-T
MM]^YH/^8;<:![J'1"B924KTU #6'*C(N+A$]UP_L.Q"'_AC^Q$?9H$G9SJ&R
MWS=Z$0,&NQ>.^]-]>H.H>86%&Q98MT!^5?0M3!/_9%.H@PG1^+. . :=<[]1
M-;;#\/:@=/3$T2MWOST$(WP71 -OFMIB2X=71(V#[Q\^).0$V#O'QQ3F'L&>
M5<=0MW-%Z=AQ4)Y/[+700(=;:Z,=QXF%."DP'!JXG1WJ'C)"Y+[4GUJ:;/*Q
MNB,K*BD<5*BC?+&QY_0A!@H8['<XEA14JF^JR($XD]1U:;TXXZHCCUVKZ)^X
MODD'#$<?$C ),C2\$ZIU>!';N0GF/>[2<%E2IN][=VZ&>X?9$[K+&#67G8D[
M:3]++DYZ\\GH2(J\7VXE[:>IQ6EO/E6.Y:@I?<JL9MI$W?58G/7FV0F;?H27
M<1YI1+'0,9XXAQM9'RY-E_\BTWCY4$\<ZJFD#_7DXSGY>,YS7427QW.FSVF4
M$N<TRKF5S46'1 &2WY< R6\7(<60_)H(BDZ?%$P",E03TGPL<D&S& ]'V+CP
M:$">GKB(I/U.F:LJ[)2>Y9!Y>@0=H509[ZP6Q,-BOJ8TS*I0*N<VMX\/.);$
M='S RHYS^Z!X8TE*!\7;<ZS1U(?AX+Z3S2)3-P0*VTM^TZ@<>-;&_V?EU[?%
M&W@ETTS&7CE0D"[ I]"O=^GOZ\GHA=N<G-$+\=A^H43XLL-C8W;NMS@>6R,;
MUY8^_!!R3#RCQMC'.I(A#O<J8L>H?L4-)K!@ QU<\ R  0EF1M0=C\--C?UC
MGGZ0D-[FF##S[!+5M5F62%TN6=+'(IZP-)[\X$PH@<&C[QI(7#2]$CD5VZQ@
M_7UXQR="3R=H-NP0>6\@_':6MFPO]*9BO4M8$8.N)V^J3,7\H*LYQ@(O7=A
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M ;":9=8Q)3K8Q5(?(ZQ<FHX3S,\60Q+1JGS@\RTQ*#YP HAB5%6^.:3$VW+
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MJ#^P*])8;V#+F0HA@5$25,=P<95T18;U#((#GH?PXA@>N4&P(>I$;"_'/KT
M\X@.O%3AEJS\"#Q$!!0(:XJ""0,,_>'NMP>7K6]!-. IV%\=U+5J>0P4B2R7
MA%Z,P"LZWL?"E\2K-%J_E/C$""+3$E%[*)X1PDN$79U/IKT  QSYM46\%]OY
MSMXJ=9/=C-;0?54]$#Y$QW4XY,DWJ?N&HT0=^QE!FQ8>L!=<0Y_K$'>#V%'
M9_@*#VM#<^#'__OAPT <*#>JKFZ02FO;PA\CA$:,MR+OEX@KA!@VM,W2<0.>
M,[#W%%Z%$5:W7RAFQ<8A-Z;J6Y1#0]HC\SM!F3^VVJJ.QC!-=+BA:6\HJD?
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M.Y_HC/E7PPL@IFE72<M%4\I@JN0!.8BCJ.!&WL@#,2'QC^UV#!3CC?CVH#*
MNQEGK!7%6!=9/5IQ M'S+ MLC?L2>Z3(/#HO1XHIU@HVE\:X/D\BNV*C'*%F
MO?DLBU#7:S7I-G+3<D%BDMF,5TI,9MCA(B:T1'+3DDZ*9G+D,\R1BSQ*K9-2
MM23)XY22($JMB,3=P7F.U;!OS\_&7-&DOAI 3IN1-!DCGVH.-R=CK?73Y>B(
M&"?B\(1T3"L]N5(R-^1-*N!-#N5<L/#[ ,7'L0WV2J9%93#,T0-T$US76M%T
M\ZG 5##0)GK.9KGBR%L=]YX=EWJVL'$,V[FA#3E+X\EW:.T^K)*VH]'T+&T+
M #(1!R&;3/*$'3DZ=@@$@YXMPMB7HE=IL!LJ?,ZN,[>IW@ 4+4]+#P)?T6)T
M>UN,'GS'L->6)@*JL(HFEV'M!"_GD(WMT!^ E& W'>TVVK[[]NM!O'DK"GUZ
MOFUL1RG[L0 J69\!<=%M3NBETNSU1G5VLR(S.[M"(#OLX ];&J.(;U'$O.61
MJK0MX!Q"UVW);WAD'6 %'/UQ= )YC'D0H G4IV,@EH%C S?1-\-2 ?I WQ'^
M&'P;"#KV #@W0$\;^)--S'14'<&>-&(\HPYTP]4B(-VVNT;S'=PRBH9,;[>%
M.]B'D:-RPG#Z^AF/+-!DR#'@$0-^FHX!S]'<.9K[N2ZBRVCNZ;UXH\1>O/2Y
MV.GS?4]A;C?J*[,%D3;)-&W.#.T2_F71ALGH8&9F2@(KLO.]HH.8M[9E"RQK
M@ON%#M%N]'*"3U-?0_HYPFH?82PED;'&A5PD*>HB)3@3Y9TE<=N1NW6-'#U\
MK<"K 0<F4L@(VBWF]\ '+ZJC1[!T X1@<$FH$:9N$+Q2 ;!:7+,-+V>!@83
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MD%*LL<$EGF>R9H:2#0P,.=ID;Q)-D],^@Q?PTN&%X:&YUP[_C7 F_8FZ1C;
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M2XF/N)?/2(T+!P]\#=$!6$ 6[-/4J0F>?R!8X%\XA+! 'GUGC2+OLM#!!O\
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M_XJ"/C-AQZ6PW@B[#Q'597O&^[AM']L]'?M\V2$@*30&B=&CRO2OOVME2B!
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MF:8,@$$- T!@L 66@2;7L P$!MMG,FAMG/A\HRAORI;05!ZVQ$7F$4H7_=W
ML)IR8BBWA;MRG8RFT;+]4^ZVN6(\[?56\,.3WAE:FA@8R0=/N9MGN1<0:C4+
M",6PIW):O$%.Q+A</V]!WU7J<;&ZH5$=SK5J2JL9AKP!_)6KE]I7[ISKI32,
M-F;(%3'?L1D5SY?=SK)4[9KT>SENW%?PG+E1EXMPHZA>;*VU(N99\U)\N99+
M<Q4VNG+RC3G7C,E<KZA!3-)JQOWXA<!D(];-Z>L<];/LBA,6T%F8F18^[H\
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ME3MO>A<%R:?I6]B3XQ< ME[D2T$T"IR)8_L.8,YQQYZ_]'P[))@XD.#]TA\
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M#:#WG(&=;#'V8/O^"DZ+3G>$]F9SM-V^RW\D3V0N*=*+30"A4>YN*P34FX>
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MI,RDV;N>3YX<\AP/\D+#+-@\!7TB^HUTF(<]GNWHPZ[T/'-PR"<<&3Q5H O
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MXO5QA893P((0RR6;J^GB='A 8)*X8,%BN.+,60+14CMO&>>)NP?7\:06ZZ
M@=^H"S"ANL!& S%$B31-4A+X+#O8<B="KY78EH"2D8W)OL^T81H:G D";^Q0
MTJ7!D=VWWZ65S>[0R5;13T_ZI_<,\LT'G^Q\8R4[PQDI0F],I8 *H&D'*N_
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M+[.EW>H,:=64^J:)734WASBM'N(R$#3H#-6\46$".860HY^*JTRY4:ZZG>5
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M";1FBW^,06=H*A6'I0I\5IECD5>F<.KDB"EWAL:@/57\-S#XI!Z]G*3(R%1
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M;S/;)P_ A.#@?26(,((C\*CM^>X_D1.N/F +( G"K*X44];VNU+@Q8RYSD&
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M>'[7#F8L$L@>$%&_% =$0.E])/.(0EO:T4X"H^# &\<\!9<&G['[5@6JU)Q
M5;^TP(G@;O=A&)0YE"MK4BL\C7%-ZI'4"SJ$286Z72S@E,+=\-%VX!O;>:13
M!].59MDZU CS*M/-6T(GCM!@N#^;ZS%:^)90B5G@N[*..%"FZ"0T4*,BQ<F$
M,R;R=8O[^<'G.1H=Q[KV&CR1JU%T3@8C@N.,/6.<+E1KX;36[1?4PF9 F+AB
MO&S0OT9Z&CT7EC6N*\+OW+V)/W[17%W[C_3.L#TVF5G 3D^OTB?8&3_QA-;0
MK,)\/ )8]B<3YKHV^NSQ=^[F(\6:U,>ED=$/_,H7N#1R"IHTL-@JC!FL$,MB
MJK;T,:&HL)\+(^+ I)'66K)UYMJ2F0.V5O2<Q*+2Z'0V-81N@\;7W</]UW@<
M)&Y")1[K+Y" !>;AH#[SL-NYN $96F@=II;R$ZW:*S=QT0U+YEHT$=(F@7/X
M;J9+@^P^&->4&6A/HC\)E$KB"V:Y]/SC\WYDAX\_PY;Q><=-9+&/FN%(F);*
M:HP:[R(XGI/]M#*?,[+??9=[^^=\-;CDPJ5XQJ4(#$8*-G.WOMB-*],-<">!
M?."O OO;=A9X##,>.C1 QDQ"T9?I7G#8D^:0Q$@(:9"Z7,3H8"*;]H)HIU,:
MP!C=F6/[F5S*))0U<^(G8Y.4QQ7&1%?-LEV4"MA)!Z8_&"X>!+"(Z [0#8=-
MO!B/W4^1PXC![J=_V+;NWCL/S'F&B;G?R"'.]'AFH AJ?R QQB7&W<^%J5D:
M1CEB B(C"Q^^Q.1\6!AM 6/T')]Q;Y]A+<!$Y$07ZS1/;H-:Z"^]," :L!@W
M/-TWJ8*%Q [+4:7X+(J*&TZF9\! ;<O#;B6P_/SO>YU>+;#[BM+NR*L'552?
MG)<T51*/O_[[MPS<O,]*J>RTL3^BW7L_\6ST&XU:E$E4!2\AEQ!U5ICOM:(L
M56$>"<*UZOFJK,]>N/ATB@'72&4>*!4K2</S^S9^KG^ ;95Q;F<%,[L*9327
M*??;0)X>Y4Z+J7F;;+7F3*AQP^1'^"L6T4;.G(R-DE<=V^WFY;J=W6ZY2WA\
MFOUQ]/LC$2.NLB=ZS9X(]X0H2WRVT<C'"J.M;0RESA9 ':DL_^\5;:FR>S_!
M\QE%H+%J#4S(Y-3[*R3>*A4J[MSO8I&GW$XC;BS5P L>*$FWDB*+2-<Y:)2L
M7\]7$E"!\B6OAFT.R;T*B=<"^9!9V9.0$%P48.UT6>.JC\95 1+/ABZ.(*D$
M_?I'[.?X9K@_KJ<.0W^PQQS,_$3O? T^CA(+M.$)NR8J4G,"+^TOY(&/P *?
M! =\*W!C),Y@Q-_.35M;\P@N(NQ)']%I=*<RT V'#G:2H:-3<@"'([&I8)4]
MATA (K(T,US/QJ(>,[K/8)1/$$M/H(\6??\L0N"Q&T4N(L\2=WV4;K':B!!%
MA3ES'O1/?)4<XQ.SF ./%'D!F#L*[QNSF?:,V1R4"TDEE2Q,IB]L>7U@4#79
M\?%O6+<S@=4/J1/+B175UD)8["!@OO5:GWLK&1Q!D)"09::&E2R&H(1[*ES%
MRKFJ9<[=O*X*Z3+GN$R.I9#47.O<':ZJ=0Z+1,9L@ME%+!J'0!ZB'";?9&'6
M#^;3A!62_(\G.&UP<&WI0Y2:@]JZQ"Q,;P[@,J0(I,6RPU=31#G,7CFV'58/
M&%0\O;MVW*:,C(8=@1MU,5]OF[A-\MZFUNM<W"CIJ4D"LJE,'GQ9")5.*0B5
M?DYFZN",(%34/ B5N^ <?_#LR0_I_@5.?G=F+*2O)LS@\JOF>.:KE$12:4GB
MZ_>:.VO@58X07N5=3!O5?&\&*N1_$PIIH '.&0L*6V[])YB') \IC6) @"R@
M$,"):+@S%,()R8W%:4^.-A>')4_'C4&XN,SDHCI0)-U0Y'NVJ)9FE*;*]0FN
MLP8/-3"9U86UC9IC[:7<>Y^%VIAQ;$DK]V\+,YQYFN_?C!<]$28BVH4&#!GK
M6Z4)F(EP$*10*H-T8%Z"93AXNIIPGR=IDPE;>)2]R"$1DC?$M)['>"9RZLD(
MWS.9@*E+CPH5S_!^Z0EX@.=/)L9,FA<^@NHHQS1Z4;RE/6FHL8:XCSD0!G_C
MNX(B?)&<_EFS-*Y*2N]LS=&!]SG"J(L9BU@\FRPDC+*/N=X2PE<ZK#*F1B:8
M@7NX@!I9]:B'B:C17=G2:SN(&CVY(J(&)_,^A4DNHL9^48KBP]H,4J.5Q+78
MYUI7P]3H*EO"U.@IA*FQ&Y")DDO36@/-8Z]G<.U((JO(71E)I-?-0Q*)'RVH
M(,2/L.!XCM=&_^,71>Z]_:_)YM(C?%:5M[#[C*"N@)=)?WN%"[^!GH<8J'8$
MQ"8.QBL)K=!7@;K!837V#].74\X403IO!NG1ZZU"NM@KS@^2+%7J94PYJ$6Z
M^"P/<O: Z;5F^5EO)0S+7FF&)4R,"C?TL""S .$B\(TE"S:7,!1$?0O%%UZE
M (U_U9U<_X8KT7PPI@9BL@N(=B -AIZHW :^01.3R\<(4%'@)"P<]FP@0"-6
M^\7J)5W\9<+T5#&C>'E<3@G%T!4%IH[Q(UXE*LT-B[2'R!E87G5<)8K%B(*C
M]AN)S,_\90\TB@ :<$+.Z2PUL0_2.=UEZ=?P$ 2-)5;4*C!=<$W6 '59-9EM
M@+KT!F WX**4 76)E']>0)Q1BRW4.]0'#-?UA76 6X#?3-@<,;B-^"-JK[-%
M^J#Q&A.-)#!>&/OA1KT\XK5CMP0S)?TA_"J? [^*$T,031;N\1LP"F--$+K$
M]>!QY((2?G(V-Z[%50X8+@YM1QS&W':Y=@SK\!\?+&?FF*^Q:R@#PI@'WUPN
MUPI7P]5OT$H0K:37H)4T:"7'-XES12L9Y,2$AA4WV)[\]Z5!&^@FKL@>/W#"
M_A(EWF$2#VD+(LK!4V)"Y'#03O#D*A= $76H0CU/1%^ 8ER[(6B1)(4)8F3.
M\P8X) E0I(6N+TH6"S%88F&4<2)OH80]("R T'0/[(-=&00I.R".Z)9C$\QQ
M485WN'X;H 16^$8V  @<9;@K&Z D'%%M-L"H K!C"1M@7<4?01>9,[<=1ML%
MX_K!;B.V1FP>5*SA.^ A!]UX3ES3#EG-<#FV*&BLKD%^YY@9':!#!B <7&S"
M0<801)Z%?9;BFR;9S8#'2LW7@,5O/SQ<D<DO\$)PXQL@W31' (B.F9? #\V'
M.N*A./3I/S$T:'2,K)"DU\BIN!S",X$!]%>^XD>7>72.V#>/20R3>$I:B'LC
M8$] -R )HDEC ^,&>$KQAH<"FP7E!M\BB(?JP0:+VH3%&NGQ_#3D(4_[ 8_G
MPGTR$0BTXG4!,T>#.S9VRE_P9*I:-O2P0##E>0^AQ$A[X2)PX#@RL("?7<8%
MCH%Y"4B;&%W:TF<0:)@BG.75SP5(QDL_?;U/M+!L2^]LD,4Q?HA::<8PCL3!
M7H2CLT3XE0EL$9[8WM&&U,XRK- Q\VQ5."0W'P^)I$L:]FCUYA9NG^XIP1BI
MO?9@5!6N:-LP1J/V8- _Z2<--L%H*EGQN'9AY'LUWM@^7:)U^^%P*Q\+(95^
M'SN_W7R!(X92QF25+-KA6L5T[_NGNTXNK1-HZ2]X8-(?']G8\5'C5V0R8NC+
M6U '3*F;@4_5<-O2*L;62QE%*_A9>Q4U%-M<P/RRO&->WZ@*)6L!B\J'<^"T
MBA;DX J$-P1"*[,,U<^0,K)Q70H<7FG].H!F777'@&:J?'$S:/?DU47W#87K
MHW!V.YHM4EBYN.F#&=!0>%<4'NR:PEW<PYT"X(QM4#A/=3AS!M@U*J7:N[@9
MM7NCC9!3CEJ[J08^N5T-YM3X.S^Y>Q<@DJIZ<2/WVBLR^\_&/J^?@KW.+BC8
MIY[1@W1N:$/!S2DH[X*" ZJZ[NQ!ASPRY\06")R=Z5PS@8= X%%[N!GVVKH:
MQ.89:CO 0<K"[ZUU)'T,MQ>G&:8SDG&QKKOMC( 08LOPK-1+>0G0H-&.]JX=
MK0LAK%)SM+:\2WOO;*A6J!&M2[5^A[2@G9ZAYT.U(BUH;:K)1+5N@6G=:#[[
MT'S6)JI"1!T6&"0GY"]9#VJ]053?$,^UNR-$]7[WXJ8']EE-<*['CL?:L&DU
M-DWJ/%MDTU[#I@V;KL^F\H[85&W8M&'3]=E4V1&;]FMETW/ :#\Q9;YBMY2S
MS/W=N.M)4H?/P"'>K.=)?X ]3](EDV>7-KLQH9):;/V$&F(:55U1Z+,FE+Q=
M0HUV3:A3<MA5H:.R53H..B@9TRUJUDCGSFU,<TS'_@8MGTJN0F4_7W)W5._K
ME-H>Y4V"P]PDM?@!-^GK-) O;CKM=#9W19N@)&$+C8+#(]UZMFW#Z-OP)&[$
MZ$K#Z VC'XDO<B-&[S:,WC#ZD7@S-V+TWBX9O9K-=GS[(*,G92YX1;H_%"8J
ME4#_N!;7U3WC7:5"[B.3-*]SU5;&-"HUI$KM8[0%(9PQ BPCX+XX7G<<L8^@
M5$2#I U[RN##3!/_F]O9(Z,36QSF?#N=K;;.+5G]5T, K-)-6(,NCL9\81KQ
MA^VV*6MZX)MW9FVPG NQG-4&R[G!<CZ^29PKEO,P!\MY= Q ;1OWH98NLQ2A
M??8<Y>=PHF/H4BW-1LA_O$OTK:4OU7$EDIO=Y2[2&;A^ [4DKE\-\GBK.@\L
M,O9)!C7 M%\01Q(A'I\1^1">C]J*@'T%S3&_N3*J/+$6D E@6G<)F=:-H4PC
M+'@ %RGI$=XGUWRPR:-.6-#ZFT(H\).$!E3;2J\:H-_VH0'E;EM1LW_:]Z.4
M8\;T*PJ1'AX*V$-"'A"46DPH;"4#X/@6Z4L9L2C6<'M+5BW?<)U:XF4B[&FY
M4U@E2PZ.2U$CM1VO5-J5EC7*6JN*UX38.[J$C%ORG?Q+LP@ D\ &%64#<+WB
M7(Q-2@OCFZ[RVA^>MSLWCL%%63J.T8W',3IIG9Q+Q?MIS#*)J]R);A'8*>):
MM\E$Q"=FIB_U+V[Z/:75Z0QVDXK6$'A%9^R0NN+$(]*ZW\/S3E Y1OSJ!$>0
M%+FEJOV6K-15FU_#27H&++&RBKA;#3\E87<GS>X8=WRRZ =R9'_57C%.<ANU
M+,@K/!X,";E!*<  *#A  PL0[F?Y)\3^K]H>6LQ^V.^SK1M3@^G[0G_90$]3
M#@#]Y?CDS67%,ZBO#$LJ&7&I\C'H.+=:IE0_CQ FIM7) ,XK4RQT6H;P5NB[
MIHZQ3.]W-=%[B  SP]9 V2G!US?C#X\?UM$OEGAB(_VBI"3(TRZ&<BE<J ;$
M;3LGN-H>;I:U)*\^P[N[.,,;&;_6&1YR5LUG^%"YN%&'W59WF#89FE-\GZ?X
M,L5K.\6[*,1;:J?3&HZ:D_P 3G+BBO*'>&G&R*!]KXX#_ C]Z]F!$^Y?#[OY
M=/?N83]5!VSV\E=VP/9V[&$?JG X#EIJ$6IQ0]\MT'</#O9AGQP:W7Y+K0W[
M]DS]ZQ4Y8J5_/;L+^U[\ZT,*P;3E O"'TSM RP>HNTV ^D#CESL_/H?-\;DW
M^N[C^!PUQ^?!&9T'=7R..G4<G_L//.\[/-WXP<_=#WZP*:IUN5 '!^0D'\D7
M-]U1:S!,8X659Y7&4UY(Y@/SE(^4BYN!C,EV:<R(QDV^13=Y=GO;W;G)1UU2
M4XKZW9Z>E5_%3;Y'._]4[<":W*CJCNW\$4:5!JW!J*X>1@U]R]-W#W;^2 5U
M2.FTNK6U?#]3*[].)[EZ0%9^GX[/HA*%$SH^Z8EO# _>-BFA%7DSYC X4I^9
MZT4V<G..[IH.-9VL";D;WTE_$7WKMDH&S6E[0%RPYOF['=88-@?S8;#.&D=U
M1?.V' -E\,BHQL/Y6&#OUSR??:OJ";T> G[Y+5@=1O:DMUE-Y_1WJ[(TGAH_
MF7[]7^;8Z4VFP/I08UI%5MYN0Q W7+"S<_J[$ $U\H9\B+QQ9$[GXSFGM\!
M2DD&JH+0W#TP@.9MQWBW!-%<#@XY#Z'Y%&&2*W&<7([AY./C-R63W[:'.KD9
M(^YQ;WS#SZXTTX #"<IY+D 1D$$GFCN#YQ)$ID0'C]N2-&!(&U5VPH!V80/-
M-7BL#E*> SGJ95GRX&#J=Y?I<D!2$&&] R0S!#%%L#@N@L D@U'>$@HJ?/C
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M[8FA(=]-?'H([@+'&/M<0X-5\$T/WT,"A_2\8+B\ T)L15$\T..3R,+A]%Z
M?^P7A!@FN@5LV^4/.JR9X@W8^&'&3#C)%T(4AE/1YJ U>5PK*"%DTL9=/RY<
MKM6T= $C#8?NWEL/-.X',>Q;2W_$E;G'F3^"H/]D3>PY@^]"D=./B1SUXF8
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M9TT_]M51$JM3L+7$0I#Z7V49]K'O5NZRV#$JD=:#^*&3&:9#DI7,?Q$!#"I
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M;XS8O_,BA/3[&=*]'D2(_8B/'?BKR)T/ZS>P]Z41,P18B0,O\HN"V&.07]B
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M">4H<./^^"8&(H9$+)'-\_?)S'3^ !)$P?^*V8?NH^GL 82$__83]]S0=.(
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M=-W0"-:,K?NH\G;2M9+1:N: _N\N,1Y'# B_RH>TSRH\4[$QNP//X"T])W"
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MQIW)M;&%(O:L;&)&ZEWTK.2+FFJY,@I^,?)Q.,5 '&DD>$5+E[%02Y<J:6E
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M_C*359=Z50_8VO?SV=>'J^4RC7@!+'>E5+:TM[>"E)F>=OP8!G,W4VK[A/%
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M=;7U7][!FL7>@BS=G_[P/U!+ P04    "  K/W18])A04T P   6\ $ %0
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M>;2*E_IJHYP!E62B:,1XL 5-X499(F-H+!QN>.4WK"N.ET,O9G62G;&24]C
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M\%O'&M\?"Y)SX/>[_ /8T]T%D([9X@.YB5HA*,T-N.+H']KSQ1<I5!DNH#N
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M#@BXECW:MT*D3+1 0;9-)9)?"AR<\1Y8)F]6J!B#'.Y@[B&4/]"C>82X]U1
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M&#=3K%_.Z8>_=SVS4M$:&0)CF8(4'2+%QK7O(H\E9>9+*<-U5+V+TF_1SCX
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MR>#3Z>P'R:6^?-OE;R?_; T76DC+C'*6Z6(D"R@U@R"%,*A+\.7__?3/G)L
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M82(K:(1/7LOL6R1M/0CB$%AO)^6[2A":96I=_%,G+4YHBEPX9YE(EE:<0E]
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MYU9O?7TW&>?S-#N>?,#)ET%:W 6<E>-.2<M$%+2G:C*^@Q><96E(P! %3_"
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M,)L'('_!\:<)?#X=)!@N'%1I3<ADED+6Y)QX5=L&&,.B05UO'-/ 6S1/N!?
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MZMO9H!GY<YI9J-G=/!G@_;6R6Q?U=V<+=$QL)[>BO1K-!K-OT_D=,Z_'DV6
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M$9DE6=9YK[+6,&/V$+1#,@2+9]9)H52[FO.C4]SGKTU_0+W=A?*A8W$_Y3J
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MF6)6P?:KRG[\\U^@ @PE[0&OL&]\KNMA2V_G#\XV- 4U9@919UTO:P30-H>
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M/N?%L#^@N$<9NO1;S1+>7$//;G%I542RSD'6,8,*M%2L-=Y8..FM4[JP=M6
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M>-I\@J(#U/ Z!*APE8RUNN$LO#Z0)PY/':QC/6-4!S%U/(&J9TH[4['%>,N
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M3""EP7%NH*@48M$,BS83Z/_SR%^&W@[,X$-]<^W:!?3SYT?H'[#;@\=K*'"
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M=/_$Q?_F=6O^:VR;8@.6938J@HBURVHHY"9Z-"""%+;(R'1FO3A_^CDGPO:
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M,K7WDKL("&N9$9/'S/.VZ'D)B[C"F!98$?)/>+9<U/]:G<TKUFU:^W&DX(8
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M&HBYQ&BT,5:,=VX=C%4/]Z@_.*EZX#0(F58UX&M%DX9V;TJL1S0#E4DT;Z2
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MZ2/=[?"3U!^A\Q]Q-DF7['KT!EAVZ]'75]&*+'Z]_@YW$][,DT'W%^;/*9F
MZ#,'^$?T1 ;!*0;0TGSAH"KL_ S&?"C7%U8LUJHSS 90PF>"R"\3S8W"PV[Z
M:;Q;9[JV_NUYLS;:VH&BU7ZH^<NPVN<P+>';JEQT/8'/3QVV,0#X=)LLB:_H
MEREDF%HD>G%?+?['C6J@39+02[FV:GE:/5B7ND<=00<..]T76?A$!J$HN.O>
M$ )]!@X!PB? !/N=;20_9Y;+!V(=T4_1B"6-?IO-HY6:WE[]S8LPJA%_VO-L
M<6PB7+@SWH%,Y:-<KG!,5:Z;S?#W\AZ6B/C;FDFWRG J>TBS[<6+C*^@A^9)
M&KP6B0W)6M'\(Y4J>NN0!&L\BKU*NFE&TLA"_X Q'K.C'*0&[-ST3'G4URE7
M;Y-:E$+?8/K[LI Z"Y6;E!OAC7$GS5L'>FG"[&'YE&ML/2X1",LF(+6A9[+.
MM\%=UW#7^AT+R5++H_>V*_HFGXH^47C"+$,21]-*E[Q]<T<I."&A&(!E!LVZ
M-W/"BV,)Z1'V5Q;PW-$8-X$3%_,4<9;SKKG@1(UZ$[7OL\/UJDC00) EVH8@
M#@/PJT9>O,3Q@;N@(PG>8 !@!A27D<UX92R?6>"J\^I\[[+PP-1QNTJ.#36]
MRSI]V-%:\'8#'Y@WG[O@B(SMI5;2O*W*:OZ^;D/5#_1+C1I7!E$@P.W1$)I7
M=]I05TDT2JC'3U:U)EUA1JI(VNY5QF5WU%GJRFSS@!&7/IK^>&'MG)*$!8T6
M_3D)O[]-XHY1B>FW=.*3Y/ES#W$PG7^_1'&MV=*[0J#2J\.2RY.>_KWE$H7.
M31;<O?B65_8[ P7\C8)P&P-&%GU\&#QS['[DV!1/]>L KO1YR:*$UYHAIQST
MLN<H!WCVGT\%7CSU>=?S^'+YT73J*'L*O9.3]/:ZF+&E>?C$/*'L^L=U#.!X
M^B=>(!=-JU]-R^V5R8W3/N":L=>VY.=9(^E_>>]W;_[1WEZ;E"E7.)F8\R'=
M%-6. [<:H1@Q@*Q7V1C O!V:\O>VC_@16>$0VNTXO?6/R?S]Z< _YO9'D[G?
M+VA+")SFM_85+93XKYE; X\1D);Z$EQ?1?A\V\XM.XT6:%]C=5ZK>%7\XF1\
MP0U-TP^Q-6ZR,:04RL\-0!J?=Z[<[G\?ZF(D#M\[ G^%']46@KPWTQ0T4MM$
M3]L#8^17]?6=A J':JK=KQ4VZP1VOZ<3,U/% $(;D>(8@!R>@NS1$*0E 4V_
M_]>":G8(WTI+$/_RO/6Y=;?2=&_SH#_N%IH6"8)WJI;YW=HWA-M-SWU+:_O!
M%K/4X)+M#W_46_C);A.MVPST2.D9OD#S=:3]ONHX-Y9=F4;==)-U8S$ E89X
MG>TB[6=I%K>G@I_TK6Q/:B;ZMENL"!HFHX3G?RZS0MYI!Y9@9/].R1>,4S^V
M[5SG*>K@96U_P<=/,\^XD;O ,(76)!I_IA30 .$4TOF'?E3MDHY%==KR/DL;
MR2K7%3I_N^ 7C,R)F]ZB+1G7K"#7#I4S"4,/I?'4QD<,07V/Q=D:*U[KY=;&
M7CX*(3G[^FC.0E,WN4>\3PF+ B^X0P:RAE[A G8Y6&<U($5_.FO@; =-.?.E
MQY5#O;EEIES/"\O0O3YD@3*W@Q9B4Q=.V(<UM 8/PRLE[U O:E=]4W2XU,T]
M%2VDW[@!4*0!!,YRI2(SSV21QYU0[J.C?)@T[::$?ZZ#AV5NGW1\NW3;YPT6
M ];;RA\?F,J94-2;1#+:%1__%6IG/T/@)S63,(*;IE%WV#4E<Y[G+ZPQ/W4K
MTS]0X',YDT)&;JI2J++UQ]L+2[O<&[OEPAT<OBU7\XZ:?\WI1\[T*%,KF[.3
M4>>1#\(\+EQ*$!=(5A61Z9F" 1@8WNOC@-3&;EBR,4FE98Y]4JOWNDJNVJU-
M^/6G WZA!0-HG$9Q_.F1A^A?@:*Q6C099Q:(=NCL7TOJ.^-!#G<VB4*I@M/I
M(77C4BQVL.FN0^*(M[K*.&\+FK2H>:/-N]2OA=Z;6;)S@/H/H$6-(^F9JYT^
M6PMLZ!E5I$3[JRS#2X.V@996?64M+-8/7=8D!05@S@$OCL 7^>!?41)T9N3+
M\+?X.]D\HOG:;+UG9_\M#CB" ;P$T^B?5$T496^Z>VBQ*R:)3!Q*ZB21NPAE
M683.**R%ZLZ[U=<8?K^<3.ITV)=6-P5MQW^Q'?/@:KPCX'@9+;R,C<D, @S@
M7R$+\E0]BD:"E@:NZ:W[ Q&QJ?F;$W*H5$7:9+_P_LD%5TTS)'UD;,YAO(0C
MHF7PV%K)\"0].4'.D5D*N;/ %RK1)F$<Z:MAEF5#T<2K/K?QW2*\G,/DU0A'
M*URX'P-H-?;]228YX/F+(.B)MS-D*=:)5+-[K"3D DW>/B^90\G53J#'<BO?
MI@M5(FACEA-ZSZ2T@)9<<7S,%NA[_?S]"YY?Z!VV3Q8S2&9U;$186D_39BR-
M*N('GJ5H5L?.H?<'E%C,0^+>?<&ML\,)NCO'GS#YD\,Z46]_D:K:3^P[.LO<
MP)JLLH.FJMP\DMHS#ZKW[6G$  3[A<!3#NTI1D%936Y,3"45:<"'U;&"W)\8
MH@J(IWAU&4]>A'\0^.QXA9 U#\!@?!U+!!@ ,_),KJ:Z4O7*>J?:R"&73ST/
MK_6VUIU=-@4E>M?@+M?+3Q0+;VG;\C^,J9S+P H/K I-^;6@&$#;T*]8A+3]
MFIZFB^:WG7R9UDO=L+[L??$B\()LE+#R/'FA-OW]JG'C^[6"/1X<\>*V;.'=
MJ?BL G79U\Y>]>,\NW+3=2# G[5R7$A%QLO5>)L)V";:R!*E%:M+FNN\?]+V
MD-5"^@O.A]"$7KL>^IBLNI])-NQ7DL7F,XZ_X?\G6R9N3F,3'-'QJC$X#>L5
M%ABPR0\$.S]N?5]R>^0E,Q/\\"C1YTC;^66*%^R-KD"0\Z)HEUT>MYBX6/<(
MF@J9LM1:3:]25%1G@P71=MT!N[K7#6P5ZI4">]Q;6ML_'9,3\H)91"-R"XQ5
MAO_@02NL,B0YQ !"?CKH B7&W^;:G4THE-/T)T90<2(.4WF=U:>-E6Y^^59]
M1T5 H^&L>*ZI<=$ST%ZU0_GE1XZ7%L0>M,?JE">T[T7*,(_[,VX:X=:/^$KR
MA;.4P_LFPNQ90ELV?T#GG9OWX\K;N>OC$@.*Z+.+%X;EG=+A_A/@?R;7C#^;
MV& L2,D=<1(X$I.CH>V[?3JW%NE+<1Z/4H:=T[0NZ8:.+PZO',RJ_Y \=U +
MU:=[$2O5PKW@%FBA06_[9M*6=<6 0V,.Z0$#1TC)BK;P$<U/-DMX@O4@8^9C
MMGI*)OIND4[,1U:#"BS?ALFXJ6&T@8Y.$UCD^C+T@V$OK-"0+:SJ /^1->[_
MZ2TVSC(/JSO/FH<CGZ6,#/3)#AXQC=J7,&-7\]OO;/:/$UP94P.E&^<6<?LE
M#?_-6SB.7+:!NMFHK3WI,#>&@D[(A:8'_[5PLK^UI3^<$8YC0TSB;,!D5GX3
ML8<$S0=E'#P3 I_M0%KB_MFRE&D^3)'M;]R?]%"K:_#Y2P6=_4,37;2F!K[Z
M_7\Z[[W_:MX378MO0I_'(MN]M.+.U%%W$ 0E)KD;<^+#NY7$&TM55=4QDQ5E
MDI?DC"3B';ERD$$(</,\D7\S!G#%(=SVX#IXU2]UYXE":KD]Z@5SZHBLF@)W
MPF-HXDY^-^_CQ[.ZRVCF\Z2EH<;+L^L4%1Y&HLGWZH=O-=:-%N_:\4#-7\P]
M_JX8<F6JOB=&"2]7T B)LX@!5!C.6B5[<U^72?XXQ:W^'?&>Y.UPPR;K-4A"
MK>$CYR_)ZK4M"_1;/P&U)@O_*N2+==8\3.%"C38*(O 4V-%UHDAM!6'07.^^
M(?=U)1>>^G1#CS,NY+>&*Y\V!F<V\K3+(6.YL9M,[D=0JX\-J;U$O%+Y^$$Q
M90I" H2,>T8>Q@B:[?I%::T??9\:1H17:N$KZ:\^=SI]GK?6@K]3MG_#4QC)
MC;B+U=..'7>)H@5VQ0[X+DCIPKEQ9\@_YC+P+V6<7NW0-##Y IQ1;=11TJ$:
MDH \:X;Z)^<6O14]2CZZGML.>Z%%:Y^9\N@JU;LD<M=U18/TPPU0RZL4! ;P
MLZ(H^:.F*G+X5T6D0M8ZQS_B]D=%%+]7^F=%-,XK"-+,DK[\O'5__\'CW1Z7
M3PCA3^4NQ9[R*KP.G-WS&O&&FAYF?55G3-V<&$#EV5&U+;@\?6RH;$7'HX,K
M!6$1)9*_2$8PT_ZY*-ZZKC!9_5Y?D.>GCDT@!^FR4,%MZ5OLE>I8$ 1A0: 2
MAF)KO%DQ&'.$ 93[%87ON]O-1^.->%MN<MK.%MJOT-X1EV3IEI(^XU'(]B6O
M'V2SVFUPX'WED2/GYY9O. /5K^AN;DA\_8;H>KE',GT\X6.+;W"\=@S JKYN
MB/= Y[8?W_TRG=PW2P(,=W*]1A5O@MF=Z\)7-'ES74*:A,>Q.?E/BCG!ZIR?
M !\(\K5<)(A5/7=U@!?'VDQ\>[\JH7,[?E7?0ZIN[T@;X>-Y764DLW;D:8DE
MN$"9:51B9Z=BZ+Z7Z#M* R_U*X0,+V.M7I**SS7L0A;YICS:O(M64E6\/H%Z
M7& ]6&4:NZ36.%P$NYLT>TM?EU)WT80%#8M^045K/N.T;OP/[1/W3SA(V\^_
M8F[%0YW7'0G+"/ARIW;.D8X<?./0?0BV!IM(&!A17S()W:3+N=>L6];"FW:%
M.&&NUCC2F @%7@1>10:IPL>S/TT-+)+8&M@X*_GQ5,3D<:NU+LMQMMZ,55!\
M2PU]L&MKWP>ZH%S&60R [8(^(#&_*B"&@9_J 0N>ST9C^@^SP)IITRG:(RX0
M.'6H%-_"+%!!16! 09GA9;4^,7%83> EM8 "KBS! ,#)^_M2J^\1% .ZH[YX
MB\K&I$]Y?._+I+I0IPF*##%U102KI$_ZY<F,=6P *]E;8L!:7T>$]A@WM+U#
M#EOT]?4[MO5TF:JR8K&D(5,Y@7HRM(H MF90;FB=!J[O&UMK:W5]KG^K;^%I
M^"BW_A*[NU^!I-"AEL02Q^/4&%'7-Z/>1#\P@(B,R\:+HFUD!#;'-((/<ZR.
MCA&&/$FY+F:N?6+!MSM?)4:B=ZIQESYO35<BPJ*%XG \O=<,)BII7;_=GK!,
M\Q!ON7W\W.!<]ZV?8HGXWU0"^SD6KT2W\AJ>%3R.,DC46]]V,1(Z3]D5OH,R
M=(!]KT@35!J5HFZD&^')L=2P$^CB"K5E,9'U#*[2+:MMUTQ88(_9E>&V]D:=
MAB;<CLO;RE8/5W 3XAY?[=S>8=!G-=+O9L@03WL_NM.-$S3Q"Z1+:-[_0JW\
M7"2J:F&07B=>;J##HOZ\2V^#Z!D[,@LZT$ZOV5%NGF,%C0O;=576L=V[W4A.
M1TMI%8R(L#,%4 Q>6='B&;6C.YA_!;GBQ@>8MZE++[<T!WV>U9O6Q0,5;4H4
M2#F&KN34L]BL]$\.$33IK]G-L%^P4C]:]H^M-+Z_RO>C>=AC]0(VB["GZ:0?
MWF;S:+]_")MO!=+KH*PF4-9+8@=^:KN/JNH,QXH+))E$.F_DD$\+UQ6O<M(K
M2?4F!! (9CC^S&:_#"/\*<.0*>L-Q(BE)N/KE1$5)43(3YWZH[<"9KY]*Z#H
MH357[[SAE*R&C.Q_[*#+4AS]6>/8A&OV>+.O9^N;A6PX/4_A-7LXJL[N(#G!
MEM"NN\>*9T):7FWWJ>3.47',-ZY42.6X<2=4N%?P$ARE9WZ@[;B'Y]:C;&4W
MS02/<!:<]OCV["=#08CT6M$4\]>FUN7/>L_NUIE*S:9Z+ $.YFI/(Z-$00S[
M\ISJ"65B);CH 7=OYJ*BS=,Y-R:M)>-183]I<(7]R\KJZ_6T,_KEE[5>%-XW
M?Q+]@;^8?N+( N&>N@ FL4ZB#PUR^++A3S'J*IHB9YWI\WXU5'$:U/90X:P:
MO^P#]7>MDGN_G#*]^(_5%_V;F,DZ]!'L3Y1B3/R0/(^5:@_[(; 4*6.1L$6V
MNN2G"6J-$PL3W ,H5HF ]-FDL1>O<^'1$HKBG!VB#\3XHTF*P5/)[?!U?V+W
MT6VW&&VYBE'N8FY(Y6Y%^&.#;E9M_2B.H=EDFX)588KETLF9B<R?8/Q[%7-1
MRE\(B&'9"T#(>,]"\( FK]!@;*$(7@ 2=2YD7%I/P>>ZZK0Q[J077$5Q.;0=
M$+S/-,/K3>!^PXQU'-S6Q]=&/QYV)$W:V7K:($@=>O8$0?/NM>&][_>?K9=4
MA'(J6LW<Q?>M):@ENV!$O\8;5DMH@GF8\I][.:1_[(PQZR5#[JQ+U'A@BV4'
MC4JD"2QU[Q*2\-Y@I8K*8=KCEF$Q]D9G%ZY77<L)<4\^+!!E=";5]1V%V5&'
MR$Z5A.;E=;'L$:>^; C9U<[0H=;L]%VLZ0,>Y2#52FS&)8Q2E](X]YY!TB5!
M(,_9*&6NK\_5.M6?$H[7DX7K<=>A@^SL2+-2]#\5?)JEFST*U7'XF)@U4!A%
M%TVZTK2G8>UB)/_F+9.,GOT&[]J3AHDTE"<2#$:(PMK'@_+:\V9FE#PLQ8,T
MW96MX[G>K7C.?!''220Z'QFO;G!#,+2"K[IZNJE2@;1.;V<(+4[Q\D80#2=:
M$#=)P6C15"W_EL(^/-_-I>0<R1K)TX2B+:DRT7W>AXU%)(OMF9Y:3<A(Z6=6
M$B2]12 SHHT?TX+WGO#'B<_=ZSRVJGGFK/BES+_/B&=4B@N4.:L$FQ8>1+%_
M]G1X4E\6;WH:-",?7FZ0'^[%*?6U_7E/LKOX$B'D'UC\(UWX_FO#[ (>TRDE
M9@-'8GRK>B?O,@BQ]6+,0YA#M)2'%]5*]GK*2D@%O=^'IR<5;[T&)!:*\2UT
MTR8(D0-X5-IZY^F'6P/!8.(#VA*[W/$&9KLYD.>A9 &#3\MK(5[JS4O7'\G_
MZ(:I/J%J972%_-L^W,^J'ORGJ.73K9^L5"6D]1%FL_,^]A!7EITZ;I-AJ![B
MK?"1O6ID6)R<OS%Q*E/BYN5DECH=G)9+H;S:(S.<:FC\(ME)/$J,6EAU:L^@
MH1%A@%#)EJ_[!,FT25J\R?I S%:N)M%]VRXX_,.MP-8W273"0W_%QU];B/]H
M&Y68^J63CF,KR\286AF&V2[$)PR@0V['OTLT=&G(U+!OC3MP44GG337.W:Y^
ME]>>AR<N'1E746;PO19H==!'^'(Z6\.$%)5EYK>5RIBQO@:/:Q4P+3J6D*:N
M=_S[O400KE#?:S+AV(6I_[DPA+]VM#(NI,7EM<4_]SVO/(]"RNDE47]!#GL?
M[CH/HP?HSYL1C'/^2?&;*7.O\EMKYYT53'G:NMOD_<U69 8%2&'Q H[S%/X#
MZ-MC0G$4.JWG"2PJBWD(ZO=NS 5>YLZ!SU\ZLH5*37>GQHZW?6^]D057T/W[
M9NO?F>LA.E;A8E(N6MNRYH&5M<GS,V-(+GC56I/,]<&%B5V>0[)KUH,STU'U
M!IRL&D_8^%'Y]-_G6;U>=Q2V43?-R'D;BV\8R8"QA4E:XXT_UAR;B?8NY+*$
MPD4FTGTLF%#_9#M/F^PI)WE*V;YTF-#_2;'4^/<3G'X?SNC_**](K=9DQIH\
MR9:J QK90=>MC:@1FK&UG^5P:GU\M-B2;G3GQBH\J8MKTU2E]K_0TX2+Q$5D
M;<S\(Q5%>J-Y:=:"US:^44U(>6AI'-R*U34:'X78J2BDOM>O+4"X=.[[\L.9
MCL/M#@[&/E6GS%%6)"U,%U2,=%[FA@&M".ZI=GLS<R5AL63%(.E3<FUCCF>D
M/ZYPO;I45YD@[BA&3S(T?G[GLLF/!5W&\%8:@IOEUNRQH AD+6)ZH;/= <<8
M:0&.D. I%'71[V*-EQ_)U\F+-0TAG0DE3]Q"&9YJ\RP-,/D23U1( Q7A VU\
M1$@-Q;*&^-4EI3#5^3RC@K;O/=SD%???49/FQ.-Q='\M6E)5?LR]S[GX\HNX
M1DIE4C*Z(<X[86D@L'T\ ^0 ]OIBL$GOJU=9(:&5Z.$[8,U"I51Z536D^[52
MAUB_ %<&'+*CL+#CT2HA7^0NK,*I\LSP6V5TBLI,^?>D;:E.346E%U1OXS_&
MZN ^KI**@_&U 8,@Q(<\MQ&-W.O0@@TT735\\97]$ VY"FNCO8>(**%:]?F'
MM=<$'L%2YO",5NUTZGAPM#?3+"3,[E!?^7EDUY)E).)-V#NT&>[WYRL!.&5B
M!BY&W1+KO>A:C5G?[G,P&9)]J"ZOLP1O0Z3.K_=T1!GD\S(EWD!/=\")4JO8
M7VG5<RB8G-G?R[VD>P:51^]N3(F2_(P<WFNI\M#6]NXKN%$;2R*SJ/AQ_MI[
MJ:XD61Z\F]_9 MAO4-RG0LPDR>*-\Q!:MJL2SO599D*M/!*VZ/'U@B2F$R**
M@@NUYM0+%W9U-7;CPQA/,8 @M*0O+3PLNL&D6 [!)??&]SY/=E%99MSV(K%K
M\ T6R5?3-8[\]=&'N9R/YS;-1]K[U0U^1&KO#7<.-ZBU>V( %XC_E_92^ /_
MOUH&Z'[#..4_7CXX;2A0+6$ _U?O*D+^V(*05/OYVL3KS]2*I0LM#. 56L97
M%IE8Q,3>*L/Y==R-*B+O3+H^?AH'4'W#492L/^RIDF%F)_EC%3:A^?SUM\_5
M>LOOO+1K977:)"7[D6]#&I 5R0' _O#8->"Q844&Q#$/Y;]"/G"H\?25*4[2
MW7@9U,F^_P4,+T9Q80 /QK'/#> '(X2'U#1[S][7.7K79*=C "$>,.-3ZHHX
M%$X45MGG8$^X_?U$<62D>.Z,4??%]R%K8)@A4AL=4L2" 0!,,8!%JY^]5?^M
M]\^O2=8@O_6VEOWM!"@K*];: UAV\7DLOZT4#>R<<U>R@(=8I;PN3O)VX+"0
MV_<;"Z_>-+,@/N]*$<)2ZR/8,UJA!B/?>_=8D]3*!:_'*W%UL:;[;7E'BF<X
MG8GIS7S^MX=:_6YA<>C?#/IO]I9.E%TQ=NK' %KJX"7GQ'H*: "V'&X;QIZH
M__N)B8=RC,.[S/\;8P^ _SD2EJ>(]EH@!SS60"0>#09PW9"$TD6YQH<3W-VX
M]&^KEHVFF@\!K^L-R\()^-"WZ^@Y5I,=CYY??(G<*?W[2 HH+@@1!C!8F0->
MN&J,4G$54NOCA6WG7WPV&.OSSY$J#KZ1/1W<@9)(M$!;"$QWF JYZ)-NX+9Q
M,"Z0^GTYI*Q-G7V;WR*1XY(!+_']!\C6)%0CI)B^@-2@2O!A$#%#U'21S(16
MS<BV'G35\VK]F):XD2;^_3M7$5]@7C=>DY7;]8/6]BZCKM6'M;M#NZUDR+]J
MCO%5:B+D$YR';22B14D<AUK93P5,%&O455-OG$\VB5]-?: _^T'SXQ+'F1B?
M-'E1KF=GDS\K'!V4OPXFBZWDK;06GJW*<,B;DG/,NAWS4F$_YY$VLY78;"#.
MC71!+2"S)ST0=].?9ZR1WL!*3^Z#/8*X2*;%ND17=$_1K#I%B[M1/Z'>"D#-
M;E-.XH"# H[YWER,NV)\7M97*'0.F#2>ONFL=]Q3%=<?GD@GKP@0;SZYML16
M8.H0)I& (A]OH&>O1(]\&]DK8DGV\;JYNN].X;Z&Y]E/>2!&D/K6(9L_1B+V
M.'+J0']=5 <#",9[A% (:Y"5#2UD'3WLHN-9"GL2,W[C9I+ACZH9^<NA]VK%
M3?.L;AH45(BA\!;Y:$#IS%_AL\$3*5+/>ISXAY?TW06D/E.(<NTG6C'IVS_(
M>)O6'+B+3&V9\!XO6NAYQQK",E1Y^ULM!07QS?+:H"L!SM.?'O83X*R)73IB
MIJNK0L85>;Y*OV[IDSNETQ&I^HXU5#_/5)X_D/W)B_28IB7^OD]K"F7'C52@
M(WU]5 _P-SX1@OQ.,(-#6$2MJ?Z,:_$]I+8_%0:0"5+$ )IHL?7GO[% Y@4+
MD)E??)3F,O_[X.#_183]3D<V[6&!*.E<0P4W\TSKJF3^M9>#>O*QM?B,=^D8
M*63IH5FQEC,V'ZB_<.T*7+Q925EIF;&1D Y!;6;B5VMUL5S"?RW0].%E0IQW
M[K]%'Q6EB\S"1HM>37:_L \8UZJ18]B5.([$^M.Q^E6UI1$8?WN ^TD8D/<'
M+1\A*_ESE'(^ZBX<$BZT0[KW%+X/HDG@!IO$$CM(X+]TOZY,=S.)6UY^VXT%
MWHO0;F8"M4,AX6[6OG;Y5L<IP6_\XD=40X>5K=2GJJ&[UG90]4>IN2]B:P0$
M8E-CW)&&BSUQ-),&,WJ>7@>MQ9V+Q/7E+ER&.9"7/Y@I'Y). ,ZGE/-_P%,)
M!/6YW-ZL*3W='1TOJ7Y8VCB,9MQPM_/P <%\]!]5B<8X2;FO1Q'<VU>2LEWV
MG16G2G/[[,M2-GQP_G1QJ]G1NBZB/7$Y7H];E%7D<DQ7Z_ZK9JD)82>X<=LS
MI*IA>57=UWH(:%I'J"+>O>I*KGX_:^1D_]?ZUALD'!0=N:/;YB^:!-:0'@O
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MUS\^@ )*"4C'4$J'=*/2(*!THY)#BH THR#=(" Y=$AW"M(BW3#DT,V,$J/
M\!ON>-Y;[^=]WGJNW_7]8\]UX-IGG;57[?599YV-\M$Z&R1"VFC,'IY!-5"X
MEE=Z^T7S)6@F?B7P]X=$6<[+K#)< B"W4=\TET["+B#[/,P9-XX^6T<&Y%9N
M:7%R8L5\"D%[PH.3?.2WDQ3D@]7R:W8H&DCW5Z,'):!3:I]XQ?P%<OD4X8@*
M>CT6["%.$10EWB>9(QH$+^J:T=72^A!Z:+6,M[=23!Y?*!HC1,>/^L7*RZC%
M2F??.F>Y,WC2IG_PR$8XX,C<ZA$^T1[;+5JR!=;6MY<:#N[SUFX=.ECT(!T%
MFY,4VJ]9/M*7? V^V?N_5 EGM[U6$K&JGD+J]W^CELT0,>C-*0SLN4N/'0";
M[G+ EK+K_*$070@:DU"H)A"Z=: 5=-T$@Y*YH2SX*CZZ7 *8_A&(8N$0F&XT
MW+TCY^$(=,/.*KV,)64_(2]V!B-.FVWK@R@=>?.;?8-&B:WALLZQ^#R*$'^M
MNKH#- EX6<M/$<U%%9X1FFV<&BFA6%&1_BXK<6J6^7FNOX(V(3]&;ZW=$ZV!
MLW25-.8/86=1>D]&\U)7U ,^E&57/K#+LR4O+TCZG@^RJK9\Q_O"G]SXY%MP
MJ;WM(MV8VR'7CJ%E1N;SX:230G*3Y![G!EIKK*]DH47;3:YMMR6EP&@9)!4_
MR+5];#2S>N'*KV8QU@<YH1;50T&G]:!1'<JJR=(;.+\$>M9?=Q#MO^P@[BBR
MZ9]W$-.?=Y#"@F'T9-!_3);Y5Y/S!O^<'(%W%>:'5L26X2<)^(BF/\*\/RXZ
MS+\)V->69ME.<2R%S>D+J1[NG5E.'C6.V5N[(I;F^O#!<#%-0;3#3!L8%W25
M[SDA%?;!]2VCEA>5>9Y^&HMG>B>!;;,NJ&'(NO6<X-VYA^_,*043(B\TY,9K
M^UT#-"OJ)AAU"9F; BT>?WHJ3$G_0D/Z..EOR.CFQ:BJ:G)ILGK:G6+EM%\W
MQ[_+3&LCR?D_*6/D_JU"$O8OJB]_+Y&0_58BN?H<>#7]5U)Y_TGU)?)_7'WY
M&^F<GU7?Q/%;]>6W[\![)7ZEI/JO2'->^4+6/,T_]P7%0@_>SA^U\TEZ3?2I
MGFYW10:E<AWW7P/ZB>,_8<%+4]A-#O2J TL="-'F-8PV+X,_&$JZ<EXOM/B$
M<JU1+7\D'1#!YO@_K/'_U>3G7T'_7XMKMD9F6!XO>V3OU+W):V>\1A$U)"0J
MI7"_] O;AF]/4;MM=@@L2,)C2C1'?]4T+ P #%26)[O[YH^3AWX=6)[;"H0N
M\B^H-[MC\\_O.^'.(,V-IMUP]V!M&=XXU4H,808LD:I49<S/74C7.#+N[6K'
M>U-]<0YL3"]S/_\QFK):@N+RL-(O2_FF7S%&O7!PVNM="#WXNK_&+KC$4H+)
MWN-^2XM!5*O;W,3'"SZ9'[[Z41U<JX@3$+0[.4=E]]9&UR8W@% V-^P3XYV7
M+PGO:22:A+H5E7K&;AMDZ@D\0Y!VHJ%"?@3T8T)!2!EWXN[9S8T#1C UO^/W
M+'PC!K<>13HUHQ$?RTSD!Z.9(Q,7]<G%+QIW=R3P&C9L@) XM9)7]72$1-@%
M"2?<ZKQ6CJ/RM\/_V6FV-$VMH(L8%*^LVYFT#_UX 7RJT=P*15LYSET+2IS=
M+W/DWH/O%-,><@2<>.H+QF;_5L8;:W9)04Z?B".!ODYP)QAVA8\(S.1.SNC^
ML>R*E+B[@^:)V#Y5W(VDO;Y:9W''@2JB!0#VJZIM,CK'EU,)^K5[HX<_-'JE
M!+K\@"-N:D2R4T)%;L7*9?LU2/)%SD!B03LFF71^I@;^@,@9!I(;JT)9%YE<
MC'">@I5]HTYIAI&:<-&%;(J'4YY_%/$RKHIXI%=%/!:.ZIL96$B9#TC9;GJ2
MMC/+5'W0#XR*MKJ':[6'20[ =&(._H@8@$O 5\8>5=VN)4(W5B1SJ8>@AMU%
M@7?!DJ$BS\E7V<&-/9;](6Q$&OO6"P*MM=8@8H\D[Q.P'P2N=F&-AO'9'JF=
MBT#(/HEMREI$(J*=V"T$US+)IW04X];GVZ2)'',/;J[;V;21,$ZV&/ $"H<6
M@P0$709!;H7R)/+>M/PL+UMLJZAN8\=)>A:F!F V!PN)A)YSNI?LH/";ZN/(
MHA4F4D[6E)2X@H8V\.]B]#LF$XE2XJ0MTZH!VU&,3J' N1_I&<$%W3=5<>9J
MBBQ$Q-/D4.L\S#:?'MSJ [;$<RG38##ECU;6"QGM3\-'CE+8LJO%.\+8,C'_
M,HA$IEM%;#* U8C2[L'$W-6.Z&ON('PVP^4O87UKZ_#Y!N ]XUO>3S/"SE8H
M@EQ+M;?=6QG']FJ?V$_G=ZQ\96FX!1@8^VY9;X]!F=@#T!HFV\C@1S*6(,/U
M$=P#%'7WYFS'C;^,?#8Z?3W33=!Z"8A9SAVM1F3@[GCDM[73:9]K0XRLZIO&
MRGC'M0142VUQI[YR%[Y6J&/K6!AZHI0P]&(@CQ"C]#NHMG'CS%C.8II[\A)0
M\)UN,0 1W9[!/"XIXHD3*EA(T\57TN10VGW$*=6C=)U8-GV@Y%6%,2R(O>FT
M1P/; ZR.H)M?9!D[L(2?\PKG6-MYXR>1GZD+H[U'O^XV=N_ _7+&%B3!:O,N
M&*_K,*?W(LDA1^ZKT:[>XP^U"=/OUW)?[?#(A7S05E<*#;>GK18J:L5 MJII
M=/OC?10>?C3ANJ PA4N8(S6@J?9B?7**_9EUU?40?BZ!IGORTJ;WH1?I$@>*
M]5W[>\/FX#!ZHJBO$K(KZ92FRM87V8E+3N&#WD]3SY=3J[2>LKY8I=VH%N2-
MI">9:A%L91:?C()DIG)Z;TPXE9?FA-U)3R>C#27LP0]4WV-WO%V)3S%<@)19
MI=-:282L2-2-[9?L'PM- #]/\2AI.TCM+Q+;5RCB1U2),;D/1+S7? S($C0+
MR. =[0TZOD<8X%R\I>OE0SRC["LR6T:_R#E#F=PZW"29-R9>G[C$7[5*Z27&
MZ-"[7RDYM39V>#1Q/&=& _(**LW7UU<1(B[4;\V[OI#*E;AQ_=[KN4Z7EL_"
M^T/WS><RS%60H]AY988&RC!?=XWQ0R'.2(XYPX8S9D-59SR5DH8H6-[CGAN8
MU3TYHD,WR*QAP_ZU#GB:DT)25E)WH2L'; ZPJE&R*2A4"&1IB?&ZGXHUGO^I
M9ZI.6):$(DD;YG$;T<+L;@KWFKL?0[#F1%EK=['M=!PHC,<BK5OP1?KV;41)
MF+3<[S6OMUG50N]V9Y5Y=;XIK)_N7P<YW2VT]V%>D;(=5OVMY*4[\$?%Z\X7
MB:MH9J^ILHK%<O-0J(U<?\M++2./(6YEZF!C:NKN:VR680Y%FI>*_4G7,C*M
M \9:D@PO4I>TJUO\I0QW*,(?5(R5U-FZ/Y&73-R_Y^R);U\DR>\95D)YCV/,
M',0P[;TZ?*T?@==.+BYT$9727K;'VEKY/KF46K0@2ODY581G^-NG(DQ!JQ*>
MG7&!D_YIE;15&X9S&IIT+BO'=?$N=_+R TKLH/X[;;-XUD^Y1]?>&89G?[%*
M$9QAEE+%BHV@SQ]^C6+?;I5N:*OW1Z=+JHU5D1:)= JB(]]8*ANNT[V9Y>+/
M>;K*'J.28-Y=OO<-1+!B:"!KEX5\)4,L79;H=7T :MY-"EJRYHAT6']GSJ/_
M^H5V6H:SH;0PDN.4VC3Z&8SJV>AJ%-51ZF8&B%I9<#>1X*7N0ZJ,U9<X>B^5
MK5ZJZZ_5"-]1)2V!J*</EHJL*@07J<$XW0(>!VUV'5P"G@>I.K\+4>0J$LR]
M1YP;BO6N;WXA:=VW7E($P<%+:C>F/[=E.*![;8"[MH@QM*0L0J/J?AZ+M6S:
MZJ <04W"@A8RNOVKK7B2_UH%^<F4%WGN],N'+]L:S^@&,,P!Q#'CK+3X6,,
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M+=M^M+C-?0*A8P?0 JZ<:\?,4WG@D R*( =R*A_5W-RF,9RQT?(5[ NE:X)
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MXYP1H58?N,=5?M1V SEU0'/Q<&^P2$,J MXRGA2T@?<N2#?H<>X!;F8P0VZ
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MMCB(Q18CRZ+H)L(>?E9L)K\R2*+*S7C^40'FQO;HE5J<\$![)=7G'AK:L&]
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MF;F0++P4J>LIS0HR'$R/>#[I&JFR>+ B%38L6?Z<B>#\D<K]SE=\UYZ2B'Z
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M7KT^@HDC#=!9\B$N>-FD'#D=< GHO-YV0=B)SJK-+EJCD4_K+P%9,^#EXDM
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M]8CL?7U,)<TT7+CDP;<KWG7*IU& K%A\0'&BC>=$^_*AODQ&@UMR2^%H=LR
M2,7\NH<3UOFU:6Y7HSDZ#=F)%-7P=!9;")2"^FG]1 9G5]P&3'>*Q5,[\Q6_
M,42H,X%-_>4[LGK:2C)>2\+-2<9P5];SDR*.NM3\V6UJW]K(R!)RW5>C7'Q&
M1CW,46P3@,(/V&3W 0!1RF+1$HW[AK\>''+599J3SQF%..T&X_G<$V;N:H*<
M.+<NG8"//"V7JAT/&PHH%S\Z3S73NAV7BR";X2*RR '7G))%6_("]6\^Y15*
MH<T#L\VOUIP.\,WIMM-FHNV+9)[&)ZDFF\&G@'AM6Y8R2(P_.^DJD"9H(,6.
MSJ_PKIH\(>=\2V_:MGA7@.>X 9> B"L8*K+L] ,/&7P)P&2X!*P*B6?(2#N<
MQYX-5:.H.V'N%_AH[ ?@:4-. G^F7AR/)D\#%[FX?BZ+AKRWP(@4&5C0.<$E
MX $8C>J6Y8#G5I&R$&&4TL7FU9'\S^#-J" M=&Y)\=N[0#NBP*4C?L@YX*I_
M5 >=_7<2(&E0_B@T?/X4(H,<!,([_;#1N69;"!C.1(024,@:3@6S^'U3-;DH
M::4O*X)= BIW8I:,:G<OZC94V2=F'W(7,%DL %GZUGL#^[I*G%\[UX#1#YF_
M!'0_ L,Q?VLD3/4(/^&%'T=5PD)<YSYZ;0Q]>^SA)I9BHUQ73YY$PO7ZNRSH
M6]RUOF$2>K'/5YVF=%?+:_ES>04C(</"S:?,I^EFYT+!'8<_J#10 !,PXH/9
M_W@U6D4^W^N_*AZ*#_]\JS:X4]^'!XVYWZ$E>/VWCE,-%*73IZ4C"@01ZMH#
MM-QM_B9V(4*?N>]HKJQ_YDH&5B)- 1[Y\N?B6?^F:T'P+VQ2!_^N^OHKU3N!
M28&_OZKM1!3L6\)/9&[L.N39OM@U?%^5!MVN%];#HYN8(_RL7_/L8?4S=25*
MQ]IT]"/$EM% ^9[3GR9PU4]*@?16A.N%\+;(N)?;BN_709R%(=8L(U6#+RKO
MA?%?NQ\S=-N<66R'(W$K=%AXW6_-[]L8^&?F-=$2_9\+)EUU<[ M3L9S\O>[
MMR\!-]A[+SRNA'-43K1[0L\V:G]LPN_L7K"H<"?H*2Y^0=KR:\61-V'P<N2S
M)4PT\C'JDD$2XUP"J,I!<)F &K0G>)AIC+A6LLZ4Q&13A?#,LB2R /B569;-
M[R;/!28*]94\TC1]M 6RR0Z8N')V,6Y5S?$<) 1V1L4E.6CH"]3,6#P''O/E
M3JERF<&%X] V4:<SI7>O<)>_$\'\<"PH(Z[3+<^60LU/^S P.V50E\&7]M$
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M"MX8ZCE((F\H8Z*[Q]?>>CR7OU(S)5LS; LW7S/<R >N*3 /0N9JL7TI'@;
M"SY,*?,3<M$>!LKH"I<=B>*=!TM>5@HNUC-G &KWHF<(;]8":R@M F+I8\Z:
M\FGXAA)MV\56G;F+=\/X'V]\T+]6;]K^.J:]+DM"9@"HS]N&I5XKLZ-P9V].
M6$"$9F)@O2\0W*$>1SYQP;36P:[W-:=H.[1=H3B7A2C$>#U']89F5/L0-"M
M6#/AYI4VTCI>?H3OODJU$R,8&A9K$IOX@06Z&+>FOF5:I!52)7BK:).]IJ_0
M!C(+?3 1:YIB@;@GT?Q)CH+F YDYG<S]TNR*4A^WV63Y!IA9E:4#6[RYM25Q
M7G9V\OZ]])B:? %MXR=>IJ1/#9Z0"B$<Z,.\RW6<$15L(A\$DN'YC!FSP#,
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M"?_=D)>>##6.S)G0Q$^!%XK,7K?E\OI+AIM@.ILGJ5''VN";:_LPJF3X^AG
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MVM#L2C OA:@A;]%Y@6Z::RP[']?9J2?>NO=8+5PKA/XOXMX[K*EM:Q^-HJ*
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MKK^I0J@WQ<R;?&VCY4:"D,'$19JJ0<;"[(;00EU"276+!UV/1UP&4"EK[T\
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MQ+R6A<!S*5@H[<CIV@0XC*%%E)]JY+<M(-K4RP$;[-]HBZ$X#1>:S^JY:2*
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MOWMTU[$TGJJ;W39N/NY]N1*_N24)YOE4"OF$OLC$$$AX\,@BF30(M,Q_7*S
MKY,K)SX?F'0AP-_!UPRGP*[3DM8%5!)CT*).::LD-++H]2?Z?@((RUFG^[%D
MD$8(AKSE!-"H*3(U+'Y[R+OO)E.#:ZQ:#Q=WX84%E$@UR$,6+^8-II/S71&
M2/FK46)4K&$->_]"#Y91J(5UCW6O^N*6#,HR-%^G7?J@9EZ$!Y7GUF3_:,*@
M!\;5#T]3C8?<&%K.4O25@IC!R\9/ '$+$\QH%EP?XS+(=6POEJ\G<AY30?<4
MD;_^)N3^UUB5J+"O^2O DMV1NT78GN,/&!=3U$',2/\ZY3>BXS1S7!.[#:6D
M -QY"A9J39F9<W93L#"=Q8"]3C)5^"Z-ID1Y_YI9/W\EE-1/=CXZL]PDD";]
MQA4&\+?S@M]N;K\R ",3ID\ P=X<*QJ"!C>W['KX4ZXLJ8Q;.A^^RU+2U5>4
M9 RH?]O$X2!65?])F?<#'\FX(J\]=#ZKM2M#^(6J5=+XKB8$WAP>('YS.?G&
M8&K?7O<(J,E=,$,XM\'\DVL8_,I'#1&U'&&?!\\DZN=\^'3PMTCB$6J5AB-4
M+9<F'[LH2*KD?RGNC'A8$5TVPTOL=[OHI4-]P=,SM$P&=/X[M(#_#5KBQ.E=
M<1L[9E]/<U^S."Q!L\PH)"<*Z$N,REY+Y*R73[D7?3S::5V4U>VC13LUN)IF
M?[=4P"JA7,%0=Q0I @(.IZ@/<-ZN@J+7D7@+$R8W6D2%\Y2H@QKNM$O:7[Y_
M@9HR!4MA?AKMI$TB3[WJ2RHG &35W-[J9H"*I_M+BS)QQI+^?*AS/[8+:2"?
M)1;Q65PM1Q.<UK0()K_3EXM3):5W>Q-F+CA(.8EE/@%L)5PU68YIT#8D<DMY
MCNWIN%+7N>@YW I< ?:BWHWNF*4IVH5N./:'XD7-H<!6@QN'%+"M#N'%GRUW
M)H9GZ^)B0^VE6<5JI %T9MFL"N1;BS"_J4#.&CSO SAXH"JQ9ZR?P3*MUY?-
MQJFDF$P:S=))@BZI!T['.'7!MFI^+![TE4G<TUQ)^2"$,&W2T1-T\0E &SJY
MN%Q6QU 6N4#S)G<C],'WNN@">UP3T!TRWUVPQFQ3/+BX>R;X'W!?IU55:R?G
M7L ;^K,8TZDF.P^(K QQK4N]:"<UZHXS//7-,_0:%AL@=C-4%E,QHI\FBDG^
M? 6OT^[_)9FXHJBR-AA5B/A84FXB5T#6Y*Q _62TS._97?R+UB8[I;,9SD!<
M#$,>6LD0[9$IES[Q,/WA=.7&A<YS:L45T6#156V^?:W6\%NX%S9?X+;I*!3H
M>0+1YM,QMO@3$ZN=+DY72R>'8C73%289JPL89>G=)-?NX7VPY<BM5(O567 I
MAD2\L6A:F;;%X'=@O@D<)Q7,A7WIG]T/I^24>&4V.7I]O9*)X*6TL^>!E!F5
MDH32@Z<L:XA/;1#.($\7]!M$A'2)G(V 5LV #$=.DZ0)._&+*S3JE;-A/HAZ
M=W#-">"R$PU]@W*5ON#!#)D+W.&!0.E58U>*9#(IP1DY;9RK@5'SA5(2PH8$
MKAIBA+/ $ %\+V'96P.E2??G:TW,R(3PQ3:F3( _$6 O5$4N=<[Z93$77JN=
M@%=^/0'\ZB;(_.Q'G)KD6:?=JW1)IF=>@S V_>$!A QKWCUYZB/\K&EG25L+
M?W4CO' .>@_Z4/V;:-P!"PCWF;=P<(2E,-0[A<?T=WCPG,$#.!V]UWW(14<$
MVS(]C;2H"C] A%E_O6O_QUT_@6I\BZY>0?-+W9TB.)?W'5=$H_(HA9!E/'1;
M#B2X-'QI[_*5+\\:DG/8AP[[UNET:+0%S%JH:<C;'K/;"KH9-A&^%DYIY/2>
M5"E%A\YT7VXB*1Z%AODZ%TG.B12]]<E:%'G9G18T!YN.$9@\Y#P!_-VU%VP\
M02IG;M?]:39%157=@Y*%X,)7=,;^ZO&SJ !DS?5E&<HWD:"8E3(WY:'W[[YZ
MYN7O$'W!3<W7.([92\KH;J$+J):YC^T+IX7M=!5AZ=%"^@,"2@'PLA&F^:;P
M "X3RXRPL:2O\*]7P"A,EJM;.0O-%YQD]HPZN*@<75A70)GW+=>41G:'A7SH
MEY)?LQQ4VXUI5BXO1)=&S.<XV@Q\6/>PZ3+!=A6Y!G6"E5JZ*59BRD\ %==/
M *#1;[$B:3N>GP6?EQ 1AMEGB5VU5#CB7]$HT7T(;+$-N*[P8H&5P4N#R5*/
MS2@'SR0II_-5U-D;Z'N?>S$/IX!^[@U:33/Y9,J/R(1L#+;Y95O\6S6D'>:Y
M1GU'MR.@,0+68 GA8Z/N)H0S7^?4*.1F-TE9JFC5DWB,)J]>R_V^ O4AKSQ_
MHH.\5RYO$X9\161S;3S8+(SIC."E2<?:O9 &CM6DNGM_N8]1?PF?'#(F?:J?
M^G1GO-V1)??6[[S=4J%G(V4_>+LN_X:WR_&#M[N'SQXX+MY-;_C%'$0V_%)S
MC""&[Y$6W_5'-_UQ8BYD=\2#H0[Y?:EM%-MB!@@3EQ- B5EZQE>F&C02>1Y.
MZA0@)YY[@\WLV:=*MI!(B195)1)"#%]G]W >%^[ZN5E8R61Q?B)L]/I:)4?&
M6^G1N_/O;@CNX8CO):4N8YEA/>I2L&";QW7^S!_C9\9%N#)C<Q!*Y]NO$.6\
M;/PJWG4^6S%4O88]"QUT9+!U&TE2_G?R YO)?YO\H+K;T+4A)G0PN]9STB'=
M\'19BD2NXYX*C].)DB,<,$C/=?92FHK/1V7+[C6TJ&<P_#<W?<603FMR"7A3
M]&&!M@XZ<#X2\3#N8W\,RI6Q/.@8"P^*F*=HU)4+?6#_KQD0ZALL9ZA&R:<C
M-^ /66L"AFPD2 *WMU59+I P/;Y^^6.&D/DW2U:58$@UN%!HHAGQPYK _K0F
MCK!?34= 'AW)L@'S'S1>3R?!_TCC102)BLP$_T'CS?@'--YX=X_)E_;*B'U;
M)4$9KR..E13CA'4(%?8V%=B_<P=*7D;2TEG-,TN>)X6F,OZX0JGH!RLU#\[;
MM$TES%Q.UR^3XZ)O:7\>;J,M88#G<Y?]4Z^MP&CA, IQ9-5WV">[Q^ZZ"2DU
M3Y:)K#>46:P44ODXH1E5 T[R[.;P_'8P,5*LKX.&--.R]PND7 %1[C5#<T8,
MM=O,,P0:;TH7U1?%5M0',1"\K3;2E!3TTXNA2'9;_32.1RF K\]5F-VFY]W=
MK[/L(OQQLI0L+*UO_9'?S*&"&1&!N#;[;9=AJ'/T,X>>U\G141F>U'V>4L;'
MT$QL7]V=@?7;[[22)/L;28M;J(MYSQ&^__#R6S,P]CYC(=1V C1A_A5(B99S
M-"0JJS"!,\K"IFEAVQD:U<F/AH4BYNOF3.^0!-X'F/2A9^64@G6BU^=C7N4F
M79M:.O2:@O796&=4#6=SA!YEI\L)-E")N"4X8W>G,/EE[^8'L8\>)[%[?(:/
M3RR80;>DZ:[I3.BOG !*;4-V<^7OWV#/WG1:=57%?4:A,OSN(@>%+&XBT=#@
M$=UPU_[3(0ZL./IPTY%HK# B]^M1FM>$WNO+WM(C0V+7^E_#BVU*(:0/9W0[
M930@URT%1VQ*>Y5R+0YE1@NRFI,(>/2_7 YZ]J7>U(CA[6T7O6OZ7E1?RO91
MPED-U9;61I\';CZN(?LL<[Z>=(R\+";T[J<F3-G(I7.\YT*('C^-U.'-[LL0
M[/>-/BJ)L1UF5P-]VM"=56HDK0REY'\_V52K'A2C[%GS\C$;0UWOTAW;WU"T
MND0)%&X958)-N1S+$/X1W2YN_H.(&+.$6?:PW,?@[E'2=:!A.^+>_W+1[XA=
M7:+K"N\*!XN? %YZ2?MO8[DQW2FPWQ;/]%_6U^\KY2'N3OI.^ED?Z?X,P/]I
M%Y=^68:W:G%0=G!',1>% 1-TR^RZHHC(IPW*YAUE:;\I!C^>5D'[D$N7:4)!
MGNX]NYV@(\(C^9F"]*V.]AV4UVNUH([URNV=ZF]'HSS-PF[^\%H'B]F1FJ>H
MH.-DW=E^BXM.TZE)[.LT8/'>!;<ZPV-^A8KM8^R^%0,+&_-P1TB6,+EV'J>X
MI66ZK6&* J' "> -60/=KI,W_0G@:UK_][K.OYQ@I_MU'_LOF0NJ[I\ :@_H
M;G<G0GJ((5N"UI"O^-/AA\(P(LBTBN59[>V?#TG"_^<M\L!]V*W%+N 2'A!]
M.N=\YMCKA@20WD'TZ?_Q@H%;^9OGEK$WMFR#\IR"PT=$5)'4&O,[F583C-#(
M$7!KJ]"G+_<X*QP&I5Z<^ON;5R!_9D!P^:7'&>TKG5@IZ0('T@QJ8D?LD=AH
MXR1I'9DA*/EF\DZS#O\^J<Z[J.$V</:CW@:>DLJ0FD9!$M%*)KURJ@F>@:!%
M+#O( !_];L1PJ.X^X:5@;B$(ZA(,3#@BM-825Y&X/F2'/=+T!9T /D]M88NF
M$ZYX6IAX.2B#Q5D46 +B.%DJQX93,CD#9A,_K\=/G #\7>5/  ]7%K%?:&&H
MB0S6YDX^2^.2]NRFJ5E;)!7=E@_:&!M6V&B(5M,Y*^#^RZ'Q&;EWX3=R[\_)
M&N"))X )3)BWYRSVY>GQ*]B.('#ZXE;+,8UA &SK4^GW*M^_'K?\VX0//W./
M4XXFWSHLTNU>I#LK[ABWY Y9&\T^2V2@A7%%OW(Q%[Y"GSRI'C@;H31N^NS-
M=:^PJ[K? 0%9*L?\"8A:^6G(*YD&(&!I@D(>,2"=0A9C\Y'JR9LB(^>Y=8I[
M."R <R-5*PUG./.*IJ:Y_S0X&_]Q^\JF=Y8O&H*R/<6-QQENFF;'O^.&MGWS
M-]RX*S4]3 OWQ7*=ZO+;;Z)BQQ'. MPEB7(H6R;,.&S=>CS<?:7LF$<OJTGA
MJ4*O^!^Y$#X+ET6!/NIWNST_ 0#O<G!UTV&N/#!LSHKKS$VR>L?ZX!,[=TW1
M["1>]ZPMGL$2ZA"5,5U90.#A),:L0O--Q$13A-SGDN3Z?1IR1,29WP7[(PIH
M__ZRT*F%N#3]OI0%R=W=57'+PJ84X,^10OOOD4+Z]TB!<%IF4?TL5. [#"6<
MQQ@>I  A__FF1:D?KQ5_W'-JXQHX0+!=7>R/F_1M3\.44Z>]H?NZ4K8^1AII
M'IP6,YP/;]&OUGXNJ4\N"U#9"?UHWAOJGL0UHICW,6]8^:OJFW=I93OF;-F6
M5=:PFS7 3_*0>:LM2\IWI/![)P!]@BBMTC[S8[\PDA- &30<J3L-/@$T9O:+
M-\V&$Z'YM=T23@#3=)5:WKTP,]%OV5WC_G2;4- *9"AEJU14;#$.,GT;VS)0
MUWCN>'*X9I6[U.;4LX8,%ZU75=76#?%75EKWIF?FL$GKZFT1_C-KNU);>H2]
M!/P_,]*_15@J_RS"VH(18CL/N_P++:M"4LAKO+);S)UH&H;U5R[WC%UXT7S_
M4I?*RR\X186RZ.CC %$1*X$=H2%(&7\A=^O1I!6VI_R("S*\@\D[,JO*ASW1
M9$,RJ/:7IEP;Z<P9@ECJ"A9EU+]=I#*+Q$[<,SF=:_L:>T@]F\-]J(/48^)G
M R2Q$YKHE"GV[H!DNK+^?%'U?%=IV8*8Z4)'MD8^V50:SV)9(!O'-3$US7=6
MAB5FJ6G+^V2($P"M]RVM8=WF/@4'N]Q'$8TO3>.&/@  A*+G#!]]6O*8J>@.
MB?>"YV]E-<$UE+OMW,2C'8AY1F469+N,;DL67%-4PKF4)!P9FA:7Y"EV/TLE
MM]K%/ BM.94/"\M?3&E(*?4/@:)OV7)I\]=Z3\P;&W?!6;-PA^)A+&N;#J0?
MXQVP/;2BX<J>UJ5@(R)VD_ODDG%S,K=I6R?\:;H#TN#BM W3\G'0\)NNF7V<
M&C(#+/),R5.2J*@[[ ]-S]L^X(X] 7"T77S%>"YB7B/Y*A(2M(GAV%<!Q0OF
M"D88E5@5,Z;IBD28YESM9KYO$JGUJFW1W0_7F5#R749^MZ#:\H-/5>"ZJI+<
M4W701CP (CVP#(1'@7]KR.GJ%OQWL)3U5<S8 .GBNUFC"5G4U0?A978K1.KW
MZGRT>W,@T9ZT'6@RP5=I(/[BHMNF3[ZG(= /&F=M@K2:'%T6=-$D6BW69U?(
M:V"0$U4^F-SN1.7<]3^F]CL'#,I*SLSN,+8U]B^VNCJQZ7)L97C:MM:IQ?S5
M@7'Y.>28]-%L+I]@*E.06'VQC)#C#DS:>)(]5UKT?K9?T:Y46O?;]A%O2-AB
M#)BN)5[HI8WJU\W&A94CR5X;Z)7"Y%\^\:A0I;V*\,.-(6GMJ-FT,3&;ED2@
M; LU>P;KCN/V],\R/12&P:[GKZ<^9"Q1R'F43?E2SLSH)>"2O5R3'.$:+$]/
M,K()V3W#$5%!D%>5^.BZ.W7 \55[=U3*#-LOV1YD_\SVX/@CV\,";Z9""LCH
MS<V%5]MGV1Z"9$4%/C9Q@,^R/13?_:)ZW81H+X.MB]TC7C55\F/\G*6VDWG0
M/S";5^F2C,^LIHCX?_N"I??L-L)//5C#T^4N;F?_?_H(](==QSJJ_'+// 0?
M2V!E> WS0#S#!4G5E,SEIVM6KDOCO&[F>\7Q^:US,EV"$2G2 BFSW2_="T-%
MU;WR1CW5D(7^SRMYUOOY$^;"1FB*<FB"E",B,\+%M!!%RA6S4&Y+]AU*+YTH
M_Y*RY+Q_9 '3=[+^^W5#9E'F[-/2_R>SYNUXYK'CK/ #8Y&0!<_C?WTTW6^M
M(WJ 271)ORYMWX?UTSJKL6L[G*7=Y^1!M2S.BY& R>L&+(#DDQX0/+WXK(G:
MS3.[F;"HT/G8$H@G=KH\ #ZKW:R%D6&-@G18\\*FTH)8 :>_<VR\;#JY^H:Z
M0WEF,Z[3.XQ$+.^G;(Q>$+M'+4LDE.4E(E\;D" KEN61\E]2MI*8HC""(/;I
M^W"\$X!9Z$,>-Z#EY%&=\4X-C"]TN*6SK#9!'L$A4)$9I5A7#@NC2![1*(LS
M(6KW)Z2ZKDBA=(%6QKVFG0IW.R=XWOW]0'AIT+Q7W'96(R30P55$<0OLWS!N
M-?K5^U*M']84X:3; GW3214:@Y1W ME?,*&@()8F&00$O@0(\2#/GP#4!P7D
M-IV:7T$]0O&_\HZ+Y?$VW6QUBF',>9RS=+\+KBQCE\R^SIM:E%R:\*";QAW>
MFY?>,Y-\[2EX![9,:%C%*O!0 <X!#<B(5:HMKPMB2YZ0X\S0/M\:HMX3S4*0
MA_?6[0(E+'Y13.#SZU?:+I2..]_ZF M=K/.D&4)OWQ%/2&?9RW^,MD4U8D?Z
MQ6^C9_7[]O5T'DP%.*XK=CKLC(YU.OJHA"';BX2 #770+$)+=H,69O;K6UN+
M\Y4HB]Z"PU"7,]J!\PD 8Q6^I@L[O+9"M[\Q>0((07PK!Y)Z>IP \ .6-$86
MHM)T1R:743'"5^<.8E5+(_DMS65OM&N;=ID>SRA1RLPO2)PO I4!*6O4ZGB+
M" L%)J#,Y9^TK;QQPIJ9P4"E-T^,J_3N?)/3F@:OWPY3$L$[UV18%.M $O9Z
M'+CZ<&ER3;XF')UL]:/M/HCQ^#H=4@SV9]?J!/L@EDJ4*P;42 ZXP1W=9L$J
MFN/05:;$8MWCS/VVBM#TL%N!OE.-S1HAB[Q1_1G(Q4!1*?Y^':L)X8%\#M'[
MR&OM7Z!/:1)QU[K!Q/5=GA&T1'/U(A)S-@1V_FN4SM:^X:\U52 (#,\>E:40
M9)<&MGS<X2UV AA\VA7L<@)X,/X0BRX_J\N^W96"?*K=MQF6 @S,QQ"ER>6X
MAB+4ROK7E?4G'KB3XC^LXO1-TAZ:]AQ^3"UNKW0/8D$8&.\7/'5 U3ABYBNV
MZ <68/?(EXLDRC.472N6+F)ZMWY?3YK@NIO2T3<?>\'"9_MDJ%"QO VOJ.-0
MMS\:/AX]=8#B TL3.AN33B?C>#SF^XRX((6:N&F6DSF07M_<,<&@5->$!_W&
MO:G0\KO=5T=&\Y;T9W?N6VJ_VU0E5)4AW@PVX(\T#$HAW.,\=?)4T++I3^#&
MH'79(3EZ!PNU#4*[\WX,."XL%U_@LV6C%)?@6JW#=?KQF#4O4D?=&DBKBS(0
MU?5=,ERA+N7 T2K_XZ,_Y@/WZ^2(;3/V#K+%9WH02EH2N:.LSZ[>8[.>"C7M
M#(SFNG$U5!SQ@L*4-Z?,F4./-*]::<1PQC0I-I 3 GV&L$WWN<]4!]5BA/:]
M'?^H^FWEEMRZ($/Y1L&SN#K)@]L4NH:Y[:@J'FS?1X00^UD:I#YL2Q4.<'3$
M'V%ZJAR4Z4>TFQ\04,*"#L\3P%+.@9 2NG:6/?M#$9*P48RWY6L4UP>PJ$+F
M@2;(2]3R6@=SA<>]6U',<FX^MPS-FKR6!C<,B[-/1V6/=NLA7',%[E(VJQV0
MC I;S$1;;C.!@87?=H&_@*+W^$]U^$,J\+1BD9"4-5#W(>&?NCO8(6()3F7G
M'$/DZ=++19_#Z9]3)\?<&3PCY@7_(5+@WA]S"3&:@/3\A3\S:&YLOS>SJXS>
M6<)KD29A3BP4!.ONSW>Z_+$R^/G(T:P&AV#R-1G<?/S66"8:*F@G0]H$;=5&
MZ@G >_W4='?2#95#=FD'@)OCIU-#D2-\NE3A+5.*E>5[S8!I?^1>F<&R_O'Q
MB71$<U'QP5FM8Y,&9,=T4U-2TYHW<*LFQOE;H,!7D&#SO;AR$H(O6_@7K<T+
M^L/>K7-]7?37<$PY:X/FSS;.IA_[^B]ED%Z<$?+E%.#D5DQI/!0E.\SA*".-
M-&PLGF#P@@?BFWX1PWL=/ZS_&"Z_S!&SP%(=)A"W#G^P0,]C*GWG/EX3]7D9
M==O''(>IV2PEE9I'E#O8UR,_GLP/,3: ]'C\/5,P/#;B4S_\U[/AO\@!_IT*
M^1U$ZW^*"UA4"%P2^P29K(9@^?Y@4G(N'N,Z$1[MVYXNZ5;R8-X%*E^7P4(N
M94@'F\;U_!:OHM<'E'UI+UD-M?3T']-R*JYT.L^:L!-1[!WTAED1KNG^UF+$
M;PH"+#J%VY+(:9.DDQBSX@UQ5E?)EL:.Z4J,9IK4#&F$$>63^!!V1_V7=]+H
M1[<?7"!PI*]*?!6%[@7=R*"PWC2^<?1U,UN[T](E5W]<I\OO_K-D?',YXA 2
MT[M3/B*4[RUB?Y)&EH4X8U^-BA%W*5BQ6Z.8JS<X@0+NNL]V.]8^DO?RK9 M
M*2OO=QA_1Q0OY(P-\+U7U;98/OG?^EP6VR,P.X(?,'*6B?BB7:U*\$4COL0;
MX:_#G!,=!6S>'A.D_ =0O.3]>]QG4_U["Y5.$%MC<H_ F7+)97)+/5:.-1(R
MQCVSVS+9MP@&4VHE2BM/L>+2?^3RDVQ_;G&P;?,#-'+D?@&][P9=AZ_^2]XZ
MN%%N5-M(WA#%M-P2:Q6LO"A$[!M2MZ66X2J[[\4DG[2YY+Q&5IHVP-,![DI)
MVVO==O@-7"5>'+QLFJ$S97?J0Z[+1+4VD6*IX[LF6&_!N9_Y,%VAMFNPS@FZ
M!  \K,<)T? -/:[+N!+?M\#^Z6&IMPD7C0L[B6GK1AY>Q,!U&2NHK-FI+DW^
MK4L6V*;J$\"'/] )0W=:'8]DFWX:M7H;9[WQO"I I-G$3V*UECJWX(%H[OF/
MSK=>2Y3>.0$8C9\ ?K((J88$;31CL?*Y!IS? HIJON(_6PO2RHG9MI?@0M.4
MTSW5?:?,Q_(_(^73!X)?[5/O;Y@XDQ;D9US(H 1.,0'],0Z03A"@#=M<<SH6
MU$^6!I'RMZ7)MV+%^<^]^%2:4#$G(]RYFY,?&?+VN7]JHW9+7U;=YQAD5'M=
M13$^HE6K:^-]UZYM7^%W7F=YRL]VAG3G)SOS!V7R5^,9?@;%OQ3D#_ '.P,7
M_E1!55W+V+MZ'.&Y!GJ?5JES+VO,U@U]P81:JJ"5<3EG:LT4N!MIKT+#E>2;
M!J#:G"9Q[Z(LTII7GM\YO&%$=,PD#BWW,!=8:"#9:XH96VPE2AH7WI0^9F=H
M1+@/%E1.L^ZV>HY2A3Z6W=,8(8P%HT1B-+IM)_,K6K$H$81,N%5!0)=(QT '
MMJGF+Y7X8;!_&F2^U1V%,V1U_X(LM_^(K'^YPKAO8S:"!IJPK*[+1'&K@?!A
MP*N6OA)Q9A"?J^UT=Y 3R$M,P"W/L3KW8_^<ZK)]V\V[ 6'3 :/A[LNMW32Y
MB>A M[QE[#DD)\+_]I%2P*U^&Y/^U!$ZK]; $/DP?^Y2XXE$=R*@;T*YQJ:#
M36^+'5-NHI&63XR!0_.4S,*=\%\L*DC+D5B5XW]%?U)^L;4#* TRTF+2V*=5
M-?H5P[R-E[R\'SV-ATD!['5BTC-;D, &%*\EUBQ?,#Q;R=:;\/"]*H@I!HBF
MDL.!C-Y9XK;.K#'9+MS@\%D4EPC96$:X"RUK5865< !O\'.R6BYS".EHI#HB
MYA71.FQY@T:XO3^R!BPC%=9"9JOW_@-@I/V4?CEE\?OX_V N_SP'Z;^,_[N&
MMV2,M]"+@(3Z<LH>\S[PH_4GP@G/,/.4A&?T.%*!WI?N#HPH:#Z!WI6M]LE#
M]$B:'C93MQ(:O40H2KNNZRV&%0KDTMR84+A$)XY><?>T9^X9*@.U:LQ_]KK%
MFXAJMDKO"<1PC-24QZQ<+QKO-/M2;.*KG.CNN=) Y_OT-],%<B914AU8Y]<7
MGSE2KO+K:I\0C 0E!%ZP.WMC]?XM $ =U?<Q]V-!.^P7YR"G*NL-F=[9SG]Y
MU0K8Y\J'Q*AR#52QU!TBG[S\*P2$J1E;66$8H=E<MP)1H1D:[L;KH^6Q_/'Z
M:YKL5,8B6NG4=,::'Y&7XF@SXZWC?7.L"'UB0GD#=6^W?C47#9AC" N8\+_6
M_=Q!>N))KOET'/^1%ACLY-$!LE Q#B)_7J86*E&O?IX:  "<>PKYS:Q"/WU4
MB?J_7:A_\@U^LN>6OUZ@:6O[K'_=M*HJ601TEHVS_]YI@XPE-^L!3HRH[%MQ
M7,_EC.P8K7'8V5IO[=X_5.;D-@;^)Q4W^U_0&O-ARWW2XMC?< 'NBK43:Y"-
MA\X7IQR8W_BJ[KI>Q0OATU$[&^7_N:;^KSAB_Z ;/UO+# 7F=6TY!/<83GNQ
M[M2Q'8E5[R\I '! 33#+%+RVF:M\7UR"P7GC#9FND5TSRXZ:U3O&KSEHE;B&
M-HVR;,C/=T2%F(9Z*!%7$,]R:3K<*1W4NE>7U6: NP4)$16881>3D2]'DB0U
M[8?N-56557A$&,'!-!T-'&_IQM]8/GJD\%+N&8[]15/7:]TSX1CZ"8[*ND&,
M/G/M">!R02JJ@X(_ :WBQ$L8C7++K(K04?Z"\@IB"GG=U5\$6DM*CS=@3Q\5
M;TG^?$6GWQT2*0Y$PS+0JPUU>#VE)P#"%&H]JQ(+OA55J[OC5BZ^>Q)O7]V4
MN;D1&D:=(SL#D"=D&PJ2[[[N6JZ+1 0;]W/5&+,$KD.3J(YX\36KL)WEH?GK
M!D@6I3U600HY[?HYGQ0>J\.#V.244(V2WC7^HX[17%UV#U "0MLFTX]),^GK
M&X(Y@B*\G _)]=<&[L U/F>\LH^>%>K?7O(,G&GU9OE6ENW@,9,$;)@<%4;&
M>(A<?;R]^J**^1MQ:3(%)HKT!,#AQV-^+I;JLB</1KL'RX96V> 6U9VYR*(@
M_\F&DXLCC8@\PMQ^2TXL&.#9'&UVA6LZ8"PTS_MK"Y1\\=Y"./AX !_'W-NE
M1V=65 KI45]W8]#P":+&<GJ<ZFFH>G*_\N M'Q,"WHR(L>N7EU?UD]S,FY)H
M]U61FU\#UZT+N-;7]@[,JF+(M>$7!,ED*5KI[FR8ZB7SUCO1%P4IK+AHO$O'
M;ZD28YZ8H1HRJBB/8/&3(J0N^FQJ*NIWP8D\ETHR<<H<7B,_&P&'3'/TQJC,
M3$\S9!IX3N#OU,$%.'NIO";DN@2O%"V$,SB+=ETNP'U:@DYP0Q8\L,M%)RCY
M.E'A9,J ,_3&=.6,&!X*I7!HJ@REV]R\(MHZHNA NM9\L3E%2)<:RO/X!BBB
M%HRFD]-&ET@.<*>70N'\1PG9.J9A$U3OA\>^?F$^]Z"-IPAO<IP%E^0S3VN3
M9WBZJU!33#*]D&"\07GF6"&&&7QQO?85-W&4_B/X1IKD)^WZL5=)#V<W76A@
M:UE.LU*V-X;1,9Q67L*W;5#N?ODH=&.8^IL@^KI+3L]]N0--@CDNF#S/R5"0
M$OPH1?WTW0#3I4*LIMC3YDE\41$DWDS7K":T4LC9KHU82(-LGY2/P_[<@K2)
MSR.C4*C]F[<O[LU47;WYJ&AK(\HT8QE>-&R)4LZOK:UA?Q,F0*4NL0O ZYUY
M&]Y>M.!!&Y1U82QRT*]W^:%T_N"#+!79:LX\OG;%:FF+[;?F\]1[6;U20Y6:
MS^MTWE[J?=47:X$#L).7NCU\MJ'@ZUF6A$/$6>J#/=T44LNRM-DF,EXM=+AZ
M;8+L(/_-2W$@_(1![>DJD!I7XY,$B?@G!UGS !NEK.I^5YI[^0PL5(F#GW(Z
MA7H.9J=. &\$PJ^@7T]O)#"'NET+)?1;K+A1^E<))NPJ!<D<8.I[O@(Y:$<*
MP)-OJU_(=]/6::&ZRF\$LB:?.[DVOBU?-?/(A^4=5\/+G$O;[=71<D[[QD&*
MQVQ5H=6EQM3T(6"R8TNL3)>]WI)S[Y+WU9*M_8#\W?NW2N*/]"!75BYY3'))
M(B4$=8V8":J3/@[1:^!3^C2E[=KBH\^XCD+!F^N[R\]>J_8Y+L;L1;_7ZRJ9
MV+@D??0MH/=JY8'R!P"KLA@=C:5@R.N)J+B/=U>X]K'5A&E!['QY?U;(_O-W
MT-],2X-T !G<>9_6-K5<\]38P<78-EU!,(.1I\%LPJO41[4@3:OG>A$I7F2T
MR*"4U)274+-P;&,*D52AE3LR:%J W"8OIAD[,?C,DL?*J J4#H!P9/:#;E0<
M[$\7@Y;6TVN9>SS,RE'Q.BVX@V1"O%%C!UE?O0D1&.ZI.)O;_DVA@J%3U2S]
MN_,#FS>=5EN<%C]H[N"T5X9<,(GJ:'RN?#VM!,,\P>;?(.R;"14**13E(0R8
MM2S(Y]CS !UP4'YY?,#.43QI3:;[\(+]"0"RD3E?F#TH\R$]BSX<5/?F6('=
MOG/)LU8\&&*:;86 WT6CI=PR+/'VR13<$9&6RUZ\8^?FCX<;+_&5GU\%\;3$
M=RDI3-,1K'HS#HH";3^-HZLF&XJ^Y'2"%PTG1A1[CPMPS%&Q!,6Q1 <)JL8U
M!2X^#\]MZLKH.<@Q6O);1])7W6U@)_ 1?M;G).I/31\,$]IS:/4FZIS1U[+J
M!PDA[,L"\='>]*;MDTKXY7%NI=2D+^AQ1+.UR<*D7NC0O<&89@U9N@1ZS%[9
MN[<N"GRANJ-2Z]KYK837T"W@F]HK<GWD6W7<3JA63&'ZKCZAXA8\UC9SZ="K
M(#9+-_3SB+;DYP;RMGMJR@ *QBV1P4U/E77K47F[8\TX)C8Q+L]7J6B/IOAR
MWXW1QGUOSH%X_'7Z39728,5!<#Q5=.W3%\^-G1@>D[@4'=%SW+O<?@E ^7;,
M=6.UQ?N.A0D2G%^[D)!7WYL?BLDUYU6Z,5+#S5\TVOK$V_A#N5;86+8;W6)A
M3BNJDRX:")XS^2PHYU R;WC)\G!O'T._3PGU#^)*Z_-482NKV7%ZLQ.]9J;F
M[+?LW4ML8!M#U6UI_)3AU>W0H!":FTI(Z=HLJUG]X&87'978!X-/E,!Y37:V
M=^L@4&G?L9J\ +6B5_3A\YJR418,:Z_#%=D$7P\\14T\V*.IW4=LB[\P7.]>
M-SL%;P@:S1KO<.H$//,JC#L!E!8$W@0?3TRRKR5X#Q^%)MT50D@AV1NJL-#9
MW-%@4/>-T1&IXV!B_$R#L89+P]Q,\@UE@GB=<Q$5GT4NP:ED+WA8ZJF\2DX<
M.%*P-5;WW7?3@^72L71F81[Z-U%*E:QXLQ9_AE9:.-:6488>/2%323+LCK-)
M#R"\I8O93Y,R:7N25(^ DS4?&@;R#WR&(@6"AE<E9^YQYNU1<&Y,Q>HDCI%N
MZ]Q3YKAG=B3QONH>3XX7ZG 5L/=QMHSMR):!^].RC;/GLE,Z>E().BA PP6Y
M*9]G1>I]6SK,HW(N3$@>>D0839P__VC"X)&IY 8NBXN./E!J$+K,R>%X%$[U
M9>H 6L8CL#>1#O::"Q647-E^W.$80?7VKKY_Y[YB7_2NI@Z;AQ*#4@[W@A=A
MU&:>)RAK24?_'8*6AV@E1D>]:6]',-L9O@^^V/^$0*,K*B<V[*+%3 RQ9&MG
M\SS$ \WGE#?IR;854G<K;(/3]HAKS"!_%TR-?1&"NT."?3;<Y3!1_9@U\2"F
MJ;?AB,(PKFA71<K(^>^M8JK*YZ^!%F$C#5]A-T4?3Y#175L<I+]^G+L^.3SR
MOJ1KDZ5C/.ZFBQP/@GJWT^M2J;'XH(IGP>(U(;RB4B;_=XFV8(VC,0SV!.#[
M].C)":![,1"VE6F(E4W'DBBM\YT @,G,)X"O<9 #>IB$ZVYZ^./^$3I.;,ZI
MNYFR!]QBV-G_?EW(<4GCT F@Z.RZNH+CA%U#JB6ZJS-0Y'KCSJKD@F2*5279
M30[&T-0Y@M$P%]J:\[A6>T\\'.3+,I\N:(AQP!@R8N&HGFPV$=T)%QHI8@WS
MOL3NP'R!X%"'KZJ6#FX:&H>)D2NY,%IP^="&BN9QX22TVO@X$5404QE.:M&W
MDGQKR_2;NX\V<U).FQ,CQY"0E;5-&M&Y,;]HDY:/CU %B4^7 L(V!\XJ8#__
MX:*>IQW\AI&"PFTQYWY)MG?_YV1[@_VT@QT8Q=YY)&$#A'CYA=65CTI>&?HZ
MF:D,:[H:KDF/,JHOLCA[9>?W)BGY)DDLL5F2G=4P_9 6Q$K^HR3ZN4Y#?1 1
M1J(7_.RU\ROF."^FN5'Q]?8."TZ$F+3*AJ+(.JK@K:;0)QT0)Q)'JM+O11U=
M\).ZH(T;4[:5EF"%:N,Z(BYI#YO]@LB41X]<O--ZI8B#_ZS!>AU58-Y25M6T
MX ^F]14:WI3.RI)CV,1/,*GQW=!D@5^,MIN\5_ >56 XPQS,53U]!+)PNMA/
M(Z ON/1MO92WP>M"/JF7"='[^@V]:[NS57S96R59BT$S6%[+?9W"KREDVL,/
M1?<=EC5Y'M*4>IN$+- 3WYF:F]NZ"X+27&3N799T=J%.[R:C77R'#A(SG\:(
M$U>F:"&Y@\"W!TW DH[%<@47."UYTTH%E9EW;QQ MK^]U;HA04'[U'QJD@Q=
MHKQ5,BZ5OW28=R@5U)G36AQHO2$5\TE(]/U\I)PQ+DO22MZU-;I</*2Z@#YM
MR_= ]G'7!/;K/,'3D;'&/^+8O,O/O*Z"*0M89[/?//58'MT0W9\F+2ITK6X0
MFF"'\?W&5;"+/IB_T59C;E_C.47@MND#]M2WFZXUDZ?PU*KRK8LR=_JS' 7O
MOY:CR%U*$!'Q$H?CZVHQE)7YDMY+]3V?QDJNKGP/<.[EQ<?"J.Q%Z"[WRKZ*
MHJXA4I3[]W(4W_:9U;9U+/XL1['@YA4G+>/0(1@^VTE7+R27-8Y^/VYHH<,)
M3Q78C2WOE^*):SKP%1V(,-DNJF*E('_F]EPOY%BD+(SM2,&9SU6?LZL["CHN
MTJB*$0KKUJU UA5E*F2N1 R5_4XU\/N3:O"F,$N4FSH&2]5G%"D8IE8:J$W^
M+/ORN0ON"U#W( #Y<B>;?)PUZ+%_,7CBZ,S!8?@7!^<__;9M U,N[ $#:.GU
M%;MG9()K6&[4?SY^_;!&ZP,CJ4C[.R!/*^X2>_0/CL??K+BZ5R-L[%J#[]2C
M[BV^21><9X(EB.+\$P:2PX\O]RE_?8,_#7Y__PB?\D^_I_]W]+)DH2FEE^Z%
M/AAUXSP]C!JR,""UC->FWPDT%SD"[BV^NG+]IL\7?S$U#9< H-FQN0$"ROD8
M&&(@UL]04Q4YS9$O<$$+W%#YG-K8_/*'*9PAS4HP;E1;!KO\2/M^79VOEVHL
M-V?II/,?^W$G9_\)Z8'EOR85 /^?\8 S_O_E/?R_1.= _TIHV=G\L:GT[V<O
MPP@\S[EM;3ZHZ"_ :.:[5LD5Q#O5(LQO=/Z^#^ZQ.A.3F;XHYQVE>':D^4M(
M P?H[[U1]*>>%$%U_A^[05..KLAT8^\;/A"Z7_A6%!_\L05Y9V3V"6S+"5XQ
MP0"7PJ:D#^4)K[V(J:7:V"!UMKR-VR%BP*3Z1'2.:SW]?D=VDRZA=)2<#$0(
M:^[Q_;'KW1ANPH#3=?CS#_K4N"W=MIXX_0G@;,;H*PM]L31% RQHT-3D=<NW
MJ^XBKCH>1UI0>3L'@L\5Q6:AKWWP9;A>$(YK!/<,'M/5PPA$1;9LOLYJ]'DR
M3$^6ZW7Y'&GU]1^)+<JQ:-7!4]/E) NF?#2I(TK]FG3?Q82^;XYF [6!16#<
M.P(G@.D8:'.7N!!&FF+Y!'#S;*8G#YKHMCKBIXQ/ &3?-W.D8X ^6?V.B'CN
M5U6^35V9!A/[:W9?G.RUM:X*[KIM /0W;ZF))%(35A&7Q*QZ<F=<%9K-"J5;
MU]14<DJSC"K1:]=CMN&NET7X/E(F?BZQI#4?][XA,=:P'D[NS@L:6QU'59X*
MLX%S-:'H!(#_IRAGV(#3,7MU_K/AC=9[)X"WB1",[4@M@]()('"QJ5/5GN)#
M#S]Z+<UZBXN+,.%NRZ<P$1LOZG"=K?7'JPWN7O/O$%5F41"D+O;&#03SIO(1
M=P"1]W! ?*_&%<;XR?:65L'&YP17C@9F56T+Y]AZ4B]Z&QP;/LP^!:XN0NC<
M:3=:9KBGLT_!W*@:/@S28X0T;:'#9([?G'6,O8M?Q!!/Z!66]<T !M=N!C^8
MTXFYJ-^:/MA02NBFS=&C51&1 L$Y-_F0+%&'E;JK)55U:/^9%+S)"<,OX@D?
MM$:\JJ[HW"_@5&AJ"X1;F_#);(MD$]#H93^%YB1^+"R<,L5S-.F;F^P\'GT'
MG(X5Z/Z^,:W8RXFU!=O_ =OA/M7L+?2'778[ ?2P!R#/+^5NO9[^@+P=OH93
MOQW*V*4(@7HF&)8<,)X .N!"![I*<2E\MN[+&.-<UU4L:9D_XP0-G%26HV#=
ML?)#9:E@9*MUN>B\)_(V1&B^@04OT:22V,#K*#C&?UL\R?#I(^\.G5E(Y]](
M#)K<XJX7T_Q2Q_9]2QX:T?CBSRUYX#^WY('/MN2E',<_580..EW>[9T^JF3N
MSY^#U6S-\4H^J[SX^H%7G)Z\(Z]<=#3C/9%W+]B7Z'$SC(6C%)I/ *_&'UZ5
MEE-3*>],UD8^G.K*0N(;E@_DBS.XEGSED;(N6S=.U<]3KKRV9G(K^Z!KBF\I
MK9(;;1KJ@@V&_+V%@AKO">W7- %3$E""TI7']O:1&.V=Y>-8)ZBJ[JFA-JUO
M.]6C=YZGDK9>#8-NT?D5EAZMHH%6*40*QL_4],=:9A($PR;=1GRD<:Y$7J:J
M2IRI,KRN[_K5<.3\B+PK1K)*QXJYW4,%]$G.! 7.JN:8D>BP(.NZD^%9_DYX
MKOW<93ZC+;J 7</SKC<;DQFBH6R.%OP)%J6U9 W[^$X@W!&P24)7J$FRMOZC
MR^)23YZW&7@;9+"=;>Z/G%8H2U58'H?1>PE-6;O#7QU79F%[O05@O6$2 _G0
M43?."G#6?E"&4F>+ 2&)+98"OEYZL'F*8@AZ:TCW(-D)@6H45S.]<L,&_)[J
M\6?1D&>+Y/D>$*&G2-\Z&&V*1Z:KKAI2H$34/30Q)EQ$QIC14O1M>\[2U?IR
MJ;&<IC1)<=6/NW1XF*?FYB"OZ>!C$9U2F+Z\6KQT34\A?0F/P-SVI2-YR5O/
M5%Z1.R1.N:O=;T<\&2&V:!LY%=8)0"<1W+*&R-;I !%/THK?^L+TS8_UAH+&
M+5.OD'DUZX.P1K/Z)9)PZY!-8L^KX?4HNPG78%0PLN"U*:,/8^7 7BMGQ-RM
MMZE)$BP ),('E-GKR<Z5#MH"Z44IQ,R@VM<C;/!J_/K:\FQ%:Q;%#::>$8R1
M/J<L8F2E3!8H1OL6@FB)>88LW)G&"TK8O[C='+/:NJP0W1Z;+!:3<85)XESK
M6$-43^)V;<$U7RZ- 8&^$1@WW\O3:(K[_Z+NO<.:W+9^T2ABH7<$I$A'FDB3
M+BH@($1 >I-> D2DA1H%Z4U  H* -*FAA]Y[$9 .H0=!.H020@L7U]IKG[77
MWON<_9WOW.>>^\=\GN1YYSO+F.TWWCE^8X N #?/&QLN ,0<2Z2;O&_[27+.
MF\ 8NZM!YCK&=7KX2EPW,DIE2$AOG=U&H']X4&#!OSPMA)A7W2N7C2^>-@H)
M'<"CTJKXS-083]P5>*8 AS";C#@=@$8*UD[<JSPAM&KQ_#_'G(S'_#J%0BTF
MK:?]]0I[JH,%3=)V+P"J:)H4]!.3M XP_M8!TK%01S(H+KO/SH*C3#HPIJ^'
MAS*4W2'/AXK[A64WOH0R;\XQW4CF+34N0G[)\OC?S(+_0B1*^9/Q9;M.6GL3
MR<;)1!0XI[(>S=_P66ZRU+ HP=N%B,&R/EZ09+);!\P>V1'@P*#GR$+^L]QN
MGFP1K1[C@$P+W:PX-80%JW0$9?J-X(_:Z.XO&^8NX7737 !D5F/T'VAQO;XG
MX&CZB?JAQOL:WV2HF!M-4[ELGD\AY@+ B&.987&/J/ J?(Z72>W6K9[^,8]1
M\:;TZ 5@MT]RX<Z9,S:R2VZ/XC?\D (9444K!BQX'D03MRW)R&((^[W6)>X&
MZ]4\F"6,'4<7?UQKZVP9UHV!]\PG+KMS>/-VH!T'.[-F4MD;1@[YA]1 D8J]
MA \-OG.[Q>AOSHH[.?BAEHT$^7N3CHY6A%6B!I+7Q@X%]''?3HHR;8C'BKO
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MM&N!-1^=/R!F^ ;SQ=YU:RBVQ+I'G$S$X 9E!<9]]/_?L#.L8436C&YT/'X
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M )A^GU.KG]BRMM8W>MB$=EV<\"E'3$QF8^Q<[\##+%9002(KF*>]@X.@#/R
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MZ.[&>G>;5T[S%182I?MTFD?7,/OI&UY%'*J9MAN0AHN:TLR]RVNI-IR:GH3
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MO\[C>\DA&5?3=\]R1(7HY;;YAH=<=G35[3$VMOX4V2"M[^6"X0[2+%W;@&V
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M__S3[]A)K_BQ:O['>\*[]WAO9RM%ZX!5DOEDI2:O %%I\-1[$+_#X1R4K]P
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M[;((\U6J+0K?LUO_/PQK_<<VRBY*0_. J+>Z[/6]4[\W-Z/U;,RW358(J(C
M"6*!\=G]X\(\[]\OS$/>_WV_AOUFOT9C1/C:X5O&]L=;_4\P15A@5X *MQ01
M-K/'.Z>I9/;C0N5OOX!'$NPI7,!N-Y39A\YK%=C'+F%T2_?4:#U. /ZJ?YK
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M\5%]9:Y(Y(K9CCL3F=+8J2+<L5PEJ]X)"ZG#?>XEN_95-,*8;L'5R9,'.'-
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M4>(.0,.,%<;8*O2$3]2'#XX%SD,TYSRM$7.ZGPG?GU,"5]D>H<[5D?I9:13
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MQ3)1#ONK+9A 1^SMJG@%[/[OVB\6")0J)%2 YKF+\>6>,SDA_EZP*N%X12(
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MS0L09R8P:_##9QM[M?K&\^F])-=W"G!SI0O.V9&&V&XO9?Z<"Z94/%^CA"L
M5*1\[5QDDL=]^IC<W=-]?B/<,9CP^*%L'$_IR+TER%,\CUU(<F"P#P7*M^4L
M:ZUE5KU5)FA:/D)]E%/J<US<*Z$F:59:HZ+;,_D<<9:B=K<K@I7$'3WF@]B@
M=?/W#68V<8H+-=@[S?,?*'*G68/G4IY_?]"28:/XZN?M/T0#QSAWS\F5VQU8
M-,0VFSK]IS+[&PF0H,8..6!["MDXX4T^]22.D2<0JN,M00+*^1\$ [D40CS^
M8\' '/'BS$XR$J;]5"45'BI]IK4KP%.WK;8SLZ ED,M>V_ Z4FN3$"Q77R!N
M25#T"<S$;9D%UIS('D]HCH*UBQN]9R? U'>EBN R>&+!#1XK6G3;=7X $UGT
M9/@A8E)3.:(_MW([B:O"Q\98S;B2$ZNTP/J1)GL8W5'U2JC2\+=STGC>$TB"
MC3"+6QSQA9I03K#/>/ZT)E!Y=KW(\I;>PYV5:9/EE^XAJ\_ZZ,SQS)W<%,4]
M]EH%>K6%)-L]N/.*]("=LHU!+'NVAGY\H0[:K8P23SJ"7<H;'@_823B&?G>:
M4>O-6R20- E'!S,4]I7\D]XO PC[GG/GD@$[);!*9J&!B\.WY3Y/XNHU2KTL
M'CY7Z9I/+;E,$QY.3MK>/]GK1-CT$ZQ4UF;'9,\ 6^'Z:<99;NJK2^_*B%*H
MPA\ROZB+0V;4<+=BXR0NPW2.\P"G[G=VBZ@I31Q&BK97@+IG4F>#X--Q%=27
M_(D-;9M4B)=83(LZ[BR0<!^5OTC&L%P-GEJ6!&$F&+YBXK3>5E/2NB@L'B F
MV6Z@=0N^ BS2$#(N*I\ESG5:-1"!A$"?X^1R"AMM7TL%+#*_EYKI,]9U%_?J
MLSSGEAPS]M0\N0*\PDI:C=5973X8)SB M.KIM)#:!!)T?BY,&T4STT7Q'&>G
M6IS;LK*ILH%K8Z)O-R8]'K9K"JT6\Q/=O&[^*10C#94RKUHZ6@0Q'J>W-!NC
MG%T!2ZB:BU3'B1,;GXBV+-_]^91WDIO7B"\S ]1ODA[,1%WRW][7BB,F*_V&
MBA7%LZ@1P;47A-=JG \$=XLN85YRG\NE2D@=%NBQTGU[2+@#&F<OGFA2$>#
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M]&+/M'05-KE:K+\X6IAUCUV6(T5;H,#Y[H02>UGWJT;M> AY';=;'Z+^E9-
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MZU$-)*_&N]8U+WX._++R__?3ZI7.^.:]\NL*C$H>E*%(QOH$.?% &H"8K^7
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MGO>DZD,'@'.7Z0 XY^/'0E9W*TFY,NAQ;-TTUVQ+$W.?E?A@DB6ZN7F:] 0
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MB\=A>H\DI_7SBK>DQ>21'(/NRC2*!]ND=\U=;#Y%".5KM-.< -B4:]W.;:;
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M9&W+%1)W%.N5[AYX?T%38ZFWD?3'9T\!2UX4GP!0AQ*(^N^8)BS-$#2^Q F
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M4TESB=\SF76(;'[Q49U- 3&E3%.F#-DR0'7HUGWB[!"QX#47H]U#_4ZVU</
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M<^-_>9)6T6'%WN'(X1#GE%[+P*T7)#M ZJ2XH]FN"6R$F8_693:F[I_Z?ZT
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MH[;J;:W<Z_8)2S,-4*KMB[G9LJZ$5S-Z4YW4O(=+X6*\)L\PPF.ZOY#$:5T
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MC?:#SB>8#M,,\8S:G_EJ&"XZ3WUS/5 3_PK>.RF%KF.U:$#I+XPC/0R;UM$
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M"BNH2\'D5OR F^5U8I[!7*^ 0E?)"W6Y@3@P(2&0Z4OD??Z=9FL"'..?O3Z
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M<"V0R*T21I-[%22=F%]P8]3,;+QLWC3FP2YI2J^$A?^A]5MHF[/W/P9F]*'
M^S4B-:BD(V/+,T9_JU7!;@_KB8H@K/$PG[>-I2NJ-V*&R:9+.YDCX#S !"FU
M4HXLA>M0X0P&E$[O"29#*WV*>8V_&C"+5>]0'@GO;1^N("N2FG3W>U!'V!J9
M-I)CQH,WM>92G2\I&C H T0#6E@6T #J+!1U\A+P&DL0>D5LB 8<U&\WFAYD
MTM]%]FH.YI751(IQJ AM[TX ^1A%&AJ\3)(U*.\RE$C#<4QPI.,)$,:==K@=
M5&/C(6_)U<9CM48%D)SF/([,T?I=71,\55(NE)W UL"';L2R-&55YU#"TSB1
M.EIMJ$S4WYQ,ZA3K/P 2O60<-D]\ "]^.T>O'N,5'U!B>F2[\9X[0^?>\$QC
M<)'H+2W[X*_G0>+A:Y.H0<G;H\>DXW8\^R4"/[,5['*CY+Y)V4:?F7)-=,^)
MX4?5F>%I@N?"U:WG9\.]3[A<]$"#R\U+=9*_T) '=EZ__RV<V*[KFOZ)3\G6
MY<K$>X%KJDZM-#USL'N%@A\U=8AER$.3V,8A9LLEW<D UVBMAT_-",@DSN #
MMW\F#?]TMEEHYL&S<\3/'IZ6.P*8*7*KX_$V!&H4[N%BOR3XK&Z-!C!==NZR
M<QE:.L@,W&C11 H=E-&]$4G[2V3.;^BH_T+'_"8$W6Y"L!29?%J-A&8A=51>
MP^UD@%RW9O5!;3F&G:>5?.S\<ON$.EI6&,&LX(>J%.\\MP<BZ7!&3L)\^#8T
MX^>WY/R$^'4-LG6&53%ER-H#)3XJM"00]73-1HKD]21,6GCI50\7-ZV\OQ&Z
M]I?0_S[NT\>;P03X,HA#*/FFHR%$U$)8Z$UR2/&>;?K;U"53'IKR=JQDOHXX
M/FG#/#!C519R::GW,H);0G1=2%B_YE2VG<I?6,A-Z,B#^"7I=X3#?75A#-;X
M'-7%:TQN[:MBB1SEF>G2VN7?\/AW'U6[QG*)NB*:^^6C.\=2TR1+:$"PW;27
MREMY6X&-L8".M4^G91*9-.+YA_#")46,ZAAI)@;@D^;*]3"?97S]GM9.NX"(
MZF31!9LPE]<6D(;X]YK=$'-&!%E<Z*[/=D^)?AHG-.Y#D<9C*9NJP\?_[HW)
MB+;ESB#4$VMAT<[ C;I4.&Y\I6M]5<R<?VAPN]T;'(IHCY_G.OR^@PL$#QM3
MIU>,'@3B[,$L:NLK4JE=DB9Y4Z4D5HCV7Q6[[G5C,C$E;7O3KTAP=%*!%C;W
MG<:[63^U'O9 1##M="@C+>1:@#K8-TNO.Q6?-$"Z/[,>]^B/JJW^JE"%6Z/^
MF42<O-G0@+3K/U+UMTMKS/2KHO9&_LL7^%Z=V-)"J;1F$V?5N) \9(B]R].(
MNN2SBJG/FKWAP6J,\@Q='[!H0J.82T9=C_CSMS4A29D37?TWCK"*5/MC G#[
MW1'4 C!19C>SSMV]7V'REHX:.5'@/O,,,3K-&K@+U!OGS*NWD](:3;J[:\3#
M\'E:*_"Y&_/2F)^3$$+80C';VV3\(=(+NCQ C'16&X&]XIN<!HL6)]20QW+4
M>X",I@G]R\,)07Z*,Y4C:U$.[7W:A:?YU=]VG*&(V85[4IL/B]" Q<A]-"#B
MUZ5XO?^: ']7Q6WWX-FCG$60UN#>%_<T^\N4[])6R7HE9&Y/[@ EE;E':0#*
M=CW8@X/BSM=U*_N$2.?+1^O= LD@B/^W^M:P9L&-Y^J2"%F(*T8R=;E21(/>
M1%TSS[*!I5YEG.RW:O%F%'7L+\_[,SM*_2ME_.6<I>GBE<>D'N!-=H\"-(!G
MV6[G0.KHP*=SX"9J9M/N07_7/N8/[;O_,='[8*SEI6?UJDG+"TJM7<E,+4,W
MEB^CTG[EZ5]B!E"P_SCM'6/'I_I%W4Q[-*-H0,(!@57(C2.$[8EC_BM8_E1Y
M'L&Z:XA  Y;E0XN]Q3+F;31M$IJL8F)_ @DSIJ@5IMR>9:W)C%X 2\\5KX>4
MRMB/;\6^W<V\DJ<P(TT0&#$*^C_%?7D\E-W[_[312BK).A6RIP@5F4J,)::%
MQJZR)R8DNZF$$!-"69I'R+ZOV<:^[T36,?:L,VB,9<;O'J5'/L_SZ7E^K]_W
M]_WC_N/,S'W.=:YS7>_K_3YNYPYV4B%'21W&NY8?-.GGRL<\IS@:YLMFM8WE
MZ@F]:S]4_6+'VQY43)*5'G6Q-D^W$W.LW??RN>=BE(&H,*%XM@B=6D*(4C->
MF!I.M,D1O_@%6-7"G[/5 7M)7Z"^(,Z,L*?QQ6D>?$&J[,Y3A-O3H^HMRU/U
MCDKS98]$&Q])&A-F/%D+Y(;()Q#(C.NZ0$&IJGFJPMG8BTRXT->6;5UA9A+M
M E\,B[<QZ"8FP#AK,-3ZAVRB4+-:<L.MJ*4UT)\8!R_%9%9Z))O,QNM]J8G0
MO,*?5!_LIQVH1FEB>M62ZOK0[?*CR\?-=9:6 K4B X:,/4*4I>69@UJ5NA[.
M&K2?"*F8RM:LL2X<"A$SC]8_Q@-RWWFXUU))Y<[U!^W^H\2$F?,(DH6P&QNR
MO R^@?>1U""3@PS_&>:=R218I0/4)\D8?=WL#_/AN8\YF+3WM79?GI8]%OUP
M?N?!*YP[.?;$(_$94N>=M/M95K3KXA+=#S7HG\^>OZ9K^E+[X=SUYU)%Q2NI
M>ZIH@C\Y6F$*.A<[8-T"CYOG@ "RT',#SZ^!$I"_)A7R&W(#7X=)7W%UTV+)
MF7<";AKFI;VHDCJL,>,^8>,E^;;>CT(\K1$XM!^5BBOD+R/,7\MOEQ**T8 2
M5\A&@_W]=W(4* T6AMD2QPYG\K_"/4'S3@68N?,7\LU5+6F@,^,>%\9W5H_\
M7 CTRK:^'XGE0JV"/[V2<BV7E!3UA32KBO\\S'2GR?B MW=EYMLRKN#;4@K'
M+#F:"@Z']P99/!<_U^ X!'<MD,C$3MSB:;**J4W+?2,G-,S0.)LNFL;P3D;^
MR\VP,;;6=,H=N)AJ*#%.JWI^=MT%WRL;E+KJXQN@!UG^"2QP/?95!N,'IXTP
M!3XR#6ROLP.><+^X%MNJ(.ARA_1!S5]<))?AV<GP+W<?=$02O$L=#$?C3(4^
M][9]36*SA1BTSB0S&"!YJPX56#+:'U-F9H@0E#'8OJT$J/T"X$M:$M/P7OO.
M50F>4C0U^C#?S?B*I.;]+UZX&3 H'LCS7*N\8]O,M :E:;^(''&NL"2T6IV9
M2\VDM^%E]:.] 4V*H^"J]Y=<*[TCE'#@ XE((XG91^\Y<P6%RI\=>R&^0[CQ
MZC ]T8UC3(WD&FC7@RU<]8536(-QT%^1[6=JK.?@3 3A),'EZ+@+7]N"HV,H
M6=MTD%UZ@A#AHSLAWTSS]MK8OE&#UQZ2=HPHG@KA(] /)%\X'NLQT.XD*=VG
M>.';DMN'4O-6RY/7LQ_6]^CM8A&K%/7?77?3%3ZRJF"=Q(0P;5UA6W? CXK&
M^3<L\!T.>>P!BZM)T/+,B[RC$?&FV(='ZZS'7AK>DNIY8NX]S_OX^!J(:?;\
M-A%'82%D+H0?;?EX5?E^VB&X&E.O'>U6W*36S%\5A=YE +QYY]J:;XW&K&(\
M79H. V' U.M$?:LSD!>;X1J,[\7\"G'-'(#XH!8 :ZKVN/1=>@ K2O4N;*MW
M_[IN\%*'?>DH!5M=U;,$TO)?6'RS 49EU7;H)5+1T-CWS-Y,V,;72=TO8J[H
M*?4^:M4)0<]13OPH5NXD)+&:9#RH;*O<,B6<)8=I/ZV?^4Q//D]61!ZG>O3L
MP'X_?SO&+TZJI!$<[/D:J,NU@HGI]0&EAA5(U\./GYJ",YXX99U? ZGG-NDZ
M"S0_H9]!U>:B/,''I#CQ?WP=JK@8T5:$'75&'VUMP!@!^3[1DN8SV<G<Y("V
MR3+@#PC?JV(3SVV19((Z__?RLP.R@= 45GH<$WD_=DF%^F\UJLBR>ZLGUT 1
MH6L@ODZ]U0=9F<A@@A1FFA^RP$A?MEJ?LBG;-[GEYN9!LI"X5 H#LKEA#?1F
M,H4B!ET5!Y<*+S-CYL)M@#MBJ5W2_^P1\Q_,V+88G45]_9<G!W\:?L;#-JXA
M7O>=U!NT8JX;776W7%W>+C _1TQK F"K$R=@:Q@007F30 3=$I[VQ/LYV(6A
M5CQTD(1X[?CN:Y;UL7RG'UYG64*^&Z><RNBPR&K:HQ3=,**A-8$X'1]*&.UQ
M]AUA1':35[3"D!GO/[L1X$,Q;M+[Q=\!FOE2Q3"X6Q?11:FCGG-3&)HQ$E>U
M7%'I,/]5UVP0T>V-<\]*ME,A8BN3S.G\XFH<K<%$YX&5:^;&UB 4&;XX!AU;
M"6P&]QS&L3K/'D:.7*0:J<I;>-K',.3N-/=>@@I9<TZ$2E"^DW3UK21=#/4C
MY 'GN)>19-= ,A*4V\D8TF<P_@MR-V;<: U4:].Y!F))$@*/K%Y'9L8"_:A"
MZ.=%,/\/.OW0 N0AY'^TS^/-R(<I[N]/=9[KXRA=476<OCHJ(']4^>37(S6<
M;C?4JY[5,/,\TPTE'&K3;'?:-:BD1Z<BY'1%.M3Z:.@%YP^2 8=WAUY*75%Q
MO%\PX/)%;W>9Y: 5+=F5.K #;?D!".4PV(W"F9[Z6;]-)2Y*NXPFUJ#[M?WK
M],0>C\OYKL;='Q1.)?I.B?._/RER(_YCIX5;"@=I7H%DCM/",ICYPSB"C4>6
MFA [ZH><O%EP!X]"1%\-/!)QA/M1H95W T:HY$=WM9;9V50JBC*^&G_8+0MJ
M*-^!6+12<-#&T_\;($E8A\W@C'* KU8L@B'_9,_FOY#77W%SLN@8I95C#PDS
MN"<3<: /"T/NRM#)ZS.=[TD)2O22-[Z\I]Z[JK.U4*H<TTOS1B[^/$@U9Y^)
MURN!.-W;R@YLT]\Z,L"H3#.3XWVXI7-U7Q&G>L)S!(3^R-'^Q@S]='XVISO5
MA7_U,3ZFQ+T-@N/)+7!=D5<B(M.[E*W1PD932P^>K($2M8U3I ,+D6:)-4/D
MHZ/,V2272R++ M5*SXI&HC/%IWU)USXQ3^?WYYV,[U-ET130_AQWKETGO GT
MGSY#;?7KY#@]X 1J#2EZ@*PCO?W?K0(>)I!L>!GDL%F>!>J><_PE8H0U8]2^
M4R@K+P._TEC!VWM%Y!0&X!])<VT:F!:AR&;C%3%\^\)7+G.<]</@UX6UP\O%
MZ:]L&P4BOQ1N?T:"BQ'VR0;K-IM3WR6L9/=-1V2\<3I3I,QY9\-19P.&M\4S
MVG3?).#:L9_E/KBJL9//\:W>(*4 JMYU^4!VVJ#&S-VT]U_-&9+,HW+U.3E3
M66\<HN&T<'C\+45DG:S=W*Q0"\EOQ$4;K%TN$<[@H<_%L >=0R0Q4_E\*5*>
MAG-!,*%]YL*N.3':; XW.71C0^)3*O9P!0<V<?U9![370+UTU(K>^M//23_2
M1*>S#.O53$IO[##K0>_']*2PU%;"]IO!$J\(>N]3')_SMNL0W_UB@#CKOZWV
M,\9$>9]"1Z*_O*T)T\$KC[M+3N]\5'.@-[]>5W>*-W/L?+&5BOA\BJ!6*\2S
M>NP.WP4US24V[+H(V<R"Z'M^S0*B]R5'E:+V+';I?IQA7ENY^9-XNB\YR2.[
MTG(DY09%7^_F I5)C7H3O$N6%T2;C.,4]=VFVS.)$@=IM3RE<KE13OKU;MB1
MPZ?UST,D:&)Z 31K6YSHC"T::ES? B.VBVTP_U]XRG<&JI9%\L$E+$6Y]]S2
M,%16U#D1>-_).S;2U  %\.2] H?ZSD]J., K4VC--'6(D<;.CXG9EE<DF<_5
MQ?:;C!JIL^PT<57A,C2$\8H/GA&QBS%!"JQ4-*@]F$C)G<=2E2 [)//G\'K4
M#S83\\ET JP*L\_.ME1DTK+&QO8$]4E1<*KV]R=%BVXZVNQ7VWA2%#N^Z!W_
M5=SVO?K+WJO^2_:-?;5T$$WPR7[AV=UY;4]\5"E0]W\%3C"J*%=V_M\D=74N
M /Y)[R$5#NY9H.)?D_,F_'OY$_]B2;/$9)(S'EL![V?O//V-UT8)(MPH?R[!
M\S7"QT#[XHG;<[GCSK(.)!\X"3JB6)W4ON-F ^MT1(R0A9*UP#)8\@$Z&UUZ
M"7X]/SWT5L<=@;?O3_%%]+F7[3^TQYNY)%GK!CG*9<^#.V<TE1+M_/0]9'*;
MX18HJV,EO"]%K>FQY-:!A>'AQRF)3M&4\>BYX'2O%I5]AJ2PN0A=O2.=O4Z>
MB!59)XXT@NC$DWXA0F!29F-&K^G!KP%)2>63NU\HKH'&*49/=M;2,O@_\SKL
M;R6E3/ >0'F>8^=1@C':E2GEM"UH%$BWJ8\WC6IW5?LE1.9W%]'/^.5 ,] 6
M M/"?) \WKD6S LU1Q/BZO7W>R.5K86<4-Z/T2CPWL,5#N^CXT@)Y0%?$7'<
MWXH"./P@75$&&5Z[_.^:NWKL8IN&[EE4T&XGHMFDZ7KLGC@?)TU6W>J.S6*Q
M#+C^#I/>T7]3\"0#42=9-=ZI33"Q]JGHF0;GX/4]&[TKL!YHSB#W\Y 5I125
ML8J8(::2HVV42F"& ?:O'SS2J>T^YZZ4YC0I. I;T.8[!*I+/4[KZC?7\0:9
MR52Z.SFE ,5F-]%T_9.CYV"KN:#%W><=]C6FIZ!*EGR2X3T&_A>WC^UYFN]2
M,M>Y\@$EA,SC<U0GKBHNA\-&]2SG],J0W= !3)E:AT%FIY1,+':2R6B9.#=9
MUK2O[E2SQ)&<+"^I]]'9%O=51J7@9AM_-;JXH6T="3Z2L5'4GJ,;#WU.*>\X
M)U!B56DJ+%/\GR&=X" Q'8ZO*V>I\'UGC(S/ZILB])0F1?;QGIXZ8O 63R,_
MW)FW9$9N@085OJ$OC0E!(\I;;I?K:7K/L"O),OIU_WQWM]<\C,E.H&(YYZ7%
MS$*#[520B/D<;L4@;:J4%\*?3'O\/;U#U1K(#3$TN\P,H^SG60,-F@U/&A^K
M53/<?=>8*_2S6 JZODBMERBCKBN(]PT<,A<T7<ZD%\L-Y/&)>"_/[77M>*)?
M':M Y<""P=U',*G.,&1I#F&1O#]F#40#:#K"N2UML6#BJ"3%[9OT AV#?X8Q
ME+X8O;V'_++JC\J/]==2P1=OW:[S4G]#IN2?/K7SO8)SE> VUO[#^%,> W8S
M'UH$7<J#A5@5BQ[Z6\SA?'=>,#I?;GER97HL+&1^EG2'(@UP_. U$/_F<;%+
M-]" 0H@A%Z* ;YUA19!18Y8CD?@O1,7S*:Q;IFZRI?T F7,6NR <MQBI KA
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M0"W6@_TV(,<W![_>]^!?#[^VO&+5E9:$LMMO5!U.G,,^7:SY6&(>1PH1Z,Q
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M5-=BV1J(34O>_,GBK<R+QJ'#:R#C.A::>7&+OD)6R*/'50[UOU,WF!S+NH>
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MV;^F6.A_2;-_*/:'7K, BG-G"."=HP4H DX-WL9<.RN_QGDU)40&;>'0$Q^
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MBZ;#?(7QS,1"UL1"@&!PR7 =S]*/3VZ1_QS5^%VO\?N]LVNS<2?Z;@HO"3?
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M[2S0&==!TX-[! ?S##DT:&OG#:19Z'X;PS?#=>UM#.#'?;F=SZ]L]P., FN
MX".%IQUIC0D*/4B :ZD.L]F]%":B$Y7N )KMP3".VL;P^8PL, TG9!P1J5XS
M65G5*F6#8DQ ?#47UZ:HA7Y*EG-X#'YM@GU315WC-_:QOET&E58#WSKFB>B]
M#TD;<!*8YB]+OFYT0_TRV\6XL/VJL[HS4)7V,>]+$L&!%I,[NU??U\NDSIES
MH>9F/_-&T-/>2@K_=H;K);\O6P-Y_ ,XZ.[72I:=H/&<-#Q (8Q@AED^351A
M E2A 8[TU&S\LE]R$-MR/7E2XXZH-M<U^E[9*S8V O'3G52>+RYV02$AT? V
MG>_SZP&K>78/2\V=F (*LX0S'=UY15R>[Z9:O.")?YVJ&;<DVUBJP!LR;";4
MK87463TRG83DEVZ4%L!4BK1(M:+H5).%%Q_I&):+L>59K)%<;:1F"?G<+H!F
M2I3@J9EPJ6AE+]TR"ZGU)/)UBU\U/Y:=>2.L<,S:=W^^MN?5[%V5=(_1&R\;
MI#>UF,GWR@^QX*\<U=78!S5?L!8XCDB5R;KR3$=D$313L\XTN4=Z(9DGR3?Z
M$EUBK@!;B;[YN8RONDAM)[C[!6>9J1BO_H*(.9/Q[;NS9MUL>K==GXSP2>?8
M45YAU4UG=G 1,?QP<S?H-BJDTPP=ZY= :6L^XK9SM:$!&JO1;&+;GD#&C-!@
M?>@-:*'H6C<U*:>[627;!7QO'=YZ2_ ()(-\W9IH$+%2N=I@RV\\YC^F]NWC
M' #<; "RC>"_60BT.XPMJ<GLR+?7G57^2&BV:ID^'!X>'67DK#.L/GMX+<*Q
M*RHH_W)V"NBZ$QV/RKR4\!H=1O<P"@6+5^!T5J <<ZW.P?4@ DW=U,/?TBEY
M7'YD>G>DZLFY?A8^VG"![OM38/MA:K^4KEF%\E+GC.[E (OZ!III'90&:<:\
M8*^J8]R+Y;=I)E;B-M(&*9GW<,,!9[$Z$'3;Y_RR39GXEZ/SIG.+&A31+GM\
M?,0O>]=>GLET<;T>KW%L^.#!Z41$>U.P*_1K0.)H>P &?G(+9$T5Y%_B.&D&
M#=]O=)63:1ZJJZISV[/83#]O^L+L@Q%"3HQTG((SJT%YM#W\J,HIB.0AL(LO
M\1)9E4ZAY&N.EU]VK+GN)+?F/9W+GBNXG+5T::G-X7S*4>KG,G3IM4+M:<2#
MTWROQAWO1F\@]1:+5PA';<0WR[:D*R<*V:MFL>'Z%*&F5&1WN5Q\J6Y=$D\'
M0HHB"[M+U,K7.2Z/> ?:0?R\0"TF&9L';G9[#X2/GS33[=E)MO!=)WFL-^25
MGDL2I%C:OY3;(-"]S"%L,J;?D':+YL:M=V<XOC"'W"?A2LE1E3&6%]I>>NO,
M.)OBW+S35K$YY>3$)C.T_(6\A;L^?:B!YA+B#BO7X$I2+)TO(]O]:OLCZ8(:
M$!Q4O>7^I1]EC620K$0LV&I,062SA7 WU"&4DG,#M^5<)J^NQ'=<%.50?CJ2
M3#KSU+,9X@IV"J8V'(4,MO'=FCJ(S5QI?^TUQ^J8L7E30)#BXB?#@7/7@H@-
M^9&-#\GZR)BV)PK4N"=@6*[%JZ[.2V:15C*=6JZ'SYL38-O'Y,O^YF;R'TJ5
M%&SC/"(VH+4\87GKS?)I*0@@[8:4F8MQ_6"9Z8)2NN=M;^D,Q^S6MV^8.BAB
MJEIN&Y%P-6S'O:TI5YVR_C2* O?P5=,%*:';(WWA6VU\&BBLY!A/H>=*HLBC
MN#ZMHKU-S;WRVLO7%^K>U3'FGMQV^IX>X>8]CNJ-OOK.'!0X)VU?&V\[?OEU
M#5O2X.JQ1UC'59^HMR\^TWM:4J6CJK5'@XRKMI*LG.GBW499M184$'?2R.0*
MII/=[$1W9U(56SOZN1PREF"'MB./4)_,R#&97:,FIG5Y8YS).XS:$JX%WZZH
MOQ7Q=P\+%Q!57[E%''6V^,CUM&?()GF,4 O)DVZ#G1.I0&8A81[YZQF3M9*U
M#-@79B:QQMZ2+HS>#F)1_?T#J3Y&[&1]GZT3P<[E?$# 9C/TN;BKLGE[ PJ!
M>7KWL/S0_-J*JG!PL6@^>S<K'P?B;/+C\Z!\5.\V'+Y+[LQBMRV34^/K8?,]
MLV=*_Z-RYJI1UCN3B,>#J?O]G_UZ[/-.KF/<UCHU\LRV%B^/5A1\>8M"KM?F
M *8.:\[3^K?DN6?[UC.?=? @X8P9.Y(2 ;$A#MN@NM^ MB=W.MQ+K)R.C*0R
M>JJF#F>#TU(+3*]J\;\WY1Y#^@M*BMX0$_$5 9P7[B5^)YX[.SFG@0D6BFXU
MS5]08=G,2"T/CK@&UW(4J+JKM<J\=F]TR<TVKK:&LDZ8TL?7NK8^C'OY:+*Y
MOJ9H<ZCD=NGMDME!ZDR0N%&LT\D[M"B#XS.*J@JJ)62"\^ZA+*IP-6LRTAI-
M'_*();ZR^T/.PDICS.%#\8'NKU="'I,^NK 0S1FC^$0K03I(P!L[N>+J?M@\
M)L>Y)$2WT7P8Z^%49*KEX%ZT<%KV^4K MSNC>Z/S5U4O7/<6- 04B% -1$[@
MF+&:(S@^C.94E]E%2-K%UB2&X,+\)+;\TFN?XD.I/U4,J))RT8#B)J#VV1<-
MT5>WOH"^'Z:7J0J8L<9*"]32?[GS4","P\IOXZ"J_&I:1%;T#$<B'$PE%.XE
M:RGAOGN@3&HSE9'=D8&PM^?_-/1A.27\'H/JV?![@,\ZV>D\:]K$,08A$U66
M8#&;&#.^BU_H?OR9ZUKAVZ?_>$(S8:F_40&9*W]^P>I:C@K%S3ZB.-Q]$'-)
MM8#^]]% 7WZZ1X[3U1:T"8HR1+NNU+E!0B=F<\"S3@%%;?!3S2U]/."Y&ZPK
M(RN#GS8X;791S<N>PP6.*B2[(24IS;Q,*12="\EWY/,FB1 WKU39]HZ7U6R=
M<'.=VJ;5\."_\A8/,'O_FLC@/-&56YJA&K(ZX>G;M7 M(-6BX\@F2T=],^I3
M"+T_BV/#:2KSM#IU:J*4J-10?"MU6H5?V"'HB_?)5A.X_F!!IF?O^[!!T^AV
MT3/7XN9ZD6-/8<?7SZY>FGCZH!BP])A"IEKU:-V?K7%'Q[Q\#HL'?&6H4'0L
MUTZ9H^0U0O-4I&=D9+(SZ:ADR()D<WDT+LAWP$+[SO? >+8KE%-9 HJ1Y'D;
M"K+O45G-1N6GA<%-+K-W0FD]+X=]IBUX,I"\!Q4\C%-E71&D9K B%"IW(I:0
M9FXMU>O-T9GWDNHH95:YLM^VO=*68Q:A*6V];G2/R_)-Y+#X--@^E]H<@U"\
MJ%P! HD'O-_2LAGKYE)T8L0#'/@_HYFSQ!U>C+)Q&+OI.!RIX 'U!?7MN;X&
M&:A$I'IS1-B;+2N>,5@GHV] 2'G)O!IWLPZ%4;)JR^B=K%2 @N2KZ=IS\4\%
M<6'ZIT40;7+=";M).5D$.P<>H*LEG9#N[4K6F$'^^KF(-D?_ZPO'ST,+P^*+
M^3:W%&? ']]MU,^ZKNR4ESFE36:$/Y?TU>^BDPWL54L6UI=P3TVYUMU V<O=
MV+FK:#]TT:1V/,4$?1Y:96U-?C-3OSWCG <]8RT9(EQ2J83)CSM:']FX4AO*
M>JB]?M<V7LNH_E3QTU;K&?35L5[8W+WN8FLGJ>_RZ+%=ESJ&. VV'#-U4I&6
M?#ZNJ \1\O[=WGC YR8H.8:N\V- 0[0$N4855Z95NZ72BKW=C612VTC2LW&"
MTR_W-/KEE@!>D1L6>W7[\C>"L.TXN(H ??R=MVDQ ,T??^O]]82:&;.$#KR'
M\47 2#88<9=1O>$NWE'N!8T30=KGM.C$R<GNW!.\PNPNTERS+LP7/0(&:3M/
MF@C):7P]*8$4H JA44(I.M%!)_)C@VS)BMDW[ 5JRI_?&PU:H.);J$L\.PVR
M$D?A ='%:2ON7NIN>0T)DGH78Y]=>K+DIL%AMD3D+3WDV2Z* >9AY@S1W <'
MBWD4S;CG<HI> @4JA@W4G)&)USQX[-QTU'3XWHH6@\3]4Z\C_.?S!(3>'@N-
M5_N>W/(+Z43HY'X=C-7"N$N0B)@MJM?P&]R,_'S%5M1_Q0>]2MK:!A/$HDTY
MJ$_+@QB6*(%6DU?,M^2!:I# X]U5D\*XCP6A8$^N>-8C6DTZ)2JE@RXT;HB#
MO0%=$,(9:S29K'Y@.)GV08,DZ3#/_?#)S%[KITMX0&3(F16?Y7%&Q?>Y88@)
MB7*DYI8AFJBY*%,RA=/YR9U1;D@%>>EK3E,[]]3'W^026E0O/5H^'8K& URA
MVK"%+Y,8W1,E/X<E^N]U]3&U:H'%*@Q=]4CYRGZ1_A9;OCEM?O\!X1LFHDNI
M@%!G+#FFJ0JK/R[GRM@$A\/31KQO(@6VN1\<\5TT[[T!Z1*YM\U%";%UO**C
MSG40<@X3B >0RDGQ"44=#--IB/;2#5;,J^(,/4HOE"2IL9SKYSY,=\%^FK;0
MAH,CFWV?>^]>W)STM-3P0/!UM3=K+&AR5ERGH7WZ)GSN$B_7GJY\&6M$&0\J
MX<J>=/N13.['&#/-OAUIH8CFB.PR/Y]-5]'.$YD9[W@CDDCI!?& \"Y/#8**
MW,8I0.24J45OYY"S9>#MIJ9<76V)I0EO63T*)XAH9["<EM"D2IRZ[I/E*=T-
M[9T["O1!,TO5L[)="DR8UXA@JL^[G;Z*,S()F0Y.\/2&%YNS;RT*>%3#NWM$
M<T#  W[AK*3)9J'(7(C+[&*;9"*"\L+F3#&:JO#MQO?"EQ=<N21[5$VF_2N%
M7MG&OVI(HWEQZS+:*O,-AEJ'0,,8.>UJ\T$/;E@43RBHX/7+GGAZO@M1'^[=
MNO$T*^5S2&I?\?8W>,GDK&3S^+*Z=PO2[_KK\QL[^1G2AJFW?,[((CLH2)EM
M8?D9V14CJR=R9NFBJ1.+.<9X ">+XNQ81Z<&6OM@(:>P.)>JUUU@HK)W)NY3
M;?]*Y\>['WD$GAK9LO*HHMY6. /KI)Y[0<^:8-[NL+:8"%4G9(- <I-)D+VG
M)B^SBQD_9=YV%]:NC7-;V!NW8CY-@P O3%N9FV+2NS)WQ#-=F0495TD?-80N
MS,!G5I2>OC!]-G_I)J^?2Q94\S0-*Y"W7NI4["Q3&%',4>7=5U>N4A>QRI</
M3/M44W!VGD\ME6_%]7+R;3?'T[[TJ<I*:#%.%:+(YHK50(4N]7)0C51A=?
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M:ZW$\^\%LC;F!ZXO(C2P#6"^)ZY.C^[[Q:@SU$#EQJQZ*_N2>X,SP4:$-"$
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MA!99X^=8=V0)M*9\^H'O'OR-[XPCE/7R!<HFV-1B*^135B4OFWZ'8./(4J-
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M$+WPD9Q/=>K3&?81S>_RM6%4&_@"4>\N@R71]-$HD;C*'[]6HF)E"C=;#FE
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MO!;WFH GLI$F2)+GLQ%V*L7*UR-?*C>\9@?-4H6_W.(]9Z>%*ZW,(HI\&-&
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MLZC04X8E)&EX;?MB^'D-0-VRFH5&_+])A?Z3*E^$M,LR0_]WRU7*[:-&ZPD
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M$P9%3]3-+'!3JH[MIF.]5KARWW0?Y;ST[0''M5VS2A>7=RKEN!V77^>^+M@
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M .H,10XH0Q!:$R5=R$/'./06^.$$,.M<8#3O!%[1P3[85#YURUFD7^957YA
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M0K>)!?0B.$O/VC/TA/O^W:?I>W_Y-"V\<;[\RR;0_#@;-30D?8):TE)[@<H
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M#B"/HZ)GT0;@E]C"4A$J)A#.J:S[Q'WST/TJH"RB=A#YTGIK8Z1_N/GE>"O
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M@)\?O_P23*!]'G)+X%(AY9X$-;4#EMTYGB^\[^M?(%,GIR)[Y^X<E7< 4>V
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M_/[/[&#4]NSB^+W?6K1XP4=&@8MBZ^OGRUQ] FLX<@+[I )W &R=R7O$J?B
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M]ILRY"GWL0A2VJC!#857=L(;$E047*#)3CM<EJXG6-.J&?E45N7#^^,\I7U
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MD(9OZ NTIG=,5-X5]@58K<M@E4>=V5BL;B*SC_NAL A+&Y5MM[C*S69^!8\
M$8=)Y=@>!;ZYL:E?:WS5KY09+Y7K9 %CSE\*>/-B %]31W.,5>WK.(/F$=,Q
M+"2VQR;*E1S7*=B$Z"LETN ]%F]ABWP/##Y6';(\\$2.H#>&(8]]6*$J*#N]
M9A%[]9JI.X&IKN5PP[K+!]SFL6+S=F9H.A-W5ISW1-A R/A-S<D.&<1SDH+"
MH6IOP4):['.XPB01,M11X>W1H6:Z)2F-RTT1=L;H4)O@BJ816_QMI#0MM4Z!
MH:CNYR:><'/@S%9/PB J7GL<7]7:-M_\>7C;&?'\X5NP\WG$UN;3NG]N8X'=
MFG.$Q0)':0H&O-@I&&C3^0Y\>[;I4AS=]UUM_2INCP@^P#Q\>YQY4=/VZ"F7
M2%R6EQ)<.5U0"-OJI_4L0OH#^#BRVC"'SYBQFJ1X.$*6BTSU9>EL76$UOF-&
M725&_5[U>L[',2O?/$\ Y& 71L\:+KI8H8&PY?,/:/Q-DS?UA((21FZY>;=*
MR&(CB(M-6@O=?#])#EV<>UC&X=?ES,@FJS<GQTX(E"U9[G.)2IV,2%/4KZ+D
M)SIU$*(4OHG#;^2E^8U9AJ&4;XJ/K7@SNMG1JF/!D,P"069'?!<YGTR-BY%\
M,Z)!GO>BX"96SF\59.N/B&_>7''X-03A2_&"[R76-CV3-DR4&CMLZ9,S'0$2
ME[7AJ$@A^4-YS&1$LH&4!G)K'V.A'LWOTSFY#&3B&ZC4_+_DA8KT[DKO%S C
M?+VH2$L6G11E2L?)._T\,?>K.$H/'D&+ZR)AMNY9+RZJ%:;7^BC;F23?44WP
M[D(DR0?9 .%+%%7M&W\,Z]J#W.ZV-K2WX S5Y$:-NNVSC8ZX(U!BUO:KE=8%
M_!E#<F%+.'U+/!D\=$IZ5N4B#MLO[R@. +X<II 5B0$X?65>>[/X=^W$6>&#
M$![_78UC5(L\=O-E 8QSBBU^+Q[__'KAR_U7W3GE%JTY*?06+4BEIA36VK];
M!BL6R:$J>1("-D+C2_XVY*L2"[KY_DW$ZV\E3.[0<A]$TNW=XL:%[85ZB_80
M UG2@4CSH_44-T6Q2W7A6KZ_&F)JW<O@[]^#350:+N'X<SC<H2BT\</N+7D$
MH=(CWL/&)<'D.OP4@!_#?SNA6I)J^H]BO) X5[6U-[9%**<T1@*O_C$?5B[K
M8X5U4]=V]<:V3*L.D4@RA#+L7)A(G!"HKCX/:>G6;6O'IL?\<)?"%V>0EV(8
M#3I:7*K_5Y>9J?\ C 1P_C6*DI*.YI@S#:7N :%D'WI,;.G=RI)@BA;-@X0>
M59'_(#GN@UU0K-W';*D27S1-%9W;W4[X[I?YJ1T88XW24T2B\M/<WCR)[-^V
MZPDD&PSA34^8='?J6^N(BA7/Z!?F(HJKRE09V2UXE^ Q;.RJJ;CQPUP.-S:@
M/E;[JY?M)3^-+_IG!3G9KT^F]6X'%+?.5C)80-&^4>EYJ*BDJ!Q^MX2 E/M!
MQ0C^I'71B'VT^H/DQHS95V47C='7H^+5FZ\O$&Q]1;:*6S,$/&3]<@L9V801
M75,=3-T+(CYS>CQ3*'0X@'J7V,[;V2)V-S?*#-(7&9>#WI3JBKK/RLQ(->10
M*(N>"<RQ3V+84HGUE"7>0()A<<DCXM\12=3N0QQ<E@<.7FL*NS1_Z]YXJ]34
M(/.1AA&,_ V 1K_94CC<Y0%Q2W"2 :<C2PQ+'$[B"F!EIR;YJ/QU;6N5;<;O
MM!'%][(6).F7> N^7XK/48^,G[:PK\>TM7PX&32]><5291P';4W_  3NH_QI
M=@-&-X,%5H:Z_#:E[<G-V";J>"$L-4<EW40#@C2>4<[V*>(&X_7JIA#+^-?A
M5H\R7-\>A ;BCA*U$T<ZS^C[R8F&NJSKS9@+A,RE"1YPN9(XWK;M$1_\IM/=
M-M5_6^^XMH<[3]$:)3>&FZX+^@S:0Q02?]1 ?@,S,V^8D^XRG->-JTN&V;L]
M*M,3#8:+>]E0^L98!O(M5!CJ"4Y=R!\*?+<RZ&+%9;C\-7JD/2IV7?X!0VJ!
M3]W/_U?JH2PD'7= \+R/#L5G=!.T%S)B1S'@Q;V:M>80'HUHU81.%J^1XG5U
M6?5DBS#ZQ.!KYA".XW*&NFEPQFB^+3!O >2E1:U6"5E?#/J58?0<\7)CD:*L
M#+;J7(^";RA8Q']$P"8I/EJN4M_QHS*"C[TLP1P<RJ[JS[YX6!C<H0C%E]*-
M3I7>A30FQY%W5WKKC2PH=2\4^X5@)CTGWP'*=5!&MM*P$_OW7<2Q (I_ .A6
M<:FD"]/N9,^[N3[M"+B]2Q38AP#$%C?>DV##O\7U"0>F[=32>L("\]%05/3F
M\=4OH$*U,'&6\I'$BBV[3K^3"L,*4T9=DS,Z=?9>DRQ)CQ3NL+#D]IB)IE\_
M(T&_3C$@U5P+YZ8I5FEP>-:4C[Z;;@EW%9('"W=J,#-B'>R"J*&P<MA/J -7
M@0?)*U7T$YEHLD;3MN<Z"@XJ:LPGP;CKCO<Z5S;)I2YQ="TY:DKG>_:4.RZ*
ME!QRKLG&;=4D$3]AO,CAPR.E1 D%)/[RJFX'7('6X45":A38-<4* ^D_M#;L
M)*A72IL^IX"'TO>OS!UJ 0H, I#7MDIO7HL%2UDD"!5A-]T-=06$P=F:"Z]#
M>LB%-F7A28+<&F\Y%!YR$6H^Q;=4$^^796)"X!:<WP[7CWQD/CM.99E*KW:3
M'C9Q,LQ]JH,T$ =H4>AB6,_U6[Q^KN;NX,P\L*P /I0"3)/S=(S*ZTOY,M:L
MUI/LO<*F#)V ,7S I]&A>@+&;<H;K& ?JCZ4W_>3RLG%!N<8V:G^D /%YEY$
M@?4W0D*HJ=]TO%Z$Y@_M="9IO2VN*.MA(Y)==;H?K*D^#Q[0"(JSYB\X7G<X
M\D44ZG9D.UG(>[3(@/ _[UB9TT_$)2'BU[@(U1JUY9>MV:VEPWQ3!ETK98]X
MC140!@REY*SA(2]U>"L%"O0Q@.\D0QEWY,YK9XAJY)I.M:_%WBD8<"QC=AI3
M=U):%(OILDJ2C[IV*#I!]I7;VSV@/TBO!":PA;7HG41QY>UKBW^LX-MNJJPH
MN]8P#&PY68,HVPX>VCADF.GI ">CI/5,O_+34K\I;=JES-M9R6W<P0:&DSL>
M,MG[;BE_!\L[U)UD>AU:SM6G6\4I.O?>)_!(& 9!+[FU"S.]QVB3N%19@\CL
M<2P</ 4R':-!BI[,,3=YHXA$KP:YL:8G_7LDWI?EZ6Y(RK?/.=?O0=1NMQUM
MS]@;R)3>A2%5L12U 2C'#$*^7KK]@#%!&'KBNS:,1Y'KE#'D$CH*^$>(53ZI
M?/IU)B[G.@RP'M_[H;>EE>YQX]P\O0\?S;Z;?=QB:T-BHJ4.@AX&$GE)$JZW
M'F9C&,*1>V5".1(N:/78BE^AL)1+6=,IK$L832<\*F?L_B0?J<<<A&:Z\G<7
M16LV31+ P)9DI]"\5ZN)@]S#KO:R!ZNA^*3P#'4.>531V<DD]QG<JMNB5S+#
M1E4)NA"6J0VVAEA*Z)3F$B$9F@7N/CX)Z8A?C'\!=[I3I6RC?.*I]26@'7':
MD\+' W[YACW837'->[=^P]N:-9:T/N7\>&$2:L;'5OQ- EJ]7F9Z+M[\-11+
M8[E%7&">..4/0*NCO9E6!@E?Q#'\&P1%K-I\,T:9\Y$/^&GGV:RUGI\C1RB5
M;;)K\X,($V";1V*N@\;XU63BB,VC&EIEPL3:Q,Z^ BCC06]7*AMYB,''.*$X
MNA^5RF5+8G: _26YRF3#:0NT];W"SM)KA#(J-;CF(U4-JMCV'N\?P "KG3=\
M^F;QMV/\$7NTYZ4@]\QV/_0&M.<E_"/.%,'VR:Y\G%(%U*'-%LH?7W=HB$XO
M_$W;:QT!:D&*= 18<(2YEAT3#!,23$W3#62T9.LG=RHRN"!BZZ1&](\X\ Y2
MX\Y[W(\UI>C+FD,#,IBE'XS$K%Y+W1\UJ*OY'*GZ"]OQI!DZ94[@C19HO)PI
M(%&5-NR-G21PQP L"T3GBS^.G7D5*1[X6 _L3<\,_ $<WSJ-?%4[M0B;MI7?
MQ2"3.'W\$LC>(3>;I<-%.GJGX/@WQ+*^FNP7T8^DZ^_()5!N9Q1*]4B(X+X<
M)8_;Z=K[?#<=BT4S>8$\O<KU0-PXBN0Z<BAO@S&5@E6*TQ(,F)$^&0,@W/R,
M]3@3V=VER.R(+HHO\Q)(2:.38G((7]M'G%,4E^/!TH5=+!<BY[F_8TK?A]02
M@)7)M&%T5SR%W?M_ -2\<'YEC5^!&<Y.-]VYL>&\0_V3\J26<IK)A9Q3],5K
M0R$)P:Z*G^RZ9.,'U:$UQC].0#%7I+>G ?-5NE[?O.*?N?3OFQ10 >3DB;&9
MJDL<=66MCK(.MU&'G.')G_='O"?RJPL>R*[[/7QOBWT\5 NRJ8;CG!HGWW2M
M<NP"&7 KEC6[4TS4L8*]IR7Q9$I-I*M'@_C[[99%;<"V&^7ZP'P5:<)&1V[G
M3+$WLX#E@.';>*I%7L;2.O:>A6H'9;"P98(AKH6#.?[8WN1#$D]A9O+X&,K'
M0*9EE15NB7134()G6QQCR2FUG*[K^$<S+V[0I5M'_XGLEP3J/9V6UD?R8<*D
M:*;L395W0UVG2.\T+O.</&>\4<OEW0/*C(>K?:!W&5?/Q=8\,DZ'&MMH_>%*
M-%R!IV'!@S^]=DO:1?C<#:3XE;=H1Q@,+/7P>$V3?M*IIZA$.#II)ZEA 41H
MHE3_ -#6?^</1V8*'5(PV"&E8'4W^8]]#0D>2B)S*0MUC5E*?0]K72J/.%Y>
M9A<1,O+J4LZPT24=^?[T&47--8(IS/AFB)IB\3I[=S'G1)^W,TK1IY)WG6G,
M92(45TK#.]5)>#]G(]PC=O+Q!(AH4I=4HDJ94;?<:]2@*YC^S=O_;%SLN@CS
MY[V!VI8%O$(DV]*59V**G!"_Q2]AT11;Y\A50[('[.L<1:"SU(HA9"YA4J5B
M;'.0E+(3O%>21B]\C%/NOKRF'EG?,FGH\?BST6YAO05!U"K>O-,Z^XN'W$Q(
M+$ ?B?DD9F7AFHJ'HOJ&G9'9T;J+.64<JZOBK8)R!(7T^E!3BJ^IQ^O@-]ZI
MHT'?1,HR0CP6#@92SKH7Q:++UPT@,9+L[869"7**B#&+J<._+?&-0?/CZ.U:
M\[S]M-(A&<"V,VO ?A4HP4V(G_TP$N*_(B=#ZQ U+U8,J!@8-L3F06//^QUB
M(+B%#6'L6.1DKX '>!+004,!,CS!X"D\G^"+/*?1OPD; #*\6R]BJQ*J+X6(
MWRP#<NPPK71K"L56V$Z(%!>NX;K?7=LE?D,8ZID[8;LO+SMRF9L^L=,W*NH>
M%^QB1]'OJMI8J/V%YYQ=;#6*?T:)4H*^#]$\,>U-7Z7\=K>5M1TG)Y/)8XFB
MV&<Z%'6NFAT@;1MOMS@*%S/"36+TZ:>&DA9#4F.86=]E&5Z;#K=N4I4>K8#7
M\ZD7Z=]Y=S$<WQK^=/MBM=Y6&I6!+I5TOO;JLTP/U,40$?ASOGP>)HGU<4[5
MV<>[[9B+;0N=S*4;FMS"#<(^<A9&+.>11 ./'K&NFRA3Q">#XK)"!".9LS34
ME!+ KMON4GC'U!R9ZLMLI^2;2T:><2\O5Q,^&-S(9GKJFT0C"A,%\O7OVR_>
MYWJZ_!H5==;7>2CQU&>(":V3(W4B72\+]IVK\89X*L?_#/(AZCXC,**GB]&H
M%*)+2[_[IL^O"2-"G6W7Z)5##ISI&U&MPJ9Q]'F+!L+YTK$-X);"@EULQ-=-
M15->(>,V>H:^?35.3PL/%\UE"=0<_RZZNURY:WO&9]"*89!SO4Y$_,N=0DE=
MJ)\,B=DB5#*RE6>E_W:Y'@BNK<0M<VB=P#T4Y*C;XG#/D"S\Q/< HZEX+V.'
MO/_Z]QH\$.Y7;DAO;9$_5>8F3^OKQ ?4NQHESH#>-A)"VW+6C0-*A,I3Z:+P
M/J+%43:>)?E:"-?BW??V5T2@IM7--P+*>/@L,/M0 KIU4LH 0_C>9'NLJ!\=
MZY]"*%-9I.33@JMT->F2=;"^>% #KA&_\,W>R^PDJ Q6?8#+#66;1^AJOEDW
MP/<Z)V6Z5]@&N#$C*#L3@=]/XP]2]I-_H'N90TH2X=::O%2H4:"E#G!=21&
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M9Z+F:TCSJZ*!>QI:&KJW(OO;P%S!Q$^G.QF'HL\2#U;9N!OOB" +=^ 8(,,
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M% PDI2==\+[2-R%YE&+/D?LL?>@4'2CO96J0D:_##(\O_]V^N8<DP0?K[5A
M-#%<:TX+:JRM59;$R<9+T?O R0*DX4*E]Y*G)1>4P.I(,J1Y/;.K\%5N0>F4
M^ELD&T/LOK!S[G/JJ%&KU?:#(\=--?$+..MGR4#]R&R&ZCPWJ 8Q!&8!R@M
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M?]14_A]"U?^3_[L2]&?U_P-02P,$%     @ *S]T6+,44!6$R@$ ]NP! !0
M  !B;G1X+3(P,C,Q,C,Q7V<S+FIP9^RZ95C;79<O'+S%78JV4"A67(JEE.(W
M3G%IB[N[!"ENQ5M:W!T*@>+%B[L&#>X)FD)(#O=S9N;,/&?>ZYTYU[G>3^].
MUH=D[;WVDKU^>ZU_@EY$;P!(5124%0 8&!B ]P\O !H"D -@86+^_7X8V ]O
MG$<X.-C8./AX>+B/"/$)"0GP"0B(B,E)B8C)B D(2*E)R2@HJ:BH"$EH:*DI
M:<DIJ2C_%H*!]; &&^<Q#LYC2B("(LK_]D#_ I ]PIC#;L/"> ; ),/ (L-
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MK9],>)Z.TDIJC9 7-;E^[5X_O[O>/#(G]:W51H26(=]D;IE>%Q<A2:8MIM"
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M0KBA7'>4B29E]G0ZT^^Y=T20QE\KTK8KT@XC(BXQ3Y!,@K.>O&*JS5TI_-@
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MT0#?I:[9H4L1V!Z2 @WHW>O/Q9+AV@^V:T9-SW(T7,BRVGQUI)#R=ZYM^<)
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MI2TA 8VM_G!G>K6L?*TG'OLO>Q+XROY';HVFH(?DFY2BM#C2G[^X_J0^STH
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MW@LG&6<.R1(#UE>:P7'*+#,->,#\\Z/G+9-0(9CIE!3M]8/9PXQLYUSW?:Y
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MLOH4G?:&;XJQ3P'$3=R1L#UE)DRRMX^X7E/<N%%3-B5G[<O'1M$FN YR/W8
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M%IQBZ2E0^VKL;),N]N8[:T8J>#J S%-X 'E^C%2PTO%W<RYP)DW[%FWQN0
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M7.(SQS8^CC!G?!2+4W2)>3$64$0BMW*^'VK#)K9CT<0\4Y!:G*QFTMXX56U
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MJP&2W +UKW_^$YP_UT>7EN !S"\HE2; &VOMK_$ ^X%X/*#4LCKT<<A*(A[
M>V^=\II>4O^&?\9C@G_#0?\@]+^E2L Q'A__F\B-\!82)5S%YLG'?IIMXN-N
MRG_@^XC;RU!4D^Z8MPL,468',75R$)1[XP'OO0Y*)N?&,T0_9:FS'EXVOU1^
M,_=7G'QDS_8)Y?ZZ\A>T[=8 LV;BT>F(U4A_1\=DL<:B;Q"]HXO9RY?IP?P^
MZ?SZ$FR0@/+G/K&7MIV0,1 %5J@":]R 9F\+65-(95E=MFGM++[IS.*9.=^Z
MRQDR@(B>9P40W:D9[-==+X0 Z_I:>>"TLS+B[I7VA3OW'UVS\-P4I>62M3Q?
M*X"P4;(G(BGG%4=K=H,Z&=%9I0@%MI<9(>4+E8P;8T'"IL\N(YV[.-9YF^A6
MK;#W4:/PGGE%$L[/.X9.2?V#!4[+S3IMP& JL0%1P(#LU^/OFV?IZ;#\G(Z+
MEG^KJ!$<4>UD^&.P2]52L(NA9FS<U^R0],.G;9E&(0O0M.8W;'<8E7Y&2@?;
MK@X4PF3>2UH-E>GH5,N9.A!\"E)Q<=;MS1,U+"=\J^NU Z_=2=_M80L;N"IK
M^6JNO!?Q:")=DN!;M..KXJ\*)MI,&P'LL=581F;X@ @E!B$EYDF?X7'^NJRZ
M1BV*FVFUW>'&11?>>Z1:WSU62J=K9&!FI^ 5W#_XK@'Z'@[SCA$,%WN016\V
MZ[39)-X>\\\B,\XBGFO#**E 7?P(L?(%+7'>B#;-K.:><GL[/Q@@U&[XB2:-
MEI^ [E%M]OBPZB^V>MMY9&&,-U(_B9T-/7[^LXGYV5W@SYM<<"ZNOE B>!%7
M?UU^>#UU"GHO5(QUFL6&+I3GWY0Z"REWGT=TVA*J!7UIW[HQN]!<^0K_KE.8
M.;BTU=&>RH8Q0BSJ0\ P\ >LTC<FCDFBPG8KR:HUIT?A-'T9<<[=W'FLID'=
M=I <F4$X7?!47Z3T0_>@"=O+^P[GD ]/RV7'>B@ =P!CRD;3<\WFX2S2=BPP
MX >[A?[^S9^-N/%K:>GPM)HC"3#(3W9Q=:%%GQ$WXE817'?49_L0[5RZUG;]
MSZ65/NR+=>W0P)P&D_?G:*UQ%3ZNW0#[[)91.IZ#C7,YZ#P"V&W'I A>LY$_
MM"JDL'S4\L[F@B1/_('+'(5Q <Y\7&HDG E-7X0 S4.1RA5E$H]/929)2O1J
ML[2R@R]>]N'H3AEZO*.O]'MLI-%"/+DO9T0^*_TK]?<3',Q("F3B/N/-2/<
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M2#_S6F6(?OHN+5LA\.,2@%CU)?:5(<C1#G(SF.]*?'.9U0ZWSNT!HFIXXT2
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MT>+%=.W#2#W8W.Y"/P1RNIBL:=S9..5_'; J-;-426L K52@ ESE=/U1%L0
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MR/!YVIQ(LR<T&\L/><$L<6]VC.U4T+_O@EO-B;6)9H4RZ\N\BZ;>2-O$75=
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M']!(RC)_"+M(.HNXSI,GA-BB6G/8Y(EGD.BL0-.*Z0.^[("<^Y().6E);QL
MPA5T2"I$*Q.J-16A]?T60-&L6[A0NQ+"*\8G9U=NEO(Z*WGMV*FIKE)&C?<A
M[7[*Z9564"M.)69.PC\7]2;3*R^3A+^B6LO+AT-71^LQU0/^CZ^JUV)T%(0
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M\[-^$"5H41_HZ?9YO)X2P\+@ASUYDR\'<TVXY2S([)+HN<VS? P?2J53G*+
M7ZP;_2&QB+GHM]Z"$E>&%F+^T($P6_)"47LRBF>($V44V"R#.NY;9H62SN_
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MK!%[$1M@O9#,3?,'PNT0E@Q!OB!'5= O2;98=RT[U4L/(O=B]4EY*Q24GA6
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MCR/IPP1%V_S/5E<,5'*,;BJU0M].5Y0+\,-A^JKFJ6()Q40+S_*I\LF4\&3
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MY27?$(W]8D/F9G;F++X45<X-V%+!(ZN&$X7<WQZ[(W'-B!)[6&]XZ ?^B\(
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M>J&PZ@ZG-P_[YVR4M(WFPY#3W!TZ'<[ES#;=9B2O\V[E!$G,,E7N %\K!^\
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M $3IR1U@71?2J %MX61U_(QS07O->"V!<0(+HLRZQ5M?#HM5M:2QP%Z:_:$
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M4*)3K;0;F\BP,O1<DK\!),=V<)RRIMX M!'UB%L$]V+_;SHY$_M$DKZE9ZM
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MG%X6Q,T+OT@,?X0^05<D [<?+1B3_T(R*!S\#O*O>0)=Z>L5H0:]6[X-*Z/
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M8E510E8KT$]73PJ6G+Z#"N#Q18OSV@&M<P.>3M_WWU6TO!4((,W+(2$LBP_
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MTSUVZ%:5B.+%Q:3-VX<1^DS&#EQM&BXTL+-9#_S&1MHOOT$U/!BC_;?H@L[
MC9G$<FPS7SVID=@H75ON2']\9Z?^N-K0+RIEIOZ'/W7WZ]$.'VX Q)\RMV\
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M_SJJ_A$:(*D6SV+1^'W7GO%T@_E]C)'S87VCPC*J[Z,K4-0IA!93T@4E=KP
M?B0?G#6?[RLQ-1GR $]\Z]M<<?.QX;:V_LZTQ21UV)P1#F8(\'9;FZTKM<[^
M?<D1;<HMW9@N 1Q>N%^H(*[^2$8\^<N&_1" & *WNG<=N1J1MGHI:%* 1L3X
M],#GN30N=+Y9WYW-,WOK^YCQ>H"!"5Z];#5^)437G2XW4V9#UQY5-#DQ<QLZ
M^1TM))%R ?SZR^<;T@E"^Q@7G'3*8]8CHB&FB:1A9?HZ11Z!^O67CYJ[_2.O
MQ/Q=H]D;@RBC[N8LV4/]O9TKO!D&C83A&R(17('E[P.8!A3%KP]R2W6+"2>@
MED'^#E-= B3]+TSY"HW_96(.R/08P N6[2Q3OCOQL/BW#F6+.Z+&\W (J#1#
M1J^KXG$G'A%;Z-!=@C7N-5XZ?^!4W:L[^N/_\9V[9SL=9-W\UH_O/2F$;/<B
M6RBZ?MT _DM*CNZ/S_]:><8^14+IG&I  V\_N@TGKB$BN%05L[3(_Y2.LWZ+
M.7>4E(8]/,E!C?M/,)DP8K!LMF']$:1!BK3_9$1VH4!!;X2+8ZFYE"==BFP=
M$/*';1=IVLIU6HT6B6HU66%Q,^H\UJ:,51 I4Z_<WB0:7W^?GV(\;K7A(-:R
M3UC6XT=T!)T;[0"RS%QI5FOG@]].@QT4]\*.NV=DD-Q.]$6MM/Q<0U0>@H>
MT*N"#S$MY8X7)7M_UZJXNL:PRZ_'@(P[XSH7*H\UO2[LNJ@VQS(,'SVL]+.1
M]ULK%OQG224/E]F2<ZTY6!N;6**+2Z178"(@=A.GV20?2_+WK(O83JQRV0X1
MT45>HNZEECK29QU&MK*L-#2GK.DWAYJ9CY3]/'<AX!+"5?D? *MB?DGFE3P2
MR"G7=Q8T6 3S8E2Z<(];$U].U!=-^1+$_;A':.AJS3#P2F(W<?"7!]*Y=TUY
M JR$D=>*&BC#LF,M%]09Y4LF;;O]DST1ZT!K]E+!%/16CR-8L&I(X3;ZZJER
M(Z=,@Q1&?#J.[[ +E@5&-,<>(N\%O^M%_;;Z"*42WA<N<'P4XR;'8Z1F45G(
M%$# &B*YXW4<E/_I]'?6FVEH\EYZ<U$N+H.BZ.ZP1\D(49-6&/QM]&=1\$FO
M4IKR:CNMXY)@Y+[IHYJWE?/<,+.1DH7"/Y5*GSYSX^];D9IAX;W(LTY*JBNZ
M'UA/5)6*\9CP:OS;S*]1L,\.]SO).\5M/<)?VE:'')J>>83""*?6L&T56!AE
M9.2J>B3/^.K$_#.'3XK7@_W&.N-=+_A4Y?%]GTAES@2+\C/:AD@6E.67XO.J
M8>A@]:7.#0WC@Y!:>S.3$KL[O)^_M0BPKN^3?<6$ZHAKN+K8PURF3[1M]+%.
M=\M[&QM.0T2GH.8-K1,\TRG&VCV3JILFW0,\71$I<PUE*VZN="].:CZ=^L,X
ML)XE3N0\*RW9^_:=)1-V=5J@QI9G$0^/OG"]YJ/F>3__K SOPRNBDW()*Y$K
MB1^3/I31[ 3$JVT&&HBJ.G+55A5/(%12.\"OW?Z^YJ^:"]OP(:@4Z;KL><)[
MQ;6^L1TD @ZE4E_M2R%WWGV9Z<KQB(G>,.K<8;-3;8#-\R."%F_*G;TN_O@]
MI=11=2KZ]."XZZ*J/B_;DSTMH.S/0PL)'7353#C !Z:6IT<VJ<DE&\6;*?KF
M66F)-YVKFS,'Y>K8P5]!_BO>Q^V4;F!+87=)>47^K<8@O\F'KT'[-@:;W8V\
MCTOC9*YFSQDC"%M 1CWTL,=UK<UU"8X%#;#F[YZRKUXFO1Q_PLB[\?A30B2!
M+7Z/VR;,=%R!R\ZFY,\R.A7$:PA#O_3/N@&D%F@6:(.LL[0Z9E(4RRM^#0.]
M"K,UM&<79,@Z2Z_XI^LAA-@8#VI0R.$;##DTU ?K:OOK0[6=MO+=U>O)U4;S
M!V)A?[3LVI'K^#O#%\P)3I]$6^/$2TE9 TG.S[K3+SXS;T7[6.TI.J,.]3%^
ML17*WAXEVCP_ZE6L>;QE59@_BPZDV2]^R*%.$<'R*D^Z@K4]KZM6K@TA41Q(
MN8^C***3.3WF1:0!L0O\4SH'SS?53_)I#R!^"C]?D>:UKW+<-P/!X7(Z;?8I
M/0YE<ST!9/X 8CKNIQVB!*$=U$G$3*.\5:[V,)7I5D*45B(Y5GKIM O4VDZT
M/=-L?TAFON,?&/+U0^M,>(IC>-S*-?2LEHJB,QV/T;"OAPU??P;(K>GIL:K)
M8O1C^B11Y/4_J@H'!P<@KI1[*2@6#&?$C"C3^->GPR\TNMG62QF _[82"A:$
M/HS<F@R1T?9^NWJ^V?0+!DLY-)B2Y-_W$+(!+:8E%/YD%!$:VC/>1YO0)>5(
M\K+>$N1;A[KK5_"& ;WCUYSMR&"8M77*$&DWZ>XAPEC-+8-@N"<_%+KDF> X
M53/<_?/>&TX.=6Q!MR&,9MQ^6J2QZO/=ET=?"0?BOALF_U3O_WI@,Z<L5<0A
ME$?)"H$>3\ \T"%0PD@<XY5N_)621[$CERJW!1(;LJ6L508<Y4O6_GP  7U5
MSTS">_37\B4XZ);TOVUJ1/<FTVUJHTRZ:AUJ,K^[7WMKV%?]N^C/O]K;!4C_
M=@D$$8[ Q356#<)O825Y4N<&4$-:<\WD80[*S<=Q2[KKJ=+-<'Z+X0_5^T\Z
M03,U;->5"LS@MV@'PZ,,W]^Y#1>B!=R?+CL@'=[GM^-MH=^KJ*7=7/O%GB4J
MBX%QE(Q(Z7>.1>YPN7H>!2_*%Q'^4HE:R/>Y/I>C1HA2[.UELZ[5K^/<NI7N
MG)SBW]-JR5 Z0R=N6^'?4A\#K%+/!2S6JX7G9W/*_380(0#'B6\5A.LY2UX$
MDW^/9Q&ZN]@E>B#QP&.]JWGGBIE#,:-Q?U\XZLQR^MSS!G"7;G(.]P"4;\/Z
MQ:WH!M!'B#7:40QQ"T%J4=1C*BP_-/Q\_.K9(@51',>NB9XE9MO^_D9QT::G
MTD]*. ;EP0*2T00U*K,(+>PF2//^AH@#KES^.JF)"JZ)S))V?'"7:K\_0']_
M26IR/QJ?)8'Y&3"4[TH[.*^NO,U5@4!(-_>@*SU&D&;R_ZLFZ?]&W6M^<J$'
M16.S5P/7[> WP1C"TY@),"E;=_IIH,=<9;*MQ^(Y H]U*&Y-WE:5^P;@OVNI
MBDF9[\!18HRBKPB+0$+I6UI-%L#1;E[]7Y<V0RQW4S0+Y+_Y>N<\]NQ5)Z _
MW(.B]0XCY#(B<0(FV)T)Y/^@[;V#FOZ^M=$@""A-D-Y"$PM5>@^@= $!Z4VZ
M@!"07J,@(#44 04$D=Y%>J^A]T[H"45Z0@T0PLOWS#GO/>=WSGWGWKES_]@S
M268^L[/79^^UGF?MM9]MD[\3K\2TK"P1M<->\R9A<EV?+;/^O6<%T6PKR&F9
M(PWY.JLKF$'[H3F]";*[I("N)1G!5IINZQTNSD4VS/Q.N\+ITN1IH[O;WV"=
MV+2X9\5E.6WZ011JZ6<\]?ICK$!JLTY1,N^5E_5T</6%0:(?#%[U1H''W,O/
M:_7#KI+Q"S*P6A@^F]6L>S"$+$5W0;>)^JZAU-U!-9LSE? #&K*C3YSARF9_
M:A4X&73,1SY=6:\,(_:%MLQ1K='.>?_<F0Y&:*J=F!JW3LMVVSA+750E]^O%
M-@LPXR5J9V+U,?U^:&'O)+M\XVU65DV37=V0D1$&6HWO6\'VZ9[0J\X[L86*
M<6Z$3C]+/ (6Z U22.9!#FU(C]V*^8JS'53O1]R#OW"B6,)*C^+MM9]1SD:T
M;U'X5\V5[@-']7O4AN9H)MQ]RM4?ANV-&ZEAR)DU--ET28>=R%D_%8PS-ON<
M2.+9/:O>USS.9YK7R8'"^8$TXYOHWL\B^QJ6;7Q^;%-[XQN?F)@X^_NO?HI1
M**X;.J.=S_10_ VHE6X#"R:4:W2^\^&[?2L/YW<)JMR6W]\(]BS!O)/^]C3?
MQ[9.F!7\G:,QW!'4PS1HAU9GA9NXYJ$FNRPX4S:/]^$%D0M*WPFB.!_LO6A0
M7HP8S%0[N5#A;I*4H\00]IIBLO,733!Q:\U,S).1.=/[2+IW55^FU:\3:A\
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MF#W3DS0.Y5A9D[-16PB#U-4;0*24\TY6\U@!E9'3</7O*]Z^\;[[%;R$JW.
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MD#*R5H _'F<!SV>/RPEPHY8D$C> :.<UO!N &X\E3OP59'YKS9& (GR9@J@
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M<\O&A*_Z;?.K#N*ES=_1,C:D?@M16\U>Z";8#"OEM J6D_:2O*#0U^G<9/P
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M 5VZZFFM+?F.VM1 IP0PF/-SKG2(WV=A4GX$G<^K#(/^BCMHZ$<L"#D*;]*
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MVL-Y<LJ$^>2L0( DU3#_1::RY89@2[@?LY5W-?U$(.6>-Y"\SH5R:=N,$K&
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M_ 0BX]]7&UD>9#PY)$YZE5\*#+S3.<=&+]/9C:\SKD9H)I"#5 VI\'_^25T
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M]60K]^"'2-RT#B#DW5/7: [YZEN4XE!A?$&7*(CT[-PE*^%,#'R[(*Y:-W:
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MH*33'MKBL:B.SL%O,)99S= Q+JD(R(+XB\'*&*Z[(F%:\+7Q;=<4^<;:=<
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MQ[7HHW,/<E+IS"I*^1EA*:+FKE+:O<ST<.#GD.7\A/>[@1G\D!W21S6(6#W
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M%^K!:P>#8HZF"JI?&7Q^O>1^69F,;?AU?I.S[)E1>I./TS?Y/\47AH@9 6A
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M#V_!.E_^E.@@4HU9MICA("E"B].# X<!*S;YBU,TYL#?@??/]D6B^@O:S-!
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MN'+CY@4(SBD=O:UWCE(U1XQ,AGKK)Y4/3NG36Z$Z>2=#Y.S>;IR9.TASH_Z
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MZZJO<]^>Q[XL\U+ A])XH<2A$7>)#B=@K)S;%+A;_1K@3 _YPULTE%(+AV@
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M?Q_@_TW2]O!_+FP='"Y_9S,">[,DPN<CXTJNF+WT:>1:O;X>PU-Y )H4V_<
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M>ZGBB..IB>"$Q!>;I(_M9]\D:2?H%*GRVEY('5".EF]2OU!F%L]A.6-&3YF
M:W\^474X^YZ8KY:CD_W-9KL+-E:S_FT)X2'D]($&CR-HR$[OX^.7*FH:*,6,
MJFPVO5'HT+VKJ715G> ,:[)W<I_K9X\NWY-W<&3^X#X]_@3T33DRRKOKB)8?
MO!/_L>Y1(11B8G]P?A^Z)V $6>)-\<4SOAR$X@8;MZ&!T1PO/ H-@]97WS]@
MBI3O$_;E>.>5->Z/.TB7[/@HV/9L_)VD!^[AI"3+_FTYR_4.7MK*NG47>NUV
M;7GS5UWQ>]9KWL^J/OLD+2)>I)DY^7_8>^^X*)9M;;@5%$F2<PZ*@( @49*
M,""2)2<E!\DY#J#D# (" I(EBY)SSC"2E3R Y##D(<U\X][GG.W>VWWON>?>
M]W[W_;[[1_-CNJO7>FJMIZIK==>J"@(*CF_[B>1M=NN$PL0*2M9\>:)URC_5
M?PIV3C%*76L>P=*3YF4K"M7B\0_I[JO!S)BC'?2]?3?%96 "036Q8V=31CGD
MPW]GX2#K.7Z2$W=J/Y;*ZP!#Y@_D,P[:.OEMC;K:U1.<G"Z##T2=5*VEXS:F
MY9S]I.T88HD[;+'O)QIA)XNM 5>&C,;%B#9U<KM*F.!!K>_&7+C!'*]3]/+F
M'IT+^K6SA<>N<!+<Z,6.D5-K4<;5YUJZGE!J1<J?XIM1J$^5>H.//V-KD_B>
M;G]&VG)L@J^>=ZL\;0V&M5%0^-YY6Q.]OOR6:J_]<1%5)PZ1Q/TY3&H0>01S
M9&5R5>3'+=.YW("7*2*XL&P56)%.NU>ICM4#YP<\%GES-$+;LTLR1I'-D.=O
MN3&^;=U@S$F"NA9X0&N<ZR%$%'FC RQR=5$0\Q@C%_<IYP.L(23 %O#PH<S6
MM;L*@#;<=+'$O(/'O;:RAJ4RKEW+VIWC=G4D+?DK_!I5)@^T.+VWNR]6Z7&V
M26S%!"Q3;-*VZJ("R]8_ZH1KXQ9763-#2-H_@NAETX[]U#]26>-<J78 -MW%
M6SU+7SHL"C>"#.0W2\Q<,D@U)">HS+02[V9]ZNF("5/4B[H.K(J(-K?H6XV[
M7(_N.'M6VU1=$;;XK<+20"Y]SIA1GHGO*^=V7+'<NM^]ZW?0LL;$N$0<IG*3
M@EU 33;/G8M265]AWKUK=. TT*JXS :"I+];(L_7O=#Z&*Q$I/-E<^IH;)*L
M\RYB$-V-6]J.54[WIM$5X@1E\M-@]AC%C1?-.$=!8UR[QI-;JAZ5[X]"KHQ2
MY^@^PR>?\7E'=HU$Z)J]A& 7L-Q@#J514H@;&3E#6!K%+9X=V3G/XUD1T=^O
MB[]R3M.2K,25-D P%E' 'H.MEM]P^:Z!.Q]LA+W+WZ6O2FXK$AX>KIXX):1+
M<#\_K;;:I4-2$N/N-8NU9G+>1CN-H"'1^UJ58=;3D4)<7!SHW#Y9)&XF[0+)
M?3(#-P=<F07ZU0_I,*RC;(X(P->#N&R8*L><I[T8_7*D7YG-%-=6&5,]"S"9
MXO?OV^'6ON">Y"BKF'ZYR$YX]Z@HS=!J71'[M&?-F**&WH:PB0HC3G IQEQ^
M 17E2BT)N]94CY85;X?=C9G1.U4@:>-^1BD0!5+K>UO D!398J()TC,/\*7K
MA2I8:XS?JBOWBGQ([S+Z O>M(T^BV(N"E;J&?(?^]T_.:+F_7@K^>?*[1E H
M$J 3H$,]>Q'A5I 27"*$F*WXY@3XDG3L2L;/OO_]O7\1+7;OY?7QY&!>3YK4
M)-*"^*#'> C?V@\+#B&-E06GB<&P#WQV:O8A9-XR-4GJ(W;;%YJE:SK\U5D<
M1VFY5:DV0O+![B/$KA8F6.0]5^86; 5Q&ANY.N<(FB;Y;+C41OEDG>NG!?.K
MS=,_SV"$Z:<&^*U7^D?*&M>X],5V.GIRM0K7"Q8[7ZH9!NM^SOP\+9DXXB/>
MGZ*5BOXAX=856;9,7TE)/TR.)/J;XY5X-.L/N()<"FARQXTJ"#=IJ:($GZAM
M/QE@?);;D2U$'I/)&G5>!);<0Q>83(D.6=SCZ,J$%O"NE94L6$"U&&3P:E_>
MM;[M0 <R[K_7;1K<CL#;,XL7"TMJ8B\?M^&=[7F2(I4[L/;T&A=]S70#(/;,
MC^YQV %4*XC&EX9..6IH6J<NRBM5?MK8Q?8]IF76HP,R;%;F#T,\._9N]E<$
MVND(K<XJZG8RRAZD*8ZLF\E>5$;D-JQ]['I+ZTJX%S_3);>I#]G?/BREDH0;
M8[RZ<+A=#MW+7?,4[4R9FK7DUWD6/F1J9IKD*4M\;P8T(T*(N1ZU"NO\R^_>
M/X8&&CX_9!Z\QLO\[FWZOWUC__% Z_9E=<]" NV^_%%?&_2+UZ9\5E)&=%N?
MYTW/T-<=&(?Q<<+$QLWLQ5S1'.AXCIN+YN&[<L,-?,4]VYQ%N.^2M& S#FW#
M2I7W[X4&)!%&+!M)OLH33BR!X'L+9W3,L=<UCG%MLWRVK:CE+7#^9(*PEEF^
M?^^MO-_T:X)]>]'3/ M:E+V3Q,*JF]@__FKO.OG<@?6*'^T-I/Z3W@N'1H?R
M^>@H>+8;V+L("^>F$?5A?IQSG]#ZO%3:9B!R=)O'<R6S :[!$&P8#!IC^E0U
M49J=OC)R_&56M_"JCD6L2&=;G]S=^Q'U;VEF^+NA-].RX1\W3IY4#CLC@9OS
M6AR1B,";,85)NMH]K@QMYJM,;X9D)+;]L)M8D]0,0VA)*BLF;+>*.9N&C\,%
M&:M-WCS*3+H[?!]G%<,:[X6+X#PIWV8D1H<!Z8&(J4 @;Z2D1\G.<F=*%W_'
M/KM=.DL[*5;-T(WM=&NIIW [%YO"M6I:XMIA$3[3W- (5Q9IGB[(G?8JIG1Z
MP6[RS?@GM3"\4"Z7Z)NH$>'M\A0;SA7= JEUI= G86LJXB/BKEG\4V)[/3-R
MO<17>G2MY_@FQ2C6T^]63:Y&\IXN>_4L5%1)CU? OST_#CPP%M-MD')OQ?)H
MT6^)EH!Q=,Z'B" ! ES7%23P:&R/,^TYL_T-:,@2;BV^$$<OUI8L!NX!6G@=
MXF7!ILY<,MN&QK!%XO:*WGK<UV3*;]VLR=XM@%K ]?:>WN,AF)+_$1?&IL[6
M2\VJ#,DQ3H.-Z<=AG5GG5.545;TK;X.6/TQ=7Y2=PD1'^_@38OY"SL^_"U]J
M\ +%-XZXBL&]1<W%WVHK7+'N9,5*NO%^%5O/_^5O]OOT[H7\W\<N%K\/;2:G
M0":^1&I+SZ6)U>[33%)0NRV)YWJ=M#>R*\:ZB'*UIC1'B#PWIPK-KPZ'EJ1_
MLBV64+D7Y57]10O'%BLW( +&;7!ES&ETI)&K314DT%[#T2"=96 E1NUCF3BT
M".G 7[<Y[@[CIG_.ZUCT3NE.TI<LT87[?@L:))IUGN1R[R%J+$O$04HA.K'Q
M*N-'[.\8=4/YIKG-7>-"QD04 "/&&U^EI9G9"OU;2#I=.UV:24AWQ*D-VCVR
MNS-Y":1P-.[-7.8:^QM)OPJM)N TOC$]MOWBVT-58!FL,T&')61UX7B$,LC[
M#K71Z,<["%$DT.L"C^S^OB&+W9EG7$VJ5W!%"@4T-BN=A9 ILU6#.@"OK-'+
MK0L212LVTG3?_;@/TCE54IE;U0S&N==M+]D5[D"OCO8!N +7X&D61X4Y&][I
M79I-FT<B]R\.LR\.2\\19"<=X#,:/O#%#5YP&P(>C02D\LJ0@/_ULGGN2J[[
M_DA %!6)B[(W(8' RSTZ1+""(2I4PJ6#-3<QH;RQ_GTS-8GL>6S5 T&Z@Y'H
M@Y'Z7;CA/ $26',>1P(P^N\O<,\7Q2]OIC0CT"E%8?^7R$2T?Q>:O?Y6T^=W
M%\2A8&\0$L@<U40"+2_EY[?HZG:&KD>A/,6VV_R[:Z +KMT0)'#XP H)P/$M
MSZ'GI5L+8,AC<<CC?[.DQ4FGE?[7%B20_AJ<GC#_>Z=$_Q[S;F"!QUN\TW70
MZ;K^R>^E_-X,M'"=I.3_6V0>[6YQ( %FVA-$ESSD\M:GLG>-UJCQ];-F*NNY
M>W".0H/-E,JA M=T^II LUK'+2;2B6(RL60SP9.R[*;Q.X!'Y.A$DSD!V HR
M\;&C*?_Q;#1?5B/[MNKW;+4'8N-<)],'I=;I^:PK%9JY/H6&N]6KH*E<Q+FO
M\PZGVJ!%V>/SI\WS=D/1E?*7QQ=K-8[IUM*>FK\6^+6T=/OK QWVD:9?)&7_
M32XG=7[*L$'"<0&X:3Z-SBKI?/MTV/Z;R$388=FO@GZ5&A[\9[5Z0DI\.2CJ
M-D.@!DG_JH _UC +VN=10K)N^*N@7Z62W?SGZ]>,&D]T#R"!HTW!323P)*6^
M^9?R&UZZH91R/,N(;90'B5 E]W?_9HK!__<Q_Q?[Y+\#GD94X]]F_S,@@6$Y
M_<FI;XC3S4$E-R>V <"5CM$-"9BH.-8J<?X)S/+^_V>,\'\<GFIU6RG3V*>9
M[N@+S_J-#MAR).,,J9"007.DS=A]]0\5*M(,H3.C)N=Y:;_\C<KRH@M(_\-G
M_,P_;*]F21,+5U"*#"16>3)@T+@YX4LM84?G?X$$\"$+[>]ZW_=5V;MG\MVG
MKY%=Y&FPR2][4ZB^B"X[3>[O]SA.),WQ"_ENV/'\S<TIO'8;DHO[[^%AS&.D
M:S.&W73^%9=6=UBFB/H.=E94GSS#=P55</L4+P38%\X61TMA]!4:*/9 F[BM
MXJS3Q1J:XW5&798<<.LYAB+16LU"&![&2$85]L7>(?!KH9L]&'00.YJX4&X:
MX\,C&^3,FWHQ>DJZ*'3HI5Y5D4Z Y:':35B(CDO;-5TIRQQ0Z(AQ2Z<="N+0
M].@]157KJ1$K*JK975J]2#(,F3_FL3(\4[]E'SF]KK_:W7S*.?_C%BZCO[U
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MZT;8;MLL6B?=M0LFFJ9LDH/&^:G#2-NA&1#_:^;7/;'39)Q[Q8_8;&8A20%
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M#_>FKOI_.H3Z\0T%-7D!.J%H-P:,;YV.EF]6D2O*D( I6J7^D2'!!H.Z^3.
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MZ<PCCRW!'LQMY^R*36CJL#^9X'[PU,:M:^HX9TKY\^#VX0G=U[!<Z=(3CF_
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M^@MPB46*8  @0?4UFZF6E"3\\X^$T]T!N/_;__YVMP:/HFZ*JOSW'\(_!S\
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M%F6S(273 IKB7YKVCQ\J1C8MZV=Q@9-7Z-_@<!G4?X)A!./PS]\:_L-__ ,
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M0R;XXNWGE4R#7(T:010E(40Y2B%A+(1AS$E(69K+G)@;E&E@/)N?'@>XUT#
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M"BYJISI63@S;I*9\\F:?C^HIVR^95V_Q:+-(A\9N; =I[@24*R6+9)VLP;U
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M2(E;_#M"S4SQL*&*H^'QN3&6BY8-M3D(GDWOF5C@1Q]&U>VG]D- $HLP$#2
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MW15"YE?U;RJ /5?U>$59P(4,<YBA,( (AQSBE$J88!2KD!)%,3&JX>$)G^^
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M(ASIVH<V^SJ>BEAD[\9^@:)N'<>ZW^539I ,><P""0-$)412<402FD,1H"Q
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M;,A;(>[[W>I81 &-TP#F64*5=9,,$O4GR B**8VSA#!L'%Z>%>?9@ WRP0!
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M3-G#&$$J9 H9SAG-:" #8K[KTD:R9POX#(I%ILN*0(,TH"]:[$S7,Q1ZO]R
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M;QEB1@!%&%)A7CI9%B5()D6![+6C)=' ^O&('KBMP9X/</0+!T5@BZ2%H@R
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M08J%@#G-\PA%:<(CARA*2%9#1U9WO.\JATSKYHY]P)[!JIW;JW_:32*K#C*
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M K3<-D,(.GY-.]=6D@N_]%2,X;;=\9WTI]C,,6^Q%UMYV[^5=SU;>:JA&VF
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MO[A@PDWQ4)?N6Q(2:=LX6"#\W!3Q:67!8:#+\5B"WS?RQP8PK8O^&:R$P!*
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M=PZEC 3;.LPR'X2.(9@#8]!P!I1FK9G6VO02:OM)\F/VP.; 7Z#Z@HG0"A_
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MII"$"=?[@;CDD&0)AH0JS#,E$I9;)3@.DPH=XFK)FO.T/!#V-$"NPF6K9*8
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M$">Z*7,60,PXA9F(4B&1Q$EF9)%?H./Y+&Y;V)$-H)IT>^8J1_I>_==")X^
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M?/E,'D0[2DI&L3)D0@$SKF<ZDYA"DNG!'@RQ+,N4/XJ,#!P+FIZ5Y< $:+D
M.S;:QC?@%\W)KT#S OZ\,I_198.I@;\Y/U)VFN_U0;)IWSP[6(Y=FTU!FZM/
MLY7<X^V9S99:L"NSE6S'S9CM'G6^Y%]72E7??:AJ4=R5[[^S>]U\_RO9B%4D
M6(I$$D$F@@ B'"8PEP&%*1<93VA(4699Y'B>F._+_HXP4%ZT80#)""'CV\-9
MY+:\0>Q%EAU1('JJXQBXW")>%,[_3>)Y%I:^3;P(QHD;Q<O/.(\,VG6A.,C,
M784L)@F5(60$,X@D51N;\PBF&#,:9A++%-GE 9RDLT0:P%&[E(.\<NN)/B>!
M,MW?D\6WV]J?+65V&:PS)I'_D3DGJ2\]#&<,@A-C;D8_/N?,KV%,PZ5)4T%*
M$\QS"FD:<H@X22'5G0J2C$82B3Q+B%%?WUFX62";#RI?<J-;MW13J4#=SQH1
M X=SC_PR?1%A*#*4, '#+,IU@V4,,8\P3$(11VE 21QELPU?F_-]3!Z^MF/&
M\_ UTS<19T1]R]1&P"E.(8I3"C%#*8R#6&(D:"CCP+9]VD*;PJFQVK=#T'^"
MG6!\H"Z#J>6Q>V;XW1[5UQ]^9PG2JPR_,^7Q)QA^9PFGV? [VT7M+WG?Z9I?
MP\X8+S[OT2759,"?5_.UO#C+O-.MY?%*BUU7GA3@\)[R] >\-)ZXK:Z%,K\>
MBE+H<K"JU%EC7?N+4Z4@+.<XEPBBC"3J?QB#A*<AS*,02Y)QP3&9L26%%7,+
M&)QMIE?[PWOW\I$97X?IZ?HZ(-OI"J-&%[SG5/^:[9C=M=@Y65SQ*JTPG$!]
MW289=BS_3.TSG,"V;*SA1L-59??UH1&E0G"40\:(TKDLRI0?*9ER*V.<AB$E
M2A?;Q>V6JY%U[(AM61GKNQ#V:O:BUX5K7%^GI/52!>ND@M5V8];/JS^^K917
MGP<I11 'E"GWGF)EB@0!C,.$8H%$%H5&:5/[)3U;$7^4[=#TMM&8X=XX$)?%
M64*35%_0)1%$ A%(,$IA2H(D3WG(\AR913/<!'8*24P3>5P1N(EAIP+^^/SQ
M]OTU^'9[=?O^VW1-\)+E$=>E_W#GOO3_V+LP!TLMLK]?LC[L[!-_<<CM^0=9
M;]O4A2O^W]NN@*6O<8JS.$U#D<$H$NJ+GX0QI E&ZI_*3F1!GJNST#B=YRP9
MSWM_1Q>0'6&+!)3SZ(SOD?EDMMLW>W'W-%VJW\[+;9%K,XO\;NDUIW"8*9/F
MHE2CR3/GGUXN7^:B!$<I,I<_[6IPOR5-P=Z36GN6S1=1MW&Z74 M3B(2H(!#
M&J3:#L<!I$@IHD!&0B1Y+C..[<(>H_0\ZZ&!K&[6T(6O;8WT<;1,;??9,+#3
M2RU9(%Z X*DUKY&4WMV <2X6]@Z,('GI-)@]YAXE[1*:/Y8?2%%K32-^5__>
MUFUL_GHK;JMW;9[.Q_+W[7I3/*[%'V5%&U$_Z<9W'\O'[::YK;X*N19L\U4]
M6I7J#\]?JJ8IU >NUFJKEFU1E_)^M@_=U<!A\@F/2"1")B$/0JR<F2R&.)*!
M'ID5DB#.$&;6P=57ELEW3+9+<"M*()5\X$D+"/XJ-O>@+WS0<<)"2Z$^P-1.
M;:]!'XKUNKW'^_=_R^,4_:?UA>BKPVH1^/V_Z M@&R_NBUR.W_[#7CS U;\W
M%6"[;\E#+R/8'@C9?4$:_<FZDQ/4.T'!8R\I('M1=6AKD/6-KX2LG^;5+1"5
M?FU)%P]FO[; (S'PGX4UA_A!%U6\8O^S+6K!#Q9M2>GK=[;><G4F_%95_"]U
M"JS2A.,P#P3D&.D.8SR"."01% RG(L<)C6-A$F!W([](&%Y]*YM" =CZ319N
MMSV8!F$(KQ"Y1/;!P OXY8 ;T+/SZQNPXP@,+'G%T"*DX15+MU#'_)C:Q4.<
M(1F-D]BONES\Q%GBH[B*^RH.6OI+73!Q(Z\>A/J!E-="F5B%>JG/G3_77"G7
MCNFOWIWZU) ZU3[T._E>/&P?5@E#L<BR'(8AIA"%2&GMF%*8YU&8RBB4*3:Z
M]9F''<\^3DM*9SA<77_3C2*)CECT#.E?#\F(X%%_\ UXZ+C2I=O[SQJZ.#.]
M'X.#8%'4[0Z&#O ;!7C/'-AS![K\VBNES<">0_WA@4?PI7L-/9N+XFYQ>"R*
MO]MALLQ[L#M@9H-M],"93F6Y V@V1(X.I/E6=:[#$9L?ZO-^(T6Y8F',J,P#
MR E21T^:ZJ,GQ)!&ZB]"\)ARRQ+9TX0\'RH??JP1W4^/;-HQ%-8U J?A,HU3
M30?!3L<K>B_K9.\4R5G3]4>%\I^)?YK\TDGVHR"<R)\?_[QS0IVV;94*40<0
M)QNQ"V[<R-9+?G?H)+?SA[O6):LXC+%(XA *%.@9?)G4"<\Q1!0+$><<D<0H
M0#"9DY\U5C =8E,=L0!P=DKDB&(WV+PC^0:0/:]0,WL0H9XUEW :)/Z3#QWY
M6SI;<1J,)](;)RXX98!'.[3T@Y+RC[;@Z$,W(Z2\NV*;XJESZH>+>IY1(74#
M2'V["%'$!<2"Y;KSG* IC_.(64[LLV/ MY$S4 9D1]IEBH %HJ:ZS!].EBIL
M/YA8;PSPR[:K:OP5R!/@><J0< -CD6D%%FR]PA0#>]!.3S=P6,<A[G>J,O);
M5\#?UT6^/5-$S'G"HU1PF#$]!R8E'%+! YA%89ZG42:3/+8HIY_&C=%FG%Q'
MW[-B7[8]$6J#T)U?Y*84:M_(/B[4<P4&%#^6W1_Z,NV>-7!E4*8]Z_?8/#ZW
M",AN<3F/8-L%XR9C-!J$<U]]N>#;9 2.@F[35W,X%?Y9U?]21\T[\E@HRWB?
MU[NWJ;(@Q1&) ZC,40(1(PQ2*2E,J#H60A9%.#&_[;E(SK--VM,'K&/@H!*@
M^7\L=-!EU P4^:Q8V"GL 8:>]D%F?&/2+L %$ OE.RLP;DIV!*"9M*>QD*-:
M\O(JRVE#8XF.M)[Y4^Z9Q8^U8$7[!?A25X^BWCSKMIZ;J[(=V//8&@<X#2G+
M4@2S+&'*&0\SJ'.08!@'F<#M]%QFF_UK0->SOCODP3[-U@0W4Y=[=C3L--XA
M^3?@L6= _:19:!L7B(&)>;-(+:1>(-/3A)O%LS$M(#J5,6GSN+,.*1JVKG0>
MYHULQ_\>).F\_ZZ_1/JK\+P*:<:XI+G2(CR%*,N4&8YBJFQQC((\1)$(<TLM
M8D;9LQ[I!E+K/I@?=@.I/[EW_S2%TUBYS ^2I7K9,:!S@JH6K8/$=']-4.P$
M]Z]A#/E96L?8P71"RU@N,,N@OV]D+1JEQGXG];^$;H4R3$VCF90AQ@1*02+=
M*#R#>1PRB#&**,UHB&DT8<+?.;J>=<SA:+]&L] >RP\#$[/,]#L+J8&_Y@<H
M.SUS9N)<RT@[;V['RBSC^\["-6ENWQRPS3JPSP6^J9/Z+H%@.:+O['*O.9OO
MDHP7AO)=?-QY9%C3; 7O7<Z^F0'!*8IRQF&8)X'R_RB&.$FT3DTCH@RWF.>6
MF64GJ'C6H%U N(]M60_P.@&*J?TU451+'=@2VX7P_GRXT-+"94C6>7G\S[PZ
M07OI$5;GQ3\QD6KDP_:=5-^7FV+S_*YK[-Y-"%0;7S<OVC8K3J1RL*2 08)U
M^TM)(!5I#&.:)I&>FAD@HQC-)4*>MVE'&O2TP8XXZ*B;S]$<!6M\[\X)@=WV
M=97>JD>MB6A.+6M'%UZL@ZV)>(<-;8T^/W5DPL>RV=2M4=;\5I-R<[$Y>20R
MF=.8P"A+!$1!'D.2MNE00<0HEH0((S=F.BN^HR==6]5-!1[5)^Y;'Z?F14GJ
MYSZ[8([^\-;XFY[N2Z!JIT/VG>&+/4_@KF/JE;K"NZ*S6$MX:P9?J1^\*Y#G
MF\$[K^BJ$K\*N2UY\Z6NGHI&>\A!%M"8QB',64 AXCC2$1L,\S"+\S3B228L
M1\/\2,*S"NO(39GX] (34_4S15([M=)3TM=#':DY]<0Y,;SO_Q>$%][7YP1_
MN5_/?M(AG-I&:=L(0N_+LC!$.,Y#B"7E$(D\A402!KF@(4]$1CGBQD'3'U=?
MY/JE#8I:Q/->0& 0Y)PBF-UFZV3J0F\.;2E?"&<1DIPBI%O@\4#8F2**YV08
MC1N^>&BYZ. Y?H]B@&<_Y'X0;TA1"CZTK5LQ'L:A\BU@+F@"4:R.9$)EJJ=3
MQTFB#F.:AK8'\3$)[P=Q1V[70='^'/X!$O-SV%U0VW/85$:G<_BT& N<PS\0
M7OP</BWXJ7/XS"?G2)_0;23UY(:J;*IUP5L]>GCG'P=42#TP/L4BZX?W)4Q"
MAM2^98G  ;)L]FI!W?/F;:EKM_6(_I3LB4MHFFYN3QC9[?OC+ HZ@,4.&5DD
ME<(0@473*2[Q](HI%89PC:=5F"[B7)RY6UCP;YMZRS:*+&\CH[K"ZGO1K$B<
M!"@2 F8H9,I%T*HGI1&4@A(:1RQC>6Q9D'F1J&>-<\@ :'8< -&S /XDB@E#
MP]L*3%/-,R]$=@IG*CHNU9;&XOJOL+S,RM)5E<;@G*BD-'_6586<S2_]*EAU
M5^H1DU>-GEVU*S^_5MRLD$A3B3F!'*<$HB!0/@<)0Q@G/$ \XT$>2#NUXL:(
M9U7SQ2FI>EZH396.?P#M%-$H=J#>,:4[T+73^79\ ?V%GU-!38/&N])R9&]A
M138-Q)?*;>)Z#O'30]-L%Y!M;G67X5ME@+_5]O>*!21(1(:A2",$$:(84IQC
MR'.1T) R&L?4.*9J0M&S"CMV0/9,6,0EC7 S",3.C8:S)W9S" 3XL^4 :!;
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MCMJ"%(>I!RY 6M7S> 74M;!G=F!M"WR<4;E0Z6._[I(E/\Y2_U#[X[Z.<VJ
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M9O5-.8U$*?T_RN91L$(6@E]7#WI$G^ HP9%DD#/$NS@593B&><J#C.91BJ/
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M8RQ(N6[]&269@"@B*:2Z99]D>8PP2T7$S W'2]0\ZTE-MVT5TOYPP 'X4[,
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M&DHQ"LGY&17CC\W1TOZJKO4(&OWC_RM(?5,.Y7\)QHF,108YX1(BPG0:5Y3
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MZR&>0&B6D"B >9:$$*% 0)PG&90XC](4"1(A\\'CY^EXUM6:\-^ I@I:LF_
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M)Q#33$"=HQQ2%J'8;%:$%57?FWM(W6SY #M&NAS.7S0OOP+-C67&BQVRXRK
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MOOI-FXV_2BB7,A84AH$(=2=A#G,94T@R3L,D"$A&+"]?SQ/S?)1<BZ>BW8J
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MGSNB<QY:%R7S?H:=YV#A(^TB%"]/N,N/N-[O?;L7Z_6[ZN&1E,^K#,5<9E3
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M*)<X8(R1R'SLCQ,+GC7DP%,W*+0!;2I&VT9OSY<NY* ]9WK0^<":A99P0]]
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MY)*%WP>3PXJ_[%.V//KHY-"9&GVX:1 %'&3I$C=Z:=Z!01YP4X,CB;I+!IG
ML5!Z8DFW++P8Q?KKO@0V1S1_V9?!\<#GK_I26)XIO<EC&3^A6I:E!<^[W@3K
MT].SMV%A3KGYE^VAQIS3O"R3'(JB(!#Q2$(<IP)&0O(LT?D&J=%PC0OK!X_@
M[NN(%<4?70JIGY$P"N+.D<\VB'LDVJQ:\6<170K$G42=6Q6NB/JN!'\EAUGY
M]_-M;U#S_8KG\X7>KR]SC3OLCXF^-A43Q_KL9Z5_E!)+HKA<<2PX(C*!5,^
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M2W1+ ^I ZB"VSTUZ49+@>_0UY86WZ$717^_0RY<Z.&AC*;R'P?2K(J&T0%+
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M:[VG+G8.>O<M^+[H%C]?*D*5)[BM1+O"6)8L+Y1W34@&$<H8I"A&,,^)2)%
M!2HM&[I?H!389AFH6@>\+\!B'/*>+ZR=JMEWL5QW';'6SR2]AK_'I0H? +]
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MZH?MD6.[_Q25$<MXR6$L10Y1(6)(DU2G1TM!BI)G66GN59K3#;S/%2- #)P
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M8T5N'BLTIQO89.Y)@EK7#PJHJ';=O[=/%D:?!88&)G(89.Q4X, #V#,!!B[
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M,PD^9Q <N'V328.F3\?_J,$ 3RG\K$$_3RO(M$%+/'V,&S0E^9>;-VB)E<O
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MA?'YI?'";W.::2OWQ;--ZX5<[<:?ALRKKZ+I:L:>9WH7-$DQ3F%:))'2TZF
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M 5YW2>%WU<,PYJY@>41(H3X?<8GT\+$"D@2G4,:$I%F>LS0WZL5U9NW RNE
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M\N-#N=4/WT3#=/G"6\AP(5)2 N5U"@"[IA)Y"4%.19SBK,29Q<6TL=C YGC
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MMV'3DXUWY&#4HMN..9_]=M1VSUJ[CN%@FW>">K_5BX7:!/XD#;_-1%G$#"5
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M)O-+\MOCF>?QW;N0/(M%>BT_DJKY@RR>Q']5HE'CW+\,N9P9SD0,4PYP1A(
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M"+U3[EYDT(THX[J!EL.?IQ2@&P='J_LY#C>Y8-]-W35.KN73IKLW$R5+&4M
M23*U95"9 0Q9 2@J2)8*P5-A&5<;D19X8]B6A%O54?.V [USQ;T#O)G&>#RQ
M86>^G8F84NKNN(+SU:\[@.%<1>F.TS%2:6[D2\XA]J%5S+4\6J+N<J'^+"J=
MXG"A;-&S:%=[]5YN,<LA3B0#19$S -,$JM,1AB!):*Y^11''R"(0XQ/;/!&8
M-<XNT\&IAF2XR3$.-L_#M5L4VI3?=Q';8%2V+*K6*'>*4GD-4GLC+7ST>CK4
MN</:WL@]$._V-[:KX5U'%';[WPSA T(78@@@T".1N8(SGDJ$ $V3!$ !E<U%
M"((,H1P3EF:4Q'9^V20\@3VW;1?I=J]5E]CBB];1["$R]SA$YL@6I'W$V]=L
MF1KAV>; *;(]D7Z?AM<+4<%M[C24,YM;+Y2^M;1^AG4ULKHWXK='L6R5(%8_
MB(O54!]?B5:_TP?I6R0*%B<L!7G7^KDH,T I2G3%TTPHMQ8FJ5&U+2NI@0VF
M%M\]R]L60K&U>";4F=HUSX3862_]JD'TTO4.H.7_&!%EFC80.I8:+Z^#G70.
M;HA,L,QL;BSH>6M4;+[L:CK^LZ[YGY7Z!^>Q.M>2&.2)SHI*8 EPEJ7JM"OR
M&,>L2 FTLP_KH0,;@;48VY6_T=QT>;OH8[>&3ZKBL$!?HPZ^"C<"9UYJKQ5]
MNY[>?,)UT7RI[I;JS,346:H_,W4O.7<2B-9EKS/!(2>I *4ZKP"8Z_8$@C(@
M<B(9A6G,(;%;5*:B R^Z77&.!<2-231=GR&HL5N_-JPX+&5;!8,O=6- ,YL"
M6Z+>F@KK$5R?]OPF'H<@S>>FOFO(P_8'_.>G1M?K%4U5\ZYGPBU+E#UA90&*
MI"@!I"P&5-?-S3%)*<*()C"U30:TAS%/N+E_1M%L<.B8J$9F^_;$CN%Q8Q.2
ML F/>+:RHP'-NYV?\:@'%/6(WD4=IK TVC[A"4;GE"<\7FEU>,#C1,KI!SQV
MP\[\@,=)Y[</>-R&F9BGUMU:7LO?U[>6']I5]:"MG_J)VE4^5<][I?1NNG/<
MMN%HFD&.* ))S!( ,9* 0IB#(L6%S DK\L+\V:8W6,']R,T+]@VLJ,<5=<"Z
MRKCW(NJAZU?I7^[K1DF*NM*$D=I8;'8$?]-EL%&<91+L]H_]?*L.)+B60(%:
M,WYD6O8:^G9H/?3SG;B W%+@9IL9'QEQ;C,4(!_."VO&Z7'3I)TG6\X+0T>3
MY_R,;K?A<5'=]F7^?Q-WE7[\NES]2A[$+6$\ECC5'8@2JK:ND@&,B0095[]!
MC/"L,$J?.R8@]#5")S+:RHRT4#,;=I23\?W!AZ9VEMY226/+<$J3 T&(5K"?
M[NKGOZBO]@TUU#^VO32.#CC+,CZESGI!GOR<CSZ&ZX((B!94RCP%"5&K"N:H
M!)2EB?(/!81)*2'++=-3#T@)O,@^V58^'J?$-"@X45&[-;9;>^DK\5?3P4B=
M6=O_S5K>P4C]\59^ODHU#(T R6)W\-7%@WY5K(Z6EW6[NE2[\)W:<H=B>7&2
M921.U&$NY0+ $@N "I2"&)*BP+0DN;2LLVN-(?#*WN#9K6[>73VO(45,87H7
ML0&5[?JW)]W4.@2ETLYV6+,8I/.Q,R'!K8\]LIEMDS-U;RV7^U .$:SWE:Z7
M_-1>+=FP>B1*I: P!@R2&,"4E(!@5@(F>"9)QA&*S1]0OAD^L#5:RXN4P)_>
M600BWO)@$.*9I)V=@=A7S*6RZUL-+4(FDS1U"WT83J5=$..H'J/!B+??FB^H
M<!3Q7G#@^*=\5%K5'0Z415);4U\]9?-F[TI-ZO*NHHLA#G&QY.LTBR[F<"MX
M+BA/"I#3D@.8I @@FA, !<Y1DJ<XM>VT[@578"NT7Q>TV4.I?\*&]ZS54A<9
M&I .[]*ZQQYW ]CHZTK#G=1RSWWR3/VHV:?$.<H=>#8F%G&=S-VLQ5W=T9ZQ
MZ.MDBL>+P4X?WCD)W*677Y=@19(L3HJ$@$1PIDPT)@ 710&2$I4PYK+@V/*5
MC3.6P&;Y9F*/3:=$-_>),36_L]!M9W+#,NV2J#Z5H_#IZ\X(YTYJGTKE@53W
MR4/:7V5=/*E!ZJ:[K1$P35"<(U"F1'FIN-"]1A$')6&Q+&B<Q]PH^>+5N('-
MV2#)\KIJ5^_3MU2.VMA9"R-%K*ZD#L!VNHG:'6>V"Z@#X'?OG0[]>F+JTE!Z
MY?*IT6OOY;>J_<=(HD51YKP0% @&,P 13@#B+ 8R+@F53%!A46#>%<5\B4F7
MI&FZ.GD7#_73<J5_]$N]%"O]ZPN+DBK32#<(1LU!I?/!ZUIN*C>M044:59A,
M(KN_9[?$H5 4^\@3.DEU@)0@%SZ,,X"L!C]/PH^+_D?S>YP&<ZE67"\O27O?
MU^*JGD4O<*6?%XH%T<4@;NJN_E;O<PFN#K3-G> _5XWZPN+EINZ+XM]FE,64
M$ %R$JM#I,X&PBRC((<X1B11)TEHOBGX0A5XDU P(Z9P1JS'U[^P'1#JJE.5
MQC@<:M0)YP?6P_Q1'8IZH/I#?>%[F_*WON;,8$\YQTS8[3%Z$C3$:(-QL'JK
MKM/;&F9T4_?5 :/+S71<KJ=CC59_Z,/9IL.F#O$9IL6Q O&\TV-9?M@SC>.%
MAWT)F['DL&=^]HL-^Q[<8?O[\/"XJ%^$Z/HZ;UH"Z"I)PPVIR"4FA!4@*7 Q
MG'7R&(,L+05+60IE:7X7?DI:X.UJ+7[H8KWM%*(16!B\DZ09["L^J;#;+T99
M<+E6/TF'A5WW28N;O7;[([$SNZ9:CIK3DX/,9R9-]=DS?\9?<C!KZYXF[=6R
M;URE,Y5WTV=97L X00BP.$L S)3+3E$I0)&D"/-2$ 2-J@$920MLUC;B=77H
MH<':@,"M9=U)]@SLFT].[.S;_'18V#>?M+C9MXGTV!DZ4W5'#=W)0>8S=*;Z
M[!DZXR^YWGS_\K1858_=>]X/WYAHVP^DT8V.VU_$ZK[FPRZ,!6.<$0RXT"^5
M1)P FM $Y 2SO(2$IYFTN^4VDAO8^'480 \B$AV*2 PPHH<.A^U]M1F=IG?3
MWDFRLX8&_ 1)I+92._C5LAF:F:^1K2AZ>V5L]W7GK)J&<+'N_SF<4#^3%QU_
M;6^SG!6,Y!B0LLP Y+H\;<Z4<8FI\JXD+9/<-G%F1%SHW!@M6E<T[81UB1EU
MMSVN?V2=]S)&G:GY\$6(G=7HN=A2L([OGJ3")3'%0,/PN2=C(.9.+S$@Y$ &
MB<FW7-\[7ZK!&K*X6G+Q[7_$RRTBG"&JW A!,K7<BR(%E.0I2+'$D, <EX51
M7;>C$D)'@OK'P(/0J),:*;&V;YY?\S*^JKUH:QGLL574X=WS$64F/'Q^/>+,
M+Y^/*/3VZ?.Q#[INMGT\5RWB0R]^,X9P+J $.=2-4)., \P*K'9<5,8Q80*2
MW&ZS'1,7>@'VS:[U#K-P?Q@]RI?I#NN+!<N%>9" 0*^F350,OL6.@IAYBS4A
MY.T6:_0M'Z^-+NNEOOY1UF5'TJ=-KSL69Z),BQRD1,8 (JXL09(4(!4Q3W)9
M4!E/>%(T+CRP7=A_J<(V4/87R4*WNJLLN@LZT6QJ0,*09V=._/$V\06/&0&S
M/M,Y >F,;W',R!I_<&,XAJM9^DTP43UWIXB/2IL;\DVTW1'CYIXL^[+LZF>W
MJ9!)C%,&<E$HDT3R$F!U_@<Y3M7_E3B73-B9)#/!@<W1%Z)# 7U6TQJ.K<4Q
M9-#4VOCGQ<[2[,B/]-^W9D>7*>SB!"N%(>J;+^B?^S0R=GH'-S"&<&8V+G8D
MO34LEM^?7$5F> JX^DBJIBM%>G/?U$]W]WT0HWYX;,2]6+;5\] !XE69DU+2
M/(D9!W$L='EY$0,4<ZG.14E,D> \(^GMLVAH[5!=9AHVFP6XB]!X'6[KI:S?
MZ:XBJ:!&SQJK6HD=V'7\;A?NL$ ]U*.9.'TYA6F**0(RC26 -!. R+P "8Z3
ME"$$I3K1+L7J>YRZ37GOE=VT_2I6T1VIEE&]'!)?U72H(T1WD]M&7+35W;(K
M9FD[G^>:1=.-ZPP+RVYG\[BBPM8F\D/@?!6+)N(]5QTC/S2/5#?R),!'Q.%G
ML2+50O"KI:R;ARZCY(+63ZNC?3-W'F/<DHP5.2TSP$3!M?-? $QP#(J2QPP3
MQG+*;+=A7^""[\,[#^4^;YK6?MXTK=U@FA*HF#0[+F&,N1B?$N3@ T9E?#<@
M(Z)1CG</CKZN]/,Z.OZ\;F(8Q >!LP9))@$^8PC%!]'C 18O$AQR6']_5+IW
M=[A=<]D2)3#-. <)Y$1GK.: DBP!A81,4$6DR+EQQNK^V(&#*(.P=;-8B\S+
M5Q2,6[*)BMF9HK5.GZ?J9)$[ZJZ;6Z:HJ8YV*:&'M1A- 'WUE?G2/0]CW4ON
M//(15Y^L>Q"D#(DZ<NCSX&TLH91(<I#FW?.;' &$40%0EB(<(RK3-+&+J[Z2
M$'CM=R_?Q%:<K1?TF@]39V:"EG:&P%A!!X?BB!+!_8+7<F?>WH^H_7:7/O9!
MA\VV>W&G>U.K#7V309 (F2)>Z&ZP6&=,\P20F,<@R2E6_T5%R;#QEGM(0N#%
M-XB,.IEN;Q\.\F*P#T_5UO9.(HRB%IOS5(7=MFAKQ>WVZC&E1G?L@U^<;]\>
MP[VW>X]^T%M+RU^?=+SF6EX\B$:WU/Q9/-9MI>OG=)]O+W[^\GG=G.V68Y$5
M G. <Y0"&&,,4,)S$">RT(%Q(1/SEVG3\00V43T4?9Q70MMHVUOPAVH9M1V:
M'R=W:K3BW\"XS<NJG2D\WKEQH/I:43T@C/@&8M1CC'Y0*'^,-CCGI7YRT\Q0
M4^"[B:;7J?#16-.%.(=&FU9BSMUXTX43@T:<3L/Z"/&_?VJKI6C;R_J!5LON
M3WDGV2U/$>)00$!)J@Z:91$#I'/[!:)4% 2E EEF%QO+GC6E<"1J3 >0^FYO
MC=);KN$X^RXQ>F^<!@K"N],Y,?9N1,RLP?5Q1&>,GAM1-1X>-QO"U8!U5Z$7
M_.]/0P?ZCW7SJU)4'?S[A0,3(F&!(9 0,N4MEPP@2#%@-$>$QSC'W#(^=D)B
M8&/5/\A?UDO0U54;4NG^$OV@RT4;>L+F[)F:'8^<V!F;G@ZRE1PI*[-#CY;N
MTXP8*AK<>)S",;/),*3EK:$P_:+#45L'_RZ6?#\&>(LQSSA*4H!DJCM%4@I(
MJ0[3)*6(0,DDSLQ#=@=%!#8 -_6*+"R.78=I,#C$3E;.(4ZNY VU\#82)ZMJ
M<6B<K++;.=!:=;L3W:A6HX>TP]^<[]PUBGSO*#7^21^G(Z<"_+MI-IB(%,>9
M!%A0W><)28 XH2"%"$(L4IC'1D^BP\ +;+5VDJ!^%@J?DA]UR>-3CDR3I\3E
M5#4GT5,.7JN)_45FR('R1>6L1[7)H,]XFO-%^/B!SYL45[/]JU@-U<$_?.L[
MEVFQMQP3+ C$ %/E_T$9*Z^OC M $X;5KW NI>6KV,." IO2=>5Z,8C<6=_M
MNV@IK!-)C]!E:ARGDV!GYO0#"?F: VW,?)JI<:6"&YPCXF<V'>,DO#4")S[O
M7&&J>JB6=\JN-&392AT:UWWAVNOFBVB>*_57/[PS@8CDJ) E0"53#E:!!2"4
MJO^$#!4%8Z7 E@Z6H>30)[X.1;>G#SCTOW7'Q58Q&;4#%NOJ4X:TFMJ! &39
M&09#GH(\O;%4/GRY*D,\<U>NLJ/I0!$KRP&<TRR'4NNZ9M;.F]=;G,2"\:0$
MN= O$C,B 44\5S:&0XDSKNR/4;7SDY)"VY17]=NVK]?M,S"/4&5J-SP08!EI
M6O<BZ3@PT=PE-7-<J_ IFD?DSYVJ.4[#@93-$U]P/A,,M^K]'?I5VSX)?EM0
M025D.2ARY39 (A@@$C,@<5FR@N2QR"TOAPZ)"1U:Z;-!JDZ6?5K4"8J,3P$3
M%;<\ VRRPMI=[;V> $84"N__'Q(^M_<_0L !WW_LTZZ+]K\$OU/;_=7V_?O@
MDR9QP6-(4X!SW4L+EC' !&5 9!2G,"$%+HUR($^+"KQX![&[3_QME^U1DDR7
MK@_5[9;O :V#>.6G- N^CH\"F'DMGR+B[7H^^8UI)2R'/]%,LA)G>08XR=4Z
M3KL[$1X#I24K8%:JM0Q=2E;.TRW(H@_:$?U-EZBK5G;+<B@Y&6(E'E)@IH*2
MYUEQAQ0^5C!RTLKJ^AVK!<KU(OVX('>W65G$(N$"I!)3  5+ ,4% 1+*3*2,
M)"4T>@C\9N3 ZVDC*]+"+-IU[VD_OJ0FZ62WF@S5L6O:?0BZ6]ONO9'F:]Q]
M2(&]UMT'/^#C O^",=V=6FUJ__W$[T2WI^E7^>VJ>B KL7<Q+#.9D5)* !$1
M:E\B$I!$IB ON<!49'F96K9"<402^NQ8W2TKJ;/,5]$65;2%]2[:H.JB11?*
ML7]X['(XI]S<V\R%Z1XY \-V!F#_/IYLZ?W[!E-?>&3#\!R7[@[4S'J_;H/O
MC%?I#C2.WYJ[#.AJ%B^8\CO:2B_CIG_@>%FWJ_8WP6IE#UK!+[0XL6S%Q[KI
M0NV$Z0]O/_!%/))&?7'QHLM [HRG%.F+5BWYUE9<RYW2LU?+ QGAMT5:YDR=
MW4%9B ) EE"=)Q4#989CD6>8Y-+R><GWIV3XF/Y:AXAI56TM]/?'F+'Q__Z@
M!W0LM]C H&P_W_HN8] F(FTD>H6[C/C5SM_&SJ?:C=)]J5ZR';K;LX8RATL]
MWEIU_8O=HN'5\N!+'I_[U_<[N\&WQN]0]9EWW>^0@:,;^G>,U>$%Q:Y[TC<A
MOY:775Z/DO4JT^>W5S[*C;ZVNU'N['OMS=["%,$X*01 LL!J>\<%P!FE("UY
M!F4J,4J-<G,\XPI]O-IF/?<X];\&I-INKE/YUF"C#JW%BP>/,S2^TYZ1=^=#
MU_6&]>LMZU?'6(]VP$9?.[B1QAN]'S^.!9T4B[<KYYD<MP<O7B;)T^L8_[R-
M/JGQ*&Z^=SC^.=I[O!-@>(?=[GU5_WHCV/W/8E$]"S6R^O>R7M1W:FO]_<NG
M3Y?#G4TAA"!Y1@$K!0,0(0RP5,=51 E',$DX28TZF=@(#;Q/K5%$:QC1+H[H
MA]^__/@N4F LC* IFP;;3@".[/844WJBK[^<N#ESY\EB)PC EYN9G_QG96?)
M+?4>-=.F8\UG@RVUVS.PMM]UOFX1+6NJX62R#6A^KA<5>U&&_$K]!2WO*F6Q
M-V<9G;[[9[58[$;\!4$DCQ,,E#%5AP6>%  5E($LHTA;6<R1;?LZ+\ "6^$M
MB*A'87W#XH=^XPN7V4FU/ IL\;VZ@'GL(':!L6I+^DZTZV[ &>Y&QBMWX2]H
M_,"=^[[&*\D'KF_\CN_@LWYX>%S4+T+T>22ZT/RG>GEW(YJ'*\610O,LU)RF
M0V6QP95 G":8"@R()!3 $I6 ,%F"M!!YF@B<Y\R\4+P+@L!V]-/-5:1EZBX/
M6JB%-^;$IX$+&YHE.\.X1A,-"5\:CW+$%"*@(44;3#V- RH7[]:)3PM7-S2O
M;GZO&[^>O. IE(RZQ$X#S^<?3]%[SUF>-)"WDL":__6[UH01KBO\,H*4O:9<
M !*3'*2PR J2$TJ0><FB4])"1\2/E#S5*R&;7$QVAS0#H^R3"CL#/,J"BYT]
M2<?DRKENM/BMBSO^1^*CS.U;+1V*V.X,<NX2M6_U,2A >^!+$R\/7S>T6_*=
M:\LN@GM+""E+QF/ :,+5F9_H,W^9*-(3BG*6%#@U.O,[R YL\O8O.[8])'L\
M7=VO3[L]V#M,KO=-!DQ;7O3YY6_*9=[YJ7.\CO-+H8\KM\E4NM^QF9-A?(]F
M,.1Y[LK,=3UZ'V8QA(.17A<2[YIY[_:ZV,E-:6^SG+"8Q F0&2N4 YI(@(E(
M &-9$DN)XR13MEG7I32PS48BK4SR1K!YIJ1E#4TSF@P,JW?E[>SI1GRDY4?[
MS6%V(7CGQL)R>N?(S6!.Y\K.1EJI/6H:S4::SR)::;9G".V^Z6#_?JF70G=6
M6-O4%V5?E1?\7+5ZY.'L%!.,$4Q*@+E^I*H<48#R,@>\I&6>(RY*CHQ=4Q.)
M@1W2-82]+%Y]Z_&XP:&3TW[_Z<M/$:\7"])8F ,C1@TLI6^>[ SEAJ*-^,Y#
MV@)P.:0;46-A*'U3Y&8G3U+ER3[::#MJ'HT&FL\ZVNBU9QRMONA2/[U>/HMF
MI:^O?JU7XH,:CW/!?Q9-]4QT%'1=BX/$G*$4@BS/E7>(10I(610@(10C6L:X
M(.;]R R%!K:0.RBBI8(1_?N_HC1)_AJ) 4_$-X!LZI,;,FI@'@/P9&<A=RG2
M"-Y%:PS1%H2+E30ER::LNW^R' N]FY#FJ^J[G=+C=> -QYJQ,KR==ONUXBV_
MZV [_R:JNWOEK%XH0>1.?/@F&E;I &O%Q% CZ;I_1;W^%;]:=C]^K]MZ#<VB
M+YI&I[QV;< ER?(TSPG("ID#2%@.$.)<.:&$IZG ^B[(V,IZAQ?8'F]0O(O^
M'* #TF./Q/ [Y;TJ]%W],_'4U&WT*)J^.IA-?TC_$V=@S,\Z'79F?PTU&K!&
M:T11AU;'%OO;FP'PYO=<)_5WOP(=Z'73^&@']EGGR6(_.>M\N>T\YYDWNQTK
M&*VC>YM_J?/M@L$8V]LOPTEQKLZ[T+F:[;4<R;"[^%:UM[E0NR,F!,0<ECIU
M@@"2%BF@"4>RS-(\H\RR7*^AZ- GE!Z&SFL]E<%*%!KKSI3&#(]O;V%YLSRQ
M^*+,I1JPI?;ARP.; IJ[7K E40<*"-N.X&J$_B"+IVX3[EY35/]\VE3,IR3A
M)2HD2#&'RNH@_=A9AT5(&BM//6.06=8R.2HKL)G9R(U6&\&GZP-:$V9J1+S0
M8&<UW!AP,!$G=0MN$XXCF-D(G*3B[:H__15G7X,TS4NUO+MXT.G]PQ\LIC&F
M62% D< ,0)0+@-3Y'- X%@ECB<B$K5]Q0$QH'V(0&9%.IK6+<(@88W=@HKJ6
M6_^^ID'6[YA&X;?S0\+GWKI'"#BP38]].FC$[0_1KDY& Q@3LL@TVX5N&\UQ
M D@N&"BRO,#JZ$ E,G\CXQ=;8*N@VX$(Y2,_=U"^HX";T;QYC;;YGHW H;8>
M[KGB;$;3$R3(YGN:9HJP39^N4.$U&T(]Q=:,1'Z/@34;KARC:E8B?%1*WJD*
M?+74^T!7C%0!>*)MQ2O25/L5>HL28B1B?>^/"8!"N<2D),H;EHG:.#E)*;8\
M[TY $WA[W"GI=;64=?/0'PX)K9]6T2ZD*>61;2? U.N>B5:[?6Z_3'*[(WZ6
M>LB./,Q:$]D6XQGK(CO2.5X;V770"<;PL6[)HOW<U,JK[5^!KG0UYG\^58_]
M?;R,4X*R F"&2P"+6 )"6 %*@?-2HB(K"GN;=T)H8-.V >!@ND[196&A/))@
M;8AZV>]T)FPG7?U+R^_+M*\1>+9$AOK.87!.09G?KAB2<]!\F'[7(=IP_5 I
M79;_[_W[GY*?\@M.'I6']HN:@V>R4$-?7O]Q]7."_R",5<MUPAHI".,9R92)
M* L \Q@!G&#E)0DU/DY2RBSR)!T !+8> Z)H@ 0&3-$65-2A @F.!EP6YU 7
MP@UB 8%IM+,_#@RZ)%BZ4&EQ;@],J=OAW.<?I]VI>P(=HT=KEW'G.S]/T'KO
MD#QE')<WZR<*.AUZ@[GC=_:?VU;O%0@+24H!*(4(P)(KBR\1![1,<YXG>9%F
M1K=$ ;"%OEH:6BP_JZ\^M=&O]1*L?]3=SW?.O.U+0\^S8[ ]G(]S2\]UI]+=
MM=SMY-1#T-64C[WTWBM[/7S<L>ZUW_FQ>6Q_MGER?(SO9[Y\O<X/PM[XZWV_
M(F=\W1^$J_W7_V%$N,9"KO6%X"5I[X>@<WM3=UTI&G&U5#N#:'4@YK_K:KGZ
M0_WV2?U@;>%UMXL^7*/O>=FJ>NZPWE(B8IKF NA6E  6E .29R6@<5$6!8U+
M3-'M4MSIU[XW-A$4[U"-+ 'N+<$;P,;68!O2TL]N:ZU$)#<%.HA3*5C_LV8:
MP3G/)+@=N#JJF<(:/0Y@HU7=-T%JA,X2[?'J:?F[1JS\F1[RNXAM0.M62]4:
M=D0VN'V&B8*1&CRJY!_YS$&H8-2_C5F%$^7C5E!70-3;SF6]Y%U'HG:XIJ2'
MKR3[DDF8%R(590I$PA-E[',(,"(2X+R$HM0!,&I4O- CIO!A])W[K)5&V,6/
MV09C=\_5W?EW,-?&)R);H-'7E44M*Y\3YG*7&'P:IMPHAIJ!B?>.DSB;]?;1
M#>D9[R G43M^$SEM:(>0E#H /#T\=95O?A:/C5 ^H19[\5 WJZKM_[WD5P^/
MI&JZFS;"69PI"H$@:0Z@1 F@4/TG$V61Q!0QG*46WK43B'G\YE[\_XYWF_3
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MCV\7YS]\Q<5R.I_]QU_X7]E??L!9FN?I[/-__.7OGWX&]Y?_\9__]F___G\
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M>FCU9BAY$;G1UH0\"K"\F]&G48 ^_8IOPBI<LS61KL@<#1V>];&FXJC >15
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M@D92ZO4J_[]7R]7:RZ:P^B.F^2Q-S_&.NUMQ>>],<%K1QO&ULD0S"$AAEJ/
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MS\KO5W$YS=-0KQ_/%NO+G)N69_BD5!@SDA47(2,S)!6+$#QYD!:==E%$K=T
M+7JZ8'7H)S*]^C[C <V8MM)F" ^)YN:@_#1?=PI<X$U6GMC]G_/I;/4/^MNK
MQ=.2\"P6RQA)HF@Z%W/2$)C7P*UC(=")R7N<B]HZ>R.LF^MNRPP+CN&WR69B
MS)J-ROZ-3UE%_VL@?J>K[V=E+:3; M9F!Z]+L3B7$;35F8(HY2$@TR!\1"95
MR.QA#+UO@D_[Q(WPLKP33VIHO8XB']1,V!/+2\3L.63'Z@1)P<'E^D5GIS%*
M9#V^ FE&\PAOT'OP;=I3XUASZM<[<J<0*6;)3!@)Q:A(IPOY7]&P *A4D-9P
MH1P;$J8':!\Z?NTWI]Z6$D=A0^\?'W4P"K&UZ;P]25D7CH$VM><47SM3^R0C
M[3SGN-4B)\?[&S2ZE\P19L!;P\>N)G0M*&MTN/MIOEC,_R!FMER4'6*<%/1:
M1^8ABUH_*U.$4/N/>G)<,&KN;.BOIN@H%D:8PNX'K]TH>118_HB7UR'F66G.
MIHP\!S0%I).F3@I2$*I[(TNP%&5Z[UU_#1:/8F'H8[]7+'>OY.%3!O=V[BVO
M[^L#@_N/"9[@F"L9/=<62*IT_N3@(&ATD*,11DB*+;%'$WTL&R-,+G=HIGM1
M]O#P/C"'\BE&;1%**$[Q@W<,5$$-CB<!J(-2=%IYG1]TQGG65- VT-AOWK9M
M-/:DF^%!>"?5K9F!3S%I9 A9E S16U$[!@APA?Q]9ZUVA6=N>TQB/8?R$69D
MN[.DG:ET)%,BFPES$AB/.DL+6=7F&B9Q<"$$,+IDDZ7,OL<FC,UH'F'&M3N8
M=J#&461<'[^+K9R^FN7ZGUH;]36<5T=GT\+_;2F85F?EIF7J1]HHUP/')JB2
MDD'I.DIN/=DDUMIM^L+H:RF<H>WSZ5U+; WMU7:8IQU&]:- _0%FSO9(85)H
M-\O:RYI'AL1DU."5%)5=)*^=6"W]-1H]@H&A/>(.D=RU.H<NY[SA;WU%73MD
MK=7V)(<^926SJL,9"SE+Y.X''S0D:;&$DHLQOE$ =M3R0SNQK<.M)TV,(CV[
MAX^8F2NB6,!8WVCYM=A,@8+"%^NU4K&_9K<GP*Y#I[3C>]43E7+B2%9B;K'J
M%F+%)H\YDUL>-!EC@Q%BJO7VDM6&*[SPV%\N] 2(=?C(O7^(/4<IHY[ZN[B<
M+TAX[V;DT5YL)H-OD=UTT.^.SVEGMN]3!)XXSG=]AKV9+M/Y?'FU0 +0CA7?
M?KL\#[/Z"=_ONC 5;KW(!0A5]033"IRA6#K)K+//Q:O2[ W($8N?Y#H]8[U/
M)-R?Z!_^:\)0:%%$!I0Y@\+,(:*B+[H(],49'ILUU3YF]0%[(':-C"U7JG/-
MM.9)M6N%?I]^GDW+--7G9YN>C]/9YP_S\VFJ.;4CS-'A#VS#+CV#Y#8,U/OI
MDLZVQRO=84X4J:47P'*L#:]- (>A .%-QU#K*$NSR.:IE=JXL;A#^:\$\$6M
M+=Y>[_MNT$^X8<$K9 1NR\FQ4W242^:!JY(XX\@][Z\+YO%\#&C/6@72KJN+
M7G3[DNS8_[S*GS?#$MXN5U/B&Y=AEE\MEU<7EYO!RVT9N*=7ZLSR/9/)-DSB
M8PQ?YQS>S>[^ZI::^JQYL9@O[H4%T1*R*#[,A@Y/Q8*!H!/],:..7&EA76QD
M,4\DI%V#NDLE=<F;Y>_O."FM\$+76OM@20+"0I"&HF9=+"HIC>QQ..^13 QH
M2OL$X&%+VY721VIF?UG,KRY/#%@??48;IO$P86T8O7N/#M?YUK>D]:TKW6!E
M?6=;FZ"G6O:J#,4>7)&.2_32L,*2:635GEJI7;/U>GYQ.5].J]#.REJ,]S&K
MK55*!MH:L7:\U+1G/&T>",SF&(JR0O4W[K8QV0.:IE9A<MCVM*>YD5J;FP?P
MQ&B<SL+1+MO.SVG#ZCQ-8!N69]<J_!9/6>3LG'50F[Y0U" E>$=J=XP"!LFR
M]KZ9V3FX3+LV9]=26P&)LR7([*!(5@B[W(,O4=0^N]H$[V3(_37!> ;A ]J=
M]D!RV.BTJ;J1FIV/^!5G5[BL$KYIO;_\8[KZ\OIJN9I?T-K'&*$&G]J&27HN
M\6T8J.LU?[Z_Y#_O+WF+0Y9<K<Y!B+JV>U<F@T>+Y )'K3.+1H=F(Z8:+]FN
MX7IRV?M;@2F>(B8#PI7:K$ZL:Y#JIJ,XP!5D7O5W07TL%P.:M&Y@==B\=:;@
MD=JZ3=OP0!'KMTN<+8_+^3_^D#8LV1.DG6BX[M3_:A;.OR^GR]K4K*[XZG;%
MN\QL%&BCBE!L\* P&(@B>8@8)1.9F^SZJP-XFM[6[B@?+K#S%JPXGU%$#4(9
M"FB0MH*W08.-3"GA"P\A-[+ISUUYZ*?C+0-G[WUDZUH8M2WZ%+X=;X/J/V[/
M]CPBI9T\TNV@AEN8%!FSC;) JF<('64%HL\*4 2M>$@R/.Q:MC=U].C#VW6
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MMI4Z4AOU83'_.ET>^\;NWK]NZ2IP)S&MQ7IW"]0Z_RGI=+:ZEQ&L?<=N?_[
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M?2?X'%)E8T+J6IC?_SE=?=D20#F_PEG"LZ^X6)]H^QD/.M&^%.1)Q'4W A7
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MMPXT,4*@O9XO5P>"I6)55LCJ.WNRX2YY\,5%,%9'S4LB:3X_Y=)DY6&"@<%
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M<!=Q3>+E?K1\2"67:TP!;&Z]"VMR$%%ZR*1\]JZX*OY="G@$4'0O!=Q%0I/
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M?!9M+"994408KHJA'YK&+L\=W<@: 1J3.!+/TG:FHFM-,/F501G!6&$A:M)
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MHE]D?;>U<7P; P)J?T'LCZ/E!N>#FP;7?SV"<7#WHX]I'CQ)QJ#Y*1(5&8Q
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MK<]*$#+4F,#Q#0[&MHZBQ6; ZJA8PP:,&\Z>?&*C)Z#L'P:SOH0T"<2]8[V
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MKHDZNC/7FWFDF]"V5ADSMQP*+Y:,"*^()J: 61\8)Q,BLQ&?N9[<[Y1B"3V
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M9D%M.@EZ2WQ41B3PA1MPN9241<I*C!=>/IN<;G%I]KP1/*[0>\-YHPY]-V5
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MI909=@+&(Q_>VA8?%!+G,G,2YL[O&:NM6!FR4<0E8!TTS<C.B*&FHI/KP'4
MJRR7UEMA1\S=OK>Y-O72XUO5Y\AD$J!Z<7FYS)>XSND.*;O<\XC%"$.FG?+D
MF\9: ,AY+05,*A2I>5$CAO3W;[2UU7,6"![&[GN2R#3@]2.S8%>IZA!)&V7
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M%+R9[R87W!KT%\(9JW0BRK6BP\AB!E='T26D*T)E=%RYT3#;*VFM;^'^T?<
MX.V@T-M):!KS^CB[G,_*+.)\_>=\$59YN9F\\&;^]9J$M,GH_G.54UDL/]1P
MS7(VO[SSMG;[;%?7(4F\+B7']:+0EW?_<KRPV*CD-(B<M1/7X,$U% P=>1%@
M:[L<Q<@<<IRN2.F3\8:,)9D[IHZ.'UQ[\-98<BY"DC%GLO%TFP1%9IWA=1A.
MX2H9:_6(,^VZ;'FJ8;9C8-'1_CE+6I,P@)XHJ$V%S$1O&;!<NQVB"N"")9XI
MGE)$44B?C5L8=5Z9_-@FRGD .;9$_AAI30)]74K)0J@#OT0!IDSU<',&5$D
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MJ<ZC+; I^E E2A%==N7^W)$)#URWRJ+TP4'8S"R2&2$D6<\_V3%TOQ0?1^S
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MB63*BEQ#EF3/.C)EZ=L0%"8IDQ@OB6CO-COASCQ_W/4CITE [O&#$PVK7=R
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MDQZO;N_ 1EMGE/0$AVXP.T$VDP#:NV6:S6]GM>TBHMDA)ED#KU'4XA$+SM@
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M(]:DZ -HY^O@LDS6L)4&=$Y(!-BH53O\M;(D#]ST@7,%A([%$@[ %<Y!\:#
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MS%;0C9&&Z]37A8/5>?1T @[6(4(ZT<%ZN<C]W.-7:?!/7!N&S)+@I(5DZE!
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M.TAP5)-KP3!X#!J\YKRZ 8)():-=*R^38249WED/Z+/L.7X0 D[N.7Z(.,X
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M1[@>S5LT*<ZS=)Q,%6LT\8H+\"888IU$)WCVW@V75O[T?J<43.@)?QT+;1)
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M#R6#J;836-M_*YGM#^H?M97D__YO_Q]02P,$%     @ *S]T6#B=(B4>"
ME2\  !X   !E>&AI8FET,3(Q8V5R=&EF:6-A=&EO;BUU<RYH=&WM6FUOV[86
M_GY_!6^*M2E@.W[+FY,6<!/W+L"6%(F#;9\&2J0L(I2H2U)VO%^_AZ3LV'&"
M.=W:N%D#-(W$0_(<G8?/>2CQ.+69?'^<<LK>_^?XO_4Z.55QF?'<DEAS:CDC
MI1'YB/S"N+DA]7IE=:**J1:CU))VL]TEORA](\8TM%MA)7\_&^=X)UP?[_A)
MCB/%IN^/F1@3P=YMB?TH:G9;;&__((Z[\?Y!E+2ZG4X<L=WFX6Z[T_Z]M86N
M, ]]C)U*_FXK$WD]Y6[^WGZ[L$<3P6S::S6;/VPMVU$]@FFDK%59[Z"P:$Y4
M;N&&QK#ASS#ZRAR6W]HZE6*4]WRD5==9<ZRDTKU73?]SY%KJ"<V$G/;>#$7&
M#3GG$W*I,IJ_J1F:F[KA6B3!T(@_.+R%X_YR4D6"<:3(^2RR$,[@-A61L*35
M;K26/7[8UQC/G.MG<O9D<#D\^WAVTA^>79R33]>75]?]\R$97FR\YY?7/PVN
M2*M#ZZWN-GU+^N>GI+7+JJOK\]/!)1G^."!7@Y/KR[/A&8P'OY[\V#__WX#T
M3X;DXB-I'7:ZM4<#78;B'IS:E-#[5Z1_>O%I.#A=S)B+U&>QTVR[Z'SP_<L/
M_?/!5?WBUY\&O\WB;C>;[?7#_N)!=A\,\JQ&KD>E)E<T%7F-Q%Q;D4R)3:E]
M_6KWX(@\(7$%90R<6)<\L;W./)4B9TACK]XZ>+8H6XU9&%]_]N7'TFHV=MUC
M.",I'7.B^5CP":J)384A-,]+*G&S4-H2E9./2F? 4?TC40GY(-3YD,<I$(C4
M'!Z]B,RT-RXS'ZA!/O#PLRFYR=5$<C;BM9"@*C-,P85<00M@!BIR)&Y*RMSJ
MDB,"J ,O%) R2C)<:8&D)C3&+4U4AJ)E5;!;,<AYS(VA>NI,,GK#,>_"F ;W
M&)S!E-*K#,SA#&*AH2I@EJ,[/&%<DTDJ@!53NE]W_2=<\VH0%T FC(3\<$IF
M(FR* $W!8^^@&[> :XHAS#&Z,1)-%Q_#RP%AY]L!(2>)R)%FAYB[M-: 0)BC
M62^TBSP!?U K,([(8UDRC GH+.2P!M@)+:>D0.8=:!V8I;Q#904(<V]J )\)
M-W#-6902!H"B E[\=,;[$U.3DD2JB9GC5&6%6RO4W0E.P\7: M;,S),55U\.
MW+H;![?A76Y>OSIHM_:/3(6F2A X@E!)(G"Y;=[ZQ)T1JKG'!_(M(LE=*@D'
M*",I3.IZ.+,,_.@XTETS86*I3*FY9TZM9 !*H57,&6X;L@UH, Z@A?P/;N.4
MYB-.^B"ERU+"PFO1W6T>O/!:U%V%2^'T8AX ZL8GCKD6<!N@Y'Q9>Z)D::($
M$[DXE]",9E?-O6#Z7(3Z_=JF(!3:?E,@NM<X;+GG<,H-=@1(EJ]H?XVDFBNV
M,2W-^EU<U8LX4%'-%.JH@CHV)=AI+(PG/%CQW(_C5/(=52[2K>:2>IA5A;2"
M2JWB8=<BP)EPQ"@IF'^A8,K("":H%LY[$6J]9__<#5,:5W_]JC2^6'MZ5(;#
M&PLN=IT*"G#'I:2.TA&3]^"NCJ-'4 6+8@9_1=P9@GC1G[._1;2;!>-H@V#<
MZ:[">&VZ6D'S^D2W-JBQ$,:".4JG1N74,3HUP+D3E;@YHIK-\ 1X"QH)*>S4
ME?:'IG5+RT//HRJLBB73!5'J"\=M%5!1Z@*H-EZ*Q+'2S#O@Y>F(YU 8$N!&
M"R_<JG$FD-X!P%A=H@!WOR (QQL$X<#$@S&5I6<LEU^>)-"'8HS,F/LZ;ZXE
MUN#></FP]/-P14=0IPGJ,E*E?7SZ=:H#G5MS)YV3O][OD&@FROT*Y.$QP!^/
M-C?!RT <VR#$5:09\KF*"Z>^*MWF6U:1]P2>=,5<Q7&I7>I7B^<2*/B]=S6^
M<TK-7 TXBO+0Y,QSM_>YXM4I-N\W7%9[_'OVM<4PWCPA@+^-PHW:(^V^D#V2
M?\O'9OBMW7&(H[1,&8L$NK?<"W3BR.@)PF!98<Y=HU"95FDS+\3^AC/+A+6<
M/T;5D4*==XU,P#,_PC;PBT5@'//B?Z=R9VN#_[\4<-P%D)1Y[/?^;[_O@[Y@
M]>U+2"=(.0&@4;CD]K"QX(!%543G^Y$)IS>N*@8IY>NB%X'^+>3L3<V3P%;M
M'L*^_P$RHPP=#9]SV3TJFRE&6 ):$':U4)$-RK$I,P #S\;'4+'J@Z^R7EBU
MW;PM2A]%-=&@BQKRS3W# 3'^;7$%K5JH=R(?*SGFKNCE=%2]]-85*?*LD&K*
MT3I)5:!!N@1< .U^U7Y*N6NLI/]Y$OCZ56NON2[;!9Q9O[>J#"*L Z[K<%?2
MPO#>[(\C%(U"TFE/Y'Y2W^EH>3C4I:.Q*SXQE=474X_KT'SW];_1#"< K,8_
M-INY:F[XIAW+5MMVVXW#YMZCS<U&Z[/:6HUVM_V9/1]WMM,XV-O_YT<]:'0/
M=M<:=L<_7CTSJ%#2"2EW^E$:@/S=5F=K9E(MOUZ3>&J?3_&\IE4<C_6):'PS
MTMASLWJUQA+_,R.37KNX=<,M?L=W_'(?J0&D7Y]VVRZ;IV"R\'W[9ZI1TMK-
MFC^Q,U_'CS^S%Q'_/=;Z\M%:53Q3J!^FRWKTGXTUG%#9L-QV(>3];_))JZ1!
M3G5CX93'TI/X-RSVKP[V?U>TF6!,\F\VVDJ @:!0S=N05,1_DB$SWS=U\:\<
M6O//X_N"_[[@OT?[35;SAQ?T22IX0@:W/"[=9PYR$=XPKJ[I';]#7-D//W"D
M>V%[NGA8O%#&'^GIA8_78_[H\?%J^]F\ZT(CD&9I'^_RY!/GU>]P+'[''\?_
M$U!+ P04    "  K/W18EXB,OQ8(  "*+P  '@   &5X:&EB:70Q,C)C97)T
M:69I8V%T:6]N+6IH+FAT;>U:[U,;MQ;]_OX*/3)-R(QM_),80S+C@&EXTP<=
M,-.^3QWM2FMKT*ZVDM;&_>O?D;0V-L932)O@T# 3Q[NZDN[=>W3NT5I'8YO*
M#T=C3MF'?QW]NUHE)RHN4IY9$FM.+6>D,"(;D5\8-S>D6BVMCE4^TV(TMJ19
M;[;)+TK?B D-[598R3_,QSG:"]='>WZ2HTBQV8<C)B9$L/<[HLNCJ%UO=)K=
M?=YN=;K=>N-=Q%FKU68'!YTF_ZVQ@ZXP#WV,G4G^?B<5677,W?R]=\W<'DX%
ML^->HU[_86?5CNH13"-EK4I[W=RB.5&9A1L:PX:O8?2U.2R_M54JQ2CK^4C+
MKO/F6$FE>Z_J_N_0M503F@HYZ[T9BI0;<LZGY%*E-'M3,30S5<.U2(*A$7]P
M> O'_>6TC 3C2)'Q>60AG,'M6$3"DD:SUESU^&%?8SQSKI_)V>/!Y?#L].RX
M/SR[."<_7U]>7??/AV1XL?6>7U[_-+@BC1:M-MJ[]"WIGY^01H>55]?G)X-+
M,OPT(%>#X^O+L^$9C >_'G_JG_\X(/WC(;DX)8V#5KNR,=!5*.[#J6T)O7]%
M^B<7/P\')\L9<Y'Z++;J31>=#[Y_^;%_/KBJ7OSZT^!_\[B;]?IF9*Z%_<6#
M;#\8Y%F%_(=GAGQ2TE@NL@J)N;8BF1$[IO;UJT[WD#PA=SEE#+18E3RQO=8B
MFR)CR&2OVN@^6Z"-VCR,KS_[ZF-IU&L=]QC.R)A..-%\(O@4!<6.A2$TRPHJ
M<3-7VA*5D5.E4T"I>DI40CX*=3[D\1@@1&H.#E]$9II;EYF/U" ?>/CIC-QD
M:BHY&_%*2%"9&:;@0J8@!S #%1D2-R-%9G7!$0$$@M<*2!DE*:ZT0%(3&N.6
M)BI%W;(JV*T99#SFQE ]<R8IO>&8=VE,@WL,SF!*Z84&YG &L= 0%C#+T!V>
M,*[)="R %5.XC[O^4ZYY.8@+(!5&0H$X,3,5=HP 3<YC[Z ;-X=KBB',";HQ
M$LV6'\/+ 6'KVP$A)XG(D&:'F+NT5H! F*-9+[6++ %_4"LPCLAB63",">@L
MY; "V DM9R1'YAUH'9BEO$-E"0AS;VH GPDW<,59%!(&@*("7OQTQOL34S,F
MB513L\"I2G.W5JB[$YR&BY4EK)FY)VNNOARXM;<.;L.[W+Q^U6TVWAV:$DVE
M(' $H9)$X'+7O/6).R-4<X\/Y%M$DKM4$@Y01E*8L>OAS%+PH^-(=\V$B:4R
MA>:>.35DA[?)M8HYPVU#=@$-Q@&TD/_!;3RFV8B3/DCILI"P\'*TL\N#%UZ.
MNJMP*9QDS ) W?C$,=<2;@.4G"^/GBA9F2C!1"[.%32CV55S+Y@^%Z%^R[8M
M"(6\WQ:([M<.&NXYG'"#30&2Y2O:GR.IXHIM3 OS^"ZNZD4<J"AG"G54%1H#
M@)TFPGC"@Q5$LQO'J>0[JERF6\TE]3 K"VD)E4K)PZY%@#/AB%%2,/].P121
M$4Q0+9SW(M1ZS_Z9&Z8PKO[Z56E\L?;TJ R'-Q9<[#KE%."."TD=I2,F[\%=
M'4>/H J6Q0R^1=P9@GC1G[._1+3;!>-HBV#<:J_#^-%TM8;FQQ/=HT&-A3 1
MS%$Z-2JCCM&I <Z=J,3-$=5LCB? 6]!(2&%GKK0_-*U;6AYZ'E5A5:R8+HE2
M7SANRX#R0N= M?%2)(Z59MX!+T]'/(/"D  W6GCN5HTS@?0. ,;J$CFX^P5!
M.-XB" <F'DRH+#QCN?SR)($^%!-DQMS7>0LM\0CN#9</2S\/5W0$=9J@+B-5
MV,W3/Z8ZT(4U=](Y^?/]#HGFHMRO0!X> _SQ:',3O S$L2U"7$F:(9_KN'#J
MJ]1MOF4=>4_@25?,51P7VJ5^O7BN@(+?>U?C.X^I6:@!1U$>FIQY[O8^E[PZ
MP^;]ALMRCW_/OK(<QILG!/"74;A5>Z3."]DC^;=\;([?RAV'.$I+E;%(H'O1
MO40GCHR>( Q6%>;"-0J5:94VBT+L;SBS5%C+^2:JCA3JO&MD I[Y$7:!7RP"
MXY@7_SN5.U\;_/="P'$70%)DL=_[O_V^#_J"U;<O(9T@Y02 1N&2V\/&@@,6
M91%=[$>FG-ZXJABDE*^+7@3ZMY#S-S5/ ENY>PC[_@?(C#)T-'S!9?>H;*X8
M80EH0=A50D4V*,>F2 $,/!L?0\FJ#[[*>F'5=ONV*'T4U42#+BK(-_<,!\3X
MM\4EM"JAWHELHN2$NZ*7T5'YTEN7I,C37*H91^MTK (-TA7@ FCWJ_93REUM
M+?W/D\#7KQK[]<>R7<"9]7NKTB#".N"Z"G<ES0WOS;\<HFCDDLYZ(O.3^DZ'
MJ\.A+AU.7/&)J2Q_-/6X#LUW!P!J]7 (P&K\8_.9R^::;]JS;+VMTZHUF_L;
MF^NUQF>U-6K-=O,S>VYVME7KM-_]_:-V:^UNYU'#[OG'J^<&)4I:(>5./TH#
MD+_?:>W,3<KEUZL33^V+*9[7M(QC4Y^(QC<CC3TWJY9K+/%_<S+I-?-;-]SR
M3_F.7^XC-8#TZ]-NTV7S!$P6?M_^+]4H:<UZQ1_:6:SCS<_L1<1_C[6^?+16
MY<\4ZL?9JA[]>V,-AU2V++=M"'G_N7J\8^41_!-6^5='^3\KVE0P)ODW&VVI
MO,!,*.--:"GB?XLA<]^W==6O'5CSS^/[2O^^TK]'^VW5[X=7\O%8\(2<+K:\
M%^&=XOJ:WO-[PK4=\ /GN)<VI,LGQ'-E_"&>7OBY>L(WGADO-YSUNRXT EL6
M=G.7)Q\S+S_#6?@]?P;__U!+ P04    "  K/W18ZSA)Q[T$  #!&@  '@
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MW;XD# [9-V3G^Y7RP.G<B^  T#)7NT4^^Y5,^5V\-VJ8]U7_ U!+ P04
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M)N#@>-S3APINNK"5F65YUFQQZNXIZ(?QG"['630P5N?3B>ITTV?K"5R3YY*
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M#Z!6&:7_C%#ZCR8D 9 YD9OPQ#&R@: 8\K91@5U4"A5%(*;)!V9PQMB:3:/
MAT&#'#<%7"<[BZ,[L*THK4%)4Z[@C(]#6?7TJL:@SC'#![\. U!X:TNG27\4
M1( K.6B"Y9/@,/LDQ(1%XE,&=<'0W5J/A$YI&+J;!''5'<G13H"KG@1N\X0M
M#F4N$0>'<LI=++UH 'T'%WFZH&39];(C$'D$(N]'7$6GX0%JF763= -:;@/C
MM\HSWT?F465144Z3Y_K]@,P[;D\0W'#X8D)U\U\807G3J+_?#X TI$R+D;R_
M,]+QGF*^P^+5$6%QY7;)'LA0K;[GTN8IFAGD/V [8TU';)-56Q .GCI3P&?2
M>Y6=$,\B_/31H\FC1X_@BJ69P=112=A/"ND_9Q1DTZ*5L*=5%9$MX!<#1*;A
M@8L[/FD_1$>A#>^6@Q9NF/88[C07: G>NNO $0XER,JJ3$2GBN+@EBH 0"U:
M G;^I[6UE/Z9O5"MF7_?JQL]SM>&(6M!+3'%0+N$XEQ9C*EZ?8#4+.NRXC[Q
M[^>]7GHV\P/7F.C&# @H!%</*^6GQ!VQW3<E\33LVJ=UNUJ1X2J.SUFF;G!$
M,-Y!9OYD_L2ZUULC4'Y  Q!N^2=\>&,IQDN>_161L_#?%O_1H2+V53UN:SU^
ME*1@S,%Z+DI![>LFN'>Z,#K[N,D[Y9AH+9R5GDMX+_YSX:L8 R(!"FB'Z7@7
M8WHUA(5Q/^WT!J1XZ 8!Y]PEJ2%F^7/&1/\\>NF#[1);A0TSHSJOCUMM1QM6
M39GUNLRTYKV]/<UGWX,_N:+"I1J1%I6]L1T"9&$(<NQZ,"@^6!9/5R9BBZ9?
ME/,YYCW*!%Q'!5QA]&K'L4X>:"LMOAX!,^3)PVJ?WZ/R'I9;44=9#?5A&RX.
M&9(@.,^VF";OG']&EM5@^<AH=U^YW>TU'\+?*")84ZH31-V_P?WF7KAX3'!=
M:U2730 8%/H.A@%A(D*,&M0(K@,0-0HR01B["M9>2XO6IA:&"0T7Q^5X>\9#
M6?1SKNXV?1?[U:8:MW0;$^/N6-'D"JL83S8GN Q>^9^VK%KIT.;$PD A7J>[
MC<MY:)-5;/A6KCF8AE5C*-CL1X.3/_'MZ.K$@F#(),F#+_T0QFJTQ6& E0 S
M)RO<2P=)%N[PMRXQQI?16DOK.<Y*MPU%=N-UN=NQCU>YR<#\UYCS:\) EM+T
M;\C$?PW/.>/.B,><,;UWXOZW3H?;0'9,0K0-N)B&#C I7->)V06ALUIQPV!F
M)7-<"0RSD!F9F"!WJ. >BE1OJI+Q8M)"(DP7N >7CMZC]HA);G".0ZG 1D#\
MFL0(=A98%41"Z?0[GESQYCEO@?=$ZV$B_:IX,X6TE94)Z7(4AA1*'>Q>T]2]
M\JH))U6ZR/3NVU.+' \7&"I/F>C3=[54 1DPAW>M.^"^B;Z/SG! @CY8!B/F
M6/\Q]^Z$.*T89E/EP&CUZV1XLG"+4K*)<U9T SNX0SNK,[ST;0$6$Y\S15!V
M2@N24VO7=,6*<\AI23&8TO5.&:YZFFC6S_!(Z&S)6,[?DCLJHS[GY;G3JV&Z
M4()1M>"@B=WNLIUT8 8,F\"(D$35.6;K'XQJV'6K.(3(+?AR&D@4=7.2@%5*
M^,8TJ=2I;FGR16?5E/P-:WC)%647E.50[[:4XN5<"#^]DQ DXT$:[W#0(ZA.
M&"Q!":T9TV$E&8C+'6)43@*N?9/H_@F(M_$1S)!-2N$[ @ EK4"@Z0/N&ARD
MH"?#9\)Q'U-D9O?A2<T*CN-EQ3N!PB6B3&J(!,4]Q..P_:-3$95:#ISZ624<
M.1N<Q'CJ.Y+8(39C>X#/;D;A<9$&T^1MB/V*'B$B0.5'%/ "&23A[Z8\L62<
ML7]-?T9C+ZQ-'0@[$ R?)1=4'.P3!@.UYVH;/J@?LIN(S\XEJ4/L$TC21R_,
M+"Z,^I];$.7,L92V<S*7.-ACF&R:N:=)AG+HB,@2#1;1LF6*Y4<%7N3D)IIU
M'+C$V^"HP^67DOZMXAS DVU7 L%#>2^K[U%TBP6XRT$%G^X$- I7:ACSZ'E&
M8>.#.D>H 0Q7%H*H-(3;(XB1&!\CN=L^W&N%3-_3!'7?'TLQ .IJ=[!&T+%H
M<R$GG@HF0V)0>MC9CZ#J+A@4!SP-'ZNZCI@(A_LA]4U;1Q:!.[NLX8$2(.F*
MD@Z'XH@0&A%">T_ OC038054T;2S&B5YT<0[7OEF._MNWVU-6JX;X=R44-G]
MLX0".D1'@N@<&X>ZDO@"SIJ70SCGH9ABE0JB2LL+<'Y),3J-VQ,3;8%<&V6>
MI>3U#78?!3\(K!".RW:S"L'PZR7H_,*BID>K#JX79EFRM%0(JEX7,D9J]>$H
M=\*WF2CR#.E8-4_EFE?0IM-PMTEQP:7_A-+9XNSDH.DMZGK$73?.O',X;]>4
MRNUAZLD*+Y969H.N+UU*33)@C1?$2T2>,'$,39-78L'J)Y*)I3H!DO8X,=2:
M6X::6C&CJ'H3C@_&B9H+3\K].Q]1NCP@#!WB,.XH;?X<N92"1()/G#A(KMV2
M@3Y-7@^H^##J$4(=]PJV"E,P62K"D,%0, R$1"P:*>N]P(TF6JB;9S%;?-6*
M@2I'1-CEP'Z'?4RAIRV<AY5_(R7M=@YK94.4DR9\Z!C@R6^9WX" XA'.IBL_
M%N:LK.ZV;7S<)?O[5:E6R41##/@O;97\ IXEE]?<NS/ZAZ]?<32T!$_;N&,D
M0=2@L$;.T[YSQ"D(=JS/;+7E_8A%.9''"*X@LCV4;=-!@[TG,I=7904R@%?O
M>-YPV&\0"+//_,$?QY#F\&4&+7CF"]%?/:?RCR<31SN)I&U\N!6H1YZH/:&<
MJJ,9QG,(_T)+'WG*F7DXJ$;KEAAPJ<,PD\LP_,>5.,5%)Y&^#6R1LEM]U.7#
M[%*V6%]90E/9:3KP@-E: M2B:5B*:S@O:WH=DI #0P(9!>8)M'!J%R4,K[H'
M>5*67/9J*A4P6IW590$2?D 8-N>**8L4EN()[XN4GN:Q3._,_42X P?OEA5G
M*F^'>)ZQBZXYQ=@+.'ZD /#AL!X/LK.'WJKY 4,PWW[S^#EBT.&TIB;Y"0M6
MDQ]11BB737K^H7+MVA65&M<<O6\5LU*[\Q]-ZX(-)UI:H4^L>2%Z9R6+9 .\
M:"O<JXIL)<ZD<\=TIQ71>W"[[)_VX)>6A,*_%* 0FDCW3O?T(S?G:A4\<'S"
MYX%J8+PS&7L3SO8$F9X83NG (K4/ZKYXNJMBLTOEI3*0L]@KX1AU<)/HQ,^L
M\SPJWW#&9<JBL+1$OM72XU Q-OLQ*>J/QO9[!$K3GUN#_SINZWJ^S.'_DS-8
MH'_AUJS@BJ8VI_P^1T?/7U:VN)D(,0$+" 4:*2\$BG$=*'K6;<$[9='F 4(_
MRF\,Z6A5S0K?S.KAZ&.K1"KP@*;%9D2&8@JU/&ME09:FMV8WO*G@;)S4&_#!
M>>3VAB[[O1/*QTDMNBHPRA$G!T,7=)VM3D!HW9:MUJXVX.SE;2%=*N!7Z)0$
M&OEF;CVVF\2;P%#KH.KH92A?[+*B[[1]]<\,IDGLXWN:!SNF-L3D2>1^-B:)
MG9Y,)]T&65E!UE(QWW)*BUJ$U1-LABP>EMY#:4X, ]IE:X5P6]UY%^D:,@ X
MWAN-T]2T9/6YN*9FC/8T>;O  >/]_6@G9)PAB+JI QN-@W=$X<J8X#PSLRSG
M=B*^JI]"?^";>58S%Y?$$:\0?N@0Q3H)0\'*K%)4T2![IAB]'*_#%"&8OU&?
M@L'XAT\S*/P"/FBL4!<MH@;@4J<CL>MR1D%NYWJ!W\UV9K!5KE5"?$%"K%UI
M<O2X+3G(, DZLS;YI]G<-%EQY>Q@N-&"8@7'7>Q.[?LWR3L""6L &2R ?[=%
M@$H^+U9'$@<?H:Q>K@RB[[\Y<B5,_G 4C>J:@P+FE)9/Q)O9U.'PX?:_3=]/
MPUNZ'EQ9?%:GR7M+R21X@YE%I$M&!7?M:H6UN &30AKLEYEM-E;(ZZYFKJ*7
M:=WH7=_8\ ?_]+UCWC?"9OS:PJ1P DMS4N6@9!4V$KQ_(#O$N]%I$+INA,P6
M*:_?3&%#.?@D*!3GX,D%G#9!)B-X!#>@P@BH"_P0>4O1@$W3$-"GLC+-^!3W
M&II[<YL&_^$C!9<153=)- V?QA'A\?40'OQJ')YVTX5(0ES[W*QK^[W^\1(I
M?G*S_3XK:,WH1R_CVX%L?TDTW7.3R_AHJ/RUO."+9],GWSW!=VQ@M$VJ#Y;7
MG]+K_[5)![X[G#Y[L?OK1]/#W3_=<]LGCZ??/;V"VQY.CYY=[+9_I9G@V8#Y
MKM>F^*^_//Z+WTW$]_?]T?IC<A@O/U( =J><9WO?'NKJ:F1BL%6DJH^$5O!F
MF2W89_E1AZ549_=R$R>OW-VMY?KJ6"5W>NJ]=SUZBD$A%?:_%100?/+=2R6%
M>&==TD9- C<G=W0V5!=&[_EES\V5ONXNE4<OQYFC]P1U^+R%W/U>^X5!1"D*
M9__)#?3H]]G,Z*;/ER52_V$,"#U8DS2;\@ \VDIZE('GVLXI6HR6F_9)&$QX
MWY9HWN_@VS8!U^Z-6K"'SF[OHW]ORP0?MXLZ0TX,V&<W<Y*GR1^6-_P<F2_1
M+4/?1??Z17V#VR(%=N7<T>/"CHN*-:S:PB$T>XCRQ<)D4M8=<59%95B(]#0Y
MA:S$;0UZ5MS%:>V?4DIP[)&Z;2=E35$+XW@$&$KM;[J0, "']OJ/2TO+KK:1
M%K-2^!17P[2-BTKT2PTD^"=Y L95:!'0KAY\TR]A3]YAQ<O A# 8,:%%]ON
ME[TMF)J[HVTG0>Q#8R-T4K,\8.*8Z89+'>L"QLFDDA7O4"(1KQ5RGJ @3M/*
M?CA1G:STPZ9G( ;"]X[1D#QNZP[$*;C;73OIP9DY5VSZ*0T60#J3(V'205,>
MI$AP "?*#!&$W"DK_9@WHW3[2).?'0#;,86,QOM>&1($=G>$,B?[%<X)[D$I
M/PO4CJ3D.D6G_<KSQ\D*N^G@C1RJA')"[#"XU-VF] 70'*,=+&J+4?CZ"VZ-
M2!42$3U8I6((1EW8*D#/#@/2/[-\\[;LC&%30 I[03();"U*JZ(1("QPJ5W;
M@G"9Y4#]L%Q4E ';Z]'AT/-X\:2EGN!Z_=KN_($OA\DP#X([FWZ,@]1&D5%S
M;:W_X<)^U6!SD*.R6WBC![!I 9KNV Y=6!4WXB9LJ2N5ZH\>%;:?$1ZNO-$G
M6T,)_O?H*>ZQFRO#S[=E!N0!5LFK63)P\+W%XH[^(OMXP5,_VV+^;MH/:_V5
M NQC%F3,@HQ9D#$+,F9!QBS(9V9!'N'K_N7.:?3=IADJ>&4-#4F9+U"LE]J<
M2.99AS-)#ME+GDRL WHC8C&GW!=>[U_4K$_>[C+6Q RF7RPL=HG7-V0NQ=K7
M:6-=%;P%W4@(2<FK#YA5M7ND!]MAJ7FG*.V"@WXX&6#/"1G(@@9S;E6836AP
ML&SIQIBBP,WKL*E*=T/K%K!G1:<EAQ.I0[V\FE2O32\A*J*3<U>B&>_L2J.B
M8_CBW*#9>6R7YP3*413U9%#_I#,+S\I\S%9P<KD[/!7X9Q^)V,&WP4"&X*K!
MB.M6\&C@PN54NKG?720V.!93\C@JZ$?L/!P<5W=3$*Z7Z"DSK<2EOATT#'[$
M>1QQ IUV YL0SA8S+A9%:[[=E0?@ K9524G<_>21\"X9=W<C'._'=58YMQA]
M;_AN*>_&%00$"S9MK32M((ZZ-%II2S#HVY*BA.' +/^*Y&'+!HY?;F\TM3BN
M$\AGB?Y3(;#+\<RPK@NKZYGM#);KMBS";\6"2_:6V<DI:-CD3VYJ4V"A#6Q8
M_A+___%+. .R6K /X:.G1R]G-W;!F&E.BQV*$L91+)")8V[#)G[[[*G;LH:_
M8]L+T]H"T\%_MC=T08+Z?U=-O[2KVN;*VD/=5[7[?)!$8P:>5284P.>([WL8
M!R1@O83Y)$S+V.RA[*33;JBG0+<Q=29S+F&MH"@9T?4Q(?]0%P):E"):.-<S
M(V@M'XYA(@T.B?4A('?&]'BVP+Y2W""T"$T15S1#;"0;:AK:8Q8/?["AAJH#
M,Y 1\W)=$YA]$N=1<7:D'RRIV4JMS4@'<Z]PHGV -]@[BJ4Y0UDR;U<M1SIQ
M=IA9:)'(FYOBG#7+:F<LR:H5I5_R>$7CA=10>L ,K67J2W+ ^/5<G53=+F !
M,NE@3*L'%Z[D-D7P'C ?>--T8*'WOHRCW&X\_2BNAJT[EPW?EZZ-9P?^P=;?
MDKGQ">LR1J;'R/08F1XCTV-D>HQ,CY'I3[ QN_VNXGC&#LRER^:S22(!% G8
M:,-TCLJXV-#GQ'VF1/RW-Y3NVM=W6V0[U*9P#B$0HQM5BE]  EN^E3WR.NYH
MP)W:>1;".[#6$LSE$^N1%!AU7@:$KTR!ZN@IU?+!YG+Z-YJ\2M6F\2@-5/'7
M-8X2?27$=$R33@!P.&;5,1Y[W@ Z QNSY27NOFA$?J-EL@%@RCD-(:->#_WB
M:.XNC2:ZIV'PW\T<MPT1LS'GG)["SXB*WR+Q1$R-*)G.<"*:1(UP-Q]]Y%N%
M^)8\WQ?('N!X" ^W8WTU'E*IH6<54E0%?^96I__4G7U[]N*UM,T>9<6BQEO4
MT55I.,CU?H #UVZ&.UI\D"^U-!DEJ<1)->0@XE_4F,\U7G(>MT\4QKW +I D
M+)Q_;(EYB&8']4IG_78NGP@J/Y>80O19S5Z6@I)ZT^3W'=NC/]/!2GW"-KB,
M0+I]IRT.. 6[&Q1@83?8@[%B9>3<\F6VK@<6K1=$"G#S&&# # Z&(& 74]8%
MU=#),HB4&,FY/I2&QJ"RR]P&'#$N+B*[%X-, SM8HS;[8D[TA ,BJAB"ZTO\
MY]S;\(@<J[SO3N>C&9QZXS@/1UTH_*3O,O&M*N@8]:>1.7K]9*KE@AU0I:U?
M3;&7/1.VXS?44(:Z.=&GO/K;@0#+'5"KQ]P\00D[_L5&SAT]VWLK4SV1X3!V
MG?&F1%I6:,^)?=D4E*(9MZQ>P<B6M8\4DMF":/6@GX5X!>??5X',1.K)#:_+
MN9R[",C>[/8R'(AEEQ<B@(R.(\),N'/WP/.93QW05D<[I$2)-$?[$CI#>N)4
MO"U:BYS-ZJ(_E.Z@KCEI+61:V)'A/NFEQN^8@&HVBN_W%H!$VCHW<YA@[#E
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M3"I&G@#;X439G$I3)"5PED 9[(<ED\TUIC@AIX L=_<O)K]LMNJ1SVQA%UG
MS1R!+/ *. 4SY3PF_[-<N#&[XCW>O"LP)AIV(7%O1N.<;65S<R05$31M;AS.
M%ZQX*]-BY@W"H!>5:1T:A.+?9N[!6_]NTY.P19=? %/KR[B@P<!PD%^N+,CK
M/;-W,Q#VS\SX-FBO_?R ;/Z%JK='3N9SX*!1ZZABZR4JM?*A.+. !B_=:<F?
MK@+V]IP@:0%I(FDGPOE4K ;M1XP:Q%FB<D_B@2+2^(#<[0*Z)Y,(>MB5:1K4
M(QHWF(7WR$BZ%,+M)^S0H+/M"2PUGE:$*2Y,FS>3F.&8I(O_I*E:ZHT7$:R'
M&<(,P]19EQ7T#FZB@!85WF6Y@P.E2)/5>91 7#RL\=X>6!:73CE%#$+%Z**@
MQRBN4&C/3%P4-S4KI$RF4&(J-U_!JG)L*EA6VC \4+?;>?%1#U5VFASCPR0Y
M4E DM)C3WM!*@0ZHE0@\PXVARI3#H&CYY29;R1 E[1),E93"S+B\Y4-P(U16
M'*.D.W B1F^C9)O&;>WFHL>,1AS002%'N- ]N.S0V +T,UN 7LPXPR5FXBU)
MC[&H3FR><<\&[KZ!_W*&.F<)82/FH:[T&;(ALX@;CM9Q=#?:3A4\&![ (C@X
M,(LL;6';PP:A8Q+GXI)_@,$("SSA(+&.?HZB X?,F9X=PUQ@PN_I\Y>?+$ ?
MO\  410S.CCLAXR^?&1H>$O@BA\]<Z_SE:TG&D*"_R,+V>NQH?RJ2KR\W)J\
MV>XPI+L;ALB)Q]7ZPJN%_#UH1Q&U'OJ]E# O.%.V,$*;1W905IP1GR#2417:
M12:KP=Z!,]HP!<]I46Z(:"LK<]?X <33N'A7L'CA0L#L>TV\-EMU]-H"9G_1
MYM00$V8N93.&W&0PEN=+,G6HN".E)!OL :4!']?KRXO&P"MG;<=\1*&<! ^A
MRJAY /C<*XX^>+4KT8>=C9W'Y.&8/!R3AV/R<$P>CLG#^Y$\_)WAFI^*7+Q7
M(8,FY*3>F7ODZLXEL8P+"(H <@ZE5I3%@2O,M@M;.=S?[>G35F#'+QA?ML*P
ME(5_9">-37XOJS_;D]J<-IDM;F;+J8D"XFMRDB57VRF\/8^SLM=EJ"@/UJ:2
M#)"FEOU.P+@V+C37US/*>YK\L<QR&^P=SSX?<TJ"M48]%!F]3]F\H!_J?OJ>
MRZ0(,*+E4XZ4*A-VXTG4==6DY5J;_.RGX63.%,ER,R_O+J)K9)D.R"Z6L&8$
MMI?K0D HW AGB]A\]5Q>FB+^+A8WA#%-7P/ H,O/*H"?]&O6LY@407>UIYC@
MC4^Q^3"]3!R;RK03W/!NYD0#RBL0C@WUDW@EB9(/WIL=->_G\^1H_FE(((72
M"P/C\#X&@SP(>5YASI.$J@@8SN5+DTA'*S.,W!^&ZW?H/N2 B<X7%:,\,B1,
M SB^'RKV^+C(L"4)03K)TXA/W*C@^\I2I(I2JN=A[_T/4RL_%#6";.[RNX &
MBQ$B#D(>S<A$8C.U+P (.L)P!YGJA%*_*$,J3?J6DNN6R\#[SYJ#<K%@- '_
MLUT[]58$;X1Q/8PA<![.G"#\G7B,;HMI]1N^0&&7,.H:SW3%[59/[$VUIZ)M
M!S:,ZUA^"R?_!PL;KZKG2VQU>PMFGZE:JA(A5?AGCMV?*4RZ0+%Y^Q;@#8B#
M69'59K;@;L++ZI8LQ9AVWS]!0@V8;[4)S2!!T[E43%%I:Z2IX3ZD2U QAO5M
M:&-.2)GDUNL@5CP3@NF5>9:*G5L;9-5'E4](1E"62U.<\ -RRA2ARFP0?(OO
MPA\N=N 'T._A%&&H L7,J,<,^A6DB89 S7W4+"?I0&".T_^%LW0Z]<)ZJH<3
M_][;-KIL&SQ51&6GM8<>.'UA@4"<:(BZ<6QISC'%1*"$Y?J/=\VV=HREV\&Y
MQ]@FA:TKC-%T22_&_.*87QSSBV-^<<POCOG%^Y9??(^*5,RO5P)V0T7]&0U)
M[XF_=/'()T'[ P Y?K^[::AR3]-2,(.&62Q,5DE\D$S)1R\YNU4QZ76:204&
M6T+KJD5)FLS:&H9=(SD^.3U'AR^Y1=:\T:#GS%(I!I*;U%V>;8;,UW-X*_TF
M@BP+V_&%WPS[TJF3V>GS-CAWR+J2>Y!UV".T"Z*_];OIO4L_XZL.37.G!*17
M)M*MH=&HLUF5F-7$B.WHTEZ)2UOJ@1JJNG7USA?-\BIKO&M8"P[4W*9MY;N0
M]_NZ9$1S/0*1KV9Y*XLQ*SUA?0%'3>@K>T(!]IFILZA'0.EKKS0K!))V/C>U
MPR./:_;%U\Q^M-4<\^B8(BL+TM!SBB[4I]@6-U*;XR)<S2)@MV+:^$8*S4E$
MMLR,4&_KQJ[&J;^:J4>8DK2^FDA@-=]R\;_^:^*UE%H-^$'9-AB,DZ(9-;OJ
M0.K-F'EBC-%>U>(1B8GERJ2B=$U=@OH*9F9;F93H/A3FYJMJ[[U]W-?2HX%\
MC=J8B'6R,YMOG22Q^[LG+6&A\SY]N+>?V2D>]<<5K1AB9;6IEI(,QTRA:M5&
M8HE+ON:4V<FWTE(18QF^(U^?X8 *YB_ =30N]95XKS3Q=O"4+;("_-F,X*&P
M&PBL,J[#E:U#F17-#G8T46\4'B@]?K&CT^+#.+/-!GG,PFL&Z$3Z,G@T[:[Z
ML-4HV^;6$?[XQ4(#_0P,'.J<>A[MBP2+-&([8ISV+D($P'?5'-KHD;NN9?.0
M*:^V#3FKB[(25ZD.,B:.'F 147=<*&SN&<KVQ,5]P-OM@490%OHN<1U(2#Q'
M3.W$1R$A2O7N:ILO#C3H/^'P%4:K#J1M)#Z;HUA,'81XC*+@2HZM#ZB@=L\S
MRVV/9W9O2B$DN[AKOHGG4MO=KJ'<#.\"E\+9PQ<B(K_+&<+[+&18"K:1@MC8
MAPRH8214[2DPPBB 4:<3S3=NT9T1[3?GDZ2)!G.&N0 ;HP7K#&;65#&%TS31
MRKR,F5$FX5!63 .&.RY99M@@>Z$XOA5L\BHC<+SK8QIN/'-FX&D8TZOLB:FX
M4WF"33\(AX1JT>O!>*)THL^;(;?IEW9@R]=[]GSM71;/A)[\P_(+H\1!5OXE
M40[R!4@/R0@ABO$[/@0DHB+N$>S VX".C@\[]BD)"$/5'N>J1A1?DT0M@9@?
M2'N?MBN&2)&L(,93BBC0GNO(@DF'.$5$ P/'"DLM-&%F%HGKJBY$$(TYA?MN
M3'V9N5+N(]HX/-*UJX&;X8+ NXM+88G[0W.?GIX'D64[Y.\T/*0D75E:YG5)
M,7HB?4WXD%,W^"&A3ST<T@N<_<VRI%G@IA@\*]RAAF<_M0M+6Q!K6 P_4&"M
M3+G75&4^-$]W3(Y&'9F',,B;I=BR0_WA=TZ_6%R,74;\L+(1GAZTZQYT<">1
M*^R\2<2C%W/5==1M.7.]HZE4$K8\%Y\."C$1^GN4Y(A1'#&*(T9QQ"B.&,41
MHWC_,(J^K/UXK,>^),?PB:_KBFB!P=RAG"(689!K&;'_9JY=(6;MB207O:J,
M/ ,3,$ 'O3:Q'R:FTN 1JXRL<V72C1[,K:.8AGA##<R(1C[)F!2N$B -]W 8
M#$J3\T ,C1$KKR:6U.6K+#@P5OI9"<\O^@^:F*A,5H=A%HZ/AI7AV.P3IJ:/
MMZ+BEYABI/_V1*BAQ,##D=:)/KT7VOLLX_[RNNGJ6PV[+F:X$]=MA7T/:-O(
M9J5Y=&BY?J@3MD<Y0[P.^4QT@^&4A:QTN/?ZTQZ4,^Y OR:GUJYK9KLF,L.T
M)-1*>=?<K@^#$R3E748HMK.0%ON\/3VX@)//6D'7T34-XN,UCK N?5O%\REL
MP$&K)%BTFQAGFE ;X=VWFL3=#C';B>$D6S<:37)2A+PO>5DIGZ4)160--[ON
M@*[OV.YZ&Q^J#)OQJ,^[:/,%8O%0QA(;_8'T1*9M8B2$-;A#*@OB1-SR?5M)
MV>OC'74>EIK:JHB?3U*=SOZ="URSL; CH-';X;-*$B$;G*)X8CNB4^<9%S;4
MT844-)0;W?T4T"2?F@*JT2.X09([+Q'M5V)RBN_ASTZX]0:9(\Q,$HV]L#:E
M<"U^X EC\.<@HN9!TYC!!D^.;H6XOGQ3<*E4AXL?/WOR$B9T LZ=&@71+Z=)
MK/R<$  %^*!^2 /$_Z)0-*248%.<+'U7!)H !X]P>/"QD\ G=1+H-@O/"E@;
M0KHP.3%+;(U>EXG%./B<X"]X[WZQ<;]]%,;(\SK\<>.Z5L"9L+CO/\B&RQ$C
M2ZF!RX+/KBV9WH\RC-" SX4&$+S&)T]X6V2+!65.XDW;8:BBOP/F;?C(\V[[
M^^A>JQWG??1]K127Y(PQ(BNU9VQ72?6\OQD86N@8]ECP+PD:&7?P'=K!TFT'
M&ZR#GK,G4@3EN:>XZ91%,"BUL:)<H_B_?FO%R1,5P]$EZ Q4VN^G64;=WK1Z
MBM(LGH7&_=@CVT!$$\AZX'D4I* .Z\(,:WLWQ33NRIQJYQA^IT\W$&_<GOJL
M$W(SS8&^%>:W%*7F*[OB8I50VJHU1ONL]2*/O5)G+]1MUK!2=]$Q\&QPE\R(
M80_+*92-#_L>K"CVI(B<(5H<9[>\PA0U%6@OT3:O!F%>^W.#\8(]^PK[:CA#
MD>S<4F/V\DMG+Y_%-_LW[/!LL;VFA3]>P>_0BWQM::D0BT'DJ_4%A0R^C7P"
MWDDO1R=O%PG0QX^G1]<G0E$4_& *(B?"6_Y/69TF_[)YCNH%;+K43<2$946%
M]>X$A,?21)O#OF?=M7ON)HFHM^/7[^MI\@:1+_"GWL_QG:KOG#P@)]:USP.M
M:5%XN0L>ZK!$-B5[WB)Y?TQIMY]_Q]>9PP*4:68*IW+]"Z)7+(FX[B )<N-'
MBL$#<>&YCW-FB?"T7KJ&F+YE+5NY@@A2WN+XR0+]<N^D-FX4,[C40X>?0X@J
M1Q:/N9 ZO *?[&X=C0E^ZRR2DKJPHGGO[7=<6)XI>$>3(M4X[A&;NKYSZRHK
M,""1(R)OWI(RTCNATUO.C9"!'SUYE/Q465ML\.[O&_BSF;A5]7\EAX^.GC^[
MJ"USZP[F_Y0M;1H*!]'\!I:KJY1\8![B,B\--R@N!D_A.SP_ZV;"W5OA9N\F
MLG88+X]XT02E)K%G11H7K4;2:2 J IB4> MZ/RG,RK(Y.@L'U!;!S=,+_!J-
M65_Z27>"]Y?A:,]TH4VC8%U6\%W5_J'[S:KRU%;^6/CR$(SW98VT4Z>.:KZ=
M85AVZB-H_(P/9.G0C&*JX /UAGT5Y I??W@U3=XN\/G!DOD:5OR<0+3A^Z-\
M8?O-KXU^@N</X:C6,RN;&J&0M;]7?'WX='<HPSI:_%8L2"RR+31W*G$Z7-_+
M3%])S)15XZ-&M6P11]+'HY\I>W6&2'4!N^+^KI>$T47RS#9GX'=W!#N?#5^D
MR+$'.YF"!&4=O0M"SN^J:'CG=U# ACATUD3#LOKTI5&!2^JE!#:7R!#3?R+A
M;SEY%\XGW+IY/*[C(P12T7J'J$&4*Y^U6E&ZN#>CJ#VJ-[S$_8H EF$&@ _&
M=!?O4G)2@@%5U(._B36P4[",9J8K0P+YFM&H^1:7D(X1VUOXFJ'4\3_%[R=^
M_#1V/QUN&,<Z"$\%+>7(K22^0BLQ//]$XX3<MFR=$& \E$F$<:5N>G,FPE5I
M3[N7:6_AB/?&%!*7!-(''Q<DY;S_ZPTM9SV$<Q]<%+YBX>7HG3T#N,46)1C*
MU#.4M"$HF96I'*FI*W((ZHWBB?5S-DU^5/I484JV86T$[S61^G"\>'Y1G5?[
M%H!*+VB[OL,S@9(^+><MBS)4A(L,251A+]B/RVR6-;5"E7G72S3$R;\P]DS
M_9+ 02V%S##_2MK_RR[Y-3FTKUW+49S,7^@8OL8IR69M#%&[V2]Y<: AO?8_
MR@V+M% 8J1Y,HSEAT92&<Z*F$4O5;[]Y]OBB,<9;>?P##8.=Z^G\,?;%;(5U
MG.>&HM#AC JP;!EWMAV:T:S1&(#WP&4]:+I%@?E?#WBD$ZYE<9UU\2HL<=&6
M'6C76,NK:C^N;5&C%_L_JMUT^>'^M>T.CPB@E?)=A(?W>F1T3J?Z4,!MU@L[
MS]3P5GD%"[TG>W/E6W78' *K%5$!%!V)MJ+?2_*Q7V\T\VAOA\><F\?\-GT_
M!>62YX;@I;BK"%62EHC@$@8UQ]3ERT_Q&M<P V\:WD@WU&\%[6BJC:W)7U,7
ME+JUE76=S;CNAXGRQ#YA7:AA]XRA(A):@>=*\)ZS0S:=[+)F4,?77:,?Z[J"
MX\W*%F:]@'-:54C1PSA4>@-4O-'Q+[%H;(5SA&I4QX_WQ.F"-VS$L%27M'=S
MGEXI;Z:%U+B<4'"IJ1$^%RO5R%;E5[<H$[+4/X[[IY]9 >7U'LHQJ2CUD6>T
MH-0ICQ@*&&QYFX_W.1UJ<%8T-6BBXS%)E&-+K?'&?)0H+I\HOR\1][/$AAE2
MH$KA!6K6EZ7.7V$Q;=/A$QSL/]IJL+IYY_S03F=KKY#;4H8._%A.8^$PZ'L5
MW=805I;O-2?+](IEUR6EJ0 .76<0+*\%_97#1!&?C0. $G["E12&_GI\;H9V
MNH1\0-3E>';KTD,QN,Q/[?A@]6_SEK_D&G!V8GJ=2JU[(G"M@@-A7"ZX8W=P
MM'>KNFMCHU]Q3-/KP04H@7B1!T\B';_@/GQZ.(B@LK5&KUN?2C[41KPY[GJ7
M-5PKS'DAXTXHX=$XV(+9G?[;L'KA.S\4WLM(,16VX0 ?XB05P&CP<,"<&3(Q
MB2N#HHBH\T7#1N_IV#1V3S(KT+![AP^E=?) /*R-C+HWJ=0)E:(4W6Y"_NF^
M9^\%9J5N,6.26:Y(0!-FT.B5>NS"!@4P))WOZ3GGMM2"Y@=Y6T=K7M\ *0 ;
M=4/Y,%N%(5T*-SK_APY\Y=Y%FB[.Q&KIOE BI@QK;&W*V/1W*.:3'$L&[S<-
MYH?@_\  FW">)CJ?P<\Z3B*G=>!Z.@K1E>>=\OA.5,M$M DC/..KPC-N0'1K
M^-Q0,9:"0%THH.K$"7:&!CZ48H,U*LP'-47)YV@A>[=9<D]L]2#(L0JCT+!K
MJ=C^RDW.O2&PMY+@Q#D*8OP:!2E*,0'%WUK=*#.(ANJ$4AR#<L()C)6,Y*:I
M3\7ND#Z6U/6\AD-?+\R<Z5CKNJVH9$1=A- ))B^<G-C<GH $#3S8G@41#TWE
MJFX&IV#(.O&BFUQE14O(&Y!<LGTA2!K?_W2@B%-;PZ/M,60SA%;))-058LUX
MB8K</#J3H= F]YJ<.#XA\KKK"@$;O1F<LKL6##HW&RYZ0C<,?B38P5F6!^W2
M=L8A=(G%(G)^9_  XOHDR+??)HO@!$J;1:T:BEY:\PK![4*#3* Z 661OH0+
M#DNDYQ[94 .I@YLG,6K+'&1Q"G)+$CNQ.>R1V%$BAJ-^H)D*-$'DKZSAT#7>
MX+1V\F&"J.Q*A VZ-W.LGGJ["*)9*R12ZKK6?(P1.&6V/5.,0N_)?%G""2-W
MBUQ!.T=11ES;\'X$==C$[L,Y-M3D@J[2+Q4)L?BA%+<;>"C=5"ET:WNN@Q2Y
ME:E#J44,6C$2CU6O.)5I1SR0X^M7ZP$+!Z((P)$\[&X!J:+.&I]RB)2#H^8B
M6$1;#RH$6=&N%_6)/E\HWCUJ[XOZ=U]8)L?*;!2O7S#KYG9[#78KQ] Y\\ G
M,=J/L)?-9M'2[&<K)W[<#HU#N3%Y%YZ;8*6FR1]6X^@!;()71$"^'!!12\+K
MY9X^;H5!T2;O_8?'\X8>0E)A^$F.<8[OZ.L9J;=#TY>A#K;2'U0LZF,A<+W&
M.$'Y6)W06FI8EI?=Y24[6<F-Y37%MU;@D?/K8^M=-@P\)<M99'7V!U[8UH$@
M@]]$FP.&=#<0#WRN)D2.D%9F8[B+SBNT_G-NU'9+WO,30 ^(AF'<)]G']PF[
MP,DD"3SS'# @%G9^""J5G]3!>0JY.;T+X7"3$NUV_+.*8  5>Y%  \-,.*-+
MF332G)PU$]H?@YRY9K7VWW/':)]2UL_Q[CUS*2[,<%5:X*VA@]E!;XL]B)AK
MAA(K)XC+K455'02N+EU4A6+C50 ]%+;=TL/[.!&(59/!,&^+;/F$,S>/0*2\
M45#P["RMN-.G4NL6:LI!XD;QL)E^Z,45OK85\MD2,L_)[9MUOL)3(2*!X*W.
M=AET)0-(;GB<8DB#D';P2>I\Y2B%:JVHE[(990/QT@A].#8N*CW4:![5I^%T
MG?]R@^]AF":%GTW(F(4U9*M>RHLS<R1]#C:'2J4FBL5B."U**\KXMDQK$245
MNW53/?-T.^BD\09A?#>NNJM4<MMJ0?4@8)!A8%G6+T2O*:-W.+;!2JJ[*_K2
MV-$FV(P &K1/1+\H 2=ZH%CA?DK%=Q<3BH(3"9#][]BD[\_C#IP<F;^LF_''
M3MEKS*PC=DP EXXJ0T0(!9<*">-@A<'@^$BJ5UR4-E"D*,VAB=+1G3]DJ\'H
MS(Y*AN%",Q*!COM H38[+E<VK>C386G))8PV+H'M3R&5VH4E=0Y"MT<FC"G,
M.YK"'):BOY>T01FB<&\4!=(3WFEY'[XLLW>Q'.M%_3%U7-)\=##G_6IP*LKK
MP,\%.>)I';L17! "V3P3H_",-UL@5.OD 6D"KL+NQ=SQ]P^'92!<"U/.#O9B
M/U$ER<E:L&@4?I*!:&E1W0]%29V/OT+,5(&\2&%2(S#D&=V2\X%BZR)G"DWO
M)RP%ES%%TR0/@?W&".NM5M(:2>H&=R)^S]10T'Q P0TKZ 9KYPP2_E3X'Q>Y
MFX21<KP1A?&[;99<69L&W^-B+5S\79W<2]\5QU553=RF).I"CMVB<0PB'V&V
M;K]>I&Z#,DXRE\Q^&L5E>0>GI=M]G[:1&>. OCC( K5K!J^#*9JX5!S#(P9@
M40T_EM[4<*!$;\-I\ZP93%.5E^#>O<%B;5B4OZ&>/40XW7&,0I*)L.[;S,HS
MQ9\@ 3X)!H*(ZVEW^7M9+ G 2=*."@8'0@ELOP:!%L5@.F<TC+&?%A@;G2F'
MD<HE6Q!G )(I8>LBAC8,W?5ZP8$%!1G@K8IFIRSVTXC7IAG,O]6<LTSL\-D,
M:B$("**G'H7K:MV$9R XQ&45+[,$%7TE*5&3%Y3*7A#$D'$Z-CWO:$=2U]&@
M/GX$ G6+W0>I;B%<1!2T@DC<!>'22.Z0_B.O O>*=A!GT@N;L@3'^6'XXL:J
M([0#0G098LRADQ\SK0WS(G6HUY[?8#J_*QY"/%V'PB9/!?QU3R/K)FZ+8 ]K
M>>?%V\2.JW9EJQ8TG!)3@&2VA'41O]:8HLD4WJR>_]IUI*/.#I[%,6'?'U7.
MY0@_QS6^FC4FH[2_/&I#J:&/#<=2T-^U@QE&/?BB]A^WW\H:7L$A%8\<.9F8
M0,XB-VVS+"NXL\+ D%7#I@*&W>]4>A.@TTK$VU@9,D2?E96>PJ"O>B.@,*J:
MKKT!D!5G6>/!'4N[SR^\ V;R\ +^814'2+ACSC(XX$>W&KWO#>-D8MD?,7/3
M#=R/Y]3R<MB#U37?>K0($=?[=H5=2UU2'N+5^1" !R)A5!0Y:,G.+['W*D9H
MP8X>LJ7P6HE=2U=2;OE:4?YKQZ]N+C+G?"=%O&VJI"54&_QL*4%ZK1O/%N&"
MN$GF>(6)4O#VPOUT;MV1"/LGG.#&Y\1;4$R/NKQJP$+CUI2[-KD)<H4>^!TO
M"X?+><<.,TEDYX3-#'KYZ+)@_;P;<^<Z#(%)0U>R49#F,8AXI;8A?GT0W7-;
M%>HI#X6M"%K1<W8"OU2Y> *?9TPA7&L*X9HB,#\J^N&-I*DO+C"NZ>3OKM:[
M_C:F,,+I(]Y(E^UC^N3Q]/D%.X->YK;/IR^>7TEWU(L.]FNW,>UX4]S$\L;D
MKGX53)M(?3)C*A<BA'^B*/%!\"C7@/F!M=E>IW4S$)+Z<NUW+K:VL3-X1#:(
M^[#BL<JG7W$;?*4&M7=MVBYY>GXLJYNX^Z]-Q+GHT*,;U3+C GO[$<[$7RY_
MZ5=J[GN5TT;-??^_IV G$$<'9J4>(E8S@0GE. E^'!1[Z></+]'^]Q+S>W5B
M9K EZU=S$&MLM<JN#B.OLF*>MRG3DO)WZ-DA4S2UWV,T6+<VR.OB;K&25ME]
MFH=]LR8K+&9Q$-J]6.IH.G>PMR8-UEP1UGBWU.PXF1+H_L3=_>R>2(_IHZ<=
MX0$K=J7B(<'_'CV=/KW)\W+L21N#4QP7[@WUBA_WX"?,-8'<$:ER9G*I,*:4
MO97H,@/NB;MO:Z0&=4<)+V.TDJ5)F7XQ*(<(0$'N:Q^"(TA]1]"/Q^!U5X?M
MG/6 &VHPE?/ "WE6?P]Y;3'H'-ZJ#[H>#]W7$_STWSF>PM14R=:::CP#0;N:
M&CNRS^VX";_0U+X+2?#11M2B-ZQU&W?>!YT.5%]1PX# G0@J\(-"VY+)-:67
M"E;4#M!HH,K3'"L3N:+N5.,[B";*P\9M_V7651,D_26Y5K_\G*;E-\W/1$,0
M#\;"S DE+DV<L4\HEP_0CK8?$4)2YUME7W. D)Z3^?!.^-],NDQQB"Z[>(=%
M?O2DOZBPICIMW[=C!Q-Y5P#'I;M+QA!("P!AQ>&J\%X?)>&:<47D_:KQ2<*E
MY6G;;%6<1\3IHXH]QIX%8-'57>$[GH3/BYW(A@>OKZ66G@/%M%6(\$+_F\WK
M3MU&Y$:.&W;_AKUX_^H;!,"Z* SC NCF&T7[@Y@0.V]JSPVRH,Y PLE I8<]
MM@G7?XZ,=^X54E91FM\G$MS/'1?\WDB[\PD(N+RRH'(JJK29J[U [%N]*D#W
M(NXEI#M'3 I&T#@=[VRKQ,>NNIQ_K3Z)66$3E3B.A#WWF*20.TP$J2MW&=E]
MCI=0E*6$"X>)[F7X+&V*HD7.,6ME,7J^?3!RK>SO!8)K&:GO!IOQD/W[\P4D
M!E6@S<KR] !V*3YL"V[:2CO)D",0M'4]?T7"UQ(*:+?)^N,W@\%L#:8^V#/K
M,1MDIY-SM"0]:DL7W1-6/=^XR^^&P?<"?6 K@MM7=M$RVEZ9D^%'!Z9I*ID?
MMV8PB5D>GS-E*Y8K<"34BV?$)MXP>H,;),!_).$D^';\[V#]+=6)"_432;U6
M2-FRU:S%\I!6*#O*NNGP0?F]#9*W5N@YLJC4>(JR>NG:2ZX,2NDBQ-A2@+8J
M3RJSFB0;@[C?/N64-Z1L[7U>'N6@$::AHS-;M-;+9[JSR!C,C^#G<75T@=%B
M[$M)D@]%>=LAW.RYV(/SB6><&?# 8TFMR>F/GO<JWX0D2O26^I*1S-D4;'-B
M->ABD>49"2!'E->I-!!>N&UB357X.6'&K7J-_4"9NJM<:7CASL+A!S4--W(*
M>J.!MEBP^\K-S0,EY.:[#NK9419C03L6N<^Y2^X:K!;4=\P 2A1>F\(U5\-E
MX3(5]A F"#C/:J2<#UMP@Y[+:!^'#4$\\9D0E]$!,=A/5[9Y@#F8T*[ 8YAG
M*ZD0FK C+51>L@$FCNQ6RF2(7WA@[*S5]$!E-3;C(P*(B?0F5E9H[M; [*K8
M8(6('I6=*B(&JJC@MT:^->LXD=QR\/K@MF1RPST'T&5"Z8Z.,VG +=-5],S4
M%$^;M5N!FJK!T#NH.Z<DVE:G5 'M2[R,K][JOWI;LW6HK02I  &MFH$IV/?V
M89_J%8AGKB(C,\A/R%S3S>YI,B;2#+3IC5;KP\XA.:,M%. +NI%O,,?(%9ON
M>W:WFTR'5\//FY2IU5$OZ3TOS//.PP3Y<;+EF:3B$QE8M]%;*S5S U-+//.>
M#Z5ELBPJ5+DM3'+[(=6>SO%#%!Z[8R+>-9Z=V5Y%7415N2>2J=Y#601EF?B3
M*+B^MYQ3=$;0#WY ]W@?P"6W:(@:Z QO0-J>>MY(*>JY?*>[*TS9HY"^.O%\
MZ!0XET)[(ICU&O,,:AF6&P]($7EYR4&(PQ2LR48*:H-J3304NUU"4\ML_?/M
M4*,8'$D].!37+H;JT *JW@D\"'1MMVI71PFK1+XH86R,)&;(U^NUO CZ/]"D
M#/;%<$[F1%Z0/%-JIP0#Q"BYZP!#$W,GQ,\'C@1Q"97(Y%_0+F FB.2=39'W
MA.R3=W:=F[G5=M-=U.5KM[;O^['3.R;-ABBKT')L>#H'3YR8#V?@J!<,,I(H
M7!62,:)\T0X=GIR#J91(?H6<BOU8' ?XG"8G>Z4LN.!9NVO,X515_<00^2+J
M$MY95^/M#JP8^Z,IFC ,S*/@%:Y99)=KBVH81VJH78I&/^.B7!.P<0X+O4%:
M VPDL@B#K,PF-R\KUIF41NN(PATM;RIW<L'R*^Q6#;L -(>/4[Y/,JRBQUZ$
MGO/V;P:N5\]8 \@IS/;8$YK[-'C,#K"M;$W"$=ST&8+%!54D?2;M/$</BCA4
MZ3+1E2L+VKR:$(]%F6>I? O7FS75$_WI[E39LCHQA7X"/I+U/&/4UV WEX7K
M2]39;,Z]HL9HT?5.%.$V)-H_T/.VU7 0MD"Z^'Z63N?4XS)0'C$9WFZB\%W^
MA2,UR_H=;:5'C*/,UH[FW"8F:E+E>CJ1;SH\OAFL2.LZ@09?S,.[=W"IG7Z?
M:B#IGL :_\&@% I\\/JU->CN23NG4>C06;Y/)SF:MQCOU*=[VT$O T>LM1?8
M(8,+&2S._J:$@Z,B-KE3]2<Z=']Q)^9W_3/+#\0O<%E@E<Y[WMW?$TPR<FY'
M@EZ=U;Z=4UDA$<^Q 1P*RCU7=Q["=$4@6K #/3@\<+,",WJ;LFJ6:/H-;JHA
MXZ"CJ"E>K-3F[D,2!\+.T>/EOAMNS#&<RM3%&C](X=:=[FVT,MMA_4A$/3@?
M=[SAT1],,\2<-$-9%O1_5C86\0-1:1*6&H\G&8M6&5ZABIM5-D4UP/\R?J^E
MG*(!D8&76,D$A_U6+%/$DI-P$; >.8.[D+ITFPB3S=DBCT:E]-_$XSV"VRJK
M,<BF%<=!0!_]&R0=9:HC3D'*P/:ZG&L2@FT>DEV6C=$SL18CU>3B6<K?PZ&4
MSAN-F?$;EAF_IL-,_.G4)#&TG1>"VI$#=[W<:,=!0B82 WP8:G\:F&V93 3A
M*40;8;95NU*XN,BR=(%7(AEW!%O1>[.H(H*L60FVA.;427*9W0*N5CUP6W3\
MEU:#KH+[;FO"H6AD5H#\H_2B-X8Z&B68*R: <R1SS)@I3=\'$B27O?D7Y8+^
M[@+K<?#X4@Q?K^!.LRK[/)3L]3+-PA ZQ+R'TT=$S/9,]*\TL:\QUUIGQ;Q'
MX->@/&HY=F(*[?J(^7]B^$<;88XHX!C#B(D1-@EL@<Y,F17:B)O;FUEAU>2O
M<$=\49+I<3M<;CMLN'U<[1I7U0K8]'$$"8#^5G ZIZ$D?1D$$T'(H&.-MU&V
M7::ICF],,!BV=L^YMW1",56%%ZT</!\,7;(G-=@MJ5XJ*4+[^0#^=4!P#XNW
MJ$[MN+MNQNZB8!6V!*3L+\/'>QL-789,6J-^SF[SA:F]_;;S$>,^N<9]TE$]
MJ$38RV8[-\^L$,QVXV43+BHC( G_&QX(4^[ )''-<H&]BU;)CP?/=O9D'_?!
M]<H+, RLJ<2_R3 ?=B8( Z+O<Q_-'8P#,8SC@EW/@F$0FF+0+ER$P'+)5YV9
MO.T6_<>1<#SHS((3I,QL1B(; 8"8=.>L(^'!\>Q&)2'C8;U>H7WQ;(HW EGH
M!E_MV!G[<R*,1_(4FN/B7\?BN_/;2[+>P]3B+K"W"SOM[149P0^5[/Y%O[-7
M&&,AIOODF OP.!+IHNK=ZP:3B Y:,+A<R;'<S>QHK>:2X0PIREPSL50],T1B
M4N?&#3[)U 'R@1%5!)]21H"]93MM4=L3;"RN5K\OFC"S+,?."-R4G#OB3'PA
M:E4BL-S +!9VD35A+5-4*D@R!QT)EU+ECFR9@H-_!@6$&FYX-FIYQ;I$Q\-W
MJ226D)WK<F</Q?'.5Z;5"[9T%Q<\B98FZ%KI,MU^4828B/O%G-=LWB7@AJI.
M8J@W!ZLHRJ4/W5/8O%.-D0?"'9O6\$=6ML@#XR)A[N:2W8!1G69:#>:WHVT:
M1.9E"P]DHFV.!3L^UZG5,&06U^=AV2__@H2J]J@BRN:9/?)#=3AR(,):[FB]
M7GILC983=^J<BQUK"1=,+B/P!AJ2[@3TJZD20'>X=23U*T_#IJX7&6P M*@5
M"OI \?UV.[BS'^(SJ+,*/ID!&XS9Y9+'0)2>7_6H&[_?ES)#('L%%YKU%X;Y
M7A/XXY^NAHZ6XY>@3 EEQ3]56]R2=[UD$HS>WG&R=5\>]T;XF6A"SR_(9K6_
MB9LMW,'_\(G8B)OTCBFN#SL.D+)XY3([&-$<F-^R/[]A>^NW<-.\+L.[> -&
M[^$_&;C#'W8 J;@_IS;")[XT?.(3/<C+M;Z\BQ[DX6,-'6&1/#95CM@Y&LS[
M$-Q!VN9)R^$Y19:P9?P"0P [&?2<5U#8$[@MU3,CNXA!EC[X:K(3Y:M-[<*2
M[DI:28*F]9\2EUG,-XSB\#*QJ''W?(G=PSD?I>/><"R**K_1UEM3^;MP^H!G
M8+9<VYB;C5#CT/<,T,NJ>;O"$";1[]AMB;B\MG*EZ%X)RFV9BX$2C;!3V0@/
M^O7-92AV@=N5,UT!545PZPN648^[Z]IW%^\L;:Q8AWWDU^A[--2L<%S"&[F$
MZMN"A^@M*Y3KOC!/*XDU3.2(J^(V*KL\/"D%Y'[-J0U8"OJZ(M@FZ+9V#<4P
M[!54#)$JQ&XEA$C^3VL9GXLN(78&I0B(69D3H>#!GZ E-5_J[?<_:]R?7W-_
M2G0GD/^\]RCCD15GF.1DDA'46'7+=-B._TP2G]S-U1.RA"F6OFVD3 G*4U/M
M)ZT9-\37W! <G@,CE_O=HMPIP2@A$V5C'0J"M9#\B^J]3LI2C%O)FH/5VR*M
MBN"$@S <D_<PV-^S/4B0?#TN_$W25$12A4?4T8EK+^6@ PH?\;+:@E+(K:'*
M?R2KFC.O&@6.N421Z!XYO /[8ES<K[2X \@FS):+"\DH1V)+B;#3E:.;Q"^S
M OT&*?@F$P6%>&,^(KEVT]:NCCS.A EGB[<6YFJF2#_VD!DY2C]RT2PVD\,]
M5VX*X=O2/)UJF9G=8UY5*)/RMI(>X"%1!;X!$5O1;X*TG'%47C1P&%O6*.]+
MRK16DI30H5""98%5$/AS(72E"RQE28A="),*:/7 /:/B:_Q GGYGTW!O=P1*
MN(-[/Q;B:DYP]*L"4]-L0M*,L=TZMQ6M7N0VWXGDP3M.#GG$<=!ZYY@C4G=U
MH_PPF)"ET)CD51.'I\2,62]?-A%QUO.7^$O.7*VR)J*#UBXR@_ $2=5]_7J1
MRRFP+]R#]CH5&0RAH\BDD\C:$]-U^CPXK^0BG&TD<()?]LI7Y4JQ2[,J959J
MZWG%PVU'YI#C(I=DZ(!W_O5Q@N,.ZNZ@&A:Y7H!5BS1)8-Z4"XU$,#6%I+_$
M>2F0\DI7&&89[!R.J)8"#O4F$4@4)&H*NA)<ULP=E_QJEGQ>KM9@(&(.1@+D
M)VTNL>ZLB2G&)L+['%%?4\$LJ!O)Z^RR9#Q)1\3DBMM+A87SI>^LH;<7[:,:
M7"UWWZ9-)LB')HEC-Q*TV#5@B'^ BORK[G54Z)R70I=K G!BGY\)BS?0Y,B*
M4]P0Q*^L(5.N-[T+1N7_X"R](Q8%>*]W E:CTA/67;]Y,+0K +^KVS1T-"DR
MA?-0Z>0XNIH(WQ>1J ;(<6VM&^PQQCF-:(AK0$/LU:#/7DQ=QZA18>Y2F"Q[
M[6I=5DQ?EQ-52I75UG'//<@>=L4H1I5$Y&)*N2NX2<C265.YW)/:$[BMW#>T
MK^6 (8%\#D:_-%!A+^ZL).XR0QA2O$Y.M1"$)RMK&XG0P+WAYI*@!T^"F[PH
MF#)J('IY&,6X[;[,MB..Z(WU]*!(GLR,0IZK2&F#Q)^[9!7.N%Y?<+T8Y>)\
M'NE1M,QF482%,D1E)5%7,LBW;$M3P-AL2#Y$OGIHI7,[$R(59R9+SBYRLG$H
MCK/?#_]L<^Y&F# ?$#3M6+&"64";6QE&$=X9D,QKWI8)8G?FX.^$O?N:>I(E
M46OM]Y1_NJM&[>X@.Q9(: 0K[J414C/-3XMRD]OT)&B(LGL6*9;Z^MU[QC+^
M6I4+)'O[5YDZ9N'P0OE^PJ%<=Y85+3#%.S%/JK:$2\&B).^0]^_K#Z]X5 LS
MQ]P.$3)0_8EP*FB_&'4JX6<N/;, >QW3!3PTI9?&<0>7B(#8)A0'RB7\GA4"
MR9$&/S@.XI&AOX)F=5,W!_0:"RO!H@6]&HLP[,E0]W^*:5.3K82""Y%\,2*B
M^TYL%@V\$O%U<3.^ >+!'5'S@)43+L*A"2BP*+$OBLO@J_<>7T^;!.=$^A5I
M!5'G%1TBEJJDULU0"ZX%MD)";[V%2RLEEW:-N.+4G8\=T%:5][FS<14XV_.R
M*"PSOHOJ9&0.3'R5^O 69>U#RAKFEW8,^^QB\E:#G?GM-T^^>^E.)X$PSA,4
MY/L2J^)@"9O#,?O6.F J<'!>-DNX,12R%AZ!F=7.CQUH4+@),M=TAR%((<5&
M$',C:A;7:[17>61]X5%B9F"!<.]IACY@BTS9C9PJ[YW-SL9\ .^-J^ X)YFJ
M,TCG><S=;T5&%52ORM4*T9SPK%=E:A]21[D=@CQ<'\F1]E? -4>"I>:XI[3^
MZD9"E5N-C"Q7--L_F2K[:/GB+>/$]>[-N*,@&7<(1E9!UC(G]2!27DMX\:4'
MRE#N@J'RWKNMM!?:0O2G.#9O"\(.R+Y^IW(/_KY_I5!.OG"2UX%;,2U'0<O,
M3Y;A3K?E8H$DTX;*/,/93;2-G>L\0*JFK2_2*X-_C(XJ#B1H9[D#;SM<VC[T
M9M0)"-W@>;G.E'&7V@;&HU<79X-AF147K Q<%@T(;RM%"O4I,RI.$^R"Q04F
M/@(JT\AAT6#'=1#$5/Y*)WF@:A>+:DW8]]@A>V8E4?>M3-,0FB. CQ(PM*TS
MSKQ5WD"\"R?]OUM8Y \52OH_L&OIY_"&W)83&XA]09/5RN7 ]@4,FKYTQ0M<
M'1.7WW.3URA(;Y)_XW0V-)V2HR4;@HN9T0OF77UB4,_AN1[HBA-WGZ6<E#>/
M?#QP<CZN.4P ^K$$ZA[I 1<V14$1"A*,?A"-]\8.#+!<KRE8&KUM:E=$7B#M
M-#D,0AN*QPF6>*4E^L-&&%\-_ZG!VX&S.[=<8B(41]R:%"V&J"1);7ML8#JD
M[=&M$ZH)N@1>[<X:Y*YW($@_XE&FC2 ;YR(E%=04DSH[*3J:%L55?.VPZ;HV
MW+YMY9N<MKE5D@H?5H/SN&IS*7I$)AW:K+>W,?A?9V6ZA?\LFU7^]_\+4$L#
M!!0    ( "L_=%B5J,OI+^$! $@>%  >    97AH:6)I=#0T-VEN<W1A9&5E
M<&%M96YD;64N:'1M[+UK=]M(DC;X?7]%;M5.%]5+JT7J7N[I<V1;KG*WR_9K
MJ:9V/LU) DDRRR# QD4RY]=O7#*!! A2DBT)$(0^I\LV"0*)C,BXQQ-_GZ>+
MX!]_GROI_^/_^OO__>*%>!-YV4*%J?!B)5/EBRS1X4S\X:ODBWCQPESU.EJN
M8CV;IV*\-SX0?T3Q%WTE^?M4IX'ZA[W/W__&__[[W^@A?Y]$_NH??_?UE=#^
M?_Z@CX[5_M0_EE+Z\F!?C4_]DX/CO=.]Z=0_W9MXD_\9_0 _A<OY-TFZ"M1_
M_K#0X8NYPN?_/#H8[9X<+-.7U]I/YS^/]O;^XX?RM3*>P>63*$VCQ<]'<*7Y
M)(V6],]4?4U?R$#/PI_IE>#GTP@VP/S>BX(H_OG'/?K?2_SFQ50N=+#Z^:=+
MO5")^*"NQ>=H(<.?AHD,DQ>)BO64+TST_RI8$CR$_GG-2SZ&^P0Z5/DKT)K/
MO\[U1*?B8/?@^.]_P^OK7OP.+_-GEJ1ZNH+72>4D4/86DRCV5?P"7BN0RT3]
M;/_RTM?),I"KGW5(BZ,?O2P_\!"><*7B5'LR,$^A!_+7A@2GI[LGQP=(A32&
M__OVP89 NT2@OZ7^^G>G)[NG>YN_WML=Y=_]C>[-]X<W2)8R_,\?]G^HO*19
M]MXN+%PD4:!]80EIK@C4--WV/7'$M@MPX^N^7DK?AX/S\WCY58S*A,%G5K>1
M5UKF7',+7N-X;_<8M]]^R L;TX</SK$'M1S[EQ]/1R__^M>_PI_[+X7EV2;.
MSFO83*E#H<-I%"]DJB/\NTCG.A&^%6ASF8B)4J&(%CI%R3:-HP5?H\S9FRA/
M9HD2\%?X%&@R%P.](\(H%7!76)L,A Q]^! ^3>=*I*NE$M&T].!T+E/Z\K.:
MZ22-)3P[16&:"%C!,@9!F<*/8N#;<*I]6!K<=K=\Y L>_QN=PV\1!27V.1[7
M2#K^0(>XAI]?[!\1)SVNL #Z[>[QF;^KM#@$.7-T.VEQE]ON'^^>'MQ)"-D+
M#$L>[O,^U@HF*Q;V4"@XS[C%I0[M:U267LR$#%)0J0LY4_^SM_OG<@:WBKWJ
M)^6U'B^_?A/91OO+KS^L<^O:9HP.US;C:/MFU'#]DU2#W\'9X_W=T<EF[OU6
MSC[<V]W?/[[WV])JQ]^NM4_OH+7OJ%47VO<#M<T>/#@I,\_^FN0<;]:[[N,]
MD*$JOG=-/+I)_QV>P.Z^.;L\_\N/AR</I86KJUBS!V@5^R/QSRQ8/=(:ZG<"
MW)']3:KT>QCOVZT]9HPU>1$M'Y]72!J].3]_(SZ^%6>_G7]X _^_I'^(BU_/
M/I^+3[]_?OWKV<6Y./OE\_DY?8N\]4:,]L0_SS[\?O;YO]'CV\]IO$7TCX_7
M1/_:CM^TG^N:83,1[R@;F (;!<-HW&Y!4'\$7ZGT&DS<C?YCBU^H_CQ?_GHN
MWOYVSNSYZ\?W;\X_7_PD/I]_^GQ^ =QY=OGNO\YOZ2W?#T7_\?<)VB==VM]W
M'_[K_.+RXV=Q<?[^_5WVM]_,NLV\N'QW^?OENX\?SM[;'6T1AW9!RH$+WAVF
M>06<<GG^^E?@E=L:+M\0Y[J3HGW@9]U;2*Q)ZI[>Q*G[^QB8^NU"O)8+%4>A
M^,W[EPI#*3[(B8SC2'P,DFL9SL3[]Y^> #??\GUE&,*K?@JDISKS4L<GPKS7
M11HKE7;FQ=Y'H0]O=?[ZX(,X.GO;F?>Z%/_OP0'X*>)X_^A8[,.S.O-J;T7I
MW<9=>C=OD>P&\KI&"SZF\ML>=3<+/CG8/:5(491H#/K_'*M IOI*;4Q#VE46
M/Y$36$V6;O[)MT4Y-YB U4CJ[;*OX]-Q'N6=QP5CS=2+2:SDEQ=R"NSRLPRN
MY2KY85..]O!H]^3DGE*TMWS1[19O6VP_<7GVZOTY!F!>HQ'XX?)&3X%BE ^0
M\1O?>$*/8+VCW;_\.#K:>[G^WW>XB\M8I90#VW35J-VO-][X>F<+%?J418RF
ME-L[FX$E@!\\T5?=W_BJ%]ER&3SE5SO8^&J_J%#%,MCT];C=[W7AS96?!4J,
M-KW X2U?H)3W/1CO'CY$#<'M7HH.EO)O/D^W?;>FB3/>] )'3X\XGY6/'Z+,
MNS6=-K_F,S.=]O=..F8ZW>7NCQ]Z?7<A*+759 94)V(A?446POXH284O5WAZ
M*"VZGIJ\[4Y7;=9FM_K5^>4?Y^<?*-_\[86*)>=TOYZ7:NN3FJ#K8+337%*[
M$I_':@O<B,>HOKO=[@"#EQ<S0/[_RX\GX_'>R^;V[8=_4.)P+F,UCP)?Q0DN
M:73\4GQ6X*DDP%2D=YK<.MJDT<L=.$RGS^8PC?O#] 0/T[OP2B5I%(L+%03]
M86K+8=IO^6%JEB&>$2,<](S0,P(RPF'/"#TC(",<]8S0,P(RPG'/"#TC(".<
M](S0,P(RPFG/"!LW9WA/3&!R-TT$;C=0?2GC5,/]P&FDB,)H]%( *X@TFJET
MKN*A:$VL ?8IS3#7(P,;<&A-:$%LJS_NF* 8[;5&4HR.=X](4C@5TXV&Z@;7
M.IT+G2;P8 G<&L4KD2B98NOY;U*'_SL4,;6 JUCYW(^NA!<M%BKVL)/<?FEK
M2H+(@T^]*(NIS,3<XA<5PTI70Y$!.\3BUU>?Q<')\7AO1US/HT2YCXBF4^TI
M;%V'19R% J__)0K\69Q-E!B-A^+P<+0_JMRYR8/>+/U:(NU>92L5MT&Z?8?F
MNT&&/50=PVT)W38%]XDU<1N(OOMM1&]73OKS^>MWEV?O+YY54OIL9U,1SL>0
M&G9EF,F8"P^8\TG2\%^-424&,@$],86[YRHJK_'9(; 3-,;D&Z66XGWJMR8=
M]3I:+!]->6T_08)*B&G_TDA(D6#*62RSV)M+4-#2;F=K]BXG<"MVC^N_PAFX
M(<1^B0P4,5Z^@V ,>0;AQYA*M,6)95B=)!EL/^^[)Y<Z!3O*7&GX9%<\%ZGP
M:J-4N(3M,(I'S.65X4P?]UUB>1\C&H%1F*Q5.3-R472E?2LF$%D)?OR-VJ-5
MM6/O+L6["T8\>-/DB<!-GD9!$%TGWZ''VJ681[MM<1_'QP8K[1TXCY\_?3['
MYO:/'QH6"Q/I?9G%$?AV+\RF3.E_+Q^+Z4:[&\O)S[]B94>BHW"SB8!"-PC$
M( L#N-1XN"&^M8C0XK[6Y*+^.]-PJQT6.RGYK0LE0]B^!-Q8%8HLJ0J6YR*P
M1[L;2\9_5=*G+4*]MK9#("L(0^Y*A5J%X/='8; BQ<DT0=0Z.9TJ+Z48A2YU
MZ'R'W'YBN[N_31V23F,.1R,C(/0_H(@8/+#8HCO^C(:*]F[Q&N7VJB:5U,ZZ
M;7 W$2"72V!3LO4L(X/>TU.1*/A!1M&S:18PT")_@[>/U11L;&#SQ-J)Q0*N
MX9NU"VXT4-K:C_! '8FWP_2L]':Y_^UD$T.[K*5Q^ZRE$DP8 MSDR& /JT$:
MTA<?0Y([%-E7K#P-3*P2/N&V3@O9,JP5A!/%[A1ZI!%*,!1'\@MWA2!,K"OI
MBJ:^LDAL3:B@VO?5BI!!8>2@#81_+K,8I+%"A%_<P 5KE0G#H='.6\\7MIFL
M4(("!@HDF3?/"4;D(8.THF'0-=-QDJ)JX]PDFJAO:RRP84'3<8E;8,7@V;%^
MG,MPAHE8/ @IF1_X2KX*%/UK1^B%:<*%WTU6XDK':59E/EA\;#KTY$QJ6!?=
M/(HU'#89\,O4>?()G#-,%ZU%"3L1"]YOGQ"]^/W3I_>/(#1;8W;O;_,J/;4D
M-K2'#OC[!I&*]J0.X0!8VQ!8V^,@(0OIY^+.[&]V%C]$*6JM)(5=P6BJ#%=L
M?Q=.3HWR*CM KJPRJ@SOB;H*G(\_,Q_3RQ@NA'L3@DQ"..:!U!PSQ,]1SH(;
M&FN:&\%)ZRV!Q66LX1;&I%_3L)T02 ?M$TB_G'\X_WSV_IF<FH/-TNBR. [D
M;P(#Y_D:5LHRCE%9\P>N06&KJ5"A%@9=Q6Z8:[ NBF.E.*0&#C U3<57*ADZ
M)@5;!]?SR&1 .*)3J&[XB Y4?LCK#!PR"P(SB\"D5++)GVC*+F3JU)ODRWPV
ML;:#S>(S9P38I!4*/O55>6CEX7XB6X398L)[YT49A6-@OYE%2($5!(!]]_64
MHA%IZ>)=<2Z!'9R/"OUF. #N5QAP)8D\ ?[":SF^XJR ;V%+'-Q[12&S$6?5
M%NI[,S9/C-8;(W\?(M)&Y?T=@-E/&VC.*&HVM,*U\G>PI$J%9'30# 'P-I*,
MYGI$)LD8IK'T@!B#ST8M3@5P5.Q;IM@19W#^1J>GIWC?(BXV61%S+>%, ]O
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MV*M\X5P%OHC"8.4T( 2KFQONERJDB 3XL8LE^4]3(>%?D?>%7:0I"*$I%CP
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MMJWLJ=B2[T(<A /?K)'M>VS)_D#=XX&ZE%_%'\"+:+3!SC1ZCH95) '0-U5
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M*=#(MJ9IGD'.L35&V3ISW(W^6\A/'+6><3-B0 ;*/G$MX%UO"Y0KNW- ,%H
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MSW'SB:*"HS1&='\&  'F#5;=/ !%[#)>P/N^!HD( J)AX'TD@R>Y@Z-O\'^
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M".@A;/Z$J0A><?@B8=ZSU.W+Z1^/(APHD>8TT)SRN#@IU#WFU#?048L5%6^
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M7 4EI>2*K%806'G]@XFAFBYP-WHRUPD5!&-M+U_;50J64ATMH!\E;.RT##.
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M_TZ-*J O+(1N,I>,B(U19!4ODOI$&7MK,4%7P@4ZM>90-3VV4V>R#YV9X/Q
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MOZ9.51Y[3]@=E  USZ0U4L:(2HRP_CK$V(%!L?7R9"EI&\6 QI1/[_"\4N>
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M/K$?7*1 M70HWH.GBHGU\]<''\31V=LA%80#$_T+Z.!'W>NWVU2]U:Q=]2P
M)3"LS&@PP>IYO/'MIN/<:8S*K:;B=/?4_KZ<QOCHDF/1?/#%+NL5%GJ6UL;N
MC(\[IS8BF3B1LK,"WB[W:2EQ!+]-,,]BZHW.V$Q_+9/YT/[CC9JD.:.8S_X
MMYP05LQ(3!Z<L8:9X:Z #0#6][&:!@;N>*"G)71\,XP6$>NI""F&Q7HNG/+F
M3:$]L5%)XTJ8]9[15CFS1H95<$"P=IS5OLV"8/7BC<:4N%\:P\Y6,!A&[E!V
MPT@=/" AFOT6R:/Y:8G=3D2T)I=E"I:(M_^E5CD#)#T2_>-GA-B+RD%K@"SL
M4*.8,X7CZX[X-=6H3DT8U7IE:A$%A$8$;OI7#_L3ZH"X!J;E #'MKV1 D$@\
M& ED)NJ10'A9'-.DS+(4=?G&78]6.#:$0@IAMK#P2_FH)"PX[9[L+*PS\<:
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MQ0@\_^JI>-FP4X.SVW@=]:Z(2.;1-=(J)%2<.)J9< [>*=E4N,>#7"TKVLF
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M]D!8W7%TA#9U!.8QFH$<:Q[D"S9!>.<O^*)8\Q1[;#74% NOY47^C3E[,>:
M1%(\"D9.M4HS^ >\SD1\[N]BC7VVQN,1:!D<V;#R'[R'#G]WQ%N*AB'_= 2V
M-!K@I[$5WX9HB9E-("GA7*#( KT'%22H55>%A#;PHSF&7)#?,ARQBCXG5;.M
MU.F*$ABB[E"HBQ::MI]OX%A@6</E61#9F?R*J1KP-DR 9 ,GV@>8W'D7FJ:
MIBF@:0IH+%- 3[^=IH"F*:!I"F@?57*P'&3'HLH2IJ#JDR9^SR:O_5B0CM>P
M3H.-)CK!)5RP[6%N4KFPX0@BN]$ +%WX)=RL ]$7<8-0%[$/.M\FJK+U"ELX
M(.HLKA[PNF/(WV2U<EEC6,V@6B>KNAOSPEOS8K(@BK-9;\OF_$RG$[V:U&>Y
M)6;UBR>2'U%1QK7=L+[.E>,'95#FKB23<BKHP>N.8"^,!LC(4NA""<>%#ES,
M@8)):/.+M%PT*\30X5@8I25Q=(4==\]B<V*WI^H>7H&3%_B\"NT,Q\MRY7VN
M,57< 6A!"1._K;2NN7\B=[%6>$BG:^$II-=@JP>GDFJX]_4U$@/9>C]L/#C6
MJZ,QK]% \GA*J*2.&'$OM;V>D0J_*CUU^R%GY/7EXH@MU_;"8G!(^I,461">
M1P4@JJVLL2VCR9=CS86M*TGH$_GL!@,ND;:;WY:Z@M_ /L" H*FJ_F]3@8O5
M,>;LIE=84TNS,K$"WE*!<S3NCJ1V1(\(::OFR&#HVF>&<KS3CY+&JH9'#%Z]
M'J@#''ISZ-E#FD-S:PET2&,I9*ULRX\M#?Q,PBPV)54TG"=9:EBM#&WY#AOY
M][\N7GPG998A;&BK3T7'X5 9^=#7\/G0&K[%5KA8_F#SOM,/=>UE4P?F]8/#
M H,3PFQ+Y.Z=8K&!&>".HRXN08^D(4#5-_KEQO2^I4S+7?3N[G3=) YS[O%1
M$ JQA^(,@4Y!O-JAK_^+;7O81K:$#^CIOO2UZ>%W&UXSSPH\"W*+XP?O'OQ$
M#,0&%OU1+7\.X1*-J,>V?,)Q#9))P &5R95B+R)G2(;M2%'DS)T-/[!W7T;.
M#SAY-N:VNX$U'UVN<4:IA4DARG;?+.BM*O]+]*<Q]F8.W5)?WL=2V?TLBF\@
M%BB),[U!7)#$JDI& 0(DCX-+Z;N._1/]V2![Z"\^@&[F@9=.YDW-D"D(1A@N
M.3,1%[,GMP-OZ6?XW5!O=P3WNZ(R2-ZBNK#16M!MEV/MR,ZT5T.6\DN!:+JK
M+LQ8[$;ZSL*E3]D./7*,.S,B?2R8@MMS.NZ,PS7Q%G "N>PNW^% @; BO%0T
M=$3+EU9VJ PV(BV9]QJ)!'E%M[[)O02V[B4?'WA:_:1NCR"S'0T2A=-/KNWR
M,J+O9M0D!*)P/IK"&/S)2_U@Z3)]):!8./"K%(_?OM @./^=3X=WPPD.5K'4
M%"K0#W+51Z9>&*D-C 9NLF6W8_R&9=HE'H94X3(U+^\X7<A@"L7[<QU"B$5<
M@ ;T;S2R_^J\2DTVRN;G69Z4Y@KOP##&:#\/Y><^8SW;FY)5+KY5"1;)',(W
M[_UJ3S#_O8(;(?;9N8CM8-4:[JBJJ4@C"1.5A'L?#QUS<:N>&%0A0\\6>T>?
M'Y?Z<4K/$Z"8%P=Z*H9 -'FELVBN8--%)QA=$9&-?3Z(@9#*$=5>6KMP%H+&
MJ-)-<Z'T'GB ^/@D8&N_M^?N#CWZ.?MV*/SY(-HBY.DZ>H9G?;,"&,2Z>0%8
M*(RG3?!*N$QLU*3FKVVT+[PJ;R->\,=W.3RKNK$"7?ZTD N*V[6%5OC=>Y%V
M16+FY@L>>0)XI%YZ/#$9JC3*1($S(6M?T4G%HPT&;"6JCOY\0HU5 M72>[2F
M]*0RX9M=^Q-\O?5@LXAZYT0DD*ET184_A%&8RI:? AR#'O1HHC@Z>7BSBWX$
M\96%8R#]9D,R@.1Y_OVO5V??_><__X'_GG\'O]I4%C,.-D4O.>F>B3WJI&UG
M:(1CJX*,:4,#64LY 6^(BHNN?JNE;-!UA%W_.A+!]9'HCLYBQPGA7$#'%J02
MXWR"&,Y<;^![M"Q _,.6:8$I1-]5B(XC5]1B;A=:3C@2HRE"<MU-><-I]7NW
M,4T@<(^]BO$.?.UI<_F;"P,T 0"XQHN7(% +9&)#V<%^\-E0)E-_?%.W!7^<
MAVUXAA6/[..@"-FW=0OY2U[XY06I;V"+EX+N/BH'4Y>#$X+*=Q !5(7&(%]=
MJ13RNLC14/"E(?7#8>40&TBM-+RY*HZR5,W3#$Q2YKJG,8IIC&(:HQC-&,79
M-$8QC5$<WQC%4.RPTTC!5VGF!("/Z,6B;)PFLDG9!$T@@LWT&CG#/6Z.WE@6
MWN4=]E/X>G?X>C3T9ON/50V;G022!#];ZK(4,K-\,MK[$P035F8@[O:=C3@+
MFAJ /_=F I+ ::S/$J@M7:'8/9:.N"%Z\/VZLZ%^W;LN *U5/6LAT!S_<K=G
M=V*PU$0K12V5!!'058,-W?Z6X+="!OTEW;LN-'AJW]W#4XZF?=?/RXA RL4"
M8E3$4CL0Z@##%H_BM>?Y$$U@9^.N"]MG;K-'TG0<?@31A8>LS[[=1T:I/+3\
M(Z$!_^?T]+H+YWIYM,,Q%*UO=1LR8#W+#S^_9<[@ZR)+>IQ%_'5/BIVN:[=Q
MN7"[4,Y5(EPF;(P\*@=9MB\5CN5KG26#Y+TG]?Y(2,U,CL_;O2>]-IXS62R:
MLF<$>?B1=KF0T>GA;!O'0V82'<P\)ID"W MYX=-IGGT;?6\ 76_\/G:?I^L_
MW^,NT68P@U'T[J!__^OET[,7W[7VD=UP[TB!#':Q?+6!EY/]?/5EZS>BKOW
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M#"^(5/(@#4]Y)*JAE] D;-_ [XKGH<*B0%W" G;Y#2=,[>Y,QDT8M^TFR\S
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M-!99NA#F=B''@A^:BC-7R&;7RM*]!PV:)Y6Y3"7XH-:5'9N (7[I7$.:$+:
M2W<=TL,3 3WSJAHU"Z3!7F#NC3U+[YO(W1]\16(0%?K>$']4T3FD.2?I+(Y>
M0 B+_YO _[Z*H[,S?*AGY]+KJR XF^'23/B3X<8^%VE<UQX9SZFM1A8?=/D\
M*O?XZ\P%/?#AK1I<R2K"_^9PWNW^^1W*=NS'S9T]&X2*^5FU[9HNHX_7:<E
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M(FD[I#H7\8H8A5C$Z!AW6EVG:Y&T6S>UW8O6<*989O?3<W<-;CSK#KZ&0.(
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MW,!'$X/\4D05_)9-FFP$O(W^K,L%&2]"X\#A(0X=_IGH3!&3@[R  2>#3BT
MC8L6:2$].4W-*3P3V>MB0,.FRG3JZ6JMTI))(31CR?!:2T@J>=J<[Y!>[EOC
MP*VHDN_6L)RWVW&/[EA'&S*]''/(](,LKZJJIL3NZP'55"Y)K]5U?6*_"RW;
M@VD$-/=;'3,112'(O4J_9\I5X9@.$?\E>-HB)\Y:JPU01#>ZX@R#&E,,7+84
M#"UPLL&(^JWT M^X3._11Z,;+:(K//'"N[,?/SB)<"@[K]^R8>>]&O/.>PT'
M,]@G^N I2=E5DM++.<(NP"HT.$W5A;=$M-.$N-%$=E@*U? #4B7YKXUQ$"R<
M[/)QI#5L;.VXJHB6RMP#G*L8O,%NS8-K'GAT-IKT@SC$O.<.H?*USNWZQ X9
MC#R=$/NDN6'?[N6\"TR(WUL75TS@XX5FN-HX!U$VA^28ATDCOQVW9\Z7*3X<
MN/;C=9E&NO-&XYS?VK'9%E5>#Q+P[%N"\WM.5+86A&,\>4MH0&;CLVM)&S+%
MVN[*Z#8NM,F#F8 7/3#JJ4!<UF0LH(S;EU)S9 S$[(CA2 QO#?8\EY0(*:2M
M )H?O95W4D7&IFK5JB48N6\1L:++,20);Z/-9#@=%GNH55%-*2LJ'9@8VP2+
MAWEL:CHTS'1I GG7!)Y&1G:PDF9DA*=Z+$$W+$128"D- CXI!+<DB/1G2+/R
M*\T5#Q+_*$K:JE?%C2YIL@\6=EXDU'NWU>:TLC[@%MGIL!Q300R PG33J,IN
MZG"O9,470H].0UU.8 47WVQEW([^=J8*<(5.?0FOYCZ#2L#!TXB*:I*T+J3U
M@8.N>&U+]VAH:)-"HW A-4)"-S!75?JH2M+CM8*]FX$_RN*O,&9CBV*E#4,P
M3B_-(6Z$9<,V/ORF+)JK:QPE7"J)$5PQ]2@6[V;_:^<&_?RU:[GPN;8;V9ZM
M?_S[7^<OOWN'DRI-R05KFDHOBT]8!<6M+'PP_JO?H\PHU>%AO^8R-F,%$GWY
M,+Q> L&ATPJ6\CHAM#*5KN3.B#F9BN-QST<=@QWMW8Q\/<4@9E/HM?5-6C3(
MUQO84%K;?AZ%Z> :KNP0L7'F"WTDC!,W(W#C[ J\5)#"K6*%2V5R,73J6"+G
M+K 9H')#W(=?<!FU3,<[>#)K38\G>OL9$NR)%FTW">P?I/?*=*-4D.AB&U*G
M7.VJ,B00H!<6F:SRJ+N&GOB1ST/^87&M42T@>C4."DBO(7>YH'+M/A@@6>/2
MJW)=G%Z,X_FT936?1!\AW*D4!T$?U>?H)X-$V<-SBX=:I%@UG*;\IBF_:<IO
M-%-^+Z<IOVG*[_BF_,9 1M?NGYV1*#9I2%K"GFX$]Z3"5Q1I7CNLD=%OL81U
M4[-I5^"5OB5R>(0W.BN0$SB._I=M\AN=)=%[[(;^K,K;=/$I^K'0X%8R"/)/
M_O?^YQ\A<OH18<W1Q^NBS&N,X\OH^S>_DE91BIVJJ0&UPP;4G[C+8"^*%J(O
M:SA,M%24,;8.@VPL%>1X9AL6^.>WJLR_^;6I0TE8#IZ[ 7Z+F\G.9#AP(=;
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M>Z:+G=/<!K]:Z<4RI3B<8H16CTZD;[837ZAN498U9S#P3MU&(<XA;$1DT"]
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MG8U*1ZCCB9/# YW P?"(>=IPJB(8F7R!&0U*M6#W5?IC]M DKG=]WGK7]\P
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M@36M2\38DJ=C^1M-+T'9#?3"S5,TQST&U.#P+_1^Y*5V/MN6;A]K=9O7A76
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M/&+#(S8\8L,C-CQBPR,VO@87^2'$QB^_O/9HC:_EJ4[.7QP?G;XZ'UM9:N1
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M+&1R>3'R6.1L,&!,6.&WX"UDV*ZJ55%TMN-\F1.F@3(2,G%E, F#XU=G5[B
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M^^6=)M'C*@RH_PKV;C-AT]IGN6$:]SNK."5&-D'H(X(P*4I82?LS!.1J?.
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M%TXV&I>0A79 24.X8J8+21BBU#,F$3X&LV3L\-'+0=+QMFH2US*<S3L$9G?
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M$'_5F5.&^!)LUHT)X9Z8<M#7?1[4*L*,<-@K+@^-^]@Y'4I430T;$D2HC7W
MAQ1+QWJ69(G3U ]UL%6A;@JUG'_[S>3LZ'N$<*SLFPXYZ6OE^]V#5>\L_> 7
M=;<S4MI"8_ZA Z))X898,$7?U&G3C5$HU?H6R]-_U452QDDD4)J&:$T"ANSH
M2[U8^EMQV0SAPC@ #<P* Y>W?P2_VQ\+CH\F9Y3U/CN_W!FEX*<W[W_?%9G
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M6A_<S:GS:E.Y=WHOJ18VQBIS,UX3MFM^6 K7A(*@UL<T:J['W4\X=64N1H.
MKH4J5H=="L$]7IG[$/;!3(MV]NF*G)NVB/I5I3X*3Q$6<($M6K)Z,644$H_M
M$L=!ZX_\)6,KMN][VSKX4A344MS;#F>YUY#Y(EZ.GAB'R&[^UM&Y_X"B',HF
MGXB3,<[V=&CN.Y;[731S3$)9%3=4A\!_FI 7=<A/TO(06J!>G* DPZGHCKO,
M(\/Y**D@;D7K'GN[UGUPS=*Y9O/A=EX"''J]KI]'OTN>L7R\0:%<-<[$'N28
M7@T'X%?46B(WQ@7#/Y8$-IKY$L;SI8N5VW2]X[=36^'.]HDM?MNI#X'XEX$]
MQG)S=,2\_5_K#!L&OI6O>3S^,TYO1JX&Q.T%IS'<^6WF?>U4IYP6 :-;DVUH
M6G;.Z<ABF9TJWX.)'0S('GO#+%<FJ,WR[,46TXRG>N/DQHUF\#2_U7[.-\QY
MO.LY=_=J<J7!^\GB:9Y_! _6F>@E>%51(MNRTT2SJZ/4SHXVKVB]#UPI/:3I
MM($HZJT8?3*>0/")*EUT_=ZUN6R=SVY<ZY0E]H0!-=OUS()O>VYFUIE-.5W7
M0^2R"]QH!\H)AFF8F)#HJ14LMCMNR17MC*/CU>SO'/UUQ/$P81-^E2(._=._
MC[G1H7!<7,! PGZ&:M2SR:&T_>9F))25F5VK,6C.3QAOA3YGW[0"LS%)3N6%
MIWIXJH>G>@R'ZC%IKT=/]?!4#T_U\%2/QSDT9T/!>OWN(G2D?3N#848.\3H;
M#,3KC90F^[JN2NS3JAX1-$2 113^@.,YJRMDN+3P5KE34(./3'6K$";*3J19
M@VELR8N$$E>)$I3$V-C(6%!%JF"1M(=*P4S2;FXG=.+$T-3FPA9B]IX;INPZ
MW@_R#@C3/>M(G1_RN)A':P&T<PNFDNN2?*U\DHJW O46"@H\*&<9"ET)9]M%
MA36 <E,(%':YDVZ" 7.'*[0O8 MK5@(+[J]"CCRD.QL,W.4:MSR:]ZLH@O,/
MK.\-E=D+*A1+6R:+NVKEF[D*#].)[@Q];HHX_TPDVXUM)7E\&)3V=^1[^"%3
MT"?FD\65V>7X7>G^7D5W8_J1^^+A\V4PL[P1+6FHAF:_:,KVK9*BJ2>T 0*X
MY]AK17/<U\UU&OB%*4&$3<(ZM!FOUM;L5"/7?I(( :J-$/ DI><VG!E-GE8%
M"<R&FP]I0LWD+>"N<TJ'SAGMG,R(Z)(3>]:=:W8I8-M!5"5;PR+GWIA9FU[Y
M/T+F]Q:,[,OT35XE<BP;@*:Y#D%1_R8.+?QD^S(6=$J-E3[JE-O>J8]:5+*,
MI8-Y= B>"QC@>9<$0QE?M1B[AL_98!"%[W(G@6E.FH (:XQW:)D&(0R;&0=[
M3*)DJ02GY4R[JKC9((K/8X;3<'T96\7"] Z\K>W:F0I0S(@K[.O:90>+\<QR
M[&N(Y^IKQMK()LT9T3PS2RK68LK.EGFKBJ2UJ[>]5P+$A4UXM(;$-]=ID&F]
MV[C[4;NANT0-7KN)+E\&'7@GR@PW;'9UHY*LK'BL[EC'2]!TC$=LA@^';&TN
MG?MHS:E\VL0B905>"784<'!HCO3A!K4C\^#?-0_^G5NG^XX;0EA$VN%6!)?6
M48H?W2](V]E@(&T_=Y94FFXR=6OC!I!,[7>-)4EC"B3CUD6:US=SH0<@_P$!
ME[<JQ;F^KWG2H?>#G]6=6>_77.@7?3XHOFS <=@BED+LT ;/A,R!8=42#Z\Z
M@%OG2K/D;SQ1D*MEBV:R(4K@CI2;C)TF!/C"GQQ,T6&$YD-;HC4R&\"W9..1
M'001/^[OEB?V8)Z#L&3_^OWZ< \ )8/QJOEX1J80>:>F[9.;REG?4^X4[4(I
M,;RS3$>5A80C/:!(Q ST;*8%(OHZ+_),W29%;24N^6>9"J[;!J^F29IPSV<^
M@1WKM(![PXQ$*/[,R@W*OK8>J8W;H 8#,D2B$\^5]9.8R^=,+[[#+\I&U64"
M)(7KK=A"_AI W^(,[39(/VCWT+@NA.^1%-U-T?&CY6,,9"2HXAVFAS:>J<;:
MEG6QS,N&'XR[UQ[8VF# C5T%5)Q3<*!P3KMRJ/C1#[CCU,7*]""#B:7T-4.=
MA$Y:!N<3<K?.S^RT.GL7=[<[/L+3K-,QS#0*6VL.M@\'VF 0DCU,GGYQW,9A
M"6[JA*.N@WNGL9-1(=6DQ_M!>V ,@P%55B[_-DH*I$)67.U#'2O:[Q.L/M1I
MC-4LZY*L6*L(W9JYG!0MF_JNY,ZRF"C\%%]XW9):Q3.PPFE=)LSNAK^:\XV]
M]H*2@9@:P?3ADOLZF>/((G?E=!RWK=WLVM8>V'@PRBGKZ0(5MF*!(Y;S/"/-
M-W!XG+X6-D@K5!W7$JXWC:Y@QO_YZ^^ONQ$]MN9Z2-/@7G/;@PUI/A0C@6U(
M:@S6.^[Q,JDQ,KV'=8R:4 *?LLO<8"83Q3Y)I=/ZM6LM!I9JA6VUT'^RV6'+
MTFTTV7;K/XV^TI;LVDC/7TZ.J1D+8D5(8,<:*<USTK4;9:K\,P<70AM,5EM]
M$OA04;=BL<:6)19;WYZ(1HK6@?($@2M/8+_<B+3)#8T^9ST4Y+YTI^BM&RU1
M5S9NUXW66U6X@1J>@F6.;50Z^GOMDD38O-=3R&^1BNVVPS]HZF=D5V*,F'^L
MLQI+N3UR16OM"-F243B7U06Z!SQJ6]$!S\5?\-C J^06,.YYN\$#)8'67G!"
M]Y$\@<$3&#R!83 $AN/V>O0$!D]@\ 2&KXW \*Q>G'$<%DHR3)Q?8GD$\!8T
MW%DBB#7J$D?"G2W]HXZ?TL6,_ G> [I?'S" .G!"K\/@X HC+(9X_\Z=N2E@
MPWAL],[S4!J"]-!>I[C2I)\&#%>^X&HJJF62K>09:1Q)'Q&5=>(E4\BOJ0U@
M&Q%IL)(=_ _KUYDREA%/%5?5N**C-XFAM/"X'REHJY\-:!6FF](N,LEL&58C
MM= 0A*$@*'G^O,'<)0@LRBA;3?P6R?$@]I4Q02U0*@4_@B!<,ZELK@BI;^%Y
M!M9J[^!>T3F1)V;LM1$H-MF#\G#T5C<4P7ZPN@?!R5WP9@MDW=DN2MS.' CK
MP920TC2W)83(N$5!,'MX#[95\*R]B86&%](/;1V]W5P.Q&Y^:\ZA4J58BC+G
MB)E\FC'63Y1TB_%=\$CK?MJ\A]D53)\$:H%)12I[W9GN,HA/XTU-#JZ%MMF1
M\"'*72<?M(Z+ES0DMQ7?8Q.;'.W8QHY>7EXVNLGB'CG-6CNR(&W%4IP\"^%Q
M?2P6%>F U]LR^,8=<I+8=$JQQ@B^T\#5S5'E-$N"PPVY9@M%\DOCMY-=$WZ-
MG5R[:*SK*H\^!K^QA/I[;!%O.L'_"!L-F(5]K25T=$_G]G;B.LZU&.12DW-T
M(+E>]T,L\BW;EA7Y/N0<<+?3@MM-H=UW@1X%[9$;+]A6"W)&]W1<P",4+L+?
MQ"8Y.A(2!D7;ZWT?UII$K+N2Y7=RBU)/=-C--FBH(+2L>D.)-+5=&+@'C^,<
MR YNE'E*]])[L'YV3=@UZZ?#/NA=19X4\'SP -%6?\HAGQQ=#'+,!U/MILW)
M#5FMIC1LD:B-NDBRNK+"[W7:X'W[3QSR44RFK62J>96C%'I^XPCB=W3T(9K_
M3VUWVD)C<U=,Z@F3V>HW3%>, L*-O=4P;<,MA<[ST)W%M]Q'QW;4*;&:3KMR
M/H5;R@P$ W\FY*9M7,^'QZ@+C!23U.0EZ%;,0W>:!38?N*8V0LPS*TL-@_+?
M*JWIOI\2?#184]^YK9^^O!13Q^EDZRC%66XX9 07XJ!\_:AN<]&:@]M9.)NN
M6]+%8NQ6C%Y.!N%=Q!18*J?$AT)6M&::IHV2:>&J8M(=.C\5TMUQ=O-O740)
M$U&=M?6D6^GIZ2#MZVK7YG7\\LSB\4WH3%/UI*M[H*/_PY!&WZZ")4023PHU
M'^KPO][]\+,?T98=X<YY HWD"&\?9N/-D&;C%@+J1 +E)]>S'NH,O-W]#)S9
M-A)+71!^/:-F34:,X!D Y\\ZYM(=3'SG>_))>X"T'Q*QF12^C!-*A84F*,O7
MFI<9GW(/)FDP9&&">+_]]6<3L)H(Y(YQM<DL:8CE3@=/55?S7-03#?VEA==U
MV2_]5<58K>S$?S&7=:#3/QC^;I9GNK/ZK DT*]?XM'%P %XM)IKO*])YLNTS
M3B!&ZFX6J@S_?_;>M;EM*]L6_2NH=)V.6 6K]+)LG=3I*L5V]O;92=HW=G;?
M\^D42"Q2B$& C05(YOWU=[[6"P E.9%(F,2'3ELD\5QSK34?8XXATW9F:*TH
M&)_EB7SO#:MA#GV*N1W\@%J''/4)2:^J(LEK3"_0]9%*5!61T+2AZ+1AL*!O
M-K7+?=63'H 9#J;-%\W0[2*^D27I,BM@T##WM(EA2_I*I*;+J]&/E/F%/VR"
M\_VG=Q^NA=>Y]S2K\LYTHM@&*AWZA5@$XP0RI4PQL^H,/T_NB-+0X3+Q1^V;
MLXR\-36N^RV -%N(+8A.459K,YGJ]8&H^0RF&1C;S0G>:^%\]4VE8,,J./%)
MBQ\Q.]9"VNQ3X%H^NDV@%6$^K3T6::200YZ\B@5+B97'K)#W%"O&CJ*QHVCL
M*!I,1]%Y.!_'CJ*QHVCL*!IL1]$0DH^ZC*1WNH5ZI/;C.+J' H?KM-B*A&1L
M$84^OI0#>S"!E[+_T*Q=TT<'T$;'O=&#ZX#Q]%IZR"]#Z*":08!,L2ZR6:5J
M;J(/;0@Z+LY.R/>[.#O]\>CU).;89N*%39G6#3NJ$.X6>JZJ2ME@VKM"*0%7
M_Y7P0OWG-TF>D,#!*HYL!!_@1P9Z$!MXIS-O#RE0$F1FF2&"MT;) 2$ (,.F
MQ].Q?3CZ.=W3 6 /=\U\'&*\9>3Z8:6([Z"[D#]QF S6.B -5QJ7]4QW24$L
M!K@M->F3,]C4D:[5BAI2"M9[<#DE3XFUU7UW#U*F#!"N81<"+[YWQ#P6+K^P
MW!K^4Y[_'^"RT:MK/ /-I/VWT5TSG1@;O<Z162F#>P!#D-4S''X?M.W610KO
M6X9(@?BCK85'_LU-LL(@_PPOQ69@K< G_ZX0DIZOA8Z)^:((&(5 \/+6@PT2
MD;A+FGKY)TJ;4IO> 2R"N^X&M@9FV@+TACVWK.PF:S9-Z@B7@[H;Z+WVU)\'
M8KFO^SHB?B8T7K14JNZF3 WVW[L)!I+"4I:JM&%?8$X]6=6J%+QJG7SQE[?3
M,X\MS/[H$_R(&<-.KHCWCM?+%)R0DDG$S<4#JFE#/+3_S:2GN^YA]G9SW_VB
MS F9$LG$U7>X3+TO8)M^JV"+_7C]T:*&I3DDQ)?2%X25=MU>YC3X7?=44DKD
MQE3#FN3/ %EZ<R9+)'-!0R+Z)@972Y]7JI:%+>R03HG@6UM?4:(U8190F#S8
M19/D,3%R,@,6R7=XJGP6PXW7<1/26X,Q'X#[#"[L8(XPAZCI+7!K.R4#[$)*
M2^:0\)_$5\9&^+9MW)VJ=5E@?)_4#94)@NE\]"P61>?YGUD-\V?V&$@->EW)
M0FDKY9;A@%JVTT+E>MN6_]T_)KXUZ'*6>6]USY>:5T.16:75/<,$QKZ_\%TW
M69J&[W</,&KC1@]^LE7B$^]8L\=+"[*W"/*ZUY(;PG4*5NS"K)HW*LFEA5PG
M<P61$')8E-7G_MW"9P$,\V'_8C4G7/])D:TO)X99+HT0@50:@;U2W70=,EO0
MMYM"02$8S%+Q\+/B#V1+%9(_NAHX+ W+9MPJH3G,"FG$V?L59-==CXZ_TG<>
MGM.60Q5+LV5(H&A*N-)9YH$&;)W_ 6\ 78&UZ34.A#)M*WQ&1 H)VRM>"#Q\
MZ?GDX^Z$+XHY5HEW]0NX#"]$I0W)AV#Z9*S"*C]^@;%B3($(_PMC!U=R'H(#
M<91698;"B&=G%S^ HQ3!JSD[/__!W>8DWKX#\1<6MQA\S7PFV!!&F3BN C$L
M\O8R"(L8H)0ME]G"J.X59?$"AZG*C,YR;"\*GZ/Y!LRJ/A#%MQ=\@@R]^X*F
MA_G1, :]PD$^^V%AZ=%J'O4J4TVU=6S(=_]PU"2^P#6Q7=\IA/_H?MHF&>&M
M[F6RZ!C));27F?6U]GYOVG799X,>( &D)3'BEH6CT#A<EMH=(+Q<089Q\@B#
MBOIE#$82@.UAQ[I2-;[/D2U7I?!JP?Z&<QI^T'9!?(L0;*P<;I(H["Z$"X+Y
MH%*S<E$0XOIKF.8.!&,XF Z7KIW882>8B6328%:G2)^&"2\37X7"L'!3MZB,
M=EC\CZ\&I %KXI%?LP7&'='/PI:X6=3LZP*5+N69N=)']AS?FR T^D1\/C\A
M(^GS9 +O2?E\]X^__^W\XH=?/[[_]!/]:P<IOC: .WQ?1?3.[L*X/:I"\U[-
M58K3D]A"NPU;A@O_K8 !K,H^.X(1!^H9)7P3ML:!#'G,UAOC?UEF!?YQUGLV
M6?KY%+\DA5%[%FB[<#G.6<7>:Y^@,S A%';8[']B<]?%YNXR\ DV7 V3\ZFF
M_PI"^4;<@6M,IX.?<'X1'17J;H*F!CY#5/S];Z>O+G^X/'EQ?H*?G5Y$;]5,
M43_[Z=7EB5$-*JM%4F3_GR6=:><TF,!&^YGR+@>L*,7:;IEV//OO!J72L:+=
M%]GNO47NNCK=QU6-MDAR5$:&K%6F0Z#!"NZC5J[KA&ST4_)%HMY?$Q&J<[M-
M,*Y<QZ/3P5J$.(JTZ6O&LOYG9\$,=6,/2A[HU6#HK-M68UFE<'B7\$_YD^E6
M<8^!33.%O5%D\& 'RA@UC8$(.J^56L">10E5C$[-^'^OA2^?P5*2S#3PA=\+
M6FS^"PY+RR6A!X)]SHN9_K??4FAE>1PIO\@)3_I:OT3V+'H=1]=ZG3?+L:UF
M;*L9VVJ&U59S$<['L:UF;*L9VVH&VU8S!*&>]ZYV1K']Z=75)==IW_M5-6_+
M-]XMNB*"6;P,2K+AL='1;P(=YC2#R2RP/,\_T:#Q%*_:<K\YDA#D%H 6P-<#
MT=^]]W>'(J2!('$/=1O"_)EO(H+!RU)Q;J<Z8UXR4HVTU-LN:@)'ME+H*!M7
MEE16J_4]KJFM%+?1N'MO!4.1Q;"2!0YGZO>UW-V4#,1 ?EQ=8A:0EH*B%A3)
MI\S@_''T/F#3@8Y^) F5CVM=J^7>C^20U"?ZD6XVN5:I55G1'.YDV5WMUF]E
MP^G9:?@@92:BUV_;Q/ZGN 8C(=$>[-X$Q0/Y";/FKIH*B[-V$PBT^'YK,;MT
M+8M*O93^\JV*L%W:8ARQU7)'=1FYA1U59G#Y]'I,W>N,SN*-;WK_O:#!:$EL
M7#7_#*829\_U0A6S-0TM&GZH6'EZ\H!C_)A<WZ1/S1N%]S0X\OACCJUH#DX5
M/(R1TV-4)5QE6OD(G8?N.(@&<.TG-2,ZQ@E7R381?HY-^E-"82;2EM]'$H3K
MD']'B/7T;F+_Y\*N45QF+OQ:;FZ&:C<O"4&3 >)1X[XO1F%DS%B)*ONBTA>D
M_./!NF;4%2?"L S?"T]8&SJJ.?&#P5:6NS8F6SJQ**&;;,6W%=ZI]!2%X# L
M418!T-DV;'FD /#4(L(40I7VWR1W#3*Q)JDR$>YSZP5VCH5##*L:!*A_8$7-
M>+!, N)IL(6H4HQ)L>N9OH@?!5D5>&K<JM\9)#HU(ONX\\HBS3L50+^R[2E]
M_9Q,RZ:"YTSW'\4TF&;YO]8G9)8@^@Q;'C;CE[R@.M.PXKV8YJP4N2IA:<D0
M?&#41BT?XTRE#39,!U"(8"FZ'[$P F"?W9 LL#$<[6"!B@U.!1VJRQ>GEU>G
M^)LKJ8/0_^$W.\.N?4Q6</MGF '>*8(-W>H,^^!Q)T:3?JMFL"][K^_L[,7I
MV>L+?'WGT3]G=3FEC//9V<[>W?ON_>[J'8Y8YEU.^8_@;H"G.*]@=>:BRX>J
MK)FDV;%2:"ZS7.(19W"G^[_3[QH7]BRA_E>W K=8'N(-S<#WBM!'KK6)[PT?
MZ3_Y4F)K5*-[4U9ED=QF%4JE^@6[273TKECD<,%)*\Y'="X5;<#W77O,O.1P
M*W!)-&IF5YG^C!I\\*?T<A*S-.O%FK ,#Z$5\,T___O]VQ>G5PRSY%4Q6JJ$
MIL'DK_2*H==#.CEF4*@2E>(+OK>+[%[M[;%%^D]/\5V#^)PRK!\6R@3G>1Q+
M^OI6=29^XD]W9"<1#O-[6DG-GF]S$:L&&S?!"*H<A2F'T5B*T<1M)MVDDE;)
M<S5YUE1\_[VTWZ"$O&^0^ 67B!D2@FN[.D0:):*C7Y(*?G0:RP+5@).5.Q4-
M7!=P62TX>91$=\F:! Y@65[;Y;,L<FHA3VI.DV;+*413G.OA%-34:W(@#5'I
M*,4+^9$AFA+E:#-M5H<]G]JOA\*?\LGU(;M8&H=PW]__K@N.!BCP:VDVST!/
MO8,;T40+69#,R(RZM3/C,IF//-XI_/XNRY&/R"2"R<\A:DGYO2YSE7/&%F==
MD]L^HW:_DR^HL_<3<]<%-!]'9%HQ#6^7:]AM<YJVB<Z<$SQ+"K0"0SC0I42=
MKEMB6'"!S_I[S])R<$MI$T??%4P(MQO'3^I*"6FR))(NXO;SNN&.2LDUH\I$
M0#26@@4G6-BRW3Z5]WUP$F9)FR=9Y<Q\W^NYKP=#1/#6R9,G < -D4RNWU!&
MAIDJ[5>PNL!+=522>:+KELTMX;9N=%L4G:NV6'^EX:>*$PHT0: 5R)P'ZQY?
MC;]W=_;6\%GNO<GLNL34@<#Y5-RQS]0<&WW[TL>X1$=W-TK:OA8\I,NR@LGN
M@#6N-9!E10O>K, RRSLFL\^;Y0J\UZ5V/ 5Y]EDYUL,2 ]%:: [I1V"]$-7>
M$$UD4PDB,RM3;HK/9I\+7 :)1)+X<>A <TN&J+I=D=K [-MS6*HPPDY$V(D<
M;[B^OK=0/[8/C>U#8_O0MMN'7H;S<6P?&MN'QO:A;ZU]:-=^VM50,D#_ 2X(
M>%?[[15?#2;?XP=2OJ,H'2&N700<,G(P,6]*K3SW5[ 8WEF2VDXINN8QE]X*
M["+*%81",;C.K0^2E 4%S-^D)$#5&I81M<?Y?U,D)O<G,$#VL3E8FYCH#UM<
M"E@,LU4BMSE5W0<SI_ BO<0H]L)KZ@D4)290!QC?70TF0=6R9&03S59P+-8S
M$RF8.I.]2ZB("S:I&RT1&P?Y965S2RNL,Z1J63H6&%5A_$25V:5C+:+Q-Y#
MB=/H"=)B HD.IYD3.UE5ZC8K&]V;B3A(RQIBL@D&;U%EB-LG"V AG7%('SND
M TH&M1HK:AY-_" O178FY6$6K+$/["29-A]WO-\C=W$R%/?P?9$VB',A^(Z4
M[??]U0_45YR5356S(E0V;9 Y"_5F8B?,*;ONM$*D1&T62B%E]5*1]Z)U7(O)
M(U96YB#$C3I]W+UZ/03V?FT3NX]3DL+!O;U7I>10M4?X];DH[W*5+A1"F<AU
ML+X$'3>/7;.5EV3U6ZIZ6JD.;NN 63 4/_/C(Z!LA>@]/52]QDT$ZP YT2I
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M"UCQ570>'3W+ZZ#S_,^LAK&?/1)HW$4-;L\LVHT!$I:C@^_E$<HJ2"/,*+X
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M9^Z>A! I'K]"^VR'Q4X_F.J$-X"&TD:L(E0HZXUQ@XQJJPXXB81Q"T/(;S.
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M5H3:V\L1)O[3'8^N@ 0[<M ^X;$W,3?/ZG"2>OS&X5S=NX'\[^M/NQU"!K'
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ME<)F963X*6Y+-$[Z.F08,1PX;LAI1HGVBQ#U6'.2<BH7).E&>@T,;U,WQ.3
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M4*AO \[A7J6>KZ+],?6%D?1GV/GR/XUF]<F.#R%.'4Q>^ROK\VZ@GJJ\NF&
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M5O]&MF6)3U=5^0(\R"1*EMCC@TXTMI&<_Q 41??/B=[D3 PIX>"IL?-8/G[
M8F&[6"4946SP\2'5@-A!E12S&^1C(?(#^5-H8F9ED5(."GY(A (LBI)8/@$(
MN_A5THW^DN5*UV7QW'RIN[*7\"%W:RHT6ATE>.7NDVKZV 1H[G?4']GB1K-A
M>+ZH6<-,)4&VHE++!#5D>55*.SUM 2VX;<-,&X?."7*)'XC\ZBF'^_3D]2#'
M.]OU>+\Z/CW#APZ6UJ=TM0?[YG?^ZB^.KP[TS>_\U9\=7[[N?_=/&,L,]OW?
M[O[U/_.B,]#=?3#9KZ*,A',U:1%X_0^S&?^76MN4I7Z"#9XV]W_ZF_LA) X&
ME6+[SXSHX3_!:[326N#F96H#CR$>@YP=3(E@8RGDM8.XK:F9,C,K]BGI<&2)
M3W=(H-L7K>U*<(R5!XA7L!C2^]@5O?#>I09@R8:=X!>ZU9VF!.*6G&4%ZU+1
MJ"#29)21I(YL(A#"*"$.FJ-R%2Y@4U7?*54PI4SK3#K)%=/IKJHR;69$3Y00
M6R?Q5N,AI"2 _[!<O4@&8W(2M<AH><?+T9$N\S0Z8A+EX-BD4N;J267(EIF[
M7G[WG[^%G#/(/'R;I?"0VNHP8 [+N[+V+JVC(YM<DV0;\MDC[VQA9(D\C5^N
MM[1I=BP+MB>ED&:ZKK)IPSJQ]J<SL-ARB?R=S6I55K6[CY 9F>YW\X_QO<Q*
M5CV:KLVH:X,R2N. D(<NG)=-B@].6F68VYMAJX^JG%03P9C*HA#FT!Z)X\[(
M22V#7CG?"L:(;2LTMK-A^/=N=0A\AMTGEV41$/?3$J:K5FIXK9+*2N':[)6O
M=LR>K%")NY1U>!J4Y'M!<TA93_AHOI'+' P>##'EDZ)E(G$9VH93J2B:)?::
MP1'NC(DF C1#64Z$47A-G$7X_W"#2.Z/IY55C:[_TR_OHH\W,'MN8,7I(1/N
M<@GOG7'V%?!W;Z.F7O4LA1!3[MCX\S]3!0%WBL 0UKF*]KMZ%CSKSAQK<7KV
M^U7_C!_<E$A=+@B/W;[OU@I_Q+IJ_W][U[;;-I)$?X68EUB [(T=)XX?=H',
M9;$&9F9G,UGLXZ)%MBQBI*; )NWH[[=NW<V;9.]8%AF)+[E()$6RJZM.59VJ
M4F@8PE"HCIO&8=6@VQL[X_B\@<:VZ(N1.:;Z#A<,#.3$5L1A5T1VK,4>>PJ-
MQ=@'+\9N=(9[QBNKO=VQ=^-8H/PM%B@/U(@/)J/G^.S/M=Y'\?8'E5US!/:3
M6H'!,M8;JW#\F>;!4-0#7]/S !QC_9\A3'=,.6.,(?24&>T['=HF\[[V0,K#
MAT2V528=>:2Y3J_W+1_D&I4TV9X"T"W[>;2"-)#0,RR+'Y$#:] 5]$Q*ROYY
M<G;@;TW]GN=4=_ML663,=-=)Y#)UG:>;GC&UI"_]V5J2OF@E8\#SL%BQ0UY7
M\)JBLDB7*7Q88TA2KAF$]D$MM=.?U2S"?X2<03-/>1 TB75/0EVYG;X4#!@*
M:@ D$Z\]<]3S*+B_Q:;*:U&5?/N,!@*(^C%9OJ(.)M(M8T'S;ND,_UF"SWKT
M[M:@P@W;MA"."7;;Z-08WH.*2&Q;(.'\1BG87V26%-I,(T![!MY@RC'4,HYQ
M5V4TI0WKO8B<1TJ-)O:YS;T&+) C<*1>7[5J+D^U:M_&U \ZAZLH'&B-E#!F
MQ DOS1'1\':8(P9H$0#I<N.^T:?"(1],C*7"8Y)5.N>9]FD<%400\V2FF79\
MIKVQESJ843NX6""O<S3B^"#B>6R]YX5Z0$\%[LQF[=NNC&UOH47I;$?OY!'U
M'3ZW9]0_N0\:$+D&C.$&TD*O "&K"7%<XTET1B0$"Z]G$JE9!G\=4QB%R)OH
M4P+F*MS;LVK5J<@PZP'Z"?1 !_4/M541YBS2]$^X;E<1.<H1'(YKB<)$&JY^
M!" +D$X\[GPMKL],PXLT ELJ@T:)3&(2^:)-2U1P$MRQ5?F&.M)7^(CUAV])
M WR&<Y'N<[5>!)%(1 Q(/ZYTT2!0T\-X\6L]5?69'-1B9VZ+\<CB&(#7\;GE
M.QJ=''F,I[$77M9*H3O^+K5#(.EIJ"SRLLP<^VOXC67V>-22-92@3V=A_[?;
ME?7/3,3X=I_K+!1C]18QZY+IL1AK3V^WH[=3_R;H109GI1*-I[VFRAFHXS:8
M@&>[PAM][W^!.PUO"8W[9RERNM<&^[&& F^NY]Z>!F"G#*]V9VRA?M1Z??Y]
MFOWZ1<=DY0M#=5T@+&#NT9EI2,>LK%;-U+G5)^+>#R:FURTE^?\G&EE#-.H(
M$^LLL4,UQ1  40+$C#GNXVH-@Z1XL9A&N]S\Y\M>KN<ZS[EZ,S5-#(H^%3M3
M+M,9.M@?H9UI[?U^S8R3LKH#&[Q1ERY88#;!!5C *5YJ[%ZNFCTLJC7-K[QV
M/:N/JZ',B+@S4J-K\(4X<Q_7IWC4(Q+.M=5.<3B@(9#B+.5KAHU8:R12GSB
MR+CS> E:%_H^X[!+\^<F4U8-6#=.M<L](6M05!$BJKX*;ZA 7<"=SI';KNY9
M&V8X0, NJ%);Q@G(J_;[4B^3>B6M6(EFG#=*5RN=I'#$<A.R!]5(F K]12H_
M(A&V3X >Q?EPHR2.>W^_&\K^_KVD7!"U9(4%5PF^'VG42('*!,?#6,PBX3'=
M$9[IKIDA/EY;]3G<.!+1)]LGK?B>#&YBB>*TT<L'E]AR=AXO56FE-<3UQ16
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MG[^<O3\[_O"0Q##1[.<$+BWR%&2U6+T7(*XSM"Z!+_U7EE_O_))? SM*01Z
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MB!_4B:M]8,CM2HFT"1,,2%N_4$6)6L7/Q\<7P6BN,@S3I:@U1&JIN9J\T;(
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M^ NIP6>H?ET5N-SR&'S7-/FD;GC]V,\\T+1#6B&U8*<](I!WK0O6!-%"WPO
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MW->1%CMANJJ2J/4 4@^BRQ +8I76*J@2:LJF<*5*SFR@6< 7MD4,#JR_1:=
MD:>[0?!/"E;AIE(HY4H54U,RY#19:U23YX'*YMB6&R2PCQ'N]*@.@O=*L"]+
MZ9VK ;[FM!TWW<T]+75:B6P[\=F""+GIE'!OE196NC.<TYO.QO#(VZ!;Y^J&
M5QCD6F*K]PH/AEM1M37L>BBH[&#74D[='U8=7:J%Z0*OTQJ(4<A4/6Z4AN4B
MB4NI?2QLGD*DX*00R/SVV-%#\5H'[;B]EDWTOS_DO*VZ[U SU%J5MZH*/H"*
MTQ]FVN'9<3._C"Z+>L&\R$&#8X<HNE5SN(J*#\M0.F^1RM!*O@$]PZ0@B4Z,
M?ED_<QI^^%!/4[Y7JT1>XUQ*UFE8D4#TL"#%"G3!V,"6Q H55 UWW-6BMJ,O
M+;I_/?4']*@\<FT ?,OU+\FM B5_J H_*534PP04<)A 4:,FCB->XP>R TAW
M,XG8O+:\D,L"X5PH5U7CFU#&CID0W(.K-Z.R?&HIB,X=!D=O;B<W[\)QR=+>
MD+L\Q305]P@]("OQ^.-V<,>W>87[1,V*M-7G1!#->>KLXD9Q2XWF5U9UO,*6
MT\N<(A;3/ L#[#M)AE!241#"_BP\D   J'4&H0>43-SE1+.&+$3[0,,*\G1&
M=48Q$#S!%857AFPG*^[VAG2GKY;N]$"O@80=9/G.LLAG2<5<>$Q<.(&GA06>
M$S\P-\&3@*G5"A@['8F)4_7AH'D8N0_&,OWK]'FL"ICS#&Q_S[-D9*>JKI7*
MM-#4<G32*CS"S%Q7?HYF+LR)M8=BS+U(IG65%^68_0@XV3DF@Q(> <@,,UUL
MK%,%12BU)XKR4JCHO3+BL#5E&,#*;>.LZ'X K(?YS-=-U1?*[RTQXLY9'U!7
MW$\!R\,Z&WE2YT[=8$A"82:SN%BL+0Z:. NNE9FN&B*F8\RFCG&%V%U$ $7+
M="4NI9H:3FPR6C-HY]3"F3YH)]A# K82>[$5"/H&\BVJV0T+$JRLPZS=CX$;
M6R3:,RORS4Q*"S3)Y)X15AY<>DQM\4;'_^>G,6C Z,O2MQX;&"!6-L,K5; O
MC_1=9@OM(.2L4V]N%%5T9FFW>A'"GXF4+K6SM$>4'##C[?<3TMT)L8=#7NFG
M+WTE8G3+SE=QB]-@3OH'%W"X@PR^QJMAPOU,@W1TG(VOON2D\6RP#/KX?<F+
M$P@"L.&.=P^)=69W.CH3ORB#D*,U3!4A1MLP.YV3F\XNEVS8^H.$QEE1U2H1
M2-><X2RXP<B)-0 -7W$;6>!>K! A,HVO$X'>H@3!()\*64VQ%E:_N%A(FC+<
M1^E=<$ZXQL#T,O@3Q@R2=2?HK) +8C*_Z(/E.7";B@(>,#RU@9Z%C$F&KZX^
MX4L4M!I<0\(5))0EA&$.+R.(^*F&E;7LLWG^N&D]&)(E8ZF%+/,X0H2M.N$I
M%*E 82Z-@]:1'P9H=#HB:QT850 -P"TU-M0D VE]'2,TM:(Q-CM-.:]@GF%H
M@GZ'1S<8AKV*OL?K^&"[:Q_GM#F\L%AO4Z$F9%8V+(V!ZRPJ*@E$ PF&-$:'
M>V.@_Q7,$#5N2X<F#=26\O!0>JO9ET#T8&[""A[DFI]L5U2?3M@UH4NU55$%
M_X#%DS1+TTW):YO>[V3L !UY#^FMPBTV"F%SLU%]O,F4%G<3$L3<$5'<#G;"
M;>W%-B8(1%$X\&I'!_8KSDK+PF(D1-U*W1%%?O%2,%*?([6L1,^(Z'SJ/E.^
M=QJ3HV#NWF$!X<!LQA@6[2=W%R.]NN'UBGS%68\@3S1^(&(6+DM$?5Q8/[GT
M'O"T+,NTO$D937&C=;411-MA6'(M<4JNT["K>@_>[Y?\&M3D G/7HWR>)?_F
M_0>V*?@,>%SA&N=E;WC18!J6[,X,P4B:46RV<J9KEZ ES:3<DRIJ$5%,]D57
M@>*?,B.B7P<6&7F8,UF/&Q-_XF@R"0ZY#F$U$6&RH(N6P$:D*F'5?,^)M3*I
MO)%0,E=$=[RK[478%BL*N-: ZM+A=LQVWA.:"9K31=##;CS<TS V;:* WV0X
MD;FT2H0#1E,WR&$Y&LC.2VU3.L* O-!:%4'#[ ^]DCJ>9WF44L57!\SH2K>2
M\#%&@34C##^) %E8#6"JG[ .36@BTC+)T"Q(8@M$"9=S<R#T$!DM\]'@@SY[
M]I ;NTVL8ZC3;;,.%TNB7PQD27/2?7_)<)&6MZ"'LKN(4,2H2(CM'+F 7#N^
M$6'#XVBAI\K%T^!^81>7Z.K8EWZ[\!-;.$#_QR6G.VH+J0?;=L>7Z-?&=O=L
M0T&AL7&&&*KA6OM##/6QQU!5)B")W6T'V015TI(A*,.9JE;&_%<S3'6)*"U;
ME2776((.U#50XN*?B\N7S'/X[>3T@J,Z)FS9FH7.ON'@(OD-=**_VI&L&PP[
M21\EM.ROT=U(;BB,2 UX5'<E#8M')045O+*SO%BWP=32G=TG6)1.B5!911&&
M"#TE'"?(ZL64^X\(2RU-HPOR>DQA11;H)!-9QG+C@!^C.?;(+1IT+Q3-E(()
M!_IJ?ZIC\1++;7>45WK,;J<B'8L0=I'?T(!-;B9;W-.(OWHK8)Z,+B2WT/(/
M'ED'-W+]+'%!3*O2CLD=;#@YW>;445W8]^_[ZYRTI[N\RBV9DC<O>+N)Z^AX
M[+Q^<V& GU^:: +!1!0J4B#K8SL0*(&A@P]!XU3U@E M2A@*5L[AG>9H^9-<
MPYH%8=9$@?3*2X4/[^I/A#\FV[>@S$O\"2B75W-BEG&B(0CS3\ *L%Q'LO6I
M^K? U\>J85@MZJAH3=W[?2MD,U=ADJ*'=9OLOP'08K,\TH<W$[:U%^[S =.A
M[8*HJYU\MG.11YBIT+>NS&V,!\F\9RP5%Z&$X5"F*^:Y7#W81$-O)P*.".9I
M1=&LUH^<0$^I\EUI?UTI?YA%4!E8; 7"/5\I)Q.M>U[;$^-Z/F @M%:EES!\
M X3<72'DIG]N"+GHSP(AMS6L>$#Z:+/BTYT>N>.EA3CZ5JCR.U9A=6E:_.T3
MG:(UF)9Y*S![<GKP[(4>3DQ*.#EEQ6X9DR[$:8,!7+P]=;S/!U"$3LKN$3:Y
M [0T3?)&ZX>;>CQPN@*]S19VK7P^H"&T*9= 9OI%LZ RU05J7#0W5"N+I00Q
M)L$<-$_Z$?0G^(3 1 C]N2!0.^_+WT#/J0)4+ @,B;MC*\QRAY]M\^LIEA%0
MWX=B'F8&91!SR[I[6V^/CC(@,K3/@QN5Z=&Q:/FQ9VMKG>2$I"N=<%R:=G'L
M2T\0SDK#EU$MR66]"+/UB T36VD)1XB\_)+.3=J.9.,3U)BJPFF>)N6B[>_G
M+&5!UB58L\_)H@:[)$]5055]<5Z&<R6V%R90*TIWL1-;ZOE0/ 7FG#FIG_:]
MI1>*KOX(#O:#D]U7N^]W XR6/7O),;/#_8/=@WTPQQF9S93U-FOI"Q-7EJK!
M]VJ.V>LY+(-F"@D7[*S%/0WRNBIU)9.'P#F1/F4:L<O"$^?%#D>P*S?D0]M?
M2C;_D"QBN-E!5Y;$D"SRF))%3'6Z'QH7:!36#1ILD#S(?@AO+ Z'L-(P?7Z8
M.^R.VN.)]2^<=E^X/>)_J(A8(_X/'JGXQS9Z-87/J6JIK#'V3B7+'4DQJ!.H
M*ZY&!-DSTIY(D/!9E"Q1Q;8RWB218_D1WZ3&.DV",U)9AUX'AS23J MJZ D6
M?S'T*>7S8(445291;:^=C*[V'?L54E.0I;YZ8,$S0.)^PJZ[91ZQW#2*2US4
M\S^J-P2B,DP?6F7 FB]"WI1B/'*PPMK/ZH*6H:$MW*#8_0'EH\&N#[X)NS[8
ME%T?;#V['JI_UK#KPT?*KHG'A)R8QM:/$K:B*C:L[ \WL%;=0/5.G#\L,0;C
ML5MAAWP<!8=!7\6\'MTA&'Y"+KLS!;:)N$AL50#G)*_*#1AE"177-WB^:SQJ
MKF_*N\?!=5C@3]P-,PKKR@;GPAAF0\U0&,-%HF%8^=?D_]WK)H$R-CJ#(LSF
MME!7\^^O)3&BAY88DFRIDR1M>WE"3%A2V;#[R"7Z#IARO[GD./PFDN-PC>38
M'H$PU'2U!4)RE5=ZIWLL$#0G@5-&Z56@/Z<KC_7&:D'XU RJOQ[V*YQ)&9BI
M#$->B^R56(6C;_MEU(:I.;+"4>X]?B^L?@?Y_F;\7CBY!D+ IC^Q^IT&GH;
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M--(S=73+9;BB07!N=M8&0G.J6#V$+^'B5'@?OX&NX2%81]+J-%LU$%8-B6$
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MQ%IWGE@0WN5X=(D@:]V95\;I+(R&8EXA08H@M=2W8;L'AJ>'+9$VGHABC<,
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MF2-U<[>GUN&VL).H3^R$!*TE1@KXK0TX3M:HF7AZ.PZ^UOJ:3*,SC0K)#Y5
MXDR5+L_&H?^\>0#E'_2H\6)>AE<-3=N8 9PPL*$-T!428M=!Q^YRE&3FB:GN
M(#9?Q_Z'0BW"A(84289U^JV'&J4<76CH[\+P1ENWIRA<\";/\K]\?_3LY<7I
MSKX7VS ,;T)9%O)$DY (Z[9<*C(-PAKX2FB"DUELHDIX1Z;$88?*ZJPNR-)@
MU,I&P/RK^DX>DH7%?6)AK!$UDTMA,S T.]<FGH2(DVP2J W9G0[]:B7"L4&0
M+CD+$?.!]>:[B88V[NM'>]?3XRC95;LZZ?L/1<O''J-NA00;,=PUP=M6K!D>
M%F&./*[!PB )+QE)F/D2NTLQ-<1C#&7P;/<HT&[V9[O/8.E>O+2% <FL*V!:
MZC!MO#YXRFE/[%BX<6W5[GQWTAV6;:_T!OD(_H/I>3;+@OS\+7YD7;<5<.*Y
M:M-,"Y_Y9M7[B/@L5BA8-P6PBP1]%"@RY"EKL)\[F3=C%=/.> [GQM"B?SO[
MK3EX20^C'(A5]SIL#1-4?6*"I,>=.TD)<:Z8.KN\%QRK,B50RZ0P^4UM#^0&
M2?;K[;>,&.07J(TWJ8>L)N#$F)5/F(UXJ8Y3\4$C^QB2%TS48V](7OAJR0L/
M]!KD5V>WSRS)$GUP6]5Z$^^ Z3BSSC,EJX!TBB4GU.O@(29N:D-!3I1-4YP$
M7H&:R4VT<KH5,$#YI-5EZZRG/$W4)%H,X'9[1)?=D4&25<G.R<?7QSM']'F:
M@WPNQZAK"3-C!])L$U9'? 082:82SKSB=\F<4D1'=: %]34H_9,Q+6[? M\P
MJXNR5K<E#+8>A_.[6;>T$\+]2\/H$RZ I-C:C5YR D'<&=L!FM?69+?=:+?&
M#Q,Y+R@LF0FAY!"19+/BM69GRRZ::J^'%)4D5V,RX>Z>,KR6LEM+L]%\3+)H
M5\KIN.G<V T:B0+;$ED_?%R1]0\Z<X*JB692[HVV>R\JX[=$7>Y;?/$FBC!L
MX[UF7(9&'M17W\ZRDXPQ-NB =IMX 6#-31H"J"UVB&$ZKUC:G#@T&#$=N9$:
M)]+S!H9+HDS2$[N\OYB%[1<8(.^TB4:Z'M/SLDG] 29 XP!2DH _=V;?64R'
M(1CY((FJEJ2"]PZA/O 1.@N!/IVI:?)U&#YEP;EI;S?1\R%',U@;=*JEV%',
M7YMJ$_@./H,US?&-*I]HCWZ)V9EB^$[NX/"GRGKW?>B9,2C865+"2(4"W81.
ML4*M6\(J*R<%$,<4E9=?UBF =Q_C\Q&JMZ:$&.W_#%D7S1=)J2%5\&L[-67\
M9K!,:&!BI1%?E,_:ID!7DJ)70T9%#<2GV/>T@)<'31>V3@9WMG3B>K76,$+0
M?R/D,S%0:E2AXV^.12>5KT<B2VHL(-P[2PJX4(^@;R07F+, '>1'<Q$OM80@
M=-2$]'%<RM(ZFT.7Y_-ZXDWN(E/,7?*44>/$FL(DHJUBDFI7XSF5:#"568)\
M#C.I*HYW)'! ".FB#E.<U5+1F3#3:](O;@N\FO5>LN]];!3D7Y<E5J8L[!1*
M\>+H%3868@,F(IDU%U4O'II 9BO];#"AL*X*F'+2&H]V)$S+?--M.18@@@WV
M!@[_ BN6[)84:@E+Y&,6&=<<K6BF(E668;'BJLI470DCHKHG[ZXEC(9U6G#A
M)Z66HB/P TQV.7O^%V',UCZR[KCCYT0'3KK.GIA>/W42I-1C>1-3!=6)8@D8
MT)DM-_()MTE%2JYV'W&33_SYQ-X)YAZH+24[#W'W)9425R,43[91#XX]1F5D
M@C6<+>=JS[*=TH**EV&368WT!,N%I;=;:_4=/2ZK[X()DIS:("9.<E,GT0?U
MA.4PIC3J @X\JC&<_;F6WTC&(F51DW:%I4.U33W&UH.LA1G;?[+[G"-TWW@E
M:,0?D@H(.OI#>ZG]5@];+$(<0H<[G'6FB5;A)ZZ8U]IA9 04B&H0A66>$5-R
M]Q&CKAW2&.N?L!P99&)8D,P^<:X*SC,B;%9,B!T7)'<P-E[Q\XRZQ!J4+FK!
M23:3%EJNL[7/<E5D@T+Z/P%SWT;(=Z,E0N(%37).8 BFH@"FK[GT%!V9(\OP
M32JY8>1C0=#H4E^Z:L5;7G3&*6BY7*661AFDL"B'MR='LT@Z24*0HJ^\^&1*
MS.D<<CTS7L0UO68ML/8;9&3,^C[E ]R$FF4>H4<02!QA%9*$T@SFWE#'%L97
MR!,G:TO9FLN&,Q@B;$8.-GL&#!&V1Q=AD]-B?%/M"DLNNW>**X?:RCNG'0\*
MQA<I&.3M]'57<K*T*'3F0MLEV56>7C$HB#'+VN%*(R :J:<EK$@Y(TI?L7M!
M58Z')X+C"B\H8*^.,G.ELA@.Q^\@=VVQ#?E(2C8X5=GTO%':YA(7G'_ Q__]
MP\G7]> ^J*'TY'$92@R#;!R%'!U[8!OI8V?QHG8N-<(2:Y.4M6+L!U38Z3'Q
M00<TYM',E,6@5\P/8 @*$OYB,JP]G?(FM.)6R;AVF#1MNVY'Z'JW6C#J)4AM
M UR[!Q4P[)R,<P\ES\!=Z60Z#3[5%?-R2FC0)<_W35PX/;:U["B>*ZOE8"L\
M>-I;/?03,0Z-\1":E(BI6N5$(NL>+Y"4VF,E*<+KG@YL.5F0 Y-M%,PL72Y5
M:K X,<=GTFDI=)MB/$UTP]DTCN[UAD=[4VD#E<E!SF]9+4'E9"K$#?.&U3D_
MXEQQAJ<EJCE1RAQSO%2?;OQ!@YBG^IS3Q3JY)F>+S;Q ]X,Z)YW7%98\L%".
M8/7P1G?5G?SQ1MV=X8M()2;2ZVRQ,ZD.[K8F)N2!5'37E-^9+;?!*CM1YVX
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M'[8!+Q1F*#B:[&:*N:B;[5"8F,LH[[SX9N89$)[_$Y;XA!JQGB8J*\$S16;
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M(3$!"U2>0ITW' 6XE@/KKE,.ZHA>CLT0B\^CLU=C*0GSRE<AF@JA/F.!JCN
M"SR 'Q[H5SA:@*R8=I!Z<ZCF?3M,O^<<<5&]F@+5D-E*6C_S)>SFT%&XM#U^
MR&2@&RT_' ^**]WT>"*@!EPCBL>""!O'.C2'6T0I!EOHBE*)#V6,/6=:UPN,
MG?-I@EXH>'"Q6(;WMK5T;HQ@X:!_2Q1<[;+IA$J: [M\B=0X]1FC=-L22^"H
M_32!@'03\/#RQ&6\Y[- $)W@IH""PFJG=?*ZYPN&:HV:6@)N9TL] ]^QNB;4
M,[$^YE!W$5-U:[PT8)MYQK4H4>8]B8Z2IH](M9EV _E6JIG7L\1N]U"R^Q%^
MZ8;*M$U-X"-P!E=O#Y)\HM+KL26%3$<+]I(E_B1FTE"T2,CU;]='PP=Q2&";
M'\C?XFZ=']6)""-),<MS][G=I=^WR-ZS6W3_J&*,*EFI<WBT AG4B\Q\HVH[
M8[W@:;=[8.0V;S"6-8#.AC6=IX.=X8CCM<(#A;$=T6:.G0?937[!5UQJ#TD&
MM.% 8(F;KKUT@EPV:*XX_H7@$(5 U9@-JI.9'H=$VHHUG5/#WIBX_>++Q?4&
MW),.UFF:1S2[-:<P5L85RKJ+)*^9[0'FK4TTCOC,N&OG/YZ_/Q_!D%[_Y?G%
ML_.7SQ+!YX#ROP-D\E+GY+#H%\V&?W9-T6;2[PLSZUVU;!!QP%ENELV_G7\X
M3X1E=\!*L1X#/=RW5VR*\"N8*OYM,(_-E,R:]8[8\<1S#HI4\+WH^O>YV28@
M8M@?O";;*S?F##DZ9 7&X:/O#C?^U3KS*F$.W_,!*RDK%N#&:.JV?=+(_.D&
MF+5:U'B5)I!4E\\&W>5UIN @,D?LW=!&=,UH++:()OA?57W_Y#_J>VD\EA%^
M@$?'SCI1_IJY4UG7*2-A,Q(7IXS$H6<D5%$'F31!2^AV:E2@Z$>^[RV)$.OG
M>/;"L_.+Q#IK7*PHO_=D31^# U=7217QIY YA#2I^7T!BL]X5!6Z8-&$BE]B
M@ATY=881_GN%]0V1&+*1#7$\&YE>DC[%$$MA>0UBF=30:GM$G2F&I(!0>*F=
MRCZO9*U<[YP"OAJO"-1=Y0PI9 +2$T=E+M0(/9X)YS3H3@2A_3HX,>V(#U*L
M<X(*AP,$*[E=BEC<A/5757]AE>-'UV!J:-EA19S78A*>$-+B.@V"L<H(.08I
MH0=2LP]09MN)XUFV>F^P2""B$^&/=#=XJ>_KILR.)OAP2&24:MNNV.,PW]@?
MNQ&#D>L*'L$)^URT2Y:,0/VF!+/&ZPZ:;BH.C02WI<7WPM,QNAG*G-BI'BM0
M-IIRR!S#57X1!ROFBT>0U5[@T=SM14TL]=E0[6$/"*] J<ZK)'/;554&!8 ;
M0$&4RGC T#9&2M=3N?WKO[Q\\Y<O*1\NGK[9G8 H]D= O#A_]2TLQ-\C!SR2
M3XKNZUI690[2<9TOI&98J_!UY,ID+S5%(?_OQXJWS$]=0;H(PG6#4)6O$ <[
MNQX/D*PI\>0"B[H06TLA\0:EO[01RC0R84YDJ>$XK$+,. F4-!ZS.:NY_9?3
M\@5N4E!+P-7>''2>TEX0<B^2-J1T7WUK%L_6+<.LX9[Z\_;*(JN5BKU1%E-W
MX!Y[ ,/(\G,IX_7U.,3FHS&"=15BC5!M6R($APEQ>^H0)9$\4O:GJY10A)'=
M&K&4.#I%.E'F>*6K/(M*_X<E6\<<NW/Y,5SU8.O7+H9+;4N_;8)8\N#*_"ZM
MED-ZQG*5<^7#[Y]1XO%#XGX 0R-4BD^QJ?B3>4IH3WLVHQ=N_9K$ZRWA<O1K
M;@-JU#!A#B=!R"![?95P$K%^YC();_=L:;"K_= TC\.CH%!V6$;JW*S^O (
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M#_[]B5Z3Z-R@50(K>(@C)$$698:JVQA5" ]0IJ9?6#JT0C8F$5DLHB5RU#=
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MW;UJ#U,">V57#7#&QC8BW7"R(HUD2)]@]_+"8I"%/V61%C$!3")JS6WLGZQ
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MX81ISLRQ?<8G'9U/6=^;Z03K>M:.*=,4+N]M>@?$BWE J!AI0(5;%LZ_JO&
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M(:NJ(@Z,5=B9YUNG9P6Q5LC=8BDJ0VW,.)$1UM4%4,$\$ *;%\,,H>0K_[R
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M-$LR=JX02L6E)>^S_GHD7"&^6^C3_6==F"GH[-]530"KFFYM,V?=Y-QP^/?
M[Z !6=XLG9TKWB4.\'R70:?C:>3U[6&E&#^FGW?LAQV);CBDO.)UA:T,S=[O
MN(';:-138!.*/I:K$?$2.J<'C71G&L.7ES #J$NL 5L%Q@X 3FXAL%N3FVJF
MF39%"S9Y5H#+*I43]E\/Y2OZ\V6W7I^R6U\LN[4W\NJ@PH9&4B$A[6U=9KM'
M0EP",949$?J[&&[CD!&5-H,5=YN701*)JIN]?(LN9F3_$F."+IEBY=XDK_)9
MH4+B(.PX[>C#\ K%+:6 PP.(U2!!HZ"RC"^SB&[G.J][CPN(&J\]\*GIX2H1
M.JVI\RO[H=!&-JWH@>C38BF;>8>1&L4<B/ML&M#"\$:,L.:#L2:YU29,,PA?
M,Y]2U- &'.MI-Z?.Q,IWQH387,V3,[]3\8AU>DZ5W@5A!C7 \\B*H,NVU;(@
M>OH&2"YFJ?FHW\L2'B=3(>^?LG1+SE.YQ8%A_C4W\ZSP**>=<>.;0K@\VGP*
M49O40:XMXR^R4L[TXNKU1X6L5QJP-I1<PJ56*XB/R3_G\P4^'P]:[U'N_,4'
MBYDA# 4&T5*)M$8O7N(-"0+--EI-[3WI2LD^+B"\4W=MN7)WFW+Z_ Y^=WR(
M'.QS*'=U ""L9<^B (4D5.TE'_U[NO:%*#1T0PLW66+D]#<!"M+A"31S#! F
ML3!14-6J8H.T9Q1$I"5++,@VTD654L@E/1F^9D1%@I(/C3Z.*E/H'FX"C(["
ML31%.KQN)_B-2(,-C.3\&O-CF+N-=L)>V=G$6;(=DBK,L7-&TN+Y[</=<RFT
MBN$[[RC:A;+$0'BF4V_;5E_D'/;Z TCQA7%+C<)/PJPO)!QF'DP%=DJBPU:[
MP4AR&]GM9UG,QQVHC#(]&KZ,_8OT;2@R#W8V;=MNSM%Z<:,*C.[.:DE:550-
MHS66F DNW(Z'P0^H\RE6/RND4ST&'OD;&5)!\>M6HVMX'3$L:5-N=):V1%@%
M/\C-]1N+JJ&*>7PWCF+H">#?Y?T")_-._:U+N@D3=/_@/W*S4#,=>F=!;24G
MI>$2;-BQ<U16?RI[ -!:MYK,J(DZ@98>"Q!086,.0\QE_K,VEGO8DS-G4. #
MV]8(#9<C\^G1L,@0 $S$D  LVV.&G>#I0'N.SBL?%ZXK@6M'X#_/$$$9*&80
MRFX?ZN0NRYDU4/EB6#%MGB$F-5R'?3A1 ]=I#X[56- 6N$>0!62Y IL%BFC2
M>HI5E+([+^9,H53DLX;R4A\VVB/<T6/16 ?%NOFWRX^H@ZXY#+<7H<C+LE18
M&-T1@@2)L<LKMJ?8(/;!C0US,;:(P9B-XI/D^$'\0_M>2X5(67Y..(MWCJ:9
M%I@]6%':^N'2IM^HQG^VK1* E" $,W&DUZ1'!P:;-FXH#I='-D>9WX$A.C,.
M#. MK)FK\4XR.FGCXS5_"0P:E\?G-^$3!@:VC84?],&Q(XZTP/FB]6\G%KCM
M<A3O]'G]0<(S.V_?1E@?%4LQ)U[<=SBG<GP0JH'8\I;O4^:"3/UB<_AZ@%?J
M=8HCW/71M#*Z>'I8F=(K;/U%27;IU[:'&HLP0K;_Z4!A@,#(C)3\P8C$M$&]
MU*HX61*4R.E";T7$( ]:-F8J=,RQ.PT_=<3&%R+=C*ZY01UYFU8W%$ILJ82F
MO751R;<=1'V,C7QE!MH8Y?%]6GUBCS4:E(K6_ITQJI[BML36#]"5MNZ:*0.Z
MH(C!J\4Q5^=68G-C&WOW+Z'/N./6"+EU&C#OJ=)$C>J42K2IQ#>G5.*A%\JY
M.X:T :W8?.M*<!TA<'V?4^NKE0YD*YP4B[6U1;@.^@W6IY-A($+N$0$*TFA&
M>:34)<JR'.(&J4) .1IP&B(WI9(?Q+X"E3G= OC!.3D!]C;, _X7I$.#6.OQ
MEX6V[%957QR6JI9V@V8W?NS*<M<0EUAE7YB@"C"7WX++=O'2K+Q?9C*<W]R8
M2TYT70I>(&C(-DKU9?.AUF'4+; T=+;A\OW'ZZN?WH[^^QK#M[..NY%">J E
M^A0,QB!!=S,ELBUR+C^9$WX\1NVSP[HI/X$8VQ-K]N]\7FRUBK/?N,85(['S
M/(,D9WJ7%J48;EZ7;-5L!)Z@BR,P8%V)/O*4#ZN4M*$R\+Q=)H-7UI8&89<R
MIDNPJ?& M!?;4'A0"M0=7@3D/FVY7?>R*-UW.(2C=<^GW(OL').2>7Y85X<@
MU6:_?UNT2V.LSIU]LE.RTS\(QST4P7?;=MUWUS3IE+WFGNI[=O[:UL*G<6[L
MT<73\V=GG\:)#05*7!32/A'@*"HO<&%#5>?GR_/83FHL"_S>-26EU+O78U-L
MU>B3@N:9"IV?C'Y.JVX&%698N7W66R)1KW\SD]:]3!FE9/1Z81[' T8@!/JD
MZ.6B8^H"V7K.*5=_2..H'D';T>CE%X<E6ZXIBKAKC1QB#FQ3F'X'&"]GSY:=
M0ZH!D"GH2ZQ0:QHRU^C@E0]_\60!TK50J#7+R^(NYUBL31NXG$1@#W10(T0:
M6?$8!IR!MME]ZCN:L?@35/T*6L"%RBR#H+Q$E0NFP=+ :()W#:<PJ(;6V@BU
MHM25V%7"83?U%N,: ,<&%$FV=<F%G/)J,VAJ+*>B?PY%!;%MD';L]68N1<(!
M,JD.=W.FY7MTWN0/BE'%\N)KR0M$"E]?7^\N<Q\D4EZ?<T9ITGQW_<O'MS_]
M]/;JXV^7/XW>O?_UW=OW'_]Q'"+\S?F!Q2!^O:_RIKTM%B?2QC]7<96E>OZO
MJKY_\A_U/>J$@*=]UYI=VEG556G]8':RN>&;^;OJ)QK4,820*V.I3_+E?<ZM
M/:T:BM6PPW_BFP#SN^2,E?C<1/#H,+3;+28@%2H+W_("74QO=$\(+T>2;Y\'
M($B8)(39)H[]*X2UH;M.CU1<<,RC:VSUEO';HW9:+W*'L2C+=,*')+9$\? V
M8"+QA?0PYH)";R! ^8I+].S\U?AH8 H'59H4;92]HUO]!??_XNF;W1V 8G\.
MP(OS5]_"0@!FR]B]P))15^3[6Q%R=G]+?0N(P\<8\"!EP(QFW"D2#0)K&\"B
M$ZSJJ-%C,?]-80#X3]63>-$ .!'H!;WH/Z"D$@EV<I4L4!)!N7^YBHDM%<+G
MD5 M+,8BP8N#%]5-RY4.B(F\PRJ2,;>BN!SK^H" N(!A:A!2O44G JIQOA\K
M&%?P WB&QWXK3\ IT3.,!CAES&W&_-M3QOS0,^9D"2!XL482,*@JM%DU>^-4
M^/#JAW=>X)&#"L*!MLQ+()F%I .52 $FAZRW)??2MDUQ0JA98I_&QA,)!DK)
MH=$1-$0_&J6R1UKEXOSY*U@)U546MIW%(AG>;8^*Y]GYQ7%V(-VW:JL#L?>.
MYF;NS_8?NKGWQUMK@;8X(B=DCXZEZ(O3L7R $V';S-GL5-0(6X;=.2(6F1_M
M"H_\D6CA@ZH@VR,U//HSW4JR1$]7\U2X-9@E=<79OUKVV%U#< /D*Y'H^F<7
MB9.#Y@7P#?:DS4&D&L,:.BC7YF?3'/XKGR_*>H6_@(K*KH0V,/0/":ZQRWTC
MI5]4OFY[0=.X,$TQ$_I><U*+S/CW-C"'[CUG3!(O91)D3(*NIE]:Q%A&>S?&
M6.-6B2U@6,$RSX2WT\-OP1R8#R>KD<]!5LF5N4KN*)8Z4NL WPO?%1)D#+Y-
M1.+O>->18#+?G!\8FIG3>^^:&@BL=BYWCD3Y'&3R7010K[#V:$(VIPRM<A4&
M'((#7^9#BHM>,6LA<P7NBPSNV7Z][IR!!P-]26-DC(D#?*IJQ1Z6-<BUJ/0K
MER0VA)]=%,3-IY@RI-):V. IK4G4-6HY%1IE28!OG\K2D5(NZGNHSP14JCGN
M396OJ!J%NJ R(-^K(\NZ)=:W3\TX:O1957,<^@%[L&P!4XNOSS@TOV)'"M4<
MZ0&RJ+3+AO]IN?34W(Y%91Y4*(6MIH]Y,Q^]A5*G=O>7]GHVPCZ:S#'@WS''
M9\EG$1#85*75,B=LVYE#+>Q6TAK)?*28+_% DF/G>F.TP@7&K<]'9P#AHN@#
M],/= ]XNWJZ]V"E'V+5.#(XF.1&Q2\F>3X**LACD3->VEN#VA "1-7[Y](0
M.70$"-5@$$-M_@DN2-!@RE9Q!.&;FL1:]J__\O+;O^Q5WYUU&D4Z\NU2-"7,
M\3+S9(TQ;" *3XOND6E_S1C.*72\G0_Q0[I,@2X!.?20+/M=UQ@]/OJ^KHD"
MB)7?^_RF:*$,ZB?S/^8%NX;3_SU0?QE,)'<3X>:"[>B,F"=;[IHF?RYA-IGD
M0O2D0PX&6_6^R#/CL#3%U!D^[1@+//F9E""1=N;0)(4-(MN#^M+<B6F94T3O
MXNGYQ5DZ/BN 3!WJ4S'8#4F79T^?7OSKO[QX_9>W5_@_;YXGMIQVV'(:8S_'
M:*V?"](T-1!)M1%[P/A=T X4'2_T,0)(?\*,C!APUYR,OGN&X\2".9_NT+OZ
MKA^@^Z6E_J:FQS!&:K1I'BA]PEV_O<']1ADDO9SMWDE1,E<)1-8#7F/[B;)J
M"&-;2<_9Q+++Q++C\*FR"Z,<O??4T[0V%NYEP!P/ PM'!.L%?O*LR,LL+(EN
MZR=3\[]Y)M9Q<$F%++CDN^J1F(!!#DOY5\A(5&RP7VJ"?SEJ;6'N;MJXQ_!Y
M$W^3_6@Z?L"[?R0"?+8_ OS%^=/GZR7X'\:%\#5JF/N-.]^</W-4^7A_5D0I
MM>K=1H\D_<H\NZG+UJ^VKR*T  ''B#0:A>8;3<[RM)J9:[OT2ZPLG:M7>1S<
M\O[K$L=?1^EW5\",Q(%U1354;:0F.C)X6ILIS38JZV.!JTCYUL?^*L2Y-HFS
MR"R+)7+ >NJ/MT7#?0P915L+YT%\V7N=4P 0[8]U8)==-?DFBEK7+<*UM5U?
MU:U(::'>VE6J1UAIX^7H7AV9WP<<V(%/?L3O\B.PT2UVTFRH+_$DIR"R[<MD
M[8;\,Y!TT$?8E6Z9+YX !8C4/D+GDY# 9+#S72UO_J(II)WFE@^,[D=+F.MJ
MABV0X9*=,LQ_K@RSL2>,(-ZOG!98 _,%P/RXHX]S@QPAI:@TXY71/6L[U'[4
MX!ZKH"NJ@^96]X4ZY<@WZ&G9N(+T51MJ&^S.M>E=7<44\?\+*2.;<P(B$VX!
MUQI+I*D739%&];,%7)HO!\'G8.32,LR,BNNO8  H9>W P)VY<8XR_A,JKVF.
M1AF;>Y1A@**K<N@7-\U3[J^#.,_JB;=X\(CU*Q7K+Y""@2%>SR79853?[G$;
MRS=X<%Z+NLCDI?H+:/@!\:3[@DO'&XW0')V!&X]JS?APN&YCP+^Y=@$4W3<Z
M\3YM<I5>55W-^BE39(B$UBP%D/TTK8LHW+E.]0X>9]7JHF[;O)4TCUB>D.X!
MFAT!FNG53_S#-7"@:%'UMO>Z_9W!FNQ-]Y9WH]U+(DG_G' M)US+(>-:CG.5
M]PZ$<)S+O&\)EFU7^<^72+\X)=*/KX_Y087'XP;]CD/D1U.PNT\G@<K( <:F
MJ<EM\]04(* KX3=U1P%JD/RFTC_^<#F25JR35B<GSCYAHM9+6#Q_>6%[;OS'
MA\O1V5XT+XT?^WWP7$952DPL_90G]Y.=Y0VZHPO^LU<1Y;F^JE7MD.L^ND6F
MO+Q"N&^FL_NZ(0EE %0C>ML(/,K^9K?^K!R?/1OK Y!P[T*DRVVI_W66M].F
MF!#>(/:(;\=G5]Y3QHE_C E'S<F,I9G-V<73\>A[()TUOOGH!TAH8# !-6C2
MCTIQ(K^V^2[O[Y OQV0[,NZ3LV]F>U>8O5<Y*=O?7OJK0:8,@@?+@J)7=O4L
M\SZL>B,S&]BB2#\.7I>+\=GW#B AB\-HU?@UKU8ZP%*[:(T76TB\T5*E<$$A
M$!?G^6?7%&U63 6_ .__"'ARS.(/GN,OLW78&WQ=/,<AVO$" &JBJWAZQ\1,
MMT=*QI((4=*HE]$<.N HTQHN+(@(/CY;/Q+6@W*()1P.KYF3=%"CFE-4,7UA
MB6FLVB) 9KJ]MAR5H2 GE*?WT)"V@]-&.2B7U;NK=':9K1.0(FU><F'GD]NZ
M:]T?H5<5TY;B7?:%"[2-:VWGJ\$9?!^9@1D80EBBZ>4 TA,0?]DOI2HGOFD=
MGH_/0'['/GHY/IN8)1J?75^/45'$OO0ZT">@8"@_F4G>W+OL?;@^[C),N7V0
M(*9(LAG_J,IOC!2"3;=0IFT$>=I25ULJ33;_V2V+TEPV<^:S8H9'=3F:Y]"-
ML&CG>#BU&+9]"LU)KUBWFRE1&\&XYM0K19EVG,+5.$1JF<'069IM?P;<[M/*
MJTT(-D!P#T.ZAQ%4#U$O$:Q!")0QGI@1],<8X;G9'YF_N9I'U>'MNH:'CM?E
M=,BL>G/^O->4[+'E>5'X9^+C/).1A+<LZHJZ(G 3WR4*+ ^0R:B?_HW$$0*Y
M"A,U=P5[# M^\0Q%=-ZJ9H-^E\,?NP;^/:\;50\#-ZT 62> 7UZ]02EOUM (
M\9[PAC]/QP*E)>1K 'HER!*O)!7R0<>X<F4AKTY<:W.OIFV%W!DZ).8J<T5?
MVIK#PES:T$TU=W\QKR[-O&[$ B&#77:!,JC2J3PS9D1%P!EXD:YU# 7,L>2=
M;@])PAPTQC.XR=B*WN/@5(#'(5PDGL@M,851P"-:<.Y%Q\-3M$?>$87@UIWC
MMY\7L"N[/KR* [8GPO\YQN/75>1_V;B3Z]$@$$DT7Q4GEC0&0!U[E*2Q_SRD
MLW99EO74(I?>YTC 5.S\[ %S79LOEZ7TCLO2>7I#I='SNLJ70", P4VD(V#6
M*#!GO)B2#W(/++X8J/[YAK*@J-5%UN'7(Z?>*1CVP/K370&ME]FIO0'"/@02
MR7;V+  T3AJL*E('&.%@BF8@!$1:_+^Y+8SD]@J[?.["4R+>)N*?G1+QAU[1
MKIE"&Y_R,R;;![J=(A2SU]"TCRWF</*9M:CIANX-&%,+!I2->Y';#*-X7]-[
MWJGV?'E@VM,<>'/*?\IOTM*H4**4Q-+J_P2V7G-9, "R:]NP+*/Q\"S:Q\PO
M-5NH2CI;,9U7$#SF<FX5\J%:9YPR LLWV(&:^%<UY+15SQEXXQF48+I\S;5.
MK\ZD]REDU&UO];"'G)Y<.OU4U?=EGMWD3.4*]!&0$DA$VL'L;;+C\=.'M[I>
M>+5/7I&VJJ%<S9AY6^WH_I%3\:AE2J+JOV53F]UKA8):LR(!J+Z8"+$L-Y]+
MJ (5;CQ$^> #\^\2#ZUY9I6"_'Y@@:U7Y9FRX76+<5,5F9SD99'/F+L6N;7=
M[NE:T$FN<!&3E6;3Y3=I@V_HW)A_\U+04X0K[<G4C +7J;@KH/[#+[M0<2):
M$^][!29D(!"L!H4G% J))[DW#YF$K5W0=PX:H=/0IT4S[>8$XF@Y$RI\O;FY
MYW>YG#X>2&)K@CUJ!3\,["+HX+WAP>X6<&YA5:9Y!DI:P530;J3D$6:/.24V
MQ:"Q^9F<#R74D(+<1G535XJLKF!OYC@"5NTSK/2@O&R^0E+Q<B4YY4G:%JW.
M;MEACWG=J%"E]P9F97 G2+JNWZ=F_:!>JAF!^3F]M0.,;O&1]$A_<_[JL+0H
MEU']G#:?S ;M.M<U\U@MRO1>E8?CK3.'X5,ON<6DWYM(]+'N'7[>8PIQC-L]
MK1E)V2J9]1.,D&[&G%;0* MA:[=YHV51=4Q7TH[*&J2[@AYPGME[Z-'<AM>'
M=1O>.O;#V>@]UIA[U.GV>"7Z:.WXU@0$"A-(!2+9>N:8S_!R<',[-&5"_0T9
M87- ;;V]^CZBUJB=!/[9G7#U+")!,K<6O4F[3JCM]5HA%BYNZ7 XGK2"N0U"
MY>0>?SR1RC>'=2\NV: W1HE?P:]Z*+[C'HH[O@V_$DZ)T$:YQV!NJYMM/P=F
MF"E)WW#T40?BX1&13*VQNKI&W#2@?$6H O_>AS,;02)CT VS.3BC5Y.P@$LR
MW 'WRK:547&SKH312&?#$ &HXD(P4;07AT)"5L.93Q?&',S.VK'^4:@<S<>)
MS["A0L'_^>&*;CA[0VTW 0L6H/>Y%$+3%]R?$4C12BV]U%NS80HS<UB6)&1I
M#KH">?G?,?Y8A*%B'E.,9;W8S=$(E&\/2Z!\GU:?FFZQG*X(X;>/DN12>I?H
M$(%Y _85M88;744E,#SN(&0.F/!DA[UJ6_)O53C'7] _3WH7WD=-OGIY5EG4
MI%M9<\.SW (?+6PQ17:'AJCK&*;H''+F'4S<=(%>W5I"[$M&F^>*+YF"6SW#
MD$4$KG;Q].+L^<O+H?$"BY4.UM@8$9KG:YOVEB*Y%+D42&# DLG;OOKX0R",
MBP\!.Y791T 9G))8-HGU_)3$.O0D%AQS(&LAGDT"7>I@X?;"*GFDM!I,R>R7
MTMO6V'CE[^X?=$%C2;FU/@&[C]?_O;NDH8\@NCA_2B;8I/'NUO7'?XPN?_EA
M].ZW[W^ZOC+_.@ZC[]OSB\,R^H:222?RMS\7^9L^!T#VM3<-+G_PG7K41C/R
M;Y&)&M26KVA6.;)N(>THJ"6K ZD"-?^\*!J5,/7;K*JB#;1SJ2XC4KGQ/L?<
M%+*.W^'7C-?TYB](#?XISQ?,>S9CSB]X B3(;$8L<#>L;SR8W64(HHY.2%Z'
MC-K"3 X8\:#V%3QLYF>+I803R;^EK4;<PD)AA?ZP]Z2*OZ "$:;4M8[WFQTB
M^WP,=O;#ET3F'HU>QKO?PK,WY;V]\IA'+PT[._EG8/B6G2.\?.^X4#+Z-E\[
M-!TZP5R%.F)+Y.7+B#:?2^3OW%".1 [N'??8VN2;O00_6++&78.9W_:%$L<E
M(^VM/89"NFAS^*97V/L@R0-):?EA<$0=*?! L^ TNRM:071\Z+4A%MQ$]-?D
M><@#^+X.#4"MP/YUM@J4Q3Y@Z,)NY40&2B7(M?'M:JZC]6HNC'EK;G-"&(8J
MIV 8((@8K' VS].*U?7*_P+A?Q1S11 ^\YNC!YN[24&H-!D.VVF:V+?'"1;!
M!R52^AW0*# PB$B!5T] VT7KP >O3U6/L,BE72*4DEC@N7G\]N^,'_^^IO8\
M>[-?H[-)A\HNZ]CJF1KU8,X1U3[W7FGS*02(P82?>3:97!:)0ALWCJ#3FQPP
M83VB;R1F38L20#>352BS J"MWZ+<_ZYM&^[PYUM(#T)H@;;=L%E]%$!\5<WW
M"LZ#Z$;K#Q:#H_N<PZ$06J4^[$;:3B +Y&0N#HA[3<[B(SH68V'?&#0?XC3]
M9*['<A^<ID'DHN 5E0T*&4U$[%39[_!.!(\W:"E#"YZRK.];YR8%A2:!3+ 8
M'*8RSK4%/RPFE40=%+PP0PMCL$/\FH(2Y<^DKM(1/&2TJ)>\AHXHW / )A;]
MVB:!:%3_"=C )2 <;XHIRI J)Q$SJ*%Q'$I(D<#!MZ0WE$7WY9;(4&FW*V4*
MS@W%5D9?CS[H8JLSO\/H\C??.9C"G^$4NR@!<I2G?'Q:>TA9R>7-'3!]O2-/
M9'?GD@2-5]8))#78\PN Z\AZ9,T$P4BS^3#%; :]T[O!CES?W>5T:O0T9?OL
M;4SD+8"TK;MF"J,J*N,$6)P['A$X%3B7H?7QK?7^L=KV.)T)-'+%S<XP'SHC
MYGDSB=R<IRG,S/UFO-T9/&50;0;UQ2F#>N@9U#]&HIZZ5CUT7Y*#6:W;^CZ_
MRYL]:/&5/\I'5WT\=43(W-\B,[H/O79$-1<$Y'^<>[W.LQYZV9?RF;EASMW8
M&Q=/W6C^QI'BCFYT&\])G6$_G%13EW@/\$H'VK#9+;56=?%E9,UI@D?$6IF*
MR/':Z0"C+#Q9?Q\L@[NT3(S]54SIM9GY O?Q0[GFOE/,H<?,2'K)N #=4,=4
MK_@VH19#9O1=2;$<!PVQ8=O?J@),Q@]+M(K-1G3<F!7&]58("0$=6]@>."(L
MA]8A%:P);Y$-J_DOJQMK(2[KZ2='?U@[PD \6JN3.'ZTA*%T'YP9?:S-NF_*
M9\8V-[$TP:UCN[@QQF(5!6IRZ"',Y+D"0%NY;SGAF,%N@ @.0KK8$ME"!>_@
MM#"TU%9)6ML;Y$RV"KGVAF:^+C[#TR//JEFI2M.P0N3ZOY,U:\L4MLY7PULY
M4&"J=8(39P%H<IU_H5JVAD!8RACP'D5$,'#Y%5 G-LKJO*5FM$1/#LZ>7-R>
M&M*'C+#]QJ0"!S3"66U&CGX.9\T<07W@.<^-60<+0P3FEG5Q=Y*+6VD&=;8)
MKHX]R<!L"/01>$*,GV9,#C,7]-;PJ3XVPJ/#'G-F7!.Z0>"BNDG64V*[)21.
M>-4UM[X7'1?IX\NTM>!_.EI(IEMLB?D5KZ5/28QV!<$ -G=?,S.NL6,:5K *
MA2RFB"HW2TOQ:*Y#*DC@BLO<;["6/'7E->Y+"@FRA':]@[W5U099SDET _QF
M[9,<CC0O.CV-7F:&9LP-J7J#F:I0:D6]WEPI20EBU+[PK:/^O$WO)"3+K+R%
M*BCWA*C@H.-++T2?ZQNM*](VUS%@X(&%6J15T$'>!9(MT^CQ, GN7?.J=2:&
M$7?&NEYY14I2Z[/C',??&>%30M)%TL8W>67N%K6KC&BB=-RK$NLY1ZS"-]'U
M2F;22^;IM&6/)JLV/YYB2%!%-U7,D_@W\LIC[27BC):W@1D[/47,\J'?+Y1B
MBZ@6VUOSP2;V$;2<4M =:4L6#/35'F4YUGM >AII,UI0UAT+[$5#^D;97UUC
M.T/7]Y4%A0\TL##?+ LC2<D%205PQ8AR>KBG[[*.Y@R#.9*2[(,##;_#,U_L
MO!K,JTI23#9D_AK+">Q"")CCF15:C+PM&C*=:C8:C0*RF4\R/.D* P\)MC)!
MZB);SZDY@39TF8@XR_C@T/^W-6;.8N=?]KA17(>;F$']#'E7@Z?K8#^P?IBI
M2/=>LS&0BJA  .GIXLUK91"ZF!592-H^&5J/P2&)4Z"!*77'<9Q-CS@>K;]O
M6'#@58BZ[-X!7-L90<!@]\9)@4"G[W7E@,!C@H]/.8.#X;)I/:&YM7S KQ\O
M>_@I'2JU]NE8A6ND?TN+)>G^6=$893C M"D.T*),*_#1B2NAR4&#$O:29FP^
M->Z>8L42%R8=94TZHTTPFA3:0$FJ;9/SAMN3W>'>G#)O-O/V\I1Y._3,&QB/
M;=LI;JK@5AF!XCZ,W+"SNDEZNL5["A.H]'\K,:(P%N^'\_GIQA2>8_R#KR$'
M+=/6TLY9"&&HQRGD55# RWZ;S'Z4#/RL1TB#&"B3X@ 0HH=UID@+2AL7$7F(
M"+/ADW[[C\TZ?2A_@"8;!^H>4.K!9B#-Q\5^<=JIT6/SQ5*O:R1^C%"0/,\F
MQH0,6BL!;AZS))1&@+G=UF76XF^DD 18!6O);=F(AF,>7*X6@*A PN81M =I
M-F\G52\ACIG;)C)S!W @\+C1D.6@\=Q&H_I*%JT_<Z'R@>L4VV$IGQ%R.*>?
M(EMN#C/T_I+ M:3<MG\;'L\4?6_SDKJ#8B3L)3E/,PGL^I'2INYN( Y)-':1
M8*Y'FL@-MYZ-'S"FHA56%%D/KB6R(\0UC=P8&JCU+%QHJ_!R #U.3HBF]W(8
M:Z]O,@)H L;,Z90F''G=8GZV/R5=9O?&+*>".9!2[3HI",@DR"S0=08(U93"
M!,0;(R1LO0/9ALC[B L3)DB\Z+]/84J'!S8>X[=TTM,1<3/Z2X$]C2;PT"5%
M3?FQ<Y 4YAPQ3P7$P]L]K5?_ */LS Z8==JI4_'-=X15RYA@T_BN\PXP<>5*
M=H-%!6_4L0#4]ZZ:[9OO/E*18S4M%B7%Y28 ^D/FU&PDG;ST#62Z5 D)3+LF
MG:X 8PDD;T.TBF0U-2[N?],5Y!QF];1C$BX5JFN!MP^=?<J-6J!DE=]0LS*0
MWA8F$$DH2)H-Q:. (JFX5A"4)%0QE:-YFB>B3KW6GA'+T:T*B9W;2-V3E4R2
M*@4<Y-3Q_&(2F9^=^OZMDYZT@)Z-8$5M0/*KB+)8E#IW6.\B8$',$4&\IAD1
MIJIN"AB<7;<Z!*94/!+R EW*F9>C34L4XJW+<P*EE\WKA.TA*85[ DZ<<&Q_
M ,HD$&.^%#/&-70<7 N*8%-E#LEW[UI0'COT\J(DTQW>*"OD5*-%Q(P,I#LW
M(&$FN<PC*J^WCX-^N]_*<]^JNVP85!GXFBP@98P<[)^N57(P&3]*VH/H>"R-
M:*J:<VK->$[.H8U.!<(,7J0<!.LNZ9W@HIO&E[YITCEY$5A ?6=M>CM,#:SX
MG2\*X[%&2I0C5]),H)=TTF(Y2*+UJ_W4^[9T-.@1L_F.)B\>E@ICSC*=%!9\
M1 7%9E2"DEB#M_()JU4L@-^ 'JT/&U$!$M<0E&=H1(,YBQVD8A;$9M%V<W,/
MN4^\GBH'E+#!V$/WE@<G-@?V1#;'#<XF]FX29%P/_/.0&(/$%W@\=JYS> BL
M)'%6% [TQM<A_FU"N0MU?@LX)I%_@,/*&^/LDM^(7/S\7&W?H13M=W+ @S&7
ME]/2;"Q+=(L(09"T;&O+:$P07QR1) ?Q>CHS$HSA'!#'=YC;QO#:,H5&&0V5
MF5OL("U#6H;W41<FR;NT)16F5Z(VIY&9BG&=^1_ YT>PT@2X'6+WS0\*Z<O'
M!Q*!A6V_>\!Z<IV,@XV$AM2!-<"AK=T^C91NZU*:.O#"A!$1_\KBUN>TXCZ"
M2T^[QQ)S2HS8Q,BK4V+DX8F1N#6UHUD$<7 6;*D"R2F=*0A@# Z"W-M$4R3W
M[7A2[GL'M/OF.U^HP=ZP!)<@;7N+0BQEZOX@FFS=!<Y%D':9%H3LG([^67=-
M14I8_:SEN+GU>+A+L^O]C$:+>T,2&)*6"(U3^3:@K4,'^!;S8J\ %P<HMK38
M""K'AB SM@'%I% SE2S$((&797='&*V.[KB7#0\WL0H(G\<Z%=C=*Q6DP:1/
M7F;)*#/Z8458>KMTB$P-=97][4"#^L!Z4<WI.PCF+#&:Q04*#/D#%=D'S#A4
M!2V83LRI"PVLV>IK+>55-/V"C@9%BWXT"[VPU%LSWI@7"[.=62*&!ORGS; B
M^#!B[3!6$PS8*?A@H,QO4R.2IGFWQ)B6$2)&ID 9!%9<TF) T#&'^]9JKZ2W
M,LME4TRP4=FQ!)[S?9)GZ#M'REA$\ CX/\:Q*)JKSUVFW&0OW26RT7.@ J]+
M.597$A3]2") 5=_-\V7Z)#5"<L7-M2A,GC+4OUV:K^7M&"]X)XW3X&L UC>C
MFRFQTV=[Z)W"R*6)]'/@!G@59*O+E%_J4S2?/X=*&;_-W-IV15^)9.P Z#AJ
M;RF<#*DS8(\ZQ:D?%7K5L0AQ^9R!H .B6\11M,KJDVQA:C-7Q4EPR?1/?F<\
M"!5]4 SG%)6#0_H7RR7!X-I[ARIB 7S]8(V-N-A5#6<RO+)[&=*Q2_C'4E)O
M*=#$G]KE5?P*Y_8KA*MRUYLH&JP*RLCZG)#^17]L*$HW'OJ2<2D_*/NHJ-2
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M]BIV(A6H68W^Z5U10XHG6MUS:_YI1JRJIR:KDD/U-!E]Z8T.MM\\ELNX;_4
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M!=ND"JR/+F!L_TXM=L.MXMDZ3?-C5C%&&J<INCC6 RJ#SK&IPN(X22,O7AW
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M**N1\XPSKX_SL@KV;"T+E5SE/C$H$_W,P:A/\[J4JFS'&:V4&#@9IER+BSI
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M]S]9?O_L0WZO.<U3K^BH=9-H4H6-9'L@E=#[P9_S:9Y6'1@=UO)A3"E"274
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MIT007>O,<5'1$4]-JK:)H3;.:-/BXOYM4_W@FPV[DL[R[)DMO;I,$(QCY70
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M0<%Q.^^RO%68CD" VQF)"YAARDN3HS%*\_EM5,RB<0+C1B)"N(G@8BH>K(Z
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M12;)=F0J)6"MY#]\"=S$1.S-!7%VC(;-D$H^$B)'3)RWD/8C'5 4W#*:)::
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MR+G\HE$*NO7-XA_*V^8]<XT8&2[*74.DB@>JX]/1@RMJ87;2.TDL+4S1 +_
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M-MDT51[2-.OJ&@/^KFIWT:N>6N.^+#->\5W6\)A@M2QIF,YB(RA$D<3,L?)
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M?!B4.27,J&RR[VA+D:Z=8TQU>R R$,UVZW! H$C4T6"WE[NI].1W<_F8';1
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M/4)R.S1N%D%D_9J)DB&K[V;]-DO"LW><O/6:+#^.X"8BM$9(H/:W)(REL1<
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M)?TL*X6N98!E#FT'_5E:B+]-P<00^7JWISX?P>:!DTC[LGD!GHS9M^,T8 (
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MV5"[US%4QQL,U1JIW4'ZT0?;L@^JA[K\PKM%.1%]PB;$*GWX@0^[$_R3J8]
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MT07E7#4#5!3_1>K;E&N-=^B<(9B+"7:MMKG=>'+(=UQU?NSW[_4I-G0-G."
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M&C VTJU,340/O);1;(2ZD33>B8K#YQJA;YX-TW!2!=S?B_MJ=.3%H!VA7[?
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M9R<;S"=2#2JX4 NQ-8/KT@O3H)Q1*%+.D/:?;$:XJWZ&F2P+GGMZ>6I^5XL
MZ"UZ![J5E7NE!90"ZE \"]YS&\XLV!PIZ/K0WM-/OI%M("/U"VK>AD&+#/S*
M0!TO.':WZN](*2+M'38"F7,X"S)]Z^98&CF$$PQ8!%DTYR2)TFS5JNB(692
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M!V9CVXL;YC['L[X)(L!03GS#!M+2CK0J!TA%2\GHI+H7VFZ<<ETU5MJ9OFW
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ME/-1$"?I,\:V4F5#17$^>K 1H@TR!HVL-".H!QELP+O-CFNX$'0SLZIM*Q7
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M>5JA^2VU9]>;6_!=$=Y%.=ZTW1%CVY!?D"7Q!_JX;5:_;A.0+;\ED8'FC+<
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MI8@M2/&BF&Z_^8+:]"R+L'5SV:F6ZTA+RQTZ3F0R126![W[M&TGVC2@HAYL
MNP_MU>AW .2=)PRG7Y58M-8 OZ.KWN,N_+4M:=2M=]V:@NU5:"-+&I]526HP
MNC(R#;:&-A5D+*,H-.TJYK>(0<@IQ>GJE@UNE9D+X1$4D7M/G3=(2_PIL076
M+ORC2M"^*4H_%@_.ZMD/FUYE[[CU:C6%M&,036"HBG-:P7<4I_.X FV#500.
M8@_7L+0<I3'FO6.IXG1U1!TYN8V,)&FY%%8:@>E9?:VD] ^:+;;CQM.7RVG0
MZY<+M.+LBQ"X]"LE^@NW4=W)W)Z]4]>#*3I>EJ3I-<QTC#[1I>2WIF HX%Y#
M#[A*:X7XJ7U+M!.J1"HT=.(BIJP&CZ-EG"\<S$UE:I*(96;PW%QB?0]B6A8&
MVRG,!'S)JXLR-WCS"L9[4=;+K+&D%0*@F1E?>JDBV)U:SEO/T [8DKO;/$=W
M444/,VO[^C%K.ZX#93P%3G2@')?1.Y#_JMXXI[+&-L/ WA1C?Y=H'4N"D$RF
MFI7=8%^C<;6;$G7"1FK2:LYK#$D@ M#$'87B2Z"'-QPYT4[7O;8GV6[<T;S]
M2T6C[UJ/7R$:TF":$FYB,D;0ZM7M)[HO+;;VO[,5,>4<2X898Z(+3H1S?V>,
M()M,,B(-/: AL.^'$CZ@>*.=LJ#\D45=P_K7W35=*J*'E2ON(G^-/[_N[HK[
MI5RT#<R5K:WM5^?W(A2\EKMP-IX338EPSNNJ!A]I6,O(YMZ0H:X-9NPSF-J,
M.Q]LF<'M9H"P5A%BTD]YQ=6M'".!#^!,R68(OX>5$8J#%U;1H;(NVPI.RQIQ
MR+'BW2??KWTXL3(-W:46")_4Y*@!<(Y2BM7")KG+ [J]IL&6ZQ1(!'2(_BM,
MM385S&F4\T5@3\BB"F<Q0ZAQW8@"254+Q5-V\X1A&)J;-8IR08F%=& *"BI
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M);$@,2L&H<8ODDLNGZ0H*S7T&WS@G#NZT \E-E]JY 7W-W5GD4>3D=> 4?I
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M+OP6U;+%9]+X2DTT9,9M\I$Q)B-5C^NZAEF%#D7\'O6ZJR1*LGO7O*8'/*0
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MHQ!TE-G0_$<[JI3UQ4X"5@O:+%3X4>9Y>85FJ"IP_\__>/EFF[$(1Q1SM+Q
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MK,:0'S5_\[9QC_6[B^^&(8Q4;H@7^H I4]4O<7:+)I%-=D7X1@Q.C$C-EZ;
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MI[ F<V]'[GI)6GAP5QA;$'M!$L&'\&DQ%UYQOQ1>.JT]N)@'!7UY+68R+[(
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MO?HP??WYZB_:WUR#&<Y05L)'T:>5^4U5(%7OLH*^Q38)98A*A348;M 569G
M"L!6&2!?:1^^W2*XQZQ6=5?8;'@XB61.B: <V?@+:G%EJ/?-SM>WWQ&CV<BG
M:+#XLH3YUD@P]7T<3)"R9;;KD\*,2L%Z086>.5]E0*P\],Z\';R'G0[T2=N
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M/:J]G\MH)APZL5L8@8!YII&W:F[C!&!MC_HCI@-D:[V8NMC6LYZ%[4W6Z^4
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MR.BR?'95;N,7?9++)T+4=#U_K5QJ#M^?@_#S+$/OV[N\>FZ2<C :]ZF:['A
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M)5ZYMK#M*]AWX!?6S@_U \4&D<Q]31>42]6<,N>JI"+U;:[MQCMTSA#,Q2R
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M+>O: 8-7&3./D^Z2L6TGTVDY7R1%QMYX(@/JT4["][],U:)!CQ[I(BA2N,7
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MTN0RSOE/"90&KL;.&L0<],FR8N"+E($(R#(%IY3W:;?+B_N*F3%"L-L, ?,
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M+Z[:'$[9*66/]!19]F2?BR_X[,SKM_JM>>6&YKJO%-^74L"G.5=293>_WNG
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M)?GV>9.A,2-&8PV)0*>1N(KAB:FYP$;**.GA<'O=.9/\C@/S&0L8F2$$W&+
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MZ_'B+Y+&H3!9N7!T6HCU=3+:NFDRQ^("'3:W99OKTY<6M2LAY2E&N5M5U*/
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MN3-U&=E0A_WC0N72'EO>FA(#BQQUX)3?^EGY@YZOYCVKZVK%J[P3U^#C9,S
MJU#L9F&[A=S;22]T3Q V#+__]\<@/7,=>?3XO82Q/@=#3ECPD!,4M^;Q(FK<
ME8QFC4UUU)*Z7\5L\A- DZ^&8RYZ_A"+,L);)CQY79(0.[U>Y#*;+VA1!#Z
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M$O]]L<G[@.MRQQ=?QKNGW$&NPR:[?YL-+BY7B*6O[>Z'LM<,/%?@!O;S?'*
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MA_4D3N:DC!@S'.5YR4 (,BFJ.::IL*9)E,4TS3 ZUFUEX0YRT$UE@7O/,>V
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M:[L%]3?YCCM&GV!WA7($NHQ_97T^$8EI2 %NK'[C2A?YWI@#=#YJ<836Q&F
M_T+U@^@1^). (0EBZ7UJ'0("[TW,3%9TP1-[=LVSR/]%$F-!C6*V; UQ7_\-
MHN-R8BJ&%T? #_S AQD!&W$*XRM'U04ANK$%VW:""IOA0KA<E-4/4JIE]<F#
M9=WADR8(HIC^R*RQ$Z"0Y@,^&J7A/5<VQ1P?D"IQSX>G51-U"[>7NGC6]WXO
M44WB78R*QX_G:4P#R4Q\@1Y3B*\T#=5,P3JF=]3<1!5:V1$)?5G7*UQ?]<4
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M"%#G<'1A,L)B]=>U844:2VY4" =&+L:RJ-HS6IU6IE+$Q?3>NTWC,BFDS.B
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MQG]R?OJ\1-6$+@ZVQ/96U'73X-C%1/?FI59!J5PO_Q!YN[8=#/=>=5UP>XQ
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M>-MP-U(U54AVO/@3,J-"1G&*1<W%FW DP;&&V6C7 .PDK)<QMC=_=4+B=N0
MGZR2>+RY85=56__[]_O @Z6@)&5D4*C@2@=ESAP&8.]J1P_KP,V.K;&6+)^N
MKLCKYWGEP4FKEH)ZY[:(,*Z8;Y54LA=2P4=PLE<?8HN+Q@UT[4^H=U9$F& $
M.2!K/3=;;_MY)1/I2I%ITK)L*W.9CO^M^E>^)V,0\"Q-H@",AKDBG6&#?<4F
MLEX=#NN=#[BKX8S(MWF+,)LL3. ,$1C5<:W##5@YB6^ [@\>%]@OO#KLE836
M(Q5DKJ-,5X:G$6';IFE+P=BHGUD56LC:W%\=0SL:[,'FC='4H=;+I+VL*2$+
MRW[P2-ZG:J_B=ZV!.;AIE[,^Q\MA(LD.1DUD$6VZ+?QWS/_QWL;4UPO!&;U:
M)D"F[F$V*XED!106[#\,MJD8VW. T/=9O*?.XFV0,;O/XFT\B^>.8GN]''+^
M4))A311,%^R*#5<T/DQ MK?'E3O?6#^X1E&VS;62<F1FJ]:Q@^ZIOE&TCKDW
M+C&)-!=1N%/.=07+G'FT<S!Y0[DD-]BT:<$>#[6481($O%CNJ<6_;(Z-7 MV
M9NM#CRV8S[>2K]1R?OXR*I6*?$63JC219SZ%!-;*YOW\T\'QFS4WG$ZO(^I\
M) W^,FQB>I;SUKS&-FQ;#G#9M:=#'2"PV^ZP5GNJLM2UM-HNN38W+5EOE1I?
M*>4E!E<0NU)(K.(IX/,:@(Z3<-2BJ$R**&Y$+F8PVFFNHFYY&:"?CXTA+C.Y
M$\#0HT#@/])TO /_?YK"5IIS8 SUGHXV8*;<CN*/E2N.L85B\;W.1"&\2Q%\
M01O5W4UH, EN[,9&6A8E D-8,8>\5#C-/E)"G&8.!!-T@=X)KXLR=;"$I80E
MC+$])8L-QXP2]0M,\4J8 #J1%B'$!O:NC]OV:5P8N9$+S/'4AY F/[IPX*XM
MJ5>3^E#&<&QFCQ1;2]PM(V+@O:T;#$LW-4\%G)L1DL6-5UVJQ= +4\G@".H8
MJE^- H8M[Z> %QU(EV^XJGQ]V_3$)"\>6LIF28Y8CVGG7M7V/;Q!MOA"RO9P
MN'?QH6Q$F=U9'3#+WV!;0QI+D!GX(B (U;]Q)XRI@$IO"A5R3":U4H$Q(;!,
MX@6AVP%=*&V<B 6>J2$KCP?>A57Q'4S3-)>Z:+921\M'OZXYNF[U@Q6*7W..
M09_&D8+]K#'@]NGF#!K(S!\[V9U5'*%+BH/-O[<JKR1NTX@=%EB7,"U'Q<I3
MQ-(GL-:T$;)H,E'%E98MH!U27^67<C <N>43/!A>$DP'E-[JLIKZP"*QUI*Y
M5X-]'_[GD.3MU>"(,*E=<!R6<B-OL <3&H/MD:P7DJ(8;K#)4#_Y>\LFP$[Q
MZDITAU)"W\$5[OZB;+ ORH_?$5WI6_!$B_+(O@7O/OWC_.KCR<?31[4N<%?Z
M]Y<W*F!#*=ZL$K*Q811 %W$F17CO!? ?PJ=ZD_169@F9>WF1E56+*K#39QC2
MDQ84M!6H\]OYU9Y6NHHA-8[%*-5>B\$M<:_I#T@IX^T/?6]O=V_?B=@;O8%+
MG5N4B=RZ-@S]<F/.WE4#O-8#=&#ZP/S_S.7757I(83)5<DQOBH@#UXJ9JOJ<
MKJXJKY:^;%^R[0[88X-=E7NPQQ\*]G"F0)LCYEQ+W5(!IS@?C,:HCKXHM]LL
MUI405;B6:^FK1\7#7#:;ECIR?TLCY$L&LX-@OZ?:"-EP==F"(27S0HRPV(F,
MJ+]=GU+.)J/0-54A>!(CTEY2SD:ZCR8R;K'QA(1<5/% I,V7&O0-@I6E2#&"
MW49]N&.:A20R6&50R$F&10BS-$%< Q,<PHE$M;!3N;K?:"8G)1P]Q&A7ZR]J
M"9?"2R]2][1Q=ZTLM;:P%/Z&R+HX^!P@DRY5)%GI1_DUF JJ3Y;%'56B6HO;
MAI-A.QK6F)#U*A6N6*\H4\'E^8W*Z6LL&%72ZU<LEXCPCP)8C(Q:27:6;]D=
MU);F6\[D;23O?%,>PTZ.WF*</;E%GRU&:QL^FE1<93;+E=HU#Y -;'X+-/<Q
M$9IU5M[<P=,8FG>[#@N.BZ(T&K=%G-9(IRHJ4ZI'64>BMKN]XN[DWE=I&'6F
M4S(,_D*R0_@05CZ<:=91_%E.H%%UN-KB@=W0M_+M9Z1U=#J:."31X44SM@PG
MLFB5_\H>Z;:XNI/Q-0KJ(7G-BS(DJ2U2&&>NT%>(-%@NIU3V2YG?2L8++GY^
M-D+<;4&4+@GB4KU)M,54R8I&6#FK:&.GW%$4"1HLJ[[-F >O1V05-&:NUUR5
MB2^A+EU/2%N9PI=W&^ME^@^5Z;$[,KT_V*5\E_;-V]R,9(>Z(5C89=_(M56'
M8!?I)S#4>F+EXM*;\)HS0SA9$GS<MNAG!U1OVY6]Y[(U<4=VZX:!*>9GG8S%
M\T6!O<J:=L!5%5TZ(?-!Q*S$K2\,1X"BQ<C+$<5&0MV-S+X)=^PH%&LT!YZ^
M0RVWC1L_X@8E5FQL)@G"2%8Y5D.5<:$H$2D&UC)$E41ZW"#[7?;TNVSJWBZS
M3@5-PCEVWC9NJVG3H).C.F=^YV0H<D>&]@='KY=H:BH@T753VGECFS=<:"<\
M3Y%2+2)X+JYB-%?5GTS<]"Y.1_#=#6INC_@JTZQ1_;6<+PT>9]/C^PL4K2<A
MEI?2S57?&/A-GU%W):.^MU&@<9]1[[O.L]K]W3VUJ]ET":;%=0KC,E$4M\RQ
ME:7SC/KC(>5LF:E:!M/QII4AH-;]J5;MT.AUEA+[8B@95+ *U]09R,#2MHUV
MHG73G<:>VV2WO\A;(F/$>FUT\/"_"ZR'!6?$*1MNL!#:#!D1-B$AVV"&*:O<
M6B(*$B/N <3=!2"C+3XN8!>)4T/%CBJPP'+8AF^\/KT>S.N-]R'UU)S\L.2[
M@#H2^1?4%:&<2Q(Z?6M]R5C?EVRW4&)[Q8*'53'&-J]=^F F5P]!A2&U");Y
M"^6@6^KRVTO^7#_&G@H1L7X':@9;75PZ [-2J%V-4B=B5]0[507I4B2NOY)>
MEBBTE_*Z;JV'OMNNU)XJG;<4'R&T8F33+-GM A.AN*]0]-Z6(\!MMQ9=:3U4
M+R[,S<7EJ0.SL>W%#2=;%61\#\!0H=C@#>LTM[4$FXHA6-4=W-4#-Z$"15G*
MOH4?8-/1S_6HFUIR,@T0I%1M6)9T2*&Y8\Q&S4S7D;#AGM6 NA9^KK(S<(]<
M!B4-DZ/4J$(277G=KD]44T[3Q<7FGZ:0>FZ0)'2PAB%Z$_@M$_,HL5@2R::"
M!QXF$[KHJW94<Q<06:(>(3I>, I5F$<UT\#0N0%+:C)J[:.P82%S8GZ9293:
M?!K-C>& @LEV8T -469( M;2357K4W6+UL=PEY=Y+ )9C2^D%D-C$^3_4>V;
M7;<[G@H9MY;=P9%O/H/L]*03A]'&+) 5AH7W.\U5:,V5JS:%<^OIF'%QUG7;
MXDS++S:ZLVL3&H6C2B5/,C*Z%R&!B"5KX7&D9G,V1DCA*?6!BON'.FFI'/0"
M#*T=M>:KGM<58*.>]^A.U<W!LA :F5"<'N$\S =U1FY8&U^,F6NLZ9=I+-@*
M7:P%@KH@H:#:<1ZG E NJ<KMBMDO()E@C5 _RAZJ9-JBKH,F,/Z0+H&/Z,=6
MHSD[58EA(SNZ92R];;]:7'XPCQT-W3$[[CP _E(E*'4[([Q=<R1M1'V\05:>
MWB"HY\U!F+;?U(C0?HS"OS#-WTXP%5$&IGU>>5Q::AN4A:OO2/=I$72E["-J
M!,K?!P)=*NP7R#?.=8LD;1ACMS YQW8DZA/8=J!$1:[:R/!GL 2E3O..TSA.
M[[QRCNR)W.D/'BEG8&-;,X.K9S@BF2WY%CPU>)]3RZJ7I@6N5N_\=$81DWZO
M"$47^U":@"7\D5M=%K$2+*(UQ@K.N$"54;37@*5J(NO+TVBKXK,SV.*@U-:T
M$%]TX+PVE*JTB-L1ZO>N9* N53AWJFP-I;@IN=8)N*42\K88;*O^2G9(/TKH
M3MB=E@[53#(]G32R3;RN%9]KRX:B7<[#LE?::K!3'Z86P6J]52@BS7,RNZVT
M&;:NRR)IW.[&&H.C6Z+N@9_CO*FM2Q-J$G%ZA-7CN!;RWV5$C6=@9!'CS&P>
MR_HKI-E$)-%_A.;N"YLM*84!JVGR4DU8FM>[:&H1(]5T7\W-\^NQM,R^.%S5
M .8#^>O>">'N\+3>L&W1V%QM&^0V4MK6-)*M3C$#E^'.M8EANL/?MVQ1OP(=
MPBVM[8Y[M1+0'OWB#/IEHTQO/?KE)?!);%&C:F1%O4U)'P1B+@(X2[:U^\N=
M$ZL6X."O)M2UF$RBL;:T%PTH)FU55-M\D:VR3)P;3]D"7"OV^TRS0GIB--9=
MZEE/4GPZ)&N#V:1 ==G,>Q87+7ZE$=2,5PG2$@RE>%LK028!U>/UK;.WD9\
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M)7EK:K]L@$120AD$.'A(Q?[UF_>13R0H2I9%B.;$1)<ED4 ^;]Z\]]QS7 .
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M*=E\D4RY;EK=CWSY*N<=9AO*AM[%?D*?VP+@H+STL8I3-->"RU15I'F-8'@
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MS9+TR$LF^NT.4Z"+EKTUV&C?JB;>43Z1YNXZA SNDA&X"N]K%E^$JNW4KN[
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MM[%D%H),^IX@-VQ/?7DMFT]S[U*;F[&:)REBC:XS<(@JN>QF!'JS^7L-62B
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MZ'8U!&@$::V[8300_&:?('5DXR'; (^>5>0ST3M*O@]T207F<HE?<@MIV8(
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MAZ?JA2_T"J=\-2?JXTQ9#_VX'1Y7Q+%WLV9;6SN>IZ4<QJQ\L1(=\)RP*U$
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MK=BY9ND8"7H8N)&L^!EK(J,G)&]^6+Q)E'/T,$TZ%VB'22)D16@KZ@XV"H_
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M<.8+7!2!#\"*HUNM$$'J+"[K9!RLM2'E\W*A]!;H$>QDX6MA#;+ZAXCD2D%
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MH<)_TLT)[P>&7$?4Q%-%U&ZHB4AJ,G'TSZ*\?O);>1U;=8DK16D.2]3PSDF
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MEA!<HNJA^A@$2TW5 >J>L,PIBBR:<C+HEA_TB2-]$E!05<5EHPL":@&Q=U8
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MXY.#\^,O)UNR49_W$\+ WMRP?W/.(">-CK+D^P;"9+#I4=*,?UJ^:TY0XR)
M'4'(Y;;(4:9<:9&DD4BJ/),G+4C:*,]!\W.186! VO/8B,W)$[!%30E@2H\P
MYT5T<OC.&)J0>.<_.V+V>PQ&VWNC-$6W/PX'L:5Z0:B;72C;=U%[W@^Z.#=
M:_3[5:E5](XXZZ3O=929[.IF#=U/3HR,W^Z0&'(<GHZ1<\->&>B%;E;*Y\"N
M^"&9N\:F"C6245T!6RS\ .;<2A#0H%P[($ 2B6W15$OX._^3X@1[4;LH"RVS
M4B!T1;,5VY $1A(XO\,+5( XV&L^-  *AX"Y$0@E4WH4?SX$::"-G1I<@]=
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MO;4@']G[(KP7FO:COQ99I6\,5NAAF^WG\ (-!]-IU<J%3C5=>.Q],9[.9F_
M)TS_(<Q2*?CLMO.W7==DAE+325.7 JY*A*+7$4-4GE;4(@[]A\4+*Y\@W72^
M?UA^[J1MT*FPI&_AFXMD27<T\P3RH!1:\,T>!&6K%IZAU;/0:1+.1K Z%F-O
MF5_7^=!=1V A;X_ @.=VGKQ=B.RB1V-N'8X/E#5H5C$,$;J.Q"%?*.X@+/H
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M=JPKSX99!]T46Y1Q.XDNZ;+,01:CFF/\0D5.5+1;\6Y9'&?,C^42K%)(HJR
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M5 5"0L^V^H_"YN8B26YFL#W12"Z"G%)4.=?*#R P?H0C.PBT%DTUS3'&H^4
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M();GS3Z;OA:(QQ$C_ $M3)%"A/YR&MZD<I:#C^<?>LQKO**!7T[R+9@,*C!
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M8&MK4&H7R*,DU'X8J?;[+Y)4?46J[2<EU6*KV\3UMWJ[>T^+>MA[$M##_F.
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M&$RI3#-46C_=<AA=6%QEFT0OF5'TB=L;.$:I,DKH>5?'K6:-,$+;7R!7 'N
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M0PW=A:Q6#%D=NI"5"UFYD-7SGUH.O*E(X;T_OGR4,^M%Z[1VYD# [](N2_)
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MBEN48YW3SQOL(NJQW>T]/?+^#NO@33__M+WSYOCFBO[=*,R)^?VB]HBU96!
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M\1%4UM>TF7\5W18.'9)>D>)]$ V!@XY/+E^Q/%D)2;_;VU8%GPJ*M184?^A
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M=%R%J%DTS#ABP_/12'J2XAHA%C?1+QI&>5:1'K^D3."EW)LU/[<#%\)\X/]
MD'@BSC8>0]X,'R!ONE1^'<F5$;UUM 1&-,H3!46NK$J+W=D.@5X54$Y"S4FH
M6-Y&8"Z0WH#8B#1+#,"BI@41=_(BH\2/5+H))\\X*2WE#XN4'L6+J@L:3S$B
MA=*GD"BJ8YC2<Q;T"7L4]<5[D#@Q:IXEKD7(A]@[30MT-*QXT6\%S*BI3%/=
M[:P&)\"'S7>14/9<C[&;"<S&(],6+3O!S-8=OAZIY9(!M-2J==PZUFW^6N?)
M:3V0U&'_FW>TENFO<D.[T-E<Z&S?A<Y<Z,R%SI[_P-IW>3V5 TN?4YO7ILYK
MJX$?&"LJCVAKIG6HX6\4KJIDAVPHDPR#<6",25PX()@@)"$('"]0QF%BKCC&
MD!6\$NVSK3>+FLQVX+G:1E.VF%3U#Q2<&VVV6M,>LL/\"%X51IF"<./%]#8:
MN@D4:HPD=;*%GZG!=: J'9AZV+J/#\PKU*,DPW3Q4'OZLK:KM?LN/\J2$ML_
MQE![T>XEPT)4ZV._QA%-"._''D8;_2/[#J3<S'8MM2:[[3]('*BXLJ-=*ZW5
MVI<@#H%U*D1K+]I@W\$9&YC$-<YR++.891S0;RG+N#99CFGFF<:AVIJ8YM4V
MQ<K#3 :U[WP^2QD%3>B&LRE"8L$"F\-[')M:I'!Y@GR6M=%\<3"K"L<X;_E3
M>LOG'2!KZRUO'&JCM[QE L(AFK2 2(1G4&S5QHD.Y.0P(8V8D .'"7&8$(<)
M68-#S($85S[$6AN)TE7,?,OX6TR.)@\MB\)@UOZ(UH$#4-W'+"[(M:KS<8C.
MQWOHV%Y_Y(%#&:W&2BX4YACK08SE<$0/92P7,'.LM1)K.4#3BJS5SK!:EV$J
M\!+3:,[=N3F</>1R-N2I3+MSX;O6VU4.!'4?8[VJZ-OJC&;(,IQMKGZU8;/G
MB/$]8%)K&?![R.A[;8[^'3@4FI%9TE.,XK,K(:?#/$FI4#T[BA% XNJQU+K5
M8(DG9-:&@B'9C'%=.@0[!' BH!8JNE84?$HJ5!Y1^4@E&4:JHPZ5?5%R0JT-
M7--=4$^*&A%X0L89%DSI,CF"S__.9:+*N5#5*F)];M<T,6.#YUAC*^I8B=$(
MK89; 6_-AZ9*RD91_J4Z@\8A+WY^1ULK'I90F?(9&XKE-H>+O\[%7P]=_-7%
M7UW\=0W4"(?+-6I$S< YNVR?68/]AN8F^GL8W6U^B.Y4K==E=E[:1MO?P6P7
M,(#9%Z]=?6XLU5>T%^_M#U@';-B1LL%!83PK2YUN$$\=X;3AF.YO5:\$=7NC
M.]?JK:&^8<514+"K[0 @I5%0 =?&^H;M]8D[$.P"]GUL!]W+9F%RZ#6Y[=;*
M.;>V/KAFJ0*CLYM%K%+6J,M62>?0JL@W.:/;*^H<5+(0=1,YI)XIF GV2)#(
M%RK?5HJ=]_N][8ZWP3H7$7N;R*%(9NT-DQ\ZE&3!)W^A4GG.0SX6B6.2Y4RR
MT]MFG:,@D-@$Q1C#-@%;W(#ST,$A"YY!$\\'*ZY4#956Y_AG.?]L]P[@@!%W
MI?Y8TK#-K., CP7KI,++BX8%YYQ:N* T=:RSG'4.>X..#^H9<,[%C? FFX:6
M-=NSS6SDP(V*%O^=P^!'IK''8X'NUR0.L90;C)\4CI%W$N4&>E-O1#*M;_MV
M;'@'.E2TN$+XQRTYD'B2S=Q9<8\MOZ4K1[U7W8D<]N1AV)/M+8<]<=@3ASU9
M@Q/005C-";BD0]XK/@\7-$ZF)H"F':GIU6?U %0@5 S:J_ZG!-:,IK%0AE03
MZA5/7MV V6?C7/KD Z1G5YM]4ARL-A[LB%IV.J7WK]2$L.BHBN&U.(:#'G]:
MJ???^=$13;#RG"Q:8:H(MQWSQ ]T[-#T>Z4G968^B1B))#$=%3%MP#3CU2UG
MRP:">DT25K;#++ZB .*=3$6/L;/1/2LI5<Q2=Z8.9N62T@B6,@D;YO0 1$%@
MG\5-<V\76S?BSH?'P(#$5V :7&/JI*UPQ6K6E/44,@E;>X(PJ2&NNI@J$@S%
MO0/@J5D\GPI2%$AC/10S$+6(>B3XH;T6O8,6%N)]C@U?NU1OPCV9_ 20A\A'
M8/D#I8!J"HP1&L;KB-ZXIY(4WYT<;711>"9\L^GWTQP;UH.\/(ZF6H"J'X[A
M59X,#,L6UWT.Z1*-]RJ^/A<^9@6(E!V-1>@A; N[VN+KX/49,7S"@@C%05*N
M-B^%KH\"/<-T@R[(*C '<A0(Y: \,R M-"TI7CP%"',;!;<DO6A\XX2'&1J*
M="C,V-G%29>=\^2+H&^/JAD3Q:,7-8JUH!S'$QERW5\E91_R*1 ![4W8:G![
M&N6)!\3XA(>;4,<MW<&T3<J.85]%4R"7#Z9-(37;*^H<B'21J%-;Z[6+.T)>
M9\*;D,K095,4**@UH')'>B/AF (=+5/BQ; -HM%L8J:J5I9.4$HK@+3B2Q )
M( [@5E 5X;]O/^)_;SG,1S\2J")( 4E)@L8!)4/I9V,+:_JHF#O@0Q$$U1?0
M]SA>E 3X(<8<*1)G:8&8!2U'J[6@%7&Z;(HJ&K::WC!BJUE-#07"VQ"FIK++
M1GE0/!8^=MF)N!5!%"N9>EY"X+0\ N&*]35@X;5T4\IF-0D-GC>447-FFFH)
M;HGSO_)$IK!N2IQ:N+=[,Q"7M]5V/KHY'UW?^>B<C\[YZ-9 LW'X^CG-YB3R
M<A3O3K,QF@UH!2;)&M-E)*H*\TI,J=TL4V?LDQ6?O4BEU.EL7I2@$1GASO"$
M\I1EF7+;1(G*+4>3B0K9-&@:4FLO^"SMA<,W^WJ-4Y5:@U]I]UH=!%_>3BJ.
M!V3C,E1&&FHWVL0$U46,(WA.?7YDM%V<')&.1NI:=Q6-HFMK)GZ2CX&\*2A"
MW*>-E)K;X?)I1/I/,26P-HWO"H>L[TE!6[NE&</Z::*@$1H@C$=]UU[[S4'K
M%2V:"Z:\?-Q)>PO!#+8<W'WNA'Y')]!K/YKG?:Q-YY?RKEH1)O+%-D;)M+U.
M1W6,G@11\7:62L#<BQO3QRHG8<,8[&?[MS+%/X813WQ]2M*Y"_<57@W+J6'[
M-% /*#P:2(-$9%&/L7?:F\!O(QWP0S]%E ]A9'.;28>%U(A%Z6ZMG-S&<5PJ
M)=IG4FA'A5:@G;S*XPVWC9,HCW$ ZCM42U99O;8>R8,MEY%@Q)K6)XMX2(O.
M965"Z&A#VR">@RV7&J#W<#3C 9I:K_A(7@G<>=#;)6RG(MB,75%5!W1[S]N=
MK<T%&&RY7 ";;_0V<+SSK;SSFEC'91746$>@2\_QSGV\@\6)JC13[CYVR6?D
M-6PQSS@<<I5G,.>J;4;&:MW!7"A^+A0_<*%X%XIWH?@U.*8<GEK1XIIC?/(<
M(Y)9% IVBF%+I^'=I^'ML$Z=<D:W>W56DL/K-K.2WA".F;Z7F5X5-SF,F.8F
M& WH>)@CDK$C;$#A,GW29797FYC 08@T$U##%91];2I<H[&.X0Q["Z:43E46
MQ^6J<@GA#$)V-$( I,X)NYG(Q-<_GR 84@[S##.Q1N:N+H;V[R;8 5U?1VE=
MF/*:%J0T*$(#H537*)2C:HQ%=^:P[#@FB8EJB2#T0POCJGT'>5*TN($QBM:U
MWVM[O\E!WV%;S/[]2D*2?W58>G.^8/,($O>*-IFF39<%XA83B7,\,KP)<GZ7
MI1$52<-:@830,]\C"IV.&EUM *%DDRCP=;+PW02.)ZP('W(J&E\K::^Z2?AL
M!,/LLEB$&!5 1%UBGH\UZ=$5#:;/!I-353)U.*,?8CXC5R<5PJ!I%!G,K=7^
M^@[IHSD:<USA#>,9NP$5)1W!)GM$I\*:'%,K.@D&K+.$'BTL:CCH.^2.X8/'
M":&^T.-LM4J&V[T^<D@R;:]OK._P."5#8 =5RR/J^.->_MAFG5/J94L%'6[*
M+K0MYAB'QBDXIJ5X?Y6W:])<M&OK+DH"O\BES?3D37HN6!BIT,5%*(,'[A)?
MC=&"]\_G2;11OW(8 ,T<I5^U?>Q1>)E7<C(7GN0V[G<7J)_;[W8<H95[WYIK
M+<QBQ9:ZJCJK;V@!YT0'BX 6O0]U>2CD%ZLXU$93?U5?)J!B!3.,IGA4N0ZX
MSR%$5T6(;E=WH4.(.H2H0X@^RVGI@#CSIZ66]NT[*=E=@I6.X%PTH7XV%-F=
M$!5=$5L'%\JBKE54027 F5> #$"U]/Z=PVE8N>(,CI0@@!,RYP&>F;' ;U5#
M*@*[84=B&6+0*=2N"RI=@%;9HB*-JBEQ8XG&^3(1>*Z7QAZ5H#!3UE42%JA'
MBP[Q%\WD#F@TS^2?8UASP:=Z\[1*,?Y!"7RM8 87=M6\D'!?P$"_/(I3?4TV
M?NDL5(4$!3:DP ,L#ZTOLF+J76"-Y!8$ -,?Z2?F)R(M/H1\B@4(@V@<4:5!
M;,T@.=XZFPXC+*NGVC7HPL?X<F6!PN)*.*KPB(KN0K /)S+NFB)Y0^V5+WR3
M;60U!UHRO":Q)!,5[+:;<[:.\]H.PW.GAZ;%YU!B7/8Z(Q,!-///O>M>Z[8S
MZE"UF8[8$5@@,+)2V(_(8E)N10]KI2Z)1+61)QR 1_-$/$KP92XC;E7[@W5J
M-&LO1F'@4#V*%G_ V'UV''#9NH(A[5=_'-!&;^*3J]9M7A38MS(AERW5I4^B
M:&J*TZ,4ER$F&NC4@K+:/6HXZOI%9>^/HVD<Y:&OKIVOAC]%,YO?<AE0.&LX
M8V\EFM!YBH^"OR\0$\WB1&)V@WKXZ5?AY46_^_;PVF#K4/.:P^TH7OO32D1Q
M[=Y74ZSV6<<FVPW_*K0SE[F64BNC%'8<2L&A%!Q*80W.0H?I:W>SE47F$RJ,
M+5/K'.#FU6WEWOP67JAMW7O0[O9VF@_:ZHKJZYYH2=7V+H(C3_7**FD&A[V#
M0YSRI\N;LT\7URMJ;^M*XV81,NCUGYG*?= [B,JQCE^7)OHW4WQ_:Y'Z.$_Q
M)R9XAV\\,\&W>TBPO_WS\OQ@:VN;*;I_#ZD/%RGJ3R(E#U%*'A5)7"I9$4Q)
M<N24GA_5/(FZ7=-?<1)YB (D#'\-HAASQ!-2CIAI4VBA"!E7==4P' =FLC)=
M5<<H3=)YEU0>9C(P_:AE4O1DK*P!IMS(R.^Q1;/IEM-!D,>P*-1DN[742[P@
M3_&V*%;^M5$B*%''E,\07Q'WF)(E!00P=_\"A(K@*S">O$2HIHUY8A+<FD9+
MQ:.B(3KU:J\VF,Y&IP)LPLYP@W4646QCKO?40MIVGI*?U';[^:?MG3<5:M W
M/W(@S?M^H\?*E9_RF5E7T;!>L%U\$<#*T'H:Z&X895+U':,J7N7]4;G9<"GT
M\C9M@?58 73AJJ%?T)2>?C%H3+@B%6V-L<\QC,[B,+T*LP?16"79+9NPNI<G
M))B4D/-%1@G;@MU-!('(=&=<QA/LG$=(:[\HVB;8A^LK+!M9PU(3I(SX$>0G
M5N$9_F4UA,O*G'!$;I" *\'48=&6#T7-'9?DTH_UI!*-;;,N\0+!$^J%US"L
MD6[3!SNU<2:='\Z'S=MQP<*@T'Z.?7@P&/3?;'1+T7 G83<,15FT;_+H\MG:
MN7-7]QY(A!LYA3U\(>[8533EX2)R#%8B!WOZ%;BA@U!O@L:C7O$G9@G*\#8*
M;E4_QUS#%Y OU'7%4V)3VW<HD('\O"JB32?*J2D&G"K-9L+QT4$BN#^#6T'@
M9XD<CPFW"@?"?*Y#!Y:V$AE;LK6M6<#>PB&1/J2V1'7:<QF/EU>?_C@[.3UA
M-Q^.;NIBPIH%3BPQS=NJ>_4(#7.X^H!UWH$ "JD0&5:HH-VI-CS,,_=T*VS/
MBQ+59;-(#D'991I-A[Y4%LB"*,C^$F[HL;-11?Z6DI>6@6MQQ62Z3.S"WS,U
M="_")!>D,8QA'(&L''$<=#'R&N?%B8BY%KNDY):=3,W17HR!HY*'U^%8>!J%
M0/,9H<HDJ8-P>YVYK5ZBV,X[UJFJN&S_SF&IB&X)EZDBM:T36\*Z-R^0U(/5
MBT>J=)O)L%EHDKS>"-*NBR"]++M4<]Q("(OO@2F&*-"EWY2S5N'57EV7/,*%
MN$\N-QS\=3Y#N;T@,PY>VZUT/B[-7;H3Q,/IUSB(9%9H>0MM,ZW1%@51Z&[5
MGSC56 _0%U5!X24ZIZTF8VD64\>N;O<6>1'F]#F[.*%!+SJ%1KI=<G6 97OD
MN2;,Z0,?IZ0_J*@:M"M(Z:7BF%$0J$.XF-Q\LF08L6FDO!1A;2OXP(KPPB"(
M[IKM\\J6 *ODJ&+FEQ9^=_6GF*/%J/]FY*AQ]O??X.WAII<G";I)/!YS3V(%
MA8J%BFP )X:B3#%UI(@,X0?FB82<"0_VLM3Z:]%8&XY]OG#U?,O'$P><#DCJ
M-'ZKULD^W_7&_NWZ^ 'DZ[72H3E<&X=F(@I_W7D."F.1)//]/L[%:(2GH_3:
MN@7OH?OW>PH]M$07OF45Y^'J-S^M-TNMK/)FW4/&)W<QJK'=XV*\;^T?Q^NX
MV@Y;VZ5[3M^D-<R-.76R%A[Y(D1<+K;2 9, _1(^U<V\E=P<>^3<"X)5.*N*
MUWT(*\H,#6:M4, X[J+D"Q405T8N'LW2%WIX*7Z]+$Y3\4ND?$HB3G#<UD)D
MNC"YGAYL^D8GSGT+/>_7(>M<.6\JVUL[1U=Q^?Q Y\[*&W<5?\\#EK9K%L_7
M*O**#B!3VEWY3I9Y@-18']<%=/"P8ZCW#;[_%26="@=8%SMOR9RW9,]Y2UZ8
MAKO*V>G"7,\1YE+K\[#CXCFTG,>)?'VWO;%<E,_'QYB+'SQZ_.#[?:^79JC&
ME01/%=CJUYS8#1ZY517%>8>MY>#4D"1TDMH^TD)ILNF@UQ,G>,L#')P>@I5?
M1SL]RK/J/M_I<-CGOX?172#\L5JXAFXA&S4MCS1FU?)MY1W>JWBN'TZ;)W5F
M/\1 ^7[_]D,\LRL3;CW\M*N;AJO[;E=>G,=RYSYHL[;3P^L]OX=WGR9=;,-/
M0Z"0*GCUTKVZ)\OQE??X3&K^+YW/Z?%4$!,/Q4;=QX/6^VHPV/)Z,MZPWUJ$
MNBP*J#Q-U;<JDUN?Y64=T%+E3> 8&:LOM6Y=J:_-XCQ)<ZZ<(W<3:<X6^Q)9
M=AM-D'*I+D&O'2:E6UG_6I-#33 4(WC8DF@>_K2Z"%OQ\B)8-;]4BX7'Z[7A
M]YT-WX83Q'_^$T3%"&N']C<?'OW^-E)Q+7-Z.O*'4KOII35J[_5V]W'28-06
M.F71%F$)1/V>7 /26VOF #X1I*Z0VM7^?:C6NK%!'O8P8J,\H=.L/'ZB4@.Y
M-U6A#( L/FW2;@T261S;>#BH6:;Y5%0C''CLT,#N0^348C"/D:?24%NK-0ST
M[!RTT]O>79&#[M,-ORE2_PB,]E GVN/PWJJ.B2I//B1P]9AL^O#1/C2$6G+T
M.YF .5^6O&?7/!#-!>\K2GDV ?W[J*SP3T7],;(OP#X8X0/,NG6K%@1>9_7+
M^7;;>+T3:)\[3;F:0&N[>UZZ:;PDI__%[9[F@,KV,^\=D^+^\>SX].+Z]%I5
MR3C]G^./GZ_/_CB[^=<+IWKSOMI>FZ1W+7C9^SG WM,'SWH,I741\FR"19 V
M:)\&W5;Z.]<K17\P?ZJ_V&Q]1> 2OLH?"FDM5$0>E@#2K@8(S3:'@JN03VKT
M#@JV9Y,DRL<3-D5E*<8OI$A2UFD(,90:[(!U"NT%%6C5;FACH]!\R_AKL4!G
ME\@[6LMCBY;/A!O>21'X<S$DYP:<=P,>.#=@&P3K^J0*+'" M%"PWI<GU@XI
MNR3Y[*%2]B4SV-I$:A_@HF@CSST,5EWW83T(YD#.I?!A]VP"JV\^X/HA3V7:
M#FE10VH^@ BO4)RL3=C.K(&QET_U-I/U\MTO3GS<E*[T$N50>M)3<J5S$[-J
M,"8VNBL4:T$A\4W UB*+HLS6JV_]+F$B"<]0NAXQE= 3<:9 HAI\B8@[NQ1_
M+!*$*)+7V/;IETS\/HB&,,SCDTN:PF^1A'7!3TN3.>;<%.WD3K$NW'DE$'T#
M"WQ5X&]P,8JOBZW2TFCA<P<+3;C]706Y6*N$2'TURE @9DG]_-/NP7=$<'?Z
MO?UU=?%VCIY[40:]_G8%LV@"A%K:(P(,^WQVRW(6(![I!" E18<[5^B" K<M
M-'[F>5 IF(7.UG !/EED^/=\T>QV;9*W:[=)U'D+:UF ,G$OF!W259O'$R6^
M4FT8./$>9[\XW^.<[_'0^1X?@=N?E+$723T;5*P0SPI0LZH\+-7A6G*@9KXB
MR<QN,[402M%CM;2?.ML3.F1UWJ?CG'7Z&Y0TCPDR:5; KI=HQZJ)=&>P833U
M5&>(!>*6!JY'($37'%[6(-0IIKZ)@;*AJLOD =$P8Q_?;6;Y2_G,)G6_.B89
M@L'A*WAY!<X-)H ( B ^=A:+$\QSP^05F/!(XED"NP?,0E4@@'P%ZC5SU$[$
ME.O,)I-,A/<$DIN\(DJ,4S8*F1FZY &:*R5-TI(HJ87T,61)+;I8EHU,C,/'
M*H#B&YU 58DR[TC41_V0$@2O]QY5,@!^(Z11BLFC*HVMS,NY@[LHC N2OEIR
M:HXH.C^]UB@-T^ ::G?@'C6.EV(_Z&&2QT?-QB0$%'I.F2:P\+1:08_1&4$V
M3X<1@^<1A5>IER6*IF^9:II>38QHR+3C0,9X5LV"FZ- .;V.J=P 2Q3ZJ@0$
MOBF+-I:D$)+<;QA<1Z5'T A4Q@#6-N"TIGHU;":@/0/LD4B@'=#+S@>TA5\H
M/)&F>(6VSW7!H$@]#>QS^!KKMXQF%B<3?TO;^K;9=Z-G8PEL5*#8 'N)=58V
M&3<LMV-"OZ:EQ+4=>ZOY_^=?L,Q345 "Q_QDW@HECB6\L@!ZXCLUU]OGB4W8
M$5"US'L42RCZ[=Z0]=;FCY];F^\7=GC"O( GE%29-O'!-OFQJ0P@+%>4:!>=
MN6"GMTL.O=/4X^K@V]!9VB"44@/%J;@(B:_ ZBU<?>J+M_#%,+JU2[?$B<IA
M+MBJ*H(4W^O00B5AMBG)O0YH?:@0-_FR\%AJ=T[SJ0&)*U-3%\=10L>&9EA5
M)J?QMK<;=MY;'*O$\P7]=)S1H\>VL^6,GC:XB$?/[2+>[1V22%SI9'KAH9S[
M86WU>EFUD$[AHNFNAM]H>EQ3SH\R\+XY//T=1;[NC1C#6;-9AI9,R'A$MN;S
MQ8L+O=VJJG')R<+2^BI>@)4S-C]$=T#HQG*^5,2@FE*]6"EC>"S97++ >=?<
M\GKA<Y4'MY*RHMT$H%Z2^5+A3%7G,YB5YF^>P"E&UI[.:%'E57PKD42FQJ!Z
MZ'B;8^F%U[FA* 2J(W3N%W5G=*F(LL9-MZGR!1BV4U MLD29FQ*+Y\%D<U@:
M3VJ[;+XDAL(_PX>A#$B9,QI(M?Z4*B525'L:-1EU9,0IR\[DS]?T+C(&U).F
MUIJH4AZDN)2&I=JVRAZL&O +;K7JBU1T)GP?;8/FI?OYIYW]-P^++_08J^B_
MLE;8*%*:&$ZE:@31,.Z=^6*SN2%G#2QDJG +&X$Z>E4=@%5^6T*%ATR_5LFD
MMZJJ^;+S*=8E!ZI!V+<R]+\V&0IE?M]+Q_%=SY?[:_25EWYI2\T@:[VD!<B%
M4L9NU HK*:]]6A+...]J001;E5#RWK)N66=QZM#&(EU)5VF!U]74$E40-@K)
MB4D-!ZR\S=39Q_/V<=_9QVV0HVN3D+! =KQPF5K5QBKA30RQ8(7+#$6=+0R-
M^&N*"FK3A6]0.=2'ASB'18B3+K:$7$/(TNC+#PE54D6GAD!D&(6;J(':SVHL
MG-#?0ME^7'U$I03_]\4N+:%/#F=+S"\*3I:+\TB11YI'O4TF=5 K)DGUO9I.
M*NU X-:HS+%FKV9IUM<.5;3"U(^UJ/("^[6NSK=4?W_N/'1+?[>"(C^ V$_K
M$,08L3(V4?$S 41K9]OR@(I*S\?[FD1.H>#9*EM:H9URHE2+[*/@)+XMKT2A
MI498%'D1X9B/A0:@6(]DNN= JEH-^&+($]-I *ZU6F4=Y=DD0NM?#0+%[L+7
M*DF6LE$>!+.YRJYX&S9]0-D5>5QA:Y0P+WLJ=)78J<Z_249)."BB'#U.(^4!
M\IF/%*3;Z35 =Q&,]+"]N6'#B&@Y,OY%.?,0$T&-(^QU'"T] JSD$SU$6]JS
MLWJ4'D\Z^"<0/"4IBW&R<*Q%+M!Y40F>YI-$3\W?,!X,JC^H:K@8K^6L@9XX
M; QGU^R2AAK*>I<C58!M;D&BIE7@?V.\7*]U&3)OW/:+XXCZ_DKA7_L@PID(
M.-[U%D+/4",@IM988M^.J1O/9V.-Y((O0"@1, 1!%6I3_SL'VH^D\'73$JG(
M612B+4X]:T-U\C" !RA$R1V5]$4J-!6NU;>8I15-NY9NKNQ8/#0)G6.ACFL>
M=^M\7<B^^!B0&X4KG,H353SEN@ROPC#)$$//Y32JHX3A+=H]9LZS1?)0<TH)
M9D%>306L0''_@A+1)$$M;_9_*E7]ZZZ_TCF-B(OETG0H;(U,1],))V355E\@
M9R4J.6CRH38T,F?&HO>MH*9J<8&G1B$723TK7C._)OA\9_S/&?\#9_R_,$V,
MF*0,W^!9O)AMJ?!<!6.&59)1^/I@.7K4$&",2DNVC/^1UQ2$IN1,?-:(RK"9
M)YH'S9^X;34U=M;$U+BW[X$+'/P(C)QQ>/UY7P>->D$@Q+7?CU56 =M<FU"6
MXP NTM>7\>_JR[THEJ)X_1\G5Z57B;1'[>3 \IOH=?)1*U<0. /4Q8%:^@$B
M.)'_+>!M%PP.+U>A5ZRDSC-NE%K=(%BW%](=@BN:^7Q[X!62?9K#EZ6^1)WJ
MT'TEBD \3MUD!%0IGDZXB93::.):F#XM=%61W5%7NE)A;6<F[H]U(S^ JVZ4
M7P!/'I/D6>\M8W%+=Q5VZ5J,81P()A6@V%B%_D\[4IE8I%/.U[U';T#)!#B
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M!EVD!9CS(V&*2]^W-G/>Q&B('B^[ H,BDP$=ZW (3NG>_6GQN)7[6+HJ\5E
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MB9:"4?T->1W;8;;@.U$QXU%>$5[G?^G=-LU'*[PTQK&.?_QR23?B^:_*&]
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M<'+-35D=(2@%[^;?^@BOQSG9'GW!MLB*?%:V=:)/8&5XN^&_\>!F/PGSOA,
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M"H!/#H*>WT$J;;M'FFWL:1J&_A9L2+/3"Y8W3I43Z4GO^K0B=X2JS@;+**$
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M.*!G3\4T@!_P_?.0.OS<]]@#PR1<(Q4R BE98P=^TJ+2ICCW]$JIO^IE0WU
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MF<MH4]7)5&])Z*PL5MT(/V]6Z_D^J[4CUG#MYO#9X='S1SZ 5[-7\MSU/WF
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M#0@20YR GZ*4 N/5.&@A_07]C+8$AM_LUL&D;[PBHL*<3E%%)$R8NZR208E
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M>;V=3*&BUM.:7=K@&I/VPZSXVH<.O--<IJQ2#&L.,VZY+"@J>=(@ [;'A\/
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M F+R)FX;0+8$<FR)$2[QS><-#(+ZANT/3=9QHFU%#9@ P?:N //:<RNC1]X
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M4/IIIS5X0>P[W",6V"^@7>&L6V$%&<XZ25=DEM#W3_J+H\/7FYH_.3C>&)[
MB0EBLF&M+ VV4=XF[E&/2(IE4<^U<UD8DJ\.0LA7!$7:!R/ER!J0/:'<+04]
MU$8U=3TO.KLIVREDZB<0@#$2TANC$7N<1MFQM'??D5Y'MAGF;^@BOJGK [^*
M=4 S9?K+>/-]-KB3#7ZQSP8_@/GZH99*;A)_.QVL"3]S/+;,BK$#8TWQ[D F
MN= 4#4E6>;IP<LI(J==ESRK49=GD&0G6DD4Q_78S_=_NWPNR++?, #+ST1B
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MYZDL=6$.::U1.8.C8:8#&F*[A]3(=*HN]3E#3*A6_J>I]%@GJDKA.Y2GY[_
M*5K2(354>O].TB#GO@Q&DQK1'A=Q&] OY*PYURQ_RK&=@$Y"MZ4B0 ;Q*O+
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MPS*&X)/TCI][P26*!&(5H ,A-0OHK#>RAO!.!05M^-#0:&TTZN:PPIH^XK:
MD):*#/ AK.A2/R7-T2PK,DQ'RI=6NZ4I1*%Z[A*^WAY=38O+8;M66HV( B[-
M&@[_C>K6BL4PF%E$#J*KB_E+W3OU7D&N\ROOB?6#=( [EFLMIQSILA6JS^ K
M.]G^Q@8"/:''U$F-NO>H=YNI2,)^/!@/DH-S^ZGCY*D'>C]/F01._ **F!A+
MBW;Y<U&R,K]+0[)<;S5'04QV+E#30JYE@R2ZR6MX*'W[^NJ6:ZRT_#W.063[
MV\!)I!%&)G&#9A%?]#XAT4U(O-HG)'8A7-L8,-^R\\&=DML>S5G_P]DK1X,>
M40(AOK!84.-QE)U^,Q0V[P#X$+*C>7/KC+APV"/$D4CN/P[<]G5&0X%_[4:_
MMK"(>.O)%]!3;8\T4P9?MJ8]]EU!@,\7HL]6O! QYR=)AZ]OJ:<2GJ+@2]I,
MO3ML&7TOZ7L$4!\P[LA=I1=C!WQ_)U=E-W$X&X-T)--##(QE$NRE+3>K%YY>
MDK27-MR\91-%8V3$;XQ&907/.UVD'48M4R7['"JLS.9HH_6V]KSI3'O3G)8<
MN*&QQ&'I\'SR"6#_6::WY$8?'4 09F$HX:W-EM-NOB^[B)C&SM5'<DZ6'2DB
M? A01R+4=))^+)*\['P)X\M>\ZX?'(019Y"PJ3)6Q+-J>]7"-FL,+%%=0GQS
MICGEDN9\*CL\^#$Q6M!&[0KQK:#$6]3>PQ9^?.T'UI$WD':(RQG[Q;A&XN,D
M59QRQHE)?9V%.-O#UV19[/#]D^9=#1!:9.'3S^KE.I<M"^#9J_*>]IRK#'^1
M)8]BLO Z,7JP^)X>ED66P(+X\:<[9:Y0P7:U))6970A01E>FN\[??S$+0^]5
MOT^(L^$U6OIYGU0^OM+L;5M"T"#_O1.*EFU5X8V7I'UV\QC>&#AL-)FRHVH
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M_$*N !0(2\R)4NB^$"Q;VBJ.\\9_LPY<7V/>JR Z5<RCS"&ODTT/ S @9R[
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M0 1N0L&# ^0QD!2U^%.W%[(@FP&)T^N\A LCAY%SQT'/$,I)*)A,C<2%W/E
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MFO;R85*V],9K"#C1>F 6PVO-M)V9-SC >442%PX/"]4M]AU1G2UH)X,@$'-
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ML!UFM=X]3GJ[9$) WEB0V#$].E;)BV@"R=ZYNX$G;\D"(6-$<S 2*'K2T&M
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M>76#F1!N&2]4,<*_,QEB(L3,N;XBJ6'@%A!*9D!.HU*P?#B=@CL%A2;X_+Z
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MMR+,WV2JMS2S;XHCQ&:P[!UXI_/BG=XIK+&!IEQ.<KDFW':\@\'B<T?.1C;
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M(EM[L\I[*R1]H?:HD8]5J<3O+B7R,*+W-"@4WF?TS0>(LH>^Y[>7$KD:7YO
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M<?(?*,9<.%%0MN38\L9AN[<2T27>NY@"&_&$L\>YFG(8TF)7FBK.^'PHQKI
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MVC0+MBAO?AV\7A;2^],\SN,D/9AH ?=!!WPIL7<\>;3X^!U ;NPGR6.=P&+
MJDWFF;R0RX.4Q <^3 ;*J9I+5$CE-T1&=VA%S>:Q3@UJJSRL).=CI6<%H@N4
M$EO*>+]Y+$W7!.;3S%?QM?TT]G!+X+$P=9QM2:+UXEMHNZ3E&W87P&_8L!=Y
M[3D7=NU-.5@&A_U36+1[JNT'M"Y>OBRS4B<N^;-1U?JQGIN]M <;V$RE;%8@
M:EJ3C:A3^)1,U;SX/51BQ!8"5LJ 9GK>;Z"F4P\W?-BN>UZJ02)[7@9KP3X!
MBV$D2>PK\[ )5K>(:&\-O5$<0",B2Z=DN?6\$30C,MJ%H"L^_H@; VV4:%7
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M_@4+K(XGX:R$JC4!JDJ,0I4@1^=O)"&)E1#?2H@SQ1/^<7?I@/-['_6Q<:3
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MX(%\4@TAC=9$*,;N".M)_W!H(Q167]#T?3T;@LNXX2,7<<,78:A(YC^*2$S
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MD!1?HO@Q0M_ VYO[X6#@A)AQ5UP0M-*H5?,\ENJ/X?&-5!?Y*+0<AP1-R;5
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M:#J>B$S]1+4W?HL>TJ6(4JL4/Z WX5.W^+6;QS,6W9Q@A,:?\)\/V\_NH8F
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M,K;HRV.,Q%NB74<G<(/+<\R%/$I9<]FI5/@-V)6%W1'64O FIK2WFB>G@1Y
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M,3RYA+Q!(A[B_T#=%)%9H7_ML(ZK\:LRH*!O;% H1#T_0Q:*;.AU\JIK=+/
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MZ$B02(9/($YDFS=]2%FN#K)36PGA/3I@F&&#K97#7@ ]?J>+0S&$!2PAP!!
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M_U),/^]C5V*( 8<_F[7BMM1V=U[DRUZI-N2M.U4T=%3JE*M6<E K!2$7A"C
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M1[?L.PON_9"D,L+#]P,=OH=52-+SNUE"[?["">:]6RRH@3M4KXD8-W_9=2M
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M0N[)L8!%7J39WLWRF7&]_\E(X,E?D6V$%/3[6MK&4KSFAP56CD01I>?:2;^
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M^M)0+B#TUV%/T?EIU>#/D)5=S)G>1)XN>4DJ7QU,5L-F><%B54ECP;8>;*/
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M.]HI7J\1DTCGA4<* /$#J#5DDA)D=,4\^&*,7%6D=Y"<K(AF#SJBS#;(P55
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MB8J2=P03YI*;70_U82 @ X*IH2@*@1>U;>[(%'%KF77IZ!U!:1=Z6\V=U&]
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MN[S?[KG-A!1/1"OZ;&J>#9.4.Y+"/O)_+^W8[%9!EL,F_#B9*G2E==$+28J
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M]44J7!]KXJI>];-7Q7L#JW545[434J79I42-C&PY,DS=EBD;\YHB'!/KS(9
M)(3!V!@[0.NH,\D7L"T0JIF"J=#RT3AC"ATJ/, 5S)50M(G88+"3;LR-NB3'
MI?7M1RD%@5I6RP[=0N&:AZN6X9-_H?A/M\92,LMBU:Q[8*6L,SYH'1<YLM#
M'7/238S@V80%_L13:+Z,QOBP[XLBH7-I^A5@[I4YE*9? ?[^0*O8ZWW92QQS
MMQU<S>8\(5]+10Z.=1(:(_8D :N+V:Q51B><)!LQU2KTG4Z_I+XP3NAPKK,I
MDCEAJ# 6A%[(VL'WR9/[O1C2;-+9!<O13E95L[2A"V,SK6%0Q<5M"@13XRS!
MAA:]B</:%@Y-U&C^-DZYMS+D^X?0S(X71<94;G9WHG&N(;Y-]K 7K5>\"/N
M!V&XD 5A2_I6J&-=?,FG8WU@<&QFPALL9M+3ZN.0F2-$* V74\@#.HU/\D+
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MG,:0B+MN4WS16D[4M==1$*8>MZ5+MLM= ,%U;CRK^;,P^+,PL4T >1A.<$5
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MI:+I+=+<X"SCTZ/0^SB]1OPN#3)_AE8I0Q5*.'SH#EW +X_IA8VBKPI<(,I
M=%H!B6.KY-: &_!S)?:YBM(.NX*>-F*$AL*Q608P;7*.SD3^!_01^#+IMBU/
MVH>&XU*31P\C*!9):.&7 YL(D1450EG[".O"\#?T'KE;03%*\RA&, I2[T0X
MD!/RS'"E:/47BIBR4D=J&49.=8QY1&L+U25P?4&OQ?TWJ>'2(^H(194Z.%NY
MFCS@]D P%_H!@8\";P+_"QN&U =]E%^9/DOS*&Y7O6(A/SQ 4LZDKE/,@L,,
M2M875.O]>IL7IW$CQ51Z"0$!@QN&K F_:HKEQS,H L&BQ (].,](;7%['1C?
M=8J.T;\*_$P?5#R(&Y)6''R]R889 "4NXYLTF8T]QQM-I^; 3H^*"Q_VM44T
MH4H[K+%%0$JXF'W'58L1\8T1A\S@9SV=+YSS*K0/5+]D]Y.H9^!'S^C1;]*(
MJMS--B@Y'VEQ>&P9=>VK'%])(LX%;O>IC_$@_MR&%X+%/7J)WF4IQ$$%RVF9
MT4ZNQU^UHU16LK+E+< W>#EK1(88Q 0#*5@MVDR;0QNKW,8PA]0UP@8%9HF'
M_9GF#JXEQLTLNA9'Z#Z4K*-V35MC:QOQ;^2S&V\KF^O@."OK S+WU2^PA>^0
MUYZ70A+6MDBG H*C5H$_L'#VKJ,RFU36$LW3:[/;.!9MA;,Y,&8'2M\S@] .
M$]T5"(]!G"4=:5T/0?U-2\>RI0ES7Z47FMU&ZB1Q2VH/[:MQC0+BGO;&(@JS
M'RFE2 =[#G5LJ0H:AC#4,AA\5".9JV"4\DIGG*GEZ56QQSCZ,I=.':8/0<6O
MRA8BW&_Q$K0;JZD/@O6:7D4'7,R^VHVA7NHAGZCE.&KQ:.N\!7K9:CDP4:8Q
MHG:^^Y2%@=+9=8J+$$,Y6, V? @!15@QC!#M+CU)Y 4W&"I;O:EZ M6&)S7I
M.R6+4\T 9Y[B689(MV^+*AIC,<&L<P=<#VO;AE#MM>1(FT-JC5+] :DS4(BA
MCZ7;XHALA/O.'!<@\^MF +$T:#H@NJ\3MB3HAVI\XZH&I&J5W!4-$$^XI!4$
MKY> ID%2I"+L9XR7"-JI9'1>D/P+2M-I?>S0[T:H-R,@[)T*QSCK40F-]_-@
MRX0:..$H[9[E>1&;/QDC/Y0Q/\88X#^W^0EH< ! A4-^PZ;Z$P"_E4?7$8+-
MJE,RG8)1NK%WVV"25?Y3@#@\!'^Y_[!M VE3',UR#&FK*71[>*M)<=$U(GR,
M,VXB$RO'QI=<9V.B/VE?)IKGU"M@[._L[D$29-'=O(0AWILDC)UN@L?J0IPA
MG,7$HQ9>E^34S%'<Q,I31P73? 3;Y ^=XEG:J :H6@/=-;Z)\FOJNHA&J7G%
M9@]$A%VF8 W R_4G7#QY78^\D3421,_!!M'S_<%#+YN] ?@*QUZSW5;>XMW6
M(*K+-G4*AUB-G2-IH/1#*V +%=Q) G4:)A4(,2N(;EZ^;8,42YTE77MP3S'
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MD0(TA061RFIA05B/3H\Y5B.L--,N <U=*6E12V#R-#Q. O_;=[=GN_T78^[
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MA&U2(FN;1]&<Z[4IA5Z4N^U@QL, C=MUNXE@R&3[3+:<.@QS@NA$STC0T9_
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M,[M76QLWIJ:J3'XY:H> IIL,8N6M0W)IY[H8^I$HF8]U>_"_"QMF*.5<#:?
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M_U?@WU!+ 0(4 Q0    ( "L_=%BR[RY!..(' 'CD30 1              "
M 0    !B;G1X+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( "L_=%@!5%1IBS$
M $-0 @ 1              "  6?B!P!B;G1X+3(P,C,Q,C,Q+GAS9%!+ 0(4
M Q0    ( "L_=%CTF%!30#   !;P 0 5              "  2$4" !B;G1X
M+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  K/W188(I-6:/.  #.70D
M%0              @ &41 @ 8FYT>"TR,#(S,3(S,5]D968N>&UL4$L! A0#
M%     @ *S]T6#'BW/2X-0( I*(" !0              ( !:A,) &)N='@M
M,C R,S$R,S%?9S$N:G!G4$L! A0#%     @ *S]T6 O&,>(D30$ GI<! !0
M             ( !5$D+ &)N='@M,C R,S$R,S%?9S(N:G!G4$L! A0#%
M  @ *S]T6+,44!6$R@$ ]NP! !0              ( !JI8, &)N='@M,C R
M,S$R,S%?9S,N:G!G4$L! A0#%     @ *S]T6![]N++<C@  ==P  !0
M         ( !8&$. &)N='@M,C R,S$R,S%?9S0N:G!G4$L! A0#%     @
M*S]T6(%B>;4IMP$ ^TL1 !4              ( !;O . &)N='@M,C R,S$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( "L_=%CI<H@P3R ! 'HC#0 5
M      "  <JG$ !B;G1X+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    "  K
M/W18.)TB)1X(  "5+P  '@              @ %,R!$ 97AH:6)I=#$R,6-E
M<G1I9FEC871I;VXM=7,N:'1M4$L! A0#%     @ *S]T6)>(C+\6"   BB\
M !X              ( !IM 1 &5X:&EB:70Q,C)C97)T:69I8V%T:6]N+6IH
M+FAT;5!+ 0(4 Q0    ( "L_=%CK.$G'O00  ,$:   >              "
M ?C8$0!E>&AI8FET,3,Q8V5R=&EF:6-A=&EO;BUU<RYH=&U02P$"% ,4
M"  K/W18W+T('K@$  "V&@  '@              @ 'QW1$ 97AH:6)I=#$S
M,F-E<G1I9FEC871I;VXM:F@N:'1M4$L! A0#%     @ *S]T6,MZ[8R4 P
MI@X  !L              ( !Y>(1 &5X:&EB:70Q-3%E>6-O;G-E;G0R,"UF
M+FAT;5!+ 0(4 Q0    ( "L_=%AM3A2N'6(  %+! @ >              "
M ;+F$0!E>&AI8FET,C1D97-C<FEP=&EO;F]F<V5C=2YH=&U02P$"% ,4
M"  K/W18E:C+Z2_A 0!('A0 '@              @ $+21( 97AH:6)I=#0T
M-VEN<W1A9&5E<&%M96YD;64N:'1M4$L! A0#%     @ *S]T6"+QTM7Q7@$
MDBD+ !X              ( !=BH4 &5X:&EB:70T-#AO;F-O8S1A9W)E96UE
M;G1R+FAT;5!+ 0(4 Q0    ( "L_=%@DHX-;3@T  !M:   >
M  "  :.)%0!E>&AI8FET-#0Y;VYC;V,T86UE;F1M96YT<BYH=&U02P$"% ,4
M    "  K/W189FZ$B^';  #_,P< '@              @ $MEQ4 97AH:6)I
M=#0U,&1U86QI='EH97(R86=R964N:'1M4$L! A0#%     @ *S]T6-6YHM'V
M\@  ?>@( !X              ( !2G,6 &5X:&EB:70T-3%D=6%L:71Y8C=H
M,V%G<F5E+FAT;5!+ 0(4 Q0    ( "L_=%C-GBT7A?,  *6Q"  >
M      "  7QF%P!E>&AI8FET-#4R9'5A;&ET>71R;W R86=R92YH=&U02P$"
M% ,4    "  K/W180653R\XG 0 &?@H '@              @ $]6A@ 97AH
M:6)I=#0U,V)I;W1H975S86=R965M96XN:'1M4$L! A0#%     @ *S]T6'O0
MK:B*'P$ .S<+ !X              ( !1X(9 &5X:&EB:70T-31A=71O;'5S
M;&EC96YS96%N+FAT;5!+ 0(4 Q0    ( "L_=%CTJM<LYP4  "M<   >
M          "  0VB&@!E>&AI8FET.'-U8G-I9&EA<FEE<V9Y,C R,RYH=&U0
M2P$"% ,4    "  K/W18IIX?E!P3  !>8   '@              @ $PJ!H
M97AH:6)I=#DW8FEO;G1E8VAC;VUP96YS870N:'1M4$L%!@     : !H 3P<
' (B[&@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>bntx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bntx="http://www.biontech.de/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bntx-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">bntx:OrdinarySharesNoParValueWithNationalAmountAttributableToEachOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">bntx:IntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:OperatingAndBusinessEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:OperatingAndBusinessEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechBioNTainerHoldingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechBioNTainerHoldingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellGeneTherapiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechCellGeneTherapiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDiagnosticsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechEuropeGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIdarObersteinServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIdarObersteinServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIndividualizedMRNAManufacturingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechIndividualizedMRNAManufacturingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationAndServicesMarburgGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationAndServicesMarburgGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovationGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechInnovativeManufacturingServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechManufacturingMarburgGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateHoldingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRealEstateVerwaltungsGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepDEGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NTSecurityAndServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NTSecurityAndServicesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ReSanoGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRDAustriaGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRDAustriaGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechShanghaiPharmaceuticalsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechShanghaiPharmaceuticalsCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepFranceSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BiopharmaBioNTechIsraelLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:NewTechnologiesReMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepNigeriaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRwandaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechRwandaLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechSenegalSuarlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsAsiaPacificPte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechPharmaceuticalsSpainS.LMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechSwitzerlandGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTaiwanCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepTunisiaSARLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechTurkeyTbbiUrunlerVeKlinikArastirmaTicaretAnonimSirketiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUKLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUKLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechResearchAndDevelopmentInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSAHoldingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechUSInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:BioNTechDeliveryTechnologiesUSLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:InstaDeepLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:JPTPeptideTechnologiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:ATImpfGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bntx:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">bntx:MedineGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:InstaDeepLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:MultiperiodExcessEarningsMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:InstaDeepLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineDirectProductSalesToCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersGrossProfitAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineSalesToCollaborationPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">bntx:ManufacturingVariancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:COVID19VaccineShareOfCollaborationPartnersSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">bntx:SalesBasedOrUsageBasedRoyaltyRecognitionConstraintModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerCOVID19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:GermanFederalMinistryOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:PfizerZosterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">bntx:UnsatisfiedOrPartiallyUnsatisfiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bntx:OmicronXBB.1.5AdaptedMonovalentCOVID19VaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LossOnDerivativeInstrumentsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:LitigationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GainOnDerivativeInstrumentsAtFairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:IncomeAndExpensesByNatureAxis">bntx:GovernmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ThereofDeferredTaxLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:FixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:Inventories1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:ContractLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:NetEmployeeDefinedBenefitLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherProvisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:SharebasedPaymentArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:OtherDeferredTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">bntx:ValuationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">bntx:DeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:CGUImmunotherapiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesToJPTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalProductSalesToJPTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalBusinessOfInstaDeepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ConsolidatedStructuredEntitiesAxis">bntx:ExternalBusinessOfInstaDeepMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:ConcessionsLicensesInProcessResearchAndDevelopmentAndSimilarRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">bntx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:DualityBiologicsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedilinkTherapeuticsSuzhouCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:BiotheusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:DeepChainTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">bntx:DeepChainTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandAndBuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:EquipmentToolsAndInstallationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">bntx:ConstructionInProgressAndAdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">us-gaap:SecuritiesInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ReverseRepoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:NonListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:ListedEquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughOCIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:OtherFinancialAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:BankDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:CashAtBanksAndOnHandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">bntx:FinancialLiabilitiesAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:LoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:TradePayablesAndOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">bntx:AmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">bntx:CashFlowProjectionsMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">bntx:CashFlowProjectionsMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:CashAndCashEquivalents1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MonetaryAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">bntx:MonetaryAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:MonetaryLiabilityAndProvisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">bntx:MonetaryLiabilityAndProvisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:PositiveFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">bntx:NegativeFivePercentageChangeInForeignExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:CurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:NoncurrentObligationsUnderLeaseContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:InterestBearingLoansAndBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">bntx:ConvertibleNoteEmbeddedDerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:EuropeanCommissionToCollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">bntx:EuropeanCommissionToCollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:OncoC4IncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:RyvuTherapeuticsSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:RyvuTherapeuticsSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedigeneImmunotherapiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">bntx:MedigeneImmunotherapiesGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgramTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:ShareRepurchaseProgramPeriodAxis">bntx:ShareRepurchaseProgram2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-07</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:AnnouncementOfResearchDevelopmentAndCommercializationCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTechEmployeeEquityPlanForEmployeesBasedInEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:SalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">bntx:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:InstaDeepEmployeeIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentivePlusProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2020ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2021ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentive2022ProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeEquityPlanLongTermIncentiveProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:VestingPeriodAxis">bntx:ShareBasedPaymentArrangementYearOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:BioNTech2020RestrictedStockUnitPlanForNorthAmericaEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2021-05-17</instant>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <startDate>2021-05-17</startDate>
            <endDate>2021-05-17</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-12-31</instant>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:ProfessorUgurSahinMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:DoctorSierkPoettingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-17</instant>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-30</instant>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-12</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-17</startDate>
            <endDate>2021-05-17</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:EstimatedAllocationDateFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ManagementBoardGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-09</instant>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:ChiefExecutiveOfficerGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-09</startDate>
            <endDate>2019-10-09</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-18</instant>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-18</startDate>
            <endDate>2017-08-18</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-18</startDate>
            <endDate>2017-08-18</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-19</startDate>
            <endDate>2019-08-19</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-15</instant>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-03</instant>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-01</instant>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-15</startDate>
            <endDate>2018-11-15</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-21</startDate>
            <endDate>2019-04-03</endDate>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-29</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-01</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:SaleOfStockAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:CashSettledShareBasedPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:ProductionFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">bntx:OtherOperatingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:SupervisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ManagementBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:JensHolsteinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bntx:EmployeeStockOwnershipPlanESOPNameAxis">bntx:EmployeeStockOwnershipPlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bntx:SeanMarettMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bntx:EmployeeStockOwnershipPlanESOPNameAxis">bntx:EmployeeStockOwnershipPlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">bntx:EmployeeStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bntx:ATHOSKGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-08</instant>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001776985</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">bntx:LicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-08</startDate>
            <endDate>2024-02-08</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-40">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-41">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-42">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-43">0001776985</dei:EntityCentralIndexKey>
    <dei:NoTradingSymbolFlag contextRef="c-4" id="f-44">true</dei:NoTradingSymbolFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-39081</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">BioNTech SE</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-10">2M</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">An der Goldgrube 12</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">D-55131</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">Mainz</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-14">DE</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Prof. Ugur Sahin, M.D.</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">An der Goldgrube 12</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-17">D-55131</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-18">Mainz</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-2" id="f-19">DE</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-2" id="f-20">+49</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-21">6131-9084-0</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber contextRef="c-2" id="f-22">+49 6131 9084-390</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c-2" id="f-23">info@biontech.de</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="c-3" id="f-24">American Depositary Shares, each Representing one ordinary share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-25">BNTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-26">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-27">Ordinary shares, no par value, with a notional amount attributable to each ordinary share of &#x20ac;1*</dei:Security12bTitle>
    <dei:SecurityExchangeName contextRef="c-4" id="f-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-29" unitRef="shares">237725735</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-30">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-32">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-33">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-34">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-35">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-36">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-37">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-38">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-39">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c-1" id="f-45">1251</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-46">EY GmbH &amp; Co. KG Wirtschaftspr&#xfc;fungsgesellschaft</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-47">Cologne, Germany</dei:AuditorLocation>
    <dei:AuditorName contextRef="c-1" id="f-48">EY GmbH &amp; Co. KG Wirtschaftspr&#xfc;fungsgesellschaft</dei:AuditorName>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-6" decimals="-5" id="f-49" unitRef="eur">3815500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-7" decimals="-5" id="f-50" unitRef="eur">17194600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-8" decimals="-5" id="f-51" unitRef="eur">18874000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-9" decimals="-5" id="f-52" unitRef="eur">3500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-10" decimals="-5" id="f-53" unitRef="eur">116000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-11" decimals="-5" id="f-54" unitRef="eur">102700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-55" unitRef="eur">3819000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-12" decimals="-5" id="f-56" unitRef="eur">17310600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-13" decimals="-5" id="f-57" unitRef="eur">18976700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-5" id="f-58" unitRef="eur">599800000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-12" decimals="-5" id="f-59" unitRef="eur">2995000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-13" decimals="-5" id="f-60" unitRef="eur">2911500000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-61" unitRef="eur">1783100000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-5" id="f-62" unitRef="eur">1537000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-5" id="f-63" unitRef="eur">949200000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-1" decimals="-5" id="f-64" unitRef="eur">62700000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-12" decimals="-5" id="f-65" unitRef="eur">59500000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-13" decimals="-5" id="f-66" unitRef="eur">50400000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-67" unitRef="eur">495000000.0</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-5" id="f-68" unitRef="eur">481700000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-5" id="f-69" unitRef="eur">276800000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-5" id="f-70" unitRef="eur">293000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-12" decimals="-5" id="f-71" unitRef="eur">410000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-13" decimals="-5" id="f-72" unitRef="eur">103400000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-5" id="f-73" unitRef="eur">105000000.0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-12" decimals="-5" id="f-74" unitRef="eur">815300000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-13" decimals="-5" id="f-75" unitRef="eur">598400000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-5" id="f-76" unitRef="eur">690400000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-12" decimals="-5" id="f-77" unitRef="eur">12642700000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-13" decimals="-5" id="f-78" unitRef="eur">15283800000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-5" id="f-79" unitRef="eur">519600000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-12" decimals="-5" id="f-80" unitRef="eur">330300000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-13" decimals="-5" id="f-81" unitRef="eur">67700000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-5" id="f-82" unitRef="eur">23900000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-12" decimals="-5" id="f-83" unitRef="eur">18900000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-13" decimals="-5" id="f-84" unitRef="eur">305100000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-5" id="f-85" unitRef="eur">1186100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-12" decimals="-5" id="f-86" unitRef="eur">12954100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-13" decimals="-5" id="f-87" unitRef="eur">15046400000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-5" id="f-88" unitRef="eur">255800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-12" decimals="-5" id="f-89" unitRef="eur">3519700000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-13" decimals="-5" id="f-90" unitRef="eur">4753900000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-91" unitRef="eur">930300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-12" decimals="-5" id="f-92" unitRef="eur">9434400000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-13" decimals="-5" id="f-93" unitRef="eur">10292500000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-94"
      unitRef="eurPerShare">3.87</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-12"
      decimals="2"
      id="f-95"
      unitRef="eurPerShare">38.78</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-13"
      decimals="2"
      id="f-96"
      unitRef="eurPerShare">42.18</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-97"
      unitRef="eurPerShare">3.83</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-12"
      decimals="2"
      id="f-98"
      unitRef="eurPerShare">37.77</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-13"
      decimals="2"
      id="f-99"
      unitRef="eurPerShare">39.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-100" unitRef="eur">930300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-12" decimals="-5" id="f-101" unitRef="eur">9434400000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-13" decimals="-5" id="f-102" unitRef="eur">10292500000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-5" id="f-103" unitRef="eur">-19800000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-12" decimals="-5" id="f-104" unitRef="eur">11200000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-13" decimals="-5" id="f-105" unitRef="eur">8400000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-5" id="f-106" unitRef="eur">-19800000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-12" decimals="-5" id="f-107" unitRef="eur">11200000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-13" decimals="-5" id="f-108" unitRef="eur">8400000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-1" decimals="-5" id="f-109" unitRef="eur">3700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-12" decimals="-5" id="f-110" unitRef="eur">10500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-13" decimals="-5" id="f-111" unitRef="eur">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-1" decimals="-5" id="f-112" unitRef="eur">300000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-12" decimals="-5" id="f-113" unitRef="eur">600000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="c-13" decimals="-5" id="f-114" unitRef="eur">300000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-5" id="f-115" unitRef="eur">4000000.0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-12" decimals="-5" id="f-116" unitRef="eur">11100000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="c-13" decimals="-5" id="f-117" unitRef="eur">300000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-5" id="f-118" unitRef="eur">-15800000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-12" decimals="-5" id="f-119" unitRef="eur">22300000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-13" decimals="-5" id="f-120" unitRef="eur">8700000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-5" id="f-121" unitRef="eur">914500000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-5" id="f-122" unitRef="eur">9456700000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-13" decimals="-5" id="f-123" unitRef="eur">10301200000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Goodwill contextRef="c-14" decimals="-5" id="f-124" unitRef="eur">362500000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-15" decimals="-5" id="f-125" unitRef="eur">61200000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-14" decimals="-5" id="f-126" unitRef="eur">804100000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-15" decimals="-5" id="f-127" unitRef="eur">158500000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-14" decimals="-5" id="f-128" unitRef="eur">757200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-15" decimals="-5" id="f-129" unitRef="eur">609200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-14" decimals="-5" id="f-130" unitRef="eur">214400000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-15" decimals="-5" id="f-131" unitRef="eur">211900000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-14" decimals="-5" id="f-132" unitRef="eur">1176100000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-15" decimals="-5" id="f-133" unitRef="eur">80200000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-14" decimals="-5" id="f-134" unitRef="eur">83400000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-15" decimals="-5" id="f-135" unitRef="eur">6500000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-14" decimals="-5" id="f-136" unitRef="eur">81300000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-15" decimals="-5" id="f-137" unitRef="eur">229600000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-14" decimals="-5" id="f-138" unitRef="eur">3479000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-15" decimals="-5" id="f-139" unitRef="eur">1357100000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-14" decimals="-5" id="f-140" unitRef="eur">357700000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-15" decimals="-5" id="f-141" unitRef="eur">439600000</ifrs-full:Inventories>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-14" decimals="-5" id="f-142" unitRef="eur">2155700000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-15" decimals="-5" id="f-143" unitRef="eur">7145600000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:ContractAssets contextRef="c-14" decimals="-5" id="f-144" unitRef="eur">4900000</ifrs-full:ContractAssets>
    <ifrs-full:ContractAssets contextRef="c-15" decimals="-5" id="f-145" unitRef="eur">0</ifrs-full:ContractAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-14" decimals="-5" id="f-146" unitRef="eur">4885300000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c-15" decimals="-5" id="f-147" unitRef="eur">189400000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets contextRef="c-14" decimals="-5" id="f-148" unitRef="eur">280900000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets contextRef="c-15" decimals="-5" id="f-149" unitRef="eur">271900000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-14" decimals="-5" id="f-150" unitRef="eur">179100000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c-15" decimals="-5" id="f-151" unitRef="eur">400000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-5" id="f-152" unitRef="eur">11663700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-15" decimals="-5" id="f-153" unitRef="eur">13875100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-14" decimals="-5" id="f-154" unitRef="eur">19527300000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-15" decimals="-5" id="f-155" unitRef="eur">21922000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-14" decimals="-5" id="f-156" unitRef="eur">23006300000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-15" decimals="-5" id="f-157" unitRef="eur">23279100000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c-14" decimals="-5" id="f-158" unitRef="eur">248600000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-15" decimals="-5" id="f-159" unitRef="eur">248600000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve contextRef="c-14" decimals="-5" id="f-160" unitRef="eur">1229400000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve contextRef="c-15" decimals="-5" id="f-161" unitRef="eur">1828200000</ifrs-full:CapitalReserve>
    <ifrs-full:TreasuryShares contextRef="c-14" decimals="-5" id="f-162" unitRef="eur">10800000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares contextRef="c-15" decimals="-5" id="f-163" unitRef="eur">5300000</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings contextRef="c-14" decimals="-5" id="f-164" unitRef="eur">19763300000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-15" decimals="-5" id="f-165" unitRef="eur">18833000000</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves contextRef="c-14" decimals="-5" id="f-166" unitRef="eur">-984600000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-15" decimals="-5" id="f-167" unitRef="eur">-848900000</ifrs-full:OtherReserves>
    <ifrs-full:Equity contextRef="c-14" decimals="-5" id="f-168" unitRef="eur">20245900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-15" decimals="-5" id="f-169" unitRef="eur">20055600000</ifrs-full:Equity>
    <bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings contextRef="c-14" decimals="-5" id="f-170" unitRef="eur">191000000.0</bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings>
    <bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings contextRef="c-15" decimals="-5" id="f-171" unitRef="eur">176200000</bntx:NonCurrentLeaseLiabilitiesLoansAndBorrowings>
    <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="c-14" decimals="-5" id="f-172" unitRef="eur">38800000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities contextRef="c-15" decimals="-5" id="f-173" unitRef="eur">6100000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-14" decimals="-5" id="f-174" unitRef="eur">0</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:CurrentTaxLiabilitiesNoncurrent contextRef="c-15" decimals="-5" id="f-175" unitRef="eur">10400000</ifrs-full:CurrentTaxLiabilitiesNoncurrent>
    <ifrs-full:NoncurrentProvisions contextRef="c-14" decimals="-5" id="f-176" unitRef="eur">8800000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-15" decimals="-5" id="f-177" unitRef="eur">8600000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-14" decimals="-5" id="f-178" unitRef="eur">398500000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-15" decimals="-5" id="f-179" unitRef="eur">48400000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="c-14" decimals="-5" id="f-180" unitRef="eur">13100000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="c-15" decimals="-5" id="f-181" unitRef="eur">17000000.0</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-14" decimals="-5" id="f-182" unitRef="eur">39700000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-15" decimals="-5" id="f-183" unitRef="eur">6200000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-14" decimals="-5" id="f-184" unitRef="eur">689900000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-15" decimals="-5" id="f-185" unitRef="eur">272900000</ifrs-full:NoncurrentLiabilities>
    <bntx:CurrentLeaseLiabilitiesLoansAndBorrowings contextRef="c-14" decimals="-5" id="f-186" unitRef="eur">28100000</bntx:CurrentLeaseLiabilitiesLoansAndBorrowings>
    <bntx:CurrentLeaseLiabilitiesLoansAndBorrowings contextRef="c-15" decimals="-5" id="f-187" unitRef="eur">36000000.0</bntx:CurrentLeaseLiabilitiesLoansAndBorrowings>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-14" decimals="-5" id="f-188" unitRef="eur">354000000.0</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-15" decimals="-5" id="f-189" unitRef="eur">204100000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c-14" decimals="-5" id="f-190" unitRef="eur">415200000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities contextRef="c-15" decimals="-5" id="f-191" unitRef="eur">785100000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentRefundsProvision contextRef="c-14" decimals="-5" id="f-192" unitRef="eur">0</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision contextRef="c-15" decimals="-5" id="f-193" unitRef="eur">24400000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-14" decimals="-5" id="f-194" unitRef="eur">525500000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent contextRef="c-15" decimals="-5" id="f-195" unitRef="eur">595900000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentProvisions contextRef="c-14" decimals="-5" id="f-196" unitRef="eur">269300000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c-15" decimals="-5" id="f-197" unitRef="eur">367200000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentContractLiabilities contextRef="c-14" decimals="-5" id="f-198" unitRef="eur">353300000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-15" decimals="-5" id="f-199" unitRef="eur">77100000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c-14" decimals="-5" id="f-200" unitRef="eur">125100000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c-15" decimals="-5" id="f-201" unitRef="eur">860800000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-14" decimals="-5" id="f-202" unitRef="eur">2070500000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-15" decimals="-5" id="f-203" unitRef="eur">2950600000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-14" decimals="-5" id="f-204" unitRef="eur">2760400000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-15" decimals="-5" id="f-205" unitRef="eur">3223500000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-14" decimals="-5" id="f-206" unitRef="eur">23006300000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-15" decimals="-5" id="f-207" unitRef="eur">23279100000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity contextRef="c-16" decimals="-5" id="f-208" unitRef="eur">246300000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-5" id="f-209" unitRef="eur">1514500000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-5" id="f-210" unitRef="eur">-4800000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-5" id="f-211" unitRef="eur">-409600000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-5" id="f-212" unitRef="eur">25400000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-5" id="f-213" unitRef="eur">1371800000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-22" decimals="-5" id="f-214" unitRef="eur">10292500000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-13" decimals="-5" id="f-215" unitRef="eur">10292500000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-23" decimals="-5" id="f-216" unitRef="eur">8700000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-13" decimals="-5" id="f-217" unitRef="eur">8700000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-22" decimals="-5" id="f-218" unitRef="eur">10292500000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-23" decimals="-5" id="f-219" unitRef="eur">8700000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-13" decimals="-5" id="f-220" unitRef="eur">10301200000</ifrs-full:ComprehensiveIncome>
    <bntx:IssuanceOfShareCapital contextRef="c-24" decimals="-5" id="f-221" unitRef="eur">162600000</bntx:IssuanceOfShareCapital>
    <bntx:IssuanceOfShareCapital contextRef="c-25" decimals="-5" id="f-222" unitRef="eur">1000000.0</bntx:IssuanceOfShareCapital>
    <bntx:IssuanceOfShareCapital contextRef="c-13" decimals="-5" id="f-223" unitRef="eur">163600000</bntx:IssuanceOfShareCapital>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-24" decimals="-5" id="f-224" unitRef="eur">2700000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-13" decimals="-5" id="f-225" unitRef="eur">2700000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-23" decimals="-5" id="f-226" unitRef="eur">59800000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-13" decimals="-5" id="f-227" unitRef="eur">59800000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-26" decimals="-5" id="f-228" unitRef="eur">246300000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-5" id="f-229" unitRef="eur">1674400000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-5" id="f-230" unitRef="eur">-3800000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-5" id="f-231" unitRef="eur">9882900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-5" id="f-232" unitRef="eur">93900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-5" id="f-233" unitRef="eur">11893700000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-32" decimals="-5" id="f-234" unitRef="eur">9434400000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-12" decimals="-5" id="f-235" unitRef="eur">9434400000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-33" decimals="-5" id="f-236" unitRef="eur">22300000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-12" decimals="-5" id="f-237" unitRef="eur">22300000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-5" id="f-238" unitRef="eur">9434400000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-33" decimals="-5" id="f-239" unitRef="eur">22300000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-5" id="f-240" unitRef="eur">9456700000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c-34" decimals="-5" id="f-241" unitRef="eur">500000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-35" decimals="-5" id="f-242" unitRef="eur">67100000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-12" decimals="-5" id="f-243" unitRef="eur">67600000</ifrs-full:IssueOfEquity>
    <bntx:RedemptionOfConvertibleNote contextRef="c-34" decimals="-5" id="f-244" unitRef="eur">1800000</bntx:RedemptionOfConvertibleNote>
    <bntx:RedemptionOfConvertibleNote contextRef="c-35" decimals="-5" id="f-245" unitRef="eur">233200000</bntx:RedemptionOfConvertibleNote>
    <bntx:RedemptionOfConvertibleNote contextRef="c-12" decimals="-5" id="f-246" unitRef="eur">235000000.0</bntx:RedemptionOfConvertibleNote>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-35" decimals="-5" id="f-247" unitRef="eur">979500000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-36" decimals="-5" id="f-248" unitRef="eur">6900000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-12" decimals="-5" id="f-249" unitRef="eur">986400000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-35" decimals="-5" id="f-250" unitRef="eur">100000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-12" decimals="-5" id="f-251" unitRef="eur">100000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:DividendsPaid contextRef="c-32" decimals="-5" id="f-252" unitRef="eur">484300000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="c-12" decimals="-5" id="f-253" unitRef="eur">484300000</ifrs-full:DividendsPaid>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-35" decimals="-5" id="f-254" unitRef="eur">833100000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-36" decimals="-5" id="f-255" unitRef="eur">5400000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-33" decimals="-5" id="f-256" unitRef="eur">-1519800000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-12" decimals="-5" id="f-257" unitRef="eur">-681300000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <bntx:CurrentAndDeferredTaxExpenseIncome contextRef="c-33" decimals="-5" id="f-258" unitRef="eur">-554700000</bntx:CurrentAndDeferredTaxExpenseIncome>
    <bntx:CurrentAndDeferredTaxExpenseIncome contextRef="c-12" decimals="-5" id="f-259" unitRef="eur">-554700000</bntx:CurrentAndDeferredTaxExpenseIncome>
    <ifrs-full:Equity contextRef="c-37" decimals="-5" id="f-260" unitRef="eur">248600000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-5" id="f-261" unitRef="eur">1828200000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-39" decimals="-5" id="f-262" unitRef="eur">-5300000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-5" id="f-263" unitRef="eur">18833000000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-5" id="f-264" unitRef="eur">-848900000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-15" decimals="-5" id="f-265" unitRef="eur">20055600000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-42" decimals="-5" id="f-266" unitRef="eur">930300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-267" unitRef="eur">930300000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-43" decimals="-5" id="f-268" unitRef="eur">-15800000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-5" id="f-269" unitRef="eur">-15800000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-42" decimals="-5" id="f-270" unitRef="eur">930300000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-43" decimals="-5" id="f-271" unitRef="eur">-15800000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-5" id="f-272" unitRef="eur">914500000</ifrs-full:ComprehensiveIncome>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-44" decimals="-5" id="f-273" unitRef="eur">731600000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-45" decimals="-5" id="f-274" unitRef="eur">6900000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue contextRef="c-1" decimals="-5" id="f-275" unitRef="eur">738500000</bntx:ShareRepurchaseProgramRepurchasedDuringPeriodValue>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-44" decimals="-5" id="f-276" unitRef="eur">30200000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-45" decimals="-5" id="f-277" unitRef="eur">300000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-43" decimals="-5" id="f-278" unitRef="eur">-15100000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-5" id="f-279" unitRef="eur">15400000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <bntx:CurrentAndDeferredTaxExpenseIncome contextRef="c-43" decimals="-5" id="f-280" unitRef="eur">104800000</bntx:CurrentAndDeferredTaxExpenseIncome>
    <bntx:CurrentAndDeferredTaxExpenseIncome contextRef="c-1" decimals="-5" id="f-281" unitRef="eur">104800000</bntx:CurrentAndDeferredTaxExpenseIncome>
    <bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination contextRef="c-44" decimals="-5" id="f-282" unitRef="eur">102600000</bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination>
    <bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination contextRef="c-45" decimals="-5" id="f-283" unitRef="eur">1100000</bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination>
    <bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination contextRef="c-1" decimals="-5" id="f-284" unitRef="eur">103700000</bntx:TreasurySharesUsedForAcquisitionOfBusinessCombination>
    <ifrs-full:Equity contextRef="c-46" decimals="-5" id="f-285" unitRef="eur">248600000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-5" id="f-286" unitRef="eur">1229400000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-5" id="f-287" unitRef="eur">-10800000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-49" decimals="-5" id="f-288" unitRef="eur">19763300000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-50" decimals="-5" id="f-289" unitRef="eur">-984600000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-5" id="f-290" unitRef="eur">20245900000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-5" id="f-291" unitRef="eur">930300000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-12" decimals="-5" id="f-292" unitRef="eur">9434400000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-13" decimals="-5" id="f-293" unitRef="eur">10292500000</ifrs-full:ProfitLoss>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-5" id="f-294" unitRef="eur">255800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-12" decimals="-5" id="f-295" unitRef="eur">3519700000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-13" decimals="-5" id="f-296" unitRef="eur">4753900000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-5" id="f-297" unitRef="eur">1186100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-12" decimals="-5" id="f-298" unitRef="eur">12954100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-13" decimals="-5" id="f-299" unitRef="eur">15046400000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-5" id="f-300" unitRef="eur">183400000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-12" decimals="-5" id="f-301" unitRef="eur">123300000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-13" decimals="-5" id="f-302" unitRef="eur">75200000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-5" id="f-303" unitRef="eur">51400000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-12" decimals="-5" id="f-304" unitRef="eur">108600000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-13" decimals="-5" id="f-305" unitRef="eur">93900000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-5" id="f-306" unitRef="eur">-298000000.0</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-12" decimals="-5" id="f-307" unitRef="eur">625500000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-13" decimals="-5" id="f-308" unitRef="eur">-387500000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-309" unitRef="eur">-3800000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="c-12" decimals="-5" id="f-310" unitRef="eur">-600000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="c-13" decimals="-5" id="f-311" unitRef="eur">-4600000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-1" decimals="-5" id="f-312" unitRef="eur">519600000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-12" decimals="-5" id="f-313" unitRef="eur">265300000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-13" decimals="-5" id="f-314" unitRef="eur">1500000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-1" decimals="-5" id="f-315" unitRef="eur">7900000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-12" decimals="-5" id="f-316" unitRef="eur">18900000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-13" decimals="-5" id="f-317" unitRef="eur">305200000</ifrs-full:AdjustmentsForFinanceCosts>
    <bntx:AdjustmentsForMovementsInGovernmentGrants contextRef="c-1" decimals="-5" id="f-318" unitRef="eur">2400000</bntx:AdjustmentsForMovementsInGovernmentGrants>
    <bntx:AdjustmentsForMovementsInGovernmentGrants contextRef="c-12" decimals="-5" id="f-319" unitRef="eur">300000</bntx:AdjustmentsForMovementsInGovernmentGrants>
    <bntx:AdjustmentsForMovementsInGovernmentGrants contextRef="c-13" decimals="-5" id="f-320" unitRef="eur">-89000000.0</bntx:AdjustmentsForMovementsInGovernmentGrants>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-1" decimals="-5" id="f-321" unitRef="eur">0</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-12" decimals="-5" id="f-322" unitRef="eur">0</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="c-13" decimals="-5" id="f-323" unitRef="eur">-2200000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c-1" decimals="-5" id="f-324" unitRef="eur">-175500000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c-12" decimals="-5" id="f-325" unitRef="eur">241000000.0</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c-13" decimals="-5" id="f-326" unitRef="eur">-57300000</ifrs-full:GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets contextRef="c-1" decimals="-5" id="f-327" unitRef="eur">5374000000</bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets>
    <bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets contextRef="c-12" decimals="-5" id="f-328" unitRef="eur">4369900000</bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets>
    <bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets contextRef="c-13" decimals="-5" id="f-329" unitRef="eur">-11808100000</bntx:AdjustmentsForDecreaseIncreaseInTradeAccountsReceivableContractAssetsAndOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-5" id="f-330" unitRef="eur">81900000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-12" decimals="-5" id="f-331" unitRef="eur">62900000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-13" decimals="-5" id="f-332" unitRef="eur">-438400000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions contextRef="c-1" decimals="-5" id="f-333" unitRef="eur">118900000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
    <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions contextRef="c-12" decimals="-5" id="f-334" unitRef="eur">85700000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
    <bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions contextRef="c-13" decimals="-5" id="f-335" unitRef="eur">1516100000</bntx:AdjustmentsForIncreaseDecreaseInTradePayablesOtherLiabilitiesContractLiabilitiesAndProvisions>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-336" unitRef="eur">258200000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-12" decimals="-5" id="f-337" unitRef="eur">29300000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-13" decimals="-5" id="f-338" unitRef="eur">1200000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-339" unitRef="eur">5400000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-12" decimals="-5" id="f-340" unitRef="eur">21500000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c-13" decimals="-5" id="f-341" unitRef="eur">12200000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-342" unitRef="eur">482900000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-12" decimals="-5" id="f-343" unitRef="eur">4222100000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-13" decimals="-5" id="f-344" unitRef="eur">3457900000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-345" unitRef="eur">-766200000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-12" decimals="-5" id="f-346" unitRef="eur">-51800000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-13" decimals="-5" id="f-347" unitRef="eur">-13400000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-348" unitRef="eur">5371400000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-12" decimals="-5" id="f-349" unitRef="eur">13577400000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-13" decimals="-5" id="f-350" unitRef="eur">889700000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-351" unitRef="eur">249400000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-352" unitRef="eur">329200000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-353" unitRef="eur">127500000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-354" unitRef="eur">-700000</bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-355" unitRef="eur">600000</bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-356" unitRef="eur">3400000</bntx:ProceedsPaymentsFromSalesOrDestructionsOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-357" unitRef="eur">455400000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities>
    <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-358" unitRef="eur">34100000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities>
    <bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-359" unitRef="eur">26500000</bntx:PurchaseOfIntangibleAssetsAndRightOfUseAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-360" unitRef="eur">336900000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-361" unitRef="eur">0</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-362" unitRef="eur">20800000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-363" unitRef="eur">7128400000</ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-364" unitRef="eur">47800000</ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities>
    <ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-365" unitRef="eur">19500000</ifrs-full:OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities>
    <bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-5" id="f-366" unitRef="eur">1216300000</bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities>
    <bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities contextRef="c-12" decimals="-5" id="f-367" unitRef="eur">375200000</bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities>
    <bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities contextRef="c-13" decimals="-5" id="f-368" unitRef="eur">-375200000</bntx:InvestmentProceedsFromMaturityOfOtherFinancialAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-369" unitRef="eur">-6954500000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-12" decimals="-5" id="f-370" unitRef="eur">-35300000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-13" decimals="-5" id="f-371" unitRef="eur">-566100000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-5" id="f-372" unitRef="eur">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-12" decimals="-5" id="f-373" unitRef="eur">110500000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-13" decimals="-5" id="f-374" unitRef="eur">160900000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-375" unitRef="eur">300000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-12" decimals="-5" id="f-376" unitRef="eur">800000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="c-13" decimals="-5" id="f-377" unitRef="eur">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-378" unitRef="eur">100000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-12" decimals="-5" id="f-379" unitRef="eur">18800000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c-13" decimals="-5" id="f-380" unitRef="eur">52600000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-381" unitRef="eur">40300000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-12" decimals="-5" id="f-382" unitRef="eur">41100000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-13" decimals="-5" id="f-383" unitRef="eur">14100000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-384" unitRef="eur">738500000</bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities>
    <bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities contextRef="c-12" decimals="-5" id="f-385" unitRef="eur">986400000</bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities>
    <bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities contextRef="c-13" decimals="-5" id="f-386" unitRef="eur">0</bntx:ShareRepurchaseProgramClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c-1" decimals="-5" id="f-387" unitRef="eur">0</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c-12" decimals="-5" id="f-388" unitRef="eur">484300000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c-13" decimals="-5" id="f-389" unitRef="eur">0</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-390" unitRef="eur">-778600000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-12" decimals="-5" id="f-391" unitRef="eur">-1419300000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-13" decimals="-5" id="f-392" unitRef="eur">94200000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-1" decimals="-5" id="f-393" unitRef="eur">-2361700000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-12" decimals="-5" id="f-394" unitRef="eur">12122800000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-13" decimals="-5" id="f-395" unitRef="eur">417800000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-396" unitRef="eur">-14500000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-12" decimals="-5" id="f-397" unitRef="eur">60100000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-13" decimals="-5" id="f-398" unitRef="eur">64700000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-5" id="f-399" unitRef="eur">164800000</bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents>
    <bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents contextRef="c-12" decimals="-5" id="f-400" unitRef="eur">-500000</bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents>
    <bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents contextRef="c-13" decimals="-5" id="f-401" unitRef="eur">0</bntx:EffectOfOtherValuationChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-15" decimals="-5" id="f-402" unitRef="eur">13875100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-31" decimals="-5" id="f-403" unitRef="eur">1692700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-21" decimals="-5" id="f-404" unitRef="eur">1210200000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-5" id="f-405" unitRef="eur">11663700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-15" decimals="-5" id="f-406" unitRef="eur">13875100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-31" decimals="-5" id="f-407" unitRef="eur">1692700000</ifrs-full:CashAndCashEquivalents>
    <bntx:DisclosureOfCorporateInformationExplanatoryTextBlock contextRef="c-1" id="f-408">Corporate Information&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioNTech SE is a limited company incorporated and domiciled in Germany. American Depositary Shares (ADS) representing BioNTech SE&#x2019;s ordinary shares have been publicly traded on the Nasdaq Global Select Market since October&#160;10, 2019. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BioNTech SE is registered in the commercial register B of the Mainz Local Court under the number HRB&#160;48720. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements, which were prepared in accordance with International Financial Reporting Standards (IFRS), present the financial position and the results of operations of BioNTech SE and its subsidiaries, hereinafter also referred to as &#x201c;BioNTech,&#x201d; the &#x201c;Group,&#x201d; &#x201c;we&#x201d; or &#x201c;us.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Supervisory Board on March 19, 2024.&lt;/span&gt;&lt;/div&gt;</bntx:DisclosureOfCorporateInformationExplanatoryTextBlock>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-409">Significant Accounting Policies&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.1&#160;&#160;&#160;&#160;Basis of Preparation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We prepare and publish our consolidated financial statements in Euros and round numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.2&#160;&#160;&#160;&#160;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group controls an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investee&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if, and only if, the Group has&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;power over the investee (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, existing rights that give it the current ability to direct the relevant activities of the investee); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;expos&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ure, or rights, to variable returns from its involvement with the investee; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ability to use its power over the investee to affect its returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, there is a presumption that a majority of voting rights results in control. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whether an investee is controlled is re-assessed if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when control is obtained over the subsidiary and ceases when control over the subsidiary is lost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with the Group&#x2019;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If control over a subsidiary is lost, the related assets (including goodwill), liabilities, non-controlling interests and other components of equity are derecognized, while any resultant gain or loss is recognized in the consolidated statements of profit or loss. Any investment retained is recognized at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.3&#160;&#160;&#160;&#160;Summary of Material Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements are presented in Euros, which is also our functional currency. For each entity, the Group determines the functional currency, and items included in the consolidated financial statements of such entities are measured using that functional currency. We use the direct method of consolidation and, on disposal of a foreign operation, the gain or loss that is reclassified to the consolidated statements of profit or loss reflects the amount that arises from using this method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transactions and Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions in foreign currencies are initially recorded by the Group&#x2019;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency translation effects from the translation of operating activities include foreign exchange differences arising on operating items such as trade receivables and trade payables and are either shown as other operating income or expenses on a cumulative basis. Foreign currency translation effects presented within finance income and expenses include foreign exchange differences arising on financing items such as loans and borrowings as well as foreign exchange differences arising on cash and cash equivalents and are either shown as finance income or expenses on a cumulative basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation on Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and the transactions recorded in their consolidated statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current versus Non-Current Classifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities in the consolidated statements of financial position are presented based on current or non-current classification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An asset is current when it is either: (i)&#160;expected to be realized or intended to be sold or consumed in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;expected to be realized within twelve months after the reporting period, or (iv)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least twelve&#160;months after the reporting period. All other assets are classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A liability is current when it is either: (i)&#160;expected to be settled in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;due to be settled within twelve months after the reporting period, or (iv)&#160;there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.3&#160;&#160;&#160;&#160;Revenue from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Identification of the Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract is an agreement between two or more parties that establishes enforceable rights and obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Identification of Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customer contracts often include bundles of licenses, goods and services. If the granting of a license is bundled together with delivering of goods and or the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determining Transaction Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply judgment when determining the consideration that is expected to be received. If the consideration in an agreement includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenues reversal in the amount of cumulative revenues recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenues are updated at each reporting date to reflect the current facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allocation of Transaction Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling prices. We have established the following hierarchy to determine the standalone selling prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Where standalone selling prices for offered licenses, goods or services are observable and reasonably consistent across customers, our standalone selling price estimates are derived from our respective pricing history. However, due to the limited number of customers and the limited company history, this approach can rarely be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Where sales prices for an offering are not directly observable or highly variable across customers, we follow a cost-plus-margin approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For offerings that have highly variable pricing and lack substantial direct costs to estimate based on a cost-plus-margin approach, we allocate the transaction price by applying a residual approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Judgment is required when estimating standalone selling prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recognition of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenues are recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of our licensing arrangements, we provide the licensee with a research and development license, which represents a right to access our intellectual property as it exists throughout the license period (as our intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time as our customers simultaneously receive and consume the benefits from our performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues based on the collaboration partners&#x2019; gross profit, which is shared under the respective collaboration agreements, are recognized based on the sales-based or usage-based royalty exemption; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the underlying sales occur, which is when the performance obligation has been satisfied. As described further in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 3,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; judgment is applied to certain aspects when accounting for the collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between us and the collaborator and the transactions between us and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenues. Any consideration related to activities in which we are considered the agent is accounted for as net revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from the sale of pharmaceutical and medical products (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;e.g&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) are recognized when we transfer control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and we have not retained any significant risks of ownership or future obligations with respect to the product. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, payments from customers are due within 30 days after invoice. However, with respect to our collaboration with Pfizer Inc., or Pfizer, there is a significant time lag between when revenues are recognized and the payments are received. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#x2019;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenues from bill-and-hold arrangements are recognized at the point in time when the customer obtains control of the product and all of the following criteria have been met: (i)&#160;the arrangement is substantive; (ii)&#160;the product is identified separately as belonging to the customer; (iii)&#160;the product is ready for physical transfer to the customer; and (iv)&#160;we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether title and significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If we transfer goods or services to a customer before the customer pays the respective consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A receivable represents our right to an amount of consideration that is unconditional (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., only the passage of time is required before payment of the consideration is due). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract liability is the obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before we transfer goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(whichever is earlier). Contract liabilities are recognized as revenue when we fulfill our performance obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Refund Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A refund liability is a consideration which has been received but which will need to be refunded to the customer in the future as it represents an amount to which we are ultimately not entitled under the contract. A refund liability is measured at the amount of consideration received (or receivable) to which we do not expect to be entitled (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounts not included in the transaction price). We update our estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.4&#160;&#160;&#160;&#160;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period in which they are incurred. Regarding internal projects, we consider that regulatory approval and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained. Payments made to third parties, such as contract research and development organizations as compensation for subcontracted research and development, that are deemed not to transfer intellectual property are expensed as internal research and development expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority. We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset unless the respective intellectual property is mainly used as part of our general ongoing research and development activities without any intent to market the respective product as such. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. Sales-based milestone or royalty payments incurred under license agreements after the approval date of the respective pharmaceutical product are recognized as expenses in cost of sales as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent internal research and development costs in relation to intellectual property rights are expensed because the technical feasibility of the internal research and development activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the second quarter of 2023, we had assessed that inventory produced prior to successful regulatory approval did not meet the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;criteria&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the second quarter of 2023, pre-launch products from the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because it is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. If regulatory approval for a product candidate is obtained, the relevant write-down would be reversed to a maximum of the original cost. Subsequently, inventory is recognized as cost of sales. This reassessment has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses are described in Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government grants and similar grants which are accounted for in accordance with IAS 20 are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs for which the grant is intended to compensate are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consolidated statements of profit or loss &lt;/span&gt;over the useful life of the underlying asset subject to funding.&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current Income Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed by tax authorities, excluding interest expenses and penalties on the underpayment of taxes. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities are recognized for all taxable temporary differences, except: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recognition of Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and deferred tax items are recognized similarly to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax assets and current tax liabilities are offset if, and only if, we have a legally enforceable right to set off the recognized amounts and intend either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when we have a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Future Tax Legislation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting (BEPS) project to tackle tax avoidance, the OECD/G20 Inclusive Framework (an association of about 140 countries) decided to introduce a global minimum taxation for large multinational groups (known as Pillar 2). The Global Anti-Base Erosion Rules are intended to ensure that large multinational groups pay a minimum level of tax on the income arising in each jurisdiction where they operate. In December 2021, the OECD published its Model Rules, which serve as a draft bill for implementation into national domestic law, followed by guidelines and commentaries published in March 2022. In December 2022, the EU adopted a corresponding directive (EU 2022/2523) that obliges EU member states to transpose the rules into national domestic law. If the effective tax rate in any jurisdiction is below the minimum rate (15%), the Group may be subject to the so-called top-up tax or a so-called qualified domestic minimum top-up tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several jurisdictions in which the Group operates have transposed the OECD Model Rules into national domestic law and brought them into force. In addition, the Group is closely following the progress of the legislative process in each country in which the Group operates. As of the balance sheet date, the BEPS Pillar 2 regulations (MinBestRL UmsG) had already been transposed into German law (MinStG). The date of application of the law in Germany is for financial years beginning after December 30, 2023. Subsequently, as the OECD Model Rules have entered into force in Germany, the Group is obliged to file top-up tax information returns for all entities which are part of the Group, beginning in financial year 2024. The Group falls within the scope of these regulations. The Group carried out an analysis as of the reporting date to determine the fundamental impact and the jurisdictions in which the Group is exposed to possible effects in connection with a Pillar 2 top-up tax.&lt;/span&gt;&lt;/div&gt;Based on this analysis, no countries were identified in which the Group would be materially affected by a Pillar 2 top-up tax. Consequently, the average effective Group tax rate would not have changed if the Pillar 2 legislation had already been in force on the balance sheet date. BioNTech applies the exception in IAS 12, according to which no deferred tax assets and liabilities in connection with the second income taxes of the second pillar of the OECD are recognized and no disclosures are made.&lt;div style="margin-top:6pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.7&#160;&#160;&#160;&#160;Business Combinations and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to executing business combinations are recognized when they are incurred and are classified as general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.10. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in these circumstances is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the consideration in in-licensing agreements paid by us to acquire intellectual property is recognized as an intangible asset. If in-licensing includes research and development services, the share of consideration attributable to these services is deferred and recognized in research and development expenses according to the utilization thereof. Payments depending on the achievement of specific milestones as part of the purchase of intangible assets, except for intangible assets acquired in a business combination, are recognized as subsequent acquisition cost of the intangible asset and as a financial liability once the milestone is reached.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The useful lives of intangible assets are assessed as either finite or indefinite. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives are amortized generally on a straight-line basis over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each reporting period at the least. The amortization expense on intangible assets with finite lives is recognized in the consolidated statements of profit or loss in the expense category that is consistent with the function of the intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the useful lives applied to the Group&#x2019;s intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite useful lives are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 2.3.10&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details). In the case of intangible assets not yet available for use, the point in time from which a capitalized asset can be expected to generate economic benefit for the Group cannot be determined. Such assets are not amortized, and therefore classified as having an indefinite useful life. The intangible assets not yet available for use are tested for impairment annually, or when there is an indication for impairment on an individual basis. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have classified advanced payments on intangible assets as intangible assets that are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An intangible asset is derecognized upon disposal (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2.3.4 for further details in connection with our accounting of internally generated intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress is stated at cost. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10-33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7-18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and business equipment has a useful life of 1-10 years and is reported under equipment, tools and installations due to immateriality. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An item of property, plant and equipment initially recognized is derecognized upon disposal (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss when the asset is derecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Non-Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, we assess whether there is an indication that a non-financial asset may be impaired. Goodwill is tested for impairment at least annually. Impairment is determined for goodwill by assessing the recoverable amount of each cash-generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, we estimate the asset&#x2019;s or CGU&#x2019;s recoverable amount. The recoverable amount is the higher of an asset&#x2019;s or CGU&#x2019;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the asset does not generate independent cash inflows, the impairment test is performed for the smallest group of assets that generate largely independent cash inflows from other assets (CGU). When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or the non-current assets of the CGU are considered impaired and written down to their recoverable amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment losses are recognized in the consolidated statements of profit or loss in expense categories consistent with the function of the impaired asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with an indefinite useful life are tested for impairment annually at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets not yet available for use are not amortized, but rather tested for impairment when a triggering event arises or at least once a year. The identification of triggering events takes place on a quarterly or on an ad hoc basis with the involvement of the responsible departments, taking internal and external information sources into consideration. The impairment test is performed annually or if there are indications of impairment by determining the asset&#x2019;s value in use. In assessing value in use, the estimated discounted future cash flows are based on long-term forecast calculations reflecting the asset&#x2019;s estimated product life cycles. The assumptions are based on internal estimates along with external market studies. The result of the valuation depends to a large extent on the estimates by the management of the future cash flows of the assets and the discount rate applied, and is therefore subject to uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;i) Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Initial Recognition and Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets mainly include money market funds, bank deposits and reverse repos, security investments, trade receivables, cash at banks as well as equity investments. Financial assets are initially measured at fair value as of the trade date and &#x2013; depending on their classification &#x2013; subsequently measured at amortized cost, fair value through other comprehensive income (OCI) or fair value through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of financial assets depends on their classification, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Measured at Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at amortized cost include trade receivables and other financial assets &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are generally measured using the effective interest rate (EIR) method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. With respect to trade receivables, we applied the practical expedient, which means that they are measured at the transaction price determined in accordance with IFRS 15. Refer to the accounting policies in Note&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Other financial assets measured at amortized cost are held to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in our consolidated statements of profit or loss when the financial asset is derecognized, modified or impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Designated at Fair Value through OCI (Equity Instruments)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon initial recognition, we can irrevocably elect to classify equity investments as equity instruments designated at fair value through OCI if they meet the definition of equity under IAS 32 and are not held for trading. The classification is determined on an instrument-by-instrument basis. Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the consolidated statements of profit or loss when the right of payment has been established. Equity instruments designated at fair value through OCI are not subject to impairment assessment. We elected to irrevocably classify our non-listed and listed equity investments under this category. They are recognized using trade date accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets at Fair Value through Profit or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedging instruments are measured at fair value through profit or loss. A financial asset exists if the derivative has a positive fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, removed from the consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance for expected credit losses (ECLs) is considered for all non-derivative financial debt investments, including cash, time deposits and debt securities of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since our financial debt investments are considered to be investments with low risk, the expected credit loss in the upcoming twelve months is used to determine the impairment loss. Wherever a considerable increase in the default risk is assumed, the lifetime expected credit loss of the financial asset is considered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. This means that the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. We have established an ECL model that is based on the probability of default (PD), considers the respective country default probabilities and takes the maturities into account. In order to determine the PD of companies, we use the maturities of the trade receivables and the score of the companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is objective evidence that certain trade receivables or contract assets are fully or partially impaired, additional loss allowances are recognized to account for expected credit losses. A debtor&#x2019;s creditworthiness is assumed to be impaired if there are objective indications that the debtor is in financial difficulties, such as the disappearance of an active market for its products or impending insolvency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ii) Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are generally measured at amortized cost using the effective interest rate (EIR) method. Derivatives with negative fair values not designated as hedging instruments and liabilities for contingent consideration in business combinations are measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities measured at amortized cost include loans and borrowings, trade payables and other financial liabilities. They are measured at amortized cost using the EIR method. Gains and losses are recognized in the consolidated statements of profit or loss when the liabilities are derecognized as well as through the EIR amortization process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;iii) Expenses and Income from Exchange Forward Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effects from foreign exchange forward contracts, which are measured at fair value through profit or loss, are shown as either other operating income or other operating expenses on a cumulative basis and might switch between those two items during the year-to-date reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, we determine whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the purpose of fair value disclosures, classes of assets and liabilities have been determined on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred in bringing each product to its present location and condition are accounted for as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raw materials and supplies: purchase cost on a first-in / first-out basis; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale. Write-offs are recorded if inventories are expected to be unsaleable, do not fulfill the specification defined by our quality standards or if their shelf-life has expired. For our inventories subject to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the collaboration partners&#x2019; gross profit share mechanism&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we consider the contractual compensation payments in the estimate of the net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning with the second quarter of 2023, pre-launch products from the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt; product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained (see also Note 2.3.4 for further information on our assessment regarding the potential of our pre-launch products to produce economic benefits).&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents comprise cash at banks and on hand and short-term investments that we consider to be highly liquid (including deposits, money market funds and reverse repos) with an original maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Deposits with an original maturity of more than three months are recognized as other financial assets.&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Treasury Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the par value method to our repurchases of outstanding American Depositary Shares, or ADSs. Accordingly, the nominal value of acquired treasury shares is deducted from equity and shown in the separate item &#x201c;Treasury shares&#x201d;. Any premium paid in excess of the nominal value of a repurchased ADS is deducted from the capital reserve. On the trade date, we recognize a liability, and on the settlement date, we settle in cash. We recognize the foreign exchange differences that may occur between the trade and settlement date as profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset &#x2013; this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the asset. We possess this right when we hold the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;we have the right to operate the asset; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;we designed the asset in a way that predetermines how and for what purpose it will be used. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception or on reassessment of a contract that contains a lease component, the consideration in the contract is allocated to each lease component on the basis of their relative standalone prices. However, for leases of land and buildings in which we are a lessee, we have elected not to separate non-lease components, and instead account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize a right-of-use asset and a lease liability at the lease commencement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#x2019;s incremental borrowing rate. Generally, the incremental borrowing rate is used as the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability comprise the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fixed payments, including in-substance fixed payments;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amounts expected to be payable under a residual value guarantee; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the exercise price under a purchase option that is reasonably certain to be exercised, lease payments in an optional renewal period if it is reasonably certain that the extension option is exercised, and penalties for early termination of a lease unless it is reasonably certain that the contract will not be terminated early.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is subsequently measured at amortized cost using the EIR method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if we change our assessment of whether we will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the consolidated statements of profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets are presented separately and lease liabilities are presented under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life or shorter lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Leases and Leases of Low-Value Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. We recognize the lease payments associated with these leases as an expense in the consolidated statements of profit or loss on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When we expect some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A provision is also recognized for certain contracts with suppliers for which the unavoidable costs of meeting the obligations exceed the economic benefits expected to be received. The economic benefits considered in the assessment comprise the future benefits we are directly entitled to under the contract as well as the anticipated future benefits that are the economic consequence of the contract if these benefits can be reliably determined.&lt;/span&gt;&lt;/div&gt;The expense relating to a provision is presented in the consolidated statements of profit or loss net of any reimbursement.&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions) or in cash (cash-settled transactions). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 2, share-based payments are generally divided into cash-settled and equity-settled. Both types of payment transactions are measured initially at their fair value as of the grant date. The fair value is determined using an appropriate valuation model, further details of which are given in Note 16. Rights granted under cash-settled transactions are remeasured at fair value at the end of each reporting period until the settlement date. The cost of share-based payment awards is recognized over the relevant service period, applying either the straight-line method or the graded vesting method, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves) or other liabilities, over the period in which the service is provided (the vesting period). The cumulative expense recognized for cash- and equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired, and also reflects the best estimate of the number of equity instruments expected to ultimately vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of our best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we have a choice of settling either in cash or by providing equity instruments, the rights granted are accounted for as an equity-settled transaction, unless there is a present obligation to settle in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If, due to local tax regulations, an amount is withheld for the employee&#x2019;s tax obligations and paid directly to the tax authorities in cash on the employee&#x2019;s behalf, the entire share-based payment program remains an equity-settled plan based on the IFRS 2 classification. Accordingly, the amount withheld for the employee&#x2019;s tax obligations expected to be paid directly to the tax authorities is reclassified from &#x201c;Other reserves&#x201d; to &#x201c;Other non-financial liabilities&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:42.25pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2.3.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Dividend&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize a liability to pay a dividend when the distribution is authorized. As per the corporate laws of Germany, a distribution is authorized when it is approved by the general shareholder meeting. A corresponding amount is recognized directly in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.4&#160;&#160;&#160;&#160;Standards Applied for the First Time&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;IFRS 17 Insurance Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#x2013; Comparative Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income taxes: International Tax Reform &#x2013; Pillar Two Model Rules&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.5&#160;&#160;&#160;&#160;Standards Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.179%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We do not expect a significant impact from the application of any of these standards and amendments.</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-410">Basis of Preparation&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). &lt;/span&gt;&lt;/div&gt;We prepare and publish our consolidated financial statements in Euros and round numbers to thousands or millions of Euros, respectively. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations. Rounding applied may differ from rounding published in different units in the previous years.</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="c-1" id="f-411">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;Decisions with respect to business operations and resource allocations are made by our Management Board, as the chief operating decision maker (CODM) based on BioNTech as a whole. Accordingly, we operate and make decisions as a single operating segment, which is also our reporting segment.</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="c-1" id="f-412">Basis of Consolidation&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements comprise the financial statements of BioNTech SE and its controlled investees (subsidiaries). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group controls an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investee&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; if, and only if, the Group has&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;power over the investee (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, existing rights that give it the current ability to direct the relevant activities of the investee); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;expos&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ure, or rights, to variable returns from its involvement with the investee; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ability to use its power over the investee to affect its returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, there is a presumption that a majority of voting rights results in control. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whether an investee is controlled is re-assessed if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when control is obtained over the subsidiary and ceases when control over the subsidiary is lost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The profit / (loss) and each component of other comprehensive income / (loss) for the period are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the consolidated financial statements of subsidiaries to bring their accounting policies in line with the Group&#x2019;s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated on consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If control over a subsidiary is lost, the related assets (including goodwill), liabilities, non-controlling interests and other components of equity are derecognized, while any resultant gain or loss is recognized in the consolidated statements of profit or loss. Any investment retained is recognized at fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-413">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currencies&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements are presented in Euros, which is also our functional currency. For each entity, the Group determines the functional currency, and items included in the consolidated financial statements of such entities are measured using that functional currency. We use the direct method of consolidation and, on disposal of a foreign operation, the gain or loss that is reclassified to the consolidated statements of profit or loss reflects the amount that arises from using this method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transactions and Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transactions in foreign currencies are initially recorded by the Group&#x2019;s entities at their respective functional currency spot rates at the date the transaction first qualifies for recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the spot exchange rate to use on initial recognition of the related asset, expense or income (or part of it) on the derecognition of a non-monetary asset or non-monetary liability relating to advance consideration, the date of the transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of advance consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency translation effects from the translation of operating activities include foreign exchange differences arising on operating items such as trade receivables and trade payables and are either shown as other operating income or expenses on a cumulative basis. Foreign currency translation effects presented within finance income and expenses include foreign exchange differences arising on financing items such as loans and borrowings as well as foreign exchange differences arising on cash and cash equivalents and are either shown as finance income or expenses on a cumulative basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation on Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consolidation, the assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date and the transactions recorded in their consolidated statements of profit or loss are translated at exchange rates prevailing at the dates of the transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange differences arising on translation for consolidation are recognized in other comprehensive income. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is reclassified to profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising upon the acquisition are treated as assets and liabilities of the foreign operation and translated at the spot rate of exchange at the reporting date.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <bntx:DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock contextRef="c-1" id="f-414">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current versus Non-Current Classifications&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities in the consolidated statements of financial position are presented based on current or non-current classification. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An asset is current when it is either: (i)&#160;expected to be realized or intended to be sold or consumed in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;expected to be realized within twelve months after the reporting period, or (iv)&#160;cash or cash equivalents, unless it is restricted from being exchanged or used to settle a liability for at least twelve&#160;months after the reporting period. All other assets are classified as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A liability is current when it is either: (i)&#160;expected to be settled in the normal operating cycle, (ii)&#160;held primarily for the purpose of trading, (iii)&#160;due to be settled within twelve months after the reporting period, or (iv)&#160;there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. The Group classifies all other liabilities as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are classified as non-current assets and liabilities, respectively.&lt;/span&gt;&lt;/div&gt;</bntx:DescriptionOfAccountingPolicyForAssetsAndLiabilitiesExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-415">Revenue from Contracts with Customers&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Identification of the Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract is an agreement between two or more parties that establishes enforceable rights and obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Identification of Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customer contracts often include bundles of licenses, goods and services. If the granting of a license is bundled together with delivering of goods and or the rendering of services, it is assessed whether these agreements are comprised of more than one performance obligation. A performance obligation is only accounted for as the grant of a license if the grant of a license is the sole or the predominant promise of the performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determining Transaction Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply judgment when determining the consideration that is expected to be received. If the consideration in an agreement includes a variable amount, we estimate the amount of consideration to which we will be entitled in exchange for transferring the goods to the customer. At contract inception, the variable consideration is estimated based on the most likely amount of consideration expected from the transaction and constrained until it is highly probable that a significant revenues reversal in the amount of cumulative revenues recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. The estimated revenues are updated at each reporting date to reflect the current facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allocation of Transaction Prices&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a contract with a customer contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling prices. We have established the following hierarchy to determine the standalone selling prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Where standalone selling prices for offered licenses, goods or services are observable and reasonably consistent across customers, our standalone selling price estimates are derived from our respective pricing history. However, due to the limited number of customers and the limited company history, this approach can rarely be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Where sales prices for an offering are not directly observable or highly variable across customers, we follow a cost-plus-margin approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For offerings that have highly variable pricing and lack substantial direct costs to estimate based on a cost-plus-margin approach, we allocate the transaction price by applying a residual approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Judgment is required when estimating standalone selling prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recognition of Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each separate performance obligation, it is evaluated whether control is transferred either at a point in time or over time. For performance obligations that are satisfied over time, revenues are recognized based on a measure of progress, which depicts the performance in transferring control to the customer. Under the terms of our licensing arrangements, we provide the licensee with a research and development license, which represents a right to access our intellectual property as it exists throughout the license period (as our intellectual property is still subject to further research). Therefore, the promise to grant a license is accounted for as a performance obligation satisfied over time as our customers simultaneously receive and consume the benefits from our performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues based on the collaboration partners&#x2019; gross profit, which is shared under the respective collaboration agreements, are recognized based on the sales-based or usage-based royalty exemption; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the underlying sales occur, which is when the performance obligation has been satisfied. As described further in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 3,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; judgment is applied to certain aspects when accounting for the collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue arrangements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations in order to determine the appropriate treatment for the transactions between us and the collaborator and the transactions between us and other third parties. The classification of transactions under such arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, is accounted for as gross revenues. Any consideration related to activities in which we are considered the agent is accounted for as net revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from the sale of pharmaceutical and medical products (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;e.g&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., COVID-19 vaccine sales and other sales of peptides and retroviral vectors for clinical supply) are recognized when we transfer control of the product to the customer. Control of the product normally transfers when the customer gains physical possession and we have not retained any significant risks of ownership or future obligations with respect to the product. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, payments from customers are due within 30 days after invoice. However, with respect to our collaboration with Pfizer Inc., or Pfizer, there is a significant time lag between when revenues are recognized and the payments are received. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#x2019;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For certain contracts, the finished product may temporarily be stored at our location under a bill-and-hold arrangement. Revenues from bill-and-hold arrangements are recognized at the point in time when the customer obtains control of the product and all of the following criteria have been met: (i)&#160;the arrangement is substantive; (ii)&#160;the product is identified separately as belonging to the customer; (iii)&#160;the product is ready for physical transfer to the customer; and (iv)&#160;we do not have the ability to use the product or direct it to another customer. In determining when the customer obtains control of the product, we consider certain indicators, including whether title and significant risks and rewards of ownership have transferred to the customer and whether customer acceptance has been received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If we transfer goods or services to a customer before the customer pays the respective consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Trade Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A receivable represents our right to an amount of consideration that is unconditional (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., only the passage of time is required before payment of the consideration is due). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract liability is the obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before we transfer goods or services to the customer, a contract liability is recognized when the payment is made or when the payment is due &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(whichever is earlier). Contract liabilities are recognized as revenue when we fulfill our performance obligations under the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Refund Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A refund liability is a consideration which has been received but which will need to be refunded to the customer in the future as it represents an amount to which we are ultimately not entitled under the contract. A refund liability is measured at the amount of consideration received (or receivable) to which we do not expect to be entitled (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounts not included in the transaction price). We update our estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers contextRef="c-1" id="f-416">payments from customers are due within 30 days after invoice</ifrs-full:DescriptionOfSignificantPaymentTermsInContractsWithCustomers>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-417">Research and Development Expenses&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period in which they are incurred. Regarding internal projects, we consider that regulatory approval and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained. Payments made to third parties, such as contract research and development organizations as compensation for subcontracted research and development, that are deemed not to transfer intellectual property are expensed as internal research and development expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority. We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset unless the respective intellectual property is mainly used as part of our general ongoing research and development activities without any intent to market the respective product as such. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. Sales-based milestone or royalty payments incurred under license agreements after the approval date of the respective pharmaceutical product are recognized as expenses in cost of sales as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent internal research and development costs in relation to intellectual property rights are expensed because the technical feasibility of the internal research and development activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the second quarter of 2023, we had assessed that inventory produced prior to successful regulatory approval did not meet the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;criteria&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the second quarter of 2023, pre-launch products from the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because it is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. If regulatory approval for a product candidate is obtained, the relevant write-down would be reversed to a maximum of the original cost. Subsequently, inventory is recognized as cost of sales. This reassessment has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses are described in Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="c-1" id="f-418">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government grants and similar grants which are accounted for in accordance with IAS 20 are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as other income on a systematic basis over the periods that the related costs for which the grant is intended to compensate are expensed. When the grant relates to an asset, it is recognized as deferred income within the consolidated statements of financial position. Other income is subsequently recognized in our&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consolidated statements of profit or loss &lt;/span&gt;over the useful life of the underlying asset subject to funding.</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c-1" id="f-419">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Taxes&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current Income Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, current income taxes presented for the period include adjustments for uncertain tax payments or tax refunds for periods not yet finally assessed by tax authorities, excluding interest expenses and penalties on the underpayment of taxes. In the event that amounts included in the tax return are considered unlikely to be accepted by the tax authorities (uncertain tax positions), a provision for income taxes is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities are recognized for all taxable temporary differences, except: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized, except:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year in which the asset is realized, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recognition of Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and deferred tax items are recognized similarly to the underlying transaction either in profit or loss, other comprehensive income or directly in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax assets and current tax liabilities are offset if, and only if, we have a legally enforceable right to set off the recognized amounts and intend either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred tax assets and deferred tax liabilities are only offset when we have a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;same taxation authority on either (i) the same taxable entity or (ii) different taxable entities, which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sales Tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses and assets are recognized net of sales tax, except when the sales tax incurred on a purchase of assets or services is not recoverable from the taxation authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net amount of sales tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the consolidated statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Future Tax Legislation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Organisation for Economic Co-operation and Development (OECD) Base Erosion and Profit Shifting (BEPS) project to tackle tax avoidance, the OECD/G20 Inclusive Framework (an association of about 140 countries) decided to introduce a global minimum taxation for large multinational groups (known as Pillar 2). The Global Anti-Base Erosion Rules are intended to ensure that large multinational groups pay a minimum level of tax on the income arising in each jurisdiction where they operate. In December 2021, the OECD published its Model Rules, which serve as a draft bill for implementation into national domestic law, followed by guidelines and commentaries published in March 2022. In December 2022, the EU adopted a corresponding directive (EU 2022/2523) that obliges EU member states to transpose the rules into national domestic law. If the effective tax rate in any jurisdiction is below the minimum rate (15%), the Group may be subject to the so-called top-up tax or a so-called qualified domestic minimum top-up tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several jurisdictions in which the Group operates have transposed the OECD Model Rules into national domestic law and brought them into force. In addition, the Group is closely following the progress of the legislative process in each country in which the Group operates. As of the balance sheet date, the BEPS Pillar 2 regulations (MinBestRL UmsG) had already been transposed into German law (MinStG). The date of application of the law in Germany is for financial years beginning after December 30, 2023. Subsequently, as the OECD Model Rules have entered into force in Germany, the Group is obliged to file top-up tax information returns for all entities which are part of the Group, beginning in financial year 2024. The Group falls within the scope of these regulations. The Group carried out an analysis as of the reporting date to determine the fundamental impact and the jurisdictions in which the Group is exposed to possible effects in connection with a Pillar 2 top-up tax.&lt;/span&gt;&lt;/div&gt;Based on this analysis, no countries were identified in which the Group would be materially affected by a Pillar 2 top-up tax. Consequently, the average effective Group tax rate would not have changed if the Pillar 2 legislation had already been in force on the balance sheet date. BioNTech applies the exception in IAS 12, according to which no deferred tax assets and liabilities in connection with the second income taxes of the second pillar of the OECD are recognized and no disclosures are made.</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="c-12" decimals="2" id="f-420" unitRef="number">0.15</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory contextRef="c-1" id="f-421">Business Combinations and Goodwill&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any non-controlling interests in the acquiree.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is initially measured at cost as the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling interests and any previous interest held over the net identifiable assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to executing business combinations are recognized when they are incurred and are classified as general and administrative expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After initial recognition, goodwill is tested at least annually or when there is an indication for impairment. See Note&#160;2.3.10. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where goodwill has been allocated to a cash-generating unit (CGU) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal. Goodwill disposed of in these circumstances is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-422">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The portion of the consideration in in-licensing agreements paid by us to acquire intellectual property is recognized as an intangible asset. If in-licensing includes research and development services, the share of consideration attributable to these services is deferred and recognized in research and development expenses according to the utilization thereof. Payments depending on the achievement of specific milestones as part of the purchase of intangible assets, except for intangible assets acquired in a business combination, are recognized as subsequent acquisition cost of the intangible asset and as a financial liability once the milestone is reached.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The useful lives of intangible assets are assessed as either finite or indefinite. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives are amortized generally on a straight-line basis over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at the end of each reporting period at the least. The amortization expense on intangible assets with finite lives is recognized in the consolidated statements of profit or loss in the expense category that is consistent with the function of the intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the useful lives applied to the Group&#x2019;s intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite useful lives are tested for impairment at least annually, or when there is an indication for impairment, either individually or at the level of a cash-generating unit (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 2.3.10&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details). In the case of intangible assets not yet available for use, the point in time from which a capitalized asset can be expected to generate economic benefit for the Group cannot be determined. Such assets are not amortized, and therefore classified as having an indefinite useful life. The intangible assets not yet available for use are tested for impairment annually, or when there is an indication for impairment on an individual basis. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have classified advanced payments on intangible assets as intangible assets that are not yet ready for use. Advanced payments on intangible assets are tested for impairment on an annual basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An intangible asset is derecognized upon disposal (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2.3.4 for further details in connection with our accounting of internally generated intangible assets.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c-1" id="f-423">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the useful lives applied to the Group&#x2019;s intangible assets is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intellectual property rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-51" id="f-424">P8Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-52" id="f-425">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-53" id="f-426">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-54" id="f-427">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-55" id="f-428">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-56" id="f-429">P8Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-430">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress is stated at cost. Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment if the recognition criteria are met. All other repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10-33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7-18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and business equipment has a useful life of 1-10 years and is reported under equipment, tools and installations due to immateriality. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An item of property, plant and equipment initially recognized is derecognized upon disposal (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statements of profit or loss when the asset is derecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year-end and adjusted prospectively, if appropriate.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-431">&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10-33&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7-18&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition and production costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;198.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;100.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;182.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;329.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;273.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;725.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;217.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;273.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;725.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;50.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;189.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;344.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;389.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;969.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cumulative depreciation and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;60.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;116.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;97.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;175.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;195.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;178.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;609.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;199.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;168.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;389.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;757.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-57" id="f-432">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-58" id="f-433">P33Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-59" id="f-434">P7Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-60" id="f-435">P18Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-61" id="f-436">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-62" id="f-437">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory contextRef="c-1" id="f-438">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Non-Financial Assets&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, we assess whether there is an indication that a non-financial asset may be impaired. Goodwill is tested for impairment at least annually. Impairment is determined for goodwill by assessing the recoverable amount of each cash-generating unit (or group of CGUs) to which the goodwill relates. If any indication exists, or when annual impairment testing is performed, we estimate the asset&#x2019;s or CGU&#x2019;s recoverable amount. The recoverable amount is the higher of an asset&#x2019;s or CGU&#x2019;s fair value less costs of disposal and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If the asset does not generate independent cash inflows, the impairment test is performed for the smallest group of assets that generate largely independent cash inflows from other assets (CGU). When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or the non-current assets of the CGU are considered impaired and written down to their recoverable amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment losses are recognized in the consolidated statements of profit or loss in expense categories consistent with the function of the impaired asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with an indefinite useful life are tested for impairment annually at the CGU level, as appropriate, and when circumstances indicate that the carrying value may be impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets not yet available for use are not amortized, but rather tested for impairment when a triggering event arises or at least once a year. The identification of triggering events takes place on a quarterly or on an ad hoc basis with the involvement of the responsible departments, taking internal and external information sources into consideration. The impairment test is performed annually or if there are indications of impairment by determining the asset&#x2019;s value in use. In assessing value in use, the estimated discounted future cash flows are based on long-term forecast calculations reflecting the asset&#x2019;s estimated product life cycles. The assumptions are based on internal estimates along with external market studies. The result of the valuation depends to a large extent on the estimates by the management of the future cash flows of the assets and the discount rate applied, and is therefore subject to uncertainty.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-439">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;i) Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Initial Recognition and Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets mainly include money market funds, bank deposits and reverse repos, security investments, trade receivables, cash at banks as well as equity investments. Financial assets are initially measured at fair value as of the trade date and &#x2013; depending on their classification &#x2013; subsequently measured at amortized cost, fair value through other comprehensive income (OCI) or fair value through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Subsequent Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement of financial assets depends on their classification, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Measured at Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at amortized cost include trade receivables and other financial assets &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are generally measured using the effective interest rate (EIR) method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. With respect to trade receivables, we applied the practical expedient, which means that they are measured at the transaction price determined in accordance with IFRS 15. Refer to the accounting policies in Note&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.3.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Other financial assets measured at amortized cost are held to collect contractual cash flows, which are solely payments of principal and interest. Gains and losses are recognized in our consolidated statements of profit or loss when the financial asset is derecognized, modified or impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Designated at Fair Value through OCI (Equity Instruments)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon initial recognition, we can irrevocably elect to classify equity investments as equity instruments designated at fair value through OCI if they meet the definition of equity under IAS 32 and are not held for trading. The classification is determined on an instrument-by-instrument basis. Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognized as other income in the consolidated statements of profit or loss when the right of payment has been established. Equity instruments designated at fair value through OCI are not subject to impairment assessment. We elected to irrevocably classify our non-listed and listed equity investments under this category. They are recognized using trade date accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets at Fair Value through Profit or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivatives not designated as hedging instruments are measured at fair value through profit or loss. A financial asset exists if the derivative has a positive fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, removed from the consolidated statements of financial position) when the rights to receive cash flows from the asset have expired or have been transferred in terms of fulfilling the derecognition criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance for expected credit losses (ECLs) is considered for all non-derivative financial debt investments, including cash, time deposits and debt securities of the Group. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all of the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since our financial debt investments are considered to be investments with low risk, the expected credit loss in the upcoming twelve months is used to determine the impairment loss. Wherever a considerable increase in the default risk is assumed, the lifetime expected credit loss of the financial asset is considered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. This means that the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. We have established an ECL model that is based on the probability of default (PD), considers the respective country default probabilities and takes the maturities into account. In order to determine the PD of companies, we use the maturities of the trade receivables and the score of the companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there is objective evidence that certain trade receivables or contract assets are fully or partially impaired, additional loss allowances are recognized to account for expected credit losses. A debtor&#x2019;s creditworthiness is assumed to be impaired if there are objective indications that the debtor is in financial difficulties, such as the disappearance of an active market for its products or impending insolvency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ii) Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are generally measured at amortized cost using the effective interest rate (EIR) method. Derivatives with negative fair values not designated as hedging instruments and liabilities for contingent consideration in business combinations are measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities measured at amortized cost include loans and borrowings, trade payables and other financial liabilities. They are measured at amortized cost using the EIR method. Gains and losses are recognized in the consolidated statements of profit or loss when the liabilities are derecognized as well as through the EIR amortization process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included as finance costs in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated statements of profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;iii) Expenses and Income from Exchange Forward Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effects from foreign exchange forward contracts, which are measured at fair value through profit or loss, are shown as either other operating income or other operating expenses on a cumulative basis and might switch between those two items during the year-to-date reporting periods.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c-1" id="f-440">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is a market-based measurement. For some assets and liabilities, observable market transactions or market information is available. For other assets and liabilities, observable market transactions or market information might not be available. When a price for an identical asset or liability is not observable, another valuation technique is used. To increase consistency and comparability in fair value measurements, there are three levels of the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 contains the use of quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 inputs are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within this hierarchy, estimated values are made by management based on reasonable assumptions, including other fair value methods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, we determine whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the purpose of fair value disclosures, classes of assets and liabilities have been determined on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c-1" id="f-441">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred in bringing each product to its present location and condition are accounted for as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;raw materials and supplies: purchase cost on a first-in / first-out basis; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;unfinished goods and finished goods: cost of direct materials and labor, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs, and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net realizable value is the estimated selling price in the ordinary course of business less estimated costs of completion and the estimated costs necessary to make the sale. Write-offs are recorded if inventories are expected to be unsaleable, do not fulfill the specification defined by our quality standards or if their shelf-life has expired. For our inventories subject to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the collaboration partners&#x2019; gross profit share mechanism&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we consider the contractual compensation payments in the estimate of the net realizable value.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning with the second quarter of 2023, pre-launch products from the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt; product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. However, because is not probable until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained (see also Note 2.3.4 for further information on our assessment regarding the potential of our pre-launch products to produce economic benefits).</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c-1" id="f-442">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;Cash and cash equivalents comprise cash at banks and on hand and short-term investments that we consider to be highly liquid (including deposits, money market funds and reverse repos) with an original maturity of three months or less that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. Deposits with an original maturity of more than three months are recognized as other financial assets.</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory contextRef="c-1" id="f-443">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Treasury Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the par value method to our repurchases of outstanding American Depositary Shares, or ADSs. Accordingly, the nominal value of acquired treasury shares is deducted from equity and shown in the separate item &#x201c;Treasury shares&#x201d;. Any premium paid in excess of the nominal value of a repurchased ADS is deducted from the capital reserve. On the trade date, we recognize a liability, and on the settlement date, we settle in cash. We recognize the foreign exchange differences that may occur between the trade and settlement date as profit or loss.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c-1" id="f-444">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset &#x2013; this may be specified explicitly or implicitly and should be physically distinct or represent substantially all of the capacity of a physically distinct asset. If the supplier has a substantive substitution right, then the asset is not identified; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the asset. We possess this right when we hold the decision-making rights that are most relevant to changing how and for what purpose the asset is used. In rare cases where the decision about how and for what purpose the asset is used is predetermined, the Group has the right to direct the use of the asset if either:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;we have the right to operate the asset; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;we designed the asset in a way that predetermines how and for what purpose it will be used. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception or on reassessment of a contract that contains a lease component, the consideration in the contract is allocated to each lease component on the basis of their relative standalone prices. However, for leases of land and buildings in which we are a lessee, we have elected not to separate non-lease components, and instead account for the lease and non-lease components as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize a right-of-use asset and a lease liability at the lease commencement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of the costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received by the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset and the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the incremental borrowing interest rate implicit in the lease or, if that rate cannot be readily determined, the Group&#x2019;s incremental borrowing rate. Generally, the incremental borrowing rate is used as the discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability comprise the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fixed payments, including in-substance fixed payments;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;variable lease payments that depend on an index or a rate, initially measured using the index or rate as of the commencement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;amounts expected to be payable under a residual value guarantee; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:45.35pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the exercise price under a purchase option that is reasonably certain to be exercised, lease payments in an optional renewal period if it is reasonably certain that the extension option is exercised, and penalties for early termination of a lease unless it is reasonably certain that the contract will not be terminated early.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is subsequently measured at amortized cost using the EIR method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the estimate of the amount expected to be payable under a residual value guarantee, or if we change our assessment of whether we will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right-of-use asset or is recorded in the consolidated statements of profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets are presented separately and lease liabilities are presented under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life or shorter lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Leases and Leases of Low-Value Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less or leases of low-value assets. We recognize the lease payments associated with these leases as an expense in the consolidated statements of profit or loss on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets or shorter lease term, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Useful life or shorter lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment, tools and installations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2-3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Automobiles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3-4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfRightOfUseAssetsEstimatedUsefulLivesExplanatoryTableTextBlock>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-63" id="f-446">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-64" id="f-447">P25Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-65" id="f-448">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-66" id="f-449">P5Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-67" id="f-450">P2Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-68" id="f-451">P3Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-69" id="f-452">P3Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets contextRef="c-70" id="f-453">P4Y</bntx:UsefulLifeMeasuredAsPeriodOfTimeRightOfUseAssets>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c-1" id="f-454">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Provisions&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions are recognized when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When we expect some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A provision is also recognized for certain contracts with suppliers for which the unavoidable costs of meeting the obligations exceed the economic benefits expected to be received. The economic benefits considered in the assessment comprise the future benefits we are directly entitled to under the contract as well as the anticipated future benefits that are the economic consequence of the contract if these benefits can be reliably determined.&lt;/span&gt;&lt;/div&gt;The expense relating to a provision is presented in the consolidated statements of profit or loss net of any reimbursement.</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-455">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees (and others providing similar services) receive remuneration in the form of share-based payments, which are settled in equity instruments (equity-settled transactions) or in cash (cash-settled transactions). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with IFRS 2, share-based payments are generally divided into cash-settled and equity-settled. Both types of payment transactions are measured initially at their fair value as of the grant date. The fair value is determined using an appropriate valuation model, further details of which are given in Note 16. Rights granted under cash-settled transactions are remeasured at fair value at the end of each reporting period until the settlement date. The cost of share-based payment awards is recognized over the relevant service period, applying either the straight-line method or the graded vesting method, where applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are recognized in cost of sales, research and development expenses, sales and marketing expenses or general and administrative expenses, together with a corresponding increase in equity (other reserves) or other liabilities, over the period in which the service is provided (the vesting period). The cumulative expense recognized for cash- and equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired, and also reflects the best estimate of the number of equity instruments expected to ultimately vest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of our best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we have a choice of settling either in cash or by providing equity instruments, the rights granted are accounted for as an equity-settled transaction, unless there is a present obligation to settle in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If, due to local tax regulations, an amount is withheld for the employee&#x2019;s tax obligations and paid directly to the tax authorities in cash on the employee&#x2019;s behalf, the entire share-based payment program remains an equity-settled plan based on the IFRS 2 classification. Accordingly, the amount withheld for the employee&#x2019;s tax obligations expected to be paid directly to the tax authorities is reclassified from &#x201c;Other reserves&#x201d; to &#x201c;Other non-financial liabilities&#x201d;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory contextRef="c-1" id="f-456">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Dividend&lt;/span&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize a liability to pay a dividend when the distribution is authorized. As per the corporate laws of Germany, a distribution is authorized when it is approved by the general shareholder meeting. A corresponding amount is recognized directly in equity.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForDividendsExplanatory>
    <bntx:DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock contextRef="c-1" id="f-457">Standards Applied for the First Time&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;IFRS 17 Insurance Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#x2013; Comparative Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income taxes: International Tax Reform &#x2013; Pillar Two Model Rules&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="c-1" id="f-458">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, the following potentially relevant new and amended standards and interpretations became effective, but did not have a material impact on our consolidated financial statements: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;IFRS 17 Insurance Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 17 Insurance contracts: Initial Application of IFRS 17 and IFRS 9 &#x2013; Comparative Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 and IFRS Practice Statement 2: Disclosure of Accounting Policies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 8 Accounting policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 12 Income taxes: International Tax Reform &#x2013; Pillar Two Model Rules&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <bntx:DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock contextRef="c-1" id="f-459">Standards Issued but Not Yet Effective&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.179%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We do not expect a significant impact from the application of any of these standards and amendments.</bntx:DescriptionOfAccountingPolicyForStandardsIssuedButNotYetEffectiveExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-460">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The new and amended standards and interpretations that are issued but not yet effective by the date of issuance of the financial statements and that might have an impact on our financial statements are disclosed below. We have not adopted any standards early and intend to adopt these new and amended standards and interpretations, if applicable, when they become effective. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.179%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Standards / Interpretations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Date of application&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 1 Presentation of Financial Statements: Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #92D050;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-461">Significant Accounting Judgements, Estimates and Assumptions&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant accounting judgments, as well as key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. We based our assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues from Contracts with Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We applied the following judgments, estimates and assumptions that significantly affect the determination of the amount and timing of revenues from contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identification and Determination of Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate revenues from collaboration and license agreements, which contain multiple elements, including licenses to use, research, develop, manufacture and commercialize candidates and products, research and development services as well as obligations to develop and manufacture preclinical and clinical material and products. We determined that those collaboration and license agreements qualify as contracts with customers. A &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract is an agreement between two or more parties that establishes enforceable rights and obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception of each agreement, we apply judgment when determining which promises represent distinct performance obligations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If promises are not distinct, they are combined until the bundle of promised goods and services is distinct. For some agreements, this results in accounting for goods and services promised in a collaboration and license agreement as a single performance obligation with a single measure of progress. For these combined performance obligations, we assess which of these promises is the predominant promise to determine the nature of the performance obligation. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When licenses are granted, we determined that the grant of the license is the predominant promise within the combined performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In our view, we grant our customers a right to access or a right to use our intellectual property due to the collaboration and license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of the Transaction Price&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration and license agreements often include variable consideration, which is contingent on the occurrence or non-occurrence of a future event (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, reaching a certain milestone). When determining deferred revenues from a collaboration and license agreement, we need to estimate the amount of consideration to which we will be entitled in exchange for transferring the promised goods or services to our customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As there are usually only two possible outcomes (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, milestone is reached or not), we have assessed that the method of the most likely amount is the best method to predict the amount of consideration to which we will be entitled. At contract inception, the most likely amount for milestone payments is estimated to be &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;zero&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have assessed that the likelihood of achieving the respective milestone decreases depending on how far the expected date of achieving the milestone lies in the future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, we use judgment to determine when to include variable consideration in the transaction price in such a way that it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with respect to the variable consideration is subsequently resolved. We have concluded that future milestone payments are fully constrained at the end of the current financial year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future milestone payments would become unconstrained upon the satisfaction of the milestone event, specifically a development event, regulatory approval or achievement of a sales milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allocation of the Transaction Price to Performance Obligations and Revenue Recognition as Performance Obligations are Satisfied&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate the transaction price to performance obligations based on their relative standalone selling prices, which are generally based on our best estimates and interpretations of facts and circumstances of each contractual agreement and may require significant judgment to determine appropriate allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments and reimbursement for expenses are initially deferred on our consolidated statements of financial position. We assessed that no significant financing component exists within our collaboration agreements since the overall business purpose of advanced payments is to support the payment structure rather than to provide a significant benefit of financing. For performance obligations in which the costs vary based on progress, an input-based measure that takes into account cost incurred is the most reliable indicator of the progress of the related research activities. In other cases, revenue recognition on a straight-line basis may be the most reliable indicator of our performance toward complete satisfaction. If the contractual activities progress, the achievement of development milestones will be used to measure the progress toward complete satisfaction. We evaluate the measure of progress in each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net profit or loss in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon successfully commercializing a pharmaceutical product, the collaboration and license agreements also provide for additional profit-sharing or tiered royalties earned when customers recognize net sales of licensed products as well as sales milestone payments. Revenue is recognized based on the sales-based or usage-based royalty exemption; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; when, or as, the underlying sales occur, which is when the performance obligation has been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal-Agent Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration agreements that involve two or more partners who contribute to the provision of a specific good or service to a customer are assessed in terms of principal-agent considerations. Under our current collaboration agreements, the allocation of marketing and distribution rights defines territories in which the collaboration partner acts as a principal in each case. We recognize revenue net based on the collaboration partners&#x2019; gross profit in territories where the partner is responsible for supply, and on a gross basis when directly supplying our customers in our territories when control has been transferred. Amounts paid to collaboration partners for their share of our profits earned where we are the principal in the transaction are recorded as cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer Agreement Characteristics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to our collaboration with Pfizer, commercial revenues are recognized based on our collaboration partner&#x2019;s gross profit from COVID-19 vaccine sales, which is shared under the respective collaboration agreement. In determining commercial revenues pursuant to this collaboration agreement, we are reliant on our collaboration partner for details regarding its gross profit for the period at hand. Some of the information which our collaboration partner provides us with to identify the gross profit is, by necessity, preliminary and subject to change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s gross profit share is calculated based on sales and takes into account transfer prices. The latter include manufacturing and shipping costs, which represent standard prices and include mark-ups on manufacturing costs as specified by the terms of the agreement. Manufacturing and shipping cost variances were considered as far as those have been identified. Nevertheless, those input parameters may be adjusted once actual costs are determined. The sales as reported by Pfizer have been used to estimate license obligations in terms of royalties and sales milestones. Sales milestones and royalties are recognized as they are earned by the partners. Sales milestones are shared equally, while royalty payments are borne by the partners on the basis of revenues in the territories for which the partners are responsible and subsequently deducted as cost under the gross profit shared. The estimated royalty fees applied to net sales reflect the license obligations to the extent currently identified from third-party contractual arrangements. Changes in estimates are accounted for prospectively, when determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing cost variances include expenses from unused contract manufacturing capacities and overstock inventories finally scrapped. As only materialized costs &#x2013; which means manufacturing capacities finally lapsed or inventories finally scrapped &#x2013; are shared with the partner in a cash-effective manner, the gross profit share impact is anticipated once assessed as being highly probable to occur. Therefore, information on Pfizer&#x2019;s write-downs of inventories is considered. Any changes to this assessment will be recognized prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer&#x2019;s determination of manufacturing and shipping costs also affects the transfer prices that have been charged to COVID-19 vaccine supplies that it manufactures and supplies to us and may be subject to adjustment whenever manufacturing and shipping cost variances are identified. Likewise, our own cost of sales and the respective gross profit share owed to our partner may be adjusted prospectively, when changes are determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contract balances related to the Pfizer agreement, see &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Judgment is required in determining whether a right to consideration is unconditional and thus qualifies as a receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provisions and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently confronted with a number of claims and legal proceedings. They include claims from third parties demanding indemnification for alleged infringement of a third-party patent or other intellectual proprietary rights, as well as product liability claims. In respect of these matters, we assess whether provisions must be recorded and whether contingencies must be reported. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to uncertainties relating to these matters, provisions and contingencies are based on the best information available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant judgment is required in the determination of whether and when a provision is to be recorded and what the appropriate amount for such provision should be. Notably, judgment is required in the following areas:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determining whether an obligation exists&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determining the probability of an outflow of economic benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determining whether the amount of an obligation is reliably estimable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Estimating the amount of the expenditure required to settle the present obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of each reporting period, we reassess the potential obligations related to our pending claims and litigation and adjust our respective provisions and contingencies to reflect the current best estimate. In addition, we monitor and evaluate new information that we receive after the end of the respective reporting period, but before the consolidated financial statements are authorized for issue, in order to determine whether this provides additional information regarding conditions that existed at the end of the reporting period. Changes to estimates, assumptions and outcomes compared to previous estimates and assumptions could require material adjustments to the carrying amounts of the respective provisions recorded and additional provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected timing or amounts of any outflows of economic benefits resulting from these lawsuits and claims are uncertain and difficult to estimate or even not estimable, as they generally depend on the duration of the legal proceedings and settlement negotiations required to resolve the litigation and claims and the unpredictability of the outcomes of legal disputes in several jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disclosures in respect of third-party claims and litigation for which no provisions have been recognized are made in the form of contingent liabilities, unless a potential outflow of resources is considered remote. It is not practicable to estimate the financial impact of contingent liabilities due to the uncertainties around lawsuits and claims as outlined above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further disclosures and carrying amounts relating to provisions as well as contingencies, see Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17 and Note 18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nature of our business and primary focus of our activities, including development of our platforms and manufacturing technologies, generate a significant amount of research and development expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research costs are expensed as incurred. Development expenditures on an individual project are recognized as an intangible asset if, and only if, the capitalization criteria are met. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our assessment, we have concluded that, d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ue to the inherent risk of failure in pharmaceutical development and the uncertainty of approval, these criteria are usually not met before regulatory approval is achieved. The related expenditure is reflected in the consolidated statements of profit or loss in the period in which the expenditure is incurred. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into agreements under which third parties grant licenses to us, which are known as in-license agreements. If in-licensing results in consideration for the acquisition of intellectual property that meets the definition of an identifiable asset, this is capitalized as an intangible asset. If the transaction also includes research and development services to be provided by the licensor, the share of consideration attributable to these services is recognized in research and development expenses in line with the performance of the services. The allocation of consideration attributable to the acquisition of intellectual property and consideration attributable to the research and development services provided by the licensor requires management to make judgements and assumptions. These judgments and assumptions can materially affect our research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our accounting for business combinations, judgment is required in determining whether an intangible asset is identifiable and whether it should be recorded separately from goodwill. Additionally, estimating the acquisition-date fair values in conjunction with purchase price allocation involves estimation uncertainty and discretionary decisions. The necessary measurements are based on information available on the acquisition date and on expectations and assumptions that have been deemed reasonable by management. These judgments, estimates and assumptions can materially affect our financial position and profit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant assumptions and estimates are required to determine the appropriate amount of amortization of intangible assets. They relate in particular to the determination of the underlying useful life. The useful life of an intangible asset is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on our estimates regarding the period over which the intangible asset is expected to generate economic benefits for us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant assumptions and estimates are also required for the identification of a potential need to recognize an impairment loss. These estimates include management&#x2019;s assumptions regarding future cash flow projections and economic risks that require significant judgment and assumptions about future developments. They can be affected by a variety of factors, including, but not limited to, changes in business strategy, internal forecasts and the estimation of weighted average cost of capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the assumptions underlying our assessment of the impairment of goodwill and intangible assets could require material adjustments to the carrying amount of our recognized goodwill and intangible assets, as well as to the amounts of impairment charges recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining the fair value of share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. We used valuation models such as a binomial or Monte Carlo simulation model for the measurement of the cash- and equity-settled transactions&#x2019; fair value, taking into account certain assumptions relating to a number of factors, including the volatility of the stock price, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching a minimum hurdle to exercise the relevant options. For awards which were granted prior to the initial public offering, at a time where no quoted market prices existed, the valuation model assumptions included the option&#x2019;s underlying share price. For awards which were granted after the initial public offering, the grant date&#x2019;s share prices on the Nasdaq Global Select Market were included in the valuation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A fluctuation assumption is applied when estimating the number of equity instruments for which service conditions are expected to be satisfied and will be revised if material differences arise. Ultimately, a true-up to the number satisfied by the settlement date will be recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further disclosures relating to share-based payments, see Note 16.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxes in more than one tax jurisdiction. Due to the increasing complexity of tax laws and the corresponding uncertainty regarding the legal interpretation by the fiscal authorities, tax calculations are generally subject to an elevated amount of uncertainty. To the extent necessary, possible tax risks are taken into account in the form of provisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not recognize or we would impair deferred tax assets if it is unlikely that a corresponding amount of future taxable profit will be available against which the deductible temporary differences, tax loss carry forwards and tax credits can be utilized. The assessment whether a deferred tax asset can be recognized or is impaired requires significant judgment, as we need to estimate future taxable profits to determine whether the utilization of the deferred tax asset is probable. In evaluating our ability to utilize our deferred tax assets, we consider all available positive and negative evidence, including the level of historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are recoverable. Based on the requirements in IAS 12, to not place reliance on future events that are uncertain as they for example cannot be controlled, managements assessment takes particular into account the fact that there is an inherent risk of failure in pharmaceutical development and an uncertainty of approval which is dependent on external regulatory agencies&#x2019; opinions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This also includes management&#x2019;s assessment on the character and amounts of taxable future profits, the periods in which those profits are expected to occur, and the availability of tax planning opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our management continued to take the view that deferred tax assets on tax losses carried forward that relate to subsidiaries which have a loss-making history cannot be recognized. This includes the assessment that those subsidiaries have neither any taxable temporary differences nor any tax planning opportunities available that could support the recognition of deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further disclosures relating to deferred taxes, see Note 8.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception contextRef="c-14" decimals="INF" id="f-462" unitRef="eur">0</bntx:EstimatedMilestonePaymentToBeReceivedAtContractInception>
    <ifrs-full:DisclosureOfCompositionOfGroupExplanatory contextRef="c-1" id="f-463">Group Information&lt;div style="margin-top:6pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Information about Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the following subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;% equity interest&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech BioNTainer Holding GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Cell &amp;amp; Gene Therapies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Delivery Technologies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Halle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Diagnostics GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Europe GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Idar-Oberstein Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Idar-Oberstein &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Individualized mRNA Manufacturing GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovation and Services Marburg GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Marburg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovation GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovative Manufacturing Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Idar-Oberstein &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Manufacturing GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Manufacturing Marburg GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Marburg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Real Estate Holding GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Holzkirchen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Real Estate Verwaltungs GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Holzkirchen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep DE GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Berlin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;JPT Peptide Technologies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Berlin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;NT Security and Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;reSano GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Australia Pty Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Melbourne&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech R&amp;amp;D (Austria) GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Austria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vienna&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech (Shanghai) Pharmaceuticals Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shanghai&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep France SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Paris&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Biopharma BioNTech Israel Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tel Aviv&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;New Technologies Re&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Nigeria Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Nigeria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Lagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Rwanda Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Rwanda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Kigali&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech S&#xe9;n&#xe9;gal Suarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Senegal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dakar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Pharmaceuticals Spain S.L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Barcelona&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Switzerland GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Basel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Taiwan Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taiwan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taipei&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Tunisia SARL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tunisia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tunis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Turkey T&#x131;bbi &#xdc;r&#xfc;nler Ve Klinik Ara&#x15f;tirma Ticaret Anonim &#x15e;irketi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;T&#xfc;rkiye&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Istanbul&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech UK Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;London&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;London&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.3%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Research and Development, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech USA Holding, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech US Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Delivery Technologies (US), LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;JPT Peptide Technologies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Included during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Fully acquired during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All entities listed above are included in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;AT Impf GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Munich&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Entity with Significant Influence over the Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Medine GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCompositionOfGroupExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory contextRef="c-1" id="f-464">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the following subsidiaries: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.193%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;% equity interest&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech BioNTainer Holding GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Cell &amp;amp; Gene Therapies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Delivery Technologies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Halle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Diagnostics GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Europe GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Idar-Oberstein Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Idar-Oberstein &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Individualized mRNA Manufacturing GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovation and Services Marburg GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Marburg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovation GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Innovative Manufacturing Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Idar-Oberstein &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Manufacturing GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Manufacturing Marburg GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Marburg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Real Estate Holding GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Holzkirchen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Real Estate Verwaltungs GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Holzkirchen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep DE GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Berlin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;JPT Peptide Technologies GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Berlin &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;NT Security and Services GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;reSano GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Australia Pty Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Melbourne&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech R&amp;amp;D (Austria) GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Austria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vienna&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech (Shanghai) Pharmaceuticals Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shanghai&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep France SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Paris&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Biopharma BioNTech Israel Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Israel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tel Aviv&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;New Technologies Re&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Nigeria Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Nigeria&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Lagos&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Rwanda Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Rwanda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Kigali&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech S&#xe9;n&#xe9;gal Suarl&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Senegal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dakar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Pharmaceuticals Asia Pacific Pte. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Pharmaceuticals Spain S.L&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Barcelona&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Switzerland GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Switzerland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Basel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Taiwan Co. Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taiwan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Taipei&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Tunisia SARL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tunisia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Tunis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Turkey T&#x131;bbi &#xdc;r&#xfc;nler Ve Klinik Ara&#x15f;tirma Ticaret Anonim &#x15e;irketi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;T&#xfc;rkiye&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Istanbul&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech UK Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;London&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;London&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.3%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Research and Development, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech USA Holding, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech US Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;BioNTech Delivery Technologies (US), LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;InstaDeep LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Dover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;JPT Peptide Technologies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Cambridge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Included during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Fully acquired during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-71" decimals="2" id="f-465" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-72" decimals="2" id="f-466" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-73" decimals="2" id="f-467" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-74" decimals="2" id="f-468" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-75" decimals="2" id="f-469" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-76" decimals="2" id="f-470" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-77" decimals="2" id="f-471" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-78" decimals="2" id="f-472" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-79" decimals="2" id="f-473" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-80" decimals="2" id="f-474" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-81" decimals="2" id="f-475" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-82" decimals="2" id="f-476" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-83" decimals="2" id="f-477" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-84" decimals="2" id="f-478" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-85" decimals="2" id="f-479" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-86" decimals="2" id="f-480" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-87" decimals="2" id="f-481" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-88" decimals="2" id="f-482" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-89" decimals="2" id="f-483" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-90" decimals="2" id="f-484" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-91" decimals="2" id="f-485" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-92" decimals="2" id="f-486" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-93" decimals="2" id="f-487" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-94" decimals="2" id="f-488" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-95" decimals="2" id="f-489" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-96" decimals="2" id="f-490" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-97" decimals="2" id="f-491" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-98" decimals="2" id="f-492" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-99" decimals="2" id="f-493" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-100" decimals="2" id="f-494" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-101" decimals="2" id="f-495" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-102" decimals="2" id="f-496" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-103" decimals="2" id="f-497" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-104" decimals="2" id="f-498" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-105" decimals="2" id="f-499" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-106" decimals="2" id="f-500" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-107" decimals="2" id="f-501" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-108" decimals="2" id="f-502" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-109" decimals="2" id="f-503" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-110" decimals="2" id="f-504" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-111" decimals="2" id="f-505" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-112" decimals="2" id="f-506" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-113" decimals="2" id="f-507" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-114" decimals="2" id="f-508" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-115" decimals="2" id="f-509" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-116" decimals="2" id="f-510" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-117" decimals="2" id="f-511" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-118" decimals="2" id="f-512" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-119" decimals="2" id="f-513" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-120" decimals="2" id="f-514" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-121" decimals="2" id="f-515" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-122" decimals="2" id="f-516" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-123" decimals="2" id="f-517" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-124" decimals="2" id="f-518" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-125" decimals="2" id="f-519" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-126" decimals="2" id="f-520" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-127" decimals="2" id="f-521" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-128" decimals="2" id="f-522" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-129" decimals="2" id="f-523" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-130" decimals="2" id="f-524" unitRef="number">5.3</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-131" decimals="2" id="f-525" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-132" decimals="2" id="f-526" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-133" decimals="2" id="f-527" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-134" decimals="2" id="f-528" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-135" decimals="2" id="f-529" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-136" decimals="2" id="f-530" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-137" decimals="2" id="f-531" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-138" decimals="2" id="f-532" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-139" decimals="2" id="f-533" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-140" decimals="2" id="f-534" unitRef="number">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ATHOS KG, Holzkirchen, Germany, is the sole shareholder of AT Impf GmbH, Munich, Germany, and beneficial owner of the following percentage of ordinary shares in BioNTech at the dates as indicated. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;AT Impf GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Munich&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfSignificantInvestmentsByParentCompanyExplanatoryTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-141" decimals="4" id="f-536" unitRef="number">0.4377</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-142" decimals="4" id="f-537" unitRef="number">0.4342</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medine GmbH, Mainz, Germany, owned the following percentage of ordinary shares in BioNTech at the following dates as indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Ownership of ordinary shares in BioNTech (in %)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Country of incorporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Registered office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Medine GmbH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Mainz&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfEntityWithSignificantInfluenceOverGroupExplanatoryTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-143" decimals="4" id="f-539" unitRef="number">0.1701</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c-144" decimals="4" id="f-540" unitRef="number">0.1738</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="c-1" id="f-541">Business Combinations&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of InstaDeep Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, we acquired InstaDeep Ltd., London, United Kingdom (InstaDeep), a leading global technology company in the field of artificial intelligence (AI) and machine learning, by purchasing 100% of the remaining shares in InstaDeep not already owned by us. The acquisition is intended to create a fully integrated, enterprise-wide capability that leverages AI and machine learning technologies across our therapeutic platforms and operations. InstaDeep also continues to provide its services to clients around the world in diverse industries, including in the technology, transport and logistics, and industrial and financial services sectors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The completion of the acquisition took place in July 2023.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed an allocation of the total consideration and the underlying assets acquired (including certain identified intangible assets such as InstaDeep&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s DeepChain technology and customer relationships) and liabilities assumed based on their fair values using the information available as of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisition date. The total consideration and the fair values in accordance with IFRS&#160;3 of the identified net assets acquired of InstaDeep as of July 31, 2023, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Fair value recognized on acquisition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;InstaDeep Ltd.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;52.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets non-current and current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;275.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other liabilities long-term and short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;64.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total identifiable net assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill from the acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;306.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;517.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;358.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash to be paid in 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Designated FX hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares transferred (approx. 1.1 million shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;103.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Previously held non-listed equity investment (stake of 5.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;517.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible assets acquired comprise DeepChain technology and customer relationships. Their fair values were determined based on the multi-period excess earnings method (MEEM) and amount to &#x20ac;176.0&#160;million and &#x20ac;7.8&#160;million respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the shares transferred is determined based on the number of shares transferred and the closing price of the ADSs as of July 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of InstaDeep is a step acquisition in accordance with IFRS 3.41-3.42A since we already held a 5.3% interest prior to the acquisition. In prior reporting periods, we recognized changes in the value of this equity interest in other comprehensive income. The amount of the remeasurement to fair value that was recognized in other comprehensive income is recognized on the same basis as would be required if we disposed directly of the previously held equity interest. Based on the total consideration for the acquired shares (94.7%), the value of the already held shares is &#x20ac;27.9&#160;million, which results in a loss of &#x20ac;2.2&#160;million shown in other comprehensive income in the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the acquisition date, the contingent consideration was recognized at its fair value of &#x20ac;31.8 million based on cash flow projections in connection with performance-based future milestone cash payments to eligible shareholders after a three-year earn-out period. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero; the upper limit is &#x20ac;124.6&#160;million. In addition, &#x20ac;12.5&#160;million of potential earn-out payments are considered remuneration and will be recognized as personnel expense over a three-year period in which services are to be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs of &#x20ac;6.0&#160;million were expensed and are included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The goodwill mainly comprises the value of expected synergies from including AI and machine learning technologies across our therapeutic platforms and operations and intangible assets that are not recognized separately, such as the acquired skilled workforce and its know-how. Therefore, the goodwill is allocated almost in full to the CGU immunotherapies and to a minor extent to a CGU comprising the external InstaDeep business. The goodwill is not tax deductible.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized in an amount of &#x20ac;45.8&#160;million. In line with the deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carry forwards which existed as of the acquisition date were recognized. The deferred tax assets and liabilities were offset to the extent that the conditions for offsetting were fulfilled.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the acquisition, InstaDeep&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;s impact on our revenue and profit for the period has been immaterial. Accordingly, hypothetical amounts for our revenue and profit for the financial year, which were calculated on the assumption that the acquisition had taken place at the beginning of the year, would not materially differ from the actual figures reported.</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-145"
      decimals="INF"
      id="f-542"
      unitRef="number">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="c-1" id="f-543">The total consideration and the fair values in accordance with IFRS&#160;3 of the identified net assets acquired of InstaDeep as of July 31, 2023, are as follows:&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Fair value recognized on acquisition&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;InstaDeep Ltd.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property, plant and equipment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financial assets - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;52.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other assets non-current and current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;275.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other liabilities long-term and short-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;64.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total identifiable net assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill from the acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;306.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;517.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;358.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash to be paid in 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Designated FX hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shares transferred (approx. 1.1 million shares)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;103.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Previously held non-listed equity investment (stake of 5.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;517.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-544" unitRef="eur">187600000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-545" unitRef="eur">2100000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-546" unitRef="eur">700000</bntx:RightOfUseAssetsRecognisedAsOfAcquisitionDate>
    <bntx:TradeReceivablesRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-547" unitRef="eur">2400000</bntx:TradeReceivablesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialAssetsRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-548" unitRef="eur">52500000</ifrs-full:FinancialAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-549" unitRef="eur">21200000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-550" unitRef="eur">8700000</bntx:OtherAssetsNonCurrentAndCurrentRecognisedAsOfAcquisitionDate>
    <bntx:AssetsRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-551" unitRef="eur">275000000.0</bntx:AssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-552" unitRef="eur">45800000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <bntx:OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-553" unitRef="eur">18200000</bntx:OtherLiabilitiesLongTermAndShortTermRecognisedAsOfAcquisitionDate>
    <bntx:LiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-554" unitRef="eur">64000000.0</bntx:LiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-146" decimals="-5" id="f-555" unitRef="eur">211000000.0</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-556" unitRef="eur">306500000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <bntx:AssetsAcquiredLiabilitiesAssumedIncludingGoodwill contextRef="c-146" decimals="-5" id="f-557" unitRef="eur">517500000</bntx:AssetsAcquiredLiabilitiesAssumedIncludingGoodwill>
    <ifrs-full:CashTransferred contextRef="c-146" decimals="-5" id="f-558" unitRef="eur">358100000</ifrs-full:CashTransferred>
    <ifrs-full:LiabilitiesIncurred contextRef="c-146" decimals="-5" id="f-559" unitRef="eur">4000000.0</ifrs-full:LiabilitiesIncurred>
    <bntx:DesignatedFXHedge contextRef="c-146" decimals="-5" id="f-560" unitRef="eur">-8100000</bntx:DesignatedFXHedge>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable
      contextRef="c-145"
      decimals="-5"
      id="f-561"
      unitRef="shares">1100000</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <ifrs-full:EquityInterestsOfAcquirer contextRef="c-146" decimals="-5" id="f-562" unitRef="eur">103700000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-563" unitRef="eur">31800000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <bntx:EquityMethodInvestmentsOwnershipPercentage contextRef="c-146" decimals="3" id="f-564" unitRef="number">0.053</bntx:EquityMethodInvestmentsOwnershipPercentage>
    <bntx:PreviouslyHeldNonListedEquityInvestment contextRef="c-146" decimals="-5" id="f-565" unitRef="eur">27900000</bntx:PreviouslyHeldNonListedEquityInvestment>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-146" decimals="-5" id="f-566" unitRef="eur">517500000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-147" decimals="-5" id="f-567" unitRef="eur">176000000</ifrs-full:TechnologybasedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-147" decimals="-5" id="f-568" unitRef="eur">7800000</ifrs-full:CustomerrelatedIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <bntx:EquityMethodInvestmentsOwnershipPercentage contextRef="c-146" decimals="3" id="f-569" unitRef="number">0.053</bntx:EquityMethodInvestmentsOwnershipPercentage>
    <bntx:PercentageOfConsiderationTransferredAcquiredShares contextRef="c-146" decimals="3" id="f-570" unitRef="number">0.947</bntx:PercentageOfConsiderationTransferredAcquiredShares>
    <bntx:PreviouslyHeldNonListedEquityInvestment contextRef="c-146" decimals="-5" id="f-571" unitRef="eur">27900000</bntx:PreviouslyHeldNonListedEquityInvestment>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-145" decimals="-5" id="f-572" unitRef="eur">2200000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-573" unitRef="eur">31800000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate contextRef="c-148" decimals="-5" id="f-574" unitRef="eur">124600000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <bntx:ConsideredRemunerationOfPotentialEarnOutPayments contextRef="c-145" decimals="-5" id="f-575" unitRef="eur">12500000</bntx:ConsideredRemunerationOfPotentialEarnOutPayments>
    <ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination contextRef="c-149" decimals="-5" id="f-576" unitRef="eur">6000000</ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-146" decimals="-5" id="f-577" unitRef="eur">45800000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-578">Revenues from Contracts with Customers&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&#160;&#160;&#160;&#160;Disaggregated Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is the disaggregation of the Group&#x2019;s revenues from contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Commercial revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,815.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,194.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,874.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;COVID-19 vaccine revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,776.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,145.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,806.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Sales to collaboration partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;275.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1,224.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;970.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Direct product sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;473.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,184.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,007.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share of collaboration partners&#x2019; gross profit and sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,027.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;12,736.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;14,828.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;67.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Research &amp;amp; development revenues from collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;102.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,819.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,310.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,976.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, revenues recognized from Pfizer Inc., or Pfizer (&#x20ac;3,293.0 million) and the German Federal Ministry of Health (&#x20ac;473.6 million), each account for more than 10% of total revenues. During the year ended December&#160;31, 2022, revenues recognized from Pfizer (&#x20ac;13,795.8 million) and the German Federal Ministry of Health (&#x20ac;3,020.5 million) represented more than 10% of total revenues. During the year ended December&#160;31, 2021, revenues recognized from Pfizer (&#x20ac;15,500.0 million) and the German Federal Ministry of Health (&#x20ac;1,945.6 million), accounted for more than 10% of total revenues. During the year ended December&#160;31, 2023, based on the geographic region in which our customers and collaboration partners are located, we mainly recognized revenues in the United States (&#x20ac;3,010.9&#160;million) and Germany (&#x20ac;482.7&#160;million). During the year ended December&#160;31, 2022, the main geographic regions were United States (&#x20ac;12,709.7&#160;million) and Germany (&#x20ac;3,031.0&#160;million). During the year ended December&#160;31, 2021, the main geographic regions were United States (&#x20ac;14,636.5&#160;million), Germany (&#x20ac;2,241.9&#160;million) and Belgium (&#x20ac;675.0&#160;million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commercial Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide. During the year ended December&#160;31, 2023, our commercial revenues decreased in line with a lower COVID-19 vaccine market demand. In addition, write-downs by our collaboration partner Pfizer Inc. (Pfizer), significantly reduced our gross profit share and hence negatively influenced our revenues for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and T&#xfc;rkiye. Shanghai Fosun Pharmaceutical (Group) Co., Ltd, or Fosun Pharma, has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales to Collaboration Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to collaboration partners represent sales of products manufactured by us to collaboration partners. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. Under the collaboration with Pfizer, from time to time, those sales are significantly influenced by amounts due to write-downs of inventories as well as costs related to production capacities derived from contracts with CMOs that became redundant. Those costs represent accrued manufacturing variances and are charged to our partner once finally materialized. These manufacturing variances are reflected as transfer price adjustments once identified. The regular reassessment of these manufacturing variances may result in adjustments to the respective prior-period revenues. Sales to collaboration partners during the years ended December&#160;31, 2023, 2022 and 2021 of &#x20ac;74.5 million, &#x20ac;850.0 million and &#x20ac;31.0&#160;million, respectively, related to the aforementioned manufacturing variances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Direct Product Sales to Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct product sales are recognized from supplying COVID-19 vaccine in our territories Germany and T&#xfc;rkiye. During the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years ended December&#160;31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized &#x20ac;473.6 million, &#x20ac;3,184.7 million and &#x20ac;3,007.2&#160;million of revenues, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share of Collaboration Partners&#x2019; Gross Profit and Sales Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on COVID-19 vaccine sales in the collaboration partners&#x2019; territories, we are eligible to receive a share of their gross profit, which represents a seasonally affected net figure and is recognized as collaboration revenue during the commercial phase, together with sales milestones. M&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anufacturing cost variances either reflected as transfer price adjustments as described above or resulting from costs highly probable to be incurred by the partner, were taken into account when determining the gross profit. During the year ended December&#160;31, 2021, those revenues included &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x20ac;476.6 million&#160;of sales milestones&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenues from contracts with customers disclosed above were recognized as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#1A1A1A;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Timing of revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goods and services transferred at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;776.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,447.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,034.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goods and services transferred over time&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;127.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;113.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue recognition applying the sales-based or usage-based royalty recognition constraint model&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,027.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,736.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,828.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,819.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,310.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,976.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents sales based on the share of the collaboration partners&#x2019; gross profit and sales milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.2&#160;&#160;&#160;&#160;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;751.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;125.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;24.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other receivables significantly decreased compared to the previous year and predominantly comprise trade receivables from our COVID-19 collaboration with Pfizer as well as our direct product sales to customers in our territory. The contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. As Pfizer&#x2019;s financial quarter for subsidiaries outside the United States differs from ours, it creates an additional time lag between the recognition of revenues and the payment receipt. Consequently, as of December&#160;31, 2023, our trade receivables included, in addition to the profit share for the fourth quarter of 2023, trade receivables which related to the gross profit share for the third quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities significantly increased compared to the previous year as advance payments in connection with the amendment of the COVID-19 vaccine purchase agreement with the European Commission, or EC, were received. As of December&#160;31, 2023, the contract liabilities included &#x20ac;386.4 million of such payments under our collaboration with Pfizer (COVID-19 vaccine), &#x20ac;302.3 million&#160;from the German Federal Ministry of Health and &#x20ac;62.3 million&#160;of remaining upfront fees from our collaboration agreement with Pfizer (Zoster) (as of December&#160;31, 2022: &#x20ac;65.7&#160;million of remaining upfront fees from collaboration and commercial supply agreements and &#x20ac;56.3&#160;million&#160;of advance payments for future COVID-19 vaccine sales). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The refund liabilities recognized as of December 31, 2022, represented consideration which was refunded to the collaboration partner during the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is the amount of revenue recognized for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts included in contract liabilities at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;63.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.3&#160;&#160;&#160;&#160;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as of year-end are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;353.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;77.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;398.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;751.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;125.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-579">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is the disaggregation of the Group&#x2019;s revenues from contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Commercial revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,815.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,194.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,874.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;COVID-19 vaccine revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,776.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,145.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18,806.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Sales to collaboration partners&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;275.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1,224.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;970.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Direct product sales to customers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;473.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,184.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,007.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share of collaboration partners&#x2019; gross profit and sales milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,027.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;12,736.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;14,828.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;67.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Research &amp;amp; development revenues from collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;102.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,819.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,310.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,976.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenues from contracts with customers disclosed above were recognized as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#1A1A1A;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Timing of revenue recognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goods and services transferred at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;776.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,447.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,034.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goods and services transferred over time&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;127.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;113.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue recognition applying the sales-based or usage-based royalty recognition constraint model&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,027.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,736.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,828.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,819.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,310.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18,976.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents sales based on the share of the collaboration partners&#x2019; gross profit and sales milestones.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-6" decimals="-5" id="f-580" unitRef="eur">3815500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-7" decimals="-5" id="f-581" unitRef="eur">17194600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-8" decimals="-5" id="f-582" unitRef="eur">18874000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-150" decimals="-5" id="f-583" unitRef="eur">3776200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-151" decimals="-5" id="f-584" unitRef="eur">17145200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-152" decimals="-5" id="f-585" unitRef="eur">18806800000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-153" decimals="-5" id="f-586" unitRef="eur">275300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-154" decimals="-5" id="f-587" unitRef="eur">1224300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-155" decimals="-5" id="f-588" unitRef="eur">970900000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-156" decimals="-5" id="f-589" unitRef="eur">473600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-157" decimals="-5" id="f-590" unitRef="eur">3184700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-158" decimals="-5" id="f-591" unitRef="eur">3007200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-159" decimals="-5" id="f-592" unitRef="eur">3027300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-160" decimals="-5" id="f-593" unitRef="eur">12736200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-161" decimals="-5" id="f-594" unitRef="eur">14828700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-162" decimals="-5" id="f-595" unitRef="eur">39300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-163" decimals="-5" id="f-596" unitRef="eur">49400000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-164" decimals="-5" id="f-597" unitRef="eur">67200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-9" decimals="-5" id="f-598" unitRef="eur">3500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-10" decimals="-5" id="f-599" unitRef="eur">116000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-11" decimals="-5" id="f-600" unitRef="eur">102700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-601" unitRef="eur">3819000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-12" decimals="-5" id="f-602" unitRef="eur">17310600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-13" decimals="-5" id="f-603" unitRef="eur">18976700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-165" decimals="-5" id="f-604" unitRef="eur">3293000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-166" decimals="-5" id="f-605" unitRef="eur">473600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-167" decimals="-5" id="f-606" unitRef="eur">13795800000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-168" decimals="-5" id="f-607" unitRef="eur">3020500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-169" decimals="-5" id="f-608" unitRef="eur">15500000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-170" decimals="-5" id="f-609" unitRef="eur">1945600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-171" decimals="-5" id="f-610" unitRef="eur">3010900000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-172" decimals="-5" id="f-611" unitRef="eur">482700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-173" decimals="-5" id="f-612" unitRef="eur">12709700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-174" decimals="-5" id="f-613" unitRef="eur">3031000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-175" decimals="-5" id="f-614" unitRef="eur">14636500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-176" decimals="-5" id="f-615" unitRef="eur">2241900000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-177" decimals="-5" id="f-616" unitRef="eur">675000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-178" decimals="-5" id="f-617" unitRef="eur">74500000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-179" decimals="-5" id="f-618" unitRef="eur">850000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-180" decimals="-5" id="f-619" unitRef="eur">31000000.0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-156" decimals="-5" id="f-620" unitRef="eur">473600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-157" decimals="-5" id="f-621" unitRef="eur">3184700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-158" decimals="-5" id="f-622" unitRef="eur">3007200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-181" decimals="-5" id="f-623" unitRef="eur">476600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-182" decimals="-5" id="f-624" unitRef="eur">776300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-183" decimals="-5" id="f-625" unitRef="eur">4447200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-184" decimals="-5" id="f-626" unitRef="eur">4034300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-185" decimals="-5" id="f-627" unitRef="eur">15400000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-186" decimals="-5" id="f-628" unitRef="eur">127200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-187" decimals="-5" id="f-629" unitRef="eur">113700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-188" decimals="-5" id="f-630" unitRef="eur">3027300000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-189" decimals="-5" id="f-631" unitRef="eur">12736200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-190" decimals="-5" id="f-632" unitRef="eur">14828700000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-5" id="f-633" unitRef="eur">3819000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-12" decimals="-5" id="f-634" unitRef="eur">17310600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-13" decimals="-5" id="f-635" unitRef="eur">18976700000</ifrs-full:RevenueFromContractsWithCustomers>
    <bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock contextRef="c-1" id="f-636">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;751.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;125.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Refund liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;24.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfContractBalancesFromContractsWithCustomersExplanatoryTableTextBlock>
    <ifrs-full:CurrentTradeReceivables contextRef="c-14" decimals="-5" id="f-637" unitRef="eur">2155700000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-15" decimals="-5" id="f-638" unitRef="eur">7145600000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:ContractLiabilities contextRef="c-14" decimals="-5" id="f-639" unitRef="eur">751800000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-15" decimals="-5" id="f-640" unitRef="eur">125500000</ifrs-full:ContractLiabilities>
    <ifrs-full:RefundsProvision contextRef="c-14" decimals="-5" id="f-641" unitRef="eur">0</ifrs-full:RefundsProvision>
    <ifrs-full:RefundsProvision contextRef="c-15" decimals="-5" id="f-642" unitRef="eur">24400000</ifrs-full:RefundsProvision>
    <ifrs-full:ContractLiabilities contextRef="c-191" decimals="-5" id="f-643" unitRef="eur">386400000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-192" decimals="-5" id="f-644" unitRef="eur">302300000</ifrs-full:ContractLiabilities>
    <bntx:RemainingUpfrontFeesContractLiabilities contextRef="c-193" decimals="-5" id="f-645" unitRef="eur">62300000</bntx:RemainingUpfrontFeesContractLiabilities>
    <bntx:RemainingUpfrontFeesContractLiabilities contextRef="c-15" decimals="-5" id="f-646" unitRef="eur">65700000</bntx:RemainingUpfrontFeesContractLiabilities>
    <bntx:AdvancePaymentReceivedForFutureCOVID19VaccineSale contextRef="c-12" decimals="-5" id="f-647" unitRef="eur">56300000</bntx:AdvancePaymentReceivedForFutureCOVID19VaccineSale>
    <bntx:DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock contextRef="c-1" id="f-648">&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is the amount of revenue recognized for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amounts included in contract liabilities at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;63.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfRecognitionOfRevenueExplanatoryTableTextBlock>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="c-1" decimals="-5" id="f-649" unitRef="eur">3500000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="c-12" decimals="-5" id="f-650" unitRef="eur">63100000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="c-13" decimals="-5" id="f-651" unitRef="eur">73700000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:DisclosureOfPerformanceObligationsExplanatory contextRef="c-1" id="f-652">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract liabilities allocated to the remaining performance obligations from collaboration or commercial supply agreements (unsatisfied or partially unsatisfied) as of year-end are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;353.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;77.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;More than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;398.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;751.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;125.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPerformanceObligationsExplanatory>
    <ifrs-full:ContractLiabilities contextRef="c-194" decimals="-5" id="f-653" unitRef="eur">353300000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-195" decimals="-5" id="f-654" unitRef="eur">77100000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-196" decimals="-5" id="f-655" unitRef="eur">398500000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-197" decimals="-5" id="f-656" unitRef="eur">48400000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-198" decimals="-5" id="f-657" unitRef="eur">751800000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-199" decimals="-5" id="f-658" unitRef="eur">125500000</ifrs-full:ContractLiabilities>
    <bntx:DisclosureOfIncomeAndExpenseExplanatoryTextBlock contextRef="c-1" id="f-659">Income and Expenses&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.1 General Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, cost of sales decreased by &#x20ac;2,395.2 million or 80% from &#x20ac;2,995.0 million&#160;to &#x20ac;599.8 million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mainly due to recognizing lower cost of sales from our decreased COVID-19 vaccine sales, which included the share of gross profit that we owe our collaboration partner  Pfizer based on our sales. In addition, cost of sales was impacted by expenses arising from inventory write-offs and expenses for production capacities derived from contracts with CMOs that became redundant. The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. Based on the regulatory approval obtained with respect to our Omicron XBB.1.5-adapted monovalent COVID-19 vaccine during the third quarter of 2023, we reversed the initial write-down of pre-launch inventory recorded in research and development expensed to a maximum of the original cost of &#x20ac;46.9&#160;million. Thereof &#x20ac;27.3&#160;million resulted in cost of sales during the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2023 as the respective inventory has been either sold or written down. The remainder is presented in inventories as of December&#160;31, 2023 and amounted to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x20ac;19.6&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the year ended December&#160;31, 2022 the amount was nil.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our research and development expenses increased by &#x20ac;246.1 million&#160;or 16% from &#x20ac;1,537.0 million&#160;to &#x20ac;1,783.1&#160;million, mainly influenced by progressing clinical studies for pipeline candidates as well as by our newly acquired product candidates and the development of variant adapted COVID-19 vaccines. The increase was further driven by an increase in wages, benefits and social security expenses resulting from a significant increase in headcount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ales and marketing expenses increased by &#x20ac;3.2 million&#160;or 5% from &#x20ac;59.5 million&#160;to &#x20ac;62.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, mainly due to increased expenses for setup and enhancement of commercial IT platforms and an increase in wages, benefits and social security expenses resulting from an increase in headcount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;From the year ended December&#160;31, 2022 to the year ended December&#160;31, 2023, our general and administrative expenses increased by &#x20ac;13.3 million&#160;or 3% from &#x20ac;481.7 million&#160;to &#x20ac;495.0 million, mainly influenced by increased expenses for IT services as well as by wages, benefits and social security expenses resulting from an increase in headcount.&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.2&#160;&#160;&#160;&#160;Other Operating Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;252.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss on derivative instruments at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;385.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation costs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;293.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;410.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;103.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to prior-year figures relate to costs for external legal advice in connection with certain legal litigations from general and administrative expenses to other operating expense to reflect changes in internal reporting also in the external reporting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the other expenses increased compared to the year ended December&#160;31, 2022, which was mainly derived from recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating expenses primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.&lt;/span&gt;&lt;/div&gt;During the year ended December&#160;31, 2022, the other operating expenses increased compared to the year ended December&#160;31, 2021, mainly from recording the change in fair value of foreign exchange forward contracts that were entered into during the year ended December&#160;31, 2022, to manage some of our transaction exposures but were not designated as hedging instruments under IFRS.&lt;div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;7.3&#160;&#160;&#160;&#160;Other Operating Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gain on derivative instruments at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;67.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;137.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;727.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;446.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;105.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;815.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;598.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the other income decreased compared to the year ended December&#160;31, 2022, as foreign exchange differences arising on operating items changed from a positive effect to a negative effect, which is recorded in other operating expenses (see Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.2). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the other income increased compared to the year ended December&#160;31, 2021, which was mainly due to recognizing foreign exchange differences arising on operating items. The foreign exchange differences included in operating income primarily arose from valuing our U.S. dollar-denominated trade receivables which were mainly incurred under our COVID-19 collaboration with Pfizer, U.S. dollar-denominated trade payables as well as U.S. dollar-denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.4&#160;&#160;&#160;&#160;Finance Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;357.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;162.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;65.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;66.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;519.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;330.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;67.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the finance income increased compared to the year ended December&#160;31, 2022, mainly due to interest income earned on bank deposits and financial securities as well as fair value adjustments in relation to our money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the finance income included the final fair value measurement adjustments of the derivative embedded within the convertible note upon the early redemption of the convertible note as of March 1, 2022, the redemption date, as well as interest income from our bank deposits and increased compared to the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;7.5&#160;&#160;&#160;&#160;Finance Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;277.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;23.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;305.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the finance expenses increased compared to the year ended December&#160;31, 2022, mainly due to exchange differences derived from our foreign exchange bank deposits and cash accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2022, the finance expenses decreased compared to the year ended December&#160;31, 2021, mainly due to final settlement of the derivative embedded within the convertible note which led to financial income whereas during the year ended December&#160;31, 2021, expenses in the amount of &#x20ac;277.8 million&#160;were derived from the respective fair value measurement adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;7.6&#160;&#160;&#160;&#160;Employee Benefits Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;617.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;544.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;345.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Social security costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;698.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;605.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;378.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wages and salaries include, among other things, expenses for share-based payments.&lt;/span&gt;&lt;/div&gt;</bntx:DisclosureOfIncomeAndExpenseExplanatoryTextBlock>
    <bntx:IncreaseDecreaseCostOfSales contextRef="c-1" decimals="-5" id="f-660" unitRef="eur">-2395200000</bntx:IncreaseDecreaseCostOfSales>
    <bntx:PercentageOfCostOfSales contextRef="c-14" decimals="2" id="f-661" unitRef="number">-0.80</bntx:PercentageOfCostOfSales>
    <ifrs-full:CostOfSales contextRef="c-12" decimals="-5" id="f-662" unitRef="eur">2995000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-5" id="f-663" unitRef="eur">599800000</ifrs-full:CostOfSales>
    <ifrs-full:WritedownsReversalsOfInventories contextRef="c-200" decimals="-5" id="f-664" unitRef="eur">-46900000</ifrs-full:WritedownsReversalsOfInventories>
    <ifrs-full:CostOfSales contextRef="c-201" decimals="-5" id="f-665" unitRef="eur">27300000</ifrs-full:CostOfSales>
    <ifrs-full:Inventories contextRef="c-202" decimals="-5" id="f-666" unitRef="eur">19600000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-203" decimals="-5" id="f-667" unitRef="eur">0</ifrs-full:Inventories>
    <bntx:IncreaseDecreaseOfResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-668" unitRef="eur">246100000</bntx:IncreaseDecreaseOfResearchAndDevelopmentExpense>
    <bntx:PercentageOfResearchAndDevelopmentExpense contextRef="c-14" decimals="2" id="f-669" unitRef="number">0.16</bntx:PercentageOfResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-5" id="f-670" unitRef="eur">1537000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-671" unitRef="eur">1783100000</ifrs-full:ResearchAndDevelopmentExpense>
    <bntx:IncreaseDecreaseOfSalesAndMarketingExpense contextRef="c-1" decimals="-5" id="f-672" unitRef="eur">3200000</bntx:IncreaseDecreaseOfSalesAndMarketingExpense>
    <bntx:PercentageOfSalesAndMarketingExpense contextRef="c-14" decimals="2" id="f-673" unitRef="number">0.05</bntx:PercentageOfSalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-12" decimals="-5" id="f-674" unitRef="eur">59500000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c-1" decimals="-5" id="f-675" unitRef="eur">62700000</ifrs-full:SalesAndMarketingExpense>
    <bntx:IncreaseDecreaseOfGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-676" unitRef="eur">13300000</bntx:IncreaseDecreaseOfGeneralAndAdministrativeExpense>
    <bntx:PercentageOfGeneralAndAdministrativeExpense contextRef="c-14" decimals="2" id="f-677" unitRef="number">0.03</bntx:PercentageOfGeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-5" id="f-678" unitRef="eur">481700000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-679" unitRef="eur">495000000</ifrs-full:GeneralAndAdministrativeExpense>
    <bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock contextRef="c-1" id="f-680">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;252.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loss on derivative instruments at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;385.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation costs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;293.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;410.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;103.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to prior-year figures relate to costs for external legal advice in connection with certain legal litigations from general and administrative expenses to other operating expense to reflect changes in internal reporting also in the external reporting.&lt;/span&gt;&lt;/div&gt;</bntx:DisclosureOfOtherOperatingExpensesExplanatoryTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-204" decimals="-5" id="f-681" unitRef="eur">252000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-205" decimals="-5" id="f-682" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-206" decimals="-5" id="f-683" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-207" decimals="-5" id="f-684" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-208" decimals="-5" id="f-685" unitRef="eur">385500000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-209" decimals="-5" id="f-686" unitRef="eur">86300000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-210" decimals="-5" id="f-687" unitRef="eur">29400000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-211" decimals="-5" id="f-688" unitRef="eur">3000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-212" decimals="-5" id="f-689" unitRef="eur">9000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-213" decimals="-5" id="f-690" unitRef="eur">11600000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-214" decimals="-5" id="f-691" unitRef="eur">21500000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-215" decimals="-5" id="f-692" unitRef="eur">8100000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-1" decimals="-5" id="f-693" unitRef="eur">293000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-12" decimals="-5" id="f-694" unitRef="eur">410000000.0</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-13" decimals="-5" id="f-695" unitRef="eur">103400000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <bntx:DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-696">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gain on derivative instruments at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;67.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;137.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;727.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;446.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;105.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;815.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;598.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfOtherOperatingIncomeExplanatoryTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-216" decimals="-5" id="f-697" unitRef="eur">67600000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-217" decimals="-5" id="f-698" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-218" decimals="-5" id="f-699" unitRef="eur">5700000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-219" decimals="-5" id="f-700" unitRef="eur">2200000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-220" decimals="-5" id="f-701" unitRef="eur">1400000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-221" decimals="-5" id="f-702" unitRef="eur">137200000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-204" decimals="-5" id="f-703" unitRef="eur">0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-205" decimals="-5" id="f-704" unitRef="eur">727400000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-206" decimals="-5" id="f-705" unitRef="eur">446300000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-213" decimals="-5" id="f-706" unitRef="eur">35200000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-214" decimals="-5" id="f-707" unitRef="eur">86500000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-215" decimals="-5" id="f-708" unitRef="eur">9200000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-1" decimals="-5" id="f-709" unitRef="eur">105000000.0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-12" decimals="-5" id="f-710" unitRef="eur">815300000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome contextRef="c-13" decimals="-5" id="f-711" unitRef="eur">598400000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <bntx:DisclosureOfFinanceIncomeExplanatoryTableTextBlock contextRef="c-1" id="f-712">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;357.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;162.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;65.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;66.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;519.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;330.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;67.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfFinanceIncomeExplanatoryTableTextBlock>
    <ifrs-full:RevenueFromInterest contextRef="c-1" decimals="-5" id="f-713" unitRef="eur">357600000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c-12" decimals="-5" id="f-714" unitRef="eur">48500000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c-13" decimals="-5" id="f-715" unitRef="eur">1500000</ifrs-full:RevenueFromInterest>
    <bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-1" decimals="-5" id="f-716" unitRef="eur">162000000.0</bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-12" decimals="-5" id="f-717" unitRef="eur">216800000</bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-13" decimals="-5" id="f-718" unitRef="eur">0</bntx:FinanceIncomeFairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <ifrs-full:NetForeignExchangeGain contextRef="c-1" decimals="-5" id="f-719" unitRef="eur">0</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain contextRef="c-12" decimals="-5" id="f-720" unitRef="eur">65000000.0</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain contextRef="c-13" decimals="-5" id="f-721" unitRef="eur">66200000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-5" id="f-722" unitRef="eur">519600000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-12" decimals="-5" id="f-723" unitRef="eur">330300000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-13" decimals="-5" id="f-724" unitRef="eur">67700000</ifrs-full:FinanceIncome>
    <bntx:DisclosureOfFinanceCostExplanatoryTableTextBlock contextRef="c-1" id="f-725">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange differences, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value adjustments of financial instruments measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;277.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;23.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;18.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;305.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfFinanceCostExplanatoryTableTextBlock>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-1" decimals="-5" id="f-726" unitRef="eur">16000000.0</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-12" decimals="-5" id="f-727" unitRef="eur">0</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss contextRef="c-13" decimals="-5" id="f-728" unitRef="eur">0</ifrs-full:NetForeignExchangeLoss>
    <bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-1" decimals="-5" id="f-729" unitRef="eur">0</bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-12" decimals="-5" id="f-730" unitRef="eur">0</bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-13" decimals="-5" id="f-731" unitRef="eur">277800000</bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <us-gaap:OtherExpenses contextRef="c-1" decimals="-5" id="f-732" unitRef="eur">7900000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c-12" decimals="-5" id="f-733" unitRef="eur">18900000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c-13" decimals="-5" id="f-734" unitRef="eur">27300000</us-gaap:OtherExpenses>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-5" id="f-735" unitRef="eur">23900000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-12" decimals="-5" id="f-736" unitRef="eur">18900000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-13" decimals="-5" id="f-737" unitRef="eur">305100000</ifrs-full:FinanceCosts>
    <bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue contextRef="c-13" decimals="-5" id="f-738" unitRef="eur">277800000</bntx:FairValueAdjustmentsOfFinancialInstrumentsMeasuredAtFairValue>
    <bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock contextRef="c-1" id="f-739">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Wages and salaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;617.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;544.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;345.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Social security costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;698.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;605.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;378.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutEmployeeBenefitsExpenseExplanatoryTableTextBlock>
    <ifrs-full:WagesAndSalaries contextRef="c-1" decimals="-5" id="f-740" unitRef="eur">617800000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-12" decimals="-5" id="f-741" unitRef="eur">544800000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-13" decimals="-5" id="f-742" unitRef="eur">345900000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions contextRef="c-1" decimals="-5" id="f-743" unitRef="eur">76700000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c-12" decimals="-5" id="f-744" unitRef="eur">58600000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="c-13" decimals="-5" id="f-745" unitRef="eur">31700000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans contextRef="c-1" decimals="-5" id="f-746" unitRef="eur">4100000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans contextRef="c-12" decimals="-5" id="f-747" unitRef="eur">2100000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans contextRef="c-13" decimals="-5" id="f-748" unitRef="eur">1200000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-5" id="f-749" unitRef="eur">698600000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-12" decimals="-5" id="f-750" unitRef="eur">605500000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-13" decimals="-5" id="f-751" unitRef="eur">378800000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-752">Income Tax&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax for the years ended December&#160;31, 2023, December&#160;31, 2022, and December&#160;31, 2021, comprised current income taxes, other taxes and deferred taxes. We are subject to corporate taxes, the solidarity surcharge and trade taxes. Our corporate tax rate in the reporting year remained unchanged (15.0%) as did the solidarity surcharge (5.5%) whereas the average trade tax rate changed resulting in a combined income tax rate of 27.1% in the year ended December&#160;31, 2023 (during the years ended December&#160;31, 2022 and 2021: 27.2% and 30.7%, respectively). Deferred taxes are calculated at a rate of 27.1%. Current taxes for Austria are calculated at a corporate tax rate of 24.0%. Austria&#x2019;s decrease of its corporate tax rate down to 23.0% in 2024 is be recognized from 2023 onwards for deferred taxes. BioNTech USA Holding, LLC is subject to Federal Corporate Income Tax (21.0%) as well as State Income Tax in various state jurisdictions (effective rate of 4.5%). The deferred tax rates calculations basis remained unchanged compared to the previous period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the current and deferred taxes for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;243.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,629.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,535.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(109.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;218.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;255.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,519.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,753.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Profit before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,186.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12,954.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15,046.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;321.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,529.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,622.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Effects &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deviation due to local tax basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deviation due to deviating income tax rate (Germany and foreign countries)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects from tax losses and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(66.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;19.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in deferred taxes due to tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non tax-effective income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(87.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non tax-effective share-based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax-effective equity transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Adjustment prior year taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-tax effective bargain purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;255.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,519.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,753.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;21.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;31.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2018, we established a share option program pursuant to which we were permitted to grant selected employees and our Management Board options to receive shares in the Company. The program is designed as an Employee Stock Ownership Plan, or ESOP. We offered the participants a certain number of rights, or option rights, subject to their explicit acceptance. Grants under the ESOP took place from November 2018 until December 2019. An exercise of option rights in accordance with the terms of the ESOP gives a participant the right to obtain shares against payment of the exercise price. By way of an updated decision of the Supervisory Board at the end of September 2022 compared to the initial settlement mechanism, an ESOP settlement may be made by delivery to the participant of such number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The respective number of ADS shall be settled with ADS acquired in the course of the share repurchase program. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise are paid in cash directly to the respective authorities. Expenses for taxation purposes resulting from the settlement are only recognized once the option rights have been exercised. After considering the settlements in the twelve months ended December 31, 2023 and taking into account the recognition criteria of IAS 12, a deferred tax is not recognized in our consolidated statement of financial position of &#x20ac;17.8&#160;million&#160;which relates to future settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current tax savings associated with the excess were directly recognized in equity in a total amount of &#x20ac;19.8&#160;million. Considering these tax amounts directly recognized in equity when calculating an effective tax rate, the tax rate would be decreased by about 1.6 percentage points. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:0.24pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intended settlement mechanism of Option Rights of the Chief Executive Officer Grant (see Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for plan details) led to a deferred tax asset in the total amount of &#x20ac;108.8&#160;million as of December&#160;31, 2023. Taking into account the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognition criteria of IAS 12 this deferred tax asset is not recognized in our consolidated statements of profit or loss neither recognized directly in equity as other reserves in our consolidated statements of changes in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes for the periods indicated relate to the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in P&amp;amp;L&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized directly in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(56.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;113.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(162.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;72.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(90.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net employee defined benefit liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(58.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;142.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other (incl. deferred expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(106.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(44.9)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax losses / tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets net (before valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(77.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(102.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;65.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(66.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets / (liabilities), net (after valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;223.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(169.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;41.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Thereof deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;229.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(169.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;81.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Thereof deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(39.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in P&amp;amp;L&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized directly in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(47.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;147.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(67.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(162.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net employee defined benefit liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other (incl. deferred expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;59.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax losses / tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets net (before valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;165.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(81.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets / (liabilities), net (after valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(66.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;109.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;223.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our accumulated tax losses comprised tax losses of German entities that were incurred prior to the establishment of a tax group with BioNTech SE or by entities that are not within the tax group (as of December&#160;31, 2023: BioNTech Real Estate Verwaltungs GmbH; as of December&#160;31, 2022: BioNTech BioNTainer Holding GmbH, BioNTech Idar-Oberstein Services GmbH, NT Security and Services GmbH, BioNTech Real Estate Verwaltungs GmbH and the Real Estate partnerships) or U.S. tax group. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up until the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Corporate tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;260.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;272.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade tax &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;140.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;170.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up until the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2023, deferred tax assets on tax losses were only partially recognized, as there was not sufficient probability in terms of IAS 12 that future taxable profits would have been available against which all the unused tax losses could have been utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of deductible temporary differences, unused tax losses, and unused tax credits for which no deferred tax asset is recognized in the statement of financial position as of December 31, 2023 is &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x20ac;531.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Thus a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, we have not recognized deferred tax assets for unused tax losses and temporary differences in an amount of &#x20ac;138.0&#160;million (December&#160;31, 2022: &#x20ac;136.7&#160;million 31&#160;December 2021 &#x20ac;81.0&#160;million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reorganization of the intellectual property rights within the group became effective as of June 30, 2023 and July 1, 2023 which led to deferred tax effects in Germany, the U.S. and Austria. As a result, BioNTech SE recognized deferred tax assets and deferred tax income at the time of the transaction. In addition, this transaction led to a revaluation of previously unrecognized U.S. federal and state deferred tax assets, including unused tax losses and unused tax credits. As of December 31, 2022, there were unrecognized U.S. federal and state deferred tax assets of &#x20ac;128.9&#160;million. As of December 31, 2023, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future, fulfilling the requirements set out by IAS 12. Therefore we no longer continue to maintain the full non-recognition of deferred tax assets of our U.S. tax group as there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized. As of December 31, 2023, we maintain the non-recognition of deferred tax assets for unused U.S. federal and state tax losses and tax credits at an amount of &#x20ac;31.9&#160;million and &#x20ac;2.8&#160;million, respectively, as there is not sufficient probability in terms of IAS 12 that future taxable income will be available against which these unused tax losses can be utilized. The material unrecognized U.S. federal and state tax losses and tax credits will begin to expire in 2036. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group does not recognize deferred tax liabilities for taxable temporary differences associated with investments in subsidiaries, in cases where the Group is able to control the timing of the reversal of the temporary difference and it is probable that the temporary differences will not reverse in the foreseeable future. The aggregate amount of temporary differences associated with investments in subsidiaries, for which deferred tax liabilities have not been recognized, is &#x20ac;2.8&#160;million.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <bntx:CorporateTaxRate contextRef="c-1" decimals="3" id="f-753" unitRef="number">0.150</bntx:CorporateTaxRate>
    <bntx:SolidaritySurchargeRate contextRef="c-1" decimals="3" id="f-754" unitRef="number">0.055</bntx:SolidaritySurchargeRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="3" id="f-755" unitRef="number">0.271</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-12" decimals="3" id="f-756" unitRef="number">0.272</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-13" decimals="3" id="f-757" unitRef="number">0.307</ifrs-full:ApplicableTaxRate>
    <bntx:TaxRateOnDeferredTaxes contextRef="c-1" decimals="3" id="f-758" unitRef="number">0.271</bntx:TaxRateOnDeferredTaxes>
    <bntx:CorporateTaxRate contextRef="c-222" decimals="3" id="f-759" unitRef="number">0.240</bntx:CorporateTaxRate>
    <bntx:DecreaseInCorporateTaxRate contextRef="c-222" decimals="3" id="f-760" unitRef="number">0.230</bntx:DecreaseInCorporateTaxRate>
    <bntx:FederalCorporateIncomeTax contextRef="c-171" decimals="3" id="f-761" unitRef="number">0.210</bntx:FederalCorporateIncomeTax>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-171" decimals="3" id="f-762" unitRef="number">0.045</ifrs-full:AverageEffectiveTaxRate>
    <bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock contextRef="c-1" id="f-763">&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table illustrates the current and deferred taxes for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;243.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,629.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,535.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(109.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;218.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;255.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,519.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,753.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfCurrentAndDeferredTaxExpenseExplanatoryTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-5" id="f-764" unitRef="eur">243100000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-12" decimals="-5" id="f-765" unitRef="eur">3629600000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-13" decimals="-5" id="f-766" unitRef="eur">4535000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-1" decimals="-5" id="f-767" unitRef="eur">12700000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-12" decimals="-5" id="f-768" unitRef="eur">-109900000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="c-13" decimals="-5" id="f-769" unitRef="eur">218900000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-5" id="f-770" unitRef="eur">255800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-12" decimals="-5" id="f-771" unitRef="eur">3519700000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-13" decimals="-5" id="f-772" unitRef="eur">4753900000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock contextRef="c-1" id="f-773">&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.033%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Profit before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,186.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12,954.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15,046.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;321.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,529.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,622.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Effects &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deviation due to local tax basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deviation due to deviating income tax rate (Germany and foreign countries)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects from tax losses and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(66.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;19.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in deferred taxes due to tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;90.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non tax-effective income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(87.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non tax-effective share-based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax-effective equity transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Adjustment prior year taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(31.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-tax effective bargain purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;255.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3,519.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,753.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;21.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;27.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;31.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfReconciliationOfExpectedIncomeTaxBenefitToActualIncomeTaxBenefitExplanatoryTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-5" id="f-774" unitRef="eur">1186100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-12" decimals="-5" id="f-775" unitRef="eur">12954100000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-13" decimals="-5" id="f-776" unitRef="eur">15046400000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-1" decimals="-5" id="f-777" unitRef="eur">321800000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-12" decimals="-5" id="f-778" unitRef="eur">3529700000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-13" decimals="-5" id="f-779" unitRef="eur">4622500000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <bntx:TaxEffectOfDeviationDueToLocalTaxBasis contextRef="c-1" decimals="-5" id="f-780" unitRef="eur">6600000</bntx:TaxEffectOfDeviationDueToLocalTaxBasis>
    <bntx:TaxEffectOfDeviationDueToLocalTaxBasis contextRef="c-12" decimals="-5" id="f-781" unitRef="eur">8900000</bntx:TaxEffectOfDeviationDueToLocalTaxBasis>
    <bntx:TaxEffectOfDeviationDueToLocalTaxBasis contextRef="c-13" decimals="-5" id="f-782" unitRef="eur">9100000</bntx:TaxEffectOfDeviationDueToLocalTaxBasis>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-1" decimals="-5" id="f-783" unitRef="eur">-100000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-12" decimals="-5" id="f-784" unitRef="eur">7300000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-13" decimals="-5" id="f-785" unitRef="eur">9400000</ifrs-full:TaxEffectOfForeignTaxRates>
    <bntx:TaxEffectOfChangeInValuationAllowance contextRef="c-1" decimals="-5" id="f-786" unitRef="eur">-14300000</bntx:TaxEffectOfChangeInValuationAllowance>
    <bntx:TaxEffectOfChangeInValuationAllowance contextRef="c-12" decimals="-5" id="f-787" unitRef="eur">30600000</bntx:TaxEffectOfChangeInValuationAllowance>
    <bntx:TaxEffectOfChangeInValuationAllowance contextRef="c-13" decimals="-5" id="f-788" unitRef="eur">3000000.0</bntx:TaxEffectOfChangeInValuationAllowance>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c-1" decimals="-5" id="f-789" unitRef="eur">-66500000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c-12" decimals="-5" id="f-790" unitRef="eur">23200000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses contextRef="c-13" decimals="-5" id="f-791" unitRef="eur">19500000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-1" decimals="-5" id="f-792" unitRef="eur">-2400000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-12" decimals="-5" id="f-793" unitRef="eur">-2300000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-13" decimals="-5" id="f-794" unitRef="eur">-7500000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-1" decimals="-5" id="f-795" unitRef="eur">3100000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-12" decimals="-5" id="f-796" unitRef="eur">2500000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-13" decimals="-5" id="f-797" unitRef="eur">90500000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <bntx:TaxEffectNonTaxEffectiveIncome contextRef="c-1" decimals="-5" id="f-798" unitRef="eur">-600000</bntx:TaxEffectNonTaxEffectiveIncome>
    <bntx:TaxEffectNonTaxEffectiveIncome contextRef="c-12" decimals="-5" id="f-799" unitRef="eur">-87900000</bntx:TaxEffectNonTaxEffectiveIncome>
    <bntx:TaxEffectNonTaxEffectiveIncome contextRef="c-13" decimals="-5" id="f-800" unitRef="eur">-300000</bntx:TaxEffectNonTaxEffectiveIncome>
    <bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses contextRef="c-1" decimals="-5" id="f-801" unitRef="eur">7700000</bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses>
    <bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses contextRef="c-12" decimals="-5" id="f-802" unitRef="eur">8700000</bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses>
    <bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses contextRef="c-13" decimals="-5" id="f-803" unitRef="eur">15500000</bntx:NonRecognitionOfTaxEffectOnShareBasedPaymentExpenses>
    <bntx:TaxEffectiveEquityTransactionCosts contextRef="c-1" decimals="-5" id="f-804" unitRef="eur">0</bntx:TaxEffectiveEquityTransactionCosts>
    <bntx:TaxEffectiveEquityTransactionCosts contextRef="c-12" decimals="-5" id="f-805" unitRef="eur">0</bntx:TaxEffectiveEquityTransactionCosts>
    <bntx:TaxEffectiveEquityTransactionCosts contextRef="c-13" decimals="-5" id="f-806" unitRef="eur">-1200000</bntx:TaxEffectiveEquityTransactionCosts>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-1" decimals="-5" id="f-807" unitRef="eur">5500000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-12" decimals="-5" id="f-808" unitRef="eur">-31500000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod contextRef="c-13" decimals="-5" id="f-809" unitRef="eur">-2900000</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <bntx:NonTaxEffectiveBargainPurchase contextRef="c-1" decimals="-5" id="f-810" unitRef="eur">0</bntx:NonTaxEffectiveBargainPurchase>
    <bntx:NonTaxEffectiveBargainPurchase contextRef="c-12" decimals="-5" id="f-811" unitRef="eur">0</bntx:NonTaxEffectiveBargainPurchase>
    <bntx:NonTaxEffectiveBargainPurchase contextRef="c-13" decimals="-5" id="f-812" unitRef="eur">700000</bntx:NonTaxEffectiveBargainPurchase>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="-5" id="f-813" unitRef="eur">-5000000.0</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-12" decimals="-5" id="f-814" unitRef="eur">30500000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-13" decimals="-5" id="f-815" unitRef="eur">-3000000.0</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-5" id="f-816" unitRef="eur">255800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-12" decimals="-5" id="f-817" unitRef="eur">3519700000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-13" decimals="-5" id="f-818" unitRef="eur">4753900000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-1" decimals="3" id="f-819" unitRef="number">0.216</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-12" decimals="3" id="f-820" unitRef="number">0.272</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c-13" decimals="3" id="f-821" unitRef="number">0.316</ifrs-full:AverageEffectiveTaxRate>
    <bntx:DeferredTaxAssetsSettlement contextRef="c-1" decimals="-5" id="f-822" unitRef="eur">17800000</bntx:DeferredTaxAssetsSettlement>
    <bntx:NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity contextRef="c-1" decimals="-5" id="f-823" unitRef="eur">19800000</bntx:NonCashEffectiveCurrentTaxRelatingToItemsCreditedChargedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-223" decimals="-5" id="f-824" unitRef="eur">108800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="c-1" id="f-825">&lt;div style="margin-top:6pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes for the periods indicated relate to the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in P&amp;amp;L&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized directly in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(56.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;113.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(162.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;72.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(90.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(43.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net employee defined benefit liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(58.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;142.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other (incl. deferred expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(106.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(44.9)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax losses / tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets net (before valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(77.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(102.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;65.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(66.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(138.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets / (liabilities), net (after valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;223.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(169.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;41.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Thereof deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;229.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(169.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;81.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Thereof deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(33.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(39.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.229%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.231%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in P&amp;amp;L&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized in OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Recognized directly in equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(47.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.8)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Inventories &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;147.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(67.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(162.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;48.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;55.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(20.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net employee defined benefit liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other (incl. deferred expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;59.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tax losses / tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;70.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets net (before valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;165.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;360.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(81.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(55.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(136.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Deferred tax assets / (liabilities), net (after valuation adjustment)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(66.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;109.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;179.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;223.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-224" decimals="-5" id="f-826" unitRef="eur">15800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-225" decimals="-5" id="f-827" unitRef="eur">20200000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-225" decimals="-5" id="f-828" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-225" decimals="-5" id="f-829" unitRef="eur">-44400000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-226" decimals="-5" id="f-830" unitRef="eur">-8400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-227" decimals="-5" id="f-831" unitRef="eur">-55800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-228" decimals="-5" id="f-832" unitRef="eur">-800000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-228" decimals="-5" id="f-833" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-228" decimals="-5" id="f-834" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-229" decimals="-5" id="f-835" unitRef="eur">-56600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-230" decimals="-5" id="f-836" unitRef="eur">148900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-231" decimals="-5" id="f-837" unitRef="eur">-35300000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-231" decimals="-5" id="f-838" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-231" decimals="-5" id="f-839" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-232" decimals="-5" id="f-840" unitRef="eur">113600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-233" decimals="-5" id="f-841" unitRef="eur">-162700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-234" decimals="-5" id="f-842" unitRef="eur">72700000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-234" decimals="-5" id="f-843" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-234" decimals="-5" id="f-844" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-235" decimals="-5" id="f-845" unitRef="eur">-90000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-236" decimals="-5" id="f-846" unitRef="eur">55200000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-237" decimals="-5" id="f-847" unitRef="eur">2000000.0</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-237" decimals="-5" id="f-848" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-237" decimals="-5" id="f-849" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-238" decimals="-5" id="f-850" unitRef="eur">57200000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-239" decimals="-5" id="f-851" unitRef="eur">-10000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-240" decimals="-5" id="f-852" unitRef="eur">-33000000.0</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-240" decimals="-5" id="f-853" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-240" decimals="-5" id="f-854" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-241" decimals="-5" id="f-855" unitRef="eur">-43000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-242" decimals="-5" id="f-856" unitRef="eur">7600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-243" decimals="-5" id="f-857" unitRef="eur">-2800000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-243" decimals="-5" id="f-858" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-243" decimals="-5" id="f-859" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-244" decimals="-5" id="f-860" unitRef="eur">4800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-245" decimals="-5" id="f-861" unitRef="eur">700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-246" decimals="-5" id="f-862" unitRef="eur">-100000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-246" decimals="-5" id="f-863" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-246" decimals="-5" id="f-864" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-247" decimals="-5" id="f-865" unitRef="eur">600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-248" decimals="-5" id="f-866" unitRef="eur">188400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-249" decimals="-5" id="f-867" unitRef="eur">12000000.0</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-249" decimals="-5" id="f-868" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-249" decimals="-5" id="f-869" unitRef="eur">-58300000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-250" decimals="-5" id="f-870" unitRef="eur">142100000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-251" decimals="-5" id="f-871" unitRef="eur">11000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-252" decimals="-5" id="f-872" unitRef="eur">-1200000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-252" decimals="-5" id="f-873" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-252" decimals="-5" id="f-874" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-253" decimals="-5" id="f-875" unitRef="eur">9800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-254" decimals="-5" id="f-876" unitRef="eur">61500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-255" decimals="-5" id="f-877" unitRef="eur">-106400000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-255" decimals="-5" id="f-878" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-255" decimals="-5" id="f-879" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-256" decimals="-5" id="f-880" unitRef="eur">-44900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-257" decimals="-5" id="f-881" unitRef="eur">99500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-258" decimals="-5" id="f-882" unitRef="eur">-5100000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-258" decimals="-5" id="f-883" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-258" decimals="-5" id="f-884" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-259" decimals="-5" id="f-885" unitRef="eur">94400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-260" decimals="-5" id="f-886" unitRef="eur">360100000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-261" decimals="-5" id="f-887" unitRef="eur">-77800000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-261" decimals="-5" id="f-888" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-261" decimals="-5" id="f-889" unitRef="eur">-102700000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-262" decimals="-5" id="f-890" unitRef="eur">179600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-263" decimals="-5" id="f-891" unitRef="eur">-136700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-264" decimals="-5" id="f-892" unitRef="eur">65100000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-264" decimals="-5" id="f-893" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-264" decimals="-5" id="f-894" unitRef="eur">-66400000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-265" decimals="-5" id="f-895" unitRef="eur">-138000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-15" decimals="-5" id="f-896" unitRef="eur">223400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-1" decimals="-5" id="f-897" unitRef="eur">-12700000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-1" decimals="-5" id="f-898" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-1" decimals="-5" id="f-899" unitRef="eur">-169100000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-14" decimals="-5" id="f-900" unitRef="eur">41600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-266" decimals="-5" id="f-901" unitRef="eur">229600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-267" decimals="-5" id="f-902" unitRef="eur">20800000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-267" decimals="-5" id="f-903" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-267" decimals="-5" id="f-904" unitRef="eur">-169100000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-268" decimals="-5" id="f-905" unitRef="eur">81300000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-269" decimals="-5" id="f-906" unitRef="eur">-6200000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-270" decimals="-5" id="f-907" unitRef="eur">-33500000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-270" decimals="-5" id="f-908" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-270" decimals="-5" id="f-909" unitRef="eur">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-271" decimals="-5" id="f-910" unitRef="eur">-39700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-272" decimals="-5" id="f-911" unitRef="eur">-6500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-273" decimals="-5" id="f-912" unitRef="eur">22300000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-273" decimals="-5" id="f-913" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-273" decimals="-5" id="f-914" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-224" decimals="-5" id="f-915" unitRef="eur">15800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-274" decimals="-5" id="f-916" unitRef="eur">-47500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-275" decimals="-5" id="f-917" unitRef="eur">-8300000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-275" decimals="-5" id="f-918" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-275" decimals="-5" id="f-919" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-227" decimals="-5" id="f-920" unitRef="eur">-55800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-276" decimals="-5" id="f-921" unitRef="eur">1800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-277" decimals="-5" id="f-922" unitRef="eur">147100000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-277" decimals="-5" id="f-923" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-277" decimals="-5" id="f-924" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-230" decimals="-5" id="f-925" unitRef="eur">148900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-278" decimals="-5" id="f-926" unitRef="eur">-95600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-279" decimals="-5" id="f-927" unitRef="eur">-67100000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-279" decimals="-5" id="f-928" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-279" decimals="-5" id="f-929" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-233" decimals="-5" id="f-930" unitRef="eur">-162700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-280" decimals="-5" id="f-931" unitRef="eur">48700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-281" decimals="-5" id="f-932" unitRef="eur">6500000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-281" decimals="-5" id="f-933" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-281" decimals="-5" id="f-934" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-236" decimals="-5" id="f-935" unitRef="eur">55200000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-282" decimals="-5" id="f-936" unitRef="eur">23100000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-283" decimals="-5" id="f-937" unitRef="eur">-15500000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-283" decimals="-5" id="f-938" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-283" decimals="-5" id="f-939" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-242" decimals="-5" id="f-940" unitRef="eur">7600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-284" decimals="-5" id="f-941" unitRef="eur">10600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-285" decimals="-5" id="f-942" unitRef="eur">-20600000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-285" decimals="-5" id="f-943" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-285" decimals="-5" id="f-944" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-239" decimals="-5" id="f-945" unitRef="eur">-10000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-286" decimals="-5" id="f-946" unitRef="eur">900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-287" decimals="-5" id="f-947" unitRef="eur">-500000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-287" decimals="-5" id="f-948" unitRef="eur">300000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-287" decimals="-5" id="f-949" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-245" decimals="-5" id="f-950" unitRef="eur">700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-288" decimals="-5" id="f-951" unitRef="eur">6300000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-289" decimals="-5" id="f-952" unitRef="eur">4700000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-289" decimals="-5" id="f-953" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-289" decimals="-5" id="f-954" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-251" decimals="-5" id="f-955" unitRef="eur">11000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-290" decimals="-5" id="f-956" unitRef="eur">0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-291" decimals="-5" id="f-957" unitRef="eur">8500000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-291" decimals="-5" id="f-958" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="c-291" decimals="-5" id="f-959" unitRef="eur">179900000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-248" decimals="-5" id="f-960" unitRef="eur">188400000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-292" decimals="-5" id="f-961" unitRef="eur">1600000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-293" decimals="-5" id="f-962" unitRef="eur">59900000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-293" decimals="-5" id="f-963" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-293" decimals="-5" id="f-964" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-254" decimals="-5" id="f-965" unitRef="eur">61500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-294" decimals="-5" id="f-966" unitRef="eur">70900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-295" decimals="-5" id="f-967" unitRef="eur">28600000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-295" decimals="-5" id="f-968" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-295" decimals="-5" id="f-969" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-257" decimals="-5" id="f-970" unitRef="eur">99500000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-296" decimals="-5" id="f-971" unitRef="eur">14300000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-297" decimals="-5" id="f-972" unitRef="eur">165600000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-297" decimals="-5" id="f-973" unitRef="eur">300000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-297" decimals="-5" id="f-974" unitRef="eur">179900000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-260" decimals="-5" id="f-975" unitRef="eur">360100000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-298" decimals="-5" id="f-976" unitRef="eur">-81000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-299" decimals="-5" id="f-977" unitRef="eur">-55700000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-299" decimals="-5" id="f-978" unitRef="eur">0</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-299" decimals="-5" id="f-979" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-263" decimals="-5" id="f-980" unitRef="eur">-136700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-31" decimals="-5" id="f-981" unitRef="eur">-66700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-12" decimals="-5" id="f-982" unitRef="eur">109900000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome contextRef="c-12" decimals="-5" id="f-983" unitRef="eur">300000</bntx:DeferredTaxExpenseIncomeRecognisedInOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="c-12" decimals="-5" id="f-984" unitRef="eur">179900000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-15" decimals="-5" id="f-985" unitRef="eur">223400000</ifrs-full:DeferredTaxLiabilityAsset>
    <bntx:DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock contextRef="c-1" id="f-986">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up until the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:&lt;/span&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Corporate tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;260.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;272.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade tax &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;140.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;170.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfAccumulatedTaxLossesExplanatoryTableTextBlock>
    <bntx:AccumulatedTaxLossesInCorporateTax contextRef="c-1" decimals="-5" id="f-987" unitRef="eur">260700000</bntx:AccumulatedTaxLossesInCorporateTax>
    <bntx:AccumulatedTaxLossesInCorporateTax contextRef="c-12" decimals="-5" id="f-988" unitRef="eur">352300000</bntx:AccumulatedTaxLossesInCorporateTax>
    <bntx:AccumulatedTaxLossesInCorporateTax contextRef="c-13" decimals="-5" id="f-989" unitRef="eur">272000000.0</bntx:AccumulatedTaxLossesInCorporateTax>
    <bntx:AccumulatedTaxLossesInTradeTax contextRef="c-1" decimals="-5" id="f-990" unitRef="eur">140100000</bntx:AccumulatedTaxLossesInTradeTax>
    <bntx:AccumulatedTaxLossesInTradeTax contextRef="c-12" decimals="-5" id="f-991" unitRef="eur">204100000</bntx:AccumulatedTaxLossesInTradeTax>
    <bntx:AccumulatedTaxLossesInTradeTax contextRef="c-13" decimals="-5" id="f-992" unitRef="eur">170600000</bntx:AccumulatedTaxLossesInTradeTax>
    <bntx:AccumulatedTaxLossesInFederalTaxCredits contextRef="c-1" decimals="-5" id="f-993" unitRef="eur">21300000</bntx:AccumulatedTaxLossesInFederalTaxCredits>
    <bntx:AccumulatedTaxLossesInFederalTaxCredits contextRef="c-12" decimals="-5" id="f-994" unitRef="eur">4000000.0</bntx:AccumulatedTaxLossesInFederalTaxCredits>
    <bntx:AccumulatedTaxLossesInFederalTaxCredits contextRef="c-13" decimals="-5" id="f-995" unitRef="eur">800000</bntx:AccumulatedTaxLossesInFederalTaxCredits>
    <bntx:AccumulatedTaxLossesInStateTaxCredits contextRef="c-1" decimals="-5" id="f-996" unitRef="eur">8700000</bntx:AccumulatedTaxLossesInStateTaxCredits>
    <bntx:AccumulatedTaxLossesInStateTaxCredits contextRef="c-12" decimals="-5" id="f-997" unitRef="eur">1600000</bntx:AccumulatedTaxLossesInStateTaxCredits>
    <bntx:AccumulatedTaxLossesInStateTaxCredits contextRef="c-13" decimals="-5" id="f-998" unitRef="eur">300000</bntx:AccumulatedTaxLossesInStateTaxCredits>
    <ifrs-full:DeferredTaxAssets contextRef="c-300" decimals="-5" id="f-999" unitRef="eur">531500000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-265" decimals="-5" id="f-1000" unitRef="eur">-138000000.0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-263" decimals="-5" id="f-1001" unitRef="eur">-136700000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-298" decimals="-5" id="f-1002" unitRef="eur">-81000000</ifrs-full:DeferredTaxLiabilityAsset>
    <bntx:StateDeferredTaxAssetsOperatingLossCarryforwards contextRef="c-12" decimals="-5" id="f-1003" unitRef="eur">128900000</bntx:StateDeferredTaxAssetsOperatingLossCarryforwards>
    <bntx:FederalDeferredTaxAssetsOperatingLossCarryforwards contextRef="c-12" decimals="-5" id="f-1004" unitRef="eur">128900000</bntx:FederalDeferredTaxAssetsOperatingLossCarryforwards>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-301" decimals="-5" id="f-1005" unitRef="eur">31900000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-302" decimals="-5" id="f-1006" unitRef="eur">2800000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-14" decimals="-5" id="f-1007" unitRef="eur">2800000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-1008">Earnings per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (EPS) is calculated by dividing the profit for the year attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted EPS is calculated by dividing the profit attributable to ordinary equity holders of the parent by the weighted average number of ordinary shares outstanding during the year, plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the income and share data used in the basic and diluted EPS calculations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Profit attributable to ordinary equity holders of the parent for basic earnings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;9,434.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;10,292.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Weighted average number of ordinary shares outstanding for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;243.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;244.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects of dilution from share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average number of ordinary shares outstanding adjusted for the effect of dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;242.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;249.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;259.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings for the period per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted earnings for the period per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;37.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-1009">&lt;div style="margin-top:12pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the income and share data used in the basic and diluted EPS calculations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Profit attributable to ordinary equity holders of the parent for basic earnings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;930.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;9,434.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;10,292.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Weighted average number of ordinary shares outstanding for basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;240.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;243.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;244.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Effects of dilution from share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average number of ordinary shares outstanding adjusted for the effect of dilution&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;242.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;249.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;259.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Earnings per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings for the period per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Diluted earnings for the period per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;37.77&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-5" id="f-1010" unitRef="eur">930300000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-12" decimals="-5" id="f-1011" unitRef="eur">9434400000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-13" decimals="-5" id="f-1012" unitRef="eur">10292500000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="-5" id="f-1013" unitRef="shares">240600000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c-12"
      decimals="-5"
      id="f-1014"
      unitRef="shares">243300000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c-13"
      decimals="-5"
      id="f-1015"
      unitRef="shares">244000000.0</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares contextRef="c-1" decimals="-5" id="f-1016" unitRef="shares">2100000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="c-12"
      decimals="-5"
      id="f-1017"
      unitRef="shares">6500000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="c-13"
      decimals="-5"
      id="f-1018"
      unitRef="shares">15700000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="-5" id="f-1019" unitRef="shares">242700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c-12"
      decimals="-5"
      id="f-1020"
      unitRef="shares">249800000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="c-13"
      decimals="-5"
      id="f-1021"
      unitRef="shares">259700000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1022"
      unitRef="eurPerShare">3.87</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-12"
      decimals="2"
      id="f-1023"
      unitRef="eurPerShare">38.78</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-13"
      decimals="2"
      id="f-1024"
      unitRef="eurPerShare">42.18</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1025"
      unitRef="eurPerShare">3.83</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-12"
      decimals="2"
      id="f-1026"
      unitRef="eurPerShare">37.77</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-13"
      decimals="2"
      id="f-1027"
      unitRef="eurPerShare">39.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-1028">Other Intangible Assets and Goodwill&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;306.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;362.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets with Indefinite Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;CGU Immunotherapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;External Product Sales of JPT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;External Business of InstaDeep&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;362.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with indefinite useful life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;796.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;807.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, we have total goodwill of &#x20ac;362.5 million, which relates almost completely to the CGU immunotherapies. The CGU immunotherapies focuses on the development of therapies to address a range of rare and infectious diseases and comprises our broad pipeline that includes mRNA-based immune activators, antigen-targeting T&#160;cells and antibodies and defined immunomodulators of various immune cell mechanisms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed our annual impairment test in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recoverable amount of the CGU immunotherapies has been determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as an observable input parameter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recoverable amount of the CGU JPT and the CGU external business of InstaDeep has been determined based on the value in use. In assessing value in use, the estimated future cash flows, which are derived based on the strategic business plan approved by the management, are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the assets. A long-term growth rate of 1.0% is applied to project future cash flows after the last year of the detailed planning period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the analysis in October 2023, we did not identify an impairment for these CGUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite useful lives mainly comprised intangible assets not yet available for use of &#x20ac;443.5&#160;million. Such assets are not amortized and therefore reviewed for impairment annually. An impairment test was performed on an individual basis of the assets in the fourth quarter of 2023. The recoverable amounts were determined based on value in use. The results did not give rise to any impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Considering updated financial information regarding our COVID 19 vaccine business an additional impairment test for our CGU immunotherapies was performed as of December 31, 2023. The recoverable amount of the CGU immunotherapies was once again determined based on a fair value less cost of disposal (FVLCD), which we derived based on our market capitalization as of December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the additional analysis for the CGU immunotherapies, we did not identify an impairment for the CGU immunotherapies. Even if our market capitalization had been approximately 10% lower, FVLCD would have still been above the respective carrying amount of the CGU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible assets resulting from licensing and collaboration agreements are combined into one class of assets due to their similar nature and use in our operations and are attributed to the CGU immunotherapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A sensitivity analysis of the key assumptions, future cash flows and weighted average cost of capital, was performed as part of the scheduled impairment testing of the intangible assets not yet available for use. The sensitivity analysis did not give rise to any impairment loss, either for a reduction of 10% in future cash flows or for a 10% increase in the weighted average cost of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;191.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;199.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;222.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;222.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;489.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;505.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;898.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;921.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cumulative amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;54.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;54.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;145.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;781.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;804.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increase in other intangible assets by &#x20ac;645.6&#160;million from December 31, 2022 to December&#160;31, 2023 was mainly related to the acquisition of InstaDeep (see&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Note 5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and licenses fulfilling the definition of identifiable assets acquired. We entered into license and collaboration agreements in which we work together with partners to develop pharmaceutical products and, provided regulatory approval is granted, commercialize them. The upfront payments in connection with the license and collaboration agreements described below resulted in the recognition of intangible assets not yet available for use in the amount of &#x20ac;443.5&#160;million and a prepayment for future development activities recognized in the other non-financial assets (&#x20ac;22.5&#160;million as at December&#160;31, 2023, see also Note 14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, we entered into license and collaboration agreements with Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, or Duality, for exclusive licenses to two investigational ADC assets (BNT323/DB-1303 and BNT324/DB-1311) directed against targets expressed in a broad range of human cancers. In August 2023, we signed another exclusive agreement with Duality to develop, manufacture and commercialize an additional ADC, BNT325/DB-1305. Duality received upfront payments totaling $220.0&#160;million (&#x20ac;203.7&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, we entered into a licensing and collaboration agreement with OncoC4 Inc., Rockville (Maryland), United States, or OncoC4, which includes joint development of BNT316/ONC-392 in a range of solid tumor indications, with the parties equally sharing development costs for such joint development studies. BioNTech holds the exclusive worldwide commercialization rights for this product candidate. OncoC4 received an upfront payment of $200.0&#160;million (&#x20ac;181.5&#160;million, thereof &#x20ac;125.2&#160;million paid for the acquisition of an intangible asset) and is eligible to receive future milestone payments as well as tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, we entered into a strategic research collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd., or MediLink Therapeutics, for the development of a next-generation ADC, BNT326/YL202, against Human Epidermal Growth Factor Receptor 3 (HER3). MediLink Therapeutics received an upfront payment of $70.0&#160;million (&#x20ac;64.1&#160;million) and is eligible to receive future milestone payments as well as tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, we entered into an exclusive global license and collaboration with Biotheus Inc., or Biotheus, under which we will be developing, manufacturing and commercializing Biotheus&#x2019; bispecific antibody candidate BNT327/PM8002 globally ex-Greater China. We agreed to an upfront payment of  $55.0&#160;million (&#x20ac;50.6&#160;million) plus future milestone and royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%"&gt;In July 2023, in connection with the acquisition of InstaDeep we acquired DeepChain technology. As of December&#160;31, 2023 the book value of DeepChain technology amounted to &#x20ac;163.3&#160;million with a remaining useful life of 6.6 years.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory contextRef="c-1" id="f-1029">&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;306.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;362.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;191.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;199.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;222.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;222.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;489.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;505.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;187.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;898.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;921.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cumulative amortization and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;54.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;54.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;76.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Concessions, licenses, in-process R&amp;amp;D and similar rights &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;145.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;158.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;781.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;804.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-303" decimals="-5" id="f-1030" unitRef="eur">57800000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-304" decimals="-5" id="f-1031" unitRef="eur">3400000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-305" decimals="-5" id="f-1032" unitRef="eur">61200000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-305" decimals="-5" id="f-1033" unitRef="eur">61200000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-306" decimals="-5" id="f-1034" unitRef="eur">306900000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-306" decimals="-5" id="f-1035" unitRef="eur">-5600000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-307" decimals="-5" id="f-1036" unitRef="eur">362500000</ifrs-full:IntangibleAssetsAndGoodwill>
    <bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock contextRef="c-1" id="f-1037">&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.141%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;CGU Immunotherapies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;External Product Sales of JPT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;External Business of InstaDeep&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;362.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Intangible assets with indefinite useful life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;444.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;796.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;807.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;61.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfGoodwillAcquiredInRespectiveBusinessCombinationsExplanatoryTableTextBlock>
    <ifrs-full:Goodwill contextRef="c-308" decimals="-5" id="f-1038" unitRef="eur">352200000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-309" decimals="-5" id="f-1039" unitRef="eur">60700000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-310" decimals="-5" id="f-1040" unitRef="eur">500000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-311" decimals="-5" id="f-1041" unitRef="eur">500000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-312" decimals="-5" id="f-1042" unitRef="eur">9800000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-313" decimals="-5" id="f-1043" unitRef="eur">0</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-14" decimals="-5" id="f-1044" unitRef="eur">362500000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-15" decimals="-5" id="f-1045" unitRef="eur">61200000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-308" decimals="-5" id="f-1046" unitRef="eur">444500000</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-309" decimals="-5" id="f-1047" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-310" decimals="-5" id="f-1048" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-311" decimals="-5" id="f-1049" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-312" decimals="-5" id="f-1050" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-313" decimals="-5" id="f-1051" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-14" decimals="-5" id="f-1052" unitRef="eur">444500000</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife contextRef="c-15" decimals="-5" id="f-1053" unitRef="eur">0</ifrs-full:IntangibleAssetsWithIndefiniteUsefulLife>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-308" decimals="-5" id="f-1054" unitRef="eur">796700000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-309" decimals="-5" id="f-1055" unitRef="eur">60700000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-310" decimals="-5" id="f-1056" unitRef="eur">500000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-311" decimals="-5" id="f-1057" unitRef="eur">500000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-312" decimals="-5" id="f-1058" unitRef="eur">9800000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-313" decimals="-5" id="f-1059" unitRef="eur">0</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-14" decimals="-5" id="f-1060" unitRef="eur">807000000.0</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill contextRef="c-15" decimals="-5" id="f-1061" unitRef="eur">61200000</bntx:IntangibleAssetsWithIndefiniteUsefulLifeAndGoodwill>
    <ifrs-full:Goodwill contextRef="c-14" decimals="-5" id="f-1062" unitRef="eur">362500000</ifrs-full:Goodwill>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections contextRef="c-14" decimals="2" id="f-1063" unitRef="number">0.010</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <bntx:UpfrontPayment contextRef="c-1" decimals="-5" id="f-1064" unitRef="eur">443500000</bntx:UpfrontPayment>
    <bntx:PercentageOfImpairmentLossForAReductionOfFutureCashFlows contextRef="c-1" decimals="2" id="f-1065" unitRef="number">0.10</bntx:PercentageOfImpairmentLossForAReductionOfFutureCashFlows>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation contextRef="c-1" decimals="2" id="f-1066" unitRef="number">0.10</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-314" decimals="-5" id="f-1067" unitRef="eur">191600000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-315" decimals="-5" id="f-1068" unitRef="eur">7800000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-296" decimals="-5" id="f-1069" unitRef="eur">199400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-316" decimals="-5" id="f-1070" unitRef="eur">22800000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-317" decimals="-5" id="f-1071" unitRef="eur">11400000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-297" decimals="-5" id="f-1072" unitRef="eur">34200000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-316" decimals="-5" id="f-1073" unitRef="eur">100000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-317" decimals="-5" id="f-1074" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-297" decimals="-5" id="f-1075" unitRef="eur">100000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-316" decimals="-5" id="f-1076" unitRef="eur">6100000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-317" decimals="-5" id="f-1077" unitRef="eur">-6100000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-297" decimals="-5" id="f-1078" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-316" decimals="-5" id="f-1079" unitRef="eur">1900000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-317" decimals="-5" id="f-1080" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-297" decimals="-5" id="f-1081" unitRef="eur">1900000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-318" decimals="-5" id="f-1082" unitRef="eur">222300000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-319" decimals="-5" id="f-1083" unitRef="eur">13100000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-260" decimals="-5" id="f-1084" unitRef="eur">235400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-318" decimals="-5" id="f-1085" unitRef="eur">222300000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-319" decimals="-5" id="f-1086" unitRef="eur">13100000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-260" decimals="-5" id="f-1087" unitRef="eur">235400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-320" decimals="-5" id="f-1088" unitRef="eur">489200000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-321" decimals="-5" id="f-1089" unitRef="eur">15800000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-261" decimals="-5" id="f-1090" unitRef="eur">505000000.0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-320" decimals="-5" id="f-1091" unitRef="eur">187400000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-321" decimals="-5" id="f-1092" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-261" decimals="-5" id="f-1093" unitRef="eur">187400000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-320" decimals="-5" id="f-1094" unitRef="eur">1600000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-321" decimals="-5" id="f-1095" unitRef="eur">1600000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-261" decimals="-5" id="f-1096" unitRef="eur">3200000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-320" decimals="-5" id="f-1097" unitRef="eur">4900000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-321" decimals="-5" id="f-1098" unitRef="eur">-4900000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill contextRef="c-261" decimals="-5" id="f-1099" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-320" decimals="-5" id="f-1100" unitRef="eur">-3600000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-321" decimals="-5" id="f-1101" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-261" decimals="-5" id="f-1102" unitRef="eur">-3600000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-322" decimals="-5" id="f-1103" unitRef="eur">898600000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-323" decimals="-5" id="f-1104" unitRef="eur">22400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-262" decimals="-5" id="f-1105" unitRef="eur">921000000.0</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-324" decimals="-5" id="f-1106" unitRef="eur">-54800000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-325" decimals="-5" id="f-1107" unitRef="eur">0</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-326" decimals="-5" id="f-1108" unitRef="eur">-54800000</ifrs-full:IntangibleAssetsAndGoodwill>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-327" decimals="-5" id="f-1109" unitRef="eur">-22000000.0</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-328" decimals="-5" id="f-1110" unitRef="eur">0</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-329" decimals="-5" id="f-1111" unitRef="eur">-22000000.0</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-327" decimals="-5" id="f-1112" unitRef="eur">-100000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-328" decimals="-5" id="f-1113" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-329" decimals="-5" id="f-1114" unitRef="eur">-100000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-327" decimals="-5" id="f-1115" unitRef="eur">-200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-328" decimals="-5" id="f-1116" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-329" decimals="-5" id="f-1117" unitRef="eur">-200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-330" decimals="-5" id="f-1118" unitRef="eur">-76900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-331" decimals="-5" id="f-1119" unitRef="eur">0</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-332" decimals="-5" id="f-1120" unitRef="eur">-76900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-330" decimals="-5" id="f-1121" unitRef="eur">-76900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-331" decimals="-5" id="f-1122" unitRef="eur">0</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-332" decimals="-5" id="f-1123" unitRef="eur">-76900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-333" decimals="-5" id="f-1124" unitRef="eur">-40500000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-334" decimals="-5" id="f-1125" unitRef="eur">0</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <bntx:AccumulatedDepreciationAmortisationAndImpairment contextRef="c-335" decimals="-5" id="f-1126" unitRef="eur">-40500000</bntx:AccumulatedDepreciationAmortisationAndImpairment>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-333" decimals="-5" id="f-1127" unitRef="eur">-300000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-334" decimals="-5" id="f-1128" unitRef="eur">0</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsAndGoodwill contextRef="c-335" decimals="-5" id="f-1129" unitRef="eur">-300000</ifrs-full:DisposalsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-333" decimals="-5" id="f-1130" unitRef="eur">200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-334" decimals="-5" id="f-1131" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-335" decimals="-5" id="f-1132" unitRef="eur">200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-336" decimals="-5" id="f-1133" unitRef="eur">-116900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-337" decimals="-5" id="f-1134" unitRef="eur">0</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-338" decimals="-5" id="f-1135" unitRef="eur">-116900000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-339" decimals="-5" id="f-1136" unitRef="eur">145400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-340" decimals="-5" id="f-1137" unitRef="eur">13100000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-15" decimals="-5" id="f-1138" unitRef="eur">158500000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-341" decimals="-5" id="f-1139" unitRef="eur">781700000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-342" decimals="-5" id="f-1140" unitRef="eur">22400000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-14" decimals="-5" id="f-1141" unitRef="eur">804100000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseInIntangibleAssetsAndGoodwill contextRef="c-1" decimals="-5" id="f-1142" unitRef="eur">645600000</ifrs-full:IncreaseDecreaseInIntangibleAssetsAndGoodwill>
    <bntx:UpfrontPayment contextRef="c-1" decimals="-5" id="f-1143" unitRef="eur">443500000</bntx:UpfrontPayment>
    <bntx:PrepaymentForFutureDevelopmentActivities contextRef="c-14" decimals="-5" id="f-1144" unitRef="eur">22500000</bntx:PrepaymentForFutureDevelopmentActivities>
    <bntx:UpfrontPayment contextRef="c-343" decimals="-5" id="f-1145" unitRef="usd">220000000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-343" decimals="-5" id="f-1146" unitRef="eur">203700000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-344" decimals="-5" id="f-1147" unitRef="usd">200000000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-344" decimals="-5" id="f-1148" unitRef="eur">181500000</bntx:UpfrontPayment>
    <bntx:UpfrontPaymentAcquisitionOfIntangibleAsset contextRef="c-345" decimals="-5" id="f-1149" unitRef="eur">125200000</bntx:UpfrontPaymentAcquisitionOfIntangibleAsset>
    <bntx:UpfrontPayment contextRef="c-346" decimals="-5" id="f-1150" unitRef="usd">70000000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-346" decimals="-5" id="f-1151" unitRef="eur">64100000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-347" decimals="-5" id="f-1152" unitRef="usd">55000000</bntx:UpfrontPayment>
    <bntx:UpfrontPayment contextRef="c-347" decimals="-5" id="f-1153" unitRef="eur">50600000</bntx:UpfrontPayment>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-348" decimals="-5" id="f-1154" unitRef="eur">163300000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-349" id="f-1155">P6Y7M6D</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-1156">Property, Plant and Equipment&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Acquisition and production costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;198.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;100.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;182.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;329.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;217.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;273.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;725.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;217.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;273.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;725.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;50.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;189.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquisition of subsidiaries and businesses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;344.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;389.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;969.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cumulative depreciation and impairment charges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;14.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;60.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;116.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;116.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;97.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Currency differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;175.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Land and buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Equipment, tools and installations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Construction in progress and advance payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-right:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;195.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;178.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;609.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;199.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;168.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;389.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;757.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current Assets by Region&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, non-current assets comprised &#x20ac;158.2 million in other intangible assets, goodwill, property, plant and equipment, right-of-use assets and other assets of our subsidiaries incorporated in the United States (as of December&#160;31, 2022: &#x20ac;188.0 million) as well as &#x20ac;511.7 million in the United Kingdom (as of December&#160;31, 2022: nil), respectively. The remaining non-current assets of &#x20ac;1,469.0 million (as of December&#160;31, 2022: &#x20ac;871.9 million) mainly relate to entities incorporated in Germany.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-350" decimals="-5" id="f-1157" unitRef="eur">104100000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-351" decimals="-5" id="f-1158" unitRef="eur">198300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-352" decimals="-5" id="f-1159" unitRef="eur">94300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-296" decimals="-5" id="f-1160" unitRef="eur">396700000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-353" decimals="-5" id="f-1161" unitRef="eur">100200000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-354" decimals="-5" id="f-1162" unitRef="eur">46700000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-355" decimals="-5" id="f-1163" unitRef="eur">182300000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-297" decimals="-5" id="f-1164" unitRef="eur">329200000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-353" decimals="-5" id="f-1165" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-354" decimals="-5" id="f-1166" unitRef="eur">1100000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-355" decimals="-5" id="f-1167" unitRef="eur">500000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-297" decimals="-5" id="f-1168" unitRef="eur">1600000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-353" decimals="-5" id="f-1169" unitRef="eur">12000000.0</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-354" decimals="-5" id="f-1170" unitRef="eur">28200000</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-355" decimals="-5" id="f-1171" unitRef="eur">-40200000</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-297" decimals="-5" id="f-1172" unitRef="eur">0</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-353" decimals="-5" id="f-1173" unitRef="eur">700000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-354" decimals="-5" id="f-1174" unitRef="eur">900000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-355" decimals="-5" id="f-1175" unitRef="eur">-400000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-297" decimals="-5" id="f-1176" unitRef="eur">1200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-356" decimals="-5" id="f-1177" unitRef="eur">217000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-357" decimals="-5" id="f-1178" unitRef="eur">273000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-358" decimals="-5" id="f-1179" unitRef="eur">235500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-260" decimals="-5" id="f-1180" unitRef="eur">725500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-356" decimals="-5" id="f-1181" unitRef="eur">217000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-357" decimals="-5" id="f-1182" unitRef="eur">273000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-358" decimals="-5" id="f-1183" unitRef="eur">235500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-260" decimals="-5" id="f-1184" unitRef="eur">725500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-359" decimals="-5" id="f-1185" unitRef="eur">9700000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-360" decimals="-5" id="f-1186" unitRef="eur">50300000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-361" decimals="-5" id="f-1187" unitRef="eur">189400000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-261" decimals="-5" id="f-1188" unitRef="eur">249400000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-359" decimals="-5" id="f-1189" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-360" decimals="-5" id="f-1190" unitRef="eur">2100000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-361" decimals="-5" id="f-1191" unitRef="eur">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-261" decimals="-5" id="f-1192" unitRef="eur">2100000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-359" decimals="-5" id="f-1193" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-360" decimals="-5" id="f-1194" unitRef="eur">2400000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-361" decimals="-5" id="f-1195" unitRef="eur">200000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-261" decimals="-5" id="f-1196" unitRef="eur">2600000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-359" decimals="-5" id="f-1197" unitRef="eur">9300000</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-360" decimals="-5" id="f-1198" unitRef="eur">22300000</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-361" decimals="-5" id="f-1199" unitRef="eur">-31600000</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <bntx:ReclassificationsOfPropertyPlantAndEquipment contextRef="c-261" decimals="-5" id="f-1200" unitRef="eur">0</bntx:ReclassificationsOfPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-359" decimals="-5" id="f-1201" unitRef="eur">-600000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-360" decimals="-5" id="f-1202" unitRef="eur">-1200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-361" decimals="-5" id="f-1203" unitRef="eur">-3600000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-261" decimals="-5" id="f-1204" unitRef="eur">-5400000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-362" decimals="-5" id="f-1205" unitRef="eur">235400000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-363" decimals="-5" id="f-1206" unitRef="eur">344100000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-364" decimals="-5" id="f-1207" unitRef="eur">389500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-262" decimals="-5" id="f-1208" unitRef="eur">969000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-365" decimals="-5" id="f-1209" unitRef="eur">-14200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-366" decimals="-5" id="f-1210" unitRef="eur">-60000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-367" decimals="-5" id="f-1211" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-326" decimals="-5" id="f-1212" unitRef="eur">-74200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-368" decimals="-5" id="f-1213" unitRef="eur">7800000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-369" decimals="-5" id="f-1214" unitRef="eur">34600000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-370" decimals="-5" id="f-1215" unitRef="eur">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-329" decimals="-5" id="f-1216" unitRef="eur">42400000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-368" decimals="-5" id="f-1217" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-369" decimals="-5" id="f-1218" unitRef="eur">-400000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-370" decimals="-5" id="f-1219" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-329" decimals="-5" id="f-1220" unitRef="eur">-400000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-368" decimals="-5" id="f-1221" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-369" decimals="-5" id="f-1222" unitRef="eur">-100000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-370" decimals="-5" id="f-1223" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-329" decimals="-5" id="f-1224" unitRef="eur">-100000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-371" decimals="-5" id="f-1225" unitRef="eur">-22000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-372" decimals="-5" id="f-1226" unitRef="eur">-94300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-373" decimals="-5" id="f-1227" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-332" decimals="-5" id="f-1228" unitRef="eur">-116300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-371" decimals="-5" id="f-1229" unitRef="eur">-22000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-372" decimals="-5" id="f-1230" unitRef="eur">-94300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-373" decimals="-5" id="f-1231" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-332" decimals="-5" id="f-1232" unitRef="eur">-116300000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-374" decimals="-5" id="f-1233" unitRef="eur">14400000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-375" decimals="-5" id="f-1234" unitRef="eur">83300000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-376" decimals="-5" id="f-1235" unitRef="eur">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-335" decimals="-5" id="f-1236" unitRef="eur">97700000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-374" decimals="-5" id="f-1237" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-375" decimals="-5" id="f-1238" unitRef="eur">-1700000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-376" decimals="-5" id="f-1239" unitRef="eur">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-335" decimals="-5" id="f-1240" unitRef="eur">-1700000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-374" decimals="-5" id="f-1241" unitRef="eur">200000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-375" decimals="-5" id="f-1242" unitRef="eur">300000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-376" decimals="-5" id="f-1243" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-335" decimals="-5" id="f-1244" unitRef="eur">500000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-377" decimals="-5" id="f-1245" unitRef="eur">-36200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-378" decimals="-5" id="f-1246" unitRef="eur">-175600000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-379" decimals="-5" id="f-1247" unitRef="eur">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-338" decimals="-5" id="f-1248" unitRef="eur">-211800000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-380" decimals="-5" id="f-1249" unitRef="eur">195000000.0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-381" decimals="-5" id="f-1250" unitRef="eur">178700000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-382" decimals="-5" id="f-1251" unitRef="eur">235500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-15" decimals="-5" id="f-1252" unitRef="eur">609200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-383" decimals="-5" id="f-1253" unitRef="eur">199200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-384" decimals="-5" id="f-1254" unitRef="eur">168500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-385" decimals="-5" id="f-1255" unitRef="eur">389500000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-14" decimals="-5" id="f-1256" unitRef="eur">757200000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:NoncurrentAssets contextRef="c-386" decimals="-5" id="f-1257" unitRef="eur">158200000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-387" decimals="-5" id="f-1258" unitRef="eur">188000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-388" decimals="-5" id="f-1259" unitRef="eur">511700000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-389" decimals="-5" id="f-1260" unitRef="eur">0</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-390" decimals="-5" id="f-1261" unitRef="eur">1469000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-391" decimals="-5" id="f-1262" unitRef="eur">871900000</ifrs-full:NoncurrentAssets>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory contextRef="c-1" id="f-1263">Financial Assets and Financial Liabilities&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.1&#160;&#160;&#160;&#160;Capital Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our capital management objectives are designed primarily to finance our growth strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our treasury committee reviews the total amount of cash and cash equivalents on a regular basis. As part of this review, the committee considers total cash and cash equivalents, cash outflow, currency translation differences and refinancing activities. We monitor cash using a burn rate. The cash burn rate is defined as the average monthly net cash flow from operating and investing activities during a financial year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11,210.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12,549.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reverse Repo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11,663.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13,875.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, the aim is to protect and maximize the financial resources available for further research and development projects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since December 1, 2021, we have an investment and asset management policy in place that contains policies and processes for managing cash and cash equivalents. Under this policy, our investment portfolio is to be maintained in a manner that minimizes risks to the invested capital. These risks include mainly credit risk and concentration risk. The portfolio must provide liquidity in a timely manner to accommodate operational and capital needs. The portfolio is managed by the Treasury department.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements. Our capital management objectives were achieved in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years ended December 31, 2023, and 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.2&#160;&#160;&#160;&#160;Categories of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets and Liabilities at Amortized Cost and at Fair Value through OCI and Profit or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reverse Repo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity investments designated at Fair Value through OCI&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net gain on equity instruments designated at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Measurement of fair values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Significant unobservable inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Actual and forecasted results&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Cash position&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Nature and pricing indication of latest financing round&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:10.91pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quoted prices on an active market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Expected future payments&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Applied cost of capital&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.3&#160;&#160;&#160;&#160;Recurring Fair Values (Level 3)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the recurring fair value measurement of the contingent considerations and the effect of the measurements on our consolidated statements of profit or loss for the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net effect on profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sensitivity of the fair values of contingent considerations in fair value level 3 to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Input factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in fair value with increasing input factor (in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in fair value with decreasing input factor (in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash flow projections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of non-listed equity investments would, for example, increase (decrease) if price of latest financing round were to increase (decrease) and the overall company value were higher (lower).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.4&#160;&#160;&#160;&#160;Financial Instruments Risk Management Objectives and Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial liabilities mainly comprise obligations derived from license agreements, trade and other payables, lease liabilities, contingent consideration, loans and borrowings, hedging liabilities as well as other financial liabilities. The main purpose of these financial liabilities is to enable our operations. Our principal financial assets include mainly cash, security investments and trade receivables that derive directly from our operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to market risk, credit risk and liquidity risk. Our Management Board oversees the management of these risks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The treasury committee provides assurance to our Management Board that our financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with our policies and risk objectives. The Management Board reviews and agrees policies for managing each of these risks, which are summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.5&#160;&#160;&#160;&#160;Market Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risks address the risks that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risks comprise three types of risk: interest risks, foreign currency risks and other price risks. Financial instruments affected by market risks include financial assets such as security investments, trade and other receivables, cash and cash equivalents as well as financial liabilities such as trade payables and other financial liabilities. We do not consider interest risks as well as other price risks as material risks to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material changes in the way the risks were managed and valued during the years ended December 31, 2023, and 2022. Because of the significantly higher cash balance and security investments &#x2013; the market risk exposure on counterparty risk increased compared to the previous period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign currency risks address the risks that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We are subject to currency risks, as our income and expenditures are denominated in Euro and the U.S. dollar. As such, we are exposed to exchange rate fluctuations between these currencies. Cash inflows denominated in U.S. dollar mainly result &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;from generating proceeds under our collaboration agreements. Our commercial revenues are primarily collaboration revenues from earnings based on our partners&#x2019; gross profit, which is shared under the respective collaboration agreements and represents payments we receive in U.S. dollar. Cash outflows dominated in U.S. dollar mainly result from amounts spent on research and development activities and license obligations as well as expanding our global footprint further. With the aim of preserving capital, surplus liquidity is mainly invested in domestic currency investments as exchange rate fluctuations can reduce the value of our financial positions. We limit the effects of the identified risks by means of a coordinated and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;consistently&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; implemented risk strategy. Besides applying natural hedging relationships where possible, foreign exchange forward contracts are concluded, as a matter of principle, as instruments to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; mitigate foreign currency exchange risk associated with foreign currency-denominated payments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. However, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;he foreign exchange forward contracts which we entered into were not designated as hedging instruments under IFRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the monetary assets and liabilities denominated in U.S. dollar at the dates indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,487.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Monetary assets in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,191.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,098.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Monetary liabilities and provisions in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;567.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,527.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;747.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;7,058.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables demonstrate the sensitivity to a reasonable, possible change in U.S. dollar exchange rates or U.S. dollar forward rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets and liabilities. The exposure to foreign currency changes for all other currencies is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1 &#x20ac; =&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0666&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0530&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in U.S. dollar rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effect on profit / (loss) before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effect on pre-tax equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;+5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;+5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(195.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(191.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;215.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;211.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12.6&#160;&#160;&#160;&#160;Credit Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risks address the risks that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risks from our operating activities, including security investments, bank deposits, reverse repos, foreign exchange transactions, trade and other receivables and cash at banks. The maximum exposure to credit risk for the components of the consolidated statements of financial position as of December&#160;31, 2023, and December&#160;31, 2022, are the carrying amounts as illustrated in Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.1 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 12.2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Security Investments, Bank Deposits, Reverse Repos and Cash at banks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial management is dedicated predominantly to the goal of capital preservation. Thus, all our financial activities are focused towards avoiding risks and, where they cannot be avoided, actively managing and minimizing them. Credit risks from balances with security investments, bank deposits, reverse repos and cash at banks are managed by our Treasury department in accordance with our investment and asset management policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our security investments are solely invested in the highest-quality liquid assets (e.g. core European sovereign, supranational and agency bonds) and bank deposits with a maturity of more than 3 months (held at selected banks, exclusively rated as investment grade). They do not bear any currency risks or material credit risks. The bank deposits are held at selected banks, exclusively rated as investment grade. We limit our investment engagements individually and track each credit risk continuously. For reverse repos, only investment-grade counterparties qualify as our business partners and even secured investments are solely collateralized by high-quality liquid assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, credit risks from these financial assets are limited. Before entering into new business relationships and during ongoing business relationships, we evaluate our business partners with regard to their individual default risk. Therefore, we do not presume an increased credit risk as of the balance sheet date and determine the impairment loss based on the upcoming twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;calculated expected credit losses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were not material as of December&#160;31, 2023, and December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and Other Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our exposure to credit risks of trade and other receivables is primarily related to transactions with corporate customers in the biopharma / biotech industry that operate in the United States or Germany, as well as &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;governments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which are customers, in connection with fulfilling our commercial obligations in our territories as defined in our contracts with customers. An analysis of the aging of receivables and the creditworthiness of customers is used to evaluate this risk at each reporting date. We follow risk control procedures to assess the credit quality of our customers taking into account their financial position, past experience and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, outstanding trade and other receivables were mainly due from our collaboration partner Pfizer.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Besides well-established pharmaceutical companies and governmental institutions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our other customers &#x2013; to a smaller extent &#x2013; are medical universities, other public institutions and peers in the biopharma industry, which have good credit ratings. Due to this customer portfolio, the credit risk on trade and other receivables is generally very low. We have not incurred material bad debt expense and do not expect that this will change with respect to the trade and other receivables outstanding as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected credit risk on trade and other receivables derived from applying the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;simplified approach in calculating expected credit losses &lt;/span&gt;was not material as of December&#160;31, 2023, and December&#160;31, 2022.&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12.7&#160;&#160;&#160;&#160;Liquidity Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We plan to invest heavily in R&amp;amp;D as we make a strong drive to build out our global development organization and diversify our therapeutic area footprint. Additionally, we plan to enhance capabilities through complementary acquisitions, technologies, infrastructure and manufacturing.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our liquidity management ensures the availability of cash and cash equivalents, short term financial instruments for operational activities and further investments through appropriate budget planning. In addition, a sufficient level of cash and cash equivalents, which are managed centrally, is always maintained to finance the operational activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor liquidity risks using a liquidity planning tool.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ultimately, the responsibility for liquidity risk management lies with our Management Board, which has established an appropriate approach to managing short-, medium- and long-term financing and liquidity requirements. We manage liquidity risks by holding appropriate reserves based on our COVID-19 sales, as well as by monitoring forecasted and actual cash flows and reconciling the maturity profiles of financial assets and liabilities. Significant reserves currently exist and were generated during the Covid-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrations arise when the number of counterparties is small or when a larger number of counterparties is engaged in similar business activities, or activities in the same geographical region, or has economic features that would cause their ability to meet contractual obligations to be affected similarly by changes in economic, political or other conditions. Concentrations indicate the relative sensitivity of our performance to developments affecting a particular industry. We only have a limited number of customers mainly comprising &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pharmaceutical companies and governmental institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;136.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;244.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;803.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;196.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,073.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;112.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;232.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,029.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;115.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;85.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,229.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12.8&#160;&#160;&#160;&#160;Changes in Liabilities Arising from Financing Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;New leases and disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Reclassifi-cation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;28.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;188.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;212.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;50.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;219.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;New leases and disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Reclassifi-cation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;33.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;153.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;52.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;119.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(99.8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible note &#x2013; embedded derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;308.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(308.7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;610.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;67.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(406.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;212.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Related to the early redemption of our convertible note during the year ended December&#160;31, 2023, as further described in Note 15.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock contextRef="c-1" id="f-1264">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11,210.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;12,549.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reverse Repo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11,663.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;13,875.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfCashAndCashEquivalentsExplanatoryTableTextBlock>
    <ifrs-full:Cash contextRef="c-14" decimals="-5" id="f-1265" unitRef="eur">453100000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-15" decimals="-5" id="f-1266" unitRef="eur">1325200000</ifrs-full:Cash>
    <ifrs-full:CashEquivalents contextRef="c-14" decimals="-5" id="f-1267" unitRef="eur">11210600000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-15" decimals="-5" id="f-1268" unitRef="eur">12549900000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-392" decimals="-5" id="f-1269" unitRef="eur">2589500000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-393" decimals="-5" id="f-1270" unitRef="eur">9401000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-394" decimals="-5" id="f-1271" unitRef="eur">7446100000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-395" decimals="-5" id="f-1272" unitRef="eur">3148900000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-396" decimals="-5" id="f-1273" unitRef="eur">1175000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-397" decimals="-5" id="f-1274" unitRef="eur">0</ifrs-full:CashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-5" id="f-1275" unitRef="eur">11663700000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-15" decimals="-5" id="f-1276" unitRef="eur">13875100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c-1" id="f-1278">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reverse Repo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial investments in equity securities measured at fair value through other comprehensive income comprise the following effects:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net gain on equity instruments designated at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #4EA72E;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-top:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-1277">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is an overview of financial assets and liabilities at amortized cost and at fair value through OCI and profit or loss, as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.392%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,446.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;26.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,155.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,989.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,589.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Reverse Repo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,175.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;453.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. Fair values are not disclosed because the book values represent a reasonable approximation of fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.977%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Category&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 1 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 2 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Level 3 (Fair value)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;183.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,148.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial assets not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other receivables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,145.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Bank deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9,401.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash at banks and on hand&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,325.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;FVTPL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Financial liabilities not measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial assets and liabilities categorized at amortized costs mainly correspond to fair value. We do not make a disclosure for cash and cash equivalents, trade receivables and trade payables. Fair values are disclosed because the book values represent a reasonable approximation of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturity profile of our financial liabilities based on contractual undiscounted payments is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;354.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;136.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;244.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign exchange forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;414.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;803.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;196.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;74.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,073.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;204.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;112.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;232.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;785.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,029.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;115.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;85.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,229.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:FinancialAssets contextRef="c-398" decimals="-5" id="f-1279" unitRef="eur">7446100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-399" decimals="-5" id="f-1280" unitRef="eur">7446100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-400" decimals="-5" id="f-1281" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-401" decimals="-5" id="f-1282" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-402" decimals="-5" id="f-1283" unitRef="eur">7446100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-403" decimals="-5" id="f-1284" unitRef="eur">27100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-404" decimals="-5" id="f-1285" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-405" decimals="-5" id="f-1286" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-406" decimals="-5" id="f-1287" unitRef="eur">27100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-407" decimals="-5" id="f-1288" unitRef="eur">27100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-408" decimals="-5" id="f-1289" unitRef="eur">26000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-409" decimals="-5" id="f-1290" unitRef="eur">26000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-410" decimals="-5" id="f-1291" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-411" decimals="-5" id="f-1292" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-412" decimals="-5" id="f-1293" unitRef="eur">26000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-413" decimals="-5" id="f-1294" unitRef="eur">2155700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-414" decimals="-5" id="f-1295" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-415" decimals="-5" id="f-1296" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-416" decimals="-5" id="f-1297" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-417" decimals="-5" id="f-1298" unitRef="eur">2155700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-418" decimals="-5" id="f-1299" unitRef="eur">5989700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-419" decimals="-5" id="f-1300" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-420" decimals="-5" id="f-1301" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-421" decimals="-5" id="f-1302" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-422" decimals="-5" id="f-1303" unitRef="eur">5989700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-423" decimals="-5" id="f-1304" unitRef="eur">18600000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-424" decimals="-5" id="f-1305" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-425" decimals="-5" id="f-1306" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-426" decimals="-5" id="f-1307" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-427" decimals="-5" id="f-1308" unitRef="eur">18600000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-428" decimals="-5" id="f-1309" unitRef="eur">2589500000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-429" decimals="-5" id="f-1310" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-430" decimals="-5" id="f-1311" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-431" decimals="-5" id="f-1312" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-432" decimals="-5" id="f-1313" unitRef="eur">2589500000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-433" decimals="-5" id="f-1314" unitRef="eur">1175000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-434" decimals="-5" id="f-1315" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-435" decimals="-5" id="f-1316" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-436" decimals="-5" id="f-1317" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-437" decimals="-5" id="f-1318" unitRef="eur">1175000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-438" decimals="-5" id="f-1319" unitRef="eur">453100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-439" decimals="-5" id="f-1320" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-440" decimals="-5" id="f-1321" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-441" decimals="-5" id="f-1322" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-442" decimals="-5" id="f-1323" unitRef="eur">453100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-443" decimals="-5" id="f-1324" unitRef="eur">400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-444" decimals="-5" id="f-1325" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-445" decimals="-5" id="f-1326" unitRef="eur">400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-446" decimals="-5" id="f-1327" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-447" decimals="-5" id="f-1328" unitRef="eur">400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-448" decimals="-5" id="f-1329" unitRef="eur">38800000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-449" decimals="-5" id="f-1330" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-450" decimals="-5" id="f-1331" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-451" decimals="-5" id="f-1332" unitRef="eur">38800000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-452" decimals="-5" id="f-1333" unitRef="eur">38800000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-453" decimals="-5" id="f-1334" unitRef="eur">216700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-454" decimals="-5" id="f-1335" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-455" decimals="-5" id="f-1336" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-456" decimals="-5" id="f-1337" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-457" decimals="-5" id="f-1338" unitRef="eur">216700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-458" decimals="-5" id="f-1339" unitRef="eur">2300000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-459" decimals="-5" id="f-1340" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-460" decimals="-5" id="f-1341" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-461" decimals="-5" id="f-1342" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-462" decimals="-5" id="f-1343" unitRef="eur">2300000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-463" decimals="-5" id="f-1344" unitRef="eur">354000000.0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-464" decimals="-5" id="f-1345" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-465" decimals="-5" id="f-1346" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-466" decimals="-5" id="f-1347" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-467" decimals="-5" id="f-1348" unitRef="eur">354000000.0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-468" decimals="-5" id="f-1349" unitRef="eur">414900000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-469" decimals="-5" id="f-1350" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-470" decimals="-5" id="f-1351" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-471" decimals="-5" id="f-1352" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-472" decimals="-5" id="f-1353" unitRef="eur">414900000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets contextRef="c-473" decimals="-5" id="f-1354" unitRef="eur">183700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-474" decimals="-5" id="f-1355" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-475" decimals="-5" id="f-1356" unitRef="eur">183700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-476" decimals="-5" id="f-1357" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-477" decimals="-5" id="f-1358" unitRef="eur">183700000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-478" decimals="-5" id="f-1359" unitRef="eur">3148900000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-479" decimals="-5" id="f-1360" unitRef="eur">3148900000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-480" decimals="-5" id="f-1361" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-481" decimals="-5" id="f-1362" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-482" decimals="-5" id="f-1363" unitRef="eur">3148900000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-483" decimals="-5" id="f-1364" unitRef="eur">57100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-484" decimals="-5" id="f-1365" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-485" decimals="-5" id="f-1366" unitRef="eur">57100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-486" decimals="-5" id="f-1367" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-487" decimals="-5" id="f-1368" unitRef="eur">57100000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-488" decimals="-5" id="f-1369" unitRef="eur">20000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-489" decimals="-5" id="f-1370" unitRef="eur">20000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-490" decimals="-5" id="f-1371" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-491" decimals="-5" id="f-1372" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-492" decimals="-5" id="f-1373" unitRef="eur">20000000.0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-493" decimals="-5" id="f-1374" unitRef="eur">7145600000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-494" decimals="-5" id="f-1375" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-495" decimals="-5" id="f-1376" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-496" decimals="-5" id="f-1377" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-497" decimals="-5" id="f-1378" unitRef="eur">7145600000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-498" decimals="-5" id="f-1379" unitRef="eur">8800000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-499" decimals="-5" id="f-1380" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-500" decimals="-5" id="f-1381" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-501" decimals="-5" id="f-1382" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-502" decimals="-5" id="f-1383" unitRef="eur">8800000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-503" decimals="-5" id="f-1384" unitRef="eur">9401000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-504" decimals="-5" id="f-1385" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-505" decimals="-5" id="f-1386" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-506" decimals="-5" id="f-1387" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-507" decimals="-5" id="f-1388" unitRef="eur">9401000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-508" decimals="-5" id="f-1389" unitRef="eur">1325200000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-509" decimals="-5" id="f-1390" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-510" decimals="-5" id="f-1391" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-511" decimals="-5" id="f-1392" unitRef="eur">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-512" decimals="-5" id="f-1393" unitRef="eur">1325200000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-513" decimals="-5" id="f-1394" unitRef="eur">6100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-514" decimals="-5" id="f-1395" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-515" decimals="-5" id="f-1396" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-516" decimals="-5" id="f-1397" unitRef="eur">6100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-517" decimals="-5" id="f-1398" unitRef="eur">6100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-518" decimals="-5" id="f-1399" unitRef="eur">210100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-519" decimals="-5" id="f-1400" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-520" decimals="-5" id="f-1401" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-521" decimals="-5" id="f-1402" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-522" decimals="-5" id="f-1403" unitRef="eur">210100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-523" decimals="-5" id="f-1404" unitRef="eur">2100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-524" decimals="-5" id="f-1405" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-525" decimals="-5" id="f-1406" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-526" decimals="-5" id="f-1407" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-527" decimals="-5" id="f-1408" unitRef="eur">2100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-528" decimals="-5" id="f-1409" unitRef="eur">204100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-529" decimals="-5" id="f-1410" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-530" decimals="-5" id="f-1411" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-531" decimals="-5" id="f-1412" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-532" decimals="-5" id="f-1413" unitRef="eur">204100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-533" decimals="-5" id="f-1414" unitRef="eur">785100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-534" decimals="-5" id="f-1415" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-535" decimals="-5" id="f-1416" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-536" decimals="-5" id="f-1417" unitRef="eur">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-537" decimals="-5" id="f-1418" unitRef="eur">785100000</ifrs-full:FinancialLiabilities>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-538" decimals="-5" id="f-1419" unitRef="eur">3700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-539" decimals="-5" id="f-1420" unitRef="eur">10500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-1" decimals="-5" id="f-1421" unitRef="eur">3700000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="c-12" decimals="-5" id="f-1422" unitRef="eur">10500000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-1423">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the valuation techniques used in measuring fair values for financial instruments in our consolidated statements of financial position, as well as the significant unobservable inputs used. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Valuation technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Significant unobservable inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.815%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discounted cash flow using par method. Expected future cash flows based on foreign exchange forwards discounted over the respective remaining term of the contracts using the respective deposit interest rates and spot rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-listed equity investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quantitative and qualitative factors such as actual and forecasted results, cash position and financing round valuations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Actual and forecasted results&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Cash position&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Nature and pricing indication of latest financing round&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:10.91pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Listed equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock prices of the listed companies and applicable exchange rates, if the listing is in a foreign currency.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Quoted prices on an active market&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;n/a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Present value of expected future payments and reflecting changes in expected achievement of underlying performance parameters and compounding effects. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Expected future payments&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:14.17pt;text-indent:-7.09pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:2.09pt"&gt;Applied cost of capital&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sensitivity of the fair values of contingent considerations in fair value level 3 to the significant, unobservable, variable input factors, with all other factors remaining constant, is shown in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Input factor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in fair value with increasing input factor (in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in fair value with decreasing input factor (in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash flow projections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-1424">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the recurring fair value measurement of the contingent considerations and the effect of the measurements on our consolidated statements of profit or loss for the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net effect on profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #4EA72E;border-right:1pt solid #4EA72E;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;38.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:Liabilities contextRef="c-540" decimals="-5" id="f-1425" unitRef="eur">6100000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-541" decimals="-5" id="f-1426" unitRef="eur">6100000</ifrs-full:Liabilities>
    <ifrs-full:PurchasesFairValueMeasurementLiabilities contextRef="c-542" decimals="-5" id="f-1427" unitRef="eur">31800000</ifrs-full:PurchasesFairValueMeasurementLiabilities>
    <bntx:NetChangeInFairValue contextRef="c-542" decimals="-5" id="f-1428" unitRef="eur">900000</bntx:NetChangeInFairValue>
    <ifrs-full:Liabilities contextRef="c-543" decimals="-5" id="f-1429" unitRef="eur">38800000</ifrs-full:Liabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-544"
      decimals="INF"
      id="f-1430"
      unitRef="number">0.10</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities contextRef="c-545" decimals="-5" id="f-1431" unitRef="eur">3400000</ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities>
    <ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities contextRef="c-545" decimals="-5" id="f-1432" unitRef="eur">3400000</ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="c-546"
      decimals="INF"
      id="f-1433"
      unitRef="number">0.01</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities contextRef="c-547" decimals="-5" id="f-1434" unitRef="eur">800000</ifrs-full:DecreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities>
    <ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities contextRef="c-547" decimals="-5" id="f-1435" unitRef="eur">800000</ifrs-full:IncreaseInFairValueMeasurementDueToChangeInMultipleUnobservableInputsToReflectReasonablyPossibleAlternativeAssumptionsLiabilities>
    <bntx:DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock contextRef="c-1" id="f-1436">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the monetary assets and liabilities denominated in U.S. dollar at the dates indicated are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;122.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,487.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Monetary assets in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,191.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,098.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Monetary liabilities and provisions in U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;567.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,527.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;747.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;7,058.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntx:DisclosureOfForeignCurrencyRiskExplanatoryTableTextBlock>
    <bntx:CashAndCashEquivalent contextRef="c-548" decimals="-5" id="f-1437" unitRef="eur">122600000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-549" decimals="-5" id="f-1438" unitRef="eur">1487400000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-550" decimals="-5" id="f-1439" unitRef="eur">1191900000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-551" decimals="-5" id="f-1440" unitRef="eur">7098500000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-552" decimals="-5" id="f-1441" unitRef="eur">567300000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-553" decimals="-5" id="f-1442" unitRef="eur">1527800000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-14" decimals="-5" id="f-1443" unitRef="eur">747200000</bntx:CashAndCashEquivalent>
    <bntx:CashAndCashEquivalent contextRef="c-15" decimals="-5" id="f-1444" unitRef="eur">7058100000</bntx:CashAndCashEquivalent>
    <bntx:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock contextRef="c-1" id="f-1445">&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables demonstrate the sensitivity to a reasonable, possible change in U.S. dollar exchange rates or U.S. dollar forward rates, with all other variables held constant. The impact on our profit before tax is due to changes in the fair value of monetary assets and liabilities. The exposure to foreign currency changes for all other currencies is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.845%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1 &#x20ac; =&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Closing rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Country&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0666&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0813&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0530&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Change in U.S. dollar rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effect on profit / (loss) before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Effect on pre-tax equity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;+5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(35.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;+5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(195.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(191.5)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;-5 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;215.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;211.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatoryTableTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-554"
      decimals="4"
      id="f-1446"
      unitRef="number">1.1050</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-555"
      decimals="4"
      id="f-1447"
      unitRef="number">1.0666</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-556"
      decimals="4"
      id="f-1448"
      unitRef="number">1.0813</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="c-557"
      decimals="4"
      id="f-1449"
      unitRef="number">1.0530</ifrs-full:AverageForeignExchangeRate>
    <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax contextRef="c-558" decimals="-5" id="f-1450" unitRef="eur">-35500000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
    <bntx:ForeignCurrencyChangesEffectOnPretaxEquity contextRef="c-558" decimals="-5" id="f-1451" unitRef="eur">-35500000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
    <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax contextRef="c-559" decimals="-5" id="f-1452" unitRef="eur">39200000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
    <bntx:ForeignCurrencyChangesEffectOnPretaxEquity contextRef="c-559" decimals="-5" id="f-1453" unitRef="eur">39300000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
    <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax contextRef="c-560" decimals="-5" id="f-1454" unitRef="eur">-195200000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
    <bntx:ForeignCurrencyChangesEffectOnPretaxEquity contextRef="c-560" decimals="-5" id="f-1455" unitRef="eur">-191500000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
    <bntx:ForeignCurrencyChangesEffectOnLossBeforeTax contextRef="c-561" decimals="-5" id="f-1456" unitRef="eur">215700000</bntx:ForeignCurrencyChangesEffectOnLossBeforeTax>
    <bntx:ForeignCurrencyChangesEffectOnPretaxEquity contextRef="c-561" decimals="-5" id="f-1457" unitRef="eur">211700000</bntx:ForeignCurrencyChangesEffectOnPretaxEquity>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-562" decimals="-5" id="f-1458" unitRef="eur">0</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-563" decimals="-5" id="f-1459" unitRef="eur">2300000</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-564" decimals="-5" id="f-1460" unitRef="eur">0</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-565" decimals="-5" id="f-1461" unitRef="eur">2300000</bntx:InterestBearingLoansAndBorrowings>
    <ifrs-full:TradeAndOtherPayables contextRef="c-562" decimals="-5" id="f-1462" unitRef="eur">354000000.0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-563" decimals="-5" id="f-1463" unitRef="eur">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-564" decimals="-5" id="f-1464" unitRef="eur">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-565" decimals="-5" id="f-1465" unitRef="eur">354000000.0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:LeaseLiabilities contextRef="c-562" decimals="-5" id="f-1466" unitRef="eur">34100000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-563" decimals="-5" id="f-1467" unitRef="eur">136600000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-564" decimals="-5" id="f-1468" unitRef="eur">73700000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-565" decimals="-5" id="f-1469" unitRef="eur">244400000</ifrs-full:LeaseLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-562" decimals="-5" id="f-1470" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-563" decimals="-5" id="f-1471" unitRef="eur">57500000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-564" decimals="-5" id="f-1472" unitRef="eur">300000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-565" decimals="-5" id="f-1473" unitRef="eur">57800000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-562" decimals="-5" id="f-1474" unitRef="eur">400000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-563" decimals="-5" id="f-1475" unitRef="eur">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-564" decimals="-5" id="f-1476" unitRef="eur">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-565" decimals="-5" id="f-1477" unitRef="eur">400000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-562" decimals="-5" id="f-1478" unitRef="eur">414900000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-563" decimals="-5" id="f-1479" unitRef="eur">0</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-564" decimals="-5" id="f-1480" unitRef="eur">0</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-565" decimals="-5" id="f-1481" unitRef="eur">414900000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-562" decimals="-5" id="f-1482" unitRef="eur">803400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-563" decimals="-5" id="f-1483" unitRef="eur">196400000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-564" decimals="-5" id="f-1484" unitRef="eur">74000000.0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-565" decimals="-5" id="f-1485" unitRef="eur">1073800000</ifrs-full:FinancialLiabilities>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-566" decimals="-5" id="f-1486" unitRef="eur">0</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-567" decimals="-5" id="f-1487" unitRef="eur">2100000</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-568" decimals="-5" id="f-1488" unitRef="eur">0</bntx:InterestBearingLoansAndBorrowings>
    <bntx:InterestBearingLoansAndBorrowings contextRef="c-569" decimals="-5" id="f-1489" unitRef="eur">2100000</bntx:InterestBearingLoansAndBorrowings>
    <ifrs-full:TradeAndOtherPayables contextRef="c-566" decimals="-5" id="f-1490" unitRef="eur">204100000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-567" decimals="-5" id="f-1491" unitRef="eur">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-568" decimals="-5" id="f-1492" unitRef="eur">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-569" decimals="-5" id="f-1493" unitRef="eur">204100000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:LeaseLiabilities contextRef="c-566" decimals="-5" id="f-1494" unitRef="eur">40500000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-567" decimals="-5" id="f-1495" unitRef="eur">112900000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-568" decimals="-5" id="f-1496" unitRef="eur">79100000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-569" decimals="-5" id="f-1497" unitRef="eur">232500000</ifrs-full:LeaseLiabilities>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-566" decimals="-5" id="f-1498" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-567" decimals="-5" id="f-1499" unitRef="eur">0</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-568" decimals="-5" id="f-1500" unitRef="eur">6100000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="c-569" decimals="-5" id="f-1501" unitRef="eur">6100000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-566" decimals="-5" id="f-1502" unitRef="eur">785100000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-567" decimals="-5" id="f-1503" unitRef="eur">0</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-568" decimals="-5" id="f-1504" unitRef="eur">0</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities contextRef="c-569" decimals="-5" id="f-1505" unitRef="eur">785100000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-566" decimals="-5" id="f-1506" unitRef="eur">1029700000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-567" decimals="-5" id="f-1507" unitRef="eur">115000000.0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-568" decimals="-5" id="f-1508" unitRef="eur">85200000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-569" decimals="-5" id="f-1509" unitRef="eur">1229900000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory contextRef="c-1" id="f-1510">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;New leases and disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Reclassifi-cation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(40.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;28.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;188.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;212.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(40.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;50.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;219.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.788%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;New leases and disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Reclassifi-cation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;33.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current obligations under lease contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;153.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;52.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(33.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Loans and borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;119.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(18.0)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(99.8)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible note &#x2013; embedded derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;308.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(308.7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;610.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(59.1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;67.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;(406.3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;212.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Related to the early redemption of our convertible note during the year ended December&#160;31, 2023, as further described in Note 15.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-570" decimals="-5" id="f-1511" unitRef="eur">36000000.0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-571" decimals="-5" id="f-1512" unitRef="eur">-40300000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-571" decimals="-5" id="f-1513" unitRef="eur">-600000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-571" decimals="-5" id="f-1514" unitRef="eur">34100000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-571" decimals="-5" id="f-1515" unitRef="eur">-1100000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-572" decimals="-5" id="f-1516" unitRef="eur">28100000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-573" decimals="-5" id="f-1517" unitRef="eur">174100000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-574" decimals="-5" id="f-1518" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-574" decimals="-5" id="f-1519" unitRef="eur">51100000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-574" decimals="-5" id="f-1520" unitRef="eur">-34100000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-574" decimals="-5" id="f-1521" unitRef="eur">-2500000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-575" decimals="-5" id="f-1522" unitRef="eur">188600000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-576" decimals="-5" id="f-1523" unitRef="eur">2100000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-577" decimals="-5" id="f-1524" unitRef="eur">200000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-577" decimals="-5" id="f-1525" unitRef="eur">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-577" decimals="-5" id="f-1526" unitRef="eur">0</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-577" decimals="-5" id="f-1527" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-578" decimals="-5" id="f-1528" unitRef="eur">2300000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-15" decimals="-5" id="f-1529" unitRef="eur">212200000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-5" id="f-1530" unitRef="eur">-40100000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-5" id="f-1531" unitRef="eur">50500000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-5" id="f-1532" unitRef="eur">0</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-5" id="f-1533" unitRef="eur">-3600000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-14" decimals="-5" id="f-1534" unitRef="eur">219000000.0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-579" decimals="-5" id="f-1535" unitRef="eur">27900000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-580" decimals="-5" id="f-1536" unitRef="eur">-41100000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-580" decimals="-5" id="f-1537" unitRef="eur">14800000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-580" decimals="-5" id="f-1538" unitRef="eur">33300000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-580" decimals="-5" id="f-1539" unitRef="eur">1100000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-570" decimals="-5" id="f-1540" unitRef="eur">36000000.0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-581" decimals="-5" id="f-1541" unitRef="eur">153700000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-582" decimals="-5" id="f-1542" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-582" decimals="-5" id="f-1543" unitRef="eur">52600000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-582" decimals="-5" id="f-1544" unitRef="eur">-33300000</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-582" decimals="-5" id="f-1545" unitRef="eur">1100000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-573" decimals="-5" id="f-1546" unitRef="eur">174100000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-583" decimals="-5" id="f-1547" unitRef="eur">119900000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-584" decimals="-5" id="f-1548" unitRef="eur">-18000000.0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-584" decimals="-5" id="f-1549" unitRef="eur">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-584" decimals="-5" id="f-1550" unitRef="eur">0</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-584" decimals="-5" id="f-1551" unitRef="eur">-99800000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-576" decimals="-5" id="f-1552" unitRef="eur">2100000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-585" decimals="-5" id="f-1553" unitRef="eur">308700000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-586" decimals="-5" id="f-1554" unitRef="eur">0</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-586" decimals="-5" id="f-1555" unitRef="eur">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-586" decimals="-5" id="f-1556" unitRef="eur">0</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-586" decimals="-5" id="f-1557" unitRef="eur">-308700000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-587" decimals="-5" id="f-1558" unitRef="eur">0</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-31" decimals="-5" id="f-1559" unitRef="eur">610200000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-12" decimals="-5" id="f-1560" unitRef="eur">-59100000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-12" decimals="-5" id="f-1561" unitRef="eur">67400000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities contextRef="c-12" decimals="-5" id="f-1562" unitRef="eur">0</bntx:IncreaseDecreaseThroughReclassificationLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="c-12" decimals="-5" id="f-1563" unitRef="eur">-406300000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-15" decimals="-5" id="f-1564" unitRef="eur">212200000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c-1" id="f-1565">Inventories&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;409.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unfinished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;357.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;439.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; expenses from inventory write-downs to net realizable value due to inventories expected to be unsellable, not fulfilling the specification defined by our quality standards, shelf-life expiry or disposals resulted in &#x20ac;94.5&#160;million, compared to &#x20ac;484.6 million in the previous period. The inventories valued at net realizable value in our consolidated statements of financial position as of December&#160;31, 2023, take contractual compensation payments into consideration.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We have not &lt;/span&gt;pledged any inventories as securities for liabilities. During the years ended December 31, 2023, and 2022, costs of inventories in the amount of &#x20ac;354.4 million and &#x20ac;1,550.6 million, respectively, were recognized as cost of sales.</ifrs-full:DisclosureOfInventoriesExplanatory>
    <bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock contextRef="c-1" id="f-1566">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;347.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;409.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unfinished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;357.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;439.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfClassesOfInventoriesExplanatoryTableTextBlock>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies contextRef="c-14" decimals="-5" id="f-1567" unitRef="eur">347500000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies contextRef="c-15" decimals="-5" id="f-1568" unitRef="eur">409700000</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <ifrs-full:WorkInProgress contextRef="c-14" decimals="-5" id="f-1569" unitRef="eur">4000000.0</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-15" decimals="-5" id="f-1570" unitRef="eur">21000000.0</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods contextRef="c-14" decimals="-5" id="f-1571" unitRef="eur">6200000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-15" decimals="-5" id="f-1572" unitRef="eur">8900000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c-14" decimals="-5" id="f-1573" unitRef="eur">357700000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-15" decimals="-5" id="f-1574" unitRef="eur">439600000</ifrs-full:Inventories>
    <ifrs-full:InventoryWritedown2011 contextRef="c-1" decimals="-5" id="f-1575" unitRef="eur">94500000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="c-12" decimals="-5" id="f-1576" unitRef="eur">484600000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="c-1" decimals="-5" id="f-1577" unitRef="eur">354400000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="c-12" decimals="-5" id="f-1578" unitRef="eur">1550600000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="c-1" id="f-1579">Other Non-Financial Assets&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;313.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;120.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;93.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepayments related to CRO and CMO contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;278.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;280.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;271.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred expenses mainly comprise prepayments for future expenses of &#x20ac;151.1&#160;million (nil as of December&#160;31, 2022) for the settlement fee of the European Commission to our collaboration partner and prepayments for our collaborations with OncoC4 Inc., Rockville, USA, &#x20ac;22.5&#160;million (nil as of December&#160;31, 2022), Ryvu Therapeutics S.A., Krakau, Poland, &#x20ac;15.7&#160;million (&#x20ac;19.7&#160;million as of December&#160;31, 2022) and Medigene Immunotherapies GmbH, Planegg/Martinsried, &#x20ac;5.1&#160;million (&#x20ac;9.4&#160;million as of December&#160;31, 2022). Prior year deferred expenses mainly comprise service contracts and insurance obligations.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-1580">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;313.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;120.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;93.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepayments related to CRO and CMO contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;364.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;278.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;280.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;271.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;83.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70AD47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutOtherAssetsExplanatoryTableTextBlock>
    <bntx:DeferredExpense contextRef="c-14" decimals="-5" id="f-1581" unitRef="eur">313200000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-15" decimals="-5" id="f-1582" unitRef="eur">120000000.0</bntx:DeferredExpense>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax contextRef="c-14" decimals="-5" id="f-1583" unitRef="eur">5200000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax contextRef="c-15" decimals="-5" id="f-1584" unitRef="eur">93800000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-14" decimals="-5" id="f-1585" unitRef="eur">0</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers contextRef="c-15" decimals="-5" id="f-1586" unitRef="eur">35300000</ifrs-full:CurrentAdvancesToSuppliers>
    <bntx:OtherCurrentAssetsOther contextRef="c-14" decimals="-5" id="f-1587" unitRef="eur">45900000</bntx:OtherCurrentAssetsOther>
    <bntx:OtherCurrentAssetsOther contextRef="c-15" decimals="-5" id="f-1588" unitRef="eur">29300000</bntx:OtherCurrentAssetsOther>
    <ifrs-full:OtherNonfinancialAssets contextRef="c-14" decimals="-5" id="f-1589" unitRef="eur">364300000</ifrs-full:OtherNonfinancialAssets>
    <ifrs-full:OtherNonfinancialAssets contextRef="c-15" decimals="-5" id="f-1590" unitRef="eur">278400000</ifrs-full:OtherNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets contextRef="c-14" decimals="-5" id="f-1591" unitRef="eur">280900000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets contextRef="c-15" decimals="-5" id="f-1592" unitRef="eur">271900000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-14" decimals="-5" id="f-1593" unitRef="eur">83400000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-15" decimals="-5" id="f-1594" unitRef="eur">6500000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <bntx:DeferredExpense contextRef="c-588" decimals="-5" id="f-1595" unitRef="eur">151100000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-589" decimals="-5" id="f-1596" unitRef="eur">0</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-590" decimals="-5" id="f-1597" unitRef="eur">22500000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-591" decimals="-5" id="f-1598" unitRef="eur">0</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-592" decimals="-5" id="f-1599" unitRef="eur">15700000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-593" decimals="-5" id="f-1600" unitRef="eur">19700000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-594" decimals="-5" id="f-1601" unitRef="eur">5100000</bntx:DeferredExpense>
    <bntx:DeferredExpense contextRef="c-595" decimals="-5" id="f-1602" unitRef="eur">9400000</bntx:DeferredExpense>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-1603">Issued Capital and Reserves&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the number of shares outstanding was 237,725,735. This amount excludes 10,826,465&#160;shares held in treasury. For the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, the number of shares outstanding was 243,215,169, excluding 5,337,031 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares held in treasury.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Capital Transactions During the Year Ended December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, our Management Board and Supervisory Board authorized the 2022 share repurchase program of ADSs, pursuant to which we were permitted to repurchase ADSs, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;each representing one ordinary share,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with a value of up to $1.5&#160;billion a two-year period, commencing on May 2, 2022. The first tranche of our 2022 share repurchase program of ADSs, with a value of up to $1.0&#160;billion, concluded on October 10, 2022. The second tranche with a value of up to $0.5&#160;billion commenced on December 7, 2022 and concluded on March 17, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following repurchases under the programs occurred:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Program first tranche ($1.0&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;917,988&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$151.76 (&#x20ac;143.99)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$139.3 (&#x20ac;132.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,160,219&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$140.82 (&#x20ac;133.35)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$163.4 (&#x20ac;154.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;519,320&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$162.03 (&#x20ac;159.40)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$84.1 (&#x20ac;82.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,666,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$149.08 (&#x20ac;148.24)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$248.4 (&#x20ac;247.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,280,988&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$135.95 (&#x20ac;137.66)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$310.1 (&#x20ac;314.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;October 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;400,483&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$136.37 (&#x20ac;139.09)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$54.6 (&#x20ac;55.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6,945,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$999.9 (&#x20ac;986.4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Program second tranche ($0.5&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;618,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$142.26 (&#x20ac;131.12)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$88.0 (&#x20ac;81.1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;February 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;857,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$138.05 (&#x20ac;129.06)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$118.4 (&#x20ac;110.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;745,196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$128.49 (&#x20ac;121.08)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$95.7 (&#x20ac;90.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2,221,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$302.1 (&#x20ac;282.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, our Management Board and Supervisory Board authorized the 2023 share repurchase program, under which we were permitted to purchase ADSs, each representing one ordinary share, with a value of up to $0.5&#160;billion, which started June&#160;2, 2023 and concluded on September 18, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following repurchases under the programs occurred:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Program 2023 ($0.5&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,532,685&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$108.92 (&#x20ac;100.45)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$166.9 (&#x20ac;154.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,738,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$107.92 (&#x20ac;97.57)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$187.6 (&#x20ac;169.6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;August 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,261,706&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$105.07 (&#x20ac;95.85)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$132.6 (&#x20ac;120.9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$112.22 (&#x20ac;105.07)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$12.9 (&#x20ac;12.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,646,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$500.0 (&#x20ac;456.5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Capital Transactions During the Year Ended December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we announced a new research, development and commercialization collaboration with Pfizer to develop potentially the first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV). In connection &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with this collaboration, Pfizer agreed to make an equity investment in us, acquiring 497,727 ordinary shares paying a total amount of &#x20ac;110.6&#160;million. The issuance of 497,727&#160;ordinary shares with the nominal amount of &#x20ac;0.5&#160;million was registered with the commercial register (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Handelsregister&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) on March 24, 2022. The equity investment, which was issued in a foreign currency, represents a derivative from the date of signing until the date of closing of the transaction. From the fair value measurement of this derivative, &#x20ac;43.0&#160;million were recognized in finance income in our consolidated statements of profit or loss during the year ended December 31, 2022. At the closing date, in February 2022, this derivative and the agreed investment amount were recognized in our capital reserve and, taking an increase in share capital of &#x20ac;0.5&#160;million into account, led to a net increase of the capital reserve of &#x20ac;67.1&#160;million in our consolidated statements of financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, we redeemed our convertible note by exercising our early redemption option (see Note 12), which was fulfilled in April 2022, by issuing 1,744,392 ordinary shares. The nominal amount of &#x20ac;1.8&#160;million was recorded in share capital and, finally, as a result of the transaction, the capital reserve increased by &#x20ac;233.2&#160;million in our consolidated statements of financial position. The declaratory registration with the commercial register (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Handelsregister&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) was made on May 20, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, at the Annual General Meeting, our shareholders approved the proposed special cash dividend of &#x20ac;2.00 per ordinary share (including those held in the form of ADSs), which led to an aggregate payment of &#x20ac;484.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2022, the ESOP 2018 and LTI-plus awards were settled by transferring ordinary shares previously held in treasury to the entitled employees and Management Board members (see Note&#160;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-1604"
      unitRef="shares">237725735</ifrs-full:NumberOfSharesOutstanding>
    <bntx:NumberOfSharesHeldInTreasury
      contextRef="c-14"
      decimals="INF"
      id="f-1605"
      unitRef="shares">10826465</bntx:NumberOfSharesHeldInTreasury>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-1606"
      unitRef="shares">243215169</ifrs-full:NumberOfSharesOutstanding>
    <bntx:NumberOfSharesHeldInTreasury
      contextRef="c-15"
      decimals="INF"
      id="f-1607"
      unitRef="shares">5337031</bntx:NumberOfSharesHeldInTreasury>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-596" decimals="-8" id="f-1608" unitRef="usd">1500000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-597" decimals="-8" id="f-1609" unitRef="usd">1000000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-598" decimals="-8" id="f-1610" unitRef="usd">500000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:DisclosureOfSharesRepurchaseProgramTableTextBlock contextRef="c-1" id="f-1611">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following repurchases under the programs occurred:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Program first tranche ($1.0&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;917,988&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$151.76 (&#x20ac;143.99)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$139.3 (&#x20ac;132.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,160,219&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$140.82 (&#x20ac;133.35)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$163.4 (&#x20ac;154.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;519,320&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$162.03 (&#x20ac;159.40)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$84.1 (&#x20ac;82.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;August 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,666,515&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$149.08 (&#x20ac;148.24)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$248.4 (&#x20ac;247.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,280,988&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$135.95 (&#x20ac;137.66)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$310.1 (&#x20ac;314.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;October 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;400,483&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$136.37 (&#x20ac;139.09)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$54.6 (&#x20ac;55.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;6,945,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$999.9 (&#x20ac;986.4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Program second tranche ($0.5&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;January 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;618,355&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$142.26 (&#x20ac;131.12)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$88.0 (&#x20ac;81.1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;February 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;857,620&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$138.05 (&#x20ac;129.06)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$118.4 (&#x20ac;110.7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;745,196&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$128.49 (&#x20ac;121.08)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$95.7 (&#x20ac;90.2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2,221,171&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$302.1 (&#x20ac;282.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following repurchases under the programs occurred:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Program 2023 ($0.5&#160;billion)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ADSs purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Average price paid per ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net amount spent (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,532,685&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$108.92 (&#x20ac;100.45)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$166.9 (&#x20ac;154.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,738,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$107.92 (&#x20ac;97.57)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$187.6 (&#x20ac;169.6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;August 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,261,706&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$105.07 (&#x20ac;95.85)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$132.6 (&#x20ac;120.9)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;September 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114,513&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$112.22 (&#x20ac;105.07)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$12.9 (&#x20ac;12.0)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;4,646,965&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;$500.0 (&#x20ac;456.5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfSharesRepurchaseProgramTableTextBlock>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-599" decimals="-8" id="f-1612" unitRef="eur">1000000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-600"
      decimals="INF"
      id="f-1613"
      unitRef="shares">917988</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-600"
      decimals="2"
      id="f-1614"
      unitRef="usdPerShare">151.76</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-600"
      decimals="2"
      id="f-1615"
      unitRef="eurPerShare">143.99</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-600" decimals="-5" id="f-1616" unitRef="usd">139300000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-600" decimals="-5" id="f-1617" unitRef="eur">132200000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-601"
      decimals="INF"
      id="f-1618"
      unitRef="shares">1160219</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-601"
      decimals="2"
      id="f-1619"
      unitRef="usdPerShare">140.82</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-601"
      decimals="2"
      id="f-1620"
      unitRef="eurPerShare">133.35</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-601" decimals="-5" id="f-1621" unitRef="usd">163400000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-601" decimals="-5" id="f-1622" unitRef="eur">154700000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-602"
      decimals="INF"
      id="f-1623"
      unitRef="shares">519320</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-602"
      decimals="2"
      id="f-1624"
      unitRef="usdPerShare">162.03</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-602"
      decimals="2"
      id="f-1625"
      unitRef="eurPerShare">159.40</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-602" decimals="-5" id="f-1626" unitRef="usd">84100000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-602" decimals="-5" id="f-1627" unitRef="eur">82800000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-603"
      decimals="INF"
      id="f-1628"
      unitRef="shares">1666515</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-603"
      decimals="2"
      id="f-1629"
      unitRef="usdPerShare">149.08</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-603"
      decimals="2"
      id="f-1630"
      unitRef="eurPerShare">148.24</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-603" decimals="-5" id="f-1631" unitRef="usd">248400000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-603" decimals="-5" id="f-1632" unitRef="eur">247000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-604"
      decimals="INF"
      id="f-1633"
      unitRef="shares">2280988</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-604"
      decimals="2"
      id="f-1634"
      unitRef="usdPerShare">135.95</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-604"
      decimals="2"
      id="f-1635"
      unitRef="eurPerShare">137.66</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-604" decimals="-5" id="f-1636" unitRef="usd">310100000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-604" decimals="-5" id="f-1637" unitRef="eur">314000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-605"
      decimals="INF"
      id="f-1638"
      unitRef="shares">400483</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-605"
      decimals="2"
      id="f-1639"
      unitRef="usdPerShare">136.37</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-605"
      decimals="2"
      id="f-1640"
      unitRef="eurPerShare">139.09</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-605" decimals="-5" id="f-1641" unitRef="usd">54600000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-605" decimals="-5" id="f-1642" unitRef="eur">55700000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-606"
      decimals="INF"
      id="f-1643"
      unitRef="shares">6945513</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-606" decimals="-5" id="f-1644" unitRef="usd">999900000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-606" decimals="-5" id="f-1645" unitRef="eur">986400000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-607" decimals="-8" id="f-1646" unitRef="eur">500000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-608"
      decimals="INF"
      id="f-1647"
      unitRef="shares">618355</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-608"
      decimals="2"
      id="f-1648"
      unitRef="usdPerShare">142.26</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-608"
      decimals="2"
      id="f-1649"
      unitRef="eurPerShare">131.12</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-608" decimals="-5" id="f-1650" unitRef="usd">88000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-608" decimals="-5" id="f-1651" unitRef="eur">81100000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-609"
      decimals="INF"
      id="f-1652"
      unitRef="shares">857620</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-609"
      decimals="2"
      id="f-1653"
      unitRef="usdPerShare">138.05</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-609"
      decimals="2"
      id="f-1654"
      unitRef="eurPerShare">129.06</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-609" decimals="-5" id="f-1655" unitRef="usd">118400000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-609" decimals="-5" id="f-1656" unitRef="eur">110700000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-610"
      decimals="INF"
      id="f-1657"
      unitRef="shares">745196</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-610"
      decimals="2"
      id="f-1658"
      unitRef="usdPerShare">128.49</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-610"
      decimals="2"
      id="f-1659"
      unitRef="eurPerShare">121.08</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-610" decimals="-5" id="f-1660" unitRef="usd">95700000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-610" decimals="-5" id="f-1661" unitRef="eur">90200000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-611"
      decimals="INF"
      id="f-1662"
      unitRef="shares">2221171</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-611" decimals="-5" id="f-1663" unitRef="usd">302100000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-611" decimals="-5" id="f-1664" unitRef="eur">282000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-610" decimals="-8" id="f-1665" unitRef="eur">500000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramAuthorizedAmount contextRef="c-612" decimals="-8" id="f-1666" unitRef="eur">500000000</bntx:ShareRepurchaseProgramAuthorizedAmount>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-613"
      decimals="INF"
      id="f-1667"
      unitRef="shares">1532685</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-613"
      decimals="2"
      id="f-1668"
      unitRef="usdPerShare">108.92</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-613"
      decimals="2"
      id="f-1669"
      unitRef="eurPerShare">100.45</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-613" decimals="-5" id="f-1670" unitRef="usd">166900000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-613" decimals="-5" id="f-1671" unitRef="eur">154000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-614"
      decimals="INF"
      id="f-1672"
      unitRef="shares">1738061</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-614"
      decimals="2"
      id="f-1673"
      unitRef="usdPerShare">107.92</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-614"
      decimals="2"
      id="f-1674"
      unitRef="eurPerShare">97.57</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-614" decimals="-5" id="f-1675" unitRef="usd">187600000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-614" decimals="-5" id="f-1676" unitRef="eur">169600000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-615"
      decimals="INF"
      id="f-1677"
      unitRef="shares">1261706</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-615"
      decimals="2"
      id="f-1678"
      unitRef="usdPerShare">105.07</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-615"
      decimals="2"
      id="f-1679"
      unitRef="eurPerShare">95.85</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-615" decimals="-5" id="f-1680" unitRef="usd">132600000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-615" decimals="-5" id="f-1681" unitRef="eur">120900000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-616"
      decimals="INF"
      id="f-1682"
      unitRef="shares">114513</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-616"
      decimals="2"
      id="f-1683"
      unitRef="usdPerShare">112.22</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS
      contextRef="c-616"
      decimals="2"
      id="f-1684"
      unitRef="eurPerShare">105.07</bntx:ShareRepurchaseProgramAveragePricePerAmericanDepositaryShareADS>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-616" decimals="-5" id="f-1685" unitRef="usd">12900000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-616" decimals="-5" id="f-1686" unitRef="eur">12000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased
      contextRef="c-617"
      decimals="INF"
      id="f-1687"
      unitRef="shares">4646965</bntx:ShareRepurchaseProgramNumberOfAmericanDepositarySharesADSPurchased>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-617" decimals="-5" id="f-1688" unitRef="usd">500000000.0</bntx:ShareRepurchaseProgramNetAmountSpent>
    <bntx:ShareRepurchaseProgramNetAmountSpent contextRef="c-617" decimals="-5" id="f-1689" unitRef="eur">456500000</bntx:ShareRepurchaseProgramNetAmountSpent>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-618"
      decimals="0"
      id="f-1690"
      unitRef="shares">497727</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-619" decimals="-5" id="f-1691" unitRef="eur">110600000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-620"
      decimals="0"
      id="f-1692"
      unitRef="shares">497727</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital contextRef="c-620" decimals="-5" id="f-1693" unitRef="eur">500000</ifrs-full:IssuedCapital>
    <ifrs-full:AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments contextRef="c-621" decimals="-5" id="f-1694" unitRef="eur">43000000</ifrs-full:AccumulatedChangesInFairValueOfFinancialAssetsRelatedCreditDerivativesOrSimilarInstruments>
    <ifrs-full:IssuedCapital contextRef="c-622" decimals="-5" id="f-1695" unitRef="eur">500000</ifrs-full:IssuedCapital>
    <ifrs-full:IssueOfEquity contextRef="c-623" decimals="-5" id="f-1696" unitRef="eur">67100000</ifrs-full:IssueOfEquity>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-624"
      decimals="INF"
      id="f-1697"
      unitRef="shares">1744392</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssueOfEquity contextRef="c-625" decimals="-5" id="f-1698" unitRef="eur">1800000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-626" decimals="-5" id="f-1699" unitRef="eur">233200000</ifrs-full:IssueOfEquity>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare
      contextRef="c-601"
      decimals="2"
      id="f-1700"
      unitRef="eurPerShare">2.00</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities contextRef="c-601" decimals="-5" id="f-1701" unitRef="eur">484300000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c-1" id="f-1702">Share-Based Payments&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense arising from equity-settled share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Employee Stock Ownership Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;13.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;20.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Chief Executive Officer Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Management Board Grant&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioNTech 2020 Employee Equity Plan for Employees Based Outside North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;36.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;25.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;32.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;InstaDeep Employee Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense / (Income) arising from cash-settled share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;32.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Employee Stock Ownership Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;53.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Management Board Grant&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.2, 16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioNTech Restricted Stock Unit Plan for North America Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;108.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;93.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;33.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;84.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;25.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;108.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;93.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of &#x20ac;1.1&#160;million and &#x20ac;3.3&#160;million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of &#xa3;15.0&#160;million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023, 2022 and 2021, our share-based payment arrangements led to a cash outflow of &#x20ac;766.2 million, &#x20ac;51.8 million and &#x20ac;13.4 million, respectively. We expect to settle the equity-settled share-based payment arrangements of our 2020 Management Board Grant (see Note &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Chief Executive Officer Grant (see Note 16.4) and the Employee Stock Ownership Plan (see Note 16.5) on a net basis by delivering to the participant a number of ADSs equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. This reduces the dilutive impact of the respective rights compared to an all-equity settlement. If all of the equity-settled rights outstanding as of December&#160;31, 2023, were to be exercised accordingly, the cash outflow to the tax authority in 2024 would amount to approximately &#x20ac;213.0&#160;million (based on the share price as of December&#160;31, 2023).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16.1&#160;&#160;&#160;&#160;BioNTech Employee Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BioNTech 2020 Employee Equity Plan for Employees Based Outside North America (Equity-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, we approved the BioNTech 2020 Employee Equity Plan for employees based outside North America, or the European Plan. Under the European Plan, Restricted Stock Units, or RSUs, are offered to our employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Award agreements were entered as of the respective grant dates in February 2021 (LTI 2020 and LTI-plus program), January 2022 (LTI 2021 program) and December 2022 (LTI 2022 program). RSUs issued under the LTI 2020, LTI 2021 and LTI 2022 programs vest annually in equal installments over respective waiting periods of four years, commencing in December 2020, December 2021 and December 2022, respectively. RSUs issued under the LTI-plus program vested annually in equal installments over the waiting period of two years, which elapsed in December 2022. Hence, during the year ended December 31, 2022, the LTI-plus awards were settled by transferring shares previously held in treasury, see Note 15. All programs were classified as equity-settled as we have the ability to determine the method of settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Measurement of Fair Values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the awards issued under the European Plan were based upon the price of our ADSs representing ordinary shares at the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of Outstanding Share-Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI-plus program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2022 program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;372,011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242,416&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;110,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited / Modified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7,932)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7,111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Granted / Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Settled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(364,079)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235,305&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;104,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;396,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235,305&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited / Modified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4,400)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(16,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;230,905&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;101,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;379,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;175,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;51,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;96,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;55,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;49,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;283,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#x20ac;171.40.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inputs Used in Measurement of the Fair Values at Grant Dates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI-plus program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2022 program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;92.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;203.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;165.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Waiting period (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BioNTech 2020 Restricted Stock Unit Plan for North America Employees (Cash-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, we approved the BioNTech 2020 Restricted Stock Unit Plan for North America Employees, or the North American Plan. Under the North American Plan, RSUs are offered to our employees. These RSUs vest over four years, with 25% vesting one year after the service commencement date and the remainder vesting in equal quarterly installments thereafter. The first awards under the North American Plan were granted in February 2021. The service date for these awards is the date as of which the employee became employed by BioNTech US. During the years ended December 31, 2023, and 2022, further awards were granted under the North American Plan, which included awards granted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to new-hire employees and ongoing, recurring awards to existing employees on the approximate anniversary of each employee&#x2019;s start date of employment with BioNTech US. As these RSUs are intended to be cash-settled upon vesting, the awards were defined as a cash-settled share-based payment arrangement. During the years ended December&#160;31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the exercise of RSUs resulted in a cash outflow of &#x20ac;10.0&#160;million, &#x20ac;9.4&#160;million and &#x20ac;10.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the liability related to these awards amounted to &#x20ac;14.4&#160;million (&#x20ac;13.4&#160;million&#160;as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;).&lt;div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;16.2&#160;&#160;&#160;&#160;Management Board Grant &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt; Short-Term Incentive (Cash-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Management Board&#x2019;s service agreements also include a short-term incentive compensation component, which is an annual performance-related bonus for the years of their respective service periods. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50% of those yearly awards are paid out one year after the achievement of the performance targets for the respective bonus year has been determined, subject to an adjustment relative to the performance of the price of the American Depositary Shares representing our ordinary shares during that year (second installment). The second installments represent cash-settled share-based payment arrangements. The fair values of the liabilities are recognized over the awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; vesting periods beginning when entering or renewing service agreements, i.e., the service commencement date, until each separate determination date and are remeasured until the settlement date. As of December&#160;31, 2023, the liability related to these awards amounted to &#x20ac;2.1&#160;million (&#x20ac;2.3&#160;million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;).&lt;div style="margin-top:12pt;padding-left:24.4pt;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;16.3&#160;&#160;&#160;&#160;Management Board Grant Long-Term Incentive (Partly Equity-Settled, Partly Cash-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Management Board&#x2019;s service agreements provide for long-term incentive compensation (Management Board Grant - LTI) through an annual grant of options to acquire BioNTech shares during their respective service periods. &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; granted each year are subject to the terms and conditions of the respective authorizations of the Annual General Meeting creating our Employee Stock Ownership Plan (ESOP) and the applicable option agreements thereunder&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options vest annually in equal installments over four years commencing on the first anniversary of the allocation date and are exercisable four years after the allocation date. The vested options can only be exercised if each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5 billion divided by the total number of the ordinary shares outstanding immediately following the initial public offering (other than ordinary shares owned by BioNTech), and (b) for each twelve-month period starting on the fifth or subsequent anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as set out in the ESOP agreement. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The right to receive options generally represents an equity-settled share-based payment arrangement. The allocation of the number of issued options in 2020 occurred in February 2020. In May 2021 and May 2022, the Management Board received phantom options equivalent to the number of options the Management Board members would have been entitled to receive for 2021 and 2022, which led to a modification from equity-settled to cash-settled share-based payment arrangement and a reclassification of &#x20ac;1.1 million and &#x20ac;3.3 million between equity and non-current other liabilities as of the respective allocation dates. During 2023, options were granted in May 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Measurement of Fair Values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte-Carlo simulation model has been used to measure the fair values at the (estimated) allocation dates of the Management Board Grant. This model incorporates the impact of the performance criteria regarding share price and index &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development described above. The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 12, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 17, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;10.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;29.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;27.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;38.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average share price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;28.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;168.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;179.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;147.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;28.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;167.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;169.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;137.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;46.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;43.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;39.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;32.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average share price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;98.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;105.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;96.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;99.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;105.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the awards with estimated allocation dates, the exercise prices of options expected to be allocated have been derived from the Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the exercise price has ultimately been determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All options are subject to an effective exercise price cap, which means that the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. With respect to the LTI 2020 agreement, the maximum economic benefit receivable in respect of any exercised option is capped at $246.24, with the effective exercise price being capped at a Euro amount equivalent to $30.78. With respect to the phantom share options issued under the LTI 2021 and 2022 as well as the options issued under the LTI 2023 programs, the maximum compensation that the Management Board members are entitled to receive under such programs, together with other compensation components received by each such board member in the respective grant year, shall not exceed &#x20ac;20.0&#160;million for Ugur Sahin as Chief Executive Officer (CEO) and &#x20ac;10.0&#160;million for all other Management Board members. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected option term. The expected term was based on general option holder behavior for employee options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of Outstanding Share-Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (phantom) share options allocated and expected to be allocated to our Management Board as of December&#160;31, 2023, are presented in the table below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 12, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 17, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Phantom) share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;248,096&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,279&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,463&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86,118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and vested but subject to performance and waiting requirements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;186,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;21,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;62,024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22,639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,231&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;64,587&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;167.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;169.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;137.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share options outstanding / expected to be allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;130,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;164,148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;118,312&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;93,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;130,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;96.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Valuation parameter derived from the Monte-Carlo simulation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the awards with estimated allocation dates, the numbers of options expected to be allocated have been derived from a Monte-Carlo simulation model. Those will be adjusted until the actual allocation has occurred and the number of options granted has ultimately been determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the share options allocated and expected to be allocated under our equity-settled share-based payment arrangements had a remaining weighted average expected life of 4.1&#160;years (as of December&#160;31, 2022: 4.0&#160;years). &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the liability related to the phantom option awards amounted to &#x20ac;3.6&#160;million (&#x20ac;5.6&#160;million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;).&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16.4&#160;&#160;&#160;&#160;Chief Executive Officer Grant (Equity-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we granted Ugur Sahin an option to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,374,963&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our ordinary shares, subject to Sahin&#x2019;s continuous employment with us. The options&#x2019; exercise price per share is the Euro translation of the public offering price from our initial public offering, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x20ac;13.60 ($15.00), &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which is subject to the effective exercise price cap and the maximum cap mechanism. Under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise price cap the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the maximum cap mechanism the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; maximum economic benefit receivable in respect of any exercised option&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is capped at $240.00 with the effective exercise price being capped at a Euro amount equivalent to $30.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options vest annually in equal installments after four years commencing on the first anniversary of the initial public offering and have a waiting period of four years after the initial public offering. The vested option rights can only be exercised if and to the extent that each of the following performance criteria has been achieved: (i) at the time of exercise, the current price is equal to or greater than the threshold amount (that is, the exercise price, provided that such amount increases by seven percentage points on each anniversary of the allocation date); (ii) at the time of exercise, the current price is at least equal to the target price (that is, (a) for the twelve-month period starting on the fourth anniversary of the allocation date, $8.5&#160;billion divided by the total number of the shares outstanding immediately following the initial public offering (other than shares owned by us), and (b) for each twelve-month period starting on the fifth or subsequent &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anniversary of the allocation date, 107% of the target share price applicable for the prior twelve-month period); and (iii) the closing price for the fifth trading day prior to the start of the relevant exercise window is higher than the exercise price by at least the same percentage by which the Nasdaq Biotechnology Index or a comparable successor index as of such time is higher than such index was as of the last trading day before the allocation date. Following the expiry of the waiting period, option rights may be exercised during the exercise windows as defined by our ESOP. The option rights can be exercised up to ten years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Measurement of Fair Values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte-Carlo simulation model has been used to measure the fair value at the grant date of the Chief Executive Officer Grant. This model incorporates the impact of the performance criteria regarding share price and index development described above in the calculation of the award&#x2019;s fair value at the grant date. The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date October 9, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;5.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;13.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;13.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility was based on an evaluation of the historical volatilities of comparable companies over the historical period commensurate with the expected term. The expected term was based on general option holder behavior for employee options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of Outstanding Share-Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 9, 2023, with the final installment vesting, all 4,374,963 options became exercisable under the rules of the ESOP and the ESOP agreement. During the year ended December 31, 2023, no options were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the share options outstanding had a remaining weighted average expected life of 1.1&#160;years (as of December&#160;31, 2022: 2.1 years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;16.5&#160;&#160;&#160;&#160;Employee Stock Ownership Plan (Partly Equity-Settled, Partly Cash-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an authorization of the general meeting on August 18, 2017, we established a share option program under which we granted selected employees options to receive our shares. The program is designed&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as an Employee Stock Ownership Plan, or ESOP. We offered participants a certain number of option rights by their explicit acceptance of an option rights agreement. The exercise of option rights in accordance with the agreement gives the participants the right to obtain shares against payment of the exercise price. With respect to the Management Board members serving at the time of allocation, the options are subject to the effective exercise price cap and maximum cap mechanisms. Under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise price cap, the exercise price shall be adjusted to ensure that the current price of an ADS as of the exercise date does not exceed 800% of the exercise price. Under &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the maximum cap mechanism, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the maximum economic benefit receivable in respect of any exercised option, is capped at &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$240&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with the effective exercise price being capped at &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a Euro amount equivalent to $30.00. Under the ESOP, the option rights (other than &#xd6;zlem T&#xfc;reci&#x2019;s, and Ryan Richardson&#x2019;s options) fully vest after &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;four years&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and can be exercised if: (i) the waiting period of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;four years&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has elapsed; and (ii) at the time of exercise, the average closing price of the shares of the Company or the average closing price of the right or certificate to be converted into an amount per share on the previous ten trading days preceding the exercise of the option right exceeds the strike price by a minimum of 32%, with this percentage increasing by eight percentage points as of the fifth anniversary of the respective issue date and as of each subsequent anniversary date. Following the expiry of the waiting period, option rights may be exercised within a period of four weeks from the date of the Annual General Meeting or the publication of the annual financial statements, the semi-annual report or our most recent quarterly report or interim report (exercise windows). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option rights can be exercised up to eight years after the allocation date. If they have not been exercised by that date, they will be forfeited without compensation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;By way of a shareholders&#x2019; resolution of the general meeting on August 19, 2019, the authorization to issue such option rights was amended such that, in order for the options to be exercisable, the average closing price of the Company&#x2019;s shares or the average closing price of the right or certificate to be converted into an amount per share on the ten trading days immediately preceding the exercise must exceed the strike price by a minimum of 28%, with this percentage increasing by seven percentage points as of the fifth anniversary of the issue date and as of each subsequent anniversary date. Furthermore, in addition to the aforementioned requirements, the exercise is only possible if the share price (calculated by reference to the price of the ordinary share underlying the ADS) has performed similar to or better than the Nasdaq Biotechnology Index. The changes made do not affect option rights already issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Measurement of Fair Values&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the ESOP has been measured using a binomial model. Service conditions attached to the arrangement were not taken into account in measuring the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The share options can only be exercised by the grantee if the price of the share is equal or greater to the threshold amount as defined in the arrangement. Moreover, the option rights can only be exercised if the IPO has occurred. Both conditions have been incorporated into the fair value at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date &lt;br/&gt;November 15, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant dates&lt;br/&gt;between &lt;br/&gt;February 21 and &lt;br/&gt;April 3, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant dates&lt;br/&gt;between&lt;br/&gt;April 29 and &lt;br/&gt;May 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;7.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;6.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;7.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;9.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;14.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;16.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;19.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;10.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility has been based on an evaluation of the historical and the implied volatilities of comparable companies over the historical period commensurate with the expected term. The expected term has been based on general option holder behavior for employee options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of Outstanding Share-Options (&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-Settled)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Share options &lt;br/&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ordinary shares underlying options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;642,007&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11,556,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Modified&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(18,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(583,383)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10,500,890)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57,584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,036,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57,584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,036,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(39,785)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(716,121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;320,393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;17,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;320,393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;11.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rights have been modified to cash-settled rights, all other terms remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was &#x20ac;96.49 and &#x20ac;160.44 for all settlements during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Supervisory Board determined the ESOP settlement by the delivery of treasury shares (in the form of ADSs) equal to the net value of the exercised option rights after deduction of (i) the exercise price and (ii) the applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from such exercise. The settlement was applied during the exercise windows in 2022 and 2023. The applicable wage taxes (including solidarity surcharge thereon and church tax, if applicable) and social security contributions resulting from and withheld upon the exercise amounted to &#x20ac;724.0 million and were paid in January 2023 in cash directly to the respective authorities. The settlement mechanism decision did not change the rights as such, neither did it change the classification as equity-settled option rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the share options outstanding under our equity-settled share-based payment arrangements had a remaining weighted average expected life of 0.8&#160;years (as of December&#160;31, 2022: 1.7 years).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Development of Share-Options (Cash&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;-Settled)&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Phantom options which were granted under the ESOP mainly during the year ended December 31, 2022 each give the participants the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an American Depositary Share of BioNTech on Nasdaq over the last ten trading days preceding the exercise date) and the exercise price. The majority of options have an &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x20ac;10.14. During the years ended December 31, 2023, and 2022, 52,100 and 289,168 cash-settled phantom option rights were exercised and resulted in a cash outflow of &#x20ac;4.5&#160;million&#160;and &#x20ac;42.2 million, respectively. The average closing prices (10-day averages) of an American Depositary Share of BioNTech on Nasdaq weighted over the various settlement dates converted from USD to Euro using the exchange rate published by the German Central Bank (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deutsche Bundesbank&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) on the same days was &#x20ac;96.25 and &#x20ac;155.39. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 109,651 cash-settled option rights remained outstanding. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the liability related to cash-settled share-based payment option rights amounted to &#x20ac;8.5&#160;million (&#x20ac;14.5&#160;million&#160;as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), of which &#x20ac;8.3&#160;million (&#x20ac;11.2&#160;million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;) related to rights already vested (partly subject to performance and waiting requirements). The liability is based on the fair value of the respective rights. The fair value is measured using a binomial model consistent with the grant date fair value measurement of the equity-based option rights described above, which is updated on every reporting date.</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss contextRef="c-1" id="f-1703">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2023, 2022, and 2021, our share-based payment arrangements led to the following expenses: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense arising from equity-settled share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Employee Stock Ownership Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;13.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;20.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Chief Executive Officer Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Management Board Grant&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioNTech 2020 Employee Equity Plan for Employees Based Outside North America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;36.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;25.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;32.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;InstaDeep Employee Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense / (Income) arising from cash-settled share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;32.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Employee Stock Ownership Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;53.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Management Board Grant&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.2, 16.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;BioNTech Restricted Stock Unit Plan for North America Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;10.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;8.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;108.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;93.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;33.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;84.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;60.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sales and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;25.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;108.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;93.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;In May 2021 and 2022, phantom options were granted under the Management Board Grant for the years 2021 and 2022 which led to a modification from an equity-settled to cash-settled share-based payment arrangement and a reclassification of &#x20ac;1.1&#160;million and &#x20ac;3.3&#160;million between equity and non-current other liabilities, respectively. Expenses incurred before and after the modification dates have been disclosed as equity-settled or cash-settled share-based payment arrangement, respectively. The amount includes expenses incurred with respect to a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board (see Note 21.2). &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&#160;&#160;&#160;&#160;As part of the acquisition of InstaDeep (see Note 5), it was agreed to issue long-term equity awards with a total target incentive value of &#xa3;15.0&#160;million, each for options and RSUs. The allocation shall be made in a manner consistent with BioNTech's existing share-based payment arrangements. The arrangement was communicated to the employees as part of the acquisition but relates to future services. Following the rules of IFRS 2, starting with the service commencement date during the year ended December 31, 2023 and in advance of the grant date, expenses were recorded based on the estimated grant date fair values and numbers of equity instruments.</ifrs-full:ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-5" id="f-1704" unitRef="eur">44100000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-12" decimals="-5" id="f-1705" unitRef="eur">46500000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-13" decimals="-5" id="f-1706" unitRef="eur">61000000.0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-627" decimals="-5" id="f-1707" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-628" decimals="-5" id="f-1708" unitRef="eur">13800000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-629" decimals="-5" id="f-1709" unitRef="eur">20200000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-630" decimals="-5" id="f-1710" unitRef="eur">1200000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-631" decimals="-5" id="f-1711" unitRef="eur">3100000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-632" decimals="-5" id="f-1712" unitRef="eur">5900000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-633" decimals="-5" id="f-1713" unitRef="eur">3200000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-634" decimals="-5" id="f-1714" unitRef="eur">4300000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-635" decimals="-5" id="f-1715" unitRef="eur">2400000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-636" decimals="-5" id="f-1716" unitRef="eur">36300000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-637" decimals="-5" id="f-1717" unitRef="eur">25300000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-638" decimals="-5" id="f-1718" unitRef="eur">32500000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-639" decimals="-5" id="f-1719" unitRef="eur">3400000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-640" decimals="-5" id="f-1720" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-641" decimals="-5" id="f-1721" unitRef="eur">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-5" id="f-1722" unitRef="eur">7300000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-12" decimals="-5" id="f-1723" unitRef="eur">61500000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-13" decimals="-5" id="f-1724" unitRef="eur">32700000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-627" decimals="-5" id="f-1725" unitRef="eur">-900000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-628" decimals="-5" id="f-1726" unitRef="eur">53400000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-629" decimals="-5" id="f-1727" unitRef="eur">6300000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-633" decimals="-5" id="f-1728" unitRef="eur">-2400000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-634" decimals="-5" id="f-1729" unitRef="eur">0</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-635" decimals="-5" id="f-1730" unitRef="eur">3600000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-642" decimals="-5" id="f-1731" unitRef="eur">10600000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-643" decimals="-5" id="f-1732" unitRef="eur">8100000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-644" decimals="-5" id="f-1733" unitRef="eur">22800000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-5" id="f-1734" unitRef="eur">51400000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-12" decimals="-5" id="f-1735" unitRef="eur">108000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-13" decimals="-5" id="f-1736" unitRef="eur">93700000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-645" decimals="-5" id="f-1737" unitRef="eur">6500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-646" decimals="-5" id="f-1738" unitRef="eur">3000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-647" decimals="-5" id="f-1739" unitRef="eur">7000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-648" decimals="-5" id="f-1740" unitRef="eur">33400000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-649" decimals="-5" id="f-1741" unitRef="eur">84600000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-650" decimals="-5" id="f-1742" unitRef="eur">60500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-651" decimals="-5" id="f-1743" unitRef="eur">1000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-652" decimals="-5" id="f-1744" unitRef="eur">800000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-653" decimals="-5" id="f-1745" unitRef="eur">500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-654" decimals="-5" id="f-1746" unitRef="eur">10500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-655" decimals="-5" id="f-1747" unitRef="eur">19600000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-656" decimals="-5" id="f-1748" unitRef="eur">25700000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-5" id="f-1749" unitRef="eur">51400000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-12" decimals="-5" id="f-1750" unitRef="eur">108000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-13" decimals="-5" id="f-1751" unitRef="eur">93700000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <bntx:ReclassificationOfShareBasedPaymentArrangement contextRef="c-657" decimals="-5" id="f-1752" unitRef="eur">1100000</bntx:ReclassificationOfShareBasedPaymentArrangement>
    <bntx:ReclassificationOfShareBasedPaymentArrangement contextRef="c-658" decimals="-5" id="f-1753" unitRef="eur">3300000</bntx:ReclassificationOfShareBasedPaymentArrangement>
    <ifrs-full:LongtermDeposits contextRef="c-659" decimals="-5" id="f-1754" unitRef="gbp">15000000</ifrs-full:LongtermDeposits>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-1" decimals="-5" id="f-1755" unitRef="eur">-766200000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-12" decimals="-5" id="f-1756" unitRef="eur">-51800000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <bntx:ShareBasedPaymentsClassifiedAsOperatingActivities contextRef="c-13" decimals="-5" id="f-1757" unitRef="eur">-13400000</bntx:ShareBasedPaymentsClassifiedAsOperatingActivities>
    <bntx:CashOutflowToTaxAuthority contextRef="c-1" decimals="-5" id="f-1758" unitRef="eur">213000000</bntx:CashOutflowToTaxAuthority>
    <bntx:OptionVestingPeriod contextRef="c-660" id="f-1759">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionVestingPeriod contextRef="c-661" id="f-1760">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionVestingPeriod contextRef="c-662" id="f-1761">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionVestingPeriod contextRef="c-663" id="f-1762">P2Y</bntx:OptionVestingPeriod>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-664" id="f-1763">&lt;div style="margin-top:12pt;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reconciliation of Outstanding Share-Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI-plus program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2022 program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;372,011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;242,416&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;110,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited / Modified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7,932)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(7,111)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(5,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Granted / Allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Settled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(364,079)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;235,305&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;104,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;396,110&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235,305&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;396,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Forfeited / Modified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4,400)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3,497)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(16,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;230,905&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;101,111&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;379,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;175,523&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;51,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;96,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;55,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;49,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;283,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The closing price of an American Depositary Share of BioNTech on Nasdaq on December 15, 2022, the settlement date, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same day was &#x20ac;171.40.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-665"
      decimals="INF"
      id="f-1764"
      unitRef="shares">372011</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-666"
      decimals="INF"
      id="f-1765"
      unitRef="shares">242416</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-667"
      decimals="INF"
      id="f-1766"
      unitRef="shares">110036</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-668"
      decimals="INF"
      id="f-1767"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-663"
      decimals="INF"
      id="f-1768"
      unitRef="shares">7932</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-669"
      decimals="INF"
      id="f-1769"
      unitRef="shares">7111</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-670"
      decimals="INF"
      id="f-1770"
      unitRef="shares">5428</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-671"
      decimals="INF"
      id="f-1771"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-663"
      decimals="INF"
      id="f-1772"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-669"
      decimals="INF"
      id="f-1773"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-670"
      decimals="INF"
      id="f-1774"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-671"
      decimals="INF"
      id="f-1775"
      unitRef="shares">396110</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement
      contextRef="c-663"
      decimals="INF"
      id="f-1776"
      unitRef="shares">364079</bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement
      contextRef="c-669"
      decimals="INF"
      id="f-1777"
      unitRef="shares">0</bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement
      contextRef="c-670"
      decimals="INF"
      id="f-1778"
      unitRef="shares">0</bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement
      contextRef="c-671"
      decimals="INF"
      id="f-1779"
      unitRef="shares">0</bntx:NumberOfShareOptionsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-672"
      decimals="INF"
      id="f-1780"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-673"
      decimals="INF"
      id="f-1781"
      unitRef="shares">235305</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-674"
      decimals="INF"
      id="f-1782"
      unitRef="shares">104608</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-675"
      decimals="INF"
      id="f-1783"
      unitRef="shares">396110</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-672"
      decimals="INF"
      id="f-1784"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-673"
      decimals="INF"
      id="f-1785"
      unitRef="shares">235305</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-674"
      decimals="INF"
      id="f-1786"
      unitRef="shares">104608</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-675"
      decimals="INF"
      id="f-1787"
      unitRef="shares">396110</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-676"
      decimals="INF"
      id="f-1788"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-677"
      decimals="INF"
      id="f-1789"
      unitRef="shares">4400</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-678"
      decimals="INF"
      id="f-1790"
      unitRef="shares">3497</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-679"
      decimals="INF"
      id="f-1791"
      unitRef="shares">16141</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-680"
      decimals="INF"
      id="f-1792"
      unitRef="shares">0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-681"
      decimals="INF"
      id="f-1793"
      unitRef="shares">230905</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-682"
      decimals="INF"
      id="f-1794"
      unitRef="shares">101111</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-683"
      decimals="INF"
      id="f-1795"
      unitRef="shares">379969</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-680"
      decimals="INF"
      id="f-1796"
      unitRef="shares">0</bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-681"
      decimals="INF"
      id="f-1797"
      unitRef="shares">175523</bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-682"
      decimals="INF"
      id="f-1798"
      unitRef="shares">51905</bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-683"
      decimals="INF"
      id="f-1799"
      unitRef="shares">96466</bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement
      contextRef="c-680"
      decimals="INF"
      id="f-1800"
      unitRef="shares">0</bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement
      contextRef="c-681"
      decimals="INF"
      id="f-1801"
      unitRef="shares">55382</bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement
      contextRef="c-682"
      decimals="INF"
      id="f-1802"
      unitRef="shares">49206</bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement
      contextRef="c-683"
      decimals="INF"
      id="f-1803"
      unitRef="shares">283503</bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-684"
      decimals="2"
      id="f-1804"
      unitRef="eurPerShare">171.40</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-664" id="f-1805">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI-plus program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2020 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2021 program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;LTI 2022 program&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;92.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;203.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;165.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Waiting period (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-680" decimals="2" id="f-1806" unitRef="eur">87.60</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-681" decimals="2" id="f-1807" unitRef="eur">92.21</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-682" decimals="2" id="f-1808" unitRef="eur">203.22</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-683" decimals="2" id="f-1809" unitRef="eur">165.03</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-676" decimals="INF" id="f-1810" unitRef="y">2.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-677" decimals="INF" id="f-1811" unitRef="y">4.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-678" decimals="INF" id="f-1812" unitRef="y">4.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-679" decimals="INF" id="f-1813" unitRef="y">4.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <bntx:OptionVestingPeriod contextRef="c-685" id="f-1814">P4Y</bntx:OptionVestingPeriod>
    <bntx:VestingPercentageOfShareBasedPaymentArrangement
      contextRef="c-686"
      decimals="INF"
      id="f-1815"
      unitRef="number">0.25</bntx:VestingPercentageOfShareBasedPaymentArrangement>
    <bntx:CashOutflowForShareBasedPaymentArrangementExercise contextRef="c-642" decimals="-5" id="f-1816" unitRef="eur">10000000</bntx:CashOutflowForShareBasedPaymentArrangementExercise>
    <bntx:CashOutflowForShareBasedPaymentArrangementExercise contextRef="c-643" decimals="-5" id="f-1817" unitRef="eur">9400000</bntx:CashOutflowForShareBasedPaymentArrangementExercise>
    <bntx:CashOutflowForShareBasedPaymentArrangementExercise contextRef="c-644" decimals="-5" id="f-1818" unitRef="eur">10100000</bntx:CashOutflowForShareBasedPaymentArrangementExercise>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-687" decimals="-5" id="f-1819" unitRef="eur">14400000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-688" decimals="-5" id="f-1820" unitRef="eur">13400000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares
      contextRef="c-633"
      decimals="2"
      id="f-1821"
      unitRef="number">0.50</bntx:PercentageOfAmericanDepositorySharesToOrdinaryShares>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-689" decimals="-5" id="f-1822" unitRef="eur">2100000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-690" decimals="-5" id="f-1823" unitRef="eur">2300000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <bntx:OptionVestingPeriod contextRef="c-633" id="f-1824">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionExercisablePeriod contextRef="c-633" id="f-1825">P4Y</bntx:OptionExercisablePeriod>
    <bntx:PercentageOfIncreaseInExercisePrice
      contextRef="c-633"
      decimals="2"
      id="f-1826"
      unitRef="number">0.07</bntx:PercentageOfIncreaseInExercisePrice>
    <bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering contextRef="c-633" decimals="-8" id="f-1827" unitRef="eur">8500000000</bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering>
    <bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth
      contextRef="c-633"
      decimals="2"
      id="f-1828"
      unitRef="number">1.07</bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth>
    <bntx:OptionExercisablePeriod contextRef="c-691" id="f-1829">P10Y</bntx:OptionExercisablePeriod>
    <bntx:ReclassificationOfShareBasedPaymentArrangement contextRef="c-657" decimals="-5" id="f-1830" unitRef="eur">1100000</bntx:ReclassificationOfShareBasedPaymentArrangement>
    <bntx:ReclassificationOfShareBasedPaymentArrangement contextRef="c-658" decimals="-5" id="f-1831" unitRef="eur">3300000</bntx:ReclassificationOfShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-633" id="f-1832">The parameters used for measuring the fair values as of the respective (estimated) allocation dates were as follows:&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 12, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 17, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;10.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;29.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;27.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;38.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average share price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;28.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;168.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;179.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;147.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;28.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;167.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;169.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;137.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The share options allocated as of February 2020 and May 2023 as well as the phantom share options allocated as of May 2021 and 2022 are subject to an effective exercise price cap.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;46.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;43.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;39.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;32.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average share price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;98.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;95.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;105.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;96.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;99.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;105.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;47.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life (years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Valuation parameter for estimated allocation dates derived from the Monte-Carlo simulation model.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-692" decimals="2" id="f-1833" unitRef="eur">10.83</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-693" decimals="2" id="f-1834" unitRef="eur">29.05</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-694" decimals="2" id="f-1835" unitRef="eur">27.64</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-695" decimals="2" id="f-1836" unitRef="eur">38.88</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-696"
      decimals="2"
      id="f-1837"
      unitRef="eurPerShare">28.20</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-697"
      decimals="2"
      id="f-1838"
      unitRef="eurPerShare">168.44</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-698"
      decimals="2"
      id="f-1839"
      unitRef="eurPerShare">179.46</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-600"
      decimals="2"
      id="f-1840"
      unitRef="eurPerShare">147.84</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-696"
      decimals="2"
      id="f-1841"
      unitRef="eurPerShare">28.32</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-697"
      decimals="2"
      id="f-1842"
      unitRef="eurPerShare">167.63</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-698"
      decimals="2"
      id="f-1843"
      unitRef="eurPerShare">169.08</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-600"
      decimals="2"
      id="f-1844"
      unitRef="eurPerShare">137.65</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-696"
      decimals="3"
      id="f-1845"
      unitRef="number">0.366</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-697"
      decimals="3"
      id="f-1846"
      unitRef="number">0.497</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-698"
      decimals="3"
      id="f-1847"
      unitRef="number">0.497</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-600"
      decimals="3"
      id="f-1848"
      unitRef="number">0.497</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-696" decimals="1" id="f-1849" unitRef="y">4.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-697" decimals="1" id="f-1850" unitRef="y">4.6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-698" decimals="1" id="f-1851" unitRef="y">4.6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-600" decimals="1" id="f-1852" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-696"
      decimals="3"
      id="f-1853"
      unitRef="number">0.016</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-697"
      decimals="3"
      id="f-1854"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-698"
      decimals="3"
      id="f-1855"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-600"
      decimals="3"
      id="f-1856"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-699" decimals="2" id="f-1857" unitRef="eur">46.29</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-700" decimals="2" id="f-1858" unitRef="eur">43.67</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-701" decimals="2" id="f-1859" unitRef="eur">39.97</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-702" decimals="2" id="f-1860" unitRef="eur">32.86</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-703"
      decimals="2"
      id="f-1861"
      unitRef="eurPerShare">98.93</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-704"
      decimals="2"
      id="f-1862"
      unitRef="eurPerShare">95.51</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-705"
      decimals="2"
      id="f-1863"
      unitRef="eurPerShare">95.51</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-706"
      decimals="2"
      id="f-1864"
      unitRef="eurPerShare">95.51</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-703"
      decimals="2"
      id="f-1865"
      unitRef="eurPerShare">105.42</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-704"
      decimals="2"
      id="f-1866"
      unitRef="eurPerShare">96.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-705"
      decimals="2"
      id="f-1867"
      unitRef="eurPerShare">99.74</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-706"
      decimals="2"
      id="f-1868"
      unitRef="eurPerShare">105.13</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-703"
      decimals="3"
      id="f-1869"
      unitRef="number">0.472</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-704"
      decimals="3"
      id="f-1870"
      unitRef="number">0.477</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-705"
      decimals="3"
      id="f-1871"
      unitRef="number">0.430</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-706"
      decimals="3"
      id="f-1872"
      unitRef="number">0.368</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-703" decimals="1" id="f-1873" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-704" decimals="1" id="f-1874" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-705" decimals="1" id="f-1875" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-706" decimals="1" id="f-1876" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-703"
      decimals="3"
      id="f-1877"
      unitRef="number">0.037</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-704"
      decimals="3"
      id="f-1878"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-705"
      decimals="3"
      id="f-1879"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-706"
      decimals="3"
      id="f-1880"
      unitRef="number">0.039</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum
      contextRef="c-707"
      decimals="INF"
      id="f-1881"
      unitRef="number">8</bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum>
    <bntx:MaximumEconomicBenefitsOfOptionsExercised contextRef="c-633" decimals="2" id="f-1882" unitRef="usd">246.24</bntx:MaximumEconomicBenefitsOfOptionsExercised>
    <bntx:EffectiveExercisePriceMaximum
      contextRef="c-633"
      decimals="2"
      id="f-1883"
      unitRef="usdPerShare">30.78</bntx:EffectiveExercisePriceMaximum>
    <bntx:MaximumCashPaymentInShareBasedPaymentArrangement contextRef="c-708" decimals="-5" id="f-1884" unitRef="eur">20000000</bntx:MaximumCashPaymentInShareBasedPaymentArrangement>
    <bntx:MaximumCashPaymentInShareBasedPaymentArrangement contextRef="c-709" decimals="-5" id="f-1885" unitRef="eur">10000000</bntx:MaximumCashPaymentInShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c-633" id="f-1886">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (phantom) share options allocated and expected to be allocated to our Management Board as of December&#160;31, 2023, are presented in the table below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date February 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 12, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation date May 17, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(Phantom) share options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;248,096&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,279&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,463&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86,118&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and vested but subject to performance and waiting requirements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;186,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,232&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;21,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;62,024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;22,639&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;3,231&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;64,587&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;167.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;169.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;137.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified as cash-settled share-based payment arrangement; all other share-based payment arrangements are classified as equity-settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Allocation date May 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated allocation date 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share options outstanding / expected to be allocated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;130,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;164,148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;118,312&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;93,561&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof allocated and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;130,586&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;96.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;99.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;Valuation parameter derived from the Monte-Carlo simulation model.</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-707"
      decimals="INF"
      id="f-1887"
      unitRef="shares">248096</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-710"
      decimals="INF"
      id="f-1888"
      unitRef="shares">45279</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-711"
      decimals="INF"
      id="f-1889"
      unitRef="shares">6463</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-712"
      decimals="INF"
      id="f-1890"
      unitRef="shares">86118</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement
      contextRef="c-713"
      decimals="INF"
      id="f-1891"
      unitRef="shares">186072</bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement
      contextRef="c-714"
      decimals="INF"
      id="f-1892"
      unitRef="shares">22640</bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement
      contextRef="c-715"
      decimals="INF"
      id="f-1893"
      unitRef="shares">3232</bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement
      contextRef="c-658"
      decimals="INF"
      id="f-1894"
      unitRef="shares">21531</bntx:NumberOfShareOptionsAllocatedAndVestedSubjectToPerformanceAndWaitingRequirementsInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-713"
      decimals="INF"
      id="f-1895"
      unitRef="shares">62024</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-714"
      decimals="INF"
      id="f-1896"
      unitRef="shares">22639</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-715"
      decimals="INF"
      id="f-1897"
      unitRef="shares">3231</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-658"
      decimals="INF"
      id="f-1898"
      unitRef="shares">64587</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-707"
      decimals="2"
      id="f-1899"
      unitRef="eurPerShare">28.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-710"
      decimals="2"
      id="f-1900"
      unitRef="eurPerShare">167.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-711"
      decimals="2"
      id="f-1901"
      unitRef="eurPerShare">169.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-712"
      decimals="2"
      id="f-1902"
      unitRef="eurPerShare">137.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-716"
      decimals="INF"
      id="f-1903"
      unitRef="shares">130586</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-717"
      decimals="INF"
      id="f-1904"
      unitRef="shares">164148</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-718"
      decimals="INF"
      id="f-1905"
      unitRef="shares">118312</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-719"
      decimals="INF"
      id="f-1906"
      unitRef="shares">93561</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-720"
      decimals="INF"
      id="f-1907"
      unitRef="shares">130586</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-721"
      decimals="INF"
      id="f-1908"
      unitRef="shares">0</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-722"
      decimals="INF"
      id="f-1909"
      unitRef="shares">0</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement
      contextRef="c-723"
      decimals="INF"
      id="f-1910"
      unitRef="shares">0</bntx:NumberOfShareOptionsAllocatedAndUnvestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-716"
      decimals="2"
      id="f-1911"
      unitRef="eurPerShare">105.42</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-717"
      decimals="2"
      id="f-1912"
      unitRef="eurPerShare">96.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-718"
      decimals="2"
      id="f-1913"
      unitRef="eurPerShare">99.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-719"
      decimals="2"
      id="f-1914"
      unitRef="eurPerShare">105.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-633" id="f-1915">P4Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-634" id="f-1916">P4Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <bntx:PhantomOptionAwardsLiability contextRef="c-689" decimals="-5" id="f-1917" unitRef="eur">3600000</bntx:PhantomOptionAwardsLiability>
    <bntx:PhantomOptionAwardsLiability contextRef="c-690" decimals="-5" id="f-1918" unitRef="eur">5600000</bntx:PhantomOptionAwardsLiability>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="c-724"
      decimals="INF"
      id="f-1919"
      unitRef="shares">4374963</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare
      contextRef="c-724"
      decimals="2"
      id="f-1920"
      unitRef="eurPerShare">13.60</bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare>
    <bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare
      contextRef="c-724"
      decimals="2"
      id="f-1921"
      unitRef="usdPerShare">15.00</bntx:ExercisePriceCurrencyTranslationOfPublicOfferingPricePerShare>
    <bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum
      contextRef="c-725"
      decimals="INF"
      id="f-1922"
      unitRef="number">8</bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum>
    <bntx:MaximumEconomicBenefitsOfOptionsExercised contextRef="c-726" decimals="2" id="f-1923" unitRef="usd">240.00</bntx:MaximumEconomicBenefitsOfOptionsExercised>
    <bntx:EffectiveExercisePriceMaximum
      contextRef="c-726"
      decimals="2"
      id="f-1924"
      unitRef="usdPerShare">30.00</bntx:EffectiveExercisePriceMaximum>
    <bntx:OptionVestingPeriod contextRef="c-724" id="f-1925">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionExercisablePeriod contextRef="c-724" id="f-1926">P4Y</bntx:OptionExercisablePeriod>
    <bntx:PercentageOfIncreaseInExercisePrice
      contextRef="c-726"
      decimals="2"
      id="f-1927"
      unitRef="number">0.07</bntx:PercentageOfIncreaseInExercisePrice>
    <bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering contextRef="c-724" decimals="-8" id="f-1928" unitRef="eur">8500000000</bntx:ThresholdAmountOfDividendByNumberOfSharesOutstandingImmediatelyFollowingInitialPublicOffering>
    <bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth
      contextRef="c-724"
      decimals="2"
      id="f-1929"
      unitRef="number">1.07</bntx:PercentageOfTargetSharePriceApplicableForPriorTwelveMonth>
    <bntx:OptionExercisablePeriod contextRef="c-727" id="f-1930">P10Y</bntx:OptionExercisablePeriod>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-630" id="f-1931">The inputs used in the measurement of the fair value at the grant date of the Chief Executive Officer Grant were as follows:&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.183%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date October 9, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;5.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;13.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;13.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;41.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-728" decimals="2" id="f-1932" unitRef="eur">5.63</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-729"
      decimals="2"
      id="f-1933"
      unitRef="eurPerShare">13.60</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-729"
      decimals="2"
      id="f-1934"
      unitRef="eurPerShare">13.60</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-729"
      decimals="3"
      id="f-1935"
      unitRef="number">0.414</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-729" decimals="INF" id="f-1936" unitRef="y">5.4</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-729"
      decimals="3"
      id="f-1937"
      unitRef="number">0.015</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-730"
      decimals="INF"
      id="f-1938"
      unitRef="shares">4374963</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-630" id="f-1939">P1Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-631" id="f-1940">P2Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum
      contextRef="c-731"
      decimals="INF"
      id="f-1941"
      unitRef="number">8</bntx:PriceOfAmericanDepositoryShareAsAPercentageOfExercisePriceMaximum>
    <bntx:MaximumEconomicBenefitsOfOptionsExercised contextRef="c-732" decimals="2" id="f-1942" unitRef="usd">240</bntx:MaximumEconomicBenefitsOfOptionsExercised>
    <bntx:EffectiveExercisePriceMaximum
      contextRef="c-732"
      decimals="2"
      id="f-1943"
      unitRef="usdPerShare">30.00</bntx:EffectiveExercisePriceMaximum>
    <bntx:OptionVestingPeriod contextRef="c-733" id="f-1944">P4Y</bntx:OptionVestingPeriod>
    <bntx:OptionExercisablePeriod contextRef="c-733" id="f-1945">P4Y</bntx:OptionExercisablePeriod>
    <bntx:ExerciseOfOptionRightsMinimumStrikePricePercent
      contextRef="c-732"
      decimals="2"
      id="f-1946"
      unitRef="number">0.32</bntx:ExerciseOfOptionRightsMinimumStrikePricePercent>
    <bntx:PercentageOfIncreaseInExercisePrice
      contextRef="c-732"
      decimals="2"
      id="f-1947"
      unitRef="number">0.08</bntx:PercentageOfIncreaseInExercisePrice>
    <bntx:ExerciseOfOptionRightsMinimumStrikePricePercent
      contextRef="c-734"
      decimals="2"
      id="f-1948"
      unitRef="number">0.28</bntx:ExerciseOfOptionRightsMinimumStrikePricePercent>
    <bntx:PercentageOfIncreaseInExercisePrice
      contextRef="c-734"
      decimals="2"
      id="f-1949"
      unitRef="number">0.07</bntx:PercentageOfIncreaseInExercisePrice>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-627" id="f-1950">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used in the measurement of the fair values at the grant date of the ESOP were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date &lt;br/&gt;November 15, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant dates&lt;br/&gt;between &lt;br/&gt;February 21 and &lt;br/&gt;April 3, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant dates&lt;br/&gt;between&lt;br/&gt;April 29 and &lt;br/&gt;May 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant date December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;7.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;6.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;7.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;9.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;14.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;16.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;19.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;10.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x20ac;15.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#c6e0b4;border-left:1pt solid #70ad47;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#c6e0b4;border-right:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-right:1pt solid #70AD47;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-735" decimals="2" id="f-1951" unitRef="eur">7.41</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-736" decimals="2" id="f-1952" unitRef="eur">6.93</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-737" decimals="2" id="f-1953" unitRef="eur">7.04</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-738" decimals="2" id="f-1954" unitRef="eur">9.49</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-739"
      decimals="2"
      id="f-1955"
      unitRef="eurPerShare">14.40</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-740"
      decimals="2"
      id="f-1956"
      unitRef="eurPerShare">15.72</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-741"
      decimals="2"
      id="f-1957"
      unitRef="eurPerShare">16.03</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-742"
      decimals="2"
      id="f-1958"
      unitRef="eurPerShare">19.84</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-739"
      decimals="2"
      id="f-1959"
      unitRef="eurPerShare">10.14</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-740"
      decimals="2"
      id="f-1960"
      unitRef="eurPerShare">15.03</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-741"
      decimals="2"
      id="f-1961"
      unitRef="eurPerShare">15.39</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-742"
      decimals="2"
      id="f-1962"
      unitRef="eurPerShare">15.82</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-739"
      decimals="3"
      id="f-1963"
      unitRef="number">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-740"
      decimals="3"
      id="f-1964"
      unitRef="number">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-741"
      decimals="3"
      id="f-1965"
      unitRef="number">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c-742"
      decimals="3"
      id="f-1966"
      unitRef="number">0.460</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-739" decimals="1" id="f-1967" unitRef="y">5.8</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-740" decimals="1" id="f-1968" unitRef="y">6.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-741" decimals="1" id="f-1969" unitRef="y">6.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-742" decimals="1" id="f-1970" unitRef="y">5.5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-739"
      decimals="3"
      id="f-1971"
      unitRef="number">0.001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-740"
      decimals="3"
      id="f-1972"
      unitRef="number">0.001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-741"
      decimals="3"
      id="f-1973"
      unitRef="number">0.001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c-742"
      decimals="3"
      id="f-1974"
      unitRef="number">0.001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c-627" id="f-1975">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Set out below is an overview of changes to share options outstanding and number of ordinary shares underlying these options that occurred during the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Share options &lt;br/&gt;outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Number of ordinary shares underlying options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Weighted average exercise price (&#x20ac;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;642,007&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11,556,124&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Modified&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(18,720)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(583,383)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(10,500,890)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;57,584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,036,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;57,584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,036,514&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(39,785)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(716,121)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;17,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;320,393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;11.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;17,799&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;320,393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;11.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;thereof unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;With respect to the Management Board members appointed as such at the time the options were granted, the options are subject to the effective exercise price cap as well as the maximum cap mechanism.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Rights have been modified to cash-settled rights, all other terms remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.02pt;text-align:justify;text-indent:-15.02pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The average closing price of an American Depositary Share of BioNTech on Nasdaq weighted over the various dates immediately preceding the settlement dates, converted from USD to Euro using the exchange rate published by the German Central Bank (Deutsche Bundesbank) on the same days was &#x20ac;96.49 and &#x20ac;160.44 for all settlements during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-743"
      decimals="0"
      id="f-1976"
      unitRef="shares">642007</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding
      contextRef="c-743"
      decimals="INF"
      id="f-1977"
      unitRef="shares">11556124</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-743"
      decimals="2"
      id="f-1978"
      unitRef="eurPerShare">10.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-628"
      decimals="0"
      id="f-1979"
      unitRef="shares">1040</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement
      contextRef="c-628"
      decimals="INF"
      id="f-1980"
      unitRef="shares">18720</bntx:NumberOfOrdinarySharesUnderlyingOptionsForfeitedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-628"
      decimals="2"
      id="f-1981"
      unitRef="eurPerShare">10.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-628"
      decimals="0"
      id="f-1982"
      unitRef="shares">583383</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement
      contextRef="c-628"
      decimals="INF"
      id="f-1983"
      unitRef="shares">10500890</bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement>
    <bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="c-628"
      decimals="2"
      id="f-1984"
      unitRef="eurPerShare">10.14</bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-744"
      decimals="0"
      id="f-1985"
      unitRef="shares">57584</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding
      contextRef="c-744"
      decimals="INF"
      id="f-1986"
      unitRef="shares">1036514</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-744"
      decimals="2"
      id="f-1987"
      unitRef="eurPerShare">11.10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-744"
      decimals="0"
      id="f-1988"
      unitRef="shares">57584</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding
      contextRef="c-744"
      decimals="INF"
      id="f-1989"
      unitRef="shares">1036514</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-744"
      decimals="2"
      id="f-1990"
      unitRef="eurPerShare">11.10</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-627"
      decimals="0"
      id="f-1991"
      unitRef="shares">39785</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement
      contextRef="c-627"
      decimals="INF"
      id="f-1992"
      unitRef="shares">716121</bntx:NumberOfOrdinarySharesUnderlyingOptionsExercisedInShareBasedPaymentArrangement>
    <bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="c-627"
      decimals="2"
      id="f-1993"
      unitRef="eurPerShare">11.04</bntx:WeightedAverageExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-745"
      decimals="0"
      id="f-1994"
      unitRef="shares">17799</ifrs-full:NumberOfOutstandingShareOptions>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding
      contextRef="c-745"
      decimals="INF"
      id="f-1995"
      unitRef="shares">320393</bntx:NumberOfOrdinarySharesUnderlyingOptionsOutstanding>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-745"
      decimals="2"
      id="f-1996"
      unitRef="eurPerShare">11.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="0"
      id="f-1997"
      unitRef="shares">17799</bntx:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="INF"
      id="f-1998"
      unitRef="shares">320393</bntx:NumberOfOrdinarySharesUnderlyingOptionsVestedInShareBasedPaymentArrangement>
    <bntx:WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="2"
      id="f-1999"
      unitRef="eurPerShare">11.24</bntx:WeightedAverageExercisePriceOfShareOptionsVestedInShareBasedPaymentArrangement>
    <bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="0"
      id="f-2000"
      unitRef="shares">0</bntx:NumberOfShareOptionsUnestedInShareBasedPaymentArrangement>
    <bntx:NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="INF"
      id="f-2001"
      unitRef="shares">0</bntx:NumberOfOrdinarySharesUnderlyingOptionsUnvestedInShareBasedPaymentArrangement>
    <bntx:WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement
      contextRef="c-745"
      decimals="2"
      id="f-2002"
      unitRef="eurPerShare">0</bntx:WeightedAverageExercisePriceOfShareOptionsUnvestedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-627"
      decimals="2"
      id="f-2003"
      unitRef="eurPerShare">96.49</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-628"
      decimals="2"
      id="f-2004"
      unitRef="eurPerShare">160.44</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="c-746" decimals="-5" id="f-2005" unitRef="eur">724000000.0</ifrs-full:PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-627" id="f-2006">P0Y9M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-628" id="f-2007">P1Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <bntx:ExercisePricePhantomOptionsGranted
      contextRef="c-747"
      decimals="2"
      id="f-2008"
      unitRef="eurPerShare">10.14</bntx:ExercisePricePhantomOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-748"
      decimals="INF"
      id="f-2009"
      unitRef="shares">52100</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-747"
      decimals="INF"
      id="f-2010"
      unitRef="shares">289168</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-748" decimals="-5" id="f-2011" unitRef="eur">4500000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-747" decimals="-5" id="f-2012" unitRef="eur">42200000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-748"
      decimals="2"
      id="f-2013"
      unitRef="eurPerShare">96.25</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="c-747"
      decimals="2"
      id="f-2014"
      unitRef="eurPerShare">155.39</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-749"
      decimals="INF"
      id="f-2015"
      unitRef="shares">109651</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-749" decimals="-5" id="f-2016" unitRef="eur">8500000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-750" decimals="-5" id="f-2017" unitRef="eur">14500000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable contextRef="c-749" decimals="-5" id="f-2018" unitRef="eur">8300000</bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable>
    <bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable contextRef="c-750" decimals="-5" id="f-2019" unitRef="eur">11200000</bntx:ShareBasedPaymentArrangementRelatedToRightsVestedAndExercisable>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="c-1" id="f-2020">Provisions&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;118.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;88.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Obligations from onerous CMO contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;80.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;278.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;375.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;269.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;367.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our current provisions included &#x20ac;118.2&#160;million in contractual disputes mainly related to purported obligations arising out of certain contractual disputes unrelated to the below-mentioned patent proceedings (&#x20ac;88.9&#160;million as of December&#160;31, 2022). Acknowledging an increase in obligations identified as contractual disputes, the change of &#x20ac;29.3&#160;million compared to the previous period related mainly to additions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our current provisions included &#x20ac;80.2&#160;million&#160;(&#x20ac;235.5&#160;million as of December&#160;31, 2022) of obligations for production capacities derived from contracts with Contract Manufacturing Organizations, or CMOs, that became redundant The effects were driven by reducing production capacities as well as further fostering the global production network with our collaboration partners during the year ended December&#160;31, 2023. The related expenses were recognized in cost of sales in our consolidated statements of profit or loss. The change of &#x20ac;(155.3)&#160;million compared to the previous period related to addition (&#x20ac;45.1&#160;million), to release (&#x20ac;126.0&#160;million) and usage (&#x20ac;74.5&#160;million). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, our current provisions included &#x20ac;79.7 million in other obligations mainly comprising inventor remunerations as well as customs and duties (&#x20ac;51.4 million as of December&#160;31, 2022, mainly comprising inventor remunerations as well as customs and duties). The change of &#x20ac;28.3&#160;million compared to the previous period related mainly to additions.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <bntx:DisclosureOfProvisionsTableTextBlock contextRef="c-1" id="f-2021">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.093%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual disputes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;118.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;88.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Obligations from onerous CMO contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;80.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;235.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;79.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;278.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;375.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;269.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;367.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfProvisionsTableTextBlock>
    <ifrs-full:LegalProceedingsProvision contextRef="c-14" decimals="-5" id="f-2022" unitRef="eur">118200000</ifrs-full:LegalProceedingsProvision>
    <ifrs-full:LegalProceedingsProvision contextRef="c-15" decimals="-5" id="f-2023" unitRef="eur">88900000</ifrs-full:LegalProceedingsProvision>
    <ifrs-full:ShorttermOnerousContractsProvision contextRef="c-14" decimals="-5" id="f-2024" unitRef="eur">80200000</ifrs-full:ShorttermOnerousContractsProvision>
    <ifrs-full:ShorttermOnerousContractsProvision contextRef="c-15" decimals="-5" id="f-2025" unitRef="eur">235500000</ifrs-full:ShorttermOnerousContractsProvision>
    <ifrs-full:OtherProvisions contextRef="c-14" decimals="-5" id="f-2026" unitRef="eur">79700000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-15" decimals="-5" id="f-2027" unitRef="eur">51400000</ifrs-full:OtherProvisions>
    <ifrs-full:Provisions contextRef="c-14" decimals="-5" id="f-2028" unitRef="eur">278100000</ifrs-full:Provisions>
    <ifrs-full:Provisions contextRef="c-15" decimals="-5" id="f-2029" unitRef="eur">375800000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-14" decimals="-5" id="f-2030" unitRef="eur">269300000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c-15" decimals="-5" id="f-2031" unitRef="eur">367200000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-14" decimals="-5" id="f-2032" unitRef="eur">8800000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-15" decimals="-5" id="f-2033" unitRef="eur">8600000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:LegalProceedingsProvision contextRef="c-14" decimals="-5" id="f-2034" unitRef="eur">118200000</ifrs-full:LegalProceedingsProvision>
    <ifrs-full:LegalProceedingsProvision contextRef="c-15" decimals="-5" id="f-2035" unitRef="eur">88900000</ifrs-full:LegalProceedingsProvision>
    <bntx:CurrentOnerousContractsProvisionAdditions contextRef="c-1" decimals="-5" id="f-2036" unitRef="eur">29300000</bntx:CurrentOnerousContractsProvisionAdditions>
    <ifrs-full:ShorttermOnerousContractsProvision contextRef="c-14" decimals="-5" id="f-2037" unitRef="eur">80200000</ifrs-full:ShorttermOnerousContractsProvision>
    <ifrs-full:ShorttermOnerousContractsProvision contextRef="c-15" decimals="-5" id="f-2038" unitRef="eur">235500000</ifrs-full:ShorttermOnerousContractsProvision>
    <bntx:CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption contextRef="c-1" decimals="-5" id="f-2039" unitRef="eur">155300000</bntx:CurrentOnerousContractsProvisionRelatedToReleaseAndConsumption>
    <bntx:CurrentOnerousContractsProvisionOtherAdditionalProvisions contextRef="c-1" decimals="-5" id="f-2040" unitRef="eur">45100000</bntx:CurrentOnerousContractsProvisionOtherAdditionalProvisions>
    <bntx:CurrentOnerousContractsProvisionRelatedToRelease contextRef="c-1" decimals="-5" id="f-2041" unitRef="eur">126000000</bntx:CurrentOnerousContractsProvisionRelatedToRelease>
    <bntx:CurrentOnerousContractsProvisionRelatedToUsage contextRef="c-1" decimals="-5" id="f-2042" unitRef="eur">74500000</bntx:CurrentOnerousContractsProvisionRelatedToUsage>
    <ifrs-full:OtherProvisions contextRef="c-14" decimals="-5" id="f-2043" unitRef="eur">79700000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions contextRef="c-15" decimals="-5" id="f-2044" unitRef="eur">51400000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c-1" decimals="-5" id="f-2045" unitRef="eur">28300000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c-1" id="f-2046">Contingencies and other financial commitments&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contingencies include, but are not limited to, intellectual property disputes and product liability and other product-related litigation. From time to time, in the normal course and conduct of our business, we may be involved in discussions with third parties about considering, for example, the use and/or remuneration for use of such third party&#x2019;s intellectual property. As of December&#160;31, 2023, none of such intellectual property-related considerations that we have been notified of, and for which potential claims could be brought against us or our subsidiaries in the future, fulfill the criteria for recording a provision. We are subject to an increasing number of product liability claims. Such claims often involve highly complex issues related to medical causation, correctness and completeness of product information (Summary of Product Characteristics/package leaflet) as well as label warnings and reliance thereon, scientific evidence and findings, actual and provable injury, and other matters. These complexities vary from matter to matter. As of December 31, 2023, none of these claims fulfill the criteria for recording a provision. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We currently do not believe that any of these matters will have a material adverse effect on our financial position, and will continue to monitor the status of these and other claims that may arise. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. We will continue to evaluate whether, if circumstances were to change in the future, the recording of a provision may be needed and whether potential indemnification entitlements exist against any such claim. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain pending matters to which we are a party are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alnylam Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Alnylam Pharmaceuticals, Inc., or Alnylam, filed a lawsuit against Pfizer and Pharmacia &amp;amp; Upjohn&#160;&#160;&#160;&#160;Co. LLC in the U.S. District Court for the District of Delaware alleging that an existing patent owned by Alnylam, U.S. Patent No. 11,246,933, or the &#x2018;933 Patent, is infringed by the cationic lipid used in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and seeking monetary relief, which is not specified in their filings. We filed a counterclaim to become party to the Alnylam proceeding, and in June 2022, Alnylam added to its claims allegations that we induced infringement of the &#x2018;933 Patent. Additionally, in July 2022, Alnylam filed a lawsuit against us, our wholly owned subsidiary, BioNTech Manufacturing GmbH, Pfizer and Pharmacia &amp;amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging that we also induced infringement of a newly issued patent, U.S. Patent No. 11,382,979, or the &#x2018;979 Patent, which is a continuation of the &#x2018;933 Patent. The two lawsuits were consolidated on July 28, 2022. In May 2023, Alnylam filed a third lawsuit against Pfizer Inc. and Pharmacia &amp;amp; Upjohn Co. LLC in the U.S. District Court for the District of Delaware alleging infringement of U.S. Patent Nos. 11,633,479; 11,633,480; 11,612,657; and 11,590,229, all of which are continuations of the &#x2018;933 Patent. We filed a counterclaim to become party to the new proceeding, and in July 2023, Alnylam added to its claims allegations that we induced infringement of the four new patents. All of the proceedings have been consolidated and&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Alnylam&#x2019;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CureVac Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Germany&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Infringement Proceedings &#x2013; EP&#x2019;122, DE&#x2019;961, DE&#x2018;974, DE&#x2019;575, and EP&#x2019;668&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, CureVac AG, or CureVac, filed a lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#xfc;sseldorf Regional Court, alleging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of one European patent, EP1857122B1, or the EP&#x2019;122 Patent, and three Utility Models DE202015009961U1, DE202015009974U1, and DE202021003575U1. In August 2022, CureVac added European Patent EP3708668B1, or the EP&#x2019;668 Patent, to its German lawsuit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2023, the D&#xfc;sseldorf Regional Court held a hearing on infringement with respect to all five IP rights. At the hearing, the Court suspended its infringement ruling with respect to EP&#x2019;122 until December 28, 2023. On September 28, 2023, the Court issued orders suspending its infringement rulings with respect to the remaining four IP rights (DE&#x2019;961, DE&#x2019;974, DE&#x2019;575, and EP&#x2019;668) pending validity decisions in the DE&#x2019;961, DE&#x2019;974, and DE&#x2019;575 cancellation proceedings before the German Patent and Trademark Office and in the EP&#x2019;668 opposition proceedings before the Opposition Division of the European Patent Office. In the September 28th orders, the Court explained that it was suspending its infringement rulings until validity decisions are reached, while contemporaneously noting concerns regarding the validity of DE&#x2019;961, DE&#x2019;974, DE&#x2019;575, and EP&#x2019;668. On December 28, 2023, the D&#xfc;sseldorf Regional Court stayed the infringement proceedings as to EP&#x2019;122 until a final appellate decision is rendered as to the validity of EP 122 by the Federal Court of Justice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Infringement Proceedings &#x2013; EP&#x2019;755, DE&#x2019;123, and DE&#x2019;130&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, CureVac SE filed a second lawsuit against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH and BioNTech Manufacturing Marburg GmbH, in the D&#xfc;sseldorf Regional Court, alleging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of one European patent, EP4023755B1, or the EP&#x2019;755 Patent, and two Utility Models DE202021004123U1, and DE202021004130U1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nullity Proceedings &#x2013; EP&#x2019;122&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, we filed a nullity action in the Federal Patent Court of Germany seeking a declaration that the EP&#x2019;122 Patent is invalid. In April 2023, the Federal Patent Court of Germany issued a preliminary opinion in the EP&#x2019;122 nullity action in support of the validity of the EP&#x2019;122 Patent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preliminary opinion did not address any infringement of the EP&#x2019;122 Patent.  The preliminary opinion is a preliminary assessment by the court of the merits of a claim, and is non-binding. On December 19, 2023, the Federal Patent Court held an oral hearing, after which it nullified EP&#x2019;122. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cancellation Proceedings&#x2013; DE&#x2019;961, DE&#x2018;974, and DE&#x2019;575&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, we filed cancellation actions seeking the cancellation of the three German Utility Models in the German Patent and Trademark Office. On December 27, 2023, the German Patent Office issued a preliminary opinion that DE&#x2019;974 is likely to be cancelled based on invalidity pursuant to para. 1 (2) no. 5 Utility Model Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, we and Pfizer filed a complaint for a declaratory judgment in the U.S. District Court for the District of Massachusetts, seeking a judgment of non-infringement by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of U.S. Patent Nos. 11,135,312, 11,149,278 and 11,241,493. In May 2023, the action in the U.S. District Court for the District of Massachusetts was transferred to the U.S. District Court for the Eastern District of Virginia, where CureVac filed counterclaims asserting infringement of six additional U.S. patents, U.S. Patent Nos. 10,760,070; 11,286,492; 11,345,920; 11,471,525; 11,576,966; and 11,596,686. In July 2023, CureVac filed amended counterclaims to assert an additional U.S. patent, U.S. Patent No. 11,667,910.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United Kingdom &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, we and Pfizer filed a declaration of non-infringement and revocation action against the EP&#x2019;122 Patent and the EP&#x2019;668 Patent in the Business and Property Courts of England and Wales. In October 2022, CureVac responded by filing a counterclaim alleging infringement of the EP&#x2019;122 and EP&#x2019;668 patents in the Business And Property Courts of England and Wales. On December 18, 2023, we amended our pleadings to further allege non-infringement and invalidity against EP&#x2019;755.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the above proceedings are currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe we have strong defenses against the allegations claimed relative to each of the patents and utility models and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of CureVac&#x2019;s claims is ongoing and complex, and we believe the ultimate outcomes remain substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Germany&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Infringement Proceedings &#x2013; EP&#x2019;949 and EP&#x2019;565&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, Moderna filed a lawsuit against us and Pfizer and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Manufacturing Belgium NV, Pfizer Ireland Pharmaceuticals and Pfizer Inc. in the D&#xfc;sseldorf Regional Court alleging Comirnaty&#x2019;s infringement of two European Patents, 3590949B1, or the EP&#x2019;949 Patent, and 3718565B1, or the EP&#x2019;565 Patent.  On November 7, 2023, the European Patent Office (&#x201c;EPO&#x201d;) Opposition Division revoked EP&#x2019;565 after a one-day oral hearing.  The Opposition Division issued a preliminary opinion on December 8, 2023 noting that it believes EP&#x2019;949 is likely invalid.  As a result of these EPO proceedings, the D&#xfc;sseldorf Regional Court postponed its hearing on infringement, originally scheduled for December 12, 2023, to January 21, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United Kingdom&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, Moderna filed a lawsuit asserting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of the EP&#x2019;949 Patent and EP&#x2019;565 Patent against us and our wholly owned subsidiaries, BioNTech Manufacturing GmbH, BioNTech Europe GmbH and BioNTech Manufacturing Marburg GmbH, Pfizer Limited, Pfizer Manufacturing Belgium NV and Pfizer Inc. in the Business and Property Courts of England and Wales. In September 2022, we and Pfizer filed a revocation action in the Business and Property Courts of England and Wales requesting revocation of the EP&#x2019;949 Patent and EP&#x2019;565 Patent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. District Court Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, Moderna filed a lawsuit in the United States District Court for the District of Massachusetts against us and our wholly owned subsidiaries BioNTech Manufacturing GmbH and BioNTech US Inc. and Pfizer Inc. alleging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of U.S. Patent Nos. 10,898,574, 10,702,600 and 10,933,127 and seeking monetary relief. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inter Partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; Review&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, Pfizer and we filed petitions seeking inter partes review of U.S. Patent Nos. 10,702,600 and 10,933,127 before the United States Patent Trial and Appeal Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Netherlands&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH and Pfizer B.V., Pfizer Export B.V., C.P. Pharmaceuticals International C.V. and Pfizer Inc. in the District Court of The Hague alleging Comirnaty&#x2019;s infringement of the EP &#x2018;949 Patent and the EP &#x2019;565 Patent. The District Court of the Hague held a hearing on October 6, 2023 on infringement and validity with respect to the EP &#x2019;949 Patent. On December 6, 2023, the Court found EP&#x2019;949 to be invalid. The EP&#x2019;565 case has been stayed pending Moderna&#x2019;s appeal of the Opposition Division&#x2019;s revocation of EP&#x2019;565.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Ireland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, Moderna filed a lawsuit against us and our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc., Pfizer Healthcare Ireland, Pfizer Ireland Pharmaceuticals, and C.P. Pharmaceuticals International C.V. alleging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of the EP&#x2019;949 Patent and EP&#x2019;565 Patent in the High Court of Ireland.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Belgium&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, Moderna filed a lawsuit against us, our wholly owned subsidiary BioNTech Manufacturing GmbH, Pfizer Inc. and Pfizer Manufacturing Belgium alleging &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s infringement of the EP&#x2019;949 Patent and the EP&#x2019;565 Patent in the Brussels Dutch-speaking Enterprise Court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the above proceedings are currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the proceedings mentioned above. However, our analysis of Moderna&#x2019;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Arbutus and Genevant Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, Arbutus Biopharma Corp., or Arbutus, and Genevant Sciences GmbH, or Genevant, filed a lawsuit against Pfizer and us in the U.S. District Court for the District of New Jersey alleging that Pfizer and we have infringed the following patents owned by Arbutus: U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098, through the use of Genevant&#x2019;s lipid nanoparticle technology and methods for producing such lipids in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and seeking monetary relief. This proceeding is currently pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe we have strong defenses against the allegations claimed relative to each of the patents and intend to vigorously defend ourselves in the lawsuit mentioned above. However, our analysis of Arbutus and Genevant&#x2019;s claims is ongoing and complex, and we believe the outcome of the suit remains substantially uncertain. Taking into account discussions with our external lawyers, we do not consider the probability of an outflow of resources to be sufficient to recognize a provision at the balance sheet date. In our opinion, these matters constitute contingent liabilities as of the balance sheet date. However, it is currently impractical for us to estimate with sufficient reliability the respective contingent liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Promosome Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, Promosome LLC filed a lawsuit against Pfizer, us, and BioNTech Manufacturing GmbH in the U.S. District Court for the Southern District of California alleging that Pfizer and our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; vaccine has infringed U.S. Patent No. 8,853,179, and seeking monetary relief. On October 4, 2023, the parties filed a joint stipulation of dismissal, dismissing the lawsuit with prejudice. As part of this stipulation of dismissal, Promosome agreed to a covenant not to assert U.S. Patent No. 8,853,179 against Pfizer and us or any of their products, including &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comirnaty&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This matter is considered closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other financial commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other financial commitments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commitments under purchase agreements for property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;154.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual obligation to acquire intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,721.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,875.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;105.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual obligations to acquire intangible assets exist in connection with in-licensing and research and development collaborations. We have entered into obligations to make milestone payments once specific targets have been reached. Provided that all of the milestone events are achieved, we would be obligated to pay up to &#x20ac;1,721.1&#160;million as of December&#160;31, 2023 (nil as of December&#160;31, 2022) in connection with the acquisition of intangible assets. The amounts shown represent the maximum payments to be made, and it is unlikely that they will all fall due. The amounts and the dates of the actual payments may both vary considerably from those stated in the table, since the achievement of the conditions for payment is possible but uncertain. Other financial obligations from possible future sales-based milestone and license payments were not included in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected maturities of payment obligations under purchase agreements for property, plant and equipment and contractual obligations to acquire intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commitments under purchase agreements for property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;152.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;154.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual obligation to acquire intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;954.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;516.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,721.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;956.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;516.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,875.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other financial obligations were recognized at nominal value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="c-1" id="f-2047">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other financial commitments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:0.24pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commitments under purchase agreements for property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;154.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;105.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual obligation to acquire intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,721.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,875.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;105.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected maturities of payment obligations under purchase agreements for property, plant and equipment and contractual obligations to acquire intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.776%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1 to 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;More than 5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Commitments under purchase agreements for property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;152.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;154.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual obligation to acquire intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;954.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;516.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,721.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;401.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;956.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;516.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;1,875.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-14" decimals="-5" id="f-2048" unitRef="eur">154400000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-15" decimals="-5" id="f-2049" unitRef="eur">105200000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-2050" unitRef="eur">1721100000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-2051" unitRef="eur">0</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-14" decimals="-5" id="f-2052" unitRef="eur">1875500000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-15" decimals="-5" id="f-2053" unitRef="eur">105200000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-2054" unitRef="eur">1721100000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-2055" unitRef="eur">0</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-751" decimals="-5" id="f-2056" unitRef="eur">152500000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-752" decimals="-5" id="f-2057" unitRef="eur">1900000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-753" decimals="-5" id="f-2058" unitRef="eur">0</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment contextRef="c-14" decimals="-5" id="f-2059" unitRef="eur">154400000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-751" decimals="-5" id="f-2060" unitRef="eur">249400000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-752" decimals="-5" id="f-2061" unitRef="eur">954900000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-753" decimals="-5" id="f-2062" unitRef="eur">516800000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-2063" unitRef="eur">1721100000</ifrs-full:ContractualCommitmentsForAcquisitionOfIntangibleAssets>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-751" decimals="-5" id="f-2064" unitRef="eur">401900000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-752" decimals="-5" id="f-2065" unitRef="eur">956800000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-753" decimals="-5" id="f-2066" unitRef="eur">516800000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-14" decimals="-5" id="f-2067" unitRef="eur">1875500000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory contextRef="c-1" id="f-2068">Other Non-Financial Liabilities&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities to employees &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;50.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities from share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities from wage taxes and social securities expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;761.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;138.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;877.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;125.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;860.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-2069">&lt;div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities to employees &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;73.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;50.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities from share-based payment arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities from wage taxes and social securities expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;761.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;138.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;877.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;125.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;860.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutOtherNonFinancialLiabilitiesExplanatoryTableTextBlock>
    <bntx:LiabilitiesForEmployeeBenefits contextRef="c-14" decimals="-5" id="f-2070" unitRef="eur">73300000</bntx:LiabilitiesForEmployeeBenefits>
    <bntx:LiabilitiesForEmployeeBenefits contextRef="c-15" decimals="-5" id="f-2071" unitRef="eur">50600000</bntx:LiabilitiesForEmployeeBenefits>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-14" decimals="-5" id="f-2072" unitRef="eur">29000000.0</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011 contextRef="c-15" decimals="-5" id="f-2073" unitRef="eur">36200000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses contextRef="c-14" decimals="-5" id="f-2074" unitRef="eur">15100000</bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses>
    <bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses contextRef="c-15" decimals="-5" id="f-2075" unitRef="eur">761800000</bntx:LiabilitiesFromWageTaxesAndSocialSecuritiesExpenses>
    <bntx:OtherLiabilitiesOther contextRef="c-14" decimals="-5" id="f-2076" unitRef="eur">20800000</bntx:OtherLiabilitiesOther>
    <bntx:OtherLiabilitiesOther contextRef="c-15" decimals="-5" id="f-2077" unitRef="eur">29200000</bntx:OtherLiabilitiesOther>
    <ifrs-full:OtherNonfinancialLiabilities contextRef="c-14" decimals="-5" id="f-2078" unitRef="eur">138200000</ifrs-full:OtherNonfinancialLiabilities>
    <ifrs-full:OtherNonfinancialLiabilities contextRef="c-15" decimals="-5" id="f-2079" unitRef="eur">877800000</ifrs-full:OtherNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c-14" decimals="-5" id="f-2080" unitRef="eur">125100000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c-15" decimals="-5" id="f-2081" unitRef="eur">860800000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="c-14" decimals="-5" id="f-2082" unitRef="eur">13100000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities contextRef="c-15" decimals="-5" id="f-2083" unitRef="eur">17000000.0</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-2084">Leases&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.1&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Financial Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;206.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other operating equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;214.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions to the right-of-use assets during the year ended December&#160;31, 2023, were &#x20ac;66.4 million&#160;(during the year ended December&#160;31, 2022: &#x20ac;118.3 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts are included in lease liabilities, loans and borrowings as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;20.2&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Profit or Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation Charge of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other operating equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;45.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;58.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;29.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense related to short-term leases and leases of low-value assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total amounts recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;109.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;91.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;41.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.3&#160;&#160;&#160;&#160;Amounts Recognized in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the total cash outflow for leases amounted to &#x20ac;46.0 million (during the year ended December&#160;31, 2022: &#x20ac;46.2 million; during the year ended December&#160;31, 2021: &#x20ac;17.0 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.4&#160;&#160;&#160;&#160;Extension Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has several lease contracts that include extension options. These options are negotiated by management to provide flexibility in managing the leased asset portfolio and align with the Group&#x2019;s business needs. Management exercises judgment in determining whether these extension options are reasonably certain to be exercised. The undiscounted potential &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future lease payments, which relate to periods after the exercise date of renewal options and are not included in lease liabilities, amount to up to &#x20ac;157.2&#160;million as of December&#160;31, 2023, considering terms up until 2049 (as of December&#160;31, 2022: &#x20ac;163.1&#160;million considering terms up until 2049).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-2085">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts are presented as right-of-use assets within the consolidated statements of financial position as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;209.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;206.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other operating equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;214.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;211.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-754" decimals="-5" id="f-2086" unitRef="eur">209800000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-755" decimals="-5" id="f-2087" unitRef="eur">206500000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-756" decimals="-5" id="f-2088" unitRef="eur">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-757" decimals="-5" id="f-2089" unitRef="eur">3000000.0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-758" decimals="-5" id="f-2090" unitRef="eur">4600000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-759" decimals="-5" id="f-2091" unitRef="eur">2400000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-14" decimals="-5" id="f-2092" unitRef="eur">214400000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-15" decimals="-5" id="f-2093" unitRef="eur">211900000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-5" id="f-2094" unitRef="eur">66400000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-12" decimals="-5" id="f-2095" unitRef="eur">118300000</ifrs-full:AdditionsToRightofuseAssets>
    <bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-2096">&lt;div style="margin-top:6pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following amounts are included in lease liabilities, loans and borrowings as of the dates indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;36.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;188.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;174.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;216.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;210.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutLeaseLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-14" decimals="-5" id="f-2097" unitRef="eur">28100000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-15" decimals="-5" id="f-2098" unitRef="eur">36000000.0</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-14" decimals="-5" id="f-2099" unitRef="eur">188600000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-15" decimals="-5" id="f-2100" unitRef="eur">174100000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-14" decimals="-5" id="f-2101" unitRef="eur">216700000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-15" decimals="-5" id="f-2102" unitRef="eur">210100000</ifrs-full:LeaseLiabilities>
    <bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock contextRef="c-1" id="f-2103">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation Charge of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Production facilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other operating equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;45.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;58.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;29.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expense related to short-term leases and leases of low-value assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;58.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total amounts recognized in profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;109.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;91.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;41.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bntx:DisclosureOfDetailedInformationAboutLeaseExpenseRecognizedInStatementOfOperationsExplanatoryTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-760" decimals="-5" id="f-2104" unitRef="eur">40700000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-761" decimals="-5" id="f-2105" unitRef="eur">35200000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-762" decimals="-5" id="f-2106" unitRef="eur">14700000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-763" decimals="-5" id="f-2107" unitRef="eur">3000000.0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-764" decimals="-5" id="f-2108" unitRef="eur">23100000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-765" decimals="-5" id="f-2109" unitRef="eur">14000000.0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-766" decimals="-5" id="f-2110" unitRef="eur">1500000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-767" decimals="-5" id="f-2111" unitRef="eur">500000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-768" decimals="-5" id="f-2112" unitRef="eur">300000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-5" id="f-2113" unitRef="eur">45200000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-12" decimals="-5" id="f-2114" unitRef="eur">58800000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-13" decimals="-5" id="f-2115" unitRef="eur">29000000.0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-5" id="f-2116" unitRef="eur">5700000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-12" decimals="-5" id="f-2117" unitRef="eur">5100000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-13" decimals="-5" id="f-2118" unitRef="eur">2900000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-1" decimals="-5" id="f-2119" unitRef="eur">58900000</bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-12" decimals="-5" id="f-2120" unitRef="eur">27100000</bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="c-13" decimals="-5" id="f-2121" unitRef="eur">9500000</bntx:ExpenseRelatingToShortTermLeasesAndLeasesOfLowValueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <bntx:LeaseExpensesRecognizedInProfitOrLoss contextRef="c-1" decimals="-5" id="f-2122" unitRef="eur">109800000</bntx:LeaseExpensesRecognizedInProfitOrLoss>
    <bntx:LeaseExpensesRecognizedInProfitOrLoss contextRef="c-12" decimals="-5" id="f-2123" unitRef="eur">91000000.0</bntx:LeaseExpensesRecognizedInProfitOrLoss>
    <bntx:LeaseExpensesRecognizedInProfitOrLoss contextRef="c-13" decimals="-5" id="f-2124" unitRef="eur">41400000</bntx:LeaseExpensesRecognizedInProfitOrLoss>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-5" id="f-2125" unitRef="eur">46000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-12" decimals="-5" id="f-2126" unitRef="eur">46200000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-13" decimals="-5" id="f-2127" unitRef="eur">17000000</ifrs-full:CashOutflowForLeases>
    <bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities contextRef="c-14" decimals="-5" id="f-2128" unitRef="eur">157200000</bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities>
    <bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities contextRef="c-15" decimals="-5" id="f-2129" unitRef="eur">163100000</bntx:UndiscountedFutureLeasePaymentsRelatedToRenewalOptionsNotIncludedInLeaseLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-2130">Related Party Disclosures&lt;div style="margin-top:6pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;21.1&#160;&#160;&#160;&#160;Parent and Ultimate Controlling Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial owner of our ordinary shares. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;21.2&#160;&#160;&#160;&#160;Transactions with Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, at the Annual General Meeting, our shareholders reappointed Ulrich Wandschneider and Michael Motschmann as members of the Supervisory Board. In addition, Nicola Blackwood was appointed to our Supervisory Board. She succeeded Christoph Huber, who left the Supervisory Board after reaching the applicable retirement age limit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Key Management Personnel Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our key management personnel has been defined as the members of the Management Board and the Supervisory Board. Key management personnel compensation is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term incentive &#x2013; first installment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term incentive &#x2013; second installment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other variable compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments (incl. long-term incentive)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Supervisory Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total compensation paid to key management personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#x201c;Share-based Payments.&#x201d; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#x2019;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes a one-time signing and retention cash payment agreed when renewing the service agreement agreed with Sean Marett.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#x201c;Stock-based Payments.&#x201d; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. During the years ended December&#160;31, 2023, 2022, and 2021, the amounts included expenses derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the form of 4,246 phantom shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management Board members participated in our ESOP program (see Note 16)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Out of the 5,152,410 option rights granted to our Management Board under the ESOP 2018 program 4,921,630 options were exercised during the year ended December 31, 2022. The remaining 230,780 option rights were exercised by Sean Marett in May 2023. As of December 31, 2023, no further options issued to our Management Board members are outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;padding-left:24.4pt;text-align:justify;text-indent:-24.4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;21.3&#160;&#160;&#160;&#160;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases of various goods and services from entities controlled by ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases of property and other assets from entities controlled by ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;62.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;62.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2022, we entered into a purchase agreement with Santo Service GmbH, pursuant to which we acquired the real estate property An der Goldgrube 12 and the existing laboratory and office building including any movable assets for a total consideration of &#x20ac;62.5 million. The purchase price was paid during the year ended December 31, 2022. Santo Service GmbH is wholly owned by AT Impf GmbH, that is controlled by ATHOS KG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;padding-left:0.28pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed by related parties.</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="c-1" id="f-2131">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our key management personnel has been defined as the members of the Management Board and the Supervisory Board. Key management personnel compensation is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Management Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term incentive &#x2013; first installment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term incentive &#x2013; second installment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other variable compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Share-based payments (incl. long-term incentive)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;16.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Supervisory Board&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total compensation paid to key management personnel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;15.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70ad47;border-right:1pt solid #70ad47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;20.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 &#x201c;Share-based Payments.&#x201d; This table shows the pro-rata share of personnel expenses for the respective financial year that are recognized over the award&#x2019;s vesting period beginning as of the service commencement date (date when entering or renewing service agreements) until each separate determination date and are remeasured until settlement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:15.1pt;text-align:justify;text-indent:-15.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Includes a one-time signing and retention cash payment agreed when renewing the service agreement agreed with Sean Marett.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&#160;&#160;&#160;&#160;The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 &#x201c;Stock-based Payments.&#x201d; This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the respective financial year. During the years ended December&#160;31, 2023, 2022, and 2021, the amounts included expenses derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the form of 4,246 phantom shares.</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-769" decimals="-5" id="f-2132" unitRef="eur">8300000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-770" decimals="-5" id="f-2133" unitRef="eur">15000000.0</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-771" decimals="-5" id="f-2134" unitRef="eur">20400000</ifrs-full:KeyManagementPersonnelCompensation>
    <bntx:KeyManagementPersonnelCompensationFixedCompensation contextRef="c-769" decimals="-5" id="f-2135" unitRef="eur">3900000</bntx:KeyManagementPersonnelCompensationFixedCompensation>
    <bntx:KeyManagementPersonnelCompensationFixedCompensation contextRef="c-770" decimals="-5" id="f-2136" unitRef="eur">2900000</bntx:KeyManagementPersonnelCompensationFixedCompensation>
    <bntx:KeyManagementPersonnelCompensationFixedCompensation contextRef="c-771" decimals="-5" id="f-2137" unitRef="eur">2200000</bntx:KeyManagementPersonnelCompensationFixedCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-769" decimals="-5" id="f-2138" unitRef="eur">700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-770" decimals="-5" id="f-2139" unitRef="eur">600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-771" decimals="-5" id="f-2140" unitRef="eur">600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment contextRef="c-769" decimals="-5" id="f-2141" unitRef="eur">1000000.0</bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment>
    <bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment contextRef="c-770" decimals="-5" id="f-2142" unitRef="eur">700000</bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment>
    <bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment contextRef="c-771" decimals="-5" id="f-2143" unitRef="eur">1200000</bntx:KeyManagementPersonnelCompensationShortTermEmployeeBenefitsSecondInstallment>
    <bntx:KeyManagementPersonnelCompensationOtherVariableCompensation contextRef="c-769" decimals="-5" id="f-2144" unitRef="eur">800000</bntx:KeyManagementPersonnelCompensationOtherVariableCompensation>
    <bntx:KeyManagementPersonnelCompensationOtherVariableCompensation contextRef="c-770" decimals="-5" id="f-2145" unitRef="eur">100000</bntx:KeyManagementPersonnelCompensationOtherVariableCompensation>
    <bntx:KeyManagementPersonnelCompensationOtherVariableCompensation contextRef="c-771" decimals="-5" id="f-2146" unitRef="eur">0</bntx:KeyManagementPersonnelCompensationOtherVariableCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-769" decimals="-5" id="f-2147" unitRef="eur">1900000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-770" decimals="-5" id="f-2148" unitRef="eur">10700000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-771" decimals="-5" id="f-2149" unitRef="eur">16400000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-772" decimals="-5" id="f-2150" unitRef="eur">600000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-773" decimals="-5" id="f-2151" unitRef="eur">500000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-774" decimals="-5" id="f-2152" unitRef="eur">400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-5" id="f-2153" unitRef="eur">8900000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-12" decimals="-5" id="f-2154" unitRef="eur">15500000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-13" decimals="-5" id="f-2155" unitRef="eur">20800000</ifrs-full:KeyManagementPersonnelCompensation>
    <bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded
      contextRef="c-775"
      decimals="INF"
      id="f-2156"
      unitRef="shares">4246</bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded>
    <bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded
      contextRef="c-776"
      decimals="INF"
      id="f-2157"
      unitRef="shares">4246</bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded>
    <bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded
      contextRef="c-777"
      decimals="INF"
      id="f-2158"
      unitRef="shares">4246</bntx:KeyManagementPersonnelCompensationPhantomSharesAwarded>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-778"
      decimals="INF"
      id="f-2159"
      unitRef="shares">5152410</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-778"
      decimals="INF"
      id="f-2160"
      unitRef="shares">4921630</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <bntx:NumberOfShareOptionsHeld
      contextRef="c-779"
      decimals="INF"
      id="f-2161"
      unitRef="shares">230780</bntx:NumberOfShareOptionsHeld>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-2162">&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Years ended &lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases of various goods and services from entities controlled by ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Purchases of property and other assets from entities controlled by ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;62.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;62.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;padding-left:0.28pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.939%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.199%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;(in millions &#x20ac;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C5E0B4;border-left:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #70ad47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;ATHOS KG&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-left:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70ad47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#C6E0B4;border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #70ad47;border-left:1pt solid #70AD47;border-right:1pt solid #70AD47;border-top:1pt solid #70AD47;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions contextRef="c-780" decimals="-5" id="f-2163" unitRef="eur">300000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
    <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions contextRef="c-781" decimals="-5" id="f-2164" unitRef="eur">300000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
    <bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions contextRef="c-782" decimals="-5" id="f-2165" unitRef="eur">900000</bntx:PurchasesOfGoodsAndServiceRelatedPartyTransactions>
    <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions contextRef="c-780" decimals="-5" id="f-2166" unitRef="eur">0</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions contextRef="c-781" decimals="-5" id="f-2167" unitRef="eur">62500000</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
    <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions contextRef="c-782" decimals="-5" id="f-2168" unitRef="eur">0</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
    <bntx:PurchasesFromRelatedPartyTransactions contextRef="c-780" decimals="-5" id="f-2169" unitRef="eur">300000</bntx:PurchasesFromRelatedPartyTransactions>
    <bntx:PurchasesFromRelatedPartyTransactions contextRef="c-781" decimals="-5" id="f-2170" unitRef="eur">62800000</bntx:PurchasesFromRelatedPartyTransactions>
    <bntx:PurchasesFromRelatedPartyTransactions contextRef="c-782" decimals="-5" id="f-2171" unitRef="eur">900000</bntx:PurchasesFromRelatedPartyTransactions>
    <ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions contextRef="c-783" decimals="-5" id="f-2172" unitRef="eur">62500000</ifrs-full:PurchasesOfPropertyAndOtherAssetsRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-784" decimals="-5" id="f-2173" unitRef="eur">400000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-785" decimals="-5" id="f-2174" unitRef="eur">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-786" decimals="-5" id="f-2175" unitRef="eur">400000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions contextRef="c-787" decimals="-5" id="f-2176" unitRef="eur">0</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction contextRef="c-14" decimals="INF" id="f-2177" unitRef="eur">0</ifrs-full:ProvisionsForDoubtfulDebtsRelatedToOutstandingBalancesOfRelatedPartyTransaction>
    <ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction contextRef="c-1" decimals="INF" id="f-2178" unitRef="eur">0</ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-2179">Events After the Reporting Period&lt;div style="margin-top:6pt;text-align:justify;text-indent:24.38pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2024, we and Autolus Therapeutics plc, or Autolus, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies' autologous CAR-T programs towards commercialization. We have entered into a license and option agreement and a securities purchase agreement under which we purchased $200.0&#160;million of Autolus' American Deposit Shares in a private placement closed on February 13, 2024 resulting in a stake in Autolus ordinary shares of 12.5%. Under the terms of the license and option agreement, we made a $50.0&#160;million upfront payment in exchange for the right to receive royalties on net sales of Autolus' lead asset obe-cel, co-commercialization options for Autolus' AUTO1/22 and AUTO6NG programs as well as an exclusive license and exclusive options to certain technologies owned by Autolus.&lt;/span&gt;&lt;/div&gt;The Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer (CCO), effective as of July 1, 2024. She will take over the role from Sean Marett, who will retire as planned from the Management Board as of June 30, 2024.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <bntx:PurchaseOfSharesUnderAgreement
      contextRef="c-788"
      decimals="-5"
      id="f-2180"
      unitRef="shares">200000000</bntx:PurchaseOfSharesUnderAgreement>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="c-789"
      decimals="3"
      id="f-2181"
      unitRef="number">0.125</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <bntx:UpfrontPayment contextRef="c-790" decimals="-5" id="f-2182" unitRef="usd">50000000</bntx:UpfrontPayment>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-72" xlink:label="f-72" xlink:type="locator"/>
        <link:loc xlink:href="#f-68" xlink:label="f-68" xlink:type="locator"/>
        <link:loc xlink:href="#f-70" xlink:label="f-70" xlink:type="locator"/>
        <link:loc xlink:href="#f-71" xlink:label="f-71" xlink:type="locator"/>
        <link:loc xlink:href="#f-69" xlink:label="f-69" xlink:type="locator"/>
        <link:loc xlink:href="#f-67" xlink:label="f-67" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;&#160;&#160;&#160;<xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-72"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-68"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-70"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-71"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-69"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-67"
          xlink:to="fn-1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
